PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gavaruzzi, T; Caserotti, M; Leo, I; Tasso, A; Speri, L; Ferro, A; Fretti, E; Sannino, A; Rubaltelli, E; Lotto, L				Gavaruzzi, Teresa; Caserotti, Marta; Leo, Irene; Tasso, Alessandra; Speri, Leonardo; Ferro, Antonio; Fretti, Elena; Sannino, Anna; Rubaltelli, Enrico; Lotto, Lorella			The Role of Emotional Competences in Parents' Vaccine Hesitancy	VACCINES			English	Article						vaccines; parents; decision making; attitude; emotions		The role of parents' emotional competencies on vaccine hesitancy and decision making has been seldom examined. Two studies investigated the relationship between parents' attitudes towards childhood vaccines and self-reported behavior (Study 1) and between parents' emotional competence and attitudes towards vaccines (Study 2). In Study 1, predictors of temporal, partial, or complete vaccine refusal (having voluntarily postponed/forgone some/all vaccines) were examined in 2778 parents. In Study 2, psychological predictors of the attitude towards vaccines were examined in 593 parents, using the Profile of Emotional Competence and the valence of mental images spontaneously associated with the term "vaccine". In Study 1, attitudes were aggregated in three independent factors (concerns about vaccine safety; diseases prevented by vaccines; and naturalistic views) that independently predicted vaccine refusal. In Study 2, a significant mediational analysis showed a positive indirect effect of intrapersonal emotional competences on attitudes towards vaccines, through mental images associated with the word "vaccine". Parents' intrapersonal emotional competences affected all dimensions of attitudes towards vaccines, suggesting that being able to manage, identify, and recognize one's own emotions is central to vaccine acceptance. These findings suggest that intervention strategies, rather than stressing the pro-social benefits of vaccinating, should focus on aspects related to one's own emotions.	[Gavaruzzi, Teresa; Caserotti, Marta; Leo, Irene; Rubaltelli, Enrico; Lotto, Lorella] Univ Padua, Dept Dev Psychol & Socializat, I-35131 Padua, Italy; [Tasso, Alessandra] Univ Ferrara, Dept Humanities, I-44121 Ferrara, Italy; [Speri, Leonardo; Fretti, Elena; Sannino, Anna] AULSS 9 Scaligera, Dept Prevent, I-37122 Verona, Italy; [Ferro, Antonio] APSS Trento, Dept Prevent, I-38123 Trento, Italy		Gavaruzzi, T (通讯作者)，Univ Padua, Dept Dev Psychol & Socializat, I-35131 Padua, Italy.	teresa.gavaruzzi@unipd.it; marta.caserotti@unipd.it; irene.leo@unipd.it; alessandra.tasso@unife.it; leonardosperi@gmail.com; antonio.ferro@apss.tn.it; elena.fretti@gmail.com; anna.sannino81@gmail.com; enrico.rubaltelli@unipd.it; lorella.lotto@unipd.it		Rubaltelli, Enrico/0000-0002-7521-755X; CASEROTTI, MARTA/0000-0001-8839-0581; LOTTO, LORELLA/0000-0002-0303-3014			Anderson EJ, 2018, CLIN INFECT DIS, V67, P464, DOI 10.1093/cid/ciy142; [Anonymous], 2011, REGIONE VENETO ASL V; [Anonymous], LEGGE REGIONALE 23 M; Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019; Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056; Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590; Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387; Biasio LR, 2016, HUM VACC IMMUNOTHER, V12, P2984, DOI 10.1080/21645515.2016.1198456; Bohm R, 2019, J BEHAV MED, V42, P381, DOI 10.1007/s10865-018-9985-9; Brasseur S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062635; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Casara BGS, 2019, J EXP PSYCHOL-APPL, V25, P354, DOI 10.1037/xap0000211; Danaei G, 2014, LANCET DIABETES ENDO, V2, P634, DOI 10.1016/S2213-8587(14)70102-0; De keersmaecker J, 2020, PERS SOC PSYCHOL B, V46, P204, DOI 10.1177/0146167219853844; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118; Dyda A, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09327-8; Enkel SL, 2018, VACCINE, V36, P6459, DOI 10.1016/j.vaccine.2017.09.088; Facciola A, 2019, J PUBLIC HEALTH RES, V8, P13, DOI 10.4081/jphr.2019.1436; Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029; Hakim H, 2020, J MED INTERNET RES, V22, DOI 10.2196/20113; Hakim H, 2019, VACCINE, V37, P235, DOI 10.1016/j.vaccine.2018.11.016; Hendrix KS, 2014, PEDIATRICS, V134, pE675, DOI 10.1542/peds.2013-4077; Hornsey MJ, 2020, J EXP SOC PSYCHOL, V88, DOI 10.1016/j.jesp.2019.103947; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Karras J, 2019, VACCINE, V37, P6594, DOI 10.1016/j.vaccine.2019.09.039; Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maurici M, 2019, HUM VACC IMMUNOTHER, V15, P631, DOI 10.1080/21645515.2018.1536587; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Peter PC, 2012, J APPL SOC PSYCHOL, V42, P1394, DOI 10.1111/j.1559-1816.2012.00904.x; Peters E, 1996, J APPL SOC PSYCHOL, V26, P1427, DOI 10.1111/j.1559-1816.1996.tb00079.x; Peters E., 2004, 0402 DEC RES EUG; Peters E, 2006, J COMMUN, V56, pS140, DOI 10.1111/j.1460-2466.2006.00287.x; Pluviano S, 2019, COGN PROCESS, V20, P325, DOI 10.1007/s10339-019-00919-w; Pluviano S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181640; Quadri-Sheriff M, 2012, PEDIATRICS, V130, P522, DOI 10.1542/peds.2012-0140; Rubaltelli E, 2018, PERS INDIV DIFFER, V123, P247, DOI 10.1016/j.paid.2017.11.036; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Schwarz N, 2000, COGNITION EMOTION, V14, P433, DOI 10.1080/026999300402745; Scrimin S, 2021, CURR PSYCHOL, V40, P2707, DOI 10.1007/s12144-019-00189-x; Siddu A., 2018, 51 NAT C IT SOC HYG; SLOVIC P, 1991, RISK ANAL, V11, P683, DOI 10.1111/j.1539-6924.1991.tb00658.x; Slovic P, 2007, EUR J OPER RES, V177, P1333, DOI 10.1016/j.ejor.2005.04.006; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Sunstein CR, 2003, J RISK UNCERTAINTY, V26, P121, DOI 10.1023/A:1024111006336; Tomljenovic H, 2020, PSYCHOL HEALTH, V35, P538, DOI 10.1080/08870446.2019.1673894	53	3	3	6	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							298	10.3390/vaccines9030298			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE4YS	33810071	Green Published, gold			2022-04-29	WOS:000634162200001
J	Pettini, E; Pastore, G; Fiorino, F; Medaglini, D; Ciabattini, A				Pettini, Elena; Pastore, Gabiria; Fiorino, Fabio; Medaglini, Donata; Ciabattini, Annalisa			Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?	VACCINES			English	Article						immunization; alum; B cell response; T cell response; antibodies; prime-boost schedules		Characterizing the impact of the vaccination schedule on the induction of B and T cell immune responses is critical for improving vaccine immunogenicity. Here we compare the effect of a short (4 weeks) or a long (18 weeks) interval between priming and boosting in mice, using a model vaccine formulation based on the chimeric tuberculosis vaccine antigen H56 combined with alum. While no significant difference was observed in serum antigen-specific IgG response and the induction of antigen-specific T follicular helper cells into draining lymph nodes after the two immunization schedules, a longer interval between priming and boosting elicited a higher number of germinal center-B cells and H56-specific antibody-secreting cells and modulated the effector function of reactivated CD4+ T cells. These data show that the scheduling of the booster immunization could affect the immune response elicited by vaccination modulating and improving the immunogenicity of the vaccine.	[Pettini, Elena; Pastore, Gabiria; Fiorino, Fabio; Medaglini, Donata; Ciabattini, Annalisa] Univ Siena, Lab Mol Microbiol & Biotechnol LAMMB, Dept Med Biotechnol, I-53100 Siena, Italy		Ciabattini, A (通讯作者)，Univ Siena, Lab Mol Microbiol & Biotechnol LAMMB, Dept Med Biotechnol, I-53100 Siena, Italy.	pettini5@unisi.it; gabiria.pastore@unisi.it; fiorino4@unisi.it; donata.medaglini@unisi.it; annalisa.ciabattini@unisi.it	; MEDAGLINI, DONATA/R-1149-2018; Pettini, Elena/R-4188-2018	Pastore, Gabiria/0000-0002-3219-6170; CIABATTINI, ANNALISA/0000-0002-4585-7783; MEDAGLINI, DONATA/0000-0003-1729-7325; Pettini, Elena/0000-0002-0308-7127; Fiorino, Fabio/0000-0002-1440-8061	Commission of the European Communities, Seventh Framework Programme [HEALTH-2011-280873]; Horizon 2020 Framework Programme [730694]	This study has been carried out with financial support from the Commission of the European Communities, Seventh Framework Programme contract HEALTH-2011-280873 Advanced Immunization Technologies (ADITEC), and Horizon 2020 Framework Programme grant number 730694 (TRANSVAC).	Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285; Belshe RB, 2011, J INFECT DIS, V203, P666, DOI 10.1093/infdis/jiq093; Boianelli A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135787; Camacho DM, 2018, CELL, V173, P1581, DOI 10.1016/j.cell.2018.05.015; Castiglione F, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/842329; Ciabattini A, 2008, VACCINE, V26, P4244, DOI 10.1016/j.vaccine.2008.05.049; Ciabattini A, 2020, SEMIN IMMUNOPATHOL, V42, P619, DOI 10.1007/s00281-020-00821-0; Ciabattini A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01305; Ciabattini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00380; Ciabattini A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00427; Ciabattini A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00421; Ciabattini A, 2010, VACCINE, V28, P1226, DOI 10.1016/j.vaccine.2009.11.021; Clements CJ, 2002, VACCINE, V20, pS24, DOI 10.1016/S0264-410X(02)00168-8; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Cunningham AL, 2016, VACCINE, V34, P6655, DOI 10.1016/j.vaccine.2016.10.016; de Mare A, 2008, GENE THER, V15, P393, DOI 10.1038/sj.gt.3303060; Ehreth J, 2003, VACCINE, V21, P4105, DOI 10.1016/S0264-410X(03)00377-3; Fiorino F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00168; Fiorino F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00128; Frey SE, 2013, VACCINE, V31, P3025, DOI 10.1016/j.vaccine.2013.04.050; Gerlach C, 2011, ANN NY ACAD SCI, V1217, P139, DOI 10.1111/j.1749-6632.2010.05830.x; Harandi AM, 2010, CURR HIV RES, V8, P330, DOI 10.2174/157016210791208695; Huang CX, 2020, ADV EXP MED BIOL, V1254, P47, DOI 10.1007/978-981-15-3532-1_4; Jackson LA, 2017, VACCINE, V35, P1675, DOI 10.1016/j.vaccine.2017.02.032; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Kolibab K, 2010, CLIN VACCINE IMMUNOL, V17, P793, DOI 10.1128/CVI.00006-10; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Lucchesi S, 2020, CYTOM PART A, V97, P259, DOI 10.1002/cyto.a.23922; Martinez LJ, 2015, AM J TROP MED HYG, V93, P454, DOI 10.4269/ajtmh.14-0819; Mbow ML, 2011, NAT MED, V17, P415, DOI 10.1038/nm0411-415; Mensah VA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01551; Misawa T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz0085; Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030; Mutua G, 2019, J INFECT DIS, V220, P57, DOI 10.1093/infdis/jiz071; Palgen JL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0175-8; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Pitisuttithum P, 2020, LANCET HIV, V7, pE238, DOI 10.1016/S2352-3018(19)30406-0; Prota G, 2015, VACCINE, V33, P6823, DOI 10.1016/j.vaccine.2015.09.024; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Santoro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01248; Venkatraman N, 2019, J INFECT DIS, V219, P1187, DOI 10.1093/infdis/jiy639; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang Z, 2019, J MATH BIOL, V79, P2157, DOI 10.1007/s00285-019-01424-6; Zhan YF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01809; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	46	4	4	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							289	10.3390/vaccines9030289			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5BF	33804604	Green Published, gold			2022-04-29	WOS:000634168700001
J	Caputo, A; Marconi, P				Caputo, Antonella; Marconi, Peggy			Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors	VACCINES			English	Editorial Material									[Caputo, Antonella; Marconi, Peggy] Univ Ferrara, Dept Chem Pharmaceut & Agr Sci, Via Fossato Mortara 64-B, I-44121 Ferrara, Italy		Caputo, A; Marconi, P (通讯作者)，Univ Ferrara, Dept Chem Pharmaceut & Agr Sci, Via Fossato Mortara 64-B, I-44121 Ferrara, Italy.	cpa@unife.it; mcy@unife.it		Caputo, Antonella/0000-0002-1241-0299; Marconi, Peggy C. R./0000-0003-3488-0491			Ayoub HH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030366; Aschner CB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020277; Esber A, 2015, J INFECT DIS, V212, P8, DOI 10.1093/infdis/jiv017; George BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104169; Gottlieb SL, 2019, VACCINE, V37, P7408, DOI 10.1016/j.vaccine.2017.10.084; Heilingloh CS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030478; Ike AC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020302; Looker KJ, 2017, LANCET GLOB HEALTH, V5, pE300, DOI [10.1016/s2214-109x(16)30362-x, 10.1016/S2214-109X(16)30362-X]; Looker KJ, 2005, SEX TRANSM INFECT, V81, P103, DOI 10.1136/sti.2004.012039; Mancuso R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020255; Mancuso R, 2019, EXPERT REV ANTI-INFE, V17, P715, DOI 10.1080/14787210.2019.1656064; Nicoli F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020274; Saylor D, 2015, CURR OPIN INFECT DIS, V28, P330, DOI 10.1097/QCO.0000000000000175; Sivarajah V, 2017, SEX TRANSM INFECT, V93, P535, DOI 10.1136/sextrans-2016-052921; Voellmy R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020230; Wu YP, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2630865	16	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							158	10.3390/vaccines9020158			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7CN	33669413	Green Published, gold			2022-04-29	WOS:000623298000001
J	Collins, C; Lester, K; Del-Pozo, J; Collet, B				Collins, Catherine; Lester, Katherine; Del-Pozo, Jorge; Collet, Bertrand			Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish-Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar	VACCINES			English	Article						SAV1; DNA vaccine; Viremia; reporter assay; individual fish monitoring; salmon	PANCREAS DISEASE; IMMUNE-RESPONSE; I INTERFERON; INTRAMUSCULAR INJECTION; MONOCLONAL-ANTIBODIES; GAMMA-INTERFERON; VIRUS; INFECTION; L.; EXPRESSION	Traditionally, commercial testing for vaccine efficacy has relied on the mass infection of vaccinated and unvaccinated animals and the comparison of mortality prevalence and incidence. For some infection models where disease does not cause mortality this approach to testing vaccine efficacy is not useful. Additionally, in fish experimental studies on vaccine efficacy and immune response the norm is that several individuals are lethally sampled at sequential timepoints, and results are extrapolated to represent the kinetics of immune and disease parameters of an individual fish over the entire experimental infection period. In the present study we developed a new approach to vaccine testing for viremic viruses in fish by following the same individuals over the course of a DNA vaccination and experimental infection through repeated blood collection and analyses. Injectable DNA vaccines are particularly efficient against viral disease in fish. To date, two DNA vaccines have been authorised for use in fish farming, one in Canada against Infectious Haemorrhagic Necrotic virus and more recently one in Europe against Salmon Pancreatic Disease virus (SPDv) subtype 3. In the current study we engineered and used an experimental DNA vaccine against SPDv subtype 1. We measured viremia using a reporter cell line system and demonstrated that the viremia phase was completely extinguished following DNA vaccination. Differences in viremia infection kinetics between fish in the placebo group could be related to subsequent antibody levels in the individual fish, with higher antibody levels at terminal sampling in fish showing earlier viremia peaks. The results indicate that sequential non-lethal sampling can highlight associations between infection traits and immune responses measured at asynchronous timepoints and, can provide biological explanations for variation in data. Similar to results observed for the SPDv subtype 3 DNA vaccine, the SPDv subtype 1 DNA vaccine also induced an interferon type 1 response after vaccination and provided high protection against SPDv under laboratory conditions when fish were challenged at 7 weeks post-vaccination.	[Collins, Catherine; Collet, Bertrand] Univ Paris Saclay, UVSQ, INRAE, VIM, F-78352 Jouy En Josas, France; [Collins, Catherine; Lester, Katherine; Collet, Bertrand] Marine Scotland, Aberdeen AB11 9DB, Scotland; [Lester, Katherine] SASA Sci & Advice Scottish Agr, Edinburgh EH12 9FJ, Midlothian, Scotland; [Del-Pozo, Jorge] Royal Dick Sch Vet Studies, Easter Bush Campus, Edinburgh EH25 9RG, Midlothian, Scotland; [Del-Pozo, Jorge] Roslin Inst, Easter Bush Campus, Edinburgh EH25 9RG, Midlothian, Scotland		Collins, C; Collet, B (通讯作者)，Univ Paris Saclay, UVSQ, INRAE, VIM, F-78352 Jouy En Josas, France.; Collins, C; Collet, B (通讯作者)，Marine Scotland, Aberdeen AB11 9DB, Scotland.	catherine.collins@inrae.fr; Katherine.Lester@sasa.gov.scot; Jorge.Del.Pozo@ed.ac.uk; bertrand.collet@inrae.fr		del Pozo, Jorge/0000-0002-9582-1228	European UnionEuropean Commission [311993]; VetBioNet project under the Horizon 2020 programme for Research and Technological Development (EU) [INFRA-2016-1 731014]	This work was funded by the European Union as a part of the collaborative project TargetFish under the 7th Framework Programme for Research and Technological Development (EU Grant Agreement 311993) and the VetBioNet project under the Horizon 2020 programme for Research and Technological Development (EU Grant Agreement INFRA-2016-1 731014).	Andreassen R, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3741-3; Attaya A, 2019, FISH SHELLFISH IMMUN, V93, P631, DOI 10.1016/j.fsi.2019.08.002; Bassity E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033196; Belisle SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019681; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bracci L, 2006, VACCINE, V24, pS56, DOI 10.1016/j.vaccine.2005.01.121; Braceland M, 2013, J PROTEOMICS, V94, P423, DOI 10.1016/j.jprot.2013.10.016; Brudeseth BE, 2013, FISH SHELLFISH IMMUN, V35, P1759, DOI 10.1016/j.fsi.2013.05.029; Bruno D, 2007, AQUACULTURE, V269, P114, DOI 10.1016/j.aquaculture.2007.04.057; Cano I, 2015, J FISH DIS, V38, P271, DOI 10.1111/jfd.12310; Castro R, 2008, MOL IMMUNOL, V45, P3454, DOI 10.1016/j.molimm.2008.03.015; Chance RJ, 2018, J FISH BIOL, V93, P1069, DOI 10.1111/jfb.13803; Chang CJ, 2017, J FISH DIS, V40, P1775, DOI 10.1111/jfd.12644; Chang CJ, 2015, VACCINE, V33, P2442, DOI 10.1016/j.vaccine.2015.03.093; Chang CJ, 2014, VACCINE, V32, P4695, DOI 10.1016/j.vaccine.2014.05.059; Christie KE, 2007, DIS AQUAT ORGAN, V75, P13, DOI 10.3354/dao075013; Collet B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137767; Collet B, 2013, J VIROL METHODS, V191, P113, DOI 10.1016/j.jviromet.2013.04.009; Collet B, 2009, VET IMMUNOL IMMUNOP, V130, P92, DOI 10.1016/j.vetimm.2008.12.022; Collins C, 2019, FISH SHELLFISH IMMUN, V85, P106, DOI 10.1016/j.fsi.2018.07.012; Desvignes L, 2002, FISH SHELLFISH IMMUN, V12, P77, DOI 10.1006/fsim.2001.0356; Embregts CWE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01340; Evensen O, 2013, FISH SHELLFISH IMMUN, V35, P1751, DOI 10.1016/j.fsi.2013.10.021; Excler JL, 2014, CLIN VACCINE IMMUNOL, V21, P1023, DOI 10.1128/CVI.00230-14; Graham DA, 2006, DIS AQUAT ORGAN, V72, P193, DOI 10.3354/dao072193; Graham DA, 2011, J FISH DIS, V34, P273, DOI 10.1111/j.1365-2761.2010.01234.x; Graham DA, 2010, J FISH DIS, V33, P123, DOI 10.1111/j.1365-2761.2009.01096.x; Graham DA, 2005, J FISH DIS, V28, P373, DOI 10.1111/j.1365-2761.2005.00638.x; Granja AG, 2015, J IMMUNOL, V195, P1825, DOI 10.4049/jimmunol.1500322; GRIFFIN DE, 1995, SEMIN VIROL, V6, P249, DOI 10.1006/smvy.1995.0030; Hall LM, 2019, FISH SHELLFISH IMMUN, V85, P126, DOI 10.1016/j.fsi.2018.01.033; Heppell J, 1998, FISH SHELLFISH IMMUN, V8, P271, DOI 10.1006/fsim.1997.0133; Herath TK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179192; Hikke MC, 2014, VACCINE, V32, P6206, DOI 10.1016/j.vaccine.2014.09.026; Hodneland K, 2006, J VIROL METHODS, V131, P184, DOI 10.1016/j.jviromet.2005.08.012; Holvold LB, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-21; Houghton G, 1996, FISH SHELLFISH IMMUN, V6, P465, DOI 10.1006/fsim.1996.0044; Ishii KJ, 2008, NATURE, V451, P725, DOI 10.1038/nature06537; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jansen MD, 2017, J FISH DIS, V40, P141, DOI 10.1111/jfd.12478; Jarungsriapisit J, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0520-8; Jenberie S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01682; Karlsen M, 2012, VACCINE, V30, P5688, DOI 10.1016/j.vaccine.2012.05.069; Laylor R, 1999, CLIN EXP IMMUNOL, V117, P106; Le Bon A, 2006, J IMMUNOL, V176, P4682, DOI 10.4049/jimmunol.176.8.4682; Long JE, 2005, WORLD J GASTROENTERO, V11, P4967, DOI 10.3748/wjg.v11.i32.4967; Lund V, 2003, DIS AQUAT ORGAN, V56, P31, DOI 10.3354/dao056031; Mayer-Barber KD, 2017, CELL MOL IMMUNOL, V14, P22, DOI 10.1038/cmi.2016.25; McBeath AJA, 2007, FISH SHELLFISH IMMUN, V22, P230, DOI 10.1016/j.fsi.2006.05.004; McLoughlin MF, 2007, J FISH DIS, V30, P511, DOI 10.1111/j.1365-2761.2007.00848.x; McLoughlin MF, 1996, DIS AQUAT ORGAN, V26, P117, DOI 10.3354/dao026117; Metzemaekers M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01970; Mikalsen AB, 2005, VACCINE, V23, P4895, DOI 10.1016/j.vaccine.2005.05.025; Monte M, 2019, DEV COMP IMMUNOL, V99, DOI 10.1016/j.dci.2019.103406; Moriette C, 2005, J GEN VIROL, V86, P3119, DOI 10.1099/vir.0.81030-0; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Munang'andu HM, 2019, FISH SHELLFISH IMMUN, V85, P132, DOI 10.1016/j.fsi.2018.03.060; Murphy T. M., 1995, Aquaculture Research, V26, P861, DOI 10.1111/j.1365-2109.1995.tb00881.x; Nagao Y, 1998, J INTERF CYTOK RES, V18, P661, DOI 10.1089/jir.1998.18.661; Robertsen B, 2016, FISH SHELLFISH IMMUN, V54, P328, DOI 10.1016/j.fsi.2016.04.027; Rosati M, 2005, J VIROL, V79, P8480, DOI 10.1128/JVI.79.13.8480-8492.2005; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; SCHMALJOHN AL, 1982, NATURE, V297, P70, DOI 10.1038/297070a0; Siegel F, 2001, J VIROL, V75, P5036, DOI 10.1128/JVI.75.11.5036-5042.2001; Skjold P, 2016, VET RES, V47, DOI 10.1186/s13567-016-0362-9; Sobhkhez M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204924; Tarradas J, 2010, VET MICROBIOL, V142, P51, DOI 10.1016/j.vetmic.2009.09.043; Teige LH, 2020, FISH SHELLFISH IMMUN, V106, P374, DOI 10.1016/j.fsi.2020.07.055; Tonheim TC, 2008, FISH SHELLFISH IMMUN, V24, P90, DOI 10.1016/j.fsi.2007.09.006; Tough DF, 2004, LEUKEMIA LYMPHOMA, V45, P257, DOI 10.1080/1042819031000149368; Urquhart K., 2016, J EXP APP ANIM SCI, V2, P1, DOI [10.20454/jeaas.2016.1077, DOI 10.20454/JEAAS.2016.1077]; Utke K, 2008, DEV COMP IMMUNOL, V32, P239, DOI 10.1016/j.dci.2007.05.010; Van Rompay KKA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aay2736; Vazirinejad R, 2014, NEUROIMMUNOMODULAT, V21, P322, DOI 10.1159/000357780; Wang C, 2020, MICROBIOL IMMUNOL, V64, P52, DOI 10.1111/1348-0421.12744; Xu C, 2012, VACCINE, V30, P3918, DOI 10.1016/j.vaccine.2012.03.081; Ye L, 2019, J VIROL, V93, DOI [10.1128/JVI.01262-13, 10.1128/JVI.01262-19]; Zhu R, 2011, J VIROL, V85, P10201, DOI 10.1128/JVI.00062-11	79	0	0	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							163	10.3390/vaccines9020163			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6RY	33671162	Green Published, gold			2022-04-29	WOS:000623270000001
J	Paixao, V; Almeida, EB; Amaral, JB; Roseira, T; Monteiro, FR; Foster, R; Sperandio, A; Rossi, M; Amirato, GR; Santos, CAF; Pires, RS; Leal, FB; Durigon, EL; Oliveira, DBL; Vieira, RP; Vaisberg, M; Santos, JMB; Bachi, ALL				Paixao, Vitoria; Almeida, Ewin B.; Amaral, Jonatas B.; Roseira, Tamaris; Monteiro, Fernanda R.; Foster, Roberta; Sperandio, Adriane; Rossi, Marcelo; Amirato, Gislene R.; Santos, Carlos A. F.; Pires, Renier S.; Leal, Fabyano B.; Durigon, Edison L.; Oliveira, Danielle B. L.; Vieira, Rodolfo P.; Vaisberg, Mauro; Santos, Juliana M. B.; Bachi, Andre L. L.			Elderly Subjects Supplemented with L-Glutamine Shows an Improvement of Mucosal Immunity in the Upper Airways in Response to Influenza Virus Vaccination	VACCINES			English	Article						L-glutamine; influenza virus; vaccine; antibodies; immunoglobulin; cytokines		Background: Although glutamine is able to improve the immune response, its action in the upper airway immunity against the influenza virus vaccine remains unclear. Therefore, we aimed to evaluate the L-glutamine supplementation effect on the mucosal immune/inflammatory response of elderly subjects vaccinated against the influenza virus. Methods: Saliva sampling from 83 physically active elderly volunteers were collected pre- and 30 days after influenza virus vaccination and supplementation with L-glutamine (Gln, n = 42) or placebo (PL, n = 41). Results: Gln group showed higher salivary levels of interleukin (IL)-17, total secretory immunoglobulin A (SIgA), and specific-SIgA post-vaccination than values found pre-vaccination and in the PL group post-vaccination. Whereas higher salivary levels of IL-6 and IL-10 were observed post-vaccination in the Gln group, IL-37 levels were lower post-vaccination in both groups than the values pre-vaccination. Tumor necrosis factor (TNF)-alpha levels were unchanged. Positive correlations between IL-6 and IL-10 were found in all volunteer groups pre- and post-vaccination and also between IL-17 and IL-6 or IL-10 in the Gln group post-vaccination. A negative correlation between IL-37 and IL-10 was found pre- and post-vaccination in the PL group. Conclusion: Gln supplementation was able to modulate salivary cytokine profile and increase SIgA levels, both total and specific to the influenza virus vaccine, in physically active elderly subjects.	[Paixao, Vitoria; Almeida, Ewin B.; Amaral, Jonatas B.; Roseira, Tamaris; Monteiro, Fernanda R.; Foster, Roberta; Rossi, Marcelo; Amirato, Gislene R.; Vaisberg, Mauro; Bachi, Andre L. L.] Fed Univ Sao Paulo UNIFESP, Dept Otorhinolaryngol, ENT Lab, BR-04021001 Sao Paulo, Brazil; [Roseira, Tamaris; Monteiro, Fernanda R.; Foster, Roberta; Sperandio, Adriane] Method Fac Sao Paulo FAMESP, BR-04046200 Sao Paulo, Brazil; [Santos, Carlos A. F.] Paulista Sch Med EPM, Dept Med, Geriatry, BR-04023062 Sao Paulo, Brazil; [Pires, Renier S.; Bachi, Andre L. L.] Santo Amaro Univ UNISA, Postgrad Program Hlth Sci, BR-04743030 Sao Paulo, Brazil; [Leal, Fabyano B.; Durigon, Edison L.; Oliveira, Danielle B. L.] Univ Sao Paulo, Inst Biomed Sci, BR-05508060 Sao Paulo, Brazil; [Durigon, Edison L.] Univ Sao Paulo, Sci Platform Pasteur, BR-05508060 Sao Paulo, Brazil; [Oliveira, Danielle B. L.] Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo, Brazil; [Vieira, Rodolfo P.; Bachi, Andre L. L.] Brazilian Inst Teaching & Res Pulm & Exercise Imm, BR-12245520 Sao Paulo, Brazil; [Vieira, Rodolfo P.] Univ Brasil, Postgrad Program Bioengn & Biomed Engn, BR-15600000 Sao Paulo, Brazil; [Vieira, Rodolfo P.; Santos, Juliana M. B.] Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human & Rehabil, BR-11015020 Santos, SP, Brazil		Santos, JMB (通讯作者)，Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human & Rehabil, BR-11015020 Santos, SP, Brazil.	v.paixao@unifesp.br; ewin.almeida@unifesp.br; jbamaral@unifesp.br; tamaris.pavao@soufamesp.com.br; fernanda.monteiro@soufamesp.com.br; roberta.foster@timefamesp.com.br; ane.sperandio@gmail.com; mrossi@dim.fm.usp.br; prof.gislene@hotmail.com; freitas.carlos@uol.com.br; rspiress@yahoo.com.br; leal@icb.usp.br; eldurigo@usp.br; danibruna@gmail.com; rpvieira@unifesp.br; vaisberg.mauro@gmail.com; juliana.melo@unifesp.br; abachi@unifesp.br	Foster, Roberta/V-8096-2019; Monteiro, Fernanda Rodrigues/AFN-1365-2022; Paixão, Vitória/AAR-5891-2021; dos Santos, Juliana de Melo Batista/U-2855-2019; Bachi, Andre L L/G-2946-2012; Bachi, Andre/T-6931-2018; Vaisberg, Mauro Walter/M-3531-2014; Paula Vieira, Rodolfo/E-9315-2011	Foster, Roberta/0000-0002-9986-9747; Monteiro, Fernanda Rodrigues/0000-0001-9413-447X; Paixão, Vitória/0000-0002-3537-4606; dos Santos, Juliana de Melo Batista/0000-0003-0527-0723; Bachi, Andre L L/0000-0001-8266-1416; Bachi, Andre/0000-0001-8266-1416; Barbosa Almeida, Ewin/0000-0001-6495-6931; Oliveira, Danielle/0000-0002-0534-0886; Roseira, Tamaris/0000-0002-1784-0490; Vaisberg, Mauro Walter/0000-0003-0292-3792; Bussador do Amaral, Jonatas/0000-0001-5819-0474; Paula Vieira, Rodolfo/0000-0001-6379-1143	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/50025-1, 2012/15165-2, 2019/14115-0, 2019/13094-0, 2019/13188-4]	This research was funded by the Sao Paulo Research Foundation (FAPESP), grant numbers 2010/50025-1, 2012/15165-2, 2019/14115-0, 2019/13094-0, and 2019/13188-4.	Almeida EB, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2852181; Moro-Garcia MA, 2012, CURR GENOMICS, V13, P589, DOI 10.2174/138920212803759749; ARDAWI MSM, 1982, BIOCHEM J, V208, P743, DOI 10.1042/bj2080743; ARRANZ E, 1992, GUT, V33, P882, DOI 10.1136/gut.33.7.882; Bachi Andre L L, 2013, Results Immunol, V3, P10, DOI 10.1016/j.rinim.2013.01.001; Bahadoran A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01841; Bandaranayake T, 2016, CLIN GERIATR MED, V32, P415, DOI 10.1016/j.cger.2016.02.007; dos Santos JDB, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224418; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01269; Caris AV, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070692; Cavalli G, 2018, IMMUNOL REV, V281, P179, DOI 10.1111/imr.12605; CDC NCIRD, 2020, VACC EFF WELL DO FLU; CHALLACOMBE SJ, 1995, CLIN EXP IMMUNOL, V100, P181; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Cruzat V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111564; Curi TCP, 1997, AM J PHYSIOL-CELL PH, V273, pC1124, DOI 10.1152/ajpcell.1997.273.4.C1124; DeFlora S, 1997, EUR RESPIR J, V10, P1535, DOI 10.1183/09031936.97.10071535; Elfeky Osama A, 2018, Egypt J Immunol, V25, P53; Essaidi-Laziosi M, 2018, J ALLERGY CLIN IMMUN, V141, P2074, DOI 10.1016/j.jaci.2017.07.018; Evans P, 2000, BRAIN BEHAV IMMUN, V14, P41, DOI 10.1006/brbi.1999.0571; Fernandez-Garrido J, 2014, ARCH GERONTOL GERIAT, V59, P7, DOI 10.1016/j.archger.2014.02.008; Finkelstein M S, 1984, Compr Ther, V10, P32; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Foo JYY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048452; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Freitas EV, 2006, TRATADO GERIATRIA GE; Furtado GE, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13485; Gleeson M, 2008, J NUTR, V138, p2045S, DOI 10.1093/jn/138.10.2045S; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Hamada H, 2009, J IMMUNOL, V182, P3469, DOI 10.4049/jimmunol.0801814; Ivanov A, 2005, J VIROL METHODS, V126, P45, DOI 10.1016/j.jviromet.2005.01.030; Johnson MO, 2018, CELL, V175, P1780, DOI 10.1016/j.cell.2018.10.001; Johnstone J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108481; Legault Z, 2015, INT J SPORT NUTR EXE, V25, P417, DOI 10.1123/ijsnem.2014-0209; Liang B, 2001, J VIROL, V75, P5416, DOI 10.1128/JVI.75.11.5416-5420.2001; Loerbroks A, 2012, EUR J PUBLIC HEALTH, V22, P562, DOI 10.1093/eurpub/ckr094; Mansour A, 2015, NUTRITION, V31, P119, DOI 10.1016/j.nut.2014.05.014; Matsudo S.M.M., 2009, BIS B I SAUDE, V47, P76; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Miyagawa K, 2008, GERIATR GERONTOL INT, V8, P243, DOI 10.1111/j.1447-0594.2008.00483.x; Mohamed R, 2012, CLIN TRANSL MED, V1, DOI 10.1186/2001-1326-1-19; MOLDOVEANU Z, 1995, VACCINE, V13, P1006, DOI 10.1016/0264-410X(95)00016-T; Monteiro FR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040685; MURPHY BR, 1989, CURR TOP MICROBIOL, V146, P107; NEWSHOLME P, 1986, BIOCHEM J, V239, P121, DOI 10.1042/bj2390121; Noda K, 2011, MICROBIOL IMMUNOL, V55, P574, DOI 10.1111/j.1348-0421.2011.00352.x; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; OGRA PL, 1971, NEW ENGL J MED, V284, P59, DOI 10.1056/NEJM197101142840201; Pfaffe T, 2011, CLIN CHEM, V57, P675, DOI 10.1373/clinchem.2010.153767; Punyadeera C, 2011, J IMMUNOL METHODS, V373, P19, DOI 10.1016/j.jim.2011.07.013; Rector JL, 2014, BRAIN BEHAV IMMUN, V38, P133, DOI 10.1016/j.bbi.2014.01.012; Ren WK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00503; Ren WK, 2014, AMINO ACIDS, V46, P2403, DOI 10.1007/s00726-014-1793-0; Ren WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088335; Ren WK, 2013, AMINO ACIDS, V45, P947, DOI 10.1007/s00726-013-1551-8; Ren WK, 2013, BRIT J NUTR, V110, P1053, DOI 10.1017/S0007114512006101; Rhoads JM, 2009, AMINO ACIDS, V37, P111, DOI 10.1007/s00726-008-0225-4; Richter V, 2003, GERONTOLOGY, V49, P293, DOI 10.1159/000071710; Russell MW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611337; Salvi R, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110267; Sayles C, 2016, NUTR CLIN PRACT, V31, P171, DOI 10.1177/0884533615611857; Shah AM, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10020326; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Trondsen M, 2015, SCAND J IMMUNOL, V81, P305, DOI 10.1111/sji.12288; Vaisberg M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071678; Vasto S, 2007, MECH AGEING DEV, V128, P83, DOI 10.1016/j.mad.2006.11.015; Webster RG, 2000, VACCINE, V18, P1686, DOI 10.1016/S0264-410X(99)00507-1; Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092; Zhao SZ, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/9316763; Zhu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01445	74	7	7	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							107	10.3390/vaccines9020107			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7MN	33572639	gold, Green Published			2022-04-29	WOS:000623324300001
J	van Leeuwen, LPM; Doornekamp, L; Goeijenbier, S; de Jong, W; de Jager, HJ; van Gorp, ECM; Goeijenbier, M				van Leeuwen, Leanne P. M.; Doornekamp, Laura; Goeijenbier, Simone; de Jong, Wesley; de Jager, Herbert J.; van Gorp, Eric C. M.; Goeijenbier, Marco			Evaluation of the Hepatitis B Vaccination Programme in Medical Students in a Dutch University Hospital	VACCINES			English	Article						hepatitis B; healthcare workers; vaccination; long-term protection; anti-HBs		Healthcare workers (HCW) are at increased risk of contracting hepatitis B virus (HBV) and are, therefore, vaccinated pre-exposure. In this study, the HBV vaccination programme for medical students in a university hospital in the Netherlands was evaluated. In the first part, the effectiveness of the programme, which consisted of a vaccination with Engerix-B (R) at 0, 1, and 6 months, was retrospectively evaluated over 7 years (2012-2019). In the second part of this study, we followed students (the 2019 cohort) who had previously been vaccinated against HBV vaccination (4-262 months prior to primary presentation) in order to investigate the most efficient strategy to obtain an adequate anti hepatitis B surface antigen titre. In the latter, titre determination was performed directly during primary presentation instead of giving previously vaccinated students a booster vaccination first. The vaccination programme, as evaluated in the retrospective first part of the study, was effective (surpassed the protection limit of 10 IU/L) in 98.8 percent of the students (95% CI (98.4-99.2)). In the second part of our study, we found that 80 percent (95% CI (70-87)) of the students who had previously been vaccinated against HBV were still sufficiently protected and did not require a booster vaccination. With this strategy, the previously vaccinated students needed an average of 1.4 appointments instead of the 2 appointments needed with the former strategy. This knowledge is important and can save time and resources in the process of occupational HBV vaccination of HCW.	[van Leeuwen, Leanne P. M.; Doornekamp, Laura; Goeijenbier, Simone; de Jong, Wesley; van Gorp, Eric C. M.; Goeijenbier, Marco] Erasmus MC, Dept Virosci, Univ Med Ctr Rotterdam, NL-3015 GD Rotterdam, Netherlands; [van Leeuwen, Leanne P. M.; Doornekamp, Laura; Goeijenbier, Simone; van Gorp, Eric C. M.] Erasmus MC, Univ Med Ctr Rotterdam, Travel Clin, NL-3015 CP Rotterdam, Netherlands; [de Jong, Wesley] Maasstad Hosp Rotterdam, Dept Internal Med, NL-3079 DZ Rotterdam, Netherlands; [de Jager, Herbert J.] Erasmus MC, Dept Human Resources, Univ Med Ctr Rotterdam, NL-3015 GD Rotterdam, Netherlands; [van Gorp, Eric C. M.; Goeijenbier, Marco] Erasmus MC, Dept Internal Med, Univ Med Ctr Rotterdam, NL-3015 GD Rotterdam, Netherlands; [van Gorp, Eric C. M.] Erasmus MC, Dept Infect Dis, Univ Med Ctr Rotterdam, NL-3015 GD Rotterdam, Netherlands		van Leeuwen, LPM (通讯作者)，Erasmus MC, Dept Virosci, Univ Med Ctr Rotterdam, NL-3015 GD Rotterdam, Netherlands.; van Leeuwen, LPM (通讯作者)，Erasmus MC, Univ Med Ctr Rotterdam, Travel Clin, NL-3015 CP Rotterdam, Netherlands.	1.p.m.vanleeuwen@erasmusmc.nl; 1.doornekamp@erasmusmc.nl; s.goeijenbier@erasmusmc.nl; w.dejong.2@erasmusmc.nl; h.dejager@erasmusmc.nl; e.vangorp@erasmusmc.nl; m.goellenbier@erasmusmc.nl		Doornekamp, Laura/0000-0002-6525-6002			[Anonymous], 2016, HEPATITIS B VACCINAT; Authority HPR, HUM VACCINES; Bagheri-Jamebozorgi M, 2014, HUM VACC IMMUNOTHER, V10, P3731, DOI 10.4161/hv.34393; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Bauer T, 2006, VACCINE, V24, P572, DOI 10.1016/j.vaccine.2005.08.058; Bini C, 2018, HUM VACC IMMUNOTHER, V14, P450, DOI 10.1080/21645515.2017.1398297; Carollo M, 2013, VACCINE, V31, P506, DOI 10.1016/j.vaccine.2012.11.029; De Schryver A, 2011, EUR J PUBLIC HEALTH, V21, P338, DOI 10.1093/eurpub/ckq122; ECDC, 2020, VACCINE SCHEDULES AL; European Centre for Disease Prevention and Control, 2019, HEPATITIS B ECDC ANN; European Centre for Disease Prevention and Control, 2020, MONITORING RESPONSES; Grosso G, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.6025; Immunization Action Coalition, HEP B HLTH CAR WORK; Lamberti M, 2015, J OCCUP MED TOXICOL, V10, DOI 10.1186/s12995-015-0083-4; Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270; Lewis JD, 2015, WORLD J HEPATOL, V7, P488, DOI 10.4254/wjh.v7.i3.488; Rijksinstituut voor Volksgezondheid en Milieu, 2020, RICHTLIJN UITVOERING; Ryan K., 2010, SHERRIS MED MICROBIO; Saffar H, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.22223; Verso MG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010001; Wang RX, 2004, WORLD J GASTROENTERO, V10, P260; World Health Organization, HEPATITIS B; World Hlth Org, 2019, VACCINE, V37, P223, DOI 10.1016/j.vaccine.2017.07.046; Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251	24	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							69	10.3390/vaccines9020069			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7LG	33498258	gold, Green Published			2022-04-29	WOS:000623321000001
J	Lin, C; Tu, P; Beitsch, LM				Lin, Cheryl; Tu, Pikuei; Beitsch, Leslie M.			Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review	VACCINES			English	Review						vaccines; vaccine hesitancy; immunization; public health; health behavior; public opinion; communication; infectious diseases; pandemic; coronavirus	INFLUENZA VACCINATION; DETERMINANTS; WILLINGNESS; INTENTION	While COVID-19 continues raging worldwide, effective vaccines are highly anticipated. However, vaccine hesitancy is widespread. Survey results on uptake intentions vary and continue to change. This review compared trends and synthesized findings in vaccination receptivity over time across US and international polls, assessing survey design influences and evaluating context to inform policies and practices. Data sources included academic literature (PubMed, Embase, and PsycINFO following PRISMA guidelines), news and official reports published by 20 October 2020. Two researchers independently screened potential peer-reviewed articles and syndicated polls for eligibility; 126 studies and surveys were selected. Declining vaccine acceptance (from >70% in March to <50% in October) with demographic, socioeconomic, and partisan divides was observed. Perceived risk, concerns over vaccine safety and effectiveness, doctors' recommendations, and inoculation history were common factors. Impacts of regional infection rates, gender, and personal COVID-19 experience were inconclusive. Unique COVID-19 factors included political party orientation, doubts toward expedited development/approval process, and perceived political interference. Many receptive participants preferred to wait until others have taken the vaccine; mandates could increase resistance. Survey wording and answer options showed influence on responses. To achieve herd immunity, communication campaigns are immediately needed, focusing on transparency and restoring trust in health authorities.	[Lin, Cheryl; Tu, Pikuei] Duke Univ, Policy & Org Management Program, 2204 Erwin Rd, Durham, NC 27705 USA; [Beitsch, Leslie M.] Florida State Univ, Coll Med, Dept Behav Sci & Social Med, 1115 W Call St, Tallahassee, FL 32306 USA		Tu, P (通讯作者)，Duke Univ, Policy & Org Management Program, 2204 Erwin Rd, Durham, NC 27705 USA.	c.lin@duke.edu; Pikuei.tu@duke.edu; les.beitsch@med.fsu.edu					Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7; Ali KF, 2020, J MED INTERNET RES, V22, DOI 10.2196/19913; [Anonymous], 2020, NPR PBS NEWSHOU 1014, P1; [Anonymous], 2020, BOSTON GLOBE 0921, P7; [Anonymous], 2020, KFF HLTH TRACKING PO, P1; [Anonymous], 2020, WASH POST, P13; [Anonymous], 2020, CURR CONTENTS, P1; [Anonymous], 2020, CNN CNN SSRS POLL 6, P1; [Anonymous], 2020, IPS 2 3 AM GET COR V; [Anonymous], 2020, FOX NEWS 0813; [Anonymous], 2020, NAT TRACK POLL 20039, P1; [Anonymous], 2020, ABC NEWS; [Anonymous], 2020, IPS ABC NEWS IPS POL; [Anonymous], 2020, SUFFOLK U US TODAY P, P7; [Anonymous], 2020, NAT TRACK POLL 20040; [Anonymous], 2020, COR DIS 2019 COVID 1; [Anonymous], 2020, AXIOS; [Anonymous], 2020, ABC NEWS IPS POLL TO; [Anonymous], 2020, GOUCH COLL POLL RES, P1; [Anonymous], 2020, IPSOS AXIOS POLL WAV; [Anonymous], 2020, COR OUTBR IS IMP PUB; [Anonymous], 2020, COVID 19 HOSP DEATH; [Anonymous], 2020, AX IPS POLL WAV 18 T, P33; [Anonymous], YAH NEWS COR 14 JUL; [Anonymous], 2020, NAT TRACK POLL 20091, P1; [Anonymous], 2020, HARRIS POLL, P1; [Anonymous], YAH NEWS COR 30 JUL; [Anonymous], 2020, EXPECTATIONS COVID 1; [Anonymous], 2020, EC YOUGOV POLL 12 OC, P1; [Anonymous], 2020, EC YOUGOV POLL 29 JU, P1; Ax J., 2020, REUTERS 0521; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Baumgaertner B, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003354; Bean M., BECKERS HOSP RE 0601; Bibbins-Domingo K, 2020, ANN INTERN MED, V173, P233, DOI 10.7326/M20-2247; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Bowman K., 2020, GIVING VACCINES SHOT; Bracken M., 2020, TREND WORRIES HLTH E; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089; Bulik B.S., 2020, FIERCEPHARMA 0924; Buttenheim AM, 2020, ANN INTERN MED, V173, P1018, DOI 10.7326/M20-6206; Callaghan T., 2020, CORRELATES DISPARITI, P20; Cohen C., 2020, CNN 0813; Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14; Crane M., 2020, 7 10 AM WILL GET COV; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Earnshaw VA, 2020, TRANSL BEHAV MED, V10, P850, DOI 10.1093/tbm/ibaa090; Ed S., 2020, STAT NEWS 0831; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freed GL, 2010, PEDIATRICS, V125, P654, DOI 10.1542/peds.2009-1962; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Freimuth VS, 2001, SOC SCI MED, V52, P797, DOI 10.1016/S0277-9536(00)00178-7; Funk C, 2020, US PUBLIC NOW DIVIDE; Futier E, 2020, JAMA-J AM MED ASSOC, V323, P225, DOI 10.1001/jama.2019.20833; Gallup, COR PAND; Galvin G., 2020, 48 US ADULTS NOW SAY; Galvin G., 2020, NEARLY 2 5 ADULTS SA; Galvin G., 2020, ANTHONY FAUCI S VACC; Garritty C, 2020, COCHRANE RAPID REV I, DOI 10.1016/j.jclinepi.2020.10.007; Goldman RD, 2020, CLIN THER, V42, P2124, DOI 10.1016/j.clinthera.2020.09.012; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hawkins RB, 2020, PUBLIC HEALTH, V189, P129, DOI 10.1016/j.puhe.2020.09.016; Hostler TJ, 2018, COGNITION EMOTION, V32, P1578, DOI 10.1080/02699931.2017.1423280; ILO, 2020, COVID 19 WORLD WORK; Ipsos, 2020, NEWS IPS POLL 25 SEP, P1; Ipsos, 2020, SURV AM GEN POP; Ipsos, 2020, COR MIS RECKL BEH LI; Ipsos, 2020, AX IP POLL WAV 22 IP; Jaimungal C., 2020, FAST TRACKED COVID 1; Kennedy Bernice Roberts, 2007, J Cult Divers, V14, P56; Kim J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020176; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Krishnan L, 2020, ANN INTERN MED, V173, P474, DOI 10.7326/M20-2223; LaFraniere S., 2020, NEW YORK TIMES 0904; Laine C, 2020, ANN INTERN MED, V173, P830, DOI 10.7326/M20-6841; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lazer D., 2020, STATE NATION 50 STAT; Leys T., 2020, DES MOINES REGI 0926; Liu A., 2020, TIME DEPENDENT SIR M; Liu XJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197170; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Martin R., 2020, NPR 1023; McAteer J, 2020, CLIN INFECT DIS, V71, P703, DOI 10.1093/cid/ciaa433; Moran KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164541; Morning Consult, 2020, NAT TRACK POLL 20057, P1; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Newsroom K.F.F., 2020, POLL MOST AM WORR PO; O'Keefe S., 2020, ONE 3 AM WOULD NOT G; O'Neill M., 2020, HERALD MAIL MED 1013; Ognyanova K., 2020, STATE NATION 50 STAT, P23; Olson O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040590; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Pransky N., 2020, NBC SAN DIEGO 0402; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rambaran V., 2020, FOX NEWS 0527; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Saad, 2020, GALLUP; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Schmidt H, 2020, JAMA-J AM MED ASSOC, V324, P2023, DOI 10.1001/jama.2020.20571; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Silverman E., 2020, STAT-US; Stern AM, 2005, HEALTH AFFAIR, V24, P611, DOI 10.1377/hlthaff.24.3.611; Suffolk University, 2020, SUFF U US TOD POLL; Suffolk University, 2020, SUFF U US TOD POLL A; SYMPHONY, 2022, JAMA-J AM MED ASSOC; The Harris Poll, 2020, HARRIS POLL WAVE, V31, P262; Thigpen C., 2020, MOST AM EXPECT COVID; Thomas K., 2020, NEW YORK TIMES 1103; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; Tufts University's Research Group on Equity in Health, 2020, ONL 57 PERC AM SAY T; University of Texas, 2020, U TEX TEX TRIB POLL, P1; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Wieber F, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00395; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Orgnization, 2019, 10 THREATS GLOB HLTH; YouGov, 2020, EC YOUGOV POLL 20 OC; YouGov, 2020, EC YOUGOV POLL 25 AU, P1; YouGov, 2020, YAH NEWS COR, P1	130	222	225	30	80	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							16	10.3390/vaccines9010016			41	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PW6UB	33396832	Green Published, gold	Y	Y	2022-04-29	WOS:000610806000001
J	Li, YB; Li, ZF; Zhao, YW; Chen, XY				Li, Yibo; Li, Zhuofan; Zhao, Yiwen; Chen, Xinyuan			Potentiation of Recombinant NP and M1-Induced Cellular Immune Responses and Protection by Physical Radiofrequency Adjuvant	VACCINES			English	Article						radiofrequency; NP; M1; cross-presentation; adjuvant; influenza	INFLUENZA; VACCINE; H5N1	Nucleoprotein (NP) and matrix protein 1 (M1) are highly conserved among influenza A viruses and have been attractive targets to develop vaccines to elicit cross-reactive cytotoxic T lymphocytes (CTLs). Yet, external antigens are often presented on major histocompatibility complex class II molecules and elicit humoral immune responses. In this study, we present a physical radiofrequency adjuvant (RFA) to assist recombinant NP and M1 to elicit potent CTL responses. We found recombinant NP/M1 immunization in the presence of RFA could elicit potent anti-NP CTLs and confer significant protection against homologous viral challenges, while NP/M1 immunization alone failed to elicit significant CTL responses or confer significant protection. Interestingly, RFA failed to elicit potent anti-M1 CTL responses or anti-NP or anti-M1 antibody responses. Different from RFA, AddaVax adjuvant was found to significantly increase NP-specific antibody responses but not CTLs. NP/M1 immunization in the presence of RFA or AddaVax similarly reduced body weight loss, while only the former significantly increased the survival. We further found NP/M1 immunization in the presence of RFA did not significantly increase serum IL-6 release (a systemic inflammatory mediator) and rather reduced serum IL-6 release after boost immunization. NP/M1 immunization in the presence of RFA did not induce significant local reactions or increase body temperature of mice. The high potency and safety strongly support further development of RFA-based recombinant NP/M1 vaccine to elicit cross-protective immunity.	[Li, Yibo; Li, Zhuofan; Zhao, Yiwen; Chen, Xinyuan] Univ Rhode Isl, Coll Pharm, Biomed & Pharmaceut Sci, Kingston, RI 02881 USA		Chen, XY (通讯作者)，Univ Rhode Isl, Coll Pharm, Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	yibo_li@uri.edu; zhuofan_li@uri.edu; yiwen_zhao@uri.edu; xchen14@uri.edu		chen, xinyuan/0000-0003-4735-3922	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI139473]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of HealthGeneral Electric [P20GM103430]	This research was funded by the National Institutes of Health grants AI139473 (to X.C.). Microplate reader and BD FACSVerse used in this work are supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health grant P20GM103430.	Arunkumar GA, 2019, VACCINE, V37, P5567, DOI 10.1016/j.vaccine.2019.07.095; Cao Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06151-y; Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168; Chen XY, 2011, EXPERT REV VACCINES, V10, P1397, DOI [10.1586/erv.11.112, 10.1586/ERV.11.112]; Cottey R, 2001, CURRENT PROTOCOLS IM; Epstein SL, 2005, VACCINE, V23, P5404, DOI 10.1016/j.vaccine.2005.04.047; Cargnelutti DE, 2013, BIOENGINEERED, V4, P374, DOI 10.4161/bioe.23573; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Huang CF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55281-w; Joe PT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1991-3; Lambe T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01443; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Lee LYY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01568; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; Li ZF, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.nsight.144627; McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005; McMahon M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02005; Nanishi E, 2020, CURR OPIN PEDIATR, V32, P125, DOI 10.1097/MOP.0000000000000868; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Ostrowsky J, 2020, CURR OPIN VIROL, V40, P28, DOI 10.1016/j.coviro.2020.02.003; Quan FS, 2012, VIROLOGY, V430, P127, DOI 10.1016/j.virol.2012.05.006; Roy S, 2007, VACCINE, V25, P6845, DOI 10.1016/j.vaccine.2007.07.035; Uchida T, 2011, MICROBIOL IMMUNOL, V55, P19, DOI 10.1111/j.1348-0421.2010.00273.x; Vitelli A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055435; Wang BZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013972; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; Zhao YW, 2020, BIOMATERIALS, V249, DOI 10.1016/j.biomaterials.2020.120030	28	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1382	10.3390/vaccines9121382			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9WK	34960128	Green Published, gold			2022-04-29	WOS:000778391900001
J	Maj, M; Fake, GM; Walker, JH; Saltzman, R; Howard, JA				Maj, Magdalena; Fake, Gina M.; Walker, John H.; Saltzman, Ryan; Howard, John A.			Oral Administration of Coronavirus Spike Protein Provides Protection to Newborn Pigs When Challenged with PEDV	VACCINES			English	Article						PEDV; spike protein; oral delivery; passive immunity; cytokines; GM-CSF; plant-produced vaccines; maize	EPIDEMIC DIARRHEA VIRUS; RECOMBINANT S1 DOMAIN; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSES; GM-CSF; VACCINES; DELIVERY; MUCOSAL; EXPRESSION; SUBUNIT	To investigate whether oral administration of maize-produced S antigen can provide passive immunity to piglets against porcine epidemic diarrhea virus (PEDV), 16 pregnant sows were randomly assigned to one of four treatments: (1) injection of PEDV vaccine (INJ), (2) maize grain without S protein (CON), (3) maize grain containing low dose of S antigen (LOV) and (4) maize grain containing a high dose of S antigen (HOV). Vaccines were administered on days 57, 85 and 110 of gestation. Sows' serum and colostrum were collected at farrowing and milk on day 6 post-challenge to quantify neutralizing antibodies (NABs) and cytokines. Piglets were challenged with PEDV 3-5 d after farrowing, and severity of disease and mortality assessed on day 11 post-challenge. Disease severity was lower in LOV and INJ compared with HOV and CON, whereas the survival rate increased in piglets from LOV sows compared with HOV and CON (p <= 0.001). Higher titers of NABs and lower levels of cytokine granulocyte-macrophage colony-stimulating factor in sows' milk were positively correlated with piglet survivability (p <= 0.05). These data suggest that feeding S protein in corn to pregnant sows protects nursing piglets against PEDV.	[Maj, Magdalena] Calif Polytech State Univ San Luis Obispo, Dept Biol Sci, San Luis Obispo, CA 93407 USA; [Fake, Gina M.; Howard, John A.] Appl Biotechnol Inst, Cal Poly Tech Pk, San Luis Obispo, CA 93407 USA; [Walker, John H.] Calif Polytech State Univ San Luis Obispo, Dept Stat, San Luis Obispo, CA 93407 USA; [Saltzman, Ryan] Vet Resources Inc, Ames, IA 50010 USA		Howard, JA (通讯作者)，Appl Biotechnol Inst, Cal Poly Tech Pk, San Luis Obispo, CA 93407 USA.	mmaj@calpoly.edu; gfake@appliedbiotech.org; jwalker@calpoly.edu; vetres2@msn.com; jhoward@appliedbiotech.org					Ansariniya H, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8870425; Bae JL, 2003, VACCINE, V21, P4052, DOI 10.1016/S0264-410X(03)00360-8; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Chang SH, 2002, MOL CELLS, V14, P295; Clement T, 2016, J SWINE HEALTH PROD, V24, P147; COUSSEMENT W, 1982, VET PATHOL, V19, P46, DOI 10.1177/030098588201900108; CURTIS J, 1971, BIOCHIM BIOPHYS ACTA, V236, P319, DOI 10.1016/0005-2795(71)90181-4; Egelkrout E, 2020, PLANT CELL TISS ORG, V142, P79, DOI 10.1007/s11240-020-01835-0; Gao Q, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.697839; Gerdts V, 2017, VET MICROBIOL, V206, P45, DOI 10.1016/j.vetmic.2016.11.029; Hansen G, 2008, CELL, V134, P496, DOI 10.1016/j.cell.2008.05.053; Hayden CA, 2015, VACCINE, V33, P2881, DOI 10.1016/j.vaccine.2015.04.080; Hood EE, 1999, ADV EXP MED BIOL, V464, P127; Hood Elizabeth E., 2009, V63, P91; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; Hou XY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030106; Kang TJ, 2005, VACCINE, V23, P2294, DOI 10.1016/j.vaccine.2005.01.027; Lamphear BJ, 2004, VACCINE, V22, P2420, DOI 10.1016/j.vaccine.2003.11.066; Lamphear BJ, 2002, J CONTROL RELEASE, V85, P169, DOI 10.1016/S0168-3659(02)00282-1; Langel SN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020130; Lee C, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0421-2; Lee KMC, 2020, IMMUNOTARGETS THER, V9, P225, DOI 10.2147/ITT.S262566; Lenth RV, emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.7.2. 2022; Li CH, 2017, J VIROL, V91, DOI [10.1128/JVI.00273-17, 10.1128/jvi.00273-17]; Liu DQ, 2012, APPL MICROBIOL BIOT, V93, P2437, DOI 10.1007/s00253-011-3734-0; Ludecke D., 2021, J OPEN SOURCE SOFTW, V6, P3139, DOI [DOI 10.21105/JOSS.03139, 10.21105/joss.03139]; Machado G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36934-8; Makadiya N, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0512-8; Man Kun, 2014, Journal of Agricultural Science and Technology (Beijing), V16, P28; Markowska-Daniel I, 2010, POL J VET SCI, V13, P21; McIntosh K., 2015, MANDELL DOUGLAS BENN, Ve2, P1928, DOI DOI 10.1016/B978-1-4557-4801-3.00157-0; Modelska A, 1998, P NATL ACAD SCI USA, V95, P2481, DOI 10.1073/pnas.95.5.2481; Mota RM, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-2; Nguyen TV, 2007, VET IMMUNOL IMMUNOP, V117, P236, DOI 10.1016/j.vetimm.2007.02.013; Noi NV, 2017, BIOTECHNOL BIOTEC EQ, V31, P619, DOI 10.1080/13102818.2017.1308231; Tien NQD, 2019, PLANT CELL TISS ORG, V137, P213, DOI 10.1007/s11240-019-01562-1; Huy NX, 2012, PLANT CELL REP, V31, P1933, DOI 10.1007/s00299-012-1306-0; Oh J, 2014, ARCH VIROL, V159, P2977, DOI 10.1007/s00705-014-2163-7; Okda FA, 2017, VIROLOGY, V509, P185, DOI 10.1016/j.virol.2017.06.013; Peiris J. S. M., 2012, Medical microbiology: a guide to microbial infections: pathogenesis, immunity, laboratory investigation and control, P587; Piao DC, 2016, PROTEIN EXPRES PURIF, V126, P77, DOI 10.1016/j.pep.2016.05.018; R Core Team, 2020, R LANGUAGE ENV STAT; Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859; Sarmento LV, 2020, J VET DIAGN INVEST, V32, P324, DOI 10.1177/1040638720903346; Song QY, 2016, VIRUS RES, V226, P85, DOI 10.1016/j.virusres.2016.06.002; Streatfield SJ, 2001, VACCINE, V19, P2742, DOI 10.1016/S0264-410X(00)00512-0; Sun DB, 2008, VET MICROBIOL, V131, P73, DOI 10.1016/j.vetmic.2008.02.022; Tacket CO, 2009, CURR TOP MICROBIOL, V332, P103, DOI 10.1007/978-3-540-70868-1_6; Wang JL, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182028; Xu RJ, 1999, BIOL NEONATE, V75, P59, DOI 10.1159/000014078	51	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1416	10.3390/vaccines9121416			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0TB	34960163	gold, Green Published			2022-04-29	WOS:000737374000001
J	Matsumoto, K; Fukushima, W; Morikawa, S; Fujioka, M; Matsushita, T; Kubota, M; Yagi, Y; Takasaki, Y; Shindo, S; Yamashita, Y; Yokoyama, T; Kiyomatsu, Y; Hiroi, S; Nakata, K; Maeda, A; Kondo, K; Ito, K; Kase, T; Ohfuji, S; Hirota, Y				Matsumoto, Kazuhiro; Fukushima, Wakaba; Morikawa, Saeko; Fujioka, Masashi; Matsushita, Tohru; Kubota, Megumi; Yagi, Yoshina; Takasaki, Yoshio; Shindo, Shizuo; Yamashita, Yuji; Yokoyama, Takato; Kiyomatsu, Yumi; Hiroi, Satoshi; Nakata, Keiko; Maeda, Akiko; Kondo, Kyoko; Ito, Kazuya; Kase, Tetsuo; Ohfuji, Satoko; Hirota, Yoshio			Influence of Prior Influenza Vaccination on Current Influenza Vaccine Effectiveness in Children Aged 1 to 5 Years	VACCINES			English	Article						influenza; repeated vaccination; test-negative design	IMPACT; VIRUS; HOSPITALIZATION; POPULATION; EFFICACY; IMMUNITY; A(H3N2); SEASON	Background: Although annual influenza vaccination is an important strategy used to prevent influenza-related morbidity and mortality, some studies have reported the negative influence of prior vaccination on vaccine effectiveness (VE) for current seasons. Currently, the influence of prior vaccination is not conclusive, especially in children. Methods: We evaluated the association between current-season VE and prior season vaccination using a test-negative design in children aged 1-5 years presenting at nine outpatient clinics in Japan during the 2016/17 and 2017/18 influenza seasons. Children with influenza-like illness were enrolled prospectively and tested for influenza using real-time RT-PCR. Their recent vaccination history was categorized into six groups according to current vaccination doses (0/1/2) and prior vaccination status (unvaccinated = 0 doses/vaccinated = 1 dose or 2 doses): (1) 0 doses in the current season and unvaccinated in prior seasons (reference group); (2) 0 doses in the current season and vaccinated in a prior season; (3) 1 dose in the current season and unvaccinated in a prior season; (4) 1 dose in the current season and vaccinated in a prior season; (5) 2 doses in the current season and unvaccinated in a prior season, and (6) 2 doses in the current season and vaccinated in a prior season. Results: A total of 799 cases and 1196 controls were analyzed. The median age of the subjects was 3 years, and the proportion of males was 54%. Overall, the vaccination rates (any vaccination in the current season) in the cases and controls were 36% and 53%, respectively. The VEs of the groups were: (2) 29% (95% confidence interval: -25% to 59%); (3) 53% (6% to 76%); (4) 70% (45% to 83%); (5) 56% (32% to 72%), and (6) 61% (42% to 73%). The one- and two-dose VEs of the current season were significant regardless of prior vaccination status. The results did not differ when stratified by influenza subtype/lineage. Conclusion: Prior vaccination did not attenuate the current-season VE in children aged 1 to 5 years, supporting the annual vaccination strategy.	[Matsumoto, Kazuhiro; Fukushima, Wakaba; Maeda, Akiko; Ito, Kazuya; Kase, Tetsuo; Ohfuji, Satoko] Osaka City Univ, Grad Sch Med, Dept Publ Hlth, Osaka 5458585, Japan; [Fukushima, Wakaba; Ito, Kazuya; Kase, Tetsuo; Ohfuji, Satoko] Osaka City Univ, Grad Sch Med, Res Ctr Infect Dis Sci, Osaka 5458585, Japan; [Morikawa, Saeko; Hiroi, Satoshi; Nakata, Keiko] Osaka Inst Publ Hlth, Dept Virol, Osaka 5370025, Japan; [Fujioka, Masashi] Fujioka Pediat Clin, Tondabayashi 5840074, Japan; [Matsushita, Tohru] Matsushita Kids Clin, Kadoma, Osaka 5710030, Japan; [Kubota, Megumi] Kubota Childrens Clin, Osaka 5440033, Japan; [Yagi, Yoshina] Yagi Pediat Clin, Yao 5810871, Japan; [Takasaki, Yoshio] Takasaki Pediat Clin, Fukuoka 8190052, Japan; [Shindo, Shizuo] Shindo Childrens Clin, Fukuoka 8140121, Japan; [Yamashita, Yuji] Yamashita Pediat Clin, Itoshima 8191112, Japan; [Yokoyama, Takato] Yokoyama Childrens Clin, Kasuga, Fukuoka 8160801, Japan; [Kiyomatsu, Yumi] Kiyomatsu Pediat Clin, Fukuoka 8140021, Japan; [Kondo, Kyoko] Osaka City Univ Hosp, Management Bur, Osaka 5458586, Japan; [Ito, Kazuya] Coll Healthcare Management, Healthcare Management, Miyama 8350018, Japan; [Ito, Kazuya; Hirota, Yoshio] SOUSEIKAI, Clin Epidemiol Res Ctr, Fukuoka 8130017, Japan		Matsumoto, K (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Publ Hlth, Osaka 5458585, Japan.	kmatsumoto0418@yahoo.co.jp; wakaba@med.osaka-cu.ac.jp; morikawa@iph.osaka.jp; fjok@silver.ocn.ne.jp; matsushita@kids-clinic.com; meg@ki.rim.or.jp; yagi-ped@hera.eonet.ne.jp; yositakasaki@nifty.com; szshindo@nifty.com; yuji-yamashita@hyu.bbiq.jp; yokoyama_rnk2101@yahoo.co.jp; yumi-ped@kb3.so-net.ne.jp; hiroi@iph.osaka.jp; knakata@iph.osaka.jp; maedaakiko@nifty.com; kyou@med.osaka-cu.ac.jp; kaz-ito@healthcare-m.ac.jp; kasetetsuo143@msic.med.osaka-cu.ac.jp; satop@med.osaka-cu.ac.jp; hiro8yoshi@lta-med.com		Fukushima, Wakaba/0000-0002-3666-6942; Kubota, Megumi/0000-0002-1169-623X	Ministry of Health, Labor and Welfare, JapanMinistry of Health, Labour and Welfare, Japan [H26-SHINKOGYOSEI-SHITEI-003, H29-SHINKOGYOSEI-SHITEI-003]; research grant for JSPS KAKENHI [19H03890]	This study was supported by a research grant for Research on Emerging and Re-emerging Infectious Diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labor and Welfare, Japan (grant number: H26-SHINKOGYOSEI-SHITEI-003 and H29-SHINKOGYOSEI-SHITEI-003) and a research grant for JSPS KAKENHI (grant number: 19H03890).	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Beyer WEP, 1999, ARCH INTERN MED, V159, P182, DOI 10.1001/archinte.159.2.182; Bodewes R, 2012, VACCINE, V30, P7407, DOI 10.1016/j.vaccine.2012.04.086; Bodewes R, 2011, J VIROL, V85, P11995, DOI 10.1128/JVI.05213-11; Caspard H, 2016, HUM VACC IMMUNOTHER, V12, P1721, DOI 10.1080/21645515.2015.1115164; Castilla J, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.7.30465; Cheng AC, 2017, CLIN INFECT DIS, V64, P1564, DOI 10.1093/cid/cix209; Foppa IM, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100008; HOSKINS TW, 1979, LANCET, V1, P33; Hsu PS, 2020, CLIN INTERV AGING, V15, P301, DOI 10.2147/CIA.S238786; Ito K, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011551, 10.1097/md.0000000000011551]; Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0; Kim JH, 2016, J INFECT DIS, V214, P1030, DOI 10.1093/infdis/jiw311; Kim SS, 2021, CLIN INFECT DIS, V73, P497, DOI 10.1093/cid/ciaa706; Kwong JC, 2020, EUROSURVEILLANCE, V25, P21, DOI 10.2807/1560-7917.ES.2020.25.1.1900245; McLean HQ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3742; McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680; Nakauchi M, 2014, J VIROL METHODS, V205, P110, DOI 10.1016/j.jviromet.2014.04.016; Nakauchi M, 2011, J VIROL METHODS, V171, P156, DOI 10.1016/j.jviromet.2010.10.018; Ohmit SE, 2015, J INFECT DIS, V211, P1519, DOI 10.1093/infdis/jiu650; Ohta A, 2007, J EPIDEMIOL, V17, pS14, DOI 10.2188/jea.17.S14; Ramsay LC, 2019, BMC MED, V17, DOI 10.1186/s12916-018-1239-8; Saito N, 2017, VACCINE, V35, P687, DOI 10.1016/j.vaccine.2016.11.024; Sasaki S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002975; Shinjoh M, 2018, VACCINE, V36, P5510, DOI 10.1016/j.vaccine.2018.07.065; Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176; Song JY, 2020, VACCINE, V38, P318, DOI 10.1016/j.vaccine.2019.10.012; Thompson MG, 2016, VACCINE, V34, P981, DOI 10.1016/j.vaccine.2015.10.119; Valenciano M, 2018, INFLUENZA OTHER RESP, V12, P567, DOI 10.1111/irv.12562	30	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1447	10.3390/vaccines9121447			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9YM	34960193	gold, Green Published			2022-04-29	WOS:000778397900001
J	Shehab, M; Alrashed, F; Alfadhli, A; Alotaibi, K; Alsahli, A; Mohammad, H; Cherian, P; Al-Khairi, I; Thanaraj, TA; Channanath, A; Ali, H; Abu-Farha, M; Abubaker, J; Al-Mulla, F				Shehab, Mohammad; Alrashed, Fatema; Alfadhli, Ahmad; Alotaibi, Khazna; Alsahli, Abdullah; Mohammad, Hussain; Cherian, Preethi; Al-Khairi, Irina; Alphonse Thanaraj, Thangavel; Channanath, Arshad; Ali, Hamad; Abu-Farha, Mohamed; Abubaker, Jehad; Al-Mulla, Fahd			Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies	VACCINES			English	Article						IBD; COVID-19; vaccine; immunogenicity; infliximab; adalimumab; vedolizumbab; ustekinumab; biologic therapies	VACCINATION	Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Methods: We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4-10 weeks after their second dose or 3-6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results: A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn's disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. Conclusions: The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time.	[Shehab, Mohammad; Alfadhli, Ahmad; Alotaibi, Khazna; Alsahli, Abdullah; Mohammad, Hussain] Kuwait Univ, Mubarak Alkabeer Univ Hosp, Dept Internal Med, Div Gastroenterol, Kuwait 47060, Kuwait; [Alrashed, Fatema] Kuwait Univ, Fac Pharm, Hlth Sci Ctr HSC, Dept Pharm Practice, Kuwait 13110, Kuwait; [Cherian, Preethi; Al-Khairi, Irina; Abu-Farha, Mohamed; Abubaker, Jehad] Dasman Diabet Inst DDI, Dept Biochem & Mol Biol, Kuwait 15462, Kuwait; [Alphonse Thanaraj, Thangavel; Channanath, Arshad; Ali, Hamad; Al-Mulla, Fahd] Dasman Diabet Inst DDI, Dept Genet & Bioinformat, Kuwait 15462, Kuwait; [Ali, Hamad] Kuwait Univ, Fac Allied Hlth Sci, Hlth Sci Ctr HSC, Dept Med Lab Sci, Kuwait 13110, Kuwait		Shehab, M (通讯作者)，Kuwait Univ, Mubarak Alkabeer Univ Hosp, Dept Internal Med, Div Gastroenterol, Kuwait 47060, Kuwait.; Al-Mulla, F (通讯作者)，Dasman Diabet Inst DDI, Dept Genet & Bioinformat, Kuwait 15462, Kuwait.	moshehab@moh.gov.kw; falra1@stu.mcphs.edu; abd0180037@ju.edu.jo; Khaznanto@agu.edu.bh; abd0180037@ju.edu.jo; Hussainmohammad@rcsi.com; preethi.cherian@dasmaninstitute.org; irina.alkhairi@dasmaninstitute.org; alphonse.thangavel@dasmaninstitute.org; arshad.channanath@dasmaninstitute.org; hamad.ali@dasmaninstitute.org; mohamed.abufarha@dasmaninstitute.org; jehad.abubakr@dasmaninstitute.org; fahd.almulla@dasmaninstitute.org	Al-Mulla, Fahd/E-2068-2015	Al-Mulla, Fahd/0000-0001-5409-3829; Abu-Farha, Mohamed/0000-0001-8357-1252; Shehab, Mohammad/0000-0003-2084-3956; Yaseen Ali, Hamad/0000-0001-6623-3374	Kuwait Foundation for the Advancement of Sciences (KFAS)Kuwait Foundation for the Advancement of Sciences (KFAS) [RA HM-2021-008]	This Study was funded by the Kuwait Foundation for the Advancement of Sciences (KFAS) grant (RA HM-2021-008).	Abu-Raddad LJ, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab083; Alexander J.L., POSITION STATEMENT S; Alrashed F, 2021, BMJ OPEN GASTROENTER, V8, DOI 10.1136/bmjgast-2021-000774; Ben-Tov A, 2021, GASTROENTEROLOGY, V161, P1715, DOI 10.1053/j.gastro.2021.06.076; Billmeier U, 2016, WORLD J GASTROENTERO, V22, P9300, DOI 10.3748/wjg.v22.i42.9300; CDC, HUM COR TYP COVID 19; Deepak P, 2021, ANN INTERN MED, V174, P1572, DOI 10.7326/M21-1757; FDA/CEDR Resources Page, FDA AUTH BOOST DOS P; Feuerstein JD, 2020, GASTROENTEROLOGY, V158, P1450, DOI 10.1053/j.gastro.2020.01.006; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Kennedy NA, 2021, GUT, V70, P1884, DOI 10.1136/gutjnl-2021-324789; Khan N, 2021, GASTROENTEROLOGY, V161, P827, DOI 10.1053/j.gastro.2021.05.044; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012; Lichtenstein GR, 2012, AM J GASTROENTEROL, V107, P1409, DOI 10.1038/ajg.2012.218; Lin S., 2021, RES SQUARE, DOI [10.21203/rs.3.rs-755879/v1, DOI 10.21203/RS.3.RS-755879/V1]; Macaluso FS, 2019, EXPERT OPIN BIOL TH, V19, P89, DOI 10.1080/14712598.2019.1561850; Melmed GY, 2021, ANN INTERN MED, V174, P1768, DOI 10.7326/M21-2483; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002; Salvagno GL, 2021, J MED BIOCHEM, V40, P327, DOI 10.5937/jomb0-32373; Shi XJ, 2021, STEM CELL RES, V50, DOI 10.1016/j.scr.2020.102125; Siegel CA, 2021, GUT, V70, P635, DOI 10.1136/gutjnl-2020-324000; Terdiman JP, 2013, GASTROENTEROLOGY, V145, P1459, DOI 10.1053/j.gastro.2013.10.047; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Wong SY, 2021, GASTROENTEROLOGY, V161, P715, DOI 10.1053/j.gastro.2021.04.025; World Health Organization, 2004, ICD 10 INT STAT CLAS; Wyant T, 2015, GUT, V64, P77, DOI 10.1136/gutjnl-2014-307127	28	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1471	10.3390/vaccines9121471			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0JI	34960217	Green Published, gold			2022-04-29	WOS:000737348600001
J	Baccolini, V; Renzi, E; Isonne, C; Migliara, G; Massimi, A; De Vito, C; Marzuillo, C; Villari, P				Baccolini, Valentina; Renzi, Erika; Isonne, Claudia; Migliara, Giuseppe; Massimi, Azzurra; De Vito, Corrado; Marzuillo, Carolina; Villari, Paolo			COVID-19 Vaccine Hesitancy among Italian University Students: A Cross-Sectional Survey during the First Months of the Vaccination Campaign	VACCINES			English	Article						vaccine hesitancy; COVID-19; students	WILLINGNESS; ATTITUDES	Achieving high levels of vaccination coverage against COVID-19 may be hindered by vaccine hesitancy. We quantified over time the prevalence of COVID-19 vaccine hesitancy among university students, investigated its determinants, and analyzed student attitudes, risk perceptions and compliance with preventive measures. The survey was administered online from 1 March to 30 June 2021. A multivariable logistic regression model was built to identify predictors of hesitancy. Overall, we collected 5369 questionnaires that were grouped into three survey periods (March, April-May, and May-June). The response rate ranged from 81.2% to 76.4%, whereas vaccine hesitancy ranged from 22% to 29%. Multivariable analysis showed that April-May participants had higher odds of hesitancy than March respondents. Other positive predictors were being male, not being a healthcare student, having a lower academic level, and not disclosing a political position. Conversely, higher levels of perceived COVID-19 severity, concern for the emergency, confidence in vaccine safety and effectiveness, and self-reported adherence to mask wearing indoors and outdoors were negatively associated with hesitancy. We found that vaccine hesitancy changed over time and in relation to several factors. Strategies aimed at increasing the students' awareness and engagement, restoring confidence in health authorities, and limiting disinformation around the vaccines should be devised.	[Baccolini, Valentina; Renzi, Erika; Isonne, Claudia; Migliara, Giuseppe; Massimi, Azzurra; De Vito, Corrado; Marzuillo, Carolina; Villari, Paolo] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy		Baccolini, V (通讯作者)，Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy.	valentina.baccolini@uniroma1.it; erika.renzi@uniroma1.it; claudia.isonne@uniroma1.it; giuseppe.migliara@uniroma1.it; azzurra.massimi@uniroma1.it; corrado.devito@uniroma1.it; carolina.marzuillo@uniroma1.it; paolo.villari@uniroma1.it		villari, paolo/0000-0002-3139-0668; Baccolini, Valentina/0000-0002-7873-7817; Renzi, Erika/0000-0001-9760-0245; MARZUILLO, CAROLINA/0000-0002-7299-5727			Adamo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226513; Adamo G, 2016, EPIDEMIOL BIOSTAT PU, V13, DOI 10.2427/12075; Afifi TO, 2021, VACCINE, V39, P3473, DOI 10.1016/j.vaccine.2021.05.026; [Anonymous], 2020, SURV TOOL GUID BEH I; Baccolini V, 2021, J GEN INTERN MED, V36, P753, DOI 10.1007/s11606-020-06407-8; Baccolini V, 2020, HUM VACC IMMUNOTHER, V16, P2618, DOI 10.1080/21645515.2020.1737458; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Dal-Re R, 2021, EUR J INTERN MED, V87, P104, DOI 10.1016/j.ejim.2021.01.030; European Centre for Disease Prevention and Control (ECDC), 2020, GUIDELINES IMPLEMENT; European Centre for Disease Prevention and Control (ECDC), 2021, INT GUID BEN FULL VA; European Centre for Disease Prevention and control (ECDC), 2021, OV IMPL COVID 19 VAC; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Italian Medicines Agency (AIFA), 2021, 3 AIFA; Kawata K, 2021, SSM-POPUL HLTH, V15, DOI 10.1016/j.ssmph.2021.100902; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; Kim C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250358; Kreps SE, 2021, VACCINE, V39, P3250, DOI 10.1016/j.vaccine.2021.04.044; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mant M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255447; Mateo-Urdiales A, 2021, VACCINE, V39, P4788, DOI 10.1016/j.vaccine.2021.07.003; Mathieu E., CORONAVIRUS PANDEMIC; Monod M, 2021, SCIENCE, V371, P1336, DOI 10.1126/science.abe8372; Napolitano F, 2016, HUM VACC IMMUNOTHER, V12, P1504, DOI 10.1080/21645515.2016.1156271; Pitini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060580; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Rosselli R, 2016, J Prev Med Hyg, V57, pE47; Rosso A, 2020, HUM VACC IMMUNOTHER, V16, P1969, DOI 10.1080/21645515.2019.1698901; Rosso A, 2019, VACCINE, V37, P1954, DOI 10.1016/j.vaccine.2019.02.049; Salerno L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080927; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schneider CR, 2021, J RISK RES, V24, P294, DOI 10.1080/13669877.2021.1890637; Sindoni A, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1950505; Sprengholz P, 2021, EUR J INTERN MED, V87, P106, DOI 10.1016/j.ejim.2021.03.015; Talbot D, 2019, EUR J EPIDEMIOL, V34, P725, DOI 10.1007/s10654-019-00529-y; Tavolacci MP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060654; van Loenhout JAF, 2021, ARCH PUBLIC HEALTH, V79, DOI 10.1186/s13690-021-00565-9; Vraga, 2021, COVID 19 VACCINE COM; Walker AN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060585; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Wilder-Smith AB, 2020, J EPIDEMIOL GLOB HEA, V10, P46, DOI 10.2991/jegh.k.191117.001; World Health Organization, 2020, BEH CONS ACC UPT COV; World Health Organization, 2016, BARR INFL VACC INT B; World Health Organization, 2020, GLOBAL TUBERCULOSIS	48	7	7	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1292	10.3390/vaccines9111292			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XG4MT	34835223	gold, Green Published			2022-04-29	WOS:000724729200001
J	Flisiak, R; Pawlowska, M; Rogalska-Plonska, M; Bociaga-Jasik, M; Klos, K; Piekarska, A; Zarebska-Michaluk, D				Flisiak, Robert; Pawlowska, Malgorzata; Rogalska-Plonska, Magdalena; Bociaga-Jasik, Monika; Klos, Krzysztof; Piekarska, Anna; Zarebska-Michaluk, Dorota			Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccination		The current study aimed to determine to what extent prior COVID-19 infection affects the response of specific antibodies following vaccination. The study involved 173 healthcare professionals who completed the two-dose vaccination course with BNT162b2, including 40 who previously experienced clinical COVID-19. The levels of anti-SARS-CoV-2 S1S2 IgG (anti-S) and, in some cases, anti-SARS-CoV-S-RBD IgG (anti-S-RBD) were determined six months after complete vaccination. A level exceeding the cut-off values for both anti-S and anti-S-RBD was observed in 100% of subjects, but after setting the analysis to 5- and 10-fold cut-off levels, the percentage of subjects meeting this criterion was significantly higher for anti-S-RBD. The 100-fold cut-off level was achieved by only 21% and 16% for anti-S and anti-S-RBD, respectively. Anti-S and anti-S-RBD levels above ten times the positive cut-off were respectively observed in 91% and 100% individuals with a history of COVID-19, while among those without COVID-19, these values were 64% and 90%, respectively. Significantly higher incidence of values above 10 and 100 times the cut-off became apparent among people with a history of COVID-19. In conclusion, vaccination against COVID-19 following infection with the disease provides higher levels of specific antibodies 6 months after vaccination than those of individuals without a history of the disease, which supports the use of a booster dose, particularly for those who have not experienced SARS-CoV-2 infection.	[Flisiak, Robert; Rogalska-Plonska, Magdalena] Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Balystok, Poland; [Pawlowska, Malgorzata] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Fac Med, Dept Infect Dis & Hepatol, PL-85067 Bydgoszcz, Poland; [Bociaga-Jasik, Monika] Jagiellonian Univ, Med Coll, Dept Infect & Trop Dis, PL-31007 Krakow, Poland; [Klos, Krzysztof] Mil Inst Med, Dept Infect Dis & Allergol, PL-04141 Warsaw, Poland; [Piekarska, Anna] Med Univ Lodz, Dept Infect Dis & Hepatol, PL-90419 Lodz, Poland; [Zarebska-Michaluk, Dorota] Jan Kochanowski Univ Humanities & Sci, Dept Infect Dis, PL-25317 Kielce, Poland		Flisiak, R (通讯作者)，Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Balystok, Poland.	mpawlowska@cm.umk.pl; monika.bociagajasik@gmail.com; kklos@wim.mil.pl; annapiekar@gmail.com; dorota1010@tlen.pl	Zarębska-Michaluk, Dorota/R-1325-2019; Pawlowska, Malgorzata/F-4209-2014; Flisiak, Robert/S-5356-2018	Zarębska-Michaluk, Dorota/0000-0003-0938-1084; Klos, Krzysztof/0000-0001-9629-5680; Piekarska, Anna/0000-0002-7188-4881; Pawlowska, Malgorzata/0000-0002-6044-0425; Flisiak, Robert/0000-0003-3394-1635	Medical Research Agency in Poland [2020/ABM/COVID19/PTEILCHZ]	FundingThis research was supported by the Medical Research Agency in Poland, grant number 2020/ABM/COVID19/PTEILCHZ.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chemaitelly H, 2021, NEW ENGL J MED, V385, pE83, DOI 10.1056/NEJMoa2114114; Dimeglio C, 2022, J INFECTION, V84, P257, DOI 10.1016/j.jinf.2021.09.013; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Haveri A, 2021, EUR J IMMUNOL, V51, P3202, DOI 10.1002/eji.202149535; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070781; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	11	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1325	10.3390/vaccines9111325			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK5YV	34835257	Green Published, gold			2022-04-29	WOS:000727541600001
J	Loubet, P; Rouviere, J; Merceron, A; Launay, O; Sotto, A				Loubet, Paul; Rouviere, Jalini; Merceron, Adeline; Launay, Odile; Sotto, Albert		AVNIR Grp	Patients' Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections	VACCINES			English	Article						COVID-19 vaccines; seasonal influenza vaccines; immunization; immunocompromised; pneumococcal vaccines; vaccination; vaccination coverage	PNEUMONIA	Introduction: The objective of our study was to assess, in an at-risk population, perception and knowledge about influenza and pneumococcal vaccinations. Methods: An anonymous web-based survey was submitted to patients recruited in France, from both an Ipsos internal panel and AVNIR patient associations. The study was conducted between July and October 2020, in the context of the COVID-19 pandemic. Results: Overall, 2177 questionnaires from patients at risk of infection were analyzed. Almost all respondents (86%, 1869/2177) declared themselves to be favorable to vaccination. Nearly half of the patients (49%, 1069/2177) were aware of which vaccine was recommended for their specific situation. This percentage was significantly (p < 0.001) higher for members of a patient association and for people affected by multiple chronic conditions and varied according to the type of condition. Almost two-thirds of patients (1373/2177) declared having been vaccinated during the 2019/2020 influenza season, and 41% (894/2177) were certain about being up to date with the pneumococcal vaccination. The main barriers to vaccination for influenza are the fear of side effects, doubt regarding the efficacy of the vaccine and for pneumococcal vaccination, and the absence of suggestions by the healthcare professionals (HCPs), as 64% of respondents were not recommended to obtain pneumococcal vaccination. To improve vaccine coverage, information is of prime importance and GPs are recognized as the main HCP to inform about vaccination. Nearly two-thirds (62%, 1360/2177) of patients declared that the COVID-19 pandemic convinced them to have all the recommended vaccines. Conclusion: Our study highlighted the nonoptimal vaccine coverage in at-risk populations despite a highly positive perception of vaccines and confirmed that physicians are on the front lines to suggest and recommend these vaccinations, especially in the current pandemic context, which may be used to promote other vaccines.	[Loubet, Paul; Sotto, Albert] Univ Montpellier, Dept Infect & Trop Dis, CHU Nimes, INSERM U1047, F-30900 Nimes, France; [Rouviere, Jalini] Pfizer, F-75668 Paris, France; [Merceron, Adeline] IPSOS, F-75013 Paris, France; [Launay, Odile] Univ Paris, Fac Med Paris Descartes, CIC Cochin Pasteur, AP HP,INSERM, F-75231 Paris, France		Loubet, P (通讯作者)，Univ Montpellier, Dept Infect & Trop Dis, CHU Nimes, INSERM U1047, F-30900 Nimes, France.	paul.loubet@chu-nimes.fr; jalini.rouviere@pfizer.com; adeline.merceron@ipsos.com; odile.launay@aphp.fr; albert.sotto@chu-nimes.fr	Sotto, Albert/AFJ-9023-2022	Sotto, Albert/0000-0002-6463-9386	PfizerPfizer	A prospective web-based survey was conducted by Ipsos, the largest French company in market and public opinion research, from 29 July 2020 to 12 October 2020. The sample has been previously targeted and investigated throughout the Ipsos Access panel and through AVNIR. Ipsos was in charge of the recruitment of 800 from its own panel, of the hosting of the whole sample data of 2177 respondents and achieved data processing. Ipsos was funded by Pfizer. Pfizer contributed to the study design with P.L. and AVNIR, and Pfizer contributed to the decision to publish. Pfizer had no role in data analysis and the preparation of the manuscript.	Akmatov MK, 2021, VACCINE, V39, P952, DOI 10.1016/j.vaccine.2020.12.081; [Anonymous], SEASONAL INFLUENZA V; [Anonymous], Donnees de Couverture Vaccinale Grippe par Groupe D'age; Berrada S, 2021, ANN PHARM FR, V79, P77, DOI 10.1016/j.pharma.2020.09.004; Boey L, 2020, HUM VACC IMMUNOTHER, V16, P2136, DOI 10.1080/21645515.2020.1763739; Chen L, 2021, ANN CLIN MICROB ANTI, V20, DOI 10.1186/s12941-021-00462-7; Chow EJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1323; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Doornekamp L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030480; Gaillat J, 2019, REV MAL RESPIR, V36, P962, DOI 10.1016/j.rmr.2018.10.620; HCSP, REC ACT; HCSP, 2017, INF PNEUM REC VACC A; Heo JY, 2018, HUM VACC IMMUNOTHER, V14, P744, DOI 10.1080/21645515.2017.1405200; Kopp A, 2021, HUM VACC IMMUNOTHER, V17, P162, DOI 10.1080/21645515.2020.1756669; Le Calendrier des Vaccinations, CAL VACC; Loubet P, 2018, DIGEST LIVER DIS, V50, P563, DOI 10.1016/j.dld.2017.12.027; Loubet P, 2016, EXPERT REV VACCINES, V15, P1507, DOI 10.1080/14760584.2016.1188696; Loubet P, 2015, VACCINE, V33, P3703, DOI 10.1016/j.vaccine.2015.06.012; Matthews I, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09613-5; Okoli GN, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab069; de la Cruz SP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020327; Robert J, 2020, MED MALADIES INFECT, V50, P670, DOI 10.1016/j.medmal.2019.12.004; Schmedt N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220848; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shigayeva A, 2016, CLIN INFECT DIS, V62, P139, DOI 10.1093/cid/civ803; Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007; Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI [10.1016/S2213-2600(18)30496-X, 10.1016/s2213-2600(18)30496-x]; van Aalst M, 2018, TRAVEL MED INFECT DI, V24, P89, DOI 10.1016/j.tmaid.2018.05.016	28	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1372	10.3390/vaccines9111372			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1GM	34835303	Green Published, gold			2022-04-29	WOS:000725189700001
J	Nioi, M; d'Aloja, E; Fossarello, M; Napoli, PE				Nioi, Matteo; d'Aloja, Ernesto; Fossarello, Maurizio; Napoli, Pietro Emanuele			Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns	VACCINES			English	Article						COVID-19; BNT162b2 vaccine; BNT162b2 vaccine side effect; COVID-19 vaccines corneal graft; COVID-19 vaccines transplant rejection; COVID-19 vaccines and corneal graft rejection; COVID-19 immunomodulation; COVID-19 vaccines side effects; COVID-19 vaccines immunomodulation; COVID-19 vaccines vitamin D	VITAMIN-D; ALLOGRAFT-REJECTION; CELLS	Present mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not described during the experimental stages. In the present study, we discuss a case of acute corneal graft rejection, which has occurred 25 years after transplantation and 13 days after the administration of the BNT162b2 vaccine (Comirnaty, BioNTech/Pfizer), which was followed-up for a period of six months. In this period, the corneal inflammation appeared twice but was successfully managed with topical therapy and supplementation of Vitamin D. A risk of corneal graft rejection must be included in the list of potential vaccine complications, in order to inform the transplanted patient to undergo a preliminary and a follow-up ocular examination, and eventually to include corneal graft in the list of contraindications to vaccination.	[Nioi, Matteo; d'Aloja, Ernesto] Univ Cagliari, Dept Med Sci & Publ Hlth, Forens Med Unit, I-09040 Cagliari, Italy; [Fossarello, Maurizio; Napoli, Pietro Emanuele] Univ Cagliari, Dept Surg Sci, Eye Clin, I-09124 Cagliari, Italy		Nioi, M (通讯作者)，Univ Cagliari, Dept Med Sci & Publ Hlth, Forens Med Unit, I-09040 Cagliari, Italy.; Napoli, PE (通讯作者)，Univ Cagliari, Dept Surg Sci, Eye Clin, I-09124 Cagliari, Italy.	matteo.nioi@unica.it; ernesto.daloja@unica.it; mfossarello@aoucagliari.it; pietroemanuele.napoli@ca.omceo.it	Nioi, Matteo/V-8635-2019; d'Aloja, Ernesto/P-4539-2017	Nioi, Matteo/0000-0002-3645-6005; d'Aloja, Ernesto/0000-0003-4456-6252			Adorini L, 2005, IMMUNOL LETT, V100, P34, DOI 10.1016/j.imlet.2005.06.017; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Bal S, 2021, CURR OPHTHALMOL REP, V9, P77, DOI 10.1007/s40135-021-00271-3; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Bozkurt B, 2021, CIRCULATION, V144, P471, DOI 10.1161/CIRCULATIONAHA.121.056135; Caso F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102524; Courbebaisse M., 2016, VITAMIN CHRONIC KIDN; Courbebaisse M, 2010, TRANSPLANTATION, V89, P131, DOI 10.1097/TP.0b013e3181c6910f; Crnej A, 2021, J FR OPHTALMOL, V44, pE445, DOI 10.1016/j.jfo.2021.06.001; d'Aloja E, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100470; DeLuca HF, 1998, NUTR REV, V56, pS4; Fanni D, 2021, EUR REV MED PHARMACO, V25, P5063, DOI 10.26355/eurrev_202108_26464; Giurgea LT, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0198-1; Lee EH, 2022, CORNEA, V41, P660, DOI 10.1097/ICO.0000000000002898; Lemire J, 2000, Z RHEUMATOL, V59, P24; LEMIRE JM, 1992, J CELL BIOCHEM, V49, P26, DOI 10.1002/jcb.240490106; Matoba Alice, 2021, Cornea, DOI 10.1097/ICO.0000000000002787; McShane C, 2021, J HEPATOL, V75, P1252, DOI 10.1016/j.jhep.2021.06.044; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Miedziak AI, 1999, OPHTHALMIC SURG LAS, V30, P133; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Napoli PE, 2021, RISK MANAG HEALTHC P, V14, P1629, DOI 10.2147/RMHP.S277067; Napoli PE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082441; Napoli PE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051403; Napoli PE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051269; Nioi M, 2021, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.591900; Phylactou M, 2021, BRIT J OPHTHALMOL, V105, P893, DOI 10.1136/bjophthalmol-2021-319338; Rallis KI, 2021, EYE, DOI 10.1038/s41433-021-01671-2; Ravichandran S, 2021, INDIAN J OPHTHALMOL, V69, P1953, DOI 10.4103/ijo.IJO_1028_21; Reins RY, 2015, INVEST OPHTH VIS SCI, V56, P7715, DOI 10.1167/iovs.15-17768; Roehrich H, 2020, CORNEA, V39, P1556, DOI 10.1097/ICO.0000000000002509; Shah AP, 2022, CORNEA, V41, P121, DOI 10.1097/ICO.0000000000002878; Solomon A, 1996, AM J OPHTHALMOL, V121, P708, DOI 10.1016/S0002-9394(14)70638-5; Solomon A, 1999, EYE, V13, P381, DOI 10.1038/eye.1999.101; Stein EM, 2011, OSTEOPOROSIS INT, V22, P2107, DOI 10.1007/s00198-010-1523-8; STEINEMANN TL, 1988, AM J OPHTHALMOL, V106, P575, DOI 10.1016/0002-9394(88)90588-0; Tahvildari M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01065-z; Talotta R, 2021, CLIN IMMUNOL, V224, DOI 10.1016/j.clim.2021.108665; Thiel N, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00325-4; Vignapiano R, 2021, OCUL IMMUNOL INFLAMM, DOI 10.1080/09273948.2020.1870146; Wasser LM, 2021, CORNEA, V40, P1070, DOI 10.1097/ICO.0000000000002761; Wertheim MS, 2006, BRIT J OPHTHALMOL, V90, P925, DOI 10.1136/bjo.2006.093187; WHO, 2019, CAUSALITY ASSESSMENT, V2nd	43	4	4	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1274	10.3390/vaccines9111274			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH3LQ	34835205	gold, Green Published			2022-04-29	WOS:000725340500001
J	Zhang, XN; Guo, YQ; Zhou, Q; Tan, ZX; Cao, JL				Zhang, Xiaoning; Guo, Yuqing; Zhou, Qiong; Tan, Zaixiang; Cao, Junli			The Mediating Roles of Medical Mistrust, Knowledge, Confidence and Complacency of Vaccines in the Pathways from Conspiracy Beliefs to Vaccine Hesitancy	VACCINES			English	Article						vaccine hesitancy; conspiracy beliefs; pathways; confidence and complacency; medical mistrust		Background: Vaccine hesitancy, associated with medical mistrust, confidence, complacency and knowledge of vaccines, presents an obstacle to the campaign against the coronavirus disease 2019 (COVID-19). The relationship between vaccine hesitancy and conspiracy beliefs may be a key determinant of the success of vaccination campaigns. This study provides a conceptual framework to explain the impact of pathways from conspiracy beliefs to COVID-19 vaccine hesitancy with regard to medical mistrust, confidence, complacency and knowledge of vaccines. Methods: A non-probability study was conducted with 1015 respondents between 17 April and 28 May 2021. Conspiracy beliefs were measured using the coronavirus conspiracy scale of Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS), and vaccine conspiracy beliefs scale. Medical mistrust was measured using the Oxford trust in doctors and developers questionnaire, and attitudes to doctors and medicine scale. Vaccine confidence and complacency were measured using the Oxford COVID-19 vaccine confidence and complacency scale. Knowledge of vaccines was measured using the vaccination knowledge scale. Vaccine hesitancy was measured using the Oxford COVID-19 vaccine hesitancy scale. Confirmatory factor analysis (CFA) was used to evaluate the measurement models for conspiracy beliefs, medical mistrust, confidence, complacency, and knowledge of vaccines and vaccine hesitancy. The structural equation modeling (SEM) approach was used to analyze the direct and indirect pathways from conspiracy beliefs to vaccine hesitancy. Results: Of the 894 (88.1%) respondents who were willing to take the COVID-19 vaccine without any hesitancy, the model fit with the CFA models for conspiracy beliefs, medical mistrust, confidence, complacency and knowledge of vaccines, and vaccine hesitancy was deemed acceptable. Conspiracy beliefs had significant direct (beta = 0.294), indirect (beta = 0.423) and total (beta = 0.717) effects on vaccine hesitancy; 41.0% of the total effect was direct, and 59.0% was indirect. Conspiracy beliefs significantly predicted vaccine hesitancy by medical mistrust (beta = 0.210), confidence and complacency (beta = 0.095), knowledge (beta = 0.079) of vaccines, explaining 29.3, 11.0, and 13.2% of the total effects, respectively. Conspiracy beliefs significantly predicted vaccine hesitancy through the sequential mediation of knowledge of vaccines and medical mistrust (beta = 0.016), explaining 2.2% of the total effects. Conspiracy beliefs significantly predicted vaccine hesitancy through the sequential mediation of confidence and complacency, and knowledge of vaccines (beta = 0.023), explaining 3.2% of the total effects. The SEM approach indicated an acceptable model fit (chi(2)/df = 2.464, RMSEA = 0.038, SRMR = 0.050, CFI = 0.930, IFI = 0.930). Conclusions: The sample in this study showed lower vaccine hesitancy, and this study identified pathways from conspiracy beliefs to COVID-19 vaccine hesitancy in China. Conspiracy beliefs had direct and indirect effects on vaccine hesitancy, and the indirect association was determined through medical mistrust, confidence, complacency, and knowledge of vaccines. In addition, both direct and indirect pathways from conspiracy beliefs to vaccine hesitancy were identified as intervention targets to reduce COVID-19 vaccine hesitancy.	[Zhang, Xiaoning; Tan, Zaixiang] Xuzhou Med Univ, Sch Management, Xuzhou 221004, Jiangsu, Peoples R China; [Guo, Yuqing; Zhou, Qiong] Xuzhou Med Univ, Sch Nursing, Xuzhou 221004, Jiangsu, Peoples R China; [Cao, Junli] Xuzhou Med Univ, Jiangsu Prov Key Lab Anesthesiol, Xuzhou 221004, Jiangsu, Peoples R China; [Cao, Junli] Xuzhou Med Univ, Jiangsu Prov Key Lab Anesthesia & Analgesia Appli, Xuzhou 221004, Jiangsu, Peoples R China		Zhang, XN; Tan, ZX (通讯作者)，Xuzhou Med Univ, Sch Management, Xuzhou 221004, Jiangsu, Peoples R China.	xiaoning.zhang@ucl.ac.uk; 300108110817@stu.xzhmu.edu.cn; 301910811587@stu.xzhmu.edu.cn; tanzaixiang@126.com; caojl0310@aliyun.com		ZHANG, XIAONING/0000-0001-6637-9728	China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2020M670077ZX]; Jiangsu Planned Projects for Postdoctoral Research Funds; Postgraduate Education Funds [XYZ202101]	FundingThis research was funded by the China Postdoctoral Science Foundation (2020M670077ZX), the Jiangsu Planned Projects for Postdoctoral Research Funds, and the Postgraduate Education Funds (XYZ202101). The funding bodies were not involved in the study design, data collection, or data analysis, or in the writing of the manuscript.	AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Allington D, 2021, PSYCHOL MED, DOI 10.1017/S0033291721001434; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Bokemper SE, 2021, VACCINE, V39, P825, DOI 10.1016/j.vaccine.2020.12.048; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2; Chen L, 2021, HEALTH COMMUN, V36, P1343, DOI 10.1080/10410236.2020.1751384; Chevallier C, 2021, TRENDS COGN SCI, V25, P331, DOI 10.1016/j.tics.2021.02.002; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Freeman D, 2017, SOC PSYCH PSYCH EPID, V52, P595, DOI 10.1007/s00127-017-1354-4; Hornsey MJ, 2020, SOC SCI MED, V255, DOI 10.1016/j.socscimed.2020.113019; Jacobson RM, 2015, MAYO CLIN PROC, V90, P1562, DOI 10.1016/j.mayocp.2015.09.006; Jalloh MF, 2020, HUM VACC IMMUNOTHER, V16, P1208, DOI 10.1080/21645515.2019.1661206; Jemmott J, UNDERSTANDING DRIVER; Kline R.B., 2005, METHODOLOGY SOCIAL S; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Lorini C, 2018, HUM VACC IMMUNOTHER, V14, P478, DOI 10.1080/21645515.2017.1392423; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Marteau T.M., 1990, PSYCHOL HEALTH, V4, P351, DOI 10.1080/08870449008400403; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Ong SWX, 2021, LANCET INFECT DIS, V21, P1195, DOI 10.1016/S1473-3099(21)00201-2; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Ratzan S, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMp2106137; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Suarez-Lledo V, 2021, J MED INTERNET RES, V23, DOI 10.2196/17187; Sun CLF, 2020, J AM MED DIR ASSOC, V21, P1533, DOI 10.1016/j.jamda.2020.08.030; Thomson A, 2018, VACCINE, V36, P6457, DOI 10.1016/j.vaccine.2018.08.031; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; VanderWeele TJ, 2016, ANNU REV PUBL HEALTH, V37, P17, DOI 10.1146/annurev-publhealth-032315-021402; Verger P, 2020, EXPERT REV VACCINES, V19, P991, DOI 10.1080/14760584.2020.1825945; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Zingg A, 2012, VACCINE, V30, P3771, DOI 10.1016/j.vaccine.2012.03.014	48	4	4	14	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1342	10.3390/vaccines9111342			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XJ2TT	34835273	Green Published, gold			2022-04-29	WOS:000726647900001
J	Levin, MJ; Divino, V; Shah, D; DeKoven, M; Mould-Quevedo, J; Pelton, SI; Postma, MJ				Levin, Myron J.; Divino, Victoria; Shah, Drishti; DeKoven, Mitch; Mould-Quevedo, Joaquin; Pelton, Stephen, I; Postma, Maarten J.			Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged >= 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis	VACCINES			English	Article						influenza; older adults; adjuvanted influenza vaccine; relative vaccine effectiveness; retrospective studies; economic outcomes	UNITED-STATES; OLDER-ADULTS; RELATIVE EFFECTIVENESS; EFFICACY	The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults & GE;65 years during the 2019-2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (n = 798,987) was similarly effective compared to HD-IIV3e (n = 1,655,979) in preventing influenza-related hospitalizations/ER visits (rVE 3.1%; 95% CI: -2.8%; 8.6%), hospitalizations due to any cause (-0.7%; 95% CI: -1.6%; 0.3%), and any CRD-related hospitalization/ER visit (0.9%; 95% CI: 0.01%; 1.7%). Adjusted HCRU and annualized costs were also statistically insignificant between the two cohorts. The adjusted clinical and economic outcomes evaluated in this study were comparable between aIIV3 and HD-IIV3e during the 2019-2020 influenza season.</p>	[Levin, Myron J.] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO 80045 USA; [Levin, Myron J.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA; [Divino, Victoria; Shah, Drishti; DeKoven, Mitch] IQVIA, Real World Solut, Falls Church, VA 22042 USA; [Mould-Quevedo, Joaquin] Seqirus USA Inc, Global Pricing & Hlth Econ, Summit, NJ 07901 USA; [Pelton, Stephen, I] Boston Univ, Dept Pediat, Sch Med, Boston, MA 02118 USA; [Pelton, Stephen, I] Boston Med Ctr, Div Pediat Infect Dis, Maxwell Finland Lab, Boston, MA 02118 USA; [Postma, Maarten J.] Univ Groningen, Groningen Res Inst Pharm, Dept PharmacoTherapy Epidemiol & Econ PTE2, NL-9713 AV Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9713 AV Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, NL-9749 AE Groningen, Netherlands		Divino, V (通讯作者)，IQVIA, Real World Solut, Falls Church, VA 22042 USA.	Myron.Levin@cuanschutz.edu; victoria.divino@iqvia.com; drishti.shah@iqvia.com; mitch.dekoven@iqvia.com; Joaquin.Mould-Quevedo@seqirus.com; spelton@bu.edu; m.j.postma@rug.nl		Postma, Maarten/0000-0002-6306-3653	Seqirus USA Inc., Summit, NJ, USA	This study was funded by Seqirus USA Inc., Summit, NJ, USA.	Agency for Healthcare Research and Quality, 2018, HCUP COST TO CHARG R; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Austin PC, 2009, MED DECIS MAKING, V29, P661, DOI 10.1177/0272989X09341755; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Basu A, 2005, BIOSTATISTICS, V6, P93, DOI 10.1093/biostatistics/kxh020; Boikos C, 2020, CLIN INFECT DIS, V71, pE665, DOI 10.1093/cid/ciaa371; Centers for Disease Control and Prevention, 2020, NEW ICD 10 900 COD 2; Centers for Disease Control and Prevention, 2021, PEOPL 65 YEARS OLD I; Centers for Disease Control and Prevention, ESTIMATED INFLUENZA; Centers for Disease Control and Prevention, DIS BURD INFL; Centers for Disease Control and Prevention, WEEKL US INFL SURV R; Centers for Medicare Medicaid Services, 2019, HOSP OUTP PROSP PAYM; Centers for Medicare Medicaid Services, 2021, SEASONAL INFLUENZA V; Deb P, 2018, ANNU REV PUBL HEALTH, V39, P489, DOI 10.1146/annurev-publhealth-040617-013517; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Funk MJ, 2011, AM J EPIDEMIOL, V173, P761, DOI 10.1093/aje/kwq439; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Izurieta HS, 2021, CLIN INFECT DIS, V73, pE4251, DOI 10.1093/cid/ciaa1727; Izurieta HS, 2020, J INFECT DIS, V222, P278, DOI 10.1093/infdis/jiaa080; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989; Lozano J.E., LOZALOJO MEM 2 RELEA; Macias AE, 2021, VACCINE, V39, pA6, DOI 10.1016/j.vaccine.2020.09.048; Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313; Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720; Peasah SK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213499; Pelton SI, 2021, VACCINE, V39, P2396, DOI 10.1016/j.vaccine.2021.03.054; Pelton SI, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030446; Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057; Sullivan Sheena G, 2019, Ther Adv Vaccines Immunother, V7, p2515135519826481, DOI 10.1177/2515135519826481; Thoemmes F, 2016, EMERG ADULTHOOD, V4, P40, DOI 10.1177/2167696815621645; Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; Zubeldia K, 2002, US patent, Patent No. [US6397224B1, 6397224]	34	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1146	10.3390/vaccines9101146			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WT0AY	34696254	Green Published			2022-04-29	WOS:000715537800001
J	Jr, CN				Ndawula Jr, Charles			From Bench to Field: A Guide to Formulating and Evaluating Anti-Tick Vaccines Delving beyond Efficacy to Effectiveness	VACCINES			English	Review						anti-tick vaccine; anti-tick vaccine efficacy; anti-tick vaccine effectiveness; anti-tick vaccine protection	SOUTHERN CATTLE TICK; HEPATITIS-B VACCINE; BOOPHILUS-MICROPLUS; NUTTALLIELLIDAE ACARI; ANTIBODY-PRODUCTION; IMMUNE-RESPONSE; BOS-INDICUS; ANTIGEN; CELL; MEMORY	Ticks are ubiquitous blood-sucking ectoparasites capable of transmitting a wide range of pathogens such as bacteria, viruses, protozoa, and fungi to animals and humans. Although the use of chemicals (acaricides) is the predominant method of tick-control, there are increasing incidents of acaricide tick resistance. Furthermore, there are concerns over accumulation of acaricide residues in meat, milk and in the environment. Therefore, alternative methods of tick-control have been proposed, of which anti-tick cattle vaccination is regarded as sustainable and user-friendly. Over the years, tremendous progress has been made in identifying and evaluating novel candidate tick vaccines, yet none of them have reached the global market. Until now, Bm86-based vaccines (Gavac (TM) in Cuba and TickGARD(PLUS)(TM) Australia-ceased in 2010) are still the only globally commercialized anti-tick vaccines. In contrast to Bm86, often, the novel candidate anti-tick vaccines show a lower protection efficacy. Why is this so? In response, herein, the potential bottlenecks to formulating efficacious anti-tick vaccines are examined. Aside from Bm86, the effectiveness of other anti-tick vaccines is rarely assessed. So, how can the researchers assess anti-tick vaccine effectiveness before field application? The approaches that are currently used to determine anti-tick vaccine efficacy are re-examined in this review. In addition, a model is proposed to aid in assessing anti-tick vaccine effectiveness. Finally, based on the principles for the development of general veterinary vaccines, a pipeline is proposed to guide in the development of anti-tick vaccines.	[Ndawula Jr, Charles] Natl Agr Res Org, POB 295, Entebbe 256, Wakiso, Uganda; [Ndawula Jr, Charles] Natl Livestock Resources Res Inst, Vaccinol Res Programme, POB 5704, Nakyesasa 256, Wakiso, Uganda		Jr, CN (通讯作者)，Natl Agr Res Org, POB 295, Entebbe 256, Wakiso, Uganda.; Jr, CN (通讯作者)，Natl Livestock Resources Res Inst, Vaccinol Res Programme, POB 5704, Nakyesasa 256, Wakiso, Uganda.	ndawulaj821@gmail.com	Charles, Ndawula/AAB-5881-2022; Charles, Ndawula/AAD-5316-2022	Charles, Ndawula/0000-0002-4978-936X; 	Uganda Government	This research received no external funding. The article processing cost (APC) was funded by Uganda Government.	Abbas A., 2018, CELL MOL IMMUNOL, V9th ed., P565; Abbas RZ, 2014, VET PARASITOL, V203, P6, DOI 10.1016/j.vetpar.2014.03.006; Agrawal B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02631; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Albas A, 2006, J VENOM ANIM TOXINS, V12, P476, DOI 10.1590/S1678-91992006000300010; Anderson JM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01784; ANDERSSON B, 1970, J EXP MED, V132, P77, DOI 10.1084/jem.132.1.77; Andreotti Renato, 2006, Rev Bras Parasitol Vet, V15, P97; Apostolico JD, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1459394; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Bailey K. P., 1960, Bulletin of epizootic diseases of Africa, V8, P33; Bakheit MA, 2002, ANN NY ACAD SCI, V969, P159, DOI 10.1111/j.1749-6632.2002.tb04370.x; Balaraju, 2014, ASIAN PACIFIC J TROP, V4, pS770, DOI [10.1016/S2222-1808(14)60725-8., DOI 10.1016/S2222-1808(14)60725-8]; Baxter D, 2007, OCCUP MED-OXFORD, V57, P552, DOI 10.1093/occmed/kqm110; BENET LZ, 1995, TOXICOL PATHOL, V23, P115, DOI 10.1177/019262339502300203; Bensaci M, 2012, VACCINE, V30, P6040, DOI 10.1016/j.vaccine.2012.07.053; Billeskov R, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01973; Brites-Neto J, 2015, VET WORLD, V8, P301, DOI 10.14202/vetworld.2015.301-315; Brossard M, 1997, MED VET ENTOMOL, V11, P270, DOI 10.1111/j.1365-2915.1997.tb00406.x; Brossard M, 2004, PARASITOLOGY, V129, pS161, DOI 10.1017/S0031182004004834; BROWN SJ, 1984, J IMMUNOL, V133, P3319; Castiglione F, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/842329; Chauhan N, 2017, EXPERT REV VACCINES, V16, P491, DOI 10.1080/14760584.2017.1306440; Christensen D, 2016, HUM VACC IMMUNOTHER, V12, P2709, DOI 10.1080/21645515.2016.1219003; Clark TG, 2005, DEV BIOLOGICALS, V121, P153; Contreras M, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00045; Couto J, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9040363; Cunha RC, 2013, REV BRAS PARASITOL V, V22, P571, DOI 10.1590/S1984-29612013000400019; De la Fuente J, 2006, PARASITE IMMUNOL, V28, P275, DOI 10.1111/j.1365-3024.2006.00828.x; de la Fuente J, 1999, GENET ANAL-BIOMOL E, V15, P143, DOI 10.1016/S1050-3862(99)00018-2; de la Fuente J, 1998, VACCINE, V16, P366, DOI 10.1016/S0264-410X(97)00208-9; de la Fuente Jose, 2007, Animal Health Research Reviews, V8, P23, DOI 10.1017/S1466252307001193; de la Fuente J, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030075; De Vos S, 2001, EXP APPL ACAROL, V25, P245, DOI 10.1023/A:1010609007009; DECASTRO JJ, 1985, PARASITOLOGY, V90, P21; Dubois B, 1999, J LEUKOCYTE BIOL, V66, P224, DOI 10.1002/jlb.66.2.224; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; Ferguson HM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-158; Fernandez-Ruvalcaba M, 2004, EXP APPL ACAROL, V32, P293, DOI 10.1023/B:APPA.0000023233.63268.cc; Fragoso H, 1998, VACCINE, V16, P1990, DOI 10.1016/S0264-410X(98)00116-9; Francis MJ, 2020, VACCINE, V38, P4512, DOI 10.1016/j.vaccine.2020.05.007; FRAZER IH, 1987, MED J AUSTRALIA, V146, P242, DOI 10.5694/j.1326-5377.1987.tb120230.x; Furlong J., 1998, Ciencia Rural, V28, P635, DOI 10.1590/S0103-84781998000400016; Gallovic MD, 2016, BIOMATER SCI-UK, V4, P483, DOI 10.1039/c5bm00451a; Garcia-Garcia JC, 1999, EXP APPL ACAROL, V23, P883, DOI 10.1023/A:1006270615158; George JE, 2008, TICKS: BIOLOGY, DISEASE AND CONTROL, P408, DOI 10.1017/CBO9780511551802.019; Glass EJ, 2007, VET IMMUNOL IMMUNOP, V120, P20, DOI 10.1016/j.vetimm.2007.07.013; GOIDL EA, 1968, J IMMUNOL, V100, P371; Graf JF, 2004, PARASITOLOGY, V129, pS427, DOI 10.1017/S0031182004006079; Greenwood M, 1915, Proc R Soc Med, V8, P113; Guglielmone AA, 2010, ZOOTAXA, P1, DOI 10.11646/zootaxa.2528.1.1; Gupta A., 2015, SHIRAZ E MED J, V16, P28061, DOI [10.17795/semj28061, DOI 10.17795/SEMJ28061]; Gustafson CE, 2020, J ALLERGY CLIN IMMUN, V145, P1309, DOI 10.1016/j.jaci.2020.03.017; HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004; Halpern LW, 2016, AM J NURS, V116, P15, DOI 10.1097/01.NAJ.0000484919.12660.0e; Handel A, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006505; Hanly W. Carey, 1995, ILAR J, V37, P93; HANNA MG, 1971, IMMUNOLOGY, V20, P707; Hassan IA, 2020, VACCINE, V38, P907, DOI 10.1016/j.vaccine.2019.10.076; HERBERT WJ, 1968, IMMUNOLOGY, V14, P301; Hernandez EP, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2667-1; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Hopf S, 2016, VACCINE, V34, P2027, DOI 10.1016/j.vaccine.2015.12.057; Horak IG, 2002, EXP APPL ACAROL, V28, P27, DOI 10.1023/A:1025381712339; Hu ZT, 2016, CELL MOL IMMUNOL, V13, P82, DOI 10.1038/cmi.2014.128; Hurn B A, 1980, Methods Enzymol, V70, P104; JACKSON LA, 1989, IMMUNOLOGY, V68, P272; Jittapalapong S., 2006, KASETSART J NAT SCI, V40, P276; John TJ, 2000, EUR J EPIDEMIOL, V16, P601, DOI 10.1023/A:1007626510002; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Kasaija PD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020319; Kurokawa C, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2020.101529; Labuda M, 2006, PLOS PATHOG, V2, P251, DOI 10.1371/journal.ppat.0020027; Leo O, 2011, PERSPECT VACCINOL, V1, P25, DOI DOI 10.1016/J.PERVAC.2011.05.002; Lesinski GB, 2001, J MICROBIOL METH, V47, P135, DOI 10.1016/S0167-7012(01)00290-1; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Marois I, 2012, J LEUKOCYTE BIOL, V92, P107, DOI 10.1189/jlb.1011490; Maruyama M, 2000, NATURE, V407, P636, DOI 10.1038/35036600; Mathers AR, 2006, IMMUNOL RES, V36, P127, DOI 10.1385/IR:36:1:127; McCluskie MJ, 2002, FEMS IMMUNOL MED MIC, V32, P179, DOI 10.1016/S0928-8244(01)00305-4; McCoy BN, 2010, J MED ENTOMOL, V47, P1164, DOI 10.1603/ME10175; Merino O, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00030; Mohan T, 2013, INDIAN J MED RES, V138, P779; Moran I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05772-7; Ndawula C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030457; Ndawula C, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2020.101445; Ndawula C, 2019, VACCINE, V37, P1918, DOI 10.1016/j.vaccine.2019.02.039; Neelakanta G, 2015, ARCH IMMUNOL THER EX, V63, P169, DOI 10.1007/s00005-014-0324-8; Newman Mark J, 2002, Curr Opin Investig Drugs, V3, P374; Ng'habi KRN, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-356; Ni YH, 2007, GASTROENTEROLOGY, V132, P1287, DOI 10.1053/j.gastro.2007.02.055; Nolz JC, 2011, ADV EXP MED BIOL, V780, P69, DOI 10.1007/978-1-4419-5632-3_7; Nuttall PA, 2006, PARASITE IMMUNOL, V28, P155, DOI 10.1111/j.1365-3024.2006.00806.x; Ols S, 2020, CELL REP, V30, P3964, DOI 10.1016/j.celrep.2020.02.111; Otczyk DC, 2010, HUM VACCINES, V6, P978, DOI 10.4161/hv.6.12.13142; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; Patarroyo JH, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2020.101461; PAUL WE, 1967, IMMUNOLOGY, V13, P147; Pereira MD, 1998, J ECON ENTOMOL, V91, P153, DOI 10.1093/jee/91.1.153; Piper EK, 2009, CLIN VACCINE IMMUNOL, V16, P1074, DOI 10.1128/CVI.00157-09; PLOWRIGHT W, 1984, J HYG-CAMBRIDGE, V92, P285, DOI 10.1017/S0022172400064524; Radaelli E, 2018, ILAR J, V59, P211, DOI 10.1093/ilar/ily026; Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1; Aguirre ADR, 2015, INT J PARASITOL, V45, P357, DOI 10.1016/j.ijpara.2015.02.003; RECHAV Y, 1992, INSECT SCI APPL, V13, P495, DOI 10.1017/S1742758400016076; Reeves E, 2017, IMMUNOLOGY, V150, P16, DOI 10.1111/imm.12675; Reichardt P, 2010, CURR TOP MICROBIOL, V340, P229, DOI 10.1007/978-3-642-03858-7_12; Robbertse L, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00522; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Samish M, 1999, ANNU REV ENTOMOL, V44, P159, DOI 10.1146/annurev.ento.44.1.159; Scheerlinck JPY, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 1: DEVELOPMENT AND PHYLOGENY OF THE IMMUNE SYSTEM, P526, DOI 10.1016/B978-0-12-374279-7.12017-X; Schetters T, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1386-8; Senbill H, 2018, SYST APPL ACAROL-UK, V23, P1169, DOI 10.11158/saa.23.6.12; Shetty VU, 2019, PEDIATR REV, V40, P26, DOI 10.1542/pir.2018-0033; Shim E, 2012, VACCINE, V30, P6700, DOI 10.1016/j.vaccine.2012.08.045; Simionatto S, 2010, PROTEIN EXPRES PURIF, V69, P132, DOI 10.1016/j.pep.2009.09.001; Singh M, 2002, PHARM RES-DORDR, V19, P715, DOI 10.1023/A:1016104910582; SISKIND GW, 1968, J EXP MED, V127, P55, DOI 10.1084/jem.127.1.55; SMITH GN, 1972, LANCET, V1, P1208; SQUIER C A, 1991, Critical Reviews in Oral Biology and Medicine, V2, P13; Stjernberg L, 2005, SCAND J INFECT DIS, V37, P361, DOI 10.1080/00365540410021216; SVEHAG SE, 1964, J EXP MED, V119, P21, DOI 10.1084/jem.119.1.21; Szabo MPJ, 1997, VET PARASITOL, V68, P283, DOI 10.1016/S0304-4017(96)01079-5; Tabor AE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00506; Taborda CP, 2003, J IMMUNOL, V170, P3621, DOI 10.4049/jimmunol.170.7.3621; THEIS GA, 1968, J IMMUNOL, V100, P138; THOMPSON KC, 1978, TROP ANIM HEALTH PRO, V10, P179, DOI 10.1007/BF02235337; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P137, DOI [10.1016/S0033-3506(39)80097-X, 10.2307/3272354]; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P57, DOI 10.2307/3272160; Phan TG, 2017, CURR OPIN IMMUNOL, V45, P132, DOI 10.1016/j.coi.2017.03.005; Turner RJ, 1997, LAB ANIM, V31, P362, DOI 10.1258/002367797780596194; Uddowla S, 2007, VACCINE, V25, P7984, DOI 10.1016/j.vaccine.2007.09.030; Uspensky I, 1999, ACAROLOGIA, V40, P9; Valle Manuel Rodriguez, 2018, Front Biosci (Elite Ed), V10, P122; Valle MR, 2004, EXP APPL ACAROL, V34, P375, DOI 10.1023/B:APPA.0000049223.92326.02; Vargas M, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-43; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; VIEIRA P, 1986, EUR J IMMUNOL, V16, P871, DOI 10.1002/eji.1830160727; WAHL M, 1987, SCAND J INFECT DIS, V19, P617, DOI 10.3109/00365548709117195; WALDMANN H, 1973, NATURE, V243, P356, DOI 10.1038/243356a0; Walker A., 2003, TICKS DOMESTIC ANIMA; Walker AR, 2014, MED VET ENTOMOL, V28, P1, DOI 10.1111/mve.12031; Wambura PN, 1998, VET PARASITOL, V77, P63, DOI 10.1016/S0304-4017(97)00229-X; Wang H, 1998, NATURE, V391, P753, DOI 10.1038/35773; Wangmo K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209946; WIKEL SK, 1984, VET PARASITOL, V14, P321, DOI 10.1016/0304-4017(84)90099-2; WIKEL SK, 1994, INT J PARASITOL, V24, P59, DOI 10.1016/0020-7519(94)90059-0; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245; WILLADSEN P, 1989, J IMMUNOL, V143, P1346; Woodland DL, 2004, TRENDS IMMUNOL, V25, P98, DOI 10.1016/j.it.2003.11.009; Yazdi AS, 2016, SEMIN IMMUNOPATHOL, V38, P3, DOI 10.1007/s00281-015-0545-x; do Amaral MAZ, 2012, REV BRAS PARASITOL V, V21, P22, DOI 10.1590/S1984-29612012000100005; Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067	155	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1185	10.3390/vaccines9101185			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO0WN	34696291	Green Published, gold			2022-04-29	WOS:000712183800001
J	Yang, F; Zhu, ZX; Liu, HA; Cao, WJ; Zhang, W; Wei, T; Zheng, M; Zhang, KS; Tian, H; Zeng, QY; Cai, XP; Zheng, HX				Yang, Fan; Zhu, Zixiang; Liu, Huanan; Cao, Weijun; Zhang, Wei; Wei, Ting; Zheng, Min; Zhang, Keshan; Tian, Hong; Zeng, Qiaoying; Cai, Xuepeng; Zheng, Haixue			Evaluation of Antibody Response in Sows after Vaccination with Senecavirus A Vaccine and the Effect of Maternal Antibody Transfer on Antibody Dynamics in Offspring	VACCINES			English	Article						Senecavirus A; vaccine; maternal antibody; immunization schedule; antibody persistence	IDIOPATHIC VESICULAR DISEASE; VALLEY VIRUS; PROTECTIVE EFFICACY; PCR ASSAY; SWINE; PIGS; IMMUNOGENICITY; PICORNAVIRUS; INFECTION; STRAINS	Senecavirus A (SVA) is a newly porcine virus that has been detected in many countries since its first detection in pigs in Canada in 2007, and it remains endemic in many countries in Asia and America, which has become a substantial problem for the pig industry. Vaccination is a potentially effective strategy for the prevention and control of SVA infection. Our lab has developed a SVA vaccine candidate previously. In this study, the antibody response to the prepared vaccine in sows and their offspring was evaluated. Vaccination of sows with inactivated SVA vaccines during pregnancy elicited SVA-specific virus-neutralizing antibodies. Vaccination with a high dose of SVA vaccine followed a booster immunization contributed to a long-term duration of the persistence of maternally derived neutralizing antibodies (MDAs) in the milk of the sows (> 14 days). In contrast, vaccination with a single low dose of SVA vaccine resulted in a short-term persistence of MDAs in the milk (2-7 days). The MDAs could be efficiently transferred from the sows to their offspring through the colostrum/milk but not the umbilical cord blood. The antibody titers and the duration of the persistence of MDAs in the offspring are highly associated with the antibody levels in the milk from the sows. Vaccination of sows with a booster dose of SVA vaccine resulted in a longer-lasting MDAs in their offspring (persisted for at least 90 days). However, vaccination with the single low dose of vaccine only brought about 42 days of MDAs persistence in their offspring. The effect of MDAs on active immunization with SVA vaccine in offspring was further evaluated, which showed that vaccination of the SVA vaccine in the presence of MDAs at the titer of approximate to 1:64 or less could overcome the MDAs' interference and give rise to effective antibody response. This will help for establishing the optimal times and schedules for SVA vaccination in pigs.	[Yang, Fan; Zeng, Qiaoying; Cai, Xuepeng] Gansu Agr Univ, Coll Vet Med, Lanzhou 730070, Peoples R China; [Yang, Fan; Zhu, Zixiang; Liu, Huanan; Cao, Weijun; Zhang, Wei; Wei, Ting; Zheng, Min; Zhang, Keshan; Tian, Hong; Zheng, Haixue] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol,Key Lab Anim Virol M, Natl Foot & Mouth Dis Reference Lab, Lanzhou 730046, Peoples R China		Cai, XP (通讯作者)，Gansu Agr Univ, Coll Vet Med, Lanzhou 730070, Peoples R China.; Zheng, HX (通讯作者)，Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol,Key Lab Anim Virol M, Natl Foot & Mouth Dis Reference Lab, Lanzhou 730046, Peoples R China.	yangfan02@caas.cn; zhuzixiang@caas.cn; liuhuanan2008@163.com; caoweijun@caas.cn; zhangwei09@caas.cn; tingting830830@163.com; zhengmin105251@163.com; zhangkeshan@caas.cn; tianhong@caas.cn; zengcly@gsau.edu.cn; caixp@vip.163.com; haixuezheng@163.com			National Natural Sciences Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31972688]; Key Technologies R&D Program of Gansu Province [19ZDNA001]; collaborative innovation project of CAAS [CAAS-ASTIP-2021-LVRI]	This research was funded by National Natural Sciences Foundation of China (31972688), the Key Technologies R&D Program of Gansu Province (19ZDNA001), and the collaborative innovation project of CAAS (No. CAAS-ASTIP-2021-LVRI).	Arzt J, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.01247-18; Bracht AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146211; Canning P, 2016, TRANSBOUND EMERG DIS, V63, P373, DOI 10.1111/tbed.12516; Agnol AMD, 2017, MOL CELL PROBE, V33, P28, DOI 10.1016/j.mcp.2017.03.002; Dritz SS, 1996, J ANIM SCI, V74, P1620; Dvorak CMT, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-0967-x; Fowler VL, 2017, J VIROL METHODS, V239, P34, DOI 10.1016/j.jviromet.2016.10.012; Gimenez-Lirola LG, 2016, J CLIN MICROBIOL, V54, P2082, DOI 10.1128/JCM.00710-16; Glezen WP, 2003, VACCINE, V21, P3389, DOI 10.1016/S0264-410X(03)00339-6; Goolia M, 2017, J VET DIAGN INVEST, V29, P250, DOI 10.1177/1040638716683214; Grindstaff JL, 2008, J EXP BIOL, V211, P654, DOI 10.1242/jeb.012344; Guo ZH, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00002; Hales LM, 2008, J GEN VIROL, V89, P1265, DOI 10.1099/vir.0.83570-0; Hole K, 2019, CAN J VET RES, V83, P242; Joshi LR, 2016, J GEN VIROL, V97, P3267, DOI 10.1099/jgv.0.000631; Joshi LR, 2016, J CLIN MICROBIOL, V54, P1536, DOI 10.1128/JCM.03390-15; Karlsson MCI, 1999, P NATL ACAD SCI USA, V96, P2244, DOI 10.1073/pnas.96.5.2244; KLASING KC, 1999, P INT ORNITHOL C, V22, P2817; Knowles N., P EUROPIC 2005 13 M, P23; Knowles N.J., 2006, P NO LIGHTS EUROPIC; Koppers-Lalic D, 2011, REV MED VIROL, V21, P227, DOI 10.1002/rmv.694; Leme RA, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070170; Leme RA, 2016, EMERG INFECT DIS, V22, P1238, DOI 10.3201/eid2207.151583; Mingxiao M, 2007, ANTIVIR RES, V76, P59, DOI 10.1016/j.antiviral.2007.05.003; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Pasma T, 2008, CAN VET J, V49, P84; Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085; Reddy PS, 2007, J NATL CANCER I, V99, P1623, DOI 10.1093/jnci/djm198; Saeng-chuto K, 2018, TRANSBOUND EMERG DIS, V65, P285, DOI 10.1111/tbed.12654; Singh K., 2012, J VET SCI TECHNOL, V3, P6; Sun D, 2017, TRANSBOUND EMERG DIS, V64, P1346, DOI 10.1111/tbed.12669; Wadhwa L, 2007, CANCER RES, V67, P10653, DOI 10.1158/0008-5472.CAN-07-2352; Xu WH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176964; Yang F, 2018, VACCINE, V36, P841, DOI 10.1016/j.vaccine.2017.12.055; Yang M, 2012, J VET DIAGN INVEST, V24, P42, DOI 10.1177/1040638711426323; Yu D., 1997, GUIDELINE ENTRY EXIT; Zhang X, 2018, TRANSBOUND EMERG DIS, V65, P297, DOI 10.1111/tbed.12750; Zhang XL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00940; Zheng HX, 2015, VACCINE, V33, P5772, DOI 10.1016/j.vaccine.2015.09.055; Zhu Z, 2017, TRANSBOUND EMERG DIS, V64, P1024, DOI 10.1111/tbed.12662	40	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1066	10.3390/vaccines9101066			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN0PN	34696174	Green Published			2022-04-29	WOS:000711478900001
J	Acevedo-Villanueva, KY; Akerele, GO; Al Hakeem, WG; Renu, S; Shanmugasundaram, R; Selvaraj, RK				Acevedo-Villanueva, Keila Y.; Akerele, Gabriel O.; Al Hakeem, Walid Ghazi; Renu, Sankar; Shanmugasundaram, Revathi; Selvaraj, Ramesh K.			A Novel Approach against Salmonella: A Review of Polymeric Nanoparticle Vaccines for Broilers and Layers	VACCINES			English	Review						Salmonella; vaccines; polymeric; nanoparticles; broilers; layers; poultry	ENTERICA SEROVAR TYPHIMURIUM; RECEPTOR-MEDIATED PHAGOCYTOSIS; CHICKEN HETEROPHILS; MESSENGER-RNA; POLY(ANHYDRIDE) NANOPARTICLES; LYMPHOCYTE SUBPOPULATIONS; PROTECTIVE IMMUNITY; SUBUNIT NANOVACCINE; NITRIC-OXIDE; B-CELL	This work discusses the present-day limitations of current commercial Salmonella vaccines for broilers and layers and explores a novel approach towards poultry vaccination using biodegradable nanoparticle vaccines against Salmonella. With the increasing global population and poultry production and consumption, Salmonella is a potential health risk for humans. The oral administration of killed or inactivated vaccines would provide a better alternative to the currently commercially available Salmonella vaccines for poultry. However, there are currently no commercial oral killed-vaccines against Salmonella for use in broilers or layers. There is a need for novel and effective interventions in the poultry industry. Polymeric nanoparticles could give way to an effective mass-administered mucosal vaccination method for Salmonella. The scope of this work is limited to polymeric nanoparticles against Salmonella for use in broilers and layers. This review is based on the information available at the time of the investigation.	[Acevedo-Villanueva, Keila Y.; Akerele, Gabriel O.; Al Hakeem, Walid Ghazi; Selvaraj, Ramesh K.] Univ Georgia, Coll Agr & Environm Sci, Dept Poultry Sci, Athens, GA 30602 USA; [Renu, Sankar] Upkara Inc, 45145 W 12 Mile Rd, Novi, MI 48377 USA; [Shanmugasundaram, Revathi] USDA ARS, Toxicol & Mycotoxins Res Unit, Athens, GA 30605 USA		Selvaraj, RK (通讯作者)，Univ Georgia, Coll Agr & Environm Sci, Dept Poultry Sci, Athens, GA 30602 USA.	ka46846@uga.edu; goa17789@uga.edu; walid.alhakeem@uga.edu; srenu@upkara.com; revathi.shan@usda.gov; selvaraj@uga.edu		Acevedo-Villanueva, Keila/0000-0002-4164-7658; Al Hakeem, Walid Ghazi/0000-0003-1225-561X; Akerele, Gabriel/0000-0002-0111-3926	Hatch grant; USDA-NIFAUnited States Department of Agriculture (USDA) [2017-05035]	This research was partially supported by the Hatch grant and USDA-NIFA grant 2017-05035 awarded to R.K.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas Abul K., 2015, CELL MOL IMMUNOL; Abramson SB, 2001, BEST PRACT RES CL RH, V15, P831, DOI 10.1053/berh.2001.0196; Acevedo-Villanueva K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247938; Acevedo-Villanueva KY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231998; Akerele G, 2020, VET IMMUNOL IMMUNOP, V224, DOI 10.1016/j.vetimm.2020.110059; Andino A, 2015, ScientificWorldJournal, V2015, P520179, DOI 10.1155/2015/520179; Anselmo AC, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10143; Arakawa CK, 2017, ADV MATER, V29, DOI 10.1002/adma.201703156; ARNOLD JW, 1995, POULTRY SCI, V74, P656, DOI 10.3382/ps.0740656; Barbut S., 2015, SCI POULTRY MEAT PRO; Beal RK, 2006, INFECT IMMUN, V74, P1442, DOI 10.1128/IAI.74.2.1442-1444.2006; Berndt A, 2004, COMP IMMUNOL MICROB, V27, P235, DOI 10.1016/j.cimid.2003.11.002; Berndt A, 2001, VET IMMUNOL IMMUNOP, V78, P143, DOI 10.1016/S0165-2427(00)00264-6; Berndt A, 2007, INFECT IMMUN, V75, P5993, DOI 10.1128/IAI.00695-07; Berndt A, 2006, INFECT IMMUN, V74, P3967, DOI 10.1128/IAI.01128-05; Bertasi F., 2019, EUR J PUBLIC HEALTH, V22, P2019; Berthelot-Herault F, 2003, VET IMMUNOL IMMUNOP, V96, P43, DOI 10.1016/S0165-2427(03)00155-7; BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232, DOI 10.1128/IAI.59.7.2232-2238.1991; Buddingh G.J., 1975, AM J TROP MED HYG, V24, P550, DOI [10.4269/ajtmh.1975.24.550, DOI 10.4269/AJTMH.1975.24.550]; Caldara M, 2012, CURR BIOL, V22, P2325, DOI 10.1016/j.cub.2012.10.028; Centers for Disease Control and Prevention, SALM FOOD; CEVA, VACC LAYERMUNE SE; CEVA, VACC CEV COR RANG BR; Chausse AM, 2014, VET IMMUNOL IMMUNOP, V159, P16, DOI 10.1016/j.vetimm.2014.03.001; Cheeseman J.H, 2007, AVIAN IMMUNOLOGY IMM, P1; Cheeseman JH, 2007, DEV COMP IMMUNOL, V31, P52, DOI 10.1016/j.dci.2006.04.001; Chellaram C., 2014, APCBEE Procedia, V8, P109, DOI 10.1016/j.apcbee.2014.03.010; Coburn B, 2007, IMMUNOL CELL BIOL, V85, P112, DOI 10.1038/sj.icb.7100007; Crhanova M, 2011, INFECT IMMUN, V79, P2755, DOI 10.1128/IAI.01375-10; Crum-Cianflone Nancy F, 2008, Curr Gastroenterol Rep, V10, P424, DOI 10.1007/s11894-008-0079-7; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Dormont F, 2019, J CONTROL RELEASE, V307, P302, DOI 10.1016/j.jconrel.2019.06.040; Ehuwa O, 2021, FOODS, V10, DOI 10.3390/foods10050907; ELANCO, AVIPRO 329 ND IB2 SE; ELANCO, AVIPRO MEG VAC 1; ELANCO, AVIPRO MEG EGG CAN; Eswarappa SM, 2009, INFECT GENET EVOL, V9, P468, DOI 10.1016/j.meegid.2009.01.004; FDA (Food and Drug Administration), 2012, BAD BUG BOOK FOODBOR, P9; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Foley SL, 2011, APPL ENVIRON MICROB, V77, P4273, DOI 10.1128/AEM.00598-11; Food and Drug Administration HHS, 2009, Fed Regist, V74, P33029; Forbes SJ, 2008, INFECT IMMUN, V76, P4137, DOI 10.1128/IAI.00416-08; Gal-Mor O, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00391; Gantois I, 2009, FEMS MICROBIOL REV, V33, P718, DOI 10.1111/j.1574-6976.2008.00161.x; Gauthier R, 2002, P 27 CONV AM ASS AV; Genovese KJ, 2013, DEV COMP IMMUNOL, V41, P334, DOI 10.1016/j.dci.2013.03.021; Gong JS, 2014, APPL ENVIRON MICROB, V80, P687, DOI 10.1128/AEM.03223-13; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Hallstrom K, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00088; Han JY, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10010031; Han Y, 2020, VET IMMUNOL IMMUNOP, V228, DOI 10.1016/j.vetimm.2020.110111; Han Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020299; Han Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00935; Hara-Kudo Y, 2011, EPIDEMIOL INFECT, V139, P1505, DOI 10.1017/S095026881000292X; Herath M, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00248; Higginson EE, 2016, CLIN VACCINE IMMUNOL, V23, P746, DOI 10.1128/CVI.00258-16; Higgs R, 2006, INFECT IMMUN, V74, P1692, DOI 10.1128/IAI.74.3.1692-1698.2006; Hill EK, 2017, J ANIM SCI BIOTECHNO, V8, DOI 10.1186/s40104-017-0157-5; Hoft DF, 2011, CELL MICROBIOL, V13, P934, DOI 10.1111/j.1462-5822.2011.01609.x; Hohmann EL, 2001, CLIN INFECT DIS, V32, P263, DOI 10.1086/318457; Homayun B, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030129; House D, 2001, CURR OPIN INFECT DIS, V14, P573, DOI 10.1097/00001432-200110000-00011; Howe SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086656; Jackson AW, 2013, POLYM CHEM-UK, V4, P31, DOI 10.1039/c2py20727c; Janeway C., 2012, IMMUNOBIOLOGY, V5th; Kannan L, 2009, MOL IMMUNOL, V46, P3151, DOI 10.1016/j.molimm.2009.07.005; Karolewicz B, 2016, SAUDI PHARM J, V24, P525, DOI 10.1016/j.jsps.2015.02.025; Kasuga F, 2004, J FOOD PROTECT, V67, P2024, DOI 10.4315/0362-028X-67.9.2024; Kaul S, 2018, J PHARMACEUTICS, V2018, DOI 10.1155/2018/3420204; Khobragade P.K., 2015, POLYMER, V4, P1829; Kim K, 2015, BIOMATERIALS, V52, P161, DOI 10.1016/j.biomaterials.2015.02.010; Kiyono H., 1996, MUCOSAL VACCINES; Klochko A., WHAT IS INFECT DOSE; Kogut MH, 2005, DEV COMP IMMUNOL, V29, P791, DOI 10.1016/j.dci.2005.02.002; Kogut MH, 2005, J INTERF CYTOK RES, V25, P73, DOI 10.1089/jir.2005.25.73; Kogut MH, 2003, MOL IMMUNOL, V40, P603, DOI 10.1016/j.molimm.2003.08.002; Kogut MH, 2003, J INTERF CYTOK RES, V23, P319, DOI 10.1089/107999003766628160; Kogut Michael H., 2012, Frontiers in Genetics, V3, P121, DOI 10.3389/fgene.2012.00121; Kothary MH, 2001, J FOOD SAFETY, V21, P49, DOI 10.1111/j.1745-4565.2001.tb00307.x; Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057; Lux CD, 2012, J AM CHEM SOC, V134, P15758, DOI 10.1021/ja303372u; Manne C, 2019, P NATL ACAD SCI USA, V116, P7425, DOI 10.1073/pnas.1818242116; MANDAL BK, 1988, BRIT MED J, V297, P1242, DOI 10.1136/bmj.297.6658.1242; Marangon S, 2007, REV SCI TECH OIE, V26, P265, DOI 10.20506/rst.26.1.1742; McDermid AS, 1996, LETT APPL MICROBIOL, V23, P107, DOI 10.1111/j.1472-765X.1996.tb00042.x; McMillan EA, 2020, GENES-BASEL, V11, DOI 10.3390/genes11121516; McNeill E, 2015, FREE RADICAL BIO MED, V79, P206, DOI 10.1016/j.freeradbiomed.2014.10.575; Melief CJM, 2003, EUR J IMMUNOL, V33, P2645, DOI 10.1002/eji.200324341; Mohammed MA, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040053; Najahi-Missaoui W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010385; Nerren JR, 2009, VET IMMUNOL IMMUNOP, V127, P162, DOI 10.1016/j.vetimm.2008.09.011; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Northcutt J.K., GEN GUIDELINES IMPLE; Ochoa J, 2007, VACCINE, V25, P4410, DOI 10.1016/j.vaccine.2007.03.025; Ochoa-Reparaz J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030216; Ojer P, 2013, J BIOMED NANOTECHNOL, V9, P1891, DOI 10.1166/jbn.2013.1695; Paul-Ehrlich-Institut, POULTR ZOOS H; Paul-Ehrlich-Institut, POULT SALM SE; Prajakta K., CHITOSAN MUCOADHESIV; Rahim SS, 2005, IMMUNOLOGY, V114, P313, DOI 10.1111/j.1365-2567.2005.02107.x; Rappl C, 2003, FEMS MICROBIOL LETT, V226, P363, DOI 10.1016/S0378-1097(03)00638-4; Redmond SB, 2009, VET IMMUNOL IMMUNOP, V132, P129, DOI 10.1016/j.vetimm.2009.05.010; Renu S, 2020, CARBOHYD POLYM, V243, DOI 10.1016/j.carbpol.2020.116434; Renu S, 2020, INT J NANOMED, V15, P761, DOI 10.2147/IJN.S238445; Renu S, 2018, INT J NANOMED, V13, P8195, DOI 10.2147/IJN.S185588; Revolledo L, 2012, J APPL POULTRY RES, V21, P418, DOI 10.3382/japr.2011-00409; Salman HH, 2009, VACCINE, V27, P4784, DOI 10.1016/j.vaccine.2009.05.091; Sasai K, 1997, VET IMMUNOL IMMUNOP, V59, P359, DOI 10.1016/S0165-2427(97)00082-2; Sauls R.S., 2020, HISTOLOGY M CELL; Scharff RL, 2020, J FOOD PROTECT, V83, P959, DOI 10.4315/JFP-19-548; Shanmugasundaram R, 2015, POULTRY SCI, V94, P1828, DOI 10.3382/ps/pev161; Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x; Spickler A.R., 2013, SALMONELLOSIS PARATY; Stern NJ, 2001, POULTRY SCI, V80, P156, DOI 10.1093/ps/80.2.156; Stewart-Brown Bruce., 2019, MERCK VET MANUAL VAC; Su S, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040656; Swaggerty CL, 2005, FEMS IMMUNOL MED MIC, V43, P149, DOI 10.1016/j.femsim.2004.07.013; Swaggerty CL, 2003, AVIAN PATHOL, V32, P95, DOI 10.1080/0307945021000070769; Tajkarimi M, 2007, CALIF DEP FOOD AGR, P1; Tamayo I, 2010, CLIN VACCINE IMMUNOL, V17, P1356, DOI 10.1128/CVI.00164-10; Tripathi P, 2007, FEMS IMMUNOL MED MIC, V51, P443, DOI 10.1111/j.1574-695X.2007.00329.x; Van Dijk A, 2009, MOL IMMUNOL, V46, P1517, DOI 10.1016/j.molimm.2008.12.015; van Oort R, 2021, POULT WORLD, V1, P18; Vert M, 2012, PURE APPL CHEM, V84, P377, DOI 10.1351/PAC-REC-10-12-04; Wang JJ, 2011, INT J NANOMED, V6, P765, DOI 10.2147/IJN.S17296; Welch RP, 2018, BIOCONJUGATE CHEM, V29, P2867, DOI 10.1021/acs.bioconjchem.8b00483; Whitworth J., 2020, FOOD SAFETY NEWS; Whitworth J., 2021, FOOD SAFETY NEWS; Withanage GSK, 2005, INFECT IMMUN, V73, P5173, DOI 10.1128/IAI.73.8.5173-5182.2005; Withanage GSK, 1998, VET IMMUNOL IMMUNOP, V66, P173, DOI 10.1016/S0165-2427(98)00177-9; Withanage GSK, 2003, AVIAN PATHOL, V32, P583, DOI 10.1080/03079450310001610631; Zhu MT, 2014, HUM VACC IMMUNOTHER, V10, P2761, DOI 10.4161/hv.29589; Zoetis, POULVAC SE ND IB; Zoetis, POULVAC ST; Zoetis, EFF SALM MAN POULVAC	139	1	1	7	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1041	10.3390/vaccines9091041			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2ZW	34579278	Green Published, gold			2022-04-29	WOS:000702079500001
J	Ligat, G; Alain, S; Hantz, S				Ligat, Gaetan; Alain, Sophie; Hantz, Sebastien			Towards a Prophylactic Vaccine for the Prevention of HCMV Infection	VACCINES			English	Editorial Material							4 LIVE; CYTOMEGALOVIRUS; PHASE-1		[Ligat, Gaetan] Univ Strasbourg, Inst Rech Sur Malad Virales & Hepat, F-67000 Strasbourg, France; [Alain, Sophie; Hantz, Sebastien] Univ Limoges, U1092, RESINFIT, CHU Limoges,INSERM, F-87000 Limoges, France; [Alain, Sophie; Hantz, Sebastien] CHU Limoges, Lab Bacteriol Virol Hyg, Natl Reference Ctr Herpesviruses NRCHV, F-87000 Limoges, France		Ligat, G (通讯作者)，Univ Strasbourg, Inst Rech Sur Malad Virales & Hepat, F-67000 Strasbourg, France.	gligat@unistra.fr; sophie.alain@unilim.fr; sebastien.hantz@unilim.fr		Ligat, Gaetan/0000-0003-1237-1936	Ministere de l'Enseignement Superieur et de la RechercheEstonian Research CouncilEuropean Commission; Conseil Regional de Nouvelle-Aquitaine; Institut National de la Sante et de la Recherche Medicale (Inserm)Institut National de la Sante et de la Recherche Medicale (Inserm); ANRS fellowshipANRSFrench National Research Agency (ANR) [ECTZ86820, ECTZ158023]; European Society of Clinical Microbiology and Infectious Diseases (ESCMID)	This work was granted by Ministere de l'Enseignement Superieur et de la Recherche, Conseil Regional de Nouvelle-Aquitaine and Institut National de la Sante et de la Recherche Medicale (Inserm). G.L. is the recipient of an ANRS fellowship (ECTZ86820 and ECTZ158023). This study has been funded by a Research Grant 2021 from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) to G.L.	Acosta E, 2020, J INFECT DIS, V221, P32, DOI 10.1093/infdis/jiz493; Adler SP, 2016, J INFECT DIS, V214, P1341, DOI 10.1093/infdis/jiw365; Brito LA, 2015, ADV GENET, V89, P179, DOI 10.1016/bs.adgen.2014.10.005; Chou SW, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104711; ELEK SD, 1974, LANCET, V1, P1; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Haidar G, 2020, J INFECT DIS, V221, P23, DOI 10.1093/infdis/jiz454; Heineman TC, 2006, J INFECT DIS, V193, P1350, DOI 10.1086/503365; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535; Ligat G, 2018, FEMS MICROBIOL REV, V42, P137, DOI 10.1093/femsre/fuy004; Ligat G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121093; Merck S., 2021, DOUBLE BLIND RANDOMI; NEFF BJ, 1979, P SOC EXP BIOL MED, V160, P32; Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749; Schleiss MR, 2013, FUTURE VIROL, V8, P1161, DOI 10.2217/fvl.13.106	16	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							968	10.3390/vaccines9090968			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2XA	34579205	Green Published, gold			2022-04-29	WOS:000702072000001
J	Maharjan, PM; Choe, S				Maharjan, Puna Maya; Choe, Sunghwa			Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines	VACCINES			English	Review						COVID-19 vaccine; SARS-CoV-2; plant-based vaccine; VLP; subunit vaccine; clinical trial; Nicotiana benthamaiana; RBD; spike protein; glycoengineering	VIRUS-LIKE PARTICLES; PROTECTIVE IMMUNE-RESPONSE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODIES; HEPATITIS-B; TRANSIENT EXPRESSION; DOSE-ESCALATION; VIRAL CHALLENGE; EDIBLE VACCINE; ORAL DELIVERY	The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco-produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more neutralizing antibody responses compared to those present in a convalescent patient's plasma. The clinical trial of the CoVLP vaccine could be concluded by the end of 2021, and the vaccine could be available for public immunization thereafter. This review encapsulates the efforts made in plant-based COVID-19 vaccine development, the strategies and technologies implemented, and the progress accomplished in clinical trials and preclinical studies so far.	[Maharjan, Puna Maya] G FLAS Life Sci, 123 Uiryodanji Gil, Cheongju 28161, South Korea; [Choe, Sunghwa] G FLAS Life Sci, 38 Nakseongdae Ro, Seoul 08790, South Korea; [Choe, Sunghwa] Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci, Seoul 08826, South Korea		Choe, S (通讯作者)，G FLAS Life Sci, 38 Nakseongdae Ro, Seoul 08790, South Korea.; Choe, S (通讯作者)，Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci, Seoul 08826, South Korea.	punamaya.maharjan@gflas.com; shchoe@snu.ac.kr	Choe, Sunghwa/K-5650-2013	Choe, Sunghwa/0000-0001-5541-484X	COVID-19 vaccine RD program [2016GFRND-GF105]	This project was supported by the COVID-19 vaccine R&D program (2016GFRND-GF105) of G+FLAS Life Sciences, Inc.	Alvarez ML, 2010, BIOTECHNOL ADV, V28, P184, DOI 10.1016/j.biotechadv.2009.11.006; Arlen PA, 2008, INFECT IMMUN, V76, P3640, DOI 10.1128/IAI.00050-08; Bao YJ, 2021, INT J INFECT DIS, V103, P540, DOI 10.1016/j.ijid.2020.12.014; Barr IG, 2020, EUROSURVEILLANCE, V25, DOI 10.2807/1560-7917.ES.2020.25.25.2001122; BAT, BAT PROGR COVID 19 C; Bian LL, 2021, EXPERT REV VACCINES, V20, P365, DOI 10.1080/14760584.2021.1903879; Bosch D, 2010, EXPERT REV VACCINES, V9, P835, DOI 10.1586/erv.10.83; BPN, BAT BIOT US TOB MAK; BPP, COVID 19 VACC DEV; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; BS, G FLAS SETT DEV PLAN; BUTLER PJG, 1984, J GEN VIROL, V65, P253, DOI 10.1099/0022-1317-65-2-253; Buyel JF, 2012, J CHROMATOGR B, V880, P19, DOI 10.1016/j.jchromb.2011.11.010; Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; Chackerian B, 2002, J IMMUNOL, V169, P6120, DOI 10.4049/jimmunol.169.11.6120; Chan HT, 2015, PLANT BIOTECHNOL J, V13, P1056, DOI 10.1111/pbi.12471; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218; Chichester JA, 2018, VACCINE, V36, P5865, DOI 10.1016/j.vaccine.2018.08.033; Chichester JA, 2012, VIRUSES-BASEL, V4, P3227, DOI 10.3390/v4113227; Chichester JA, 2009, VACCINE, V27, P3471, DOI 10.1016/j.vaccine.2009.01.050; ClinicalTrial, STUD EV SAF IMM KBP; ClinicalTrial, KBP 201 COVID 19 VAC; ClinicalTrial, SAF TOL IMM COR LIK; CNN, CNN; CNN, IBIO ANN ADV COVID 1; Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048; Cummings JF, 2014, VACCINE, V32, P2251, DOI 10.1016/j.vaccine.2013.10.017; D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P2913, DOI 10.1080/21645515.2020.1842034; Donini M, 2019, BIOTECHNOL LETT, V41, P335, DOI 10.1007/s10529-019-02651-z; Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20; Dynavax, CPG 1018; EMINI EA, 1983, NATURE, V304, P699, DOI 10.1038/304699a0; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519; Fox J. L., 2012, Nature Biotechnology, V30, P472, DOI 10.1038/nbt0612-472; Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]; Gleba YY, 2014, CURR TOP MICROBIOL, V375, P155, DOI 10.1007/82_2013_352; GLS, GFLAS LIF SCI SUCC E; Gobeil P., 2021, INTERIM REPORT PHASE, DOI [10.1101/2021.05.14.21257248, DOI 10.1101/2021.05.14.21257248]; Govea-Alonso DO, 2013, PLANTA, V238, P785, DOI 10.1007/s00425-013-1932-y; Guimaraes R., 2017, P SEM ANN CIENT TECH, P52; HAYNES JR, 1986, BIO-TECHNOL, V4, P637, DOI 10.1038/nbt0786-637; Huang Z, 2005, VACCINE, V23, P1851, DOI 10.1016/j.vaccine.2004.11.017; IBIO, VACC IBIO 202 COVID; IconGenetics, IC GEN CLIN DEV ITS; IGN, IBIO REP SUCC COVID; IGN, IBIO PLAN BIOT ENT E; Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064; Jones RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079538; Joung YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101715; Kang SS, 2020, ACTA PHARM SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009; Kapusta J, 1999, FASEB J, V13, P1796, DOI 10.1096/fasebj.13.13.1796; Karamloo F, 2020, ALLERGY, V75, P1822, DOI 10.1111/all.14360; Kashima K, 2016, PLANT CELL REP, V35, P667, DOI 10.1007/s00299-015-1911-9; KBP, OUR DISC PIP; Kumar AU, 2021, CLIN EXP VACCINE RES, V10, P13, DOI 10.7774/cevr.2021.10.1.13; Kurup VM, 2020, MOL BIOTECHNOL, V62, P79, DOI 10.1007/s12033-019-00222-1; Landry N, 2014, CLIN IMMUNOL, V154, P164, DOI 10.1016/j.clim.2014.08.003; Landry N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015559; LeBlanc Z, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010005; Lee MF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201281; Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480; Li HY, 2006, EXP BIOL MED, V231, P1346, DOI 10.1177/153537020623100808; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Li YZ, 2021, ACS CENTRAL SCI, V7, P512, DOI 10.1021/acscentsci.1c00120; Liang ZH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589833; Lico C, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.609910; Lindh I, 2014, VACCINE, V32, P2288, DOI 10.1016/j.vaccine.2014.02.073; Liu FX, 2012, RES VET SCI, V93, P553, DOI 10.1016/j.rvsc.2011.10.018; Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20; Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013; Maharjan PM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090978; Makatsa MS, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.589940; Mamedov T., 2020, ENG PRODUCTION CHARA, DOI [10.1101/2020.12.29.424779, DOI 10.1101/2020.12.29.424779]; Marillonnet S, 2005, NAT BIOTECHNOL, V23, P718, DOI 10.1038/nbt1094; Marusic C, 2018, BIOTECHNOL BIOENG, V115, P565, DOI 10.1002/bit.26503; Massa S, 2007, VACCINE, V25, P3018, DOI 10.1016/j.vaccine.2007.01.018; McDonald KA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00782; Medicago, MED ANN POS PHAS 1 R; Medicago, HLTH CAN IN REV ROLL; Medicago, COVID 19 VACC DEV PR; Medicago, MED GSK START PHAS 3; Medicago, MED PIP; Medicago, DISC PLATF; Medicago, MED GSK ANN START PH; Mett V, 2008, INFLUENZA OTHER RESP, V2, P33, DOI 10.1111/j.1750-2659.2008.00037.x; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Moon KB, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9010030; Mor TS, 2015, BIOTECHNOL LETT, V37, P2147, DOI 10.1007/s10529-015-1908-z; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Musiychuk K, 2007, INFLUENZA OTHER RESP, V1, P19, DOI 10.1111/j.1750-2659.2006.00005.x; Nature, NATURE; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Nochi T, 2009, J IMMUNOL, V183, P6538, DOI 10.4049/jimmunol.0901480; NPR, TOB PLANTS CONTR KEY; NYT, NYT; NYT, NYT; O'Hagan DT, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101426; Oliveira SC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587615; Ozdilek A, 2020, P NATL ACAD SCI USA, V117, P1280, DOI 10.1073/pnas.1916131117; Papageorgiou AC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112343; Pera FFPG, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0436-8; Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x; Pillet S, 2015, VACCINE, V33, P6282, DOI 10.1016/j.vaccine.2015.09.065; Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3; PMLiVE, GSK MED IN LAT STAG; Pogrebnyak N, 2005, P NATL ACAD SCI USA, V102, P9062, DOI 10.1073/pnas.0503760102; Ponndorf D, 2021, PLANT BIOTECHNOL J, V19, P745, DOI 10.1111/pbi.13501; Prompetchara E., 2021, BIOMATER TRANSL, V2, P43, DOI [10.3877/cma.j.issn.2096-112X.2021.01.006, DOI 10.3877/CMA.J.ISSN.2096-112X.2021.01.006]; Pulse, PULSE; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rattanapisit K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74904-1; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Rosales-Mendoza S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020183; Rosales-Mendoza S, 2020, EXPERT OPIN BIOL TH, V20, P545, DOI 10.1080/14712598.2020.1752177; RT, DARPAS BLUE ANG PENT; Rubio-Infante N, 2015, MOL BIOTECHNOL, V57, P662, DOI 10.1007/s12033-015-9856-3; Rybicki EP, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0205-0; Rybicki ER, 2009, DRUG DISCOV TODAY, V14, P16, DOI 10.1016/j.drudis.2008.10.002; Salazar E, 2020, J CLIN INVEST, V130, P6728, DOI 10.1172/JCI141206; Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5; Shaaltiel Y, 2007, PLANT BIOTECHNOL J, V5, P579, DOI 10.1111/j.1467-7652.2007.00263.x; Shanmugaraj B, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.589995; Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842; Shim BS, 2019, CLIN EXP VACCINE RES, V8, P136, DOI 10.7774/cevr.2019.8.2.136; Shohag MJI, 2021, PLANTS-BASEL, V10, DOI 10.3390/plants10020352; Shoji Y, 2012, INFLUENZA OTHER RESP, V6, P204, DOI 10.1111/j.1750-2659.2011.00295.x; Siriwattananon K, 2021, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.604663; Streatfield SJ, 2015, PLANT BIOTECHNOL J, V13, P1136, DOI 10.1111/pbi.12475; Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653; Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Thanavala Y, 2005, P NATL ACAD SCI USA, V102, P3378, DOI 10.1073/pnas.0409899102; Tottey S, 2018, AM J TROP MED HYG, V98, P420, DOI 10.4269/ajtmh.16-0293; Tremouillaux-Guiller J, 2020, CURR OPIN BIOTECH, V61, P209, DOI 10.1016/j.copbio.2020.01.004; Tuse D, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.594019; van Eerde A, 2019, PLANT BIOTECHNOL J, V17, P1408, DOI 10.1111/pbi.13065; Venuti A, 2015, CANCER IMMUNOL IMMUN, V64, P1329, DOI 10.1007/s00262-015-1734-0; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang MY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587269; Ward BJ, 2021, NAT MED, V27, P1071, DOI 10.1038/s41591-021-01370-1; Ward BJ, 2021, VACCINE, V39, P1528, DOI 10.1016/j.vaccine.2021.01.004; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; Wintjens R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00237-9; Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/nchembio.1403, 10.1038/NCHEMBIO.1403]; World Health Organization, DRAFT LANDSC TRACK C; Worldometer, COVID 19 COR PAND; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Yao J, 2015, INT J MOL SCI, V16, P28549, DOI 10.3390/ijms161226122; Yusibov V, 2002, VACCINE, V20, P3155, DOI 10.1016/S0264-410X(02)00260-8; Zhang YF, 2014, SCI CHINA LIFE SCI, V57, P987, DOI 10.1007/s11427-014-4746-7	158	9	9	100	128	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							992	10.3390/vaccines9090992			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3AZ	34579229	Green Published, gold			2022-04-29	WOS:000702082400001
J	Sabree, SA; Lemke-Miltner, CD; Blackwell, SE; Yin, CB; Bossler, A; Ebeid, K; Salem, AK; Weiner, GJ				Sabree, Shakoora A.; Lemke-Miltner, Caitlin D.; Blackwell, Sue E.; Yin, Chaobo; Bossler, Aaron; Ebeid, Kareem; Salem, Aliasger K.; Weiner, George J.			Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod	VACCINES			English	Article						vidutolimod; Fc gamma receptor; TLR9; pDCs; Type 1 Interferon; monocytes	PLASMACYTOID DENDRITIC CELLS; MONOCLONAL-ANTIBODIES; IFN-ALPHA; TNF-ALPHA; T-CELLS; MACROPHAGES; ACTIVATION	Vidutolimod, also known as CMP-001, is a virus-like particle composed of the Q beta bacteriophage coat protein encasing a TLR9 agonist. Vidutolimod injected intratumorally is showing promise in early phase clinical trials based on its ability to alter the tumor microenvironment and induce an anti-tumor immune response. We previously demonstrated that the in vivo efficacy of vidutolimod is dependent on the presence of anti-Q beta antibodies that enhance opsonization and uptake of vidutolimod by TLR9-expressing plasmacytoid dendritic cells (pDCs). Here, we evaluated the effect of immune complexes, including anti-Q beta-coated vidutolimod, on induction of Type 1 Interferon production by peripheral blood mononuclear cells in response to vidutolimod and soluble TLR9 agonists. Immune complexes, including but not limited to anti-Q beta-coated vidutolimod, indirectly suppressed TLR9-mediated Type 1 Interferon production by pDCs in a monocyte-dependent manner. These findings indicate that anti-Q beta-coated vidutolimod has effects in addition to those mediated by TLR9 that could have important clinical implications for understanding the mechanism of action of this exciting new approach to in situ immunization and cancer immunotherapy.	[Sabree, Shakoora A.] Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; [Sabree, Shakoora A.] Univ Iowa, Med Scientist Training Program, Carver Coll Med, Iowa City, IA 52242 USA; [Sabree, Shakoora A.; Lemke-Miltner, Caitlin D.; Blackwell, Sue E.; Yin, Chaobo; Salem, Aliasger K.; Weiner, George J.] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Bossler, Aaron] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA; [Ebeid, Kareem; Salem, Aliasger K.] Univ Iowa, Coll Pharm, Dept Pharmaceut & Translat Therapeut, Iowa City, IA 52242 USA; [Weiner, George J.] Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA		Weiner, GJ (通讯作者)，Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.; Weiner, GJ (通讯作者)，Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA.	shakoora-sabree@uiowa.edu; caitlin-lemke@uiowa.edu; sue-blackwell@uiowa.edu; chaobo-yin@uiowa.edu; aaron-bossler@uiowa.edu; kareematefnassar-ebeid@uiowa.edu; aliasger-salem@uiowa.edu; george-weiner@uiowa.edu		weiner, george/0000-0003-3427-0562; Bossler, Aaron/0000-0002-8748-2510	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 CA86862, P50 CA97274]; Checkmate Pharmaceuticals	Research funding was provided by NIH grants P30 CA86862 and P50 CA97274, including an NCI Diversity Supplement provided to Shakoora Sabree, as well as by funding from Checkmate Pharmaceuticals.	Aman MJ, 1996, BLOOD, V87, P4731, DOI 10.1182/blood.V87.11.4731.bloodjournal87114731; Ambarus CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035994; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Conrad C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02466-4; Dewald HK, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020162; Duramad O, 2003, BLOOD, V102, P4487, DOI 10.1182/blood-2003-07-2465; Gao XJ, 2017, EUR REV MED PHARMACO, V21, P1810; Hammerich L, 2015, MOL ONCOL, V9, P1966, DOI 10.1016/j.molonc.2015.10.016; Hart SP, 2004, J IMMUNOL, V172, P1882, DOI 10.4049/jimmunol.172.3.1882; Hoepel W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00739; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; KIM JW, 1991, AM J RESP CELL MOL, V5, P249, DOI 10.1165/ajrcmb/5.3.249; Lemke-Miltner CD, 2020, J IMMUNOL, V204, P1386, DOI 10.4049/jimmunol.1900742; MANCA F, 1988, J IMMUNOL, V140, P2893; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; Mathsson L, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1926; Menon M, 2016, IMMUNITY, V44, P683, DOI 10.1016/j.immuni.2016.02.012; Miller AM, 2021, ANN SURG ONCOL, V28, P1187, DOI 10.1245/s10434-020-08591-7; Newling M, 2018, EUR J IMMUNOL, V48, P1796, DOI 10.1002/eji.201847615; Palucka AK, 2005, P NATL ACAD SCI USA, V102, P3372, DOI 10.1073/pnas.0408506102; Psarras A, 2021, J IMMUNOL, V206, P785, DOI 10.4049/jimmunol.1901358; Ribas A, 2021, CANCER DISCOV, V11, P2998, DOI 10.1158/2159-8290.CD-21-0425; Sabree SA, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002484; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Shi BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044900; Steinitz M, 2014, METHODS MOL BIOL, V1060, P111, DOI 10.1007/978-1-62703-586-6_6; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Vogelpoel LTC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6444; Waibler Z, 2008, EUR J IMMUNOL, V38, P3127, DOI 10.1002/eji.200838184	29	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							982	10.3390/vaccines9090982			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2WC	34579220	Green Published, gold			2022-04-29	WOS:000702069600001
J	Teherani, M; Banskota, S; Camacho-Gonzalez, A; Smith, AGC; Anderson, EJ; Kao, CM; D'Orleans, CC; Shane, AL; Lu, A; Jaggi, P				Teherani, Mehgan; Banskota, Samridhi; Camacho-Gonzalez, Andres; Smith, Alison G. C.; Anderson, Evan J.; Kao, Carol M.; D'Orleans, Charles Crepy; Shane, Andi L.; Lu, Austin; Jaggi, Preeti			Intent to Vaccinate SARS-CoV-2 Infected Children in US Households: A Survey	VACCINES			English	Article						vaccine hesitancy; pediatrics; children; COVID-19; SARS-CoV-2; mRNA; intent-to-vaccinate		A paucity of data exists evaluating a guardian's intent to vaccinate their child against COVID-19 in the United States. We administered 102 first (April-November 2020) and 45 second (December-January 2020-2021) surveys to guardians of children (<18 years) who had a laboratory-confirmed diagnosis of COVID-19 and assessed their intent to give a COVID-19 vaccine to their child, when one becomes available. The first and second surveys of the same cohort of guardians were conducted before and following the press releases detailing the adult Pfizer-BioNTech and Moderna Phase 3 results. Both surveys included an intent-to-vaccinate question using the subjective language of "if a safe and effective vaccine" became available, and a second question was added to second surveys using the objective language of "would prevent 19 of 20 people from getting disease". When using subjective language, 24 of 45 (53%) guardians endorsed vaccine administration for their children in the first survey, which decreased to 21 (46%) in the second survey. When adding objective language, acceptance of vaccination increased to 31 (69%, p = 0.03). Common reasons for declining vaccination were concerns about adverse effects and/or vaccine safety. Providing additional facts on vaccine efficacy increased vaccine acceptance. Evidence-based strategies are needed to increase pediatric COVID-19 vaccine uptake.	[Teherani, Mehgan; Camacho-Gonzalez, Andres; Anderson, Evan J.; Shane, Andi L.; Jaggi, Preeti] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Dept Pediat, Atlanta, GA 30322 USA; [Banskota, Samridhi; Smith, Alison G. C.; D'Orleans, Charles Crepy; Lu, Austin] Emory Univ, Sch Med, Atlanta, GA 30322 USA; [Kao, Carol M.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA		Teherani, M; Jaggi, P (通讯作者)，Emory Univ, Sch Med, Childrens Healthcare Atlanta, Dept Pediat, Atlanta, GA 30322 USA.	mehgan.kidd@gmail.com; samridhi.banskota@emory.edu; acamac2@emory.edu; alison.smith@emory.edu; evanderson@emory.edu; kaoc@wustl.edu; charles.edouard.crepy.dorleans@emory.edu; ashane@emory.edu; austin.lu@emory.edu; preeti.jaggi@emory.edu		Banskota, Samridhi/0000-0002-3934-2273; Anderson, Evan/0000-0002-1576-4420			Anderson EJ, 2021, CLIN INFECT DIS, V73, P336, DOI 10.1093/cid/ciaa1425; [Anonymous], CHILDREN COVID 19 VA; [Anonymous], COVID 19 VACCINATION; [Anonymous], PFIZER BIONTECH ANNO; [Anonymous], MODERNA ANNOUNCES PR; Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Children and COVID-19: State-Level Data Report, CHILDREN COVID 19 ST; Choi SH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e227; Clark S.J., 2021, MORE PARENT PROVIDER, V39; Donovan Joan, 2020, Nature, DOI 10.1038/d41586-020-01107-z; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Gomes M Gabriela M, 2022, medRxiv, DOI 10.1101/2020.04.27.20081893; Grijalva CG, 2020, MMWR-MORBID MORTAL W, V69, P1631, DOI [10.15585/mmwr. mm6944e1, 10.15585/mmwr.mm6944e1]; He KD, 2022, J COMMUN HEALTH, V47, P39, DOI 10.1007/s10900-021-01017-9; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Li F, 2021, LANCET INFECT DIS, V21, P617, DOI [10.1016/S1473-3099(20)30981-6, 10.1016/S1473-3099(20)30981-6Hubei430030]; Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604; Madewell ZJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.31756; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; SteelFisher GK, 2021, NEW ENGL J MED, V384, P1483, DOI 10.1056/NEJMp2100351; Teherani MF, 2020, J PEDIAT INF DIS SOC, V9, P613, DOI 10.1093/jpids/piaa097; Viceconte G, 2020, INFECT DIS REP, V12, P1, DOI 10.4081/idr.2020.8516; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; World Health Organization (WHO), TOP 10 THREATS GLOB	32	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1049	10.3390/vaccines9091049			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YA	34579286	gold, Green Published			2022-04-29	WOS:000702074700001
J	Dang, M; Cao, T; Vasquez, I; Hossain, A; Gnanagobal, H; Kumar, S; Hall, JR; Monk, J; Boyce, D; Westcott, J; Santander, J				Dang, My; Cao, Trung; Vasquez, Ignacio; Hossain, Ahmed; Gnanagobal, Hajarooba; Kumar, Surendra; Hall, Jennifer R.; Monk, Jennifer; Boyce, Danny; Westcott, Jillian; Santander, Javier			Oral Immunization of Larvae and Juvenile of Lumpfish (Cyclopterus lumpus) against Vibrio anguillarum Does Not Influence Systemic Immunity	VACCINES			English	Article						lumpfish; cleaner fish; fish larvae; oral vaccine; Vibrio anguillarum bacterin; vibriosis; bio-encapsulation; Artemia salina	IMMUNOGLOBULIN HEAVY-CHAIN; DICENTRARCHUS-LABRAX L.; NECROSIS VIRUS-VACCINE; SEA LICE; YERSINIA-RUCKERI; RAINBOW-TROUT; AEROMONAS-SALMONICIDA; ATLANTIC SALMON; DELIVERY-SYSTEM; CLEANER FISH	Vibrio anguillarum, a marine bacterial pathogen that causes vibriosis, is a recurrent pathogen of lumpfish (Cyclopterus lumpus). Lumpfish is utilized as a cleaner fish in the Atlantic salmon (Salmo salar) aquaculture in the North Atlantic region because of its ability to visualize and prey on the ectoparasite sea lice (Lepeophtheirus salmonis) on the skin of Atlantic salmon, and its performance in cold environments. Lumpfish immunity is critical for optimal performance and sea lice removal. Oral vaccine delivery at a young age is the desired method for fish immunization because is easy to use, reduces fish stress during immunization, and can be applied on a large scale while the fish are at a young age. However, the efficacy of orally delivered inactivated vaccines is controversial. In this study, we evaluated the effectiveness of a V. anguillarum bacterin orally delivered to cultured lumpfish and contrasted it to an intraperitoneal (i.p.) boost delivery. We bio-encapsulated V. anguillarum bacterin in Artemia salina live-feed and orally immunized lumpfish larvae. Vaccine intake and immune response were evaluated by microscopy and quantitative polymerase chain reaction (qPCR) analysis, respectively. qPCR analyses showed that the oral immunization of lumpfish larvae resulted in a subtle stimulation of canonical immune transcripts such as il8b, il10, igha, ighmc, ighb, ccl19, ccl20, cd8a, cd74, ifng, and lgp2. Nine months after oral immunization, one group was orally boosted, and a second group was both orally and i.p. boosted. Two months after boost immunization, lumpfish were challenged with V. anguillarum (7.8 x 10(5) CFU dose(-1)). Orally boosted fish showed a relative percentage of survival (RPS) of 2%. In contrast, the oral and i.p. boosted group showed a RPS of 75.5% (p < 0.0001). V. anguillarum bacterin that had been orally delivered was not effective in lumpfish, which is in contrast to the i.p. delivered bacterin that protected the lumpfish against vibriosis. This suggests that orally administered V. anguillarum bacterin did not reach the deep lymphoid tissues, either in the larvae or juvenile fish, therefore oral immunization was not effective. Oral vaccines that are capable of crossing the epithelium and reach deep lymphoid tissues are required to confer an effective protection to lumpfish against V. anguillarum	[Dang, My; Cao, Trung; Vasquez, Ignacio; Hossain, Ahmed; Gnanagobal, Hajarooba; Santander, Javier] Mem Univ Newfoundland, Dept Ocean Sci, Marine Microbial Pathogenesis & Vaccinol Lab, St John, NF A1C 5S7, Canada; [Kumar, Surendra] Mem Univ Newfoundland, Ocean Frontier Inst, Dept Ocean Sci, St John, NF A1C 5S7, Canada; [Hall, Jennifer R.] Mem Univ Newfoundland, Dept Ocean Sci, Aquat Res Cluster, CREAIT Network, St John, NF A1C 5S7, Canada; [Monk, Jennifer; Boyce, Danny] Mem Univ Newfoundland, Dr Joe Brown Aquat Res Bldg JBARB, St John, NF A1C 5S7, Canada; [Westcott, Jillian] Mem Univ Newfoundland, Fisheries & Marine Inst, St John, NF A1C 5S7, Canada		Santander, J (通讯作者)，Mem Univ Newfoundland, Dept Ocean Sci, Marine Microbial Pathogenesis & Vaccinol Lab, St John, NF A1C 5S7, Canada.	tmtdang@mun.ca; ttcao@mun.ca; ivasquezsoli@mun.ca; ahossain@mun.ca; hgnanagobal@mun.ca; surendrak@mun.ca; jrhall@mun.ca; jmonk@mun.ca; dboyce@mun.ca; jillian.westcott@mi.mun.ca; jillian.westcott@mi.mun.ca	Kumar, Surendra/C-9238-2011	Kumar, Surendra/0000-0001-5396-5509	Ocean Frontier Institute through the Canada First Research Excellence Fund (sub-module J3); Vietnam International Education Development (VIED) fellowship; Government of Newfoundland and Labrador; Department of Fisheries and Land Resources, NSERC [RGPIN-2018-05942]; Atlantic Fisheries Fund, Canada	Research funding was provided by the Ocean Frontier Institute through an award from the Canada First Research Excellence Fund (sub-module J3), the Vietnam International Education Development (VIED) fellowship, the Government of Newfoundland and Labrador, Department of Fisheries and Land Resources, NSERC-Discovery grant (RGPIN-2018-05942), and the Atlantic Fisheries Fund, Canada.	Aaen SM, 2015, TRENDS PARASITOL, V31, P72, DOI 10.1016/j.pt.2014.12.006; Amend DF., 1981, FISH BIOLOGICS SEROD, V49, P447; AMLOT PL, 1986, CLIN EXP IMMUNOL, V64, P125; ANDERSON DP, 1983, DEV COMP IMMUNOL, V7, P261, DOI 10.1016/0145-305X(83)90007-1; Arancibia SA, 2007, BIOL RES, V40, P97, DOI 10.4067/S0716-97602007000200001; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Beswick EJ, 2009, WORLD J GASTROENTERO, V15, P2855, DOI 10.3748/wjg.15.2855; Bolton-Warberg M, 2018, J FISH DIS, V41, P935, DOI 10.1111/jfd.12731; Boyce D., 2018, CLEANER FISH BIOL AQ; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Brooker AJ, 2018, VET REC, V183, P383, DOI 10.1136/vr.104966; Brooks KM, 2009, J FISH DIS, V32, P59, DOI 10.1111/j.1365-2761.2008.01013.x; BROWN JA, 1986, J FISH BIOL, V29, P171, DOI 10.1111/j.1095-8649.1986.tb05008.x; Buonocore F, 2006, FISH SHELLFISH IMMUN, V20, P637, DOI 10.1016/j.fsi.2005.08.006; CAMPBELL R, 1993, FISH SHELLFISH IMMUN, V3, P451, DOI 10.1006/fsim.1993.1044; Chakraborty S, 2019, J FISH DIS, V42, P1057, DOI 10.1111/jfd.13010; Chang MX, 2011, J VIROL, V85, P8403, DOI 10.1128/JVI.00445-10; Charmley K.J., 2019, SURG J, V11, DOI [10.21083/surg.v11i0.4656, DOI 10.21083/SURG.V11I0.4656]; Chen YM, 2011, AQUACULTURE, V321, P26, DOI 10.1016/j.aquaculture.2011.08.035; Chettri JK, 2015, AQUACULTURE, V440, P1, DOI 10.1016/j.aquaculture.2015.01.027; Costello MJ, 2009, J FISH DIS, V32, P115, DOI 10.1111/j.1365-2761.2008.01011.x; Dadar M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02478; Danilova N, 2005, NAT IMMUNOL, V6, P295, DOI 10.1038/ni1166; Dijkstra Johannes M, 2018, F1000Res, V7, P963, DOI 10.12688/f1000research.15386.2; Dubin A, 2019, BIOL LETTERS, V15, DOI 10.1098/rsbl.2019.0594; Eggestol HO, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23667-x; Ellul RM, 2019, FISH SHELLFISH IMMUN, V95, P650, DOI 10.1016/j.fsi.2019.11.016; Erkinharju T, 2021, REV AQUACULT, V13, P189, DOI 10.1111/raq.12470; Eslamloo K, 2020, FISH SHELLFISH IMMUN, V98, P937, DOI 10.1016/j.fsi.2019.11.057; Fast MD, 2014, DEV COMP IMMUNOL, V43, P300, DOI 10.1016/j.dci.2013.08.019; Fissell WH, 2007, AM J PHYSIOL-RENAL, V293, pF1209, DOI 10.1152/ajprenal.00097.2007; Foss A, 2020, AQUACULT ENG, V90, DOI 10.1016/j.aquaeng.2020.102074; Frans I, 2011, J FISH DIS, V34, P643, DOI 10.1111/j.1365-2761.2011.01279.x; Galeottia M, 2013, VACCINE, V31, P1224, DOI 10.1016/j.vaccine.2012.12.041; Holm KO, 2015, STAND GENOMIC SCI, V10, DOI 10.1186/s40793-015-0060-7; Imsland AK, 2014, AQUACULTURE, V424, P18, DOI 10.1016/j.aquaculture.2013.12.033; Imsland AKD, 2019, AQUACULTURE, V498, P217, DOI 10.1016/j.aquaculture.2018.08.061; INMAN JK, 1975, J IMMUNOL, V114, P704; Jayaramu PK, 2017, FISH SHELLFISH IMMUN, V63, P68, DOI 10.1016/j.fsi.2017.01.041; Ji JF, 2018, J IMMUNOL, V200, P573, DOI 10.4049/jimmunol.1701149; JOHNSON KA, 1983, J FISH DIS, V6, P331, DOI 10.1111/j.1365-2761.1983.tb00084.x; JOHNSON KA, 1982, J FISH DIS, V5, P207, DOI 10.1111/j.1365-2761.1982.tb00475.x; JOHNSON KA, 1983, J FISH DIS, V6, P473, DOI 10.1111/j.1365-2761.1983.tb00101.x; Kumari J, 2013, J FISH DIS, V36, P881, DOI 10.1111/jfd.12100; Leboffe M.J., 2019, MICROBIOLOGY LAB THE; Lin CC, 2007, AQUACULTURE, V268, P265, DOI 10.1016/j.aquaculture.2007.04.066; Lin JHY, 2005, DEV BIOLOGICALS, V121, P175; Liu FG, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103502; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loughner CL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0074-2; MACNEIL I, 1993, J IMMUNOL, V151, P6913; Mallya M, 2006, PROTEIN SCI, V15, P2244, DOI 10.1110/ps.062242606; Marcos-Lopez M, 2013, VET REC, V173, DOI 10.1136/vr.101763; Mikkelsen H, 2011, FISH SHELLFISH IMMUN, V30, P330, DOI 10.1016/j.fsi.2010.11.007; Milley B, 2016, BIOCONJUGATE CHEM, V27, P1293, DOI 10.1021/acs.bioconjchem.6b00107; Min WG, 2001, VACCINE, V20, P267, DOI 10.1016/S0264-410X(01)00270-5; Moldenhauer G, 1999, IMMUNOLOGY, V96, P473; Monk J., 2016, Bulletin of the Aquaculture Association of Canada, V2016-2, P39; Mutoloki S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00519; NDF Fisheries, 2019, NORW DIR FISH; Ohtani M, 2010, J IMMUNOL, V185, P7507, DOI 10.4049/jimmunol.1001850; Overton K, 2020, AQUACULT ENV INTERAC, V12, P31, DOI 10.3354/aei00345; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007; Powell A, 2018, REV AQUACULT, V10, P683, DOI 10.1111/raq.12194; Ronneseth A, 2017, FISH SHELLFISH IMMUN, V64, P383, DOI 10.1016/j.fsi.2017.03.040; Rueness E., 2019, ASSESSMENT RISK NORW, P2535; Sambrook J, 2001, MOL CLONING LAB MANU; Santander J, 2012, INFECT IMMUN, V80, P2689, DOI 10.1128/IAI.00013-12; Savan R, 2005, EUR J IMMUNOL, V35, P3320, DOI 10.1002/eji.200535248; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Soto-Davila M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01237; Star B, 2011, NATURE, V477, P207, DOI 10.1038/nature10342; Toffan A, 2019, J FISH DIS, V42, P1667, DOI 10.1111/jfd.13088; Treasurer JW, 2002, PEST MANAG SCI, V58, P546, DOI 10.1002/ps.509; Trowsdale J, 2013, ANNU REV GENOM HUM G, V14, P301, DOI 10.1146/annurev-genom-091212-153455; Umasuthan N, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040812; Upadhyay G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00819; Valderrama K, 2019, J FISH DIS, V42, P1601, DOI 10.1111/jfd.13077; van der Veen AG, 2018, EMBO J, V37, DOI 10.15252/embj.201797479; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vasquez I, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111666; Vasquez I, 2020, FISH SHELLFISH IMMUN, V104, P557, DOI 10.1016/j.fsi.2020.06.005; Villumsen KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093845; Wessman P, 2013, JOVE-J VIS EXP, DOI 10.3791/4058; Whittaker BA, 2018, PEERJ, V6, DOI 10.7717/peerj.5974; Xu C, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-78; Yan Y, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00212; Yasuike M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-486; Zhang QM, 2018, J IMMUNOL, V200, P688, DOI 10.4049/jimmunol.1701388	90	2	2	0	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							819	10.3390/vaccines9080819			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2UL	34451944	gold, Green Published			2022-04-29	WOS:000689792700001
J	Al-Lahham, A; Khanfar, N; Albataina, N; Al Shwayat, R; Altwal, R; Abulfeilat, T; Alawneh, G; Khurd, M; Altamimi, AA				Al-Lahham, Adnan; Khanfar, Nashat; Albataina, Noor; Al Shwayat, Rana; Altwal, Rawsan; Abulfeilat, Talal; Alawneh, Ghaith; Khurd, Mohammad; Altamimi, Abdelsalam Alqadi			Urban and Rural Disparities in Pneumococcal Carriage and Resistance in Jordanian Children, 2015-2019	VACCINES			English	Article						Streptococcus pneumoniae; carriage; resistance; PCVs; urban; rural	STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; COLONIZATION; IMPACT; INFANTS; DISEASE	Background: A pneumococcal carriage surveillance study took place examining Jordanian children in urban and rural areas in the period 2015-2019. Objectives: To determine urban and rural differences in pneumococcal carriage rate, resistance, and serotypes among healthy Jordanian children from Amman (urban) and eastern Madaba (rural). Methods: Nasopharyngeal swabs (NP) were taken from 682 children aged 1 to 163 months. Pneumococcal identification, serotyping, and resistance were performed according to standard method. Results: The number of cases tested for Amman was 267 and there were 415 cases tested for eastern Madaba. Carriage rate for eastern Madaba was 39.5% and 31.1% for Amman. Predominant serotypes for eastern Madaba and Amman were 19F (21.3%; 15.7%), 23F (12.2%; 9.6%), 14 (6.7%; 2.4%), 19A (4.9%; 2.4%), and 6A (5.5%; 3.6%). Resistance rates for eastern Madaba and Amman were as follows: penicillin (95.8%; 81.9%), clarithromycin (68.9%; 59.0%), clindamycin (40.8%; 31.3%), and trimethoprim-sulfamethoxazole (73.2%; 61.4%). Coverage of PCV7, PCV13, and the future PCV20 for Amman was 42.2%, 48.2%, and 60.2%; for eastern Madaba, coverage was 50.0%, 62.2%, and 73.2%, respectively. In Amman 25.8% of children received 1-3 PCV7 injections compared to 1.9% of children in eastern Madaba. Conclusions: There were significant differences in carriage, resistance, and coverage between both regions. The potential inclusion of a PCV vaccination program for rural areas is essential.	[Al-Lahham, Adnan; Albataina, Noor; Al Shwayat, Rana; Altwal, Rawsan; Abulfeilat, Talal; Alawneh, Ghaith; Khurd, Mohammad; Altamimi, Abdelsalam Alqadi] German Jordanian Univ, Sch Appl Med Sci, Dept Biomed Engn, Amman 11180, Jordan; [Khanfar, Nashat] Pediat Clin, Salim Khouri Str 48, Amman 11953, Jordan		Al-Lahham, A (通讯作者)，German Jordanian Univ, Sch Appl Med Sci, Dept Biomed Engn, Amman 11180, Jordan.	adnan.lahham@giu.edu.jo; nashatkhanfar@yahoo.com; Nootalbataina@giu.edu.jo; R.Alshwayat@gju.edu.jo; R.Altwall@gju.edu.jo; T.abulfeilat@gju.edu.jo; G.Alawnehl@gju.edu.jo; M.khurd@gju.edu.jo; A.Alqadialtamimi@gju.edu.jo		Al-Lahham, Adnan/0000-0002-5661-3426	deanship of scientific research at the GERMAN JORDANIAN UNIVERSITY [SAMS 22/2015, SAMS 45/2017]	This research was funded by the deanship of scientific research at the GERMAN JORDANIAN UNIVERSITY under the research grant numbers SAMS 22/2015 and SAMS 45/2017.	Abdullahi O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030787; Adegbola RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103293; Al-Lahham A., 2018, Jordan Journal of Biological Sciences (JJBS), V11, P155; Al-Lahham A., 2014, INT ARAB J ANTIMICRO, V4, P1, DOI [10.3823/752, DOI 10.3823/752]; Al-Lahham A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237247; Allemann A, 2017, VACCINE, V35, P1946, DOI 10.1016/j.vaccine.2017.02.010; Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5; Boken DJ, 1996, PEDIATR INFECT DIS J, V15, P667, DOI 10.1097/00006454-199608000-00006; Bruce MG, 2015, VACCINE, V33, P4813, DOI 10.1016/j.vaccine.2015.07.080; Buie KA, 2004, J INFECT DIS, V189, P1996, DOI 10.1086/386548; Burton DC, 2010, AM J PUBLIC HEALTH, V100, P1904, DOI 10.2105/AJPH.2009.181313; Chaguza C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17327-w; Clinical and Laboratory Standards Institute (CLSI), 2020, M100 PERF STAND ANT, V30th; de St Maurice A, 2016, J INFECT DIS, V214, P792, DOI 10.1093/infdis/jiw222; de St Maurice A, 2015, PEDIATRICS, V136, pE1186, DOI 10.1542/peds.2015-1773; Devine VT, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/394368; Garcia-Rodriguez JA, 2002, J ANTIMICROB CHEMOTH, V50, P59, DOI 10.1093/jac/dkf506; Koliou MG, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1119-6; Krone CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119875; Lee NY, 2001, CLIN INFECT DIS, V32, P1463, DOI 10.1086/320165; Magliano E, 2012, SCI WORLD J, DOI 10.1100/2012/349597; Monali R, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001077; Nisar MI, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3608-5; Otoom S, 2002, East Mediterr Health J, V8, P537; Schaumburg F, 2013, T ROY SOC TROP MED H, V107, P105, DOI 10.1093/trstmh/trs018; Schultsz C, 2007, T ROY SOC TROP MED H, V101, P484, DOI 10.1016/j.trstmh.2006.08.010; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]; Soto K, 2011, PUBLIC HEALTH REP, V126, P81, DOI 10.1177/00333549111260S313; Verani JR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191113; Wardlow T.J.E., 2006, Pneumonia: The Forgotten Killer of Children; Wiese AD, 2019, EXPERT REV VACCINES, V18, P327, DOI 10.1080/14760584.2019.1582337; Williams JD, 2002, INT J ANTIMICROB AG, V20, P75; Wouters I, 2019, VACCINE, V37, P1080, DOI 10.1016/j.vaccine.2018.12.068; Wouters I, 2018, VACCINE, V36, P15, DOI 10.1016/j.vaccine.2017.11.052	34	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							789	10.3390/vaccines9070789			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7SB	34358205	Green Submitted, Green Published			2022-04-29	WOS:000677105200001
J	Lee, EJ; Kwon, OD; Kim, SJ				Lee, Eung-Joon; Kwon, Oh Deog; Kim, Seung Jae			Influenza Vaccination Status and Its Affecting Factors among Stroke Survivors: Findings from the Korea National Health and Nutrition Examination Survey	VACCINES			English	Article						influenza; vaccination; stroke survivors; associated factors; KNHANES	SEASONAL INFLUENZA; CARDIOVASCULAR-DISEASE; REDUCED RISK; ASSOCIATION; MORTALITY; COVERAGE; PREVENTION; COUNTRIES; EFFICACY; SMOKING	Few studies have examined the influenza vaccination rates among stroke survivors despite the importance of vaccines in preventing influenza- and stroke-related complications. Thus, we investigated the vaccination rates and the associated factors among stroke survivors using the representative Korea National Health and Nutrition Examination Survey 2014-2018. We measured and compared the vaccination rates of 591 stroke survivors and 17,997 non-stroke survivors. Multivariate logistic regression analyses of all stroke survivors and age subgroups (<65 and >= 65 years) were performed to identify the factors influencing vaccination. The overall vaccination rate was significantly higher in the stroke survivors (64.8%) than in the non-stroke survivors (41.1%), but it was low compared to global standards. Among stroke survivors aged <65 years, the rate was low (37.5%), but it improved in those aged >= 65 years (85.6%). Age >= 65 years, the eligible age for the national free vaccination program was the most prominent predictor of vaccination for all stroke survivors, while smoking was a negative predictor. No significant factors were found in the subgroup analyses according to age (<65 and >= 65 years). Therefore, implementing strategic public health policies, such as expanding the free vaccination program to stroke survivors aged <65 years, may improve vaccine coverage.	[Lee, Eung-Joon] Seoul Natl Univ Hosp, Inst Publ Hlth & Med Care, Seoul 03080, South Korea; [Lee, Eung-Joon] Seoul Natl Univ Hosp, Dept Neurol, Seoul 03080, South Korea; [Kwon, Oh Deog] Movinci Clin, Seoul 06030, South Korea; [Kim, Seung Jae] Catholic Univ Korea, Coll Med, Int Healthcare Ctr, Seoul St Marys Hosp, Seoul 06591, South Korea; [Kim, Seung Jae] Catholic Univ Korea, Coll Med, Dept Family Med, Seoul St Marys Hosp, Seoul 06591, South Korea		Kim, SJ (通讯作者)，Catholic Univ Korea, Coll Med, Int Healthcare Ctr, Seoul St Marys Hosp, Seoul 06591, South Korea.; Kim, SJ (通讯作者)，Catholic Univ Korea, Coll Med, Dept Family Med, Seoul St Marys Hosp, Seoul 06591, South Korea.	lejoon0824@gmail.com; ovirtue@gmail.com; vincanity@hanmail.net		Kim, Seung Jae/0000-0001-8885-7137			AHLSIO B, 1984, STROKE, V15, P886, DOI 10.1161/01.STR.15.5.886; Ajani UA, 2005, AM HEART J, V149, P254, DOI 10.1016/j.ahj.2004.07.028; [Anonymous]; Atkinson W., 2011, CONTROL CFD PREVENTI; Baek JH, 2014, KOREAN J INTERN MED, V29, P265, DOI 10.3904/kjim.2014.29.2.265; Blank Patricia, 2012, Hum Vaccin Immunother, V8, P328, DOI 10.4161/hv.18629; Chiang MH, 2017, AM HEART J, V193, P1, DOI 10.1016/j.ahj.2017.07.020; Davis MM, 2006, J AM COLL CARDIOL, V48, P1498, DOI 10.1016/j.jacc.2006.09.004; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Grau AJ, 2005, STROKE, V36, P1501, DOI 10.1161/01.STR.0000170674.45136.80; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Hak E, 2005, ARCH INTERN MED, V165, P274, DOI 10.1001/archinte.165.3.274; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kim EY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018540; Kim YS, 2020, KOREAN J FAM MED, V41, P45, DOI 10.4082/kjfm.18.0165; Kim Y, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014002; Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228; Kwon DS, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012618; Lavallee P, 2002, STROKE, V33, P513, DOI 10.1161/hs0202.102328; Muhammad S, 2011, STROKE, V42, P783, DOI 10.1161/STROKEAHA.110.596783; Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Oh SW, 2011, DIABETES METAB J, V35, P561, DOI 10.4093/dmj.2011.35.6.561; Ovbiagele B, 2006, CEREBROVASC DIS, V21, P260, DOI 10.1159/000091224; Ovbiagele B, 2009, J STROKE CEREBROVASC, V18, P38, DOI 10.1016/j.jstrokecerebrovasdis.2008.08.002; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Palache A, 2011, VACCINE, V29, P9459, DOI 10.1016/j.vaccine.2011.10.030; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Sanossian N, 2009, NEUROEPIDEMIOLOGY, V32, P165, DOI 10.1159/000186500; Seo J, 2018, VACCINE, V36, P3666, DOI 10.1016/j.vaccine.2018.05.024; Shin HY, 2018, VACCINE, V36, P91, DOI 10.1016/j.vaccine.2017.11.035; SPRENGER MJW, 1993, INT J EPIDEMIOL, V22, P334, DOI 10.1093/ije/22.2.334; Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206; Wong CM, 2013, INFLUENZA OTHER RESP, V7, P531, DOI 10.1111/j.1750-2659.2012.00411.x; Yang HJ, 2014, INT J ENV RES PUB HE, V11, P12162, DOI 10.3390/ijerph111212162; Yun JW, 2017, INFECT CHEMOTHER, V49, P247, DOI 10.3947/ic.2017.49.4.247	40	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							763	10.3390/vaccines9070763			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7KK	34358179	gold, Green Published			2022-04-29	WOS:000677085300001
J	Ahmed, MAM; Colebunders, R; Gele, AA; Farah, AA; Osman, S; Guled, IA; Abdullahi, AAM; Hussein, AM; Ali, AM; Fodjo, JNS				Ahmed, Mohammed A. M.; Colebunders, Robert; Gele, Abdi A.; Farah, Abdiqani A.; Osman, Shariff; Guled, Ibraahim Abdullahi; Abdullahi, Aweis Ahmed Moalim; Hussein, Ahmed Mohamud; Ali, Abdiaziz Mohamed; Siewe Fodjo, Joseph Nelson			COVID-19 Vaccine Acceptability and Adherence to Preventive Measures in Somalia: Results of an Online Survey	VACCINES			English	Article						COVID-19; vaccination hesitancy; Somalia; adherence; preventive measures	ACCEPTANCE	Most countries are currently gravitating towards vaccination as mainstay strategy to quell COVID-19 transmission. Between December 2020 and January 2021, we conducted a follow-up online survey in Somalia to monitor adherence to COVID-19 preventive measures, and COVID-19 vaccine acceptability and reasons for vaccine hesitancy. Adherence was measured via a composite adherence score based on four measures (physical distancing, face mask use, hand hygiene, and mouth covering when coughing/sneezing). We analyzed 4543 responses (mean age: 23.5 +/- 6.4 years, 62.4% males). The mean adherence score during this survey was lower than the score during a similar survey in April 2020. A total of 76.8% of respondents were willing to receive the COVID-19 vaccine. Flu-like symptoms were more frequently reported in the current survey compared to previous surveys. Multiple logistic regression showed that participants who experienced flu-like symptoms, those in the healthcare sector, and those with higher adherence scores had higher odds for vaccine acceptability while being a female reduced the willingness to be vaccinated. In conclusion, our data suggest that the decreasing adherence to COVID-19 preventive measures may have caused increased flu-like symptoms over time. COVID-19 vaccine acceptance in Somalia is relatively high but could be improved by addressing factors that contribute to vaccine hesitancy.	[Ahmed, Mohammed A. M.; Osman, Shariff; Guled, Ibraahim Abdullahi; Abdullahi, Aweis Ahmed Moalim; Hussein, Ahmed Mohamud; Ali, Abdiaziz Mohamed] Mogadishu Univ, Fac Med & Surg, Dept Paediat, POB 004, Mogadishu, Somalia; [Ahmed, Mohammed A. M.] Uganda Heart Inst, Dept Paediat Cardiol, POB 7051, Kampala, Uganda; [Colebunders, Robert; Siewe Fodjo, Joseph Nelson] Univ Antwerp, Global Hlth Inst, B-2610 Antwerp, Belgium; [Gele, Abdi A.] Norwegian Inst Publ Hlth, N-0213 Oslo, Norway; [Farah, Abdiqani A.] Puntland State Univ, Dept Econ, POB 090, Wadajir, Garowe, Somalia; [Guled, Ibraahim Abdullahi] Mogadishu Somali Turkey Training & Res Hosp, POB 004, Mogadishu, Somalia; [Ali, Abdiaziz Mohamed] De Martino Hosp, POB 004, Hamar Jajab, Mogadishu, Somalia; [Siewe Fodjo, Joseph Nelson] Brain Res Africa Initiat BRAIN, POB 25625, Yaounde, Cameroon		Fodjo, JNS (通讯作者)，Univ Antwerp, Global Hlth Inst, B-2610 Antwerp, Belgium.; Fodjo, JNS (通讯作者)，Brain Res Africa Initiat BRAIN, POB 25625, Yaounde, Cameroon.	ahmed.m@mu.edu.so; robert.colebunders@uantwerpen.be; abdi.gele@fhi.no; abdiqani.farah@psu.edu.so; shariff.osman@mu.edu.so; ibrahimguled@mu.edu.so; aweis@mu.edu.so; ahmedmh@mu.edu.so; drabdiaziz@mu.edu.so; josephnelson.siewefodjo@uantwerpen.be		Siewe Fodjo, Joseph Nelson/0000-0003-3544-1239; Ahmed, Mohammed AM/0000-0002-9176-0835; Colebunders, Robert/0000-0002-1919-1340	VLIRUOS (Flemish Interuniversity Council for University Development Cooperation)	The study was supported by a grant from the VLIRUOS (Flemish Interuniversity Council for University Development Cooperation). The study sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the paper for publication.	Abdi A, 2021, INT J INFECT DIS, V104, P734, DOI 10.1016/j.ijid.2021.01.066; Ahmed MAM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090735; Ahmed MAM, 2020, INT J INFECT DIS, V98, P206, DOI 10.1016/j.ijid.2020.06.068; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; [Anonymous], 2021, NAT MED, V27, P183, DOI 10.1038/s41591-021-01261-5; [Anonymous], WHO COR DIS COVID 19; CDC, 2020, COR DIS 2019 COVID 1; Dimka Ritgak A, 2013, Afr J Reprod Health, V17, P102; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Farhana KM., 2020, INT RES J BUS SOC SC, V4, P1, DOI [10.2139/ssrn.3763373, DOI 10.2139/SSRN.3763373]; Fu Chuanxi, 2020, ACCEPTANCE PREFRENCE, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103, 0.1101/2020.04.09.2006010314]; Jain S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040649; Khoo YSK, 2020, HUM VACC IMMUNOTHER, V16, P530, DOI 10.1080/21645515.2019.1667206; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Ministry of Health Somalia, 2021, COVID 19 SIT UPD SOM; Mohamud MFY, 2020, INFECT DRUG RESIST, V13, P2631, DOI 10.2147/IDR.S263632; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; UNFPA, 2014, POP COMP DEM CHAR SO; WHO, COVID 19 CAS DEF	23	7	7	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							543	10.3390/vaccines9060543			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA6UD	34064159	Green Published, gold			2022-04-29	WOS:000667382600001
J	Chen, KD; Li, CN; Wang, Y; Shen, ZW; Guo, YK; Li, XP; Zhang, YJ				Chen, Keda; Li, Chaonan; Wang, Ying; Shen, Zhenwei; Guo, Yikai; Li, Xiaoping; Zhang, Yanjun			Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development	VACCINES			English	Article						coxsackie virus A16; polymer fiber paper carriers; disposable mini bioreactor; vaccine	MOUTH-DISEASE; ENTEROVIRUS 71; HAND; FOOT; INFECTION; JAPAN; EPIDEMIOLOGY; ANTIBODIES; CHILDREN	At present, there are no vaccines available for hand, foot, and mouth disease, which is caused by Coxsackie virus A16 (CVA16) infection. In the present study, we isolated epidemic strains of CVA16 and optimized the production of the virus in Vero cells. The system comprised growing the infected cells on polymer fiber paper carriers in a serum-free medium containing 0.5% (w/v) lactalbumin hydrolysate a mini bioreactor. Disposable Bioflo310 and AmProtein Current perfusion bioreactors were used to monitor virus infection and Vero cell culture. The total number of cells increased from 1.5 x 10(9) to 3.0 x 10(10). In our optimized culture process, the virus titer reached 7.8 x 10(7) TCID50/mL at three days after infection. The inactivated CVA16 prepared from our optimized culture procedure elicited a slightly higher neutralizing antibody titer compared with that derived from routine culture procedures. These results will promote the large-scale production of inactivated CVA16 vaccines using nonwoven polymer fiber paper cell cultures.	[Chen, Keda; Li, Chaonan; Wang, Ying; Shen, Zhenwei; Guo, Yikai; Li, Xiaoping] Zhejiang Shuren Univ, Shulan Int Med Coll, Hangzhou 310015, Peoples R China; [Zhang, Yanjun] Zhejiang Prov Ctr Dis Control & Prevent, Dept Virus Inspect, Hangzhou 310051, Peoples R China		Zhang, YJ (通讯作者)，Zhejiang Prov Ctr Dis Control & Prevent, Dept Virus Inspect, Hangzhou 310051, Peoples R China.	chenkd@zjsru.edu.cn; 201930001207@stu.zjsru.edu.cn; Ywang@Zjsru.edu.cn; shenlin7818@126.com; 201930001235@stu.zjsru.edu.cn; li-xp@zjsru.edu.cn; yjzhang@cdc.zj.cn		Chen, Keda/0000-0002-9469-0991; Li, Chaonan/0000-0002-5514-842X	Monitor Technology Platform of Infectious Diseases of The State Major Science and Technology Special Projects during the 13th Five-year Plan of China [2017ZX10103008-002]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LGF21H200007]; Zhejiang Shuren University [2019A11001]; National innovation and entrepreneurship training program for college students in 2019 [201911842035]	This work was supported by the Monitor Technology Platform of Infectious Diseases of The State Major Science and Technology Special Projects during the 13th Five-year Plan of China (grant number 2017ZX10103008-002); and the Zhejiang Provincial Natural Science Foundation of China, Project Name: "Research on Key Technology of SARS-CoV-2 and Influenza A, B Virus Antigen Rapid Quantitative Combined Test Strip"(Project Number LGF21H200007), and the General Research Project of Zhejiang Shuren University in 2019 (grant number 2019A11001), and the National innovation and entrepreneurship training program for college students in 2019 (grant number 201911842035).	Ang LW, 2009, ANN ACAD MED SINGAP, V38, P106; Butler M, 2000, BIOTECHNOL PROGR, V16, P854, DOI 10.1021/bp000110+; Cai YC, 2014, VACCINE, V32, P2406, DOI 10.1016/j.vaccine.2014.03.012; Cai YC, 2013, VACCINE, V31, P2215, DOI 10.1016/j.vaccine.2013.03.007; Chang LY, 1999, PEDIATR INFECT DIS J, V18, P1092, DOI 10.1097/00006454-199912000-00013; Chatproedprai S, 2010, JPN J INFECT DIS, V63, P229; Chen KD, 2018, APPL MICROBIOL BIOT, V102, P6469, DOI 10.1007/s00253-018-9091-5; Chong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049973; Chou AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034834; FISHBEIN DB, 1993, VACCINE, V11, P1390, DOI 10.1016/0264-410X(93)90167-V; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Hosoya M, 2007, J CLIN MICROBIOL, V45, P112, DOI 10.1128/JCM.00718-06; Hu AYC, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014578, 10.1371/journal.pone.0029229]; Iwai M, 2009, JPN J INFECT DIS, V62, P254; Kaptein LCM, 1997, GENE THER, V4, P172, DOI 10.1038/sj.gt.3300373; Le Doux JM, 1999, BIOTECHNOL BIOENG, V63, P654, DOI 10.1002/(SICI)1097-0290(19990620)63:6<654::AID-BIT3>3.0.CO;2-1; Li L, 2009, BIOPROCESS INT, V7, P46; Li LL, 2005, J CLIN MICROBIOL, V43, P3835, DOI 10.1128/JCM.43.8.3835-3839.2005; Liu CC, 2007, VACCINE, V25, P19, DOI 10.1016/j.vaccine.2006.06.083; Liu QW, 2014, ANTIVIR RES, V105, P26, DOI 10.1016/j.antiviral.2014.02.015; Liu QW, 2011, J VIROL METHODS, V173, P115, DOI 10.1016/j.jviromet.2011.01.016; Luo ST, 2009, EMERG INFECT DIS, V15, P581, DOI 10.3201/eid1504.081550; McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1016/S0168-6445(02)00070-0; Mizuta K, 2014, J MED MICROBIOL, V63, P1356, DOI 10.1099/jmm.0.079699-0; REED L. J., 1938, AMER JOUR HYG, V27, P493; Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8; Sun B, 2013, APPL MICROBIOL BIOT, V97, P1063, DOI 10.1007/s00253-012-4375-7; Van Tu P, 2007, EMERG INFECT DIS, V13, P1733, DOI 10.3201/eid1311.070632; Wang CY, 2004, PEDIATR INFECT DIS J, V23, P275, DOI 10.1097/01.inf.0000115950.63906.78; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; WRIGHT HT, 1963, NEW ENGL J MED, V268, P1041, DOI 10.1056/NEJM196305092681904; Wu SC, 2004, VACCINE, V22, P3858, DOI 10.1016/j.vaccine.2004.05.037; Xiao X, 2017, ENVIRON INT, V100, P102, DOI 10.1016/j.envint.2016.11.021; Xiao X, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3762-x; Xu W, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-8; Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4, 10.7774/cevr.2017.6.1.4.]; Yin XG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-251; Zhang Y, 2009, J CLIN VIROL, V44, P262, DOI 10.1016/j.jcv.2009.02.002; Zhuang ZC, 2015, VIRUSES-BASEL, V7, P6400, DOI 10.3390/v7122947	39	1	1	2	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							613	10.3390/vaccines9060613			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6XK	34200441	Green Published, gold			2022-04-29	WOS:000666705300001
J	George, ST; Lai, J; Ma, JL; Stacey, HD; Miller, MS; Mullarkey, CE				George, Sneha T.; Lai, Jonathan; Ma, Julia; Stacey, Hannah D.; Miller, Matthew S.; Mullarkey, Caitlin E.			Neutrophils and Influenza: A Thin Line between Helpful and Harmful	VACCINES			English	Review						influenza virus; neutrophils; NETs; ADCP; universal influenza virus vaccines; broadly neutralizing antibodies; Fc-mediated effector functions	RESPIRATORY-DISTRESS-SYNDROME; T-CELL RESPONSES; EXTRACELLULAR TRAPS; VIRUS-INFECTION; RECEPTOR ENGAGEMENT; SYNCYTIAL VIRUS; SEVERE DISEASE; PROTECTS MICE; NET FORMATION; BONE-MARROW	Influenza viruses are one of the most prevalent respiratory pathogens known to humans and pose a significant threat to global public health each year. Annual influenza epidemics are responsible for 3-5 million infections worldwide and approximately 500,000 deaths. Presently, yearly vaccinations represent the most effective means of combating these viruses. In humans, influenza viruses infect respiratory epithelial cells and typically cause localized infections of mild to moderate severity. Neutrophils are the first innate cells to be recruited to the site of the infection and possess a wide range of effector functions to eliminate viruses. Some well-described effector functions include phagocytosis, degranulation, the production of reactive oxygen species (ROS), and the formation of neutrophil extracellular traps (NETs). However, while these mechanisms can promote infection resolution, they can also contribute to the pathology of severe disease. Thus, the role of neutrophils in influenza viral infection is nuanced, and the threshold at which protective functions give way to immunopathology is not well understood. Moreover, notable differences between human and murine neutrophils underscore the need to exercise caution when applying murine findings to human physiology. This review aims to provide an overview of neutrophil characteristics, their classic effector functions, as well as more recently described antibody-mediated effector functions. Finally, we discuss the controversial role these cells play in the context of influenza virus infections and how our knowledge of this cell type can be leveraged in the design of universal influenza virus vaccines.	[George, Sneha T.; Ma, Julia] McMaster Univ, Fac Hlth Sci, Hamilton, ON L8S 4L8, Canada; [Lai, Jonathan] McMaster Univ, Fac Sci, Hamilton, ON L8S 4L8, Canada; [Stacey, Hannah D.; Miller, Matthew S.] McMaster Univ, Michael G DeGroote Inst Infect Dis Res, Hamilton, ON L8S 4L8, Canada; [Stacey, Hannah D.; Miller, Matthew S.] McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON L8S 4L8, Canada; [Stacey, Hannah D.; Miller, Matthew S.; Mullarkey, Caitlin E.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8S 4L8, Canada		Mullarkey, CE (通讯作者)，McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8S 4L8, Canada.	georgs16@mcmaster.ca; laij32@mcmaster.ca; maj100@mcmaster.ca; staceyhd@mcmaster.ca; mmiller@mcmaster.ca; mullarkc@mcmaster.ca		Miller, Matthew/0000-0003-3426-5069			Ackermann M, 2021, CELL DEATH DIFFER, V28, P3125, DOI 10.1038/s41418-021-00805-z; Aleyd E, 2014, J IMMUNOL, V192, P2374, DOI 10.4049/jimmunol.1300261; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Alon R, 2021, NAT REV IMMUNOL, V21, P49, DOI 10.1038/s41577-020-00470-2; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Ana-Sosa-Batiz F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154461; Anjani G, 2020, GENES DIS, V7, P84, DOI 10.1016/j.gendis.2019.07.010; Banerjee A, 2020, TRENDS MICROBIOL, V28, P703, DOI 10.1016/j.tim.2020.04.006; Behnen M, 2014, J IMMUNOL, V193, P1954, DOI 10.4049/jimmunol.1400478; Bendib I, 2019, ANESTHESIOLOGY, V130, P581, DOI 10.1097/ALN.0000000000002619; Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606; Bjornsdottir H, 2015, FREE RADICAL BIO MED, V89, P1024, DOI 10.1016/j.freeradbiomed.2015.10.398; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Boxio R, 2004, J LEUKOCYTE BIOL, V75, P604, DOI 10.1189/jlb.0703340; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Bruschi M, 2020, J RHEUMATOL, V47, P377, DOI 10.3899/jrheum.181232; Carlet J, 2020, LANCET, V396, pE61, DOI 10.1016/S0140-6736(20)32132-2; CARTWRIGHT GE, 1964, BLOOD, V24, P780, DOI 10.1182/blood.V24.6.780.780; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Cowland JB, 2016, IMMUNOL REV, V273, P11, DOI 10.1111/imr.12440; Dahlgren C, 2019, J IMMUNOL, V202, P3127, DOI 10.4049/jimmunol.1900235; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Deng GC, 2010, ARCH VIROL, V155, P187, DOI 10.1007/s00705-009-0560-0; Devi S, 2013, J EXP MED, V210, P2321, DOI 10.1084/jem.20130056; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fujisawa H, 2008, J VIROL, V82, P2772, DOI 10.1128/JVI.01210-07; Giotis ES, 2019, NAT MICROBIOL, V4, P2035, DOI 10.1038/s41564-019-0517-3; Gregoire M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.02590-2017; Grunwell JR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39726-w; Hamdan TA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020140; Hasenberg M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017314; He WQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00928-3; He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113; Heaton NS, 2013, P NATL ACAD SCI USA, V110, P20248, DOI 10.1073/pnas.1320524110; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; Herant M, 2006, J CELL SCI, V119, P1903, DOI 10.1242/jcs.02876; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Jenne CN, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004546; Jenne CN, 2013, CELL HOST MICROBE, V13, P169, DOI 10.1016/j.chom.2013.01.005; Joos C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009871; Kapelski S, 2014, J LEUKOCYTE BIOL, V96, P1131, DOI 10.1189/jlb.4A0614-283RR; Karakus U, 2019, NATURE, V567, P109, DOI 10.1038/s41586-019-0955-3; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Kim TH, 2014, CLIN EXP VACCINE RES, V3, P128, DOI 10.7774/cevr.2014.3.2.128; Kohler A, 2011, BLOOD, V117, P4349, DOI 10.1182/blood-2010-09-308387; Koernig S, 2019, MUCOSAL IMMUNOL, V12, P1013, DOI 10.1038/s41385-019-0167-z; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Kulkarni U, 2019, MUCOSAL IMMUNOL, V12, P545, DOI 10.1038/s41385-018-0115-3; Launay P, 2000, J EXP MED, V191, P1999, DOI 10.1084/jem.191.11.1999; Lawrence SM, 2020, TRENDS IMMUNOL, V41, P531, DOI 10.1016/j.it.2020.03.008; Leon PE, 2016, P NATL ACAD SCI USA, V113, pE5944, DOI 10.1073/pnas.1613225113; Li FB, 2011, SCIENCE, V333, P1030, DOI 10.1126/science.1206954; Li M, 1996, J EXP MED, V183, P1259, DOI 10.1084/jem.183.3.1259; Li Q, 2012, P NATL ACAD SCI USA, V109, P18897, DOI 10.1073/pnas.1211037109; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Lim K, 2015, SCIENCE, V349, DOI 10.1126/science.aaa4352; Liu D, 2019, CLIN SCI, V133, P565, DOI 10.1042/CS20180600; Llewellyn D, 2014, J LEUKOCYTE BIOL, V95, P369, DOI 10.1189/jlb.0513274; Mackey JBG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01912; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Manley HR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02867; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MAUER AM, 1960, J CLIN INVEST, V39, P1481, DOI 10.1172/JCI104167; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; McKenzie SE, 1999, J IMMUNOL, V162, P4311; Menk M, 2020, INTENS CARE MED, V46, P2157, DOI 10.1007/s00134-020-06299-6; Minns D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21533-5; Mitra S, 2006, BBA-MOL BASIS DIS, V1762, P732, DOI 10.1016/j.bbadis.2006.06.011; Mullarkey CE, 2016, MBIO, V7, DOI 10.1128/mBio.01624-16; Muraro SP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32576-y; Nachbagauer R, 2016, J VIROL, V90, P3268, DOI 10.1128/JVI.02481-15; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; Neyt K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00312; Niu JL, 2019, CYTOKINE, V120, P115, DOI 10.1016/j.cyto.2019.04.019; Pang IK, 2013, NAT IMMUNOL, V14, P246, DOI 10.1038/ni.2514; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Peiro T, 2018, THORAX, V73, P546, DOI 10.1136/thoraxjnl-2017-210010; Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115; Peteranderl C, 2016, SEMIN RESP CRIT CARE, V37, P487, DOI 10.1055/s-0036-1584801; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Aleman OR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2908034; Rebetz J, 2018, TRANSFUS MED HEMOTH, V45, P290, DOI 10.1159/000492950; Risso A, 2000, J LEUKOCYTE BIOL, V68, P785; Rosales C, 2020, J LEUKOCYTE BIOL, V108, P377, DOI 10.1002/JLB.4MIR0220-574RR; Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015; Salvatore M, 2007, J INFECT DIS, V196, P835, DOI 10.1086/521027; Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005; Schnoor M, 2021, CURR OPIN PHYSIOL, V19, P119, DOI 10.1016/j.cophys.2020.09.014; Scott BNV, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01274-2018; Sheehy SH, 2013, HUM VACC IMMUNOTHER, V9, P1831, DOI 10.4161/hv.25383; Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115; Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Southgate EL, 2008, J IMMUNOL, V181, P1429, DOI 10.4049/jimmunol.181.2.1429; Stacey H.D., 2021, BIORXIV PREPRINT, DOI [10.1101/2021.01.04.424830, DOI 10.1101/2021.01.04.424830]; Stackowicz J, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03130; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736; Stout-Delgado HW, 2012, J IMMUNOL, V188, P2815, DOI 10.4049/jimmunol.1103051; Sugamata R, 2012, MICROBIOL IMMUNOL, V56, P171, DOI 10.1111/j.1348-0421.2011.00424.x; Tak T, 2018, AM J RESP CELL MOL, V58, P492, DOI 10.1165/rcmb.2017-0021OC; Tamassia N, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12952; Tang BM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11249-y; Tate MD, 2012, IMMUNOL CELL BIOL, V90, P197, DOI 10.1038/icb.2011.26; Tate MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017618; Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Taubenberger JK, 2013, MBIO, V4, DOI 10.1128/mBio.00365-13; Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009; Taubenberger JK, 2010, PUBLIC HEALTH REP, V125, P16, DOI 10.1177/00333549101250S305; Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; van Egmond M, 1999, BLOOD, V93, P4387, DOI 10.1182/blood.V93.12.4387.412k08_4387_4394; Vorobjeva NV, 2020, BIOCHEMISTRY-MOSCOW+, V85, P1178, DOI 10.1134/S0006297920100065; Wang JP, 2008, BLOOD, V112, P2028, DOI 10.1182/blood-2008-01-132860; Wang Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01958; Wareing MD, 2007, VIRAL IMMUNOL, V20, P369, DOI 10.1089/vim.2006.0101; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; Winterbourn CC, 2016, ANNU REV BIOCHEM, V85, P765, DOI 10.1146/annurev-biochem-060815-014442; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Wohlbold TJ, 2015, VACCINE, V33, P3314, DOI 10.1016/j.vaccine.2015.05.038; Wong CK, 2017, J IMMUNOL, V199, P1060, DOI 10.4049/jimmunol.1700397; Xu T, 2006, AM J RESP CRIT CARE, V174, P1011, DOI 10.1164/rccm.200511-1751OC; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777; Zhu LL, 2018, J INFECT DIS, V217, P428, DOI 10.1093/infdis/jix475; Zhu XY, 2012, P NATL ACAD SCI USA, V109, P18903, DOI 10.1073/pnas.1212579109	143	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							597	10.3390/vaccines9060597			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3TS	34199803	Green Published			2022-04-29	WOS:000666492400001
J	Jaramillo-Monge, J; Obimpeh, M; Vega, B; Acurio, D; Boven, A; Verhoeven, V; Colebunders, R				Jaramillo-Monge, Julio; Obimpeh, Michael; Vega, Bernardo; Acurio, David; Boven, Annelies; Verhoeven, Veronique; Colebunders, Robert			COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey	VACCINES			English	Article						COVID-9; Ecuador; vaccine acceptance; hesitancy	HESITANCY	We investigated the COVID-19 vaccination acceptance level in Azuay province, Ecuador through an online survey from 12th to 26th February (before the start of the COVID-19 vaccination campaign in Ecuador). Overall, 1219 respondents participated in the survey. The mean age was 32 +/- 13 years; 693 participants (57%) were female. In total, 1109 (91%) of the participants indicated they were willing to be vaccinated with a COVID-19 vaccine, if the vaccine is at least 95% effective; 835 (68.5%) if it is 90% effective and 493 (40.5%) if it is 70% effective; 676 (55.5%) participants indicated they feared side effects and 237 (19.4%) thought the vaccine was not effective. Older age, having had a postgraduate education, a history of a negative COVID-19 test, a high level of worry of contracting COVID-19, believing that COVID-19 infection can be prevented with a vaccine and understanding there is currently an effective vaccine against COVID-19 were associated with higher vaccination acceptance. A vaccination education campaign will be needed to increase the knowledge of Ecuadorians about the COVID-19 vaccine and to increase their trust in the vaccine. People with a lower education level and living in rural areas may need to be targeted during such a campaign.	[Jaramillo-Monge, Julio; Vega, Bernardo; Acurio, David] Univ Cuenca, Fac Hlth Sci, Cuenca 010203, Ecuador; [Obimpeh, Michael; Boven, Annelies; Verhoeven, Veronique; Colebunders, Robert] Univ Antwerp, Family Med & Populat Hlth, B-2610 Antwerp, Belgium		Colebunders, R (通讯作者)，Univ Antwerp, Family Med & Populat Hlth, B-2610 Antwerp, Belgium.	julio.jaramillo@ucuenca.edu.ec; Michael.Obimpeh@student.uantwerpen.be; bernardo.vegac@ucuenca.edu.ec; david.acurio@ucuenca.edu.ec; Annelies.Boven@studentuantwerpen.be; veronique.verhoeven@uantwerpen.be; robert.colebunders@uantwerpen.be	Verhoeven, Veronique/B-5915-2017	Verhoeven, Veronique/0000-0002-3708-6501; Jaramillo Monge, Julio Cesar/0000-0002-1710-1778; Obimpeh, Michael/0000-0001-7140-4932; Colebunders, Robert/0000-0002-1919-1340; Acurio Paez, David/0000-0003-3258-2837	VLIRUOS (Flemish University development aid)	Funding was obtained from VLIRUOS (Flemish University development aid).	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Chen WX, 2020, HUM VACC IMMUNOTHER, V16, P2604, DOI 10.1080/21645515.2020.1787067; COVID-19 Vaccine Tracker, 2021 UPDATED 2021 AP; De Salazar Pablo M, 2021, medRxiv, DOI 10.1101/2021.04.08.21255108; Matos CCDA, 2021, GLOB PUBLIC HEALTH, DOI 10.1080/17441692.2021.1912138; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Dubova A, 2015, VACCINE, V33, P2530, DOI 10.1016/j.vaccine.2015.03.048; Farhana, 2020, INT RES J BUS SOC SC, V6, P1, DOI [10.2139/ssrn.3763373, DOI 10.2139/SSRN.3763373]; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Gavi, 2021 UPDATED 2020 AP; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088; Holder J., 2020, NEW YORK TIMES; Kaplan RM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021726118; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Megget K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2184; Ministerio de Salud PuCblica del Ecuador, 2021, PLAN VACUNARSE WEBSI; Ministerio de Salud PuCblica del Ecuador, VACUNADOS COVID 19 2; Ministerio de Salud PuCblica del Ecuador, SITUACI N NACL COVID; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; World Health Organization, 2021, COVID 19 STRATEGY UP; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	32	4	4	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							678	10.3390/vaccines9060678			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7HR	34205483	Green Published, gold			2022-04-29	WOS:000666732000001
J	Xu, H; Huang, J; Liu, ZL; Li, X; Wang, KF; Feng, EL; Wu, J; Zhu, L; Yao, KH; Pan, C; Wang, HL				Xu, Han; Huang, Jing; Liu, Zhaolu; Li, Xin; Wang, Kangfeng; Feng, Erling; Wu, Jun; Zhu, Li; Yao, Kaihu; Pan, Chao; Wang, Hengliang			Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines	VACCINES			English	Article						pertussis; Bordetella pertussis; fimbriae; pertussis toxin; filamentous hemagglutinin; fusion antigen; immunological evaluation	LINKED GLYCOSYLATION SYSTEM; TOXIN SUBUNIT B; WHOLE-CELL	Pertussis is an acute respiratory tract infection caused by Bordetella pertussis. Even though its current vaccine coverage is relatively broad, they still have some shortcomings such as short protection time and might be incapable of blocking the spread of the disease. In this study, we developed new pertussis vaccine candidates by separately fusing three pertussis antigens (B. pertussis fimbriae 2 "Fim2", pertussis toxin S1 subunit "PtxS1", and filamentous hemagglutinin "FHA(1877-2250)") to each of two immune-boosting carrier proteins (B subunits of AB5 toxin family: cholera toxin B subunit "CTB" and shiga toxin B subunit "StxB"). We then immunized mice with these fusion antigens and found that they significantly increased the serum antibody titers and elicited high bactericidal activity against B. pertussis. After CTB-or StxB-fused antigen-immunized mice were challenged with a non-lethal dose of B. pertussis, the bacterial loads in different tissues of these mice were significantly reduced, and their lung damage was nearly invisible. Furthermore, we also demonstrated that these candidate vaccines could provide strong prophylactic effects against a lethal challenge with B. pertussis. Overall, our candidate vaccines conferred better immune protection to mice compared with pertussis antigen alone. This B5 subunit-based vaccine strategy provides a promising option for vaccine design.	[Xu, Han; Huang, Jing; Liu, Zhaolu; Li, Xin; Wang, Kangfeng; Feng, Erling; Wu, Jun; Zhu, Li; Pan, Chao; Wang, Hengliang] Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, 20 Dongdajie St, Beijing 100071, Peoples R China; [Yao, Kaihu] Capital Univ Med Sci, Beijing Childrens Hosp, Nan Lishi Rd, Beijing 100045, Peoples R China		Pan, C; Wang, HL (通讯作者)，Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, 20 Dongdajie St, Beijing 100071, Peoples R China.	Hanx15666259216@163.com; jinghuangpaper0203@163.com; 13173224823@163.com; xinli0531@163.com; wangkf1220@126.com; fengel@sohu.com; junwu1969@163.com; jewly54@126.com; yaokaihu@bch.com.cn; panchaosunny@163.com; wanghl@bmi.ac.cn	Zhu, Li/Q-7499-2017	Zhu, Li/0000-0001-9975-8978	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31700802, 81930122]	This work was supported by the National Natural Science Foundation of China (nos. 31700802 and 81930122).	Asgarian-Omran H, 2016, INFECT DIS-NOR, V48, P127, DOI 10.3109/23744235.2015.1093655; Ausar SF, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01153-3; Beddoe T, 2010, TRENDS BIOCHEM SCI, V35, P411, DOI 10.1016/j.tibs.2010.02.003; Belchior E, 2020, MED MALADIES INFECT, V50, P617, DOI 10.1016/j.medmal.2020.07.004; Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234; Choi NW, 2005, VACCINE, V23, P5168, DOI 10.1016/j.vaccine.2005.06.015; Clark Thomas A, 2012, NASN Sch Nurse, V27, P297; Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344; Fabricius G, 2018, EPIDEMIOL INFECT, V146, P858, DOI 10.1017/S0950268818000808; George-Chandy A, 2001, INFECT IMMUN, V69, P5716, DOI 10.1128/IAI.69.9.5716-5725.2001; Han JY, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10010031; Huang J, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030436; Ibrahim EH, 2019, SAUDI J BIOL SCI, V26, P1676, DOI 10.1016/j.sjbs.2018.08.019; Kamachi K, 2003, VACCINE, V21, P4609, DOI 10.1016/S0264-410X(03)00441-9; Kapil P, 2019, CURR OPIN IMMUNOL, V59, P72, DOI 10.1016/j.coi.2019.03.006; Kaslow DC, 2011, ANNU REV MED, V62, P201, DOI 10.1146/annurev-med-051109-101544; Kuchar E, 2016, ADV EXP MED BIOL, V934, P77, DOI 10.1007/5584_2016_21; Lambert LC, 2014, J INFECT DIS, V209, pS4, DOI 10.1093/infdis/jit592; Li X, 2022, MICROB BIOTECHNOL, V15, P703, DOI 10.1111/1751-7915.13770; Pan C, 2020, ADV MATER, V32, DOI 10.1002/adma.202002940; Pan C, 2016, MBIO, V7, DOI 10.1128/mBio.00443-16; Sapon K, 2020, MEMBRANES-BASEL, V10, DOI 10.3390/membranes10080172; Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579; Sun P, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0037-1; Tan TN, 2015, PEDIATR INFECT DIS J, V34, pE222, DOI 10.1097/INF.0000000000000795; Nguyen VTN, 2018, PRIMARY CARE, V45, P423, DOI 10.1016/j.pop.2018.05.003; Vidor E, 2008, HUM VACCINES, V4, P328, DOI 10.4161/hv.4.5.6008; Wiedinger Kari, 2017, Ther Adv Vaccines, V5, P15, DOI 10.1177/2051013617691041; Xu YH, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-274; Yamaji T, 2020, METHODS MOL BIOL, V2132, P463, DOI 10.1007/978-1-0716-0430-4_45; Zhang JS, 2020, WORLD J PEDIATR, V16, P185, DOI 10.1007/s12519-019-00308-5	31	3	3	11	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							542	10.3390/vaccines9060542			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ1GJ	34064136	gold, Green Published			2022-04-29	WOS:000666322500001
J	Baghdadi, LR; Alghaihb, SG; Abuhaimed, AA; Alkelabi, DM; Alqahtani, RS				Baghdadi, Leena R.; Alghaihb, Shatha G.; Abuhaimed, Alanoud A.; Alkelabi, Dania M.; Alqahtani, Rawan S.			Healthcare Workers' Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study	VACCINES			English	Article						COVID-19; pandemic; SARS-CoV-2; vaccine; acceptance	DETERMINANTS; ACCEPTANCE; INTENTION	In 2019, a novel severe acute respiratory syndrome (SARS-CoV-2 (COVID-19)) caused a global pandemic. There was an urgent need to develop a vaccine against COVID-19 to reduce its spread and economic burden. The main objective of this study was to understand the attitudes and concerns of healthcare workers (HCWs) towards the upcoming COVID-19 vaccine, whether their decision was influenced by their history of taking the seasonal influenza vaccine, and factors that influence the acceptance of the upcoming COVID-19 vaccine. This was a cross-sectional study conducted in Riyadh, Saudi Arabia. We selected and surveyed 356 HCWs via an electronic self-administered questionnaire. A total of 61.16% of HCWs were willing to receive the COVID-19 vaccine, and 55.9% of them had received the seasonal influenza vaccine in the preceding year (2019-2020). The strongest predictors for taking the COVID-19 vaccine were the HCWs' belief that the COVID-19 vaccine would be safe, needed even for healthy people, that all HCWs should be vaccinated against COVID-19, and that HCWs will have time to take the vaccine. Being female, being middle aged, having <5 years of work experience, having no fear of injections, and being a non-smoker were predictive factors for taking the upcoming COVID-19 vaccine. No associations were found between the intention to take the COVID-19 vaccine and a history of taking the seasonal influenza vaccine.	[Baghdadi, Leena R.] King Saud Univ, Coll Med, Dept Family & Community Med, Riyadh 11362, Saudi Arabia; [Alghaihb, Shatha G.; Abuhaimed, Alanoud A.; Alkelabi, Dania M.; Alqahtani, Rawan S.] King Saud Univ, Coll Med, Riyadh 11362, Saudi Arabia		Baghdadi, LR (通讯作者)，King Saud Univ, Coll Med, Dept Family & Community Med, Riyadh 11362, Saudi Arabia.	lbaghdadi@ksu.edu.sa; 436200412@student.ksu.edu.sa; 436202916@student.ksu.edu.sa; 436200669@student.ksu.edu.sa; 436200252@student.ksu.edu.sa	Baghdadi, Leena R./ABC-8527-2020	Baghdadi, Leena R./0000-0003-3315-6266; Alkelabi, Dania/0000-0003-3021-8599; Abuhaimed, Alanoud/0000-0002-9594-1924	College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Riyadh, Saudi ArabiaKing Saud University; Deanship of Scientific Research at King Saud University through the Undergraduate Research Support Program	Special thanks for support by the College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. We would also like to thank the Deanship of Scientific Research at King Saud University through the Undergraduate Research Support Program for their support.	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alenazi Bashayer Reda, 2018, Electron Physician, V10, P7217, DOI 10.19082/7217; Algaissi AA, 2020, J INFECT PUBLIC HEAL, V13, P834, DOI 10.1016/j.jiph.2020.04.016; [Anonymous], 2019, 10 HLTH ISSUES WHO W; Awadalla NJ, 2020, HUM VACC IMMUNOTHER, V16, P321, DOI 10.1080/21645515.2019.1666500; Barbadoro P, 2013, HUM VACC IMMUNOTHER, V9, P911, DOI 10.4161/hv.22997; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Barry M., 2020, COVID 19 VACCINE CON, DOI [DOI 10.1101/2020.12.09.20246447, 10.1101/2020.12.09.20246447]; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Blue Carolyn L, 2002, AAOHN J, V50, P227; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Centers for Disease Control and Prevention (CDC), 2021, CDCS COVID 19 VACC R; Corace K, 2013, AM J INFECT CONTROL, V41, P679, DOI 10.1016/j.ajic.2013.01.014; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Flood CM, 2021, CAN MED ASSOC J, V193, pE217, DOI 10.1503/cmaj.202755; Fu Chuanxi, 2020, ACCEPTANCE PREFRENCE, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103, 0.1101/2020.04.09.2006010314]; Gruben V, 2014, CAN MED ASSOC J, V186, P1076, DOI 10.1503/cmaj.140035; Johns Hopkins Coronavirus Resource Center, COVID 19 MAP; Kaboli F, 2010, INFECT CONT HOSP EP, V31, P1017, DOI 10.1086/655465; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ling M, 2014, MAKING GLOBAL HEALTH CARE INNOVATION WORK: STANDARDIZATION AND LOCALIZATION, P139; Martin CA., 2021, ASS DEMOGRAPHIC OCCU, DOI DOI 10.1101/2021.02.11.21251548; Martinello RA, 2003, INFECT CONT HOSP EP, V24, P845, DOI 10.1086/502147; Ministry of Health (MOH), NEWS MOH REP 1 CAS C; Ministry of Health (MOH), HLTH VIS NEWSL VIS R; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Radwan R., 2021, ARABNEWS        0405; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rimoin A.W., 2020, ASSESSMENT COVID 19, DOI [10.1101/2020.11.18.20234468, DOI 10.1101/2020.11.18.20234468]; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; World Health Organization (WHO), COR DIS COVID 19 EV; Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7; Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153	35	5	5	8	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							465	10.3390/vaccines9050465			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1UN	34066397	Green Published, gold			2022-04-29	WOS:000654611200001
J	Barsoe, S; Toffan, A; Pascoli, F; Stratmann, A; Pretto, T; Marsella, A; Er-Rafik, M; Vendramin, N; Olesen, NJ; Sepulveda, D; Lorenzen, N				Barsoe, Sofie; Toffan, Anna; Pascoli, Francesco; Stratmann, Ansgar; Pretto, Tobia; Marsella, Andrea; Er-Rafik, Meriem; Vendramin, Niccolo; Olesen, Niels J.; Sepulveda, Dagoberto; Lorenzen, Niels			Long-Term Protection and Serologic Response of European Sea Bass Vaccinated with a Betanodavirus Virus-Like Particle Produced in Pichia pastoris	VACCINES			English	Article						VLP vaccine; recombinant vaccine; betanodavirus; efficacy; correlate of protection	NERVOUS-NECROSIS-VIRUS; DICENTRARCHUS-LABRAX L.; SALMON SALMO-SALAR; MASS MORTALITIES; INTRAPERITONEAL VACCINATION; SEVENBAND GROUPER; IMMUNE-RESPONSE; INFECTION; FISH; PROTEIN	Viral Nervous Necrosis (VNN) causes high mortality and reduced growth in farmed European sea bass (Dicentrarchus labrax) in the Mediterranean. In the current studies, we tested a novel Pichia-produced virus-like particle (VLP) vaccine against VNN in European sea bass, caused by the betanodavirus "Red-Spotted Grouper Nervous Necrosis Virus" (RGNNV). European sea bass were immunized with a VLP-based vaccine formulated with different concentrations of antigen and with or without adjuvant. Antibody response was evaluated by ELISA and serum neutralization. The efficacy of these VLP-vaccine formulations was evaluated by an intramuscular challenge with RGNNV at different time points (1, 2 and 10 months post-vaccination) and both dead and surviving fish were sampled to evaluate the level of viable virus in the brain. The VLP-based vaccines induced an effective protective immunity against experimental infection at 2 months post-vaccination, and even to some degree at 10 months post-vaccination. Furthermore, the vaccine formulations triggered a dose-dependent response in neutralizing antibodies. Serologic response and clinical efficacy, measured as relative percent survival (RPS), seem to be correlated with the administered dose, although for the individual fish, a high titer of neutralizing antibodies prior to challenge was not always enough to protect against disease. The efficacy of the VLP vaccine could not be improved by formulation with a water-in-oil (W/O) adjuvant. The developed RGNNV-VLPs show a promising effect as a vaccine candidate, even without adjuvant, to protect sea bass against disease caused by RGNNV. However, detection of virus in vaccinated survivors means that it cannot be ruled out that survivors can transmit the virus.	[Barsoe, Sofie; Vendramin, Niccolo; Olesen, Niels J.; Sepulveda, Dagoberto; Lorenzen, Niels] Tech Univ Denmark, Natl Inst Aquat Resources DTU AQUA, DK-2800 Lyngby, Denmark; [Toffan, Anna; Pascoli, Francesco; Pretto, Tobia; Marsella, Andrea] Ist Zooprofilatt Sperimentale Venezie IZSVe, I-35020 Padua, Italy; [Stratmann, Ansgar] W42 Biotechnol GmbH, D-44227 Dortmund, Germany; [Er-Rafik, Meriem] Tech Univ Denmark, Natl Ctr Nano Fabricat & Characterizat DTU Nanola, DK-2800 Lyngby, Denmark		Lorenzen, N (通讯作者)，Tech Univ Denmark, Natl Inst Aquat Resources DTU AQUA, DK-2800 Lyngby, Denmark.	sofhan@aqua.dtu.dk; atoffan@izsvenezie.it; fpascoli@izsvenezie.it; ansgar@marinnovac.com; tpretto@izsvenezie.it; AMarsella@izsvenezie.it; merafik@dtu.dk; niven@aqua.dtu.dk; njol@aqua.dtu.dk; dsep@aqua.dtu.dk; nilo@aqua.dtu.dk	Olesen, Niels Jørgen/AAJ-8851-2021; Pascoli, Francesco/AAL-8206-2020; Er-Rafik, Meriem/A-6850-2017	Olesen, Niels Jørgen/0000-0002-0152-4135; Pascoli, Francesco/0000-0003-2239-3098; Er-Rafik, Meriem/0000-0002-9552-926X; PRETTO, TOBIA/0000-0001-7699-9728; Toffan, Anna/0000-0003-4389-3489; marsella, andrea/0000-0001-9776-221X; Barsoe, Sofie/0000-0003-0768-8859; Vendramin, Niccolo/0000-0002-9217-7887; Sepulveda, Dagoberto/0000-0001-8553-5861	European Union's H2020 program [727315]; EU project TargetFish [311993]; TNA-grant through VetBioNet-Veterinary Biocontained facility Network [731014]	This paper is part of the MedAID project which has received funding from the European Union's H2020 program under grant agreement 727315. The VLPs were developed during the EU project TargetFish (grant agreement no. 311993). Sofie Barsoe (DTU Aqua) received a TNA-grant through VetBioNet-Veterinary Biocontained facility Network (grant agreement no. 731014)-to partake in Study 1 at IZSVe.	Afonso A, 2005, FISH SHELLFISH IMMUN, V19, P1, DOI 10.1016/j.fsi.2004.09.001; Amend DF., 1981, FISH BIOLOGICS SEROD, V49, P447; Bandin I, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020106; Barsoe S, 2021, AQUACULT REP, V19, DOI 10.1016/j.aqrep.2021.100621; Baud M, 2015, J VIROL METHODS, V211, P1, DOI 10.1016/j.jviromet.2014.09.016; BREUIL G, 1991, AQUACULTURE, V97, P109, DOI 10.1016/0044-8486(91)90258-9; Cecchini S, 2002, AQUAC RES, V33, P607, DOI 10.1046/j.1365-2109.2002.00698.x; Chen NC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005203; Chi SC, 1997, J FISH DIS, V20, P185, DOI 10.1046/j.1365-2761.1997.00291.x; Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026; FRERICHS GN, 1991, J GEN VIROL, V72, P2537, DOI 10.1099/0022-1317-72-10-2537; Gonzalez-Silvera D, 2019, FISH SHELLFISH IMMUN, V88, P458, DOI 10.1016/j.fsi.2019.03.013; Gye HJ, 2018, VACCINE, V36, P1863, DOI 10.1016/j.vaccine.2018.02.063; Hipra Icthiovac, VNN; Iwamoto T, 2005, J GEN VIROL, V86, P2807, DOI 10.1099/vir.0.80902-0; Iwamoto T, 2001, J FISH DIS, V24, P231, DOI 10.1046/j.1365-2761.2001.00291.x; Jeong H, 2017, J MICROBIOL, V55, P220, DOI 10.1007/s12275-017-7058-3; Jeong KH, 2020, FISH SHELLFISH IMMUN, V100, P49, DOI 10.1016/j.fsi.2020.02.060; Kassambara Alboukadel, 2021, CRAN; Kim HJ, 2017, LETT APPL MICROBIOL, V64, P111, DOI 10.1111/lam.12695; Le Morvan C, 1998, J EXP BIOL, V201, P165; LeBreton A, 1997, J FISH DIS, V20, P145, DOI 10.1046/j.1365-2761.1997.00284.x; Lin CS, 2001, VIROLOGY, V290, P50, DOI 10.1006/viro.2001.1157; Liu WT, 2006, VACCINE, V24, P6282, DOI 10.1016/j.vaccine.2006.05.073; Luu VT, 2017, J MICROBIOL, V55, P655, DOI 10.1007/s12275-017-7218-5; Marsian J, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00880; Midtlying PJ, 1996, FISH SHELLFISH IMMUN, V6, P335, DOI 10.1006/fsim.1996.0034; Midtlyng PJ, 2016, BIRKHAUSER ADV INFEC, P119, DOI 10.1007/978-3-0348-0980-1_6; Midtlyng PJ, 1998, DIS AQUAT ORGAN, V32, P91, DOI 10.3354/dao032091; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Mori K, 2003, DIS AQUAT ORGAN, V57, P19, DOI 10.3354/dao057019; Lan NT, 2018, BIOLOGICALS, V51, P25, DOI 10.1016/j.biologicals.2017.11.002; Nunez-Ortiz N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0376-3; OIE, 2019, MANUAL DIAGNOSTIC TE; Olveira JG, 2009, J GEN VIROL, V90, P2940, DOI 10.1099/vir.0.013912-0; Panzarin V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158814; Panzarin V, 2012, INFECT GENET EVOL, V12, P63, DOI 10.1016/j.meegid.2011.10.007; Pascoli F, 2019, FISH SHELLFISH IMMUN, V85, P85, DOI 10.1016/j.fsi.2017.10.033; Pharmaq, ALPHA JECT MICR 1 NO; R Core Team, 2018, R LANG ENV STAT COMP; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rocha A, 2009, GEN COMP ENDOCR, V162, P265, DOI 10.1016/j.ygcen.2009.03.023; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029; Therneau T., 2020, Package for Survival Analysis in R [; Therneau T.M., 2002, MODELING SURVIVAL DA; Thiery R, 2006, J VIROL, V80, P10201, DOI 10.1128/JVI.01098-06; Toffan A, 2019, J FISH DIS, V42, P1667, DOI 10.1111/jfd.13088; Valero Y, 2018, DEV COMP IMMUNOL, V86, P171, DOI 10.1016/j.dci.2018.05.013; Valero Y, 2016, DEV COMP IMMUNOL, V65, P64, DOI 10.1016/j.dci.2016.06.021; Vandeputte M, 2014, AQUACULTURE, V424, P239, DOI 10.1016/j.aquaculture.2014.01.005; Vendramin N, 2014, J FISH DIS, V37, P371, DOI 10.1111/jfd.12117; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yamashita H, 2009, J FISH DIS, V32, P767, DOI 10.1111/j.1365-2761.2009.01054.x	53	3	3	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							447	10.3390/vaccines9050447			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1YH	34063318	gold, Green Published			2022-04-29	WOS:000654621000001
J	Choi, H; Chun, J; Park, M; Kim, S; Kim, N; Lee, HJ; Kim, M; Shin, H; Oh, YK; Kim, YB				Choi, Hanul; Chun, Jungmin; Park, Mina; Kim, Suyeon; Kim, Nahyun; Lee, Hee-Jung; Kim, Minjee; Shin, Ha Youn; Oh, Yu-Kyoung; Kim, Young Bong			The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice	VACCINES			English	Article						vaccine; ZIKV; baculovirus system; arbovirus; nonreplicated viral vector	GENE-TRANSFER; NS5 PROTEIN; VECTOR; INTERFERON; IMMUNIZATION; INFECTION; PREGNANCY; CELLS	The Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family of enveloped RNA viruses. The correlation between viral infection and fetal microcephaly was revealed in 2015, yet we still lack a vaccine against ZIKV. Here, we present a genetic vaccine that delivers the premembrane (prM) and envelope (E) genes of ZIKV using a recombinant baculovirus vector that expresses a human endogenous retrovirus (HERV) envelope on its surface to enhance gene delivery. We observed that baculoviruses with HERV envelopes (AcHERV) exhibited specifically higher gene transfer efficiency in human cells compared to the wild-type baculovirus vector. Using the AcHERV baculovirus vector, we constructed a recombinant baculovirus vaccine encoding ZIKV prM/E genes (AcHERV-ZIKV), which are major targets of neutralizing antibodies. Mice immunized twice with AcHERV-ZIKV exhibited high levels of IgG, neutralizing antibodies, and IFN-gamma. In challenge tests in IFN knock-out mice (A129), AcHERV-ZIKV showed complete protection in both challenge and pregnancy tests. These results suggest that AcHERV-ZIKV could be a potential vaccine candidate for human application.	[Choi, Hanul; Kim, Young Bong] Konkuk Univ, Dept Bioind Technol, Seoul 05029, South Korea; [Chun, Jungmin; Kim, Young Bong] KR BioTech, Ctr Glocal Dis Control, Seoul 05029, South Korea; [Park, Mina; Kim, Suyeon; Kim, Nahyun; Lee, Hee-Jung; Kim, Minjee; Shin, Ha Youn] Konkuk Univ, Dept Biomed Sci & Engn, Seoul 05029, South Korea; [Oh, Yu-Kyoung] Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea; [Oh, Yu-Kyoung] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 08826, South Korea		Kim, YB (通讯作者)，Konkuk Univ, Dept Bioind Technol, Seoul 05029, South Korea.; Kim, YB (通讯作者)，KR BioTech, Ctr Glocal Dis Control, Seoul 05029, South Korea.	chlgksmf9977@hanmail.net; anananq@naver.com; min.a@outlook.kr; 0924tndus123@naver.com; knh64@naver.com; ziniga@konkuk.ac.kr; mj0411@konkuk.ac.kr; hayounshin@konkuk.ac.kr; ohyk@snu.ac.kr; kimera@konkuk.ac.kr		Oh, Yu-Kyoung/0000-0002-0969-3339; Shin, Ha Youn/0000-0002-8553-2107	Korean Health Technology RD Project [HI18C2177, HW20C2115, HI15C2842]; National Research Foundation (NRF) - Ministry of Science ICT [2016M3A9B6913600]; Konkuk University Researcher Fund in 2019	This research was funded by Korean Health Technology R&D Project (grant number HI18C2177, HW20C2115, and HI15C2842) and Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (grant number 2016M3A9B6913600) and Konkuk University Researcher Fund in 2019 to S.K.	Airenne KJ, 2013, MOL THER, V21, P739, DOI 10.1038/mt.2012.286; Brave A, 2007, MOL PHARMACEUT, V4, P18, DOI 10.1021/mp060098+; Bullard BL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60238-5; Cho H, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00303-w; Cragan JD, 2017, MMWR-MORBID MORTAL W, V66, P19, DOI 10.15585/mmwr.mm6608a4; Diamond MS, 2019, ANNU REV MED, V70, P121, DOI 10.1146/annurev-med-040717-051127; Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049; Elshahawi H, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040169; Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036; Garcia-Sastre A, 2017, CELL HOST MICROBE, V22, P176, DOI 10.1016/j.chom.2017.07.012; Gorman MJ, 2018, CELL HOST MICROBE, V23, P672, DOI 10.1016/j.chom.2018.04.003; Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009; Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477; HOFMANN C, 1995, P NATL ACAD SCI USA, V92, P10099, DOI 10.1073/pnas.92.22.10099; Hung CF, 2008, EXPERT OPIN BIOL TH, V8, P421, DOI 10.1517/14712598.8.4.421 ; Imperato PJ, 2016, J COMMUN HEALTH, V41, P674, DOI 10.1007/s10900-016-0177-7; Laurent-Rolle M, 2014, CELL HOST MICROBE, V16, P314, DOI 10.1016/j.chom.2014.07.015; Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16; Lee HP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0028033, 10.1371/journal.pone.0044670, 10.1186/1747-597X-7-11, 10.1371/journal.pone.0050296]; Lin SL, 2019, VIROLOGY, V527, P180, DOI 10.1016/j.virol.2018.11.009; Lopez-Camacho C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04859-5; Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4; Marston HD, 2016, NEW ENGL J MED, V375, P1209, DOI 10.1056/NEJMp1607762; McIntosh CJ, 2012, REPRODUCTION, V143, P195, DOI 10.1530/REP-11-0336; Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008; Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17; Ostrand-Rosenberg S, 2017, J LEUKOCYTE BIOL, V101, P1091, DOI 10.1189/jlb.1HI1016-306RR; Perez P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35724-6; Poland GA, 2018, LANCET INFECT DIS, V18, pE211, DOI 10.1016/S1473-3099(18)30063-X; Prow NA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03662-6; Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010; Shen HQ, 2020, VIRUS RES, V275, DOI 10.1016/j.virusres.2019.197804; Shin H, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111306; Steffen T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020170; Trus I, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03077; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; Yang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08247-9; Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052; Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004	42	1	1	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							438	10.3390/vaccines9050438			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LS	33946611	Green Published, gold			2022-04-29	WOS:000654588200001
J	Lainscek, D; Fink, T; Forstneric, V; Hafner-Bratkovic, I; Orehek, S; Strmsek, Z; Mancek-Keber, M; Pecan, P; Esih, H; Malensek, S; Aupic, J; Dekleva, P; Plaper, T; Vidmar, S; Kadunc, L; Bencina, M; Omersa, N; Anderluh, G; Pojer, F; Lau, K; Hacker, D; Correia, BE; Peterhoff, D; Wagner, R; Bergant, V; Herrmann, A; Pichlmair, A; Jerala, R				Lainscek, Dusko; Fink, Tina; Forstneric, Vida; Hafner-Bratkovic, Iva; Orehek, Sara; Strmsek, Ziga; Mancek-Keber, Mateja; Pecan, Peter; Esih, Hana; Malensek, Spela; Aupic, Jana; Dekleva, Petra; Plaper, Tjasa; Vidmar, Sara; Kadunc, Lucija; Bencina, Mojca; Omersa, Neza; Anderluh, Gregor; Pojer, Florence; Lau, Kelvin; Hacker, David; Correia, Bruno E.; Peterhoff, David; Wagner, Ralf; Bergant, Valter; Herrmann, Alexander; Pichlmair, Andreas; Jerala, Roman			A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response	VACCINES			English	Article						SARS-CoV-2; RBD-bann; nano-scaffolding domains; vaccine; T-cell response	LUMAZINE SYNTHASE; DNA VACCINE; PROTEIN; DESIGN; DELIVERY; NANOPARTICLES; ACTIVATION; MECHANISMS; DOMAIN	The response of the adaptive immune system is augmented by multimeric presentation of a specific antigen, resembling viral particles. Several vaccines have been designed based on natural or designed protein scaffolds, which exhibited a potent adaptive immune response to antigens; however, antibodies are also generated against the scaffold, which may impair subsequent vaccination. In order to compare polypeptide scaffolds of different size and oligomerization state with respect to their efficiency, including anti-scaffold immunity, we compared several strategies of presentation of the RBD domain of the SARS-CoV-2 spike protein, an antigen aiming to generate neutralizing antibodies. A comparison of several genetic fusions of RBD to different nanoscaffolding domains (foldon, ferritin, lumazine synthase, and beta-annulus peptide) delivered as DNA plasmids demonstrated a strongly augmented immune response, with high titers of neutralizing antibodies and a robust T-cell response in mice. Antibody titers and virus neutralization were most potently enhanced by fusion to the small beta-annulus peptide scaffold, which itself triggered a minimal response in contrast to larger scaffolds. The beta-annulus fused RBD protein increased residence in lymph nodes and triggered the most potent viral neutralization in immunization by a recombinant protein. Results of the study support the use of a nanoscaffolding platform using the beta-annulus peptide for vaccine design.	[Lainscek, Dusko; Hafner-Bratkovic, Iva; Mancek-Keber, Mateja; Bencina, Mojca; Jerala, Roman] EN FIST, Ctr Excellence, Ljubljana 1000, Slovenia; [Lainscek, Dusko; Fink, Tina; Forstneric, Vida; Hafner-Bratkovic, Iva; Orehek, Sara; Strmsek, Ziga; Mancek-Keber, Mateja; Pecan, Peter; Esih, Hana; Malensek, Spela; Aupic, Jana; Dekleva, Petra; Plaper, Tjasa; Vidmar, Sara; Kadunc, Lucija; Bencina, Mojca; Jerala, Roman] Natl Inst Chem, Dept Synthet Biol & Immunol, Ljubljana 1000, Slovenia; [Orehek, Sara; Strmsek, Ziga; Pecan, Peter; Esih, Hana; Malensek, Spela; Dekleva, Petra; Plaper, Tjasa; Vidmar, Sara] Univ Ljubljana, Grad Sch Biomed, Ljubljana 1000, Slovenia; [Omersa, Neza; Anderluh, Gregor] Natl Inst Chem, Dept Mol Biol & Nanobiotechnol, Ljubljana 1000, Slovenia; [Pojer, Florence; Lau, Kelvin; Hacker, David; Correia, Bruno E.] Prot Prod & Struct Core Facil PTPSP EPFL SV PTECH, CH-1015 Lausanne, Switzerland; [Peterhoff, David; Wagner, Ralf] Univ Regensburg, Mol Microbiol Virol, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany; [Wagner, Ralf] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany; [Bergant, Valter; Herrmann, Alexander; Pichlmair, Andreas] Tech Univ Munich, Immunopathol Virus Infect Lab, Inst Virol, D-81675 Munich, Germany; [Pichlmair, Andreas] German Ctr Infect Res DZIF, Munich Partner Site, D-38124 Braunschweig, Germany		Jerala, R (通讯作者)，EN FIST, Ctr Excellence, Ljubljana 1000, Slovenia.; Jerala, R (通讯作者)，Natl Inst Chem, Dept Synthet Biol & Immunol, Ljubljana 1000, Slovenia.	dusko.lainscek@ki.si; tina.fink@ki.si; vida.forstneric@ki.si; iva.hafner@ki.si; sara.orehek@ki.si; ziga.strmsek@ki.si; mateja.mancek@ki.si; peter.pecan@ki.si; hana.esih@ki.si; spela.malensek@ki.si; jana.aupic@ki.si; petra.dekleva@ki.si; tjasa.plaper@ki.si; sara.vidmar@ki.si; lucija.kadunc@ki.si; mojca.bencina@ki.si; neza.omersa@ki.si; gregor.anderluh@ki.si; florence.pojer@epfl.ch; kelvin.lau@epfl.ch; david.hacker@epfl.ch; bruno.correia@epfl.ch; david.peterhoff@klinik.uni-regensburg.de; ralf.wagner@klinik.uni-regensburg.de; valter.bergant@tum.de; alexander.herrmann@tum.de; andreas.pichlmair@tum.de; roman.jerala@ki.si	Peterhoff, David/ABD-6746-2020; Anderluh, Gregor/C-6905-2014	Anderluh, Gregor/0000-0002-9916-8465; Hafner Bratkovic, Iva/0000-0001-5635-931X; Pecan, Peter/0000-0002-4385-3471; Lau, Kelvin/0000-0002-9040-7597; Pichlmair, Andreas/0000-0002-0166-1367; Omersa, Neza/0000-0003-3889-7645; Peterhoff, David/0000-0001-5911-6233	Slovenian Research AgencySlovenian Research Agency - Slovenia [P4-0176, Z3-9276, Z3-9260]; H2020 project Virofight; ERC AdG project MaCChines; German Research FoundationGerman Research Foundation (DFG) [TRR179/TP11, TRR237/A07]; German Federal Ministry of Education and Research (COVINET); ERC-CoG project ProDAP	This work was supported by the Slovenian Research Agency (program P4-0176, projects Z3-9276, Z3-9260), H2020 project Virofight and ERC AdG project MaCChines to R.J., the German Research Foundation (TRR179/TP11, TRR237/A07), the German Federal Ministry of Education and Research (COVINET), and ERC-CoG project ProDAP to A.P.	Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Batra J, 2018, CELL, V175, P1917, DOI 10.1016/j.cell.2018.08.044; Bernelin-Cottet C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060576; Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897; Choi B, 2016, ACS NANO, V10, P7339, DOI 10.1021/acsnano.5b08084; Correia, 2020, PREPRINT BIORXIV, DOI [10.1101/2020.08.28.244269, DOI 10.1101/2020.08.28.244269]; Da Silva DM, 2001, VIROLOGY, V290, P350, DOI 10.1006/viro.2001.1179; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025; Eo SK, 2001, J IMMUNOL, V166, P5473, DOI 10.4049/jimmunol.166.9.5473; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Guthe S, 2004, J MOL BIOL, V337, P905, DOI 10.1016/j.jmb.2004.02.020; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hudalla GA, 2014, NAT MATER, V13, P829, DOI [10.1038/NMAT3998, 10.1038/nmat3998]; Israelow B, 2020, J EXP MED, V217, DOI [10.1084/jem.20201241, 10.1101/2020.05.27.118893]; Kamp HD, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0183-8; Kanekiyo M., 2017, VIRUS LIKE PARTICLE; Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; King NP, 2012, SCIENCE, V336, P1171, DOI 10.1126/science.1219364; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762; Lienert F, 2014, NAT REV MOL CELL BIO, V15, P95, DOI 10.1038/nrm3738; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Ljubetic A, 2017, NAT BIOTECHNOL, V35, P1094, DOI 10.1038/nbt.3994; Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001; Ma XC, 2020, IMMUNITY, V53, P1315, DOI 10.1016/j.immuni.2020.11.015; Maity PC, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005887; Matsuura K, 2020, J ORG CHEM, V85, P1668, DOI 10.1021/acs.joc.9b02295; Matsuura K, 2013, POLYM J, V45, P529, DOI 10.1038/pj.2012.235; Matsuura K, 2010, ANGEW CHEM INT EDIT, V49, P9662, DOI 10.1002/anie.201004606; McCluskie MJ, 2016, IMMUNOPHARM IMMUNOT, V38, P184, DOI 10.3109/08923973.2016.1165246; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Nakamura Y, 2017, J PEPT SCI, V23, P636, DOI 10.1002/psc.2967; Prather KJ, 2003, ENZYME MICROB TECH, V33, P865, DOI 10.1016/S0141-0229(03)00205-9; Ra JS, 2014, CLIN EXP VACCINE RES, V3, P227, DOI 10.7774/cevr.2014.3.2.227; Racz R, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-S4-S2; Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI 10.1038/nbtl332; Rentsch MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025858; Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4; Sliepen K, 2015, J BIOL CHEM, V290, P7436, DOI 10.1074/jbc.M114.620534; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Swanson KA, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba6466; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Ueda G, 2020, ELIFE, V9, DOI 10.7554/eLife.57659; Veneziano R, 2020, NAT NANOTECHNOL, V15, P716, DOI 10.1038/s41565-020-0719-0; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang Chunyan, 2020, Nat Commun, V11, P2251, DOI 10.1038/s41467-020-16256-y; Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/cpps.20, 10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3]; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Wu YY, 2020, BIOMATER SCI-UK, V8, P3522, DOI 10.1039/d0bm00521e; XU C, 2016, NATURE, V535, P136, DOI DOI 10.1038/NATURE18010; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435; Zhang YN, 2019, NANO LETT, V19, P7226, DOI 10.1021/acs.nanolett.9b02834	65	3	3	4	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							431	10.3390/vaccines9050431			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1OL	33925446	gold, Green Published			2022-04-29	WOS:000654595400001
J	Um, H; Yang, S; Oh, T; Park, K; Cho, H; Suh, J; Min, KD; Chae, C				Um, Hyungmin; Yang, Siyeon; Oh, Taehwan; Park, Keehwan; Cho, Hyejean; Suh, Jeongmin; Min, Kyung-Duk; Chae, Chanhee			Comparative Evaluation of Growth Performance between Bivalent and Trivalent Vaccines Containing Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae in a Herd with Subclinical PCV2d Infection and Enzootic Pneumonia	VACCINES			English	Article						Mycoplasma hyopneumoniae; porcine circovirus type 2; trivalent vaccine	RESPIRATORY SYNDROME VIRUS; 2B MUTANT; PIGS; VACCINATION; CHALLENGE; EFFICACY; CIRCULATION; GENOTYPES; REVEALS; GAIN	The present field trial compared two combined vaccines of porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae, each administered in herd with subclinical PCV2d infection and enzootic pneumonia. One vaccine was a bivalent containing PCV2a and M. hyopneumoniae and the other was a trivalent vaccine containing PCV2a and 2b (PCV2a/b), and M. hyopneumoniae. The defining difference between these two vaccines was the inclusion or absence of PCV2b antigen. A total of 480, 21day-old pigs were randomly allocated to one of four treatment groups (120 pigs per group, male = 60 and female = 60). These groups included; one-dose trivalent-vaccinated, two-dose trivalent-vaccinated, one-dose bivalent-vaccinated, and unvaccinated. The one- and two-dose trivalent vaccinated pigs exhibited significantly better growth performance when compared with those vaccinated with the bivalent vaccine. The one- and two-dose trivalent vaccinated pigs also reduced the amount of PCV2d loads in the blood and feces, and resulted in a lower M. hyopneumoniae load in the larynx when compared with one-dose bivalent vaccinated pigs. Statistical differences were not observed between the one- and two-dose trivalent-vaccinated groups in terms of growth performance, serology, amount of PCV2d loads in the blood and feces, amount of M. hyopneumoniae load in larynx, and pathological lesions. The results of the present study will provide swine practitioners and producer with comparative clinical field data to select the proper vaccine and vaccination regiment for herds suffering from subclinical PCV2d infection and enzootic pneumonia.	[Um, Hyungmin; Yang, Siyeon; Oh, Taehwan; Park, Keehwan; Cho, Hyejean; Suh, Jeongmin; Chae, Chanhee] Seoul Natl Univ, Coll Vet Med, Dept Vet Pathol, Gwanak Ro 1, Seoul 08826, South Korea; [Min, Kyung-Duk] Seoul Natl Univ, Inst Hlth & Environm, 1 Gwanak Ro, Seoul 08826, South Korea		Chae, C (通讯作者)，Seoul Natl Univ, Coll Vet Med, Dept Vet Pathol, Gwanak Ro 1, Seoul 08826, South Korea.	uhmhope1@snu.ac.kr; didtldus12@gmail.com; Ohth93@gmail.com; kylinhp@snu.ac.kr; hcho21@snu.ac.kr; tobin1210@snu.ac.kr; fortop@snu.ac.kr; swine@snu.ac.kr		Oh, Taehwan/0000-0001-9308-5573; Chae, Chanhee/0000-0002-0190-1957; Suh, Jeongmin/0000-0002-8909-911X	Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine [550-20190068]; BK 21 FOUR Future Veterinary Medicine Leading Education and Research Center [A0449-20200100]	This research was supported by contract research funds (Grant no. 550-20190068) of the Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine and by the BK 21 FOUR Future Veterinary Medicine Leading Education and Research Center (Grant no. A0449-20200100).	Bandrick M, 2020, VET IMMUNOL IMMUNOP, V223, DOI 10.1016/j.vetimm.2020.110034; Chae C, 2005, VET J, V169, P326, DOI 10.1016/j.tvjl.2004.01.012; Chae C, 2016, VET J, V212, P1, DOI 10.1016/j.tvjl.2015.10.030; Dubosson CR, 2004, VET MICROBIOL, V102, P55, DOI 10.1016/j.vetmic.2004.05.007; Dvorak CMT, 2016, VET MICROBIOL, V189, P86, DOI 10.1016/j.vetmic.2016.05.002; Fort M, 2009, VACCINE, V27, P4031, DOI 10.1016/j.vaccine.2009.04.028; Franzo G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208585; Franzo G, 2016, MOL PHYLOGENET EVOL, V100, P269, DOI 10.1016/j.ympev.2016.04.028; Galliher-Beckley A, 2015, VACCINE, V33, P2903, DOI 10.1016/j.vaccine.2015.04.065; HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606; Huan CC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00455; Jensen CS, 2002, PREV VET MED, V54, P265, DOI 10.1016/S0167-5877(02)00005-3; Jeong J, 2015, VET MICROBIOL, V177, P43, DOI 10.1016/j.vetmic.2015.02.027; Kim J, 2004, J COMP PATHOL, V131, P121, DOI 10.1016/j.jcpa.2004.02.001; Kwon T, 2017, VIRUS RES, V228, P24, DOI 10.1016/j.virusres.2016.11.015; Maes D, 2018, TRANSBOUND EMERG DIS, V65, P110, DOI 10.1111/tbed.12677; Maes D, 1999, VACCINE, V17, P1024, DOI 10.1016/S0264-410X(98)00254-0; Martelli P, 2011, VET MICROBIOL, V149, P339, DOI 10.1016/j.vetmic.2010.12.008; Opriessnig T, 2004, VET PATHOL, V41, P624, DOI 10.1354/vp.41-6-624; Opriessnig T, 2017, VACCINE, V35, P248, DOI 10.1016/j.vaccine.2016.11.085; Opriessnig T, 2014, VACCINE, V32, P4342, DOI 10.1016/j.vaccine.2014.06.004; Opriessnig T, 2014, VACCINE, V32, P230, DOI 10.1016/j.vaccine.2013.11.010; Opriessnig T, 2013, VET MICROBIOL, V163, P177, DOI 10.1016/j.vetmic.2012.12.019; Park KH, 2019, VET MICROBIOL, V231, P87, DOI 10.1016/j.vetmic.2019.03.002; Pieters M, 2017, VET MICROBIOL, V203, P103, DOI 10.1016/j.vetmic.2017.02.014; Ramos N, 2015, INFECT GENET EVOL, V33, P320, DOI 10.1016/j.meegid.2015.05.023; Segales J, 2012, VIRUS RES, V164, P10, DOI 10.1016/j.virusres.2011.10.007; Seo HW, 2014, ARCH VIROL, V159, P3107, DOI 10.1007/s00705-014-2164-6; Seo HW, 2012, VACCINE, V30, P6671, DOI 10.1016/j.vaccine.2012.08.065; Wilson S, 2012, VACCINE, V30, P7625, DOI 10.1016/j.vaccine.2012.10.028; Xiao CT, 2015, J GEN VIROL, V96, P1830, DOI 10.1099/vir.0.000100	31	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							450	10.3390/vaccines9050450			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1GS	34063582	Green Published			2022-04-29	WOS:000654575200001
J	Wolfson, B; Franks, SE; Hodge, JW				Wolfson, Benjamin; Franks, S. Elizabeth; Hodge, James W.			Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy	VACCINES			English	Review						immunotherapy; combination therapy; cancer; vaccine; clinical trial; adjuvant cytokines; multifunctional	CELL-TRANSFER; PHASE-I; T-CELLS; CHEMOTHERAPY; TRIAL; INTERLEUKIN-12; NEOANTIGENS; IPILIMUMAB; THERAPY; HOMEOSTASIS	Effective treatment of established tumors requires rational multicombination immunotherapy strategies designed to target all functions of the patient immune system and tumor immune microenvironment. While these combinations build on the foundation of successful immune checkpoint blockade antibodies, it is increasingly apparent that successful immunotherapy will also require a cancer vaccine backbone to engage the immune system, thereby ensuring that additional immuno-oncology agents will engage a tumor-specific immune response. This review summarizes ongoing clinical trials built upon the backbone of cancer vaccines and focusing on those clinical trials that utilize multicombination (3+) immuno-oncology agents. We examine combining cancer vaccines with multiple checkpoint blockade antibodies, novel multifunctional molecules, adoptive cell therapy and immune system agonists. These combinations and those yet to enter the clinic represent the future of cancer immunotherapy. With a cancer vaccine backbone, we are confident that current and coming generations of rationally designed multicombination immunotherapy can result in effective therapy of established tumors.	[Wolfson, Benjamin; Franks, S. Elizabeth; Hodge, James W.] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, Bethesda, MD 20892 USA		Hodge, JW (通讯作者)，NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, Bethesda, MD 20892 USA.	ben.wolfson@nih.gov; frankssae@nih.gov; jh241d@nih.gov			Intramural Research Program of the Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health	This research was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health.	Amato RJ, 2010, CLIN CANCER RES, V16, P5539, DOI 10.1158/1078-0432.CCR-10-2082; Aspeslagh S, 2016, EUR J CANCER, V52, P50, DOI 10.1016/j.ejca.2015.08.021; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Bansal D, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.TPS192; Beatty GL, 2013, CLIN CANCER RES, V19, P6286, DOI 10.1158/1078-0432.CCR-13-1320; Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y; Boyer M., 2021, J CLIN ONCOL, DOI [10.1200/JCO.20.03579, DOI 10.1200/JCO.20.03579]; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Byrd JC, 2012, LEUKEMIA LYMPHOMA, V53, P2136, DOI 10.3109/10428194.2012.681655; Cameron F, 2011, DRUGS, V71, P1093, DOI 10.2165/11594010-000000000-00000; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Connolly RM, 2017, FUTURE ONCOL, V13, P1137, DOI 10.2217/fon-2016-0526; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Curti BD, 2013, CANCER RES, V73, P7189, DOI 10.1158/0008-5472.CAN-12-4174; Cuzzubbo S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615240; Della Chiesa M, 2006, BLOOD, V108, P4118, DOI 10.1182/blood-2006-06-006700; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Drake CG, 2020, J CLIN ONCOL, V38; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Dudley ME, 2007, SEMIN ONCOL, V34, P524, DOI 10.1053/j.seminoncol.2007.09.002; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Emambux S, 2018, EXPERT OPIN BIOL TH, V18, P561, DOI 10.1080/14712598.2018.1445222; Fabian KP, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001691; Fallon J, 2014, ONCOTARGET, V5, P1869, DOI 10.18632/oncotarget.1853; Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837; Forero-Torres A, 2013, LEUKEMIA LYMPHOMA, V54, P277, DOI 10.3109/10428194.2012.710328; Franks SE, 2020, CANCERS, V12, DOI 10.3390/cancers12082131; Fujii R, 2018, CANCER IMMUNOL IMMUN, V67, P675, DOI 10.1007/s00262-018-2121-4; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gollob JA, 2000, CLIN CANCER RES, V6, P1678; GONG JH, 1994, LEUKEMIA, V8, P652; Graham Rondell P, 2018, Surg Pathol Clin, V11, P377, DOI 10.1016/j.path.2018.02.006; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; Gulley JL, 2019, J CLIN ONCOL, V37, P1051, DOI 10.1200/JCO.18.02031; Guo ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089350; Gutierrez M, 2021, CLIN CANCER RES, V27, P460, DOI 10.1158/1078-0432.CCR-20-1830; Hernandez-Aya LF, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS1114; Hilton T.L., 2013, J IMMUNOTHER CANCER, V1, pP260, DOI [10.1186/2051-1426-1-S1-P260, DOI 10.1186/2051-1426-1-S1-P260]; Hodge JW, 2013, INT J CANCER, V133, P624, DOI 10.1002/ijc.28070; Hodge JW, 1999, CANCER RES, V59, P5800; Hodge JW, 2021, IMMUNOMEDICINE, pE1020, DOI [10.1002/imed.1020, DOI 10.1002/IMED.1020]; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Horn LA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000326; Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4; Jochems C, 2016, ONCOTARGET, V7, P86359, DOI 10.18632/oncotarget.13411; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kim AK, 2019, CANCER IMMUNOL RES, V7, P805, DOI 10.1158/2326-6066.CIR-18-0499; Lan Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5488; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Larocca C, 2011, CANCER J, V17, P359, DOI 10.1097/PPO.0b013e3182325e63; Lasek W, 2014, CANCER IMMUNOL IMMUN, V63, P419, DOI 10.1007/s00262-014-1523-1; Lee KL, 2021, CANCER IMMUNOL IMMUN, V70, P875, DOI 10.1007/s00262-020-02729-y; Madan RA, 2012, SEMIN ONCOL, V39, P296, DOI 10.1053/j.seminoncol.2012.02.010; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Miles D, 2011, ONCOLOGIST, V16, P1092, DOI 10.1634/theoncologist.2010-0307; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Olszanski A.J., 2017, P SOC IMM CANC SITC; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Overman MJ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.635; Papachristofilou A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0520-5; Peng M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1055-6; PREHN RT, 1957, J NATL CANCER I, V18, P769; Rapoport AP, 2014, CLIN CANCER RES, V20, P1355, DOI 10.1158/1078-0432.CCR-13-2817; Rapoport AP, 2011, BLOOD, V117, P788, DOI 10.1182/blood-2010-08-299396; Redman JM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0409-8; Redmond WL, 2014, CANCER IMMUNOL RES, V2, P142, DOI 10.1158/2326-6066.CIR-13-0031-T; Rhode PR, 2016, CANCER IMMUNOL RES, V4, P49, DOI 10.1158/2326-6066.CIR-15-0093-T; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Rouce RH, 2016, LEUKEMIA, V30, P800, DOI 10.1038/leu.2015.327; Sabari J, 2019, CANCER IMMUNOL RES, V7, DOI 10.1158/2326-6074.CRICIMTEATIAACR18-B209; Schlom J, 2014, ADV CANCER RES, V121, P67, DOI 10.1016/B978-0-12-800249-0.00002-0; Sharifi J, 2001, HYBRIDOMA HYBRIDOM, V20, P305, DOI 10.1089/15368590152740707; Skolnik J, 2020, J IMMUNOTHER CANCER, V8, pA8, DOI 10.1136/LBA2019.12; Sun L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126853; Sundar R, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4234-8; Supabphol S, 2021, EXPERT OPIN INV DRUG, V30, P529, DOI 10.1080/13543784.2021.1896702; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trotta R, 2008, J IMMUNOL, V181, P3784, DOI 10.4049/jimmunol.181.6.3784; van de Laar L, 2012, BLOOD, V119, P3383, DOI 10.1182/blood-2011-11-370130; Vonderheide RH, 2013, CLIN CANCER RES, V19, P1035, DOI 10.1158/1078-0432.CCR-12-2064; Wang R, 2019, CLIN CANCER RES, V25, P6709, DOI 10.1158/1078-0432.CCR-19-0526; Wang-Gillam A, 2013, INVEST NEW DRUG, V31, P707, DOI 10.1007/s10637-012-9866-y; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wilson EB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022842; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; Zhang XL, 2017, CANCER IMMUNOL RES, V5, P516, DOI 10.1158/2326-6066.CIR-16-0264; Zhu Yanni, 2015, Lancet Oncol, V16, pe543, DOI 10.1016/S1470-2045(15)00039-X	98	0	0	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							509	10.3390/vaccines9050509			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3EL	34063388	Green Published, gold			2022-04-29	WOS:000654708300001
J	Czerwinska, E; Nittner-Marszalska, M; Pawlowicz, R; Szenborn, L				Czerwinska, Ewa; Nittner-Marszalska, Marita; Pawlowicz, Robert; Szenborn, Leszek			Simultaneous Influenza Vaccination and Hymenoptera Venom Immunotherapy Is Safe	VACCINES			English	Article						allergen immunotherapy; Hymenoptera venom allergy; influenza vaccination; simultaneous administration	ALLERGEN-SPECIFIC IMMUNOTHERAPY; VACCINES; ILLNESS; ADULTS	Allergen immunotherapy (AIT) is a standard treatment for venom allergy. Our purpose was to determine if the administration of both allergen and protective vaccines during one visit is safe and if such a procedure does not deteriorate the tolerance of both vaccines. As current guidelines are based on theoretical assumptions, our aim was to establish the safety and tolerance of shortening the recommended interval between vaccinations. During two influenza seasons, 44 adult patients, with a history of systemic allergic reactions after a Hymenoptera sting, underwent 58 simultaneous allergen and seasonal influenza vaccinations (study group) while in the maintenance phase of venom immunotherapy (VIT). The control group consisted of 57 healthy adults who were vaccinated against influenza only. The conditions of the patients were monitored during hospital visits, and via telecommunication methods to evaluate the safety and tolerance of the procedure. Within the study group, there were no immediate or delayed allergic reactions after vaccinations. The presence of common, adverse influenza vaccine reactions among study group patients (29%) and control group patients (32%) did not differ significantly (p = 0.841). We did not observe a difference in the frequency of various adverse reactions in either group or a dependence of previous vaccinations against influenza on the occurrence of adverse reactions. The most frequent occurrences were local adverse reactions. All adverse reactions were resolved without treatment. These findings demonstrate the safety and tolerance of an influenza vaccination and Hymenoptera venom immunotherapy administration during one visit.	[Czerwinska, Ewa; Szenborn, Leszek] Wroclaw Med Univ, Dept Paediat & Infect Dis, Ul Tytusa Chalubinskiego 2-2a, PL-50368 Wroclaw, Poland; [Nittner-Marszalska, Marita; Pawlowicz, Robert] Wroclaw Med Univ, Dept Internal Med Pneumol & Allergol, Ul Marii Sklodowskiej Curie 66, PL-50369 Wroclaw, Poland		Czerwinska, E (通讯作者)，Wroclaw Med Univ, Dept Paediat & Infect Dis, Ul Tytusa Chalubinskiego 2-2a, PL-50368 Wroclaw, Poland.	czerwinska.ed@gmail.com; marmarsz@gmail.com; robert.pa@wp.pl; leszek.szenborn@umed.wroc.pl		Szenborn, Leszek/0000-0001-6574-8229	Wroclaw Medical University [ST.C.180.16.081]	This work was supported by Wroclaw Medical University (ST.C.180.16.081). The source of funding did not have any role in study design, collection, analysis, interpretation of data, and writing of the report.	Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; [Anonymous], ALUTARD BEE VENOM MA; [Anonymous], PHARMALGEN WASP VENO; [Anonymous], GRAZAX 75000 SQ T OR; [Anonymous], ALUTARD WASP VENOM M; [Anonymous], CHARAKTERYSTYKA PROD; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Ferdinands JM, 2014, J INFECT DIS, V210, P674, DOI 10.1093/infdis/jiu185; Flannery B, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4244; Garner-Spitzer E, 2018, VACCINE, V36, P2816, DOI 10.1016/j.vaccine.2018.03.076; Greenhawt M, 2018, ANN ALLERG ASTHMA IM, V120, P49, DOI 10.1016/j.anai.2017.10.020; James C, 2017, CURR OPIN ALLERGY CL, V17, P55, DOI 10.1097/ACI.0000000000000335; Kroger AT, GEN BEST PRACTICE GU; Lee HJ, 2017, CLIN EXP VACCINE RES, V6, P22, DOI [10.7774/cevr.2017.6.1.22., 10.7774/cevr.2017.6.1.22]; Moriarty LF, 2014, HUM VACC IMMUNOTHER, V10, P2721, DOI 10.4161/hv.29669; National Institute for Health and Clinical Excellence, PHARMALGEN TREATMENT; Pawankar R., 2013, WAO WHITE BOOK ALLER; Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010; Ullrich D, 2015, EUR ANN ALLERGY CLIN, V47, P10; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x	21	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							344	10.3390/vaccines9040344			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5JL	33918358	Green Published, gold			2022-04-29	WOS:000643815200001
J	Mazuz, ML; Leibovitz, B; Savitsky, I; Blinder, E; Yasur-Landau, D; Lavon, Y; Sharir, B; Tirosh-Levy, S				Mazuz, Monica L.; Leibovitz, Benjamin; Savitsky, Igor; Blinder, Elena; Yasur-Landau, Daniel; Lavon, Yaniv; Sharir, Binyamin; Tirosh-Levy, Sharon			The Effect of Vaccination with Neospora caninum Live-Frozen Tachyzoites on Abortion Rates of Naturally Infected Pregnant Cows	VACCINES			English	Article						N. caninum; neosporosis; abortion; cattle; vaccination; control		Neosporosis is a major cause of abortions in cattle worldwide. Recently a live attenuated vaccine showing promising results in preventing abortions, when administered at mid-pregnancy to seropositive cows, was developed. In this study, vaccination with 2 x 10(8) live frozen N. caninum tachyzoites (NcIs491) was used to immunize naturally infected seropositive pregnant dairy dams. The study was performed under field conditions in four herds, and a follow-up of three subsequent pregnancies was analyzed. A total of 1136 cows were serologically examined. Total seroprevalence was 41.4%, with 25.1% of the cows having titers of 1:800 or higher. Abortion rates were significantly higher in cows with high antibody titers (>= 1:800) for two consecutive pregnancies. Vaccination was administered to 114 out of 285 cows with antibody titers higher than 1:800. Immunization resulted in lower abortion rates at three of the farms. Vaccine efficacy ranged from -19.8% to 75% at different farms, with overall efficacy of 28.4% in all four farms and overall efficacy of 58.2% in the three farms with positive results. Our results showed different vaccine efficacy in studied farms, suggesting that frozen live vaccination may generally be an effective method to control neosporosis in cattle.	[Mazuz, Monica L.; Leibovitz, Benjamin; Savitsky, Igor; Blinder, Elena; Yasur-Landau, Daniel; Tirosh-Levy, Sharon] Kimron Vet Inst, Div Parasitol, IL-50200 Bet Dagan, Israel; [Lavon, Yaniv] Israel Cattle Breeders Assoc, IL-38900 Caesarea, Israel; [Sharir, Binyamin] Hachaklait Vet Serv, IL-3039 Caesarea, Israel; [Tirosh-Levy, Sharon] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Koret Sch Vet Med, IL-7610001 Rehovot, Israel		Mazuz, ML (通讯作者)，Kimron Vet Inst, Div Parasitol, IL-50200 Bet Dagan, Israel.	monical@moag.gov.il; borisl@moag.gov.il; igors@moag.gov.il; elenab@moag.gov.il; DanielY@moag.gov.il; yaniv@icba.co.il; sharir@hak.org.il; sharontirosh@gmail.com	Mazuz, Monica Leszkowicz/AAN-8648-2021; Lavon, Yaniv/ABZ-1072-2022	Leszkowicz Mazuz, Monica/0000-0001-5357-0136; Tirosh-Levy, Sharon/0000-0002-3810-8418	Israeli Cattle Breeders Association [8510350-17]; Israeli Veterinary Services and Animal Health, Israel	This research was funded by The Israeli Cattle Breeders Association, grant number: 8510350-17 and by the Israeli Veterinary Services and Animal Health, Israel.	de Waal DT, 2006, VET PARASITOL, V138, P88, DOI 10.1016/j.vetpar.2006.01.042; Dubey J., 2017, NEOSPOROSIS ANIMALS; Dubey JP, 2007, CLIN MICROBIOL REV, V20, P323, DOI 10.1128/CMR.00031-06; Dubey JP, 2011, VET PARASITOL, V180, P90, DOI 10.1016/j.vetpar.2011.05.031; Eastick FA, 2010, PARASITOL RES, V106, P1009, DOI 10.1007/s00436-010-1788-z; Fish L, 2007, VET PARASITOL, V149, P167, DOI 10.1016/j.vetpar.2007.08.009; Haldorson GJ, 2005, INT J PARASITOL, V35, P1407, DOI 10.1016/j.ijpara.2005.05.013; Innes EA, 2001, INT J PARASITOL, V31, P1523, DOI 10.1016/S0020-7519(01)00284-3; Lopez-Gatius F, 2012, THERIOGENOLOGY, V77, P1029, DOI 10.1016/j.theriogenology.2011.10.014; Mazuz LM, 2011, ISR J VET MED, V66, P14; Mazuz ML, 2015, PREV VET MED, V120, P232, DOI 10.1016/j.prevetmed.2015.03.020; Mazuz ML, 2014, VET PARASITOL, V205, P85, DOI 10.1016/j.vetpar.2014.06.009; Miller C, 2005, INT J PARASITOL, V35, P821, DOI 10.1016/j.ijpara.2005.03.006; Nishimura M, 2013, VACCINE, V31, P3528, DOI 10.1016/j.vaccine.2013.05.083; Pare J, 1996, CAN J VET RES, V60, P133; Pipano E, 1997, TROP ANIM HEALTH PRO, V29, p86S, DOI 10.1007/BF02632940; Reichel MP, 2015, VACCINE, V33, P1299, DOI 10.1016/j.vaccine.2015.01.064; Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022; Reichel MP, 2009, INT J PARASITOL, V39, P1173, DOI 10.1016/j.ijpara.2009.05.007; Rojo-Montejo S, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-106; Romero JJ, 2004, VET PARASITOL, V123, P149, DOI 10.1016/j.vetpar.2004.06.016; Schares G, 1998, VET PARASITOL, V80, P87, DOI 10.1016/S0304-4017(98)00195-2; Shkap V, 2002, VET PARASITOL, V106, P35, DOI 10.1016/S0304-4017(02)00030-4; Shkap V, 2007, TRENDS PARASITOL, V23, P420, DOI 10.1016/j.pt.2007.07.003; Stenlund S, 1999, VET PARASITOL, V85, P227, DOI 10.1016/S0304-4017(99)00120-X; Weber FH, 2013, CLIN VACCINE IMMUNOL, V20, P99, DOI 10.1128/CVI.00225-12; Weston JF, 2012, PREV VET MED, V103, P136, DOI 10.1016/j.prevetmed.2011.08.010; Williams DJL, 2007, INFECT IMMUN, V75, P1343, DOI 10.1128/IAI.00777-06	28	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							401	10.3390/vaccines9040401			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6BG	33921584	gold, Green Published			2022-04-29	WOS:000643861600001
J	Wang, ZH; Liu, MY; Zhao, HR; Wang, PP; Ma, WG; Zhang, YK; Wu, WX; Peng, C				Wang, Zhanhui; Liu, Mengyao; Zhao, Haoran; Wang, Pengpeng; Ma, Wenge; Zhang, Yunke; Wu, Wenxue; Peng, Chen			Induction of Robust and Specific Humoral and Cellular Immune Responses by Bovine Viral Diarrhea Virus Virus-Like Particles (BVDV-VLPs) Engineered with Baculovirus Expression Vector System	VACCINES			English	Article						bovine viral diarrhea virus; virus-like particles; baculovirus expression vector system; E-rns; E2; vaccine		Bovine viral diarrhea virus (BVDV) is an important animal pathogen that affects cattle. Infections caused by the virus have resulted in substantial economic losses and outbreaks of BVDV are reported globally. Virus-like particles (VLPs) are promising vaccine technology largely due to their safety and strong ability to elicit robust immune responses. In this study, we developed a strategy to generate BVDV-VLPs using a baculovirus expression vector system (BEVS). We were able to assemble BVDV-VLPs composed of dimerized viral proteins E2 and E-rns, and the VLPs were spherical particles with the diameters of about 50 nm. Mice immunized with 15 mu g of VLPs adjuvanted with ISA201 elicited higher levels of E2-specific IgG, IgG1, and IgG2a antibodies as well as higher BVDV-neutralizing activity in comparison with controls. Re-stimulation of the splenocytes collected from mice immunized with VLPs led to significantly increased levels of CD3(+)CD4(+)T cells and CD3(+)CD8(+)T cells. In addition, the splenocytes showed dramatically enhanced proliferation and the secretion of Th1-associated IFN-gamma and Th2-associated IL-4 compared to that of the unstimulated control group. Taken together, our data indicate that BVDV-VLPs efficiently induced BVDV-specific humoral and cellular immune responses in mice, showing a promising potential of developing BVDV-VLP-based vaccines for the prevention of BVDV infections.	[Wang, Zhanhui; Liu, Mengyao; Zhao, Haoran; Wang, Pengpeng; Ma, Wenge; Zhang, Yunke; Wu, Wenxue; Peng, Chen] China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Beijing 100193, Peoples R China		Wu, WX; Peng, C (通讯作者)，China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Beijing 100193, Peoples R China.	wangzhanhui2016@163.com; mengyaoliu@cau.edu.cn; zhaohrr@yeah.net; 18754881870@163.com; Wenge_Ma@163.com; zhangyk@cau.edu.cn; labboard@126.com; chenpengup@outlook.com	Wang, Zhanhui/AAH-8601-2019	Wang, Pengpeng/0000-0003-2160-9360	China Agriculture Research System [CARS-36]	This work was financially supported by the China Agriculture Research System (CARS-36).	Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005; Abe T, 2003, J IMMUNOL, V171, P1133, DOI 10.4049/jimmunol.171.3.1133; Abe T, 2009, J VIROL, V83, P7629, DOI 10.1128/JVI.00679-09; Asfor AS, 2014, VIRUS RES, V189, P147, DOI 10.1016/j.virusres.2014.05.016; Bauermann FV, 2013, J VET DIAGN INVEST, V25, P6, DOI 10.1177/1040638712473103; Bhuyan AA, 2018, J BIOTECHNOL, V270, P51, DOI 10.1016/j.jbiotec.2018.01.016; Branza-Nichita N, 2004, BIOCHEM BIOPH RES CO, V319, P655, DOI 10.1016/j.bbrc.2004.05.039; Branza-Nichita N, 2002, BIOCHEM BIOPH RES CO, V296, P470, DOI 10.1016/S0006-291X(02)00907-5; Brock KV, 2003, BIOLOGICALS, V31, P133, DOI 10.1016/S1045-1056(03)00029-0; Callens N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005476; Chambers Adam C, 2018, Curr Protoc Protein Sci, V91, DOI 10.1002/cpps.47; Chang YH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030336; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; Dai SY, 2018, VIROL SIN, V33, P213, DOI 10.1007/s12250-018-0030-5; Deng M, 2020, VET MICROBIOL, V242, DOI 10.1016/j.vetmic.2019.108565; Deschuyteneer M, 2010, HUM VACCINES, V6, P407, DOI 10.4161/hv.6.5.11023; Donofrio G, 2006, CLIN VACCINE IMMUNOL, V13, P698, DOI 10.1128/CVI.00071-06; Dubovi E J, 1990, Rev Sci Tech, V9, P105; El Omari K, 2013, CELL REP, V3, P30, DOI 10.1016/j.celrep.2012.12.001; Elmowalid GA, 2007, P NATL ACAD SCI USA, V104, P8427, DOI 10.1073/pnas.0702162104; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Huang JS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111067; Hulst MM, 2001, METHOD ENZYMOL, V342, P431, DOI 10.1016/S0076-6879(01)42564-X; Iqbal M, 2000, J GEN VIROL, V81, P451, DOI 10.1099/0022-1317-81-2-451; Khodakaram-Tafti A, 2017, IRAN J VET RES, V18, P154; Krey T, 2006, J VIROL, V80, P3912, DOI 10.1128/JVI.80.8.3912-3922.2006; Krey T, 2012, STRUCTURE, V20, P862, DOI 10.1016/j.str.2012.03.018; Li Y, 2013, P NATL ACAD SCI USA, V110, P6805, DOI 10.1073/pnas.1300524110; Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9; Nelson DD, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01415; Ono C, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090510; Palomares LA, 2003, BIOTECHNOL PROGR, V19, P185, DOI 10.1021/bp025598o; Pande A, 2005, VIRUS RES, V114, P54, DOI 10.1016/j.virusres.2005.05.011; Pinior B, 2017, PREV VET MED, V137, P77, DOI 10.1016/j.prevetmed.2016.12.014; Ran XH, 2019, ACTA TROP, V190, P296, DOI 10.1016/j.actatropica.2018.08.031; Rebollo B, 2018, DIAGN MICR INFEC DIS, V91, P233, DOI 10.1016/j.diagmicrobio.2018.02.003; Riedmann Eva M, 2014, Hum Vaccin Immunother, V10, P1139, DOI 10.4161/hv.29344; Schmeiser S, 2014, J VIROL, V88, P2717, DOI 10.1128/JVI.03237-13; SISK WP, 1994, J VIROL, V68, P766, DOI 10.1128/JVI.68.2.766-775.1994; Suphatrakul A, 2015, VACCINE, V33, P5613, DOI 10.1016/j.vaccine.2015.08.090; Tautz N, 1998, CLIN DIAGN VIROL, V10, P121, DOI 10.1016/S0928-0197(98)00037-3; Tautz N, 2015, ADV VIRUS RES, V93, P47, DOI 10.1016/bs.aivir.2015.03.002; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Tews BA, 2009, J VIROL, V83, P4823, DOI 10.1128/JVI.01710-08; Thomas C, 2009, VACCINE, V27, P2387, DOI 10.1016/j.vaccine.2009.02.010; Wang SH, 2020, VACCINE, V38, P3881, DOI 10.1016/j.vaccine.2020.03.020; Wang YX, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060575; Yesilbag K, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060128; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zoth SC, 2007, BRAZ J MED BIOL RES, V40, P813, DOI 10.1590/S0100-879X2007000600010	51	2	2	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							350	10.3390/vaccines9040350			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4WX	33917272	gold, Green Published			2022-04-29	WOS:000643782500001
J	Gomez, CE; Perdiguero, B; Esteban, M				Gomez, Carmen Elena; Perdiguero, Beatriz; Esteban, Mariano			Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19	VACCINES			English	Review						SARS-CoV-2; COVID-19; variant; spike protein; mutation; lineage; vaccine efficacy; neutralizing antibodies	SPIKE	The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants in different continents is causing a major concern in human global health. These variants have in common a higher transmissibility, becoming dominant within populations in a short time, and an accumulation of a high number of mutations in the spike (S) protein, especially within the amino terminal domain (NTD) and the receptor binding domain (RBD). These mutations have direct implications on virus infection rates through higher affinity of S RBD for the cellular angiotensin-converting enzyme-2 (ACE-2) receptor. There are also signs of enhanced virulence, re-infection frequency, and increased resistance to the action of monoclonal and polyclonal antibodies from convalescence sera and in vaccinated individuals in regions where the variants spread dominantly. In this review, we describe the different SARS-CoV-2 variants that have thus far been identified in various parts of the world with mutational changes and biological properties as well as their impact in medical countermeasures and human health.	[Gomez, Carmen Elena; Perdiguero, Beatriz; Esteban, Mariano] CSIC, CNB, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Cantoblanco, Madrid 28049, Spain		Gomez, CE; Esteban, M (通讯作者)，CSIC, CNB, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Cantoblanco, Madrid 28049, Spain.	cegomez@cnb.csic.es; perdigue@cnb.csic.es; mesteban@cnb.csic.es	Perdiguero, Beatriz/K-6587-2017; Gomez, Carmen E/K-1940-2014	Perdiguero, Beatriz/0000-0001-6276-7766; Gomez, Carmen E/0000-0002-5414-7935; ESTEBAN, MARIANO/0000-0003-0846-2827	Spanish CSIC; Obra Social La CaixaLa Caixa Foundation [CaixaImpulse CF01-0008]	This investigation was supported by grants from Spanish CSIC and Obra Social La Caixa (CaixaImpulse CF01-0008).	[Anonymous], 2021, INV NOV SARS COV 2 V; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bugembe D. L., 2021, MEDRXIV, DOI DOI 10.1101/2021.02.08.21251393; Buss Lewis F, 2021, Science, V371, P288, DOI 10.1126/science.abe9728; Callaway E, 2021, NATURE, V590, P17, DOI 10.1038/d41586-021-00268-9; Cele S., 2021, ESCAPE SARS COV 2 50, DOI [10.1101/2021.01.26.21250224v1(2021), DOI 10.1101/2021.01.26.21250224]; Collier Dami A, 2021, medRxiv, DOI 10.1101/2021.01.19.21249840; Davies NG, 2020, MEDRXIV, DOI [10.1101/2020.12.24.20248822, DOI 10.1101/2021.02.01.21250959, 10.1126/science.abg3055]; de Oliveira T., S AFRICAN SCI WHO DI; Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013; Gamage AM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009130; Grabowski F., 2021, L18F SUBSTRAIN SARS, DOI [10.1101/2021.02.07.21251262, DOI 10.1101/2021.02.07.21251262]; Greaney AJ., 2020, 425021 BIORXIV, DOI [10.1101/2020.12.31.425021, DOI 10.1101/2020.12.31.425021, 12.31.425021]; Grzelak L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3103; Gu HJ, 2020, SCIENCE, V369, P1603, DOI 10.1126/science.abc4730; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685; Jangra Sonia, 2021, medRxiv, DOI 10.1101/2021.01.26.21250543; Kassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6; Kemp S., 2020, RECURRENT EMERGENCE, DOI [DOI 10.1101/2020.12.14.422555, 10.1101/2020.12.14.422555, 10.2139/ssrn.3780277]; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Ledford Heidi, 2021, Nature, DOI 10.1038/d41586-021-00119-7; Ledford Heidi, 2021, Nature, DOI 10.1038/d41586-021-00071-6; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Madhi SAB, 2021, MEDRXIV, DOI [10.1101/2021.02.10.21251247, DOI 10.1101/2021.02.10.21251247, 10.21251247]; Mallapaty Smriti, 2021, Nature, DOI 10.1038/d41586-021-00094-z; McCarthy KR, 2021, SCIENCE, V371, P1139, DOI 10.1126/science.abf6950; Meng T., 2020, BIORXIV, DOI 10.1101/2020.02.08.926006; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Nakagawa K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82188-2; Nelson G., 2021, BIORXIV, DOI [10.1101/2021.01.13.426558, DOI 10.1101/2021.01.13.426558]; Munnink BOB, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0997-y; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Shannon A, 2020, bioRxiv, DOI 10.1101/2020.05.15.098731; Starr Tyler N, 2020, Cell, V182, P1295, DOI [10.1101/2020.06.17.157982, 10.1016/j.cell.2020.08.012]; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; West Jr A.P., 2021, SARS COV 2 LINEAGE B, DOI [10.1101/2021.02.14.431043, DOI 10.1101/2021.02.14.431043]; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wu Kai, 2021, bioRxiv, DOI 10.1101/2021.01.25.427948; Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740; Zhang WJ, 2021, JAMA-J AM MED ASSOC, V325, P1324, DOI 10.1001/jama.2021.1612	48	86	87	15	26	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							243	10.3390/vaccines9030243			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5BA	33799505	Green Published, gold	Y	N	2022-04-29	WOS:000634168200001
J	Tsitsilonis, OE; Paraskevis, D; Lianidou, E; Terpos, E; Akalestos, A; Pierros, V; Kostaki, EG; Kastritis, E; Moutsatsou, P; Politou, M; Scorilas, A; Sphicopoulos, T; Thomaidis, N; Trougakos, IP; Tsakris, A; Voulgaris, N; Daskalaki, CC; Evangelakou, Z; Fouki, C; Gianniou, DD; Gumeni, S; Kostopoulos, IV; Manola, MS; Orologas-Stavrou, N; Panteli, C; Papanagnou, ED; Rousakis, P; Sklirou, AD; Smilkou, S; Stergiopoulou, D; Tsiodras, S; Dimopoulos, MA; Sfikakis, PP				Tsitsilonis, Ourania E.; Paraskevis, Dimitrios; Lianidou, Evi; Terpos, Evangelos; Akalestos, Athanasios; Pierros, Vassilios; Kostaki, Evangelia Georgia; Kastritis, Efstathios; Moutsatsou, Paraskevi; Politou, Marianna; Scorilas, Andreas; Sphicopoulos, Thomas; Thomaidis, Nikolaos; Trougakos, Ioannis P.; Tsakris, Athanassios; Voulgaris, Nikolaos; Daskalaki, Christina C.; Evangelakou, Zoi; Fouki, Christina; Gianniou, Despoina D.; Gumeni, Sentiljana; Kostopoulos, Ioannis V.; Manola, Maria S.; Orologas-Stavrou, Nikolaos; Panteli, Chrysanthi; Papanagnou, Eleni-Dimitra; Rousakis, Pantelis; Sklirou, Aimilia D.; Smilkou, Stavroula; Stergiopoulou, Dimitra; Tsiodras, Sotirios; Dimopoulos, Meletios-Athanasios; Sfikakis, Petros P.			SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response	VACCINES			English	Article						SARS-CoV-2; seroepidemiology; asymptomatic; unsuspected; asymptomatic; antibodies	ANTI-SARS-COV-2 ANTIBODIES; COVID-19	Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18-82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARS-CoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptor-binding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic.	[Tsitsilonis, Ourania E.; Scorilas, Andreas; Trougakos, Ioannis P.; Daskalaki, Christina C.; Evangelakou, Zoi; Gianniou, Despoina D.; Gumeni, Sentiljana; Kostopoulos, Ioannis V.; Manola, Maria S.; Orologas-Stavrou, Nikolaos; Panteli, Chrysanthi; Papanagnou, Eleni-Dimitra; Rousakis, Pantelis; Sklirou, Aimilia D.] Natl & Kapodistrian Univ Athens NKUA, Dept Biol, Athens 15784, Greece; [Paraskevis, Dimitrios; Kostaki, Evangelia Georgia; Fouki, Christina] NKUA, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece; [Lianidou, Evi; Thomaidis, Nikolaos; Smilkou, Stavroula; Stergiopoulou, Dimitra] NKUA, Dept Chem, Athens 15771, Greece; [Terpos, Evangelos; Kastritis, Efstathios; Dimopoulos, Meletios-Athanasios] NKUA, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens 11528, Greece; [Akalestos, Athanasios] Roche Diagnost Hellas SA, Athens 15125, Greece; [Pierros, Vassilios; Sphicopoulos, Thomas] NKUA, Dept Informat & Telecommun, Athens 15784, Greece; [Moutsatsou, Paraskevi] NKUA, Univ Gen Hosp Attikon, Sch Med, Dept Clin Biochem, Haidari 12462, Greece; [Politou, Marianna] NKUA, Sch Med, Aretaieio Hosp, Hematol Lab,Blood Bank, Athens 11528, Greece; [Tsakris, Athanassios] NKUA, Sch Med, Dept Microbiol, Athens 11527, Greece; [Voulgaris, Nikolaos] NKUA, Dept Geol & Geoenvironm, Athens 15784, Greece; [Tsiodras, Sotirios] NKUA, Univ Hosp Attikon, Sch Med, Dept Internal Med 4, Haidari 12462, Greece; [Sfikakis, Petros P.] NKUA, Sch Med, Laiko Gen Hosp, Dept Propaedeut Internal Med 1, Athens 15772, Greece		Tsitsilonis, OE (通讯作者)，Natl & Kapodistrian Univ Athens NKUA, Dept Biol, Athens 15784, Greece.; Paraskevis, D (通讯作者)，NKUA, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece.	rtsitsil@biol.uoa.gr; dparask@med.uoa.gr; lianidou@chem.uoa.gr; eterpos@med.uoa.gr; thanasis.akalestos@roche.com; pierrosv@di.uoa.gr; ekostakh@med.uoa.gr; ekastritis@med.uoa.gr; pmoutsatsou@med.uoa.gr; mpolitou@med.uoa.gr; ascorilas@biol.uoa.gr; thomas@di.uoa.gr; ntho@chem.uoa.gr; itrougakos@biol.uoa.gr; atsakris@med.uoa.gr; voulgaris@geol.uoa.gr; xristin1.dask@gmail.com; zoievag@biol.uoa.gr; chrfouki@hotmail.com; gndespoina@biol.uoa.gr; sgumeni@biol.uoa.gr; gikosto@gmail.com; mmanola@biol.uoa.gr; norologas@biol.uoa.gr; chrysanthipanteli23@gmail.com; epapanagnou@biol.uoa.gr; rousakisp@gmail.com; asklirou@biol.uoa.gr; ssmilkou@chem.uoa.gr; dimitrastergiopoulou@yahoo.com; sotirios.tsiodras@gmail.com; mdimop@med.uoa.gr; psfikakis@med.uoa.gr	Kostopoulos, Ioannis V/AAS-8324-2021; Kostaki, Evangelia Georgia/AAE-7014-2021; Trougakos, Ioannis/R-6149-2018; Thomaidis, Nikolaos/A-1189-2008	Kostopoulos, Ioannis V/0000-0003-1152-6959; Papanagnou, Eleni-Dimitra/0000-0003-1277-8007; Terpos, Evangelos/0000-0001-5133-1422; Paraskevis, Dimitrios/0000-0001-6167-7152; Tsitsilonis, Ourania/0000-0001-6954-0740; Scorilas, Andreas/0000-0003-2427-4949; Dimopoulos, Meletios/0000-0001-8990-3254; Lianidou, Evi/0000-0002-7796-5914; Sklirou, Aimilia/0000-0001-5060-4847; Smilkou, Stavroula/0000-0002-5338-0276; Tsiodras, Sotirios/0000-0002-0463-4321; Trougakos, Ioannis/0000-0002-6179-2772; GIANNIOU, DESPOINA/0000-0002-8111-6528; Kostaki, Evangelia Georgia/0000-0002-3346-0930; Manola, Maria/0000-0002-6975-2812; Thomaidis, Nikolaos/0000-0002-4624-4735	NKUA-SARG	The authors would like to thank Roche Diagnostics for kindly donating the laboratory testing kits used in the study; Aggelos Toskas (First Department of Propaedeutic Medicine, Laikon General Hospital, Athens), and Hara Karageorgou (School of Science, NKUA) for assistance in blood collection; NKUA-SARG for financial support; and all NKUA members who voluntarily participated to the study.	Anna F, 2021, EUR J IMMUNOL, V51, P180, DOI 10.1002/eji.202049058; Birrell P, 2021, PHILOS T R SOC B, V376, DOI 10.1098/rstb.2020.0279; Buitrago-Garcia D, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003346; Cao SY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19802-w; Chen YZ, 2020, CELL, V183, P1496, DOI 10.1016/j.cell.2020.10.051; Emery JC, 2020, ELIFE, V9, DOI 10.7554/eLife.58699; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Garcia-Basteiro AL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17318-x; Graham NR, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1189; Grossberg AN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21040-7; Hashem AM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121390; Kasper MR, 2020, NEW ENGL J MED, V383, P2417, DOI 10.1056/NEJMoa2019375; Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1; Li KN, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19943-y; Meyerowitz EA, 2021, LANCET INFECT DIS, V21, pE163, DOI 10.1016/S1473-3099(20)30837-9; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Sasisekharan V, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021615118; Shioda Kayoko, 2020, medRxiv, DOI 10.1101/2020.11.13.20231266; Slot E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19481-7; Terpos E, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121885; Terpos E, 2020, NEW ENGL J MED, V383, P1695, DOI 10.1056/NEJMc2027051; Tsitsilonis OE, 2020, LIFE-BASEL, V10, DOI 10.3390/life10090214; Vuilleumier N., 2020, HOUSEHOLD TRANSMISSI, V2021, DOI [10.1101/2020.11.04.20225573, DOI 10.1101/2020.11.04.20225573]; Wadhwa A, 2021, CLIN INFECT DIS, V72, pE128, DOI 10.1093/cid/ciaa1802; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	26	7	7	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							207	10.3390/vaccines9030207			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6SO	33801380	Green Published, gold			2022-04-29	WOS:000634281500001
J	Buades, J; Losada, I; Gonzalez-Moreno, J; Penaranda, M; Vilaplana, L; Roda, N; Rey, A; Rodriguez, A; Garau, M; de Gopegui, ER; Serra, A; Saurina, J; Payeras, A				Buades, Juan; Losada, Ines; Gonzalez-Moreno, Juan; Penaranda, Maria; Vilaplana, Laia; Roda, Nuria; Rey, Adelaida; Rodriguez, Adrian; Garau, Margarita; Ruiz de Gopegui, Enrique; Serra, Antoni; Saurina, Juan; Payeras, Antoni			Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old	VACCINES			English	Article						pneumococcal disease; invasive pneumococcal disease; pneumococcal conjugate vaccine; serotypes; antibiotic sensitivity	INFECTIONS; IMPACT	Invasive pneumococcal disease (IPD) presents high mortality in the population at risk. The aim of this work is to know the evolution, clinical and microbiological characteristics of IPD in the adult population of Majorca, since the introduction of a public funded program for pneumococcal conjugate vaccine (PCV-13) in the pediatric population in the Balearic Islands in 2016. For this purpose, a retrospective multicenter study was carried out in which all episodes of IPD in adult patients from the four hospitals of the public health system of Majorca were included, comparing the periods between 2012 and 2015 and between 2016 and 2019. Clinical variables, serotypes and antibiotic sensitivity were collected. There were 498 cases of IPD; 56.8% were male with a mean age of 67 (standard deviation: 16). Most infections were bacterial pneumonias (73.7%). Of the total cases, 264 (53%) presented complications. Of the 498 cases, 351 strains were obtained, of which 145 (41.3%) belong to vaccinal serotypes (included in the PCV-13 vaccine) and 206 (58.7%) to non-vaccinal serotypes (not included in the PCV-13 vaccine). The percentage of IPD caused by vaccinal serotypes was lower in the second period (47.8% vs. 34.5%; p = 0.012).	[Buades, Juan; Losada, Ines; Gonzalez-Moreno, Juan; Rodriguez, Adrian; Payeras, Antoni] Son Llatzer Univ Hosp HUSLL, Internal Med Serv, Palma De Mallorca 07198, Spain; [Losada, Ines; Gonzalez-Moreno, Juan; Payeras, Antoni] Inst Hlth Res Balearic Isl IdISBa, Palma De Mallorca 07120, Spain; [Penaranda, Maria] Hosp Univ Son Espases HUSE, Infect Dis Sect, Palma De Mallorca 07120, Spain; [Vilaplana, Laia; Roda, Nuria] Hosp Manacor, Dept Internal Med, Manacor 07500, Spain; [Rey, Adelaida] Hosp Inca, Internal Med Serv, Inca 07300, Spain; [Garau, Margarita] Son Llatzer Univ Hosp HUSLL, Microbiol Serv, Palma De Mallorca 07198, Spain; [Ruiz de Gopegui, Enrique] Hosp Univ Son Espases HUSE, Microbiol Serv, Palma De Mallorca 07120, Spain; [Serra, Antoni] Hosp Manacor, Microbiol Serv, Manacor 07500, Spain; [Saurina, Juan] Hosp Inca, Microbiol Serv, Inca 07300, Spain		Buades, J (通讯作者)，Son Llatzer Univ Hosp HUSLL, Internal Med Serv, Palma De Mallorca 07198, Spain.	juansebastian.buades@hsll.es; ialosada@hsll.es; jgonzalez4@hsll.es; maria.penaranda@ssib.es; lvilaplana@hmanacor.org; nroda@hmanacor.org; adelaida.rey@hcin.es; adrian.rodriguez@hsll.es; margagaraucolom2@gmail.com; enrique.ruiz@ssib.es; tserra@hmanacor.org; juan.saurina@hcin.es; apayeras@hsll.es		Losada, Ines/0000-0002-4834-0843			Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Cafiero-Fonseca ET, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186903; Cilloniz C, 2013, CHEST, V144, P999, DOI 10.1378/chest.13-0062; de Miguel S, 2021, CLIN INFECT DIS, V73, pE3778, DOI 10.1093/cid/ciaa1483; Flores-Copete M, 2019, ATEN PRIM, V51, P571, DOI 10.1016/j.aprim.2018.07.009; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Gonzalez-Diaz A, 2020, CLIN MICROBIOL INFEC, V26, P753, DOI 10.1016/j.cmi.2019.10.034; Grau I, 2016, J INFECTION, V72, P439, DOI 10.1016/j.jinf.2016.01.011; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6; Institut d&PRIME;Estadistica de les Illes Balears (IBESTAT), AD POP 2019 HLTH SEC; Kandasamy R, 2020, J INFECT DIS, V221, P1361, DOI 10.1093/infdis/jiz178; Lewnard JA, 2019, LANCET INFECT DIS, V19, pE213, DOI 10.1016/S1473-3099(18)30660-1; Lopez-Gobernado Miguel, 2019, Rev Esp Geriatr Gerontol, V54, P309, DOI 10.1016/j.regg.2019.05.004; Marimon JM, 2021, ENFERM INFEC MICR CL, V39, P142, DOI 10.1016/j.eimc.2020.02.016; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3; Payeras A, 2017, INFECT DIS-NOR, V49, P71, DOI 10.1080/23744235.2016.1218044; Payeras A, 2015, INT J INFECT DIS, V33, P22, DOI 10.1016/j.ijid.2014.12.035; Picazo JJ, 2019, VACCINE, V37, P2200, DOI 10.1016/j.vaccine.2019.03.015; Principi N, 2015, EXPERT REV VACCINES, V14, P1359, DOI 10.1586/14760584.2015.1075884; Sangil A, 2018, INFECT GENET EVOL, V59, P126, DOI 10.1016/j.meegid.2018.01.024; SEIMC, 2017, PROC CLIN MICR DOC 1; Shoji H, 2018, INFECT DRUG RESIST, V11, P1387, DOI 10.2147/IDR.S165093; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Torres A, 2015, EUR J CLIN MICROBIOL, V34, P19, DOI 10.1007/s10096-014-2208-6; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Vadlamudi NK, 2019, CLIN INFECT DIS, V69, P34, DOI 10.1093/cid/ciy872; Verani JR, 2015, VACCINE, V33, P6145, DOI 10.1016/j.vaccine.2015.10.007; Vila-Corcoles A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3096-7; Vila-Corcoles A, 2011, VACCINE, V29, P7430, DOI 10.1016/j.vaccine.2011.07.066; World Health Organisation, 2012, WKLY EPIDEMIOL REC, V87, P129	32	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							93	10.3390/vaccines9020093			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QZ	33513726	Green Published, gold			2022-04-29	WOS:000623267500001
J	Fraleigh, NL; Lewicky, JD; Martel, AL; Diaz-Mitoma, F; Le, HT				Fraleigh, Nya L.; Lewicky, Jordan D.; Martel, Alexandrine L.; Diaz-Mitoma, Francisco; Hoang-Thanh Le			Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine	VACCINES			English	Article						nicotine vaccine; mucosal; intranasal; nicotine distribution; nicotine analysis method	IMMUNOGENICITY; IMMUNOTHERAPY; ADJUVANTS; SAFETY	Tobacco smoking continues to be a global epidemic and the leading preventable cause of cancer and cardiovascular disease. Nicotine vaccines have been investigated as an alternative to currently available smoking cessation strategies as a means to increase rates of success and long-term abstinence. Recently, we demonstrated that a mucosal nicotine vaccine was able to induce robust mucosal and systemic antibodies when delivered heterologously using intranasal and intramuscular routes. Herein, we investigated the neutralization ability of the anti-nicotine antibodies using both intranasal and intracardiac nicotine challenges. Combining the extraction of lyophilized organ samples with RP-HPLC methods, we were able to recover between 47% and 56% of the nicotine administered from the blood, brain, heart, and lungs up to 10 min after challenge, suggesting that the interaction of the antibodies with nicotine forms a stable complex independently of the route of vaccination or challenge. Although both challenge routes can be used for assessing systemic antibodies, only the intranasal administration of nicotine, which is more physiologically similar to the inhalation of nicotine, permitted the crucial interaction of nicotine with the mucosal antibodies generated using the heterologous vaccination route. Notably, these results were obtained 6 months after the final vaccination, demonstrating stable mucosal and systemic antibody responses.	[Fraleigh, Nya L.; Lewicky, Jordan D.; Martel, Alexandrine L.; Hoang-Thanh Le] Hlth Sci North Res Inst HSNRI, Dept Res, 56 Walford Rd, Sudbury, ON P3E 2H3, Canada; [Diaz-Mitoma, Francisco; Hoang-Thanh Le] Laurentian Univ, Dept Chem & Biochem, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada; [Diaz-Mitoma, Francisco] VBI Vaccines Inc, 310 Hunt Club Rd Suite 201, Ottawa, ON K1V 1C1, Canada; [Hoang-Thanh Le] Northern Ontario Sch Med, Med Sci Div, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada		Le, HT (通讯作者)，Hlth Sci North Res Inst HSNRI, Dept Res, 56 Walford Rd, Sudbury, ON P3E 2H3, Canada.; Le, HT (通讯作者)，Laurentian Univ, Dept Chem & Biochem, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.; Le, HT (通讯作者)，Northern Ontario Sch Med, Med Sci Div, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.	nfraleigh@hsnri.ca; jlewicky@hsnri.ca; amartel@hsnri.ca; fdiazmitoma@vbivaccines.com; hle@hsnri.ca		Diaz-Mitoma, Francisco/0000-0003-0292-4859	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [PJT-148531]; Northern Cancer Foundation (NCF)	This work was graciously supported by Le's Canadian Institutes of Health Research (CIHR) Project Grant (PJT-148531) and a grant from the Northern Cancer Foundation (NCF, 2017-2019).	Alzhrani RF, 2020, DRUG DEV IND PHARM, V46, P1656, DOI 10.1080/03639045.2020.1820033; Azizi A, 2013, HUM VACC IMMUNOTHER, V9, P1445, DOI 10.4161/hv.24200; Benowitz NL, 2019, NICOTINE TOB RES, V21, P16, DOI 10.1093/ntr/ntz120; Brandtzaeg P, 2005, IMMUNOL REV, V206, P32, DOI 10.1111/j.0105-2896.2005.00283.x; Brewer BG, 2004, DRUG ALCOHOL DEPEN, V75, P193, DOI 10.1016/j.drugalcdep.2004.02.011; Chakravarty S, 2005, J NEUROSCI, V25, P1788, DOI 10.1523/jneurosci.4268-04.2005; Cohen Ami, 2013, Front Psychiatry, V4, P41, DOI 10.3389/fpsyt.2013.00041; Dinh T., 2012 P C BOARD CAN O; Fahim REF, 2013, EXPERT REV VACCINES, V12, P333, DOI [10.1586/erv.13.13, 10.1586/ERV.13.13]; Fraleigh NL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221708; Fraleigh NL, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00147; Hatsukami DK, 2011, CLIN PHARMACOL THER, V89, P392, DOI 10.1038/clpt.2010.317; Hatsukami DK, 2005, CLIN PHARMACOL THER, V78, P456, DOI 10.1016/j.clpt.2005.08.007; Le HT, 2020, MOLECULES, V25, DOI 10.3390/molecules25061290; Hu Y, 2016, BIOMATERIALS, V106, P228, DOI 10.1016/j.biomaterials.2016.08.028; LeSage MG, 2006, PSYCHOPHARMACOLOGY, V184, P409, DOI 10.1007/s00213-005-0027-2; Matta SG, 2007, PSYCHOPHARMACOLOGY, V190, P269, DOI 10.1007/s00213-006-0441-0; Maurer P, 2005, EUR J IMMUNOL, V35, P2031, DOI 10.1002/eji.200526285; O'Dell LE, 2009, PHARMACOL BIOCHEM BE, V91, P481, DOI 10.1016/j.pbb.2008.12.011; Oliva R, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120626; Pentel PR, 2014, ADV PHARMACOL, V69, P553, DOI 10.1016/B978-0-12-420118-7.00014-7; Perez O, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00407; Pravetoni M, 2019, NEUROPHARMACOLOGY, V158, DOI 10.1016/j.neuropharm.2019.06.001; Prochaska JJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aay9763; Refinetti R, 2010, FRONT BIOSCI-LANDMRK, V15, P564, DOI 10.2741/3634; Rose JE, 2010, P NATL ACAD SCI USA, V107, P5190, DOI 10.1073/pnas.0909184107; Thorn JM, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5020011; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Zalewska-Kaszubska J, 2015, VACCINE, V33, P6545, DOI 10.1016/j.vaccine.2015.09.079; Zeigler DF, 2019, VACCINE, V37, P1584, DOI 10.1016/j.vaccine.2019.02.003; Zeigler DF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178835; Zhao ZM, 2019, MOL PHARMACEUT, V16, P2766, DOI 10.1021/acs.molpharmaceut.9b00279; Zhao ZM, 2018, BIOMATERIALS, V155, P165, DOI 10.1016/j.biomaterials.2017.11.021; Zhao ZM, 2017, BIOMATERIALS, V138, P46, DOI 10.1016/j.biomaterials.2017.05.031; Zhao ZM, 2017, NANOMED-NANOTECHNOL, V13, P443, DOI 10.1016/j.nano.2016.07.015	36	0	0	5	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							118	10.3390/vaccines9020118			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6WW	33546163	Green Published			2022-04-29	WOS:000623283000001
J	Napolitano, F; Pelullo, CP; Della Polla, G; Angelillo, IF				Napolitano, Francesco; Pelullo, Concetta Paola; Della Polla, Giorgia; Angelillo, Italo Francesco			HPV Vaccination Attitudes and Behaviors among General Practitioners in Italy	VACCINES			English	Article						attitudes; behaviors; GPs; HPV; Italy; vaccination		This cross-sectional electronic online or telephone survey assessed the attitudes and behaviors regarding human papillomavirus (HPV) vaccination and the effect of different factors among a nationally representative random sample of 349 general practitioners (GPs) in Italy. A semi-structured interview was performed between September 2018 and October 2020. Almost all respondents considered the HPV vaccine safe with an overall mean value of 8.8, on a scale ranging from 1 to 10, and 59.9% and 32.6% believed that the vaccination was very effective in preventing the related diseases among 12-26 years' girls and boys. Multivariate logistic regression analysis showed that GPs who had received information about HPV vaccination from scientific journals were more likely to have positive attitude towards the effectiveness of the vaccine in preventing HPV-related diseases in girls between 12-26 years. A large majority (81.5%) of GPs who provided assistance to girls' patients aged 11-12 years often or always recommend the HPV vaccine to them, and this behavior was more likely to occur in those who believed that the vaccine was very effective in preventing HPV-related diseases in girls between 12-26 years. GPs were more likely to often or always recommend the HPV vaccine to boys aged 11-12 years if they often or always recommended the vaccine to girls aged 11-12 years, if they believed that the vaccine was very effective in preventing HPV-related diseases in boys between 12-26 years, and if they considered the HPV vaccine very safe. GPs should receive information about the HPV immunization to ensure that they routinely communicate with their patient population in order to achieve better coverage rates.	[Napolitano, Francesco; Pelullo, Concetta Paola; Angelillo, Italo Francesco] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy; [Della Polla, Giorgia] Univ Campania Luigi Vanvitelli, Teaching Hosp, Hlth Direct, Via Santa Maria Costantinopoli 104, I-80138 Naples, Italy		Angelillo, IF (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy.	francesco.napolitano2@unicampania.it; concettapaola.pelullo@unicampania.it; giorgia.dellapolla@unicampania.it; italof.angelillo@unicampania.it	Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602; Napolitano, Francesco/0000-0003-4694-2418; Della Polla, Giorgia/0000-0002-3182-4905; Pelullo, Concetta Paola/0000-0003-4228-8703			Acquavia MA, 2021, TALANTA, V224, DOI 10.1016/j.talanta.2020.121862; Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Beavis A, 2018, J ADOLESCENT HEALTH, V63, P652, DOI 10.1016/j.jadohealth.2018.06.024; Bystrom E, 2020, VACCINE, V38, P3909, DOI 10.1016/j.vaccine.2020.01.078; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2744, DOI 10.1080/21645515.2020.1744367; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2422, DOI 10.1080/21645515.2020.1720441; Hooi DJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199624; Huon JF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234693; Kempe A, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1475; Kops NL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027438; Lechner M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023339; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Lobao WM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206726; Ministero DELLA Salute, COP VACC 31 12 2018; Ministero della Salute, PIAN NAZ PREV VACC 2; Napolitano F, 2018, VACCINE, V36, P7536, DOI 10.1016/j.vaccine.2018.10.050; Napolitano F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194920; Palmer T, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1161; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Pelullo CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042856; Sricharoenchai S, 2020, PEDIATR INFECT DIS J, V39, P615, DOI 10.1097/INF.0000000000002659; Stata Corporation, 2017, STATA REFERENCE MANU; Stefanoff P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232722; Trucchi C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155278; Vautrin H, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-032950	26	6	6	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							63	10.3390/vaccines9010063			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VE	33477779	gold, Green Published			2022-04-29	WOS:000610809000001
J	Gustiananda, M; Sulistyo, BP; Agustriawan, D; Andarini, S				Gustiananda, Marsia; Sulistyo, Bobby Prabowo; Agustriawan, David; Andarini, Sita			Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population	VACCINES			English	Article						SARS-CoV-2; immunoinformatics; T-cell epitopes; multi-epitope peptide-based vaccine; cytotoxic T-cells; helper T-cells; human leukocyte antigen; HLA-A*24; 07	PROTEIN-PROTEIN; WEB SERVER; B-CELL; 3-DIMENSIONAL STRUCTURES; IDENTIFICATION; RECOGNITION; PREDICTION; DIVERSITY; RESPONSES; IMMUNITY	SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using NetCTLpan and NetMHCIIpan algorithms, respectively. These epitopes were generated from ORF1ab regions that are evolutionary stable as reflected by zero Shannon's entropy and are presented by 56 human leukocyte antigen (HLA) Class I and 22 HLA Class II, ensuring good coverage for the Indonesian and world population. Having fulfilled other criteria such as immunogenicity, IFN gamma inducing ability, and non-homology to human and microbiome peptides, the epitopes were assembled into a vaccine construct (VC) together with beta-defensin as adjuvant and appropriate linkers. The VC was shown to have good physicochemical characteristics and capability of inducing CTL as well as HTL responses, which stem from the engagement of the vaccine with toll-like receptor 4 (TLR4) as revealed by docking simulations. The most promiscuous peptide (899)WSMATYYLF(907) was shown via docking simulation to interact well with HLA-A*24:07, the most predominant allele in Indonesia. The data presented here will contribute to the in vitro study of T-cell epitope mapping and vaccine design in Indonesia.	[Gustiananda, Marsia; Sulistyo, Bobby Prabowo] Indonesia Int Inst Life Sci, Sch Life Sci, Dept Biomed, Jl Pulomas Barat Kav 88, Jakarta 13210, Indonesia; [Agustriawan, David] Indonesia Int Inst Life Sci, Sch Life Sci, Dept Bioinformat, Jl Pulomas Barat Kav 88, Jakarta 13210, Indonesia; [Andarini, Sita] Univ Indonesia, Fac Med, Persahabatan Hosp, Dept Pulmonol & Resp Med, Jl Persahabatan Raya 1, Jakarta 13230, Indonesia		Gustiananda, M (通讯作者)，Indonesia Int Inst Life Sci, Sch Life Sci, Dept Biomed, Jl Pulomas Barat Kav 88, Jakarta 13210, Indonesia.	marsia.gustiananda@i3l.ac.id; bobby.sulistyo@i3l.ac.id; david.agustriawan@i3l.ac.id; sita.laksmi@ui.ac.id	Gustiananda, Marsia/AFB-4475-2022	Gustiananda, Marsia/0000-0003-3583-733X	Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi Republik Indonesia (Ministry of Education, Culture, Research and Technology, Republic of Indonesia), Southeast Asia-Europe Joint Funding Scheme for Research and Innovation [356/E4.1/AK.04.PT/202];  [356/E4.1/AK.04];  [PT/202]	This research was funded by Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi Republik Indonesia (Ministry of Education, Culture, Research and Technology, Republic of Indonesia), Southeast Asia-Europe Joint Funding Scheme for Research and Innovation, contract grant number 356/E4.1/AK.04.PT/202.	Al Saba A, 2021, COMPUT BIOL MED, V136, DOI 10.1016/j.compbiomed.2021.104703; An LL, 2005, LEUKEMIA RES, V29, P535, DOI 10.1016/j.leukres.2004.11.009; Babu R. O., 2021, HLA DEPENDENT VARIAT, DOI [10.1101/2021.07.17.452778, DOI 10.1101/2021.07.17.452778]; Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0; Baldwin KM, 2015, TISSUE ANTIGENS, V85, P117, DOI 10.1111/tan.12507; Balz K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84320-8; Bange EM, 2021, NAT MED, V27, P1280, DOI 10.1038/s41591-021-01386-7; Bhattacharya M, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104587; Blaszczyk M, 2019, BRIEF BIOINFORM, V20, P2299, DOI 10.1093/bib/bby080; Blaszczyk M, 2016, METHODS, V93, P72, DOI 10.1016/j.ymeth.2015.07.004; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Calis JJA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002412; Cascella M, 2021, STATPEARLS; Chakraborty C, 2021, ARCH MED RES, V52, P362, DOI 10.1016/j.arcmed.2021.01.004; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Chukwudozie OS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248061; Crooke SN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70864-8; Cuspoca AF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060581; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619; Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Fath, 2021, FRONT IMMUNOL, V12, DOI DOI 10.3389/FIMMU.2021.705772; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Gangaev A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22811-y; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Geretz A, 2018, HUM IMMUNOL, V79, P773, DOI 10.1016/j.humimm.2018.09.005; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Gorkhali R, 2021, BIOINFORM BIOL INSIG, V15, DOI 10.1177/11779322211025876; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Haddad-Boubaker S, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859-021-04045-3; Hassan MM, 2021, OPEN LIFE SCI, V16, P630, DOI 10.1515/biol-2021-0062; Hossain Md Shakhawat, 2021, Informatics in Medicine Unlocked, V22, DOI 10.1016/j.imu.2020.100500; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Jakhar R, 2020, CAN J INFECT DIS MED, V2020, DOI 10.1155/2020/7079356; Jung JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24377-1; Khan AM, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0301-2; Khan Md Tahsin, 2021, Inform Med Unlocked, V24, P100578, DOI 10.1016/j.imu.2021.100578; Khan S, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00187-20; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044; Kurcinski M, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0363-6; Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531; Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Mallajosyula V, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg5669; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McGinley MP, 2021, JAMA-J AM MED ASSOC, V325, P765, DOI 10.1001/jama.2020.26858; Miller Mark A, 2010, 2010 Gateway Computing Environments Workshop (GCE 2010), DOI 10.1109/GCE.2010.5676129; Miotto O, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S1-S18; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Mo P., 2020, CLIN INFECT DIS, V16, P270, DOI [DOI 10.1093/CID/CIAA270/5805508, 10.1093/cid/ciaa270]; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Mullick B, 2021, COMPUT BIOL MED, V138, DOI 10.1016/j.compbiomed.2021.104915; Murdocca M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081667; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Noh JY, 2021, NAT REV IMMUNOL, V21, P687, DOI 10.1038/s41577-021-00625-9; Oladipo Elijah Kolawole, 2021, In Silico Pharmacology, V9, P8, DOI 10.1007/s40203-020-00062-x; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Prachar M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77466-4; Prentice HA, 2014, IMMUNOGENETICS, V66, P299, DOI 10.1007/s00251-014-0765-6; Priyadarshni MS, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1977702; Pro SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196551; Qiao L, 2021, BIOMATER SCI-UK, V9, P7287, DOI 10.1039/d1bm01060c; Rahman N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030423; Rakib A, 2020, MOLECULES, V25, DOI 10.3390/molecules25215088; Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862; Requena D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02008; Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Saini SK, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf7550; Santerre M, 2021, J NEUROL, V268, P2013, DOI 10.1007/s00415-020-10197-8; Sarma VR, 2021, BIOMED J, V44, P447, DOI 10.1016/j.bj.2021.05.001; Shanehbandi D, 2017, CURR CANCER DRUG TAR, V17, P423, DOI 10.2174/1568009617666170109151128; Shende G, 2017, BIOINFORMATICS, V33, P929, DOI 10.1093/bioinformatics/btw760; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Snyder Thomas M, 2020, medRxiv, DOI 10.1101/2020.07.31.20165647; Sohail MS, 2021, ADV DRUG DELIVER REV, V171, P29, DOI 10.1016/j.addr.2021.01.007; Stern A., 2021, UNIQUE EVOLUTIONARY, DOI [10.1101/2021.08.05.21261642, DOI 10.1101/2021.08.05.21261642]; Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4; Tan AT, 2014, J VIROL, V88, P1332, DOI 10.1128/JVI.02600-13; Thomas S, 2021, J COMPUT BIOL, V28, P909, DOI 10.1089/cmb.2020.0627; Toyoshima Y, 2020, J HUM GENET, V65, P1075, DOI 10.1038/s10038-020-0808-9; Tumer G., GENETICS HUMAN MAJOR; Vilar S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10020091; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wang S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005324; Waqas M, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/1596834; WHO, COVID 19 VACC TRACK; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Xu JB, 2019, P NATL ACAD SCI USA, V116, P16856, DOI 10.1073/pnas.1821309116; Yadav R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040821; Yan YM, 2020, NAT PROTOC, V15, P1829, DOI 10.1038/s41596-020-0312-x; Yan YM, 2017, NUCLEIC ACIDS RES, V45, pW365, DOI 10.1093/nar/gkx407; Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4; Yuliwulandari R, 2009, TISSUE ANTIGENS, V73, P46, DOI 10.1111/j.1399-0039.2008.01178.x; Zhang H, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109708; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	108	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1459	10.3390/vaccines9121459			39	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0DP	34960205	gold, Green Published			2022-04-29	WOS:000737333700001
J	Khalis, M; Boucham, M; Luo, AMY; Marfak, A; Saad, S; Aboubacar, CM; El Haj, SA; Jallal, M; Aazi, FZ; Charaka, H; Nejjari, C				Khalis, Mohamed; Boucham, Mouna; Luo, Amy; Marfak, Abdelghafour; Saad, Soukaina; Mariama Aboubacar, Camara; Ait El Haj, Soukaina; Jallal, Manar; Aazi, Fatima-Zahra; Charaka, Hafida; Nejjari, Chakib			COVID-19 Vaccination Acceptance among Health Science Students in Morocco: A Cross-Sectional Study	VACCINES			English	Article						COVID-19 vaccine acceptance; decision making; risk perception; public health; Morocco; Middle East and North Africa		While students in the health sciences occupy pivotal roles in the Moroccan COVID-19 response and vaccination campaigns, factors associated with COVID-19 vaccine acceptability among students have not been reported. This study aimed to determine the willingness and identify predictive attitudes and beliefs of COVID-19 vaccine acceptance among health science students in Morocco. A cross-sectional, self-administered online questionnaire was conducted among students of the Mohammed VI University of Health Sciences in Casablanca, Morocco in January 2021. In total, 1272 students participated. Univariate and multivariate logistic regression models were used to calculate odds ratios and 95% confidence intervals. Overall, 26.9% of participants reported being willing to receive the COVID-19 vaccine. Between genders, male students were more likely to accept the vaccine. Regarding individual attitudes and beliefs about COVID-19 infection, students with greater confidence in COVID-19 information, and higher perceived likelihood and perceived severity of infection were more likely to be willing to get the vaccine. Concerning a COVID-19 vaccine, students who reported lower levels of perceived harm and higher levels of perceived vaccine effectiveness were more willing to get vaccinated. Our findings help guide future efforts to tailor communication and identify strategies to increase COVID-19 vaccine uptake among students.	[Khalis, Mohamed; Boucham, Mouna; Mariama Aboubacar, Camara; Ait El Haj, Soukaina; Jallal, Manar; Nejjari, Chakib] Mohammed VI Univ Hlth Sci, Int Sch Publ Hlth, Casablanca 82403, Morocco; [Luo, Amy] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Marfak, Abdelghafour] Natl Sch Publ Hlth Rabat, Minist Hlth, Rabat 10000, Morocco; [Marfak, Abdelghafour] Hassan Ist Univ Settat, Higher Inst Hlth Sci, Lab Hlth Sci & Technol, Settat 26000, Morocco; [Saad, Soukaina] Mohammed VI Univ Hlth Sci, Sch Med, Casablanca 82403, Morocco; [Aazi, Fatima-Zahra] Hassan II Univ Casablanca, Fac Legal Econ & Social Sci Ain Chock, Casablanca 20470, Morocco; [Charaka, Hafida] Ibn Sina Univ Hosp, Dept Res & Dev, Rabat 10000, Morocco		Khalis, M (通讯作者)，Mohammed VI Univ Hlth Sci, Int Sch Publ Hlth, Casablanca 82403, Morocco.	mkhalis@um6ss.ma; mboucham@um6ss.ma; amyluo@hsph.harvard.edu; ab.marfak@gmail.com; saadsoukaina00@gmail.com; abmaca13@gmail.com; soukai1999@gmail.com; mjallal@um6ss.ma; aazi.zf@gmail.com; hafida572010@gmail.com; cnejjari@um6ss.ma		Khalis, Mohamed/0000-0003-4639-049X			Almutairi A, 2021, IJMDC, V5, P1217, DOI [10.24911/IJMDC.51-1617940736, DOI 10.24911/IJMDC.51-1617940736]; AlShurman BA, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18179342; Balan A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080854; Belingheri M, 2021, J PROF NURS, V37, P923, DOI 10.1016/j.profnurs.2021.07.015; Forman R, 2021, HEALTH POLICY, V125, P553, DOI 10.1016/j.healthpol.2021.03.013; High Commission for Planning, MOR EV MOR BEH FAC C; Hilber AM, 2010, GENDER IMMUNISATION; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Jiang N, 2021, NURSE EDUC PRACT, V55, DOI 10.1016/j.nepr.2021.103148; Kanyike AM, 2021, TROP MED HEALTH, V49, DOI 10.1186/s41182-021-00331-1; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; Li M, 2021, HUM VACC IMMUNOTHER, V17, P4021, DOI 10.1080/21645515.2021.1957648; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Luo CX, 2021, AM J INFECT CONTROL, V49, P1295, DOI 10.1016/j.ajic.2021.06.020; Luo M, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113190; Manning ML, 2021, NURS OUTLOOK, V69, P565, DOI 10.1016/j.outlook.2021.01.019; Mascarenhas AK, 2021, J DENT EDUC, V85, P1504, DOI 10.1002/jdd.12632; Ministry of Health of Morocco, 2021, OFF COR PORT MOR; Mustapha Toheeb, 2021, Brain Behav Immun Health, V16, P100289, DOI 10.1016/j.bbih.2021.100289; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060566; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Salomoni MG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080873; Samouh Y, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.381.27748; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Snehota M, 2021, BRATISL MED J, V122, P538, DOI 10.4149/BLL_2021_086; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Sovicova M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18136815; Talarek E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070709; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Usman J., 2021, JRMC, V25, P61; Velikonja NK, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9070781; WHO, COVID 19 VACC TRACK; World Health Organization World Health Organization, 10 THREATS GLOB HLTH	39	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1451	10.3390/vaccines9121451			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XZ7XJ	34960197	Green Published, gold			2022-04-29	WOS:000737861600001
J	Palano, MT; Gallazzi, M; Cucchiara, M; Barbaro, AD; Gallo, D; Bassani, B; Bruno, A; Mortara, L				Palano, Maria Teresa; Gallazzi, Matteo; Cucchiara, Martina; De Lerma Barbaro, Andrea; Gallo, Daniela; Bassani, Barbara; Bruno, Antonino; Mortara, Lorenzo			Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis	VACCINES			English	Article						neutrophils; natural killer cells; neutrophil-NK cell crosstalk; immunosuppression; tumor angiogenesis; tumor microenvironment	NK CELLS; IFN-GAMMA; T-CELLS; PHENOTYPE; INNATE; NEOVASCULARIZATION; INFLAMMATION; ACTIVATION; INHIBITION; EXPRESSION	The tumor immune microenvironment (TIME) has largely been reported to cooperate on tumor onset and progression, as a consequence of the phenotype/functional plasticity and adaptation capabilities of tumor-infiltrating and tumor-associated immune cells. Immune cells within the tumor micro (tissue-local) and macro (peripheral blood) environment closely interact by cell-to-cell contact and/or via soluble factors, also generating a tumor-permissive soil. These dangerous liaisons have been investigated for pillars of tumor immunology, such as tumor associated macrophages and T cell subsets. Here, we reviewed and discussed the contribution of selected innate immunity effector cells, namely neutrophils and natural killer cells, as "soloists" or by their "dangerous liaisons", in favoring tumor progression by dissecting the cellular and molecular mechanisms involved.	[Palano, Maria Teresa; Bruno, Antonino] IRCCS MultiMed, Unit Mol Pathol Biochem & Immunol, Lab Innate Immun, I-20138 Milan, Italy; [Gallazzi, Matteo; Cucchiara, Martina; Mortara, Lorenzo] Univ Insubria, Dept Biotechnol & Life Sci, Lab Immunol & Gen Pathol, I-21100 Varese, Italy; [De Lerma Barbaro, Andrea] Univ Insubria, Dept Biotechnol & Life Sci, Lab Comparat Physiopathol, I-20145 Varese, Italy; [Gallo, Daniela] Univ Insubria, ASST Sette Laghi, Dept Med & Surg, Endocrine Unit, I-21100 Varese, Italy; [Bassani, Barbara] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, I-20133 Milan, Italy		Palano, MT; Bruno, A (通讯作者)，IRCCS MultiMed, Unit Mol Pathol Biochem & Immunol, Lab Innate Immun, I-20138 Milan, Italy.	mariateresa.palano@multimedica.it; matteo.gallazzi@uninsubria.it; a.delermabarbaro@uninsubria.it; dgallo@hotmail.it; barbara.bassani@istitutotumori.mi.it; antonino.bruno@multimedica.it; lorenzo.mortara@uninsubria.it	gallo, daniela/AAD-7839-2019; Bruno, Antonino/J-7066-2016	gallo, daniela/0000-0002-1873-3048; Bruno, Antonino/0000-0002-4790-0861; GALLAZZI, Matteo/0000-0001-6662-9352; PALANO, MARIA TERESA/0000-0002-0867-9527; MORTARA, LORENZO/0000-0002-4757-7101; CUCCHIARA, MARTINA/0000-0003-0030-5149	Italian Association for Cancer Research (AIRC)Fondazione AIRC per la ricerca sul cancro [MFAG2019-ID-22818, ID-22369]; Cariplo FoundationFondazione Cariplo [ID-2019-1609]; Italian Ministry of University and Research PRIN 2017 grant [2017NTK4HY]; Italian Ministry of Health Ricerca Corrente-IRCCS MultiMedica; University of Insubria	A.B. received funds from the Italian Association for Cancer Research (AIRC), MFAG2019-ID-22818 and the Cariplo Foundation (ID-2019-1609). This work was supported by the Italian Ministry of Health Ricerca Corrente-IRCCS MultiMedica (AB) and the University of Insubria, Fondi di Ateneo per la Ricerca 2019 and 2020 (L.M). B.B. was funded the three years fellowship "Guglielmina Lucarelli e Gino Mazzega", Italian Association for Cancer Research (AIRC, ID-22369). M.C. is a participant in the PhD course in Experimental and Translational Medicine at the University of Insubria, Varese, Italy. M.G. is a participant in the PhD course in Life Sciences and Biotechnology at the University of Insubria, Varese, Italy and is funded by an "Assegno di ricerca", by the Italian Ministry of University and Research PRIN 2017 grant 2017NTK4HY.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Ballesteros I, 2020, CELL, V183, P1282, DOI 10.1016/j.cell.2020.10.003; Balsamo M, 2012, EUR J IMMUNOL, V42, P1833, DOI 10.1002/eji.201142179; Bassani B, 2019, CANCERS, V11, DOI 10.3390/cancers11040461; Bhatnagar N, 2010, BLOOD, V116, P1308, DOI 10.1182/blood-2010-01-264903; Blaisdell A, 2015, CANCER CELL, V28, P785, DOI 10.1016/j.ccell.2015.11.005; Bosi A, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2438598; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Bruno A, 2018, FASEB J, V32, P5365, DOI 10.1096/fj.201701103R; Bruno A, 2013, NEOPLASIA, V15, P133, DOI 10.1593/neo.121758; Canli O, 2017, CANCER CELL, V32, P869, DOI 10.1016/j.ccell.2017.11.004; Carrega P, 2008, CANCER-AM CANCER SOC, V112, P863, DOI 10.1002/cncr.23239; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; COLOMBO MP, 1992, CANCER RES, V52, P4853; Costantini C, 2011, J LEUKOCYTE BIOL, V89, P221, DOI 10.1189/jlb.0510250; Costantini C, 2010, INT IMMUNOL, V22, P827, DOI 10.1093/intimm/dxq434; Cozar B, 2021, CANCER DISCOV, V11, P34, DOI 10.1158/2159-8290.CD-20-0655; Esendagli G, 2008, LUNG CANCER, V59, P32, DOI 10.1016/j.lungcan.2007.07.022; Gaggero S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.621225; Gallazzi M, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586126; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gershkovitz M, 2018, CANCER RES, V78, P5050, DOI 10.1158/0008-5472.CAN-18-0540; Gershkovitz M, 2018, CANCER RES, V78, P2680, DOI 10.1158/0008-5472.CAN-17-3614; Gonzalez VD, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109632; Gotthardt D, 2016, CANCER DISCOV, V6, P414, DOI 10.1158/2159-8290.CD-15-0732; Guan Yue, 2020, Oncotarget, V11, P2571, DOI 10.18632/oncotarget.27654; Habif G, 2019, CELL MOL IMMUNOL, V16, P415, DOI 10.1038/s41423-019-0224-2; He L, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.67; Hedrick CC, 2022, NAT REV IMMUNOL, V22, P173, DOI 10.1038/s41577-021-00571-6; Hidalgo A, 2019, TRENDS IMMUNOL, V40, P584, DOI 10.1016/j.it.2019.04.013; Jaeger BN, 2012, J EXP MED, V209, P565, DOI 10.1084/jem.20111908; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Jensen KN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570380; Karin M, 2005, NAT MED, V11, P20, DOI 10.1038/nm0105-20; Koga Y, 2004, CANCER RES, V64, P1037, DOI 10.1158/0008-5472.CAN-03-1808; Levi I, 2015, ONCOTARGET, V6, P1, DOI 10.18632/oncotarget.3453; Li PS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18125-0; Liang W, 2016, CANCER IMMUNOL RES, V4, P83, DOI 10.1158/2326-6066.CIR-15-0313; Mahiddine K, 2020, J CLIN INVEST, V130, P389, DOI 10.1172/JCI130952; Mamessier E, 2011, J CLIN INVEST, V121, P3609, DOI 10.1172/JCI45816; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Marcais A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00450; Masucci MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01749; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; McFarlane AJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143759; McKenna E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602963; Molgora M, 2018, SCAND J IMMUNOL, V88, DOI 10.1111/sji.12705; Noonan DM, 2008, CANCER METAST REV, V27, P31, DOI 10.1007/s10555-007-9108-5; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Oberlies J, 2009, J IMMUNOL, V182, P5259, DOI 10.4049/jimmunol.0803523; Ogura K, 2018, CANCER IMMUNOL RES, V6, P348, DOI 10.1158/2326-6066.CIR-17-0204; Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179; Pulze L, 2016, CLIN EXP IMMUNOL, V183, P469, DOI 10.1111/cei.12730; Remark R, 2013, CLIN CANCER RES, V19, P4079, DOI 10.1158/1078-0432.CCR-12-3847; Romano A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58859-x; Romero AI, 2006, BRIT J HAEMATOL, V132, P91, DOI 10.1111/j.1365-2141.2005.05842.x; Rusakiewicz S, 2013, CANCER RES, V73, P3499, DOI 10.1158/0008-5472.CAN-13-0371; Sandel MH, 2005, MOL IMMUNOL, V42, P541, DOI 10.1016/j.molimm.2004.07.039; Scapini P, 2004, J IMMUNOL, V172, P5034, DOI 10.4049/jimmunol.172.8.5034; Scapini P, 2002, J IMMUNOL, V168, P5798, DOI 10.4049/jimmunol.168.11.5798; Schruefer R, 2006, J VASC RES, V43, P1, DOI 10.1159/000088975; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; Shaul ME, 2019, NAT REV CLIN ONCOL, V16, P601, DOI 10.1038/s41571-019-0222-4; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Sierra JM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.745939; Sionov RV, 2015, CANCER MICROENVIRON, V8, P125, DOI 10.1007/s12307-014-0147-5; Spiegel A, 2016, CANCER DISCOV, V6, P630, DOI 10.1158/2159-8290.CD-15-1157; Stojanovic A, 2011, J INNATE IMMUN, V3, P355, DOI 10.1159/000325465; Strieter RM, 2005, NAT MED, V11, P925, DOI 10.1038/nm0905-925; Sun R, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100825; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Valayer A, 2017, J LEUKOCYTE BIOL, V101, P253, DOI 10.1189/jlb.3AB0316-140RR; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Wang J, 2018, CELL TISSUE RES, V371, P531, DOI 10.1007/s00441-017-2785-7; Wang RP, 2012, J LEUKOCYTE BIOL, V91, P299, DOI 10.1189/jlb.0611308; Wu SY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01238-x; Yamamoto K, 2002, BIOCHEM BIOPH RES CO, V297, P1245, DOI 10.1016/S0006-291X(02)02378-1; Yao L, 1999, BLOOD, V93, P1612, DOI 10.1182/blood.V93.5.1612.405a13_1612_1621; Zhu YFPP, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000473	83	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1488	10.3390/vaccines9121488			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0FI	34960234	Green Published, gold			2022-04-29	WOS:000737338200001
J	Sangster, AV; Barratt, JM				Sangster, Anna Victoria; Barratt, Jane M.			Towards Ending Immunization Inequity	VACCINES			English	Article						adult vaccination; immunization; equity; social determinants of health	PATIENT SAFETY	Vaccine-preventable diseases (VPD) are responsible for a significant portion of mortality across the life course in both low-income countries and in medium- and high-income countries. Yet, countries are consistently below the adult influenza vaccination targets, with rates in recent times even falling in some areas. (1) The study Towards Ending Immunization Inequity seeks to understand the various factors that contribute to the accessibility and effectiveness of vaccine-related messages and campaigns including the effects of social determinants, with the knowledge that these opportunities for communication represent a unique policy lever to improving uptake rates of vaccination in the most at-risk communities. (2) To address this knowledge gap, a 3-phase mixed-methods study was conducted including a preliminary scan of existing vaccine schedules and NITAG recommendations, focus groups and a cross-sectional survey. (3) Study results indicated that social determinants play a key role in an individual's knowledge of vaccine-related information including types of vaccines available, vaccination gateways, vaccine recommendations and vaccine safety. (4) However, knowing that social determinants can influence uptake rates does not readily create opportunities and entry points for governments to implement tangible actions. An accessible entry point to reducing and ending immunization inequity is through changes in public health messaging to reach those who are currently unreachable.	[Sangster, Anna Victoria; Barratt, Jane M.] Int Federat Ageing, Toronto, ON M4K 2N1, Canada		Sangster, AV (通讯作者)，Int Federat Ageing, Toronto, ON M4K 2N1, Canada.	asangster@ifa.ngo; jbarratt@ifa.ngo					A Canadian Perspective on Pneumonia Vaccination among at Risk Groups, 2020, INCR REL PAND ER; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], FACE FACTS CULTURAL; [Anonymous], INTERNET ACCESS SOCI; [Anonymous], 2017, FINDINGS GLOBAL BURD; Boyce T, 2019, EUROSURVEILLANCE, V24, P17, DOI 10.2807/1560-7917.ES.2019.24.2.1800204; Braveman Paula, 2010, Health Hum Rights, V12, P31; Canada P.H.A, TET TOX CAN IMM GUID; Canada R, EX MOB EQ RENEW CAN; Chauhan A, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01223-2; Doherty TM, 2018, EUR GERIATR MED, V9, P289, DOI 10.1007/s41999-018-0040-8; Duclos P, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S2; Glatman-Freedman Aharona, 2012, Hum Vaccin Immunother, V8, P293, DOI 10.4161/hv.19003; Hajat Cother, 2018, Prev Med Rep, V12, P284, DOI 10.1016/j.pmedr.2018.10.008; Hunsaker A, 2018, NEW MEDIA SOC, V20, P3937, DOI 10.1177/1461444818787348; Jetten J, 2018, INT J QUAL STUD HEAL, V13, DOI 10.1080/17482631.2018.1508198; Johnstone MJ, 2006, INT J QUAL HEALTH C, V18, P383, DOI 10.1093/intqhc/mzl039; Kickbusch I, 2013, HLTH LIT SOL FACTS; Link BG, 1998, MILBANK Q, V76, P375, DOI 10.1111/1468-0009.00096; Lopalco P L, 2016, J Prev Med Hyg, V57, pE5; McGibbon Elizabeth, 2008, Can Nurse, V104, P22; Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388; Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0; Population Division, 2017, WORLD POP AG 2017 HI; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041; Scheifele DW, 2014, VACCINE, V32, P766, DOI 10.1016/j.vaccine.2013.12.027; Solar O., 2010, CONCEPTUAL FRAMEWORK; Suurmond J, 2010, AM J PUBLIC HEALTH, V100, pS113, DOI 10.2105/AJPH.2009.167064; Turner NM, 2017, BMC NURS, V16, DOI 10.1186/s12912-017-0226-2; Vamos S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041436; Wang MY, 2020, J BIOMED MATER RES B, V108, P2889, DOI 10.1002/jbm.b.34620; Wheelock A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014668; Wiese-Posselt M, 2011, DTSCH ARZTEBL INT, V108, P771, DOI 10.3238/arztebl.2011.0771	33	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1378	10.3390/vaccines9121378			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9WW	34960124	Green Published, gold			2022-04-29	WOS:000737316200001
J	Shalash, AO; Azuar, A; Madge, HYR; Modhiran, N; Amarilla, AA; Liang, B; Khromykh, AA; Watterson, D; Young, PR; Toth, I; Skwarczynski, M				Shalash, Ahmed O.; Azuar, Armira; Madge, Harrison Y. R.; Modhiran, Naphak; Amarilla, Alberto A.; Liang, Benjamin; Khromykh, Alexander A.; Watterson, Daniel; Young, Paul R.; Toth, Istvan; Skwarczynski, Mariusz			Detection and Quantification of SARS-CoV-2 Receptor Binding Domain Neutralization by a Sensitive Competitive ELISA Assay	VACCINES			English	Article						SARS-CoV-2; receptor binding domain; spike protein; binding inhibition assay; neutralization assay; competitive ELISA; validation; high throughput	CORONAVIRUS; ANTIBODIES; INFECTION; EPITOPES; SPIKE	This protocol describes an ELISA-based procedure for accurate measurement of SARS-CoV-2 spike protein-receptor binding domain (RBD) neutralization efficacy by murine immune serum. The procedure requires a small amount of S-protein/RBD and angiotensin converting enzyme-2 (ACE2). A high-throughput, simple ELISA technique is employed. Plate-coated-RBDs are allowed to interact with the serum, then soluble ACE2 is added, followed by secondary antibodies and substrate. The key steps in this procedure include (1) serum heat treatment to prevent non-specific interactions, (2) proper use of blank controls to detect side reactions and eliminate secondary antibody cross-reactivity, (3) the addition of an optimal amount of saturating ACE2 to maximize sensitivity and prevent non-competitive co-occurrence of RBD-ACE2 binding and neutralization, and (4) mechanistically derived neutralization calculation using a calibration curve. Even manually, the protocol can be completed in 16 h for >30 serum samples; this includes the 7.5 h of incubation time. This automatable, high-throughput, competitive ELISA assay can screen a large number of sera, and does not require sterile conditions or special containment measures, as live viruses are not employed. In comparison to the 'gold standard' assays (virus neutralization titers (VNT) or plaque reduction neutralization titers (PRNT)), which are laborious and time consuming and require special containment measures due to their use of live viruses. This simple, alternative neutralization efficacy assay can be a great asset for initial vaccine development stages. The assay successfully passed conventional validation parameters (sensitivity, specificity, precision, and accuracy) and results with moderately neutralizing murine sera correlated with VNT assay results (R-2 = 0.975, n = 25), demonstrating high sensitivity.	[Shalash, Ahmed O.; Azuar, Armira; Madge, Harrison Y. R.; Modhiran, Naphak; Amarilla, Alberto A.; Liang, Benjamin; Khromykh, Alexander A.; Watterson, Daniel; Young, Paul R.; Toth, Istvan; Skwarczynski, Mariusz] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Modhiran, Naphak; Watterson, Daniel; Young, Paul R.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld 4072, Australia; [Toth, Istvan] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; [Toth, Istvan] Univ Queensland, Sch Pharm, Woolloongabba, Qld 4102, Australia		Skwarczynski, M (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.	a.shalash@uq.net.au; armira.azuar@uq.net.au; harrison.madge@uq.net.au; n.modhiran@uq.edu.au; a.amarillaortiz@uq.edu.au; harrison.madge@uq.net.au; alexander.khromykh@uq.edu.au; d.watterson@uq.edu.au; p.young@uq.edu.au; i.toth@uq.edu.au; m.skwarczynski@uq.edu.au	Amarilla, Alberto Anastacio/AFO-4805-2022; Young, Paul/A-6176-2010; Skwarczynski, Mariusz/A-6707-2009	Amarilla, Alberto Anastacio/0000-0002-6640-3377; Young, Paul/0000-0002-2040-5190; Liang, Benjamin/0000-0003-3304-4715; Modhiran, Naphak/0000-0003-3205-4970; Skwarczynski, Mariusz/0000-0001-7257-807X			Abe KT, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142362; Amarilla AA, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.625136; Butler J.E, 1992, STRUCT ANTIGENS, V1, P208; Charbonneau R, 1991, IDRC Rep, V19, P22; Chen L, 2020, SMALL, V16, DOI 10.1002/smll.202004237; Crowther Jr, 2000, METHODS MOL BIOL, V149, P9; He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Huang YY, 2008, J MOL RECOGNIT, V21, P122, DOI 10.1002/jmr.880; Koishi AC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006342; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Padoan A, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103101; Pandey M, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1260; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Sadana A, 1997, APPL BIOCHEM BIOTECH, V67, P1, DOI 10.1007/BF02787837; Shalash AO, 2021, ADV SCI, V8, DOI 10.1002/advs.202100985; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Stevens FJ, 2007, J IMMUNOL METHODS, V328, P53, DOI 10.1016/j.jim.2007.08.007; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; von Rhein C, 2021, J VIROL METHODS, V288, DOI 10.1016/j.jviromet.2020.114031; Walker SN, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01533-20; Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006; Watterson D, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1269; Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9; Whiteman MC, 2018, AM J TROP MED HYG, V99, P1430, DOI 10.4269/ajtmh.17-0948; Wrobel AG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19146-5; Yu M, 2008, J IMMUNOL METHODS, V331, P1, DOI 10.1016/j.jim.2007.11.009; Zhang F, 2006, ARCH VIROL, V151, P37, DOI 10.1007/s00705-005-0623-9	29	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1493	10.3390/vaccines9121493			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YI3RG	34960239	Green Submitted, Green Published, gold			2022-04-29	WOS:000743768200001
J	Wolszczak-Biedrzycka, B; Bienkowska, A; Dorf, J				Wolszczak-Biedrzycka, Blanka; Bienkowska, Anna; Dorf, Justyna			Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection	VACCINES			English	Article						COVID-19; anti-SARS-CoV-2 S antibodies; BNT162b2; humoral immune response		At the end of 2020, COVID-19 vaccination programs were initiated in many countries, including Poland. The first vaccine approved in Poland was the BNT162b2 mRNA preparation (Pfizer/BioNTech), and the first vaccinated group were healthcare workers. The aim of the present study was to evaluate post-vaccine antibody titers 8 months after the second vaccine dose had been administered to a group of employees of the Hospital of the Ministry of the Interior and Administration in Olsztyn (Poland). The employees were divided into two groups: persons who had COVID-19 in the fourth quarter of 2020 and were vaccinated in January-February 2021, and persons without a history of COVID-19 who were vaccinated during the same period. The analyzed material was venous blood serum collected from 100 hospital employees on 23-28 September 2021. The level of anti-SARS-CoV-2 S antibodies was measured with a Roche Cobas e411 analyzer using the electrochemiluminescence (ECLIA) method. The study demonstrated that persons with a history of SARS-CoV-2 infection had significantly higher antibody levels (taking into account gender, age, type of work performed, and severity of post-vaccination symptoms) than employees without a history of COVID-19. The study also revealed that the type of work, age, gender, and the course of SARS-CoV-2 infection can influence the humoral immune response. The presented results may prove helpful in the context of administering additional vaccine doses.	[Wolszczak-Biedrzycka, Blanka; Bienkowska, Anna] Univ Warmia & Mazury, Dept Psychol & Sociol Hlth & Publ Hlth, Warszawska 30, PL-10082 Olsztyn, Poland; [Wolszczak-Biedrzycka, Blanka; Bienkowska, Anna] Hosp Minist Interior & Adm, Oncol Ctr Reg Warmia & Mazury Olsztyn, Wojska Polskiego 37, PL-10228 Olsztyn, Poland; [Dorf, Justyna] Med Univ Bialystok, Dept Clin Lab Diagnost, Waszyngtona 15A, PL-15269 Bialystok, Poland		Wolszczak-Biedrzycka, B (通讯作者)，Univ Warmia & Mazury, Dept Psychol & Sociol Hlth & Publ Hlth, Warszawska 30, PL-10082 Olsztyn, Poland.; Wolszczak-Biedrzycka, B (通讯作者)，Hosp Minist Interior & Adm, Oncol Ctr Reg Warmia & Mazury Olsztyn, Wojska Polskiego 37, PL-10228 Olsztyn, Poland.	blanka.wolszczak@gmail.com; anna.bienkowska@uwm.edu.pl; justyna.dorf@umb.edu.pl	Dorf, Justyna/R-6264-2018	Dorf, Justyna/0000-0003-2391-3307; Wolszczak-Biedrzycka, Blanka/0000-0003-4724-4689	Roche Diagnostics, Hospital of the Ministry of the Interior and Administration in Olsztyn; University of Warmia and Mazury in Olsztyn	This research was funded by Roche Diagnostics, Hospital of the Ministry of the Interior and Administration in Olsztyn, University of Warmia and Mazury in Olsztyn.	Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Angyal A, T CELL ANTIBODY RESP; Campo F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101125; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dorschug A, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11030426; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; European Medicines Agency, COVID 19 MRNA VACC C; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Morales-Nunez JJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070742; Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Mazzoni A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149150; Parry H., 2021, EXTENDED INTERVAL BN, DOI [10.1101/2021.05.15.21257017, DOI 10.1101/2021.05.15.21257017]; Pawelec G, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979-021-00219-y; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Rastawicki Waldemar, 2021, Przegl Epidemiol, V75, P3, DOI 10.32394/pe.75.01; Roche, 2020, ELECSYS ANTI SARS CO; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Salvagno GL, 2021, J INFECTION, V83, pE4, DOI 10.1016/j.jinf.2021.06.024; Salvagno GL, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11050832; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Subbarao S, 2021, EUROSURVEILLANCE, V26, P2, DOI 10.2807/1560-7917.ES.2021.26.12.2100329; Tretyn A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081952; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Ward H., REACT 2 ROUND 5 INCR, DOI [10.1101/2021.02.26.21252512, DOI 10.1101/2021.02.26.21252512(2021, 10.1101/2021.02.26.21252512 (2021]; World Health Organization, WHO DIR GEN OP REM M; Zhong D, 2021, JAMA-J AM MED ASSOC, V326, P2524, DOI 10.1001/jama.2021.19996	39	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1508	10.3390/vaccines9121508			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1MI	34960254	Green Published, gold			2022-04-29	WOS:000737424100001
J	Yadete, T; Batra, K; Netski, DM; Antonio, S; Patros, MJ; Bester, JC				Yadete, Tesfaye; Batra, Kavita; Netski, Dale M.; Antonio, Sabrina; Patros, Michael J.; Bester, Johan C.			Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study	VACCINES			English	Article						COVID-19; vaccine hesitancy; vaccine literacy; functional literacy; communicative literacy; critical literacy; vaccine confidence index; herd immunity; vaccine booster	HERD-IMMUNITY; HESITANCY; LITERACY; INFORMATION; EDUCATION; TRUST; TESTS	Given the emergence of breakthrough infections, new variants, and concerns of waning immunity from the primary COVID-19 vaccines, booster shots emerged as a viable option to shore-up protection against COVID-19. Following the recent authorization of vaccine boosters among vulnerable Americans, this study aims to assess COVID-19 vaccine booster hesitancy and its associated factors in a nationally representative sample. A web-based 48-item psychometric valid survey was used to measure vaccine literacy, vaccine confidence, trust, and general attitudes towards vaccines. Data were analyzed through Chi-square (with a post hoc contingency table analysis) and independent-sample t-/Welch tests. Among 2138 participants, nearly 62% intended to take booster doses and the remaining were COVID-19 vaccine booster hesitant. The vaccine-booster-hesitant group was more likely to be unvaccinated (62.6% vs. 12.9%) and did not intend to have their children vaccinated (86.1% vs. 27.5%) compared to their non-hesitant counterparts. A significantly higher proportion of booster dose hesitant individuals had very little to no trust in the COVID-19 vaccine information given by public health/government agencies (55% vs. 12%) compared to non-hesitant ones. The mean scores of vaccine confidence index and vaccine literacy were lower among the hesitant group compared to the non-hesitant group. Compared to the non-hesitant group, vaccine hesitant participants were single or never married (41.8% vs. 28.7%), less educated, and living in a southern region of the nation (40.9% vs. 33.3%). These findings underscore the need of developing effective communication strategies emphasizing vaccine science in ways that are accessible to individuals with lower levels of education and vaccine literacy to increase vaccination uptake.	[Yadete, Tesfaye; Antonio, Sabrina; Patros, Michael J.] Univ Nevada, Kirk Kerkorian Sch Med, Las Vegas, NV 89102 USA; [Batra, Kavita] Univ Nevada, Kirk Kerkorian Sch Med, Off Res, Las Vegas, NV 89102 USA; [Netski, Dale M.; Bester, Johan C.] Univ Nevada, Kirk Kerkorian Sch Med, Dept Med Educ, Las Vegas, NV 89102 USA; [Netski, Dale M.; Bester, Johan C.] Univ Nevada, Kirk Kerkorian Sch Med, Off Acad Affairs, Las Vegas, NV 89102 USA		Batra, K (通讯作者)，Univ Nevada, Kirk Kerkorian Sch Med, Off Res, Las Vegas, NV 89102 USA.	yadete@unlv.nevada.edu; kavita.batra@unlv.edu; Dale.netski@unlv.edu; antons1@unlv.nevada.edu; PATROM1@unlv.nevada.edu; johan.bester@unlv.edu		Netski, Dale/0000-0002-7695-2038; Antonio, Sabrina/0000-0002-1698-4214; Bester, Johan/0000-0002-8038-6454; Batra, Kavita/0000-0002-0722-0191			Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bester JC, 2015, J BIOETHIC INQ, V12, P555, DOI 10.1007/s11673-015-9673-1; Biasio LR, 2020, ANN IG MED PREV COMU, V32, P205, DOI 10.7416/ai.2020.2344; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Bolotin S, 2021, CAN MED ASSOC J, V193, pE1089, DOI 10.1503/cmaj.210892; Brandstetter S, 2021, EUR J PEDIATR, V180, P3405, DOI 10.1007/s00431-021-04094-z; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Callaway E, 2021, NATURE, V596, P178, DOI 10.1038/d41586-021-02158-6; CDC, COVID DAT TRACK COVI; CDC Case Surveillance Task Force, COVID 19 CAS SURV PU; Centers for Disease Control and Prevention, COVID 19 VACC MOD SE; Cohen J., 1977, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Danthu C, 2021, J AM SOC NEPHROL, V32, P2154, DOI 10.1681/ASN.2021040490; Department for Health and Human Services, JOINT STAT HHS PUBL; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Gebru Addis Adera, 2021, Human Antibodies, V29, P139, DOI 10.3233/HAB-200420; Griffin S, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1686; Hodgson D, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.20.2100428; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Kozlov Max, 2021, Nature, DOI 10.1038/d41586-021-02516-4; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Larson Heidi J, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lopes L., KFF COVID 19 VACCINE; Lorini C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020154; LUDDEN TM, 1994, J PHARMACOKINET BIOP, V22, P431, DOI 10.1007/BF02353864; Luyten J, 2019, VACCINE, V37, P2494, DOI 10.1016/j.vaccine.2019.03.041; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1116; Mansournia Mohammad Ali, 2021, Br J Sports Med, V55, P1009, DOI 10.1136/bjsports-2020-103652; Miller CA, 2020, CANCER EPIDEM BIOMAR, V29, P731, DOI 10.1158/1055-9965.EPI-19-0846; Mizrahi B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26672-3; Momplaisir FM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21931; Morris Randy S, 2021, F S Rep, V2, P253, DOI 10.1016/j.xfre.2021.05.010; Nanduri S, 2021, MMWR-MORBID MORTAL W, V70, P1163, DOI 10.15585/mmwr.mm7034e3; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Oliver S., DATA CLIN CONSIDERAT; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Plotkin SA, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2021-050531; Rawal, 2019, EUR J PUBLIC HEALTH, V29, DOI DOI 10.1093/EURPUB/CKZ185.374; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Rosenberg ES, 2021, MMWR-MORBID MORTAL W, V70, P1306, DOI 10.15585/mmwr.mm7037a7; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sharma M, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9101273; Siegler AJ, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.26882; Silva-Cayetano A, 2021, MED-CAMBRIDGE, V2, P243, DOI 10.1016/j.medj.2020.12.006; Soundararajan, 2021, FDA AUTHORIZED COVID, DOI [10.1101/2021.02.15.21251623, DOI 10.1101/2021.02.15.21251623]; Tanne JH, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n232; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P1156, DOI 10.15585/mmwr.mm7034e2; THOMPSON B, 1993, J EXP EDUC, V61, P361, DOI 10.1080/00220973.1993.10806596; Trostle ME, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2021.100464; Viner RM, 2021, JAMA PEDIATR, V175, P143, DOI 10.1001/jamapediatrics.2020.4573; Wang XM, 2018, J HEALTH COMMUN, V23, P413, DOI 10.1080/10810730.2018.1455771; WHO, WHO COVID 19 DASHB; Wickware C, 2021, PHARMA J, V307, P7951, DOI [10.1211/pj.2021.1.96183, DOI 10.1211/PJ.2021.1.96183]; Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X	60	6	6	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1424	10.3390/vaccines9121424			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XZ0IO	34960170	Green Published, gold			2022-04-29	WOS:000737346600001
J	Di Lorenzo, A; Bianchi, FP; Martinelli, A; Lattanzio, S; Carbonara, A; Diella, G; Tafuri, S; Stefanizzi, P				Di Lorenzo, Antonio; Bianchi, Francesco Paolo; Martinelli, Andrea; Lattanzio, Sabrina; Carbonara, Antonella; Diella, Giusy; Tafuri, Silvio; Stefanizzi, Pasquale			Safety Profile of Recommended Vaccinations in Adolescents: Data from Surveillance of Adverse Events Following Immunization in Puglia (Italy), 2016-2020	VACCINES			English	Article						AEFIs; causality assessment; vaccination; adolescents	APULIA REGION; VACCINES	Adolescence is a critical period for immunization, in which the adhesion rate to recommended vaccinations is often lower than desired. Since the safety of new vaccines is one of the most important factors determining vaccination hesitancy, post-marketing surveillance of adverse events following immunization (AEFIs) is recommended by the World Health Organization (WHO) to better understand the safety of these drugs. This report describes AEFIs notified in Puglia (Italy) after recommended vaccinations in adolescents aged 12 to 18 years in 2016-2020 to determine the safety profile of these products in a real-life scenario. This is a retrospective observational study. Data were gathered from the list of AEFIs notified in subjects between 12 and 18 years of age following administration of recommended vaccines in Puglia in 2016-2020. AEFIs were classified according to the WHO's decisional algorithm, and causality assessment was carried out for serious AEFIs. From 2016 to 2020, 323,627 doses of vaccine were administered to adolescents in Puglia and 50 AEFIs were reported (reporting rate: 15.4 x 100,000 doses). Of these, 17 (34.0%) were classified as serious, and causality assessment identified 13 of them (76.5%) as vaccine related. The most common symptoms were local reactions, fever and neurological symptoms. No deaths were notified. The benefits of immunization in adolescents appear to be greater than the risk of AEFIs for all studied vaccines; in fact, AEFIs occur in less than 0.1 & PTSTHOUSND; of patients and are generally mild and self-limiting.	[Di Lorenzo, Antonio; Bianchi, Francesco Paolo; Martinelli, Andrea; Lattanzio, Sabrina; Carbonara, Antonella; Diella, Giusy; Tafuri, Silvio; Stefanizzi, Pasquale] Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, Piazza Giulio Cesare 11, I-70124 Bari, Italy		Tafuri, S (通讯作者)，Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	antoniodilorenzo95@gmail.com; frapabi@gmail.com; dott.a.martinelli@gmail.com; sabrina.lattanzio@uniba.it; antonellacarbonara82@gmail.com; giusy.diella@uniba.it; silvio.tafuri@uniba.it; pasquale.stefanizzi@uniba.it	Bianchi, Francesco Paolo/AAU-2597-2020	Bianchi, Francesco Paolo/0000-0002-9659-0193; Martinelli, Andrea/0000-0002-8068-6246; tafuri, silvio/0000-0003-4194-0210			AIFA Polioboostrix, SUMMARY PRODUCT CHAR; AIFA Priorix Tetra, SUMMARY PRODUCT CHAR; AIFA-gruppo di Lavoro sull'analisi dei segnali dei vaccini, 2016, GUID VAL REAZ AVV OS; Broder KR, 2008, PEDIATRICS, V121, pS25, DOI 10.1542/peds.2007-1115D; Faranda D, 2021, CHAOS, V31, DOI 10.1063/5.0050887; Giambi C, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0545-9; Guarinoni MG, 2021, ANN IG MED PREV COMU, V33, P55, DOI 10.7416/ai.2021.2408; Laughlin JJ, 2014, PEDIATRICS, V133, pE794, DOI 10.1542/peds.2013-4080; Lee SY, 2009, VACCINE, V27, P3209, DOI 10.1016/j.vaccine.2009.03.037; Phillips A, 2020, VACCINE, V38, P6038, DOI 10.1016/j.vaccine.2020.06.039; Pomara C, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11060955; Principi N, 2013, VACCINE, V31, P5366, DOI 10.1016/j.vaccine.2013.08.092; Stefanizzi P, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1963171; Stefanizzi P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050456; Stefanizzi P, 2020, HUM VACC IMMUNOTHER, V16, P1875, DOI 10.1080/21645515.2019.1704124; Stefanizzi P, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040140; Tafuri S, 2014, VACCINE, V32, P4860, DOI 10.1016/j.vaccine.2013.11.006; Tafuri S, 2018, VACCINE, V36, P1072, DOI 10.1016/j.vaccine.2018.01.018; Tafuri S, 2015, EXPERT REV VACCINES, V14, P625, DOI 10.1586/14760584.2015.1029460; Tosti ME, 2008, J VIRAL HEPATITIS, V15, P26, DOI 10.1111/j.1365-2893.2008.01025.x; U.S. Food and Drug Administration Bexsero, PACK INS 2020; U.S. Food and Drug Administration Cervarix, PACK INS 2020; U.S. Food and Drug Administration Gardasil, PACK INS 2020; U.S. Food and Drug Administration Havrix, PACK INS 2020; U.S. Food and Drug Administration MMR-II, PACK INS 2020; U.S. Food and Drug Administration Trumenba, PACK INS 2020; U.S. Food and Drug Administration Varivax, PACK INS 2020; Vernon N, 2014, J AM OSTEOPATH ASSOC, V114, pS13, DOI 10.7556/jaoa.2014.044; WHO, CAUSALITY ASSESSMENT	29	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1302	10.3390/vaccines9111302			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ9LB	34835232	gold, Green Published			2022-04-29	WOS:000727098800001
J	Rademacher, JG; Tampe, B; Korsten, P				Rademacher, Jan-Gerd; Tampe, Bjoern; Korsten, Peter			First Report of Two Cases of Lofgren's Syndrome after SARS-CoV-2 Vaccination-Coincidence or Causality?	VACCINES			English	Article						sarcoidosis; Lofgren's syndrome; vaccination; SARS-CoV-2; COVID-19	SARCOIDOSIS; BCG	Sarcoidosis can present as an acute form or take a chronic course. One of the acute presentations is Lofgren's syndrome (LS), consisting of the symptom triad of bilateral hilar lymphadenopathy, erythema nodosum, and ankle periarthritis. In addition, there are occasional reports of sarcoid-like reactions following drug exposures. Nevertheless, reports of sarcoidosis or LS after vaccination have not been published. Here, we report two cases of de novo LS in a temporal association with different vaccines against the new coronavirus SARS-CoV-2. One patient developed the first symptoms three days after the second vaccination (first vaccination ChadOx-1, Astra Zeneca; second vaccination CX-024414, Moderna); in the second patient, symptoms started 28 days after the first vaccination (ChadOx-1, Astra Zeneca). Both patients eventually required treatment with glucocorticoids. Both patients achieved clinical improvement with treatment. In conclusion, we report the first two cases of LS shortly after SARS-CoV-2 vaccination.	[Rademacher, Jan-Gerd; Tampe, Bjoern; Korsten, Peter] Univ Med Ctr Gottingen, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany		Korsten, P (通讯作者)，Univ Med Ctr Gottingen, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany.	jan-gerd.rademacher@med.uni-goettingen.de; bjoern.tampe@med.uni-goettingen.de; peter.korsten@med.uni-goettingen.de	Tampe, Björn/ABA-6091-2021	Tampe, Björn/0000-0002-4357-9863; Rademacher, Jan-Gerd/0000-0001-9764-3421; Korsten, Peter/0000-0001-6065-5680	Open Access Publication Funds of the Goettingen University	FundingWe acknowledge support from the Open Access Publication Funds of the Goettingen University.	Andrade Gabriel, 2021, Vacunas, DOI 10.1016/j.vacun.2021.07.009; Arakawa A, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8020117; Barbhaiya M, 2021, ANN RHEUM DIS, V80, P1352, DOI 10.1136/annrheumdis-2021-220732; Bauckneht M, 2021, EUR J NUCL MED MOL I, V48, P2661, DOI 10.1007/s00259-021-05360-w; Boekel L, 2021, LANCET RHEUMATOL, V3, pE541, DOI 10.1016/S2665-9913(21)00181-8; Bogdanov G, 2021, CLIN DERMATOL, V39, P523, DOI 10.1016/j.clindermatol.2021.04.001; Chen ES, 2014, SEMIN RESP CRIT CARE, V35, P285, DOI 10.1055/s-0034-1376859; Crouser ED, 2020, AM J RESP CRIT CARE, V201, pE26, DOI 10.1164/rccm.202002-0251ST; ELLMAN P, 1959, BRIT MED J, V1, P1433, DOI 10.1136/bmj.1.5135.1433; FRIED K H, 1958, Tuberkulosearzt, V12, P558; FRIED KH, 1964, ACTA MED SCAND, VS176, P260; Greally J F, 1989, Sarcoidosis, V6, P156; Grunewald J, 2009, AM J RESP CRIT CARE, V179, P307, DOI 10.1164/rccm.200807-1082OC; Heydari-Kamjani M, 2019, CUREUS, V11, DOI 10.7759/cureus.4920; Holzmann-Littig C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070777; Keshavarz P, 2021, ACAD RADIOL, V28, P1058, DOI 10.1016/j.acra.2021.04.007; Manansala M, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.672028; Mondal P, 2021, PUBLIC HEALTH, V198, P252, DOI 10.1016/j.puhe.2021.07.028; Osborne GEN, 2003, J AM ACAD DERMATOL, V48, pS99, DOI 10.1067/mjd.2003.158; Oswald-Richter KA, 2012, J CLIN IMMUNOL, V32, P1129, DOI 10.1007/s10875-012-9700-5; Oswald-Richter KA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-161; Patel SP, 2021, CLIN EXP VACCINE RES, V10, P154, DOI 10.7774/cevr.2021.10.2.154; Pavord S, 2021, NEW ENGL J MED, V385, P1680, DOI 10.1056/NEJMoa2109908; PFISTERER R., 1954, HELVETICA MED ACTA, V21, P439; PRESS P, 1962, Poumon Coeur, V18, P937; Psaltis NM, 2014, OCUL IMMUNOL INFLAMM, V22, P314, DOI 10.3109/09273948.2014.891041; RENARD J, 1962, Poumon Coeur, V18, P951; Rosenblum HG, 2021, MMWR-MORBID MORTAL W, V70, P1094, DOI 10.15585/mmwr.mm7032e4; SUTHERLAND I, 1965, BMJ-BRIT MED J, V2, P497, DOI 10.1136/bmj.2.5460.497; Svendsen CB, 2011, CLIN RESPIR J, V5, P99, DOI 10.1111/j.1752-699X.2010.00205.x; Sweiss NJ, 2020, CHEST, V158, P892, DOI 10.1016/j.chest.2020.04.033; Segura BT, 2014, MED CLIN-BARCELONA, V143, P166, DOI 10.1016/j.medcli.2014.02.029; Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7; Visser H, 2002, ANN RHEUM DIS, V61, P499, DOI 10.1136/ard.61.6.499; Watad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050435	35	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1313	10.3390/vaccines9111313			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ7WI	34835244	Green Published, gold			2022-04-29	WOS:000726992700001
J	Barve, V; Adams, N; Stanbery, L; Manning, L; Horvath, S; Wallraven, G; Bognar, E; Barve, M; Nemunaitis, J				Barve, Vedin; Adams, Ned; Stanbery, Laura; Manning, Luisa; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Barve, Minal; Nemunaitis, John			Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6	VACCINES			English	Article						colorectal cancer; immunotherapy; liver metastases	OVARIAN-CANCER; IMMUNOTHERAPY; MAINTENANCE	Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis. Vigil is an immunotherapy manufactured from autologous tumor cells and transfected ex vivo with a plasmid that encodes the GM-CSF gene and bifunctional shRNA construct to knockdown furin. Here, we report two patients with colorectal cancer and resectable liver metastasis entered into a clinical trial involving Vigil in combination with standard of care modified FOLFOX-6 chemotherapy. The first dose of Vigil was given two weeks before the modified FOLFOX-6 regimen. Vigil treatment continued until Vigil supply was exhausted. Both patients exhibited remarkable response to combination therapy, demonstrating no evidence of disease recurrence for over eight years. Additionally, both patients demonstrated systemic immune response to Vigil therapy as tested by ELISPOT.</p>	[Barve, Vedin; Barve, Minal] Texas Oncol Phys Assoc, Dallas, TX 75251 USA; [Adams, Ned; Barve, Minal] Mary Crowley Canc Res, Dallas, TX 75230 USA; [Stanbery, Laura; Manning, Luisa; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Nemunaitis, John] Gradalis Inc, Carrollton, TX 75006 USA		Nemunaitis, J (通讯作者)，Gradalis Inc, Carrollton, TX 75006 USA.	vedin.barve@utexas.edu; NAdams@marycrowley.org; lnejedlik@gradalisinc.com; lmanning@gradalisinc.com; shorvath@gradalisinc.com; gwallraven@gradalisinc.com; ebognar@gradalisinc.com; mbarve@marycrowley.org; jnemunaitis@gradalisinc.com		Barve, Vedin/0000-0002-7966-2247			Bognar, 2020, CANC SCI RES, V3, P1, DOI [10.33425/2639-8478.1055, DOI 10.33425/2639-8478.1055]; Engstrand J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3925-x; Ghisoli M, 2017, J PEDIAT HEMATOL ONC, V39, pE183, DOI 10.1097/MPH.0000000000000822; Ghisoli M, 2016, MOL THER, V24, P1478, DOI 10.1038/mt.2016.86; Hwang WT, 2012, GYNECOL ONCOL, V124, P192, DOI 10.1016/j.ygyno.2011.09.039; Jenab-Wolcott J, 2013, CURR COLORECT CANC R, V9, P230, DOI 10.1007/s11888-013-0178-1; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Mitry E, 2008, J CLIN ONCOL, V26, P4906, DOI 10.1200/JCO.2008.17.3781; Oh J, 2020, GYNECOL ONCOL REP, V34, DOI 10.1016/j.gore.2020.100648; Oh J, 2016, GYNECOL ONCOL, V143, P504, DOI 10.1016/j.ygyno.2016.09.018; Oh S, 2016, CELL DEATH DIFFER, V23, P1804, DOI 10.1038/cdd.2016.68; Rocconi RP, 2021, GYNECOL ONCOL, V161, P676, DOI 10.1016/j.ygyno.2021.03.009; Rocconi RP, 2022, CANCER GENE THER, V29, P369, DOI 10.1038/s41417-021-00317-5; Rocconi RP, 2020, LANCET ONCOL, V21, P1661, DOI 10.1016/S1470-2045(20)30533-7; Senzer N., 2013, J VACCINES VACCIN, V4, P209, DOI DOI 10.4172/2157-7560.1000209; Senzer N, 2012, MOL THER, V20, P679, DOI 10.1038/mt.2011.269; Siota M, 2011, EXPERT REV VACCINES, V10, P299, DOI [10.1586/ERV.10.169, 10.1586/erv.10.169]; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100	19	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1201	10.3390/vaccines9101201			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS8KK	34696309	gold, Green Published			2022-04-29	WOS:000715425800001
J	Bechini, A; Zanella, B; Bonito, B; Paoli, S; Di Pisa, G; Moscadelli, A; Ancillotti, L; Bonanni, P; Boccalini, S				Bechini, Angela; Zanella, Beatrice; Bonito, Benedetta; Paoli, Sonia; Di Pisa, Giulia; Moscadelli, Andrea; Ancillotti, Leonardo; Bonanni, Paolo; Boccalini, Sara			Quality and Safety of Vaccines Manufacturing: An Online Survey on Attitudes and Perceptions of Italian Internet Users	VACCINES			English	Article						hesitancy; vaccination; Italy; perceptions; healthcare workers; questionnaire; parents	HESITANCY; VACCINATION	Background: Vaccination is a worldwide public health practice that requires high uptake levels in order to effectively reduce the incidence of vaccine-preventable diseases. The manufacturing of vaccines is a complex process, and little is known about people's feelings and opinions on that. Our study aimed at investigating perceptions and attitudes of the general population towards the vaccine production process before the availability of COVID-19 vaccines. Methods: We designed a 15-question online survey in the Italian language which was spread via Facebook and an Italian website "Vaccinarsintoscana" between January and May 2020. We performed a descriptive analysis and applied statistical tests to assess differences in the given answers according to participants' sociodemographic characteristics. Results: The collected responses (135 participants) about the perceptions on vaccine production process were largely positive: not being concerned about the vaccine production (70.3%); believing the vials did not contain harmful substances (75.6%) and considering the precautionary withdrawal of some batches as highly effective (83.7%). In contrast, a less positive perception was found for the question about the conflict of interest between manufacturing companies and the control systems (48.9%). Moreover, people's perceptions towards the vaccine components (i.e., microorganism, adjuvants and opinion on batches withdrawal) also showed a good level of confidence and trust. Conclusions: Our study highlighted a generally positive attitude towards the vaccine production process and showed people's confidence in the control systems, safety and high standards of quality of the vaccine production process.	[Bechini, Angela; Zanella, Beatrice; Bonito, Benedetta; Ancillotti, Leonardo; Bonanni, Paolo; Boccalini, Sara] Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy; [Paoli, Sonia; Di Pisa, Giulia; Moscadelli, Andrea] Univ Florence, Med Specializat Sch Hyg & Prevent Med, I-50134 Florence, Italy		Boccalini, S (通讯作者)，Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy.	angela.bechini@unifi.it; beatrice.zanella@unifi.it; benedetta.bonito@unifi.it; sonia.paoli@unifi.it; giulia.dipisa@unifi.it; andrea.moscadelli@unifi.it; leonardo.ancillotti@stud.unifi.it; paolo.bonanni@unifi.it; sara.boccalini@unifi.it		Bonito, Benedetta/0000-0002-6116-8777; Bechini, Angela/0000-0002-6013-8779; Bonanni, Paolo/0000-0003-2875-3744; Zanella, Beatrice/0000-0001-6718-1932; Boccalini, Sara/0000-0002-9695-7549	GSK S.p.A. [3001980298/2019]; University of Florence, Department of Health Sciences	This research was partially funded by GSK S.p.A., grant number 3001980298/2019, and the APC was funded by the University of Florence, Department of Health Sciences.	[Anonymous], 1999, Wkly Epidemiol Rec, V74, P337; [Anonymous], WHO WHO IMMUNIZATION; Baylor NW, 2002, VACCINE, V20, pS18, DOI 10.1016/S0264-410X(02)00166-4; Bechini A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060564; Boccalini S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040644; Caudal H, 2020, ANN PHARM FR, V78, P294, DOI 10.1016/j.pharma.2020.03.003; Centers for Disease Control and Prevention (CDC), JOURN YOUR CHILDS VA; Descamps D, 2009, HUM VACCINES, V5, P332, DOI 10.4161/hv.5.5.7211; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; ECDC, 2016, LETS TALK HES; European Commission, GOOD MAN PRACT GMP G; Geoghegan S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00372; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Preiss S, 2016, VACCINE, V34, P6665, DOI 10.1016/j.vaccine.2016.10.079; SALK JE, 1952, AM J HYG, V55, P439, DOI 10.1093/oxfordjournals.aje.a119534; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; WHO, INT TRAV HLTH ASS; WHO, REG QUAL CONTR VACC; Williams SE, 2014, HUM VACC IMMUNOTHER, V10, P2584, DOI 10.4161/hv.28596; Wilson R, 2020, VACCINE, V38, P1144, DOI 10.1016/j.vaccine.2019.11.018; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	26	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1015	10.3390/vaccines9091015			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3FN	34579252	Green Published, gold			2022-04-29	WOS:000702094300001
J	Celis-Giraldo, CT; Lopez-Aban, J; Muro, A; Patarroyo, MA; Manzano-Roman, R				Celis-Giraldo, Carmen Teresa; Lopez-Aban, Julio; Muro, Antonio; Patarroyo, Manuel Alfonso; Manzano-Roman, Raul			Nanovaccines against Animal Pathogens: The Latest Findings	VACCINES			English	Review						nanoparticle; nanovaccine; pathogen; immune response; nanoplatform	SWINE LEUKOCYTE ANTIGEN; IMMUNE-RESPONSE; T-CELLS; VACCINE; VIRUS; NANOPARTICLES; ADJUVANT; DELIVERY; PARTICLE; DIVERSITY	Nowadays, safe and efficacious vaccines represent powerful and cost-effective tools for global health and economic growth. In the veterinary field, these are undoubtedly key tools for improving productivity and fighting zoonoses. However, cases of persistent infections, rapidly evolving pathogens having high variability or emerging/re-emerging pathogens for which no effective vaccines have been developed point out the continuing need for new vaccine alternatives to control outbreaks. Most licensed vaccines have been successfully used for many years now; however, they have intrinsic limitations, such as variable efficacy, adverse effects, and some shortcomings. More effective adjuvants and novel delivery systems may foster real vaccine effectiveness and timely implementation. Emerging vaccine technologies involving nanoparticles such as self-assembling proteins, virus-like particles, liposomes, virosomes, and polymeric nanoparticles offer novel, safe, and high-potential approaches to address many vaccine development-related challenges. Nanotechnology is accelerating the evolution of vaccines because nanomaterials having encapsulation ability and very advantageous properties due to their size and surface area serve as effective vehicles for antigen delivery and immunostimulatory agents. This review discusses the requirements for an effective, broad-coverage-elicited immune response, the main nanoplatforms for producing it, and the latest nanovaccine applications for fighting animal pathogens.	[Celis-Giraldo, Carmen Teresa; Patarroyo, Manuel Alfonso] Fdn Inst Inmunol Colombia FIDIC, Mol Biol & Immunol Dept, Bogota 111321, Colombia; [Celis-Giraldo, Carmen Teresa] Univ Ciencias Aplicadas & Ambient UDCA, Anim Sci Fac, Bogota 111166, Colombia; [Lopez-Aban, Julio; Muro, Antonio; Manzano-Roman, Raul] Univ Salamanca, Fac Pharm, Res Ctr Trop Dis IBSAL CIETUS, Inst Biomed Res Salamanca,Infect & Tropical Dis R, Salamanca 37007, Spain; [Patarroyo, Manuel Alfonso] Univ Nacl Colombia, Dept Microbiol, Fac Med, Bogota 111321, Colombia; [Patarroyo, Manuel Alfonso] Univ Santo Tomas, Div Hlth Sci, Main Campus, Bogota 110231, Colombia		Patarroyo, MA (通讯作者)，Fdn Inst Inmunol Colombia FIDIC, Mol Biol & Immunol Dept, Bogota 111321, Colombia.; Manzano-Roman, R (通讯作者)，Univ Salamanca, Fac Pharm, Res Ctr Trop Dis IBSAL CIETUS, Inst Biomed Res Salamanca,Infect & Tropical Dis R, Salamanca 37007, Spain.; Patarroyo, MA (通讯作者)，Univ Nacl Colombia, Dept Microbiol, Fac Med, Bogota 111321, Colombia.; Patarroyo, MA (通讯作者)，Univ Santo Tomas, Div Hlth Sci, Main Campus, Bogota 110231, Colombia.	ccelis@udca.edu.co; jlaban@usal.es; ama@usal.es; mapatarr.fidic@gmail.com; rmanzano@usal.es	Patarroyo, Manuel-Alfonso/I-8046-2016	Patarroyo, Manuel-Alfonso/0000-0002-4751-2500; MANZANO ROMAN, RAUL/0000-0002-5066-9496; Muro, Antonio/0000-0003-0244-4740	RICET [RD16/0027/0018, PI19/01727]; Ministerio de Ciencia e Innovacion (MICINN) SpainSpanish Government [RTI2018-099474-B-I00]	A.M.A. and J.L.-A. were funded by RICET RD16/0027/0018 and PI19/01727. J.L.-A. was funded by the Ministerio de Ciencia e Innovacion (MICINN) Spain, ref. RTI2018-099474-B-I00.	Abudula T, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.598160; Acevedo-Villanueva K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247938; Aida V, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.654289; Bohorquez JA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090822; Amanna IJ, 2020, CURR TOP MICROBIOL, V428, P1, DOI 10.1007/82_2018_102; Anderson CJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01983; Arenas M, 2018, INFECT GENET EVOL, V63, P295, DOI 10.1016/j.meegid.2017.09.029; Asadi K, 2021, INT J BIOL MACROMOL, V182, P648, DOI 10.1016/j.ijbiomac.2021.04.005; Asadikaram G, 2021, BIOCHEM BIOPH RES CO, V534, P980, DOI 10.1016/j.bbrc.2020.10.054; de Medeiros ASA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100927; Aza-Conde J, 2021, BIOCHEM BIOPH RES CO, V534, P86, DOI 10.1016/j.bbrc.2020.11.090; Azuar A, 2021, J MED CHEM, V64, P2648, DOI 10.1021/acs.jmedchem.0c01660; Babych M, 2018, NANOSCALE, V10, P19547, DOI 10.1039/c8nr05948a; Bakkari MA, 2021, MOL PHARMACEUT, V18, P2233, DOI 10.1021/acs.molpharmaceut.0c01256; Barsoe S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050447; Bartlett S, 2020, J INFECT DIS, V221, P934, DOI 10.1093/infdis/jiz528; Bartlett S, 2020, CURR MED CHEM, V27, P2887, DOI 10.2174/0929867325666181026100849; Bernstein Justin, 2021, Food Ethics, V6, P9, DOI 10.1007/s41055-021-00089-6; Bettencourt P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00190; Bhardwaj P, 2020, ACTA BIOMATER, V108, P1, DOI 10.1016/j.actbio.2020.03.020; Boggiatto PM, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02370; Boyoglu-Barnum S, 2021, NATURE, V592, P623, DOI 10.1038/s41586-021-03365-x; Nguyen B, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00330-7; Buchy P, 2020, INT J INFECT DIS, V90, P188, DOI 10.1016/j.ijid.2019.10.005; Butkovich N, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1681; Byrne KA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01099; Cascella M., 2021, FEATURES EVALUATION; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Caugant DA, 2020, NAT REV MICROBIOL, V18, P84, DOI 10.1038/s41579-019-0282-6; Celis-Giraldo CT, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83637-8; Chan YQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030417; Chan YH, 2021, LIFE SCI, V280, DOI 10.1016/j.lfs.2021.119744; Chen FM, 2021, BIOMATERIALS, V270, DOI 10.1016/j.biomaterials.2021.120709; Chien MH, 2018, VET IMMUNOL IMMUNOP, V197, P69, DOI 10.1016/j.vetimm.2018.01.012; Chowdhury IH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.595039; Cimica V, 2017, CLIN IMMUNOL, V183, P99, DOI 10.1016/j.clim.2017.08.004; Clemmons EA, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11072039; Cotugno N, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8732191; CUREVAC, 2019, CEPI AW US 34M CONTR; D'Amico C, 2021, DRUG DELIV TRANSL RE, V11, P353, DOI 10.1007/s13346-021-00924-7; Bohorquez MD, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01293; Viana IMD, 2021, ACTA PHARM SIN B, V11, P852, DOI 10.1016/j.apsb.2021.02.022; de Souza GAP, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10010036; Detsi A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070669; Dewangan HK, 2020, J IMMUNOL METHODS, V481, DOI 10.1016/j.jim.2020.112791; Diego-Gonzalez L, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060489; Ding PY, 2019, INT J NANOMED, V14, P7533, DOI 10.2147/IJN.S218057; Ding PY, 2019, ADV HEALTHC MATER, DOI 10.1002/adhm.201900456; Dos Santos WG, 2021, BIOMED PHARMACOTHER, V136, DOI 10.1016/j.biopha.2021.111272; Dykman LA, 2020, EXPERT REV VACCINES, V19, P465, DOI 10.1080/14760584.2020.1758070; El Bissati K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73210-0; El Daous H, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11030647; El-Sayed A, 2020, ENVIRON SCI POLLUT R, V27, P19073, DOI 10.1007/s11356-018-3913-y; Ferrari L, 2018, VET MICROBIOL, V216, P85, DOI 10.1016/j.vetmic.2018.02.001; Fisch A, 2021, J IMMUNOL, V206, P2489, DOI 10.4049/jimmunol.2001409; Fontana D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030251; Franklyne JS, 2021, CURR OPIN COLLOID IN, V54, DOI 10.1016/j.cocis.2021.101458; Gan YY, 2021, NANOMED-NANOTECHNOL, V35, DOI 10.1016/j.nano.2021.102398; Gang C, 2020, THERANOSTICS, V10, P7131, DOI 10.7150/thno.44564; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Gebre MS, 2021, CELL, V184, P1589, DOI 10.1016/j.cell.2021.02.030; Genito CJ, 2021, ADV NANOBIOMED RES, V1, DOI 10.1002/anbr.202000041; Giovambattista G, 2020, BMC GENET, V21, DOI 10.1186/s12863-020-00905-8; Guzman E, 2014, J IMMUNOL, V193, P208, DOI 10.4049/jimmunol.1303398; Halabi K, 2021, J MOL EVOL, V89, P329, DOI 10.1007/s00239-021-10013-5; Hammer SE, 2021, ANIM GENET, V52, P523, DOI 10.1111/age.13090; Hammer SE, 2020, ANNU REV ANIM BIOSCI, V8, P171, DOI 10.1146/annurev-animal-020518-115014; Han Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00935; Hassanzadeh P, 2021, LIFE SCI, V274, DOI 10.1016/j.lfs.2021.119289; Heaton PM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.517290; Ho W, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001812; Hoelzer K, 2018, VET RES, V49, DOI 10.1186/s13567-018-0561-7; Hotez PJ, 2018, HUM VACC IMMUNOTHER, V14, P2128, DOI 10.1080/21645515.2018.1430542; Hu RJ, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10112293; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Jeong KH, 2020, FISH SHELLFISH IMMUN, V100, P49, DOI 10.1016/j.fsi.2020.02.060; Jiang ZX, 2021, NANO LETT, V21, P4744, DOI 10.1021/acs.nanolett.1c01133; Jin Z, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118731; Kaufmann SHE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00684; Kelly SM, 2021, VACCINE, V39, P3862, DOI 10.1016/j.vaccine.2021.05.077; Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042; Kim D, 2021, DRUG DELIV TRANSL RE, V11, P1401, DOI 10.1007/s13346-021-00945-2; Kim J, 2019, THERANOSTICS, V9, P3191, DOI 10.7150/thno.33921; Kitiyodom S, 2021, FISH SHELLFISH IMMUN, V112, P81, DOI 10.1016/j.fsi.2021.02.017; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kumar R, 2015, VACCINE, V33, P5064, DOI 10.1016/j.vaccine.2015.08.025; Kurtovic L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641421; Lacasta A, 2021, J IMMUNOL, V206, P686, DOI 10.4049/jimmunol.2000442; Lee LA, 2013, VACCINE, V31, pB61, DOI 10.1016/j.vaccine.2012.11.035; Lee W, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009168; Li Y, 2021, LIFE SCI, V265, DOI 10.1016/j.lfs.2020.118761; Liang XY, 2018, NANOSCALE, V10, P9489, DOI 10.1039/c8nr00355f; Liu D, 2021, BIOMATER SCI-UK, V9, P84, DOI 10.1039/d0bm01333a; Liu LX, 2016, ACS APPL MATER INTER, V8, P11969, DOI 10.1021/acsami.6b01135; Maina TW, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.608050; Maleki M, 2019, ARTIF CELL NANOMED B, V47, P4248, DOI 10.1080/21691401.2019.1687490; Manczinger M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000131; Mandefro A, 2021, J ANIM SCI TECHNOL, V63, P248, DOI 10.5187/jast.2021.e37; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Matsuda T, 2020, BIOCHEM ENG J, V163, DOI 10.1016/j.bej.2020.107757; Micoli F, 2021, NAT REV MICROBIOL, V19, P287, DOI 10.1038/s41579-020-00506-3; Minakshi P, 2019, CURR PHARM DESIGN, V25, P1554, DOI 10.2174/1381612825666190620094041; Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004; Mody KT, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.606652; Mohammed GM, 2021, INT J BIOL MACROMOL, V167, P395, DOI 10.1016/j.ijbiomac.2020.11.200; Moise L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563362; Monrad JT, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00290-y; Mottram L, 2019, VACCINE, V37, P4805, DOI 10.1016/j.vaccine.2019.01.016; Muller H, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00219-x; Mukhopadhyay D, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.580425; Munira SL, 2019, VACCINE, V37, P1245, DOI 10.1016/j.vaccine.2018.11.050; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nevagi RJ, 2019, EUR J MED CHEM, V179, P100, DOI 10.1016/j.ejmech.2019.06.047; Nevagi RJ, 2019, BIOORGAN MED CHEM, V27, P3082, DOI 10.1016/j.bmc.2019.05.033; Nguyen QD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041934; Nielsen M, 2018, J PROTEOME RES, V17, P559, DOI 10.1021/acs.jproteome.7b00675; Nooraei S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00806-7; Opriessnig T, 2021, PORCINE HEALTH MANAG, V7, DOI 10.1186/s40813-020-00179-7; Patarroyo ME, 2016, CURR ISSUES MOL BIOL, V18, P57; Peddireddy V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00084; Peleteiro M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00791; Peng RC, 2021, TRENDS BIOCHEM SCI, V46, P848, DOI 10.1016/j.tibs.2021.06.001; Petkar KC, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040455; Pilkington EH, 2021, ACTA BIOMATER, V131, P16, DOI 10.1016/j.actbio.2021.06.023; Pimentel LS, 2020, NANOMED-NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102137; Favaro MTP, 2021, NANOMED-NANOTECHNOL, V32, DOI 10.1016/j.nano.2020.102334; Pippa N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060558; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Qin L, 2021, SMALL, V17, DOI 10.1002/smll.202006000; Rambe D.S., 2015, INT CURR PHARM J, V4, P420, DOI [10.3329/icpj.v4i8.24024, DOI 10.3329/ICPJ.V4I8.24024]; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Rasool MH, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8879277; Renu S, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.558349; Renu S, 2020, CARBOHYD POLYM, V243, DOI 10.1016/j.carbpol.2020.116434; Reyes C, 2020, BIOCHEM BIOPH RES CO, V527, P1021, DOI 10.1016/j.bbrc.2020.05.025; ROBBINS JB, 1989, CURR TOP MICROBIOL, V146, P169; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; Rodriguez-Habibe I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040764; Ross K, 2019, BIOMATER SCI-UK, V7, P809, DOI 10.1039/c8bm01443d; Sahu R, 2018, EXPERT REV VACCINES, V17, P217, DOI 10.1080/14760584.2018.1435279; Sanchez-Cordon Pedro J, 2020, J Virol, V94, DOI 10.1128/JVI.00350-20; Schnierle BS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111078; Senel Sevda, 2021, Pharmaceutical Nanotechnology, V9, P26, DOI 10.2174/2211738508666200910101504; Shah RR, 2017, METHODS MOL BIOL, V1494, P1, DOI 10.1007/978-1-4939-6445-1_1; Sharun K, 2021, VET QUART, V41, P181, DOI 10.1080/01652176.2021.1921311; Shepherd FR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176144; Sinani G, 2019, INT J PHARMACEUT, V569, DOI 10.1016/j.ijpharm.2019.118592; Singh J, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01633-w; Skwarczynski M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2285; Sulczewski FB, 2018, ARCH VIROL, V163, P2313, DOI 10.1007/s00705-018-3856-0; Takeshima S, 2018, BMC GENET, V19, DOI 10.1186/s12863-018-0618-7; Tamborrini M, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0158-9; Tan M, 2014, CURR OPIN VIROL, V6, P24, DOI 10.1016/j.coviro.2014.02.009; Techakriengkrai N, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.637682; Tenchov R, 2021, ACS NANO, V15, P16982, DOI 10.1021/acsnano.1c04996; Teng M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050779; Thakur A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1356540; Thukral Akanksha, 2020, NPJ Vaccines, V5, P15, DOI 10.1038/s41541-020-0164-y; Tomlin H, 2018, IMMUNOLOGY, V155, P186, DOI 10.1111/imm.12972; Tosyali OA, 2021, MAT SCI ENG C-MATER, V120, DOI 10.1016/j.msec.2020.111684; Trovato M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02130; Vahedi SM, 2019, ACTA VET SCAND, V61, DOI 10.1186/s13028-019-0491-z; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Veiga-Parga T, 2016, VET PATHOL, V53, P737, DOI 10.1177/0300985816629719; Vijayan V, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100534; Wang Fengyuan, 2020, Smart Mater Med, V1, P21, DOI 10.1016/j.smaim.2020.03.001; Wang J, 2021, J COLLOID INTERF SCI, V589, P378, DOI 10.1016/j.jcis.2021.01.011; Wang N, 2019, J CONTROL RELEASE, V303, P130, DOI 10.1016/j.jconrel.2019.04.025; Wang YL, 2021, NANO TODAY, V38, DOI 10.1016/j.nantod.2021.101139; Warimwe GM, 2021, NAT REV IMMUNOL, V21, P814, DOI 10.1038/s41577-021-00567-2; Wetzel D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221394; WHO, 2020, CHILD MORT CAUS DEAT; Wong G, 2019, J VIROL, V93, DOI 10.1128/JVI.01098-18; World Health Organization, PRIOR DIS RES DEV EM; Wu Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50065-8; Yamaguchi T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040378; Yan XY, 2020, VACCINE, V38, P1096, DOI 10.1016/j.vaccine.2019.11.031; Zaheer T, 2021, PROCESS BIOCHEM, V100, P237, DOI 10.1016/j.procbio.2020.09.028; Zaman M, 2013, METHODS, V60, P226, DOI 10.1016/j.ymeth.2013.04.014; Zeng Chunxi, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_217; Zhang C, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-0584-x; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594; Zhang HR, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111042; Zhang QZ, 2020, NANO LETT, V20, P5570, DOI 10.1021/acs.nanolett.0c02278; Zhang R, 2021, CELL MOL IMMUNOL, V18, P1222, DOI 10.1038/s41423-021-00669-w; Zhao LH, 2020, INT J NANOMED, V15, P2071, DOI [10.2147/JN.S232677, 10.2147/IJN.S232677]; Zhao ZK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010045; Zheng B, 2021, CHEM ENG J, V418, DOI 10.1016/j.cej.2021.129392; Zottig X, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10051008	189	0	0	14	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							988	10.3390/vaccines9090988			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW1IK	34579225	Green Published, gold			2022-04-29	WOS:000699918500001
J	Gomez, CE; Perdiguero, B; Usero, L; Marcos-Villar, L; Miralles, L; Leal, L; Sorzano, COS; Sanchez-Corzo, C; Plana, M; Garcia, F; Esteban, M				Elena Gomez, Carmen; Perdiguero, Beatriz; Usero, Lorena; Marcos-Villar, Laura; Miralles, Laia; Leal, Lorna; Sorzano, Carlos Oscar S.; Sanchez-Corzo, Cristina; Plana, Montserrat; Garcia, Felipe; Esteban, Mariano			Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen	VACCINES			English	Article						HIV-1 mRNA vaccines; multiepitopic protein; intranodal delivery; T cells; poxvirus MVA vector; mice; combined vaccines; prime; boost; immune responses	CD8(+) T-CELL; INFLUENZA	Development of a vaccine against HIV remains a major target goal in the field. The recent success of mRNA vaccines against the coronavirus SARS-CoV-2 is pointing out a new era of vaccine designs against pathogens. Here, we have generated two types of mRNA vaccine candidates against HIV-1; one based on unmodified vectors and the other on 1-methyl-3 '-pseudouridylyl modified vectors expressing a T cell multiepitopic construct including protective conserved epitopes from HIV-1 Gag, Pol and Nef proteins (referred to as RNA-TMEP and RNA-TMEPmod, respectively) and defined their biological and immunological properties in cultured cells and in mice. In cultured cells, both mRNA vectors expressed the corresponding protein, with higher levels observed in the unmodified mRNA, leading to activated macrophages with differential induction of innate immune molecules. In mice, intranodal administration of the mRNAs induced the activation of specific T cell (CD4 and CD8) responses, and the levels were markedly enhanced after a booster immunization with the poxvirus vector MVA-TMEP expressing the same antigen. This immune activation was maintained even three months later. These findings revealed a potent combined immunization regimen able to enhance the HIV-1-specific immune responses induced by an mRNA vaccine that might be applicable to human vaccination programs with mRNA and MVA vectors.	[Elena Gomez, Carmen; Perdiguero, Beatriz; Marcos-Villar, Laura; Sanchez-Corzo, Cristina; Esteban, Mariano] CSIC, Ctr Nacl Biotecnol CNB, Dept Mol & Cellular Biol, Madrid 28049, Spain; [Usero, Lorena; Miralles, Laia; Leal, Lorna; Plana, Montserrat; Garcia, Felipe] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, AIDS Res Grp, Barcelona 08036, Spain; [Sorzano, Carlos Oscar S.] CSIC, CNB, Biocomp Unit, Madrid 28049, Spain; [Sorzano, Carlos Oscar S.] CSIC, CNB, Computat Genom, Madrid 28049, Spain		Gomez, CE; Esteban, M (通讯作者)，CSIC, Ctr Nacl Biotecnol CNB, Dept Mol & Cellular Biol, Madrid 28049, Spain.	cegomez@cnb.csic.es; perdigue@cnb.csic.es; usero@clinic.cat; lmarcos@cnb.csic.es; lmiralle@clinic.cat; laleal@clinic.cat; coss@cnb.csic.es; cscorzo@cnb.csic.es; mplana@clinic.cat; fgarcia@clinic.cat; mesteban@cnb.csic.es	S. Sorzano, Carlos Oscar/ABE-4884-2021; Gomez, Carmen E/K-1940-2014; , Felipe/F-4242-2014; Leal, Lorna/L-2773-2015	S. Sorzano, Carlos Oscar/0000-0002-9473-283X; Gomez, Carmen E/0000-0002-5414-7935; , Felipe/0000-0001-7658-5832; Miralles, Laia/0000-0002-0754-5607	Spanish Ministry of Economy (MINECO) [SAF2015-66193-R, SAF-2017-88089-R, RTI2018-096309-B-I00]; Fondo Europeo para el Desarrollo Regional (FEDER)European Commission; SPANISH AIDS Research Network [RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER (RIS)]; Fondo de Investigacion Sanitaria (FIS)Instituto de Salud Carlos III [AC16/00051, PI18/00699]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [COV20/00214, ICI20/00067]; CERCA Programme/Generalitat de Catalunya [SGR 615, SGR 653]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-HEALTH-2013-INNOVATION-1 602570-2, H2020-SC1-2016-2017 (H2020-SC1-2016-RTD), 731626-HIVACAR]	This study was partially supported by grants from the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, SAF-2017-88089-R, RTI2018-096309-B-I00); the Fondo Europeo para el Desarrollo Regional (FEDER); the SPANISH AIDS Research Network RD16/0025/0002 and RD16/0025/0014-ISCIII-FEDER (RIS); the Fondo de Investigacion Sanitaria (FIS) AC16/00051 and PI18/00699; the Instituto de Salud Carlos III (grants: COV20/00214; ICI20/00067) and the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653. This manuscript was funded by the European Commission [grant numbers: FP7-HEALTH-2013-INNOVATION-1 602570-2, H2020-SC1-2016-2017 (H2020-SC1-2016-RTD) Proposal: 731626-HIVACAR].	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Borobia AM, 2021, LANCET, V398, P121, DOI 10.1016/S0140-6736(21)01420-3; Esprit A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040776; Esteban I, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030501; Guardo AC, 2017, AIDS, V31, P321, DOI 10.1097/QAD.0000000000001276; Guo YG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01499; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kreiter S, 2010, CANCER RES, V70, P9031, DOI 10.1158/0008-5472.CAN-10-0699; LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214; Liu XX, 2021, LANCET, V398, P856, DOI 10.1016/S0140-6736(21)01694-9; Najera JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011406; Miao L, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01335-5; Miyahira Y, 1998, P NATL ACAD SCI USA, V95, P3954, DOI 10.1073/pnas.95.7.3954; Palucka K, 2011, CURR TOP MICROBIOL, V344, P173, DOI 10.1007/82_2010_48; Perdiguero B, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030057; Perdiguero B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080424; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; RODRIGUES M, 1994, J IMMUNOL, V153, P4636; Spencer AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23173-1; Tscharke DC, 2006, J VIROL, V80, P6318, DOI 10.1128/JVI.00427-06	21	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							959	10.3390/vaccines9090959			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3PX	34579196	gold, Green Published			2022-04-29	WOS:000702121500001
J	Kerekes, S; Ji, MD; Shih, SF; Chang, HY; Harapan, H; Rajamoorthy, Y; Singh, A; Kanwar, S; Wagner, AL				Kerekes, Stefania; Ji, Mengdi; Shih, Shu-Fang; Chang, Hao-Yuan; Harapan, Harapan; Rajamoorthy, Yogambigai; Singh, Awnish; Kanwar, Shailja; Wagner, Abram L.			Differential Effect of Vaccine Effectiveness and Safety on COVID-19 Vaccine Acceptance across Socioeconomic Groups in an International Sample	VACCINES			English	Article						vaccines; COVID-19 vaccines; cross-sectional studies; SARS-CoV-2; surveys and questionnaires; international sample; immunization	HESITANCY; SCALE	Controlling the spread of SARS-CoV-2 will require high vaccination coverage, but acceptance of the vaccine could be impacted by perceptions of vaccine safety and effectiveness. The aim of this study was to characterize how vaccine safety and effectiveness impact acceptance of a vaccine, and whether this impact varied over time or across socioeconomic and demographic groups. Repeated cross-sectional surveys of an opt-in internet sample were conducted in 2020 in the US, mainland China, Taiwan, Malaysia, Indonesia, and India. Individuals were randomized into receiving information about a hypothetical COVID-19 vaccine with different safety and effectiveness profiles (risk of fever 5% vs. 20% and vaccine effectiveness 50% vs. 95%). We examined the effect of the vaccine profile on vaccine acceptance in a logistic regression model, and included interaction terms between vaccine profile and socioeconomic/demographic variables to examine the differences in sensitivity to the vaccine profile. In total, 12,915 participants were enrolled in the six-country study, including the US (4054), China (2797), Taiwan (1278), Malaysia (1497), Indonesia (1527), and India (1762). Across time and countries, respondents had stronger preferences for a safer and more effective vaccine. For example, in the US in November 2020, acceptance was 3.10 times higher for a 95% effective vaccine with a 5% risk of fever, vs a vaccine 50% effective, with a 20% risk of fever (95% CI: 2.07, 4.63). Across all countries, there was an increase in the effect of the vaccine profile over time (p < 0.0001), with stronger preferences for a more effective and safer vaccine in November 2020 compared to August 2020. Sensitivity to the vaccine profile was also stronger in August compared to November 2020, in younger age groups, among those with lower income; and in those that are vaccine hesitant. Uptake of COVID-19 vaccines could vary in a country based upon effectiveness and availability. Effective communication tools will need to be developed for certain sensitive groups, including young adults, those with lower income, and those more vaccine hesitant.	[Kerekes, Stefania; Ji, Mengdi; Wagner, Abram L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA; [Kerekes, Stefania] Babes Bolyai Univ Cluj Napoca, Fac European Studies, Cluj Napoca 400090, Romania; [Shih, Shu-Fang] Virginia Commonwealth Univ, Dept Hlth Adm, Coll Hlth Profess, Richmond, VA 23298 USA; [Chang, Hao-Yuan] Natl Taiwan Univ, Sch Nursing, Coll Med, 1 Jen Rd,Sect 1, Taipei 100233, Taiwan; [Chang, Hao-Yuan] Natl Taiwan Univ Hosp, Dept Nursing, 7 Chung Shan S Rd, Taipei 100225, Taiwan; [Harapan, Harapan] Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh 23111, Indonesia; [Harapan, Harapan] Univ Syiah Kuala, Sch Med, Trop Dis Ctr, Banda Aceh 23111, Indonesia; [Harapan, Harapan] Univ Syiah Kuala, Sch Med, Dept Microbiol, Banda Aceh 23111, Indonesia; [Rajamoorthy, Yogambigai] Univ Tunku Abdul Rahman, Fac Accountancy & Management, Dept Econ, Sungai Long Campus,Jalan Sungai Long, Cheras 43000, Kajang, Malaysia; [Singh, Awnish] Natl Inst Hlth & Family Welfare, Natl Tech Advisory Grp Immunizat Secretariat, Delhi 110067, India; [Kanwar, Shailja] Sapiens Publ Hlth Solut, Delhi 110092, India		Wagner, AL (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.	stefaniakerekes@gmail.com; mengdiji@umich.edu; shihs2@vcu.edu; changh@ntu.edu.tw; harapan@unsyiah.ac.id; yogambigai@utar.edu.my; singhak.24@gmail.com; drshailjakanwar@sphs.in; awag@umich.edu	Harapan, Harapan/I-8741-2016	Harapan, Harapan/0000-0001-7630-8413; CHANG, HAO-YUAN/0000-0001-5810-7562; Rajamoorthy, Yogambigai/0000-0002-3222-4346; Wagner, Abram/0000-0003-4691-7802; Shih, Shu-Fang/0000-0003-2229-8461	National Science Foundation, Division of Social and Economic SciencesNational Science Foundation (NSF) [2027836]; National Institute of Allergy And Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [K01AI137123]	This project was supported by an award from the National Science Foundation, Division of Social and Economic Sciences (#2027836), and from the National Institute of Allergy And Infectious Diseases (#K01AI137123).	Akel KB, 2021, HUM VACC IMMUNOTHER, V17, P2639, DOI 10.1080/21645515.2021.1884476; [Anonymous], 2021, DW NEWS 0616; [Anonymous], 2021, VACCINES COVID19 VAC; Azlan AA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233668; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bright B, 2021, GLOBALIZATION HEALTH, V17, DOI 10.1186/s12992-021-00668-6; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; CSSE Johns Hopkins, 2020, COVID 19 MAP J HOPK; Fu Chuanxi, 2020, ACCEPTANCE PREFRENCE, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103, 0.1101/2020.04.09.2006010314]; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Gidengil C, 2012, VACCINE, V30, P3445, DOI 10.1016/j.vaccine.2012.03.022; Google News, 2020, COR COVID 19 GOOGL N; Kadoya Y, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094864; Kreps S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00335-2; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li JL, 2020, BMC PLANT BIOL, V20, DOI 10.1186/s12870-020-02440-1; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Masters NB, 2020, P NATL ACAD SCI USA, V117, P28506, DOI 10.1073/pnas.2011529117; Motta M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113642; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Robertson E., 2021, BRAIN BEHAV IMMUN, V94, P41, DOI [10.1016/j.bbi.2021.03.008, DOI 10.1016/j.bbi.2021.03.008]; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Rozek LS, 2021, INT J PUBLIC HEALTH, V66, DOI 10.3389/ijph.2021.636255; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Shi Y, 2020, J ZHEJIANG UNIV-SC B, V21, P343, DOI 10.1631/jzus.B2000083; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sun XD, 2020, VACCINE, V38, P1520, DOI 10.1016/j.vaccine.2019.11.062; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; Wagner A.L., 2021, HEALTH COMMUN, V17, P2940, DOI [10.1080/21645515.2021.1917233, DOI 10.1080/10410236.2021.1989786]; Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239; World Data, 2020, COVID 19 DAT EXPL OU; World Health Organization, 2020, GLOBAL TUBERCULOSIS	34	2	2	10	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1010	10.3390/vaccines9091010			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW4TS	34579247	gold, Green Published			2022-04-29	WOS:000700150900001
J	Principi, N; Esposito, S				Principi, Nicola; Esposito, Susanna			Is the Immunization of Pregnant Women against COVID-19 Justified?	VACCINES			English	Review						COVID-19; COVID-19 vaccine; maternal immunization; mother-to-child transmission; pregnancy	SARS-COV-2 INFECTION; VACCINE; OUTCOMES; ANTIBODIES; HEALTH	Maternal immunization against some infectious diseases can offer significant advantages for women, preventing maternal morbidity and mortality, or for offspring, preventing fetal disease and conferring passive immunity to neonates. Recently, clinical trials specifically to evaluate the immunogenicity, safety, and tolerability of some of the available coronavirus disease 2019 (COVID-19) vaccines in pregnant and lactating women have been planned, initiated and, in some cases, completed. This paper discusses whether the immunization of pregnant women against COVID-19 is justified and presents knowledge about the immunogenicity and safety of mRNA COVID-19 vaccines for these subjects. The results of recent studies indicate that pregnant women are at increased risk of developing severe disease compared with nonpregnant women of the same age. Studies carried out with mRNA vaccines indicate that the immunogenicity, safety and tolerability of these preventive measures in pregnant women are not different from those in nonpregnant women of the same age. Moreover, antibodies are efficiently transferred through the placenta and can be detected in breastmilk, suggesting a potential prevention of infection in the child. All these findings authorize the use of mRNA vaccines in pregnant women to protect both the mother and the child. However, further studies with larger sample size and with follow-up of the pregnant women vaccinated during different periods of pregnancy and their children are needed to better characterize the immune response of pregnant women, to define when these vaccines should be administered to obtain the best protection, and to measure vaccine efficacy against virus variants in both mothers and infants. COVID-19 vaccines based on different technological platforms cannot presently be used, and their role in pregnant women should be clarified.	[Principi, Nicola] Univ Milan, Via Festa Perdono 7, I-20122 Milan, Italy; [Esposito, Susanna] Univ Parma, Pietro Barilla Childrens Hosp, Dept Med & Surg, Pediat Clin, Via Gramsci 14, I-43126 Parma, Italy		Esposito, S (通讯作者)，Univ Parma, Pietro Barilla Childrens Hosp, Dept Med & Surg, Pediat Clin, Via Gramsci 14, I-43126 Parma, Italy.	nicola.principi@unimi.it; susannamariaroberta.esposito@unipr.it	Esposito, Susanna/AAA-8275-2022	Principi, Nicola/0000-0002-3468-5568	Ri.Cli.Ped.-University of Parma, Parma, Italy	This research was funded by Ri.Cli.Ped.-University of Parma, Parma, Italy.	Abramson JS, 2016, LANCET, V388, P2562, DOI 10.1016/S0140-6736(16)30882-0; Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01282; ACOG Committee Opinion, 2014, OBSTET GYNECOL, V124, P3; Adhikari EH, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29256; Ahlberg M, 2020, JAMA-J AM MED ASSOC, V324, P1782, DOI 10.1001/jama.2020.19124; Andersson Monique I, 2020, Wellcome Open Res, V5, P181, DOI [10.12688/wellcomeopenres.16002.2, 10.12688/wellcomeopenres.16002.1]; Badr DA, 2020, AM J OBSTET GYNECOL, V223, P764, DOI 10.1016/j.ajog.2020.07.045; Bentov Y, 2021, HUM REPROD, V36, P2506, DOI 10.1093/humrep/deab182; Brandt JS, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.09.043; Breslin N, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100118; Bwire GM, 2021, J MED VIROL, V93, P1361, DOI 10.1002/jmv.26622; Carosso A, 2020, EUR J OBSTET GYN R B, V249, P98, DOI 10.1016/j.ejogrb.2020.04.023; Cavicchiolo ME, 2022, PEDIATR RES, V91, P513, DOI 10.1038/s41390-021-01477-8; Centers for Disease Control and Prevention, COVID 19 VACC REC; Centers for Disease Control and Prevention (CDC), INF COVID 19 VACC PE; Ceulemans M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186766; Chae SY, 2021, OBSTET GYNECOL SURV, V76, P504, DOI 10.1097/OGX.0000000000000925; Chambers C, 2020, JAMA-J AM MED ASSOC, V324, P1347, DOI 10.1001/jama.2020.15580; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Chen S, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P418, DOI 10.3760/cma.j.cn112151-20200225-00138; Cheng BH, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa294; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Collin J, 2020, ACTA OBSTET GYN SCAN, V99, P819, DOI 10.1111/aogs.13901; Cunarro-Lopez Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113552; Delahoy MJ, 2020, MMWR-MORBID MORTAL W, V69, P1347, DOI 10.15585/mmwr.mm6938e1; Diaz P, 2021, ANDROLOGIA, V53, DOI 10.1111/and.14156; Diaz-Corvillon P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239887; Douxfils J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080907; Edlow AG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.30455; Erol SA, 2021, J MED VIROL, V93, P2350, DOI 10.1002/jmv.26725; Esposito S, 2017, EXPERT REV VACCINES, V16, P175, DOI 10.1080/14760584.2017.1237875; European Commission, EU VACC STRAT; Facchetti F, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102951; Flaherman V.J., 2020, CLIN INFECT DIS, V184, P628, DOI [10.1093/cid/ciaa1411, DOI 10.1093/CID/CIAA1411]; Food and Drug Administration, FACT SHEET HEALTHC P; Freedman D, 2007, PREGNANCY OUTCOMES N, DOI DOI 10.1101/2020.04.11.20062356; Freiesleben NL, 2021, HUM REPROD, V36, P40, DOI 10.1093/humrep/deaa311; Garg I, 2021, INFECT DIS REP, V13, P685, DOI 10.3390/idr13030064; GOV, 2020, UK PRIOR GROUPS COR; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; GroSS Rudiger, 2020, Lancet, V395, P1757, DOI 10.1016/S0140-6736(20)31181-8; Gulersen M, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100211; Heath PT, 2020, LANCET INFECT DIS, V20, P1007, DOI 10.1016/S1473-3099(20)30638-1; Hosier H, 2020, J CLIN INVEST, V130, P4947, DOI 10.1172/JCI139569; Hu XL, 2021, NEONATOLOGY, V117, P592, DOI 10.1159/000509141; Hu XL, 2020, OBSTET GYNECOL, V136, P65, DOI 10.1097/AOG.0000000000003926; Kalafat E, 2021, LANCET, V398, P951, DOI 10.1016/S0140-6736(21)01756-6; Kayem G, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101826; Khalil A, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100446; Khoury R, 2020, OBSTET GYNECOL, V136, P273, DOI 10.1097/AOG.0000000000004025; Kirtsman M, 2020, CAN MED ASSOC J, V192, pE647, DOI 10.1503/cmaj.200821; Knight M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2107; Kotlyar AM, 2021, AM J OBSTET GYNECOL, V224, P35, DOI 10.1016/j.ajog.2020.07.049; Krubiner CB, 2021, VACCINE, V39, P85, DOI 10.1016/j.vaccine.2019.01.011; Kumar Vijay, 2021, Urol J, DOI 10.22037/uj.v18i.6897; Li XC, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11990; Liao J, 2020, INT J GYNECOL OBSTET, V150, P53, DOI 10.1002/ijgo.13188; Liu H, 2020, J REPROD IMMUNOL, V139, DOI 10.1016/j.jri.2020.103122; Liu W, 2020, AM J PERINAT, V37, P1317, DOI 10.1055/s-0040-1716505; Lokken EM, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.05.031; Luo QQ, 2021, J WOMENS HEALTH, V30, P1546, DOI 10.1089/jwh.2020.8978; Mackin DW, 2021, BEST PRACT RES CL OB, V76, P13, DOI 10.1016/j.bpobgyn.2020.09.005; Martinez-Perez O, 2020, JAMA-J AM MED ASSOC, V324, P296, DOI 10.1001/jama.2020.10125; Mei CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02886; Mendoza M, 2020, BJOG-INT J OBSTET GY, V127, P1374, DOI 10.1111/1471-0528.16339; Mithal LB, 2021, AM J OBSTET GYNECOL, V225, P192, DOI 10.1016/j.ajog.2021.03.035; Moore KM, 2021, BIOCHEM BIOPH RES CO, V538, P180, DOI 10.1016/j.bbrc.2020.12.064; Nayak AH, 2020, J OBSTET GYN INDIA, V70, P256, DOI 10.1007/s13224-020-01335-3; Norman M, 2021, JAMA-J AM MED ASSOC, V325, P2076, DOI 10.1001/jama.2021.5775; Ory S, 2021, HUM REPROD OPEN, V2021, DOI 10.1093/hropen/hoab016; Panagiotakopoulos L, 2020, MMWR-MORBID MORTAL W, V69, P1355, DOI [10.15585/mmwr.mm6938e2, 10.15585/mmwr.mm6938e1, 10.15585/mmwr.mm6938e2externalicon]; Patberg ET, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.10.020; Pereira A, 2020, ACTA OBSTET GYN SCAN, V99, P839, DOI 10.1111/aogs.13921; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Pineles BL, 2020, EUR J OBSTET GYN R B, V254, P329, DOI 10.1016/j.ejogrb.2020.09.012; Pique-Regi R, 2020, ELIFE, V9, DOI 10.7554/eLife.58716; Pirjani R, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa158; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Selim M, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8888; Sentilhes L, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.06.022; Sharps MC, 2020, PLACENTA, V101, P13, DOI 10.1016/j.placenta.2020.08.018; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Shmakov RG, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1850683; Smithgall MC, 2020, HISTOPATHOLOGY, V77, P994, DOI 10.1111/his.14215; Society of Graduate Students, SOGC STAT COVID 19 V; Swamy GK, 2015, VACCINE, V33, P6436, DOI 10.1016/j.vaccine.2015.08.035; Trevisanuto D, 2021, ARCH DIS CHILD-FETAL, V106, pF330, DOI 10.1136/archdischild-2020-319837; Tsui K.H., 2021, J CHIN MED ASSOC, DOI [10.1097/JCMA.0000000000000612, DOI 10.1097/JCMA.0000000000000612]; Villar J, 2021, JAMA PEDIATR, V175, P817, DOI 10.1001/jamapediatrics.2021.1050; Wang MJ, 2020, AM J PERINAT, V37, P1411, DOI 10.1055/s-0040-1718403; Wang Q, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00375-20; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Wei LJ, 2020, J MED INTERNET RES, V22, DOI 10.2196/19642; Wei SQ, 2021, CAN MED ASSOC J, V193, pE540, DOI 10.1503/cmaj.202604; Whitehead CL, 2020, LANCET, V395, pE92, DOI 10.1016/S0140-6736(20)31029-1; Woodworth KR, 2020, MMWR-MORBID MORTAL W, V69, P1635, DOI 10.15585/mmwr.mm6944e2; Xu QC, 2020, INT J INFECT DIS, V95, P376, DOI 10.1016/j.ijid.2020.04.065; Xu S, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa283; Yan J, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.014; Yang H, 2020, J INFECTION, V81, pE40, DOI 10.1016/j.jinf.2020.04.003; Yang R, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01798-1; Yazihan N, 2021, J MED VIROL, V93, P2204, DOI 10.1002/jmv.26631; Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3; Zhang L, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P166, DOI 10.3760/cma.j.cn112141-20200218-00111; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071	105	7	7	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							970	10.3390/vaccines9090970			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2ZO	34579207	gold, Green Published			2022-04-29	WOS:000702078700001
J	Balan, A; Bejan, I; Bonciu, S; Eni, CE; Ruta, S				Balan, Ana; Bejan, Ioana; Bonciu, Simona; Eni, Cristina Elena; Ruta, Simona			Romanian Medical Students' Attitude towards and Perceived Knowledge on COVID-19 Vaccination	VACCINES			English	Article						COVID-19 vaccination; medical students; SARS CoV-2 vaccine; vaccine hesitancy		In Romania, the first phase of the COVID-19 vaccination campaign prioritized medical personnel, which included healthcare students. This study aimed to assess their knowledge, attitudes towards, and perception of COVID-19 vaccination. An anonymous, single-answer, 42-item online survey was conducted from 12 January until 3 March 2021, in the country's largest University of Medicine and Pharmacy. Among the 1581 respondents (14.9% response rate), 88.5% were pro-vaccination, 7.8% were undecided, and 3.7% were vaccine resistant. The main reason for vaccine rejection was the perceived speed of vaccine development (strong agreement among the vaccine resistant, moderate agreement among the undecided, p < 0.001). Concern over long-term adverse reaction was present in only 11.5% of the respondents, significantly more frequent in the undecided and vaccine resistant. Perceived knowledge on the vaccines' safety, efficacy, and technology correlated with a pro-vaccine attitude (p < 0.001). Most respondents had a positive stance towards vaccination in general, influencing their behaviour as future parents (99.3% of the pro-vaccination, 95.1% of the undecided, and 89.1% of the vaccine resistant will vaccinate their children, p < 0.001) and as medical professionals (99.7% of the pro-vaccination, 93.5% of those undecided, and 89.8% of the vaccine resistant would advise parents to vaccinate their children, p < 0.001). Healthcare students can thus serve as important vectors for scientifically sound information, influencing vaccine uptake in the community.	[Balan, Ana; Bejan, Ioana; Bonciu, Simona; Eni, Cristina Elena; Ruta, Simona] Carol Davila Univ Med & Pharm, Fac Med, Bucharest 050474, Romania; [Ruta, Simona] Stefan S Nicolau Inst Virol, 285 Sos Mihai Bravu, Bucharest 030304, Romania		Balan, A (通讯作者)，Carol Davila Univ Med & Pharm, Fac Med, Bucharest 050474, Romania.	ana.balan@stud.umfcd.ro; ioana.bejan@stud.umfcd.ro; simona.bonciu@stud.umfcd.ro; cristina.eni@stud.umfcd.ro; simona.ruta@umfcd.ro	; Ruta, Simona/A-9569-2010	Eni, Cristina Elena/0000-0001-7853-158X; Ruta, Simona/0000-0002-2492-6073; Bejan, Ioana/0000-0003-2356-0679; Balan, Ana/0000-0003-4902-9958	Carol Davila University of Medicine and Pharmacy	The authors express their gratitude to the students participating in the study as well as to the student representatives for increasing their peers' awareness of the questionnaire, and to the Carol Davila University of Medicine and Pharmacy.	Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Hildreth JEK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050489; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Kanyike AM, 2021, TROP MED HEALTH, V49, DOI 10.1186/s41182-021-00331-1; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Miko D, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060282; MONTAGNI I, 2021, J PUBLIC HLTH, V43, P1, DOI DOI 10.1093/PUBMED/FDAB028; Popescu CP, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101662; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Shimizu Y., 2019, VACCINES IMMUNIZATIO; Statista J.A., MOST IMPORTANT REASO; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; WHO/R, AKBAR 10 THREATS GLO	14	9	9	5	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							854	10.3390/vaccines9080854			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9IM	34451979	Green Published, gold			2022-04-29	WOS:000690234800001
J	Petrone-Garcia, VM; Gonzalez-Soto, J; Lopez-Arellano, R; Delgadillo-Gonzalez, M; Valdes-Narvaez, VM; Alba-Hurtado, F; Hernandez-Velasco, X; Castellanos-Huerta, I; Tellez-Isaias, G				Petrone-Garcia, Victor Manuel; Gonzalez-Soto, Joshua; Lopez-Arellano, Raquel; Delgadillo-Gonzalez, Mariano; Valdes-Narvaez, Victor M.; Alba-Hurtado, Fernando; Hernandez-Velasco, Xochitl; Castellanos-Huerta, Inkar; Tellez-Isaias, Guillermo			Evaluation of Avian Reovirus S1133 Vaccine Strain in Neonatal Broiler Chickens in Gastrointestinal Integrity and Performance in a Large-Scale Commercial Field Trial	VACCINES			English	Article						reovirus S1133 vaccine; pancreatic and enteric histology; ELISA	INDUCED TENOSYNOVITIS; ANTIBODIES; INFECTION; LESIONS	Avian reovirus (ARV) is the principal cause of several diseases. The vaccination of breeders allows for the control of viral arthritis and delivery of maternal-derived antibodies to the progeny. The vaccination of broiler chickens with ARV strain S1133 is used to prevent viral arthritis. However, the post-vaccination enteric effects have not been well-characterized. The purpose of this study was to evaluate the effect of vaccination with the S1133 strain on the weight gain and feed conversion of broiler chickens and to characterize the gastric, enteric, and pancreatic lesions that the strain could induce. A total of 672,000 chickens were divided into two groups: a group vaccinated with ARV strain S1133 (S1133ARV) and a control group (not vaccinated). Upon histological analysis, the vaccine group showed less proventricular glandular tissue and atrophy of the pancreas and duodenal villi, as well as having a lower average daily profit. The conclusion based on the results of this investigation is that neonatal vaccination with S1133ARV causes atrophy of the pancreatic acini, proventricular glands, and intestinal villi, leading to an increased diameter of the glandular lumen and atrophy of the enteric villous, as well as weight loss, in broiler chickens.	[Petrone-Garcia, Victor Manuel; Castellanos-Huerta, Inkar] Univ Nacl Autonoma Mexico, Fac Estudios Super Cuautitlan, Programa Doctorado Ciencias Salud & Prod Anim, Cuautitlan 54714, Mexico; [Gonzalez-Soto, Joshua; Alba-Hurtado, Fernando] Univ Nacl Autonoma Mexico, Fac Estudios Super Cuautitlan, Dept Ciencias Biol, Cuautitlan 54714, Mexico; [Lopez-Arellano, Raquel] Univ Nacl Autonoma Mexico, Fac Estudios Super Cuautitlan, Unidad Invest Multidisciplinaria, Lab LEDEFAR 5, Cuautitlan 54714, Mexico; [Delgadillo-Gonzalez, Mariano] Independent Poultry Zootech, Aguascalientes 20000, Aguascalientes, Mexico; [Hernandez-Velasco, Xochitl] UNAM, Fac Med Vet & Zootecnia, Dept Med & Zootecnia Aves, Coyoacan 04510, Mexico; [Tellez-Isaias, Guillermo] Univ Arkansas, Dept Poultry Sci, Fayetteville, NC 72701 USA		Petrone-Garcia, VM (通讯作者)，Univ Nacl Autonoma Mexico, Fac Estudios Super Cuautitlan, Programa Doctorado Ciencias Salud & Prod Anim, Cuautitlan 54714, Mexico.	petrone@unam.mx; joshuagsotomvz@gmail.com; lopezar@unam.mx; degomariano@hotmail.com; valdesnv@gmail.com; drfernandoalbafesc@gmail.com; xhernandezvelasco@gmail.com; castellanos.inkar@gmail.com; gtellez@uark.edu	Petrone-Garcia, Victor/AER-0008-2022	Petrone-Garcia, Victor/0000-0001-6109-6366; Tellez-Isaias, Guillermo/0000-0002-2416-2747; Lopez-Arellano, Raquel/0000-0002-2050-6119	PAPIIT project of DGAPA-UNAM, Universidad Nacional Autonoma de Mexico [IT201620]; CONACyTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [494367]; USDA-NIFA, Sustainable Agriculture Systems [2019-69012-29905]	This research obtained funding from the PAPIIT IT201620 project of DGAPA-UNAM, Universidad Nacional Autonoma de Mexico. The authors thank CONACyT for doctoral grant number 494367. This research was also partly supported by funds provided by the USDA-NIFA, Sustainable Agriculture Systems, Grant No. 2019-69012-29905; title of project: Empowering US Broiler Production for Transformation and Sustainability USDA-NIFA (Sustainable Agriculture Systems), No. 2019-69012-29905.	Abdul-Aziz T., 2016, AVIAN HISTOPATHOLOGY, P545; [Anonymous], 2018, ROSS BROILER MANAGEM; [Anonymous], 2019, ROSS BROIL NUTR SPEC; Brown C.C., 2016, JUBB KENNEDY PALMERS, V1, P271; Brown JJ, 2018, J VIROL, V92, DOI 10.1128/JVI.02062-17; CEBRA JJ, 1989, IMMUNOL INVEST, V18, P545, DOI 10.3109/08820138909112262; CLARK FD, 1990, AVIAN DIS, V34, P304, DOI 10.2307/1591412; Dandar E, 2013, ARCH VIROL, V158, P2583, DOI 10.1007/s00705-013-1739-y; Davis JF, 2013, AVIAN DIS, V57, P321, DOI 10.1637/10515-021313-Case.1; Denbow DM, 2015, STURKIE'S AVIAN PHYSIOLOGY, 6TH EDITION, P337; GIAMBRONE JJ, 1991, AVIAN DIS, V35, P380, DOI 10.2307/1591193; HIERONYMUS DRK, 1983, AVIAN DIS, V27, P246, DOI 10.2307/1590390; HILL JE, 1989, AVIAN DIS, V33, P86, DOI 10.2307/1591072; JONES RC, 1984, AVIAN PATHOL, V13, P511, DOI 10.1080/03079458408418552; JONES RC, 1984, AVIAN PATHOL, V13, P441, DOI 10.1080/03079458408418546; JONES RC, 1989, AVIAN PATHOL, V18, P239, DOI 10.1080/03079458908418599; Jones RC, 2000, REV SCI TECH OIE, V19, P614, DOI 10.20506/rst.19.2.1237; KIBENGE FSB, 1987, AVIAN PATHOL, V16, P73, DOI 10.1080/03079458708436354; Liu HJ, 2002, J VIROL METHODS, V102, P129, DOI 10.1016/S0166-0934(02)00010-1; Pitcovski J, 2020, DIS POULT, V14th, P382, DOI DOI 10.1002/9781119371199.CH11; RANDALL CJ, 1981, VET REC, V109, P125, DOI 10.1136/vr.109.6.125; REKIK MR, 1991, AVIAN PATHOL, V20, P607, DOI 10.1080/03079459108418800; ROSENBERGER JK, 1989, AVIAN DIS, V33, P535, DOI 10.2307/1591118; Scott ML, 1982, NUTR CHICKEN, V3rd; Songserm T, 2003, VET RES, V34, P285, DOI 10.1051/vetres:2003004; Union Nacional de Avicultores (UNA), 2020, COMP IND EC SECT AV; van der Heide L, 2000, AVIAN DIS, V44, P638, DOI 10.2307/1593104; VANDERHEIDE L, 1976, AVIAN DIS, V20, P641, DOI 10.2307/1589443; WHITACRE ME, 1987, J NUTR, V117, P460, DOI 10.1093/jn/117.3.460; Xu JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182079; Zhong L, 2016, SCI REP-UK, V6, DOI 10.1038/srep35271	34	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							817	10.3390/vaccines9080817			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5IJ	34451942	Green Published			2022-04-29	WOS:000689964100001
J	Reddi, D; Durant, L; Bernardo, D; Noble, A; English, NR; Hendy, P; Clark, GC; Prior, JL; Williamson, ED; Knight, SC				Reddi, Durga; Durant, Lydia; Bernardo, David; Noble, Alistair; English, Nicholas R.; Hendy, Philip; Clark, Graeme C.; Prior, Joann L.; Williamson, Ethel Diane; Knight, Stella C.			In Vitro Priming of Human T Cells by Dendritic Cells Provides a Screening Tool for Candidate Vaccines for Burkholderia pseudomallei	VACCINES			English	Article						dendritic cells; Burkholderia pseudomallei; T cell priming	MELIOIDOSIS; SUBSETS	Murine dendritic cells, when pulsed with heat-killed Burkholderia pseudomallei and used to immunise naive mice, have previously been shown to induce protective immunity in vivo. We have now demonstrated the in vitro priming of naive human T cells against heat-killed B. pseudomallei, by co-culture with syngeneic B. pseudomallei-pulsed dendritic cells. Additionally, we have enriched the DC fraction such that a study of the differential response induced by pulsed DCs of either myeloid or plasmacytoid lineage in syngeneic human T cells was achievable. Whilst both mDCs and pDCs were activated by pulsing, the mDCs contributed the major response to B. pseudomallei with the expression of the migration marker CCR7 and a significantly greater secretion of the proinflammatory TNF alpha and IL1 beta. When these DC factions were combined and used to prime syngeneic T cells, a significant proliferation was observed in the CD4(+) fraction. Here, we have achieved human T cell priming in vitro with unadjuvanted B. pseudomallei, the causative organism of melioidosis, for which there is currently no approved vaccine. We propose that the approach we have taken could be used to screen for the human cellular response to candidate vaccines and formulations, in order to enhance the cell-mediated immunity required to protect against this intracellular pathogen and potentially more broadly against other, difficult-to-treat intracellular pathogens. To date, the polysaccharide capsule of B. pseudomallei, fused to a standard carrier protein, e.g., Crm, looks a likely vaccine candidate. Dendritic cells (DCs), providing, as they do, the first line of defence to infection, process and present microbial products to the immune system to direct downstream immune responses. Here, we have sought to use DCs ex vivo to identify immunogenic products from heat-killed B. pseudomallei. Using practical volumes of fresh human donor blood, we show that heat-killed B. pseudomallei activated and stimulated the expression of pro-inflammatory cytokines TNF-alpha, IL-1 beta and IL-6 from both myeloid and plasmacytoid DCs. Furthermore, B. pseudomallei-pulsed DCs cultured with naive syngeneic T cells ex vivo, induced the activation and proliferation of the CD4(+) T-cell population, which was identified by cell surface marker staining using flow cytometry. Thus, both DC subsets are important for driving primary T helper cell responses to B. pseudomallei in healthy individuals and have the potential to be used to identify immunogenic components of B. pseudomallei for future therapies and vaccines.	[Reddi, Durga; Durant, Lydia; Bernardo, David; Noble, Alistair; English, Nicholas R.; Hendy, Philip; Knight, Stella C.] Imperial Ctr Translat & Expt Med, Antigen Presentat Res Grp, 72 Du Cane Rd, London W12 0NN, England; [Noble, Alistair] Quadram Inst Biosci, Gut Microbes & Hlth Program, Norwich NR4 7UQ, Norfolk, England; [Hendy, Philip] London North West Univ Healthcare NHS Trust, St Marks Hosp, Harrow, Middx, England; [Clark, Graeme C.; Prior, Joann L.; Williamson, Ethel Diane] Def Sci & Technol Lab, Porton Down SP4 0JQ, England; [Reddi, Durga] Parkinsons UK, London SW1V 1EJ, England; [Bernardo, David] Univ Valladolid, Inst Biol & Genet Mol IBGM, Mucosal Immunol Lab, Valladolid 47002, Spain; [Hendy, Philip] Chelsea & Westminster Hosp, Chelsea andWestminster Hosp NHS Fdn Trust, London SW10 9NH, England		Williamson, ED (通讯作者)，Def Sci & Technol Lab, Porton Down SP4 0JQ, England.	dreddi@parkinsons.org.uk; l.durant@imperial.ac.uk; d.bernardo.ordiz@gmail.com; Alistair.Noble@pirbright.ac.uk; n.english@imperial.ac.uk; p.hendy@imperial.ac.uk; gcclark@dstl.gov.uk; jlprior@dstl.gov.uk; dewilliamson@dstl.gov.uk; s.knight@imperial.ac.uk		Durant, Lydia/0000-0002-5068-1479	Dstl [DSTL/AGR/00254/01]	This research was funded by Dstl under contract DSTL/AGR/00254/01.	Cheng AC, 2005, CLIN MICROBIOL REV, V18, P383, DOI 10.1128/CMR.18.2.383-416.2005; Elvin SJ, 2006, INFECT IMMUN, V74, P1706, DOI 10.1128/IAI.74.3.1706-1711.2006; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Palucka K, 2013, CURR OPIN IMMUNOL, V25, P396, DOI 10.1016/j.coi.2013.05.001; Parcina M, 2008, J IMMUNOL, V181, P3823, DOI 10.4049/jimmunol.181.6.3823; Piccioli D, 2009, BLOOD, V113, P4232, DOI 10.1182/blood-2008-10-186890; Sarkar-Tyson M, 2009, VACCINE, V27, P4447, DOI 10.1016/j.vaccine.2009.05.040; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583; Tippayawat P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000407; Veckman V, 2008, J LEUKOCYTE BIOL, V83, P296, DOI 10.1189/jlb.0707457; Westera L, 2013, BLOOD, V122, P2205, DOI 10.1182/blood-2013-03-488411; Willcocks SJ, 2016, CURR OPIN MICROBIOL, V29, P94, DOI 10.1016/j.mib.2015.11.007; Williams NL, 2015, MICROBES INFECT, V17, P311, DOI 10.1016/j.micinf.2014.12.007; Williams NL, 2014, INFECT IMMUN, V82, P4233, DOI 10.1128/IAI.01880-14	15	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							929	10.3390/vaccines9080929			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5CT	34452057	Green Published, gold			2022-04-29	WOS:000689949500001
J	Rijkers, GT; Weterings, N; Obregon-Henao, A; Lepolder, M; Dutt, TS; van Overveld, FJ; Henao-Tamayo, M				Rijkers, Ger T.; Weterings, Nynke; Obregon-Henao, Andres; Lepolder, Michaela; Dutt, Taru S.; van Overveld, Frans J.; Henao-Tamayo, Marcela			Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines	VACCINES			English	Review						mRNA vaccine; viral vector vaccine; Spike protein; antigen presentation; polyethylene glycol; platelet factor 4; thrombosis	LIPID NANOPARTICLES; POLYETHYLENE-GLYCOLS; MOLECULAR MIMICRY; IN-VIVO; ADENOVIRUS; DELIVERY; IMMUNOGENICITY; GAMMA; GENE; PSEUDOURIDINE	Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19), which has reached pandemic proportions. A number of effective vaccines have been produced, including mRNA vaccines and viral vector vaccines, which are now being implemented on a large scale in order to control the pandemic. The mRNA vaccines are composed of viral Spike S1 protein encoding mRNA incorporated in a lipid nanoparticle and stabilized by polyethylene glycol (PEG). The mRNA vaccines are novel in many respects, including cellular uptake and the intracellular routing, processing, and secretion of the viral protein. Viral vector vaccines have incorporated DNA sequences, encoding the SARS-CoV-2 Spike protein into (attenuated) adenoviruses. The antigen presentation routes in MHC class I and class II, in relation to the induction of virus-neutralizing antibodies and cytotoxic T-lymphocytes, will be reviewed. In rare cases, mRNA vaccines induce unwanted immune mediated side effects. The mRNA-based vaccines may lead to an anaphylactic reaction. This reaction may be triggered by PEG. The intracellular routing of PEG and potential presentation in the context of CD1 will be discussed. Adenovirus vector-based vaccines have been associated with thrombocytopenic thrombosis events. The anti-platelet factor 4 antibodies found in these patients could be generated due to conformational changes of relevant epitopes presented to the immune system.	[Rijkers, Ger T.; Weterings, Nynke; Lepolder, Michaela; van Overveld, Frans J.] Univ Coll Roosevelt, Sci Dept, NL-4331 CB Middelburg, Netherlands; [Rijkers, Ger T.] St Elizabeth Hosp, Microvida Lab Med Microbiol & Immunol, NL-5022 GC Tilburg, Netherlands; [Obregon-Henao, Andres; Dutt, Taru S.; Henao-Tamayo, Marcela] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA		Rijkers, GT (通讯作者)，Univ Coll Roosevelt, Sci Dept, NL-4331 CB Middelburg, Netherlands.; Rijkers, GT (通讯作者)，St Elizabeth Hosp, Microvida Lab Med Microbiol & Immunol, NL-5022 GC Tilburg, Netherlands.	g.rijkers@ucr.nl; n.weterings@ucr.nl; Andres.Obregon@ColoState.edu; m.lepolder@ucr.nl; taru.Dutt@colostate.edu; f.vanoverveld@ucr.nl; Marcela.Henao_Tamayo@ColoState.edu	Dutt, Taru S./AAN-1183-2021	Dutt, Taru S./0000-0002-5101-1311; Rijkers, Ger/0000-0001-6948-6123			Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202; Althaus K, 2021, BLOOD, V137, P1061, DOI 10.1182/blood.2020008762; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051; Arepally G, 1997, BLOOD, V89, P370, DOI 10.1182/blood.V89.2.370; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Bezbaruah R, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.635337; Bhattacharjee Sukrita, 2020, SN Compr Clin Med, V2, P2048, DOI 10.1007/s42399-020-00521-8; Bisgin A, 2021, HUM GENE THER, V32, P541, DOI 10.1089/hum.2021.052; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Calogiuri G, 2019, J ALLER CL IMM-PRACT, V7, P2509, DOI 10.1016/j.jaip.2019.05.058; Castelli E.C., 2021, IMMUNOGENETICS RESIS, DOI [10.1101/2021.04.21.21255872, DOI 10.1101/2021.04.21.21255872]; Cines DB, 2021, NEW ENGL J MED, V384, P2254, DOI 10.1056/NEJMe2106315; Clancy R, 2019, J THROMB HAEMOST, V17, P532, DOI 10.1111/jth.14385; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742; Crystal RG, 2014, HUM GENE THER, V25, P3, DOI 10.1089/hum.2013.2527; Dhingra A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37249-4; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; Eifer M, 2022, J NUCL MED, V63, P134, DOI 10.2967/jnumed.121.262194; EMA, COV 19 LAT UPD; Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014; Excoffon KJDA, 2020, FEBS LETT, V594, P1828, DOI 10.1002/1873-3468.13794; Gao J, 2019, FEBS LETT, V593, P3609, DOI 10.1002/1873-3468.13691; Geisbert TW, 2011, J VIROL, V85, P4222, DOI 10.1128/JVI.02407-10; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Guo JG, 2018, HUM VACC IMMUNOTHER, V14, P1679, DOI 10.1080/21645515.2017.1419108; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Hogan M, 2020, VASC MED, V25, P160, DOI 10.1177/1358863X19898253; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Huang QR, 2021, J GENET GENOMICS, V48, P107, DOI 10.1016/j.jgg.2021.02.006; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263; Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254; Kanduc D, 2020, IMMUNOL RES, V68, P310, DOI 10.1007/s12026-020-09152-6; Kanduc D, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108426; Kanduc Darja, 2012, Front Biosci (Schol Ed), V4, P1393; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kauffman KJ, 2016, BIOMATERIALS, V109, P78, DOI 10.1016/j.biomaterials.2016.09.006; Kelso JM, 2021, VACCINE, V39, P865, DOI 10.1016/j.vaccine.2020.12.084; Kramps T, 2013, WIRES RNA, V4, P737, DOI 10.1002/wrna.1189; Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Lemckert AAC, 2006, J GEN VIROL, V87, P2891, DOI 10.1099/vir.0.82079-0; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Linares-Fernandez S, 2020, TRENDS MOL MED, V26, P311, DOI 10.1016/j.molmed.2019.10.002; Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Mahevas M, 2020, BRIT J HAEMATOL, V190, pE224, DOI 10.1111/bjh.17024; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116; McCoy K, 2007, J VIROL, V81, P6594, DOI 10.1128/JVI.02497-06; Merchant HA, 2021, J PHARM POLICY PRACT, V14, DOI 10.1186/s40545-021-00315-w; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Oldstone Michael B. A., 2014, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V33, P158, DOI 10.1089/mab.2013.0090; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Park EJ, 2019, EXPERT OPIN EMERG DR, V24, P107, DOI 10.1080/14728214.2019.1604684; Patel S, 2017, NANO LETT, V17, P5711, DOI 10.1021/acs.nanolett.7b02664; Pavkovic M, 2018, HEMATOLOGY, V23, P163, DOI 10.1080/10245332.2017.1377902; Perricone C, 2014, IMMUNOL RES, V60, P226, DOI 10.1007/s12026-014-8597-x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pruss BM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010030; Qiao JL, 2015, IMMUNOL REV, V268, P241, DOI 10.1111/imr.12370; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Reche PA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586984; Robinson J., WHAT ARE AUTOIMMUNE; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Salabei JK, 2021, HEART LUNG, V50, P357, DOI 10.1016/j.hrtlng.2021.01.011; Sample PJ, 2019, NAT BIOTECHNOL, V37, P803, DOI 10.1038/s41587-019-0164-5; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Sellaturay P, 2021, J ALLER CL IMM-PRACT, V9, P670, DOI 10.1016/j.jaip.2020.09.029; Seregin SS, 2009, EXPERT OPIN BIOL TH, V9, P1521, DOI 10.1517/14712590903307388; Shah VK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01949; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Shott JP, 2008, VACCINE, V26, P2818, DOI 10.1016/j.vaccine.2008.03.080; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Stanley DA, 2014, NAT MED, V20, P1126, DOI 10.1038/nm.3702; Stephenson KE, 2021, JAMA-J AM MED ASSOC, V325, P1535, DOI 10.1001/jama.2021.3645; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Svitkin YV, 2017, NUCLEIC ACIDS RES, V45, P6023, DOI 10.1093/nar/gkx135; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Ulmer JB, 2016, CURR OPIN IMMUNOL, V41, P18, DOI 10.1016/j.coi.2016.05.008; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; VAERS, VACC ADV EV REP SYST; Velikova T, 2021, RHEUMATOL INT, V41, P509, DOI 10.1007/s00296-021-04792-9; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Watanabe Yasunori, 2021, ACS Cent Sci, V7, P594, DOI 10.1021/acscentsci.1c00080; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760; Weyrich AS, 2009, J THROMB HAEMOST, V7, P241, DOI 10.1111/j.1538-7836.2008.03211.x; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Wold WSM, 2013, CURR GENE THER, V13, P421; Wolf ME, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081599; World Health Organization, WHO COR COV 19 DASHB; Xiang ZQ, 2006, EMERG INFECT DIS, V12, P1596, DOI 10.3201/eid1210.060078; Xiang ZQ, 2002, J VIROL, V76, P2667, DOI 10.1128/JVI.76.6.2667-2675.2002; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	114	7	7	6	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							848	10.3390/vaccines9080848			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4ZP	34451973	gold, Green Submitted, Green Published			2022-04-29	WOS:000689941300001
J	Su, FJ; Chen, MM				Su, Feng-Jie; Chen, Meei-Mei			Protective Efficacy of Novel Oral Biofilm Vaccines against Lactococcus garvieae Infection in Mullet, Mugil cephalus	VACCINES			English	Article						oral biofilm vaccine; Lactococcus garvieae; Mugil cephalus; IgM	LARGE YELLOW CROAKER; AEROMONAS-HYDROPHILA; STAPHYLOCOCCUS-AUREUS; STREPTOCOCCUS-AGALACTIAE; OREOCHROMIS-NILOTICUS; BACTERIAL BIOFILMS; GREY MULLET; WHOLE-CELL; VACCINATION; RESISTANCE	Lactococcus garvieae (L. garvieae) is an important pathogen that causes enormous economic losses in both marine and freshwater aquaculture. At present, antibiotics are the only option for farmers to reduce the losses caused by L. garvieae. However, the usage of antibiotics leads to environmental pollution and the production of drug-resistant strains of bacteria. Therefore, vaccination is preferred as an alternative method to prevent infectious diseases. In this study, we describe an effective approach to the production of an oral biofilm vaccine, using bacteria grown on chitosan particles to form biofilms, and thus providing an inactive pathogen that enhances the immune response in fish. We observed the formation of a biofilm on chitosan particles and administered the novel oral biofilm vaccine to fish. We analyzed the immune responses, including antibody production, phagocytic ability, albumin/globulin ratio and immune-related genes, of vaccinated and control groups of black mullet. Our results show that the phagocytic ability of the biofilm vaccine group was 84%, which is significantly higher than that of the control group, and the antibody production in this group was significantly higher compared with the other group. The mRNA expression levels of immune-related genes (TLR2, IL-1 beta, TNF-alpha) were significantly upregulated in the spleen after vaccination. In challenge experiments, the relative percent survival (RPS) was 77% in the biofilm vaccine group, 18% in the whole-cell vaccine group, and 0% in the chitosan particle group at 32 days post-vaccination. In addition, we also found that the relative percent survival (RPS) at 1 day post-vaccination was 74% in the biofilm vaccine group, 42% in the whole-cell vaccine group, and 26% in the chitosan particle group. In both long-term and short-term challenge experiments, the viability of the biofilm vaccine group was significantly higher than that of the whole-cell, chitosan particle and PBS groups. We conclude that based on its protective effect, the L. garvieae biofilm vaccine is better than the whole-cell vaccine when challenged several weeks after vaccination. In addition, the biofilm vaccine also has a greater protective effect than the whole-cell vaccine when challenged immediately after vaccination. Therefore, the biofilm vaccine might represent a novel method for the prevention and treatment of L. garvieae infection.	[Su, Feng-Jie; Chen, Meei-Mei] Natl Taiwan Univ, Dept Vet Med, 1,Sect 4,Roosevelt Rd, Taipei 10617, Taiwan		Chen, MM (通讯作者)，Natl Taiwan Univ, Dept Vet Med, 1,Sect 4,Roosevelt Rd, Taipei 10617, Taiwan.	d06629003@ntu.edu.tw; cmm@ntu.edu.tw		FENG-JIE, SU/0000-0002-6922-5764	Animal and Plant Health Inspection and Quarantine Bureau of the Agriculture Committee of the Executive Yuan [No.107MG-8.3.2-B1(2), 108-2926-I-002-002-MY4]; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan	This work was funded by the Animal and Plant Health Inspection and Quarantine Bureau of the Agriculture Committee of the Executive Yuan (Grant No.107MG-8.3.2-B1(2)). This article was subsidised for English editing by National Taiwan University under the Excellence Improvement Program for Doctoral Students (Grant No. 108-2926-I-002-002-MY4), sponsored by the Ministry of Science and Technology, Taiwan.	Anderson DP, 1997, DEV BIOLOGICALS, V90, P257; Azad IS, 1999, FISH SHELLFISH IMMUN, V9, P519, DOI 10.1006/fsim.1998.0206; Azad IS, 2000, DIS AQUAT ORGAN, V43, P103, DOI 10.3354/dao043103; BENTON KA, 1995, INFECT IMMUN, V63, P448, DOI 10.1128/IAI.63.2.448-455.1995; Byadgi O, 2016, FISH SHELLFISH IMMUN, V58, P593, DOI 10.1016/j.fsi.2016.10.006; Chen SC, 2002, J FISH DIS, V25, P727, DOI 10.1046/j.1365-2761.2002.00415.x; Clay H, 2008, IMMUNITY, V29, P283, DOI 10.1016/j.immuni.2008.06.011; Corsini B, 2016, VACCINE, V34, P6148, DOI 10.1016/j.vaccine.2016.11.001; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DAVIDSON GA, 1993, DEV COMP IMMUNOL, V17, P373, DOI 10.1016/0145-305X(93)90008-E; Evans JJ, 2009, J FISH DIS, V32, P943, DOI 10.1111/j.1365-2761.2009.01075.x; Fan ZJ, 2015, FISH SHELLFISH IMMUN, V44, P129, DOI 10.1016/j.fsi.2015.01.037; Firdaus-Nawi M, 2013, AQUAC RES, V45, P87, DOI 10.1111/j.1365-2109.2012.03207.x; Forchielli ML, 2005, BRIT J NUTR, V93, pS41, DOI 10.1079/BJN20041356; Halimi M, 2019, FISH SHELLFISH IMMUN, V90, P431, DOI 10.1016/j.fsi.2019.05.020; JENKINS PG, 1994, FISH SHELLFISH IMMUN, V4, P167, DOI 10.1006/fsim.1994.1016; Kahieshesfandiari M, 2019, AQUACULT INT, V27, P817, DOI 10.1007/s10499-019-00372-8; Kaur B, 2021, FISH SHELLFISH IMMUN, V114, P132, DOI 10.1016/j.fsi.2021.04.019; Kitiyodom S, 2021, FISH SHELLFISH IMMUN, V112, P81, DOI 10.1016/j.fsi.2021.02.017; Kitiyodom S, 2019, FISH SHELLFISH IMMUN, V95, P213, DOI 10.1016/j.fsi.2019.09.064; Le KY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00359; Loera-Muro A, 2021, EXPERT REV VACCINES, V20, P385, DOI 10.1080/14760584.2021.1892492; Mao ZJ, 2013, FISH SHELLFISH IMMUN, V35, P375, DOI 10.1016/j.fsi.2013.04.030; Mckenney D, 2000, J BIOTECHNOL, V83, P37, DOI 10.1016/S0168-1656(00)00296-0; Mutoloki S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00519; Nayak DK, 2004, FISH SHELLFISH IMMUN, V16, P613, DOI 10.1016/j.fsi.2003.09.012; Oushani AK, 2020, FISH SHELLFISH IMMUN, V98, P210, DOI 10.1016/j.fsi.2020.01.016; Park KH, 1996, AQUACULTURE, V143, P135, DOI 10.1016/0044-8486(95)01224-9; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Patel Prittesh, 2020, Biotechnology Reports, V28, pe00555, DOI 10.1016/j.btre.2020.e00555; Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007; Ram MK, 2019, FISH SHELLFISH IMMUN, V94, P746, DOI 10.1016/j.fsi.2019.09.053; Ranjan R, 2014, AQUAC RES, V45, P983, DOI 10.1111/are.12050; Rao S, 2020, J FISH DIS, V43, P1579, DOI 10.1111/jfd.13260; Rombout JHWM, 2014, FISH VACCINATION, P56; Sanchez CJ, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-245; Siripornadulsil S, 2007, ADV EXP MED BIOL, V616, P122; Siriyappagouder P, 2014, FISH SHELLFISH IMMUN, V41, P581, DOI 10.1016/j.fsi.2014.09.021; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029; Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794; Tian JY, 2008, VET IMMUNOL IMMUNOP, V126, P220, DOI 10.1016/j.vetimm.2008.07.002; Tote K, 2008, LETT APPL MICROBIOL, V46, P249, DOI 10.1111/j.1472-765X.2007.02298.x; Vendrell D, 2006, COMP IMMUNOL MICROB, V29, P177, DOI 10.1016/j.cimid.2006.06.003; Viji VT, 2013, DIS AQUAT ORGAN, V104, P45, DOI 10.3354/dao02581; Vinay T. N., 2016, Indian Journal of Comparative Microbiology, Immunology and Infectious Diseases, V37, P57; Watters C, 2016, PROG MOL BIOL TRANSL, V142, P193, DOI 10.1016/bs.pmbts.2016.05.007; WONG G, 1992, IMMUNOL INVEST, V21, P353, DOI 10.3109/08820139209069375; Yin Z, 2000, FISH SHELLFISH IMMUN, V10, P375, DOI 10.1006/fsim.1999.0241; Zhang J, 2014, FISH SHELLFISH IMMUN, V41, P380, DOI 10.1016/j.fsi.2014.09.022; Zlotkin A, 1998, J CLIN MICROBIOL, V36, P983, DOI 10.1128/JCM.36.4.983-985.1998	51	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							844	10.3390/vaccines9080844			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5LW	34451969	gold, Green Published			2022-04-29	WOS:000689973200001
J	Wi, YM; Kim, SH; Peck, KR				Wi, Yu-Mi; Kim, Si-Ho; Peck, Kyong-Ran			Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers	VACCINES			English	Article						coronavirus disease 2019; vaccine; adverse event; BNT162b2 mRNA vaccine; AZD1222 vaccines		Mass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and systemic reactions for 7 days after each dose, respectively. A total of 80 and 1440 healthcare workers received two doses of BNT162b2 and a first dose of AZD1222 vaccines. Any AEs were reported by 52.5% of recipients after the first dose of BNT162b2, by 76.2% after the second dose of BNT162b2, and by 90.9% after the first dose of AZD1222 (p < 0.001). Younger vaccinees had more AEs after the second dose of BNT162b2 and first dose of AZD1222. Sex based differences were only observed in the AZD1222 recipient group. No incidence of anaphylaxis or neurologic AEs were observed. In conclusion, early AEs were mostly mild to moderate in severity and generally transient in both BNT162b2 and AZD1222 groups. Sufficient explanation of the expected AEs of the vaccine would be helpful for wider vaccination.	[Wi, Yu-Mi; Kim, Si-Ho] Sungkyunkwan Univ, Samsung Changwon Hosp, Div Infect Dis, Chang Won 51353, South Korea; [Peck, Kyong-Ran] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Infect Dis, Seoul 06351, South Korea		Peck, KR (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Infect Dis, Seoul 06351, South Korea.	yrhg95@naver.com; wychhazel@naver.com; krpeck@skku.edu	Peck, Kyong Ran/AGV-5205-2022	Peck, Kyong Ran/0000-0002-7464-9780; Kim, Si-Ho/0000-0001-7763-8940; Wi, Yu Mi/0000-0003-3625-3328			Centers for Disease Control and Prevention, COVID 19; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Cines DB, 2021, NEW ENGL J MED, V384, P2254, DOI 10.1056/NEJMe2106315; European Medicines Agency, COVID 19 PAND; Jung J, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e59; Kim SH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e107; Korea Disease Control and Prevention Agency, UPD COVID 19 VACC; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lee YW, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e153; Longchamps C, 2021, VACCINE, V39, P3315, DOI 10.1016/j.vaccine.2021.05.012; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967	15	5	5	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							931	10.3390/vaccines9080931			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8JU	34452055	gold, Green Published			2022-04-29	WOS:000690170600001
J	Montes-Grajales, D; Olivero-Verbel, J				Montes-Grajales, Diana; Olivero-Verbel, Jesus			Bioinformatics Prediction of SARS-CoV-2 Epitopes as Vaccine Candidates for the Colombian Population	VACCINES			English	Article						severe acute respiratory syndrome; immuno-informatics; HLA; vaccine design; T-cell epitope; peptide; interaction; immunogenicity	T-CELL-RECEPTOR; MOLECULES; DYNAMICS; PROTEIN; DRUG	Coronavirus disease (COVID-19) pandemic caused by the coronavirus SARS-CoV-2 represents an enormous challenge to global public health, with thousands of infections and deaths in over 200 countries worldwide. The purpose of this study was to identify SARS-CoV-2 epitopes with potential to interact in silico with the alleles of the human leukocyte antigen class I (HLA I) and class II (HLA II) commonly found in the Colombian population to promote both CD4 and CD8 immune responses against this virus. The generation and evaluation of the peptides in terms of HLA I and HLA II binding, immune response, toxicity and allergenicity were performed by using computer-aided tools, such as NetMHCpan 4.1, NetMHCIIpan 4.0, VaxiJem, ToxinPred and AllerTop. Furthermore, the interaction between the predicted epitopes with HLA I and HLA II proteins frequently found in the Colombian population was studied through molecular docking simulations in AutoDock Vina and interaction analysis in LigPlot+. One of the promising peptides proposed in this study is the HLA I epitope YQPYRVVVL, which displayed an estimated coverage of over 82% and 96% for the Colombian and worldwide population, respectively. These findings could be useful for the design of new epitope-vaccines that include Colombia among their population target.	[Montes-Grajales, Diana; Olivero-Verbel, Jesus] Univ Cartagena, Sch Pharmaceut Sci, Environm & Computat Chem Grp, Zaragocilla Campus, Cartagena 130015, Colombia		Olivero-Verbel, J (通讯作者)，Univ Cartagena, Sch Pharmaceut Sci, Environm & Computat Chem Grp, Zaragocilla Campus, Cartagena 130015, Colombia.	dmontesg@unicartagena.edu.co; joliverov@unicartagena.edu.co		Olivero-Verbel, Jesus/0000-0003-3089-5872	Ministry of Science, Technology and Innovation of Colombia (Minciencias); Sistema General de Regalias; University of Cartagena [BPIN 2020000100093]	This research was funded by the Ministry of Science, Technology and Innovation of Colombia (Minciencias), Sistema General de Regalias, and the University of Cartagena (Grant BPIN 2020000100093, Gobernacion de Bolivar).	Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Acter T, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138996; Al-Rohaimi AH, 2020, GENES DIS, V7, P491, DOI 10.1016/j.gendis.2020.06.004; Anand R, 2020, PEERJ, V8, DOI 10.7717/peerj.9855; [Anonymous], 2019, R COR DEV TEAM R R COR DEV TEAM R; Arnaiz-Villena A, 2018, HUM IMMUNOL, V79, P530, DOI 10.1016/j.humimm.2018.04.016; Arnaiz-Villena A, 2018, HUM IMMUNOL, V79, P189, DOI 10.1016/j.humimm.2018.02.004; Ashik AI, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04865; Paez-Gutierrez IA, 2019, HUM IMMUNOL, V80, P425, DOI 10.1016/j.humimm.2019.03.006; Bachmann MF, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00264-6; Bahrami M, 2020, PHYTOTHER RES, V34, P2429, DOI 10.1002/ptr.6776; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004; Chen HZ, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00713-3; Chen ZW, 2021, J CELL MOL MED, V25, P1274, DOI 10.1111/jcmm.16200; Diao B, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2020.09.057; Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4; Dobano C, 2021, TRANSL RES, V232, P60, DOI 10.1016/j.trsl.2021.02.006; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Galanakis CM, 2020, FOODS, V9, DOI 10.3390/foods9040523; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Tan HX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21665-8; Ita K, 2021, ARCH MED RES, V52, P15, DOI 10.1016/j.arcmed.2020.09.010; Karwaciak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010054; Kiyotani K, 2020, J HUM GENET, V65, P569, DOI 10.1038/s10038-020-0771-5; Knapp B, 2016, J CHEM INF MODEL, V56, P46, DOI 10.1021/acs.jcim.5b00511; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lim HX, 2021, BIOMED J, V44, P18, DOI 10.1016/j.bj.2020.09.005; Lu S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20768-y; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Ambrose JM, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10050535; Mandala VS, 2020, NAT STRUCT MOL BIOL, V27, P1202, DOI 10.1038/s41594-020-00536-8; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Painter CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002403; Pooladanda V, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117765; Poran A, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00767-w; Rastogi M, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01581-z; Requena D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02008; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Satarker S, 2020, ARCH MED RES, V51, P482, DOI 10.1016/j.arcmed.2020.05.012; Single RM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241282; Smith KD, 1997, IMMUNOL RES, V16, P243, DOI 10.1007/BF02786393; Sohail MS, 2021, ADV DRUG DELIVER REV, V171, P29, DOI 10.1016/j.addr.2021.01.007; Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419; Thomas S., 2020, PATHOG IMMUN, V5, P342, DOI 10.20411/pai.v5i1.377; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009; van Deutekom HWM, 2015, IMMUNOGENETICS, V67, P425, DOI 10.1007/s00251-015-0849-y; Veldhoen M, 2021, NAT REV IMMUNOL, V21, P131, DOI 10.1038/s41577-020-00493-9; Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277; Warnes G.R., 2019, GPLOTS VARIOUS R PRO, V2, P1; WHO, **NON-TRADITIONAL**; World Health Organization, TRACK SARS COV 2 VAR TRACK SARS COV 2 VAR; Yao X., 2020, NAT IMMUNOL, V21, P1336, DOI [DOI 10.1038/s41590-020-0782-6, 10.1038/s41590-020-0782-6]	56	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							797	10.3390/vaccines9070797			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5ES	34358213	gold, Green Published			2022-04-29	WOS:000676935300001
J	Warner, NL; Frietze, KM				Warner, Nikole L.; Frietze, Kathryn M.			Development of Bacteriophage Virus-Like Particle Vaccines Displaying Conserved Epitopes of Dengue Virus Non-Structural Protein 1	VACCINES			English	Article						dengue virus; non-structural protein 1; vaccine; bacteriophage; virus-like particle; VLP; immunization; ELISA; epitope	INFECTED VERO; DNA VACCINE; NS1; ANTIBODIES; MICE; GLYCOPROTEINS; ENCEPHALITIS; IMMUNIZATION	Dengue virus (DENV) is a major global health problem, with over half of the world's population at risk of infection. Despite over 60 years of efforts, no licensed vaccine suitable for population-based immunization against DENV is available. Here, we describe efforts to engineer epitope-based vaccines against DENV non-structural protein 1 (NS1). NS1 is present in DENV-infected cells as well as secreted into the blood of infected individuals. NS1 causes disruption of endothelial cell barriers, resulting in plasma leakage and hemorrhage. Immunizing against NS1 could elicit antibodies that block NS1 function and also target NS1-infected cells for antibody-dependent cell cytotoxicity. We identified highly conserved regions of NS1 from all four DENV serotypes. We generated synthetic peptides to these regions and chemically conjugated them to bacteriophage Q beta virus-like particles (VLPs). Mice were immunized two times with the candidate vaccines and sera were tested for the presence of antibodies that bound to the cognate peptide, recombinant NS1 from all four DENV serotypes, and DENV-2-infected cells. We found that two of the candidate vaccines elicited antibodies that bound to recombinant NS1, and one candidate vaccine elicited antibodies that bound to DENV-infected cells. These results show that an epitope-specific vaccine against conserved regions of NS1 could be a promising approach for DENV vaccines or therapeutics to bind circulating NS1 protein.	[Warner, Nikole L.; Frietze, Kathryn M.] Univ New Mexico Hlth Sci, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; [Frietze, Kathryn M.] Univ New Mexico Hlth Sci, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA		Frietze, KM (通讯作者)，Univ New Mexico Hlth Sci, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA.; Frietze, KM (通讯作者)，Univ New Mexico Hlth Sci, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA.	nlwarner@salud.unm.edu; kfrietze@salud.unm.edu			National Institutes of Allergy and Infectious DiseaseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI148836]; University of New Mexico School of Medicine Research Allocation Committee; National Center for Advancing Translational Science [KL2 TR001448, UL1TR001449]; ASERT Fellowship [K12 GM088021]; Biology of Infectious Disease and Inflammation Fellowship [T32AI007538]; UNM Comprehensive Cancer Center [NCI P30CA118100]	This work was funded by the National Institutes of Allergy and Infectious Disease, grant number R21AI148836 to KMF, the University of New Mexico School of Medicine Research Allocation Committee Grant to KMF, and the National Center for Advancing Translational Science (KL2 TR001448, UL1TR001449). NLW was previously supported by the ASERT Fellowship (K12 GM088021) and currently funded by the Biology of Infectious Disease and Inflammation Fellowship (T32AI007538). This research was partially supported by UNM Comprehensive Cancer Center Support Grant NCI P30CA118100 and made use of the Fluorescence Microscopy and Cell Imaging shared resource.	Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749; Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034; Beatty PR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3787; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Caldeira JD, 2010, VACCINE, V28, P4384, DOI 10.1016/j.vaccine.2010.04.049; Chao CH, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007625; Chen HR, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0462-0; Chen HR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004828; Chen MC, 2009, J IMMUNOL, V183, P1797, DOI 10.4049/jimmunol.0800672; Cheng HJ, 2009, MOL IMMUNOL, V47, P398, DOI 10.1016/j.molimm.2009.08.033; Chu YT, 2017, LAB INVEST, V97, P602, DOI 10.1038/labinvest.2017.10; Chuang YC, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-42; Chuang YC, 2011, CYTOKINE, V54, P222, DOI 10.1016/j.cyto.2011.01.013; Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052; Costa SM, 2006, VACCINE, V24, P4562, DOI 10.1016/j.vaccine.2005.08.022; Crill WD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004991; Crossey E, 2015, VACCINE, V33, P5747, DOI 10.1016/j.vaccine.2015.09.044; Donaldson B, 2018, EXPERT REV VACCINES, V17, P833, DOI 10.1080/14760584.2018.1516552; Falconar AKI, 1997, ARCH VIROL, V142, P897, DOI 10.1007/s007050050127; Falconar AKI, 2007, CLIN VACCINE IMMUNOL, V14, P493, DOI 10.1128/CVI.00371-06; Falgout B, 1990, J VIROL, V64, P8; Frietze KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171511; Frietze KM, 2016, CURR OPIN VIROL, V18, P44, DOI 10.1016/j.coviro.2016.03.001; Glasner DR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006673; Goncalves AJS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004277; Gutsche I, 2011, P NATL ACAD SCI USA, V108, P8003, DOI 10.1073/pnas.1017338108; Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9; Halstead SB, 2018, HUM VACC IMMUNOTHER, V14, P2158, DOI 10.1080/21645515.2018.1445448; HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101; Hertz T, 2017, J IMMUNOL, V198, P4025, DOI 10.4049/jimmunol.1700029; Jelinkova L, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00274-4; Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08; Lai CY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002451; Lai YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07308-3; Lin CF, 2008, LAB INVEST, V88, P1079, DOI 10.1038/labinvest.2008.70; Lin HE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001447; Lin YS, 2011, EXP BIOL MED, V236, P515, DOI 10.1258/ebm.2011.010339; Liu IJ, 2011, J BIOL CHEM, V286, P9726, DOI 10.1074/jbc.M110.170993; Maphis NM, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0118-4; MASON PW, 1989, VIROLOGY, V169, P354, DOI 10.1016/0042-6822(89)90161-X; Messina JP, 2019, NAT MICROBIOL, V4, P1508, DOI 10.1038/s41564-019-0476-8; Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863; Mogus AT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040765; O'Rourke JP, 2015, CURR OPIN VIROL, V11, P76, DOI 10.1016/j.coviro.2015.03.005; Puerta-Guardo H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005738; SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853; SMITH GW, 1985, J GEN VIROL, V66, P559, DOI 10.1099/0022-1317-66-3-559; SRIVASTAVA AK, 1995, VACCINE, V13, P1251, DOI 10.1016/0264-410X(94)00059-V; Stanaway JD, 2016, LANCET INFECT DIS, V16, P712, DOI 10.1016/S1473-3099(16)00026-8; Sun DS, 2007, J THROMB HAEMOST, V5, P2291, DOI 10.1111/j.1538-7836.2007.02754.x; Tumban E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023310; Wahala WMPB, 2009, VIROLOGY, V392, P103, DOI 10.1016/j.virol.2009.06.037; Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374; Wan SW, 2017, J IMMUNOL, V199, P2834, DOI 10.4049/jimmunol.1601523; Wan SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092495; Wang CL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007938; Warner NL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101114; WESTAWAY EG, 1987, ARCH VIROL, V94, P215, DOI 10.1007/BF01310715; WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4; Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4	60	2	2	6	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							726	10.3390/vaccines9070726			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6SM	34358143	Green Published			2022-04-29	WOS:000677038700001
J	Guerrini, G; Vivi, A; Gioria, S; Ponti, J; Magri, D; Hoeveler, A; Medaglini, D; Calzolai, L				Guerrini, Giuditta; Vivi, Antonio; Gioria, Sabrina; Ponti, Jessica; Magri, Davide; Hoeveler, Arnd; Medaglini, Donata; Calzolai, Luigi			Physicochemical Characterization Cascade of Nanoadjuvant-Antigen Systems for Improving Vaccines	VACCINES			English	Article						adjuvants; antigens; characterization; vaccines	ALUMINUM; ADJUVANT; ADSORPTION; STABILITY; MODEL; ACTIVATION; OVALBUMIN	Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based adjuvants. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate physicochemical characterization of the nanoaluminum-ovalbumin complex. Using a combination of existing techniques, we developed a multi-staged characterization strategy based on measurements of increased complexity. This characterization cascade has the advantage of being very flexible and easily adaptable to any adjuvant-protein antigen combinations. It will contribute to control the quality of antigen-adjuvant complexes and immunological outcomes, ultimately leading to improved vaccines.	[Guerrini, Giuditta; Vivi, Antonio; Medaglini, Donata] Univ Siena, Dept Med Biotechnol, Lab Mol Microbiol & Biotechnol, I-53100 Siena, Italy; [Gioria, Sabrina; Ponti, Jessica; Magri, Davide; Hoeveler, Arnd; Calzolai, Luigi] European Commiss, Joint Res Ctr JRC, I-21027 Ispra, Italy		Calzolai, L (通讯作者)，European Commiss, Joint Res Ctr JRC, I-21027 Ispra, Italy.	guerrini12@student.unisi.it; antonio.vivi@unisi.it; Sabrina.GIORIA@ec.europa.eu; Jessica.PONTI@ec.europa.eu; Davide.MAGRI@ec.europa.eu; Arnd.Hoeveler@ec.europa.eu; donata.medaglini@unisi.it; luigi.calzolai@ec.europa.eu	MEDAGLINI, DONATA/R-1149-2018	MEDAGLINI, DONATA/0000-0003-1729-7325; Magri, Davide/0000-0003-3790-5332; Guerrini, Giuditta/0000-0002-1446-0556	EC Joint Research Centre Exploratory Research program under the project "NanoMicrobials"; EC Seventh Framework Programme under the project ADITEC [HEALTH-2011-280873]; Horizon 2020 Framework Programme under the project TRANSVAC [730694]	This research was partly funded by the EC Joint Research Centre Exploratory Research program under the project "NanoMicrobials" and by the EC Seventh Framework Programme under the project ADITEC (grant number HEALTH-2011-280873) and Horizon 2020 Framework Programme under the project TRANSVAC (grant number 730694).	ALSHAKHSHIR R, 1994, VACCINE, V12, P472, DOI 10.1016/0264-410X(94)90127-9; [Anonymous], ADJUVANTS VACCINES V; Betts JN, 2013, ENVIRON TOXICOL CHEM, V32, P889, DOI 10.1002/etc.2123; Calzolai L, 2012, ACS SYM SER, V1120, P839; Capomaccio R, 2015, NANOSCALE, V7, P17653, DOI 10.1039/c5nr05147a; Clapp T, 2011, J PHARM SCI-US, V100, P388, DOI 10.1002/jps.22284; Courtenay AJ, 2019, MOL PHARMACEUT, V16, P118, DOI 10.1021/acs.molpharmaceut.8b00895; Deng ZJ, 2011, NAT NANOTECHNOL, V6, P39, DOI [10.1038/nnano.2010.250, 10.1038/NNANO.2010.250]; Farjadian F, 2019, NANOMEDICINE-UK, V14, P93, DOI 10.2217/nnm-2018-0120; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; HogenEsch H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00406; Huntington JA, 2001, J CHROMATOGR B, V756, P189, DOI 10.1016/S0378-4347(01)00108-6; Iyer V, 2012, J PHARM SCI-US, V101, P3078, DOI 10.1002/jps.23175; Jones LS, 2005, J BIOL CHEM, V280, P13406, DOI 10.1074/jbc.M500687200; KIM JH, 1995, BIOL PHARM BULL, V18, P854; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Laera S, 2011, NANO LETT, V11, P4480, DOI 10.1021/nl202909s; Li XR, 2014, J CONTROL RELEASE, V173, P148, DOI 10.1016/j.jconrel.2013.10.032; Mahony D, 2013, SMALL, V9, P3138, DOI 10.1002/smll.201300012; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Micsonai A, 2018, NUCLEIC ACIDS RES, V46, pW315, DOI 10.1093/nar/gky497; Murdaca G, 2014, AUTOIMMUN REV, V13, P75, DOI 10.1016/j.autrev.2013.07.007; O'Hagan DT, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101426; Orr MT, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-018-0094-0; Regnier M, 2012, VACCINE, V30, P6783, DOI 10.1016/j.vaccine.2012.09.020; Scheiblhofer S, 2017, EXPERT REV VACCINES, V16, P479, DOI 10.1080/14760584.2017.1306441; Singh A, 2021, NAT NANOTECHNOL, V16, P16, DOI 10.1038/s41565-020-00790-3; Sokolovska A, 2007, VACCINE, V25, P4575, DOI 10.1016/j.vaccine.2007.03.045; Ting BPCP, 2010, WOODHEAD PUBL FOOD S, P595, DOI 10.1533/9780857090751.2.595; Wang Y, 2015, CURR PHARM DESIGN, V21, P1831, DOI 10.2174/1381612821666150302113906; Watad A, 2018, CLIN RHEUMATOL, V37, P483, DOI 10.1007/s10067-017-3748-9; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371	34	0	0	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							544	10.3390/vaccines9060544			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA0CB	34064212	Green Published, gold			2022-04-29	WOS:000666922300001
J	Koj, S; Ucieklak, K; Lugowski, C; Niedziela, T				Koj, Sabina; Ucieklak, Karolina; Lugowski, Czeslaw; Niedziela, Tomasz			Structure and Immunogenicity of the Bordetella pertussis LOS-Derived Oligosaccharides in the Endosomal-Like Pre-Processing Mice Model	VACCINES			English	Article						Bordetella pertussis; lipooligosaccharide; core oligosaccharide; neoglycoconjugates; endosomal glycan processing; reactive nitrogen species; vaccine design	GROUP-B; LIPOPOLYSACCHARIDE; VACCINE; LIPOOLIGOSACCHARIDE; POLYSACCHARIDE; ANTIBODIES; ENDOTOXIN; RESPONSES; EPITOPES	Glycoproteins are processed endosomally prior to presentation to T cells and subsequent induction of specific antibodies. The sugar part of glycoconjugate may be degraded while the type of the process depends on the features of the particular structure. The generated carbohydrate epitopes may differ from native structures and influence immunogenicity of the antigens. We have devised a model of endosomal-like pre-processing of Bordetella pertussis 186 oligosaccharides (OSs) to verify how it affects the immunogenicity of their conjugates. The glycoconjugates of structurally defined forms of the dodecasaccharide OS were synthesized and their immunogenicity was assessed using immunochemical methods. The structural features of the oligosaccharides and their sensitivity to deamination were analyzed by NMR spectroscopy. The distal trisaccharide-comprising pentasaccharide conjugated to a protein was the most effective in inducing immune response against the B. pertussis 186 LOS and the immune response to the complete OS conjugates was significantly lower. This could be explained by the loss of the distal trisaccharide during the in-cell deamination process suggesting that the native structure is not optimal for a vaccine antigen. Consequently, our research has shown that designing of new glycoconjugate vaccines requires the antigen structures to be verified in context of possible endosomal reactions beforehand.	[Koj, Sabina; Ucieklak, Karolina; Lugowski, Czeslaw; Niedziela, Tomasz] Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland		Niedziela, T (通讯作者)，Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland.	sabina.koj@hirszfeld.pl; karolina.ucieklak@hirszfeld.pl; czeslaw.lugowski@hirszfeld.pl; tomasz.niedziela@hirszfeld.pl		Koj, Sabina/0000-0003-4615-9570; Ucieklak, Karolina/0000-0003-4067-4379; Niedziela, Tomasz/0000-0002-9333-3175; Lugowski, Czeslaw/0000-0002-2336-0530	National Science Centre (NCN), PolandNational Science Centre, Poland [2013/09/N/NZ6/03488]	This research was funded by the National Science Centre (NCN), Poland, grant number. 2013/09/N/NZ6/03488 (Preludium 5).	AlBitar-Nehme S, 2013, CARBOHYD RES, V378, P56, DOI 10.1016/j.carres.2013.05.002; Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535; AYME G, 1980, INFECT IMMUN, V27, P739, DOI 10.1128/IAI.27.3.739-745.1980; Baldridge JR, 1999, METHODS, V19, P103, DOI 10.1006/meth.1999.0834; CAROFF M, 1990, J BACTERIOL, V172, P1121, DOI 10.1128/jb.172.2.1121-1128.1990; Caroff M, 2000, FEBS LETT, V477, P8, DOI 10.1016/S0014-5793(00)01720-8; Centers for Disease Control and Prevention, 2015, PINK BOOK COURS TEXT, V13th; Cherry JD, 2012, PEDIATRICS, V129, P968, DOI 10.1542/peds.2011-2594; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; de Gouw D, 2011, FEMS MICROBIOL REV, V35, P441, DOI 10.1111/j.1574-6976.2010.00257.x; Di Mattia G, 2019, PAEDIATR RESPIR REV, V29, P68, DOI 10.1016/j.prrv.2018.03.011; Duan JY, 2008, P NATL ACAD SCI USA, V105, P5183, DOI 10.1073/pnas.0800974105; Duan JY, 2011, GLYCOBIOLOGY, V21, P401, DOI 10.1093/glycob/cwq171; Esposito S, 2018, J Prev Med Hyg, V59, pE177, DOI 10.15167/2421-4248/jpmh2018.59.3.1041; Esposito S, 2018, HUM VACC IMMUNOTHER, V14, P2452, DOI 10.1080/21645515.2018.1480298; Flak TA, 2000, INFECT IMMUN, V68, P1235, DOI 10.1128/IAI.68.3.1235-1242.2000; Flak TA, 1999, CELL MICROBIOL, V1, P51, DOI 10.1046/j.1462-5822.1999.00004.x; JENNINGS HJ, 1984, INFECT IMMUN, V43, P407, DOI 10.1128/IAI.43.1.407-412.1984; JENNINGS HJ, 1981, J IMMUNOL, V127, P1011; Klein NP, 2019, HUM VACC IMMUNOTHER, V15, P809, DOI 10.1080/21645515.2018.1549449; Klein NP, 2013, PEDIATRICS, V131, pE1716, DOI 10.1542/peds.2012-3836; Kneller D., 2001, SPARKY; Kubler-Kielb J, 2011, P NATL ACAD SCI USA, V108, P4087, DOI 10.1073/pnas.1100782108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBlay K, 1996, MICROBIOL-SGM, V142, P971, DOI 10.1099/00221287-142-4-971; Lugowski C, 2018, U.S. Patent, Patent No. [9,878,051, 9878051]; Maaheimo H, 2000, BIOCHEMISTRY-US, V39, P12778, DOI 10.1021/bi000780o; Mbayei SA, 2019, CLIN INFECT DIS, V69, P218, DOI 10.1093/cid/ciy889; Morton T, 2018, CAN FAM PHYSICIAN, V64, pE317; MOUNTZOUROS KT, 1992, INFECT IMMUN, V60, P5316, DOI 10.1128/IAI.60.12.5316-5318.1992; Niedziela T, 2005, INFECT IMMUN, V73, P7381, DOI 10.1128/IAI.73.11.7381-7389.2005; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Ozcengiz E, 2004, VACCINE, V22, P1570, DOI 10.1016/j.vaccine.2003.09.040; Petersson C, 1997, EUR J BIOCHEM, V244, P580, DOI 10.1111/j.1432-1033.1997.00580.x; Rumik Agnieszka, 2018, Przegl Epidemiol, V72, P259, DOI 10.32394/pe.72.3.1; Sadkowska-Todys Mlgorzata, 2018, Przegl Epidemiol, V72, P129; Skoff TH, 2019, CLIN INFECT DIS, V68, P1634, DOI 10.1093/cid/ciy757; STAINER DW, 1970, J GEN MICROBIOL, V63, P211, DOI 10.1099/00221287-63-2-211; Sun XM, 2019, P NATL ACAD SCI USA, V116, P193, DOI 10.1073/pnas.1816401115; Tefon BE, 2011, VACCINE, V29, P3583, DOI 10.1016/j.vaccine.2011.02.086; Trollfors B, 2001, CLIN DIAGN LAB IMMUN, V8, P1015, DOI 10.1128/CDLI.8.5.1015-1017.2001; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VOLLER A, 1975, LANCET, V1, P426; WATANABE M, 1990, J GEN MICROBIOL, V136, P489, DOI 10.1099/00221287-136-3-489; Weiss AA, 2004, INFECT IMMUN, V72, P7346, DOI 10.1128/IAI.72.12.7346-7351.2004; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83	46	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							645	10.3390/vaccines9060645			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0BK	34199173	Green Published, gold			2022-04-29	WOS:000666242000001
J	Munz, C				Munz, Christian			Natural Killer Cell Responses during Human gamma-Herpesvirus Infections	VACCINES			English	Review						Epstein-Barr virus (EBV); Kaposi sarcoma associated herpesvirus (KSHV); NKG2D; NKG2A; DNAM-1	BARR-VIRUS INFECTION; LINKED LYMPHOPROLIFERATIVE-DISEASE; CD56(NEG)CD16(POS) NK CELLS; CLASSIC KAPOSI-SARCOMA; CD8(+) T-CELLS; EBV INFECTION; KSHV INFECTION; B-CELLS; CYTOMEGALOVIRUS-INFECTION; PRIMARY IMMUNODEFICIENCY	Herpesviruses are main sculptors of natural killer (NK) cell repertoires. While the beta-herpesvirus human cytomegalovirus (CMV) drives the accumulation of adaptive NKG2C-positive NK cells, the human gamma-herpesvirus Epstein-Barr virus (EBV) expands early differentiated NKG2A-positive NK cells. While adaptive NK cells support adaptive immunity by antibody-dependent cellular cytotoxicity, NKG2A-positive NK cells seem to preferentially target lytic EBV replicating B cells. The importance of this restriction of EBV replication during gamma-herpesvirus pathogenesis will be discussed. Furthermore, the modification of EBV-driven NK cell expansion by coinfections, including by the other human gamma-herpesvirus Kaposi sarcoma-associated herpesvirus (KSHV), will be summarized.	[Munz, Christian] Univ Zurich, Inst Expt Immunol, Viral Immunobiol, CH-8057 Zurich, Switzerland		Munz, C (通讯作者)，Univ Zurich, Inst Expt Immunol, Viral Immunobiol, CH-8057 Zurich, Switzerland.	christian.muenz@uzh.ch		Munz, Christian/0000-0001-6419-1940	Cancer Research Switzerland [KFS4091-02-2017, KFS-4962-02-2020]; Cancer Research Center Zurich; Vontobel Foundation; Sobek Foundation; Swiss Vaccine Research Institute; RocheRoche Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [310030B_182827, 310030L_197952/1, CRSII5_180323]; NovartisNovartis; KFSP-PrecisionMS and HMZ ImmunoTargET of the University of Zurich	Research in the author's laboratory is funded by Cancer Research Switzerland (KFS4091-02-2017 and KFS-4962-02-2020), KFSP-PrecisionMS and HMZ ImmunoTargET of the University of Zurich, the Cancer Research Center Zurich, the Vontobel Foundation, the Sobek Foundation, the Swiss Vaccine Research Institute, Roche, Novartis, and the Swiss National Science Foundation (310030B_182827, 310030L_197952/1 and CRSII5_180323).	Aavikko M, 2015, J INFECT DIS, V211, P1842, DOI 10.1093/infdis/jiu667; Azzi T, 2014, BLOOD, V124, P2533, DOI 10.1182/blood-2014-01-553024; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bachanova V, 2016, BIOL BLOOD MARROW TR, V22, P1602, DOI 10.1016/j.bbmt.2016.05.016; Balfour HH, 2013, J INFECT DIS, V207, P80, DOI 10.1093/infdis/jis646; Bekerman E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003748; Beldi-Ferchiou A, 2016, ONCOTARGET, V7, P72961, DOI 10.18632/oncotarget.12150; Beziat V, 2013, BLOOD, V121, P2678, DOI 10.1182/blood-2012-10-459545; Beziat V, 2012, EUR J IMMUNOL, V42, P447, DOI 10.1002/eji.201141826; Bigi R, 2018, P NATL ACAD SCI USA, V115, pE11379, DOI 10.1073/pnas.1810128115; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Blackbourn DJ, 2000, AIDS, V14, P1123, DOI 10.1097/00002030-200006160-00009; Booth C, 2011, BLOOD, V117, P53, DOI 10.1182/blood-2010-06-284935; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Brigida I, 2017, J CLIN IMMUNOL, V37, P32, DOI 10.1007/s10875-016-0341-y; Bristol JA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007179; Caduff N, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109056; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Callan MFC, 1996, NAT MED, V2, P906, DOI 10.1038/nm0896-906; Camcioglu Y, 2004, J PEDIATR-US, V144, P519, DOI 10.1016/j.jpeds.2003.11.012; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Cesarman E, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0060-9; Cesarman E, 2014, ANNU REV PATHOL-MECH, V9, P349, DOI 10.1146/annurev-pathol-012513-104656; Chaigne-Delalande B, 2013, SCIENCE, V341, P186, DOI 10.1126/science.1240094; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen J, 2018, NAT MICROBIOL, V3, P172, DOI 10.1038/s41564-017-0081-7; Chijioke O, 2013, CELL REP, V5, P1489, DOI 10.1016/j.celrep.2013.11.041; Chu YY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1341031; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Cohen JI, 2015, J CLIN IMMUNOL, V35, P445, DOI 10.1007/s10875-015-0168-y; Daher M, 2021, BLOOD, V137, P624, DOI 10.1182/blood.2020007748; Damania B, 2019, FEMS MICROBIOL REV, V43, P181, DOI 10.1093/femsre/fuy044; Davis DA, 2017, ONCOTARGET, V8, P50342, DOI 10.18632/oncotarget.17960; Deng Y, 2021, BLOOD, V137, P3225, DOI 10.1182/blood.2020009482; deVries E, 1996, BLOOD, V88, P3022, DOI 10.1182/blood.V88.8.3022.bloodjournal8883022; Dhalla F, 2015, J CLIN IMMUNOL, V35, P112, DOI 10.1007/s10875-014-0116-2; Digitale J.C., 2020, J INFECT DIS, V12, P650028, DOI [10.1093/infdis/jiaa698, DOI 10.1093/INFDIS/JIAA698]; Digitale JC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.650028; Dunmire SK, 2018, J CLIN VIROL, V102, P84, DOI 10.1016/j.jcv.2018.03.001; Dunmire SK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005286; Dupuy S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002486; Eidenschenk C, 2006, AM J HUM GENET, V78, P721, DOI 10.1086/503269; EPSTEIN MA, 1965, J EXP MED, V121, P761, DOI 10.1084/jem.121.5.761; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Faure A, 2019, P NATL ACAD SCI USA, V116, P16519, DOI 10.1073/pnas.1905025116; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455; Forconi CS, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00162; Forconi CS, 2018, BLOOD ADV, V2, P1101, DOI 10.1182/bloodadvances.2017015404; Gabaev I, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108249; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Goedert JJ, 2016, J INFECT DIS, V213, P432, DOI 10.1093/infdis/jiv413; Grier JT, 2012, J CLIN INVEST, V122, P3769, DOI 10.1172/JCI64837; Guerini FR, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-9; Guma M, 2006, BLOOD, V107, P3624, DOI 10.1182/blood-2005-09-3682; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Hahn AS, 2012, NAT MED, V18, P961, DOI 10.1038/nm.2805; Hemmatazad H, 2021, EXPERT OPIN THER TAR, V25, P311, DOI 10.1080/14728222.2021.1902505; Hendricks DW, 2014, J IMMUNOL, V192, P4492, DOI 10.4049/jimmunol.1303211; Herndler-Brandstetter D, 2017, P NATL ACAD SCI USA, V114, pE9626, DOI 10.1073/pnas.1705301114; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; Ishido S, 2000, IMMUNITY, V13, P365, DOI 10.1016/S1074-7613(00)00036-4; Jawahar S, 1996, CLIN EXP IMMUNOL, V103, P408; Katano H, 2004, BLOOD, V103, P1244, DOI 10.1182/blood-2003-06-2171; Kerbauy LN, 2021, CLIN CANCER RES, V27, P3744, DOI 10.1158/1078-0432.CCR-21-0164; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Labo N, 2019, INT J CANCER, V145, P2468, DOI 10.1002/ijc.32546; Laichalk LL, 2005, J VIROL, V79, P1296, DOI 10.1128/JVI.79.2.1296-1307.2005; Lam JKP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01231; Landtwing V, 2016, J CLIN INVEST, V126, P3772, DOI 10.1172/JCI86923; Latour S, 2019, IMMUNOL REV, V291, P174, DOI 10.1111/imr.12791; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu LL, 2016, CELL REP, V15, P1088, DOI 10.1016/j.celrep.2016.04.005; Luzuriaga K, 2010, NEW ENGL J MED, V362, P1993, DOI 10.1056/NEJMcp1001116; Ma SD, 2012, J VIROL, V86, P7976, DOI 10.1128/JVI.00770-12; Ma SD, 2011, J VIROL, V85, P165, DOI 10.1128/JVI.01512-10; Mace EM, 2019, IMMUNOL REV, V287, P202, DOI 10.1111/imr.12725; Mace EM, 2017, J CLIN INVEST, V127, P306, DOI 10.1172/JCI86276; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Madrid AS, 2012, J VIROL, V86, P8693, DOI 10.1128/JVI.00252-12; Malmberg KJ, 2017, SEMIN IMMUNOL, V31, P20, DOI 10.1016/j.smim.2017.08.002; Mariggio G, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0275; Matthews NC, 2011, EUR J IMMUNOL, V41, P1958, DOI 10.1002/eji.201040661; McHugh D, 2017, CELL HOST MICROBE, V22, P61, DOI 10.1016/j.chom.2017.06.009; Moesta AK, 2020, NAT REV IMMUNOL, V20, P739, DOI 10.1038/s41577-020-0376-4; Munz C, 2019, NAT REV MICROBIOL, V17, P691, DOI 10.1038/s41579-019-0249-7; Mukaida N, 2020, ADV EXP MED BIOL, V1231, P23, DOI 10.1007/978-3-030-36667-4_3; Nachmani D, 2009, CELL HOST MICROBE, V5, P376, DOI 10.1016/j.chom.2009.03.003; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Okuno Y, 2019, NAT MICROBIOL, V4, P404, DOI 10.1038/s41564-018-0334-0; Oluoch PO, 2020, J INFECT DIS, V222, P111, DOI 10.1093/infdis/jiaa060; Pappworth IY, 2007, J VIROL, V81, P474, DOI 10.1128/JVI.01777-06; Parham P, 2003, NAT REV IMMUNOL, V3, P108, DOI 10.1038/nri999; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Quintana MD, 2020, APMIS, V128, P129, DOI 10.1111/apm.13018; Rathmann S, 2010, BIOL BLOOD MARROW TR, V16, P469, DOI 10.1016/j.bbmt.2009.12.008; Rohr J, 2010, HAEMATOL-HEMATOL J, V95, P2080, DOI 10.3324/haematol.2010.029389; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Rostgaard K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226436; Sallah N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17696-2; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Shannon-Lowe C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00713; Shrestha P, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009091; Sin SH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005135; Sirianni MC, 2007, ANN NY ACAD SCI, V1096, P37, DOI 10.1196/annals.1397.068; Sirianni MC, 2005, BRIT J HAEMATOL, V130, P92, DOI 10.1111/j.1365-2141.2005.05581.x; Sirianni MC, 2002, EUR J IMMUNOL, V32, P2711, DOI 10.1002/1521-4141(2002010)32:10<2711::AID-IMMU2711>3.0.CO;2-3; Strowig T, 2010, BLOOD, V116, P4158, DOI 10.1182/blood-2010-02-270678; Sumegi J, 2000, BLOOD, V96, P3118; Sundstrom Y, 2007, SCAND J IMMUNOL, V66, P335, DOI 10.1111/j.1365-3083.2007.01980.x; Tanaka J, 2021, CYTOTHERAPY, DOI [10.1016/j.jcyt.2020.12.007, DOI 10.1016/J.JCYT.2020.12.007]; Tangye SG, 2020, BLOOD, V135, P644, DOI 10.1182/blood.2019000928; Thomas M, 2008, P NATL ACAD SCI USA, V105, P1656, DOI 10.1073/pnas.0707883105; Totonchy J, 2016, CURR OPIN VIROL, V20, P71, DOI 10.1016/j.coviro.2016.09.001; Tsai MH, 2017, ONCOTARGET, V8, P10238, DOI 10.18632/oncotarget.14380; Tsai MH, 2013, CELL REP, V5, P458, DOI 10.1016/j.celrep.2013.09.012; Tsukada N, 1997, J EXP CLIN CANC RES, V16, P171; Tugizov SM, 2003, NAT MED, V9, P307, DOI 10.1038/nm830; Williams H, 2005, BRIT J HAEMATOL, V129, P266, DOI 10.1111/j.1365-2141.2005.05452.x; Williams LR, 2016, J VIROL, V90, P947, DOI 10.1128/JVI.01932-15; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Yamin R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003568; Zhang H, 2018, NAT MICROBIOL, V3, P164, DOI 10.1038/s41564-017-0080-8	127	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							655	10.3390/vaccines9060655			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5MY	34203904	Green Accepted, Green Published, gold			2022-04-29	WOS:000665933100001
J	Rideg, O; Oszter, A; Makk, E; Kalman, E; Farkas, K; Tornoczky, T; Kovacs, K				Rideg, Orsolya; Oszter, Angela; Makk, Evelin; Kalman, Endre; Farkas, Kornelia; Tornoczky, Tamas; Kovacs, Krisztina			Wide Spectrum Analysis of Human Papillomavirus Genotypes in External Anogenital Warts	VACCINES			English	Article						external anogenital warts; prevalence; multi-infection; HPV genotyping; HPV Direct Flow CHIP	PREVALENCE; INFECTION; POPULATION	External anogenital warts (EGW) are primarily associated with the low-risk human papillomavirus (HPV) genotypes 6 and 11, though coinfection with other low-risk and oncogenic high-risk HPV genotypes also occurs. Although there have been many studies on HPV-associated disease, the prevalence of HPV genotypes associated with EGW is not well characterized. The objective of our retrospective study was to determine the prevalence of HPV genotypes among patients diagnosed with EGW in the south-west of Hungary. Archived formalin-fixed paraffin-embedded tissues from 94 patients were processed in our study. HPV genotypes were determined, applying HPV Direct Flow CHIP test. The overall prevalence of HPV DNA in the EGW samples was 100%, yielding 131 infections among the 94 samples. Of these cases, 72.3% were mono while 27.6% were multi-infections. Out of the 131 infections, the cumulative prevalence of HPV 6 and 11 was 71%. A total of 98.9% of the samples were carrying at least one of these genotypes, while 19.1% of the cases occurred with at least one high-risk genotype. Data from our study could provide invaluable information concerning the prevalence of HPV types among patients with EGW, enabling improved assessment of the actual and future efficacy of vaccination programs, vaccine development, and forecast changes in infection patterns.	[Rideg, Orsolya; Oszter, Angela; Makk, Evelin; Kalman, Endre; Tornoczky, Tamas; Kovacs, Krisztina] Univ Pecs, Sch Med, Dept Pathol, H-7624 Pecs, Hungary; [Rideg, Orsolya; Oszter, Angela; Makk, Evelin; Kalman, Endre; Farkas, Kornelia; Tornoczky, Tamas; Kovacs, Krisztina] Univ Pecs, Ctr Clin, H-7624 Pecs, Hungary; [Makk, Evelin] Univ Pecs, Sch Med, Dept Med Imaging, H-7624 Pecs, Hungary; [Farkas, Kornelia] Univ Pecs, Sch Med, Inst Bioanal, H-7624 Pecs, Hungary		Tornoczky, T (通讯作者)，Univ Pecs, Sch Med, Dept Pathol, H-7624 Pecs, Hungary.; Tornoczky, T (通讯作者)，Univ Pecs, Ctr Clin, H-7624 Pecs, Hungary.	rideg.orsolya@pte.hu; angela.oszter@pte.hu; makk.evelin@pte.hu; kalman.endre@pte.hu; farkas.kornelia@pte.hu; tornoczki.tamas@pte.hu; kovacs.krisztina2@pte.hu		Farkas, Nelli/0000-0002-5349-6527	Scientific Research Fund of the University of Pecs, Medical School [3/2019 (01.09)]	The study was funded by the Scientific Research Fund of the University of Pecs, Medical School. The number of the fellowship is 3/2019 (01.09).	Aubin F, 2008, CLIN INFECT DIS, V47, P610, DOI 10.1086/590560; Ault KA, 2007, GYNECOL ONCOL, V107, pS31, DOI 10.1016/j.ygyno.2007.08.059; Balla BC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010001; Carusi A.D., 2019, CONDYLOMATA ACUMINAT, P1; Castle PE, 2016, EPIDEMIOL INFECT, V144, P449, DOI 10.1017/S0950268815002198; Chaturwedi A.K., 2010, HPV INCIDENCE TRENDS; Cubie HA, 2013, VIROLOGY, V445, P21, DOI 10.1016/j.virol.2013.06.007; Dillner J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3493; Donovan B, 2011, LANCET INFECT DIS, V11, P39, DOI 10.1016/S1473-3099(10)70225-5; Fischer S, 2016, ONCOL LETT, V12, P601, DOI 10.3892/ol.2016.4668; Giuliano AR, 2010, GYNECOL ONCOL, V117, pS15, DOI 10.1016/j.ygyno.2010.01.026; Hartwig S, 2015, PAPILLOMAVIRUS RES, V1, P90, DOI 10.1016/j.pvr.2015.06.003; Herraez-Hernandez Elsa, 2013, Open Virol J, V7, P91, DOI 10.2174/1874357920130927004; Herraez-Hernandez E, 2013, J VIROL METHODS, V193, P9, DOI 10.1016/j.jviromet.2013.04.018; Kasler M, 2012, ORVOSI HETILAP, V153, P33; Kasler M, 2012, ORVOSI HETILAP, V153, P3; Kasler M, 2012, ORVOSI HETILAP, V153, P16; Kocjan BJ, 2016, J CLIN VIROL, V76, pS88, DOI 10.1016/j.jcv.2015.10.007; Kovacs K, 2008, J MED VIROL, V80, P1814, DOI 10.1002/jmv.21282; Kraut AA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-360; Lacey CJN, 2013, J EUR ACAD DERMATOL, V27, pe263, DOI 10.1111/j.1468-3083.2012.04493.x; Leite KRM, 2020, ACTA CYTOL, V64, P420, DOI 10.1159/000506725; Leonard B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/480573; Leung AKC, 2005, ADV THER, V22, P187, DOI 10.1007/BF02849928; Li Q., 2006, CHIN J CLIN ONCOL, V3, P419, DOI [10.1007/s11805-006-0131-z, DOI 10.1007/S11805-006-0131-Z]; Li ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07199-6; Mayeaux EJ, 2008, J AM OSTEOPATH ASSOC, V108, pS2; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Patel H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-39; Pennycook B.K., 2019, CONDYLOMA ACUMINATA, P1; Rosen T., 2019, CONDYLOMATA ACUMINAT, P1; Arroyo LS, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2713-x; Scheinfeld Noah, 2013, Dermatol Online J, V19, P18559; Sichero L, 2019, ACTA CYTOL, V63, P109, DOI 10.1159/000493737; Sousa H, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100179; Stern PL, 2012, VACCINE, V30, pF71, DOI 10.1016/j.vaccine.2012.05.091; Sycuro LK, 2008, J INFECT DIS, V198, P971, DOI 10.1086/591625; Tachezy R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021913; Tchernev G, 2009, AN BRAS DERMATOL, V84, P377, DOI 10.1590/S0365-05962009000400009; Varkonyi V., 2016, Borgyogyaszati es Venerologiai Szemle, V92, P90	40	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							604	10.3390/vaccines9060604			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA7RZ	34198774	Green Published			2022-04-29	WOS:000667444600001
J	Zeng, YJ; Hsu, MK; Tsai, CA; Chu, CY; Wu, HC; Wang, HY				Zeng, Yu-Jing; Hsu, Min-Kung; Tsai, Chiao-An; Chu, Chun-Yen; Wu, Hsing-Chieh; Wang, Hsian-Yu			A Senescence-Like Cellular Response Inhibits Bovine Ephemeral Fever Virus Proliferation	VACCINES			English	Article						anti-viral response; senescence-like response; viral vaccine production; BEFV; Rhabdoviridae; GSEA; BHK-21; bioreactor	GENE; VACCINE; INFECTION; TAIWAN; CELLS	During industrial-scale production of viruses for vaccine manufacturing, anti-viral response of host cells can dampen maximal viral antigen yield. In addition to interferon responses, many other cellular responses, such as the AMPK signaling pathway or senescence-like response may inhibit or slow down virus amplification in the cell culture system. In this study, we first performed a Gene Set Enrichment Analysis of the whole-genome mRNA transcriptome and found a senescence-like cellular response in BHK-21 cells when infected with bovine ephemeral fever virus (BEFV). To demonstrate that this senescence-like state may reduce virus growth, BHK-21 subclones showing varying degrees of a senescence-like state were infected with BEFV. The results showed that the BHK-21 subclones showing high senescence staining could inhibit BEFV replication while low senescence-staining subclones are permissive to virus replication. Using a different approach, a senescence-like state was induced in BHK-21 using a small molecule, camptothecin (CPT), and BEFV susceptibility were examined. The results showed that CPT-treated BHK-21 is more resistant to virus infection. Overall, these results indicate that a senescence-like response may be at play in BHK-21 upon virus infection. Furthermore, cell clone selection and modulating treatments using small molecules may be tools in countering anti-viral responses.	[Zeng, Yu-Jing; Chu, Chun-Yen; Wu, Hsing-Chieh; Wang, Hsian-Yu] Natl Pingtung Univ Sci & Technol, Int Coll, Int Program Anim Vaccine Technol, Pingtung 91201, Taiwan; [Hsu, Min-Kung] China Med Univ, Res Ctr Tumor Med Sci, Taichung 40402, Taiwan; [Tsai, Chiao-An; Chu, Chun-Yen; Wang, Hsian-Yu] Natl Pingtung Univ Sci & Technol, Coll Vet Med, Grad Inst Anim Vaccine Technol, Pingtung 91201, Taiwan		Wang, HY (通讯作者)，Natl Pingtung Univ Sci & Technol, Int Coll, Int Program Anim Vaccine Technol, Pingtung 91201, Taiwan.; Wang, HY (通讯作者)，Natl Pingtung Univ Sci & Technol, Coll Vet Med, Grad Inst Anim Vaccine Technol, Pingtung 91201, Taiwan.	J10885002@mail.npust.edu.tw; mkh@tms.cmu.edu.tw; ananbirdhome@yahoo.com.tw; cychu@mail.npust.edu.tw; hcwu@mail.npust.edu.tw; hyw@mail.npust.edu.tw		Wang, Hsian-Yu/0000-0002-7060-3005	Ministry of Science and Technology, Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [MOST 107-2313-B-020-003, MOST 109-2313-B-020-005]	This study was supported by a grant from the Ministry of Science and Technology, Taiwan, R.O.C. (MOST 107-2313-B-020-003 and MOST 109-2313-B-020-005). The funding agency played no role in study design, data analysis, or manuscript writing.	Aziz-Boaron O, 2014, VET MICROBIOL, V173, P1, DOI 10.1016/j.vetmic.2014.06.021; Baz-Martinez M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37007; Cheng HL, 2006, MOL CELL BIOCHEM, V291, P29, DOI 10.1007/s11010-006-9191-x; Cheng LT, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2059-6; Chung YC, 2016, RES VET SCI, V109, P161, DOI 10.1016/j.rvsc.2016.10.004; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dobin A., 2016, CURR PROTOC BIOINFOR, V51, P586; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247; Genzel Y, 2015, BIOTECHNOL J, V10, P728, DOI 10.1002/biot.201400388; Hamidi H, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2646; Han LL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23478-0; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Hoare M, 2010, J HEPATOL, V53, P950, DOI 10.1016/j.jhep.2010.06.009; Hsieh YC, 2006, J VET MED SCI, V68, P543, DOI 10.1292/jvms.68.543; Johmura Y, 2016, CANCER SCI, V107, P1550, DOI 10.1111/cas.13060; Kowalski P., 2008, EMERGING EC, P283; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NAGAI Y, 1981, J GEN VIROL, V55, P109, DOI 10.1099/0022-1317-55-1-109; Ovadya Y, 2018, J CLIN INVEST, V128, P1247, DOI 10.1172/JCI95149; REED L. J., 1938, AMER JOUR HYG, V27, P493; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Terzi MY, 2016, MOL BIOL REP, V43, P1213, DOI 10.1007/s11033-016-4065-0; Ting LJ, 2016, VET MICROBIOL, V182, P15, DOI 10.1016/j.vetmic.2015.10.025; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Walker PJ, 2015, VET RES, V46, DOI 10.1186/s13567-015-0262-4; Wengerodt D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121546; WILD TF, 1981, J GEN VIROL, V57, P169, DOI 10.1099/0022-1317-57-1-169; Zheng FY, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-268	33	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							601	10.3390/vaccines9060601			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8FC	34200003	Green Published, Green Submitted			2022-04-29	WOS:000666792900001
J	Cardillo, F; Bonfim, M; Sousa, PDV; Mengel, J; Castello-Branco, LRR; Pinho, RT				Cardillo, Fabiola; Bonfim, Maiara; da Silva Vasconcelos Sousa, Periela; Mengel, Jose; Ribeiro Castello-Branco, Luiz Roberto; Pinho, Rosa Teixeira			Bacillus Calmette-Guerin Immunotherapy for Cancer	VACCINES			English	Review						BCG; cancer; trained immunity	CELL-WALL SKELETON; IMMUNE CHECKPOINT BLOCKADE; SUPERFICIAL BLADDER-CANCER; ADJUVANT IMMUNOTHERAPY; DENDRITIC CELLS; NONSPECIFIC PROTECTION; VACCINATION PROTECTS; BCG IMMUNOTHERAPY; TUMOR-REGRESSION; TRAINED IMMUNITY	Bacillus Calmette-Guerin (BCG), an attenuated vaccine from Mycobacterium bovis, was initially developed as an agent for vaccination against tuberculosis. BCG proved to be the first successful immunotherapy against established human bladder cancer and other neoplasms. The use of BCG has been shown to induce a long-lasting antitumor response over all other forms of treatment against intermediate, non-invasive muscle bladder cancer Several types of tumors may now be treated by releasing the immune response through the blockade of checkpoint inhibitory molecules, such as CTLA-4 and PD-1. In addition, Toll-Like Receptor (TLR) agonists and BCG are used to potentiate the immune response against tumors. Studies concerning TLR-ligands combined with BCG to treat melanoma have demonstrated efficacy in treating mice and patients This review addresses several interventions using BCG on neoplasms, such as Leukemia, Bladder Cancer, Lung Cancer, and Melanoma, describing treatments and antitumor responses promoted by this attenuated bacillus. Of essential importance, BCG is described recently to participate in an adequate microbiome, establishing an effective response during cell-target therapy when combined with anti-PD-1 antibody, which stimulates T cell responses against the melanoma. Finally, trained immunity is discussed, and reprogramming events to shape innate immune responses are addressed.	[Cardillo, Fabiola; Bonfim, Maiara] Fiocruz MS, Lab Mol & Struct Pathol, Goncalo Moniz Inst, BR-40296710 Salvador, BA, Brazil; [da Silva Vasconcelos Sousa, Periela; Mengel, Jose; Pinho, Rosa Teixeira] Fiocruz MS, Clin Immunol Lab, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ, Brazil; [da Silva Vasconcelos Sousa, Periela] Fluminense Fed Univ, Lab Mol Virol & Marine Biotechnol, BR-24220008 Niteroi, RJ, Brazil; [Mengel, Jose] UNIFASE, Fac Med Petropolis, BR-25680120 Petropolis, RJ, Brazil; [Ribeiro Castello-Branco, Luiz Roberto] Ataulpho Paiva Fdn, BR-20941070 Rio De Janeiro, RJ, Brazil		Cardillo, F (通讯作者)，Fiocruz MS, Lab Mol & Struct Pathol, Goncalo Moniz Inst, BR-40296710 Salvador, BA, Brazil.	fabiola.cardillo@fiocruz.br; maiara.bonfim@ufba.br; perielavasconcelos@id.uff.br; jomengel@ioc.fiocruz.br; branco@bcgfap.com.br; rospinho@ioc.fiocruz.br		Castello-Branco, Luiz R R/0000-0001-6771-3791	FIOCRUZ; National Institutes of Science and Technology in Tuberculosis (INCT); Fundacao Ataulpho de Paiva (FAP)	This work was supported by FIOCRUZ, Fundacao Ataulpho de Paiva (FAP) and National Institutes of Science and Technology in Tuberculosis (INCT).	Ahn J, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0333-0; American Cancer Society, 2019, KEY STAT LUNG CANC; Antonelli AC, 2020, P NATL ACAD SCI USA, V117, P18627, DOI 10.1073/pnas.2004421117; Vilanova CMA, 2013, AN BRAS DERMATOL, V88, P545, DOI 10.1590/abd1806-4841.20132036; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Askenase MH, 2015, IMMUNITY, V42, P1130, DOI 10.1016/j.immuni.2015.05.011; Associacao Medica Brasileira Conselho Federal de Medicina Sociedade Brasileira de Urologia Sociedade Brasileira de Patologia, 2006, PROJ DIR CANC BEX PA; AZUMA I, 1974, JPN J MICROBIOL, V18, P327, DOI 10.1111/j.1348-0421.1974.tb00817.x; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Biot C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003586; Birkeland E, 2013, CLIN EXP METASTAS, V30, P867, DOI 10.1007/s10585-013-9587-4; Broussard Lindsey, 2018, Chonnam Med J, V54, P135, DOI 10.4068/cmj.2018.54.3.135; Buffen K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004485; Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Calmette A., 1926, ANN I PASTEUR PARIS, V2, P89; Carmody RN, 2019, NAT MICROBIOL, V4, P2052, DOI 10.1038/s41564-019-0569-4; Chade DC, 2009, INT BRAZ J UROL, V35, P640, DOI 10.1590/S1677-55382009000600002; Chang SS, 2016, J UROLOGY, V196, P1021, DOI 10.1016/j.juro.2016.06.049; Cheng CW, 2004, ANZ J SURG, V74, P569, DOI 10.1111/j.1445-2197.2004.02941.x; Chickarmane V, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000268; Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014; COE JE, 1966, IMMUNOLOGY, V10, P127; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Craft N, 2005, J IMMUNOL, V175, P1983, DOI 10.4049/jimmunol.175.3.1983; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; da Silva IP, 2019, CLIN CANCER RES, V25, P1272, DOI 10.1158/1078-0432.CCR-18-1680; de Laval B, 2020, CELL STEM CELL, V26, P657, DOI 10.1016/j.stem.2020.01.017; Dey B, 2015, NAT MED, V21, P401, DOI 10.1038/nm.3813; Dey RJ, 2020, J INFECT DIS, V221, P1048, DOI 10.1093/infdis/jiz116; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Faries MB, 2017, ANN SURG ONCOL, V24, P3991, DOI 10.1245/s10434-017-6072-3; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Flaherty KT, 2010, CANCER-AM CANCER SOC, V116, P4902, DOI 10.1002/cncr.25261; Fluckiger A, 2020, SCIENCE, V369, P936, DOI 10.1126/science.aax0701; Fonseca Francisco P, 2002, Int Braz J Urol, V28, P426; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P268, DOI 10.1016/j.coi.2013.02.009; Gan C, 2013, NAT REV UROL, V10, P580, DOI 10.1038/nrurol.2013.194; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gershteyn IM, 2020, INT IMMUNOL, V32, P771, DOI 10.1093/intimm/dxaa054; Giamarellos-Bourboulis EJ, 2020, CELL, V183, P315, DOI 10.1016/j.cell.2020.08.051; Gil-Cruz C, 2019, SCIENCE, V366, P881, DOI 10.1126/science.aav3487; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grange JM, 2003, J ROY SOC MED, V96, P389, DOI 10.1258/jrsm.96.8.389; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907; HERSH EM, 1977, ANNU REV MED, V28, P489, DOI 10.1146/annurev.me.28.020177.002421; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; HOLOSHITZ J, 1983, SCIENCE, V219, P56, DOI 10.1126/science.6336851; Hsueh EC, 2002, J CLIN ONCOL, V20, P4549, DOI 10.1200/JCO.2002.01.151; Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036; Instituto Nacional de Cancer Ministerio da Saude, 2018, EST CANC; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; JACKSON AM, 1995, CLIN EXP IMMUNOL, V99, P369, DOI 10.1111/j.1365-2249.1995.tb05560.x; Ji NN, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1614857; Juliusson G, 2016, PROG TUMOR RES, V43, P87, DOI 10.1159/000447076; Kalaora S, 2021, NATURE, V592, P138, DOI 10.1038/s41586-021-03368-8; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Kidner TB, 2012, J IMMUNOTHER, V35, P716, DOI 10.1097/CJI.0b013e31827457bd; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Knight SB, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170070; Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002; Lardone RD, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00965; Li B, 2019, CURR MED CHEM, V26, P3009, DOI 10.2174/0929867324666170804143706; Long GV, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9506; Lovly CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035309; Luo Y, 2012, ONCOIMMUNOLOGY, V1, P1183, DOI 10.4161/onci.20640; Luther C, 2019, CRIT REV ONCOL HEMAT, V133, P99, DOI 10.1016/j.critrevonc.2018.11.002; Mantovani A, 2020, NEW ENGL J MED, V383, P1078, DOI 10.1056/NEJMcibr2011679; MATHE G, 1969, LANCET, V1, P697, DOI 10.1016/S0140-6736(69)92648-8; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; MCKHANN CF, 1975, CANCER-AM CANCER SOC, V35, P514, DOI 10.1002/1097-0142(197502)35:2<514::AID-CNCR2820350233>3.0.CO;2-F; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; MORI K, 1986, UROL INT, V41, P254, DOI 10.1159/000281212; Morra ME, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16067-0; Mortaz E, 2015, J CLIN IMMUNOL, V35, P1, DOI 10.1007/s10875-014-0103-7; MORTON DL, 1970, SURGERY, V68, P158; MORTON DL, 1974, ANN SURG, V180, P635, DOI 10.1097/00000658-197410000-00029; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nishida S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016771; Niu J, 2017, ACS APPL MATER INTER, V9, P9388, DOI 10.1021/acsami.6b16378; Noreldeen HAA, 2020, J SEP SCI, V43, P120, DOI 10.1002/jssc.201900736; OCHIAI T, 1983, CANCER IMMUNOL IMMUN, V14, P167, DOI 10.1007/BF00205355; Oh JK, 2014, ANN GLOB HEALTH, V80, P384, DOI 10.1016/j.aogh.2014.09.013; OLD LJ, 1959, NATURE, V184, P291, DOI 10.1038/184291a0; Pandya P, 2017, MOL ONCOL, V11, P5, DOI 10.1002/1878-0261.12019; Pearl R, 1929, AM J HYG, V9, P97, DOI 10.1093/oxfordjournals.aje.a121646; Quintin J, 2014, CURR OPIN IMMUNOL, V29, P1, DOI 10.1016/j.coi.2014.02.006; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rezai Omran, 2015, Asian Pac J Cancer Prev, V16, P7303; Riordan A, 2014, ARCH DIS CHILDHOOD-E, V99, P87, DOI 10.1136/archdischild-2013-304457; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roskoski R, 2010, BIOCHEM BIOPH RES CO, V399, P313, DOI 10.1016/j.bbrc.2010.07.092; Rothenberg EV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00228; Rothenberg EV, 2016, ADV IMMUNOL, V129, P109, DOI 10.1016/bs.ai.2015.09.002; Benitez MLR, 2019, APPL MICROBIOL BIOT, V103, P7903, DOI 10.1007/s00253-019-10057-0; Shoenfeld Y, 2001, J AUTOIMMUN, V16, P235, DOI 10.1006/jaut.2000.0494; Simeone E, 2017, MELANOMA MANAG, V4, P175, DOI 10.2217/mmt-2017-0018; Singh AK, 2020, UROL ONCOL-SEMIN ORI, V38, P899, DOI 10.1016/j.urolonc.2020.10.030; Slusarczyk A, 2019, INT UROL NEPHROL, V51, P1089, DOI 10.1007/s11255-019-02183-5; Sociedade Brasileira de Urologia, 2018, CANC BEX; Stamm CE, 2015, IMMUNOL REV, V264, P204, DOI 10.1111/imr.12263; Stewart JH, 2011, EXPERT REV ANTICANC, V11, P1671, DOI [10.1586/era.11.163, 10.1586/ERA.11.163]; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Tanaka F, 2007, SURG TODAY, V37, P923, DOI 10.1007/s00595-007-3578-5; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; THORNS CJ, 1985, CLIN EXP IMMUNOL, V61, P323; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Udagawa M, 2006, CLIN CANCER RES, V12, P7465, DOI 10.1158/1078-0432.CCR-06-1840; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003; Vandamme N, 2019, CELL MOL LIFE SCI, V76, P1919, DOI 10.1007/s00018-019-03049-w; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; Villumsen M, 2009, VACCINE, V27, P6950, DOI 10.1016/j.vaccine.2009.08.103; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; World Health Organization, 2018, CANC FACT SHEETS ALL; YAMAMURA Y, 1979, CANCER-AM CANCER SOC, V43, P1314, DOI 10.1002/1097-0142(197904)43:4<1314::AID-CNCR2820430420>3.0.CO;2-6; Yang L, 2014, CELL DEATH DIFFER, V21, P1677, DOI 10.1038/cdd.2014.131; YASUMOTO K, 1979, CANCER RES, V39, P3262; Yi M, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0120-y; Yu VWC, 2017, CELL, V168, P944, DOI 10.1016/j.cell.2017.02.010; ZBAR B, 1972, JNCI-J NATL CANCER I, V49, P119; Zhang P, 2000, BLOOD, V96, P2641; Zitvogel L, 2019, SCIENCE, V366, P1077, DOI 10.1126/science.aaz7595	134	3	3	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							439	10.3390/vaccines9050439			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NI	34062708	gold, Green Published			2022-04-29	WOS:000654592500001
J	Kostinov, PM; Zhuravlev, IP; Filatov, NN; Kostinova, MA; Polishchuk, BV; Shmitko, DA; Mashilov, VC; Vlasenko, EA; Ryzhov, AA; Kostinov, MA				Kostinov, P. Mikhail; Zhuravlev, I. Pavel; Filatov, N. Nikolay; Kostinova, M. Aristitsa; Polishchuk, B. Valentina; Shmitko, D. Anna; Mashilov, V. Cyrill; Vlasenko, E. Anna; Ryzhov, A. Alexey; Kostinov, M. Anton			Gender Differences in the Level of Antibodies to Measles Virus in Adults	VACCINES			English	Article						measles; measles immunity among men and women; age characteristics of measles immunity	IMMUNE-RESPONSES; RUBELLA; VACCINE	Individuals without a protective antibody level are susceptible to measles infection. There are differences in the persistence of antibodies after vaccination and infection, while the impact of gender on this process has not been sufficiently studied. Measles Ig G antibodies were measured in 1742 employees of a large hospital facility-403 men and 1339 women aged from 25 to 67 years; 15% participants had antibody levels less than the protective threshold of >= 0.18 IU/mL. Significant differences were found in the age group 40-49, where the level of IgG antibodies to measles among men was higher than among women (1.51 IU/mL (0.41; 3.38) vs. 0.70 IU/mL (0.22;1.98) respectively, (U = 3.2, p = 0,001)); in the age group 60 and older, by contrast, the level of antibodies among women was higher compared to men (3.29 IU/mL (1.72; 4.07) vs. 2.90 IU/mL (1.46; 3.53) respectively (U = 2.2, p = 0.03)). The proportion of seronegative women in the age group 40-49 was significantly higher than of seronegative men: 22 [18-26]% and 11 [6-18]% respectively (chi(2) = 7.0, p = 0.001). The revealed gender characteristics that affect persistence of measles immunity may be important in personalization of vaccinal prevention for men and women.	[Kostinov, P. Mikhail; Zhuravlev, I. Pavel; Filatov, N. Nikolay; Polishchuk, B. Valentina; Shmitko, D. Anna; Mashilov, V. Cyrill; Ryzhov, A. Alexey; Kostinov, M. Anton] II Mechnikov Res Inst Vaccines & Sera, Fed State Budgetary Sci Inst, Maliyi Kazenniy Pereulok 5a, Moscow 105064, Russia; [Kostinov, P. Mikhail; Filatov, N. Nikolay] Sechenov Univ, Fed State Autonomous Educ Inst Higher Educ, Minist Hlth Russian Federat, IM Sechenov First Moscow State Med Univ, Trubetskaya Str 8-2, Moscow 119991, Russia; [Kostinova, M. Aristitsa] Fed Med Biol Agcy Russia, Natl Res Ctr Inst Immunol, Kashirskoe Shosse 24, Moscow 115478, Russia; [Vlasenko, E. Anna] Russian Med Acad Continuous Profess Educ, Novokuznetsk State Inst Adv Training Phys, Branch Campus,Prospect Stroiteley 5, Novokuznetsk 654005, Russia		Kostinova, MA (通讯作者)，Fed Med Biol Agcy Russia, Natl Res Ctr Inst Immunol, Kashirskoe Shosse 24, Moscow 115478, Russia.	monolit.96@mail.ru; pvazhurik@gmail.com; n.n.filatov@yandex.ru; aristica_kostino@mail.ru; polischook@mail.ru; violadellanna@gmail.com; k.v.mashilov@gmail.com; VlasenkoAnna@inbox.ru; vaccinums@gmail.com; mono469@gmail.com	Kostinov, Mikhail P/J-8296-2018				Afinogenova V.P., 2010, TREAT DR, V4, P9; Balabolkin I.I., 1988, VACCINATION LIVE MEA, P8; Boulton ML, 2016, VACCINE, V34, P3037, DOI 10.1016/j.vaccine.2016.04.094; Brown T., MEDSCAPE MED NEWS; Chuchalin A.G., 2017, FEDERAL GUIDANCE APP, P848; Clemmons NS, 2017, JAMA-J AM MED ASSOC, V318, P1279, DOI 10.1001/jama.2017.9984; Dominguez A, 2006, EUR J CLIN MICROBIOL, V25, P310, DOI 10.1007/s10096-006-0133-z; Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115; France EK, 2008, PEDIATRICS, V121, pE687, DOI 10.1542/peds.2007-1578; Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166; Ibragimova E.M., 2005, EPIDEMIOL VACCINAL P, V3, P21; Khaitov R.M., 2014, ALLERGOLOGY IMMUNOLO, P656; Khalil M K, 2003, East Mediterr Health J, V9, P152; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kostinov M.P., 1988, THESIS FEDERAL STATE, P23; Kostinov M.P., 2009, VACCINATION HEPATITI, P196; Kostinov M.P., 1997, IMMUNOTHERAPY PEDIAT, P111; Kostinov M.P., 1990, IMMUNOLOGY, V1, P41; Kostinov M.P., 1990, J MICROBIOL EPIDEMIO, V3, P81; Kostinov M.P., 2018, PULMONOLOGY, V28, P701, DOI [10.18093/0869-0189-2018-28-6-701-707, DOI 10.18093/0869-0189-2018-28-6-701-707]; Kostinov M.P., 2016, J MICROBIOL EPIDEMIO, V5, P88; [Костинов Михаил Петрович Kostinov Mikhail Petrovich], 2017, [Педиатрия. Журнал им. Г.Н. Сперанского, Pediatriya. Zhurnal im. G.N. Speranskogo], V96, P140, DOI 10.24110/0031-403X-2017-96-4-140-145; Leonova G.N., 2009, TICK BORNE ENCEPHALI, P168; Mazankova L. N., 2013, Pediatriya (Moscow), V92, P18; Mossong J, 2000, VACCINE, V19, P523, DOI 10.1016/S0264-410X(00)00175-4; Ovsyannikova IG, 2007, VACCINE, V25, P3090, DOI 10.1016/j.vaccine.2007.01.020; Poethko-Muller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042867; Polischuk V. B., 2016, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P55; Prokofiev V.I., 1988, B SIB BRANCH ACAD ME, V5, P49; Robesyn E., 2018, EUR CTR DIS PREV CON; Solovyeva I.L., 2006, FEATURES VACCINATION, P296; Solovyeva I.L., 2013, ULYANOVSK MED BIOL J, V2, P20; Solovyeva I.L., 2007, ALLERGOL IMMUNOL, V2, P206; Tarasova A.A., 2005, MED DEP, V1, P45; [Тимченко Владимир Николаевич Timchenko Vladimir N.], 2017, [Педиатр, Pediatr], V8, P120, DOI 10.17816/PED83120-129; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zverev V.V., 2014, VACCINES VACCINATION, P640	37	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							494	10.3390/vaccines9050494			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1EU	34065880	gold, Green Published			2022-04-29	WOS:000654570100001
J	Li, ZY; Roy, S; Ranasinghe, C				Li, Zheyi; Roy, Sreeja; Ranasinghe, Charani			IL-13R alpha 2 Regulates the IL-13/IFN-gamma Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination	VACCINES			English	Article						ILC; DC; IL-4R antagonist and IL-13R alpha 2 adjuvants; STAT6; IL-13; IL-4/IL-13 receptor regulation; viral vector vaccination	RECEPTOR-ALPHA CHAIN; SIGNAL-TRANSDUCTION; GAMMA-INTERFERON; IL-13 RECEPTORS; I INTERFERONS; MICE LACKING; TNF-ALPHA; T-CELLS; B-CELLS; EXPRESSION	We have shown that manipulation of IL-13 and STAT6 signaling at the vaccination site can lead to different innate lymphoid cell (ILC)/dendritic cell (DC) recruitment, resulting in high avidity/poly-functional T cells and effective antibody differentiation. Here we show that permanent versus transient blockage of IL-13 and STAT6 at the vaccination site can lead to unique ILC-derived IL-13 and IFN-gamma profiles, and differential IL-13R alpha 2, type I and II IL-4 receptor regulation on ILC. Specifically, STAT6(-/-) BALB/c mice given fowl pox virus (FPV) expressing HIV antigens induced elevated ST2/IL-33R(+) ILC2-derived IL-13 and reduced NKp46(+/-) ILC1/ILC3-derived IFN-gamma expression, whilst the opposite (reduced IL-13 and elevated IFN-gamma expression) was observed during transient inhibition of STAT6 signaling in wild type BALB/c mice given FPV-HIV-IL-4R antagonist vaccination. Interestingly, disruption/inhibition of STAT6 signaling considerably impacted IL-13R alpha 2 expression by ST2/IL-33R(+) ILC2 and NKp46(-) ILC1/ILC3, unlike direct IL-13 inhibition. Consistently with our previous findings, this further indicated that inhibition of STAT6 most likely promoted IL-13 regulation via IL-13R alpha 2. Moreover, the elevated ST2/IL-33R(+) IL-13R alpha 2(+) lung ILC2, 24 h post FPV-HIV-IL-4R antagonist vaccination was also suggestive of an autocrine regulation of ILC2-derived IL-13 and IL-13R alpha 2, under certain conditions. Knowing that IL-13 can modulate IFN-gamma expression, the elevated expression of IFN-gamma R on lung ST2/IL-33R(+) ILC2 provoked the notion that there could also be inter-regulation of lung ILC2-derived IL-13 and NKp46(-) ILC1/ILC3-derived IFN-gamma via their respective receptors (IFN-gamma R and IL-13R alpha 2) at the lung mucosae early stages of vaccination. Intriguingly, under different IL-13 conditions differential regulation of IL-13/IL-13R alpha 2 on lung DC was also observed. Collectively these findings further substantiated that IL-13 is the master regulator of, not only DC, but also different ILC subsets at early stages of viral vector vaccination, and responsible for shaping the downstream adaptive immune outcomes. Thus, thoughtful selection of vaccine strategies/adjuvants that can manipulate IL-13R alpha 2, and STAT6 signaling at the ILC/DC level may prove useful in designing more efficacious vaccines against different/chronic pathogens.	[Li, Zheyi; Roy, Sreeja; Ranasinghe, Charani] Australian Natl Univ, Mol Mucosal Vaccine Immunol Grp, Dept Immunol & Infect Dis, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; [Roy, Sreeja] Albany Med Coll, Dept Immunol & Microbial Dis, 47 New Scotland Ave, Albany, NY 12208 USA		Ranasinghe, C (通讯作者)，Australian Natl Univ, Mol Mucosal Vaccine Immunol Grp, Dept Immunol & Infect Dis, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.	zheyi.li@anu.edu.au; roys3@amc.edu; Charani.ranasinghe@anu.edu.au		Li, Zheyi/0000-0002-1128-8631	ANU Connect Ventures grant award [DTF 230]; Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1136351]; Coalition for Epidemic Preparedness Innovations; Australian Centre for HIV and Hepatitis Virology Research (ACH2)	This work was supported by the Australian Centre for HIV and Hepatitis Virology Research (ACH2), ANU Connect Ventures grant award DTF 230, and Australian National Health and Medical Research Council (NHMRC) development grant APP1136351 awarded to C.R. Z.L. currently supported by The Coalition for Epidemic Preparedness Innovations grant awarded to C.R.	Abd Hamid M, 2018, EUR J IMMUNOL, V48, P1153, DOI 10.1002/eji.201747463; Albanesi C, 2007, J IMMUNOL, V179, P984, DOI 10.4049/jimmunol.179.2.984; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bal SM, 2020, NAT REV IMMUNOL, V20, P552, DOI 10.1038/s41577-020-0282-9; Bao K, 2015, CYTOKINE, V75, P25, DOI 10.1016/j.cyto.2015.05.008; Bartolome RA, 2015, CANCER RES, V75, P2434, DOI 10.1158/0008-5472.CAN-14-3650; Campbell-Harding G, 2013, J ALLERGY CLIN IMMUN, V131, P849, DOI 10.1016/j.jaci.2012.08.030; Catley MC, 2011, PHARMACOL THERAPEUT, V132, P333, DOI 10.1016/j.pharmthera.2011.09.005; Cerutti A, 2005, IMMUNOL CELL BIOL, V83, P554, DOI 10.1111/j.1440-1711.2005.01389.x; Colonna M, 2018, IMMUNITY, V48, P1104, DOI 10.1016/j.immuni.2018.05.013; Coupar BEH, 2006, VACCINE, V24, P1378, DOI 10.1016/j.vaccine.2005.09.044; COUTELIER JP, 1990, J VIROL, V64, P5383, DOI 10.1128/JVI.64.11.5383-5388.1990; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Fujisawa T, 2012, INT J CANCER, V131, P344, DOI 10.1002/ijc.26366; Garcia B, 1996, EUR J IMMUNOL, V26, P2364, DOI 10.1002/eji.1830261014; GRAHAM MB, 1993, J EXP MED, V178, P1725, DOI 10.1084/jem.178.5.1725; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; Han MY, 2017, AM J RESP CELL MOL, V56, P242, DOI 10.1165/rcmb.2016-0056OC; Hurdayal R, 2014, IMMUNOL LETT, V161, P179, DOI 10.1016/j.imlet.2013.12.022; Jackson R., 2014, METHODS MOL BIOL; Jackson RJ, 2014, VACCINE, V32, P5703, DOI 10.1016/j.vaccine.2014.08.023; Jiang SP, 2013, IMMUNOL REV, V252, P5, DOI 10.1111/imr.12041; Junttila IS, 2012, NAT CHEM BIOL, V8, P990, DOI [10.1038/NCHEMBIO.1096, 10.1038/nchembio.1096]; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Khanna M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41506-5; Kim BS, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016337; Klose CSN, 2020, CELL RES, V30, P475, DOI 10.1038/s41422-020-0323-8; Ko C, 2008, J PATHOL, V214, P603, DOI 10.1002/path.2316; Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1; Li Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79172-7; Li Z, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100035; Li ZY, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0048-6; Lupardus PJ, 2010, STRUCTURE, V18, P332, DOI 10.1016/j.str.2010.01.003; Maizels RM, 2012, CURR OPIN IMMUNOL, V24, P459, DOI 10.1016/j.coi.2012.06.003; Maloy KJ, 1998, P NATL ACAD SCI USA, V95, P1160, DOI 10.1073/pnas.95.3.1160; McCormick SM, 2015, CYTOKINE, V75, P38, DOI 10.1016/j.cyto.2015.05.023; Metwali A, 2002, INFECT IMMUN, V70, P5651, DOI 10.1128/IAI.70.10.5651-5658.2002; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Munitz A, 2008, P NATL ACAD SCI USA, V105, P7240, DOI 10.1073/pnas.0802465105; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1996, J IMMUNOL, V156, P2972; Nakashima H, 2011, J IMMUNOL, V187, P4935, DOI 10.4049/jimmunol.1102095; Papageorgis P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0607-y; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rahaman SO, 2002, CANCER RES, V62, P1103; Ranasinghe C, 2013, MUCOSAL IMMUNOL, V6, P1068, DOI 10.1038/mi.2013.1; Ranasinghe C, 2006, VACCINE, V24, P5881, DOI 10.1016/j.vaccine.2006.04.023; Ranasinghe C, 2009, EUR J IMMUNOL, V39, P1819, DOI 10.1002/eji.200838995; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Roy S, 2019, VACCINE, V37, P1266, DOI 10.1016/j.vaccine.2019.01.045; Roy S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57815-z; Tabata Y, 2007, CURR ALLERGY ASTHM R, V7, P338, DOI 10.1007/s11882-007-0051-x; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Thio CLP, 2019, J ALLERGY CLIN IMMUN, V144, P682, DOI 10.1016/j.jaci.2019.03.008; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; Townsend DG, 2017, J GEN VIROL, V98, P496, DOI 10.1099/jgv.0.000702; Trivedi S, 2014, VIROLOGY, V468, P479, DOI 10.1016/j.virol.2014.09.004; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; Wijesundara DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105366; Wijesundara DK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00412; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Xiao T, 2003, J DERMATOL SCI, V31, P111, DOI 10.1016/S0923-1811(02)00149-4	65	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							440	10.3390/vaccines9050440			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1VL	34062727	Green Published, Green Submitted, gold			2022-04-29	WOS:000654613600001
J	Park, S; Kim, JY; Ryu, KH; Kim, AY; Kim, J; Ko, YJ; Lee, EG				Park, Soonyong; Kim, Ji Yul; Ryu, Kyoung-Hwa; Kim, Ah-Young; Kim, Jaemun; Ko, Young-Joon; Lee, Eun Gyo			Production of a Foot-and-Mouth Disease Vaccine Antigen Using Suspension-Adapted BHK-21 Cells in a Bioreactor	VACCINES			English	Article						adherent; baby hamster kidney cell; foot-and-mouth disease; virus productivity; suspension culture; vaccine	HAMSTER-KIDNEY CELLS; EXTRACELLULAR-MATRIX; SERUM-FREE; HIGH-YIELD; CHO-CELLS; GROWTH; CULTURE; VIRUS; ANOIKIS; OPTIMIZATION	The baby hamster kidney-21 (BHK-21) cell line is a continuous cell line used to propagate foot-and-mouth disease (FMD) virus for vaccine manufacturing. BHK-21 cells are anchorage-dependent, although suspension cultures would enable rapid growth in bioreactors, large-scale virus propagation, and cost-effective vaccine production with serum-free medium. Here, we report the successful adaptation of adherent BHK-21 cells to growth in suspension to a viable cell density of 7.65 x 10(6) cells/mL on day 3 in serum-free culture medium. The suspension-adapted BHK-21 cells showed lower adhesion to five types of extracellular matrix proteins than adherent BHK-21 cells, which contributed to the suspension culture. In addition, a chemically defined medium (selected by screening various prototype media) led to increased FMD virus production yields in the batch culture, even at a cell density of only 3.5 x 10(6) cells/mL. The suspension BHK-21 cell culture could be expanded to a 200 L bioreactor from a 20 mL flask, which resulted in a comparable FMD virus titer. This platform technology improved virus productivity, indicating its potential for enhancing FMD vaccine production.	[Park, Soonyong; Kim, Ji Yul; Ryu, Kyoung-Hwa; Kim, Jaemun; Lee, Eun Gyo] KRIBB, Bioproc Engn Ctr, 30 Yeongudanjiro Ochang Eup, Chungju Si 28116, South Korea; [Kim, Ji Yul; Kim, Jaemun] Korea Univ Sci & Technol UST, Dept Bioproc Engn, Daejeon 34113, South Korea; [Kim, Ah-Young; Ko, Young-Joon] Anim & Plant Quarantine Agcy, Ctr FMD Vaccine Res, Gimcheon 39660, South Korea		Lee, EG (通讯作者)，KRIBB, Bioproc Engn Ctr, 30 Yeongudanjiro Ochang Eup, Chungju Si 28116, South Korea.	sypark@kribb.re.kr; jykim@kribb.re.kr; khryu@kribb.re.kr; mochsha@korea.kr; redoorkim@kribb.re.kr; koyoungjoon@korea.kr; eglee@kribb.re.kr		Kim, Ah-Young/0000-0003-0600-1816	Animal and Plant Quarantine Agency; Animal Disease Management Technology Development Program of IPET (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries), the Ministry of Agriculture, Food and Rural Affairs, Republic of Korea [315039-3]; KRIBB Research Initiative Program	This research was supported by grants from the Animal and Plant Quarantine Agency and from the Animal Disease Management Technology Development Program (No. 315039-3) of IPET (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries), the Ministry of Agriculture, Food and Rural Affairs, Republic of Korea, and by a grant from the KRIBB Research Initiative Program.	Bachir AI, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a023234; Bellani CF, 2020, FRONT NUTR, V7, DOI 10.3389/fnut.2020.575146; Bernal V, 2009, BIOTECHNOL BIOENG, V104, P162, DOI 10.1002/bit.22364; CAPSTICK PB, 1962, NATURE, V195, P1163, DOI 10.1038/1951163a0; CARTWRIGHT B, 1980, J GEN VIROL, V50, P369, DOI 10.1099/0022-1317-50-2-369; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; D'Anna, 1996, J TISSUE CULT METHOD, V18, P115, DOI DOI 10.1007/BF00122162; Dill V, 2019, BMC BIOTECHNOL, V19, DOI 10.1186/s12896-019-0527-5; Dimitrijevic-Bussod M, 1999, CANCER RES, V59, P4843; DOEL TR, 1982, DEV BIOL STAND, V50, P209; DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726; Even MS, 2006, TRENDS BIOTECHNOL, V24, P105, DOI 10.1016/j.tibtech.2006.01.001; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; FRENKEL HS, 1950, AM J VET RES, V11, P371; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gigout A, 2008, BIOTECHNOL BIOENG, V100, P975, DOI 10.1002/bit.21840; Grilo AL, 2019, BIOTECHNOL ADV, V37, P459, DOI 10.1016/j.biotechadv.2019.02.012; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Gstraunthaler G, 2013, CYTOTECHNOLOGY, V65, P791, DOI 10.1007/s10616-013-9633-8; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Henry O, 2004, BIOTECHNOL BIOENG, V86, P765, DOI 10.1002/bit.20074; JAYME DW, 1991, CYTOTECHNOLOGY, V5, P15, DOI 10.1007/BF00365531; Jean C, 2011, ONCOGENE, V30, P2697, DOI 10.1038/onc.2011.27; Jing Y, 2011, PROCESS BIOCHEM, V46, P427, DOI 10.1016/j.procbio.2010.09.015; Kamen A, 2004, J GENE MED, V6, pS184, DOI 10.1002/jgm.503; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Kim MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156038; Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE-10-0377; Kuschel C, 2006, BIOTECHNIQUES, V40, P523, DOI 10.2144/000112134; Lee N, 2016, ACS SYNTH BIOL, V5, P1211, DOI 10.1021/acssynbio.5b00249; Liu H, 2009, J BIOSCI BIOENG, V107, P524, DOI 10.1016/j.jbiosc.2009.01.004; Liu ML, 2013, BIOTECHNOL BIOENG, V110, P483, DOI 10.1002/bit.24730; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; Malm M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76137-8; Martin-Acebes MA, 2010, J VIROL, V84, P2902, DOI 10.1128/JVI.02311-09; MOREIRA JL, 1995, ENZYME MICROB TECH, V17, P437, DOI 10.1016/0141-0229(94)00071-X; MOWAT GN, 1962, NATURE, V194, P253, DOI 10.1038/194253a0; MOWAT GN, 1962, NATURE, V196, P655, DOI 10.1038/196655a0; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Park JH, 2018, J VET SCI, V19, P271, DOI 10.4142/jvs.2018.19.2.271; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Poltavets V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00431; RENNER WA, 1993, BIOTECHNOL BIOENG, V41, P188, DOI 10.1002/bit.260410204; Rourou S, 2019, VACCINE, V37, P6987, DOI 10.1016/j.vaccine.2019.05.092; Shridhar S, 2017, J BIOTECHNOL, V257, P13, DOI 10.1016/j.jbiotec.2017.03.012; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; Streuli CH, 2009, J CELL SCI, V122, P171, DOI 10.1242/jcs.018945; TELLING RC, 1965, BIOTECHNOL BIOENG, V7, P417, DOI 10.1002/bit.260070309; Thomassen YE, 2014, VACCINE, V32, P2782, DOI 10.1016/j.vaccine.2014.02.022; van der Valk J, 2010, TOXICOL IN VITRO, V24, P1053, DOI 10.1016/j.tiv.2010.03.016; WALDMANN O., 1955, ZENTRALBL BAKT ABT I ORIG, V163, P239; Walther CG, 2016, APPL BIOCHEM BIOTECH, V178, P1286, DOI 10.1007/s12010-015-1945-z; Warnock JN, 2006, BIOTECHNOL APPL BIOC, V45, P1, DOI 10.1042/BA2005023; WOOD HA, 1982, VIROLOGY, V119, P245, DOI 10.1016/0042-6822(82)90085-X; Wu YX, 2021, APPL MICROBIOL BIOT, V105, P1421, DOI 10.1007/s00253-020-11050-8; Yao T, 2017, REPROD MED BIOL, V16, P99, DOI 10.1002/rmb2.12024; Zanghi JA, 1999, BIOTECHNOL BIOENG, V64, P108, DOI 10.1002/(SICI)1097-0290(19990705)64:1&lt;108::AID-BIT12&gt;3.0.CO;2-B	57	2	2	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							505	10.3390/vaccines9050505			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3EW	34068378	Green Published, gold			2022-04-29	WOS:000654709400001
J	Evans, WD; French, J				Evans, William Douglas; French, Jeff			Demand Creation for COVID-19 Vaccination: Overcoming Vaccine Hesitancy through Social Marketing	VACCINES			English	Review						COVID-19; vaccination; vaccine hesitancy; demand creation; health communication; social marketing; branding; behavioral economics	PERSPECTIVE; DEFAULTS; CHOICE	The COVID-19 pandemic has led to millions of deaths and tested the capabilities of the medical and public health systems worldwide. Over the next two years as more approved vaccines are made available and supply meets or exceeds demand, medical and public health professionals will increasingly be faced with the challenge of vaccine hesitancy. There is an urgent need to create demand in groups that are either uninformed, vaccine hesitant, or actively resistant to COVID-19 vaccination. This study reviews theory, evidence, and practice recommendations to develop a vaccine demand creation strategy that has wide applicability. Specifically, we focus on key elements including supply side confidence, vaccine brand promotion strategy, service marketing as it relates to vaccine distribution, and competition strategy. We present evidence that these strategies can make a significant contribution to overcoming COVID-19 hesitancy in a high supply scenario. The paper also makes recommendations about factors that need to be considered in relation to vaccine delivery services and systems that, if done badly, may reduce uptake or result in the creation of more vaccine hesitancy. In summary, there is a need for well researched and tested demand creation strategies that integrate with brand strategy, supply side, and service delivery.	[Evans, William Douglas] George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC 20052 USA; [French, Jeff] Strateg Social Mkt Ltd, Liphook GU30 7QW, Hants, England		Evans, WD (通讯作者)，George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC 20052 USA.	wdevans@gwu.edu; jeff.french@strategic-social-marketing.org		Evans, William/0000-0002-7559-1592			Aaker D.A., 2009, MANAGING BRAND EQUIT; Aaker JL, 1997, J MARKETING RES, V34, P347, DOI 10.2307/3151897; Arede M, 2019, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00381; Bahri P., 2020, COMMUNICATING RISKS; Cakmakli C., 2021, Working Paper Series - National Bureau of Economic Research (Massachusetts), DOI 10.3386/w28395; European Centre for Disease Prevention and Control, 2017, CAT INT ADDR VACC HE; Evans W.D., 2008, PUBLIC HLTH BRANDING; Evans W.D., 2018, P AM PUBL HLTH ASS A; Evans WD, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010162; Evans WD, 2015, TRANSL BEHAV MED, V5, P24, DOI 10.1007/s13142-014-0272-1; Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8; French J., 2017, SOCIAL MARKETING PUB; French J., 2019, STRATEGIC SOCIAL MAR, V2nd ed.; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; French J, 2011, J SOC MARKET, V1, P154, DOI 10.1108/20426761111141896; Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y; Ghesla C, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00178; Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023; Gummesson E., 2002, TOTAL RELATIONSHIP M; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Johnson EJ, 2003, SCIENCE, V302, P1338, DOI 10.1126/science.1091721; Johnson EJ, 2012, MARKET LETT, V23, P487, DOI 10.1007/s11002-012-9186-1; KAHNEMAN D, 1993, MANAGE SCI, V39, P17, DOI 10.1287/mnsc.39.1.17; Kahneman D, 2003, AM ECON REV, V93, P162, DOI 10.1257/000282803321946985; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Keller KL, 2002, HARVARD BUS REV, V80, P80; Kennedy J, 2019, EUR J PUBLIC HEALTH, V29, P512, DOI 10.1093/eurpub/ckz004; Kotler P., 2008, PRINCIPLES MARKETING; Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lee N.R., 2011, SOCIAL MARKETING INF, V4th ed.; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Macintosh JLB, 2017, MCN-AM J MATERN-CHIL, V42, P139, DOI 10.1097/NMC.0000000000000337; Mols F, 2015, EUR J POLIT RES, V54, P81, DOI 10.1111/1475-6765.12073; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Oliver A, 2018, INT J HEALTH PLAN M, V33, P272, DOI 10.1002/hpm.2419; Porter E., 2011, PRICE EVERYTHING; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rogers E.M, 2010, DIFFUSION INNOVATION, V4th ed.; Sarpatwari A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002872; Shawky S, 2019, J SOC MARKET, V9, P204, DOI 10.1108/JSOCM-05-2018-0046; Solis-Moreira J., DID WE DEV COVID 19; TVERSKY A, 1986, J BUS, V59, pS251, DOI 10.1086/296365; Vargo S.L., 2009, SERV SCI, V1, P32, DOI 10.1287/serv.1.1.32; World Health Organization (WHO), 2020, TECHN ADV GROUP BEH	45	5	5	7	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							319	10.3390/vaccines9040319			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4WW	33915695	gold, Green Published			2022-04-29	WOS:000643782400001
J	Hasan, T; Beardsley, J; Marais, B; Nguyen, TA; Fox, GJ				Hasan, Tasnim; Beardsley, Justin; Marais, Ben J.; Thu Anh Nguyen; Fox, Greg J.			The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines	VACCINES			English	Review						covid; vaccination; national policy data; implementation	UNITED-STATES; COVID-19; PROGRAM; HEALTH	The global drive to vaccinate against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) began in December 2020 with countries in Europe, Middle East, and North America leading the roll out of a mass-vaccination program. This systematic review synthesised all available English-language guidelines and research regarding mass-vaccination for COVID-19 until 1 March 2021-the first three months of the global mass-vaccination effort. Data were extracted from national websites, PubMed, Embase, Medline and medRxiv, including peer and non-peer review research findings. A total of 15 national policy documents were included. Policies were summarised according to the World Health Organisation (WHO) framework for mass vaccination. All included policies prioritised front-line health care workers and the elderly. Limited information was available regarding staffing, cold chain, communication strategies and infrastructure requirements for effective vaccine delivery. A total of 26 research studies were identified, reporting roll-out strategies, vaccine uptake and reasons for refusal, adverse effects, and real-life estimates of efficacy. Early data showed a reduction in SARS-CoV-2 cases, hospitalisation and deaths in settings with good coverage. Very low rates of vaccine-related serious adverse events were observed. These findings provide an overview of current practice and early outcomes of COVID-19 mass-vaccination, guiding countries where roll-out is yet to commence.	[Hasan, Tasnim; Beardsley, Justin; Fox, Greg J.] Univ Sydney, Fac Med & Hlth, Sydney, NSW 2006, Australia; [Hasan, Tasnim; Thu Anh Nguyen; Fox, Greg J.] Woolcock Inst Med Res, Glebe, NSW 2037, Australia; [Marais, Ben J.] Univ Sydney, Marie Bahir Inst, Westmead, NSW 2145, Australia		Fox, GJ (通讯作者)，Univ Sydney, Fac Med & Hlth, Sydney, NSW 2006, Australia.; Fox, GJ (通讯作者)，Woolcock Inst Med Res, Glebe, NSW 2037, Australia.	tasnim.hasan@sydney.edu.au; justin.beardsley@sydney.edu.au; ben.marais@health.nsw.gov.au; thuanh.nguyen@sydney.edu.au; greg.fox@sydney.edu.au	Marais, Ben/AAX-2626-2021	Marais, Ben/0000-0003-3404-2690; Nguyen, Thu Anh/0000-0002-2089-2902; Fox, Gregory/0000-0002-4085-1411	Australian Department of Foreign Affairs and TradeAustralian Government [APP1153346]	This work was supported by a grant funded by the Australian Department of Foreign Affairs and Trade (APP1153346).	Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Amit S, 2021, EMERG INFECT DIS, V27, P1220, DOI 10.3201/eid2704.210016; Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; [Anonymous], 2021, LANCET; Aran D., 2021, ESTIMATING REAL WORL, DOI [10.1101/2021.02.05.21251139, DOI 10.1101/2021.02.05.21251139]; Australian Government, 2021, AUSTR COVID 19 VACC; Barry M, 2021, VACCINE, V39, P5762, DOI 10.1016/j.vaccine.2021.08.083; Borbone N, 2021, MOLECULES, V26, DOI 10.3390/molecules26040986; Bradley Todd, 2021, medRxiv, DOI 10.1101/2021.02.03.21251078; Centers for Disease Control and Prevention, 2021, COVID 19 VACC PROGR; Chodick G., 2021, EFFECTIVENESS 1 DOSE, DOI [10.1101/2021.01.27.21250612, DOI 10.1101/2021.01.27.21250612]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; datrix.be, 2021, COV VACC BELG; De-Leon H, 2021, 1 INDICATION EFFECT, V2021, DOI [10.1101/2021.02.02.21250630, DOI 10.1101/2021.02.02.21250630]; Department of Health & Social Care, 2021, UK COVID 19 VACC DEL; European Centre for Disease Prevention and Control, 2021, OVERVIEW IMPLEMENTAT; FOPH Federal Office of Public Health, 2021, COR VACC; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Gharpure R, 2021, MMWR-MORBID MORTAL W, V70, P178, DOI 10.15585/mmwr.mm7005e2; Gouvernement Princier, 2021, VACC COVID 19; GOV.UK, 2021, COR COVID 19 UK; Government of Singapore, 2021, COVID 19 VACC; Health Service Executive, 2021, ROLL COVID 19 VACC I; Jayadevan R, SURVEY SYMPTOMS FOLL, V2021, DOI [10.1101/2021.02.08.21251366, DOI 10.1101/2021.02.08.21251366]; Johns Hopkins University, 2020, COVID 19 DASHB CTR S; Kim D., 2021, ASS RACE ETHNICITY O, V2021, DOI [10.1101/2021.02.16.21251769, DOI 10.1101/2021.02.16.21251769]; Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112; Levine-Tiefenbrum M., 2021, DECREASED SARS COV 2, DOI [10.1101/2021.02.06.21251283, DOI 10.1101/2021.02.06.21251283]; Martin CA., 2021, ASS DEMOGRAPHIC OCCU, DOI DOI 10.1101/2021.02.11.21251548; Ministry of Health, 2021, COVID 19 VACC STRAT; Ministry of Health, 2021, NAT VACC PLAN COVID; Ministry of Public Health, 2021, LEB NAT DEPL VACC PL; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; O'Horo, 2021, REAL TIME ANAL MASS, DOI [10.1101/2021.02.20.21252134, DOI 10.1101/2021.02.20.21252134]; Our World in Data, 2021, OUR WORLD DAT COR CO; Pagotto V, 2021, ACTIVE SURVEILLANCE, DOI [10.1101/2021.02.03.21251071, DOI 10.1101/2021.02.03.21251071]; Painter EM, 2021, MMWR-MORBID MORTAL W, V70, P174, DOI 10.15585/mmwr.mm7005e1; Paltiel AD, 2021, HEALTH AFFAIR, V40, P42, DOI 10.1377/hlthaff.2020.02054; Pamplona GM, 2021, KIDNEY INT REP, V6, P1192, DOI 10.1016/j.ekir.2021.02.001; Petter E.MorO.ZuckermanN.Oz-LeviD.YoungerA.AranD.andErlichY., 2021, MEDRXIV, DOI [10.1101/2021.02.08.21251329, DOI 10.1101/2021.02.08.21251329]; Pierce M, 2020, LANCET PSYCHIAT, V7, P883, DOI 10.1016/S2215-0366(20)30308-4; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; Rossman H, 2021, PATTERNS COVID 19 PA, V27, P1055, DOI [10.1038/s41591-021-01337-2, DOI 10.1101/2021.02.08.21251325, 10.1101/2021.02.08.21251325]; Schrading WA, 2021, ACAD EMERG MED, V28, P455, DOI 10.1111/acem.14236; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P125, DOI [10.15585/mmwr.mm7004e1, 10.1111/ajt.16517, 10.15585/mmwr.mm7004e1externalicon]; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; South African Government, 2021, COVID 19 NOV COR S A; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n494; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Vnitra M., 2021, DOES PRIORITIZATION; Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Bank, 2021, COUNTR EC; World Health Organisation, 2021, WHO SAGE ROADM PRIOR; World Health Organisation, 2021, COVID 19 CAND VACC L; World Health Organisation, 2020, FRAM DEC MAK IMPL MA; Yuan SF, 2021, NATURE, V593, P418, DOI 10.1038/s41586-021-03431-4	58	10	10	5	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							326	10.3390/vaccines9040326			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4RR	33915829	gold, Green Published			2022-04-29	WOS:000643768800001
J	Jang, YH; Seong, BL				Jang, Yo Han; Seong, Baik L.			Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses	VACCINES			English	Review						influenza live attenuated vaccine; universal vaccine; antibody; T cell; correlate of protection	PRIME-BOOST VACCINATION; T-CELL RESPONSES; A VIRUS; HETEROSUBTYPIC IMMUNITY; CROSS-PROTECTION; INTRANASAL VACCINE; IGA ANTIBODIES; SECRETORY IGA; BROAD-SPECTRUM; CLEAVAGE SITE	Influenza virus infection remains a major public health challenge, causing significant morbidity and mortality by annual epidemics and intermittent pandemics. Although current seasonal influenza vaccines provide efficient protection, antigenic changes of the viruses often significantly compromise the protection efficacy of vaccines, rendering most populations vulnerable to the viral infection. Considerable efforts have been made to develop a universal influenza vaccine (UIV) able to confer long-lasting and broad protection. Recent studies have characterized multiple immune correlates required for providing broad protection against influenza viruses, including neutralizing antibodies, non-neutralizing antibodies, antibody effector functions, T cell responses, and mucosal immunity. To induce broadly protective immune responses by vaccination, various strategies using live attenuated influenza vaccines (LAIVs) and novel vaccine platforms are under investigation. Despite superior cross-protection ability, very little attention has been paid to LAIVs for the development of UIV. This review focuses on immune responses induced by LAIVs, with special emphasis placed on the breadth and the potency of individual immune correlates. The promising prospect of LAIVs to serve as an attractive and reliable vaccine platforms for a UIV is also discussed. Several important issues that should be addressed with respect to the use of LAIVs as UIV are also reviewed.	[Jang, Yo Han] Andong Natl Univ, Dept Biol Sci & Biotechnol Major Biovaccine Engn, Andong 1375, South Korea; [Jang, Yo Han] Andong Natl Univ, Vaccine Ind Res Inst, Andong 1375, South Korea; [Seong, Baik L.] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 03722, South Korea; [Seong, Baik L.] Yonsei Univ, Vaccine Innovat Technol Alliance VITAL Korea, Seoul 03722, South Korea		Seong, BL (通讯作者)，Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 03722, South Korea.; Seong, BL (通讯作者)，Yonsei Univ, Vaccine Innovat Technol Alliance VITAL Korea, Seoul 03722, South Korea.	yhjh0323@anu.ac.kr; blseong@yonsei.ac.kr		Seong, Baik/0000-0002-7301-082X	National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2018R1D1A1B07048881]; Nature Bioindustry Technology Development and Enterprise Support Project in Gyeongsangbuk-do, South Korea; Ministry of Health and Welfare from the Korean Government [HI20C0144]	This research was funded by National Research Foundation of Korea (NRF-2018R1D1A1B07048881), Nature Bioindustry Technology Development and Enterprise Support Project in Gyeongsangbuk-do, South Korea, and the Ministry of Health and Welfare from the Korean Government (HI20C0144).	Aljurayyan A, 2018, J VIROL, V92, DOI 10.1128/JVI.00114-18; Altenburg AF, 2015, VACCINE, V33, P500, DOI 10.1016/j.vaccine.2014.11.054; Arinaminpathy N, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2019.0879; Arinaminpathy N, 2012, P NATL ACAD SCI USA, V109, P3173, DOI 10.1073/pnas.1113342109; Asahi Y, 2002, J IMMUNOL, V168, P2930, DOI 10.4049/jimmunol.168.6.2930; Balz K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00513; Barria MI, 2013, J INFECT DIS, V207, P115, DOI 10.1093/infdis/jis641; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Blok BA, 2015, J LEUKOCYTE BIOL, V98, P347, DOI 10.1189/jlb.5RI0315-096R; Bodewes R, 2013, CLIN VACCINE IMMUNOL, V20, P1333, DOI 10.1128/CVI.00339-13; Bodewes R, 2011, J VIROL, V85, P11995, DOI 10.1128/JVI.05213-11; Bodewes R, 2010, J GEN VIROL, V91, P1743, DOI 10.1099/vir.0.020784-0; Bodewes R, 2009, LANCET INFECT DIS, V9, P784, DOI 10.1016/S1473-3099(09)70263-4; Bodewes R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005538; Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168; Chen YQ, 2019, J VIROL, V93, DOI 10.1128/JVI.01526-18; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Chen ZY, 2006, VIROLOGY, V345, P416, DOI 10.1016/j.virol.2005.10.005; Cheng X, 2013, J INFECT DIS, V208, P594, DOI 10.1093/infdis/jit207; Cheng X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004436; Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018; CLOVER RD, 1991, J INFECT DIS, V163, P300, DOI 10.1093/infdis/163.2.300; Cohen M, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-321; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Feng JQ, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-102; Fu TM, 2009, VIROLOGY, V385, P218, DOI 10.1016/j.virol.2008.11.035; Gao FX, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010065; Gauger PC, 2014, VIROLOGY, V471, P93, DOI 10.1016/j.virol.2014.10.003; Giurgea LT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030409; GORSE GJ, 1995, J INFECT DIS, V172, P1, DOI 10.1093/infdis/172.1.1; Haaheim R, 1977, Dev Biol Stand, V39, P481; Hatta Y, 2018, VACCINE, V36, P5097, DOI 10.1016/j.vaccine.2018.06.053; Heinen PP, 2001, J GEN VIROL, V82, P2697, DOI 10.1099/0022-1317-82-11-2697; Heinonen S, 2011, LANCET INFECT DIS, V11, P23, DOI 10.1016/S1473-3099(10)70255-3; Ichinohe T, 2006, J MED VIROL, V78, P954, DOI 10.1002/jmv.20647; Ichinohe T, 2010, J MED VIROL, V82, P128, DOI 10.1002/jmv.21670; Ichinohe T, 2009, VACCINE, V27, P6276, DOI 10.1016/j.vaccine.2009.04.074; Ilyushina NA, 2015, J INFECT DIS, V211, P352, DOI 10.1093/infdis/jiu458; Isakova-Sivak I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030061; Isakova-Sivak I, 2015, EXPERT REV VACCINES, V14, P1313, DOI 10.1586/14760584.2015.1075883; Isakova-Sivak I, 2011, VIROLOGY, V412, P297, DOI 10.1016/j.virol.2011.01.004; Islam S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12801; Islam S, 2017, VACCINE, V35, P5666, DOI 10.1016/j.vaccine.2017.08.044; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jang YH, 2020, EXPERT OPIN DRUG DIS, V15, P1441, DOI 10.1080/17460441.2020.1801629; Jang YH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00116; Jang YH, 2016, VACCINE, V34, P1343, DOI 10.1016/j.vaccine.2016.01.053; Jang YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075043; Jang YH, 2013, YONSEI MED J, V54, P271, DOI 10.3349/ymj.2013.54.2.271; Jang YH, 2012, J VIROL, V86, P5953, DOI 10.1128/JVI.07149-11; Jegaskanda S, 2017, J INFECT DIS, V215, P818, DOI 10.1093/infdis/jiw629; Kamijuku H, 2008, MUCOSAL IMMUNOL, V1, P208, DOI 10.1038/mi.2008.2; Khurana S, 2016, J VIROL, V90, P9383, DOI 10.1128/JVI.01408-16; Khurana S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000049; Kiseleva IV, 2010, J GEN VIROL, V91, P931, DOI 10.1099/vir.0.017996-0; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Korenkov D, 2018, HUM VACC IMMUNOTHER, V14, P941, DOI 10.1080/21645515.2017.1417713; Kosik I, 2013, VIROLOGY, V447, P1, DOI 10.1016/j.virol.2013.08.022; Krammer F, 2020, INFLUENZA OTHER RESP, V14, P237, DOI 10.1111/irv.12706; Krejnusova I, 2009, ARCH VIROL, V154, P1599, DOI 10.1007/s00705-009-0479-5; Laidlaw BJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003207; LaMere MW, 2011, J IMMUNOL, V186, P4331, DOI 10.4049/jimmunol.1003057; Lartey S, 2020, J INFECT DIS, V221, P21, DOI 10.1093/infdis/jiz321; Laursen NS, 2018, SCIENCE, V362, P598, DOI 10.1126/science.aaq0620; Lee YJ, 2016, VIROLOGY, V491, P1, DOI 10.1016/j.virol.2016.01.022; Lee YJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00083; Li JW, 2014, INT J INFECT DIS, V27, P37, DOI 10.1016/j.ijid.2014.05.016; Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057; LIEW FY, 1984, EUR J IMMUNOL, V14, P350, DOI 10.1002/eji.1830140414; Lin YP, 2010, J VIROL, V84, P6769, DOI 10.1128/JVI.00458-10; Liu WC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00756; Mamerow S, 2019, VET MICROBIOL, V231, P160, DOI 10.1016/j.vetmic.2019.03.013; Mbawuike IN, 1996, J MED VIROL, V50, P105, DOI 10.1002/(SICI)1096-9071(199610)50:2&lt;105::AID-JMV1&gt;3.0.CO;2-E; McMillan CLD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010026; Mohn KGI, 2020, J INFECT DIS, V221, P1528, DOI 10.1093/infdis/jiz583; Mohn KGI, 2017, J INFECT DIS, V215, P1527, DOI 10.1093/infdis/jix165; Mok DZL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050520; Muramatsu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085582; Nakamura G, 2013, CELL HOST MICROBE, V14, P93, DOI 10.1016/j.chom.2013.06.004; Neerukonda SN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030382; Nogales A, 2016, J VIROL, V90, P6291, DOI 10.1128/JVI.00410-16; Nogales A, 2014, J VIROL, V88, P10525, DOI 10.1128/JVI.01565-14; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Okuya K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070780; Okuya K, 2020, J VIROL, V94, DOI 10.1128/JVI.00408-20; Overton ET, 2014, VACCINE, V32, P5490, DOI 10.1016/j.vaccine.2014.07.078; Peng YC, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00287; Perez JT, 2009, NAT BIOTECHNOL, V27, P572, DOI 10.1038/nbt.1542; REYNOLDS HY, 1988, MAYO CLIN PROC, V63, P161, DOI 10.1016/S0025-6196(12)64949-0; Richt JA, 2009, CURR TOP MICROBIOL, V333, P177, DOI 10.1007/978-3-540-92165-3_9; Sakai T, 2017, SCI REP-UK, V7, DOI 10.1038/srep45043; Sarawar S, 2016, VACCINE, V34, P5090, DOI 10.1016/j.vaccine.2016.08.061; Seo SU, 2007, VACCINE, V25, P8067, DOI 10.1016/j.vaccine.2007.09.012; Shi JZ, 2012, ANTIVIR RES, V93, P346, DOI 10.1016/j.antiviral.2012.01.001; Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258; Smith A, 2020, J VIROL, V94, DOI 10.1128/JVI.01065-19; Stadlbauer D, 2019, SCIENCE, V366, P499, DOI 10.1126/science.aay0678; Stech J, 2005, NAT MED, V11, P683, DOI 10.1038/nm1256; Stech J, 2011, J INFECT DIS, V204, P1483, DOI 10.1093/infdis/jir613; STEINHOFF MC, 1993, J CLIN MICROBIOL, V31, P836, DOI 10.1128/JCM.31.4.836-838.1993; Subramanian R, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005204; Suguitan AL, 2006, PLOS MED, V3, P1541, DOI 10.1371/journal.pmed.0030360; Sun JC, 2011, J IMMUNOL, V186, P1891, DOI 10.4049/jimmunol.1003035; Sun WQ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091033; Sunwoo SY, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030064; Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112; Takada A, 2003, VACCINE, V21, P3212, DOI 10.1016/S0264-410X(03)00234-2; TAMURA S, 1990, VACCINE, V8, P479, DOI 10.1016/0264-410X(90)90250-P; TAMURA S, 1991, EUR J IMMUNOL, V21, P1337, DOI 10.1002/eji.1830210602; TAMURA S, 1992, EUR J IMMUNOL, V22, P477, DOI 10.1002/eji.1830220228; TAYLOR HP, 1985, J EXP MED, V161, P198, DOI 10.1084/jem.161.1.198; Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001; Vanderven HA, 2016, EBIOMEDICINE, V8, P277, DOI 10.1016/j.ebiom.2016.04.029; Vincent AL, 2012, J VIROL, V86, P10597, DOI 10.1128/JVI.01439-12; VIRELIZIER JL, 1977, NATURE, V266, P52, DOI 10.1038/266052a0; Wang P, 2019, MBIO, V10, DOI 10.1128/mBio.02180-19; Wang ZF, 2016, J GEN VIROL, V97, P3205, DOI 10.1099/jgv.0.000651; Waring BM, 2018, J VIROL, V92, DOI 10.1128/JVI.01741-17; Winarski KL, 2019, P NATL ACAD SCI USA, V116, P15194, DOI 10.1073/pnas.1821317116; Wolf AI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028445; Wu NC, 2018, NAT STRUCT MOL BIOL, V25, P115, DOI 10.1038/s41594-018-0025-9; YEWDELL JW, 1981, J IMMUNOL, V126, P1814; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832; Zhong WM, 2014, J INFECT DIS, V209, P986, DOI 10.1093/infdis/jit811; Zhou B, 2016, J VIROL, V90, P8454, DOI 10.1128/JVI.00163-16	128	5	5	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							353	10.3390/vaccines9040353			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UD	33916924	gold, Green Published			2022-04-29	WOS:000643775200001
J	Safadi, R; Khoury, T; Saed, N; Hakim, M; Jamalia, J; Nijim, Y; Farah, N; Nuser, T; Natur, N; Mahamid, M; Amer, J; Roppert, PL; Gerlich, WH; Glebe, D				Safadi, Rifaat; Khoury, Tawfik; Saed, Nizar; Hakim, Marwan; Jamalia, Jeryes; Nijim, Yousef; Farah, Nicola; Nuser, Tawfik; Natur, Nidaa; Mahamid, Mahmud; Amer, Johnny; Roppert, Pia L.; Gerlich, Wolfram H.; Glebe, Dieter			Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac	VACCINES			English	Article						HBV; vaccines; transmission; vertical; infection		Background and aims: Peripartum transmission of hepatitis B virus (HBV) from an infected mother to the child can be prevented in most but not all cases by immediate vaccination of the newborn. The aim of this study was to compare the efficacy of two licensed hepatitis B vaccines, Engerix-B versus Sci-B-Vac, in preventing peripartum HBV transmission. Methods: A prospective multicenter randomized controlled study in 4 delivery centers was performed from 2009 to 2014. HBsAg positive pregnant women and their newborns were recruited at the delivery rooms. All newborns received Hepatitis B Immune Globulin within 10 h after birth, as well as active HBV vaccination at 0, 1 and 6 months of age. Maternal assessment at delivery included transaminases, blood count, international normalized ratio and viral status. Infants were tested for HBsAg, anti-HBc and anti-HBs at 12 months of age. Results: In the intention to treat (ITT), 171 infant and mother pairs fulfilled the study enrollment criteria and completed follow up, 82 received Engerix-B and 89 Sci-B-Vac. Maternal parameters and viral status were similar in both groups. At 12 months of age, the Sci-B-Vac group had lower HBsAg carriage rates (1/89, 1.1%) than the Engerix-B group (5/82, 6.1%) with borderline significance (risk difference of -0.05, 95% CI -0.11-0.007, t-test = 0.05), and borderline significance lower vaccine failure rates with anti-HBs < 10 mIU/mL in the Sci-B-Vac (2/89, 2.2%) than in the Engerix-B (8/82, 9.8%, p = 0.05). Higher seroprotection rates were found in the Sci-B-Vac group with all anti-HBs titer stratifications of >10 mIU/mL (p = 0.05), >100 mIU/mL (p = 0.05) and >1000 mIU/mL (p = 0.01). Active/passive vaccination was effective in 10/13 cases with maternal HBV DNA levels > 7 log10 IU/mL up to 9.5 log10 IU/mL, but failed in 3 cases for unknown reasons. Conclusion: Sci-B-Vac was superior to Engerix-B in preventing peripartum HBV transmission in neonates from HBsAg+ mothers and induces significantly higher anti-HBs levels. NIH registration number: NCT 01133184.	[Safadi, Rifaat; Khoury, Tawfik; Natur, Nidaa; Amer, Johnny] Hadassah Hebrew Univ Hosp, Inst Gastroenterol, Liver Unit, IL-91120 Jerusalem, Israel; [Safadi, Rifaat; Saed, Nizar; Farah, Nicola; Mahamid, Mahmud] Holy Family Hosp, Liver Unit, IL-1613101 Nazareth, Israel; [Khoury, Tawfik] Galilee Med Ctr, Dept Gastroenterol, IL-22100 Nahariyya, Israel; [Khoury, Tawfik] Bar Ilan Univ, Fac Med Galilee, IL-1311502 Safed, Israel; [Hakim, Marwan; Nijim, Yousef] Nazareth Hosp, IL-1613101 Nazareth, Israel; [Jamalia, Jeryes; Nuser, Tawfik] French Hosp, IL-1613101 Nazareth, Israel; [Natur, Nidaa] Univ Haifa, Fac Social Welf & Hlth Sci, Cheryl Spencer Dept Nursing, IL-3498838 Haifa, Israel; [Mahamid, Mahmud] Hebrew Univ Jerusalem, Fac Med, Shaare Zedek Med Ctr, Dept Gastroenterol & Liver Dis, IL-91120 Jerusalem, Israel; [Amer, Johnny] Dajani Hosp, IL-91120 Jerusalem, Israel; [Roppert, Pia L.; Gerlich, Wolfram H.; Glebe, Dieter] Justus Liebig Univ Giessen, Natl Reference Ctr Hepatitis B Viruses & Hepatiti, Inst Med Virol, D-35392 Giessen, Germany; [Glebe, Dieter] German Ctr Infect Res DZIF, Partner Site Giessen Marburg Langen, D-35392 Giessen, Germany		Khoury, T (通讯作者)，Hadassah Hebrew Univ Hosp, Inst Gastroenterol, Liver Unit, IL-91120 Jerusalem, Israel.; Khoury, T (通讯作者)，Galilee Med Ctr, Dept Gastroenterol, IL-22100 Nahariyya, Israel.; Khoury, T (通讯作者)，Bar Ilan Univ, Fac Med Galilee, IL-1311502 Safed, Israel.	safadi@hadassah.org.il; tawfikk@gmc.gov.il; dr.nizarsaad@yahoo.com; mhakim@bezeqint.net; jjeryes@st-vincent-hospital.com; yousifnijim@nazhosp.com; n.farah@hfhosp.org; nseirt@yahoo.com; nidaa@hadassah.org.il; mmahamid@szmc.org.il; joni@hadassah.org.il; p_roppert@gmx.de; wolfram.h.gerlich@viro.med.uni-giessen.de; dieter.glebe@viro.med.uni-giessen.de		Hakim, Marwan/0000-0003-4177-3811; natour, nidaa/0000-0002-7045-5989	DFG (Deutsche Forschungsgemeinschaft, German Research foundation)German Research Foundation (DFG) [GL595/2-1]; German Ministry of Health via the Robert Koch Institute, Berlin, Germany	The study was supported by the grant (GL595/2-1) to DG and RS from the DFG (Deutsche Forschungsgemeinschaft, German Research foundation). The National Reference Center for Hepatitis B viruses and Hepatitis D viruses at the Justus Liebig University Giessen is supported by the German Ministry of Health via the Robert Koch Institute, Berlin, Germany.	Abdelnabi Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113821; Alter MJ, 2003, J HEPATOL, V39, pS64, DOI 10.1016/S0168-8278(03)00141-7; [Anonymous], 2015, GUIDELINES PREVENTIO; Boucheron P, 2021, LANCET INFECT DIS, V21, P85, DOI 10.1016/S1473-3099(20)30593-4; Bremer CM, 2011, J HEPATOL, V55, P29, DOI 10.1016/j.jhep.2010.10.019; Brown RS, 2016, HEPATOLOGY, V63, P319, DOI 10.1002/hep.28302; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen HL, 2017, J INFECT DIS, V216, pS785, DOI 10.1093/infdis/jix429; Chen HL, 2012, GASTROENTEROLOGY, V142, P773, DOI 10.1053/j.gastro.2011.12.035; delCanho R, 1997, VACCINE, V15, P1624, DOI 10.1016/S0264-410X(97)00080-7; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Funk AL, 2021, LANCET INFECT DIS, V21, P70, DOI 10.1016/S1473-3099(20)30586-7; Furuncuoglu Y, 2016, POSTGRAD MED J, V92, P510, DOI 10.1136/postgradmedj-2015-133876; Gerlich WH, 2021, LANCET INFECT DIS, V21, P6, DOI 10.1016/S1473-3099(20)30654-X; Glebe D, 2003, J VIROL, V77, P9511, DOI 10.1128/JVI.77.17.9511-9521.2003; Hu KQ, 2011, DIGEST DIS SCI, V56, P3163, DOI 10.1007/s10620-011-1840-6; Jonas MM, 2009, LIVER INT, V29, P133, DOI 10.1111/j.1478-3231.2008.01933.x; Kao JH, 2001, J PEDIATR-US, V139, P349, DOI 10.1067/mpd.2001.116277; Kao JH, 2008, AM J MED, V121, P1029, DOI 10.1016/j.amjmed.2008.09.002; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Madalinski K, 2004, MED SCI MONITOR, V10, pPI10; Michaiel Rani, 2012, Harefuah, V151, P671; Milich D R, 1987, Adv Exp Med Biol, V225, P233; Nelson NP, 2014, J PEDIATR INFECT DIS, V3, pS7, DOI 10.1093/jpids/piu064; NEURATH AR, 1986, VACCINE, V4, P35, DOI 10.1016/S0264-410X(86)80001-9; Ni YH, 2012, J HEPATOL, V57, P730, DOI 10.1016/j.jhep.2012.05.021; Perumalswami PV, 2013, J HEPATOL, V58, P890, DOI 10.1016/j.jhep.2013.01.004; Qawasmi M, 2015, HUM VACC IMMUNOTHER, V11, P1717, DOI 10.1080/21645515.2015.1041687; Seiz PL, 2015, INT J MED MICROBIOL, V305, P663, DOI 10.1016/j.ijmm.2015.08.016; Shouval D, 2015, MED MICROBIOL IMMUN, V204, P57, DOI 10.1007/s00430-014-0374-x; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644; Su WJ, 2012, J INFECT DIS, V205, P757, DOI 10.1093/infdis/jir852; Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156; Tong MJ, 2011, DIGEST DIS SCI, V56, P3143, DOI 10.1007/s10620-011-1841-5; WHO Publication, 2010, Vaccine, V28, P589, DOI 10.1016/j.vaccine.2009.10.110; Wiseman E, 2009, MED J AUSTRALIA, V190, P489, DOI 10.5694/j.1326-5377.2009.tb02524.x; Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049	38	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							331	10.3390/vaccines9040331			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5FS	33915943	Green Published, gold			2022-04-29	WOS:000643805500001
J	Sergeeva, M; Romanovskaya-Romanko, E; Zabolotnyh, N; Pulkina, A; Vasilyev, K; Shurigina, AP; Buzitskaya, J; Zabrodskaya, Y; Fadeev, A; Vasin, A; Vinogradova, TI; Stukova, MA				Sergeeva, Mariia; Romanovskaya-Romanko, Ekaterina; Zabolotnyh, Natalia; Pulkina, Anastasia; Vasilyev, Kirin; Shurigina, Anna Polina; Buzitskaya, Janna; Zabrodskaya, Yana; Fadeev, Artem; Vasin, Andrey; Vinogradova, Tatiana, I; Stukova, Marina A.			Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs	VACCINES			English	Article						M. tuberculosis multistage vaccine; TB10.4; HspX; influenza vector; mucosal immunization	NS1 PROTEIN; A VIRUSES; BCG; TEMPERATURE; EXPRESSION; GENERATION; RESPONSES; ANIMALS; CD4(+); DOSR	New strategies providing protection against tuberculosis (TB) are still pending. The airborne nature of Mycobacterium tuberculosis (M.tb) infection assumes that the mucosal delivery of the TB vaccine could be a more promising strategy than the systemic route of immunization. We developed a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1-124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. The Flu/THSP vector was safe and stimulated a systemic TB-specific CD4+ and CD8+ T-cell immune response after intranasal immunization in mice. Double intranasal immunization with the Flu/THSP vector induced protection against two virulent M.tb strains equal to the effect of BCG subcutaneous injection in mice. In a guinea pig TB model, one intranasal immunization with Flu/THSP improved protection against M.tb when tested as a vaccine candidate for boosting BCG-primed immunity. Importantly, enhanced protection provided by a heterologous BCG-prime -> Flu/THSP vector boost immunization scheme was associated with a significantly reduced lung and spleen bacterial burden (mean decrease of 0.77 lg CFU and 0.72 lg CFU, respectively) and improved lung pathology 8.5 weeks post-infection with virulent M.tb strain H37Rv.	[Sergeeva, Mariia; Romanovskaya-Romanko, Ekaterina; Pulkina, Anastasia; Vasilyev, Kirin; Shurigina, Anna Polina; Buzitskaya, Janna; Zabrodskaya, Yana; Fadeev, Artem; Vasin, Andrey; Stukova, Marina A.] Minist Hlth Russian Federat, Smorodintsev Res Inst Influenza, St Petersburg 197376, Russia; [Zabolotnyh, Natalia; Vinogradova, Tatiana, I] Minist Hlth Russian Federat, St Petersburg State Res Inst Phthisiopulmonol, St Petersburg 191036, Russia; [Pulkina, Anastasia; Zabrodskaya, Yana; Vasin, Andrey] Peter Great St Petersburg Polytech Univ, St Petersburg 195251, Russia		Sergeeva, M (通讯作者)，Minist Hlth Russian Federat, Smorodintsev Res Inst Influenza, St Petersburg 197376, Russia.	mari.v.sergeeva@gmail.com; romromka@yandex.ru; zabol-natal@yandex.ru; pureska@mail.ru; kirillv5@yandex.ru; ann-polin@yandex.ru; janna.buzitskaya@influenza.spb.ru; zabryaka@yandex.ru; afadeew@gmail.com; vasin_av@spbstu.ru; vinogradova@spbniif.ru; marina.stukova@influenza.spb.ru	Fadeev, Artem V/I-9397-2016; Zabolotnykh, Natalia/ABC-9559-2021; Romanovskaya-Romanko, Ekaterina/J-1022-2018; Zabrodskaya, Yana A/K-6999-2016; Sergeeva, Mariia/F-8963-2017; Vasilev, Kirill/I-8895-2018; Vasin, Andrey Vladimirovich/AAM-7288-2020; Shurygina, Anna-Polina/C-4948-2014	Fadeev, Artem V/0000-0003-3558-3261; Romanovskaya-Romanko, Ekaterina/0000-0001-7560-398X; Zabrodskaya, Yana A/0000-0003-2012-9461; Sergeeva, Mariia/0000-0003-0411-9896; Vasilev, Kirill/0000-0002-7750-9652; Vasin, Andrey Vladimirovich/0000-0002-1391-7139; Shurygina, Anna-Polina/0000-0003-3685-7068	Ministry of Education and Science of the Russian FederationMinistry of Education and Science, Russian Federation [14.N08.11.0173]	This research was funded by the Ministry of Education and Science of the Russian Federation, government contract number 14.N08.11.0173 (2017-2019).	Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285; Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Boon C, 2012, FUTURE MICROBIOL, V7, P513, DOI [10.2217/fmb.12.14, 10.2217/FMB.12.14]; Chauhan P, 2013, SCI REP-UK, V3, DOI 10.1038/srep01821; Davenne T, 2016, EXPERT REV VACCINES, V15, P1009, DOI 10.1586/14760584.2016.1170599; Dey B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018773; Egorov A, 1998, J VIROL, V72, P6437, DOI 10.1128/JVI.72.8.6437-6441.1998; Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259; Falcon AM, 2004, J VIROL, V78, P3880, DOI 10.1128/JVI.78.8.3880-3888.2004; Florido M, 2015, EUR J IMMUNOL, V45, P780, DOI 10.1002/eji.201444954; Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Kaufmann SHE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00316; Komissarov A, 2016, INFLUENZA OTHER RESP, V10, P247, DOI 10.1111/irv.12389; Krivitskaya VZ, 2018, APPL BIOCHEM MICRO+, V54, P756, DOI 10.1134/S0003683818070049; Kuznetsova I, 2014, J GEN VIROL, V95, P337, DOI 10.1099/vir.0.056036-0; Lalvani A, 2010, ENFERM INFEC MICR CL, V28, P245, DOI 10.1016/j.eimc.2009.05.012; Lin MY, 2007, INFECT IMMUN, V75, P3523, DOI 10.1128/IAI.01999-06; Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407; Niu HX, 2011, VACCINE, V29, P9451, DOI 10.1016/j.vaccine.2011.10.032; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; REED L. J., 1938, AMER JOUR HYG, V27, P493; RICHMAN DD, 1979, REV INFECT DIS, V1, P413; Sereinig S, 2006, CLIN VACCINE IMMUNOL, V13, P898, DOI 10.1128/CVI.00056-06; Shurygina A. -P. S., 2013, Voprosy Virusologii, V58, P28; Singh S, 2014, VACCINE, V32, P712, DOI 10.1016/j.vaccine.2013.11.065; Stasakova J, 2005, J GEN VIROL, V86, P185, DOI 10.1099/vir.0.80422-0; Stukova MA, 2006, TUBERCULOSIS, V86, P236, DOI 10.1016/j.tube.2006.01.010; Stylianou E, 2019, EXPERT REV VACCINES, V18, P1271, DOI 10.1080/14760584.2019.1692657; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Vasilyev K.A., 2018, MIR J, V5, P48, DOI 10.18527/2500-2236-2018-5-1-48-58; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Wilkins MR, 1999, METH MOL B, V112, P531; Yousefi-Avarvand Arshid, 2018, [Frontiers in Biology, 生物学前沿], V13, P293; Zumla A, 2000, POSTGRAD MED J, V76, P259, DOI 10.1136/pmj.76.895.259	36	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							394	10.3390/vaccines9040394			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4QQ	33923548	gold, Green Published			2022-04-29	WOS:000643766000001
J	Ramirez, JD; Munoz, M; Ballesteros, N; Patino, LH; Castaneda, S; Rincon, CA; Mendez, C; Oliveros, C; Perez, J; Marquez, EK; Ortiz, FD; Correa-Cardenas, CA; Duque, MC; Paniz-Mondolfi, A				David Ramirez, Juan; Munoz, Marina; Ballesteros, Nathalia; Patino, Luz H.; Castaneda, Sergio; Rincon, Carlos A.; Mendez, Claudia; Oliveros, Carolina; Perez, Julie; Marquez, Elizabeth K.; de los Santos Ortiz, Frank; Correa-Cardenas, Camilo A.; Clara Duque, Maria; Paniz-Mondolfi, Alberto			Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia	VACCINES			English	Article						SARS-CoV-2; reinfections; genomic surveillance; Colombia		The continuing evolution of SARS-CoV-2 and the emergence of novel variants have raised concerns about possible reinfection events and potential changes in the coronavirus disease 2019 (COVID-19) transmission dynamics. Utilizing Oxford Nanopore technologies, we sequenced paired samples of three patients with positive RT-PCR results in a 1-2-month window period, and subsequent phylogenetics and genetic polymorphism analysis of these genomes was performed. Herein, we report, for the first time, genomic evidence of one case of reinfection in Colombia, exhibiting different SARS-CoV-2 lineage classifications between samples (B.1 and B.1.1.269). Furthermore, we report two cases of possible viral persistence, highlighting the importance of deepening our understanding on the evolutionary intra-host traits of this virus throughout different timeframes of disease progression. These results emphasize the relevance of genomic surveillance as a tool for understanding SARS-CoV-2 infection dynamics, and how this may translate effectively to future control and mitigations efforts, such as the national vaccination program.	[David Ramirez, Juan; Munoz, Marina; Ballesteros, Nathalia; Patino, Luz H.; Castaneda, Sergio] Univ Rosario, Fac Ciencias Nat, Ctr Invest Microbiol & Biotecnol UR CIMBIUR, Bogota 110111, Colombia; [Rincon, Carlos A.; Mendez, Claudia; Oliveros, Carolina; Perez, Julie; Marquez, Elizabeth K.; de los Santos Ortiz, Frank; Correa-Cardenas, Camilo A.; Clara Duque, Maria] Direcc Sanidad Ejercito, Lab Referencia & Invest, Grp Invest Enfermedades Trop Ejercito GINETEJ, Bogota 110111, Colombia; [Paniz-Mondolfi, Alberto] Icahn Sch Med Mt Sinai, New York, NY 10001 USA; [Paniz-Mondolfi, Alberto] Inst Invest Biomed IDB Incubadora Venezolana Cien, Barquisimeto 3001, Venezuela		Ramirez, JD (通讯作者)，Univ Rosario, Fac Ciencias Nat, Ctr Invest Microbiol & Biotecnol UR CIMBIUR, Bogota 110111, Colombia.	juand.ramirez@urosario.edu.co; Claudiamendez11@gmail.com; nathalia.ballesteros@urosario.edu.co; lhpatinoblan@yahoo.com; scastanedagarzon@gmail.com; rinconarangocarlos@gmail.com; claudia.munoz@urosario.edu.co; Carolinaesm6012@hotmail.com; Julieperez8228@gmail.com; Marqueze_llk11@hotmail.com; frankortizserrano@gmail.com; camilocc510@gmail.com; Duquemacla@outlook.com; Alberto.Paniz-mondolfi@mountsinai.org	Correa-Cárdenas, Camilo A/ABF-1490-2020; Ramirez, Juan David/F-3524-2016	Correa-Cárdenas, Camilo A/0000-0001-5009-6213; Castaneda Garzon, Sergio Andres/0000-0001-8720-9664; Ramirez, Juan David/0000-0002-1344-9312; Duque-Ramirez, Maria Clara/0000-0001-9861-5932; Mendez Bejarano, Claudia Patricia/0000-0002-9280-2531; PEREZ RICO, JULIE JANETH/0000-0002-2908-6982; Munoz, Marina/0000-0002-4216-6928; ORTIZ SERRANO, FRANK DE LOS SANTOS/0000-0001-5224-6764	University of Glasgow; Scottish Funding Council; Global Challenges Research Fund (GCRF); GCRF Research Network [EP/T003782/1]	This research was funded by the University of Glasgow, Scottish Funding Council and the Global Challenges Research Fund (GCRF) and GCRF Research Network EP/T003782/1.	[Anonymous], 2021, INSTITUTO NACL SALUD; Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457; Bull RA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20075-6; Bussani R, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103104; Candido DS, 2020, SCIENCE, V369, P1255, DOI 10.1126/science.abd2161; Chan WS, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01454-3; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Ramirez JD, 2021, J MED VIROL, V93, P1158, DOI 10.1002/jmv.26393; Faria NR, GENOMIC CHARACTERISA; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Kim Y.-G., 2020, CLIN, DOI [10.1093/cid/ciaa1421, DOI 10.1093/CID/CIAA1421]; Martin D., EMERGENCE ONGOING CO; Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015; Mofatto L.S., 2021, SSRN ELECT J, DOI [10.2139/ssrn.3793486, DOI 10.2139/SSRN.3793486]; Munoz M, 2021, INT J INFECT DIS, V105, P329, DOI 10.1016/j.ijid.2021.02.073; Naveca F., 2021, SARS COV 2 REINFECTI; Novoa W, 2021, ANN CLIN MICROB ANTI, V20, DOI 10.1186/s12941-020-00413-8; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091; Oude Munnink, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1538, DOI 10.1093/CID/CIAA1538]; Prado-Vivar B, 2020, LANCET INFECT DIS, V21, pE142, DOI 10.1016/S1473-3099(20)30910-5; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Song SH, 2020, GENOM PROTEOM BIOINF, V18, P749, DOI 10.1016/j.gpb.2020.09.001; Stokel-Walker C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n99; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; Truong Thao T, 2021, medRxiv, DOI 10.1101/2021.02.27.21252099; Vibholm LK, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2021.103230; Wang LT, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00900; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; Williams TC, 2021, LANCET RESP MED, V9, P333, DOI 10.1016/S2213-2600(21)00075-8; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Zucman N, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab129, DOI 10.1093/cid/ciab129]	33	6	6	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							282	10.3390/vaccines9030282			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5RN	33808687	Green Published, gold			2022-04-29	WOS:000634211100001
J	Estevez-Herrera, J; Perez-Yanes, S; Cabrera-Rodriguez, R; Marquez-Arce, D; Trujillo-Gonzalez, R; Machado, JD; Madrid, R; Valenzuela-Fernandez, A				Estevez-Herrera, Judith; Perez-Yanes, Silvia; Cabrera-Rodriguez, Romina; Marquez-Arce, Daniel; Trujillo-Gonzalez, Rodrigo; Machado, Jose-David; Madrid, Ricardo; Valenzuela-Fernandez, Agustin			Zika Virus Pathogenesis: A Battle for Immune Evasion	VACCINES			English	Review						Zika virus (ZIKV); immune evasion; infection; tissue propagation; congenital and neurological disorders	UNFOLDED PROTEIN RESPONSE; CENTRAL-NERVOUS-SYSTEM; ANTIBODY-DEPENDENT ENHANCEMENT; HUMAN PLACENTAL TROPHOBLASTS; INTERFERON-STIMULATED GENES; GUILLAIN-BARRE-SYNDROME; RIG-I; NONSTRUCTURAL PROTEINS; HUMAN BRAIN; STEM-CELLS	Zika virus (ZIKV) infection and its associated congenital and other neurological disorders, particularly microcephaly and other fetal developmental abnormalities, constitute a World Health Organization (WHO) Zika Virus Research Agenda within the WHO's R&D Blueprint for Action to Prevent Epidemics, and continue to be a Public Health Emergency of International Concern (PHEIC) today. ZIKV pathogenicity is initiated by viral infection and propagation across multiple placental and fetal tissue barriers, and is critically strengthened by subverting host immunity. ZIKV immune evasion involves viral non-structural proteins, genomic and non-coding RNA and microRNA (miRNA) to modulate interferon (IFN) signaling and production, interfering with intracellular signal pathways and autophagy, and promoting cellular environment changes together with secretion of cellular components to escape innate and adaptive immunity and further infect privileged immune organs/tissues such as the placenta and eyes. This review includes a description of recent advances in the understanding of the mechanisms underlying ZIKV immune modulation and evasion that strongly condition viral pathogenesis, which would certainly contribute to the development of anti-ZIKV strategies, drugs, and vaccines.	[Estevez-Herrera, Judith; Perez-Yanes, Silvia; Cabrera-Rodriguez, Romina; Marquez-Arce, Daniel; Trujillo-Gonzalez, Rodrigo; Machado, Jose-David; Valenzuela-Fernandez, Agustin] Univ La Laguna, Secc Med, Fac Med, Lab Inmunol Celular & Viral,Unidad Farmacol, Tenerife 38320, Spain; [Estevez-Herrera, Judith; Perez-Yanes, Silvia; Cabrera-Rodriguez, Romina; Marquez-Arce, Daniel; Machado, Jose-David; Valenzuela-Fernandez, Agustin] Univ La Laguna, Unidad Virol & Microbiol IUETSPC, Tenerife 38296, Spain; [Trujillo-Gonzalez, Rodrigo] Univ La Laguna, Fac Ciencias, Dept Anal Matemat, Tenerife 38296, Spain; [Madrid, Ricardo] BioAssays SL, Campus Cantoblanco, Madrid 28049, Spain; [Madrid, Ricardo] UCM, Fac Biol, Dept Genet Fisiol & Microbiol, Madrid 28040, Spain		Valenzuela-Fernandez, A (通讯作者)，Univ La Laguna, Secc Med, Fac Med, Lab Inmunol Celular & Viral,Unidad Farmacol, Tenerife 38320, Spain.; Valenzuela-Fernandez, A (通讯作者)，Univ La Laguna, Unidad Virol & Microbiol IUETSPC, Tenerife 38296, Spain.	jesteveh@ull.edu.es; alu0101073996@ull.edu.es; rcabrerr@ull.edu.es; alu0100540420@ull.edu.es; rotrujil@ull.edu.es; jdmacha@ull.edu.es; rimadrid@ucm.es; avalenzu@ull.edu.es	; Estevez Herrera, Judith/R-5333-2018; Valenzuela-Fernandez, Agustin/B-6219-2014	Madrid Gonzalez, Ricardo/0000-0002-1350-9864; Estevez Herrera, Judith/0000-0001-8130-2294; Trujillo-Gonzalez, Rodrigo/0000-0001-7321-5430; Cabrera Rodriguez, Romina/0000-0001-5671-6196; Valenzuela-Fernandez, Agustin/0000-0002-2585-8703	"Ministerio de Ciencia, Innovacion y Universidades", SpainSpanish Government [RTI2018-093747-B-100]; European Regional Development Fund (ERDF)European Commission [ProID2020010093]; ERDFEuropean Commission [UNLL10-3E-783]; Fundacion CajaCanarias [UNLL10-3E-783]; Spanish AIDS network "Red Tematica Cooperativa de Investigacion en SIDA" as part of the Plan Nacional R+D+I [RD12/0017/0034]; Spanish "Instituto de Salud Carlos III (ISCIII)-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER)"; M-ULL PhD-training contract ("Contratos predoctorales M-ULL para la Formacion de Doctores, Convocatoria 2019, Universidad de La Laguna and Ministerio de Ciencia, Innovacion y Universidades", Spain) [RD12/0017/0034]; Fundacion Doctor Manuel Morales; "Programa Predoctoral de Formacion del Personal Investigador, Agencia Canaria de Investigacion, Innovacion y Sociedad de la Informacion" fellowship [TESIS2017010116]; European Social Fund-fellowship [TESIS2017010116]; Cabildo of Tenerife "Agustin de Betancourt" 2017 Program	This research and A.V.-F.'s Lab was funded by RTI2018-093747-B-100 ("Ministerio de Ciencia, Innovacion y Universidades", Spain) and the European Regional Development Fund (ERDF), ProID2020010093 (RIS-3 Canarias Strategy-"Maria del Carmen Betancourt y Molina" Program, "Consejeria de Economia, Conocimiento y Empleo, Gobierno de Canarias"), UNLL10-3E-783 (ERDF and "Fundacion CajaCanarias"), and by the Spanish AIDS network "Red Tematica Cooperativa de Investigacion en SIDA" RD12/0017/0034 as part of the Plan Nacional R+D+I and cofunded by Spanish "Instituto de Salud Carlos III (ISCIII)-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER)". R.C.-R., S.P.-Y. and D.M.-A. are funded by RD12/0017/0034, M-ULL PhD-training contract ("Contratos predoctorales M-ULL para la Formacion de Doctores, Convocatoria 2019, Universidad de La Laguna and Ministerio de Ciencia, Innovacion y Universidades", Spain), "Fundacion Doctor Manuel Morales" and "TESIS2017010116" ("Programa Predoctoral de Formacion del Personal Investigador, Agencia Canaria de Investigacion, Innovacion y Sociedad de la Informacion" and European Social Fund-fellowships). J.E.-H. is funded by the Cabildo of Tenerife "Agustin de Betancourt" 2017 Program.	Aagaard KM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41389; Abbink P, 2018, NAT REV MICROBIOL, V16, P594, DOI 10.1038/s41579-018-0039-7; Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157; Ades AE, 2020, LANCET INFECT DIS, V20, pE61, DOI 10.1016/S1473-3099(20)30021-9; Agrelli A, 2019, INFECT GENET EVOL, V69, P22, DOI 10.1016/j.meegid.2019.01.018; Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008; Akiyama BM, 2016, SCIENCE, V354, P1148, DOI 10.1126/science.aah3963; Ali S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005135; Alves-Leon SV, 2019, MULT SCLER J, V25, P427, DOI 10.1177/1352458518781992; Amara A, 2015, NAT REV MICROBIOL, V13, P461, DOI 10.1038/nrmicro3469; [Anonymous], 2016, JAMA-J AM MED ASSOC, V316, P2588, DOI [10.1001/jama.2016.19328, 10.1001/jama.2016.18655]; [Anonymous], 2014, STAT 1 M IHR EM COMM; [Anonymous], 2020, CORONAVIRUS DIS COVI; [Anonymous], 2016, ZIK VIR DIS EP POT A; de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016; Aviles-Vergara PA, 2020, INT J INFECT DIS, V99, P458, DOI 10.1016/j.ijid.2020.08.008; Azevedo RSS, 2016, J CLIN VIROL, V85, P56, DOI 10.1016/j.jcv.2016.10.024; Azouz F, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020162; Barbi L, 2018, BRAZ J INFECT DIS, V22, P137, DOI 10.1016/j.bjid.2018.02.005; Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365; Baril M, 2009, J VIROL, V83, P1299, DOI 10.1128/JVI.01659-08; Barouch DH, 2017, IMMUNITY, V46, P176, DOI 10.1016/j.immuni.2017.02.005; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]; Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008; Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558; Bernatchez JA, 2020, J MED CHEM, V63, P470, DOI 10.1021/acs.jmedchem.9b00775; Berthet N, 2014, VECTOR-BORNE ZOONOT, V14, P862, DOI 10.1089/vbz.2014.1607; Best SM, 2017, J VIROL, V91, DOI [10.1128/JVI.01970-16, 10.1128/jvi.01970-16]; Bhattacharyya S, 2014, J GEN VIROL, V95, P71, DOI 10.1099/vir.0.057265-0; Bido-Medina R, 2018, ANN CLIN TRANSL NEUR, V5, P752, DOI 10.1002/acn3.575; Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5; Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816; Bourdon M, 2020, GENES IMMUN, V21, P365, DOI 10.1038/s41435-020-00116-2; Bowen JR, 2018, VIRUS RES, V254, P21, DOI 10.1016/j.virusres.2017.08.018; Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164; Boyer S, 2018, MICROBES INFECT, V20, P646, DOI 10.1016/j.micinf.2018.01.006; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636; BRES P, 1970, B WORLD HEALTH ORGAN, V43, P223; Ferreira MLB, 2017, AM J TROP MED HYG, V97, P1405, DOI 10.4269/ajtmh.17-0106; Brown C, 2016, CAN MED ASSOC J, V188, pE34, DOI 10.1503/cmaj.109-5212; Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005; Buggele WA, 2013, J VIROL, V87, P9260, DOI 10.1128/JVI.01064-13; Bullard BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35755-z; Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5; Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847; Campos JLS, 2018, NAT IMMUNOL, V19, P1189, DOI 10.1038/s41590-018-0210-3; Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6; Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI [10.3201/eid2006.140138, 10.3201/eid2011.141380]; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964; Casazza RL, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3446; Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6; Chan M., 2016, WHO DIRECTOR GEN BRI; Chaves BA, 2018, J INFECT DIS, V218, P563, DOI 10.1093/infdis/jiy196; Chen JC, 2016, INT J INFECT DIS, V51, P139, DOI 10.1016/j.ijid.2016.07.015; Chevaliez Stephane, 2009, V189, P203, DOI 10.1007/978-3-540-79086-0_8; Chiu CF, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00214; Coffey LL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04777-6; Coldbeck-Shackley RC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030530; Coletti AM, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.170100; Collins ND, 2019, EMERG MICROBES INFEC, V8, P1126, DOI 10.1080/22221751.2019.1645572; Coloma J, 2016, CELL REP, V16, P3097, DOI 10.1016/j.celrep.2016.08.091; Conde JN, 2020, J VIROL, V94, DOI 10.1128/JVI.01086-20; Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990; Counotte MJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002611; Coutard B, 2017, J VIROL, V91, DOI 10.1128/JVI.02202-16; Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125; Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296; Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489; Dang JW, 2019, CELL REP, V27, P3618, DOI 10.1016/j.celrep.2019.05.059; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; de Weerd NA, 2012, IMMUNOL CELL BIOL, V90, P483, DOI 10.1038/icb.2012.9; Desvignes T, 2015, TRENDS GENET, V31, P613, DOI 10.1016/j.tig.2015.09.002; Devillers J, 2018, SAR QSAR ENVIRON RES, V29, P103, DOI 10.1080/1062936X.2017.1411642; Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442; Diamond MS, 2019, ANNU REV MED, V70, P121, DOI 10.1146/annurev-med-040717-051127; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Dickey LL, 2017, J NEUROIMMUNOL, V308, P17, DOI 10.1016/j.jneuroim.2017.01.016; Ding Q, 2018, P NATL ACAD SCI USA, V115, pE6310, DOI 10.1073/pnas.1803406115; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048; Dong HP, 2014, J GEN VIROL, V95, P763, DOI 10.1099/vir.0.062208-0; Dong HP, 2010, VIROLOGY, V405, P568, DOI 10.1016/j.virol.2010.06.039; dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015; Dowall SD, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154864; Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824; Duan WQ, 2017, EMBO J, V36, P919, DOI 10.15252/embj.201696241; Dudley DM, 2018, NAT MED, V24, P1104, DOI 10.1038/s41591-018-0088-5; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Dukhovny A, 2019, J VIROL, V93, DOI 10.1128/JVI.00211-19; Dyer O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6983; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296; Eligio-Garcia L, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008880; Elshahawi H, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040169; Enfissi A, 2016, LANCET, V387, P227, DOI 10.1016/S0140-6736(16)00003-9; Erbelding E, 2017, J INFECT DIS, V216, pS991, DOI 10.1093/infdis/jix492; Esser-Nobis K, 2019, J VIROL, V93, DOI 10.1128/JVI.00640-19; Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297; Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636; Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311; Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744-14; Ferraris P, 2019, MICROBES INFECT, V21, P353, DOI 10.1016/j.micinf.2019.04.005; da Silva IRF, 2017, JAMA NEUROL, V74, P1190, DOI 10.1001/jamaneurol.2017.1703; Ferreira RN, 2018, VIRAL IMMUNOL, V31, P583, DOI 10.1089/vim.2017.0186; Figueiredo CP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11866-7; Filomatori CV, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006265; Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3; Freitas BD, 2017, OPHTHALMOLOGY, V124, P1876, DOI 10.1016/j.ophtha.2017.06.009; Frumence E, 2016, VIROLOGY, V493, P217, DOI 10.1016/j.virol.2016.03.006; Funk A, 2010, J VIROL, V84, P11407, DOI 10.1128/JVI.01159-10; Galliez RM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw203; Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116; Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381; Gautret P, 2016, TRAVEL MED INFECT DI, V14, P7, DOI 10.1016/j.tmaid.2015.12.004; Global Preparedness Monitoring Board (GPMB), 2019, WORLD RISK ANN REP G; Goertz GP, 2018, VIRUS RES, V254, P41, DOI 10.1016/j.virusres.2017.08.015; Gonce A, 2018, EMERG INFECT DIS, V24, P933, DOI 10.3201/eid2405.171479; Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726; Goubau D, 2013, IMMUNITY, V38, P855, DOI 10.1016/j.immuni.2013.05.007; Gourbal B, 2018, IMMUNOL REV, V283, P21, DOI 10.1111/imr.12647; Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009; Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681; GRIFONI A, 2017, J VIROL, V91, DOI DOI 10.1128/JVI.01469-17; Grossi-Soyster EN, 2017, CURR OPIN PEDIATR, V29, P102, DOI 10.1097/MOP.0000000000000449; Grubor-Bauk B, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2388; Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05; Haby MM, 2018, B WORLD HEALTH ORGAN, V96, P402, DOI 10.2471/BLT.17.201541; HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57; Haddow AD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005083; Haddow AD, 2016, B WORLD HEALTH ORGAN, V94, P711, DOI 10.2471/BLT.16.181503; Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472; Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15; Hassert M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01678; Hazlewood JE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030496; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/mmbr.00055-16, 10.1128/MMBR.00055-16]; Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1; Hermanns K, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0199-6; Herrera BB, 2018, J VIROL, V92, DOI 10.1128/JVI.01992-17; Hertzog J, 2018, EUR J IMMUNOL, V48, P1120, DOI 10.1002/eji.201847483; Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481; Hou WH, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2338-4; Hu YW, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0308-9; Huber RG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09391-8; Icardi L, 2012, P NATL ACAD SCI USA, V109, P12058, DOI 10.1073/pnas.1206458109; Ikejezie J, 2017, MMWR-MORBID MORTAL W, V66, P329, DOI 10.15585/mmwr.mm6612a4; Imperato PJ, 2016, J COMMUN HEALTH, V41, P674, DOI 10.1007/s10900-016-0177-7; In HJ, 2020, VIROLOGY, V549, P25, DOI 10.1016/j.virol.2020.07.014; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jagger BW, 2017, CELL HOST MICROBE, V22, P366, DOI 10.1016/j.chom.2017.08.012; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang M, 2014, J VIRAL HEPATITIS, V21, P99, DOI 10.1111/jvh.12126; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Khan S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12371-7; Khandia R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00597; Kim SY, 2017, BIOCHEMISTRY-US, V56, P1151, DOI 10.1021/acs.biochem.6b01056; Kleber de Oliveira Wanderson, 2016, MMWR Morb Mortal Wkly Rep, V65, P242, DOI 10.15585/mmwr.mm6509e2; Koenig KL, 2014, WEST J EMERG MED, V15, P728, DOI 10.5811/westjem.2014.9.24011; Korhonen Essi Marjana, 2016, Euro Surveill, V21, DOI 10.2807/1560-7917.ES.2016.21.2.30107; Kozak RA, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100297; Kummerer BM, 2018, ADV EXP MED BIOL, V1062, P165, DOI 10.1007/978-981-10-8727-1_12; Kumar A, 2016, EMBO REP, V17, P1766, DOI 10.15252/embr.201642627; Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z; Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065; Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952; Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010; Leao VHP, 2020, CURR NEUROL NEUROSCI, V20, DOI 10.1007/s11910-020-01072-0; Ledur PF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57914-x; Lee JK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051101; Leisher SH, 2021, TROP MED INT HEALTH, V26, P133, DOI 10.1111/tmi.13522; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Li AX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00051; Li HD, 2016, CELL STEM CELL, V19, P593, DOI 10.1016/j.stem.2016.08.005; Li SH, 2013, J VIROL, V87, P5812, DOI 10.1128/JVI.02806-12; Liang B, 2019, VIRULENCE, V10, P768, DOI 10.1080/21505594.2019.1656503; Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019; Lim MQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02225; Lin HH, 2018, BIOTECHNOL ADV, V36, P47, DOI 10.1016/j.biotechadv.2017.09.004; Lin JP, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007582; Lin SL, 2019, VIROLOGY, V527, P180, DOI 10.1016/j.virol.2018.11.009; Lindsay MA, 2008, TRENDS IMMUNOL, V29, P343, DOI [10.1016/j.it.2008.04.004, 10.1016/j.coph.2009.05.003]; Liu HB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123035; Liu HM, 2012, CELL HOST MICROBE, V11, P528, DOI 10.1016/j.chom.2012.04.006; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Lopez-Camacho C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04859-5; Lundberg R, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111024; Ma JZ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01350; MacMicking JD, 2012, NAT REV IMMUNOL, V12, P367, DOI 10.1038/nri3210; MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1; Hurtado-Monzon AM, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2100; Maloney BE, 2020, CLIN IMMUNOL, V212, P5, DOI 10.1016/j.clim.2020.108351; MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411; Marques VD, 2019, PEDIATR NEUROL, V91, P3, DOI 10.1016/j.pediatrneurol.2018.11.003; Martin-Acebes MA, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00044; Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2; Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1; Martinez-Pulgarin DF, 2016, TRAVEL MED INFECT DI, V14, P55, DOI 10.1016/j.tmaid.2015.07.005; Martins PR, 2020, PEDIATR NEUROL, V110, P20, DOI 10.1016/j.pediatrneurol.2020.05.007; Marzi A, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00117; Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020; McCarthy M, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4235; McCoy CE, 2014, WEST J EMERG MED, V15, P723, DOI 10.5811/westjem.2014.10.24155; MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Meaney-Delman D, 2016, MMWR-MORBID MORTAL W, V65, P211, DOI 10.15585/mmwr.mm6508e1; Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9; Medina MT, 2016, J NEUROL SCI, V369, P271, DOI 10.1016/j.jns.2016.08.044; Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045; Mercado-Reyes M, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S095026881800359X, 10.1017/s095026881800359x]; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Metz SW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12677-6; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004; Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Moon SL, 2012, RNA, V18, P2029, DOI 10.1261/rna.034330.112; Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982; Morabito KM, 2017, J INFECT DIS, V216, pS957, DOI 10.1093/infdis/jix464; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; Munoz LS, 2016, SEMIN REPROD MED, V34, P273, DOI 10.1055/s-0036-1592066; Murray CL, 2008, NAT REV MICROBIOL, V6, P699, DOI 10.1038/nrmicro1928; Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707; Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761; Musso D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050302; Musso D, 2016, LANCET INFECT DIS, V16, P1108, DOI 10.1016/S1473-3099(16)30337-1; Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15; Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125; Nancy P, 2012, SCIENCE, V336, P1317, DOI 10.1126/science.1220030; Nelson BR, 2020, VIRAL IMMUNOL, V33, P22, DOI 10.1089/vim.2019.0082; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2019, CELL HOST MICROBE, V25, P13, DOI 10.1016/j.chom.2018.12.006; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; Ng IHW, 2019, ACS INFECT DIS, V5, P932, DOI 10.1021/acsinfecdis.8b00373; Ngono AE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb2154; Ngono AE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01316; Ngono AE, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007474; Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142; Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010; Ngan NTT, 2019, J MICROBIOL BIOTECHN, V29, P1665, DOI 10.4014/jmb.1909.09017; Nicastri E, 2016, EMERG INFECT DIS, V22, P2228, DOI 10.3201/eid2212.161280; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Niemeyer B, 2017, EUR NEUROL, V77, P45, DOI 10.1159/000453396; Nowakowski A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4956063; Nunes BTD, 2020, EMERG MICROBES INFEC, V9, P1023, DOI 10.1080/22221751.2020.1753583; Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2; Oehler E, 2014, Euro Surveill, V19; Ojha CR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208543; OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0; Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038; Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206; Paixao ES, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000530; Pallares HM, 2020, J VIROL, V94, DOI 10.1128/JVI.00343-20; Pardy RD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006184; Pareek S, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-97; Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564; Patterson J, 2016, WEST J EMERG MED, V17, P671, DOI 10.5811/westjem.2016.9.30904; Pattnaik A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020266; Pedroso C, 2019, EMERG INFECT DIS, V25, P1485, DOI 10.3201/eid2508.190113; Petersen E, 2016, INT J INFECT DIS, V44, P11, DOI 10.1016/j.ijid.2016.02.001; Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113; Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]; Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y; Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020; Pijlman GP, 2008, CELL HOST MICROBE, V4, P579, DOI 10.1016/j.chom.2008.10.007; Plourde AR, 2016, EMERG INFECT DIS, V22, P1185, DOI 10.3201/eid2207.151990; Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032; Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1; Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338; Rastogi M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0590-7; Rathore APS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00334; Rathore APS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3208; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Ray D, 2006, J VIROL, V80, P8362, DOI 10.1128/JVI.00814-06; Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0; Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113; Reyes-Ruiz JM, 2018, VIROLOGY, V515, P74, DOI 10.1016/j.virol.2017.12.014; Ribeiro BG, 2017, RADIOGRAPHICS, V37, P1840, DOI 10.1148/rg.2017170023; Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114; Riedl W, 2019, CELL HOST MICROBE, V26, P493, DOI 10.1016/j.chom.2019.09.012; Robbiani DF, 2019, J EXP MED, V216, P2302, DOI 10.1084/jem.20191061; Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618; Rodriguez-Morales AJ, 2015, J INFECT DEV COUNTR, V9, P684, DOI 10.3855/jidc.7230; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Rossati A, 2017, INT J OCCUP ENV MED, V8, P7, DOI 10.15171/ijoem.2017.963; Roze B, 2016, EUROSURVEILLANCE, V21, P5, DOI 10.2807/1560-7917.ES.2016.21.16.30205; Roze Benoit, 2016, Euro Surveill, V21, P30154, DOI 10.2807/1560-7917.ES.2016.21.9.30154; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Russo FB, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12744; Safari S, 2015, EMERGENCY, V3, P3; Sager G, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100559; Salvador FS, 2016, TRAVEL MED INFECT DI, V14, P49, DOI 10.1016/j.tmaid.2015.10.004; Sariol CA, 2018, TRENDS MICROBIOL, V26, P186, DOI 10.1016/j.tim.2017.10.004; Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517; Satterfield-Nash A, 2017, MMWR-MORBID MORTAL W, V66, P1347, DOI 10.15585/mmwr.mm6649a2; Savidis G, 2016, CELL REP, V15, P2323, DOI 10.1016/j.celrep.2016.05.074; Schaub B, 2016, EUR J OBSTET GYN R B, V207, P240, DOI 10.1016/j.ejogrb.2016.10.041; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2; Schwartzmann PV, 2017, MAYO CLIN PROC, V92, P460, DOI 10.1016/j.mayocp.2016.12.019; Serman TM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100970; Shan C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13589-1; Shan C, 2018, CELL HOST MICROBE, V24, P12, DOI 10.1016/j.chom.2018.05.021; Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322; Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004; Shao Q, 2017, DEVELOPMENT, V144, P4114, DOI 10.1242/dev.156752; Silva PAGC, 2010, J VIROL, V84, P11395, DOI 10.1128/JVI.01047-10; Simonin Y, 2016, EBIOMEDICINE, V12, P161, DOI 10.1016/j.ebiom.2016.09.020; Singh PK, 2019, OCUL SURF, V17, P551, DOI 10.1016/j.jtos.2019.03.006; Singh S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100530; Sinigaglia A, 2018, EXPERT OPIN DRUG DIS, V13, P825, DOI 10.1080/17460441.2018.1515909; Sirohi D, 2017, J INFECT DIS, V216, pS935, DOI 10.1093/infdis/jix515; Slonchak A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16086-y; Smith DR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005296; Soares CN, 2016, J CLIN VIROL, V83, P63, DOI 10.1016/j.jcv.2016.08.297; de Araujo JSS, 2016, B WORLD HEALTH ORGAN, V94, P835, DOI 10.2471/BLT.16.170639; Sotelo JR, 2017, EMERG INFECT DIS, V23, P854, DOI 10.3201/eid2305.161538; Spadoni I, 2017, NAT REV IMMUNOL, V17, P761, DOI 10.1038/nri.2017.100; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Stephen P, 2016, J AM CHEM SOC, V138, P16212, DOI 10.1021/jacs.6b10399; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Strange DP, 2019, MBIO, V10, DOI 10.1128/mBio.01372-19; Sultan N, 2018, CRIT REV EUKAR GENE, V28, P357, DOI 10.1615/CritRevEukaryotGeneExpr.2018025061; Suthar MS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003541; Szretter KJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002698; Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002; Tan MJA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121519; Tan ZY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1311-5; Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016; Thounaojam MC, 2014, J NEUROCHEM, V129, P143, DOI 10.1111/jnc.12609; Tonnerre P, 2020, NAT MICROBIOL, V5, P76, DOI 10.1038/s41564-019-0618-z; Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258; Turco MY, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.163428; Valente AP, 2019, J VENOM ANIM TOXINS, V25, DOI [10.1590/1678-9199-JVATITD-2019-0013, 10.1590/1678-9199-jvatitd-2019-0013]; van der Eijk AA, 2016, NEW ENGL J MED, V375, P1002, DOI 10.1056/NEJMc1605898; Vanwalscappel B, 2018, VIROLOGY, V522, P199, DOI 10.1016/j.virol.2018.07.014; Villamil-Gomez WE, 2016, J INFECT PUBLIC HEAL, V9, P684, DOI 10.1016/j.jiph.2015.12.002; Villordo SM, 2016, TRENDS MICROBIOL, V24, P270, DOI 10.1016/j.tim.2016.01.002; Waldorf KMA, 2018, NAT MED, V24, P368, DOI 10.1038/nm.4485; Waldorf KMA, 2016, NAT MED, V22, P1256, DOI 10.1038/nm.4193; Wang BX, 2018, CELL MOL LIFE SCI, V75, P1723, DOI 10.1007/s00018-018-2751-x; Wang YC, 2020, VIRUS RES, V287, DOI 10.1016/j.virusres.2020.198087; Weaver SC, 2004, NAT REV MICROBIOL, V2, P789, DOI 10.1038/nrmicro1006; WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P263, DOI 10.1016/0035-9203(58)90085-3; Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309; Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z; Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36; White MK, 2016, ANN NEUROL, V80, P479, DOI 10.1002/ana.24748; WHO, 2017, WHO SIT REP ZIK VIR; Wichit S, 2019, EXCLI J, V18, P467, DOI 10.17179/excli2019-1271; Wikan N, 2016, LANCET INFECT DIS, V16, pE119, DOI 10.1016/S1473-3099(16)30010-X; Wikan N, 2016, ASIAN PAC J TROP MED, V9, P136, DOI 10.1016/j.apjtm.2016.01.017; Willis E, 2017, VIROLOGY, V508, P1, DOI 10.1016/j.virol.2017.04.031; Wiwanitkit S, 2016, ASIAN PAC J TROP MED, V9, P499, DOI 10.1016/j.apjtm.2016.03.036; Wiwanitkit V, 2018, EUR J INTERN MED, V47, pE17, DOI 10.1016/j.ejim.2017.06.007; Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58; Wu YX, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.6; Xia HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02816-2; Xu H, 2019, J VIROL, V93, DOI 10.1128/JVI.00758-19; Xu YP, 2019, CELL RES, V29, P265, DOI 10.1038/s41422-019-0152-9; Yoshikawa FSY, 2019, J INFECT DIS, V220, P32, DOI 10.1093/infdis/jiz075; Ye Q, 2016, INFECT GENET EVOL, V43, P43, DOI 10.1016/j.meegid.2016.05.004; Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192; Zhang DX, 2011, J INTERF CYTOK RES, V31, P119, DOI 10.1089/jir.2010.0110; Zhang QZ, 2008, CELL RES, V18, P1077, DOI 10.1038/cr.2008.287; Zhang S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25073-9; ZHAO Z, 2019, THE J, DOI DOI 10.1099/JGV.0.001376; Zheng YY, 2018, EMBO J, V37, DOI 10.15252/embj.201899347; Zhou YS, 2007, J VIROL, V81, P3891, DOI 10.1128/JVI.02704-06; Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48; Zimmerman MG, 2020, CELL HOST MICROBE, V27, P14, DOI 10.1016/j.chom.2019.12.003; Zimmerman MG, 2018, CELL HOST MICROBE, V24, P731, DOI 10.1016/j.chom.2018.10.008; Zust R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003521	381	5	5	6	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							294	10.3390/vaccines9030294			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4ZV	33810028	gold, Green Published			2022-04-29	WOS:000634165100001
J	Kasozi, KI; Laudisoit, A; Osuwat, LO; Batiha, GE; Al Omairi, NE; Aigbogun, E; Ninsiima, HI; Usman, IM; DeTora, LM; MacLeod, ET; Nalugo, H; Crawley, FP; Bierer, BE; Mwandah, DC; Kato, CD; Kiyimba, K; Ayikobua, ET; Lillian, L; Matama, K; Mak, SCN; Onanyang, D; Pius, T; Nalumenya, DP; Ssebuufu, R; Rugambwa, NO; Musoke, GH; Bardosh, K; Ochieng, JJ; Ssempijja, F; Kyamanywa, P; Tumwine, G; Alzahrani, KJ; Welburn, SC				Kasozi, Keneth Iceland; Laudisoit, Anne; Osuwat, Lawrence Obado; Batiha, Gaber El-Saber; Al Omairi, Naif E.; Aigbogun, Eric; Ninsiima, Herbert Izo; Usman, Ibe Michael; DeTora, Lisa M.; MacLeod, Ewan Thomas; Nalugo, Halima; Crawley, Francis P.; Bierer, Barbara E.; Mwandah, Daniel Chans; Kato, Charles Drago; Kiyimba, Kenedy; Ayikobua, Emmanuel Tiyo; Lillian, Linda; Matama, Kevin; Nelly Mak, Shui Ching; Onanyang, David; Pius, Theophilus; Nalumenya, David Paul; Ssebuufu, Robinson; Rugambwa, Nina Olivia; Musoke, Grace Henry; Bardosh, Kevin; Ochieng, Juma John; Ssempijja, Fred; Kyamanywa, Patrick; Tumwine, Gabriel; Alzahrani, Khalid J.; Welburn, Susan Christina			A Descriptive-Multivariate Analysis of Community Knowledge, Confidence, and Trust in COVID-19 Clinical Trials among Healthcare Workers in Uganda	VACCINES			English	Article						COVID-19 clinical trials in resource poor countries; COVID-19; clinical trials in Africa; COVID-19 and medical workers; vaccines; COVAX		Background-misinformation and mistrust often undermines community vaccine uptake, yet information in rural communities, especially of developing countries, is scarce. This study aimed to identify major challenges associated with coronavirus disease 2019 (COVID-19) vaccine clinical trials among healthcare workers and staff in Uganda. Methods-a rapid exploratory survey was conducted over 5 weeks among 260 respondents (66% male) from healthcare centers across the country using an online questionnaire. Twenty-seven questions assessed knowledge, confidence, and trust scores on COVID-19 vaccine clinical trials from participants in 46 districts in Uganda. Results-we found low levels of knowledge (i.e., confusing COVID-19 with Ebola) with males being more informed than females (OR = 1.5, 95% CI: 0.7-3.0), and mistrust associated with policy decisions to promote herbal treatments in Uganda and the rushed international clinical trials, highlighting challenges for the upcoming Oxford-AstraZeneca vaccinations. Knowledge, confidence and trust scores were higher among the least educated (certificate vs. bachelor degree holders). We also found a high level of skepticism and possible community resistance to DNA recombinant vaccines, such as the Oxford-AstraZeneca vaccine. Preference for herbal treatments (38/260; 14.6%, 95% CI: 10.7-19.3) currently being promoted by the Ugandan government raises major policy concerns. High fear and mistrust for COVID-19 vaccine clinical trials was more common among wealthier participants and more affluent regions of the country. Conclusion-our study found that knowledge, confidence, and trust in COVID-19 vaccines was low among healthcare workers in Uganda, especially those with higher wealth and educational status. There is a need to increase transparency and inclusive participation to address these issues before new trials of COVID-19 vaccines are initiated.	[Kasozi, Keneth Iceland; MacLeod, Ewan Thomas; Nelly Mak, Shui Ching; Welburn, Susan Christina] Univ Edinburgh, Coll Med & Vet Med, Infect Med Deanery Biomed Sci, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland; [Kasozi, Keneth Iceland; Ninsiima, Herbert Izo] Kabale Univ, Sch Med, POB 317, Kabale, Uganda; [Laudisoit, Anne] EcoHlth Alliance, 520 Eighth Ave,Suite 1201, New York, NY 10018 USA; [Osuwat, Lawrence Obado; Ayikobua, Emmanuel Tiyo] Soroti Univ, Sch Hlth Sci, POB 211, Soroti, Uganda; [Batiha, Gaber El-Saber] Damanhour Univ, Dept Pharmacol & Therapeut, Fac Vet Med, Damanhour 22511, Albeheira, Egypt; [Al Omairi, Naif E.] Taif Univ, Dept Internal Med, Coll Med, POB 11099, At Taif 21944, Saudi Arabia; [Aigbogun, Eric; Usman, Ibe Michael; Matama, Kevin; Pius, Theophilus; Ssebuufu, Robinson; Ochieng, Juma John; Ssempijja, Fred; Kyamanywa, Patrick] Kampala Int Univ Western Campus, POB 71, Bushenyi, Uganda; [DeTora, Lisa M.] Hofstra Univ, Dept Writing Studies & Rhetor, Hempstead, NY 11549 USA; [Nalugo, Halima] Mbarara Univ Sci & Technol, Fac Med, POB 1410, Mbarara, Uganda; [Crawley, Francis P.] Good Clin Practice Alliance Europe & Strateg Init, BE-1050 Brussels, Belgium; [Bierer, Barbara E.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA; [Mwandah, Daniel Chans] Muni Univ, Fac Sci, POB 725, Arua, Uganda; [Kato, Charles Drago; Nalumenya, David Paul; Tumwine, Gabriel] Makerere Univ, Coll Vet Med Anim Resources & Biosecur, POB 7062, Kampala, Uganda; [Kiyimba, Kenedy] Busitema Univ, Dept Pharmacol & Therapeut, Fac Hlth Sci, POB 206, Mbale, Uganda; [Lillian, Linda] Minist Hlth, Uganda Natl Hlth Lab Serv, POB 7272, Kampala, Uganda; [Onanyang, David] Gulu Univ, Dept Biol, Fac Sci, POB 166, Gulu, Uganda; [Rugambwa, Nina Olivia] Fac Comp Lib & Informat Sci, Dept Lib & Informat Sci, POB 317, Kabale, Uganda; [Musoke, Grace Henry] Cavendish Univ, Fac Sci & Technol, POB 33145, Kampala, Uganda; [Bardosh, Kevin] Univ Washington, Sch Publ Hlth, Ctr One Hlth Res, Seattle, WA 98195 USA; [Alzahrani, Khalid J.] Taif Univ, Dept Clin Labs Sci, Coll Appl Med Sci, POB 11099, At Taif 21944, Saudi Arabia; [Welburn, Susan Christina] Zhejiang Univ, Zhejiang Univ Univ Edinburgh Joint Inst, Int Campus,718 East Haizhou Rd, Haining 314400, Peoples R China		Kasozi, KI; Welburn, SC (通讯作者)，Univ Edinburgh, Coll Med & Vet Med, Infect Med Deanery Biomed Sci, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.; Kasozi, KI (通讯作者)，Kabale Univ, Sch Med, POB 317, Kabale, Uganda.; Welburn, SC (通讯作者)，Zhejiang Univ, Zhejiang Univ Univ Edinburgh Joint Inst, Int Campus,718 East Haizhou Rd, Haining 314400, Peoples R China.	kicelandy@gmail.com; Laudisoit@ecohealthalliance.org; losuwat@sun.ac.ug; gaberbatiha@gmail.com; n.edah@tu.edu.sa; kyeric007@gmail.com; hninsiima@kab.ac; gopama13@gmail.com; lisa.m.detora@hofstra.edu; Ewan.MacLeod@ed.ac.uk; hnalugo@must.ac.ug; fpc@gcpalliance.org; bbierer@bwh.harvard.edu; dc.mwandah@muni.ac.ug; katodrago@gmail.com; kiyimbakennedy@gmail.com; tiyosbase@gmail.com; lindalilliane32@gmail.com; kevicematama@gmail.com; s.c.n.mak@sms.ed.ac.uk; donanyang@yahoo.com; piustheophillus@kiu.ac.ug; nalumenyad@gmail.com; rssebuufu@gmail.com; nrugambwa@kab.ac.ug; gracemusoke2medic@gmail.com; bardosh_kevin@hotmail.com; john.juma@kiu.ac.ug; kalanzifr@yahoo.com; pkyamanywa0@gmail.com; tumwinegabriel@gmail.com; Ak.jamaan@tu.edu.sa; sue.welburn@ed.ac.uk	Kasozi, Keneth Iceland/W-1956-2018; Linda, Lillian/AAP-2626-2021; Alzahrani, Khalid/AAJ-4886-2021; Ssempijja, Fred/W-2653-2018; Usman, Ibe/AAZ-1414-2020; LAUDISOIT, Anne/G-8040-2016	Kasozi, Keneth Iceland/0000-0002-5763-7964; Linda, Lillian/0000-0002-4915-193X; Alzahrani, Khalid/0000-0002-6688-0106; Ssempijja, Fred/0000-0003-1849-7185; Usman, Ibe/0000-0001-6624-1286; DeTora, Lisa/0000-0001-5348-2638; Bierer, Barbara/0000-0001-6448-8170; Kato, Charles Drago/0000-0003-3160-6657; Ssebuufu, Robinson/0000-0003-2053-1696; Osuwat, Lawrence, Obado/0000-0003-3821-1527; Batiha, Gaber/0000-0002-7817-425X; Aigbogun, Eric/0000-0001-8230-2771; Kiyimba, Kenedy/0000-0001-8031-9051; Pius, Theophilus/0000-0002-5495-7743; Crawley, Francis P./0000-0002-6893-5916; LAUDISOIT, Anne/0000-0001-7626-9426; Juma, John/0000-0003-2679-8949	Zhejiang University Education Foundation Emergency Research Fund; Global Challenges Research Fund; University of Edinburgh	This work was supported by Zhejiang University Education Foundation Emergency Research Fund (SCW, KB and KIK); Global Challenges Research Fund and the University of Edinburgh.	Antananarivo R.I., 2020, BBC NEWS        0813; Asiimwe R., 2021, UGANDA ACCESS COVID; Atukunda N., 2020, UGANDA TURNS HERBS S; Conradie A, 2018, BRIT J ANAESTH, V121, P813, DOI 10.1016/j.bja.2018.06.013; DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; ELSADR W, 1992, JAMA-J AM MED ASSOC, V267, P954, DOI 10.1001/jama.267.7.954; Enria L, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3799-x; Erku DA, 2021, RES SOC ADMIN PHARM, V17, P1954, DOI 10.1016/j.sapharm.2020.04.032; Evans G., 1997, RISK COMM VACC SUMM; Ezeome ER, 2010, DEV WORLD BIOETH, V10, P1, DOI 10.1111/j.1471-8847.2008.00239.x; Felix T., 2020, NIGERIA MADAGASCARS; Folayan MO, 2019, DEV WORLD BIOETH, V19, P96, DOI 10.1111/dewb.12215; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Kasozi KI, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00416; Kasozi KI, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.2020.35.3.22637; Kennedy SB, 2016, CLIN TRIALS, V13, P49, DOI 10.1177/1740774515621037; Kiguli J, 2009, PATIENT PREFER ADHER, V3, P77; KREJCIE RV, 1970, EDUC PSYCHOL MEAS, V30, P607, DOI 10.1177/001316447003000308; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4042; Mathpati Mahesh Madhav, 2022, J Ayurveda Integr Med, V13, P100354, DOI 10.1016/j.jaim.2020.09.003; McKinstry B, 2008, BRIT MED J, V336, P748, DOI 10.1136/bmj.39505.491065.94; Natural Chemotherapeutics Research Institute, 2020, CLIN EV EFF SAF IMM; Nugraha RV, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/2560645; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Omaswa F., 2017, BRAIN BRAIN GAIN HLT; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pratt B, 2018, BIOETHICS, V32, P454, DOI 10.1111/bioe.12465; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Seth B., 2020, COVAX EXPLAINED; Shannon G, 2019, LANCET, V393, P560, DOI 10.1016/S0140-6736(18)33135-0; Singh JA, 2020, J INFECT DIS, V222, P351, DOI 10.1093/infdis/jiaa303; Ssebuufu R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.618731; Usman IM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00340; Witter S, 2017, HEALTH POLICY PLANN, V32, pV52, DOI 10.1093/heapol/czx102; World Health Organization, 2020, VACC ACC IS NEXT HUR	37	5	5	3	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							253	10.3390/vaccines9030253			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5LK	33809269	Green Submitted, gold, Green Published			2022-04-29	WOS:000634195200001
J	Kowalewicz-Kulbat, M; Szpakowski, P; Krawczyk, KT; Kowalski, ML; Kosinski, S; Biet, F; Rudnicka, W; Locht, C				Kowalewicz-Kulbat, Magdalena; Szpakowski, Piotr; Krawczyk, Krzysztof T.; Kowalski, Marek L.; Kosinski, Slawomir; Biet, Franck; Rudnicka, Wieslawa; Locht, Camille			Decrease of IL-5 Production by Naive T Cells Cocultured with IL-18-Producing BCG-Pulsed Dendritic Cells from Patients Allergic to House Dust Mite	VACCINES			English	Article						BCG; rBCG-hIL-18; dendritic cells; Th1/Th2 cells; asthma; Der p 1		The only currently available anti-tuberculosis vaccine, Bacillus Calmette-Guerin (BCG), has been reported to also protect against unrelated diseases, including inflammatory diseases such as allergic asthma. Recombinant BCG strains that produce IL-18 have been shown to enhance Th1 responses over non-recombinant BCG and to reduce IL-5 production and bronchoalveolar eosinophilia in mice. However, their ability to decrease the immune polarization of human Th2 cells is not known. Here, we show that BCG and recombinant BCG producing human IL-18 (rBCG-hIL-18) induced the maturation of Der p 1-stimulated monocyte-derived dendritic cells (MD-DCs) from healthy controls and from patients allergic to house dust mites. After incubation with mycobacteria and Der p 1, MD-DCs produced significantly more IL-23 and IP-10 but had no effect on IL-12p70 or IL-10 production compared to Der p 1-pulsed MD-DCs in the absence of mycobacteria. In the presence of Der p 1, BCG- and rBCG-hIL-18-pulsed MD-DCs cocultured with naive, but not with memory T cells from allergic patients, resulted in a decrease in IL-5 production compared to non-pulsed MD-DCs cultured in the presence of Der p 1. BCG, and especially rBCG-hIL-18, may thus be potential therapeutic tools to reduce exacerbated Th2 responses in patients with allergic asthma.	[Kowalewicz-Kulbat, Magdalena; Szpakowski, Piotr; Krawczyk, Krzysztof T.; Rudnicka, Wieslawa; Locht, Camille] Univ Lodz, Inst Microbiol Biotechnol & Immunol, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, PL-90237 Lodz, Poland; [Szpakowski, Piotr] Med Univ Lodz, Dept Neurol & Stroke, PL-90549 Lodz, Poland; [Kowalski, Marek L.] Med Univ Lodz, Dept Immunol & Allergy, PL-92213 Lodz, Poland; [Kosinski, Slawomir] Med Univ Lodz, Dept Immunol & Allergy, Cent Clin Hosp, PL-92213 Lodz, Poland; [Biet, Franck] Univ Tours, ISP, Inst Natl Rech Agr Alimentat & Environm INRAE, F-37390 Nouzilly, France; [Locht, Camille] Univ Lille, CHU Lille, INSERM,CNRS,Inst Pasteur Lille, U1019,UMR9017,CIIL Ctr Infect & Immun Lille, F-59000 Lille, France		Kowalewicz-Kulbat, M (通讯作者)，Univ Lodz, Inst Microbiol Biotechnol & Immunol, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, PL-90237 Lodz, Poland.	magdalena.kowalewicz@biol.uni.lodz.pl; piotr.szpakowski@umed.lodz.pl; krzysztof.krawczyk@biol.uni.lodz.pl; marek.kowalski@umed.lodz.pl; kosinski@csk.umed.lodz.pl; franck.biet@inrae.fr; wieslawa.rudnicka@biol.uni.lodz.pl; camille.locht@pasteur-lille.fr	Biet, Franck/ABA-4151-2021	Biet, Franck/0000-0001-8425-6158; Szpakowski, Piotr/0000-0002-0189-7652; Krawczyk, Krzysztof/0000-0003-0415-6363; Kowalewicz-Kulbat, Magdalena/0000-0003-4447-0859	Polish Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland [N N401 015236]	This research was funded by the grant from the Polish Ministry of Science and Higher Education No N N401 015236.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alyasin S, 2017, IRAN J IMMUNOL, V14, P73, DOI IJIv14i1A7; Ansotegui IJ, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2019.100080; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Becattini S, 2015, SCIENCE, V347, P400, DOI 10.1126/science.1260668; Biet F, 2005, ALLERGY, V60, P1065, DOI 10.1111/j.1398-9995.2005.00826.x; Biet F, 2002, INFECT IMMUN, V70, P6549, DOI 10.1128/IAI.70.12.6549-6557.2002; Bisset LR, 2005, CURR OPIN PULM MED, V11, P35, DOI 10.1097/01.mcp.0000144502.50149.e0; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Caccamo N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02832; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Choi IS, 2008, J KOREAN MED SCI, V23, P628, DOI 10.3346/jkms.2008.23.4.628; Dreborg S, 1989, ALLERGY, V44, pS22; EBNER C, 1995, J IMMUNOL, V154, P1932; El Biaze M, 2003, ALLERGY, V58, P844, DOI 10.1034/j.1398-9995.2003.00282.x; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Goel C, 2015, IMMUNOBIOLOGY, V220, P1113, DOI 10.1016/j.imbio.2015.05.010; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Henry E, 2008, J IMMUNOL, V181, P7230, DOI 10.4049/jimmunol.181.10.7230; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Jan RH, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-31; Ko FWS, 2007, CLIN EXP IMMUNOL, V147, P526, DOI 10.1111/j.1365-2249.2006.03315.x; Kohno K, 1997, J IMMUNOL, V158, P1541; Kowalewicz-Kulbat M, 2018, VACCINE, V36, P4566, DOI 10.1016/j.vaccine.2018.05.068; Kowalewicz-Kulbat M, 2017, EXPERT REV VACCINES, V16, P699, DOI 10.1080/14760584.2017.1333906; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Lantz O, 2000, NAT IMMUNOL, V1, P54, DOI 10.1038/76917; Lee HS, 2017, AM J PHYSIOL-LUNG C, V312, pL13, DOI 10.1152/ajplung.00114.2016; Lun SWM, 2006, J CLIN IMMUNOL, V26, P145, DOI 10.1007/s10875-006-9003-9; Marchant A, 1999, J IMMUNOL, V163, P2249; Matsunaga K, 2009, RESPIRATION, V78, P393, DOI 10.1159/000243551; Mendez-Samperio P, 1998, CELL IMMUNOL, V189, P25, DOI 10.1006/cimm.1998.1361; Na H, 2016, IMMUNE NETW, V16, P1, DOI 10.4110/in.2016.16.1.1; Ogawa R, 2015, ALLERGOL INT, V64, pS24, DOI 10.1016/j.alit.2015.04.005; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pochard P, 2005, J ALLERGY CLIN IMMUN, V116, P198, DOI 10.1016/j.jaci.2005.02.037; Sanders NL, 2016, CYTOKINE GROWTH F R, V32, P31, DOI 10.1016/j.cytogfr.2016.07.001; Sender LY, 2010, MOL IMMUNOL, V47, P1255, DOI 10.1016/j.molimm.2009.12.008; Shen H, 2008, ALLERGY, V63, P555, DOI 10.1111/j.1398-9995.2008.01637.x; Sims JE, 2002, CURR OPIN IMMUNOL, V14, P117, DOI 10.1016/S0952-7915(01)00306-5; Stewart GA, 2014, MIDDLETONS ALLERGY P, P398; Szpakowski P, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/359153; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Thomsen SF, 2015, EUR CLIN RESPIR J, V2, DOI 10.3402/ecrj.v2.24642; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; Wada K, 2013, INT ARCH ALLERGY IMM, V161, P75, DOI 10.1159/000350365; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Walsh MC, 2014, J IMMUNOL, V193, P3992, DOI 10.4049/jimmunol.1400396; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wang M, 2013, CLIN EXP ALLERGY, V43, P956, DOI 10.1111/cea.12123; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Warwick G, 2013, RESPIROLOGY, V18, P874, DOI 10.1111/resp.12089; Weinreich MA, 2008, J IMMUNOL, V181, P2265, DOI 10.4049/jimmunol.181.4.2265; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701	55	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							277	10.3390/vaccines9030277			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5JX	33803752	Green Published, gold			2022-04-29	WOS:000634191300001
J	Malkova, A; Kudlay, D; Kudryavtsev, I; Starshinova, A; Yablonskiy, P; Shoenfeld, Y				Malkova, Anna; Kudlay, Dmitriy; Kudryavtsev, Igor; Starshinova, Anna; Yablonskiy, Piotr; Shoenfeld, Yehuda			Immunogenetic Predictors of Severe COVID-19	VACCINES			English	Review						new coronavirus infection; COVID-19; biomarkers; immunological parameters; genes; HLA; ACE-2	SARS CORONAVIRUS; ACE2; EXPRESSION; RECEPTOR; PROTEIN; PATHOGENESIS; INTERFERON; TMPRSS2	According to an analysis of published data, only 20% of patients with the new coronavirus infection develop severe life-threatening complications. Currently, there are no known biomarkers, the determination of which before the onset of the disease would allow assessing the likelihood of its severe course. The purpose of this literature review was to analyze possible genetic factors characterizing the immune response to the new coronavirus infection that could be associated with the expression of angiotension-converting enzyme 2 (ACE-2) and related proteins as predictors of severe Corona virus disease 2019 (COVID-19). We analyzed original articles published in Medline, PubMed and Scopus databases from December 2019 to November 2020. For searching articles, we used the following keywords: New coronavirus infection, Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), COVID-19, severe course, complications, thrombosis, cytokine storm, ACE-2, biomarkers. In total, 3714 publications were selected using the keywords, of which 8 were in congruence with all the criteria. The literature analysis of the association of immunogenic characteristics and the expression of ACE-2 and related proteins with the development of severe COVID-19 revealed following genetic factors: HLA-B*46:01 genotype, CXCR6 gene hypoexpression, CCR9 gene expression, TLR7, rs150892504 mutations in the ERAP2 gene, overexpression of wild-type ACE-2, TMPRSS2 and its different polymorphisms. Genes, associated with the severe course, are more common among men. According to the analysis data, it can be assumed that there are population differences. However, the diagnostic significance of the markers described must be confirmed with additional clinical studies.	[Malkova, Anna; Yablonskiy, Piotr; Shoenfeld, Yehuda] St Petersburg State Univ, St Petersburg 199034, Russia; [Kudlay, Dmitriy] Sechenov First Moscow State Med Univ, Moscow 119435, Russia; [Kudlay, Dmitriy] NRC Inst Immunol FMBA Russia, Moscow 115478, Russia; [Kudryavtsev, Igor] FSBI Inst Expt Med, St Petersburg 197376, Russia; [Kudryavtsev, Igor] Far Eastern Fed Univ, Vladivostok 690091, Russia; [Starshinova, Anna] FSBI VA Almazov Natl Med Res Ctr, Minist Hlth Russia, St Petersburg 197241, Russia; [Yablonskiy, Piotr] St Petersburg Res Inst Phthisiopulmonol, St Petersburg 191036, Russia; [Shoenfeld, Yehuda] Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, IL-5265601 Tel Hashomer, Israel; [Shoenfeld, Yehuda] Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel		Malkova, A (通讯作者)，St Petersburg State Univ, St Petersburg 199034, Russia.	anya.malkova.95@mail.ru; D624254@gmail.com; igorek1981@yandex.ru; starshinova_777@mail.ru; piotr_yablonskii@mail.ru; yehuda.shoenfeld@sheba.health.gov.il	Malkova, Anna/AAS-3410-2021; Yablonskiy, Petr/T-8804-2017; Kudriavtsev, Igor V/D-2124-2013	Yablonskiy, Petr/0000-0003-4385-9643; Kudriavtsev, Igor V/0000-0001-7204-7850; Starsinova, Anna/0000-0002-9023-6986; Kudlay, Dmitry/0000-0003-1878-4467; Malkova, Anna/0000-0002-6008-1354			Achiron A, 2020, EUR J RHEUMATOL, V7, pS99, DOI 10.5152/eurjrheum.2020.2068; Arango MT, 2017, IMMUNOL RES, V65, P82, DOI 10.1007/s12026-016-8817-7; Azer SA, 2020, NEW MICROB NEW INFEC, V37, DOI 10.1016/j.nmni.2020.100738; Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004; BOSCH BJ, 2004, J VIROL, V101, P8455, DOI DOI 10.1073/PNAS.0400576101; BRASS AL, 2009, BIOCHEM BIOPH RES CO, V139, P1243, DOI DOI 10.1016/J.CELL.2009.12.017; Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1; CERVANTESBARRAG.L, 2007, PHARMACOL THERAPEUT, V109, P1131, DOI DOI 10.1182/BLOOD-2006-05-023770; Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896; Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071; CHOO SY, 2007, IMMUNOL RES, V48, P11, DOI DOI 10.3349/YMJ.2007.48.1.11; Ciceri F, 2020, CRIT CARE RESUSC, V22, P95; Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742; Dai YJ, 2020, INT J BIOL SCI, V16, P3028, DOI 10.7150/ijbs.51234; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08; FURMAN D, 2014, J MED VIROL, V111, P869, DOI DOI 10.1073/PNAS.1321060111; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hou Y, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01673-z; HUGHES GC, 2014, FRONT IMMUNOL, V10, P740, DOI DOI 10.1038/NRRHEUM.2014.144; Imai Y, 2007, CELL MOL LIFE SCI, V64, P2006, DOI 10.1007/s00018-007-6228-6; IMAI Y, 2005, GUT, V436, P112, DOI DOI 10.1038/NATURE03712; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; KUBA K, 2010, J EXP MED, V128, P119, DOI DOI 10.1016/J.PHARMTHERA.2010.06.003; Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236; LI F, 2005, BIOCHEM BIOPH RES CO, V309, P1864, DOI DOI 10.1126/SCIENCE.1116480; Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lu C., 2020, MEDRXIV, DOI [10.1101/2020.07.01.20144592, DOI 10.1101/2020.07.01.20144592]; MOORE JB, 2020, IMMUNITY, V55, P5954, DOI DOI 10.1126/SCIENCE.ABB8925; MORENOEUTIMIO MA, 2020, BLOOD, V22, P226, DOI DOI 10.1016/J.MICINF.2020.04.009; Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07; NGUYEN A, 2020, YONSEI MED J, V94, DOI DOI 10.1128/JVI.00510-20; Ni WT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03120-0; Pathak Gita A, 2020, medRxiv, DOI 10.1101/2020.12.07.20245308; Siu KL, 2014, J VIROL, V88, P4866, DOI 10.1128/JVI.03649-13; [Старшинова А.А. Starshinova Anna A.], 2020, [Вопросы современной педиатрии, Current Pediatrics (Moscow), Voprosy sovremennoi pediatrii], V19, P123, DOI 10.15690/vsp.v19i2.2105; STRAUB RH, 2013, J IMMUNOL, V43, P392, DOI DOI 10.1016/J.SEMARTHRIT.2013.04.008; Sun L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030802; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tan CW, 2020, AM J HEMATOL, V95, pE156, DOI 10.1002/ajh.25822; Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020; TANEJA V, 2018, P NATL ACAD SCI USA, V9, P1931, DOI DOI 10.3389/FIMMU.2018.01931; van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719; WAKIM LM, 2013, CELL, V14, P238, DOI DOI 10.1038/NI.2525; Wan S., 2020, CHARACTERISTICS LYMP, DOI 10.1101/2020.02.10.20021832; Wang W, 2020, HLA, V96, P194, DOI 10.1111/tan.13941; Wein AN, 2019, J EXP MED, V216, P2748, DOI 10.1084/jem.20181308; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; XIAO X, 2003, MICROBES INFECT, V312, P1159, DOI DOI 10.1016/J.BBRC.2003.11.054; YANG M, 2020, CURR EYE RES, DOI DOI 10.2139/SSRN.3527420; Yang XH, 2007, COMPARATIVE MED, V57, P450; Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989; Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953; Zhang H, 2020, INT J INFECT DIS, V96, P19, DOI 10.1016/j.ijid.2020.04.027; Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533; Zhang YH, 2020, J INFECT DIS, V222, P34, DOI 10.1093/infdis/jiaa224; Zhao Yu, 2020, American Journal of Respiratory and Critical Care Medicine, V202, P756, DOI 10.1164/rccm.202001-0179LE; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z; Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0; 2020, VITAL SURVEILL, V41, P145	68	9	10	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							211	10.3390/vaccines9030211			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5IV	33802310	Green Published, gold			2022-04-29	WOS:000634188500001
J	Petravic, L; Arh, R; Gabrovec, T; Jazbec, L; Rupcic, N; Staresinic, N; Zorman, L; Pretnar, A; Srakar, A; Zwitter, M; Slavec, A				Petravic, Luka; Arh, Rok; Gabrovec, Tina; Jazbec, Lucija; Rupcic, Nika; Staresinic, Nina; Zorman, Lea; Pretnar, Ajda; Srakar, Andrej; Zwitter, Matjaz; Slavec, Ana			Factors Affecting Attitudes towards COVID-19 Vaccination: An Online Survey in Slovenia	VACCINES			English	Article						cross-sectional studies; intention; public opinion; trust; ordinal regression; COVID-19; vaccination; surveys and questionnaires; Europe; immune system; SARS-CoV-2	INFLUENZA VACCINATION; DISEASE; VACCINES	While the problem of vaccine hesitancy is not new, it has become more pronounced with the new COVID-19 vaccines and represents an obstacle to resolving the crisis. Even people who would usually trust vaccines and experts now prefer to wait for more information. A cross-sectional online survey was conducted in Slovenia in December 2020 to find out the attitudes of the population regarding COVID-19 vaccination and the factors that affect these attitudes. Based on 12,042 fully completed questionnaires, we find that higher intention to get vaccinated is associated with men, older respondents, physicians and medical students, respondents who got the influenza vaccination, those who knew someone who had gotten hospitalised or died from COVID-19 and those who have more trust in experts, institutions and vaccines. Nurses and technicians were less likely to get vaccinated. In answers to an open question, sceptics were split into those doubting the quality due to the rapid development of the vaccine and those that reported personal experiences with side effects of prior vaccinations. Although the Slovenian population is diverse in its attitudes towards vaccination, the results are comparable to those found in other countries. However, there are potential limitations to the generalizability of the findings that should be addressed in future studies.	[Petravic, Luka; Arh, Rok; Gabrovec, Tina; Jazbec, Lucija; Rupcic, Nika; Staresinic, Nina; Zorman, Lea; Zwitter, Matjaz] Univ Maribor, Fac Med, Maribor 2000, Slovenia; [Pretnar, Ajda] Univ Ljubljana, Fac Comp & Informat Sci, Ljubljana 1000, Slovenia; [Srakar, Andrej] Inst Econ Res, Ljubljana 1000, Slovenia; [Slavec, Ana] InnoRenew CoE, Livade 6, Izola 6310, Slovenia		Petravic, L (通讯作者)，Univ Maribor, Fac Med, Maribor 2000, Slovenia.	lpetravic@me.com; rok.arh@student.um.si; tina.gabrovec@student.um.si; lucija.jazbec@student.um.si; nika.rupcic@student.um.si; nina.staresinic@student.um.si; lea.zorman@student.um.si; Ajda.Pretnar@fri.uni-lj.si; andrej.srakar@ier.si; matjaz.zwitter@guest.arnes.si; ana.slavec@innorenew.eu	Petravić, Luka/AAK-9786-2021; Slavec, Ana/A-5091-2019	Petravić, Luka/0000-0001-7087-7316; Arh, Rok/0000-0003-3275-8409; Rupcic, Nika/0000-0003-1509-9069; Jazbec, Lucija/0000-0002-1232-6740; Staresinic, Nina/0000-0002-4218-1968; Slavec, Ana/0000-0002-0171-2144; Zorman, Lea/0000-0003-4766-9732; Pretnar, Ajda/0000-0002-5927-4538	Slovenian Research AgencySlovenian Research Agency - Slovenia [Z5-1879]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [739574]; Republic of Slovenia; Republic of Slovenia (European Regional Development Fund)	The authors acknowledge the support of the Slovenian Research Agency for funding the project using questionnaires to measure attitudes and behaviours of building users (Z5-1879), the European Commission for funding the InnoRenew project [Grant Agreement #739574] under the Horizon 2020Widespread-Teaming program, and the Republic of Slovenia (investment funding from the Republic of Slovenia and the European Regional Development Fund).	Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Engin C, 2020, POPUL REV, V59, P156, DOI 10.1353/prv.2020.0007; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Feleszko W., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3631972., DOI 10.2139/SSRN.3631972, 10.2139/ssrn.3631972]; Funk C., 2020, INTENT GET COVID 19; Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015; Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Hossain M.M., 2020, SOCARXIV, DOI [DOI 10.31235/OSF.IO/VC9JB, 10.31235/OSF.IO/VC9JB]; Irwin KL, 2017, VACCINE, V35, P6915, DOI 10.1016/j.vaccine.2017.06.026; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Keske S, 2020, VACCINE, V38, P8357, DOI 10.1016/j.vaccine.2020.11.003; Kraigher A., 2018, CEPLJENJE STALISCA O; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Marcec R, 2021, POSTGRAD MED J, V97, P143, DOI 10.1136/postgradmedj-2020-138903; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Petersen M., 2020, PSYARXIV, DOI [10.31234/osf.io/8kn5f, DOI 10.31234/OSF.IO/8KN5F]; Petravic L., 2020, ATTITUDES SARS COV 2, DOI [10.17898/ADP_SARSVE20_V1, DOI 10.17898/ADP_SARSVE20_V1]; Petravic L., 2020, ATTITUDES SARS COV 2, DOI [10.17898/ADP_SARSPR20_V1, DOI 10.17898/ADP_SARSPR20_V1]; Pless A, 2017, BMC NURS, V16, DOI 10.1186/s12912-017-0215-5; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Ridda I, 2009, VACCINE, V27, P3775, DOI 10.1016/j.vaccine.2009.03.075; Rimoin A.W., 2020, ASSESSMENT COVID 19, DOI [10.1101/2020.11.18.20234468, DOI 10.1101/2020.11.18.20234468]; Rus M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020113; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; SECHREST S, 1995, LIBR J, V120, P36; Straka M., 2018, P CONLL 2018 SHAR TA, P197, DOI [DOI 10.18653/V1/K18-2020, 10.18653/v1/K18-2020]; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482	34	22	22	5	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							247	10.3390/vaccines9030247			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5FW	33808958	gold, Green Published			2022-04-29	WOS:000634180800001
J	Plans-Rubio, P				Plans-Rubio, Pedro			Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019	VACCINES			English	Article						routine vaccines; vaccination coverage; anti-measles herd immunity; anti-pertussis herd immunity; WHO regions; vaccination program performance	ESTABLISHMENT	In 2012, the World Health Organization (WHO) established the Global Vaccine Action Plan with the objective to promote essential vaccinations in all countries and achieve at least 90% vaccination coverage for all routine vaccines by 2020. The study assessed the mean percentages of vaccination coverage in 2019 for 13 routine vaccines, vaccination coverage variation from 2015 to 2019, and herd immunity levels against measles and pertussis in 2019 in countries and regions of WHO. In 2019, the mean percentages of vaccination coverage were lower than 90% for 10 (78.9%) routine vaccines. The mean percentages of vaccination coverage also decreased from 2015 to 2019 for six (46.2%) routine vaccines. The prevalence of individuals with vaccine-induced measles immunity in the target measles vaccination population was 88.1%, and the prevalence of individuals with vaccine-induced pertussis immunity in the target pertussis vaccination population was 81.1%. Herd immunity against measles viruses with Ro = 18 was established in 63 (32.5%) countries but not established in any region. Herd immunity against pertussis agents was not established in any country and in any region of WHO. National immunization programs must be improved to achieve >= 90% vaccination coverage in all countries and regions. Likewise, it is necessary to achieve >= 95% vaccination coverage with two doses of measles vaccines and three doses of pertussis vaccines in all countries and regions.	[Plans-Rubio, Pedro] Publ Hlth Agcy Catalonia, Dept Hlth Catalonia, Barcelona 08005, Spain; [Plans-Rubio, Pedro] Ciber Epidemiol & Publ Hlth CIBERESP, Madrid 28028, Spain		Plans-Rubio, P (通讯作者)，Publ Hlth Agcy Catalonia, Dept Hlth Catalonia, Barcelona 08005, Spain.; Plans-Rubio, P (通讯作者)，Ciber Epidemiol & Publ Hlth CIBERESP, Madrid 28028, Spain.	pedro.plans@gencat.cat	Plans-Rubió, Pedro/AAB-1778-2022	Plans-Rubió, Pedro/0000-0002-4424-2971			ANDERSON R M, 1991; ANDERSON RM, 1992, VACCINE, V10, P928, DOI 10.1016/0264-410X(92)90327-G; Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819; Chard AN, 2020, MMWR-MORBID MORTAL W, V69, P1706, DOI 10.15585/mmwr.mm6945a7; Demicheli V, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub3; ECDC, 2020, MEASL ANN EP REP 201; European Centre for Disease Prevention and Control (ECDC), 2020, MONTHL MEASL RUB MON; Gay NJ, 2004, J INFECT DIS, V189, pS27, DOI 10.1086/381592; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9; Juretzko P, 2002, CLIN INFECT DIS, V35, P162, DOI 10.1086/341027; Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1; MacDonald N, 2020, VACCINE, V38, P5364, DOI 10.1016/j.vaccine.2020.05.003; Marin M, 2006, CLIN INFECT DIS, V42, P315, DOI 10.1086/498902; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pannuti CS, 2004, CLIN DIAGN LAB IMMUN, V11, P119, DOI 10.1128/CDLI.11.1.119-122.2004; Patel MK, 2020, MMWR-MORBID MORTAL W, V69, P1700, DOI 10.15585/mmwr.mm6945a6; Plans P, 2013, EUR J CLIN MICROBIOL, V32, P961, DOI 10.1007/s10096-013-1836-6; Plans P, 2010, MED DECIS MAKING, V30, P438, DOI 10.1177/0272989X09353453; Plans-Rubio P, 2017, EUR J CLIN MICROBIOL, V36, P1899, DOI 10.1007/s10096-017-3011-y; Plans-Rubio P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020218; Plans-Rubio P, 2019, EUR J CLIN MICROBIOL, V38, P1719, DOI 10.1007/s10096-019-03604-0; Plans-Rubio P, 2012, HUM VACC IMMUNOTHER, V8, DOI 10.4161/hv.18444; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111; Strategic Advisory Group of Experts on Immunization, 2019, GLOB VACC ACT PLAN 2; UNICEF, 2019, LEAV NO ON ALL CHILD; UNICEF, 2019, IMM COV AR WE LOS GR; WHO, VACC PREV DIS MON SY; WHO, 2013, GLOB VACC ACT PLAN 2; World Health Assembly (27th: 1974), 1985, Assignment Child, V69-72, P87; World Health Organization, 2016, GLOB ROUT IMM STRAT; World Health Organization, 2012, GLOB MEASL RUB STRAT; World Health Organization, 2003, STRAT PLAN MEASL CON; World Health Organization, 2015, WHO UNICEF EST ROUT; World Health Organization, 2019, WHO UNICEF EST ROUT; World Health Organization. Regional Office for Europe, 2014, EL MEASL RUB FRAM VE; World Health Organization (WHO), 2020, GLOB VACC ACT PLAN M; Zhang LJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001478.pub6	39	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							256	10.3390/vaccines9030256			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5CX	33805681	gold, Green Published			2022-04-29	WOS:000634173100001
J	Vanshylla, K; Held, K; Eser, TM; Gruell, H; Kleipass, F; Stumpf, R; Jain, K; Weiland, D; Munch, J; Gruttner, B; Geldmacher, C; Klein, F				Vanshylla, Kanika; Held, Kathrin; Eser, Tabea M.; Gruell, Henning; Kleipass, Franziska; Stumpf, Ricarda; Jain, Kanika; Weiland, Daniela; Muench, Jan; Gruettner, Berthold; Geldmacher, Christof; Klein, Florian			CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention	VACCINES			English	Article						humanized mice; mucosal HIV-1 prevention; broadly neutralizing antibodies		Humanized mice are critical for HIV-1 research, but humanized mice generated from cord blood are inefficient at mucosal HIV-1 transmission. Most mucosal HIV-1 transmission studies in mice require fetal tissue-engraftment, the use of which is highly restricted or prohibited. We present a fetal tissue-independent model called CD34T+ with enhanced human leukocyte levels in the blood and improved T cell homing to the gut-associated lymphoid tissue. CD34T+ mice are highly permissive to intra-rectal HIV-1 infection and also show normal env diversification in vivo despite high viral replication. Moreover, mucosal infection in CD34T+ mice can be prevented by infusion of broadly neutralizing antibodies. CD34T+ mice can be rapidly and easily generated using only cord blood cells and do not require any complicated surgical procedures for the humanization process. Therefore, CD34T+ mice provide a novel platform for mucosal HIV-1 transmission studies as well as rapid in vivo testing of novel prevention molecules against HIV-1.	[Vanshylla, Kanika; Gruell, Henning; Kleipass, Franziska; Stumpf, Ricarda; Jain, Kanika; Weiland, Daniela; Klein, Florian] Univ Cologne, Lab Expt Immunol, Inst Virol, Fac Med, D-50931 Cologne, Germany; [Vanshylla, Kanika; Gruell, Henning; Kleipass, Franziska; Stumpf, Ricarda; Jain, Kanika; Weiland, Daniela; Gruettner, Berthold; Klein, Florian] Univ Cologne, Univ Hosp Cologne, D-50931 Cologne, Germany; [Held, Kathrin; Eser, Tabea M.; Geldmacher, Christof] LMU, Univ Hosp, Div Infect Dis & Trop Med, D-80802 Munich, Germany; [Held, Kathrin; Eser, Tabea M.; Geldmacher, Christof] German Ctr Infect Res, Partner Site Munich, D-80802 Munich, Germany; [Gruell, Henning; Klein, Florian] German Ctr Infect Res, Partner Site Bonn Cologne, D-50937 Cologne, Germany; [Muench, Jan] Ulm Univ, Med Ctr, Inst Mol Virol, D-89081 Ulm, Germany; [Gruettner, Berthold] Univ Cologne, Fac Med, Dept Gynecol & Obstet, D-50931 Cologne, Germany; [Klein, Florian] Univ Cologne, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany		Klein, F (通讯作者)，Univ Cologne, Lab Expt Immunol, Inst Virol, Fac Med, D-50931 Cologne, Germany.; Klein, F (通讯作者)，Univ Cologne, Univ Hosp Cologne, D-50931 Cologne, Germany.; Klein, F (通讯作者)，German Ctr Infect Res, Partner Site Bonn Cologne, D-50937 Cologne, Germany.; Klein, F (通讯作者)，Univ Cologne, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany.	kanika.vanshylla@uk-koeln.de; Kathrin.Held@med.uni-muenchen.de; T.Eser@lrz.uni-muenchen.de; henning.gruell@uk-koeln.de; franziska.kleipass@hhu.de; ricarda.stumpf@uk-koeln.de; kanikajain2006@gmail.com; daniela.weiland@uk-koeln.de; Jan.Muench@uni-ulm.de; berthold.gruettner@uk-koeln.de; geldmacher@lrz.uni-muenchen.de; florian.klein@uk-koeln.de		Held, Kathrin/0000-0001-7057-6935; Grull, Henning/0000-0002-0725-7138; Vanshylla, Kanika/0000-0003-4552-9170; Jan, Munch/0000-0001-7316-7141	Verein zur Forderung vonWissenschaft und Forschung an der Medizinischen Fakultat der Ludwig-Maximilians-Universitat Munchen e.V.; German Center for Infection Research (DZIF); German Research Foundation (CRC 1279); European Research CouncilEuropean Research Council (ERC)European Commission [ERC-StG639961]; German Research Foundation (CRC 1310)	Imaging analysis of mouse tissue was partly funded by a grant of the Verein zur Forderung vonWissenschaft und Forschung an der Medizinischen Fakultat der Ludwig-Maximilians-Universitat Munchen e.V. (to K.H.). This work was mainly funded by grants from the German Center for Infection Research (DZIF; to F.K.), the German Research Foundation (CRC 1279 and CRC 1310 to F.K.), and the European Research Council (ERC-StG639961 to F.K.).	Allen TM, 2019, NAT IMMUNOL, V20, P770, DOI 10.1038/s41590-019-0416-z; Alter G, 2020, CELL, V183, P185, DOI 10.1016/j.cell.2020.08.033; Audige A, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0209-9; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Balazs AB, 2014, NAT MED, V20, P296, DOI 10.1038/nm.3471; Berges BK, 2008, VIROLOGY, V373, P342, DOI 10.1016/j.virol.2007.11.020; Blumich S, 2021, VET PATHOL, V58, P161, DOI 10.1177/0300985820948822; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Brehm MA, 2010, CLIN IMMUNOL, V135, P84, DOI 10.1016/j.clim.2009.12.008; Chateau ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060024; Cimbro R, 2012, BLOOD, V120, P2610, DOI 10.1182/blood-2012-06-434779; Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120-11; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; Deruaz M, 2016, J INFECT DIS, V214, P612, DOI 10.1093/infdis/jiw203; Escolano A, 2017, J EXP MED, V214, P3, DOI 10.1084/jem.20161765; Estes JD, 2018, NAT REV IMMUNOL, V18, P390, DOI 10.1038/s41577-018-0005-7; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Gaebler C, 2019, J EXP MED, V216, P2253, DOI 10.1084/jem.20190896; Greenblatt MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044664; Gruell H, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0455-9; Harris DT, 2013, CLIN EXP IMMUNOL, V174, P402, DOI 10.1111/cei.12192; Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911; Hofer U, 2008, J VIROL, V82, P12145, DOI 10.1128/JVI.01105-08; Horwitz JA, 2013, P NATL ACAD SCI USA, V110, P16538, DOI 10.1073/pnas.1315295110; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365-2249.2009.03933.x; Kitchen SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008208; Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604; Kryazhimskiy S, 2014, SCIENCE, V344, P1519, DOI 10.1126/science.1250939; Li Y, 2018, NAT METHODS, V15, P623, DOI 10.1038/s41592-018-0071-6; Lin AE, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-115462; Lopez MC, 2009, CYTOM PART B-CLIN CY, V76B, P37, DOI 10.1002/cyto.b.20441; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; McHugh D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000640; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Neff CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020209; Nishimura Y, 2017, CELL HOST MICROBE, V22, P207, DOI 10.1016/j.chom.2017.07.010; O'Connell RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012009; Olesen R, 2016, J CLIN INVEST, V126, P892, DOI 10.1172/JCI64212; Robinson HL, 2018, CLIN PHARMACOL THER, V104, P1062, DOI 10.1002/cpt.1208; Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Schommers P, 2020, CELL, V180, P471, DOI 10.1016/j.cell.2020.01.010; Schoofs T, 2019, IMMUNITY, V50, P1513, DOI 10.1016/j.immuni.2019.04.014; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; Stripecke R, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201708662; Sun ZF, 2007, J EXP MED, V204, P705, DOI 10.1084/jem.20062411; Wang PF, 2020, P NATL ACAD SCI USA, V117, P18002, DOI 10.1073/pnas.2008190117; Yu H, 2017, BLOOD, V129, P959, DOI 10.1182/blood-2016-04-709584; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002	54	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							198	10.3390/vaccines9030198			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6IS	33673566	gold, Green Published			2022-04-29	WOS:000634255800001
J	Welner, S; Ruggli, N; Liniger, M; Summerfield, A; Larsen, LE; Jungersen, G				Welner, Simon; Ruggli, Nicolas; Liniger, Matthias; Summerfield, Artur; Larsen, Lars Erik; Jungersen, Gregers			Reduced Virus Load in Lungs of Pigs Challenged with Porcine Reproductive and Respiratory Syndrome Virus after Vaccination with Virus Replicon Particles Encoding Conserved PRRSV Cytotoxic T-Cell Epitopes	VACCINES			English	Article						porcine reproductive and respiratory syndrome virus (PRRSV); virus replicon particles (VRP); classical swine fever virus (CSFV); viral vector; vaccine; polyepitope antigen; cytotoxic T cells; cell-mediated immunity		Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe respiratory distress and reproductive failure in swine. Modified live virus (MLV) vaccines provide the highest degree of protection and are most often the preferred choice. While somewhat protective, the use of MLVs is accompanied by multiple safety issues, why safer alternatives are urgently needed. Here, we describe the generation of virus replicon particles (VRPs) based on a classical swine fever virus genome incapable of producing infectious progeny and designed to express conserved PRRSV-2 cytotoxic T-cell epitopes. Eighteen pigs matched with the epitopes by their swine leucocyte antigen-profiles were vaccinated (N = 11, test group) or sham-vaccinated (N = 7, control group) with the VRPs and subsequently challenged with PRRSV-2. The responses to vaccination and challenge were monitored using serological, immunological, and virological analyses. Challenge virus load in serum did not differ significantly between the groups, whereas the virus load in the caudal part of the lung was significantly lower in the test group compared to the control group. The number of peptide-induced interferon-gamma secreting cells after challenge was higher and more frequent in the test group than in the control group. Together, our results provide indications of a shapeable PRRSV-specific cell-mediated immune response that may inspire future development of effective PRRSV vaccines.	[Welner, Simon; Larsen, Lars Erik] Univ Copenhagen, Sect Vet Clin Microbiol, Dept Vet & Anim Sci, Dyrlaegevej 88, DK-1870 Frederiksberg C, Denmark; [Ruggli, Nicolas; Liniger, Matthias; Summerfield, Artur] Inst Virol & Immunol IVI, Sensemattstr 293, CH-3147 Mittelhausern, Switzerland; [Ruggli, Nicolas; Liniger, Matthias; Summerfield, Artur] Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol DIP, Langgassstr 120, CH-3012 Bern, Switzerland; [Jungersen, Gregers] Statens Serum Inst, Ctr Vaccine Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark		Welner, S (通讯作者)，Univ Copenhagen, Sect Vet Clin Microbiol, Dept Vet & Anim Sci, Dyrlaegevej 88, DK-1870 Frederiksberg C, Denmark.	simon.welner@sund.ku.dk; nicolas.ruggli@ivi.admin.ch; matthias.liniger@ivi.admin.ch; artur.summerfield@ivi.admin.ch; lael@sund.ku.dk; grju@ssi.dk	Summerfield, Artur/H-6025-2019; Summerfield, Artur/K-2105-2016; Larsen, Lars Erik/G-3827-2015; Jungersen, Gregers/C-3940-2011	Summerfield, Artur/0000-0001-8292-4634; Summerfield, Artur/0000-0001-8292-4634; Welner, Simon/0000-0002-8829-3703; Ruggli, Nicolas/0000-0002-7679-6290; Larsen, Lars Erik/0000-0003-0730-5555; Jungersen, Gregers/0000-0003-3147-6960	Danish Council for Strategic ResearchDanske Strategiske Forskningsrad (DSF)	L.E.L.: G.J., N.R. and A.S. were partly funded by the PIGVAC project supported by The Danish Council for Strategic Research. This research received no additional external funding.	Alexander N, 2013, J IMMUNOL METHODS, V392, P57, DOI 10.1016/j.jim.2013.02.014; Bauhofer O, 2007, J VIROL, V81, P3087, DOI 10.1128/JVI.02032-06; Bautista EM, 1997, VIRAL IMMUNOL, V10, P83, DOI 10.1089/vim.1997.10.83; Bazhan SI, 2010, MOL IMMUNOL, V47, P1507, DOI 10.1016/j.molimm.2010.01.020; Beilage EG, 2009, PREV VET MED, V92, P31, DOI 10.1016/j.prevetmed.2009.07.010; Blomquist DV, 2002, VIRAL IMMUNOL, V15, P337, DOI 10.1089/08828240260066260; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; Chapiro J, 2006, J IMMUNOL, V176, P1053, DOI 10.4049/jimmunol.176.2.1053; Chen NH, 2011, J GEN VIROL, V92, P880, DOI 10.1099/vir.0.027995-0; De Baets S, 2013, J VIROL, V87, P3314, DOI 10.1128/JVI.03019-12; Demoulins T, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622385; Du J, 2016, J VIROL, V90, P682, DOI 10.1128/JVI.02307-15; Eck M, 2016, VET RES, V47, DOI 10.1186/s13567-016-0318-0; Feng WH, 2002, VIROLOGY, V302, P363, DOI 10.1006/viro.2002.1650; Franzoni G, 2013, CLIN VACCINE IMMUNOL, V20, P1604, DOI 10.1128/CVI.00415-13; Frey CF, 2006, VET RES, V37, P655, DOI 10.1051/vetres:2006028; Fuertes LL, 1999, VIRUS RES, V64, P33, DOI 10.1016/S0168-1702(99)00073-8; GREISERWILKE I, 1990, ARCH VIROL, V111, P213, DOI 10.1007/BF01311055; Han J, 2006, VIRUS RES, V122, P175, DOI 10.1016/j.virusres.2006.06.003; Henrickson SE, 2007, CURR OPIN IMMUNOL, V19, P249, DOI 10.1016/j.coi.2007.04.013; Herd KA, 2004, VIROLOGY, V319, P237, DOI 10.1016/j.virol.2003.10.032; Hernandez J, 2017, VET MICROBIOL, V212, P7, DOI 10.1016/j.vetmic.2017.10.020; Hikke MC, 2017, ANNU REV ANIM BIOSCI, V5, P89, DOI 10.1146/annurev-animal-031716-032328; Huang C, 2015, VIRUS RES, V202, P101, DOI 10.1016/j.virusres.2014.12.014; Jamin A, 2008, VET RES, V39, DOI 10.1051/vetres:2007045; Jiang YF, 2015, VET MICROBIOL, V179, P242, DOI 10.1016/j.vetmic.2015.06.015; Karniychuk UU, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-95; Kick AR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090796; Kleiboeker SB, 2005, J VET DIAGN INVEST, V17, P165, DOI 10.1177/104063870501700211; Kvisgaard LK, 2017, VET MICROBIOL, V211, P74, DOI 10.1016/j.vetmic.2017.10.001; Kvisgaard LK, 2013, VIRUS RES, V178, P197, DOI 10.1016/j.virusres.2013.10.009; Kvisgaard LK, 2020, TRANSBOUND EMERG DIS, V67, P1786, DOI 10.1111/tbed.13555; Lundegaard C., 2010, P 1 ACM INT C BIOINF, P658; Lundstrom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145130; Lundstrom K, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040039; Madsen KG, 1998, ARCH VIROL, V143, P1683, DOI 10.1007/s007050050409; Martini V, 2021, J IMMUNOL, V206, P652, DOI 10.4049/jimmunol.2001086; McCullough KC, 2014, VACCINES-BASEL, V2, P735, DOI 10.3390/vaccines2040735; McCullough KC, 2009, VET IMMUNOL IMMUNOP, V128, P7, DOI 10.1016/j.vetimm.2008.10.290; Moodie Z, 2006, J IMMUNOL METHODS, V315, P121, DOI 10.1016/j.jim.2006.07.015; Nilubol D, 2013, ARCH VIROL, V158, P943, DOI 10.1007/s00705-012-1573-7; Osorio FA, 2002, VIROLOGY, V302, P9, DOI 10.1006/viro.2002.1612; Python S, 2013, PLOS PATHOG, V9, DOI [10.1371/annotation/4290dfee-64fd-4157-89e3-8edbba912420, 10.1371/journal.ppat.1003412]; Rahe MC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060148; Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360; Renukaradhya GJ, 2015, VACCINE, V33, P4069, DOI 10.1016/j.vaccine.2015.06.092; Renukaradhya GJ, 2015, VACCINE, V33, P3065, DOI 10.1016/j.vaccine.2015.04.102; Ricklin ME, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16419-w; Rossow KD, 1998, VET PATHOL, V35, P1, DOI 10.1177/030098589803500101; Rowland RRR, 2003, VET MICROBIOL, V96, P219, DOI 10.1016/j.vetmic.2003.07.006; Ruggli N, 1996, J VIROL, V70, P3478, DOI 10.1128/JVI.70.6.3478-3487.1996; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; Suter R, 2011, VACCINE, V29, P1491, DOI 10.1016/j.vaccine.2010.12.026; Szymanski MR, 2009, J MOL BIOL, V391, P438, DOI 10.1016/j.jmb.2009.06.040; Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526; Walker PJ, 2019, ARCH VIROL, V164, P2417, DOI 10.1007/s00705-019-04306-w; Wang FJ, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-204; Welner S, 2017, IMMUNOGENETICS, V69, P689, DOI 10.1007/s00251-017-1004-8; Wernike K, 2012, J VET DIAGN INVEST, V24, P855, DOI 10.1177/1040638712452724; Xiao ZG, 2004, J VIROL, V78, P5923, DOI 10.1128/JVI.78.11.5923-5933.2004; Zuckermann FA, 2007, VET MICROBIOL, V123, P69, DOI 10.1016/j.vetmic.2007.02.009	61	0	0	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							208	10.3390/vaccines9030208			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6SL	33801369	Green Published, gold			2022-04-29	WOS:000634281200001
J	Zhang, MY; Chen, HB; Wu, F; Li, QS; Lin, QH; Cao, H; Zhou, XF; Gu, ZH; Chen, Q				Zhang, Minyi; Chen, Hongbiao; Wu, Fei; Li, Qiushuang; Lin, Qihui; Cao, He; Zhou, Xiaofeng; Gu, Zihao; Chen, Qing			Heightened Willingness toward Pneumococcal Vaccination in the Elderly Population in Shenzhen, China: A Cross-Sectional Study during the COVID-19 Pandemic	VACCINES			English	Article						23-valent pneumococcal polysaccharide vaccine; older adults; positive attitude; influencing factors; COVID-19		Background: Elderly population is considered at high risk for pneumococcal diseases. The pneumococcal vaccine coverage presents extremely low among elderly people in China. However, the serious event of COVID-19 drives interest in the pneumococcal vaccine, prompting us investigating the willingness to accept the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and influencing factors among people aged over 60 years during the COVID-19 pandemic. Methods: A cross-sectional study was employed using a self-administered questionnaire in Shenzhen City of China, elaborating the willingness toward PPSV23 in the elderly persons. Binomial logistic analyses were performed to estimate the influencing factors using odds ratios (ORs) and 95% confidence interval (CI). Results: Among 15,066 respondents, 91.5% presented a positive attitude toward PPSV23. Logistic analyses suggested the influencing factors included knowledge about pneumonia (adjusted OR [aOR] 1.391, 95%CI 1.214-1.593), perception of the seriousness of pneumonia (aOR 1.437, 95%CI 1.230-1.680) and preventing way for pneumonia (aOR 1.639, 95%CI 1.440-1.865), worried about getting pneumonia (aOR 2.751, 95%CI 2.444-3.096), understanding vaccine policy (aOR 1.774, 95%CI 1.514-2.079), and influenza vaccine (aOR 3.516 and 95%CI 2.261-5.468) and PPSV23 histories (aOR 3.199, 95%CI 1.492-6.860). Conclusions: The interest surge in pneumococcal vaccine coincided with the COVID-19 outbreak, foreshadowing higher demand for pneumococcal vaccine in the near future.	[Zhang, Minyi; Wu, Fei; Li, Qiushuang; Chen, Qing] Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangzhou 510515, Peoples R China; [Chen, Hongbiao; Lin, Qihui; Cao, He; Zhou, Xiaofeng; Gu, Zihao] Longhua Ctr Dis Control & Prevent, Dept Epidemiol & Infect Dis Control, Shenzhen 518109, Peoples R China; [Chen, Hongbiao] Longhua Key Discipline Control & Prevent Infect D, Dept Epidemiol & Infect Dis Control, Shenzhen 518109, Peoples R China		Chen, Q (通讯作者)，Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangzhou 510515, Peoples R China.	zhangminyi1993@outlook.com; luojingwei001@163.com; wufei1996123@outlook.com; li15938303617@163.com; lhjkzx@szlhq.gov.cn; lhjbkz@163.com; ct502528528@163.com; 13711762051@163.com; qingchen@smu.edu.cn		Zhang, Minyi/0000-0003-0059-2440	Science and Technology Innovation Funding Project of Shenzhen Longhua [2020206]; Key Discipline of Control and Prevention of Infectious Diseases and Public Health of Shenzhen Longhua	This research was funded by the Science and Technology Innovation Funding Project of Shenzhen Longhua (grant number 2020206) and the Key Discipline of Control and Prevention of Infectious Diseases and Public Health of Shenzhen Longhua.	[Anonymous], HLTH PROTECTION REPO; Artz AS, 2003, CLIN MICROBIOL REV, V16, P308, DOI 10.1128/CMR.16.2.308-318.2003; Dominguez A, 2016, HUM VACC IMMUNOTHER, V12, P1891, DOI 10.1080/21645515.2016.1149661; Ferdous MZ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239254; Grabenstein JD, 2012, CLIN MICROBIOL INFEC, V18, P15, DOI 10.1111/j.1469-0691.2012.03943.x; Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047; Ramos MI, 2019, INT J HEALTH PLAN M, V34, pE1215, DOI 10.1002/hpm.2763; Jiang YT, 2019, HUM VACC IMMUNOTHER, V15, P1100, DOI 10.1080/21645515.2019.1568160; [李耘 Li Yun], 2014, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V30, P260; Liu Hui, 2007, Zhonghua Nei Ke Za Zhi, V46, P810; Liu SJ, 2014, HUM VACC IMMUNOTHER, V10, P2994, DOI 10.4161/21645515.2014.972155; Liu Y, 2021, HUM VACC IMMUNOTHER, V17, P157, DOI 10.1080/21645515.2020.1765620; Ma W, 2018, INFECT DIS-NOR, V50, P728, DOI 10.1080/23744235.2018.1472805; Mgbere O, 2017, EPIDEMIOL INFECT, V145, P2611, DOI 10.1017/S0950268817001467; Morimoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122247; Paguio JA, 2020, VACCINE, V38, P5430, DOI 10.1016/j.vaccine.2020.06.069; Peto L, 2014, T ROY SOC TROP MED H, V108, P326, DOI 10.1093/trstmh/tru058; Qin Ying, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P1101; Schanzer DL, 2013, ACAD EMERG MED, V20, P388, DOI 10.1111/acem.12111; Shen KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201245; Siu JYM, 2021, GERONTOLOGIST, V61, P439, DOI 10.1093/geront/gny139; Sun H, 2008, CHIN J INFECT CHEMOT, V8, P24; Sun YX, 2020, VACCINE, V38, P8362, DOI 10.1016/j.vaccine.2020.11.004; Wang Hui, 2004, Zhonghua Jiehe He Huxi Zazhi, V27, P155; Wang XL, 2020, J CELL MOL MED, V24, P2573, DOI 10.1111/jcmm.14951; Wang YH, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8388-3; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502; Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1; Wright AE, 1914, LANCET, V1, P1; Ye CC, 2018, HUM VACC IMMUNOTHER, V14, P2715, DOI 10.1080/21645515.2018.1491246; Yuan X, 2018, LANCET, V392, P371, DOI 10.1016/S0140-6736(18)31725-2	31	4	4	2	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							212	10.3390/vaccines9030212			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5CK	33802327	gold, Green Published			2022-04-29	WOS:000634171800001
J	Benest, J; Rhodes, S; Quaife, M; Evans, TG; White, RG				Benest, John; Rhodes, Sophie; Quaife, Matthew; Evans, Thomas G.; White, Richard G.			Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy	VACCINES			English	Article						dosing; dose-response; adenovirus-vectored vaccines; dose dynamics; COVID-19	COVID-19 VACCINE; ESCALATION	Developing a vaccine against the global pandemic SARS-CoV-2 is a critical area of active research. Modelling can be used to identify optimal vaccine dosing; maximising vaccine efficacy and safety and minimising cost. We calibrated statistical models to published dose-dependent seroconversion and adverse event data of a recombinant adenovirus type-5 (Ad5) SARS-CoV-2 vaccine given at doses 5.0 x 10(10), 1.0 x 10(11) and 1.5 x 10(11) viral particles. We estimated the optimal dose for three objectives, finding: (A) the minimum dose that may induce herd immunity, (B) the dose that maximises immunogenicity and safety and (C) the dose that maximises immunogenicity and safety whilst minimising cost. Results suggest optimal dose [95% confidence interval] in viral particles per person was (A) 1.3 x 10(11) [0.8-7.9 x 10(11)], (B) 1.5 x 10(11) [0.3-5.0 x 10(11)] and (C) 1.1 x 10(11) [0.2-1.5 x 10(11)]. Optimal dose exceeded 5.0 x 10(10) viral particles only if the cost of delivery exceeded 0.65 pound or cost per 10(11) viral particles was less than 6.23 pound. Optimal dose may differ depending on the objectives of developers and policy-makers, but further research is required to improve the accuracy of optimal-dose estimates.	[Benest, John; Rhodes, Sophie; Quaife, Matthew; White, Richard G.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England; [Evans, Thomas G.] Vaccitech Ltd, Schrodinger Bldg,Heatley Rd,Oxford Sci Pk, Oxford OX4 4GE, England		Benest, J (通讯作者)，London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.	john.benest@lshtm.ac.uk; sophie.rhodes@lshtm.ac.uk; matthew.quaife@lshtm.ac.uk; tom.evans@vaccitech.co.uk; Richard.White@lshtm.ac.uk	White, Richard G/D-5407-2009	White, Richard G/0000-0003-4410-6635; Quaife, Matthew/0000-0001-9291-1511; , John/0000-0003-0537-5437	BBSRC LIDo PhD studentshipUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M009513/1]; Wellcome TrustWellcome TrustEuropean Commission [218261/Z/19/Z]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AI147321-01]; EDTCP [RIA208D2505B]; UK MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [CCF17-7779]; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/P008011/1]; BMGF [OPP1084276, OPP1135288, INV-001754]; WHOWorld Health Organization [2020/985800-0]; Vaccitech Ltd.; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [INV-001754]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/P002404/1] Funding Source: UKRI	This work was supported by a BBSRC LIDo PhD studentship: BB/M009513/1 (J.B.). R.G.W is funded by the Wellcome Trust (218261/Z/19/Z), NIH (1R01AI147321-01), EDTCP (RIA208D2505B), UK MRC (CCF17-7779 via SET Bloomsbury), ESRC (ES/P008011/1), BMGF (OPP1084276, OPP1135288 & INV-001754), and theWHO(2020/985800-0). The research received additional funding from Vaccitech Ltd. M.Q. is funded by the Bill and Melinda Gates Foundation INV-001754. The APC was funded by BBSRC LIDo PhD studentship.	Afrough S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010131; [Anonymous], 2017, VACCINATING ADULTS S; Benest J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020155; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Frazao TDC, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0663-1; GE Healthcare, 2018, SCALABLE PROCESS ADE; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Grothendieck G., 2013, **DATA OBJECT**; Handel A, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006505; Izda V, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108634; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027; Le Tourneau C, 2009, JNCI-J NATL CANCER I, V101, P708, DOI 10.1093/jnci/djp079; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4347; Manners C, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8399; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Newall AT, 2018, INFLUENZA OTHER RESP, V12, P211, DOI 10.1111/irv.12510; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Pereira CC, 2010, EXPERT REV VACCINES, V9, P1343, DOI [10.1586/erv.10.129, 10.1586/ERV.10.129]; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; R DEVELOPMENT CORE TEAM, 2008, R LANGUAGE ENV STAT; Raja AT, 2020, SAUDI PHARM J, V28, P1743, DOI 10.1016/j.jsps.2020.10.019; Rhodes SJ, 2019, J THEOR BIOL, V465, P51, DOI 10.1016/j.jtbi.2019.01.017; Rhodes SJ, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0075-3; Rhodes SJ, 2016, VACCINE, V34, P6285, DOI 10.1016/j.vaccine.2016.10.060; Sharma A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106054; Sibille M, 2010, BRIT J CLIN PHARMACO, V70, P736, DOI 10.1111/j.1365-2125.2010.03741.x; US Food and Drug Administration, 2007, GUID IND TOX GRAD SC; Wages NA, 2020, STAT BIOSCI, V12, P104, DOI 10.1007/s12561-019-09245-3; Wang CG, 2019, STAT MED, V38, P1170, DOI 10.1002/sim.8021; World Health Organisation, DRAFT LANDSC COVID 1; World Health Organization, 2002, GUID EST COSTS INTR; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	35	6	6	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							78	10.3390/vaccines9020078			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6ZS	33499326	Green Published, gold, Green Submitted			2022-04-29	WOS:000623290500001
J	Chandrasekar, SS; Phanse, Y; Hildebrand, RE; Hanafy, M; Wu, CW; Hansen, CH; Osorio, JE; Suresh, M; Talaat, AM				Chandrasekar, Shaswath S.; Phanse, Yashdeep; Hildebrand, Rachel E.; Hanafy, Mostafa; Wu, Chia-Wei; Hansen, Chungyi H.; Osorio, Jorge E.; Suresh, M.; Talaat, Adel M.			Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization	VACCINES			English	Article						SARS-CoV-2; COVID-19; intranasal vaccine; nanovaccine; heterologous vaccine	INFLUENZA; VACCINE; MEMORY; PROTECTION; VIRUS; SARS; IGA	The rapid transmission of SARS-CoV-2 in the USA and worldwide necessitates the development of multiple vaccines to combat the COVID-19 global pandemic. Previously, we showed that a particulate adjuvant system, quil-A-loaded chitosan (QAC) nanoparticles, can elicit robust immunity combined with plasmid vaccines when used against avian coronavirus. Here, we report on the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens. Only the heterologous intranasal immunization strategy elicited neutralizing antibodies against SARS-CoV-2 in serum and bronchoalveolar lavage of mice, suggesting a protective vaccine. The same prime/boost strategy led to the induction of type 1 and type 17 T-cell responses and polyfunctional T-cells expressing multiple type 1 cytokines (e.g., IFN-gamma, TNF alpha, IL-2) in the lungs and spleens of vaccinated mice. In contrast, the plasmid homologous vaccine strategy led to the induction of local mono and polyfunctional T-cells secreting IFN-gamma. Outcomes of this study support the potential of QAC-nano vaccines to elicit significant mucosal immune responses against respiratory coronaviruses.	[Chandrasekar, Shaswath S.; Hildebrand, Rachel E.; Hanafy, Mostafa; Wu, Chia-Wei; Hansen, Chungyi H.; Osorio, Jorge E.; Suresh, M.; Talaat, Adel M.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; [Phanse, Yashdeep; Talaat, Adel M.] Pan Genome Syst, Madison, WI 53719 USA; [Hanafy, Mostafa] Cairo Univ, Fac Vet Med, Dept Microbiol & Immunol, Giza 12211, Egypt; [Osorio, Jorge E.] Univ Nacl Medellin, Colombia Wisconsin One Hlth Consortium, Calle 75 79a 5, Medellin, Colombia		Talaat, AM (通讯作者)，Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.; Talaat, AM (通讯作者)，Pan Genome Syst, Madison, WI 53719 USA.	schandrasek5@wisc.edu; phanse@pangenosys.com; rhildebrand@wisc.edu; hanafy@wisc.edu; chiaweiwu@wisc.edu; chungyi.hansen@wisc.edu; jorge.osorio@wisc.edu; suresh.marulasiddappa@wisc.edu; adel.talaat@wisc.edu		Talaat, Adel/0000-0003-3305-7903; Hanafy, Mostafa/0000-0002-4776-0352	grants USDA-NIFA, Nanotechnology program [2019-05849]; Wisconsin Alumni Research Foundation-SEED fund; PHS grants from the National Institutes of Health [R21 AI141090, U01AI124299, R21 AI149793]	This work was partially supported by grants USDA-NIFA, Nanotechnology program (Award #2019-05849) and Wisconsin Alumni Research Foundation-SEED fund awarded to A.M.T. Additional support for this work was also provided by PHS grants from the National Institutes of Health to AT (R21 AI141090) and MS (U01AI124299 and R21 AI149793).	Acharya D, 2017, J VIROL, V91, DOI [10.1128/JVI.01529-16, 10.1128/jvi.01529-16]; Altenburg AF, 2014, VIRUSES-BASEL, V6, P2735, DOI 10.3390/v6072735; Anipindi VC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005589; [Anonymous], 2020, IGA DOMINATES EARLY, DOI [DOI 10.1101/2020.1106.1110.20126532, 10.1101/2020.1106.1110.20126532, DOI 10.1101/2020.06.10.20126532]; Bagri P, 2017, J VIROL, V91, DOI 10.1128/JVI.01234-17; Borges O, 2005, INT J PHARMACEUT, V299, P155, DOI 10.1016/j.ijpharm.2005.04.037; Cai PQ, 2018, ACS NANO, V12, P5078, DOI 10.1021/acsnano.8b03285; Chandrasekar SS, 2020, J VIROL, V94, DOI 10.1128/JVI.01016-20; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Chao YX, 2020, BRAIN BEHAV IMMUN, V87, P182, DOI 10.1016/j.bbi.2020.05.057; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corthesy B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00185; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Graham BS, 2018, JAMA-J AM MED ASSOC, V319, P1431, DOI 10.1001/jama.2018.0345; Hernandez Raquel, 2010, Curr Protoc Microbiol, VAppendix 4, p4I, DOI 10.1002/9780471729259.mca04is17; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x; Huang HQ, 2015, IMMUNOL CELL BIOL, V93, P126, DOI 10.1038/icb.2014.79; Kamlangdee A, 2016, J VIROL, V90, P6771, DOI 10.1128/JVI.00730-16; Kamlangdee A, 2014, J VIROL, V88, P13300, DOI 10.1128/JVI.01532-14; Kingstad-Bakke BA, 2019, VACCINE, V37, P5051, DOI 10.1016/j.vaccine.2019.06.077; Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2; Ma WT, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190109; Maeto C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107524; Manrique M, 2009, MUCOSAL IMMUNOL, V2, P536, DOI 10.1038/mi.2009.103; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738; Novelli F, 2004, CYTOKINE GROWTH F R, V15, P367, DOI 10.1016/j.cytogfr.2004.03.009; Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757; Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036; Prevost J, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100126; Rajput Zahid Iqbal, 2007, Journal of Zhejiang University-Science B, V8, P153, DOI 10.1631/jzus.2007.B0153; Riteau N, 2016, IMMUNITY, V44, P522, DOI 10.1016/j.immuni.2016.03.002; Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/ERV.11.188, 10.1586/erv.11.188]; Seow J., 2020, NAT MICROBIOL, V5, P1598, DOI [10.1101/2020.07.09.20148429, DOI 10.1038/S41564-020-00813-8, 10.1038/s41564-020-00813-8]; Siracusano G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01049; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Sogias IA, 2008, BIOMACROMOLECULES, V9, P1837, DOI 10.1021/bm800276d; Stading BR, 2016, VACCINE, V34, P5352, DOI 10.1016/j.vaccine.2016.08.088; Talaat AM, 2001, VACCINE, V20, P538, DOI 10.1016/S0264-410X(01)00352-8; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Valosky J, 2005, CLIN DIAGN LAB IMMUN, V12, P171, DOI 10.1128/CDLI.12.1.171-179.2005; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298; Wang XH, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005367; Wang XH, 2011, CELL MOL IMMUNOL, V8, P462, DOI 10.1038/cmi.2011.38; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134; Zhi Y, 2005, CELL MOL IMMUNOL, V2, P101; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	55	6	6	4	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							132	10.3390/vaccines9020132			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UE	33562141	Green Published, gold			2022-04-29	WOS:000623275800001
J	Kanakoudi-Tsakalidou, F; Farmaki, E; Papadimitriou, E; Taparkou, A; Agakidou, E; Glykou, S; Papachristou, F				Kanakoudi-Tsakalidou, Florentia; Farmaki, Evangelia; Papadimitriou, Eleni; Taparkou, Anna; Agakidou, Eleni; Glykou, Styliani; Papachristou, Fotios			Humoral Immunity against Measles in Mother-Infant Pairs during the First Year of Life in Greece: A Cross-Sectional Study	VACCINES			English	Article						maternal-infant measles immunity; measles antibodies; waning measles immunity; vaccine-induced immunity; measles susceptible infants; measles passive immunity	MATERNAL ANTIBODIES; MUMPS VACCINATION; ELIMINATION; CHILDREN; RUBELLA	Measles outbreaks have surfaced in Europe during the last decades. Infants <12 months of age were the most severely affected pediatric population. The aim of this study was to investigate the duration of maternally derived measles antibodies in infants aged 1 to 12 months in relation to maternal humoral immune status and other parameters. In a prospective, cross-sectional cohort study, 124 mother/infant pairs and 63 additional infants were recruited from October 2015 through December 2019. Infants were hospitalized in a university pediatric department of a general hospital. Demographic and epidemiological data were recorded and blood samples were collected from mothers and their infants. Commercially available enzyme-linked immunosorbent assay (ELISA) was used for measuring measles antibodies. Fifty nine percent of mothers had vaccine-induced and 15% infection-acquired measles immunity. Eighty-eight percent and 94% of infants were unprotected by 5 and 10 months of age, respectively. Maternal antibody levels and infant age were significant independent predictors of infants' antibody levels whereas the method of maternal immunity acquisition, age, and origin [Greek/non-Greek] were not. Our findings suggest that about 90% of infants are susceptible to measles beyond the age of 4 months. To our knowledge, these are the first data from Greece reported under the current community composition and epidemiological conditions.	[Kanakoudi-Tsakalidou, Florentia; Farmaki, Evangelia; Papadimitriou, Eleni; Taparkou, Anna; Agakidou, Eleni; Glykou, Styliani; Papachristou, Fotios] Aristotle Univ Thessaloniki, Ippokrate Gen Hosp, Fac Med, Dept Pediat 1, 49 Konstantinoupoleos Str, Thessaloniki 54246, Greece		Kanakoudi-Tsakalidou, F (通讯作者)，Aristotle Univ Thessaloniki, Ippokrate Gen Hosp, Fac Med, Dept Pediat 1, 49 Konstantinoupoleos Str, Thessaloniki 54246, Greece.	flkan@auth.gr; farmakg@med.auth.gr; epapadimitriu@gmail.com; annatapark@gmail.com; eagaki@hotmail.com; stella83g@gmail.com; fotios@med.auth.gr	Farmaki, Evangelia/AAA-6768-2022	GLYKOU, STYLIANI/0000-0001-9833-9739; AGAKIDOU, ELENI/0000-0001-7361-0510; Farmaki, Evangelia/0000-0002-5132-8255	GSK pharmaceutical Co through the account of the Research Committee of the Aristotle University of Thessaloniki ELKE (Eidikos Logariasmos Kondylion Erevnas) [108378/10-09-2018]	The study was partly supported by the GSK pharmaceutical Co through the account of the Research Committee of the Aristotle University of Thessaloniki ELKE (Eidikos Logariasmos Kondylion Erevnas) (No 108378/10-09-2018). The article processing charges are covered by the Research Committee (Eidikos Logariasmos Kondylion Erevnas) of the Aristotle University of Thessaloniki. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.	Boulton ML, 2017, J INFECT DIS, V216, P1122, DOI 10.1093/infdis/jix453; Brugha R, 1996, EPIDEMIOL INFECT, V117, P519, DOI 10.1017/S0950268800059203; Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6; DAGAN R, 1995, PEDIATR INFECT DIS J, V14, P965, DOI 10.1097/00006454-199511000-00008; European Centre for Disease Prevention and Control, 2018, MONTHL MEASL RUB SUR; Gagneur A, 2010, EXPERT REV ANTI-INFE, V8, P1339, DOI 10.1586/ERI.10.126; Gans H, 2003, VACCINE, V21, P3398, DOI 10.1016/S0264-410X(03)00341-4; Gans H, 2001, J INFECT DIS, V184, P817, DOI 10.1086/323346; Georgakopoulou T, 2018, EPIDEMIOL INFECT, V146, P1692, DOI [10.1017/S0950268818002170, 10.1017/s0950268818002170]; Georgakopoulou T, 2017, HUM VACC IMMUNOTHER, V13, P190, DOI 10.1080/21645515.2016.1230577; Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002; Cilleruelo MJ, 2019, VACCINE, V37, P4164, DOI 10.1016/j.vaccine.2019.05.056; Kumar ML, 1998, VACCINE, V16, P2047, DOI 10.1016/S0264-410X(98)00083-8; Leuridan E, 2007, VACCINE, V25, P6296, DOI 10.1016/j.vaccine.2007.06.020; Leuridan E, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1626; MALDONADO YA, 1995, PEDIATRICS, V96, P447; Markowitz LE, 1996, PEDIATRICS, V97, P53; Montalti M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010086; Muscat M, 2009, LANCET, V373, P383, DOI 10.1016/S0140-6736(08)61849-8; Plans-Rubio P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020218; Redd SC, 2004, J INFECT DIS, V189, pS116, DOI 10.1086/378691; Science M, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0630; Waaijenborg S, 2013, J INFECT DIS, V208, P10, DOI 10.1093/infdis/jit143; World Health Organization, 2012, GLOB MEASL RUB STRAT; Zhang XW, 2012, VACCINE, V30, P752, DOI 10.1016/j.vaccine.2011.11.078	25	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							143	10.3390/vaccines9020143			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QF	33579024	Green Published, gold			2022-04-29	WOS:000623265500001
J	Costa, JH; Aziz, S; Noceda, C; Arnholdt-Schmitt, B				Costa, Jose Helio; Aziz, Shahid; Noceda, Carlos; Arnholdt-Schmitt, Birgit			Major Complex Trait for Early De Novo Programming 'CoV-MAC-TED' Detected in Human Nasal Epithelial Cells Infected by Two SARS-CoV-2 Variants Is Promising to Help in Designing Therapeutic Strategies	VACCINES			English	Article						immunology paradigm shift; melatonin; ADH5; cell cycle; SARS-CoV-2 Delta 382; SARS-CoV-2 helicase; SARS-CoV-2 RdRp; anti-viral diagnosis and strategies; microbiota; repurposing drugs	FUNCTIONAL-MARKER; PLANT-NUTRITION; AOX; CALORESPIROMETRY; GENOME; ENERGY; TOOL	Background: Early metabolic reorganization was only recently recognized as an essentially integrated part of immunology. In this context, unbalanced ROS/RNS levels connected to increased aerobic fermentation, which is linked to alpha-tubulin-based cell restructuring and control of cell cycle progression, were identified as a major complex trait for early de novo programming ('CoV-MAC-TED') during SARS-CoV-2 infection. This trait was highlighted as a critical target for developing early anti-viral/anti-SARS-CoV-2 strategies. To obtain this result, analyses had been performed on transcriptome data from diverse experimental cell systems. A call was released for wide data collection of the defined set of genes for transcriptome analyses, named 'ReprogVirus', which should be based on strictly standardized protocols and data entry from diverse virus types and variants into the 'ReprogVirus Platform'. This platform is currently under development. However, so far, an in vitro cell system from primary target cells for virus attacks that could ideally serve for standardizing the data collection of early SARS-CoV-2 infection responses has not been defined. Results: Here, we demonstrate transcriptome-level profiles of the most critical 'ReprogVirus' gene sets for identifying 'CoV-MAC-TED' in cultured human nasal epithelial cells infected by two SARS-CoV-2 variants differing in disease severity. Our results (a) validate 'Cov-MAC-TED' as a crucial trait for early SARS-CoV-2 reprogramming for the tested virus variants and (b) demonstrate its relevance in cultured human nasal epithelial cells. Conclusion: In vitro-cultured human nasal epithelial cells proved to be appropriate for standardized transcriptome data collection in the 'ReprogVirus Platform'. Thus, this cell system is highly promising to advance integrative data analyses with the help of artificial intelligence methodologies for designing anti-SARS-CoV-2 strategies.	[Costa, Jose Helio; Aziz, Shahid; Arnholdt-Schmitt, Birgit] Univ Fed Ceara, Dept Biochem & Mol Biol, Funct Genom & Bioinformat Grp, BR-60451970 Fortaleza, Brazil; [Costa, Jose Helio; Aziz, Shahid; Noceda, Carlos; Arnholdt-Schmitt, Birgit] NonInst Competence Focus NICFocus, Coordinated Foros Vale Figueira, Funct Cell Reprogramming & Organism Plast FunCRO, Montemor O Novo, Portugal; [Noceda, Carlos] Univ Fuerzas Armadas ESPE, Ind Biotechnol & Bioprod, Dept Life & Agr Sci, Plant Mol & Cellular Biotechnol, Quito 171103, Ecuador		Costa, JH; Arnholdt-Schmitt, B (通讯作者)，Univ Fed Ceara, Dept Biochem & Mol Biol, Funct Genom & Bioinformat Grp, BR-60451970 Fortaleza, Brazil.; Costa, JH; Arnholdt-Schmitt, B (通讯作者)，NonInst Competence Focus NICFocus, Coordinated Foros Vale Figueira, Funct Cell Reprogramming & Organism Plast FunCRO, Montemor O Novo, Portugal.	helio.costa@ufc.br; shahidaziz.cl@gmail.com; cana293@yahoo.es; biarnaflora@gmail.com	Costa, Jose Helio/I-4961-2014	Costa, Jose Helio/0000-0001-7914-0150; , Shahid Aziz/0000-0002-4657-1066	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [309795/2017-6]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	J.H.C. is grateful to CNPq for the Researcher fellowship (CNPq grant309795/2017-6). S.A. is grateful to CAPES for the Doctoral fellowship. CN Acknowledges the international scientific network BIOALI CYTED, which contributed to establish FunCROP contacts.	Akaike T, 2000, IMMUNOLOGY, V101, P300, DOI 10.1046/j.1365-2567.2000.00142.x; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Arnholdt-Schmitt B, 2005, PLANT PHYSIOL BIOCH, V43, P817, DOI 10.1016/j.plaphy.2005.08.011; Arnholdt-Schmitt B, 2005, J PLANT NUTR SOIL SC, V168, P617, DOI 10.1002/jpln.200420493; Arnholdt-Schmitt B, 2004, PLANT PHYSIOL, V136, P2579, DOI 10.1104/pp.104.042531; Arnholdt-Schmitt B., 2018, BIOFUELS GREENHOUSE, DOI [10.1007/978-81-322-3763-1, DOI 10.1007/978-81-322-3763-1]; Arnholdt-Schmitt B, 2006, TRENDS PLANT SCI, V11, P281, DOI 10.1016/j.tplants.2006.05.001; Arnholdt-Schmitt B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.673723; Arnholdt-Schmitt B, 2017, METHODS MOL BIOL, V1670, P193, DOI 10.1007/978-1-4939-7292-0_16; Arnholdt-Schmitt B, 2017, METHODS MOL BIOL, V1670, P235, DOI 10.1007/978-1-4939-7292-0_20; Arnholdt-Schmitt B, 2016, BRIEF FUNCT GENOMICS, V15, P10, DOI 10.1093/bfgp/elv008; Arnholdt-Schmitt B, 2016, METHODS MOL BIOL, V1359, P87, DOI 10.1007/978-1-4939-3061-6_4; Bailey-Serres J, 2018, PLANT PHYSIOL, V176, P961, DOI 10.1104/pp.18.00041; Barnett SD, 2017, CRIT REV BIOCHEM MOL, V52, P340, DOI 10.1080/10409238.2017.1304353; Bharadwaj R, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.686274; Boratyn GM, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2996-x; Cardoso H.G., 2013, DIAGNOSTICS PLANT BR, P467, DOI [10.1007/978-94-007-5687-8_21, DOI 10.1007/978-94-007-5687-8_]; Costa J.H., 2021, TRANSCRIPTOME DATA, DOI [10.1101/2021.10.18.464828, DOI 10.1101/2021.10.18.464828]; Costa JH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.673692; Delmastro-Greenwood MM, 2013, AM J CLIN EXP IMMUNO, V2, P30; Fernandes P.A., 2021, MELATONIN RES, V4, P189, DOI [10.32794/mr11250090, DOI 10.32794/MR11250090]; Gamage AM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009130; Ganeshan K, 2019, CELL, V177, P399, DOI 10.1016/j.cell.2019.01.050; Gourbal B, 2018, IMMUNOL REV, V283, P21, DOI 10.1111/imr.12647; Haaf JM, 2019, NATURE, V567, P461, DOI 10.1038/d41586-019-00972-7; Hakkaart GAJ, 2006, EMBO REP, V7, P341, DOI 10.1038/sj.embor.7400601; Haney C.H., 2014, BIOCHEMIST, V36, P40, DOI DOI 10.1042/BIO03605040; Hirschauer N., 2020, SIGNIFIKANZTESTS FOR, V6, P20; Hou WN, 2021, FUNCT PLANT BIOL, V48, P936, DOI 10.1071/FP20292; Huang SH, 2019, J FUNCT FOODS, V58, P189, DOI 10.1016/j.jff.2019.04.062; Isola M, 2018, ANAT REC, V301, P711, DOI 10.1002/ar.23750; Juybari K.B., 2021, VIRUS RES, V48, P936; Kirman JR, 2019, IMMUNOL CELL BIOL, V97, P615, DOI 10.1111/imcb.12280; Kutschera U, 2020, PLANT SIGNAL BEHAV, V15, DOI 10.1080/15592324.2020.1776477; Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00791; McNulty S, 2013, J VIROL, V87, P912, DOI 10.1128/JVI.02415-12; Melkonian EA., 2021, STATPEARLS; Mohanapriya G, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01134; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; National Academies of Sciences Engineering and Medicine, 2019, REPRODUCIBILITY REPL; Nejat N, 2017, CURR ISSUES MOL BIOL, V23, P1, DOI 10.21775/cimb.023.001; O'Sullivan D, 2019, IMMUNOL CELL BIOL, V97, P636, DOI 10.1111/imcb.12274; Olah J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020357; Orfanoudakis M, 2015, ALTERNATIVE RESPIRATORY PATHWAYS IN HIGHER PLANTS, P311; Popovic M, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04943; Popovic M, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03933; Priyadarshini S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043232; Rizza S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00334; Sakr S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092506; Shi YF, 2015, MOL PLANT, V8, P1350, DOI 10.1016/j.molp.2015.04.008; Silvestri M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-61; Sircar D, 2012, J PLANT PHYSIOL, V169, P657, DOI 10.1016/j.jplph.2011.11.019; Tan KS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090986; Wasserstein RL, 2019, AM STAT, V73, P1, DOI 10.1080/00031305.2019.1583913; Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108; Wurzinger B, 2018, PLANT PHYSIOL, V176, P1085, DOI 10.1104/pp.17.01404; Young BE, 2020, LANCET, V396, P603, DOI 10.1016/S0140-6736(20)31757-8; Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583; Zhao D, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00249; Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3; Zia SF, 2019, BMC PLANT BIOL, V19, DOI 10.1186/s12870-019-2158-3	61	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1399	10.3390/vaccines9121399			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YI2GA	34960145	gold, Green Published			2022-04-29	WOS:000743671400001
J	Hansen, KP; Benn, CS; Aamand, T; Buus, M; da Silva, I; Aaby, P; Fisker, AB; Thysen, SM				Hansen, Katrine Pedersbaek; Benn, Christine Stabell; Aamand, Thomas; Buus, Martin; da Silva, Isaquel; Aaby, Peter; Fisker, Ane Baerent; Thysen, Sanne Marie			Does Influenza Vaccination during Pregnancy Have Effects on Non-Influenza Infectious Morbidity? A Systematic Review and Meta-Analysis of Randomised Controlled Trials	VACCINES			English	Article						non-specific effects; vaccination; immune system; influenza vaccine; pregnancy; all-cause mortality	BIRTH OUTCOMES; MALE MORTALITY; SPONTANEOUS-ABORTION; POOLED ANALYSIS; PHASE 4; IMMUNIZATION; INFANTS; PLACEBO; FEMALE; PROTECTION	The recommendation to provide inactivated influenza vaccine (IIV) to pregnant women is based on observed protection against influenza-related morbidity in mother and infant. Non-live vaccines may have non-specific effects (NSEs), increasing the risk of non-targeted infections in females. We reviewed the evidence from available randomised controlled trials (RCTs) of IIV to pregnant women, to assess whether IIV may have NSEs. Four RCTs, all conducted in low- and middle-income settings, were identified. We extracted information on all-cause and infectious mortality and adverse events in women and their infants. We conducted meta-analyses providing risk ratios (RR). The meta-analysis for maternal all-cause mortality provided a RR of 1.48 (95% CI = 0.52-4.16). The estimates for miscarriage/stillbirth and infant all-cause mortality up to 6 months of age were 1.06 (0.78-1.44) and 1.11 (0.87-1.41), respectively. IIV was associated with a higher risk of non-influenza infectious adverse events, with meta-estimates of 2.01 (1.15-3.50) in women and 1.36 (1.12-1.67) in infants up to 6 months of age. Thus, following a pattern seen for other non-live vaccines, IIV was associated with a higher risk of non-influenza infectious adverse events. To ensure that scarce resources are used well, and no harm is inflicted, further RCTs are warranted.	[Hansen, Katrine Pedersbaek; Benn, Christine Stabell; Aamand, Thomas; Buus, Martin; Aaby, Peter; Fisker, Ane Baerent; Thysen, Sanne Marie] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Bandim Hlth Project,OPEN, Studiestr 6, DK-1455 Copenhagen, Denmark; [Benn, Christine Stabell] Univ Southern Denmark, Danish Inst Adv Sci, Fioniavej 34, DK-5230 Odense, Denmark; [Benn, Christine Stabell; da Silva, Isaquel; Aaby, Peter; Fisker, Ane Baerent; Thysen, Sanne Marie] Indepth Network, Bandim Hlth Project, Apartado 861, Bissau 1004, Guinea Bissau; [Aamand, Thomas; Buus, Martin] Aarhus Univ, Dept Publ Hlth, Bartholins Alle 2, DK-8000 Aarhus, Denmark		Benn, CS (通讯作者)，Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Bandim Hlth Project,OPEN, Studiestr 6, DK-1455 Copenhagen, Denmark.; Benn, CS (通讯作者)，Univ Southern Denmark, Danish Inst Adv Sci, Fioniavej 34, DK-5230 Odense, Denmark.; Benn, CS (通讯作者)，Indepth Network, Bandim Hlth Project, Apartado 861, Bissau 1004, Guinea Bissau.	kpedersbaek@gmail.com; cbenn@health.sdu.dk; thomas.aamand@post.au.dk; martin.kindberg.buus@post.au.dk; i.silva@bandim.org; p.aaby@bandim.org; afisker@health.sdu.dk; d109381@dadlnet.dk	; Fisker, Ane/E-9283-2019	Thysen, Sanne Marie/0000-0003-4541-3901; Fisker, Ane/0000-0002-8521-0992			Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01; Aaby P, 2016, T ROY SOC TROP MED H, V110, P570, DOI 10.1093/trstmh/trw073; Aaby P, 2015, LANCET, V386, P1735, DOI 10.1016/S0140-6736(15)00693-5; Andersen A, 2021, CLIN INFECT DIS, V72, pE596, DOI 10.1093/cid/ciaa1351; Andersen A, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00013; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P221; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Benn CS, 2020, LANCET INFECT DIS, V20, pE274, DOI 10.1016/S1473-3099(19)30742-X; Beumer MC, 2019, J CRIT CARE, V50, P59, DOI 10.1016/j.jcrc.2018.11.013; Blok BA, 2019, CLIN INFECT DIS, V70, P455, DOI DOI 10.1093/CID/CIZ246; Blok BA, 2019, EUR J CLIN MICROBIOL, V38, P449, DOI 10.1007/s10096-018-03449-z; Bratton KN, 2015, CLIN INFECT DIS, V60, pE11, DOI 10.1093/cid/ciu915; Byberg S, 2017, VACCINE, V35, P1211, DOI 10.1016/j.vaccine.2015.03.024; Clark DR, 2020, PEDIATR INFECT DIS J, V39, P641, DOI 10.1097/INF.0000000000002629; Cowling BJ, 2012, CLIN INFECT DIS, V54, P1778, DOI 10.1093/cid/cis307; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; Donzelli A, 2019, HUM VACC IMMUNOTHER, V15, P2159, DOI 10.1080/21645515.2019.1568161; Edwards KM, 2015, VACCINE, V33, P6469, DOI 10.1016/j.vaccine.2015.07.085; Fisker AB, 2016, VACCINE, V34, P4551, DOI 10.1016/j.vaccine.2016.07.034; Garly ML, 2004, PEDIATR INFECT DIS J, V23, P1086, DOI 10.1097/01.inf.0000145700.77286.94; Hansen OB, 2019, J TROP PEDIATRICS, V65, P446, DOI 10.1093/tropej/fmy075; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Klein SL, 2016, MBIO, V7, DOI 10.1128/mBio.00514-16; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332; Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480; McMillan M, 2015, VACCINE, V33, P2108, DOI 10.1016/j.vaccine.2015.02.068; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Nunes MC, 2018, HUM VACC IMMUNOTHER, V14, P758, DOI 10.1080/21645515.2017.1345385; Nunes MC, 2017, CLIN INFECT DIS, V65, P1066, DOI 10.1093/cid/cix497; Nunes MC, 2016, AM J PERINAT, V33, P1104, DOI 10.1055/s-0036-1586101; Omer SB, 2020, LANCET RESP MED, V8, P597, DOI 10.1016/S2213-2600(19)30479-5; Omer SB, 2018, PEDIATR INFECT DIS J, V37, P436, DOI [10.1097/INF.0000000000001914, 10.1097/inf.0000000000001914]; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9; Steinhoff MC, 2012, CAN MED ASSOC J, V184, P645, DOI 10.1503/cmaj.110754; Tapia MD, 2016, LANCET INFECT DIS, V16, P1026, DOI 10.1016/S1473-3099(16)30054-8; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	40	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1452	10.3390/vaccines9121452			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2KR	34960198	gold, Green Published			2022-04-29	WOS:000737487400001
J	Liu, Y; Han, JY; Li, X; Chen, DY; Zhao, XS; Qiu, YR; Zhang, LD; Xiao, J; Li, B; Zhao, HX				Liu, Ying; Han, Junyan; Li, Xin; Chen, Danying; Zhao, Xuesen; Qiu, Yaruo; Zhang, Leidan; Xiao, Jing; Li, Bei; Zhao, Hongxin			COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity	VACCINES			English	Article						HIV; COVID-19; SARS-CoV-2 vaccine; vaccine hesitancy; safety; immunogenicity	INFLUENZA VACCINATION; INFECTED PATIENTS; ASSOCIATION	The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines among PLWH have not been fully characterized. We estimated vaccine hesitancy and status of COVID-19 vaccination in Chinese PLWH, explored the safety and impact on antiviral therapy (ART) efficacy and compared the immunogenicity of an inactivated vaccine between PLWH and healthy controls (HC). In total, 27.5% (104/378) of PLWH hesitated to take the vaccine. The barriers included concerns about safety and efficacy, and physician counselling might help patients overcome this vaccine hesitancy. A COVID-19 vaccination did not cause severe side effects and had no negative impact on CD4(+) T cell counts and HIV RNA viral load. Comparable spike receptor binding domain IgG titer were elicited in PLWH and HC after a second dose of the CoronaVac vaccine, but antibody responses were lower in poor immunological responders (CD4(+) T cell counts < 350 cells/mu L) compared with immunological responders (CD4(+) T cell counts >= 350 cells/mu L). These data showed that PLWH have comparable safety and immune response following inactivated COVID-19 vaccination compared with HC, but the poor immunological response in PLWH is associated with impaired humoral response.	[Liu, Ying; Li, Bei; Zhao, Hongxin] Capital Med Univ, Beijing Ditan Hosp, Clin Ctr HIV AIDS, Clin & Res Ctr Infect Dis, Beijing 100015, Peoples R China; [Han, Junyan; Chen, Danying; Zhao, Xuesen] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Beijing Key Lab Emerging Infect Dis, Beijing 100015, Peoples R China; [Li, Xin] Capital Med Univ, Beijing Ditan Hosp, Dept Ctr Integrated Tradit Chinese & Western Med, Beijing 100015, Peoples R China; [Qiu, Yaruo; Zhang, Leidan; Xiao, Jing] Peking Univ, Clin Ctr HIV AIDS, Clin & Res Ctr Infect Dis, Ditan Teaching Hosp, Beijing 100015, Peoples R China		Zhao, HX (通讯作者)，Capital Med Univ, Beijing Ditan Hosp, Clin Ctr HIV AIDS, Clin & Res Ctr Infect Dis, Beijing 100015, Peoples R China.	liuying9509@mail.ccmu.edu.cn; hanjunyan@ccmu.edu.cn; leaxin@ccmu.edu.cn; chendanying@ccmu.edu.cn; zhaoxuesen@ccmu.edu.cn; 2011210686@bjmu.edu.cn; 2011210683@bjmu.edu.cn; 2011210598@bjmu.edu.cn; libei@ccmu.edu.cn; drzhao66@ccmu.edu.cn		Han, Junyan/0000-0002-5266-033X	Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20191802]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX202126]; Beijing Municipal Science and Technology CommissionBeijing Municipal Science & Technology Commission [Z191100006619045]	This research was funded by Beijing Municipal Administration of Hospitals' Ascent Plan, DFL20191802 (Hongxin Zhao), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support, ZYLX202126 (Hongxin Zhao), Beijing Municipal Science and Technology Commission, Z191100006619045 (Junyan Han).	AIDS and Hepatitis C Professional Group Chinese Society of Infectious Diseases, 2021, Zhonghua Nei Ke Za Zhi, V60, P615, DOI 10.3760/cma.j.cn112138.20210403-00259; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Brown LB, 2021, CURR OPIN HIV AIDS, V16, P63, DOI 10.1097/COH.0000000000000659; Ekstrand ML, 2021, JAIDS-J ACQ IMM DEF, V88, P421, DOI 10.1097/QAI.0000000000002803; Feng Y., 2021, IMMUNOGEN SAFETY INA, DOI [10.2139/ssrn.3943152, DOI 10.2139/SSRN.3943152]; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gianotti N, 2021, AIDS, V35, P1513, DOI 10.1097/QAD.0000000000002908; Grace D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207953; Harrison N, 2017, HIV MED, V18, P500, DOI 10.1111/hiv.12483; Jeger-Madiot R, 2019, CURR OPIN HIV AIDS, V14, P246, DOI 10.1097/COH.0000000000000557; Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025; Kanwugu ON, 2021, J MED VIROL, V93, P726, DOI 10.1002/jmv.26321; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Liu RG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030292; Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016; Madhi SA, 2021, LANCET HIV, V8, pE568, DOI 10.1016/S2352-3018(21)00157-0; Mondi A, 2021, J MED VIROL, V93, P1796, DOI 10.1002/jmv.26556; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Rief W., 2021, JAMA HLTH FORUM, V2, pe210804, DOI [10.1001/jamahealthforum.2021.0804, DOI 10.1001/JAMAHEALTHFORUM.2021.0804]; Rossheim AEB, 2016, HUM VACC IMMUNOTHER, V12, P2117, DOI 10.1080/21645515.2016.1160987; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.2307/2335739; Skiest DJ, 2003, J CLIN VIROL, V26, P307, DOI 10.1016/S1386-6532(02)00047-1; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Vallee A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040302; Vigezzi Giacomo Pietro, 2021, Acta Biomed, V92, pe2021450, DOI 10.23750/abm.v92iS6.12217; Vizcarra P, 2020, LANCET HIV, V7, pE554, DOI 10.1016/S2352-3018(20)30164-8; Wang YD, 2021, AIDS, V35, P1875, DOI 10.1097/QAD.0000000000002968; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Woldemeskel BA, 2022, CLIN INFECT DIS, V74, P1268, DOI 10.1093/cid/ciab648; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Yang TT, 2018, J MED VIROL, V90, P101, DOI 10.1002/jmv.24912; Yang XY, 2021, LANCET HIV, V8, pE690, DOI 10.1016/S2352-3018(21)00239-3; Yorsaeng R., 2021, IMMUNOGENICITY 3 DOS, DOI [10.1016/j.vaccine.2021.11.083, DOI 10.1016/J.VACCINE.2021.11.083]; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	36	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1458	10.3390/vaccines9121458			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9VJ	34960204	Green Published, gold			2022-04-29	WOS:000778389000001
J	Pageaud, S; Pothier, C; Rigotti, C; Eyraud-Loisel, A; Bertoglio, JP; Bienvenuee, A; Leboisne, N; Ponthus, N; Gauchon, R; Gueyffier, F; Vanhems, P; Iwaz, J; Loisel, S; Roy, P				Pageaud, Simon; Pothier, Catherine; Rigotti, Christophe; Eyraud-Loisel, Anne; Bertoglio, Jean-Pierre; Bienvenuee, Alexis; Leboisne, Nicolas; Ponthus, Nicolas; Gauchon, Romain; Gueyffier, Francois; Vanhems, Philippe; Iwaz, Jean; Loisel, Stephane; Roy, Pascal		Grp CovDyn Covid Dynamics	Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures	VACCINES			English	Article						vaccination; COVID-19; agent-based model; decision support techniques		The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and the first six months of 2022. The study compares the efficiencies of four theoretical vaccination campaigns (over 6, 9, 12, and 18 months), combined with various non-pharmaceutical interventions. In France, with the emergence of the Alpha variant, without vaccination and despite strict barrier measures, more than 600,000 deaths would be observed. An efficient vaccination campaign (i.e., total coverage of the French population) over six months would divide the death toll by 10. A vaccination campaign of 12, instead of 6, months would slightly increase the disease-related mortality (+6%) but require a 77% increase in ICU bed-days. A campaign over 18 months would increase the disease-related mortality by 17% and require a 244% increase in ICU bed-days. Thus, it seems mandatory to vaccinate the highest possible percentage of the population within 12, or better yet, 9 months. The race against the epidemic and virus variants is really a matter of vaccination strategy.	[Pageaud, Simon; Gueyffier, Francois; Iwaz, Jean; Roy, Pascal] Univ Lyon, F-69000 Lyon, France; [Pageaud, Simon; Gueyffier, Francois; Iwaz, Jean; Roy, Pascal] Univ Claude Bernard Lyon 1, F-69100 Villeurbanne, France; [Pageaud, Simon; Gueyffier, Francois; Iwaz, Jean; Roy, Pascal] CNRS, UMR 5558, Lab Biometrie & Biol Evolut, F-69100 Villeurbanne, France; [Pageaud, Simon; Gueyffier, Francois; Iwaz, Jean; Roy, Pascal] Hosp Civils Lyon, Serv Biostat Bioinformat, Pole Sante Publ, F-69003 Lyon, France; [Pageaud, Simon; Eyraud-Loisel, Anne; Bienvenuee, Alexis; Leboisne, Nicolas; Gauchon, Romain; Loisel, Stephane] Univ Claude Bernard Lyon 1, Inst Sci Financiere & Assurances ISFA, Lab Sci Actuarielle & Financiere LSAF, F-69007 Lyon, France; [Pageaud, Simon] Fdn Risque, Grp Louis Bachelier, F-75002 Paris, France; [Pothier, Catherine; Rigotti, Christophe] CNRS, UMR 5205, Lab InfoRmat Image & Syst Informat LIRIS, F-69621 Villeurbanne, France; [Pothier, Catherine; Rigotti, Christophe] Inst Natl Sci Appl Lyon INSA, F-69621 Villeurbanne, France; [Rigotti, Christophe] INRIA Grenoble Rhone Alpes, F-38334 Montbonnot St Martin, France; [Bertoglio, Jean-Pierre] CNRS, UMR 5509, Lab Mecan Fluides & Acoust LMFA, F-69130 Ecully, France; [Bertoglio, Jean-Pierre; Ponthus, Nicolas] Ecole Cent Lyon, F-69130 Lyon, France; [Leboisne, Nicolas; Roy, Pascal] CNRS, UMR 5513, Lab Tribol & Dynam Syst LTDS, F-69130 Ecully, France; [Ponthus, Nicolas] Ecole Natl Travaux Publ Etat ENTPE, F-69120 Vaulx En Velin, France; [Vanhems, Philippe] Hosp Civils Lyon, Hop Edouard Herriot, Serv Hyg Epidemiol Infectiovigilance & Prevent, F-69003 Lyon, France; [Vanhems, Philippe] CNRS, UMR 5308, INSERM, U1111,Ctr Int Rech Infectiol CIRI,Ecole Natl Supe, F-69007 Lyon, France		Roy, P (通讯作者)，Univ Lyon, F-69000 Lyon, France.; Roy, P (通讯作者)，Univ Claude Bernard Lyon 1, F-69100 Villeurbanne, France.; Roy, P (通讯作者)，CNRS, UMR 5558, Lab Biometrie & Biol Evolut, F-69100 Villeurbanne, France.; Roy, P (通讯作者)，Hosp Civils Lyon, Serv Biostat Bioinformat, Pole Sante Publ, F-69003 Lyon, France.; Roy, P (通讯作者)，CNRS, UMR 5513, Lab Tribol & Dynam Syst LTDS, F-69130 Ecully, France.	simon.pageaud@gmail.com; catherine.pothier@insa-lyon.fr; christophe.rigotti@insa-lyon.fr; anne.loisel@univ-lyon1.fr; jean-pierre.bertoglio@ec-lyon.fr; alexis.bienvenue@univ-lyon1.fr; nicolas.leboisne@univ-lyon1.fr; nicolas.ponthus@gmx.fr; romain.gauchon@laposte.net; francois.gueyffier@univ-lyon1.fr; philippe.vanhems@chu-lyon.fr; jean.iwaz@chu-lyon.fr; stephane.loisel@univ-lyon1.fr; pascal.roy@chu-lyon.fr		Roy, Pascal/0000-0003-3837-3198	Region Auvergne-Rhone-Alpes, Initiative d'excellence (IDEXLYON)-Universite de Lyon, Universite Claude Bernard Lyon 1, Ecole Centrale de Lyon; GIRCI Auvergne Rhone-Alpes; excellence chair 'DIALog, Digital Insurance And Long-term risks' - CNP Assurance; research initiative 'Actuariat Durable et stabilite du secteur de l'assurance a long terme' - Milliman; ISFA SAF Lab; Fondation du Risque; PHRCi-2020 COVID-3S	This work was supported by Region Auvergne-Rhone-Alpes, Initiative d'excellence (IDEXLYON)-Universite de Lyon, Universite Claude Bernard Lyon 1, Ecole Centrale de Lyon, and by the PHRCi-2020 COVID-3S, supported by GIRCI Auvergne Rhone-Alpes. This work was also supported by the excellence chair `DIALog, Digital Insurance And Long-term risks', financed by CNP Assurance and the research initiative `Actuariat Durable et stabilite du secteur de l'assurance a long terme' financed by Milliman, joined projects with ISFA SAF Lab and Fondation du Risque.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Beale S., 2020, RAPID REV ASYMPTOMAT; Bosetti P., 2021, RACE SARS COV 2 VARI; BYRD RH, 1995, SIAM J SCI COMPUT, V16, P1190, DOI 10.1137/0916069; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Di Domenico L, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01698-4; European Centre for Disease Prevention and Control, 2021, EM SARS COV 2 B 1 61; Gauchon R., 2021, LESSONS LEARNT USE C, DOI [10.1101/2021.01.11.21249565, DOI 10.1101/2021.01.11.21249565]; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; Pageaud S., 2021, MEDRXIV, DOI [10.1101/2021.03.17.21253739, DOI 10.1101/2021.03.17.21253739]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697; Tran Kiem C. Tran, 2021, ECLINICALMEDICINE, V111, P1049, DOI [10.1016/j.eclinm.2021.101001, DOI 10.1016/j.eclinm.2021.101001]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	21	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1462	10.3390/vaccines9121462			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YK5VA	34960207	gold, Green Published			2022-04-29	WOS:000745278800001
J	Berg, A; Wright, D; Dulal, P; Stedman, A; Fedosyuk, S; Francis, MJ; Charleston, B; Warimwe, GM; Douglas, AD				Berg, Adam; Wright, Daniel; Dulal, Pawan; Stedman, Anna; Fedosyuk, Sofiya; Francis, Michael J.; Charleston, Bryan; Warimwe, George M.; Douglas, Alexander D.			Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations	VACCINES			English	Article						stability; vaccine formulation; adenovirus	VIRAL VECTORS	Adenovirus vectored vaccines have entered global use during the COVID-19 pandemic, and are in development for multiple other human and veterinary applications. An attraction of the technology is the suitability of the vaccines for storage at 2-8 & DEG;C for months. Widely used COVID-19 vaccine ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca) is based on a species E simian adenovirus. Species E simian serotypes have been used in a wide range of other development programs, but the stability of such vectors has not been extensively described in the peer-reviewed literature. Here, we explore the stability of two candidate vaccines based on two species E serotypes: a Rift Valley fever vaccine based upon the ChAdOx1 vector (Y25 serotype) used in ChAdOx1 nCoV-19, and a rabies vaccine based upon a ChAdOx2 vector (AdC68 serotype). We describe each vector's stability in liquid and lyophilised formulations using in vitro and in vivo potency measurements. Our data support the suitability of liquid formulations of these vectors for storage at 2-8 & DEG;C for up to 1 year, and potentially for nonrefrigerated storage for a brief period during last-leg distribution (perhaps 1-3 days at 20 & DEG;C-the precise definition of acceptable last-leg storage conditions would require further product-specific data). Depending upon the level of inprocess potency loss that is economically acceptable, and the level of instorage loss that is compatible with maintenance of acceptable end-of-storage potency, a previously reported lyophilised formulation may enable longer term storage at 20 & DEG;C or storage for a number of days at 30 & DEG;C.	[Berg, Adam; Wright, Daniel; Dulal, Pawan; Fedosyuk, Sofiya; Douglas, Alexander D.] Univ Oxford, Wellcome Trust Ctr Human Genet, Jenner Inst, Roosevelt Dr, Oxford OX3 7BN, England; [Stedman, Anna; Charleston, Bryan; Warimwe, George M.] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England; [Francis, Michael J.] BioVacc Consulting Ltd, Red House,10 Market Sq, Amersham HP7 0DQ, England; [Warimwe, George M.] KEMRI Wellcome Trust Res Programme, POB 230-80108, Kilifi, Kenya; [Warimwe, George M.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford OX3 7LG, England		Wright, D; Douglas, AD (通讯作者)，Univ Oxford, Wellcome Trust Ctr Human Genet, Jenner Inst, Roosevelt Dr, Oxford OX3 7BN, England.	adam.berg@ndm.ox.ac.uk; danny.wright@ndm.ox.ac.uk; pawan.dulal@ndm.ox.ac.uk; anasteadman@hotmail.com; sofiya.fedosyuk@ndm.ox.ac.uk; mike.francis@biovacc.com; bryan.charleston@pirbright.ac.uk; GWarimwe@kemri-wellcome.org; sandy.douglas@ndm.ox.ac.uk		Wright, Daniel/0000-0002-8114-1838	International Veterinary Vaccines Network Pump-Priming Grant scheme; UK Vaccines Network; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/P017339/1]; Wellcome TrustWellcome TrustEuropean Commission [201477/Z/16/Z]	This work was supported by the International Veterinary Vaccines Network Pump-Priming Grant scheme, the UK Vaccines Network, and the Medical Research Council (grant MR/P017339/1). ADD was supported by the Wellcome Trust (fellowship award 201477/Z/16/Z) and is a Jenner Investigator.	Afkhami S, 2017, VACCINE, V35, P2916, DOI 10.1016/j.vaccine.2017.04.026; [Anonymous], 2011, HIGHLIGHTS PRESCRIBI; [Anonymous], GUIDELINES STABILITY; Buckler A., 2020, EP Patent, Patent No. [2968112-B2, 2968112]; Chen SN, 2012, INT J PHARMACEUT, V427, P145, DOI 10.1016/j.ijpharm.2011.12.056; Colloca S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002925; Croyle MA, 2001, GENE THER, V8, P1281, DOI 10.1038/sj.gt.3301527; Croyle MA, 2001, MOL THER, V4, P22, DOI 10.1006/mthe.2001.0411; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; European Medicines Agency, ZABDENO EUR PUBL ASS; Evans RK, 2004, J PHARM SCI-US, V93, P2458, DOI 10.1002/jps.20157; Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014; Fedosyuk S, 2019, VACCINE, V37, P6951, DOI 10.1016/j.vaccine.2019.04.056; Isopi L., 2008, U.S, Patent No. [Patent 7456009B2, 7456009]; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; Malenovska H, 2014, J APPL MICROBIOL, V117, P1810, DOI 10.1111/jam.12654; Mathot F., 2020, U.S. Patent, Patent No. [US10722470B2, 10722470]; Morris SJ, 2016, FUTURE VIROL, V11, P649, DOI 10.2217/fvl-2016-0070; O'Hara GA, 2012, J INFECT DIS, V205, P772, DOI 10.1093/infdis/jir850; Pelliccia M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13520; Reinauer EB, 2020, J PHARM SCI-US, V109, P818, DOI 10.1016/j.xphs.2019.10.063; Smith AC, 2009, J VIROL, V83, P2025, DOI 10.1128/JVI.01644-08; Stedman A, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0138-0; Stewart M, 2014, VACCINE, V32, P2931, DOI 10.1016/j.vaccine.2014.02.033; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang C, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006870; Warimwe GM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20617; Warimwe GM, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-349; Wright D, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101669	29	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1249	10.3390/vaccines9111249			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE6GV	34835180	gold, Green Published			2022-04-29	WOS:000723484600001
J	Galle, F; Sabella, EA; Roma, P; Da Molin, G; Diella, G; Montagna, MT; Ferracuti, S; Liguori, G; Orsi, GB; Napoli, C				Galle, Francesca; Sabella, Elita Anna; Roma, Paolo; Da Molin, Giovanna; Diella, Giusy; Montagna, Maria Teresa; Ferracuti, Stefano; Liguori, Giorgio; Orsi, Giovanni Battista; Napoli, Christian			Acceptance of COVID-19 Vaccination in the Elderly: A Cross-Sectional Study in Southern Italy	VACCINES			English	Article						COVID-19; immunization campaign; elderly; vaccine acceptance; green pass		In Italy, at the end of 2020, a voluntary immunization plan against COVID-19 was introduced, involving elderly among the first target categories. The aim of this study was to assess, through an online questionnaire, the acceptance of COVID-19 vaccination in a sample of older adults from southern Italy. Of a total of 1041 respondents (41.7% males, mean age 76.6 & PLUSMN; 6.5), 965 (92.7%) were vaccinated or willing to be vaccinated against COVID-19, although less than half of the sample was favorable to vaccinations and agreed with mandatory immunization. Acceptance of COVID-19 vaccination was found to be positively related with higher educational level (OR = 1.875, CI95% = 1.113-3.161; p = 0.018) and having social/mass media as a main source of information (OR = 2.415 CI95% = 1.358-4.296, p = 0.003). On the contrary, an inverse relationship was found between acceptance of COVID-19 vaccination and having fulfilled the questionnaire after the introduction of green pass (OR = 0.218, CI95% = 0.129-0.369; p < 0.001). Therefore, although this evidence needs to be further confirmed, it is possible to agree with previous studies reporting that compulsory measures, such as green pass implementation, must be accompanied by effective education and information strategies of the target population.	[Galle, Francesca; Liguori, Giorgio] Univ Naples Parthenope, Dept Movement Sci & Wellbeing, I-80133 Naples, Italy; [Sabella, Elita Anna; Da Molin, Giovanna] Univ Bari Aldo Moro, Interuniv Res Ctr Populat Environm & Hlth, I-70121 Bari, Italy; [Roma, Paolo; Ferracuti, Stefano] Sapienza Univ Rome, Dept Human Neurosci, I-00185 Rome, Italy; [Diella, Giusy; Montagna, Maria Teresa] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy; [Orsi, Giovanni Battista] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy; [Napoli, Christian] Sapienza Univ Rome, Dept Med Surg Sci & Translat Med, I-00189 Rome, Italy		Galle, F (通讯作者)，Univ Naples Parthenope, Dept Movement Sci & Wellbeing, I-80133 Naples, Italy.	francesca.galle@uniparthenope.it; elita.sabella@uniba.it; paolo.roma@uniroma1.it; giovanna.damolin@uniba.it; giusy.diella@uniba.it; mariateresa.montagna@uniba.it; stefano.ferracuti@uniroma1.it; giorgio.liguori@uniparthenope.it; giovanni.orsi@uniroma1.it; christian.napoli@uniroma1.it	Gallè, Francesca/AAF-6054-2020; napoli, christian/H-1862-2012; napoli, christian/B-9924-2018; Ferracuti, Stefano/K-8437-2012	Gallè, Francesca/0000-0002-0504-9562; napoli, christian/0000-0002-5775-2276; napoli, christian/0000-0002-5775-2276; Roma, Paolo/0000-0002-1031-0948; Montagna, Maria Teresa/0000-0002-2958-5458; Ferracuti, Stefano/0000-0003-1150-1460			[Anonymous], ITALIAN PREMIERSHIP; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Biasio LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030268; Callaghan T., 2020, CORRELATES DISPARITI, DOI DOI 10.2139/SSRN.3667971; Cave E, 2017, LEGAL STUD, V37, P279, DOI 10.1111/lest.12144; Charron J, 2020, MED MALADIES INFECT, V50, P727, DOI 10.1016/j.medmal.2020.01.010; De Giglio O, 2015, ENVIRON RES, V142, P586, DOI 10.1016/j.envres.2015.08.013; Del Riccio M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060633; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Fadda M, 2021, VACCINE-X, V8, DOI 10.1016/j.jvacx.2021.100108; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Galle F, 2021, BEHAV SCI-BASEL, V11, DOI 10.3390/bs11040045; Galle F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176171; Galle F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103481; Galle F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17031034; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Graeber D, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248372; Italian Council of Ministers, EU DIG COVID CERT; Italian Ministry of Health, VACC ANT COV 2 COVID; Italian National Institute of Health, CAR PAZ DEC POS AL S; Kline P., 1999, HDB PSYCHOL TESTING, V2nd ed., P627; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malani P.N., OLDER ADULTS PERSPEC, DOI [10.1001/jamahealthforum.2020.0961, DOI 10.1001/JAMAHEALTHFORUM.2020.0961]; Napoli C, 2015, INT J ENV RES PUB HE, V12, P15550, DOI 10.3390/ijerph121215002; Napoli C, 2014, INT J ENV RES PUB HE, V11, P8529, DOI 10.3390/ijerph110808529; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Nikolovski J., 2021, PLOS ONE, V16, DOI [10.1371/journal.pone.0251963, DOI 10.1371/journal.pone.0251963]; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, V2nd ed.; Pai SM, 2021, J CLIN PHARMACOL, V61, P277, DOI 10.1002/jcph.1794; Porat T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080902; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Taber KS, 2018, RES SCI EDUC, V48, P1273, DOI 10.1007/s11165-016-9602-2; World Health Organization Regional Office for Europe, COR DIS COVID 19 PAN	35	19	19	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1222	10.3390/vaccines9111222			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ5PH	34835152	gold, Green Published			2022-04-29	WOS:000726839100001
J	Esen, BK; Can, G; Pirdal, BZ; Aydin, SN; Ozdil, A; Balkan, II; Budak, B; Keskindemirci, Y; Karaali, R; Saltoglu, N				Kara Esen, Beril; Can, Gunay; Pirdal, Betul Zehra; Aydin, Sumeyye Nur; Ozdil, Aysenur; Balkan, Ilker Inanc; Budak, Beyhan; Keskindemirci, Yilmaz; Karaali, Ridvan; Saltoglu, Nese			COVID-19 Vaccine Hesitancy in Healthcare Personnel: A University Hospital Experience	VACCINES			English	Article						COVID-19; vaccination; healthcare personnel; vaccine hesitancy		Healthcare workers are among risk groups in the COVID-19. Even if they are not infected with the disease, they witness the effects of the pandemic. The aim of the study is to determine the factors affecting COVID-19 vaccination status and reasons for vaccine hesitancy of healthcare personnel in our hospital. Firstly, the vaccination status and demographic characteristics of all healthcare personnel was evaluated. After that, a survey was applied to 408 vaccinated and 297 nonvaccinated personnel. Within the first month after the beginning of vaccination, 66% of 3937 healthcare personnel received a COVID-19 vaccine. The number of vaccinated personnel was higher among doctors, master graduates or higher educational levels and basic science-laboratory unit workers. In the surveyed group, being under the age of 50 (OR:1.85), being nondoctor healthcare personnel (nurse/midwife OR:1.78, administrative personnel OR:3.42, patient attendant/cleaning staff OR:4.11, security guard/other OR:2.96), having had the disease before (OR:2.36), not having the flu vaccine (OR:3.24) and hesitancy about other vaccines (OR:6.61) were found to be independent risk factors for not having a COVID-19 vaccine or having it late. The three most common reasons for not getting vaccinated were doubt on the efficacy of the vaccine, distrust of its content, and fear of side effects. Taking steps by considering the main factors of hesitancy among healthcare personnel will increase the vaccine acceptance.	[Kara Esen, Beril; Can, Gunay; Pirdal, Betul Zehra; Aydin, Sumeyye Nur; Ozdil, Aysenur] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Publ Hlth, Kocamustafapasa, TR-34098 Istanbul, Turkey; [Balkan, Ilker Inanc; Budak, Beyhan; Karaali, Ridvan; Saltoglu, Nese] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Infect Dis, Kocamustafapasa, TR-34098 Istanbul, Turkey; [Keskindemirci, Yilmaz] Istanbul Univ Cerrahpasa, Vocat Sch Hlth Serv, Cerrahpasa Fac Med, Dept Med Serv & Techn, Kocamustafapasa, TR-34098 Istanbul, Turkey		Esen, BK (通讯作者)，Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Publ Hlth, Kocamustafapasa, TR-34098 Istanbul, Turkey.	beril.kara@istanbul.edu.tr; gunay.can@iuc.edu.tr; zehrapirdal@istanbul.edu.tr; nur.aydin@istanbul.edu.tr; aysenur.ozdil@istanbul.edu.tr; ilker.balkan@istanbul.edu.tr; beyhan.budak@iuc.edu.tr; kdemirci@istanbul.edu.tr; ridvan.karaali@iuc.edu.tr; saltoglu@iuc.edu.tr	KARAALİ, Rıdvan/AAQ-1018-2020; Kara Esen, Beril/ABF-2674-2021	KARAALİ, Rıdvan/0000-0003-2440-7529; Ozdil, Aysenur/0000-0002-4114-0830; PIRDAL, Betul Zehra/0000-0003-0127-9296; Kara Esen, Beril/0000-0001-5296-0001			Abuown A, 2021, OCCUP MED-OXFORD, V71, P211, DOI 10.1093/occmed/kqab057; Amin DP, 2021, AM J EMERG MED, V48, P372, DOI 10.1016/j.ajem.2021.01.089; [Anonymous], DIRECTOR GEN OPENING; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Chew NWS, 2021, INT J INFECT DIS, V106, P52, DOI 10.1016/j.ijid.2021.03.069; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fares Samar, 2021, J Prim Care Community Health, V12, p21501327211013303, DOI 10.1177/21501327211013303; FDA, FDA TAK KEY ACT FIGH; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Janssen C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060547; Kaplan AK, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14226; Kose S, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13917; Maraqa B, 2021, PREV MED, V149, DOI 10.1016/j.ypmed.2021.106618; Parente DJ, 2021, J AM BOARD FAM MED, V34, P498, DOI 10.3122/jabfm.2021.03.200541; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Sun YF, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.664905; WHO, COVID 19 VACC EUL	17	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1343	10.3390/vaccines9111343			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XL2JL	34835274	gold, Green Published			2022-04-29	WOS:000727975400001
J	Sharma, P; Nayak, K; Reddy, ES; Farooqi, H; Murali-Krishna, K; Chandele, A				Sharma, Pragati; Nayak, Kaustuv; Reddy, Elluri Seetharami; Farooqi, Humaira; Murali-Krishna, Kaja; Chandele, Anmol			Optimization of Flow-Cytometry Based Assay for Measuring Neutralizing Antibody Responses against Each of the Four Dengue Virus Serotypes	VACCINES			English	Article						dengue; flowcytometry; neutralization; focus reduction neutralizing tests	INFECTION	Dengue is an important public health problem worldwide, with India contributing nearly a third of global dengue disease burden. The measurement of neutralizing antibody responses is critical for understanding dengue pathophysiology, vaccine development and evaluation. Historically, dengue virus neutralization titers were measured using plaque reduction neutralization tests (PRNTs), which were later adapted to focus reduction neutralization tests (FRNTs). Given the slow and laborious nature of both these assays, there has been interest in adapting a high-throughput flow cytometry based neutralization assay. However, flow cytometry based assays typically underestimate neutralization titers, and in situations where the titers are low they can even fail to detect neutralization activity. In this study, by evaluating graded numbers of input Vero cell numbers and viral inoculum, we optimized the flow cytometry based neutralization assay in such a way that it is sensitive and scores titers that are in concordance with focus reduction neutralization tests for each of the four dengue virus serotypes (p < 0.0001). Given that dengue is a global public health concern, and several research groups are making efforts to understand its pathophysiology and accelerate vaccine development and evaluation both in India and worldwide, our findings have timely significance for facilitating these efforts.	[Sharma, Pragati; Nayak, Kaustuv; Reddy, Elluri Seetharami; Murali-Krishna, Kaja; Chandele, Anmol] Int Ctr Genet Engn & Biotechnol, ICGEB Emory Vaccine Ctr, Aruna Asaf Ali Marg, New Delhi 110067, India; [Sharma, Pragati; Farooqi, Humaira] Jamia Hamdard, Sch Chem & Life Sci, Dept Biotechnol, New Delhi 110062, India; [Reddy, Elluri Seetharami] Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi 110016, India; [Murali-Krishna, Kaja] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA; [Murali-Krishna, Kaja] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA		Murali-Krishna, K; Chandele, A (通讯作者)，Int Ctr Genet Engn & Biotechnol, ICGEB Emory Vaccine Ctr, Aruna Asaf Ali Marg, New Delhi 110067, India.; Farooqi, H (通讯作者)，Jamia Hamdard, Sch Chem & Life Sci, Dept Biotechnol, New Delhi 110062, India.; Murali-Krishna, K (通讯作者)，Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA.; Murali-Krishna, K (通讯作者)，Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.	sharmapragati80@gmail.com; kaustuvnayak@gmail.com; rammku.rr@gmail.com; hfarooqi@jamiahamdard.ac.in; murali.kaja@emory.edu; chandeleanmol@gmail.com		Chandele, Anmol/0000-0002-5702-7170; Nayak, Kaustuv/0000-0002-7898-0294	Dengue Translational Research Consortia-National Biopharma Mission [BT/NBM0099/02/18]; Indian Council of Medical Research (ICMR) VIR/Fellowship [13/2018-ECD-1]	This research was funded by Dengue Translational Research Consortia-National Biopharma Mission BT/NBM0099/02/18. Pragati Sharma was supported by Indian Council of Medical Research (ICMR) VIR/Fellowship/13/2018-ECD-1.	Aggarwal Rakesh, 2016, Perspect Clin Res, V7, P187; Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Chan AHY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033451; de Alwis R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004386; de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3; Deng SQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010063; Gunisetty S, 2019, INT J INFECT DIS, V84, pS57, DOI 10.1016/j.ijid.2019.01.018; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830; Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07; Lambeth CR, 2005, J CLIN MICROBIOL, V43, P3267, DOI 10.1128/JCM.43.7.3267-3272.2005; Lim XN, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007996; Magnani DM, 2017, J VIROL, V91, DOI 10.1128/JVI.00867-17; Martin NC, 2006, J VIROL METHODS, V134, P74, DOI 10.1016/j.jviromet.2005.12.002; Matsuda M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34865-y; Mutheneni SR, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.57; Priyamvada L, 2016, J VIROL, V90, P5574, DOI 10.1128/JVI.03203-15; Programme for Research and Training in Tropical Diseases, 2009, Dengue: guidelines for diagnosis, treatment, prevention and control; Rajamanonmani R, 2009, J GEN VIROL, V90, P799, DOI 10.1099/vir.0.006874-0; Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007; RUSSELL PK, 1967, J IMMUNOL, V99, P285; Schwartz LM, 2015, VACCINE, V33, P3293, DOI 10.1016/j.vaccine.2015.05.010; SUMMERS PL, 1989, VIRUS RES, V12, P383, DOI 10.1016/0168-1702(89)90095-6; Timiryasova TM, 2013, AM J TROP MED HYG, V88, P962, DOI 10.4269/ajtmh.12-0461; Upasani V, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594813; Waickman AT, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102733; Whitehead SS, 2016, EXPERT REV VACCINES, V15, P509, DOI 10.1586/14760584.2016.1115727	29	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1339	10.3390/vaccines9111339			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE5KR	34835270	gold, Green Published			2022-04-29	WOS:000723426900001
J	Urrunaga-Pastor, D; Herrera-Anazco, P; Uyen-Cateriano, A; Toro-Huamanchumo, CJ; Rodriguez-Morales, AJ; Hernandez, AV; Benites-Zapata, VA; Bendezu-Quispe, G				Urrunaga-Pastor, Diego; Herrera-Anazco, Percy; Uyen-Cateriano, Angela; Toro-Huamanchumo, Carlos J.; Rodriguez-Morales, Alfonso J.; Hernandez, Adrian, V; Benites-Zapata, Vicente A.; Bendezu-Quispe, Guido			Prevalence and Factors Associated with Parents' Non-Intention to Vaccinate Their Children and Adolescents against COVID-19 in Latin America and the Caribbean	VACCINES			English	Article						COVID-19; SARS-CoV-2; COVID-19 vaccines; vaccination refusal; vaccination; child; adolescent; parents; Latin America	SARS-COV-2 INFECTION; CHALLENGES; RISK	We aimed to estimate the prevalence and factors associated with parents' non-intention to vaccinate their children and adolescents against COVID-19 in Latin America and the Caribbean (LAC). We performed a secondary analysis using a database generated by the University of Maryland and Facebook (Facebook, Inc., Menlo Park, CA, USA). We included adult (18 and over) Facebook users residing in LAC who responded to the survey between 20 May 2021 and 14 July 2021. We included sociodemographic characteristics, comorbidities, mental health, economic and food insecurity, compliance with mitigation strategies against COVID-19, and practices related to vaccination against this disease. We estimated the crude (cPR) and adjusted (aPR) prevalence ratios with their respective 95%CI. We analyzed a sample of 227,740 adults from 20 LAC countries. The prevalence of parents' non-intention to vaccinate their children and adolescents against COVID-19 was 7.8% (n = 15,196). An age above 35 years old, educational level above college, compliance with physical distancing, use of masks, having economic insecurity, having had COVID-19, anxiety symptoms, depressive symptoms, having a chronic condition or two or more comorbidities, and being vaccinated were associated with a lower prevalence of non-intention to vaccinate children and adolescents against COVID-19. Living in a town, a village, or a rural area was associated with a higher prevalence of non-intention to vaccinate children and adolescents against COVID-19. Approximately nine out of ten parents in LAC intended to vaccinate their children and adolescents against COVID-19. Our results allow for understanding parents' intentions to vaccinate children and adolescents and help promote and develop education strategies for national vaccination plans against COVID-19.	[Urrunaga-Pastor, Diego] Univ Cient Sur, Fac Ciencias Salud, Lima 15067, Peru; [Herrera-Anazco, Percy] EsSalud, Inst Evaluac Tecnol Salud & Invest IETSI, Lima 14072, Peru; [Herrera-Anazco, Percy; Benites-Zapata, Vicente A.; Bendezu-Quispe, Guido] Red Int Salud Colect & Salud Intercultural, Mexico City 56690, DF, Mexico; [Herrera-Anazco, Percy] Univ Privada San Juan Bautista, Hosp Nacl Mayo, Lima 15067, Peru; [Uyen-Cateriano, Angela] Hlth Polit, Med Sans Frontieres, B-1050 Brussels, Belgium; [Toro-Huamanchumo, Carlos J.; Benites-Zapata, Vicente A.] Univ San Ignacio Loyola USIL, Unidad Generac & Sintesis Evidencias Salud, Lima 15012, Peru; [Toro-Huamanchumo, Carlos J.] Clin Avendatio, Unidad Invest Multidisciplinaria, Lima 15074, Peru; [Rodriguez-Morales, Alfonso J.] Latin Amer Network Coronavirus Dis 2019 Res LANCO, Pereira 660003, Colombia; [Rodriguez-Morales, Alfonso J.] Fdn Univ Autonoma Amer, Fac Med, Grp Invest Biomed, Pereira 660003, Colombia; [Hernandez, Adrian, V] Univ Connecticut, Sch Pharm, Hlth Outcomes Policy & Evidence Synth HOPES Grp, Storrs, CT 06269 USA; [Hernandez, Adrian, V] Univ San Ignacio Loyola USIL, Unidad Revis Sistemat & Metaanal, Guias Pract Clin & Evaluac Tecnol Sanitarias, Vicerrectorado Invest, Lima 15024, Peru; [Bendezu-Quispe, Guido] Univ Privada Norbert Wiener, Ctr Invest Epidemiol Salud Global, Lima 14072, Peru		Urrunaga-Pastor, D (通讯作者)，Univ Cient Sur, Fac Ciencias Salud, Lima 15067, Peru.; Benites-Zapata, VA (通讯作者)，Red Int Salud Colect & Salud Intercultural, Mexico City 56690, DF, Mexico.; Benites-Zapata, VA (通讯作者)，Univ San Ignacio Loyola USIL, Unidad Generac & Sintesis Evidencias Salud, Lima 15012, Peru.	diego.urrunaga.pastorl@gmail.com; silamud@gmail.com; dra.uyen@gmail.com; ctoro@usil.edu.pe; ajrodriguezmmd@gmail.com; adrian.hernandez-diaz@uconn.edu; vbenites@usil.edu.pe; guidobq@gmail.com	Bendezu-Quispe, Guido/H-7415-2014	Bendezu-Quispe, Guido/0000-0002-5140-0843; Hernandez, Adrian V./0000-0002-9999-4003; Urrunaga-Pastor, Diego/0000-0002-8339-162X; Herrera-Anazco, Percy/0000-0003-0282-6634	Universidad Cientifica del Sur; Universidad Privada Norbert Wiener	This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The APC was covered by the Universidad Cientifica del Sur and the Universidad Privada Norbert Wiener.	Al-Amer R, 2022, J CLIN NURS, V31, P62, DOI 10.1111/jocn.15951; Benitez MA, 2020, HEALTH POLICY TECHN, V9, P525, DOI 10.1016/j.hlpt.2020.08.014; Alvarez-Risco A, 2020, AM J TROP MED HYG, V103, P583, DOI 10.4269/ajtmh.20-0536; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Barkay, 2020, WEIGHTS METHODOLOGY; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Boyle J, 2020, VACCINE, V38, P2416, DOI 10.1016/j.vaccine.2020.01.032; Ceron W, 2021, SOC NETW ANAL MIN, V11, DOI 10.1007/s13278-021-00753-z; de Puig H, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh2944; Del Brutto OH, 2021, J COMMUN HEALTH, V46, P292, DOI 10.1007/s10900-020-00887-9; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2744, DOI 10.1080/21645515.2020.1744367; Di Giuseppe G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030275; Duarte R, 2021, PULMONOLOGY, V27, P338, DOI 10.1016/j.pulmoe.2021.02.002; European Medicines Agency, 1 COVID 19 VACC APPR; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Nunez-Zapata SF, 2021, INT J INFECT DIS, V109, P244, DOI 10.1016/j.ijid.2021.07.022; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088; Han BH, 2021, LANCET INFECT DIS, V21, P1645, DOI 10.1016/S1473-3099(21)00319-4; He KD, 2022, J COMMUN HEALTH, V47, P39, DOI 10.1007/s10900-021-01017-9; Hetherington Erin, 2021, CMAJ Open, V9, pE548, DOI 10.9778/cmajo.20200302; Kaur R, 2021, PREV MED, V147, DOI 10.1016/j.ypmed.2021.106531; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Leeb RT, 2020, MMWR-MORBID MORTAL W, V69, P1410, DOI 10.15585/mmwr.mm6939e2; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Martinez-Valle A, 2021, J PUBLIC HEALTH POL, V42, P27, DOI 10.1057/s41271-020-00269-4; Michelle S, 2021, SWISS MED WKLY, V151, DOI 10.4414/smw.2021.20508; ModernaTX Inc, STUD EV SAF EFF MRNA; Murthy BP, 2021, MMWR-MORBID MORTAL W, V70, P759, DOI 10.15585/mmwr.mm7020e3; PAHO, PAHO DIR CALLS FAIR; Plotkin SA, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2021-050531; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Shah S, 2021, PEDIATR RES, V90, P237, DOI 10.1038/s41390-021-01590-8; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; U.S. Food and Drug Administration, COR COVID 19 UPD FDA; Urrunaga-Pastor D, 2021, TRAVEL MED INFECT DI, V41, DOI 10.1016/j.tmaid.2021.102059; Vanderpool RC, 2019, HUM VACC IMMUNOTHER, V15, P1527, DOI 10.1080/21645515.2018.1553475; Wang Q, 2021, PREV MED, V150, DOI 10.1016/j.ypmed.2021.106694; Wang Q, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040342; World Health Organization, 2020, GLOBAL TUBERCULOSIS; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Zhai YS, 2020, VACCINE, V38, P7596, DOI 10.1016/j.vaccine.2020.10.030; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827; Zimet GD, 2021, J PEDIATR-US, V231, P254, DOI 10.1016/j.jpeds.2020.11.002	47	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1303	10.3390/vaccines9111303			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI0DF	34835233	gold, Green Published			2022-04-29	WOS:000725793200001
J	Zaidi, A; Elmasaad, A; Alobaidli, H; Sayed, R; Al-Ali, D; Al-Kuwari, D; Al-Kubaisi, S; Mekki, Y; Emara, MM; Daher-Nashif, S				Zaidi, Amine; Elmasaad, Amal; Alobaidli, Hend; Sayed, Rana; Al-Ali, Dana; Al-Kuwari, Dana; Al-Kubaisi, Shaikha; Mekki, Yosra; Emara, Mohamed M.; Daher-Nashif, Suhad			Attitudes and Intentions toward COVID-19 Vaccination among Health Professions Students and Faculty in Qatar	VACCINES			English	Article						COVID-19 vaccination; attitudes towards vaccine; vaccine hesitancy; sociodemographic factors; knowledge; health professions students and faculty; Middle East		A population's desire to take the COVID-19 vaccine is an important predictor of a country's future pandemic management. This cross-sectional study examines the impact of psychological and sociodemographic factors on attitudes toward and intentions to take the COVID-19 vaccine among students and faculty at four colleges of health professions and sciences at Qatar University. The data were collected through an online survey using Google Forms. The survey was distributed through various online platforms. Data analysis was conducted using Stata 16. Of the 364 participants, 9.89% expressed a high mistrust of vaccine safety, and 21.7% were uncertain about their levels of trust; 28% expressed strong worries about unforeseen side effects, whereas 54.95% expressed moderate worries. Furthermore, 7.69% expressed strong concerns and 39.84% showed moderate concerns about commercial profiteering. Approximately 13% of the participants expressed a strong preference towards natural immunity, whilst 45.33% appeared to believe that natural immunity might be better than a vaccine. Importantly, 68.13% of the participants intended to receive the COVID-19 vaccine once it became available, compared to 17.03% who were uncertain and 14.83% who were unwilling to be vaccinated. Our findings differ from the data on vaccine hesitancy among the general population of Qatar. We argue that this gap is due to scientific knowledge and domain of education. Furthermore, although knowledge and awareness may affect vaccine attitudes, mental health and sociodemographic factors play a role in shaping attitudes towards vaccines.	[Zaidi, Amine; Elmasaad, Amal; Alobaidli, Hend; Sayed, Rana; Al-Ali, Dana; Al-Kuwari, Dana; Al-Kubaisi, Shaikha; Mekki, Yosra; Emara, Mohamed M.] Qatar Univ, Coll Med, Basic Med Sci Dept, QU Hlth, Doha 2713, Qatar; [Emara, Mohamed M.] Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, Doha 2713, Qatar; [Daher-Nashif, Suhad] Qatar Univ, Coll Med, Populat Med Dept, QU Hlth, Doha 2713, Qatar		Daher-Nashif, S (通讯作者)，Qatar Univ, Coll Med, Populat Med Dept, QU Hlth, Doha 2713, Qatar.	az1708239@student.qu.edu.qa; ae1800819@student.qu.edu.qa; ha1704865@student.qu.edu.qa; rs1703961@student.qu.edu.qa; da1802872@student.qu.edu.qa; da1701937@student.qu.edu.qa; sa1601106@student.qu.edu.qa; ym1707134@student.qu.edu.qa; memara@qu.edu.qa; snashif@qu.edu.qa	Daher-Nashif, Suhad/AAL-7765-2020	Daher-Nashif, Suhad/0000-0002-8767-4619; Elmasaad, Amal/0000-0002-1858-8370	College of Medicine-QU Health, Qatar University	This publication was funded by the College of Medicine-QU Health, Qatar University.	Al Halabi CK, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10902-w; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; [Anonymous], 2020, COR VACC CLIN TRIAL; [Anonymous], 2021, 5 THINGS YOU CAN BUI; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Catching A., 2020, EPIDEMIOLOGY, DOI [10.1101/2020.08.12.20173047, DOI 10.1101/2020.08.12.20173047]; Daher-Nashif S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17031059; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Ayhan SG, 2021, INT J GYNECOL OBSTET, V154, P291, DOI 10.1002/ijgo.13713; Khaled SM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050471; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee SA, 2020, DEATH STUD, DOI [10.1080/07481187.2020.1853885, 10.1080/07481187.2020.1748481]; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Martin LR, 2017, ANN BEHAV MED, V51, P652, DOI 10.1007/s12160-017-9888-y; Mathieu E., CORONAVIRUS PANDEMIC; Mjrby LM, 2020, J FAM MED PRIM CARE, V9, P2079, DOI 10.4103/jfmpc.jfmpc_1061_19; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shaban RZ, 2020, AM J INFECT CONTROL, V48, P1445, DOI 10.1016/j.ajic.2020.08.032; Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	32	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1275	10.3390/vaccines9111275			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI3MF	34835206	Green Published, gold			2022-04-29	WOS:000726019500001
J	Jeon, M; Kim, J; Oh, CE; Lee, JY				Jeon, Minji; Kim, Jehun; Oh, Chi Eun; Lee, Jin-Young			Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea	VACCINES			English	Article						COVID-19; vaccination; ChAdOx1 nCoV-19 vaccine; adverse events following immunization		As worldwide large-scale inoculation of novel vaccines is on the way, the importance of real-world data on safety cannot be overemphasized. We aimed to investigate the adverse events following immunization (AEFIs) associated with the ChAdOx1 nCoV-19 vaccine among healthcare workers (HCWs). We investigated the systemic and local adverse events reported within seven days following the first and second doses of vaccination, using the mobile vaccine adverse events reporting system (MVAERS) developed by our hospital. The response rates were 71.8% (994/1384) and 52.9% (727/1375) after the first and second doses, respectively. The most commonly reported AEFIs were tenderness and pain at the injection site and fatigue after the first and second doses. In comparison to the first dose, the incidence and severity of AEFIs were lower following the second dose. Since the Korean government does not recommend the ChAdOx1 nCoV-19 vaccination for those under 30 years of age, with greater risk than benefit, we additionally compared the AEFIs of age groups under and above 30 years of age. The overall incidence of AEFIs was similar in both the under and over 30 age groups. In conclusion, AEFIs associated with the ChAdOx1 nCoV-19 vaccine were found to be tolerable, and AEFIs associated with the second dose were less common and severe compared to the first dose. Further safety surveillance studies on COVID-19 vaccines are required to validate our findings.	[Jeon, Minji; Lee, Jin-Young] Kosin Univ, Coll Med, Dept Internal Med, Div Infect Dis,Gospel Hosp, Busan 49267, South Korea; [Kim, Jehun] Kosin Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med,Gospel Hosp, Busan 49267, South Korea; [Oh, Chi Eun] Kosin Univ, Coll Med, Dept Pediat, Gospel Hosp, Busan 49267, South Korea		Lee, JY (通讯作者)，Kosin Univ, Coll Med, Dept Internal Med, Div Infect Dis,Gospel Hosp, Busan 49267, South Korea.	thehatter57@gmail.com; libertier@gmail.com; chieunoh@kosin.ac.kr; rejim@hanmail.net	Oh, Chi Eun/AAB-8027-2022	Kim, Jehun/0000-0002-2594-0256	National Research Foundation of Korea (NRF) - Korea governmentNational Research Foundation of Korea [2021R1F1A1062638]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (grant No. 2021R1F1A1062638).	Alhazmi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060674; Aw J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080900; Bunn C., 2021, NBC NEWS; Cheng HY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060582; Enwezor CH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080916; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Hatmal MM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060556; Jeon M, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e114; Kim SH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e107; Kim T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060648; Korea Centers for Disease Control and Prevention, COV 19 VACC STRAT IM; Medicines & Healthcare products Regulatory Agency, COR VACC WEEKL SUMM; Oldenburg J, 2021, HAMOSTASEOLOGIE, V41, P184, DOI 10.1055/a-1469-7481; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060673; U.S. Food & Drug Administration, TOX GRAD SCAL HLTH A; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	18	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1096	10.3390/vaccines9101096			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI9AF	34696204	Green Published, gold			2022-04-29	WOS:000726394100001
J	Marinos, G; Lamprinos, D; Georgakopoulos, P; Patoulis, G; Vogiatzi, G; Damaskos, C; Papaioannou, A; Sofroni, A; Pouletidis, T; Papagiannis, D; Symvoulakis, EK; Konstantopoulos, K; Rachiotis, G				Marinos, Georgios; Lamprinos, Dimitris; Georgakopoulos, Panagiotis; Patoulis, Georgios; Vogiatzi, Georgia; Damaskos, Christos; Papaioannou, Anastasia; Sofroni, Anastasia; Pouletidis, Theodoros; Papagiannis, Dimitrios; Symvoulakis, Emmanouil K.; Konstantopoulos, Kostas; Rachiotis, Georgios			Reported COVID-19 Vaccination Coverage and Associated Factors among Members of Athens Medical Association: Results from a Cross-Sectional Study	VACCINES			English	Article						COVID-19; vaccination coverage; vaccines hesitancy; health professionals	HEALTH-CARE WORKERS; HESITANCY; DETERMINANTS; VACCINES; IMPACT; EUROPE	There are limited data on the prevalence and determinants of COVID-19 vaccination coverage among physicians. A cross-sectional, questionnaire-based, online study was conducted among the members of the Athens Medical Association (I.S.A.) over the period 25 February to 13 March 2021. All members of I.S.A. were invited to participate in the anonymous online survey. A structured, anonymous questionnaire was used. Overall, 1993 physicians participated in the survey. The reported vaccination coverage was 85.3%. The main reasons of no vaccination were pending vaccination appointment followed by safety concerns. Participants being informed about the COVID-19 vaccines by social media resulted in lower COVID-19 vaccination coverage than health workers being informed by other sources. Logistic regression analysis demonstrated that no fear over COVID-19 vaccination-related side effects, history of influenza vaccination for flu season 2020-2021, and the perception that the information on COVID-19 vaccination from the national public health authorities is reliable, were independent factors of reported COVID-19 vaccination coverage. Our results demonstrate a considerable improvement of the COVID-19 vaccination uptake among Greek physicians. The finding that participants reported high reliability of the information related to COVID-19 vaccination provided by the Greek public health authorities is an opportunity which should be broadly exploited by policymakers in order to combat vaccination hesitancy, and further improve COVID-19 vaccination uptake and coverage among physicians/HCWs, and the general population.	[Marinos, Georgios] Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece; [Lamprinos, Dimitris; Georgakopoulos, Panagiotis; Sofroni, Anastasia; Pouletidis, Theodoros] Laikon Gen Hosp, Emergency Dept, Athens 11527, Greece; [Patoulis, Georgios] Athenss Med Assoc, Athens 11526, Greece; [Vogiatzi, Georgia] Natl & Kapodistrian Univ Athens, Hippokration Hosp, Med Sch, Cardiol Dept 1, Athens 11527, Greece; [Damaskos, Christos] Natl & Kapodistrian Univ Athens, Med Sch, NS Christeas Lab Expt Surg & Surg Res, Athens 11527, Greece; [Papaioannou, Anastasia] Hlth Ctr Nea Makri, Attica 19005, Greece; [Papagiannis, Dimitrios] Univ Thessaly, Sch Hlth Sci, Dept Nursing, Publ Hlth & Vaccines Lab, Larisa 41110, Greece; [Symvoulakis, Emmanouil K.] Univ Crete, Fac Med, Clin Social & Family Med, Iraklion 71003, Greece; [Konstantopoulos, Kostas] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Haematol, Sch Med, Athens 11527, Greece; [Konstantopoulos, Kostas] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Bone Marrow Transplantat Unit, Sch Med, Athens 11527, Greece; [Rachiotis, Georgios] Univ Thessaly, Fac Med, Dept Hyg & Epidemiol, Larisa 41222, Greece		Marinos, G (通讯作者)，Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece.	gmarino@med.uoa.gr; dimitrislamprinos@gmail.com; panos.k.georgakopoulos@gmail.com; gipattt@gmail.com; gvogiatz@yahoo.gr; x_damaskos@yahoo.gr; anpapai@yahoo.com; a.sofroni@hotmail.com; tpouletidis@gmail.com; dpapajon@gmail.com; symvouman@yahoo.com; kkonstan@med.uoa.gr; grach@uth.gr		Lamprinos, Dimitrios/0000-0003-1512-9301; Damaskos, Christos/0000-0002-5454-2564	Athens Medical Association	FundingArticle Processing Charges were covered by Athens Medical Association.	Abohelwa M, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/21501327211022978; Ali K. A., 2017, Eurohealth, V23, P16; [Anonymous], 2014, WHO REPORT SAGE WORK; Ares-Blanco S, 2021, ATEN PRIM, V53, DOI 10.1016/j.aprim.2021.102132; Benis A, 2021, J MED INTERNET RES, V23, DOI 10.2196/25977; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Centers for Disease Control and Prevention (CDC), 2021, COVID 19 STEPS STAYI; Cheung KL, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4189-8; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fan WM, 2010, COMPUT HUM BEHAV, V26, P132, DOI 10.1016/j.chb.2009.10.015; Giannouchos TV, 2021, J EVAL CLIN PRACT, V27, P996, DOI 10.1111/jep.13588; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Harnden A, 2021, BRIT J GEN PRACT, V71, P52, DOI 10.3399/bjgp21X714929; Janssen C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060547; Jordan R, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3398; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Katzman JG, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/21501327211007026; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lillie PJ, 2021, CLIN INFECT DIS, V73, P1906, DOI 10.1093/cid/ciab351; Lionis C, 2019, PRIM HEALTH CARE RES, V20, DOI 10.1017/S1463423619000446; Maltezou HC, 2021, INFECT DIS HEALTH, V26, P189, DOI 10.1016/j.idh.2021.03.002; Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Papagiannis D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144925; Piltch-Loeb R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251095; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Raftopoulos V, 2021, HUM VACC IMMUNOTHER, V17, P2397, DOI 10.1080/21645515.2021.1896907; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Symvoulakis EK, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00730-2020; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; Zarocostas J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2877	37	6	6	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1134	10.3390/vaccines9101134			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI8IR	34696242	Green Published, gold			2022-04-29	WOS:000726348400001
J	Mosteiro-Miguens, DG; Roca, DD; Dominguez-Martis, EM; Vieito-Perez, N; Alvarez-Padin, P; Novio, S				Mosteiro-Miguens, Diego Gabriel; Roca, Daniel De Bernardo; Dominguez-Martis, Eva Maria; Vieito-Perez, Natalia; Alvarez-Padin, Pilar; Novio, Silvia			Attitudes and Intentions toward COVID-19 Vaccination among Spanish Adults: A Descriptive Cross-Sectional Study	VACCINES			English	Article						attitude; COVID-19; intention; prevention; SARS-CoV-2; vaccines	SARS-COV-2; WILLINGNESS; RECEIVE	Vaccination against SARS-CoV-2 is postulated as the most effective measure to control the COVID-19 pandemic. However, the use of other protection measures is necessary to efficiently combat the spread of the virus. The aim of the present study was to determine the attitudes and intentions toward COVID-19 vaccination among non-regular social media users in Spain and to analyze how these factors could condition the acceptance of other personal protective measures once an individual has received the COVID-19 vaccine. A cross-sectional design was used in this work. In total, 719 subjects, >= 18 years old and of both sexes, were recruited from primary public healthcare centers to self-complete a questionnaire between March and April 2021. The majority of participants had a positive attitude toward vaccination and showed high levels of intention to be vaccinated. Likewise, except those participants who considered the vaccine to be the most effective measure to fight the COVID-19 pandemic, the rest of the participants highlighted the importance of continuing to limit social interactions and/or wearing masks even after being vaccinated. Since vaccination can create a perception of total immunity against SARS-CoV-2, it is necessary that healthcare staff organize effective awareness campaigns on the importance of maintaining personal protective measures until vaccination coverage is greater.	[Mosteiro-Miguens, Diego Gabriel; Dominguez-Martis, Eva Maria] Healthcare Ctr Concepc Arenal, Galician Publ Healthcare Serv, C Santiago Leon Caracas 12, La Coruna 15701, Spain; [Roca, Daniel De Bernardo] Healthcare Ctr A Bandeira, Galician Publ Healthcare Serv, Pza Camilo Jose Cela S-N, Pontevedra 36570, Spain; [Vieito-Perez, Natalia] Univ Hosp Complex Santiago Compostela CHUS, Galician Publ Healthcare Serv, C Choupana S-N, La Coruna 15706, Spain; [Alvarez-Padin, Pilar] Univ Hosp Burgos, Castilla & Leon Publ Healthcare Serv, Avd Islas Baleares 3, Burgos 09006, Spain; [Novio, Silvia] Univ Santiago Compostela, Dept Psiquiat Radiol Publ Hlth, Nursing & Med, C San Francisco S-N, La Coruna 15782, Spain		Novio, S (通讯作者)，Univ Santiago Compostela, Dept Psiquiat Radiol Publ Hlth, Nursing & Med, C San Francisco S-N, La Coruna 15782, Spain.	diego.gabriel.mosteiro.miguens@sergas.es; daniel.de.bernardo.roca@sergas.es; eva.maria.dominguez.martis@sergas.es; natalia.vieito.perez@sergas.es; papadin@saludcastillayleon.es; silvia.novio@usc.es		Novio, Silvia/0000-0002-6169-8356			Al-Jayyousi GF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060548; Berardi A, 2020, INT J PHARMACEUT, V584, DOI 10.1016/j.ijpharm.2020.119431; Catalan-Matamoros D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218136; Centers for Disease Control and Prevention, PEOPL CERT MED COND; Chen TE, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1876814; Claessens M., 2021, SCI POLITICS COVID 1; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Covino M, 2021, ARCH GERONTOL GERIAT, V95, DOI 10.1016/j.archger.2021.104383; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Di Carlo P, 2021, J MED MICROBIOL, V70, DOI 10.1099/jmm.0.001328; Di Carlo P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235943; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eguia H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020170; Eibensteiner F, 2021, J MED INTERNET RES, V23, DOI 10.2196/28973; European Centre for Disease Prevention and Control European Centre for Disease Prevention and Control, OV COVID 19 VACC STR; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Gavriatopoulou M, 2021, CLIN EXP MED, V21, P167, DOI 10.1007/s10238-020-00671-y; Gildea F, 2020, PERSPECT PUBLIC HEAL, V140, P301, DOI 10.1177/1757913920963012; Grupo de Trabajo Tecnico de Vacunacion COVID-19 de la Ponencia de Programa y Registro de Vacunaciones, ESTR VAC FRENT COVID; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Herrera-Peco I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060656; Hou ZY, 2021, J MED INTERNET RES, V23, DOI 10.2196/27632; Howard J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2014564118; Hsiang SL, 2020, NATURE, V585, pE7, DOI 10.1038/s41586-020-2691-0; Insanguine Mingarro Ferdinando A, 2021, Cuad Bioet, V32, P63, DOI 10.30444/CB.88; Ioannidis JPA, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109890; Kaplan S, 2022, APPL ECON PERSPECT P, V44, P477, DOI 10.1002/aepp.13164; Katzman JG, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/21501327211007026; Kirby T, 2021, LANCET RESP MED, V9, pE20, DOI 10.1016/S2213-2600(21)00005-9; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lazarus JV, 2021, NAT MED, V27, P354, DOI 10.1038/s41591-020-01226-0; Li YN, 2021, AM J INFECT CONTROL, V49, P900, DOI 10.1016/j.ajic.2020.12.007; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Luo M, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113190; Majumder J, 2021, AAPS J, V23, DOI 10.1208/s12248-020-00532-2; Mallah SI, 2021, ANN CLIN MICROB ANTI, V20, DOI 10.1186/s12941-021-00438-7; Malta M, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100757; Maykrantz SA, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115867; Mesesle M, 2021, INFECT DRUG RESIST, V14, P2193, DOI 10.2147/IDR.S316461; Moloney K, 2020, PUBLIC ADMIN REV, V80, P671, DOI 10.1111/puar.13224; Moreno-Torres V, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025634; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Noorimotlagh Z, 2021, ENVIRON SCI POLLUT R, V28, P1, DOI 10.1007/s11356-020-11060-z; Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013574; Petersen E, 2021, TURK J MED SCI, V51, P3157, DOI 10.3906/sag-2106-236; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Porto MH, 2021, INT J INFECT DIS, DOI DOI 10.1016/J.IJID.2021.06.010; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6; Priesemann V, 2021, LANCET, V397, P469, DOI 10.1016/S0140-6736(21)00150-1; Pullan S, 2021, VACCINE, V39, P1877, DOI 10.1016/j.vaccine.2021.03.019; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Rodriguez-Blanco N, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105272; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Singh Lisa, 2020, ArXiv; Sociedad Espanola de Medicina de Familia y Comunitaria, AB PAC CON COV 19 AT; Spanish Agency for Medicines and Health Products, ESTR VAC COVID 19 ES; Tutak AS, 2021, J INFECT PUBLIC HEAL, V14, P1395, DOI 10.1016/j.jiph.2021.05.017; Ucciferri C, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.048; van Oosterhout C, 2021, VIRULENCE, V12, P507, DOI 10.1080/21505594.2021.1877066; Wake AD, 2021, RISK MANAG HEALTHC P, V14, P2609, DOI 10.2147/RMHP.S311074; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Webb Erin, 2021, Health Policy, DOI 10.1016/j.healthpol.2021.04.016; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization United Nations Children's Fund (UNICEF), WATER SANITATION HYG; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yin FL, 2021, J MED INTERNET RES, V23, DOI 10.2196/26089; Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	82	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1135	10.3390/vaccines9101135			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WO3ZW	34696243	Green Published, gold			2022-04-29	WOS:000712397300001
J	Tuppurainen, E; Dietze, K; Wolff, J; Bergmann, H; Beltran-Alcrudo, D; Fahrion, A; Lamien, CE; Busch, F; Sauter-Louis, C; Conraths, FJ; De Clercq, K; Hoffmann, B; Knauf, S				Tuppurainen, Eeva; Dietze, Klaas; Wolff, Janika; Bergmann, Hannes; Beltran-Alcrudo, Daniel; Fahrion, Anna; Lamien, Charles Euloge; Busch, Frank; Sauter-Louis, Carola; Conraths, Franz J.; De Clercq, Kris; Hoffmann, Bernd; Knauf, Sascha			Review: Vaccines and Vaccination against Lumpy Skin Disease	VACCINES			English	Review						capripoxvirus; lumpy skin disease; cattle; LSD; immunization; vaccination	MECHANICAL TRANSMISSION; MAMMALIAN POXVIRUSES; VIRUS; CAPRIPOXVIRUS; CATTLE; SHEEP; FIELD; OUTBREAKS; EFFICACY; STRAIN	The geographical distribution of lumpy skin disease (LSD), an economically important cattle disease caused by a capripoxvirus, has reached an unprecedented extent. Vaccination is the only way to prevent the spread of the infection in endemic and newly affected regions. Yet, in the event of an outbreak, selection of the best vaccine is a major challenge for veterinary authorities and farmers. Decision makers need sound scientific information to support their decisions and subsequent actions. The available vaccine products vary in terms of quality, efficacy, safety, side effects, and price. The pros and cons of different types of live attenuated and inactivated vaccines, vaccination strategies, and associated risks are discussed. Seroconversion, which typically follows vaccination, places specific demands on the tools and methods used to evaluate the effectiveness of the LSD vaccination campaigns in the field. We aimed to give a comprehensive update on available vaccines and vaccination against LSD, to better prepare affected and at-risk countries to control LSD and ensure the safe trade of cattle.</p>	[Tuppurainen, Eeva; Dietze, Klaas; Fahrion, Anna; Busch, Frank; Knauf, Sascha] Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Inst Int Anim Hlth Hlth 1, Sudufer 10, D-17493 Greifswald, Germany; [Wolff, Janika; Hoffmann, Bernd] Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Inst Diagnost Virol, Sudufer 10, D-17493 Greifswald, Germany; [Bergmann, Hannes; Sauter-Louis, Carola; Conraths, Franz J.] Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Inst Epidemiol, Sudufer 10, D-17493 Greifswald, Germany; [Beltran-Alcrudo, Daniel] Food & Agr Org, Reg Off Europe & Cent Asia, 20 Kalman Imre Utca, H-1054 Budapest, Hungary; [Lamien, Charles Euloge] Int Atom Energy Agcy IAEA, Dept Nucl Sci & Applicat, FAO IAEA Div Nucl Tech Food & Agr, Friedenstr 1, A-2444 Seibersdorf, Austria; [De Clercq, Kris] Sciensano, Sci Directorate Infect Dis Anim, Unit Exot & Particular Dis, Groeselenberg 99, B-1180 Brussels, Belgium		Tuppurainen, E (通讯作者)，Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Inst Int Anim Hlth Hlth 1, Sudufer 10, D-17493 Greifswald, Germany.	Eeva.Tuppurainen@fli.de; Klaas.Dietze@fli.de; Janika.Wolff@fli.de; Hannes.Bergmann@fli.de; Daniel.BeltranAlcrudo@fao.org; Anna.Fahrion@fli.de; C.Lamien@iaea.org; Frank.Busch@fli.de; Carola.Sauter-Louis@fli.de; Franz.Conraths@fli.de; kris.declercq@sciensano.be; Bernd.Hoffmann@fli.de; Sascha.Knauf@fli.de	; Knauf, Sascha/F-1661-2017	Hoffmann, Bernd/0000-0001-5358-6445; LAMIEN, Charles Euloge/0000-0003-1899-7614; Dietze, Klaas/0000-0002-6138-6707; Sauter-Louis, Carola/0000-0002-6440-1933; De Clercq, Kris/0000-0002-2928-3521; Conraths, Franz/0000-0002-7400-9409; Knauf, Sascha/0000-0001-5744-4946	European UnionEuropean Commission [773701]	FundingThis research was partly funded by the European Unions Horizon 2020 Research and Innovation Program, under grant agreement No. 773701, DEFEND project (www.defend2020.eu, accessed on 29 September 2021).	Abdallah FM, 2018, VET WORLD, V11, P1150, DOI 10.14202/vetworld.2018.1150-1158; Abutarbush SM, 2014, VET REC, V175, DOI 10.1136/vr.102271; Abutarbush SM, 2018, TRANSBOUND EMERG DIS, V65, P1657, DOI 10.1111/tbed.12923; Agianniotaki EI, 2018, TRANSBOUND EMERG DIS, V65, P2043, DOI 10.1111/tbed.12983; Agianniotaki EI, 2017, J VIROL METHODS, V249, P48, DOI 10.1016/j.jviromet.2017.08.011; Aleksandr K, 2020, SCI REP-UK, V10, P7436, DOI 10.1038/s41598-020-64029-w; Allepuz A, 2019, TRANSBOUND EMERG DIS, V66, P813, DOI 10.1111/tbed.13090; Annandale CH, 2014, TRANSBOUND EMERG DIS, V61, P443, DOI [10.1111/tbed.12045, 10.1111/tbed]; Annandale CH, 2019, TRANSBOUND EMERG DIS, V66, P1539, DOI 10.1111/tbed.13179; Aspden K, 2002, VACCINE, V20, P2693, DOI 10.1016/S0264-410X(02)00203-7; Ayelet G, 2013, ANTIVIR RES, V98, P261, DOI 10.1016/j.antiviral.2013.02.008; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P263, DOI 10.1111/j.1865-1682.2008.01043.x; Babiuk S., 2018, LUMPY SKIN DIS; Badhy SC, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02751-x; Beard PM, 2016, VET REC, V178, P557, DOI 10.1136/vr.i2800; Bedekovic T, 2018, TRANSBOUND EMERG DIS, V65, P491, DOI 10.1111/tbed.12730; BEDSON HS, 1964, J HYG-CAMBRIDGE, V62, P147, DOI 10.1017/S0022172400039887; Ben-Gera J, 2015, VACCINE, V33, P4837, DOI 10.1016/j.vaccine.2015.07.071; Berg C, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.3986; Bessell PR, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00223; Boumart Z, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0754-0; Brenner J, 2009, VACCINE, V27, P1500, DOI 10.1016/j.vaccine.2009.01.020; Buller RM, 2005, VIRUS TAXONOMY CLASS, P117; Burgers WA, 2014, J GEN VIROL, V95, P2267, DOI 10.1099/vir.0.067835-0; Calistri P, 2020, EFSA J, V18, DOI 10.2903/j.efsa.2020.6010; Calistri P, 2018, EFSA J, V16, DOI 10.2903/j.efsa.2018.5452; CARN VM, 1993, VACCINE, V11, P1275, DOI 10.1016/0264-410X(93)90094-E; Casal J, 2018, TRANSBOUND EMERG DIS, V65, P1680, DOI 10.1111/tbed.12926; Chamchod F, 2018, J THEOR BIOL, V437, P179, DOI 10.1016/j.jtbi.2017.10.009; Chihota CM, 2001, EPIDEMIOL INFECT, V126, P317, DOI 10.1017/S0950268801005179; Cumming DHM, 2015, ONE HEALTH: THE THEORY AND PRACTICE OF INTEGRATED HEALTH APPROACHES, P38, DOI [10.1079/9781780643410.0000, 10.1079/9781780643410.0038]; Davies F. G., 1991, World Animal Review, V68, P37; DAVIES FG, 1976, J HYG-CAMBRIDGE, V76, P163, DOI 10.1017/S0022172400055066; DAVIES FG, 1991, BRIT VET J, V147, P489, DOI 10.1016/0007-1935(91)90019-J; DAVIES FG, 1978, J COMP PATHOL, V88, P205, DOI 10.1016/0021-9975(78)90024-5; Disney WT, 2001, REV SCI TECH OIE, V20, P385, DOI 10.20506/rst.20.2.1277; Edwards K.M., 2018, PLOTKINS VACCINES, P7, DOI [10.1016/B978-0-323-35761-6.00002-X, DOI 10.1016/B978-0-323-35761-6.00002-X]; EFSA, 2018, EFSA J, V16, DOI 10.2903/j.efsa.2018.5176; EFSA, 2016, EFSA J, V14, DOI 10.2903/j.efsa.2016.4497; FAO, 2015, EMPRES WATCH, V33; FAO, 2017, FAO ANIM PROD HLTH P, V2; FAO, 2013, EMPRES WATCH, V29; FENNER F, 1958, VIROLOGY, V5, P530, DOI 10.1016/0042-6822(58)90043-6; Friedrich-Loeffler-Institut, 2016, QUAL RIS EINSCHL LUM; Gale P, 2016, MICROB RISK ANAL, V1, P13, DOI 10.1016/j.mran.2015.07.001; Gari G, 2015, VACCINE, V33, P3256, DOI 10.1016/j.vaccine.2015.01.035; GERSHON PD, 1989, VIROLOGY, V172, P350, DOI 10.1016/0042-6822(89)90138-4; Givens MD, 2018, ANIMAL, V12, pS165, DOI [10.1017/S1751731118000708, 10.1017/s1751731118000708]; Gupta T, 2020, VET RES COMMUN, V44, P111, DOI 10.1007/s11259-020-09780-1; Haegeman A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050473; Hamdi J, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108689; Haralambieva IH, 2012, J INFECT DIS, V206, P1512, DOI 10.1093/infdis/jis546; Horigan V, 2018, MICROB RISK ANAL, V9, P1, DOI 10.1016/j.mran.2018.05.001; Ince OB, 2019, J HELL VET MED SOC, V70, P1797; Ince OB, 2016, INDIAN J ANIM RES, V50, P1013, DOI 10.18805/ijar.9370; Kahana-Sutin E, 2017, MED VET ENTOMOL, V31, P150, DOI 10.1111/mve.12217; Kasem S, 2018, TRANSBOUND EMERG DIS, V65, pe494, DOI 10.1111/tbed.12769; Katsoulos PD, 2018, TRANSBOUND EMERG DIS, V65, P174, DOI 10.1111/tbed.12646; Kayesh M.E.H., 2020, HOSTS VIRUSES, V7, P97; Kennedy RB, 2013, GENES IMMUN, V14, P277, DOI 10.1038/gene.2013.14; Khalafalla A I, 1993, Rev Elev Med Vet Pays Trop, V46, P548; Kiplagat SK, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00259; KITCHING P, 1983, Vaccine, V1, P4, DOI 10.1016/0264-410X(83)90004-X; Kitching R P, 1986, Rev Sci Tech, V5, P503, DOI 10.20506/rst.5.2.241; Kitching R.P., 1992, ENCY IMMUNOLOGY, P1261; KITCHING RP, 1986, J GEN VIROL, V67, P139, DOI 10.1099/0022-1317-67-1-139; Kumar SM, 2011, ASIAN J ANIM VET ADV, V6, P851, DOI 10.3923/ajava.2011.851.859; Lamien CE, 2011, VET MICROBIOL, V149, P30, DOI 10.1016/j.vetmic.2010.09.038; Le Goff C, 2009, J GEN VIROL, V90, P1967, DOI 10.1099/vir.0.010686-0; Lojkic I, 2018, MICROBIOL RESOUR ANN, V6, DOI 10.1128/genomeA.00482-18; Lu G, 2021, TRANSBOUND EMERG DIS, V68, P216, DOI 10.1111/tbed.13898; Lubinga JC, 2013, EXP APPL ACAROL, V61, P129, DOI 10.1007/s10493-013-9679-5; Machado G, 2019, TRANSBOUND EMERG DIS, V66, P2045, DOI 10.1111/tbed.13253; Mainda G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14162; Mainda G, 2015, SCI REP-UK, V5, DOI 10.1038/srep12439; Mathijs E, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01255-16; Menasherow S, 2016, J VIROL METHODS, V232, P12, DOI 10.1016/j.jviromet.2016.02.008; Milovanovic M, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01298-x; Milovanovic M, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1831-y; Molini U, 2018, ARCH VIROL, V163, P2525, DOI 10.1007/s00705-018-3891-x; Molla W, 2017, PREV VET MED, V147, P100, DOI 10.1016/j.prevetmed.2017.09.003; Morgenstern M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020324; Nash A.A., 2015, MIMS PATHOGENESIS IN, V6th, P291; Ngichabe CK, 1999, VET REC, V145, P231, DOI 10.1136/vr.145.8.231; Ngichabe CK, 1997, EPIDEMIOL INFECT, V118, P63, DOI 10.1017/S0950268896007200; Norian R., 2017, Research in Molecular Medicine, V5, P3, DOI 10.29252/rmm.5.2.3; Norian R., 2016, IRAN J VIROL, V10, P1, DOI [10.21859/isv.10.4.1, DOI 10.21859/ISV.10.4.1]; Ochwo S, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1983-9; Ochwo S, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1503-3; OIE, 2021, TERR AN HLTH COD, V2; OIE, 2019, MANUAL DIAGNOSTIC TE, V1; OIE, 2021, MANUAL DIAGNOSTIC TE, V3; OIE, 2019, MINIMUM REQUIREMENTS, V1; Osuagwuh UI, 2007, VACCINE, V25, P2238, DOI 10.1016/j.vaccine.2006.12.010; PROZESKY L, 1982, ONDERSTEPOORT J VET, V49, P167; Qin L, 2015, J VIROL, V89, P1809, DOI 10.1128/JVI.02797-14; Qin L, 2011, J VIROL, V85, P13049, DOI 10.1128/JVI.05779-11; Roche X., 2020, INTRO SPREAD LUMPY S; Rouby S, 2016, VET J, V209, P193, DOI 10.1016/j.tvjl.2015.11.010; Rouby SR., 2017, ADV ANIMAL VET SCI, V5, P185; Rozstalnyy A., 2017, EMPRES ANIM HLTH 360, V47, P45; Saegerman C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198506; Salib FA, 2011, VET WORLD, V4, P162; Saltykov YV, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10060716; Samojlovic M, 2019, ACTA VET-BEOGRAD, V69, P47, DOI 10.2478/acve-2019-0003; Schelling E, 2005, BMJ-BRIT MED J, V331, P1264, DOI 10.1136/bmj.331.7527.1264; Schelling E, 2007, EMERG INFECT DIS, V13, P373, DOI 10.3201/eid1303.060391; Sevik M, 2017, TRANSBOUND EMERG DIS, V64, P1268, DOI 10.1111/tbed.12501; Shen Y, 2008, AIDS RES HUM RETROV, V24, P137; Sohier C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56605-6; SOLYOM F, 1982, ACTA MICROBIOL HUNG, V29, P69; Sprygin A, 2019, VIRUS RES, V269, DOI 10.1016/j.virusres.2019.05.015; Sprygin A, 2018, TRANSBOUND EMERG DIS, V65, P1137, DOI 10.1111/tbed.12897; Sprygin A, 2018, TRANSBOUND EMERG DIS, V65, P1514, DOI 10.1111/tbed.12889; Sprygin A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232584; Sprygin A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207480; Tageldin MH, 2014, TROP ANIM HEALTH PRO, V46, P241, DOI 10.1007/s11250-013-0483-3; Taylor RA, 2019, TRANSBOUND EMERG DIS, V66, P131, DOI 10.1111/tbed.12993; Tran HTT, 2021, TRANSBOUND EMERG DIS, V68, P977, DOI 10.1111/tbed.14022; Tulman ER, 2002, J VIROL, V76, P6054, DOI 10.1128/JVI.76.12.6054-6061.2002; Tuppurainen E., 2017, LUMPY SKIN DIS FIELD, V20, P60; Tuppurainen ESM, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.006; Tuppurainen ESM, 2015, TICKS TICK-BORNE DIS, V6, P134, DOI 10.1016/j.ttbdis.2014.11.002; Tuppurainen ESM, 2013, EPIDEMIOL INFECT, V141, P425, DOI 10.1017/S0950268812000805; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Varshovi H. R., 2017, Iranian Journal of Veterinary Science and Technology, V9, P33; Vidanovic D, 2016, ACTA VET-BEOGRAD, V66, P444, DOI 10.1515/acve-2016-0038; Wallace DB, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00256; Wallace DB, 2005, VACCINE, V23, P3061, DOI 10.1016/j.vaccine.2004.10.006; WEISS K. E., 1968, Lumpy skin disease virus., P111; Wolff J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010004; Wolff J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070768; WOODROOFE GM, 1960, VIROLOGY, V12, P272, DOI 10.1016/0042-6822(60)90200-2; Woods J. A., 1990, Virus infections of ruminants., P53; YERUHAM I, 1995, VET REC, V137, P91, DOI 10.1136/vr.137.4.91; Zhugunissov K, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108695	137	3	3	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1136	10.3390/vaccines9101136			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN8YY	34696244	Green Published			2022-04-29	WOS:000712054200001
J	Abu-Halaweh, S; Alqassieh, R; Suleiman, A; Al-Sabbagh, MQ; AbuHalaweh, M; AlKhader, D; Abu-Nejem, R; Nabulsi, R; Al-Tamimi, M; Alwreikat, M; Alnouti, M; Suleiman, B; Yousef, M; El Jarbeh, M; Al-Shudifat, AE; Alqassieh, A; Bsisu, I				Abu-Halaweh, Sami; Alqassieh, Rami; Suleiman, Aiman; Al-Sabbagh, Mohammed Qussay; AbuHalaweh, Maram; AlKhader, Duaa; Abu-Nejem, Rozan; Nabulsi, Roa'a; Al-Tamimi, Mohammad; Alwreikat, Mallak; Alnouti, Mazen; Suleiman, Bayan; Yousef, Moh'd; El Jarbeh, Mohammad; Al-Shudifat, Abdel-Ellah; Alqassieh, Ahmad; Bsisu, Isam			Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews	VACCINES			English	Article						COVID-19; pandemic; vaccine; Pfizer-BioNTech; Sinopharm		Vaccines are considered the best approach for countering the COVID-19 pandemic. In this study, we compared early side effects associated with vaccination with the Sinopharm and Pfizer-BioNTech COVID-19 vaccines. Participants of this observational cohort were interviewed based on semi-structured telephone interviews, with enquiries about side effects that developed after vaccination with each dose of these vaccines. Overall, 1004 participants were enrolled, of which 51.1% received Sinopharm vaccine and 48.9% received the Pfizer-BioNTech vaccine. After the first dose, 46.3% of participants had an adverse reaction, with injection site pain most commonly being reported (33.2%). Participants who received the Pfizer-BioNTech vaccine had significantly higher frequencies of all types of adverse reactions (p < 0.01), with no significant differences in the duration of adverse reactions between the two vaccines. Regarding the second dose, 48.6% of participants had adverse reactions, with injection site pain being most commonly reported (29%). Those who received the Pfizer vaccine reported higher frequencies of all adverse reactions (p < 0.01). However, a longer duration of adverse reactions was seen among Sinopharm vaccine recipients as compared to Pfizer-BioNTech vaccine recipients (p = 0.01). In conclusion, early adverse effects are reported following all types of vaccines but these are more likely to be encountered following the administration of new-generation vaccines. These side effects are mostly mild and treatable.	[Abu-Halaweh, Sami; Alnouti, Mazen; Suleiman, Bayan; Yousef, Moh'd; El Jarbeh, Mohammad; Bsisu, Isam] Univ Jordan, Sch Med, Dept Anesthesia & Intens Care, Amman 11942, Jordan; [Alqassieh, Rami] Hashemite Univ, Fac Med, Dept Gen & Specialized Surg, Zarqa 13133, Jordan; [Suleiman, Aiman] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Anesthesia & Intens Care Dept, Boston, MA 02215 USA; [Al-Sabbagh, Mohammed Qussay] Univ Kansas, Dept Neurol, Med Ctr, Kansas City, KS 66160 USA; [AbuHalaweh, Maram] Univ Jordan, Sch Med, Dept Internal Med, Amman 11942, Jordan; [AlKhader, Duaa] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA; [Abu-Nejem, Rozan; Nabulsi, Roa'a; Al-Tamimi, Mohammad; Alwreikat, Mallak; Al-Shudifat, Abdel-Ellah] Hashemite Univ, Fac Med, Zarqa 13133, Jordan; [Alqassieh, Ahmad] Med Univ South Carolina, Dept Surg, Div Transplant Surg, Charleston, SC 29425 USA		Bsisu, I (通讯作者)，Univ Jordan, Sch Med, Dept Anesthesia & Intens Care, Amman 11942, Jordan.	s.halaweh@ju.edu.jo; Rami_qaisieh@yahoo.com; Asuleima@bidmc.harvard.edu; mqs.sabbagh@gmail.com; maram.halaweh@gmail.com; do3a2_alkader@yahoo.com; Rozannijem.rn@gmail.com; Roaa.nabulsi@hotmail.com; mohammad.altamimi@hu.edujo; mawreikat@gmail.com; Mazen.alnouti@yahoo.com; Bayan.suleiman93@gmail.com; Yousefmohammad1993a@gmail.com; Mhmd.sum@hotmail.com; amalmufleh@hotmail.com; ahmadsq1988@yahoo.com; isam_bsisu@hotmail.com	; Al-Tamimi, Mohammad/B-1734-2018	Suleiman, Aiman/0000-0003-2625-4028; Al-sabbagh, Mohammed/0000-0002-4872-7116; Abu-halaweh, sami/0000-0001-6981-7789; El Jarbeh, Mohammad/0000-0002-5884-8384; Bsisu, Isam/0000-0002-8999-8334; Al-Tamimi, Mohammad/0000-0001-7486-4192; Alqassieh, Ahmad/0000-0001-7903-1034; Alqassieh, RAMI/0000-0002-0270-0436			Abu-Hammad O, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060577; Aloweidi A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105111; BioNTech SE, 2021, STUD DESCR SAF TOL I; Centres for Diseases Control and Prevention (CDC), 2021, REACT ADV EV PFIZ BI; El-Shitany NA, 2021, INT J GEN MED, V14, P1389, DOI 10.2147/IJGM.S310497; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Haidere MF, 2021, BIOMOL THER, V29, P1, DOI 10.4062/biomolther.2020.178; Jordanian Ministry of Health, 2021, COVID 19 VACC PLATF; Kaur RJ, 2021, INDIAN J CLIN BIOCHE, V36, P427, DOI 10.1007/s12291-021-00968-z; Laboratorio Elea Phoenix S.A, 2020, CLIN TRIAL EV EFF IM; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Milken Institute, 2020, COVID 19 TREATM VACC; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ratan Z. A., 2020, Bangladesh Journal of Infectious Diseases, V7, P58, DOI 10.3329/bjid.v7i0.46805; Rottingen, 2020, INFECT DIS NEW MILLE, P137; Spencer JP, 2017, AM FAM PHYSICIAN, V95, P786; University of Oxford, 2021, STUD CAND COVID 19 V; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8	26	3	3	9	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							950	10.3390/vaccines9090950			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3LO	34579187	gold, Green Published			2022-04-29	WOS:000702110100001
J	Khan, MA; Khan, A				Khan, Masood Alam; Khan, Arif			Role of NKT Cells during Viral Infection and the Development of NKT Cell-Based Nanovaccines	VACCINES			English	Review						NKT cells; vaccine; lipid ligands; immunoadjuvant; nanoparticles	KILLER T-CELLS; CD1D-MEDIATED ANTIGEN PRESENTATION; INFLUENZA-VIRUS VACCINE; INVARIANT NKT; ALPHA-GALACTOSYLCERAMIDE; IMMUNE-RESPONSES; SPHINGOMONAS-PAUCIMOBILIS; PD-1 EXPRESSION; SELECTIVE LOSS; HUMAN CD1D	Natural killer T (NKT) cells, a small population of T cells, are capable of influencing a wide range of the immune cells, including T cells, B cells, dendritic cells and macrophages. In the present review, the antiviral role of the NKT cells and the strategies of viruses to evade the functioning of NKT cell have been illustrated. The nanoparticle-based formulations have superior immunoadjuvant potential by facilitating the efficient antigen processing and presentation that favorably elicits the antigen-specific immune response. Finally, the immunoadjuvant potential of the NKT cell ligand was explored in the development of antiviral vaccines. The use of an NKT cell-activating nanoparticle-based vaccine delivery system was supported in order to avoid the NKT cell anergy. The results from the animal and preclinical studies demonstrated that nanoparticle-incorporated NKT cell ligands may have potential implications as an immunoadjuvant in the formulation of an effective antiviral vaccine that is capable of eliciting the antigen-specific activation of the cell-mediated and humoral immune responses.	[Khan, Masood Alam; Khan, Arif] Qassim Univ, Coll Appl Med Sci, Dept Basic Hlth Sci, Buraydah 51452, Saudi Arabia		Khan, MA (通讯作者)，Qassim Univ, Coll Appl Med Sci, Dept Basic Hlth Sci, Buraydah 51452, Saudi Arabia.	a_khan@qu.edu.sa; 4140@qu.edu.sa	Khan, Masood A./G-9693-2011	Khan, Masood A./0000-0003-4031-4189; Khan, Arif/0000-0002-4528-2668	Deanship of Scientific Research, Qassim University [5575-cams1-2019-2-2-I]	The authors would like to thank the Deanship of Scientific Research, Qassim University for the Grant # 5575-cams1-2019-2-2-I to Masood A. Khan.	Ahmad N, 2001, EUR J BIOCHEM, V268, P5667, DOI 10.1046/j.0014-2956.2001.02507.x; Ajuebor MN, 2007, AM J PHYSIOL-GASTR L, V293, pG651, DOI 10.1152/ajpgi.00298.2007; Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903; Albacker LA, 2013, NAT MED, V19, P1297, DOI 10.1038/nm.3321; Artiaga BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37999; Artiaga BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23593; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Berzins SP, 2011, NAT REV IMMUNOL, V11, P131, DOI 10.1038/nri2904; Blom RAM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163539; Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; Brown LCW, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001610; Broxmeyer HE, 2007, EXP HEMATOL, V35, P87, DOI 10.1016/j.exphem.2007.01.015; Brunel F, 1999, VACCINE, V17, P2192, DOI 10.1016/S0264-410X(98)00492-7; Brutkiewicz RR, 2006, J IMMUNOL, V177, P769, DOI 10.4049/jimmunol.177.2.769; Brutkiewicz RR, 2016, J IMMUNOL, V197, P2971, DOI 10.4049/jimmunol.1600460; Brutkiewicz RR, 2003, CRIT REV IMMUNOL, V23, P403, DOI 10.1615/CritRevImmunol.v23.i56.30; Chen N, 2006, EUR J IMMUNOL, V36, P278, DOI 10.1002/eji.200535487; Cho S, 2005, VIROLOGY, V337, P242, DOI 10.1016/j.virol.2005.04.020; Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105; Courtney AN, 2009, VACCINE, V27, P3335, DOI 10.1016/j.vaccine.2009.01.083; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; De Santo C, 2008, J CLIN INVEST, V118, P4036, DOI 10.1172/JCI36264; Dhakal S, 2017, J CONTROL RELEASE, V247, P194, DOI 10.1016/j.jconrel.2016.12.039; Dhodapkar MV, 2017, J IMMUNOL, V198, P1015, DOI 10.4049/jimmunol.1601399; Diana J, 2009, IMMUNITY, V30, P289, DOI 10.1016/j.immuni.2008.12.017; Dolen Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1068493; Driver JP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02172; Dwivedi V, 2016, VET MICROBIOL, V186, P157, DOI 10.1016/j.vetmic.2016.02.028; East JE, 2014, MED RES REV, V34, P45, DOI 10.1002/med.21276; Exley MA, 2001, J LEUKOCYTE BIOL, V69, P713; Fernandez CS, 2014, IMMUNOL CELL BIOL, V92, P578, DOI 10.1038/icb.2014.25; Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Fujii SI, 2006, P NATL ACAD SCI USA, V103, P11252, DOI 10.1073/pnas.0604812103; Galli G, 2003, J EXP MED, V197, P1051, DOI 10.1084/jem.20021616; Godfrey DI, 2010, NAT IMMUNOL, V11, P197, DOI 10.1038/ni.1841; Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407; Grubor-Bauk B, 2003, J IMMUNOL, V170, P1430, DOI 10.4049/jimmunol.170.3.1430; Gu PF, 2019, MOL PHARMACEUT, V16, P5000, DOI 10.1021/acs.molpharmaceut.9b00860; Guo HC, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-108; He Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113690; Ho LP, 2008, EUR J IMMUNOL, V38, P1913, DOI 10.1002/eji.200738017; Hobbs JA, 2001, J VIROL, V75, P10746, DOI 10.1128/JVI.75.22.10746-10754.2001; Huang YX, 2008, VACCINE, V26, P1807, DOI 10.1016/j.vaccine.2008.02.002; Inoue J, 2009, J CONTROL RELEASE, V133, P18, DOI 10.1016/j.jconrel.2008.09.078; Iyer AK, 2015, IMMUNOLOGY, V146, P444, DOI 10.1111/imm.12521; Jin Z, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118731; Johnson TR, 2002, J VIROL, V76, P4294, DOI 10.1128/JVI.76.9.4294-4303.2002; Joseph A, 2006, VACCINE, V24, P3990, DOI 10.1016/j.vaccine.2005.12.017; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Khan AA, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205-020-2144-3; Khan MA, 2005, FEMS IMMUNOL MED MIC, V44, P269, DOI 10.1016/j.femsim.2004.12.013; Khan MA, 2018, J DRUG TARGET, V26, P709, DOI 10.1080/1061186X.2018.1424857; Kok WL, 2012, J LEUKOCYTE BIOL, V91, P357, DOI 10.1189/jlb.0411184; Kovats S, 2016, CLIN EXP IMMUNOL, V186, P214, DOI 10.1111/cei.12850; Kulkarni RR, 2010, J LEUKOCYTE BIOL, V88, P635, DOI 10.1189/jlb.0410191; Kumari S, 2021, APL BIOENG, V5, DOI 10.1063/5.0029486; Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890; Lepore M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4866; Levy O, 2003, J INFECT DIS, V188, P948, DOI 10.1086/378503; Lin YL, 2005, EUR J IMMUNOL, V35, P879, DOI 10.1002/eji.200425495; Liu JY, 2019, EUR J IMMUNOL, V49, P255, DOI 10.1002/eji.201847755; Liu JY, 2013, IMMUNOLOGY, V140, P191, DOI 10.1111/imm.12127; Liu QF, 2015, J MED VIROL, V87, P1807, DOI 10.1002/jmv.24253; Liu Z, 2017, CARBOHYD RES, V452, P78, DOI 10.1016/j.carres.2017.10.006; Locci M, 2009, J EXP MED, V206, P735, DOI 10.1084/jem.20081773; Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113; Mehrabi M, 2018, Arch Razi Inst, V73, P165, DOI 10.22092/ari.2017.109235.1101; Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712; Mureithi MW, 2011, AIDS RES HUM RETROV, V27, P501, DOI 10.1089/aid.2010.0237; Neumann S, 2015, VACCINE, V33, P5838, DOI 10.1016/j.vaccine.2015.08.083; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; Paget C, 2011, J IMMUNOL, V186, P5590, DOI 10.4049/jimmunol.1002348; Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011; Parekh VV, 2009, J IMMUNOL, V182, P2816, DOI 10.4049/jimmunol.0803648; Pegu A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9447; Peralbo E, 2007, EXP GERONTOL, V42, P703, DOI 10.1016/j.exger.2007.05.002; Rao P, 2011, J VIROL, V85, P8093, DOI 10.1128/JVI.02689-10; Reantragoon R, 2013, J EXP MED, V210, P2305, DOI 10.1084/jem.20130958; Renukaradhya GJ, 2005, J IMMUNOL, V175, P4301, DOI 10.4049/jimmunol.175.7.4301; Renukaradhya GJ, 2011, J CLIN IMMUNOL, V31, P228, DOI 10.1007/s10875-010-9476-4; Renukaradhya GJ, 2008, J VIROL, V82, P12535, DOI 10.1128/JVI.00881-08; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Salio M, 2014, ANNU REV IMMUNOL, V32, P323, DOI 10.1146/annurev-immunol-032713-120243; Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002; Schafer A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01380; Sei JJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00553; Singh AK, 2014, HUM IMMUNOL, V75, P250, DOI 10.1016/j.humimm.2013.12.004; Singh D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01152; Sriram V, 2005, EUR J IMMUNOL, V35, P1692, DOI 10.1002/eji.200526157; Syed FM, 2003, VACCINE, V21, P2383, DOI 10.1016/S0264-410X(03)00106-3; Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218; Tao WQ, 2015, VACCINE, V33, P2307, DOI 10.1016/j.vaccine.2015.03.063; Tefit JN, 2014, VACCINE, V32, P6138, DOI 10.1016/j.vaccine.2014.08.070; Terrazzano G, 2020, NAT METAB, V2, P142, DOI 10.1038/s42255-020-0173-1; Thapa P, 2009, VACCINE, V27, P3484, DOI 10.1016/j.vaccine.2009.01.047; Tyznik AJ, 2008, J IMMUNOL, V181, P4452, DOI 10.4049/jimmunol.181.7.4452; Uldrich AP, 2011, NAT IMMUNOL, V12, P616, DOI 10.1038/ni.2051; van Dommelen SLH, 2003, J VIROL, V77, P1877, DOI 10.1128/JVI.77.3.1877-1884.2003; Villanueva AI, 2015, INNATE IMMUN-LONDON, V21, P275, DOI 10.1177/1753425914527327; von Gerichten J, 2017, J LIPID RES, V58, P1247, DOI 10.1194/jlr.D076190; Wang XF, 2013, J VIRAL HEPATITIS, V20, P27, DOI 10.1111/jvh.12061; Wu CY, 2010, CLIN EXP IMMUNOL, V162, P178, DOI 10.1111/j.1365-2249.2010.04233.x; Yuan WM, 2006, NAT IMMUNOL, V7, P835, DOI 10.1038/ni1364; Zeissig S, 2012, NAT MED, V18, P1060, DOI 10.1038/nm.2811; Zingaropoli MA, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108630	109	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							949	10.3390/vaccines9090949			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YP	34579186	Green Published, gold			2022-04-29	WOS:000702076200001
J	Pan, N; Liu, BH; Bao, XM; Zhang, HC; Sheng, SX; Liang, YC; Pan, HT; Wang, X				Pan, Na; Liu, Bohui; Bao, Xuemei; Zhang, Haochi; Sheng, Shouxin; Liang, Yanchen; Pan, Haiting; Wang, Xiao			Oral Delivery of Novel Recombinant Lactobacillus Elicit High Protection against Staphylococcus aureus Pulmonary and Skin Infections	VACCINES			English	Article						Staphylococcus aureus; oral vaccine; Lactobacillus; mucosal delivery	DELTA T-CELLS; MUCOSAL IMMUNE-RESPONSE; INTRANASAL IMMUNIZATION; PASSIVE-IMMUNIZATION; LACTOCOCCUS-LACTIS; BACILLUS-ANTHRACIS; ALPHA-HEMOLYSIN; VACCINE; ANTIGEN; EXPRESSION	Staphylococcus aureus is a leading cause of nosocomial and community-associated infection worldwide; however, there is no licensed vaccine available. S. aureus initiates infection via the mucosa; therefore, a mucosal vaccine is likely to be a promising approach against S. aureus infection. Lactobacilli, a non-pathogenic bacterium, has gained increasing interest as a mucosal delivery vehicle. Hence, we attempted to develop an oral S. aureus vaccine based on lactobacilli to cushion the stress of drug resistance and vaccine needs. In this study, we designed, constructed, and evaluated recombinant Lactobacillus strains synthesizing S. aureus nontoxic mutated alpha-hemolysins (Hla(H35L)). The results from animal clinical trials showed that recombinant Lactobacillus can persist for at least 72 h and can stably express heterologous protein in vivo. Recombinant L. plantarum WXD234 (pNZ8148-Hla) could induce robust mucosal immunity in the GALT, as evidenced by a significant increase in IgA and IL-17 production and the strong proliferation of T-lymphocytes derived from Peyer's patches. WXD234 (pNZ8148-Hla) conferred up to 83% protection against S. aureus pulmonary infection and significantly reduced the abscess size in a S. aureus skin infection model. Of particular interest is the sharp reduction of the protective effect offered by WXD234 (pNZ8148-Hla) vaccination in gamma delta T cell-deficient or IL-17-deficient mice. In conclusion, for the first time, genetically engineered Lactobacillus WXD234 (pNZ8148-Hla) as an oral vaccine induced superior mucosal immunity, which was associated with high protection against pulmonary and skin infections caused by S. aureus. Taken together, our findings suggest the great potential for a delivery system based on lactobacilli and provide experimental data for the development of mucosal vaccines for S. aureus.	[Pan, Na; Liu, Bohui; Bao, Xuemei; Zhang, Haochi; Sheng, Shouxin; Liang, Yanchen; Pan, Haiting; Wang, Xiao] Inner Mongolia Univ, State Key Lab Reprod Regulat & Breeding Grassland, Hohhot 010070, Peoples R China; [Pan, Haiting] Inner Mongolia Med Univ, Basic Med Coll, Hohhot 010110, Peoples R China		Wang, X (通讯作者)，Inner Mongolia Univ, State Key Lab Reprod Regulat & Breeding Grassland, Hohhot 010070, Peoples R China.	22008032@mail.imu.edu.cn; 31808136@mail.imu.edu.cn; 31908096@mail.imu.edu.cn; 21908028@mail.imu.edu.cn; shouxins1230@mail.imu.edu.cn; yanchenliang@mail.imu.edu.cn; 131985999@imu.edu.cn; wangxiao@imu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32060800, 31660706]; Science and Technology Major Project of the Inner Mongolia Autonomous Region of China; State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock [2019ZD031, zdzx2018065]	This work was supported by the National Natural Science Foundation of China (grant numbers 32060800 and 31660706). This study is supported by the Science and Technology Major Project of the Inner Mongolia Autonomous Region of China to the State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock (grant numbers 2019ZD031 and zdzx2018065).	Aktas B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156374; Ansari S, 2019, INFECT DRUG RESIST, V12, P1243, DOI 10.2147/IDR.S175014; Avtushenko SS, 1996, J BIOTECHNOL, V44, P21, DOI 10.1016/0168-1656(95)00105-0; Bagnoli F, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00016; Bedoya SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/986789; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Castagliuolo I, 2006, VACCINE, V24, P4393, DOI 10.1016/j.vaccine.2006.02.055; Cheng P, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-38; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Chumakov K, 2007, NAT REV MICROBIOL, V5, P952, DOI 10.1038/nrmicro1769; Dillen CA, 2018, J CLIN INVEST, V128, P1026, DOI 10.1172/JCI96481; Duwat P, 2000, INT J FOOD MICROBIOL, V55, P83, DOI 10.1016/S0168-1605(00)00179-3; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Gao XW, 2019, VIRULENCE, V10, P166, DOI 10.1080/21505594.2019.1582975; GARCIA VE, 1994, FEMS IMMUNOL MED MIC, V9, P55, DOI 10.1016/0928-8244(94)90081-7; Guglielmotti DM, 2007, INT DAIRY J, V17, P916, DOI 10.1016/j.idairyj.2006.11.004; Han Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020299; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ho PS, 2005, VACCINE, V23, P1335, DOI 10.1016/j.vaccine.2004.09.015; Holtmeier W, 2003, CRIT REV IMMUNOL, V23, P473; Hong SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100499; Irene C, 2019, P NATL ACAD SCI USA, V116, P21780, DOI 10.1073/pnas.1905112116; Kennedy AD, 2010, J INFECT DIS, V202, P1050, DOI 10.1086/656043; Kidd Parris, 2003, Altern Med Rev, V8, P223; Kim SR, 2007, J IMMUNOL, V179, P6820, DOI 10.4049/jimmunol.179.10.6820; Lalor SJ, 2016, TRENDS IMMUNOL, V37, P690, DOI 10.1016/j.it.2016.07.006; LAZZELL V, 1984, J BIOL STAND, V12, P315, DOI 10.1016/S0092-1157(84)80012-8; Lee AS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.33; Licciardi PV, 2011, DISCOV MED, V12, P525; Longini IM, 2007, PLOS MED, V4, P1776, DOI 10.1371/journal.pmed.0040336; Lucero CA, 2009, VACCINE, V27, P5061, DOI 10.1016/j.vaccine.2009.06.055; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Ma ST, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0861-7; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mao RF, 2017, APPL MICROBIOL BIOT, V101, P3259, DOI 10.1007/s00253-017-8125-8; Mao RF, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0478-7; Maragkoudakis PA, 2006, INT DAIRY J, V16, P189, DOI 10.1016/j.idairyj.2005.02.009; Menzies BE, 1996, INFECT IMMUN, V64, P1839, DOI 10.1128/IAI.64.5.1839-1841.1996; MENZIES BE, 1994, INFECT IMMUN, V62, P1843, DOI 10.1128/IAI.62.5.1843-1847.1994; Mierau I, 2005, APPL MICROBIOL BIOT, V68, P705, DOI 10.1007/s00253-005-0107-6; Miller LS, 2020, FEMS MICROBIOL REV, V44, P123, DOI 10.1093/femsre/fuz030; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Mohamadzadeh M, 2009, P NATL ACAD SCI USA, V106, P4331, DOI 10.1073/pnas.0900029106; Narita K, 2008, FEMS IMMUNOL MED MIC, V52, P389, DOI 10.1111/j.1574-695X.2008.00384.x; O'Brien EC, 2019, TRENDS MOL MED, V25, P171, DOI 10.1016/j.molmed.2018.12.010; Oliveira MLS, 2006, MICROBES INFECT, V8, P1016, DOI 10.1016/j.micinf.2005.10.020; Pant N, 2006, J INFECT DIS, V194, P1580, DOI 10.1086/508747; Poquet I, 1998, J BACTERIOL, V180, P1904, DOI 10.1128/JB.180.7.1904-1912.1998; Proctor RA, 2012, CLIN INFECT DIS, V54, P1179, DOI 10.1093/cid/cis033; Quan FS, 2012, VACCINE, V30, P180, DOI 10.1016/j.vaccine.2011.11.028; Ravn P, 2000, GENE, V242, P347, DOI 10.1016/S0378-1119(99)00530-2; Romagnani S, 1999, INFLAMM BOWEL DIS, V5, P285, DOI 10.1097/00054725-199911000-00009; Scully IL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00109; Seegers JFML, 2002, TRENDS BIOTECHNOL, V20, P508, DOI 10.1016/S0167-7799(02)02075-9; Seo SU, 2012, VACCINE, V30, P6816, DOI 10.1016/j.vaccine.2012.09.015; Shaw DM, 2000, IMMUNOLOGY, V100, P510, DOI 10.1046/j.1365-2567.2000.00069.x; Sisto A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100635; Song BF, 2014, APPL ENVIRON MICROB, V80, P3321, DOI 10.1128/AEM.00175-14; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Song XY, 2016, CELL MOL IMMUNOL, V13, P418, DOI 10.1038/cmi.2015.105; Su YT, 2017, J ANIM SCI BIOTECHNO, V8, DOI 10.1186/s40104-017-0183-3; Sun HW, 2015, INT J NANOMED, V10, P7275, DOI 10.2147/IJN.S91529; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; VanCott JL, 1996, J IMMUNOL, V156, P1504; VIDGREN G, 1992, J BACTERIOL, V174, P7419, DOI 10.1128/jb.174.22.7419-7427.1992; Wang XN, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110312; Wardenburg JB, 2008, J EXP MED, V205, P287, DOI 10.1084/jem.20072208; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Xiu L, 2020, INT J BIOL MACROMOL, V161, P10, DOI 10.1016/j.ijbiomac.2020.06.005; Yu ML, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100274; Zegers ND, 1999, J APPL MICROBIOL, V87, P309, DOI 10.1046/j.1365-2672.1999.00900.x; Zhang QX, 2010, BIOTECHNOL LETT, V32, P1271, DOI 10.1007/s10529-010-0285-x; Zhang Y, 2014, ADV EXP MED BIOL, V841, P15, DOI 10.1007/978-94-017-9487-9_2; Zhang ZW, 2018, APPL MICROBIOL BIOT, V102, P8135, DOI 10.1007/s00253-018-9217-9; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	78	1	1	10	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							984	10.3390/vaccines9090984			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3HB	34579221	Green Published, gold			2022-04-29	WOS:000702098300001
J	Shallal, A; Abada, E; Musallam, R; Fehmi, O; Kaljee, L; Fehmi, Z; Alzouhayli, S; Ujayli, D; Dankerlui, D; Kim, S; Cote, ML; Kumar, VA; Zervos, M; Ali-Fehmi, R				Shallal, Anita; Abada, Evi; Musallam, Rami; Fehmi, Omar; Kaljee, Linda; Fehmi, Ziad; Alzouhayli, Suma; Ujayli, Deema; Dankerlui, Doreen; Kim, Seongho; Cote, Michele L.; Kumar, Vijaya Arun; Zervos, Marcus; Ali-Fehmi, Rouba			Evaluation of COVID-19 Vaccine Attitudes among Arab American Healthcare Professionals Living in the United States	VACCINES			English	Article						COVID-19; vaccine hesitancy; vaccine confidence; vaccine attitudes; Arab Americans		Background: Vaccine hesitancy is the next great barrier for public health. Arab Americans are a rapidly growing demographic in the United States with limited information on the prevalence of vaccine hesitancy. We therefore sought to study the attitudes towards the coronavirus disease 2019 (COVID-19) vaccine amongst Arab American health professionals living in the United States. Methods: This was a cross sectional study utilizing an anonymous online survey. The survey was distributed via e-mail to National Arab American Medical Association members and Arab-American Center for Economic and Social Services healthcare employees. Respondents were considered vaccine hesitant if they selected responses other than a willingness to receive the COVID-19 vaccine. Results: A total of 4000 surveys were sent via e-mail from 28 December 2020 to 31 January 2021, and 513 responses were received. The highest group of respondents were between the ages of 18-29 years and physicians constituted 48% of the respondents. On multivariable analysis, we found that respondents who had declined an influenza vaccine in the preceding 5 years (p < 0.001) and allied health professionals (medical assistants, hospital administrators, case managers, researchers, scribes, pharmacists, dieticians and social workers) were more likely to be vaccine hesitant (p = 0.025). In addition, respondents earning over $150,000 US dollars annually were less likely to be vaccine hesitant and this finding was significant on multivariable analysis (p = 0.011). Conclusions: Vaccine hesitancy among health care providers could have substantial impact on vaccine attitudes of the general population, and such data may help inform vaccine advocacy efforts.	[Shallal, Anita; Zervos, Marcus] Henry Ford Hosp, Div Infect Dis, 2799 W Grand Blvd,CFP 303, Detroit, MI 48202 USA; [Abada, Evi; Ali-Fehmi, Rouba] Wayne State Univ, Dept Pathol, Detroit Med Ctr, Sch Med, 3990 John R Rd, Detroit, MI 48201 USA; [Musallam, Rami; Alzouhayli, Suma] Wayne State Univ, Sch Med, 4201 St Antoine, Detroit, MI 48201 USA; [Fehmi, Omar; Fehmi, Ziad] Univ Michigan, Coll Literature Sci & Arts, 101 N Main St, Ann Arbor, MI 48104 USA; [Kaljee, Linda; Dankerlui, Doreen] Henry Ford Hlth Syst, Global Hlth Initiat, One Ford Pl,1E, Detroit, MI 48202 USA; [Ujayli, Deema] Michigan State Univ, Coll Human Med, 965 Fee Rd A110, E Lansing, MI 48824 USA; [Kim, Seongho] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Biostat Core,Sch Med, 4100 John R St, Detroit, MI 48201 USA; [Cote, Michele L.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Populat Sci & Dispar Res,Sch Med, 4100 John R Rd, Detroit, MI 48201 USA; [Kumar, Vijaya Arun] Wayne State Univ, Dept Emergency Med, Sch Med, Detroit Med Ctr, 3990 John R Rd, Detroit, MI 48201 USA		Ali-Fehmi, R (通讯作者)，Wayne State Univ, Dept Pathol, Detroit Med Ctr, Sch Med, 3990 John R Rd, Detroit, MI 48201 USA.	ashalla2@hfhs.org; gs5839@wayne.edu; rami.musallam@wayne.edu; ofehmi@umich.edu; lkaljee1@hfhs.org; zfehmi@umich.edu; suma.alzouhayli95@gmail.com; ujaylide@msu.edu; ddanker1@hfhs.org; kimse@karmanos.org; cotem@karmanos.org; vkumar@med.wayne.edu; mzervos1@hfhs.org; rali@med.wayne.edu		Shallal, Anita/0000-0002-1940-3622; Kim, Seongho/0000-0003-1120-073X; Abada, Evi/0000-0001-5061-2687			Abboud S, 2017, ONCOL NURS FORUM, V44, pE20, DOI 10.1188/17.ONF.E20-E33; Abu-Farha R, 2021, SAUDI PHARM J, V29, P734, DOI 10.1016/j.jsps.2021.05.005; Alwahaibi N, 2020, J INFECT DEV COUNTR, V14, P1238, DOI 10.3855/jidc.13270; Arab Community Center for Economic and Social Services, 2021, ACCESS WEBS; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; Elhadi M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10987-3; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Grochowska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050475; Hargreaves AL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0783; He KD, 2022, J COMMUN HEALTH, V47, P39, DOI 10.1007/s10900-021-01017-9; Kaadan MI, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00202-6; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li M, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140195; Male V, 2021, NAT REV IMMUNOL, V21, P268, DOI 10.1038/s41577-021-00533-y; McAteer J, 2020, CLIN INFECT DIS, V71, P703, DOI 10.1093/cid/ciaa433; National Arab American Medical Association, 2021, NEXTGEN; National Arab American Medical Association, 2021, NAT AR AM MED ASS WE; Ojikutu BO, 2021, AM J PUBLIC HEALTH, V111, P366, DOI 10.2105/AJPH.2020.306087; Paris C, 2021, INFECT DIS NOW, V51, P484, DOI 10.1016/j.idnow.2021.04.001; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Quinn Sandra, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.3e4a5ea39d8620494e2a2c874a3c4201; Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Sun YF, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.664905; Swingle Christopher A, 2018, Mo Med, V115, P180; Toll M, 2021, VACCINE, V39, P751, DOI 10.1016/j.vaccine.2020.11.021; van Smeden M, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0267-3; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; World Health Oragnization, 2019, 10 THREATS GLOB HLTH; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	39	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							942	10.3390/vaccines9090942			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ2UV	34579179	gold, Green Published			2022-04-29	WOS:000702066300001
J	Caminati, M; Guarnieri, G; Batani, V; Scarpieri, E; Finocchiaro, A; Chieco-Bianchi, F; Senna, G; Vianello, A				Caminati, Marco; Guarnieri, Gabriella; Batani, Veronica; Scarpieri, Elena; Finocchiaro, Anita; Chieco-Bianchi, Fulvia; Senna, Gianenrico; Vianello, Andrea			COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control	VACCINES			English	Article						Pfizer mRNA SARS-CoV-2; COVID 19 vaccine; severe asthma; biologics; safety; tolerability; quality of life		Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient's quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.	[Caminati, Marco; Batani, Veronica; Scarpieri, Elena; Senna, Gianenrico] Univ Verona, Dept Med, I-37124 Verona, Italy; [Guarnieri, Gabriella; Chieco-Bianchi, Fulvia; Vianello, Andrea] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Resp Pathophysiol Div, I-35121 Padua, Italy; [Finocchiaro, Anita; Senna, Gianenrico] Univ Verona, Asthma Ctr, I-37124 Verona, Italy; [Finocchiaro, Anita; Senna, Gianenrico] Univ Verona, Allergy Unit, I-37124 Verona, Italy; [Finocchiaro, Anita; Senna, Gianenrico] Verona Univ Hosp, I-37124 Verona, Italy		Caminati, M (通讯作者)，Univ Verona, Dept Med, I-37124 Verona, Italy.	marco.caminati@univr.it; gabriella.guarnieri@unipd.it; veronica.batani@univr.it; elena.scarpieri@univr.it; anita.finocchiaro@aovr.veneto.it; fulvia.chiecobianchi@aopd.veneto.it; gianenrico.senna_01@univr.it; andrea.vianello.1@unipd.it	Senna, Gianenrico/AAC-6896-2022; Caminati, Marco/AAC-6302-2022	Caminati, Marco/0000-0001-7383-1487; Vianello, Andrea/0000-0002-8790-6029			Bhalla A, 2021, ALLERGY, V76, P957, DOI 10.1111/all.14534; Bijlsma JWJ, 2021, ANN RHEUM DIS, V80, P411, DOI 10.1136/annrheumdis-2020-219773; Blauvelt A, 2019, J AM ACAD DERMATOL, V80, P158, DOI 10.1016/j.jaad.2018.07.048; Caminati M, 2021, RESP MED, V176, DOI 10.1016/j.rmed.2020.106261; Caminati M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010038; Choi YJ, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.02226-2020; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Italian Society of Allergy and Clinical Immunology, POS STAT COVID 19 VA; Izquierdo JL, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03142-2020; Kelso JM, 2021, VACCINE, V39, P865, DOI 10.1016/j.vaccine.2020.12.084; Klimek L, 2021, ALLERGY, V76, P1624, DOI [10.1111/all.14726, 10.1007/s40629-021-00165-7]; Matucci A, 2021, ALLERGY, V76, P871, DOI 10.1111/all.14516; Morais-Almeida M, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100126; Pfaar O, 2021, ALLERGOLOGIE, V44, P261, DOI [10.5414/ALX02241, 10.5414/ALX02241E]; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Turner PJ, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100517; Woo EJ, 2021, VACCINE, V39, P1812, DOI 10.1016/j.vaccine.2021.02.052; Zeitlin PL, 2018, J ASTHMA ALLERGY, V11, P181, DOI 10.2147/JAA.S172338	18	8	8	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							853	10.3390/vaccines9080853			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5HE	34451978	Green Published, gold			2022-04-29	WOS:000689961000001
J	Chai, LF; Hardaway, JC; Heatherton, KR; O'Connell, KP; Lopes, MC; Rabinowitz, BA; Ghosh, CC; Guha, P; Jaroch, D; Cox, BF; Katz, SC				Chai, Louis F.; Hardaway, John C.; Heatherton, Kara R.; O'Connell, Kyle P.; Lopes, Mikayla C.; Rabinowitz, Benjamin A.; Ghosh, Chandra C.; Guha, Prajna; Jaroch, David; Cox, Bryan F.; Katz, Steven C.			Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity	VACCINES			English	Article						liver metastasis; regional delivery; PD-1; PD-L1; myeloid-derived suppressor cells; systemic delivery; bioluminescence	IMMUNE CHECKPOINT BLOCKADE; ISOLATED LUNG PERFUSION; OPEN-LABEL; UROTHELIAL CARCINOMA; ADVANCED MELANOMA; TUMOR RESPONSE; ADVERSE EVENTS; PHASE-I; NIVOLUMAB; PEMBROLIZUMAB	Metastatic liver tumors have presented challenges with the use of checkpoint inhibitors (CPIs), with only limited success. We hypothesize that regional delivery (RD) of CPIs can improve activity in the liver and minimize systemic exposure, thereby reducing immune-related adverse events (irAE). Using a murine model of colorectal cancer liver metastases (LM), we confirmed high levels of PD-L1 expression on the tumor cells and liver myeloid-derived suppressor cells (L-MDSC). In vivo, we detected improved LM response at 3 mg/kg on PTD7 via portal vein (PV) regional delivery as compared to 3 mg/kg via tail vein (TV) systemic delivery (p = 0.04). The minimal effective dose at PTD7 was 5 mg/kg (p = 0.01) via TV and 0.3 mg/kg (p = 0.02) via PV. We detected 6.7-fold lower circulating CPI antibody levels in the serum using the 0.3 mg/kg PV treatment compared to the 5 mg/kg TV cohort (p < 0.001) without increased liver toxicity. Additionally, 3 mg/kg PV treatment resulted in increased tumor cell apoptotic signaling compared to 5 mg/kg TV (p < 0.05). Therefore, RD of an anti-PD-1 CPI therapy for CRCLM may improve the therapeutic index by reducing the total dose required and limiting the systemic exposure. These advantages could expand CPI indications for liver tumors.	[Chai, Louis F.; Hardaway, John C.; Heatherton, Kara R.; O'Connell, Kyle P.; Lopes, Mikayla C.; Rabinowitz, Benjamin A.; Ghosh, Chandra C.; Guha, Prajna; Katz, Steven C.] Roger Williams Med Ctr, Immunooncol Inst, Providence, RI 02908 USA; [Guha, Prajna; Katz, Steven C.] Boston Univ, Med Ctr, Dept Surg, Boston, MA 02118 USA; [Jaroch, David; Cox, Bryan F.; Katz, Steven C.] TriSalusT Life Sci Inc, Westminster, CO 80031 USA; [Katz, Steven C.] Roger Williams Med Ctr, Dept Med, Providence, RI 02908 USA		Guha, P (通讯作者)，Roger Williams Med Ctr, Immunooncol Inst, Providence, RI 02908 USA.; Guha, P (通讯作者)，Boston Univ, Med Ctr, Dept Surg, Boston, MA 02118 USA.	louisfchai@gmail.com; jchardaway@gmail.com; kara.heatherton@chartercare.org; kyle.oconnell@chartercare.org; lopesmikayla@gmail.com; brabinowitz7@gmail.com; chandra.ghosh@chartercare.org; prajna.guha@chartercare.org; david.jaroch@trisaluslifesci.com; bryan.cox@trisaluslifesci.com; skatz@chartercare.org			TriSalus(TM) Life Sciences, Inc. (Westminster, CO, USA)	This research was funded by TriSalus (TM) Life Sciences, Inc. (Westminster, CO, USA) in part to support this research.	Agrawal S, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0177-2; Akbari O, 2010, MUCOSAL IMMUNOL, V3, P81, DOI 10.1038/mi.2009.112; Bajaj G, 2017, CPT-PHARMACOMET SYST, V6, P58, DOI 10.1002/psp4.12143; Bang YJ, 2019, GASTRIC CANCER, V22, P828, DOI 10.1007/s10120-018-00909-5; Bracco S, 2013, BRIT J OPHTHALMOL, V97, P1219, DOI 10.1136/bjophthalmol-2013-303267; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Burga RA, 2015, CANCER IMMUNOL IMMUN, V64, P817, DOI 10.1007/s00262-015-1692-6; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Centanni M, 2019, CLIN PHARMACOKINET, V58, P835, DOI 10.1007/s40262-019-00748-2; Chai LF, 2020, CANCER GENE THER, V27, P528, DOI 10.1038/s41417-019-0155-1; Chatterjee MS, 2017, CPT-PHARMACOMET SYST, V6, P29, DOI 10.1002/psp4.12140; COLLINS JM, 1984, J CLIN ONCOL, V2, P498, DOI 10.1200/JCO.1984.2.5.498; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; Das S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0805-8; Du XX, 2018, CELL RES, V28, P433, DOI 10.1038/s41422-018-0012-z; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Elassaiss-Schaap J, 2017, CPT-PHARMACOMET SYST, V6, P21, DOI 10.1002/psp4.12132; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Ferris R, 2017, NEW ENGL J MED, V376, P596, DOI 10.1056/NEJMc1615565; Fessas P, 2017, SEMIN ONCOL, V44, P136, DOI 10.1053/j.seminoncol.2017.06.002; Fu J, 2019, BIOANALYSIS, V11, P1347, DOI 10.4155/bio-2019-0090; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Goldstein DA, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx063; Grootenboers MJJH, 2006, PERFUSION-UK, V21, P267, DOI 10.1177/0267659106073984; Guha P, 2021, ONCOGENE, V40, P693, DOI 10.1038/s41388-020-01559-7; Guha P, 2019, ONCOGENE, V38, P533, DOI 10.1038/s41388-018-0449-z; Guha P, 2017, J LEUKOCYTE BIOL, V102, P201, DOI 10.1189/jlb.5HI0716-322RR; Gyorki DE, 2013, CLIN TRANSL IMMUNOL, V2, DOI 10.1038/cti.2013.5; Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang PY, 2016, ONCOTARGET, V7, P13060, DOI 10.18632/oncotarget.7421; Institute CR, 2020, TIMELINE PROGR TREAT, V2020; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; June CH, 2017, NAT MED, V23, P540, DOI 10.1038/nm.4321; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Katz SC, 2020, CANCER GENE THER, V27, P341, DOI 10.1038/s41417-019-0104-z; Katz SC, 2015, CLIN CANCER RES, V21, P3149, DOI 10.1158/1078-0432.CCR-14-1421; Khan Z, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0652-8; Kroon HM, 2019, ANN SURG ONCOL, V26, P8, DOI 10.1245/s10434-018-7067-4; Lee C.W., 2020, HLTH PROMOT CHRONIC, V40, P325; Li HS, 2017, J PHARMACOKINET PHAR, V44, P403, DOI 10.1007/s10928-017-9528-y; Liang MN, 2016, CYTOM PART B-CLIN CY, V90, P117, DOI 10.1002/cyto.b.21259; Liu FH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040847; Liu J, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.18; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mo HN, 2018, BRIT J CANCER, V119, P538, DOI 10.1038/s41416-018-0100-3; Ohyama C, 2019, INT J CLIN ONCOL, V24, P1089, DOI 10.1007/s10147-019-01450-w; Olson B, 2018, CANCER DISCOV, V8, P1358, DOI 10.1158/2159-8290.CD-18-0044; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Paulsen EE, 2017, CANCER IMMUNOL IMMUN, V66, P1449, DOI 10.1007/s00262-017-2039-2; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Renner A, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00142; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schrump DS, 2002, J THORAC CARDIOV SUR, V123, P686, DOI 10.1067/mtc.2002.120713; Sharma P, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.19.00538; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Sheng J, 2017, J CLIN PHARMACOL, V57, pS26, DOI 10.1002/jcph.990; Sridhar P, 2017, CANCERS, V9, DOI 10.3390/cancers9070092; SUGARBAKER PH, 1990, PROG CLIN BIOL RES, V354, P141; SUGARBAKER PH, 1985, SURGERY, V98, P414; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Theofilopoulos AN, 2017, NAT IMMUNOL, V18, P716, DOI 10.1038/ni.3731; Thorn M, 2016, CANCER GENE THER, V23, P188, DOI 10.1038/cgt.2016.19; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trinh S, 2019, ASIA-PAC J ONCOL NUR, V6, P154, DOI 10.4103/apjon.apjon_3_19; Uemura K, 2012, J INFECT CHEMOTHER, V18, P753, DOI 10.1007/s10156-011-0352-9; Vicente D, 2020, J CLIN ONCOL, V38; Wang J., 2016, MABS-AUSTIN, V11, P1443; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Xing PY, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0779-6; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zhao YH, 2018, CELL PHYSIOL BIOCHEM, V47, P721, DOI 10.1159/000490025	80	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							807	10.3390/vaccines9080807			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7HR	34451932	Green Published			2022-04-29	WOS:000690097500001
J	Farhang-Sardroodi, S; Korosec, CS; Gholami, S; Craig, M; Moyles, IR; Ghaemi, MS; Ooi, HK; Heffernan, JM				Farhang-Sardroodi, Suzan; Korosec, Chapin S.; Gholami, Samaneh; Craig, Morgan; Moyles, Iain R.; Ghaemi, Mohammad Sajjad; Ooi, Hsu Kiang; Heffernan, Jane M.			Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines	VACCINES			English	Article						adenovirus-based vaccine; SARS-CoV-2; COVID-19; adaptive immune response; neutralizing antibody (NAb); IgG antibody; mathematical modeling	IMMUNE	During the SARS-CoV-2 global pandemic, several vaccines, including mRNA and adenovirus vector approaches, have received emergency or full approval. However, supply chain logistics have hampered global vaccine delivery, which is impacting mass vaccination strategies. Recent studies have identified different strategies for vaccine dose administration so that supply constraints issues are diminished. These include increasing the time between consecutive doses in a two-dose vaccine regimen and reducing the dosage of the second dose. We consider both of these strategies in a mathematical modeling study of a non-replicating viral vector adenovirus vaccine in this work. We investigate the impact of different prime-boost strategies by quantifying their effects on immunological outcomes based on simple system of ordinary differential equations. The boost dose is administered either at a standard dose (SD) of 1000 or at a low dose (LD) of 500 or 250 vaccine particles. Results show dose-dependent immune response activity. Our model predictions show that by stretching the prime-boost interval to 18 or 20, in an SD/SD or SD/LD regimen, the minimum promoted antibody (Nab) response will be comparable with the neutralizing antibody level measured in COVID-19 recovered patients. Results also show that the minimum stimulated antibody in SD/SD regimen is identical with the high level observed in clinical trial data. We conclude that an SD/LD regimen may provide protective capacity, which will allow for conservation of vaccine doses.	[Farhang-Sardroodi, Suzan; Korosec, Chapin S.; Gholami, Samaneh; Heffernan, Jane M.] York Univ, Math Stat, Modelling Infect & Immun Lab, Toronto, ON M3J 1P3, Canada; [Farhang-Sardroodi, Suzan; Korosec, Chapin S.; Gholami, Samaneh; Moyles, Iain R.; Heffernan, Jane M.] York Univ, Math Stat, CDM, Toronto, ON M3J 1P3, Canada; [Craig, Morgan] Univ Montreal, Sainte Justine Univ Hosp Res Ctr, Montreal, PQ H3T 1J4, Canada; [Craig, Morgan] Univ Montreal, Dept Math & Stat, Montreal, PQ H3T 1J4, Canada; [Ghaemi, Mohammad Sajjad; Ooi, Hsu Kiang] Digital Technol Res Ctr, Natl Res Council Canada, Toronto, ON C1A 4P3, Canada		Farhang-Sardroodi, S; Heffernan, JM (通讯作者)，York Univ, Math Stat, Modelling Infect & Immun Lab, Toronto, ON M3J 1P3, Canada.; Farhang-Sardroodi, S; Heffernan, JM (通讯作者)，York Univ, Math Stat, CDM, Toronto, ON M3J 1P3, Canada.	suzanfa@yorku.ca; chapinskorosec@gmail.com; s.gh3495@gmail.com; morgan.craig@umontreal.ca; imoyles@yorku.ca; mghaemi@fields.utoronto.ca; hsukiang.ooi@nrc-cnrc.gc.ca; jmheffer@yorku.ca	FarhangSardroodi, Suzan/AAE-1393-2022	FarhangSardroodi, Suzan/0000-0001-7654-8804; Ooi, Hsu Kiang/0000-0001-7934-4866; Moyles, Iain/0000-0003-1127-4085; Korosec, Chapin/0000-0001-5137-2195; Craig, Morgan/0000-0003-4852-4770	NSERC Discovery GrantNatural Sciences and Engineering Research Council of Canada (NSERC) [ALLRP 554923-20]; NRC Pandemic Response Challenge Program [PR016-1]; CIHR-Fields COVID Immunity Task Force	This research is supported by NSERC Discovery Grant, NSERC COVID-19 Alliance Grant ALLRP 554923-20, CIHR-Fields COVID Immunity Task Force, NRC Pandemic Response Challenge Program Grant No. PR016-1.	AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Dong L, 2020, JAMA-J AM MED ASSOC, V323, P1846, DOI 10.1001/jama.2020.4621; Estrada E, 2020, PHYS REP, V869, P1, DOI 10.1016/j.physrep.2020.07.005; Geoffroy F., 2021, VACCINATION STRATEGI, DOI [10.1101/2021.05.04.21256623, DOI 10.1101/2021.05.04.21256623]; Gomero B., 2012, THESIS U TENNESSEE K; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th; Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lees JR, 2015, CYTOKINE, V74, P18, DOI 10.1016/j.cyto.2014.10.014; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; MILLER JFA, 1968, J EXP MED, V128, P801, DOI 10.1084/jem.128.4.801; Morris R, 2018, PROTEIN SCI, V27, P1984, DOI 10.1002/pro.3519; Nezlin, 1998, IMMUNOGLOBULINS STRU; Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647; Quinn KM, 2015, J CLIN INVEST, V125, P1129, DOI 10.1172/JCI78280; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Sanchez Sarah, 2021, bioRxiv, DOI 10.1101/2021.03.31.437931; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; Weyand C.M., 2019, CLIN IMMUNOLOGY, P235; Wu, 2020, DEFINITION RISKS CYT, DOI [10.1101/2020.02.26.20026989, 10.1101/2020.02.26. 20026989, DOI 10.1101/2020.02.26.20026989]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu F., 2020, medRxiv, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]; Wu JY, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.1018; Yang Y, 2020, MEDRXIV, DOI [10.1101/2020.02.11.20021493, 10.1101/2020.02.11.20021493v2, DOI 10.1101/2020.02.11.20021493]; Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92	41	0	0	5	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							861	10.3390/vaccines9080861			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7VC	34451985	Green Published, gold, Green Submitted			2022-04-29	WOS:000690132400001
J	Seesuay, W; Phanthong, S; Densumite, J; Mahasongkram, K; Sookrung, N; Chaicumpa, W				Seesuay, Watee; Phanthong, Siratcha; Densumite, Jaslan; Mahasongkram, Kodchakorn; Sookrung, Nitat; Chaicumpa, Wanpen			Human Transbodies to Reverse Transcriptase Connection Subdomain of HIV-1 Gag-Pol Polyprotein Reduce Infectiousness of the Virus Progeny	VACCINES			English	Article						human single-chain antibodies (HuscFvs); cell-penetrating antibodies (transbodies); human immunodeficiency virus 1 (HIV-1); reverse transcriptase connection subdomain (RTCD); Gag-Pol polyprotein	PROTEIN-STRUCTURE; PLASMA; AUTOINDUCTION; ANTIBODIES; ACCURACY; MODELS; SERVER; CXCR4; RNA	HIV-1 progeny are released from infected cells as immature particles that are unable to infect new cells. Gag-Pol polyprotein dimerization via the reverse transcriptase connection domain (RTCDs) is pivotal for proper activation of the virus protease (PR protein) in an early event of the progeny virus maturation process. Thus, the RTCD is a potential therapeutic target for a broadly effective anti-HIV agent through impediment of virus maturation. In this study, human single-chain antibodies (HuscFvs) that bound to HIV-1 RTCD were generated using phage display technology. Computerized simulation guided the selection of the transformed Escherichia coli-derived HuscFvs that bound to the RTCD dimer interface. The selected HuscFvs were linked molecularly to human-derived-cell-penetrating peptide (CPP) to make them cell-penetrable (i.e., become transbodies). The CPP-HuscFvs/transbodies produced by a selected transformed E. coli clone were tested for anti-HIV-1 activity. CPP-HuscFvs of transformed E. coli clone 11 (CPP-HuscFv11) that presumptively bound at the RTCD dimer interface effectively reduced reverse transcriptase activity in the newly released virus progeny. Infectiousness of the progeny viruses obtained from CPP-HuscFv11-treated cells were reduced by a similar magnitude to those obtained from protease/reverse transcriptase inhibitor-treated cells, indicating anti-HIV-1 activity of the transbodies. The CPP-HuscFv11/transbodies to HIV-1 RTCD could be an alternative, anti-retroviral agent for long-term HIV-1 treatment.	[Seesuay, Watee; Densumite, Jaslan] Mahidol Univ, Dept Immunol, Grad Program Immunol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand; [Seesuay, Watee; Densumite, Jaslan; Mahasongkram, Kodchakorn; Sookrung, Nitat; Chaicumpa, Wanpen] Mahidol Univ, Ctr Res Excellence Therapeut Prot & Antibody Engn, Dept Parasitol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand; [Phanthong, Siratcha; Sookrung, Nitat; Chaicumpa, Wanpen] Mahidol Univ, Dept Res, Ctr Excellent Res Allergy & Immunol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand; [Sookrung, Nitat] Mahidol Univ, Dept Res, Biomed Res Incubat Unit, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand		Chaicumpa, W (通讯作者)，Mahidol Univ, Ctr Res Excellence Therapeut Prot & Antibody Engn, Dept Parasitol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand.; Chaicumpa, W (通讯作者)，Mahidol Univ, Dept Res, Ctr Excellent Res Allergy & Immunol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand.	watee.see@student.mahidol.ac.th; siratcha.pha@mahidol.ac.th; jaslan.den@student.mahidol.ac.th; kodchakorn.mah@mahidol.ac.th; nitat.soo@mahidol.ac.th; wanpen.cha@mahidol.ac.th		Chaicumpa, Wanpen/0000-0001-6973-8255	Mahidol University; NSTDA Chair Professor Grant - Crown Property Bureau of Thailand [P-1450624]	The work was supported by Mahidol University and the NSTDA Chair Professor Grant funded by the Crown Property Bureau of Thailand (P-1450624) to W.C.	Abhinandan KR, 2008, MOL IMMUNOL, V45, P3832, DOI 10.1016/j.molimm.2008.05.022; Adolf-Bryfogle J, 2015, NUCLEIC ACIDS RES, V43, pD432, DOI 10.1093/nar/gku1106; Auewarakul P, 1996, VIRAL IMMUNOL, V9, P175, DOI 10.1089/vim.1996.9.175; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Blommel PG, 2007, BIOTECHNOL PROGR, V23, P585, DOI 10.1021/bp070011x; Brenke R, 2012, BIOINFORMATICS, V28, P2608, DOI 10.1093/bioinformatics/bts493; Chiang CC, 2012, VIROLOGY, V422, P278, DOI 10.1016/j.virol.2011.11.001; Chiang CC, 2009, VIROLOGY, V383, P261, DOI 10.1016/j.virol.2008.10.027; Chojnacki J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00515-6; Chu MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01858-2; Cunningham AL, 2010, CURR OPIN MICROBIOL, V13, P524, DOI 10.1016/j.mib.2010.06.002; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dereeper A, 2008, NUCLEIC ACIDS RES, V36, pW465, DOI 10.1093/nar/gkn180; Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80; Gilbert PB, 2003, STAT MED, V22, P573, DOI 10.1002/sim.1342; Grant AD, 2001, BRIT MED J, V322, P1475, DOI 10.1136/bmj.322.7300.1475; Gunthard HF, 2019, CLIN INFECT DIS, V68, P177, DOI 10.1093/cid/ciy463; Hong FYF, 2015, CURR OPIN HIV AIDS, V10, P43, DOI 10.1097/COH.0000000000000119; Julian MC, 2017, SCI REP-UK, V7, DOI 10.1038/srep45259; Sadiq SK, 2012, P NATL ACAD SCI USA, V109, P20449, DOI 10.1073/pnas.1210983109; Kim HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11719; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kulkeaw K, 2009, J PROTEOMICS, V72, P270, DOI 10.1016/j.jprot.2008.12.007; Leem J, 2016, MABS-AUSTIN, V8, P1259, DOI 10.1080/19420862.2016.1205773; Lehmann A, 2015, MABS-AUSTIN, V7, P1058, DOI 10.1080/19420862.2015.1088618; Li XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129559; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Mattei S, 2018, P NATL ACAD SCI USA, V115, pE9401, DOI 10.1073/pnas.1811237115; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; North B, 2011, J MOL BIOL, V406, P228, DOI 10.1016/j.jmb.2010.10.030; Penn ML, 1999, P NATL ACAD SCI USA, V96, P663, DOI 10.1073/pnas.96.2.663; Retter I, 2005, NUCLEIC ACIDS RES, V33, pD671, DOI 10.1093/nar/gki088; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Subbaraman R, 2007, CLIN INFECT DIS, V45, P1093, DOI 10.1086/521150; Sudo S, 2013, J VIROL, V87, P3348, DOI 10.1128/JVI.02306-12; Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924; Tachedjian G, 2001, P NATL ACAD SCI USA, V98, P7188, DOI 10.1073/pnas.121055998; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024; Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342; Yu FH, 2017, J VIROL, V91, DOI 10.1128/JVI.00103-17; Zhang J, 2011, STRUCTURE, V19, P1784, DOI 10.1016/j.str.2011.09.022; Zolfo M, 2011, AIDS RES HUM RETROV, V27, P727, DOI 10.1089/AID.2010.0037	43	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							893	10.3390/vaccines9080893			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4WL	34452018	Green Published, gold			2022-04-29	WOS:000689933100001
J	Si, YN; Zhang, Y; Guan, JS; Ngo, HG; Totoro, A; Singh, AP; Chen, K; Xu, YX; Yang, ES; Zhou, LF; Liu, RH; Liu, XG				Si, Yingnan; Zhang, Ya; Guan, Jia-Shiung; Ngo, Hanh Giai; Totoro, Angela; Singh, Ajeet Pal; Chen, Kai; Xu, Yuanxin; Yang, Eddy S.; Zhou, Lufang; Liu, Runhua; Liu, Xiaoguang (Margaret)			Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers	VACCINES			English	Article						triple-negative breast cancers; targeted therapy; CD47 receptor; monoclonal antibody; antibody-drug conjugate	SACITUZUMAB GOVITECAN; MEDIATED DESTRUCTION; CELLS; CD47; CHEMOTHERAPY; EXPRESSION; PHAGOCYTOSIS; HYPOXIA	Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated in chemotherapy-treated TNBC cells. The goal of this study was to develop a monoclonal antibody (mAb)-based targeting strategy to treat TNBC after standard treatment. Specifically, a new mAb that targets the extracellular domain of receptor CD47 was developed using hybridoma technology and produced in fed-batch culture. Flow cytometry, confocal microscopy, and in vivo imaging system (IVIS) showed that the anti-CD47 mAb effectively targeted human and mouse TNBC cells and xenograft models with high specificity. The antibody-drug conjugate (ADC) carrying mertansine was constructed and demonstrated higher potency with reduced IC50 in TNBC cells than did the free drug and significantly inhibited tumor growth post gemcitabine treatment in MDA-MB-231 xenograft NSG model. Finally, whole blood analysis indicated that the anti-CD47 mAb had no general immune toxicity, flow cytometry analysis of lymph nodes revealed an increase of CD69(+) NK, CD11c(+) DC, and CD4(+) T cells, and IHC staining showed tumoral infiltration of macrophage in the 4T1 xenograft BALB/cJ model. This study demonstrated that targeting CD47 with ADC has great potential to treat TNBCs as a targeted therapy.	[Si, Yingnan; Zhang, Ya; Guan, Jia-Shiung; Ngo, Hanh Giai; Totoro, Angela; Singh, Ajeet Pal; Chen, Kai; Zhou, Lufang; Liu, Xiaoguang (Margaret)] Univ Alabama Birmingham UAB, Dept Biomed Engn, 1825 Univ Blvd, Birmingham, AL 35294 USA; [Xu, Yuanxin; Zhou, Lufang] Univ Alabama Birmingham UAB, Dept Med, 703 19th St South, Birmingham, AL 35294 USA; [Yang, Eddy S.] Univ Alabama Birmingham UAB, Dept Radiat Oncol, 1808 7th Ave South, Birmingham, AL 35294 USA; [Yang, Eddy S.; Liu, Xiaoguang (Margaret)] Univ Alabama Birmingham UAB, O Neal Comprehens Canc Ctr, 1824 6th Ave South, Birmingham, AL 35233 USA; [Liu, Runhua] Univ Alabama Birmingham UAB, Dept Genet, 702 20th St, Birmingham, AL 35233 USA		Liu, XG (通讯作者)，Univ Alabama Birmingham UAB, Dept Biomed Engn, 1825 Univ Blvd, Birmingham, AL 35294 USA.; Liu, XG (通讯作者)，Univ Alabama Birmingham UAB, O Neal Comprehens Canc Ctr, 1824 6th Ave South, Birmingham, AL 35233 USA.	yingnan@uab.edu; yazhang9@uab.edu; guan0926@uab.edu; hanh96@uab.edu; angmshel@uab.edu; ajeeetts@uab.edu; kaisdzb@uab.edu; yuanxin8@uab.edu; shyang@uabmc.edu; lfzhou@uab.edu; runhua@uab.edu; mliu@uab.edu	Si, Yingnan/ABB-7587-2021	Si, Yingnan/0000-0002-4569-8057; Liu, Xiaoguang (Margaret)/0000-0002-4617-9750	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01CA238273-01A1, 1R01CA242917-01A1]	This research was funded by the National Institute of Health (NIH) 1R01CA238273-01A1 and 1R01CA242917-01A1.	Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3; Almasbak H, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5474602; Bardia A, 2021, NEW ENGL J MED, V384, P1529, DOI 10.1056/NEJMoa2028485; Bardia A, 2019, NEW ENGL J MED, V380, P741, DOI 10.1056/NEJMoa1814213; Campbell KJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0035-2; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Cheung A, 2018, CLIN CANCER RES, V24, P5098, DOI 10.1158/1078-0432.CCR-18-0652; Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798; Dai HR, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv439; De Vita A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84492-3; Flynn JF, 2009, J ONCOL, V2009, DOI 10.1155/2009/526963; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Frontera ED, 2018, BREAST CANCER RES TR, V172, P551, DOI 10.1007/s10549-018-4941-5; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gautam M, 2020, EXPERT OPIN DRUG DEL, V17, P423, DOI 10.1080/17425247.2020.1727442; Huang YT, 2017, J THORAC DIS, V9, pE168, DOI 10.21037/jtd.2017.02.30; Inao Touko, 2018, Oncotarget, V9, P25545, DOI 10.18632/oncotarget.25370; Kershaw MH, 2013, SCIENCE, V341, P41, DOI 10.1126/science.1241716; Khan AQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080840; Kunert R, 2016, APPL MICROBIOL BIOT, V100, P3451, DOI 10.1007/s00253-016-7388-9; Lebert JM, 2018, CURR ONCOL, V25, pS142, DOI 10.3747/co.25.3954; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Magee MS, 2014, DISCOV MED, V18, P265; Mahmood NA, 2018, INT J MOL CELL MED, V7, P234, DOI 10.22088/IJMCM.BUMS.7.4.234; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Marra A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1326-5; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; McGuinness JE, 2021, EXPERT OPIN BIOL TH, V21, P903, DOI 10.1080/14712598.2021.1840547; Molinaro R, 2020, BIOMATER SCI-UK, V8, P333, DOI 10.1039/c9bm01766f; Nedeljkovic M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090957; Nigro A, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03135; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Ou JF, 2019, J BIOL ENG, V13, DOI 10.1186/s13036-019-0167-2; Ou JF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206246; Polakis P, 2016, PHARMACOL REV, V68, P3, DOI 10.1124/pr.114.009373; Romero D, 2019, NAT REV CLIN ONCOL, V16, P6, DOI 10.1038/s41571-018-0127-7; Samanta D, 2018, P NATL ACAD SCI USA, V115, pE1239, DOI 10.1073/pnas.1718197115; Seaman S, 2017, CANCER CELL, V31, P501, DOI 10.1016/j.ccell.2017.03.005; Seligson JM, 2021, ANN PHARMACOTHER, V55, P921, DOI 10.1177/1060028020966548; Shibata M, 2019, CANCERS, V11, DOI 10.3390/cancers11050732; Si YN, 2021, CHINESE J CHEM ENG, V30, P301, DOI 10.1016/j.cjche.2020.11.009; Si YN, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111079; Si YN, 2021, ENG LIFE SCI, V21, P37, DOI 10.1002/elsc.202000027; Si YN, 2021, CANCER GENE THER, V28, P799, DOI 10.1038/s41417-020-0196-5; Si YN, 2020, BIOTECHNOL J, V15, DOI 10.1002/biot.201900163; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sissung TM, 2010, MOL BIOTECHNOL, V44, P152, DOI 10.1007/s12033-009-9220-6; Vaupel P, 2008, ONCOLOGIST, V13, P21, DOI 10.1634/theoncologist.13-S3-21; Wahby S, 2021, CLIN CANCER RES, V27, P1850, DOI 10.1158/1078-0432.CCR-20-3119; Wein L, 2017, BREAST, V34, pS27, DOI 10.1016/j.breast.2017.06.023; Weiskopf K, 2017, EUR J CANCER, V76, P100, DOI 10.1016/j.ejca.2017.02.013; Weiskopf K, 2016, J CLIN INVEST, V126, P2610, DOI 10.1172/JCI81603; Weiskopf K, 2013, SCIENCE, V341, P88, DOI 10.1126/science.1238856; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Xu NN, 2019, BIOCHEM ENG J, V145, P177, DOI 10.1016/j.bej.2019.02.022; Xu NN, 2015, FRONT CHEM SCI ENG, V9, P376, DOI 10.1007/s11705-015-1531-5; Yamada A, 2013, BREAST CANCER RES TR, V137, P773, DOI 10.1007/s10549-012-2398-5; Zhang BL, 2016, SCI CHINA LIFE SCI, V59, P340, DOI 10.1007/s11427-016-5027-4; Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112; Zhou LF, 2014, CANCER LETT, V352, P145, DOI 10.1016/j.canlet.2014.06.020; Zhu XD, 2019, CANCER BIOL THER, V20, P1105, DOI [10.1080/15384047.2018.1564566, 10.1080/15384047.2019.1595282]	64	3	3	7	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							882	10.3390/vaccines9080882			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3MS	34452008	gold, Green Published			2022-04-29	WOS:000689840200001
J	Hong, J; Choi, Y; Choi, Y; Lee, J; Hong, HJ				Hong, Jisu; Choi, Youngjin; Choi, Yoonjoo; Lee, Jiwoo; Hong, Hyo Jeong			Epitope-Paratope Interaction of a Neutralizing Human Anti-Hepatitis B Virus PreS1 Antibody That Recognizes the Receptor-Binding Motif	VACCINES			English	Article						hepatitis B virus; human monoclonal antibody; virus entry inhibitor; PreS1; epitope; paratope; receptor-binding motif	STRUCTURE PREDICTION; GENOTYPES; GENERATION; DIVERSITY; INFECTION; PROTEINS; DATABASE; ENTRY	Hepatitis B virus (HBV) is a global health burden that causes acute and chronic hepatitis. To develop an HBV-neutralizing antibody that effectively prevents HBV infection, we previously generated a human anti-preS1 monoclonal antibody (1A8) that binds to genotypes A-D and validated its HBV-neutralizing activity in vitro. In the present study, we aimed to determine the fine epitope and paratope of 1A8 to understand the mechanism of HBV neutralization. We performed alanine-scanning mutagenesis on the preS1 (aa 19-34, genotype C) and the heavy (HCDR) and light (LCDR) chain complementarity-determining regions. The 1A8 recognized the three residues (Leu22, Gly23, and Phe25) within the highly conserved receptor-binding motif (NPLGFFP) of the preS1, while four CDR residues of 1A8 were critical in antigen binding. Structural analysis of the epitope-paratope interaction by molecular modeling revealed that Leu100 in the HCDR3, Ala50 in the HCDR2, and Tyr96 in the LCDR3 closely interacted with Leu22, Gly23, and Phe25 of the preS1. Additionally, we found that 1A8 also binds to the receptor-binding motif (NPLGFLP) of infrequently occurring HBV. The results suggest that 1A8 may broadly and effectively block HBV entry and thus have potential as a promising candidate for the prevention and treatment of HBV infection.	[Hong, Jisu; Choi, Youngjin; Lee, Jiwoo; Hong, Hyo Jeong] Kangwon Natl Univ, Coll Biomed Sci, Dept Syst Immunol, Chunchon 24341, South Korea; [Choi, Yoonjoo] Chonnam Natl Univ, Med Res Ctr, Med Sch, Hwasun 58128, South Korea		Hong, HJ (通讯作者)，Kangwon Natl Univ, Coll Biomed Sci, Dept Syst Immunol, Chunchon 24341, South Korea.	ghdwltn55@kangwon.ac.kr; yoonjoo.choi@jnu.ac.kr; skdnaltmxk1@kangwon.ac.kr; snm04062@kangwon.ac.kr; hjhong@kangwon.ac.kr		Choi, Yoonjoo/0000-0001-9687-8093	Basic Science Research Program [NRF-2020R1A5A8019180]; Combinatorial Tumor Immunotherapy MRC grant [NRF-2020R1A5A2031185]	This research was funded by a Basic Science Research Program grant (NRF-2020R1A5A8019 180) to H.J.H. and a Combinatorial Tumor Immunotherapy MRC grant (NRF-2020R1A5A2031185) to Y.C.	BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; Choi Y, 2010, PROTEINS, V78, P1431, DOI 10.1002/prot.22658; Delgado J, 2019, BIOINFORMATICS, V35, P4168, DOI 10.1093/bioinformatics/btz184; Eke AC, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008545.pub2; Hayer J, 2013, NUCLEIC ACIDS RES, V41, pD566, DOI 10.1093/nar/gks1022; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Herrscher C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061486; Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123; Hu JM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9030056; Huang CF, 2006, CELL MOL IMMUNOL, V3, P97; Jo G, 2018, J MICROBIOL BIOTECHN, V28, P1376, DOI 10.4014/jmb.1803.03056; Katz LH, 2010, TRANSPL INFECT DIS, V12, P292, DOI 10.1111/j.1399-3062.2009.00470.x; Kim S, 2017, MOL CELLS, V40, P655, DOI 10.14348/molcells.2017.0106; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x; Kramvis A, 2014, INTERVIROLOGY, V57, P141, DOI 10.1159/000360947; Leem J, 2016, MABS-AUSTIN, V8, P1259, DOI 10.1080/19420862.2016.1205773; Lok ASF, 2002, NEW ENGL J MED, V346, P1682, DOI 10.1056/NEJM200205303462202; Maeng CY, 2001, BIOCHEM BIOPH RES CO, V282, P787, DOI 10.1006/bbrc.2001.4641; Maeng CY, 2000, VIROLOGY, V270, P9, DOI 10.1006/viro.2000.0250; Market E, 2003, PLOS BIOL, V1, P24, DOI 10.1371/journal.pbio.0000016; Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024; Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872; Rackers JA, 2018, J CHEM THEORY COMPUT, V14, P5273, DOI 10.1021/acs.jctc.8b00529; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; RHYUM SB, 1994, J BIOTECHNOL, V36, P221, DOI 10.1016/0168-1656(94)90153-8; Schatz DG, 2004, IMMUNOL REV, V200, P5, DOI 10.1111/j.0105-2896.2004.00173.x; Seto WK, 2018, LANCET, V392, P2313, DOI 10.1016/S0140-6736(18)31865-8; Shahmoradi S, 2012, J HEPATOL, V57, P515, DOI 10.1016/j.jhep.2012.04.021; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Sunbul M, 2014, WORLD J GASTROENTERO, V20, P5427, DOI 10.3748/wjg.v20.i18.5427; Tatematsu K, 2009, J VIROL, V83, P10538, DOI 10.1128/JVI.00462-09; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; Westland C, 2003, GASTROENTEROLOGY, V125, P107, DOI 10.1016/S0016-5085(03)00700-5; Wi J, 2017, J MICROBIOL BIOTECHN, V27, P1336, DOI 10.4014/jmb.1703.03066; Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049	36	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							754	10.3390/vaccines9070754			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7GS	34358170	gold, Green Published			2022-04-29	WOS:000677075700001
J	Offersgaard, A; Hernandez, CRD; Pihl, AF; Costa, R; Venkatesan, NP; Lin, XL; Pham, LV; Feng, S; Fahnoe, U; Scheel, TKH; Ramirez, S; Reichl, U; Bukh, J; Genzel, Y; Gottwein, JM				Offersgaard, Anna; Hernandez, Carlos Rene Duarte; Pihl, Anne Finne; Costa, Rui; Venkatesan, Nandini Prabhakar; Lin, Xiangliang; Long Van Pham; Feng, Shan; Fahnoe, Ulrik; Scheel, Troels Kasper Hoyer; Ramirez, Santseharay; Reichl, Udo; Bukh, Jens; Genzel, Yvonne; Gottwein, Judith Margarete			SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor	VACCINES			English	Article						severe acute respiratory syndrome coronavirus 2; COVID-19; scalable bioreactor; CelCradle; packed-bed; whole virus vaccine; inactivated vaccine; animal component-free; Vero cells	TEMPERATURE; VACCINES; PLATFORM; CULTURE; PH	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production in the scalable packed-bed CelCradle (TM) 500-AP bioreactor. CelCradle (TM) 500-AP bottles with 0.5 L working volume and 5.5 g BioNOC (TM) II carriers were seeded with 1.5 x 10(8) Vero (WHO) cells, approved for vaccine production, in animal component-free medium and infected at a multiplicity of infection of 0.006 at a total cell number of 2.22.5 x 10(9) cells/bottle seven days post cell seeding. Among several tested conditions, two harvests per day and a virus production temperature of 33 degrees C resulted in the highest virus yield with a peak SARS-CoV-2 infectivity titer of 7.3 log(10) 50% tissue culture infectious dose (TCID50)/mL at 72 h post-infection. Six harvests had titers of >= 6.5 log(10) TCID50/mL, and a total of 10.5 log(10) TCID50 were produced in similar to 5 L. While trypsin was reported to enhance virus spread in cell culture, addition of 0.5% recombinant trypsin after infection did not improve virus yields. Overall, we demonstrated successful animal component-free production of SARS-CoV-2 in well-characterized Vero (WHO) cells in a scalable packed-bed bioreactor.	[Offersgaard, Anna; Hernandez, Carlos Rene Duarte; Pihl, Anne Finne; Costa, Rui; Long Van Pham; Feng, Shan; Fahnoe, Ulrik; Scheel, Troels Kasper Hoyer; Ramirez, Santseharay; Bukh, Jens; Gottwein, Judith Margarete] Copenhagen Univ Hosp Hvidovre, Copenhagen Hepatitis C Program CO HEP, Dept Infect Dis, DK-2650 Hvidovre, Denmark; [Offersgaard, Anna; Hernandez, Carlos Rene Duarte; Pihl, Anne Finne; Costa, Rui; Long Van Pham; Feng, Shan; Fahnoe, Ulrik; Scheel, Troels Kasper Hoyer; Ramirez, Santseharay; Bukh, Jens; Gottwein, Judith Margarete] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen Hepatitis C Program CO HEP, DK-2200 Copenhagen, Denmark; [Venkatesan, Nandini Prabhakar; Lin, Xiangliang] Esco Aster Pte Ltd, Singapore 486777, Singapore; [Reichl, Udo; Genzel, Yvonne] Max Planck Inst Dynam Complex Tech Syst, Bioproc Engn, D-39106 Magdeburg, Germany		Gottwein, JM (通讯作者)，Copenhagen Univ Hosp Hvidovre, Copenhagen Hepatitis C Program CO HEP, Dept Infect Dis, DK-2650 Hvidovre, Denmark.; Gottwein, JM (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen Hepatitis C Program CO HEP, DK-2200 Copenhagen, Denmark.	anna.offersgaard@regionh.dk; carlos.rene.duarte.hernandez@regionh.dk; anne.finne.pihl@regionh.dk; rcosta@sund.ku.dk; nandini.prabhakar@escoaster.com; xl.lin@escoaster.com; pham@sund.ku.dk; sfeng@sund.ku.dk; ulrik@sund.ku.dk; tscheel@sund.ku.dk; santseharayra@sund.ku.dk; ureichl@mpi-magdeburg.mpg.de; jbukh@sund.ku.dk; genzel@mpi-magdeburg.mpg.de; jgottwein@sund.ku.dk	; Ramirez Almeida, Santseharay/R-9257-2016	Scheel, Troels/0000-0003-1545-4067; Bukh, Jens/0000-0002-7815-4806; Offersgaard, Anna/0000-0002-7748-2840; Marques da Costa, Rui Pedro/0000-0003-3048-6366; Fahnoe, Ulrik/0000-0002-2527-5751; Gottwein, Judith/0000-0003-2805-0256; Ramirez Almeida, Santseharay/0000-0003-3699-1814	Candys Foundation; Danish Agency for Science and Higher Education; Danish Cancer SocietyDanish Cancer Society; Hvidovre Hospital Research Foundation; Independent Research Fund Denmark (DFF) Medical Sciences; Innovation Fund Denmark; Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' Foundation; Mauritzen La Fontaine Fonden; Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited; Region H Foundation; Toyota Foundation; Weimann Foundation	This study was supported by grants from the Candys Foundation (A.O., A.F.P., L.V.P., J.B., J.M.G.), the Danish Agency for Science and Higher Education (S.R., J.B.), the Danish Cancer Society (J.B.), Hvidovre Hospital Research Foundation (C.R.D.H., J.M.G.), Independent Research Fund Denmark (DFF) Medical Sciences (J.B., J.M.G.), Innovation Fund Denmark (J.B., J.M.G.), the Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' Foundation (J.M.G.), Mauritzen La Fontaine Fonden (J.B., J.M.G.), the Novo Nordisk Foundation (J.B.), the Region H Foundation (J.B., J.M.G.), the Toyota Foundation (A.O., J.M.G.), the Weimann Foundation (U.F.).	Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; [Anonymous], 2020, LANCET, V396, P1861, DOI 10.1016/S0140-6736(20)32662-3; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P69; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Barrett PN, 2009, EXPERT REV VACCINES, V8, P607, DOI [10.1586/erv.09.19, 10.1586/ERV.09.19]; Bissinger T, 2019, VACCINE, V37, P7003, DOI 10.1016/j.vaccine.2019.04.054; Bukh, 2019, FULL LENGTH OPEN REA; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Chen YH, 2005, J BIOTECHNOL, V118, P135, DOI 10.1016/j.jbiotec.2005.02.018; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dill V, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060511; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Esco Aster Pte Ltd, 2018, CULT SER FREE VER CE; Esco VacciXcell, GENTL GIANT ADH BIOP; Fauvelle C, 2016, EXPERT REV VACCINES, V15, P1535, DOI 10.1080/14760584.2016.1194759; Gammeltoft KA, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02680-20; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gottwein JM, 2010, J VIROL, V84, P5277, DOI 10.1128/JVI.02667-09; HASSELL T, 1991, APPL BIOCHEM BIOTECH, V30, P29, DOI 10.1007/BF02922022; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Jardon M, 2003, BIOTECHNOL PROGR, V19, P202, DOI 10.1021/bp025585a; Jensen SB, 2019, HEPATOLOGY, V70, P771, DOI 10.1002/hep.30647; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lai CC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220803; Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700; Lesch HP, 2021, BIOTECHNOL J, V16, DOI 10.1002/biot.202000020; Lesch HP, 2015, HUM GENE THER, V26, P560, DOI 10.1089/hum.2015.081; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Masterton RJ, 2014, PHARM BIOPROCESS, V2, P49, DOI 10.4155/PBP.14.3; Oguchi S, 2006, CYTOTECHNOLOGY, V52, P199, DOI 10.1007/s10616-007-9059-2; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Ragan IK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040340; Ramirez S, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.00097-21; Reed LJ., 1938, AM J HYG, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; Seo SH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040584; Thakur V, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030446; Thomassen YE, 2014, VACCINE, V32, P2782, DOI 10.1016/j.vaccine.2014.02.022; Toriniwa H, 2007, BIOLOGICALS, V35, P221, DOI 10.1016/j.biologicals.2007.02.002; Trimpert J., 2021, SCI REP-UK; Vazquez-Ramirez D, 2019, APPL MICROBIOL BIOT, V103, P3025, DOI 10.1007/s00253-019-09694-2; Vazquez-Ramirez D, 2018, VACCINE, V36, P3124, DOI 10.1016/j.vaccine.2017.10.112; Venkatesan N.P., 2020, COMMUNICATION; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; WHO, 2011, WKLY EPIDEMIOL REC, V24, P241; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia XH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010109; Yuk IH, 2006, CYTOTECHNOLOGY, V51, P183, DOI 10.1007/s10616-006-9030-7; Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	56	2	2	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							706	10.3390/vaccines9070706			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6DX	34209694	Green Published, gold			2022-04-29	WOS:000677000800001
J	Peyret, H; Steele, JFC; Jung, JW; Thuenemann, EC; Meshcheriakova, Y; Lomonossoff, GP				Peyret, Hadrien; Steele, John F. C.; Jung, Jae-Wan; Thuenemann, Eva C.; Meshcheriakova, Yulia; Lomonossoff, George P.			Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult	VACCINES			English	Review						alphavirus; Bunyavirales; coronavirus; Flaviviridae; hepatitis B virus; human immunodeficiency virus; Influenza virus; newcastle disease virus; plant molecular farming; plant-produced vaccines; rhabdovirus; virus-like particles	NEWCASTLE-DISEASE-VIRUS; B SURFACE-ANTIGEN; CUCUMBER-MOSAIC-VIRUS; PROTECTIVE IMMUNE-RESPONSE; EPIDEMIC DIARRHEA VIRUS; HEMAGGLUTININ-NEURAMINIDASE PROTEIN; HEMORRHAGIC SEPTICEMIA VIRUS; ARABIDOPSIS-THALIANA PLANTS; PARTICLE INFLUENZA VACCINE; WEST NILE VIRUS	The past 30 years have seen the growth of plant molecular farming as an approach to the production of recombinant proteins for pharmaceutical and biotechnological uses. Much of this effort has focused on producing vaccine candidates against viral diseases, including those caused by enveloped viruses. These represent a particular challenge given the difficulties associated with expressing and purifying membrane-bound proteins and achieving correct assembly. Despite this, there have been notable successes both from a biochemical and a clinical perspective, with a number of clinical trials showing great promise. This review will explore the history and current status of plant-produced vaccine candidates against enveloped viruses to date, with a particular focus on virus-like particles (VLPs), which mimic authentic virus structures but do not contain infectious genetic material.	[Peyret, Hadrien; Steele, John F. C.; Jung, Jae-Wan; Thuenemann, Eva C.; Meshcheriakova, Yulia; Lomonossoff, George P.] John Innes Ctr, Dept Biochem & Metab, Norwich NR4 7UH, England; [Steele, John F. C.] Piramal Healthcare UK Ltd, Piramal Pharma Solut, Northumberland NE61 3YA, England		Lomonossoff, GP (通讯作者)，John Innes Ctr, Dept Biochem & Metab, Norwich NR4 7UH, England.	hadrien.peyret@jic.ac.uk; jfcsteele@gmail.com; Jae-Wan.Jung@jic.ac.uk; eva.thuenemann@jic.ac.uk; Yulia.Meshcheriakova@jic.ac.uk; george.lomonossoff@jic.ac.uk	Peyret, Hadrien/A-3836-2019	Peyret, Hadrien/0000-0002-7808-5089; Jung, Jaewan/0000-0002-2708-0704; Lomonossoff, George/0000-0003-0700-906X	United Kingdom Biotechnology and Biological Sciences Research Council (BBSRC)UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/L020955/1, BB/L014130/1, BB/M027856/1]; Institute Strategic Programme Grant "Molecules from Nature-Enhanced Research Capacity" [BBS/E/J/000PR9794]; Core Capability Grant [BB/KEC1740/1]; John Innes Foundation; Department of Health and Social Care; Korean Agriculture, Food and Rural Affairs Research Center Support Program of Ministry of Agriculture, Food and Rural Affairs [714001-7]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Korean Ministry of EducationNational Research Foundation of Korea [NRF-2018R1A6A3A01011033]	This work was supported by the United Kingdom Biotechnology and Biological Sciences Research Council (BBSRC) Grants BB/L020955/1, BB/L014130/1 and BB/M027856/1, the Institute Strategic Programme Grant "Molecules from Nature-Enhanced Research Capacity" (BBS/E/J/000PR9794), the Core Capability Grant, BB/KEC1740/1 and the John Innes Foundation. This research was also funded by the Department of Health and Social Care using UK Aid funding and was managed by the BBSRC. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care. This work was further supported by the Korean Agriculture, Food and Rural Affairs Research Center Support Program of Ministry of Agriculture, Food and Rural Affairs (714001-7), Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean Ministry of Education (NRF-2018R1A6A3A01011033).	Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105; Martinez CA, 2010, BIOTECHNOL LETT, V32, P867, DOI 10.1007/s10529-010-0236-6; Arango IP, 2008, PLANT CELL REP, V27, P677, DOI 10.1007/s00299-007-0324-9; Attar A.E., 2004, AFR J BIOTECHNOL, V3, P7; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Belanger H, 2000, FASEB J, V14, P2323, DOI 10.1096/fj.00-0144com; Belot L, 2019, ADV VIRUS RES, V104, P147, DOI 10.1016/bs.aivir.2019.05.003; Berinstein A, 2005, VACCINE, V23, P5583, DOI 10.1016/j.vaccine.2005.06.033; Biacchesi S, 2002, J VIROL, V76, P2881, DOI 10.1128/JVI.76.6.2881-2889.2002; Blokhina EA, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9020162; Bouche FB, 2003, VACCINE, V21, P2065, DOI 10.1016/S0264-410X(02)00747-8; Brown VR, 2017, VET RES, V48, DOI 10.1186/s13567-017-0475-9; Buratti E, 1998, J GEN VIROL, V79, P2709, DOI 10.1099/0022-1317-79-11-2709; Buyel JF, 2015, BIOTECHNOL ADV, V33, P902, DOI 10.1016/j.biotechadv.2015.04.010; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; Cardona-Ospina Jaime A, 2016, F1000Res, V5, P2121; Ceballo Y, 2017, TRANSGENIC RES, V26, P775, DOI 10.1007/s11248-017-0047-9; Chen Q, 2015, BIOTECHNOL J, V10, P671, DOI 10.1002/biot.201400428; Chen TH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00788; Chichester JA, 2012, VIRUSES-BASEL, V4, P3227, DOI 10.3390/v4113227; Clarke JL, 2017, PLANT BIOTECHNOL J, V15, P1611, DOI 10.1111/pbi.12743; Clarke JL, 2013, PLANT MOL BIOL, V83, P33, DOI 10.1007/s11103-013-0081-9; Cox RM, 2017, CURR OPIN VIROL, V24, P105, DOI 10.1016/j.coviro.2017.05.004; Cummings JF, 2014, VACCINE, V32, P2251, DOI 10.1016/j.vaccine.2013.10.017; D'Aoust M.-A., RABIES VIRUS PARTICL; D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x; Dalsgaard K, 1997, NAT BIOTECHNOL, V15, P248, DOI 10.1038/nbt0397-248; Demurtas OC, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00054; Diamos AG, 2020, VACCINE, V38, P3455, DOI 10.1016/j.vaccine.2020.02.089; DIETZSCHOLD B, 1990, J VIROL, V64, P3804, DOI 10.1128/JVI.64.8.3804-3809.1990; Egelkrout E, 2020, PLANT CELL TISS ORG, V142, P79, DOI 10.1007/s11240-020-01835-0; Encinas Paloma, 2011, BMC Res Notes, V4, P210, DOI 10.1186/1756-0500-4-210; Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519; Ghiasi SM, 2011, CLIN VACCINE IMMUNOL, V18, P2031, DOI 10.1128/CVI.05352-11; Gomez E, 2009, J BIOTECHNOL, V144, P337, DOI 10.1016/j.jbiotec.2009.09.015; Gomez N, 2000, ARCH VIROL, V145, P1725, DOI 10.1007/s007050070087; Gomez N, 1998, VIROLOGY, V249, P352, DOI 10.1006/viro.1998.9315; Gottschamel J, 2016, PLANT MOL BIOL, V91, P497, DOI 10.1007/s11103-016-0484-5; Greco R, 2007, VACCINE, V25, P8228, DOI 10.1016/j.vaccine.2007.09.061; Guerrero-Andrade O, 2006, TRANSGENIC RES, V15, P455, DOI 10.1007/s11248-006-0017-0; Guetard D, 2008, VACCINE, V26, P4477, DOI 10.1016/j.vaccine.2008.06.059; Hahn BS, 2007, PLANT BIOTECHNOL REP, V1, P85, DOI 10.1007/s11816-007-0012-9; He JY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010060; He JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/952865; Ho JKT, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020126; Ho TT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02152; Phan HT, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00115; Phan HT, 2017, VET RES, V48, DOI 10.1186/s13567-017-0458-x; Phan HT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099347; Huang Z, 2006, VACCINE, V24, P2506, DOI 10.1016/j.vaccine.2005.12.024; Huang Z, 2001, VACCINE, V19, P2163, DOI 10.1016/S0264-410X(00)00390-X; Huang Z, 2008, PLANT BIOTECHNOL J, V6, P202, DOI 10.1111/j.1467-7652.2007.00316.x; Huy NX, 2011, MOL BIOTECHNOL, V48, P201, DOI 10.1007/s12033-010-9359-1; Huy NX, 2009, BIOTECHNOL BIOPROC E, V14, P731, DOI 10.1007/s12257-009-3012-5; Ibrahim AEC, 2020, PROTEIN EXPRES PURIF, V175, DOI 10.1016/j.pep.2020.105691; Jackson AO, 1998, METH MOL B, V81, P77; Joung YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101715; Kalbina I, 2016, PROTEIN EXPRES PURIF, V127, P61, DOI 10.1016/j.pep.2016.07.003; Kanagaraj AP, 2011, PLANT MOL BIOL, V76, P323, DOI 10.1007/s11103-011-9766-0; Kapusta J, 2001, ADV EXP MED BIOL, V495, P299; Kapusta J, 1999, FASEB J, V13, P1796, DOI 10.1096/fasebj.13.13.1796; Karasev AV, 2005, VACCINE, V23, P1875, DOI 10.1016/j.vaccine.2004.11.021; Kessans SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151842; Kessans SA, 2013, PLANT BIOTECHNOL J, V11, P681, DOI 10.1111/pbi.12058; Kibenge FSB, 2019, CURR OPIN VIROL, V34, P97, DOI 10.1016/j.coviro.2018.12.008; Kim HH, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0789-2; Kim MY, 2015, VACCINE, V33, P1830, DOI 10.1016/j.vaccine.2015.02.036; Kim MY, 2009, BIOTECHNOL BIOPROC E, V14, P725, DOI 10.1007/s12257-009-3011-6; Kong QX, 2001, P NATL ACAD SCI USA, V98, P11539, DOI 10.1073/pnas.191617598; Kumar GBS, 2005, PLANTA, V222, P484, DOI 10.1007/s00425-005-1556-y; Lai HF, 2018, VACCINE, V36, P1846, DOI 10.1016/j.vaccine.2018.02.073; Lai KS, 2013, PLANT CELL TISS ORG, V112, P117, DOI 10.1007/s11240-012-0214-x; Lamphear BJ, 2002, J CONTROL RELEASE, V85, P169, DOI 10.1016/S0168-3659(02)00282-1; Landry N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015559; LECOCQXHONNEUX F, 1994, J GEN VIROL, V75, P1579, DOI 10.1099/0022-1317-75-7-1579; Li HY, 2006, EXP BIOL MED, V231, P1346, DOI 10.1177/153537020623100808; Lomonossoff G.P., 2011, RECENT ADV PLANT VIR, DOI [10.21775/9781910190357, DOI 10.21775/9781910190357]; Lomonossoff GP, 1996, CURR OPIN STRUC BIOL, V6, P176, DOI 10.1016/S0959-440X(96)80072-8; LORENZEN N, 1993, J GEN VIROL, V74, P623, DOI 10.1099/0022-1317-74-4-623; Loza-Rubio E, 2012, VACCINE, V30, P5551, DOI 10.1016/j.vaccine.2012.06.039; Ma XN, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121459; MacDonald J., 2018, PROSPECTS PLANT BASE, DOI [10.1007/978-3-319-90137-4, DOI 10.1007/978-3-319-90137-4]; Maki J, 2017, VET RES, V48, DOI 10.1186/s13567-017-0459-9; Mallajosyula JK, 2014, HUM VACC IMMUNOTHER, V10, P586, DOI 10.4161/hv.27567; Mamedov T., 2020, ENG PRODUCTION CHARA, DOI [10.1101/2020.12.29.424779, DOI 10.1101/2020.12.29.424779]; Mardanova ES, 2016, BIOENGINEERED, V7, P28, DOI 10.1080/21655979.2015.1126017; Mardanova ES, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0164-6; Margolin E, 2020, PLANT BIOTECHNOL J, V18, P2109, DOI 10.1111/pbi.13369; Margolin E, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01378; Margolin E, 2018, PLANT BIOTECHNOL J, V16, P1531, DOI 10.1111/pbi.12963; Margolin EA, 2020, TRENDS BIOTECHNOL, V38, P1034, DOI 10.1016/j.tibtech.2020.03.004; Marquet-Blouin E, 2003, PLANT MOL BIOL, V51, P459, DOI 10.1023/A:1022354322226; Marsian J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00090-w; Marsian J, 2016, CURR OPIN BIOTECH, V37, P201, DOI 10.1016/j.copbio.2015.12.007; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mbewana S, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800238; MCGARVEY PB, 1995, BIO-TECHNOL, V13, P1484, DOI 10.1038/nbt1295-1484; MCLAIN L, 1995, AIDS RES HUM RETROV, V11, P327, DOI 10.1089/aid.1995.11.327; McLain L, 1996, VACCINE, V14, P799, DOI 10.1016/0264-410X(95)00229-T; Mechtcheriakova IA, 2006, J VIROL METHODS, V131, P10, DOI 10.1016/j.jviromet.2005.06.020; Meshcheriakova Iu A, 2009, Mol Biol (Mosk), V43, P741; Mett V, 2008, INFLUENZA OTHER RESP, V2, P33, DOI 10.1111/j.1750-2659.2008.00037.x; Meyers A, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-53; Modelska A, 1998, P NATL ACAD SCI USA, V95, P2481, DOI 10.1073/pnas.95.5.2481; Mohammadzadeh S, 2016, PHARM BIOL, V54, P465, DOI 10.3109/13880209.2015.1048371; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mortimer E, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-14; Motamedi MJ, 2020, MOL BIOTECHNOL, V62, P344, DOI 10.1007/s12033-020-00254-y; Nahampun HN, 2015, PLANT CELL REP, V34, P969, DOI 10.1007/s00299-015-1758-0; Natilla A, 2006, ARCH VIROL, V151, P1373, DOI 10.1007/s00705-005-0711-x; Natilla A, 2004, ARCH VIROL, V149, P137, DOI 10.1007/s00705-003-0190-x; Natilla A, 2008, PROTEIN EXPRES PURIF, V59, P117, DOI 10.1016/j.pep.2008.01.011; Nemchinov LG, 2000, ARCH VIROL, V145, P2557, DOI 10.1007/s007050070008; Neuhaus V, 2014, VACCINE, V32, P3216, DOI 10.1016/j.vaccine.2014.04.011; Pham NB, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0305-2; Tien NQD, 2019, PLANT CELL TISS ORG, V137, P213, DOI 10.1007/s11240-019-01562-1; Tien NQD, 2017, PROTEIN EXPRES PURIF, V133, P170, DOI 10.1016/j.pep.2017.02.006; Huy NX, 2016, PLANT CELL TISS ORG, V127, P369, DOI 10.1007/s11240-016-1059-5; Huy NX, 2012, PLANT CELL REP, V31, P1933, DOI 10.1007/s00299-012-1306-0; Nieto-Gomez R, 2019, J BIOTECHNOL, V295, P41, DOI 10.1016/j.jbiotec.2019.02.003; Nuzzaci M, 2007, ARCH VIROL, V152, P915, DOI 10.1007/s00705-006-0916-7; Nuzzaci M, 2010, J VIROL METHODS, V165, P211, DOI 10.1016/j.jviromet.2010.01.021; Pang EL, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00455; Pantua HD, 2006, J VIROL, V80, P11062, DOI 10.1128/JVI.00726-06; PARKS GD, 1990, VIROLOGY, V178, P498, DOI 10.1016/0042-6822(90)90347-T; Perez L, 1998, J VIROL METHODS, V76, P1, DOI 10.1016/S0166-0934(98)00028-7; Peyret H, 2019, PLANT METHODS, V15, DOI 10.1186/s13007-019-0494-9; Peyret H, 2015, PLANT BIOTECHNOL J, V13, P1121, DOI 10.1111/pbi.12412; Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751; Phan HT, 2013, PLANT BIOTECHNOL J, V11, P582, DOI 10.1111/pbi.12049; Phan HT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040593; Phoolcharoen W, 2011, P NATL ACAD SCI USA, V108, P20695, DOI 10.1073/pnas.1117715108; Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x; Piazzolla G, 2005, J CLIN IMMUNOL, V25, P142, DOI 10.1007/s10875-005-2820-4; Pickering RJ, 2006, VACCINE, V24, P144, DOI 10.1016/j.vaccine.2005.07.097; Pillet S, 2015, VACCINE, V33, P6282, DOI 10.1016/j.vaccine.2015.09.065; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3; Pniewski T, 2013, INT J MOL SCI, V14, P1978, DOI 10.3390/ijms14011978; Pniewski T, 2012, CURR PHARM BIOTECHNO, V13, P2692, DOI 10.2174/138920112804724837; Pniewski T, 2011, J APPL GENET, V52, P125, DOI 10.1007/s13353-010-0001-5; Ponndorf D, 2021, PLANT BIOTECHNOL J, V19, P745, DOI 10.1111/pbi.13501; PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417; Pyrski M, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040211; Ravin NV, 2012, BIOCHEMISTRY-MOSCOW+, V77, P33, DOI 10.1134/S000629791201004X; Richter LJ, 2000, NAT BIOTECHNOL, V18, P1167, DOI 10.1038/81153; Rosenberg Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058724; Rybicki EP, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0205-0; Saejung W, 2007, VACCINE, V25, P6646, DOI 10.1016/j.vaccine.2007.06.029; Salazar-Gonzalez JA, 2015, VACCINE, V33, P3650, DOI 10.1016/j.vaccine.2015.05.104; Schillberg S, 2021, J PLANT PHYSIOL, V258, DOI 10.1016/j.jplph.2020.153359; Scotti N, 2009, PLANTA, V229, P1109, DOI 10.1007/s00425-009-0898-2; Shahid N, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00499; Shchelkunov SN, 2006, BIOTECHNOL LETT, V28, P959, DOI 10.1007/s10529-006-9028-4; Shoji Y, 2009, VACCINE, V27, P1087, DOI 10.1016/j.vaccine.2008.11.108; Shoji Y, 2008, VACCINE, V26, P2930, DOI 10.1016/j.vaccine.2008.03.045; Shoji Y, 2013, HUM VACC IMMUNOTHER, V9, P553, DOI 10.4161/hv.23234; Shoji Y, 2011, HUM VACCINES, V7, P41, DOI 10.4161/hv.7.0.14561; Singh A, 2015, MOL BIOTECHNOL, V57, P359, DOI 10.1007/s12033-014-9829-y; Smith ML, 2003, VACCINE, V21, P4011, DOI 10.1016/S0264-410X(03)00268-8; Smith T, 2020, PLANT BIOTECHNOL J, V18, P502, DOI 10.1111/pbi.13219; Thanavala Y, 2005, P NATL ACAD SCI USA, V102, P3378, DOI 10.1073/pnas.0409899102; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; Thomas D. R., 2018, Prospects of plant-based vaccines in veterinary medicine, P149; Thuenemann EC, 2013, PLANT BIOTECHNOL J, V11, P839, DOI 10.1111/pbi.12076; Thuenemann EC, 2013, CURR PHARM DESIGN, V19, P5564, DOI 10.2174/1381612811319310011; Tremouillaux-Guiller J, 2020, CURR OPIN BIOTECH, V61, P209, DOI 10.1016/j.copbio.2020.01.004; Tsuda S, 1998, VOX SANG, V74, P148, DOI 10.1046/j.1423-0410.1998.7430148.x; van Eerde A, 2019, PLANT BIOTECHNOL J, V17, P1408, DOI 10.1111/pbi.13065; Vermij P, 2006, NAT BIOTECHNOL, V24, P1301, DOI 10.1038/nbt1106-1301; Walker PJ, 2018, J GEN VIROL, V99, P447, DOI 10.1099/jgv.0.001020; Wang Q, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005223; Wang YY, 2009, BIOCHEM BIOPH RES CO, V380, P292, DOI 10.1016/j.bbrc.2009.01.061; Ward BJ, 2021, NAT MED, V27, P1071, DOI 10.1038/s41591-021-01370-1; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Webster DE, 2006, VACCINE, V24, P3538, DOI 10.1016/j.vaccine.2006.02.002; Webster DE, 2005, VACCINE, V23, P1859, DOI 10.1016/j.vaccine.2004.11.018; WUNNER WH, 1985, VIROLOGY, V140, P1, DOI 10.1016/0042-6822(85)90440-4; Yang M, 2018, PLANT BIOTECHNOL J, V16, P572, DOI 10.1111/pbi.12796; Yang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08247-9; Yang ZQ, 2007, VACCINE, V25, P591, DOI 10.1016/j.vaccine.2006.08.016; Yuan P, 2011, P NATL ACAD SCI USA, V108, P14920, DOI 10.1073/pnas.1111691108; Yusibov V, 2005, VACCINE, V23, P2261, DOI 10.1016/j.vaccine.2005.01.039; Yusibov V, 2002, VACCINE, V20, P3155, DOI 10.1016/S0264-410X(02)00260-8; Yusibov V, 1997, P NATL ACAD SCI USA, V94, P5784, DOI 10.1073/pnas.94.11.5784; Zahmanova G, 2021, LIFE-BASEL, V11, DOI 10.3390/life11010064; Zhang GG, 2002, MOL BIOTECHNOL, V20, P131, DOI 10.1385/MB:20:2:131; Zhao Y, 2005, BIOTECHNOL LETT, V27, P375, DOI 10.1007/s10529-005-1773-2; Zheng NY, 2009, VACCINE, V27, P5001, DOI 10.1016/j.vaccine.2009.05.073	191	6	6	3	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							780	10.3390/vaccines9070780			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5DJ	34358196	gold, Green Published			2022-04-29	WOS:000676931800001
J	Pincus, SH; Craig, RB; Weachter, L; LaBranche, CC; Nabi, R; Watt, C; Raymond, M; Peters, T; Song, KJ; Maresh, GA; Montefiori, DC; Kozlowski, PA				Pincus, Seth H.; Craig, Ryan B.; Weachter, Lauren; LaBranche, Celia C.; Nabi, Rafiq; Watt, Connie; Raymond, Mark; Peters, Tami; Song, Kejing; Maresh, Grace A.; Montefiori, David C.; Kozlowski, Pamela A.			Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity	VACCINES			English	Article						HIV; immunotherapy; immunoadhesin; AIDS	IMMUNODEFICIENCY-VIRUS TYPE-1; ANTI-HIV-1 ANTIBODIES; DIFFERENT EPITOPES; MONOCLONAL-ANTIBODIES; SOLUBLE CD4; IMMUNOTOXINS; INHIBITORS; EFFICACY; CELLS; CHAIN	We have constructed bispecific immunoglobulin-like immunoadhesins that bind to both the HIV-envelope glycoproteins: gp120 and gp41. These immunoadhesins have N terminal domains of human CD4 engrafted onto the N-terminus of the heavy chain of human anti-gp41 mAb 7B2. Binding of these constructs to recombinant Env and their antiviral activities were compared to that of the parental mAbs and CD4, as well as to control mAbs. The CD4/7B2 constructs bind to both gp41 and gp140, as well as to native Env expressed on the surface of infected cells. These constructs deliver cytotoxic immunoconjugates to HIV-infected cells, but not as well as a mixture of 7B2 and sCD4, and opsonize for antibody-mediated phagocytosis. Most surprisingly, given that 7B2 neutralizes weakly, if at all, is that the chimeric CD4/7B2 immunoadhesins exhibit broad and potent neutralization of HIV, comparable to that of well-known neutralizing mAbs. These data add to the growing evidence that enhanced neutralizing activity can be obtained with bifunctional mAbs/immunoadhesins. The enhanced neutralization activity of the CD4/7B2 chimeras may result from cross-linking of the two Env subunits with subsequent inhibition of the pre-fusion conformational events that are necessary for entry.	[Pincus, Seth H.; Watt, Connie; Raymond, Mark; Peters, Tami] Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59715 USA; [Craig, Ryan B.; Weachter, Lauren; Song, Kejing; Maresh, Grace A.] Childrens Hosp, Res Inst Children, New Orleans, LA 70118 USA; [Craig, Ryan B.] Tulane Univ, Dept Pathol, New Orleans, LA 70112 USA; [LaBranche, Celia C.; Montefiori, David C.] Duke Univ, Dept Surg, Durham, NC 27707 USA; [Nabi, Rafiq; Kozlowski, Pamela A.] LSU Sch Med, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA		Pincus, SH (通讯作者)，Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59715 USA.	seth.pincus@montana.edu; rycraig@gmail.com; lweachter@gmail.com; celia.labranche@duke.edu; rnabi1@lsu.edu; cmwatt29@gmail.com; markcraymond@gmail.com; tami.peters@montana.edu; kjingsong@gmail.com; gmaresh10@gmail.com; david.montefiori@duke.edu; pkozlo@lsuhsc.edu			Children's Hospital of New Orleans; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA074690, AI058714, AI136758]; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1045974]; Louisiana Vaccine Center (LA Board of Regents) [LEQSF-ENH-PKSFI-PRS-02]; Louisiana Vaccine Center; NIAID, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN272201800004C]	Research support was provided to R.B.C., S.H.P., K.S., L.W., and G.A.M. by Children's Hospital of New Orleans, NIH grants CA074690, AI058714, and AI136758 (the latter also supporting M.R., T.P., C.W.), Bill and Melinda Gates Foundation Grand Challenges Explorations: OPP1045974, and the Louisiana Vaccine Center (LA Board of Regents, LEQSF-ENH-PKSFI-PRS-02). P.A.K. and R.N. were also supported by the Louisiana Vaccine Center. D.C.M. and C.C.L. were supported by contract HHSN272201800004C (NIAID, NIH). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; Asokan M, 2015, J VIROL, V89, P12501, DOI 10.1128/JVI.02097-15; Asokan M, 2020, P NATL ACAD SCI USA, V117, P18754, DOI 10.1073/pnas.2008236117; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Barouch DH, 2014, SCIENCE, V345, P169, DOI 10.1126/science.1255512; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008; Bonsignori M, 2012, J VIROL, V86, P4688, DOI 10.1128/JVI.07163-11; Bournazos S, 2016, CELL, V165, P1609, DOI 10.1016/j.cell.2016.04.050; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Chen J, 2015, SCIENCE, V349, P191, DOI 10.1126/science.aaa9804; Chen WZ, 2014, J VIROL, V88, P1125, DOI 10.1128/JVI.02566-13; Chen WZ, 2010, ANTIVIR RES, V88, P107, DOI 10.1016/j.antiviral.2010.08.004; Craig RB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046778; Davis-Gardner ME, 2020, MBIO, V11, DOI 10.1128/mBio.03080-19; deCamp A, 2014, J VIROL, V88, P2489, DOI 10.1128/JVI.02853-13; Dey B, 2003, J VIROL, V77, P2859, DOI 10.1128/JVI.77.5.2859-2865.2003; Ferrari G, 2011, J VIROL, V85, P7029, DOI 10.1128/JVI.00171-11; Forthal DN, 2007, J IMMUNOL, V178, P6596, DOI 10.4049/jimmunol.178.10.6596; Gardner MR, 2017, CURR OPIN HIV AIDS, V12, P294, DOI 10.1097/COH.0000000000000367; GARLICK RL, 1990, AIDS RES HUM RETROV, V6, P465, DOI 10.1089/aid.1990.6.465; Gauduin MC, 1998, J VIROL, V72, P3475, DOI 10.1128/JVI.72.4.3475-3478.1998; Grobben M, 2019, CURR OPIN VIROL, V38, P70, DOI 10.1016/j.coviro.2019.07.007; Haynes BF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaz2686; Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200; Horwitz JA, 2017, CELL, V170, P637, DOI 10.1016/j.cell.2017.06.048; Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601; Huang YX, 2016, CELL, V165, P1621, DOI 10.1016/j.cell.2016.05.024; Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Klasse PJ, 2020, CELL HOST MICROBE, V27, P507, DOI 10.1016/j.chom.2020.03.018; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; Lewis GK, 2014, IMMUNOLOGY, V142, P46, DOI 10.1111/imm.12232; Loos C, 2020, CURR OPIN IMMUNOL, V65, P89, DOI 10.1016/j.coi.2020.06.003; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; MAY RD, 1990, J IMMUNOL, V144, P3637; MAY RD, 1991, CELL IMMUNOL, V135, P490, DOI 10.1016/0008-8749(91)90292-J; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Montefiori DC, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2018027118; Montefiori DC, 2016, CELL, V165, P1563, DOI 10.1016/j.cell.2016.06.004; Mouquet H, 2017, IMMUNITY, V46, P527, DOI 10.1016/j.immuni.2017.04.001; Mouquet H, 2012, P NATL ACAD SCI USA, V109, P875, DOI 10.1073/pnas.1120059109; Pegu A, 2019, CELL HOST MICROBE, V26, P336, DOI 10.1016/j.chom.2019.08.014; Pincus SH, 2014, RICIN TOXIN, P130; Pincus SH, 2017, J VIROL, V91, DOI 10.1128/JVI.01955-16; Pincus SH, 2017, J VIROL, V91, DOI 10.1128/JVI.01360-16; Pincus SH, 1996, AIDS RES HUM RETROV, V12, P1041, DOI 10.1089/aid.1996.12.1041; PINCUS SH, 1990, J INFECT DIS, V162, P1233, DOI 10.1093/infdis/162.6.1233; Pincus SH, 2003, J IMMUNOL, V170, P2236, DOI 10.4049/jimmunol.170.4.2236; PINCUS SH, 1993, P NATL ACAD SCI USA, V90, P332, DOI 10.1073/pnas.90.1.332; Robinson JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11544; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Scharf L, 2015, CELL, V162, P1379, DOI 10.1016/j.cell.2015.08.035; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Sellhorn G, 2009, VACCINE, V28, P430, DOI 10.1016/j.vaccine.2009.10.028; Shearer WT, 2000, J INFECT DIS, V182, P1774, DOI 10.1086/317622; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; TILL M, 1988, CANCER RES, V48, P1119; Tuyishime M, 2020, J CLIN INVEST, V130, P5157, DOI 10.1172/JCI135557; Veillette M, 2014, J VIROL, V88, P2633, DOI 10.1128/JVI.03230-13; Wagh K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006860; Wang PF, 2020, P NATL ACAD SCI USA, V117, P18002, DOI 10.1073/pnas.2008190117; Ward AB, 2017, IMMUNOL REV, V275, P21, DOI 10.1111/imr.12507; West AP, 2010, J VIROL, V84, P261, DOI 10.1128/JVI.01528-09; Wu XL, 2018, J CLIN INVEST, V128, P2239, DOI 10.1172/JCI96764; Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630; Yoon H, 2015, NUCLEIC ACIDS RES, V43, pW213, DOI 10.1093/nar/gkv404; Zhang MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044241	73	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							774	10.3390/vaccines9070774			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8FN	34358190	gold, Green Published			2022-04-29	WOS:000677140200001
J							Vaccines Editorial Off	撤稿声明: The Safety of COVID-19 Vaccinations-We Should Rethink the Policy (Retraction of Vol 9, art no 693, 2021)	VACCINES			English	Retraction									[Vaccines Editorial Off] MDPI, St Alban Anlage 66, CH-4052 Basel, Switzerland		MDPI, St Alban Anlage 66, CH-4052 Basel, Switzerland.						Walach H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070693	1	0	0	5	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							729	10.3390/vaccines9070729			1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8KD		gold, Green Published			2022-04-29	WOS:000677152200001
J	Zhang, MD; Fu, M; Hu, QX				Zhang, Mudan; Fu, Ming; Hu, Qinxue			Advances in Human Norovirus Vaccine Research	VACCINES			English	Review						human norovirus; acute gastroenteritis; HuNoV vaccine; VLPs; culture system	CELLULAR IMMUNE-RESPONSES; VIRUS-LIKE PARTICLES; NORWALK VIRUS; CAPSID PROTEIN; EXPERIMENTAL-INFECTION; HEALTHY-ADULTS; GASTROENTERITIS; CANDIDATE; ROTAVIRUS; MUCOSAL	Human norovirus (HuNoV) is the leading cause of acute gastroenteritis (AGE) worldwide, which is highly stable and contagious, with a few virus particles being sufficient to establish infection. Although the World Health Organization in 2016 stated that it should be an absolute priority to develop a HuNoV vaccine, unfortunately, there is currently no licensed HuNoV vaccine available. The major barrier to the development of an effective HuNoV vaccine is the lack of a robust and reproducible in vitro cultivation system. To develop a HuNoV vaccine, HuNoV immunogen alone or in combination with other viral immunogens have been designed to assess whether they can simultaneously induce protective immune responses against different viruses. Additionally, monovalent and multivalent vaccines from different HuNoV genotypes, including GI and GII HuNoV virus-like particles (VLPs), have been assessed in order to induce broad protection. Although there are several HuNoV vaccine candidates based on VLPs that are being tested in clinical trials, the challenges to develop effective HuNoV vaccines remain largely unresolved. In this review, we summarize the advances of the HuNoV cultivation system and HuNoV vaccine research and discuss current challenges and future perspectives in HuNoV vaccine development.	[Zhang, Mudan] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Gastroenterol, Guangzhou 510623, Peoples R China; [Fu, Ming] Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Joint Ctr Translat Precis Med, Guangzhou 510623, Peoples R China; [Fu, Ming] Chinese Acad Sci, Wuhan Inst Virol, Joint Ctr Translat Precis Med, Wuhan 430071, Peoples R China; [Hu, Qinxue] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China; [Hu, Qinxue] St Georges Univ London, Inst Infect & Immun, London SW17 0RE, England		Hu, QX (通讯作者)，Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.; Hu, QX (通讯作者)，St Georges Univ London, Inst Infect & Immun, London SW17 0RE, England.	mudan@wh.iov.cn; fuming199142@foxmail.com; qhu@wh.iov.cn		Hu, Qinxue/0000-0002-4594-9215; , Zhang/0000-0002-5164-5891	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31700151, 81772192]; National Mega-Projects against Infectious Diseases [2018ZX10301406-002]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2015M582364]; State Key Laboratory of Virology [2021IOV003, klv-2016-02]	This work was supported by the National Natural Science Foundation of China (31700151 and 81772192), the National Mega-Projects against Infectious Diseases (2018ZX10301406-002), the China Postdoctoral Science Foundation (2015M582364), and the State Key Laboratory of Virology (2021IOV003 and klv-2016-02).	Ahmed SM, 2014, LANCET INFECT DIS, V14, P725, DOI 10.1016/S1473-3099(14)70767-4; Alvarado G, 2018, GASTROENTEROLOGY, V155, P1898, DOI 10.1053/j.gastro.2018.08.039; Atmar RL, 2018, CURR OPIN INFECT DIS, V31, P422, DOI [10.1097/QCO.0000000000000476, 10.1097/qco.0000000000000476]; Atmar RL, 2016, J INFECT DIS, V214, P845, DOI 10.1093/infdis/jiw259; Atmar RL, 2011, NEW ENGL J MED, V365, P2178, DOI 10.1056/NEJMoa1101245; Ball JP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177310; Banyai K, 2018, LANCET, V392, P175, DOI 10.1016/S0140-6736(18)31128-0; Baric RS, 2002, J VIROL, V76, P3023, DOI 10.1128/JVI.76.6.3023-3030.2002; BARON RC, 1984, J INFECT DIS, V150, P531, DOI 10.1093/infdis/150.4.531; Bernstein DI, 2015, J INFECT DIS, V211, P870, DOI 10.1093/infdis/jiu497; Bertolotti-Ciarlet A, 2002, J VIROL, V76, P4044, DOI 10.1128/JVI.76.8.4044-4055.2002; Blazevic V, 2011, VACCINE, V29, P8126, DOI 10.1016/j.vaccine.2011.08.026; Brown JR, 2017, J CLIN VIROL, V96, P44, DOI 10.1016/j.jcv.2017.09.009; Caddy SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008732; Cates JE, 2020, EXPERT REV VACCINES, V19, P539, DOI 10.1080/14760584.2020.1777860; Chen R, 2004, J VIROL, V78, P6469, DOI 10.1128/JVI.78.12.6469-6479.2004; Chhabra P, 2019, J GEN VIROL, V100, P1393, DOI 10.1099/jgv.0.001318; Costantini V, 2018, EMERG INFECT DIS, V24, P1453, DOI 10.3201/eid2408.180126; Costantini VP, 2020, J INFECT DIS, V221, P1864, DOI 10.1093/infdis/jiaa021; Dai YC, 2013, ANTIVIR RES, V97, P293, DOI 10.1016/j.antiviral.2012.12.011; de Graaf M, 2015, EUROSURVEILLANCE, V20, P8, DOI 10.2807/1560-7917.ES2015.20.26.21178; Debbink K, 2014, J VIROL, V88, P7244, DOI 10.1128/JVI.00203-14; Debbink K, 2014, CLIN INFECT DIS, V58, P1746, DOI 10.1093/cid/ciu120; Donaldson EF, 2008, IMMUNOL REV, V225, P190, DOI 10.1111/j.1600-065X.2008.00680.x; Esposito S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01383; Ettayebi K, 2016, SCIENCE, V353, P1387, DOI 10.1126/science.aaf5211; Fu J, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.24.21157; Giersing BK, 2019, VACCINE, V37, P7315, DOI 10.1016/j.vaccine.2016.10.090; GRAY JJ, 1994, J CLIN MICROBIOL, V32, P3059, DOI 10.1128/JCM.32.12.3059-3063.1994; GREEN KY, 1993, J CLIN MICROBIOL, V31, P2185, DOI 10.1128/JCM.31.8.2185-2191.1993; Guo L, 2008, VACCINE, V26, P460, DOI 10.1016/j.vaccine.2007.11.039; Guo L, 2009, VACCINE, V27, P5233, DOI 10.1016/j.vaccine.2009.06.065; Hall AJ, 2013, EMERG INFECT DIS, V19, P1198, DOI 10.3201/eid1908.130465; Hallowell BD, 2019, HUM VACC IMMUNOTHER, V15, P1279, DOI 10.1080/21645515.2018.1553594; Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; Jin M, 2020, EMERG INFECT DIS, V26, P437, DOI 10.3201/eid2603.191183; JOHNSON PC, 1990, J INFECT DIS, V161, P18, DOI 10.1093/infdis/161.1.18; Jones MK, 2015, NAT PROTOC, V10, P1939, DOI 10.1038/nprot.2015.121; Jones MK, 2014, SCIENCE, V346, P755, DOI 10.1126/science.1257147; Karst SM, 2014, CELL HOST MICROBE, V15, P668, DOI 10.1016/j.chom.2014.05.015; Kim L, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121077; Kirk MD, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001921, 10.1371/journal.pmed.1001940]; Kocher J, 2014, J VIROL, V88, P9728, DOI 10.1128/JVI.01249-14; Kolawole AO, 2016, ANTIVIR RES, V132, P46, DOI 10.1016/j.antiviral.2016.05.011; Koo Hoonmo L, 2013, J Pediatric Infect Dis Soc, V2, P57, DOI 10.1093/jpids/pis070; Kroneman A, 2013, ARCH VIROL, V158, P2059, DOI 10.1007/s00705-013-1708-5; Lappalainen S, 2015, ARCH VIROL, V160, P2075, DOI 10.1007/s00705-015-2461-8; Leroux-Roels G, 2018, J INFECT DIS, V217, P597, DOI 10.1093/infdis/jix572; Lindesmith L, 2003, NAT MED, V9, P548, DOI 10.1038/nm860; Lindesmith LC, 2019, J VIROL, V93, DOI 10.1128/JVI.01813-18; Lindesmith LC, 2010, J VIROL, V84, P1800, DOI 10.1128/JVI.02179-09; Lu J, 2015, EMERG INFECT DIS, V21, P1240, DOI 10.3201/eid2107.150226; Mallory ML, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020177; Malm M, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050229; Malm M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39840-9; Malm M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01570; Malm M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9171632; Masuda T, 2018, OPEN FORUM INFECT DI, V5, DOI [10.1093/ofid/ofy210.1929, DOI 10.1093/OFID/OFY210.1929]; Mathew LG, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/807539; OKHUYSEN PC, 1995, J INFECT DIS, V171, P566, DOI 10.1093/infdis/171.3.566; Parra GI, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006136; Parra GI, 2012, VACCINE, V30, P3580, DOI 10.1016/j.vaccine.2012.03.050; PARRINO TA, 1977, NEW ENGL J MED, V297, P86, DOI 10.1056/NEJM197707142970204; Payne DC, 2015, CURR OPIN PEDIATR, V27, P105, DOI 10.1097/MOP.0000000000000166; Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287; Ramani S, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00571-16; Ramirez K, 2012, CLIN IMMUNOL, V144, P98, DOI 10.1016/j.clim.2012.05.006; Santi L, 2008, VACCINE, V26, P1846, DOI 10.1016/j.vaccine.2008.01.053; Sato S, 2019, CELL MOL GASTROENTER, V7, P686, DOI 10.1016/j.jcmgh.2018.11.001; Shah MP, 2017, NOROVIRUS: FEATURES, DETECTION, AND PREVENTION OF FOODBORNE DISEASE, P3, DOI 10.1016/B978-0-12-804177-2.00001-4; Simmons K, 2013, EMERG INFECT DIS, V19, P1260, DOI 10.3201/eid1908.130472; Souza M, 2007, VACCINE, V25, P8448, DOI 10.1016/j.vaccine.2007.09.040; Subekti DS, 2002, J MED VIROL, V66, P400, DOI 10.1002/jmv.2159; Sundararajan A, 2015, VACCINE, V33, P568, DOI 10.1016/j.vaccine.2014.09.073; Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653; Tamminen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070409; Tan M, 2004, J VIROL, V78, P6233, DOI 10.1128/JVI.78.12.6233-6242.2004; Tan M, 2008, VIROLOGY, V382, P115, DOI 10.1016/j.virol.2008.08.047; Taube S, 2013, MBIO, V4, DOI 10.1128/mBio.00450-13; Todd KV, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020151; Treanor J, 2020, VACCINE, V38, P5842, DOI 10.1016/j.vaccine.2020.06.011; Treanor JJ, 2014, J INFECT DIS, V210, P1763, DOI 10.1093/infdis/jiu337; van Beek J, 2018, LANCET INFECT DIS, V18, P545, DOI 10.1016/S1473-3099(18)30059-8; Van Dycke J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008009; Wang LY, 2013, BIOMATERIALS, V34, P4480, DOI 10.1016/j.biomaterials.2013.02.041; Wang XL, 2015, VACCINE, V33, P5779, DOI 10.1016/j.vaccine.2015.09.043; WYATT RG, 1978, J MED VIROL, V2, P89, DOI 10.1002/jmv.1890020203; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992; Xia M, 2011, VACCINE, V29, P7670, DOI 10.1016/j.vaccine.2011.07.139; Yen C, 2013, J PEDIATR INFECT DIS, V2, P61, DOI 10.1093/jpids/pis134	91	4	4	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							732	10.3390/vaccines9070732			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6MN	34358148	Green Published, Green Accepted			2022-04-29	WOS:000677023200001
J	Mi, YJ; Xie, T; Zhu, BD; Tan, JY; Li, XF; Luo, YP; Li, F; Niu, HX; Han, JY; Lv, W; Wang, J				Mi, Youjun; Xie, Tao; Zhu, Bingdong; Tan, Jiying; Li, Xuefeng; Luo, Yanping; Li, Fei; Niu, Hongxia; Han, Jiangyuan; Lv, Wei; Wang, Juan			Production of SARS-CoV-2 Virus-Like Particles in Insect Cells	VACCINES			English	Article						SARS-CoV-2; virus-like particles; insect cells		Coronavirus disease (COVID-19) causes a serious threat to human health. Virus-like particles (VLPs) constitute a promising platform in SARS-CoV-2 vaccine development. In this study, the E, M, and S genes were cloned into multiple cloning sites of a new triple expression plasmid with one p10 promoter, two pPH promoters, and three multiple cloning sites. The plasmid was transformed into DH10 Bac(TM) Escherichia coli competent cells to obtain recombinant bacmid. Then the recombinant bacmid was transfected in ExpiSf9(TM) insect cells to generate recombinant baculovirus. After ExpiSf9(TM) cells infection with the recombinant baculovirus, the E, M, and S proteins were expressed in insect cells. Finally, SARS-CoV-2 VLPs were self-assembled in insect cells after infection. The morphology and the size of SARS-CoV-2 VLPs are similar to the native virions.	[Mi, Youjun; Xie, Tao; Zhu, Bingdong; Li, Fei; Niu, Hongxia; Han, Jiangyuan; Lv, Wei; Wang, Juan] Lanzhou Univ, Lanzhou Ctr TB Res, Sch Basic Med Sci, Lanzhou 730070, Peoples R China; [Mi, Youjun; Xie, Tao; Zhu, Bingdong; Li, Fei; Niu, Hongxia; Han, Jiangyuan; Lv, Wei; Wang, Juan] Lanzhou Univ, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Sch Basic Med Sci, Lanzhou 730070, Peoples R China; [Tan, Jiying; Luo, Yanping] Lanzhou Univ, Sch Basic Med, Inst Immunol, Lanzhou 730070, Peoples R China; [Li, Xuefeng] Lanzhou Univ, Inst Combined Western & Chinese Tradit Med, Lanzhou 730070, Peoples R China		Zhu, BD (通讯作者)，Lanzhou Univ, Lanzhou Ctr TB Res, Sch Basic Med Sci, Lanzhou 730070, Peoples R China.; Zhu, BD (通讯作者)，Lanzhou Univ, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Sch Basic Med Sci, Lanzhou 730070, Peoples R China.	miyoujun@126.com; 13643819274@163.com; zhubingd@163.com; tanjy@lzu.edu.cn; lixuefeng@lzu.edu.cn; luoyp@lzu.edu.cn; lf@lzu.edu.cn; niuhx@lzu.edu.cn; hanjy17@lzu.edu.cn; lvw18@lzu.edu.cn; wangj19@lzu.edu.cn		TAN, JIYING/0000-0002-8361-1012; Mi, Youjun/0000-0002-9878-8179	Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [lzujbky-2020-sp06, lzujbky-2017-22]; main research and development program of Gansu Province [20YF8FA072]; Lanzhou science and technology planning project [2020-XG-33]	This research was funded by the Fundamental Research Funds for the Central Universities, grant number lzujbky-2020-sp06 and lzujbky-2017-22, funded by the main research and development program of Gansu Province in 2020, grant number 20YF8FA072, and funded by Lanzhou science and technology planning project, grant number 2020-XG-33.	Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Chung YH, 2020, ADV DRUG DELIVER REV, V156, P214, DOI 10.1016/j.addr.2020.06.024; Durous L, 2019, EXPERT REV VACCINES, V18, P1285, DOI 10.1080/14760584.2019.1704262; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135; Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010; Ji M, 2020, NANOMED-NANOTECHNOL, V28, DOI 10.1016/j.nano.2020.102223; Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272; Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020; Lu XY, 2007, IMMUNOLOGY, V122, P496, DOI 10.1111/j.1365-2567.2007.02676.x; Matsuda T, 2020, BIOCHEM ENG J, V163, DOI 10.1016/j.bej.2020.107757; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009; National Microbiology Data Center of China, 2020, EL MICR WUH STRAIN 0; Naupu PN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040740; Nooraei S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00806-7; Plescia CB, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016148; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.29284; Roden RBS, 2018, NAT REV CANCER, V18, P240, DOI 10.1038/nrc.2018.13; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Soleimanpour S, 2021, EXPERT REV VACCINES, V20, P23, DOI [10.1080/14760584.2021.1875824, 10.1080/14760584.2021.1875824CrossMarkLogo]; Stanley M, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0268; Swann H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78656-w; Tamminen K, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/3194704; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475; WHO, 2021, DRAFT LANDSC COVID 1; World Health Organization, 2021, WEEKLY EPIDEMIOLOGIC; Xu RD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00862; Zhao J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602256; Zhao YW, 2020, BIOMATERIALS, V249, DOI 10.1016/j.biomaterials.2020.120030; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	34	4	4	2	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							554	10.3390/vaccines9060554			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2WV	34073159	Green Published, gold, Green Submitted			2022-04-29	WOS:000666432900001
J	Rzymski, P; Perek, B; Flisiak, R				Rzymski, Piotr; Perek, Bartlomiej; Flisiak, Robert			Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism	VACCINES			English	Review						vector vaccines; mRNA vaccines; thrombosis; thrombocytopenia; adverse effects; COVID-19	HEPARIN-INDUCED THROMBOCYTOPENIA; EDTA-DEPENDENT PSEUDOTHROMBOCYTOPENIA; MOLECULAR-WEIGHT HEPARIN; IMMUNE-RESPONSE; NEUTRALIZING ANTIBODIES; PLATELET ACTIVATION; CROSS-REACTIVITY; POLYMORPHISM; SARS-COV-2; VECTORS	The rollout of COVID-19 vaccines brings hope for successful pandemic mitigation and getting the transmission of SARS-CoV-2 under control. The vaccines authorized in Europe displayed a good safety profile in the clinical trials. However, during their post-authorization use, unusual thrombotic events associated with thrombocytopenia have rarely been reported for vector vaccines. This led to the temporary suspension of the AZD1222 vaccine (Oxford/AstraZeneca) in various European countries and the Ad26.COV2 vaccine (Janssen/Johnson&Johnson) in the United States, with regulatory bodies launching investigations into potential causal associations. The thromboembolic reactions were also rarely reported after mRNA vaccines. The exact cause of these adverse effects remains to be elucidated. The present paper outlines the hypotheses on the mechanisms behind the very rare thrombotic thrombocytopenia reported after the COVID-19 vaccination, along with currently existing evidence and future research prospects. The following are discussed: (i) the role of antibodies against platelet factor 4 (PF4), (ii) the direct interaction between adenoviral vector and platelets, (iii) the cross-reactivity of antibodies against SARS-CoV-2 spike protein with PF4, (iv) cross-reactivity of anti-adenovirus antibodies and PF4, (v) interaction between spike protein and platelets, (vi) the platelet expression of spike protein and subsequent immune response, and (vii) the platelet expression of other adenoviral proteins and subsequent reactions. It is also plausible that thrombotic thrombocytopenia after the COVID-19 vaccine is multifactorial. The elucidation of the causes of these adverse events is pivotal in taking precautionary measures and managing vaccine hesitancy. It needs to be stressed, however, that the reported cases are currently sporadic and that the benefits of COVID-19 vaccines vastly outweigh their potential risks.	[Rzymski, Piotr] Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland; [Rzymski, Piotr] Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland; [Perek, Bartlomiej] Poznan Univ Med Sci, Dept Cardiac Surg & Transplantol, PL-61848 Poznan, Poland; [Flisiak, Robert] Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Bialystok, Poland		Rzymski, P (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland.; Rzymski, P (通讯作者)，Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland.	rzymskipiotr@ump.edu.pl; bperek@ump.edu.pl; robert.flisiak@umb.edu.pl	Perek, Bartłomiej/AAS-6564-2021; Rzymski, Piotr/I-2240-2012; Flisiak, Robert/S-5356-2018	Perek, Bartłomiej/0000-0003-2398-9571; Rzymski, Piotr/0000-0002-4713-0801; Flisiak, Robert/0000-0003-3394-1635	Medical Research Agency [2020/ABM/COVID19/]; Department of Environmental Medicine, Poznan University of Medical Sciences	This research was financially supported by the Medical Research Agency (grant number 2020/ABM/COVID19/) and by the statutory funds of the Department of Environmental Medicine, Poznan University of Medical Sciences.	Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06; Ahn Hae Lyun, 2002, Korean J Intern Med, V17, P65; Akbayram S, 2011, CLIN APPL THROMB-HEM, V17, P494, DOI 10.1177/1076029610373367; Almuqrin A, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00859-1; Arepally G, 1997, BLOOD, V89, P370, DOI 10.1182/blood.V89.2.370; Arepally G, 2007, AUTOANTIBODIES, 2ND EDITION, P511, DOI 10.1016/B978-044452763-9/50067-6; Arepally GM, 2017, BLOOD, V129, P2864, DOI 10.1182/blood-2016-11-709873; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baker AT, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax3567; Banfi G, 2007, CLIN CHEM LAB MED, V45, P565, DOI 10.1515/CCLM.2007.110; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; BERKMAN N, 1991, AM J HEMATOL, V36, P195, DOI 10.1002/ajh.2830360307; Bestle D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000786; BIZZARO N, 1995, AM J HEMATOL, V50, P103, DOI 10.1002/ajh.2830500206; Bos R, 2020, NPJ VACCINES, V5, P91, DOI DOI 10.1038/s41541-020-00243-x; Burgos Rodrigo M, 2021, Drugs Context, V10, DOI 10.7573/dic.2020-12-2; Capecchi M, 2018, J THROMB HAEMOST, V16, P1918, DOI 10.1111/jth.14210; Chapman LM, 2012, J IMMUNOL, V189, P916, DOI 10.4049/jimmunol.1200580; Chen H, 2010, J VIROL, V84, P10522, DOI 10.1128/JVI.00450-10; Cheng M, 2005, BIOCHEM BIOPH RES CO, V338, P1654, DOI 10.1016/j.bbrc.2005.10.088; Cichon G, 1999, J GENE MED, V1, P360, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<360::AID-JGM54>3.0.CO;2-Q; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Coutinho JM, 2012, STROKE, V43, P3375, DOI 10.1161/STROKEAHA.112.671453; Crook M, 1991, Platelets, V2, P1, DOI 10.3109/09537109109005496; Devasagayam S, 2016, STROKE, V47, P2180, DOI 10.1161/STROKEAHA.116.013617; Dicks MDJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16756; European Medicines Agency, ASTRAZENECAS COVID 1; Excler JL, 2021, NAT MED, V27, P591, DOI 10.1038/s41591-021-01301-0; Fausther-Bovendo H, 2014, HUM VACC IMMUNOTHER, V10, P2875, DOI 10.4161/hv.29594; Greinacher A., 2021, RES SQ, DOI [10.21203/rs.3.rs-404769/v1, DOI 10.21203/RS.3.RS-404769/V1]; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Gupalo E, 2013, PLATELETS, V24, P383, DOI 10.3109/09537104.2012.703792; Gupalo E, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-456; Harris K, 2008, AM J CLIN PATHOL, V129, P282, DOI 10.1309/BMW4M8NQBV0TKFRX; Horsewood P, 2000, PLATELETS, V11, P23; Jaax ME, 2013, BLOOD, V122, P272, DOI 10.1182/blood-2013-01-478966; Jin YY, 2014, MOL MED REP, V9, P370, DOI 10.3892/mmr.2013.1805; Kaur S., 2021, BLOOD REV, V46, P100743, DOI [10.1016/j.blre.2020.100743, DOI 10.1016/j.blre.2020.100743]; Kim SY, 2018, DRUG DELIV, V25, P49, DOI 10.1080/10717544.2017.1413450; Kleiman NS, 2017, PLATELETS THROMBOTIC, P1085; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Li HL, 2012, J VIROL, V86, P10862, DOI 10.1128/JVI.00928-12; Lozier JN, 2002, HUM GENE THER, V13, P113, DOI 10.1089/10430340152712665; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n970; Martinez-Ribaya B, 2020, FOOD CONTROL, V109, DOI 10.1016/j.foodcont.2019.106895; Mast TC, 2010, VACCINE, V28, P950, DOI 10.1016/j.vaccine.2009.10.145; Medicines & Healthcare Products Regulatory Agency, SUMMARY PUBLIC ASSES; Miyata Shigeki, 2016, Rinsho Ketsueki, V57, P2124; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Muruve DA, 2004, HUM GENE THER, V15, P1157, DOI 10.1089/hum.2004.15.1157; Muster V, 2021, LANCET, V397, P1842, DOI 10.1016/S0140-6736(21)00871-0; Nowakowska J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110451; Nwanegbo E, 2004, CLIN DIAGN LAB IMMUN, V11, P351, DOI 10.1128/CDLI.11.2.351-357.2004; Okata T, 2015, PLATELETS, V26, P602, DOI 10.3109/09537104.2014.979338; Othman M, 2007, BLOOD, V109, P2832, DOI 10.1182/blood-2006-06-032524; PEGELS JG, 1982, BLOOD, V59, P157; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Pouplard C, 1999, CIRCULATION, V99, P2530, DOI 10.1161/01.CIR.99.19.2530; Pouplard C, 2012, THROMB RES, V129, P465, DOI 10.1016/j.thromres.2011.09.033; Rollin J, 2015, BLOOD, V125, P2397, DOI 10.1182/blood-2014-09-594515; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sadoff J, 2021, NEW ENGL J MED, V384, P1965, DOI 10.1056/NEJMc2106075; Sadrzadeh H, 2017, ENDOCRINE BIOMARKERS: CLINICIANS AND CLINICAL CHEMISTS IN PARTNERSHIP, P1, DOI 10.1016/B978-0-12-803412-5.00001-X; Salunkhe V, 2015, BIOPROTOCOL, V5, DOI 10.21769/BioProtoc.1639; Schubert S, 2014, BLOOD, V124, P493, DOI 10.1182/blood-2014-04-512756; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Shayakhmetov, 2016, ADENOVIRAL VECTORS G, DOI [10.1016/B978-0-12-800276-6.00014-0, DOI 10.1016/B978-0-12-800276-6.00014-0]; Smadja DM, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.00956-2021; Stone D, 2007, J VIROL, V81, P4866, DOI 10.1128/JVI.02819-06; Suvarna S, 2007, BLOOD, V110, P4253, DOI 10.1182/blood-2007-08-105098; Taquet M., CEREBRAL VENOUS THRO; Tinazzi E, 2009, INT IMMUNOL, V21, P237, DOI 10.1093/intimm/dxn142; Defendi HGT, 2021, J PHARM INNOV, DOI 10.1007/s12247-021-09535-8; Torjesen I, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1005; Valeriani E, 2019, VASC HEALTH RISK MAN, V15, P449, DOI 10.2147/VHRM.S197732; Vinayagam S, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118431; Visentin GP, 2001, J LAB CLIN MED, V138, P22, DOI 10.1067/mlc.2001.115525; Vogel A.B., 2020, BIORXIV, V370, P1022, DOI 10.1101/2020.09.08.280818; Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Warkentin TE, 2005, BLOOD, V106, P3791, DOI 10.1182/blood-2005-05-1938; Watanabe Y, 2021, ACS CENTRAL SCI, V7, P594, DOI 10.1021/acscentsci.1c00080; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Zhang S, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00954-7	91	29	29	3	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							559	10.3390/vaccines9060559			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4PL	34071883	Green Published, gold			2022-04-29	WOS:000666548900001
J	Sanz-Munoz, I; Tamames-Gomez, S; Castrodeza-Sanz, J; Eiros-Bouza, JM; de Lejarazu-Leonardo, RO				Sanz-Munoz, Ivan; Tamames-Gomez, Sonia; Castrodeza-Sanz, Javier; Maria Eiros-Bouza, Jose; Ortiz de Lejarazu-Leonardo, Raul			Social Distancing, Lockdown and the Wide Use of Mask; A Magic Solution or a Double-Edged Sword for Respiratory Viruses Epidemiology?	VACCINES			English	Article						influenza; respiratory syncytial virus; COVID-19; epidemic; pandemic; respiratory virus	COVID-19	The use of non-pharmaceutical interventions (NPIs), such as social distancing, lockdowns and the massive use of masks, have not only largely prevented the spread of SARS-CoV-2, but also of other respiratory viruses such as influenza or respiratory syncytial virus (RSV). This decrease has been so high that, in most countries, the influenza and RSV epidemic has not occurred. Far from being a beneficial fact, this can be problematic, since the absence of circulation of certain pathogens can lead to a decrease in herd immunity against them. This can promote the rise of more serious, longer-lasting epidemics that start sooner. To alleviate the collateral effects that may occur due to the decrease in circulation of viruses such as influenza, it is necessary to increase the production of influenza vaccines, carry out mass vaccination campaigns and focus on vaccinating the main drivers of this virus, children.	[Sanz-Munoz, Ivan; Tamames-Gomez, Sonia; Castrodeza-Sanz, Javier; Maria Eiros-Bouza, Jose; Ortiz de Lejarazu-Leonardo, Raul] Hosp Clin Univ Valladolid, Natl Influenza Ctr, Edificio Rondilla, Valladolid 47009, Spain; [Tamames-Gomez, Sonia] Consejeria Sanidad Junta Castilla & Leon, Direcc Gen Salud Publ, Valladolid 47001, Spain; [Castrodeza-Sanz, Javier] Hosp Clin Univ Valladolid, Prevent Med & Publ Hlth Unit, Valladolid 47005, Spain; [Maria Eiros-Bouza, Jose] Hosp Univ Rio Hortega, Microbiol Unit, Valladolid 47012, Spain		Sanz-Munoz, I (通讯作者)，Hosp Clin Univ Valladolid, Natl Influenza Ctr, Edificio Rondilla, Valladolid 47009, Spain.	isanzm@saludcastillayleon.es; TamGomSo@jcyl.es; jjcastrodeza@saludcastillayleon.es; jmeiros@uva.es; lejarazu@gmail.com	Sanz, Ivan/W-3657-2019	Sanz, Ivan/0000-0003-4725-6663; Ortiz de Lejarazu, Raul/0000-0002-4117-1186; Tamames, Sonia/0000-0001-5548-2594			Adlhoch C, 2021, EUROSURVEILLANCE, V26, P2, DOI 10.2807/1560-7917.ES.2021.26.11.2100221; Bo YC, 2021, INT J INFECT DIS, V102, P247, DOI 10.1016/j.ijid.2020.10.066; Chiu NC, 2020, J MED INTERNET RES, V22, DOI 10.2196/21257; DGSP Junta de Castilla y Leon, PROGR VIG IRA VIGIRA; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Foley DA, 2021, CLIN INFECT DIS, V73, pE2829, DOI 10.1093/cid/ciaa1906; Gandhi M, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2026913; Huang QS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21157-9; Mak GC, 2012, INFLUENZA OTHER RESP, V6, pe6, DOI 10.1111/j.1750-2659.2011.00323.x; Olsen SJ, 2020, AM J TRANSPLANT, V20, P3681, DOI 10.1111/ajt.16381; PHE, 2021, WEEKL NAT INFL COVID; Tang JW, 2021, J MED VIROL, V93, P4099, DOI 10.1002/jmv.26964; Trenholme A, 2021, EMERG INFECT DIS, V27, P641, DOI 10.3201/eid2702.204041; Wang XX, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0060872, 10.1371/currents.flu.3679b56a3a5313dc7c043fb944c6f138]; Young B, 2017, VACCINE, V35, P212, DOI 10.1016/j.vaccine.2016.11.013	15	11	11	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							595	10.3390/vaccines9060595			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7AS	34205119	Green Published, gold			2022-04-29	WOS:000666713900001
J	Toh, ZQ; Higgins, RA; Mazarakis, N; Abbott, E; Nathanielsz, J; Balloch, A; Mulholland, K; Licciardi, PV				Toh, Zheng Quan; Higgins, Rachel A.; Mazarakis, Nadia; Abbott, Elysia; Nathanielsz, Jordan; Balloch, Anne; Mulholland, Kim; Licciardi, Paul V.			Evaluating Functional Immunity Following Encapsulated Bacterial Infection and Vaccination	VACCINES			English	Article						functional antibodies; assays; opsonophagocytosis; serum bactericidal assays; encapsulated bacteria	INFLUENZAE TYPE-B; NEISSERIA-MENINGITIDIS SEROGROUP; PNEUMOCOCCAL CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; IMMUNOGENICITY; PROTECTION; ADULTS; STANDARDIZATION; SAFETY; ASSAY	Encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis cause significant morbidity and mortality in young children despite the availability of vaccines. Highly specific antibodies are the primary mechanism of protection against invasive disease. Robust and standardised assays that measure functional antibodies are also necessary for vaccine evaluation and allow for the accurate comparison of data between clinical studies. This mini review describes the current state of functional antibody assays and their importance in measuring protective immunity.	[Toh, Zheng Quan; Higgins, Rachel A.; Mazarakis, Nadia; Abbott, Elysia; Nathanielsz, Jordan; Balloch, Anne; Mulholland, Kim; Licciardi, Paul V.] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Toh, Zheng Quan; Mulholland, Kim; Licciardi, Paul V.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Mulholland, Kim] Univ London, London Sch Hyg & Trop Med, London WC1E 7HT, England		Licciardi, PV (通讯作者)，Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.; Licciardi, PV (通讯作者)，Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.	zheng.quantoh@mcri.edu.au; Rachel.higgins@mcri.edu.au; Nadia.mazarakis@mcri.edu.au; elysiaabbott@outlook.com; jmnathanielsz@gmail.com; anne.balloch@mcri.edu.au; kim.mulholland@lshtm.ac.uk; paul.licciardi@mcri.edu.au		Licciardi, Paul/0000-0001-6086-6285; Toh, Zheng Quan/0000-0002-0282-5837			Aase A, 2003, VACCINE, V21, P2042, DOI 10.1016/S0264-410X(02)00774-0; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Arnold KB, 2018, IMMUNOLOGY, V153, P279, DOI 10.1111/imm.12861; Borrow R, 2005, CLIN DIAGN LAB IMMUN, V12, P970, DOI 10.1128/CDLI.12.8.970-976.2005; BOSLEGO J, 1995, VACCINE, V13, P821, DOI 10.1016/0264-410X(94)00037-N; Chiappini E, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3316-1; Choi MJ, 2018, HUM VACC IMMUNOTHER, V14, P67, DOI 10.1080/21645515.2017.1377379; Correa V.A., 2020, BIOMED J, DOI [10.1016/j.bj.2020.10.009, DOI 10.1016/J.BJ.2020.10.009]; Dentinger CM, 2006, HUM VACCINES, V2, P24, DOI 10.4161/hv.2.1.2445; Feavers I, 2010, METHODS MOL BIOL, V626, P199, DOI 10.1007/978-1-60761-585-9_14; Feyssaguet M, 2019, VACCINE, V37, P2208, DOI 10.1016/j.vaccine.2019.03.011; Findlow H, 2009, CLIN VACCINE IMMUNOL, V16, P969, DOI 10.1128/CVI.00068-09; Findlow J, 2019, HUM VACC IMMUNOTHER, V15, P2491, DOI 10.1080/21645515.2019.1593082; Gioia CAC, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431X20175590, 10.1590/1414-431x20175590]; Hoe E, 2017, MICROBIOL IMMUNOL, V61, P49, DOI 10.1111/1348-0421.12471; Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5; Jones S, 2018, VACCINE, V36, P3756, DOI 10.1016/j.vaccine.2018.05.056; Kim HW, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1808-4; Licciardi PV, 2012, J ALLERGY CLIN IMMUN, V129, P794, DOI 10.1016/j.jaci.2011.11.043; Lottenbach KR, 2004, J AM GERIATR SOC, V52, P1883, DOI 10.1111/j.1532-5415.2004.52511.x; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Martinez J, 2002, CLIN DIAGN LAB IMMUN, V9, P485, DOI 10.1128/CDLI.9.2.485-488.2002; Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156, DOI 10.1128/CDLI.4.2.156-167.1997; Mubarak A, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.05.017; Nix EB, 2012, CLIN VACCINE IMMUNOL, V19, P766, DOI 10.1128/CVI.05675-11; Oliveira JB, 2010, J ALLERGY CLIN IMMUN, V125, pS297, DOI 10.1016/j.jaci.2009.08.043; Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10; Perkins BA, 1998, J INFECT DIS, V177, P683, DOI 10.1086/514232; Plested JS, 2008, CLIN VACCINE IMMUNOL, V15, P799, DOI 10.1128/CVI.00036-08; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200; Sadarangani M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02674; Siegel SJ, 2015, ANNU REV MICROBIOL, V69, P425, DOI 10.1146/annurev-micro-091014-104209; Temple B, 2019, LANCET INFECT DIS, V19, P497, DOI 10.1016/S1473-3099(18)30734-5; Townsend K, 2014, VACCINE, V32, P5650, DOI 10.1016/j.vaccine.2014.08.010; Tsoi SK, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/167089; Ulanova M, 1996, CLIN EXP IMMUNOL, V105, P422, DOI 10.1046/j.1365-2249.1996.d01-788.x; van den Broek B, 2019, CLIN EXP IMMUNOL, V198, P381, DOI 10.1111/cei.13368; Vermont C, 2002, FEMS IMMUNOL MED MIC, V34, P89, DOI 10.1016/S0928-8244(02)00342-5; Voysey M, 2018, CLIN INFECT DIS, V66, P913, DOI 10.1093/cid/cix895; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; WHO, 2017, WHO TECH REP SER, V1004, P1; World Health Organization, 2007, WHO WORKSH STAND PNE; World Health Organization, 2010, IMM BAS IMM SER; Zunt JR, 2018, LANCET NEUROL, V17, P1061, DOI 10.1016/S1474-4422(18)30387-9	45	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							677	10.3390/vaccines9060677			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6ZO	34203030	Green Published, gold			2022-04-29	WOS:000666033800001
J	Fortmann, I; Dammann, MT; Humberg, A; Siller, B; Stichtenoth, G; Engels, G; Marissen, J; Faust, K; Hanke, K; Goedicke-Fritz, S; Derouet, C; Meyer, S; Stutz, R; Kaiser, E; Herting, E; Gopel, W; Hartel, C; Zemlin, M				Fortmann, Ingmar; Dammann, Marie-Theres; Humberg, Alexander; Siller, Bastian; Stichtenoth, Guido; Engels, Geraldine; Marissen, Janina; Faust, Kirstin; Hanke, Kathrin; Goedicke-Fritz, Sybelle; Derouet, Christoph; Meyer, Sascha; Stutz, Regine; Kaiser, Elisabeth; Herting, Egbert; Goepel, Wolfgang; Haertel, Christoph; Zemlin, Michael		German Neonatal Network GNN; PRIMAL Consortium	Five Year Follow Up of Extremely Low Gestational Age Infants after Timely or Delayed Administration of Routine Vaccinations	VACCINES			English	Article						immunization; prematurity; trained immunity; long-term outcome	BIRTH-WEIGHT INFANTS; RESPIRATORY OUTCOMES; PRETERM INFANTS; INCREASED RISK; 1ST YEAR; VACCINE; LIFE; SEPSIS	This study is aimed at detecting the rate of untimely immunization in a large cohort of extremely low gestational age neonates (ELGANs) of the German Neonatal Network (GNN) and at addressing risk factors for delayed vaccination and associated long-term consequences. We performed an observational study of the GNN between 1st January 2010 and 31st December 2019. The immunization status for the hexavalent and pneumococcal immunization was evaluated in n = 8401 preterm infants <29 weeks of gestation. Univariate analysis and logistic/linear regression models were used to identify risk factors for vaccination delay and outcomes at a 5-year follow-up. In our cohort n = 824 (9.8%) ELGANs did not receive a timely first immunization with the hexavalent and pneumococcal vaccine. Risk factors for delayed vaccination were SGA status (18.1% vs. 13.5%; OR 1.3; 95% CI: 1.1-1.7), impaired growth and surrogates for complicated clinical courses (i.e., need for inotropes, necrotizing enterocolitis). At 5 years of age, timely immunized children had a lower risk of bronchitis (episodes within last year: 27.3% vs. 37.7%; OR 0.60, 95% CI: 0.42-0.86) but spirometry measures were unaffected. In conclusion, a significant proportion of ELGANs are untimely immunized, specifically those with increased vulnerability, even though they might particularly benefit from the immune-promoting effects of a timely vaccination.	[Fortmann, Ingmar; Dammann, Marie-Theres; Humberg, Alexander; Siller, Bastian; Stichtenoth, Guido; Faust, Kirstin; Hanke, Kathrin; Herting, Egbert; Goepel, Wolfgang] Univ Lubeck, Dept Pediat, D-23538 Lubeck, Germany; [Fortmann, Ingmar] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, D-23538 Lubeck, Germany; [Engels, Geraldine; Marissen, Janina; Haertel, Christoph] Univ Wurzburg, Dept Pediat, D-97080 Wurzburg, Germany; [Goedicke-Fritz, Sybelle; Derouet, Christoph; Meyer, Sascha; Stutz, Regine; Kaiser, Elisabeth; Zemlin, Michael] Saarland Univ, Dept Gen Pediat & Neonatol, D-66421 Homburg, Germany		Fortmann, I (通讯作者)，Univ Lubeck, Dept Pediat, D-23538 Lubeck, Germany.; Fortmann, I (通讯作者)，German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, D-23538 Lubeck, Germany.	matsingmar.fortmann@uksh.de; dammann@stupa.uni-luebeck.de; alexander.humberg@uksh.de; bastian.siller@uksh.de; guido.stichtenoth@uksh.de; engels_g@ukw.de; marissen_j@ukw.de; kirstin.faust@uksh.de; kathrin.hanke@uksh.de; sybelle.goedicke-fritz@uks.eu; christoph.derouet@uks.eu; sascha.meyer@uks.eu; regine.stutz@uks.eu; elisabeth.kaiser@uks.eu; Egbert.Herting@uksh.de; wolfgang.goepel@uksh.de; haertel_C1@ukw.de; michael.zemlin@uks.eu			German Ministry for Education and ResearchFederal Ministry of Education & Research (BMBF) [01ER0805, 01ER1501, 01GL1746D]	This research was funded by the German Ministry for Education and Research (GNN grant No. 01ER0805 and 01ER1501 and PRIMAL grant No. 01GL1746D).	Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240; AG 6-fach-Impfung (DTaP-IPV-Hib-HepB) der Stundigen Impfkommission (STIKO), 2020, EPID B, V26, P3, DOI [10.25646/6955.2, DOI 10.25646/6955.2]; Batra JS, 2009, PEDIATRICS, V123, P951, DOI 10.1542/peds.2008-0231; Blok BA, 2015, J LEUKOCYTE BIOL, V98, P347, DOI 10.1189/jlb.5RI0315-096R; Chiappini E, 2019, EXPERT REV VACCINES, V18, P523, DOI 10.1080/14760584.2019.1604230; Cuervo AM, 2012, MOL ASPECTS MED, V33, P2, DOI 10.1016/j.mam.2011.09.001; de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002; Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015; Domm W, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00055; Doyle Lex W, 2003, Semin Neonatol, V8, P137, DOI 10.1016/S1084-2756(02)00221-X; Faldella G, 2007, VACCINE, V25, P1036, DOI 10.1016/j.vaccine.2006.09.065; Fortmann I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030850; Greenough A, 2012, SEMIN FETAL NEONAT M, V17, P73, DOI 10.1016/j.siny.2012.01.009; Houtepen LC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10967; Humberg A, 2020, SEMIN IMMUNOPATHOL, V42, P451, DOI 10.1007/s00281-020-00803-2; Humberg A, 2020, ARCH DIS CHILD-FETAL, V105, pF190, DOI 10.1136/archdischild-2018-316770; Keller RL, 2017, J PEDIATR-US, V187, P89, DOI 10.1016/j.jpeds.2017.04.026; Khosravi A, 2014, CELL HOST MICROBE, V15, P374, DOI 10.1016/j.chom.2014.02.006; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lin CB, 2012, EARLY HUM DEV, V88, P905, DOI 10.1016/j.earlhumdev.2012.07.009; Marchant EA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/586076; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Pagel J, 2016, CLIN EXP IMMUNOL, V185, P219, DOI 10.1111/cei.12810; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Puri K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162734; Quintin J, 2014, CURR OPIN IMMUNOL, V29, P1, DOI 10.1016/j.coi.2014.02.006; Ruckinger S, 2010, VACCINE, V28, P5012, DOI 10.1016/j.vaccine.2010.05.021; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Sisson H, 2017, J CLIN NURS, V26, P4094, DOI 10.1111/jocn.13916; Stichtenoth G, 2015, KLIN PADIATR, V227, P80, DOI 10.1055/s-0034-1396865; Townsi N, 2018, EUR CLIN RESPIR J, V5, DOI 10.1080/20018525.2018.1487214; Voigt M, 2010, J PERINAT MED, V38, P289, DOI [10.1515/JPM.2010.031, 10.1515/jpm.2010.031]; Woestenberg PJ, 2014, PEDIATR INFECT DIS J, V33, P190, DOI 10.1097/INF.0000000000000106; Ziegler B, 2010, KLIN PADIATR, V222, P243, DOI 10.1055/s-0030-1247586	34	1	1	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							493	10.3390/vaccines9050493			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1PA	34065878	Green Published, gold			2022-04-29	WOS:000654596900001
J	Rammensee, HG; Gouttefangeas, C; Heidu, S; Klein, R; Preuss, B; Walz, JS; Nelde, A; Haen, SP; Reth, M; Yang, JY; Tabatabai, G; Bosmuller, H; Hoffmann, H; Schindler, M; Planz, O; Wiesmuller, KH; Loffler, MW				Rammensee, Hans-Georg; Gouttefangeas, Cecile; Heidu, Sonja; Klein, Reinhild; Preuss, Beate; Walz, Juliane Sarah; Nelde, Annika; Haen, Sebastian P.; Reth, Michael; Yang, Jianying; Tabatabai, Ghazaleh; Bosmuller, Hans; Hoffmann, Helen; Schindler, Michael; Planz, Oliver; Wiesmuller, Karl-Heinz; Loffler, Markus W.			Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups	VACCINES			English	Article						peptide vaccine; adjuvant; lipopeptide; high-risk patient; COVID-19; SARS-CoV-2	IMMUNE-RESPONSE; VIRUS	We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-gamma ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to HLA-DR after 19 days, following vaccination, for one peptide already at day 12. We used these results to support the design of a T-cell-inducing vaccine for application in high-risk patients, with weakened lymphocyte performance. Meanwhile, an according vaccine, incorporating T cell epitopes predominant in convalescents, is undergoing clinical trial testing.	[Rammensee, Hans-Georg; Gouttefangeas, Cecile; Heidu, Sonja; Walz, Juliane Sarah; Nelde, Annika; Haen, Sebastian P.; Hoffmann, Helen; Planz, Oliver; Loffler, Markus W.] Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany; [Rammensee, Hans-Georg; Gouttefangeas, Cecile; Haen, Sebastian P.; Tabatabai, Ghazaleh; Loffler, Markus W.] German Canc Consortium DKTK, Partner Site Tubingen, D-72076 Tubingen, Germany; [Rammensee, Hans-Georg; Gouttefangeas, Cecile; Haen, Sebastian P.; Tabatabai, Ghazaleh; Loffler, Markus W.] German Canc Res Ctr, Partner Site Tubingen, D-72076 Tubingen, Germany; [Rammensee, Hans-Georg; Gouttefangeas, Cecile; Walz, Juliane Sarah; Nelde, Annika; Loffler, Markus W.] Univ Tubingen, Cluster Excellence iFIT EXC2180 Image Guided & Fu, D-72076 Tubingen, Germany; [Rammensee, Hans-Georg] Univ Tubingen, Cluster Excellence CMFI EXC2124 Controlling Micro, D-72076 Tubingen, Germany; [Klein, Reinhild; Preuss, Beate] Univ Hosp Tubingen, Dept Hematol Oncol Clin Immunol & Rheumatol, Otfried Muller Str 10, D-72076 Tubingen, Germany; [Walz, Juliane Sarah; Nelde, Annika] Univ Hosp Tubingen, Clin Collaborat Unit Translat Immunol, German Canc Consortium DKTK, Otfried Muller Str 10, D-72076 Tubingen, Germany; [Walz, Juliane Sarah] Dr Margarete Fischer Bosch Inst Clin Pharmacol IK, Auerbachstr 112, D-70376 Stuttgart, Germany; [Walz, Juliane Sarah] Robert Bosch Ctr Tumor Dis RBCT, Auerbachstr 112, D-70376 Stuttgart, Germany; [Haen, Sebastian P.] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Martinistr 52, D-20246 Hamburg, Germany; [Reth, Michael; Yang, Jianying] Univ Freiburg, Dept Mol Immunol, Signaling Res Centres BIOSS & CIBSS, Inst Biol 3, D-79104 Freiburg, Germany; [Tabatabai, Ghazaleh] Univ Hosp Tubingen, Comprehens Canc Ctr Tubingen Stuttgart, Ctr Neurooncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany; [Tabatabai, Ghazaleh] Univ Hosp Tubingen, Hertie Inst Clin Brain Res, Dept Neurol & Interdisciplinary Neurooncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany; [Bosmuller, Hans] Univ Hosp Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany; [Schindler, Michael] Univ Hosp Tubingen, Inst Med Virol & Epidemiol Viral Dis, Elfriede Aulhorn Str 6, D-72076 Tubingen, Germany; [Wiesmuller, Karl-Heinz] EMC Microcollect GmbH, Sindelfinger Str 3, D-72070 Tubingen, Germany; [Loffler, Markus W.] Univ Hosp Tubingen, Dept Gen Visceral & Transplant Surg, Hoppe Seyler Str 3, D-72076 Tubingen, Germany; [Loffler, Markus W.] Univ Hosp Tubingen, Dept Clin Pharmacol, Morgenstelle 8, D-72076 Tubingen, Germany		Rammensee, HG (通讯作者)，Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.; Rammensee, HG (通讯作者)，German Canc Consortium DKTK, Partner Site Tubingen, D-72076 Tubingen, Germany.; Rammensee, HG (通讯作者)，German Canc Res Ctr, Partner Site Tubingen, D-72076 Tubingen, Germany.; Rammensee, HG (通讯作者)，Univ Tubingen, Cluster Excellence iFIT EXC2180 Image Guided & Fu, D-72076 Tubingen, Germany.; Rammensee, HG (通讯作者)，Univ Tubingen, Cluster Excellence CMFI EXC2124 Controlling Micro, D-72076 Tubingen, Germany.	rammensee@uni-tuebingen.de; cecile.gouttefangeas@uni-tuebingen.de; sonja.heidu@uni-tuebingen.de; reinhild.klein@med.uni-tuebingen.de; beate.preuss@med.uni-tuebingen.de; juliane.walz@med.uni-tuebingen.de; annika.nelde@uni-tuebingen.de; michael.reth@bioss.uni-freiburg.de; yang@biologie.uni-freiburg.de; ghazaleh.tabatabai@uni-tuebingen.de; hans.boesmueller@med.uni-tuebingen.de; helen.hoffmann@uni-tuebingen.de; michael.schindler@med.uni-tuebingen.de; oliver.planz@uni-tuebingen.de; karl-heinz.wiesmueller@uni-tuebingen.de; markus.loeffler@uni-tuebingen.de	Löffler, Markus/K-2239-2014; Walz, Juliane/ABE-1748-2021; Tabatabai, Ghazaleh/A-6365-2015	Löffler, Markus/0000-0003-2513-1317; Walz, Juliane/0000-0001-6404-7391; Tabatabai, Ghazaleh/0000-0003-3702-923X; Reth, Michael/0000-0002-1025-7198; gouttefangeas, cecile/0000-0002-6410-2378; Nelde, Annika/0000-0001-8504-8481; Klein, Reinhild/0000-0002-6111-3901; Tabatabai, Ghazaleh/0000-0002-3542-8782; Rammensee, Hans-Georg/0000-0003-1614-2647	University of Tubingen; University Hospital Tubingen; DFG Cluster of Excellence "iFIT-Image-Guided and Functionally Instructed Tumor Therapies" [EXC 2180]; Medical Faculty at the University of Tubingen; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [EXC 2180 (390900677)]; Ernst-Jung Stiftung	Generic funding was provided by the University of Tubingen, the University Hospital Tubingen as well as the DFG Cluster of Excellence "iFIT-Image-Guided and Functionally Instructed Tumor Therapies" (EXC 2180, to H.-G. Rammensee, C. Gouttefangeas, J.S. Walz and M.W. Loffler). Additional funding was granted to H.-G. Rammensee by the Ernst-Jung Stiftung and from the Medical Faculty at the University of Tubingen by an intramural grant ("Angewandte Klinische Forschung" (AKF) program to G. Tabatabai and H.G. Rammensee) with regard to GMP-manufacturing of XS15. Gefordert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Lander-EXC 2180 (390900677). We acknowledge support by Deutsche Forschungsgemeinschaft (DFG) and Open Access Publishing Fund of University of Tubingen.	Avelos AM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00092; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; Erdal GS, 2021, INT J CLIN ONCOL, V26, P826, DOI 10.1007/s10147-021-01863-6; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Hanley BP, 2019, REJUV RES, V22, P31, DOI 10.1089/rej.2018.2059; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Loffler MW, 2016, J HEPATOL, V65, P849, DOI 10.1016/j.jhep.2016.06.027; Markovic-Plese S, 2005, J NEUROIMMUNOL, V169, P31, DOI 10.1016/j.jneuroim.2005.07.014; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Panagiotou OA, 2021, JAMA INTERN MED, V181, P439, DOI 10.1001/jamainternmed.2020.7968; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Rammensee H.S., 2020, BIORXIV PREPRINT, DOI [10.21203/rs.3.rs-27316/v1, DOI 10.21203/RS.3.RS-27316/V1]; Rammensee HG, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0796-5; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Takano T, 2008, J VET MED SCI, V70, P1315, DOI 10.1292/jvms.70.1315; Tania MR, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20415; Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017; West JB, 2017, AM J PHYSIOL-LUNG C, V313, pL651, DOI 10.1152/ajplung.00133.2017; Widenmeyer M, 2012, INT J CANCER, V131, P140, DOI 10.1002/ijc.26365; Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3; Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	27	4	4	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							428	10.3390/vaccines9050428			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1RX	33923363	gold, Green Published			2022-04-29	WOS:000654604400001
J	Scelfo, C; Menzella, F; Fontana, M; Ghidoni, G; Galeone, C; Facciolongo, NC				Scelfo, Chiara; Menzella, Francesco; Fontana, Matteo; Ghidoni, Giulia; Galeone, Carla; Facciolongo, Nicola Cosimo			Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance	VACCINES			English	Review						pneumococcal colonization; pneumonia; vaccines; anticapsular antibodies; humoral immunity; serotypes	COMMUNITY-ACQUIRED PNEUMONIA; PLAIN POLYSACCHARIDE VACCINES; B-CELL RESPONSE; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; ECONOMIC-EVALUATION; COST-EFFECTIVENESS; PROTEIN-CONJUGATE; IMMUNE-RESPONSES; UNITED-STATES	Streptococcus pneumoniae related diseases are a leading cause of morbidity and mortality, especially in children and in the elderly population. It is transmitted to other individuals through droplets and it can spread to other parts of the human host, causing a wide spectrum of clinical syndromes, affecting between 10 and 100 cases per 100,000 people in Europe and the USA. In order to reduce morbidity and mortality caused by this agent, pneumococcal vaccines have been developed over the years and have shown incredible effectiveness in reducing the spread of this bacterium and the development of related diseases, obtaining a significant reduction in mortality, especially in developing countries. However, considerable problems are emerging mainly due to the replacement phenomenon, multi-drug resistance, and the high production costs of conjugated vaccines. There is still a debate about the indications given by various countries to different age groups; this is one of the reasons for the diffusion of different serotypes. To cope with these problems, significant efforts have been made in the research field to further improve vaccination serotypes coverage. On the other hand, an equally important commitment by health care systems to all age group populations is needed to improve vaccination coverage.	[Scelfo, Chiara; Menzella, Francesco; Fontana, Matteo; Ghidoni, Giulia; Galeone, Carla; Facciolongo, Nicola Cosimo] IRCCS Reggio Emilia, Azienda Unita Sanit Locale, Dept Med Specialties, Pneumol Unit, I-42100 Reggio Emilia, Italy		Scelfo, C (通讯作者)，IRCCS Reggio Emilia, Azienda Unita Sanit Locale, Dept Med Specialties, Pneumol Unit, I-42100 Reggio Emilia, Italy.	chiara.scelfo@ausl.re.it; francesco.menzella@ausl.re.it; matteo.fontana@ausl.re.it; giulia.ghidoni@ausl.re.it; carla.galeone@ausl.re.it; nicola.facciolongo@ausl.re.it	Fontana, Matteo/AAU-4692-2021; Menzella, Francesco/AAK-3075-2021	Fontana, Matteo/0000-0001-8758-8449; Menzella, Francesco/0000-0003-3950-5789; Scelfo, Chiara/0000-0002-3192-3882			Ahl J, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-492; Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019; [Anonymous], 2019, Weekly Epidemiological Record, V94, P85; Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P258; Artz AS, 2003, CLIN MICROBIOL REV, V16, P308, DOI 10.1128/CMR.16.2.308-318.2003; Baxendale HE, 2010, VACCINE, V28, P4763, DOI 10.1016/j.vaccine.2010.04.103; Ben-Shimol S, 2014, CLIN INFECT DIS, V59, P1724, DOI 10.1093/cid/ciu683; Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Berman-Rosa M, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0377; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Blasi F, 2012, CLIN MICROBIOL INFEC, V18, P7, DOI 10.1111/j.1469-0691.2012.03937.x; Bonnave C, 2019, EUR J CLIN MICROBIOL, V38, P785, DOI 10.1007/s10096-019-03485-3; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Burgos J, 2014, EUR RESPIR J, V43, P545, DOI 10.1183/09031936.00050413; Cafiero-Fonseca ET, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186903; Center for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT; Center for Disease Control and Prevention (CDC) Center for Disease Control and Prevention (CDC), 2019, EAR INF; Center for Disease Control and Prevention (CDC) Center for Disease Control and Prevention (CDC), 2019, SIN INF SIN; Chalmers JD, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0242-0; Chan TC, 2012, J AM MED DIR ASSOC, V13, P698, DOI 10.1016/j.jamda.2012.05.009; Cheng A, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20631; Clarke E, 2021, LANCET INFECT DIS, V21, P834, DOI 10.1016/S1473-3099(20)30735-0; Clutterbuck EA, 2008, CLIN VACCINE IMMUNOL, V15, P182, DOI 10.1128/CVI.00336-07; Clutterbuck EA, 2006, IMMUNOLOGY, V119, P328, DOI 10.1111/j.1365-2567.2006.02436.x; Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212; Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC; Converso TR, 2020, EXPERT REV VACCINES, V19, P57, DOI 10.1080/14760584.2020.1711055; Cools F, 2021, FEMS MICROBIOL REV, V45, DOI 10.1093/femsre/fuaa072; Cortes I, 2013, VACCINE, V31, P3473, DOI 10.1016/j.vaccine.2013.05.097; de Roux A, 2008, CLIN INFECT DIS, V46, P1015, DOI 10.1086/529142; Demirdal T, 2021, EXPERT REV ANTI-INFE, V19, P927, DOI 10.1080/14787210.2021.1858799; Dirmesropian S, 2015, HUM VACC IMMUNOTHER, V11, P818, DOI 10.1080/21645515.2015.1011954; Dockrell DH, 2012, CHEST, V142, P482, DOI 10.1378/chest.12-0210; Dransfield MT, 2009, AM J RESP CRIT CARE, V180, P499, DOI 10.1164/rccm.200903-0488OC; Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461; Esposito S, 2019, FUTURE MICROBIOL, V14, P921, DOI 10.2217/fmb-2019-0151; Esposito S, 2015, PULM PHARMACOL THER, V32, P124, DOI 10.1016/j.pupt.2014.02.003; Esposito S, 2013, EXPERT OPIN PHARMACO, V14, P65, DOI 10.1517/14656566.2013.756867; European Centre for Disease Prevention and Control European Centre for Disease Prevention and Control, 2017, INV PNEUM DIS ANN EP; Falleiros-Arlant LH, 2015, INT J INFECT DIS, V38, P1, DOI 10.1016/j.ijid.2015.06.016; Farmaki PF, 2018, J INFECT DIS, V218, P26, DOI 10.1093/infdis/jiy135; Feldman C, 2011, DRUGS, V71, P131, DOI 10.2165/11585310-000000000-00000; Forstner C, 2020, VACCINE, V38, P1129, DOI 10.1016/j.vaccine.2019.11.026; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; French N, 2010, NEW ENGL J MED, V362, P812, DOI 10.1056/NEJMoa0903029; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Garattini L, 2016, PHARMACOECONOMICS, V34, P221, DOI 10.1007/s40273-015-0341-4; Garcia-Altes A, 2013, VACCINE, V31, P1656, DOI 10.1016/j.vaccine.2013.01.029; Ginsburg AS, 2017, LANCET GLOB HEALTH, V5, pE1176, DOI 10.1016/S2214-109X(17)30364-9; Goldblatt D, 2009, CLIN INFECT DIS, V49, P1318, DOI 10.1086/606046; Grabenstein JD, 2011, VACCINE, V29, P6149, DOI 10.1016/j.vaccine.2011.06.116; Greenberg D, 2015, VACCINE, V33, P4623, DOI 10.1016/j.vaccine.2015.06.062; Griffin MR, 2014, MMWR-MORBID MORTAL W, V63, P995; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Istituto Superiore di Sanita Istituto Superiore di Sanita, REP 2019 SORV MAL BA; Izurieta P, 2018, EXPERT REV VACCINES, V17, P479, DOI 10.1080/14760584.2018.1413354; Jackson LA, 2007, VACCINE, V25, P4029, DOI 10.1016/j.vaccine.2007.02.062; Jokinen JT, 2004, J INFECT DIS, V190, P545, DOI 10.1086/422531; Jose RJ, 2017, CURR OPIN PULM MED, V23, P225, DOI 10.1097/MCP.0000000000000369; Kim GL, 2017, ARCH PHARM RES, V40, P885, DOI 10.1007/s12272-017-0933-y; Klugman KP, 2018, P NATL ACAD SCI USA, V115, P12896, DOI 10.1073/pnas.1721095115; Kohler S, 2016, FEBS LETT, V590, P3820, DOI 10.1002/1873-3468.12352; Kontou P, 2009, AM J EMERG MED, V27, P968, DOI 10.1016/j.ajem.2008.07.037; Kuronum K, 2018, VACCINE, V36, P4968, DOI 10.1016/j.vaccine.2018.06.062; Kuronuma K, 2019, HUM VACC IMMUNOTHER, V15, P859, DOI 10.1080/21645515.2018.1564443; Kuster SP, 2014, CLIN INFECT DIS, V59, P944, DOI 10.1093/cid/ciu497; Kyaw MH, 2002, EPIDEMIOL INFECT, V128, P21, DOI 10.1017/S0950268801006331; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lagousi T, 2020, EXPERT REV VACCINES, V19, P959, DOI 10.1080/14760584.2020.1843433; Lagousi T, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010009; Lazarus R, 2011, CLIN INFECT DIS, V52, P736, DOI 10.1093/cid/cir003; Lee C, 2019, BIOLOGICALS, V61, P32, DOI 10.1016/j.biologicals.2019.07.005; Levy C, 2019, J PEDIATR-US, V213, P252, DOI 10.1016/j.jpeds.2019.07.057; Linares J, 2010, CLIN MICROBIOL INFEC, V16, P402, DOI 10.1111/j.1469-0691.2010.03182.x; Lochen A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75691-5; Loo JD, 2014, PEDIATR INFECT DIS J, V33, pS161, DOI 10.1097/INF.0000000000000084; Lynch JP, 2009, SEMIN RESP CRIT CARE, V30, P189, DOI 10.1055/s-0029-1202938; Mahamat A, 2013, HUM VACC IMMUNOTHER, V9, P128, DOI 10.4161/hv.22550; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; Matanock A., CONSIDERATIONS PCV13; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; McGirr A, 2019, HUM VACC IMMUNOTHER, V15, P2713, DOI 10.1080/21645515.2019.1612667; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; Ministero della Salute, PIAN NAZ PREV VACC 2; Mirsaeidi Mehdi, 2014, Ann Am Thorac Soc, V11, P980, DOI 10.1513/AnnalsATS.201401-042CME; Mohammadzadeh M, 2018, MICROB PATHOGENESIS, V122, P122, DOI 10.1016/j.micpath.2018.06.026; Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685; Torne AN, 2014, VACCINE, V32, P3644, DOI 10.1016/j.vaccine.2014.04.066; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Ochoa-Gondar O, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-222; Ogilvie I, 2009, VACCINE, V27, P4891, DOI 10.1016/j.vaccine.2009.05.061; Oligbu G, 2019, METHODS MOL BIOL, V1968, P205, DOI 10.1007/978-1-4939-9199-0_17; Papadatou I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010013; Papadatou I, 2014, CLIN INFECT DIS, V59, P862, DOI 10.1093/cid/ciu409; Parameswarappa SG, 2016, CELL CHEM BIOL, V23, P1407, DOI 10.1016/j.chembiol.2016.09.016; Pettigrew MM, 2014, INFECT IMMUN, V82, P4607, DOI 10.1128/IAI.02225-14; Pichichero ME, 2017, EXPERT REV VACCINES, V16, P1181, DOI 10.1080/14760584.2017.1393335; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Porchia BR, 2017, EXPERT REV VACCINES, V16, P93, DOI 10.1080/14760584.2017.1242419; Principi N, 2018, CURR INFECT DIS REP, V20, DOI 10.1007/s11908-018-0607-z; Principi N, 2018, EXPERT OPIN BIOL TH, V18, P7, DOI 10.1080/14712598.2018.1384462; Prymula R, 2014, VACCINE, V32, P3025, DOI 10.1016/j.vaccine.2014.03.066; Reinert RR, 2009, CLIN MICROBIOL INFEC, V15, P7, DOI 10.1111/j.1469-0691.2009.02724.x; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016; Rodriguez CA, 2004, J INFECT DIS, V190, P1481, DOI 10.1086/424467; Schmoele-Thoma B, 2015, J VACCINES IMMUN, V3, P7, DOI [10.14312/2053-1273.2015-2, DOI 10.14312/2053-1273.2015-2]; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3; Sings HL, 2019, CLIN INFECT DIS, V68, P2135, DOI 10.1093/cid/ciy920; Song JH, 2013, EXPERT REV RESP MED, V7, P491, DOI 10.1586/17476348.2013.816572; Suaya JA, 2020, J INFECTION, V81, P557, DOI 10.1016/j.jinf.2020.07.035; Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942; Tan TQ, 2003, CURR OPIN INFECT DIS, V16, P271, DOI 10.1097/00001432-200306000-00015; Temple B, 2019, LANCET INFECT DIS, V19, P497, DOI 10.1016/S1473-3099(18)30734-5; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; Torres A, 2015, EUR J CLIN MICROBIOL, V34, P19, DOI 10.1007/s10096-014-2208-6; TORRES A, 1984, CHEST, V85, P584, DOI 10.1378/chest.85.4.584; Ulanova M, 2021, VACCINE, V39, P699, DOI 10.1016/j.vaccine.2020.12.035; Vadlamudi NK, 2019, CLIN INFECT DIS, V69, P34, DOI 10.1093/cid/ciy872; Van Bambeke F, 2007, DRUGS, V67, P2355, DOI 10.2165/00003495-200767160-00005; van de Vooren K, 2014, PHARMACOECONOMICS, V32, P29, DOI 10.1007/s40273-013-0113-y; van Hoek AJ, 2014, VACCINE, V32, P4349, DOI 10.1016/j.vaccine.2014.03.017; van Werkhoven CH, 2018, CLIN CHEST MED, V39, P733, DOI 10.1016/j.ccm.2018.07.007; van Werkhoven CH, 2015, CLIN INFECT DIS, V61, P1835, DOI 10.1093/cid/civ686; Vestjens SMT, 2019, VACCINE, V37, P6558, DOI 10.1016/j.vaccine.2019.08.025; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Weil-Olivier C, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-207; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; Wiese AD, 2019, EXPERT REV VACCINES, V18, P327, DOI 10.1080/14760584.2019.1582337; World Health Organization, PNEUM DIS; World Health Organization, 2008, EST HIB PNEUM DEATHS	134	3	3	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							420	10.3390/vaccines9050420			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1JJ	33922273	gold, Green Published			2022-04-29	WOS:000654582100001
J	Kim, KH; Bhatnagar, N; Jeeva, S; Oh, J; Park, BR; Shin, CH; Wang, BZ; Kang, SM				Kim, Ki-Hye; Bhatnagar, Noopur; Jeeva, Subbiah; Oh, Judy; Park, Bo Ryoung; Shin, Chong Hyun; Wang, Bao-Zhong; Kang, Sang-Moo			Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice	VACCINES			English	Article						SARS-CoV-2; spike; neutralizing activity; RBD-hACE2 inhibition; cellular immunity; aged mice	VACCINE; PROTECTS	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be expanding the pandemic disease across the globe. Although SARS-CoV-2 vaccines were rapidly developed and approved for emergency use of vaccination in humans, supply and production difficulties are slowing down the global vaccination program. The efficacy of many different versions of vaccine candidates and adjuvant effects remain unknown, particularly in the elderly. In this study, we compared the immunogenic properties of SARS-CoV-2 full-length spike (S) ectodomain in young adult and aged mice, S1 with receptor binding domain, and S2 with fusion domain. Full-length S was more immunogenic and effective in inducing IgG antibodies after low dose vaccination, compared to the S1 subunit. Old-aged mice induced SARS-CoV-2 spike-specific IgG antibodies with neutralizing activity after high dose S vaccination. With an increased vaccine dose, S1 was highly effective in inducing neutralizing and receptor-binding inhibiting antibodies, although both S1 and S2 subunit domain vaccines were similarly immunogenic. Adjuvant effects were significant for effective induction of IgG1 and IgG2a isotypes, neutralizing and receptor-binding inhibiting antibodies, and antibody-secreting B cell and interferon-gamma secreting T cell immune responses. Results of this study provide information in designing SARS-CoV-2 spike vaccine antigens and effective vaccination in the elderly.	[Kim, Ki-Hye; Bhatnagar, Noopur; Jeeva, Subbiah; Oh, Judy; Park, Bo Ryoung; Shin, Chong Hyun; Wang, Bao-Zhong; Kang, Sang-Moo] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30302 USA		Kang, SM (通讯作者)，Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30302 USA.	kkim39@gsu.edu; nbhatnagar1@student.gsu.edu; jsubbiah@gsu.edu; joh27@gsu.edu; bpark9@student.gsu.edu; cshin@gsu.edu; bwang23@gsu.edu; skang24@gsu.edu		Shin, Chong/0000-0002-6385-5992; Bhatnagar, Noopur/0000-0001-9260-3957; Kang, SAng Moo/0000-0001-6198-331X; Wang, Bao-Zhong/0000-0002-1561-4318	NIH/NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI093772]	This research was partially supported by NIH/NIAID grants AI093772 (S.M.K.). The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line, NR-52511; SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated, NR-52286; Gamma-Irradiated, NR-52287; Peptide Array, SARS-Related Coronavirus 2 Spike (S) Glycoprotein, NR-52402.	Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Ashraf MU, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020171; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Bagdonaite Ieva, 2021, bioRxiv, DOI 10.1101/2021.02.03.429627; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; James SF, 2018, ANN PHARMACOTHER, V52, P673, DOI 10.1177/1060028018758431; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Ku MW, 2021, CELL HOST MICROBE, V29, P236, DOI 10.1016/j.chom.2020.12.010; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5; Lee K, 2009, GLOB INST, P1; Lee WT, 2021, J INFECT DIS, V223, P47, DOI 10.1093/infdis/jiaa673; Liu Y, 2020, ACS PHARMACOL TRANSL, V3, P844, DOI 10.1021/acsptsci.0c00109; Liu ZZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00402-5; Lombardi A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657711; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2; Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539; Routhu NK, 2021, IMMUNITY, V54, P542, DOI 10.1016/j.immuni.2021.02.001; Sanchez-Felipe L, 2021, NATURE, V590, DOI 10.1038/s41586-020-3035-9; Saunders Kevin O, 2021, bioRxiv, DOI 10.1101/2021.02.17.431492; Walls AC, 2020, CELL, V183, P1367, DOI 10.1016/j.cell.2020.10.043; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	37	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							316	10.3390/vaccines9040316			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4VT	33805473	gold, Green Published			2022-04-29	WOS:000643779500001
J	Riste, M; Marshall, J; Satti, I; Harris, S; Wilkie, M; Ramon, RL; Wright, D; Wittenberg, R; Vermaak, S; Doherty, RP; Lawrie, A; Conlon, C; Cosgrove, C; Gleeson, F; Lipman, M; Moss, P; Perrin, F; Dedicoat, M; Bettinson, H; McShane, H				Riste, Michael; Marshall, Julia; Satti, Iman; Harris, Stephanie; Wilkie, Morven; Ramon, Raquel Lopez; Wright, Danny; Wittenberg, Rachel; Vermaak, Samantha; Doherty, Rebecca Powell; Lawrie, Alison; Conlon, Christopher; Cosgrove, Catherine; Gleeson, Fergus; Lipman, Marc; Moss, Paul; Perrin, Felicity; Dedicoat, Martin; Bettinson, Henry; McShane, Helen			Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults	VACCINES			English	Article						aerosol vaccine; MVA85A; mycobacteria; latent TB infection	TUBERCULOSIS VACCINE; MYCOBACTERIUM-TUBERCULOSIS; IMMUNE-RESPONSES; PROTECTION; EFFICACY; IMMUNIZATION; CHILDHOOD; LUNGS	The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a Phase I trial to evaluate the safety and immunogenicity of MVA85A delivered by aerosol in UK adults with LTBI (NCT02532036). Two volunteers were recruited, and the vaccine was well-tolerated with no safety concerns. Aerosolised vaccination with MVA85A induced mycobacterium- and vector-specific IFN-gamma in blood and mycobacterium-specific Th1 cytokines in bronchoalveolar lavage. We identified several important barriers that could hamper recruitment into clinical trials in this patient population. The trial did not show any safety concerns in the aerosol delivery of a candidate viral-vectored TB vaccine to two UK adults with Mycobacterium tuberculosis (M.tb) infection. It also systemically and mucosally demonstrated inducible immune responses following aerosol vaccination. A further trial in a country with higher incidence of LTBI would confirm these findings.	[Riste, Michael; Marshall, Julia; Satti, Iman; Harris, Stephanie; Wilkie, Morven; Ramon, Raquel Lopez; Wright, Danny; Wittenberg, Rachel; Vermaak, Samantha; Doherty, Rebecca Powell; Lawrie, Alison; McShane, Helen] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England; [Riste, Michael; Dedicoat, Martin] Heartlands Hosp, Dept Infect & Trop Med, Birmingham B9 5SS, W Midlands, England; [Conlon, Christopher] Univ Oxford, Nuffield Dept Med, Oxford OX3 7DQ, England; [Cosgrove, Catherine] St Georges Univ Hosp NHS Fdn Trust, TB Chest Clin, London SW15 5PN, England; [Gleeson, Fergus] Univ Oxford, Dept Oncol, Oxford OX3 7DQ, England; [Lipman, Marc] Royal Free London NHS Fdn Trust, London NW3 2QG, England; [Lipman, Marc] UCL, UCL Resp, London NW3 2PF, England; [Moss, Paul] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England; [Perrin, Felicity] Kings Coll Hosp NHS Fdn Trust, Resp Med, London SE5 9PJ, England; [Bettinson, Henry] Oxford Univ Hosp NHS Trust, Oxford Ctr Resp Med, Oxford OX3 7LE, England		McShane, H (通讯作者)，Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England.	michael.riste@nhs.net; julia.marshall@ndm.ox.ac.uk; Iman.Satti@ndm.ox.ac.uk; stephanie.harris@ndm.ox.ac.uk; morvenwilkie@hotmail.co.uk; raquel.lopezramon@ndm.ox.ac.uk; danny.wright@ndm.ox.ac.uk; rachel_wittenberg@hms.harvard.edu; Samantha.Vermaak@NDM.ox.ac.uk; rebecca.powelldoherty@ndm.ox.ac.uk; alison.lawrie@ndm.ox.ac.uk; chris.conlon@ndm.ox.ac.uk; ccosgrov@sgul.ac.uk; fergus.gleeson@oncology.ox.ac.uk; marclipman@nhs.net; p.moss@bham.ac.uk; felicity.perrin@nhs.net; martin.dedicoat@heartofengland.nhs.uk; Henry.Bettinson@ndm.ox.ac.uk; Helen.Mcshane@ndm.ox.ac.uk	Dedicoat, Martin/AFC-7815-2022; Cosgrove, Catherine/AGF-2877-2022; Moss, Paul/D-1728-2009	Wright, Daniel/0000-0002-8114-1838; McShane, Helen/0000-0002-2126-5142; Lipman, Marc/0000-0001-7501-4448; Dedicoat, Martin/0000-0001-9833-4882; Moss, Paul/0000-0002-6895-1967	TuBerculosis Vaccine Initiative (TBVI)/DFID; Wellcome TrustWellcome TrustEuropean Commission [WT 206331/Z/17/Z]; European Union's Horizon 2020 research and innovation programme TBVAC2020 [643381]; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust; University of Oxford [IS-BRC-1215-20008]; National Institute for Health Research (NIHR)/Wellcome Trust King's Clinical Research Facility; NIHR Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust, King's College London; National Institute for Health Research Clinical Research Network	This research was funded by the TuBerculosis Vaccine Initiative (TBVI)/DFID) and by the Wellcome Trust. HMcS is a Wellcome Trust Investigator (grant code WT 206331/Z/17/Z). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. We also acknowledge the financial support from the European Union's Horizon 2020 research and innovation programme TBVAC2020 (grant agreement No 643381) and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford (grant code IS-BRC-1215-20008). In addition, this study represents independent research supported by the National Institute for Health Research (NIHR)/Wellcome Trust King's Clinical Research Facility and the NIHR Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust, King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Lastly, the authors acknowledge the support of the National Institute for Health Research Clinical Research Network.	[Anonymous], GLOBAL PLAN END TB P; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Cutts FT, 1997, BIOLOGICALS, V25, P323, DOI 10.1006/biol.1997.0103; Goonetilleke NP, 2003, J IMMUNOL, V171, P1602, DOI 10.4049/jimmunol.171.3.1602; Low N, 2008, VACCINE, V26, P383, DOI 10.1016/j.vaccine.2007.11.010; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Meyer J, 2013, VACCINE, V31, P1026, DOI 10.1016/j.vaccine.2012.12.042; Minassian AM, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000223; Minhinnick A, 2016, VACCINE, V34, P1412, DOI 10.1016/j.vaccine.2016.01.062; Morrison H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640916; Ndiaye BP, 2015, LANCET RESP MED, V3, P190, DOI 10.1016/S2213-2600(15)00037-5; Pathan AA, 2012, VACCINE, V30, P5616, DOI 10.1016/j.vaccine.2012.06.084; Perdomo C, 2016, MBIO, V7, DOI 10.1128/mBio.01686-16; Roth Y, 2003, ANN OTO RHINOL LARYN, V112, P264, DOI 10.1177/000348940311200313; Sander CR, 2009, AM J RESP CRIT CARE, V179, P724, DOI 10.1164/rccm.200809-1486OC; Santosuosso M, 2006, INFECT IMMUN, V74, P4634, DOI 10.1128/IAI.00517-06; Satti I, 2014, LANCET INFECT DIS, V14, P939, DOI 10.1016/S1473-3099(14)70845-X; Scriba TJ, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101431; Scriba TJ, 2012, AM J RESP CRIT CARE, V185, P769, DOI 10.1164/rccm.201108-1548OC; Sheehan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141687; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Thomas ZRM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002790; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Verreck FAW, 2017, TUBERCULOSIS, V104, P46, DOI 10.1016/j.tube.2017.02.003; White AD, 2015, CLIN VACCINE IMMUNOL, V22, P992, DOI 10.1128/CVI.00289-15; White AD, 2013, CLIN VACCINE IMMUNOL, V20, P663, DOI 10.1128/CVI.00690-12; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Wilkie M, 2020, VACCINE, V38, P779, DOI 10.1016/j.vaccine.2019.10.102	30	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							396	10.3390/vaccines9040396			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4QW	33923628	Green Accepted, gold, Green Published			2022-04-29	WOS:000643766600001
J	Strain, WD; Mansi, J; Boikos, C; Boivin, M; Fisher, WA				Strain, William David; Mansi, James; Boikos, Constantina; Boivin, Michael; Fisher, William A.			Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019-2020 Season	VACCINES			English	Article						influenza; vaccine; immunisation; vaccine hesitancy		Older adults (>= 65 years) are at elevated risk of influenza-related morbidity and mortality. Many developed countries do not achieve the World Health Organization influenza immunization target of 75% in people >= 65 years. We aimed to determine whether a brief pharmacy phone call could increase vaccine uptake of standard and enhanced influenza. Twenty-eight community pharmacists across Canada performed a telephone consultation with 643 older adults whose primary care records indicated that they had not received their influenza vaccination from their usual practitioner. Of these 643 adults, 169 (26.3%) had been vaccinated in another setting. Of the remaining 474, 313 (66%) agreed to receive the vaccine. Of those who refused vaccination, 69 provided a rationale for not wanting it, including that the flu shot "causes the flu" (n = 25), "doesn't work" (n = 25), "is too painful" (n = 10), and other (n = 10). Overall, of the 643 individuals who had not received their vaccination from their usual health care provider in the first wave of vaccinations, 75.4% (n = 485) ultimately received their vaccination in the 2019-2020 season. This highlights the important role of the community pharmacist in achieving the World Health Organization (WHO) targets for vaccination.	[Strain, William David] Univ Exeter, Diabet & Vasc Res Ctr, Med Sch, Exeter EX2 5AX, Devon, England; [Strain, William David] Royal Devon & Exeter Hosp, Acad Dept Healthcare Older People, Exeter EX2 5DW, Devon, England; [Mansi, James; Boikos, Constantina] Ctr Outcomes Res & Evaluat CORE, Seqirus, PQ H9H 4M7, Canada; [Fisher, William A.] Western Univ Canada, Dept Obstet & Gynaecol, London, ON N6A 5C2, Canada		Strain, WD (通讯作者)，Univ Exeter, Diabet & Vasc Res Ctr, Med Sch, Exeter EX2 5AX, Devon, England.; Strain, WD (通讯作者)，Royal Devon & Exeter Hosp, Acad Dept Healthcare Older People, Exeter EX2 5DW, Devon, England.	d.strain@exeter.ac.uk; James.Mansi@Seqirus.com; Constantina.Boikos@Seqirus.com; mike@commpharm.com; fisher@uwo.ca		Strain, William/0000-0002-6826-418X; Boivin, Michael R./0000-0002-3458-2462	Seqirus	This study was funded by an unrestricted educational grant from Seqirus to MDBriefCase for the development and dissemination of this learning intervention. (No relevant grant number).	Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171; Al Hamarneh YN, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003154; Andrews M, 2016, IMPACT FRAILTY INFLU; Ang LW, 2017, EPIDEMIOL INFECT, V145, P775, DOI 10.1017/S0950268816002491; Balasubramani GK, 2020, VACCINE, V38, P6562, DOI 10.1016/j.vaccine.2020.08.011; Baroy J, 2016, J AM PHARM ASSOC, V56, P418, DOI 10.1016/j.japh.2016.03.006; Beal JL, 2020, VACCINE, V38, P2456, DOI 10.1016/j.vaccine.2020.01.061; Bella A, 2019, EXPERT REV VACCINES, V18, P671, DOI 10.1080/14760584.2019.1627206; Buchan SA, 2017, CAN MED ASSOC J, V189, pE146, DOI 10.1503/cmaj.151027; Center for Disease Control Flu, VACCINATION COVERAGE; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Health Protection Scotland, INFLUENZA; Isenor JE, 2018, HUM VACC IMMUNOTHER, V14, P706, DOI 10.1080/21645515.2018.1423930; Jackson LA, 2006, INT J EPIDEMIOL, V35, P345, DOI 10.1093/ije/dyi275; Korkmaz P, 2019, CENT EUR J PUBL HEAL, V27, P44, DOI 10.21101/cejph.a5231; Kwon DS, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012618; Lapi F, 2019, EXPERT REV VACCINES, V18, P663, DOI 10.1080/14760584.2019.1622418; Leung C, 2020, MECH AGEING DEV, V188, DOI 10.1016/j.mad.2020.111255; Mangtani P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-249; Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313; Mansell K, 2017, CAN J DIABETES, V41, P558, DOI 10.1016/j.jcjd.2017.08.243; Nanda A, 2020, AGING CLIN EXP RES, V32, P1199, DOI 10.1007/s40520-020-01581-5; Okoli GN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234702; Papastergiou John, 2014, Can Pharm J (Ott), V147, P359, DOI 10.1177/1715163514552557; Pebody R, 2020, VACCINE, V38, P173, DOI 10.1016/j.vaccine.2019.10.032; Pelton SI, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030446; Public Health Agency, INFLUENZA WEEKLY SUR; Public Health Agency of Canada, CANADIAN IMMUNIZATIO; Public Health Agency of Canada, 2019, VACCINE UPTAKE CANAD; Public Health England, SEASONAL INFLUENZA V; Public Health England, IMMUNISATION INFECT; Public Health England Department of Health and Social Care, NATL FLU IMMUNISATIO; Public Health Wales, SEASONAL INFLUENZA W; Pullagura GR, 2019, J AM PHARM ASSOC, V59, P489, DOI 10.1016/j.japh.2019.02.011; Schaffner W, 2018, AM J MED, V131, P865, DOI 10.1016/j.amjmed.2018.02.019; Service Canada, VACCINE UPTAKE CANAD; Thomas RE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005188.pub4; Tsuyuki RT, 2016, J AM COLL CARDIOL, V67, P2846, DOI 10.1016/j.jacc.2016.03.528; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059; Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197	42	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							312	10.3390/vaccines9040312			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PV	33810215	Green Published, gold			2022-04-29	WOS:000643763900001
J	Dispinseri, S; Cavarelli, M; Tolazzi, M; Plebani, AM; Jansson, M; Scarlatti, G				Dispinseri, Stefania; Cavarelli, Mariangela; Tolazzi, Monica; Plebani, Anna Maria; Jansson, Marianne; Scarlatti, Gabriella			Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children	VACCINES			English	Article						HIV-1; neutralization; ADCC; children; humoral immunity; disease progression	IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT CELLULAR CYTOTOXICITY; MONOCLONAL-ANTIBODIES; HUMORAL IMMUNITY; B-CELLS; TRANSMISSION; VARIANTS; EVOLUTION; ENVELOPE; MOTHERS	The antibodies with different effector functions evoked by Human Immunodeficiency Virus type 1 (HIV-1) transmitted from mother to child, and their role in the pathogenesis of infected children remain unresolved. So, too, the kinetics and breadth of these responses remain to be clearly defined, compared to those developing in adults. Here, we studied the kinetics of the autologous and heterologous neutralizing antibody (Nab) responses, in addition to antibody-dependent cellular cytotoxicity (ADCC), in HIV-1 infected children with different disease progression rates followed from close after birth and five years on. Autologous and heterologous neutralization were determined by Peripheral blood mononuclear cells (PBMC)- and TZMbl-based assays, and ADCC was assessed with the GranToxiLux assay. The reactivity to an immunodominant HIV-1 gp41 epitope, and childhood vaccine antigens, was assessed by ELISA. Newborns displayed antibodies directed towards the HIV-1 gp41 epitope. However, antibodies neutralizing the transmitted virus were undetectable. Nabs directed against the transmitted virus developed usually within 12 months of age in children with slow progression, but rarely in rapid progressors. Thereafter, autologous Nabs persisted throughout the follow-up of the slow progressors and induced a continuous emergence of escape variants. Heterologous cross-Nabs were detected within two years, but their subsequent increase in potency and breadth was mainly a trait of slow progressors. Analogously, titers of antibodies mediating ADCC to gp120 BaL pulsed target cells increased in slow progressors during follow-up. The kinetics of antibody responses to the immunodominant viral antigen and the vaccine antigens were sustained and independent of disease progression. Persistent autologous Nabs triggering viral escape and an increase in the breadth and potency of cross-Nabs are exclusive to HIV-1 infected slowly progressing children.	[Dispinseri, Stefania; Tolazzi, Monica; Scarlatti, Gabriella] IRCCS Osped San Raffaele, Div Immunol Transplantat & Infect Dis, Viral Evolut & Transmiss Unit, I-20132 Milan, Italy; [Cavarelli, Mariangela] Univ Paris Saclay, Ctr Immunol Viral AutoImmune Hematol & Bacterial, INSERM, CEA, F-92265 Fontenay Aux Roses, France; [Plebani, Anna Maria] Univ Paris Saclay, Ctr Immunol Viral AutoImmune Hematol & Bacterial, INSERM, CEA, F-92265 Le Kremlin Bicetre, France; [Plebani, Anna Maria] ASST Settelaghi, Filippo Ponte Hosp, Pediat Emergency Unit, I-21100 Varese, Italy; [Jansson, Marianne] Lund Univ, Dept Lab Med, S-22242 Lund, Sweden		Scarlatti, G (通讯作者)，IRCCS Osped San Raffaele, Div Immunol Transplantat & Infect Dis, Viral Evolut & Transmiss Unit, I-20132 Milan, Italy.	dispinseri.stefania@hsr.it; mariangela.cavarelli@cea.fr; tolazzi.monica@hsr.it; annample@yahoo.it; marianne.jansson@med.lu.se; scarlatti.gabriella@hsr.it		Scarlatti, Gabriella/0000-0003-2316-2689; CAVARELLI, MARIANGELA/0000-0002-8468-0263; Jansson, Marianne/0000-0001-6536-8146	EAVI2020, the European Union's Horizon 2020 research and innovation programme [681137]	Financial support was obtained from EAVI2020, the European Union's Horizon 2020 research and innovation programme under grant agreement No. 681137.	AHMAD N, 1995, J VIROL, V69, P1001, DOI 10.1128/JVI.69.2.1001-1012.1995; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; Baan E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069274; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BROLIDEN K, 1993, CLIN EXP IMMUNOL, V93, P56; Bunnik EM, 2008, J VIROL, V82, P7932, DOI 10.1128/JVI.00757-08; Cavarelli M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003292; Dickover R, 2006, J VIROL, V80, P6525, DOI 10.1128/JVI.02658-05; Ditse Z, 2018, J VIROL, V92, DOI [10.1128/JVI.00878-18, 10.1128/jvi.00878-18]; Doepker LE, 2020, J VIROL, V94, DOI 10.1128/JVI.01594-19; Doria-Rose NA, 2010, J VIROL, V84, P1631, DOI 10.1128/JVI.01482-09; Euler Z, 2010, J INFECT DIS, V201, P1045, DOI 10.1086/651144; Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505; Ferrantelli F, 2007, VIROLOGY, V358, P69, DOI 10.1016/j.virol.2006.07.056; Fouda GG, 2020, VACCINE, V38, P411, DOI 10.1016/j.vaccine.2019.11.011; Geffin R, 2003, VIROLOGY, V310, P207, DOI 10.1016/S0042-6822(03)00137-5; Goo L, 2014, NAT MED, V20, P655, DOI 10.1038/nm.3565; Gray ES, 2009, J VIROL, V83, P8925, DOI 10.1128/JVI.00758-09; Gray GE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax1880; Halapi E, 1997, AIDS, V11, P1709, DOI 10.1097/00002030-199714000-00007; Heyndrickx L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036438; Kumar A, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006944; LJUNGGREN K, 1990, J INFECT DIS, V161, P198, DOI 10.1093/infdis/161.2.198; Lynch JB, 2011, J VIROL, V85, P5252, DOI 10.1128/JVI.02216-10; Mabuka J, 2013, AIDS, V27, P1535, DOI 10.1097/QAD.0b013e32835faba5; McFarland EJ, 2006, AIDS, V20, P1481, DOI 10.1097/01.aids.0000237363.33994.45; Milligan C, 2015, CELL HOST MICROBE, V17, P500, DOI 10.1016/j.chom.2015.03.002; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Muenchhoff M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1048; Naiman NE, 2019, EBIOMEDICINE, V47, P257, DOI 10.1016/j.ebiom.2019.08.072; Omenda MM, 2013, JAIDS-J ACQ IMM DEF, V64, P163, DOI 10.1097/QAI.0b013e31829f6e41; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; Pollara J, 2011, CYTOM PART A, V79A, P603, DOI 10.1002/cyto.a.21084; Prakash SS, 2012, ARCH VIROL, V157, P1797, DOI 10.1007/s00705-012-1357-0; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Russell ES, 2013, AIDS RES HUM RETROV, V29, P511, DOI [10.1089/aid.2012.0197, 10.1089/AID.2012.0197]; Russell ES, 2011, J VIROL, V85, P8253, DOI 10.1128/JVI.00197-11; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; Scarlatti G, 2004, AIDS REV, V6, P67; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; Scarlatti G, 1996, LANCET, V348, P863, DOI 10.1016/S0140-6736(95)11030-5; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637; Simek MD, 2009, J VIROL, V83, P7337, DOI 10.1128/JVI.00110-09; Thenin S, 2012, VIROLOGY, V426, P12, DOI 10.1016/j.virol.2012.01.017; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; Tranchat C, 1999, J INFECTION, V39, P213, DOI 10.1016/S0163-4453(99)90052-X; van Gils MJ, 2009, AIDS, V23, P2405, DOI 10.1097/QAD.0b013e32833243e7; VANDEPERRE P, 1992, AIDS RES HUM RETROV, V8, P435, DOI 10.1089/aid.1992.8.435; Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006	54	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							260	10.3390/vaccines9030260			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6FA	33799407	Green Published, gold			2022-04-29	WOS:000634246200001
J	Coronado, L; Perera, CL; Rios, L; Frias, MT; Perez, LJ				Coronado, Liani; Perera, Carmen L.; Rios, Liliam; Frias, Maria T.; Perez, Lester J.			A Critical Review about Different Vaccines against Classical Swine Fever Virus and Their Repercussions in Endemic Regions	VACCINES			English	Review						classical swine fever; vaccine; DIVA concept; genetic variability; multi-epitope vaccines	SUBUNIT MARKER-VACCINE; HOG-CHOLERA VIRUS; REDUCING HORIZONTAL TRANSMISSION; MATERNALLY DERIVED ANTIBODIES; LINKED-IMMUNOSORBENT-ASSAY; RESPIRATORY SYNDROME VIRUS; CELLULAR IMMUNE-RESPONSE; EARLY FULL PROTECTION; C-STRAIN VACCINE; E-RNS	Classical swine fever (CSF) is, without any doubt, one of the most devasting viral infectious diseases affecting the members of Suidae family, which causes a severe impact on the global economy. The reemergence of CSF virus (CSFV) in several countries in America, Asia, and sporadic outbreaks in Europe, sheds light about the serious concern that a potential global reemergence of this disease represents. The negative aspects related with the application of mass stamping out policies, including elevated costs and ethical issues, point out vaccination as the main control measure against future outbreaks. Hence, it is imperative for the scientific community to continue with the active investigations for more effective vaccines against CSFV. The current review pursues to gather all the available information about the vaccines in use or under developing stages against CSFV. From the perspective concerning the evolutionary viral process, this review also discusses the current problematic in CSF-endemic countries.	[Coronado, Liani; Perera, Carmen L.; Frias, Maria T.] Natl Ctr Anim & Plant Hlth CENSA, OIE Collaborating Ctr Disaster Risk Reduct Anim H, San Jose De Las Lajas 32700, Cuba; [Rios, Liliam] Univ New Brunswick, Fac Med, Reiman Canc Res Lab, St John, NB E2L 4L5, Canada; [Perez, Lester J.] Univ Illinois, Coll Vet Med, Vet Diagnost Lab, Champaign, IL 61802 USA; [Perez, Lester J.] Abbott Diagnost, Virus Discovery Grp, Abbott Pk, IL 60064 USA		Perez, LJ (通讯作者)，Univ Illinois, Coll Vet Med, Vet Diagnost Lab, Champaign, IL 61802 USA.; Perez, LJ (通讯作者)，Abbott Diagnost, Virus Discovery Grp, Abbott Pk, IL 60064 USA.	lcoronado@censa.edu.cu; claura@censa.edu.cu; Liliam.rios@gmail.com; mariat.frias@infomed.sld.cu; ljperez@illinois.edu	Coronado, Liani/AAK-3387-2021; Perez, Lester J/A-1339-2016	Coronado, Liani/0000-0003-4278-0589; Perez, Lester J/0000-0002-5717-5181			Alfonso-Morales A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125853; Amin Nevis, 2013, Vaccimonitor, V22, P14; Ashraf NM, 2016, INFECT GENET EVOL, V43, P58, DOI 10.1016/j.meegid.2016.05.009; Ayala M.A.C., 1992, REV MEX CIENC PECU, V30, P91; Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0; Baez Ruiz U. A., 1995, Tecnica Pecuaria en Mexico, V33, P135; Barrera M, 2010, VET IMMUNOL IMMUNOP, V133, P25, DOI 10.1016/j.vetimm.2009.06.015; Beer M, 2007, VACCINE, V25, P5665, DOI 10.1016/j.vaccine.2006.12.036; Beer M, 2015, ANIM HEALTH RES REV, V16, P33, DOI 10.1017/S1466252315000109; Bersano J.G., 2005, BIOLOGICO, V67, P31; Blome S, 2006, REV SCI TECH OIE, V25, P1025, DOI 10.20506/rst.25.3.1715; Blome S, 2017, VET RES, V48, DOI 10.1186/s13567-017-0457-y; Blome S, 2017, VET MICROBIOL, V206, P10, DOI 10.1016/j.vetmic.2017.01.001; Blome S, 2014, VET MICROBIOL, V169, P8, DOI 10.1016/j.vetmic.2013.12.002; Blome S, 2013, BERL MUNCH TIERARZTL, V126, P481, DOI 10.2376/0005-9366-126-481; Blome S, 2012, VET MICROBIOL, V158, P42, DOI 10.1016/j.vetmic.2012.02.015; Borca MV, 2019, VIROLOGY, V526, P38, DOI 10.1016/j.virol.2018.10.004; Bouma A, 2000, VACCINE, V18, P1374, DOI 10.1016/S0264-410X(99)00398-9; Bouma A, 1999, VET MICROBIOL, V66, P101, DOI 10.1016/S0378-1135(99)00003-6; Cao J, 2010, VACCINE, V28, P7514, DOI 10.1016/j.vaccine.2010.09.002; Chakraborty A. K., 2018, VirusDisease, V29, P89, DOI 10.1007/s13337-018-0433-9; Cho HS, 2006, CAN J VET RES, V70, P226; Choe S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080608; Choe S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9040244; Choe S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030169; Choori P, 2015, VET WORLD, V8, P541, DOI 10.14202/vetworld.2015.541-544; Coronado L, 2019, TRANSBOUND EMERG DIS, V66, P2362, DOI 10.1111/tbed.13293; Coronado L, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1982-x; Coronado L, 2017, VET MICROBIOL, V201, P103, DOI 10.1016/j.vetmic.2017.01.013; de Arce HD, 2005, VIRUS RES, V112, P123, DOI 10.1016/j.virusres.2005.03.018; de Arce HD, 1999, VIRUS RES, V64, P61, DOI 10.1016/S0168-1702(99)00077-5; de Oliveira LG, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111327; de Smit AJ, 2001, VET MICROBIOL, V78, P307, DOI 10.1016/S0378-1135(00)00306-0; de Smit AJ, 2001, VACCINE, V19, P1467, DOI 10.1016/S0264-410X(00)00347-9; de Smit AJ, 2000, VET QUART, V22, P182, DOI 10.1080/01652176.2000.9695054; Depner KR, 2001, VET MICROBIOL, V83, P107, DOI 10.1016/S0378-1135(01)00410-2; Desai GS, 2010, ACTA VIROL, V54, P79, DOI 10.4149/av_2010_01_79; Dewulf J, 2000, VACCINE, V19, P475, DOI 10.1016/S0264-410X(00)00189-4; Dewulf J, 2004, PREV VET MED, V65, P121, DOI 10.1016/j.prevetmed.2004.05.010; Dikhit MR, 2015, INFECT GENET EVOL, V36, P369, DOI 10.1016/j.meegid.2015.10.012; Ding Xiong, 2020, bioRxiv, DOI 10.1101/2020.03.19.998724; Dong XY, 2012, ISR J VET MED, V67, P203; Dong XN, 2007, VACCINE, V25, P205, DOI 10.1016/j.vaccine.2006.07.033; Dong XN, 2006, VACCINE, V24, P4029, DOI 10.1016/j.vaccine.2006.01.003; Dong XN, 2006, VACCINE, V24, P1906, DOI 10.1016/j.vaccine.2005.10.039; Dortmans JCFM, 2008, VACCINE, V26, P1235, DOI 10.1016/j.vaccine.2007.12.039; Drager C, 2015, VACCINE, V33, P3100, DOI 10.1016/j.vaccine.2015.04.103; Eble PL, 2014, VET MICROBIOL, V174, P27, DOI 10.1016/j.vetmic.2014.08.030; Eble PL, 2013, VET MICROBIOL, V162, P437, DOI 10.1016/j.vetmic.2012.10.030; Edwards S, 2000, VET MICROBIOL, V73, P103, DOI 10.1016/S0378-1135(00)00138-3; EDWARDS S, 1991, VET MICROBIOL, V29, P101, DOI 10.1016/0378-1135(91)90118-Y; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Everett HE, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0281-9; Fonseca O, 2018, SPAN J AGRIC RES, V16, DOI 10.5424/sjar/2018162-12487; Fonseca-Rodriguez O, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00038; Frey CF, 2006, VET RES, V37, P655, DOI 10.1051/vetres:2006028; Frias-Lepoureau M. T., 2003, Revista de Salud Animal, V25, P1; Fukai K, 2020, VET RES, V51, DOI 10.1186/s13567-020-00821-w; Gabriel C, 2012, VACCINE, V30, P2928, DOI 10.1016/j.vaccine.2012.02.065; Ganges L, 2005, VACCINE, V23, P3741, DOI 10.1016/j.vaccine.2005.01.153; Ganges L, 2008, VET J, V177, P169, DOI 10.1016/j.tvjl.2007.01.030; Garner MG, 2001, REV SCI TECH OIE, V20, P671, DOI 10.20506/rst.20.3.1303; Haro ADG, 2018, TRANSBOUND EMERG DIS, V65, P782, DOI 10.1111/tbed.12803; Giangaspero M., 2019, ADV MICROBIOL, V9, P7, DOI [10.4236/aim.2019.93019, DOI 10.4236/AIM.2019.93019]; Giangaspero M, 2020, OPEN VET J, V10, P94, DOI 10.4314/ovj.v10i1.15; Goller KV, 2015, ARCH VIROL, V160, P3121, DOI 10.1007/s00705-015-2611-z; Gong WJ, 2019, VET MICROBIOL, V237, DOI 10.1016/j.vetmic.2019.108403; Gong WJ, 2019, VET MICROBIOL, V232, P114, DOI 10.1016/j.vetmic.2019.04.001; Gong WJ, 2016, INFECT GENET EVOL, V41, P218, DOI 10.1016/j.meegid.2016.04.002; Gonzalez C, 2001, J VET MED SCI, V63, P991, DOI 10.1292/jvms.63.991; Pose AG, 2011, VET MICROBIOL, V152, P328, DOI 10.1016/j.vetmic.2011.05.033; Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321; Graham SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029310; Greiser-Wilke Irene, 2004, Animal Health Research Reviews, V5, P223, DOI 10.1079/AHR200472; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gupta Vikas, 2018, Virusdisease, V29, P565, DOI 10.1007/s13337-018-0491-z; Tran HT, 2020, CLIN EXP VACCINE RES, V9, P26, DOI 10.7774/cevr.2020.9.1.26; Han YY, 2020, VET MICROBIOL, V247, DOI 10.1016/j.vetmic.2020.108741; He CQ, 2007, VIRUS RES, V126, P179, DOI 10.1016/j.virusres.2007.02.019; Henke J, 2018, VACCINE, V36, P4181, DOI 10.1016/j.vaccine.2018.06.014; Holinka LG, 2014, VIROLOGY, V471, P13, DOI 10.1016/j.virol.2014.09.021; Holinka LG, 2009, VIROLOGY, V384, P106, DOI 10.1016/j.virol.2008.10.039; Holinka LG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177433; Huang YL, 2014, VIRUS RES, V179, P1, DOI 10.1016/j.virusres.2013.10.025; Huang Yu-Liang, 2012, Taiwan Veterinary Journal, V38, P164; Huang YL, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-115; HULST MM, 1993, J VIROL, V67, P5435, DOI 10.1128/JVI.67.9.5435-5442.1993; Hung N. P., 2017, VIETNAM J AGR SCI, V15, P230; Isoda N, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020119; Ito S, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040206; Izzati UZ, 2021, VET MED SCI, V7, P164, DOI 10.1002/vms3.339; Jang G, 2020, ARCH VIROL, V165, P1691, DOI 10.1007/s00705-020-04651-1; Jang G, 2019, TRANSBOUND EMERG DIS, V66, P634, DOI 10.1111/tbed.13121; Je SH, 2018, EMERG INFECT DIS, V24, P798, DOI 10.3201/eid2404.171319; Ji W, 2014, INFECT GENET EVOL, V25, P69, DOI 10.1016/j.meegid.2014.04.008; Perez LJ, 2012, INFECT GENET EVOL, V12, P1405, DOI 10.1016/j.meegid.2012.04.030; Perez LJ, 2011, J VIROL METHODS, V174, P53, DOI 10.1016/j.jviromet.2011.03.022; Kaden V, 2008, EUR J WILDLIFE RES, V54, P237, DOI 10.1007/s10344-007-0136-9; Kaden V, 2001, VET MICROBIOL, V82, P301, DOI 10.1016/S0378-1135(01)00400-X; Kaden V, 2010, VET MICROBIOL, V143, P133, DOI 10.1016/j.vetmic.2009.11.020; Kamakawa A, 2006, VET MICROBIOL, V118, P47, DOI 10.1016/j.vetmic.2006.07.003; Kang B., 1971, RES RURAL DEV ADM, V17, P27; Karnell JL, 2019, ADV DRUG DELIVER REV, V141, P92, DOI 10.1016/j.addr.2018.12.005; Khatoon E, 2019, ACTA VIROL, V63, P60, DOI 10.4149/av_2019_105; Khromykh AA, 2000, CURR OPIN MOL THER, V2, P555; Kim B, 2008, VET REC, V162, P12, DOI 10.1136/vr.162.1.12; Kim Y., 1967, KOREA VET MED ASS, V11, P33; Klinkenberg D, 2002, VACCINE, V20, P3005, DOI 10.1016/S0042-207X(02)00283-X; Koenig P, 2007, VACCINE, V25, P3391, DOI 10.1016/j.vaccine.2006.12.052; Koenig P, 2007, VET MICROBIOL, V120, P343, DOI 10.1016/j.vetmic.2006.10.034; Krishnamurthy D., 1962, INDIAN VET J, V39, P12; Lacerda J.B., 1899, RELATORIO PESTE SUIN; LAUNAIS M, 1974, ANN ZOOTECH, V23, P372, DOI 10.1051/animres:19740311; LAUNAIS M, 1978, VET MICROBIOL, V3, P31, DOI 10.1016/0378-1135(78)90013-5; Leifer I, 2010, J VIROL METHODS, V166, P98, DOI 10.1016/j.jviromet.2010.03.004; Leifer I, 2009, VACCINE, V27, P6522, DOI 10.1016/j.vaccine.2009.08.057; Leifer I, 2009, J VIROL METHODS, V158, P114, DOI 10.1016/j.jviromet.2009.02.002; Liao YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084443; Lim SI, 2019, VACCINE, V37, P3598, DOI 10.1016/j.vaccine.2019.04.076; Lim SI, 2017, J VET SCI, V18, P201, DOI 10.4142/jvs.2017.18.2.201; Lin GJ, 2009, VET MICROBIOL, V139, P369, DOI 10.1016/j.vetmic.2009.06.027; Lin YX, 2020, J VIROL METHODS, V280, DOI 10.1016/j.jviromet.2020.113875; Liu LH, 2011, J VIROL METHODS, V175, P170, DOI 10.1016/j.jviromet.2011.05.003; LOWINGS JP, 1994, J GEN VIROL, V75, P3461, DOI 10.1099/0022-1317-75-12-3461; Luo Y, 2017, TRANSBOUND EMERG DIS, V64, P1848, DOI 10.1111/tbed.12581; Luo YZ, 2017, VET MICROBIOL, V201, P154, DOI 10.1016/j.vetmic.2017.01.012; Luo YZ, 2015, J VIROL METHODS, V222, P22, DOI 10.1016/j.jviromet.2015.05.006; Luo YZ, 2014, VET MICROBIOL, V172, P1, DOI 10.1016/j.vetmic.2014.04.004; Madera R, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0823-4; Madera RF, 2018, J VET SCI, V19, P393, DOI 10.4142/jvs.2018.19.3.393; Malik YS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060500; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Meyer D, 2018, TRANSBOUND EMERG DIS, V65, pe505, DOI 10.1111/tbed.12795; Meyer D, 2017, TRANSBOUND EMERG DIS, V64, P2013, DOI 10.1111/tbed.12611; Moennig V, 2003, VET J, V165, P11, DOI 10.1016/S1090-0233(02)00112-0; Moennig V, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01211; Monso M, 2011, J PEPT SCI, V17, P24, DOI 10.1002/psc.1292; Moormann RJM, 2000, VET MICROBIOL, V73, P209, DOI 10.1016/S0378-1135(00)00146-2; Munoz-Gonzalez S, 2017, VET MICROBIOL, V205, P110, DOI 10.1016/j.vetmic.2017.05.003; Munoz-Gonzalez S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125692; Narula A, 2018, INFECT GENET EVOL, V61, P4, DOI 10.1016/j.meegid.2018.03.007; Nishi T, 2019, MICROBIOL RESOUR ANN, V8, DOI [10.1128/MRA.01362-18, 10.1128/mra.01362-18]; Nishimura Y, 1964, Nihon Juigaku Zasshi, V26, P133; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; OIE M., 2014, OIE MANUAL DIAGNOSTI, V2, P1; OKANIWA A, 1969, NATL I ANIM HEALTH Q, V9, P92; Palacio N, 2020, J EXP MED, V217, DOI 10.1084/jem.20191220; Pannhorst K, 2015, J VET DIAGN INVEST, V27, P449, DOI 10.1177/1040638715592446; Park GS, 2012, J VET SCI, V13, P81, DOI 10.4142/jvs.2012.13.1.81; Pereda AJ, 2005, VIRUS RES, V110, P111, DOI 10.1016/j.virusres.2005.01.011; Freitas TRP, 2007, SEMIN-CIENC AGRAR, V28, P277; Pijlman GP, 2006, EXPERT OPIN BIOL TH, V6, P135, DOI 10.1517/14712598.6.2.135; Pikula A, 2020, TRANSBOUND EMERG DIS, V67, P1739, DOI 10.1111/tbed.13510; Pineda P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234490; Postel A, 2019, EMERG INFECT DIS, V25, P1228, DOI 10.3201/eid2506.181578; Postel A, 2018, TRANSBOUND EMERG DIS, V65, P248, DOI 10.1111/tbed.12676; Postel A, 2015, ARCH VIROL, V160, P1435, DOI 10.1007/s00705-015-2407-1; Postel A, 2013, BERL MUNCH TIERARZTL, V126, P468, DOI 10.2376/0005-9366-126-468; Qiu HuaJi, 2006, Agricultural Sciences in China, V5, P1, DOI 10.1016/S1671-2927(06)60013-8; Rangelova D, 2012, VACCINE, V30, P6376, DOI 10.1016/j.vaccine.2012.08.035; Rasmussen TB, 2007, J GEN VIROL, V88, P481, DOI 10.1099/vir.0.82453-0; Reimann I, 2004, VIROLOGY, V322, P143, DOI 10.1016/j.virol.2004.01.028; Reimann I, 2016, METHODS MOL BIOL, V1349, P239, DOI 10.1007/978-1-4939-3008-1_15; Reimann I, 2010, VET MICROBIOL, V142, P45, DOI 10.1016/j.vetmic.2009.09.042; Rios L, 2018, TRANSBOUND EMERG DIS, V65, P963, DOI 10.1111/tbed.12909; Rios L, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00055; Rios L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18196-y; Risatti GR, 2007, J VIROL, V81, P924, DOI 10.1128/JVI.01824-06; Risatti GR, 2006, VIROLOGY, V355, P94, DOI 10.1016/j.virol.2006.07.005; Risatti GR, 2005, J VIROL, V79, P3787, DOI 10.1128/JVI.79.6.3787-3796.2005; Rossi S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01141; Saatkamp HW, 2000, VET MICROBIOL, V73, P221, DOI 10.1016/S0378-1135(00)00147-4; Sabogal ZY, 2006, VIRUS RES, V115, P99, DOI 10.1016/j.virusres.2005.06.016; Sanchez O, 2008, VACCINE, V26, P988, DOI 10.1016/j.vaccine.2007.11.014; Ramos OS, 2011, COMP IMMUNOL MICROB, V34, P259, DOI 10.1016/j.cimid.2010.12.001; Santafé-Huera Viviana Natalia, 2019, Rev Salud Anim., V41, pe02; Sapre S.N., 1962, INDIAN VET J, V39, P3; SASAHARA J, 1969, NATL I ANIM HEALTH Q, V9, P83; SATO USABURO, 1964, ARCH GESAMTE VIRUSFORSCH, V15, P113, DOI 10.1007/BF01241427; Schroeder S, 2012, REV SCI TECH OIE, V31, P997; Shen H, 2011, VIRUS GENES, V43, P234, DOI 10.1007/s11262-011-0625-5; SHIMIZU Y, 1970, AM J VET RES, V31, P1787; Shivaraj D. B., 2015, VirusDisease, V26, P170, DOI 10.1007/s13337-015-0273-9; Silva MNF, 2017, ARCH VIROL, V162, P817, DOI 10.1007/s00705-016-3145-8; Singh VK, 2018, TROP ANIM HEALTH PRO, V50, P1181, DOI 10.1007/s11250-018-1608-5; Singh Vinod Kumar, 2017, VirusDisease, V28, P174, DOI 10.1007/s13337-017-0368-6; Smith DB, 2017, J GEN VIROL, V98, P2106, DOI 10.1099/jgv.0.000873; Song JY, 2013, TRANSBOUND EMERG DIS, V60, P546, DOI 10.1111/j.1865-1682.2012.01371.x; Sordo Y, 2018, BIOLOGICALS, V52, P67, DOI 10.1016/j.biologicals.2017.12.004; Sordo-Puga Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010007; STALHEIM OHV, 1988, AGR HIST, V62, P116; Suarez M, 2017, VACCINE, V35, P4437, DOI 10.1016/j.vaccine.2017.05.028; Sun SQ, 2013, TRANSBOUND EMERG DIS, V60, P370, DOI 10.1111/j.1865-1682.2012.01346.x; Sun Y, 2013, VACCINE, V31, P538, DOI 10.1016/j.vaccine.2012.11.013; Sun Y, 2011, VACCINE, V29, P8364, DOI 10.1016/j.vaccine.2011.08.085; Suradhat S, 2007, VET MICROBIOL, V119, P1, DOI 10.1016/j.vetmic.2006.10.003; Suradhat S, 2006, VACCINE, V24, P2634, DOI 10.1016/j.vaccine.2005.12.010; Suradhat S, 2001, VET IMMUNOL IMMUNOP, V83, P177, DOI 10.1016/S0165-2427(01)00389-0; Tamura T, 2012, J VIROL, V86, P8602, DOI 10.1128/JVI.00551-12; Tarradas J, 2010, VET MICROBIOL, V142, P51, DOI 10.1016/j.vetmic.2009.09.043; Tarradas J, 2014, VIRUS RES, V185, P82, DOI 10.1016/j.virusres.2014.03.004; Tarradas J, 2012, VET IMMUNOL IMMUNOP, V150, P36, DOI 10.1016/j.vetimm.2012.08.006; Tarradas J, 2011, VACCINE, V29, P4422, DOI 10.1016/j.vaccine.2011.03.095; Teran MV, 2004, ANN NY ACAD SCI, V1026, P54, DOI 10.1196/annals.1307.007; TERPSTRA C, 1990, DEUT TIERARZTL WOCH, V97, P77; Tignon M, 2010, VET MICROBIOL, V142, P59, DOI 10.1016/j.vetmic.2009.09.044; Titov I, 2015, J VIROL METHODS, V224, P53, DOI 10.1016/j.jviromet.2015.08.012; Toledo JR, 2010, VACCINE, V28, P7907, DOI 10.1016/j.vaccine.2010.09.073; Tonkin DR, 2010, VACCINE, V28, P3238, DOI 10.1016/j.vaccine.2010.02.010; Tu CC, 2001, VIRUS RES, V81, P29, DOI 10.1016/S0168-1702(01)00366-5; Uttenthal A, 2001, VET MICROBIOL, V83, P85, DOI 10.1016/S0378-1135(01)00409-6; van Gennip HGP, 2002, VACCINE, V20, P1544, DOI 10.1016/S0264-410X(01)00497-2; van Oirschot JT, 2003, VET MICROBIOL, V96, P367, DOI 10.1016/j.vetmic.2003.09.008; van Schalkwyk A, 2019, J VIROL METHODS, V266, P89, DOI 10.1016/j.jviromet.2019.01.016; vanRijn PA, 1996, J GEN VIROL, V77, P2737, DOI 10.1099/0022-1317-77-11-2737; Vlasova A, 2003, J VET MED B, V50, P363, DOI 10.1046/j.1439-0450.2003.00695.x; von Rosen T, 2014, VET MICROBIOL, V170, P224, DOI 10.1016/j.vetmic.2014.02.018; Wang Z., 2018, CHIN J ANIMAL INFECT, V26, P18; Weesendorp E, 2009, VET MICROBIOL, V133, P9, DOI 10.1016/j.vetmic.2008.06.008; Wehrle F, 2007, J GEN VIROL, V88, P2247, DOI 10.1099/vir.0.82798-0; Widjojoatmodjo MN, 2000, J VIROL, V74, P2973, DOI 10.1128/JVI.74.7.2973-2980.2000; Wong YP, 2018, J APPL MICROBIOL, V124, P626, DOI 10.1111/jam.13647; Xia HY, 2011, ARCH VIROL, V156, P1041, DOI 10.1007/s00705-011-0948-5; Xia SL, 2016, VET RES, V47, DOI 10.1186/s13567-016-0346-9; Xia SL, 2016, VET MICROBIOL, V190, P38, DOI 10.1016/j.vetmic.2016.05.007; Xing CN, 2019, INFECT GENET EVOL, V68, P212, DOI 10.1016/j.meegid.2018.12.029; Xu HL, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-1713-2; Xu L, 2018, VIRAL IMMUNOL, V31, P34, DOI 10.1089/vim.2017.0010; Xu YF, 2004, J BIOMED SCI, V11, P426, DOI 10.1159/000077892; Zhang HL, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1504-2; Zhang HL, 2015, INFECT GENET EVOL, V34, P94, DOI 10.1016/j.meegid.2015.05.031; Zhang HW, 2018, VACCINE, V36, P7353, DOI 10.1016/j.vaccine.2018.10.030; Zhang SQ, 2014, INFECT GENET EVOL, V27, P230, DOI 10.1016/j.meegid.2014.07.021; Zhou B, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00187; Zhou WG, 2014, VACCINE, V32, P6639, DOI 10.1016/j.vaccine.2014.09.058	235	7	7	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							154	10.3390/vaccines9020154			32	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6SI	33671909	Green Published, gold			2022-04-29	WOS:000623271000001
J	Dodds, WJ				Dodds, W. Jean			Early Life Vaccination of Companion Animal Pets	VACCINES			English	Review						early life innate and adaptive immunity; vaccines	CANINE-DISTEMPER VIRUS; ADAPTIVE IMMUNE-RESPONSE; ADVERSE EVENTS; SEROLOGICAL RESPONSE; VETERINARY VACCINES; ADENOVIRUS TYPE-1; ANTIBODY-TITERS; VIRAL-ANTIGENS; DOGS; PARVOVIRUS	Development of the immune system of mammalian animal species parallels that of humans and involves the innate and adaptive (acquired) immune responses acting together with the thymus gland. Consequently, issues surrounding the adequacy and safety of vaccinations to protect pet animals from their relevant infectious diseases need to be addressed just as they are for humans. Pet animals, especially canines, also have unique needs because of the wide diversity of purebred and mixed breeds that vary greatly in size, type, temperament, and even maturation rates. Furthermore, pets in early life encounter a series of changes that can affect their development and induce stressors including parasite control, new homes and environment, novel foods, and the socialization that is essential at a time when vaccinations need to be given. While recognizing that this overall need is becoming more understood, current vaccination policy guidelines for companion animals are still only adhered to by about 40% of veterinarians worldwide. Clearly, vaccination of pets should no longer be considered as "one size fits all".	[Dodds, W. Jean] Hemopet, 11561 Salinaz Ave, Garden Grove, CA 92843 USA		Dodds, WJ (通讯作者)，Hemopet, 11561 Salinaz Ave, Garden Grove, CA 92843 USA.	info@hemopet.org					Ameratunga R, 2017, J ALLER CL IMM-PRACT, V5, P1551, DOI 10.1016/j.jaip.2017.06.033; American Animal Hospital Association (AAHA) Canine Vaccination Task Force, 2011, J Am Anim Hosp Assoc, V47, P1; Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166; BUDASZEWSKI RDF, 2017, THE J, V91, DOI DOI 10.1128/JVI.02077-16; Calder PC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041181; Cerpa-Cruz SS, 2013, IMMUNOL RES, V56, P299, DOI 10.1007/s12026-013-8400-4; Day M J, 2016, J Small Anim Pract, V57, P4, DOI 10.1111/jsap.12431; Day MJ, 2017, IN PRACTICE, V39, P110, DOI 10.1136/inp.j615; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Dodds, 2016, GLOB VACCINES IMMUNO, V1, P51, DOI [10.15761/GVI.1000115, DOI 10.15761/GVI.1000115]; Dodds W. J., 2020, Journal of the American Holistic Veterinary Medical Association, V61, P42; Dodds WJ, 2018, ISR J VET MED, V73, P3; Dodds W.J., 2020, ADV VACCINES VACCIN, V2, P74; Dodds W.J., 2015, J AM HOL VET MED ASS, V41, P12; Dodds W.J., 2016, MED RES ARCH, V2, P1; Dodds W.J., 2018, J IMMUNOL SCI, V2, P19, DOI [10.29245/2578-3009/2018/1.1114, DOI 10.29245/2578-3009/2018/1.1114]; Dodds W.J., 2016, GLOB VACCINES IMMUNO, V2, P1, DOI [10.15761/GVI.2000121, DOI 10.15761/GVI.2000121]; Dodds WJ, 2020, CAN J VET RES, V84, P153; Dodds WJ, 2001, J AM ANIM HOSP ASSOC, V37, P211, DOI 10.5326/15473317-37-3-211; Dodds WJ, 2002, CLIN TECH SMALL AN P, V17, P58, DOI 10.1053/svms.2002.30835; Dodds WJ, 1999, ADV VETER MED AP, V41, P715; Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002; Eng Liane, 2020, Neoreviews, V21, pe30, DOI 10.1542/neo.21-1-e30; Erdman MM, 2020, JAVMA-J AM VET MED A, V257, P1142, DOI 10.2460/javma.2020.257.11.1142; Felsburg PJ, 2002, HUM EXP TOXICOL, V21, P487, DOI 10.1191/0960327102ht286oa; Gershwin LJ, 2018, VET CLIN N AM-SMALL, V48, P279, DOI 10.1016/j.cvsm.2017.10.005; Goulle JP, 2020, MED MALADIES INFECT, V50, P16, DOI 10.1016/j.medmal.2019.09.012; Gray LK, 2012, JAVMA-J AM VET MED A, V240, P1084, DOI 10.2460/javma.240.9.1084; Heegaard PMH, 2011, ARCH VIROL, V156, P183, DOI 10.1007/s00705-010-0863-1; Herman K., 2019, Journal of the American Holistic Veterinary Medical Association, V57, P16; Holder A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165968; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE; Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048; Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185; Libbey JE, 2014, HAND CLINIC, V123, P225, DOI 10.1016/B978-0-444-53488-0.00010-9; Lyons-Weiler J, 2018, J TRACE ELEM MED BIO, V48, P67, DOI 10.1016/j.jtemb.2018.02.025; Mansfield KL, 2004, VET REC, V154, P423, DOI 10.1136/vr.154.14.423; Mitchell SA, 2012, AUST VET J, V90, P468, DOI 10.1111/j.1751-0813.2012.01009.x; Montanari S., 2016, INT J VACCIN VACCIN, V4, P00072; Moore GE, 2005, JAVMA-J AM VET MED A, V227, P1102, DOI 10.2460/javma.2005.227.1102; Moore GE, 2004, JAVMA-J AM VET MED A, V224, P200, DOI 10.2460/javma.2004.224.200; Moore GE, 2007, JAVMA-J AM VET MED A, V231, P94, DOI 10.2460/javma.231.1.94; Morein B, 2002, VET IMMUNOL IMMUNOP, V87, P207, DOI 10.1016/S0165-2427(02)00078-8; Mouzin DE, 2004, JAVMA-J AM VET MED A, V224, P55, DOI 10.2460/javma.2004.224.55; Mouzin DE, 2004, JAVMA-J AM VET MED A, V224, P61, DOI 10.2460/javma.2004.224.61; Moxon R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02776; Nicholson LB, 2016, ESSAYS BIOCHEM, V60, P275, DOI 10.1042/EBC20160017; Open Markets Institute, 2020, CORP MON DECL IND; Perdrizet JA, 2019, VACCINE, V37, P1889, DOI 10.1016/j.vaccine.2018.10.076; Pereira M, 2019, VET SCI, V6, DOI 10.3390/vetsci6040083; Plummer JR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007800; Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P21; Riley MC, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0445-7; Sakala IG, 2019, EXPERT REV CLIN IMMU, V15, P869, DOI 10.1080/1744666X.2019.1642748; Schmidt B.R., 2008, HDB SMALL ANIMAL PRA, P757; Schuller S, 2015, J SMALL ANIM PRACT, V56, P159, DOI 10.1111/jsap.12328; Schultz RD, 2010, J COMP PATHOL, V141, pS102, DOI 10.1016/j.jcpa.2009.10.009; SHOENFELD Y, 2013, CURR MED CHEM, V20, P4030, DOI DOI 10.2174/09298673113209990253; Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003; Spickler AR, 2003, J VET INTERN MED, V17, P273, DOI 10.1892/0891-6640(2003)017&lt;0273:AIVVMO&gt;2.3.CO;2; Stejskal V, 2013, ISR MED ASSOC J, V15, P714; Stepita ME, 2013, J AM ANIM HOSP ASSOC, V49, P95, DOI 10.5326/JAAHA-MS-5825; Stoffel NU, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01313; Taguchi M, 2012, CAN J VET RES, V76, P317; Thapa P, 2019, THORAC SURG CLIN, V29, P123, DOI 10.1016/j.thorsurg.2018.12.001; Tizard I, 1998, J AM VET MED ASSOC, V213, P54; Tizard I., 2017, VET IMMUNOLOGY, V10th; Twark L, 2000, J AM VET MED ASSOC, V217, P1021, DOI 10.2460/javma.2000.217.1021; Valdezi Y, 2014, TRENDS IMMUNOL, V35, P526, DOI 10.1016/j.it.2014.07.003; Yao PJ, 2015, JAVMA-J AM VET MED A, V247, P1139, DOI 10.2460/javma.247.10.1139	71	0	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							92	10.3390/vaccines9020092			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7IP	33513703	gold, Green Published			2022-04-29	WOS:000623313800001
J	Naranjo-Gomez, M; Cahen, M; Lambour, J; Boyer-Clavel, M; Pelegrin, M				Naranjo-Gomez, Mar; Cahen, Marine; Lambour, Jennifer; Boyer-Clavel, Myriam; Pelegrin, Mireia			Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy	VACCINES			English	Article						antiviral immunity; antiviral monoclonal antibodies; immunotherapy; NK cells; inhibitory receptors; B-cell helper neutrophils; vaccine-like effects; CD39; PD-1; PD-L1		Monoclonal antibodies (mAbs) are now considered as a therapeutic approach to prevent and treat severe viral infections. Using a mouse retroviral model, we showed that mAbs induce protective immunity (vaccinal effects). Here, we investigated the role of natural killer (NK) cells on this effect. NK cells are effector cells that are crucial to control viral propagation upon mAb treatment. However, their immunomodulatory activity during antiviral mAb immunotherapies has been little studied. Our data reveal that the mAb treatment of infected mice preserves the functional activation of NK cells. Importantly, functional NK cells play an essential role in preventing immune dysfunction and inducing antiviral protective immunity upon mAb therapy. Thus, NK cell depletion in mAb-treated, viral-infected mice leads to the upregulation of molecules involved in immunosuppressive pathways (i.e., PD-1, PD-L1 and CD39) on dendritic cells and T cells. NK cell depletion also abrogates the vaccinal effects induced by mAb therapy. Our data also reveal a role for IFN gamma-producing NK cells in the enhancement of the B-cell responses through the potentiation of the B-cell helper properties of neutrophils. These findings suggest that preserved NK cell functions and counts might be required for achieving mAb-induced protective immunity. They open new prospects for improving antiviral immunotherapies.	[Naranjo-Gomez, Mar; Cahen, Marine; Lambour, Jennifer; Pelegrin, Mireia] Univ Montpellier, IGMM, CNRS, Montpellier, France; [Boyer-Clavel, Myriam] Univ Montpellier, Montpellier Ressources Imagerie, CNRS, Biocampus, Montpellier, France; [Naranjo-Gomez, Mar; Pelegrin, Mireia] Univ Montpellier, IRMB, INSERM, CNRS, Montpellier, France; [Cahen, Marine] CNRS UMR 7276, INSERM U1262, Limoges, France		Pelegrin, M (通讯作者)，Univ Montpellier, IGMM, CNRS, Montpellier, France.; Pelegrin, M (通讯作者)，Univ Montpellier, IRMB, INSERM, CNRS, Montpellier, France.	maria.naranjo@inserm.fr; marine.cahen@unilim.fr; jenniferlambour@gmail.com; myriam.boyer-clavel@igmm.cnrs.fr; myriam.boyer-clavel@igmm.cnrs.fr		NARANJO-GOMEZ, Mar/0000-0002-7068-2671; Pelegrin, Mireia/0000-0002-0117-2010	Ligue Nationale Contre le CancerLigue nationale contre le cancer; Sidaction [BI25-1-02278, A014-2-AEQ-08-01]; French National Research Agency (ANR)French National Research Agency (ANR) [ANR-10-LABX -53-01]; Cellnex [ACT4COVID]	Ligue Nationale Contre le Cancer: AAP2016, AAP2018, AAP2019; Sidaction (BI25-1-02278 and A014-2-AEQ-08-01. French National Research Agency (ANR, ANR-10-LABX -53-01). APC was funded by Cellnex (ACT4COVID).	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Agaugue S, 2008, BLOOD, V112, P1776, DOI 10.1182/blood-2008-02-135871; Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Balanca C.-C., 2020, JCI INSIGHT; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Benlahrech A, 2012, CLIN EXP IMMUNOL, V170, P212, DOI 10.1111/j.1365-2249.2012.04647.x; Bhatnagar N, 2010, BLOOD, V116, P1308, DOI 10.1182/blood-2010-01-264903; Bodhankar S, 2009, J IMMUNOL, V183, P2622, DOI 10.4049/jimmunol.0802180; Bossart KN, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002901; Bournazos S, 2020, NATURE, V588, P485, DOI 10.1038/s41586-020-2838-z; Brooks DG, 2005, J VIROL, V79, P10514, DOI 10.1128/JVI.79.16.10514-10527.2005; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Carlyle JR, 2006, J IMMUNOL, V176, P7511, DOI 10.4049/jimmunol.176.12.7511; Chen W, 1996, J VIROL, V70, P7773, DOI 10.1128/JVI.70.11.7773-7782.1996; CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; Cichocki F, 2016, CURR TOP MICROBIOL, V395, P63, DOI 10.1007/82_2015_487; Cortez VS, 2015, CURR OPIN IMMUNOL, V32, P71, DOI 10.1016/j.coi.2015.01.004; Costantini C, 2011, J LEUKOCYTE BIOL, V89, P221, DOI 10.1189/jlb.0510250; D'Souza M, 2007, J IMMUNOL, V179, P1979, DOI 10.4049/jimmunol.179.3.1979; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Deligne C, 2015, LEUKEMIA, V29, P947, DOI 10.1038/leu.2014.275; Dibo M, 2019, CURR PHARM BIOTECHNO, V20, P1108, DOI 10.2174/1389201020666190809112704; Dorner BG, 2004, J IMMUNOL, V172, P3119, DOI 10.4049/jimmunol.172.5.3119; Drabczyk-Pluta M, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0364-3; Dwyer KM, 2007, PURINERG SIGNAL, V3, P171, DOI 10.1007/s11302-006-9050-y; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Ferlazzo G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00159; Florez-Alvarez L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02290; Gao RY, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030276; Gehrie E, 2011, METHODS MOL BIOL, V677, P127, DOI 10.1007/978-1-60761-869-0_9; Giordano D, 2020, J IMMUNOL, V204, P1508, DOI 10.4049/jimmunol.1901120; Gros L, 2005, J VIROL, V79, P6272, DOI 10.1128/JVI.79.10.6272-6280.2005; Gupta PK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005177; Guyre CA, 2008, J IMMUNOL METHODS, V333, P51, DOI 10.1016/j.jim.2008.01.002; Klausz K, 2021, HAEMATOLOGICA, V106, P1857, DOI 10.3324/haematol.2020.251371; Lee WS, 2018, CURR OPIN HIV AIDS, V13, P160, DOI [10.1097/COH.0000000000000439, 10.1097/coh.0000000000000439]; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Lucar O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01850; Mailliard RB, 2003, J IMMUNOL, V171, P2366, DOI 10.4049/jimmunol.171.5.2366; Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363; Market M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01512; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; Mayoux M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav7431; MCATEE FJ, 1985, J VIROL, V56, P1018, DOI 10.1128/JVI.56.3.1018-1022.1985; Michaud HA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000948; Mikulak J, 2017, AIDS, V31, P2317, DOI 10.1097/QAD.0000000000001645; Naranjo-Gomez M, 2019, CURR OPIN HIV AIDS, V14, P325, DOI 10.1097/COH.0000000000000555; Naranjo-Gomez M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97339; Nasser R, 2013, BLOOD, V121, P1102, DOI 10.1182/blood-2012-06-432153; Nasser R, 2010, J VIROL, V84, P10169, DOI 10.1128/JVI.00568-10; Ng CT, 2010, NAT MED, V16, P1117, DOI 10.1038/nm.2233; Niessl J, 2020, NAT MED, V26, P222, DOI 10.1038/s41591-019-0747-1; Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110; Nishikado H, 2011, J IMMUNOL, V186, P5766, DOI 10.4049/jimmunol.1100370; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Ong S, 2015, AM J PATHOL, V185, P847, DOI 10.1016/j.ajpath.2014.11.023; Parsa R, 2016, J EXP MED, V213, P1537, DOI 10.1084/jem.20150577; Pelegrin M, 2000, HUM GENE THER, V11, P1407, DOI 10.1089/10430340050057486; Pelegrin M, 2015, TRENDS MICROBIOL, V23, P653, DOI 10.1016/j.tim.2015.07.005; Peng Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18570-x; Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091; Porichis F, 2018, J IMMUNOL, V201, P971, DOI 10.4049/jimmunol.1701551; Porichis F, 2011, BLOOD, V118, P965, DOI 10.1182/blood-2010-12-328070; PORTIS JL, 1990, J VIROL, V64, P1648, DOI 10.1128/JVI.64.4.1648-1656.1990; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Reitz M, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006992; Riemann D, 2020, CANCERS, V12, DOI 10.3390/cancers12102966; Roda JM, 2006, CANCER RES, V66, P517, DOI 10.1158/0008-5472.CAN-05-2429; Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3; Schmied BJ, 2019, CANCERS, V11, DOI 10.3390/cancers11060789; Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972; Schuster IS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00235; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Song JW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02465; Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426; Sun C, 2015, ACTA PHARMACOL SIN, V36, P1191, DOI 10.1038/aps.2015.41; Teigler JE, 2017, J VIROL, V91, DOI 10.1128/JVI.01263-17; Thoren FB, 2012, J IMMUNOL, V188, P1668, DOI 10.4049/jimmunol.1102002; Tian YY, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136774; Trad M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/891236; Turini M, 2014, ONCOTARGET, V5, P5304, DOI 10.18632/oncotarget.2093; van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548; van Huijsduijnen RH, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007860; Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662; Vitale M, 2005, BLOOD, V106, P566, DOI 10.1182/blood-2004-10-4035; Voehringer D, 2013, ADV EXP MED BIOL, V785, P37, DOI 10.1007/978-1-4614-6217-0_4; Watkins JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018207; Yang YL, 2017, CELL MOL IMMUNOL, V14, P465, DOI 10.1038/cmi.2016.24; Yoshida O, 2013, HEPATOLOGY, V58, P2163, DOI 10.1002/hep.26593	92	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							137	10.3390/vaccines9020137			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6XY	33567792	Green Published, gold			2022-04-29	WOS:000623285900001
J	Boey, L; Bosmans, E; Ferreira, LB; Heyvaert, N; Nelen, M; Smans, L; Tuerlinckx, H; Roelants, M; Claes, K; Derdelinckx, I; Janssens, W; Mathieu, C; Van Cleemput, J; Vos, R; Desombere, I; Vandermeulen, C				Boey, Lise; Bosmans, Eline; Ferreira, Liane Braz; Heyvaert, Nathalie; Nelen, Melissa; Smans, Lisa; Tuerlinckx, Hanne; Roelants, Mathieu; Claes, Kathleen; Derdelinckx, Inge; Janssens, Wim; Mathieu, Chantal; Van Cleemput, Johan; Vos, Robin; Desombere, Isabelle; Vandermeulen, Corinne			Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients	VACCINES			English	Article						seroprevalence; patients; diphtheria; tetanus; pertussis	OBSTRUCTIVE PULMONARY-DISEASE; VACCINATION	Patients with chronic diseases are at increased risk of complications following infection. It remains, however, unknown to what extend they are protected against vaccine-preventable diseases. We assessed seroprevalence of antibodies against diphtheria, tetanus and pertussis to evaluate whether current vaccination programs in Belgium are adequate. Antibody titers were assessed with a bead-based multiplex assay in serum of 1052 adults with chronic diseases. We included patients with diabetes mellitus type 1 (DM1) (n = 172), DM2 (n = 77), chronic kidney disease (n = 130), chronic obstructive pulmonary disease (COPD) (n = 170), heart failure (n = 77), HIV (n = 196) and solid organ transplant (SOT) recipients (n = 230). Factors associated with seroprevalence were analysed with multiple logistic regression. We found seroprotective titers in 29% for diphtheria (>= 0.1 IU/mL), in 83% for tetanus (>= 0.1 IU/mL) and 22% had antibodies against pertussis (>= 5 IU/mL). Seroprotection rates were higher (p < 0.001) when vaccinated within the last ten years. Furthermore, diphtheria seroprotection decreased with age (p < 0.001). Tetanus seroprotection was less reached in women (p < 0.001) and older age groups (p < 0.001). For pertussis, women had more often a titer suggestive of a recent infection or vaccination (>= 100 IU/mL, p < 0.01). We conclude that except for tetanus, the vast majority of at-risk patients remains susceptible to vaccine-preventable diseases such as diphtheria and pertussis.	[Boey, Lise; Bosmans, Eline; Ferreira, Liane Braz; Heyvaert, Nathalie; Nelen, Melissa; Smans, Lisa; Tuerlinckx, Hanne; Vandermeulen, Corinne] Leuven Univ, KU Leuven, Vaccinol Ctr, Dept Publ Hlth & Primary Care, Kapucijnenvoer 35,POB 7001, B-3000 Leuven, Belgium; [Roelants, Mathieu; Vandermeulen, Corinne] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Environm & Hlth, Kapucijnenvoer 35,POB 7001, B-3000 Leuven, Belgium; [Claes, Kathleen] Univ Hosp Leuven, Dept Nephrol & Renal Transplantat, Herestr 49, B-3000 Leuven, Belgium; [Derdelinckx, Inge] Univ Hosp Leuven, Dept Gen Internal Med, Herestr 49, B-3000 Leuven, Belgium; [Janssens, Wim] Univ Hosp Leuven, Dept Resp Dis, Herestr 49, B-3000 Leuven, Belgium; [Mathieu, Chantal] Univ Hosp Leuven, Dept Endocrinol, Herestr 49, B-3000 Leuven, Belgium; [Van Cleemput, Johan] Univ Hosp Leuven, Dept Cardiol, Herestr 49, B-3000 Leuven, Belgium; [Vos, Robin] Univ Hosp Leuven, Dept Resp Dis, Lung Transplantat Unit, Herestr 49, B-3000 Leuven, Belgium; [Desombere, Isabelle] Sciensano Publ Hlth Belgium, NRC Bordetella Pertussis & NRC Toxigen Corynebact, Engelandstr 642, B-1180 Uccle, Belgium		Boey, L (通讯作者)，Leuven Univ, KU Leuven, Vaccinol Ctr, Dept Publ Hlth & Primary Care, Kapucijnenvoer 35,POB 7001, B-3000 Leuven, Belgium.	lise.boey@kuleuven.be; Eline.Bosmans@sfz.be; liane.braz.ferreira@gmail.com; nathalie.heyvaert@telenet.be; melissa.nelen@gmail.com; lisa.smans@zna.be; hanne.tuerlinckx@uzleuven.be; mathieu.roelants@kuleuven.be; kathleen.claes@uzleuven.be; inge.derdelinckx@uzleuven.be; wim.janssens@uzleuven.be; chantal.mathieu@uzleuven.be; johan.vancleemput@uzleuven.be; robin.vos@uzleuven.be; isabelle.desombere@sciensano.be; corinne.vandermeulen@kuleuven.be	mathieu, chantal/ABD-5505-2021; Boey, Lise/AAA-7429-2021; Roelants, Mathieu/M-4515-2018; Vandermeulen, Corinne/V-4592-2017	mathieu, chantal/0000-0002-4055-5233; Boey, Lise/0000-0001-9623-4482; Claes, Kathleen/0000-0001-8510-2345; Roelants, Mathieu/0000-0002-3749-0475; Janssens, Wim/0000-0003-1830-2982; Vandermeulen, Corinne/0000-0002-1954-7554	Clinical Research and Education Board of the University hospitals of Leuven	This research was funded by an internal grant from the Clinical Research and Education Board of the University hospitals of Leuven.	Alsina L, 2013, VACCINE, V31, P2417, DOI 10.1016/j.vaccine.2013.03.035; American Heart Association, CLASS HEART FAIL; Blasi F, 2020, HUM VACC IMMUNOTHER, V16, P340, DOI 10.1080/21645515.2019.1652517; Boey L, 2020, HUM VACC IMMUNOTHER, V16, P2136, DOI 10.1080/21645515.2020.1763739; Buck PO, 2017, EPIDEMIOL INFECT, V145, P2109, DOI [10.1017/s0950268817000887, 10.1017/S0950268817000887]; Cabore RN, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020016; Cherry JD, 2005, PEDIATRICS, V115, P1422, DOI 10.1542/peds.2004-2648; Chua AN, 2012, PEDIATRIC DIALYSIS, SECOND EDITION, P569, DOI 10.1007/978-1-4614-0721-8_28; Dhondt D.E., 2013, WELKE MATE ZIJN OUDE; Di Giovine P, 2013, EPIDEMIOL INFECT, V141, P132, DOI 10.1017/S0950268812000210; Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015; European Centre for Disease Prevention and Control (ECDC), PERT ANN EP REP 2017; Feldman AG, 2019, JAMA PEDIATR, V173, P260, DOI 10.1001/jamapediatrics.2018.4954; GIRNDT M, 1995, AM J KIDNEY DIS, V26, P454, DOI 10.1016/0272-6386(95)90491-3; Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y; Hashemi Seyyed Hamid, 2015, Tanaffos, V14, P172; Kanitz EE, 2012, VACCINE, V30, P5222, DOI 10.1016/j.vaccine.2012.06.012; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kruger S, 2001, AM J KIDNEY DIS, V38, P1264, DOI 10.1053/ajkd.2001.29223; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Litzroth A., 2018, EPIDEMIOLOGISCHE SUR; Lobermann M, 2012, AUTOIMMUN REV, V11, P212, DOI 10.1016/j.autrev.2011.05.015; Martini H, 2019, J MED MICROBIOL, V68, P1517, DOI 10.1099/jmm.0.001039; Mbayei SA, 2019, CLIN INFECT DIS, V69, P218, DOI 10.1093/cid/ciy889; McNamara LA, 2017, CLIN INFECT DIS, V65, P811, DOI 10.1093/cid/cix421; Pedrazzi C, 1999, Pediatr Transplant, V3, P109, DOI 10.1034/j.1399-3046.1999.00013.x; Pichichero ME, 2009, PEDIATRICS, V124, P1633, DOI 10.1542/peds.2008-3645; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Rafi A, 2005, ANN ALLERG ASTHMA IM, V94, P445, DOI 10.1016/S1081-1206(10)61114-3; Sanei F, 2016, THER ADV RESPIR DIS, V10, P349, DOI 10.1177/1753465816646050; Sester Martina, 2008, Transplant Rev (Orlando), V22, P274, DOI 10.1016/j.trre.2008.07.001; Siegrist C.-A., 2018, PLOTKINS VACCINES, V7th; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Tafforeau J., HLTH SURVEY BELGIUM; Theeten H, 2011, EPIDEMIOL INFECT, V139, P494, DOI 10.1017/S0950268810001536; Van Damme P., 2013, STUDY VACCINATION CO; Van der Wielen M, 2003, VACCINE, V21, P2412, DOI 10.1016/S0264-410X(03)00062-8; Weinberger B, 2017, CLIN EXP IMMUNOL, V187, P93, DOI 10.1111/cei.12822	38	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							18	10.3390/vaccines9010018			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6XQ	33406698	gold, Green Published			2022-04-29	WOS:000610815500001
J	Chowdhury, SI; Pannhorst, K; Sangewar, N; Pavulraj, S; Wen, X; Stout, RW; Mwangi, W; Paulsen, DB				Chowdhury, Shafiqul I.; Pannhorst, Katrin; Sangewar, Neha; Pavulraj, Selvaraj; Wen, Xue; Stout, Rhett W.; Mwangi, Waithaka; Paulsen, Daniel B.			BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge	VACCINES			English	Article						BoHV-1; quadruple mutant; vaccine vector; BVDV-2; glycoproteins E2 and Erns; BVDV subunit vaccine; granulocyte monocyte colony-stimulating factor (GM-CSF); vaccine efficacy		The bovine respiratory disease complex (BRDC) remains a major problem for both beef and dairy cattle industries worldwide. BRDC frequently involves an initial viral respiratory infection resulting in immunosuppression, which creates a favorable condition for fatal secondary bacterial infection. Current polyvalent modified live vaccines against bovine herpesvirus type 1(BoHV-1) and bovine viral diarrhea virus (BVDV) have limitations concerning their safety and efficacy. To address these shortcomings and safety issues, we have constructed a quadruple gene mutated BoHV-1 vaccine vector (BoHV-1 QMV), which expresses BVDV type 2, chimeric E2 and Flag-tagged Erns-fused with bovine granulocyte monocyte colony-stimulating factor (GM-CSF) designated here as QMV-BVD2*. Here we compared the safety, immunogenicity, and protective efficacy of QMV-BVD2* vaccination in calves against BVDV-2 with Zoetis Bovi-shield Gold 3 trivalent (BoHV-1, BVDV types 1 and 2) vaccine. The QMV-BVD2* prototype subunit vaccine induced the BoHV-1 and BVDV-2 neutralizing antibody responses along with BVDV-1 and -2 cross-reactive cellular immune responses. Moreover, after a virulent BVDV-2 challenge, the QMV-BVD2* prototype subunit vaccine conferred a more rapid recall BVDV-2-specific neutralizing antibody response and considerably better recall BVDV types 1 and 2-cross protective cellular immune responses than that of the Zoetis Bovi-shield Gold 3.	[Chowdhury, Shafiqul I.; Pannhorst, Katrin; Pavulraj, Selvaraj; Wen, Xue; Stout, Rhett W.; Paulsen, Daniel B.] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA; [Sangewar, Neha; Mwangi, Waithaka] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA		Chowdhury, SI (通讯作者)，Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.	chowdh@lsu.edu; katrinpannhorst@aol.com; nsangewar@vet.k-state.edu; pselvaraj1@lsu.edu; xwen12@lsu.edu; rstout1@lsu.edu; wmwangi@vet.k-state.edu; dpauls1@lsu.edu	Selvaraj, Pavulraj/AAV-8266-2021	Mwangi, Waithaka/0000-0002-2705-7571; raj, pavul/0000-0001-6804-0808	USDA/NIFAUnited States Department of Agriculture (USDA) [2015-67015-23277]	This work was supported by USDA/NIFA grant (2015-67015-23277) to S.I. Chowdhury.	Al-Mubarak A, 2007, VIROLOGY, V365, P398, DOI 10.1016/j.virol.2007.03.040; [Anonymous], 2007, REFERENCE DAIRY CA 1; Bachofen C, 2013, BERL MUNCH TIERARZTL, V126, P452, DOI 10.2376/0005-9366-126-452; Beer M, 2003, BERL MUNCH TIERARZTL, V116, P183; Beer M, 2000, VET MICROBIOL, V77, P195, DOI 10.1016/S0378-1135(00)00276-5; Bryant NA, 2003, EMBO J, V22, P833, DOI 10.1093/emboj/cdg092; Chase CCL, 2015, ANIM HEALTH RES REV, V16, P4, DOI 10.1017/S1466252315000110; Chowdhury SI, 2016, J VIROL METHODS, V233, P97, DOI 10.1016/j.jviromet.2016.02.012; Chowdhury SI, 2014, VACCINE, V32, P4909, DOI 10.1016/j.vaccine.2014.07.004; Chowdhury SI, 2006, J VIROL, V80, P4396, DOI 10.1128/JVI.80.9.4396-4405.2006; Chowdhury SI, 2000, J VIROL, V74, P2094, DOI 10.1128/JVI.74.5.2094-2106.2000; Deutskens F, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-97; Fetzer C, 2005, J VIROL, V79, P11901, DOI 10.1128/JVI.79.18.11901-11913.2005; Feys J, 2016, J MOD APPL STAT METH, V15, P78; Fulton RW, 2002, CAN J VET RES, V66, P173; HUTCHINGS DL, 1990, J VIROL, V64, P5114, DOI 10.1128/JVI.64.10.5114-5122.1990; Iott B, 2019, PREV VET MED, V165, P23, DOI 10.1016/j.prevetmed.2019.02.001; Jones Clinton, 2007, Animal Health Research Reviews, V8, P187, DOI 10.1017/S146625230700134X; Jones C, 2010, VET CLIN N AM-FOOD A, V26, P303, DOI 10.1016/j.cvfa.2010.04.007; Kaashoek MJ, 1998, VACCINE, V16, P802, DOI 10.1016/S0264-410X(97)00269-7; Kasonta R, 2012, VACCINE, V30, P6649, DOI 10.1016/j.vaccine.2012.08.069; Koppers-Lalic D, 2005, P NATL ACAD SCI USA, V102, P5144, DOI 10.1073/pnas.0501463102; Koppers-Lalic D, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000080; Kweon CH, 1999, J VET MED SCI, V61, P395, DOI 10.1292/jvms.61.395; Lindberg ALE, 1999, VET MICROBIOL, V64, P197, DOI 10.1016/S0378-1135(98)00270-3; Lokhandwala S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170425; Lorenz I, 2011, IRISH VET J, V64, DOI 10.1186/2046-0481-64-14; Martinod S, 1995, REV SCI TECH OIE, V14, P979, DOI 10.20506/rst.14.4.886; Moennig V, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010029; Njongmeta LM, 2012, VACCINE, V30, P1624, DOI 10.1016/j.vaccine.2011.12.110; O'Rourke K, 2002, J AM VET MED ASSOC, V220, P1770; O'Toole D, 2012, JAVMA-J AM VET MED A, V241, P189, DOI 10.2460/javma.241.2.189; O'Toole D, 2010, JAVMA-J AM VET MED A, V237, P259; Peterhans E, 2006, DEUT TIERARZTL WOCH, V113, P124; Presi P, 2010, VET MICROBIOL, V142, P137, DOI 10.1016/j.vetmic.2009.09.054; Purtle L, 2016, VACCINE, V34, P1582, DOI 10.1016/j.vaccine.2016.02.009; Rajput MKS, 2017, VET IMMUNOL IMMUNOP, V193, P1, DOI 10.1016/j.vetimm.2017.09.006; Ridpath J, 2010, VET CLIN N AM-FOOD A, V26, P335, DOI 10.1016/j.cvfa.2010.04.003; Ridpath JF, 2007, VACCINE, V25, P8058, DOI 10.1016/j.vaccine.2007.09.014; Ridpath JF, 2010, VET CLIN N AM-FOOD A, V26, P105, DOI 10.1016/j.cvfa.2009.10.007; ROTH JA, 1983, AM J VET RES, V44, P2366; Schmitt J, 1999, J GEN VIROL, V80, P2839, DOI 10.1099/0022-1317-80-11-2839; Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017; Stahl K, 2012, JPN J VET RES, V60, pS31; Taylor JD, 2010, CAN VET J, V51, P1351; van Oirschot J, 1999, VET MICROBIOL, V64, P169, DOI 10.1016/S0378-1135(98)00268-5; Wei HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025742; Wernike K, 2017, VET MICROBIOL, V208, P25, DOI 10.1016/j.vetmic.2017.07.009; Winkler MTC, 1999, J VIROL, V73, P8657, DOI 10.1128/JVI.73.10.8657-8668.1999; Wobbrock JO, 2011, 29TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P143, DOI 10.1145/1978942.1978963	50	5	6	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							46	10.3390/vaccines9010046			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6XG	33451136	gold, Green Published			2022-04-29	WOS:000610814500001
J	Suzuki, YJ; Gychka, SG				Suzuki, Yuichiro J.; Gychka, Sergiy G.			SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines	VACCINES			English	Review						cell signaling; coronavirus; COVID-19; SARS-CoV-2; spike protein; vaccine	PULMONARY ARTERIAL-HYPERTENSION; SURVIVAL	The world is suffering from the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses its spike protein to enter the host cells. Vaccines that introduce the spike protein into our body to elicit virus-neutralizing antibodies are currently being developed. In this article, we note that human host cells sensitively respond to the spike protein to elicit cell signaling. Thus, it is important to be aware that the spike protein produced by the new COVID-19 vaccines may also affect the host cells. We should monitor the long-term consequences of these vaccines carefully, especially when they are administered to otherwise healthy individuals. Further investigations on the effects of the SARS-CoV-2 spike protein on human cells and appropriate experimental animal models are warranted.	[Suzuki, Yuichiro J.] Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Washington, DC 20007 USA; [Gychka, Sergiy G.] Bogomolets Natl Med Univ, Dept Pathol Anat N2, UA-01601 Kiev, Ukraine		Suzuki, YJ (通讯作者)，Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Washington, DC 20007 USA.	ys82@georgetown.edu; gychka59@gmail.com		Suzuki, Yuichiro/0000-0001-6689-0497; Hychka, Sergiy/0000-0002-6821-0085	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AI142649, R03AG059554, R03AA026516]	This research was funded by the National Institutes of Health (NIH), grant numbers R21AI142649, R03AG059554, and R03AA026516, with funding awarded to Y.J.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823; Benza RL, 2010, TRANSPLANTATION, V90, P298, DOI 10.1097/TP.0b013e3181e49b83; Chen IY, 2010, J VIROL, V84, P7703, DOI 10.1128/JVI.02560-09; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Fishman AP, 1999, CIRCULATION, V99, P156, DOI 10.1161/01.CIR.99.1.156; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Hoeper MM, 2013, J AM COLL CARDIOL, V62, pD42, DOI 10.1016/j.jacc.2013.10.032; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Humbert M, 2010, EUR RESPIR J, V36, P549, DOI 10.1183/09031936.00057010; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Montani D, 2013, EUR RESPIR REV, V22, P244, DOI 10.1183/09059180.00003313; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nuche J, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080548; Olsson KM, 2014, CIRCULATION, V129, P57, DOI 10.1161/CIRCULATIONAHA.113.004526; Patra T, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009128; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Potus F, 2020, AM J PHYSIOL-LUNG C, V319, pL277, DOI 10.1152/ajplung.00195.2020; Runo JR, 2003, LANCET, V361, P1533, DOI 10.1016/S0140-6736(03)13167-4; Suzuki YJ, 2021, VASC PHARMACOL, V137, DOI 10.1016/j.vph.2020.106823; Suzuki YJ, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110267; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Thenappan T, 2010, EUR RESPIR J, V35, P1079, DOI 10.1183/09031936.00072709; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Warner FJ, 2004, CELL MOL LIFE SCI, V61, P2704, DOI 10.1007/s00018-004-4240-7; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	42	9	9	7	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							36	10.3390/vaccines9010036			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VR	33440640	gold, Green Published			2022-04-29	WOS:000610810300001
J	Zhi, Y; Ji, HJ; Guo, HC; Lim, JH; Byun, EB; Kim, WS; Seo, HS				Zhi, Yong; Ji, Hyun Jung; Guo, Huichen; Lim, Jae Hyang; Byun, Eui-Baek; Kim, Woo Sik; Seo, Ho Seong			Salmonella Vaccine Vector System for Foot-and-Mouth Disease Virus and Evaluation of Its Efficacy with Virus-Like Particles	VACCINES			English	Article						foot-and-mouth disease; VP1; live attenuated Salmonella vector; mucosal immunity; virus-like particle; radiation mutation		Foot-and-mouth disease virus (FMDV) causes a highly contagious and devastating disease in livestock animals and has a great potential to cause severe economic loss worldwide. The major antigen of FMDV capsid protein, VP1, contains the major B-cell epitope responsible for effectively eliciting protective humoral immunity. In this study, irradiated Salmonella Typhimurium (KST0666) were used as transgenic vectors containing stress-inducible plasmid pRECN-VP1 to deliver the VP1 protein from FMDV-type A/WH/CHA/09. Mice were orally inoculated with ATOMASal-L3 harboring pRECN-VP1, and FMDV virus-like particles, where (VLPFMDV)-specific humoral, mucosal, and cellular immune responses were evaluated. Mice vaccinated with attenuated Salmonella (KST0666) expressing VP1 (named KST0669) showed high levels of VLP-specific IgA in feces and IgG in serum, with high FMDV neutralization titer. Moreover, KST0669-vaccinated mice showed increased population of IFN-gamma (type 1 T helper cells; Th1 cells)-, IL-5 (Th2 cells)-, and IL-17A (Th17 cells)-expressing CD4(+) as well as activated CD8(+) T cells (IFN-gamma(+)CD8(+) cells), detected by stimulating VLPFMDV. All data indicate that our Salmonella vector system successfully delivered FMDV VP1 to immune cells and that the humoral and cellular efficacy of the vaccine can be easily evaluated using VLPFMDV in a Biosafety Level I (BSL1) laboratory.	[Zhi, Yong; Ji, Hyun Jung; Byun, Eui-Baek; Seo, Ho Seong] Korea Atom Energy Res Inst, Res Div Radiat Sci, Jeongeup 56212, South Korea; [Zhi, Yong; Seo, Ho Seong] Univ Sci & Technol, Dept Radiat Sci, Daejeon 34113, South Korea; [Ji, Hyun Jung] Seoul Natl Univ, Sch Dent, DRI, Dept Oral Microbiol & Immunol, Seoul 08826, South Korea; [Ji, Hyun Jung] Seoul Natl Univ, Sch Dent, BK21 Plus Program, Seoul 08826, South Korea; [Guo, Huichen] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Natl Foot & Mouth Dis Reference Lab, State Key Lab Vet Etiol Biol, Lanzhou 730000, Peoples R China; [Lim, Jae Hyang] Ewha Womans Univ, Coll Med, Dept Microbiol, Seoul 07804, South Korea; [Lim, Jae Hyang] Ewha Womans Univ, Med Ctr, Ewha Educ & Res Ctr Infect, Seoul 07985, South Korea; [Kim, Woo Sik] Korea Res Inst Biosci & Biotechnol, Funct Biomat Res Ctr, Jeongeup 56212, South Korea		Seo, HS (通讯作者)，Korea Atom Energy Res Inst, Res Div Radiat Sci, Jeongeup 56212, South Korea.; Seo, HS (通讯作者)，Univ Sci & Technol, Dept Radiat Sci, Daejeon 34113, South Korea.; Kim, WS (通讯作者)，Korea Res Inst Biosci & Biotechnol, Funct Biomat Res Ctr, Jeongeup 56212, South Korea.	yongzhi@kaeri.re.kr; hyunjung@kaeri.re.kr; guohuichen@caas.cn; jlim19@ewha.ac.kr; ebbyun80@kaeri.re.kr; kws6144@kribb.re.kr; hoseongseo@kaeri.re.kr		Seo, Ho Seong/0000-0002-7103-1344; Lim, Jae Hyang/0000-0003-0972-9271; Zhi, Yong/0000-0003-1433-0361	National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2019R1C1C1002484, NRF-2020M2D8A3094054]	This work was supported by the National Research Foundation of Korea under grants NRF-2019R1C1C1002484 to E.-B.B. and NRF-2020M2D8A3094054 to H.S.S.	Alexandersen S, 2003, J COMP PATHOL, V129, P1, DOI 10.1016/S0021-9975(03)00041-0; Awan MS, 2011, MOL BIOL REP, V38, P1367, DOI 10.1007/s11033-010-0239-3; Babb R, 2016, CLIN SCI, V130, P697, DOI 10.1042/CS20150699; Bhat SA, 2013, RES VET SCI, V95, P1217, DOI 10.1016/j.rvsc.2013.07.007; Biasino W, 2018, FOOD MICROBIOL, V70, P192, DOI 10.1016/j.fm.2017.10.003; Brito PP, 2011, J FOOD SCI, V76, pS133, DOI 10.1111/j.1750-3841.2010.02004.x; Cao YM, 2016, EXPERT REV VACCINES, V15, P783, DOI 10.1586/14760584.2016.1140042; Cao YM, 2009, VET MICROBIOL, V137, P10, DOI 10.1016/j.vetmic.2008.12.007; Carr BV, 2013, J GEN VIROL, V94, P97, DOI 10.1099/vir.0.045732-0; Chin'ombe N, 2013, VIRUSES-BASEL, V5, P2062, DOI 10.3390/v5092062; Choi JI, 2014, BIOPROC BIOSYST ENG, V37, P2437, DOI 10.1007/s00449-014-1220-7; Clark-Curtiss JE, 2018, J IMMUNOL, V200, P39, DOI 10.4049/jimmunol.1600608; CROWTHER JR, 1993, J GEN VIROL, V74, P1547, DOI 10.1099/0022-1317-74-8-1547; Defaus S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030406; Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7; Fernandez-Sainz I, 2017, VIROLOGY, V502, P123, DOI 10.1016/j.virol.2016.12.021; FINNEY DJ, 1964, STAT METHOD BIOL ASS, P668; Food and Agriculture Organization of the United Nations; International Atomic Energy Agency, 1965, USE INDUCED MUTATION, V1st ed., P832; Frey SE, 2013, VACCINE, V31, P4874, DOI 10.1016/j.vaccine.2013.07.049; Furbank RT, 2019, NEW PHYTOL, V223, P1714, DOI 10.1111/nph.15817; Galen JE, 2009, IMMUNOL CELL BIOL, V87, P400, DOI 10.1038/icb.2009.31; Gao S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60396-6; GRUBMAN MJ, 1980, ARCH VIROL, V63, P311, DOI 10.1007/BF01315038; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Guo HC, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-48; Guzman E, 2010, J VIROL, V84, P12375, DOI 10.1128/JVI.01545-10; Horsington J, 2015, VACCINE, V33, P422, DOI 10.1016/j.vaccine.2014.11.043; Hungund BS, 2010, AFR J BIOTECHNOL, V9, P5170; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Kong W, 2021, METHODS MOL BIOL, V2225, P39, DOI 10.1007/978-1-0716-1012-1_3; Kotton CN, 2004, INFECT IMMUN, V72, P5535, DOI 10.1128/IAI.72.10.5535-5547.2004; Lee CD, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-69; LEVINE MM, 1990, RES MICROBIOL, V141, P807, DOI 10.1016/0923-2508(90)90114-6; Li Q, 2020, VACCINE, V38, P6904, DOI 10.1016/j.vaccine.2020.08.062; Li Y, 2016, J APPL MICROBIOL, V121, P1323, DOI 10.1111/jam.13244; Lin IYC, 2015, VACCINES-BASEL, V3, P940, DOI 10.3390/vaccines3040940; Liu J, 2019, BENEF MICROBES, V10, P589, DOI 10.3920/BM2018.0157; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lv PH, 2020, J VET MED SCI, V82, P1693, DOI 10.1292/jvms.20-0363; Mahdy SE, 2019, APPL MICROBIOL BIOT, V103, P1919, DOI 10.1007/s00253-018-09605-x; MARTIN WB, 1965, RES VET SCI, V6, P196; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; MCCULLOUGH KC, 1986, IMMUNOLOGY, V58, P421; McLachlan I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53658-5; Naranjo J, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0381; Neilan JG, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1582-1; Parida S, 2006, VACCINE, V24, P1107, DOI 10.1016/j.vaccine.2005.09.006; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; Paton DJ, 2009, PHILOS T R SOC B, V364, P2657, DOI 10.1098/rstb.2009.0100; Rao S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243477; Rodriguez LL, 2011, EXPERT REV VACCINES, V10, P377, DOI [10.1586/ERV.11.4, 10.1586/erv.11.4]; Ruiz N, 2008, P NATL ACAD SCI USA, V105, P5537, DOI 10.1073/pnas.0801196105; Rweyemamu M M, 1989, Rev Sci Tech, V8, P747, DOI 10.20506/rst.8.3.425; Sedgwick B, 2002, ONCOGENE, V21, P8886, DOI 10.1038/sj.onc.1205998; Shi HY, 2010, CLIN VACCINE IMMUNOL, V17, P363, DOI 10.1128/CVI.00413-09; Shirdast H, 2021, PROBIOTICS ANTIMICRO, V13, P80, DOI 10.1007/s12602-020-09684-1; SKINNER HH, 1951, P ROY SOC MED, V44, P1041, DOI 10.1177/003591575104401213; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Song JJ, 2020, IMMUNOL LETT, V225, P57, DOI 10.1016/j.imlet.2020.06.007; Stevens MP, 2009, PHILOS T R SOC B, V364, P2709, DOI 10.1098/rstb.2009.0094; Terhuja M, 2015, BIOLOGICALS, V43, P437, DOI 10.1016/j.biologicals.2015.09.004; Wang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143750; Wilson CN, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008796; Xie YL, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7849203; Zhang HY, 2003, VACCINE, V21, P4704, DOI 10.1016/S0264-410X(03)00519-X; Ziraldo M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.591019	66	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							22	10.3390/vaccines9010022			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PY2AC	33466461	Green Published, gold			2022-04-29	WOS:000611850600001
J	Lagousi, T; Papadatou, I; Strempas, P; Chatzikalil, E; Spoulou, V				Lagousi, Theano; Papadatou, Ioanna; Strempas, Petros; Chatzikalil, Elena; Spoulou, Vana			Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All	VACCINES			English	Article						Streptococcus pneumoniae; high-risk children; pneumococcal vaccines; high-income countries; middle- and low-income countries	SICKLE-CELL-DISEASE; CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; STREPTOCOCCUS-PNEUMONIAE; PROTECTIVE EFFICACY; SEROTYPE DISTRIBUTION; ANTIBODY PERSISTENCE; IMMUNE-RESPONSES; HEALTHY INFANTS; CHILDREN	Despite the significant reduction in pneumococcal disease due to pneumococcal vaccines, protection of vulnerable high-risk individuals, especially pediatric populations, remains a great challenge. In an effort to maximize the protection of high-risk children against pneumococcal disease, a combined schedule that includes both conjugate and polysaccharide vaccines is recommended by several countries in the developed world. On the other hand, middle- and low-income countries do not have in place established policies for pneumococcal immunization of children at risk. Pneumococcal conjugate vaccines, despite their benefits, have several limitations, mainly associated with serotype replacement and the wide range of serotype coverage worldwide. In addition, PPV23-impaired immunogenicity and the hyporesponsiveness effect among populations at risk have been well-documented. Therefore, the added value of continuing to include PPV23 in vaccination schedules for high-risk individuals in the years to come remains to be determined by monitoring whether the replacing/remaining serotypes causing IPD are covered by PPV23 to determine whether its benefits outweigh its limitations. In this review, we aim to describe serotype distribution and vaccine efficacy data on pneumococcal disease in the pre- and post-PCV implementation era among high-risk children in both developed and developing countries, assessing the optimization of current recommendations for their vaccination against pneumococcal disease.	[Lagousi, Theano; Papadatou, Ioanna; Spoulou, Vana] Athens Med Sch, Aghia Sophia Childrens Hosp, Dept Paediat 1, Immunobiol Res Lab, Athens 11527, Greece; [Lagousi, Theano; Papadatou, Ioanna; Spoulou, Vana] Athens Med Sch, Aghia Sophia Childrens Hosp, Dept Paediat 1, Infect Dis Dept MAKKA, Athens 11527, Greece; [Strempas, Petros; Chatzikalil, Elena] Natl & Kapodistrian Univ Athens, Univ Res Inst Maternal & Child Hlth & Precis Med, Athens Med Sch, Athens 11527, Greece; Athens Med Sch, Aghia Sophia Childrens Hosp, Dept Paediat 1, Athens 11527, Greece		Lagousi, T (通讯作者)，Athens Med Sch, Aghia Sophia Childrens Hosp, Dept Paediat 1, Immunobiol Res Lab, Athens 11527, Greece.; Lagousi, T (通讯作者)，Athens Med Sch, Aghia Sophia Childrens Hosp, Dept Paediat 1, Infect Dis Dept MAKKA, Athens 11527, Greece.	heanolagousi@hotmail.com; joanna-pap@hotmail.com; petrosstrempas@gmail.com; ehatzikali@gmail.com; vspoulou@med.uoa.gr			University Research Institute for the Study of Genetic and Malignant Disorders in Childhood, 1st Department of Paediatrics, Aghia Sofia Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece; Special Account for Research Grants, National and Kapodistrian University of Athens, Athens, Greece	This work was supported by the University Research Institute for the Study of Genetic and Malignant Disorders in Childhood, 1st Department of Paediatrics, Aghia Sofia Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece and the Special Account for Research Grants, National and Kapodistrian University of Athens, Athens, Greece.	Adamkiewicz TV, 2008, PEDIATRICS, V121, P562, DOI 10.1542/peds.2007-0018; [Anonymous], VACCINE SCHEDULER EC; [Anonymous], SAGE WORKING GROUP P; [Anonymous], VIEW HUB IVAC; Asner SA, 2019, CLIN INFECT DIS, V69, P1574, DOI 10.1093/cid/ciy1139; Australian Technical Advisory Group on Immunisation (ATAGI), 2020, AUSTR IMM HDB 2020; Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113; Benin AL, 2003, J INFECT DIS, V188, P81, DOI 10.1086/375782; Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521; Bennett NM, 2013, AM J TRANSPLANT, V13, P232, DOI 10.1111/ajt.12073; Berman-Rosa M, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0377; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Bocchini JA, 2010, PEDIATRICS, V126, P186, DOI 10.1542/peds.2010-1280; Borrow R, 2001, J INFECT DIS, V184, P377, DOI 10.1086/322024; Cadoz M, 1998, VACCINE, V16, P1391, DOI 10.1016/S0264-410X(98)00097-8; Castro-Rodriguez JA, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1200; Centers for Disease Control and Prevention, 2005, J AM MED ASS, V294, P2022, DOI [10.1001/jama.294.16.2022, DOI 10.1001/JAMA.294.16.2022]; Cernuschi T, 2011, B WORLD HEALTH ORGAN, V89, P913, DOI 10.2471/BLT.11.087700; Chang CC, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006316.pub3; Cohen C, 2017, LANCET GLOB HEALTH, V5, pE359, DOI 10.1016/S2214-109X(17)30043-8; Donkor ES, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2224-0; Esposito S, 2015, FUTURE MICROBIOL, V10, P1599, DOI 10.2217/fmb.15.81; Falleiros-Arlant LH, 2015, INT J INFECT DIS, V38, P1, DOI 10.1016/j.ijid.2015.06.016; Faye PM, 2019, CLIN INFECT DIS, V69, pS66, DOI 10.1093/cid/ciz457; Fiore AE, 1999, EMERG INFECT DIS, V5, P828, DOI 10.3201/eid0506.990616; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Fireman B, 2003, PEDIATR INFECT DIS J, V22, P10, DOI 10.1097/00006454-200301000-00006; Fletcher MA, 2015, EXPERT REV VACCINES, V14, P975, DOI 10.1586/14760584.2015.1037743; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; Gamil A, 2021, INT J INFECT DIS, V102, P429, DOI 10.1016/j.ijid.2020.10.048; Gandhi G, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2521-8; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; Goldblatt D, 2018, LANCET INFECT DIS, V18, P171, DOI 10.1016/S1473-3099(17)30654-0; Hall E., 2021, EPIDEMIOLOGY PREVENT, V14th ed., P255; Nguyen HAT, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3861-2; Hjuler T, 2008, PEDIATRICS, V122, pE26, DOI 10.1542/peds.2007-1510; Isturiz R, 2018, LANCET INFECT DIS, V18, P382, DOI 10.1016/S1473-3099(18)30133-6; Jayasinghe S, 2018, CLIN INFECT DIS, V67, P367, DOI 10.1093/cid/ciy129; Jayasinghe S, 2017, CLIN INFECT DIS, V64, P175, DOI 10.1093/cid/ciw720; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Kilpi T, 2003, CLIN INFECT DIS, V37, P1155, DOI 10.1086/378744; Klugman KP, 2007, CURR OPIN INFECT DIS, V20, P11, DOI 10.1097/QCO.0b013e328012c5f1; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Kwambana-Adams BA, 2020, PNEUMONIA, V12, DOI 10.1186/s41479-019-0064-y; Kwambana-Adams BA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1914-3; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Ladhani SN, 2013, EMERG INFECT DIS, V19, P61, DOI 10.3201/eid1901.120741; Lages PM, 2020, BRAZ J INFECT DIS, V24, P489, DOI [10.1016/j.bjid.2020.09.003, 10.1016/j.bjid.2070.09.003]; Lapidot R, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050396; Lo SW, 2019, LANCET INFECT DIS, V19, P759, DOI 10.1016/S1473-3099(19)30297-X; Mackenzie GA, 2016, LANCET INFECT DIS, V16, P703, DOI 10.1016/S1473-3099(16)00054-2; Mackenzie GA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001161; Madhi SA, 2016, HUM VACC IMMUNOTHER, V12, P314, DOI 10.1080/21645515.2015.1084450; Marangu D, 2019, PAEDIATR RESPIR REV, V32, P3, DOI 10.1016/j.prrv.2019.06.001; McCavit TL, 2012, PEDIATR BLOOD CANCER, V58, P945, DOI 10.1002/pbc.23259; Mera RM, 2005, DIAGN MICR INFEC DIS, V51, P195, DOI 10.1016/j.diagmicrobio.2004.10.009; Moberley SA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub2; Moraga-Llop F, 2016, PEDIATR INFECT DIS J, V35, P460, DOI 10.1097/INF.0000000000001041; Musher DM, 2011, HUM VACCINES, V7, P919, DOI 10.4161/hv.7.9.15996; Musher DM, 2010, J INFECT DIS, V201, P516, DOI 10.1086/649839; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Olarte L, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12630; Oligbu G, 2019, METHODS MOL BIOL, V1968, P215, DOI 10.1007/978-1-4939-9199-0_18; Oligbu G, 2017, CLIN INFECT DIS, V65, P1191, DOI 10.1093/cid/cix418; Onwuchekwa Chukwuemeka, 2020, F1000Res, V9, P765, DOI 10.12688/f1000research.25227.1; Orami T, 2020, VACCINE, V38, P7977, DOI 10.1016/j.vaccine.2020.10.042; Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15; Pelton SI, 2014, CLIN INFECT DIS, V59, P615, DOI 10.1093/cid/ciu348; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Poolman JT, 2013, EXPERT REV VACCINES, V12, P1379, DOI 10.1586/14760584.2013.852475; Ramakrishnan M, 2010, LANCET INFECT DIS, V10, P329, DOI 10.1016/S1473-3099(10)70055-4; Reacher MH, 2000, BMJ-BRIT MED J, V320, P213, DOI 10.1136/bmj.320.7229.213; Rodgers GL, 2016, HUM VACC IMMUNOTHER, V12, P417, DOI 10.1080/21645515.2015.1057671; Russell FM, 2010, VACCINE, V28, P3341, DOI 10.1016/j.vaccine.2010.02.087; Scott JAG, 2007, VACCINE, V25, P2398, DOI 10.1016/j.vaccine.2006.09.008; Senders S, 2021, PEDIATR INFECT DIS J, V40, P944, DOI 10.1097/INF.0000000000003277; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; Shatz DV, 2005, EXPERT REV VACCINES, V4, P27, DOI 10.1586/14760584.4.1.27; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Sigurdardottir ST, 2014, VACCINE, V32, P417, DOI 10.1016/j.vaccine.2013.11.029; Skosana Z, 2021, SAMJ S AFR MED J, V111, P143, DOI [10.7196/SAMJ.2021.v111i2.14626, 10.7196/samj.2021.v111i2.14626]; Solorzano-Santos F, 2017, REV INVEST CLIN, V69, P270, DOI 10.24875/RIC.17002241; Spoulou V, 2000, J INFECT DIS, V182, P965, DOI 10.1086/315798; Sutcliffe CG, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4254-2; Swarthout TD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15786-9; Tam PYI, 2017, VACCINE, V35, P1817, DOI 10.1016/j.vaccine.2017.02.045; Thadchanamoorthy V, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.14913; The GAVI Alliance, 2016, GAVI WELC NEW REC LO; TOMASZ A, 1995, NEW ENGL J MED, V333, P514, DOI 10.1056/NEJM199508243330810; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; Usuf E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085001; van Hoek AJ, 2012, J INFECTION, V65, P17, DOI 10.1016/j.jinf.2012.02.017; Varon E, 2015, VACCINE, V33, P6178, DOI 10.1016/j.vaccine.2015.10.015; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7; Walters JAE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001390.pub3; Weinberger DM, 2019, CLIN INFECT DIS, V69, P100, DOI 10.1093/cid/ciy875; Westerink MAJ, 2012, AGING DIS, V3, P51; Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2; Yildirim I, 2015, PEDIATRICS, V135, P495, DOI 10.1542/peds.2014-2426; Yildirim M, 2020, VACCINE, V38, P1671, DOI 10.1016/j.vaccine.2019.12.060; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	104	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1390	10.3390/vaccines9121390			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1PW	34960136	gold, Green Published			2022-04-29	WOS:000737433300001
J	Lee, DSY; Rundle-Thiele, S; Li, GB				Lee, Daisy; Rundle-Thiele, Sharyn; Li, Gabriel			Motivating Seasonal Influenza Vaccination and Cross-Promoting COVID-19 Vaccination: An Audience Segmentation Study among University Students	VACCINES			English	Article						seasonal influenza vaccination; COVID-19 vaccination; segmentation; social marketing; health promotion	CONTINUUM; HESITANCY	In the response to the coronavirus pandemic, much attention has been invested in promoting COVID-19 vaccination. However, the impact of seasonal influenza should not be neglected, particularly during the winter influenza surge. Currently, most influenza vaccination campaigns target at healthcare workers or high-risk population groups, while COVID-19 vaccination programmes are targeting the whole population as a single homogeneous group. There is limited research on the promotion of influenza vaccination for university students who study, live, and socialise in close contact with a large variety of people on campus, resulting in a low vaccination rate among this underserved group. Thus, a vaccination programme tailored for university students should be developed to increase protection against influenza-like illnesses and complications, and to help achieve herd immunity across populations who spread viruses. WHO has advocated the potential value of social marketing in vaccination campaigns and highlighted the need for audience segmentation as a major prerequisite component of intervention design. This study aims to identify distinct and homogeneous groups of university students based on sociodemographic, psychographic, and behavioural attributes to inform interventions. Two-step cluster analysis was applied in a sample size of 530 university students and revealed four segments that demonstrate statistically significant differences in their attitudes, behaviours, intentions, and responses to promotion messages about seasonal influenza and COVID-19 vaccination. The findings provide a detailed understanding of segment characteristics among university students that can be applied to develop an effective social marketing campaign that can motivate influenza vaccination and cross-promote uptake of the COVID-19 vaccine.	[Lee, Daisy; Li, Gabriel] Hong Kong Polytech Univ, Sch Profess Educ & Execut Dev, Hong Kong, Peoples R China; [Rundle-Thiele, Sharyn] Griffith Univ, Social Mkt Griffith, Nathan, Qld 4111, Australia		Lee, DSY (通讯作者)，Hong Kong Polytech Univ, Sch Profess Educ & Execut Dev, Hong Kong, Peoples R China.	daisy.lee@cpce-polyu.edu.hk; s.rundle-thiele@griffith.edu.au; tlgab.li@speed-polyu.edu.hk	Lee, Daisy/E-7877-2019	Lee, Daisy/0000-0002-9630-1689; Rundle-Thiele, Sharyn/0000-0003-2536-3767	Research Grants Council of the Hong Kong Special Administrative Region, ChinaHong Kong Research Grants Council [UGC/FDS24/B03/20]	FundingThe work described in this paper and APC was fully supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. UGC/FDS24/B03/20).	Almalki MJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090943; Andreasen A. R., 2003, MARKETING THEORY, V3, P293, DOI DOI 10.1177/147059310333004; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Benassi M, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01085; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Bin Shams A, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9020156; CDC, FLU SPREADS 2018; CDC Flu Vaccination Coverage, US 2019 2020 INFL SE; Dietrich T., 2017, SEGMENTATION SOCIAL, V1; George D., 2019, IBM SPSS STAT 26 STE; Griffin B, 2014, ANN BEHAV MED, V48, P205, DOI 10.1007/s12160-014-9589-8; Himelein-Wachowiak M, 2021, J MED INTERNET RES, V23, DOI 10.2196/26933; Ihm J, 2021, HEALTH COMMUN, V36, P98, DOI 10.1080/10410236.2020.1847450; Jamison A.M., 2020, HARV KENNEDY SCH MIS, P1, DOI [10.37016/mr-2020-38, DOI 10.37016/MR-2020-38]; Kanyike AM, 2021, TROP MED HEALTH, V49, DOI 10.1186/s41182-021-00331-1; Kitunen A, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6696-2; Lau LHW, 2020, VACCINE, V38, P6785, DOI 10.1016/j.vaccine.2020.08.038; Nichol KL, 2008, ARCH PEDIAT ADOL MED, V162, P1113, DOI 10.1001/archpedi.162.12.1113; Norusis M. J., 2012, IBM SPSS STAT 19 STA; Nowak GJ, 2015, VACCINE, V33, P2741, DOI 10.1016/j.vaccine.2015.04.064; Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015; Ramanadhan S, 2015, VACCINES, V3, P556, DOI 10.3390/vaccines3030556; Rundle-Thiele S, 2015, MARK INTELL PLAN, V33, P522, DOI 10.1108/MIP-03-2014-0050; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Uchida M, 2012, AM J INFECT CONTROL, V40, P218, DOI 10.1016/j.ajic.2011.03.012; Wang LG, 2014, SCI REP-UK, V4, DOI 10.1038/srep05982; WHO, HOW REP MIS; WHO, 2013, GUID TAIL IMM PROGR; WHO TIP, AIL IMM PROGR; World Health Organization, FIGHT MIS TIM COVID; ZAICHKOWSKY JL, 1994, J ADVERTISING, V23, P59, DOI 10.1080/00913367.1943.10673459	31	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1397	10.3390/vaccines9121397			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2JJ	34960143	Green Published, gold			2022-04-29	WOS:000737484000001
J	Paul, KT; Janny, A; Riesinger, K				Paul, Katharina T.; Janny, Anna; Riesinger, Katharina			Austria's Digital Vaccination Registry: Stakeholder Views and Implications for Governance	VACCINES			English	Article						digitalization; health; data; policy; vaccination; immunization; Austria; COVID-19	ELECTRONIC HEALTH RECORD; ACCOUNTABILITY	In this study, we explore the recent setup of a digital vaccination record in Austria. Working from a social-scientific perspective, we find that the introduction of the electronic vaccination pass was substantially accelerated by the COVID-19 pandemic. Our interviews with key stakeholders (n = 16) indicated that three main factors drove this acceleration. The pandemic (1) sidelined historical conflicts regarding data ownership and invoked a shared sense of the value of data, (2) accentuated the need for enhanced administrative efficiency in an institutionally fragmented system, and (3) helped invoke the national vaccination registry as an indispensable infrastructure for public health governance with the potential to innovate its healthcare system in the long term.	[Paul, Katharina T.; Janny, Anna; Riesinger, Katharina] Univ Vienna, Fac Social Sci, Dept Polit Sci, A-1010 Vienna, Austria		Paul, KT (通讯作者)，Univ Vienna, Fac Social Sci, Dept Polit Sci, A-1010 Vienna, Austria.	katharina.t.paul@univie.ac.at; anna.janny@univie.ac.at; katharina.riesinger@univie.ac.at		Paul, Katharina T./0000-0002-3851-8951			Ammenwerth E, 2014, INT J MED INFORM, V83, P655, DOI 10.1016/j.ijmedinf.2014.06.004; Bester JC, 2015, J BIOETHIC INQ, V12, P555, DOI 10.1007/s11673-015-9673-1; Council of the European Union, 2018, COUNCIL RECOMMENDATI; Deutsch E, 2010, INT J MED INFORM, V79, P211, DOI 10.1016/j.ijmedinf.2009.12.002; Dorda W, 2005, ST HEAL T, V116, P119; ELGA GmbH, ELGA ZAHL DAT FAKT; European Centre for Disease Prevention and Control, 2017, IMM INF SYST EU EEA; European Commission, 2012, EHEALTH ACT PLAN 201; Federal Ministry of Social Affairs, HLTH CAR CONS PROT E; Felt U., 2009, SCI TECHNOL STUD, V22, P24, DOI [10.23987/sts.55244, DOI 10.23987/STS.55244]; Fisher A., 2012, GOVERNANCE INDICATOR, P217, DOI [10.1093/acprof:oso/9780199658244.003.0009, DOI 10.1093/ACPROF:OSO/9780199658244.003.0009]; Forgo N., 2021, LECT U VIENN; Gottweis H., 2012, DEBATTE OFFENTLICHEN; Gunter TD, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.1.e3; Guttmann A, 2011, PAED CHILD HEALT-CAN, V16, P16, DOI 10.1093/pch/16.1.16; Herbek S, 2012, EUR SURG, V44, P155, DOI 10.1007/s10353-012-0092-9; Hoerbst A, 2010, INT J MED INFORM, V79, P81, DOI 10.1016/j.ijmedinf.2009.11.002; Hoeyer K, 2019, SOC STUD SCI, V49, P459, DOI 10.1177/0306312719860202; Hoeyer K, 2019, SOC STUD SCI, V49, P531, DOI 10.1177/0306312719858697; Holmberg C, 2013, SCI TECHNOL HUM VAL, V38, P398, DOI 10.1177/0162243912439610; Jahn B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050434; Lohninger T.., 2020, E IMPFPASS OPT OUT M; Lupton D., 2018, DIGITAL HLTH CRITICA; Madsen AK, 2016, INT POLIT SOCIOL, V10, P275, DOI 10.1093/ips/olw010; Martani A, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045717; Mayer-Schonberger V., 2013, BIG DATA REVOLUTION; Paul KT, 2019, J PUBLIC HEALTH POL, V40, P166, DOI 10.1057/s41271-019-00163-8; Pichelstorfer A., 2020, IN PRESS, DOI [10.1093/ips/olab031, DOI 10.1093/IPS/OLAB031]; Porter Theodor., 1995, TRUST NUMBERS PURSUI; Robbins A, 1998, PUBLIC HEALTH REP, V113, P533; Ruppert E, 2017, BIG DATA SOC, V4, DOI 10.1177/2053951717717749; Sabutsch S.W, 2017, GMS MED INFORM BIOME, V13, P1, DOI [10.3205/mibe000177, DOI 10.3205/MIBE000177, 10.3205/MIBE000177]; Sadoughi F, 2019, HEALTH TECHNOL-GER, V9, P383, DOI 10.1007/s12553-018-0277-8; Sadowski J, 2019, BIG DATA SOC, V6, DOI 10.1177/2053951718820549; Schmid D, 2010, EPIDEMIOL INFECT, V138, P415, DOI 10.1017/S0950268809990604; Strauss R, 2008, Euro Surveill, V13; Szilagyi PG, 2000, JAMA-J AM MED ASSOC, V284, P1820, DOI 10.1001/jama.284.14.1820; Taylor L, 2020, BIG DATA SOC, V7, DOI 10.1177/2053951720942539; van Lier A, 2012, EUROSURVEILLANCE, V17, P11; Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3	40	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1495	10.3390/vaccines9121495			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8HH	34960241	gold, Green Published			2022-04-29	WOS:000737206200001
J	Cao, H; Yang, SR; Wang, YF; Luan, N; Yin, XX; Lin, KY; Liu, CB				Cao, Han; Yang, Shengran; Wang, Yunfei; Luan, Ning; Yin, Xingxiao; Lin, Kangyang; Liu, Cunbao			An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines	VACCINES			English	Article						SARS-CoV-2 subunit vaccine; Th1/Th2 orientation; alum adjuvant; nucleic acid adjuvant; prime-boost; homogenous boost immunization; heterologous boost immunization	INACTIVATED VACCINE; IMMUNOGENICITY; COVID-19; PROTECTION; MICE	A recently reported parallel preclinical study between a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine and an inactivated SARS-CoV-2 vaccine adjuvanted with alum showed pulmonary immunopathology typical of eosinophil accumulation in a mouse pneumonia model for the latter, which implied a potential role of cellular immunity in the difference in the protection rate between these two forms of vaccines. For those who have been vaccinated with alum-adjuvanted subunit or inactivated SARS-CoV-2 vaccines, whether the Th2 responses that have been established and the absence of induced cellular immunity could be changed is an open question. Using two heterologous boosts with Th1-oriented CpG ODN-adjuvanted S1-based SARS-CoV-2 subunit vaccines for mice that were primed with two doses of Th2-oriented alum-adjuvanted S1-based SARS-CoV-2 subunit vaccines, we demonstrated that established Th2 orientation could not be reversed to Th1 orientation and that no cellular immunity was induced, which should have been induced if the boosting vaccines were used as the prime vaccines. These results remind us that if widely administered alum-adjuvanted SARS-CoV-2 vaccines cannot overcome the challenge of coronavirus disease 2019 (COVID-19) and that if cellular immunity is important for the efficacy of SARS-CoV-2 vaccines in the future, the choice of more powerful heterologous boosting vaccine forms that can induce cellular immunity should be considered very carefully before application.	[Cao, Han; Yang, Shengran; Wang, Yunfei; Luan, Ning; Yin, Xingxiao; Lin, Kangyang; Liu, Cunbao] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Peoples R China		Liu, CB (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Peoples R China.	caohan@imbcams.com.cn; YSR@imbcams.com.cn; wangyf@imbcams.com.cn; luanning@imbcams.com.cn; xingxiao_y@imbcams.com.cn; linky6679@163.com; cunbao_liu@163.com		Liu, Cunbao/0000-0002-2101-2612	National Key R&D Program of China [2020YFC0849700, 2020YFC0860600]; Major Science and Technology Special Projects of Yunnan Province, China [202003AC100009, 202002AA100009]; China Health and Longevity Innovation Competition [2021-JKCS-012]; Special Biomedicine Projects of Yunnan Province [202102AA310035]; Basic Research Projects of Yunnan Province [202101AT070286]; Funds for the Training of High-level Health Technical Personnel in Yunnan Province [H-2019063]; Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province	This research was funded by the National Key R&D Program of China (grant numbers 2020YFC0849700 and 2020YFC0860600), the Major Science and Technology Special Projects of Yunnan Province, China (grant numbers 202003AC100009 and 202002AA100009), China Health and Longevity Innovation Competition (grant number 2021-JKCS-012), Special Biomedicine Projects of Yunnan Province (grant number 202102AA310035), Basic Research Projects of Yunnan Province (grant number 202101AT070286), Funds for the Training of High-level Health Technical Personnel in Yunnan Province (grant number H-2019063) and Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province.	Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; [Anonymous], EFFICACY SAFETY COVI; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bian LL, 2021, EXPERT REV VACCINES, V20, P1201, DOI 10.1080/14760584.2021.1976153; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Cao H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040310; Chiu NC, 2021, EXPERT REV VACCINES, V20, P1211, DOI 10.1080/14760584.2021.1971522; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; DiPiazza AT, 2021, IMMUNITY, V54, P1869, DOI 10.1016/j.immuni.2021.06.018; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; He Qian, 2021, Emerging Microbes & Infections, V10, P629, DOI 10.1080/22221751.2021.1902245; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5; Liao Y, 2021, EMERG MICROBES INFEC, V10, P1112, DOI 10.1080/22221751.2021.1937328; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Pan HX, 2021, CHINESE MED J-PEKING, V134, P1289, DOI 10.1097/CM9.0000000000001573; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Rosenberg HF, 2021, SEMIN IMMUNOPATHOL, V43, P383, DOI 10.1007/s00281-021-00850-3; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wang YF, 2021, VIROL SIN, V36, P122, DOI 10.1007/s12250-020-00261-y; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Wang ZJ, 2020, EMERG MICROBES INFEC, V9, P2606, DOI 10.1080/22221751.2020.1852059; Williamson BN, 2020, NATURE, V585, P273, DOI [10.1038/s41586-020-2423-5, 10.1101/2020.04.15.043166]; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Zhang JL, 2021, EMERG MICROBES INFEC, V10, P1598, DOI 10.1080/22221751.2021.1957401; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	47	1	1	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1261	10.3390/vaccines9111261			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK0AL	34835192	gold, Green Published			2022-04-29	WOS:000727138900001
J	Carini, E; Cadeddu, C; Castagna, C; Nurchis, MC; Lanza, TE; Grossi, A; Barbara, A; Axelrod, S; Goletti, M; Parente, P				Carini, Elettra; Cadeddu, Chiara; Castagna, Carolina; Nurchis, Mario Cesare; Lanza, Teresa Eleonora; Grossi, Adriano; Barbara, Andrea; Axelrod, Svetlana; Goletti, Mauro; Parente, Paolo			Organisational Model and Coverage of At-Home COVID-19 Vaccination in an Italian Urban Context	VACCINES			English	Article						at-home vaccination; immunisation campaign; SARS-CoV-2; organisational model	FRAILTY	The COVID-19 pandemic called for a reorganisation of the methods for providing health services. The aim of this paper is to describe the organisational model implemented by one of Rome's Local Health Units (LHU), ASL Roma 1, for the "at-home COVID-19 vaccination campaign " dedicated to a target population and to outline data related to vaccination coverage stratified by health districts. A cross-sectional study was designed to describe the strategies implemented by LHU to deliver at-home vaccination programmes. People eligible for the at-home vaccination programme included patients living in the area of the LHU, being assisted by the district home care centre or not transportable or individuals with social situations that make traveling difficult. Priority for vaccination was given to (I) age > 80 years, (II) ventilated patients with no age limit, (III) very seriously disabled people with no age limit. Patients' data were acquired from regional and LHU databases. From 5 February until the 16 May, 6127 people got at least one dose of Pfizer-Biontech Comirnaty(R) vaccine, while 5278 (86.14%) completed the necessary two doses. The highest number of vaccines was administered during the first week of April, reaching 1296 doses overall. The number of vaccines administered were similar across the districts. The average number of people vaccinated at home was 6 per 1000 inhabitants in the LHU. This model proved to be extremely complex but effective, reaching satisfying results in terms of vaccination coverage.	[Carini, Elettra; Grossi, Adriano; Barbara, Andrea; Goletti, Mauro; Parente, Paolo] Local Hlth Author Asl Roma 1, Hlth Directorate, I-00193 Rome, Italy; [Carini, Elettra; Cadeddu, Chiara; Castagna, Carolina; Lanza, Teresa Eleonora; Grossi, Adriano] Univ Cattolica Sacro Cuore, Dept Life Sci & Publ Hlth, Sect Hyg, I-00168 Rome, Italy; [Nurchis, Mario Cesare] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, I-00168 Rome, Italy; [Axelrod, Svetlana] Univ Sechenov, Inst Leadership, Moscow 119435, Russia		Cadeddu, C (通讯作者)，Univ Cattolica Sacro Cuore, Dept Life Sci & Publ Hlth, Sect Hyg, I-00168 Rome, Italy.	elettra.carini1@gmail.com; chiara.cadeddu@unicatt.it; carolina.castagna@gmail.com; nurchismario@gmail.com; lanza_teresaeleonora@libero.it; adriano.grossi@yahoo.it; andrea.barbara@aslroma1.it; akselrod@who.int; mauro.goletti@aslroma1.it; paolo.parente@aslroma1.it	Cadeddu, Chiara/K-3089-2018; Barbara, Andrea/J-3954-2018	Cadeddu, Chiara/0000-0003-0149-1078; Nurchis, Mario Cesare/0000-0002-9345-4292; Parente, Paolo/0000-0002-5208-3704; Barbara, Andrea/0000-0001-5321-4537			ASL Roma 1, VACC DOM ASL ROM 1 S; ASL Roma 1, VACC ANT COVID 19; Bond LM, 1998, MED J AUSTRALIA, V168, P487, DOI 10.5694/j.1326-5377.1998.tb141411.x; Chaignat CL, 2007, J HEALTH POPUL NUTR, V25, P244; Cloudnine, VACC YOUR BAB CLOUDN; Deshpande S., 2021, NO HOME VACCINATION; European Commission, 2021, COMM COMM EUR PARL E; Hewitt J, 2020, LANCET PUBLIC HEALTH, V5, pE444, DOI 10.1016/S2468-2667(20)30146-8; Kojima G, 2019, ARCH GERONTOL GERIAT, V84, DOI 10.1016/j.archger.2019.06.003; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Ministero del Lavoro e delle Politiche Sociali, 2016, RIP RIS FIN FOND NAZ; Ministero della Salute, 2020, EL PREP IMPL STRAT V; Ministero della Salute, 2021, RACC AD INT GRUPP TA; Ministero della Salute, 2021, AGG VACC DISP SARS C; Noakes K, 2006, CURR TOP MICROBIOL, V304, P53; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; van Kan GA, 2008, J AM MED DIR ASSOC, V9, P71, DOI 10.1016/j.jamda.2007.11.005; Waitzberg R., 2021, PLANNING SERVICES VA	18	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1256	10.3390/vaccines9111256			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XM1FW	34835187	gold, Green Published			2022-04-29	WOS:000728582200001
J	Cristea, D; Ilie, DG; Constantinescu, C; Firtala, V				Cristea, Darie; Ilie, Dragos-Georgian; Constantinescu, Claudia; Firtala, Valeriu			Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated	VACCINES			English	Article						vaccines; sociological survey; social norms; vaccine acceptance; vaccine hesitancy; COVID-19 vaccination; pro-vaccination attitude; pandemic; society		This study verifies whether there is a strong correlation between the pro-vaccination, against COVID-19 attitude of the respondents and their belief that most of those around them want to be vaccinated against COVID-19. For this purpose, we analyzed data from a sociological survey conducted in April 2021 in Romania. The sample size was of 1001 respondents, the selection process was randomized and the population included in the sample is representative of the socio-demographic structure of Romania. The tool used to collect the data was CATI (telephonic interview). In order to test the existence of these correlations we performed the following tests: Chi-Square test, Kendall tau, Spearman rho tests and Freeman's z-test. The pro-vaccination attitude strongly correlates with the perception of subjects that their primary group accepts vaccination and even correlates with the perception that the general public is rather pro-vaccination. The vaccination decision is closely linked to the social relations system and the rules of the community in which the subject lives. In this paper we discuss the correlation between attitude and belief, not the existence of a causal relation between the two of them.	[Cristea, Darie; Ilie, Dragos-Georgian; Constantinescu, Claudia; Firtala, Valeriu] Univ Bucharest, Fac Sociol & Social Work, Bucharest 010181, Romania		Cristea, D (通讯作者)，Univ Bucharest, Fac Sociol & Social Work, Bucharest 010181, Romania.	darie.cristea@unibuc.ro; dragos.ilie@unibuc.ro; claudia.constantinescu@unibuc.ro; valeriu.firtala@unibuc.ro		Ilie, Dragos-Georgian/0000-0002-3392-9890; Firtala, Valeriu/0000-0002-1936-8484			Ajzen I., 1980, UNDERSTANDING ATTITU; AlShurman BA, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18179342; [Anonymous], 2021, GLOBAL HLTH OBSERVAT; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Bicchieri C., 2006, GRAMMAR SOC NATURE D, DOI 10.1017/CBO9780511616037; Cristea D., 2021, Proceedings of the Romanian Academy. Series B, Chemistry, Life Sciences and Geosciences, V23, P25; Cristea D, 2019, ATITUDINEA POPULA IE; Darie C., 2021, BAROMETRUL SECURITAT; European Commission, 2021, EUR ATT VACC COVID 1; European Commission, 2019, EUR EUR ATT VACC; GIBBONS JD, 1975, AM STAT, V29, P20, DOI 10.2307/2683674; INS, 2019, AN STAT ROM; Kalambayi F, 2015, STUDIU PRIVIND NORME; Kerr A.W., 2002, DOING STAT SPSS; King I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070790; Konstantinou P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060607; Lau K, 2019, LANCET, V394, P65; Moore JX, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080879; Puth MT, 2015, ANIM BEHAV, V102, P77, DOI 10.1016/j.anbehav.2015.01.010; Salomoni MG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080873; Tonnies F., 1957, GEMEINSCHAFT GESELLS; Viswanath K, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10862-1; Wellcome Global Monitor, 2018, DOES WORLD FEEL SCI; World Health Organization, 2020, BEH CONS ACC UPD COV	24	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1366	10.3390/vaccines9111366			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE5LH	34835297	gold, Green Published			2022-04-29	WOS:000723428500001
J	Karimabad, MN; Kounis, NG; Hassanshahi, G; Hassanshahi, F; Mplani, V; Koniari, I; Hung, MY; Nadimi, AE				Karimabad, Mojgan Noroozi; Kounis, Nicholas G.; Hassanshahi, Gholamhossein; Hassanshahi, Farzaneh; Mplani, Virginia; Koniari, Ioanna; Hung, Ming-Yow; Nadimi, Ali Esmaeili			The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review	VACCINES			English	Review						acute coronary syndromes; CXCL10; Chemokines; coronary artery disease; COVID-19; vaccines	INTERFERON-INDUCIBLE PROTEIN-10; IP-10 GENE-EXPRESSION; REGULATORY T-CELLS; IFN-GAMMA; DIFFERENTIAL EXPRESSION; HEART-DISEASE; TNF-ALPHA; HUMAN CARDIOMYOCYTES; PRIMARY HEPATOCYTES; CIRCULATING LEVELS	Coronary artery disease (CAD) and coronary heart disease (CHD) constitute two of the leading causes of death in Europe, USA and the rest of the world. According to the latest reports of the Iranian National Health Ministry, CAD is the main cause of death in Iranian patients with an age over 35 years despite a significant reduction in mortality due to early interventional treatments in the context of an acute coronary syndrome (ACS). Inflammation plays a fundamental role in coronary atherogenesis, atherosclerotic plaque formation, acute coronary thrombosis and CAD establishment. Chemokines are well-recognized mediators of inflammation involved in several bio-functions such as leucocyte migration in response to inflammatory signals and oxidative vascular injury. Different chemokines serve as chemo-attractants for a wide variety of cell types including immune cells. CXC motif chemokine ligand 10 (CXCL10), also known as interferon gamma-induced protein 10 (IP-10/CXLC10), is a chemokine with inflammatory features whereas CXC chemokine receptor 3 (CXCR3) serves as a shared receptor for CXCL9, 10 and 11. These chemokines mediate immune responses through the activation and recruitment of leukocytes, eosinophils, monocytes and natural killer (NK) cells. CXCL10, interleukin (IL-15) and interferon (IFN-g) are increased after a COVID-19 vaccination with a BNT162b2 mRNA (Pfizer/BioNTech) vaccine and are enriched by tumor necrosis factor alpha (TNF-alpha) and IL-6 after the second vaccination. The aim of the present study is the presentation of the elucidation of the crucial role of CXCL10 in the patho-physiology and pathogenesis of CAD and in identifying markers associated with the vaccination resulting in antibody development.	[Karimabad, Mojgan Noroozi; Hassanshahi, Gholamhossein] Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Mol Med Res Ctr, Rafsanjan 7717933777, Iran; [Kounis, Nicholas G.] Univ Patras, Div Cardiol, Dept Internal Med, Sch Med, Patras 26500, Greece; [Hassanshahi, Farzaneh] Islamic Azad Univ, Fac Vet Med, Shahr e Kord Branch, Shahr E Kord 8813733395, Iran; [Mplani, Virginia] Patras Univ Hosp, Intens Care Unit, Patras 26500, Greece; [Koniari, Ioanna] NHS Fdn Trust, Dept Cardiol, Univ Hosp South Manchester, Manchester M23 9LT, Lancs, England; [Hung, Ming-Yow] Taipei Med Univ, Shuang Ho Hosp, Div Cardiol, Dept Internal Med, New Taipei 23561, Taiwan; [Hung, Ming-Yow] Taipei Med Univ, Sch Med, Div Cardiol, Dept Internal Med,Coll Med, Taipei 110, Taiwan; [Hung, Ming-Yow] Taipei Med Univ, Taipei Heart Inst, Taipei 110, Taiwan; [Nadimi, Ali Esmaeili] Rafsanjan Univ Med Sci, Sch Med, Dept Cardiol, Rafsanjan 7717933777, Iran; [Nadimi, Ali Esmaeili] Rafsanjan Univ Med Sci, Occupat Environm Res Ctr, Rafsanjan 7717933777, Iran		Kounis, NG (通讯作者)，Univ Patras, Div Cardiol, Dept Internal Med, Sch Med, Patras 26500, Greece.	ngkounis@otenet.gr; Farzanehhassanshahi12@gmail.com; virginiamplani@yahoo.gr; iokoniari@yahoo.gr; myhung6@ms77.hinet.net; dr_esmaeili_n@yahoo.com		Hung, Ming-Yow/0000-0002-6912-7523; Mplani, Virginia-Aikaterini/0000-0003-1610-0156; Kounis, Nicholas/0000-0002-9751-6710	Rafsanjan University of Medical Sciences	This project was supported by a grant from the Rafsanjan University of Medical Sciences.	Ahmadi Z, 2013, INFLAMMATION, V36, P364, DOI 10.1007/s10753-012-9555-1; Altara R, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4396368; Altara R, 2016, CLIN SCI, V130, P463, DOI 10.1042/CS20150666; Ammirati E, 2015, CLIN EXP IMMUNOL, V179, P173, DOI 10.1111/cei.12477; Andersen-Nissen E, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009363; Ardigo D, 2007, PHYSIOL GENOMICS, V31, P402, DOI 10.1152/physiolgenomics.00104.2007; Azamor T, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010096; Benetos G, 2020, INT J CARDIOVAS IMAG, V36, P713, DOI 10.1007/s10554-019-01750-2; Bergamaschi C, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109504; Bergamaschi C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000599; Bodnar RJ, 2009, J CELL SCI, V122, P2064, DOI 10.1242/jcs.048793; Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10; Boivin Z, 2021, CUREUS, V13, DOI 10.7759/cureus.13651; Chang J, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e6; Chang SF, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00400-8; Chatterjee S, 2021, DIABETES METAB SYND, V15, P1055, DOI 10.1016/j.dsx.2021.04.006; Cheng C, 2007, J CLIN INVEST, V117, P616, DOI 10.1172/JCI28180; Ciesielski CJ, 2002, EUR J IMMUNOL, V32, P2037, DOI 10.1002/1521-4141(200207)32:7<2037::AID-IMMU2037>3.0.CO;2-I; Dahlof Bjorn, 2010, Am J Cardiol, V105, p3A, DOI 10.1016/j.amjcard.2009.10.007; Darakhshan S, 2019, J DIABETES METAB DIS, V18, P371, DOI 10.1007/s40200-019-00421-2; Darakhshan S, 2019, PREGNANCY HYPERTENS, V17, P36, DOI 10.1016/j.preghy.2019.05.001; Das A, 2015, PHARMACOL THERAPEUT, V147, P12, DOI 10.1016/j.pharmthera.2014.10.003; David BA, 2019, IMMUNOL REV, V289, P9, DOI 10.1111/imr.12757; DENG WL, 1994, J IMMUNOL, V153, P2130; Derakhshan R, 2012, INFLAMMATION, V35, P900, DOI 10.1007/s10753-011-9391-8; Di Luigi L, 2016, INFLAMMATION, V39, P1238, DOI 10.1007/s10753-016-0359-6; de Oliveira RTD, 2009, INT J CARDIOL, V136, P17, DOI 10.1016/j.ijcard.2008.04.009; Dillman JF, 2004, TOXICOL IN VITRO, V18, P593, DOI 10.1016/j.tiv.2004.01.009; Dusi V, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5902947; Elkind MSV, 2002, STROKE, V33, P2587, DOI 10.1161/01.STR.0000034400.71491.10; Emoto T, 2014, CIRC J, V78, P2935, DOI 10.1253/circj.CJ-14-0644; Erdmann E, 2010, QJM-INT J MED, V103, P213, DOI 10.1093/qjmed/hcp168; Fatehi F, 2017, J BIOMED RES, V31, P468, DOI 10.7555/JBR.31.20150166; Ferdousie VT, 2017, INT J CARDIOL, V233, P23, DOI 10.1016/j.ijcard.2017.02.011; Ferrari SM, 2014, RECENT PATENTS INFLA, V8, P132, DOI 10.2174/1872213X08666140623114845; Ge MQ, 2012, J IMMUNOL, V189, P2099, DOI 10.4049/jimmunol.1103474; Gniewkiewicz MS, 2019, POL ARCH INTERN MED, V129, P592, DOI 10.20452/pamw.14926; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Goncalves E, 2019, J CLIN INVEST, V129, P1960, DOI 10.1172/JCI125372; Groom JR, 2012, IMMUNITY, V37, P1091, DOI 10.1016/j.immuni.2012.08.016; Ha YJ, 2017, AM J PATHOL, V187, P352, DOI 10.1016/j.ajpath.2016.10.009; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; Han B, 1999, AM J PHYSIOL-CELL PH, V277, pC74, DOI 10.1152/ajpcell.1999.277.1.C74; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hasib L, 2016, J INTERN MED, V279, P63, DOI 10.1111/joim.12398; Hassanshahi GG, 2007, SAUDI MED J, V28, P514; Heller EA, 2006, CIRCULATION, V113, P2301, DOI 10.1161/CIRCULATIONAHA.105.605121; Hu ZJ, 2012, CELL BIOCHEM BIOPHYS, V62, P125, DOI 10.1007/s12013-011-9270-9; Jamali Z, 2013, CLIN LAB, V59, P993, DOI 10.7754/Clin.Lab.2012.120810; Johrer K, 2008, EXPERT OPIN BIOL TH, V8, P269, DOI 10.1517/14712598.8.3.269 ; Kanda N, 2002, J INVEST DERMATOL, V119, P1411, DOI 10.1046/j.1523-1747.2002.19627.x; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; Karimabad MN, 2016, NEUROIMMUNOMODULAT, V23, P197, DOI 10.1159/000449427; Karimabad MN, 2015, INFLAMMATION, V38, P710, DOI 10.1007/s10753-014-9981-3; Karin N, 2018, CYTOKINE, V109, P24, DOI 10.1016/j.cyto.2018.02.012; Karin N, 2016, J LEUKOCYTE BIOL, V99, P857, DOI 10.1189/jlb.2MR0915-441R; Karin N, 2015, INT IMMUNOPHARMACOL, V28, P829, DOI 10.1016/j.intimp.2015.03.037; Kawamura A, 2003, CIRC J, V67, P851, DOI 10.1253/circj.67.851; Keeley EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021174; Kelsen SG, 2004, AM J PHYSIOL-LUNG C, V287, pL584, DOI 10.1152/ajplung.00453.2003; Klinghammer L, 2013, CYTOKINE, V62, P290, DOI 10.1016/j.cyto.2013.02.001; Kopydlowski KM, 1999, J IMMUNOL, V163, P1537; Kounis NG, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080959; Kounis NG, 2021, AM J EMERG MED, V47, P313, DOI 10.1016/j.ajem.2021.01.035; Kounis NG, 2021, BALK MED J, V38, P145, DOI 10.5152/balkanmedj.2021.21097; Laing KJ, 2004, DEV COMP IMMUNOL, V28, P443, DOI 10.1016/j.dci.2003.09.006; Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lloyd AR, 1996, J IMMUNOL, V156, P932; Lloyd-Jones DM, 2010, CIRCULATION, V121, P1768, DOI 10.1161/CIRCULATIONAHA.109.849166; Lupieri A, 2020, CARDIOVASC RES, V116, P438, DOI 10.1093/cvr/cvz122; Maadarani Ossama, 2021, JRSM Open, V12, p20542704211025259, DOI 10.1177/20542704211025259; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Mendes D, 2015, PHARMACOEPIDEM DR S, V24, P1259, DOI 10.1002/pds.3874; Milanos L, 2016, J MED CHEM, V59, P2222, DOI 10.1021/acs.jmedchem.5b01965; Mordillo-Mateos L, 2019, SPINAL CORD, V57, P953, DOI 10.1038/s41393-019-0311-3; Munjal A, 2020, ADV PROTEIN CHEM STR, V120, P85, DOI 10.1016/bs.apcsb.2019.11.002; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Neville LF, 1995, AM J PHYSIOL-LUNG C, V269, pL884, DOI 10.1152/ajplung.1995.269.6.L884; Niki T, 2015, INT HEART J, V56, P269, DOI 10.1536/ihj.14-300; OHMORI Y, 1995, J IMMUNOL, V154, P5235; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Orn S, 2009, AM J CARDIOL, V104, P1179, DOI 10.1016/j.amjcard.2009.06.028; Ostadebrahimi H, 2014, CLIN LAB, V60, P99, DOI 10.7754/Clin.Lab.2013.121237; Ow KW, 2020, PLATELETS, V31, P945, DOI 10.1080/09537104.2019.1709631; Ozdemir IH, 2021, J EMERG MED, V61, DOI 10.1016/j.jemermed.2021.04.018; Park JW, 2001, J IMMUNOL, V166, P3763, DOI 10.4049/jimmunol.166.6.3763; Qiu HN, 2016, MOL CELL BIOCHEM, V411, P1, DOI 10.1007/s11010-015-2563-3; Ranjbaran H, 2006, CIRCULATION, V114, P1293, DOI 10.1161/CIRCULATIONAHA.106.631457; Rechtien A, 2017, CELL REP, V20, P2251, DOI 10.1016/j.celrep.2017.08.023; Rohm I, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/364710; Romagnani P, 2002, J AM SOC NEPHROL, V13, P53, DOI 10.1681/ASN.V13153; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothenbacher D, 2006, ARTERIOSCL THROM VAS, V26, P194, DOI 10.1161/01.ATV.0000191633.52585.14; Rotondi M, 2007, ENDOCR REV, V28, P492, DOI 10.1210/er.2006-0044; Sabatine MS, 2002, J AM COLL CARDIOL, V40, P1761, DOI 10.1016/S0735-1097(02)02484-1; Safa A, 2016, CYTOKINE, V83, P147, DOI 10.1016/j.cyto.2016.04.006; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089; Segers D, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/936109; Shields PL, 1999, J IMMUNOL, V163, P6236; Singh S, 2009, CANCER RES, V69, P411, DOI 10.1158/0008-5472.CAN-08-3378; Sottili M, 2009, EXP CELL RES, V315, P264, DOI 10.1016/j.yexcr.2008.10.025; Srinivasan KN., 2021, IHJ CARDIOVASC CASE, V5, P71, DOI [10.1016/j.ihjccr.2021.05.003, DOI 10.1016/J.IHJCCR.2021.05.003]; Standl E, 2016, CIRC RES, V118, P1830, DOI 10.1161/CIRCRESAHA.116.306924; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szentes V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01932; Tajstra M, 2021, JACC-CARDIOVASC INTE, V14, pE103, DOI 10.1016/j.jcin.2021.03.003; Taub DD, 1996, BLOOD, V87, P1423, DOI 10.1182/blood.V87.4.1423.bloodjournal8741423; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Teunissen PFA, 2015, CARDIOVASC RES, V107, P255, DOI 10.1093/cvr/cvv138; Treacy O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042662; van den Borne P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/893106; Varley CL, 2003, CYTOKINE, V23, P64, DOI 10.1016/S1043-4666(03)00198-4; Wang XK, 1996, J BIOL CHEM, V271, P24286, DOI 10.1074/jbc.271.39.24286; Yang LL, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1168-3; Zarandi ER, 2012, LAB MED, V43, P27, DOI [10.1309/LMY9ILPGSETU2CO0, DOI 10.1309/LMY9ILPGSETU2CO0]; Zeissig S, 2012, NAT MED, V18, P1060, DOI 10.1038/nm.2811; Zohar Y, 2014, J CLIN INVEST, V124, P2009, DOI 10.1172/JCI71951	121	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1224	10.3390/vaccines9111224			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ6HN	34835155	Green Published, gold			2022-04-29	WOS:000726886600001
J	Tramuto, F; Maida, CM; Di Naro, D; Randazzo, G; Vitale, F; Restivo, V; Costantino, C; Amodio, E; Casuccio, A; Graziano, G; Immordino, P; Mazzucco, W				Tramuto, Fabio; Maida, Carmelo Massimo; Di Naro, Daniela; Randazzo, Giulia; Vitale, Francesco; Restivo, Vincenzo; Costantino, Claudio; Amodio, Emanuele; Casuccio, Alessandra; Graziano, Giorgio; Immordino, Palmira; Mazzucco, Walter			Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI	VACCINES			English	Article						respiratory syncytial virus; molecular surveillance; risk factors; vaccination; community; hospitalization	INFLUENZA-LIKE ILLNESS; CIRCULATION PATTERNS; UNITED-STATES; CHILDREN; INFECTIONS; PREVALENCE; SEASONALITY; GENOTYPES; SEVERITY; STRAINS	Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups < 5 years old (range: 17.6-19.1%) and & GE;50 years old (range: 4.8-5.1%). While the two subgroups co-circulated throughout the study period, hRSV-B was slightly predominant over hRSV-A, except for the season 2019-2020 when hRSV-A strongly prevailed (82.9%). In the community setting, the distribution of hRSV subgroups was balanced (47.8% vs. 49.7% for hRSV-A and hRSV-B, respectively), while most infections identified in the hospital setting were caused by hRSV-B (69.5%); also, this latter one was more represented among hRSV cases with underlying diseases, as well as among those who developed a respiratory complication. The molecular surveillance of hRSV infections may provide a valuable insight into the epidemiological features of ILI/SARI. Our findings add new evidence to the existing knowledge on viral aetiology of ILI and SARI in support of public health strategies and may help to define high-risk categories that could benefit from currently available and future vaccines.	[Tramuto, Fabio; Maida, Carmelo Massimo; Vitale, Francesco; Restivo, Vincenzo; Costantino, Claudio; Amodio, Emanuele; Casuccio, Alessandra; Immordino, Palmira; Mazzucco, Walter] Univ Palermo, Internal Med & Med Specialt G DAlessandro Hyg Sec, Dept Hlth Promot Sci Maternal & Infant Care, I-90127 Palermo, Italy; [Tramuto, Fabio; Maida, Carmelo Massimo; Di Naro, Daniela; Randazzo, Giulia; Vitale, Francesco; Restivo, Vincenzo; Costantino, Claudio; Graziano, Giorgio; Mazzucco, Walter] Univ Hosp Paolo Giaccone, Clin Epidemiol Unit, Reg Reference Lab Mol Surveillance Influenza, I-90127 Palermo, Italy		Tramuto, F (通讯作者)，Univ Palermo, Internal Med & Med Specialt G DAlessandro Hyg Sec, Dept Hlth Promot Sci Maternal & Infant Care, I-90127 Palermo, Italy.; Tramuto, F (通讯作者)，Univ Hosp Paolo Giaccone, Clin Epidemiol Unit, Reg Reference Lab Mol Surveillance Influenza, I-90127 Palermo, Italy.	fabio.tramuto@unipa.it; carmelo.maida@unipa.it; dinaro.d@libero.it; giulia.randazzo1986@gmail.com; francesco.vitale@unipa.it; vincenzo.restivo@unipa.it; claudio.costantino01@unipa.it; emanuele.amodio@unipa.it; alessandra.casuccio@unipa.it; giorgio.graziano@policlinico.pa.it; palmira.immordino@unipa.it; walter.mazzucco@unipa.it	; Costantino, Claudio/F-4742-2018	Vitale, Francesco/0000-0002-6354-8060; Tramuto, Fabio/0000-0003-0108-4608; MAZZUCCO, WALTER/0000-0001-5090-1366; maida, carmelo massimo/0000-0002-6989-9259; Amodio, Emanuele/0000-0001-5482-5268; casuccio, alessandra/0000-0002-5676-9535; Costantino, Claudio/0000-0002-3397-7331; Restivo, Vincenzo/0000-0002-5406-884X	Investigator-Initiated Studies Program of Merck Sharp Dohme Corp [IIS58826]	FundingThe study was supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp (IIS58826). The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp.	Ackerson B, 2019, CLIN INFECT DIS, V69, P197, DOI 10.1093/cid/ciy991; Al-Romaihi HE, 2020, INT J INFECT DIS, V95, P133, DOI 10.1016/j.ijid.2020.04.008; Atamna A, 2021, INT J INFECT DIS, V103, P489, DOI 10.1016/j.ijid.2020.11.185; Azzari C, 2021, ITAL J PEDIATR, V47, DOI 10.1186/s13052-021-01148-8; Bloom-Feshbach K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054445; Boattini M, 2020, EUR J CLIN MICROBIOL, V39, P2085, DOI 10.1007/s10096-020-03959-9; Bosco E, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11806; Branche AR, 2022, CLIN INFECT DIS, V74, P1004, DOI 10.1093/cid/ciab595; Broberg EK, 2018, EUROSURVEILLANCE, V23, P9, DOI 10.2807/1560-7917.ES.2018.23.5.17-00284; Caini S, 2019, J INFECT PUBLIC HEAL, V12, P357, DOI 10.1016/j.jiph.2018.12.003; Centers for Disease Control and Prevention, CDC INFL SARS COV 2; Chadha M, 2020, INFLUENZA OTHER RESP, V14, P638, DOI 10.1111/irv.12726; Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350; Cui DW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165437; Drysdale SB, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax2466; Esposito S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129369; Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z; Grunberg M, 2021, INFLUENZA OTHER RESP, V15, P72, DOI 10.1111/irv.12791; Gunson RN, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-192; Horton KC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180954; Jin XT, 2021, ECLINICALMEDICINE, V37, DOI 10.1016/j.eclinm.2021.100986; Khor CS, 2013, INFECT GENET EVOL, V14, P357, DOI 10.1016/j.meegid.2012.12.017; Kim L, 2017, CLIN INFECT DIS, V65, P1020, DOI 10.1093/cid/cix432; Liu PC, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01627-8; Liu WK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165108; Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5; Ministero della Salute Direzione Generale della Prevenzione Sanitaria, MON AND FORM GRAV CO; Opek MW, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.29.2100706; Paynter S, 2014, SCI TOTAL ENVIRON, V493, P521, DOI 10.1016/j.scitotenv.2014.06.021; Pebody R, 2020, INFLUENZA OTHER RESP, V14, P615, DOI 10.1111/irv.12667; Pellegrinelli L, 2020, J MED VIROL, V92, P2999, DOI 10.1002/jmv.25917; Pellegrinelli L, 2017, J GEN VIROL, V98, P2699, DOI 10.1099/jgv.0.000937; Peret TCT, 2000, J INFECT DIS, V181, P1891, DOI 10.1086/315508; Pitzer VE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004591; Prasad N, 2021, CLIN INFECT DIS, V73, pE158, DOI 10.1093/cid/ciaa730; Rijsbergen LC, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00237-21; Saez-Lopez E, 2019, EUROSURVEILLANCE, V24, P19, DOI 10.2807/1560-7917.ES.2019.24.45.1900140; Salimi V, 2016, J INFECT PUBLIC HEAL, V9, P125, DOI 10.1016/j.jiph.2015.05.005; Saxena S, 2017, J MED VIROL, V89, P49, DOI 10.1002/jmv.24607; Shan J, 2021, INFLUENZA OTHER RESP, V15, P539, DOI 10.1111/irv.12850; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Stephens LM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060624; Suleiman-Martos N, 2021, J PERS MED, V11, DOI 10.3390/jpm11050416; Tang JW, 2017, LANCET INFECT DIS, V17, pE320, DOI 10.1016/S1473-3099(17)30238-4; Tempia Stefano, 2021, Euro Surveill, V26, DOI 10.2807/1560-7917.ES.2021.26.29.2001600; Tramuto Fabio, 2021, J Prev Med Hyg, V62, pE10, DOI 10.15167/2421-4248/jpmh2021.62.1.1870; Tramuto F, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632645; Tramuto F, 2019, AM J TROP MED HYG, V101, P1232, DOI 10.4269/ajtmh.19-0059; Tramuto F, 2016, MICROBES INFECT, V18, P270, DOI 10.1016/j.micinf.2015.11.008; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI [10.1016/S2213-2600(18)30496-X, 10.1016/s2213-2600(18)30496-x]; Ursin RL, 2021, ANNU REV VIROL, V8, P393, DOI 10.1146/annurev-virology-091919-092720; van Niekerk S, 2011, J VIROL, V85, P8789, DOI 10.1128/JVI.02623-10; Vandini S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081717; Vekemans J, 2019, VACCINE, V37, P7394, DOI 10.1016/j.vaccine.2017.09.092; Walsh EE, 2011, SEMIN RESP CRIT CARE, V32, P423, DOI 10.1055/s-0031-1283282; Wang R, 2021, GENOMICS, V113, P2158, DOI 10.1016/j.ygeno.2021.05.006; World Health Organization, WHO GLOB INFL PROGR; Yanis A, 2021, PEDIATR INFECT DIS J, V40, P808, DOI 10.1097/INF.0000000000003193; Zlateva KT, 2007, J CLIN MICROBIOL, V45, P3022, DOI 10.1128/JCM.00339-07	60	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1334	10.3390/vaccines9111334			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ6EQ	34835265	Green Published, gold			2022-04-29	WOS:000726879100001
J	Frau, N; Meloni, F; Fostinelli, J; Portas, L; Portoghese, I; Sala, E; Pilia, I; Lecca, LI; De Palma, G; Campagna, M				Frau, Nicola; Meloni, Federico; Fostinelli, Jacopo; Portas, Laura; Portoghese, Igor; Sala, Emma; Pilia, Ilaria; Lecca, Luigi Isaia; De Palma, Giuseppe; Campagna, Marcello			Seroepidemiology of Measles, Mumps, Rubella and Varicella in Italian Female School Workers: A Cross-Sectional Study	VACCINES			English	Article						early childhood teacher; school teacher; protective immunity; vaccine-preventable disease; public health surveillance; seroprevalence	HEALTH-CARE WORKERS; VACCINATION PERCEPTIONS; IMMUNITY; OUTBREAK; ELIMINATION; HESITANCY; EMPLOYEES; DISEASES; ERA	Background: Determining the proportion of susceptible workers can represent a first step to the biological risk assessment related to measles, mumps, rubella and varicella exposure. This study aimed to assess the immunity against measles, mumps, rubella and varicella viruses in a cohort of female school workers. Methods: A cross-sectional seroepidemiological study in a sample of 263 school workers undergoing routine annual workplace health surveillance program was conducted. As part of the health surveillance program, serum samples were collected and tested for measles, mumps, rubella and varicella IgG antibodies. Results: Overall seropositivity was 90.5%, 85.2%, 94.7% and 97.3% for measles, mumps, rubella and varicella, respectively. In relation to mumps occupation-specific seropositivity, a statistically significant difference was observed, showing the lowest prevalence of protected individuals in other occupation groups. Moreover, in relation to rubella, school workers born in Centre Italy had the lowest seropositivity of protective antibodies and the difference between groups was statistically significant. Measles and rubella seropositivity showed a significant decrease after 2015. Conclusions: This study showed a relevant proportion of school workers susceptible to the aforementioned diseases. These results highlighted the need for proper health surveillance and immunological controls in school workers, especially for females, and provided useful insights to policymakers to select effective strategies aimed at containing the risk of vaccine-preventable diseases at schools.	[Frau, Nicola; Meloni, Federico; Portoghese, Igor; Pilia, Ilaria; Lecca, Luigi Isaia; Campagna, Marcello] Univ Cagliari, Dept Med Sci & Publ Hlth, SS 554 Bivio Per Sestu, I-09042 Cagliari, Italy; [Fostinelli, Jacopo; Sala, Emma; De Palma, Giuseppe] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, I-25123 Brescia, Italy; [Portas, Laura] Imperial Coll London, Natl Heart & Lung Inst, London SW7 2AZ, England		Meloni, F (通讯作者)，Univ Cagliari, Dept Med Sci & Publ Hlth, SS 554 Bivio Per Sestu, I-09042 Cagliari, Italy.	n.frau4@studenti.unica.it; fe.meloni@aoucagliari.it; jacopo.fostinelli@unibs.it; l.portas18@imperial.ac.uk; igor.portoghese@unica.it; emma.sala@unibs.it; ilaria.pilia@ca.omceo.it; luigiisaia.lecca@unifi.it; giuseppe.depalma@unibs.it; mcampagna@unica.it	, De Palma Giuseppe/F-1147-2010; Portoghese, Igor/A-5273-2011	, De Palma Giuseppe/0000-0001-9821-3060; Portoghese, Igor/0000-0003-3700-8594; Lecca, Luigi Isaia/0000-0001-8310-411X			Almuneef M, 2003, AM J INFECT CONTROL, V31, P375, DOI 10.1016/S0196-6553(02)48204-1; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Anichini G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010066; Barrabeig I, 2011, VACCINE, V29, P8024, DOI 10.1016/j.vaccine.2011.08.056; Bianchi FP, 2021, HUM VACC IMMUNOTHER, V17, P2078, DOI 10.1080/21645515.2020.1871296; Campagna M, 2010, G Ital Med Lav Ergon, V32, P298; Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937; Copello F, 2015, J Prev Med Hyg, V56, pE102; D'Agaro P, 2011, EPIDEMIOL INFECT, V139, P1727, DOI 10.1017/S095026881100032X; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; European Centre for Disease Prevention and Control, 2020, ANN EPIDEMIOLOGICAL; European Centre for Diseases Prevention and Control, 2019, MONTHL MEASL RUB MON; Filia A, 2017, EUROSURVEILLANCE, V22, P2, DOI [10.2807/1560-7917.ES.2017.22.37.30614, 10.2807/1560-7917.es.2017.22.37.30614]; Filia A., MORBILLO ROSOLIA NEW; Filia A., 2018, MORBILLO ROSOLIA NEW; Filia A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-169; Gallone MS, 2017, HUM VACC IMMUNOTHER, V13, P117, DOI 10.1080/21645515.2016.1227519; Giambi C., 2018, ROSOLIA CONGENITA GR; Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088; Haagsma JA, 2012, OCCUP ENVIRON MED, V69, P140, DOI 10.1136/oemed-2011-100068; HARRIS RW, 1969, AM J EPIDEMIOL, V89, P264, DOI 10.1093/oxfordjournals.aje.a120939; Heininger U, 2006, LANCET, V368, P1365, DOI 10.1016/S0140-6736(06)69561-5; Hviid A, 2008, LANCET, V371, P932, DOI 10.1016/S0140-6736(08)60419-5; International Labour Office, 2012, INT STANDARD CLASSIF, P141; Koivisto K, 2017, VACCINE, V35, P1608, DOI 10.1016/j.vaccine.2017.02.018; Kutter JS, 2018, CURR OPIN VIROL, V28, P142, DOI 10.1016/j.coviro.2018.01.001; Lambert N, 2015, LANCET, V385, P2297, DOI 10.1016/S0140-6736(14)60539-0; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Luthy KE, 2013, J SCH NURS, V29, P284, DOI 10.1177/1059840513490029; Macintosh J, 2014, VACCINE, V32, P4766, DOI 10.1016/j.vaccine.2014.06.029; Macintosh JLB, 2016, JNP-J NURSE PRACT, V12, P438, DOI 10.1016/j.nurpra.2016.05.014; Maria Cristina R., VARICELLA ASPETTI EP; McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003; Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0; O'Connor P, 2017, CLIN MICROBIOL INFEC, V23, P504, DOI 10.1016/j.cmi.2017.01.003; OECD, 2018, IT COUNTR NOT ED GLA, P1; OECD, 2019, OECD IND, DOI [10.1787/f8d7880d-en, DOI 10.1787/F8D7880D-EN]; Pontrelli G., INDAGINE ASPETTI ORG; Porru S, 2007, G Ital Med Lav Ergon, V29, P407; Ricco Matteo, 2018, Minerva Pediatr, DOI 10.23736/S0026-4946.18.05206-4; Signorelli C, 2018, ANN IG MED PREV COMU, V30, P1, DOI 10.7416/ai.2018.2227; Smetana J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170257; Sydnor E, 2014, VACCINE, V32, P4814, DOI 10.1016/j.vaccine.2014.03.097; Tafuri S, 2014, VACCINE, V32, P6544, DOI 10.1016/j.vaccine.2014.08.088; Trevisan A, 2007, INFECT CONT HOSP EP, V28, P564, DOI 10.1086/516657; Watson J C, 1998, MMWR Recomm Rep, V47, P1; World Health Organization, 2012, GLOB MEASL RUB STRAT; World Health Organization WHO, WHO REC ROUT IMM SUM	48	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1191	10.3390/vaccines9101191			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WT9FW	34696299	Green Published			2022-04-29	WOS:000716163800001
J	Li, FS; Wang, XN; Fan, XL; Sui, L; Zhang, HL; Li, Y; Zhou, H; Wang, L; Qiao, XY; Tang, LJ; Li, YJ				Li, Fengsai; Wang, Xiaona; Fan, Xiaolong; Sui, Ling; Zhang, Hailin; Li, Yue; Zhou, Han; Wang, Li; Qiao, Xinyuan; Tang, Lijie; Li, Yijing			Immunogenicity of Recombinant-Deficient Lactobacillus casei with Complementary Plasmid Expressing Alanine Racemase Gene and Core Neutralizing Epitope Antigen against Porcine Epidemic Diarrhea Virus	VACCINES			English	Article						Lactobacillus casei; PEDV COE antigen; alanine racemase gene; oral mucosal vaccine	TRANSMISSIBLE GASTROENTERITIS VIRUS; LACTIC-ACID BACTERIA; ORAL IMMUNIZATION; IMMUNE-RESPONSES; VACCINE; CORONAVIRUS; CELLS; MICE; CONSTRUCTION; DELIVERY	Porcine epidemic diarrhea (PED), which is caused by the porcine epidemic diarrhea virus (PEDV), has occurred worldwide and poses a serious threat to the pig industry. Intestine is the main function site of PEDV; therefore, it is important to develop an oral mucosal immunity vaccine against this virus infection. Most traditional plasmid delivery vectors use antibiotic genes as a selective marker, easily leading to antibiotic accumulation and gene contamination. In this study, to explore whether the alanine racemase gene (Alr) could be used as a screening marker and develop an efficient oral vaccine against PEDV infection, a recombinant strain was constructed using Lactobacillus casei with Alr deletion (L. casei & UDelta;Alr W56) to deliver the Alr gene and a core-neutralizing epitope (COE) antigen. This recombinant bacterium efficiently induced secretory immunoglobulin A (SIgA)-based mucosal and immunoglobulin G (IgG)-based humoral immune responses via oral vaccination in mice. Compared to the other strains, the recombinant bacteria were able to grow without the addition of D-alanine, revealing that Alr in the plasmid could function normally in defective bacteria. This oral mucosal vaccine would provide a useful strategy to substitute the application of antibiotics in the future and induce efficient immune responses against PEDV infection.</p>	[Li, Fengsai; Wang, Xiaona; Fan, Xiaolong; Sui, Ling; Zhang, Hailin; Li, Yue; Zhou, Han; Wang, Li; Qiao, Xinyuan; Tang, Lijie; Li, Yijing] Northeast Agr Univ, Coll Vet Med, Harbin 150030, Peoples R China; [Qiao, Xinyuan; Tang, Lijie; Li, Yijing] Heilongjiang Key Lab Anim Dis Control & Pharmaceu, Harbin 150030, Peoples R China		Tang, LJ; Li, YJ (通讯作者)，Northeast Agr Univ, Coll Vet Med, Harbin 150030, Peoples R China.; Tang, LJ; Li, YJ (通讯作者)，Heilongjiang Key Lab Anim Dis Control & Pharmaceu, Harbin 150030, Peoples R China.	Yilvwenrou@126.com; xiaonawang0319@163.com; fxl13796687571@163.com; lsseven111@163.com; zhanghl0523@163.com; Y1925729473@163.com; zhouhan9659@163.com; wanglicau@163.com; qiaoxinyuan@126.com; tanglijie@neau.edu.cn; yijingli@163.com			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [31772779]	FundingThis research was funded by the National Natural Science Foundation of China (NSFC; grant number: 31772779).	Ashiuchi M, 2001, EUR J BIOCHEM, V268, P5321, DOI 10.1046/j.0014-2956.2001.02475.x; Barman NN, 2003, INDIAN J ANIM SCI, V73, P576; Boniotti MB, 2016, EMERG INFECT DIS, V22, P83, DOI 10.3201/eid2201.150544; Bron PA, 2002, APPL ENVIRON MICROB, V68, P5663, DOI 10.1128/AEM.68.11.5663-5670.2002; CAVANAGH D, 1993, ADV EXP MED BIOL, V342, P255; Chen JF, 2013, VIRUSES-BASEL, V5, P2601, DOI 10.3390/v5102601; Chiou HY, 2017, TRANSBOUND EMERG DIS, V64, P157, DOI 10.1111/tbed.12357; Choi SH, 2012, J APPL MICROBIOL, V113, P248, DOI 10.1111/j.1365-2672.2012.05328.x; Cui LC, 2015, VACCINE, V33, P3092, DOI 10.1016/j.vaccine.2015.05.002; Daniel C, 2011, TRENDS BIOTECHNOL, V29, P499, DOI 10.1016/j.tibtech.2011.05.002; Esvaran M, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030024; Eun CS, 2011, APMIS, V119, P49, DOI 10.1111/j.1600-0463.2010.02691.x; FERRARI E, 1985, BIO-TECHNOL, V3, P1003, DOI 10.1038/nbt1185-1003; Ge JW, 2012, CAN J MICROBIOL, V58, P1258, DOI 10.1139/w2012-098; Gibson GR, 2004, NUTR RES REV, V17, P259, DOI 10.1079/NRR200479; HEATON MP, 1988, CAN J MICROBIOL, V34, P256, DOI 10.1139/m88-047; Hols P, 1997, J BACTERIOL, V179, P3804, DOI 10.1128/jb.179.11.3804-3807.1997; Hou XY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030106; Islam MA, 2012, INT J NANOMED, V7, P6077, DOI 10.2147/IJN.S38330; Jiang XP, 2016, APPL MICROBIOL BIOT, V100, P7457, DOI 10.1007/s00253-016-7424-9; Jiang XP, 2014, APPL MICROBIOL BIOT, V98, P8301, DOI 10.1007/s00253-014-5893-2; Kim SY, 2001, J VET DIAGN INVEST, V13, P516, DOI 10.1177/104063870101300611; Langel SN, 2016, VIRUS RES, V226, P93, DOI 10.1016/j.virusres.2016.05.016; Lee S, 2014, EMERG INFECT DIS, V20, P1223, DOI 10.3201/eid2007.140294; Ma ST, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0861-7; Mohamadzadeh M, 2009, P NATL ACAD SCI USA, V106, P4331, DOI 10.1073/pnas.0900029106; OSULLIVAN DJ, 1993, GENE, V137, P227, DOI 10.1016/0378-1119(93)90011-Q; Palumbo E, 2004, FEMS MICROBIOL LETT, V233, P131, DOI 10.1016/j.femsle.2004.02.001; Pouwels PH, 1996, J BIOTECHNOL, V44, P183, DOI 10.1016/0168-1656(95)00140-9; Qiao XY, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-249; Robinson K, 1997, NAT BIOTECHNOL, V15, P653, DOI 10.1038/nbt0797-653; Shima H, 2014, INT IMMUNOL, V26, P619, DOI 10.1093/intimm/dxu061; Song BF, 2014, APPL ENVIRON MICROB, V80, P3321, DOI 10.1128/AEM.00175-14; Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1; Su YF, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0646-8; Sun DB, 2016, J VET MED SCI, V78, P355, DOI 10.1292/jvms.15-0446; Nguyen T, 2011, J AGR FOOD CHEM, V59, P5617, DOI 10.1021/jf104755r; Tsai YT, 2012, APPL MICROBIOL BIOT, V96, P853, DOI 10.1007/s00253-012-4407-3; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P2438, DOI 10.1128/IAI.58.8.2438-2445.1990; Wang L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040172; Wang XN, 2018, J APPL MICROBIOL, V124, P368, DOI 10.1111/jam.13652; Wells JM, 2008, NAT REV MICROBIOL, V6, P349, DOI 10.1038/nrmicro1840; WILLIAMS RC, 1972, SCIENCE, V177, P697, DOI 10.1126/science.177.4050.697; Xia Y, 2005, FOOD RES INT, V38, P251, DOI 10.1016/j.foodres.2004.06.014; Xu YG, 2007, APPL ENVIRON MICROB, V73, P7041, DOI 10.1128/AEM.00436-07; Xu YG, 2011, CLIN VACCINE IMMUNOL, V18, P1979, DOI 10.1128/CVI.05204-11; Yang G, 2017, BENEF MICROBES, V8, P379, DOI 10.3920/BM2016.0116; Yang WT, 2018, APPL MICROBIOL BIOT, V102, P5077, DOI 10.1007/s00253-018-8924-6; Ye M, 2010, APPL MICROBIOL BIOT, V87, P1023, DOI 10.1007/s00253-010-2507-5; Yu ML, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100274; Zhang Ning, 2010, Wei Sheng Wu Xue Bao, V50, P1232	51	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1084	10.3390/vaccines9101084			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN1DT	34696192	Green Published, gold			2022-04-29	WOS:000711516700001
J	Li, QS; Zhang, MY; Chen, HB; Wu, F; Xian, JX; Zheng, LT; Liang, MY; Cao, H; Zhou, XF; Gu, ZH; Lin, QH; Chen, Q				Li, Qiushuang; Zhang, Minyi; Chen, Hongbiao; Wu, Fei; Xian, Juxian; Zheng, Liting; Liang, Minyi; Cao, He; Zhou, Xiaofeng; Gu, Zihao; Lin, Qihui; Chen, Qing			Influenza Vaccination Coverage among Older Adults with Hypertension in Shenzhen, China: A Cross-Sectional Survey during the COVID-19 Pandemic	VACCINES			English	Article						older adults; hypertension; influenza vaccination coverage; COVID-19	PNEUMOCOCCAL VACCINATION; ELDERLY PERSONS; SOUTH-AFRICA; POPULATION; KNOWLEDGE; ATTITUDES; COUNTRIES; WORKERS	Background: Older individuals with hypertension are at a high risk of being infected with influenza. However, there have been few studies investigating the influenza vaccination status among older people with hypertension. The present work aimed to estimate the vaccination coverage and determine the predictors of seasonal influenza vaccinations among hypertensive patients aged over 60 years in Shenzhen, China. Method: The study used data from an online cross-sectional survey that was conducted in Shenzhen City, China, in October 2020. Frequencies and proportions of all the variables including sociodemographic characteristics and health-related information were described and tabulated based on the influenza vaccination status. Bivariate and multivariable logistic regression analyses were used to identify independent predictors associated with the influenza vaccination. Results: A total of 5216 older people with hypertension aged above 60 years were recruited. Overall, only 4.7% had received an influenza vaccine in the latest influenza season. Using the action toward being vaccinated as the primary outcome, the multivariable regression analysis showed that participants aged over 80 years (aOR 2.957, 95% CI: 1.784-4.900), obtaining higher education levels (aOR 1.424, 95% CI: 1.060-1.914 for high school, aOR 1.681, 95% CI: 1.066-2.650 for college or above), living with a partner (aOR 1.432, 95% CI: 1.068-1.920), using a family doctor (aOR 2.275, 95% CI: 1.744-2.968), and taking a physical examination 1-2 and & GE;3 times each year (aOR 2.107, 95% CI: 1.601-2.772 and aOR 2.118, 95% CI: 1.083-4.143, respectively) were more likely to be vaccinated. In contrast, smokers had less likelihood of having the influenza vaccination than non-smokers (aOR 1.829, 95% CI: 1.208-2.767). Conclusions: The coverage rate of influenza vaccinations is far away from optimistic among older adults with hypertension. Additional works should be undertaken immediately to improve the influenza vaccination status.	[Li, Qiushuang; Zhang, Minyi; Wu, Fei; Xian, Juxian; Zheng, Liting; Liang, Minyi; Chen, Qing] Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China; [Chen, Hongbiao; Cao, He; Zhou, Xiaofeng; Gu, Zihao; Lin, Qihui] Longhua Ctr Dis Control & Prevent, Longhua Key Discipline Publ Hlth Prevent & Contro, Dept Epidemiol & Infect Dis Control, Shenzhen 518109, Peoples R China		Chen, Q (通讯作者)，Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China.; Lin, QH (通讯作者)，Longhua Ctr Dis Control & Prevent, Longhua Key Discipline Publ Hlth Prevent & Contro, Dept Epidemiol & Infect Dis Control, Shenzhen 518109, Peoples R China.	qiushuang@smu.edu.cn; myalison@smu.edu.cn; gesila2021@163.com; wudiedie1996@smu.edu.cn; juxian123@smu.edu.cn; 3160090116@smu.edu.cn; lmy1065516308@smu.edu.cn; luojingwei001@163.com; ct502528528@163.com; 13711762051@163.com; lhjkzx@szlhq.gov.cn; qingchen@smu.edu.cn		Chen, Qing/0000-0002-2474-6697; Zhang, Minyi/0000-0003-0059-2440	Science and Technology Innovation Funding Project of Shenzhen Longhua [2020206]; Key Discipline of Control and Prevention of Infectious Diseases and Public Health of Shenzhen Longhua	FundingThis research was funded by the Science and Technology Innovation Funding Project of Shenzhen Longhua (grant number 2020206) and the Key Discipline of Control and Prevention of Infectious Diseases and Public Health of Shenzhen Longhua.	Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; [Anonymous], 2016, CANADIAN IMMUNIZATIO; [Anonymous], 2019, SCI DAILY; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; Byeon KH, 2018, EPIDEMIOL HEALTH, V40, DOI 10.4178/epih.e2018034; CDC, PEOPL HIGH RISK FLU; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P987; Chen Qiong, 2020, Aging Med (Milton), V3, P1, DOI 10.1002/agm2.12102; Clar C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005050.pub3; Bacurau AGD, 2020, SAO PAULO MED J, V138, P322, DOI [10.1590/1516-3180.2020.0042.R1.15052020, 10.1590/1516-3180.2020.0042.r1.15052020]; Dube Eve, 2010, BMC Res Notes, V3, P102, DOI 10.1186/1756-0500-3-102; Ge Nan, 2018, Chinese Journal of Clinical Healthcare, V21, P296; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Jimenez-Garcia R, 2007, J INFECTION, V54, P65, DOI 10.1016/j.jinf.2005.11.020; Kamal Khalid M, 2003, J Am Pharm Assoc (2003), V43, P403, DOI 10.1331/154434503321831120; Kroneman M, 2006, VACCINE, V24, P622, DOI 10.1016/j.vaccine.2005.08.040; Kwon DS, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012618; Lee KC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117305; Li L, 2019, LANCET PUBLIC HEALTH, V4, pE473, DOI 10.1016/S2468-2667(19)30163-X; de Andres A, 2007, EUR J PUBLIC HEALTH, V17, P272, DOI 10.1093/eurpub/ckl242; Ma Y, 2018, HUM VACC IMMUNOTHER, V14, P1283, DOI 10.1080/21645515.2017.1423157; McAnerney JM, 2015, INFLUENZA OTHER RESP, V9, P143, DOI 10.1111/irv.12305; National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) Influenza Vaccination TWG, 2020, ZHONGHUA LIU XING BI, V41, P1555; Nitsch-Osuch A, 2015, ADV EXP MED BIOL, V857, P39, DOI 10.1007/5584_2015_120; Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6; Ott JJ, 2013, HUM VACC IMMUNOTHER, V9, P1500, DOI 10.4161/hv.24704; Palache A, 2015, VACCINE, V33, P5598, DOI 10.1016/j.vaccine.2015.08.082; Pfeil A, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-402; Ricco Matteo, 2019, Acta Biomed, V90, P439, DOI 10.23750/abm.v90i4.7631; Schoefer Y, 2007, J INFECTION, V55, P347, DOI 10.1016/j.jinf.2007.06.002; Shono A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0821-3; Sintes X, 2011, EPIDEMIOL INFECT, V139, P666, DOI 10.1017/S0950268810001846; Song Y, 2017, VACCINE, V35, P4060, DOI 10.1016/j.vaccine.2017.06.054; Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045; Wang YH, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8388-3; Wong KK, 2016, INFLUENZA OTHER RESP, V10, P421, DOI 10.1111/irv.12388; World Health Organization, 2018, INFL SEAS 2019, P17; Yan Z, 2018, AM J HYPERTENS, V31, P486, DOI 10.1093/ajh/hpx222; Yap J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-442; Ye CC, 2018, HUM VACC IMMUNOTHER, V14, P2715, DOI 10.1080/21645515.2018.1491246; Zhang MY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030212; Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073724	43	0	0	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1105	10.3390/vaccines9101105			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN5PE	34696213	gold, Green Published			2022-04-29	WOS:000711818600001
J	Lim, LJ; Lim, AJW; Fong, KK; Lee, CG				Lim, Lee Jin; Lim, Ashley J. W.; Fong, Kevin K.; Lee, Caroline G.			Sentiments Regarding COVID-19 Vaccination among Graduate Students in Singapore	VACCINES			English	Article						COVID-19; coronavirus; SARS-CoV-2; vaccination; vaccine acceptance; vaccine hesitancy; vaccine rejection; graduate student; Singapore	UNITED-STATES; WILLINGNESS; PERCEPTIONS; ATTITUDES; VACCINES	As the COVID-19 pandemic rages unabated, and with more infectious variants, vaccination may offer a way to transit out of strict restrictions on physical human interactions to curb the virus spread and prevent overwhelming the healthcare system. However, vaccine hesitancy threatens to significantly impact our progress towards achieving this. It is thus important to understand the sentiments regarding vaccination for different segments of the population to facilitate the development of effective strategies to persuade these groups. Here, we surveyed the COVID-19 vaccination sentiments among a highly educated group of graduate students from the National University of Singapore (NUS). Graduate students who are citizens of 54 different countries, mainly from Asia, pursue studies in diverse fields, with 32% expressing vaccine hesitancy. Citizenship, religion, country of undergraduate/postgraduate studies, exposure risk and field of study are significantly associated with vaccine sentiments. Students who are Chinese citizens or studied in Chinese Universities prior to joining NUS are more hesitant, while students of Indian descent or studied in India are less hesitant about vaccination. Side effects, safety issues and vaccine choice are the major concerns of the hesitant group. Hence, this study would facilitate the development of strategies that focus on these determinants to enhance vaccine acceptance.	[Lim, Lee Jin; Lim, Ashley J. W.; Lee, Caroline G.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117596, Singapore; [Fong, Kevin K.; Lee, Caroline G.] Natl Univ Singapore, NUS Grad Sch, Singapore 119077, Singapore; [Lee, Caroline G.] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore 169857, Singapore; [Lee, Caroline G.] Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore		Lee, CG (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117596, Singapore.; Lee, CG (通讯作者)，Natl Univ Singapore, NUS Grad Sch, Singapore 119077, Singapore.; Lee, CG (通讯作者)，Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore 169857, Singapore.; Lee, CG (通讯作者)，Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore.		Fong, Kevin/ABD-3853-2021	Fong, Kevin/0000-0003-1956-903X; Lee, Caroline/0000-0002-4323-3635			[Anonymous], ABC NEWS; [Anonymous], STRAITS TIMES; Aschwanden C, 2020, NATURE, V587, P26, DOI 10.1038/d41586-020-02948-4; Atkinson Beth, 2019, CRAN; Authers J., BLOOMBERG; Bai W, 2021, INT J BIOL SCI, V17, P1469, DOI 10.7150/ijbs.58835; Ball P, 2021, NATURE, V589, P16, DOI 10.1038/d41586-020-03626-1; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Banks D.L., 2001, INT ENCY SOC BEHAV S, P5164, DOI [10.1016/B0-08-043076-7/00424-1, DOI 10.1016/B0-08-043076-7/00424-1]; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Burge R., YOUNG SECULAR ARE LE; Burke PF, 2021, VACCINE, V39, P5116, DOI 10.1016/j.vaccine.2021.07.056; Chen PJ, 2021, DIAGNOSIS, V8, P403, DOI 10.1515/dx-2021-0046; Chew NWS, 2021, INT J INFECT DIS, V106, P52, DOI 10.1016/j.ijid.2021.03.069; Choo Y.T., 2020, STRAITS TIMES 1230; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Dabla-Norris E., 2021, IMF WORKING PAPER WH; Davidson H, GUARDIAN; Deng C., TRAVELING CHINA JUST; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Dror AA, 2021, EUR J EPIDEMIOL, V36, P709, DOI 10.1007/s10654-021-00758-0; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Goh T., STRAITS TIMES; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Clemente-Suarez VJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020236; Kadkhoda K, 2021, AM J CLIN PATHOL, V155, P471, DOI 10.1093/ajcp/aqaa272; Kessels R, 2021, VACCINE, V39, P4716, DOI 10.1016/j.vaccine.2021.05.069; Kimberly C, 2020, IMPACT COVID 19 PEOP, P4; Lai L., 2021, STRAITS TIMES 0413; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Mant M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255447; Mathews M., 2021, IPS WORKING PAPERS, V40; Milano M, 2021, NETW MODEL ANAL HLTH, V10, DOI 10.1007/s13721-021-00323-5; Miles DK, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14191; Ministry of Health, MOH COVID 19 VACC; Ministry of Health of Singapore, UPD COVID 19 LOC SIT; Ministry of Health of Singapore,, COVID 19 SIT REP; Morgan J., 2014, CLASSIFICATION REGRE; O'Brien E., BLOOMBERG; Onyeaka Helen, 2021, Sci Prog, V104, p368504211019854, DOI 10.1177/00368504211019854; Pazos R.S.A., STRAITS TIMES; Question Pro, SNOWB SAMPL DEF METH; Riley, 2021, REACT 1 ROUND 12 REP, DOI DOI 10.1101/2021.06.17.21259103; Robinson N., ADVANTAGES DISADVANT; Roccetti Marco, 2017, JMIR Public Health Surveill, V3, pe51, DOI 10.2196/publichealth.7004; Rostkowska OM, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073595; Sharma G., 2017, INT J APPL RES, V3, P749, DOI DOI 10.22271/ALLRESEARCH.2017.V3.I3I; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shen MW, 2021, VACCINE, V39, P2295, DOI 10.1016/j.vaccine.2021.02.056; Statista, SING COVID 19 VACC W; Statista, SING RES POP ETHN GR; Tavolacci MP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060654; Toh T, STRAITS TIMES; VaxDashboard, SING COVID 19 VACC I; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; WHO, COR COVID 19 DASHB; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; World Population Review, SING POP 2021 DEM MA; Yin FL, 2021, J MED INTERNET RES, V23, DOI 10.2196/26089	69	5	5	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1141	10.3390/vaccines9101141			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN6ZM	34696249	Green Published, gold			2022-04-29	WOS:000711916100001
J	Odone, A; Gianfredi, V; Sorbello, S; Capraro, M; Frascella, B; Vigezzi, GP; Signorelli, C				Odone, Anna; Gianfredi, Vincenza; Sorbello, Sebastiano; Capraro, Michele; Frascella, Beatrice; Vigezzi, Giacomo Pietro; Signorelli, Carlo			The Use of Digital Technologies to Support Vaccination Programmes in Europe: State of the Art and Best Practices from Experts' Interviews	VACCINES			English	Article						vaccination; immunisation programmes; digitalisation; information and communication technology; Europe; public health practice	IMMUNIZATION INFORMATION-SYSTEMS; PUBLIC-HEALTH; COMMUNICATION; COVERAGE; COMPLETION; DISEASE; RECORDS; CANADA; MEDIA	Digitalisation offers great potential to improve vaccine uptake, supporting the need for effective life-course immunisation services. We conducted semi-structured in-depth interviews with public health experts from 10 Western European countries (Germany, Greece, Italy, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, and the United Kingdom) to assess the current level of digitalisation in immunisation programmes and retrieve data on interventions and best practices. Interviews were performed using an ad hoc questionnaire, piloted on a sample of national experts. We report a mixed level of digital technologies deployment within vaccination services across Europe: Some countries are currently developing eHealth strategies, while others have already put in place robust programmes. Institutional websites, educational videos, and electronic immunisation records are the most frequently adopted digital tools. Webinars and dashboards represent valuable resources to train and support healthcare professionals in immunisation services organisation. Text messages, email-based communication, and smartphone apps use is scattered across Europe. The main reported barrier to the implementation of digital-based programmes is the lack of resources and shared standards. Our study offers a comprehensive picture of the European context and shows the need for robust collaboration between states and international institutions to share best practices and inform the planning of digital intervention models with the aim of countering vaccine hesitancy and increasing vaccine uptake.</p>	[Odone, Anna; Sorbello, Sebastiano] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy; [Gianfredi, Vincenza; Capraro, Michele; Frascella, Beatrice; Vigezzi, Giacomo Pietro; Signorelli, Carlo] Univ Vita Salute San Raffaele, Sch Med, Via Olgettina 58, I-20132 Milan, Italy		Odone, A (通讯作者)，Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy.	anna.odone@unipv.it; gianfredi.vincenza@hsr.it; sebastianosorbello@hsph.harvard.edu; capraro.michele@hsr.it; frascella.beatrice@hsr.it; vigezzi.giacomopietro@hsr.it; signorelli.carlo@hsr.it	Gianfredi, Vincenza/W-1408-2017; Odone, Anna/AAC-4715-2022; Signorelli, Carlo/AAC-7630-2022	Gianfredi, Vincenza/0000-0003-3848-981X; Vigezzi, Giacomo Pietro/0000-0001-6425-2926; Odone, Anna/0000-0002-5657-9774; Capraro, Michele/0000-0002-8115-2377; SIGNORELLI, Carlo/0000-0002-0960-9563			Abdullahi LH, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011895.pub2; Alderwick H, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l84; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Atkinson KM, 2019, VACCINE, V37, P3050, DOI 10.1016/j.vaccine.2019.03.063; Audisio RA, 2016, CRIT REV ONCOL HEMAT, V97, P157, DOI 10.1016/j.critrevonc.2015.07.015; Balzarini F, 2020, VACCINE, V38, P5966, DOI 10.1016/j.vaccine.2020.05.083; Bonanni P, 2015, EPIDEMIOL PREV, V39, P146; Bonanni Paolo, 2014, Epidemiol Prev, V38, P131; Bozzola E, 2020, RISK MANAG HEALTHC P, V13, P2819, DOI 10.2147/RMHP.S201279; Burgess RA, 2021, LANCET, V397, P8, DOI 10.1016/S0140-6736(20)32642-8; Burioni R, 2018, NATURE, V555, P27, DOI 10.1038/d41586-018-02267-9; Cella Paola, 2020, J Prev Med Hyg, V61, pE340, DOI 10.15167/2421-4248/jpmh2020.61.3.1448; Chen L, 2021, TELEMED E-HEALTH, V27, P763, DOI 10.1089/tmj.2020.0263; D'Ancona F, 2018, ANN IG MED PREV COMU, V30, P77, DOI 10.7416/ai.2018.2199; Derrough T, 2017, EUROSURVEILLANCE, V22, P10, DOI [10.2807/1560-7917.ES.2017.22.17.30519, 10.2807/1560-7917.es.2017.22.17.30519]; Dumit EM, 2018, VACCINE, V36, P7923, DOI 10.1016/j.vaccine.2018.06.076; Esteban-Navarro MA, 2020, INFORMATICS-BASEL, V7, DOI 10.3390/informatics7040054; European Commission, DIG SOL PAND; European Commission, COMM EN DIG TRANSF H; Eurostat, DIG EC SOC OV; Ferro A, 2015, EPIDEMIOL PREV, V39, P88; Fragidis L. L., 2011, Proceedings of the 2011 IEEE 11th International Conference on Computer and Information Technology (CIT 2011), P475, DOI 10.1109/CIT.2011.42; Francis DB, 2017, PATIENT EDUC COUNS, V100, P1280, DOI 10.1016/j.pec.2017.02.004; Frascella B, 2020, VACCINE, V38, P433, DOI 10.1016/j.vaccine.2019.10.089; Gianfredi V., 2019, J PREV MED HYG, V60, pE108; Gianfredi V, 2019, HUM VACC IMMUNOTHER, V15, P2508, DOI 10.1080/21645515.2019.1599675; Gianfredi Vincenza, 2018, Recenti Prog Med, V109, P374, DOI 10.1701/2955.29706; Gostin LO, 2020, LANCET INFECT DIS, V20, pE11, DOI 10.1016/S1473-3099(19)30558-4; Groom H, 2015, J PUBLIC HEALTH MAN, V21, P227, DOI 10.1097/PHH.0000000000000069; Kolff CA, 2018, HUM VACC IMMUNOTHER, V14, P1636, DOI 10.1080/21645515.2018.1477458; Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618; McKee, ORG DEL VACC SERV EU; Murthy BP, 2021, MMWR-MORBID MORTAL W, V70, P840, DOI 10.15585/mmwr.mm7023a2; Nictiz, 2014, EHEALTH NETH POL DEV; Odone A, 2017, VACCINE, V35, P1209, DOI 10.1016/j.vaccine.2015.11.051; Odone A, 2020, ACTA BIOMED, V91; Odone Anna, 2019, Eur J Public Health, V29, P28, DOI 10.1093/eurpub/ckz161; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313; Ohannessian R, 2016, VACCINE, V34, P4478, DOI 10.1016/j.vaccine.2016.07.048; Police Rachel L, 2010, Inform Prim Care, V18, P245; Poorman E, 2015, MATERN CHILD HLTH J, V19, P969, DOI 10.1007/s10995-014-1595-8; Rigby M, 2018, STUD HEALTH TECHNOL, V247, P930, DOI 10.3233/978-1-61499-852-5-930; Scobie HM, 2020, VACCINE, V38, P7183, DOI 10.1016/j.vaccine.2020.09.017; Shelov E., 2015, CURRENT TREATMENT OP, V1, P48, DOI 10.1007/s40746-014-0001-5; Sicurello, MED INFORM; Signorelli C, 2018, LANCET INFECT DIS, V18, P26, DOI 10.1016/S1473-3099(17)30696-5; Sinclair DR, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9768; Steffens MS, 2020, DIGIT HEALTH, V6, DOI 10.1177/2055207620970785; Stockwell MS, 2013, HUM VACC IMMUNOTHER, V9, P1802, DOI 10.4161/hv.25031; Tozzi AE, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00036; Urquhart GA, 2007, J PUBLIC HEALTH MAN, V13, P481; Vaghefi I, 2016, JMIR MED INF, V4, P82, DOI 10.2196/medinform.4577; Valluru N, 2018, DIGEST DIS SCI, V63, P1782, DOI 10.1007/s10620-018-5093-5; Valluru N, 2017, GASTROENTEROLOGY, V152, pS787, DOI 10.1016/S0016-5085(17)32730-0; Wagner AL, 2018, AM J PREV MED, V54, P96, DOI 10.1016/j.amepre.2017.09.014; Wald JS, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2016-3894; Walker RD, 2006, PEDIATRICS, V118, P1293, DOI 10.1542/peds.2006-1723; Walllinga J, 2005, PLOS MED, V2, P1152, DOI 10.1371/journal.pmed.0020316; Wangia Victoria, 2012, Online J Public Health Inform, V4, DOI 10.5210/ojphi.v4i3.4238; Wilson K, 2016, AM J TROP MED HYG, V94, P485, DOI 10.4269/ajtmh.15-0510; Wilson M, 2017, CHEST, V152, p568A, DOI 10.1016/j.chest.2017.08.598; Wilson RM, 2015, J COMMUN HEALTH, V40, P395, DOI 10.1007/s10900-014-9950-7; Wilson SE, 2017, HUM VACC IMMUNOTHER, V13, P1928, DOI 10.1080/21645515.2017.1319022; Wilson SE, 2016, CAN J PUBLIC HEALTH, V107, pE575, DOI [10.17269/cjph.107.5679, 10.17269/CJPH.107.5679]; World Health Organization Regional Office for Europe, EUR IMM AG 2030; World Health Organization Regional Office for Europe, EUR PROGR WORK 2020	66	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1126	10.3390/vaccines9101126			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WV2VS	34696234	Green Published, gold			2022-04-29	WOS:000717096600001
J	Speer, C; Schaier, M; Nusshag, C; Tollner, M; Buylaert, M; Kalble, F; Reichel, P; Grenz, J; Susal, C; Zeier, M; Schnitzler, P; Morath, C; Klein, K; Benning, L				Speer, Claudius; Schaier, Matthias; Nusshag, Christian; Toellner, Maximilian; Buylaert, Mirabel; Kaelble, Florian; Reichel, Paula; Grenz, Julia; Suesal, Caner; Zeier, Martin; Schnitzler, Paul; Morath, Christian; Klein, Katrin; Benning, Louise			Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks	VACCINES			English	Article						COVID-19; COVID-19 vaccination; hemodialysis; peritoneal dialysis; humoral response; BNT162b2; vaccination strategy; SARS-CoV-2	DIALYSIS PATIENTS; BNT162B2; MESSENGER-RNA-1273	It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8-24.3) and 21.8 (5.8-103.9) versus 134.9 (23.8-283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein-ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40-81) and 77% (52-89) versus 96% (90-98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein-ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31-60) in hemodialysis patients and 55% (36-78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed.	[Speer, Claudius; Schaier, Matthias; Nusshag, Christian; Toellner, Maximilian; Buylaert, Mirabel; Kaelble, Florian; Reichel, Paula; Grenz, Julia; Zeier, Martin; Morath, Christian; Klein, Katrin; Benning, Louise] Univ Hosp Heidelberg, Dept Nephrol, D-69120 Heidelberg, Germany; [Speer, Claudius] EMBL, Mol Med Partnership Unit Heidelberg, D-69120 Heidelberg, Germany; [Suesal, Caner] Univ Hosp Heidelberg, Inst Immunol, D-69120 Heidelberg, Germany; [Schnitzler, Paul] Univ Hosp Heidelberg, Dept Infect Dis, Virol, D-69120 Heidelberg, Germany		Speer, C; Benning, L (通讯作者)，Univ Hosp Heidelberg, Dept Nephrol, D-69120 Heidelberg, Germany.; Speer, C (通讯作者)，EMBL, Mol Med Partnership Unit Heidelberg, D-69120 Heidelberg, Germany.	claudius.speer@med.uni-heidelberg.de; matthias.schaier@med.uni-heidelberg.de; christian.nusshag@med.uni-heidelberg.de; maximilianconstantin.toellner@med.uni-heidelberg.de; mirabel.buylaert@med.uni-heidelberg.de; florian.kaelble@med.uni-heidelberg.de; paulareichel@web.de; julia.grenz@med.uni-heidelberg.de; caner.suesal@med.uni-heidelberg.de; Martin.Zeier@med.uni-heidelberg.de; paul.schnitzler@med.uni-heidelberg.de; christian.morath@med.uni-heidelberg.de; katrin.klein@med.uni-heidelberg.de; louise.benning@med.uni-heidelberg.de	Morath, Christian/ABC-5091-2021	Schaier, Matthias/0000-0003-1040-1150; Benning, Louise/0000-0002-8366-2100	Dietmar Hopp Stiftung - Physician Scientist Program of the Heidelberg Faculty of Medicine; Rahel Goitein-Straus Program of the Heidelberg Faculty of Medicine	Funding for this study has been received by the Dietmar Hopp Stiftung. Claudius Speer is funded by the Physician Scientist Program of the Heidelberg Faculty of Medicine. Louise Benning is funded by the Rahel Goitein-Straus Program of the Heidelberg Faculty of Medicine.	Benning L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080857; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Ducloux D, 2021, KIDNEY INT, V100, P702, DOI 10.1016/j.kint.2021.06.025; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Frantzen L, 2021, NEPHROL DIAL TRANSPL, V36, P1756, DOI 10.1093/ndt/gfab165; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Jiang HJ, 2021, CLIN J AM SOC NEPHRO, V16, P121, DOI 10.2215/CJN.07200520; Kim YI, 2021, EMERG MICROBES INFEC, V10, P152, DOI 10.1080/22221751.2021.1872352; Liu JY, 2021, NATURE, V596, P273, DOI 10.1038/s41586-021-03693-y; Liu YL, 2005, VACCINE, V23, P3957, DOI 10.1016/j.vaccine.2005.02.033; Meyer B, 2021, LANCET REG HEALTH-EU, V4, DOI 10.1016/j.lanepe.2021.100115; Ng JH, 2020, KIDNEY INT, V98, P1530, DOI 10.1016/j.kint.2020.07.030; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Rodriguez-Espinosa D, 2021, KIDNEY INT, V100, P476, DOI 10.1016/j.kint.2021.05.018; Schaier M, 2018, IMMUNOLOGY, V155, P211, DOI 10.1111/imm.12947; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Speer C, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.721286; Speer C, 2021, KIDNEY INT, V100, P700, DOI 10.1016/j.kint.2021.07.002; Speer C, 2021, CLIN J AM SOC NEPHRO, V16, P1073, DOI 10.2215/CJN.03700321; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]	27	10	10	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1130	10.3390/vaccines9101130			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN0LO	34696238	Green Published, gold			2022-04-29	WOS:000711468600001
J	Psichogiou, M; Karabinis, A; Poulakou, G; Antoniadou, A; Kotanidou, A; Degiannis, D; Pavlopoulou, ID; Chaidaroglou, A; Roussos, S; Mastrogianni, E; Eliadi, I; Basoulis, D; Petsios, K; Leontis, K; Kakalou, E; Protopapas, K; Jahaj, E; Pratikaki, M; Syrigos, KN; Lagiou, P; Gogas, H; Tsiodras, S; Magiorkinis, G; Paraskevis, D; Sypsa, V; Hatzakis, A				Psichogiou, Mina; Karabinis, Andreas; Poulakou, Garyphallia; Antoniadou, Anastasia; Kotanidou, Anastasia; Degiannis, Dimitrios; Pavlopoulou, Ioanna D.; Chaidaroglou, Antigoni; Roussos, Sotirios; Mastrogianni, Elpida; Eliadi, Irene; Basoulis, Dimitrios; Petsios, Konstantinos; Leontis, Konstantinos; Kakalou, Eleni; Protopapas, Konstantinos; Jahaj, Edison; Pratikaki, Maria; Syrigos, Konstantinos N.; Lagiou, Pagona; Gogas, Helen; Tsiodras, Sotirios; Magiorkinis, Gkikas; Paraskevis, Dimitrios; Sypsa, Vana; Hatzakis, Angelos			Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection	VACCINES			English	Article						COVID-19; BNT162b2 vaccine; health care workers; immune response; anti-RBD		BNT162b2 has proven to be highly effective, but there is a paucity of data regarding immunogenicity factors and comparison between response to vaccination and natural infection. This study included 871 vaccinated healthcare workers (HCW) and 181 patients with natural infection. Immunogenicity was assessed by measuring anti-SARS-CoV-2 against the RBD domain of the spike protein (anti-RBD). Samples were collected 1-2 weeks after vaccination or 15-59 days post-onset of symptoms. Post-vaccine anti-RBD concentrations were associated with age, gender, vaccination side-effects (VSE) and prior infection (Pr-CoV). Anti-RBD median levels (95%CI) were lower by 2466 (651-5583), 6228 (3254-9203) and 7651 (4479-10,823) AU/mL in 35-44, 45-54, 55-70 yrs, respectively, compared with the 18-34 yrs group. In females, the median levels were higher by 2823 (859-4787), 5024 (3122-6926) in individuals with VSE, and 9971 (5158-14,783) AU/mL in HCWs with Pr-CoV. The ratio of anti-RBD in vaccinated individuals versus those with natural infection varied from 1.0 to 19.4. The high immunogenicity of BNT162b2 is verified, although its sustainability has yet to be elucidated. The use of comparative data from natural infection serological panels, expressing the clinical heterogeneity of natural infection, may facilitate early decisions for candidate vaccines to be evaluated in clinical trials.	[Psichogiou, Mina; Mastrogianni, Elpida; Eliadi, Irene; Basoulis, Dimitrios; Gogas, Helen] Natl & Kapodistrian Univ Athens, Sch Med, Laiko Gen Hosp, Dept Internal Med 1, Athens 11527, Greece; [Karabinis, Andreas; Degiannis, Dimitrios; Chaidaroglou, Antigoni] Onassis Cardiac Surg Ctr, Athens 17674, Greece; [Poulakou, Garyphallia; Leontis, Konstantinos; Kakalou, Eleni; Syrigos, Konstantinos N.] Natl & Kapodistrian Univ Athens, Sch Med, Sotiria Gen Hosp, Dept Internal Med 3, Athens 11527, Greece; [Antoniadou, Anastasia; Protopapas, Konstantinos; Tsiodras, Sotirios] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 4, Athens 12462, Greece; [Kotanidou, Anastasia; Jahaj, Edison; Pratikaki, Maria] Natl & Kapodistrian Univ Athens, Sch Med, Evangelismos Hosp, Dept Crit Care & Pulm Serv 1, Athens 10676, Greece; [Pavlopoulou, Ioanna D.] Natl & Kapodistrian Univ Athens, Fac Nursing, Pediat Res Lab, Athens 11527, Greece; [Roussos, Sotirios; Lagiou, Pagona; Magiorkinis, Gkikas; Paraskevis, Dimitrios; Sypsa, Vana; Hatzakis, Angelos] Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece; [Petsios, Konstantinos] Onassis Cardiac Surg Ctr, Clin Res Off, Athens 17674, Greece; [Hatzakis, Angelos] Hellen Sci Soc Study AIDS Sexually Transmitted &, Athens 11527, Greece		Psichogiou, M (通讯作者)，Natl & Kapodistrian Univ Athens, Sch Med, Laiko Gen Hosp, Dept Internal Med 1, Athens 11527, Greece.	mpsichog@med.uoa.gr; karabinis291@hotmail.com; gpoulakou@gmail.com; ananto@med.uoa.gr; akotanid@gmail.com; degiannis@yahoo.com; idpavlop@yahoo.gr; achaidaroglou@yahoo.com; sotirisroussos@yahoo.co.uk; elpidoulama@hotmail.com; eirini.iliadi@gmail.com; dimitris.bassoulis@gmail.com; petsiosk@gmail.com; kostas.leontis@hotmail.com; ekakalou@gmail.com; kprotopapas@hotmail.com; edison.jahaj@gmail.com; mpratikaki@yahoo.com; ksyrigos@med.uoa.gr; pdlagiou@med.uoa.gr; helgogas@gmail.com; sotirios.tsiodras@gmail.com; gmagi@med.uoa.gr; dparask@med.uoa.gr; vsipsa@med.uoa.gr; ahatzak@med.uoa.gr	Jahaj, Edison/AAB-5502-2020	Jahaj, Edison/0000-0002-7306-713X; Roussos, Sotirios/0000-0003-2347-0817; psichogiou, mina/0000-0002-3000-8447; Paraskevis, Dimitrios/0000-0001-6167-7152; ANTONIADOU, ANASTASIA/0000-0003-0991-9198; Gogas, Helen/0000-0002-0451-2885; SYPSA, VANA/0000-0002-9430-7614; Tsiodras, Sotirios/0000-0002-0463-4321	SYN-ENOSIS [55/13-10-2020]	This work was supported by SYN-ENOSIS (protocol number 55/13-10-2020) and donations from the Onassis Cardiac Surgery Center; SB Bioanalytica S.A.; Viatris Hellas and the Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases.	Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, COVID 19 CLIN MAN LI; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Collier D.A., 2021, CITIID NIHR BIORESOU, DOI [10.1101/2021.02.03.21251054, DOI 10.1101/2021.02.03.21251054]; Corbett KS, 2021, SCIENCE, V373, P1325, DOI 10.1126/science.abj0299; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dolgin E, 2021, NATURE, V594, P483, DOI 10.1038/d41586-021-01661-0; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Feng S., 2021, CORRELATES PROTECTIO, DOI [10.1101/2021.06.21.21258528, DOI 10.1101/2021.06.21.21258528]; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Hall VJ, 2021, LANCET, V397, P1459, DOI 10.1016/S0140-6736(21)00675-9; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Irsara C., 2021, CLIN VALIDATION QUAN, DOI [10.1101/2021.02.17.21251907, DOI 10.1101/2021.02.17.21251907]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jin PF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00481-y; Johnson M, 2020, J CLIN VIROL, V130, DOI 10.1016/j.jcv.2020.104572; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Letizia AG, 2021, LANCET RESP MED, V9, P712, DOI 10.1016/S2213-2600(21)00158-2; Lucas Carolina, 2020, medRxiv, DOI 10.1101/2020.12.18.20248331; Lynch KL, 2021, CLIN INFECT DIS, V72, P301, DOI 10.1093/cid/ciaa979; Marinaki S, 2021, AM J TRANSPLANT, V21, P2913, DOI 10.1111/ajt.16607; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Naaber P, MEDRXIV, V2021, DOI [10.1101/2021.04.19.21255714, DOI 10.1101/2021.04.19.21255714]; Pellini R., 2021, OBESITY MAY HAMPER S, DOI [10.1101/2021.02.24.21251664, DOI 10.1101/2021.02.24.21251664]; Perkmann-Nagele N., 2021, ANTISPIKE PROTEIN AS, V383, P1782, DOI [10.1101/2021.03.05.21252977, DOI 10.1101/2021.03.05.21252977]; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	40	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1017	10.3390/vaccines9091017			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW0BD	34579254	Green Published, gold			2022-04-29	WOS:000699831900001
J	Wang, YX; Yang, GH; Zhang, LL; Wang, J; Wang, JF				Wang, Yi-Xuan; Yang, Guang-Hui; Zhang, Lin-Lin; Wang, Jing; Wang, Jiu-Feng			Melatonin as Immune Potentiator for Enhancing Subunit Vaccine Efficacy against Bovine Viral Diarrhea Virus	VACCINES			English	Article						BVDV; melatonin; the NF-kappa B inflammation pathway; T-cell immunity	INFECTION; ANTIGEN; BVDV	Bovine viral diarrhea virus (BVDV) is a pathogen associated with substantial economic losses in the dairy cattle industry. Currently, there are no effective vaccines against BVDV. Melatonin (MT) has been shown to have anti-inflammatory and anti-viral properties, and the use of MF59 in vaccines significantly enhances vaccine efficiency. Here, MT and MF59 were added into the E-rns-LTB vaccine. Subsequently, their inhibitory activity on the NF-kappa B signaling pathway in Mardin-Darby Bovine Kidney cells and the hippocampus was assessed using western blot and quantitative reverse transcription PCR. The findings revealed that MT in the E-rns-LTB vaccine decreases the phosphorylation of p65 proteins caused by BVDV infection. In addition, MT decreased the mRNA levels of IL-1 beta and IL-6 in vitro, but increased the production of IFN-alpha, IFN-beta, Mx1 in vitro, brain-derived neurotrophic factor, cyclic amp response element-binding protein, and the stem cell factor in vivo. Furthermore, treatment with E-rns-LTB + MF59 + MT stimulated the production of T lymphocytes, alleviated pathological damage, decreased expressions of BVDV antigen, and tight junction proteins in mice. These findings imply that MT has potential for use in the E-rns-LTB vaccine to inhibit BVDV infection and regulate the immune responses of T-cells by inhibiting the NF-kappa B signaling pathway.	[Wang, Yi-Xuan; Yang, Guang-Hui; Zhang, Lin-Lin; Wang, Jing; Wang, Jiu-Feng] China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China		Wang, JF (通讯作者)，China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.	wangyixuan20201018@163.com; ygh564701721@163.com; zhanglinlin0902@163.com; wangjing100193@163.com; jiufeng_wang@hotmail.com		Wang, Jiufeng/0000-0002-0183-5611; guanghui, yang/0000-0003-4652-6166	National key R&D Program of China [2017YFD0502200]; Program for the Beijing Dairy Industry Innovation Team (Beijing, China)	This work was supported by grants from the National key R&D Program of China (project no. 2017YFD0502200) and the Program for the Beijing Dairy Industry Innovation Team (Beijing, China).	Bonmati-Carrion MA, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020210; Cai DJ, 2018, VACCINE, V36, P5591, DOI 10.1016/j.vaccine.2018.07.054; Cao Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06151-y; Chen P, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00949; Deng Yu, 2018, J Vet Med, V2018, P8274397, DOI 10.1155/2018/8274397; Duan QD, 2017, MICROBIOL IMMUNOL, V61, P251, DOI 10.1111/1348-0421.12494; Quintana ME, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00045; Gallina L, 2021, VET MICROBIOL, V256, DOI 10.1016/j.vetmic.2021.109047; Garoussi MT, 2019, TROP ANIM HEALTH PRO, V51, P853, DOI 10.1007/s11250-018-1765-6; Gupta M, 2005, J CHILD NEUROL, V20, P112, DOI 10.1177/08830738050200020501; Hibaoui Y, 2011, J PINEAL RES, V51, P163, DOI 10.1111/j.1600-079X.2011.00871.x; Knapek KJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080816; Kottwitz JJ, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01496; Liu CP, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.580064; Luo JH, 2018, INT IMMUNOPHARMACOL, V64, P116, DOI 10.1016/j.intimp.2018.08.034; Luo YG, 2012, VACCINE, V30, P3843, DOI 10.1016/j.vaccine.2012.04.016; Maldonado N, 2020, MOL IMMUNOL, V128, P33, DOI 10.1016/j.molimm.2020.09.018; McMorrow C, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091630; Montgomery DL, 2008, VET PATHOL, V45, P288, DOI 10.1354/vp.45-3-288; Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105; Patterson R, 2012, DEV COMP IMMUNOL, V37, P107, DOI 10.1016/j.dci.2011.10.009; Regodon S, 2009, VACCINE, V27, P1566, DOI 10.1016/j.vaccine.2009.01.001; Ren X, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01338-6; Riitho V, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101134; Oliveira LGR, 2013, ACTA TROP, V128, P652, DOI 10.1016/j.actatropica.2013.09.014; Sangewar N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589537; Sharif Muhammad, 2021, J Virol, DOI 10.1128/JVI.00051-21; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Song QJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162791; Torres-Flores JM, 2015, VIRUSES-BASEL, V7, P5145, DOI 10.3390/v7092865; Veneroso C, 2009, J PINEAL RES, V47, P184, DOI 10.1111/j.1600-079X.2009.00699.x; Villalba M, 2017, MOL IMMUNOL, V92, P169, DOI 10.1016/j.molimm.2017.10.012; Wang HS, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01941; Wang SH, 2021, VET MICROBIOL, V259, DOI 10.1016/j.vetmic.2021.109084; Wang SH, 2020, VACCINE, V38, P3881, DOI 10.1016/j.vaccine.2020.03.020; Wieckowska G.A., 2021, AGEING RES REV, V70, DOI [10.1016/j.arr.2021.101397, DOI 10.1016/J.ARR.2021.101397]; Wu GC, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1325-2; Wu X, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4087298; Xia DY, 2021, J HAZARD MATER, V413, DOI 10.1016/j.jhazmat.2021.125239; Zhang CM, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6668887; Zhang H, 2021, J HAZARD MATER, V407, DOI 10.1016/j.jhazmat.2020.124489; Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583; Zhao CN, 2019, CYTOKINE GROWTH F R, V48, P1, DOI 10.1016/j.cytogfr.2019.07.002	43	0	0	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1039	10.3390/vaccines9091039			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY1EA	34579276	gold, Green Published			2022-04-29	WOS:000701273400001
J	Antonini, C; Calandrini, S; Bianconi, F				Antonini, Chiara; Calandrini, Sara; Bianconi, Fortunato			A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy	VACCINES			English	Article						SEIR model; COVID-19; SARS-CoV-2 variants; vaccines; model calibration; Italy	HERD-IMMUNITY; INFECTION	From the end of 2020, different vaccines against COVID-19 have been approved, offering a glimmer of hope and relief worldwide. However, in late 2020, new cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started to re-surge, worsened by the emergence of highly infectious variants. To study this scenario, we extend the Susceptible-Exposed-Infectious-Removed model with lockdown measures used in our previous work with the inclusion of new lineages and mass vaccination campaign. We estimate model parameters using the Bayesian method Conditional Robust Calibration in two case studies: Italy and the Umbria region, the Italian region being worse affected by the emergence of variants. We then use the model to explore the dynamics of COVID-19, given different vaccination paces and a policy of gradual reopening. Our findings confirm the higher reproduction number of Umbria and the increase of transmission parameters due to the presence of new variants. The results illustrate the importance of preserving population-wide interventions, especially during the beginning of vaccination. Finally, under the hypothesis of waning immunity, the predictions show that a seasonal vaccination with a constant rate would probably be necessary to control the epidemic.	[Antonini, Chiara; Calandrini, Sara] ICT4life Srl, Via Mario Donati Guerrieri 16, I-06132 Perugia, Italy; [Calandrini, Sara] Univ Perugia, Dept Engn, Via Goffredo Duranti 93, I-06125 Perugia, Italy; [Bianconi, Fortunato] Reg Govt Umbria, COVID 19 Epidemiol Unit, Corso Vannucci 96, I-06121 Perugia, Italy		Antonini, C (通讯作者)，ICT4life Srl, Via Mario Donati Guerrieri 16, I-06132 Perugia, Italy.	chiara.antonini@i4l.company; sara.calandrini@i4l.company; fortunato.bianconi@gmail.com	Bianconi, Fortunato/L-7359-2019	Bianconi, Fortunato/0000-0002-3132-0061; calandrini, sara/0000-0002-4671-8670	Department of Health, Regional Government of UmbriaRegione Umbria [D.G.R. 206/2020]	We thank all the components of the COVID-19 epidemiological unit, Department of Health, Regional Government of Umbria (D.G.R. 206/2020, 25 June 2020). We also thank ICT4Life Srl for free support on mathematical modeling and for providing computational resources.	Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Antonini C, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9110394; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bianconi F, 2020, FRONT APPL MATH STAT, V6, DOI 10.3389/fams.2020.00025; Bianconi F, 2020, IET SYST BIOL, V14, P107, DOI 10.1049/iet-syb.2018.5091; Bianconi F, 2020, IEEE T CONTR SYST T, V28, P196, DOI 10.1109/TCST.2018.2844362; Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Di Giallonardo F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050794; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Dowdy D., 2020, WHATS HERD IMMUNITY, P10; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Fosu G.O., 2020, OPEN J MATH SCI, V4, P261; Giordano G, 2021, NAT MED, V27, P993, DOI 10.1038/s41591-021-01334-5; Ledford Heidi, 2021, Nature, DOI 10.1038/d41586-021-00071-6; Lopez L, 2021, RESULTS PHYS, V21, DOI 10.1016/j.rinp.2020.103746; Mateo-Urdiales A, 2020, EUROSURVEILLANCE, V26, P1, DOI 10.2807/1560-7917.ES.2021.26.25.2100507; Moore S, 2021, LANCET INFECT DIS, V21, P793, DOI 10.1016/S1473-3099(21)00143-2; Nguyen LK, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-51; Pearson C.A.B., ESTIMATES SEVERITY T; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Saad-Roy CM, 2020, SCIENCE, V370, P811, DOI 10.1126/science.abd7343; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica Istituto Superiore di SanituSS, EP COVID 19; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Vinceti M, 2021, ENVIRON RES, V197, DOI 10.1016/j.envres.2021.111097; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; World Health Organization, 2020, COVID 19 DASHB	31	0	0	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							915	10.3390/vaccines9080915			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7DK	34452040	gold, Green Published			2022-04-29	WOS:000690086400001
J	Bohnhorst, B; Weidlich, C; Peter, C; Bohne, C; Kattner, E; Pirr, S				Bohnhorst, Bettina; Weidlich, Cornelia; Peter, Corinna; Boehne, Carolin; Kattner, Evelyn; Pirr, Sabine			Cardiorespiratory Events Following the Second Routine Immunization in Preterm Infants: Risk Assessment and Monitoring Recommendations	VACCINES			English	Article						preterm infant; routine immunization; second vaccination; cardiorespiratory events; monitoring	PREMATURE-INFANTS; OXYGEN-SATURATION; CONJUGATE VACCINE; RECURRENT APNEA; GESTATIONAL-AGE; ADVERSE EVENTS; TERM INFANTS; SAFETY; BRADYCARDIA; NEWBORN	Due to frequent cardiorespiratory events (CREs) in response to the first routine immunization (rIM), current guidelines recommend readmitting and monitoring extremely preterm infants after the second rIM, though evidence on CREs in response to the second rIM is weak. In a prospective observational study, preterm infants with an increase in CREs after the first rIM were monitored for CREs before and after the second rIM. Seventy-one infants with a median gestational age of 26.4 weeks and a median weight of 820 g at birth were investigated at a median postnatal age of 94 days. All but seven infants showed an increase in CREs after the second rIM. The frequency of hypoxemias (p < 0.0001), apneas (p = 0.0003) and cardiorespiratory events requiring tactile stimulation (CRE-ts) (p = 0.0034) increased significantly. The 25 infants (35%) presenting with CRE-ts were significantly more likely to have been continuously hospitalized since birth (p = 0.001) and to receive analeptic therapy at the first rIM (p = 0.002) or some kind of respiratory support at the first (p = 0.005) and second rIM (p < 0.0001). At a postmenstruational age of 43.5 weeks, CRE-ts ceased. Our data support the recommendation to monitor infants who fulfil the above-mentioned criteria during the second rIM up to a postmenstruational age of 44 weeks.	[Bohnhorst, Bettina; Weidlich, Cornelia; Peter, Corinna; Boehne, Carolin; Pirr, Sabine] Hannover Med Sch, Dept Pediat Pneumol Allergol & Neonatol, D-30625 Hannover, Lower Saxony, Germany; [Kattner, Evelyn] Childrens Hosp Bult, Dept Neonatol, D-30173 Hannover, Lower Saxony, Germany		Pirr, S (通讯作者)，Hannover Med Sch, Dept Pediat Pneumol Allergol & Neonatol, D-30625 Hannover, Lower Saxony, Germany.	bohnhorst.bettina@mh-hannover.de; weidlich.cornelia@mh-hannover.de; peter.corinna@mh-hannover.de; boehne.carolin@mh-hannover.de; ekattner@t-online.de; pirr.sabine@mh-hannover.de		Pirr, Sabine/0000-0002-3624-6251	Childrens' Hospital "Auf der Bult"	We are grateful to all the families that participated in this study. Furthermore, we thank the nursing staff of the neonatology at Hannover Medical School and the Childrens' Hospital "Auf der Bult" for their support.	Amin SB, 2013, AM J PERINAT, V30, P643, DOI 10.1055/s-0032-1329694; Anderson J, 2013, J PAEDIATR CHILD H, V49, pE217, DOI 10.1111/jpc.12110; [Anonymous], 2019, EPIDEMIOL B, V34, P313, DOI [10.25646/6233.7, DOI 10.25646/6233.7]; [Anonymous], IMMUNIZATION INFANTS; Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB; Beresford Michael W, 2005, J Perinatol, V25, P30, DOI 10.1038/sj.jp.7211206; Bohnhorst B, 2019, ACTA PAEDIATR, V108, P231, DOI 10.1111/apa.14470; Bonafide CP, 2013, PEDIATRICS, V131, pE1150, DOI 10.1542/peds.2012-2443; Brockmann PE, 2013, ARCH DIS CHILD-FETAL, V98, pF524, DOI 10.1136/archdischild-2012-303369; Cerar LK, 2009, PEDIATRICS, V124, pE396, DOI 10.1542/peds.2009-0160; Chiappini E, 2019, EXPERT REV VACCINES, V18, P523, DOI 10.1080/14760584.2019.1604230; Clifford V, 2011, VACCINE, V29, P5681, DOI 10.1016/j.vaccine.2011.06.005; Demeo SD, 2015, JAMA PEDIATR, V169, P740, DOI 10.1001/jamapediatrics.2015.0418; Eichenwald EC, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3757; Ezeanolue E, GEN BEST PRACTICE GU; Flatz-Jequier A, 2008, J PEDIATR-US, V153, P429, DOI 10.1016/j.jpeds.2008.03.043; Gaudelus J, 2007, ARCH PEDIATRIE, V14, pS24, DOI 10.1016/S0929-693X(07)80007-8; Gottlob S, 2019, NEONATOLOGY, V116, P315, DOI 10.1159/000501338; Heininger U., 2013, KINDERHEILKD, V161, P946, DOI [10.1007/s00112-013-2988-2, DOI 10.1007/S00112-013-2988-2]; HENDERSONSMART DJ, 1981, AUST PAEDIATR J, V17, P273; Javorka K, 2017, PHYSIOL RES, V66, pS203, DOI 10.33549/physiolres.933676; Kent A, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3945; Klein NP, 2019, HUM VACC IMMUNOTHER, V15, P809, DOI 10.1080/21645515.2018.1549449; Lee Jackie, 2006, BMC Pediatr, V6, P20, DOI 10.1186/1471-2431-6-20; Martinon-Torres F, 2015, PEDIATRICS, V135, pE876, DOI 10.1542/peds.2014-2941; Mialet-Marty T, 2013, NEONATOLOGY, V104, P151, DOI 10.1159/000351035; Ng DK, 2013, PEDIATR NEONATOL, V54, P82, DOI 10.1016/j.pedneo.2012.11.011; Omenaca F, 2018, VACCINE, V36, P986, DOI 10.1016/j.vaccine.2018.01.005; PERLMAN JM, 1985, PEDIATRICS, V76, P333; Pfister RE, 2004, J PEDIATR-US, V145, P58, DOI 10.1016/j.jpeds.2004.04.006; Poets C., THERAPIE IDIOPATHISC; Poets CF, 2010, ACTA PAEDIATR, V99, P172, DOI 10.1111/j.1651-2227.2009.01604.x; POETS CF, 1993, PEDIATR RES, V34, P144, DOI 10.1203/00006450-199308000-00007; POETS CF, 1992, J PEDIATR-US, V120, P447, DOI 10.1016/S0022-3476(05)80919-9; Pourcyrous M, 2007, J PEDIATR-US, V151, P167, DOI 10.1016/j.jpeds.2007.02.059; Public Health England, UK IMM SCHED GREEN B; Ramanathan R, 2001, JAMA-J AM MED ASSOC, V285, P2199, DOI 10.1001/jama.285.17.2199; Rhein L, 2012, PEDIATR PULM, V47, P453, DOI 10.1002/ppul.21562; Saari TN, 2003, PEDIATRICS, V112, P193, DOI 10.1542/peds.112.1.193; Schluter B, 2001, SOMNOLOGIE, V5, P3, DOI [10.1046/j.1439-054x.2001.01148.x, DOI 10.1046/J.1439-054X.2001.01148.X]; Sen S, 2001, ACTA PAEDIATR, V90, P916, DOI 10.1111/j.1651-2227.2001.tb02457.x; Shah PS, 2014, J PERINATOL, V34, P917, DOI 10.1038/jp.2014.107; Wellington G, 2019, J PAEDIATR CHILD H, V55, P938, DOI 10.1111/jpc.14320; Wellington G, 2018, ACTA PAEDIATR, V107, P1362, DOI 10.1111/apa.14293	44	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							909	10.3390/vaccines9080909			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2SK	34452034	gold, Green Published			2022-04-29	WOS:000689787400001
J	Livingstone, M; Wattegedera, SR; Palarea-Albaladejo, J; Aitchison, K; Corbett, C; Sait, M; Wilson, K; Chianini, F; Rocchi, MS; Wheelhouse, N; Entrican, G; Longbottom, D				Livingstone, Morag; Wattegedera, Sean Ranjan; Palarea-Albaladejo, Javier; Aitchison, Kevin; Corbett, Cecilia; Sait, Michelle; Wilson, Kim; Chianini, Francesca; Rocchi, Mara Silvia; Wheelhouse, Nicholas; Entrican, Gary; Longbottom, David			Efficacy of Two Chlamydia abortus Subcellular Vaccines in a Pregnant Ewe Challenge Model for Ovine Enzootic Abortion	VACCINES			English	Article						Chlamydia abortus; enzootic abortion of ewes; vaccine development; vaccine efficacy; quantitative real-time polymerase chain reaction (PCR); serological analysis; cytokine analysis	MEDIATED DNA VACCINE; CHLAMYDOPHILA-ABORTUS; INACTIVATED VACCINES; PROTECTIVE EFFICACY; PSITTACI INFECTION; REPRODUCTIVE-TRACT; STRAIN 1B; SHEEP; IDENTIFICATION; IMMUNIZATION	Chlamydia abortus, the aetiological agent of enzootic abortion of ewes, is a major cause of reproductive loss in small ruminants worldwide, accounting for significant economic losses to the farming industry. Disease can be managed through the use of commercial inactivated or live whole organism-based vaccines, although both have limitations particularly in terms of efficacy, safety and disease-associated outbreaks. Here we report a comparison of two experimental vaccines (chlamydial outer membrane complex (COMC) and octyl glucoside (OG)-COMC) based on detergent extracted outer membrane preparations of C. abortus and delivered as prime-boost immunisations, with the commercial live vaccine Cevac(R) Chlamydia in a pregnant sheep challenge model. No abortions occurred in either experimental vaccine group, while a single abortion occurred in the commercial vaccine group. Bacterial shedding, as a measure of potential risk of transmission of infection to naive animals, was lowest in the COMC vaccinated group, with reductions of 87.5%, 86.4% and 74% observed for the COMC, OG-COMC and live commercial vaccine groups, respectively, compared to the unvaccinated challenge control group. The results show that the COMC vaccine performed the best and is a safer efficacious alternative to the commercial vaccines. However, to improve commercial viability, future studies should optimise the antigen dose and number of inoculations required.	[Livingstone, Morag; Wattegedera, Sean Ranjan; Aitchison, Kevin; Corbett, Cecilia; Sait, Michelle; Wilson, Kim; Chianini, Francesca; Rocchi, Mara Silvia; Wheelhouse, Nicholas; Entrican, Gary; Longbottom, David] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland; [Palarea-Albaladejo, Javier] Biomath & Stat Scotland, Edinburgh EH9 3FD, Midlothian, Scotland; [Palarea-Albaladejo, Javier] Univ Girona, Dept Comp Sci Appl Math & Stat, Girona 17003, Spain; [Corbett, Cecilia] Anim Plant & Hlth Agcy, Vet Invest Ctr, Thirsk YO7 1PZ, England; [Sait, Michelle] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Microbiol Diagnost Unit, Melbourne, Vic 3010, Australia; [Wilson, Kim] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh EH9 3FL, Midlothian, Scotland; [Wheelhouse, Nicholas] Edinburgh Napier Univ, Sch Appl Sci, Edinburgh EH11 4BN, Midlothian, Scotland; [Entrican, Gary] Univ Edinburgh, Roslin Inst, Easter Bush Campus, Roslin EH25 9RG, Midlothian, Scotland		Longbottom, D (通讯作者)，Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.	morag.livingstone@moredun.ac.uk; sean.wattegedera@moredun.ac.uk; javier.palarea@udg.edu; kevin.aitchison@moredun.ac.uk; Cecilia.Corbett@apha.gov.uk; michelle.sait@unimelb.edu.au; kim.wilson@ed.ac.uk; francesca.chianini@moredun.ac.uk; mara.rocchi@moredun.ac.uk; n.wheelhouse@napier.ac.uk; Gary.Entrican@roslin.ed.ac.uk; david.longbottom@moredun.ac.uk	Palarea-Albaladejo, Javier/J-5591-2013	Palarea-Albaladejo, Javier/0000-0003-0162-669X; Rocchi, Mara/0000-0003-0276-8040; Wheelhouse, Nick/0000-0002-2803-0055; Wattegedera, Sean/0000-0002-2218-5144	Scottish Government Rural and Environment Science and Analytical Services (RESAS) division	This research was funded by the Scottish Government Rural and Environment Science and Analytical Services (RESAS) division. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; AITKEN ID, 1990, VET REC, V126, P136, DOI 10.1136/vr.126.6.136; Arif ED, 2020, POL J MICROBIOL, V69, P65, DOI 10.33073/pjm-2020-009; Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9; BATTEIGER BE, 1993, J GEN MICROBIOL, V139, P2965, DOI 10.1099/00221287-139-12-2965; Begg DJ, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01911; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett R, 2003, J AGR ECON, V54, P55, DOI 10.1111/j.1477-9552.2003.tb00048.x; Borel N, 2018, VET PATHOL, V55, P374, DOI 10.1177/0300985817751218; BUXTON D, 1986, VET REC, V118, P510, DOI 10.1136/vr.118.18.510; Caro MR, 2001, VET REC, V149, P492, DOI 10.1136/vr.149.16.492; Caspe SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242526; Chalmers WSK, 1997, VET REC, V141, P63, DOI 10.1136/vr.141.3.63; DESA C, 1995, INFECT IMMUN, V63, P4912, DOI 10.1128/IAI.63.12.4912-4916.1995; Entrican G, 2012, COMP IMMUNOL MICROB, V35, P271, DOI 10.1016/j.cimid.2011.12.001; Garcia de la Fuente JN, 2004, VET MICROBIOL, V100, P65, DOI 10.1016/j.vetmic.2004.01.015; Garcia-Seco T, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00067; GIROUD P, 1956, CR HEBD ACAD SCI, V242, P697; GRAHAM SP, 1995, J COMP PATHOL, V112, P185, DOI 10.1016/S0021-9975(05)80060-X; Hechard C, 2004, J MED MICROBIOL, V53, P861, DOI 10.1099/jmm.0.05442-0; Herring A. J., 1996, Alpe Adria Microbiology Journal, V5, P223; Herring A.J., 1998, P 9 INT S HUM CHLAM, P434; HOBSON D, 1977, J COMP PATHOL, V87, P155, DOI 10.1016/0021-9975(77)90091-3; Igietseme JU, 2002, BIODRUGS, V16, P19, DOI 10.2165/00063030-200216010-00003; JOHNSON FWA, 1985, BRIT MED J, V290, P592, DOI 10.1136/bmj.290.6468.592; JONES GE, 1995, VACCINE, V13, P715, DOI 10.1016/0264-410X(94)00068-X; Laroucau K, 2018, VET MICROBIOL, V225, P31, DOI 10.1016/j.vetmic.2018.09.012; Laroucau K, 2010, VACCINE, V28, P5653, DOI 10.1016/j.vaccine.2010.06.064; Ling Y, 2011, VET IMMUNOL IMMUNOP, V144, P389, DOI 10.1016/j.vetimm.2011.08.003; Livingstone M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177653; Livingstone M, 2009, VET MICROBIOL, V135, P134, DOI 10.1016/j.vetmic.2008.09.033; Longbottom D, 2006, VET J, V171, P263, DOI 10.1016/j.tvjl.2004.09.006; Longbottom D, 2003, J COMP PATHOL, V128, P217, DOI 10.1053/jcpa.2002.0629; Longbottom D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224070; Longbottom D, 2018, VACCINE, V36, P3593, DOI 10.1016/j.vaccine.2018.05.042; Longbottom D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057950; MCCLENAGHAN M, 1984, INFECT IMMUN, V45, P384, DOI 10.1128/IAI.45.2.384-389.1984; Montbrau C, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00593; Moore T, 2002, IMMUNOLOGY, V105, P213, DOI 10.1046/j.0019-2805.2001.01354.x; Nietfeld JC, 2001, VET CLIN N AM-FOOD A, V17, P301, DOI 10.1016/S0749-0720(15)30030-X; O'Neill LM, 2019, VACCINE, V37, P5428, DOI 10.1016/j.vaccine.2019.06.088; Ou CB, 2013, INT IMMUNOPHARMACOL, V16, P505, DOI 10.1016/j.intimp.2013.04.027; Pal S, 1997, INFECT IMMUN, V65, P3361, DOI 10.1128/IAI.65.8.3361-3369.1997; Pan Q, 2015, VACCINE, V33, P1865, DOI 10.1016/j.vaccine.2015.02.007; Papp JR, 1996, J INFECT DIS, V174, P1296, DOI 10.1093/infdis/174.6.1296; PAPP JR, 1994, INFECT IMMUN, V62, P3786, DOI 10.1128/IAI.62.9.3786-3792.1994; Pospischil A, 2002, SCHWEIZ ARCH TIERH, V144, P463, DOI 10.1024/0036-7281.144.9.463; R-Core-Team, R LANG ENV STAT COMP; Rocchi MS, 2009, VET MICROBIOL, V135, P112, DOI 10.1016/j.vetmic.2008.09.030; Rodolakis A, 2015, VET MICROBIOL, V181, P107, DOI 10.1016/j.vetmic.2015.07.010; RODOLAKIS A, 1986, AM J VET RES, V47, P2627; Sammin D, 2009, VET MICROBIOL, V135, P90, DOI 10.1016/j.vetmic.2008.09.054; Sammin DJ, 2006, J COMP PATHOL, V135, P83, DOI 10.1016/j.jcpa.2006.04.005; Sargison ND, 2015, NEW ZEAL VET J, V63, P284, DOI 10.1080/00480169.2015.1018365; Schautteet K, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-29; STUDDERT MJ, 1968, RES VET SCI, V9, P57; Su H, 1997, INFECT IMMUN, V65, P1993, DOI 10.1128/IAI.65.6.1993-1999.1997; TAN TW, 1990, INFECT IMMUN, V58, P3101, DOI 10.1128/IAI.58.9.3101-3108.1990; Wattegedera SR, 2020, VET RES, V51, DOI 10.1186/s13567-020-00798-6; Wattegedera SR, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03025; Wheelhouse N, 2010, VACCINE, V28, P5657, DOI 10.1016/j.vaccine.2010.04.114; WILSMORE AJ, 1990, VET REC, V126, P40; Wilson K, 2009, VET MICROBIOL, V135, P38, DOI 10.1016/j.vetmic.2008.09.043; WONG SY, 1985, J CLIN PATHOL, V38, P707, DOI 10.1136/jcp.38.6.707; Wood R., 1992, Farmers Weekly, V117, P60	65	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							898	10.3390/vaccines9080898			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9TV	34452023	Green Published, gold			2022-04-29	WOS:000690264300001
J	Loconsole, D; Stea, ED; Sallustio, A; Fonto, G; Pronzo, V; Simone, S; Centrone, F; Accogli, M; Gesualdo, L; Chironna, M				Loconsole, Daniela; Stea, Emma Diletta; Sallustio, Anna; Fonto, Giulia; Pronzo, Virginia; Simone, Simona; Centrone, Francesca; Accogli, Marisa; Gesualdo, Loreto; Chironna, Maria			Severe COVID-19 by SARS-CoV-2 Lineage B.1.1.7 in Vaccinated Solid-Organ Transplant Recipients: New Preventive Strategies Needed to Protect Immunocompromised Patients	VACCINES			English	Article						solid-organ transplant recipients; SARS-CoV-2 infection; B.1.1.7 lineage; COVID-19 vaccine; whole-genome sequencing		Background: Solid-organ transplant (SOT) recipients are at a high risk of severe COVID-19, and are priority for vaccination. Here, we describe three cases of severe COVID-19 caused by SARS-CoV-2 B.1.1.7 lineage in vaccinated SOT recipients. Methods: Three SOT patients were hospitalized in the Policlinico Hospital of Bari (southern Italy) and underwent nasopharyngeal swabs for molecular detection of SARS-CoV-2 genes and spike protein mutations by real-time PCR. One sample was subjected to whole-genome sequencing. Results: One patient was a heart transplant recipient and two were kidney transplant recipients. All were hospitalized with severe COVID-19 between March and May 2021. Two patients were fully vaccinated and one had received only one dose of the BNT162b2 mRNA vaccine. All the patients showed a high viral load at diagnosis, and molecular typing revealed the presence of B.1.1.7 lineage SARS-CoV-2. In all three cases, prolonged viral shedding was reported. Conclusions: The three cases pose concern about the role of the B.1.1.7 lineage in severe COVID-19 and about the efficacy of COVID-19 vaccination in immunocompromised patients. Protecting immunocompromised patients from COVID-19 is a challenge. SOT recipients show a suboptimal response to standard vaccination, and thus, an additive booster or a combined vaccination strategy with mRNA, protein/subunit, and vector-based vaccines may be necessary. This population should continue to practice strict COVID-19 precautions post-vaccination, until new strategies for protection are available.	[Loconsole, Daniela; Stea, Emma Diletta; Centrone, Francesca; Accogli, Marisa; Chironna, Maria] Univ Bari, Dept Biomed Sci & Human Oncol, Hyg Sect, I-70124 Bari, Italy; [Stea, Emma Diletta; Fonto, Giulia; Pronzo, Virginia; Simone, Simona; Gesualdo, Loreto] Univ Bari, Dept Emergency & Organ Transplantat, Nephrol Dialysis & Transplantat Unit, I-70124 Bari, Italy; [Sallustio, Anna] Azienda Osped Univ, Hyg Unit, Consorziale Policlin Bari, I-70124 Bari, Italy		Chironna, M (通讯作者)，Univ Bari, Dept Biomed Sci & Human Oncol, Hyg Sect, I-70124 Bari, Italy.	daniela.loconsole@uniba.it; emmadiletta.stea@libero.it; annasallustio@libero.it; giuliafonto@gmail.com; virginia.pronzo@gmail.com; simonasimone1976@gmail.com; francesca.centrone.fc@gmail.com; accoisa@gmail.com; loreto.gesualdo@uniba.it; maria.chironna@uniba.it		Pronzo, Virginia/0000-0002-3955-6319; chironna, maria/0000-0002-1043-1256; Loconsole, Daniela/0000-0003-2057-9745; Centrone, Francesca/0000-0003-3018-5408			Abayasingam A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100228; Ali NM, 2021, TRANSPLANTATION, V105, pE104, DOI 10.1097/TP.0000000000003836; Aslam S, 2021, J HEART LUNG TRANSPL, V40, P169, DOI 10.1016/j.healun.2020.12.009; Bajpai D, 2021, TRANSPL INT, V34, P1074, DOI 10.1111/tri.13886; Benotmane I, 2021, AM J TRANSPLANT, V21, P2871, DOI 10.1111/ajt.16636; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; CDC, SARS COV 2 VAR CLASS; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; ECDC, COVID 19 VACC PRIOR; Eckerle I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056974; Hadi Yousaf B, 2021, Transplantation, V105, P1365, DOI 10.1097/TP.0000000000003670; Hugo C, 2021, TRANSPL INT, V34, P378, DOI 10.1111/tri.13795; Ikizler TA, 2021, KIDNEY INT, V99, P1275, DOI 10.1016/j.kint.2021.04.007; International Society of Heart and Lung Transplantation, SARS COV 2 VACC HEAR; Istituto Superiore di Sanita, PREV VOC VAR VIR SAR; Ben Zadok OI, 2021, EUR J HEART FAIL, V23, P1555, DOI 10.1002/ejhf.2199; Kates Olivia S, 2021, Clin Infect Dis, V73, pe4090, DOI 10.1093/cid/ciaa1097; Kidd M, 2021, J INFECT DIS, V223, P1666, DOI 10.1093/infdis/jiab082; Kinoshita H, 2021, J CLIN IMMUNOL, V41, P1146, DOI 10.1007/s10875-021-01046-y; Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756; Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159; Loconsole D, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.007; Loconsole D, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094766; Loconsole D, 2021, MICROBIOL RESOUR ANN, V10, DOI 10.1128/MRA.01487-20; Miele M, 2021, AM J TRANSPLANT, V21, P2919, DOI 10.1111/ajt.16702; Nair V, 2021, AM J TRANSPLANT, V21, P2522, DOI 10.1111/ajt.16460; National Institute of Health, COR DIS 2019 COVID 1; Natori Y, 2018, CLIN INFECT DIS, V66, P1698, DOI 10.1093/cid/cix1082; Patel SR, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14329; Pereira MR, 2021, TRANSPL INFECT DIS, DOI 10.1111/tid.13637; Romero-Gomez MP, 2021, J INFECTION, V82, pE35, DOI 10.1016/j.jinf.2020.11.025; Rozen-Zvi B, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.04.028; Sokal A, 2021, CELL, V184, P1201, DOI 10.1016/j.cell.2021.01.050; Vistoli F, 2020, J NEPHROL, V33, P667, DOI 10.1007/s40620-020-00755-8; Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282	35	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							806	10.3390/vaccines9080806			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3FY	34451931	Green Published, gold			2022-04-29	WOS:000689822600001
J	McManus, DP				McManus, Donald P.			The Search for a Schistosomiasis Vaccine: Australia's Contribution	VACCINES			English	Review						Schistosoma; schistosomiasis; vaccine; vaccination; Australia; Australian researchers	ANTI-EMBRYONATION IMMUNITY; REPUBLIC-OF-CHINA; GLUTATHIONE-S-TRANSFERASE; HUMAN BLOOD FLUKE; PROTEOMIC ANALYSIS; BASE-LINE; ZOONOTIC SCHISTOSOMIASIS; EXTRACELLULAR VESICLES; JAPONICUM PARAMYOSIN; FECUNDITY IMMUNITY	Schistosomiasis, a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma, results in considerable human morbidity in sub-Saharan Africa, in particular, but also parts of the Middle East, South America, and Southeast Asia. The anti-schistosome drug praziquantel is efficacious and safe against the adult parasites of all Schistosoma species infecting humans; however, it does not prevent reinfection and the development of drug resistance is a constant concern. The need to develop an effective vaccine is of great importance if the health of many in the developing world is to be improved. Indeed, vaccination, in combination with other public health measures, can provide an invaluable tool to achieve lasting control, leading to schistosomiasis elimination. Australia has played a leading role in schistosomiasis vaccine research over many years and this review presents an overview of some of the significant contributions made by Australian scientists in this important area.	[McManus, Donald P.] QIMR Berghofer Med Res Inst, Div Infect Dis, Mol Parasitol Lab, Brisbane, Qld 4006, Australia		McManus, DP (通讯作者)，QIMR Berghofer Med Res Inst, Div Infect Dis, Mol Parasitol Lab, Brisbane, Qld 4006, Australia.	Don.McManus@qimrberghofer.edu.au		McManus, Donald/0000-0001-6443-1449	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council (NHMRC) of Australia [APP1132975, APP1098244, APP1102926, APP1194462]	This work was supported by a Program Grant (APP1132975), a Project Grant (APP1098244), a Research Fellowship (APP1102926) and an Investigator Grant and Leadership Fellowship (APP1194462) from the National Health and Medical Research Council of Australia.	Bergquist R., 2016, SCHISTOSOMA BIOL PAT, P462; Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; Braschi S, 2006, MEM I OSWALDO CRUZ, V101, P205, DOI 10.1590/S0074-02762006000900032; Cai PF, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-016-1947-x; Cai P, 2016, INT J PARASITOL, V46, P453, DOI 10.1016/j.ijpara.2016.01.002; Cai PF, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004684; Capron A, 2005, TRENDS PARASITOL, V21, P143, DOI 10.1016/j.pt.2005.01.003; Capron A, 1998, PARASITOL TODAY, V14, P379, DOI 10.1016/S0169-4758(98)01322-2; Capron Andre, 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P281, DOI 10.2174/1568008023340587; Carson JP, 2020, MOL BIOCHEM PARASIT, V240, DOI 10.1016/j.molbiopara.2020.111322; Chai M, 2006, CELL MOL LIFE SCI, V63, P919, DOI 10.1007/s00018-005-5578-1; Da'Dara AA, 2008, VACCINE, V26, P3617, DOI 10.1016/j.vaccine.2008.04.080; de Assis RR, 2016, INT J PARASITOL, V46, P411, DOI 10.1016/j.ijpara.2016.04.001; Driguez P, 2016, IMMUNOL CELL BIOL, V94, P52, DOI 10.1038/icb.2015.61; Driguez P, 2016, J INFECT DIS, V213, P122, DOI 10.1093/infdis/jiv356; Driguez P, 2016, EXPERT REV PROTEOMIC, V13, P19, DOI 10.1586/14789450.2016.1116390; Driguez P, 2015, METHODS MOL BIOL, V1201, P221, DOI 10.1007/978-1-4939-1438-8_13; Driguez P, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-4; Du XF, 2021, BIOESSAYS, V43, DOI 10.1002/bies.202000185; Du XF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071565; Eyayu T, 2020, PARASITE EPIDEM CONT, V11, DOI 10.1016/j.parepi.2020.e00176; Garcia E. G., 1982, Acta Medica Philippina, V18, P107; GARCIA E G, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P272; GARCIA EG, 1987, ASIAN PAC J ALLERGY, V5, P137; GARCIA EG, 1989, ACTA TROP, V46, P93, DOI 10.1016/0001-706X(89)90002-8; Gaze S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004033; Gobert GN, 2006, EXP PARASITOL, V114, P160, DOI 10.1016/j.exppara.2006.03.003; Gobert GN, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000600; Gobert GN, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000469; Gobert GN, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-128; Gobert GN, 1997, PARASITOLOGY, V114, P45, DOI 10.1017/S0031182096008001; Gordon CA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001778; Gray DJ, 2007, AM J TROP MED HYG, V77, P866, DOI 10.4269/ajtmh.2007.77.866; Gray DJ, 2014, INT J PARASITOL, V44, P659, DOI 10.1016/j.ijpara.2014.05.005; Gray DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005900; Gray DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004058; Grevelding C.G., 2018, FASEB J, V7, DOI [10.1096/fj.201800725R, DOI 10.1096/fj.201800725R]; Guo JG, 2006, AM J TROP MED HYG, V74, P335, DOI 10.4269/ajtmh.2006.74.335; Guo JG, 2001, AM J TROP MED HYG, V65, P272, DOI 10.4269/ajtmh.2001.65.272; Hagen J, 2015, TRENDS PARASITOL, V31, P324, DOI 10.1016/j.pt.2015.03.009; He Y. K., 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P473; Hosking CG, 2015, INT J PARASITOL, V45, P729, DOI 10.1016/j.ijpara.2015.05.002; Hotez PJ, 2019, TRENDS PARASITOL, V35, P104, DOI 10.1016/j.pt.2018.10.005; Ittiprasert W, 2019, ELIFE, V8, DOI 10.7554/eLife.41337; Jiz Mario Antonio L. II, 2016, Annals of Parasitology, V62, P295, DOI 10.17420/ap6204.64; Keitel WA, 2019, VACCINE, V37, P6500, DOI 10.1016/j.vaccine.2019.08.075; Kifle DW, 2020, INT J PARASITOL, V50, P685, DOI 10.1016/j.ijpara.2020.05.005; Kifle DW, 2020, MOL BIOCHEM PARASIT, V236, DOI 10.1016/j.molbiopara.2020.111264; King M, 2021, EXP PARASITOL, V223, DOI 10.1016/j.exppara.2021.108080; Liu SX, 1997, VET PARASITOL, V69, P39, DOI 10.1016/S0304-4017(96)01092-8; LIU SX, 1995, VACCINE, V13, P603, DOI 10.1016/0264-410X(94)00045-O; LIU SX, 1995, PARASITE IMMUNOL, V17, P335, DOI 10.1111/j.1365-3024.1995.tb00900.x; Lo NC, 2017, LANCET INFECT DIS, V17, pE64, DOI 10.1016/S1473-3099(16)30535-7; Loukas A, 2007, INT J PARASITOL, V37, P257, DOI 10.1016/j.ijpara.2006.12.001; Loukas A, 2011, OMICS, V15, P567, DOI 10.1089/omi.2010.0150; Luo F, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007612; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; McManus DP, 2020, SEMIN IMMUNOPATHOL, V42, P355, DOI 10.1007/s00281-020-00789-x; McManus DP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0013-8; McManus DP, 2010, CLIN MICROBIOL REV, V23, P442, DOI 10.1128/CMR.00044-09; McManus DP, 1998, INT J PARASITOL, V28, P1739, DOI 10.1016/S0020-7519(98)00151-9; McManus DR, 2001, VACCINE, V20, P870, DOI 10.1016/S0264-410X(01)00405-4; McWilliam HEG, 2012, PARASITE IMMUNOL, V34, P276, DOI 10.1111/j.1365-3024.2011.01330.x; McWilliam HEG, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-290; McWilliam HEG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002460; McWilliam HEG, 2013, IMMUNOL CELL BIOL, V91, P477, DOI 10.1038/icb.2013.33; Mekonnen GG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030416; Mitchell G. F., 1991, Advances in Parasitology, V30, P167, DOI 10.1016/S0065-308X(08)60308-5; MITCHELL GF, 1989, PARASITOL TODAY, V5, P34, DOI 10.1016/0169-4758(89)90185-3; MITCHELL GF, 1990, IMMUNOL CELL BIOL, V68, P377, DOI 10.1038/icb.1990.51; MITCHELL GF, 1994, EXP PARASITOL, V79, P546, DOI 10.1006/expr.1994.1116; MITCHELL GF, 1995, MEM I OSWALDO CRUZ, V90, P293, DOI 10.1590/S0074-02761995000200030; MITCHELL GF, 1990, IMMUNOL CELL BIOL, V68, P349, DOI 10.1038/icb.1990.48; Moertel L, 2006, MOL CELL PROBE, V20, P280, DOI 10.1016/j.mcp.2006.02.002; Molehin AJ, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0621-y; Mu Y, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.708952; Mulvenna J, 2010, INT J PARASITOL, V40, P543, DOI 10.1016/j.ijpara.2009.10.002; Nawaratna SSK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15069; Nawaratna SSK, 2014, MOL BIOCHEM PARASIT, V196, P82, DOI 10.1016/j.molbiopara.2014.08.002; Nawaratna SSK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001043; Oey H, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007513; Pearson MS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.663041; Pearson MS, 2020, METHODS MOL BIOL, V2151, P85, DOI 10.1007/978-1-0716-0635-3_8; Pearson MS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00213; Pearson MS, 2005, FEMS IMMUNOL MED MIC, V45, P201, DOI 10.1016/j.femsim.2005.03.009; Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455; Riveau G, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006968; Ross AGP, 2001, CLIN MICROBIOL REV, V14, P270, DOI 10.1128/CMR.14.2.270-295.2001; Sankaranarayanan G, 2021, WELLCOME OPEN RES, V5, P178, DOI [DOI 10.12688/WELLCOMEOPENRES.16031.2, 10.12688/wellcomeopenres.16031.2]; Scott JC, 2000, PARASITOL INT, V49, P289, DOI 10.1016/S1383-5769(00)00058-1; Smit CH, 2016, INFECT IMMUN, V84, P21, DOI 10.1128/IAI.00954-15; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; Smyth D, 2003, INFECT IMMUN, V71, P2548, DOI 10.1128/IAI.71.5.2548-2554.2003; Sotillo J, 2019, ADV EXP MED BIOL, V1154, P411, DOI 10.1007/978-3-030-18616-6_13; Sotillo J, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007362; Sotillo J, 2017, EXPERT REV PROTEOMIC, V14, P171, DOI 10.1080/14789450.2017.1271327; Sotillo J, 2016, INT J PARASITOL, V46, P1, DOI 10.1016/j.ijpara.2015.09.002; Sotillo J, 2015, INT J PARASITOL, V45, P505, DOI 10.1016/j.ijpara.2015.03.004; Stroehlein AJ, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz108; Tebeje BM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1799-4; Tedla BA, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008213; Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430; Tran MH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000840; Verissimo CD, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3403-1; Wang LD, 2009, NEW ENGL J MED, V360, P121, DOI 10.1056/NEJMoa0800135; Wendt GR, 2018, ELIFE, V7, DOI [10.7554/eLife.33221, 10.7554/elife.33221]; Williams GM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00645; Williams GM, 2002, ACTA TROP, V82, P253, DOI 10.1016/S0001-706X(02)00017-7; Wilson RA, 2020, PARASITOLOGY, V147, P507, DOI 10.1017/S0031182020000049; WRIGHT MD, 1991, PARASITOL TODAY, V7, P56, DOI 10.1016/0169-4758(91)90191-P; You H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.599014; You H, 2021, FASEB J, V35, DOI 10.1096/fj.202001745RR; You H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103088; You H, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3020068; You H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082426; You H, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003730; You H, 2015, PARASITOLOGY, V142, P271, DOI 10.1017/S0031182014001310; You H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003254; You H, 2012, INT J PARASITOL, V42, P801, DOI 10.1016/j.ijpara.2012.06.002; You H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009868; Young ND, 2012, NAT GENET, V44, P221, DOI 10.1038/ng.1065; Zhang DM, 2006, PARASITE IMMUNOL, V28, P77, DOI 10.1111/j.1365-3024.2005.00814.x; Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140	124	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							872	10.3390/vaccines9080872			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9CU	34451997	Green Published, gold			2022-04-29	WOS:000690220000001
J	Peletta, A; Prompetchara, E; Tharakhet, K; Kaewpang, P; Buranapraditkun, S; Techawiwattanaboon, T; Jbilou, T; Krangvichian, P; Sirivichayakul, S; Manopwisedjaroen, S; Thitithanyanont, A; Patarakul, K; Ruxrungtham, K; Ketloy, C; Borchard, G				Peletta, Allegra; Prompetchara, Eakachai; Tharakhet, Kittipan; Kaewpang, Papatsara; Buranapraditkun, Supranee; Techawiwattanaboon, Teerasit; Jbilou, Tayeb; Krangvichian, Pratomporn; Sirivichayakul, Sunee; Manopwisedjaroen, Suwimon; Thitithanyanont, Arunee; Patarakul, Kanitha; Ruxrungtham, Kiat; Ketloy, Chutitorn; Borchard, Gerrit			DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice	VACCINES			English	Article						DNA vaccines; SARS-CoV-2; cationic liposomes; lipoplexes; immunogenicity	ACUTE-RESPIRATORY-SYNDROME; VIRUS; LIPOSOMES; IMMUNOGENICITY; BINDING; SIZE	In view of addressing the global necessity of an effective vaccine in the SARS-CoV-2 pandemic, a plasmid DNA vaccine, expressing for the spike (S) protein and formulated in lipoplexes, was manufactured and tested for in vitro transfection and in vivo immunogenicity. Blank cationic liposomes of 130.9 +/- 5.8 nm in size and with a zeta potential of +48 +/- 12 mV were formulated using the thin-film layer rehydration method. Liposomes were complexed with pCMVkan-S at different N/P ratios. Ratios of 0.25:1 and 1:1 were selected according to their complex stability and controlled size compared to other ratios and tested in vitro for transfection studies and in vivo for immunogenicity. Both selected formulations showed enhanced neutralizing antibody responses compared to pCMVkan-S injected alone, as well as an increased T cell response. The titers observed were similar to those of intramuscular electroporation (IM-EP), which was set as an efficacy goal.	[Peletta, Allegra; Jbilou, Tayeb; Borchard, Gerrit] Univ Geneva, Inst Pharmaceut Sci Western Switzerland ISPSO, Sect Pharmaceut Sci, CH-1211 Geneva, Switzerland; [Prompetchara, Eakachai; Tharakhet, Kittipan; Buranapraditkun, Supranee; Krangvichian, Pratomporn; Ketloy, Chutitorn] Chulalongkorn Univ, Dept Lab Med, Fac Med, Bangkok 10330, Thailand; [Prompetchara, Eakachai; Tharakhet, Kittipan; Kaewpang, Papatsara; Buranapraditkun, Supranee; Techawiwattanaboon, Teerasit; Krangvichian, Pratomporn; Sirivichayakul, Sunee; Ruxrungtham, Kiat; Ketloy, Chutitorn] Chulalongkorn Univ, Chula Vaccine Res Ctr, Chula VRC, Ctr Excellence Vaccine Res & Dev,Fac Med, Bangkok 10330, Thailand; [Buranapraditkun, Supranee] Chulalongkorn Univ, Fac Med, Thai Pediat Gastroenterol Hepatol & Immunol TPGHA, Bangkok 10330, Thailand; [Techawiwattanaboon, Teerasit] Chulalongkorn Univ, Dept Microbiol, Fac Med, Bangkok 10330, Thailand; [Krangvichian, Pratomporn] Chulalongkorn Univ, Grad Sch, Multidisciplinary Program Med Microbiol, Bangkok 10330, Thailand; [Manopwisedjaroen, Suwimon; Thitithanyanont, Arunee] Mahidol Univ, Dept Microbiol, Fac Sci, Bangkok 10400, Thailand		Borchard, G (通讯作者)，Univ Geneva, Inst Pharmaceut Sci Western Switzerland ISPSO, Sect Pharmaceut Sci, CH-1211 Geneva, Switzerland.; Ketloy, C (通讯作者)，Chulalongkorn Univ, Dept Lab Med, Fac Med, Bangkok 10330, Thailand.; Ketloy, C (通讯作者)，Chulalongkorn Univ, Chula Vaccine Res Ctr, Chula VRC, Ctr Excellence Vaccine Res & Dev,Fac Med, Bangkok 10330, Thailand.	allegra.peletta@unige.ch; Eakachai.p@chula.ac.th; kankittipan12@hotmail.com; Kaewpangpapatsara@gmail.com; bsuprane2001@yahoo.com; teerasit.kku@gmail.com; tayeb.jbilou@unige.ch; Pratomporn88@gmail.com; Sunee.S@chula.ac.th; swiboonut@gmail.com; arunee.thi@mahidol.edu; kpatarakul@gmail.com; rkiatchula@gmail.com; chutitorn.k@chula.ac.th; gerrit.borchard@unige.ch	Thitithanyanont, Arunee/AAN-4383-2021	Thitithanyanont, Arunee/0000-0002-9756-4763; Buranapraditkun, Supranee/0000-0001-9971-4318; Manopwisedjaroen, Suwimon/0000-0002-7571-8733; techawiwattanaboon, teerasit/0000-0002-8188-9934	National Vaccine Institute (NVI) [2563.1/8]; National Research Council of Thailand NRCTNational Research Council of Thailand (NRCT); Emerging Infectious Diseases and Vaccines Cluster; Ratchadapisek Sompoch Endowment Fund (2021), Chulalongkorn University [764002-HE04]; Second Century Fund (C2F), Chulalongkorn University; Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn UniversityChulalongkorn University [RA-MF-28/64]; Ratchadapiseksompote Endowment Fund [DNS 63_031_30_009_2]	This study was funded by National Vaccine Institute (NVI), grant No. 2563.1/8, National Research Council of Thailand NRCT, Emerging Infectious Diseases and Vaccines Cluster, Ratchadapisek Sompoch Endowment Fund (2021), Chulalongkorn University (764002-HE04), the Second Century Fund (C2F), Chulalongkorn University and Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University, grant No. RA-MF-28/64. EP was also supported by the Grants for Development of New Faculty Staff, Ratchadapiseksompote Endowment Fund, grant No. DNS 63_031_30_009_2.	Anna Marchetti P.H, 2020, ANTIB REP, V3, P192, DOI [10.24450/journals/abrep.2020.e192, DOI 10.24450/JOURNALS/ABREP.2020.E192]; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Choudhury A, 2020, J MED VIROL, V92, P2105, DOI 10.1002/jmv.25987; Christensen D, 2011, EXPERT REV VACCINES, V10, P513, DOI [10.1586/erv.11.17, 10.1586/ERV.11.17]; Crommelin DJA, 2021, J PHARM SCI-US, V110, P997, DOI 10.1016/j.xphs.2020.12.006; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Even-Chen S, 2012, CHEM PHYS LIPIDS, V165, P414, DOI 10.1016/j.chemphyslip.2012.03.006; Fitzpatrick Z, 2018, MOL THER-METH CLIN D, V9, P119, DOI 10.1016/j.omtm.2018.02.003; Flingai S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00354; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Gary EN, 2020, CURR OPIN IMMUNOL, V65, P21, DOI 10.1016/j.coi.2020.01.006; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Heidari Z, 2017, PHARM RES-DORDR, V34, P1796, DOI 10.1007/s11095-017-2187-2; Jonathan Corum S.-L.W., 2021, CORONAVIRUS VACCINE; Kastner E, 2014, INT J PHARMACEUT, V477, P361, DOI 10.1016/j.ijpharm.2014.10.030; Khan Kishwar Hayat, 2013, Germs, V3, P26, DOI 10.11599/germs.2013.1034; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Ledwith B J, 2000, Dev Biol (Basel), V104, P33; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Meyer O, 2000, EUR J PHARM BIOPHARM, V50, P353, DOI 10.1016/S0939-6411(00)00115-6; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Prompetchara E, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248007; Prompetchara E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092643; Shanmugaraj B, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.589995; Sheets RL, 2006, TOXICOL SCI, V91, P620, DOI 10.1093/toxsci/kfj170; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Wang W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4704; WHO, 2021, DRAFT LANDSC COVID 1; WHO, 2020, WHO DIR GEN OP REM M; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493	43	2	2	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							874	10.3390/vaccines9080874			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6YD	34451998	Green Published, gold			2022-04-29	WOS:000690072700001
J	Jin, Q; Raza, SH; Yousaf, M; Zaman, U; Siang, JMLD				Jin, Qiang; Raza, Syed Hassan; Yousaf, Muhammad; Zaman, Umer; Siang, Jenny Marisa Lim Dao			Can Communication Strategies Combat COVID-19 Vaccine Hesitancy with Trade-Off between Public Service Messages and Public Skepticism? Experimental Evidence from Pakistan	VACCINES			English	Article						COVID-19 vaccine; vaccine hesitancy; public service message; health belief model; affect theory; public skepticism; willingness to take COVID-19 vaccine	HEALTH BELIEF MODEL; CONFIRMATORY FACTOR-ANALYSIS; COVERAGE; KNOWLEDGE; VARIABLES; CANCER	The COVID-19 pandemic may have reached a turning point as the World Health Organization and the global community of nations step up plans for mass vaccination campaigns. However, the COVID-19 vaccine-related conspiracy theories (e.g., falsehoods about birth control, women infertility, surveillance, and microchip humanity, etc.) have built new momentum for vaccine hesitancy. To this end, several nations worldwide, including Pakistan, are struggling to boost public trust and enthusiasm to get vaccinated, especially in an anxious and complicated atmosphere propelled by multiple, new and the deadliest variants of COVID-19. To address this critical research gap during these intensifying conditions of vaccine hesitancy, the present study makes the first attempt to explore the potential effects of various communication strategies, including public service message (safety benefits versus fear appraisals), media types (i.e., traditional versus digital), self-efficacy, perceived benefits and threats (susceptibility and severity), on the willingness to get vaccinated for COVID-19. Importantly, the underlying effects of public skepticism (in a moderating role) on these relationships were empirically examined. Using four fictitious COVID-19 immunization campaigns in a series of experiments with 2 (media type: traditional vs. digital) X 2 (service attribute: health and safety benefits vs. fear) message frames (represented as Group one to Group four), the findings identified fear appraisal as the most viable communication strategy in combating vaccine hesitancy. Moreover, public skepticism negatively moderated the effects of media types and public service message attributes on willingness to get vaccinated in relatively high (i.e., Group two), moderate (i.e., Group one and four), and low intensities (i.e., Group three). The pioneering findings of this research offer new strategic insights for the global health authorities and vaccine promoters to proactively address the downward spiral of people's willingness to take the COVID-19 vaccine.	[Jin, Qiang] Hebei Univ, Intercultural Commun Res Ctr, Baoding 071000, Peoples R China; [Raza, Syed Hassan] Bahauddin Zakariya Univ, Dept Commun Studies, Multan 66000, Pakistan; [Yousaf, Muhammad] Univ Gujrat, Ctr Media & Commun Studies, Gujrat 50700, Pakistan; [Zaman, Umer] Woosong Univ, Endicott Coll Int Studies, Daejeon 34606, South Korea; [Siang, Jenny Marisa Lim Dao] Natl Cent Univ, Sch Management, Dept Business Adm, Taoyuan 32001, Taiwan		Zaman, U (通讯作者)，Woosong Univ, Endicott Coll Int Studies, Daejeon 34606, South Korea.	jinqiang@hbu.cn; hassansherazi@bzu.edu.pk; m.yousaf@uog.edu.pk; umerzaman@endicott.ac.kr; 109481606@cc.ncu.edu.tw	Raza, Syed Hassan/I-7274-2017; Yousaf, Muhammad/AAZ-4017-2020	Raza, Syed Hassan/0000-0002-1318-7818; Yousaf, Muhammad/0000-0003-3203-2966; Zaman, Umer/0000-0002-3729-3543; Lim Dao Saing, Jenny Marisa/0000-0003-1082-6108			Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Alhazmi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060674; Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2019.02.033, 10.1016/j.jiph.2020.02.033]; Alsulaiman S.A, 2018, J INT CRISIS RISK CO, V1, P3, DOI [10.30658/jicrcr.1.1.3, DOI 10.30658/JICRCR.1.1.3]; Artime O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71231-3; Baines A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050421; Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3; Basch CH, 2017, CHILD CARE HLTH DEV, V43, P499, DOI 10.1111/cch.12442; Basch CH, 2019, HUM VACC IMMUNOTHER, V15, P1476, DOI 10.1080/21645515.2018.1560774; BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004; Black W., 2019, GREAT FACILITATOR, DOI [10.1007/978-3-030-06031-2_16, DOI 10.1007/978-3-030-06031-2_16]; Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Carpenter CJ, 2010, HEALTH COMMUN, V25, P661, DOI 10.1080/10410236.2010.521906; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Chang CC, 2010, INT J ADVERT, V29, P765, DOI 10.2501/S0265048710201452; Chen L, 2021, HEALTH COMMUN, V36, P1343, DOI 10.1080/10410236.2020.1751384; De Meulenaer S, 2018, HEALTH COMMUN, V33, P291, DOI 10.1080/10410236.2016.1266573; Diaz AA, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100860; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Ejaz W, 2021, HEALTH RISK SOC, V23, P162, DOI 10.1080/13698575.2021.1929865; Fatima M., 2020, MEDIA ASIA, V47, P75, DOI [10.1080/01296612.2020.1817264, DOI 10.1080/01296612.2020.1817264]; Geuens M, 2017, J ADVERTISING, V46, P83, DOI 10.1080/00913367.2016.1225233; Green E.C., 2020, WILEY ENCY HLTH PSYC, P211, DOI [10.1002/9781119057840.ch68, DOI 10.1002/9781119057840.CH68]; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Imhoff R, 2020, SOC PSYCHOL PERS SCI, V11, P1110, DOI 10.1177/1948550620934692; Jones CL, 2015, HEALTH COMMUN, V30, P566, DOI 10.1080/10410236.2013.873363; Latkin CA, 2021, SOC SCI MED, V270, DOI 10.1016/j.socscimed.2021.113684; LAWSHE CH, 1975, PERS PSYCHOL, V28, P563, DOI 10.1111/j.1744-6570.1975.tb01393.x; Lazic A, 2021, PUBLIC UNDERST SCI, V30, P644, DOI 10.1177/09636625211011881; Lee EWJ, 2013, J RISK RES, V16, P879, DOI 10.1080/13669877.2012.761264; Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604; Li L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050445; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Luquis RR, 2019, INT J HEALTH PROMOT, V57, P37, DOI 10.1080/14635240.2018.1549958; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; McWhirter JE, 2016, J HEALTH COMMUN, V21, P424, DOI 10.1080/10810730.2015.1095819; Motta M., 2021, FRONTIERS POLITICAL, V3, P1, DOI [DOI 10.3389/FPOS.2021.630133, 10.3389/fpos.2021.630133]; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Paek H.J., 2017, RISK PERCEPTIONS RIS, P1, DOI [DOI 10.1093/ACREFORE/9780190228613.013.283, 10.1093/acrefore/9780190228613.013.283]; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Perry JL, 2015, MEAS PHYS EDUC EXERC, V19, P12, DOI 10.1080/1091367X.2014.952370; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Quick BL, 2010, HEALTH COMMUN, V25, P247, DOI 10.1080/10410231003698929; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Raza SH, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105264; Raza SH, 2018, J ASIAN PAC COMMUN, V28, P61, DOI 10.1075/japc.00004.raz; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Sallam M. A. A., 2012, INT BUSINESS RES, V5, P55, DOI [10.5539/ibr.v5n4p55, DOI 10.5539/IBR.V5N4P55]; Shafer A, 2018, HEALTH COMMUN, V33, P833, DOI 10.1080/10410236.2017.1315678; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Simonetti V, 2021, J CLIN NURS, V30, P1360, DOI 10.1111/jocn.15685; Smit B, 2016, CORP OWNERSH CONTROL, V13, P393, DOI [10.22495/cocv13i3c2p11, DOI 10.22495/COCV13I3C2P11]; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sulat JS, 2018, HEALTH EDUC, V118, P499, DOI 10.1108/HE-05-2018-0027; Van Reijmersdal, 2012, J MARK COMMUN, V18, P39, DOI [DOI 10.1080/13527266.2011.620764, 10.1080/13527266.2011.620764]; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Yoo SW, 2018, HEALTH COMMUN, V33, P32, DOI 10.1080/10410236.2016.1242033; Yuen KF, 2020, J TRANSP HEALTH, V16, DOI 10.1016/j.jth.2019.100810; Zhong B, 2021, COMPUT HUM BEHAV, V114, DOI 10.1016/j.chb.2020.106524; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	65	8	8	4	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							757	10.3390/vaccines9070757			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4VS	34358173	Green Published, gold			2022-04-29	WOS:000676911900001
J	Mumtaz, GR; El-Jardali, F; Jabbour, M; Harb, A; Abu-Raddad, LJ; Makhoul, M				Mumtaz, Ghina R.; El-Jardali, Fadi; Jabbour, Mathilda; Harb, Aya; Abu-Raddad, Laith J.; Makhoul, Monia			Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out	VACCINES			English	Article						SARS-CoV-2; COVID-19; coronavirus; epidemiology; vaccine; mathematicalmodel; Lebanon	SARS-COV-2 INFECTION	Four months into the SARS-CoV-2 vaccination campaign, only 10.7% of the Lebanese population have received at least one dose, raising serious concerns over the speed of vaccine roll-out and its impact in the event of a future surge. Using mathematical modeling, we assessed the short-term impact of various vaccine roll-out scenarios on SARS-CoV-2 epidemic course in Lebanon. At current population immunity levels, estimated by the model at 40% on 15 April 2021, a large epidemic wave is predicted if all social distancing restrictions are gradually eased and variants of concern are introduced. Reaching 80% vaccine coverage by the end of 2021 will flatten the epidemic curve and will result in a 37% and 34% decrease in the peak daily numbers of severe/critical disease cases and deaths, respectively; while reaching intermediate coverage of 40% will result in only a 10-11% decrease in each. Reaching 80% vaccine coverage by August would prevent twice as many severe/critical disease cases and deaths than if it were reached by December. Easing restrictions over a longer duration resulted in more favorable vaccination impact. In conclusion, for vaccination to have impact in the short-term, scale-up has to be rapid and reach high coverage (at least 70%), while sustaining social distancing measures during roll-out. At current vaccination pace, this is unlikely to be achieved. Concerted efforts need to be made to overcome local challenges and substantially scale up vaccination to avoid a surge that the country, with its multiple crises and limited health-care capacity, is largely unprepared for.	[Mumtaz, Ghina R.] Amer Univ Beirut, Fac Hlth Sci, Dept Epidemiol & Populat Hlth, Beirut 11072020, Lebanon; [Mumtaz, Ghina R.] Amer Univ Beirut, Fac Med, Ctr Infect Dis Res, Beirut 11072020, Lebanon; [El-Jardali, Fadi; Jabbour, Mathilda; Harb, Aya] Amer Univ Beirut, Fac Hlth Sci, Dept Hlth Management & Policy, Beirut 11072020, Lebanon; [El-Jardali, Fadi; Jabbour, Mathilda; Harb, Aya] Amer Univ Beirut, Fac Hlth Sci, Knowledge Policy Ctr K2P, Beirut 11072020, Lebanon; [El-Jardali, Fadi] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8N 3Z5, Canada; [Abu-Raddad, Laith J.; Makhoul, Monia] Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha 24144, Qatar; [Abu-Raddad, Laith J.; Makhoul, Monia] Cornell Univ, Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10022 USA		Mumtaz, GR (通讯作者)，Amer Univ Beirut, Fac Hlth Sci, Dept Epidemiol & Populat Hlth, Beirut 11072020, Lebanon.; Mumtaz, GR (通讯作者)，Amer Univ Beirut, Fac Med, Ctr Infect Dis Res, Beirut 11072020, Lebanon.; Makhoul, M (通讯作者)，Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha 24144, Qatar.; Makhoul, M (通讯作者)，Cornell Univ, Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10022 USA.	gm15@aub.edu.lb; fe08@aub.edu.lb; mj93@aub.edu.lb; ah291@aub.edu.lb; lja2002@qatar-med.cornell.edu; mom2039@qatar-med.cornell.edu		Abu-Raddad, Laith/0000-0003-0790-0506; Mumtaz, Ghina/0000-0003-4332-4702	Global Challenges Research Fund (GCRF) through UKRI/ESRC [ES/P010873/1]; Qatar National Research Fund (Qatar Foundation) [12S-0216-190094, 9-040-3-008]	This paper was supported with funding from the Global Challenges Research Fund (GCRF) through UKRI/ESRC for the 'RECAP' project (ES/P010873/1). The developed mathematical models were made possible by NPRP grant number 9-040-3-008 (Principal investigator: LJA) and NPRP grant number 12S-0216-190094 (Principal investigator: LJA) from the Qatar National Research Fund (a member of Qatar Foundation; https://www.qnrf.org, accessed on 22 June 2021). The statements made herein are solely the responsibility of the authors.	Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Abu-Raddad LJ, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100861; Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; [Anonymous], 2021, LANCET, V397, P1683, DOI 10.1016/S0140-6736(21)01052-7; [Anonymous], 2019, LANG TECHN COMP; Ayoub Houssein H, 2021, BMJ Innov, V7, P327, DOI 10.1136/bmjinnov-2021-000677; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies Nicholas G, 2021, Science, V372, DOI 10.1126/science.abg3055; European Centre for Disease Prevention and Control, 2021, OVERV IMPL COVID 19; Fouad FM, 2021, CONFL HEALTH, V15, DOI 10.1186/s13031-021-00349-6; Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Halsey, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab068, DOI 10.1093/CID/CIAB068]; He WQ, 2020, J MED VIROL, V92, P2543, DOI 10.1002/jmv.26041; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Lauring AS, 2021, JAMA-J AM MED ASSOC, V325, P529, DOI 10.1001/jama.2020.27124; Lebanon COVID-19 Dashboard, KEY IND BAS PUBL; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Makhoul M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030223; Makhoul M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040668; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; MIDAS Online COVID-19 Portal, COVID 19 PAR EST BAS; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; Tande AJ, 2022, CLIN INFECT DIS, V74, P59, DOI 10.1093/cid/ciab229; U.S. Food and Drug Administration, JANSS COVID 19 VACC; UNHCR, 2020, SYR REG REF RESP; United Nations Department of Economic and Social Affairs Population Dynamics, 2019 REV WORLD POP P; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wajnberg A, 2020, LANCET MICROBE, V1, pE283, DOI 10.1016/S2666-5247(20)30120-8; WHO, 2021, WHY ARE THER EXTR DO; World Health Organization, INT GUID CERT CLASS; World Health Organization (WHO), CLIN MAN COVID 19; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Younuskunju, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1846, DOI 10.1093/CID/CIAA1846]	41	0	0	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							697	10.3390/vaccines9070697			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8DG	34202107	Green Published, gold, Green Submitted			2022-04-29	WOS:000677134300001
J							Vaccines Editorial Off	The Safety of COVID-19 Vaccinations-We Should Rethink the Policy (Expression of Concern of Vol 9, art no 693, 2021)	VACCINES			English	Expression of Concern									[Vaccines Editorial Off] MDPI, St Alban Anlage 66, CH-4052 Basel, Switzerland		MDPI, St Alban Anlage 66, CH-4052 Basel, Switzerland.						Walach H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070693	1	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							705	10.3390/vaccines9070705			1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7FC		Green Published, gold			2022-04-29	WOS:000677071500001
J	Adeniyi, OV; Stead, D; Singata-Madliki, M; Batting, J; Wright, M; Jelliman, E; Abrahams, S; Parrish, A				Adeniyi, Oladele Vincent; Stead, David; Singata-Madliki, Mandisa; Batting, Joanne; Wright, Matthew; Jelliman, Eloise; Abrahams, Shareef; Parrish, Andrew			Acceptance of COVID-19 Vaccine among the Healthcare Workers in the Eastern Cape, South Africa: A Cross Sectional Study	VACCINES			English	Article						Eastern Cape; healthcare workers; SARS-CoV-2; South Africa; vaccine acceptance	HESITANCY; INTENTION	Background: This study assesses the perceptions and acceptance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination. It also examines its influencing factors among the healthcare workers (HCWs) in the Eastern Cape, South Africa. Methods: In this cross-sectional study performed in November and December 2020, a total of 1308 HCWs from two large academic hospitals participated in the Eastern Cape Healthcare Workers Acquisition of SARS-CoV-2 (ECHAS) study. Validated measures of vaccine hesitancy were explored using a questionnaire. Logistic regression was used to identify the determinants of vaccine hesitancy. Results: The majority were nurses (45.2%), and at risk for unfavourable Covid-19 outcome, due to obesity (62.9%) and having direct contact with individuals confirmed to have Covid-19 (77.1%). The overall acceptance of SARS-CoV-2 vaccine was 90.1%, which differed significantly by level of education. Individuals with lower educational attainment (primary and secondary education) and those with prior vaccine refusal were less likely to accept the SARS-CoV-2 vaccine. However, positive perceptions about the SARS-CoV-2 vaccine were independently associated with vaccine acceptance. Conclusions: The high level of acceptance of SARS-CoV-2 vaccine is reassuring; however, HCWs with a lower level of education and those with prior vaccine refusal should be targeted for further engagements to address their concerns and fears.	[Adeniyi, Oladele Vincent] Walter Sisulu Univ, Cecilia Makiwane Hosp, Dept Family Med & Rural Hlth, East London Hosp Complex, ZA-5219 East London, South Africa; [Stead, David; Wright, Matthew; Parrish, Andrew] Walter Sisulu Univ, Cecilia Makiwane & Frere Hosp, Dept Internal Med, ZA-5219 East London, South Africa; [Singata-Madliki, Mandisa; Batting, Joanne] Univ Witwatersrand, Univ Ft Hare, Frere Hosp, Dept Obstet & Gynaecol,Effect Care Res Unit, ZA-5200 East London, South Africa; [Jelliman, Eloise] Walter Sisulu Univ, Frere Hosp, Dept Radiol, ZA-5200 East London, South Africa; [Abrahams, Shareef] Natl Hlth Lab Serv, Dept Pathol, Div Med Microbiol, ZA-6001 Port Elizabeth, South Africa		Adeniyi, OV (通讯作者)，Walter Sisulu Univ, Cecilia Makiwane Hosp, Dept Family Med & Rural Hlth, East London Hosp Complex, ZA-5219 East London, South Africa.	oadeniyi@wsu.ac.za; dfstead@gmail.com; mandisa.singata@gmail.com; joannebatting@hotmail.com; mattymoowright@gmail.com; jellimaneloise@gmail.com; shareef.abrahams@nhls.ac.za; andygp@mweb.co.za			Walter Sisulu University; South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [0000062597106824]	This project is supported by the Walter Sisulu University research proceeds for Oladele Vincent Adeniyi and Andrew Parrish. Additional support was obtained from the South African Medical Research Council through grant awarded to the ECHAS Study Team (MRC-NIH AED Project: 0000062597106824) led by Oladele Vincent Adeniyi.	Adeniyi OV, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010323; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632; Davies Mary-Ann, 2020, medRxiv, DOI 10.1101/2020.07.02.20145185; de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6; Di Giuseppe G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030275; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eastern Cape DoH, 2021, 321 E CAP DOH; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Iversen K, 2020, LANCET INFECT DIS, V20, P1401, DOI 10.1016/S1473-3099(20)30589-2; Jacobson RM, 2015, MAYO CLIN PROC, V90, P1562, DOI 10.1016/j.mayocp.2015.09.006; Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lehohla, 2014, E CAPE STAT S AFRICA; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Pugliese-Garcia M, 2018, VACCINE, V36, P5617, DOI [10.1016/j.vaccine.2017.10.108, 10.1016/j.vaccine.2018.07.042]; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; WHO, 1995, WHO TECHN REP SER, P854; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wiley KE, 2013, VACCINE, V31, P3972, DOI 10.1016/j.vaccine.2013.06.015	31	11	11	10	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							666	10.3390/vaccines9060666			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0SD	34207018	Green Published, gold			2022-04-29	WOS:000666285500001
J	Barrios, Y; Franco, A; Sanchez-Machin, I; Poza-Guedes, P; Gonzalez-Perez, R; Matheu, V				Barrios, Yvelise; Franco, Andres; Sanchez-Machin, Inmaculada; Poza-Guedes, Paloma; Gonzalez-Perez, Ruperto; Matheu, Victor			The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals	VACCINES			English	Article						SARS-CoV-2; DTH; skin test; delayed-type hypersensitivity; T-cell response; COVID-19; cell response; humoral response	COVID-19	Background: Monitoring cellular immune responses elicited in vaccinated individuals is highly complicated. Methods: 28 individuals participated during the vaccination process with 12 BNT162b2 mRNA (Pfizer) vaccine. Specific anti-RBD IgG using a classic ELISA was performed in days 10 and 20 (after one dose of the vaccine) and on day 35 (after two vaccine doses) in serum samples of all participants. In parallel, DTH (delayed-type hypersensitivity) Skin Test using S protein was performed before (11/28) and after two doses (28/28) of the vaccine. Results: 6/28 individuals were considered positive for the specific anti-RBD IgG positive at day 10, whereas all 28 individuals were positive at day 20. Moreover, 28/28 individuals increased the OD ratios at day 36 (2 doses). DTH cutaneous test was performed on 11/28 participants at day 20 (1 dose) showing 8/11 a positive reaction at 12 h. DTH of all participants was performed on day 36 (2 doses), showing 28/28 positive reactions at 12 h. Conclusion: This report describes the first publication of the results obtained using an in vivo method, the classical DTH response to the Spike protein to assess T-cell immune responses in vaccinated individuals. This affordable and simple test would help to answer basic immunogenicity questions on large-scale population vaccine studies.	[Barrios, Yvelise; Franco, Andres] Hosp Univ Canarias, Dept Immunol, San Cristobal De La Lagu 38320, Spain; [Sanchez-Machin, Inmaculada; Poza-Guedes, Paloma; Gonzalez-Perez, Ruperto; Matheu, Victor] Hosp Univ Canarias, Dept Allergy, San Cristobal De La Lagu 38320, Spain		Matheu, V (通讯作者)，Hosp Univ Canarias, Dept Allergy, San Cristobal De La Lagu 38320, Spain.	ybarpin@gobiernodecanarias.org; aframas@gobiernodecanarias.org; msanmack@gobiernodecanarias.org; ppozgue@gobiernodecanarias.org; rgonperl@gobiernodecanarias.org; vmatheu@ull.edu.es	Ruperto, González-Pérez/AAE-6200-2022; Poza-Guedes, Paloma/AAE-6848-2022; Matheu, Victor/AAU-3043-2020; Barrios, Yvelise/AGR-9501-2022	Poza-Guedes, Paloma/0000-0001-8516-6648; Matheu, Victor/0000-0002-0469-800X; Barrios, Yvelise/0000-0002-6994-2034; Sanchez-Machin, Inmaculada/0000-0003-0109-8735			Badaro R, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01068-6; Barrios Y, 2021, CLIN IMMUNOL, V226, DOI 10.1016/j.clim.2021.108730; Borah P, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.635245; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Meyer B, 2020, Clin Microbiol Infect, V26, P1386, DOI 10.1016/j.cmi.2020.06.024; Nagar Rahul, 2006, Indian J Dermatol Venereol Leprol, V72, P461; Pavia CS, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115148; POULTER LW, 1982, CELL IMMUNOL, V74, P358, DOI 10.1016/0008-8749(82)90036-3; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Schwarzkopf Sina, 2021, Emerg Infect Dis, V27, DOI 10.3201/2701.203772; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Vidal C, 2018, J INVEST ALLERG CLIN, V28, P1, DOI 10.18176/jiaci.0267; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	17	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							575	10.3390/vaccines9060575			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4AW	34205888	gold, Green Published			2022-04-29	WOS:000666511000001
J	Carpio, KL; Barrett, ADT				Carpio, Kassandra L.; Barrett, Alan D. T.			Flavivirus NS1 and Its Potential in Vaccine Development	VACCINES			English	Review						flavivirus; NS1; vaccine	NONSTRUCTURAL PROTEIN NS1; WEST-NILE-VIRUS; JAPANESE ENCEPHALITIS-VIRUS; YELLOW-FEVER VIRUS; TICK-BORNE ENCEPHALITIS; DISULFIDE BOND ARRANGEMENT; N-LINKED GLYCOSYLATION; B-CELL EPITOPES; DENGUE VIRUS; MONOCLONAL-ANTIBODIES	The Flavivirus genus contains many important human pathogens, including dengue, Japanese encephalitis (JE), tick-borne encephalitis (TBE), West Nile (WN), yellow fever (YF) and Zika (ZIK) viruses. While there are effective vaccines for a few flavivirus diseases (JE, TBE and YF), the majority do not have vaccines, including WN and ZIK. The flavivirus nonstructural 1 (NS1) protein has an unusual structure-function because it is glycosylated and forms different structures to facilitate different roles intracellularly and extracellularly, including roles in the replication complex, assisting in virus assembly, and complement antagonism. It also plays a role in protective immunity through antibody-mediated cellular cytotoxicity, and anti-NS1 antibodies elicit passive protection in animal models against a virus challenge. Historically, NS1 has been used as a diagnostic marker for the flavivirus infection due to its complement fixing properties and specificity. Its role in disease pathogenesis, and the strong humoral immune response resulting from infection, makes NS1 an excellent target for inclusion in candidate flavivirus vaccines.	[Carpio, Kassandra L.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Barrett, Alan D. T.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Barrett, Alan D. T.] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA		Barrett, ADT (通讯作者)，Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.; Barrett, ADT (通讯作者)，Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.	klcarpio@utmb.edu; abarrett@utmb.edu			Sealy and Smith Foundation	This work was funded in part by a grant from the Sealy and Smith Foundation.	Akey DL, 2015, BIOESSAYS, V37, P489, DOI 10.1002/bies.201400182; Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749; Annamalai AS, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030112; Annamalai AS, 2017, J VIROL, V91, DOI [10.1128/JVI.01348-17, 10.1128/jvi.01348-17]; [Anonymous], 2018, LANCET INFECT DIS, V18, P123, DOI [10.1016/S1473-3099(17)30752-1, 10.1016/S1473-3099(18)30023-9]; Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545; Bailey MJ, 2019, MBIO, V10, DOI [10.1128/mBio.02861-18, 10.1128/mbio.02861-18]; Barrett ADT, 2017, VACCINE, V35, P5951, DOI 10.1016/j.vaccine.2017.03.032; Biering SB, 2021, SCIENCE, V371, P194, DOI 10.1126/science.abc0476; Wang B, 2009, VIRUS RES, V141, P90, DOI 10.1016/j.virusres.2009.01.004; Blitvich BJ, 2001, J GEN VIROL, V82, P2251, DOI 10.1099/0022-1317-82-9-2251; BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902; Brault AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15039-8; Bugrysheva JV, 2001, VIRUS RES, V76, P161, DOI 10.1016/S0168-1702(01)00274-X; Butrapet S, 2000, J VIROL, V74, P3011, DOI 10.1128/JVI.74.7.3011-3019.2000; CANE PA, 1988, J GEN VIROL, V69, P1241, DOI 10.1099/0022-1317-69-6-1241; Chan KWK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat7726; Chang JH, 2009, ANTIMICROB AGENTS CH, V53, P1501, DOI 10.1128/AAC.01457-08; Chao CH, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007625; Charles A., 2001, IMMUNOBIOLOGY IMMUNE, V5th; Chen CL, 2013, J IMMUNOL, V191, P1744, DOI 10.4049/jimmunol.1201976; Chen HR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004828; Choy MM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107617; Chuang YC, 2014, J VIROL, V88, P13759, DOI 10.1128/JVI.02166-14; Chuang YC, 2011, J IMMUNOL, V187, P6483, DOI 10.4049/jimmunol.1102218; Chung KM, 2006, J VIROL, V80, P1340, DOI 10.1128/JVI.80.3.1340-1351.2006; Chung KM, 2007, J VIROL, V81, P9551, DOI 10.1128/JVI.00879-07; Clark DC, 2007, J GEN VIROL, V88, P1175, DOI 10.1099/vir.0.82609-0; Collins ND, 2018, MBIO, V9, DOI 10.1128/mBio.01871-18; Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059; Crabtree MB, 2005, ARCH VIROL, V150, P771, DOI 10.1007/s00705-004-0430-8; CROOKS AJ, 1994, J GEN VIROL, V75, P3453, DOI 10.1099/0022-1317-75-12-3453; Davis E.H., 2021, JAPANESE ENCEPHALITI; Davis EH, 2019, MBIO, V10, DOI 10.1128/mBio.02294-19; DESPRES P, 1991, J GEN VIROL, V72, P2811, DOI 10.1099/0022-1317-72-11-2811; ECKELS KH, 1994, AM J TROP MED HYG, V50, P472, DOI 10.4269/ajtmh.1994.50.472; Edeling MA, 2014, P NATL ACAD SCI USA, V111, P4285, DOI 10.1073/pnas.1322036111; FALCONAR AKI, 1994, ARCH VIROL, V137, P315, DOI 10.1007/BF01309478; FALGOUT B, 1990, J VIROL, V64, P4356, DOI 10.1128/JVI.64.9.4356-4363.1990; FALKLER WA, 1973, J IMMUNOL, V111, P1804; Fan Jingjing, 2014, Virologica Sinica, V29, P162, DOI 10.1007/s12250-014-3459-1; FAN W, 1990, VIROLOGY, V177, P470, DOI 10.1016/0042-6822(90)90511-O; Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999; GOULD EA, 1986, J GEN VIROL, V67, P591, DOI 10.1099/0022-1317-67-3-591; Grubor-Bauk B, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2388; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Gutsche I, 2011, P NATL ACAD SCI USA, V108, P8003, DOI 10.1073/pnas.1017338108; HAHN CS, 1987, P NATL ACAD SCI USA, V84, P2019, DOI 10.1073/pnas.84.7.2019; Hall RA, 1999, VIROLOGY, V264, P66, DOI 10.1006/viro.1999.9956; Hall RA, 1996, J GEN VIROL, V77, P1287, DOI 10.1099/0022-1317-77-6-1287; HALL RA, 1990, J GEN VIROL, V71, P2923, DOI 10.1099/0022-1317-71-12-2923; Hertz T, 2017, J IMMUNOL, V198, P4025, DOI 10.4049/jimmunol.1700029; Hirota J, 2012, CLIN VACCINE IMMUNOL, V19, P1853, DOI 10.1128/CVI.00492-12; HODES HL, 1945, P SOC EXP BIOL MED, V60, P220; Hua RH, 2014, VIRUS RES, V185, P103, DOI 10.1016/j.virusres.2014.03.001; Idris F, 2016, ARCH VIROL, V161, P1751, DOI 10.1007/s00705-016-2855-2; Ishikawa T, 2011, VACCINE, V29, P7444, DOI 10.1016/j.vaccine.2011.07.058; JACOBS SC, 1992, J VIROL, V66, P2086, DOI 10.1128/JVI.66.4.2086-2095.1992; Khromykh AA, 2000, J VIROL, V74, P3253, DOI 10.1128/JVI.74.7.3253-3263.2000; Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998; Kuno G, 2006, AM J TROP MED HYG, V75, P1165, DOI 10.4269/ajtmh.2006.75.1165; Lai YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07308-3; Lee HJ, 2018, BIOCHEM BIOPH RES CO, V505, P1010, DOI 10.1016/j.bbrc.2018.10.024; Lee PX, 2020, J EXP MED, V217, DOI 10.1084/jem.20191548; Li AZ, 2020, J VIROL, V94, DOI 10.1128/JVI.00048-20; Li AZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05276-4; Li N, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00220-4; Li N, 2019, J VIROL, V93, DOI 10.1128/JVI.00720-19; Li X, 2014, HUM VACC IMMUNOTHER, V10, P3579, DOI 10.4161/21645515.2014.980197; Lin CF, 2005, J IMMUNOL, V174, P395, DOI 10.4049/jimmunol.174.1.395; Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261; Lin DL, 2017, MBIO, V8, DOI [10.1128/mBio.00939-17, 10.1128/mbio.00939-17]; Lin YL, 1998, J VIROL, V72, P191, DOI 10.1128/JVI.72.1.191-200.1998; Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Low JG, 2014, LANCET INFECT DIS, V14, P706, DOI 10.1016/S1473-3099(14)70730-3; Lu ZY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249702; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MANDL CW, 1989, VIROLOGY, V173, P291, DOI 10.1016/0042-6822(89)90246-8; MASON PW, 1991, VIROLOGY, V180, P294, DOI 10.1016/0042-6822(91)90034-9; Mishra N, 2020, MBIO, V11, DOI 10.1128/mBio.02494-19; Modhiran N, 2021, SCIENCE, V371, P190, DOI 10.1126/science.abb9425; Modhiran N, 2017, IMMUNOL CELL BIOL, V95, P491, DOI 10.1038/icb.2017.5; Mohan S, 2012, INT J ANTIMICROB AG, V40, P273, DOI 10.1016/j.ijantimicag.2012.05.002; MONATH TP, 1980, AM J TROP MED HYG, V29, P624, DOI 10.4269/ajtmh.1980.29.624; Muylaert IR, 1996, VIROLOGY, V222, P159, DOI 10.1006/viro.1996.0406; NITAYAPHAN S, 1990, VIROLOGY, V177, P541, DOI 10.1016/0042-6822(90)90519-W; Noisakran S, 2008, J GEN VIROL, V89, P2492, DOI 10.1099/vir.0.83620-0; Omokoko MD, 2014, AM J TROP MED HYG, V91, P146, DOI 10.4269/ajtmh.13-0624; Osorio JE, 2011, VACCINE, V29, P7251, DOI 10.1016/j.vaccine.2011.07.020; Perry ST, 2013, ANTIVIR RES, V98, P35, DOI 10.1016/j.antiviral.2013.01.004; PLETNEV AG, 1993, J VIROL, V67, P4956, DOI 10.1128/JVI.67.8.4956-4963.1993; Poonsiri T, 2018, J VIROL, V92, DOI [10.1128/JVI.01868-17, 10.1128/jvi.01868-17]; PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183; PRYOR MJ, 1993, VIROLOGY, V194, P769, DOI 10.1006/viro.1993.1318; Puerta-Guardo H, 2020, J INFECT DIS, V221, P313, DOI 10.1093/infdis/jiz331; Puerta-Guardo H, 2019, CELL REP, V26, P1598, DOI 10.1016/j.celrep.2019.01.036; PUTNAK JR, 1990, J GEN VIROL, V71, P1697, DOI 10.1099/0022-1317-71-8-1697; QU XY, 1993, J GEN VIROL, V74, P89, DOI 10.1099/0022-1317-74-1-89; Rathore APS, 2011, ANTIVIR RES, V92, P453, DOI 10.1016/j.antiviral.2011.10.002; Reyes-Sandoval A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01651; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Rocha LB, 2017, ANTIBODIES, V6, DOI 10.3390/antib6040014; Sarathy VV, 2015, VACCINE, V33, P7051, DOI 10.1016/j.vaccine.2015.09.112; SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853; SCHLESINGER JJ, 1985, J IMMUNOL, V135, P2805; SCHLESINGER JJ, 1986, J VIROL, V60, P1153, DOI 10.1128/JVI.60.3.1153-1155.1986; Soe HJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237141; Somnuke P, 2011, VIROLOGY, V413, P253, DOI 10.1016/j.virol.2011.02.022; SRIVASTAVA AK, 1995, VACCINE, V13, P1251, DOI 10.1016/0264-410X(94)00059-V; Sun EC, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-160; Suputtamongkol Y, 2021, CLIN INFECT DIS, V72, pE586, DOI 10.1093/cid/ciaa1332; Tajima S, 2008, VIRUS GENES, V36, P323, DOI 10.1007/s11262-008-0211-7; Tan MJA, 2020, J GEN VIROL, V101, P941, DOI 10.1099/jgv.0.001462; Tang YL, 2017, AM J TROP MED HYG, V97, P1049, DOI 10.4269/ajtmh.17-0003; Ti JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181177; Timofeev AV, 1998, J GEN VIROL, V79, P689, DOI 10.1099/0022-1317-79-4-689; Wallis TP, 2004, J BIOL CHEM, V279, P20729, DOI 10.1074/jbc.M312907200; Wang CL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007938; Warfield KL, 2015, VIRUSES-BASEL, V7, P2404, DOI 10.3390/v7052404; Watanabe S, 2012, ANTIVIR RES, V96, P32, DOI 10.1016/j.antiviral.2012.07.008; Wessel AW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19096-y; Whitby K, 2005, J VIROL, V79, P8698, DOI 10.1128/JVI.79.14.8698-8706.2005; Whiteman MC, 2015, J VIROL, V89, P1474, DOI 10.1128/JVI.02215-14; Whiteman MC, 2011, VACCINE, V29, P9702, DOI 10.1016/j.vaccine.2011.09.036; Whiteman MC, 2010, VACCINE, V28, P1075, DOI 10.1016/j.vaccine.2009.10.112; Wilson JR, 2008, J VIROL, V82, P8262, DOI 10.1128/JVI.00226-08; WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4; WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8; Wu HC, 2001, J CLIN MICROBIOL, V39, P977, DOI 10.1128/JCM.39.3.977-982.2001; Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4; Xia HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02816-2; Xu XY, 2016, EMBO J, V35, P2170, DOI 10.15252/embj.201695290; Youn S, 2012, J VIROL, V86, P7360, DOI 10.1128/JVI.00157-12; Youn S, 2010, J VIROL, V84, P9516, DOI 10.1128/JVI.00775-10; Yu L, 2021, MBIO, V12, DOI 10.1128/mBio.03179-20; ZHAO B, 1987, J VIROL, V61, P4019, DOI 10.1128/JVI.61.12.4019-4022.1987; Zhou DY, 2020, ANTIVIR RES, V182, DOI 10.1016/j.antiviral.2020.104930	138	4	4	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							622	10.3390/vaccines9060622			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3KU	34207516	Green Published, gold			2022-04-29	WOS:000666469200001
J	De Vincenzo, R; Caporale, N; Bertoldo, V; Ricci, C; Evangelista, MT; Bizzarri, N; Anchora, LP; Scambia, G; Capelli, G				De Vincenzo, Rosa; Caporale, Nicola; Bertoldo, Valentina; Ricci, Caterina; Evangelista, Maria Teresa; Bizzarri, Nicolo; Anchora, Luigi Pedone; Scambia, Giovanni; Capelli, Giovanni			HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study	VACCINES			English	Article						human papillomavirus (HPV); 9vHPV vaccine; adult women; Pap smear; HPV DNA test; HPV clearance	HUMAN-PAPILLOMAVIRUS VACCINATION; INTRAEPITHELIAL NEOPLASIA; AS04-ADJUVANTED VACCINE; ADVISORY-COMMITTEE; CERVICAL LESIONS; NATURAL-HISTORY; INFECTION; EFFICACY; SAFETY; IMMUNOGENICITY	Background: This study evaluates the possible effect of 9-valent (9vHPV) vaccination on the results of HPV and cytological tests in a cohort of adult women. Methods: This study is a retrospective, single-cohort, monocentric study. Sexually active women aged 14-70 years, who underwent 9vHPV vaccination, were enrolled. Dose administration dates, side effects and data on Pap smears and HPV tests performed before and after the first vaccine dose were collected. Subjects were considered "unexposed" to the vaccine for all time intervals before the first dose administration, and "exposed" to the first, second and third vaccine doses in all time intervals following each specific dose. Results: A total of 512 women underwent the first 9vHPV dose administration and were enrolled in the study. Median age at vaccination was 30.5 (14-70). Log-rank tests and Cox regression analyses showed a highly statistically significant (p < 0.0001) difference in the time to negativization after the exposure to the third vaccine dose in the 207 women starting with a Pap+ smear (HR (95% C.I.), 2.66 (1.83-3.86)) and in the 198 women starting with an HPV HR+ test (HR (95% C.I.), 7.80 (4.83-12.60)). Conclusions: 9vHPV vaccination may play a role in shortening the clearance time of HPV HR+ or Pap positivity in sexually active adult women.	[De Vincenzo, Rosa; Caporale, Nicola; Bertoldo, Valentina; Ricci, Caterina; Evangelista, Maria Teresa; Bizzarri, Nicolo; Anchora, Luigi Pedone; Scambia, Giovanni] Fdn Policlin Univ A Gemelli, Dept Woman & Child Hlth & Publ Hlth, Gynecol Oncol Unit, I-00168 Rome, Italy; [De Vincenzo, Rosa; Caporale, Nicola; Scambia, Giovanni] Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I-00168 Rome, Italy; [Capelli, Giovanni] Univ Cassino & Lazio Merid, Dipartimento Sci Umane Sociali & Salute, I-03043 Cassino, Italy		De Vincenzo, R (通讯作者)，Fdn Policlin Univ A Gemelli, Dept Woman & Child Hlth & Publ Hlth, Gynecol Oncol Unit, I-00168 Rome, Italy.; De Vincenzo, R (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I-00168 Rome, Italy.; Capelli, G (通讯作者)，Univ Cassino & Lazio Merid, Dipartimento Sci Umane Sociali & Salute, I-03043 Cassino, Italy.	rosa.devincenzo@unicatt.it; nicola.caporale01@icatt.it; valentina.bertoldo@guest.policlinicogemelli.it; caterina.ricci@policlinicogemelli.it; mariateresa.evangelista@policlinicogemelli.it; nicolo.bizzarri@policlinicogemelli.it; luigi.pedoneanchora@policlinicogemelli.it; giovanni.scambia@policlinicogemelli.it; g.capelli@unicas.it	Ricci, Caterina/AAC-6077-2022; Bizzarri, Nicolò/AAC-7686-2022; Capelli, Giovanni/F-6329-2011	Ricci, Caterina/0000-0002-0808-999X; Bizzarri, Nicolò/0000-0002-1727-904X; Capelli, Giovanni/0000-0002-9065-2218; de vincenzo, rosa/0000-0001-7408-0435			[Anonymous], 2018, GARD 9 PRESCR INF; [Anonymous], 2019, CALENDARIO VACCINALE; Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Bogani G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040717; Bonanni P, 2020, EXPERT REV VACCINES, V19, P1073, DOI 10.1080/14760584.2020.1858057; Bruni L, 2019, 17 HPV INF CTR; Ciavattini A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030354; Cleves MA, 2004, INTRO SURVIVAL ANAL; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5; De Vincenzo R, 2014, INT J WOMENS HEALTH, V6, P999, DOI 10.2147/IJWH.S50365; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Elfstrom KM, 2015, VACCINE, V33, P1673, DOI 10.1016/j.vaccine.2015.02.028; European Centre for Disease Prevention and Control, 2012, INTR HPV VACC EU COU; Ferris DG, 2020, PAPILLOMAVIRUS RES, V10, DOI 10.1016/j.pvr.2020.100202; Garland SM, 2016, INT J CANCER, V139, P2812, DOI 10.1002/ijc.30391; Garolla A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19369-z; Ghelardi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020083; Ghelardi A, 2018, GYNECOL ONCOL, V151, P229, DOI 10.1016/j.ygyno.2018.08.033; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; Gravitt P., 2017, VIRUSES-BASEL, V9, P267, DOI [10.3390/v9100267, DOI 10.3390/v9100267]; Gruppo Tecnico Nazionale PASSI, 2018, DAT IT SCREEN CERV; Gultekin M, 2020, INT J GYNECOL CANCER, V30, P426, DOI 10.1136/ijgc-2020-001285; Herrero R, 2005, J INFECT DIS, V191, P1796, DOI 10.1086/428850; Herweijer E, 2016, INT J CANCER, V138, P2867, DOI 10.1002/ijc.30035; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; Joura EA, 2021, VACCINE, V39, P2800, DOI 10.1016/j.vaccine.2021.01.074; Joura EA, 2019, EUR J CANCER, V116, P21, DOI 10.1016/j.ejca.2019.04.032; Joura EA, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1401; Kjaer SK, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100401; Lehtinen M, 2019, EXPERT REV VACCINES, V18, P153, DOI 10.1080/14760584.2019.1568876; Lichter K, 2020, OBSTET GYNECOL, V135, P1070, DOI 10.1097/AOG.0000000000003833; Luna J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083431; Markowitz LE, 2014, MMWR RECOMM REP, V63, P1; Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI [10.15585/mmwr.mm6832a3, 10.1111/ajt.15633]; Ministero della Salute, PIAN NAZ PREV VACC P; Moscicki AB, 2012, VACCINE, V30, pF24, DOI 10.1016/j.vaccine.2012.05.089; Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7; Olsson SE, 2009, HUM VACCINES, V5, P696, DOI 10.4161/hv.5.10.9515; Origoni M, 2020, EUR REV MED PHARMACO, V24, P8510, DOI 10.26355/eurrev_202008_22648; Ronco G, 2015, EUROPEAN GUIDELINES, P1; Schwarz TF, 2017, CANCER MED-US, V6, P2723, DOI 10.1002/cam4.1155; Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006; Skinner SR, 2016, INT J CANCER, V138, P2428, DOI 10.1002/ijc.29971; Skinner SR, 2014, LANCET, V384, P2213, DOI 10.1016/S0140-6736(14)60920-X; Stanley M, 2006, VACCINE, V24, P16, DOI 10.1016/j.vaccine.2005.09.002; StataCorp, 2019, STAT STAT SOFTW REL; Valasoulis G, 2020, CANCERS, V12, DOI 10.3390/cancers12051164; Vorsters A, 2019, INT J INFECT DIS, V88, P110, DOI 10.1016/j.ijid.2019.09.006; Winer RL, 2005, J INFECT DIS, V191, P1787, DOI 10.1086/430275; World Health Organization, 2007, IARC MONOGRAPHS EVAL, V90; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069	52	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							643	10.3390/vaccines9060643			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3OP	34204645	Green Published, gold			2022-04-29	WOS:000666479100001
J	Konstantinou, P; Georgiou, K; Kumar, N; Kyprianidou, M; Nicolaides, C; Karekla, M; Kassianos, AP				Konstantinou, Pinelopi; Georgiou, Katerina; Kumar, Navin; Kyprianidou, Maria; Nicolaides, Christos; Karekla, Maria; Kassianos, Angelos P.			Transmission of Vaccination Attitudes and Uptake Based on Social Contagion Theory: A Scoping Review	VACCINES			English	Review						vaccination; immunization; vaccine hesitancy; social contagion theory; social network analysis; scoping review	NETWORKS; HESITANCY; BEHAVIOR; SMOKING; FRIENDS; SPREAD; IMPACT	Vaccine hesitancy is a complex health problem, with various factors involved including the influence of an individual's network. According to the Social Contagion Theory, attitudes and behaviours of an individual can be contagious to others in their social networks. This scoping review aims to collate evidence on how attitudes and vaccination uptake are spread within social networks. Databases of PubMed, PsycINFO, Embase, and Scopus were searched with the full text of 24 studies being screened. A narrative synthesis approach was used to collate the evidence and interpret findings. Eleven cross-sectional studies were included. Participants held more positive vaccination attitudes and greater likelihood to get vaccinated or vaccinate their child when they were frequently exposed to positive attitudes and frequently discussing vaccinations with family and friends. We also observed that vaccination uptake was decreased when family and friends were hesitant to take the vaccine. Homophily-the tendency of similar individuals to be connected in a social network-was identified as a significant factor that drives the results, especially with respect to race and ethnicity. This review highlights the key role that social networks play in shaping attitudes and vaccination uptake. Public health authorities should tailor interventions and involve family and friends to result in greater vaccination uptake.	[Konstantinou, Pinelopi; Georgiou, Katerina; Kyprianidou, Maria; Karekla, Maria; Kassianos, Angelos P.] Univ Cyprus, Dept Psychol, CY-1678 Nicosia, Cyprus; [Kumar, Navin] Yale Univ, Yale Inst Network Sci, New Haven, CT 06520 USA; [Nicolaides, Christos] Univ Cyprus, Dept Business & Publ Adm, CY-1678 Nicosia, Cyprus; [Nicolaides, Christos] MIT, Sloan Sch Management, Initiat Digital Econ, Cambridge, MA 02142 USA; [Kassianos, Angelos P.] UCL, Dept Appl Hlth Res, London WC1E 6BT, England		Kassianos, AP (通讯作者)，Univ Cyprus, Dept Psychol, CY-1678 Nicosia, Cyprus.	pconst09@ucy.ac.cy; katerinageorgiou1588@gmail.com; navin.kumar@yale.edu; mkyprill@ucy.ac.cy; nicolaides.christos@ucy.ac.cy; mkarekla@ucy.ac.cy; kassianos.angelos@ucy.ac.cy	Nicolaides, Christos/O-5991-2017	Nicolaides, Christos/0000-0002-1485-2736; Kassianos, Angelos/0000-0001-6428-2623; Karekla, Maria/0000-0001-7021-7908; Konstantinou, Pinelopi/0000-0001-8079-0417	European Regional Development FundEuropean Commission; Republic of Cyprus through the Research and Innovation Foundation [EXCELLENCE/0918/0115]; European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [786247]	This work was co-funded by the European Regional Development Fund and the Republic of Cyprus through the Research and Innovation Foundation (project: EXCELLENCE/0918/0115). CN has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 786247.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Aral S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14753; Beck C, 2010, NURS OUTLOOK, V58, P104, DOI 10.1016/j.outlook.2009.10.004; Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452; Casillas A, 2011, ETHNIC DIS, V21, P495; Centola D, 2007, J CONFLICT RESOLUT, V51, P905, DOI 10.1177/0022002707307632; Christakis NA, 2004, BRIT MED J, V329, P184, DOI 10.1136/bmj.329.7459.184; Christakis NA, 2008, NEW ENGL J MED, V358, P2249, DOI 10.1056/NEJMsa0706154; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; Christakis NA, 2013, STAT MED, V32, P556, DOI 10.1002/sim.5408; Christakis NA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012948; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Edge R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026997; Edge R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140085; Fowler JH, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2338; Frank L.B, 2011, CONTAGIOUS SOCIAL NO; Fu LY, 2019, J ADOLESCENT HEALTH, V65, P124, DOI 10.1016/j.jadohealth.2019.01.029; Ghio D., PSYARXIV, P2020, DOI [10.31234/osf.io/nz7tr, DOI 10.31234/OSF.IO/NZ7TR]; Goldberg A.B., 2014, THESIS COLUMBIA U NY, V75; Hernandez EM, 2019, SOC NETWORKS, V58, P156, DOI 10.1016/j.socnet.2019.03.002; Holtz D, 2020, P NATL ACAD SCI USA, V117, P19837, DOI 10.1073/pnas.2009522117; Jacob M, 2005, SEX TRANSM DIS, V32, P635, DOI 10.1097/01.olq.0000179892.78342.79; Karimi F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29405-7; Lawes-Wickwar S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020072; Malchodi CS, 2003, OBSTET GYNECOL, V101, P504, DOI 10.1016/S0029-7844(02)03070-3; Mascia D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010055; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Mednick SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009775; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Moehring A., 2021, SSRN, P1, DOI [10.2139/ssrn.3782082, DOI 10.2139/SSRN.3782082]; Nyhan B, 2012, J ADOLESCENT HEALTH, V51, P302, DOI 10.1016/j.jadohealth.2012.02.014; Oraby T, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.3172; Pachucki MA, 2011, AM J PUBLIC HEALTH, V101, P2170, DOI 10.2105/AJPH.2011.300282; Pontius RG, 2011, INT J REMOTE SENS, V32, P4407, DOI 10.1080/01431161.2011.552923; Popay J, 2006, GUIDANCE CONDUCT NAR, V1, pb92; Hong QN, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0454-2; Richardson W S, 1995, ACP J Club, V123, pA12; Rosenquist JN, 2011, MOL PSYCHIATR, V16, P273, DOI 10.1038/mp.2010.13; Rosenquist JN, 2010, ANN INTERN MED, V152, P426, DOI 10.7326/0003-4819-152-7-201004060-00007; Ruiz J.B, 2015, IMMUNIZING VACCINE H; Rulison KL, 2015, J ADOLESCENT HEALTH, V57, P433, DOI 10.1016/j.jadohealth.2015.06.007; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Scherer CW, 2003, RISK ANAL, V23, P261, DOI 10.1111/1539-6924.00306; Sinclair S., 2021, PSYARXIV, DOI [10.31234/osf.io/sybta, DOI 10.31234/OSF.IO/SYBTA]; Smith KP, 2008, ANNU REV SOCIOL, V34, P405, DOI 10.1146/annurev.soc.34.040507.134601; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; World Health Organization, 2014, REP SAGE WORK GROUP; Wrzus C, 2013, PSYCHOL BULL, V139, P53, DOI 10.1037/a0028601	48	5	5	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							607	10.3390/vaccines9060607			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3TO	34198885	Green Published, gold			2022-04-29	WOS:000666492000001
J	Tun, MMN; Kyaw, AK; Nwe, KM; Inoue, S; Thant, KZ; Morita, K				Tun, Mya Myat Ngwe; Kyaw, Aung Kyaw; Nwe, Khine Mya; Inoue, Shingo; Thant, Kyaw Zin; Morita, Kouichi			Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar	VACCINES			English	Article						SA-14-14-2 vaccine; Japanese encephalitis virus; children; catch-up campaign; Myanmar	VIRUS; IMMUNIZATION; EFFICACY	Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-attenuated JEV vaccine was first introduced as a catch-up vaccination campaign in 2017. To determine the effectiveness of vaccination by means of neutralizing antibody titers against JEV, a cross-sectional descriptive study was conducted among five to 15-year-old monastic school children in Mandalay, Myanmar. A total of 198 students who had received vaccines were recruited, and single-time investigation of anti-JEV IgG and neutralizing antibodies against wild-type JEV were determined using anti-JEV IgG ELISA and plaque reduction neutralization tests (PRNT50). All students 100% (198/198) showed positive results on the anti-JEV IgG ELISA, and 87% (172/198) of the students had neutralizing antibodies against JEV six months after immunization. The geometric mean titers of both IgG antibodies and neutralizing antibodies increased with the participants' age groups, and statistically significant differences in anti-JEV IgG titers were noted across age groups. In this study, we could not investigate the persistence of neutralizing antibodies as only single-time blood collection was done. This study, which is the first report of JEV vaccination among children in Myanmar, showed similar neutralizing antibody production rates among vaccinated individuals as did studies in other countries.	[Tun, Mya Myat Ngwe; Nwe, Khine Mya; Inoue, Shingo; Morita, Kouichi] Nagasaki Univ, Inst Trop Med & Leading Program, Dept Virol, Nagasaki 8528523, Japan; [Kyaw, Aung Kyaw] Dept Med Res, Pyin Oo Lwin Branch, Pyin Oo Lwin 05082, Myanmar; [Thant, Kyaw Zin] Myanmar Acad Med Sci, Yangon 11181, Myanmar		Tun, MMN (通讯作者)，Nagasaki Univ, Inst Trop Med & Leading Program, Dept Virol, Nagasaki 8528523, Japan.	myamyat@tm.nagasaki-u.ac.jp; aungkyawkyaw@mohs.gov.mm; bb55418851@ms.nagasaki-u.ac.jp; pampanga@nagasaki-u.ac.jp; kyawzinthant@mohs.gov.mm; moritak@nagasaki-u.ac.jp	KYAW, Aung KYAW/R-7376-2017	KYAW, Aung KYAW/0000-0002-1384-8030	Japan Agency of Medical Research (AMED) (Japan program for Infectious Diseases Research and Infrastructure) [JP21wm0125006, JP21wm0225017]; Japan Agency of Medical Research (AMED) (Department of Medical Research, Ministry of Health and Sports, Myanmar) [JP21wm0125006, JP21wm0225017]; Japan Agency of Medical Research (AMED) (Institute of Tropical Medicine Nagasaki University, Japan) [2020-Ippan-25, 2021-Ippan-30]	This research was supported by Japan Agency of Medical Research (AMED) under the grant number JP21wm0125006, JP21wm0225017 (Japan program for Infectious Diseases Research and Infrastructure, and Joint research of Department of Medical Research, Ministry of Health and Sports, Myanmar and Institute of Tropical Medicine Nagasaki University, Japan (2020-Ippan-25 and 2021-Ippan-30).	Bista MB, 2001, LANCET, V358, P791, DOI 10.1016/S0140-6736(01)05967-0; Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233; Endy TP, 2002, CURR TOP MICROBIOL, V267, P11; Hegde NR, 2017, HUM VACC IMMUNOTHER, V13, P1320, DOI 10.1080/21645515.2017.1285472; Inoue S, 2010, VECTOR-BORNE ZOONOT, V10, P143, DOI 10.1089/vbz.2008.0153; Kyaw AK, 2019, AM J TROP MED HYG, V100, P643, DOI 10.4269/ajtmh.18-0530; Kyaw Pyae Phyo, 2020, F1000Res, V9, P6, DOI [10.12688/f1000research.21702.1, 10.12688/f1000research.21702.2, 10.12688/f1000research.21702.3]; Latt A.Z., 2015, MYANMAR HLTH SCI RES, V27, P1; Liu W, 2006, VACCINE, V24, P5178, DOI 10.1016/j.vaccine.2006.04.006; Maeki T, 2019, J INFECT CHEMOTHER, V25, P786, DOI 10.1016/j.jiac.2019.04.003; Markoff L, 2000, VACCINE, V18, P26, DOI 10.1016/S0264-410X(00)00038-4; Ministry of Health and Sports Department of Public Health, MYANM MONTHL EP B; Tun MMN, 2013, J MED VIROL, V85, P1258, DOI 10.1002/jmv.23577; Sohn YM, 2000, EMERG INFECT DIS, V6, P17; Sohn YM, 1999, VACCINE, V17, P2259, DOI 10.1016/S0264-410X(99)00006-7; Solomon T, 2004, NEW ENGL J MED, V351, P370, DOI 10.1056/NEJMra030476; SWE T, 1979, BIKEN J, V22, P125; THEIN S, 1988, AM J EPIDEMIOL, V128, P1376, DOI 10.1093/oxfordjournals.aje.a115090; Tseng HF, 2003, AM J INFECT CONTROL, V31, P435, DOI 10.1067/mic.2003.73; Van Gessel Y, 2011, VACCINE, V29, P5925, DOI 10.1016/j.vaccine.2011.06.062; Vashishtha VM, 2013, INDIAN PEDIATR, V50, P1095, DOI 10.1007/s13312-013-0292-9; Win AYN, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00200-3; YU YX, 1988, AM J TROP MED HYG, V39, P214, DOI 10.4269/ajtmh.1988.39.214	23	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							568	10.3390/vaccines9060568			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8BV	34072933	Green Published, gold			2022-04-29	WOS:000666784400001
J	Campbell, K; Young, VL; Donaldson, BC; Woodall, MJ; Shields, NJ; Walker, GF; Ward, VK; Young, SL				Campbell, Katrin; Young, Vivienne L.; Donaldson, Braeden C.; Woodall, Matthew J.; Shields, Nicholas J.; Walker, Greg F.; Ward, Vernon K.; Young, Sarah L.			Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses	VACCINES			English	Article						breast cancer; nanoparticles; virus-like particles (VLPs); conjugated VLPs; multimeric presentation; therapeutic vaccines; cancer immunotherapy	BREAST-CANCER; MUC1; VACCINE; PROTEIN; TOLERANCE; GLYCOSYLATION; IMMUNOTHERAPY; RECOGNITION; EPITOPES; ANTIBODY	Breast cancer (BC) is the most frequently diagnosed cancer in women, with many patients experiencing recurrence following treatment. Antigens delivered on virus-like particles (VLPs) induce a targeted immune response and here we investigated whether the co-delivery of multiple antigens could induce a superior anti-cancer response for BC immunotherapy. VLPs were designed to recombinantly express murine survivin and conjugated with an aberrantly glycosylated mucin-1 (MUC1) peptide using an intracellular cleavable bis-arylhydrazone linker. Western blotting, electron microscopy and UV absorption confirmed survivin-VLP expression and MUC1 conjugation. To assess the therapeutic efficacy of VLPs, orthotopic BC tumours were established by injecting C57mg.MUC1 cells into the mammary fat pad of mice, which were then vaccinated with surv.VLP-SS-MUC1 or VLP controls. While wild-type mice vaccinated with surv.VLP-SS-MUC1 showed enhanced survival compared to VLPs delivering either antigen alone, MUC1 transgenic mice vaccinated with surv.VLP-SS-MUC1 showed no enhanced survival compared to controls. Hence, while co-delivery of two tumour antigens on VLPs can induce a superior anti-tumour immune response compared to the delivery of single antigens, additional strategies must be employed to break tolerance when targeted tumour antigens are expressed as endogenous self-proteins. Using VLPs for the delivery of multiple antigens represents a promising approach to improving BC immunotherapy, and has the potential to be an integral part of combination therapy in the future.	[Campbell, Katrin; Donaldson, Braeden C.; Woodall, Matthew J.] Univ Otago, Otago Med Sch, Dept Pathol, Dunedin 9016, New Zealand; [Young, Vivienne L.; Ward, Vernon K.] Univ Otago, Sch Biomed Sci, Dept Microbiol & Immunol, Dunedin 9016, New Zealand; [Shields, Nicholas J.; Young, Sarah L.] Univ Sydney, Sch Med Sci, Fac Med & Hlth, Sydney, NSW 2006, Australia; [Walker, Greg F.] Univ Otago, Sch Pharm, Dunedin 9016, New Zealand		Young, SL (通讯作者)，Univ Sydney, Sch Med Sci, Fac Med & Hlth, Sydney, NSW 2006, Australia.	katrin.campbell@otago.ac.nz; vivienne.young@otago.ac.nz; Braeden.donaldson@otago.ac.nz; matthew.woodall@otago.ac.nz; nicholas.shields@sydney.edu.au; greg.walker@otago.ac.nz; vernon.ward@otago.ac.nz; sarah.l.young@sydney.edu.au		Walker, Greg/0000-0002-9817-4767; Young, Vivienne/0000-0002-9216-5552; Young, Sarah/0000-0003-0374-2221; Woodall, Matt/0000-0002-4034-4428; Shields, Nicholas/0000-0003-2990-0478	New Zealand Breast Cancer Foundation [RES1807]; Karen Louisa Foundation	This research was funded by the New Zealand Breast Cancer Foundation, grant number RES1807 and the Karen Louisa Foundation.	Abdel-Aal AM, 2014, CHEMBIOCHEM, V15, P1508, DOI 10.1002/cbic.201402077; Al-Barwani F, 2014, THER DELIV, V5, P1223, DOI [10.4155/tde.14.74, 10.4155/TDE.14.74]; Ali OA, 2016, CANCER IMMUNOL RES, V4, P95, DOI 10.1158/2326-6066.CIR-14-0126; Antonilli M, 2016, INT J ONCOL, V48, P1369, DOI 10.3892/ijo.2016.3386; Cai H, 2014, ANGEW CHEM INT EDIT, V53, P1699, DOI 10.1002/anie.201308875; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Collins JM, 2018, EXPERT REV VACCINES, V17, P697, DOI 10.1080/14760584.2018.1506332; Donaldson B, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0270-1; Duperret EK, 2018, MOL THER, V26, P435, DOI 10.1016/j.ymthe.2017.11.010; Garg H, 2018, WORLD J CLIN ONCOL, V9, P188, DOI 10.5306/wjco.v9.i8.188; Hofmann UB, 2009, EUR J IMMUNOL, V39, P1419, DOI 10.1002/eji.200839098; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Hossain MK, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030025; Jha K, 2012, SURG ONCOL, V21, P125, DOI 10.1016/j.suronc.2011.01.001; Kobukai S, 2011, TRANSL ONCOL, V4, P1, DOI 10.1593/tlo.10166; Kramer K, 2017, MOL THER, V25, P62, DOI 10.1016/j.ymthe.2016.10.001; Lacunza E, 2010, CANCER GENET CYTOGEN, V201, P102, DOI 10.1016/j.cancergencyto.2010.05.015; Lakshminarayanan V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145920; Lakshminarayanan V, 2012, P NATL ACAD SCI USA, V109, P261, DOI 10.1073/pnas.1115166109; Li KY, 2013, J IMMUNOTHER, V36, P11, DOI 10.1097/CJI.0b013e3182787f5e; Lopes A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33933-7; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Mavratzas A, 2020, FUTURE ONCOL, V16, P4439, DOI 10.2217/fon-2019-0468; McKee SJ, 2012, J CONTROL RELEASE, V159, P338, DOI 10.1016/j.jconrel.2012.02.015; Mukherjee P, 2003, J IMMUNOTHER, V26, P47, DOI 10.1097/00002371-200301000-00006; Dominguez-Romero AN, 2020, IMMUNOLOGY, V161, P123, DOI 10.1111/imm.13233; Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004; Pathangey LB, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030031; Peacey M, 2008, VACCINE, V26, P5334, DOI 10.1016/j.vaccine.2008.07.074; Peacey M, 2007, BIOTECHNOL BIOENG, V98, P968, DOI 10.1002/bit.21518; Romanowski B, 2011, HUM VACCINES, V7, P161, DOI 10.4161/hv.7.2.13690; Rowse GJ, 1998, CANCER RES, V58, P315; Shi XZ, 2007, CURR DRUG TARGETS, V8, P1116, DOI 10.2174/138945007782151360; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stergiou N, 2017, CHEMMEDCHEM, V12, P1424, DOI 10.1002/cmdc.201700387; Wang YQ, 2013, INT IMMUNOPHARMACOL, V17, P9, DOI 10.1016/j.intimp.2013.04.015; Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zepeda-Cervantes J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01100; Zhou DP, 2018, MOLECULES, V23, DOI 10.3390/molecules23061326	41	4	4	8	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							463	10.3390/vaccines9050463			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NF	34066318	Green Published, gold			2022-04-29	WOS:000654592200001
J	Chaffey, A; Hamonic, G; Chand, D; Mutwiri, GK; Wilson, HL				Chaffey, Alyssa; Hamonic, Glenn; Chand, Dylan; Mutwiri, George K.; Wilson, Heather L.			The Adjuvants Polyphosphazene (PCEP) and a Combination of Curdlan Plus Leptin Promote a Th17-Type Immune Response to an Intramuscular Vaccine in Mice	VACCINES			English	Article						mice; ovalbumin; cell-mediated immunity; flow cytometry; interleukin-17; Th17-type T cells; polyphosphazene; curdlan; leptin	T-CELLS; DENDRITIC CELLS; INNATE IMMUNITY; INJECTION SITE; CUTTING EDGE; TH17 CELLS; TGF-BETA; IL-17; ACTIVATION; INDUCTION	Our aim was to determine whether polyphosphazene (PCEP), Curdlan (beta-glucan, a dectin-1 agonist), and Leptin could act as adjuvants to promote a Th17-type adaptive immune response in mice. Mice were vaccinated via the intramuscular route then boosted three weeks later with Ovalbumin plus: PCEP, Leptin, Curdlan, PCEP+Curdlan, Curdlan+Leptin, or saline. Mice vaccinated with OVA+PCEP and OVA+Curdlan+Leptin showed significantly higher frequency of antigen-specific CD4+ T cells secreting IL-17 relative to OVA-vaccinated mice. No formulation increased the frequency of CD4+ T cells secreting IL-4 or IFN gamma. Since activation of innate immunity precedes the development of adaptive immunity, we wished to establish whether induction of Th17-type immunity could be predicted from in vitro experiments and/or from the local cytokine environment after immunization with adjuvants alone. Elevated IL-6 and TGF beta with reduced secretion of IL-12 is a cytokine milieu known to promote differentiation of Th17-type immunity. We injected the immunostimulants or saline buffer into murine thigh muscles and measured acute local cytokine production. PCEP induced significant production of IL-6 and reduced IL-12 production in muscle but it did not lead to elevated TGF beta production. Curdlan+Leptin injected into muscle induced significant production of TGF beta and IL-17 but not IL-6 or IL-12. We also stimulated splenocytes with media or PCEP, Leptin, Curdlan, PCEP+Curdlan, Curdlan+Leptin, PCEP+Leptin, and PCEP+Curdlan+Leptin and measured cytokine production. PCEP stimulation of splenocytes failed to induce significant production of IL-6, IL-12, TGF beta, or IL-17 and therefore ex vivo splenocyte stimulation failed to predict the increased frequency of Th17-type T cells in response to the vaccine. Curdlan-stimulated splenocytes produced Th1-type, inducing cytokine, IL-12. Curdlan+/-PCEP stimulated TGF-beta production and Curdlan+Leptin+/- PCEP induced secretion of IL-17. We conclude that PCEP as well as Curdlan+Leptin are Th17-type vaccine adjuvants in mice but that cytokines produced in response to these adjuvants in muscle after injection or in ex vivo cultured splenocytes did not predict their role as a Th17-type adjuvant. Together, these data suggest that the cytokine environments induced by these immunostimulants did not predict induction of an antigen-specific Th17-type adaptive immune response. This is the first report of these adjuvants inducing a Th17-type adaptive immune response.	[Chaffey, Alyssa; Chand, Dylan; Mutwiri, George K.; Wilson, Heather L.] Univ Saskatchewan, Sch Publ Hlth, Vaccinol & Immunotherapeut Program, 104 Clin Pl, Saskatoon, SK S7N 2Z4, Canada; [Chaffey, Alyssa; Chand, Dylan; Mutwiri, George K.; Wilson, Heather L.] Univ Saskatchewan, Vaccine & Infect Dis Org, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada; [Hamonic, Glenn] Univ Saskatchewan, Western Coll Vet Med, Large Anim Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada		Wilson, HL (通讯作者)，Univ Saskatchewan, Sch Publ Hlth, Vaccinol & Immunotherapeut Program, 104 Clin Pl, Saskatoon, SK S7N 2Z4, Canada.; Wilson, HL (通讯作者)，Univ Saskatchewan, Vaccine & Infect Dis Org, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada.	alyssa.chaffey@usask.ca; glenn.hamonic@usask.ca; djc672@mail.usask.ca; george.mutwiri@usask.ca; heather.wilson@usask.ca		Hamonic, Glenn/0000-0001-5188-131X; Wilson, Heather/0000-0002-1261-0901; Chand, Dylan/0000-0001-8739-9736	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [402993]	This research was funded by Natural Sciences and Engineering Research Council of Canada, grant number 402993.	Abella V, 2017, NAT REV RHEUMATOL, V13, P100, DOI 10.1038/nrrheum.2016.209; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Agrawal S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013418; Awate S, 2014, VACCINES-BASEL, V2, P500, DOI 10.3390/vaccines2030500; Awate S, 2014, VACCINE, V32, P2420, DOI 10.1016/j.vaccine.2014.03.014; Awate S, 2012, MOL IMMUNOL, V51, P292, DOI 10.1016/j.molimm.2012.03.026; BacaEstrada ME, 1996, VIRAL IMMUNOL, V9, P11, DOI 10.1089/vim.1996.9.11; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Capone A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00348; Chaffey A.M., 2017, THESIS U SASKATCHEWA; Datta SK, 2010, P NATL ACAD SCI USA, V107, P10638, DOI 10.1073/pnas.1002348107; De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011; Duluc D, 2014, J IMMUNOL, V192, P5776, DOI 10.4049/jimmunol.1301661; Gao C, 2017, CLIN IMMUNOL, V183, P354, DOI 10.1016/j.clim.2017.09.022; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Goyal S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01261; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Hou WQ, 2009, J EXP MED, V206, P313, DOI 10.1084/jem.20082030; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; La Cava A, 2017, CYTOKINE, V98, P51, DOI 10.1016/j.cyto.2016.10.011; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Li PL, 2014, CARBOHYD POLYM, V102, P852, DOI 10.1016/j.carbpol.2013.10.078; Li WC, 2018, P NATL ACAD SCI USA, V115, pE7149, DOI 10.1073/pnas.1802261115; Luz-Crawford P, 2014, ANN RHEUM DIS, V73, pA80, DOI 10.1136/annrheumdis-2013-205124.185; Magiri RB, 2016, VET IMMUNOL IMMUNOP, V175, P57, DOI 10.1016/j.vetimm.2016.05.003; Margetic S, 2002, INT J OBESITY, V26, P1407, DOI 10.1038/sj.ijo.0802142; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Martinez A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051317; Matarese G, 2008, TRENDS IMMUNOL, V29, P12, DOI 10.1016/j.it.2007.10.006; Mattioli B, 2009, FEBS LETT, V583, P1102, DOI 10.1016/j.febslet.2009.02.029; Meyer-Wentrup F, 2005, IMMUNITY, V22, P399, DOI 10.1016/j.immuni.2005.04.001; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Mutwiri G, 2007, REV SCI TECH OIE, V26, P147, DOI 10.20506/rst.26.1.1731; Mutwiri G, 2008, VACCINE, V26, P2680, DOI 10.1016/j.vaccine.2008.03.031; Mutwiri G, 2007, VACCINE, V25, P1204, DOI 10.1016/j.vaccine.2006.10.011; Mutwiri G, 2011, EXPERT REV VACCINES, V10, P95, DOI 10.1586/ERV.10.154; Osorio F, 2008, EUR J IMMUNOL, V38, P3274, DOI 10.1002/eji.200838950; Procaccini C, 2012, MOL ASPECTS MED, V33, P35, DOI 10.1016/j.mam.2011.10.012; Reis BS, 2015, J IMMUNOL, V194, P5253, DOI 10.4049/jimmunol.1402996; Ritter K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010009; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X; Sanchez-Margalet V, 2003, CLIN EXP IMMUNOL, V133, P11, DOI 10.1046/j.1365-2249.2003.02190.x; Schaefers MM, 2018, VACCINE, V36, P6926, DOI 10.1016/j.vaccine.2018.10.010; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Warfel JM, 2013, MUCOSAL IMMUNOL, V6, P787, DOI 10.1038/mi.2012.117; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11; Wu RF, 2018, J CLIN INVEST, V128, P2551, DOI 10.1172/JCI97426; Xie AY, 2018, J AUTOIMMUN, V94, P122, DOI 10.1016/j.jaut.2018.07.022; Xu H, 2018, CELL RES, V28, P139, DOI 10.1038/cr.2017.156; Yu YY, 2013, J IMMUNOL, V190, P3054, DOI 10.4049/jimmunol.1203275; Yuan QH, 2020, CLIN RHEUMATOL, V39, P305, DOI 10.1007/s10067-019-04831-8; Zhang S, 2019, MOL IMMUNOL, V114, P260, DOI 10.1016/j.molimm.2019.07.029; Zhang S, 2018, IMMUNOLOGY, V155, P24, DOI 10.1111/imm.12938; Zhang S, 2017, NATURE, V551, P105, DOI 10.1038/nature24283; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao YN, 2020, P NATL ACAD SCI USA, V117, P2160, DOI 10.1073/pnas.1901294117	61	1	1	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							507	10.3390/vaccines9050507			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1YF	34069081	Green Published, gold			2022-04-29	WOS:000654620800001
J	Kabir, R; Mahmud, I; Chowdhury, MTH; Vinnakota, D; Jahan, SS; Siddika, N; Isha, SN; Nath, SK; Apu, EH				Kabir, Russell; Mahmud, Ilias; Chowdhury, Mohammad Tawfique Hossain; Vinnakota, Divya; Jahan, Shah Saif; Siddika, Nazeeba; Isha, Samia Naz; Nath, Sujan Kanti; Hoque Apu, Ehsanul			COVID-19 Vaccination Intent and Willingness to Pay in Bangladesh: A Cross-Sectional Study	VACCINES			English	Article						COVID-19 vaccine; health belief model; vaccination intent; Bangladesh	MISINFORMATION; HESITANCY	This article reports the intent to receive a SARS-COV-2 vaccine, its predictors and willingness to pay in Bangladesh. We carried out an online cross-sectional survey of 697 adults from the general population of Bangladesh in January 2021. A structured questionnaire was used to assess vaccination intent. The questionnaire included sociodemographic variables and health belief model constructs which may predict vaccination intent. Among the participants, 26% demonstrated a definite intent, 43% probable intent, 24% probable negative, and 7% a definite negative intention. Multivariable logistic regression analyses suggest an association between definite intent and previous COVID-19 infection (OR: 2.86; 95% CI: 1.71-4.78), perceiving COVID-19 as serious (OR: 1.93; 1.04-3.59), the belief that vaccination would make them feel less worried about catching COVID-19 (OR: 4.42; 2.25-8.68), and concerns about vaccine affordability (OR: 1.51; 1.01-2.25). Individuals afraid of the side effects (OR: 0.34; 0.21-0.53) and those who would take the vaccine if the vaccine were taken by many others (OR: 0.44; 0.29-0.67) are less likely to have a definite intent. A definite negative intent is associated with the concern that the vaccine may not be halal (OR: 2.03; 1.04-3.96). Furthermore, 68.4% are willing to pay for the vaccine. The median amount that they are willing to pay is USD 7.08. The study findings reveal that the definite intent to receive the SARS-CoV-2 vaccination among the general population varies depending on their COVID-19-related health beliefs and no significant association was found with sociodemographic variables.	[Kabir, Russell; Vinnakota, Divya; Jahan, Shah Saif] Anglia Ruskin Univ, Sch Allied Hlth, Fac Hlth Educ Med & Social Care, Chelmsford CM1 1SQ, Essex, England; [Mahmud, Ilias] Qassim Univ, Dept Publ Hlth, Coll Publ Hlth & Hlth Informat, Al Bukairiyah 52741, Saudi Arabia; [Chowdhury, Mohammad Tawfique Hossain; Nath, Sujan Kanti] Sapporo Dent Coll, Dept Dent Publ Hlth, Dhaka 1230, Bangladesh; [Siddika, Nazeeba] Univ Oulu, Ctr Environm & Resp Hlth Res CERH, Fac Med, Oulu 90014, Finland; [Isha, Samia Naz] Univ Cambridge, CAPABLE Cambridge Led Programme Bangladesh A, Cambridge CB2 1TN, England; [Hoque Apu, Ehsanul] Oslo Univ Hosp, Intervent Ctr, N-0372 Oslo, Norway; [Hoque Apu, Ehsanul] Michigan State Univ, Dept Biomed Engn, Inst Quantitat Hlth Sci, E Lansing, MI 48824 USA		Kabir, R (通讯作者)，Anglia Ruskin Univ, Sch Allied Hlth, Fac Hlth Educ Med & Social Care, Chelmsford CM1 1SQ, Essex, England.	russell.kabir@aru.ac.uk; i.emdadulhaque@qu.edu.sa; tawfique@sdch.edu.bd; dv234@student.aru.ac.uk; ssj151@student.aru.ac.uk; nazeeba.siddika@oulu.fi; sni25@medschl.cam.ac.uk; knsujan@yahoo.com; hoqueapu@msu.edu	Vinnakota, Dr Divya/AAR-1301-2021; Hoque Apu, Ehsanul/AAA-9569-2020; Kabir, Russell/H-9715-2019; Mahmud, Ilias/N-5085-2017	Vinnakota, Dr Divya/0000-0002-9707-1491; Hoque Apu, Ehsanul/0000-0001-6840-3787; Kabir, Russell/0000-0001-9257-2775; Mahmud, Ilias/0000-0003-1330-7813; Jahan, Shah Saif/0000-0002-7161-614X; CHOWDHURY, MOHAMMAD TAWFIQUE/0000-0001-9199-2444; Siddika, Nazeeba/0000-0003-4434-4019; Isha, Samia Naz/0000-0002-6209-284X			Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Ahmed M.U., 2021, SOCARXIV, DOI [10.31235/osf.io/kn6ts, DOI 10.31235/OSF.IO/KN6TS]; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; [Anonymous], NEW YORK TIMES; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bin Shams A, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9020156; Biswas RK, 2020, J EVAL CLIN PRACT, V26, P1599, DOI 10.1111/jep.13467; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Cousins S, 2020, LANCET, V396, P591, DOI 10.1016/S0140-6736(20)31819-5; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Edwards B., 2020, COVID 19 VACCINE HES, DOI [10.1101/2020.11.13.20231480, DOI 10.1101/2020.11.13.20231480]; Ess SM, 2002, CLIN INFECT DIS, V35, P294, DOI 10.1086/341419; Feleszko W., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3631972., DOI 10.2139/SSRN.3631972, 10.2139/ssrn.3631972]; Figueroa JP, 2021, LANCET, V397, P562, DOI 10.1016/S0140-6736(21)00242-7; Fu Chuanxi, 2020, ACCEPTANCE PREFRENCE, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103, 0.1101/2020.04.09.2006010314]; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Iboi EA, 2020, INFECT DIS MODEL, V5, P510, DOI 10.1016/j.idm.2020.07.006; Isha SN, 2021, ADV HUM BIOL, V11, P135, DOI 10.4103/aihb.aihb_111_20; Khoo YSK, 2020, HUM VACC IMMUNOTHER, V16, P530, DOI 10.1080/21645515.2019.1667206; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee K, 2009, GLOB INST, P1; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; McArthur L, 2020, AM J TROP MED HYG, V103, P625, DOI 10.4269/ajtmh.20-0564; Mishra SK, 2021, ACTA TROP, V214, DOI 10.1016/j.actatropica.2020.105778; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Pillai S, 2020, ARCH MED RES, V51, P723, DOI 10.1016/j.arcmed.2020.05.015; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Siam ZS, 2021, CLIN EPIDEMIOL GLOB, V10, DOI 10.1016/j.cegh.2020.100684; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Thunstrom L., 2020, HESITANCY COVID 19 V, DOI [10.2139/ssrn.3593098, DOI 10.2139/SSRN.3593098]; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; World Health Organization, WHO LISTS 2 ADD COVI; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Zainudin ENHE, 2018, INT MED J MALAYS, V17, P273; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	44	18	18	1	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							416	10.3390/vaccines9050416			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI7KK	33919254	Green Published, Green Submitted, gold, Green Accepted			2022-04-29	WOS:000655006400001
J	Khaled, SM; Petcu, C; Bader, L; Amro, I; Al-Hamadi, AMHA; Al Assi, M; Ali, AAM; Trung, KL; Diop, A; Bellaj, T; Al-Thani, MH; Woodruff, PW; Alabdulla, M; Haddad, PM				Khaled, Salma M.; Petcu, Catalina; Bader, Lina; Amro, Iman; Al-Hamadi, Aisha Mohammed H. A.; Al Assi, Marwa; Ali, Amal Awadalla Mohamed; Le Trung, Kien; Diop, Abdoulaye; Bellaj, Tarek; Al-Thani, Mohamed H.; Woodruff, Peter W.; Alabdulla, Majid; Haddad, Peter M.			Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021	VACCINES			English	Article						COVID-19; vaccine willingness; hesitancy or refusal; Middle East and North Africa (MENA); Arab; migrant; Qatar	CONFIDENCE; VALIDITY; BARRIERS; SPREAD; HEALTH; PHQ-9	Global COVID-19 pandemic containment necessitates understanding the risk of hesitance or resistance to vaccine uptake in different populations. The Middle East and North Africa currently lack vital representative vaccine hesitancy data. We conducted the first representative national phone survey among the adult population of Qatar, between December 2020 and January 2021, to estimate the prevalence and identify potential determinants of vaccine willingness: acceptance (strongly agree), resistance (strongly disagree), and hesitance (somewhat agree, neutral, somewhat disagree). Bivariate and multinomial logistic regression models estimated associations between willingness groups and fifteen variables. In the total sample, 42.7% (95% CI: 39.5-46.1) were accepting, 45.2% (95% CI: 41.9-48.4) hesitant, and 12.1% (95% CI: 10.1-14.4) resistant. Vaccine resistant compared with hesistant and accepting groups reported no endorsement source will increase vaccine confidence (58.9% vs. 5.6% vs. 0.2%, respectively). Female gender, Arab ethnicity, migrant status/type, and vaccine side-effects concerns were associated with hesitancy and resistance. COVID-19 related bereavement, infection, and quarantine status were not significantly associated with any willingness group. Absence of or lack of concern about contracting the virus was solely associated with resistance. COVID-19 vaccine resistance, hesitance, and side-effects concerns are high in Qatar's population compared with those globally. Urgent public health engagement should focus on women, Qataris (non-migrants), and those of Arab ethnicity.	[Khaled, Salma M.; Petcu, Catalina; Bader, Lina; Amro, Iman; Al-Hamadi, Aisha Mohammed H. A.; Al Assi, Marwa; Ali, Amal Awadalla Mohamed; Le Trung, Kien; Diop, Abdoulaye] Qatar Univ, Social & Econ Survey Res Inst, POB 2713, Doha, Qatar; [Khaled, Salma M.] Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, POB 2713, Doha, Qatar; [Khaled, Salma M.] Qatar Univ, Coll Med, Dept Populat Med, POB 2713, Doha, Qatar; [Bellaj, Tarek] Qatar Univ, Coll Art & Sci, POB 2713, Doha, Qatar; [Al-Thani, Mohamed H.] Minist Publ Hlth, Dept Publ Hlth, Al Khaleej St,POB 42, Doha, Qatar; [Woodruff, Peter W.] Univ Sheffield, Dept Neurosci, Western Bank, Sheffield S10 2TN, S Yorkshire, England; [Alabdulla, Majid; Haddad, Peter M.] Hamad Med Corp, Dept Psychiat, POB 3050, Doha, Qatar; [Alabdulla, Majid; Haddad, Peter M.] Qatar Univ, Coll Med, Dept Clin Sci, POB 2713, Doha, Qatar		Khaled, SM (通讯作者)，Qatar Univ, Social & Econ Survey Res Inst, POB 2713, Doha, Qatar.; Khaled, SM (通讯作者)，Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, POB 2713, Doha, Qatar.; Khaled, SM (通讯作者)，Qatar Univ, Coll Med, Dept Populat Med, POB 2713, Doha, Qatar.	skhaled@qu.edu.qa; cpetcu@qu.edu.qa; lina.bader@qu.edu.qa; iman.amro@qu.edu.qa; aisha.alhamadi@qu.edu.qa; marwa.alassi@qu.edu.qa; amal.ali@qu.edu.qa; kienle@qu.edu.qa; adiop@qu.edu.qa; tbellaj@qu.edu.qa; malthani@moph.gov.qa; p.w.woodruff@sheffield.ac.uk; malabdulla3@hamad.qa; phaddad@hamad.qa		Haddad, Peter/0000-0003-3383-9294; Alabdulla, Majid/0000-0002-3631-2650; Khaled, Salma/0000-0002-8844-3441; Bellaj, Tarek/0000-0001-6673-5040	Emergency Response Grant Fund from Qatar University [QUERG-CAS-2020-1]	The study received an Emergency Response Grant Fund from Qatar University (QUERG-CAS-2020-1).	AAPOR, STAND DEF AAPOR; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Alsuwaidi AR, 2020, HUM VACC IMMUNOTHER, V16, P3163, DOI 10.1080/21645515.2020.1753439; American Association for Public Opinion Research, 2015, STAND DEF; [Anonymous], QATAR REPORTS 1 CASE; [Anonymous], POLIOMYELITIS PAKIST; [Anonymous], Qatar population 2021 -worldometer; [Anonymous], STATA STATACORP LLC; [Anonymous], CORONAVIRUS UPDATE L; [Anonymous], COUNTRIES CORONAVIRU; [Anonymous], QATAR ADMINISTERS ON; [Anonymous], CORONAVIRUS DIS COVI; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2020 IMPACT REPORT S; [Anonymous], 2020, WHO NOVEL CORONAVIRU; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647; Casady R.J., 1993, SURV METHODOL, V19, P103; Chatters LM, 2000, ANNU REV PUBL HEALTH, V21, P335, DOI 10.1146/annurev.publhealth.21.1.335; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Elbarazi I, 2021, HUM VACC IMMUNOTHER, V17, P2018, DOI 10.1080/21645515.2020.1855953; Eriksson K, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1883389; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gardner A., 2013, J ARABIAN STUD, V3, P1, DOI [10.1080/21534764.2013.806076, DOI 10.1080/21534764.2013.806076]; Gomes M Gabriela M, 2022, medRxiv, DOI 10.1101/2020.04.27.20081893; Grant A., 2021, IMMUNISATION ASYMPTO, V2021, DOI [10.1101/2021.01.16.21249946, DOI 10.1101/2021.01.16.21249946]; Kelly J., COMPUTER ASSISTED TE; Kestenbaum LA, 2015, PEDIATR ANN, V44, pE71, DOI 10.3928/00904481-20150410-07; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800376; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lowe B, 2010, J AFFECT DISORDERS, V122, P86, DOI 10.1016/j.jad.2009.06.019; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003; Massey PM, 2020, J MED INTERNET RES, V22, DOI 10.2196/21451; Ministry of Development Planning and Statistics, 2015, GEN SIMPL CENS POP H; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Omari K, 2013, TRANSPORT RES F-TRAF, V16, P53, DOI 10.1016/j.trf.2012.08.010; Pitzer Virginia E, 2020, medRxiv, DOI 10.1101/2020.04.20.20073338; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rancans E, 2018, ANN GEN PSYCHIATR, V17, DOI 10.1186/s12991-018-0203-5; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Schoch-Spana M, 2021, VACCINE, V39, P6004, DOI 10.1016/j.vaccine.2020.10.059; Shao CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06930-7; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Varedian M., 2003, COMPARING PROPENSITY; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430	56	14	14	0	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							471	10.3390/vaccines9050471			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1OM	34067103	gold, Green Published			2022-04-29	WOS:000654595500001
J	Restivo, V; Candore, G; Barrale, M; Caravello, E; Graziano, G; Onida, R; Raineri, M; Tiralongo, S; Brusca, I				Restivo, Vincenzo; Candore, Giuseppina; Barrale, Maria; Caravello, Ester; Graziano, Giorgio; Onida, Rosa; Raineri, Maurizio; Tiralongo, Salvatore; Brusca, Ignazio			Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2	VACCINES			English	Article						SARS CoV2; vaccine; PEG; adverse reaction; m-RNA vaccine; anaphylaxis; contraindication; basophil activation test	DIAGNOSIS	The main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first dose of anti-SARS CoV2 vaccine. For 5 h after the administration of the vaccine, she had the appearance of erythematous spots on the face and neck, and a feeling of a slurred mouth and hoarseness. In order to treat the event, she was administered 8 mg intravenous dexamethasone, 1 vial intravenous chlorphenamine maleate, 250 mL intravenous 0.9% NaCl, and conventional oxygen therapy (2 L/min) with complete resolution of the suspected adverse drug reaction. According to the contraindication to the cutaneous test for this patient, BAT was used for further investigations. The patient who suffered the adverse reaction to the COVID-19 vaccine and other five allergic patients who did not report any adverse reaction after the vaccination were tested. There was a significant activation of the vaccine-reactive patient's basophils with 14.79 CD203chigh% at the concentration of 0.2 mg/mL, while other patients were negative. People who have a confirmed reaction to a vaccine component should undergo further investigation to discover other possible cross-reactions and select the right vaccine to immunize them.	[Restivo, Vincenzo; Caravello, Ester; Graziano, Giorgio; Tiralongo, Salvatore] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, I-90127 Palermo, Italy; [Candore, Giuseppina] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, I-90127 Palermo, Italy; [Barrale, Maria; Onida, Rosa; Brusca, Ignazio] Buccheri La Ferla Hosp, Clin Pathol Lab, I-90127 Palermo, Italy; [Raineri, Maurizio] Univ Palermo, Dept Biopathol & Med Biotechnol, I-90127 Palermo, Italy		Restivo, V (通讯作者)，Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, I-90127 Palermo, Italy.	vincenzo.restivo@unipa.it; giuseppina.candore@unipa.it; marbarrale@gmail.com; caravelloester@hotmail.com; giorgio.graziano@gmail.com; rossellaonida@gmail.com; maurizio.raineri@unipa.it; salvatore.tiralongo@unipa.it; brusca.ignazio@fbfpa.it		Restivo, Vincenzo/0000-0002-5406-884X			Ansotegui IJ, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2019.100080; Bossuyt X, 2020, NAT REV RHEUMATOL, V16, P715, DOI 10.1038/s41584-020-00522-w; Brunton LL., 2018, GOODMAN GILMANS PHAR, V13; Bruusgaard-Mouritsen MA, 2021, CLIN EXP ALLERGY, V51, P463, DOI 10.1111/cea.13822; Chirumbolo S, 2013, IRAN J ALLERGY ASTHM, V12, P196; Chirumbolo Salvatore, 2008, Clin Mol Allergy, V6, P12, DOI 10.1186/1476-7961-6-12; European Medication Agency, COMINARNATY MEDICAL; Garvey LH, 2021, BRIT J ANAESTH, V126, pE106, DOI 10.1016/j.bja.2020.12.020; GOV.UK, CORONAVIRUS VACCINE; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Kato M, 2019, J DERMATOL, V46, pE230, DOI 10.1111/1346-8138.14808; London School of Hygiene and Tropical Medicine, COVID 19 VACCINE TRA; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Nilsson L, 2017, PEDIAT ALLERG IMM-UK, V28, P628, DOI 10.1111/pai.12762; Perino E, 2018, ANN ALLERG ASTHMA IM, V120, P664, DOI 10.1016/j.anai.2018.02.018; Public Health England Public Health England, COVID 19 GREEN BOOK; SAGEl WHO, ROADMAP PRIORITIZING; Sekine H, 2001, J IMMUNOL, V166, P6444, DOI 10.4049/jimmunol.166.10.6444; Shaker MS, 2020, J ALLERGY CLIN IMMUN, V145, P1082, DOI 10.1016/j.jaci.2020.01.017; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P125, DOI [10.15585/mmwr.mm7004e1, 10.1111/ajt.16517, 10.15585/mmwr.mm7004e1externalicon]; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Su JR, 2019, J ALLERGY CLIN IMMUN, V143, P1465, DOI 10.1016/j.jaci.2018.12.1003; Worm Margitta, 2021, Allergol Select, V5, P72, DOI 10.5414/ALX02225E	24	7	7	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							412	10.3390/vaccines9050412			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1JK	33919151	Green Published, gold			2022-04-29	WOS:000654582200001
J	Tan, S; Gutierrez, AH; Gauger, PC; Opriessnig, T; Bahl, J; Moise, L; De Groot, AS				Tan, Swan; Gutierrez, Andres Hazaet; Gauger, Phillip Charles; Opriessnig, Tanja; Bahl, Justin; Moise, Leonard; De Groot, Anne Searls			Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017	VACCINES			English	Article						swine IAV; immunoinformatics; T cell epitope conservation	CONTENT COMPARISON EPICC; MOLECULAR CHARACTERIZATION; VIRUS; PROTECTION; INFECTION; IDENTIFICATION; CHALLENGE; RESPONSES; DISEASE; CD4(+)	When swine flu vaccines and circulating influenza A virus (IAV) strains are poorly matched, vaccine-induced antibodies may not protect from infection. Highly conserved T cell epitopes may, however, have a disease-mitigating effect. The degree of T cell epitope conservation among circulating strains and vaccine strains can vary, which may also explain differences in vaccine efficacy. Here, we evaluate a previously developed conserved T cell epitope-based vaccine and determine the persistence of T cell epitope conservation over time. We used a pair-wise homology score to define the conservation between the vaccine's swine leukocyte antigen (SLA) class I and II-restricted epitopes and T cell epitopes found in 1272 swine IAV strains sequenced between 2013 and 2017. Twenty-four of the 48 total T cell epitopes included in the epitope-based vaccine were highly conserved and found in >1000 circulating swine IAV strains over the 5-year period. In contrast, commercial swine IAV vaccines developed in 2013 exhibited a declining conservation with the circulating IAV strains over the same 5-year period. Conserved T cell epitope vaccines may be a useful adjunct for commercial swine flu vaccines and to improve protection against influenza when antibodies are not cross-reactive.	[Tan, Swan; Bahl, Justin] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Tan, Swan; Bahl, Justin; Moise, Leonard; De Groot, Anne Searls] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Gutierrez, Andres Hazaet; Moise, Leonard; De Groot, Anne Searls] EpiVax Inc, Providence, RI 02909 USA; [Gauger, Phillip Charles; Opriessnig, Tanja] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA; [Opriessnig, Tanja] Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland		De Groot, AS (通讯作者)，Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA.; De Groot, AS (通讯作者)，EpiVax Inc, Providence, RI 02909 USA.	swan.tan@uga.edu; agutierrez@epivax.com; pcgauger@iastate.edu; Tanja.Opriessnig@roslin.ed.ac.uk; JUSTIN.BAHL@uga.edu; lmoise@uga.edu; dr.annie.degroot@gmail.com	Gauger, Phillip/AAQ-9806-2021; De Groot, Annie/B-6221-2013; Bahl, Justin/A-4728-2011	Gutierrez, Andres/0000-0002-6127-8327; De Groot, Annie/0000-0001-5911-1459; Moise, Lenny/0000-0002-4410-865X; Gauger, Phillip/0000-0003-2540-8769; Tan, Swan/0000-0002-0658-3396; Bahl, Justin/0000-0001-7572-4300	National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services [75N93019C00052]; NIH CEIRSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HHSN272201400006C, HHSN27220140000]	This research was funded in part from the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052 (S.T. and J. B.) and NIH CEIRS contracts HHSN272201400006C and HHSN27220140000 (J.B).	Bandrick M, 2020, VET IMMUNOL IMMUNOP, V223, DOI 10.1016/j.vetimm.2020.110034; Baratelli M, 2017, J GEN VIROL, V98, P895, DOI 10.1099/jgv.0.000748; Busquets N, 2010, VET RES, V41, DOI 10.1051/vetres/2010046; Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018; De Groot AS, 2009, VACCINE, V27, P5740, DOI 10.1016/j.vaccine.2009.07.040; Ellebedy AH, 2010, CLIN VACCINE IMMUNOL, V17, P1998, DOI 10.1128/CVI.00247-10; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Garcia-Garcia L, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3928; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gutierrez AH, 2017, INFLUENZA OTHER RESP, V11, P531, DOI 10.1111/irv.12513; Gutierrez AH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159237; Gutierrez AH, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0724-8; He L, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-S4-S1; Hewitt JS, 2019, VACCINE, V37, P4302, DOI 10.1016/j.vaccine.2019.06.044; Ho CS, 2010, ANIM GENET, V41, P428, DOI 10.1111/j.1365-2052.2010.02019.x; Ho CS, 2009, ANIM GENET, V40, P468, DOI 10.1111/j.1365-2052.2009.01860.x; Liu R, 2015, HUM VACC IMMUNOTHER, V11, P2241, DOI 10.1080/21645515.2015.1052197; Lowell GH, 2017, VACCINE, V35, P713, DOI 10.1016/j.vaccine.2016.12.063; Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159; Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1577, DOI 10.4161/hv.24615; Pedersen JC, 2014, METHODS MOL BIOL, V1161, P11, DOI 10.1007/978-1-4939-0758-8_2; Powell TJ, 2007, J IMMUNOL, V178, P1030, DOI 10.4049/jimmunol.178.2.1030; Qiu Y, 2015, VET RES, V46, DOI 10.1186/s13567-015-0236-6; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Tungatt K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007017; Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998; van Doorn E, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006339, 10.1097/md.0000000000006339]; Vincent AL, 2014, METHODS MOL BIOL, V1161, P243, DOI 10.1007/978-1-4939-0758-8_20; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; Wu T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10661-8; Yu GC, 2017, METHODS ECOL EVOL, V8, P28, DOI 10.1111/2041-210X.12628; Zhang Y, 2017, NUCLEIC ACIDS RES, V45, pD466, DOI 10.1093/nar/gkw857; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10	34	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							468	10.3390/vaccines9050468			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1TX	34066605	Green Published, gold			2022-04-29	WOS:000654609600001
J	Wang, HL; Xu, YY; Feng, WH				Wang, Honglei; Xu, Yangyang; Feng, Wenhai			Porcine Reproductive and Respiratory Syndrome Virus: Immune Escape and Application of Reverse Genetics in Attenuated Live Vaccine Development	VACCINES			English	Review						PRRSV; immune evasion; vaccine; reverse genetics	CYSTEINE PROTEASE DOMAIN; REGULATORY T-CELLS; DENDRITIC CELLS; NONSTRUCTURAL PROTEIN-2; MESSENGER-RNA; BONE-MARROW; AMINO-ACID; NEUTRALIZING ANTIBODIES; PROTECTIVE EFFICACY; NSP1-BETA PROTEIN	Porcine reproductive and respiratory syndrome virus (PRRSV), an RNA virus widely prevalent in pigs, results in significant economic losses worldwide. PRRSV can escape from the host immune response in several processes. Vaccines, including modified live vaccines and inactivated vaccines, are the best available countermeasures against PRRSV infection. However, challenges still exist as the vaccines are not able to induce broad protection. The reason lies in several facts, mainly the variability of PRRSV and the complexity of the interaction between PRRSV and host immune responses, and overcoming these obstacles will require more exploration. Many novel strategies have been proposed to construct more effective vaccines against this evolving and smart virus. In this review, we will describe the mechanisms of how PRRSV induces weak and delayed immune responses, the current vaccines of PRRSV, and the strategies to develop modified live vaccines using reverse genetics systems.	[Wang, Honglei; Xu, Yangyang; Feng, Wenhai] China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China; [Wang, Honglei; Xu, Yangyang; Feng, Wenhai] China Agr Univ, Minist Agr, Key Lab Soil Microbiol, Beijing 100193, Peoples R China; [Wang, Honglei; Xu, Yangyang; Feng, Wenhai] China Agr Univ, Coll Biol Sci, Dept Microbiol & Immunol, Beijing 100193, Peoples R China		Feng, WH (通讯作者)，China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China.; Feng, WH (通讯作者)，China Agr Univ, Minist Agr, Key Lab Soil Microbiol, Beijing 100193, Peoples R China.; Feng, WH (通讯作者)，China Agr Univ, Coll Biol Sci, Dept Microbiol & Immunol, Beijing 100193, Peoples R China.	wanghl@cau.edu.cn; SZ20183020174@cau.edu.cn; whfeng@cau.edu.cn			National Key Research and Development Program of China [2017YFD0500601-1]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31630076]	This work was supported by funds from the National Key Research and Development Program of China (Grant No. 2017YFD0500601-1) and the National Natural Science Foundation of China (Grant No. 31630076).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Albina E, 1998, VET IMMUNOL IMMUNOP, V61, P49, DOI 10.1016/S0165-2427(97)00134-7; Allende R, 2000, J VIROL, V74, P10834, DOI 10.1128/JVI.74.22.10834-10837.2000; An CH, 2018, PLANTA, V247, P973, DOI 10.1007/s00425-017-2836-z; An TQ, 2011, VET MICROBIOL, V149, P104, DOI 10.1016/j.vetmic.2010.11.001; Bai XF, 2016, VACCINE, V34, P5540, DOI 10.1016/j.vaccine.2016.09.048; Bernelin-Cottet C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060551; Beura LK, 2012, VIROLOGY, V433, P431, DOI 10.1016/j.virol.2012.08.034; Beura LK, 2010, J VIROL, V84, P1574, DOI 10.1128/JVI.01326-09; Beyer J, 2000, J VET MED B, V47, P9, DOI 10.1046/j.1439-0450.2000.00305.x; Bian T, 2017, INFECT GENET EVOL, V54, P279, DOI 10.1016/j.meegid.2017.07.016; Binjawadagi B, 2014, INT J NANOMED, V9, P2259, DOI 10.2147/IJN.S66411; Binjawadagi B, 2016, ARCH VIROL, V161, P1579, DOI 10.1007/s00705-016-2812-0; Brockmeier SL, 2012, CLIN VACCINE IMMUNOL, V19, P508, DOI 10.1128/CVI.05490-11; Butler JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01077; Calzada-Nova G, 2011, J VIROL, V85, P2703, DOI 10.1128/JVI.01616-10; Cano JP, 2007, VACCINE, V25, P4382, DOI 10.1016/j.vaccine.2007.03.031; Cao QM, 2018, J VIROL, V92, DOI [10.1128/JVI.00007-18, 10.1128/jvi.00007-18]; Chae C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020185; Chang HC, 2008, VET MICROBIOL, V129, P281, DOI 10.1016/j.vetmic.2007.12.002; Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23; Chen JY, 2019, J VIROL, V93, DOI 10.1128/JVI.00385-19; Chen Z, 2014, VIRUS RES, V189, P226, DOI 10.1016/j.virusres.2014.05.027; Cho Y, 2020, ANIM BIOTECHNOL, V31, P32, DOI 10.1080/10495398.2018.1531014; Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761; Cruz JLG, 2010, VIRUS RES, V154, P150, DOI 10.1016/j.virusres.2010.06.017; Cui JR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010106; Dokland T, 2010, VIRUS RES, V154, P86, DOI 10.1016/j.virusres.2010.07.029; Duan X, 1997, VET MICROBIOL, V56, P9, DOI 10.1016/S0378-1135(96)01347-8; Ellingson JS, 2010, VACCINE, V28, P2679, DOI 10.1016/j.vaccine.2009.12.073; Evenson D, 2016, VACCINE, V34, P5546, DOI 10.1016/j.vaccine.2016.09.049; Fang Y, 2010, VIRUS RES, V154, P61, DOI 10.1016/j.virusres.2010.07.030; Flores-Mendoza L, 2008, CLIN VACCINE IMMUNOL, V15, P720, DOI 10.1128/CVI.00224-07; Gao L, 2015, VIROLOGY, V485, P135, DOI 10.1016/j.virol.2015.07.012; Gomez-Laguna J, 2013, TRANSBOUND EMERG DIS, V60, P273, DOI 10.1111/j.1865-1682.2012.01338.x; Han J, 2017, VET MICROBIOL, V209, P30, DOI 10.1016/j.vetmic.2017.02.020; Han J, 2010, J VIROL, V84, P10102, DOI 10.1128/JVI.01208-10; Han MY, 2017, METHODS MOL BIOL, V1602, P29, DOI 10.1007/978-1-4939-6964-7_3; Han MY, 2017, VIROLOGY, V505, P42, DOI 10.1016/j.virol.2017.02.004; Hanson G, 2018, NAT REV MOL CELL BIO, V19, P20, DOI 10.1038/nrm.2017.91; He YL, 2012, VET MICROBIOL, V160, P455, DOI 10.1016/j.vetmic.2012.05.040; Henao-Diaz A, 2020, RES VET SCI, V131, P173, DOI 10.1016/j.rvsc.2020.04.023; Hoenen T, 2011, ANTIVIR RES, V91, P195, DOI 10.1016/j.antiviral.2011.06.003; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Huang C, 2016, SCI REP-UK, V6, DOI 10.1038/srep28497; Huang C, 2015, VIRUS RES, V202, P101, DOI 10.1016/j.virusres.2014.12.014; Huang C, 2014, J VIROL, V88, P10934, DOI 10.1128/JVI.01396-14; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jiang WM, 2008, VIRUS RES, V136, P50, DOI 10.1016/j.virusres.2008.04.016; Jiang YB, 2007, VACCINE, V25, P547, DOI 10.1016/j.vaccine.2006.07.032; Kanamori M, 2016, TRENDS IMMUNOL, V37, P803, DOI 10.1016/j.it.2016.08.012; Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012; Ke HZ, 2018, VIROLOGY, V517, P177, DOI 10.1016/j.virol.2018.01.016; Kick AR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090796; Kim O, 2010, VIROLOGY, V402, P315, DOI 10.1016/j.virol.2010.03.039; Kim WI, 2008, VIRUS GENES, V37, P380, DOI 10.1007/s11262-008-0278-1; Kroese MV, 2008, J GEN VIROL, V89, P494, DOI 10.1099/vir.0.83253-0; Lee JA, 2014, J MICROBIOL, V52, P345, DOI 10.1007/s12275-014-4074-4; Leng CL, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0825-2; Li HX, 2010, J GEN VIROL, V91, P2947, DOI 10.1099/vir.0.025205-0; Li LW, 2015, VIRUS RES, V195, P86, DOI 10.1016/j.virusres.2014.08.012; Li Y, 2018, VIROLOGY, V517, P164, DOI 10.1016/j.virol.2017.12.017; Li YH, 2016, J VIROL, V90, P3584, DOI 10.1128/JVI.03069-15; Li ZJ, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0380-7; Li ZJ, 2015, VET IMMUNOL IMMUNOP, V168, P40, DOI 10.1016/j.vetimm.2015.08.003; Lim B, 2020, VET RES, V51, DOI 10.1186/s13567-020-00850-5; Lin L, 2012, J VIROL, V86, P10359, DOI 10.1128/JVI.00665-12; Liu JL, 2016, DEV COMP IMMUNOL, V65, P245, DOI 10.1016/j.dci.2016.07.012; Liu K, 2019, VET MICROBIOL, V229, P28, DOI 10.1016/j.vetmic.2018.12.015; Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06; Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Manickam C, 2013, VET MICROBIOL, V162, P68, DOI 10.1016/j.vetmic.2012.08.021; Meier WA, 2000, AMERICAN ASSOCIATION OF SWINE PRACTITIONERS 2000, PROCEEDINGS, P415; Meulenberg JJM, 1998, J VIROL, V72, P380, DOI 10.1128/JVI.72.1.380-387.1998; Morgan SB, 2016, TRANSBOUND EMERG DIS, V63, P285, DOI 10.1111/tbed.12272; Mount A, 2013, EXPERT REV VACCINES, V12, P733, DOI 10.1586/14760584.2013.811185; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Nazki S, 2020, VET RES, V51, DOI 10.1186/s13567-020-00789-7; Nedialkova DD, 2009, J VIROL, V83, P5671, DOI 10.1128/JVI.00261-09; Nedumpun T, 2018, VET MICROBIOL, V216, P13, DOI 10.1016/j.vetmic.2018.01.014; Ni YY, 2014, VIROLOGY, V450, P132, DOI 10.1016/j.virol.2013.12.009; Ni YY, 2013, J VIROL, V87, P304, DOI 10.1128/JVI.01789-12; Nogales A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010020; Ogno G, 2019, VET MICROBIOL, V232, P137, DOI 10.1016/j.vetmic.2019.04.016; Osorio FA, 2002, VIROLOGY, V302, P9, DOI 10.1006/viro.2002.1612; Ostrowski M, 2002, J VIROL, V76, P4241, DOI 10.1128/JVI.76.9.4241-4250.2002; Amarilla SP, 2017, VET MICROBIOL, V201, P126, DOI 10.1016/j.vetmic.2016.12.040; Park C, 2020, VIROLOGY, V540, P172, DOI 10.1016/j.virol.2019.10.019; Patel D, 2010, J VIROL, V84, P11045, DOI 10.1128/JVI.00655-10; Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020; Pineyro PE, 2016, VIRAL IMMUNOL, V29, P546, DOI 10.1089/vim.2016.0104; Quax TEF, 2015, MOL CELL, V59, P149, DOI 10.1016/j.molcel.2015.05.035; Rascon-Castelo E, 2015, VIRUSES-BASEL, V7, P873, DOI 10.3390/v7030873; Renukaradhya GJ, 2015, VACCINE, V33, P4069, DOI 10.1016/j.vaccine.2015.06.092; Renukaradhya GJ, 2015, VACCINE, V33, P3065, DOI 10.1016/j.vaccine.2015.04.102; Robinson SR, 2015, VIRUS RES, V203, P56, DOI 10.1016/j.virusres.2015.03.016; Rodriguez-Gomez Irene M, 2013, World J Virol, V2, P146, DOI 10.5501/wjv.v2.i4.146; Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040; Rossi M, 2005, J IMMUNOL, V175, P1373, DOI 10.4049/jimmunol.175.3.1373; Ruedas-Torres I, 2020, VET MICROBIOL, V243, DOI 10.1016/j.vetmic.2020.108639; Sagong M, 2011, ARCH VIROL, V156, P2187, DOI 10.1007/s00705-011-1116-7; Sarkar I, 2019, EXPERT REV VACCINES, V18, P505, DOI 10.1080/14760584.2019.1604231; Sautter CA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090829; Shabir N, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8080240; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; Silva-Campa E, 2012, VIROLOGY, V430, P73, DOI 10.1016/j.virol.2012.04.009; Sirisereewan C, 2017, VET IMMUNOL IMMUNOP, V183, P7, DOI 10.1016/j.vetimm.2016.11.002; Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985; Snijder EJ, 2013, J GEN VIROL, V94, P2141, DOI 10.1099/vir.0.056341-0; Stoian AMM, 2019, VET SCI, V6, DOI 10.3390/vetsci6010009; Su F, 2019, J VET MED SCI, V81, P1475, DOI 10.1292/jvms.19-0057; Su J, 2019, VIROL SIN, V34, P631, DOI 10.1007/s12250-019-00149-6; Subramaniam S, 2014, VACCINE, V32, P6768, DOI 10.1016/j.vaccine.2014.10.005; Sun D, 2016, VACCINE, V34, P4335, DOI 10.1016/j.vaccine.2016.06.069; Sun Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168314; Sun Z, 2012, J VIROL, V86, P3839, DOI 10.1128/JVI.06466-11; Sun Z, 2010, J VIROL, V84, P7832, DOI 10.1128/JVI.00217-10; Tats A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-463; Tian DB, 2017, VACCINE, V35, P2427, DOI 10.1016/j.vaccine.2017.03.046; Tian DB, 2015, VIROLOGY, V485, P402, DOI 10.1016/j.virol.2015.08.021; Tian Kegong, 2017, Open Virol J, V11, P59, DOI 10.2174/1874357901711010059; Tian XS, 2009, J MOL BIOL, V392, P977, DOI 10.1016/j.jmb.2009.07.062; Trible BR, 2015, J VIROL, V89, P6515, DOI 10.1128/JVI.03287-14; Vu HLX, 2015, J VIROL, V89, P12070, DOI 10.1128/JVI.01657-15; Walker PJ, 2019, ARCH VIROL, V164, P2417, DOI 10.1007/s00705-019-04306-w; Wang AP, 2019, EMERG INFECT DIS, V25, P2335, DOI 10.3201/eid2512.191111; Wang D, 2019, J VIROL, V93, DOI 10.1128/JVI.00623-19; Wang G, 2016, J GEN VIROL, V97, P1356, DOI 10.1099/jgv.0.000454; Wang LH, 2014, VACCINE, V32, P5740, DOI 10.1016/j.vaccine.2014.08.036; Wang R, 2013, J VIROL, V87, P5219, DOI 10.1128/JVI.02643-12; Wang X, 2007, ARCH VIROL, V152, P289, DOI 10.1007/s00705-006-0857-1; Wang XL, 2009, VIRUS RES, V143, P24, DOI 10.1016/j.virusres.2009.02.017; Wang YL, 2013, VET IMMUNOL IMMUNOP, V154, P121, DOI 10.1016/j.vetimm.2013.05.008; Wang Y, 2008, VIROLOGY, V371, P418, DOI 10.1016/j.virol.2007.09.032; Weesendorp E, 2014, VET MICROBIOL, V174, P127, DOI 10.1016/j.vetmic.2014.09.010; Wei ZY, 2020, VIROLOGY, V546, P79, DOI 10.1016/j.virol.2020.04.007; Wu CY, 2020, J VIROL, V94, DOI 10.1128/JVI.01423-20; Wu CY, 2020, ANTIVIR RES, V175, DOI 10.1016/j.antiviral.2020.104716; Yang C, 2013, P NATL ACAD SCI USA, V110, P9481, DOI 10.1073/pnas.1307473110; Yang L, 2000, ARCH VIROL, V145, P1599, DOI 10.1007/s007050070079; Yang LP, 2019, J VIROL, V93, DOI 10.1128/JVI.01352-19; Yoon KJ, 1996, VIRAL IMMUNOL, V9, P51, DOI 10.1089/vim.1996.9.51; Yu DB, 2015, IMMUNOL LETT, V168, P293, DOI 10.1016/j.imlet.2015.10.007; Yu HY, 2019, VIRAL IMMUNOL, V32, P383, DOI 10.1089/vim.2019.0092; Zhang Q, 2014, VIROLOGY, V450, P182, DOI 10.1016/j.virol.2013.12.020; Zhao HY, 2014, J VET SCI, V15, P199, DOI 10.4142/jvs.2014.15.2.199; Zhao K, 2019, VET MICROBIOL, V233, P140, DOI 10.1016/j.vetmic.2019.05.003; Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066645; Zhou L, 2012, VIROLOGY, V434, P96, DOI 10.1016/j.virol.2012.09.005; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	151	1	1	13	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							480	10.3390/vaccines9050480			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3EZ	34068505	gold, Green Published			2022-04-29	WOS:000654709700001
J	Hwang, JH; Lee, G; Kim, A; Park, JH; Lee, MJ; Kim, B; Kim, SM				Hwang, Ji-Hyeon; Lee, Gyeongmin; Kim, Aro; Park, Jong-Hyeon; Lee, Min Ja; Kim, Byounghan; Kim, Su-Mi			A Vaccine Strain of the A/ASIA/Sea-97 Lineage of Foot-and-Mouth Disease Virus with a Single Amino Acid Substitution in the P1 Region That Is Adapted to Suspension Culture Provides High Immunogenicity	VACCINES			English	Article						foot-and-mouth disease virus; vaccine; A/ASIA/Sea-97; immunogenicity		There are seven viral serotypes of foot-and-mouth disease virus (FMDV): A, O, C, Asia 1, and Southern African Territories 1, 2, and 3 (SAT 1-3). Unlike serotype O FMDV vaccine strains, vaccine strains of serotype A FMDV do not provide broad-range cross-reactivity in serological matching tests with field isolates. Therefore, the topotype/lineage vaccine strain circulating in many countries and a highly immunogenic strain might be advantageous to control serotype A FMDV. We developed a new vaccine strain, A/SKR/Yeoncheon/2017 (A-1), which belongs to the A/ASIA/Sea-97 lineage that frequently occurs in Asian countries. Using virus plaque purification, we selected a vaccine virus with high antigen productivity and the lowest numbers of P1 mutations among cell-adapted virus populations. The A/SKR/Yeoncheon/2017 (A-1) vaccine strain has a single amino acid mutation, VP2 E82K, in the P1 region, and it is perfectly adapted to suspension culture. The A/SKR/Yeoncheon/2017 (A-1) experimental vaccine conferred high immunogenicity in pigs. The vaccine strain was serologically matched with various field isolates in two-dimensional virus neutralization tests using bovine serum. Vaccinated mice were protected against an A/MAY/97 virus that was serologically mismatched with the vaccine strain. Thus, A/SKR/Yeoncheon/2017 (A-1) might be a promising vaccine candidate for protection against the emerging FMDV serotype A in Asia.	[Hwang, Ji-Hyeon; Lee, Gyeongmin; Kim, Aro; Park, Jong-Hyeon; Lee, Min Ja; Kim, Byounghan; Kim, Su-Mi] Anim & Plant Quarantine Agcy, Ctr Foot & Mouth Dis Vaccine Res, 177 Hyeoksin 8 Ro, Gimcheon City 39660, South Korea		Kim, SM (通讯作者)，Anim & Plant Quarantine Agcy, Ctr Foot & Mouth Dis Vaccine Res, 177 Hyeoksin 8 Ro, Gimcheon City 39660, South Korea.	jihyeonh87@korea.kr; lgm6004@korea.kr; arokim728@korea.kr; parkjhvet@korea.kr; herb12@korea.kr; kimbh61@korea.kr; beliefsk@korea.kr		Kim, Su-Mi/0000-0002-9242-2731; Park, Jong-Hyeon/0000-0003-0825-8121; Lee, Min Ja/0000-0002-5916-5083	Animal and Plant Quarantine Agency, Republic of Korea	This work was supported by the Animal and Plant Quarantine Agency, Republic of Korea.	Alexandersen S, 2003, J COMP PATHOL, V129, P1, DOI 10.1016/S0021-9975(03)00041-0; Amadori M, 1997, BIOLOGICALS, V25, P65, DOI 10.1006/biol.1996.0061; Anil KU, 2012, BIOLOGICALS, V40, P426, DOI 10.1016/j.biologicals.2012.08.002; [Anonymous], 2020, FOOT AND MOUTH DIS Q, P13; Bankowska K., 2017, GU240NF FAO; Baranowski E, 2000, J VIROL, V74, P1641, DOI 10.1128/JVI.74.4.1641-1647.2000; BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879; BAXT B, 1989, J VIROL, V63, P2143, DOI 10.1128/JVI.63.5.2143-2151.1989; Bochkov YA, 2016, VIROLOGY, V499, P350, DOI 10.1016/j.virol.2016.09.025; Brehm KE, 2008, VACCINE, V26, P1681, DOI 10.1016/j.vaccine.2008.01.038; Chamberlain K, 2015, J GEN VIROL, V96, P2684, DOI 10.1099/jgv.0.000222; Choi JH, 2019, VET MICROBIOL, V236, DOI 10.1016/j.vetmic.2019.07.026; Curry S, 1996, STRUCTURE, V4, P135, DOI 10.1016/S0969-2126(96)00017-2; Dill V, 2020, VIRUS GENES, V56, P1, DOI 10.1007/s11262-019-01714-7; Dill V, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080231; Domingo E, 2003, VIRUS RES, V91, P47, DOI 10.1016/S0168-1702(02)00259-9; Domingo E, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008271; Ferrari G., 2016, FOOT MOUTH DIS VACCI, P28; Frings W, 2001, J GEN VIROL, V82, P597, DOI 10.1099/0022-1317-82-3-597; Fry EE, 2005, J GEN VIROL, V86, P1909, DOI 10.1099/vir.0.80730-0; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Jo HE, 2019, J VET SCI, V20, DOI 10.4142/jvs.2019.20.e42; Kim SM, 2015, J VIROL, V89, P8267, DOI 10.1128/JVI.00766-15; Kim SM, 2010, ANTIVIR RES, V87, P307, DOI 10.1016/j.antiviral.2010.06.004; Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5; Ko MK, 2019, VET MICROBIOL, V229, P124, DOI 10.1016/j.vetmic.2018.12.023; LaRocco M, 2015, J CLIN MICROBIOL, V53, P755, DOI 10.1128/JCM.03220-14; Lawrence P, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-2; LEWIS AM, 1970, J VIROL, V5, P413, DOI 10.1128/JVI.5.4.413-420.1970; Mahapatra M, 2016, VACCINE, V34, P3199, DOI 10.1016/j.vaccine.2016.02.057; Mohapatra JK, 2015, J GEN VIROL, V96, P553, DOI 10.1099/vir.0.071597-0; Moraes MP, 2007, J VIROL, V81, P7124, DOI 10.1128/JVI.02775-06; Nunez JI, 2001, J VIROL, V75, P3977, DOI 10.1128/JVI.75.8.3977-3983.2001; OIE, MANUAL DIAGNOSTIC TE; Pandey LK, 2014, VIRUS RES, V181, P72, DOI 10.1016/j.virusres.2014.01.009; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; Paton DJ, 2005, REV SCI TECH OIE, V24, P981, DOI 10.20506/rst.24.3.1632; PAY TWF, 1992, VACCINE, V10, P699, DOI 10.1016/0264-410X(92)90092-X; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reeve R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159360; SaCarvalho D, 1997, J VIROL, V71, P5115, DOI 10.1128/JVI.71.7.5115-5123.1997; Singanallur NB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010080; Tami C, 2003, J VIROL, V77, P1219, DOI 10.1128/JVI.77.2.1219-1226.2003; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zhao QZ, 2003, J VIROL, V77, P3269, DOI 10.1128/JVI.77.5.3269-3280.2003	45	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							308	10.3390/vaccines9040308			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5RO	33805012	gold, Green Published			2022-04-29	WOS:000643836300001
J	Kowalzik, F; Schreiner, D; Jensen, C; Teschner, D; Gehring, S; Zepp, F				Kowalzik, Frank; Schreiner, Daniel; Jensen, Christian; Teschner, Daniel; Gehring, Stephan; Zepp, Fred			mRNA-Based Vaccines	VACCINES			English	Review						mRNA; vaccine constructs; delivery systems; lipid nanoparticles; cancer; infectious disease	RABIES VACCINE; CIRCULAR RNAS; DELIVERY; NANOPARTICLES; RECOGNITION; GENERATION; PROTECTION; INDUCTION; INFLUENZA; RESPONSES	Increases in the world's population and population density promote the spread of emerging pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional methods used to identify and produce new vaccines are not adequate, in most instances, to ensure global protection. New technologies are urgently needed to expedite large scale vaccine development. mRNA-based vaccines promise to meet this need. mRNA-based vaccines exhibit a number of potential advantages relative to conventional vaccines, namely they (1) involve neither infectious elements nor a risk of stable integration into the host cell genome; (2) generate humoral and cell-mediated immunity; (3) are well-tolerated by healthy individuals; and (4) are less expensive and produced more rapidly by processes that are readily standardized and scaled-up, improving responsiveness to large emerging outbreaks. Multiple mRNA vaccine platforms have demonstrated efficacy in preventing infectious diseases and treating several types of cancers in humans as well as animal models. This review describes the factors that contribute to maximizing the production of effective mRNA vaccine transcripts and delivery systems, and the clinical applications are discussed in detail.	[Kowalzik, Frank; Schreiner, Daniel; Jensen, Christian; Gehring, Stephan; Zepp, Fred] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Pediat Dept, D-55128 Mainz, Germany; [Teschner, Daniel] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Hematol Med Oncol & Pneumol, D-55122 Mainz, Germany		Kowalzik, F (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Pediat Dept, D-55128 Mainz, Germany.	frank.kowalzik@unimedizin-mainz.de; daniel.schreiner@unimedizin-mainz.de; christian.jensen@unimedizin-mainz.de; daniel.teschner@unimedizin-mainz.de; Stephan.Gehring@unimedizin-mainz.de; fred.zepp@unimedizin-mainz.de	Teschner, Daniel/AAG-2110-2019	Teschner, Daniel/0000-0001-7351-8060; Kowalzik, Frank/0000-0002-0407-124X; Jensen, Christian/0000-0003-0577-1624; Schreiner, Daniel/0000-0001-9363-8051			Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Aldrich C, 2021, VACCINE, V39, P1310, DOI 10.1016/j.vaccine.2020.12.070; Alfagih IM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010045; [Anonymous], Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids; Armbruster N, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040132; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074; Benteyn D, 2015, EXPERT REV VACCINES, V14, P161, DOI 10.1586/14760584.2014.957684; Bordon Y, 2020, NAT REV IMMUNOL, V20, P517, DOI 10.1038/s41577-020-00417-7; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Broderick KE, 2017, METHODS MOL BIOL, V1499, P193, DOI 10.1007/978-1-4939-6481-9_12; Broos Katrijn, 2016, Mol Ther Nucleic Acids, V5, pe326, DOI 10.1038/mtna.2016.38; Burki T, 2021, LANCET, V397, P462, DOI 10.1016/S0140-6736(21)00298-1; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; CONRY RM, 1995, CANCER RES, V55, P1397; Devarkar SC, 2016, P NATL ACAD SCI USA, V113, P596, DOI 10.1073/pnas.1515152113; Durymanov M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00971; Feng ZY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00500; Fiedler K, 2016, RECENT RESULTS CANC, V209, P61, DOI 10.1007/978-3-319-42934-2_5; Goldstrohm AC, 2008, NAT REV MOL CELL BIO, V9, P337, DOI 10.1038/nrm2370; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Hattinger E, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/797421; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Jackson LA, 2020, NEW ENGL J MED, V383, P1190, DOI 10.1056/NEJMc2026616; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kremsner PG, 2021, WIEN KLIN WOCHENSCHR, V133, P931, DOI 10.1007/s00508-021-01922-y; Krienke Christina, 2021, Science, V371, P145, DOI 10.1126/science.aay3638; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lima SA, 2017, NAT STRUCT MOL BIOL, V24, P1057, DOI 10.1038/nsmb.3499; Ljungberg K, 2015, EXPERT REV VACCINES, V14, P177, DOI 10.1586/14760584.2015.965690; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pepini T, 2017, J IMMUNOL, V198, P4012, DOI 10.4049/jimmunol.1601877; Perche F, 2011, NANOMED-NANOTECHNOL, V7, P445, DOI 10.1016/j.nano.2010.12.010; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; Rauch S., 2020, MRNA VACCINE CVNCOV, DOI [10.1101/2020.12.23.424138, DOI 10.1101/2020.12.23.424138]; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Rauch S, 2017, METHODS MOL BIOL, V1499, P89, DOI 10.1007/978-1-4939-6481-9_5; Rausch S, 2014, HUM VACC IMMUNOTHER, V10, P3146, DOI 10.4161/hv.29553; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Scheiblhofer S, 2018, PEDIAT ALLERG IMM-UK, V29, P679, DOI 10.1111/pai.12964; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Smits ELJM, 2009, HUM GENE THER, V20, P1106, DOI 10.1089/hum.2009.145; Stanton MG, 2018, NUCLEIC ACID THER, V28, P158, DOI 10.1089/nat.2018.0726; Swaminathan G, 2016, VACCINE, V34, P110, DOI 10.1016/j.vaccine.2015.10.132; Tacken PJ, 2006, IMMUNOBIOLOGY, V211, P599, DOI 10.1016/j.imbio.2006.05.021; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; Veiga N, 2020, ADV DRUG DELIVER REV, V159, P364, DOI 10.1016/j.addr.2020.04.002; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Vormehr M, 2016, CURR OPIN IMMUNOL, V39, P14, DOI 10.1016/j.coi.2015.12.001; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wesselhoeft RA, 2019, MOL CELL, V74, P508, DOI 10.1016/j.molcel.2019.02.015; Wesselhoeft RA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05096-6; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Zeng Chunxi, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_217; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	87	12	13	91	140	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							390	10.3390/vaccines9040390			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX5RR	33921028	Green Published, gold			2022-04-29	WOS:000647281400001
J	Philippens, IHCHM; Langermans, JAM				Philippens, Ingrid H. C. H. M.; Langermans, Jan A. M.			Preclinical Marmoset Model for Targeting Chronic Inflammation as a Strategy to Prevent Alzheimer's Disease	VACCINES			English	Review						Alzheimer's disease; amyloidosis; amyloid-beta plaques; inflammation; microglia; non-human primates	ANTIINFLAMMATORY DRUG-USE; MARROW-DERIVED MICROGLIA; INNATE IMMUNE-SYSTEM; AMYLOID-BETA; COMMON MARMOSET; NONHUMAN-PRIMATES; A-BETA; NEUROINFLAMMATORY PHENOTYPE; COGNITIVE IMPAIRMENT; LONG-TERM	Due to the aging population, modern society is facing an increasing prevalence of neurological diseases such as Alzheimer's disease (AD). AD is an age-related chronic neurodegenerative disorder for which no satisfying therapy exists. Understanding the mechanisms underlying the onset of AD is necessary to find targets for protective treatment. There is growing awareness of the essential role of the immune system in the early AD pathology. Amyloidopathy, the main feature of early-stage AD, has a deregulating effect on the immune function. This is reciprocal as the immune system also affects amyloidopathy. It seems that the inflammatory reaction shows a heterogeneous pattern depending on the stage of the disease and the variation between individuals, making not only the target but also the timing of treatment important. The lack of relevant translational animal models that faithfully reproduce clinical and pathogenic features of AD is a major cause of the delay in developing new disease-modifying therapies and their optimal timing of administration. This review describes the communication between amyloidopathy and inflammation and the possibility of using nonhuman primates as a relevant animal model for preclinical AD research.	[Philippens, Ingrid H. C. H. M.; Langermans, Jan A. M.] Biomed Primate Res Ctr BPRC, Dept Anim Sci, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands; [Langermans, Jan A. M.] Univ Utrecht, Fac Vet Med, Dept Populat Hlth Sci, Unit Anim Sci & Soc, Yalelaan 1, NL-3584 CL Utrecht, Netherlands		Philippens, IHCHM (通讯作者)，Biomed Primate Res Ctr BPRC, Dept Anim Sci, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands.	philippens@bprc.nl; langermans@bprc.nl		Langermans, Jan/0000-0002-4806-4412			Ahmed M, 2010, NAT STRUCT MOL BIOL, V17, P561, DOI 10.1038/nsmb.1799; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alvarez-Rodriguez L, 2012, CELL IMMUNOL, V273, P124, DOI 10.1016/j.cellimm.2012.01.001; Alzheimer's Assoc, 2018, ALZHEIMERS DEMENT, V14, P367, DOI 10.1016/j.jalz.2018.02.001; Antunes SG, 1998, P NATL ACAD SCI USA, V95, P11745, DOI 10.1073/pnas.95.20.11745; Austad SN, 2009, J GERONTOL A-BIOL, V64, P199, DOI 10.1093/gerona/gln060; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Barkholt P, 2012, NEUROSCIENCE, V208, P85, DOI 10.1016/j.neuroscience.2012.02.004; Baron R, 2014, AGING CELL, V13, P584, DOI 10.1111/acel.12210; Beckman D, 2021, ALZHEIMERS DEMENT, V17, P933, DOI 10.1002/alz.12318; Bertini Giuseppe, 2010, Italian Journal of Anatomy and Embryology, V115, P31; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Braak H, 2012, ALZHEIMERS DEMENT, V8, P227, DOI 10.1016/j.jalz.2012.01.011; Carrion R, 2012, CURR OPIN VIROL, V2, P357, DOI 10.1016/j.coviro.2012.02.007; Colman RJ, 2018, BBA-MOL BASIS DIS, V1864, P2733, DOI 10.1016/j.bbadis.2017.07.008; Conde JR, 2006, J NEUROPATH EXP NEUR, V65, P199, DOI 10.1097/01.jnen.0000202887.22082.63; Cote S, 2012, ALZHEIMERS DEMENT, V8, P219, DOI 10.1016/j.jalz.2011.03.012; Cuello AC, 2012, NEURODEGENER DIS, V10, P104, DOI 10.1159/000333339; Cuello AC, 2010, NEURODEGENER DIS, V7, P96, DOI 10.1159/000285514; Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350; Didier ES, 2016, VET PATHOL, V53, P277, DOI 10.1177/0300985815622974; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; Doens D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-48; DONNELLY RJ, 1990, CELL MOL NEUROBIOL, V10, P485, DOI 10.1007/BF00712843; Egan K J, 2016, Evid Based Preclin Med, V3, pe00015, DOI 10.1002/ebm2.15; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Fang F, 2018, HUM MOL GENET, V27, P1002, DOI 10.1093/hmg/ddy017; Fiala M, 2010, EXP GERONTOL, V45, P57, DOI 10.1016/j.exger.2009.08.003; Finch CE, 2012, AGE, V34, P1075, DOI 10.1007/s11357-011-9355-9; Folch J, 2018, CURR NEUROPHARMACOL, V16, P1466, DOI 10.2174/1570159X15666170707155345; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Franke SK, 2016, NEUROSCIENCE, V312, P247, DOI 10.1016/j.neuroscience.2015.09.065; Franke SK, 2016, NEURODEGENER DIS, V16, P293, DOI 10.1159/000442574; Frautschy SA, 1998, AM J PATHOL, V152, P307; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Geula C, 2002, ACTA NEUROPATHOL, V103, P48, DOI 10.1007/s004010100429; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Gotz J, 2009, ASN NEURO, V1, DOI 10.1042/AN20090042; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270; Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069; Hanzel CE, 2014, NEUROBIOL AGING, V35, P2249, DOI 10.1016/j.neurobiolaging.2014.03.026; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Jaeger LB, 2009, BRAIN BEHAV IMMUN, V23, P507, DOI 10.1016/j.bbi.2009.01.017; Johnston H, 2011, BIOCHEM SOC T, V39, P886, DOI 10.1042/BST0390886; Kaas JH, 2013, WIRES COGN SCI, V4, P33, DOI 10.1002/wcs.1206; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; Kametani F, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00025; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Kobayashi R, 2016, NEUROSCI RES, V106, P55, DOI 10.1016/j.neures.2015.11.006; Kraft AW, 2013, FASEB J, V27, P187, DOI 10.1096/fj.12-208660; Kwan C, 2021, NEUROPHARMACOLOGY, V186, DOI 10.1016/j.neuropharm.2021.108465; Lacreuse A, 2020, PHILOS T R SOC B, V375, DOI 10.1098/rstb.2019.0618; Latimer CS, 2019, ALZHEIMERS DEMENT, V15, P93, DOI 10.1016/j.jalz.2018.06.3057; Latta CH, 2015, NEUROSCIENCE, V302, P103, DOI 10.1016/j.neuroscience.2014.09.061; Launer LJ, 2003, DRUGS, V63, P731, DOI 10.2165/00003495-200363080-00001; Lee HG, 2005, TRENDS MOL MED, V11, P164, DOI 10.1016/j.molmed.2005.02.008; Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/437483; Logan AC, 1996, TOXICOL PATHOL, V24, P707, DOI 10.1177/019262339602400605; Lombardi VRM, 1999, J NEUROIMMUNOL, V97, P163, DOI 10.1016/S0165-5728(99)00046-6; Maclean CJ, 2000, J NEURAL TRANSM, V107, P799, DOI 10.1007/s007020070060; Maezawa I, 2011, J BIOL CHEM, V286, P3693, DOI 10.1074/jbc.M110.135244; Mandavilli A, 2006, NAT MED, V12, P747, DOI 10.1038/nm0706-747; Mansfield K, 2003, COMPARATIVE MED, V53, P383; Marlatt MW, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/693851; McCusker SM, 2001, LANCET, V357, P436, DOI 10.1016/S0140-6736(00)04008-3; McGeer PL, 1996, ANN NY ACAD SCI, V777, P213, DOI 10.1111/j.1749-6632.1996.tb34421.x; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mietsch M, 2020, AM J PRIMATOL, V82, DOI 10.1002/ajp.23128; Minhas PS, 2021, NATURE, V590, P122, DOI 10.1038/s41586-020-03160-0; Montine TJ, 1999, NEUROLOGY, V53, P1495, DOI 10.1212/WNL.53.7.1495; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Nakashima E, 2013, J VET MED SCI, V75, P1633, DOI 10.1292/jvms.13-0257; Narayan P, 2014, BIOCHEMISTRY-US, V53, P2442, DOI 10.1021/bi401606f; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Noorbakhsh F, 2009, TRENDS NEUROSCI, V32, P88, DOI 10.1016/j.tins.2008.10.003; Okano H, 2016, NEURON, V92, P582, DOI 10.1016/j.neuron.2016.10.018; Papassotiropoulos A, 1999, ANN NEUROL, V45, P666, DOI 10.1002/1531-8249(199905)45:5<666::AID-ANA18>3.0.CO;2-3; Parthsarathy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054769; Paspalas CD, 2018, ALZHEIMERS DEMENT, V14, P680, DOI 10.1016/j.jalz.2017.11.005; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Philippens I.H.C.H.M., 2019, COMMON MARMOSET CAPT; Philippens IHCHM, 2000, BEHAV RES METH INS C, V32, P173, DOI 10.3758/BF03200799; Philippens IH, 2017, J ALZHEIMERS DIS, V55, P101, DOI 10.3233/JAD-160673; Philippens IHCHM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37381-1; Philippens IHCHM, 2010, DRUG DISCOV TODAY, V15, P985, DOI 10.1016/j.drudis.2010.08.009; Philipson O, 2010, FEBS J, V277, P1389, DOI 10.1111/j.1742-4658.2010.07564.x; Phillips KA, 2019, AM J PRIMATOL, V81, DOI 10.1002/ajp.22949; Plaza DF, 2020, CELL IMMUNOL, V347, DOI 10.1016/j.cellimm.2019.103999; QUINT DJ, 1990, IMMUNOLOGY, V69, P616; Rezai-Zadeh K, 2009, J NEUROIMMUNE PHARM, V4, P462, DOI 10.1007/s11481-009-9166-2; Ridley RM, 2006, J NEURAL TRANSM, V113, P1243, DOI 10.1007/s00702-005-0385-2; Rodriguez-Callejas JD, 2016, FRONT AGING NEUROSCI, V8, DOI [10.3389/fnagi.2016.00375, 10.3389/fnagi.2016.00315]; Rosen RF, 2011, NEUROBIOL AGING, V32, P223, DOI 10.1016/j.neurobiolaging.2009.02.011; Ross Corinna N, 2012, J Aging Res, V2012, P567143, DOI 10.1155/2012/567143; Sadoun A, 2019, NEUROBIOL AGING, V74, P1, DOI 10.1016/j.neurobiolaging.2018.10.003; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Sasaki E, 2009, NATURE, V459, P523, DOI 10.1038/nature08090; Serpente M, 2014, NEUROIMMUNOMODULAT, V21, P79, DOI 10.1159/000356529; Serrano-Pozo A, 2013, J NEUROPATH EXP NEUR, V72, P462, DOI 10.1097/NEN.0b013e3182933788; Sharma G, 2019, J BIOL CHEM, V294, P11433, DOI 10.1074/jbc.RA119.008415; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Solito E, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00014; Sondag CM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-1; Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002; Soulet D, 2008, CURR BIOL, V18, pR506, DOI 10.1016/j.cub.2008.04.047; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Sudduth TL, 2013, NEUROBIOL AGING, V34, P1051, DOI 10.1016/j.neurobiolaging.2012.09.012; Sweeney Carolyn, 2012, Chimerism, V3, P43, DOI 10.4161/chim.20729; Swomley AM, 2014, BBA-MOL BASIS DIS, V1842, P1248, DOI 10.1016/j.bbadis.2013.09.015; 't Hart BA, 2012, DRUG DISCOV TODAY, V17, P1160, DOI 10.1016/j.drudis.2012.06.009; Takahashi M, 2015, ACTA NEUROPATHOL, V129, P895, DOI 10.1007/s00401-015-1415-2; Tan J, 2002, J NEUROIMMUNOL, V132, P164, DOI 10.1016/S0165-5728(02)00309-0; Tardif SD, 2011, ILAR J, V52, P54, DOI 10.1093/ilar.52.1.54; Thal DR, 2012, EXP NEUROL, V236, P1, DOI 10.1016/j.expneurol.2012.04.021; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Van Dam D, 2017, EXPERT OPIN DRUG DIS, V12, P187, DOI 10.1080/17460441.2017.1271320; Veld BAI, 1998, NEUROBIOL AGING, V19, P607, DOI 10.1016/S0197-4580(98)00096-7; Verhave PS, 2012, NEUROPHARMACOLOGY, V62, P1700, DOI 10.1016/j.neuropharm.2011.11.016; Verhave PS, 2011, SLEEP, V34, P1119, DOI 10.5665/SLEEP.1174; Verhave PS, 2009, BEHAV BRAIN RES, V200, P214, DOI 10.1016/j.bbr.2009.01.022; Walker DG, 2005, J NEUROSCI RES, V81, P412, DOI 10.1002/jnr.20484; Walker L.C., 1999, ALZHEIMER DIS, P233; Wang P, 2014, AGING CELL, V13, P605, DOI 10.1111/acel.12209; Weekman EM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-127; Weerts EM, 2007, EXP CLIN PSYCHOPHARM, V15, P309, DOI 10.1037/1064-1297.15.4.309; White JA, 2005, NEUROBIOL DIS, V18, P459, DOI 10.1016/j.nbd.2004.12.013; Wilcock DM, 2015, NEUROBIOL AGING, V36, P2468, DOI 10.1016/j.neurobiolaging.2015.05.016; Worley KC, 2014, NAT GENET, V46, P850, DOI 10.1038/ng.3042; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Zhang D, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-3; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150	144	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							388	10.3390/vaccines9040388			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6QH	33920929	Green Published, gold			2022-04-29	WOS:000643900800001
J	Principi, N; Esposito, S				Principi, Nicola; Esposito, Susanna			Pneumococcal Disease Prevention: Are We on the Right Track?	VACCINES			English	Article						invasive pneumococcal diseases; pneumococcal conjugate vaccine; protein vaccine; serotype 3; Streptococcus pneumoniae	CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; PROTECTION	The history of Streptococcus pneumoniae diseases dramatically changed with the introduction into the immunization schedule of infants and children of the first pneumococcal conjugate vaccine, the one containing 7 (PCV7) of the most common pneumococcal serotypes (STs) causing invasive pneumococcal diseases (IPDs). Where PCV7 was largely used, incidence of both IPDs and non-invasive pneumococcal diseases (nIPDs) in vaccinated children and in unvaccinated subjects of any age, mainly the elderly, significantly decreased. Unfortunately, the impact of PCV7 administration was slightly lower than expected, as the reduction in infections due to vaccine serotypes (STs) was accompanied by a significant increase in the number of IPDs and nIPDs due to STs not included in the vaccine. To overcome this problem, two PCVs containing 10 (PCV10) and 13 (PCV13) STs, chosen among those emerging, were developed and licensed. However, ST replacement occurred again. Moreover, the new PCVs showed little effectiveness in the prevention of infection due to non-encapsulated STs and to ST3. Next-generation S. pneumoniae vaccines able to prevent pneumococcal infections regardless of infecting ST are urgently needed. For the moment, the use of available PCVs remains fundamental because their benefits far outweigh any concerns for emerging STs.	[Principi, Nicola] Univ Milan, I-20122 Milan, Italy; [Esposito, Susanna] Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, I-43126 Parma, Italy		Esposito, S (通讯作者)，Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, I-43126 Parma, Italy.	nicola.principi@unimi.it; susannamariaroberta.esposito@unipr.it	Esposito, Susanna/AAA-8275-2022	Principi, Nicola/0000-0002-3468-5568			Anderson R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041147; Andrews N, 2019, VACCINE, V37, P4491, DOI 10.1016/j.vaccine.2019.06.071; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Carloni I, 2021, PEDIATR PULM, V56, P1127, DOI 10.1002/ppul.25270; Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15; Corsini B, 2016, VACCINE, V34, P6148, DOI 10.1016/j.vaccine.2016.11.001; de Miguel S, 2021, CLIN INFECT DIS, V73, pE3778, DOI 10.1093/cid/ciaa1483; Dobay O, 2019, HUM VACC IMMUNOTHER, V15, P2725, DOI 10.1080/21645515.2019.1621068; Dominguez A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183191; Esposito S, 2015, FUTURE MICROBIOL, V10, P1599, DOI 10.2217/fmb.15.81; Fukusumi M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2113-y; Goettler D, 2020, VACCINE, V38, P570, DOI 10.1016/j.vaccine.2019.10.056; Langereis JD, 2017, VIRULENCE, V8, P637, DOI 10.1080/21505594.2017.1309492; Luck JN, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.613287; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; McLaughlin JM, 2019, VACCINE, V37, P6310, DOI 10.1016/j.vaccine.2019.08.059; Mrkvan T, 2018, EXPERT REV VACCINES, V17, P797, DOI 10.1080/14760584.2018.1516551; Platt HL, 2020, PEDIATR INFECT DIS J, V39, P763, DOI 10.1097/INF.0000000000002765; Principi N, 2018, CURR INFECT DIS REP, V20, DOI 10.1007/s11908-018-0607-z; Principi N, 2018, EXPERT OPIN BIOL TH, V18, P7, DOI 10.1080/14712598.2018.1384462; Sings HL, 2019, CLIN INFECT DIS, V68, P2135, DOI 10.1093/cid/ciy920; Slotved HC, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00198; Strachan R, 2021, THORAX, V76, P487, DOI 10.1136/thoraxjnl-2020-216032; Syrogiannopoulos GA, 2016, INFECT DIS-NOR, V48, P749, DOI 10.1080/23744235.2016.1192720; Tarancon R, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008404; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8	27	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							305	10.3390/vaccines9040305			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4OD	33804822	gold, Green Published			2022-04-29	WOS:000643759500001
J	Sartoretti, J; Eberhardt, CS				Sartoretti, Julie; Eberhardt, Christiane S.			The Potential Role of Nonhuman Primate Models to Better Comprehend Early Life Immunity and Maternal Antibody Transfer	VACCINES			English	Article						early human life immunity; vaccinology; nonhuman primate model	PLACENTAL-TRANSFER; HELPER-CELLS; BONE-MARROW; RESPONSES; IGG; VACCINATION; PRETERM; IMMUNIZATION; INFECTION; INFANTS	Early life immunity is a complex field of research and there are still gaps in knowledge regarding the detailed mechanism of maternal antibody transfer, the impact of maternal antibodies on infant vaccine responses and the ontogeny of human early life immunity. A comprehensive understanding is necessary to identify requirements for early life vaccines and to improve early childhood immunization. New immunological methods have facilitated performing research in the youngest, however, some questions can only be addressed in animal models. To date, mostly murine models are used to study neonatal and infant immunity since they are well-described, easy to use and cost effective. Given their limitations especially in the transfer biology of maternal antibodies and the lack of infectivity of numerous human pathogens, this opinion piece discusses the potential and prerequisites of the nonhuman primate model in studying early life immunity and maternal antibody transfer.	[Sartoretti, Julie; Eberhardt, Christiane S.] Univ Geneva, Fac Med, Ctr Vaccinol, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland; [Sartoretti, Julie; Eberhardt, Christiane S.] Geneva Univ Hosp, Dept Woman Child & Adolescent Med, 6 Rue Willy Donze, CH-1211 Geneva 4, Switzerland; [Sartoretti, Julie; Eberhardt, Christiane S.] Fac Med, 6 Rue Willy Donze, CH-1211 Geneva 4, Switzerland; [Eberhardt, Christiane S.] Univ Hosp Geneva, Ctr Vaccinol, CH-1205 Geneva, Switzerland; [Eberhardt, Christiane S.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA		Eberhardt, CS (通讯作者)，Univ Geneva, Fac Med, Ctr Vaccinol, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland.; Eberhardt, CS (通讯作者)，Geneva Univ Hosp, Dept Woman Child & Adolescent Med, 6 Rue Willy Donze, CH-1211 Geneva 4, Switzerland.; Eberhardt, CS (通讯作者)，Fac Med, 6 Rue Willy Donze, CH-1211 Geneva 4, Switzerland.; Eberhardt, CS (通讯作者)，Univ Hosp Geneva, Ctr Vaccinol, CH-1205 Geneva, Switzerland.; Eberhardt, CS (通讯作者)，Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.	julie.sartoretti@unige.ch; Christiane.eberhardt@unige.ch					ANDRE FE, 1994, J MED VIROL, V44, P144, DOI 10.1002/jmv.1890440206; [Anonymous], WORLD HLTH STAT 2020; [Anonymous], VACCINOLOGY PRINCIPL; Atyeo C, 2021, CELL, V184, P628, DOI 10.1016/j.cell.2020.12.027; BARNES JM, 1959, J PATHOL BACTERIOL, V77, P371, DOI 10.1002/path.1700770206; Barug D, 2019, LANCET INFECT DIS, V19, P392, DOI 10.1016/S1473-3099(18)30717-5; Batchelder CA, 2014, ANAT REC, V297, P1392, DOI 10.1002/ar.22943; Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858; Borghi S, 2020, P NATL ACAD SCI USA, V117, P12943, DOI 10.1073/pnas.2004325117; Broeckel R, 2015, PATHOGENS, V4, P662, DOI 10.3390/pathogens4030662; Carter AM, 2007, PLACENTA, V28, pS41, DOI 10.1016/j.placenta.2006.11.002; Chege GK, 2005, VACCINE, V23, P1522, DOI 10.1016/j.vaccine.2004.06.055; CHIRICO G, 1993, PEDIATRICS, V92, P717; COE CL, 1993, J MED PRIMATOL, V22, P294; COE CL, 1994, AM J PRIMATOL, V32, P51, DOI 10.1002/ajp.1350320106; Colby LA, 2017, COMPARATIVE MED, V67, P222; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077, DOI 10.1093/infdis/173.5.1077; Dhakal M, 2015, J IMMUNOL, V195, P507, DOI 10.4049/jimmunol.1500027; Doroudchi M, 2003, INT J GYNECOL OBSTET, V81, P157, DOI 10.1016/S0020-7292(02)00442-3; Dowling DJ, 2014, TRENDS IMMUNOL, V35, P299, DOI 10.1016/j.it.2014.04.007; Eberhardt CS, 2017, CLIN INFECT DIS, V64, P1129, DOI 10.1093/cid/cix046; Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027; Estes JD, 2018, NAT REV IMMUNOL, V18, P390, DOI 10.1038/s41577-018-0005-7; FUJIMOTO K, 1983, JPN J MED SCI BIOL, V36, P171, DOI 10.7883/yoken1952.36.171; Gavillet BM, 2015, J IMMUNOL, V194, P4836, DOI 10.4049/jimmunol.1402071; GITLIN D, 1964, J CLIN INVEST, V43, P1938, DOI 10.1172/JCI105068; Hodgins DC, 2012, VACCINE, V30, P1541, DOI 10.1016/j.vaccine.2011.12.047; Jennewein MF, 2019, CELL, V178, P202, DOI 10.1016/j.cell.2019.05.044; Kachikis A, 2016, J INFECTION, V72, pS83, DOI 10.1016/j.jinf.2016.04.027; Kaushal D, 2012, J MED PRIMATOL, V41, P191, DOI 10.1111/j.1600-0684.2012.00536.x; Kollmann TR, 2013, VACCINE, V31, P2481, DOI 10.1016/j.vaccine.2013.04.025; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; MacPhail M, 2004, J GEN VIROL, V85, P1655, DOI 10.1099/vir.0.79805-0; Martinov T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643852; Mastelic B, 2012, J IMMUNOL, V189, P5764, DOI 10.4049/jimmunol.1201143; Messaoudi I, 2011, ANTIOXID REDOX SIGN, V14, P261, DOI 10.1089/ars.2010.3241; Mohr E, 2016, CURR OPIN IMMUNOL, V41, P1, DOI 10.1016/j.coi.2016.04.004; NEWELL KW, 1966, B WORLD HEALTH ORGAN, V35, P863; Palfi M, 1998, AM J REPROD IMMUNOL, V39, P24; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; Pentsuk N, 2009, BIRTH DEFECTS RES B, V86, P328, DOI 10.1002/bdrb.20201; Pihlgren M, 2003, J IMMUNOL, V170, P2824, DOI 10.4049/jimmunol.170.6.2824; Pihlgren M, 2001, EUR J IMMUNOL, V31, P939, DOI 10.1002/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I; Pind AAA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02214; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Ramos L, 2019, VET IMMUNOL IMMUNOP, V215, DOI 10.1016/j.vetimm.2019.109884; Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/revreprod/4.2.81; Salisch NC, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0150-4; Scheffer-Mendoza S, 2020, ALLERGOL IMMUNOPATH, V48, P295, DOI 10.1016/j.aller.2019.12.009; Sestak K, 2004, J VIROL, V78, P10258, DOI 10.1128/JVI.78.19.10258-10264.2004; Sibal L R, 2001, ILAR J, V42, P74; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6; Lessa ALS, 2011, FEMS IMMUNOL MED MIC, V62, P236, DOI 10.1111/j.1574-695X.2011.00807.x; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; Solans L, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03068; Struble EB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/538701; Thwaites CL, 2015, LANCET, V385, P362, DOI 10.1016/S0140-6736(14)60236-1; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Twisselmann N, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03166; van den Berg JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094714; Vono M, 2019, CELL REP, V28, P1773, DOI 10.1016/j.celrep.2019.07.047; Warfel JM, 2014, EXPERT REV VACCINES, V13, P1241, DOI 10.1586/14760584.2014.946016; Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110; Wassenaar TM, 2014, LETT APPL MICROBIOL, V59, P572, DOI 10.1111/lam.12334	67	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							306	10.3390/vaccines9040306			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4TU	33804886	Green Published, gold			2022-04-29	WOS:000643774300001
J	Thi, TTH; Suys, EJA; Lee, JS; Nguyen, DH; Park, KD; Truong, NP				Thai Thanh Hoang Thi; Suys, Estelle J. A.; Lee, Jung Seok; Nguyen, Dai Hai; Park, Ki Dong; Truong, Nghia P.			Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines	VACCINES			English	Review						lipid nanoparticles; liposomes; vaccines; immunotherapy; COVID-19	MESSENGER-RNA VACCINE; LYMPH-NODE; PHASE-II; LIPOSOMAL FORMULATIONS; SYSTEMIC DELIVERY; CISPLATIN SPI-77; RATIONAL DESIGN; SIRNA; CELL; ADJUVANTS	COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil(R) and Onpattro(R), and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.	[Thai Thanh Hoang Thi] Ton Duc Thang Univ, Fac Appl Sci, Biomat & Nanotechnol Res Grp, Ho Chi Minh City 700000, Vietnam; [Suys, Estelle J. A.; Truong, Nghia P.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia; [Lee, Jung Seok] Yale Univ, Biomed Engn, Malone Engn Ctr 402A,55 Prospect St, New Haven, CT 06511 USA; [Nguyen, Dai Hai] Grad Univ Sci & Technol, Vietnam Acad Sci & Technol, Hanoi 100000, Vietnam; [Nguyen, Dai Hai] Vietnam Acad Sci & Technol, Inst Appl Mat Sci, 01 TL29 Dist 12, Ho Chi Minh City 700000, Vietnam; [Park, Ki Dong] Ajou Univ, Dept Mol Sci & Technol, Suwon 16499, South Korea		Truong, NP (通讯作者)，Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia.	hoangthithaithanh@tdtu.edu.vn; estelle.suys@monash.edu; jungseok.lee78@gmail.com; nguyendaihai@iams.vast.vn; kdp@ajou.ac.kr; nghia.truong@monash.edu	Lee, Jung Seok/AAP-7829-2021; Thi, Thai Thanh Hoang/L-5117-2019; Truong, Nghia/J-5876-2014	Thi, Thai Thanh Hoang/0000-0002-2245-9029; Truong, Nghia/0000-0001-9900-2644; Suys, Estelle J.A./0000-0002-4285-0332	Australian Research CouncilAustralian Research Council; National Health and Medical Research CouncilNational Health and Medical Research Council (NHMRC) of Australia [DE180100076, DP200100231, GNT2002827]	This research was funded by the Australian Research Council and the National Health and Medical Research Council, grant number DE180100076, DP200100231 and GNT2002827.	Agrawal M, 2020, J CONTROL RELEASE, V321, P372, DOI 10.1016/j.jconrel.2020.02.020; Akinc A, 2019, NAT NANOTECHNOL, V14, P1084, DOI 10.1038/s41565-019-0591-y; Akita H, 2010, J CONTROL RELEASE, V143, P311, DOI 10.1016/j.jconrel.2010.01.012; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Anderluzzi G, 2021, J CONTROL RELEASE, V330, P933, DOI 10.1016/j.jconrel.2020.10.066; Anselmo AC, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10143; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Basha SK, 2021, MATER TODAY-PROC, V36, P313, DOI 10.1016/j.matpr.2020.04.109; Bhardwaj P, 2020, J DRUG DELIV SCI TEC, V56, DOI 10.1016/j.jddst.2020.101581; Bobo D, 2016, PHARM RES-DORDR, V33, P2373, DOI 10.1007/s11095-016-1958-5; Bottger R, 2020, ADV DRUG DELIVER REV, V154, P79, DOI 10.1016/j.addr.2020.06.017; Bonam SR, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101051; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Brown S, 2020, PRS-GLOB OPEN, V8, DOI 10.1097/GOX.0000000000003206; Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012; Cervantes A, 2011, J CLIN ONCOL, V29; Chacko IA, 2020, COLLOID SURFACE B, V195, DOI 10.1016/j.colsurfb.2020.111262; Chauhan G, 2020, ACS NANO, V14, P7760, DOI 10.1021/acsnano.0c04006; Deken MM, 2020, J CONTROL RELEASE, V323, P269, DOI 10.1016/j.jconrel.2020.04.030; Demeure MJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2547; Du ZX, 2014, SCI REP-UK, V4, DOI 10.1038/srep07107; Duan YT, 2020, RSC ADV, V10, P26777, DOI 10.1039/d0ra03491f; El Dika I, 2019, ONCOLOGIST, V24, P747, DOI 10.1634/theoncologist.2018-0838; ElBagoury M, 2021, J INFECT PUBLIC HEAL, V14, P389, DOI 10.1016/j.jiph.2020.12.025; Ely A, 2021, ADV DRUG DELIVER REV, V168, P134, DOI 10.1016/j.addr.2020.05.010; Fan YC, 2021, J PHARMACEUT BIOMED, V192, DOI 10.1016/j.jpba.2020.113642; Fan YC, 2013, ASIAN J PHARM SCI, V8, P81, DOI 10.1016/j.ajps.2013.07.010; Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5; Germain M, 2020, J CONTROL RELEASE, V326, P164, DOI 10.1016/j.jconrel.2020.07.007; Halfdanarson TR, 2016, PANCREAS, V45, P475; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Henriksen-Lacey M, 2011, MOL PHARMACEUT, V8, P153, DOI 10.1021/mp100208f; Hirai Y, 2020, INT J PHARMACEUT, V585, DOI 10.1016/j.ijpharm.2020.119479; Hu B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0207-x; Hunt H, 2017, J CONTROL RELEASE, V260, P142, DOI 10.1016/j.jconrel.2017.06.005; Ickenstein LM, 2019, EXPERT OPIN DRUG DEL, V16, P1205, DOI 10.1080/17425247.2019.1669558; Jain S, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2020.102166; Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263; Kadelka S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80594-6; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Kedmi R, 2018, NAT NANOTECHNOL, V13, P214, DOI 10.1038/s41565-017-0043-5; Khvorova A, 2017, NAT BIOTECHNOL, V35, P238, DOI 10.1038/nbt.3765; Kim ES, 2001, LUNG CANCER-J IASLC, V34, P427, DOI 10.1016/S0169-5002(01)00278-1; Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kulkarni JA, 2019, NANOSCALE, V11, P21733, DOI 10.1039/c9nr09347h; Kulkarni JA, 2018, NUCLEIC ACID THER, V28, P146, DOI 10.1089/nat.2018.0721; Kulkarni JA, 2018, ACS NANO, V12, P4787, DOI 10.1021/acsnano.8b01516; Kuo YC, 2021, MAT SCI ENG C-MATER, V118, DOI 10.1016/j.msec.2020.111339; Laffleur F, 2020, INT J PHARMACEUT, V590, DOI 10.1016/j.ijpharm.2020.119912; Lamichhane N, 2018, MOLECULES, V23, DOI 10.3390/molecules23020288; Lee K, 2020, BIOMATER SCI-UK, V8, P1101, DOI 10.1039/c9bm01564g; Lou G, 2020, J CONTROL RELEASE, V325, P370, DOI 10.1016/j.jconrel.2020.06.027; Lu J, 2020, CELL RES, V30, P936, DOI 10.1038/s41422-020-00392-7; Lu WJ, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111103; Manabe Yoshiyuki, 2020, Drug Discov Today Technol, V37, P61, DOI 10.1016/j.ddtec.2020.11.006; Mashel TV, 2020, BIOMATERIALS, V258, DOI 10.1016/j.biomaterials.2020.120282; McCormack S., 2020, BIOMEDCENTRAL, DOI [10.1186/isrctn17072692, DOI 10.1186/ISRCTN17072692]; McGoron AJ, 2020, BIOCONJUGATE CHEM, V31, P436, DOI 10.1021/acs.bioconjchem.9b00818; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Midoux P, 2015, EXPERT REV VACCINES, V14, P221, DOI 10.1586/14760584.2015.986104; Moghimi SM, 2006, BIOMATERIALS, V27, P136, DOI 10.1016/j.biomaterials.2005.05.082; Mucker EM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65059-0; Munster P, 2018, BRIT J CANCER, V119, P1086, DOI 10.1038/s41416-018-0235-2; Nakamura T, 2020, ADV DRUG DELIVER REV, V167, P78, DOI 10.1016/j.addr.2020.06.003; Nakamura T, 2020, MOL PHARMACEUT, V17, P944, DOI 10.1021/acs.molpharmaceut.9b01182; Nasirizadeh S, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101458; Ng Wern Hann, 2020, F1000Res, V9, DOI 10.12688/f1000research.25998.1; O'Hagan DT, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101426; Opatha SAT, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090855; Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3; Ozcan G, 2015, ADV DRUG DELIVER REV, V87, P108, DOI 10.1016/j.addr.2015.01.007; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Patel MR, 2020, J CLIN ONCOL, V38; Ramaswamy S, 2017, P NATL ACAD SCI USA, V114, pE1941, DOI 10.1073/pnas.1619653114; Ramezanpour M, 2019, NANOSCALE, V11, P14141, DOI 10.1039/c9nr02297j; Reed SG, 2020, CURR OPIN IMMUNOL, V65, P97, DOI 10.1016/j.coi.2020.08.008; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Rudra A, 2020, BIOCONJUGATE CHEM, V31, P462, DOI 10.1021/acs.bioconjchem.9b00828; Saalik P, 2019, J CONTROL RELEASE, V308, P109, DOI 10.1016/j.jconrel.2019.06.018; Sabnis S, 2018, MOL THER, V26, P1509, DOI 10.1016/j.ymthe.2018.03.010; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Salah E, 2020, COLLOID SURFACE B, V196, DOI 10.1016/j.colsurfb.2020.111305; Samaridou E, 2020, ADV DRUG DELIVER REV, V154, P37, DOI 10.1016/j.addr.2020.06.002; Sanofi, TRANSL BIOST PHAS 1; Sato Y, 2012, J CONTROL RELEASE, V163, P267, DOI 10.1016/j.jconrel.2012.09.009; Scott LJ, 2020, DRUGS, V80, P335, DOI 10.1007/s40265-020-01269-0; Seetharamu N, 2010, ANTICANCER RES, V30, P541; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Shah S, 2020, ADV DRUG DELIVER REV, V154, P102, DOI 10.1016/j.addr.2020.07.002; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Shi Y, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.201900215; Shih HI, 2020, BIOMED J, V43, P341, DOI 10.1016/j.bj.2020.05.021; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Shirai S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030433; Soininen SK, 2015, TOXICOL LETT, V239, P108, DOI 10.1016/j.toxlet.2015.09.011; Swaminathan G, 2016, VACCINE, V34, P110, DOI 10.1016/j.vaccine.2015.10.132; Tapeinos C, 2017, J CONTROL RELEASE, V264, P306, DOI 10.1016/j.jconrel.2017.08.033; Thi TTH, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12020298; Theobald N, 2020, DRUG DISCOV TODAY, V25, P1556, DOI 10.1016/j.drudis.2020.06.020; Tolcher AW, 2015, J CLIN ONCOL, V33; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Veiga N, 2020, ADV DRUG DELIVER REV, V159, P364, DOI 10.1016/j.addr.2020.04.002; Veiga N, 2019, J CONTROL RELEASE, V313, P33, DOI 10.1016/j.jconrel.2019.10.001; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; Ventola C Lee, 2017, P T, V42, P742; Vu MN, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202002142; Vu MN, 2020, SMALL, V16, DOI 10.1002/smll.202002861; Wagner MJ, 2017, MOL CANCER THER, V16, P1114, DOI 10.1158/1535-7163.MCT-16-0541; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang HT, 2016, MOL THER, V24, P2100, DOI 10.1038/mt.2016.179; Wei L, 2016, INT J PHARMACEUT, V510, P394, DOI 10.1016/j.ijpharm.2016.06.127; Wei T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17029-3; Wei YH, 2019, ACTA BIOMATER, V92, P196, DOI 10.1016/j.actbio.2019.05.034; Weiss C, 2020, ACS NANO, V14, P6383, DOI 10.1021/acsnano.0c03697; White SC, 2006, BRIT J CANCER, V95, P822, DOI 10.1038/sj.bjc.6603345; Widmer J, 2018, INT J PHARMACEUT, V535, P444, DOI 10.1016/j.ijpharm.2017.11.031; WISSE E, 1985, HEPATOLOGY, V5, P683, DOI 10.1002/hep.1840050427; Wu H, 2012, J CLIN PHARMACOL, V52, P180, DOI 10.1177/0091270010394851; Wu Y, 2016, COLLOID SURFACE B, V138, P60, DOI 10.1016/j.colsurfb.2015.11.041; Xu YN, 2021, CURR OPIN COLLOID IN, V52, DOI 10.1016/j.cocis.2020.101414; Yarosh D, 1996, PHOTODERMATOL PHOTO, V12, P122, DOI 10.1111/j.1600-0781.1996.tb00188.x; Yonezawa S, 2020, ADV DRUG DELIVER REV, V154, P64, DOI 10.1016/j.addr.2020.07.022; Younis MA, 2021, J CONTROL RELEASE, V331, P335, DOI 10.1016/j.jconrel.2021.01.021; Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang YL, 2019, BIOMED PHARMACOTHER, V109, P475, DOI 10.1016/j.biopha.2018.10.158; Zukancic D, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111068	128	45	46	77	101	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							359	10.3390/vaccines9040359			29	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5CA	33918072	gold, Green Published	Y	N	2022-04-29	WOS:000643795800001
J	Uruena, A; Micone, P; Magneres, C; Mould-Quevedo, J; Giglio, N				Uruena, Analia; Micone, Paula; Magneres, Cecilia; Mould-Quevedo, Joaquin; Giglio, Norberto			Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina	VACCINES			English	Article						influenza; vaccine; cost-effectiveness; trivalent; quadrivalent; Argentina; TIV; QIV	EFFICACY; IMPACT; BURDEN; BRAZIL; VIRUS	The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influenza season. Main outcomes included: numbers of influenza cases; general practitioner (GP) visits; complicated ambulatory cases; hospitalizations; deaths averted; and costs per quality-adjusted life years (QALYs) gained. Epidemiological data from Argentina for 2014-2019 were used to determine the proportion of A and B strain cases, and the frequency of mismatch between vaccine and circulating B strains. To manage uncertainty, one-way and probabilistic sensitivity analyses were performed. Switching from TIV to QIV would prevent 19,128 influenza cases, 16,164 GP visits, 2440 complicated ambulatory cases, 524 hospitalizations, and 82 deaths. Incremental cost-effectiveness ratios (ICERs) per QALY were 13,590 and 11,678 USD from the payer's and societal perspectives, respectively. The greatest health benefits and direct medical cost savings would occur in >= 65-year-olds. One-way sensitivity analyses demonstrated the principal drivers of ICER to be vaccine acquisition costs, environmental B strain predominance, and B strain mismatch. Introducing QIV in Argentina would be beneficial and cost-effective relative to TIV, particularly in older adults.	[Uruena, Analia] Univ Isalud, Ctr Estudios Prevenc & Control Enfermedades Trans, C1095AAS, Buenos Aires, DF, Argentina; [Micone, Paula] Hosp Carlos G Durand, RA-1405 Buenos Aires, DF, Argentina; [Magneres, Cecilia] Seqirus SA, B1636AKJ, Buenos Aires, DF, Argentina; [Mould-Quevedo, Joaquin] Seqirus USA Inc, Summit, NJ 07901 USA; [Giglio, Norberto] Hosp Ninos Dr Ricardo Gutierrez, RA-1425 Buenos Aires, DF, Argentina		Magneres, C (通讯作者)，Seqirus SA, B1636AKJ, Buenos Aires, DF, Argentina.	uruenaanalia@gmail.com; paulamicone@gmail.com; maria.magneres@seqirus.com; Joaquin.Mould-Quevedo@seqirus.com; norbergiglio@gmail.com	Mould-Quevedo, Joaquin/AAT-7532-2021	Uruena, Analia/0000-0001-5108-2534	Seqirus USA Inc.	This study was funded by Seqirus USA Inc.	Argentinean and Brazilian Influenza Vaccine Working Group, 2017, Rev Panam Salud Publica, V41, pe76; Baxter D, 2016, HUM VACC IMMUNOTHER, V12, P2712, DOI 10.1080/21645515.2015.1091130; Beran J, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-2; Bonvehi P., 2011, P 11 C ARG SOC INF B; Castellano V., 2021, P 12 NAT M PED RES B; Chit A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133606; Chotpitayasunondh T, 2021, INFLUENZA OTHER RESP, V15, P407, DOI 10.1111/irv.12824; Crepey P, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09409-7; Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013; Cuadrado-Payan E, 2020, LANCET, V395, pE84, DOI 10.1016/S0140-6736(20)31052-7; de Boer PT, 2017, EXPERT REV PHARM OUT, V17, P249, DOI 10.1080/14737167.2017.1343145; de Boer PT, 2016, VALUE HEALTH, V19, P964, DOI 10.1016/j.jval.2016.05.012; Fongaro G, 2021, SCI TOTAL ENVIRON, V778, DOI 10.1016/j.scitotenv.2021.146198; Frey S, 2010, CLIN INFECT DIS, V51, P997, DOI 10.1086/656578; Garcia A, 2016, HUM VACC IMMUNOTHER, V12, P2269, DOI 10.1080/21645515.2016.1182275; Giglio N, 2012, HUM VACC IMMUNOTHER, V8, DOI [10.4161/hv.8.3.18569, 10.4161/hv.18569]; Heikkinen T, 2004, J INFECT DIS, V190, P1369, DOI 10.1086/424527; Jamotte A, 2017, HUM VACC IMMUNOTHER, V13, P877, DOI 10.1080/21645515.2016.1256928; Jefferson T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004879.pub4; Jefferson T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub3; Jefferson T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub4; Jiang MH, 2020, VACCINE, V38, P1057, DOI 10.1016/j.vaccine.2019.11.045; Khodamoradi Z, 2020, ARCH IRAN MED, V23, P239, DOI [10.34172/aim.2020.04, 10.34172/aim.2020.04 Abstract View:]; Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266; Lee K, 2009, GLOB INST, P1; Mennini FS, 2018, HUM VACC IMMUNOTHER, V14, P1867, DOI 10.1080/21645515.2018.1469368; Moscoso N., 2010, DOCUMENTS CONTRIBUTI, V10, P29; Nagy L, 2016, PHARMACOECONOMICS, V34, P939, DOI 10.1007/s40273-016-0430-z; National Institute of Statistics and Censuses, LAB MARK; National Ministry of Health, COVID 19 VACC CAMP T; National Ministry of Health, NATL IMMUNIZATION PR; National Ministry of Health, INT SURV B YEARS 201; National Ministry of Health, CONF 1 CAS COVID 19; National Ministry of Health, B LAB STAT; National Ministry of Health and Social Development, 4 NAT SURV RISK FACT; National Ministry of Health Surveillance Area, NAT EP DEP; National Ministry of Health Vital Statistics, BAS INF ARG YEAR 201; Palekar R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219595; Pan American Health Organization, REV FUND VACC PRIC 2; Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; Ruiz-Palacios GM, 2020, HUM VACC IMMUNOTHER, V16, P827, DOI 10.1080/21645515.2019.1678997; Seqirus S.A., ARGENTINA; Thommes EW, 2017, HUM VACC IMMUNOTHER, V13, P867, DOI 10.1080/21645515.2016.1251537; Thommes EW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1193-4; Thorrington D, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0932-3; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; U.S. Government Centers for Disease Control and Prevention, SEAS INFL FLU KEY FA; Van Bellinghen LA, 2018, BRAZ J INFECT DIS, V22, P1, DOI 10.1016/j.bjid.2017.11.004; Van Bellinghen LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098437; Nguyen VH, 2020, VACCINE, V38, P3682, DOI 10.1016/j.vaccine.2020.02.081; World Bank, ARG; World Health Organization Immunization Vaccines and Biologicals, WHO GUID STAND EC EV; World Health Organization Influenza (Seasonal), FACT SHEET; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	55	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							335	10.3390/vaccines9040335			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4SO	33916048	Green Published, gold			2022-04-29	WOS:000643771100001
J	Yu, ZQ; Lu, YJ; Liu, ZY; Aleem, MT; Liu, JL; Luo, JX; Yan, RF; Xu, LX; Song, XK; Li, XR				Yu, Zhengqing; Lu, Yujia; Liu, Zhaoyi; Aleem, Muhammad Tahir; Liu, Junlong; Luo, Jianxun; Yan, Ruofeng; Xu, Lixin; Song, Xiaokai; Li, Xiangrui			Recombinant Toxoplasma gondii Ribosomal Protein P2 Modulates the Functions of Murine Macrophages In Vitro and Provides Immunity against Acute Toxoplasmosis In Vivo	VACCINES			English	Article						Toxoplasma gondii; ribosomal protein P2; murine macrophage; immune protection	PROTECTIVE IMMUNITY; CONGENITAL TOXOPLASMOSIS; VACCINE CANDIDATE; IFN-GAMMA; DNA; CELLS; RESISTANCE; CYCLE; POLARIZATION; IMMUNIZATION	Almost every warm-blooded animal can be an intermediate host for Toxoplasma gondii (T. gondii); there is still no efficient vaccine and medicine available for T. gondii infections. Detected on the surface of free tachyzoites of T. gondii, T. gondii ribosomal protein P2 (TgRPP2) has been identified as a target for protection against toxoplasmosis. In the present study, TgRPP2 was firstly expressed in a prokaryotic expression system, and the purified recombinant TgRPP2 (rTgRPP2) was characterized by its modulation effects on murine macrophages. Then, the purified rTgRPP2 was injected into mice to evaluate the immune protection of rTgRPP2. The results indicated that rTgRPP2 could bind to murine Ana-1 cells and showed good reactogenicity. After incubation with purified rTgRPP2, the proliferation, apoptosis, phagocytosis, nitric oxide (NO) production, and cytokines secreted by murine macrophages were modulated. Furthermore, the in vivo experiments indicated that animals immunized with rTgRPP2 could generate a significantly high level of antibodies, cytokines, and major histocompatibility complex (MHC) molecules, leading to a prolonged survival time. All of the results indicated that murine macrophages could be regulated by rTgRPP2 and are essential for the maintenance of tissue homeostasis. Immunization with rTgRPP2 triggered significant protection, with prolonged survival time in a mice model of acute toxoplasmosis. Our results lend credibility to the idea that rTgRPP2 could be a potential target for drug design and vaccine development.	[Yu, Zhengqing; Lu, Yujia; Liu, Zhaoyi; Aleem, Muhammad Tahir; Yan, Ruofeng; Xu, Lixin; Song, Xiaokai; Li, Xiangrui] Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210000, Peoples R China; [Liu, Junlong; Luo, Jianxun] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Key Lab Vet Parasitol Gansu Prov, Lanzhou 730046, Peoples R China		Li, XR (通讯作者)，Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210000, Peoples R China.	2018207044@njau.edu.cn; 11118310@njau.edu.cn; 17118306@njau.edu.cn; 2018207076@njau.edu.cn; liujunlong@caas.cn; luojianxun@caas.cn; yanruofeng@njau.edu.cn; xulixin@njau.edu.cn; songxiaokai@njau.edu.cn; lixiangrui@njau.edu.cn	ALEEM, MUHAMMAD TAHIR/AAL-1660-2021	ALEEM, MUHAMMAD TAHIR/0000-0001-8899-2777; Li, Xiangrui/0000-0002-7143-6827	Key Scientific and Technological Project of XPCC [2020AB025]; State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences	This research was funded by the Key Scientific and Technological Project of XPCC (2020AB025). The APC was funded by the State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.	Ahmadpour E, 2014, J INFECT DEV COUNTR, V8, P1503, DOI 10.3855/jidc.4796; Barragan A, 2002, J EXP MED, V195, P1625, DOI 10.1084/jem.20020258; Ben-Harari RR, 2017, DRUGS R&D, V17, P523, DOI 10.1007/s40268-017-0206-8; Brake DA, 2002, INT J PARASITOL, V32, P509, DOI 10.1016/S0020-7519(01)00353-8; Brown AS, 2005, AM J PSYCHIAT, V162, P767, DOI 10.1176/appi.ajp.162.4.767; Brunet J, 2008, CELL MICROBIOL, V10, P908, DOI 10.1111/j.1462-5822.2007.01093.x; BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X; Chen J, 2014, EXP PARASITOL, V139, P42, DOI 10.1016/j.exppara.2014.02.016; Ching XT, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00609; Correa D, 2007, PARASITE IMMUNOL, V29, P651, DOI 10.1111/j.1365-3024.2007.00982.x; D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137; Das S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002858; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; Dittmar AJ, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00042-15; Dubey JP, 2009, INT J PARASITOL, V39, P877, DOI 10.1016/j.ijpara.2009.01.005; DUBEY JP, 1980, AM J VET RES, V41, P427; Dupont CD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004047; Fallahi S, 2018, J GYNECOL OBSTET HUM, V47, P133, DOI 10.1016/j.jogoh.2017.12.003; Ghaffarifar F, 2019, IRAN J BASIC MED SCI, V22, P901, DOI 10.22038/ijbms.2019.34872.8276; Goebel S, 1999, MED MICROBIOL IMMUN, V187, P221, DOI 10.1007/s004300050096; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grzybek M, 2015, PARASITOL RES, V114, P523, DOI 10.1007/s00436-014-4214-0; Hassan IA, 2014, EXP PARASITOL, V146, P1, DOI 10.1016/j.exppara.2014.08.011; Hernandez-Cortazar IB, 2017, FOODBORNE PATHOG DIS, V14, P288, DOI 10.1089/fpd.2016.2224; Howe DK, 1997, J CLIN MICROBIOL, V35, P1411, DOI 10.1128/JCM.35.6.1411-1414.1997; Jeffers V, 2018, CELL MOL LIFE SCI, V75, P2355, DOI 10.1007/s00018-018-2808-x; Kang H, 2000, J IMMUNOL, V164, P2629, DOI 10.4049/jimmunol.164.5.2629; Ke H, 2017, CURR CLIN MICROBIOL, V4, P175, DOI 10.1007/s40588-017-0075-5; Khan K, 2018, PARASITOL INT, V67, P715, DOI 10.1016/j.parint.2018.07.004; Kim MJ, 2016, KOREAN J PARASITOL, V54, P147, DOI 10.3347/kjp.2016.54.2.147; Kugler DG, 2013, J EXP MED, V210, P1919, DOI 10.1084/jem.20122300; Labonte AC, 2014, MOL CELLS, V37, P275, DOI 10.14348/molcells.2014.2374; Lacombe A, 2019, MOL MICROBIOL, V112, P1235, DOI 10.1111/mmi.14357; Lamarque M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001276; Lambert H, 2006, CELL MICROBIOL, V8, P1611, DOI 10.1111/j.1462-5822.2006.00735.x; Lavine MD, 2009, MOL BIOCHEM PARASIT, V164, P95, DOI 10.1016/j.molbiopara.2008.11.014; Liu XC, 2018, J EUKARYOT MICROBIOL, V65, P860, DOI 10.1111/jeu.12630; Liu XX, 2016, INFLAMMATION, V39, P1421, DOI 10.1007/s10753-016-0374-7; Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879; Lyons RE, 2002, TRENDS PARASITOL, V18, P198, DOI 10.1016/S1471-4922(02)02248-1; Lyons RE, 2001, INFECT IMMUN, V69, P2589, DOI 10.1128/IAI.69.4.2589-2595.2001; Mammari N, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6152489; Mandelbrot L, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.05.031; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Marques CS, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04040-2; Matowicka-Karna J, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/374696; Medina CB, 2020, NATURE, V580, P130, DOI 10.1038/s41586-020-2121-3; Melchor SJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00185; Mishra P, 2020, BIOCHIMIE, V176, P181, DOI 10.1016/j.biochi.2020.07.007; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Ndao O, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00207; Nilsen A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005029; Olariu TR, 2011, PEDIATR INFECT DIS J, V30, P1056, DOI 10.1097/INF.0b013e3182343096; Park J, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12712; Payne TM, 2003, J CELL SCI, V116, P4345, DOI 10.1242/jcs.00756; Penner RC, 2020, J COMPUT BIOL, V27, P1495, DOI 10.1089/cmb.2020.0120; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Phillips MA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa6645; Qu DF, 2013, EXP PARASITOL, V135, P234, DOI 10.1016/j.exppara.2013.07.013; Sanchez VR, 2011, EXP PARASITOL, V128, P448, DOI 10.1016/j.exppara.2011.04.004; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Sasai M, 2018, INT IMMUNOL, V30, P113, DOI 10.1093/intimm/dxy004; Sayles PC, 2000, INFECT IMMUN, V68, P1026, DOI 10.1128/IAI.68.3.1026-1033.2000; Sonaimuthu P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00808; Song HY, 2010, EXP PARASITOL, V126, P224, DOI 10.1016/j.exppara.2010.05.015; Sroka J, 2019, FOODBORNE PATHOG DIS, V16, P195, DOI 10.1089/fpd.2018.2537; Stern PL, 2020, ANN ALLERG ASTHMA IM, V125, P17, DOI 10.1016/j.anai.2020.01.025; Sturge CR, 2013, P NATL ACAD SCI USA, V110, P10711, DOI 10.1073/pnas.1307868110; Sudarsan R, 2015, PARASITOL INT, V64, P43, DOI 10.1016/j.parint.2014.08.006; Szuster-Ciesielska A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9264217; Tang XM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29379; Tchorzewski M, 2002, INT J BIOCHEM CELL B, V34, P911, DOI 10.1016/S1357-2725(02)00012-2; Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730; Wang T, 2017, PARASITE, V24, DOI 10.1051/parasite/2017013; Wipasa J, 2007, EXPERT OPIN BIOL TH, V7, P1841, DOI 10.1517/14712598.7.12.1841; Wu MM, 2019, ACTA TROP, V199, DOI 10.1016/j.actatropica.2019.105148; Xu XB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180992; Zhao GW, 2012, J INTEGR AGR, V11, P1347, DOI 10.1016/S2095-3119(12)60133-6; Zheng B, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00216; Zheng B, 2013, VACCINE, V31, P4578, DOI 10.1016/j.vaccine.2013.07.058; Zheng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep34448	84	2	2	3	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							357	10.3390/vaccines9040357			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4RQ	33917244	Green Published, gold			2022-04-29	WOS:000643768700001
J	Colant, N; Melinek, B; Frank, S; Rosenberg, W; Bracewell, DG				Colant, Noelle; Melinek, Beatrice; Frank, Stefanie; Rosenberg, William; Bracewell, Daniel G.			Escherichia coli-Based Cell-Free Protein Synthesis for Iterative Design of Tandem-Core Virus-Like Particles	VACCINES			English	Article						cell-free protein synthesis; virus-like particle; tandem-core; influenza vaccine		Tandem-core hepatitis B core antigen (HBcAg) virus-like particles (VLPs), in which two HBcAg monomers are joined together by a peptide linker, can be used to display two different antigens on the VLP surface. We produced universal influenza vaccine candidates that use this scaffold in an Escherichia coli-based cell-free protein synthesis (CFPS) platform. We then used the CFPS system to rapidly test modifications to the arginine-rich region typically found in wild-type HBcAg, the peptide linkers around the influenza antigen inserts, and the plasmid vector backbone to improve titer and quality. Using a minimal plasmid vector backbone designed for CFPS improved titers by at least 1.4-fold over the original constructs. When the linker lengths for the influenza inserts were more consistent in length and a greater variety of codons for glycine and serine were utilized, titers were further increased to over 70 mu g/mL (4.0-fold greater than the original construct) and the presence of lower molecular weight product-related impurities was significantly reduced, although improvements in particle assembly were not seen. Furthermore, any constructs with the C-terminal arginine-rich region removed resulted in asymmetric particles of poor quality. This demonstrates the potential for CFPS as a screening platform for VLPs.	[Colant, Noelle; Melinek, Beatrice; Frank, Stefanie; Bracewell, Daniel G.] UCL, Dept Biochem Engn, London WC1E 6BT, England; [Rosenberg, William] UCL Inst Liver & Digest Hlth, Div Med, Royal Free Campus, London NW3 2PF, England		Bracewell, DG (通讯作者)，UCL, Dept Biochem Engn, London WC1E 6BT, England.	noelle.colant.17@ucl.ac.uk; b.melinek@ucl.ac.uk; stefanie.frank@ucl.ac.uk; w.rosenberg@ucl.ac.uk; d.bracewell@ucl.ac.uk	Rosenberg, William/ABA-1071-2021; Bracewell, Daniel/B-1988-2008	Frank, Stefanie/0000-0003-3153-6417; Bracewell, Daniel/0000-0003-3866-3304; Rosenberg, William/0000-0002-2732-2304; Colant, Noelle/0000-0003-4832-5341; Melinek, Beatrice/0000-0002-2721-3941	U.K. Engineering & Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/P006485/1]; UCL Overseas Research Scholarship; UCL Graduate Research Scholarship; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/P006485/1, EP/R013756/1] Funding Source: UKRI	Funding from the U.K. Engineering & Physical Sciences Research Council (EPSRC) for the Future Targeted Healthcare Manufacturing Hub is gratefully acknowledged (EP/P006485/1). Financial and in-kind support from the consortium of industrial users and sector organizations is also acknowledged. N.A.C. was supported by the UCL Overseas Research Scholarship and the UCL Graduate Research Scholarship.	Bachmann M.F., 2004, NOVEL VACCINATINO ST, P415; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Blaha B.A.F., 2019, PLATFORM PROCESSES V; Bundy BC, 2008, BIOTECHNOL BIOENG, V100, P28, DOI 10.1002/bit.21716; Caschera F, 2014, BIOCHIMIE, V99, P162, DOI 10.1016/j.biochi.2013.11.025; Colant N, 2021, BIOTECHNOL PROGR, V37, DOI 10.1002/btpr.3062; Ding Y, 2010, BIOTECHNOL BIOENG, V107, P550, DOI 10.1002/bit.22821; Doerr A, 2019, PHYS BIOL, V16, DOI 10.1088/1478-3975/aaf33d; Fan X, 2015, MUCOSAL IMMUNOL, V8, P211, DOI 10.1038/mi.2014.59; Garcia-Fruitos E., 2015, INSOLUBLE PROTEINS; Gong P, 2006, J BIOL CHEM, V281, P23533, DOI 10.1074/jbc.M604023200; Hansen MMK, 2016, ACS SYNTH BIOL, V5, P1433, DOI 10.1021/acssynbio.6b00010; Holmes K, 2015, J BIOL CHEM, V290, P16238, DOI 10.1074/jbc.M114.622035; Jewett MC, 2004, BIOTECHNOL BIOENG, V86, P19, DOI 10.1002/bit.20026; Kim TW, 2006, J BIOTECHNOL, V124, P373, DOI 10.1016/j.jbiotec.2005.12.030; Kobayashi T, 2012, BIOTECHNOL LETT, V34, P67, DOI 10.1007/s10529-011-0744-z; Kwon YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep08663; Ludgate L, 2016, J VIROL, V90, P5830, DOI 10.1128/JVI.00394-16; Maurer P, 2005, EUR J IMMUNOL, V35, P2031, DOI 10.1002/eji.200526285; Mozdzanowska K, 2003, VACCINE, V21, P2616, DOI 10.1016/S0264-410X(03)00040-9; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; NIRENBERG M, 1961, P NATL ACAD SCI USA, V47, P1588, DOI 10.1073/pnas.47.10.1588; Ogonah OW, 2017, CURR OPIN CHEM ENG, V18, P77, DOI 10.1016/j.coche.2017.10.003; Pattenden LK, 2005, TRENDS BIOTECHNOL, V23, P523, DOI 10.1016/j.tibtech.2005.07.011; Paules CI, 2017, IMMUNITY, V47, P599, DOI 10.1016/j.immuni.2017.09.007; Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751; Ramirez A, 2018, VACCINE, V36, P873, DOI 10.1016/j.vaccine.2017.12.053; Ramqvist T, 2007, EXPERT OPIN BIOL TH, V7, P997, DOI 10.1517/14712598.7.7.997; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Rosenblum G, 2014, FEBS LETT, V588, P261, DOI 10.1016/j.febslet.2013.10.016; Schinn SM, 2016, NEW BIOTECHNOL, V33, P480, DOI 10.1016/j.nbt.2016.04.002; Schumacher J, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0363-0; Schumann W, 2004, GENET MOL BIOL, V27, P442, DOI 10.1590/S1415-47572004000300022; Sheng JY, 2017, RSC ADV, V7, P28837, DOI 10.1039/c7ra03742b; Stephen SL, 2018, METHODS MOL BIOL, V1776, P97, DOI 10.1007/978-1-4939-7808-3_7; Walker A, 2008, J BIOL CHEM, V283, P33508, DOI 10.1074/jbc.M805211200	36	0	0	1	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							193	10.3390/vaccines9030193			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6CE	33669126	Green Published, gold			2022-04-29	WOS:000634238800001
J	Dowlath, S; Campbell, K; Al-Barwani, F; Young, VL; Young, SL; Walker, GF; Ward, VK				Dowlath, Sasheen; Campbell, Katrin; Al-Barwani, Farah; Young, Vivienne L.; Young, Sarah L.; Walker, Greg F.; Ward, Vernon K.			Dry Formulation of Virus-Like Particles in Electrospun Nanofibers	VACCINES			English	Article						electrospinning; nanofiber; dry-formulation; virus-like particle; vaccine	VACCINE COLD CHAIN; CROSS-PRESENTATION; DRUG-DELIVERY; VLP; STABILIZATION; GENERATION; ANTIGEN; CELLS; MATS	Biologics can be combined with liquid polymer materials and electrospun to produce a dry nanofibrous scaffold. Unlike spray-drying and freeze-drying, electrospinning minimizes the physiological stress on sensitive materials, and nanofiber mat properties such as hydrophobicity, solubility, and melting temperature can be tuned based on the polymer composition. In this study, we explored the dry formulation of a virus-like particle (VLP) vaccine by electrospinning VLP derived from rabbit hemorrhagic disease virus modified to carry the MHC-I gp100 tumor-associated antigen epitope. VLP were added to a polyvinylpyrrolidone (PVP) solution (15% w/v) followed by electrospinning at 24 kV. Formation of a nanofibrous mat was confirmed by scanning electron microscopy, and the presence of VLP was confirmed by transmission electron microscopy and Western blot. VLP from the nanofibers induced T-cell activation and interferon- (IFN-) gamma production in vitro. To confirm in vivo cytotoxicity, Pmel mice treated by injection with gp100 VLP from nanofibers induced a gp100 specific immune response, lysing approximately 65% of gp100-pulsed target cells, comparable to mice vaccinated with gp100 VLP in PBS. VLP from nanofibers also induced an antibody response. This work shows that electrospinning can be used to dry-formulate VLP, preserving both humoral and cell-mediated immunity.	[Dowlath, Sasheen; Al-Barwani, Farah; Young, Vivienne L.; Ward, Vernon K.] Univ Otago, Sch Biomed Sci, Dept Microbiol & Immunol, POB 56,720 Cumberland St, Dunedin 9054, New Zealand; [Campbell, Katrin; Young, Sarah L.] Univ Otago, Dunedin Sch Med, Dept Pathol, POB 56,720 Cumberland St, Dunedin 9054, New Zealand; [Young, Sarah L.] Univ Sydney, Sch Med Sci, Fac Med & Hlth, Sydney, NSW 2006, Australia; [Walker, Greg F.] Univ Otago, Sch Pharm, POB 56,720 Cumberland St, Dunedin 9054, New Zealand		Ward, VK (通讯作者)，Univ Otago, Sch Biomed Sci, Dept Microbiol & Immunol, POB 56,720 Cumberland St, Dunedin 9054, New Zealand.	sasheen.dowlath@yahoo.co.nz; katrin.campbell@otago.ac.nz; farahalbarwani@gmail.com; vivienne.young@otago.ac.nz; sarah.young@otago.ac.nz; greg.walker@otago.ac.nz; vernon.ward@otago.ac.nz		Young, Sarah/0000-0003-0374-2221; Walker, Greg/0000-0002-9817-4767; Young, Vivienne/0000-0002-9216-5552			Abutaleb A, 2017, FIBERS, V5, DOI 10.3390/fib5030033; Al-Barwani F, 2014, THER DELIV, V5, P1223, DOI [10.4155/tde.14.74, 10.4155/TDE.14.74]; Babitha S, 2017, INT J PHARMACEUT, V523, P52, DOI 10.1016/j.ijpharm.2017.03.013; Chen X, 2011, J CONTROL RELEASE, V152, P349, DOI 10.1016/j.jconrel.2011.02.026; Cimica V, 2017, CLIN IMMUNOL, V183, P99, DOI 10.1016/j.clim.2017.08.004; Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4; Czy M, 2016, SUSTAINABLE DRYING T; Dai MH, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/22/225101; Dai MH, 2012, BIOSENSORS-BASEL, V2, P388, DOI 10.3390/bios2040388; Donaldson B, 2018, EXPERT REV VACCINES, V17, P833, DOI 10.1080/14760584.2018.1516552; Donaldson B, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0270-1; Faure F, 2009, EUR J IMMUNOL, V39, P380, DOI 10.1002/eji.200838669; Godi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140926; Gokmese F, 2013, POLYM-PLAST TECHNOL, V52, P1259, DOI 10.1080/03602559.2013.814144; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Haider A, 2018, ARAB J CHEM, V11, P1165, DOI 10.1016/j.arabjc.2015.11.015; Hu XL, 2014, J CONTROL RELEASE, V185, P12, DOI 10.1016/j.jconrel.2014.04.018; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kadajji VG, 2011, POLYMERS-BASEL, V3, P1972, DOI 10.3390/polym3041972; Kamble RN, 2016, J ADV RES, V7, P483, DOI 10.1016/j.jare.2016.03.009; Kanojia G, 2017, HUM VACC IMMUNOTHER, V13, P2364, DOI [10.1080/21645515.2017.1359363, 10.1080/21645515.2017.1356952]; Kramer K, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5364632; Lang R, 2009, DRUG DEV IND PHARM, V35, P83, DOI 10.1080/03639040802192806 ; LeClair DA, 2016, PHARM RES-DORDR, V33, P2763, DOI 10.1007/s11095-016-2003-4; Leung V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44020-w; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; Lovalenti PM, 2016, PHARM RES-DORDR, V33, P1144, DOI 10.1007/s11095-016-1860-1; Maltesen Morten Jonas, 2008, Drug Discov Today Technol, V5, pe81, DOI 10.1016/j.ddtec.2008.11.001; Matthias DM, 2007, VACCINE, V25, P3980, DOI 10.1016/j.vaccine.2007.02.052; McKee SJ, 2012, J CONTROL RELEASE, V159, P338, DOI 10.1016/j.jconrel.2012.02.015; Mitra AK, 2017, EMERGING NANOTECHNOL, P189; MUMENTHALER M, 1994, PHARMACEUT RES, V11, P12, DOI 10.1023/A:1018929224005; Patel PM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433516; Peacey M, 2008, VACCINE, V26, P5334, DOI 10.1016/j.vaccine.2008.07.074; Peacey M, 2007, BIOTECHNOL BIOENG, V98, P968, DOI 10.1002/bit.21518; POL S, 1994, LANCET, V344, P342, DOI 10.1016/S0140-6736(94)91384-6; Purssell Edward, 2015, Br J Community Nurs, V20, P481, DOI 10.12968/bjcn.2015.20.10.481; Ramakrishna S, 2005, INTRODUCTION TO ELECTROSPINNING AND NANOFIBERS, P1, DOI 10.1142/9789812567611; Ramakrishna S, 2006, MATER TODAY, V9, P40, DOI 10.1016/S1369-7021(06)71389-X; Rieger KA, 2013, J MATER CHEM B, V1, P4531, DOI 10.1039/c3tb20795a; Saboo S, 2016, MOL PHARMACEUT, V13, P1646, DOI 10.1021/acs.molpharmaceut.6b00072; Sriyanti I, 2018, INT J NANOMED, V13, P4927, DOI 10.2147/IJN.S167670; Tipduangta P, 2016, MOL PHARMACEUT, V13, P25, DOI 10.1021/acs.molpharmaceut.5b00359; Wang Y, 2017, CHEM-EUR J, V23, P419, DOI 10.1002/chem.201604468; Webb SD, 2002, J PHARM SCI, V91, P1474, DOI 10.1002/jps.10135; Win SJ, 2012, BRIT J CANCER, V106, P92, DOI 10.1038/bjc.2011.538; Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161; Wirkas T, 2007, VACCINE, V25, P691, DOI 10.1016/j.vaccine.2006.08.028; Wu X, 2016, HUM VACC IMMUNOTHER, V12, P2603, DOI 10.1080/21645515.2016.1184806; Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593; Zhang S, 2009, MOL IMMUNOL, V46, P1988, DOI 10.1016/j.molimm.2009.03.008; Zhang X, 2016, VACCINE, V34, P5871, DOI 10.1016/j.vaccine.2016.10.045	52	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							213	10.3390/vaccines9030213			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6AF	33802376	gold, Green Published			2022-04-29	WOS:000634233700001
J	Klimowicz-Bodys, MD; Ploneczka-Janeczko, K; Czopowicz, M; Polak, MP; Lachowicz-Wolak, A; Rypula, K				Klimowicz-Bodys, Malgorzata D.; Ploneczka-Janeczko, Katarzyna; Czopowicz, Michal; Polak, Miroslaw Pawel; Lachowicz-Wolak, Agnieszka; Rypula, Krzysztof			Antibody Response to a Live-Modified Virus Vaccine against Bovine Viral Diarrhoea in Dairy Cattle in a Field Trial	VACCINES			English	Article						BVDV; dairy cattle; life-modified virus vaccine; vaccination		(1) Background: The objective of the study was to evaluate the long-term antibody response of dairy cows to a single dose of a commercial modified-live virus (MLV) vaccine against bovine viral diarrhea (Mucosiffa (R) CEVA Sante Animale, Liburne, France). (2) Methods: The study was carried out in a dairy cattle herd counting 290 animals negative for bovine viral diarrhoea virus (BVDV). The vaccination was implemented following the manufacturer's instructions. Twelve dairy cows were randomly selected before the study, and blood samples were collected right before the vaccination and then 12 times at 1-month intervals. The serum samples were screened using a virus neutralization test (VNT) and ELISA. (3) Results: Both tests showed that antibody titers increased significantly in all animals within the first month post-vaccination, and continued to increase significantly until the second (VNT) and third (ELISA) month post-vaccination. Antibody titers remained high and stable until the end of the study. Moreover, cows did not show any adverse reactions or clinical symptoms of the disease. (4) Conclusion: The results of this study indicated that the administration of one dose MLV vaccine was able to stimulate long-lasting (12-months) and strong antibody response in all vaccinated cows.	[Klimowicz-Bodys, Malgorzata D.; Ploneczka-Janeczko, Katarzyna; Lachowicz-Wolak, Agnieszka; Rypula, Krzysztof] Wroclaw Univ Environm & Life Sci, Fac Vet Med, Dept Epizootiol & Clin Birds & Exot Anim, Div Infect Dis Anim & Vet Adm, Pl Grunwaldzki 45, PL-50366 Wroclaw, Poland; [Czopowicz, Michal] Warsaw Univ Life Sci SGGW, Inst Vet Med, Div Vet Epidemiol & Econ, Ul Nowoursynowska 159c, PL-02776 Warsaw, Poland; [Polak, Miroslaw Pawel] Natl Vet Res Inst, Dept Virol, Al Partyzantow 57, PL-24100 Pulawy, Poland		Rypula, K (通讯作者)，Wroclaw Univ Environm & Life Sci, Fac Vet Med, Dept Epizootiol & Clin Birds & Exot Anim, Div Infect Dis Anim & Vet Adm, Pl Grunwaldzki 45, PL-50366 Wroclaw, Poland.	malgorzata.klimowicz-bodys@upwr.edu.pl; katarzyna.ploneczka-janeczko@upwr.edu.pl; mczopowicz@gmail.com; ppolak@piwet.pulawy.pl; agnieszka.lachowicz-wolak@upwr.edu.pl; krzysztof.rypula@upwr.edu.pl	Czopowicz, Michał/U-5452-2018; Klimowicz-Bodys, Małgorzata D./ABB-1467-2020	Czopowicz, Michał/0000-0002-4238-8360; Klimowicz-Bodys, Małgorzata D./0000-0002-8596-0822; Rypula, Krzysztof/0000-0003-3884-4834	Leading Research Groups support project	The research was co-financed under the Leading Research Groups support project from the subsidy increased for the period 2020-2025 in the amount of 2% of the subsidy referred to Art. 387 (3) of the Law of 20 July 2018 on Higher Education and Science, obtained in 2019. The authors want to thank the technicians from the Diagnostic Laboratory EPI-VET of Faculty of Veterinary Medicine in Wroclaw, and the Diagnostic Laboratory of Department of Virology of National Veterinary Research Institute in Pulawy who performed the laboratory work and Radoslaw Proban DVM for technical support and help with vaccination and blood collection.	Fulton RW, 2015, ANIM HEALTH RES REV, V16, P40, DOI 10.1017/S1466252315000079; Griebel PJ, 2015, ANIM HEALTH RES REV, V16, P27, DOI 10.1017/S1466252315000080; Hawkes P.W., FETAL BOVINE SERUM F; Houe H, 2003, BIOLOGICALS, V31, P137, DOI 10.1016/S1045-1056(03)00030-7; International Committee on Taxonomy of Viruses (ICTV), 2019, FFLAV VIR TAX CLASS; Kuta A, 2013, VET MICROBIOL, V166, P639, DOI 10.1016/j.vetmic.2013.07.002; Kuta A, 2013, B VET I PULAWY, V57, P149, DOI 10.2478/bvip-2013-0028; Lanyon SR, 2013, AUST VET J, V91, P52, DOI 10.1111/j.1751-0813.2012.01010.x; Meyer G, 2012, VET J, V192, P242, DOI 10.1016/j.tvjl.2011.05.011; Miroslaw P, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2029-z; Moennig Volker, 2005, Animal Health Research Reviews, V6, P63, DOI 10.1079/AHR2005102; Newcomer BW, 2017, VET MICROBIOL, V206, P78, DOI 10.1016/j.vetmic.2017.04.003; Newcomer BW, 2015, THERIOGENOLOGY, V83, P360, DOI 10.1016/j.theriogenology.2014.09.028; Polak MP, 2016, J VET RES, V60, P379, DOI 10.1515/jvetres-2016-0056; Ridpath JF, 2013, BIOLOGICALS, V41, P14, DOI 10.1016/j.biologicals.2012.07.003; Rodning SP, 2012, THERIOGENOLOGY, V78, P1508, DOI 10.1016/j.theriogenology.2012.05.031; Rodning SP, 2010, THERIOGENOLOGY, V73, P1154, DOI 10.1016/j.theriogenology.2010.01.017; Rypula K, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10020230; Rypula Krzysztof, 2010, Medycyna Weterynaryjna, V66, P684; Simmonds P, 2017, J GEN VIROL, V98, P2, DOI 10.1099/jgv.0.000672; Sozzi E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030374; Stott AW, 2010, VET J, V185, P138, DOI 10.1016/j.tvjl.2009.05.020; Thrusfield M., 2018, SURVEYS VET EPIDEMIO, V4th, P270	23	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							259	10.3390/vaccines9030259			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5KK	33804010	Green Published, gold, Green Submitted			2022-04-29	WOS:000634192600001
J	Bugya, Z; Prechl, J; Szenasi, T; Nemes, E; Bacsi, A; Koncz, G				Bugya, Zsofia; Prechl, Jozsef; Szenasi, Tibor; Nemes, Eva; Bacsi, Attila; Koncz, Gabor			Multiple Levels of Immunological Memory and Their Association with Vaccination	VACCINES			English	Review						immunological memory; vaccination; B cell; T cell; elderly; newborn	HELPER T-CELLS; INNATE IMMUNE MEMORY; MARROW PLASMA-CELLS; IG CLASS SWITCH; ZONE B-CELLS; GERMINAL CENTER; RESIDENT MEMORY; MARGINAL ZONE; INFECTIOUS-DISEASES; BCG VACCINATION	Immunological memory is divided into many levels to counteract the provocations of diverse and ever-changing infections. Fast functions of effector memory and the superposition of both quantitatively and qualitatively plastic anticipatory memory responses together form the walls of protection against pathogens. Here we provide an overview of the role of different B and T cell subsets and their interplay, the parallel and independent functions of the B1, marginal zone B cells, T-independent- and T-dependent B cell responses, as well as functions of central and effector memory T cells, tissue-resident and follicular helper T cells in the memory responses. Age-related limitations in the immunological memory of these cell types in neonates and the elderly are also discussed. We review how certain aspects of immunological memory and the interactions of components can affect the efficacy of vaccines, in order to link our knowledge of immunological memory with the practical application of vaccination.	[Bugya, Zsofia; Szenasi, Tibor; Bacsi, Attila; Koncz, Gabor] Univ Debrecen, Fac Med, Dept Immunol, H-4032 Debrecen, Hungary; [Prechl, Jozsef] Diagnosticum Zrt, R&D Lab, H-1047 Budapest, Hungary; [Nemes, Eva] Univ Debrecen, Clin Ctr, Dept Pediat, H-4032 Debrecen, Hungary		Koncz, G (通讯作者)，Univ Debrecen, Fac Med, Dept Immunol, H-4032 Debrecen, Hungary.	bugyazsofia5@gmail.com; jprechl@gmail.com; szenatiborr@gmail.com; enemes@med.unideb.hu; etele@med.unideb.hu; koncz.gabor@med.unideb.hu	Koncz, Gabor/AAL-4415-2021; Prechl, Jozsef/B-2094-2009	Koncz, Gabor/0000-0002-4888-6838; Prechl, Jozsef/0000-0003-3859-4353	European UnionEuropean Commission; European Regional Development FundEuropean Commission; National Research, Development and Innovation Office-NKFIHNational Research, Development & Innovation Office (NRDIO) - Hungary [K 125224, VEKOP-2.1.1-15-2016-00098];  [GINOP-2.3.2-15-2016-00050]	The work/publication is supported by the GINOP-2.3.2-15-2016-00050 project. The project is cofinanced by the European Union and the European Regional Development Fund, the National Research, Development and Innovation Office-NKFIH K 125224 and VEKOP-2.1.1-15-2016-00098 are acknowledged for financial support of this work.	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Ahmed M, 2009, J IMMUNOL, V182, P784, DOI 10.4049/jimmunol.182.2.784; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736; Alugupalli KR, 2004, IMMUNITY, V21, P379, DOI 10.1016/j.immuni.2004.06.019; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Asrir A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00843-7; Auladell M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01400; Auner HW, 2010, BLOOD, V116, P3445, DOI 10.1182/blood-2009-10-250423; Barski A, 2017, SCI REP-UK, V7, DOI 10.1038/srep39785; Batista FD, 2009, NAT REV IMMUNOL, V9, P15, DOI 10.1038/nri2454; Bektas A, 2017, J LEUKOCYTE BIOL, V102, P977, DOI 10.1189/jlb.3RI0716-335R; Beura LK, 2018, NAT IMMUNOL, V19, P173, DOI 10.1038/s41590-017-0029-3; Billeskov R, 2019, HUM VACC IMMUNOTHER, V15, P407, DOI 10.1080/21645515.2018.1527496; Blanchard-Rohner G, 2009, BLOOD, V114, P4998, DOI 10.1182/blood-2009-03-211052; Blomberg BB, 2013, IMMUNOL RES, V57, P354, DOI 10.1007/s12026-013-8440-9; Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217; Boraschi D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00799; Bortnick A, 2013, J IMMUNOL, V190, P5913, DOI 10.4049/jimmunol.1300161; Bortnick A, 2012, J IMMUNOL, V188, P5389, DOI 10.4049/jimmunol.1102808; Bouneauld C, 2005, J EXP MED, V201, P579, DOI 10.1084/jem.20040876; Breukels MA, 2001, INFECT IMMUN, V69, P7583, DOI 10.1128/IAI.69.12.7583-7587.2001; Burt TD, 2013, AM J REPROD IMMUNOL, V69, P346, DOI 10.1111/aji.12083; Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007; Castiglione F, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/842329; Chan TD, 2009, J IMMUNOL, V183, P3139, DOI 10.4049/jimmunol.0901690; Chen Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02826; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003; Cortegano I, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.351; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Dal Porto JM, 2002, J EXP MED, V195, P1215, DOI 10.1084/jem.20011550; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27; De Rosa SC, 2004, J IMMUNOL, V172, P1637, DOI 10.4049/jimmunol.172.3.1637; Defrance T, 2011, CURR OPIN IMMUNOL, V23, P330, DOI 10.1016/j.coi.2011.03.004; Demirjian A, 2009, EUR J IMMUNOL, V39, P36, DOI 10.1002/eji.200838620; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; Dominguez-Andres J, 2020, SCIENCE, V368, P1052, DOI 10.1126/science.abc2660; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Fazilleau N, 2009, NAT IMMUNOL, V10, P375, DOI 10.1038/ni.1704; Finney J, 2018, IMMUNOL REV, V284, P42, DOI 10.1111/imr.12661; Frasca D, 2004, J IMMUNOL, V172, P2155, DOI 10.4049/jimmunol.172.4.2155; Frasca D, 2008, J IMMUNOL, V180, P5283, DOI 10.4049/jimmunol.180.8.5283; Frasca D, 2007, EXP GERONTOL, V42, P192, DOI 10.1016/j.exger.2006.09.003; Frasca D, 2016, BIOGERONTOLOGY, V17, P7, DOI 10.1007/s10522-015-9578-8; Fuentes E, 2017, AN ACAD BRAS CIENC, V89, P285, DOI 10.1590/0001-3765201720160487; Garg AK, 2019, CELL REP, V29, P3946, DOI 10.1016/j.celrep.2019.11.030; Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gibson KL, 2009, AGING CELL, V8, P18, DOI 10.1111/j.1474-9726.2008.00443.x; Gonzalez-Garcia I, 2008, BLOOD, V111, P741, DOI 10.1182/blood-2007-08-108118; Good-Jacobson KL, 2010, NAT IMMUNOL, V11, P535, DOI 10.1038/ni.1877; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Goronzy JJ, 2015, J IMMUNOL, V194, P4073, DOI 10.4049/jimmunol.1500046; Gustafson CE, 2020, J ALLERGY CLIN IMMUN, V145, P1309, DOI 10.1016/j.jaci.2020.03.017; Haas KM, 2005, IMMUNITY, V23, P7, DOI 10.1016/j.immuni.2005.04.011; Hale JS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00016; Hammarlund E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01901-w; Han SS, 2003, J IMMUNOL, V170, P1267, DOI 10.4049/jimmunol.170.3.1267; Heldwein KA, 2003, J LEUKOCYTE BIOL, V74, P277, DOI 10.1189/jlb.0103026; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; Holtmeier W, 1997, J IMMUNOL, V158, P5632; Howard WA, 2006, REJUV RES, V9, P117, DOI 10.1089/rej.2006.9.117; Hsu MC, 2006, P NATL ACAD SCI USA, V103, P5905, DOI 10.1073/pnas.0601502103; Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087; Huygens A, 2015, J INFECT DIS, V212, P484, DOI 10.1093/infdis/jiv071; Inamine A, 2005, INT IMMUNOL, V17, P581, DOI 10.1093/intimm/dxh241; Inoue T, 2018, IMMUNOL REV, V283, P138, DOI 10.1111/imr.12640; Ise W, 2014, P NATL ACAD SCI USA, V111, P11792, DOI 10.1073/pnas.1404671111; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Jayasekera JP, 2007, J VIROL, V81, P3487, DOI 10.1128/JVI.02128-06; Kaji T, 2012, J EXP MED, V209, P2079, DOI 10.1084/jem.20120127; Kaminski DA, 2006, J IMMUNOL, V177, P6025, DOI 10.4049/jimmunol.177.9.6025; Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025; KAYHTY H, 1983, J INFECT DIS, V147, P1100; Keck S, 2014, P NATL ACAD SCI USA, V111, P14852, DOI 10.1073/pnas.1403271111; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Klouwenberg PK, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/628963; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Kunzli M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay5552; Kurosaki T, 2015, NAT REV IMMUNOL, V15, P149, DOI 10.1038/nri3802; Landers CD, 2005, IMMUNOL RES, V31, P25, DOI 10.1385/IR:31:1:25; Lefebvre JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25051; Lu KT, 2011, IMMUNITY, V35, P622, DOI 10.1016/j.immuni.2011.07.015; Luthje K, 2012, NAT IMMUNOL, V13, P491, DOI 10.1038/ni.2261; Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Malkiel S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00427; Marchant A, 1999, J IMMUNOL, V163, P2249; Marraco SAF, 2015, GENOM DATA, V5, P297, DOI 10.1016/j.gdata.2015.06.024; Maruyama M, 2000, NATURE, V407, P636, DOI 10.1038/35036600; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mastelic B, 2012, J IMMUNOL, V189, P5764, DOI 10.4049/jimmunol.1201143; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Moberley SA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub2; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Morra ME, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16067-0; Morris MC, 2016, NEONATOLOGY, V109, P161, DOI 10.1159/000442460; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Muruganandah V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01574; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Netea MG, 2015, NAT IMMUNOL, V16, P675, DOI 10.1038/ni.3178; Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; O'Brien KL, 2007, LANCET INFECT DIS, V7, P597, DOI 10.1016/S1473-3099(07)70210-4; O'Connor BP, 2006, J IMMUNOL, V177, P7723, DOI 10.4049/jimmunol.177.11.7723; Obukhanych TV, 2006, J EXP MED, V203, P305, DOI 10.1084/jem.20052036; OCHSENBEIN AF, 1999, SCIENCE, V286, P2156; Papadatou I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010013; Pape KA, 2003, J EXP MED, V197, P1677, DOI 10.1084/jem.20012065; Pape KA, 2018, IMMUNITY, V48, P1135, DOI 10.1016/j.immuni.2018.04.019; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; Park SL, 2018, NAT IMMUNOL, V19, P183, DOI 10.1038/s41590-017-0027-5; Parker ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00042; Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355; Patel M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001093.pub2; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862; Plotkin SA, 2020, VACCINE, V38, P2250, DOI 10.1016/j.vaccine.2019.10.046; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282; Pritz T, 2015, EUR J IMMUNOL, V45, P738, DOI 10.1002/eji.201444878; Renkema KR, 2014, J IMMUNOL, V192, P151, DOI 10.4049/jimmunol.1301453; Riksen NP, 2018, AGING-US, V10, P2218, DOI 10.18632/aging.101552; RISDON G, 1995, P NATL ACAD SCI USA, V92, P2413, DOI 10.1073/pnas.92.6.2413; Rousseau MC, 2016, PAEDIATR PERINAT EP, V30, P141, DOI 10.1111/ppe.12263; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936; Saso A, 2017, SEMIN IMMUNOPATHOL, V39, P627, DOI 10.1007/s00281-017-0654-9; Saunders SP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00715; Sautois B, 1997, EXP HEMATOL, V25, P103; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536; Schmader KE, 2010, J AM GERIATR SOC, V58, P1634, DOI 10.1111/j.1532-5415.2010.03021.x; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Shi YH, 2005, J IMMUNOL, V175, P3262, DOI 10.4049/jimmunol.175.5.3262; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Smith KGC, 1996, EUR J IMMUNOL, V26, P444, DOI 10.1002/eji.1830260226; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; Stuber E, 1996, J EXP MED, V183, P979, DOI 10.1084/jem.183.3.979; Su S, 2021, NAT REV MICROBIOL, V19, P211, DOI 10.1038/s41579-020-00462-y; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Taillardet M, 2009, BLOOD, V114, P4432, DOI 10.1182/blood-2009-01-200014; Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367; Thostesen LM, 2018, ALLERGY, V73, P498, DOI 10.1111/all.13314; Toyama H, 2002, IMMUNITY, V17, P329, DOI 10.1016/S1074-7613(02)00387-4; Tseng HF, 2016, J INFECT DIS, V213, P1872, DOI 10.1093/infdis/jiw047; Turner JS, 2018, CELL REP, V25, P1395, DOI 10.1016/j.celrep.2018.10.042; Turner VM, 2017, BIOGERONTOLOGY, V18, P723, DOI 10.1007/s10522-017-9707-7; Turner VM, 2017, IMMUNOLOGY, V151, P349, DOI 10.1111/imm.12737; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Vojtek I, 2018, ANN MED, V50, P193, DOI 10.1080/07853890.2017.1421320; Vono M, 2019, CELL REP, V28, P1773, DOI 10.1016/j.celrep.2019.07.047; Walker JC, 2011, SCAND J IMMUNOL, V73, P53, DOI 10.1111/j.1365-3083.2010.02473.x; Warfel JM, 2015, CURR OPIN IMMUNOL, V35, P48, DOI 10.1016/j.coi.2015.05.008; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Winarski KL, 2019, P NATL ACAD SCI USA, V116, P15194, DOI 10.1073/pnas.1821317116; Wood N, 2011, CURR OPIN INFECT DIS, V24, P190, DOI 10.1097/QCO.0b013e328345d563; Ygberg S, 2012, ACTA PAEDIATR, V101, P120, DOI 10.1111/j.1651-2227.2011.02494.x; Young B, 2017, VACCINE, V35, P212, DOI 10.1016/j.vaccine.2016.11.013; Youngblood B, 2017, NATURE, V552, P404, DOI 10.1038/nature25144; Zandvoort A, 2002, CLIN EXP IMMUNOL, V130, P4, DOI 10.1046/j.1365-2249.2002.01953.x; Zouali M, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00063	184	2	2	5	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							174	10.3390/vaccines9020174			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QE	33669597	gold, Green Published			2022-04-29	WOS:000623265400001
J	Carnell, GW; Trombetta, CM; Ferrara, F; Montomoli, E; Temperton, NJ				Carnell, George W.; Trombetta, Claudia M.; Ferrara, Francesca; Montomoli, Emanuele; Temperton, Nigel J.			Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines	VACCINES			English	Article						influenza B viruses; serology		Influenza B is responsible for a significant proportion of the global morbidity, mortality and economic loss caused by influenza-related disease. Two antigenically distinct lineages co-circulate worldwide, often resulting in mismatches in vaccine coverage when vaccine predictions fail. There are currently operational issues with gold standard serological assays for influenza B, such as lack of sensitivity and requirement for specific antigen treatment. This study encompasses the gold standard assays with the more recent Pseudotype-based Microneutralisation assay in order to study comparative serological outcomes. Haemagglutination Inhibition, Single Radial Haemolysis and Pseudotype-based Microneutralisation correlated strongly for strains in the Yamagata lineage; however, it correlated with neither gold standard assays for the Victoria lineage.	[Carnell, George W.; Ferrara, Francesca; Temperton, Nigel J.] Univ Kent & Greenwich, Viral Pseudotype Unit, Chatham ME4 4TB, England; [Trombetta, Claudia M.; Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy; [Montomoli, Emanuele] VisMederi Srl, I-53100 Siena, Italy; [Carnell, George W.] Univ Cambridge, Lab Viral Zoonot, Cambridge CB2 1TN, England; [Ferrara, Francesca] St Jude Childrens Res Hosp, Vector Dev & Prod, Memphis, TN 38105 USA		Temperton, NJ (通讯作者)，Univ Kent & Greenwich, Viral Pseudotype Unit, Chatham ME4 4TB, England.	gwc26@cam.ac.uk; trombetta@unisi.it; francesca.ferrara@stjude.org; emanuele.montomoli@unisi.it; n.temperton@kentac.uk	Carnell, George/AAB-4421-2022; Temperton, Nigel/M-1164-2019; Ferrara, Francesca/I-3686-2014	Carnell, George/0000-0001-8875-0989; Temperton, Nigel/0000-0002-7978-3815; Ferrara, Francesca/0000-0002-4973-1520; Trombetta, Claudia Maria/0000-0001-7229-9919			ALKHAYATT R, 1984, J HYG-CAMBRIDGE, V93, P301, DOI 10.1017/S0022172400064834; Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623; [Anonymous], WHO WEEKLY EPIDEMIOL, V88, P73; Belshe RB, 2010, VACCINE, V28, pD45, DOI 10.1016/j.vaccine.2010.08.028; Bodle J, 2013, INFLUENZA OTHER RESP, V7, P191, DOI 10.1111/j.1750-2659.2012.00375.x; Bottcher E, 2009, VACCINE, V27, P6324, DOI 10.1016/j.vaccine.2009.03.029; Bottcher-Friebertshauser E, 2013, PATHOG DIS, V69, P87, DOI 10.1111/2049-632X.12053; Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06; CATE TR, 1983, REV INFECT DIS, V5, P737; CHAKRAVERTY P, 1980, ARCH VIROL, V63, P285, DOI 10.1007/BF01315034; Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908; Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Ferrara F., 2018, DEV USE LENTIVIRAL V, DOI [10.1101/492785, DOI 10.1101/492785]; Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137; Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12; Hashem AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055428; Hause BM, 2014, MBIO, V5, DOI 10.1128/mBio.00031-14; Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664; Hirst GK, 1941, SCIENCE, V94, P22, DOI 10.1126/science.94.2427.22; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; JULKUNEN I, 1985, J VIROL METHODS, V10, P75, DOI 10.1016/0166-0934(85)90091-6; Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914; KENDAL AP, 1983, J CLIN MICROBIOL, V18, P930, DOI 10.1128/JCM.18.4.930-934.1983; Khurana S, 2014, VACCINE, V32, P2188, DOI 10.1016/j.vaccine.2014.02.049; Kuck LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109616; LAMBRE C, 1979, J IMMUNOL METHODS, V26, P61, DOI 10.1016/0022-1759(79)90041-3; LAMONTAGNE JR, 1983, REV INFECT DIS, V5, P723; McCullers JA, 2004, J VIROL, V78, P12817, DOI 10.1128/JVI.78.23.12817-12828.2004; MONTO AS, 1981, J CLIN MICROBIOL, V13, P54, DOI 10.1128/JCM.13.1.54-57.1981; Ni FY, 2013, VIROLOGY, V446, P112, DOI 10.1016/j.virol.2013.07.035; Nilsson CE, 2010, VACCINE, V28, P759, DOI 10.1016/j.vaccine.2009.10.070; OXFORD JS, 1982, J HYG-CAMBRIDGE, V88, P325, DOI 10.1017/S0022172400070170; Pierce CL, 2011, ANAL CHEM, V83, P4729, DOI 10.1021/ac2006526; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; PYHALA R, 1985, J HYG-CAMBRIDGE, V94, P341, DOI 10.1017/S002217240006157X; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; ROBERTSON JS, 1985, VIROLOGY, V143, P166, DOI 10.1016/0042-6822(85)90105-9; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; Saito T, 2004, J MED VIROL, V74, P336, DOI 10.1002/jmv.20178; SCHILD GC, 1975, B WORLD HEALTH ORGAN, V52, P43; Schmeisser F, 2014, INFLUENZA OTHER RESP, V8, P587, DOI 10.1111/irv.12272; Shaw MW, 2002, VIROLOGY, V303, P1, DOI 10.1006/viro.2002.1719; Temperton NJ, 2007, INFLUENZA OTHER RESP, V1, P105, DOI 10.1111/j.1750-2659.2007.00016.x; Trombetta CM, 2018, INFLUENZA OTHER RESP, V12, P675, DOI 10.1111/irv.12591; Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707; Trombetta CM, 2015, J IMMUNOL METHODS, V422, P95, DOI 10.1016/j.jim.2015.04.009; TURNER R, 1982, J CLIN MICROBIOL, V15, P824, DOI 10.1128/JCM.15.5.824-829.1982; Verma S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175733; Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383; Wen YX, 2015, VACCINE, V33, P5342, DOI 10.1016/j.vaccine.2015.08.077; WILLIAMS MS, 1980, J BIOL STAND, V8, P289, DOI 10.1016/S0092-1157(80)80006-0; WILLIAMS MS, 1993, VET MICROBIOL, V37, P253, DOI 10.1016/0378-1135(93)90027-5; WISE TG, 1977, J INFECT DIS, V136, pS507, DOI 10.1093/infdis/136.Supplement_3.S507; WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5; WOOD JM, 1994, VACCINE, V12, P167, DOI 10.1016/0264-410X(94)90056-6; WRIGHT PF, 1983, REV INFECT DIS, V5, P758; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	58	4	4	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							100	10.3390/vaccines9020100			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7BQ	33525543	Green Accepted, gold, Green Published			2022-04-29	WOS:000623295700001
J	Janitzek, CM; Carlsen, PHR; Thrane, S; Khanna, VM; Jakob, V; Barnier-Quer, C; Collin, N; Theander, TG; Salanti, A; Nielsen, MA; Sander, AF				Janitzek, Christoph M.; Carlsen, Philip H. R.; Thrane, Susan; Khanna, Vijansh M.; Jakob, Virginie; Barnier-Quer, Christophe; Collin, Nicolas; Theander, Thor G.; Salanti, Ali; Nielsen, Morten A.; Sander, Adam F.			The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration	VACCINES			English	Article						vaccine; capsid-like particle; virus-like particle; adjuvants; AP205; route of immunization	VIRUS-LIKE PARTICLES; MONOPHOSPHORYL-LIPID-A; DENDRITIC CELLS; CROSS-PRESENTATION; AS04-ADJUVANTED VACCINE; ANTIBODY-RESPONSES; IMMUNE-RESPONSE; ANTIGEN; PROTEIN; MF59	Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. This study compared the humoral immune responses in mice elicited against two different vaccine antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six different adjuvant formulations. In comparison to antibody responses obtained after immunization with the unadjuvanted CLP vaccine, three of the adjuvant systems (neutral liposomes/monophosphoryl lipid A/quillaja saponaria 21, squalene-in-water emulsion, and monophosphoryl lipid A) caused significantly increased antibody levels, whereas formulation with the three other adjuvants (aluminum hydroxide, cationic liposomes, and cationic microparticles) resulted in similar or even decreased antibody responses. When delivering the soluble bacterial protein in a squalene-in-water emulsion, 4-log lower IgG levels were obtained compared to when the protein was delivered on CLPs without the adjuvant. The AP205 CLP platform promoted induction of both IgG1 and IgG2 subclasses, which could be skewed towards a higher production of IgG1 (aluminum hydroxide). Compared to other routes, intramuscular administration elicited the highest IgG levels. These results indicate that the effect of the external adjuvant does not always synergize with the adjuvant effect of the CLP display, which underscores the need for empirical testing of different extrinsic adjuvants.	[Janitzek, Christoph M.; Carlsen, Philip H. R.; Thrane, Susan; Khanna, Vijansh M.; Theander, Thor G.; Salanti, Ali; Nielsen, Morten A.; Sander, Adam F.] Univ Copenhagen, Ctr Med Parasitol, Dept Immunol & Microbiol, DK-1165 Copenhagen, Denmark; [Janitzek, Christoph M.; Carlsen, Philip H. R.; Thrane, Susan; Khanna, Vijansh M.; Theander, Thor G.; Salanti, Ali; Nielsen, Morten A.; Sander, Adam F.] Copenhagen Univ Hosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; [Jakob, Virginie] Vaccine Formulat Inst, CH-1228 Geneva, Switzerland; [Barnier-Quer, Christophe; Collin, Nicolas] Univ Lausanne, Vaccine Formulat Lab, CH-1015 Lausanne, Switzerland		Sander, AF (通讯作者)，Univ Copenhagen, Ctr Med Parasitol, Dept Immunol & Microbiol, DK-1165 Copenhagen, Denmark.; Sander, AF (通讯作者)，Copenhagen Univ Hosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark.	rdx520@alumni.ku.dk; phrc@dtu.dk; susanthrane@gmail.com; vijanshpr@gmail.com; virginie.jakob@vformulation.org; barnierquer@gmail.com; nicolas.collin@unil.ch; thor@sund.ku.dk; salanti@sund.ku.dk; mortenn@sund.ku.dk; asander@sund.ku.dk	; Theander, Thor G./F-6714-2015	Salanti, Ali/0000-0003-2207-5575; Janitzek, Christoph Mikkel/0000-0001-6529-9355; Nielsen, Morten Agertoug/0000-0003-2668-4992; Thrane, Susan/0000-0001-6596-3527; Theander, Thor G./0000-0002-3509-7514; Bertelsen, Adam Frederik Sander/0000-0002-8782-7830	Independent Research Fund Denmark [6110-00177B]; Eurostars; Innovation fund Denmark [E11019]; European commissionEuropean CommissionEuropean Commission Joint Research Centre	This research was funded by Independent Research Fund Denmark, grant number 6110-00177B, and by Eurostars, funded by the European commission and Innovation fund Denmark, grant number E11019.	AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bekeredjian-Ding I, 2009, IMMUNOLOGY, V128, P311, DOI 10.1111/j.1365-2567.2009.03173.x; Bessa J, 2009, J IMMUNOL, V183, P3788, DOI 10.4049/jimmunol.0804004; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Brewer JM, 1999, J IMMUNOL, V163, P6448; Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234; Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090; Chackerian B, 2010, HUM VACCINES, V6, P926, DOI [10.4161/hv.6.11.12655, 10.4161/hv.7.1.12655]; Christensen D, 2016, HUM VACC IMMUNOTHER, V12, P2709, DOI 10.1080/21645515.2016.1219003; Christensen D, 2012, J CONTROL RELEASE, V160, P468, DOI 10.1016/j.jconrel.2012.03.016; Christensen D, 2011, EXPERT REV VACCINES, V10, P513, DOI [10.1586/erv.11.17, 10.1586/ERV.11.17]; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Cook IF, 2008, HUM VACCINES, V4, P67, DOI 10.4161/hv.4.1.4747; Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Einstein MH, 2014, HUM VACC IMMUNOTHER, V10, P3435, DOI 10.4161/hv.36121; Einstein MH, 2009, HUM VACCINES, V5, P705, DOI 10.4161/hv.5.10.9518; Fausch SC, 2003, CANCER RES, V63, P3478; GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329; Ghimire TR, 2012, IMMUNOL LETT, V147, P55, DOI 10.1016/j.imlet.2012.06.002; Gomes AC, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020047; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021; HARO VM, 2007, SCIENCE, V316, P1628; Hou BD, 2011, IMMUNITY, V34, P375, DOI 10.1016/j.immuni.2011.01.011; Janitzek CM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41522-5; Janitzek CM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1574-1; Jegerlehner A, 2007, J IMMUNOL, V178, P2415, DOI 10.4049/jimmunol.178.4.2415; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Kaur R, 2012, J CONTROL RELEASE, V158, P72, DOI 10.1016/j.jconrel.2011.10.012; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9; LACEY MH, 2011, J CONTROL RELEASE, V154, P131, DOI DOI 10.1016/J.JCONREL.2011.05.019; LACEY MH, 2010, J CONTROL RELEASE, V145, P102, DOI DOI 10.1016/J.JCONREL.2010.03.027; Makarkov AI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0111-y; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Maphis NM, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0118-4; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; Mohsen MO, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1579; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; O'Rourke JP, 2015, CURR OPIN VIROL, V11, P76, DOI 10.1016/j.coviro.2015.03.005; Ott G, 1995, Pharm Biotechnol, V6, P277; Palladini A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1408749; Panagioti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00276; Patel KG, 2011, BIOCONJUGATE CHEM, V22, P376, DOI 10.1021/bc100367u; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; ROELS GL, 2016, CLIN IMMUNOL, V169, P16, DOI DOI 10.1016/J.CLIM.2016.05.007; ROIX RM, 2016, J BIOL CHEM, V291, P1123, DOI DOI 10.1074/JBC.M115.683011; Schoonen L, 2015, BIOCONJUGATE CHEM, V26, P2429, DOI 10.1021/acs.bioconjchem.5b00485; Seubert A, 2011, P NATL ACAD SCI USA, V108, P11169, DOI 10.1073/pnas.1107941108; SHIRAZI MN, 2018, IMMUNOL LETT, V193, P58, DOI DOI 10.1016/J.IMLET.2017.10.015; Silva AL, 2016, HUM VACC IMMUNOTHER, V12, P1056, DOI 10.1080/21645515.2015.1117714; Singh SK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01256; Singh SK, 2017, VACCINE, V35, P3726, DOI 10.1016/j.vaccine.2017.05.054; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; TEEMU TK, 2015, EUR J PHARM BIOPHARM, V96, P22; Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1; Thrane S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143071; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Vartak A, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020012; Vono M, 2013, P NATL ACAD SCI USA, V110, P21095, DOI 10.1073/pnas.1319784110; Wang YF, 2012, J BIOL CHEM, V287, P17152, DOI 10.1074/jbc.M112.347179; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Wiley SR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002135; Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161; Wu ZJ, 2012, NANOSCALE, V4, P3567, DOI 10.1039/c2nr30366c	75	0	0	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							131	10.3390/vaccines9020131			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AY	33562114	Green Published, gold			2022-04-29	WOS:000623293800001
J	Ike, AC; Ononugbo, CM; Obi, OJ; Onu, CJ; Olovo, CV; Muo, SO; Chukwu, OS; Reward, EE; Omeke, OP				Ike, Anthony C.; Ononugbo, Chukwuebuka M.; Obi, Okechukwu J.; Onu, Chisom J.; Olovo, Chinasa V.; Muo, Sophia O.; Chukwu, Okoro S.; Reward, Eleazar E.; Omeke, Odinakachukwu P.			Towards Improved Use of Vaccination in the Control of Infectious Bronchitis and Newcastle Disease in Poultry: Understanding the Immunological Mechanisms	VACCINES			English	Review						infectious bronchitis; Newcastle disease; poultry; vaccine; immunity	HUMORAL IMMUNE-RESPONSES; AVIAN BETA-DEFENSIN; TOLL-LIKE RECEPTOR; VIRUS-VACCINE; GENOTYPE VII; PROTECTS CHICKENS; DNA VACCINE; CHLORIDE CHITOSAN; MEDIATED-IMMUNITY; CLINICAL SIGNS	Infectious bronchitis (IB) and Newcastle disease (ND) are two important diseases of poultry and have remained a threat to the development of the poultry industry in many parts of the world. The immunology of avian has been well studied and numerous vaccines have been developed against the two viruses. Most of these vaccines are either inactivated vaccines or live attenuated vaccines. Inactivated vaccines induce weak cellular immune responses and require priming with live or other types of vaccines. Advanced technology has been used to produce several types of vaccines that can initiate prime immune responses. However, as a result of rapid genetic variations, the control of these two viral infections through vaccination has remained a challenge. Using various strategies such as combination of live attenuated and inactivated vaccines, development of IB/ND vaccines, use of DNA vaccines and transgenic plant vaccines, the problem is being surmounted. It is hoped that with increasing understanding of the immunological mechanisms in birds that are used in fighting these viruses, a more successful control of the diseases will be achieved. This will go a long way in contributing to global food security and the economic development of many developing countries, given the role of poultry in the attainment of these goals.	[Ike, Anthony C.; Obi, Okechukwu J.; Onu, Chisom J.; Olovo, Chinasa V.; Muo, Sophia O.; Chukwu, Okoro S.; Omeke, Odinakachukwu P.] Univ Nigeria, Dept Microbiol, Fac Biol Sci, Nsukka 410001, Enugu, Nigeria; [Ononugbo, Chukwuebuka M.] Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan; [Onu, Chisom J.; Reward, Eleazar E.] Wayne State Univ, Dept Biol Sci, Coll Liberal Arts & Sci, Detroit, MI 48202 USA; [Olovo, Chinasa V.] Jiangsu Univ, Sch Med, Zhenjiang 212013, Jiangsu, Peoples R China; [Chukwu, Okoro S.] Alex Ekwueme Fed Univ Ndufu Alike, Dept Biol Microbiol Biotechnol, Ebonyi 1010, Nigeria		Ike, AC (通讯作者)，Univ Nigeria, Dept Microbiol, Fac Biol Sci, Nsukka 410001, Enugu, Nigeria.	anthonyc.ike@unn.edu.ng; ononugbocm@gmail.com; obi.okey@yahoo.com; chisomjoshua982@yahoo.com; chinasa.olovo@unn.edu.ng; muosophia0@gmail.com; cokorosamuel@gmail.com; reward.eleazar@wayne.edu; omekeprisca123@gmail.com		Ike, Anthony/0000-0003-2706-6141; Obi, Okechukwu/0000-0002-1806-3670; Reward, Eleazar/0000-0003-0287-7255; Muo, Sophia/0000-0002-4954-1081; ONONUGBO, CHUKWUEBUKA/0000-0001-9995-5867			Abdisa T., 2017, J VET SCI TECHNOLOGY, V8, DOI [10.4172/2157-7579.1000441, DOI 10.4172/2157-7579.1000441]; Abozeid HH, 2019, VET RES, V50, DOI 10.1186/s13567-019-0631-5; Albanese GA, 2018, VACCINE, V36, P6077, DOI 10.1016/j.vaccine.2018.08.078; Ali A, 2018, POULTRY SCI, V97, P4238, DOI 10.3382/ps/pey312; Amarasinghe A, 2018, VET MICROBIOL, V215, P1, DOI 10.1016/j.vetmic.2018.01.001; ANTIPAS BBB, 2012, EUR J EXP BIOL, V2, P2286; Armesto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024352; Assayag Junior M. S., 2012, VII. International symposium on avian corona- and pneumoviruses and complicating pathogens, Rauischholzhausen, Germany, 18-21 June 2012, P80; Awad F, 2016, AVIAN PATHOL, V45, P169, DOI 10.1080/03079457.2015.1137866; Bande F., 2016, ADV VIROL, V2016, DOI 10.1155/2016/4621659; Bande F, 2016, ADV VIROL, V2016, DOI 10.1155/2016/4621659; Bello MB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020270; Benyeda Z, 2010, J COMP PATHOL, V143, P276, DOI 10.1016/j.jcpa.2010.04.007; Bezuidenhout A, 2011, J COMP PATHOL, V145, P319, DOI 10.1016/j.jcpa.2011.01.011; BIENENSTOCK J, 1973, LAB INVEST, V28, P686; Bijlenga G, 2004, AVIAN PATHOL, V33, P550, DOI 10.1080/03079450400013154; Brujeni GN, 2019, ACTA VET SCAND, V61, DOI 10.1186/s13028-019-0476-y; Caron LF, 2010, BRAZ J POULTRY SCI, V12, P115, DOI 10.1590/S1516-635X2010000200007; Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055; CHEN CH, 1994, POULTRY SCI, V73, P1012, DOI 10.3382/ps.0731012; Chen Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02006; Chhabra R, 2016, VIROLOGY, V488, P232, DOI 10.1016/j.virol.2015.11.011; Chhabra R, 2015, CLIN VACCINE IMMUNOL, V22, P1050, DOI 10.1128/CVI.00368-15; Colvero LP, 2015, REV SCI TECH OIE, V34, P993, DOI 10.20506/rst.34.3.2411; Cong F, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-743; Cormican P, 2009, DEV COMP IMMUNOL, V33, P967, DOI 10.1016/j.dci.2009.04.001; CRINION RAP, 1972, AVIAN DIS, V16, P351, DOI 10.2307/1588800; Deist MS, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00027-17, 10.1128/cvi.00027-17]; Dhama Kuldeep, 2014, Pak J Biol Sci, V17, P751, DOI 10.3923/pjbs.2014.751.767; Dimitrov KM, 2019, VIROLOGY, V531, P203, DOI 10.1016/j.virol.2019.03.010; dos Santos RM, 2019, J VET MED SCI, V81, P612, DOI 10.1292/jvms.18-0065; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Ecco R, 2011, VET IMMUNOL IMMUNOP, V141, P221, DOI 10.1016/j.vetimm.2011.03.002; Elhady MA, 2018, VET SCI, V5, DOI 10.3390/vetsci5020049; Elhamouly M, 2018, THERIOGENOLOGY, V110, P122, DOI 10.1016/j.theriogenology.2017.12.047; Ellis S, 2018, J VIROL, V92, DOI 10.1128/JVI.01473-18; Emecheta AO, 2018, WORLD POULTRY SCI J, V74, P665, DOI 10.1017/S0043933918000533; Erfanmanesh A, 2020, COMP IMMUNOL MICROB, V71, DOI 10.1016/j.cimid.2020.101497; Fan WS, 2018, J VET MED SCI, V80, P1438, DOI 10.1292/jvms.18-0249; Feng KY, 2015, VACCINE, V33, P1113, DOI 10.1016/j.vaccine.2015.01.036; Ferreira AF, 2018, CIENC RURAL, V48, DOI 10.1590/0103-8478cr20180250; Fung TS, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0053-0; Gao P, 2020, VET RES, V51, DOI 10.1186/s13567-020-00774-0; Gao Y, 2020, MOLECULES, V25, DOI 10.3390/molecules25112505; Guo ZC, 2010, J VIROL METHODS, V167, P84, DOI 10.1016/j.jviromet.2010.03.016; Han XX, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080198; Han ZX, 2016, VIRUS RES, V213, P140, DOI 10.1016/j.virusres.2015.11.021; He YN, 2016, VIROL SIN, V31, P57, DOI 10.1007/s12250-015-3696-y; Hu ZL, 2018, J PROTEOMICS, V181, P201, DOI 10.1016/j.jprot.2018.04.019; Hu ZL, 2011, AVIAN DIS, V55, P391, DOI 10.1637/9633-122410-Reg.1; Huang YP, 2006, VACCINE, V24, P785, DOI 10.1016/j.vaccine.2005.08.081; Hughes S, 2007, DEV COMP IMMUNOL, V31, P72, DOI 10.1016/j.dci.2006.04.003; Ignjatovic J, 2000, REV SCI TECH OIE, V19, P493, DOI 10.20506/rst.19.2.1228; Ike AC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020302; Ingrao F, 2017, AVIAN PATHOL, V46, P289, DOI 10.1080/03079457.2016.1265083; Izquierdo-Lara R, 2019, PLOS ONE, V14, DOI [10.1371/journ, 10.1371/journal.pone.0209539]; Jackwood MW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176709; Jackwood MW, 2015, AVIAN DIS, V59, P368, DOI 10.1637/11026-012415-Reg.1; Jackwood MW, 2010, AVIAN PATHOL, V39, P227, DOI 10.1080/03079451003801516; Jackwood MW, 2013, DIS POULTRY, V13th, P117; Jeurissen S. H. M., 1994, Poultry Science Reviews, V5, P183; Ji YH, 2018, VET MICROBIOL, V216, P99, DOI 10.1016/j.vetmic.2018.01.021; Jiang Y, 2020, VACCINE, V38, P3157, DOI 10.1016/j.vaccine.2020.01.001; Jin Z, 2017, CARBOHYD POLYM, V171, P267, DOI 10.1016/j.carbpol.2017.05.022; Joiner KS, 2007, AVIAN DIS, V51, P758, DOI 10.1637/0005-2086(2007)51[758:POIBVI]2.0.CO;2; Kaiser P, 2010, AVIAN PATHOL, V39, P309, DOI 10.1080/03079457.2010.508777; Kang XL, 2016, PROTEIN EXPRES PURIF, V128, P73, DOI 10.1016/j.pep.2016.08.009; Kang YF, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01283; Kapczynski DR, 2013, DEV COMP IMMUNOL, V41, P447, DOI 10.1016/j.dci.2013.04.012; Kaspers B, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 1: DEVELOPMENT AND PHYLOGENY OF THE IMMUNE SYSTEM, P498, DOI 10.1016/B978-0-12-374279-7.12013-2; KEENEY AH, 1950, ARCH OPHTHALMOL-CHIC, V44, P573; Khataby K, 2016, VET QUART, V36, P71, DOI 10.1080/01652176.2015.1126869; Khatun M., 2018, J ECON BUS, V1, P358, DOI [10.31014/aior.1992.01.03.33, DOI 10.31014/AIOR.1992.01.03.33]; Khulape SA, 2019, TROP ANIM HEALTH PRO, V51, P2529, DOI 10.1007/s11250-019-01967-2; Kim JY, 2016, POULTRY SCI, V95, P790, DOI 10.3382/ps/pev377; Kjaerup RM, 2014, VIRAL IMMUNOL, V27, P529, DOI 10.1089/vim.2014.0088; Kristeen-Teo YW, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1071-y; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Kumar S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.122; Larsen FT, 2019, DEV COMP IMMUNOL, V96, P93, DOI 10.1016/j.dci.2019.02.004; Le Gros FX, 2009, VACCINE, V27, P592, DOI 10.1016/j.vaccine.2008.10.094; Lee HJ, 2010, VACCINE, V28, P2887, DOI 10.1016/j.vaccine.2010.01.062; Lemiere S, 2011, AVIAN DIS, V55, P642, DOI 10.1637/9751-040511-ResNote.1; Leyson CM, 2017, AVIAN DIS, V61, P123, DOI 10.1637/11474-072216-ResNote; Li JP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203771; Li RQ, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0886-2; Li SY, 2020, BIOLOGICALS, V63, P74, DOI 10.1016/j.biologicals.2019.11.001; Li XQ, 2019, VET MICROBIOL, V228, P147, DOI 10.1016/j.vetmic.2018.11.017; Li YL, 2016, INFECT GENET EVOL, V37, P37, DOI 10.1016/j.meegid.2015.10.021; Li YR, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2128-6; Liang JQ, 2019, VIROLOGY, V531, P48, DOI 10.1016/j.virol.2019.02.017; Liao Y, 2013, J VIROL, V87, P8124, DOI 10.1128/JVI.00626-13; Liao Y, 2011, VIROLOGY, V420, P106, DOI 10.1016/j.virol.2011.09.003; Lim TH, 2015, VACCINE, V33, P7370, DOI 10.1016/j.vaccine.2015.07.043; Lin MY, 2003, AVIAN PATHOL, V32, P345, DOI 10.1080/0307945031000121086; Liu CG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00751; Liu JJ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080225; Liu MM, 2015, BIOTECHNOL LETT, V37, P1287, DOI 10.1007/s10529-015-1799-z; Lopes PD, 2018, VACCINE, V36, P2630, DOI 10.1016/j.vaccine.2018.03.065; Ma FS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010122; Mammo Mengesha, 2011, Livestock Research for Rural Development, V23, P37; Manoharan VK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197253; McMartin Duncan A., 1993, V4, P249; Mebrahtu K, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1355-x; Melkamu S., 2018, INT J ADV RES BIOL S, V5, P117; Miller PJ, 2007, VACCINE, V25, P7238, DOI 10.1016/j.vaccine.2007.07.017; Miller PJ, 2010, INFECT GENET EVOL, V10, P26, DOI 10.1016/j.meegid.2009.09.012; Miller PJ, 2009, VIROLOGY, V391, P64, DOI 10.1016/j.virol.2009.05.033; Miller PJ, 2009, AVIAN DIS, V53, P39, DOI 10.1637/8407-071208-Reg.1; Moreno A, 2017, AVIAN PATHOL, V46, P28, DOI 10.1080/03079457.2016.1200011; Moscoso H, 2005, AVIAN DIS, V49, P24, DOI 10.1637/7220; Muller S, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0067-3; Nii T, 2014, THERIOGENOLOGY, V81, P1129, DOI 10.1016/j.theriogenology.2014.02.002; Nochi T, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00060; Ohshima K, 2000, HISTOL HISTOPATHOL, V15, P713, DOI 10.14670/HH-15.713; Okino CH, 2014, VIRAL IMMUNOL, V27, P383, DOI 10.1089/vim.2014.0054; Okino CH, 2013, VIRAL IMMUNOL, V26, P259, DOI 10.1089/vim.2013.0015; Orr-Burks N, 2014, AVIAN DIS, V58, P279, DOI 10.1637/10740-120313-Reg.1; Palya V, 2012, AVIAN DIS, V56, P282, DOI 10.1637/9935-091511-Reg.1; Parra D, 2013, ANNU REV ANIM BIOSCI, V1, P65, DOI 10.1146/annurev-animal-031412-103651; Perozo F, 2008, AVIAN PATHOL, V37, P237, DOI 10.1080/03079450802043734; PURCHASE HG, 1972, AVIAN DIS, V16, P57, DOI 10.2307/1588900; Qian J, 2017, VET MICROBIOL, V203, P158, DOI 10.1016/j.vetmic.2017.03.002; Qu YR, 2018, VIROLOGY, V525, P19, DOI 10.1016/j.virol.2018.09.001; Rasoli M, 2014, COMP IMMUNOL MICROB, V37, P11, DOI 10.1016/j.cimid.2013.10.003; Rauw F, 2017, AVIAN PATHOL, V46, P434, DOI 10.1080/03079457.2017.1304528; Rauw F, 2014, AVIAN PATHOL, V43, P26, DOI 10.1080/03079457.2013.859655; Roohani K, 2015, J VET SCI, V16, P447, DOI 10.4142/jvs.2015.16.4.447; ROSE ME, 1974, EUR J IMMUNOL, V4, P521, DOI 10.1002/eji.1830040715; Rue CA, 2011, J GEN VIROL, V92, P931, DOI 10.1099/vir.0.025486-0; Sadiq M. B., 2017, Sokoto Journal of Veterinary Sciences, V15, P7, DOI 10.4314/sokjvs.v15i2.2; Saiada F, 2019, AVIAN DIS, V63, P38, DOI 10.1637/11951-081418-Reg.1; Schilling MA, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00061; Schirrmacher V, 1998, SEMIN ONCOL, V25, P677; Sedeik ME, 2019, POULTRY SCI, V98, P2000, DOI 10.3382/ps/pey559; Seo SH, 1997, J VIROL, V71, P5173, DOI 10.1128/JVI.71.7.5173-5177.1997; SHAFIEI BH, 2020, IRAN J VET RES, V21, P84; Shah M, 2019, CYTOKINE, V120, P28, DOI 10.1016/j.cyto.2019.04.007; Shahriari AG, 2019, IRAN J BIOTECHNOL, V17, P54, DOI 10.21859/ijb.2215; Shirvani E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30356-2; Singh S.B., 2008, AGR EC RES REV, V21, P37; Smith J, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0575-6; Subbaiah KCV, 2015, INT J BIOCHEM CELL B, V64, P97, DOI 10.1016/j.biocel.2015.03.019; Sun JF, 2017, J BIOL CHEM, V292, P20141, DOI [10.1074/jbc.M116.772897, 10.1074/jbc.m116.772897]; Sun MH, 2017, VIRUS GENES, V53, P35, DOI 10.1007/s11262-016-1397-8; Tan L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040170; Tan L, 2016, VACCINE, V34, P5209, DOI 10.1016/j.vaccine.2016.09.022; Temperley ND, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-62; Thomazelli LM, 2012, BRAZ J POULTRY SCI, V14, P1, DOI 10.1590/S1516-635X2012000100001; Tian L, 2008, BIOCHEM BIOPH RES CO, V377, P221, DOI 10.1016/j.bbrc.2008.09.125; van Ginkel FW, 2015, VACCINE, V33, P2655, DOI 10.1016/j.vaccine.2015.04.026; Wang BB, 2016, VIROLOGY, V496, P90, DOI 10.1016/j.virol.2016.05.023; Wang ZX, 2014, ACTA VET HUNG, V62, P500, DOI 10.1556/AVet.2014.023; Wu Q, 2019, VET MICROBIOL, V236, DOI 10.1016/j.vetmic.2019.108391; Wu X, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030254; Xia J, 2018, VACCINE, V36, P4087, DOI 10.1016/j.vaccine.2018.05.094; Xiang B, 2018, ARCH VIROL, V163, P1407, DOI 10.1007/s00705-018-3745-6; Xiao S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052751; Xu QQ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01587; Xu Y, 2015, APPL MICROBIOL BIOT, V99, P9011, DOI 10.1007/s00253-015-6786-8; Yadav K, 2018, MICROB PATHOGENESIS, V118, P230, DOI 10.1016/j.micpath.2018.03.038; Yan SH, 2018, VACCINE, V36, P1880, DOI 10.1016/j.vaccine.2018.02.053; Yang HM, 2017, VACCINE, V35, P27, DOI 10.1016/j.vaccine.2016.11.048; Yang X, 2020, ACTA BIOCH BIOPH SIN, V52, P268, DOI 10.1093/abbs/gmz158; Yang X, 2018, MICROB PATHOGENESIS, V116, P54, DOI 10.1016/j.micpath.2018.01.008; Yang X, 2016, ARCH VIROL, V161, P1209, DOI 10.1007/s00705-016-2764-4; Yu LP, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1253-7; Zegpi RA, 2020, AVIAN DIS, V64, P92, DOI 10.1637/0005-2086-64.1.92; Zhang SL, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-62; Zhang WD, 2017, VIROLOGY, V509, P252, DOI 10.1016/j.virol.2017.06.028; Zhang WX, 2016, MOL IMMUNOL, V76, P1, DOI 10.1016/j.molimm.2016.06.006; Zhang Y, 2018, VACCINE, V36, P4245, DOI 10.1016/j.vaccine.2018.05.123; Zhao K, 2018, MOL PHARMACEUT, V15, P226, DOI 10.1021/acs.molpharmaceut.7b00826; Zhao K, 2017, DRUG DELIV, V24, P1574, DOI 10.1080/10717544.2017.1388450; Zhao K, 2016, SCI REP-UK, V6, DOI 10.1038/srep25720; Zhao K, 2014, INT J NANOMED, V9, P4609, DOI 10.2147/IJN.S70633; Zhao K, 2014, INT J NANOMED, V9, P389, DOI 10.2147/IJN.S54226; Zhao R, 2017, VACCINE, V35, P2435, DOI 10.1016/j.vaccine.2017.03.045; Zhao Y, 2019, VIRUS RES, V267, P59, DOI 10.1016/j.virusres.2019.05.006	179	5	6	7	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							20	10.3390/vaccines9010020			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PY1ZG	33406695	gold, Green Published			2022-04-29	WOS:000611848400001
J	Mu, CY; Zhong, QW; Meng, Y; Zhou, Y; Jiang, N; Liu, WZ; Li, YQ; Xue, MY; Zeng, LB; Vakharia, VN; Fan, YD				Mu, Changyong; Zhong, Qiwang; Meng, Yan; Zhou, Yong; Jiang, Nan; Liu, Wenzhi; Li, Yiqun; Xue, Mingyang; Zeng, Lingbing; Vakharia, Vikram N.; Fan, Yuding			Oral Vaccination of Grass Carp (Ctenopharyngodon idella) with Baculovirus-Expressed Grass Carp Reovirus (GCRV) Proteins Induces Protective Immunity against GCRV Infection	VACCINES			English	Article						grass carp reovirus (GCRV); baculovirus expression; oral vaccine; immune response		The grass carp reovirus (GCRV) causes severe hemorrhagic disease with high mortality and leads to serious economic losses in the grass carp (Ctenopharyngodon idella) industry in China. Oral vaccine has been proven to be an effective method to provide protection against fish viruses. In this study, a recombinant baculovirus BmNPV-VP35-VP4 was generated to express VP35 and VP4 proteins from GCRV type II via Bac-to-Bac baculovirus expression system. The expression of recombinant VP35-VP4 protein (rVP35-VP4) in Bombyx mori embryo cells (BmE) and silkworm pupae was confirmed by Western blotting and immunofluorescence assay (IFA) after infection with BmNPV-VP35-VP4. To vaccinate the grass carp by oral route, the silkworm pupae expressing the rVP35-VP4 proteins were converted into a powder after freeze-drying, added to artificial feed at 5% and fed to grass carp (18 +/- 1.5 g) for six weeks, and the immune response and protective efficacy in grass carp after oral vaccination trial was thoroughly investigated. This included blood cell counting and classification, serum antibody titer detection, immune-related gene expression and the relative percent survival rate in immunized grass carp. The results of blood cell counts show that the number of white blood cells in the peripheral blood of immunized grass carp increased significantly from 14 to 28 days post-immunization (dpi). The differential leukocyte count of neutrophils and monocytes were significantly higher than those in the control group at 14 dpi. Additionally, the number of lymphocytes increased significantly and reached a peak at 28 dpi. The serum antibody levels were significantly increased at Day 14 and continued until 42 days post-vaccination. The mRNA expression levels of immune-related genes (IFN-1, TLR22, IL-1 beta, MHC I, Mx and IgM) were significantly upregulated in liver, spleen, kidney and hindgut after immunization. Four weeks post-immunization, fish were challenged with virulent GCRV by intraperitoneal injection. The results of this challenge study show that orally immunized group exhibited a survival rate of 60% and relative percent survival (RPS) of 56%, whereas the control group had a survival rate of 13% and RPS of 4%. Taken together, our results demonstrate that the silkworm pupae powder containing baculovirus-expressed VP35-VP4 proteins could induce both non-specific and specific immune responses and protect grass carp against GCRV infection, suggesting it could be used as an oral vaccine.	[Mu, Changyong; Meng, Yan; Zhou, Yong; Jiang, Nan; Liu, Wenzhi; Li, Yiqun; Xue, Mingyang; Zeng, Lingbing; Fan, Yuding] Chinese Acad Fishery Sci, Yangtze River Fisheries Res Inst, Wuhan 430223, Peoples R China; [Mu, Changyong; Zhong, Qiwang; Fan, Yuding] Jiangxi Agr Univ, Coll Biol Sci & Engn, Nanchang 330045, Jiangxi, Peoples R China; [Vakharia, Vikram N.; Fan, Yuding] Univ Maryland Baltimore Country, Inst Marine & Environm Technol, Baltimore, MD 21202 USA; [Fan, Yuding] Hunan Normal Univ, Coll Life Sci, State Key Lab Dev Biol Freshwater Fish, Changsha 410081, Peoples R China		Fan, YD (通讯作者)，Chinese Acad Fishery Sci, Yangtze River Fisheries Res Inst, Wuhan 430223, Peoples R China.; Fan, YD (通讯作者)，Jiangxi Agr Univ, Coll Biol Sci & Engn, Nanchang 330045, Jiangxi, Peoples R China.; Vakharia, VN; Fan, YD (通讯作者)，Univ Maryland Baltimore Country, Inst Marine & Environm Technol, Baltimore, MD 21202 USA.; Fan, YD (通讯作者)，Hunan Normal Univ, Coll Life Sci, State Key Lab Dev Biol Freshwater Fish, Changsha 410081, Peoples R China.	muchangyong@yfi.ac.cn; zhongqiwang@jxau.edu.cn; mengy@yfi.ac.cn; zhouy@yfi.ac.cn; jn851027@yfi.ac.cn; liuwenzhialisa@yfi.ac.cn; liyq@yfi.ac.cn; xmy@yfi.ac.cn; zlb@yfi.ac.cn; vakharia@umbc.edu; fanyd@yfi.ac.cn		Vakharia, Vikram/0000-0002-0955-3010	National Key R&D Program of China [2019YFD0900101]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31772894]; State Key Laboratory of Developmental Biology of Freshwater Fish [2017KF004]; Central Public-interest Scientific Institution Basal Research Fund, CAFS [2017GH16, 2020TD44]; Earmarked Fund for China Agriculture Research System [CARS-46-11]	This work was supported by the National Key R&D Program of China (2019YFD0900101), the National Natural Science Foundation of China (Grant No. 31772894), the State Key Laboratory of Developmental Biology of Freshwater Fish (2017KF004), the Central Public-interest Scientific Institution Basal Research Fund, CAFS (2017GH16, 2020TD44) and the Earmarked Fund for China Agriculture Research System (CARS-46-11).	BLAXHALL PC, 1973, J FISH BIOL, V5, P771, DOI 10.1111/j.1095-8649.1973.tb04510.x; Chen CY, 2011, BIOTECHNOL ADV, V29, P618, DOI 10.1016/j.biotechadv.2011.04.004; Chen DD, 2018, FISH SHELLFISH IMMUN, V75, P66, DOI 10.1016/j.fsi.2018.01.047; CHEN YX, 1984, KEXUE TONGBAO, V29, P832; Galindo-Villegas J, 2013, FISH SHELLFISH IMMUN, V35, P1260, DOI 10.1016/j.fsi.2013.07.046; Gao H, 2007, J BIOTECHNOL, V131, P138, DOI 10.1016/j.jbiotec.2007.06.002; Gao Y, 2018, VACCINE, V36, P3613, DOI 10.1016/j.vaccine.2018.05.043; Gao Y, 2018, FISH SHELLFISH IMMUN, V75, P91, DOI 10.1016/j.fsi.2018.01.050; Gomez D, 2013, FISH SHELLFISH IMMUN, V35, P1729, DOI 10.1016/j.fsi.2013.09.032; Hao K, 2018, FISH SHELLFISH IMMUN, V72, P199, DOI 10.1016/j.fsi.2017.10.060; Hao K, 2017, FISH SHELLFISH IMMUN, V64, P414, DOI 10.1016/j.fsi.2017.03.021; He LB, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3824-1; Jiang HY, 2019, FISH SHELLFISH IMMUN, V84, P768, DOI 10.1016/j.fsi.2018.10.008; Kato T, 2016, SCI REP-UK, V6, DOI 10.1038/srep32283; Kost TA, 2016, ADV EXP MED BIOL, V896, P187, DOI 10.1007/978-3-319-27216-0_12; Liu B, 2016, MOL BIOL REP, V43, P509, DOI 10.1007/s11033-016-3984-0; Liu HI, 2015, INT J MOL SCI, V16, P28647, DOI 10.3390/ijms161226118; Liu J, 2016, ARCH VIROL, V161, P573, DOI 10.1007/s00705-015-2675-9; Liu WZ, 2014, VET MICROBIOL, V174, P382, DOI 10.1016/j.vetmic.2014.10.028; Lorenzen N, 1999, FISH SHELLFISH IMMUN, V9, P345, DOI 10.1006/fsim.1999.0194; Mir FA, 2009, CLIN VACCINE IMMUNOL, V16, P1467, DOI 10.1128/CVI.00237-09; Mu CY, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110945; Pei C, 2019, FISH SHELLFISH IMMUN, V90, P12, DOI 10.1016/j.fsi.2019.04.055; Rao YL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/670437; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seng EK, 2005, ARCH VIROL, V150, P2021, DOI 10.1007/s00705-005-0550-9; Siriyappagouder P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01868; Su H, 2017, ONCOTARGET, V8, P86576, DOI 10.18632/oncotarget.21245; Szymczak-Workman Andrea L, 2012, Cold Spring Harb Protoc, V2012, P251, DOI 10.1101/pdb.prot067884; Tian YY, 2013, FISH SHELLFISH IMMUN, V35, P351, DOI 10.1016/j.fsi.2013.04.022; Uribe C, 2011, VET MED-CZECH, V56, P486, DOI 10.17221/3294-VETMED; van Oers MM, 2015, J GEN VIROL, V96, P6, DOI 10.1099/vir.0.067108-0; Wang Q, 2012, J VIROL, V86, P12466, DOI 10.1128/JVI.02333-12; Xue RY, 2013, FISH SHELLFISH IMMUN, V34, P348, DOI 10.1016/j.fsi.2012.11.024; Yan LM, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-89; Yan XY, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-190; Zhang LL, 2016, FISH SHELLFISH IMMUN, V49, P344, DOI 10.1016/j.fsi.2016.01.003; Zhang QS, 2019, PROTEIN EXPRES PURIF, V158, P1, DOI 10.1016/j.pep.2019.02.007	38	1	2	12	20	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							41	10.3390/vaccines9010041			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WA	33445494	Green Published, gold			2022-04-29	WOS:000610811200001
J	Cheng, JJ; Lin, SY; Wu, CQ; Howard, N; Zou, JT; Sun, FY; Sun, M; Chantler, T				Cheng, Jiejie; Lin, Shiyu; Wu, Chaoqi; Howard, Natasha; Zou, Jiatong; Sun, Fiona Yueqian; Sun, Mei; Chantler, Tracey			What Influences Health Professionals' Recommendations for Non-Scheduled Childhood Vaccinations? A Qualitative Study of Health Professionals' Perspectives in Three Provinces of China	VACCINES			English	Article						vaccines; recommendations; economic incentives; motivation; qualitative research	HUMAN-PAPILLOMAVIRUS; PERFORMANCE; INCENTIVES; PHYSICIANS; SERVICES; VACCINE; PARENTS; IMPACT	Recommendations by health professionals are important for vaccines that are not included in national schedules. This study explored health professionals' perspectives on recommending non-scheduled (user-fee) childhood vaccinations in China, identifying key influences on professionals' interactions with caregivers. We conducted individual semi-structured interviews with 20 health professionals from three provinces in China and analyzed data thematically using deductive and inductive coding. Health professionals from all three provinces were uncomfortable about being perceived to encourage parents to accept vaccines that incurred a fee. They provided information about non-scheduled vaccines but emphasized parental autonomy in decision-making. Rural parents were less aware of unscheduled vaccines and health professionals were more likely to encourage parents living in more affluent areas to consider these vaccines; varicella vaccine was preferred by parents as a way of preventing school absence. Economic incentives for unscheduled vaccines were given to staff at most study sites, although the amount given varied widely. These variations meant that staff receiving lower incentives were not motivated to promote non-scheduled vaccines if their workload was high; on the contrary, those receiving higher incentives were more likely to promote these vaccines. Health professionals need more guidance on how to recommend unscheduled vaccines in an informative, positive and appropriate manner. It is evident that parents' awareness of these vaccines, and their economic circumstances, influence vaccinators recommendation practice. Economic incentives prompted health professionals to recommend non-scheduled vaccines; however, the application of such staff incentives varied widely in China. To adopt appropriate economic incentives, professional organizations should develop protocols for the use of incentives that account for their influence on recommendation practices. Suitable recommendation policy needs to balance basic salaries with performance-based incentives, consider overall workload, and include monitoring and evaluation of economic incentives.	[Cheng, Jiejie; Lin, Shiyu; Wu, Chaoqi; Sun, Mei] Fudan Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Cheng, Jiejie; Lin, Shiyu; Wu, Chaoqi; Sun, Mei] Fudan Univ, NHC Key Lab Hlth Technol Assessment, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Howard, Natasha; Chantler, Tracey] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, 15-17 Tavistock Pl, London WC1H 9SH, England; [Howard, Natasha] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2, Singapore 117549, Singapore; [Howard, Natasha] Natl Univ Hlth Syst, 12 Sci Dr 2, Singapore 117549, Singapore; [Zou, Jiatong] Shanghai Municipal Ctr Dis Control & Prevent, Dept Org & Personnel, 1380 West Zhongshan Rd, Shanghai 200336, Peoples R China; [Sun, Fiona Yueqian] Univ London, London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England		Sun, M (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 130 Dongan Rd, Shanghai 200032, Peoples R China.; Sun, M (通讯作者)，Fudan Univ, NHC Key Lab Hlth Technol Assessment, 130 Dongan Rd, Shanghai 200032, Peoples R China.	18211020050@fudan.edu.cn; 20211020128@fudan.edu.cn; 17301020145@fudan.edu.cn; natasha.howard@nus.edu.sg; zoujiatong@scdc.sh.cn; Fiona.Sun@lshtm.ac.uk; sunmei@fudan.edu.cn; Tracey.Chantler@lshtm.ac.uk		Chantler, Tracey/0000-0001-7776-7339; Howard, Natasha/0000-0003-4174-7349	National Institute for Health Research from the UK Government [EPIDZL9012]; National Institute for Health Research Health Protection Research Unit in Vaccines and Immunisation at London School of Hygiene and Tropical Medicine; Public Health England (PHE); National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71974035]; Ministry of Education of Humanities and Social Science project [19YJCZH143]; Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) [GWV-10.1-XK23]; National University of Singapore Saw Swee Hock School of Public HealthNational University of Singapore	This research was funded by the National Institute for Health Research (reference EPIDZL9012), using UK aid from the UK Government to support global health research and supported by the National Institute for Health Research Health Protection Research Unit in Vaccines and Immunisation at London School of Hygiene and Tropical Medicine, in partnership with Public Health England (PHE). The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. M.S. is supported by the National Natural Science Foundation of China (71974035), the Ministry of Education of Humanities and Social Science project (19YJCZH143), and the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) (GWV-10.1-XK23). N.H. is funded by the National University of Singapore Saw Swee Hock School of Public Health. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, UK Department of Health and Social Care, NHS, PHE, or any other funders. Funders had no input into study design, implementation, analysis or conclusions.	Ashir Garba Mohammed, 2013, Glob J Health Sci, V5, P34, DOI 10.5539/gjhs.v5n3p34; Barnack JL, 2010, WOMEN HEALTH ISS, V20, P28, DOI 10.1016/j.whi.2009.08.007; Basinga P, 2011, LANCET, V377, P1421, DOI 10.1016/S0140-6736(11)60177-3; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI DOI 10.1191/1478088706QP063OA; Cerasoli CP, 2014, PSYCHOL BULL, V140, P980, DOI 10.1037/a0035661; Connor C., 2011, BETHESDA ABT ASS, V1, P77; Cui J., 2017, J PREV MED, V29, P1062, DOI [10.19485/j.cnki.issn1007-0931.2017.10.025, DOI 10.19485/J.CNKI.ISSN1007-0931.2017.10.025]; de Walque D, 2015, J HEALTH ECON, V40, P1, DOI 10.1016/j.jhealeco.2014.12.001; Duan J., 2017, THESIS CHINESE CTR D; Eichler R., 2013, Journal of Health, Population and Nutrition, V31, pS36; Fairbrother G, 1999, AM J PUBLIC HEALTH, V89, P171, DOI 10.2105/AJPH.89.2.171; Guo W., 2018, PREV MED TRIB, V24, P171, DOI [10.16406/j.pmt.issn.1672-9153.2018.03.005, DOI 10.16406/J.PMT.ISSN.1672-9153.2018.03.005]; Hoque ME, 2014, J OBSTET GYNAECOL, V34, P182, DOI 10.3109/01443615.2013.861395; Hswen Y, 2017, SEX TRANSM DIS, V44, P43, DOI 10.1097/OLQ.0000000000000543; Joseph A.M., 2012, REALIST APPROACH QUA; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Li P., 2020, J PREV MED, V32, P573, DOI [10.19485/j.cnki.issn2096-5087.2020.06.008, DOI 10.19485/J.CNKI.ISSN2096-5087.2020.06.008]; Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Mays RM, 2004, SEX TRANSM DIS, V31, P428, DOI 10.1097/01.olq.0000130536.71812.E5; Morgan L.E., 2011, PERFORMANCE BASED IN; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Schuster RC, 2016, HUM RESOUR HEALTH, V14, DOI 10.1186/s12960-016-0157-0; Stefanoff P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232722; Tuckerman JL, 2015, HUM VACC IMMUNOTHER, V11, P704, DOI 10.1080/21645515.2015.1008886; Wang J., 2017, PREV MED TRIB, V23, P650, DOI [10.16406/j.pmt.issn.1672-9153.2017.09.004, DOI 10.16406/J.PMT.ISSN.1672-9153.2017.09.004]; Watkins J, 2004, INT CONGR SER, V1263, P573, DOI 10.1016/j.ics.2004.02.127; WHO, EXP PROGR IMM; Wu J., 2019, J PREV MED, V31, P1143, DOI [10.19485/j.cnki.issn2096-5087.2019.11.016, DOI 10.19485/J.CNKI.ISSN2096-5087.2019.11.016]; Yin C., 2020, CHIN J VACCINES IMMU, V26, P314; Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0	32	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1433	10.3390/vaccines9121433			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8TN	34960179	Green Published, gold, Green Accepted			2022-04-29	WOS:000737238000001
J	Dennehy, KM; Loll, E; Dhillon, C; Classen, JM; Warm, TD; Schuierer, L; Hyhlik-Durr, A; Rommele, C; Gosslau, Y; Kling, E; Hoffmann, R				Dennehy, Kevin M.; Loll, Eva; Dhillon, Christine; Classen, Johanna-Maria; Warm, Tobias D.; Schuierer, Lukas; Hyhlik-Durr, Alexander; Rommele, Christoph; Gosslau, Yvonne; Kling, Elisabeth; Hoffmann, Reinhard			Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccination; cellular immunity; memory T-cells		Memory T-cell responses following infection with coronaviruses are reportedly long-lived and provide long-term protection against severe disease. Whether vaccination induces similar long-lived responses is not yet clear since, to date, there are limited data comparing memory CD4+ T-cell responses induced after SARS-CoV-2 infection versus following vaccination with BioNTech/Pfizer BNT162b2. We compared T-cell immune responses over time after infection or vaccination using ELISpot, and memory CD4+ T-cell responses three months after infection/vaccination using activation-induced marker flow cytometric assays. Levels of cytokine-producing T-cells were remarkably stable between three and twelve months after infection, and were comparable to IFN gamma+ and IFN gamma+IL-2+ T-cell responses but lower than IL-2+ T-cell responses at three months after vaccination. Consistent with this finding, vaccination and infection elicited comparable levels of SARS-CoV-2 specific CD4+ T-cells after three months in addition to comparable proportions of specific central memory CD4+ T-cells. By contrast, the proportions of specific effector memory CD4+ T-cells were significantly lower, whereas specific effector CD4+ T-cells were higher after infection than after vaccination. Our results suggest that T-cell responses-as measured by cytokine expression-and the frequencies of SARS-CoV-2-specific central memory CD4+T-cells-indicative of the formation of the long-lived memory T-cell compartment-are comparably induced after infection and vaccination.	[Dennehy, Kevin M.; Loll, Eva; Schuierer, Lukas; Kling, Elisabeth; Hoffmann, Reinhard] Univ Hosp Augsburg, Inst Lab Med & Microbiol, Med Fac, D-86156 Augsburg, Germany; [Dhillon, Christine] Univ Hosp Augsburg, Med Fac, Dept Pathol, D-86156 Augsburg, Germany; [Classen, Johanna-Maria; Rommele, Christoph] Univ Hosp Augsburg, Med Fac, Internal Med Gastroenterol & Infect Dis 3, D-86156 Augsburg, Germany; [Warm, Tobias D.; Hyhlik-Durr, Alexander; Gosslau, Yvonne] Univ Hosp Augsburg, Med Fac, Clin Vasc Surg, D-86156 Augsburg, Germany		Dennehy, KM (通讯作者)，Univ Hosp Augsburg, Inst Lab Med & Microbiol, Med Fac, D-86156 Augsburg, Germany.	kevin.dennehy@uk-augsburg.de; eva.loell@uk-augsburg.de; christine.dhillon@uk-augsburg.de; Johanna-maria.classen@uk-augsburg.de; tobias.warm@uk-augsburg.de; lukas.schuierer@uk-augsburg.de; alexander.hyhlik-duerr@uk-augsburg.de; christoph.roemmele@uk-augsburg.de; yvonne.gosslau@uk-augsburg.de; elisabeth.kling@uk-augsburg.de; reinhard.hoffmann@uk-augsburg.de		Rommele, Christoph/0000-0002-8745-8510; Schuierer, Lukas/0000-0002-9800-8873; Dennehy, Kevin/0000-0003-1822-1189	Bavarian State Ministry for Science; chair of Microbiology, University Hospital, Augsburg	This study was funded by the Bavarian State Ministry for Science and the Arts, and by the chair of Microbiology, University Hospital, Augsburg.	Assis R., 2021, DISTINCT SARS COV 2, DOI [10.1101/2021.04.15.440089, DOI 10.1101/2021.04.15.440089]; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Cohen KW, 2021, CELL REP MED, V2, DOI [10.1016/j.xcrm.2021.100354, 10.1101/2021.04.19.21255739]; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Divekar AA, 2006, J IMMUNOL, V176, P1465, DOI 10.4049/jimmunol.176.3.1465; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gazit S., 2021, COMP SARS COV 2 NATU, DOI [10.1101/2021.08.24.21262415, DOI 10.1101/2021.08.24.21262415]; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Harty JT, 2008, NAT REV IMMUNOL, V8, P107, DOI 10.1038/nri2251; Ivanova E.N., 2021, medRxiv, P255677, DOI [10.1101/2021.04.20.21255677, DOI 10.1101/2021.04.20.21255677, 10.2139/ssrn.3838993]; Jordan SC, 2021, CELL MOL IMMUNOL, V18, P2554, DOI 10.1038/s41423-021-00767-9; Kaeuferle T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0701-1; Langenkamp A, 2003, EUR J IMMUNOL, V33, P474, DOI 10.1002/immu.200310023; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lu, 2020, SARS COV 2 SPECIFIC, DOI [10.1101/2020.11.15.383463, DOI 10.1101/2020.11.15.383463]; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Painter MM, 2021, IMMUNITY, V54, P2133, DOI 10.1016/j.immuni.2021.08.001; Panagioti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00276; Rank A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153305; Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998; Tan AT, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108728; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906	26	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1439	10.3390/vaccines9121439			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0AB	34960185	Green Published, gold			2022-04-29	WOS:000737324500001
J	Gendler, Y; Ofri, L				Gendler, Yulia; Ofri, Lani			Investigating the Influence of Vaccine Literacy, Vaccine Perception and Vaccine Hesitancy on Israeli Parents' Acceptance of the COVID-19 Vaccine for Their Children: A Cross-Sectional Study	VACCINES			English	Article						COVID-19 vaccine; children's vaccination; vaccine literacy; vaccine hesitancy; vaccine perception; vaccine acceptance	HEALTH INFORMATION	Vaccination is currently the most effective strategy for combating COVID-19. COVID-19 vaccines were introduced to the adult population in Israel in early December 2020 and have been available for children aged 12-15 since June 2021. Our study aimed at assessing the influence of vaccine literacy, perception, hesitancy, and behavior on Israeli parents' intentions to have their children vaccinated. Using an anonymous online questionnaire, we recruited 520 parents; 70.4% of the parents indicated that they would get their children vaccinated. The participants' COVID-19 vaccination status was the only socio-demographic factor significantly associated with COVID-19 vaccination acceptability (OR = 32.89; 95%CI = [13.11, 82.54]). The most common sources of information regarding the COVID-19 vaccine were health-care providers and the Internet. Parents who intend to vaccinate their children had higher mean levels of vaccine literacy (2.99 +/- 0.47 vs. 3.07 +/- 0.44 respectively, p = 0.06), more positive perception of the vaccine (mean scores of 2.26 +/- 0.75 vs. 3.44 +/- 0.68 respectively, p < 0.001), and lower perceived vaccine hesitancy (7.53 +/- 2.37 vs. 4.68 +/- 2.71 respectively, p < 0.001) than parents who do not intend to do so. Vaccine behavior was measured using the 5C model of psychological antecedents. All 5C components were significantly correlated with parents' willingness to vaccinate their children. Understanding of parents' willingness to have their children receive the COVID-19 vaccine and the barriers to and facilitators of the vaccination is crucial, as vaccination of children aged 5-11 has recently been approved by the FDA. Providing the population with reliable information regarding the COVID-19 vaccine is an important measure in the attempt to increase COVID-19 vaccine acceptance.	[Gendler, Yulia; Ofri, Lani] Ariel Univ, Sch Hlth Sci, Dept Nursing, IL-40700 Ariel, Israel		Gendler, Y (通讯作者)，Ariel Univ, Sch Hlth Sci, Dept Nursing, IL-40700 Ariel, Israel.	yuliage@ariel.ac.il; laniof@ariel.ac.il		Gendler, Yulia/0000-0001-9958-7777			Aharon AA, 2017, PATIENT EDUC COUNS, V100, P768, DOI 10.1016/j.pec.2016.11.016; Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; [Anonymous], COVID-19 Vaccine; [Anonymous], ISRAEL WHO CORONAVIR; Barouki R, 2021, ENVIRON INT, V146, DOI 10.1016/j.envint.2020.106272; Bates LC, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7090138; Betsch C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034869; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Biasio LR, 2020, ANN IG MED PREV COMU, V32, P205, DOI 10.7416/ai.2020.2344; Biasio LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030268; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Biasio LR, 2019, HUM VACC IMMUNOTHER, V15, P2552, DOI 10.1080/21645515.2019.1609850; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Glikman D, 2021, ACTA PAEDIATR, V110, P2496, DOI 10.1111/apa.15982; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Gorman DR, 2020, VACCINE, V38, P2795, DOI 10.1016/j.vaccine.2020.02.028; Gusar I, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18137073; Kamidani S, 2021, CURR OPIN PEDIATR, V33, P144, DOI 10.1097/MOP.0000000000000978; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Leshem E, 2021, LANCET, V397, P1783, DOI 10.1016/S0140-6736(21)01018-7; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Muhsen K, 2021, CLIN MICROBIOL INFEC, V27, P1570, DOI 10.1016/j.cmi.2021.07.041; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Opel DJ, 2021, JAMA PEDIATR, V175, P125, DOI 10.1001/jamapediatrics.2020.3019; Patil U, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063301; Rains SA, 2007, J HEALTH COMMUN, V12, P667, DOI 10.1080/10810730701619992; Redmond N, 2010, AM J PREV MED, V38, P620, DOI 10.1016/j.amepre.2010.03.001; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Smith D., 2011, J COMMUN HEALTHC, V4, P200, DOI 10.1179/1753807611Y.0000000010; Sowa P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080876; Szilagyi PG, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052335; World Health Organization (WHO), 2019, TEN THREATS GLOB HLT; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Yilmaz M, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14364; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827	38	3	3	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1391	10.3390/vaccines9121391			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YE9FZ	34960137	Green Published, gold			2022-04-29	WOS:000741425100001
J	Morales-Nunez, JJ; Munoz-Valle, JF; Torres-Hernandez, PC; Hernandez-Bello, J				Morales-Nunez, Jose Javier; Munoz-Valle, Jose Francisco; Torres-Hernandez, Paola Carolina; Hernandez-Bello, Jorge			Overview of Neutralizing Antibodies and Their Potential in COVID-19	VACCINES			English	Article						neutralizing antibodies; SARS-CoV-2; neutralization assays; COVID-19; monoclonal antibodies	MEMORY B-CELLS; DEPENDENT ENHANCEMENT; VIRUS ENTRY; MEDIATED NEUTRALIZATION; MONOCLONAL-ANTIBODIES; AFFINITY MATURATION; SARS-COV-2 SPIKE; MECHANISMS; INFECTION; ASSAY	The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.	[Morales-Nunez, Jose Javier; Munoz-Valle, Jose Francisco; Hernandez-Bello, Jorge] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Biomed Sci, Guadalajara 44340, Jalisco, Mexico; [Torres-Hernandez, Paola Carolina] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Immunol Lab, Guadalajara 44340, Jalisco, Mexico		Hernandez-Bello, J (通讯作者)，Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Biomed Sci, Guadalajara 44340, Jalisco, Mexico.	jose.morales2599@alumnos.udg.mx; drjosefranciscomv@cucs.udg.mx; paola.torres3435@alumnos.udg.mx; jorge.hernandezbello@cucs.udg.mx		Munoz-Valle, Jose Francisco/0000-0002-2272-9260			Abe KT, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142362; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Ali A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71188-3; Ali MG, 2020, IMMUNOL RES, V68, P325, DOI 10.1007/s12026-020-09159-z; Altawalah H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080910; Andabaka T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006602.pub4; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Astronomo RD, 2016, EBIOMEDICINE, V14, P97, DOI 10.1016/j.ebiom.2016.11.024; Bachmann MF, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00264-6; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Baum LL, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 4: IMMUNITY TO PATHOGENS AND TUMORS, P342, DOI 10.1016/B978-0-12-374279-7.14021-4; Brynjolfsson SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02673; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Munar BAC, 2019, ACTA BIOL COLOMB, V24, P439, DOI 10.15446/abc.v24n3.79410; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Case JB, 2020, CELL HOST MICROBE, V28, P475, DOI 10.1016/j.chom.2020.06.021; Cathcart A.L., 2022, BIORXIV, DOI [10.1101/2021.03.09.434607, DOI 10.1101/2021.03.09.434607]; Cheedarla N, 2019, RECENT DEVELOPMENTS IN APPLIED MICROBIOLOGY AND BIOCHEMISTRY, P83, DOI 10.1016/B978-0-12-816328-3.00007-6; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chen QQ, 2018, HUM VACC IMMUNOTHER, V14, P199, DOI 10.1080/21645515.2017.1373922; Chen W, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110629; Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7; Chen ZG, 2019, ADV IMMUNOL, V141, P105, DOI 10.1016/bs.ai.2019.01.001; Ciabattini A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740708; Corthesy B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00185; Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Daha NA, 2011, MOL IMMUNOL, V48, P1656, DOI 10.1016/j.molimm.2011.04.024; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies AM, 2015, IMMUNOL REV, V268, P139, DOI 10.1111/imr.12349; Demonbreun AR, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101018; Derdeyn CA, 2014, CURR OPIN HIV AIDS, V9, P210, DOI 10.1097/COH.0000000000000057; Dieterle ME, 2020, CELL HOST MICROBE, V28, P486, DOI 10.1016/j.chom.2020.06.020; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002; Dolgin E, 2021, NATURE, V597, P606, DOI 10.1038/d41586-021-02532-4; Doria-Rose NA, 2015, CURR OPIN VIROL, V11, P137, DOI 10.1016/j.coviro.2015.04.002; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Duan LW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576622; Dugan HL, 2021, IMMUNITY, V54, P1290, DOI 10.1016/j.immuni.2021.05.001; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Eroshenko N, 2020, NAT BIOTECHNOL, V38, P789, DOI 10.1038/s41587-020-0577-1; Ferrara F, 2018, METHOD PROTOCOL, V1, DOI 10.3390/mps1010008; Florese R.H., 2007, FUTUR HIV THER, V1, P259, DOI [10.2217/17469600.1.3.259, DOI 10.2217/17469600.1.3.259]; Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Gozalbo-Rovira R, 2020, J CLIN VIROL, V131, DOI 10.1016/j.jcv.2020.104611; Graham C, 2021, IMMUNITY, V54, P1276, DOI 10.1016/j.immuni.2021.03.023; Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Halstead SB, 2020, J INFECT DIS, V222, P1946, DOI 10.1093/infdis/jiaa518; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horwitz JA, 2017, CELL, V170, P637, DOI 10.1016/j.cell.2017.06.048; Hua CK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01655; Huang CX, 2014, BLOOD, V123, P1012, DOI 10.1182/blood-2013-07-518605; Huang XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22303; Morales-Nunez JJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070742; Jhamnani RD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02172; Jiang SB, 2020, TRENDS IMMUNOL, V41, P853, DOI 10.1016/j.it.2020.08.003; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Johns Hopkins University-Baltimore, JOHNS HOPKINS U CORO; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Kallolimath S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107249118; Katz LM, 2021, NEW ENGL J MED, V384, P666, DOI 10.1056/NEJMe2035678; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Khoury DS, 2021, WHAT LEVEL NEUTRALIS, DOI [10.1101/2021.03.09.21252641, DOI 10.1101/2021.03.09.21252641]; Kim C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20602-5; Klasse P J, 2014, Adv Biol, V2014; Klasse PJ, 1998, ADV DRUG DELIVER REV, V34, P65, DOI 10.1016/S0169-409X(98)00002-7; Klasse PJ, 2002, J GEN VIROL, V83, P2091, DOI 10.1099/0022-1317-83-9-2091; Klein S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19619-7; Koenig PA, 2021, SCIENCE, V371, P691, DOI 10.1126/science.abe6230; Krammer F, 2021, NAT MED, V27, P1147, DOI 10.1038/s41591-021-01432-4; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Levine MM, 2019, NEW ENGL J MED, V381, P2365, DOI 10.1056/NEJMe1915350; Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0; Liechti T, 2019, CYTOM PART A, V95A, P419, DOI 10.1002/cyto.a.23639; Lightman SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00965; Liu J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00529; Liu L, 2020, EMERG MICROBES INFEC, V9, P1664, DOI 10.1080/22221751.2020.1791738; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Marot S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21111-9; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; Mayr LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01590; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; Mendoza Emelissa J, 2020, Curr Protoc Microbiol, V57, pecpmc105, DOI 10.1002/cpmc.105; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Meyer B, 2020, EMERG MICROBES INFEC, V9, P2394, DOI 10.1080/22221751.2020.1835448; Mishra N, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009958; Morrone SR, 2019, CURR OPIN VIROL, V36, P1, DOI 10.1016/j.coviro.2019.02.002; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Murin CD, 2019, NAT MICROBIOL, V4, P734, DOI 10.1038/s41564-019-0392-y; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Nakane S, 2015, METHODS MOL BIOL, P229, DOI 10.1007/978-1-4939-2703-6_17; Nelson CDS, 2007, VIROLOGY, V361, P283, DOI 10.1016/j.virol.2006.11.032; Neurath A. R., 2008, ENCY VIROLOGY, P56, DOI [10.1016/B978-012374410-4.00591-4, DOI 10.1016/B978-012374410-4.00591-4]; Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767; Nimmerjahn F, 2007, ADV IMMUNOL, V96, P179, DOI 10.1016/S0065-2776(07)96005-8; Nouri N, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007977; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Oropallo MA, 2014, TRENDS IMMUNOL, V35, P287, DOI 10.1016/j.it.2014.06.001; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Overbaugh J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007039; Padilla-Quirarte HO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01677; Pallikkuth S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01380; Palm AKE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01787; Pang NYL, 2021, MILITARY MED RES, V8, DOI 10.1186/s40779-021-00342-3; Papa I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01858; Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421; Pilzecker B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00438; Purtha WE, 2011, J EXP MED, V208, P2599, DOI 10.1084/jem.20110740; Putcharoen O, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246864; Radtke D, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03106; Raybould Matthew I J, 2021, Bioinformatics, V37, P734, DOI 10.1093/bioinformatics/btaa739; Reading SA, 2007, ARCH VIROL, V152, P1047, DOI 10.1007/s00705-006-0923-8; Recaldin T, 2016, CLIN EXP IMMUNOL, V183, P65, DOI 10.1111/cei.12702; Renn A, 2020, TRENDS PHARMACOL SCI, V41, P815, DOI 10.1016/j.tips.2020.07.004; Ricke DO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640093; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Ronen K, 2017, EBIOMEDICINE, V18, P216, DOI 10.1016/j.ebiom.2017.04.005; Sanchez-Zuno GA, 2021, INT J IMMUNOPATH PH, V35, DOI 10.1177/20587384211050199; Sasisekharan R, 2021, NEW ENGL J MED, V384, P1568, DOI 10.1056/NEJMcibr2101205; Schmitz AJ, 2021, IMMUNITY, V54, P2159, DOI 10.1016/j.immuni.2021.08.013; Schreiber G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.595739; Sedova ES, 2019, ACTA NATURAE, V11, P22, DOI 10.32607/20758251-2019-11-4-22-32; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Sharp TH, 2019, P NATL ACAD SCI USA, V116, P11900, DOI 10.1073/pnas.1901841116; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Song G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23074-3; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Subbaraman H, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0433-2; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.07.19.452771; Tas JMJ, 2016, SCIENCE, V351, P1048, DOI 10.1126/science.aad3439; Teng G, 2007, ANNU REV GENET, V41, P107, DOI 10.1146/annurev.genet.41.110306.130340; Thorley JA, 2010, PROTOPLASMA, V244, P15, DOI 10.1007/s00709-010-0152-6; Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465; Tuccori M, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1854149; van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548; VanBlargan LA, 2016, MICROBIOL MOL BIOL R, V80, DOI 10.1128/MMBR.00024-15; Vandergaast Rianna, 2020, bioRxiv, DOI 10.1101/2020.05.26.117549; Vangelista L, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00226; Vanlandschoot P, 2011, ANTIVIR RES, V92, P389, DOI 10.1016/j.antiviral.2011.09.002; Vukovic N, 2021, CLIN EXP IMMUNOL, V203, P351, DOI 10.1111/cei.13545; Wang ZJ, 2021, NATURE, V595, P426, DOI 10.1038/s41586-021-03696-9; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Weisel F, 2017, ANNU REV IMMUNOL, V35, P255, DOI 10.1146/annurev-immunol-041015-055531; Wen JQ, 2020, INT J INFECT DIS, V100, P483, DOI 10.1016/j.ijid.2020.09.015; West AP, 2012, P NATL ACAD SCI USA, V109, pE2083, DOI 10.1073/pnas.1208984109; Willey S, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-16; Wong R, 2019, IMMUNOLOGY, V156, P120, DOI 10.1111/imm.13019; Woof JM, 2011, MUCOSAL IMMUNOL, V4, P590, DOI 10.1038/mi.2011.39; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Xiang Yufei, 2020, bioRxiv, DOI 10.1101/2020.08.24.264333; Xiao Y, 2002, IMMUNOL RES, V25, P193, DOI 10.1385/IR:25:3:193; Xiong HL, 2020, EMERG MICROBES INFEC, V9, P2105, DOI 10.1080/22221751.2020.1815589; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427; Zhang M, 2004, CELL MOL IMMUNOL, V1, P89; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhao MM, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00558-8; Zheng QB, 2019, P NATL ACAD SCI USA, V116, P26933, DOI 10.1073/pnas.1916028116; Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123; Zhou YJ, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108699; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	173	1	1	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1376	10.3390/vaccines9121376			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8YK	34960121	gold, Green Published			2022-04-29	WOS:000737250700001
J	Song, KR; Lim, JK; Park, SE; Saluja, T; Cho, SI; Wartel, TA; Lynch, J				Song, Katerina Rok; Lim, Jacqueline Kyungah; Park, Se Eun; Saluja, Tarun; Cho, Sung-Il; Wartel, Tram Anh; Lynch, Julia			Oral Cholera Vaccine Efficacy and Effectiveness	VACCINES			English	Article						vaccine efficacy; vaccine effectiveness; oral cholera vaccine (OCV); cholera; prevention; vaccine	LONG-TERM EFFECTIVENESS; WHOLE-CELL VACCINE; VIBRIO-CHOLERAE; FIELD TRIAL; B-SUBUNIT; MASS VACCINATION; CVD 103-HGR; PROTECTIVE EFFICACY; COST-EFFECTIVENESS; DOUBLE-BLIND	Although measuring vaccine efficacy through the conventional phase III study design, randomized, double-blinded controlled trial serves as the "gold standard", effectiveness studies, conducted in the context of a public health program, seek to broaden the understanding of the impact of a vaccine in a real world setting including both individual and population level impacts. Cholera is an acute diarrheal infection caused by the ingestion of food or water contaminated with the bacterium Vibrio cholerae. Since the 1980s, either killed or live oral cholera vaccines (OCVs) have been developed and efficacy and effectiveness studies have been conducted on OCV. Although the results of OCV effectiveness studies sometimes showed outliers, the tendency seen is for effectiveness of the vaccine used in public health settings to be somewhat higher than estimated in randomized controlled trials due to the influence of indirect herd protection. Efficacy and Effectiveness studies both generate important information about the vaccine performance characteristics and its impact when used in real world populations at risk for the disease.	[Song, Katerina Rok; Lim, Jacqueline Kyungah; Park, Se Eun; Saluja, Tarun; Wartel, Tram Anh; Lynch, Julia] Int Vaccine Inst, Seoul 08826, South Korea; [Song, Katerina Rok; Cho, Sung-Il] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 08826, South Korea; [Park, Se Eun] Yonsei Univ, Grad Sch Publ Hlth, Seoul 03722, South Korea		Lynch, J (通讯作者)，Int Vaccine Inst, Seoul 08826, South Korea.	katerina.song@ivi.int; kalim@ivi.int; seeun.park@ivi.int; tarun.saluja@ivi.int; scho@snu.ac.kr; anh.wartel@ivi.int; julia.lynch@ivi.int	Cho, Sung-il/D-5703-2012	Cho, Sung-il/0000-0003-4085-1494			Abubakar A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001901; Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832; Anh Dang Duc, 2011, PLoS Negl Trop Dis, V5, pe1006, DOI 10.1371/journal.pntd.0001006; Azman AS, 2016, LANCET GLOB HEALTH, V4, pE856, DOI 10.1016/s2214-109x(16)30211-x; Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1; BLACK RE, 1987, INFECT IMMUN, V55, P1116, DOI 10.1128/IAI.55.5.1116-1120.1987; Calain P, 2004, VACCINE, V22, P2444, DOI 10.1016/j.vaccine.2003.11.070; Cavailler P, 2006, VACCINE, V24, P4890, DOI 10.1016/j.vaccine.2005.10.006; Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145; Clemens J.D., 1990, NEW GENERATION VACCI, P18; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Clemens JD, 2001, J INFECT DIS, V183, P1306, DOI 10.1086/319673; Clemens JD, 2017, LANCET, V390, P1539, DOI 10.1016/S0140-6736(17)30559-7; Anh DD, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001712; Dorlencourt F, 1999, B WORLD HEALTH ORGAN, V77, P949; European Medicines Agency, ANN 1 SUMM PROD CHAR; Ferreras E, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S095026882000062X; Franke MF, 2018, LANCET GLOB HEALTH, V6, pE1028, DOI 10.1016/S2214-109X(18)30284-5; Grandesso F, 2019, VACCINE, V37, P3668, DOI 10.1016/j.vaccine.2019.05.044; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; HABER M, 1991, INT J EPIDEMIOL, V20, P300, DOI 10.1093/ije/20.1.300; Halloran ME, 1997, AM J EPIDEMIOL, V146, P789; Hashim R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001743; ICG, 2013, OR CHOL VACC STOCKP; Ilboudo PG, 2021, COST EFFECT RESOUR A, V19, DOI 10.1186/s12962-021-00270-y; Islam MT, 2020, VACCINE, V38, pA127, DOI 10.1016/j.vaccine.2019.06.082; Ivers LC, 2015, LANCET GLOB HEALTH, V3, pE162, DOI 10.1016/S2214-109X(14)70368-7; Jertborn M, 1996, VACCINE, V14, P1459, DOI 10.1016/S0264-410X(96)00071-0; JERTBORN M, 1993, VACCINE, V11, P1007, DOI 10.1016/0264-410X(93)90125-H; Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x; Kabir S, 2014, CLIN VACCINE IMMUNOL, V21, P1195, DOI 10.1128/CVI.00378-14; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629; Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2; Legros D, 1999, B WORLD HEALTH ORGAN, V77, P837; LEVINE MM, 1981, J INFECT DIS, V143, P818, DOI 10.1093/infdis/143.6.818; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; LEVINE MM, 1979, T ROY SOC TROP MED H, V73, P3, DOI 10.1016/0035-9203(79)90119-6; Levine MM, 2017, EXPERT REV VACCINES, V16, P197, DOI 10.1080/14760584.2017.1291348; Lopez-Gigosos R, 2007, Travel Med Infect Dis, V5, P380, DOI 10.1016/j.tmaid.2007.06.001; Lopez-Gigosos R, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-65; Lucas MES, 2005, NEW ENGL J MED, V352, P757, DOI 10.1056/NEJMoa043323; Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680; Nair GB, 2002, J CLIN MICROBIOL, V40, P3296, DOI 10.1128/JCM.40.9.3296-3299.2002; Odevall L, 2018, VACCINE, V36, P6606, DOI 10.1016/j.vaccine.2018.09.026; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; Pezzoli L, 2020, VACCINE, V38, pA132, DOI 10.1016/j.vaccine.2019.08.086; Qadri F, 2018, LANCET INFECT DIS, V18, P666, DOI 10.1016/S1473-3099(18)30108-7; Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330; Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0; Richie E, 2000, VACCINE, V18, P2399, DOI 10.1016/S0264-410X(00)00006-2; SANCHEZ J, 1989, P NATL ACAD SCI USA, V86, P481, DOI 10.1073/pnas.86.2.481; Schaetti C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001844; Schaetti C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041527; Severe K, 2016, AM J TROP MED HYG, V94, P1136, DOI 10.4269/ajtmh.15-0700; Shaikh H, 2020, VACCINE, V38, pA118, DOI 10.1016/j.vaccine.2019.12.011; Sharma NC, 2007, INDIAN J MED RES, V125, P633; Shin S, 2011, CLIN INFECT DIS, V52, P1343, DOI 10.1093/cid/cir141; Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6; Tacket CO, 1999, INFECT IMMUN, V67, P6341; Taylor DN, 2000, J INFECT DIS, V181, P1667, DOI 10.1086/315462; Tembo T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215972; Thiem VD, 2003, J HEALTH POPUL NUTR, V21, P304; Thiem VD, 2006, VACCINE, V24, P4297, DOI 10.1016/j.vaccine.2006.03.008; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; vanLoon FPL, 1996, VACCINE, V14, P162, DOI 10.1016/0264-410X(95)00122-H; Wierzba TF, 2015, VACCINE, V33, P2463, DOI 10.1016/j.vaccine.2015.03.073; World Health Organization Cholera, FACT SHEETS; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	74	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1482	10.3390/vaccines9121482			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ7VV	34960228	gold, Green Published			2022-04-29	WOS:000737857600001
J	Subedi, D; Pantha, S; Subedi, S; Gautam, A; Gaire, A; Sapkota, D; Sapkota, S; Kandel, M; Parajuli, A; Ghimire, H; Ghimire, S; Devkota, J; Dhakal, S				Subedi, Deepak; Pantha, Saurav; Subedi, Sanju; Gautam, Anil; Gaire, Asmita; Sapkota, Deepak; Sapkota, Sachin; Kandel, Milan; Parajuli, Aabishkar; Ghimire, Harishchandra; Ghimire, Shristi; Devkota, Janardan; Dhakal, Santosh			Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal	VACCINES			English	Article						COVID-19 vaccine; vaccine acceptance; vaccine perception; Nepal	HESITANCY; HEALTH	Vaccination is the most effective preventive measure of COVID-19 available at present, but its success depends on the global accessibility of vaccines and the willingness of people to be vaccinated. As the vaccination rollouts are increasing worldwide, it is important to assess public perception and willingness towards vaccination, so that the aim of mass vaccination will be successful. This study aimed to understand public perception towards COVID-19 vaccines and their willingness to get vaccinated in Nepal. This cross-sectional online survey was conducted among 1196 residents of Nepal in August 2021; most of the participants of this online survey were young adults (18-47 years) with university-level education. A total of 64.5% (771/1196) of the participants perceived COVID-19 vaccines to be safe and risk-free, while 68.6% (820/1196) agreed that vaccination would be efficient in the fight against this pandemic. Most of the participants (841/1196, 70.3%) disagreed that people are getting COVID-19 vaccines easily in Nepal, while they agree with the prioritization of older adults and healthcare workers for vaccination. A total of 61.1% (731/1196) of the participants had received at least one dose of the vaccine. Among the unvaccinated, 93.3% (434/465) were willing to get vaccinated when their turn came. The higher confidence of younger adults in vaccines and the vaccination process is encouraging, as that can help educate others who are hesitant or are not positive towards the idea of receiving vaccines. Dissemination of correct and current information, acquisition of enough doses of vaccines, and equitable distribution of vaccines will be required to achieve successful completion of the COVID-19 vaccination campaign in Nepal.	[Subedi, Deepak; Pantha, Saurav; Gautam, Anil; Gaire, Asmita] Tribhuvan Univ, Inst Agr & Anim Sci IAAS, Paklihawa Campus, Siddharthanagar 32900, Nepal; [Pantha, Saurav; Sapkota, Deepak] Agr & Forestry Univ, Fac Anim Sci Vet Sci & Fisheries FAVF, Bharatpur 44200, Nepal; [Subedi, Sanju; Ghimire, Harishchandra] Chitwan Med Coll, Sch Publ Hlth, Chitwan 44200, Bharatpur, Nepal; [Sapkota, Sachin] Chitwan Med Coll, Sch Med, Chitwan 44200, Bharatpur, Nepal; [Kandel, Milan] Purbanchal Univ, Himalayan Coll Agr Sci & Technol HICAST, Kathmandu 44618, Nepal; [Parajuli, Aabishkar] Kathmandu Univ, Devdaha Med Coll, Rupandehi 32907, Nepal; [Devkota, Janardan; Dhakal, Santosh] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA		Dhakal, S (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	subedideepu26@gmail.com; sauravvet@gmail.com; subedisanju23@gmail.com; anilg6623@gmail.com; asmitagaire1@gmail.com; sapkotadeepak2113@gmail.com; hinsac12@gmail.com; milankandel377@gmail.com; aabishkar2000@gmail.com; ghimire.harishchandra@cmc.edu.np; sghimir2@jhu.edu; jdevkot1@jhu.edu; santoshdhakal88@gmail.com	Subedi, Deepak/AAA-1622-2022	Subedi, Deepak/0000-0002-0677-7094; Sapkota, Sachin/0000-0002-1394-7135; Gautam, Anil/0000-0002-6500-4999; Kandel, Milan/0000-0002-5515-3405			Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Awale S., 2021, NEPALI TIMES; Basnet BB, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.613402; Bloom BR, 2020, NEW ENGL J MED, V383, P2202, DOI 10.1056/NEJMp2025331; Callender D, 2016, HUM VACC IMMUNOTHER, V12, P2464, DOI 10.1080/21645515.2016.1178434; Chu HR, 2021, PATIENT EDUC COUNS, V104, P1878, DOI 10.1016/j.pec.2021.02.031; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dhakal S, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00524; Dhillon P, 2021, FEBS J, V288, P4996, DOI 10.1111/febs.16094; Figueroa JP, 2021, LANCET, V397, P562, DOI 10.1016/S0140-6736(21)00242-7; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Goodman J, 2020, BBC; Government of Nepal Ministry of Health and Population, 2021, HLTH SECT RESP COVID; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Hawlader Mohammad Delwer Hossain, 2022, Int J Infect Dis, V114, P1, DOI 10.1016/j.ijid.2021.09.056; Holder J, COVID WORLD VACCINAT; Horton R, 2020, LANCET, V396, P1474, DOI 10.1016/S0140-6736(20)32315-1; Hotez PJ, 2020, CURR OPIN VIROL, V41, P1, DOI 10.1016/j.coviro.2020.01.001; Kathmandu Post, 2021, KATHMANDU POST; Kennedy J, 2020, PEDIATR DRUGS, V22, P105, DOI 10.1007/s40272-020-00385-4; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kumar S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.752227; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lo NC, 2017, JAMA PEDIATR, V171, P887, DOI 10.1001/jamapediatrics.2017.1695; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Manohar S., ONCE NEPAL GETS VACC; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Patel PN, 2021, VACCINE, V39, P5831, DOI 10.1016/j.vaccine.2021.08.059; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Paudel S, 2021, RISK MANAG HEALTHC P, V14, P2253, DOI 10.2147/RMHP.S310289; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Poudel A, 2021, KATHMANDU POST; Poudel A, 2021, NEPAL BEGINS 1 PHASE; Raoufi M., 2021, TRENDS PHARM SCI, V7, P151, DOI [10.30476/TIPS.2021.91504.1100, DOI 10.30476/TIPS.2021.91504.1100]; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; RStudio Team, 2020, RSTUDIO INT DEV R RS; Rucker J, 57 LEADING SCI DOCTO; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Shahi I, 2021, NEPAL READIES VACCIN; Siegal E, UNFILTERED TRUTH HUM; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	49	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1448	10.3390/vaccines9121448			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8ZO	34960194	gold, Green Published			2022-04-29	WOS:000737253700001
J	Kromann, S; Olsen, RH; Bojesen, AM; Jensen, HE; Thofner, I				Kromann, Sofie; Olsen, Rikke Heidemann; Bojesen, Anders Miki; Jensen, Henrik Elvang; Thofner, Ida			Protective Potential of an Autogenous Vaccine in an Aerogenous Model of Escherichia coli Infection in Broiler Breeders	VACCINES			English	Article						APEC; colibacillosis; challenge study; poultry disease; disease prevention; bacterin vaccine	CHICKEN MEAT; PERITONITIS SYNDROME; STRAINS; HUMANS; GENES; RESISTANCE; EFFICACY; POULTRY; STRESS	In poultry, Escherichia coli is a common cause of high-cost infections. Consequently, autogenous vaccines are often used despite limited and conflicting evidence on their effectiveness have been presented. The present study aimed to investigate the efficacy of a commonly used autogenous vaccine, previously deemed ineffective, in an aerosol model of colibacillosis. Methods: Broiler breeders (n = 47) were randomly allocated to one of four groups (vaccinated and unvaccinated birds receiving an autogenous vaccine or sterile saline intramuscularly) and challenged with either aerosolised E. coli or vehicle at 29 weeks of age. Two days following inoculation, the birds were euthanised, thoroughly necropsied, and samples for bacteriology and histopathology were collected. Results: Vaccinated birds had a significantly lower bacteriology score compared to the unvaccinated group challenged with E. coli (p < 0.01) and a lower overall air sac lesion score (p < 0.05). Overall lung and spleen lesion scores only differed significantly between the unvaccinated E. coli challenged group compared to the vehicle inoculated groups. The overall gross pathology score was 2.8 and 1.95 in the unvaccinated and vaccinated E. coli challenge groups, respectively, whereas the vaccinated vehicle group had a score of 0.9 and the unvaccinated vehicle group a score of 1. Conclusions: A protective effect of an autogenous vaccine was found utilising an aerogenous model of colibacillosis through multiple methods of evaluation. The findings encourage the continued use of autogenous vaccines and underlines the necessity of discriminative experimental models with high predictive validity when evaluating vaccine interventions.	[Kromann, Sofie; Olsen, Rikke Heidemann; Bojesen, Anders Miki; Jensen, Henrik Elvang; Thofner, Ida] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, DK-1870 Frederiksberg, Denmark; [Kromann, Sofie] DanHatch Denmark AS, Rugerivej 26, DK-9760 Vra, Denmark		Kromann, S (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, DK-1870 Frederiksberg, Denmark.; Kromann, S (通讯作者)，DanHatch Denmark AS, Rugerivej 26, DK-9760 Vra, Denmark.	sok@sund.ku.dk; cava@sund.ku.dk; miki@sund.kmdk; elvang@sund.ku.dk; icnt@sund.ku.dk	Thøfner, Ida C. N./A-1387-2017	Thøfner, Ida C. N./0000-0003-2461-7024; Jensen, Henrik Elvang/0000-0001-7277-7829	Danish Poultry levy board; Innovation Fund of Denmark [8053-00115B]	This research was funded by the Danish Poultry levy board with the grant project title: "Afprovning af en universel E. coli vaccine", 2019, as well as the Innovation Fund of Denmark (Grant case number: 8053-00115B).	Antao EM, 2008, MICROB PATHOGENESIS, V45, P361, DOI 10.1016/j.micpath.2008.08.005; Chen J, 1998, LETT APPL MICROBIOL, V27, P369, DOI 10.1046/j.1472-765X.1998.00445.x; Cortes P, 2010, APPL ENVIRON MICROB, V76, P2799, DOI 10.1128/AEM.02421-09; Costa D, 2009, VET MICROBIOL, V138, P339, DOI 10.1016/j.vetmic.2009.03.029; Dho-Moulin M, 1999, VET RES, V30, P299; Ewers C, 2009, APPL ENVIRON MICROB, V75, P184, DOI 10.1128/AEM.01324-08; Ghunaim H, 2014, VET MICROBIOL, V172, P13, DOI 10.1016/j.vetmic.2014.04.019; Gutman N., 2018, COLI CHALLENGE UNPUB; HELLER ED, 1990, AVIAN PATHOL, V19, P345, DOI 10.1080/03079459008418685; Isling LK, 2010, ACTA VET SCAND, V52, DOI 10.1186/1751-0147-52-48; Jakobsen L, 2010, INT J FOOD MICROBIOL, V142, P264, DOI 10.1016/j.ijfoodmicro.2010.06.025; Johnson TJ, 2007, J BACTERIOL, V189, P3228, DOI 10.1128/JB.01726-06; Kluytmans JAJW, 2013, CLIN INFECT DIS, V56, P478, DOI 10.1093/cid/cis929; Koutsianos D, 2020, VET SCI, V7, DOI 10.3390/vetsci7030080; Kromann S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-98270-8; Landman WJM, 2017, AVIAN PATHOL, V46, P658, DOI 10.1080/03079457.2017.1346231; Landman WJM, 2013, AVIAN PATHOL, V42, P157, DOI 10.1080/03079457.2013.775694; Lara Lucas J, 2013, Animals (Basel), V3, P356, DOI 10.3390/ani3020356; Li LL, 2017, AVIAN PATHOL, V46, P300, DOI 10.1080/03079457.2016.1267857; LINTON AH, 1977, J APPL BACTERIOL, V43, P465, DOI 10.1111/j.1365-2672.1977.tb00773.x; Nolan L.K., 2020, COLIBACILLOSIS DIS P, P770, DOI DOI 10.1002/9781119371199.CH18; OJENIYI AA, 1989, EPIDEMIOL INFECT, V103, P513, DOI 10.1017/S0950268800030910; Overdevest I, 2011, EMERG INFECT DIS, V17, P1216, DOI 10.3201/eid1707.110209; Ronco T, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3415-6; ROSENBERGER JK, 1985, AVIAN DIS, V29, P1108, DOI 10.2307/1590465	25	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1233	10.3390/vaccines9111233			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG8EU	34835164	gold, Green Published			2022-04-29	WOS:000724981800001
J	Swaminathan, G; Citron, M; Xiao, JY; Norton, JE; Reens, AL; Topcuoglu, BD; Maritz, JM; Lee, KJ; Freed, DC; Weber, TM; White, CH; Kadam, M; Spofford, E; Bryant-Hall, E; Salituro, G; Kommineni, S; Liang, X; Danilchanka, O; Fontenot, JA; Woelk, CH; Gutierrez, DA; Hazuda, DJ; Hannigan, GD				Swaminathan, Gokul; Citron, Michael; Xiao, Jianying; Norton, James E., Jr.; Reens, Abigail L.; Topcuoglu, Begum D.; Maritz, Julia M.; Lee, Keun-Joong; Freed, Daniel C.; Weber, Teresa M.; White, Cory H.; Kadam, Mahika; Spofford, Erin; Bryant-Hall, Erin; Salituro, Gino; Kommineni, Sushma; Liang, Xue; Danilchanka, Olga; Fontenot, Jane A.; Woelk, Christopher H.; Gutierrez, Dario A.; Hazuda, Daria J.; Hannigan, Geoffrey D.			Vaccine Hyporesponse Induced by Individual Antibiotic Treatment in Mice and Non-Human Primates Is Diminished upon Recovery of the Gut Microbiome	VACCINES			English	Article						microbiome; vaccines; immunity	INTESTINAL MICROBIOTA; ROTAVIRUS VACCINE; IMMUNE-RESPONSES; DYSBIOSIS; SYSTEMS; RECRUITMENT; METABOLISM; INFECTION; EFFICACY; HEALTH	Emerging evidence demonstrates a connection between microbiome composition and suboptimal response to vaccines (vaccine hyporesponse). Harnessing the interaction between microbes and the immune system could provide novel therapeutic strategies for improving vaccine response. Currently we do not fully understand the mechanisms and dynamics by which the microbiome influences vaccine response. Using both mouse and non-human primate models, we report that short-term oral treatment with a single antibiotic (vancomycin) results in the disruption of the gut microbiome and this correlates with a decrease in systemic levels of antigen-specific IgG upon subsequent parenteral vaccination. We further show that recovery of microbial diversity before vaccination prevents antibiotic-induced vaccine hyporesponse, and that the antigen specific IgG response correlates with the recovery of microbiome diversity. RNA sequencing analysis of small intestine, spleen, whole blood, and secondary lymphoid organs from antibiotic treated mice revealed a dramatic impact on the immune system, and a muted inflammatory signature is correlated with loss of bacteria from Lachnospiraceae, Ruminococcaceae, and Clostridiaceae. These results suggest that microbially modulated immune pathways may be leveraged to promote vaccine response and will inform future vaccine design and development strategies.	[Swaminathan, Gokul; Norton, James E., Jr.; Reens, Abigail L.; Topcuoglu, Begum D.; Maritz, Julia M.; White, Cory H.; Kadam, Mahika; Kommineni, Sushma; Liang, Xue; Danilchanka, Olga; Woelk, Christopher H.; Gutierrez, Dario A.; Hazuda, Daria J.; Hannigan, Geoffrey D.] Merck & Co Inc, Exploratory Sci Ctr, Cambridge, MA 02141 USA; [Citron, Michael; Xiao, Jianying; Freed, Daniel C.; Weber, Teresa M.; Hazuda, Daria J.] Merck & Co Inc, MRL, Infect Dis & Vaccine Res, West Point, PA 19486 USA; [Lee, Keun-Joong; Salituro, Gino] Merck & Co Inc, MRL, Pharmacokinet Pharmacodynam & Drug Metab, Rahway, NJ 07065 USA; [Spofford, Erin; Bryant-Hall, Erin] Merck & Co Inc, Safety Assessment & Lab Anim Res, MRL, Boston, MA 02115 USA; [Fontenot, Jane A.] Univ Louisiana Lafayette, New Iberia Res Ctr, Lafayette, LA 70503 USA; [Swaminathan, Gokul] Boehringer Ingelheim GmbH & Co KG, Vaccine Innovat Dept, F-69002 Lyon, France; [Reens, Abigail L.] Prolacta Biosci Inc, Watertown, MA 02472 USA; [Kadam, Mahika] Emulate Inc, Boston, MA 02210 USA; [Gutierrez, Dario A.] Third Rock Ventures, Boston, MA 02116 USA		Swaminathan, G; Hannigan, GD (通讯作者)，Merck & Co Inc, Exploratory Sci Ctr, Cambridge, MA 02141 USA.	gokul.swaminathan@boehringer-ingelheim.com; michael_citron@merck.com; jianying_xiao@merck.com; james.norton@merck.com; abigail.reens@merck.com; begum.topcuoglu@merck.com; julia.maritz@merck.com; keun-joong.lee@merck.com; dan_freed@merck.com; teresa_weber@merck.com; cory.white@merck.com; mahika.kadam27@gmail.com; Spofford.erin@gmail.com; erin.bryant.hall@merck.com; gino_salituro@merck.com; sushma.kommineni@merck.com; liangxue.tina@hotmail.com; olga.danilchanka@merck.com; jfontenot@louisiana.edu; christopher.woelk@merck.com; dario.gutierrez@tcr2.com; daria_hazuda@merck.com; geoffrey.hannigan@merck.com		Hannigan, Geoffrey/0000-0002-7128-2143	Merck Sharp Dohme CorpMerck & Company	This work was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ 07033, USA.	Arnold IC, 2015, VACCINE, V33, P1808, DOI 10.1016/j.vaccine.2015.02.041; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176; Candon S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125448; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Ciabattini A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01305; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Duchene J, 2007, J IMMUNOL, V179, P4849, DOI 10.4049/jimmunol.179.7.4849; Eloe-Fadrosh EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062026; Fourati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10369; Fung TC, 2017, NAT NEUROSCI, V20, P145, DOI 10.1038/nn.4476; Gharib SA, 2014, J LEUKOCYTE BIOL, V95, P9, DOI 10.1189/jlb.1112587; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gindy ME, 2014, MOL PHARMACEUT, V11, P4143, DOI 10.1021/mp500367k; Gopinath S, 2018, NAT MICROBIOL, V3, P611, DOI 10.1038/s41564-018-0138-2; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Hannigan GD, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015362; Harris V, 2018, GUT MICROBES, V9, P93, DOI 10.1080/19490976.2017.1376162; Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518; Holodniy M, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014764, 10.1371/journal.pone.0025792]; Huda MN, 2014, PEDIATRICS, V134, pE362, DOI 10.1542/peds.2013-3937; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; Jena PK, 2017, AM J PATHOL, V187, P1800, DOI 10.1016/j.ajpath.2017.04.019; Jones BV, 2008, P NATL ACAD SCI USA, V105, P13580, DOI 10.1073/pnas.0804437105; Kanehisa M, 2021, NUCLEIC ACIDS RES, V49, pD545, DOI 10.1093/nar/gkaa970; Kanehisa M, 2019, PROTEIN SCI, V28, P1947, DOI 10.1002/pro.3715; Kim D, 2019, IMMUNOLOGY, V158, P219, DOI 10.1111/imm.13105; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Lam KCK, 2020, J LEUKOCYTE BIOL, V108, P1787, DOI 10.1002/JLB.3A0420-386R; Lamouse-Smith ES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027662; Levine MM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-129; Levy M, 2015, CELL, V163, P1428, DOI 10.1016/j.cell.2015.10.048; Li BB, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02125; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R; Lynn MA, 2018, CELL HOST MICROBE, V23, P653, DOI 10.1016/j.chom.2018.04.009; Manicone AM, 2009, J IMMUNOL, V182, P3866, DOI 10.4049/jimmunol.0713949; Manor O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0610-8; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Morris JH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-436; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Nikolaus S, 2017, GASTROENTEROLOGY, V153, P1504, DOI 10.1053/j.gastro.2017.08.028; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Parker EPK, 2018, FUTURE MICROBIOL, V13, P97, DOI 10.2217/fmb-2017-0128; Parker EPK, 2018, VACCINE, V36, P264, DOI 10.1016/j.vaccine.2017.11.031; Preidis GA, 2015, J NUTR BIOCHEM, V26, P1050, DOI 10.1016/j.jnutbio.2015.04.010; Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111; R Core Team, 2020, R LANGUAGE ENV STAT; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schenk RL, 2017, CELL DEATH DIFFER, V24, P534, DOI 10.1038/cdd.2016.156; Schloss PD, 2013, ISME J, V7, P457, DOI 10.1038/ismej.2012.102; Schubert AM, 2015, MBIO, V6, DOI 10.1128/mBio.00974-15; Shao Z, 2011, J LEUKOCYTE BIOL, V89, P21, DOI 10.1189/jlb.0510315; Shin NR, 2015, TRENDS BIOTECHNOL, V33, P496, DOI 10.1016/j.tibtech.2015.06.011; Sommer F, 2017, NAT REV MICROBIOL, V15, P630, DOI 10.1038/nrmicro.2017.58; Spinner CA, 2019, CANCER IMMUNOL RES, V7, P1332, DOI 10.1158/2326-6066.CIR-18-0562; Sun L, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00099; Swaminathan G, 2016, VACCINE, V34, P110, DOI 10.1016/j.vaccine.2015.10.132; Thackray LB, 2018, CELL REP, V22, P3440, DOI 10.1016/j.celrep.2018.03.001; Thomas AM, 2019, NAT MED, V25, P667, DOI 10.1038/s41591-019-0405-7; Thoryk EA, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040047; Tilocca B, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0362-7; Tulstrup MVL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144854; Uchiyama R, 2014, J INFECT DIS, V210, P171, DOI 10.1093/infdis/jiu037; Ursell LK, 2014, GASTROENTEROLOGY, V146, P1470, DOI 10.1053/j.gastro.2014.03.001; Ussar S, 2016, MOL METAB, V5, P795, DOI 10.1016/j.molmet.2016.07.004; Vazquez-Castellanos JF, 2015, MUCOSAL IMMUNOL, V8, P760, DOI 10.1038/mi.2014.107; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wang ZQ, 2009, J IMMUNOL, V183, P6646, DOI 10.4049/jimmunol.0802348; Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263; Woo PCY, 1999, CLIN DIAGN LAB IMMUN, V6, P832, DOI 10.1128/CDLI.6.6.832-837.1999; Xu XJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00814; Yang JH, 2017, CELL HOST MICROBE, V22, P757, DOI 10.1016/j.chom.2017.10.020; Yang WJ, 2019, J IMMUNOL, V203, P282, DOI 10.4049/jimmunol.1801068; Zackular JP, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00001-15; Zhang YC, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.161; Zimmermann P, 2018, VACCINE, V36, P4433, DOI 10.1016/j.vaccine.2018.04.066	85	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1340	10.3390/vaccines9111340			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI6PR	34835271	Green Published, gold, Green Submitted			2022-04-29	WOS:000726231400001
J	Cavaliere, AF; Zaami, S; Pallottini, M; Perelli, F; Vidiri, A; Marinelli, E; Straface, G; Signore, F; Scambia, G; Marchi, L				Cavaliere, Anna Franca; Zaami, Simona; Pallottini, Marta; Perelli, Federica; Vidiri, Annalisa; Marinelli, Enrico; Straface, Gianluca; Signore, Fabrizio; Scambia, Giovanni; Marchi, Laura			Flu and Tdap Maternal Immunization Hesitancy in Times of COVID-19: An Italian Survey on Multiethnic Sample	VACCINES			English	Article						COVID-19 vaccine; Tdap; influenza vaccine; maternally acquired immunity; pregnancy	PERTUSSIS VACCINATION; PREGNANT-WOMEN; INFLUENZA; DIPHTHERIA; BARRIERS; TETANUS	Background: Tdap and flu immunization in pregnancy has been proven to be both effective and safe. Despite this, the vaccination rate in pregnant women is low in Italy. The COVID-19 pandemic has focused the attention of public opinion on communicable diseases, underlining the importance of primary prevention measures such as vaccination. We conducted a survey to investigate the behavior of pregnant women during the COVID-19 pandemic regarding maternal immunization to identify the reasons for vaccine hesitancy in order to overcome them. The new challenge is COVID-19 vaccination in pregnancy, and preliminary data show hesitancy towards it. Our analysis may be useful to improve immunization in the pregnant population, including through the COVID-19 vaccine. Methods: A targeted survey was performed in Italy including 520 women who experienced in the first trimester of pregnancy, prior to the novel coronavirus spread, the 2019-2020 influenza vaccination campaign and the Tdap vaccine recommendation in the third trimester during the COVID pandemic. They represent a unique model to investigate if the new coronavirus outbreak might have changed attitudes towards vaccination in pregnancy in the same patients. Data were collected from a self-completed paper questionnaire. Descriptive statistics were calculated and percentages were compared using the chi-2 test or Fisher's exact test. Results: We obtained data from 195 of the 520 women who gave birth during the inclusion period; 325 cases declined to participate in the survey. A total of 8.7% (17 cases) performed flu vaccination in the first trimester of pregnancy (pre-COVID era), 50.8% (99 cases) accepted Tdap immunization during their third trimester of gestation (COVID-19 pandemic) and 6.7% (13 cases) received both vaccines during pregnancy. For both the flu and Tdap shots, pregnant patients were more likely to accept the vaccines if they were recommended by a healthcare provider, whereas the main reason not to be vaccinated was the lack of such a recommendation. Conclusions: Our survey shows that the COVID-19 experience, which has raised awareness as to the role of vaccines in preventable diseases, may positively change attitudes toward immunization in pregnancy. Vaccination must be recommended to all pregnant women and organized during routine prenatal care as an important element for the prevention of communicable diseases. Vaccination hesitancy can be minimized through consistent recommendation to all pregnant women offered by obstetric staff during routine prenatal care. This approach is likely to be effective in terms of building trust in flu and Tdpa immunization among pregnant women, as well as to avoid unjustified hesitancy towards the more recent COVID-19 vaccines.	[Cavaliere, Anna Franca; Pallottini, Marta; Marchi, Laura] AUSL Toscana Ctr, Santo Stefano Hosp Prato, Obstet & Gynaecol Unit, Via Suor Niccolina Infermiera 20-22, I-59100 Prato, Italy; [Zaami, Simona; Marinelli, Enrico] Sapienza Univ Rome, Dept Anat Histol Forens & Orthoped Sci, I-00185 Rome, Italy; [Perelli, Federica] AUSL Toscana Ctr, Santa Maria Annunziata Hosp, Obstet & Gynecol Unit, Via Antella 58, I-50012 Florence, Italy; [Vidiri, Annalisa; Scambia, Giovanni] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth, Via Pineta Sacchetti 217, I-00168 Rome, Italy; [Straface, Gianluca] Abano Terme Polyclin, Obstet & Gynecol Unit, Piazza Cristoforo Colombo 1, I-35031 Abano Terme, Italy; [Signore, Fabrizio] ASL Roma 2, Obstet & Gynecol Unit, Santo Eugenio Hosp, Piazzale Umanesimo 10, I-00144 Rome, Italy		Zaami, S (通讯作者)，Sapienza Univ Rome, Dept Anat Histol Forens & Orthoped Sci, I-00185 Rome, Italy.	annafranca.cavaliere@uslcentro.toscana.it; simona.zaami@uniroma1.it; marta.pallottini@uslcentro.toscana.it; federica.perelli@uslcentro.toscana.it; annalisavidiri@gmail.com; enrico.marinelli@uniroma1.it; glstraface@gmail.com; fabrizio.signore@aslroma2.it; giovanni.scambia@policlinicogemelli.it; laura.marchi@uslcentro.toscana.it	Cavaliere, Anna Franca/AAC-5177-2022	Marinelli, Enrico/0000-0002-7104-8744; ZAAMI, Simona/0000-0001-5741-7139			Abu Raya B, 2017, LANCET INFECT DIS, V17, pE209, DOI 10.1016/S1473-3099(17)30190-1; Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01282; [Anonymous], 2018, Obstet Gynecol, V131, pe109, DOI 10.1097/AOG.0000000000002588; [Anonymous], VACCINAZIONI GRAVIDA; Bartolo S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2628-5; Beigi R, 2017, OBSTET GYNECOL, V130, pE153, DOI 10.1097/AOG.0000000000002301; Blakeway H, 2022, AM J OBSTET GYNECOL, V226, DOI 10.1016/j.ajog.2021.08.007; Cavaliere AF, 2021, J MED VIROL, V93, P1810, DOI 10.1002/jmv.26609; Cavaliere AF, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1793317; Chamberlain Allison T, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.d37b61bceebae5a7a06d40a301cfa819; Chervenak FA, 2021, AM J OBSTET GYNECOL, V224, P470, DOI 10.1016/j.ajog.2021.01.027; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809; Giles ML, 2019, HUM VACC IMMUNOTHER, V15, P687, DOI 10.1080/21645515.2018.1540807; Hill L, 2018, J PRIM HEALTH CARE, V10, P62, DOI 10.1071/HC17040; Laenen J, 2015, VACCINE, V33, P2125, DOI 10.1016/j.vaccine.2015.03.020; Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046; Madhi SA, 2018, HUM VACC IMMUNOTHER, V14, P2183, DOI 10.1080/21645515.2018.1483810; Maisa A, 2018, PUBLIC HEALTH, V162, P111, DOI 10.1016/j.puhe.2018.05.025; Marchetti F, 2021, J MATERN-FETAL NEO M, V34, P2132, DOI 10.1080/14767058.2019.1659240; Marinelli E, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00562-7; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Ogilvie GS, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11098-9; Principi N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090970; Saso A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030556; Strassberg ER, 2018, VACCINE, V36, P4548, DOI 10.1016/j.vaccine.2018.05.121; Vilca LM, 2020, EUR J OBSTET GYN R B, V247, P10, DOI 10.1016/j.ejogrb.2020.02.007; Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046	29	8	8	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1107	10.3390/vaccines9101107			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV4AM	34696217	Green Published, gold			2022-04-29	WOS:000717180900001
J	Fernandes, N; Costa, D; Costa, D; Keating, J; Arantes, J				Fernandes, Nuno; Costa, Daniela; Costa, Diogo; Keating, Jose; Arantes, Joana			Predicting COVID-19 Vaccination Intention: The Determinants of Vaccine Hesitancy	VACCINES			English	Article						vaccine hesitancy; COVID-19; vaccination barriers; children vaccination; machine learning	RISK-TAKING; PARENTS	Do people want to be vaccinated against COVID-19? Herd immunity is dependent on individuals' willingness to be vaccinated since vaccination is not mandatory. Our main goal was to investigate people's intention to be vaccinated and their intentions to vaccinate their children. Moreover, we were interested in understanding the role of the personal characteristics, psychological factors, and the lockdown context on that decision. Therefore, we conducted an online survey during the lockdown in Portugal (15 January 2021 until 14 March 2021). Participants completed a socio-demographic questionnaire, questions about their intentions of being vaccinated, concerns about the vaccine, a COVID-19 attitudes and beliefs scale, a COVID-19 vaccine attitudes and beliefs scale, and the Domain-Specific Risk-Taking (DOSPERT) Scale. Our results showed that from the 649 participants, 63% of the participants reported being very likely to have the vaccine, while 60% reported being very likely to vaccinate their children. We conducted two linear regression models, explaining 65% of the variance for personal vaccination and 56% of the variance for children vaccination. We found that the COVID-19 vaccine general beliefs and attitudes were the main determinants of vaccination intention. Additionally, our proposed artificial neural network model was able to predict with 85% accuracy vaccination intention. Thus, our results suggest that psychological factors are an essential determinant of vaccination intention. Thus, public policy decision makers may use these insights for predicting vaccine hesitancy and designing effective vaccination communication strategies.	[Fernandes, Nuno; Costa, Daniela; Keating, Jose; Arantes, Joana] Univ Minho, Psychol Res Ctr CIPsi, Sch Psychol, P-4710057 Braga, Portugal; [Costa, Diogo] Univ Aveiro, Dept Mech Engn, P-3810193 Aveiro, Portugal		Fernandes, N (通讯作者)，Univ Minho, Psychol Res Ctr CIPsi, Sch Psychol, P-4710057 Braga, Portugal.	nuno.fernandes@psi.uminho.pt; id7743@alunos.uminho.pt; d.costa@ua.pt; keating@psi.uminho.pt; joana.arantes@psi.uminho.pt	Costa, Diogo/AAC-1042-2022	Costa, Diogo/0000-0002-4995-0539; Keating, Jose/0000-0002-8105-9148; Ferreira da Costa, Daniela Cristina/0000-0002-8565-0058; Arantes, Joana/0000-0002-7705-6366; Fernandes, Nuno/0000-0003-1959-7671	Fundacao para a Ciencia e Tecnologia (FCT)Portuguese Foundation for Science and TechnologyEuropean Commission [UIDB/PSI/01662/2020]	This research was funded by Fundacao para a Ciencia e Tecnologia (FCT), grant number UIDB/PSI/01662/2020.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Anderson EJ, 2021, CLIN INFECT DIS, V73, P336, DOI 10.1093/cid/ciaa1425; [Anonymous], DGS PONTO SITUACAO A; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Binder S, 2017, HEALTH ECON, V26, P76, DOI 10.1002/hec.3620; Blais AR, 2006, JUDGM DECIS MAK, V1, P33; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Chriscaden K., 2020, IMPACT COVID 19 PEOP; Cialdini R. B., 2002, Cornell Hotel and Restaurant Administration Quarterly, V43, P40, DOI 10.1016/S0010-8804(02)80030-1; Cialdini Robert B., 1998, HDB SOCIAL PSYCHOL, V1, P151; Crainich D, 2019, ITAL ECON J, V5, P455, DOI 10.1007/s40797-019-00089-w; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Graupensperger S, 2021, VACCINE, V39, P2060, DOI 10.1016/j.vaccine.2021.03.018; Gu, COVID 19 PROJECTIONS; Guo N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030527; Hawkins DM, 2004, J CHEM INF COMP SCI, V44, P1, DOI 10.1021/ci0342472; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kelkar AH, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9030351; Kim YC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0188-3; Larson HJ, 2021, SCIENCE, V371, P1289, DOI 10.1126/science.abi6488; Lewin K, 1947, HUM RELAT, V1, P5, DOI 10.1177/001872674700100103; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4944; Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Niazkar HR, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00175-y; Palm R., 2021, EFFECT FRAMES COVID, V3, P661257, DOI [10.3389/fpos.2021.661257, DOI 10.1101/2021.01.04.21249241]; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Qualtrics, 2021, QUALTRICS; R Core Team, 2020, R LANGUAGE ENV STAT; Ribas A, 2021, CANCER DISCOV, V11, P233, DOI 10.1158/2159-8290.CD-20-1817; Ripley B.D., 1996, PATTERN RECOGN, DOI [10.1017/CBO9780511812651BOOK, DOI 10.1017/CBO9780511812651BOOK]; RStudio Team, 2021, RSTUDIO INTEGRATED D; Saez C, 2021, J AM MED INFORM ASSN, V28, P360, DOI 10.1093/jamia/ocaa258; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Silva R., 2012, RISK PROFILING DOSPE; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Tamang SK, 2020, GLOB J ENVIRON SCI M, V6, P53, DOI 10.22034/GJESM.2019.06.SI.06; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; TVERSKY A, 1973, COGNITIVE PSYCHOL, V5, P207, DOI 10.1016/0010-0285(73)90033-9; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; van Der Linden S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.566790; Vogel G, 2021, SCIENCE, V372, P14, DOI 10.1126/science.372.6537.14; West PM, 1997, MARKET SCI, V16, P370, DOI 10.1287/mksc.16.4.370; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wise T, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.200742; Xiao XZ, 2021, HEALTH COMMUN, V36, P1476, DOI 10.1080/10410236.2020.1770506	51	5	5	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1161	10.3390/vaccines9101161			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI9JC	34696269	Green Published, gold			2022-04-29	WOS:000726417200001
J	Jo, DH; Minn, D; Lim, J; Lee, KD; Kang, YM; Choe, KW; Kim, KN				Jo, Dong-Ho; Minn, Dohsik; Lim, Jaegyun; Lee, Ki-Deok; Kang, Yu-Min; Choe, Kang-Won; Kim, Kwang-Nam			Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination	VACCINES			English	Article						SARS-CoV-2; vaccine immunogenicity; BNT162 vaccine; antibodies; neutralizing antibodies		The efficacy and safety of the BNT162b2 vaccine are known, but antibodies are expected to decrease over time after vaccination. We collected blood samples from 104 fully vaccinated health care workers at 3 and 5 weeks after first vaccination and 4 months after second vaccination. Antibody titers and neutralizing antibodies were measured. In our study, both antibody titers and neutralizing antibodies increased significantly at 5 weeks after first vaccination but decreased rapidly at 4 months after second vaccination. Additionally, the results showed a significant decrease regardless of gender or age. Further studies are needed to help determine the interval of SARS-CoV-2 vaccinations.</p>	[Jo, Dong-Ho; Lee, Ki-Deok; Kang, Yu-Min; Choe, Kang-Won] Myongji Hosp, Dept Internal Med, Div Infect Dis, Goyang 10475, South Korea; [Minn, Dohsik] Seegene Med Fdn, Seoul 05548, South Korea; [Lim, Jaegyun] Myongji Hosp, Dept Lab Med, Goyang 10475, South Korea; [Kim, Kwang-Nam] Myongji Hosp, Dept Pediat, Goyang 10475, South Korea		Kim, KN (通讯作者)，Myongji Hosp, Dept Pediat, Goyang 10475, South Korea.	feeldhy@hanmail.net; dsmin@naf.seegene.com; jaegyun@mjh.or.kr; kdlee.snmeulli@gmail.com; notjustblue@gmail.com; choekw@mjh.or.kr; kwangnamkim@naver.com		Kang, Yu Min/0000-0002-4368-9878; Jo, Dong Ho/0000-0003-4560-9082; Lim, Jaegyun/0000-0002-3553-0058			Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Chung YH, 2020, ACS NANO, V14, P12522, DOI 10.1021/acsnano.0c07197; Goel Rishi R, 2021, bioRxiv, DOI 10.1101/2021.08.23.457229; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Israel A, 2022, VACCINES-BASEL, V10, DOI [10.3390/vaccines10010064, 10.1101/2021.08.19.21262111]; Israel Ariel, 2021, medRxiv, DOI 10.1101/2021.08.03.21261496; Kohmer N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102128; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Trieu MC, 2019, CLIN INFECT DIS, V68, P382, DOI 10.1093/cid/ciy487; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; WHO, COR COVID 19 DASHB	13	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1145	10.3390/vaccines9101145			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR5DE	34696253	gold, Green Published			2022-04-29	WOS:000714519200001
J	Montalti, M; Di Valerio, Z; Rallo, F; Squillace, L; Costantino, C; Tomasello, F; Mauro, GL; Stillo, M; Perrone, P; Resi, D; Gori, D; Vitale, F; Fantini, MP				Montalti, Marco; Di Valerio, Zeno; Rallo, Flavia; Squillace, Lorena; Costantino, Claudio; Tomasello, Francesco; Mauro, Giulia Letizia; Stillo, Michela; Perrone, Paola; Resi, Davide; Gori, Davide; Vitale, Francesco; Fantini, Maria Pia			Attitudes toward the SARS-CoV-2 and Influenza Vaccination in the Metropolitan Cities of Bologna and Palermo, Italy	VACCINES			English	Article						vaccine hesitancy; vaccination; COVID-19; SARS-CoV-2; influenza; survey; Italy	HESITANCY; COVID-19; VACCINES	Vaccine hesitancy (VH) is known to play a relevant role in thwarting the efforts toward reaching satisfactory influenza vaccination coverage, and has caused similar difficulties during the COVID-19 pandemic. This study aims to describe the phenomenon and produce insights on the reasons behind VH. A survey was administered between December 2020 and February 2021 to adults living in the cities of Bologna and Palermo. Of the 443 subjects enrolled, 47.3% were likely to get the influenza vaccination, while 75.6% were willing to receive the COVID-19 vaccination. The most frequent determinants that motivated the willingness to get the COVID-19 vaccine were trust in the safety of vaccines and belief that the vaccine is an effective tool. As for people's unwillingness to be vaccinated, being exposed to information that produced doubts about the vaccine and lack of trust in a newly developed vaccine were the most frequently involved determinants. Statistically significant positive associations were found between the willingness to be vaccinated and postgraduate education and the propensity towards influenza vaccination. A negative association with being over 40 years old and of female gender was also found. These results might have an impact in better understanding individual reasons behind VH, identifying which categories are more exposed to it and which strategies should be implemented.	[Montalti, Marco; Di Valerio, Zeno; Rallo, Flavia; Gori, Davide; Fantini, Maria Pia] Univ Bologna, Unit Hyg, Dept Biomed & Neuromotor Sci, Publ Hlth & Med Stat, I-40126 Bologna, Italy; [Squillace, Lorena; Stillo, Michela; Perrone, Paola; Resi, Davide] Bologna Local Hlth Author, Dept Publ Hlth, I-40124 Bologna, Italy; [Costantino, Claudio; Tomasello, Francesco; Vitale, Francesco] Univ Palermo, Dept Hlth Promot Sci Maternal & Infant Care Inter, I-90127 Palermo, Italy; [Mauro, Giulia Letizia] Univ Palermo, Dept Surg Oncol & Stomatol Sci, I-90127 Palermo, Italy		Rallo, F (通讯作者)，Univ Bologna, Unit Hyg, Dept Biomed & Neuromotor Sci, Publ Hlth & Med Stat, I-40126 Bologna, Italy.	marco.montalti7@studio.unibo.it; zeno.divalerio@studio.unibo.it; flavia.rallo@studio.unibo.it; lorena.squillace@ausl.bologna.it; daudio.costantino01@unipa.it; francescotomasello111@gmail.com; giulia.letiziamauro@unipa.it; michela.stillo@ausl.bologna.it; paola.perrone@ausl.bologna.it; davide.resi@ausl.bologna.it; davide.gori4@unibo.it; francesco.vitale@unipa.it; mariapia.fantini@unibo.it	Montalti, Marco/AAQ-2494-2021; Gori, Davide/AAC-3486-2022; Costantino, Claudio/F-4742-2018	Montalti, Marco/0000-0001-7276-0277; Gori, Davide/0000-0003-4954-9419; Fantini, Maria Pia/0000-0002-3257-6552; Vitale, Francesco/0000-0002-6354-8060; Costantino, Claudio/0000-0002-3397-7331			Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; Amore S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91992-9; Basch CH, 2017, CHILD CARE HLTH DEV, V43, P499, DOI 10.1111/cch.12442; Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Costantino A, 2022, INFLAMM BOWEL DIS, V28, P474, DOI 10.1093/ibd/izab172; Costantino A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050511; Costantino C., 2021, EUROMEDITERR BIOMED, V16, DOI [10.3269/1970-5492.2021.16.19, DOI 10.3269/1970-5492.2021.16.19]; De Pue S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84127-7; Deiner MS, 2019, HEALTH INFORM J, V25, P1116, DOI 10.1177/1460458217740723; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Di Valerio Z, 2022, ANN IG MED PREV COMU, V34, P217, DOI 10.7416/ai.2021.2463; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; ECDC, VACC HES; Fink G, 2021, BMJ EVID-BASED MED, V26, DOI 10.1136/bmjebm-2020-111549; Gori D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020173; Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Guaraldi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050460; Guess AM, 2020, VACCINE, V38, P7799, DOI 10.1016/j.vaccine.2020.10.018; Gunaratne K, 2019, VACCINE, V37, P4867, DOI 10.1016/j.vaccine.2019.06.086; Italian Ministry of Health, COV 19 SIT WORLD; Italian Ministry of Health, INFL VACC COV DAT; Italian Ministry of Health, ANT 19 NAT VACC PLAN; Kang GJ, 2017, VACCINE, V35, P3621, DOI 10.1016/j.vaccine.2017.05.052; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ledda C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052703; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Ministry of Health National Institute of Health, 63 MIN HLTH NAT I HL; Ministry of Health National Institute of Health, MON PHAS 2 WEEKL REP; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reno C, 2021, INFECT DIS REP, V13, P712, DOI 10.3390/idr13030066; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Salomoni MG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080873; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Toth F, 2014, HEALTH ECON POLICY L, V9, P231, DOI 10.1017/S1744133114000012; Verger P, 2021, LANCET PUBLIC HEALTH, V6, pE195, DOI 10.1016/S2468-2667(21)00029-3; World Health Organization, INF	48	5	5	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1200	10.3390/vaccines9101200			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR5BT	34696308	Green Published, gold			2022-04-29	WOS:000714515500001
J	Anwar, MN; Jiang, CY; Di, D; Zhang, JJ; Guo, S; Wang, X; Hameed, M; Wahaab, A; Shao, DH; Li, ZJ; Liu, K; Li, BB; Qiu, YF; Ma, ZY; Wei, JC				Anwar, Muhammad Naveed; Jiang, Chunying; Di, Di; Zhang, Junjie; Guo, Shuang; Wang, Xin; Hameed, Muddassar; Wahaab, Abdul; Shao, Donghua; Li, Zongjie; Liu, Ke; Li, Beibei; Qiu, Yafeng; Ma, Zhiyong; Wei, Jianchao			A Novel Recombinant Virus-Like Particles Displaying B and T Cell Epitopes of Japanese Encephalitis Virus Offers Protective Immunity in Mice and Guinea Pigs	VACCINES			English	Article						Japanese encephalitis virus; porcine parvovirus; virus-like particle; immunogenicity	PARVOVIRUS-LIKE PARTICLES; PORCINE PARVOVIRUS; ADVISORY-COMMITTEE; ANTIGEN CARRIER; VACCINE; IMMUNIZATION; RECOMMENDATIONS; IMMUNOGENICITY; ANTIBODIES; ECOLOGY	Virus-like particles (VLPs) are non-replicative vectors for the delivery of heterologous epitopes and are considered one of the most potent inducers of cellular and humoral immune responses in mice and guinea pigs. In the present study, VLP-JEVe was constructed by the insertion of six Japanese encephalitis virus (JEV) envelope protein epitopes into different surface loop regions of PPV VP2 by the substitution of specific amino acid sequences without altering the assembly of the virus; subsequently, the protective efficacy of this VLP-JEVe was evaluated against JEV challenge in mice and guinea pigs. Mice immunized with the VLP-JEVe antigen developed high titers of neutralizing antibodies and 100% protection against lethal JEV challenge. The neutralizing and hemagglutination inhibition (HI) antibody responses were also induced in guinea pigs vaccinated with VLP-JEVe. In addition, immunization with VLP-JEVe in mice induced effective neutralizing antibodies and protective immunity against PPV (porcine parvovirus) challenge in guinea pigs. These studies suggest that VLP-JEVe produced as described here could be a potential candidate for vaccine development.	[Anwar, Muhammad Naveed; Jiang, Chunying; Di, Di; Zhang, Junjie; Guo, Shuang; Wang, Xin; Hameed, Muddassar; Wahaab, Abdul; Shao, Donghua; Li, Zongjie; Liu, Ke; Li, Beibei; Qiu, Yafeng; Ma, Zhiyong; Wei, Jianchao] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai 200241, Peoples R China		Ma, ZY; Wei, JC (通讯作者)，Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai 200241, Peoples R China.	dr.naveed903@gmail.com; xiaoyuanzi17@163.com; di.di@merck.com; 17317271403@163.com; guo1412634651@outlook.com; wang1655609668@outlook.com; mudasar386@gmail.com; abdul.wahaab@uaf.edu.pk; shaodonghua@shvri.ac.cn; lizongjie@shvri.ac.cn; liuke@shvri.ac.cn; lbb@shvri.ac.cn; yafengq@shvri.ac.cn; zhiyongma@shvri.ac.cn; jianchaowei@shvri.ac.cn		Anwar, Muhammad Naveed/0000-0002-4762-1635; Qiu, Yafeng/0000-0003-4211-0817; WAHAAB, ABDUL/0000-0002-1919-3653; Wang, Xin/0000-0002-7762-1935	Project of Shanghai Science and Technology Development Funds [17391901600]; Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [19ZR1469000]; Central Public-interest Scientific Institution Basal Research Fund [Y2020PT40]	The study was supported by the Project of Shanghai Science and Technology Development Funds (No. 17391901600) awarded to Z.M., the Natural Science Foundation of Shanghai (No. 19ZR1469000) awarded to J.W., and the Central Public-interest Scientific Institution Basal Research Fund (No. Y2020PT40) awarded to J.W. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai S, 2008, JPN J INFECT DIS, V61, P333; Bharati K, 2009, VACCINE, V27, P10, DOI 10.1016/j.vaccine.2008.10.050; Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1; Ding J, 2000, FEMS IMMUNOL MED MIC, V29, P123, DOI 10.1111/j.1574-695X.2000.tb01514.x; Endy TP, 2002, CURR TOP MICROBIOL, V267, P11; Fan YC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004167; Fan YC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001834; Fiedler JD, 2012, BIOMACROMOLECULES, V13, P2339, DOI 10.1021/bm300590x; Fischer Marc, 2010, Morbidity and Mortality Weekly Report, V59, P1; Ge FF, 2007, ARCH VIROL, V152, P125, DOI 10.1007/s00705-006-0822-z; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Hills SL, 2019, MMWR RECOMM REP, V68, P1; Hollidge BS, 2010, J NEUROIMMUNE PHARM, V5, P428, DOI 10.1007/s11481-010-9234-7; HSU ST, 1972, B WORLD HEALTH ORGAN, V46, P465; Hueffer K, 2003, CURR OPIN MICROBIOL, V6, P392, DOI 10.1016/S1369-5274(03)00083-3; Ji PC, 2017, ANTIVIR RES, V139, P146, DOI 10.1016/j.antiviral.2017.01.003; JOO HS, 1976, AUST VET J, V52, P422, DOI 10.1111/j.1751-0813.1976.tb09517.x; Kaur R, 2003, J NEUROVIROL, V9, P421, DOI 10.1080/13550280390218454; Kim JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124318; KONNO J, 1966, AM J EPIDEMIOL, V84, P292, DOI 10.1093/oxfordjournals.aje.a120643; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lin YL, 1998, J VIROL, V72, P191, DOI 10.1128/JVI.72.1.191-200.1998; Liu H, 2012, VECTOR-BORNE ZOONOT, V12, P1042, DOI 10.1089/vbz.2012.0991; Liu WJ, 2013, VIRUS RES, V178, P547, DOI 10.1016/j.virusres.2013.09.002; Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499; Mengeling WL, 2000, ANIM REPROD SCI, V60, P199, DOI 10.1016/S0378-4320(00)00135-4; Pan QX, 2008, VACCINE, V26, P2119, DOI 10.1016/j.vaccine.2008.02.037; Pan QX, 2016, VACCINE, V34, P578, DOI 10.1016/j.vaccine.2015.11.003; Rueda P, 2004, J GEN VIROL, V85, P563, DOI 10.1099/vir.0.19525-0; SCOLNICK EM, 1984, JAMA-J AM MED ASSOC, V251, P2812; Sedlik C, 1997, P NATL ACAD SCI USA, V94, P7503, DOI 10.1073/pnas.94.14.7503; Unni SK, 2011, MICROBES INFECT, V13, P312, DOI 10.1016/j.micinf.2011.01.002; van den Hurk AF, 2009, ANNU REV ENTOMOL, V54, P17, DOI 10.1146/annurev.ento.54.110807.090510; Wang DL, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00232; Wang ND, 2019, VET MICROBIOL, V235, P86, DOI 10.1016/j.vetmic.2019.06.002; Wei JC, 2010, BIOCHEM BIOPH RES CO, V396, P787, DOI 10.1016/j.bbrc.2010.04.133; Wei JC, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104673; Wei JC, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007601; Xiao CG, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0007046; Yang D, 2014, VACCINE, V32, P2675, DOI 10.1016/j.vaccine.2014.03.074; Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052; Young CL, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104675; Yun SI, 2014, HUM VACC IMMUNOTHER, V10, P263, DOI 10.4161/hv.26902; Zhu D, 2008, INFECT IMMUN, V76, P334, DOI 10.1128/IAI.00943-07	46	1	1	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							980	10.3390/vaccines9090980			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW0JQ	34579217	Green Published, gold			2022-04-29	WOS:000699854000001
J	Chan, L; Alizadeh, K; Alizadeh, K; Fazel, F; Kakish, JE; Karimi, N; Knapp, JP; Mehrani, Y; Minott, JA; Morovati, S; Rghei, A; Stegelmeier, AA; Vanderkamp, S; Karimi, K; Bridle, BW				Chan, Lily; Alizadeh, Kasra; Alizadeh, Kimia; Fazel, Fatemeh; Kakish, Julia E.; Karimi, Negar; Knapp, Jason P.; Mehrani, Yeganeh; Minott, Jessica A.; Morovati, Solmaz; Rghei, Amira; Stegelmeier, Ashley A.; Vanderkamp, Sierra; Karimi, Khalil; Bridle, Byram W.			Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration	VACCINES			English	Review						influenza virus; trained immunity; mRNA vaccine; sex-mediated antiviral response	MESSENGER-RNA VACCINES; HOST-RANGE RESTRICTION; SURFACTANT PROTEIN-D; T-CELL RESPONSES; A-VIRUS; GENETIC-CHARACTERIZATION; ANTIBODY-RESPONSES; B VIRUS; DENDRITIC CELLS; HEMAGGLUTININ GENE	Influenza viruses have affected the world for over a century, causing multiple pandemics. Throughout the years, many prophylactic vaccines have been developed for influenza; however, these viruses are still a global issue and take many lives. In this paper, we review influenza viruses, associated immunological mechanisms, current influenza vaccine platforms, and influenza infection, in the context of immunocompromised populations. This review focuses on the qualitative nature of immune responses against influenza viruses, with an emphasis on trained immunity and an assessment of the characteristics of the host-pathogen that compromise the effectiveness of immunization. We also highlight innovative immunological concepts that are important considerations for the development of the next generation of vaccines against influenza viruses.	[Chan, Lily; Fazel, Fatemeh; Kakish, Julia E.; Knapp, Jason P.; Mehrani, Yeganeh; Minott, Jessica A.; Rghei, Amira; Stegelmeier, Ashley A.; Vanderkamp, Sierra; Karimi, Khalil; Bridle, Byram W.] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Alizadeh, Kasra] Univ Illinois, Coll Pharm, Dept Pharmaceut Sci, Chicago, IL 60612 USA; [Alizadeh, Kimia] Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA; [Karimi, Negar; Mehrani, Yeganeh] Ferdowsi Univ Mashhad, Sch Vet Med, Dept Clin Sci, Azadi Sq, Mashhad 9177948974, Razavi Khorasan, Iran; [Morovati, Solmaz] Shiraz Univ, Sch Vet Med, Dept Pathobiol, Div Biotechnol, Shiraz 7144169155, Iran		Karimi, K; Bridle, BW (通讯作者)，Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.	lchan12@uoguelph.ca; kaliza2@uic.edu; kimia@vet.k-state.edu; ffazel@uoguelph.ca; jkakish@uoguelph.ca; n.karimi@mail.um.ac.ir; jknapp03@uoguelph.ca; ymehrani@uoguelph.ca; minott@uoguelph.ca; s.morovati@shirazu.ac.ir; arghei@uoguelph.ca; astegelm@uoguelph.ca; vanderka@uoguelph.ca; kkarimi@uoguelph.ca; bbridle@uoguelph.ca		Karimi, Negar/0000-0001-9951-9651; Bridle, Byram/0000-0002-8335-1118; Alizadeh, Kimia/0000-0002-9096-7463; Mehrani, Yeganeh/0000-0002-3132-9795; Morovati, Solmaz/0000-0002-6269-1228; Minott, Jessica/0000-0002-2065-1869	Pet Trust Foundation [054725]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [04069]; Canadian Cancer Society Research InstituteCanadian Cancer Society (CCS) [705965]; Canadian Institutes of Health Research-Institute of Cancer Research (CIHR-ICR)Canadian Institutes of Health Research (CIHR) [160399]; Cancer Research Society [25222]; Ontario Ministry of Colleges and Universities; National Research Council of Canada	Funding for K.K. was provided by an operating grant (#054725) from the Pet Trust Foundation, awarded 12 June 2020. Funding for B.W.B was provided by a discovery grant (#04069; awarded 1 April 2021) from the Natural Sciences and Engineering Research Council of Canada, an innovation grant that was jointly funded by the Canadian Cancer Society Research Institute (#705965; awarded 1 August 2019) and the Canadian Institutes of Health Research-Institute of Cancer Research (CIHR-ICR; #160399; awarded 1 August 2018), an operating grant from the Cancer Research Society (#25222; awarded 1 September 2018), a grant from the COVID-19 Rapid Research Fund from the Ontario Ministry of Colleges and Universities (awarded 1 March 2020), and a Pandemic Response Challenge Program grant from the National Research Council of Canada (awarded 21 January 2021).	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Agarwal D, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-018-0124-9; Agrawal A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00896; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Allen JC, 2020, VACCINE, V38, P8264, DOI 10.1016/j.vaccine.2020.11.002; Altenburg AF, 2015, VACCINE, V33, P500, DOI 10.1016/j.vaccine.2014.11.054; Anderson TC, 2013, JAVMA-J AM VET MED A, V242, P209, DOI 10.2460/javma.242.2.209; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Arevalo CP, 2020, P NATL ACAD SCI USA, V117, P17221, DOI 10.1073/pnas.1920321117; Ariza-Heredia EJ, 2014, TRANSPL INFECT DIS, V16, P878, DOI 10.1111/tid.12312; Aspinall R, 2000, J CLIN IMMUNOL, V20, P250, DOI 10.1023/A:1006611518223; Avila-Morales S, 2021, INT J INFECT DIS, V105, P763, DOI 10.1016/j.ijid.2021.03.006; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; BLOK J, 1982, BIOCHEMISTRY-US, V21, P4001, DOI 10.1021/bi00260a015; Blumel J, 2009, TRANSFUS MED HEMOTH, V36, P32, DOI 10.1159/000197314; Bodewes R, 2013, EMERG INFECT DIS, V19, P511, DOI 10.3201/eid1903.120965; Bongen E, 2019, CELL REP, V29, P1961, DOI 10.1016/j.celrep.2019.10.019; Brown IH, 1997, J GEN VIROL, V78, P553, DOI 10.1099/0022-1317-78-3-553; Brown IH, 1998, J GEN VIROL, V79, P2947, DOI 10.1099/0022-1317-79-12-2947; Bufan B, 2020, EXP GERONTOL, V133, DOI 10.1016/j.exger.2020.110857; Bulut O, 2020, INT IMMUNOL, V32, P741, DOI 10.1093/intimm/dxaa052; BUONAGURIO DA, 1986, SCIENCE, V232, P980, DOI 10.1126/science.2939560; Caldera F, 2021, VACCINE, V39, pA15, DOI 10.1016/j.vaccine.2020.11.037; Castilla J, 2013, EUROSURVEILLANCE, V18, P17; CASTRUCCI MR, 1993, VIROLOGY, V193, P503, DOI 10.1006/viro.1993.1155; CASTRUCCI MR, 1993, J VIROL, V67, P759, DOI 10.1128/JVI.67.2.759-764.1993; Chang WC, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-64; Chen K, 2013, ANNU REV IMMUNOL, V31, P605, DOI 10.1146/annurev-immunol-032712-100019; Chen XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00320; Chinn IK, 2012, SEMIN IMMUNOL, V24, P309, DOI 10.1016/j.smim.2012.04.005; Choi YK, 2002, VIRUS RES, V87, P173, DOI 10.1016/S0168-1702(02)00053-9; Choi YK, 2005, J VIROL, V79, P10821, DOI 10.1128/JVI.79.16.10821-10825.2005; Ciarlo E, 2020, J INFECT DIS, V222, P1869, DOI 10.1093/infdis/jiz692; COADY JH, 1977, J AM VET MED ASSOC, V170, P668; Cohen J, 2017, SCIENCE, V357, P1222, DOI 10.1126/science.357.6357.1222; Collins JP, 2020, CLIN INFECT DIS, V70, P2121, DOI 10.1093/cid/ciz638; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Cordero E, 2017, CLIN INFECT DIS, V64, P829, DOI 10.1093/cid/ciw855; Cowan M, 2014, TRANSPLANTATION, V97, P846, DOI 10.1097/01.TP.0000438024.10375.2d; Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014; Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407; Crawford PC, 2005, SCIENCE, V310, P482, DOI 10.1126/science.1117950; Crotty S, 2004, SEMIN IMMUNOL, V16, P197, DOI 10.1016/j.smim.2004.02.008; Dalton RM, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-58; Dalziel BD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004455; de Bree CLCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00869; Debisarun P.A., EFFECT INFLUENZA VAC, DOI [10.1101/2020.10.14.20212498v1.full.pdf+html, DOI 10.1101/2020.10.14.20212498V1.FULL.PDF+HTML]; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Dobson AP, 1996, BIOSCIENCE, V46, P115, DOI 10.2307/1312814; DONATELLI I, 1991, J MED VIROL, V34, P248, DOI 10.1002/jmv.1890340410; Dou YL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121258; Doyle TM, 2013, ANTIVIR RES, V100, P567, DOI 10.1016/j.antiviral.2013.09.018; Du YP, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01348-4; Dunham EJ, 2009, J VIROL, V83, P5485, DOI 10.1128/JVI.02565-08; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115; Fink G, 2021, BMJ EVID-BASED MED, V26, DOI 10.1136/bmjebm-2020-111549; Fouchier RAM, 2005, J VIROL, V79, P2814, DOI 10.1128/JVI.79.5.2814-2822.2005; Francis JR M T., 1960, P AM PHILOS SOC, P572; Frasca D, 2008, J IMMUNOL, V180, P5283, DOI 10.4049/jimmunol.180.8.5283; Frasca D, 2016, OBESITY, V24, P615, DOI 10.1002/oby.21383; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Gangappa S, 2019, TRANSPL IMMUNOL, V53, P51, DOI 10.1016/j.trim.2019.01.001; Gao QS, 2008, J VIROL, V82, P6419, DOI 10.1128/JVI.00514-08; GARCON NM, 1990, ANTIVIR RES, V14, P109, DOI 10.1016/0166-3542(90)90048-C; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Grant EJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07815-5; Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7; Green WD, 2017, ANN AM THORAC SOC, V14, pS406, DOI 10.1513/AnnalsATS.201706-447AW; Greenberg DP, 2013, VACCINE, V31, P770, DOI 10.1016/j.vaccine.2012.11.074; Guan Y, 1996, J VIROL, V70, P8041, DOI 10.1128/JVI.70.11.8041-8046.1996; Guevara-Hoyer K, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070203; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hajam IA, 2020, VET RES, V51, DOI 10.1186/s13567-020-00762-4; Hartshorn KL, 2006, J IMMUNOL, V176, P6962, DOI 10.4049/jimmunol.176.11.6962; Hatta M, 2002, TRENDS MICROBIOL, V10, P340, DOI 10.1016/S0966-842X(02)02388-0; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hayward JJ, 2010, J VIROL, V84, P12636, DOI 10.1128/JVI.01350-10; Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Herausragende Charakteristikum D, 2007, BUNDESGESUNDHEITSBLA, V50, P1184; Herndler-Brandstetter D, 2012, J LEUKOCYTE BIOL, V91, P197, DOI 10.1189/jlb.0611299; HERRLER G, 1991, ADV VIRUS RES, V40, P213; Hiromoto Y, 2000, J GEN VIROL, V81, P1293, DOI 10.1099/0022-1317-81-5-1293; HIRST GK, 1953, J EXP MED, V98, P41, DOI 10.1084/jem.98.1.41; Hirzel C, 2021, AM J TRANSPLANT, V21, P2709, DOI 10.1111/ajt.16503; Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]; Holland D, 2008, J INFECT DIS, V198, P650, DOI 10.1086/590434; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Hsu ACY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032947; Hughes K, 2021, CLIN INFECT DIS, V73, pE4353, DOI 10.1093/cid/ciaa1927; Hussain M, 2017, INFECT DRUG RESIST, V10, P121, DOI 10.2147/IDR.S105473; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Ison M.G., 2017, ANTIMICROBIAL DRUG R, P1165, DOI DOI 10.1007/978-3-319-47266-9_23; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Jarvis JR, 2020, VACCINE, V38, P1601, DOI 10.1016/j.vaccine.2019.12.056; Jefferson T, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004879.pub5; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Jeoung HY, 2013, VET MICROBIOL, V165, P281, DOI 10.1016/j.vetmic.2013.03.021; Jewell NA, 2010, J VIROL, V84, P11515, DOI 10.1128/JVI.01703-09; Jiang N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004794; Jung HE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050504; KANEGAE Y, 1990, J VIROL, V64, P2860, DOI 10.1128/JVI.64.6.2860-2865.1990; Kang IS, 2004, J IMMUNOL, V173, P673, DOI 10.4049/jimmunol.173.1.673; Karakus U, 2019, NATURE, V567, P109, DOI 10.1038/s41586-019-0955-3; Karasin AI, 2000, VIRUS RES, V68, P71, DOI 10.1016/S0168-1702(00)00154-4; Karasin AI, 2006, J CLIN MICROBIOL, V44, P1123, DOI 10.1128/JCM.44.3.1123-1126.2006; Karasin AI, 2000, J CLIN MICROBIOL, V38, P2453; Karasin AI, 2002, J CLIN MICROBIOL, V40, P1073, DOI 10.1128/JCM.40.3.1073-1079.2002; Karasin AI, 2004, J CLIN MICROBIOL, V42, P4349, DOI 10.1128/JCM.42.9.4349-4354.2004; Katz J, 2018, CLIN INFECT DIS, V67, P334, DOI 10.1093/cid/ciy090; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; KEITEL WA, 1994, J CLIN MICROBIOL, V32, P2468, DOI 10.1128/JCM.32.10.2468-2473.1994; Kelvin AA, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.48.1900720; KIDA H, 1994, J GEN VIROL, V75, P2183, DOI 10.1099/0022-1317-75-9-2183; KIDA H, 1988, VIROLOGY, V162, P160, DOI 10.1016/0042-6822(88)90405-9; Kim H, 2013, INFLUENZA OTHER RESP, V7, P265, DOI 10.1111/j.1750-2659.2012.00379.x; Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141; Kim TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004204; Kissin E, 1997, J INFECT DIS, V175, P1004, DOI 10.1086/513959; Koerner I, 2007, J VIROL, V81, P2025, DOI 10.1128/JVI.01718-06; Kosaraju R, 2017, J IMMUNOL, V198, P4738, DOI 10.4049/jimmunol.1601031; Kovaiou RD, 2006, IMMUNOL LETT, V107, P8, DOI 10.1016/j.imlet.2006.07.006; Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Kreijtz JHCM, 2011, VIRUS RES, V162, P19, DOI 10.1016/j.virusres.2011.09.022; Kuo HE, 2022, VACCINE, V40, P1634, DOI 10.1016/j.vaccine.2021.02.047; L'Huillier AG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67172-6; La Montagne JR, 2004, NEW ENGL J MED, V351, P2330, DOI 10.1056/NEJMe048314; Lamichhane PP, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8028725; Lawrence CW, 2004, J IMMUNOL, V173, P1209, DOI 10.4049/jimmunol.173.2.1209; Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x; Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368; Lee YJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00083; Lee YN, 2013, J GEN VIROL, V94, P293, DOI [10.1099/vir.0.42473-0, 10.1099/vir.0.042473-0]; Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332; Lekcharoensuk P, 2006, EMERG INFECT DIS, V12, P787; LeVine AM, 2002, AM J PHYSIOL-LUNG C, V282, pL563, DOI 10.1152/ajplung.00280.2001; Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Li ZJ, 2005, J VIROL, V79, P12058, DOI 10.1128/JVI.79.18.12058-12064.2005; Liu M, 2003, AVIAN DIS, V47, P849, DOI 10.1637/0005-2086-47.s3.849; Liu YX, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-37; Liva SM, 2001, J IMMUNOL, V167, P2060, DOI 10.4049/jimmunol.167.4.2060; Lorenzo MMG, 2013, CHEST, V143, P502, DOI 10.1378/chest.12-1711; Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152; Loulergue P, 2008, Ann Oncol, V19, P1658, DOI 10.1093/annonc/mdn531; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; Ma WJ, 2006, J VIROL, V80, P5092, DOI 10.1128/JVI.80.10.5092-5096.2006; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mendez-Legaza JM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010030; Mascola JR, 2020, NAT REV IMMUNOL, V20, P87, DOI 10.1038/s41577-019-0243-3; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999; Mazagatos C, 2020, VACCINE, V38, P8405, DOI 10.1016/j.vaccine.2020.07.014; McGill J, 2008, J EXP MED, V205, P1635, DOI 10.1084/jem.20080314; Meade P, 2020, MBIO, V11, DOI 10.1128/mBio.03243-19; Memoli MJ, 2014, CLIN INFECT DIS, V58, P214, DOI 10.1093/cid/cit725; Milner JJ, 2015, J IMMUNOL, V194, P4846, DOI 10.4049/jimmunol.1402295; Moghadami M, 2017, IRAN J MED SCI, V42, P2; Mondal A, 2017, ELIFE, V6, DOI 10.7554/eLife.26910; Monier A, 2020, MED MALADIES INFECT, V50, P263, DOI 10.1016/j.medmal.2019.11.006; Moon H, 2015, EPIDEMIOL INFECT, V143, P772, DOI 10.1017/S0950268814001617; Morgan R, 2019, CURR OPIN VIROL, V35, P35, DOI 10.1016/j.coviro.2019.02.009; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mosnier A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136186; Mould RC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08665-9; Mourits VP, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/5812743; Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180143; Murcia PR, 2011, J VIROL, V85, P5312, DOI 10.1128/JVI.02619-10; MURPHY BR, 1989, VACCINE, V7, P557, DOI 10.1016/0264-410X(89)90283-1; NAEVE CW, 1984, J VIROL, V51, P567, DOI 10.1128/JVI.51.2.567-569.1984; National Advisory Committee on Immunization, 2020, CAN IMM GUID CHAPT I; Natori Y, 2018, CLIN INFECT DIS, V66, P1698, DOI 10.1093/cid/cix1082; Neidich SD, 2017, INT J OBESITY, V41, P1324, DOI 10.1038/ijo.2017.131; Nerome R, 1998, ARCH VIROL, V143, P1569, DOI 10.1007/s007050050399; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Neumann G, 2006, EMERG INFECT DIS, V12, P881, DOI 10.3201/eid1206.051336; O'Brien KB, 2012, J INFECT DIS, V205, P252, DOI 10.1093/infdis/jir729; Olsen CW, 2006, EMERG INFECT DIS, V12, P1132, DOI 10.3201/eid1207.060268; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Palma P, 2014, HUM VACC IMMUNOTHER, V10, P2083, DOI 10.4161/hv.28698; Pan Q, 2012, J INNATE IMMUN, V4, P312, DOI 10.1159/000335670; Panda A, 2010, J IMMUNOL, V184, P2518, DOI 10.4049/jimmunol.0901022; Pape KA, 1997, J IMMUNOL, V159, P591; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Patel MM, 2020, VACCINE, V38, P608, DOI 10.1016/j.vaccine.2019.10.053; Patel SS, 2019, INT J INFECT DIS, V85, pS26, DOI 10.1016/j.ijid.2019.05.009; Pecoraro HL, 2014, J VET INTERN MED, V28, P311, DOI 10.1111/jvim.12301; Peiris JSM, 2001, J VIROL, V75, P9679, DOI 10.1128/JVI.75.20.9679-9686.2001; PENSAERT M, 1981, B WORLD HEALTH ORGAN, V59, P75; Pepin S, 2019, VACCINE, V37, P1876, DOI 10.1016/j.vaccine.2018.11.074; Peretz J, 2016, AM J PHYSIOL-LUNG C, V310, pL415, DOI 10.1152/ajplung.00398.2015; Perez DR, 2003, AVIAN DIS, V47, P1114, DOI 10.1637/0005-2086-47.s3.1114; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Poon LLM, 2016, NAT GENET, V48, P195, DOI 10.1038/ng.3479; Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256; Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6; Price GE, 2000, J VIROL, V74, P3996, DOI 10.1128/JVI.74.9.3996-4003.2000; Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123; Rajendran M, 2017, MBIO, V8, DOI [10.1128/mBio.02281-16, 10.1128/mbio.02281-16]; Ramos I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00361; Ramos I, 2011, J VIROL, V85, P4421, DOI 10.1128/JVI.02356-10; Ranjeva S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09652-6; Rebuli ME, 2021, AM J RESP CELL MOL, V64, P126, DOI 10.1165/rcmb.2020-0164OC; ROGERS GN, 1983, VIROLOGY, V131, P394, DOI 10.1016/0042-6822(83)90507-X; Rose VL, 1998, AM FAM PHYSICIAN, V58, P567; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; Sage PT, 2015, CELL REP, V12, P163, DOI 10.1016/j.celrep.2015.06.015; Salvatore M, 2007, J INFECT DIS, V196, P835, DOI 10.1086/521027; Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936; Scheuring UJ, 2002, HUM IMMUNOL, V63, P1000, DOI 10.1016/S0198-8859(02)00683-3; SCHOLTISSEK C, 1985, VIROLOGY, V147, P287, DOI 10.1016/0042-6822(85)90131-X; SCHOLTISSEK C, 1983, VIROLOGY, V129, P521, DOI 10.1016/0042-6822(83)90194-0; SCHULTZ U, 1991, VIROLOGY, V183, P61, DOI 10.1016/0042-6822(91)90118-U; Shaw M.L., 2011, FIELDS VIROLOGY ORTH, V6th ed.; Shepherd R, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604000; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Sieczkarski SB, 2003, J VIROL, V77, P460, DOI 10.1128/JVI.77.1.460-469.2003; Simell B, 2011, VACCINE, V29, P1929, DOI 10.1016/j.vaccine.2010.12.121; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; SNYDER MH, 1990, VIRUS RES, V15, P69, DOI 10.1016/0168-1702(90)90014-3; SNYDER MH, 1987, J VIROL, V61, P2857, DOI 10.1128/JVI.61.9.2857-2863.1987; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Song D, 2012, J GEN VIROL, V93, P551, DOI 10.1099/vir.0.037739-0; Song DS, 2003, J VET DIAGN INVEST, V15, P30, DOI 10.1177/104063870301500107; SOVINOVA O, 1958, Acta Virol, V2, P52; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Struijk GH, 2015, TRANSPL INFECT DIS, V17, P192, DOI 10.1111/tid.12368; Su S, 2017, VIRULENCE, V8, P1580, DOI 10.1080/21505594.2017.1365216; Su S, 2012, J VIROL, V86, P10238, DOI 10.1128/JVI.01601-12; SUBBARAO EK, 1993, J VIROL, V67, P1761, DOI 10.1128/JVI.67.4.1761-1764.1993; Tang BM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11249-y; Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; TIAN SF, 1985, J VIROL, V53, P771, DOI 10.1128/JVI.53.3.771-775.1985; Tisa V, 2016, J Prev Med Hyg, V57, pE28; Tong SX, 2012, P NATL ACAD SCI USA, V109, P4269, DOI 10.1073/pnas.1116200109; Tran K., 2020, D34 INFECT IMMUNE RE, P6531; Treanor J, 2004, NEW ENGL J MED, V350, P218, DOI 10.1056/NEJMp038238; Treanor JJ, 2016, NEW ENGL J MED, V375, P1261, DOI 10.1056/NEJMcp1512870; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Tripathi S, 2015, INNATE IMMUN-LONDON, V21, P73, DOI 10.1177/1753425913508992; Tripathi S, 2013, J GEN VIROL, V94, P40, DOI 10.1099/vir.0.045013-0; Tuku B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00697; van de Sandt CE, 2012, VIRUSES-BASEL, V4, P1438, DOI 10.3390/v4091438; van der Velden MVW, 2012, VACCINE, V30, P6127, DOI 10.1016/j.vaccine.2012.07.077; van Eijk M, 2002, AM J RESP CELL MOL, V26, P739, DOI 10.1165/ajrcmb.26.6.4520; Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/s2213-2600(18)30108-5, 10.1016/S2213-2600(18)30108-5]; Vines A, 1998, J VIROL, V72, P7626, DOI 10.1128/JVI.72.9.7626-7631.1998; Voigt EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00180; vom Steeg LG, 2019, SEMIN IMMUNOPATHOL, V41, P189, DOI 10.1007/s00281-018-0718-5; WADDELL GH, 1963, J AM VET MED ASSOC, V143, P587; Wardhana, 2011, Acta Med Indones, V43, P185; WARRELL MJ, 1984, LANCET, V1, P874; Webby RJ, 2004, VIRUS RES, V103, P67, DOI 10.1016/j.virusres.2004.02.015; Webby RJ, 2000, J VIROL, V74, P8243, DOI 10.1128/JVI.74.18.8243-8251.2000; Webby RJ, 2001, PHILOS T R SOC B, V356, P1817, DOI 10.1098/rstb.2001.0997; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0; Webster RG, 2014, ANN NY ACAD SCI, V1323, P115, DOI 10.1111/nyas.12462; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.immunol.8.1.737; Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14; Wong KC, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3681-4; Worobey M, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038471; Wright PF, 2004, CLIN INFECT DIS, V39, P928, DOI 10.1086/423003; Wu WX, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6808934; Wu Y, 2014, TRENDS MICROBIOL, V22, P183, DOI 10.1016/j.tim.2014.01.010; Xia C, 2016, J VIROL, V90, P2403, DOI 10.1128/JVI.02749-15; Xu CT, 2004, MICROBES INFECT, V6, P919, DOI 10.1016/j.micinf.2004.04.015; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; Young B, 2017, VACCINE, V35, P212, DOI 10.1016/j.vaccine.2016.11.013; Zhou NN, 1999, J VIROL, V73, P8851, DOI 10.1128/JVI.73.10.8851-8856.1999; Zhu LL, 2018, J INFECT DIS, V217, P428, DOI 10.1093/infdis/jix475; Zivkovic I, 2015, VACCINE, V33, P5546, DOI 10.1016/j.vaccine.2015.09.006	287	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							979	10.3390/vaccines9090979			33	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW1IX	34579216	Green Published, gold			2022-04-29	WOS:000699919800001
J	Ding, YZ; Wubshet, AK; Ding, XL; Zhang, ZW; Li, Q; Dai, JF; Hou, Q; Hu, YH; Zhang, J				Ding, Yaozhong; Wubshet, Ashenafi Kiros; Ding, Xiaolong; Zhang, Zhongwang; Li, Qian; Dai, Junfei; Hou, Qian; Hu, Yonghao; Zhang, Jie			Evaluation of Four Commercial Vaccines for the Protection of Piglets against the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus (hp-PRRSV) QH-08 Strain	VACCINES			English	Article						PRRSV; phylogenetic analysis; vaccine efficacy; vaccine design ORF1a-1bs of PRRSV; piglets	GENETIC DIVERSITY; EFFICACY; DISEASE	Vaccination is the best way to prevent economic losses from highly pathogenic porcine reproductive and respiratory syndrome virus (hp-PRRSV) disease. However, the commercially available vaccines need to periodically evaluate their efficacy against infections caused by new hp-PRRSV variants. Therefore, the objective of this study was to evaluate the efficacy of four (two modified live vaccines (MLV) and two inactivated) PRRSV commercial vaccines in piglets challenged with QH-08 and to estimate the genetic distance of the vaccine strains from recently isolated (QH-08) filed strain. Randomly, piglets (n = 5) allocated in groups 1-4 were immunized with Ingelvac PRRS MLV, CH-1a, JXA1, and JXA1-RMLV vaccines, whereas the infected and non-infected control piglets in groups 5 and 6 (n = 3), respectively, were subjected to PBS. Results indicated that JXA1 and JXA1-R MLV vaccines showed complete protection, but Ingelvac PRRS MLV and CH-1 alpha vaccines revealed partial protection against the QH-08 PRRSV challenge. Similarly, vaccinated and challenged pigs showed lower macroscopic and microscopic lesions than the pigs in group 5. Our findings demonstrated a new insight that the variation in ORF1a and 1b coding sequence could significantly affect PRRSV vaccines efficacy. In conclusion, QH-08 is a good candidate for the design and development of an innovative PRRSV vaccine that ultimately helps in the control and prevention strategies.	[Ding, Yaozhong; Wubshet, Ashenafi Kiros; Ding, Xiaolong; Zhang, Zhongwang; Li, Qian; Dai, Junfei; Hou, Qian; Zhang, Jie] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Natl Foot & Mouth Dis Reference Lab, Lanzhou 730046, Peoples R China; [Ding, Yaozhong; Hu, Yonghao] Gansu Agr Univ, Coll Vet Med, Lanzhou 730070, Peoples R China; [Wubshet, Ashenafi Kiros] Mekelle Univ, Coll Vet Sci, Dept Basic & Diagnost Sci, Mekelle 280, Ethiopia; [Zhang, Jie] Hebei Normal Univ Sci & Technol, Qinhuangdao 066004, Hebei, Peoples R China		Ding, YZ; Zhang, J (通讯作者)，Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Natl Foot & Mouth Dis Reference Lab, Lanzhou 730046, Peoples R China.; Ding, YZ (通讯作者)，Gansu Agr Univ, Coll Vet Med, Lanzhou 730070, Peoples R China.; Zhang, J (通讯作者)，Hebei Normal Univ Sci & Technol, Qinhuangdao 066004, Hebei, Peoples R China.	dingyaozhong@caas.cn; nafikw@gmail.com; dyz1953@126.com; zhangzhongwang@caas.cn; qanli985@163.com; aixinjueluofei@hotmail.com; qianh910@163.com; yhh0817@126.com; Zhanglie03@caas.cn		Wubshet, Ashenafi Kiros/0000-0002-9008-2075	Gansu Province Key RD Program [20YF3NA005]; National Key Research and Development Program of China [2017YFD0501800, 2016YFD0501500]; National Pig Industrial System [CARS-36-06B]; Science and Technology Cooperation Program of Gansu Province [1504NKC054-5]	This work was supported in part by grants from Gansu Province Key R&D Program (20YF3NA005), the National Key Research and Development Program of China (2017YFD0501800 and 2016YFD0501500), the National Pig Industrial System (CARS-36-06B), and the Science and Technology Cooperation Program of Gansu Province (No. 1504NKC054-5). The funders had no role in study design, data collection, analysis and interpretation, the decision to publish, or manuscript preparation.	An TQ, 2007, VET MICROBIOL, V123, P43, DOI 10.1016/j.vetmic.2007.02.025; Charoenchanikran P, 2016, TROP ANIM HEALTH PRO, V48, P1351, DOI 10.1007/s11250-016-1099-1; COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201; Darwich L, 2011, VET MICROBIOL, V150, P49, DOI 10.1016/j.vetmic.2011.01.008; Ding YZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/765320; Ding YZ, 2020, J BASIC MICROB, V60, P400, DOI 10.1002/jobm.201900485; Do DT, 2015, VET MICROBIOL, V179, P233, DOI 10.1016/j.vetmic.2015.06.013; Guo ZH, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0910-6; Jiang YF, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00618; Kim WI, 2013, VET MICROBIOL, V162, P10, DOI 10.1016/j.vetmic.2012.08.005; Kuhn JH, 2016, ARCH VIROL, V161, P755, DOI 10.1007/s00705-015-2672-z; Labarque G, 2004, VACCINE, V22, P4183, DOI 10.1016/j.vaccine.2004.05.008; Li C, 2016, TRANSBOUND EMERG DIS, V63, P474, DOI 10.1111/tbed.12530; Li X, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/416727; Liu YS, 2010, INFECT GENET EVOL, V10, P797, DOI 10.1016/j.meegid.2010.04.010; Mengeling WL, 1999, AM J VET RES, V60, P334; Sirisereewan C, 2018, TROP ANIM HEALTH PRO, V50, P1509, DOI 10.1007/s11250-018-1589-4; Snijder EJ, 2013, J GEN VIROL, V94, P2141, DOI 10.1099/vir.0.056341-0; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/oxfordjournals.molbev.a040023]; Thanawongnuwech R, 1998, VET PATHOL, V35, P398, DOI 10.1177/030098589803500509; Wang AP, 2019, EMERG INFECT DIS, V25, P2335, DOI 10.3201/eid2512.191111; Wei ZZ, 2013, VACCINE, V31, P2062, DOI 10.1016/j.vaccine.2013.02.012; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Yu XL, 2015, CLIN VACCINE IMMUNOL, V22, P493, DOI 10.1128/CVI.00722-14; Zhao HJ, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0735-3; Zhou L, 2010, VIRUS RES, V154, P31, DOI 10.1016/j.virusres.2010.07.016	26	1	1	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1020	10.3390/vaccines9091020			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2UK	34579257	Green Published, gold			2022-04-29	WOS:000702065200001
J	Lin, SY; Jing, ZY; Howard, N; Chantler, T; Cheng, JJ; Zhang, SY; Zhou, CC; Sun, M				Lin, Shiyu; Jing, Zhengyue; Howard, Natasha; Chantler, Tracey; Cheng, Jiejie; Zhang, Shiya; Zhou, Chengchao; Sun, Mei			Associations of Elements of Parental Social Integration with Migrant Children's Vaccination: An Epidemiological Analysis of National Survey Data in China	VACCINES			English	Article						vaccination; migrant; children; social integration; China	CHILDHOOD IMMUNIZATION; MIGRATION; HEALTH; COVERAGE	Our study explored the effects of parental social integration on migrant children's vaccination status in China. Using data obtained from the 2014 China Migrants Dynamic Survey, a total of 4915 participants were included in this study. Social integration was measured by economic, social, cultural, and internal identity. Univariate chi-square testing was used to calculate associations between all variables and migrant children's vaccination status. Binary logistic regression was employed to calculate the impacts of social integration on migrant children's vaccination status. In total, 94.7% of migrant children had complete vaccinations for their age. Migrants who had medical insurance, spoke the native language when communicating with locals, lived mainly with locals, and did not perceive discrimination were more likely to have their children completely vaccinated. Social integration was positively associated with migrant children's vaccination status. Our study indicated that to improve vaccination coverage of migrant children, more policy support for migrant employment and housing, promotion of health services for migrants, and language support in health institutions is needed.	[Lin, Shiyu; Zhang, Shiya; Sun, Mei] Fudan Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Lin, Shiyu; Cheng, Jiejie; Zhang, Shiya; Sun, Mei] Fudan Univ, NHC Key Lab Hlth Technol Assessment, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Jing, Zhengyue] Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China; [Jing, Zhengyue; Zhou, Chengchao] Shandong Univ, Ctr Hlth Management & Policy, Sch Publ Hlth, Cheeloo Coll Med, Jinan 250012, Peoples R China; [Howard, Natasha; Chantler, Tracey] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, 15-17 Tavistock Pl, London WC1H 9SH, England; [Howard, Natasha] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2, Singapore 117549, Singapore; [Zhou, Chengchao] Shandong Univ, NHC Key Lab Hlth Econ & Policy Res, 44 Wen hua xi Rd, Jinan 250012, Peoples R China		Sun, M (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 130 Dongan Rd, Shanghai 200032, Peoples R China.; Sun, M (通讯作者)，Fudan Univ, NHC Key Lab Hlth Technol Assessment, 130 Dongan Rd, Shanghai 200032, Peoples R China.; Zhou, CC (通讯作者)，Shandong Univ, Ctr Hlth Management & Policy, Sch Publ Hlth, Cheeloo Coll Med, Jinan 250012, Peoples R China.; Zhou, CC (通讯作者)，Shandong Univ, NHC Key Lab Hlth Econ & Policy Res, 44 Wen hua xi Rd, Jinan 250012, Peoples R China.	20211020128@fudan.edu.cn; jingzhengyue@mail.sdu.edu.cn; natasha.howard@nus.edu.sg; Tracey.Chantler@lshtm.ac.uk; 18211020050@fudan.edu.cn; 20211020100@fudan.edu.cn; zhouchengchao@sdu.edu.cn; sunmei@fudan.edu.cn		sun, mei/0000-0001-5987-5977; Chantler, Tracey/0000-0001-7776-7339; Howard, Natasha/0000-0003-4174-7349; Zhou, Chengchao/0000-0002-9364-3579	National Institute for Health ResearchNational Institute for Health Research (NIHR) [EPIDZL9012]; UK Government; National Institute for Health Research Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71974035]; Ministry of Education of Humanities and Social Science project [19YJCZH143]; Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) [GWV-10.1-XK23]; National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71974117, 71774104, 71473152]; Chinese Medical Board [CMB-16-257]; Shandong University [IFYT1810, 2012DX006]; National University of Singapore Saw Swee Hock School of Public HealthNational University of Singapore; Cheeloo Youth Scholar Grant; Public Health England (PHE)	This research was funded by the National Institute for Health Research (reference EPIDZL9012), using aid from the UK Government to support global health research and was supported by the National Institute for Health Research Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine, in partnership with Public Health England (PHE). The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. MS was supported by the National Natural Science Foundation of China (71974035), the Ministry of Education of Humanities and Social Science project (19YJCZH143), and the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) (GWV-10.1-XK23). CZ was supported by the National Science Foundation of China (71974117, 71774104, 71473152), Chinese Medical Board (CMB-16-257), Cheeloo Youth Scholar Grant, and Shandong University (IFYT1810, 2012DX006). NH was funded by the National University of Singapore Saw Swee Hock School of Public Health. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, UK Department of Health and Social Care, NHS, PHE, or any other funders. Funders had no input into study design, implementation, analysis, or conclusions.	Antai D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-181; BARRETO TV, 1992, J EPIDEMIOL COMMUN H, V46, P357, DOI 10.1136/jech.46.4.357; Borrell C, 2015, INT J ENV RES PUB HE, V12, P10687, DOI 10.3390/ijerph120910687; Fang H, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-016-0504-8; Fleischman Y, 2015, SOC SCI MED, V147, P89, DOI 10.1016/j.socscimed.2015.10.046; [郭静 Guo Jing], 2016, [中国卫生政策研究, Chinese Journal of Health Policy], V9, P75; Han K, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-203; Hosseinpoor AR, 2016, LANCET GLOB HEALTH, V4, pE617, DOI 10.1016/S2214-109X(16)30141-3; Kagone M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5244-9; Kiros GE, 2004, SOC SCI MED, V59, P2603, DOI 10.1016/j.socscimed.2004.04.009; Koumare AK, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S13; Kusuma YS, 2010, TROP MED INT HEALTH, V15, P1326, DOI 10.1111/j.1365-3156.2010.02628.x; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Martinez O, 2016, J IMMIGR MINOR HEALT, V18, P288, DOI 10.1007/s10903-014-9976-z; McKay M.A., 2016, THESIS OHIO STATE U; Mikolajczyk RT, 2008, INT J PUBLIC HEALTH, V53, P180, DOI 10.1007/s00038-008-8002-4; NHC, 2015, CHIN MIGR POP DEV RE; Pan YingZi, 2012, Modern Preventive Medicine, V39, P4266; Park Y, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-19; Simonnot N., 2016, ACCESS HEALTHCARE PE; Sun M, 2019, J PUBLIC HEALTH-UK, V41, P158, DOI 10.1093/pubmed/fdy015; Tao X, 2019, J SICHUAN U SCI ENG, V34, P18, DOI [10.11965/xbew20190302, DOI 10.11965/XBEW20190302]; WHO, SAGE ISS ITS 2018 AS; Yang J., 2010, POPULATION EC, V2, P64; Zhang Cong, 2015, Modern Preventive Medicine, V42, P1519; Zhang YanXia, 2011, Occupation and Health, V27, P1021; Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0; Zhou H., 2012, POPUL RES, V36, P27; Zimmerman C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001034	29	1	1	7	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							884	10.3390/vaccines9080884			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4YN	34452009	Green Published, gold, Green Accepted			2022-04-29	WOS:000689938500001
J	Penkert, RR; Chandramouli, S; Dormitzer, PR; Settembre, EC; Sealy, RE; Wong, SS; Young, NS; Sun, YL; Tang, L; Cotton, A; Dowdy, J; Hayden, RT; Hankins, JS; Hurwitz, JL				Penkert, Rhiannon R.; Chandramouli, Sumana; Dormitzer, Philip R.; Settembre, Ethan C.; Sealy, Robert E.; Wong, Susan; Young, Neal S.; Sun, Yilun; Tang, Li; Cotton, Alyssa; Dowdy, Jola; Hayden, Randall T.; Hankins, Jane S.; Hurwitz, Julia L.			Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease	VACCINES			English	Article						parvovirus B19; VP1u; neutralization assay; aplastic crisis; sickle cell disease; vaccine; enzyme-linked immunosorbent assay	HUMAN MONOCLONAL-ANTIBODIES; APLASTIC CRISIS; IDENTIFICATION; GENERATION; EPITOPE; REGION; CAPSIDS; UNIQUE	Children with sickle cell disease (SCD) suffer life-threatening transient aplastic crisis (TAC) when infected with parvovirus B19. In utero, infection of healthy fetuses may result in anemia, hydrops, and death. Unfortunately, although promising vaccine candidates exist, no product has yet been licensed. One barrier to vaccine development has been the lack of a cost-effective, standardized parvovirus B19 neutralization assay. To fill this void, we evaluated the unique region of VP1 (VP1u), which contains prominent targets of neutralizing antibodies. We discovered an antigenic cross-reactivity between VP1 and VP2 that, at first, thwarted the development of a surrogate neutralization assay. We overcame the cross-reactivity by designing a mutated VP1u (VP1uAT) fragment. A new VP1uAT ELISA yielded results well correlated with neutralization (Spearman's correlation coefficient = 0.581; p = 0.001), superior to results from a standard clinical diagnostic ELISA or an ELISA with virus-like particles. Virus-specific antibodies from children with TAC, measured by the VP1uAT and neutralization assays, but not other assays, gradually increased from days 0 to 120 post-hospitalization. We propose that this novel and technically simple VP1uAT ELISA might now serve as a surrogate for the neutralization assay to support rapid development of a parvovirus B19 vaccine.	[Penkert, Rhiannon R.; Sealy, Robert E.; Hurwitz, Julia L.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; [Chandramouli, Sumana; Dormitzer, Philip R.; Settembre, Ethan C.] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA; [Wong, Susan; Young, Neal S.] NHLBI, Hematol Branch, Bethesda, MD 20892 USA; [Sun, Yilun; Tang, Li] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Cotton, Alyssa; Dowdy, Jola; Hankins, Jane S.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA; [Hayden, Randall T.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Hurwitz, Julia L.] Univ Tennessee, Dept Microbiol Immunol & Biochem, Hlth Sci Ctr, Memphis, TN 38163 USA; [Penkert, Rhiannon R.] Univ Oregon, Eugene, OR 97403 USA; [Chandramouli, Sumana] Moderna Therapeut, Cambridge, MA 02139 USA; [Dormitzer, Philip R.] Pfizer Vaccine Res & Dev, Pearl River, NY 10965 USA; [Settembre, Ethan C.] Seqirus, Cambridge, MA 02139 USA; [Dowdy, Jola] St Jude Childrens Res Hosp, Bone Marrow Transplant & Cellular Therapy, Memphis, TN 38105 USA		Hurwitz, JL (通讯作者)，St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.; Hurwitz, JL (通讯作者)，Univ Tennessee, Dept Microbiol Immunol & Biochem, Hlth Sci Ctr, Memphis, TN 38163 USA.	rpenkert@uoregon.edu; sumana.chandramouli@gmail.com; philip.dormitzer@pfizer.com; ethan.settembre@seqirus.com; bob.sealy@stjude.org; wongsu@nhlbi.nih.gov; youngns@nhlbi.nih.gov; yilun.sun@stjude.org; li.tang@stjude.org; alyssa.cotton@stjude.org; jola.dowdy@stjude.org; randall.hayden@stjude.org; jane.hankins@stjude.org; julia.hurwitz@stjude.org		Chandramouli, Sumana/0000-0001-6994-506X; Dormitzer, Philip/0000-0003-0671-6360	NIH NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA21765]; Children's Infection Defense Center at St. Jude Children's Research Hospital; Intramural Research Program of NHLBI, NIH; Novartis Vaccines and Diagnostics; ALSACAmerican Lebanese Syrian Associated Charities (ALSAC)	We thank Denise Thurber for assistance with the neutralization assay using The work was supported in part by NIH NCI [P30CA21765], the Children's Infection Defense Center at St. Jude Children's Research Hospital, ALSAC, the Intramural Research Program of NHLBI, NIH, and Novartis Vaccines and Diagnostics.	ARAKELOV S, 1993, J INFECT DIS, V168, P580, DOI 10.1093/infdis/168.3.580; Bernstein DI, 2011, VACCINE, V29, P7357, DOI 10.1016/j.vaccine.2011.07.080; Bostic JR, 1999, J INFECT DIS, V179, P619, DOI 10.1086/314648; Chandramouli S, 2013, VACCINE, V31, P3872, DOI 10.1016/j.vaccine.2013.06.062; Gigler A, 1999, J VIROL, V73, P1974, DOI 10.1128/JVI.73.3.1974-1979.1999; Hankins JS, 2016, EXP BIOL MED, V241, P749, DOI 10.1177/1535370216636723; KAJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646, DOI 10.1073/pnas.88.11.4646; KELLEHER JF, 1984, AM J DIS CHILD, V138, P401, DOI 10.1001/archpedi.1984.02140420067020; LOUGHREY AC, 1993, J MED VIROL, V39, P97, DOI 10.1002/jmv.1890390204; Oakley J, 2018, AM J HEMATOL, V93, pE198, DOI 10.1002/ajh.25140; Ogunsile FJ, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26767; ONEILL HJ, 1992, ARCH VIROL, V123, P125, DOI 10.1007/BF01317143; Penkert RR, 2017, VACCINE, V35, P3615, DOI 10.1016/j.vaccine.2017.05.022; Qiu JM, 2017, CLIN MICROBIOL REV, V30, P43, DOI 10.1128/CMR.00040-16; RAO SP, 1992, AM J DIS CHILD, V146, P1328, DOI 10.1001/archpedi.1992.02160230086025; ROSENFELD SJ, 1992, J CLIN INVEST, V89, P2023, DOI 10.1172/JCI115812; SAIKAWA T, 1993, J VIROL, V67, P3004, DOI 10.1128/JVI.67.6.3004-3009.1993; SATO H, 1991, J VIROL, V65, P1667, DOI 10.1128/JVI.65.4.1667-1672.1991; SATO H, 1991, J VIROL, V65, P5485, DOI 10.1128/JVI.65.10.5485-5490.1991; Smith-Whitley K, 2004, BLOOD, V103, P422, DOI 10.1182/blood-2003-01-0069; WONG S, 1994, J VIROL, V68, P4690, DOI 10.1128/JVI.68.7.4690-4694.1994; Wong S, 2008, J VIROL, V82, P2470, DOI 10.1128/JVI.02247-07; Wong S, 2006, J CLIN VIROL, V35, P407, DOI 10.1016/j.jcv.2005.12.008; YOSHIMOTO K, 1991, J VIROL, V65, P7056, DOI 10.1128/JVI.65.12.7056-7060.1991; Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840	25	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							860	10.3390/vaccines9080860			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3GM	34451986	Green Published, gold			2022-04-29	WOS:000689824000001
J	Stasiuk, K; Polak, M; Dolinski, D; Maciuszek, J				Stasiuk, Katarzyna; Polak, Mateusz; Dolinski, Dariusz; Maciuszek, Jozef			The Credibility of Health Information Sources as Predictors of Attitudes toward Vaccination-The Results from a Longitudinal Study in Poland	VACCINES			English	Article						attitude towards vaccination; trust in physicians; trust in science; Internet as the source of health information; COVID-19	KNOWLEDGE; SCIENCE; SKEPTICISM; CHALLENGE; HESITANCY; MOVEMENT; INTERNET; IMPACT; TRUST; CARE	Background: The research focused on the relationships between attitudes towards vaccination and the trust placed in different sources of information (science, experts and the information available on the Internet) before and during COVID-19. Method: A longitudinal design was applied with the first measurement in February 2018 (N = 1039). The second measurement (N = 400) was carried out in December 2020 to test if the pandemic influenced the trust in different sources of information. Results: The final analyses carried out on final sample of 400 participants showed that there has been no change in trust in the Internet as a source of knowledge about health during the pandemic. However, the trust in science, physicians, subjective health knowledge, as well as the attitude towards the vaccination has declined. Regression analysis also showed that changes in the level of trust in physicians and science were associated with analogous (in the same direction) changes in attitudes toward vaccination. The study was also focused on the trust in different sources of health knowledge as possible predictors of willingness to be vaccinated against SARS-nCoV-2. However, it appeared that the selected predictors explained a small part of the variance. This suggests that attitudes toward the new COVID vaccines may have different sources than attitudes toward vaccines that have been known to the public for a long time.	[Stasiuk, Katarzyna; Polak, Mateusz; Maciuszek, Jozef] Jagiellonian Univ, Inst Appl Psychol, PL-31007 Krakow, Poland; [Dolinski, Dariusz] SWPS Univ Social Sci & Humanities, Dept Psychol Wroclaw, PL-03815 Warsaw, Poland		Stasiuk, K (通讯作者)，Jagiellonian Univ, Inst Appl Psychol, PL-31007 Krakow, Poland.	katarzyna.stasiuk@uj.edu.pl; mateusz.polak@uj.edu.pl; ddolinsk@swps.edu.pl; jozef.maciuszek@uj.edu.pl		Dolinski, Dariusz/0000-0002-4225-4258; Stasiuk, Katarzyna/0000-0003-4627-2557	SWPS University of Social Sciences and Humanities; Institute of Applied Psychology at Jagiellonian University - Polish Ministry of Science and Higher Education; Priority Research Area Society of the Future under the program "Excellence Initiative-Research University" at the Jagiellonian University in Krakow	The research and the publication was financed by the funds from the SWPS University of Social Sciences and Humanities and Institute of Applied Psychology at Jagiellonian University awarded by the Polish Ministry of Science and Higher Education in the form of a subvention for maintaining and developing research potential in 2018 and 2020. The proofreading of the publication was funded by the Priority Research Area Society of the Future under the program "Excellence Initiative-Research University" at the Jagiellonian University in Krakow.	Adamed, POTR ZDROW SEN PODCZ; Alba JW, 2000, J CONSUM RES, V27, P123, DOI 10.1086/314317; Baker DW, 2020, JAMA-J AM MED ASSOC, V324, P2373, DOI 10.1001/jama.2020.23343; Bechini A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060564; Broom A, 2005, J SOCIOL, V41, P87, DOI 10.1177/1440783305050965; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Carlson JP, 2009, J CONSUM RES, V35, P864, DOI 10.1086/593688; Czajka H, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124461; de Bruin WB, 2020, AM J PREV MED, V59, P157, DOI 10.1016/j.amepre.2020.05.001; Diviani N, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4018; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dunning D, 2011, ADV EXP SOC PSYCHOL, V44, P247, DOI 10.1016/B978-0-12-385522-0.00005-6; Eyal G., 2019, CRISIS EXPERTISE; Farias M, 2013, J EXP SOC PSYCHOL, V49, P1210, DOI 10.1016/j.jesp.2013.05.008; Hakim MS, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2222; Hardey M, 1999, SOCIOL HEALTH ILL, V21, P820, DOI 10.1111/1467-9566.00185; Hardt K, 2013, VACCINES-BASEL, V1, P204, DOI 10.3390/vaccines1030204; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Hossain F, 2021, DEV WORLD BIOETH, V21, P187, DOI 10.1111/dewb.12291; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Kundi M, 2015, CURR DRUG SAF, V10, P16, DOI 10.2174/157488631001150407104320; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Lavazza A, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00356; Lewandowsky S, 2013, PSYCHOL SCI, V24, P622, DOI 10.1177/0956797612457686; Lewis D, 2020, NATURE, V580, P175, DOI 10.1038/d41586-020-00974-w; Manika Danae, 2017, Health Mark Q, V34, P247, DOI 10.1080/07359683.2017.1375236; McConnell AR, 2008, J PERS SOC PSYCHOL, V94, P792, DOI 10.1037/0022-3514.94.5.792; Motta M, 2018, SOC SCI MED, V211, P274, DOI 10.1016/j.socscimed.2018.06.032; Nagler RH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240776; Nagy P, 2020, SCI ENG ETHICS, V26, P737, DOI 10.1007/s11948-019-00121-3; Nichols Tom M., 2017, DEATH EXPERTISE CAMP; Pahus L, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00509-y; Pillai KG, 2015, EUR J MARKETING, V49, P82, DOI 10.1108/EJM-05-2012-0288; Rutjens BT, 2021, GROUP PROCESS INTERG, V24, P276, DOI 10.1177/1368430220981415; Rutjens BT, 2018, ADV EXP SOC PSYCHOL, V57, P125, DOI 10.1016/bs.aesp.2017.08.001; Rutjens BT, 2018, PERS SOC PSYCHOL B, V44, P384, DOI 10.1177/0146167217741314; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Shanteau J, 2001, EXP RES APPL, P229; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Sobkow A, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.582720; Ward JK, 2016, HUM VACC IMMUNOTHER, V12, P1924, DOI 10.1080/21645515.2016.1146430; Watson S., 2005, TRUST RISK UNCERTAIN; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	45	2	2	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							933	10.3390/vaccines9080933			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7GC	34452058	Green Published, gold			2022-04-29	WOS:000690093400001
J	Alberca, RW; Gomes, E; Russo, M				Alberca, Ricardo Wesley; Gomes, Eliane; Russo, Momtchilo			CpG-ODN Signaling via Dendritic Cells-Expressing MyD88, but Not IL-10, Inhibits Allergic Sensitization	VACCINES			English	Article						allergic sensitization; eosinophils; dendritic cells; CpG-ODN; toll-like receptor; MyD88; IL-10	INDUCED EOSINOPHIL RECRUITMENT; INTERFERON-GAMMA; AIRWAY HYPERRESPONSIVENESS; T-CELLS; B-CELLS; ANTIGEN; RESPONSES; CYTOKINE; OLIGONUCLEOTIDE; INFLAMMATION	Allergen-specific T helper (Th)2 cells orchestrate upon allergen challenge the development of allergic eosinophilic lung inflammation. Sensitization with alum adjuvant, a type 2 adjuvant, has been used extensively in animal models of allergic lung disease. In contrast, type 1 adjuvants like CpG-ODN, a synthetic toll-like receptor 9 agonist, inhibit the development of Th2 immunity. CpG-ODN induce type 1 and suppressive cytokines that influence Th2 cell differentiation. Here, we investigated the immune modulatory effect of CpG-ODN on allergic sensitization to OVA with alum focusing on dendritic cells (DCs) expressing the MyD88 molecule and the suppressive IL-10 cytokine. Using mice with specific cell deletion of MyD88 molecule, we showed that CpG-ODN suppressed allergic sensitization and consequent lung allergic inflammation signaling through the MyD88 pathway on dendritic cells, but not on B-cells. This inhibition was associated with an increased production of IL-10 in the bronchoalveolar lavage fluid. Sensitization to OVA with CpG-ODN of IL-10-deficient, but not wild-type mice, induced a shift towards Th1 pattern of inflammation. Employing bone marrow-derived dendritic cells (BM-DCs) pulsed with OVA for sensitizations with or without CpG-ODN, we showed that IL-10 is dispensable for the inhibition of allergic lung Th2 responses by CpG-ODN. Moreover, the lack of IL-10 on DCs was not sufficient for the CpG-ODN-induced immune-deviation towards a Th1 pattern. Accordingly, we confirmed directly the role of MyD88 pathway on DCs in the inhibition of allergic sensitization.	[Alberca, Ricardo Wesley; Gomes, Eliane; Russo, Momtchilo] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil; [Alberca, Ricardo Wesley] Univ Sao Paulo, Fac Med FMUSP, Inst Trop Med, Dept Dermatol,Lab Dermatol & Immunodeficiencies L, BR-01246903 Sao Paulo, Brazil		Russo, M (通讯作者)，Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil.	ricardowesley@usp.br; momrusso@usp.br; melloeag@usp.br		Alberca, Ricardo Wesley/0000-0002-3602-3306	 [2013/24694-1];  [2019/02679-7]	The Sao Paulo Research Foundation-FAPESP-funded this research, grants number 2013/24694-1 and 2019/02679-7.	Custodio RWA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101165; Alcaide EG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040409; Bagaev A, 2018, J IMMUNOL, V200, P2656, DOI 10.4049/jimmunol.1701126; Besnard AG, 2011, ALLERGY, V66, P1047, DOI 10.1111/j.1398-9995.2011.02586.x; Bouaziz JD, 2010, EUR J IMMUNOL, V40, P2686, DOI 10.1002/eji.201040673; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Eisenbarth SC, 2008, CLIN EXP ALLERGY, V38, P1572, DOI 10.1111/j.1365-2222.2008.03069.x; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Esterhazy D, 2016, NAT IMMUNOL, V17, P545, DOI 10.1038/ni.3408; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Fonseca DM, 2015, ALLERGY, V70, P275, DOI 10.1111/all.12555; Fu CM, 2020, P NATL ACAD SCI USA, V117, P23730, DOI 10.1073/pnas.2002345117; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hoene V, 2006, J LEUKOCYTE BIOL, V80, P1328, DOI 10.1189/jlb.0106011; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Humeniuk P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071491; Hyer R, 2018, VACCINE, V36, P2604, DOI 10.1016/j.vaccine.2018.03.067; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Jay DC, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0473-1; Karacs J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040321; Kowalewicz-Kulbat M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030277; Koya T, 2009, AM J RESP CELL MOL, V41, P271, DOI 10.1165/rcmb.2008-0256OC; Kushwah R, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-20; Lack G, 1996, J IMMUNOL, V157, P1432; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Matisz CE, 2017, SCI REP-UK, V7, DOI 10.1038/srep40631; Min ZH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.595369; Mirotti LC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00047; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; NAKAJIMA H, 1993, AM REV RESPIR DIS, V148, P1102, DOI 10.1164/ajrccm/148.4_Pt_1.1102; Nunes FPB, 2019, J LEUKOCYTE BIOL, V106, P653, DOI 10.1002/JLB.MA1218-475RR; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Ren SR, 2018, INT IMMUNOPHARMACOL, V64, P69, DOI 10.1016/j.intimp.2018.08.026; Samarasinghe R, 2006, J INTERF CYTOK RES, V26, P893, DOI 10.1089/jir.2006.26.893; Satitsuksanoa P., 2020, ALLERGY EUR J ALLERG, V76, P1707; Schmitt H, 2020, J CROHNS COLITIS, V14, P508, DOI 10.1093/ecco-jcc/jjz170; Shirota H, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P163, DOI 10.1016/B978-0-12-804019-5.00009-8; Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002; Thomas SY, 2018, MUCOSAL IMMUNOL, V11, P796, DOI 10.1038/mi.2017.84; Trujillo-Vargas CM, 2005, INT ARCH ALLERGY IMM, V137, P219, DOI 10.1159/000086334; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; Vicari AP, 2002, J EXP MED, V196, P541, DOI 10.1084/jem.20020732; Waibler Z, 2008, EUR J IMMUNOL, V38, P3127, DOI 10.1002/eji.200838184; Wang WG, 2016, MED SCI MONITOR, V22, P244, DOI 10.12659/MSM.896951; Xu K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70467-3; Yoshida M, 2002, AM J RESP CRIT CARE, V166, P451, DOI 10.1164/rccm.200202-095OC; Zakeri A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01027; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	48	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							743	10.3390/vaccines9070743			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7XJ	34358159	Green Published, gold			2022-04-29	WOS:000677119000001
J	Amodio, E; Capra, G; Casuccio, A; De Grazia, S; Genovese, D; Pizzo, S; Calamusa, G; Ferraro, D; Giammanco, GM; Vitale, F; Bonura, F				Amodio, Emanuele; Capra, Giuseppina; Casuccio, Alessandra; De Grazia, Simona; Genovese, Dario; Pizzo, Stefano; Calamusa, Giuseppe; Ferraro, Donatella; Giammanco, Giovanni Maurizio; Vitale, Francesco; Bonura, Floriana			Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients	VACCINES			English	Article						COVID-19 vaccine; SARS-CoV-2 infection; antibody concentrations		COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations > 200 AU/mL. In a Tobit multivariable regression analysis, SARS-CoV-2 vaccination was statistically significantly associated with increased IgG concentrations (beta coef = 266.4; p < 0.001). A statistically significant reduction in SARS-CoV-2 IgG concentrations was found with older age (beta coef = -1.96 per year increase; p < 0.001), male sex (beta coef = -22.3; p < 0.001), and days after immunization (beta coef = -1.67 per day increase; p < 0.001). Our findings could support the vaccination campaigns confirming the high immunogenicity of the SARS-CoV-2 vaccine under investigation with respect to the natural infection. Further studies will be required for evaluating the role of age and days after immunization in the persistence of vaccine antibodies and protection from the disease.	[Amodio, Emanuele; Capra, Giuseppina; Casuccio, Alessandra; De Grazia, Simona; Genovese, Dario; Pizzo, Stefano; Calamusa, Giuseppe; Ferraro, Donatella; Giammanco, Giovanni Maurizio; Vitale, Francesco; Bonura, Floriana] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Piazza Clin 2, I-90127 Palermo, Italy		Amodio, E (通讯作者)，Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Piazza Clin 2, I-90127 Palermo, Italy.	emanuele.amodio@unipa.it; giuseppina.capra@unipa.it; alessandra.casuccio@unipa.it; simona.degrazia@unipa.it; dario.genovese@unipa.it; stefano.pizzo@unipa.it; giuseppe.calamusa@unipa.it; donatella.ferraro@unipa.it; giovanni.giammanco@unipa.it; francesco.vitale@unipa.it; floriana.bonura82@gmail.com	; Giammanco, Giovanni/G-4000-2012	Vitale, Francesco/0000-0002-6354-8060; Giammanco, Giovanni/0000-0002-7874-6289; Amodio, Emanuele/0000-0001-5482-5268; casuccio, alessandra/0000-0002-5676-9535; CAPRA, Giuseppina/0000-0002-1407-7282; Genovese, Dario/0000-0001-6977-9268; Calamusa, Giuseppe/0000-0002-6780-5044			Amodio E., 2021, HEALTHCARE; [Anonymous], 2020, NAT MED, DOI DOI 10.1038/S41591-020-0897-1; Bonelli F, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01224-20; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706; Criscuolo E, 2021, J MED VIROL, V93, P2160, DOI 10.1002/jmv.26605; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Garcia-Basteiro Alberto L, 2020, Nat Commun, V11, P3500, DOI 10.1038/s41467-020-17318-x; Gray CM, 2020, SAMJ S AFR MED J, V110, P837, DOI 10.7196/SAMJ.2020.v110i9.15155; Hall VJ, 2021, LANCET, V397, P1459, DOI 10.1016/S0140-6736(21)00675-9; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; Harvey RA, 2021, JAMA INTERN MED, V181, P672, DOI 10.1001/jamainternmed.2021.0366; Klein SL, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00301-y; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z; Madariaga MLL, 2021, J INTERN MED, V289, P559, DOI 10.1111/joim.13185; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Pilz Stefan, 2021, Eur J Clin Invest, V51, pe13520, DOI 10.1111/eci.13520; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Prevost J, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100126; R Core Team, 2020, R LANGUAGE ENV STAT; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Stephens DS, 2020, JAMA-J AM MED ASSOC, V324, P1279, DOI 10.1001/jama.2020.16656; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Valdivia A, 2021, EUR J CLIN MICROBIOL, V40, P485, DOI 10.1007/s10096-020-04128-8; Weisberg SP, 2021, NAT IMMUNOL, V22, P25, DOI 10.1038/s41590-020-00826-9; WHO, 2021, CLIN MAN COVID 19 LI CLIN MAN COVID 19 LI; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; World Health Organization, MRNA VACC COVID 19 MRNA VACC COVID 19; Zhou P., 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/s41586-020-2012-7]; Zhou W, 2021, J MED VIROL, V93, P924, DOI 10.1002/jmv.26353; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	36	9	9	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							714	10.3390/vaccines9070714			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6TK	34358130	gold, Green Published			2022-04-29	WOS:000677041100001
J	El-Husseiny, MH; Hagag, NM; Pushko, P; Tretyakova, I; Naguib, MM; Arafa, AS				El-Husseiny, Mohamed H.; Hagag, Naglaa M.; Pushko, Peter; Tretyakova, Irina; Naguib, Mahmoud M.; Arafa, Abdel Satar			Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens	VACCINES			English	Article						virus like particles; highly pathogenic avian influenza H5N1; clade 2.2.1.2; protection; study	AVIAN INFLUENZA; VACCINE; PATHOGENICITY; EGYPT	Highly pathogenic Avian Influenza (HPAI) viruses continue to cause severe economic losses in poultry species worldwide. HPAI virus of subtype H5N1 was reported in Egypt in 2006, and despite vaccination efforts, the virus has become endemic. The current study aims to evaluate the efficacy of a virus-like particle (VLP) based vaccine in vivo using specific pathogen-free (SPF) chickens. The vaccine was prepared from the HPAI H5N1 virus of clade 2.2.1.2 using the baculovirus expression system. The VLPs were quantitated and characterized, including electron microscopy. In addition, the protection level of the VLPs was evaluated by using two different regimens, including one dose and two-dose vaccinated groups, which gave up to 70% and 100% protection level, respectively. The results of this study emphasize the potential usefulness of the VLPs-based vaccine as an alternative vaccine candidate for the control of AIV infection in poultry.	[El-Husseiny, Mohamed H.; Hagag, Naglaa M.; Naguib, Mahmoud M.; Arafa, Abdel Satar] Agr Res Ctr ARC, Anim Hlth Res Inst AHRI, Reference Lab Vet Qual Control Poultry Prod RLQP, Giza 12618, Egypt; [Pushko, Peter; Tretyakova, Irina] Medigen Inc, Frederick, MD 21701 USA		El-Husseiny, MH (通讯作者)，Agr Res Ctr ARC, Anim Hlth Res Inst AHRI, Reference Lab Vet Qual Control Poultry Prod RLQP, Giza 12618, Egypt.	elhussienyvet@gmail.com; naglaahagagahri@gmail.com; ppushko@medigen-usa.com; itretyakova@medigen-usa.com; mahmoud.naguib@imbim.uu.se; abd.arafa@gmail.com	Naguib, Mahmoud/X-2924-2018	Naguib, Mahmoud/0000-0001-6876-8903	CRDF global [EGB1-31125-GI-13]	This research was supported by Grant no. EGB1-31125-GI-13. from the CRDF global.	Abdelwhab EM, 2016, INFECT GENET EVOL, V40, P80, DOI 10.1016/j.meegid.2016.02.023; Arafa AS, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES2015.20.13.21085; Awad E. T., 2015, The Journal of American Science, V11, P1; Buffin S, 2019, VACCINE, V37, P6857, DOI 10.1016/j.vaccine.2019.09.057; Guyonnet Vincent, 2020, Gates Open Res, V4, P122, DOI 10.12688/gatesopenres.13171.1; Jackwood DJ, 2013, AVIAN DIS, V57, P41, DOI 10.1637/10312-080212-Reg.1; Kang SM, 2009, VIRUS RES, V143, P140, DOI 10.1016/j.virusres.2009.04.005; Kapczynski DR, 2016, VACCINE, V34, P1575, DOI 10.1016/j.vaccine.2016.02.011; Kong L, 2010, J MOL BIOL, V403, P131, DOI 10.1016/j.jmb.2010.08.033; Lee DH, 2014, CLIN EXP VACCINE RES, V3, P133, DOI 10.7774/cevr.2014.3.2.133; Liu M, 2003, VIROLOGY, V314, P580, DOI 10.1016/S0042-6822(03)00458-6; Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07; Naeem K, 2006, DEV BIOLOGICALS, V124, P145; Ninyio NN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040694; Park JK, 2014, CLIN VACCINE IMMUNOL, V21, P360, DOI 10.1128/CVI.00636-13; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Peyre Marisa, 2009, J Mol Genet Med, V3, P198; Pushko P, 2005, VACCINE, V23, P5751, DOI 10.1016/j.vaccine.2005.07.098; Pushko P, 2018, VACCINE, V36, P4346, DOI 10.1016/j.vaccine.2018.05.092; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Schwartzman LM, 2015, MBIO, V6, DOI 10.1128/mBio.01044-15; Shen HF, 2013, VIRUS RES, V178, P430, DOI 10.1016/j.virusres.2013.09.009; Song JM, 2010, VIROLOGY, V405, P165, DOI 10.1016/j.virol.2010.05.034; Spackman E, 2014, INFLUENZA OTHER RESP, V8, P654, DOI 10.1111/irv.12290; Tosh PK, 2008, EXPERT OPIN EMERG DR, V13, P21, DOI [10.1517/14728214.13.1.21, 10.1517/14728214.13.1.21 ]; Tretyakova I, 2016, VIROLOGY, V487, P163, DOI 10.1016/j.virol.2015.10.007; Tretyakova I, 2013, VIROLOGY, V442, P67, DOI 10.1016/j.virol.2013.03.027; van Oers MM, 2011, J INVERTEBR PATHOL, V107, pS3, DOI 10.1016/j.jip.2011.05.001; Wetzel D, 2019, J BIOTECHNOL, V306, P203, DOI 10.1016/j.jbiotec.2019.10.008	29	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							715	10.3390/vaccines9070715			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5NO	34358131	Green Published, gold			2022-04-29	WOS:000676958300001
J	Gori, D; Montalti, M; Guaraldi, F				Gori, Davide; Montalti, Marco; Guaraldi, Federica			Mass Immunization and Vaccine Hesitancy in Children and Their Families: A Long and Winding Road Ahead to Address without a Second Thought	VACCINES			English	Editorial Material									[Gori, Davide; Montalti, Marco] Univ Bologna, Unit Hyg, Dept Biomed & Neuromotor Sci Publ Hlth & Med Stat, I-40126 Bologna, Italy; [Guaraldi, Federica] IRCCS Ist Sci Neurol Bologna, Pituitary Unit, I-40126 Bologna, Italy		Gori, D (通讯作者)，Univ Bologna, Unit Hyg, Dept Biomed & Neuromotor Sci Publ Hlth & Med Stat, I-40126 Bologna, Italy.	davide.gori4@unibo.it; marco.montalti7@studio.unibo.it; federica.guaraldi@yahoo.it	Gori, Davide/AAC-3486-2022; Montalti, Marco/AAQ-2494-2021	Gori, Davide/0000-0003-4954-9419; Montalti, Marco/0000-0001-7276-0277; Guaraldi, Federica/0000-0001-8416-1669			D'Errico S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020110; Du FX, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030201; Garzon-Chavez D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020091; Gori D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020173; Gori D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010057; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Montalti M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010086; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Odone A, 2021, EXPERT REV VACCINES, V20, P559, DOI 10.1080/14760584.2021.1912603; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Piedrahita-Valdes H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010028; Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446; Rus M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020113; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Torracinta L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040402; Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1167, DOI 10.1503/cmaj.109-3993; World Health Organization, REP SAGE WORK GROUP	18	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							752	10.3390/vaccines9070752			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7VT	34358168	gold, Green Published			2022-04-29	WOS:000677114800001
J	Hsiao, CB; Bedi, H; Gomez, R; Khan, A; Meciszewski, T; Aalinkeel, R; Khoo, TC; Sharikova, AV; Khmaladze, A; Mahajan, SD				Hsiao, Chiu-Bin; Bedi, Harneet; Gomez, Raquel; Khan, Ayesha; Meciszewski, Taylor; Aalinkeel, Ravikumar; Khoo, Ting Chean; Sharikova, Anna, V; Khmaladze, Alexander; Mahajan, Supriya D.			Telomere Length Shortening in Microglia: Implication for Accelerated Senescence and Neurocognitive Deficits in HIV	VACCINES			English	Article						HIV-associated neurocognitive disorders (HAND); telomere length; telomerase; microglia; neuro-inflammation; oxidative stress	OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; NEURONAL INJURY; CELLS; TAT; ACTIVATION; INHIBITORS; INFECTION; PATHWAYS; DAMAGE	The widespread use of combination antiretroviral therapy (cART) has led to the accelerated aging of the HIV-infected population, and these patients continue to have a range of mild to moderate HIV-associated neurocognitive disorders (HAND). Infection results in altered mitochondrial function. The HIV-1 viral protein Tat significantly alters mtDNA content and enhances oxidative stress in immune cells. Microglia are the immune cells of the central nervous system (CNS) that exhibit a significant mitotic potential and are thus susceptible to telomere shortening. HIV disrupts the normal interplay between microglia and neurons, thereby inducing neurodegeneration. HIV cART contributes to the inhibition of telomerase activity and premature telomere shortening in activated peripheral blood mononuclear cells (PBMC). However, limited information is available on the effect of cART on telomere length (TL) in microglia. Although it is well established that telomere shortening induces cell senescence and contributes to the development of age-related neuro-pathologies, the effect of HIV-Tat on telomere length in human microglial cells and its potential contribution to HAND are not well understood. It is speculated that in HAND intrinsic molecular mechanisms that control energy production underlie microglia-mediated neuronal injury. TL, telomerase and mtDNA expression were quantified in microglial cells using real time PCR. Cellular energetics were measured using the Seahorse assay. The changes in mitochondrial function were examined by Raman Spectroscopy. We have also examined TL in the PBMC obtained from HIV-1 infected rapid progressors (RP) on cART and those who were cART naive, and observed a significant decrease in telomere length in RP on cART as compared to RP's who were cART naive. We observed a significant decrease in telomerase activity, telomere length and mitochondrial function, and an increase in oxidative stress in human microglial cells treated with HIV Tat. Neurocognitive impairment in HIV disease may in part be due to accelerated neuro-pathogenesis in microglial cells, which is attributable to increased oxidative stress and mitochondrial dysfunction.	[Hsiao, Chiu-Bin] Drexel Univ, Med Inst, Sch Med,Allegheny Hlth Network, Infect Dis,Posit Hlth Clin,Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; [Bedi, Harneet; Gomez, Raquel; Khan, Ayesha; Meciszewski, Taylor; Aalinkeel, Ravikumar; Mahajan, Supriya D.] Univ Buffalo, Dept Med, Div Allergy Immunol & Rheumatol, Clin Translat Res Ctr, Buffalo, NY 14203 USA; [Khoo, Ting Chean; Sharikova, Anna, V; Khmaladze, Alexander] SUNY Albany, Dept Phys, Univ Albany, Albany, NY 12222 USA		Mahajan, SD (通讯作者)，Univ Buffalo, Dept Med, Div Allergy Immunol & Rheumatol, Clin Translat Res Ctr, Buffalo, NY 14203 USA.	Chiubin.hsiao@ahn.org; harneetb@buffalo.edu; raquel-gomez@uiowa.edu; akhan26@buffalo.edu; meciszet@my.canisius.edu; ra5@buffalo.edu; tkhoo@albany.edu; asharikova@albany.edu; akhmaladze@albany.edu; smahajan@buffalo.edu		Khoo, Ting Chean/0000-0002-0451-4653			Blanco JR, 2015, JAIDS-J ACQ IMM DEF, V68, P21, DOI 10.1097/QAI.0000000000000398; Blasco MA, 2007, NAT CHEM BIOL, V3, P640, DOI 10.1038/nchembio.2007.38; Brabers NACH, 2006, EUR J CLIN INVEST, V36, P447, DOI 10.1111/j.1365-2362.2006.01657.x; BREEN EC, 1990, J IMMUNOL, V144, P480; Caron M, 2008, ANTIVIR THER, V13, P27; D'Brant LY, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.4.046503; Dragovic G, 2021, EXP GERONTOL, V147, DOI 10.1016/j.exger.2021.111269; Easley R, 2010, BBA-GENE REGUL MECH, V1799, P275, DOI 10.1016/j.bbagrm.2009.08.008; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; Fauci AS, 2015, NEW ENGL J MED, V373, P2197, DOI 10.1056/NEJMp1502020; Garcia-Mesa Y, 2017, J NEUROVIROL, V23, P47, DOI 10.1007/s13365-016-0499-3; Gatignol A, 2007, ADV PHARMACOL, V55, P137, DOI 10.1016/S1054-3589(07)55004-0; Gomez DE, 2012, INT J ONCOL, V41, P1561, DOI 10.3892/ijo.2012.1611; Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Hukezalie KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047505; Islam MT, 2017, NEUROL RES, V39, P73, DOI 10.1080/01616412.2016.1251711; Jasensky J, 2016, ANALYST, V141, P4694, DOI 10.1039/c6an00629a; Jin JJ, 2012, AM J TRANSL RES, V4, P302; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Khmaladze A, 2014, APPL SPECTROSC, V68, P1116, DOI 10.1366/13-07183; Khmaladze A, 2013, TISSUE ENG PART C-ME, V19, P299, DOI [10.1089/ten.tec.2012.0287, 10.1089/ten.TEC.2012.0287]; Khoo TC, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101617; Kronenberg G, 2017, EUR ARCH PSY CLIN N, V267, P473, DOI 10.1007/s00406-016-0750-1; Lauro C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00493; Leeansyah E, 2013, J INFECT DIS, V207, P1157, DOI 10.1093/infdis/jit006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Margot N, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.02557-19; Maschke M, 2000, J NEUROL NEUROSUR PS, V69, P376, DOI 10.1136/jnnp.69.3.376; Mattson MP, 2008, NEURON, V60, P748, DOI 10.1016/j.neuron.2008.10.010; Montejano R, 2017, JAIDS-J ACQ IMM DEF, V76, P102, DOI 10.1097/QAI.0000000000001391; Munoz P, 2009, MOL CELL BIOL, V29, P1608, DOI 10.1128/MCB.01339-08; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Price TO, 2005, BRAIN RES, V1045, P57, DOI 10.1016/j.brainres.2005.03.031; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI [10.1038/nrneurol.2016.53, 10.1038/nrneurol.2016.27]; Sfakis L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041031; Sharikova A, 2020, SPECTROCHIM ACTA A, V227, DOI 10.1016/j.saa.2019.117670; Stella-Ascariz N, 2017, JAIDS-J ACQ IMM DEF, V74, P91, DOI 10.1097/QAI.0000000000001154; Streit WJ, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0142-6; Surmacki J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-48; Thangaraj A, 2018, AUTOPHAGY, V14, P1596, DOI 10.1080/15548627.2018.1476810; Thomas JB, 2013, NEUROLOGY, V80, P1186, DOI 10.1212/WNL.0b013e318288792b; Tubbesing K, 2021, FREE RADICAL BIO MED, V169, P416, DOI 10.1016/j.freeradbiomed.2021.04.030; Voloboueva LA, 2013, FEBS LETT, V587, P756, DOI 10.1016/j.febslet.2013.01.067; Yang S, 2021, NEUROBIOL DIS, V152, DOI 10.1016/j.nbd.2021.105290; Ye JL, 2016, EXP CELL RES, V340, P315, DOI 10.1016/j.yexcr.2015.10.026; Yu CX, 2006, CANCER DETECT PREV, V30, P515, DOI 10.1016/j.cdp.2006.10.007	49	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							721	10.3390/vaccines9070721			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8SG	34358137	Green Published, gold			2022-04-29	WOS:000677173300001
J	Qokoyi, NK; Masamba, P; Kappo, AP				Qokoyi, Ndibonani Kebonang; Masamba, Priscilla; Kappo, Abidemi Paul			Proteins as Targets in Anti-Schistosomal Drug Discovery and Vaccine Development	VACCINES			English	Review						protein-protein interactions; schistosomiasis; praziquantel; Sm-Tsp-2/Alhydrogel; Sm-P80/Gla-Se; Sm14/Gla-Se	SERINE-PROTEASE INHIBITOR; ACID-BINDING PROTEIN; MANSONI SCHISTOSOMULA; PROTEOMIC ANALYSIS; CANDIDATE VACCINE; SM-P80 VACCINE; BLOOD FLUKE; EGG; SERPINS; MICE	Proteins hardly function in isolation; they form complexes with other proteins or molecules to mediate cell signaling and control cellular processes in various organisms. Protein interactions control mechanisms that lead to normal and/or disease states. The use of competitive small molecule inhibitors to disrupt disease-relevant protein-protein interactions (PPIs) holds great promise for the development of new drugs. Schistosome invasion of the human host involves a variety of cross-species protein interactions. The pathogen expresses specific proteins that not only facilitate the breach of physical and biochemical barriers present in skin, but also evade the immune system and digestion of human hemoglobin, allowing for survival in the host for years. However, only a small number of specific protein interactions between the host and parasite have been functionally characterized; thus, in-depth understanding of the molecular mechanisms of these interactions is a key component in the development of new treatment methods. Efforts are now focused on developing a schistosomiasis vaccine, as a proposed better strategy used either alone or in combination with Praziquantel to control and eliminate this disease. This review will highlight protein interactions in schistosomes that can be targeted by specific PPI inhibitors for the design of an alternative treatment to Praziquantel.	[Qokoyi, Ndibonani Kebonang; Masamba, Priscilla; Kappo, Abidemi Paul] Univ Johannesburg, Dept Biochem, Mol Biophys & Struct Biol MBSB Grp, Kingsway Campus, ZA-2006 Auckland Pk, South Africa		Kappo, AP (通讯作者)，Univ Johannesburg, Dept Biochem, Mol Biophys & Struct Biol MBSB Grp, Kingsway Campus, ZA-2006 Auckland Pk, South Africa.	nqoks96@gmail.com; presh4u@rocketmail.com; akappo@uj.ac.za		Kappo, Abidemi Paul/0000-0003-2521-8957	National Research Foundation (NRF) of South AfricaNational Research Foundation - South Africa [MND190612446978, 120802]; University of Johannesburg	Ndibonani Kebonang Qokoyi and Priscilla Masamba would like to thank the National Research Foundation (NRF) of South Africa for a Scarce Skills Doctoral Fellowship (Grant No: MND190612446978) and Postdoctoral Research Fellowship (Grant No: 120802), respectively. Abidemi Paul Kappo is grateful to the University Research Committee [45] of the University of Johannesburg for their research support.	Abath FGC, 2000, PARASITOL RES, V86, P745, DOI 10.1007/PL00008562; Abaza M., 2014, PARASITOL UNITED J, V7, P93; Abou-El-Naga IF, 2020, PARASITOLOGY, V147, P634, DOI 10.1017/S0031182020000347; Abouel-Nour MF, 2006, MEM I OSWALDO CRUZ, V101, P365, DOI 10.1590/S0074-02762006000400004; Adebayo A.S., 2013, J BIOINF COMPUT BIOL, V5, P6, DOI [10.5897/JCBBR12.013, DOI 10.5897/JCBBR12.013]; Adekiya TA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010181; Adenowo AF, 2015, BRAZ J INFECT DIS, V19, P196, DOI 10.1016/j.bjid.2014.11.004; Ahmad G, 2011, J INFECT DIS, V204, P1437, DOI 10.1093/infdis/jir545; Ahmad G, 2010, INT J INFECT DIS, V14, pE781, DOI 10.1016/j.ijid.2010.02.2266; Ahmad G, 2009, PARASITOL RES, V105, P1767, DOI 10.1007/s00436-009-1646-z; Alves CC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02488; Alves CC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003537; Aragon AD, 2009, MOL BIOCHEM PARASIT, V164, P57, DOI 10.1016/j.molbiopara.2008.11.007; Aruleba Raphael Taiwo, 2019, Infectious Disorders - Drug Targets, V19, P337, DOI 10.2174/1871526519666181231153139; Ashton PD, 2001, PARASITOLOGY, V122, P329, DOI 10.1017/S0031182001007351; Bachler M, 2019, J THROMB THROMBOLYS, V48, P466, DOI 10.1007/s11239-019-01879-w; Bear JW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31272-1; Becker JM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60654-7; Berditchevski F, 2007, TRAFFIC, V8, P89, DOI 10.1111/j.1600-0854.2006.00515.x; BERGQUIST NR, 1995, MEM I OSWALDO CRUZ, V90, P221, DOI 10.1590/S0074-02761995000200017; Bergquist NR, 2002, TRENDS PARASITOL, V18, P309, DOI 10.1016/S1471-4922(02)02301-2; Brito CFA, 2000, SCAND J IMMUNOL, V51, P595; Calixto NM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203340; Cardoso FC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000308; Cascao R, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3168; Chacon N, 2003, IMMUNOL LETT, V88, P199, DOI 10.1016/S0165-2478(03)00084-1; Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906; CHEEVER AW, 1994, AM J TROP MED HYG, V50, P281, DOI 10.4269/ajtmh.1994.50.281; Chitsulo L, 2004, NAT REV MICROBIOL, V2, P12, DOI 10.1038/nrmicro801; Chlichlia K, 2001, VACCINE, V20, P439, DOI 10.1016/S0264-410X(01)00345-0; Chuah C, 2014, TRENDS PARASITOL, V30, P141, DOI 10.1016/j.pt.2013.12.009; Cioli D, 2014, MOL BIOCHEM PARASIT, V195, P23, DOI 10.1016/j.molbiopara.2014.06.002; Cleenewerk L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01821; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Crellen T, 2016, SCI REP-UK, V6, DOI 10.1038/srep20954; CROWTHER D C, 1992, Current Opinion in Biotechnology, V3, P399, DOI 10.1016/0958-1669(92)90169-J; Cuesta-Astroz Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00212; Cuesta-Astroz Y, 2017, INT J PARASITOL, V47, P529, DOI 10.1016/j.ijpara.2017.01.007; Da'Dara AA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00284; Dalton JP, 1997, PARASITOLOGY, V114, P105, DOI 10.1017/S003118209600830X; de Macedo Soares Maria Fernanda, 2008, Inflammation & Allergy Drug Targets, V7, P113; de Magalhaes MTQ, 2018, MICROBES INFECT, V20, P606, DOI 10.1016/j.micinf.2018.01.003; Bernardes WPDS, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6793596; Delcroix M, 2006, J BIOL CHEM, V281, P39316, DOI 10.1074/jbc.M607128200; DELGADO V, 1990, PARASITE IMMUNOL, V12, P15, DOI 10.1111/j.1365-3024.1990.tb00933.x; Diab T, 2011, INT J INFECT DIS, V15, pS97, DOI 10.1016/S1201-9712(11)60338-X; Driguez P, 2016, EXPERT REV PROTEOMIC, V13, P19, DOI 10.1586/14789450.2016.1116390; DUNNE DW, 1987, PARASITOLOGY, V94, P269, DOI 10.1017/S0031182000053944; Eyayu T, 2020, PARASITE EPIDEM CONT, V11, DOI 10.1016/j.parepi.2020.e00176; FILE S, 1995, J PARASITOL, V81, P234, DOI 10.2307/3283925; FISHELSON Z, 1992, EXP PARASITOL, V75, P87, DOI 10.1016/0014-4894(92)90124-S; Fogarty CE, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3708-0; Freudenstein-Dan A, 2003, J PARASITOL, V89, P1129, DOI 10.1645/GE-96R; FURLONG ST, 1991, PARASITOL TODAY, V7, P59, DOI 10.1016/0169-4758(91)90192-Q; Gader AGMA, 2009, J TAIBAH UNIV MED SC, V4, P1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GHENDLER Y, 1994, EXP PARASITOL, V78, P121, DOI 10.1006/expr.1994.1013; Gobert GN, 2006, EXP PARASITOL, V114, P160, DOI 10.1016/j.exppara.2006.03.003; Gramegna A, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0691-x; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Haas W, 2009, PARASITOL RES, V105, P1061, DOI 10.1007/s00436-009-1516-8; Haeberlein S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006539; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; Hansell E, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000262; Harder A, 2002, PARASITOL RES, V88, P395, DOI 10.1007/s00436-001-0588-x; Hayer-Hartl M, 2016, TRENDS BIOCHEM SCI, V41, P62, DOI 10.1016/j.tibs.2015.07.009; Hernandez-Goenaga J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02498; Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Horn M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002766; Horwich A., 2016, STRUCTURE ACTION MOL STRUCTURE ACTION MOL, V6, P49; Huang WY, 1999, ACTA CRYSTALLOGR D, V55, P350, DOI 10.1107/S0907444998008658; Hunt KK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3374; Huntington JA, 2006, TRENDS BIOCHEM SCI, V31, P427, DOI 10.1016/j.tibs.2006.06.005; Hwang JH, 2009, PARASITOL RES, V104, P495, DOI 10.1007/s00436-008-1219-6; Iizuka R, 2003, J BIOL CHEM, V278, P44959, DOI 10.1074/jbc.M305484200; Ingram JR, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001589; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Ishida K., 2017, THESIS CASE W RESERV THESIS CASE W RESERV; Ishida K, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004986; Ishida K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003051; Jang-Lee J, 2007, MOL CELL PROTEOMICS, V6, P1485, DOI 10.1074/mcp.M700004-MCP200; Jiz MA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00347; Jones MK, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000334; Kalinda C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14010080; Karmakar S, 2014, VACCINE, V32, P1296, DOI 10.1016/j.vaccine.2013.12.057; Khan Mohammad Sazzad, 2011, J Amino Acids, V2011, P606797, DOI 10.4061/2011/606797; Knudsen GM, 2005, MOL CELL PROTEOMICS, V4, P1862, DOI 10.1074/mcp.M500097-MCP200; Krishna S, 2008, TRENDS PHARMACOL SCI, V29, P520, DOI 10.1016/j.tips.2008.07.004; Leenstra T, 2006, INFECT IMMUN, V74, P370, DOI 10.1128/IAI.74.1.370-381.2006; Lim KC, 1999, AM J TROP MED HYG, V60, P487, DOI 10.4269/ajtmh.1999.60.487; Liu F, 2009, MOL CELL PROTEOMICS, V8, P1236, DOI 10.1074/mcp.M800538-MCP200; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Ludolf F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002745; Lyu HN, 2020, ACS INFECT DIS, V6, P393, DOI 10.1021/acsinfecdis.9b00354; Mangal TD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001438; Masamba P, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13100972; Mathieson W, 2010, INT J PARASITOL, V40, P617, DOI 10.1016/j.ijpara.2009.10.014; McCarthy BJ, 1997, J MOL BIOL, V267, P561, DOI 10.1006/jmbi.1996.0909; McCreesh N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101462; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; Mebius MM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003781; Melman SD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000504; Meng QL, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00035; Merrifield M, 2016, VACCINE, V34, P2988, DOI 10.1016/j.vaccine.2016.03.079; MEYER F, 1970, BIOCHIM BIOPHYS ACTA, V210, P257, DOI 10.1016/0005-2760(70)90170-0; Mo AX, 2014, AM J TROP MED HYG, V90, P54, DOI 10.4269/ajtmh.13-0467; Molehin AJ, 2016, EXPERT REV VACCINES, V15, P619, DOI 10.1586/14760584.2016.1131127; Molehin AJ, 2014, PARASITOLOGY, V141, P1746, DOI 10.1017/S0031182014001061; Molehin AJ, 2012, PARASITOLOGY, V139, P681, DOI 10.1017/S0031182011002435; Morais SB, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006870; MOSER D, 1990, PARASITE IMMUNOL, V12, P341, DOI 10.1111/j.1365-3024.1990.tb00973.x; MOSER D, 1991, J BIOL CHEM, V266, P8447; Mossallam SF, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0906-z; Nakamoto H, 2007, CELL MOL LIFE SCI, V64, P294, DOI 10.1007/s00018-006-6321-2; Neves BJ, 2015, MOLECULES, V20, P1872, DOI 10.3390/molecules20021872; Nowacki FC, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28665; Noya O, 2003, IMMUNOL LETT, V88, P211, DOI 10.1016/S0165-2478(03)00086-5; Oyinloye BE, 2015, PHARMACEUTICALS-BASE, V8, P151, DOI 10.3390/ph8020151; Pakchotanon P, 2016, PARASITOL RES, V115, P2981, DOI 10.1007/s00436-016-5053-y; Periayah Mercy Halleluyah, 2017, Int J Hematol Oncol Stem Cell Res, V11, P319; Pinheiro CS, 2014, PARASITE IMMUNOL, V36, P303, DOI 10.1111/pim.12118; Quezada L.A.L., 2011, THESIS U CALIFORNIA THESIS U CALIFORNIA; Quezada LAL, 2012, J BIOL CHEM, V287, P7074, DOI 10.1074/jbc.M111.313304; Quezada LAL, 2011, AN ACAD BRAS CIENC, V83, P663, DOI 10.1590/S0001-37652011000200025; Radons Juergen, 2017, Current Immunology Reviews, V13, P19, DOI 10.2174/1573395513666170327165811; Ramajo-Hernandez A, 2007, EXP PARASITOL, V115, P83, DOI 10.1016/j.exppara.2006.07.003; Ramirez BL, 1996, PARASITE IMMUNOL, V18, P49, DOI 10.1046/j.1365-3024.1996.d01-4.x; Ran X, 2018, CURR OPIN CHEM BIOL, V44, P75, DOI 10.1016/j.cbpa.2018.06.004; Ranasinghe SL, 2018, INT J INFECT DIS, V66, P26, DOI 10.1016/j.ijid.2017.10.024; Ranasinghe SL, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1022-z; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Rawlings JS, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-38; Roger E, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000330; ROGERS MV, 1991, PARASITOL TODAY, V7, P117, DOI 10.1016/0169-4758(91)90170-S; Salari P, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008098; Salter JP, 2000, J BIOL CHEM, V275, P38667, DOI 10.1074/jbc.M006997200; Santini-Oliveira M, 2016, VACCINE, V34, P586, DOI 10.1016/j.vaccine.2015.10.027; SHER A, 1978, J EXP MED, V148, P46, DOI 10.1084/jem.148.1.46; Siddiqui AA, 2017, TRENDS PARASITOL, V33, P194, DOI 10.1016/j.pt.2016.10.010; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; Siqueira LD, 2017, ACTA TROP, V176, P179, DOI 10.1016/j.actatropica.2017.08.002; SMITHERS SR, 1990, PARASITOL RES, V76, P454, DOI 10.1007/BF00933557; Soria CLD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20092-5; Sotillo J, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007362; Sotillo J, 2015, INT J PARASITOL, V45, P505, DOI 10.1016/j.ijpara.2015.03.004; Stack C, 2011, ADV EXP MED BIOL, V712, P116, DOI 10.1007/978-1-4419-8414-2_8; Tebeje BM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1799-4; Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269; Tendler M, 2008, ACTA TROP, V108, P263, DOI 10.1016/j.actatropica.2008.09.002; Tendler M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00218; TIELENS AGM, 1993, EXP PARASITOL, V77, P495, DOI 10.1006/expr.1993.1112; Toor J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006717; Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430; Utzinger J, 2004, EXPERT OPIN PHARMACO, V5, P263, DOI 10.1517/eoph.5.2.263.26469; van Gent D, 2003, INT J BIOCHEM CELL B, V35, P1536, DOI 10.1016/S1357-2725(03)00134-1; Van Hellemond JJ, 2006, INT J PARASITOL, V36, P691, DOI 10.1016/j.ijpara.2006.01.007; Wan H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053343; Wang JN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231796; Wang TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147247; White Bear J., 2012, THESIS UCSF SAN FRAN THESIS UCSF SAN FRAN; Wolberg AS, 2012, ANESTH ANALG, V114, P275, DOI 10.1213/ANE.0b013e31823a088c; Xavier RP, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04140-z; Xiao Q, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104423; Yamamoto H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010047; Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012; Zahoor Z, 2010, CELL STRESS CHAPERON, V15, P639, DOI 10.1007/s12192-010-0176-z; Zhang T, 2018, ACTA TROP, V187, P15, DOI 10.1016/j.actatropica.2018.07.009; Zhang WD, 2014, PARASITOL RES, V113, P2239, DOI 10.1007/s00436-014-3879-8; Zhang WD, 2010, J INFECT DIS, V201, P1105, DOI 10.1086/651147; Zininga T, 2014, AM J BIOCH BIOTECHNO, V10, P208	172	0	0	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							762	10.3390/vaccines9070762			29	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5TU	34358178	gold, Green Published			2022-04-29	WOS:000676974500001
J	Rashidi-Alavijeh, J; Frey, A; Passenberg, M; Korth, J; Zmudzinski, J; Anastasiou, OE; Saner, FH; Jahn, M; Lange, CM; Willuweit, K				Rashidi-Alavijeh, Jassin; Frey, Alexandra; Passenberg, Moritz; Korth, Johannes; Zmudzinski, Jaqueline; Anastasiou, Olympia E.; Saner, Fuat H.; Jahn, Michael; Lange, Christian M.; Willuweit, Katharina			Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients-A Single-Center Experience	VACCINES			English	Article						SARS-Cov-2; vaccination; liver transplant recipients; liver transplantation; COVID-19		Vaccination against SARS-CoV-2 infection is currently approved and shows favorable outcomes, but little known about antibody responses in solid organ transplant recipients, since these patients are known to have an impaired immune response upon vaccination and have not been included in admission studies. We therefore analyzed immunogenicity in 43 liver transplant (LT) recipients in a median of 15 days (IQR, 12-24) after receiving two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol, and compared these results to a control group consisting of 20 healthcare workers (HCWs). Thirty-four of the 43 (79%) LT recipients developed antibodies, compared to 20 out of 20 (100%) in the control group (p = 0.047). The median SARS-CoV-2 IgG titer was significantly lower in the LT recipients compared to the control group (216 vs. >2080 BAU/mL, p = 0.0001). Age and sex distribution was similar in the LT patients that developed antibodies after vaccination compared to those who did not. Interestingly, the patients who received mycophenolate mofetil exhibited a reduced vaccination response compared to the other LT patients (5 of 11 (45.5%) vs. 29 of 32 (90.6%), p = 0.004). In conclusion, our data reveal lower immunogenicity of SARS-CoV-2 vaccine BNT162b2 in LT patients compared to the control group, but still show superior results compared to other solid organ transplant recipients reported so far.	[Rashidi-Alavijeh, Jassin; Frey, Alexandra; Passenberg, Moritz; Zmudzinski, Jaqueline; Lange, Christian M.; Willuweit, Katharina] Univ Duisburg Essen, Univ Hosp Essen, Dept Gastroenterol & Hepatol, Hufelandstr 55, D-45147 Essen, Germany; [Korth, Johannes; Jahn, Michael] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Hufelandstr 55, D-45147 Essen, Germany; [Anastasiou, Olympia E.] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Virchowstr 179, D-45147 Essen, Germany; [Saner, Fuat H.] Univ Duisburg Essen, Univ Hosp Essen, Dept Gen Visceral & Transplantat Surg, Hufelandstr 55, D-45147 Essen, Germany		Willuweit, K (通讯作者)，Univ Duisburg Essen, Univ Hosp Essen, Dept Gastroenterol & Hepatol, Hufelandstr 55, D-45147 Essen, Germany.	jassin.rashidi@uk-essen.de; alexandra.frey@uk-essen.de; moritz.passenberg@uk-essen.de; johannes.korth@uk-essen.de; jaqueline.zmudzinski@uk-essen.de; olympia.anastasiou@uk-essen.de; fuat.saner@uk-essen.de; michael.jahn@uk-essen.de; christian.lange@uk-essen.de; katharina.willuweit@uk-essen.de		Willuweit, Katharina/0000-0002-1474-7733; Korth, Johannes/0000-0003-4898-0389; Jahn, Michael/0000-0002-7493-205X	Open Access Publication Fund of the University of Duisburg-Essen	The authors acknowledge support from the Open Access Publication Fund of the University of Duisburg-Essen.	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Benseler V, 2007, SEMIN LIVER DIS, V27, P194, DOI 10.1055/s-2007-979471; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Clavien PA, 2017, LANCET GASTROENTEROL, V2, P531, DOI 10.1016/S2468-1253(16)30208-4; Cornberg M, 2021, J HEPATOL, V74, P944, DOI 10.1016/j.jhep.2021.01.032; Del Bello A, 2021, KIDNEY INT, V100, P238, DOI 10.1016/j.kint.2021.04.025; Eckerle I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056974; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Fix OK, 2021, HEPATOLOGY, V74, P1049, DOI [10.1002/hep.31751, 10.1002/hep.31751/suppinfo]; Hugo C, 2021, TRANSPL INT, V34, P378, DOI 10.1111/tri.13795; Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944; Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756; Kumar D, 2011, AM J TRANSPLANT, V11, P2020, DOI 10.1111/j.1600-6143.2011.03753.x; Marinaki S, 2021, AM J TRANSPLANT, V21, P2913, DOI 10.1111/ajt.16607; Rabinowich L., J HEPATOL; Rozen-Zvi B, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.04.028; Stucchi RSB, 2018, TRANSPLANTATION, V102, pS72, DOI 10.1097/TP.0000000000002012; Tacke F, 2021, Z GASTROENTEROL, V59, P345, DOI 10.1055/a-1372-5595; Vyhmeister R, 2021, LIVER TRANSPLANT, V27, P1339, DOI 10.1002/lt.26097; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, COR DIS COVID 2019 S	22	16	16	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							738	10.3390/vaccines9070738			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8GO	34358154	Green Published, gold			2022-04-29	WOS:000677142900001
J	You, G; Won, J; Lee, Y; Moon, D; Park, Y; Lee, SH; Lee, SW				You, Gihoon; Won, Jonghwa; Lee, Yangsoon; Moon, Dain; Park, Yunji; Lee, Sang Hoon; Lee, Seung-Woo			Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies	VACCINES			English	Review						bispecific antibody; cancer immunotherapy	SINGLE-CHAIN ANTIBODY; CD8(+) T-CELLS; DOSE-ESCALATION; PHASE-I; DART(R) MOLECULE; CROSS-LINKING; FC-RECEPTOR; TUMOR; 4-1BB; RESISTANCE	Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential to improve clinical efficacy and safety further. Here, we describe four classes of BsAbs: (a) immune effector cell redirectors; (b) tumor-targeted immunomodulators; (c) dual immunomodulators; and (d) dual tumor-targeting BsAbs. This review describes each of these classes of BsAbs and presents examples of BsAbs in development. We reviewed the biological rationales and characteristics of BsAbs and summarized the current status and limitations of clinical development of BsAbs and strategies to overcome limitations. The field of BsAb-based cancer immunotherapy is growing, and more data from clinical trials are accumulating. Thus, BsAbs could be the next generation of new treatment options for cancer patients.	[You, Gihoon; Moon, Dain; Lee, Seung-Woo] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, South Korea; [Won, Jonghwa; Lee, Yangsoon; Lee, Sang Hoon] ABL Bio Inc, Seongnam 13488, South Korea; [Park, Yunji] POSTECH, Biotechctr, Pohang 37673, South Korea		Lee, SW (通讯作者)，Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, South Korea.	ygh0824@postech.ac.kr; jonghwa.won@ablbio.com; yangsoon.lee@ablbio.com; dain9730@postech.ac.kr; yunji@postech.ac.kr; sang.lee@ablbio.com; sw_lee@postech.ac.kr		Moon, Dain/0000-0001-5244-3215; Won, Jonghwa/0000-0003-2853-8948; Lee, Yangsoon/0000-0003-1556-686X; You, Gihoon/0000-0002-8325-8810	Korea Initiative for fostering the University of Research and Innovation Program of the National Research Foundation (NRF) - Korean government (MIST) [2020M3H1A1075314]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [2017M3A9C8033570]; ABL Bio Inc.	This research was supported by the Korea Initiative for fostering the University of Research and Innovation Program of the National Research Foundation (NRF) funded by the Korean government (MIST) (No.2020M3H1A1075314), by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (2017M3A9C8033570) and by grants from ABL Bio Inc.	Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975-1483.66810; Bacac M, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1836.1836; Bacac M, 2016, CLIN CANCER RES, V22, P3286, DOI 10.1158/1078-0432.CCR-15-1696; Bai RL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01290; Banaszek A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13196-0; Bannas P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01603; Bendell J, 2018, MOL CANCER THER, V17, DOI 10.1158/1535-7163.TARG-17-A092; Bortoletto N, 2002, EUR J IMMUNOL, V32, P3102, DOI 10.1002/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C; Boustany LM, 2018, MOL CANCER THER, V17, DOI 10.1158/1535-7163.TARG-17-A164; Brunker P, 2016, MOL CANCER THER, V15, P946, DOI 10.1158/1535-7163.MCT-15-0647; Burckhart T, 2010, J IMMUNOTHER, V33, P925, DOI 10.1097/CJI.0b013e3181f3cc87; Chan WK, 2018, CANCER IMMUNOL RES, V6, P776, DOI 10.1158/2326-6066.CIR-17-0649; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chester C, 2018, BLOOD, V131, P49, DOI 10.1182/blood-2017-06-741041; Chiang SCC, 2013, BLOOD, V121, P1345, DOI 10.1182/blood-2012-07-442558; Chretien AS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00122; Chu S.Y., 2014, BLOOD, V124, P4727, DOI [10.1182/blood.V124.21.4727.4727, DOI 10.1182/BLOOD.V124.21.4727.4727]; Claus C, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5989; Corgnac S, 2013, CANCER IMMUNOL IMMUN, V62, P747, DOI 10.1007/s00262-012-1381-7; Damato BE, 2019, CANCERS, V11, DOI 10.3390/cancers11070971; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; de Goeij BECG, 2016, MOL CANCER THER, V15, P2688, DOI 10.1158/1535-7163.MCT-16-0364; De Vlieger D, 2018, ANTIBODIES, V8, DOI 10.3390/antib8010001; Dheilly E, 2017, MOL THER, V25, P523, DOI 10.1016/j.ymthe.2016.11.006; Dovedi SJ, 2021, CANCER DISCOV, V11, P1100, DOI 10.1158/2159-8290.CD-20-1445; Dovedi SJ, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-2776; Dufner V, 2019, BLOOD ADV, V3, P2491, DOI 10.1182/bloodadvances.2019000025; Ellerman D, 2019, METHODS, V154, P102, DOI 10.1016/j.ymeth.2018.10.026; Esfahani K, 2020, CURR ONCOL, V27, pS87, DOI 10.3747/co.27.5223; Farkona S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0623-5; Feugier P, 2015, FUTURE ONCOL, V11, P1327, DOI 10.2217/fon.15.57; Fisher TS, 2012, CANCER IMMUNOL IMMUN, V61, P1721, DOI 10.1007/s00262-012-1237-1; Franquiz MJ, 2020, BIOL-TARGETS THER, V14, P23, DOI 10.2147/BTT.S202746; Fury MG, 2008, CANCER IMMUNOL IMMUN, V57, P155, DOI 10.1007/s00262-007-0357-5; Gantke T, 2017, PROTEIN ENG DES SEL, V30, P673, DOI 10.1093/protein/gzx043; Gaspar M, 2020, CANCER IMMUNOL RES, V8, P781, DOI 10.1158/2326-6066.CIR-19-0798; Gauthier L, 2019, CELL, V177, P1701, DOI 10.1016/j.cell.2019.04.041; Geiger M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16838-w; Godar M, 2018, EXPERT OPIN THER PAT, V28, P251, DOI 10.1080/13543776.2018.1428307; Guo FF, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118163; Hamblett KJ, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3914; Hedvat M., 2020, J IMMUNOTHER CANCER, V8, pA419, DOI [10.1136/jitc-2020-SITC2020.0697, DOI 10.1136/JITC-2020-SITC2020.0697]; Hernandez-Hoyos G, 2016, MOL CANCER THER, V15, P2155, DOI 10.1158/1535-7163.MCT-15-0242; Hickingbottom B, 2020, J CLIN ONCOL, V38; Hinner MJ, 2019, CLIN CANCER RES, V25, P5878, DOI 10.1158/1078-0432.CCR-18-3654; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Horton NC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00031; Hutchings M, 2020, J CLIN ONCOL, V38; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jeong S, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e3; Jiang WQ, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-5644; Jurchison S., 2018, APTEVO THERAPEUTICS; Jure-Kunkel Maria N., 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P1117; Jurichson J., 2017, APTEVO THERAPEUTICS; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Khan KA, 2018, NAT REV CLIN ONCOL, V15, P310, DOI 10.1038/nrclinonc.2018.9; Killock D, 2021, NAT REV CLIN ONCOL, V18, P257, DOI 10.1038/s41571-021-00510-3; Kim HD, 2020, HEPATOLOGY, V71, P955, DOI 10.1002/hep.30881; Kontos F, 2019, J AM COLL SURGEONS, V229, pS176; Koopmans I, 2019, J INVEST DERMATOL, V139, P2343, DOI 10.1016/j.jid.2019.01.038; Koopmans I, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466016; Krishna M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00021; Ku G, 2020, ANN ONCOL, V31, pS462, DOI 10.1016/j.annonc.2020.08.639; Kvarnhammar AM, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0570-8; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Lakins MA, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-4547; Lan Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5488; Leong SR, 2017, BLOOD, V129, P609, DOI 10.1182/blood-2016-08-735365; Li JY, 2016, CANCER CELL, V29, P117, DOI 10.1016/j.ccell.2015.12.008; Liddy N, 2012, NAT MED, V18, P980, DOI 10.1038/nm.2764; Lim SI, 2020, PHARMACOL THERAPEUT, V212, DOI 10.1016/j.pharmthera.2020.107582; Linke R, 2010, MABS-AUSTIN, V2, P129, DOI 10.4161/mabs.2.2.11221; Liu HY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00038; Liu RN, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040064; Loffler A, 2000, BLOOD, V95, P2098, DOI 10.1182/blood.V95.6.2098; Lowe KL, 2019, CANCER TREAT REV, V77, P35, DOI 10.1016/j.ctrv.2019.06.001; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Mandikian D, 2018, MOL CANCER THER, V17, P776, DOI 10.1158/1535-7163.MCT-17-0657; Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0; Mayes P., 2019, CANCER RES, V79, P539, DOI [10.1158/1538-7445.Am2019-539, DOI 10.1158/1538-7445.AM2019-539]; Moek KL, 2017, ANN ONCOL, V28, P3083, DOI 10.1093/annonc/mdx541; Moore GL, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.1798.1798; Moore PA, 2011, BLOOD, V117, P4542, DOI 10.1182/blood-2010-09-306449; Moran AE, 2013, CURR OPIN IMMUNOL, V25, P230, DOI 10.1016/j.coi.2013.01.004; Nelson M, 2020, J IMMUNOTHER CANCER, V8, pA507, DOI 10.1136/jitc-2020-SITC2020.0851; Nie Siwei, 2020, Antib Ther, V3, P18, DOI 10.1093/abt/tbaa003; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Ott MG, 2012, INT J CANCER, V130, P2195, DOI 10.1002/ijc.26258; Otz T, 2009, LEUKEMIA, V23, P71, DOI 10.1038/leu.2008.271; Park E., 2019, PEGS BOSTON; Patel M, 2020, J IMMUNOTHER CANCER, V8, pA193, DOI 10.1136/jitc-2020-SITC2020.0313; Piha-Paul S, 2020, J IMMUNOTHER CANCER, V8, pA1, DOI 10.1136/LBA2019.2; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Przepiorka D, 2015, CLIN CANCER RES, V21, P4035, DOI 10.1158/1078-0432.CCR-15-0612; Ravandi F, 2020, BLOOD, V136, DOI 10.1182/blood-2020-134746; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Rothe A, 2015, BLOOD, V125, P4024, DOI 10.1182/blood-2014-12-614636; Rothe C, 2018, BIODRUGS, V32, P233, DOI 10.1007/s40259-018-0278-1; Saunders KO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01296; Schaer DA, 2012, CURR OPIN IMMUNOL, V24, P217, DOI 10.1016/j.coi.2011.12.011; Schmohl JU, 2017, CANCER RES TREAT, V49, P1140, DOI 10.4143/crt.2016.491; Sedykh SE, 2018, DRUG DES DEV THER, V12, P195, DOI 10.2147/DDDT.S151282; Sharma M, 2020, ANN ONCOL, V31, pS704, DOI 10.1016/j.annonc.2020.08.1140; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Skokos D, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw7888; Staflin K, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133757; Suurs FV, 2019, PHARMACOL THERAPEUT, V201, P103, DOI 10.1016/j.pharmthera.2019.04.006; Tabernero J, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3002; Tacke M, 1997, EUR J IMMUNOL, V27, P239, DOI 10.1002/eji.1830270136; Thakur A, 2018, BLOOD REV, V32, P339, DOI 10.1016/j.blre.2018.02.004; Uy GL, 2021, BLOOD, V137, P751, DOI 10.1182/blood.2020007732; Vallera DA, 2016, CLIN CANCER RES, V22, P3440, DOI 10.1158/1078-0432.CCR-15-2710; Vonderheide RH, 2020, ANNU REV MED, V71, P47, DOI 10.1146/annurev-med-062518-045435; Waite JC, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba2325; Walczak H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008698; Williams JB, 2017, J EXP MED, V214, P381, DOI 10.1084/jem.20160485; Wolfl M, 2007, BLOOD, V110, P201, DOI 10.1182/blood-2006-11-056168; Wu JJ, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0188-3; Yap T, 2020, J IMMUNOTHER CANCER, V8, pA240, DOI 10.1136/jitc-2020-SITC2020.0395; Ye SM, 2019, CANCER IMMUNOL RES, V7, P1864, DOI 10.1158/2326-6066.CIR-18-0805; You G, 2021, SCI ADV, V7, DOI 10.1126/sciadv.aax3160; Yu SN, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0522-z; Zhang Jing, 2020, Antib Ther, V3, P126, DOI 10.1093/abt/tbaa011; Zhang WT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00018; Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012; Zhao HY, 2020, J CLIN ONCOL, V38; Zhong TT, 2020, J IMMUNOTHER CANCER, V8, pA422, DOI 10.1136/jitc-2020-SITC2020.0702	133	3	3	6	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							724	10.3390/vaccines9070724			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6VZ	34358141	Green Published			2022-04-29	WOS:000677047800001
J	Bechini, A; Bonanni, P; Zanella, B; Di Pisa, G; Moscadelli, A; Paoli, S; Ancillotti, L; Bonito, B; Boccalini, S				Bechini, Angela; Bonanni, Paolo; Zanella, Beatrice; Di Pisa, Giulia; Moscadelli, Andrea; Paoli, Sonia; Ancillotti, Leonardo; Bonito, Benedetta; Boccalini, Sara			Vaccine Production Process: How Much Does the General Population Know about This Topic? A Web-Based Survey	VACCINES			English	Article						vaccine manufacturing; immunization; hesitancy; pharmaceutical industry; quality control; knowledge; online survey; safety	HEALTH-CARE WORKERS; LOGISTIC-REGRESSION; QUALITY-CONTROL; HESITANCY; ATTITUDES	Background: Vaccine hesitancy has been recognized as a major global health threat by the World Health Organization. Many studies have investigated vaccine safety as a determinant for vaccine hesitancy; however, not much attention has been paid to vaccine production and quality control during the vaccine production process or whether knowledge about this topic may influence vaccine confidence. The aim of this study was to characterize the common knowledge about the vaccine production process. Methods: A freely accessible online questionnaire was developed on Google Modules and disseminated through social networks. A descriptive analysis of the collected answers was performed, and the chi-square test was used to assess significant differences for the sociodemographic characteristics of the study population (age, gender, work or education and training in the healthcare setting, minor offspring). A binary logistic regression model was performed considering these socio-demographic categories as independent variables. Results: The number of collected questionnaire was 135. Most of the participants (127/135, 94.1%) were aware that quality control measures are carried out during manufacturing, although some knowledge gaps emerged in specific aspects of the vaccine production process, without statistically significant differences between age groups. Working in the healthcare setting or being educated in healthcare may be considered predictors for a better understanding that more than 50% of the production time is spent on quality control (AOR = 3.43; 95% CI: 1.84-8.14, p = 0.01) and that considering quality control performed during the vaccine production process is adequate for avoiding contamination (AOR = 7.90; 95% CI: 0.97-64.34; p = 0.05). Conclusions: This study allowed for a characterization of common knowledge about the vaccine production process. It highlighted the need to implement specific strategies to spread correct information about the vaccine production process. This study may contribute to increased confidence and trust in vaccines and vaccination among the general population.	[Bechini, Angela; Bonanni, Paolo; Zanella, Beatrice; Ancillotti, Leonardo; Bonito, Benedetta; Boccalini, Sara] Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy; [Di Pisa, Giulia; Moscadelli, Andrea; Paoli, Sonia] Univ Florence, Med Specializat Sch Hyg & Prevent Med, I-50134 Florence, Italy		Boccalini, S (通讯作者)，Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy.	angela.bechini@unifi.it; paolo.bonanni@unifi.it; beatrice.zanella@unifi.it; giulia.dipisa@unifi.it; andrea.moscadelli@unifi.it; sonia.paoli@unifi.it; leonardo.ancillotti@stud.unifi.it; benedetta.bonito@unifi.it; sara.boccalini@unifi.it		Bonito, Benedetta/0000-0002-6116-8777; Bechini, Angela/0000-0002-6013-8779; Bonanni, Paolo/0000-0003-2875-3744; Zanella, Beatrice/0000-0001-6718-1932; Boccalini, Sara/0000-0002-9695-7549	GSK S.p.A [3001980298/2019]; University of Florence, Department of Health Sciences	This research was partially funded by GSK S.p.A., grant number 3001980298/2019, and the APC was funded by the University of Florence, Department of Health Sciences.	AIFA, QUAL VACC PRIM DUR D; AIFA, QUAL ISP; Bechini A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063110; Bonanni P, 2018, VACCINE, V36, P5424, DOI 10.1016/j.vaccine.2017.05.071; Bonhoeffer J, 2007, CURR OPIN INFECT DIS, V20, P237, DOI 10.1097/QCO.0b013e32811ebfb0; Brunelli L, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9010004; CDC, JOURN YOUR CHILDS VA; Chen H, 2021, HUM VACC IMMUNOTHER, V17, P443, DOI 10.1080/21645515.2020.1780093; Crescitelli MED, 2020, PUBLIC HEALTH, V180, P38, DOI 10.1016/j.puhe.2019.10.027; Dalma Archontoula, 2018, Hosp Top, V96, P18, DOI 10.1080/00185868.2017.1365571; De Figueiredo A., 2020, STATE VACCINE CONFID; Diomidous Marianna, 2020, Mater Sociomed, V32, P307, DOI 10.5455/msm.2020.32.307-314; Du FX, 2020, VACCINE, V38, P7464, DOI 10.1016/j.vaccine.2020.09.075; Dube E, 2017, CLIN MICROBIOL INFEC, V23, P279, DOI 10.1016/j.cmi.2016.11.007; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; ECDC, 2013, REV SCI LIT DRIV BAR; Geoghegan S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00372; Giambi C., 2013, 1347 ISTISAN; Gidengil C, 2019, VACCINE, V37, P6793, DOI 10.1016/j.vaccine.2019.08.068; Gomez PL, 2013, VACCINES-BASEL, P44, DOI [10.1016/B978-1-4557-0090-5.00019-7, DOI 10.1016/B978-1-4557-0090-5.00019-7]; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Harmsen IA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1183; HOSMER DW, 1991, AM J PUBLIC HEALTH, V81, P1630, DOI 10.2105/AJPH.81.12.1630; ISS, LAB UFF CONTR MED IT; Kalil AC, 2010, AM J TRANSPLANT, V10, P1686, DOI 10.1111/j.1600-6143.2010.03141.x; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Leroux-Roels G, 2011, UNDERSTANDING MODERN, V1, P115; MacDonald NE, 2015, EBIOMEDICINE, V2, P792, DOI 10.1016/j.ebiom.2015.06.028; Metz B, 2009, EXPERT REV VACCINES, V8, P227, DOI 10.1586/14760584.8.2.227; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; PEETERMANS J, 1992, VACCINE, V10, pS99, DOI 10.1016/0264-410X(92)90557-Z; Preiss S, 2016, VACCINE, V34, P6665, DOI 10.1016/j.vaccine.2016.10.079; Ranganathan Priya, 2017, Perspect Clin Res, V8, P148, DOI 10.4103/picr.PICR_87_17; Regione Veneto, IND DET RIF OFF VACC; Rezqalla J, 2021, J INFECT PUBLIC HEAL, V14, P661, DOI 10.1016/j.jiph.2021.01.015; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Stefanoff P, 2010, VACCINE, V28, P5731, DOI 10.1016/j.vaccine.2010.06.009; WHO, VACC IMM; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, 2 OUT 3 WILD POL STR; World Health Organization, 2014, REP SAGE WORK GROUP; World Health Organization Regional Office for Europe, CERT MAINT POL FREE; World Health Organization Smallpox, OVERVIEW; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Zhang J, 2010, VACCINE, V28, P7207, DOI 10.1016/j.vaccine.2010.08.065; Zhang YY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006972; Zhao Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.600273	48	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							564	10.3390/vaccines9060564			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0DM	34072288	gold, Green Published			2022-04-29	WOS:000666247400001
J	Bolcato, M; Rodriguez, D; Feola, A; Di Mizio, G; Bonsignore, A; Ciliberti, R; Tettamanti, C; Aurilio, MT; Aprile, A				Bolcato, Matteo; Rodriguez, Daniele; Feola, Alessandro; Di Mizio, Giulio; Bonsignore, Alessandro; Ciliberti, Rosagemma; Tettamanti, Camilla; Trabucco Aurilio, Marco; Aprile, Anna			COVID-19 Pandemic and Equal Access to Vaccines	VACCINES			English	Editorial Material						vaccination; equity; public health; COVID-19; COVAX	ALLOCATION; ETHICS	The COVID-19 pandemic has evidenced the chronic inequality that exists between populations and communities as regards global healthcare. Vaccination, an appropriate tool for the prevention of infection, should be guaranteed by means of proportionate interventions to defeat such inequality in populations and communities affected by a higher risk of infection. Equitable criteria of justice should be identified and applied with respect to access to vaccination and to the order in which it should be administered. This article analyzes, as regards the worldwide distribution of anti-COVID-19 vaccines, the various ways the principle of equity has been construed and applied or even overlooked. The main obstacle to equal access to vaccines is vaccine nationalism. The perception of equity varies with the differing reference values adopted. Adequate response to needs appears to be the principal rule for achieving the criterion of equity in line with distributive justice. Priorities must be set equitably based on rational parameters in accordance with current needs. The entire process must be governed by transparency, from parameter identification to implementation. The issue of equal access to vaccination affects the entire world population, necessitating specific protective interventions. In light of this, the World Health Organization (WHO) has devised the COVAX plan to ensure that even the poorest nations of the world receive the vaccine; certain initiatives are also supported by the European Union (EU). This pandemic has brought to the fore the need to build a culture of equitable relationships both in each country's own domain and with the rest of the world.	[Bolcato, Matteo; Rodriguez, Daniele; Aprile, Anna] Univ Padua, Legal Med, Via G Falloppio 50, I-35121 Padua, Italy; [Feola, Alessandro] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy; [Di Mizio, Giulio] Magna Graecia Univ Catanzaro, Forens Med, Dept Law, I-88100 Catanzaro, Italy; [Bonsignore, Alessandro; Tettamanti, Camilla] Univ Genoa, Dept Hlth Sci, Sect Legal & Forens Med, I-16132 Genoa, Italy; [Ciliberti, Rosagemma] Univ Genoa, Dept Hlth Sci, Sect Hist Med & Bioeth, I-16132 Genoa, Italy; [Trabucco Aurilio, Marco] Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy		Bolcato, M (通讯作者)，Univ Padua, Legal Med, Via G Falloppio 50, I-35121 Padua, Italy.	matteo.bolcato@unipd.it; danielec.rodriguez@gmail.com; alessandro.feola@unicampania.it; giulio.dimizio@unicz.it; alessandro.bonsignore@unige.it; rosellaciliberti@yahoo.it; camilla.tettamanti85@gmail.com; marco.trabuccoaurilio@unimol.it; anna.aprile@unipd.it	Feola, Alessandro/AAI-4601-2020; Di Mizio, Giulio/AAZ-9722-2021	Feola, Alessandro/0000-0002-9666-2636; Di Mizio, Giulio/0000-0001-7279-3693; , Matteo Bolcato/0000-0002-8784-8463; Bonsignore, Alessandro/0000-0001-6616-0347; Trabucco Aurilio, Marco/0000-0003-2327-1455			Alaran Aishat Jumoke, 2021, Public Health Pract (Oxf), V2, P100096, DOI 10.1016/j.puhip.2021.100096; Barranco R, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020489; Beaton E, 2021, ETHICAL THEORY MORAL, V24, P285, DOI 10.1007/s10677-021-10160-0; Beauchamp T.L., 2001, PRINCIPLES BIOMEDICA, P228; Benjamin GC, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.70; Bolcato M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052484; Bolcato M, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9010017; Boudjelal M, 2021, INT J INFECT DIS, V105, P448, DOI 10.1016/j.ijid.2021.02.093; Choudhary Om Prakash, 2021, J Travel Med, DOI 10.1093/jtm/taab031; Coccia M, 2020, ENVIRON RES, V191, DOI 10.1016/j.envres.2020.110155; Commission on Social Determinants of Health, 2008, COMMISSION SOCIAL DE; Communication from the Commission to the European Parliament and the Council, PREP COVID 19 VACC S; Consolazio D, 2021, INT J HEALTH SERV, V51, P311, DOI 10.1177/0020731421994842; Cook DC, 2020, BRIT J ANAESTH, V125, pE181, DOI 10.1016/j.bja.2020.04.061; Coppeta L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17239082; Cummings Christopher L., 2021, Environment Systems & Decisions, V41, DOI 10.1007/s10669-021-09806-2; del Castillo FA, 2021, J PUBLIC HEALTH-UK, V43, pE346, DOI 10.1093/pubmed/fdab051; Eaton L, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n292; Eccleston-Turner M, 2021, MILBANK Q, V99, P426, DOI 10.1111/1468-0009.12503; Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Excler JL, 2021, CURR OPIN IMMUNOL, V71, P13, DOI 10.1016/j.coi.2021.03.009; Felicitas H, 2021, SWISS MED WKLY, V151, DOI 10.4414/smw.2021.20488; Ferguson K, 2021, J MED ETHICS, V47, DOI 10.1136/medethics-2020-106887; Fidler DP, 2020, SCIENCE, V369, P749, DOI 10.1126/science.abe2275; Franco-Paredes C, 2021, INT J INFECT DIS, V105, DOI 10.1016/j.ijid.2021.02.061; Gavi, 2020, GAV COVAX AMC EXPL; Gavi The Vaccine Alliance, 2020, VACC ALL COVAX; Gaynor TS, 2020, PUBLIC ADMIN REV, V80, P832, DOI 10.1111/puar.13264; Ghorui N, 2021, RESULTS PHYS, V21, DOI 10.1016/j.rinp.2020.103811; Gorry C, 2020, MEDICC REV, V22, P10, DOI 10.37757/MR2020.V22.N4.11; Harsanyi JC, 1955, J POLIT ECON, V63, P309, DOI 10.1086/257678; Hassoun N, 2021, J MED ETHICS, V47, P773, DOI 10.1136/medethics-2020-107193; Herzog LM, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4853; Ismail SJ, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004087; Jung J, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e59; Kahn B., 2020, FRAMEWORK EQUITABLE; Kejzar N, 2020, EPIDEMIOL PREV, V44, P271, DOI 10.19191/EP20.5-6.S2.127; Kirksey L, 2021, J NATL MED ASSOC, V113, P368, DOI 10.1016/j.jnma.2021.01.001; Lie RK, 2021, MILBANK Q, V99, P450, DOI 10.1111/1468-0009.12494; McAdams D, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003627; Nhamo G, 2021, GLOB PUBLIC HEALTH, V16, P319, DOI 10.1080/17441692.2020.1860249; Pawlikowski J, 2020, POL ARCH INTERN MED, V130, P466, DOI 10.20452/pamw.15334; Pepperrell T, 2021, GLOBAL HEALTH ACTION, V14, DOI 10.1080/16549716.2021.1892309; Rawls J., 1971, THEORY JUSTICE; Reid L, 2020, J MED ETHICS, V46, P526, DOI 10.1136/medethics-2020-106320; ROSENBAUM L, 2020, RECENT PROG MED, V111, P195, DOI DOI 10.1056/NEJMp2005492; Sandrini M, 2020, EPIDEMIOL PREV, V44, P244, DOI 10.19191/EP20.5-6.S2.124; Schmidt H, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3795; Schwartz JL, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4735; So AD, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4750; Usher AD, 2021, LANCET, V397, P265, DOI 10.1016/S0140-6736(21)00143-4; Wang W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4704; WHO, ACC COVID 19 TOOLS A; World Health Organization, WHO SAGE VAL FRAM AL; Yates J.F., 1992, WILEY SERIES HUMAN P	56	16	16	4	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							538	10.3390/vaccines9060538			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6CN	34063863	Green Published, gold			2022-04-29	WOS:000666651000001
J	Chakraborty, C; Sharma, AR; Bhattacharya, M; Agoramoorthy, G; Lee, SS				Chakraborty, Chiranjib; Sharma, Ashish Ranjan; Bhattacharya, Manojit; Agoramoorthy, Govindasamy; Lee, Sang-Soo			Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis	VACCINES			English	Article						Asia; COVID-19 vaccines; COVID-19 vaccination; factors infusing COVID-19 vaccination	UNITED-STATES; SPUTNIK V; HESITANCY; EFFICACY; EUROPE; INDIA; SAFE	COVID-19 vaccination has started throughout the globe. The vaccination program has also begun in most Asian countries. This paper analyzed the Asian-origin COVID-19 vaccines and vaccination program status in Asia till March 2021 under three sections. In the first section, we mapped the approved vaccines that originated from Asia, their technological platforms, collaborations during vaccine development, and regulatory approval from other countries. We found that a total of eight Asian COVID-19 vaccines originated and got approval from three countries: China, India, and Russia. In the second section, we critically evaluated the recent progress of COVID-19 vaccination programs. We analyzed the overall vaccination status across the Asian region. We also calculated the cumulative COVID-19 vaccine doses administered in different Asian countries, vaccine rolling in 7-day average in various Asian countries, and COVID-19 vaccine per day doses administrated in several Asian countries. We found that China and India vaccinated the maximum number of people. Finally, we evaluated the factors affecting the COVID-19 vaccination program in Asia, such as vaccine hesitancy, basic reproduction numbers (R0) and vaccination campaigns, and the cost of the vaccines. Our analysis will assist the implementation of the COVID-19 vaccination program successfully in Asia.	[Chakraborty, Chiranjib] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India; [Sharma, Ashish Ranjan; Lee, Sang-Soo] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea; [Bhattacharya, Manojit] Fakir Mohan Univ, Dept Zool, Balasore 756020, Odisha, India; [Agoramoorthy, Govindasamy] Tajen Univ, Coll Pharm & Hlth Care, Pingtung 907, Taiwan		Chakraborty, C (通讯作者)，Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.; Lee, SS (通讯作者)，Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea.	drchiranjib@yahoo.com; boneresearch@hallym.ac.kr; mbhattacharya09@gmail.com; agoram@tajen.edu.tw; 123sslee@gmail.com	Chakraborty, Chiranjib/J-4847-2013; Bhattacharya, Manojit/A-2027-2012; Sharma, Ashish Ranjan/W-4816-2019	Chakraborty, Chiranjib/0000-0002-3958-239X; Bhattacharya, Manojit/0000-0001-9669-1835; Sharma, Ashish Ranjan/0000-0003-3973-6755; lee, Sang Soo/0000-0001-5074-7581; Agoramoorthy, Govindasamy/0000-0002-8936-6978	Hallym University Research Fund; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2020R1C1C1008694, NRF-2020R1I1A3074575]	This study was supported by Hallym University Research Fund and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1C1C1008694 and NRF-2020R1I1A3074575).	Agoramoorthy G, 2020, INTERCIENCIA, V45, P173; Akel KB, 2021, HUM VACC IMMUNOTHER, V17, P2639, DOI 10.1080/21645515.2021.1884476; Ali Sheraz, 2019, Perspect Clin Res, V10, P121, DOI 10.4103/picr.PICR_109_18; Alimohamadi Yousef, 2020, J Prev Med Public Health, V53, P151, DOI 10.3961/jpmph.20.076; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n743; Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728; Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736; Biotech B., BHAR BIOT ANN PHASE; Blyth CC, 2021, MED J AUSTRALIA, V214, P249, DOI 10.5694/mja2.50978; Boutron I, 2020, ANN INTERN MED, V173, P1015, DOI 10.7326/M20-5261; Buchholz K., COVID 19 VACC RACE A; Chakraborty C, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e5; Chakraborty Chiranjib, 2021, Infez Med, V29, P165; Chakraborty C, 2020, VACCINE, V38, P7883, DOI 10.1016/j.vaccine.2020.10.056; Chang I.W.J, 2020, COVID 19 MIDDLE E AS; Cheng HY, 2021, BIOCHEM BIOPH RES CO, V538, P238, DOI 10.1016/j.bbrc.2020.10.100; Choi EM, 2021, T ROY SOC TROP MED H, V115, P447, DOI 10.1093/trstmh/trab045; Cohen J., 2020, SCIENCE, DOI [10.1126/science. abb9996, DOI 10.1126/SCIENCE.ABB9996]; Cyranoski D, 2020, NATURE, V584, P17, DOI 10.1038/d41586-020-02244-1; Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Elbek O, 2020, TURK THORAC J, V21, P215, DOI 10.5152/TurkThoracJ.2020.20073; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Farooq R, 2021, J FAM COMMUNITY MED, V28, P1, DOI 10.4103/jfcm.JFCM_332_20; Farrington CP, 2003, MATH BIOSCI, V185, P89, DOI 10.1016/S0025-5564(03)00061-0; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Haug N, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-01009-0; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Kafieh R, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/6927985; Khan S.F, 2021, GSC BIOL PHARM SCI, V14, P075, DOI [10.30574/gscbps.2021.14.1.0009, DOI 10.30574/GSCBPS.2021.14.1.0009]; Kumar SU, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00250; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lahariya C, 2014, INDIAN J MED RES, V139, P491; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; LEE KJ, 2014, OPEN ACCESS J CLIN T, V6, P75, DOI DOI 10.2147/OAJCT.S57060; Li JX, 2021, LANCET INFECT DIS, V21, P891, DOI 10.1016/S1473-3099(21)00094-3; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; Lipsitch M, 2020, SCIENCE, V370, P763, DOI 10.1126/science.abe5938; Liu, 2020, ACTA BIOMED, V91; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Moberly T, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n837; Nuismer SL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196978; Obregon R, 2020, J HEALTH COMMUN, V25, P808, DOI 10.1080/10810730.2021.1879366; OECD/WHO, 2020, HLTH GLANC AS PAC 20, DOI [10.1787/aaa5448f-en, DOI 10.1787/AAA5448F-EN]; Olliaro P, 2021, LANCET INFECT DIS, V21, P769, DOI 10.1016/S1473-3099(21)00075-X; Omer SB, 2020, JAMA-J AM MED ASSOC, V323, P1767, DOI 10.1001/jama.2020.5788; Painter EM, 2021, MMWR-MORBID MORTAL W, V70, P174, DOI 10.15585/mmwr.mm7005e1; Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI [10.1016/S1473-3099(20)30484-9, 10.1016/S1473-3099(20)30648-4]; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Roser M, 2020, CORONAVIRUS DIS COVI; Ruck DJ, 2021, ECON HUM BIOL, V41, DOI 10.1016/j.ehb.2021.100988; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Santos AF, 2021, ENERGIES, V14, DOI 10.3390/en14071849; Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Staff R., CHIN SIN CHIEF RUL O; Susanto AP, 2020, ACTA MED INDONES, V52, P423; Taneja P., 2021, ROUND TABLE, V110, P46, DOI [10.1080/00358533.2021.1875685, DOI 10.1080/00358533.2021.1875685]; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; The World Health Organization, 2021, COVID 19 VACC; Thiagarajan K, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n196; Thoma B, 2019, PERSPECT MED EDUC, V8, P201, DOI 10.1007/s40037-019-0515-4; Triggle CR, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00317-20; Vaidyanathan G, 2020, NATURE, V585, P167, DOI 10.1038/d41586-020-02507-x; Winiewska, RUSSIA GLOBAL VACCIN; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xiong C, 2020, EVOLUTION VARIATION, DOI DOI 10.1101/2020.01.30.926477; Yamamoto N, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110160; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Zarin DA, 2016, NEW ENGL J MED, V375, P1998, DOI 10.1056/NEJMsr1611785; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zimmer C, CORONAVIRUS VACCINE; Zuo X, 2021, BRIEF BIOINFORM, V22, P800, DOI 10.1093/bib/bbaa331	81	5	5	14	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							600	10.3390/vaccines9060600			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7YM	34199995	gold, Green Published, Green Submitted			2022-04-29	WOS:000666098700001
J	Maple, PAC				Maple, Peter A. C.			Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective	VACCINES			English	Review						COVID-19; SARS-CoV-2; antibodies; immunity; seroepidemiology; England	SEROLOGICAL SURVEILLANCE; SARS-COV-2 INFECTION; ENGLAND; COVID-19; RESPONSES; IMMUNITY; SEROEPIDEMIOLOGY; TRANSMISSION; MUTATIONS; DYNAMICS	In the UK, population virus or antibody testing using virus swabs, serum samples, blood spots or oral fluids has been performed to a limited extent for several diseases including measles, mumps, rubella and hepatitis and HIV. The collection of population-based infection and immunity data is key to the monitoring of disease prevalence and assessing the effectiveness of interventions such as behavioural modifications and vaccination. In particular, the biological properties of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its interaction with the human host have presented several challenges towards the development of population-based immunity testing. Measuring SARS-CoV-2 immunity requires the development of antibody assays of acceptable sensitivity and specificity which are capable of accurately detecting seroprevalence and differentiating protection from non-protective responses. Now that anti-COVID-19 vaccines are becoming available there is a pressing need to measure vaccine efficacy and the development of herd immunity. The unprecedented impact of the SARS-CoV-2 pandemic in the UK in terms of morbidity, mortality, and economic and social disruption has mobilized a national scientific effort to learn more about this virus. In this article, the challenges of testing for SARS-CoV-2 infection, particularly in relation to population-based immunity testing, will be considered and examples given of relevant national level studies.	[Maple, Peter A. C.] Univ Nottingham, Queens Med Ctr, Dept Neurol, Div Clin Neurosci,Sch Med,Clin Neurol Res Grp, Nottingham NG7 2UH, England; [Maple, Peter A. C.] UK Lighthouse Lab, Mol COVID Dept, Cheshire SK10 4TG, England		Maple, PAC (通讯作者)，Univ Nottingham, Queens Med Ctr, Dept Neurol, Div Clin Neurosci,Sch Med,Clin Neurol Res Grp, Nottingham NG7 2UH, England.; Maple, PAC (通讯作者)，UK Lighthouse Lab, Mol COVID Dept, Cheshire SK10 4TG, England.	peter.maple@nottingham.ac.uk		Maple, Peter/0000-0002-5534-5191			Alipoor SD, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.563085; Almahboub SA, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02020; Almeida JD, 1968, NATURE, V220, P650; Angyal A., 2021, T CELL ANTIBODY RESP, DOI DOI 10.2139/SSRN.3812375; ATCHISON C, 2021, CLIN INFECT DIS, V72, DOI DOI 10.1093/CID/CIAA1178; Bahadir EB, 2016, TRAC-TREND ANAL CHEM, V82, P286, DOI 10.1016/j.trac.2016.06.006; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Balogun MA, 2002, J INFECTION, V45, P219, DOI 10.1053/jinf.2002.1059; Bian LL, 2021, EXPERT REV VACCINES, V20, P365, DOI 10.1080/14760584.2021.1903879; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bundle N, 2019, EUROSURVEILLANCE, V24, P17, DOI 10.2807/1560-7917.ES.2019.24.27.1800377; Chen PF, 2020, WORLD J CLIN CASES, V8, DOI 10.12998/wjcc.v8.i24.6252; Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071; Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; den Hartog G., 2021, CLIN INFECT DIS, DOI [DOI 10.1093/CID/CIAB172, 10.1093/cid/ciab172]; Department of Health and Social Care, 2020, COR COVID 19 SCAL OU; Department of Health and Social Care, COVID 19 SURV IMM ST; Department of Health and Social Care, 2012, PROT IMM T CELLS HEA; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Dropkin G, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00256; Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20; Farrar J, 2021, WELLCOME OPEN RES, V5, P232, DOI DOI 10.12688/WELLCOMEOPENRES.16193.2; Gale Chris, 2020, Arch Dis Child Fetal Neonatal Ed, V105, P346, DOI 10.1136/archdischild-2020-319372; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Garneret P, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243712; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Groves DC, 2021, BIOCHEM BIOPH RES CO, V538, P104, DOI 10.1016/j.bbrc.2020.10.109; Grubaugh ND, 2021, CELL, V184, P1127, DOI 10.1016/j.cell.2021.01.044; Hall VJ, 2021, LANCET, V397, P1459, DOI 10.1016/S0140-6736(21)00675-9; Hanson KE, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab557, 10.1093/cid/ciaa760]; Harris RJ, 2021, J INFECTION, V82, P162, DOI 10.1016/j.jinf.2021.03.015; Hayward A., 2021, INCIDENCE SARS COV 2, DOI [10.1101/2021.03.08.21253110, DOI 10.1101/2021.03.08.21253110]; Iacobucci G, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1222; Ismail SA, 2021, LANCET INFECT DIS, V21, P344, DOI 10.1016/S1473-3099(20)30882-3; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Kohmer N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020328; Kumar A, 2021, CURR INFECT DIS REP, V23, DOI 10.1007/s11908-021-00752-3; Ladhani SN, 2021, LANCET CHILD ADOLESC, V5, P417, DOI 10.1016/S2352-4642(21)00061-4; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lauring AS, 2021, JAMA-J AM MED ASSOC, V325, P529, DOI 10.1001/jama.2020.27124; Lillie PJ, 2020, J INFECTION, V80, P600, DOI 10.1016/j.jinf.2020.02.020; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Lu S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20768-y; Mak GCK, 2021, J CLIN VIROL, V134, DOI 10.1016/j.jcv.2020.104712; Mak GCK, 2020, J CLIN VIROL, V133, DOI 10.1016/j.jcv.2020.104684; Manisty C, 2021, EBIOMEDICINE, V65, DOI 10.1016/j.ebiom.2021.103259; Maple PAC, 2021, CLIN ONCOL-UK, V33, pE73, DOI 10.1016/j.clon.2020.10.008; Maple PAC, 2000, VACCINE, V19, P167, DOI 10.1016/S0264-410X(00)00184-5; McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991; Moshe M, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n423; Mulchandani R, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4262; Nagu P, 2021, REV NEUROSCIENCE, V32, P219, DOI 10.1515/revneuro-2020-0070; Nakagawa S, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00126-7; Nardone A, 2004, VACCINE, V22, P1314, DOI 10.1016/j.vaccine.2003.08.039; Office for National Statistics, 2021, COVID 19 SCH INF SUR; Office for National Statistics, COR COVID 19 INF SUR; Office for National Statistics, 2020, COVID 19 SCH INF SUR; Offices of the Nuffield Professor of Medicine University of Oxford, 2020, COVID 19 INF SURV; Ogimi C, 2020, J PEDIAT INF DIS SOC, V9, P210, DOI 10.1093/jpids/piaa037; Oshorne K., 2000, International Journal of Epidemiology, V29, P362, DOI 10.1093/ije/29.2.362; Padma TV, 2021, NATURE, V593, P9, DOI 10.1038/d41586-021-01140-6; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Pradenas E, 2021, MED-CAMBRIDGE, V2, P313, DOI 10.1016/j.medj.2021.01.005; Prevost J, 2021, CELL HOST MICROBE, V29, P322, DOI 10.1016/j.chom.2021.02.010; Public Health England, 2020, REPORTS-BASEL; Public Health England, 2020, COVID 19 PAED SURV; Sallard E, 2021, ENVIRON CHEM LETT, V19, P769, DOI 10.1007/s10311-020-01151-1; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Sherina N, 2021, MED-CAMBRIDGE, V2, P281, DOI 10.1016/j.medj.2021.02.001; Shultz JM, 2020, DISASTER MED PUBLIC, V14, pE28, DOI 10.1017/dmp.2020.103; Machado BAS, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010040; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Sui YJ, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020138; Theel ES, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02148-20; Toptan T, 2021, J CLIN VIROL, V135, DOI 10.1016/j.jcv.2020.104713; van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351; Venter M, 2020, J CLIN PATHOL, V73, P370, DOI 10.1136/jclinpath-2020-206685; Vyse AJ, 2006, EPIDEMIOL INFECT, V134, P1303, DOI 10.1017/S0950268806006340; Wang XL, 2020, PEDIATR INVEST, V4, P281, DOI 10.1002/ped4.12228; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Ward H., REACT 2 ROUND 5 INCR, DOI [10.1101/2021.02.26.21252512, DOI 10.1101/2021.02.26.21252512(2021, 10.1101/2021.02.26.21252512 (2021]; Ward H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21237-w; Whitman Jeffrey D, 2020, medRxiv, DOI 10.1101/2020.04.25.20074856; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Xia XH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010109; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zambon, 2021, SIREN PROTOCOL IMPAC, DOI [10.1101/2020.12.15.20247981, DOI 10.1101/2020.12.15.20247981]; Zhang XY, 2020, VIROL SIN, V35, P820, DOI 10.1007/s12250-020-00329-9; Zhou R, 2020, INT J INFECT DIS, V96, P288, DOI 10.1016/j.ijid.2020.05.030; Zhou X, 2020, CLIN MICROBIOL INFEC, V26, P957, DOI 10.1016/j.cmi.2020.03.024; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	96	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							550	10.3390/vaccines9060550			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8FL	34073985	Green Published, gold			2022-04-29	WOS:000666793800001
J	Moussaoui, S; Aurousseau, AM; Nappez, S; Cornaglia, J; Delobre, G; Blanchi, S; Luan, L; Vandentorren, S; Bouchaud, O; Launay, O; Nutte, L; Liard, R; Skendi, M; Mechain, M; Vignier, N				Moussaoui, Sohela; Aurousseau, Anne Marie; Nappez, Sylvain; Cornaglia, Julian; Delobre, Gaylord; Blanchi, Sophie; Luan, Louise; Vandentorren, Stephanie; Bouchaud, Olivier; Launay, Odile; Nutte, Louise; Liard, Roxane; Skendi, Mariela; Mechain, Matthieu; Vignier, Nicolas			Immunization Catch-Up for Newly Arrived Migrants in France: A Cross-Sectional Study among French General Practitioners	VACCINES			English	Article						family health; immigrants; transients and migrants; vaccine; catch-up	REFUGEES; MEASLES; RECOMMENDATIONS; SEROPREVALENCE; GERMANY	Background: Migrants often undergo an incomplete vaccination program in regards to the French recommendations. The aim of this study was to evaluate the practices of French General Practitioners' (GPs) in terms of catch-up vaccination. Methods: A cross-sectional study was carried-out in 2017-2018 in France. An online questionnaire was disseminated by email through scholarly societies to GPs involved in the care and the vaccination of migrants. Analyses included univariate and multivariate analysis with a logistic regression model. Results: A total of 216 GPs completed the survey. A majority identified themselves with an average level regarding the prevention of infectious diseases among migrant populations (56.7%) and confirmed this is part of their daily practice (83.3%). The majority of respondents do not perform more than two injections on the same day. When compared to GPs working in health centres, those with a private practice are more likely to report returning to a full primary vaccination schedule (adjusted OR = 2.90, 95% CI [1.29-6.53]). Aside from the serology for hepatitis B and to a lesser extent for measles, other pre-vaccination serologies were not frequently used by GPs. When a migrant declares to be up-to-date with his immunisations, only 56.5% of doctors consider this information reliable. Conclusions: This study clarified the vaccination practices of GPs receiving migrant patients in consultation and showed its heterogeneity. An important need for benchmarks has been identified and these results were used for the elaboration of the French guidelines on vaccines catch-up.	[Moussaoui, Sohela; Vandentorren, Stephanie; Vignier, Nicolas] Sorbonne Univ, INSERM, Dept Social Epidemiol, Inst Pierre Louis Epidemiol & Sante Publ IPLESP, F-75012 Paris, France; [Moussaoui, Sohela; Nutte, Louise; Liard, Roxane; Skendi, Mariela] Sorbonne Univ, Dept Educ & Res Gen Med, F-75012 Paris, France; [Aurousseau, Anne Marie; Mechain, Matthieu] Bordeaux Univ, Bordeaux Univ Hosp, F-33000 Bordeaux, France; [Nappez, Sylvain] Amiens Univ Hosp, F-80000 Amiens, France; [Cornaglia, Julian] Perpignan Hosp, F-66000 Perpignan, France; [Delobre, Gaylord] Louis Guilloux Network, F-35000 Rennes, France; [Blanchi, Sophie] Le Mans Hosp, F-72000 Le Mans, France; [Luan, Louise; Vignier, Nicolas] Grp Hosp Sud Ile de France, Dept Infect & Trop Dis, F-77000 Melun, France; [Bouchaud, Olivier; Vignier, Nicolas] Univ Sorbonne Paris Nord, Hop Univ Paris Seine St Denis, Hop Avicenne, AP HP,Dept Trop & Infect Dis,UFR SMBH,LEPS, F-93000 Bobigny, France; [Bouchaud, Olivier; Vignier, Nicolas] Soc Med Voyages, F-75013 Paris, France; [Launay, Odile] Univ Paris, Hop Cochin, AP HP, INSERM CIC 1417,F CRIN I REIVAC, F-75014 Paris, France; [Vignier, Nicolas] Ctr Hosp Cayenne Andree Rosemon, Ctr Invest Clin Antilles Guyane, CIC Inserm 1424, DRISP, Cayenne 97300, French Guiana; [Vignier, Nicolas] CNRS, French Collaborat Inst Migrat, ICM, F-93300 Aubervilliers, France		Vignier, N (通讯作者)，Sorbonne Univ, INSERM, Dept Social Epidemiol, Inst Pierre Louis Epidemiol & Sante Publ IPLESP, F-75012 Paris, France.; Vignier, N (通讯作者)，Grp Hosp Sud Ile de France, Dept Infect & Trop Dis, F-77000 Melun, France.; Vignier, N (通讯作者)，Univ Sorbonne Paris Nord, Hop Univ Paris Seine St Denis, Hop Avicenne, AP HP,Dept Trop & Infect Dis,UFR SMBH,LEPS, F-93000 Bobigny, France.; Vignier, N (通讯作者)，Soc Med Voyages, F-75013 Paris, France.; Vignier, N (通讯作者)，Ctr Hosp Cayenne Andree Rosemon, Ctr Invest Clin Antilles Guyane, CIC Inserm 1424, DRISP, Cayenne 97300, French Guiana.; Vignier, N (通讯作者)，CNRS, French Collaborat Inst Migrat, ICM, F-93300 Aubervilliers, France.	sohela.moussaoui@sorbonne-universite.fr; a-marie.aurousseau@hotmail.fr; nappez.sylvain@chu-amiens.fr; julinaglia@hotmail.com; g.delobre@rlg35.org; sblanchi@ch-lemans.fr; louise.luan@gmail.com; Stephanie.VANDENTORREN@santepubliquefrance.fr; olivier.bouchaud@aphp.fr; odile.launay@aphp.fr; louisenutte@gmail.com; roxane.liard@gmail.com; mariela.skendi@gmail.com; matthieu.mechain@gmail.com; dr.vignier@gmail.com	Vignier, Nicolas/AAH-8382-2021	Vignier, Nicolas/0000-0002-9410-9327	Society for Therapeutic Training of the General Practitioner (SFTG/SFTG recherche); Sentinel network; National Federation of Health Centres; Union of health Center physicians; Syndicat National des Jeunes Medecins Generalistes; French federation of Health centres (Federation francaise des maisons et des poles de sante); National Collective of Health Care Access Centres (Collectif national des Permanences d'acces aux soins de sante); French mission network of Doctors of the World; Society of Travel Medicine; Corevih; French AIDS Society	The authors thank all the physicians who took the time to answer the survey. We also thank the scholarly societies and associations for their support in disseminating the survey: the Society for Therapeutic Training of the General Practitioner (SFTG/SFTG recherche), the Sentinel network, the National Federation of Health Centres, the Union of health Center physicians, the Syndicat National des Jeunes Medecins Generalistes, the French federation of Health centres (Federation francaise des maisons et des poles de sante), the National Collective of Health Care Access Centres (Collectif national des Permanences d'acces aux soins de sante), the French mission network of Doctors of the World, the Society of Travel Medicine, the Corevih, the French AIDS Society, the Gervih and the anti-tuberculosis centre networks. Finally, the authors thank the INSERM Research Team in Social Epidemiology ERES as well as Department of Education and Research in General Medicine.	Aldridge RW, 2016, LANCET, V388, P2510, DOI 10.1016/S0140-6736(16)31008-X; Australian Technical Advisory Group on Immunisation Australian Government Department of Health, 2020, AUSTR IMM HDB; Brutel C, 2016, INSEE PREMIERE; Caubet JC, 2014, IMMUNOL ALLERGY CLIN, V34, P597, DOI 10.1016/j.iac.2014.04.004; Charania NA, 2019, VACCINE, V37, P2661, DOI 10.1016/j.vaccine.2019.04.001; Chaud P., 2017, B EPIDEMIOL HEBD, V19 20, P374; Conseil National de l'Ordre des Medecins, 2018, ATL DEM MED FRANC SI; de la Fuente IG, 2013, PEDIATR INFECT DIS J, V32, P274, DOI 10.1097/INF.0b013e3182748f0b; De Vito E, 2017, REV EVIDENCE EQUITAB; Doctors of the World, 2020, RAPPORT; Dourgnon P., 2009, QUEST EC SANTE, V146, P1; European Centre for Disease Prevention and Control, 2015, INF DIS SPEC REL NEW INF DIS SPEC REL NEW; Giambi C, 2019, VACCINE, V37, P5439, DOI 10.1016/j.vaccine.2019.06.068; Hatamabadi HR, 2011, AM J EMERG MED, V29, P717, DOI 10.1016/j.ajem.2010.01.046; Haute Autorite de Sante, 2019, UNKN INC INC KNOWN I; Havers FP, 2020, MMWR-MORBID MORTAL W, V69, P77, DOI 10.15585/mmwr.mm6903a5; Hui C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102065; Jablonka A, 2017, EUR J GASTROEN HEPAT, V29, P939, DOI 10.1097/MEG.0000000000000889; Jablonka A, 2016, INFECTION, V44, P781, DOI 10.1007/s15010-016-0926-7; Jones G, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.11.30167; Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374; Pottie K, 2011, CAN MED ASSOC J, V183, pE824, DOI 10.1503/cmaj.090313; Public Health England, 2019, VACC IND UNC IMC IMM; Robert Koch-Institut, 2016, REC STAND COMM VACC; Vie le Sage F., 2019, J PEDIAT PUERICULTUR, V32, P199, DOI [10.1016/j.jpp.2019.06.007, DOI 10.1016/J.JPP.2019.06.007]; Vignier N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192916; WASSILAK SGK, 2008, VACCINES; Weinbaum Cindy M., 2008, Morbidity and Mortality Weekly Report, V57, P1, DOI 10.1002/hep.22882; Williams GA, 2016, SCAND J PUBLIC HEALT, V44, P6, DOI 10.1177/1403494815610182; Woo EJ, 2003, CLIN INFECT DIS, V37, P351, DOI 10.1086/375820; World Health Organization, 2014, INF SHEET OBS RAT VA; Zhou W., 2004, P 20 INT C PHARM THE	32	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							681	10.3390/vaccines9060681			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA7VV	34205585	gold, Green Published			2022-04-29	WOS:000667455100001
J	Scarpini, S; Morigi, F; Betti, L; Dondi, A; Biagi, C; Lanari, M				Scarpini, Sara; Morigi, Francesca; Betti, Ludovica; Dondi, Arianna; Biagi, Carlotta; Lanari, Marcello			Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice	VACCINES			English	Review						hCMV; vaccine; mRNA vaccines; congenital CMV; congenital infection; prevention; CMV long-term sequelae; sensorineural hearing loss	CELL TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; CONGENITAL CMV INFECTION; GLYCOPROTEIN-B VACCINE; PREGNANT-WOMEN; HEARING-LOSS; DNA VACCINE; T-CELLS; INTRAUTERINE TRANSMISSION; MATERNAL INFECTION	Human cytomegalovirus (hCMV) is one of the most common causes of congenital infection in the post-rubella era, representing a major public health concern. Although most cases are asymptomatic in the neonatal period, congenital CMV (cCMV) disease can result in permanent impairment of cognitive development and represents the leading cause of non-genetic sensorineural hearing loss. Moreover, even if hCMV mostly causes asymptomatic or pauci-symptomatic infections in immunocompetent hosts, it may lead to severe and life-threatening disease in immunocompromised patients. Since immunity reduces the severity of disease, in the last years, the development of an effective and safe hCMV vaccine has been of great interest to pharmacologic researchers. Both hCMV live vaccines-e.g., live-attenuated, chimeric, viral-based-and non-living ones-subunit, RNA-based, virus-like particles, plasmid-based DNA-have been investigated. Encouraging data are emerging from clinical trials, but a hCMV vaccine has not been licensed yet. Major difficulties in the development of a satisfactory vaccine include hCMV's capacity to evade the immune response, unclear immune correlates for protection, low number of available animal models, and insufficient general awareness. Moreover, there is a need to determine which may be the best target populations for vaccine administration. The aim of the present paper is to examine the status of hCMV vaccines undergoing clinical trials and understand barriers limiting their development.	[Scarpini, Sara; Morigi, Francesca; Betti, Ludovica] Univ Bologna, Specialty Sch Pediat, Alma Mater Studiorum, I-40126 Bologna, Italy; [Dondi, Arianna; Biagi, Carlotta; Lanari, Marcello] Univ Bologna, Pediat Emergency Unit, IRCCS Azienda Osped, I-40138 Bologna, Italy		Dondi, A (通讯作者)，Univ Bologna, Pediat Emergency Unit, IRCCS Azienda Osped, I-40138 Bologna, Italy.	sara.scarpini2@studio.unibo.it; francesca.morigi@gmail.com; ludovicabettimail@gmail.com; arianna.dondi2@unibo.it; carlotta.biagi@aosp.bo.it; marcello.lanari@unibo.it	Biagi, Carlotta/AAC-3181-2022	Biagi, Carlotta/0000-0002-9782-6313; Dondi, Arianna/0000-0002-7516-243X			Adler SP, 2019, J INFECT DIS, V220, P411, DOI 10.1093/infdis/jiz141; Aldoss I, 2020, ANN INTERN MED, V172, P306, DOI 10.7326/M19-2511; Anderholm KM, 2016, DRUGS, V76, P1625, DOI 10.1007/s40265-016-0653-5; Astellas Pharma Global Development Inc, 2021, RAND DOUBL BLIND PLA; Astellas Pharma Global Development Inc, 2021, RAND DOUBL BLIND PLA; Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438; Bernstein DI, 2016, VACCINE, V34, P313, DOI 10.1016/j.vaccine.2015.11.056; Bilavsky E, 2016, ARCH DIS CHILD, V101, P433, DOI 10.1136/archdischild-2015-309154; Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804; Boppana SB, 2013, CLIN INFECT DIS, V57, pS178, DOI 10.1093/cid/cit629; Boppana SB, 2011, NEW ENGL J MED, V364, P2111, DOI 10.1056/NEJMoa1006561; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Cannon MJ, 2014, REV MED VIROL, V24, P291, DOI 10.1002/rmv.1790; Cannon MJ, 2011, REV MED VIROL, V21, P240, DOI 10.1002/rmv.695; Cervera Carlos, 2011, Enferm Infecc Microbiol Clin, V29 Suppl 6, P11, DOI 10.1016/S0213-005X(11)70051-9; Chan ST, 2017, BLOOD REV, V31, P173, DOI 10.1016/j.blre.2017.01.002; Chauhan V, 2020, EUR J PHARM SCI, V147, DOI 10.1016/j.ejps.2020.105279; Ciferri C, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005230; City of Hope Medical Center, 2020, CMV MVA TRIPL VACC S; City of Hope Medical Center, 2021, PHAS 2 RAND PLAC CON; Coppola T, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040129; Dahle A J, 2000, J Am Acad Audiol, V11, P283; de Vries JJC, 2013, REV MED VIROL, V23, P241, DOI 10.1002/rmv.1744; de Vries JJC, 2012, J CLIN VIROL, V53, P167, DOI 10.1016/j.jcv.2011.11.006; Diamond DJ, 2018, EXPERT REV VACCINES, V17, P889, DOI 10.1080/14760584.2018.1526085; Diener ML, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-0789; Dioverti MV, 2016, DIAGNOSTIC MICROBIOLOGY OF THE IMMUNOCOMPROMISED HOST, 2 EDITION, P97, DOI 10.1128/microbiolspec.DMIH2-0022-2015; Dreher AM, 2014, J PEDIATR-US, V164, P855, DOI 10.1016/j.jpeds.2013.12.007; Drew WL, 2007, CURR OPIN INFECT DIS, V20, P408, DOI 10.1097/QCO.0b013e32821f6010; ELEK SD, 1974, LANCET, V1, P1; Enders G, 2011, J CLIN VIROL, V52, P244, DOI 10.1016/j.jcv.2011.07.005; Enders M, 2017, PRENATAL DIAG, V37, P389, DOI 10.1002/pd.5025; Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928; Fornara C, 2016, J MED VIROL, V88, P1238, DOI 10.1002/jmv.24449; Foulon I, 2008, J PEDIATR-US, V153, P84, DOI 10.1016/j.jpeds.2007.12.049; Fouts AE, 2012, J VIROL, V86, P7444, DOI 10.1128/JVI.00467-12; Fowler KB, 2018, SEMIN PERINATOL, V42, P149, DOI 10.1053/j.semperi.2018.02.002; Freed DC, 2013, P NATL ACAD SCI USA, V110, pE4997, DOI 10.1073/pnas.1316517110; Frey SE, 1999, J INFECT DIS, V180, P1700, DOI 10.1086/315060; Fu TM, 2012, VACCINE, V30, P7469, DOI 10.1016/j.vaccine.2012.10.053; George B, 2010, TRANSPL INFECT DIS, V12, P322, DOI 10.1111/j.1399-3062.2010.00504.x; Gerna G, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030070; Gerna G, 2019, NEW MICROBIOL, V42, P1; Goderis J, 2014, PEDIATRICS, V134, P972, DOI 10.1542/peds.2014-1173; GONCZOL E, 1990, VACCINE, V8, P130, DOI 10.1016/0264-410X(90)90135-9; Gratama JW, 2010, BLOOD, V116, P1655, DOI 10.1182/blood-2010-03-273508; Griffiths P, 2015, J PATHOL, V235, P288, DOI 10.1002/path.4437; Griffiths PD, 2011, LANCET, V377, P1256, DOI 10.1016/S0140-6736(11)60136-0; Grosse SD, 2008, J CLIN VIROL, V41, P57, DOI 10.1016/j.jcv.2007.09.004; GRUNDY JE, 1988, LANCET, V2, P132; Guerra B, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.09.052; Gugliesi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020260; Gugliesi F, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050685; Gwee A, 2014, PEDIATR INFECT DIS J, V33, P115, DOI 10.1097/INF.0000000000000032; Hahn G, 2004, J VIROL, V78, P10023, DOI 10.1128/JVI.78.18.10023-10033.2004; Hookipa Biotech GmbH, 2018, RAND PLAC CONTR DOUB; Hookipa Biotech GmbH, 2021, RAND PLAC CONTR PHAS; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; Huang SN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040623; Hughes BL, 2016, AM J OBSTET GYNECOL, V214, pB5, DOI 10.1016/j.ajog.2016.02.042; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Kabanova A, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.82, 10.1038/NMICROBIOL.2016.82]; Kagan KO, 2019, ULTRASOUND OBST GYN, V53, P383, DOI 10.1002/uog.19164; Kalejta RF, 2008, MICROBIOL MOL BIOL R, V72, P249, DOI 10.1128/MMBR.00040-07; Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535; Kharfan-Dabaja MA, 2012, LANCET INFECT DIS, V12, P290, DOI 10.1016/S1473-3099(11)70344-9; Kimberlin DW, 2015, NEW ENGL J MED, V372, P933, DOI 10.1056/NEJMoa1404599; Kimberlin DW, 2008, J INFECT DIS, V197, P836, DOI 10.1086/528376; Kimberlin DW, 2003, J PEDIATR-US, V143, P16, DOI 10.1016/S0022-3476(03)00192-6; Kirchmeier M, 2014, CLIN VACCINE IMMUNOL, V21, P174, DOI 10.1128/CVI.00662-13; Kotton CN, 2018, TRANSPLANTATION, V102, P900, DOI 10.1097/TP.0000000000002191; Kylat RI, 2006, EUR J PEDIATR, V165, P773, DOI 10.1007/s00431-006-0172-6; La Rosa C, 2002, BLOOD, V100, P3681, DOI 10.1182/blood-2002-03-0926; La Rosa C, 2001, BLOOD, V97, P1776; La Rosa C, 2017, BLOOD, V129, P114, DOI 10.1182/blood-2016-07-729756; La Rosa C, 2012, FUTURE VIROL, V7, P279, DOI 10.2217/FVL.12.8; La Rosa C, 2012, J INFECT DIS, V205, P1294, DOI 10.1093/infdis/jis107; Lazzarotto T, 2000, VIRAL IMMUNOL, V13, P137, DOI 10.1089/vim.2000.13.137; Lazzarotto T, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00013; Leppek Kathrin, 2021, bioRxiv, DOI 10.1101/2021.03.29.437587; Leruez-Ville M, 2017, CLIN INFECT DIS, V65, P398, DOI 10.1093/cid/cix337; Leung AYH, 2007, BONE MARROW TRANSPL, V39, P661, DOI 10.1038/sj.bmt.1705673; Lilleri D, 2007, J INFECT DIS, V195, P1062, DOI 10.1086/512245; Limaye AP, 2010, REV MED VIROL, V20, P372, DOI 10.1002/rmv.664; Lindemann M, 2003, TRANSPLANTATION, V75, P833, DOI 10.1097/01.TP.0000054841.42796.68; Locatelli F, 2016, EXPERT REV HEMATOL, V9, P1093, DOI 10.1080/17474086.2016.1242406; Lombardi G, 2009, EUR J CLIN MICROBIOL, V28, P1465, DOI 10.1007/s10096-009-0806-5; Luck SE, 2017, PEDIATR INFECT DIS J, V36, P1205, DOI 10.1097/INF.0000000000001763; Lumbreras C, 2014, CLIN MICROBIOL INFEC, V20, P19, DOI 10.1111/1469-0691.12594; Maffini E, 2016, EXPERT REV HEMATOL, V9, P585, DOI 10.1080/17474086.2016.1174571; Marsico C, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0358-8; Martinez-Martin N, 2018, CELL, V174, P1158, DOI 10.1016/j.cell.2018.06.028; Marty FM, 2017, NEW ENGL J MED, V377, P2433, DOI 10.1056/NEJMoa1706640; Meesing A, 2018, DRUGS, V78, P1085, DOI 10.1007/s40265-018-0943-1; Merck S., 2021, DOUBLE BLIND RANDOMI; Merck S., 2019, PHASE 1 RANDOMIZED D; Mitchell DK, 2002, PEDIATR INFECT DIS J, V21, P133, DOI 10.1097/00006454-200202000-00009; ModernaTX Inc, 2021, **NON-TRADITIONAL**; ModernaTX Inc, 2021, PHAS 2 RAND OBS BLIN; Moretti S, 1998, BONE MARROW TRANSPL, V22, P175, DOI 10.1038/sj.bmt.1701302; Morton CC, 2006, NEW ENGL J MED, V354, P2151, DOI 10.1056/NEJMra050700; Nakamura R, 2016, LANCET HAEMATOL, V3, pE87, DOI 10.1016/S2352-3026(15)00246-X; Nelson CS, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0074-4; Oliver SE, 2009, J CLIN VIROL, V46, pS22, DOI 10.1016/j.jcv.2009.08.012; Ott G, 1995, Pharm Biotechnol, V6, P277; Owers DS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005133.pub3; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Park SY, 2012, J ANTIMICROB CHEMOTH, V67, P1486, DOI 10.1093/jac/dks043; Pass RF, 2006, J CLIN VIROL, V35, P216, DOI 10.1016/j.jcv.2005.09.015; Pass RF, 1999, J INFECT DIS, V180, P970, DOI 10.1086/315022; Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749; Paulus C, 2009, VIRUSES-BASEL, V1, P760, DOI 10.3390/v1030760; Pawelec Graham, 2010, Immun Ageing, V7, P13, DOI 10.1186/1742-4933-7-13; Paya C, 2004, AM J TRANSPLANT, V4, P611, DOI 10.1111/j.1600-6143.2004.00382.x; PLOTKIN SA, 1994, TRANSPLANTATION, V58, P1176, DOI 10.1097/00007890-199412270-00006; PLOTKIN SA, 1991, ANN INTERN MED, V114, P525, DOI 10.7326/0003-4819-114-7-525; PLOTKIN SA, 1975, INFECT IMMUN, V12, P521, DOI 10.1128/IAI.12.3.521-527.1975; Plotkin SA, 2019, VACCINE, V37, P7437, DOI 10.1016/j.vaccine.2018.02.089; Port AD, 2017, J OCUL PHARMACOL TH, V33, P224, DOI 10.1089/jop.2016.0140; Prince HE, 2014, CLIN VACCINE IMMUNOL, V21, P1377, DOI 10.1128/CVI.00487-14; Rawlinson WD, 2017, LANCET INFECT DIS, V17, pE177, DOI 10.1016/S1473-3099(17)30143-3; Razonable RR, 2013, AM J TRANSPLANT, V13, P93, DOI 10.1111/ajt.12103; Razonable RR, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13512; Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735; Retzler J, 2019, ARCH DIS CHILD, V104, P559, DOI 10.1136/archdischild-2018-316010; Revello MG, 2011, J CLIN VIROL, V50, P303, DOI 10.1016/j.jcv.2010.12.012; Ross SA, 2015, PEDIATR INFECT DIS J, V34, P903, DOI 10.1097/INF.0000000000000757; Ryckman BJ, 2006, J VIROL, V80, P710, DOI 10.1128/JVI.80.2.710-722.2006; Ryckman BJ, 2008, J VIROL, V82, P60, DOI 10.1128/JVI.01910-07; Sabbaj S, 2011, J INFECT DIS, V203, P1534, DOI 10.1093/infdis/jir138; Sandonis V, 2020, TRENDS MICROBIOL, V28, P900, DOI 10.1016/j.tim.2020.04.003; Schleiss MR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030526; Schleiss MR, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00268-17; Schwendinger M, 2022, J INFECT DIS, V225, P1399, DOI 10.1093/infdis/jiaa121; Selinsky C, 2005, HUM VACCINES, V1, P16, DOI 10.4161/hv.1.1.1335; Shenk T., 2008, CURRENT TOPICS MICRO; Sijmons S, 2015, J VIROL, V89, P7673, DOI 10.1128/JVI.00578-15; Smith LR, 2013, VACCINES-BASEL, V1, DOI 10.3390/vaccines1040398; Sommerer C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020133; Stenberg R.M., 1993, MOL ASPECTS HUMAN CY, VVolume 2, P330; Stratton KR., 2000, NATL ACAD COLLECTION; Sungkanuparph S, 2008, J INFECTION, V56, P40, DOI 10.1016/j.jinf.2007.10.005; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Tabata T, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040135; Teira P, 2016, BLOOD, V127, P2427, DOI 10.1182/blood-2015-11-679639; Thigpen J, 2020, NEONATAL NETW, V39, P293, DOI 10.1891/0730-0832.39.5.293; Tomtishen JP, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-22; Travi G, 2014, J INTENSIVE CARE MED, V29, P200, DOI 10.1177/0885066613476454; University of California San Francisco, 2008, RAND PHAS 1 TRIAL EV; Vancor E, 2019, J PEDIAT INF DIS SOC, V8, P55, DOI 10.1093/jpids/pix105; Vasilieva Elena, 2020, Pathog Immun, V5, P240, DOI 10.20411/pai.v5i1.382; VBI Vaccines Inc, 2020, PHAS 1 RAND OBS BLIN; Vincenti F, 2018, AM J TRANSPLANT, V18, P2945, DOI 10.1111/ajt.14925; Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102; Wang D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9387; Wilski NA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030062; Wloch MK, 2008, J INFECT DIS, V197, P1634, DOI 10.1086/588385; Zaia JA, 2001, J VIROL, V75, P2472, DOI 10.1128/JVI.75.5.2472-2474.2001; Zhou WD, 2009, BLOOD, V113, P6465, DOI 10.1182/blood-2009-02-203307; Zhou X., 2021, ONCOL LETT, V21, P1, DOI [10.3892/ol.2020, DOI 10.3892/OL.2020]	160	6	6	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							551	10.3390/vaccines9060551			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ1JV	34070277	Green Published, gold			2022-04-29	WOS:000666331500001
J	Hsueh, FC; Wang, SY; Lin, WH; Lin, CF; Tsai, CY; Huang, CW; Sun, N; Chiou, MT; Lin, CN				Hsueh, Fu-Chun; Wang, Sheng-Yuan; Lin, Wei-Hao; Lin, Chuen-Fu; Tsai, Chen-Yu; Huang, Chin-Wen; Sun, Ning; Chiou, Ming-Tang; Lin, Chao-Nan			Correlation of Neutralizing Antibodies (NAbs) between Sows and Piglets and Evaluation of Protectability Associated with Maternally Derived NAbs in Pigs against Circulating Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) under Field Conditions	VACCINES			English	Article						maternal neutralizing antibody; correlates of protections; porcine reproductive and respiratory syndrome virus; viral load; field experiment; survival rate	PASSIVE TRANSFER; INFECTION; IMMUNITY; DISEASE; POLYMORPHISMS; PROTECTION; RESPONSES; VACCINE; VIREMIA; STRAIN	Porcine reproductive and respiratory syndrome (PRRS), which is caused by a highly transmissible pathogen called porcine reproductive and respiratory syndrome virus (PRRSV), has caused severe problems, including reproductive disorders in sows and respiratory symptoms in nursery pigs worldwide, since the early 1990s. However, currently available PRRSV vaccines do not supply complete immunity to confront the viral infection. Elicitation of PRRSV-specific neutralizing antibodies (NAbs) during the preinfectious period has been deemed to be a feasible strategy to modulate this virus, especially in farms where nursery pigs are seized with PRRSVs. A total of 180 piglets in a farrow-to-finish farm that had a natural outbreak of PRRS were distributed into three groups based on the different PRRSV NAbs levels in their dams. In the present study, piglets that received superior maternal-transferred NAbs showed delayed and relatively slight viral loads in serum and, on the whole, higher survival rates against wild PRRSV infections. A positive correlation of maternal NAbs between sows and their piglets was identified; moreover, high NAbs titers in piglets can last for at least 4 weeks. These results provide updated information to develop an appropriate immune strategy for breeding and for future PRRSV control under field conditions.	[Hsueh, Fu-Chun; Wang, Sheng-Yuan; Lin, Wei-Hao; Lin, Chuen-Fu; Tsai, Chen-Yu; Chiou, Ming-Tang; Lin, Chao-Nan] Natl Pingtung Univ Sci & Technol, Coll Vet Med, Anim Dis Diagnost Ctr, Pingtung 91201, Taiwan; [Lin, Wei-Hao; Lin, Chuen-Fu; Tsai, Chen-Yu; Huang, Chin-Wen; Sun, Ning; Chiou, Ming-Tang; Lin, Chao-Nan] Natl Pingtung Univ Sci & Technol, Dept Vet Med, Coll Vet Med, Pingtung 91201, Taiwan		Chiou, MT; Lin, CN (通讯作者)，Natl Pingtung Univ Sci & Technol, Coll Vet Med, Anim Dis Diagnost Ctr, Pingtung 91201, Taiwan.; Chiou, MT; Lin, CN (通讯作者)，Natl Pingtung Univ Sci & Technol, Dept Vet Med, Coll Vet Med, Pingtung 91201, Taiwan.	jim820723@gmail.com; april89000@gmail.com; whlin@g4e.npust.edu.tw; cflin2283@mail.npust.edu.tw; a0911701551@gmail.com; a0986814635@gmail.com; putindog88@gmail.com; mtchiou@mail.npust.edu.tw; cnlin6@mail.npust.edu.tw			Ministry of Science and Technology, Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [MOST 109-2313-B-020-004]	This research was funded by Ministry of Science and Technology, Taiwan, R.O.C. (MOST 109-2313-B-020-004).	Adams MJ, 2017, ARCH VIROL, V162, P2505, DOI 10.1007/s00705-017-3358-5; Chueh LL, 1998, ADV EXP MED BIOL, V440, P795; COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201; Diaz I, 2005, J GEN VIROL, V86, P1943, DOI 10.1099/vir.0.80959-0; Du TF, 2017, TRENDS MICROBIOL, V25, P968, DOI 10.1016/j.tim.2017.06.001; Geldhof MF, 2013, VET MICROBIOL, V167, P260, DOI 10.1016/j.vetmic.2013.08.017; Go N, 2019, BMC SYST BIOL, V13, DOI 10.1186/s12918-018-0666-7; Hsueh FC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010102; Jiang P, 2000, J VET DIAGN INVEST, V12, P156, DOI 10.1177/104063870001200211; Kick AR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020106; Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022; Kraft C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223060; Labarque GG, 2000, J GEN VIROL, V81, P1327, DOI 10.1099/0022-1317-81-5-1327; Li YC, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060427; Lim B, 2018, ANIM GENET, V49, P98, DOI 10.1111/age.12630; Lin CN, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-181; Lin WH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030316; Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06; Lopez OJ, 2004, VET IMMUNOL IMMUNOP, V102, P155, DOI 10.1016/j.vetimm.2004.09.005; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Nazki S, 2020, VET RES, V51, DOI 10.1186/s13567-020-00789-7; Niu P, 2016, VET MICROBIOL, V182, P187, DOI 10.1016/j.vetmic.2015.11.010; Osorio FA, 2002, VIROLOGY, V302, P9, DOI 10.1006/viro.2002.1612; Pomorska-Mol M, 2020, RES VET SCI, V128, P9, DOI 10.1016/j.rvsc.2019.10.020; Rahe MC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060148; SHIMIZU M, 1994, J VET MED SCI, V56, P389, DOI 10.1292/jvms.56.389; Vanhee M, 2009, VET RES, V40, DOI 10.1051/vetres/2009046; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Yoon KJ, 1996, VIRAL IMMUNOL, V9, P51, DOI 10.1089/vim.1996.9.51; Yu CH, 2019, THAI J VET MED, V49, P167; Zimmerman JJ, 1997, VET MICROBIOL, V55, P187, DOI 10.1016/S0378-1135(96)01330-2	32	2	2	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							414	10.3390/vaccines9050414			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1FT	33919161	gold, Green Published			2022-04-29	WOS:000654572700001
J	Lee, EK; Li, ZNL; Liu, YFK; LeDuc, J				Lee, Eva K.; Li, Zhuonan L.; Liu, Yifan K.; LeDuc, James			Strategies for Vaccine Prioritization and Mass Dispensing	VACCINES			English	Article						vaccine prioritization; mixed vaccination strategy; switch trigger; mass vaccination; vaccine efficacy; biological-behavior-logistics-queueing computational framework	YELLOW-FEVER VACCINE; PANDEMIC INFLUENZA; SYSTEMS-ANALYSIS; PUBLIC-HEALTH; UNITED-STATES; ALLOCATION; MODEL; SHORTAGE; OUTBREAK; COVID-19	We propose a system that helps decision makers during a pandemic find, in real time, the mass vaccination strategies that best utilize limited medical resources to achieve fast containments and population protection. Our general-purpose framework integrates into a single computational platform a multi-purpose compartmental disease propagation model, a human behavior network, a resource logistics model, and a stochastic queueing model for vaccination operations. We apply the modeling framework to the current COVID-19 pandemic and derive an optimal trigger for switching from a prioritized vaccination strategy to a non-prioritized strategy so as to minimize the overall attack rate and mortality rate. When vaccine supply is limited, such a mixed vaccination strategy is broadly effective. Our analysis suggests that delays in vaccine supply and inefficiencies in vaccination delivery can substantially impede the containment effort. Employing an optimal mixed strategy can significantly reduce the attack and mortality rates. The more infectious the virus, the earlier it helps to open the vaccine to the public. As vaccine efficacy decreases, the attack and mortality rates rapidly increase by multiples; this highlights the importance of early vaccination to reduce spreading as quickly as possible to lower the chances for further mutations to evolve and to reduce the excessive healthcare burden. To maximize the protective effect of available vaccines, of equal importance are determining the optimal mixed strategy and implementing effective on-the-ground dispensing. The optimal mixed strategy is quite robust against variations in model parameters and can be implemented readily in practice. Studies with our holistic modeling framework strongly support the urgent need for early vaccination in combating the COVID-19 pandemic. Our framework permits rapid custom modeling in practice. Additionally, it is generalizable for different types of infectious disease outbreaks, whereby a user may determine for a given type the effects of different interventions including the optimal switch trigger.	[Lee, Eva K.; Li, Zhuonan L.; Liu, Yifan K.] Georgia Inst Technol, NSF Whitaker Ctr Operat Res Med & HealthCare, Atlanta, GA 30332 USA; [LeDuc, James] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77550 USA		Lee, EK (通讯作者)，Georgia Inst Technol, NSF Whitaker Ctr Operat Res Med & HealthCare, Atlanta, GA 30332 USA.	evalee-gatech@pm.me; leon.li@gatech.edu; yifanliu@gatech.edu; jwleduc@utmb.edu		Lee, Eva/0000-0003-0415-4640; Li, Zhuonan/0000-0003-3970-7014	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [200-2016-90873]; National Science FoundationNational Science Foundation (NSF)	This work is partially supported by grants from the Centers for Disease Control and Prevention, 200-2016-90873 and the National Science Foundation, IIP-1516074. Findings and conclusions in this paper are those of the authors and do not necessarily reflect the views of the Centers for Disease Control and Prevention and the National Science Foundation.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Buckner JH, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025786118; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]; CHALUMEAU HP, 1994, EUR J EPIDEMIOL, V10, P487, DOI 10.1007/BF01719684; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Conway JM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-932; Cosgrove SE, 2005, JAMA-J AM MED ASSOC, V293, P229, DOI 10.1001/jama.293.2.229; Emanuel EJ, 2006, SCIENCE, V312, P854, DOI 10.1126/science.1125347; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Gayle H, 2020, FRAMEWORK EQUITABLE; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Gershman MD, 2017, MMWR-MORBID MORTAL W, V66, P457, DOI 10.15585/mmwr.mm6617e2; Hamborsky J., 2007, SMALLPOX, V10th; Johansson MA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35057; Jung CY, 2020, INT J INFECT DIS, V99, P266, DOI 10.1016/j.ijid.2020.08.001; Kaufmann JR, 2011, HEALTH AFFAIR, V30, P1113, DOI 10.1377/hlthaff.2011.0368; Kazmin D, 2017, P NATL ACAD SCI USA, V114, P2425, DOI 10.1073/pnas.1621489114; Kirby T, 2021, LANCET RESP MED, V9, pE20, DOI 10.1016/S2213-2600(21)00005-9; Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/S1473-3099(16)30513-8, 10.1016/s1473-3099(16)30513-8]; Kucirka LM, 2020, ANN INTERN MED, V173, P262, DOI 10.7326/M20-1495; La Montagne JR, 2004, NEW ENGL J MED, V351, P2330, DOI 10.1056/NEJMe048314; Lee BY, 2010, VACCINE, V28, P4875, DOI 10.1016/j.vaccine.2010.05.002; Lee BY, 2010, AM J PREV MED, V38, P247, DOI 10.1016/j.amepre.2009.11.009; Lee E.K, 2020, MODELING EVALUATING; Lee EK, 2006, ANN OPER RES, V148, P25, DOI 10.1007/s10479-006-0087-7; Lee Eva K, 2017, AMIA Annu Symp Proc, V2017, P1090; Lee Eva K, 2010, AMIA Annu Symp Proc, V2010, P427; Lee EK, 2016, INTERFACES, V46, P368, DOI 10.1287/inte.2016.0862; Lee EK, 2015, INTERFACES, V45, P425, DOI 10.1287/inte.2015.0814; Lee EK, 2013, INTERFACES, V43, P79, DOI 10.1287/inte.2013.0676; Lee S, 2020, JAMA INTERN MED, V180, P1447, DOI 10.1001/jamainternmed.2020.3862; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liu Y., 2017, P 2017 INT C DIG HLT, P137, DOI [10.1145/3079452.3079473, DOI 10.1145/3079452.3079473]; LONGINI IM, 1978, MATH BIOSCI, V38, P141, DOI 10.1016/0025-5564(78)90023-8; Matrajt Laura, 2020, medRxiv, DOI 10.1101/2020.08.14.20175257; Medlock Jan, 2009, PLoS Curr, V1, pRRN1134; Medlock J, 2009, SCIENCE, V325, P1705, DOI 10.1126/science.1175570; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Miller MA, 2008, J INFECT DIS, V198, P305, DOI 10.1086/589716; Munana C., 2020, COVID 19 RISKS IMPAC; Mylius SD, 2008, VACCINE, V26, P3742, DOI 10.1016/j.vaccine.2008.04.043; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Nathan N, 2001, LANCET, V358, P2129, DOI 10.1016/S0140-6736(01)07185-9; Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4; Patel R, 2005, J THEOR BIOL, V234, P201, DOI 10.1016/j.jtbi.2004.11.032; Pearson M.L, 2006, MMWR-MORBID MORTAL W, V55; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; SALK JE, 1955, JAMA-J AM MED ASSOC, V158, P1239, DOI 10.1001/jama.1955.02960140001001; Schwartz B, 2009, CURR TOP MICROBIOL, V333, P495, DOI 10.1007/978-3-540-92165-3_24; Treanor J, 2002, VACCINE, V20, P1099, DOI 10.1016/S0264-410X(01)00440-6; Tuite AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010520; Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261; Uscher-Pines L, 2006, PLOS MED, V3, P1721, DOI 10.1371/journal.pmed.0030436; Wallinga J, 2010, P NATL ACAD SCI USA, V107, P923, DOI 10.1073/pnas.0908491107; Wu JT, 2007, P ROY SOC B-BIOL SCI, V274, P2811, DOI 10.1098/rspb.2007.0893	59	2	2	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							506	10.3390/vaccines9050506			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NT	34068985	gold, Green Published			2022-04-29	WOS:000654593600001
J	Nicoli, F; Pacifico, S; Gallerani, E; Marzola, E; Albanese, V; Finessi, V; Llewellyn-Lacey, S; Price, DA; Appay, V; Marconi, P; Guerrini, R; Caputo, A; Gavioli, R				Nicoli, Francesco; Pacifico, Salvatore; Gallerani, Eleonora; Marzola, Erika; Albanese, Valentina; Finessi, Valentina; Llewellyn-Lacey, Sian; Price, David A.; Appay, Victor; Marconi, Peggy; Guerrini, Remo; Caputo, Antonella; Gavioli, Riccardo			Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines	VACCINES			English	Article						adaptive immune responses; B-cell epitopes; peptide vaccines; T-cell epitopes	HIV-1 TAT PROTEIN; TYPE-1 TAT; IMMUNIZATION; RESPONSES; ACTIVATION; ANTIBODIES; INDUCTION; RESISTANT; STRATEGY; HUMANS	Peptide vaccines incorporating B- and T-cell epitopes have shown promise in the context of various cancers and infections. These vaccines are relatively simple to manufacture, but more immunogenic formulations are considered a priority. We developed tetrabranched derivatives for this purpose based on a novel peptide welding technology (PWT). PWTs provide molecular scaffolds for the efficient synthesis of ultrapure peptide dendrimers, which allow the delivery of multiple ligands within a single macromolecular structure. Peptide vaccines incorporating T-cell epitopes derived from melanoma and B-cell epitopes derived from human immunodeficiency virus, synthesized using this approach, elicited primary immune responses in vitro and in vivo. Subcutaneous administration of the B-cell epitope-based vaccines also elicited more potent humoral responses than subcutaneous administration of the corresponding peptides alone. Highly immunogenic peptide epitope-based vaccines can therefore be generated quickly and easily using a novel PWT.	[Nicoli, Francesco; Pacifico, Salvatore; Gallerani, Eleonora; Marzola, Erika; Albanese, Valentina; Finessi, Valentina; Marconi, Peggy; Guerrini, Remo; Caputo, Antonella; Gavioli, Riccardo] Univ Ferrara, Dept Chem Pharmaceut & Agr Sci, I-44121 Ferrara, Italy; [Llewellyn-Lacey, Sian; Price, David A.] Cardiff Univ, Div Infect & Immun, Sch Med, Cardiff CF14 4XN, Wales; [Price, David A.] Cardiff Univ, Sch Med, Syst Immun Res Inst, Cardiff CF14 4XN, Wales; [Appay, Victor] Univ Bordeaux, CNRS UMR 5164, ImmunoConcEpT, F-33000 Bordeaux, France		Caputo, A (通讯作者)，Univ Ferrara, Dept Chem Pharmaceut & Agr Sci, I-44121 Ferrara, Italy.	nclfnc1@unife.it; pcfsvt@unife.it; glllnr@unife.it; mrzrke@unife.it; lbnvnt@unife.it; fnsvnt@unife.it; Llewellyn-LaceyS@cardiff.ac.uk; PriceD6@cardiff.ac.uk; victor.appay@immuconcept.org; mcy@unife.it; grm@unife.it; cpa@unife.it; gvr@unife.it	Price, David A/C-7876-2013; Gavioli, Riccardo/K-7594-2016	Price, David A/0000-0001-9416-2737; Gavioli, Riccardo/0000-0002-7805-4290; pacifico, Salvatore/0000-0002-3377-5107; Nicoli, Francesco/0000-0001-6327-5958; Appay, Victor/0000-0001-5434-3963; Caputo, Antonella/0000-0002-1241-0299; Marconi, Peggy C. R./0000-0003-3488-0491	Wellcome TrustWellcome TrustEuropean Commission [100326/Z/12/Z]; University of Ferrara (Fondo di Ateneo per la Ricerca Scientifica); University of Ferrara (Bando per l'Acquisizione di Strumenti per la Ricerca di Ateneo 2015)	This work was supported by grants from theWellcome Trust (100326/Z/12/Z) to D.A.P. and by grants from the University of Ferrara (Fondo di Ateneo per la Ricerca Scientifica) to R.G. (Remo Guerrini), A.C., and R.G. (Riccardo Gavioli). Core provision of the FACSCanto II was funded by the University of Ferrara (Bando per l'Acquisizione di Strumenti per la Ricerca di Ateneo 2015).	Azuar A, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030058; Bachler BC, 2013, J VIROL, V87, P4403, DOI 10.1128/JVI.02888-12; Behrendt R, 2016, J PEPT SCI, V22, P4, DOI 10.1002/psc.2836; Bellini C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122673; Bracci L, 2003, J BIOL CHEM, V278, P46590, DOI 10.1074/jbc.M308615200; Butto S, 2003, J INFECT DIS, V188, P1171, DOI 10.1086/378412; Calo G, 2018, PEPTIDES, V99, P195, DOI 10.1016/j.peptides.2017.10.004; Caputo A, 2008, VACCINE, V26, P1214, DOI 10.1016/j.vaccine.2007.12.030; Carretero-Iglesia L, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03016; Cerlesi MC, 2017, EUR J PHARMACOL, V794, P115, DOI 10.1016/j.ejphar.2016.11.026; CHANG KJ, 1988, P NATL ACAD SCI USA, V85, P4929, DOI 10.1073/pnas.85.13.4929; Ensoli B, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0261-1; Ensoli B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013540; Ensoli F, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0151-y; Finessi V, 2015, HUM VACC IMMUNOTHER, V11, P1489, DOI 10.1080/21645515.2015.1016676; Gayet R, 2020, EUR J IMMUNOL, V50, P1295, DOI 10.1002/eji.201948177; Guerrini R, 2014, BIOORGAN MED CHEM, V22, P3703, DOI 10.1016/j.bmc.2014.05.005; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4; Kurnaeva MA, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2031; Lambert TH, 2006, J AM CHEM SOC, V128, P426, DOI 10.1021/ja0574567; Lissina A, 2016, J IMMUNOL, V196, P256, DOI 10.4049/jimmunol.1501140; Longo O, 2009, VACCINE, V27, P3306, DOI 10.1016/j.vaccine.2009.01.090; Ma MJ, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12875; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Moreau E, 2004, J GEN VIROL, V85, P2893, DOI 10.1099/vir.0.80365-0; MUKHERJI B, 1995, P NATL ACAD SCI USA, V92, P8078, DOI 10.1073/pnas.92.17.8078; Nair DP, 2014, CHEM MATER, V26, P724, DOI 10.1021/cm402180t; Nelde A, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1074/mcp.R120.002309; Nicoli F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020274; Nicoli F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02736; Nicoli F, 2018, AIDS, V32, P575, DOI 10.1097/QAD.0000000000001734; Nicoli F, 2017, VACCINE, V35, P3012, DOI 10.1016/j.vaccine.2017.04.030; Nicoli F, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1647-3; Nicoli F, 2016, VACCINE, V34, P2216, DOI 10.1016/j.vaccine.2016.03.022; Nicoli F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077746; Niederhafner P, 2005, J PEPT SCI, V11, P757, DOI 10.1002/psc.721; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Papagno L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67704-0; Re MC, 2001, J CLIN VIROL, V21, P81, DOI 10.1016/S1386-6532(00)00189-X; Sabatino D, 2020, J MED CHEM, V63, P14184, DOI 10.1021/acs.jmedchem.0c00848; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schneble E, 2016, METHODS MOL BIOL, V1403, P797, DOI 10.1007/978-1-4939-3387-7_46; Sicurella M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100844; Skwarczynski M, 2020, EXPERT OPIN DRUG DEL, V17, P435, DOI 10.1080/17425247.2020.1731468; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Song HY, 2009, ORG BIOMOL CHEM, V7, P3400, DOI 10.1039/b904060a; Tam JP, 1996, J IMMUNOL METHODS, V196, P17, DOI 10.1016/0022-1759(96)00066-X; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Telatin V, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00190; Yoshida K, 2011, ONCOL REP, V25, P57, DOI 10.3892/or_00001041	51	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							526	10.3390/vaccines9050526			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NQ	34069535	gold, Green Accepted, Green Published			2022-04-29	WOS:000654593300001
J	Qunaibi, E; Basheti, I; Soudy, M; Sultan, I				Qunaibi, Eyad; Basheti, Iman; Soudy, Mohamed; Sultan, Iyad			Hesitancy of Arab Healthcare Workers towards COVID-19 Vaccination: A Large-Scale Multinational Study	VACCINES			English	Article						COVID-19 vaccines		Background: Health care workers (HCWs) are at increased risk of acquiring and transmitting COVID-19 infection. Moreover, they present role models for communities with regards to attitudes towards COVID-19 vaccination. Hence, hesitancy of HCWs towards vaccination can crucially affect the efforts aiming to contain the pandemic. Previously published studies paid little attention to HCWs in Arab countries, which have a population of over 440 million. Objectives: To assess the rates of COVID-19 vaccine hesitancy in Arabic-speaking HCWs residing in and outside Arab countries, and their perceived barriers towards vaccination. Methods: A cross-sectional study based on an online survey was conducted from 14-29 January 2021, targeting Arabic-speaking HCWs from all around the world. Results: The survey recruited 5708 eligible participants (55.6% males, 44.4% females, age 30.6 +/- 10 years) from 21 Arab countries (87.5%) and 54 other countries (12.5%). Our analysis showed a significant rate of vaccine hesitancy among Arabic-speaking HCWs residing in and outside of Arab countries (25.8% and 32.8%, respectively). The highest rates of hesitancy were among participants from the western regions of the Arab world (Egypt, Morocco, Tunisia, and Algeria). The most cited reasons for hesitancy were concerns about side effects and distrust of the expedited vaccine production and healthcare policies. Factors associated with higher hesitancy included age of 30-59, previous or current suspected or confirmed COVID-19, female gender, not knowing the vaccine type authorized in the participant's country, and not regularly receiving the influenza vaccine. Conclusion: This is the first large-scale multinational post-vaccine-availability study on COVID-19 vaccine hesitancy among HCWs. It reveals high rates of hesitancy among Arab-speaking HCWs. Unless addressed properly, this hesitancy can impede the efforts for achieving widespread vaccination and collective immunity.	[Qunaibi, Eyad] Jerash Private Univ, Coll Pharm, Jerash 26150, Jordan; [Basheti, Iman] Appl Sci Private Univ, Dept Clin Pharm & Therapeut, Fac Pharm, Amman 11931, Jordan; [Soudy, Mohamed] Childrens Canc Hosp, Basic Res Dept, Prote & Metabol Unit, Cairo 11562, Egypt; [Sultan, Iyad] King Hussein Canc Ctr, Dept Paediat, Amman 11941, Jordan; [Sultan, Iyad] King Hussein Canc Ctr, Canc Care Informat Program, Amman 11941, Jordan; [Sultan, Iyad] Univ Jordan, Dept Paediat, Amman 19328, Jordan		Qunaibi, E (通讯作者)，Jerash Private Univ, Coll Pharm, Jerash 26150, Jordan.	eyad.aqunaibi@jpu.edu.jo; dr_iman@asu.edu.jo; Mohamed.soudy@57357.org; isultan@khcc.jo	Soudy, Mohmed/AAU-7578-2020	Soudy, Mohmed/0000-0003-2735-0038; Basheti, Iman/0000-0002-8460-1158			Chew N.W., 2021, INT J INFECT DIS, V26, P1201; Cyranoski D, 2020, NATURE, V588, P548, DOI 10.1038/d41586-020-03563-z; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Gadoth A., 2021, ANN INTERN MED, P20; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Guidotti E., 2020, J OPEN SOURCE SOFTW, V5, P2376, DOI [10.21105/joss.02376, DOI 10.21105/JOSS.02376]; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Ledda C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052703; Mohamed-Hussein AAR, 2021, NATL SURVEY POTENTIA; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Qunaibi E.A., 2021, HIGH RATE COVID 19 V; Raftopoulos V, 2021, HUM VACC IMMUNOTHER, V17, P2397, DOI 10.1080/21645515.2021.1896907; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Yurttas B., 2021, RHEUMATOL INT, V29, P1	17	22	22	5	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							446	10.3390/vaccines9050446			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3GH	34063313	Green Submitted, gold, Green Published			2022-04-29	WOS:000654713100001
J	Liu, XL; Chang, XY; Rothen, D; Derveni, M; Krenger, P; Roongta, S; Wright, E; Vogel, M; Tars, K; Mohsen, MO; Bachmann, MF				Liu, Xuelan; Chang, Xinyue; Rothen, Dominik; Derveni, Mariliza; Krenger, Pascal; Roongta, Salony; Wright, Edward; Vogel, Monique; Tars, Kaspars; Mohsen, Mona O.; Bachmann, Martin F.			AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate	VACCINES			English	Article						virus-like particles; AP205-VLPs; RB motif; humoral immune response	ANTIBODY; SUBCLASS	COVID-19 is a novel disease caused by SARS-CoV-2 which has conquered the world rapidly resulting in a pandemic that massively impacts our health, social activities, and economy. It is likely that vaccination is the only way to form "herd immunity" and restore the world to normal. Here we developed a vaccine candidate for COVID-19 based on the virus-like particle AP205 displaying the spike receptor binding motif (RBM), which is the major target of neutralizing antibodies in convalescent patients. To this end, we genetically fused the RBM domain of SARS-CoV-2 to the C terminus of AP205 of dimerized capsid proteins. The fused VLPs were expressed in E. coli, which resulted in insoluble aggregates. These aggregates were denatured in 8 M urea followed by refolding, which reconstituted VLP formation as confirmed by electron microscopy analysis. Importantly, immunized mice were able to generate high levels of IgG antibodies recognizing eukaryotically expressed receptor binding domain (RBD) as well as spike protein of SARS-CoV-2. Furthermore, induced antibodies were able to neutralize SARS-CoV-2/ABS/NL20. Additionally, this vaccine candidate has the potential to be produced at large scale for immunization programs.	[Liu, Xuelan] Anhui Agr Univ, Int Immunol Ctr, Hefei 230036, Peoples R China; [Liu, Xuelan; Chang, Xinyue; Rothen, Dominik; Krenger, Pascal; Roongta, Salony; Vogel, Monique; Mohsen, Mona O.; Bachmann, Martin F.] Bern Univ Hosp, Dept Immunol, RIA, CH-3010 Bern, Switzerland; [Chang, Xinyue; Rothen, Dominik; Krenger, Pascal; Roongta, Salony; Vogel, Monique; Mohsen, Mona O.; Bachmann, Martin F.] Univ Bern, Dept BioMed Res, CH-3012 Bern, Switzerland; [Derveni, Mariliza; Wright, Edward] Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England; [Tars, Kaspars] Latvian Biomed Res & Study Ctr, Ratsupites Iela1, LV-1067 Riga, Latvia; [Mohsen, Mona O.] Saiba AG, CH-8808 Pfaffikon, Switzerland		Liu, XL (通讯作者)，Anhui Agr Univ, Int Immunol Ctr, Hefei 230036, Peoples R China.; Liu, XL; Mohsen, MO (通讯作者)，Bern Univ Hosp, Dept Immunol, RIA, CH-3010 Bern, Switzerland.; Mohsen, MO (通讯作者)，Univ Bern, Dept BioMed Res, CH-3012 Bern, Switzerland.; Mohsen, MO (通讯作者)，Saiba AG, CH-8808 Pfaffikon, Switzerland.	xuelan.liu@dbmr.unibe.ch; xinyue.chang@dbmr.unibe.ch; dominik.rothen@students.unibe.ch; m.derveni@hvivo.com; pascal.krenger@students.unibe.ch; salony.roongta@dbmr.unibe.ch; ew323@sussex.ac.uk; Monique.vogel@dbmr.unibe.ch; kaspars@biomed.lu.lv; mona.mohsen@dbmr.unibe.ch; martin.bachmann@me.com		Wright, Edward/0000-0001-7041-5138; Bachmann, Martin/0000-0003-4370-2099	Saiba GmbH; Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [CRSII3_154490]; Qatar National Research Fund (PDRA grant) [PDRA4-0118-18002]	This work was funded by Saiba GmbH, The Swiss National Science Foundation (SNF Grant CRSII3_154490) and Qatar National Research Fund (PDRA grant PDRA4-0118-18002).	Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; Bachmann M.F., 2021, BNT162B2 MRNA COVID, DOI [10.1101/2021.03.13.435222, DOI 10.1101/2021.03.13.435222]; Bachmann M.F, 2021, SARS COV 2 VARIANT H, DOI [10.1101/2021.03.04.433887, DOI 10.1101/2021.03.04.433887]; Bachmann MF, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00264-6; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bessa J, 2008, EUR J IMMUNOL, V38, P114, DOI 10.1002/eji.200636959; Bessa J, 2009, J IMMUNOL, V183, P3788, DOI 10.4049/jimmunol.0804004; Cabral-Miranda G, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030072; Cabral-Miranda G, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5020010; Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI200111849; Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071; Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P1258, DOI 10.1017/ice.2020.282; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; Gilfillan CB, 2020, EUR J IMMUNOL, V50, P505, DOI 10.1002/eji.201948355; Gomes AC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01679; Gomes AC, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020047; Gomes AC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00226; Grant Oliver C, 2020, bioRxiv, DOI 10.1101/2020.04.07.030445; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Hazenbos WLW, 1998, J IMMUNOL, V161, P3026; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; HEUSSER CH, 1977, J EXP MED, V145, P1316, DOI 10.1084/jem.145.5.1316; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; KIPPS TJ, 1985, J EXP MED, V161, P1, DOI 10.1084/jem.161.1.1; Klasse PJ, 2016, EXPERT REV VACCINES, V15, P295, DOI 10.1586/14760584.2016.1128831; KLAUS GGB, 1979, IMMUNOLOGY, V38, P687; Li J, 2013, VIRAL IMMUNOL, V26, P126, DOI 10.1089/vim.2012.0076; Link A, 2012, J IMMUNOL, V188, P3724, DOI 10.4049/jimmunol.1103312; Marcel S, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20225; Markine-Goriaynoff D, 2002, J VIROL, V76, P432, DOI 10.1128/JVI.76.1.432-435.2002; Mohsen MO, 2020, IMMUNOL REV, V296, P155, DOI 10.1111/imr.12863; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mohsen MO, 2017, J CONTROL RELEASE, V251, P92, DOI 10.1016/j.jconrel.2017.02.031; Morita M., 2011, HITACHI REV, V60, P257; OISHI K, 1992, J INFECT DIS, V165, P34, DOI 10.1093/infdis/165.1.34; Polack FP, 2003, NAT MED, V9, P1209, DOI 10.1038/nm918; Schmitz N, 2012, EUR J IMMUNOL, V42, P863, DOI 10.1002/eji.201041225; Shishovs M, 2016, J MOL BIOL, V428, P4267, DOI 10.1016/j.jmb.2016.08.025; Skibinski DAG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076571; Tissot AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009809; Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006; Zha LS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040395; Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153; Zinkhan S, 2021, J CONTROL RELEASE, V331, P296, DOI 10.1016/j.jconrel.2021.01.012	47	7	7	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							403	10.3390/vaccines9040403			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4TJ	33921677	gold, Green Accepted, Green Published			2022-04-29	WOS:000643773200001
J	Mohamad, A; Zamri-Saad, M; Amal, MNA; Al-saari, N; Monir, MS; Chin, YK; Yasin, ISM				Mohamad, Aslah; Zamri-Saad, Mohd; Amal, Mohammad Noor Azmai; Al-saari, Nurhidayu; Monir, Md Shirajum; Chin, Yong Kit; Yasin, Ina-Salwany Md			Vaccine Efficacy of a Newly Developed Feed-Based Whole-Cell Polyvalent Vaccine against Vibriosis, Streptococcosis and Motile Aeromonad Septicemia in Asian Seabass, Lates calcarifer	VACCINES			English	Article						vibriosis; streptococcosis; MAS; fish vaccination; oral vaccination	TILAPIA OREOCHROMIS-NILOTICUS; TROUT ONCORHYNCHUS-MYKISS; FATTY-ACID-COMPOSITION; RED HYBRID TILAPIA; EDWARDSIELLA-TARDA; GROWTH-PERFORMANCE; ATLANTIC SALMON; ORAL VACCINE; DNA VACCINE; NERVOUS NECROSIS	Multiple infections of several bacterial species are often observed under natural farm conditions. The infections would cause a much more significant loss compared to a single infectious agent. Vaccination is an essential strategy to prevent diseases in aquaculture, and oral vaccination has been proposed as a promising technique since it requires no handling of the fish and is easy to perform. This research attempts to develop and evaluate a potential feed-based polyvalent vaccine that can be used to treat multiple infections by Vibrios spp., Streptococcus agalactiae, and Aeromonas hydrophila, simultaneously. The oral polyvalent vaccine was prepared by mixing formalin-killed vaccine of V. harveyi, S. agalactiae, and A. hydrophila strains with commercial feed pellet, and palm oil as an adjuvant was added to improve their antigenicity. Thereafter, a vaccinated feed pellet was tested for feed quality analysis in terms of feed stability in water, proximate nutrient analysis, and palatability, safety, and growth performance using Asian seabass, Lates calcarifer as a fish host model. For immune response analysis, a total of 300 Asian seabass juveniles (15.8 +/- 2.6 g) were divided into two groups in triplicate. Fish of group 1 were not vaccinated, while group 2 was vaccinated with the feed-based polyvalent vaccine. Vaccinations were carried out on days 0 and 14 with oral administration of the feed containing the bacterin at 5% body weight. Samples of serum for antibody and lysozyme study and the spleen and gut for gene expression analysis were collected at 7-day intervals for 6 weeks. Its efficacy in protecting fish was evaluated in aquarium challenge. Following vaccination by the polyvalent feed-based vaccine, IgM antibody levels showed a significant (p < 0.05) increase in serum against Vibrio harveyi, Aeromonas hydrophila, and Streptococcus agalactiae and reached the peak at week 3, 5, and 6, respectively. The high-stimulated antibody in the serum remained significantly higher than the control (p < 0.05) at the end of the 6 weeks vaccination trial. Not only that, but the serum lysozyme level was also increased significantly at week 4 (p < 0.05) as compared to the control treatment. The immune-related gene, dendritic cells, C3, Chemokine ligand 4 (CCL4), and major histocompatibility complex class I (MHC I) showed significantly higher expression (p < 0.05) after the fish were vaccinated with the oral vaccine. In the aquarium challenge, the vaccine provided a relative percentage survival of 75 +/- 7.1%, 80 +/- 0.0%, and 80 +/- 0.0% after challenge with V. harveyi, A. hydrophila, and S. agalactiae, respectively. Combining our results demonstrate that the feed-based polyvalent vaccine could elicit significant innate and adaptive immunological responses, and this offers an opportunity for a comprehensive immunization against vibriosis, streptococcosis, and motile aeromonad septicemia in Asian seabass, Lates calcarifer. Nevertheless, this newly developed feed-based polyvalent vaccination can be a promising technique for effective and large-scale fish immunization in the aquaculture industry shortly.	[Mohamad, Aslah; Zamri-Saad, Mohd; Amal, Mohammad Noor Azmai; Chin, Yong Kit; Yasin, Ina-Salwany Md] Univ Putra Malaysia, Inst Biosci, Aquat Anim Hlth & Therapeut Lab, Serdang 43400, Selangor, Malaysia; [Zamri-Saad, Mohd] Univ Putra Malaysia, Fac Vet Med, Dept Vet Lab Diag, Serdang 43400, Selangor, Malaysia; [Amal, Mohammad Noor Azmai] Univ Putra Malaysia, Fac Sci, Dept Biol, Serdang 43400, Selangor, Malaysia; [Al-saari, Nurhidayu] Int Islamic Univ Malaysia IIUM, Int Inst Halal Res & Training INHART, Level 3,KICT Bldg, Gombak 53100, Selangor, Malaysia; [Monir, Md Shirajum; Yasin, Ina-Salwany Md] Univ Putra Malaysia, Fac Agr, Dept Aquaculture, Serdang 43400, Selangor, Malaysia		Yasin, ISM (通讯作者)，Univ Putra Malaysia, Inst Biosci, Aquat Anim Hlth & Therapeut Lab, Serdang 43400, Selangor, Malaysia.; Yasin, ISM (通讯作者)，Univ Putra Malaysia, Fac Agr, Dept Aquaculture, Serdang 43400, Selangor, Malaysia.	gs51699@student.upm.edu.my; mzamri@upm.edu.my; mnamal@upm.edu.my; hidayusaari@iium.edu.my; gs51935@student.upm.edu.my; gs57258@student.upm.edu.my; salwany@upm.edu.my	Azmai, Mohammad Noor Amal/Y-5552-2019	Saad, M Zamri/0000-0002-9013-4883; Md Yasin, Ina Salwany/0000-0003-2905-2915; /0000-0002-7664-9821	GP-Berimpak grant - Universiti Putra Malaysia [9630200]; Animal Vaccine and Therapeutics, HICOE grant by MOHE, Malaysia [6369100]; Transdiciplinary Research Grant Scheme, Ministry of Higher Education, Malaysia [TRGS/1/2019/UPM/02/5]	This research was funded by GP-Berimpak grant no. 9630200, funded by Universiti Putra Malaysia, Animal Vaccine and Therapeutics, HICOE grant no. 6369100 by MOHE, Malaysia and Transdiciplinary Research Grant Scheme (TRGS/1/2019/UPM/02/5), Ministry of Higher Education, Malaysia.	Abdolnabi S, 2015, IRAN J FISH SCI, V14, P232; Adams A, 2019, FISH SHELLFISH IMMUN, V90, P210, DOI 10.1016/j.fsi.2019.04.066; Adelmann M, 2008, VACCINE, V26, P837, DOI 10.1016/j.vaccine.2007.11.065; Amal M. N. A., 2011, Pertanika Journal of Tropical Agricultural Science, V34, P195; Austin B, 2012, WOODHEAD PUBL FOOD S, P1, DOI 10.1533/9780857095732; Awad E, 2017, FISH SHELLFISH IMMUN, V67, P40, DOI 10.1016/j.fsi.2017.05.034; Ayisi Christian Larbi, 2017, Aquaculture and Fisheries, V2, P67, DOI 10.1016/j.aaf.2017.02.001; Bahurmiz OM, 2007, AQUACULTURE, V262, P382, DOI 10.1016/j.aquaculture.2006.11.023; Bao PC, 2019, FISH SHELLFISH IMMUN, V88, P84, DOI 10.1016/j.fsi.2019.02.014; Bastardo A, 2012, FISH SHELLFISH IMMUN, V32, P756, DOI 10.1016/j.fsi.2012.01.028; Beck BR, 2017, FISH SHELLFISH IMMUN, V68, P19, DOI 10.1016/j.fsi.2017.07.004; Bondad-Reantaso MG, 2005, VET PARASITOL, V132, P249, DOI 10.1016/j.vetpar.2005.07.005; Byadgi O, 2018, AQUACULTURE, V492, P369, DOI 10.1016/j.aquaculture.2018.04.035; Chalmers L, 2016, FISH SHELLFISH IMMUN, V57, P301, DOI 10.1016/j.fsi.2016.08.049; Chen WJ, 2017, FISH SHELLFISH IMMUN, V63, P228, DOI 10.1016/j.fsi.2017.02.031; Cheng S, 2010, VACCINE, V28, P2716, DOI 10.1016/j.vaccine.2010.01.023; Cheng ZX, 2018, FISH SHELLFISH IMMUN, V75, P308, DOI 10.1016/j.fsi.2018.02.022; Cheng ZX, 2014, FISH SHELLFISH IMMUN, V40, P524, DOI 10.1016/j.fsi.2014.08.008; Chettri JK, 2015, AQUACULTURE, V440, P1, DOI 10.1016/j.aquaculture.2015.01.027; Chideroli RT, 2017, AQUACULTURE, V479, P45, DOI 10.1016/j.aquaculture.2017.05.013; Chin Y.K., 2019, INT J BIOSCI, V14, P1, DOI [10.12692/ijb/14.4.1-14, DOI 10.12692/ijb/14.4.1-14]; Chin YK, 2020, AQUAC RES, V51, P389, DOI 10.1111/are.14386; Cruz-Lacierda E.R., 2004, DIS CULTURED GROUPER; Defoirdt T, 2011, CURR OPIN MICROBIOL, V14, P251, DOI 10.1016/j.mib.2011.03.004; Dong C, 2016, J OCEAN U CHINA, V15, P561, DOI 10.1007/s11802-016-2898-8; Dong HT, 2017, AQUACULTURE, V473, P89, DOI 10.1016/j.aquaculture.2017.02.005; Firdaus-Nawi M, 2013, AQUAC RES, V45, P87, DOI 10.1111/j.1365-2109.2012.03207.x; Fraser TWK, 2014, AQUACULTURE, V433, P481, DOI 10.1016/j.aquaculture.2014.07.009; Fredriksen BN, 2013, VACCINE, V31, P1994, DOI 10.1016/j.vaccine.2013.01.016; Galindo-Villegas J, 2013, FISH SHELLFISH IMMUN, V35, P1260, DOI 10.1016/j.fsi.2013.07.046; Ghosh B, 2016, VACCINE, V34, P599, DOI 10.1016/j.vaccine.2015.12.044; GhoshBikramjit, 2015, AQUACULTURE, V446, P242, DOI 10.1016/j.aquaculture.2015.04.035; Giri SS, 2016, FISH SHELLFISH IMMUN, V54, P220, DOI 10.1016/j.fsi.2016.04.004; Gravningen K, 2008, FISH SHELLFISH IMMUN, V24, P523, DOI 10.1016/j.fsi.2007.10.014; Gudding R, 2013, FISH SHELLFISH IMMUN, V35, P1683, DOI 10.1016/j.fsi.2013.09.031; Guo SL, 2015, FISH SHELLFISH IMMUN, V43, P477, DOI 10.1016/j.fsi.2015.01.017; Hounmanou YMG, 2018, AQUACULTURE, V493, P123, DOI 10.1016/j.aquaculture.2018.05.001; Huang LY, 2014, FISH SHELLFISH IMMUN, V38, P34, DOI 10.1016/j.fsi.2014.02.017; Ina-Salwany MY, 2019, J AQUAT ANIM HEALTH, V31, P3, DOI 10.1002/aah.10045; Ismail MS, 2017, FISH SHELLFISH IMMUN, V60, P21, DOI 10.1016/j.fsi.2016.11.040; Ismail MS, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0834-1; Ismail NIA, 2016, AQUACULT REP, V4, P57, DOI 10.1016/j.aqrep.2016.06.004; Lima PC, 2013, FISH SHELLFISH IMMUN, V34, P729, DOI 10.1016/j.fsi.2012.11.037; Lin HL, 2017, FISH SHELLFISH IMMUN, V60, P474, DOI 10.1016/j.fsi.2016.11.026; Liu L, 2016, FISH SHELLFISH IMMUN, V55, P516, DOI 10.1016/j.fsi.2016.06.026; Liu XH, 2016, FISH SHELLFISH IMMUN, V59, P189, DOI 10.1016/j.fsi.2016.10.029; Lopez JR, 2012, AQUACULTURE, V324, P33, DOI 10.1016/j.aquaculture.2011.10.043; Mao ZJ, 2011, AQUACULTURE, V318, P268, DOI 10.1016/j.aquaculture.2011.05.047; Martinez D, 2018, FISH SHELLFISH IMMUN, V75, P139, DOI 10.1016/j.fsi.2018.01.012; Mayo C, 2017, VET MICROBIOL, V206, P84, DOI 10.1016/j.vetmic.2017.03.015; Mohd-Aris A, 2019, AQUACULT INT, V27, P125, DOI 10.1007/s10499-018-0311-x; Mohd-Shaharuddin N, 2013, FISH SHELLFISH IMMUN, V34, P762, DOI 10.1016/j.fsi.2012.11.052; Monir MS, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02443-y; Mursidi F., 2018, ANTIGENIC ANAL OUTER; Nehlah R, 2017, AQUACULT INT, V25, P2047, DOI 10.1007/s10499-017-0172-8; Lan NGT, 2021, FISH SHELLFISH IMMUN, V108, P7, DOI 10.1016/j.fsi.2020.11.014; Obaldo LG, 2002, AQUAC RES, V33, P369, DOI 10.1046/j.1365-2109.2002.00681.x; Park SB, 2016, AQUACULTURE, V461, P25, DOI 10.1016/j.aquaculture.2016.04.022; Pasaribu W, 2018, FISHES-BASEL, V3, DOI 10.3390/fishes3010016; Pereira GD, 2015, AQUAC RES, V46, P1831, DOI 10.1111/are.12339; Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007; Ransangan J, 2010, VET MICROBIOL, V145, P153, DOI 10.1016/j.vetmic.2010.03.016; Reyes M, 2017, VACCINE, V35, P626, DOI 10.1016/j.vaccine.2016.12.013; Romero J, 2012, HEALTH AND ENVIRONMENT IN AQUACULTURE, P159; Samuelsen OB, 2006, AQUACULTURE, V255, P55, DOI 10.1016/j.aquaculture.2005.12.008; Shoemaker CA, 2012, AQUACULTURE, V354, P45, DOI 10.1016/j.aquaculture.2012.04.033; Sommerset I, 2005, EXPERT REV VACCINES, V4, P89, DOI 10.1586/14760584.4.1.89; Sompayrac L., 1999, IMMUNE SYSTEM WORKS, V108, DOI [10.1057/9780230380011_7, DOI 10.1057/9780230380011_7]; Sulaiman MA, 2020, AQUACULT REP, V16, DOI 10.1016/j.aqrep.2019.100250; Sun K, 2009, VACCINE, V27, P2733, DOI 10.1016/j.vaccine.2009.03.012; Sun Y, 2020, FISH SHELLFISH IMMUN, V98, P45, DOI 10.1016/j.fsi.2019.12.079; Sun Y, 2010, VACCINE, V28, P6344, DOI 10.1016/j.vaccine.2010.06.101; Terpstra A.H.M., 2015, COMPOSITION PRODUCTI; Thompson B, 2011, COMBATING MICRONUTRIENT DEFICIENCIES: FOOD-BASED APPROACHES, P150, DOI 10.1079/9781845937140.0150; Toranzo A. E., 2009, Options Mediterraneennes. Serie A, Seminaires Mediterraneens, P155; Tu FP, 2010, LETT APPL MICROBIOL, V50, P13, DOI 10.1111/j.1472-765X.2009.02746.x; Le TS, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7010016; Tumbol RA, 2009, AQUACULTURE, V292, P180, DOI 10.1016/j.aquaculture.2009.04.030; Villumsen KR, 2015, FISH SHELLFISH IMMUN, V42, P193, DOI 10.1016/j.fsi.2014.09.024; Wang HR, 2009, VACCINE, V27, P4047, DOI 10.1016/j.vaccine.2009.04.023; Wei GB, 2020, FISH SHELLFISH IMMUN, V98, P186, DOI 10.1016/j.fsi.2020.01.015; Xing J, 2018, FISH SHELLFISH IMMUN, V74, P341, DOI 10.1016/j.fsi.2017.12.055; Yamaguchi T, 2019, FISH SHELLFISH IMMUN, V95, P422, DOI 10.1016/j.fsi.2019.10.041; Yamaguchi T, 2019, FISH SHELLFISH IMMUN, V85, P3, DOI 10.1016/j.fsi.2018.01.035; Yin B, 2020, FISH SHELLFISH IMMUN, V106, P341, DOI 10.1016/j.fsi.2020.07.026; Zamri-Saad M., 2014, Pertanika Journal of Tropical Agricultural Science, V37, P389; Zoccola E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132687	87	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							368	10.3390/vaccines9040368			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UG	33920311	Green Published, gold, Green Accepted			2022-04-29	WOS:000643775500001
J	Reno, C; Maietti, E; Fantini, MP; Savoia, E; Manzoli, L; Montalti, M; Gori, D				Reno, Chiara; Maietti, Elisa; Fantini, Maria Pia; Savoia, Elena; Manzoli, Lamberto; Montalti, Marco; Gori, Davide			Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy	VACCINES			English	Article						vaccine hesitancy; COVID-19; SARS-CoV-2; vaccine hesitancy predictors; Italy; classification tree; survey; past vaccination refusal; risk perception	INTENTION	In March 2021, the coronavirus disease 2019 (COVID-19) pandemic still poses a threat to the global population, and is a public health challenge that needs to be overcome. Now more than ever, action is needed to tackle vaccine hesitancy, especially in light of the availability of effective and safe vaccines. A cross-sectional online survey was carried out on a representative random sample of 1011 citizens from the Emilia-Romagna region, in Italy, in January 2021. The questionnaire collected information on socio-demographics, comorbidities, past vaccination refusal, COVID-19-related experiences, risk perception of infection, and likelihood to accept COVID-19 vaccination. Multiple logistic regression analyses and classification tree analyses were performed to identify significant predictors of vaccine hesitancy and to distinguish groups with different levels of hesitancy. Overall, 31.1% of the sample reported hesitancy. Past vaccination refusal was the key discriminating variable followed by perceived risk of infection. Other significant predictors of hesitancy were: ages between 35 and 54 years, female gender, low educational level, low income, and absence of comorbidities. The most common concerns about the COVID-19 vaccine involved safety (54%) and efficacy (27%). Studying the main determinants of vaccine hesitancy can help with targeting vaccination strategies, in order to gain widespread acceptance-a key path to ensure a rapid way out of the current pandemic emergency.	[Reno, Chiara; Maietti, Elisa; Fantini, Maria Pia; Montalti, Marco; Gori, Davide] Univ Bologna, Dept Biomed & Neuromotor Sci, Alma Mater Studiorum, I-40126 Bologna, Italy; [Savoia, Elena] Harvard TH Chan Sch Publ Hlth, Div Policy Translat & Leadership Dev, Emergency Preparedness Res Evaluat & Practice EPR, Boston, MA 01451 USA; [Manzoli, Lamberto] Univ Ferrara, Dept Med Sci, Via Fossato Mortara 64B, I-44121 Ferrara, Italy		Maietti, E (通讯作者)，Univ Bologna, Dept Biomed & Neuromotor Sci, Alma Mater Studiorum, I-40126 Bologna, Italy.	chiara.reno@studio.unibo.it; elisa.maietti2@unibo.it; mariapia.fantini@unibo.it; esavoia@hsph.harvard.edu; lmanzoli@postharvard.edu; marco.montalti7@studio.unibo.it; davide.gori4@unibo.it	Montalti, Marco/AAQ-2494-2021; Gori, Davide/AAC-3486-2022; Reno, Chiara/ABA-5613-2020; Manzoli, Lamberto/K-1895-2018	Montalti, Marco/0000-0001-7276-0277; Gori, Davide/0000-0003-4954-9419; Reno, Chiara/0000-0002-7933-2141; Maietti, Elisa/0000-0003-0363-5784; Manzoli, Lamberto/0000-0002-8129-9344; Fantini, Maria Pia/0000-0002-3257-6552			Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; [Anonymous], Ten Health Issues WHO Will Tackle This Year-World Health Organization; [Anonymous], COVID 19 VACCINATION; [Anonymous], CAN WE ADDRESS COVID; [Anonymous], Coronavirus: Vaccines and the Origin; [Anonymous], EU VACCINATION DAYS; [Anonymous], VACCINE HESITANCY IS; [Anonymous], RAPID LIT REV MOTIVA; [Anonymous], CATALOGUE INTERVENTI; [Anonymous], COVID-19 Vaccines; Bert F, 2020, EUR J PUBLIC HEALTH, V30, P286, DOI 10.1093/eurpub/ckz209; Carpiano RM, 2019, PREV MED, V123, P278, DOI 10.1016/j.ypmed.2019.03.033; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Cata-Preta BD, 2021, AM J PREV MED, V60, pS24, DOI 10.1016/j.amepre.2020.07.028; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kempe A, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3852; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lewis J.R., 2020, JAMA HLTH FORUM, V1, DOI [10.1001/jamahealthforum.2020.1393, DOI 10.1001/JAMAHEALTHFORUM.2020.1393]; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Piltch-Loeb R., 2021, MEDRXIV, DOI [10.1101/2021.01.18.21250049, DOI 10.1101/2021.01.18.21250049]; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Savoia E., 2021, Vaccines, V9, DOI 10.3390/vaccines9070767; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Silveira MF, 2020, VACCINE, V38, P482, DOI 10.1016/j.vaccine.2019.10.070; SteelFisher GK, 2021, NEW ENGL J MED, V384, P1483, DOI 10.1056/NEJMp2100351; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Verger P, 2021, LANCET PUBLIC HEALTH, V6, pE195, DOI 10.1016/S2468-2667(21)00029-3; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062	38	30	31	6	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							378	10.3390/vaccines9040378			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4NY	33924534	gold, Green Published			2022-04-29	WOS:000643759000001
J	Seo, YB; Suh, YS; Ryu, JI; Jang, H; Oh, H; Koo, BS; Seo, SH; Hong, JJ; Song, M; Kim, SJ; Sung, YC				Seo, Yong Bok; Suh, You Suk; Ryu, Ji In; Jang, Hwanhee; Oh, Hanseul; Koo, Bon-Sang; Seo, Sang-Hwan; Hong, Jung Joo; Song, Manki; Kim, Sung-Joo; Sung, Young Chul			Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates	VACCINES			English	Article						COVID-19; DNA vaccine	T-CELL RESPONSES; CORONAVIRUS; VIRUS; SAFETY; IMMUNOGENICITY; IMMUNIZATION; CLEARANCE; INFECTION; EFFICACY; DISEASE	The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2.	[Seo, Yong Bok; Ryu, Ji In; Jang, Hwanhee; Sung, Young Chul] SL VaxiGen Inc, Res Inst, Korea Bio Pk, Seongnam 13488, South Korea; [Suh, You Suk; Sung, Young Chul] Genexine Inc, Res Inst, Korea Bio Pk, Seongnam 13488, South Korea; [Oh, Hanseul; Koo, Bon-Sang; Hong, Jung Joo] Korea Res Inst Biosci & Biotechnol, Natl Primate Res Ctr, Cheongju 34141, Chungcheongbuk, South Korea; [Seo, Sang-Hwan; Song, Manki] Int Vaccine Inst, Sci Unit, Seoul 08826, South Korea; [Kim, Sung-Joo] GenNBio Inc, Seoul 06026, South Korea		Sung, YC (通讯作者)，SL VaxiGen Inc, Res Inst, Korea Bio Pk, Seongnam 13488, South Korea.; Sung, YC (通讯作者)，Genexine Inc, Res Inst, Korea Bio Pk, Seongnam 13488, South Korea.	ybseo@slvaxigen.com; yssuh@genexine.com; jiryu@slvaxigen.com; hhjang@slvaxigen.com; seul3198@kribb.re.kr; porco9@kribb.re.kr; SangHwan.Seo@ivi.int; hong75@kribb.re.kr; mksong@ivi.int; sungjoo.kim@gennbio.com; ycsung@postech.ac.kr	Koo, Bon-Sang/AAT-6063-2021		Korea Research Institute of Bioscience and Biotechnology [KGM4572121]; ministry of Science and ICS [PRM1752011]	This Work was supported by Korea Research Institute of Bioscience and Biotechnology (grant number KGM4572121) and ministry of Science and ICS (grand number PRM1752011).	Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Bagarazzi ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004414; Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Bonam SR, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101051; Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), COVID 19 DASHB; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Choi H., 2017, NEW ENGL J MED, DOI [10.1056/NEJMoa1708120, DOI 10.1056/NEJMOA1708120]; Chong WP, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-82; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Das M, 2019, LANCET ONCOL, V20, pE671, DOI 10.1016/S1470-2045(19)30752-1; Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137; Edridge A. W., 2020, NAT MED 0914, DOI [10.1101/2020.05.11.20086439, DOI 10.1101/2020.05.11.20086439]; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; Gallais F., 2020, INFECT DIS EXCEPT HI, DOI [10.1101/2020.06.21.20132449, DOI 10.1101/2020.06.21.20132449]; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Graham BS, 2018, JAMA-J AM MED ASSOC, V319, P1431, DOI 10.1001/jama.2018.0345; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Kim TJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6317; Koo BS, 2020, J INFECT DIS, V222, P1596, DOI 10.1093/infdis/jiaa486; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Lee AH, 1997, MOL CELLS, V7, P495; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X; Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011; Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Seow J., 2020, NAT MICROBIOL, V5, P1598, DOI [10.1101/2020.07.09.20148429, DOI 10.1038/S41564-020-00813-8, 10.1038/s41564-020-00813-8]; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Tiriveedhi V, 2014, CLIN CANCER RES, V20, P5964, DOI 10.1158/1078-0432.CCR-14-0059; Tiriveedhi V, 2013, BREAST CANCER RES TR, V138, P109, DOI 10.1007/s10549-012-2110-9; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10	51	7	7	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							307	10.3390/vaccines9040307			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5GF	33804981	Green Published, Green Submitted, gold			2022-04-29	WOS:000643806800001
J	Toor, SM; Nair, VS; Saleh, R; Taha, RZ; Murshed, K; Al-Dhaheri, M; Khawar, M; Ahmed, AA; Kurer, MA; Abu Nada, M; Elkord, E				Toor, Salman M.; Nair, Varun Sasidharan; Saleh, Reem; Taha, Rowaida Z.; Murshed, Khaled; Al-Dhaheri, Mahmood; Khawar, Mahwish; Ahmed, Ayman A.; Kurer, Mohamed A.; Abu Nada, Mohamed; Elkord, Eyad			Transcriptome of Tumor-Infiltrating T Cells in Colorectal Cancer Patients Uncovered a Unique Gene Signature in CD4(+) T Cells Associated with Poor Disease-Specific Survival	VACCINES			English	Article						colorectal cancer; tumor microenvironment; T cells; transcriptomics		Colorectal cancer (CRC) is influenced by infiltration of immune cell populations in the tumor microenvironment. While elevated levels of cytotoxic T cells are associated with improved prognosis, limited studies have reported associations between CD4(+) T cells and disease outcomes. We recently performed transcriptomic profiling and comparative analyses of sorted CD4(+) and CD8(+) tumor-infiltrating lymphocytes (TILs) from bulk tumors of CRC patients with varying disease stages. In this study, we compared the transcriptomes of CD4(+) with CD8(+) TILs. Functional annotation pathway analyses revealed the downregulation of inflammatory response-related genes, while T cell activation and angiogenesis-related genes were upregulated in CD4(+) TILs. The top 200 deregulated genes in CD4(+) TILs were aligned with the cancer genome atlas (TCGA) CRC dataset to identify a unique gene signature associated with poor prognosis. Moreover, 69 upregulated and 20 downregulated genes showed similar trends of up/downregulation in the TCGA dataset and were used to calculate "poor prognosis score" (ppScore), which was significantly associated with disease-specific survival. High ppScore patients showed lower expression of Treg-, Th1-, and Th17-related genes, and higher expression of Th2-related genes. Our data highlight the significance of T cells within the TME and identify a unique candidate prognostic gene signature for CD4(+) TILs in CRC patients.	[Toor, Salman M.; Nair, Varun Sasidharan; Saleh, Reem; Taha, Rowaida Z.] Hamad Bin Khalifa Univ HBKU, Qatar Fdn QF, Canc Res Ctr, Qatar Biomed Res Inst QBRI, POB 34110, Doha, Qatar; [Murshed, Khaled] Hamad Med Corp, Dept Pathol, POB 3050, Doha, Qatar; [Al-Dhaheri, Mahmood; Khawar, Mahwish; Ahmed, Ayman A.; Kurer, Mohamed A.; Abu Nada, Mohamed] Hamad Med Corp, Dept Surg, POB 3050, Doha, Qatar; [Elkord, Eyad] Univ Salford, Biomed Res Ctr, Sch Sci Engn & Environm, Manchester M5 4WT, Lancs, England		Elkord, E (通讯作者)，Univ Salford, Biomed Res Ctr, Sch Sci Engn & Environm, Manchester M5 4WT, Lancs, England.	mstoor@hbku.edu.qa; vsnair@hbku.edu.qa; rsaleh@hbku.edu.qa; rotaha@hbku.edu.qa; kmurshed@hamad.qa; maldhaheri@hamad.qa; mkhawar@hamad.qa; aahmed40@hamad.qa; mkurer@hamad.qa; mabunada@hamad.qa; e.elkord@salford.ac.uk	Toor, Salman M/AAY-4682-2021; Nair, Varun Sasidharan/AAQ-5533-2021; Murshed, Khaled/AAE-9720-2019	Nair, Varun Sasidharan/0000-0001-5047-2338; Murshed, Khaled/0000-0001-8045-363X; M Toor, Salman/0000-0002-4683-3329; Taha, Rowaida Z./0000-0001-6119-8389	Qatar Foundation [VR04]	This research was funded by Qatar Foundation, grant number VR04.	Amicarella F, 2017, GUT, V66, P692, DOI 10.1136/gutjnl-2015-310016; Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168; Chew V, 2012, J ONCOL, V2012, DOI 10.1155/2012/608406; de Araujo-Souza PS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/849573; De Simone V, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26617; Deschoolmeester V, 2011, CANCER MICROENVIRON, V4, P377, DOI 10.1007/s12307-011-0068-5; di Bari MG, 2009, CANCER IMMUNOL IMMUN, V58, P1811, DOI 10.1007/s00262-009-0692-9; Fountzilas Elena, 2018, Oncotarget, V9, P35623, DOI 10.18632/oncotarget.26256; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Gerstel D, 2011, ONCOGENE, V30, P4275, DOI 10.1038/onc.2011.146; Horvath Curt M, 2004, Sci STKE, V2004, ptr10, DOI 10.1126/stke.2602004tr10; Hu GM, 2017, ONCOTARGET, V8, P75361, DOI 10.18632/oncotarget.17722; Huh JW, 2012, ARCH SURG-CHICAGO, V147, P366, DOI 10.1001/archsurg.2012.35; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Khaja ASS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00619; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kuwahara T, 2019, BRIT J CANCER, V121, P659, DOI 10.1038/s41416-019-0559-6; Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755; Li QT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6780; Lin YC, 2013, INT J CANCER, V132, P1341, DOI 10.1002/ijc.27784; Ling A, 2016, J PATHOL CLIN RES, V2, P21, DOI 10.1002/cjp2.31; Liu YJ, 2019, CANCERS, V11, DOI 10.3390/cancers11040554; Malone BM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025260; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Nair VS, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1825178; Nair VS, 2018, IMMUNOL CELL BIOL, V96, P21, DOI 10.1111/imcb.1003; Parekh S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25533; Ptaschinski C, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004978; Reissfelder C, 2015, J CLIN INVEST, V125, P739, DOI 10.1172/JCI74894; Ropponen KM, 1997, J PATHOL, V182, P318, DOI 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Saleh R, 2020, SEMIN CANCER BIOL, V65, P13, DOI 10.1016/j.semcancer.2019.07.017; Saleh R, 2020, CANCER LETT, V490, P174, DOI 10.1016/j.canlet.2020.07.022; Nair VS, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-0808-9; Scurr M, 2012, CELL IMMUNOL, V279, P21, DOI 10.1016/j.cellimm.2012.08.004; Sercan O, 2010, J IMMUNOL, V184, P2855, DOI 10.4049/jimmunol.0902708; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Taylor ES, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1234573; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Toor SM, 2019, CLIN EXP IMMUNOL, V196, P345, DOI 10.1111/cei.13264; Toor SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02936; Toor SM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00560; Toyoda H, 2010, J MED GENET, V47, P631, DOI 10.1136/jmg.2009.072108; Villagra A, 2010, ONCOGENE, V29, P157, DOI 10.1038/onc.2009.334; Vishnubalaji R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00910; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Xiao HY, 2016, INT J CANCER, V138, P2477, DOI 10.1002/ijc.29979; Xu PP, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00950	53	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							334	10.3390/vaccines9040334			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5GU	33916009	gold, Green Published			2022-04-29	WOS:000643808300001
J	Ayechu-Muruzabal, V; Xiao, L; Wehkamp, T; van Ark, I; Hoogendoorn, EJ; Leusink-Muis, T; Folkerts, G; Garssen, J; Willemsen, LEM; van't Land, B				Ayechu-Muruzabal, Veronica; Xiao, Ling; Wehkamp, Tjalling; van Ark, Ingrid; Hoogendoorn, Elisabeth J.; Leusink-Muis, Thea; Folkerts, Gert; Garssen, Johan; Willemsen, Linette E. M.; Van't Land, Belinda			A Fermented Milk Matrix Containing Postbiotics Supports Th1- and Th17-Type Immunity In Vitro and Modulates the Influenza-Specific Vaccination Response In Vivo in Association with Altered Serum Galectin Ratios	VACCINES			English	Article						postbiotics; vaccination; influenza; galectins; fermentation; adaptive immunity		During a specific milk fermentation process with Bifidobacterium breve C50 and Streptococcus thermophilus 065 (Lactofidus(TM)), postbiotics with possible immunomodulatory properties are produced. We investigated the effects of this fermentation product (FP) in vitro using a model that allows crosstalk between intestinal epithelial (IEC) and immune cells. IECs were exposed to FP and alpha CD3/CD28-activated peripheral blood mononuclear cells after which the mediator secretion was measured. Additionally, using a murine influenza vaccination model, immune development was assessed. Mice were fed an AIN93G diet containing FP or lactose as control. Vaccine-specific immunity was measured as delayed-type hypersensitivity (DTH) and correlated to intestinal and systemic immunomodulation levels. In vitro, exposure to FP enhanced IFN gamma, TNF alpha and IL-17A concentrations. Moreover, IEC-derived galectin-3/galectin-9 and galectin-4/galectin-9 ratios were increased. In vivo, dietary intervention with FP increased vaccine-specific DTH responses as compared to the lactose-receiving group. Although no effects on humoral immunity and vaccine-specific T-cell responses were detected, an enhanced systemic serum galectin-3/galectin-9 and galectin-4/galectin-9 ratio correlated with a shift in ROR gamma (Th17) mRNA expression over regulatory TGF beta 1 in the ileum. This was also positively correlated with the increased DTH response. These results indicate that FP can enhance epithelial galectin-3 and -4 over galectin-9 release, and boost adaptive immunity by promoting Th1- and Th17-type cytokines under inflammatory conditions in vitro. Similar variations in galectin and immune balance were observed in the vaccination model, where FP improved the influenza-specific DTH response.	[Ayechu-Muruzabal, Veronica; Xiao, Ling; van Ark, Ingrid; Hoogendoorn, Elisabeth J.; Leusink-Muis, Thea; Folkerts, Gert; Garssen, Johan; Willemsen, Linette E. M.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol, NL-3584 CG Utrecht, Netherlands; [Wehkamp, Tjalling; Garssen, Johan; Van't Land, Belinda] Danone Nutr Res, NL-3584 CT Utrecht, Netherlands; [Van't Land, Belinda] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Translat Immunol, NL-3584 EA Utrecht, Netherlands		van't Land, B (通讯作者)，Danone Nutr Res, NL-3584 CT Utrecht, Netherlands.; van't Land, B (通讯作者)，Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Translat Immunol, NL-3584 EA Utrecht, Netherlands.	v.ayechumuruzabal@uu.nl; Ling.Xiao@joslin.harvard.edu; Tjalling.Wehkamp@danone.com; I.vanArk@uu.nl; E.J.Hoogendoorn@students.uu.nl; A.Leusink@uu.nl; G.Folkerts@uu.nl; Johan.Garssen@danone.com; L.E.M.Willemsen@uu.nl; b.vantland@umcutrecht.nl	Land, Belinda van't/K-2986-2012	Land, Belinda van't/0000-0001-8601-5032; garssen, johan/0000-0002-8678-9182; Ayechu Muruzabal, Veronica/0000-0003-4063-2961; Leusink-Muis, Thea/0000-0003-4986-5497	Danone Nutricia Research B.V.Danone Nutricia	This research was funded by Danone Nutricia Research B.V.	Aguilar-Toala JE, 2018, TRENDS FOOD SCI TECH, V75, P105, DOI 10.1016/j.tifs.2018.03.009; Ayechu-Muruzabal V, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050784; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Campeotto F, 2011, BRIT J NUTR, V105, P1843, DOI 10.1017/S0007114510005702; Cao ZQ, 2016, PROTEIN CELL, V7, P314, DOI 10.1007/s13238-016-0262-9; Cerliani JP, 2011, J CLIN IMMUNOL, V31, P10, DOI 10.1007/s10875-010-9494-2; Collado MC, 2019, BENEF MICROBES, V10, P711, DOI 10.3920/BM2019.0015; de Kivit S, 2012, ALLERGY, V67, P343, DOI 10.1111/j.1398-9995.2011.02771.x; de Kivit S, 2011, IMMUNOBIOLOGY, V216, P518, DOI 10.1016/j.imbio.2010.08.005; de Kivita S, 2013, J INNATE IMMUN, V5, P625, DOI 10.1159/000350515; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; Garcia-Vallejo JJ, 2004, ANAL BIOCHEM, V329, P293, DOI 10.1016/j.ab.2004.02.037; Granier A, 2013, PEDIATR RES, V74, P238, DOI 10.1038/pr.2013.76; Gruson D, 2012, CLIN BIOCHEM, V45, P719, DOI 10.1016/j.clinbiochem.2012.04.009; Hayen SM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00923; Hoarau C, 2006, J ALLERGY CLIN IMMUN, V117, P696, DOI 10.1016/j.jaci.2005.10.043; Hokama A, 2004, IMMUNITY, V20, P681, DOI 10.1016/j.immuni.2004.05.009; Indrio F, 2007, PEDIATR RES, V62, P98, DOI 10.1203/pdr.0b013e31806772d3; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jijon H, 2004, GASTROENTEROLOGY, V126, P1358, DOI 10.1053/j.gastro.2004.02.003; Katoh S, 2014, TOHOKU J EXP MED, V232, P263, DOI 10.1620/tjem.232.263; Khader SA, 2009, MUCOSAL IMMUNOL, V2, P403, DOI 10.1038/mi.2009.100; Lin YY, 2010, SEMIN IMMUNOPATHOL, V32, P79, DOI 10.1007/s00281-009-0191-2; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Lv K, 2013, MOL MED REP, V7, P205, DOI 10.3892/mmr.2012.1125; Machala EA, 2019, J GEN VIROL, V100, P333, DOI 10.1099/jgv.0.001208; Martin R, 2010, BENEF MICROBES, V1, P367, DOI 10.3920/BM2010.0027; Menard S, 2005, EXP BIOL MED, V230, P749, DOI 10.1177/153537020523001008; Morisset M, 2011, EUR J CLIN NUTR, V65, P175, DOI 10.1038/ejcn.2010.250; Mullie C, 2004, PEDIATR RES, V56, P791, DOI 10.1203/01.PDR.0000141955.47550.A0; Paclik D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002629; Rodriguez-Herrera A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071530; Salminen S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071952; Sanders ME, 2019, NAT REV GASTRO HEPAT, V16, P605, DOI 10.1038/s41575-019-0173-3; Schijf MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075148; Schouten B, 2009, J NUTR, V139, P1398, DOI 10.3945/jn.109.108514; Seki M, 2008, CLIN IMMUNOL, V127, P78, DOI 10.1016/j.clim.2008.01.006; Smit J, 2016, TOXICOL LETT, V262, P62, DOI 10.1016/j.toxlet.2016.09.005; Szajewska H, 2015, EUR J PEDIATR, V174, P1413, DOI 10.1007/s00431-015-2629-y; Thibault H, 2004, J PEDIATR GASTR NUTR, V39, P147, DOI 10.1097/00005176-200408000-00004; Thiemann S, 2016, ANNU REV IMMUNOL, V34, P243, DOI 10.1146/annurev-immunol-041015-055402; Torow N, 2017, MUCOSAL IMMUNOL, V10, P5, DOI 10.1038/mi.2016.81; Tsai HF, 2016, J MOL MED, V94, P545, DOI 10.1007/s00109-015-1368-x; van't Land B, 2010, VACCINE, V28, P5711, DOI 10.1016/j.vaccine.2010.06.046; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Vos AP, 2006, INT IMMUNOPHARMACOL, V6, P1277, DOI 10.1016/j.intimp.2006.03.010; Vos AP, 2007, PEDIAT ALLERG IMM-UK, V18, P304, DOI 10.1111/j.1399-3038.2007.00515.x; Vos AP, 2010, INT IMMUNOPHARMACOL, V10, P619, DOI 10.1016/j.intimp.2010.02.014; Wang WH, 2020, J MICROBIOL IMMUNOL, V53, P925, DOI 10.1016/j.jmii.2019.09.005; Wegh CAM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194673; Xiao L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00452	52	2	2	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							254	10.3390/vaccines9030254			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5TS	33805597	Green Published, gold			2022-04-29	WOS:000634216800001
J	Hossain, MK; Hassanzadeganroudsari, M; Feehan, J; Apostolopoulos, V				Hossain, Md Kamal; Hassanzadeganroudsari, Majid; Feehan, Jack; Apostolopoulos, Vasso			COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?	VACCINES			English	Editorial Material									[Hossain, Md Kamal; Hassanzadeganroudsari, Majid; Feehan, Jack; Apostolopoulos, Vasso] Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 3011, Australia; [Feehan, Jack] Univ Melbourne VIC, Dept Med Western Hlth, Melbourne, Vic 3021, Australia		Apostolopoulos, V (通讯作者)，Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 3011, Australia.	md.hossain18@live.vu.edu.au; majid.hassanzadeganroudsari@vu.edu.au; jack.feehan@vu.edu.au; vasso.apostolopoulos@vu.edu.au		Feehan, Jack/0000-0002-9627-1299; Apostolopoulos, Vasso/0000-0001-6788-2771	Mechanisms and Interventions in Health and Disease Program within the Institute for Health and Sport, Victoria University Australia; Victoria University Postgraduate Scholarship; Vice-Chancellors top-up Scholarship Award; University of Melbourne Postgraduate Scholarship	The authors would like to thank The Thelma and Paul Constantinou Foundation, and The Pappas Family, whose generous philanthropic support made possible the preparation of this paper. The authors would also like to thank the Immunology and Translational Research Group for their significant contribution. The Mechanisms and Interventions in Health and Disease Program within the Institute for Health and Sport, Victoria University Australia are also appreciated for their support. Md. K.H was supported by the Victoria University Postgraduate Scholarship and the Vice-Chancellors top-up Scholarship Award and J.F was supported by University of Melbourne Postgraduate Scholarship.	Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348; Feehana J, 2021, MATURITAS, V149, P56, DOI 10.1016/j.maturitas.2021.02.001; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937; Gadanec LK, 2021, FUTURE MICROBIOL, V16, P205, DOI 10.2217/fmb-2021-0018; Gadanec LK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22030992; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Mahase E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3205; Matsoukas J, 2021, MOLECULES, V26, DOI 10.3390/molecules26030618; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Perrotta F, 2020, RESP MED, V168, DOI 10.1016/j.rmed.2020.105996; PEY SC, 2020, LIFE SCI, P17956, DOI DOI 10.1016/J.LFS.2020.117956; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wadman M., 2020, SCIENCE	20	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							241	10.3390/vaccines9030241			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4ZN	33802086	Green Published, gold			2022-04-29	WOS:000634164300001
J	Lourenco, J; Daon, Y; Gori, A; Obolski, U				Lourenco, Jose; Daon, Yair; Gori, Andrea; Obolski, Uri			Pneumococcal Competition Modulates Antibiotic Resistance in the Pre-Vaccination Era: A Modelling Study	VACCINES			English	Article						antibiotic resistance; Streptococcus pneumoniae; ecological competition; immunological competition; pre-vaccination	STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; NONVACCINE SEROTYPES; ANTIMICROBIAL RESISTANCE; TRANSMISSION PARAMETERS; CARRIAGE; POPULATION; IMPACT; DISEASE; CHILDREN	The ongoing emergence of antibiotic resistant strains and high frequencies of antibiotic resistance of Streptococcus pneumoniae poses a major public health challenge. How and which ecological and evolutionary mechanisms maintain the coexistence of antibiotic resistant and susceptible strains remains largely an open question. We developed an individual-based, stochastic model expanding on a previous pneumococci modelling framework. We explore how between- and within-host mechanisms of competition can sustain observed levels of resistance to antibiotics in the pre-vaccination era. Our framework considers that within-host competition for co-colonization between resistant and susceptible strains can arise via pre-existing immunity (immunological competition) or intrinsic fitness differences due to resistance costs (ecological competition). We find that beyond stochasticity, population structure or movement, competition at the within-host level can explain observed resistance frequencies. We compare our simulation results to pneumococcal antibiotic resistance data in the European region using approximate Bayesian computation. Our results demonstrate that ecological competition for co-colonization can explain the variation in co-existence of resistant and susceptible pneumococci observed in the pre-vaccination era. Furthermore, we show that within-host pneumococcal competition can facilitate the maintenance of resistance in the pre-vaccination era. Accounting for these competition-related components of pneumococcal dynamics can improve our understanding of drivers for the emergence and maintenance of antibiotic resistance in pneumococci.	[Lourenco, Jose] Univ Oxford, Dept Zool, Oxford OX1 3SZ, England; [Daon, Yair; Obolski, Uri] Tel Aviv Univ, Sch Publ Hlth, Fac Med, IL-69978 Tel Aviv, Israel; [Daon, Yair; Obolski, Uri] Tel Aviv Univ, Porter Sch Environm & Earth Sci, Fac Exact Sci, IL-69978 Tel Aviv, Israel; [Gori, Andrea] UCL, Div Infect & Immun, NIHR Global Hlth Res Unit Mucosal Pathogens, London WC1E 6BT, England		Lourenco, J (通讯作者)，Univ Oxford, Dept Zool, Oxford OX1 3SZ, England.; Obolski, U (通讯作者)，Tel Aviv Univ, Sch Publ Hlth, Fac Med, IL-69978 Tel Aviv, Israel.; Obolski, U (通讯作者)，Tel Aviv Univ, Porter Sch Environm & Earth Sci, Fac Exact Sci, IL-69978 Tel Aviv, Israel.	jose.lourenco@zoo.ox.ac.uk; yair.daon@gmail.com; a.gori@ucl.ac.uk; uriobols@tauex.tau.ac.il	Gori, Andrea/AAC-6078-2022	Lourenco, Jose/0000-0002-9318-2581; Obolski, Uri/0000-0001-7594-9745; Gori, Andrea/0000-0003-0931-0454; Daon, Yair/0000-0002-7491-2008	Raymond and Beverly Sackler Post-Doctoral Scholarship; Tel Aviv University Center for Combating Pandemics; NIHR Mucosal Pathogens Research Unit; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [INC-004301-AG]	This study was supported by a lectureship by the Department of Zoology, University of Oxford (JL); The Raymond and Beverly Sackler Post-Doctoral Scholarship and a post-doctoral fellowship from the Tel Aviv University Center for Combating Pandemics (YD); NIHR Mucosal Pathogens Research Unit and the Bill and Melinda Gates Foundation (INC-004301-AG).	Adetifa IMO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030548; [Anonymous], ANTIBIOTIC RESISTANC; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Beall BW, 2011, J INFECT DIS, V203, P1360, DOI 10.1093/infdis/jir052; Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031; Blanquart F, 2017, P ROY SOC B-BIOL SCI, V284, DOI 10.1098/rspb.2017.0679; Blommaert A, 2014, J ANTIMICROB CHEMOTH, V69, P535, DOI 10.1093/jac/dkt377; Bottomley C, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0786; Brown J., 2015, STREPTOCOCCUS PNEUMO; Bruinsma N, 2003, J ANTIMICROB CHEMOTH, V51, P385, DOI 10.1093/jac/dkg072; Chiba N, 2013, MICROB DRUG RESIST, V19, P308, DOI 10.1089/mdr.2012.0180; Cobey S, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0295; Cobey S, 2012, SCIENCE, V335, P1376, DOI 10.1126/science.1215947; Colijn C, 2010, J R SOC INTERFACE, V7, P905, DOI 10.1098/rsif.2009.0400; Collignon P, 2018, LANCET PLANET HEALTH, V2, pE398, DOI 10.1016/S2542-5196(18)30186-4; Croucher NJ, 2013, NAT GENET, V45, P656, DOI 10.1038/ng.2625; Dagan R, 2003, PEDIATR INFECT DIS J, V22, P532, DOI 10.1097/00006454-200306000-00009; Dagan R, 2008, LANCET INFECT DIS, V8, P785, DOI 10.1016/S1473-3099(08)70281-0; Danino D, 2019, CLIN INFECT DIS, V69, P648, DOI 10.1093/cid/ciy926; Davies NG, 2019, NAT ECOL EVOL, V3, P440, DOI 10.1038/s41559-018-0786-x; de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736; European Food Safety Authority, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5926; Farrell DJ, 2007, PEDIATR INFECT DIS J, V26, P123, DOI 10.1097/01.inf.0000253059.84602.c3; Feikin DR, 2002, CLIN INFECT DIS, V35, P547, DOI 10.1086/341896; Flasche S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002181; Flasche S, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1939; Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017; Gao B, 2020, ELIFE, V9, DOI 10.7554/eLife.51773; Gherardi G, 2012, ANTIMICROB AGENTS CH, V56, P4965, DOI 10.1128/AAC.00830-12; Gidding HE, 2019, PEDIATR INFECT DIS J, V38, P860, DOI 10.1097/INF.0000000000002314; Gupta RK, 2018, LANCET INFECT DIS, V18, P346, DOI [10.1016/S1473-3099(17)30702-8, 10.1016/s1473-3099(17)30702-8]; Gupta S, 1997, P ROY SOC B-BIOL SCI, V264, P1435, DOI 10.1098/rspb.1997.0200; Hanage WP, 2007, J INFECT DIS, V195, P347, DOI 10.1086/510249; Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6; Heinsbroek E, 2018, VACCINE, V36, P7369, DOI 10.1016/j.vaccine.2018.10.021; Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338; Janoir C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090935; Jefferson T, 2006, LANCET INFECT DIS, V6, P405, DOI 10.1016/S1473-3099(06)70520-5; Kamng'ona AW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0980-2; Keenan JD, 2015, J INFECT DIS, V211, P988, DOI 10.1093/infdis/jiu552; Kremer K, 2009, EMERG INFECT DIS, V15, P335, DOI 10.3201/eid1502.080795; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Lehtinen S, 2017, P NATL ACAD SCI USA, V114, P1075, DOI 10.1073/pnas.1617849114; Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571; Lipsitch M, 2012, EPIDEMIOLOGY, V23, P510, DOI 10.1097/EDE.0b013e31824f2f32; Lipsitch M, 2009, EPIDEMICS-NETH, V1, P2, DOI 10.1016/j.epidem.2008.07.001; Lourenco J, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1450-2; Lourenco J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08990-z; Lourenco J, 2016, EPIDEMICS-NETH, V16, P40, DOI 10.1016/j.epidem.2016.05.003; Lourenco J, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003308; MacFadden DR, 2018, NAT CLIM CHANGE, V8, P510, DOI 10.1038/s41558-018-0161-6; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Melegaro A, 2004, EPIDEMIOL INFECT, V132, P433, DOI 10.1017/S0950268804001980; Melegaro A, 2007, AM J EPIDEMIOL, V166, P228, DOI 10.1093/aje/kwm076; Melegaro A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-90; Melnyk AH, 2015, EVOL APPL, V8, P273, DOI 10.1111/eva.12196; Minter A, 2019, EPIDEMICS-NETH, V29, DOI 10.1016/j.epidem.2019.100368; Mishra RPN, 2012, CURR OPIN MICROBIOL, V15, P596, DOI 10.1016/j.mib.2012.08.002; Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Obolski U, 2018, P NATL ACAD SCI USA, V115, P3102, DOI 10.1073/pnas.1718712115; Park SY, 2008, PEDIATR INFECT DIS J, V27, P335, DOI 10.1097/INF.0b013e318161434d; Parks T, 2015, BRIT MED BULL, V115, P77, DOI 10.1093/bmb/ldv027; Pillai DR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-642; Puertas MC, 2020, LANCET MICROBE, V1, pE130, DOI 10.1016/S2666-5247(20)30006-9; Reinert RR, 2009, CLIN MICROBIOL INFEC, V15, P7, DOI 10.1111/j.1469-0691.2009.02724.x; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]; Swarthout TD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15786-9; Tabatabaei SR, 2014, INT J INFECT DIS, V21, P418, DOI 10.1016/j.ijid.2014.03.1284; Tsaban G, 2017, VACCINE, V35, P2882, DOI 10.1016/j.vaccine.2017.04.032; Watkins ER, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005034; Willem L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2699-8	73	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							265	10.3390/vaccines9030265			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6SY	33809706	Green Submitted, gold, Green Published			2022-04-29	WOS:000634282500001
J	Tasker, S; O'Rourke, AW; Suyundikov, A; Booth, PGJ; Bart, S; Krishnan, V; Zhang, JF; Anderson, KJ; Georges, B; Roberts, MS				Tasker, Sybil; Wight O'Rourke, Anna; Suyundikov, Anvar; Jackson Booth, Peta-Gay; Bart, Stephan; Krishnan, Vyjayanthi; Zhang, Jianfeng; Anderson, Katie J.; Georges, Bertrand; Roberts, M. Scot			Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial	VACCINES			English	Article						influenza vaccine; intranasal vaccine; adenovirus vector; NasoVAX; mucosal immunity; pre-existing immunity	T-CELLS; IMMUNE-RESPONSE; NASAL IGA; PROTECTION; CHALLENGE; LIVE; ANTIBODIES; SERUM	Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and insufficiently durable immune responses. The safety and immunogenicity of NasoVAX, a monovalent intranasal influenza vaccine based on a replication-deficient adenovirus type 5 platform, were evaluated in a placebo-controlled single ascending-dose study. Sixty healthy adults (18-49 years) received a single intranasal dose of 1x10(9) viral particles (vp), 1 x 10(10) vp, or 1 x 10(11) vp of NasoVAX or placebo. NasoVAX was well-tolerated and elicited robust influenza-specific systemic and mucosal immune responses. The highest NasoVAX dose and the approved Fluzone(R) influenza vaccine elicited comparable hemagglutination inhibition (HAI) geometric mean titers (152.8 vs. 293.4) and microneutralization (MN) geometric mean titers (142.5 vs. 162.8), with NasoVAX HAI titers maintained more than 1-year on average following a single dose. Hemagglutinin-specific T cells responses were also documented in peripheral mononuclear cell (PBMC) preparations. Consistent with the intranasal route of administration, NasoVAX elicited antigen-specific mucosal IgA responses in the nasopharyngeal cavity with an increase of approximately 2-fold over baseline GMT at the mid- and high-doses. In summary, NasoVAX appeared safe and elicited a broad immune response, including humoral, cellular, and mucosal immunity, with no impact of baseline anti-adenovirus antibody at the most immunogenic dose.	[Tasker, Sybil; Wight O'Rourke, Anna; Suyundikov, Anvar; Krishnan, Vyjayanthi; Zhang, Jianfeng; Anderson, Katie J.; Georges, Bertrand; Roberts, M. Scot] Altimmune Inc, Gaithersburg, MD 20878 USA; [Tasker, Sybil] Codagenix Inc, Farmingdale, NY 11735 USA; [Wight O'Rourke, Anna] Biomed Adv Res & Dev Author, Washington, DC 20201 USA; [Jackson Booth, Peta-Gay; Bart, Stephan] Optimal Res LLC, Rockville, MD 20850 USA; [Anderson, Katie J.] Vaccitech Ltd, Oxford OX4 4GE, England		Roberts, MS (通讯作者)，Altimmune Inc, Gaithersburg, MD 20878 USA.	sybil.tasker@me.com; 1217anna@gmail.com; asuyundikov@altimmune.com; pgjacksonbooth@optimalsites.net; sbart@optimalsites.net; vkrishnan@altimmune.com; jzhang@altimmune.com; katieanderson1@gmail.com; bgeorges@altimmune.com; sroberts@altimmune.com		Suyundikov, Anvar/0000-0002-1184-9734	Altimmune, Inc., Gaithersburg, MD, USA	This work was supported by Altimmune, Inc., Gaithersburg, MD, USA.	Ambrose CS, 2012, VACCINE, V30, P6794, DOI 10.1016/j.vaccine.2012.09.018; Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025; Belshe RB, 2000, J INFECT DIS, V181, P1133, DOI 10.1086/315323; Choi JH, 2012, MOL PHARMACEUT, V9, P156, DOI 10.1021/mp200392g; CLEMENTS ML, 1986, J CLIN MICROBIOL, V24, P157, DOI 10.1128/JCM.24.1.157-160.1986; Croyle MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003548; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Gould VMW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00900; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kim EH, 2014, J VIROL, V88, P9693, DOI 10.1128/JVI.00823-14; King Rodney G, 2020, bioRxiv, DOI 10.1101/2020.10.10.331348; Kwong JC, 2015, VACCINE, V33, P4910, DOI 10.1016/j.vaccine.2015.07.044; Ledgerwood JE, 2010, VACCINE, V29, P304, DOI 10.1016/j.vaccine.2010.10.037; Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pesonen S, 2011, MOL PHARMACEUT, V8, P12, DOI 10.1021/mp100219n; Song JY, 2010, VACCINE, V28, P3929, DOI 10.1016/j.vaccine.2010.03.067; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Sumida SM, 2005, J IMMUNOL, V174, P7179, DOI 10.4049/jimmunol.174.11.7179; Takamura S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00733; Tan WG, 2013, J VIROL, V87, P1359, DOI 10.1128/JVI.02055-12; Van Kampen KR, 2005, VACCINE, V23, P1029, DOI 10.1016/j.vaccine.2004.07.043; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; Wu XJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02093; Zaiss AK, 2009, J CELL BIOCHEM, V108, P778, DOI 10.1002/jcb.22328; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	27	5	6	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							224	10.3390/vaccines9030224			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5QW	33807649	gold, Green Published			2022-04-29	WOS:000634209400001
J	Tkaczyszyn, K; Kuchar, E; Augustynowicz, E; Szenborn, L				Tkaczyszyn, Katarzyna; Kuchar, Ernest; Augustynowicz, Ewa; Szenborn, Leszek			The Impact of a Single Educational Lecture on the Vaccine Confidence among Pregnant Women and Young Mothers	VACCINES			English	Article						education; vaccine; vaccine confidence; visual analogue scale		Background: We investigated the impact of a single unstructured educational lecture about vaccinations on the vaccine confidence in volunteer participants. Methods: We conducted a survey-based study during a series of open meetings related to pregnancy and parenting. Before and after the pediatrician's lecture related to vaccinations, listeners completed the visual analogue scales (VAS, 0-15 cm), evaluating (1) self-declared knowledge on vaccinations and (2) how they perceive the safety and efficacy of this preventive method. Results: In total, 484 women aged 30 +/- 4 years participated in the lecture (pregnant = 68%; >= 1 children = 56%). Participants declared to have more comprehensive knowledge on preventive vaccinations and perceived vaccines to be safer and more useful (the role for the immunity) after vs. before the lecture (median VAS: 10.4 vs. 7.2, 10.8 vs. 8.7, and 11.0 vs. 10.4 cm, all p < 0.001). Importantly, the prevalence of vaccine-related adverse events was also assessed as being higher after the lecture (median VAS: 9.9 vs. 8.0 cm, p < 0.001). The increase in self-declared knowledge on vaccinations and perceived need for vaccinations (delta VAS-VAS after minus before the lecture, expressed as % of baseline) was lower among participants who rated the lecture less vs. more useful. Importantly, both participants who liked vs. did not like the lecture comparably rated vaccines safer after vs. before the lecture (delta VAS (median, interquartile range): 16% (0-39%) vs. 18% (2-42%), p = 0.39). Conclusions: An educational lecture on vaccinations positively impacts vaccine confidence in young adult women. Irrespective of the subjective rating of the lecture, all listeners perceived vaccinations to be safer after vs. before the speech.	[Tkaczyszyn, Katarzyna; Szenborn, Leszek] Wroclaw Med Univ, Dept Pediat Infect Dis, PL-50368 Wroclaw, Poland; [Tkaczyszyn, Katarzyna; Szenborn, Leszek] Univ Hosp, Dept Pediat Infect Dis, PL-50556 Wroclaw, Poland; [Kuchar, Ernest] Warsaw Med Univ, Dept Pediat Clin Assessment Unit, PL-02091 Warsaw, Poland; [Augustynowicz, Ewa] Natl Inst Publ Hlth, Dept Epidemiol Infect Dis & Surveillance, Natl Inst Hyg, PL-00791 Warsaw, Poland		Kuchar, E (通讯作者)，Warsaw Med Univ, Dept Pediat Clin Assessment Unit, PL-02091 Warsaw, Poland.	katarzyna.tkaczyszyn@student.umed.wroc.pl; ernest.kuchar@wum.edu.pl; eaugustynowicz@pzh.gov.pl; leszek.szenborn@umed.wroc.pl	Kuchar, Ernest/D-6761-2015	Kuchar, Ernest/0000-0002-7883-2427; Szenborn, Leszek/0000-0001-6574-8229	Department of Pediatric Infectious Diseases, Wroclaw Medical University, Poland [SUB.C 180.21.080]	This research was financially supported by subsidy no. SUB.C 180.21.080 of the Department of Pediatric Infectious Diseases, Wroclaw Medical University, Poland.	Alshammari TM, 2018, VACCINE, V36, P23, DOI 10.1016/j.vaccine.2017.11.050; [Anonymous], 2018, STATE VACCINE CONFID; [Anonymous], NATL I PUBLIC HLTH N; Awadh AI, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-255; Bianco A, 2019, VACCINE, V37, P984, DOI 10.1016/j.vaccine.2018.12.062; Czajka H, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124461; Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025; Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447; Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004; Fleurier A, 2015, DIGEST LIVER DIS, V47, P460, DOI 10.1016/j.dld.2015.02.009; Forster AS, 2016, SSM-POPUL HLTH, V2, P603, DOI 10.1016/j.ssmph.2016.07.005; Furman FM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124565; Hadjipanayis A, 2020, VACCINE, V38, P1505, DOI 10.1016/j.vaccine.2019.11.068; Hu Y, 2015, INT J ENV RES PUB HE, V12, P3469, DOI 10.3390/ijerph120403469; Kieslich K, 2018, EUR J PUBLIC HEALTH, V28, P30, DOI 10.1093/eurpub/cky155; Kundi M, 2015, CURR DRUG SAF, V10, P16, DOI 10.2174/157488631001150407104320; Larson Heidi J, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maltezou HC, 2019, HUM VACC IMMUNOTHER, V15, P1070, DOI 10.1080/21645515.2019.1568158; Owais A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-239; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P402, DOI 10.15585/mmwr.mm6817e1; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Poland CM, 2021, VACCINE, V39, P1547, DOI 10.1016/j.vaccine.2021.02.008; Prospero E, 2019, INFLUENZA OTHER RESP, V13, P201, DOI 10.1111/irv.12600; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Taylor JA, 2002, PEDIATRICS, V110, P1110, DOI 10.1542/peds.110.6.1110; Uddin MJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1758-x; Wegwarth O, 2014, VACCINE, V32, P1388, DOI 10.1016/j.vaccine.2013.12.038; WHO, 10 THREATS GLOBAL HL; World Health Organization, 2017, ASSESSMENT REPORT GL; Zimmerman RK, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e17; Zuk P, 2019, VACCINE, V37, P1491, DOI 10.1016/j.vaccine.2019.01.073	33	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							290	10.3390/vaccines9030290			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5FE	33804621	gold, Green Published			2022-04-29	WOS:000634179000001
J	Tokuhara, D; Hikita, N				Tokuhara, Daisuke; Hikita, Norikatsu			Cord Blood-Based Approach to Assess Candidate Vaccine Adjuvants Designed for Neonates and Infants	VACCINES			English	Review						vaccine; adjuvant; children; innate immunity; cord blood; toll-like receptor; zymosan	TOLL-LIKE RECEPTORS; PENTAVALENT ROTAVIRUS VACCINE; MESSENGER-RNA EXPRESSION; DENDRITIC CELL-FUNCTION; T-CELL; IMMUNE-RESPONSE; INNATE IMMUNITY; ANTIBODY-RESPONSE; VIRUS-VACCINE; DOUBLE-BLIND	Neonates and infants are particularly susceptible to infections, for which outcomes tend to be severe. Vaccination is a key strategy for preventing infectious diseases, but the protective immunity achieved through vaccination typically is weaker in infants than in healthy adults. One possible explanation for the poor acquisition of vaccine-induced immunity in infants is that their innate immune response, represented by toll-like receptors, is immature. The current system for developing pediatric vaccines relies on the confirmation of their safety and effectiveness in studies involving the use of mature animals or adult humans. However, creating vaccines for neonates and infants requires an understanding of their uniquely immature innate immunity. Here we review current knowledge regarding the innate immune system of neonates and infants and challenges in developing vaccine adjuvants for those children through analyses of cord blood.	[Tokuhara, Daisuke; Hikita, Norikatsu] Osaka City Univ, Grad Sch Med, Dept Pediat, Osaka 5458585, Japan		Tokuhara, D (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Pediat, Osaka 5458585, Japan.	m1155519@med.osaka-cu.ac.jp; nhikita0104@yahoo.co.jp	Tokuhara, Daisuke/AAY-2554-2021	Tokuhara, Daisuke/0000-0002-2441-5062; Hikita, Norikatsu/0000-0002-7087-3515	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Fund for the Promotion of Joint International Research [17 KK0196]; Danone Institute of Japan FoundationDanone Nutricia; Takano Life Science Research Foundation; AMED Translational Research [A142]	This work was supported by grants from the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research (C)16 K (to D.T.) and Fund for the Promotion of Joint International Research 17 KK0196 (to D.T.)), the Danone Institute of Japan Foundation (to D.T.), and the Takano Life Science Research Foundation (to D.T.) and from AMED Translational Research under grant number A142 (to D.T.).	Abou Elazab MF, 2017, J VET MED SCI, V79, P1335, DOI 10.1292/jvms.16-0636; Ainai A, 2010, J MED VIROL, V82, P476, DOI 10.1002/jmv.21694; Andersen-Nissen E, 2007, J EXP MED, V204, P393, DOI 10.1084/jem.20061400; Ara Y, 2001, IMMUNOLOGY, V103, P98, DOI 10.1046/j.1365-2567.2001.01201.x; Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6; Asanuma H, 2012, VACCINE, V30, P803, DOI 10.1016/j.vaccine.2011.10.093; Ategbo JM, 2006, J CLIN ENDOCR METAB, V91, P4137, DOI 10.1210/jc.2006-0980; Barman NN, 1997, ANAT EMBRYOL, V195, P41; Belderbos ME, 2011, PEDIATRICS, V127, pE1513, DOI 10.1542/peds.2010-3054; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; Biswas B, 2009, AM J REPROD IMMUNOL, V62, P243, DOI 10.1111/j.1600-0897.2009.00732.x; Bucardo F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19718-y; Butler JE, 2009, VET IMMUNOL IMMUNOP, V128, P147, DOI 10.1016/j.vetimm.2008.10.321; Chattha KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082966; Choi JH, 2020, J VET SCI, V21, DOI 10.4142/jvs.2020.21.e74; Ciarlet M, 2009, VACCINE, V27, pG72, DOI 10.1016/j.vaccine.2009.09.107; Colson V, 2006, APPL ANIM BEHAV SCI, V98, P70, DOI 10.1016/j.applanim.2005.08.014; CORNES JS, 1965, GUT, V6, P225, DOI 10.1136/gut.6.3.225; de Waal L, 2004, VACCINE, V22, P915, DOI 10.1016/j.vaccine.2003.10.008; De Wit D, 2003, J AUTOIMMUN, V21, P277, DOI 10.1016/j.jaut.2003.08.003; Dillon S, 2006, J CLIN INVEST, V116, P916, DOI 10.1172/JCI27203; Dominguez PM, 2010, IMMUNOL REV, V234, P90, DOI 10.1111/j.0105-2896.2009.00876.x; Dowling DJ, 2017, J ALLERGY CLIN IMMUN, V140, P1339, DOI 10.1016/j.jaci.2016.12.985; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; Elahi S, 2006, INFECT IMMUN, V74, P2619, DOI 10.1128/IAI.74.5.2619-2627.2006; Enioutina EY, 2009, J IMMUNOL, V182, P4296, DOI 10.4049/jimmunol.0804344; Esposito S, 2020, PEDIATR INFECT DIS J, V39, pE185, DOI 10.1097/INF.0000000000002727; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Fujkuyama Y, 2012, EXPERT REV VACCINES, V11, P367, DOI [10.1586/ERV.11.196, 10.1586/erv.11.196]; Fukuyama Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060453; Fukuyama Y, 2012, BIOCHEM BIOPH RES CO, V418, P6, DOI 10.1016/j.bbrc.2011.12.046; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; Gans HA, 1999, J IMMUNOL, V162, P5569; Garmory Helen S, 2003, Genet Vaccines Ther, V1, P2, DOI 10.1186/1479-0556-1-2; Gauthier TW, 2005, ALCOHOL CLIN EXP RES, V29, P1035, DOI 10.1097/01.ALC.0000167956.28160.5E; Ge ZZ, 2013, EXP NEUROL, V241, P56, DOI 10.1016/j.expneurol.2012.12.006; Gruber WC, 1997, VACCINE, V15, P1379, DOI 10.1016/S0264-410X(97)00032-7; Halliday A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1381-0; Hamada H, 2002, J IMMUNOL, V168, P57, DOI 10.4049/jimmunol.168.1.57; Hikita N, 2019, J REPROD IMMUNOL, V136, DOI 10.1016/j.jri.2019.102614; Hill DR, 2006, LANCET INFECT DIS, V6, P361, DOI 10.1016/S1473-3099(06)70494-7; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hornsby E, 2018, J ALLERGY CLIN IMMUN, V141, P269, DOI 10.1016/j.jaci.2017.02.039; Hurley WL, 2011, NUTRIENTS, V3, P442, DOI 10.3390/nu3040442; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; Kandasamy S, 2014, VACCINE, V32, P816, DOI 10.1016/j.vaccine.2013.12.039; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Klinge J, 2000, VACCINE, V18, P3134, DOI 10.1016/S0264-410X(00)00096-7; Ko HJ, 2014, J IMMUNOL, V192, P2202, DOI 10.4049/jimmunol.1302040; Kobayashi M, 2009, BRIT J DERMATOL, V160, P297, DOI 10.1111/j.1365-2133.2008.08897.x; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lemoine S, 2015, J ALLERGY CLIN IMMUN, V136, P1355, DOI 10.1016/j.jaci.2015.02.030; Leroux-Roels G, 2018, J INFECT DIS, V217, P597, DOI 10.1093/infdis/jix572; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; LIEBERMAN JM, 1995, J PEDIATR-US, V126, P198, DOI 10.1016/S0022-3476(95)70545-7; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lima L, 2019, VACCINE, V37, P2569, DOI 10.1016/j.vaccine.2019.03.070; Madhi SA, 2010, NEW ENGL J MED, V362, P289, DOI 10.1056/NEJMoa0904797; Malloy AMW, 2017, J IMMUNOL, V198, P394, DOI 10.4049/jimmunol.1600486; Marodi L, 2006, INFECT IMMUN, V74, P1999, DOI 10.1128/IAI.74.4.1999-2006.2006; Marshall-Clarke S, 2000, IMMUNOL TODAY, V21, P35, DOI 10.1016/S0167-5699(99)01548-0; MAUPAS P, 1981, LANCET, V1, P289; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Mendelman PM, 2001, VACCINE, V19, P2221, DOI 10.1016/S0264-410X(00)00449-7; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Nagai Y, 2005, J IMMUNOL, V174, P7043, DOI 10.4049/jimmunol.174.11.7043; Nahori MA, 2005, J IMMUNOL, V175, P6022, DOI 10.4049/jimmunol.175.9.6022; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Namakula R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229287; Naylor C, 2015, EBIOMEDICINE, V2, P1759, DOI 10.1016/j.ebiom.2015.09.036; Neimert-Andersson T, 2014, VACCINE, V32, P5967, DOI 10.1016/j.vaccine.2014.08.057; Nguyen M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010407; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Nochi T, 2009, J IMMUNOL, V183, P6538, DOI 10.4049/jimmunol.0901480; Nohmi K, 2015, J PEDIATR-US, V167, P155, DOI 10.1016/j.jpeds.2015.03.035; O'Hagan DT, 2011, EXPERT REV VACCINES, V10, P447, DOI [10.1586/ERV.11.23, 10.1586/erv.11.23]; O'Ryan M, 2009, EXPERT REV VACCINES, V8, P1627, DOI 10.1586/ERV.09.136; Openshaw PJM, 2001, VACCINE, V20, pS27, DOI 10.1016/S0264-410X(01)00301-2; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Patel MM, 2020, VACCINE, V38, P608, DOI 10.1016/j.vaccine.2019.10.053; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Reitsema LJ, 2016, AM J PRIMATOL, V78, DOI 10.1002/ajp.22456; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rijkers G, 1998, VACCINE, V16, P1396, DOI 10.1016/S0264-410X(98)00098-X; Schuller SS, 2013, J LEUKOCYTE BIOL, V93, P781, DOI 10.1189/jlb.1011525; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Shao LL, 2016, VET IMMUNOL IMMUNOP, V171, P7, DOI 10.1016/j.vetimm.2016.01.008; Simonsen L, 2005, J INFECT DIS, V192, pS36, DOI 10.1086/431512; Skinner JM, 2011, VACCINE, V29, P8870, DOI 10.1016/j.vaccine.2011.09.078; SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536; Surman SL, 2012, VIRAL IMMUNOL, V25, P341, DOI 10.1089/vim.2012.0023; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; Takeda Y, 2018, INNATE IMMUN-LONDON, V24, P323, DOI 10.1177/1753425918777598; Takeyama N, 2015, VACCINE, V33, P5204, DOI 10.1016/j.vaccine.2015.07.074; Terry RL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-270; Thompson EA, 2017, CURR OPIN IMMUNOL, V47, P1, DOI 10.1016/j.coi.2017.06.006; Tokuhara D, COMP ZYMOSAN M UNPUB; Tokuhara D, 2019, ALLERGOL INT, V68, P17, DOI 10.1016/j.alit.2018.09.004; Tokuhara D, 2018, PEDIATR INT, V60, P214, DOI 10.1111/ped.13497; Tokuhara D, 2014, DIGEST DIS SCI, V59, P2682, DOI 10.1007/s10620-014-3203-6; Tokuhara D, 2010, P NATL ACAD SCI USA, V107, P8794, DOI 10.1073/pnas.0914121107; Trivedi HN, 1997, HUM IMMUNOL, V57, P69, DOI 10.1016/S0198-8859(97)00202-4; Uddin MJ, 2013, RES VET SCI, V95, P92, DOI 10.1016/j.rvsc.2013.01.027; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Upham JW, 2006, INFECT IMMUN, V74, P1106, DOI 10.1128/IAI.74.2.1106-1112.2006; Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316; Vekemans J, 2002, CLIN EXP IMMUNOL, V127, P495, DOI 10.1046/j.1365-2249.2002.01788.x; Vono M, 2019, CELL REP, V28, P1773, DOI 10.1016/j.celrep.2019.07.047; Werling D, 2009, TRENDS IMMUNOL, V30, P124, DOI 10.1016/j.it.2008.12.001; WIEDERMANN U, 1993, INFECT IMMUN, V61, P3952, DOI 10.1128/IAI.61.9.3952-3957.1993; Wright PF, 2000, J INFECT DIS, V182, P1331, DOI 10.1086/315859; Xia YF, 2015, VACCINE, V33, P5997, DOI 10.1016/j.vaccine.2015.07.101; Yamamoto M, 2004, J IMMUNOL, V173, P762, DOI 10.4049/jimmunol.173.2.762; Yanai S, 2016, J REPROD IMMUNOL, V117, P17, DOI 10.1016/j.jri.2016.06.007; Yuki Y, 2010, J IMMUNOL, V185, P5436, DOI 10.4049/jimmunol.1001789; Zhang SY, 2013, CURR OPIN IMMUNOL, V25, P19, DOI 10.1016/j.coi.2012.11.001; Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1	125	3	3	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							95	10.3390/vaccines9020095			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UW	33514054	Green Published			2022-04-29	WOS:000623277600001
J	Baloch, Z; Ikram, A; Hakim, MS; Awan, FM				Baloch, Zulqarnain; Ikram, Aqsa; Hakim, Mohamad S.; Awan, Faryal Mehwish			The Impact of Mutations on the Pathogenic and Antigenic Activity of SARS-CoV-2 during the First Wave of the COVID-19 Pandemic: A Comprehensive Immunoinformatics Analysis	VACCINES			English	Article						mutation; RdRp; spike; SARS-CoV-2; 3CLpro; epitope		An in-depth analysis of first-wave SARS-CoV-2 genome is required to identify various mutations that significantly affect viral fitness. In the present study, we performed a comprehensive in silico mutational analysis of 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), and spike (S) proteins with the aim of gaining important insights into first-wave virus mutations and their functional and structural impact on SARS-CoV-2 proteins. Our integrated analysis gathered 6000 SARS-CoV-2 sequences and identified 92 mutations in S, 37 in RdRp, and 11 in 3CLpro regions. The impact of these mutations was also investigated using various in silico approaches. Among these, 32 mutations in S, 15 in RdRp, and 3 in 3CLpro proteins were found to be deleterious in nature and could alter the structural and functional behavior of the encoded proteins. The D614G mutation in spike and the P323Lmutation in RdRp are the globally dominant variants with a high frequency. Most of the identified mutations were also found in the binding moiety of the viral proteins which determine their critical involvement in host-pathogen interactions and may represent drug targets. Furthermore, potential CD4(+) and CD8(+) T cell epitopes were predicted, and their overlap with genetic variations was explored. This study also highlights several hot spots in which HLA and drug selective pressure overlap. The findings of the current study may allow a better understanding of COVID-19 diagnostics, vaccines, and therapeutics.	[Baloch, Zulqarnain] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming 650500, Yunnan, Peoples R China; [Ikram, Aqsa] Univ Lahore UOL, Inst Mol Biol & Biotechnol IMBB, Lahore 54000, Pakistan; [Hakim, Mohamad S.] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Microbiol, Yogyakarta 55281, Indonesia; [Hakim, Mohamad S.] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Ctr Child Hlth PRO, Yogyakarta 55281, Indonesia; [Awan, Faryal Mehwish] Univ Haripur UOH, Dept Med Lab Technol, Haripur 22620, Pakistan		Ikram, A (通讯作者)，Univ Lahore UOL, Inst Mol Biol & Biotechnol IMBB, Lahore 54000, Pakistan.	znbalooch@yahoo.com; Aqsa.ikram@imbb.uol.edu.pk; m.s.hakim@ugm.ac.id; faryal.mehwish@uoh.edu.pk	baloch, zulqarnain/A-8455-2017	baloch, zulqarnain/0000-0002-7873-1343; Awan, Faryal Mehwish/0000-0002-8146-8929; Ikram, Aqsa/0000-0001-7292-6134	key research and development programs of Yunnan province [2019ZF004, 202103AC100001]	The work was supported by the key research and development programs (2019ZF004 and 202103AC100001 of Yunnan province).	Capriotti E, 2005, NUCLEIC ACIDS RES, V33, pW306, DOI 10.1093/nar/gki375; Capriotti E, 2017, NUCLEIC ACIDS RES, V45, pW247, DOI 10.1093/nar/gkx369; Chen JH, 2020, J MOL BIOL, V432, P5212, DOI 10.1016/j.jmb.2020.07.009; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Duarte AJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113409; Grubaugh ND, 2020, NAT MICROBIOL, V5, P529, DOI 10.1038/s41564-020-0690-4; Hall T., 2011, GERF B BIOSCI, V2, P60; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hecht M, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S1; Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6; Petrova VN, 2018, NAT REV MICROBIOL, V16, P60, DOI [10.1038/nrmicro.2017.118, 10.1038/nrmicro.2017.146]; Pires DEV, 2014, NUCLEIC ACIDS RES, V42, pW314, DOI 10.1093/nar/gku411; Ristevski B, 2018, J INTEGR BIOINFORMAT, V15, DOI 10.1515/jib-2017-0030; Rodrigues CHM, 2018, NUCLEIC ACIDS RES, V46, pW350, DOI 10.1093/nar/gky300; Samad FA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153999; Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6; Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wu CR, 2020, ACTA PHARM SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008; Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053	24	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1410	10.3390/vaccines9121410			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YH0MW	34960156	gold, Green Published			2022-04-29	WOS:000742871900001
J	Eiden, J; Gordon, G; Fierro, C; Herber, R; Aitchison, R; Belshe, R; Greenberg, H; Hoft, D; Hatta, Y; Moser, MJ; Tary-Lehmann, M; Kawaoka, Y; Neumann, G; Radspinner, P; Bilsel, P				Eiden, Joseph; Gordon, Gilad; Fierro, Carlos; Herber, Renee; Aitchison, Roger; Belshe, Robert; Greenberg, Harry; Hoft, Daniel; Hatta, Yasuko; Moser, Michael J.; Tary-Lehmann, Magdalena; Kawaoka, Yoshihiro; Neumann, Gabriele; Radspinner, Paul; Bilsel, Pamuk			Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults	VACCINES			English	Article						influenza; vaccine; clinical trial; M2SR; immunity	T-CELL RESPONSES; PROTECTION; VIRUS; TRIVALENT; INFECTION; CHILDREN; EFFICACY; CHALLENGE	M2SR (M2-deficient single replication) is an investigational live intranasal vaccine that protects against multiple influenza A subtypes in influenza-naive and previously infected ferrets. We conducted a phase 1, first-in-human, randomized, dose-escalation, placebo-controlled study of M2SR safety and immunogenicity. Adult subjects received a single intranasal administration with either placebo or one of three M2SR dose levels (10(6), 10(7) or 10(8) tissue culture infectious dose (TCID50)) expressing hemagglutinin and neuraminidase from A/Brisbane/10/2007 (H3N2) (24 subjects per group). Subjects were evaluated for virus replication, local and systemic reactions, adverse events (AE), and immune responses post-vaccination. Infectious virus was not detected in nasal swabs from vaccinated subjects. At least one AE (most commonly mild nasal rhinorrhea/congestion) was reported among 29%, 58%, and 83% of M2SR subjects administered a low, medium or high dose, respectively, and among 46% of placebo subjects. No subject had fever or a severe reaction to the vaccine. Influenza-specific serum and mucosal antibody responses and B- and T-cell responses were significantly more frequent among vaccinated subjects vs. placebo recipients. The M2SR vaccine was safe and well tolerated and generated dose-dependent durable serum antibody responses against diverse H3N2 influenza strains. M2SR demonstrated a multi-faceted immune response in seronegative and seropositive subjects.	[Eiden, Joseph] Celyn Consulting LLC, Lewes, DE 19958 USA; [Gordon, Gilad] ORRA Grp LLC, Boulder, CO 80305 USA; [Fierro, Carlos] Johnson Cty Clin Trials, Lenexa, KS 66219 USA; [Herber, Renee; Hatta, Yasuko; Moser, Michael J.; Radspinner, Paul; Bilsel, Pamuk] FluGen Inc, Madison, WI 53711 USA; [Aitchison, Roger] North Rim Consulting, Longmont, CO 80504 USA; [Belshe, Robert; Hoft, Daniel] St Louis Univ, Dept Internal Med, St Louis, MO 63104 USA; [Belshe, Robert; Hoft, Daniel] St Louis Univ, Dept Mol Microbiol, St Louis, MO 63104 USA; [Greenberg, Harry] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA; [Greenberg, Harry] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Tary-Lehmann, Magdalena] Cellular Technol Ltd, Shaker Hts, OH 44122 USA; [Kawaoka, Yoshihiro; Neumann, Gabriele] Univ Wisconsin, Influenza Res Inst, Madison, WI 53711 USA		Bilsel, P (通讯作者)，FluGen Inc, Madison, WI 53711 USA.	jeiden@flugen.com; ggordon@orragroup.com; cfierro@jcct.com; rherber@flugen.com; raitchison@northrimgroup.com; belsherb@gmail.com; hbgreen@stanford.edu; hoftdf@slu.edu; yhatta@flugen.com; mmoser@flugen.com; magda.tary-lehmann@immunospot.com; yoshihiro.kawaoka@wisc.edu; gabriele.neumann@wisc.edu; pradspinner@flugen.com; PBilsel@flugen.com		greenberg, harry/0000-0002-2128-9080	FluGen, Inc	This study was funded by FluGen, Inc.	Ambrose CS, 2011, INFLUENZA OTHER RESP, V5, P67, DOI 10.1111/j.1750-2659.2010.00183.x; Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411; Belshe RB, 2000, J INFECT DIS, V181, P1133, DOI 10.1086/315323; Belshe RB, 2008, VACCINE, V26, pD10, DOI 10.1016/j.vaccine.2008.06.083; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Bodewes R, 2009, LANCET INFECT DIS, V9, P784, DOI 10.1016/S1473-3099(09)70263-4; Centers for Disease Control and Prevention, SEAS VACC EFF EST; Centers for Disease Control and Prevention, DIS BURD INFL; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; CLEMENTS ML, 1986, J CLIN MICROBIOL, V24, P157, DOI 10.1128/JCM.24.1.157-160.1986; Esposito S, 2012, HUM VACC IMMUNOTHER, V8, P76, DOI 10.4161/hv.8.1.18809; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Gostic KM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008109; Gostic KM, 2016, SCIENCE, V354, P722, DOI 10.1126/science.aag1322; Gould VMW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00900; Guthmiller JJ, 2018, CURR OPIN IMMUNOL, V53, P187, DOI 10.1016/j.coi.2018.05.010; Hatta Y, 2018, VACCINE, V36, P5097, DOI 10.1016/j.vaccine.2018.06.053; Hatta Y, 2017, VACCINE, V35, P4177, DOI 10.1016/j.vaccine.2017.06.039; Hatta Y, 2011, VACCINE, V29, P2308, DOI 10.1016/j.vaccine.2011.01.023; Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]; Hoft DF, 2011, J INFECT DIS, V204, P845, DOI 10.1093/infdis/jir436; Islam S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12801; Jahnmatz M, 2013, J IMMUNOL METHODS, V391, P50, DOI 10.1016/j.jim.2013.02.009; Kim JH, 2016, VACCINE, V34, P495, DOI 10.1016/j.vaccine.2015.11.077; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Kreijtz JHCM, 2011, VIRUS RES, V162, P19, DOI 10.1016/j.virusres.2011.09.022; McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333; Moser MJ, 2019, VACCINE, V37, P4533, DOI 10.1016/j.vaccine.2019.06.043; Pebody RG, 2013, EUROSURVEILLANCE, V18, P25; Pinna D, 2009, EUR J IMMUNOL, V39, P1260, DOI 10.1002/eji.200839129; Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035; Ray GT, 2019, CLIN INFECT DIS, V68, P1623, DOI 10.1093/cid/ciy770; Roy S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040683; Sarawar S, 2016, VACCINE, V34, P5090, DOI 10.1016/j.vaccine.2016.08.061; Sasaki S, 2007, J VIROL, V81, P215, DOI 10.1128/JVI.01957-06; Schlingmann TR, 2009, CELL IMMUNOL, V258, P131, DOI 10.1016/j.cellimm.2009.04.002; Sridhar S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00195; Sridhar S, 2015, VACCINES, V3, P373, DOI 10.3390/vaccines3020373; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; World Health Organization, 2011, GLOB INFL SURV NETW; Zhang A, 2019, J IMMUNOL, V202, P335, DOI 10.4049/jimmunol.1801149; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	45	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1388	10.3390/vaccines9121388			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9TB	34960134	gold, Green Published			2022-04-29	WOS:000737306300001
J	Firinu, D; Perra, A; Campagna, M; Littera, R; Meloni, F; Sedda, F; Conti, M; Costanzo, G; Erbi, M; Usai, G; Locci, C; Carta, MG; Cappai, R; Orru, G; Del Giacco, S; Coghe, F; Chessa, L				Firinu, Davide; Perra, Andrea; Campagna, Marcello; Littera, Roberto; Meloni, Federico; Sedda, Francesca; Conti, Maria; Costanzo, Giulia; Erbi, Monica; Usai, Gianmario; Locci, Carlotta; Carta, Mauro Giovanni; Cappai, Riccardo; Orru, Germano; Del Giacco, Stefano; Coghe, Ferdinando; Chessa, Luchino			Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study	VACCINES			English	Article						COVID-19; vaccination; immunogenicity; heterologous; ChAdOx1; BNT162b2		In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BNT162b2(ChAd/BNT), comparing data of homologous regimen (BNT/BNT, ChAd/ChAd) subjects positive for SARS-CoV-2 after the first dose of BNT162b2 (BNT1dose/CoV2) and convalescent COVID-19. Methods: healthy subjects naive for SARS-CoV-2 infection were assessed for serum IgG anti-S-RBD response 21 days after priming (T1), 4 (T-FULL) and 15 (T-15W) weeks after booster dose. Results: The median IgG anti-S-RBD levels at T-FULL of Chad/BNT group were significantly higher than the BNT/BNT group and ChAd/ChAd. Those of BNT/BNT group were significantly higher than ChAd/ChAd. IgG anti-S-RBD of BNT1dose/CoV2 group were similar to BNT/BNT, ChAd/BNT and ChAd/Chad group. The levels among COVID-19 convalescents were significantly lower than ChAd/BNT, BNT/BNT, ChAd/Chad and BNT1dose/CoV2. The proportion of subjects reaching an anti-S-RBD titer >75 AU/mL, correlated with high neutralizing titer, was 94% in ChAd/BNT and BNT/BNT, 60% in BNT1dose/CoV2, 25% in ChAd/ChAd and 4.2% in convalescents. At T-15W the titer of ChAd/BNT was still significantly higher than other vaccine schedules, while the anti-S-RBD decline was reduced for ChAd/ChAd and similar for other combinations. Conclusion: Our data highlight the magnitude of IgG anti-S-RBD response in ChAd/BNT dosing, supporting the current national guidelines for heterologous boosting	[Firinu, Davide; Campagna, Marcello; Meloni, Federico; Conti, Maria; Costanzo, Giulia; Erbi, Monica; Usai, Gianmario; Locci, Carlotta; Carta, Mauro Giovanni; Orru, Germano; Del Giacco, Stefano; Chessa, Luchino] Univ Cagliari, Dept Med Sci & Publ Hlth, I-09100 Cagliari, Italy; [Perra, Andrea; Sedda, Francesca] Univ Cagliari, Dept Biomed Sci, I-09100 Cagliari, Italy; [Perra, Andrea; Littera, Roberto; Chessa, Luchino] Non Profit Org, Assoc Avanzamento Ric & Trapianti OdV, I-09100 Cagliari, Italy; [Littera, Roberto] Univ Cagliari, Dept Med Sci & Publ Hlth, Med Genet, I-09100 Cagliari, Italy; [Cappai, Riccardo; Coghe, Ferdinando] Univ Hosp Cagliari, Lab Clin Chem Anal & Microbiol, I-09042 Cagliari, Italy		Firinu, D (通讯作者)，Univ Cagliari, Dept Med Sci & Publ Hlth, I-09100 Cagliari, Italy.	giuliacostanzo14@gmail.com; andrea.perra@unica.it; mam.campagna@gmail.com; roby.litter@gmail.com; federicomeloni@hotmail.it; francisedda@hotmail.com; mariaconti14@gmail.com; giuliacostanzo14@gmail.com; momo_erbi@tiscali.it; gianmariousaimed@outlook.com; loccicarlotta@gmail.com; mgcarta@tiscali.it; r.cappai@aoucagliari.it; gerorru@gmail.com; delgiacco@unica.it; fcoghe@aoucagliari.it; luchinochessa@unica.it	; Chessa, Luchino/H-7561-2012	Meloni, Federico/0000-0001-8120-2103; Costanzo, Giulia Anna Maria Luigia/0000-0003-2269-0439; Chessa, Luchino/0000-0002-9474-0995; Firinu, Davide/0000-0002-5768-391X; Perra, Alessandra/0000-0001-5791-1655; Littera, Roberto/0000-0003-3143-3792	Fondazione di SardegnaFondazione Banco di Sardegna [2020.2197]; Associazione per l'Avanzamento della Ricerca per i Trapianti O.D.V	This research was funded by a grant #2020.2197 of Fondazione di Sardegna and by Associazione per l'Avanzamento della Ricerca per i Trapianti O.D.V.	Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Bohn MK, 2020, CLIN CHEM LAB MED, V58, P2001, DOI 10.1515/cclm-2020-1413; Borobia AM, 2021, LANCET, V398, P121, DOI 10.1016/S0140-6736(21)01420-3; D'Amelio R, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091163; Dehgani-Mobaraki P, 2022, ANN IG MED PREV COMU, V34, P1, DOI 10.7416/ai.2021.2455; Dehgani-Mobaraki P, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108814; Deming ME, 2021, NAT MED, V27, P1510, DOI 10.1038/s41591-021-01463-x; Dittadi R, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11091709; FARMACO A.I.D., 2021, GAZZETTA UFFICIALE, VVolume 141; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gilbert Peter B, 2021, medRxiv, DOI 10.1101/2021.08.09.21261290; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Hammerschmidt SI, 2021, CELL MOL IMMUNOL, V18, P2455, DOI 10.1038/s41423-021-00755-z; Hillus D, 2021, LANCET RESP MED, V9, P1255, DOI 10.1016/S2213-2600(21)00357-X; Hippisley-Cox J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1931; Hirotsu Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.722766; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Laterza R, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13573; Liu XX, 2021, LANCET, V398, P856, DOI 10.1016/S0140-6736(21)01694-9; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Padoan A, 2021, CLIN CHEM LAB MED, V59, P1444, DOI 10.1515/cclm-2021-0313; Petersen I, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4515; Prendecki M, 2021, ANN RHEUM DIS, V80, P1322, DOI 10.1136/annrheumdis-2021-220626; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Salvagno GL, 2021, J INFECTION, V83, pE4, DOI 10.1016/j.jinf.2021.06.024; Schmidt T, 2021, NAT MED, V27, P1530, DOI 10.1038/s41591-021-01464-w; Simpson CR, 2021, NAT MED, V27, P1290, DOI 10.1038/s41591-021-01408-4; Steensels D, 2021, JAMA-J AM MED ASSOC, V326, P1533, DOI 10.1001/jama.2021.15125; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Tenbusch M, 2021, LANCET INFECT DIS, V21, P1212, DOI 10.1016/S1473-3099(21)00420-5; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n781; Zaffina S, 2021, J VIRUS ERAD, V7, DOI 10.1016/j.jve.2021.100046	34	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1478	10.3390/vaccines9121478			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1YN	34960224	gold, Green Published			2022-04-29	WOS:000737455800001
J	Fujisawa, S; Murata, S; Isezaki, M; Ariizumi, T; Sato, T; Oishi, E; Taneno, A; Maekawa, N; Okagawa, T; Ichii, O; Konnai, S; Ohashi, K				Fujisawa, Sotaro; Murata, Shiro; Isezaki, Masayoshi; Ariizumi, Takuma; Sato, Takumi; Oishi, Eiji; Taneno, Akira; Maekawa, Naoya; Okagawa, Tomohiro; Ichii, Osamu; Konnai, Satoru; Ohashi, Kazuhiko			Characterization of a Novel Cysteine Protease Inhibitor from Poultry Red Mites: Potential Vaccine for Chickens	VACCINES			English	Article						Dermanyssus gallinae; poultry red mite; cystatin; vaccine; cocktail vaccine	TICK HAEMAPHYSALIS-LONGICORNIS; CATHEPSIN-L; DERMANYSSUS-GALLINAE; SALIVARY CYSTATIN; CATTLE; EXPRESSION; ANTIGEN; MIDGUT; GENE	Poultry red mite (PRM; Dermanyssus gallinae) is a hazardous, blood-sucking ectoparasite of birds that constitutes a threat to poultry farming worldwide. Acaricides, commonly used in poultry farms to prevent PRMs, are not effective because of the rapid emergence of acaricide-resistant PRMs. However, vaccination may be a promising strategy to control PRM. We identified a novel cystatin-like molecule in PRMs: Dg-Cys. Dg-Cys mRNA expression was detected in the midgut and ovaries, in all stages of life. The PRM nymphs that were artificially fed with the plasma from chickens that were immunized with Dg-Cys in vitro had a significantly reduced reproductive capacity and survival rate. Moreover, combination of Dg-Cys with other antigen candidates, like copper transporter 1 or adipocyte plasma membrane-associated protein, enhanced vaccine efficacies. vaccination and its application as an antigen for cocktail vaccines could be an effective strategy to reduce the damage caused by PRMs in poultry farming.	[Fujisawa, Sotaro; Murata, Shiro; Isezaki, Masayoshi; Ariizumi, Takuma; Konnai, Satoru; Ohashi, Kazuhiko] Hokkaido Univ, Dept Dis Control, Fac Vet Med, Kita Ku, Kita 18,Nishi 9, Sapporo, Hokkaido 0600818, Japan; [Murata, Shiro; Maekawa, Naoya; Okagawa, Tomohiro; Konnai, Satoru; Ohashi, Kazuhiko] Hokkaido Univ, Dept Adv Pharmaceut, Fac Vet Med, Sapporo, Hokkaido 0600818, Japan; [Ariizumi, Takuma] Hokkaido Univ, Int Inst Zoonosis Control, Div Mol Pathol, Sapporo, Hokkaido 0010020, Japan; [Sato, Takumi; Oishi, Eiji; Taneno, Akira] Vaxxinova Japan KK, Tokyo 1050013, Japan; [Ichii, Osamu] Hokkaido Univ, Dept Vet Basic Sci, Fac Vet Med, Sapporo, Hokkaido 0600818, Japan; [Ichii, Osamu] Hokkaido Univ, Lab Agrobiomed Sci, Fac Agr, Sapporo, Hokkaido 0608589, Japan		Murata, S (通讯作者)，Hokkaido Univ, Dept Dis Control, Fac Vet Med, Kita Ku, Kita 18,Nishi 9, Sapporo, Hokkaido 0600818, Japan.; Murata, S (通讯作者)，Hokkaido Univ, Dept Adv Pharmaceut, Fac Vet Med, Sapporo, Hokkaido 0600818, Japan.	murata@vetmed.hokudai.ac.jp; m-isezak@photon.chitose.ac.jp; ariizumi@czc.hokudai.ac.jp; t-sato@vaxxinova.co.jp; e-oishi@vaxxinova.co.jp; a-taneno@vaxxinova.co.jp; maekawa@vetmed.hokudai.ac.jp; okagawa@vetmed.hokudai.ac.jp; ichi-o@vetmed.hokudai.ac.jp; konnai@vetmed.hokudai.ac.jp; okazu@vetmed.hokudai.ac.jp		Murata, Shiro/0000-0002-2569-899X; Ichii, Osamu/0000-0002-6643-1554; Satoru, Konnai/0000-0002-3230-7109	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [20J22235]	This work was partially supported by Grants-in-Aid for Scientific Research (B: 18H02332 and B: 20H03137); a Grant-in-Aid for Challenging Research (Exploratory) (20K21357); and a Grant-in-Aid for the Japan Society for the Promotion of Science Research Fellow (grant no. 20J22235) from the Japan Society for the Promotion of Science.	Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Alim MA, 2008, J INSECT PHYSIOL, V54, P573, DOI 10.1016/j.jinsphys.2007.12.006; Alim MA, 2009, INT J PARASITOL, V39, P97, DOI 10.1016/j.ijpara.2008.06.012; Almazan C, 2012, VACCINE, V30, P265, DOI 10.1016/j.vaccine.2011.10.102; Ariizumi T, 2021, J VET MED SCI, V83, P558, DOI 10.1292/jvms.20-0677; Bartley K, 2017, VET PARASITOL, V244, P25, DOI 10.1016/j.vetpar.2017.06.020; Bartley K, 2015, INT J PARASITOL, V45, P819, DOI 10.1016/j.ijpara.2015.07.004; Chmelar J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00216; Dai LS, 2017, FISH SHELLFISH IMMUN, V71, P246, DOI 10.1016/j.fsi.2017.10.021; Fujisawa S, 2022, PARASITOLOGY, V149, P105, DOI 10.1017/S0031182021001608; Fujisawa S, 2021, VACCINE, V39, P6057, DOI 10.1016/j.vaccine.2021.08.104; Fujisawa S, 2020, PARASITOL INT, V78, DOI 10.1016/j.parint.2020.102156; Grunclova L, 2006, BIOL CHEM, V387, P1635, DOI 10.1515/BC.2006.204; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Hope M, 2010, PARASITE IMMUNOL, V32, P135, DOI 10.1111/j.1365-3024.2009.01168.x; Ichii O, 2017, SCI REP-UK, V7, DOI 10.1038/srep40340; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Karim S, 2005, BIOCHEM BIOPH RES CO, V334, P1336, DOI 10.1016/j.bbrc.2005.07.036; Kobpornchai P, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008192; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Lieskovska J, 2015, PARASITE IMMUNOL, V37, P70, DOI 10.1111/pim.12162; Lima CA, 2006, BIOCHEM BIOPH RES CO, V347, P44, DOI 10.1016/j.bbrc.2006.06.018; Lima-Barbero JF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040190; Lombardi G, 2005, J IMMUNOL, V174, P7022, DOI 10.4049/jimmunol.174.11.7022; McKenna RV, 1998, PARASITE IMMUNOL, V20, P325, DOI 10.1046/j.1365-3024.1998.00149.x; Ndawula C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030457; Perez-Sanchez R, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3768-1; Pritchard J, 2015, AVIAN PATHOL, V44, P143, DOI 10.1080/03079457.2015.1030589; Rahman MK, 2018, INSECTS, V9, DOI 10.3390/insects9020039; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; Sajiki Y, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2019.101332; Salat J, 2010, BIOCHEM J, V429, P103, DOI 10.1042/BJ20100280; Schwarz A, 2012, TICKS TICK-BORNE DIS, V3, P117, DOI 10.1016/j.ttbdis.2012.03.004; Turk V, 2008, FRONT BIOSCI-LANDMRK, V13, P5406, DOI 10.2741/3089; Wang YJ, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0725-5; Wille A, 2004, BIOL CHEM, V385, P665, DOI 10.1515/BC.2004.082; Wright Harry W, 2016, Parasit Vectors, V9, P544; Yamaji K, 2010, J VET MED SCI, V72, P599, DOI 10.1292/jvms.09-0561; Yamaji K, 2009, PARASITOL INT, V58, P232, DOI 10.1016/j.parint.2009.05.003; Yan X, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/4517587; Zhou J, 2009, VET PARASITOL, V160, P180, DOI 10.1016/j.vetpar.2008.10.086	41	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1472	10.3390/vaccines9121472			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YH0SB	34960218	gold, Green Published			2022-04-29	WOS:000742885500001
J	Gotlib, J; Jaworski, M; Wawrzuta, D; Sobierajski, T; Panczyk, M				Gotlib, Joanna; Jaworski, Mariusz; Wawrzuta, Dominik; Sobierajski, Tomasz; Panczyk, Mariusz			Impact of Anxiety on Readiness for COVID-19 Vaccination among Polish Nursing Undergraduate Students: Nationwide Cross-Sectional Study	VACCINES			English	Article						undergraduate nursing students; COVID-19 vaccine; knowledge; anxiety; GAD-7	DISORDER; ISRAEL; GAD-7	The COVID-19 pandemic had a huge impact on the mental health of people around the world, and it increased the level of fear of infection and anxiety about the consequences of the disease caused by the SARS-CoV-2 virus. We examined the relationship between the level of anxiety among nursing students and their knowledge about COVID-19 vaccination. In addition, we explored the correlations among the level of anxiety, knowledge about vaccination, and the willingness to vaccinate against COVID-19. A total of 790 undergraduate nursing students participated in the study. The results demonstrated that the level of anxiety among the surveyed nursing students was low; 40% of the study participants did not report any anxiety at all, 30% reported mild anxiety, 20% reported moderate anxiety, and 9% reported severe anxiety. At the time of the study, 77.2% of the participants were already vaccinated against COVID-19. Student knowledge about vaccination against COVID-19 was high and anxiety levels were low, with no direct correlation between the knowledge of vaccination and the severity of anxiety.	[Gotlib, Joanna; Jaworski, Mariusz; Wawrzuta, Dominik; Panczyk, Mariusz] Med Univ Warsaw, Fac Hlth Sci, Dept Educ & Hlth Sci Res, PL-02091 Warsaw, Poland; [Sobierajski, Tomasz] Univ Warsaw, Fac Appl Social Sci & Resocializat, PL-00325 Warsaw, Poland		Wawrzuta, D (通讯作者)，Med Univ Warsaw, Fac Hlth Sci, Dept Educ & Hlth Sci Res, PL-02091 Warsaw, Poland.	joanna.gotlib@wum.edu.pl; mariusz.jaworski@wum.edu.pl; dominik.wawrzuta@wum.edu.pl; tomasz.sobierajski@uw.edu.pl; mariusz.panczyk@wum.edu.pl	Wawrzuta, Dominik/ABB-1890-2021; Panczyk, Mariusz/B-4412-2011	Sobierajski, Tomasz/0000-0002-6853-9358; Gotlib, Joanna/0000-0002-2717-7741; Panczyk, Mariusz/0000-0003-1830-2114; Wawrzuta, Dominik/0000-0002-0846-8906			Agu CF, 2021, INT NURS REV, V68, P153, DOI 10.1111/inr.12663; [Anonymous], 2020, SOCIAL IMPACTS COVID; Bartolo A, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00212716, 10.1590/0102-311x00212716]; Dewart G, 2020, NURS EDUC TODAY, V92, DOI 10.1016/j.nedt.2020.104471; ElBagoury M, 2021, J INFECT PUBLIC HEAL, V14, P389, DOI 10.1016/j.jiph.2020.12.025; Farrer LM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0961-z; Fitzgerald A, 2021, NURS FORUM, V56, P298, DOI 10.1111/nuf.12547; Fortgang RG, 2021, CLIN PSYCHOL SCI, V9, P482, DOI 10.1177/2167702621993857; Garcia-Gonzalez J, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9030252; Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790; Gotlib J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091029; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hlatshwako TG, 2021, LANCET DIGIT HEALTH, V3, pe76, DOI 10.1016/S2589-7500(21)00002-9; Jungmann SM, 2020, J ANXIETY DISORD, V73, DOI 10.1016/j.janxdis.2020.102239; Ugurlu YK, 2021, PERSPECT PSYCHIATR C, V57, P507, DOI 10.1111/ppc.12703; Killgore William D S, 2020, Psychiatry Res, V290, P113134, DOI 10.1016/j.psychres.2020.113134; Kochuvilayil T, 2021, J CLIN NURS, V30, P882, DOI 10.1111/jocn.15634; Dalcali BK, 2021, PERSPECT PSYCHIATR C, V57, P1999, DOI 10.1111/ppc.12839; Leshem E, 2021, LANCET, V397, P1783, DOI 10.1016/S0140-6736(21)01018-7; Li W, 2021, HUM RESOUR HEALTH, V19, DOI 10.1186/s12960-021-00609-9; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Lovric R, 2020, EDUC SCI, V10, DOI 10.3390/educsci10070188; Lukasik KM, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00004; Lun KWC, 2018, HONG KONG MED J, V24, P466, DOI 10.12809/hkmj176915; Mertens G, 2020, J ANXIETY DISORD, V74, DOI 10.1016/j.janxdis.2020.102258; Panchal N, IMPLICATIONS COVID 1; Quek TTC, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16152735; Rodriguez-Hidalgo AJ, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.591797; Rutter LA, 2017, J PSYCHOPATHOL BEHAV, V39, P140, DOI 10.1007/s10862-016-9571-9; Salameh B, 2021, INQUIRY-J HEALTH CAR, V58, DOI 10.1177/0046958021993944; Savitsky B, 2020, NURSE EDUC PRACT, V46, DOI 10.1016/j.nepr.2020.102809; Singh HK, 2021, NURS EDUC TODAY, V99, DOI 10.1016/j.nedt.2021.104796; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Sun YY, 2020, J KOREAN ACAD NURS, V50, P533, DOI 10.4040/jkan.20125; Swinson Richard P, 2006, Evid Based Med, V11, P184, DOI 10.1136/ebm.11.6.184; Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212; Wang XT, 2021, EMERG INFECT DIS, V27, P1976, DOI 10.3201/eid2707.210118; Wawrzuta D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050481; Zhong QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125096	40	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1385	10.3390/vaccines9121385			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8ZW	34960130	gold, Green Published			2022-04-29	WOS:000737254600001
J	Nomura, Y; Sawahata, M; Nakamura, Y; Koike, R; Katsube, O; Hagiwara, K; Niho, S; Masuda, N; Tanaka, T; Sugiyama, K				Nomura, Yushi; Sawahata, Michiru; Nakamura, Yosikazu; Koike, Ryousuke; Katsube, Otohiro; Hagiwara, Koichi; Niho, Seiji; Masuda, Norihiro; Tanaka, Takaaki; Sugiyama, Kumiya			Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months	VACCINES			English	Article						SARS-CoV-2; viral infection; clinical epidemiology		Objective: We aimed to determine antibody titers at six months and their percentage change from three to six months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) and to explore clinical variables associated with titers in Japan. Methods: We enrolled 365 healthcare workers (250 women, 115 men) whose three-month antibody titers were analyzed in our previous study and whose blood samples were collected 183 +/- 15 days after the second dose. Participant characteristics, collected previously, were used. The relationships of these factors with antibody titers at six months and percentage changes in antibody titers from three to six months were analyzed. Results: Median age was 44 years. Median antibody titer at six months was 539 U/mL. Older participants had significantly lower antibody titers (20s, 752 U/mL; 60s-70s, 365 U/mL). In age-adjusted analysis, smoking was the only factor associated with lower antibody titers. Median percentage change in antibody titers from three to six months was -29.4%. The only factor significantly associated with the percentage change in Ab titers was not age or smoking, but sex (women, -31.6%; men, -25.1%). Conclusion: The most important factors associated with lower antibody titers at six months were age and smoking, as at three months, probably reflecting their effect on peak antibody titers. However, the only factor significantly associated with the attenuation in Ab titers from three to six months was sex, which reduced the sex difference seen during the first three months. Antibody titers may be affected by different factors at different time points.	[Nomura, Yushi; Sawahata, Michiru; Koike, Ryousuke; Katsube, Otohiro; Sugiyama, Kumiya] Natl Hosp Org, Dept Resp Med & Clin Immunol, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan; [Nomura, Yushi; Koike, Ryousuke; Niho, Seiji] Dokkyo Med Univ, Dept Pulm Med & Clin Immunol, Shimotsuga 3210293, Japan; [Sawahata, Michiru] Jichi Med Univ, Div Pulm Med, Dept Med, Shimotsuke, Tochigi 3290498, Japan; [Nakamura, Yosikazu] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi 3290498, Japan; [Masuda, Norihiro] Natl Hosp Org, Dept Surg, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan; [Tanaka, Takaaki] Natl Hosp Org, Dept Orthopaed Surg, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan; [Sugiyama, Kumiya] Dokkyo Med Univ, Saitama Med Ctr, Dept Resp Med & Clin Immunol, Shimotsuga 3210293, Japan		Sawahata, M (通讯作者)，Natl Hosp Org, Dept Resp Med & Clin Immunol, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan.; Sawahata, M (通讯作者)，Jichi Med Univ, Div Pulm Med, Dept Med, Shimotsuke, Tochigi 3290498, Japan.	uc.nomura@gmail.com; sawahata@jichi.ac.jp; nakamuyk@jichi.ac.jp; ryou.k.1207@gmail.com; 5okatsube@gmail.com; hagiwark@me.com; siniho@dokkyomed.ac.jp; norim0507@gmail.com; tanaka.takaaki.vh@mail.hosp.go.jp; sugiyama@dokkyomed.ac.jp		Sawahata, Michiru/0000-0001-9220-3419; Sugiyama, Kumiya/0000-0002-0624-946X			Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Callegaro A, 2021, J MED VIROL, V93, P4612, DOI 10.1002/jmv.26982; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Kennedy NA, 2021, GUT, V70, P1884, DOI 10.1136/gutjnl-2021-324789; L'Huillier AG, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.01.005; Ledford H, 2020, NATURE, V586, P488, DOI 10.1038/d41586-020-02946-6; MACKENZIE JS, 1976, J HYG-CAMBRIDGE, V77, P409, DOI 10.1017/S0022172400055790; Monin-Aldama L., 2021, MEDRXIV, DOI [10.1101/2021.03.17.21253131, DOI 10.1101/2021.03.17.21253131]; Muller L, 2021, CLIN INFECT DIS, V73, P2065, DOI 10.1093/cid/ciab381; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Nomura Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091042; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; Watanabe M, 2022, DIABETES-METAB RES, V38, DOI 10.1002/dmrr.3465; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	17	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1500	10.3390/vaccines9121500			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1XO	34960246	Green Published, gold			2022-04-29	WOS:000737453300001
J	Syundyukov, E; Mednis, M; Zaharenko, L; Pildegovica, E; Danovska, I; Kistkins, S; Seidmann, A; Benis, A; Pirags, V; Tzivian, L				Syundyukov, Emil; Mednis, Martins; Zaharenko, Linda; Pildegovica, Eva; Danovska, Ieva; Kistkins, Svjatoslavs; Seidmann, Abraham; Benis, Arriel; Pirags, Valdis; Tzivian, Lilian			Data-Driven Decision Making and Proactive Citizen-Scientist Communication: A Cross-Sectional Study on COVID-19 Vaccination Adherence	VACCINES			English	Article						digital health; data-driven communication; COVID-19 vaccination readiness; coronavirus; SARS-CoV-2; immunization programs; vaccination refusal; vaccination hesitancy; health communication; web-based survey	HESITANCY	Due to the severe impact of COVID-19 on public health, rollout of the vaccines must be large-scale. Current solutions are not intended to promote an active collaboration between communities and public health researchers. We aimed to develop a digital platform for communication between scientists and the general population, and to use it for an exploratory study on factors associated with vaccination readiness. The digital platform was developed in Latvia and was equipped with dynamic consent management. During a period of six weeks 467 participants were enrolled in the population-based cross-sectional exploratory study using this platform. We assessed demographics, COVID-19-related behavioral and personal factors, and reasons for vaccination. Logistic regression models adjusted for the level of education, anxiety, factors affecting the motivation to vaccinate, and risk of infection/severe disease were built to investigate their association with vaccination readiness. In the fully adjusted multiple logistic regression model, factors associated with vaccination readiness were anxiety (odds ratio, OR = 3.09 [95% confidence interval 1.88; 5.09]), feelings of social responsibility (OR = 1.61 [1.16; 2.22]), and trust in pharmaceutical companies (OR = 1.53 [1.03; 2.27]). The assessment of a large number of participants in a six-week period show the potential of a digital platform to create a data-driven dialogue on vaccination readiness.	[Syundyukov, Emil; Mednis, Martins; Zaharenko, Linda; Pildegovica, Eva; Danovska, Ieva] Longenesis Ltd, Zaubes Str 9A-23, LV-1013 Riga, Latvia; [Syundyukov, Emil] Univ Latvia, Fac Comp, Raina Blvd 19, LV-1050 Riga, Latvia; [Pildegovica, Eva] Univ Edinburgh, Sch Hlth Social Sci, Old Med Sch, Edinburgh EH8 9AG, Midlothian, Scotland; [Kistkins, Svjatoslavs; Pirags, Valdis] Paul Stradins Clin Univ Hosp, Dept Internal Med, Pilsonu Str 13, LV-1002 Riga, Latvia; [Seidmann, Abraham] Boston Univ, Questrom Business Sch, Boston, MA 02215 USA; [Seidmann, Abraham] Boston Univ, Digital Business Inst, Hlth Analyt & Digital Hlth, Boston, MA 02215 USA; [Benis, Arriel] Holon Inst Technol, Fac Ind Engn & Technol Management, IL-5810201 Holon, Israel; [Benis, Arriel] Holon Inst Technol, Fac Digital Technol Med, IL-58102013 Holon, Israel; [Tzivian, Lilian] Univ Latvia, Fac Med, Jelgavas Str 3, LV-1004 Riga, Latvia		Syundyukov, E (通讯作者)，Longenesis Ltd, Zaubes Str 9A-23, LV-1013 Riga, Latvia.; Syundyukov, E (通讯作者)，Univ Latvia, Fac Comp, Raina Blvd 19, LV-1050 Riga, Latvia.	es@longenesis.com; m-mednis@longenesis.com; lz@longenesis.com; eva@skrinings.lv; id@longenesis.com; svjatoslavs.kistkins@stradini.lv; avis@bu.edu; arrielb@hit.ac.il; valdis.pirags@stradini.lv; liliana.civjane@lu.lv	Benis, Arriel/M-6262-2016	Benis, Arriel/0000-0002-9125-8300			Alwi SARS, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11071-6; Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; [Anonymous], The Global Risks Report 2022, V17th; Benis A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040315; Benis A, 2021, J MED INTERNET RES, V23, DOI 10.2196/25977; Bidmon S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4127; Budd J, 2020, NAT MED, V26, P1183, DOI 10.1038/s41591-020-1011-4; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038; Cerda AA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.626852; Chatterjee R, 2020, PROG DISASTER SCI, V7, DOI 10.1016/j.pdisas.2020.100109; Chaudhary FA, 2021, HUM VACC IMMUNOTHER, V17, P3365, DOI 10.1080/21645515.2021.1944743; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; El-Elimat T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250555; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Gao YD, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100507; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Gelfand MJ, 2021, LANCET PLANET HEALTH, V5, pe135, DOI 10.1016/S2542-5196(20)30301-6; Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0; Hyland P, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258871; IBM Corp, 2019, REL 2019 IBM SPSS ST; Jin J, 2021, NAT MED, V27, P264, DOI 10.1038/s41591-020-01191-8; Konig R, 2018, UNIVERSAL ACCESS INF, V17, P621, DOI 10.1007/s10209-018-0609-5; Kretzschmar ME, 2020, LANCET PUBLIC HEALTH, V5, pE452, DOI 10.1016/S2468-2667(20)30157-2; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Van Jaarsveld GM, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.577427; Merkel S, 2019, GERONTOLOGIST, V59, pE16, DOI 10.1093/geront/gny034; Rader B, 2021, LANCET DIGIT HEALTH, V3, pE148, DOI 10.1016/S2589-7500(20)30293-4; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Tam CC, 2022, PSYCHOL HEALTH MED, V27, P150, DOI 10.1080/13548506.2021.1983185; Wolff D, 2021, INFECTION, V49, P15, DOI 10.1007/s15010-020-01509-1; Wymant C, 2021, NATURE, V594, P408, DOI 10.1038/s41586-021-03606-z; Zhang M, 2020, J MED INTERNET RES, V22, DOI 10.2196/19706	35	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1384	10.3390/vaccines9121384			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ7ZR	34960129	Green Published, gold			2022-04-29	WOS:000737867700001
J	Douine, M; Granier, S; Brureau, K; Breton, J; Michaud, C; Gaillet, M; Agostini, C; Ballet, M; Nacher, M; Valdes, A; Abboud, P; Adenis, A; Djossou, F; Epelboin, L; Vignier, N				Douine, Maylis; Granier, Sibylle; Brureau, Kepha; Breton, Jacques; Michaud, Celine; Gaillet, Melanie; Agostini, Camille; Ballet, Mathilde; Nacher, Mathieu; Valdes, Audrey; Abboud, Philippe; Adenis, Antoine; Djossou, Felix; Epelboin, Loic; Vignier, Nicolas			Levers and Barriers to Vaccinate against COVID-19 in the Multicultural Context of French Guiana: A Qualitative Cross-Sectional Survey among Health Care Workers	VACCINES			English	Article						COVID-19; vaccination; French Guiana; willingness; barriers; multiculturalism; information; qualitative research		In French Guiana, a French overseas territory in South America facing a fourth wave of COVID-19, vaccination coverage is very low, both in the population and among health care workers (HCWs). Vaccine hesitancy concerned 35.7% of the latter in early 2021. The objective of this complementary study is to understand barriers and levers and to adapt messages to increase vaccination coverage among HCWs. We conducted a regional cross-sectional survey of HCWs with a questionnaire containing open-ended questions exploring factors associated with vaccine hesitancy and the needs to adapt the vaccination campaign in French Guiana. The discourses were analyzed using a qualitative approach based on grounded theory, with open coding of data by themes and construction of abstract categories. The analysis of the 357 responses collected from January to March 2021 reveals several trends. The ethical aspect of the HCWs' role emphasizes the importance of getting vaccinated themselves (to protect patients, to set an example...) and of vaccinating as many people as possible, including the most geographically or socially distant, such as undocumented migrants. However, some HCWs remain suspicious of the vaccine with concerns over the efficacy and side effects, of health institutions, and of the pharmaceutical industry. The role of fake news circulating on social networks has been widely discussed. Efforts to explain and convince HCWs must be continued in French Guiana using the identified levers to improve the acceptability of vaccination.	[Douine, Maylis; Granier, Sibylle; Brureau, Kepha; Nacher, Mathieu; Adenis, Antoine; Vignier, Nicolas] Ctr Hosp Cayenne, Ctr Invest Clin Antilles Guyane, Inserm 1424, CIC,DRISP, Av Flamboyants, F-97300 Cayenne, France; [Douine, Maylis; Nacher, Mathieu; Djossou, Felix; Epelboin, Loic] Univ Guyane, TBIP Trop Biome & Immuno Physiopathol, CIIL Ctr Infect & Immunite Lille, CNRS,INSERM,Inst Pasteur Lille,U1019,UMR9017, Campus Troubiran, F-97337 Guyane Francaise, France; [Granier, Sibylle] Univ Montpellier, Dept Univ Med Gen Montpellier Nimes, 163 Rue Auguste Broussonnet, F-34090 Montpellier, France; [Brureau, Kepha] Univ Antilles, Dept Univ Med Gen, Campus Fouillole,BP 145, F-97145 Pointe A Pitre, Guadeloupe, France; [Breton, Jacques] Union Reg Profess Sante Med Liberaux Guyane, Av Flamboyants, F-97300 Cayenne, France; [Michaud, Celine; Gaillet, Melanie] Ctr Hosp Cayenne Andree Rosemon, Ctr Delocalises Prevent & Soins, Av Flamboyants, F-97300 Cayenne, France; [Agostini, Camille] Ctr Hosp Ouest Guyanais, Av Paul Castaing, F-97320 St Laurent Du Maroni, France; [Ballet, Mathilde] Agence Reg Sante Guyane, Av Flamboyants, F-97300 Cayenne, France; [Valdes, Audrey] Ctr Hosp Cayenne Andree Rosemon, Hyg Dept, Av Flamboyants, F-97300 Cayenne, France; [Abboud, Philippe; Adenis, Antoine; Djossou, Felix; Epelboin, Loic] Ctr Hosp Cayenne Andree Rosemon, Unite Malad Infect & Trop, F-97300 Cayenne, France; [Vignier, Nicolas] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, Dept Social Epidemiol, INSERM,UMR 1136,IPLESP, 27 Rue Chaligny, F-75012 Paris, France; [Vignier, Nicolas] Univ Sorbonne Paris Nord, UFR SMBH, Fac Med, F-93000 Bobigny, France		Douine, M (通讯作者)，Ctr Hosp Cayenne, Ctr Invest Clin Antilles Guyane, Inserm 1424, CIC,DRISP, Av Flamboyants, F-97300 Cayenne, France.; Douine, M (通讯作者)，Univ Guyane, TBIP Trop Biome & Immuno Physiopathol, CIIL Ctr Infect & Immunite Lille, CNRS,INSERM,Inst Pasteur Lille,U1019,UMR9017, Campus Troubiran, F-97337 Guyane Francaise, France.	maylis.douine@ch-cayenne.fr; graniersibylle@gmail.com; k97.brureau@gmail.com; jacques.14@icloud.com; celine.michaud@ch-cayenne.fr; melanie.gaillet@ch-cayenne.fr; c.agostini@ch-ouestguyane.fr; mathilde.ballet@ars.sante.fr; mathieu.nacher66@gmail.com; audrey.valdes@ch-cayenne.fr; philippe.abboud@ch-cayenne.fr; antoine.adenis@ch-cayenne.fr; felix.djossou@ch-cayenne.fr; epelboincrh@hotmail.fr; vigniernicolas@yahoo.fr	Vignier, Nicolas/AAH-8382-2021; nacher, mathieu/AAH-4796-2021	Vignier, Nicolas/0000-0002-9410-9327; nacher, mathieu/0000-0001-9397-3204; adenis, antoine/0000-0003-4000-4981			Basurko C., 2020, Bulletin Epidemiologique Hebdomadaire, P582; Celestine A., 2021, VACCINATION ANTILLES; DePaolo CA, 2014, TECHTRENDS, V58, P38, DOI 10.1007/s11528-014-0750-9; Elliott P, 2021, REACT 1 ROUND 13 FIN; Epelboin L., BRAZ SOC TROP UNPUB; Epelboin L., 2021, LETT INFECT, V36; Flamand C., 2021, PRINCIPAUX RESULTATS; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Holzmann-Littig C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070777; INSEE, 2006, ATL POP IMM GUYAN IN, P32; Kallel H, 2021, REV PANAM SALUD PUBL, V45, DOI 10.26633/RPSP.2021.46; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kupferschmidt K, 2021, SCIENCE, V372, P1375, DOI 10.1126/science.372.6549.1375; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Leglise I., 2017, LANG CITE, V29, P2; Ministry of Health, TABL BORD VACC; Mueller J. E., 2021, Bulletin Epidemiologique Hebdomadaire, P2; Nacher M, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.586299; Nacher M, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008426; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Odonne G, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114384; Regional Health Agency of French Guiana, 2021, COV 19 COVID 19 PRO; Sante Publique France, 2021, POINT EP REG SPEC CO; Tareau MA, 2017, J ETHNOPHARMACOL, V203, P200, DOI 10.1016/j.jep.2017.03.031; Valmy L, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1284-y; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Vignier N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060682; WHO, 2013, WHO TRAD MED STRAT 2; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Woodhead C., 2021, ETHNIC HEALTH, P1, DOI [10.1080/13557858.2021.1936464, DOI 10.1080/13557858.2021.1936464]	30	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1216	10.3390/vaccines9111216			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK2JQ	34835147	gold, Green Published			2022-04-29	WOS:000727298400001
J	Pavel, STI; Yetiskin, H; Uygut, MA; Aslan, AF; Aydin, G; Inan, O; Kaplan, B; Ozdarendeli, A				Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Uygut, Muhammet Ali; Aslan, Ahmet Furkan; Aydin, Gunsu; Inan, Oznur; Kaplan, Busra; Ozdarendeli, Aykut			Development of an Inactivated Vaccine against SARS CoV-2	VACCINES			English	Article						SARS-CoV-2; vaccine; inactivated vaccine; immunogenicity; ERUCoV-VAC; COVID-19 vaccine; TURKOVAC	SARS-COV-2; INFECTION; EFFICACY; MODELS	The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates in preclinical development worldwide as per the WHO on 1 October 2021. The various types of vaccines that are currently approved for emergency use include viral vectors (e.g., adenovirus, University of Oxford/AstraZeneca, Gamaleya Sputnik V, and Johnson & Johnson), mRNA (Moderna and Pfizer-BioNTech), and whole inactivated (Sinovac Biotech and Sinopharm) vaccines. Amidst the emerging cases and shortages of vaccines for global distribution, it is vital to develop a vaccine candidate that recapitulates the severe and fatal progression of COVID-19 and further helps to cope with the current outbreak. Hence, we present the preclinical immunogenicity, protective efficacy, and safety evaluation of a whole-virion inactivated SARS-CoV-2 vaccine candidate (ERUCoV-VAC) formulated in aluminium hydroxide, in three animal models, BALB/c mice, transgenic mice (K18-hACE2), and ferrets. The hCoV-19/Turkey/ERAGEM-001/2020 strain was used for the safety evaluation of ERUCoV-VAC. It was found that ERUCoV-VAC was highly immunogenic and elicited a strong immune response in BALB/c mice. The protective efficacy of the vaccine in K18-hACE2 showed that ERUCoV-VAC induced complete protection of the mice from a lethal SARS-CoV-2 challenge. Similar viral clearance rates with the safety evaluation of the vaccine in upper respiratory tracts were also positively appreciable in the ferret models. ERUCoV-VAC has been authorized by the Turkish Medicines and Medical Devices Agency and has now entered phase 3 clinical development (NCT04942405). The name of ERUCoV-VAC has been changed to TURKOVAC in the phase 3 clinical trial.	[Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Aslan, Ahmet Furkan; Aydin, Gunsu; Kaplan, Busra; Ozdarendeli, Aykut] Erciyes Univ, Med Fac, Dept Microbiol, TR-38280 Kayseri, Turkey; [Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Uygut, Muhammet Ali; Aslan, Ahmet Furkan; Aydin, Gunsu; Kaplan, Busra; Ozdarendeli, Aykut] Erciyes Univ, Vaccine Res Dev & Applicat Ctr, TR-38280 Kayseri, Turkey; [Inan, Oznur] Istanbul Expt Res Dev & Educ Ctr IDEA, TR-34303 Istanbul, Turkey		Ozdarendeli, A (通讯作者)，Erciyes Univ, Med Fac, Dept Microbiol, TR-38280 Kayseri, Turkey.; Ozdarendeli, A (通讯作者)，Erciyes Univ, Vaccine Res Dev & Applicat Ctr, TR-38280 Kayseri, Turkey.	biotech.pavel@outlook.com; hazelyetiskin@gmail.com; mauygut@gmail.com; afaslan95@gmail.com; gunsuaydinn@gmail.com; oznurinan.vet@gmail.com; busra.kaplan.3@gmail.com; aozdarendeli@erciyes.edu.tr		PAVEL, SHAIKH TERKIS ISLAM/0000-0002-7178-0943; KAPLAN, BUSRA/0000-0002-2029-6270; INAN, OZNUR/0000-0002-3929-8882; Ozdarendeli, Aykut/0000-0002-6950-8545	Health Institutes of Turkey (TUSEB) [2020-AG/Ar-Ge ID-7112]; Erciyes University Scientific Research FoundationErciyes University [TSG-2019-9644]	The present study was financially supported by Health Institutes of Turkey (TUSEB) (Project No: 2020-AG/Ar-Ge ID-7112) and the Erciyes University Scientific Research Foundation (Project No: TSG-2019-9644). The funders had no role in the study design, data collection and analysis, the decision to publish, or in the preparation of the manuscript.	Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Baldwin WR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34735-7; Barrett PN, 2017, EXPERT REV VACCINES, V16, P883, DOI 10.1080/14760584.2017.1357471; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhatta M, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2020.1865774; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Cui XN, 2021, DRUG DISCOV THER, V15, P222, DOI 10.5582/ddt.2021.01064; Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525; Deng Y, 2021, CELL MOL IMMUNOL, V18, P2040, DOI 10.1038/s41423-021-00730-8; Enkirch T, 2015, VIROLOGY, V479, P259, DOI 10.1016/j.virol.2015.03.017; Everett HE, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010113; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gerdts V, 2015, ILAR J, V56, P53, DOI 10.1093/ilar/ilv009; Ghimire TR, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0972-0; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135; He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hotez PJ, 2020, NAT REV IMMUNOL, V20, P399, DOI 10.1038/s41577-020-0358-6; Hotez PJ, 2020, NAT REV IMMUNOL, V20, P347, DOI 10.1038/s41577-020-0323-4; Huang HY, 2021, HUM VACC IMMUNOTHER, V17, P3276, DOI 10.1080/21645515.2021.1945901; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Kandeil A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030214; Kim YI, 2021, MBIO, V12, DOI 10.1128/mBio.00230-21; Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kulkarni R, 2020, DYNAMICS OF IMMUNE ACTIVATION IN VIRAL DISEASES, P9, DOI 10.1007/978-981-15-1045-8_2; Kumar S., 2020, CORONAVIRUS DIS 2019, P43, DOI DOI 10.1007/978-981-15-4814-7_5; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Loembe MM, 2021, IMMUNITY, V54, P1353, DOI 10.1016/j.immuni.2021.06.017; Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2; Mamedov T, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081595; Mariano G, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.605236; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Marsh GA, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00315-6; Masters PS., 2013, FIELDS VIROLOGY, P825; Monchatre-Leroy E, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001567; Mukhopadhyay L, 2021, INDIAN J MED RES, V153, P93, DOI 10.4103/ijmr.IJMR_4431_20; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Ozdarendeli A, 2001, J VIROL, V75, P7362, DOI 10.1128/JVI.75.16.7362-7374.2001; Pan XQ, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198057; Pandey K, 2021, TRANSBOUND EMERG DIS, V68, P1868, DOI 10.1111/tbed.13907; Pavel STI, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008834; Pavel STI, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238614; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Ragan IK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040340; Reed LJ., 1938, AM J HYG, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; Richman Douglas D, 2021, Glob Health Med, V3, P1, DOI 10.35772/ghm.2021.01010; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Ryan KA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20439-y; Sanders B., 2014, VACCINE ANAL STRATEG, P45, DOI [10.1007/978-3- 662-45024-6_2, DOI 10.1007/978-3-662-45024-6_2]; Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tostanoski LH, 2020, NAT MED, V26, P1694, DOI 10.1038/s41591-020-1070-6; Wang GL, 2021, NEW ENGL J MED, V384, P2354, DOI 10.1056/NEJMc2103022; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu HY, 2006, J VIROL, V80, P2183, DOI 10.1128/JVI.80.5.2183-2193.2006; Yao YF, 2021, VIROL SIN, V36, P879, DOI 10.1007/s12250-021-00376-w; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; Yinda CK, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009195; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhao J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602256; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	73	3	3	26	26	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1266	10.3390/vaccines9111266			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI0UH	34835197	Green Published, gold			2022-04-29	WOS:000725837600001
J	Lapazio, L; Braun, M; Grandien, K				Lapazio, Lucia; Braun, Monika; Grandien, Kaj			H2-M and H2-O as Targeting Vehicles for the MHC Class II Processing Compartment Promote Antigen-Specific CD4+ T Cell Activation	VACCINES			English	Article						vaccine; mRNA; antigen presentation; fusion protein; T cell activation	HLA-DM; DENDRITIC CELLS; INVARIANT CHAIN; PEPTIDE; EXPRESSION; EPITOPES; VACCINE; STRATEGY; VIRUS	CD8 and CD4 T cell activation are both required for a strong and long-lasting T cell immune response. Endogenously expressed proteins are readily processed by the MHC class I antigen presentation pathway, enabling activation of CD8+ T cells. However, the MHC class II antigen presentation pathway, necessary for CD4+ T cell activation, is generally not sufficiently accessible to endogenously expressed proteins, limiting the efficiency of mRNA- or DNA-based vaccines. In the current study, we have evaluated the feasibility of using antigen sequences fused to sequences derived from the H2-M and H2-O proteins, two complexes known to participate in MHC class II antigen processing, for the enhancement of CD4 T-cell activation. We analyzed T cell activation after genetic immunization with mRNA-encoding fusion proteins with the model antigen ovalbumin and sequences derived from H2-M or H2-O. Our results show that H2-M- or H2-O-derived sequences robustly improve antigen-specific CD4 T-cell activation when fused to the antigen of interest and suggest that the approach could be used to improve the efficiency of mRNA- or DNA-based vaccines.	[Lapazio, Lucia; Braun, Monika; Grandien, Kaj] Sanofi Aventis Deutschland GmbH, R&D, Biol Res, Ind Pk Hoechst, D-65926 Frankfurt, Germany; [Braun, Monika] Medigene, Lochhamer Str 11, D-82152 Martinsried, Planegg, Germany		Lapazio, L (通讯作者)，Sanofi Aventis Deutschland GmbH, R&D, Biol Res, Ind Pk Hoechst, D-65926 Frankfurt, Germany.	lucia.lapazio@sanofi.com; monika.braun79@gmx.de; Kaj.Grandien@sanofi.com					Amria S, 2008, EUR J IMMUNOL, V38, P1961, DOI 10.1002/eji.200738100; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bonehill A, 2005, J GENE MED, V7, P686, DOI 10.1002/jgm.713; Bonehill A, 2003, CANCER RES, V63, P5587; Bonehill A, 2004, J IMMUNOL, V172, P6649, DOI 10.4049/jimmunol.172.11.6649; Broos Katrijn, 2016, Mol Ther Nucleic Acids, V5, pe326, DOI 10.1038/mtna.2016.38; Chen XJ, 2006, J IMMUNOL, V176, P3548, DOI 10.4049/jimmunol.176.6.3548; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Diebold SS, 2001, GENE THER, V8, P487, DOI 10.1038/sj.gt.3301433; Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F; Hartman IZ, 2010, NAT MED, V16, P1333, DOI 10.1038/nm.2248; Kim TW, 2003, J IMMUNOL, V171, P2970, DOI 10.4049/jimmunol.171.6.2970; Kreiter S, 2008, J IMMUNOL, V180, P309, DOI 10.4049/jimmunol.180.1.309; Kremer AN, 2012, BLOOD, V120, P3246, DOI 10.1182/blood-2011-12-399311; Lautwein A, 2002, EUR J IMMUNOL, V32, P3348, DOI 10.1002/1521-4141(200212)32:12<3348::AID-IMMU3348>3.0.CO;2-S; Lazarski CA, 2006, J EXP MED, V203, P1319, DOI 10.1084/jem.20060058; LIN XL, 1993, FASEB J, V7, P1070, DOI 10.1096/fasebj.7.11.8370478; Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; ParraLopez CA, 1997, J IMMUNOL, V158, P2670; Pu Z, 2004, IMMUNITY, V20, P467, DOI 10.1016/S1074-7613(04)00073-1; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; SANDERSON S, 1995, P NATL ACAD SCI USA, V92, P7217, DOI 10.1073/pnas.92.16.7217; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Thomson SA, 1998, J VIROL, V72, P2246, DOI 10.1128/JVI.72.3.2246-2252.1998; Toribio-Fernandez R, 2018, JOVE-J VIS EXP, DOI 10.3791/58118; Vaidyanathan S, 2018, MOL THER-NUCL ACIDS, V12, P530, DOI 10.1016/j.omtn.2018.06.010; Van Meirvenne S, 2002, CANCER GENE THER, V9, P787, DOI 10.1038/sj.cgt.7700499; Welsh R, 2019, IMMUNOGENETICS, V71, P189, DOI 10.1007/s00251-018-01097-3; Yin LS, 2012, J IMMUNOL, V189, P3983, DOI 10.4049/jimmunol.1200626	32	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1053	10.3390/vaccines9101053			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV3KL	34696161	Green Published, gold			2022-04-29	WOS:000717135500001
J	Lindemann, M; Klisanin, V; Thummler, L; Fisenkci, N; Tsachakis-Muck, N; Ditschkowski, M; Schwarzkopf, S; Klump, H; Reinhardt, HC; Horn, PA; Koldehoff, M				Lindemann, Monika; Klisanin, Vesna; Thuemmler, Laura; Fisenkci, Neslinur; Tsachakis-Mueck, Nikolaos; Ditschkowski, Markus; Schwarzkopf, Sina; Klump, Hannes; Reinhardt, Hans Christian; Horn, Peter A.; Koldehoff, Michael			Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients	VACCINES			English	Article						SARS-CoV-2; vaccination; allogeneic hematopoietic stem cell transplantation; antibodies; ELISpot; sex-dependency		The cellular response to SARS-CoV-2 vaccination and infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients is not yet clear. In the current study, HSCT recipients prior to and post vaccination were tested for SARS-CoV-2-specific humoral and cellular immunity. Antibodies against spike (S) 1 were assessed by Anti-SARS-CoV-2 IgG ELISA (Euroimmun). Cellular immunity was analyzed by an in house interferon-gamma ELISpot and T-SPOT.COVID (Oxford Immunotec), using altogether seven SARS-CoV-2-specific antigens. In 117 HSCT patients vaccinated twice, SARS-CoV-2 IgG antibodies were significantly higher than in HSCT controls pre vaccination (p < 0.0001). After the second vaccination, we observed a median antibody ratio of 4.7 and 68% positive results, whereas 35 healthy controls reached a median ratio of 9.0 and 100% positivity. ELISpot responses in patients were significantly (p < 0.001) reduced to & LE;33% of the controls. After the second vaccination, female HSCT patients and female healthy controls showed significantly higher antibody responses than males (6.0 vs. 2.1 and 9.2 vs. 8.2, respectively; p < 0.05). Cellular immunity was diminished in patients irrespective of sex. In conclusion, especially male HSCT recipients showed impaired antibody responses after SARS-CoV-2 vaccination. Changing the vaccine schedule or composition could help increase vaccine responses.	[Lindemann, Monika; Thuemmler, Laura; Fisenkci, Neslinur; Schwarzkopf, Sina; Klump, Hannes; Horn, Peter A.] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, D-45147 Essen, Germany; [Klisanin, Vesna; Tsachakis-Mueck, Nikolaos; Ditschkowski, Markus; Reinhardt, Hans Christian; Koldehoff, Michael] Univ Duisburg Essen, Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, D-45147 Essen, Germany		Lindemann, M (通讯作者)，Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, D-45147 Essen, Germany.	monika.lindemann@uk-essen.de; vesna.klisanin@uk-essen.de; laura.thuemmler@stud.uni-due.de; neslinurfisenkci@gmail.com; nikolaos.tsachakis-mueck@uk-essen.de; markus.ditschkowski@uk-essen.de; sina.schwarzkopf@gmx.de; hannes.klump@uk-essen.de; christian.reinhardt@uk-essen.de; peter.horn@uk-essen.de; michael.koldehoff@uk-essen.de	; Klump, Hannes/B-5397-2018	Koldehoff, Michael/0000-0002-8738-5884; Lindemann, Monika/0000-0001-6708-4390; Klump, Hannes/0000-0003-3536-1212	Babette Grosse-Rhode	We are grateful to Babette Gro ss e-Rhode, Sascha Janz and Gabriela Graf for their excellent technical assistance. This research received no external funding. We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.	Ali H, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.07.008; Bienzle U, 2003, HEPATOLOGY, V38, P811, DOI 10.1053/jhep.2003.50396; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Chevallier Patrice, 2021, EJHaem, DOI 10.1002/jha2.242; Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5; Cucchiari D, 2021, AM J TRANSPLANT, V21, P2727, DOI 10.1111/ajt.16701; Easdale S, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.07.011; Havlin J, 2021, J HEART LUNG TRANSPL, V40, P754, DOI 10.1016/j.healun.2021.05.004; Herrera S, 2021, AM J TRANSPLANT, V21, P3971, DOI 10.1111/ajt.16768; Kolb T., 2021, KIDNEY360, DOI [10.34067/KID.0003512021, DOI 10.34067/KID.0003512021]; Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756; Lemieux Jacob E, 2021, medRxiv, DOI 10.1101/2021.07.11.21260338; Ljungman P, 2021, LEUKEMIA, V35, P2885, DOI 10.1038/s41375-021-01302-5; Maneikis K, 2021, LANCET HAEMATOL, V8, pE583, DOI 10.1016/S2352-3026(21)00169-1; Mazzola A, 2022, CLIN INFECT DIS, V74, P1093, DOI 10.1093/cid/ciab580; Miele M, 2021, AM J TRANSPLANT, V21, P2919, DOI 10.1111/ajt.16702; Parry H., BNT162B2 VACCINATION; Polewska K, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57070732; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Rahimi G, 2021, INT IMMUNOPHARMACOL, V92, DOI 10.1016/j.intimp.2021.107365; Rashidi-Alavijeh J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070738; Rimar D, 2021, ANN RHEUM DIS, V80, P1354, DOI 10.1136/annrheumdis-2021-220677; Schwarzkopf S, 2021, EMERG INFECT DIS, V27, P122, DOI 10.3201/eid2701.203772; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Thieme CJ, 2021, TRANSPLANTATION, V105, P2156, DOI 10.1097/TP.0000000000003755; Van Damme P., 2018, PLOTKINS VACCINES, V25, P342	26	9	9	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1075	10.3390/vaccines9101075			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN2UW	34696183	Green Published, gold			2022-04-29	WOS:000711629900001
J	Lopez, MV; Vinzon, SE; Cafferata, EGA; Nunez, FJ; Soto, A; Sanchez-Lamas, M; Afonso, MJ; Aguilar-Cortes, D; Rios, GD; Maricato, JT; Braconi, CT; Silveira, VB; Andrad, TM; Bonetti, TCS; Janini, LRM; Girao, MJBC; Llera, AS; Gomez, KA; Ortega, HH; Berguer, PM; Podhajcer, OL				Lopez, M. Veronica; Vinzon, Sabrina E.; Cafferata, Eduardo G. A.; Nunez, Felipe J.; Soto, Ariadna; Sanchez-Lamas, Maximiliano; Afonso, M. Jimena; Aguilar-Cortes, Diana; Rios, Gregorio D.; Maricato, Juliana T.; T. Braconi, Carla; B. Silveira, Vanessa; M. Andrad, Tatiane; C. S. Bonetti, Tatiana; Ramos Janini, Luiz M.; Girao, Manoel J. B. C.; Llera, Andrea S.; Gomez, Karina A.; Ortega, Hugo H.; Berguer, Paula M.; Podhajcer, Osvaldo L.			A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC	VACCINES			English	Article						COVID vaccine; hybrid adenovirus vector; immune response; variants of concern	CD8(+) T-CELLS; MEMORY; EFFECTOR; SUBSETS; VECTORS	Most approved vaccines against COVID-19 have to be administered in a prime/boost regimen. We engineered a novel vaccine based on a chimeric human adenovirus 5 (hAdV5) vector. The vaccine (named CoroVaxG.3) is based on three pillars: (i) high expression of Spike to enhance its immunodominance by using a potent promoter and an mRNA stabilizer; (ii) enhanced infection of muscle and dendritic cells by replacing the fiber knob domain of hAdV5 by hAdV3; (iii) use of Spike stabilized in a prefusion conformation. The transduction with CoroVaxG.3-expressing Spike (D614G) dramatically enhanced the Spike expression in human muscle cells, monocytes and dendritic cells compared to CoroVaxG.5 that expressed the native fiber knob domain. A single dose of CoroVaxG.3 induced a potent humoral immunity with a balanced Th1/Th2 ratio and potent T-cell immunity, both lasting for at least 5 months. Sera from CoroVaxG.3-vaccinated mice was able to neutralize pseudoviruses expressing B.1 (wild type D614G), B.1.117 (alpha), P.1 (gamma) and B.1.617.2 (delta) Spikes, as well as an authentic P.1 SARS-CoV-2 isolate. Neutralizing antibodies did not wane even after 5 months, making this kind of vaccine a likely candidate to enter clinical trials.</p>	[Lopez, M. Veronica; Vinzon, Sabrina E.; Cafferata, Eduardo G. A.; Nunez, Felipe J.; Aguilar-Cortes, Diana; Rios, Gregorio D.; Llera, Andrea S.; Podhajcer, Osvaldo L.] Fdn Inst Leloir CONICET IIBBA, Lab Mol & Cellular Therapy, C1405BWE, Buenos Aires, DF, Argentina; [Soto, Ariadna; Berguer, Paula M.] Fdn Inst Leloir CONICET IIBBA, Lab Immunol & Mol Microbiol, C1405BWE, Buenos Aires, DF, Argentina; [Sanchez-Lamas, Maximiliano] Securitas Biosci, Montevideo 11100, Uruguay; [Afonso, M. Jimena] Fdn Inst Leloir, C1405BWE, Buenos Aires, DF, Argentina; [Maricato, Juliana T.; T. Braconi, Carla; B. Silveira, Vanessa; M. Andrad, Tatiane; Ramos Janini, Luiz M.] Fed Univ Sao Paulo UNIFESP, Paulista Sch Med, Dept Microbiol Immunol & Parasitol DMIP, Discipline Microbiol, BR-04021001 Sao Pablo, Brazil; [C. S. Bonetti, Tatiana; Girao, Manoel J. B. C.] Fed Univ Sao Paulo UNIFESP, Paulista Sch Med, Dept Med, Discipline Gynecol, BR-04021001 Sao Pablo, Brazil; [Gomez, Karina A.] Inst Invest Ingn Genet & Biol Mol Dr Hector N Tor, Lab Biol & Inmunol Infecc Tripanosomatidos, C1428ADN, Buenos Aires, DF, Argentina; [Ortega, Hugo H.] Univ Nacl Litoral CONICET, Ctr Med Comparada ICiVet Litoral, S3080HOF, Santa Fe, Santa Fe, Argentina		Podhajcer, OL (通讯作者)，Fdn Inst Leloir CONICET IIBBA, Lab Mol & Cellular Therapy, C1405BWE, Buenos Aires, DF, Argentina.	msanchezlamas@gmail.com; mafonso@leloir.org.ar; gomez@dna.uba.ar; hhortega@fcv.unl.edu.ar	Llera, Andrea S/AAW-8116-2021; Braconi, Carla T./B-3320-2014; Vinzón, Sabrina/Q-1631-2019	Braconi, Carla T./0000-0002-5370-8980; Vinzón, Sabrina/0000-0002-1330-9125; Sanchez-Lamas, Maximiliano/0000-0003-0112-5641; Ortega, Hugo/0000-0002-7663-3133; Llera, Andrea/0000-0002-0089-0061	Fundacion Instituto Leloir-CONICET; Vaxinz Inc.	This study has been supported in part by a Sponsored Research Agreement of Fundacion Instituto Leloir-CONICET with Vaxinz Inc.	Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06; Afrough S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010131; [Anonymous], 2021, LANCET, V398, P93, DOI 10.1016/S0140-6736(21)01551-8; Berges C, 2005, BIOCHEM BIOPH RES CO, V333, P896, DOI 10.1016/j.bbrc.2005.05.171; Binder AM, 2017, MMWR-MORBID MORTAL W, V66, P1039, DOI 10.15585/mmwr.mm6639a2; Blinder D, 2021, J WORLD SYST RES, V27, P494, DOI 10.5195/JWSR.2021.1049; Bliss CM, 2020, MOL THER-METH CLIN D, V16, P108, DOI 10.1016/j.omtm.2019.12.003; BLOOM ET, 1994, IMMUNOL LETT, V40, P251, DOI 10.1016/0165-2478(94)00072-7; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516; Chakraborty S, 2021, ADV DRUG DELIVER REV, V172, P314, DOI 10.1016/j.addr.2021.01.014; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Chondronasiou D, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030042; Committee for Medicinal Products for Human Use, 2021, EMA1584242021 COMM M; Committee for Medicinal Products for Human Use, 2021, EMA949072021 COMM ME; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Coughlan L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00909; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055; Dicks MDJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16756; Donello JE, 1998, J VIROL, V72, P5085, DOI 10.1128/JVI.72.6.5085-5092.1998; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Gonzalez-Candelas F, 2021, INFECT GENET EVOL, V92, DOI 10.1016/j.meegid.2021.104869; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Gray SJ, 2011, HUM GENE THER, V22, P1143, DOI 10.1089/hum.2010.245; Guse K, 2012, HUM GENE THER, V23, P1065, DOI 10.1089/hum.2012.003; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Heinio C, 2019, HUM GENE THER, V30, P740, DOI 10.1089/hum.2018.240; Hensley SE, 2007, MOL THER, V15, P393, DOI 10.1038/sj.mt.6300024; Israel Ariel, 2021, medRxiv, DOI 10.1101/2021.08.03.21261496; Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6; Krammer F, 2021, NAT MED, V27, P1147, DOI 10.1038/s41591-021-01432-4; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Lefrancois L, 2002, CURR OPIN IMMUNOL, V14, P503, DOI 10.1016/S0952-7915(02)00360-6; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Lockhart, 2021, 6 MONTH SAFETY EFFIC, DOI [10.1101/2021.07.28.21261159, DOI 10.1101/2021.07.28.21261159]; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mennechet FJD, 2019, EXPERT REV VACCINES, V18, P597, DOI 10.1080/14760584.2019.1588113; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mercier S, 2004, J GEN VIROL, V85, P1227, DOI 10.1099/vir.0.79846-0; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Nie JH, 2020, NAT PROTOC, V15, DOI 10.1038/s41596-020-0394-5; Pinto AR, 2003, J IMMUNOL, V171, P6774, DOI 10.4049/jimmunol.171.12.6774; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Quinn KM, 2013, J IMMUNOL, V190, P2720, DOI 10.4049/jimmunol.1202861; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Remakus S, 2013, ADV EXP MED BIOL, V785, P77, DOI 10.1007/978-1-4614-6217-0_9; Roberts AD, 2005, J EXP MED, V202, P123, DOI 10.1084/jem.20050137; Rosa SS, 2021, VACCINE, V39, P2190, DOI 10.1016/j.vaccine.2021.03.038; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Sayedahmed EE, 2018, VACCINE, V36, P6744, DOI 10.1016/j.vaccine.2018.09.031; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Sester M, 2002, J INFECT DIS, V185, P1379, DOI 10.1086/340502; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.07.19.452771; Tan WG, 2013, J VIROL, V87, P1359, DOI 10.1128/JVI.02055-12; van de Ven R, 2009, J IMMUNOTHER, V32, P895, DOI 10.1097/CJI.0b013e3181b56deb; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; Viale DL, 2013, J INVEST DERMATOL, V133, P2576, DOI 10.1038/jid.2013.191; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang HJ, 2011, NAT MED, V17, P96, DOI 10.1038/nm.2270; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Woods JA, 2003, BRAIN BEHAV IMMUN, V17, P384, DOI 10.1016/S0889-1591(03)00030-8; Xia XF, 2007, STEM CELLS DEV, V16, P167, DOI 10.1089/scd.2006.0057; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang J, 2020, Patent, Patent No. [111218459B, 111218459]; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zubrova O.V., 2021, RU Patent, Patent No. [2021/076010, 2021076010]	74	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1106	10.3390/vaccines9101106			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP3FW	34696219	Green Published, gold			2022-04-29	WOS:000713022900001
J	Rivasi, G; Bulgaresi, M; Mossello, E; Buscemi, P; Lorini, C; Balzi, D; Barucci, R; Del Lungo, I; Gangemi, S; Giardini, S; Piga, C; Barghini, E; Boni, S; Bulli, G; Carrai, P; Crociani, A; Faraone, A; Lo Forte, A; Martella, L; Pupo, S; Fortini, G; Marozzi, I; Bandini, G; Cosma, C; Stacchini, L; Vaccaro, G; Baggiani, L; Landini, G; Bonaccorsi, G; Ungar, A; Benvenuti, E				Rivasi, Giulia; Bulgaresi, Matteo; Mossello, Enrico; Buscemi, Primo; Lorini, Chiara; Balzi, Daniela; Barucci, Riccardo; Del Lungo, Ilaria; Gangemi, Salvatore; Giardini, Sante; Piga, Cecilia; Barghini, Eleonora; Boni, Serena; Bulli, Giulia; Carrai, Paolo; Crociani, Andrea; Faraone, Antonio; Lo Forte, Aldo; Martella, Letizia; Pupo, Simone; Fortini, Giacomo; Marozzi, Irene; Bandini, Giulia; Cosma, Claudia; Stacchini, Lorenzo; Vaccaro, Gabriele; Baggiani, Lorenzo; Landini, Giancarlo; Bonaccorsi, Guglielmo; Ungar, Andrea; Benvenuti, Enrico			Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy	VACCINES			English	Article						COVID-19; vaccine; mortality; hospitalization; lethality; nursing home residents; older adults	COVID-19; RESIDENTS; SYMPTOMS	Evidence on the effectiveness of SARS-CoV-2 vaccines in nursing home (NHs) residents is limited. We examined the impact of the BNT162b2 mRNA SARS-CoV-2 vaccine on the course of the epidemic in NHs in the Florence Health District, Italy, before and after vaccination. Moreover, we assessed survival and hospitalization by vaccination status in SARS-CoV-2-positive cases occurring during the post-vaccination period. We calculated the weekly infection rates during the pre-vaccination (1 October-26 December 2020) and post-vaccination period (27 December 2020-31 March 2021). Cox analysis was used to analyze survival by vaccination status. The study involved 3730 residents (mean age 84, 69% female). Weekly infection rates fluctuated during the pre-vaccination period (1.8%-6.5%) and dropped to zero during the post-vaccination period. Nine unvaccinated (UN), 56 partially vaccinated (PV) and 35 fully vaccinated (FV) residents tested SARS-CoV-2+ during the post-vaccination period. FV showed significantly lower hospitalization and mortality rates than PV and UV (hospitalization: FV 3%, PV 14%, UV 33%; mortality: FV 6%, PV 18%, UV 56%). The death risk was 84% and 96% lower in PV (HR 0.157, 95%CI 0.049-0.491) and FV (HR 0.037, 95%CI 0.006-0.223) versus UV. SARS-CoV-2 vaccination was followed by a marked decline in infection rates and was associated with lower morbidity and mortality among infected NH residents.</p>	[Rivasi, Giulia; Mossello, Enrico; Marozzi, Irene; Ungar, Andrea] Careggi Hosp, Div Geriatr & Intens Care Med, I-50134 Florence, Tuscany, Italy; [Rivasi, Giulia; Mossello, Enrico; Marozzi, Irene; Ungar, Andrea] Univ Florence, I-50134 Florence, Tuscany, Italy; [Bulgaresi, Matteo; Barucci, Riccardo; Del Lungo, Ilaria; Gangemi, Salvatore; Giardini, Sante; Piga, Cecilia; Barghini, Eleonora; Boni, Serena; Bulli, Giulia; Martella, Letizia; Pupo, Simone; Fortini, Giacomo; Benvenuti, Enrico] Santa Maria Annunziata Hosp, Geriatr Unit, Local Hlth Unit Toscana Ctr, I-50134 Florence, Tuscany, Italy; [Buscemi, Primo; Lorini, Chiara; Cosma, Claudia; Stacchini, Lorenzo; Vaccaro, Gabriele; Bonaccorsi, Guglielmo] Univ Florence, Dept Hlth Sci, I-50134 Florence, Tuscany, Italy; [Balzi, Daniela] Local Hlth Unit Toscana Ctr, Epidemiol Unit, I-50134 Florence, Tuscany, Italy; [Carrai, Paolo; Crociani, Andrea; Faraone, Antonio; Lo Forte, Aldo] San Giovanni di Dio Hosp, Dept Internal Med, I-50134 Florence, Tuscany, Italy; [Bandini, Giulia] Careggi Hosp, Div Internal Med, I-50134 Florence, Tuscany, Italy; [Baggiani, Lorenzo] Dept Terr Hlth Network, I-50134 Florence, Tuscany, Italy; [Landini, Giancarlo] Santa Maria Nuova Hosp, Local Hlth Unit Toscana Ctr, Dept Internal Med, I-50134 Florence, Tuscany, Italy		Rivasi, G (通讯作者)，Careggi Hosp, Div Geriatr & Intens Care Med, I-50134 Florence, Tuscany, Italy.; Rivasi, G (通讯作者)，Univ Florence, I-50134 Florence, Tuscany, Italy.	giulia.rivasi@unifi.it; matteo.bulgaresi@uslcentro.toscana.it; enrico.mossello@unifi.it; primo.buscemi@unifi.it; chiara.lorini@unifi.it; daniela.balzi@uslcentro.toscana.it; riccardo.barucci@uslcentro.toscana.it; ilaria.dellungo@uslcentro.toscana.it; salvatore.gangemi@uslcentro.toscana.it; sante.giardini@uslcentro.toscana.it; cecilia.piga@uslcentro.toscana.it; eleonora.barghini@uslcentro.toscana.it; serena.boni@uslcentro.toscana.it; giulia2.bulli@uslcentro.toscana.it; paolo.carrai@uslcentro.toscana.it; andrea.crociani@uslcentro.toscana.it; antonio.faraone@uslcentro.toscana.it; aldo.loforte@uslcentro.toscana.it; letizia.martella@uslcentro.toscana.it; simone.pupo@uslcentro.toscana.it; giacomo.fortini@uslcentro.toscana.it; irene.marozzi@libero.it; giulia.bandini@unifi.it; claudia.cosma@unifi.it; lorenzo.stacchini@unifi.it; gabriele.vaccaro@unifi.it; lorenzo.baggiani@uslcentro.toscana.it; giancarlo.landini@uslcentro.toscana.it; guglielmo.bonaccorsi@unifi.it; aungar@unifi.it; enrico.benvenuti@uslcentro.toscana.it	; Mossello, Enrico/K-2864-2018	Rivasi, Giulia/0000-0002-2736-2242; Stacchini, Lorenzo/0000-0002-7405-4904; Lorini, Chiara/0000-0003-3170-1857; bonaccorsi, guglielmo/0000-0002-5171-4308; Mossello, Enrico/0000-0002-7730-5836	Azienda USL Toscana Centro and Azienda Ospedaliero-Universitaria Careggi	The GIROT activity was funded by Azienda USL Toscana Centro and Azienda Ospedaliero-Universitaria Careggi. This research received no external funding.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bellei N.C.J., 2006, Braz J Infect Dis, V10, P269, DOI 10.1590/S1413-86702006000400011; Benvenuti E, 2021, AGING CLIN EXP RES, V33, P2917, DOI 10.1007/s40520-021-01959-z; Burton JK, 2020, LANCET HEALTH LONGEV, V1, pE21, DOI 10.1016/S2666-7568(20)30012-X; Canaday David H, 2021, medRxiv, DOI 10.1101/2021.03.19.21253920; CDC, YOUV BEEN FULL VACC; Chidambaram P., NEW COVID 19 CASES D; Domi M, 2021, J AM GERIATR SOC, V69, P2079, DOI 10.1111/jgs.17224; Fulop T, 2009, CLIN INFECT DIS, V48, P443, DOI 10.1086/596475; Graham NSN, 2020, J INFECTION, V81, P411, DOI 10.1016/j.jinf.2020.05.073; Helfand BKI, 2020, JAMA INTERN MED, V180, P1546, DOI 10.1001/jamainternmed.2020.5084; Incalzi RA, 2021, VACCINE, V39, P2325, DOI 10.1016/j.vaccine.2021.03.066; Lord JM, 2013, HUM VACC IMMUNOTHER, V9, P1364, DOI 10.4161/hv.24696; McEllistrem MC, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab263, DOI 10.1093/cid/ciab263]; Menendez Colino R., 2021, ESP SALUD PUBLICA, V95, P1; Mor V, 2021, J AM GERIATR SOC, V69, P2063, DOI 10.1111/jgs.17176; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rudolph JL, 2021, J AM GERIATR SOC, V69, P2090, DOI 10.1111/jgs.17180; Rutten JJS, 2020, J AM MED DIR ASSOC, V21, P1791, DOI 10.1016/j.jamda.2020.10.034; Sato M, 2005, INFECT CONT HOSP EP, V26, P859, DOI 10.1086/502509; Tang O, 2020, J AM MED DIR ASSOC, V21, P1767, DOI 10.1016/j.jamda.2020.10.011; Teran RA, 2021, MMWR-MORBID MORTAL W, V70, P632, DOI 10.15585/mmwr.mm7017e1; Van Praet J.T., 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab300, DOI 10.1093/CID/CIAB300]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Woodfield MC, 2021, CANCER-AM CANCER SOC, V127, P2861, DOI 10.1002/cncr.33598	26	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1174	10.3390/vaccines9101174			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR3VK	34696282	Green Published, gold			2022-04-29	WOS:000714431400001
J	Shah, SRM; Alsaab, HO; Rawas-Qalaji, MM; Uddin, MN				Shah, Sarthak M.; Alsaab, Hashem O.; Rawas-Qalaji, Mutasem M.; Uddin, Mohammad N.			A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems	VACCINES			English	Review						COVID-19; vaccines; SARS-CoV-2; pandemic; oral particulate vaccine	RECEPTOR-BINDING DOMAIN; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; PROTECTIVE IMMUNITY; DENDRITIC CELLS; MICROPARTICLES; NANOPARTICLES; IMMUNIZATION; ANTIGEN; MICROSPHERES	First detected in Wuhan, China, a highly contagious coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), also known as COVID-19, spread globally in December of 2019. As of 19 September 2021, approximately 4.5 million people have died globally, and 215 million active cases have been reported. To date, six vaccines have been developed and approved for human use. However, current production and supply capabilities are unable to meet global demands to immunize the entire world population. Only a few countries have been able to successfully vaccinate many of their residents. Therefore, an alternative vaccine that can be prepared in an easy and cost-effective manner is urgently needed. A vaccine that could be prepared in this manner, as well as can be preserved and transported at room temperature, would be of great benefit to public health. It is possible to develop such an alternative vaccine by using nano- or microparticle platforms. These platforms address most of the existing vaccine limitations as they are stable at room temperature, are inexpensive to produce and distribute, can be administered orally, and do not require cold chain storage for transportation or preservation. Particulate vaccines can be administered as either oral solutions or in sublingual or buccal film dosage forms. Besides improved patient compliance, the major advantage of oral, sublingual, and buccal routes of administration is that they can elicit mucosal immunity. Mucosal immunity, along with systemic immunity, can be a strong defense against SARS-CoV-2 as the virus enters the system through inhalation or saliva. This review discusses the possibility to produce a particulate COVID vaccine by using nano- or microparticles as platforms for oral administration or in sublingual or buccal film dosage forms in order to accelerate global vaccination.	[Shah, Sarthak M.; Uddin, Mohammad N.] Mercer Univ, Coll Pharm, Atlanta, GA 31207 USA; [Alsaab, Hashem O.] Taif Univ, Dept Pharmaceut & Pharmaceut Technol, POB 11099, At Taif 21944, Saudi Arabia; [Rawas-Qalaji, Mutasem M.] Univ Sharjah, Coll Pharm, Sharjah 26666, U Arab Emirates; [Rawas-Qalaji, Mutasem M.] Univ Sharjah, Res Inst Med & Hlth Sci, Sharjah 26666, U Arab Emirates; [Rawas-Qalaji, Mutasem M.] Nova Southeastern Univ, Dr Kiran C Patel Coll Allopath Med, Ft Lauderdale, FL USA		Uddin, MN (通讯作者)，Mercer Univ, Coll Pharm, Atlanta, GA 31207 USA.	h.alsaab@tu.edu.sa; mqalaji@sharjah.ac.ae	Alsaab, Hashem O./K-5627-2019	Alsaab, Hashem/0000-0001-5448-1004			Amorij JP, 2012, J CONTROL RELEASE, V161, P363, DOI 10.1016/j.jconrel.2011.12.039; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], NEW TYPE CORONAVIRUS; [Anonymous], CORONAVIRUS HUMAN CO; [Anonymous], PFIZER VS MODERNA VA; [Anonymous], CORONAVIRUS COVID 19; [Anonymous], POLIOMYELITIS; [Anonymous], NEW YORK TIMES; Anselmo AC, 2019, NAT REV DRUG DISCOV, V18, P19, DOI 10.1038/nrd.2018.183; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011; Belyakov IM, 2009, J IMMUNOL, V183, P6883, DOI 10.4049/jimmunol.0901466; Blumenthal KG, 2021, NEW ENGL J MED, V384, P1273, DOI 10.1056/NEJMc2102131; Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Cesta MF, 2006, TOXICOL PATHOL, V34, P599, DOI 10.1080/01926230600865531; Chang S, 2009, BIOLOGICALS, V37, P141, DOI 10.1016/j.biologicals.2009.02.019; Cohen J., 2020, SCIENCE, V10, DOI [10.1126/science.abe2848, DOI 10.1126/SCIENCE.ABE2848]; Combadiere B, 2008, COMP IMMUNOL MICROB, V31, P293, DOI 10.1016/j.cimid.2007.07.015; Copland MJ, 2003, VACCINE, V21, P883, DOI 10.1016/S0264-410X(02)00536-4; Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948; Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031; Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032; Elamanchili P, 2007, J IMMUNOTHER, V30, P378, DOI 10.1097/CJI.0b013e31802cf3e3; Fang M, 2006, VIROLOGY, V345, P231, DOI 10.1016/j.virol.2005.09.056; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Gala RP, 2017, AAPS PHARMSCITECH, V18, P283, DOI 10.1208/s12249-016-0566-3; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; Gamvrellis A, 2013, VET IMMUNOL IMMUNOP, V155, P21, DOI 10.1016/j.vetimm.2013.05.015; Goldsby R. A., 2002, IMMUNOLOGY; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021; He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106; Hou XC, 2021, NAT REV MATER, V6, P1078, DOI 10.1038/s41578-021-00358-0; Huang N, 2021, NAT MED, V27, P892, DOI 10.1038/s41591-021-01296-8; Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101; Joshi D, 2021, AAPS J, V23, DOI 10.1208/s12248-021-00617-6; Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; Kreuter J, 1996, J ANAT, V189, P503; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Ledford H, 2021, NATURE, V592, P495, DOI 10.1038/d41586-021-00998-w; Levi Riccardo, 2021, J Clin Invest, V131, DOI 10.1172/JCI149154; Lewis D, 2020, NATURE, V585, P494, DOI 10.1038/d41586-020-02523-x; MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933; McLenon J, 2019, J ADV NURS, V75, P30, DOI 10.1111/jan.13818; Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012; Nettey H, 2006, J MICROENCAPSUL, V23, P632, DOI 10.1080/02652040600776564; O'Grady M., 2021, POLIO VACCINE STATPE; O'Hagan DT, 1998, ADV DRUG DELIVER REV, V34, P305, DOI 10.1016/S0169-409X(98)00045-3; PABST R, 1987, ANAT EMBRYOL, V176, P135, DOI 10.1007/BF00310046; Panraksa P, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12112666; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7; Parums DV, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.932899; Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5; Sinjari B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103218; Slutter B, 2010, J CONTROL RELEASE, V143, P207, DOI 10.1016/j.jconrel.2010.01.007; Smith JH, 2012, VACCINE, V30, P3026, DOI 10.1016/j.vaccine.2011.10.092; Thi TTH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040359; Thiele L, 2003, PHARM RES-DORDR, V20, P221, DOI 10.1023/A:1022271020390; Thones N, 2007, VIROLOGY, V369, P375, DOI 10.1016/j.virol.2007.08.004; Tobio M, 1998, PHARMACEUT RES, V15, P270, DOI 10.1023/A:1011922819926; TYRRELL DAJ, 1975, INTERVIROLOGY, V5, P76, DOI 10.1159/000149883; Uddin M, 2019, J PHARM PHARM SCI, V22, P536, DOI 10.18433/jpps30768; Uddin M, 2019, J PHARM PHARM SCI, V22, P388, DOI 10.18433/jpps30528; Uddin MN, 2015, J PHARM PHARM SCI, V18, P220, DOI 10.18433/J3RS3V; Verga D., MRNA FUTURE VACCINE; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168-3659(01)00413-8; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Yeh MT, 2020, CELL HOST MICROBE, V27, P736, DOI 10.1016/j.chom.2020.04.003; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042	73	2	2	18	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1086	10.3390/vaccines9101086			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN9VD	34696194	Green Published, gold			2022-04-29	WOS:000712111900001
J	Almalki, MJ; Alotaibi, AA; Alabdali, SH; Zaalah, AA; Maghfuri, MW; Qirati, NH; Jandali, YM; Almalki, SM				Almalki, Mohammed J.; Alotaibi, Amani A.; Alabdali, Salman H.; Zaalah, Ayman A.; Maghfuri, Mohsen W.; Qirati, Naif H.; Jandali, Yahya M.; Almalki, Sami M.			Acceptability of the COVID-19 Vaccine and Its Determinants among University Students in Saudi Arabia: A Cross-Sectional Study	VACCINES			English	Article						acceptability of vaccine; vaccination hesitancy; COVID-19; university students; Saudi Arabia	ACCEPTANCE	COVID-19 vaccine hesitancy is a significant threat to the efforts that have been taken to combat the pandemic. This study assessed the acceptability of the COVID-19 vaccine among university students in Saudi Arabia. A cross-sectional online survey using a Google Form was conducted between 2 April and 23 April 2021. A snowball technique was used to recruit participants for this study. The final sample consisted of 407 participants. More than one-third of the participants (36.1%) had received the COVID-19 vaccine, and 13.3% had registered to receive the vaccine. Of the participants who were not yet vaccinated (n = 260), 90.4% indicated that they would like to be vaccinated when given the opportunity. Of the unvaccinated participants, 82.3% trusted the COVID-19 vaccines that had been provided in Saudi Arabia. The most reported reasons for the participants' acceptance to receive the COVID-19 vaccine included preventive purposes (95.8%), a belief in the safety of the vaccines (84.3%), and the availability of public awareness information regarding the vaccines (77.3%). A small portion of participants (6.1%) were refusing to receive the vaccine due to the potential long-term side effects (92.0%) and expedited vaccine trials (80.0%). Acceptability of the COVID-19 vaccine was strongly associated with participants who regularly received the flu vaccine (p < 0.05). All other demographic variables were not statistically associated with the acceptability of the COVID-19 vaccine. In conclusion, it would be appropriate for universities to launch peer programs to urge reluctant students to receive the vaccine voluntarily. In terms of further research, it is valuable to follow up with unvaccinated participants to investigate if they received the vaccine since the data were collected, and their reasons for doing so. This research would reveal changes toward vaccine acceptability over time and any related determinants. Future research should consider students from non-Arabic speaking backgrounds.	[Almalki, Mohammed J.] Jazan Univ, Fac Publ Hlth & Trop Med, Dept Hlth Serv Management, Jazan 45142, Saudi Arabia; [Alotaibi, Amani A.] Jazan Univ, Fac Publ Hlth & Trop Med, Dept Hlth Educ & Promot, Jazan 45142, Saudi Arabia; [Alabdali, Salman H.; Zaalah, Ayman A.; Maghfuri, Mohsen W.; Qirati, Naif H.; Jandali, Yahya M.] Jazan Univ, Fac Publ Hlth & Trop Med, Dept Epidemiol, Jazan 45142, Saudi Arabia; [Almalki, Sami M.] Jazan Univ, Fac Publ Hlth & Trop Med, Dept Hlth Informat, Jazan 45142, Saudi Arabia		Almalki, MJ (通讯作者)，Jazan Univ, Fac Publ Hlth & Trop Med, Dept Hlth Serv Management, Jazan 45142, Saudi Arabia.	mjalmalki@jazanu.edu.sa; alotaibi@jazanu.edu.sa; 201802961@stu.jazanu.edu.sa; 201807853@stu.jazanu.edu.sa; 201704650@stu.jazanu.edu.sa; 201701885@stu.jazanu.edu.sa; 201807881@stu.jazanu.edu.sa; 201803002@stu.jazanu.edu.sa					Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Almaghaslah D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040330; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Centers for Disease Control and Prevention, SAF COVID 19 VACC; Centres for Disease Control and Prevention, EP INF WIND; COVID19 Vaccine Tracker, 2 VACC APPR US SAUD; Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Jackson SE, 2015, JAMA INTERN MED, V175, P385, DOI 10.1001/jamainternmed.2014.7554; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Jazan University, STAT NUMB U STUD; Latkin C, 2021, VACCINE, V39, P2237, DOI 10.1016/j.vaccine.2021.02.058; Lawes-Wickwar S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020072; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Ministry of Health, SEH; Ministry of Health, MIN HLTH STARTS REG; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Mylan S, 2021, LANCET, V397, P1181, DOI 10.1016/S0140-6736(21)00443-8; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Ransing R, 2021, ASIAN J PSYCHIATR, V58, DOI 10.1016/j.ajp.2021.102614; Razai MS, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1138; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052407; Saudi Food and Drug Authority, SAUD FOOD DRUG AUTH; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sonawane K, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100016; WHO, COVID 19 VACC TRACK; World Health Organization, COR DIS COVID 19 SSI	31	6	6	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							943	10.3390/vaccines9090943			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3AW	34579180	Green Published, gold			2022-04-29	WOS:000702082100001
J	Gelbenegger, G; Cacioppo, F; Firbas, C; Jilma, B				Gelbenegger, Georg; Cacioppo, Filippo; Firbas, Christa; Jilma, Bernd			Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination	VACCINES			English	Article						COVID-19; vaccine; Ad26.COV2.S; rhabdomyolysis; myoglobinuria	NECROSIS	We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis.	[Gelbenegger, Georg; Firbas, Christa; Jilma, Bernd] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria; [Cacioppo, Filippo] Med Univ Vienna, Dept Emergency Med, A-1090 Vienna, Austria		Jilma, B (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.	georg.gelbenegger@meduniwien.ac.at; filippo.cacioppo@meduniwien.ac.at; christa.firbas@meduniwien.ac.at; bernd.jilma@meduniwien.ac.at		Jilma, Bernd/0000-0001-5652-7977; Cacioppo, Filippo/0000-0002-6095-4899			Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Bosch X, 2009, NEW ENGL J MED, V361, P62, DOI 10.1056/NEJMra0801327; Callado RB, 2013, TRAVEL MED INFECT DI, V11, P130, DOI 10.1016/j.tmaid.2012.11.004; Chedid NR, 2020, J GEN INTERN MED, V35, P3087, DOI 10.1007/s11606-020-06039-y; Giannoglou GD, 2007, EUR J INTERN MED, V18, P90, DOI 10.1016/j.ejim.2006.09.020; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Holt SG, 2001, INTENS CARE MED, V27, P803, DOI 10.1007/s001340100878; Jin M, 2020, EMERG INFECT DIS, V26, P1618, DOI 10.3201/eid2607.200445; KNOCHEL JP, 1982, ANNU REV MED, V33, P435, DOI 10.1146/annurev.me.33.020182.002251; KONRAD RJ, 1993, ANN INTERN MED, V119, P861, DOI 10.7326/0003-4819-119-8-199310150-00024; Mack M, 2021, CUREUS, V13, DOI 10.7759/cureus.15004; Melli G, 2005, MEDICINE, V84, P377, DOI 10.1097/01.md.0000188565.48918.41; Nassar M, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.06.007; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Tan A, 2021, QJM-INT J MED, V114, P596, DOI 10.1093/qjmed/hcab077; Vanholder R, 2000, J AM SOC NEPHROL, V11, P1553, DOI 10.1681/ASN.V1181553; WARD MM, 1988, ARCH INTERN MED, V148, P1553, DOI 10.1001/archinte.148.7.1553; Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053; WROGEMANN K, 1976, LANCET, V1, P672; ZAGER RA, 1989, LAB INVEST, V60, P619	21	3	3	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							956	10.3390/vaccines9090956			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3AS	34579193	Green Published, gold			2022-04-29	WOS:000702081700001
J	Li, ZX; Wang, Q; Ma, JH; Li, Z; Huang, D; Huang, YZ; Zhou, HC				Li, Zhenxing; Wang, Qiao; Ma, Jiahui; Li, Zhi; Huang, Dong; Huang, Yuzhao; Zhou, Haocheng			Risk Factors for Herpes Zoster in Patients with Chronic Kidney Disease: A Case-Control Study	VACCINES			English	Article						chronic kidney disease; herpes zoster; risk factor; case-control	POSTHERPETIC NEURALGIA; TRANSPLANT RECIPIENTS; MORTALITY RISK; INFECTION; OLDER	(1) Background: Chronic kidney disease (CKD) increases the susceptibility to the presence of herpes zoster (HZ). Little is known about the risk factors of HZ in CKD patients; (2) Methods: This is a case-control study. CKD patients diagnosed with HZ between January 2015 and June 2021 in a tertiary hospital were identified. One age- and gender- matched control was paired for each case, matched to the date of initial HZ diagnosis. Conditional multiple logistic regression was used to evaluate the risk factors associated with the presence of HZ; (3) Results: Forty-seven HZ patients and controls were identified. In general, about 73.40% (69 out of 94) patients were classified at IV to V stages of CKD. Immunosuppressive agents (p = 0.0012) and dialysis therapy (p = 0.021) were reported more frequently in the HZ cohort. Compared with the control group, the total white cell count and lymphocyte count were significantly lower in the HZ group (p value of 0.032 and 0.003, respectively). The conditional logistics regression model revealed that previous immunosuppressants administration (odds ratio: 10.861, 95% CI: 2.092 similar to 56.392, p = 0.005) and dialysis therapy (odds ratio: 3.293, 95% CI: 1.047 similar to 10.355, p = 0.041) were independent risk factors of HZ in the CKD population; (4) Conclusions: Dialysis and immunosuppressants therapy were associated with greater risk of HZ disease in CKD patients. Further guideline may highlight the necessity of zoster vaccine for patients with CKD, who undertake associated treatment.	[Li, Zhenxing; Wang, Qiao; Ma, Jiahui; Huang, Dong; Zhou, Haocheng] Cent South Univ, Xiangya Hosp 3, Inst Pain Med, Dept Pain, Changsha 410013, Peoples R China; [Li, Zhi] Cent South Univ, Xiangya Hosp 3, Dept Nephrol, Changsha 410013, Peoples R China; [Huang, Dong; Zhou, Haocheng] Cent South Univ, Hunan Key Lab Brain Homeostasis, Changsha 410013, Peoples R China; [Huang, Yuzhao] Cent South Univ, Xiangya Hosp 3, Dept Orthoped, Changsha 410013, Peoples R China		Zhou, HC (通讯作者)，Cent South Univ, Xiangya Hosp 3, Inst Pain Med, Dept Pain, Changsha 410013, Peoples R China.; Zhou, HC (通讯作者)，Cent South Univ, Hunan Key Lab Brain Homeostasis, Changsha 410013, Peoples R China.	Zhenxing_Li@csu.edu.cn; 198312208@csu.edu.cn; 198302074@csu.edu.cn; lizhi080108@sina.com; huangdong6619@vip.163.com; hyzxiangya3@outlook.com; Haocheng.Zhou@csu.edu.cn		Zhou, Haocheng/0000-0001-6260-2005	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81901146, 81771101]; Key Laboratory of Hunan Province grants [2018TP1009]; "Huizhiyucai" Project of the Third Xiangya Hospital, Central South University	This research was funded by National Natural Science Foundation of China, grant number 81901146 to H.Z. and 81771101 to H.Z. and D.H.; the Key Laboratory of Hunan Province grants, grant number 2018TP1009 to H.Z and D.H and the "Huizhiyucai" Project of the Third Xiangya Hospital, Central South University.	Ahn JH, 2019, CLIN KIDNEY J, V12, P101, DOI 10.1093/ckj/sfy058; Arness T, 2008, TRANSPL INFECT DIS, V10, P260, DOI 10.1111/j.1399-3062.2007.00289.x; Centers for Disease Control and Prevention, 2019, CHRON KIDN DIS US; Chang CH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59794-7; Dalrymple LS, 2008, CLIN J AM SOC NEPHRO, V3, P1487, DOI 10.2215/CJN.01290308; Forbes HJ, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2911; Forbes HJ, 2016, NEUROLOGY, V87, P94, DOI 10.1212/WNL.0000000000002808; Friedman AN, 2010, J AM SOC NEPHROL, V21, P223, DOI 10.1681/ASN.2009020213; Hassan HIC, 2016, KIDNEY INT, V90, P897, DOI 10.1016/j.kint.2016.07.013; Hu SCS, 2016, J AM ACAD DERMATOL, V75, P49, DOI 10.1016/j.jaad.2015.12.059; Hutchinson P, 2003, NEPHROL DIAL TRANSPL, V18, P983, DOI 10.1093/ndt/gfg190; John AR, 2017, INFECT DIS CLIN N AM, V31, P811, DOI 10.1016/j.idc.2017.07.016; Kang JH, 2009, STROKE, V40, P3443, DOI 10.1161/STROKEAHA.109.562017; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kausz AT, 2005, J AM SOC NEPHROL, V16, P3092, DOI 10.1681/ASN.2004110910; Kawai K, 2017, MAYO CLIN PROC, V92, P1806, DOI 10.1016/j.mayocp.2017.10.009; Kuo CC, 2012, AM J KIDNEY DIS, V59, P428, DOI 10.1053/j.ajkd.2011.10.049; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lamarche Caroline, 2019, Can J Kidney Health Dis, V6, p2054358119839080, DOI 10.1177/2054358119839080; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Liao TL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014032; Lin SY, 2014, EUR J CLIN MICROBIOL, V33, P1809, DOI 10.1007/s10096-014-2143-6; Lin SY, 2012, AM J NEPHROL, V36, P27, DOI 10.1159/000339004; Makharita MY, 2017, PAIN PHYSICIAN, V20, pE209; Minatoguchi S, 2018, RENAL REPLACE THER, V4, P30, DOI [10.1186/s41100-018-0173-8, DOI 10.1186/S41100-018-0173-8]; Mustapic Z, 2011, KIDNEY BLOOD PRESS R, V34, P382, DOI 10.1159/000328730; Nogue M, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4052-y; Oh GJ, 2019, KIDNEY INT REP, V4, P1608, DOI 10.1016/j.ekir.2019.08.019; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Prakash S, 2009, SEMIN NEPHROL, V29, P497, DOI 10.1016/j.semnephrol.2009.06.006; Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1046/j.1523-1755.2000.00337.x; Sato T, 2009, CLIN KIDNEY J, V2, P263, DOI 10.1093/ndtplus/sfp024; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; Tseng HF, 2016, CLIN INFECT DIS, V62, P462, DOI 10.1093/cid/civ930; van Dijk PCW, 2001, NEPHROL DIAL TRANSPL, V16, P1120, DOI 10.1093/ndt/16.6.1120; Weinberg A, 2018, J INFECT DIS, V218, pS81, DOI 10.1093/infdis/jiy383; Wu MY, 2012, AM J KIDNEY DIS, V60, P548, DOI 10.1053/j.ajkd.2012.03.018	37	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							963	10.3390/vaccines9090963			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3WQ	34579200	gold, Green Published			2022-04-29	WOS:000702139300001
J	Rodriguez, M; Lopez-Cepero, A; Ortiz-Martinez, AP; Fernandez-Repollet, E; Perez, CM				Rodriguez, McClaren; Lopez-Cepero, Andrea; Ortiz-Martinez, Ana P.; Fernandez-Repollet, Emma; Perez, Cynthia M.			Influence of Health Beliefs on COVID-19 Vaccination among Individuals with Cancer and Other Comorbidities in Puerto Rico	VACCINES			English	Article						COVID-19; vaccination; cancer; Puerto Rico; Health Belief Model	VACCINES	Ethnic minority populations are more likely to suffer from chronic comorbidities, making them more susceptible to the poor health outcomes associated with COVID-19 infection. Therefore, ensuring COVID-19 vaccination among vulnerable populations is of utmost importance. We aimed to investigate health behaviors and perceptions of COVID-19 vaccination among adults self-reporting diagnosis of cancer and of other chronic comorbidities in Puerto Rico (PR). This secondary analysis used data from 1911 participants who completed an online survey from December 2020 to February 2021. The Health Belief Model was used to measure perceptions surrounding COVID-19 vaccination among individuals self-reporting diagnosis of cancer and of other chronic comorbidities, and healthy adults. Among study participants, 76% were female, 34% were 50 years or older, 5% self-reported cancer diagnosis, and 70% had other chronic comorbidities. Participants self-reporting a cancer diagnosis had two times higher odds of getting vaccinated than healthy individuals (95% CI: 1.00-4.30). Compared to healthy participants, those self-reporting being diagnosed with cancer and those with chronic conditions other than cancer had significantly higher perceived COVID-19 susceptibility and severity. Our findings elucidate the effect of disease status on health-related decision-making and highlights information needed to be included in education campaigns to increase vaccine uptake among ethnic minority populations.	[Rodriguez, McClaren] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Lopez-Cepero, Andrea] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Ortiz-Martinez, Ana P.] Univ Puerto Rico, Comprehens Canc Ctr, Div Canc Control & Populat Sci, San Juan, PR 00936 USA; [Ortiz-Martinez, Ana P.; Perez, Cynthia M.] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Biostat & Epidemiol, Med Sci Campus, San Juan, PR 00936 USA; [Fernandez-Repollet, Emma] Univ Puerto Rico, Ctr Collaborat Res Hlth Dispar, Sch Med, Dept Pharmacol, Med Sci Campus, San Juan, PR 00936 USA		Lopez-Cepero, A (通讯作者)，Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.	mrr103@pitt.edu; andrea.lopez11@upr.edu; ana.ortiz7@upr.edu; e.fernandez@upr.edu; cynthia.perezl@upr.edu		Fernandez-Repollet, Emma/0000-0002-1918-0609	National Cancer Institute (NCI) of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R25CA240120]; RCMI from the National Institute of Minority Health and Health Disparities (NIMHD) National Institutes of Health [U54-MD007600]	This research was funded by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), award grant number R25CA240120. This work has been partially supported by RCMI grant number U54-MD007600 from the National Institute of Minority Health and Health Disparities (NIMHD) National Institutes of Health.	Addeo A, 2021, CANCER CELL, V39, P1091, DOI 10.1016/j.ccell.2021.06.009; Agha Mounzer, 2021, medRxiv, DOI 10.1101/2021.04.06.21254949; Alam MR, 2021, PREV MED REP, V21, DOI 10.1016/j.pmedr.2021.101319; Ariza-Heredia EJ, 2015, INFECT CONT HOSP EP, V36, P1239, DOI 10.1017/ice.2015.150; Arriola CS, 2015, VACCINE, V33, P3829, DOI 10.1016/j.vaccine.2015.06.093; Barriere J, 2021, ANN ONCOL, V32, P673, DOI 10.1016/j.annonc.2021.01.066; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Brodziak A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050411; CDC, COVID DAT TRACK; Chew LD, 2004, FAM MED, V36, P588; Corti C, 2021, ANN ONCOL, V32, P569, DOI 10.1016/j.annonc.2020.12.019; Desai A, 2021, NAT REV CLIN ONCOL, V18, P313, DOI 10.1038/s41571-021-00487-z; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Garcia C, 2021, J GERONTOL B-PSYCHOL, V76, pE263, DOI 10.1093/geronb/gbaa186; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Kelkar AH, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9030351; Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9; Lefever S, 2007, BRIT J EDUC TECHNOL, V38, P574, DOI 10.1111/j.1467-8535.2006.00638.x; Lopez L, 2021, JAMA-J AM MED ASSOC, V325, P719, DOI 10.1001/jama.2020.26443; Lopez-Cepero A., HUM VACC IMMUNOTHER; Lou E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241741; Massarweh A, 2021, JAMA ONCOL, V7, P1133, DOI 10.1001/jamaoncol.2021.2155; Mattei J, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5359-z; Meng YF, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00907-0; Perez-Pedrogo C, 2020, PSYCHOL TRAUMA-US, V12, P515, DOI 10.1037/tra0000664; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Saini KS, 2020, EUR J CANCER, V139, P43, DOI 10.1016/j.ejca.2020.08.011; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Tsai R., 2021, COVID 19 VACCINE HES, DOI [10.1101/2021.04.06.21254014, DOI 10.1101/2021.04.06.21254014]; Tucker KL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-107; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yang LD, 2021, CANCER BIOL MED, V18, P298, DOI 10.20892/j.issn.2095-3941.2020.0559	34	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							994	10.3390/vaccines9090994			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3GE	34579231	gold, Green Published			2022-04-29	WOS:000702096000001
J	Seddiki, N; Le Grand, R				Seddiki, Nabila; Le Grand, Roger			Special Issue "Immune Ontogeny and Vaccination in Early Life: How the Non-Human Primate Model Can Help Expand the Current Knowledge in Pediatric Immunology and Infectious Diseases Research"	VACCINES			English	Editorial Material									[Seddiki, Nabila; Le Grand, Roger] Univ Paris Saclay, CEA, Ctr Immunol Viral Autoimmune Hematol & Bacterial, IDMIT Dept,UMR1184, F-92265 Fontenay Aux Roses, France		Seddiki, N (通讯作者)，Univ Paris Saclay, CEA, Ctr Immunol Viral Autoimmune Hematol & Bacterial, IDMIT Dept,UMR1184, F-92265 Fontenay Aux Roses, France.	nabila.seddiki@cea.fr; roger.legrand@cea.fr					Blanchard-Rohner G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091002; Dispinseri S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030260; Joma M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040391; Lemaitre J, 2021, MOL IMMUNOL, V135, P147, DOI 10.1016/j.molimm.2021.04.010; Locht C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030228; Nunez N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060584; Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045; Sartoretti J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040306; Saso A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080877; Tokuhara D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020095	10	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1014	10.3390/vaccines9091014			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YK	34579251	Green Published, gold			2022-04-29	WOS:000702075700001
J	Altawalah, H				Altawalah, Haya			Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination	VACCINES			English	Review						COVID-19; humoral immunity; neutralizing antibody; SARS-CoV-2; serology assays	NEUTRALIZATION; CORONAVIRUS; EFFICACY; IGA	The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). The clinical severity of COVID-19 ranges from asymptomatic to critical disease and, eventually, death in smaller subsets of patients. The first case of COVID-19 was declared at the end of 2019 and it has since spread worldwide and remained a challenge in 2021, with the emergence of variants of concern. In fact, new concerns were the still unclear situation of SARS-CoV-2 immunity during the ongoing pandemic and progress with vaccination. If maintained at sufficiently high levels, the immune response could effectively block reinfection, which might confer long-lived protection. Understanding the protective capacity and the duration of humoral immunity during SARS-CoV-2 infection or after vaccination is critical for managing the pandemic and would also provide more evidence about the efficacy of SARS-CoV-2 vaccines. However, the exact features of antibody responses that govern SARS-CoV-2 infection or after vaccination remain unclear. This review summarizes the main knowledge that we have about the humoral immune response during COVID-19 disease or after vaccination. Such knowledge should help to optimize vaccination strategies and public health decisions.	[Altawalah, Haya] Kuwait Univ, Fac Med, Dept Microbiol, Safat 24923, Kuwait; [Altawalah, Haya] Sabah Hosp, Yacoub Behbehani Ctr, Minist Hlth, Virol Unit, Safat 24923, Kuwait		Altawalah, H (通讯作者)，Kuwait Univ, Fac Med, Dept Microbiol, Safat 24923, Kuwait.; Altawalah, H (通讯作者)，Sabah Hosp, Yacoub Behbehani Ctr, Minist Hlth, Virol Unit, Safat 24923, Kuwait.	haya.altawalah@ku.edu.kw					Abe KT, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142362; Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Braun-Moscovici Y, 2021, ANN RHEUM DIS, V80, P1317, DOI 10.1136/annrheumdis-2021-220503; Burrell CJ., 2017, VACCINES VACCINATION, P155; Cameron A, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02489-20; Cele S, 2021, NATURE, V593, P142, DOI 10.1038/s41586-021-03471-w; Charlton Carmen, 2021, Can Commun Dis Rep, V47, P171, DOI 10.14745/ccdr.v47i04a01; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Song CC, 2021, TRANSPL INFECT DIS, DOI 10.1111/tid.13654; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Cucchiari D, 2021, AM J TRANSPLANT, V21, P2727, DOI 10.1111/ajt.16701; Custers J, 2021, VACCINE, V39, P3081, DOI 10.1016/j.vaccine.2020.09.018; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Deeks JJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013652; Deming ME, 2021, NAT MED, V27, P1510, DOI 10.1038/s41591-021-01463-x; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Ezzikouri S, 2020, HUM VACC IMMUNOTHER, V16, P2992, DOI 10.1080/21645515.2020.1787068; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; FRATER J, 2021, LANCET HIV, V2352; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Garcia-Beltran Wilfredo F, 2020, medRxiv, DOI 10.1101/2020.10.15.20213512; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Greaney AJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abi9915; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783; Hartley GE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abf8891; Hashem AM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121390; Hoang VT, 2020, J MED VIROL, V92, P2366, DOI 10.1002/jmv.26056; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x; Huang BY, 2021, LANCET MICROBE, V2, pE285, DOI 10.1016/S2666-5247(21)00082-3; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jiang HW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17488-8; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Jones D, 2020, LANCET, V396, P810, DOI 10.1016/S0140-6736(20)31924-3; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Laugel E., 2021, ANTISARS COV 2 ANTIB, DOI [10.1101/2021.05.07.21256823, DOI 10.1101/2021.05.07.21256823]; Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520; Lipsitch M, 2020, SCIENCE, V370, P763, DOI 10.1126/science.abe5938; Liu LD, 2020, J MOL CELL BIOL, V12, P980, DOI 10.1093/jmcb/mjaa070; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lv Z, 2020, SCIENCE, V369, P1505, DOI 10.1126/science.abc5881; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mekonnen D, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2181; Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018; Moscato G, 2021, J CLIN VIROL PLUS, V1, DOI 10.1016/j.jcvp.2021.100016; Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0; Nie JH, 2020, NAT PROTOC, V15, DOI 10.1038/s41596-020-0394-5; Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Overbaugh J, 2020, NAT MED, V26, P1680, DOI 10.1038/s41591-020-1121-z; Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443; Park WB, 2015, EMERG INFECT DIS, V21, P2186, DOI 10.3201/eid2112.151421; Payne DC, 2016, EMERG INFECT DIS, V22, P1824, DOI 10.3201/eid2210.160706; Phillips N, 2021, NATURE, V590, P382, DOI 10.1038/d41586-021-00396-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Rasmussen AL, 2020, MED-CAMBRIDGE, V1, P21, DOI 10.1016/j.medj.2020.12.004; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Rodriguez-Espinosa D, 2021, KIDNEY INT, V100, P476, DOI 10.1016/j.kint.2021.05.018; Roy Sayak, 2020, SN Compr Clin Med, V2, P710, DOI 10.1007/s42399-020-00335-8; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Schmidt T, 2021, NAT MED, V27, P1530, DOI 10.1038/s41591-021-01464-w; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; Shastri J, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.631769; Stephenson KE, 2021, JAMA-J AM MED ASSOC, V325, P1535, DOI 10.1001/jama.2021.3645; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; The World Health Organization,, WHO LISTS ADD COVID; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Ura T, 2021, VACCINE, V39, P197, DOI 10.1016/j.vaccine.2020.11.054; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Vetter P, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.02.010; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wall EC, 2021, LANCET, V398, P207, DOI 10.1016/S0140-6736(21)01462-8; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang JZ, 2021, J INVEST MED, V69, P1253, DOI 10.1136/jim-2021-001853; Wang PF, 2020, EMERG MICROBES INFEC, V9, P2091, DOI 10.1080/22221751.2020.1823890; Wang ZJ, 2021, NATURE, V595, P426, DOI 10.1038/s41586-021-03696-9; Weissleder R, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc1931; West J, 2021, CLIN MED, V21, pE52, DOI 10.7861/clinmed.2020-0912; Won JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249775; World Health Organization, DRAFT LANDSC COVID 1; Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yao L, 2021, J INFECT DIS, V224, P586, DOI 10.1093/infdis/jiab255; Yen T.H., 2021, QJM-INT J MED, pHCAB171, DOI [10.1093/qjmed/hcab171, DOI 10.1093/QJMED/HCAB171]; Yoo JH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e54; Zettl F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030386; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou P., 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/s41586-020-2012-7]	123	10	10	8	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							910	10.3390/vaccines9080910			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2DI	34452035	gold, Green Published			2022-04-29	WOS:000689748200001
J	Harrison, N; Grabmeier-Pfistershammer, K; Graf, A; Trapin, D; Tauber, P; Aberle, JH; Stiasny, K; Schmidt, R; Greinix, H; Rabitsch, W; Ramharter, M; Burgmann, H; Pickl, WF; Bahrs, C				Harrison, Nicole; Grabmeier-Pfistershammer, Katharina; Graf, Alexandra; Trapin, Doris; Tauber, Peter; Aberle, Judith H.; Stiasny, Karin; Schmidt, Ralf; Greinix, Hildegard; Rabitsch, Werner; Ramharter, Michael; Burgmann, Heinz; Pickl, Winfried F.; Bahrs, Christina			Tick-Borne Encephalitis Specific Lymphocyte Response after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Humoral Immunity after Vaccination	VACCINES			English	Article						allogeneic stem cell transplant; tick-borne encephalitis vaccination; lymphocyte proliferation; cytokine response; interleukin 13; sibling donors; humoral responders	DONOR IMMUNIZATION; DEFICIENCY; VACCINES	The aim of this prospective study was to assess lymphocyte proliferative and cytokine response prior to and following tick-borne encephalitis (TBE) immunization among patients after allogeneic hematopoietic stem cell transplantation (HSCT). Seventeen adult patients 11-13 months after HSCT and eight unvaccinated healthy adults received up to three TBE vaccinations. Following in vitro stimulation with TBE-antigen, lymphocyte proliferation and cytokine secretion (IL-2, IL-10, IL-13, TNF-alpha, IFN-gamma, GM-CSF) were analyzed by thymidine incorporation assay and the Luminex system. Ten patients (59%) showed significant baseline TBE-specific lymphocyte proliferation (stimulation index (SI) > 3) prior to vaccination, but none of the unvaccinated controls (p = 0.002). All patients with a TBE-specific antibody response after two vaccinations (at least 2-fold increase of neutralization test titers) exhibited a strong TBE-specific lymphocyte proliferative response at baseline (SI > 10). Patients with sibling donors had a significantly stronger baseline TBE-specific lymphocyte proliferative and IL-13 cytokine response than patients with unrelated donors (p < 0.05). In conclusion, a relevant proportion of patients showed TBE-specific lymphocyte proliferative and cytokine responses prior to vaccination after HSCT, which predicted the humoral response to the vaccine. Patients with vaccinated sibling donors were more likely to elicit a cellular immune response than patients with unrelated donors of unknown vaccination status.	[Harrison, Nicole; Burgmann, Heinz; Bahrs, Christina] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, A-1090 Vienna, Austria; [Grabmeier-Pfistershammer, Katharina; Trapin, Doris; Tauber, Peter; Pickl, Winfried F.] Med Univ Vienna, Div Cellular Immunol & Immunohematol, Inst Immunol, Ctr Pathophysiol Infect & Immunol, A-1090 Vienna, Austria; [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Med Stat, A-1090 Vienna, Austria; [Aberle, Judith H.; Stiasny, Karin] Med Univ Vienna, Ctr Virol, A-1090 Vienna, Austria; [Schmidt, Ralf] Med Univ Vienna, Dept Lab Med, Div Virol, A-1090 Vienna, Austria; [Greinix, Hildegard] Med Univ Graz, Dept Internal Med, Div Hematol, A-8036 Graz, Austria; [Rabitsch, Werner] Med Univ Vienna, Dept Med 1, Bone Marrow Transplantat Unit, A-1090 Vienna, Austria; [Ramharter, Michael] Univ Med Ctr Hamburg Eppendorf, Bernhard Nocht Inst Trop Med & I, Dept Med, Dept Trop Med, D-20359 Hamburg, Germany; [Bahrs, Christina] Friedrich Schiller Univ, Jena Univ Hosp, Inst Infect Dis & Infect Control, D-07747 Jena, Germany		Bahrs, C (通讯作者)，Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, A-1090 Vienna, Austria.; Bahrs, C (通讯作者)，Friedrich Schiller Univ, Jena Univ Hosp, Inst Infect Dis & Infect Control, D-07747 Jena, Germany.	nicole.harrison@meduniwien.ac.at; katharina.grabmeier-pfistershammer@meduniwien.ac.at; alexandra.graf@meduniwien.ac.at; doris.trapin@meduniwien.ac.at; peter.tauber@meduniwien.ac.at; judith.aberle@meduniwien.ac.at; karin.stiasny@meduniwien.ac.at; ralf.schmidt@meduniwien.ac.at; hildegard.greinix@medunigraz.at; werner.rabitsch@meduniwien.ac.at; ramharter@bnitm.de; heinz.burgmann@meduniwien.ac.at; winfried.pickl@meduniwien.ac.at; christina.bahrs@meduniwien.ac.at	Bahrs, Christina/AAM-2511-2021; Ramharter, Michael/C-5273-2013; Harrison, Nicole/Q-5569-2016	Bahrs, Christina/0000-0002-4427-2839; Pickl, Winfried F./0000-0003-0430-4952; Graf, Alexandra/0000-0003-0035-2658; Ramharter, Michael/0000-0002-9259-1885; Harrison, Nicole/0000-0001-5971-0662	Austrian Science FundAustrian Science Fund (FWF) [KLI 372]; PfizerPfizer	This study was funded by the Austrian Science Fund (grant number KLI 372) and received additional support by Pfizer (TBE-vaccines and TBE-antigen were sponsored).	Aberle JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140545; Avetisyan G, 2008, TRANSPLANTATION, V86, P257, DOI 10.1097/TP.0b013e3181772a75; Baron F, 2006, BIOL BLOOD MARROW TR, V12, P1176, DOI 10.1016/j.bbmt.2006.07.004; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Divekar AA, 2006, J IMMUNOL, V176, P1465, DOI 10.4049/jimmunol.176.3.1465; ECDC, 2019, TICK BORNE ENCEPHALI; Einarsdottir S, 2021, VACCINE, V39, P1035, DOI 10.1016/j.vaccine.2020.12.073; Erber W., 2019, TBE BOOK; Greinix HT, 2008, BIOL BLOOD MARROW TR, V14, P208, DOI 10.1016/j.bbmt.2007.10.009; Gress RE, 2010, BIOL BLOOD MARROW TR, V16, pS133, DOI 10.1016/j.bbmt.2009.10.003; Harris AE, 2015, BONE MARROW TRANSPL, V50, P899, DOI 10.1038/bmt.2015.49; Harrison N, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00215-1; Hilgendorf Inken, 2011, Vaccine, V29, P2825, DOI 10.1016/j.vaccine.2011.02.018; Kuzmina Z, 2011, BLOOD, V117, P2265, DOI 10.1182/blood-2010-07-295766; Li GY, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040073; Lipowski D, 2017, J INFECT DIS, V215, P896, DOI 10.1093/infdis/jix040; Lum L G, 1987, Prog Clin Biol Res, V244, P449; Mackall C, 2009, BONE MARROW TRANSPL, V44, P457, DOI 10.1038/bmt.2009.255; Maury S, 2001, BRIT J HAEMATOL, V115, P630, DOI 10.1046/j.1365-2141.2001.03135.x; Molrine DC, 2003, BLOOD, V101, P831, DOI 10.1182/blood-2002-03-0832; Parkkali T, 2007, BONE MARROW TRANSPL, V39, P179, DOI 10.1038/sj.bmt.1705562; Poulin JF, 2003, BLOOD, V102, P4600, DOI 10.1182/blood-2003-05-1428; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Salat J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010081; Storek J, 2004, BONE MARROW TRANSPL, V33, P337, DOI 10.1038/sj.bmt.1704336; Taba P, 2017, EUR J NEUROL, V24, P1214, DOI 10.1111/ene.13356; van der Velden AMT, 2007, BONE MARROW TRANSPL, V40, P261, DOI 10.1038/sj.bmt.1705706; Who Publication, 2011, Vaccine, V29, P8769, DOI 10.1016/j.vaccine.2011.07.024	28	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							908	10.3390/vaccines9080908			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9NZ	34452033	Green Published, gold			2022-04-29	WOS:000690249100001
J	Hou, YC; Lu, KC; Kuo, KL				Hou, Yi-Chou; Lu, Kuo-Cheng; Kuo, Ko-Lin			The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review	VACCINES			English	Review						chronic kidney disease; COVID-19; dialysis; kidney transplantation; SARS-CoV-2; vaccine	CLINICAL-PRACTICE GUIDELINE; STAGE RENAL-DISEASE; DIALYSIS PATIENTS; MYCOPHENOLIC-ACID; SPIKE PROTEIN; VACCINATION; OUTCOMES; IMMUNIZATION; HEMODIALYSIS; EXPRESSION	The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic has posed a huge threat to global health because of its rapid spread and various mutant variants. Critical illness occurs in the elderly and vulnerable individuals, such as those with chronic kidney disease. The severity of SARS-CoV-2 infection is associated with the severity of chronic kidney disease (CKD)and even kidney transplantation (KT) because of the chronic use of immunosuppressive agents. To develop adaptive immunity against SARS-CoV-2, vaccination against the spike protein is important. Current phase III trials of vaccines against SARS-CoV-2 have not focused on a specific group of individuals, such as patients with CKD or those undergoing dialysis or kidney transplantation. Chronic use of immunosuppressive agents might disturb the immune response to the SARS-CoV-2 spike protein. On the basis of limited evidence, the immune compromised status of CKD patients might decrease neutralizing antibody development after a single dose of a specific vaccine. Boosting dosage more than the protocol might increase the titer of the neutralizing antibody in CKD patients. Further evidence is needed to understand the factors disturbing the immunogenicity of the SARS-CoV-2 vaccine, and CKD patients should receive the recommended dose of the SARS-CoV-2 vaccine due to their relatively immune compromised status.	[Hou, Yi-Chou] Cardinal Tien Hosp, Div Nephrol, Dept Med, New Taipei 231, Taiwan; [Hou, Yi-Chou] Fu Jen Catholic Univ, Sch Med, New Taipei 242, Taiwan; [Lu, Kuo-Cheng; Kuo, Ko-Lin] Taipei Tzu Chi Hosp, Div Nephrol, Dept Med, Buddhist Tzu Chi Med Fdn, New Taipei 231, Taiwan; [Lu, Kuo-Cheng; Kuo, Ko-Lin] Buddhist Tzu Chi Univ, Sch Med, Hualien 970, Taiwan		Kuo, KL (通讯作者)，Taipei Tzu Chi Hosp, Div Nephrol, Dept Med, Buddhist Tzu Chi Med Fdn, New Taipei 231, Taiwan.; Kuo, KL (通讯作者)，Buddhist Tzu Chi Univ, Sch Med, Hualien 970, Taiwan.	athletics910@gmail.com; kuochenglu@gmail.com; kolinkuo8@gmail.com		Kuo, Ko-Lin/0000-0002-7477-0388	Ministry of Science and Technology [MOST 108-2314-B-303-006-MY3]; Taipei Tzu Chi Hospital [TCRD-TPE-MOST-109-08, TCRD-TPE-110-03]; Buddhist Tzu Chi Medical Foundation, Taiwan [TCMF-EP 109-02]; Foundation for Poison Control	This work was supported by grants from the Ministry of Science and Technology (MOST 108-2314-B-303-006-MY3), Taipei Tzu Chi Hospital (TCRD-TPE-MOST-109-08) and TCRD-TPE-110-03), Buddhist Tzu Chi Medical Foundation, Taiwan (TCMF-EP 109-02) and Foundation for Poison Control.	Alam MR, 2021, PREV MED REP, V21, DOI 10.1016/j.pmedr.2021.101319; Allison AC, 2005, LUPUS, V14, pS2, DOI 10.1191/0961203305lu2109oa; Ando M, 2006, KIDNEY INT, V70, P358, DOI 10.1038/sj.ki.5001548; Babu TM, 2021, CURR TREAT OPT INFEC, V13, P47, DOI 10.1007/s40506-021-00248-7; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baluch A, 2013, AM J TRANSPLANT, V13, P1026, DOI 10.1111/ajt.12149; Benotmane I, 2021, KIDNEY INT, V99, P1498, DOI 10.1016/j.kint.2021.04.005; Benotmane I, 2021, KIDNEY INT, V99, P1487, DOI 10.1016/j.kint.2021.03.014; Billany RE, 2021, KIDNEY INT, V99, P1492, DOI 10.1016/j.kint.2021.04.008; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Cai RY, 2021, INT UROL NEPHROL, V53, P1623, DOI 10.1007/s11255-020-02740-3; Cantarelli C, 2019, AM J TRANSPLANT, V19, P2407, DOI 10.1111/ajt.15369; Charytan DM, 2021, KIDNEY INT REP, V6, P916, DOI 10.1016/j.ekir.2021.01.036; Danziger-Isakov L, 2010, TRANSPLANTATION, V89, P838, DOI 10.1097/TP.0b013e3181ca56f8; Davidson AM, 2020, HYPERTENSION, V76, P1339, DOI 10.1161/HYPERTENSIONAHA.120.15256; de Roux A, 2004, RESP MED, V98, P1187, DOI 10.1016/j.rmed.2004.04.012; Deepak Parakkal, 2021, medRxiv, DOI 10.1101/2021.04.05.21254656; Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x; Ehrenreich H, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00186-y; Eleftheriadis T, 2007, SEMIN DIALYSIS, V20, P440, DOI 10.1111/J.1525-139X.2007.00283.x; Firket L, 2021, AM J TRANSPLANT, V21, P3806, DOI 10.1111/ajt.16726; Floege J, 2019, KIDNEY INT, V95, P268, DOI 10.1016/j.kint.2018.10.018; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Frasca D, 2013, VACCINE, V31, P3603, DOI 10.1016/j.vaccine.2013.05.003; Gansevoort RT, 2020, NAT REV NEPHROL, V16, P705, DOI 10.1038/s41581-020-00349-4; Garcia G, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108940; Girndt M, 2001, KIDNEY INT, V59, P1382, DOI 10.1046/j.1523-1755.2001.0590041382.x; Glenn DA, 2021, KIDNEY INT REP, V6, P1407, DOI 10.1016/j.ekir.2021.02.011; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Guebre-Xabier M., 2020, SARS COV 2 SPIKE GLY, DOI [10.1101/2020.06.29.178509, DOI 10.1101/2020.06.29.178509]; Gunsilius E, 2019, MEMO-MAG EUR MED ONC, V12, P191, DOI 10.1007/s12254-019-00519-6; Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540; Haneda M, 2014, TRANSPLANTATION, V97, P405, DOI 10.1097/01.TP.0000441826.70687.f6; He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06; Hou YC, 2018, CANCER MED-US, V7, P4296, DOI 10.1002/cam4.1676; Hou YC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2803579; HRICIK DE, 1994, TRANSPLANTATION, V57, P979, DOI 10.1097/00007890-199404150-00001; Hsu CM, 2021, AM J KIDNEY DIS, V77, P748, DOI [10.1053/j.ajkd.2021.01.003, 10.1053/.ajkd.2021.01.003]; Huang CY, 2021, MAYO CLIN PROC, V96, P183, DOI 10.1016/j.mayocp.2020.10.022; Iwasaki M, 2021, INFLAMMATION, V44, P13, DOI 10.1007/s10753-020-01337-3; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kant S, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02112-0; Karnell JL, 2011, J IMMUNOL, V187, P3603, DOI 10.4049/jimmunol.1003319; Kates Olivia S, 2021, Clin Infect Dis, V73, pe4090, DOI 10.1093/cid/ciaa1097; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001; Kim KW, 2012, EXP MOL MED, V44, P465, DOI 10.3858/emm.2012.44.8.053; Kliger AS, 2013, AM J KIDNEY DIS, V62, P849, DOI 10.1053/j.ajkd.2013.06.008; Kosugi T, 2015, NEPHROL DIAL TRANSPL, V30, P1097, DOI 10.1093/ndt/gfu302; Labriola L, 2021, CLIN J AM SOC NEPHRO, V16, P613, DOI 10.2215/CJN.12490720; LAMANNA A, 1992, PEDIATR NEPHROL, V6, P251, DOI 10.1007/BF00878360; Lentine KL, 2021, AM J KIDNEY DIS, V77, P777, DOI 10.1053/j.ajkd.2020.12.003; Lesny P, 2021, J NEPHROL, V34, P975, DOI 10.1007/s40620-021-01076-0; Liberman AC, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00235; Lin YC, 2021, THER ADV CHRONIC DIS, V12, DOI 10.1177/2040622321998860; Liu JH, 2009, INT J CLIN PRACT, V63, P387, DOI 10.1111/j.1742-1241.2008.01732.x; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lowe R, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882-021-02296-z; Lundstrom K, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020317; Ma Y., 2020, NOVEL CORONAVIRUS DI, DOI [10.1101/2020.02.24.20027201(dateofaccessJune17, 10.1101/2020.02.24.20027201, DOI 10.1101/2020.02.24.20027201, 10.1101/2020.02.24.20027201v2]; Mancianti N, 2021, J NEPHROL, V34, P1039, DOI 10.1007/s40620-021-01091-1; Mariat C, 1998, TRANSPL INT, V11, P231, DOI 10.1007/s001470050133; Menon R., 2020, KIDNEY INT, V98, P1502, DOI [DOI 10.1016/j.kint.2020.09.015, 10.1016/j.kint.2020.09.015]; Negrea L, 2021, KIDNEY INT, V99, P1487, DOI 10.1016/j.kint.2021.03.002; Ou MT, 2021, TRANSPLANTATION, V105, P2170, DOI 10.1097/TP.0000000000003780; Pahl MV, 2010, NEPHROL DIAL TRANSPL, V25, P205, DOI 10.1093/ndt/gfp397; Pakhchanian H, 2021, CLIN J AM SOC NEPHRO, V16, P785, DOI 10.2215/CJN.13820820; Parikh SV, 2020, AM J KIDNEY DIS, V76, P265, DOI 10.1053/j.ajkd.2019.10.017; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]; Rodriguez-Espinosa D, 2021, KIDNEY INT, V100, P476, DOI 10.1016/j.kint.2021.05.018; Rozen-Zvi B, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.04.028; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Scialo F, 2020, LUNG, V198, P867, DOI 10.1007/s00408-020-00408-4; Singh AK, 2020, DIABETES OBES METAB, V22, P1915, DOI 10.1111/dom.14124; Souma T, 2013, J AM SOC NEPHROL, V24, P1599, DOI 10.1681/ASN.2013010030; Steiner RW, 2011, SEMIN IMMUNOPATHOL, V33, P157, DOI 10.1007/s00281-011-0259-7; Syed-Ahmed M, 2019, ADV CHRONIC KIDNEY D, V26, P8, DOI 10.1053/j.ackd.2019.01.004; Tangpricha V, 2014, AM J KIDNEY DIS, V64, P667, DOI 10.1053/j.ajkd.2014.08.004; Tsapepas D, 2021, AM J KIDNEY DIS, V78, P314, DOI 10.1053/j.ajkd.2021.05.004; Valeri AM, 2020, J AM SOC NEPHROL, V31, P1409, DOI 10.1681/ASN.2020040470; Xie P, 2019, BLOOD PURIFICAT, V47, P73, DOI 10.1159/000493521; Yanay NB, 2021, KIDNEY INT, V99, P1496, DOI 10.1016/j.kint.2021.04.006; Zarkhin V, 2008, AM J TRANSPLANT, V8, P2607, DOI 10.1111/j.1600-6143.2008.02411.x; Zeng WH, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00478-7; Zheng JQ, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110708; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zitt E, 2012, VACCINE, V30, P931, DOI 10.1016/j.vaccine.2011.11.086	91	9	9	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							885	10.3390/vaccines9080885			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8VY	34452010	Green Published, gold			2022-04-29	WOS:000690202200001
J	Kreps, SE; Goldfarb, JL; Brownstein, JS; Kriner, DL				Kreps, Sarah E.; Goldfarb, Jillian L.; Brownstein, John S.; Kriner, Douglas L.			The Relationship between US Adults' Misconceptions about COVID-19 Vaccines and Vaccination Preferences	VACCINES			English	Article						COVID-19; public opinion; misconceptions; vaccine hesitancy	AMERICANS; BARRIERS	While mass vaccination has blunted the pandemic in the United States, pockets of vaccine hesitancy remain. Through a nationally representative survey of 1027 adult Americans conducted in February 2021, this study examined individual misconceptions about COVID-19 vaccine safety; the demographic factors associated with these misconceptions; and the relationship between misconceptions and willingness to vaccinate. Misconceptions about vaccine safety were widespread. A sizeable minority (40%) believed that vaccine side effects are commonly severe or somewhat severe; 85% significantly underestimated the size and scale of the clinical trials; and a sizeable share believed either that the vaccines contain live coronavirus (10%) or were unsure (38%), a proxy for fears that vaccination itself may cause infection. These misconceptions were particularly acute among Republicans, Blacks, individuals with lower levels of educational attainment, and unvaccinated individuals. Perceived side effect severity and underestimating the size of the clinical trials were both significantly associated with vaccine hesitancy.	[Kreps, Sarah E.; Kriner, Douglas L.] Cornell Univ, Dept Govt, Ithaca, NY 14850 USA; [Goldfarb, Jillian L.] Cornell Univ, Dept Biol & Environm Engn, Ithaca, NY 14850 USA; [Brownstein, John S.] Boston Childrens Hosp, Computat Epidemiol Lab, Boston, MA 02115 USA		Kriner, DL (通讯作者)，Cornell Univ, Dept Govt, Ithaca, NY 14850 USA.	sarah.kreps@cornell.edu; jlg459@cornell.edu; john.brownstein@childrens.harvard.edu; kriner@cornell.edu					[Anonymous], CDC SELECTED ADVERSE; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Barry CL, 2021, AM J PUBLIC HEALTH, V111, P937, DOI 10.2105/AJPH.2020.306148; Baumgaertner B, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003354; Dennis J., 2019, TECHNICAL OVERVIEW A; Ferdinand KC, 2021, AM J PUBLIC HEALTH, V111, P586, DOI 10.2105/AJPH.2020.306135; Ferdinand KC, 2020, J NATL MED ASSOC, V112, P681, DOI 10.1016/j.jnma.2020.11.001; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Frieden T., WALL STREET J; Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255; Kreps S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00335-2; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lee JJ, 2020, J MED INTERNET RES, V22, DOI 10.2196/22205; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Lyons K., VERGE; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Parmet WE, 2020, AM J PUBLIC HEALTH, V110, P945, DOI 10.2105/AJPH.2020.305721; Quinn SC, 2021, AM J PUBLIC HEALTH, V111, P355, DOI 10.2105/AJPH.2020.306036; Rosenbaum L, 2021, NEW ENGL J MED, V384, P1367, DOI 10.1056/NEJMms2101220; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Woko C, 2020, J HEALTH COMMUN, V25, P819, DOI 10.1080/10810730.2020.1864521	24	3	3	2	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							901	10.3390/vaccines9080901			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2RQ	34452025	Green Published, gold			2022-04-29	WOS:000689785400001
J	Lanfermann, C; Kohn, M; Laudeley, R; Rheinheimer, C; Klos, A				Lanfermann, Christian; Kohn, Martin; Laudeley, Robert; Rheinheimer, Claudia; Klos, Andreas			Chlamydia trachomatis Cross-Serovar Protection during Experimental Lung Reinfection in Mice	VACCINES			English	Article						Chlamydia trachomatis; reinfection; cross-serovar; protection; vaccination; lung; mouse; animal model	OUTER-MEMBRANE PROTEIN; GENITAL-TRACT INFECTION; IMMUNE-RESPONSE; ANTIBODY; ATTACHMENT; ELICIT; WOMEN	Chlamydia trachomatis causes most bacterial sexually transmitted diseases worldwide. Different major outer membrane proteins (MOMPs) define various serovars of this intracellular pathogen: In women, D to L3 can cause urethritis, cervicitis, salpingitis, and oophoritis, and, thus, infertility. Protective immunity might be serovar-specific since chlamydial infection does not appear to induce an effective acquired immunity and reinfections occur. A better understanding of induced cross-serovar protection is essential for the selection of suitable antigens in vaccine development. In our mouse lung infection screening model, we evaluated the urogenital serovars D, E, and L2 in this regard. Seven weeks after primary infection or mock-infection, respectively, mice were infected a second time with the identical or one of the other serovars. Body weight and clinical score were monitored for 7 days. Near the peak of the second lung infection, bacterial load, myeloperoxidase, IFN-gamma, and TNF-alpha in lung homogenate, as well as chlamydia-specific IgG levels in blood were determined. Surprisingly, compared with mice that were infected then for the first time, almost independent of the serovar combination used, all acquired parameters of disease were similarly diminished. Our reinfection study suggests that efficient cross-serovar protection could be achieved by a vaccine combining chlamydial antigens that do not include nonconserved MOMP regions.	[Lanfermann, Christian; Kohn, Martin; Laudeley, Robert; Rheinheimer, Claudia; Klos, Andreas] Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, D-30625 Hannover, Germany		Klos, A (通讯作者)，Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, D-30625 Hannover, Germany.	Lanfermann.Christian@mh-hannover.de; Kohn.Martin@mh-hannover.de; Laudeley.Robert@mh-hannover.de; Rheinheimer.Claudia@mh-hannover.de; Klos.Andreas@mh-hannover.de			ZIB PhD program from the Hannover Medical School	This study was mainly funded by MHH-LOM of the research group Klos. In addition, Christian Lanfermann and Martin Kohn were partially funded by the ZIB PhD program from the Hannover Medical School.	Abraham S, 2019, LANCET INFECT DIS, V19, P1091, DOI 10.1016/S1473-3099(19)30279-8; [Anonymous], 2016, WHO GUIDELINES TREAT; Bakshi RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01981; Becker E, 2014, MICROBIOLOGYOPEN, V3, P544, DOI 10.1002/mbo3.186; Borges V, 2019, MICROB GENOMICS, V5, DOI 10.1099/mgen.0.000313; Crane DD, 2006, P NATL ACAD SCI USA, V103, P1894, DOI 10.1073/pnas.0508983103; De Clercq E, 2013, INFECT IMMUN, V81, P3060, DOI 10.1128/IAI.00357-13; de la Maza LM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00543-16, 10.1128/cvi.00543-16]; Dutow P, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv120; Dutow P, 2014, J INFECT DIS, V209, P1269, DOI 10.1093/infdis/jit640; Gaston JSH, 2000, SEX TRANSM INFECT, V76, P156, DOI 10.1136/sti.76.3.156; Hoenderboom BM, 2019, SEX TRANSM INFECT, V95, P300, DOI 10.1136/sextrans-2018-053778; Joseph SJ, 2012, MOL BIOL EVOL, V29, P3933, DOI 10.1093/molbev/mss198; Karunakaran KP, 2015, VACCINE, V33, P2159, DOI 10.1016/j.vaccine.2015.02.055; Kohn M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.580594; Kohn M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626627; Kuo CC, 1996, J CLIN INVEST, V98, P2813, DOI 10.1172/JCI119109; KUO CC, 1983, INFECT IMMUN, V41, P865, DOI 10.1128/IAI.41.2.865-868.1983; Lanfermann C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060609; Lesiak-Markowicz I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54886-5; Li LX, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003707; Malaviarachchi PA, 2020, EUR J IMMUNOL, V50, P676, DOI 10.1002/eji.201948391; Morre SA, 2000, J CLIN MICROBIOL, V38, P2292; Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536; O'Meara CP, 2014, CURR MOL MED, V14, P396, DOI 10.2174/15665240113136660078; Pal S, 2005, INFECT IMMUN, V73, P8153, DOI 10.1128/IAI.73.12.8153-8160.2005; Pal S, 2001, INFECT IMMUN, V69, P6240, DOI 10.1128/IAI.69.10.6240-6247.2001; Pal S, 2015, IMMUNOLOGY, V146, P432, DOI 10.1111/imm.12520; Phillips S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00070; Qu YY, 2015, INFECT IMMUN, V83, P4056, DOI 10.1128/IAI.00841-15; Rank RG, 2014, INFECT IMMUN, V82, P1362, DOI 10.1128/IAI.01244-13; Roan NR, 2008, CELL MICROBIOL, V10, P9, DOI 10.1111/j.1462-5822.2007.01069.x; Rother M, 2018, CELL HOST MICROBE, V23, P661, DOI 10.1016/j.chom.2018.04.002; Rowley J, 2019, B WORLD HEALTH ORGAN, V97, P548, DOI 10.2471/BLT.18.228486; Schachter J, 1999, CHLAMYDIA, P139; Schlott T, 2005, GYNECOL ONCOL, V98, P409, DOI 10.1016/j.ygyno.2005.04.034; Sethi S, 2017, INDIAN J MED RES, V146, P59, DOI [10.4103/ijmr.IJMR_981_15, 10.4103/ijmr.ijmr_981_15]; STEPHENS RS, 1987, J BACTERIOL, V169, P3879, DOI 10.1128/jb.169.9.3879-3885.1987; Stevens MP, 2010, J CLIN MICROBIOL, V48, P2060, DOI 10.1128/JCM.02308-09; Su H, 1997, INFECT IMMUN, V65, P1993, DOI 10.1128/IAI.65.6.1993-1999.1997; Tan M., 2020, CHLAMYDIA BIOL GENOM; Vasilevsky S, 2016, VIRULENCE, V7, P11, DOI 10.1080/21505594.2015.1111509; Verweij SP, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-3; Williams DM, 1997, INFECT IMMUN, V65, P2876, DOI 10.1128/IAI.65.7.2876-2882.1997; World Health Organization, STAT EL TRACH PUBL H; Yu H, 2012, INFECT IMMUN, V80, P1510, DOI 10.1128/IAI.06338-11; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O	47	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							871	10.3390/vaccines9080871			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5GB	34451996	gold, Green Published			2022-04-29	WOS:000689958100001
J	Noushad, M; Nassani, MZ; Koppolu, P; Alsalhani, AB; Samran, A; Alqerban, A; Abusalim, GS; Barakat, A; Alshalhoub, MB; Rastam, S				Noushad, Mohammed; Nassani, Mohammad Zakaria; Koppolu, Pradeep; Alsalhani, Anas B.; Samran, Abdulaziz; Alqerban, Ali; Abusalim, Ghadah Salim; Barakat, Ali; Alshalhoub, Mashari Bandar; Rastam, Samer			Predictors of COVID-19 Vaccine Intention among the Saudi Arabian Population: A Cross-Sectional Survey	VACCINES			English	Article						COVID-19; vaccine intention; Saudi Arabia; population immunity	DETERMINANTS; KINGDOM	The long-term solution to managing the current COVID-19 pandemic is through mass immunization of the population. However, uncertainty or unwillingness to receive the vaccine could be a barrier in attaining sufficient vaccine coverage. Therefore, understanding the psychology of the population towards the vaccines against COVID-19 is of paramount importance. Our study was aimed at determining the predictors of COVID-19 vaccine intention in the Saudi Arabian population. A structured questionnaire guided by the 'Report of the SAGE working group on vaccine hesitancy' was administered during a span of two months among the general population from all administrative regions of Saudi Arabia, proceeding the launch of the vaccination campaign. In total, 879 out of 1600 subjects responded and completed the survey (response rate 54.9%). About 56 percent of the participants intended to be vaccinated. The predictors of a higher intention to vaccinate included those 50 years of age or older, male subjects, people suffering from systemic disease/s, subjects who were not previously infected with COVID-19, those who follow the updates about COVID-19 vaccines, and adults with a higher level of anxiety about contracting coronavirus (p < 0.05). Results from our study and other similar studies can aid policy makers and stakeholders in planning effective strategies based on the changing behavior of the population.	[Noushad, Mohammed; Nassani, Mohammad Zakaria; Samran, Abdulaziz; Barakat, Ali; Alshalhoub, Mashari Bandar] Dar Al Uloom Univ, Coll Dent, Dept Restorat & Prosthet Dent Sci, Riyadh 13313, Saudi Arabia; [Noushad, Mohammed] Univ Sains Malaysia, Sch Dent Sci, Biomat Unit, Hlth Campus, Kubang Kerian 16150, Malaysia; [Koppolu, Pradeep; Alqerban, Ali] Dar Al Uloom Univ, Coll Dent, Dept Prevent Dent Sci, Riyadh 13313, Saudi Arabia; [Alsalhani, Anas B.] Vision Coll Dent & Nursing, Vision Coll, Dept Oral Med & Diagnost Sci, Riyadh 11691, Saudi Arabia; [Samran, Abdulaziz] Ibb Univ, Dept Prosthodont, Coll Dent, Ibb 70270, Yemen; [Alqerban, Ali] Prince Sattam Bin Abdulaziz Univ, Coll Dent, Dept Prevent Dent Sci, Al Kharj 11942, Saudi Arabia; [Abusalim, Ghadah Salim] Prince Sattam Bin Abdulaziz Univ, Coll Appl Med Sci, Dept Med Lab Sci, Al Kharj 11942, Saudi Arabia; [Rastam, Samer] Vision Coll Med, Vision Coll, Dept Clin Sci, Riyadh 11691, Saudi Arabia		Noushad, M (通讯作者)，Dar Al Uloom Univ, Coll Dent, Dept Restorat & Prosthet Dent Sci, Riyadh 13313, Saudi Arabia.; Noushad, M (通讯作者)，Univ Sains Malaysia, Sch Dent Sci, Biomat Unit, Hlth Campus, Kubang Kerian 16150, Malaysia.	m.noushad@dau.edu.sa; mznassani@dau.edu.sa; pradeep@dau.edu.sa; aalsalhani@vision.edu.sa; asamran@dau.edu.sa; a.alqerban@psau.edu.sa; g.abusalim@psau.edu.sa; ali.ab@dau.edu.sa; 1141460@du.edu.sa; mroustom@vision.edu.sa	Alqerban, Ali/AAE-5487-2021; Rastam, M. Samer/N-6365-2017; koppolu, Pradeep/AAJ-6106-2021	Alqerban, Ali/0000-0002-8145-5466; Rastam, M. Samer/0000-0002-4004-7773; koppolu, Pradeep/0000-0001-8226-6926; Samran, Abdulaziz/0000-0002-2934-4830; Abusalim, Ghadah/0000-0002-4986-9503; Alsalhani, Anas/0000-0002-5158-7222; Nassani, Mohammad Zakaria/0000-0003-0927-895X; Noushad, Mohammed/0000-0002-0157-3666	Deanship of Postgraduate and Scientific Research at Dar Al UIoom University	The authors extend their appreciation to the Deanship of Postgraduate and Scientific Research at Dar Al UIoom University for their support for this work.	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Alobaidi S, 2021, J MULTIDISCIP HEALTH, V14, P1119, DOI 10.2147/JMDH.S306654; Alzahrani SH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070798; Awadhi EA, 2021, RISK MANAG HEALTHC P, V14, P1413, DOI 10.2147/RMHP.S300602; Barry M, 2020, J EPIDEMIOL GLOB HEA, V10, P1, DOI 10.2991/jegh.k.200218.003; Bashir S, 2021, ONE HEALTH-AMSTERDAM, V12, DOI 10.1016/j.onehlt.2021.100229; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Coe AB, 2022, RES SOC ADMIN PHARM, V18, P2593, DOI 10.1016/j.sapharm.2021.04.023; Halpin Carmel, 2019, Nurs Older People, V31, P32, DOI 10.7748/nop.2019.e1154; Kumari A, 2021, DIABETES METAB SYND, V15, P679, DOI 10.1016/j.dsx.2021.03.021; Liverpool L, 2021, NEW SCI, V249, P7, DOI [10.1016/S0262-4079(21)00439-5, DOI 10.1016/S0262-4079(21)00439-5]; Maltezou HC, 2021, INFECT DIS HEALTH, V26, P189, DOI 10.1016/j.idh.2021.03.002; Naar I., 2021, ALARABIYA NEWS; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Noushad M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080835; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Petravic L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030247; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Sage Working Group, 2014, REP SAG WORK GROUP V; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Saudi Gazette Report, 2021, SAUDI GAZETTE; Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; WHO, 2021, WHO HLTH EM DASHB WH; World Health Organization World Health Organization, 10 THREATS GLOB HLTH	31	2	2	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							892	10.3390/vaccines9080892			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6TU	34452017	Green Published, gold			2022-04-29	WOS:000690061400001
J	Seow, J; Das, SC; Morales, RAV; Ataide, R; Krishnarjuna, B; Silk, M; Chalmers, DK; Richards, J; Anders, RF; MacRaild, CA; Norton, RS				Seow, Jeffrey; Das, Sreedam C.; Morales, Rodrigo A. V.; Ataide, Ricardo; Krishnarjuna, Bankala; Silk, Mitchell; Chalmers, David K.; Richards, Jack; Anders, Robin F.; MacRaild, Christopher A.; Norton, Raymond S.			Guiding the Immune Response to a Conserved Epitope in MSP2, an Intrinsically Disordered Malaria Vaccine Candidate	VACCINES			English	Article						malaria; merozoite surface protein 2; disordered protein; peptide vaccines; structural vaccinology	PLASMODIUM-FALCIPARUM; STRUCTURAL VACCINOLOGY; DISULFIDE FORMATION; DESIGN; PROTEIN; ANTIBODIES; DYNAMICS; CHILDREN; EFFICACY; INVASION	The malaria vaccine candidate merozoite surface protein 2 (MSP2) has shown promise in clinical trials and is in part responsible for a reduction in parasite densities. However, strain-specific reductions in parasitaemia suggested that polymorphic regions of MSP2 are immuno-dominant. One strategy to bypass the hurdle of strain-specificity is to bias the immune response towards the conserved regions. Two mouse monoclonal antibodies, 4D11 and 9H4, recognise the conserved C-terminal region of MSP2. Although they bind overlapping epitopes, 4D11 reacts more strongly with native MSP2, suggesting that its epitope is more accessible on the parasite surface. In this study, a structure-based vaccine design approach was applied to the intrinsically disordered antigen, MSP2, using a crystal structure of 4D11 Fv in complex with its minimal binding epitope. Molecular dynamics simulations and surface plasmon resonance informed the design of a series of constrained peptides that mimicked the 4D11-bound epitope structure. These peptides were conjugated to keyhole limpet hemocyanin and used to immunise mice, with high to moderate antibody titres being generated in all groups. The specificities of antibody responses revealed that a single point mutation can focus the antibody response towards a more favourable epitope. This structure-based approach to peptide vaccine design may be useful not only for MSP2-based malaria vaccines, but also for other intrinsically disordered antigens.	[Seow, Jeffrey; Das, Sreedam C.; Morales, Rodrigo A. V.; Krishnarjuna, Bankala; Silk, Mitchell; Chalmers, David K.; MacRaild, Christopher A.; Norton, Raymond S.] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Parkville, Vic 3052, Australia; [Ataide, Ricardo; Richards, Jack] Burnet Inst, Malaria & Trop Dis Grp, Melbourne, Vic 3004, Australia; [Anders, Robin F.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia; [Norton, Raymond S.] Monash Univ, ARC Ctr Fragment Based Design, Parkville, Vic 3052, Australia		MacRaild, CA; Norton, RS (通讯作者)，Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Parkville, Vic 3052, Australia.; Norton, RS (通讯作者)，Monash Univ, ARC Ctr Fragment Based Design, Parkville, Vic 3052, Australia.	jeffreytjs@gmail.com; sreedam@du.ac.bd; rodrigo.morales@csl.com.au; ricardo.ataide@burnet.edu.au; krishnarjuna.bio@gmail.com; msi100@post.uit.no; david.chalmers@monash.edu; jack.richards@burnet.edu.au; r.anders@latrobe.edu.au; chris.macraild@monash.edu; ray.norton@monash.edu	Bankala, Krishnarjuna/H-4562-2013; Chalmers, David/L-8533-2013; Ataide, Ricardo/B-7307-2017	Bankala, Krishnarjuna/0000-0002-4575-0011; Chalmers, David/0000-0003-2366-569X; Norton, Raymond/0000-0001-8893-0584; MacRaild, Christopher/0000-0002-3694-3989; Ataide, Ricardo/0000-0002-1014-0432	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council (NHMRC) of Australia [1042520]; Australian Government Research Training Program ScholarshipAustralian GovernmentDepartment of Industry, Innovation and Science	This research was funded in part by the National Health and Medical Research Council of Australia (project grant 1042520 and fellowships to J.S.R. and R.S.N.) and in part by an Australian Government Research Training Program Scholarship (to J.S.).	Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Adda CG, 2012, INFECT IMMUN, V80, P4177, DOI 10.1128/IAI.00665-12; Adda CG, 2009, MOL BIOCHEM PARASIT, V166, P159, DOI 10.1016/j.molbiopara.2009.03.012; Azoitei ML, 2012, J MOL BIOL, V415, P175, DOI 10.1016/j.jmb.2011.10.003; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; Boyle MJ, 2010, P NATL ACAD SCI USA, V107, P14378, DOI 10.1073/pnas.1009198107; Burton DR, 2010, P NATL ACAD SCI USA, V107, P17859, DOI 10.1073/pnas.1012923107; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Cozzi R, 2013, CURR TOP MED CHEM, V13, P2629; Crank MC, 2019, SCIENCE, V365, P505, DOI 10.1126/science.aav9033; Cui JJ, 2011, J MED CHEM, V54, P6342, DOI 10.1021/jm2007613; Datoo MS, 2021, LANCET, V397, P1809, DOI 10.1016/S0140-6736(21)00943-0; Dormitzer PR, 2012, NAT REV MICROBIOL, V10, P807, DOI 10.1038/nrmicro2893; Duncan CJA, 2012, HUM VACC IMMUNOTHER, V8, P706, DOI 10.4161/hv.19712; Eacret JS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45440-4; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Feng ZP, 2006, MOL BIOCHEM PARASIT, V150, P256, DOI 10.1016/j.molbiopara.2006.08.011; FENTON B, 1991, MOL CELL BIOL, V11, P963, DOI 10.1128/MCB.11.2.963; Frimpong A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02769; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; Guenaga J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016074; Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150; Kaufmann SHE, 2014, CURR OPIN IMMUNOL, V28, P18, DOI 10.1016/j.coi.2014.01.009; Krishnarjuna B, 2016, SCI REP-UK, V6, DOI 10.1038/srep20613; Kulp DW, 2013, CURR OPIN VIROL, V3, P322, DOI 10.1016/j.coviro.2013.05.010; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; Lounnas V, 2013, COMPUT STRUCT BIOTEC, V5, DOI 10.5936/csbj.201302011; MacRaild CA, 2018, PEPTIDE SCI, V110, DOI 10.1002/pep2.24067; MacRaild CA, 2016, STRUCTURE, V24, P148, DOI 10.1016/j.str.2015.10.028; McCarthy JS, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024413, 10.1371/journal.pone.0021914]; McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283; Menezes-Souza D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099216; Meola A, 2015, J VIROL, V89, P2170, DOI 10.1128/JVI.02190-14; Nuccitelli A, 2011, P NATL ACAD SCI USA, V108, P10278, DOI 10.1073/pnas.1106590108; Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107; Osier FHA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-108; Oyen D, 2017, P NATL ACAD SCI USA, V114, pE10438, DOI 10.1073/pnas.1715812114; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Patarroyo ME, 2008, ACCOUNTS CHEM RES, V41, P377, DOI 10.1021/ar700120t; Postma TM, 2014, EUR J ORG CHEM, V2014, P3519, DOI 10.1002/ejoc.201402149; Postma TM, 2013, ORG LETT, V15, P616, DOI 10.1021/ol303428d; Ramamurthy M, 2019, J CELL BIOCHEM, V120, P17534, DOI 10.1002/jcb.29017; Rappuoli R, 2016, J EXP MED, V213, P469, DOI 10.1084/jem.20151960; Sabatino D, 2020, J MED CHEM, V63, P14184, DOI 10.1021/acs.jmedchem.0c00848; Salinas ND, 2019, J MOL BIOL, V431, P4259, DOI 10.1016/j.jmb.2019.05.018; Scarselli M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002234; Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9; Seow J, 2017, J MOL BIOL, V429, P836, DOI 10.1016/j.jmb.2017.02.003; Skwarczynski M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2285; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Skwarczynski M, 2011, CURR DRUG DELIV, V8, P282, DOI 10.2174/156720111795256192; SMYTHE JA, 1991, P NATL ACAD SCI USA, V88, P1751, DOI 10.1073/pnas.88.5.1751; Stephens AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.696791; Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Triller G, 2017, IMMUNITY, V47, P1197, DOI 10.1016/j.immuni.2017.11.007; Vekemans J, 2021, VACCINE, V39, P2907, DOI 10.1016/j.vaccine.2021.03.093; WHO, 2012, WORLD MALARIA REPORT 2012, P1; Zhang XC, 2008, J MOL BIOL, V379, P105, DOI 10.1016/j.jmb.2008.03.039	59	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							855	10.3390/vaccines9080855			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2OW	34451980	Green Published, gold			2022-04-29	WOS:000689778200001
J	Jearanaiwitayakul, T; Seesen, M; Chawengkirttikul, R; Limthongkul, J; Apichirapokey, S; Sapsutthipas, S; Phumiamorn, S; Sunintaboon, P; Ubol, S				Jearanaiwitayakul, Tuksin; Seesen, Mathurin; Chawengkirttikul, Runglawan; Limthongkul, Jitra; Apichirapokey, Suttikarn; Sapsutthipas, Sompong; Phumiamorn, Supaporn; Sunintaboon, Panya; Ubol, Sukathida			Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2	VACCINES			English	Article						intranasal vaccine; RBD; COVID-19; nano-delivery vaccine	N-TRIMETHYL CHITOSAN; IMMUNOGENICITY; VACCINATION; ANTIBODY; ANTIGEN; MICE; IDENTIFICATION; PROTECTION	Mucosal immunity plays a significant role in host defense against viruses in the respiratory tract. Because the upper respiratory airway is a primary site of SARS-CoV-2 entry, immunization at the mucosa via the intranasal route could potentially lead to induction of local sterilizing immunity that protects against SARS-CoV-2 infection. In this study, we evaluated the immunogenicity of a receptor-binding domain (RBD) of SARS-CoV-2 spike glycoprotein loaded into N,N,N-trimethyl chitosan nanoparticles (RBD-TMC NPs). We showed that intranasal delivery of RBD-TMC NPs into mice induced robust local mucosal immunity, as evidenced by the presence of IgG and IgA responses in BALs and the lungs of immunized mice. Furthermore, mice intranasally administered with this platform of immunogens developed robust systemic antibody responses including serum IgG, IgG1, IgG2a, IgA and neutralizing antibodies. In addition, these immunized mice had significantly higher levels of activated splenic CD4(+) and CD8(+) cells compared with those that were administered with soluble RBD immunogen. Collectively, these findings shed light on an alternative route of vaccination that mimics the natural route of SARS-CoV-2 infection. This route of administration stimulated not only local mucosal responses but also the systemic compartment of the immune system.	[Jearanaiwitayakul, Tuksin; Seesen, Mathurin; Chawengkirttikul, Runglawan; Limthongkul, Jitra; Apichirapokey, Suttikarn; Ubol, Sukathida] Mahidol Univ, Fac Sci, Dept Microbiol, Bangkok 10400, Thailand; [Sapsutthipas, Sompong; Phumiamorn, Supaporn] Minist Publ Hlth, Inst Biol Prod, Dept Med Sci, Nonthaburi 11000, Thailand; [Sunintaboon, Panya] Mahidol Univ, Fac Sci, Dept Chem, Salaya 73170, Nakhon Pathom, Thailand		Ubol, S (通讯作者)，Mahidol Univ, Fac Sci, Dept Microbiol, Bangkok 10400, Thailand.	tuksin.jear@gmail.com; mathurin.jj@gmail.com; runglawan.cha@mahidol.ac.th; jitra.kas@mahidol.ac.th; Suttikarn.api@gmail.com; sompong.s@dmsc.mail.go.th; supaporn.p@dmsc.mail.go.th; panya.sun@mahidol.ac.th; sukathida.ubo@mahidol.ac.th		Jearanaiwitayakul, Tuksin/0000-0002-2555-8516	National Vaccine Institute, Thailand [2563.1/9]	This research was funded by National Vaccine Institute, Thailand, granted to Ubol S (grant number 2563.1/9).	Abkar M, 2017, INT J NANOMED, V12, P8769, DOI 10.2147/IJN.S149774; Amidi M, 2007, VACCINE, V25, P144, DOI 10.1016/j.vaccine.2006.06.086; Bestle D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000786; Bidgood SR, 2014, P NATL ACAD SCI USA, V111, P13463, DOI 10.1073/pnas.1410980111; Bilich T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf7517; Cervia C, 2021, J ALLERGY CLIN IMMUN, V147, P545, DOI 10.1016/j.jaci.2020.10.040; Cetre C, 1999, INFECT IMMUN, V67, P2713; Chang SY, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.16; Cuervo NZ, 2020, ELIFE, V9, DOI 10.7554/eLife.61390; Dabaghian M, 2018, VACCINE, V36, P2886, DOI 10.1016/j.vaccine.2018.02.072; Firacative C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21039-z; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Guthmiller JJ, 2021, MBIO, V12, DOI 10.1128/mBio.02940-20; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang PH, 2021, HUM VACC IMMUNOTHER, V17, P654, DOI 10.1080/21645515.2020.1814098; Jearanaiwitayakul T, 2020, VACCINE, V38, P6814, DOI 10.1016/j.vaccine.2020.08.021; Lambrecht, 2015, MUCOSAL IMMUNOLOGY, P1985, DOI DOI 10.1016/13978-0-12-415847-4.00103-8; Li L, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198082; Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057; LIEW FY, 1984, EUR J IMMUNOL, V14, P350, DOI 10.1002/eji.1830140414; Liu QF, 2015, J MED VIROL, V87, P1807, DOI 10.1002/jmv.24253; Marasini N, 2017, THER DELIV, V8, P151, DOI 10.4155/tde-2016-0068; Mohammed MA, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040053; Muraoka D, 2020, VACCINE, V38, P7697, DOI 10.1016/j.vaccine.2020.10.039; Najminejad H, 2019, ARTIF CELL NANOMED B, V47, P2605, DOI 10.1080/21691401.2019.1629948; Pabst R, 2015, VACCINE, V33, P4406, DOI 10.1016/j.vaccine.2015.07.022; Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2; Ren LL, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01526-8; Rungrojcharoenkit K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237218; Sato S, 2012, CURR OPIN VIROL, V2, P225, DOI 10.1016/j.coviro.2012.03.009; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Shah HB, 2015, METHODS MOL BIOL, V1312, P419, DOI 10.1007/978-1-4939-2694-7_42; Shim S, 2020, MAR DRUGS, V18, DOI 10.3390/md18120605; Slutter B, 2010, VACCINE, V28, P6282, DOI 10.1016/j.vaccine.2010.06.121; Smith SA, 2019, BIOCONJUGATE CHEM, V30, P263, DOI 10.1021/acs.bioconjchem.8b00732; Sperandio B, 2015, SEMIN IMMUNOL, V27, P111, DOI 10.1016/j.smim.2015.03.011; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Tsatsakis A, 2020, FOOD CHEM TOXICOL, V146, DOI 10.1016/j.fct.2020.111769; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walter F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239369; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2; Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x; Zhang P, 2014, INT IMMUNOPHARMACOL, V23, P254, DOI 10.1016/j.intimp.2014.09.007; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	49	8	8	4	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							768	10.3390/vaccines9070768			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5UL	34358183	gold, Green Published			2022-04-29	WOS:000676976200001
J	Al-Marshoudi, S; Al-Balushi, H; Al-Wahaibi, A; Al-Khalili, S; Al-Maani, A; Al-Farsi, N; Al-Jahwari, A; Al-Habsi, Z; Al-Shaibi, M; Al-Msharfi, M; Al-Ismaili, A; Al-Buloshi, H; Al-Rawahi, B; Al-Barwani, K; Al-Abri, S				Al-Marshoudi, Sabria; Al-Balushi, Haleema; Al-Wahaibi, Adil; Al-Khalili, Sulien; Al-Maani, Amal; Al-Farsi, Noura; Al-Jahwari, Adhari; Al-Habsi, Zeyana; Al-Shaibi, Maryam; Al-Msharfi, Mahfoodh; Al-Ismaili, Ahlam; Al-Buloshi, Hood; Al-Rawahi, Bader; Al-Barwani, Khalifa; Al-Abri, Seif			Knowledge, Attitudes, and Practices (KAP) toward the COVID-19 Vaccine in Oman: A Pre-Campaign Cross-Sectional Study	VACCINES			English	Article						COVID-19; Oman; vaccines; knowledge; attitude; practice; immunization programs; pandemics	POPULATION; DETERMINANTS; MORTALITY	Oman is globally acknowledged for its well-structured immunization program with high vaccination coverage. The massive spread of misinformation brought on by the COVID-19 pandemic, as well as the easy access to various media channels, may affect acceptance of a vaccine, despite the inherent trust in the local system. This cross-sectional study evaluated the knowledge, attitudes, and practice (KAP) in Oman toward COVID-19 vaccines. It included 3000 randomly selected adults answering a structured questionnaire via telephone. Participants were 66.7% Omani, 76% male, and 83.7% without comorbidities. Their mean age was 38.27 years (SD +/- 10.45). Knowledge of COVID-19 ' s symptoms, mode of transmission, and attitudes toward the disease was adequate; 88.4% had heard of the vaccine, 59.3% would advise others to take it, 56.8% would take it themselves, and 47.5% would take a second dose. Males (CI = 2.37, OR = (2.00-2.81)) and Omani (CI = 1.956, OR = (4.595-2.397)) were more willing to be vaccinated. The history of chronic disease, source of vaccine knowledge, and education level were factors that affected the willingness to accept the vaccine. The Omani community's willingness to take the COVID-19 vaccine can be enhanced by utilizing social media and community influencers to spread awareness about the vaccine's safety and efficacy.	[Al-Marshoudi, Sabria; Al-Balushi, Haleema; Al-Wahaibi, Adil; Al-Khalili, Sulien; Al-Maani, Amal; Al-Farsi, Noura; Al-Jahwari, Adhari; Al-Habsi, Zeyana; Al-Shaibi, Maryam; Al-Rawahi, Bader; Al-Abri, Seif] Minist Hlth, Directorate Gen Dis Surveillance & Control DGDSC, Muscat 393, Oman; [Al-Msharfi, Mahfoodh; Al-Ismaili, Ahlam; Al-Buloshi, Hood; Al-Barwani, Khalifa] Natl Ctr Statist & Informat NCSI, Muscat 133, Oman		Al-Marshoudi, S (通讯作者)，Minist Hlth, Directorate Gen Dis Surveillance & Control DGDSC, Muscat 393, Oman.	dr.salmarshoudi@gmail.com; haleema9292@yahoo.com; adilwahaibi@gmail.com; sulienkhalili18@gmail.com; amalsaifalmaani@gmail.com; nouralfarsi@gmail.com; athari-91@hotmail.com; nada000_000@hotmail.com; mariamalshaibi@gmail.com; msharfi@ncsi.gov.om; aismaili@ncsi.gov.om; hbuloshi@ncsi.gov.om; bderalrawahi4@gmail.com; ceo@ncsi.gov.om; salabri@gmail.com	Maani, Amal SS Al/L-5202-2015	Maani, Amal SS Al/0000-0001-8322-8331; Al-Wahaibi, Adil/0000-0002-5052-0800; Al-Abri, Seif/0000-0002-2669-6814			Al Wahaibi A, 2021, TRAVEL MED INFECT DI, V39, DOI 10.1016/j.tmaid.2020.101923; Al-Abri SS, 2018, J INFECT PUBLIC HEAL, V11, P742, DOI 10.1016/j.jiph.2018.04.015; Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217; Awaidy S., 2015, J VACCINES IMMUN, V3, P1, DOI [10.14312/2053-1273.2015-1, DOI 10.14312/2053-1273.2015-1]; Brooks D.J., 2020, COVID 19 RESPONSES M; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dube E, 2017, CLIN MICROBIOL INFEC, V23, P279, DOI 10.1016/j.cmi.2016.11.007; Freed GL, 2010, PEDIATRICS, V125, P654, DOI 10.1542/peds.2009-1962; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mannan D.K.A., 2020, INT RES J BUS SOC SC, V6, P1; McAteer J, 2020, CLIN INFECT DIS, V71, P703, DOI 10.1093/cid/ciaa433; MoH Oman, 2020, OM VACC ACT PLAN 201; MoH Oman, 2020, NAT MEASL RUB STRAT; MoH Oman, 2021, CORONAVIRUS CASES; Moran KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164541; National Center for Statistic and Information, 2020, ASSESSMENT KAP COIVD; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nguyen KH, 2021, AM J TRANSPLANT, V21, P1650, DOI 10.1111/ajt.16560; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Papagiannis D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144925; Patel PK, 2018, E MEDITERR HEALTH J, V24, P119, DOI 10.26719/2018.24.2.119; Reuben R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237755; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; ul Haq N, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-692; Al Wahaibi A, 2020, INT J INFECT DIS, V104, P102, DOI 10.1016/j.ijid.2020.12.054; World Health Organization, 2020, WHO SAGE VAL FRAM AL; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	29	14	14	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							602	10.3390/vaccines9060602			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5XU	34200001	Green Published, gold			2022-04-29	WOS:000665961400001
J	Cappellano, G; Abreu, H; Casale, C; Dianzani, U; Chiocchetti, A				Cappellano, Giuseppe; Abreu, Hugo; Casale, Chiara; Dianzani, Umberto; Chiocchetti, Annalisa			Nano-Microparticle Platforms in Developing Next-Generation Vaccines	VACCINES			English	Review						advanced vaccines; PLGA; liposome; extracellular vesicles; virus infection	VIRUS; NANOPARTICLES	The first vaccines ever made were based on live-attenuated or inactivated pathogens, either whole cells or fragments. Although these vaccines required the co-administration of antigens with adjuvants to induce a strong humoral response, they could only elicit a poor CD8(+) T-cell response. In contrast, next-generation nano/microparticle-based vaccines offer several advantages over traditional ones because they can induce a more potent CD8(+) T-cell response and, at the same time, are ideal carriers for proteins, adjuvants, and nucleic acids. The fact that these nanocarriers can be loaded with molecules able to modulate the immune response by inducing different effector functions and regulatory activities makes them ideal tools for inverse vaccination, whose goal is to shut down the immune response in autoimmune diseases. Poly (lactic-co-glycolic acid) (PLGA) and liposomes are biocompatible materials approved by the Food and Drug Administration (FDA) for clinical use and are, therefore, suitable for nanoparticle-based vaccines. Recently, another candidate platform for innovative vaccines based on extracellular vesicles (EVs) has been shown to efficiently co-deliver antigens and adjuvants. This review will discuss the potential use of PLGA-NPs, liposomes, and EVs as carriers of peptides, adjuvants, mRNA, and DNA for the development of next-generation vaccines against endemic and emerging viruses in light of the recent COVID-19 pandemic.	[Cappellano, Giuseppe; Abreu, Hugo; Casale, Chiara; Dianzani, Umberto; Chiocchetti, Annalisa] Univ Piemonte Orientale, Interdisciplinary Res Ctr Autoimmune Dis IRCAD, Dipartimento Sci Salute, I-28100 Novara, Italy; [Cappellano, Giuseppe; Chiocchetti, Annalisa] Univ Piemonte Orientale, Ctr Translat Res Autoimmune & Allerg Dis CAAD, I-28100 Novara, Italy; [Dianzani, Umberto] Univ Piemonte Orientale, AOU Maggiore della Carita, Dipartimento Sci Salute, Lab Biochim Clin, Corso Mazzini 18, I-28100 Novara, Italy		Dianzani, U (通讯作者)，Univ Piemonte Orientale, Interdisciplinary Res Ctr Autoimmune Dis IRCAD, Dipartimento Sci Salute, I-28100 Novara, Italy.; Dianzani, U (通讯作者)，Univ Piemonte Orientale, AOU Maggiore della Carita, Dipartimento Sci Salute, Lab Biochim Clin, Corso Mazzini 18, I-28100 Novara, Italy.	giuseppe.cappellano@med.uniupo.it; hugo.abreu@uniupo.it; chiara.casale@uniupo.it; umberto.dianzani@med.uniupo.it; annalisa.chiocchetti@med.uniupo.it		Cappellano, Giuseppe/0000-0001-5193-4688; de Sousa Abreu, Hugo Miguel/0000-0003-4720-6519; Chiocchetti, Annalisa/0000-0002-4349-1087	Fondazione Italiana Sclerosi MultiplaFondazione Italiana Sclerosi Multipla (FISM) [2020/PR-Single/021]; Italian Ministry of Education, University and Research (MIUR)Ministry of Education, Universities and Research (MIUR); Fondazione CariploFondazione Cariplo [2017-0535, 2019-3277]; European UnionEuropean Commission [953121]; Associazione Italiana Ricerca sul Cancro, MilanoFondazione AIRC per la ricerca sul cancro [IG 20714]	This research was funded by Fondazione Italiana Sclerosi Multipla (2020/PR-Single/021 (to GC); Italian Ministry of Education, University and Research (MIUR) program "Departments of Excellence 2018-2022", FOHN (to AC); Fondazione Cariplo 2017-0535 (to UD) and 2019-3277 (to AC); European Union's Horizon 2020 Research and Innovation Program under Grant Agreement No.953121-project FLAMIN-GO; Associazione Italiana Ricerca sul Cancro-IG 20714, Milano (to UD).	Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615; Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102; Allahyari M, 2016, HUM VACC IMMUNOTHER, V12, P806, DOI 10.1080/21645515.2015.1102804; Anticoli S, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700443; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barberis E, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.632290; Beissert T, 2020, MOL THER, V28, P119, DOI 10.1016/j.ymthe.2019.09.009; Benne N, 2018, J CONTROL RELEASE, V291, P135, DOI 10.1016/j.jconrel.2018.10.028; Berche P, 2012, CLIN MICROBIOL INFEC, V18, P1, DOI 10.1111/j.1469-0691.2012.03945.x; Birge RB, 2016, CELL DEATH DIFFER, V23, P962, DOI 10.1038/cdd.2016.11; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Bohn MK, 2020, PHYSIOLOGY, V35, P288, DOI 10.1152/physiol.00019.2020; Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017; Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014; Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012; Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2; Cappellano G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010085; Cappellano G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010204; Cappellano G, 2014, VACCINE, V32, P5681, DOI 10.1016/j.vaccine.2014.08.016; Capurso Noah A, 2010, Self Nonself, V1, P335, DOI 10.4161/self.1.4.13946; Centers for Disease Control and Prevention, 2020, PROC ASS MOD, P1; Chong CSW, 2005, J CONTROL RELEASE, V102, P85, DOI 10.1016/j.jconrel.2004.09.014; Cui FD, 2007, J PHARM SCI-US, V96, P421, DOI 10.1002/jps.20750; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Di Bonito P, 2017, INT J NANOMED, V12, P4579, DOI 10.2147/IJN.S131309; DIMITRIADIS GJ, 1978, NATURE, V274, P923, DOI 10.1038/274923a0; Dong LB, 2012, VACCINE, V30, P254, DOI 10.1016/j.vaccine.2011.10.103; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Elmowafy Enas M., 2019, Journal of Pharmaceutical Investigation, V49, P347, DOI 10.1007/s40005-019-00439-x; Erasmus JH, 2020, MOL THER-METH CLIN D, V18, P402, DOI 10.1016/j.omtm.2020.06.011; Filskov J, 2017, J VIROL, V91, DOI 10.1128/JVI.00130-17; Foged C, 2012, EUR J PHARM SCI, V45, P482, DOI 10.1016/j.ejps.2011.08.016; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Frezard F, 1999, BRAZ J MED BIOL RES, V32, P181, DOI 10.1590/S0100-879X1999000200006; Ghimire TR, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0972-0; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Glenny AT, 1931, J PATHOL BACTERIOL, V34, P267, DOI 10.1002/path.1700340214; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; Guevara ML, 2019, CURR PHARM DESIGN, V25, P1443, DOI 10.2174/1381612825666190619150221; Hasegawa H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00350; He XW, 2005, J GEN VIROL, V86, P601, DOI 10.1099/vir.0.80575-0; He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Higaki M, 2005, ANN RHEUM DIS, V64, P1132, DOI 10.1136/ard.2004.030759; Houston R, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.4689; Huang SS, 2013, INT J NANOMED, V8, P3161, DOI 10.2147/IJN.S49972; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jesus S, 2018, EUR J PHARM BIOPHARM, V133, P1, DOI 10.1016/j.ejpb.2018.09.029; Joshi SS, 2016, VIRAL IMMUNOL, V29, P350, DOI 10.1089/vim.2016.0024; Kabiri M, 2018, EUR J PHARM BIOPHARM, V133, P321, DOI 10.1016/j.ejpb.2018.11.003; Kawakita A, 2012, ALLERGY, V67, P371, DOI 10.1111/j.1398-9995.2011.02777.x; Keijzer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026684; Kenison JE, 2020, P NATL ACAD SCI USA, V117, P32017, DOI 10.1073/pnas.2016451117; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Ko EJ, 2018, HUM VACC IMMUNOTHER, V14, P3041, DOI 10.1080/21645515.2018.1495301; Kogut MH, 2020, POULTRY SCI, V99, P1906, DOI 10.1016/j.psj.2019.12.011; Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775; Ledwith BJ, 2000, INTERVIROLOGY, V43, P258, DOI 10.1159/000053993; Li PY, 2021, J CONTROL RELEASE, V331, P164, DOI 10.1016/j.jconrel.2021.01.013; Li Y, 2011, J GENE MED, V13, P60, DOI 10.1002/jgm.1536; Liu J, 2014, J MED VIROL, V86, P886, DOI 10.1002/jmv.23768; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Loomis RJ, 2015, VACCINES-BASEL, V3, P429, DOI 10.3390/vaccines3020429; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Lyons DM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080407; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Martins P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26508-z; Metz SW, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006793; Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mok DZL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050520; Monslow MA, 2020, VACCINE, V38, P5793, DOI 10.1016/j.vaccine.2020.06.062; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049; Nojszewska M, 2021, NEUROL NEUROCHIR POL, V55, P8, DOI 10.5603/PJNNS.a2021.0016; Ohno S, 2009, VACCINE, V27, P3912, DOI 10.1016/j.vaccine.2009.04.001; Okoye IS, 2014, IMMUNITY, V41, P89, DOI [10.1016/j.immuni.2014.05.019, 10.1016/j.immuni.2014.08.008]; Owen JA., 2013, KUBY IMMUNOLOGY; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Park K, 2019, J CONTROL RELEASE, V304, P125, DOI 10.1016/j.jconrel.2019.05.003; Park WH, 1932, AM J PUBLIC HEALTH N, V22, P7, DOI 10.2105/AJPH.22.1.7; Pascolo Steve, 2008, V183, P221; Peng J, 2015, TUMOR BIOL, V36, P8545, DOI 10.1007/s13277-015-3600-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Polak K., 2020, EXTRACELLULAR VESICL, DOI 10.1101/2020.10.28.357137; Pradeu T, 2018, IMMUNOL REV, V283, P7, DOI 10.1111/imr.12652; Pujol-Autonell I, 2017, NANOMEDICINE-UK, V12, P1231, DOI 10.2217/nnm-2016-0410; Pujol-Autonell I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127057; Qiao CM, 2016, BIOMATERIALS, V85, P1, DOI 10.1016/j.biomaterials.2016.01.054; Qiu YQ, 2016, DRUG DELIV, V23, P2391, DOI 10.3109/10717544.2014.992497; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Robba C, 2020, EXPERT REV RESP MED, V14, P865, DOI 10.1080/17476348.2020.1778470; Robinson HL, 2000, ADV VIRUS RES, V55, P1, DOI 10.1016/S0065-3527(00)55001-5; Rodriguez AE, 2013, VET J, V196, P550, DOI 10.1016/j.tvjl.2012.10.036; Rojas C, 2020, J LEUKOCYTE BIOL, V108, P813, DOI 10.1002/JLB.3MR0420-533RR; Roopngam P, 2016, INT J NANOMED, V11, P5361, DOI 10.2147/IJN.S109081; Rosenkrands I, 2011, VACCINE, V29, P6283, DOI 10.1016/j.vaccine.2011.06.040; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; Sabanovic B, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10020094; Senchi K, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00346; Seth A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117203; Sharifnia Z, 2019, IRAN J PHARM RES, V18, P1659, DOI 10.22037/ijpr.2019.1100872; Sheets RL, 2006, TOXICOL SCI, V91, P610, DOI 10.1093/toxsci/kfj169; Smyth LA, 2013, EUR J IMMUNOL, V43, P2430, DOI 10.1002/eji.201242909; Sun BB, 2013, SMALL, V9, P1595, DOI 10.1002/smll.201201962; Syomin BV, 2019, MOL BIOL+, V53, P323, DOI 10.1134/S0026893319030154; Takagi A, 2013, BIOCHEM BIOPH RES CO, V430, P183, DOI 10.1016/j.bbrc.2012.11.028; Tamura T, 2005, LARYNGOSCOPE, V115, P2000, DOI 10.1097/01.mlg.0000180174.81036.5a; Tanaka Y, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0015225, 10.1371/journal.pone.0015091]; Thomas C, 2009, INT J PHARMACEUT, V379, P41, DOI 10.1016/j.ijpharm.2009.06.006; Tregoning JS, 2020, CLIN EXP IMMUNOL, V202, P162, DOI 10.1111/cei.13517; Tukhvatulin A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030519; Vives-Pi M, 2015, APOPTOSIS, V20, P263, DOI 10.1007/s10495-015-1090-8; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Waheed AA, 2012, AIDS RES HUM RETROV, V28, P54, DOI [10.1089/aid.2011.0230, 10.1089/AID.2011.0230]; Waldmann H, 2006, IMMUNOL REV, V212, P301, DOI 10.1111/j.0105-2896.2006.00406.x; Walker JD, 2009, J IMMUNOL, V182, P1548, DOI 10.4049/jimmunol.182.3.1548; Willis NJ, 1997, SCOT MED J, V42, P118, DOI 10.1177/003693309704200407; World Health Organization, DRAFT LANDSC COVID 1; World Health Organization, 2013, VACC SAF BAS LEARN M, P38; Worzner K, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103197; Wui SR, 2019, VACCINE, V37, P2131, DOI 10.1016/j.vaccine.2019.02.048; Yang HW, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600750; Zeng Chunxi, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_217; Zhang WF, 2015, PHARM RES-DORDR, V32, P2837, DOI 10.1007/s11095-015-1666-6; Zhao XY, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110237; Zhou XF, 2008, EUR J PHARM BIOPHARM, V68, P589, DOI 10.1016/j.ejpb.2007.09.006; Zhu JH, 2019, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-019-1526-5; Zhu P, 2007, CLIN IMMUNOL, V122, P75, DOI 10.1016/j.clim.2006.08.004	135	6	6	17	32	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							606	10.3390/vaccines9060606			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4VW	34198865	Green Published			2022-04-29	WOS:000665888700001
J	Pippa, N; Gazouli, M; Pispas, S				Pippa, Natassa; Gazouli, Maria; Pispas, Stergios			Recent Advances and Future Perspectives in Polymer-Based Nanovaccines	VACCINES			English	Review						polymers; biodegradable polymers; poly(lactic-co-glycolic acid) (PLGA); nanoparticles; nanovaccines; adjuvants; antigen-presenting cells (APCs); depot effect; antigens	POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES; ALHAGI HONEY POLYSACCHARIDES; ANTIGEN-DELIVERY-SYSTEM; DENDRITIC CELLS; IMMUNE-RESPONSE; COVID-19 PERSPECTIVES; HYDROGEL PATCH; IN-VITRO; CPG-ODN; VACCINE	Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Novel technologies such as nanoparticulate systems and adjuvants can enable safe and effective vaccines for difficult target populations such as newborns, elderly, and the immune-compromised. More recently, polymer-based particles have found application as vaccine platforms and vaccine adjuvants due to their ability to prevent antigen degradation and clearance, coupled with enhanced uptake by professional antigen-presenting cells (APCs). Polymeric nanoparticles have been applied in vaccine delivery, showing significant adjuvant effects as they can easily be taken up by APCs. In other words, polymer-based systems offer a lot of advantages, including versatility and flexibility in the design process, the ability to incorporate a range of immunomodulators/antigens, mimicking infection in different ways, and acting as a depot, thereby persisting long enough to generate adaptive immune responses. The aim of this review is to summarize the properties, the characteristics, the added value, and the limitations of the polymer-based nanovaccines, as well as the process of their development by the pharmaceutical industry.	[Pippa, Natassa; Pispas, Stergios] Natl Hellen Res Fdn, Theoret & Phys Chem Inst, 48 Vassileos Constantinou Ave, Athens 11635, Greece; [Pippa, Natassa] Natl & Kapodistrian Univ Athens, Dept Pharmaceut Technol, Fac Pharm, Athens 15771, Greece; [Gazouli, Maria] Kapodistrian Univ Athens, Sch Med Natl, Dept Basic Med Sci, Lab Biol, Athens 11527, Greece; [Gazouli, Maria] Natl & Kapodistrian Univ Athens, Univ Gen Hosp Attikon, Sch Med, Dept Radiol, Athens 11527, Greece		Pispas, S (通讯作者)，Natl Hellen Res Fdn, Theoret & Phys Chem Inst, 48 Vassileos Constantinou Ave, Athens 11635, Greece.	natpippa@pharm.uoa.gr; mgazouli@med.uoa.gr; pispas@eie.gr	Gazouli, Maria/I-2572-2018	Gazouli, Maria/0000-0002-3295-6811			Aikins ME, 2020, ACCOUNTS CHEM RES, V53, P2094, DOI 10.1021/acs.accounts.0c00456; Al-Halifa S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00022; Bernocchi B, 2017, INT J PHARMACEUT, V530, P128, DOI 10.1016/j.ijpharm.2017.07.012; Bhardwaj P, 2020, ACTA BIOMATER, V108, P1, DOI 10.1016/j.actbio.2020.03.020; Borges O, 2008, EUR J PHARM BIOPHARM, V69, P405, DOI 10.1016/j.ejpb.2008.01.019; Borges O, 2008, INT IMMUNOPHARMACOL, V8, P1773, DOI 10.1016/j.intimp.2008.08.013; Campos EVR, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00685-4; Chakravarty M, 2021, DRUG DELIV TRANSL RE, V11, P748, DOI 10.1007/s13346-020-00818-0; Cruz LJ, 2011, BIOMATERIALS, V32, P6791, DOI 10.1016/j.biomaterials.2011.04.082; de Queiroz NMGP, 2020, MICROBES INFECT, V22, P515, DOI 10.1016/j.micinf.2020.09.004; De Temmerman ML, 2012, J CONTROL RELEASE, V158, P233, DOI 10.1016/j.jconrel.2011.10.029; Demoulins T, 2014, NANOMED-NANOTECHNOL, V10, P1739, DOI 10.1016/j.nano.2014.06.003; Demoulins T, 2013, NANOMED-NANOTECHNOL, V9, P806, DOI 10.1016/j.nano.2013.01.002; Diwan M, 2002, J CONTROL RELEASE, V85, P247, DOI 10.1016/S0168-3659(02)00275-4; Duncan R, 2017, J DRUG TARGET, V25, P759, DOI 10.1080/1061186X.2017.1358729; Dykman LA, 2020, EXPERT REV VACCINES, V19, P465, DOI 10.1080/14760584.2020.1758070; Feng GZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061135; Flanary S, 2009, BIOCONJUGATE CHEM, V20, P241, DOI 10.1021/bc800317a; Foster S, 2010, BIOCONJUGATE CHEM, V21, P2205, DOI 10.1021/bc100204m; Glaffig M, 2014, CHEM-EUR J, V20, P4232, DOI 10.1002/chem.201400256; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Gu PF, 2019, MOL PHARMACEUT, V16, P5000, DOI 10.1021/acs.molpharmaceut.9b00860; Gu PF, 2019, CARBOHYD POLYM, V223, DOI 10.1016/j.carbpol.2019.115128; Gu PF, 2019, INT J PHARMACEUT, V554, P72, DOI 10.1016/j.ijpharm.2018.11.008; Gupta NK, 2011, VACCINE, V29, P9026, DOI 10.1016/j.vaccine.2011.09.033; Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021; Han JY, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10010031; Han RL, 2011, J BIOMED MATER RES A, V96A, P142, DOI 10.1002/jbm.a.32860; Hasegawa K, 2006, CLIN CANCER RES, V12, P1921, DOI 10.1158/1078-0432.CCR-05-1900; Heo MB, 2014, ACTA BIOMATER, V10, P2169, DOI 10.1016/j.actbio.2013.12.050; Hirobe S, 2012, VACCINE, V30, P1847, DOI 10.1016/j.vaccine.2011.12.130; Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003; Jiang X, 2021, MATER TODAY ADV, V10, DOI 10.1016/j.mtadv.2021.100140; Kasturi SP, 2017, J VIROL, V91, DOI 10.1128/JVI.01844-16; Keller S, 2014, J CONTROL RELEASE, V191, P24, DOI 10.1016/j.jconrel.2014.03.041; Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042; Koerner J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00707; Li L, 2020, ACCOUNTS CHEM RES, V53, P2044, DOI 10.1021/acs.accounts.0c00334; Li P, 2013, J CONTROL RELEASE, V168, P271, DOI 10.1016/j.jconrel.2013.03.025; Lima VMF, 2001, INFECT IMMUN, V69, P5305, DOI 10.1128/IAI.69.9.5305-5312.2001; Liu Q, 2015, ACS NANO, V9, P4925, DOI 10.1021/nn5066793; Liu Y, 2020, THERANOSTICS, V10, P3099, DOI 10.7150/thno.42998; Luo ZC, 2015, COLLOID SURFACE B, V135, P556, DOI 10.1016/j.colsurfb.2015.07.079; Luo ZC, 2013, J CONTROL RELEASE, V170, P259, DOI 10.1016/j.jconrel.2013.05.027; Manish M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061885; Matsuo K, 2011, J CONTROL RELEASE, V149, P15, DOI 10.1016/j.jconrel.2010.05.012; Patel P, 2017, CURR CLIN PHARMACOL, V12, P73, DOI 10.2174/1574884712666170509161252; Perrie Y, 2013, HUM VACC IMMUNOTHER, V9, P1374, DOI 10.4161/hv.24694; Prego C, 2010, VACCINE, V28, P2607, DOI 10.1016/j.vaccine.2010.01.011; Rauta PR, 2015, FISH SHELLFISH IMMUN, V44, P287, DOI 10.1016/j.fsi.2015.02.007; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Rietscher R, 2016, EUR J PHARM BIOPHARM, V102, P20, DOI 10.1016/j.ejpb.2016.02.014; Roman BS, 2008, EUR J PHARM BIOPHARM, V70, P98, DOI 10.1016/j.ejpb.2008.03.015; Saade F, 2013, VACCINE, V31, P1999, DOI 10.1016/j.vaccine.2012.12.077; Sah H, 2013, INT J NANOMED, V8, P747, DOI 10.2147/IJN.S40579; Santos Diego M, 2012, Int J Nanomedicine, V7, P2115, DOI 10.2147/IJN.S30093; Sarti F, 2011, BIOMATERIALS, V32, P4052, DOI 10.1016/j.biomaterials.2011.02.011; Shen YB, 2018, MEDCHEMCOMM, V9, P226, DOI 10.1039/c7md00158d; Shima F, 2015, BIOCONJUGATE CHEM, V26, P890, DOI 10.1021/acs.bioconjchem.5b00106; Shima F, 2013, ACTA BIOMATER, V9, P8894, DOI 10.1016/j.actbio.2013.06.010; Shima F, 2013, BIOMATERIALS, V34, P9709, DOI 10.1016/j.biomaterials.2013.08.064; Siegrist S, 2019, NANOTOXICOLOGY, V13, P73, DOI 10.1080/17435390.2018.1505000; Silva AL, 2016, HUM VACC IMMUNOTHER, V12, P1056, DOI 10.1080/21645515.2015.1117714; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; Slutter B, 2010, VACCINE, V28, P6282, DOI 10.1016/j.vaccine.2010.06.121; Song C, 2016, INT J NANOMED, V11, P3753, DOI 10.2147/IJN.S110796; Stojanowski Jakub, 2020, Polim Med, V50, P75, DOI 10.17219/pim/131644; Swierczewska M, 2018, METHODS MOL BIOL, V1682, P3, DOI 10.1007/978-1-4939-7352-1_1; Thomann-Harwood LJ, 2013, J CONTROL RELEASE, V166, P95, DOI 10.1016/j.jconrel.2012.11.015; Thomas C, 2011, MOL PHARMACEUT, V8, P405, DOI 10.1021/mp100255c; Trimaille T, 2019, EUR J PHARM BIOPHARM, V142, P232, DOI 10.1016/j.ejpb.2019.06.022; Trimaille T, 2015, VACCINES, V3, P803, DOI 10.3390/vaccines3040803; Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979; Uto T, 2011, IMMUNOL LETT, V140, P36, DOI 10.1016/j.imlet.2011.06.002; Uto T, 2011, BIOMATERIALS, V32, P5206, DOI 10.1016/j.biomaterials.2011.03.052; Uto T, 2009, IMMUNOL LETT, V125, P46, DOI 10.1016/j.imlet.2009.05.008; van der Weken H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010001; Vijayan V, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100534; Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029; Wibowo D, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120597; Wilson JT, 2013, ACS NANO, V7, P3912, DOI 10.1021/nn305466z; Wusiman A, 2019, INT J NANOMED, V14, P3221, DOI 10.2147/IJN.S203072; Wusiman A, 2019, INT J BIOL MACROMOL, V134, P730, DOI 10.1016/j.ijbiomac.2019.05.038; Wusiman A, 2019, CARBOHYD POLYM, V211, P217, DOI 10.1016/j.carbpol.2019.01.102; Xia YF, 2020, ACCOUNTS CHEM RES, V53, P2068, DOI 10.1021/acs.accounts.0c00336; Yan YF, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10081613; Yun CH, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050418; Zhang CN, 2017, J CONTROL RELEASE, V256, P170, DOI 10.1016/j.jconrel.2017.04.020; Zhang Y, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1559; Zheng SS, 2018, INT J NANOMED, V13, P569, DOI 10.2147/IJN.S153567; Zheng SS, 2016, INT J NANOMED, V11, P4891, DOI 10.2147/IJN.S115742; Zhou JR, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101031	92	9	9	13	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							558	10.3390/vaccines9060558			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6ZU	34073648	gold, Green Published			2022-04-29	WOS:000666034400001
J	Puro, V; Castilletti, C; Agrati, C; Goletti, D; Leone, S; Agresta, A; Cimini, E; Tartaglia, E; Casetti, R; Colavita, F; Meschi, S; Matusali, G; Lapa, D; Fard, SN; Aiello, A; Farrone, C; Galli, P; Capobianchi, MR; Ippolito, G				Puro, Vincenzo; Castilletti, Concetta; Agrati, Chiara; Goletti, Delia; Leone, Sara; Agresta, Alessandro; Cimini, Eleonora; Tartaglia, Eleonora; Casetti, Rita; Colavita, Francesca; Meschi, Silvia; Matusali, Giulia; Lapa, Daniele; Najafi Fard, Saeid; Aiello, Alessandra; Farrone, Chiara; Galli, Paola; Capobianchi, Maria Rosaria; Ippolito, Giuseppe		INMI COVID 19 Vaccine Study Grp	Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination	VACCINES			English	Article						influenza; pneumoccocus; COVID-19; SARS-CoV-2; vaccine; immune response		Vaccination against SARS-CoV-2 is considered the most effective method of prevention to contain the pandemic. While highly effective SARS-CoV-2 vaccines are being applied on a large-scale, whether and to what extent the strength of the vaccine-induced immune response could be further potentiated is still an object of debate. Several reports studied the effect of different vaccines on the susceptibility and mortality of COVID-19, with conflicting results. We aimed to evaluate whether previous influenza and/or pneumococcal vaccination had an impact on the specific immune response to the SARS-CoV-2 BNT162b2 mRNA vaccine. The study population consists of 710 workers from our Institute who completed the BNT162b2 schedule and have been tested at least once after the second dose, from 27 December 2020 up to 15 April 2021. Of these, 152 (21.4%) had received an influenza and 215 (30.3%) a concomitant influenza and pneumococcal vaccination, a median of 102 days before the second dose of BNT162b2. Overall, 100% of workers were tested for anti-Spike receptor-binding domain (anti-S/RBD) antibodies, 224 workers for neutralization titer (Micro-neutralization assay, MNA), and 155 workers for a spike-specific T cell interferon-gamma response (IFN-gamma). The levels of anti-S/RBD, MNA and IFN-gamma were evaluated and compared according to sex, age, involvement in direct care of COVID-19 patients, and previous influenza/pneumococcal vaccination. At the univariate analysis, no statistically significant association was observed with regard to a previous influenza and pneumococcal vaccination. A significant lower anti-S/RBD response was observed according to an older age and male sex, while MNA titers were significantly associated to sex but not to age. At the multivariable analysis, workers receiving a concomitant influenza and pneumococcal vaccination or only influenza showed a 58% (p 0.01) and 42% (p 0.07) increase in MNA titers, respectively, compared to those who did not receive an influenza/pneumococcal vaccination. Female workers showed an 81% MNA and a 44% anti-S/RBD increase compared to male workers (p < 0.001). Compared to workers aged 21 to 49 years, those aged 50 or older were associated with a reduction in the anti-S/RBD (16%; p 0.005), MNA (31%; p 0.019), and IFN.g (32%) immune response. Maintaining the influenza and pneumococcal immunization program for the coming season, in which COVID-19 could still be spreading, remains strongly recommended to protect those who are more vulnerable and to limit the potential burden of these infections on the healthcare system.	[Puro, Vincenzo; Castilletti, Concetta; Agrati, Chiara; Goletti, Delia; Leone, Sara; Agresta, Alessandro; Cimini, Eleonora; Tartaglia, Eleonora; Casetti, Rita; Colavita, Francesca; Meschi, Silvia; Matusali, Giulia; Lapa, Daniele; Najafi Fard, Saeid; Aiello, Alessandra; Farrone, Chiara; Galli, Paola; Capobianchi, Maria Rosaria; Ippolito, Giuseppe; INMI COVID 19 Vaccine Study Grp] Natl Inst Infect Dis Lazzaro Spallanzani, I-00149 Rome, Italy		Puro, V (通讯作者)，Natl Inst Infect Dis Lazzaro Spallanzani, I-00149 Rome, Italy.	vincenzo.puro@inmi.it; concetta.castilletti@inmi.it; chiara.agrati@inmi.it; delia.goletti@inmi.it; sara.leone@inmi.it; alessandro.agresta@inmi.it; eleonora.cimini@inmi.it; eleonora.tartaglia@inmi.it; rita.casetti@inmi.it; francesca.colavita@inmi.it; silvia.meschi@inmi.it; giulia.matusali@inmi.it; daniele.lapa@inmi.it; saeid.najafi@inmi.it; alessandra.aiello@inmi.it; chiara.farroni@inmi.it; paola.galli@inmi.it; maria.capobianchi@inmi.it; giuseppe.ippolito@inmi.it	Tartaglia, Eleonora/AAD-1937-2020; Najafi Fard, Saeid/AAC-3571-2022; Aiello, Alessandra/AAC-1244-2022; Colavita, Francesca/I-8848-2018	Tartaglia, Eleonora/0000-0001-5773-7781; Najafi Fard, Saeid/0000-0001-9957-8934; Aiello, Alessandra/0000-0003-2681-9383; Colavita, Francesca/0000-0003-0640-8667; Goletti, Delia/0000-0001-8360-4376	Italian Ministry of Health (Ricerca Corrente, Linea 1); Istituto Nazionale Assicurazione Infortuni Lavoro (INAIL, Bando BRIC)	This work was supported by the Italian Ministry of Health (Ricerca Corrente, Linea 1) and by the Istituto Nazionale Assicurazione Infortuni Lavoro (INAIL, Bando BRIC).	Brueggemann AB, 2021, LANCET DIGIT HEALTH, V3, pE360, DOI 10.1016/S2589-7500(21)00077-7; Candelli M, 2021, INTERN EMERG MED, V16, P1849, DOI 10.1007/s11739-021-02702-2; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Howard LM, 2021, CLIN INFECT DIS, V72, pE76, DOI 10.1093/cid/ciaa1812; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332; Lewnard JA, 2021, J INFECT DIS, DOI 10.1093/infdis/jiab128; Mantovani A, 2020, NEW ENGL J MED, V383, P1078, DOI 10.1056/NEJMcibr2011679; Matusali G, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040655; McCartney PR, 2020, JOGNN-J OBST GYN NEO, V49, P405, DOI 10.1016/j.jogn.2020.08.001; Messina NL, 2019, CLIN MICROBIOL INFEC, V25, P1484, DOI 10.1016/j.cmi.2019.02.016; Nachega JB, 2021, INT J INFECT DIS, V113, pS78, DOI 10.1016/j.ijid.2021.03.060; Olsen SJ, 2020, AM J TRANSPLANT, V20, P3681, DOI 10.1111/ajt.16381; Pawlowski C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83641-y; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; WHO, SAGE SEAS INFL VACC; Wilcox C.R., 2021, BMJ OPEN RESP RES, V8, DOI [10.1136/bmjresp-2020-000857, DOI 10.1136/BMJRESP-2020-000857]; Zanettini C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050427	21	7	7	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							615	10.3390/vaccines9060615			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4XJ	34201065	gold, Green Published			2022-04-29	WOS:000665892600001
J	Johannessen, A; Mekasha, B; Desalegn, H; Aberra, H; Stene-Johansen, K; Berhe, N				Johannessen, Asgeir; Mekasha, Bitsatab; Desalegn, Hailemichael; Aberra, Hanna; Stene-Johansen, Kathrine; Berhe, Nega			Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia	VACCINES			English	Article						viral hepatitis; resource-limited settings; Africa; transmission; pregnancy; pediatric	SUB-SAHARAN AFRICA; VIRAL-HEPATITIS; E-ANTIGEN; INFECTION; INFANT; ELIMINATION; VACCINATION; PREVALENCE; PREVENTION; WOMEN	High viral load and positive hepatitis B e-antigen (HBeAg) results are risk factors for mother-to-child transmission (MTCT) of hepatitis B virus (HBV). In sub-Saharan Africa, little is known about the distribution of these risk factors, as well as early childhood HBV transmission. In this study, Ethiopian women aged 18-45 years with chronic hepatitis B were assessed for the presence of HBeAg and high viral load. Their children below 4 years of age were invited for assessment of viral markers, defining active HBV infection as a positive hepatitis B s-antigen (HBsAg) and/or detectable HBV DNA. In total, 61 of 428 HBV-infected women (14.3%) had a positive HBeAg result and/or a high viral load. Of note, 26 of 49 women (53.1%) with viral load above 200,000 IU/mL were HBeAg negative. Among 89 children born of HBV-infected mothers (median age 20 months), 9 (10.1%) had evidence of active HBV infection. In conclusion, one in seven women with chronic hepatitis B had risk factors for MTCT, and HBeAg was a poor predictor of high viral load. One in ten children born of HBV-infected women acquired HBV-infection despite completing their scheduled HBV vaccination at 6, 10 and 14 weeks of age.	[Johannessen, Asgeir] Vestfold Hosp Trust, Dept Infect Dis, N-3103 Tonsberg, Norway; [Johannessen, Asgeir] Univ Oslo, Inst Clin Med, Fac Med, N-0315 Oslo, Norway; [Johannessen, Asgeir; Berhe, Nega] Oslo Univ Hosp, Reg Ctr Imported & Trop Dis, N-0424 Oslo, Norway; [Mekasha, Bitsatab; Desalegn, Hailemichael; Aberra, Hanna] St Pauls Hosp Millennium Med Coll, Dept Med, Addis Ababa 1230, Ethiopia; [Stene-Johansen, Kathrine] Norwegian Inst Publ Hlth, Dept Virol, N-0456 Oslo, Norway; [Berhe, Nega] Univ Addis Ababa, Aklilu Lemma Inst Pathobiol, Addis Ababa 1230, Ethiopia		Johannessen, A (通讯作者)，Vestfold Hosp Trust, Dept Infect Dis, N-3103 Tonsberg, Norway.; Johannessen, A (通讯作者)，Univ Oslo, Inst Clin Med, Fac Med, N-0315 Oslo, Norway.; Johannessen, A (通讯作者)，Oslo Univ Hosp, Reg Ctr Imported & Trop Dis, N-0424 Oslo, Norway.	uxasoh@siv.no; bitsatabm@gmail.com; hailemichael.desalegn@sphmmc.edu.et; hanna.aberra@aau.edu.et; Kathrine.Stene-Johansen@fhi.no; nega.berhe@aau.edu.et		Mekonnen, Hailemichael Desalegn/0000-0003-2042-5797	Norwegian Research CouncilResearch Council of NorwayEuropean Commission [220622/H10]; South-Eastern Norway Regional Health Authority [2011068]	This research was funded by The Norwegian Research Council, grant number 220622/H10, and the South-Eastern Norway Regional Health Authority, grant number 2011068.	Aberra H, 2019, J HEPATOL, V70, P1065, DOI 10.1016/j.jhep.2019.01.037; Aberra H, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2549-8; Andersson MI, 2013, VACCINE, V31, P5579, DOI 10.1016/j.vaccine.2013.08.028; BEASLEY RP, 1983, LANCET, V2, P1099; Boucheron P, 2021, LANCET INFECT DIS, V21, P85, DOI 10.1016/S1473-3099(20)30593-4; Chakvetadze C, 2011, VACCINE, V29, P2846, DOI 10.1016/j.vaccine.2011.01.101; Desalegn H, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-0993-1; Desalegn H, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1229-x; Doganci T, 2005, WORLD J GASTROENTERO, V11, P418, DOI 10.3748/wjg.v11.i3.418; Ducancelle A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080346; Ekouevi DK, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05574-7; Faustini A, 2001, VACCINE, V19, P2812, DOI 10.1016/S0264-410X(01)00005-6; Funk AL, 2021, LANCET INFECT DIS, V21, P70, DOI 10.1016/S1473-3099(20)30586-7; Hadziyannis SJ, 2011, J HEPATOL, V55, P183, DOI 10.1016/j.jhep.2010.12.030; Howell J, 2014, J VIRAL HEPATITIS, V21, P381, DOI 10.1111/jvh.12263; Indolfi G, 2019, LANCET GASTROENTEROL, V4, P466, DOI 10.1016/S2468-1253(19)30042-1; Keane E, 2016, ALIMENT PHARM THER, V44, P1005, DOI 10.1111/apt.13795; Liu CP, 2015, INTERNAL MED, V54, P711, DOI 10.2169/internalmedicine.54.3514; Mendy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058029; Metodi J, 2010, ANN TROP PAEDIATR, V30, P129, DOI 10.1179/146532810X12703902516167; Nayagam S, 2016, LANCET INFECT DIS, V16, P1399, DOI 10.1016/S1473-3099(16)30204-3; Ni YH, 2007, GASTROENTEROLOGY, V132, P1287, DOI 10.1053/j.gastro.2007.02.055; Organization WH, 2016, WHO GLOBAL HLTH SECT; Ott JJ, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-131; Pan CQ, 2016, NEW ENGL J MED, V374, P2324, DOI 10.1056/NEJMoa1508660; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Seck A, 2018, AM J TROP MED HYG, V99, P428, DOI 10.4269/ajtmh.18-0116; Shimakawa Y, 2016, GUT, V65, P2007, DOI 10.1136/gutjnl-2015-309892; Smith S, 2019, JHEP REP, V1, P81, DOI 10.1016/j.jhepr.2019.04.002; Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7; Tan MJ, 2021, LANCET GASTROENTEROL, V6, P106, DOI 10.1016/S2468-1253(20)30307-1; Wang JS, 2005, WORLD J GASTROENTERO, V11, P3582, DOI 10.3748/wjg.v11.i23.3582; Weldemariam A.G., 2020, P WORLD SUMM INF DIS; Wen WH, 2013, J HEPATOL, V59, P24, DOI 10.1016/j.jhep.2013.02.015; WHO, 2012, WORLD MALARIA REPORT 2012, P1; World Health Organization, 2015, ACC PROGR HIV TUB MA; World Health Organization, 2015, GUIDELINES PREVENTIO; Zhang L, 2010, INT J INFECT DIS, V14, pE483, DOI 10.1016/j.ijid.2009.08.005; Zou H, 2012, J VIRAL HEPATITIS, V19, pE18, DOI 10.1111/j.1365-2893.2011.01492.x	39	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							430	10.3390/vaccines9050430			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1GH	33925930	gold, Green Published			2022-04-29	WOS:000654574100001
J	Perieres, L; Marcellin, F; Lo, G; Protopopescu, C; Ba, E; Coste, M; Kane, CT; Maradan, G; Diallo, A; Sokhna, C; Boyer, S				Perieres, Lauren; Marcellin, Fabienne; Lo, Gora; Protopopescu, Camelia; Ba, El Hadji; Coste, Marion; Toure Kane, Coumba; Maradan, Gwenaelle; Diallo, Aldiouma; Sokhna, Cheikh; Boyer, Sylvie		ANRS 12356 AmBASS Survey Stud	Hepatitis B Vaccination in Senegalese Children: Coverage, Timeliness, and Sociodemographic Determinants of Non-Adherence to Immunisation Schedules (ANRS 12356 AmBASS Survey)	VACCINES			English	Article						birth dose vaccination; hepatitis B vaccine; pentavalent vaccination; Senegal; vaccination timeliness; vaccination coverage	MIDDLE-INCOME COUNTRIES; HEALTH; ELIMINATION	Detailed knowledge about hepatitis B virus (HBV) vaccination coverage and timeliness for sub-Saharan Africa is scarce. We used data from a community-based cross-sectional survey conducted in 2018-2019 in the area of Niakhar, Senegal, to estimate coverage, timeliness, and factors associated with non-adherence to the World Health Organisation-recommended vaccination schedules in children born in 2016 (year of the birth dose (BD) introduction in Senegal) and 2017-2018. Vaccination status was assessed from vaccination cards, surveillance data, and healthcare post vaccination records. Among 241 children with available data, for 2016 and 2017-2018, respectively, 31.0% and 66.8% received the BD within 24 h of birth (BD schedule), and 24.3% and 53.7% received the BD plus at least two pentavalent vaccine doses within the recommended timeframes (three-dose schedule). In logistic regression models, home birth, dry season birth, and birth in 2016 were all associated with non-adherence to the recommended BD and three-dose schedules. Living over three kilometres from the nearest healthcare post, being the firstborn, and living in an agriculturally poorer household were only associated with non-adherence to the three-dose schedule. The substantial proportion of children not vaccinated according to recommended schedules highlights the importance of considering vaccination timeliness when evaluating vaccination programme effectiveness. Outreach vaccination activities and incentives to bring children born at home to healthcare facilities within 24 h of birth, must be strengthened to improve timely HBV vaccination.	[Perieres, Lauren; Ba, El Hadji; Diallo, Aldiouma] VITROME, Campus IRD UCAD, Dakar 18524, Senegal; [Marcellin, Fabienne; Protopopescu, Camelia; Coste, Marion; Maradan, Gwenaelle; Boyer, Sylvie] Aix Marseille Univ, Sci Econ & Sociales Sante & Traitement Informat M, INSERM, IRD,SESSTIM, F-13385 Marseille, France; [Lo, Gora; Toure Kane, Coumba] Inst Rech Sante Surveillance Epidemiol & Format, BP 7325, Diamniadio, Senegal; [Coste, Marion] Aix Marseille Univ, CNRS, Cent Marseille, EHESS,AMSE, F-13001 Marseille, France; [Maradan, Gwenaelle] Observ Reg Sante Provence Alpes Cote dAzur, ORS PACA, F-13385 Marseille, France; [Sokhna, Cheikh] Aix Marseille Univ, IRD, SSA, VITROME, F-13385 Marseille, France		Marcellin, F (通讯作者)，Aix Marseille Univ, Sci Econ & Sociales Sante & Traitement Informat M, INSERM, IRD,SESSTIM, F-13385 Marseille, France.	lauren.perieres@etu.univ-amu.fr; fabienne.marcellin@inserm.fr; gora.lo@iressef.org; camelia.protopopescu@inserm.fr; el-hadj.ba@ird.fr; marion.coste@inserm.fr; coumba.toure@ucad.edu.sn; gwenaelle.maradan@inserm.fr; aldiouma.diallo@ird.fr; cheikh.sokhna@ird.fr; sylvie.boyer@inserm.fr		Perieres, Lauren/0000-0001-8895-5909; Protopopescu, Camelia/0000-0003-0164-7917; Coste, Marion/0000-0001-9005-240X; Marcellin, Fabienne/0000-0001-8853-3829	French National Agency for AIDS and Viral Hepatitis Research (ANRS) under French National Institute for Health and Medical Research (INSERM) (INSEMR-ANRS) [12356]	The AmBASS research project was funded in full by the French National Agency for AIDS and Viral Hepatitis Research (ANRS) under the auspices of the French National Institute for Health and Medical Research (INSERM) (INSEMR-ANRS), grant number 12356.	Adetifa IMO, 2018, VACCINE, V36, P7965, DOI 10.1016/j.vaccine.2018.11.005; Agence Nationale de la Statistique et de la Demographie (ANSD) [Senegal], 2019, SEN ENQ DEM SANT CON; Agence Nationale de la Statistique et de la Demographie (ANSD) [Senegal], 2020, SEN ENQ DEM SANT CON; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P369; Bassoum O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020301; Coste M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030211; Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100; Dionne-Odom J, 2018, PEDIATR INFECT DIS J, V37, P103, DOI 10.1097/INF.0000000000001728; Djaogol T, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4416-3; Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313, DOI 10.1017/S0950268800001497; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI 10.1016/s2214-109x(17)30072-4; Gibson DG, 2015, VACCINE, V33, P6778, DOI 10.1016/j.vaccine.2015.10.021; Global Burden of Disease Collaborative Network, 2020, GLOBAL BURDEN DIS ST; Gram L, 2014, TROP MED INT HEALTH, V19, P802, DOI 10.1111/tmi.12324; Guerra Fernando A, 2007, Paediatr Drugs, V9, P143, DOI 10.2165/00148581-200709030-00002; Kroger AT, GEN BEST PRACTICE GU; Marefiaw TA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218470; Martinson FEA, 1998, AM J EPIDEMIOL, V147, P478, DOI 10.1093/oxfordjournals.aje.a009474; Masters NB, 2019, HUM VACC IMMUNOTHER, V15, P2790, DOI 10.1080/21645515.2019.1616503; Mbengue MAS, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4493-3; Miyahara R, 2016, VACCINE, V34, P3335, DOI 10.1016/j.vaccine.2016.05.017; Nayagam S, 2016, LANCET INFECT DIS, V16, P1399, DOI 10.1016/S1473-3099(16)30204-3; Okwaraji YB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-476; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Peretti-Watel P, 2020, HUM VACC IMMUNOTHER, V16, P363, DOI 10.1080/21645515.2019.1649553; Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0; Programme National de Lutte Contre les H?patites, 2019, STRAT PLAN VIR HEP S; Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Sarker AR, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55080480; Schoeps A, 2013, VACCINE, V32, P96, DOI 10.1016/j.vaccine.2013.10.063; Shimakawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069430; Soares-Weisner, OMPITMIZING HEPATITI; Spearman CW, 2017, LANCET GASTROENTEROL, V2, P900, DOI 10.1016/S2468-1253(17)30295-9; UNICEF, 2020, UNICEF SEN WHO UNICE; VANDEVEN WPMM, 1981, J ECONOMETRICS, V17, P229, DOI 10.1016/0304-4076(81)90028-2; Voxco, INS PLATF CHANG; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO, 2016, GLOB HLTH SECT STRAT	40	4	4	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							510	10.3390/vaccines9050510			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3GK	34063390	gold, Green Published			2022-04-29	WOS:000654713400001
J	Dicks, F; Marks, T; Karafillakis, E; Chambers, MA				Dicks, Frederika; Marks, Tatjana; Karafillakis, Emilie; Chambers, Mark A.			Vaccination as a Control Tool in Bovine Tuberculosis: Social Media Monitoring to Assess Public Response to Government Policy Development and Implementation	VACCINES			English	Article						badger; cattle; cull; media monitoring; policy; tuberculosis; vaccination	FAKE NEWS	Vaccine hesitancy does not only concern human vaccines but incorporates One Health policies also; including vaccination of cattle and badgers as part of the government's bovine tuberculosis eradication strategy for England. Both digital and social media can propagate healthcare misinformation and thus affect vaccine policy support. The use of social media monitoring to understand real-time public perceptions of One Health policies is crucial to identify misinformation and address public concerns appropriately to achieve successful policy implementation. Digital and social media data surrounding two government announcements regarding the bovine tuberculosis eradication strategy for England were collected and screened using the Meltwater media monitoring platform. Communication patterns were studied using InfraNodus. Twitter analysis was conducted to identify key influencers, public engagement, and trending communications. Online social media activity increased rapidly after each announcement. Initially, badger culling took primary public concern and major influencers were identified. Cattle vaccination dominated discussion after the second announcement, with public perception being influenced by increased online activity from news sites, animal welfare charities, governmental bodies, and medical professionals. The greatest ambiguity towards the strategy was detected within farming communities, with the main disparity existing between cattle vaccination and badger culling opinions. Social media monitoring has potential use in surveying public perception of government policy, both prior to, and after implementation to identify and address areas of miscommunication and misinformation to improve public support for One Health policies.	[Dicks, Frederika; Chambers, Mark A.] Univ Surrey, Sch Vet Med, VSM Bldg,Daphne Jackson Rd, Guildford GU2 7AL, Surrey, England; [Marks, Tatjana; Karafillakis, Emilie] London Sch Hyg & Trop Med, Vaccine Confidence Project, Keppel St, London WC1E 7HT, England; [Chambers, Mark A.] Univ Surrey, Sch Biosci & Med, Edward Jenner Bldg, Guildford GU2 7XH, Surrey, England		Chambers, MA (通讯作者)，Univ Surrey, Sch Vet Med, VSM Bldg,Daphne Jackson Rd, Guildford GU2 7AL, Surrey, England.; Chambers, MA (通讯作者)，Univ Surrey, Sch Biosci & Med, Edward Jenner Bldg, Guildford GU2 7XH, Surrey, England.	fd00185@surrey.ac.xn; Tatjana.Marks2@student.lshtm.ac.uk; Emilie.Karafillakis@lshtm.ac.uk; m.chambers@surrey.ac.uk	Chambers, Mark/M-6189-2019	Chambers, Mark/0000-0002-8073-8069; Marks, Tatjana/0000-0002-1426-1581			[Anonymous], 2015, PUBLIC TRUSTS VET PR; Brooks-Pollock E, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.0374; Dahlgreen W., 2014, 2 YEARS BADGER CULL; Department for Environment Food and Rural Affairs, 2020, NEXT STEPS STRAT ACH; Dor D, 2003, J PRAGMATICS, V35, P695, DOI 10.1016/S0378-2166(02)00134-0; Eggertson L, 2010, CAN MED ASSOC J, V182, pE199, DOI 10.1503/cmaj.109-3179; European Centre for Disease Prevention and Control, 2020, SYST SCOP REV SOC ME; Godfray C, 2018, BOVINE TB STRATEGY R; GOV.UK, 2014, STRAT ACH OFF BOV TU; Horton H., TELEGRAPH; Jelastopulu E, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-241; Kummervold P., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3548789, DOI 10.2139/SSRN.3548789]; Loeb J, 2019, VET REC, V184, P629, DOI 10.1136/vr.l3113; Martin S, 2020, VACCINE, V38, P6627, DOI 10.1016/j.vaccine.2020.07.072; McCombs Maxwell., 2014, SETTING AGENDA MASS; MCGILL I, 2020, J ARTIC, V187, DOI DOI 10.1136/vr.m3411; Media P.A., BOVINE TB VACCINE TR; Millward Gareth, 2019, VACCINATING BRITAIN; Natural England, BOV TB AUTH BADG CON; Nguyen, 2010, JOURNALISM, V11, P223, DOI [10.1177/1464884909355910, DOI 10.1177/1464884909355910]; Ofcom, 2020, EFF COVID 19 ONL CON; Paranyushkin D, 2019, WEB CONFERENCE 2019: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW 2019), P3584; Pulido CM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072430; Screening & Immunisations Team COVER Team, CHILDH VACC COV STAT; Srinivasan S, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00391; Thornhill C, 2019, FRONT BIG DATA, V2, DOI 10.3389/fdata.2019.00011; Vargo CJ, 2018, NEW MEDIA SOC, V20, P2028, DOI 10.1177/1461444817712086; Waszak PM, 2018, HEALTH POLICY TECHN, V7, P115, DOI 10.1016/j.hlpt.2018.03.002; Whetten K, 2006, AM J PUBLIC HEALTH, V96, P716, DOI 10.2105/AJPH.2005.063255	29	0	0	2	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							314	10.3390/vaccines9040314			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS5PW	33805272	gold, Green Published, Green Accepted			2022-04-29	WOS:000643831900001
J	Killgore, WDS; Cloonan, SA; Taylor, EC; Dailey, NS				Killgore, William D. S.; Cloonan, Sara A.; Taylor, Emily C.; Dailey, Natalie S.			The COVID-19 Vaccine Is Here-Now Who Is Willing to Get It?	VACCINES			English	Article						vaccine hesitancy; COVID-19; political worldview	MECHANICAL TURK; LONELINESS; RESILIENCE; VALIDITY; ANXIETY	The U.S. vaccine campaign against COVID-19 began in December 2020, but many individuals seem reluctant to get vaccinated. During the first week of the vaccination campaign, we collected data from 1017 individuals with an online survey to identify factors that were associated with willingness to get the vaccine once it is available. Most participants (55.3%) were willing to get the vaccine, although 46.2% also expressed some fear of the vaccine. Political ideology was by far the most consistent predictor of both willingness to be vaccinated and fear of the vaccine, followed by participant sex, education level, income, and race/ethnicity. Our findings suggest that, for the vaccine campaign to be broadly supported and successful, it will be important for frontline healthcare workers to discuss the role of inoculation for COVID-19 in a manner consistent with each individual patient's political and sociological worldview.	[Killgore, William D. S.; Cloonan, Sara A.; Taylor, Emily C.; Dailey, Natalie S.] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85724 USA		Killgore, WDS (通讯作者)，Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85724 USA.	killgore@psychiatry.arizona.edu; scloonan@psychiatry.arizona.edu; emilytaylor@psychiatry.arizona.edu; ndailey@psychiatry.arizona.edu		Cloonan, Sara/0000-0001-8221-7737; Killgore, William/0000-0002-5328-0208; Taylor, Emily C/0000-0002-0887-3004			Albarracin D, 2018, ANNU REV PSYCHOL, V69, P299, DOI 10.1146/annurev-psych-122216-011911; Attwell K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245907; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bajaj SS, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMpv2035827; Bartneck C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121595; Bloom BR, 2020, NEW ENGL J MED, V383, P2202, DOI 10.1056/NEJMp2025331; Bunch L, 2021, HEC FORUM, V33, P143, DOI 10.1007/s10730-021-09440-0; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Clifford S, 2015, RES POLITICS, V2, DOI 10.1177/2053168015622072; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Hauser DJ, 2016, BEHAV RES METHODS, V48, P400, DOI 10.3758/s13428-015-0578-z; Heffner J, 2021, PERS INDIV DIFFER, V170, DOI 10.1016/j.paid.2020.110420; Killgore WDS, 2020, PSYCHIAT RES, V294, DOI 10.1016/j.psychres.2020.113551; Killgore WDS, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113392; Killgore WDS, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113390; Killgore WDS, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113216; Killgore William D S, 2020, Psychiatry Res, V290, P113134, DOI 10.1016/j.psychres.2020.113134; Killgore WDS, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113117; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lahijani AY, 2021, SOC SCI MED, V268, DOI 10.1016/j.socscimed.2020.113375; Ledoux JE, 2001, AM J PSYCHIAT, V158, P1953, DOI 10.1176/appi.ajp.158.12.1953; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Litman L, 2017, BEHAV RES METHODS, V49, P433, DOI 10.3758/s13428-016-0727-z; Lyons BA, 2019, PUBLIC UNDERST SCI, V28, P320, DOI 10.1177/0963662518821017; Mortensen K, 2018, J GEN INTERN MED, V33, P533, DOI 10.1007/s11606-017-4246-0; Mortensen K, 2018, MED CARE, V56, P211, DOI 10.1097/MLR.0000000000000871; Nkwihoreze H., 2021, CLIN INFECT DIS, pCIAB102, DOI [10.1093/cid/ciab102, DOI 10.1093/CID/CIAB102]; Prins A, 2004, PRIMARY CARE PSYCHIA, V9, P151, DOI 10.1185/135525703125002360; Redmiles EM, 2019, P IEEE S SECUR PRIV, P1326, DOI 10.1109/SP.2019.00014; Robinson J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226394; Ruiter RAC, 2014, INT J PSYCHOL, V49, P63, DOI 10.1002/ijop.12042; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Thomas KA, 2017, COMPUT HUM BEHAV, V77, P184, DOI 10.1016/j.chb.2017.08.038; Vergara RJD, 2021, J PUBLIC HEALTH-UK, V43, pE291, DOI 10.1093/pubmed/fdaa282; Walters K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198835	37	8	8	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							339	10.3390/vaccines9040339			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4WE	33916161	Green Published, gold			2022-04-29	WOS:000643780600001
J	Kim, KG; Kee, HY; Park, HJ; Chung, JK; Kim, TS; Kim, MJ				Kim, Kwang Gon; Kee, Hye-young; Park, Hye Jung; Chung, Jae Keun; Kim, Tae Sun; Kim, Min Ji			The Long-Term Impact of Rotavirus Vaccines in Korea, 2008-2020; Emergence of G8P[8] Strain	VACCINES			English	Article						rotavirus; genotype; Rotarix; RotaTeq; G8P[8]	UNITED-STATES; VACCINATION; GENOTYPES; HOSPITALIZATIONS; INFECTION; DIARRHEA	This study evaluated the long-term impact of rotavirus vaccination on prevalence, seasonality, and genotype distribution in Gwangju, Korea for 13 seasons. Rotavirus was identified using ELISA and then sequenced for G and P genotypes by Reverse Transcription Polymerase Chain Reactions for diarrhoeagenic patient specimens from local hospitals between January 2008 and August2020. Of 26,902 fecal samples, 2919 samples (10.9%) were ELISA positive. The prevalence declined from 16.3% in pre-vaccine era to 5.4% in post-vaccine era. In the pre-vaccine period, G1P[8] was the most common genotype, followed by G2P[4], G3P[8], and G9P[8], etc. In the transitional period, the proportion of G2P[4] became the dominant genotype and G1P[8] was still commonly identified. In contrast, the novel genotype G8P[8] was predominant in the post-vaccine period. Meanwhile, G2P[4] and G8P[8] were major genotypes in both Rotarix and RotaTeq groups. The substantial decline of G1P[8] prevalence, reemergence of G1P[8], G3P[8], and G2P[4] rotavirus strains, and surge of the rare G8P[8] after vaccine introduction were interesting points to note. The continuous surveillance on the genotypes of RV will be needed to understand rotavirus epidemiology and their evolutionary patterns, as caution is required when interpreting temporal changes in RV genotype dynamic.	[Kim, Kwang Gon; Kee, Hye-young; Park, Hye Jung; Chung, Jae Keun; Kim, Tae Sun; Kim, Min Ji] Hlth & Environm Res Inst Gwangju, Gwangju 61954, South Korea		Kim, MJ (通讯作者)，Hlth & Environm Res Inst Gwangju, Gwangju 61954, South Korea.	kkg1229@korea.kr; vetkhy@korea.kr; sdgenie@korea.kr; jkchung@korea.kr; kts2877@korea.kr; vetmj@korea.kr		kwang gon, Kim/0000-0002-4461-3592	infectious disease surveillance program of the Korea Center for Disease Control and Prevention (KCDC), Korea	This work was supported by the infectious disease surveillance program of the Korea Center for Disease Control and Prevention (KCDC), Korea.	Aliabadi N, 2015, MMWR-MORBID MORTAL W, V64, P337; Bibera GL, 2020, VACCINE, V38, P5591, DOI 10.1016/j.vaccine.2020.06.059; Bowen MD, 2016, J INFECT DIS, V214, P732, DOI 10.1093/infdis/jiw233; Burnett E, 2020, LANCET GLOB HEALTH, V8, pE1195, DOI 10.1016/S2214-109X(20)30262-X; Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186; Chen SC, 2012, J FORMOS MED ASSOC, V111, P183, DOI 10.1016/j.jfma.2011.09.024; Cho H, 2020, PEDIATR INFECT DIS J, V39, P460, DOI 10.1097/INF.0000000000002582; Crawford SE, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.83; Huyen DTT, 2018, VACCINE, V36, P7894, DOI 10.1016/j.vaccine.2018.05.008; Degiuseppe J.I., 2020, RES SQ, P2017, DOI [10.21203/rs.3.rs-72107/v1, DOI 10.21203/RS.3.RS-72107/V1]; Dhama K, 2009, VET RES COMMUN, V33, P1, DOI 10.1007/s11259-008-9070-x; Doro R, 2014, INFECT GENET EVOL, V28, P446, DOI 10.1016/j.meegid.2014.08.017; Gil-Prieto R, 2013, VACCINE, V31, P5000, DOI 10.1016/j.vaccine.2013.05.109; Gozalbo-Rovira R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031010; Han TH, 2010, ARCH VIROL, V155, P1663, DOI 10.1007/s00705-010-0752-7; Hoa-Tran TN, 2016, ARCH VIROL, V161, P479, DOI 10.1007/s00705-015-2682-x; Hoque SA, 2020, VACCINE, V38, P3980, DOI 10.1016/j.vaccine.2020.03.061; Hoque SA, 2018, VACCINE, V36, P43, DOI 10.1016/j.vaccine.2017.11.056; Karafillakis E, 2015, VACCINE, V33, P2097, DOI 10.1016/j.vaccine.2015.03.016; Kim J.H., 2020, MEDICINE, V99, P40; Le VP, 2008, J MED VIROL, V80, P175, DOI 10.1002/jmv.21044; Lee SY, 2009, VACCINE, V27, pF97, DOI 10.1016/j.vaccine.2009.09.002; Lee Sok Goo, 2019, [JOURNAL OF THE KOREAN SOCIETY OF MATERNAL AND CHILD HEALTH, 한국모자보건학회지], V23, P175, DOI 10.21896/jksmch.2019.23.3.175; Lee SK, 2018, GUT PATHOG, V10, DOI 10.1186/s13099-018-0255-8; Leshem E, 2018, J PEDIAT INF DIS SOC, V7, P257, DOI 10.1093/jpids/pix057; Markkula J, 2020, J INFECTION, V80, P76, DOI 10.1016/j.jinf.2019.09.009; Moutelikova R, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111015; Pasittungkul S, 2021, PEERJ, V9, DOI 10.7717/peerj.10954; Pitzer V.E., 2015, SCI REP-UK, V5, P1; Sadiq A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220387; Suzuki H, 2005, PEDIATR INFECT DIS J, V24, P257, DOI 10.1097/01.inf.0000154327.00232.4d; Tanaka T, 2017, JPN J INFECT DIS, V70, P448, DOI 10.7883/yoken.JJID.2016.286; Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528; Thanh H.D., 2018, SCI REP-UK, V8, P1; Troeger C, 2018, JAMA PEDIATR, V172, P958, DOI 10.1001/jamapediatrics.2018.1960; Zeller M, 2010, VACCINE, V28, P7507, DOI 10.1016/j.vaccine.2010.09.004; Zlamy M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-112	37	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							406	10.3390/vaccines9040406			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6AU	33923945	Green Published, gold			2022-04-29	WOS:000643860400001
J	Betancourt-Cravioto, M; Falcon-Lezama, JA; Saucedo-Martinez, R; Alfaro-Cortes, MM; Tapia-Conyer, R				Betancourt-Cravioto, Miguel; Falcon-Lezama, Jorge Abelardo; Saucedo-Martinez, Rodrigo; Alfaro-Cortes, Myrna Maria; Tapia-Conyer, Roberto			Public Health and Economic Benefits of Influenza Vaccination of the Population Aged 50 to 59 Years without Risk Factors for Influenza Complications in Mexico: A Cross-Sectional Epidemiological Study	VACCINES			English	Article						influenza; vaccination; adult-aged population; cost effectiveness; Mexico; burden of disease; middle-income countries	YOUNGER ADULTS; BURDEN; COMORBIDITY	The Mexican influenza vaccination program does not include a recommendation for people aged 50-59 years without risk factors for influenza complications, and there are limited data regarding the cost-effectiveness of vaccinating this population. To explore the clinical and economic effects of including this population in the vaccination schedule, we performed a cross-sectional epidemiological study using records (2009-2018) from Mexico's Influenza Surveillance System (SISVEFLU), death records (2010-2015) from the National Mortality Epidemiological and Statistical System, and discharge and hospitalization records (2010-2015) from the Automated Hospital Discharge System databases. A 1-year decision-analytic model was used to assess cost-effectiveness through a decision-tree based on data from SISVEFLU. The primary outcome was influenza cases avoided; with associated influenza-related events as secondary outcomes. Including the population aged 50-59 years without risk factors in Mexico's influenza immunization program would have resulted in 199,500 fewer cases; 67,008 fewer outpatient consultations; 33,024 fewer emergency room consultations; 33,091 fewer hospitalizations; 12 fewer deaths. These reductions equate to a substantial public health benefit as well as an economic benefit; yielding net savings of 49.8 million US dollars over a typical influenza season. Expansion of the current Mexican vaccination schedule to include these people would be a cost-saving and dominant strategy.	[Betancourt-Cravioto, Miguel; Falcon-Lezama, Jorge Abelardo; Saucedo-Martinez, Rodrigo; Alfaro-Cortes, Myrna Maria; Tapia-Conyer, Roberto] Soc Mexicana Salud Publ, Vaccinol Sect, Mexico City 11590, DF, Mexico; [Tapia-Conyer, Roberto] Univ Nacl Autonoma Mexico, Sch Med, Mexico City 04510, DF, Mexico		Tapia-Conyer, R (通讯作者)，Soc Mexicana Salud Publ, Vaccinol Sect, Mexico City 11590, DF, Mexico.; Tapia-Conyer, R (通讯作者)，Univ Nacl Autonoma Mexico, Sch Med, Mexico City 04510, DF, Mexico.	betancom70@gmail.com; jfalcon@fundacioncarlosslim.org; rosaucedo@gmail.com; myrna.alfaro.fcs@gmail.com; tapiaconyer@yahoo.com.mx		Tapia-Conyer, Roberto/0000-0001-9425-7322; Falcon-Lezama, Jorge Abelardo/0000-0001-9081-4064	Sanofi Pasteur	This research and the article processing charges are fully funded by Sanofi Pasteur.	Falcon-Lezama JA, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4948-5; Anderson LJ, 2018, AM J PREV MED, V54, P299, DOI 10.1016/j.amepre.2017.11.010; Backer JA, 2019, EPIDEMICS-NETH, V26, P95, DOI 10.1016/j.epidem.2018.10.003; Baltussen R.M.P.M., 2003, DISCOUNTING WHO GUID, P67; Balzi D, 2006, AM HEART J, V151, P1094, DOI 10.1016/j.ahj.2005.06.037; Barberis I, 2016, J Prev Med Hyg, V57, pE115; Barratt J, 2019, AGING CLIN EXP RES, V31, P339, DOI 10.1007/s40520-019-01156-z; Bouvier NM, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030058; Centers for Disease Control and Prevention, US MEX PUBL HLTH; Centers for Disease Control and Prevention, NAT REG STAT LEV OUT; Centers for Disease Control and Prevention, 2018, DIS BURD INFL; Centers for Disease Control and Prevention, 2019, PREV CONTR SEAS INFL; Centro Nacional de Excelencia Tecnologica en Salud (CENETEC), 2015, CAT MAESTR GUIAS PRA; Consejo Nacional de Poblacion-CONAPO, PROYEC POBL MEX ENT; Dabestani NM, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.05.022; de Waure C, 2012, HUM VACC IMMUNOTHER, V8, P119, DOI 10.4161/hv.8.1.18420; Direccion General de Epidemiologia, 2014, MAN VIG EP INFL; Doyon-Plourde P, 2019, VACCINE, V37, P3179, DOI 10.1016/j.vaccine.2019.04.051; European Centre for Disease Prevention and Control, 2017, SEASONAL INFLUENZA V; European Centre for Disease Prevention and Control, 2009, TIM PAND H1N1; European Centre for Disease Prevention and Control, 2018, SEASONAL INFLUENZA V; Fraser SDS, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0189-z; Gamino-Arroyo AE, 2019, CLIN INFECT DIS, V69, P1903, DOI 10.1093/cid/ciz100; Dantes OG, 2011, SALUD PUBLICA MEXICO, V53, pS220; Gutierrez JP, 2005, SALUD PUBLICA MEXICO, V47, P234, DOI 10.1590/S0036-36342005000300007; Hannoun C, 2013, EXPERT REV VACCINES, V12, P1085, DOI 10.1586/14760584.2013.824709; Instituto de Diagnostico y Referencia Epidemiologicos, 2017, LIN VIG EP INFL; Instituto Mexicano del Seguro Social, 2013, DIR PREST MED REC TR; Instituto Nacional de Estadistica y Geografia (INEGI), ENC NAC INGR GAST HO; Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312; Leidner AJ, 2019, VACCINE, V37, P226, DOI 10.1016/j.vaccine.2018.11.056; Longmore RB, 2011, AM HEART J, V161, P631, DOI 10.1016/j.ahj.2010.12.005; Ministerio de Salud, VACCINATION CALENDAR; Ministerio de Salud (MINSA) de Panama, 2017, ESQ NAC VAC; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Nguyen NT, 2011, OBES SURG, V21, P351, DOI 10.1007/s11695-010-0335-4; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Principi N, 2018, HUM VACC IMMUNOTHER, V14, P684, DOI 10.1080/21645515.2017.1405188; Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057; Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036; Secretaria de Salud, MEM DOC PROGR ACC ES; Secretaria de Salud, 2015, GEN GUIDELINES; Secretaria de Salud, ESQ VAC; Secretaria de Salud-SAEH, EGR HOSP SECR SAL; Secretaria de Salud-SEED, BAS DAT DEF; Taksler GB, 2015, CLIN INFECT DIS, V61, P1495, DOI 10.1093/cid/civ630; Nazco CV, 2018, REV ESP SALUD PUBLIC, V92; van der Molen T, 2013, INT J CHRONIC OBSTR, V8, P461, DOI 10.2147/COPD.S49392; WHO, WHO VACC PREV DIS MO; World Health Organization, 2020, INT TRAV HLTH SEAS I; World Health Organization, INT STAT CLASS DIS R; World Health Organization, 2018, SEAS INFL FACT SHEET; Yang KC, 2018, INT J INFECT DIS, V73, P102, DOI 10.1016/j.ijid.2018.05.024	53	3	3	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							188	10.3390/vaccines9030188			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MA	33668199	gold, Green Published			2022-04-29	WOS:000634196800001
J	Di Giuseppe, G; Pelullo, CP; Della Polla, G; Pavia, M; Angelillo, IF				Di Giuseppe, Gabriella; Pelullo, Concetta Paola; Della Polla, Giorgia; Pavia, Maria; Angelillo, Italo Francesco			Exploring the Willingness to Accept SARS-CoV-2 Vaccine in a University Population in Southern Italy, September to November 2020	VACCINES			English	Article						attitudes; COVID-19; university population; Italy; vaccination; willingness	SEASONAL INFLUENZA VACCINATION; COVID-19 VACCINE; UNITED-STATES; ACCEPTABILITY; KNOWLEDGE; ATTITUDES	Understanding whether members of the university population are willing to receive a future vaccination against COVID-19 and identifying barriers may help public health authorities to develop effective strategies and interventions to contain COVID-19. This cross-sectional study explored the willingness to accept a future SARS-CoV-2 vaccine in a university population in Southern Italy. The perceived risk level of developing COVID-19 was 6.5 and it was significantly higher among females, younger subjects, and those who agreed/strongly agreed that COVID-19 is a severe disease. Only 21.4% of respondents were not worried at all regarding the safety of the vaccine. Males, not being married/cohabitant, being a faculty member, those who perceived a lower risk of developing COVID-19, and those who did not need information regarding the vaccination against COVID-19 were significantly more likely to have no concern at all regarding the safety of the vaccine. The vast majority (84.1%) were willing to receive a future vaccine against COVID-19. Almost coherently with predictors of concern on the safety of the vaccine, being male, not being married/cohabitant, being a faculty member, not being concerned at all that COVID-19 vaccination might not be safe, and agreeing that COVID-19 can have serious health consequences were significant predictors of the willingness to receive the vaccine against COVID-19. A considerable proportion of the population had a positive willingness to receive the future COVID-19 vaccine, although some concerns have been expressed regarding the effectiveness and safety and public health activities seem necessary to achieve the rate that can lead to the protection of the community.	[Di Giuseppe, Gabriella; Pelullo, Concetta Paola; Pavia, Maria; Angelillo, Italo Francesco] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy; [Della Polla, Giorgia] Univ Campania Luigi Vanvitelli, Hlth Direct, Teaching Hosp, Via S Maria di Costantinopoli 104, I-80138 Naples, Italy		Angelillo, IF (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy.	gabriella.digiuseppe@unicampania.it; concettapaola.pelullo@unicampania.it; giorgia.dellapolla@unicampania.it; maria.pavia@unicampania.it; italof.angelillo@unicampania.it	Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602; Pelullo, Concetta Paola/0000-0003-4228-8703; Della Polla, Giorgia/0000-0002-3182-4905; PAVIA, Maria/0000-0003-3879-1322			Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; [Anonymous], 2017, STATA REFERENCE MANU; [Anonymous], MINISTERO SALUTE COV; Attwell K, 2019, VACCINE, V37, P677, DOI 10.1016/j.vaccine.2018.12.014; Bertoldo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215978; Casalino E, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0193029, 10.1371/journa.pone.0193029]; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y; Galasso V, 2020, P NATL ACAD SCI USA, V117, P27285, DOI 10.1073/pnas.2012520117; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; He S, 2021, J COMMUN HEALTH, V46, P278, DOI 10.1007/s10900-020-00870-4; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Kaufman J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub2; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lee K, 2009, GLOB INST, P1; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Luz PM, 2017, VACCINE, V35, P5890, DOI 10.1016/j.vaccine.2017.08.078; Ministero della Salute, LEGG 31 LUGL 2017 11; Morrone T, 2017, HUM VACC IMMUNOTHER, V13, P1921, DOI 10.1080/21645515.2017.1313940; Napolitano F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16101807; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2020, WHO DIR GEN OP REM M; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	33	25	25	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							275	10.3390/vaccines9030275			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5WA	33803730	Green Published, gold			2022-04-29	WOS:000634222800001
J	Fontana, D; Garay, E; Cervera, L; Kratje, R; Prieto, C; Godia, F				Fontana, Diego; Garay, Ernesto; Cervera, Laura; Kratje, Ricardo; Prieto, Claudio; Godia, Francesc			Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus	VACCINES			English	Article						virus-like particles; rabies; foot-and-mouth disease; HIV-1; chimeric; vaccine	TRANSIENT TRANSFECTION; PARTICLES; VACCINES; LOOP	Foot and mouth disease is a livestock acute disease, causing economic losses in affected areas. Currently, control of this disease is performed by mandatory vaccination campaigns using inactivated viral vaccines. In this work, we describe the development of a chimeric VLP-based vaccine candidate for foot-and-mouth disease virus (FMDV), based on the co-expression of the HIV-1 Gag protein and a novel fusion rabies glycoprotein (RVG), which carries in its N-term the FMDV main antigen: the G-H loop. It is demonstrated by confocal microscopy that both Gag-GFP polyprotein and the G-H loop colocalize at the cell membrane and, that the Gag polyprotein of the HIV virus acts as a scaffold for enveloped VLPs that during the budding process acquires the proteins that are being expressed in the cell membrane. The obtained VLPs were spherical particles of 130 +/- 40 nm in diameter (analyzed by TEM, Cryo-TEM and NTA) carrying an envelope membrane that efficiently display the GH-RVG on its surface (analyzed by gold immunolabeling). Immunostainings with a FMDV hyperimmune serum showed that the heterologous antigenic site, genetically fused to RVG, is recognized by specific G-H loop antibodies. Additionally, the cVLPs produced expose the G-H loop to the liquid surrounding (analyzed by specific ELISA). Finally, we confirmed that these FMD cVLPs are able to induce a specific humoral immune response, based on antibodies directed to the G-H loop in experimental animals.	[Fontana, Diego; Garay, Ernesto; Kratje, Ricardo] UNL, FBCB Sch Biochem & Biol Sci, CONICET, Cell Culture Lab,CBL Biotechnol Ctr Litoral, S3000ZAA, Santa Fe, Argentina; [Fontana, Diego; Prieto, Claudio] UNL, FBCB Sch Biochem & Biol Sci, Biotechnol Dev Lab, CBL Biotechnol Ctr Litoral, S3000ZAA, Santa Fe, Argentina; [Cervera, Laura; Godia, Francesc] Univ Autonoma Barcelona, Dept Engn Quim Biol & Ambiental, Bellaterra 08193, Spain		Fontana, D (通讯作者)，UNL, FBCB Sch Biochem & Biol Sci, CONICET, Cell Culture Lab,CBL Biotechnol Ctr Litoral, S3000ZAA, Santa Fe, Argentina.; Fontana, D (通讯作者)，UNL, FBCB Sch Biochem & Biol Sci, Biotechnol Dev Lab, CBL Biotechnol Ctr Litoral, S3000ZAA, Santa Fe, Argentina.	dfontana@fbcb.unl.edu.ar; egaray@fbcb.unl.edu.ar; Laura.Cervera@uab.cat; rkratje@fbcb.unl.edu.ar; cprieto@fbcb.unl.edu.ar; Francesc.Godia@uab.cat		Garay, Ernesto/0000-0002-3694-8982; Fontana, Diego/0000-0002-5109-7637; Prieto, Claudio/0000-0002-0422-0153	AGENCIA NACIONAL DE PROMOCION CIENTIFICO/TECNOLOGICA (Argentina) [PICT Joven 2017-1087]	This research was funded by AGENCIA NACIONAL DE PROMOCION CIENTIFICO/TECNOLOGICA (Argentina), grant number PICT Joven 2017-1087.	[Anonymous], 1913, J R SANIT I, V34, P132, DOI [10.1177/146642401303400206, DOI 10.1177/146642401303400206]; Azuma H, 2009, J MOL GRAPH MODEL, V28, P278, DOI 10.1016/j.jmgm.2009.08.006; Belsham GJ, 2020, ACTA VET SCAND, V62, DOI 10.1186/s13028-020-00519-1; Bertona D, 2017, J PHARM PHARMACOL, V69, P1293, DOI 10.1111/jphp.12768; Bidart J, 2021, VIRUS RES, V297, DOI 10.1016/j.virusres.2021.198339; Bidart J, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00396; Bucafusco D, 2015, VIROLOGY, V476, P11, DOI 10.1016/j.virol.2014.11.023; Burman A, 2006, J VIROL, V80, P9798, DOI 10.1128/JVI.00577-06; Cao YM, 2016, EXPERT REV VACCINES, V15, P783, DOI 10.1586/14760584.2016.1140042; Cervera L, 2019, APPL MICROBIOL BIOT, V103, P7367, DOI 10.1007/s00253-019-10038-3; Cervera L, 2017, BIOTECHNOL BIOENG, V114, P2507, DOI 10.1002/bit.26367; Cervera L, 2015, APPL MICROBIOL BIOT, V99, P9935, DOI 10.1007/s00253-015-6842-4; Cervera L, 2013, J BIOTECHNOL, V166, P152, DOI 10.1016/j.jbiotec.2013.05.001; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; Mignaqui AC, 2019, CRIT REV BIOTECHNOL, V39, P306, DOI 10.1080/07388551.2018.1554619; Crisci Elisa, 2013, Inmunologia, V32, P102, DOI 10.1016/j.inmuno.2012.08.002; Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026; de los Santos T, 2018, CURR OPIN VIROL, V29, P16, DOI 10.1016/j.coviro.2018.02.005; Diaz-San Segundo F, 2017, VET MICROBIOL, V206, P102, DOI 10.1016/j.vetmic.2016.12.018; DOEL TR, 1981, ARCH VIROL, V70, P21, DOI 10.1007/BF01320790; Donaldson B, 2018, EXPERT REV VACCINES, V17, P833, DOI 10.1080/14760584.2018.1516552; Donaldson B, 2015, ADV DEL SCI TECHNOL, P159, DOI 10.1007/978-1-4939-1417-3_9; Fernandez-Sainz I, 2019, VACCINE, V37, P3435, DOI 10.1016/j.vaccine.2019.05.019; Fontana D, 2020, J VIROL METHODS, V286, DOI 10.1016/j.jviromet.2020.113966; Fontana D, 2015, VACCINE, V33, P4238, DOI 10.1016/j.vaccine.2015.03.088; Fontana D, 2014, VACCINE, V32, P2799, DOI 10.1016/j.vaccine.2014.02.031; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Fuenmayor J, 2019, J CHEM TECHNOL BIOT, V94, P302, DOI 10.1002/jctb.5777; Fuenmayor J, 2018, APPL MICROBIOL BIOT, V102, P4477, DOI 10.1007/s00253-018-8930-8; Fuenmayor J, 2018, APPL MICROBIOL BIOT, V102, P165, DOI 10.1007/s00253-017-8605-x; Gonzalez-Dominguez I, 2020, BIOTECHNOL BIOENG, V117, P1929, DOI 10.1002/bit.27345; Gonzalez-Dominguez I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020223; Gonzalez-Dominguez I, 2016, BIOPHYS J, V111, P1173, DOI 10.1016/j.bpj.2016.07.046; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Gutierrez-Granados S, 2018, CRIT REV BIOTECHNOL, V38, P918, DOI 10.1080/07388551.2017.1419459; Gutierrez-Granados S, 2013, J VIROL METHODS, V193, P85, DOI 10.1016/j.jviromet.2013.05.010; Kurg R, 2016, SCI REP-UK, V6, DOI 10.1038/srep29425; Lavado-Garcia J, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00617; Liu FX, 2012, RES VET SCI, V93, P553, DOI 10.1016/j.rvsc.2011.10.018; Liu JL, 2016, VIROL SIN, V31, P279, DOI 10.1007/s12250-016-3756-y; Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159; Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Prehaud C, 2003, J VIROL, V77, P10537, DOI 10.1128/JVI.77.19.10537-10547.2003; Rodriguez LL, 2009, VACCINE, V27, pD90, DOI 10.1016/j.vaccine.2009.08.039; Roldao A., 2017, COMPR BIOTECHNOL, P633, DOI DOI 10.1016/B978-0-12-809633-8.09046-4; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Schnell MJ, 2010, NAT REV MICROBIOL, V8, P51, DOI 10.1038/nrmicro2260; Singh RK, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030090; Soares HR, 2016, VACCINE, V34, P1634, DOI 10.1016/j.vaccine.2015.12.015; Soares HR, 2018, BIOTECHNOL LETT, V40, P633, DOI 10.1007/s10529-018-2515-6; Steppert P, 2017, J CHROMATOGR A, V1487, P89, DOI 10.1016/j.chroma.2016.12.085; Venereo-Sanchez A, 2017, VACCINE, V35, P4220, DOI 10.1016/j.vaccine.2017.06.024; Verdaguer N, 1999, VIROLOGY, V255, P260, DOI 10.1006/viro.1998.9554; Heimann Franz, 1948, SCHWEIZ ZEITSCHR PATH U BAKT, V11, P1; WHO, 2013, WHO TECH REP SER, V982, P1	57	2	2	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							251	10.3390/vaccines9030251			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5RH	33809060	gold, Green Published			2022-04-29	WOS:000634210500001
J	Koch, T; Mellinghoff, SC; Shamsrizi, P; Addo, MM; Dahlke, C				Koch, Till; Mellinghoff, Sibylle C.; Shamsrizi, Parichehr; Addo, Marylyn M.; Dahlke, Christine			Correlates of Vaccine-Induced Protection against SARS-CoV-2	VACCINES			English	Review						COVID-19; correlates of protection; immunogenicity; SARS-CoV-2; vaccine; pandemic	T-CELL RESPONSES; POXVIRUS INFECTION; VIRUS CLEARANCE; IMMUNE-RESPONSE; DISEASE; COVID-19; ANTIBODY	We are in the midst of a pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS-CoV-2 has caused more than two million deaths after one year of the pandemic. The world is experiencing a deep economic recession. Safe and effective vaccines are needed to prevent further morbidity and mortality. Vaccine candidates against COVID-19 have been developed at an unprecedented speed, with more than 200 vaccine candidates currently under investigation. Among those, 20 candidates have entered the clinical Phase 3 to evaluate efficacy, and three have been approved by the European Medicines Agency. The aim of immunization is to act against infection, disease and/or transmission. However, the measurement of vaccine efficacy is challenging, as efficacy trials need to include large cohorts with verum and placebo cohorts. In the future, this will be even more challenging as further vaccine candidates will receive approval, an increasing number of humans will receive vaccinations and incidence might decrease. To evaluate novel and second-generation vaccine candidates, randomized placebo-controlled trials might not be appropriate anymore. Correlates of protection (CoP) could be an important tool to evaluate novel vaccine candidates, but vaccine-induced CoP have not been clearly defined for SARS-CoV-2 vaccines. In this review, we report on immunogenicity against natural SARS-CoV-2 infection, vaccine-induced immune responses and discuss immunological markers that can be linked to protection. By discussing the immunogenicity and efficacy of forerunner vaccines, we aim to give a comprehensive overview of possible efficacy measures and CoP.	[Koch, Till; Mellinghoff, Sibylle C.; Shamsrizi, Parichehr; Addo, Marylyn M.; Dahlke, Christine] Univ Med Ctr Hamburg Eppendorf, Div Infect Dis, Dept Med 1, D-20246 Hamburg, Germany; [Koch, Till; Shamsrizi, Parichehr; Addo, Marylyn M.; Dahlke, Christine] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, D-20359 Hamburg, Germany; [Koch, Till; Shamsrizi, Parichehr; Addo, Marylyn M.; Dahlke, Christine] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, D-20359 Hamburg, Germany; [Mellinghoff, Sibylle C.] Univ Cologne, Excellence Ctr Med Mycol ECMM, Dept Med 1, Fac Med, D-50937 Cologne, Germany; [Mellinghoff, Sibylle C.] Univ Cologne, Univ Hosp Cologne, D-50937 Cologne, Germany; [Mellinghoff, Sibylle C.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Translat Res, Fac Med, D-50931 Cologne, Germany; [Mellinghoff, Sibylle C.] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, D-50937 Cologne, Germany		Dahlke, C (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Div Infect Dis, Dept Med 1, D-20246 Hamburg, Germany.; Dahlke, C (通讯作者)，German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, D-20359 Hamburg, Germany.; Dahlke, C (通讯作者)，Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, D-20359 Hamburg, Germany.	t.koch@uke.de; sibylle.mellinghoff@uk-koeln.de; p.shamsrizi@uke.de; m.addo@uke.de; c.dahlke@uke.de		Addo, Marylyn/0000-0003-2836-9224; Dahlke, Christine/0000-0002-2056-9195; Shamsrizi, Dr. Parichehr/0000-0002-0376-0967; Koch, Till/0000-0002-0140-2808	DZIF [TTU 01.924]	This research received funding by DZIF (TTU 01.924).	Adams Emily R, 2020, Wellcome Open Res, V5, P139, DOI 10.12688/wellcomeopenres.15927.1; Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; [Anonymous], 2021, NEW YORK TIMES; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bao L, 2020, BIORXIV, DOI 10.1101/2020.03.13.990226; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bolotin S, 2020, J INFECT DIS, V221, P1576, DOI 10.1093/infdis/jiz380; BRADBURNE AF, 1972, J HYG-CAMB, V70, P235, DOI 10.1017/S0022172400022294; Brodin P, 2021, NAT MED, V27, P28, DOI 10.1038/s41591-020-01202-8; Calabrese LH, 2021, LANCET RHEUMATOL, V3, pE246, DOI 10.1016/S2665-9913(21)00034-5; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019; Case J.B., 2020, SINGLE INTRANASAL DO, DOI [10.1101/2020.07.16.205088, DOI 10.1101/2020.07.16.205088]; Chakraborty S, 2021, NAT IMMUNOL, V22, P67, DOI [10.1038/s41590-020-00828-7, 10.1101/2020.05.15.20103341]; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Dan J.M., 2020, IMMUNOLOGICAL MEMORY, DOI [10.1101/2020.11.15.383323, DOI 10.1101/2020.11.15.383323]; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Edwards K.M., 2018, PLOTKINS VACCINES, P7, DOI [10.1016/B978-0-323-35761-6.00002-X, DOI 10.1016/B978-0-323-35761-6.00002-X]; European Medicines Agency (EMA), EMA REC COVID 19 VAC; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Holmgren J, 2017, VACCINE, V35, P3355, DOI 10.1016/j.vaccine.2017.05.005; Huang Angkana T, 2020, medRxiv, DOI [10.1038/s41467-020-18450-4, 10.1101/2020.04.14.20065771]; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jin PF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00481-y; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Larsen MD, 2021, SCIENCE, V371, P907, DOI 10.1126/science.abc8378; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469; Liu WJ, 2017, J IMMUNOL, V198, P873, DOI 10.4049/jimmunol.1601542; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020; Madhi SAB, 2021, MEDRXIV, DOI [10.1101/2021.02.10.21251247, DOI 10.1101/2021.02.10.21251247, 10.21251247]; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; Miorin L, 2020, P NATL ACAD SCI USA, V117, P28344, DOI 10.1073/pnas.2016650117; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Of fit P, 2018, PLOTKINS VACCINES, P35, DOI DOI 10.1016/B978-0-323-35761-6.00003-1; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443; Pan CH, 2005, P NATL ACAD SCI USA, V102, P11581, DOI 10.1073/pnas.0504592102; Panchanathan V, 2008, IMMUNOL CELL BIOL, V86, P80, DOI 10.1038/sj.icb.7100118; Panchanathan V, 2006, J VIROL, V80, P6333, DOI 10.1128/JVI.00115-06; Payne DC, 2016, EMERG INFECT DIS, V22, P1824, DOI 10.3201/eid2210.160706; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674; SANTOSHAM M, 1991, PEDIATR INFECT DIS J, V10, P113, DOI 10.1097/00006454-199102000-00007; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Seow J., 2020, NAT MICROBIOL, V5, P1598, DOI [10.1101/2020.07.09.20148429, DOI 10.1038/S41564-020-00813-8, 10.1038/s41564-020-00813-8]; Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015; Su F, 2016, HUM VACC IMMUNOTHER, V12, P1070, DOI 10.1080/21645515.2015.1114195; Takahashi Takehiro, 2020, medRxiv, DOI 10.1101/2020.06.06.20123414; Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002; Truyers, 2020, SAFETY IMMUNOGENICIT, DOI [10.1101/2020.09.23.20199604, DOI 10.1101/2020.09.23.20199604, 10.1101/2020.09.23.20199604v1]; UK_Biobank_Limited, UK BIOB 2021; Vaxart, VAX ANN POS PREL DAT; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; WHO, 2021, WHO COR DIS COVID 19; WHO, 2020, WHOBS20202403; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang, 2020, GLOBAL PROFILING SAR, DOI [10.1101/2020.03.20.20039495, DOI 10.1101/2020.03.20.20039495]; Zhang J, 2021, NAT MICROBIOL, V6, P51, DOI 10.1038/s41564-020-00824-5; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005	92	19	19	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							238	10.3390/vaccines9030238			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5GO	33801831	gold, Green Published			2022-04-29	WOS:000634182600001
J	Bettini, E; Locci, M				Bettini, Emily; Locci, Michela			SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond	VACCINES			English	Review						SARS-CoV-2; coronavirus; mRNA vaccines; adaptive immunity; antibodies; germinal centers; long-lived plasma cells; memory B cells; T follicular helper cells; Th1 cells	NEUTRALIZING ANTIBODIES; LIPID NANOPARTICLES; RESPONSES; SPIKE; PROTECTION; MICE	To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive immunity, including B and T cell responses. While B cell responses are key, as they can mediate antibody-dependent protection, T cells can modulate B cell activity and directly contribute to the elimination of pathogen-infected cells. In the unprecedented race to develop an effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the respiratory disease coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) vaccines have emerged as front runners thanks to their capacity for rapid development and ability to drive potent adaptive immune responses. In this review article, we provide an overview of the results from pre-clinical studies in animal models as well as clinical studies in humans that assessed the efficacy of SARS-CoV-2 mRNA vaccines, with a primary focus on adaptive immune responses post vaccination.	[Bettini, Emily; Locci, Michela] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA		Locci, M (通讯作者)，Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.	ebettini@pennmedicine.upenn.edu; michela.locci@pennmedicine.upenn.edu		Bettini, Emily/0000-0003-0424-2472	NIH NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI123738, R01 AI153064]	M.L. is supported by NIH NIAID grants R01 AI123738 and R01 AI153064.	Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], DEV LICENSURE VACCIN; [Anonymous], COVID 19 DASHB CTR S; [Anonymous], FACT SHEET HEALTHCAR; [Anonymous], SAFETY IMMUNOGENICIT; [Anonymous], TRIAL INVESTIGATING; [Anonymous], COVID 19 VACCINES AL; [Anonymous], MRNA VACCINES COVID; [Anonymous], STUDY DESCRIBE SAFET; [Anonymous], DRAFT LANDSCAPE COVI; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Beaudoin-Bussieres G, 2020, MBIO, V11, DOI 10.1128/mBio.02590-20; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; CAGIGI A, 2021, NATO ADV, V9, P61, DOI DOI 10.3390/VACCINES9010061; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; Cullis PR, 2017, MOL THER, V25, P1467, DOI 10.1016/j.ymthe.2017.03.013; Dan Jennifer M, 2020, bioRxiv, DOI 10.1101/2020.11.15.383323; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kauffman KJ, 2016, J CONTROL RELEASE, V240, P227, DOI 10.1016/j.jconrel.2015.12.032; Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lang PO, 2011, MATURITAS, V68, P322, DOI 10.1016/j.maturitas.2011.01.011; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Letko Michael, 2020, bioRxiv, DOI 10.1101/2020.01.22.915660; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1101/2020.06.17.153486, 10.1109/TKDE.2020.3004939]; Lu J, 2020, CELL RES, V30, P936, DOI 10.1038/s41422-020-00392-7; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Rauch S, 2020, MRNA BASED SARS COV2, V2020, DOI [10.23.351775, 10.1101/2020.10.23.351775., DOI 10.1101/2020.10.23.351775, 10.1101/2020.10.23.351775]; Rauch S., 2020, MRNA VACCINE CVNCOV, DOI [10.1101/2020.12.23.424138, DOI 10.1101/2020.12.23.424138]; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Schultheiss C, 2020, IMMUNITY, V53, P442, DOI 10.1016/j.immuni.2020.06.024; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Tai WB, 2020, CELL RES, V30, P932, DOI 10.1038/s41422-020-0387-5; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Vogel A.B., 2020, BIORXIV, V370, P1022, DOI 10.1101/2020.09.08.280818; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	83	49	50	14	34	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							147	10.3390/vaccines9020147			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6PP	33673048	Green Published, gold	Y	N	2022-04-29	WOS:000623263900001
J	Fens, T; de Boer, PT; van Puijenbroek, EP; Postma, MJ				Fens, Tanja; de Boer, Pieter T.; van Puijenbroek, Eugene P.; Postma, Maarten J.			Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review	VACCINES			English	Review						seasonal influenza vaccines; economic evaluations; adverse events following immunization	GUILLAIN-BARRE-SYNDROME; COST-EFFECTIVENESS ANALYSIS; AGED 3-14 YEARS; PREVENTING INFLUENZA; VACCINATION PROGRAM; BENEFIT-ANALYSIS; WORKING ADULTS; CHILDREN; HEALTHY; IMPACT	(1) Background: Vaccines for seasonal influenza are a good preventive and cost-effective strategy. However, it is unknown if and how these economic evaluations include the adverse events following immunization (AEFI), and what the impact of such inclusion is on the health economic outcomes. (2) Methods: We searched the literature, up to January 2020, to identify economic evaluations of seasonal influenza vaccines that considered AEFIs. The review protocol was published in PROSPERO (CDR42017058523). (3) Results: A total of 52 economic evaluations considered AEFI-related parameters in their analyses, reflecting 16% of the economic evaluations on seasonal influenza vaccines in the initial study selection. Most studies used the societal perspective (64%) and evaluated vaccination of children (37%). Where considered, studies included direct medical costs of AEFIs (90%), indirect costs (27%), and disutilities/quality-adjusted life years loss due to AEFIs (37%). The majority of these studies accounted for the effects of the costs of AEFI on cost-effectiveness for Guillain-Barre syndrome. In those papers allowing cost share estimation, direct medical cost of AFEIs was less than 2% of total direct costs. (4) Conclusions: Although the overall impact of AEFIs on the cost-effectiveness outcomes was found to be low, we urge their inclusion in economic evaluations of seasonal influenza vaccines to reflect comprehensive reports for the decision makers and end-users of the vaccination strategies.	[Fens, Tanja; de Boer, Pieter T.; van Puijenbroek, Eugene P.; Postma, Maarten J.] Univ Groningen, Groningen Res Inst Pharm, Dept PharmacoTherapy Epidemiol & Econ PTE2, NL-9713 AV Groningen, Netherlands; [Fens, Tanja; Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9713 GZ Groningen, Netherlands; [van Puijenbroek, Eugene P.] Netherlands Pharmacovigilance Ctr Lareb, NL-5237 MH Shertogenbosch, Netherlands; [Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, NL-9747 AE Groningen, Netherlands; [Postma, Maarten J.] Univ Airlangga, Fac Med, Dept Pharmacol & Therapy, Surabaya 60132, Indonesia; [Postma, Maarten J.] Univ Padjadjaran, Ctr Excellence Higher Educ Pharmaceut Care Innova, Bandung 45363, Indonesia		Fens, T (通讯作者)，Univ Groningen, Groningen Res Inst Pharm, Dept PharmacoTherapy Epidemiol & Econ PTE2, NL-9713 AV Groningen, Netherlands.; Fens, T (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9713 GZ Groningen, Netherlands.	t.fens@rug.nl; ptdeboer@hotmail.com; E.P.van.Pullenbroek@rug.nl; M.J.Postma@rug.nl		Postma, Maarten/0000-0002-6306-3653; van Puijenbroek, Eugene/0000-0002-2236-1398; Fens, Tanja/0000-0003-3995-447X			Altman DG, 1991, PRACTICAL STAT MED R, P455; Beigi RH, 2009, CLIN INFECT DIS, V49, P1784, DOI 10.1086/649013; Briggs AH, 2017, MED DECIS MAKING, V37, P469, DOI 10.1177/0272989X16653118; Brogan AJ, 2017, HUM VACC IMMUNOTHER, V13, P533, DOI 10.1080/21645515.2016.1242541; CDC, SEASONAL INFLUENZA V; Colombo Giorgio L, 2006, Ther Clin Risk Manag, V2, P219, DOI 10.2147/tcrm.2006.2.2.219; Craig D, 2010, INT J TECHNOL ASSESS, V26, P323, DOI 10.1017/S0266462310000371; Crovari P., 2011, J PREV MED HYG, V52, DOI [10.15167/2421-4248/jpmh2011.52.3.256, DOI 10.15167/2421-4248/JPMH2011.52.3.256]; Damm O, 2015, EUR J HEALTH ECON, V16, P471, DOI 10.1007/s10198-014-0586-4; Dayan GH, 2001, VACCINE, V19, P4204, DOI 10.1016/S0264-410X(01)00160-8; de Boer PT, 2017, EXPERT REV PHARM OUT, V17, P249, DOI 10.1080/14737167.2017.1343145; Ding Y, 2012, OBSTET GYNECOL, V119, P306, DOI 10.1097/AOG.0b013e318242af27; Drummond M.F., 2015, METHODS EC EVALUATIO; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; ECDC, TYP SEAS INFL VACC; Esposito S, 2006, VACCINE, V24, P629, DOI 10.1016/j.vaccine.2005.08.054; European Centre for Disease Prevention and Control (ECDC), SEASONAL INFLUENZA V; Evers S, 2005, INT J TECHNOL ASSESS, V21, P240, DOI 10.1017/S0266462305050324; Fens T, 2021, EXPERT OPIN PHARMACO, V22, P923, DOI 10.1080/14656566.2021.1873953; Fleiss J.L., 2013, STAT METHODS RATES P; France G, 2018, INNOV AGING, V2, DOI 10.1093/geroni/igy035; Gao Jian-min, 2008, Zhonghua Liu Xing Bing Xue Za Zhi, V29, P17; Gasparini R, 2002, VACCINE, V20, pB50, DOI 10.1016/S0264-410X(02)00507-8; Gatwood J, 2012, DRUGS, V72, P35, DOI 10.2165/11597310-000000000-00000; Giglio N, 2012, HUM VACC IMMUNOTHER, V8, DOI [10.4161/hv.8.3.18569, 10.4161/hv.18569]; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Hanskamp-Sebregts M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011078; HELLIWELL BE, 1988, CAN J PUBLIC HEALTH, V79, P175; Hibbert CL, 2007, VACCINE, V25, P8010, DOI 10.1016/j.vaccine.2007.09.018; Hodgson D, 2017, LANCET PUBLIC HEALTH, V2, pE74, DOI 10.1016/S2468-2667(16)30044-5; Imai Chisato, 2018, PLoS One, V13, pe0198685, DOI 10.1371/journal.pone.0198685; Jit M, 2013, HUM VACC IMMUNOTHER, V9, P834, DOI 10.4161/hv.23637; Jit M, 2010, VACCINE, V29, P115, DOI 10.1016/j.vaccine.2010.08.078; Kwong JC, 2013, LANCET INFECT DIS, V13, P769, DOI 10.1016/S1473-3099(13)70104-X; Lee BY, 2012, INFLUENZA OTHER RESP, V6, P167, DOI 10.1111/j.1750-2659.2011.00288.x; Lee BY, 2011, AM J KIDNEY DIS, V57, P724, DOI 10.1053/j.ajkd.2010.12.016; Lee BY, 2011, VACCINE, V29, P2149, DOI 10.1016/j.vaccine.2010.12.078; Lee BY, 2010, VACCINE, V28, P5952, DOI 10.1016/j.vaccine.2010.07.003; Lee BY, 2010, AM J MANAG CARE, V16, pE75; Lee BY, 2009, VACCINE, V27, P7110, DOI 10.1016/j.vaccine.2009.09.056; Lee BY, 2009, VACCINE, V27, P2251, DOI 10.1016/j.vaccine.2009.02.024; Leung MK, 2016, VACCINE, V34, P2469, DOI 10.1016/j.vaccine.2016.04.008; Loperto I, 2019, HUM VACC IMMUNOTHER, V15, P1035, DOI 10.1080/21645515.2019.1578597; Luce BR, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e24; Luce BR, 2008, VACCINE, V26, P2841, DOI 10.1016/j.vaccine.2008.03.046; Luyten J, 2019, SOC SCI MED, V228, P181, DOI 10.1016/j.socscimed.2019.03.025; Marchetti M, 2007, HUM VACCINES, V3, P14, DOI 10.4161/hv.3.1.3657; Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013; Meeyai A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001829; Meijboom MJ, 2018, INFLUENZA OTHER RESP, V12, P457, DOI 10.1111/irv.12558; Meltzer MI, 2005, VACCINE, V23, P1004, DOI 10.1016/j.vaccine.2004.07.040; Michaelidis CI, 2011, VACCINE, V29, P3525, DOI 10.1016/j.vaccine.2011.02.098; Myers ER, 2011, AM J OBSTET GYNECOL, V204, pS128, DOI 10.1016/j.ajog.2011.04.009; Navas E, 2007, VACCINE, V25, P3233, DOI 10.1016/j.vaccine.2007.01.038; Newall AT, 2018, INFLUENZA OTHER RESP, V12, P211, DOI 10.1111/irv.12510; Newall AT, 2012, PHARMACOECONOMICS, V30, P647, DOI 10.2165/11599130-000000000-00000; NICE, SINGL TECHN APPR US; Nichol KL, 2003, VACCINE, V21, P2207, DOI 10.1016/S0264-410X(03)00029-X; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 2001, ARCH INTERN MED, V161, P749, DOI 10.1001/archinte.161.5.749; Odnoletkova I, 2014, J DIABETES METAB, V5, DOI 10.4172/2155-6156.1000438; Ott JJ, 2013, HUM VACC IMMUNOTHER, V9, P1500, DOI 10.4161/hv.24704; Philips Z, 2006, PHARMACOECONOMICS, V24, P355, DOI 10.2165/00019053-200624040-00006; Postma MJ, 1999, PHARMACOECONOMICS, V16, P33, DOI 10.2165/00019053-199916001-00005; Prosser LA, 2008, PHARMACOECONOMICS, V26, P163, DOI 10.2165/00019053-200826020-00006; Prosser LA, 2006, EMERG INFECT DIS, V12, P1548, DOI 10.3201/eid1210.051015; Prosser LA, 2011, ARCH PEDIAT ADOL MED, V165, P112, DOI 10.1001/archpediatrics.2010.182; Regan, 2003, HEALTH TECHNOL ASSES, V7, DOI [10.3310/hta7240, DOI 10.3310/HTA7240]; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; Roberts S, 2006, OBSTET GYNECOL, V107, P1323, DOI 10.1097/01.AOG.0000210225.45986.99; Salleras L, 2009, VACCINE, V27, P3454, DOI 10.1016/j.vaccine.2009.01.053; Sarntivijai S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049941; Schmier J, 2008, HEALTH AFFAIR, V27, pW96, DOI 10.1377/hlthaff.27.2.w96; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Sim J, 2005, PHYS THER, V85, P257; Skedgel C, 2011, CAN J PUBLIC HEALTH, V102, P445, DOI 10.1007/BF03404197; Smith KJ, 2010, VACCINE, V28, P7620, DOI 10.1016/j.vaccine.2010.09.053; Tarride JE, 2012, CLINICOECONOMIC OUTC, V4, P287, DOI 10.2147/CEOR.S33444; Teufel RJ, 2008, J HOSP MED, V3, P134, DOI 10.1002/jhm.286; Thommes EW, 2017, HUM VACC IMMUNOTHER, V13, P867, DOI 10.1080/21645515.2016.1251537; Ting EEK, 2017, VACCINE, V35, P1828, DOI 10.1016/j.vaccine.2017.02.044; Turner DA, 2006, VACCINE, V24, P1035, DOI 10.1016/j.vaccine.2004.12.033; Nazco CV, 2018, REV ESP SALUD PUBLIC, V92; van Mastrigt GAPG, 2016, EXPERT REV PHARM OUT, V16, P689, DOI 10.1080/14737167.2016.1246960; Vellozzi C, 2014, CLIN INFECT DIS, V58, P1149, DOI 10.1093/cid/ciu005; Wang ST, 2005, VACCINE, V23, P1973, DOI 10.1016/j.vaccine.2004.10.011; Weaver M, 2001, ARCH INTERN MED, V161, P111, DOI 10.1001/archinte.161.1.111; Weidemann F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2344-6; Weingart SN, 2002, HEALTH SERV RES, V37, P483, DOI 10.1111/1475-6773.033; Werker GR, 2014, VACCINE, V32, P677, DOI 10.1016/j.vaccine.2013.11.103; WHO, ADV EV FOLL IMM AEFI; WHO, INFL SEAS; World Health Organization, TYP SEAS INFL VACC; Xu J, 2016, VACCINE, V34, P3149, DOI 10.1016/j.vaccine.2016.04.057; Yang KC, 2018, INT J INFECT DIS, V73, P102, DOI 10.1016/j.ijid.2018.05.024; You JHS, 2009, J EPIDEMIOL COMMUN H, V63, P906, DOI 10.1136/jech.2008.081885; Zorzela L, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i157	99	2	2	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							111	10.3390/vaccines9020111			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6XL	33540633	gold, Green Published			2022-04-29	WOS:000623284500001
J	Li, ZF; Zhao, YW; Li, YB; Chen, XY				Li, Zhuofan; Zhao, Yiwen; Li, Yibo; Chen, Xinyuan			Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity	VACCINES			English	Review						vaccine adjuvant; influenza vaccine; cross-protection; MF59; AS03; physical adjuvant		Influenza poses a huge threat to global public health. Influenza vaccines are the most effective and cost-effective means to control influenza. Current influenza vaccines mainly induce neutralizing antibodies against highly variable globular head of hemagglutinin and lack cross-protection. Vaccine adjuvants have been approved to enhance seasonal influenza vaccine efficacy in the elderly and spare influenza vaccine doses. Clinical studies found that MF59 and AS03-adjuvanted influenza vaccines could induce cross-protective immunity against non-vaccine viral strains. In addition to MF59 and AS03 adjuvants, experimental adjuvants, such as Toll-like receptor agonists, saponin-based adjuvants, cholera toxin and heat-labile enterotoxin-based mucosal adjuvants, and physical adjuvants, are also able to broaden influenza vaccine-induced immune responses against non-vaccine strains. This review focuses on introducing the various types of adjuvants capable of assisting current influenza vaccines to induce cross-protective immunity in preclinical and clinical studies. Mechanisms of licensed MF59 and AS03 adjuvants to induce cross-protective immunity are also introduced. Vaccine adjuvants hold a great promise to adjuvant influenza vaccines to induce cross-protective immunity.	[Li, Zhuofan; Zhao, Yiwen; Li, Yibo; Chen, Xinyuan] Univ Rhode Isl, Biomed & Pharmaceut Sci, Coll Pharm, 7 Greenhouse Rd,Avedisian Hall,Room 480, Kingston, RI 02881 USA		Chen, XY (通讯作者)，Univ Rhode Isl, Biomed & Pharmaceut Sci, Coll Pharm, 7 Greenhouse Rd,Avedisian Hall,Room 480, Kingston, RI 02881 USA.	zhuofan_li@uri.edu; yiwen_zhao@uri.edu; yibo_li@uri.edu; xchen14@uri.edu	Zhao, Yiwen/AAA-2739-2022		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI139473]	This work is supported by the National Institutes of Health grant AI139473 (to X.Y.C.).	Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116; Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623; Amorij JP, 2010, LANCET INFECT DIS, V10, P699, DOI 10.1016/S1473-3099(10)70157-2; Ampofo WK, 2012, INFLUENZA OTHER RESP, V6, P142, DOI 10.1111/j.1750-2659.2011.00277.x; Ansaldi F, 2008, VACCINE, V26, P1525, DOI 10.1016/j.vaccine.2008.01.019; Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384; Barr IG, 1998, ADV DRUG DELIVER REV, V32, P247, DOI 10.1016/S0169-409X(98)00013-1; Baz M, 2013, VIRUS RES, V178, P78, DOI 10.1016/j.virusres.2013.05.006; Beddoe T, 2010, TRENDS BIOCHEM SCI, V35, P411, DOI 10.1016/j.tibs.2010.02.003; Behzad H, 2012, J INFECT DIS, V205, P466, DOI 10.1093/infdis/jir769; Belongia EA, 2009, J INFECT DIS, V199, P159, DOI 10.1086/595861; Bengtsson KL, 2011, EXPERT REV VACCINES, V10, P401, DOI [10.1586/ERV.11.25, 10.1586/erv.11.25]; Bernstein DI, 2008, J INFECT DIS, V197, P667, DOI 10.1086/527489; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Bodewes R, 2013, EMERG INFECT DIS, V19, P511, DOI 10.3201/eid1903.120965; Boivin S, 2010, J BIOL CHEM, V285, P28411, DOI 10.1074/jbc.R110.117531; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Brito LA, 2013, SEMIN IMMUNOL, V25, P130, DOI 10.1016/j.smim.2013.05.007; Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2; Cao Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06151-y; Carter D, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9930; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Chen XY, 2012, VACCINE, V31, P159, DOI 10.1016/j.vaccine.2012.10.069; Chen XY, 2012, CLIN CANCER RES, V18, P2240, DOI 10.1158/1078-0432.CCR-11-2654; Chen XY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013776; Christensen D, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01928; Chu DWS, 2009, VACCINE, V27, P7428, DOI 10.1016/j.vaccine.2009.07.102; Clayville Lisa R, 2011, P T, V36, P659; Clegg CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088979; Clegg CH, 2013, EXPERT REV VACCINES, V12, P767, DOI 10.1586/14760584.2013.811178; Clements JD, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00215-18; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333; Cox F, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0435-9; Cox F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135723; Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595; Cox RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131652; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; da Hora VP, 2011, VACCINE, V29, P1538, DOI 10.1016/j.vaccine.2010.11.091; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; de Boer PT, 2016, VALUE HEALTH, V19, P964, DOI 10.1016/j.jval.2016.05.012; de Jonge J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0187-4; De la Herran-Arita AK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007762; Dean Hansi J, 2006, Expert Opin Drug Deliv, V3, P557, DOI 10.1517/17425247.3.5.557; Di Mario S, 2012, LANCET ONCOL, V13, pE50, DOI 10.1016/S1470-2045(12)70054-2; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; El Sahlyt HM, 2008, EXPERT REV VACCINES, V7, P241, DOI 10.1586/14760584.7.2.241; Estrada LD, 2019, J IMMUNOL, V202, P392, DOI 10.4049/jimmunol.1801054; Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]; Garcon N, 2011, BIODRUGS, V25, P217, DOI 10.2165/11591760-000000000-00000; Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/ERV.11.29, 10.1586/erv.11.29]; Gelfand JA, 2019, FASEB J, V33, P3074, DOI 10.1096/fj.201801095R; Goff PH, 2015, J VIROL, V89, P3221, DOI 10.1128/JVI.03337-14; Gosling R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001994; Guan Y, 2009, REV SCI TECH OIE, V28, P39, DOI 10.20506/rst.28.1.1868; Hajam IA, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.172; Halff EF, 2012, J BIOL CHEM, V287, P38460, DOI 10.1074/jbc.M112.393512; Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587; Hatta M, 2018, EMERG INFECT DIS, V24, P1910, DOI 10.3201/eid2410.180403; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Herzog C, 2009, VACCINE, V27, P4381, DOI 10.1016/j.vaccine.2009.05.029; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Hu ZL, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01898; Huckriede A, 2005, VACCINE, V23, pS26, DOI 10.1016/j.vaccine.2005.04.026; Hung IFN, 2016, LANCET INFECT DIS, V16, P209, DOI 10.1016/S1473-3099(15)00354-0; Hutchison S, 2012, FASEB J, V26, P1272, DOI 10.1096/fj.11-184556; Icardi G, 2012, HUM VACC IMMUNOTHER, V8, P67, DOI 10.4161/hv.8.1.18419; Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916; Jennings LC, 2008, LANCET INFECT DIS, V8, P650, DOI 10.1016/S1473-3099(08)70232-9; Johansen K, 2009, EUROSURVEILLANCE, V14, P12; Kashiwagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082899; Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475; KENSIL CR, 1991, J IMMUNOL, V146, P431; Khurana S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0076-2; Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336; Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254; Kim WJ, 2015, VACCINE, V33, P4868, DOI 10.1016/j.vaccine.2015.07.055; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Kis EE, 2012, VACCINE, V30, P523, DOI 10.1016/j.vaccine.2011.11.020; Ko EJ, 2018, ANTIVIR RES, V156, P107, DOI 10.1016/j.antiviral.2018.06.004; Kon TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150700; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2012, J MED MICROBIOL, V61, P927, DOI 10.1099/jmm.0.038943-0; Koutsakos M, 2019, J IMMUNOL, V202, P382, DOI 10.4049/jimmunol.1801070; Kwon HI, 2017, J VIROL, V91, DOI [10.1128/JVI.02259-16, 10.1128/jvi.02259-16]; Langley JM, 2010, J INFECT DIS, V201, P1644, DOI 10.1086/652701; Laupeze B, 2019, VACCINE, V37, P5660, DOI 10.1016/j.vaccine.2019.07.098; Leroux-Roels G, 2009, EXPERT OPIN BIOL TH, V9, P1057, DOI 10.1517/14712590903066695; Leroux-Roels I, 2010, VACCINE, V28, P849, DOI 10.1016/j.vaccine.2009.10.017; Levin Y, 2015, HUM VACC IMMUNOTHER, V11, P991, DOI 10.1080/21645515.2015.1010871; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Lin YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29858-w; Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x; Long JS, 2019, NAT REV MICROBIOL, V17, P67, DOI 10.1038/s41579-018-0115-z; Lopes PP, 2018, J VIROL, V92, DOI 10.1128/JVI.02156-17; Lowen AC, 2017, ANNU REV VIROL, V4, P105, DOI 10.1146/annurev-virology-101416-041726; Lu J, 2018, EMERG INFECT DIS, V24, P1795, DOI 10.3201/eid2410.171063; Mair CM, 2014, BBA-BIOMEMBRANES, V1838, P1153, DOI 10.1016/j.bbamem.2013.10.004; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mastelic Beatris, 2010, Biologicals, V38, P594, DOI 10.1016/j.biologicals.2010.06.002; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; McAllister L, 2014, LANCET, V384, P674, DOI 10.1016/S0140-6736(14)60524-9; McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005; Milian E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/504831; Miller E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f794; Minutello M, 1999, VACCINE, V17, P99, DOI 10.1016/S0264-410X(98)00185-6; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6; Morse K, 2017, J IMMUNOL, V199, P1319, DOI 10.4049/jimmunol.1601873; Mulligan MJ, 2014, JAMA-J AM MED ASSOC, V312, P1409, DOI 10.1001/jama.2014.12854; Nichol KL, 2006, J INFECT DIS, V194, pS111, DOI 10.1086/507544; Nobusawa E, 2006, J VIROL, V80, P3675, DOI 10.1128/JVI.80.7.3675-3678.2006; Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536; Nolan T, 2014, VACCINE, V32, P6146, DOI 10.1016/j.vaccine.2014.08.068; O'Hagan DT, 2013, HUM VACC IMMUNOTHER, V9, P1698, DOI 10.4161/hv.24829; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; Pantel A, 2012, EUR J IMMUNOL, V42, P101, DOI 10.1002/eji.201141855; Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916; Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3; Pizza M, 2001, VACCINE, V19, P2534, DOI 10.1016/S0264-410X(00)00137-7; Poovorawan Y, 2013, PATHOG GLOB HEALTH, V107, P217, DOI 10.1179/2047773213Y.0000000103; POWERS DC, 1995, J INFECT DIS, V171, P1595, DOI 10.1093/infdis/171.6.1595; Quan FS, 2008, J VIROL, V82, P1350, DOI 10.1128/JVI.01615-07; Rambhia KJ, 2010, BIOSECUR BIOTERROR, V8, P321, DOI 10.1089/bsp.2010.0043; Ravi AD, 2015, INT J PHARM INVESTIG, V5, P192, DOI 10.4103/2230-973X.167662; Raymond DD, 2018, P NATL ACAD SCI USA, V115, P168, DOI 10.1073/pnas.1715471115; Rizza Paola, 2002, Trends in Immunology, V23, P381, DOI 10.1016/S1471-4906(02)02276-7; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Rosenkrands I, 2011, VACCINE, V29, P6283, DOI 10.1016/j.vaccine.2011.06.040; Sambhara S, 1998, J INFECT DIS, V177, P1266, DOI 10.1086/515285; Saunders-Hastings PR, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040066; Schaffner W, 2018, AM J MED, V131, P865, DOI 10.1016/j.amjmed.2018.02.019; Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5; Schwarz TF, 2009, VACCINE, V27, P6284, DOI 10.1016/j.vaccine.2009.01.040; Scorza FB, 2016, VACCINE, V34, P2926, DOI 10.1016/j.vaccine.2016.03.085; Shao WH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081650; Smith G, 2017, VACCINE, V35, P5366, DOI 10.1016/j.vaccine.2017.08.021; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Song WS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40878; Sticchi L, 2010, J Prev Med Hyg, V51, P7; Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032; Sun XJ, 2017, VIROLOGY, V508, P164, DOI 10.1016/j.virol.2017.05.010; TAMURA SI, 1992, J IMMUNOL, V149, P981; Taubenberger JK, 2009, REV SCI TECH OIE, V28, P187, DOI 10.20506/rst.28.1.1879; Taubenberger JK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5485; Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009; Temizoz B, 2016, INT IMMUNOL, V28, P329, DOI 10.1093/intimm/dxw015; Thompson BS, 2005, J LEUKOCYTE BIOL, V78, P1273, DOI 10.1189/jlb.0305172; Tosh PK, 2010, MAYO CLIN PROC, V85, P257, DOI 10.4065/mcp.2009.0615; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Trifonov V, 2009, NEW ENGL J MED, V361, P115, DOI 10.1056/NEJMp0904572; Tsai TF, 2013, INFECT CHEMOTHER, V45, P159, DOI 10.3947/ic.2013.45.2.159; Tsai TF, 2011, SCAND J INFECT DIS, V43, P702, DOI 10.3109/00365548.2011.580777; Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001; Valli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51356-w; Van Hoeven N, 2017, SCI REP-UK, V7, DOI 10.1038/srep46426; Vesikari T, 2012, HUM VACC IMMUNOTHER, V8, P921, DOI 10.4161/hv.20248; Wagstaff AJ, 2007, DRUGS, V67, P2187, DOI 10.2165/00003495-200767150-00006; Wang BZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013972; Wang BZ, 2008, J VIROL, V82, P11813, DOI 10.1128/JVI.01076-08; Wang J, 2015, P NATL ACAD SCI USA, V112, P5005, DOI 10.1073/pnas.1500408112; Wang J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5447; Wang XL, 2019, CLIN INFECT DIS, V68, P623, DOI 10.1093/cid/ciy541; Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383; Wen YM, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.40; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Wu NC, 2017, J MOL BIOL, V429, P2694, DOI 10.1016/j.jmb.2017.06.015; Xie H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15279; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; Yin DP, 2011, BIOMED ENVIRON SCI, V24, P624, DOI 10.3967/0895-3988.2011.06.006; Zhu Daming, 2016, Nat Prod Chem Res, V3; Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635	187	4	5	10	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							75	10.3390/vaccines9020075			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6PZ	33494477	Green Published, gold			2022-04-29	WOS:000623264900001
J	Shivam, S; El-Matbouli, M; Kumar, G				Shivam, Saloni; El-Matbouli, Mansour; Kumar, Gokhlesh			Development of Fish Parasite Vaccines in the OMICs Era: Progress and Opportunities	VACCINES			English	Review						fish parasites; immune response; omics; vaccines	PROLIFERATIVE KIDNEY-DISEASE; TROUT ONCORHYNCHUS-MYKISS; ICHTHYOPHTHIRIUS-MULTIFILIIS FOUQUET; ICTALURUS-PUNCTATUS RAFINESQUE; LICE LEPEOPHTHEIRUS-SALMONIS; TURBOT SCOPHTHALMUS-MAXIMUS; TOLL-LIKE RECEPTORS; CHANNEL CATFISH; SEA LICE; IMMUNE-RESPONSES	Globally, parasites are increasingly being recognized as catastrophic agents in both aquaculture sector and in the wild aquatic habitats leading to an estimated annual loss between 1.05 billion and 9.58 billion USD. The currently available therapeutic and control measures are accompanied by many limitations. Hence, vaccines are recommended as the "only green and effective solution" to address these concerns and protect fish from pathogens. However, vaccine development warrants a better understanding of host-parasite interaction and parasite biology. Currently, only one commercial parasite vaccine is available against the ectoparasite sea lice. Additionally, only a few trials have reported potential vaccine candidates against endoparasites. Transcriptome, genome, and proteomic data at present are available only for a limited number of aquatic parasites. Omics-based interventions can be significant in the identification of suitable vaccine candidates, finally leading to the development of multivalent vaccines for significant protection against parasitic infections in fish. The present review highlights the progress in the immunobiology of pathogenic parasites and the prospects of vaccine development. Finally, an approach for developing a multivalent vaccine for parasitic diseases is presented. Data sources to prepare this review included Pubmed, google scholar, official reports, and websites.	[Shivam, Saloni; El-Matbouli, Mansour; Kumar, Gokhlesh] Univ Vet Med Vienna, Clin Div Fish Med, A-1210 Vienna, Austria; [Shivam, Saloni] Cent Marine Fisheries Res Inst, Karwar 581301, India		Kumar, G (通讯作者)，Univ Vet Med Vienna, Clin Div Fish Med, A-1210 Vienna, Austria.	salonis@staff.vetmeduni.ac.at; mansour.el-matbouli@vetmeduni.ac.at; Gokhlesh.Kumar@vetmeduni.ac.at		Kumar, Gokhlesh/0000-0002-1958-2579; El-Matbouli, Mansour/0000-0001-8148-0218	Austrian Science Fund (FWF)Austrian Science Fund (FWF) [P 30981-B32]; Indian Council of Agricultural Research, New Delhi, India under Netaji Subhas ICAR International Fellowship	We are thankful to the Austrian Science Fund (FWF) Project Number P 30981-B32 for providing Open Access Funding. S.S. is thankful to the Indian Council of Agricultural Research, New Delhi, India for providing her with the scholarship to pursue PhD under Netaji Subhas ICAR International Fellowship 2018-2019.	Abos B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01203; Adams A, 2019, FISH SHELLFISH IMMUN, V90, P210, DOI 10.1016/j.fsi.2019.04.066; Agius C, 2003, J FISH DIS, V26, P499, DOI 10.1046/j.1365-2761.2003.00485.x; Amambua-Ngwa A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002992; [Anonymous], 2020, STATE WORLD FISHERIE; [Anonymous], NATL CTR BIOTECHNOLO; ARKOOSH MR, 1991, DEV COMP IMMUNOL, V15, P279, DOI 10.1016/0145-305X(91)90021-P; Baerwald MR, 2013, FISH SHELLFISH IMMUN, V35, P965, DOI 10.1016/j.fsi.2013.07.008; Bakke TA, 2007, ADV PARASIT, V64, P161, DOI 10.1016/S0065-308X(06)64003-7; Barker SE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209178; Bartholomew JL, 2002, AM FISH S S, V29, P3; Bartholomew JL, 1998, J AQUAT ANIM HEALTH, V10, P112, DOI 10.1577/1548-8667(1998)010&lt;0112:HRTIBT&gt;2.0.CO;2; Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9; Bethony J, 2005, FASEB J, V19, P1743, DOI 10.1096/fj.05-3936fje; Bjork SJ, 2014, FISH SHELLFISH IMMUN, V37, P87, DOI 10.1016/j.fsi.2013.12.024; Bogwald J, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120627; Boxall ABA, 2004, EMBO REP, V5, P1110, DOI 10.1038/sj.embor.7400307; Braden LM, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00556-17; Bravo S, 2008, AQUACULTURE, V282, P7, DOI 10.1016/j.aquaculture.2008.06.011; Brown GV, 2002, MED J AUSTRALIA, V177, P230, DOI 10.5694/j.1326-5377.2002.tb04752.x; Buchmann K, 2001, ACTA PARASITOL, V46, P71; Buchmann K, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12675; Budino B, 2011, VET PARASITOL, V175, P260, DOI 10.1016/j.vetpar.2010.10.011; BURKART MA, 1990, J FISH DIS, V13, P401, DOI 10.1111/j.1365-2761.1990.tb00799.x; Piazzon MC, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3007-1; Piazzon MC, 2014, DEV COMP IMMUNOL, V43, P280, DOI 10.1016/j.dci.2013.11.015; Cecilio P, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005951; Chang ES, 2015, P NATL ACAD SCI USA, V112, P14912, DOI 10.1073/pnas.1511468112; Chen K, 2017, PARASITE, V24, DOI 10.1051/parasite/2017045; Chin A, 2005, PARASITOL RES, V95, P299, DOI 10.1007/s00436-004-1270-x; CLARK TG, 1992, P NATL ACAD SCI USA, V89, P6363, DOI 10.1073/pnas.89.14.6363; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; CLIFTONHADLEY RS, 1986, AQUACULTURE, V55, P165, DOI 10.1016/0044-8486(86)90112-2; Coyne RS, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r100; Cuesta A, 2006, PARASITOLOGY, V132, P95, DOI 10.1017/S0031182005008759; Dalgaard M, 2002, B EUR ASSOC FISH PAT, V22, P288; Dalvin S, 2020, FISH SHELLFISH IMMUN, V103, P200, DOI 10.1016/j.fsi.2020.05.014; Davey GC, 2011, MOL IMMUNOL, V48, P2102, DOI 10.1016/j.molimm.2011.07.003; de Sousa TN, 2013, INFECT GENET EVOL, V19, P258, DOI 10.1016/j.meegid.2013.07.008; Dickerson HW, 2014, DEV COMP IMMUNOL, V43, P290, DOI 10.1016/j.dci.2013.06.004; Doolan DL, 2011, INT J PARASITOL, V41, P3, DOI 10.1016/j.ijpara.2010.08.002; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Dzikowski R, 2006, MOL MICROBIOL, V59, P364, DOI 10.1111/j.1365-2958.2005.05007.x; Ekor M, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00177; El-Matbouli M, 1999, DIS AQUAT ORGAN, V35, P1, DOI 10.3354/dao035001; Faber MN, 2019, FISH SHELLFISH IMMUN, V91, P423, DOI 10.1016/j.fsi.2019.04.159; Fast MD, 2014, DEV COMP IMMUNOL, V43, P300, DOI 10.1016/j.dci.2013.08.019; Feder ME, 2005, J EVOLUTION BIOL, V18, P901, DOI 10.1111/j.1420-9101.2005.00921.x; Feist Stephen W., 2006, P230, DOI 10.1079/9780851990156.0230; FERGUSON HW, 1979, J FISH DIS, V2, P219, DOI 10.1111/j.1365-2761.1979.tb00161.x; Findly RC, 2013, DEV COMP IMMUNOL, V39, P302, DOI 10.1016/j.dci.2012.08.007; Flamarique IN, 2009, CAN J FISH AQUAT SCI, V66, P1371, DOI 10.1139/F09-094; Fontenla F, 2016, MOL IMMUNOL, V75, P188, DOI 10.1016/j.molimm.2016.06.001; Frazer LN, 2009, CONSERV BIOL, V23, P599, DOI 10.1111/j.1523-1739.2008.01128.x; GIBBONS IR, 1963, P NATL ACAD SCI USA, V50, P1002, DOI 10.1073/pnas.50.5.1002; Gorgoglione B, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-55; GOVEN BA, 1980, J FISH BIOL, V17, P311, DOI 10.1111/j.1095-8649.1980.tb02764.x; GRAVES SS, 1985, COMP IMMUNOL MICROB, V8, P43, DOI 10.1016/0147-9571(85)90053-0; Grayson TH, 1995, J FISH BIOL, V47, P85, DOI 10.1111/j.1095-8649.1995.tb06046.x; Griffiths KL, 2014, CURR OPIN IMMUNOL, V28, P58, DOI 10.1016/j.coi.2014.02.003; Haase S, 2008, INFECT IMMUN, V76, P879, DOI 10.1128/IAI.00144-07; Hahn C, 2014, GENOME BIOL EVOL, V6, P1105, DOI 10.1093/gbe/evu078; Hallett SL, 2012, APPL ENVIRON MICROB, V78, P3724, DOI 10.1128/AEM.07801-11; Harikrishnan R, 2012, EXP PARASITOL, V131, P325, DOI 10.1016/j.exppara.2012.04.017; Hartigan A, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6705-y; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; Hedrick RP, 1998, IMMUNOL REV, V166, P365, DOI 10.1111/j.1600-065X.1998.tb01276.x; Hegde PS, 2003, CURR OPIN BIOTECH, V14, P647, DOI 10.1016/j.copbio.2003.10.006; HOFFMAN G L, 1990, Journal of Aquatic Animal Health, V2, P30, DOI 10.1577/1548-8667(1990)002&lt;0030:MCAWCO&gt;2.3.CO;2; Holzer AS, 2001, PARASITOLOGY, V122, P55, DOI 10.1017/S003118200000706X; Horne MT, 1997, DEV BIOLOGICALS, V90, P79; Hull R, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-53; Ivory Catherine, 2004, Genet Vaccines Ther, V2, P17, DOI 10.1186/1479-0556-2-17; JasoFriedmann L, 1996, CELL IMMUNOL, V170, P195, DOI 10.1006/cimm.1996.0152; Jayaraj R, 2009, VET PARASITOL, V160, P230, DOI 10.1016/j.vetpar.2008.10.099; Johnson AC, 2008, J HYDROL, V348, P167, DOI 10.1016/j.jhydrol.2007.09.054; Johnson SC, 2004, ZOOL STUD, V43, P229; Jones SRM, 2001, DEV COMP IMMUNOL, V25, P841, DOI 10.1016/S0145-305X(01)00039-8; Jorgensen LV, 2017, J FISH DIS, V40, P1815, DOI 10.1111/jfd.12653; Jorgensen LV, 2008, DIS AQUAT ORGAN, V80, P189, DOI 10.3354/dao01935; Jorgensen LV, 2017, FISH SHELLFISH IMMUN, V67, P586, DOI 10.1016/j.fsi.2017.06.044; Jorgensen LV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048129; Kane S.N., 2016, J PHYS C SER, V755, DOI [10.1088/1742-6596/755/1/011001, DOI 10.1088/1742-6596/755/1/011001]; Katzenback BA, 2008, VET PARASITOL, V151, P36, DOI 10.1016/j.vetpar.2007.09.030; Kavallaris M, 2005, MED J AUSTRALIA, V182, P575, DOI 10.5694/j.1326-5377.2005.tb06817.x; KENT ML, 1994, FOLIA PARASIT, V41, P27; Knox DP, 2006, PARASITOLOGY, V133, pS1, DOI 10.1017/S0031182006001776; KORTING W, 1975, J FISH BIOL, V7, P727, DOI 10.1111/j.1095-8649.1975.tb04645.x; Korytar T, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3462-3; Kotob MH, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2912-7; Kumar G, 2017, FISH RES, V186, P11, DOI 10.1016/j.fishres.2016.07.021; Kumar G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165910; Kumar G, 2020, PEERJ, V8, DOI 10.7717/peerj.9027; Kumar G, 2015, PARASITOL RES, V114, P1721, DOI 10.1007/s00436-015-4357-7; Kumar G, 2014, VET RES, V45, DOI 10.1186/s13567-014-0101-z; Leiro J, 2008, PARASITE IMMUNOL, V30, P535, DOI 10.1111/j.1365-3024.2008.01052.x; Li YW, 2016, DEV COMP IMMUNOL, V61, P180, DOI 10.1016/j.dci.2016.03.028; Lindner SE, 2013, MOL CELL PROTEOMICS, V12, P1127, DOI 10.1074/mcp.M112.024505; Lofthouse SA, 1996, INT J PARASITOL, V26, P835, DOI 10.1016/S0020-7519(96)80052-X; LOM J, 1983, PARASITOLOGY, V86, P529, DOI 10.1017/S003118200005071X; Lowe R, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005457; MACKINNON BM, 1993, CAN J FISH AQUAT SCI, V50, P789, DOI 10.1139/f93-091; Mai YZ, 2015, VET PARASITOL, V211, P1, DOI 10.1016/j.vetpar.2015.05.004; Matthews RA, 2005, ADV PARASIT, V59, P159, DOI 10.1016/S0065-308X(05)59003-1; Mendez S, 2001, J IMMUNOL, V166, P5122, DOI 10.4049/jimmunol.166.8.5122; Mo ZQ, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1919-1; Mo ZQ, 2016, FISH SHELLFISH IMMUN, V57, P198, DOI 10.1016/j.fsi.2016.08.011; Moller OS, 2012, FISH PARASITES: PATHOBIOLOGY AND PROTECTION, P327, DOI 10.1079/9781845938062.0327; Morris DJ, 2003, AQUACULTURE, V221, P51, DOI 10.1016/S0044-8486(03)00024-3; Munoz P, 2000, FISH SHELLFISH IMMUN, V10, P567, DOI 10.1006/fsim.2000.0272; Munoz P, 1999, INT J PARASITOL, V29, P521, DOI 10.1016/S0020-7519(98)00214-8; Murray AG, 2005, PREV VET MED, V67, P223, DOI 10.1016/j.prevetmed.2004.10.012; Mustafa A, 2000, FISH SHELLFISH IMMUN, V10, P47, DOI 10.1006/fsim.1999.0229; Mutoloki S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00519; Nakanishi Teruyuki, 2015, Biology-Basel, V4, P640, DOI 10.3390/biology4040640; National Centre for Biotechnology Information, NATL CTR BIOTECHNOLO; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Palikova M, 2017, VET PARASITOL, V238, P5, DOI 10.1016/j.vetpar.2017.03.003; Palti Y, 2011, DEV COMP IMMUNOL, V35, P1263, DOI 10.1016/j.dci.2011.03.006; Piazzon MC, 2011, FISH SHELLFISH IMMUN, V30, P1339, DOI 10.1016/j.fsi.2011.02.026; Picard-Sanchez A, 2019, FISH SHELLFISH IMMUN, V90, P349, DOI 10.1016/j.fsi.2019.04.300; Piriatinskiy G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09955-y; Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007; Prasenjit Mali, 2017, Journal of Interacademicia, V21, P372; Rauta PR, 2012, IMMUNOL LETT, V148, P23, DOI 10.1016/j.imlet.2012.08.003; Rigos G, 2001, BULL EUR ASSN FISH P, V21, P33; Riveau G, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001704; Rognlie NC, 1998, J PARASITOL, V84, P711, DOI 10.2307/3284575; Ronza P, 2016, INT J PARASITOL, V46, P507, DOI 10.1016/j.ijpara.2016.03.007; Sahoo PK, 2013, EXP PARASITOL, V135, P629, DOI 10.1016/j.exppara.2013.09.018; Saleh M, 2019, FISH SHELLFISH IMMUN, V84, P834, DOI 10.1016/j.fsi.2018.10.078; Salinas I, 2011, DEV COMP IMMUNOL, V35, P1346, DOI 10.1016/j.dci.2011.11.009; Saulnier D, 1996, DIS AQUAT ORGAN, V27, P103, DOI 10.3354/dao027103; Sepulcre MP, 2002, CELL TISSUE RES, V308, P97, DOI 10.1007/s00441-002-0531-1; Sevatdal S, 2005, AQUACULTURE, V244, P19, DOI 10.1016/j.aquaculture.2004.11.009; Shinn AP, 2015, PARASITOLOGY, V142, P196, DOI 10.1017/S0031182014001437; Sitja-Bobadilla A, 2008, FISH SHELLFISH IMMUN, V24, P1, DOI 10.1016/j.fsi.2007.06.007; Sitja-Bobadilla A, 2006, FISH SHELLFISH IMMUN, V21, P485, DOI 10.1016/j.fsi.2006.02.004; Sitja-Bobadilla A, 2004, FISH SHELLFISH IMMUN, V17, P335, DOI 10.1016/j.fsi.2004.04.007; Sitja-Bobadilla A, 2016, DEV COMP IMMUNOL, V64, P187, DOI 10.1016/j.dci.2016.01.014; Sitja-Bobadilla A, 2012, FISH PARASITES: PATHOBIOLOGY AND PROTECTION, P163, DOI 10.1079/9781845938062.0163; Skilton DC, 2020, AQUACULTURE, V516, DOI 10.1016/j.aquaculture.2019.734557; Sleigh M., 1974, CILIA AND FLAGELLA; Smith NC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02292; Sudhagar A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113755; Sudhagar A, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9010016; Sudhagar A, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3823-y; Sudhagar A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010245; Takano T., 2011, DIS ASIAN AQUACULTUR, V385, P197; Tarleton RL, 2005, CELL MICROBIOL, V7, P1379, DOI 10.1111/j.1462-5822.2005.00589.x; Valenzuela-Munoz V, 2016, FISH SHELLFISH IMMUN, V59, P276, DOI 10.1016/j.fsi.2016.10.046; Valladao GMR, 2015, J VET PHARMACOL THER, V38, P417, DOI 10.1111/jvp.12202; Villegas A., 1 EVER SEA LICE VACC; Wallace JL, 2005, MEM I OSWALDO CRUZ, V100, P5, DOI 10.1590/S0074-02762005000900002; Wang B, 2019, MOL BIOL EVOL, V36, P393, DOI 10.1093/molbev/msy230; Woo PTK, 2003, J FISH DIS, V26, P627, DOI 10.1046/j.1365-2761.2003.00500.x; Xu DH, 2008, FISH SHELLFISH IMMUN, V25, P124, DOI 10.1016/j.fsi.2008.03.012; Xu DH, 2019, FISH SHELLFISH IMMUN, V94, P308, DOI 10.1016/j.fsi.2019.08.071; Xu DH, 2013, FISH SHELLFISH IMMUN, V34, P1356, DOI 10.1016/j.fsi.2013.01.022; Xu Z, 2013, P NATL ACAD SCI USA, V110, P13097, DOI 10.1073/pnas.1304319110; Yambot AV, 2006, AQUACULTURE, V260, P1, DOI 10.1016/j.aquaculture.2006.05.055; Yeoh LM, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1756-6; YOKOYAMA H, 1990, FISH PATHOL, V25, P157, DOI 10.3147/jsfp.25.157; Yokoyama H, 2003, FISH PATHOL, V38, P125, DOI 10.3147/jsfp.38.125; Zhang YA, 2010, NAT IMMUNOL, V11, P827, DOI 10.1038/ni.1913; Zhao F, 2013, FISH SHELLFISH IMMUN, V35, P993, DOI 10.1016/j.fsi.2013.05.023; Zhao GH, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-175; Zhao YL, 2019, FISH SHELLFISH IMMUN, V94, P99, DOI 10.1016/j.fsi.2019.08.076	170	5	5	11	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							179	10.3390/vaccines9020179			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7KA	33672552	gold, Green Published			2022-04-29	WOS:000623317600001
J	Sordo-Puga, Y; Suarez-Pedroso, M; Naranjo-Valdez, P; Perez-Perez, D; Santana-Rodriguez, E; Sardinas-Gonzalez, T; Mendez-Orta, MK; Duarte-Cano, CA; Estrada-Garcia, MP; Rodriguez-Molto, MP				Sordo-Puga, Yusmel; Suarez-Pedroso, Marisela; Naranjo-Valdez, Paula; Perez-Perez, Danny; Santana-Rodriguez, Elaine; Sardinas-Gonzalez, Talia; Mendez-Orta, Mary Karla; Duarte-Cano, Carlos A.; Estrada-Garcia, Mario Pablo; Rodriguez-Molto, Maria Pilar			Porvac(R) Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus	VACCINES			English	Article						classical swine fever virus; Porvac (R) subunit vaccine E2-CD154; early protection; T cell IFN gamma responses	INTERFERON-GAMMA; CD40 LIGAND; HIGHLY VIRULENT; MARKER VACCINE; IFN-GAMMA; REPLICATION; DISEASE; INFECTION; RESPONSES; CD154	Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5-7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac(R) vaccine protects against highly virulent classical swine fever virus (CSFV) "Margarita" strain as early as seven days post-vaccination. In order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac(R) subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac(R), were challenged intranasally at five, three, and one day post-vaccination with 2 x 10(3) LD50 of the highly pathogenic Cuban "Margarita" strain of the classical swine fever virus. Another five animals were the negative control of the experiment. The results provided clinical and virological data confirming protection at five days post-vaccination. Classical swine fever (CSF)-specific IFN gamma T cell responses were detected in vaccinated animals but not detected in unvaccinated control animals. These results provided the first data that a subunit protein vaccine demonstrates clinical and viral protection at five days post-vaccination, as modified live vaccines.	[Sordo-Puga, Yusmel; Suarez-Pedroso, Marisela; Perez-Perez, Danny; Santana-Rodriguez, Elaine; Sardinas-Gonzalez, Talia; Mendez-Orta, Mary Karla; Duarte-Cano, Carlos A.; Estrada-Garcia, Mario Pablo; Rodriguez-Molto, Maria Pilar] Ctr Genet Engn & Biotechnol, Anim Biotechnol Dept, POB 6162, Havana 10600, Cuba; [Naranjo-Valdez, Paula] Cent Lab Unit Anim Hlth ULCSA, Havana 11400, Cuba		Rodriguez-Molto, MP (通讯作者)，Ctr Genet Engn & Biotechnol, Anim Biotechnol Dept, POB 6162, Havana 10600, Cuba.	yusmel.sordo@cigb.edu.cu; marisela.suarez@cigb.edu.cu; labconestatal@hab.minag.cu; danny.perez@cigb.edu.cu; elaine.santana@cigb.edu.cu; talia.sardina@cigb.edu.cu; mary.mendez@cigb.edu.cu; carlos.duarte@cigb.edu.cu; mario.pablo@cigb.edu.cu; pilar.rodriguez@cigb.edu.cu		Estrada, Mario Pablo/0000-0002-9776-719X; Sordo Puga, Yusmel/0000-0002-0866-195X; Suarez, Marisela/0000-0002-6051-2652	Centro de Ingenieria Genetica y Biotecnologia, La Habana, Cuba	This research was funded by the Centro de Ingenieria Genetica y Biotecnologia, La Habana, Cuba. This research received no external funding.	BIRONT P, 1987, VET MICROBIOL, V14, P105, DOI 10.1016/0378-1135(87)90002-2; Blome S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040086; Bouma A, 2000, VACCINE, V18, P1374, DOI 10.1016/S0264-410X(99)00398-9; Cao J, 2010, VACCINE, V28, P7514, DOI 10.1016/j.vaccine.2010.09.002; de Smit AJ, 2001, VET MICROBIOL, V78, P307, DOI 10.1016/S0378-1135(00)00306-0; Dewulf J, 2001, J VET MED B, V48, P583, DOI 10.1046/j.1439-0450.2001.00467.x; Dong XN, 2007, VACCINE, V25, P205, DOI 10.1016/j.vaccine.2006.07.033; Edwards S, 2000, VET MICROBIOL, V73, P103, DOI 10.1016/S0378-1135(00)00138-3; Fernandez-Sainz I, 2015, VIROLOGY, V483, P284, DOI 10.1016/j.virol.2015.04.024; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Ganges L, 2008, VET J, V177, P169, DOI 10.1016/j.tvjl.2007.01.030; Ganges L, 2020, VIRUS RES, V289, DOI 10.1016/j.virusres.2020.198151; Gares SL, 2006, CLIN VACCINE IMMUNOL, V13, P958, DOI 10.1128/CVI.00080-06; Graham SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029310; Graham SP, 2012, VACCINE, V30, P2742, DOI 10.1016/j.vaccine.2012.02.029; Graham SP, 2010, VET MICROBIOL, V142, P34, DOI 10.1016/j.vetmic.2009.09.040; Huang Y, 2006, HEPATOLOGY, V43, P81, DOI 10.1002/hep.21011; Kanda T, 2009, J VIROL, V83, P8463, DOI 10.1128/JVI.00751-09; Leifer I, 2009, VACCINE, V27, P6522, DOI 10.1016/j.vaccine.2009.08.057; Lieberman LA, 2002, MICROBES INFECT, V4, P1531, DOI 10.1016/S1286-4579(02)00036-9; Mittelholzer C, 2000, VET MICROBIOL, V74, P293, DOI 10.1016/S0378-1135(00)00195-4; Moennig V, 2000, VET MICROBIOL, V73, P93, DOI 10.1016/S0378-1135(00)00137-1; Moennig V, 2003, VET J, V165, P11, DOI 10.1016/S1090-0233(02)00112-0; Munoz-Gonzalez S, 2017, VET MICROBIOL, V205, P110, DOI 10.1016/j.vetmic.2017.05.003; Neves PCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081953; OIE, 2014, OIE TERR MAN; Postel A, 2013, VET MICROBIOL, V161, P334, DOI 10.1016/j.vetmic.2012.07.045; Ramos OS, 2011, COMP IMMUNOL MICROB, V34, P259, DOI 10.1016/j.cimid.2010.12.001; Segundo FDS, 2010, J VIROL, V84, P2063, DOI 10.1128/JVI.01874-09; Suarez M, 2017, VACCINE, V35, P4437, DOI 10.1016/j.vaccine.2017.05.028; Suradhat S, 2001, VET IMMUNOL IMMUNOP, V83, P177, DOI 10.1016/S0165-2427(01)00389-0; TERPSTRA C, 1984, VET MICROBIOL, V9, P113, DOI 10.1016/0378-1135(84)90026-9; Tregaskes CA, 2005, DEV COMP IMMUNOL, V29, P361, DOI 10.1016/j.dci.2004.09.001; van Oirschot JT, 2003, VET MICROBIOL, V96, P367, DOI 10.1016/j.vetmic.2003.09.008; Wang FI, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090745; Xu YF, 2004, J BIOMED SCI, V11, P426, DOI 10.1159/000077892	36	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							167	10.3390/vaccines9020167			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UC	33671399	Green Published, gold			2022-04-29	WOS:000623275600001
J	Liprandi, AS; Zaidel, EJ; Santi, RL; Araujo, JJ; Gonzalez, MAB; Busso, JM; Cabral, L; Camilletti, J; Erriest, J; Flores, R; Forte, E; Ramos, MG; Castillo, MM; Zambrano, LJR; Roa, C; Custodio-Sanchez, P; Ortiz, GS; Spitz, B; Baranchuk, A				Sosa Liprandi, Alvaro; Jose Zaidel, Ezequiel; Lopez Santi, Ricardo; Jairo Araujo, John; Banos Gonzalez, Manuel Alfonso; Martin Busso, Juan; Cabral, Luz; Camilletti, Jorge; Erriest, Juan; Flores, Roberto; Forte, Ezequiel; Guzman Ramos, Mirecly; Mendez Castillo, Maxima; Ramirez Zambrano, Leonardo Josue; Roa, Carmen; Custodio-Sanchez, Piero; Solache Ortiz, Gustavo; Spitz, Bernardo; Baranchuk, Adrian			Influenza and Pneumococcal Vaccination in Non-Infected Cardiometabolic Patients from the Americas during the COVID-19 Pandemic. A Sub-Analysis of the CorCOVID-LATAM Study	VACCINES			English	Article						COVID-19; SARS-CoV-2; Influenza vaccination; pneumococcal vaccination; cardio-metabolic	ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; ELDERLY PERSONS; RISK; RECOMMENDATIONS; ASSOCIATION; EVENTS; STROKE; HOSPITALIZATION	Background: Influenza vaccination (IV) and Pneumococcus vaccination (PV) are recommended for patients with cardiometabolic diseases. This study aimed to evaluate the immunization rate of ambulatory cardiometabolic patients during the COVID-19 pandemic in the Americas. Methods: Electronic surveys were collected from 13 Spanish speaking countries between 15 June and 15 July 2020. Results: 4216 patients were analyzed. Mean age 60 (+/- 15) years and 49% females. Global IV rate was 46.5% and PV 24.6%. Vaccinated patients were older (IV = 63 vs. 58 years; PV = 68 vs. 59, p < 0.01) but without gender difference. Vaccination rates were greater in higher-risk groups (65+, diabetics, heart failure), but not in coronary artery disease patients. In the Southern cone, the rate of IV and PV was approximately double that in the tropical regions of the Americas. In a multivariate model, geographic zone (IV = OR 2.02, PV = OR 2.42, p < 0.001), age (IV = OR 1.023, PV = OR 1.035, p < 0.001), and incomes (IV = OR 1.28, PV = OR 1.58, p < 0.001) were predictors for vaccination. Conclusions: During the COVID-19 pandemic, ambulatory patients with cardiometabolic diseases from the Americas with no evidence of COVID-19 infection had lower-than-expected rates of IV and PV. Geographic, social, and cultural differences were found, and they should be explored in depth.	[Sosa Liprandi, Alvaro; Jose Zaidel, Ezequiel] Sanatorio Guemes Hosp Privado, C1180AAX, Buenos Aires, DF, Argentina; [Lopez Santi, Ricardo; Camilletti, Jorge; Erriest, Juan] Hosp Italiano La Plata, RA-1900 La Plata B, Argentina; [Jairo Araujo, John] Ctr Cardiovasc Somer Incare, Rionegro 054040, Colombia; [Banos Gonzalez, Manuel Alfonso] Univ Juarez Autonoma Tabasco, Cardiol Dept, Villahermosa Tabasco 86040, Mexico; [Martin Busso, Juan] Sanatorio San Jose, RA-1425 Buenos Aires C, DF, Argentina; [Cabral, Luz] Hosp Nacl Itaugua, Ctr Med Nacl, Itaugua 2740, Paraguay; [Flores, Roberto] Hosp Ramon Carrillo, RA-4200 Santiago Del Estero G, Argentina; [Forte, Ezequiel] CENDIC Ctr Diagnost Cardiovasc, RA-3202 Concordia E, Argentina; [Guzman Ramos, Mirecly] IVSS Dr Luis Guada Lacau, Valencia 2300, Venezuela; [Mendez Castillo, Maxima] CEDIMAT, Santo Domingo 10514, Dominican Rep; [Ramirez Zambrano, Leonardo Josue] Ctr Clin San Cristobal, San Cristobal 5001, Venezuela; [Roa, Carmen] Hosp Metropolitano Santiago, Santo Domingo 51000, Dominican Rep; [Custodio-Sanchez, Piero] Hosp Nacl Almanzor Aguinaga Asenjo Essalud, Chiclayo 14001, Peru; [Solache Ortiz, Gustavo] Inst Cardiol Prevent, San Juan Del Rio 76800, Mexico; [Spitz, Bernardo] Clin Cuyo, RA-5500 Mendoza M, Argentina; [Baranchuk, Adrian] Queens Univ, Kingston, ON K7L 3N6, Canada		Liprandi, AS (通讯作者)，Sanatorio Guemes Hosp Privado, C1180AAX, Buenos Aires, DF, Argentina.	asosaliprandi@gmail.com; ezaidel@fsg.edu.ar; lopezsan@live.com.ar; Johnjairoaraujo@gmail.com; manuel_banos@hotmail.com; j.m.busso@gmail.com; luzcabral@yahoo.com; jcamil@speedy.com.ar; erriestjuan@gmail.com; roberto_flores77@yahoo.es; ezeforte@yahoo.com; mireclyguzman@gmail.com; drammendez18@gmail.com; cardiolecturas@gmail.com; encarnacionroa@yahoo.es; custodiomed@hotmail.com; gustavosolache@gmail.com; spitzbeni@gmail.com; Adrian.Baranchuk@kingstonhsc.ca	Araujo, John Jairo/ABG-8173-2021; , BAÑOS-GONZALEZ/AAP-2589-2021	Araujo, John Jairo/0000-0002-2182-0687; , BAÑOS-GONZALEZ/0000-0002-6155-2939; Forte, Ezequiel Hernan/0000-0002-6222-4312; Cabral, Luz/0000-0002-1355-9837; Custodio - Sanchez, Piero/0000-0003-4215-7682; Lopez Santi, Ricardo/0000-0002-1713-326X	Inter American Society of Cardiology IASC	This research was funded by the Inter American Society of Cardiology IASC.	Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.016, 10.1016/j.jacc.2014.09.017]; Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131; Bambra C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/jech-2020-214401; Black D, 2017, VALUE HEALTH, V20, pPA934, DOI [10.1016/j.jval.2017.08.2951, DOI 10.1016/J.JVAL.2017.08.2951]; Bovier PA, 2001, VACCINE, V19, P4760, DOI 10.1016/S0264-410X(01)00223-7; Bridges Carolyn B, 2002, MMWR Recomm Rep, V51, P1; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Burki T, 2019, LANCET DIGIT HEALTH, V1, pE258, DOI 10.1016/S2589-7500(19)30136-0; Centers for Disease Control, 1988, JAMA-J AM MED ASSOC, V260, P3253, DOI [10.1001/jama.1988.03410220023007, DOI 10.1001/JAMA.1988.03410220023007]; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P886; Chan MPS, 2020, VACCINE, V38, P6236, DOI 10.1016/j.vaccine.2020.07.054; Christenson B, 2004, EUR RESPIR J, V23, P363, DOI 10.1183/09031936.04.00063504; Ciszewski A, 2008, EUR HEART J, V29, P1350, DOI 10.1093/eurheartj/ehm581; Clar C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005050.pub3; Clayton TC, 2008, EUR HEART J, V29, P96, DOI 10.1093/eurheartj/ehm516; Conrad N, 2019, JAMA CARDIOL, V4, P1102, DOI 10.1001/jamacardio.2019.3593; Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006; Germain S, 2020, FEM LEGAL STUD, V28, P301, DOI 10.1007/s10691-020-09437-z; Godoy P, 2018, EUR J PUBLIC HEALTH, V28, P150, DOI 10.1093/eurpub/ckx130; Grohskopf LA, 2020, JAMA-J AM MED ASSOC, V324, P1029, DOI 10.1001/jama.2020.15845; Gurfinkel EP, 2002, CIRCULATION, V105, P2143, DOI 10.1161/01.CIR.0000016182.85461.F4; Hill JA, 2019, INT J CARDIOL, V277, P1, DOI 10.1016/j.ijcard.2018.12.071; Hung IFN, 2010, CLIN INFECT DIS, V51, P1007, DOI 10.1086/656587; Khargekar NC, 2020, ASIA-PAC J ONCOL NUR, V7, P308, DOI 10.4103/apjon.apjon_21_20; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Kwok CS, 2015, INT J CLIN PRACT, V69, P928, DOI 10.1111/ijcp.12646; Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090; Lamontagne F, 2008, CAN MED ASSOC J, V179, P773, DOI 10.1503/cmaj.070221; Lane D, 2002, BRIT J HEALTH PSYCH, V7, P11, DOI 10.1348/135910702169321; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; LeBras MH, 2017, CAN J HOSP PHARM, V70, P27; Looijmans-van den Akker I, 2007, PREV MED, V45, P380, DOI 10.1016/j.ypmed.2007.07.009; Lopez Santi Ricardo, 2020, CJC Open, V2, P671, DOI 10.1016/j.cjco.2020.08.007; MacIntyre CR, 2016, HEART, V102, P1953, DOI 10.1136/heartjnl-2016-309983; Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035; Mazzone PJ, 2020, CHEST, V158, P406, DOI 10.1016/j.chest.2020.04.020; McLaughlin JM, 2019, HUM VACC IMMUNOTHER, V15, P841, DOI 10.1080/21645515.2018.1564434; Mitchell EP, 2020, J NATL MED ASSOC, V112, P563, DOI 10.1016/j.jnma.2020.12.004; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Nichol KL, 2005, DRUG AGING, V22, P495, DOI 10.2165/00002512-200522060-00004; Nuorti J.P., 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; O'Dowd A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4035; PAHO, INFL VACC AM RISK GR; PAHO, COVID STAT AM; Phrommintikul A, 2011, EUR HEART J, V32, P1730, DOI 10.1093/eurheartj/ehr004; Piskorz D, 2021, CURR PROB CARDIOLOGY, V46, DOI 10.1016/j.cpcardiol.2020.100737; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Rahnavardi M., 2009, CLIN MICROBIOL INFEC, V15, pS395; Rodrigues BS, 2020, HEART, V106, P350, DOI 10.1136/heartjnl-2019-315193; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shaukat A, 2020, LANCET GASTROENTEROL, V5, DOI 10.1016/S2468-1253(20)30191-6; Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206; United Nations, 2020, WORLD EC SIT PROSP M; Vensentini N, 2020, MEDICINA-BUENOS AIRE, V80, P425; Vila-Corcoles A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-222; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/S0140-6736(07)61602-X; Vose JM, 2020, ONCOLOGY-NY, V34, P343, DOI 10.46883/ONC.2020.3409.0343; Warren-Gash C, 2009, LANCET INFECT DIS, V9, P601, DOI 10.1016/S1473-3099(09)70233-6; Whitney CG, 2001, CLIN INFECT DIS, V33, P662, DOI 10.1086/322676; Wong CM, 2013, INFLUENZA OTHER RESP, V7, P531, DOI 10.1111/j.1750-2659.2012.00411.x; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Zimmerman RK, 2003, VACCINE, V21, P1510, DOI 10.1016/S0264-410X(02)00698-9	63	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							123	10.3390/vaccines9020123			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6TK	33557082	Green Published, gold			2022-04-29	WOS:000623273800001
J	Sordo-Puga, Y; Perez-Perez, D; Montero-Espinosa, C; Oliva-Cardenas, A; Sosa-Teste, I; Duarte, CA; Rodriguez-Molto, MP; Sardina-Gonzalez, T; Santana-Rodriguez, E; Vargas-Hernandez, M; Cabrera-Otano, Y; Ancizar-Fragoso, JA; Fuentes-Rodriguez, Y; Estrada, MP; Suarez-Pedroso, M				Sordo-Puga, Yusmel; Perez-Perez, Danny; Montero-Espinosa, Carlos; Oliva-Cardenas, Ayme; Sosa-Teste, Iliana; Duarte, Carlos A.; Rodriguez-Molto, Maria Pilar; Sardina-Gonzalez, Talia; Santana-Rodriguez, Elaine; Vargas-Hernandez, Milagros; Cabrera-Otano, Yaneris; Ancizar-Fragoso, Julio A.; Fuentes-Rodriguez, Yohandy; Pablo Estrada, Mario; Suarez-Pedroso, Marisela			Immunogenicity of E2CD154 Subunit Vaccine Candidate against Classical Swine Fever in Piglets with Different Levels of Maternally Derived Antibodies	VACCINES			English	Article						classical swine fever virus; E2CD154; maternally derived antibodies; subunit vaccine candidate		E2CD154 is a novel subunit vaccine candidate against classical swine fever virus (CSFV). It contains the E2 envelope protein from CSFV fused to the porcine CD154 molecule formulated in the oil adjuvant Montanide(TM) ISA50 V2. Previous works evidenced the safety and immunogenicity of this candidate. Here, two other important parameters related to vaccine efficacy were assessed. First, the existence of high maternally derived antibody (MDA) titers in piglets born to sows vaccinated with E2CD154 was demonstrated. These MDA titers remained above 1:200 during the first seven weeks of life. To assess whether the titers interfere with active vaccination, 79 piglets from sows immunized with either E2CD154 or a modified live vaccine were vaccinated with E2CD154 following a 0-21-day biphasic schedule. Animals immunized at either 15, 21, or 33 days of age responded to vaccination by eliciting protective neutralizing antibody (NAb) titers higher than 1:600, with a geometric mean of 1:4335, one week after the booster. Those protective levels of NAb were sustained up to six months of age. No vaccination-related adverse effects were described. As a conclusion, E2CD154 is able to induce protective NAb in piglets with different MDA levels and at different days of age.	[Sordo-Puga, Yusmel; Perez-Perez, Danny; Montero-Espinosa, Carlos; Oliva-Cardenas, Ayme; Duarte, Carlos A.; Rodriguez-Molto, Maria Pilar; Sardina-Gonzalez, Talia; Santana-Rodriguez, Elaine; Vargas-Hernandez, Milagros; Fuentes-Rodriguez, Yohandy; Pablo Estrada, Mario; Suarez-Pedroso, Marisela] Ctr Ingn Genet & Biotecnol, Havana 10600, Cubanacan, Cuba; [Sosa-Teste, Iliana] Ctr Nacl Prod Anim Lab, Havana 10600, Cubanacan, Cuba; [Cabrera-Otano, Yaneris; Ancizar-Fragoso, Julio A.] Inst Invest Porcinas, Artemisa 19200, Cuba		Suarez-Pedroso, M (通讯作者)，Ctr Ingn Genet & Biotecnol, Havana 10600, Cubanacan, Cuba.	yusmel.sordo@cigb.edu.cu; danny.perez@cigb.edu.cu; carlos.montero@cigb.edu.cu; ayme.oliva@cigb.edu.cu; iliana.sosa@cenpalab.cu; carlos.duarte@cigb.edu.cu; pilar.rodriguez@cigb.edu.cu; talia.sardina@cigb.edu.cu; elaine.santana@cigb.edu.cu; milagros.vargas@cigb.edu.cu; yaneriscabrera72@gmail.com; jancizarjr@gmail.com; yohandy.fuentes@cigb.edu.cu; mario.pablo@cigb.edu.cu; marisela.suarez@cigb.edu.cu		Estrada, Mario Pablo/0000-0002-9776-719X; Suarez, Marisela/0000-0002-6051-2652; Sordo Puga, Yusmel/0000-0002-0866-195X	Centro de Ingenieria Genetica y Biotecnologia, La Habana, Cuba	This research was funded by the Centro de Ingenieria Genetica y Biotecnologia, La Habana, Cuba. This research received no external funding.	[Anonymous], 2014, OIE TERR MAN, P1; Blome S, 2010, VET MICROBIOL, V146, P276, DOI 10.1016/j.vetmic.2010.05.035; de Arce HD, 1999, VIRUS RES, V64, P61, DOI 10.1016/S0168-1702(99)00077-5; Fonseca O, 2018, SPAN J AGRIC RES, V16, DOI 10.5424/sjar/2018162-12487; Graham SP, 2010, VET MICROBIOL, V142, P34, DOI 10.1016/j.vetmic.2009.09.040; Greiser-Wilke Irene, 2004, Animal Health Research Reviews, V5, P223, DOI 10.1079/AHR200472; Ji W, 2014, INFECT GENET EVOL, V25, P69, DOI 10.1016/j.meegid.2014.04.008; Klinkenberg D, 2002, VACCINE, V20, P3005, DOI 10.1016/S0042-207X(02)00283-X; Lai S. S., 1980, Journal of the Chinese Society of Veterinary Science, V6, P77; Lipowski A, 2000, VET MICROBIOL, V77, P99, DOI 10.1016/S0378-1135(00)00266-2; Lopez O., 2008, I INVESTIG PORC, V1, P47; Luo YZ, 2017, VET MICROBIOL, V201, P154, DOI 10.1016/j.vetmic.2017.01.012; Luo YZ, 2014, VET MICROBIOL, V172, P1, DOI 10.1016/j.vetmic.2014.04.004; Munoz-Gonzalez S, 2017, VET MICROBIOL, V205, P110, DOI 10.1016/j.vetmic.2017.05.003; Nguyen TV, 2007, VET IMMUNOL IMMUNOP, V117, P236, DOI 10.1016/j.vetimm.2007.02.013; Parchariyanon S., 1994, J THAI VET MED ASS, V45, P37; Prodanov-Radulovic J, 2014, ACTA VET-BEOGRAD, V64, P493, DOI 10.2478/acve-2014-0046; Rogan D, 2005, REV SCI TECH OIE, V24, P159, DOI 10.20506/rst.24.1.1561; Suarez M, 2017, VACCINE, V35, P4437, DOI 10.1016/j.vaccine.2017.05.028; Suradhat S, 2007, VET MICROBIOL, V119, P1, DOI 10.1016/j.vetmic.2006.10.003; Suradhat S, 2003, VET MICROBIOL, V92, P187, DOI 10.1016/S0378-1135(02)00357-7; Suvintarakorn K., 1993, Thai Journal of Veterinary Medicine, V23, P93; TERPSTRA C, 1984, VET MICROBIOL, V9, P113, DOI 10.1016/0378-1135(84)90026-9; Toledo JR, 2008, J BIOTECHNOL, V133, P370, DOI 10.1016/j.jbiotec.2007.09.014; Vandeputte J, 2001, AM J VET RES, V62, P1805, DOI 10.2460/ajvr.2001.62.1805; Vega E, 2011, Rev Salud Anim., V33, P170; Vega E, 2011, Rev Salud Anim., V33, P51	27	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							7	10.3390/vaccines9010007			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TY	33374172	Green Published, gold			2022-04-29	WOS:000610805700001
J	Achtnichts, L; Jakopp, B; Oberle, M; Nedeltchev, K; Fux, CA; Sellner, J; Findling, O				Achtnichts, Lutz; Jakopp, Barbara; Oberle, Michael; Nedeltchev, Krassen; Fux, Christoph Andreas; Sellner, Johann; Findling, Oliver			Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis	VACCINES			English	Article						SARS-CoV-2; B cell depletion; humoral immune response; vaccination; COVID-19		CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS (pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell-depleted individuals is limited. We studied the seroconversion after the third mRNA SARS-CoV-2 vaccine in B cell-depleted pwMS with limited or no IgG response after the standard immunization. Sixteen pwMS treated with ocrelizumab or rituximab received a third homologous SARS-CoV-2 mRNA vaccine, either the Moderna mRNA-1273 or Pfizer-BioNTech's BNT162b2 vaccine. We quantified the response of IgG antibodies against the spike receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered clinically relevant. The median time between the last infusion of the anti-CD20 treatment and the third vaccination was 22.9 weeks (range 15.1-31.3). After the third vaccination, one out of 16 patients showed an IgG titer deemed clinically relevant. Only the seroconverted patient had measurable B-cell counts at the time of the third vaccination. The development of a humoral immune response remains rare in pwMS on anti-CD20 therapy, even after third dose of the homologous SARS-CoV-2 mRNA vaccine. It remains to be determined whether T-cell responses can compensate for the lack of seroconversion and provide sufficient protection against CoV-2 infections.	[Achtnichts, Lutz; Nedeltchev, Krassen; Findling, Oliver] Aarau Cantonal Hosp, Dept Neurol, CH-5000 Aarau, Switzerland; [Jakopp, Barbara; Fux, Christoph Andreas] Aarau Cantonal Hosp, Dept Infect Dis & Hosp Infect Prevent, CH-5000 Aarau, Switzerland; [Oberle, Michael] Aarau Cantonal Hosp, Inst Lab Med, CH-5000 Aarau, Switzerland; [Nedeltchev, Krassen] Univ Bern, Dept Neurol, CH-3012 Bern, Switzerland; [Sellner, Johann] Landesklinikum Mistelbach Ganserndorf, Dept Neurol, A-2130 Mistelbach, Austria; [Findling, Oliver] Univ Hosp, Head Spine & Neuromed Clin Res & Biomed & Biomed, MS Ctr, CH-4031 Basel, Switzerland; [Findling, Oliver] Univ Hosp, Head Spine & Neuromed Clin Res & Biomed & Biomed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, CH-4031 Basel, Switzerland; [Findling, Oliver] Univ Basel, CH-4031 Basel, Switzerland		Findling, O (通讯作者)，Aarau Cantonal Hosp, Dept Neurol, CH-5000 Aarau, Switzerland.; Findling, O (通讯作者)，Univ Hosp, Head Spine & Neuromed Clin Res & Biomed & Biomed, MS Ctr, CH-4031 Basel, Switzerland.; Findling, O (通讯作者)，Univ Hosp, Head Spine & Neuromed Clin Res & Biomed & Biomed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, CH-4031 Basel, Switzerland.; Findling, O (通讯作者)，Univ Basel, CH-4031 Basel, Switzerland.	Lutz.Achtnichts@ksa.ch; Barbara.jakopp@ksa.ch; Michael.Oberle@ksa.ch; Krassen.Nedeltchev@ksa.ch; Christoph.Fux@ksa.ch; Johann.Sellner@mistelbach.lknoe.at; Oliver.Findling@ksa.ch		Achtnichts, Lutz/0000-0002-3713-9570			Achiron A, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211012835; Ali A, 2021, VACCINE, V39, P6111, DOI 10.1016/j.vaccine.2021.08.078; Apostolidis SA, 2021, NAT MED, V27, P1990, DOI 10.1038/s41591-021-01507-2; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339; Brill L, 2021, JAMA NEUROL, V78, P1510, DOI 10.1001/jamaneurol.2021.3599; Bsteh G, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103692; Castelo-Branco A, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102420; Dimeglio C, 2022, J INFECTION, V84, P257, DOI 10.1016/j.jinf.2021.09.013; Disanto G, 2021, JAMA NEUROL, V78, P1529, DOI 10.1001/jamaneurol.2021.3609; Finding O, 2021, DRUG DISCOV TODAY, V26, P416, DOI 10.1016/j.drudis.2020.11.022; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Ho Tzu-Chuan, 2021, Vaccines (Basel), V9, DOI 10.3390/vaccines9101163; Hosseini ES, 2020, VIROLOGY, V551, P1, DOI 10.1016/j.virol.2020.08.011; Li MC, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00767-1; Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Nehal KR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101071; Nelson Richard E, 2015, Int J MS Care, V17, P221, DOI 10.7224/1537-2073.2014-035; Novak F, 2021, MULT SCLER RELAT DIS, V56, DOI 10.1016/j.msard.2021.103251; Persson R, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.101982; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rolfes L, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001035; Sacco PL, 2020, B WORLD HEALTH ORGAN, V99, P529, DOI 10.2471/BLT.20.267757; Safavi F, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102195; Sahraian MA, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102472; Schulte EC, 2021, EBIOMEDICINE, V73, DOI 10.1016/j.ebiom.2021.103635; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Sellner J, 2021, EUR J NEUROL, V28, P3226, DOI 10.1111/ene.14713; Sormani MP, 2021, ANN NEUROL, V89, P780, DOI 10.1002/ana.26028; Sormani MP, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103581; Sormani MP, 2021, ANN CLIN TRANSL NEUR, V8, P1738, DOI 10.1002/acn3.51408; Steelman AJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00520; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355	34	6	6	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1470	10.3390/vaccines9121470			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2LE	34960216	Green Published, gold			2022-04-29	WOS:000737488700001
J	Kwiecinska-Pirog, J; Przekwas, J; Kraszewska, Z; Sekowska, A; Brodzka, S; Wiktorczyk-Kapischke, N; Grudlewska-Buda, K; Walecka-Zacharska, E; Zacharski, M; Mankowska-Cyl, A; Gospodarek-Komkowska, E; Skowron, K				Kwiecinska-Pirog, Joanna; Przekwas, Jana; Kraszewska, Zuzanna; Sekowska, Alicja; Brodzka, Sylwia; Wiktorczyk-Kapischke, Natalia; Grudlewska-Buda, Katarzyna; Walecka-Zacharska, Ewa; Zacharski, Maciej; Mankowska-Cyl, Aneta; Gospodarek-Komkowska, Eugenia; Skowron, Krzysztof			The Differences in the Level of Anti-SARS-CoV-2 Antibodies after mRNA Vaccine between Convalescent and Non-Previously Infected People Disappear after the Second Dose-Study in Healthcare Workers Group in Poland	VACCINES			English	Article						antibodies; SARS-CoV-2; vaccination; immunological response	SEROPREVALENCE; SARS-COV-2	(1) Background: In many infections, antibodies play a crucial role in controlling infection. In COVID-19, the dynamics of the immune system response to SARS-CoV-2 is not fully understood. (2) Methods: The study was conducted on 120 healthcare workers from Dr. Antoni Jurasz University Hospital No. 1 in Bydgoszcz, between June and December 2020. In all participants, IgA and IgG antibody serum concentrations were measured using the semi-quantitative Anti-SARS-CoV-2 ELISA test (Euroimmun). After vaccination, in January and February 2021, antibody levels were examined using the quantitative IgG Anti-SARS-CoV-2 Quantivac ELISA test (Euroimmun). (3) Results: During the whole study period, the SARS-CoV-2 infection was confirmed in 29 (24.2%) participants. In all infected participants, IgA and IgG antibodies were detectable after infection by semi-quantitative serological tests. Levels of antibodies were higher one month after the first dose in the convalescents than in the non-previously infected participants. In this second group, the level of antibodies increased significantly after the second dose of vaccines compared to the first dose. (4) Conclusions: The level of antibodies after the first dose of vaccine in the convalescents' group is higher than in the SARS-CoV-2 non-infected group, but the differences disappear after the second vaccination.	[Kwiecinska-Pirog, Joanna; Przekwas, Jana; Kraszewska, Zuzanna; Sekowska, Alicja; Wiktorczyk-Kapischke, Natalia; Grudlewska-Buda, Katarzyna; Gospodarek-Komkowska, Eugenia; Skowron, Krzysztof] Nicolaus Copernicus Univ Torun, L Rydygier Coll Med Bydgoszcz, Dept Microbiol, PL-85094 Bydgoszcz, Poland; [Brodzka, Sylwia] Univ Zielona Gora, Fac Biol Sci, Dept Biotechnol, PL-65417 Zielona Gora, Poland; [Walecka-Zacharska, Ewa] Wroclaw Univ Environm & Life Sci, Dept Food Hyg & Consumer Hlth, PL-50375 Wroclaw, Poland; [Zacharski, Maciej] Wroclaw Univ Environm & Life Sci, Dept Biochem & Mol Biol, PL-50375 Wroclaw, Poland; [Mankowska-Cyl, Aneta] Nicolaus Copernicus Univ Torun, L Rydygier Coll Med Bydgoszcz, Dept Lab Med, PL-85094 Bydgoszcz, Poland		Skowron, K (通讯作者)，Nicolaus Copernicus Univ Torun, L Rydygier Coll Med Bydgoszcz, Dept Microbiol, PL-85094 Bydgoszcz, Poland.	j.kwiecinska@cm.umk.pl; jana.przekwas@doktorant.umk.pl; z.kraszewska@cm.umk.pl; asekowska@cm.umk.pl; sylwia_florczak89@wp.pl; n.wiktorczyk@cm.umk.pl; katinkag@gazeta.pl; ewa.walecka@upwr.edu.pl; maciej.zacharski@upwr.edu.pl; aneta.mankowska@cm.umk.pl; gospodareke@cm.umk.pl; skowron238@wp.pl	Wiktorczyk-Kapischke, Natalia/C-1427-2018; Skowron, Krzysztof/I-2403-2012	Wiktorczyk-Kapischke, Natalia/0000-0003-1885-9182; , Alicja/0000-0001-6380-3968; Skowron, Krzysztof/0000-0003-0868-864X; Walecka-Zacharska, Ewa/0000-0002-1840-9731			[Anonymous], 2020, FACT CHECK NO PROOF; Bichara CDA, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06156-x; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Bajaj V, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.571416; Batra M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83108-0; Callaway E, 2021, NATURE, V598, P393, DOI 10.1038/d41586-021-02795-x; Cook T., 2020, HEALTH SERV J; Demonbreun A. R., 2020, PATTERNS PERSISTENCE, DOI [10.1101/2020.11.17.20233452, DOI 10.1101/2020.11.17.20233452]; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Ghaffari A, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10070453; Grzelak L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3103; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Harvey RA, 2021, JAMA INTERN MED, V181, P672, DOI 10.1001/jamainternmed.2021.0366; Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8; Jiang HW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17488-8; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Jurgiel J, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109831; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Lumley SF, 2021, CLIN INFECT DIS, V73, pE699, DOI 10.1093/cid/ciab004; Ma H, 2021, SCI CHINA LIFE SCI, V64, P482, DOI 10.1007/s11427-020-1805-0; Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z; Martin Christopher A, 2020, J Public Health (Oxf), DOI 10.1093/pubmed/fdaa199; McCartney DM, 2021, IRISH J MED SCI, V190, P1253, DOI 10.1007/s11845-020-02427-9; Meltzer DO, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19722; Merzon E, 2020, FEBS J, V287, P3693, DOI 10.1111/febs.15495; More GD, 2020, NEW ZEAL VET J, V68, P54, DOI 10.1080/00480169.2019.1667282; Muecksch F, 2021, J INFECT DIS, V223, P389, DOI 10.1093/infdis/jiaa659; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Patel MM, 2020, JAMA-J AM MED ASSOC, V324, P1781, DOI 10.1001/jama.2020.18796; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Priestnall SL, 2006, VET MICROBIOL, V115, P43, DOI 10.1016/j.vetmic.2006.02.008; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Shields A, 2020, THORAX, V75, P1089, DOI 10.1136/thoraxjnl-2020-215414; Shields AM, 2020, SARS COV 2 SEROCONVE, DOI [10.1101/2020.05.18.20105197, DOI 10.1101/2020.05.18.20105197]; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0; Szarpak L, 2021, CARDIOL J, V28, P647, DOI 10.5603/CJ.a2021.0072; The U.S. Food and Drug Administration (FDA), ANT TEST IS NOT CURR; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Worldometer S., COVID 19 CORONAVIRUS; Yang HS, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4302; Yu HQ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01526-2020; Zhao J, 2020, ADV POLYM SCI, V71, P2027, DOI [DOI 10.1093/CID/CIAA344, 10.1093/cid/ciaa344]; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	47	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1402	10.3390/vaccines9121402			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9RO	34960148	Green Published, gold			2022-04-29	WOS:000737302000001
J	Tipih, T; Heise, M; Burt, FJ				Tipih, Thomas; Heise, Mark; Burt, Felicity Jane			Immunogenicity of a DNA-Based Sindbis Replicon Expressing Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein	VACCINES			English	Article						Crimean-Congo hemorrhagic fever virus; nucleoprotein; Sindbis virus replicon vector; immune response	POLYMERASE-CHAIN-REACTION; IMMUNE-RESPONSES; INNATE; IDENTIFICATION; DIAGNOSIS; BIOLOGY; MICE	Crimean-Congo hemorrhagic fever virus (CCHFV) infrequently causes hemorrhagic fever in humans with a case fatality rate of 30%. Currently, there is neither an internationally approved antiviral drug nor a vaccine against the virus. A replicon based on the Sindbis virus vector encoding the complete open reading frame of a CCHFV nucleoprotein from a South African isolate was prepared and investigated as a possible candidate vaccine. The transcription of CCHFV RNA and recombinant protein production by the replicon were characterized in transfected baby hamster kidney cells. A replicon encoding CCHFV nucleoprotein inserted in plasmid DNA, pSinCCHF-52S, directed transcription of CCHFV RNA in the transfected cells. NIH-III heterozygous mice immunized with pSinCCHF-52S generated CCHFV IgG specific antibodies with notably higher levels of IgG2a compared to IgG1. Splenocytes from mice immunized with pSinCCHF-52S secreted IFN-gamma and IL-2, low levels of IL-6 or IL-10, and no IL-4. No specific cytokine production was registered in splenocytes of mock-immunized mice (p < 0.05). Thus, our study demonstrated the expression of CCHFV nucleoprotein by a Sindbis virus vector and its immunogenicity in mice. The spectrum of cytokine production and antibody profile indicated predominantly Th1-type of an anti-CCHFV immune response. Further studies in CCHFV-susceptible animals are necessary to determine whether the induced immune response is protective.	[Tipih, Thomas; Burt, Felicity Jane] Univ Free State, Div Virol, ZA-9300 Bloemfontein, South Africa; [Heise, Mark] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Burt, Felicity Jane] Natl Hlth Lab Serv, Div Virol, ZA-9300 Bloemfontein, South Africa		Burt, FJ (通讯作者)，Univ Free State, Div Virol, ZA-9300 Bloemfontein, South Africa.; Burt, FJ (通讯作者)，Natl Hlth Lab Serv, Div Virol, ZA-9300 Bloemfontein, South Africa.	ttipih@gmail.com; mark_heisem@med.unc.edu; burtfj@ufs.ac.za	Burt, Felicity/AAB-6993-2020	Burt, Felicity/0000-0002-7238-7799; TIPIH, THOMAS/0000-0003-3845-1942			Altamura LA, 2007, J VIROL, V81, P6632, DOI 10.1128/JVI.02730-06; Barnwal B, 2016, J BIOL CHEM, V291, P582, DOI 10.1074/jbc.M115.667436; Berlanga JJ, 2006, EMBO J, V25, P1730, DOI 10.1038/sj.emboj.7601073; Bertolotti-Ciarlet A, 2005, J VIROL, V79, P6152, DOI 10.1128/JVI.79.10.6152-6161.2005; Boshra H, 2011, VACCINE, V29, P4469, DOI 10.1016/j.vaccine.2011.04.043; Burt FJ, 1998, J VIROL METHODS, V70, P129, DOI 10.1016/S0166-0934(97)00182-1; Buttigieg KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091516; Canakoglu N, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003579; CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Dowall SD, 2016, HUM VACC IMMUNOTHER, V12, P519, DOI 10.1080/21645515.2015.1078045; Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996; Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2; Ergonul O., 2007, CRIMEAN CONGO HEMORR, P75; Eroglu E, 2016, ADV VIROL, V2016, DOI 10.1155/2016/7971847; Farzani TA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030237; Farzani TA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010075; Freitas N, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008850; Gargili A, 2017, ANTIVIR RES, V144, P93, DOI 10.1016/j.antiviral.2017.05.010; Garrison AR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005908; Goedhals D, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006149; Gorchakov R, 2007, VIROLOGY, V366, P212, DOI 10.1016/j.virol.2007.04.014; Hauge S, 2007, SCAND J IMMUNOL, V65, P14, DOI 10.1111/j.1365-3083.2006.01862.x; Hawman DW, 2021, NAT MICROBIOL, V6, P187, DOI 10.1038/s41564-020-00815-6; HERWEIJER H, 1995, HUM GENE THER, V6, P1161, DOI 10.1089/hum.1995.6.9-1161; Hinkula J, 2017, J VIROL, V91, DOI [10.1128/jvi.02076-16, 10.1128/JVI.02076-16]; Kortekaas J, 2011, J VIROL, V85, P12622, DOI 10.1128/JVI.00841-11; Lasecka L, 2014, ARCH VIROL, V159, P1249, DOI 10.1007/s00705-013-1940-z; Latanova AA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26281-z; Leitner WW, 2006, VACCINE, V24, P5110, DOI 10.1016/j.vaccine.2006.04.059; Leitner WW, 2000, CANCER RES, V60, P51; Li YG, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-114; Ljungberg K, 2007, J VIROL, V81, P13412, DOI 10.1128/JVI.01799-07; Lombe BP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81752-0; Lundstrom K, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010029; Lundstrom K, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040039; Maes P, 2008, VIRAL IMMUNOL, V21, P49, DOI 10.1089/vim.2007.0059; Maes P, 2009, EXPERT REV VACCINES, V8, P67, DOI 10.1586/14760584.8.1.67; Moming A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204264; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Negredo A, 2017, NEW ENGL J MED, V377, P154, DOI [10.1056/NEJMoa1615162, 10.1056/nejmoa1615162]; Okuda K, 2014, VACCINES, V2, P89, DOI 10.3390/vaccines2010089; Papa A, 2011, SCAND J INFECT DIS, V43, P225, DOI 10.3109/00365548.2010.540036; Pasare C, 2004, MICROBES INFECT, V6, P1382, DOI 10.1016/j.micinf.2004.08.018; Portillo A, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9030649; Rodriguez LL, 1997, AM J TROP MED HYG, V57, P512, DOI 10.4269/ajtmh.1997.57.512; Rodriguez SE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44210-6; Sanchez AJ, 2006, J VIROL, V80, P514, DOI 10.1128/JVI.80.1.514-525.2006; Sanchez AJ, 2002, J VIROL, V76, P7263, DOI 10.1128/JVI.76.14.7263-7275.2002; Scholte FEM, 2017, CELL REP, V20, P2396, DOI 10.1016/j.celrep.2017.08.040; Schwarz TF, 1996, AM J TROP MED HYG, V55, P190, DOI 10.4269/ajtmh.1996.55.190; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Starodubova ES, 2008, VACCINE, V26, P5170, DOI 10.1016/j.vaccine.2008.03.070; Tipih T, 2020, BIORESEARCH OPEN ACC, V9, P137, DOI 10.1089/biores.2019.0057; Venticinque L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-37; Vorou R, 2007, CURR OPIN INFECT DIS, V20, P495, DOI 10.1097/QCO.0b013e3282a56a0a; Walter CT, 2011, J GEN VIROL, V92, P2467, DOI 10.1099/vir.0.035105-0; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Zivcec M, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006628; Zivcec M, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8040106	60	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1491	10.3390/vaccines9121491			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9HX	34960237	gold, Green Published			2022-04-29	WOS:000737276600001
J	Alqassieh, R; Suleiman, A; Abu-Halaweh, S; Santarisi, A; Shatnawi, O; Shdaifat, L; Tarifi, A; Al-Tamimi, M; Al-Shudifat, AE; Alsmadi, H; Al Sharqawi, A; Alnawaiseh, H; Anasweh, Y; Domaidah, FA; Abu Jaber, H; Al-Zarir, MR; Bsisu, I				Alqassieh, Rami; Suleiman, Aiman; Abu-Halaweh, Sami; Santarisi, Abeer; Shatnawi, Omar; Shdaifat, Lara; Tarifi, Amjed; Al-Tamimi, Mohammad; Al-Shudifat, Abdel-Ellah; Alsmadi, Heba; Al Sharqawi, Ahmed; Alnawaiseh, Hadeel; Anasweh, Yara; Domaidah, Farah Abo; Abu Jaber, Haneen; Al-Zarir, Mohammad Rashid; Bsisu, Isam			Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers	VACCINES			English	Article						COVID-19; vaccine; Pfizer-BioNTech; Sinopharm; antibody; titers		COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 & PLUSMN; 1143.5 BAU/mL, compared to 170.0 & PLUSMN; 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25-196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11-0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.	[Alqassieh, Rami; Tarifi, Amjed] Hashemite Univ, Fac Med, Dept Gen & Specialized Surg, Zarqa 13133, Jordan; [Suleiman, Aiman] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Anesthesia & Intens Care Dept, Boston, MA 02215 USA; [Abu-Halaweh, Sami; Alsmadi, Heba; Al Sharqawi, Ahmed; Alnawaiseh, Hadeel; Anasweh, Yara; Domaidah, Farah Abo; Abu Jaber, Haneen; Al-Zarir, Mohammad Rashid; Bsisu, Isam] Univ Jordan, Sch Med, Dept Anesthesia & Intens Care, Amman 11942, Jordan; [Santarisi, Abeer] Univ Jordan, Sch Med, Dept Emergency Med & Accid, Amman 11942, Jordan; [Shatnawi, Omar] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; [Shatnawi, Omar] Wake Forest Baptist Hlth, Winston Salem, NC 27157 USA; [Shdaifat, Lara] Mutah Univ, Sch Med, Al Karak 61710, Jordan; [Al-Tamimi, Mohammad; Al-Shudifat, Abdel-Ellah] Hashemite Univ, Fac Med, Zarqa 13133, Jordan		Bsisu, I (通讯作者)，Univ Jordan, Sch Med, Dept Anesthesia & Intens Care, Amman 11942, Jordan.	Rami_qaisieh@yahoo.com; Asuleima@bidmc.harvard.edu; s.halaweh@ju.edu.jo; abeer_santarisi@yahoo.com; Omar.juve10@gmail.com; Shdaifatlara@gmail.com; amjed.tarifi@gmail.com; mohammad.altamimi@hu.edu.jo; amalmufleh@hotmail.com; Sw006999@gmail.com; sharqawiahmed@gmail.com; Hanabrklna@gmail.com; Yara.anasweh@gmail.com; farahabodomaidah@gmail.com; abujaber.haneen@gmail.com; rashed.zaareer@gmail.com; isam_bsisu@hotmail.com	; Al-Tamimi, Mohammad/B-1734-2018	Abu-halaweh, sami/0000-0001-6981-7789; Tarifi, Amjed/0000-0001-8519-9431; Suleiman, Aiman/0000-0003-2625-4028; Al-Tamimi, Mohammad/0000-0001-7486-4192; Alqassieh, RAMI/0000-0002-0270-0436; Shatnawi, Omar/0000-0002-2304-8969; Bsisu, Isam/0000-0002-8999-8334	Hashemite University, Zarqa , Jordan [639/2021]	This research was funded by the Deanship of Scientific Research at the Hashemite University, Zarqa 13133, Jordan, grant number 639/2021.	Adam L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040365; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Aloweidi A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105111; Bastos ML, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2516; Berbudi A, 2020, CURR DIABETES REV, V16, P442, DOI 10.2174/1573399815666191024085838; DEMARTINI RM, 1988, CLIN IMMUNOL IMMUNOP, V46, P258, DOI 10.1016/0090-1229(88)90188-2; Demonbreun AR, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101018; Dogan M, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01649-6; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Ferenci T., 2021, VIRUS NEUTRALIZING A, DOI [10.1101/2021.07.15.21260362, DOI 10.1101/2021.07.15.21260362]; Gambino CM, 2020, BIOCHEM MEDICA, V30, DOI 10.11613/BM.2020.030901; Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1016/S0928-8244(99)00142-X; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106; Jacofsky D, 2020, J ARTHROPLASTY, V35, pS74, DOI 10.1016/j.arth.2020.04.055; John ALS, 2020, J IMMUNOL, V205, P555, DOI 10.4049/jimmunol.2000526; Jordanian Ministry of Health, 2021, COVID 19 VACC PLATTF; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727; Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763; Lo Sasso B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11071135; Lo Sasso B, 2021, LAB MED, V52, P493, DOI 10.1093/labmed/lmab032; Nagappa B, 2020, CLIN INFECT DIS, V71, P3016, DOI 10.1093/cid/ciaa676; Padoan A, 2021, CLIN CHIM ACTA, V519, P60, DOI 10.1016/j.cca.2021.04.006; Rubin R, 2021, JAMA-J AM MED ASSOC, V325, P1241, DOI 10.1001/jama.2021.3370; Salvagno GL, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11050832; Schemm P., 2021, 3 DOSE SINOPHARM COR; Suleiman A, 2021, SCI PHARM, V89, DOI 10.3390/scipharm89010006; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; Torjesen I, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1445; Vitiello A, 2021, INFLAMMOPHARMACOLOGY, V29, P645, DOI 10.1007/s10787-021-00811-0; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Wu H, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10895; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Younes S, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9020245; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zitt E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.704773	38	3	3	18	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1223	10.3390/vaccines9111223			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI5MH	34835153	gold, Green Published			2022-04-29	WOS:000726155000001
J	Karrow, NA; Shandilya, UK; Pelech, S; Wagter-Lesperance, L; McLeod, D; Bridle, B; Mallard, BA				Karrow, Niel A.; Shandilya, Umesh K.; Pelech, Steven; Wagter-Lesperance, Lauraine; McLeod, Deanna; Bridle, Byram; Mallard, Bonnie A.			Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development	VACCINES			English	Review						COVID-19; SARS-CoV-2; vaccines; fetal development; neonatal development	MILK EXOSOMES; FISH-MEAL; SARS-COV-2; VACCINES; EXPRESSION; INFECTION; STRESS; MECHANISMS; PROTECTION; PREGNANCY	Vaccines have been developed at "warp speed " to combat the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Although they are considered the best approach for preventing mortality, when assessing the safety of these vaccines, pregnant women have not been included in clinical trials. Thus, vaccine safety for this demographic, as well as for the developing fetus and neonate, remains to be determined. A global effort has been underway to encourage pregnant women to get vaccinated despite the uncertain risk posed to them and their offspring. Given this, post-hoc data collection, potentially for years, will be required to determine the outcomes of COVID-19 and vaccination on the next generation. Most COVID-19 vaccine reactions include injection site erythema, pain, swelling, fatigue, headache, fever and lymphadenopathy, which may be sufficient to affect fetal/neonatal development. In this review, we have explored components of the first-generation viral vector and mRNA COVID-19 vaccines that are believed to contribute to adverse reactions and which may negatively impact fetal and neonatal development. We have followed this with a discussion of the potential for using an ovine model to explore the long-term outcomes of COVID-19 vaccination during the prenatal and neonatal periods.	[Karrow, Niel A.; Shandilya, Umesh K.] Univ Guelph, Dept Anim Biosci, Guelph, ON N1G 2W1, Canada; [Pelech, Steven] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Wagter-Lesperance, Lauraine; Bridle, Byram; Mallard, Bonnie A.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [McLeod, Deanna] Kaleidoscope Strateg Inc, Toronto, ON M6R 1E7, Canada		Karrow, NA (通讯作者)，Univ Guelph, Dept Anim Biosci, Guelph, ON N1G 2W1, Canada.	nkarrow@uoguelph.ca; ushand@uoguelph.ca; spelech@shaw.ca; lwagterl@uoguelph.ca; deanna@kstrategic.com; bbridle@uoguelph.ca; bmallard@ovc.uoguelph.ca		Shandilya, Umesh Kumar/0000-0003-0148-8485; Bridle, Byram/0000-0002-8335-1118			Adiguzel Y, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102791; Al-Benna Sammy, 2020, Obes Med, V19, P100283, DOI 10.1016/j.obmed.2020.100283; Alvites RD, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10030249; Aminimoghaddam S, 2021, J MED CASE REP, V15, DOI 10.1186/s13256-020-02577-5; Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916; [Anonymous], 2021, CANADA PHA DEMOGRAPH; [Anonymous], 2021, PRELIMINARY FINDINGS, DOI [10.1056/NEJMx210016, DOI 10.1056/NEJMX210016]; Arashkia A, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2183; Argueta Lissenya B, 2021, bioRxiv, DOI 10.1101/2021.06.01.446676; Arthur JM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257016; Ashraf UM, 2021, PHYSIOL GENOMICS, V53, P51, DOI 10.1152/physiolgenomics.00087.2020; Baird JK, 2021, J HUM LACT, V37, P492, DOI 10.1177/08903344211030168; Bansal S, 2021, J IMMUNOL, V207, P2405, DOI 10.4049/jimmunol.2100637; Beena V., 2021, J DAIRY VET ANIM RES, V8, P107; Biancatelli RMLC, 2021, AM J PHYSIOL-LUNG C, V321, pL477, DOI 10.1152/ajplung.00223.2021; Bianco-Miotto T, 2017, J DEV ORIG HLTH DIS, V8, P513, DOI 10.1017/S2040174417000733; Bozkurt B, 2021, CIRCULATION, V144, P471, DOI 10.1161/CIRCULATIONAHA.121.056135; Brock A., 2021, SCI PUB HLTH POL LAW, V4, P130; Campbell RA, 2021, J THROMB HAEMOST, V19, P46, DOI 10.1111/jth.15156; Cantuti-Castelvetri L, 2020, SCIENCE, V370, P856, DOI 10.1126/science.abd2985; Cappello F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072038; Casazza RL, 2020, VIRAL IMMUNOL, V33, P3, DOI 10.1089/vim.2019.0076; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; CDC, 2020, COVID 19 VACC INT CT; Chen IY, 2010, J VIROL, V84, P7703, DOI 10.1128/JVI.02560-09; Cheng MH, 2021, STRUCTURE, V29, P951, DOI 10.1016/j.str.2021.04.005; Cheng MH, 2020, P NATL ACAD SCI USA, V117, P25254, DOI 10.1073/pnas.2010722117; Choudhury A, 2020, J MED VIROL, V92, P2105, DOI 10.1002/jmv.25987; Ciarambino Tiziana, 2021, Womens Health (Lond), V17, p17455065211022262, DOI 10.1177/17455065211022262; Cimolai Nevio, 2021, SN Compr Clin Med, P1, DOI 10.1007/s42399-021-00992-3; Classen J.B., 2021, MICROBIOL INFECT DIS, V5, DOI [10.33425/2639-9458.1109, DOI 10.33425/2639-9458.1109]; Dakal TC, 2021, IMMUNOBIOLOGY, V226, DOI 10.1016/j.imbio.2021.152091; Daly JL, 2020, SCIENCE, V370, P861, DOI 10.1126/science.abd3072; Viana IMD, 2021, ACTA PHARM SIN B, V11, P852, DOI 10.1016/j.apsb.2021.02.022; Dhaundiyal A, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118676; Di Teodoro G, 2021, VET MICROBIOL, V252, DOI 10.1016/j.vetmic.2020.108933; Doerfler W, 2021, VIRUS RES, V302, DOI 10.1016/j.virusres.2021.198466; Donofrio Peter D, 2017, Continuum (Minneap Minn), V23, P1295, DOI 10.1212/CON.0000000000000513; Doshi P, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1244; Dotan A, 2021, AM J REPROD IMMUNOL, V86, DOI 10.1111/aji.13494; Entrican G, 2015, MOL IMMUNOL, V66, P68, DOI 10.1016/j.molimm.2014.09.002; Fang SB, 2021, BRIEF BIOINFORM, V22, P963, DOI 10.1093/bib/bbaa329; Fisher RE, 2014, J DEV ORIG HLTH DIS, V5, P206, DOI 10.1017/S2040174414000191; Fisher-Heffernan RE, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0573-8; Flores-Pliego A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020364; Forestieri S, 2021, EARLY HUM DEV, V155, DOI 10.1016/j.earlhumdev.2021.105322; Fowler Nicholas, 2021, Am J Ophthalmol Case Rep, V23, P101136, DOI 10.1016/j.ajoc.2021.101136; Fowlkes A, 2021, MMWR-MORBID MORTAL W, V70, P1167, DOI 10.15585/mmwr.mm7034e4; Gao SX, 2020, J MED MICROBIOL, V69, P591, DOI 10.1099/jmm.0.001152; Gatford KL, 2017, J REPROD IMMUNOL, V123, P88, DOI 10.1016/j.jri.2017.07.002; Gautam I, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9100343; Gengler C, 2021, CLIN MICROBIOL INFEC, V27, P489, DOI 10.1016/j.cmi.2020.09.049; Glass R, 2019, BRAIN BEHAV IMMUN, V75, P12, DOI 10.1016/j.bbi.2018.05.005; Golan Y, 2021, JAMA PEDIATR, V175, P1069, DOI 10.1001/jamapediatrics.2021.1929; Goldstein JA, 2017, J DEV ORIG HLTH DIS, V8, P273, DOI 10.1017/S2040174417000010; Gomez JMM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004536; Gomez-Chavez F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679106; Greinacher Andreas, 2021, Blood, V138, P1269, DOI 10.1182/blood.2021012938; Grobbelaar LM, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20210611; Gupta M, 2021, ACS CHEM NEUROSCI, V12, P2558, DOI 10.1021/acschemneuro.1c00403; Harel M, 2005, IMMUNOBIOLOGY, V210, P743, DOI 10.1016/j.imbio.2005.10.004; He YY, 2021, NUTRIENTS, V13, DOI 10.3390/nu13093198; Hernandez Antonio F, 2021, Toxicol Rep, V8, P871, DOI 10.1016/j.toxrep.2021.04.003; Holm S, 2021, EUR HEART J, V42, P4064, DOI 10.1093/eurheartj/ehab506; Hsu CN, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060623; Huynh A, 2021, NATURE, V596, P565, DOI 10.1038/s41586-021-03744-4; Iacobucci G, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2113; Idrees D, 2021, BIOCHEM BIOPH RES CO, V554, P94, DOI 10.1016/j.bbrc.2021.03.100; IIes J.K., 2021, SARS COV 2 SPIKE PRO, DOI [10.1101/2021.06.14.21258871v3, DOI 10.1101/2021.06.14.21258871V3]; Jacobs JJL, 2021, MED HYPOTHESES, V149, DOI 10.1016/j.mehy.2021.110538; Jawed M, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab343; Kanduc D, 2020, IMMUNOL RES, V68, P310, DOI 10.1007/s12026-020-09152-6; Karagoz IK, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108433; Karrow NA, 2017, ANIM NUTR, V3, P39, DOI 10.1016/j.aninu.2016.10.001; Klein SL, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147553; Lagoumintzis G, 2021, FOOD CHEM TOXICOL, V149, DOI 10.1016/j.fct.2021.112009; Lee PX, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004805; Lei YY, 2021, CIRC RES, V128, P1323, DOI 10.1161/CIRCRESAHA.121.318902; Liu LP, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015733; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; Liu Y, 2021, CURR OPIN RHEUMATOL, V33, P155, DOI 10.1097/BOR.0000000000000776; Lujan L, 2013, IMMUNOL RES, V56, P317, DOI 10.1007/s12026-013-8404-0; Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701; Mandy M, 2018, INT HEALTH, V10, P66, DOI 10.1093/inthealth/ihy006; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Martinez YA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246901; Martirosyan A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01609; Maykin MM, 2021, VACCINE, V39, P171, DOI 10.1016/j.vaccine.2020.12.007; McCall SJ, 2020, ANAESTHESIA, V75, P1469, DOI 10.1111/anae.15069; Mohkhedkar M, 2021, J INFECT DIS, V223, P536, DOI 10.1093/infdis/jiaa703; Morsy S, 2021, J MOL GRAPH MODEL, V105, DOI 10.1016/j.jmgm.2021.107836; Moutal A, 2021, PAIN, V162, P243, DOI 10.1097/j.pain.0000000000002097; Nader D, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253347; Naylor D, 2021, STRESS, V24, P888, DOI 10.1080/10253890.2021.1954905; Naylor D, 2020, J DAIRY SCI, V103, P5501, DOI 10.3168/jds.2019-17718; Ndeupen S., 2021, 430128 BIORXIV, V24, P103479, DOI [DOI 10.1101/2021.03.04.430128, 10.1101/2021.03.04.430128]; Ogata AF, 2022, CLIN INFECT DIS, V74, P715, DOI 10.1093/cid/ciab465; Othman M, 2007, BLOOD, V109, P2832, DOI 10.1182/blood-2006-06-032524; Ouyang WM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147540; Pace RM, 2021, MBIO, V12, DOI 10.1128/mBio.03192-20; Pakbaz Z, 2020, MICROB PATHOGENESIS, V142, DOI 10.1016/j.micpath.2020.104064; Pant SD, 2016, LIVEST SCI, V187, P40, DOI 10.1016/j.livsci.2016.02.006; Patel SU, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242956; Patel S, 2016, J OCUL PHARMACOL TH, V32, P97, DOI 10.1089/jop.2015.0069; Patterson B.K., 2021, PERSISTENCE SARS COV, DOI [10.1101/2021.06.25.449905v3, DOI 10.1101/2021.06.25.449905V3]; Peden AH, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.716452; Petruk G, 2020, J MOL CELL BIOL, V12, P916, DOI 10.1093/jmcb/mjaa067; Pineles BL, 2021, ANN INTERN MED, V174, P1186, DOI 10.7326/M21-0974; Ratajczak MZ, 2021, STEM CELL REV REP, V17, P266, DOI 10.1007/s12015-020-10010-z; Reuters, 2021, REUTERS 0714; Ricke DO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640093; Rivas MN, 2021, J ALLERGY CLIN IMMUN, V147, P57, DOI 10.1016/j.jaci.2020.10.008; Ropa J, 2021, STEM CELL REV REP, V17, P253, DOI 10.1007/s12015-020-10056-z; Ross M, 2021, J DAIRY SCI, V104, P2499, DOI 10.3168/jds.2020-18405; Rothan HA, 2021, PEDIAT ALLERG IMM-UK, V32, P17, DOI 10.1111/pai.13361; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060559; Sacchi MC, 2021, CTS-CLIN TRANSL SCI, V14, P898, DOI 10.1111/cts.12953; Salamat MKF, 2021, VET IMMUNOL IMMUNOP, V233, DOI 10.1016/j.vetimm.2021.110194; Samaridou E, 2020, ADV DRUG DELIVER REV, V154, P37, DOI 10.1016/j.addr.2020.06.002; Schadlich A, 2012, J CONTROL RELEASE, V160, P105, DOI 10.1016/j.jconrel.2012.02.012; Scheerlinck JPY, 2008, TRENDS BIOTECHNOL, V26, P259, DOI 10.1016/j.tibtech.2008.02.002; Schoenmaker L, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120586; Schwartzberg LS, 2018, ADV THER, V35, P754, DOI 10.1007/s12325-018-0707-z; Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062; Selvaraj G, 2021, INTERDISCIP SCI, V13, P344, DOI 10.1007/s12539-021-00438-3; Seneff S., 2021, INT J VACCINE THEORY, V2, P38; Serrano C., 2021, FREQUENTLY RELAPSING, DOI [10.1007/s42399-021-01019-7, DOI 10.1007/S42399-021-01019-7]; Sharma A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217920; Sharma SR, 2015, ANN INDIAN ACAD NEUR, V18, P215, DOI 10.4103/0972-2327.150608; Shen S, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01082-6; Shiers S., 2020, ACE2 EXPRESSION HUMA, DOI [10.1101/2020.05.28.122374v1, DOI 10.1101/2020.05.28.122374V1]; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Shirato K, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06187; Sokolowska M, 2021, ALLERGY, V76, P1629, DOI 10.1111/all.14739; Sprent J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj9256; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Subramony R, 2021, J EMERG MED, V61, pE146, DOI 10.1016/j.jemermed.2021.07.034; Suzuki YJ, 2021, VASC PHARMACOL, V137, DOI 10.1016/j.vph.2020.106823; Talotta R, 2021, CYTOKINE GROWTH F R, V60, P52, DOI 10.1016/j.cytogfr.2021.05.001; Tang MW, 2020, AM J HEMATOL, V95, pE191, DOI 10.1002/ajh.25877; Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191; Tsilingiris Dimitrios, 2021, Metabol Open, V11, P100101, DOI 10.1016/j.metop.2021.100101; Verbeke R, 2021, J CONTROL RELEASE, V333, P511, DOI 10.1016/j.jconrel.2021.03.043; Virani A., 2020, IDCASES, V20, pe00771, DOI [10.1016/j.idcr.2020.e00771, DOI 10.1016/j.idcr.2020.e00771]; Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480; Wen JQ, 2020, INT J INFECT DIS, V100, P483, DOI 10.1016/j.ijid.2020.09.015; Wooldridge AL, 2019, J PHYSIOL-LONDON, V597, P4251, DOI 10.1113/JP277952; Yahi Nouara, 2021, J Infect, V83, P607, DOI 10.1016/j.jinf.2021.08.010; Zhang LG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2105968118; Zhao H., 2020, LANCET NEUROL, V19, P383, DOI DOI 10.1016/S1474-4422(20)30109-5; Zheng Y, 2020, MICROB PATHOGENESIS, V138, DOI 10.1016/j.micpath.2019.103797; Zhou Y, 2021, IMMUNOL LETT, V237, P33, DOI 10.1016/j.imlet.2021.06.008; Zuo Y, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.150111; Zussman R, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102437	154	1	1	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1351	10.3390/vaccines9111351			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF9OI	34835282	Green Published, gold			2022-04-29	WOS:000724393100001
J	Komiya, T; Honda-Okubo, Y; Baldwin, J; Petrovsky, N				Komiya, Tomoyoshi; Honda-Okubo, Yoshikazu; Baldwin, Jeremy; Petrovsky, Nikolai			An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection	VACCINES			English	Article						Japanese encephalitis; vaccine; singles dose protection; flaviviruses; antibody-dependent enhancement; Advax; interferon gamma; cell culture-grown inactivated JE vaccine	WEST-NILE-VIRUS; DELTA INULIN; INFLUENZA VACCINE; DENGUE VIRUS; IMMUNOGENICITY; SAFETY; INFECTION; MICE; IMMUNIZATION; STRAIN	ccJE+Advax is an inactivated cell culture Japanese encephalitis (JE) vaccine formulated with Advax, a novel polysaccharide adjuvant based on delta inulin. This vaccine has previously shown promise in murine and equine studies and the current study sought to better understand its mechanism of action and assess the feasibility of single dose vaccine protection. Mice immunised with ccJE+Advax had higher serum neutralisation titres than those immunised with ccJE alone or with alum adjuvant. ccJE+Advax induced extraordinarily broad cross-neutralising antibodies against multiple flaviviruses including West Nile virus (WNV), Murray Valley encephalitis virus (MVEV), St Louis encephalitis virus (SLEV) and Dengue virus-1 and -2 (DENV-1 and -2). Notably, the DENV-2 cross-neutralising antibodies from ccJE+Advax immunised mice uniquely had no DENV-2 antibody-dependent infection enhancement (ADIE) activity, in contrast to high ADIE activity seen with DENV-1 cross-reactive antibodies induced by mbJE or ccJE alone or with alum adjuvant. JEV-stimulated splenocytes from ccJE+Advax immunised mice showed increased IL-17 and IFN-gamma production, consistent with a mixed Th1 and Th17 response, whereas ccJE-alum was associated with production of mainly Th2 cytokines. In a mouse lethal challenge study against highly virulent JaTH160 JEV strain, ccJE+Advax conferred complete protection in a two-dose schedule with 50 ng of vaccine antigen and near complete protection after a single 200 ng dose of vaccine antigen. There is an ongoing lack of human vaccines against particular flaviviruses, including WNV, SLEV and MVEV. Given its ability to provide single-dose JEV protection and induce broadly neutralising antibodies devoid of ADIE activity, ccJE+Advax vaccine could be useful in situations where rapid protection is desirable, e.g., during a local outbreak or for use in travellers or armies requiring rapid deployment to JEV endemic regions.	[Komiya, Tomoyoshi] Hokuriku Univ, Fac Hlth & Med Sci, Kanazawa, Ishikawa 9201180, Japan; [Honda-Okubo, Yoshikazu; Baldwin, Jeremy; Petrovsky, Nikolai] Vaxine Pty Ltd, Adelaide, SA 5046, Australia; [Honda-Okubo, Yoshikazu; Petrovsky, Nikolai] Flinders Univ S Australia, Coll Med & Publ Hlth, Dept Endocrinol, Adelaide, SA 5042, Australia		Petrovsky, N (通讯作者)，Vaxine Pty Ltd, Adelaide, SA 5046, Australia.; Petrovsky, N (通讯作者)，Flinders Univ S Australia, Coll Med & Publ Hlth, Dept Endocrinol, Adelaide, SA 5042, Australia.	t-komiya@hokuriku-u.ac.jp; yoshikazu.hondaokubo@flinders.edu.au; jeremy.baldwin@flinders.edu.au; nikolai.petrovsky@flinders.edu.au	Honda-Okubo, Yoshikazu/AAM-5898-2021; Petrovsky, Nikolai/P-1912-2017	Honda-Okubo, Yoshikazu/0000-0002-2872-8621; Petrovsky, Nikolai/0000-0002-1580-5245	National Institutes of Health, National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U01-AI061142, HHSN272200800039C]	This work was supported by grant Nos. U01-AI061142 and HHSN272200800039C from the National Institutes of Health, National Institute of Allergy and Infectious Diseases.	Ashok MS, 1999, VACCINE, V18, P68, DOI 10.1016/S0264-410X(99)00180-2; Broom AK, 2000, J MED VIROL, V61, P259, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;259::AID-JMV13&gt;3.0.CO;2-M; Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233; Clark DC, 2012, ARCH VIROL, V157, P1423, DOI 10.1007/s00705-012-1337-4; Connor Bradley, 2017, Trop Dis Travel Med Vaccines, V3, P14, DOI 10.1186/s40794-017-0057-x; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Erlanger TE, 2009, EMERG INFECT DIS, V15, P1, DOI 10.3201/eid1501.080311; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Gordon D, 2014, VACCINE, V32, P6469, DOI 10.1016/j.vaccine.2014.09.034; Gordon DL, 2016, VACCINE, V34, P3780, DOI 10.1016/j.vaccine.2016.05.071; Gordon DL, 2012, VACCINE, V30, P5407, DOI 10.1016/j.vaccine.2012.06.009; Gromowski GD, 2015, AM J TROP MED HYG, V92, P98, DOI 10.4269/ajtmh.14-0427; Halstead SB, 2008, VACCINES, V311-52; Hayasaka D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071643; Hayashi M, 2017, EBIOMEDICINE, V15, P127, DOI 10.1016/j.ebiom.2016.11.015; Heddle R, 2019, J ALLERGY CLIN IMMUN, V144, P504, DOI 10.1016/j.jaci.2019.03.035; Hegde NR, 2017, HUM VACC IMMUNOTHER, V13, P1320, DOI 10.1080/21645515.2017.1285472; HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004; Jelinek T, 2018, TRAVEL MED INFECT DI, V22, P18, DOI 10.1016/j.tmaid.2018.03.003; Kanesa-Thasan N, 2002, AM J TROP MED HYG, V66, P115, DOI 10.4269/ajtmh.2002.66.115; Kimura T, 2010, VET PATHOL, V47, P806, DOI 10.1177/0300985810372507; Kool M, 2012, J MED MICROBIOL, V61, P927, DOI 10.1099/jmm.0.038943-0; Kumar P, 2004, J INFECT DIS, V189, P880, DOI 10.1086/381768; Kuzuhara S, 2003, VACCINE, V21, P4519, DOI 10.1016/S0264-410X(03)00506-1; Larena M, 2013, EUR J IMMUNOL, V43, P1789, DOI 10.1002/eji.201243152; Le Flohic G, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002208; Lobigs M, 2003, VACCINE, V21, P1572, DOI 10.1016/S0264-410X(02)00743-0; Lobigs M, 2010, J GEN VIROL, V91, P1407, DOI 10.1099/vir.0.019190-0; Lobigs M, 2009, J VIROL, V83, P2436, DOI 10.1128/JVI.02273-08; Luna RML, 2002, J VIROL, V76, P3202, DOI 10.1128/JVI.76.7.3202-3211.2002; Martina BE, 2008, VACCINE, V26, P153, DOI 10.1016/j.vaccine.2007.10.055; Moi ML, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001536; MuraliKrishna K, 1996, J GEN VIROL, V77, P705, DOI 10.1099/0022-1317-77-4-705; NI HL, 1995, J GEN VIROL, V76, P409, DOI 10.1099/0022-1317-76-2-409; NITAYAPHAN S, 1990, VIROLOGY, V177, P541, DOI 10.1016/0042-6822(90)90519-W; Nolan T, 2008, VACCINE, V26, P6383, DOI 10.1016/j.vaccine.2008.08.046; Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030; Petrovsky N, 2013, J VIROL, V87, P10324, DOI 10.1128/JVI.00480-13; POLAND JD, 1990, J INFECT DIS, V161, P878, DOI 10.1093/infdis/161.5.878; Rathore APS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00334; Saito Y, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1873-8; Singh KP, 2014, ASIAN PAC J TROP MED, V7, P124, DOI 10.1016/S1995-7645(14)60007-9; Takasaki T, 2003, VACCINE, V21, P4514, DOI 10.1016/S0264-410X(03)00507-3; Tang F, 2008, AM J TROP MED HYG, V78, P999, DOI 10.4269/ajtmh.2008.78.999; Tauber E, 2007, LANCET, V370, P1847, DOI 10.1016/S0140-6736(07)61780-2; Tauber E, 2008, BIOL CHEM, V389, P547, DOI 10.1515/BC.2008.062; Toriniwa H, 2008, VACCINE, V26, P3680, DOI 10.1016/j.vaccine.2008.04.076; Van Gessel Y, 2011, VACCINE, V29, P5925, DOI 10.1016/j.vaccine.2011.06.062; Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374; Wallace MJ, 2003, J GEN VIROL, V84, P1723, DOI 10.1099/vir.0.18980-0; Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1	51	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1235	10.3390/vaccines9111235			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XL1TG	34835166	Green Published, gold			2022-04-29	WOS:000727933200001
J	Bidram, M; Zhao, Y; Shebardina, NG; Baldin, AV; Bazhin, AV; Ganjalikhany, MR; Zamyatnin, AA; Ganjalikhani-hakemi, M				Bidram, Maryam; Zhao, Yue; Shebardina, Natalia G.; Baldin, Alexey V.; Bazhin, Alexandr V.; Ganjalikhany, Mohamad Reza; Zamyatnin, Andrey A.; Ganjalikhani-hakemi, Mazdak			mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients	VACCINES			English	Review						melanoma cancer; mRNA vaccine; therapeutic; delivery systems; immune checkpoint	T-CELL RESPONSES; CANCER/TESTIS ANTIGEN-EXPRESSION; HUMAN DENDRITIC CELLS; IN-VIVO; GENE-THERAPY; STIMULATORY CAPACITY; LIPID NANOPARTICLES; IMMUNE CHECKPOINTS; NONVIRAL DELIVERY; STEM-CELLS	Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of death from skin tumors. Given the increased incidence of melanoma diagnoses in recent years, it is essential to develop effective treatments to control this disease. In this regard, the use of cancer vaccines to enhance cell-mediated immunity is considered to be one of the most modern immunotherapy options for cancer treatment. The most recent cancer vaccine options are mRNA vaccines, with a focus on their usage as modern treatments. Advantages of mRNA cancer vaccines include their rapid production and low manufacturing costs. mRNA-based vaccines are also able to induce both humoral and cellular immune responses. In addition to the many advantages of mRNA vaccines for the treatment of cancer, their use is associated with a number of challenges. For this reason, before mRNA vaccines can be used for the treatment of cancer, comprehensive information about them is required and a large number of trials need to be conducted. Here, we reviewed the general features of mRNA vaccines, including their basis, stabilization, and delivery methods. We also covered clinical trials involving the use of mRNA vaccines in melanoma cancer and the challenges involved with this type of treatment. This review also emphasized the combination of treatment with mRNA vaccines with the use of immune-checkpoint blockers to enhance cell-mediated immunity.</p>	[Bidram, Maryam; Ganjalikhany, Mohamad Reza] Univ Isfahan, Fac Biol Sci & Technol, Dept Cell & Mol Biol, Esfahan 8174673441, Iran; [Zhao, Yue; Bazhin, Alexandr V.] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, D-81377 Munich, Germany; [Shebardina, Natalia G.; Zamyatnin, Andrey A.] Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia; [Baldin, Alexey V.; Zamyatnin, Andrey A.] Lomonosov Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow 119992, Russia; [Baldin, Alexey V.] VI Kulakov Natl Med Res Ctr Obstet Gynecol & Peri, Moscow 117997, Russia; [Bazhin, Alexandr V.] German Canc Consortium DKTK, Partner Site Munich, D-81377 Munich, Germany; [Zamyatnin, Andrey A.] Sirius Univ Sci & Technol, Dept Biotechnol, 1 Olymp Ave, Soci 354340, Russia; [Zamyatnin, Andrey A.] Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 7X, Surrey, England; [Ganjalikhani-hakemi, Mazdak] Isfahan Univ Med Sci, Fac Med, Dept Immunol, Esfahan 8174673441, Iran		Zamyatnin, AA (通讯作者)，Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia.; Zamyatnin, AA (通讯作者)，Lomonosov Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow 119992, Russia.; Zamyatnin, AA (通讯作者)，Sirius Univ Sci & Technol, Dept Biotechnol, 1 Olymp Ave, Soci 354340, Russia.; Zamyatnin, AA (通讯作者)，Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 7X, Surrey, England.; Ganjalikhani-hakemi, M (通讯作者)，Isfahan Univ Med Sci, Fac Med, Dept Immunol, Esfahan 8174673441, Iran.	m.bidram@sci.ui.ac.ir; yue.zhao@med.uni-muenchen.de; natuskasheb@gmail.com; alexey-baldin@belozersky.msu.ru; alexandr.bazhin@med.uni-muenchen.de; m.ganjalikhany@sci.ui.ac.ir; zamyat@belozersky.msu.ru; mghakemi@med.mui.ac.ir	Zamyatnin, Andrey A./D-6443-2012; Hakemi, Mazdak Ganjalikhani/V-7950-2017; Baldin, Alexey/ABC-7462-2021	Zamyatnin, Andrey A./0000-0002-3046-4565; Hakemi, Mazdak Ganjalikhani/0000-0002-4764-7616; Baldin, Alexey/0000-0001-6220-5341; Ganjalikhany, Mohamad Reza/0000-0002-6865-0814	Russian Science FoundationRussian Science Foundation (RSF) [21-75-30020]	This research was funded by the Russian Science Foundation (grant # 21-75-30020).	Aarntzen EHJG, 2012, CLIN CANCER RES, V18, P5460, DOI 10.1158/1078-0432.CCR-11-3368; Ahmed R, 2020, CURR OPIN BIOTECH, V65, P142, DOI 10.1016/j.copbio.2020.02.009; Ai MD, 2015, CANCER IMMUNOL IMMUN, V64, P885, DOI 10.1007/s00262-014-1650-8; Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Almeida M, 2017, J POLYM RES, V25, DOI 10.1007/s10965-017-1426-x; Fernandez AMA, 2019, J CLIN ONCOL, V37; Baldin AV, 2020, CANCERS, V12, DOI 10.3390/cancers12030590; Barone A, 2017, CLIN CANCER RES, V23, P5661, DOI 10.1158/1078-0432.CCR-16-0664; Barrow C, 2006, CLIN CANCER RES, V12, P764, DOI 10.1158/1078-0432.CCR-05-1544; Baru M, 1998, J DRUG TARGET, V6, P191, DOI 10.3109/10611869808997893; Beissert T, 2020, MOL THER, V28, P119, DOI 10.1016/j.ymthe.2019.09.009; Bell GD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201464; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Boespflug A, 2017, THER ADV MED ONCOL, V9, P481, DOI 10.1177/1758834017708160; Bonehill A, 2008, MOL THER, V16, P1170, DOI 10.1038/mt.2008.77; Bonehill A, 2009, CLIN CANCER RES, V15, P3366, DOI 10.1158/1078-0432.CCR-08-2982; Boudewijns S, 2020, CANCER IMMUNOL IMMUN, V69, P477, DOI 10.1007/s00262-019-02466-x; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239; Burris HA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2523; Cannarrozzi G, 2010, CELL, V141, P355, DOI 10.1016/j.cell.2010.02.036; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chou JY, 2011, EXPERT OPIN BIOL TH, V11, P1011, DOI 10.1517/14712598.2011.578067; Ciuffi A., 2012, VIRUSES ESSENTIAL AG, P147, DOI DOI 10.1007/978-94-007-4899-6_7; Colombo SF, 2015, J CONTROL RELEASE, V201, P22, DOI 10.1016/j.jconrel.2014.12.026; CONRY RM, 1995, CANCER RES, V55, P1397; Cronwright G, 2005, CANCER RES, V65, P2207, DOI 10.1158/0008-5472.CAN-04-1882; De Keersmaecker B, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000329; De Temmerman ML, 2011, BIOMATERIALS, V32, P9128, DOI 10.1016/j.biomaterials.2011.08.024; de Vries IJM, 2003, CANCER RES, V63, P12; Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308; Del Prete A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113930; Demoulins T, 2016, NANOMED-NANOTECHNOL, V12, P711, DOI 10.1016/j.nano.2015.11.001; Diken M, 2011, GENE THER, V18, P702, DOI 10.1038/gt.2011.17; Duraiswamy J, 2013, CANCER RES, V73, P6900, DOI 10.1158/0008-5472.CAN-13-1550; Duraiswamy J, 2013, CANCER RES, V73, P3591, DOI 10.1158/0008-5472.CAN-12-4100; Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875; Ehrengruber Markus U, 2011, Curr Protoc Neurosci, VChapter 4, DOI 10.1002/0471142301.ns0422s57; Fecek RJ, 2016, IMMUNOTHERAPY-UK, V8, P1205, DOI 10.2217/imt-2016-0071; Fogal S, 2015, MOL BIOTECHNOL, V57, P45, DOI 10.1007/s12033-014-9800-y; Frey AB, 2015, VACCINE, V33, P7393, DOI 10.1016/j.vaccine.2015.08.096; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z; Gary DJ, 2011, ACS NANO, V5, P3493, DOI 10.1021/nn102540y; Gjerstorff MF, 2007, HUM REPROD, V22, P953, DOI 10.1093/humrep/del494; Grabbe S, 2016, NANOMEDICINE-UK, V11, P2723, DOI 10.2217/nnm-2016-0275; Guan S, 2017, GENE THER, V24, P133, DOI 10.1038/gt.2017.5; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; HADDEN JW, 1993, TRENDS PHARMACOL SCI, V14, P169, DOI 10.1016/0165-6147(93)90203-V; Hajj KA, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.56; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hazarika M, 2017, CLIN CANCER RES, V23, P3484, DOI 10.1158/1078-0432.CCR-16-0712; Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014; Hewitt SL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat9143; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2006, CLIN CANCER RES, V12, P673, DOI 10.1158/1078-0432.CCR-05-2616; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Hornung Veit, 2008, V183, P71; Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010; Hoyer J, 2012, ACCOUNTS CHEM RES, V45, P1048, DOI 10.1021/ar2002304; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Jansen Y, 2020, CANCER IMMUNOL IMMUN, V69, P2589, DOI 10.1007/s00262-020-02618-4; Jhaveri AM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00077; Jiang YH, 2018, BIOMATERIALS, V176, P122, DOI 10.1016/j.biomaterials.2018.05.043; Johansen P, 2005, EUR J IMMUNOL, V35, P568, DOI 10.1002/eji.200425599; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kallen Karl-Josef, 2014, Ther Adv Vaccines, V2, P10, DOI 10.1177/2051013613508729; Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kobayashi H, 2001, CANCER RES, V61, P7577; Kongsted P, 2017, CYTOTHERAPY, V19, P500, DOI 10.1016/j.jcyt.2017.01.007; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kramps T, 2017, METHODS MOL BIOL, V1499, P1, DOI 10.1007/978-1-4939-6481-9_1; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180; Kuhn AN, 2012, CURR GENE THER, V12, P347; Kyte JA, 2006, CANCER GENE THER, V13, P905, DOI 10.1038/sj.cgt.7700961; Kyte JA, 2007, CANCER IMMUNOL IMMUN, V56, P659, DOI 10.1007/s00262-006-0222-y; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Le Moignic A, 2018, J CONTROL RELEASE, V278, P110, DOI 10.1016/j.jconrel.2018.03.035; LEE JA, 1981, ANAESTHESIA, V36, P1115, DOI 10.1111/j.1365-2044.1981.tb08698.x; Lesterhuis WJ, 2010, ANTICANCER RES, V30, P5091; Li L, 2017, ANN ONCOL, V28, P11, DOI 10.1093/annonc/mdx681; Liu CC, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12446; Lokugamage MP, 2020, ADV MATER, V32, DOI 10.1002/adma.201904905; Lorenz C, 2011, RNA BIOL, V8, P627, DOI 10.4161/rna.8.4.15394; Lou B, 2019, BIOCONJUGATE CHEM, V30, P461, DOI 10.1021/acs.bioconjchem.8b00524; Lovelyn C., 2011, J BIOMATER NANOBIOTE, V2, P626, DOI DOI 10.4236/JBNB.2011.225075; Lundstrom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145130; Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Markov OO, 2012, J CONTROL RELEASE, V160, P200, DOI 10.1016/j.jconrel.2011.11.034; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; McNamara MG, 2020, CANCER TREAT REV, V89, DOI 10.1016/j.ctrv.2020.102084; Melhem NM, 2008, CLIN VACCINE IMMUNOL, V15, P1337, DOI 10.1128/CVI.00154-08; Miao L, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01335-5; Midoux P, 2015, EXPERT REV VACCINES, V14, P221, DOI 10.1586/14760584.2015.986104; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Mockey M, 2007, CANCER GENE THER, V14, P802, DOI 10.1038/sj.cgt.7701072; Morse MA, 1999, CANCER RES, V59, P56; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Oberli MA, 2017, NANO LETT, V17, P1326, DOI 10.1021/acs.nanolett.6b03329; Ordonez NG, 2014, HUM PATHOL, V45, P191, DOI 10.1016/j.humpath.2013.02.007; Ott G, 1995, Pharm Biotechnol, V6, P277; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Payandeh Z, 2019, J CELL PHYSIOL, V234, P14612, DOI 10.1002/jcp.28181; Peng WY, 2012, CANCER RES, V72, P5209, DOI 10.1158/0008-5472.CAN-12-1187; Perche F, 2011, NANOMED-NANOTECHNOL, V7, P445, DOI 10.1016/j.nano.2010.12.010; Persano S, 2017, BIOMATERIALS, V125, P81, DOI 10.1016/j.biomaterials.2017.02.019; Pitcovski J, 2017, CRIT REV ONCOL HEMAT, V115, P36, DOI 10.1016/j.critrevonc.2017.05.001; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964; Qiu YS, 2019, J CONTROL RELEASE, V314, P102, DOI 10.1016/j.jconrel.2019.10.026; Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394; Ramishetti S, 2020, ADV MATER, V32, DOI 10.1002/adma.201906128; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Reiman JM, 2007, SEMIN CANCER BIOL, V17, P275, DOI 10.1016/j.semcancer.2007.06.009; Rezaee M, 2016, J CONTROL RELEASE, V236, P1, DOI 10.1016/j.jconrel.2016.06.023; Ringer S, 1882, J Physiol, V3, P195; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; ROSS J, 1985, BLOOD, V66, P1149; Rozovics JM, 2012, MBIO, V3, DOI 10.1128/mBio.00431-12; Rubinsteyn A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01807; Sabado RL, 2016, METHODS MOL BIOL, V1403, P763, DOI 10.1007/978-1-4939-3387-7_44; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Samaridou E, 2020, ADV DRUG DELIVER REV, V154, P37, DOI 10.1016/j.addr.2020.06.002; Sang MX, 2011, VACCINE, V29, P8496, DOI 10.1016/j.vaccine.2011.09.014; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Schott JW, 2016, MOL THER, V24, P1513, DOI 10.1038/mt.2016.143; Selmi A, 2016, CANCER IMMUNOL IMMUN, V65, P1075, DOI 10.1007/s00262-016-1869-7; Senti G, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-014-0047-7; Shi Y, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.201900215; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stefan J, 2018, J PHYSIOL PHARMACOL, V69, P995, DOI 10.26402/jpp.2018.6.15; Stepinski J, 2001, RNA, V7, P1486; Stewart MP, 2018, CHEM REV, V118, P7409, DOI 10.1021/acs.chemrev.7b00678; Tan L, 2018, NANO RES, V11, P5338, DOI 10.1007/s12274-018-2091-z; Tandler N, 2012, AMINO ACIDS, V43, P2203, DOI 10.1007/s00726-012-1409-5; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Tezel A, 2004, PHARM RES-DORDR, V21, P2219, DOI 10.1007/s11095-004-7674-6; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Thomas S, 2016, METHODS MOL BIOL, V1403, P755, DOI 10.1007/978-1-4939-3387-7_43; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Udhayakumar VK, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601412; Uzgun S, 2011, PHARM RES-DORDR, V28, P2223, DOI 10.1007/s11095-011-0464-z; Ulmer A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001604; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Vaidyanathan S, 2016, ACCOUNTS CHEM RES, V49, P1486, DOI 10.1021/acs.accounts.6b00200; Van der Jeught K, 2014, ONCOTARGET, V5, P10100; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Van Gulck ERA, 2006, BLOOD, V107, P1818, DOI 10.1182/blood-2005-01-0339; Van Hoecke L, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01329-3; Van Lint S, 2016, CANCER IMMUNOL RES, V4, P146, DOI 10.1158/2326-6066.CIR-15-0163; Van Lint S, 2012, CANCER RES, V72, P1661, DOI 10.1158/0008-5472.CAN-11-2957; Van Nuffel AMT, 2012, MOL THER, V20, P1063, DOI 10.1038/mt.2012.11; Van Tendeloo VF, 2010, P NATL ACAD SCI USA, V107, P13824, DOI 10.1073/pnas.1008051107; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Vik-Mo EO, 2013, CANCER IMMUNOL IMMUN, V62, P1499, DOI 10.1007/s00262-013-1453-3; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Walker EB, 2004, CLIN CANCER RES, V10, P668, DOI 10.1158/1078-0432.CCR-0095-03; Wang Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01311-z; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; Weissman D, 2015, MOL THER, V23, P1416, DOI 10.1038/mt.2015.138; Weng YH, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107534; Wilgenhof S, 2013, ANN ONCOL, V24, P2686, DOI 10.1093/annonc/mdt245; Wilgenhof S, 2016, J CLIN ONCOL, V34, P1330, DOI 10.1200/JCO.2015.63.4121; Wilgenhof S, 2015, CANCER IMMUNOL IMMUN, V64, P381, DOI 10.1007/s00262-014-1642-8; Wilgenhof S, 2011, J IMMUNOTHER, V34, P448, DOI 10.1097/CJI.0b013e31821dcb31; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Yang XZ, 2011, J CONTROL RELEASE, V156, P203, DOI 10.1016/j.jconrel.2011.07.035; Yao J, 2014, CANCER IMMUNOL RES, V2, P371, DOI 10.1158/2326-6066.CIR-13-0088; Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154; Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763; Zhao MN, 2016, DRUG DELIV, V23, P2596, DOI 10.3109/10717544.2015.1038856; Zhao Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020085; Zhong F, 2005, IMMUNOLOGY, V114, P83, DOI 10.1111/j.1365-2567.2004.02007.x; Ziemniak M, 2013, FUTURE MED CHEM, V5, P1141, DOI [10.4155/FMC.13.96, 10.4155/fmc.13.96]	200	3	3	28	28	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1060	10.3390/vaccines9101060			33	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN8TO	34696168	Green Published			2022-04-29	WOS:000712040000001
J	Guenl, F; Mecate-Zambrano, A; Rehlaender, S; Hinse, S; Ludwig, S; Brunotte, L				Guenl, Franziska; Mecate-Zambrano, Angeles; Rehlaender, Selina; Hinse, Saskia; Ludwig, Stephan; Brunotte, Linda			Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development	VACCINES			English	Review						SARS-CoV-2; vaccines; variants; vaccine safety; vaccine effectiveness; adverse effects; heterologous vaccination; breakthrough infection; long Covid; second generation vaccines	RECEPTOR-BINDING DOMAIN; NCOV-19 AZD1222 VACCINE; COVID-19 VACCINE; SPIKE PROTEIN; CLEAVAGE SITE; MUTATIONS; EFFICACY; VARIANT; CHADOX1; ACE2	Since late 2019 the newly emerged pandemic SARS-CoV-2, the causative agent of COVID-19, has hit the world with recurring waves of infections necessitating the global implementation of non-pharmaceutical interventions, including strict social distancing rules, the wearing of masks and the isolation of infected individuals in order to restrict virus transmissions and prevent the breakdown of our healthcare systems. These measures are not only challenging on an economic level but also have a strong impact on social lifestyles. Using traditional and novel technologies, highly efficient vaccines against SARS-CoV-2 were developed and underwent rapid clinical evaluation and approval to accelerate the immunization of the world population, aiming to end the pandemic and return to normality. However, the emergence of virus variants with improved transmission, enhanced fitness and partial immune escape from the first generation of vaccines poses new challenges, which are currently being addressed by scientists and pharmaceutical companies all over the world. In this ongoing pandemic, the evaluation of SARS-CoV-2 vaccines underlies diverse unpredictable dynamics, posed by the first broad application of the mRNA vaccine technology and their compliance, the occurrence of unexpected side effects and the rapid emergence of variations in the viral antigen. However, despite these hurdles, we conclude that the available SARS-CoV-2 vaccines are very safe and efficiently protect from severe COVID-19 and are thereby the most powerful tools to prevent further harm to our healthcare systems, economics and individual lives. This review summarizes the unprecedented pathways of vaccine development and approval during the ongoing SARS-CoV-2 pandemic. We focus on the real-world effectiveness and unexpected positive and negative side effects of the available vaccines and summarize the timeline of the applied adaptations to the recommended vaccination strategies in the light of emerging virus variants. Finally, we highlight upcoming strategies to improve the next generations of SARS-CoV-2 vaccines.</p>	[Guenl, Franziska; Mecate-Zambrano, Angeles; Rehlaender, Selina; Hinse, Saskia; Ludwig, Stephan; Brunotte, Linda] Univ Munster, Inst Virol IVM, D-48149 Munster, Germany; [Mecate-Zambrano, Angeles; Ludwig, Stephan; Brunotte, Linda] Univ Munster, Med Fac, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany		Brunotte, L (通讯作者)，Univ Munster, Med Fac, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany.			Mecate-Zambrano, Angeles/0000-0002-2224-5645; Gunl, Franziska/0000-0002-4841-4363; Rehlander, Selina/0000-0002-5452-1384; Ludwig, Stephan/0000-0003-4490-3052	German Research Foundation (DFG)German Research Foundation (DFG) [BR 5189/1-1]; Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [01KI20218]; Network University Medicine (NUM) [01KX2021]; Faculty of Medicine, University of Muenster, through the Interdisciplinary Centre for Clinical Research (IZKF) [Bru2/015/19]; University of Muenster; German Research Foundation (DFG) through Clinical Research Unit CRU342German Research Foundation (DFG)	The authors of this review are supported by funding provided by the German Research Foundation (DFG) through project BR 5189/1-1 and the Clinical Research Unit CRU342 (for Project P6 granted to L.B. and S.L.); the Federal Ministry of Education and Research (BMBF) for the project CoIMMUNE (Grant No. 01KI20218 to L.B.) and through the Network University Medicine (NUM) for the COVID-19 project Organo-Strat (Grant No. 01KX2021 to L.B. and S.L.). Furthermore, we are grateful for financial support by the Faculty of Medicine, University of Muenster, through the Interdisciplinary Centre for Clinical Research (IZKF) (Grant No. Bru2/015/19 to L.B.). The work is part of the activities within the Research Alliance VIRAL.NRW of the state of North Rhine Westfalia, Germany, in the research line "immunity against SARS-CoV-2". We acknowledge the financial support from the University of Muenster through the Open Access Publication Fund.	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Alharbi NK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52730-4; Amanat F, 2021, MBIO, V12, DOI 10.1128/mBio.02648-20; [Anonymous], 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMclde2101987; [Anonymous], 2021, PFIZ BIONTECH GEB HI; Antrobus RD, 2014, MOL THER, V22, P668, DOI 10.1038/mt.2013.284; Arnold DT, 2021, ARE VACCINES SAFE PA, DOI [10.1101/2021.03.11.21253225, DOI 10.1101/2021.03.11.21253225]; Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barouch DH, 2021, NEW ENGL J MED, V385, P951, DOI 10.1056/NEJMc2108829; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Baum U, 2021, EFFECTIVENESS VACCIN, DOI [10.1101/2021, DOI 10.1101/2021.06.21.21258686]; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bestle D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000786; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Bloom J.D., 2021, SITES SARS COV 2 RBD; Blumenthal KG, 2021, NEW ENGL J MED, V384, P1273, DOI 10.1056/NEJMc2102131; Blumenthal KG, 2021, JAMA-J AM MED ASSOC, V325, P1562, DOI 10.1001/jama.2021.3976; Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4; Brosh-Nissimov T, 2021, CLIN MICROBIOL INFEC, V27, P1652, DOI 10.1016/j.cmi.2021.06.036; Brown JC., 2021, INCREASED TRANSMISSI, DOI [10.1101/2021.02.24.432576 (2021), DOI 10.1101/2021.02.24.432576, 10.1101/2021.02.24.432576]; Brussow H, 2021, ENVIRON MICROBIOL, V23, P2878, DOI 10.1111/1462-2920.15549; Buchbinder SP, 2020, LANCET, V396, pE68, DOI 10.1016/S0140-6736(20)32156-5; Cappuccini, 2021, LANCET, DOI [10.2139/ssrn.3873839, DOI 10.2139/SSRN.3873839]; CDC, COVID 19 BREAKTHR CA; Chakraborty C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679344; Chan C.K., 2021, STRUCTURE CHADOX1 AZ, DOI [10.1101/2021.05.19.444882, DOI 10.1101/2021.05.19.444882]; Charmet T, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100171; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; Cheng MH., 2021, IMPACT S AFRICAN 501, V9, P1008, DOI DOI 10.1101/2021.01.10.426143; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Chung, 2021, SIMULTANEOUS EVALUAT, DOI [10.1101/2021.03.20.21254037, DOI 10.1101/2021.03.20.21254037]; Comas-Herrera A, 2020, MORTALITY ASS COVID; Conceicao C, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3001016; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Daniloski Zharko, 2020, bioRxiv, DOI 10.1101/2020.06.14.151357; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Doan A., 2021, DESIGN IMMUNOGENICIT, DOI [10.1101/2021.05.11.443592, DOI 10.1101/2021.05.11.443592]; Dolgin Elie, 2020, Nat Biotechnol, DOI 10.1038/d41587-020-00022-y; Eguia RT, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009453; Ella R., 2021, EFFICACY SAFETY LOT, DOI [10.1101/2021.06.30.21259439, DOI 10.1101/2021.06.30.21259439]; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; European Centre for Disease Prevention and Control, 2021, PART COVID 19 VACC V, DOI [10.1787/23f2c52b-en, DOI 10.1787/23F2C52B-EN]; Fadda E., 2021, FINE TURNING SPIKE R, DOI [10.1101/2021.04.01.438036, DOI 10.1101/2021.04.01.438036]; Faria N. R., 2021, GENOMIC CHARACTERISA; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Faulkner N, 2021, ELIFE, V10, DOI 10.7554/eLife.69317; Fernandes GM, 2021, JMIR RES PROTOC, V10, DOI 10.2196/26477; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gil-Etayo FJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624483; Gobeil SMC, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108630; Goel Rishi R, 2021, medRxiv, DOI 10.1101/2021.03.03.21252872; Gorman Matthew J, 2021, bioRxiv, DOI 10.1101/2021.02.05.429759; GOV.IL, 2021, DECL VACC EFF INF SY; Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09; Gray Kathryn J, 2021, medRxiv, DOI 10.1101/2021.03.07.21253094; Greaney Allison J, 2021, Cell Host Microbe, V29, P463, DOI 10.1016/j.chom.2021.02.003; Greaney Allison J, 2021, bioRxiv, DOI 10.1101/2021.03.17.435863; Greaney Allison J, 2021, Cell Host Microbe, V29, P44, DOI [10.1101/2020.09.10.292078, 10.1016/j.chom.2020.11.007]; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Gushchin VA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070779; Gustafson CE, 2020, J ALLERGY CLIN IMMUN, V145, P1309, DOI 10.1016/j.jaci.2020.03.017; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Haynes W.A., 2021, MEDRXIV, DOI 10.1101/2021.01.06.20248960; He Qian, 2021, Emerging Microbes & Infections, V10, P629, DOI 10.1080/22221751.2021.1902245; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Isabel S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70827-z; Jensen B, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100164; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; Joyce Michael G, 2021, bioRxiv, DOI 10.1101/2021.03.24.436523; Jungreis I, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22905-7; Kahn F., 2021, EFFECTIVENESS BNT162, DOI [10.1101/2021.04.20.21254636, DOI 10.1101/2021.04.20.21254636]; Kemp S A, 2020, medRxiv, DOI 10.1101/2020.12.05.20241927; Ketas Thomas J, 2021, bioRxiv, DOI [10.20411/pai.v6i1.441, 10.1101/2021.03.11.434841]; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kowalska MA, 2010, THROMB RES, V125, P292, DOI 10.1016/j.thromres.2009.11.023; Kremer EJ, 2020, MOL THER, V28, P2303, DOI 10.1016/j.ymthe.2020.10.002; Kustin T, 2021, NAT MED, V27, P1379, DOI 10.1038/s41591-021-01413-7; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Leung K, 2021, EUROSURVEILLANCE, V26, P15, DOI 10.2807/1560-7917.ES.2020.26.1.2002106; Li MC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020333; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liu XaS, 2021, LANCET PREPRINT, DOI [10.2139/ssrn.3874014, DOI 10.2139/SSRN.3874014]; Liu Yang, 2021, N Engl J Med, DOI 10.1056/NEJMc2102017; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lopez-Camacho C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020307; Lubinski Bailey, 2021, bioRxiv, DOI 10.1101/2021.04.06.438731; Lytras S., 2021, EXPLORING NATURAL OR, DOI [10.1101/2021.01.22.427830, DOI 10.1101/2021.01.22.427830]; Mades A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-03931-3; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n931; McCallum Matthew, 2021, bioRxiv, DOI 10.1101/2021.03.31.437925; McCallum M, 2021, CELL, V184, P2332, DOI [10.1101/2021.01.14.426475, 10.1016/j.cell.2021.03.028]; McCarthy KR, 2021, SCIENCE, V371, P1139, DOI 10.1126/science.abf6950; Meng B, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109292; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Minervina A.A., 2021, CONVERGENT EPITOPESP, DOI [10.1101/2021.07.12.21260227, DOI 10.1101/2021.07.12.21260227]; Mishra Pankaj Kumar, 2021, medRxiv, DOI 10.1101/2021.04.11.21255153; Mlcochova P., 2021, BIORXIV, DOI [10.1101/2021.05.08.443253, DOI 10.1101/2021.05.08.443253]; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Moderna Inc., 2021, MOD PROV CLIN UPD NE; Moghadas SM, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001211; Moss, 2021, EXTENDED INTERVAL BN, DOI [10.1101/2021.05.15.21257017, DOI 10.1101/2021.05.15.21257017]; Moustsen-Helms I.R., 2021, VACCINE EFFECTIVENE, DOI [10.1101/2021.03.08.21252200, DOI 10.1101/2021.03.08.21252200]; Moyo-Gwete Thandeka, 2021, bioRxiv, DOI 10.1101/2021.03.06.434193; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Nanduri S, 2021, MMWR-MORBID MORTAL W, V70, P1163, DOI 10.15585/mmwr.mm7034e3; Nasreen S., 2021, EFFECTIVENESS COVID, DOI [10.1101/2021.06.28.21259420, DOI 10.1101/2021.06.28.21259420]; Nkengasong J., 2021, NOVEL VARIANT INTERE, DOI [10.1101/2021.03.30.21254323, DOI 10.1101/2021.03.30.21254323]; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5; Ozono S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21118-2; Pak A, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00241; Peacock TP, 2021, NAT MICROBIOL, V6, P899, DOI 10.1038/s41564-021-00908-w; Peacock TP, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001584; Pessoa K., 2021, EMERGENCE SPREAD SAR; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Raveendran AV, 2021, DIABETES METAB SYND, V15, P869, DOI 10.1016/j.dsx.2021.04.007; Robert Koch-Institut, 2021, WOCH LAG RKI 22 07 2; Romero-Brufau S, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1087; Rosenberg E. S., 2021, Morbidity and Mortality Weekly Report, V70, P1306, DOI 10.15585/mmwr.mm7037a7; Roser M., CORONAVIRUS PANDEMIC; Rosner CM, 2021, CIRCULATION, V144, P502, DOI 10.1161/CIRCULATIONAHA.121.055891; Rossman J., 2021, PATIENT SAFETY LEARN; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Saito A, 2021, PREPRINT BIORXIV, DOI [10.1101/2021.06.17.448820, DOI 10.1101/2021.06.17.448820]; Saunders KO, 2021, NATURE, V594, P553, DOI 10.1038/s41586-021-03594-0; Scheepers C, 2021, CONTINUOUS EVOLUTION, DOI [10.1101/2021.08.20.21262342, DOI 10.1101/2021.08.20.21262342]; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01115-6, 10.1016/S0140-6736(21)01158-2]; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Sin, 2021, EPIDEMIOLOGISCHES B; Spencer A. J., 2021, CHADOX1 VECTORED VAC, DOI [10.1101/2021.06.08.447308, DOI 10.1101/2021.06.08.447308]; Starr TN, 2021, NATURE, V597, P97, DOI 10.1038/s41586-021-03807-6; Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255; Starr Tyler N, 2021, Science, V371, P850, DOI [10.1101/2020.11.30.405472, 10.1126/science.abf9302]; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.07.19.452771; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Tenforde Mark W, 2021, Clin Infect Dis, V73, pe4244, DOI 10.1093/cid/ciaa1884; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Thomson EC, 2021, CELL, V184, P1171, DOI 10.1016/j.cell.2021.01.037; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tortorici MA, 2020, SCIENCE, V370, P950, DOI 10.1126/science.abe3354; Uriu K., 2021, INFECTIVE NEUTRALIZA, DOI [10.1101/2021.09.06.459005, DOI 10.1101/2021.09.06.459005]; van der Merwe, 2021, EFFECTS COMMON MUTAT, DOI [10.1101/2021.05.18.444646, DOI 10.1101/2021.05.18.444646]; van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058; Villar J, 2021, JAMA PEDIATR, V175, P817, DOI 10.1001/jamapediatrics.2021.1050; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Volz Erik, 2021, Cell, V184, P64, DOI 10.1016/j.cell.2020.11.020; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang Pengfei, 2021, bioRxiv, DOI [10.1016/j.chom.2021.04.007, 10.1101/2021.03.01.433466]; Wang RK, 2021, IMMUNITY, V54, P1611, DOI 10.1016/j.immuni.2021.06.003; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; Weissman D, 2021, CELL HOST MICROBE, V29, P23, DOI 10.1016/j.chom.2020.11.012; Welkers MRA, 2021, VIRUS EVOL, V7, DOI 10.1093/ve/veaa094; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n359; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179; Xiao K., 2020, ISOLATION CHARACTERI, DOI [10.1101/2020.02.17.951335, DOI 10.1101/2020.02.17.951335]; Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740; Yadav PD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21639-w; Yurkovetskiy Leonid, 2020, bioRxiv, DOI 10.1101/2020.07.04.187757; Zahradnik, 2021, EMERGING SARS COV 2, DOI [10.1101/2021.04.02.438288, DOI 10.1101/2021.04.02.438288]; Zhang J, 2021, SCIENCE, V372, P525, DOI 10.1126/science.abf2303; Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726; Zhao S, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab011; Zhou Bin, 2020, bioRxiv, DOI 10.1101/2020.10.27.357558; Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zuckerman NS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060616; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	200	9	9	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1052	10.3390/vaccines9101052			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP5FD	34696160	Green Published, gold			2022-04-29	WOS:000713156500001
J	Walkowiak, MP; Walkowiak, D				Walkowiak, Marcin Piotr; Walkowiak, Dariusz			Predictors of COVID-19 Vaccination Campaign Success: Lessons Learnt from the Pandemic So Far. A Case Study from Poland	VACCINES			English	Article						COVID-19; vaccination; trust in vaccine; public health; health policy	LARGE-SCALE; CONFIDENCE; ADULTS	The high effectiveness of a vaccination-promotion campaign, which may be measured by the number of those successfully convinced to get vaccinated, is a key factor in combating the COVID-19 pandemic. This, however, appears to be linked to the precise identification of the underlying causes for vaccine hesitancy behaviours. Based on a regression model (adjusted R-2 of 0.78) analysing 378 sub-regions of Poland, we showed that such behaviours, even when going against the party agenda, can be indirectly yet precisely gauged predominantly through voting patterns. Additionally, education and population density were found to be positively related to low vaccine hesitancy, while markers of social exclusion, both external (employment rate) and psychological (voter turnout) ones, affected it negatively. In the second, follow-up part of our study, which analyses the changes that took place in two months (adjusted R-2 of 0.53), we found a further increase in vaccination rate to be positively related to the number of those already vaccinated and to the political views of the population, and negatively related to its level of education. In both cases, there was a surprisingly weak relationship between the potential markers of accessibility and vaccination rate. In spite of the known overall differences in vaccination rates for different age and sex groups, these variables did not have any additional informative value in explaining the observed regional differences.	[Walkowiak, Marcin Piotr] Poznan Univ Med Sci, Dept Prevent Med, PL-60179 Poznan, Poland; [Walkowiak, Dariusz] Poznan Univ Med Sci, Dept Org & Management Hlth Care, PL-60356 Poznan, Poland		Walkowiak, D (通讯作者)，Poznan Univ Med Sci, Dept Org & Management Hlth Care, PL-60356 Poznan, Poland.	MarcinWalkowiak@wir.pl; dariuszwalkowiak@ump.edu.pl	Walkowiak, Dariusz/AAV-6786-2020	Walkowiak, Dariusz/0000-0001-8874-2401			Afifi TO, 2021, VACCINE, V39, P3473, DOI 10.1016/j.vaccine.2021.05.026; [Anonymous], Fact Check: Outdated Video of Fauci Saying "There's No Reason to Be Walking around with a Mask"; [Anonymous], COVID 19 VACCINE TRA; [Anonymous], RAPORT SZCZEPIE PRZE; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Cialdini R.B., 1993, INFLUENCE SCI PRACTI; Claeys AS, 2010, PUBLIC RELAT REV, V36, P256, DOI 10.1016/j.pubrev.2010.05.004; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Gollust SE, 2020, J HEALTH POLIT POLIC, V45, P967, DOI 10.1215/03616878-8641506; Hadjipanayis A, 2020, VACCINE, V38, P1505, DOI 10.1016/j.vaccine.2019.11.068; Hammer CC, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001114; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Hyland P, 2021, PUBLIC HEALTH, V195, P54, DOI 10.1016/j.puhe.2021.04.009; Kadoya Y, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094864; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee S, 2012, PUBLIC RELAT REV, V38, P932, DOI 10.1016/j.pubrev.2012.08.006; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lindholt MF, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-048172; MacCoun RJ, 2012, PSYCHOL REV, V119, P345, DOI 10.1037/a0027121; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Noar SM, 2020, HEALTH COMMUN, V35, P1735, DOI 10.1080/10410236.2020.1838093; Pagliaro S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248334; Pivetti M, 2021, SOC SCI-BASEL, V10, DOI 10.3390/socsci10030108; Prats M., 2020, OECD STAT NEWSLETTER; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Raciborski F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080832; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sowa P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080876; Trent Mallory, 2022, Vaccine, V40, P2498, DOI 10.1016/j.vaccine.2021.06.048; Wang H, 2020, LANCET DIGIT HEALTH, V2, pE503, DOI 10.1016/S2589-7500(20)30197-7; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wike R., 2019, MOST EMBRACE DEMOCRA; Xie Y, 2009, PSYCHOL MARKET, V26, P572, DOI 10.1002/mar.20289; Zuk P, 2020, GLOB PUBLIC HEALTH, V15, P790, DOI 10.1080/17441692.2020.1718733	49	10	10	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1153	10.3390/vaccines9101153			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS0PH	34696261	gold, Green Published			2022-04-29	WOS:000714891700001
J	Dalton, KP; Alvarado, C; Reytor, E; Nunez, MD; Podadera, A; Martinez-Alonso, D; Alonso, JMM; Nicieza, I; Gomez-Sebastian, S; Dalton, RM; Parra, F; Escribano, JM				Dalton, Kevin P.; Alvarado, Carmen; Reytor, Edel; Del Carmen Nunez, Maria; Podadera, Ana; Martinez-Alonso, Diego; Martin Alonso, Jose Manuel; Nicieza, Ines; Gomez-Sebastian, Silvia; Dalton, Romy M.; Parra, Francisco; Escribano, Jose M.			Chimeric VLPs Bearing VP60 from Two Serotypes of Rabbit Haemorrhagic Disease Virus Are Protective against Both Viruses	VACCINES			English	Article						calicivirus; RHDV; chimeric VLP; bivalent vaccine; Trichoplusia ni; baculovirus	MOLECULAR-CLONING; PARTICLES; VACCINE; VARIANT; IMMUNIZATION; CALICIVIRUS; EXPRESSION; RHDV; IMMUNOGENICITY; EPIDEMIOLOGY	The VP60 capsid protein from rabbit haemorrhagic disease virus (RHDV), the causative agent of one of the most economically important disease in rabbits worldwide, forms virus-like particles (VLPs) when expressed using heterologous protein expression systems such as recombinant baculovirus, yeasts, plants or mammalian cell cultures. To prevent RHDV dissemination, it would be beneficial to develop a bivalent vaccine including both RHDV GI.1- and RHDV GI.2-derived VLPs to achieve robust immunisation against both serotypes. In the present work, we developed a strategy of production of a dual-serving RHDV vaccine co-expressing the VP60 proteins from the two RHDV predominant serotypes using CrisBio technology, which uses Tricholusia ni insect pupae as natural bioreactors, which are programmed by recombinant baculovirus vectors. Co-infecting the insect pupae with two baculovirus vectors expressing the RHDV GI.1- and RHDV GI.2-derived VP60 proteins, we obtained chimeric VLPs incorporating both proteins as determined by using serotype-specific monoclonal antibodies. The resulting VLPs showed the typical size and shape of this calicivirus as determined by electron microscopy. Rabbits immunised with the chimeric VLPs were fully protected against a lethal challenge infection with the two RHDV serotypes. This study demonstrates that it is possible to generate a dual cost-effective vaccine against this virus using a single production and purification process, greatly simplifying vaccine manufacturing.	[Dalton, Kevin P.; Podadera, Ana; Martin Alonso, Jose Manuel; Nicieza, Ines; Parra, Francisco] Univ Oviedo, Inst Univ Biotecnol Asturias, Dept Bioquim & Biol Mol, Campus Cristo,Edificio Santiago Gascon, E-33006 Oviedo, Spain; [Alvarado, Carmen; Reytor, Edel; Del Carmen Nunez, Maria; Martinez-Alonso, Diego; Gomez-Sebastian, Silvia; Dalton, Romy M.; Escribano, Jose M.] Alternat Gene Express SL, Ronda Poniente 14, Madrid 28760, Spain		Escribano, JM (通讯作者)，Alternat Gene Express SL, Ronda Poniente 14, Madrid 28760, Spain.	daltonkevin@uniovi.es; calvarado@algenex.com; edel.reytor@avantorsciences.com; cnunez@algenex.com; anapoda@uwindsor.ca; diegomartinezalonso91@gmail.com; jmmartin@uniovi.es; inesnila@gmail.com; sgosebastian@gmail.com; romydalton@algenex.com; fparra@uniovi.es; jmescribano@algenex.com	Gómez-Sebastián, Silvia/ABC-5878-2020; Parra, Francisco/D-5401-2009; Martin Alonso, Jose Manuel/C-7763-2013	Gómez-Sebastián, Silvia/0000-0002-7326-3181; Parra, Francisco/0000-0002-1885-9521; Martin Alonso, Jose Manuel/0000-0003-1725-6216; Martinez Alonso, Diego/0000-0003-0521-5134; Dalton, Kevin P./0000-0002-7086-1979	company Alternative Gene Expression S.L; FEDEREuropean Commission; Principado de Asturias (Spain) [GRUPIN14-099]; Spanish Ministry for Science Innovation and Universities (INTERCUN) [AGL2017-83395-R]; Spanish Ministry for Science Innovation and Universities (Ayuntamiento Ribera de Arriba, Asturias, Spain); Spanish Ministry for Science Innovation and UniversitiesSpanish Government [PID2020-120349RB-100];  [AGL2013-48550-C2-1-R]	This research was funded by the company Alternative Gene Expression S.L. and by the grant number AGL2013-48550-C2-1-R co-financed by FEDER and GRUPIN14-099 from Principado de Asturias (Spain). FP also received funding the Spanish Ministry for Science Innovation and Universities (reference number AGL2017-83395-R from INTERCUN and the Ayuntamiento Ribera de Arriba, Asturias, Spain). KPD and JMMA acknowledge funding from the Spanish Ministry for Science Innovation and Universities (reference number PID2020-120349RB-100).	Arguello Villares J L, 1991, Rev Sci Tech, V10, P459; Bertagnoli S, 1996, VACCINE, V14, P506, DOI 10.1016/0264-410X(95)00232-P; Bertagnoli S, 1996, J VIROL, V70, P5061, DOI 10.1128/JVI.70.8.5061-5066.1996; BOGA JA, 1994, J GEN VIROL, V75, P2409, DOI 10.1099/0022-1317-75-9-2409; Boga JA, 1997, J GEN VIROL, V78, P2315, DOI 10.1099/0022-1317-78-9-2315; BOGA JA, 1992, VIRUS RES, V26, P33, DOI 10.1016/0168-1702(92)90144-X; Calvete C, 2018, VET MICROBIOL, V219, P87, DOI 10.1016/j.vetmic.2018.04.018; Capucci L, 2017, VET REC, V180, DOI 10.1136/vr.104132; Castanon S, 1999, J VIROL, V73, P4452; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; Cheng YJ, 2013, ANTIVIR RES, V97, P227, DOI 10.1016/j.antiviral.2012.12.028; Cooke BD, 2002, REV SCI TECH OIE, V21, P347, DOI 10.20506/rst.21.2.1337; Cortes-Penfield NW, 2017, CLIN THER, V39, P1537, DOI 10.1016/j.clinthera.2017.07.002; Dalton KP, 2018, J VIROL METHODS, V251, P118, DOI 10.1016/j.jviromet.2017.10.009; Dalton KP, 2014, VET MICROBIOL, V169, P67, DOI 10.1016/j.vetmic.2013.12.015; Dalton KP, 2012, EMERG INFECT DIS, V18, P2009, DOI 10.3201/eid1812.120341; Debbink K, 2014, J VIROL, V88, P7256, DOI 10.1128/JVI.00785-14; Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028; Escribano JM, 2020, J BIOTECHNOL, V324, DOI 10.1016/j.btecx.2020.100019; Fernandez-Fernandez MR, 2001, VIROLOGY, V280, P283, DOI 10.1006/viro.2000.0762; Fischer L, 1997, VACCINE, V15, P90, DOI 10.1016/S0264-410X(96)00102-8; Gomez-Sebastian S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096562; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Kerr PJ, 2009, J VIROL, V83, P12129, DOI 10.1128/JVI.01523-09; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; LAURENT S, 1994, J VIROL, V68, P6794, DOI 10.1128/JVI.68.10.6794-6798.1994; Le Gall-Recule G, 2011, VET REC, V168, P137, DOI 10.1136/vr.d697; Le Pendu J, 2017, J GEN VIROL, V98, P1658, DOI 10.1099/jgv.0.000840; Lopez-Vidal J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140039; Mahar JE, 2018, J VIROL, V92, DOI 10.1128/JVI.01374-17; Marin MS, 1995, VIRUS RES, V39, P119, DOI 10.1016/0168-1702(95)00074-7; McIntosh MT, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-96; Meyers G, 2000, VIROLOGY, V276, P349, DOI 10.1006/viro.2000.0545; MEYERS G, 1991, VIROLOGY, V184, P664, DOI 10.1016/0042-6822(91)90436-F; Moreno N, 2016, SCI REP-UK, V6, DOI 10.1038/srep31844; Moss SR, 2002, J GEN VIROL, V83, P2461, DOI 10.1099/0022-1317-83-10-2461; NAGESHA HS, 1995, ARCH VIROL, V140, P1095, DOI 10.1007/BF01315418; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; PARRA F, 1993, VIRUS RES, V27, P219, DOI 10.1016/0168-1702(93)90034-K; PARRA F, 1990, J VIROL, V64, P4013, DOI 10.1128/JVI.64.8.4013-4015.1990; Perez-Filgueira DM, 2007, VIROLOGY, V364, P422, DOI 10.1016/j.virol.2007.03.016; PRASAD BVV, 1994, J MOL BIOL, V240, P256, DOI 10.1006/jmbi.1994.1439; SIBILIA M, 1995, J VIROL, V69, P5812, DOI 10.1128/JVI.69.9.5812-5815.1995; Treanor JJ, 2014, J INFECT DIS, V210, P1763, DOI 10.1093/infdis/jiu337; Tzeyung AS, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010026; Verardi R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00260-w	46	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1005	10.3390/vaccines9091005			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YX	34579243	Green Published, gold			2022-04-29	WOS:000702077000001
J	Fan, YJ; Chan, KH; Hung, IFN				Fan, Yu-Jing; Chan, Kwok-Hung; Hung, Ivan Fan-Ngai			Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3	VACCINES			English	Review						mRNA vaccines; inactivated vaccines; non-replicating vaccines	NCOV-19 AZD1222 VACCINE; IMMUNOGENICITY	This systematic review and meta-analysis was conducted to compare the safety and efficacy of 2019 novel coronavirus disease (COVID-19) vaccines according to vaccine platform and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection severity. Articles published between 24 January 2020 and 30 May 2021 were retrieved via a PubMed and EMBASE search. A total of 12 reports on phase-3 clinical trials and observational studies of COVID-19 vaccines were included in the review. In terms of vaccine safety, mRNA vaccines showed more relevance to serious adverse events than viral vector and inactivated vaccines, but no solid evidence indicated that COVID-19 vaccines directly caused serious adverse events. Serious metabolic, musculoskeletal, immune-system, and renal disorders were more common among inactivated vaccine recipients, and serious gastrointestinal complications and infections were more common among viral vector and inactivated vaccine recipients. The occurrence of serious vessel disorders was more frequent in mRNA vaccines. In terms of efficacy, two mRNA vaccine doses conferred a lesser risk of SARS-COV-2 infection (odds ratio: 0.05; 95% confidence interval: 0.02-0.13) than did vaccination with viral vector and inactivated vaccines. All vaccines protected more against symptomatic than asymptomatic cases (risk ratio, 0.11 vs. 0.34), but reduced the risk of severe SARS-COV-2 infection. The COVID-19 vaccines assessed in this study are sufficiently safe and effective. The results indicate that two mRNA vaccine doses prevent SARS-COV-2 infection most effectively, but further research is needed due to the high degree of heterogeneity among studies in this sample. Interventions should be implemented continuously to reduce the risks of infection after one vaccine dose and asymptomatic infection.	[Fan, Yu-Jing] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China; [Chan, Kwok-Hung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China; [Hung, Ivan Fan-Ngai] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China		Hung, IFN (通讯作者)，Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.	u3571448@connect.hku.hk; chankh2@hku.hk; ivanhung@hku.hk	Chan, Kwok Hung/ABD-5399-2021; Hung, Ivan FN/ABD-5916-2021	Hung, Ivan FN/0000-0002-1556-2538; /0000-0003-1771-8249			Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Higgins J.P.T., 2011, COCHRANE HDB SYSTEMA; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Lee K, 2009, GLOB INST, P1; Li J, 2013, VIRAL IMMUNOL, V26, P126, DOI 10.1089/vim.2012.0076; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; MedDRA, 2019, INTR GUID STAND MEDD; Palacios R., 2021, SSRN, DOI [10.2139/ssrn.3822780, DOI 10.2139/SSRN.3822780]; Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Qin CX, 2020, EUR J NUCL MED MOL I, V47, P1281, DOI 10.1007/s00259-020-04734-w; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Swift MD, 2021, CLIN INFECT DIS, V73, pE1376, DOI 10.1093/cid/ciab361; US Food and Drug Administration, 2007, GUID IND TOX GRAD SC; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020; World Health Organization, 2021, WHAT IS COVID 19 VAC; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	32	10	10	13	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							989	10.3390/vaccines9090989			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3HK	34579226	Green Published, gold			2022-04-29	WOS:000702099200001
J	Terrade, G; Huot, N; Petitdemange, C; Lazzerini, M; Resendiz, AO; Jacquelin, B; Muller-Trutwin, M				Terrade, Gauthier; Huot, Nicolas; Petitdemange, Caroline; Lazzerini, Marie; Orta Resendiz, Aurelio; Jacquelin, Beatrice; Muller-Trutwin, Michaela			Interests of the Non-Human Primate Models for HIV Cure Research	VACCINES			English	Review						animal model; non-human primate; HIV; SIV; natural host; cure; therapies; immunity	SIMIAN IMMUNODEFICIENCY VIRUS; CD4(+) T-CELLS; MAURITIAN CYNOMOLGUS MACAQUES; NONPATHOGENIC SIV INFECTION; HIGHLY PATHOGENIC SIV; SOOTY MANGABEYS; IMMUNE ACTIVATION; IN-VIVO; MICROBIAL TRANSLOCATION; LYMPHOID-TISSUE	Non-human primate (NHP) models are important for vaccine development and also contribute to HIV cure research. Although none of the animal models are perfect, NHPs enable the exploration of important questions about tissue viral reservoirs and the development of intervention strategies. In this review, we describe recent advances in the use of these models for HIV cure research and highlight the progress that has been made as well as limitations using these models. The main NHP models used are (i) the macaque, in which simian immunodeficiency virus (SIVmac) infection displays similar replication profiles as to HIV in humans, and (ii) the macaque infected by a recombinant virus (SHIV) consisting of SIVmac expressing the HIV envelope gene serving for studies analyzing the impact of anti-HIV Env broadly neutralizing antibodies. Lessons for HIV cure that can be learned from studying the natural host of SW are also presented here. An overview of the most promising and less well explored HIV cure strategies tested in NHP models will be given.	[Terrade, Gauthier; Huot, Nicolas; Petitdemange, Caroline; Lazzerini, Marie; Orta Resendiz, Aurelio; Jacquelin, Beatrice; Muller-Trutwin, Michaela] Inst Pasteur, Unite HIV Inflammat & Persistance, F-75015 Paris, France; [Terrade, Gauthier; Orta Resendiz, Aurelio] Univ Paris, Bio Sorbonne Paris Cite, F-75013 Paris, France		Jacquelin, B (通讯作者)，Inst Pasteur, Unite HIV Inflammat & Persistance, F-75015 Paris, France.	gauthier.terrade@pasteur.fr; nicolas.huot@pasteur.fr; caroline.petitdemange@pasteur.fr; marie.lazzerini@pasteur.fr; aurelio.orta-resendiz@pasteur.fr; beatrice.jacquelin@pasteur.fr; michaela.muller-trutwin@pasteur.fr		Orta-Resendiz, Aurelio/0000-0002-6632-883X; Muller-Trutwin, Michaela/0000-0002-3854-2396	Institut PasteurEuropean Commission; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI143457]; Fondation J. Beytout; University of Paris	G.T. was partially supported by Institut Pasteur and by a NIH grant (R01AI143457). N.H. was supported by the Fondation J. Beytout, the Institut Pasteur and a NIH grant (R01AI143457). C.P. was supported by a Roux-Cantarini fellowship and Institut Pasteur. A.O.R. was supported by a doctoral fellowship from the University of Paris.	Abad-Fernandez M, 2019, CURR OPIN HIV AIDS, V14, P137, DOI [10.1097/COH.0000000000000524, 10.1097/coh.0000000000000524]; Agarwal Y, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-00515-3; Apetrei C, 2011, J VIROL, V85, P13077, DOI 10.1128/JVI.05693-11; Arainga M, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0344-7; Ayala VI, 2017, J VIROL, V91, DOI 10.1128/JVI.02507-16; Balls M, 2020, ATLA-ALTERN LAB ANIM, V48, P40, DOI 10.1177/0261192920911339; Barber-Axthelm IM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.141502; Barker BR, 2010, EUR J IMMUNOL, V40, P3085, DOI 10.1002/eji.200939939; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Barre-Sinoussi F, 2015, FUTUR SCI OA, V1, DOI [10.4155/FSO.15.63, 10.4155/fso.15.63]; Barrenas F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12987-9; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Borducchi EN, 2018, NATURE, V564, pE8, DOI 10.1038/s41586-018-0721-y; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Borducchi EN, 2016, NATURE, V540, P284, DOI 10.1038/nature20583; Bosinger SE, 2009, J CLIN INVEST, V119, P3556, DOI 10.1172/JCI40115; Bowen A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00789; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Bruel T, 2015, J VIROL, V89, P3542, DOI 10.1128/JVI.03723-14; Buckmaster C.A., 2018, MANAGEMENT ANIMAL CA, V2nd; Bugide S, 2018, TRENDS CANCER, V4, P553, DOI 10.1016/j.trecan.2018.06.004; Byrareddy SN, 2016, SCIENCE, V354, P197, DOI 10.1126/science.aag1276; Calenda G, 2018, J IMMUNOL, V200, P810, DOI 10.4049/jimmunol.1701150; Chahroudi A, 2012, SCIENCE, V335, P1188, DOI 10.1126/science.1217550; Chang CC, 2018, AIDS, V32, P2119, DOI 10.1097/QAD.0000000000001937; Colby DJ, 2020, NAT MED, V26, P498, DOI 10.1038/s41591-020-0774-y; Compton AA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0496; Courgnaud V, 1998, VIROLOGY, V247, P41, DOI 10.1006/viro.1998.9217; Courgnaud V, 2004, M S-MED SCI, V20, P448, DOI 10.1051/medsci/2004204448; Cumont MC, 2008, J VIROL, V82, P1175, DOI 10.1128/JVI.00450-07; Dashti A, 2020, J VIROL, V94, DOI 10.1128/JVI.00793-20; Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a; DeGrazia D, 2019, ILAR J, V60, P308, DOI 10.1093/ilar/ilz011; Del Prete GQ, 2018, CURR TOP MICROBIOL, V417, P69, DOI 10.1007/82_2017_73; Del Prete GQ, 2016, CURR OPIN HIV AIDS, V11, P546, DOI 10.1097/COH.0000000000000311; Donahoe RM, 2009, JAIDS-J ACQ IMM DEF, V50, P241, DOI 10.1097/QAI.0b013e3181967354; Eroshkin AM, 2014, NUCLEIC ACIDS RES, V42, pD1133, DOI 10.1093/nar/gkt1083; Estes JD, 2008, J IMMUNOL, V180, P6798, DOI 10.4049/jimmunol.180.10.6798; Etienne L, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-4; Fauci A. S., 1997, P587; Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295; Ferlazzo G, 2004, P NATL ACAD SCI USA, V101, P16606, DOI 10.1073/pnas.0407522101; Fisher L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02741; Francica JR, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000328; Fukazawa Y, 2015, NAT MED, V21, P132, DOI 10.1038/nm.3781; Fulda S, 2014, CLIN CANCER RES, V20, P3915, DOI 10.1158/1078-0432.CCR-13-2376; Garcia JV, 2016, CURR OPIN VIROL, V19, P56, DOI 10.1016/j.coviro.2016.06.010; Garcia JV, 2016, J CLIN INVEST, V126, P424, DOI 10.1172/JCI80562; Garcia-Tellez T, 2016, INFECT GENET EVOL, V46, P324, DOI 10.1016/j.meegid.2016.07.012; Gardner MR, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00176; Gardner MB, 2008, ILAR J, V49, P220, DOI 10.1093/ilar.49.2.220; Garrido C, 2018, J VIROL, V92, DOI 10.1128/JVI.00235-18; Goldstein S, 2006, J VIROL, V80, P4868, DOI 10.1128/JVI.80.10.4868-4877.2006; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959; Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757; Hampshire VA, 2019, TOXICOL PATHOL, V47, P329, DOI 10.1177/0192623318797289; Hansen SG, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2607; Hansen SG, 2016, SCIENCE, V351, P714, DOI 10.1126/science.aac9475; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Harper J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23189-7; Harper J, 2020, NAT MED, V26, P519, DOI 10.1038/s41591-020-0782-y; Harris LD, 2010, J VIROL, V84, P7886, DOI 10.1128/JVI.02612-09; Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911; HEENEY JL, 1995, IMMUNOL TODAY, V16, P515, DOI 10.1016/0167-5699(95)80043-3; Hirsch V M, 2000, Adv Pharmacol, V49, P437; Honeycutt JB, 2017, NAT MED, V23, P638, DOI 10.1038/nm.4319; Honeycutt JB, 2016, J CLIN INVEST, V126, P1353, DOI 10.1172/JCI84456; Hosur V, 2020, DRUG DISCOV TODAY, V25, P1013, DOI 10.1016/j.drudis.2020.03.018; Huot N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695148; Huot N, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102314; Huot N, 2019, VIROLOGIE, V23, P229, DOI 10.1684/vir.2019.0783; Huot N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00780; Huot N, 2017, NAT MED, V23, P1277, DOI 10.1038/nm.4421; Huot N, 2016, CURR OPIN VIROL, V19, P37, DOI 10.1016/j.coviro.2016.06.011; Imamura M, 2014, BLOOD, V124, P1081, DOI 10.1182/blood-2014-02-556837; Iwamoto N, 2019, SCIENCE, V365, P1033, DOI 10.1126/science.aaw7765; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jacquelin B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004241; Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093; Jiang GC, 2018, J CLIN INVEST, V128, P1190, DOI 10.1172/JCI98071; Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200; Khatissian E, 2001, J VIROL, V75, P1507, DOI 10.1128/JVI.75.3.1507-1515.2001; Klatt NR, 2010, MUCOSAL IMMUNOL, V3, P387, DOI 10.1038/mi.2010.14; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Krakoff E, 2019, J VIROL, V93, DOI 10.1128/JVI.00538-19; Krebs KC, 2005, J IMMUNOL, V175, P5230, DOI 10.4049/jimmunol.175.8.5230; Lederer S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000296; Leibman RS, 2015, MOL THER, V23, P1149, DOI 10.1038/mt.2015.70; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Lim SY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4521; Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07; Ma DZ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003011; Macedo AB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02450; Mandell DT, 2014, J VIROL, V88, P6778, DOI 10.1128/JVI.03785-13; Marsden MD, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-00516-2; Martin JT, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00223-1; Martins R, 2019, ANNU REV IMMUNOL, V37, P405, DOI 10.1146/annurev-immunol-042718-041739; Martinsen JT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01112; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657; Mavigner M, 2021, J VIROL, V95, DOI 10.1128/JVI.01429-20; McBrien JB, 2020, J VIROL, V94, DOI 10.1128/JVI.00755-20; McBrien JB, 2020, NATURE, V578, pE21, DOI 10.1038/s41586-020-2002-9; McBrien JB, 2020, NATURE, V578, P154, DOI 10.1038/s41586-020-1946-0; McGary CS, 2017, IMMUNITY, V47, P776, DOI 10.1016/j.immuni.2017.09.018; Mediouni S, 2019, FASEB J, V33, P8280, DOI 10.1096/fj.201801165R; Mee ET, 2009, J MED PRIMATOL, V38, P1, DOI 10.1111/j.1600-0684.2008.00299.x; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Meythaler M, 2011, J IMMUNOL, V186, P5151, DOI 10.4049/jimmunol.1004110; Micci L, 2015, J CLIN INVEST, V125, P4497, DOI 10.1172/JCI81400; Minetto P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02836; Mohammadi H, 2012, VIRUSES-BASEL, V4, P708, DOI 10.3390/v4050708; Mohns MS, 2015, J VIROL, V89, P9748, DOI 10.1128/JVI.00993-15; Mothe B, 2020, NAT MED, V26, P466, DOI 10.1038/s41591-020-0837-0; Mylvaganam GH, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122940; Nakamura-Hoshi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68267-w; Nath BM, 2000, TRENDS MICROBIOL, V8, P426, DOI 10.1016/S0966-842X(00)01816-3; Navarro AG, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00202; Ndung'u T, 2019, NATURE, V576, P397, DOI 10.1038/s41586-019-1841-8; Ngassaki-Yoka C.-D., 2021, CIRCADIAN CLOCK MACH; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Nixon CC, 2020, NATURE, V578, P160, DOI 10.1038/s41586-020-1951-3; Nomura T, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00234; O'Connor SL, 2007, IMMUNOGENETICS, V59, P449, DOI 10.1007/s00251-007-0209-7; Okoye AA, 2019, J IMMUNOL, V203, P2928, DOI 10.4049/jimmunol.1900792; Ortiz AM, 2016, MUCOSAL IMMUNOL, V9, P458, DOI 10.1038/mi.2015.75; Pache L, 2015, CELL HOST MICROBE, V18, P345, DOI 10.1016/j.chom.2015.08.009; Paiardini M, 2013, IMMUNOL REV, V254, P78, DOI 10.1111/imr.12079; Paiardini M, 2011, NAT MED, V17, P830, DOI 10.1038/nm.2395; Paiardini M, 2010, CURR OPIN HIV AIDS, V5, P166, DOI 10.1097/COH.0b013e328335c161; Pallikkuth S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003471; Pandrea I, 2006, J MED PRIMATOL, V35, P194, DOI 10.1111/j.1600-0684.2006.00168.x; Pandrea I, 2012, BLOOD, V120, P1357, DOI 10.1182/blood-2012-03-414706; Pandrea I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002170; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Papasavvas E, 2019, J IMMUNOL, V203, P705, DOI 10.4049/jimmunol.1801511; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Petitdemange C, 2020, EUR J IMMUNOL, V50, P342, DOI 10.1002/eji.201948284; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Pino M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01275; Pino M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008081; Policicchio BB, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00012; Raehtz KD, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008333; Ramsuran V, 2018, SCIENCE, V359, P86, DOI 10.1126/science.aam8825; Reeves RK, 2012, J INFECT DIS, V206, P1462, DOI 10.1093/infdis/jis408; Reeves RK, 2010, J VIROL, V84, P8959, DOI 10.1128/JVI.01126-10; Reeves RK, 2010, BLOOD, V115, P4439, DOI 10.1182/blood-2010-01-265595; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Reynolds MR, 2005, J VIROL, V79, P9228, DOI 10.1128/JVI.79.14.9228-9235.2005; Rotger M, 2011, J CLIN INVEST, V121, P2391, DOI 10.1172/JCI45235; Rudicell RS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001116; Rust BJ, 2020, BLOOD, V136, P1722, DOI 10.1182/blood.2020006372; Saez-Cirion A, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0436; Santangelo PJ, 2018, MUCOSAL IMMUNOL, V11, P932, DOI 10.1038/mi.2017.112; Santiago ML, 2005, J VIROL, V79, P12515, DOI 10.1128/JVI.79.19.12515-12527.2005; Sauter D, 2014, NATURAL HOSTS OF SIV: IMPLICATION IN AIDS, P69, DOI 10.1016/B978-0-12-404734-1.00004-8; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Silvestri G, 2007, J CLIN INVEST, V117, P3148, DOI 10.1172/JCI33034; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Sodora DL, 1998, AIDS RES HUM RETROV, V14, pS119; Sodora DL, 2009, NAT MED, V15, P861, DOI 10.1038/nm.2013; Surve DH, 2020, MOL PHARMACEUT, V17, P3990, DOI 10.1021/acs.molpharmaceut.0c00773; Surve DH, 2020, J CONTROL RELEASE, V324, P379, DOI 10.1016/j.jconrel.2020.05.022; Tebas P, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144486; Thalhauser S, 2020, J CONTROL RELEASE, V317, P322, DOI 10.1016/j.jconrel.2019.11.035; UNAIDS, FACT SHEET 2021; Understanding Animal Research, NOB PRIZ; Valle-Casuso JC, 2019, CELL METAB, V29, P611, DOI 10.1016/j.cmet.2018.11.015; Van Rompay KKA, 2017, LAB ANIMAL, V46, P259, DOI 10.1038/laban.1279; Van Rompay KKA, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-22; Vansant G, 2019, RETROVIROLOGY, V16, DOI 10.1186/s12977-019-0472-3; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662; Veluchamy JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00631; Webb GM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008339; Weichseldorfer M., 2020, J AIDS HIV TREAT, V2, DOI [10.33696/aids.2.003, DOI 10.33696/AIDS.2.003]; Wiederin JL, 2010, J PROTEOME RES, V9, P4721, DOI 10.1021/pr1004345; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Younan P, 2013, VIRUSES-BASEL, V5, P2946, DOI 10.3390/v5122946; Zerbato JM, 2019, CURR OPIN VIROL, V38, P1, DOI 10.1016/j.coviro.2019.03.004	187	0	0	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							958	10.3390/vaccines9090958			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW5IP	34579195	Green Published, gold			2022-04-29	WOS:000700189700001
J	Amanova, Z; Zhugunissov, K; Barakbayev, K; Kondybaeva, Z; Sametova, Z; Shayakhmetov, Y; Kaissenov, D; Dzhekebekov, K; Zhunushov, A; Abduraimov, Y; Zakarya, K; Bulatov, Y				Amanova, Zhanat; Zhugunissov, Kuandyk; Barakbayev, Kainar; Kondybaeva, Zhanat; Sametova, Zhanna; Shayakhmetov, Yeraly; Kaissenov, Dastan; Dzhekebekov, Kuanysh; Zhunushov, Asankadyr; Abduraimov, Yergaly; Zakarya, Kunsulu; Bulatov, Yerbol			Duration of Protective Immunity in Sheep Vaccinated with a Combined Vaccine against Peste des Petits Ruminants and Sheep Pox	VACCINES			English	Article						combined vaccine; peste des petites ruminants; sheep pox; immunity	VIRUS; PROSPECTS; CAPRIPOX; PPR	In this study, the ability of the combined vaccine against peste des petits ruminants (PPR) (Nigeria strain 75/1) and sheep pox (SPP) (NISKhI strain) to form a protective immune response for 12 months in Kazakh breed fine-fleeced sheep aged 6-12 months was demonstrated. The duration of the protective immunity of immunized sheep from PPR and from SPP was evaluated using a serum neutralization test (SNT), followed by testing of the resistance of vaccinated sheep to infection with the field strain Kentau-7 of the PPRV and the virulent strain A of the SPPV. The PPR antibody response was additionally measured by c-ELISA. A single immunization of sheep with a combined vaccine in a volume of 2.0 mL, containing the PPR and SPP vaccine viruses in the titers of 10(3.0) TCID50/mL, provided reliable protection of animals from two infections simultaneously for 12 months (observation period). At the same time, in sheep immunized with the combined vaccine, antibodies of PPRV persisted for up to 12 months, with slight fluctuations. The combined vaccine induced 100% clinical protection against the field strain of PPRV and the virulent strain of SPPV in immunized sheep for up to 12 months, while unvaccinated animals became ill with the manifestation of clinical signs specific to PPRV and SPPV.	[Amanova, Zhanat; Zhugunissov, Kuandyk; Barakbayev, Kainar; Kondybaeva, Zhanat; Sametova, Zhanna; Shayakhmetov, Yeraly; Kaissenov, Dastan; Dzhekebekov, Kuanysh; Abduraimov, Yergaly; Zakarya, Kunsulu; Bulatov, Yerbol] Res Inst Biol Safety Problems, Gvardeiskiy 080409, Kazakhstan; [Zhunushov, Asankadyr] Natl Acad Sci Kyrgyz Republ, Inst Biotechnol, Bishkek 720071, Kyrgyzstan		Amanova, Z (通讯作者)，Res Inst Biol Safety Problems, Gvardeiskiy 080409, Kazakhstan.	amanova-janka@mail.ru; kuandyk_83@mail.ru; kainar7@mail.ru; Zhanat.Kondybaeva@mail.ru; sametova_zh.zh@mail.ru; Eraly.Shax@gmail.com; k_dosik@mail.ru; zhekebekov_87@mail.ru; junushov@mail.ru; abduraimov_72@mail.ru; rkm_kz@mail.ru; erbol_km@mail.ru	Sametova, Zhanna/AGG-7444-2022; Zhugunissov, Kuandyk/G-2087-2015; Kaissenov, Dastan/AAD-2663-2022; Kondybaeva, Zhanat/AAW-5381-2020; Shayakhmetov, Yeraly/AAD-6249-2022	Kaissenov, Dastan/0000-0003-4095-109X; Kondybaeva, Zhanat/0000-0002-8224-8047; Shayakhmetov, Yeraly/0000-0002-4486-3188; Bulatov, Yerbol/0000-0001-8543-4219; Zhugunissov, Kuandyk/0000-0003-4238-5116	Science Committee of the Ministry of Education and Science, Republic of KazakhstanGovernment of the Republic of KazakhstanMinistry of Education and Science of the Republic of Kazakhstan	This work was supported by the Science Committee of the Ministry of Education and Science, Republic of Kazakhstan [G 2012/].	Abduraimov Y.O., 2016, B ASAU, V2, P121; Abduraimov Y.O., 2009, Sheeppox. Patent, Patent No. 16059; Akimov T.P., 2019, J VET VRACH, V3, P3, DOI [10.33632/1998-698X.2019-3-3-9, DOI 10.33632/1998-698X.2019-3-3-9]; Amanova Z.T., 2021, THEORY PRACTICE VET, P19; Amarasinghe GK, 2019, ARCH VIROL, V164, P1967, DOI 10.1007/s00705-019-04247-4; Ayelet G., 2012, AFR J MICROBIOL RES, V6, P7212; Bamouh Z, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2164-6; Banyard AC, 2010, J GEN VIROL, V91, P2885, DOI 10.1099/vir.0.025841-0; Bhanuprakash V, 2011, ANTIVIR RES, V91, P225, DOI 10.1016/j.antiviral.2011.06.004; Boumart Z, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0754-0; Chaudhary SS, 2009, VACCINE, V27, P2548, DOI 10.1016/j.vaccine.2009.01.104; Couacy-Hymann E, 2002, J VIROL METHODS, V100, P17, DOI 10.1016/S0166-0934(01)00386-X; Fakri F., 2015, Trials in Vaccinology, V4, P33, DOI 10.1016/j.trivac.2015.03.004; Fakri F., 2015, J VACCINES VACCIN, V6, DOI [10.1016/j.trivac.2015.03.004, DOI 10.1016/J.TRIVAC.2015.03.004]; Fakri F.Z., 2020, J VET MED RES, V7, P1200; FAO OIE, 2015, GLOB STRAT CONTR ER; Hamdi J, 2021, ACTA VET SCAND, V63, DOI 10.1186/s13028-021-00574-2; Hosamani M, 2006, VACCINE, V24, P6058, DOI 10.1016/j.vaccine.2006.05.021; [Константинов А.В. Konstantinov A.V.], 2017, [Ветеринария сегодня, Veterinary science today, Veterinariya segodnya], P28; Mamadaliev S.M., 2010, Ruminants. Patent, Patent No. 16916; Mamadaliev S.M., 2007, Vaccine. Patent, Patent No. 10105; Mambetaliev M., 2010, Strains. Patent, Patent No. [Kentau-7 PK-4-05D, 7405]; Martrenchar A, 1997, SMALL RUMINANT RES, V26, P39, DOI 10.1016/S0921-4488(96)00989-3; [Мищенко Алексей Владимирович Mischenko A.V.], 2016, [Ветеринария, Veterinariya], P3; Mischenko A.V., 2018, J VET VRACH, V6, P40; Newberry K, 2018, MANUAL DIAGNOSTIC TE, P109; OIE, 2018, TERR AN HLTH COD, P1; OIE World Organisation for Animal Health, 2018, OIE TEST MAN 2018; Parida S, 2016, SMALL RUMINANT RES, V142, P16, DOI 10.1016/j.smallrumres.2016.02.018; Pope RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055830; Rajak KK, 2005, COMP IMMUNOL MICROB, V28, P287, DOI 10.1016/j.cimid.2005.08.002; Rao T. V. S., 2000, Animal Health Research Reviews, V1, P127, DOI 10.1017/S1466252300000116; REED L. J., 1938, AMER JOUR HYG, V27, P493; Semakina V., 2019, J VET VRACH, V1, P43, DOI [10.33632/1998-698X.2019-1-43-50, DOI 10.33632/1998-698X.2019-1-43-50]; Zeidan Z., 2016, INT J ADV RES, V4, P212, DOI [10.21474/IJAR01/126, DOI 10.21474/IJAR01/126]; Zhao H, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010059	36	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							912	10.3390/vaccines9080912			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3ZY	34452037	gold, Green Published			2022-04-29	WOS:000689874600001
J	Duan, YQ; Shi, JY; Wang, ZB; Zhou, SD; Jin, YZ; Zheng, ZJ				Duan, Yuqi; Shi, Junyi; Wang, Zongbin; Zhou, Shuduo; Jin, Yinzi; Zheng, Zhi-Jie			Disparities in COVID-19 Vaccination among Low-, Middle-, and High-Income Countries: The Mediating Role of Vaccination Policy	VACCINES			English	Article						COVID-19 vaccine; equitable access; income level; policy strength; mediation effect	ALLOCATION	Inequity in the access to and deployment of the coronavirus disease 2019 (COVID-19) vaccines has brought about great challenges in terms of resolving the pandemic. Aiming to analyze the association between country income level and COVID-19 vaccination coverage and explore the mediating role of vaccination policy, we conducted a cross-sectional ecological study. The dependent variable was COVID-19 vaccination coverage in 138 countries as of May 31, 2021. A single-mediator model based on structural equation modeling was developed to analyze mediation effects in different country income groups. Compared with high-income countries, upper-middle- (beta = -1.44, 95% CI: -1.86--1.02, p < 0.001), lower-middle- (beta = -2.24, 95% CI: -2.67--1.82, p < 0.001), and low- (beta = -4.05, 95% CI: -4.59--3.51, p < 0.001) income countries had lower vaccination coverage. Vaccination policies mediated 14.6% and 15.6% of the effect in upper-middle- (beta = -0.21, 95% CI: -0.39--0.03, p = 0.020) and lower-middle- (beta = -0.35, 95% CI: -0.56--0.13, p = 0.002) income countries, respectively, whereas the mediation effect was not significant in low-income countries (beta = -0.21, 95% CI: -0.43-0.01, p = 0.062). The results were similar after adjusting for demographic structure and underlying health conditions. Income disparity remains an important cause of vaccine inequity, and the tendency toward "vaccine nationalism" restricts the functioning of the global vaccine allocation framework. Stronger mechanisms are needed to foster countries' political will to promote vaccine equity.	[Duan, Yuqi; Shi, Junyi; Wang, Zongbin; Zhou, Shuduo; Jin, Yinzi; Zheng, Zhi-Jie] Peking Univ, Sch Publ Hlth, Dept Global Hlth, 38 Xue Yuan Rd, Beijing 100191, Peoples R China; [Duan, Yuqi; Shi, Junyi; Wang, Zongbin; Zhou, Shuduo; Jin, Yinzi; Zheng, Zhi-Jie] Peking Univ, Inst Global Hlth & Dev, Beijing 100191, Peoples R China		Jin, YZ (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Global Hlth, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.; Jin, YZ (通讯作者)，Peking Univ, Inst Global Hlth & Dev, Beijing 100191, Peoples R China.	18811318259@163.com; shijunyi_2009@163.com; wangzongbin@bjmu.edu.cn; zhoushuduo@pku.edu.cn; yzjin@bjmu.edu.cn; zhengzj@bjmu.edu.cn		Jin, Yinzi/0000-0003-0634-3955; Zhou, Shuduo/0000-0002-5463-3116	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [72042014]; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [INV-016183]	This research was funded by the National Natural Science Foundation of China (No. 72042014) and Bill and Melinda Gates Foundation (INV-016183).	Acharya KP, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00323-6; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Eccleston-Turner M, 2021, MILBANK Q, V99, P426, DOI 10.1111/1468-0009.12503; Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803; Fidler DP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000247; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028; Herlitz A, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004812; Hirvonen K, 2020, LANCET GLOB HEALTH, V8, pE59, DOI 10.1016/S2214-109X(19)30447-4; Hogan AB, 2021, VACCINE, V39, P2995, DOI 10.1016/j.vaccine.2021.04.002; Hughes MM, 2021, MMWR-MORBID MORTAL W, V70, P431, DOI 10.15585/mmwr.mm7012e1; Khan JR, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00347; Liu YZ, 2020, J MED ETHICS, V46, P499, DOI 10.1136/medethics-2020-106516; MacKinnon D. P., 2008, INTRO STAT MEDIATION; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Nhamo G, 2021, GLOB PUBLIC HEALTH, V16, P319, DOI 10.1080/17441692.2020.1860249; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Persad G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.7943; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Roghani A., 2021, GLOBAL DISTRIBUTION, DOI 10.1101/2021.02.09.21251436; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Sheikh A, 2021, INFECT DIS REP, V13, P429, DOI 10.3390/idr13020041; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; So AD, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4750; Stephenson J., 2021, JAMA HLTH FORUM, V2, pe210505, DOI DOI 10.1001/JAMAHEALTHFORUM.2021.0505; Turner M, 2016, GLOB PUBLIC HEALTH, V11, P322, DOI 10.1080/17441692.2015.1043743; WHO, 2020, FAIR ALL MECH COVID, P17; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Yusuf A, 2021, LANCET ONCOL, V22, P749, DOI 10.1016/S1470-2045(21)00244-8	30	7	7	6	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							905	10.3390/vaccines9080905			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3JK	34452030	gold, Green Published			2022-04-29	WOS:000689831600001
J	Rapaka, RR; Cross, AS; McArthur, MA				Rapaka, Rekha R.; Cross, Alan S.; McArthur, Monica A.			Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines	VACCINES			English	Review						T cell; adjuvant; differentiation; antigen presenting cell; CD8+ T cell; CD4+ T cell; Th; memory; TLR; APC	WATER EMULSION MF59; CHOLERA-TOXIN; HOST-DEFENSE; TH17 CELLS; MYCOBACTERIUM-TUBERCULOSIS; DENDRITIC CELLS; NY-ESO-1 PROTEIN; IMMUNE-RESPONSES; VIRUS-INFECTION; IN-VIVO	Using adjuvants to drive features of T cell responses to vaccine antigens is an important technological challenge in the design of new and improved vaccines against infections. Properties such as T helper cell function, T cell memory, and CD8+ T cell cytotoxicity may play critical roles in optimal and long-lived immunity through vaccination. Directly manipulating specific immune activation or antigen delivery pathways with adjuvants may selectively augment desired T cell responses in vaccination and may improve the effectiveness and durability of vaccine responses in humans. In this review we outline recently studied adjuvants in their potential for antigen presenting cell and T cell programming during vaccination, with an emphasis on what has been observed in studies in humans as available.	[Rapaka, Rekha R.; Cross, Alan S.; McArthur, Monica A.] Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, 685 West Baltimore St, Baltimore, MD 21210 USA		Rapaka, RR (通讯作者)，Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, 685 West Baltimore St, Baltimore, MD 21210 USA.	rrapaka@som.umaryland.edu; across@som.umaryland.edu; mmcarthu@som.umaryland.edu		Rapaka, Rekha/0000-0002-4770-4422	 [K08 AI143923]	R.R.R was supported by K08 AI143923 during the writing of this review.	Ahmed R, 2011, IMMUNOL CELL BIOL, V89, P340, DOI 10.1038/icb.2010.155; Akondy RS, 2015, P NATL ACAD SCI USA, V112, P3050, DOI 10.1073/pnas.1500475112; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, NAT REV MATER, V6, P99, DOI 10.1038/s41578-021-00281-4; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Barr AM, 2020, CANCER IMMUNOL IMMUN, V69, P1959, DOI 10.1007/s00262-020-02597-6; Bengtsson KL, 2016, VACCINE, V34, P1927, DOI 10.1016/j.vaccine.2016.02.033; Bengtsson KL, 2011, EXPERT REV VACCINES, V10, P401, DOI [10.1586/ERV.11.25, 10.1586/erv.11.25]; Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Beura LK, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028910; Bialkowski L, 2016, SCI REP-UK, V6, DOI 10.1038/srep22509; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; BOULANGER D, 1991, PARASITE IMMUNOL, V13, P473, DOI 10.1111/j.1365-3024.1991.tb00545.x; Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0; CalvoCalle JM, 1997, J IMMUNOL, V159, P1362; Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3; Chappell Keith J, 2021, Lancet Infect Dis, V21, P1383, DOI 10.1016/S1473-3099(21)00200-0; Chen C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121118; Chen JL, 2015, INT J CANCER, V136, pE590, DOI 10.1002/ijc.29118; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Cibulski S, 2018, VACCINE, V36, P55, DOI 10.1016/j.vaccine.2017.11.030; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Cooper CL, 2008, CLIN INFECT DIS, V46, P1310, DOI 10.1086/533467; Da Silva DM, 2015, CLIN IMMUNOL, V161, P197, DOI 10.1016/j.clim.2015.09.003; Datta SK, 2010, P NATL ACAD SCI USA, V107, P10638, DOI 10.1073/pnas.1002348107; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Desbien AL, 2016, J IMMUNOL, V197, P4351, DOI 10.4049/jimmunol.1600993; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Diemert DJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005574; Dong SF, 2007, INT IMMUNOPHARMACOL, V7, P725, DOI 10.1016/j.intimp.2007.01.004; Duluc D, 2014, J IMMUNOL, V192, P5776, DOI 10.4049/jimmunol.1301661; Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fries L, 2020, J INFECT DIS, V222, P572, DOI 10.1093/infdis/jiz518; Fukuyama Y, 2015, MUCOSAL IMMUNOL, V8, P1144, DOI 10.1038/mi.2015.5; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Gavillet BM, 2015, J IMMUNOL, V194, P4836, DOI 10.4049/jimmunol.1402071; Gopal R, 2013, MUCOSAL IMMUNOL, V6, P972, DOI 10.1038/mi.2012.135; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Gregg KA, 2017, MBIO, V8, DOI [10.1128/mBio.00492-17, 10.1128/mbio.00492-17]; Grencis RK, 2015, ANNU REV IMMUNOL, V33, P201, DOI 10.1146/annurev-immunol-032713-120218; Halperin SA, 2012, VACCINE, V30, P2556, DOI 10.1016/j.vaccine.2012.01.087; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Higashi Takehiro, 2010, Allergology International, V59, P161, DOI 10.2332/allergolint.09-OA-0103; Hill DL, 2019, J EXP MED, V216, P1857, DOI 10.1084/jem.20190301; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Ignatius R, 2000, BLOOD, V96, P3505; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kasturi SP, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1025; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; KENSIL CR, 1991, J IMMUNOL, V146, P431; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Kong IG, 2013, INFECT IMMUN, V81, P1625, DOI 10.1128/IAI.00240-13; Koup RA, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007252; Larena M, 2015, J IMMUNOL, V194, P3829, DOI 10.4049/jimmunol.1401633; Lazzaro S, 2015, IMMUNOLOGY, V146, P312, DOI 10.1111/imm.12505; Lee YN, 2014, VACCINE, V32, P4578, DOI 10.1016/j.vaccine.2014.06.040; Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035; Li PL, 2015, DRUG DISCOV THER, V9, P88, DOI 10.5582/ddt.2015.01025; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lindenstrom T, 2012, INFECT IMMUN, V80, P3533, DOI 10.1128/IAI.00550-12; Lofano G, 2015, J IMMUNOL, V195, P1617, DOI 10.4049/jimmunol.1402604; Maraskovsky E, 2004, CLIN CANCER RES, V10, P2879, DOI 10.1158/1078-0432.CCR-03-0245; MARINARO M, 1995, J IMMUNOL, V155, P4621; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Martins KAO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089735; Mattsson J, 2015, MUCOSAL IMMUNOL, V8, P815, DOI 10.1038/mi.2014.111; McDonald DR, 2012, J ALLERGY CLIN IMMUN, V129, P1429, DOI 10.1016/j.jaci.2012.03.034; Mendez S, 2003, INFECT IMMUN, V71, P5121, DOI 10.1128/IAI.71.9.5121-5129.2003; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109; Morelli AB, 2012, J MED MICROBIOL, V61, P935, DOI 10.1099/jmm.0.040857-0; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; Pallikkuth S, 2012, BLOOD, V120, P985, DOI 10.1182/blood-2011-12-396648; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Perez-Giron JV, 2014, J IMMUNOL, V193, P1324, DOI 10.4049/jimmunol.1400222; Radtke AJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40312; Ragupathi G, 2011, EXPERT REV VACCINES, V10, P463, DOI [10.1586/ERV.11.18, 10.1586/erv.11.18]; Riveau G, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001704; Rose WA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13146; Rothenfusser S, 2004, BLOOD, V103, P2162, DOI 10.1182/blood-2003-04-1091; Ruterbusch M, 2020, ANNU REV IMMUNOL, V38, P705, DOI 10.1146/annurev-immunol-103019-085803; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440; Seubert A, 2011, P NATL ACAD SCI USA, V108, P11169, DOI 10.1073/pnas.1107941108; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Snyder LD, 2016, AM J RESP CRIT CARE, V193, P78, DOI 10.1164/rccm.201504-0733OC; Solforosi L, 2021, J EXP MED, V218, DOI 10.1084/jem.20202756; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Spensieri F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157066; Sullivan NJ, 2011, NAT MED, V17, P1128, DOI 10.1038/nm.2447; Taneichi M, 2006, J IMMUNOL, V177, P2324, DOI 10.4049/jimmunol.177.4.2324; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tomori O, 2021, CURR OPIN IMMUNOL, V71, P27, DOI 10.1016/j.coi.2021.03.008; Turner JD, 2003, J INFECT DIS, V188, P1768, DOI 10.1086/379370; Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8; Verthelyi D, 2002, J IMMUNOL, V168, P1659, DOI 10.4049/jimmunol.168.4.1659; Vogel AJ, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00327; Warfield KL, 2005, J IMMUNOL, V175, P1184, DOI 10.4049/jimmunol.175.2.1184; Wei WC, 2011, CYTOKINE, V55, P79, DOI 10.1016/j.cyto.2011.03.017; Welsby I, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00663; Woodworth JSM, 2006, CRIT REV IMMUNOL, V26, P317, DOI 10.1615/CritRevImmunol.v26.i4.30; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; YAP KL, 1979, CELL IMMUNOL, V43, P341, DOI 10.1016/0008-8749(79)90178-3; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424; Yuki Y, 2013, BIOTECHNOL GENET ENG, V29, P61, DOI 10.1080/02648725.2013.801226; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010	123	0	0	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							820	10.3390/vaccines9080820			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2JA	34451945	Green Published			2022-04-29	WOS:000689763000001
J	Wright, M; Pazdernik, V; Luebbering, C; Davis, JM				Wright, Marjorie; Pazdernik, Vanessa; Luebbering, Corey; Davis, Joan M.			Dental Students' Knowledge and Attitudes about Human Papillomavirus Prevention	VACCINES			English	Article						HPV; dental student; HPV vaccine	UPDATED RECOMMENDATIONS; ADVISORY-COMMITTEE; VACCINATION	The purpose of the current study was to assess knowledge and attitudes about human papillomavirus (HPV) and HPV vaccination for oropharyngeal cancer (OPC) prevention in first-year through fourth-year dental students. Methods: In this cross-sectional quantitative study, surveys assessed knowledge and attitudes about HPV, HPV-related OPC, and HPV vaccination of incoming first-year dental students (D1), outgoing first- and second-year dental students (D1-D2), and outgoing third- and fourth-year dental students (D3-D4). After completing a 40-item pre-training knowledge and attitude assessment survey, a one-time, one-hour national HPV training session was conducted. An 8-item attitudinal post-survey was completed after training. Results: Of 173 participants (75.9% response rate), over 85% did not know that the rate of HPV is not highest among women in their 30s, and only 11% to 28% knew that smoking-associated OPC is more deadly than HPV-associated OPC. While participants overall expressed willingness to administer the HPV vaccine, the willingness of dental students to do so in their future practice tapered off progressively through dental school year categories (p < 0.001). Among outgoing D1-D4 students, the one-hour HPV training increased participants' self-perceived ability to describe the burden of HPV disease, discuss the importance of HPV vaccination for cancer prevention, and provide needed HPV vaccination information to parents (all p <= 0.004). Conclusions: Understanding deficits in dental student knowledge and attitudes across the 4 years of dental school may help dental educators better understand the timing and content needed for effective HPV training in the dental school curriculum to reduce HPV-associated OPC prevalence.	[Wright, Marjorie] AT Still Univ, Coll Grad Hlth Studies, Kirksville, MO 63501 USA; [Pazdernik, Vanessa; Luebbering, Corey] AT Still Univ, Dept Res Support, Kirksville, MO 63501 USA; [Davis, Joan M.] AT Still Univ, Missouri Sch Dent & Oral Hlth, Kirksville, MO 63501 USA		Wright, M (通讯作者)，AT Still Univ, Coll Grad Hlth Studies, Kirksville, MO 63501 USA.	mlwright01@atsu.edu; vpazdernik@atsu.edu; coreyluebbering@atsu.edu; joandavis@atsu.edu		Davis, Joan M/0000-0003-4007-0129	National AHEC Organization; Missouri Area Health Education Center (AHEC)	Funding for the HPV presentation and participant lunch was made possible by the Missouri Area Health Education Center (AHEC) in collaboration with the National AHEC Organization.	American Association of Pediatric Dentistry, 2017, POL HUM PAP VACC; American Association of Public Health Dentistry. (n.d.), INTERDISCIPLINARY AP; American Dental Association, 2018, NAT HPV VACC ROUNDT; [Anonymous], 2020, J AM DENT ASSOC, V151, P303, DOI 10.1016/j.adaj.2020.01.027; Arnell TL, 2021, J CANCER EDUC, V36, P299, DOI 10.1007/s13187-019-01628-w; Centers for Disease Control and Prevention, 2018, HPV OR CANC; Centers for Disease Control and Prevention, 2018, BAS INF HPV CANC; Cotter JC, 2020, J DENT EDUC, V84, P88, DOI 10.21815/JDE.019.164; Daley EM, 2019, J DENT EDUC, V83, P161, DOI 10.21815/JDE.019.019; Harris KL, 2020, HUM VACC IMMUNOTHER, V16, P436, DOI 10.1080/21645515.2019.1649550; Kepka D, 2019, PREV MED REP, V15, DOI 10.1016/j.pmedr.2019.100957; Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI [10.15585/mmwr.mm6832a3, 10.1111/ajt.15633]; Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5; Okuji D, 2020, PEDIATR DENT, V42, P203; Patel S, 2020, J PUBLIC HEALTH DENT, V80, P61, DOI 10.1111/jphd.12350; Rutkoski H, 2020, J CANCER EDUC, V35, P1017, DOI 10.1007/s13187-019-01561-y; Rutkoski H, 2018, J CANCER EDUC, V33, P907, DOI 10.1007/s13187-017-1165-z; Sheedy T, 2019, JAAPA-J AM ACAD PHYS, V32, P26, DOI 10.1097/01.JAA.0000578756.52642.cb; Stull Cynthia L, 2019, J Dent Hyg, V93, P33; Torres E, 2020, J CANCER EDUC, DOI 10.1007/s13187-020-01905-z; Walker KK, 2019, HUM VACC IMMUNOTHER, V15, P1863, DOI 10.1080/21645515.2018.1558690; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2	22	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							888	10.3390/vaccines9080888			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5ZB	34452013	gold, Green Published			2022-04-29	WOS:000690007500001
J	Momtazi-Borojeni, AA; Jaafari, MR; Banach, M; Gorabi, AM; Sahraei, H; Sahebkar, A				Momtazi-Borojeni, Amir Abbas; Jaafari, Mahmoud R.; Banach, Maciej; Gorabi, Armita Mahdavi; Sahraei, Hedayat; Sahebkar, Amirhossein			Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates	VACCINES			English	Article						nanoliposome; non-human primate; PCSK9; vaccine; cholesterol	REDUCING LIPIDS; PCSK9; DISEASE; CHOLESTEROL; SAFETY; IMMUNIZATION; ANTIBODIES; EVOLOCUMAB; EFFICACY; RISK	Background: Our previous studies showed the safe preventive and therapeutic effects of immunization using the nanoliposomal antiPCSK9 vaccine called "Liposomal Immunogenic Fused PCSK9-Tetanus plus Alum adjuvant" (L-IFPTA), in mouse models of atherosclerosis. Here we aimed to ascertain the immunogenicity and safety of the L-IFPTA vaccine in a pre-clinical study in healthy non-human primates. Methods: Five male rhesus macaque monkeys were subcutaneously immunized with the L-IFPTA vaccine, four times with bi-weekly intervals. To evaluate immunogenicity, the plasma antiPCSK9 antibody in immunized monkeys was detected and quantified using the ELISA method. The functionality of the induced antiPCSK9 antibodies was determined by the PCSK9/LDLR in vitro binding assay kit. The safety of the vaccine was tested using the evaluation of several major circulating indicators including plasma lipid alterations, inflammatory biomarkers and organ injury biomarkers. Results: The resultant data indicated that the L-IFPTA vaccine significantly and highly induced the generation of functional and safe antiPCSK9 antibodies in immunized monkeys. Plasma levels of specific biomarkers indicating organ performance including creatinine, urea, uric acid, bilirubin, ALP, AS, ALT and TSH were not significantly altered. After immunization in healthy monkeys, non-prespecified endpoints (plasma levels of TC, LDL-C, VLDL-C and TG) were non-significantly reduced by 11.6 +/- 36%; 16 +/- 28%; 22 +/- 53% and 24 +/- 51%, respectively, while HDL-C was slightly increased by 2 +/- 64%. There were also no significant changes in plasma levels of pro- and anti-inflammatory biomarkers. Conclusion: The L-IFPTA vaccine could efficiently stimulate the host humoral immune response to produce active antibodies that inhibit plasma PCSK9 while not provoking systemic inflammation and not adversely affecting organ performance.	[Momtazi-Borojeni, Amir Abbas; Jaafari, Mahmoud R.] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad 9177948564, Razavi Khorasan, Iran; [Momtazi-Borojeni, Amir Abbas] Alborz Univ Med Sci, Sch Med, Dept Med Biotechnol, Karaj 3149969415, Iran; [Momtazi-Borojeni, Amir Abbas] Irans Natl Elites Fdn, Tehran 9311114578, Iran; [Jaafari, Mahmoud R.; Sahebkar, Amirhossein] Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad 9177948564, Razavi Khorasan, Iran; [Banach, Maciej] Med Univ Lodz, Dept Prevent Cardiol & Lipidol, PL-93338 Lodz, Poland; [Banach, Maciej] Univ Zielona Gora, Cardiovasc Res Ctr, PL-65046 Zielona Gora, Poland; [Gorabi, Armita Mahdavi] Univ Tehran Med Sci, Res Ctr Adv Technol Cardiovasc Med, Tehran Heart Ctr, Tehran 1411713138, Iran; [Sahraei, Hedayat] Baqiyatallah Univ Med Sci, Neurosci Res Ctr, Tehran 9311114578, Iran; [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran; [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Sch Pharm, Mashhad 9177948564, Razavi Khorasan, Iran		Sahebkar, A (通讯作者)，Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad 9177948564, Razavi Khorasan, Iran.; Sahebkar, A (通讯作者)，Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran.; Sahebkar, A (通讯作者)，Mashhad Univ Med Sci, Sch Pharm, Mashhad 9177948564, Razavi Khorasan, Iran.	abbasmomtazi@yahoo.com; jafarimr@mums.ac.ir; maciej.banach@icloud.com; armitamandavi61@gmail.com; hsahraei1343@gmail.com; sahebkara@mums.ac.ir	Banach, Maciej/A-1271-2009	Banach, Maciej/0000-0001-6690-6874	Elite Researcher Grant Committee from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran [963401]; Mashhad University of Medical Sciences, Mashhad, Iran [971266]	Research reported in this publication was supported by Elite Researcher Grant Committee under award number 963401 from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran. We are also thankful for the support from Mashhad University of Medical Sciences, Mashhad, Iran (grant number: 971266).	Banach M, 2019, CARDIOVASC RES, V115, pE26, DOI 10.1093/cvr/cvy301; Bartelds GM, 2011, JAMA-J AM MED ASSOC, V305, P1460, DOI 10.1001/jama.2011.406; Catapano AL, 2013, ATHEROSCLEROSIS, V228, P18, DOI 10.1016/j.atherosclerosis.2013.01.044; Crossey E, 2015, VACCINE, V33, P5747, DOI 10.1016/j.vaccine.2015.09.044; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Do RQ, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886-012-0345-z; Fattori E, 2012, J LIPID RES, V53, P1654, DOI 10.1194/jlr.M028340; Galabova G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114469; Hall SS, 2013, NATURE, V496, P152, DOI 10.1038/496152a; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Kazi DS, 2016, JAMA-J AM MED ASSOC, V316, P743, DOI 10.1001/jama.2016.11004; Lakoski SG, 2009, J CLIN ENDOCR METAB, V94, P2537, DOI 10.1210/jc.2009-0141; Landlinger C, 2017, EUR HEART J, V38, P2499, DOI 10.1093/eurheartj/ehx260; Lien MY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.592415; Lim PW, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6958293; Maningat P, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-012-0291-7; Marquina C, 2020, PHARMACOECONOMICS, V38, P1095, DOI 10.1007/s40273-020-00936-0; Mitchell LA, 2012, J IMMUNOL, V189, P5612, DOI 10.4049/jimmunol.1202151; Momtazi-Borojeni A., 2019, EUR HEART J, V40, DOI DOI 10.1093/EURHEARTJ/EHZ746.0800; Momtazi-Borojeni A., 2019, EUR HEART J, V40, DOI [10.1093/eurheartj/ehz747.0309, DOI 10.1093/EURHEARTJ/EHZ747.0309]; Momtazi-Borojeni A., 2019, EUR HEART J, V40, DOI DOI 10.1093/EURHEARTJ/EHZ746.0799; Momtazi-Borojeni Amir Abbas, 2021, Arch Med Sci, V17, P1365, DOI 10.5114/aoms/133885; Momtazi-Borojeni AA, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1457-8; Momtazi-Borojeni AA, 2019, EUR HEART J-CARD PHA, V5, P237, DOI 10.1093/ehjcvp/pvz022; Momtazi-Borojeni AA, 2019, ARCH MED SCI, V15, P570, DOI 10.5114/aoms.2019.84734; Momtazi-Borojeni AA, 2019, ATHEROSCLEROSIS, V283, P69, DOI 10.1016/j.atherosclerosis.2019.02.001; Nicholls SJ, 2016, JAMA-J AM MED ASSOC, V316, P2373, DOI 10.1001/jama.2016.16951; Pan YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13069-w; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Sabatine MS, 2015, NEW ENGL J MED, V372, P1500, DOI 10.1056/NEJMoa1500858; Sahebkar A, 2021, EUR HEART J, V42, P4007, DOI 10.1093/eurheartj/ehab299; Sahebkar A, 2013, CARDIOVASC DRUG THER, V27, P559, DOI 10.1007/s10557-013-6479-4; Schneeberger A, 2009, J NUTR HEALTH AGING, V13, P264, DOI 10.1007/s12603-009-0070-5; Wu DY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014358; You SS, 2019, ACS BIOMATER SCI ENG, V5, P4263, DOI 10.1021/acsbiomaterials.9b00434	37	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							749	10.3390/vaccines9070749			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7AJ	34358164	Green Published, gold			2022-04-29	WOS:000677059200001
J	Narasimhan, M; Mahimainathan, L; Clark, AE; Usmani, A; Cao, J; Araj, E; Torres, F; Sarode, R; Kaza, V; Lacelle, C; Muthukumar, A				Narasimhan, Madhusudhanan; Mahimainathan, Lenin; Clark, Andrew E.; Usmani, Amena; Cao, Jing; Araj, Ellen; Torres, Fernando; Sarode, Ravi; Kaza, Vaidehi; Lacelle, Chantale; Muthukumar, Alagarraju			Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines	VACCINES			English	Article						lung transplantation; SARS-CoV-2; IgG; IgM; Spike; nucleocapsid; COVID-19 mRNA vaccines; two doses; serological response	IMMUNE FUNCTION	Background: Lung-transplant (LT) recipients are at high risk for COVID-19 due to immunosuppression and respiratory tropism of SARS-CoV-2. The information on the effect of COVID-19 mRNA vaccines to elicit immunogenic responses after a two-dose (2D) regimen in LT recipients is sparse. Thus, we assessed the effect of Pfizer-BioNTech and Moderna mRNA vaccines' 2D regimen on anti-spike responses in immunocompromised LT recipients. Methods: We utilized serum samples from LT recipients vaccinated for SARS-CoV-2 with 2D of either the Pfizer-BioNTech or Moderna vaccines and 2D-vaccinated naive (non-transplanted and non-exposed to COVID-19) group. Antibody responses were assessed using the FDA-approved SARS-CoV-2 anti-nucleocapsid protein IgG assay (IgG(NC)), the SARS-CoV-2 anti-spike protein IgM assay (IgM(SP)), and the SARS-CoV-2 anti-spike protein IgG II assay (IgG(SP)). CD4+ T-cell activity was assessed as a marker of immune competence using the ImmuKnow (R) assay. Results: About 25% (18/73) of SARS-CoV-2 uninfected-LT patients generated a positive spike-IgG response following 2D of vaccines, with 36% (9/25) in the Moderna cohort and only 19% (9/48) in the Pfizer cohort. 2D in LT patients elicited a significantly lesser median IgG(SP) response (1.7 AU/mL, 95% CI: 0.6-7.5 AU/mL) compared to non-transplanted, uninfected naive subjects (14,209 AU/mL, 95% CI: 11,261-18,836 AU/mL; p < 0.0001). In LT patients, the Moderna-evoked seropositivity trend was higher than Pfizer. Conclusion: 2D COVID-19 vaccination elicits a dampened serological response in LT patients. Whether assessing other arms of host immunity combined with a higher vaccine dose can better capture and elicit improved immunogenicity in this immunocompromised population warrants investigation.	[Narasimhan, Madhusudhanan; Mahimainathan, Lenin; Clark, Andrew E.; Usmani, Amena; Cao, Jing; Araj, Ellen; Sarode, Ravi; Lacelle, Chantale; Muthukumar, Alagarraju] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Torres, Fernando; Sarode, Ravi; Kaza, Vaidehi] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA		Lacelle, C; Muthukumar, A (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.	madhusudhanan.narasimhan@utsouthwestern.edu; lenin.mahimainathan@utsouthwestern.edu; andrew.clark@utsouthwestern.edu; amena.usmani@UTSouthwestern.edu; jing.cao2@UTSouthwestern.edu; ellen.araj@utsouthwestern.edu; fernando.torres@UTSouthwestern.edu; ravi.sarode@utsouthwestern.edu; vaidehi.kaza@UTSouthwestern.edu; chantale.lacelle@UTSouthwestern.edu; alagarraju.muthukumar@utsouthwestern.edu					Bavaro DF, 2021, J MED VIROL, V93, P3158, DOI 10.1002/jmv.26878; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; BRUCKNER HW, 1974, CANCER RES, V34, P181; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Gralla J, 2012, NEPHROL DIAL TRANSPL, V27, P2565, DOI 10.1093/ndt/gfr675; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Havlin J, 2021, J HEART LUNG TRANSPL, V40, P754, DOI 10.1016/j.healun.2021.05.004; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Husain S, 2009, TRANSPLANTATION, V87, P1852, DOI 10.1097/TP.0b013e3181a75ad2; Kowalski RJ, 2006, TRANSPLANTATION, V82, P663, DOI 10.1097/01.tp.0000234837.02126.70; Mombelli M, 2018, VACCINE, V36, P6163, DOI 10.1016/j.vaccine.2018.08.057; Narasimhan M, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00388-21; Phipps William S, 2020, Am J Clin Pathol, V154, P459, DOI 10.1093/ajcp/aqaa123; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Qu W, 2017, TRANSPL P, V49, P316, DOI 10.1016/j.transproceed.2016.11.044; Quaglia M, 2014, TRANSPL P, V46, P2220, DOI 10.1016/j.transproceed.2014.07.050; Schmidt T., 2021, CELLULAR IMMUNITY PR, DOI [10.1101/2021.05.07.21256809, DOI 10.1101/2021.05.07.21256809]; Tang MS, 2020, CLIN CHEM, V66, P1538, DOI 10.1093/clinchem/hvaa211	20	11	11	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							708	10.3390/vaccines9070708			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6ZY	34208884	Green Submitted, gold, Green Published			2022-04-29	WOS:000677058100001
J	Tamminen, K; Heinimaki, S; Grohn, S; Blazevic, V				Tamminen, Kirsi; Heinimaki, Suvi; Grohn, Stina; Blazevic, Vesna			Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses	VACCINES			English	Article						SARS-CoV-2; COVID-19; delivery platform; vaccines; VP6; T cells; antibodies; immune response	PROTECTION; VACCINE; INTERNALIZATION; IMMUNOGENICITY; CHALLENGE; MICE	Vaccines based on mRNA and viral vectors are currently used in the frontline to combat the ongoing pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). However, there is still an urgent need for alternative vaccine technologies inducing/boosting long-lasting and cross-reactive immunity in different populations. As a possible vaccine candidate, we employed the rotavirus VP6-protein platform to construct a fusion protein (FP) displaying receptor-binding domain (RBD) of SARS-CoV-2 spike protein (S) at the N-terminus of VP6. The recombinant baculovirus-insect cell produced VP6-RBD FP was proven antigenic in vitro and bound to the human angiotensin-converting enzyme 2 (hACE2) receptor. The FP was used to immunize BALB/c mice, and humoral- and T cell-mediated immune responses were investigated. SARS-CoV-2 RBD-specific T cells were induced at a high quantity; however, no RBD or S-specific antibodies were detected. The results suggest that conformational B cell epitopes might be buried inside the VP6, while RBD-specific T cell epitopes are available for T cell recognition after the processing and presentation of FP by the antigen-presenting cells. Further immunogenicity studies are needed to confirm these findings and to assess whether, under different experimental conditions, the VP6 platform may present SARS-CoV-2 antigens to B cells as well.	[Tamminen, Kirsi; Heinimaki, Suvi; Grohn, Stina; Blazevic, Vesna] Tampere Univ, Fac Med & Hlth Technol, Vaccine Dev & Immunol, Vaccine Res Ctr, Arvo Ylpon Katu 34, FI-33520 Tampere, Finland		Tamminen, K; Blazevic, V (通讯作者)，Tampere Univ, Fac Med & Hlth Technol, Vaccine Dev & Immunol, Vaccine Res Ctr, Arvo Ylpon Katu 34, FI-33520 Tampere, Finland.	kirsi.tamminen@tuni.fi; suvi.heinimaki@tuni.fi; stina.grohn@tuni.fi; vesna.blazevic@tuni.fi	; Blazevic, Vesna/Q-3183-2017	Heinimaki, Suvi/0000-0001-9374-4583; Tamminen, Kirsi/0000-0002-9708-732X; Grohn, Stina/0000-0002-3772-7233; Blazevic, Vesna/0000-0001-8201-6118	Tampere Immunoexellence project under Profi4 program of Academy of Finland	Kirsi Tamminen received funding from Tampere Immunoexellence project under Profi4 program of Academy of Finland.	Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Blazevic V, 2011, VACCINE, V29, P8126, DOI 10.1016/j.vaccine.2011.08.026; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Caddy SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008732; Chan JFW, 2020, CLIN INFECT DIS, V71, P2428, DOI 10.1093/cid/ciaa325; Cohen AA, 2021, SCIENCE, V371, P735, DOI 10.1126/science.abf6840; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Foged C, 2011, THER DELIV, V2, P1057, DOI 10.4155/TDE.11.68; Garcia-Beltran WF, 2021, CELL, V184, P2523, DOI 10.1016/j.cell.2021.04.006; Golob JL, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149187; Grohn S, 2021, ARCH VIROL, V166, P213, DOI 10.1007/s00705-020-04847-5; He Qian, 2021, Emerging Microbes & Infections, V10, P629, DOI 10.1080/22221751.2021.1902245; Iqbal H, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110152; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lappalainen S, 2014, HUM VACC IMMUNOTHER, V10, P2039, DOI 10.4161/hv.28858; Lappalainen S, 2013, HUM VACC IMMUNOTHER, V9, P1991, DOI 10.4161/hv.25249; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Malm M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9171632; Morgan J, 2021, IMMUNOL REV, V301, P10, DOI 10.1111/imr.12963; Mothe B, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-208; O'Shaughnessy L, 2011, METHODS MOL BIOL, V681, P295, DOI 10.1007/978-1-60761-913-0_16; Overgaard NH, 2017, VACCINE, V35, P5629, DOI 10.1016/j.vaccine.2017.08.057; Peralta A, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-192; Rodriguez M, 2014, ARCH VIROL, V159, P1005, DOI 10.1007/s00705-013-1916-z; Pastor AR, 2014, VACCINE, V32, P2874, DOI 10.1016/j.vaccine.2014.02.018; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Tamminen K, 2020, MOL IMMUNOL, V123, P26, DOI 10.1016/j.molimm.2020.04.001; Tamminen K, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/3194704; Tamminen K, 2012, IMMUNOLOGY, V135, P89, DOI 10.1111/j.1365-2567.2011.03516.x; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Teng YM, 2014, VIRAL IMMUNOL, V27, P96, DOI 10.1089/vim.2013.0110; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; Zaira R., 2021, RES SQ, DOI [10.21203/rs.3.rs-25501/v1, DOI 10.21203/RS.3.RS-25501/V1]	37	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							733	10.3390/vaccines9070733			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5KM	34358149	Green Published, gold			2022-04-29	WOS:000676950300001
J	Utset, HA; Guthmiller, JJ; Wilson, PC				Utset, Henry A.; Guthmiller, Jenna J.; Wilson, Patrick C.			Bridging the B Cell Gap: Novel Technologies to Study Antigen-Specific Human B Cell Responses	VACCINES			English	Review						human B cells; B cell repertoires; humoral immunity; broadly neutralizing antibodies; RNA-sequencing; humanized mice; germinal center; bone marrow; lymph node; fine needle aspirates	NEUTRALIZING ANTIBODY-RESPONSES; HUMAN MONOCLONAL-ANTIBODIES; SINGLE-CELL; LYMPH-NODE; NONHUMAN-PRIMATES; HUMORAL IMMUNITY; EXPRESSION; VACCINE; AUTOREACTIVITY; PROMISE	The generation of high affinity antibodies is a crucial aspect of immunity induced by vaccination or infection. Investigation into the B cells that produce these antibodies grants key insights into the effectiveness of novel immunogens to induce a lasting protective response against endemic or pandemic pathogens, such as influenza viruses, human immunodeficiency virus, or severe acute respiratory syndrome coronavirus-2. However, humoral immunity has largely been studied at the serological level, limiting our knowledge on the specificity and function of B cells recruited to respond to pathogens. In this review, we cover a number of recent innovations in the field that have increased our ability to connect B cell function to the B cell repertoire and antigen specificity. Moreover, we will highlight recent advances in the development of both ex vivo and in vivo models to study human B cell responses. Together, the technologies highlighted in this review can be used to help design and validate new vaccine designs and platforms.	[Utset, Henry A.; Guthmiller, Jenna J.; Wilson, Patrick C.] Univ Chicago, Sect Rheumatol, Dept Med, Chicago, IL 60637 USA; [Wilson, Patrick C.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA		Guthmiller, JJ (通讯作者)，Univ Chicago, Sect Rheumatol, Dept Med, Chicago, IL 60637 USA.	hutset@medicine.bsd.uchicago.edu; jguthmiller@uchicago.edu; wilsonp@uchicago.edu		Guthmiller, Jenna/0000-0001-7566-3536; Utset, Henry/0000-0003-0607-3086	National Institute of Allergy and Infectious Diseases (NIAID)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U19AI082724, U19AI109946, U19AI057266]; NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400005C]; NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007605-35]	This work was funded in part by the National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health grant numbers U19AI082724 (PCW), U19AI109946 (PCW), U19AI057266 (PCW), the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) grant number HHSN272201400005C (PCW), and the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) grant number 75N93019C00051 (PCW). This work was also supported by the National Heart, Lung, and Blood Institute grant number T32HL007605-35 (J.J.G.).	Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Baccin C, 2020, NAT CELL BIOL, V22, P38, DOI 10.1038/s41556-019-0439-6; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009; Brummelman J, 2019, NAT PROTOC, V14, P1946, DOI 10.1038/s41596-019-0166-2; Chappaz S, 2010, J IMMUNOL, V184, P3562, DOI 10.4049/jimmunol.0901647; Cirelli KM, 2019, CELL, V177, P1153, DOI 10.1016/j.cell.2019.04.012; Davis CW, 2020, SCIENCE, V370, P237, DOI 10.1126/science.aaz8432; DeFalco J, 2018, CLIN IMMUNOL, V187, P37, DOI 10.1016/j.clim.2017.10.002; DeKosky BJ, 2013, NAT BIOTECHNOL, V31, P166, DOI 10.1038/nbt.2492; Dougan SK, 2012, P NATL ACAD SCI USA, V109, P13739, DOI 10.1073/pnas.1210273109; Dugan HL, 2021, IMMUNITY, V54, P1290, DOI 10.1016/j.immuni.2021.05.001; Dzangue-Tchoupou G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194593; Ehrhardt GRA, 2005, J EXP MED, V202, P783, DOI 10.1084/jem.20050879; Eng CHL, 2019, NATURE, V568, P235, DOI 10.1038/s41586-019-1049-y; Ferrer-Font L, 2020, CYTOM PART A, V97, P824, DOI 10.1002/cyto.a.24016; Garimilla S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126732; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Germain RN, 2010, IMMUNITY, V33, P441, DOI 10.1016/j.immuni.2010.09.014; Glass DR, 2020, IMMUNITY, V53, P217, DOI 10.1016/j.immuni.2020.06.013; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Guthmiller JJ, 2020, IMMUNITY, V53, P1230, DOI 10.1016/j.immuni.2020.10.005; Guthmiller JJ, 2019, METHODS MOL BIOL, V1904, P109, DOI 10.1007/978-1-4939-8958-4_5; Han J, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108682; Havenar-Daughton C, 2020, J IMMUNOL METHODS, V479, DOI 10.1016/j.jim.2020.112746; Havenar-Daughton C, 2016, CELL REP, V17, P2195, DOI 10.1016/j.celrep.2016.10.085; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Jacobsen JT, 2018, J EXP MED, V215, P2686, DOI 10.1084/jem.20172064; Jameson SC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029132; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Lau D, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai8153; Li Y, 2018, NAT METHODS, V15, P623, DOI 10.1038/s41592-018-0071-6; Lin YC, 2018, EMBO J, V37, DOI 10.15252/embj.201899243; Liu MF, 2015, J VIROL, V89, P784, DOI 10.1128/JVI.02378-14; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011; Moyer TJ, 2020, NAT MED, V26, P804, DOI 10.1038/s41591-020-0861-0; Muellenbeck MF, 2013, J EXP MED, V210, P389, DOI 10.1084/jem.20121970; Neu KE, 2019, J CLIN INVEST, V129, P93, DOI 10.1172/JCI121341; Nguyen DC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05853-7; Nogal B, 2020, CELL REP, V30, P3755, DOI 10.1016/j.celrep.2020.02.061; Nolan John P, 2013, Curr Protoc Cytom, VChapter 1, DOI 10.1002/0471142956.cy0127s63; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Rappuoli R, 2007, NAT BIOTECHNOL, V25, P1361, DOI 10.1038/nbt1207-1361; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Sangesland M, 2019, IMMUNITY, V51, P735, DOI 10.1016/j.immuni.2019.09.001; Schmidt A, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102684; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/NMETH.4380, 10.1038/nmeth.4380]; Sutton HJ, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108684; Tatovic D, 2015, J IMMUNOL, V195, P386, DOI 10.4049/jimmunol.1500364; Turner JS, 2020, NATURE, V586, P127, DOI 10.1038/s41586-020-2711-0; Vickovic S, 2019, NAT METHODS, V16, P987, DOI 10.1038/s41592-019-0548-y; Wagar LE, 2021, NAT MED, V27, P125, DOI 10.1038/s41591-020-01145-0; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Weisel NM, 2020, BLOOD, V136, P2774, DOI 10.1182/blood.2019002782; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890	65	1	1	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							711	10.3390/vaccines9070711			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6RV	34358128	Green Published, gold			2022-04-29	WOS:000677037000001
J	Xia, XH				Xia, Xuhua			Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines	VACCINES			English	Article						SARS-CoV-2; mRNA vaccine; translation initiation; codon optimization; translation termination; RNA secondary structure; RNA stability	SYNONYMOUS CODON USAGE; AUG INITIATOR CODON; SECONDARY STRUCTURE; PROTEIN-SYNTHESIS; RELEASE FACTORS; TRANSLATIONAL TERMINATION; ESCHERICHIA-COLI; NUCLEOTIDES; SEQUENCE; EFFICIENCY	The design of Pfizer/BioNTech and Moderna mRNA vaccines involves many different types of optimizations. Proper optimization of vaccine mRNA can reduce dosage required for each injection leading to more efficient immunization programs. The mRNA components of the vaccine need to have a 5 '-UTR to load ribosomes efficiently onto the mRNA for translation initiation, optimized codon usage for efficient translation elongation, and optimal stop codon for efficient translation termination. Both 5 '-UTR and the downstream 3 '-UTR should be optimized for mRNA stability. The replacement of uridine by N1-methylpseudourinine (psi) complicates some of these optimization processes because psi is more versatile in wobbling than U. Different optimizations can conflict with each other, and compromises would need to be made. I highlight the similarities and differences between Pfizer/BioNTech and Moderna mRNA vaccines and discuss the advantage and disadvantage of each to facilitate future vaccine improvement. In particular, I point out a few optimizations in the design of the two mRNA vaccines that have not been performed properly.	[Xia, Xuhua] Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; [Xia, Xuhua] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON K1H 8M5, Canada		Xia, XH (通讯作者)，Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada.; Xia, XH (通讯作者)，Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON K1H 8M5, Canada.	xxia@uottawa.ca	Xia, Xuhua/E-5264-2010	Xia, Xuhua/0000-0002-3092-7566	Natural Science and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN/2018-03878]	This research was funded by Discovery Grant from Natural Science and Engineering Research Council (NSERC) of Canada, grant number RGPIN/2018-03878.	Adachi H, 2019, BBA-GENE REGUL MECH, V1862, P230, DOI 10.1016/j.bbagrm.2018.11.002; Adibzadeh Setare, 2019, Avicenna Journal of Medical Biotechnology, V11, P112; AKASHI H, 1994, GENETICS, V136, P927; Alexandersen S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19883-7; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; BOSSI L, 1980, NATURE, V286, P123, DOI 10.1038/286123a0; BOSSI L, 1983, J MOL BIOL, V164, P73, DOI 10.1016/0022-2836(83)90088-8; Brown A, 2015, NATURE, V524, P493, DOI 10.1038/nature14896; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; CIGAN AM, 1987, GENE, V59, P1; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Courel M, 2019, ELIFE, V8, DOI 10.7554/eLife.49708; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; DAVIES J, 1966, J MOL BIOL, V18, P48, DOI 10.1016/S0022-2836(66)80075-X; Dvir S, 2013, P NATL ACAD SCI USA, V110, pE2792, DOI 10.1073/pnas.1222534110; European Medicines Agency, 2021, ASS REP COM COMM NAM ASS REP COM COMM NAM; Guild J., 2020, U.S. Patent, Patent No. [US 10,703,789 B2, 10703789]; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Hofhuis J, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160246; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jeong D., Assemblies-of- putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines- BNT-162b2- and- mRNA-1273; JOHNSTON TC, 1984, MOL GEN GENET, V195, P459, DOI 10.1007/BF00341447; JOHNSTON TC, 1985, J MOL BIOL, V181, P313, DOI 10.1016/0022-2836(85)90094-4; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kierzek E, 2014, NUCLEIC ACIDS RES, V42, P3492, DOI 10.1093/nar/gkt1330; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kozak M, 2003, BLOOD, V101, P1202, DOI 10.1182/blood-2002-10-3194; Kozak M, 2001, Sci STKE, V2001, ppe1, DOI 10.1126/stke.2001.71.pe1; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1980, CELL, V22, P7, DOI 10.1016/0092-8674(80)90148-8; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kracht MJL, 2017, NAT MED, V23, P501, DOI 10.1038/nm.4289; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Matheisl S, 2015, NUCLEIC ACIDS RES, V43, P8615, DOI 10.1093/nar/gkv909; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MILLER JH, 1983, J MOL BIOL, V164, P59, DOI 10.1016/0022-2836(83)90087-6; Nakamoto T, 2006, BIOCHEM BIOPH RES CO, V341, P675, DOI 10.1016/j.bbrc.2006.01.019; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Nchioua R, 2020, MBIO, V11, DOI 10.1128/mBio.01930-20; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Peixeiro I, 2011, HAEMATOL-HEMATOL J, V96, P905, DOI 10.3324/haematol.2010.039206; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Percudani R, 1997, J MOL BIOL, V268, P322, DOI 10.1006/jmbi.1997.0942; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROTH JR, 1970, J BACTERIOL, V102, P467, DOI 10.1128/JB.102.2.467-475.1970; RYDEN SM, 1984, MOL GEN GENET, V193, P38, DOI 10.1007/BF00327411; SAMBROOK JF, 1967, NATURE, V214, P452, DOI 10.1038/214452a0; Schueren F, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006196; Schueren F, 2014, ELIFE, V3, DOI 10.7554/eLife.03640; Shao SC, 2016, CELL, V167, P1229, DOI 10.1016/j.cell.2016.10.046; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Snijder EJ, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000715; Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218; STORMO GD, 1986, NUCLEIC ACIDS RES, V14, P6661, DOI 10.1093/nar/14.16.6661; STRIGINI P, 1973, J MOL BIOL, V75, P659, DOI 10.1016/0022-2836(73)90299-4; Takata MA, 2017, NATURE, V550, P124, DOI 10.1038/nature24039; TATE WP, 1973, P NATL ACAD SCI USA, V70, P2350, DOI 10.1073/pnas.70.8.2350; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; Tate WP, 1996, MOL MICROBIOL, V21, P213, DOI 10.1046/j.1365-2958.1996.6391352.x; Torres AG, 2019, BIOINFORM BIOL INSIG, V13, DOI 10.1177/1177932219868454; Trotta E, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2692-4; Tuller T, 2010, P NATL ACAD SCI USA, V107, P3645, DOI 10.1073/pnas.0909910107; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Valiante N., 2021, U.S. Patent, Patent No. [US 10,881,730 B2, 10881730]; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Waggoner SA, 2003, EXP BIOL MED, V228, P387, DOI 10.1177/153537020322800409; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Wei YL, 2016, MOL BIOL EVOL, V33, P2357, DOI 10.1093/molbev/msw107; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; Weissman D, 2015, EXPERT REV VACCINES, V14, P265, DOI 10.1586/14760584.2015.973859; World Health Organization, 2020, MESS RNA ENC FULL LE; Xia X., 2018, BIOINFORMATICS CELL, P197; Xia X., 2018, BIOINFORMATICS CELL, P239; Xia X., 2018, BIOINFORMATICS CELL, P173; Xia X., 2018, BIOINFORMATICS CELL, P77; Xia XH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000188; Xia XH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010109; Xia XH, 2020, MOL BIOL EVOL, V37, P2699, DOI 10.1093/molbev/msaa094; Xia XH, 2018, MOL BIOL EVOL, V35, P1550, DOI 10.1093/molbev/msy073; Xia XH, 2015, GENETICS, V199, P573, DOI 10.1534/genetics.114.172106; Xia XH, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/917540; Xia XH, 2011, GENETICS, V189, P469, DOI 10.1534/genetics.111.132068; Xia XH, 2007, EVOL BIOINFORM, V3, P53	99	8	8	30	57	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							734	10.3390/vaccines9070734			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7WL	34358150	Green Published, gold			2022-04-29	WOS:000677116600001
J	Zhang, HC; Pan, N; Ma, C; Liu, BH; Xiu, L; Tong, H; Sheng, SX; Liang, YC; Li, HT; Ma, FF; Bao, XM; Hu, W; Wang, X				Zhang, Haochi; Pan, Na; Ma, Cheng; Liu, Bohui; Xiu, Lei; Tong, He; Sheng, Shouxin; Liang, Yanchen; Li, Haotian; Ma, Fangfei; Bao, Xuemei; Hu, Wei; Wang, Xiao			Vaccine Composition Formulated with a Novel Lactobacillus-Derived Exopolysaccharides Adjuvant Provided High Protection against Staphylococcus aureus	VACCINES			English	Article						exopolysaccharides; vaccine; S. aureus; gamma delta T cells; IL-17A	DELTA-T-CELLS; INFECTION; PROFILE; STRAIN; SAFETY; TH1	A vaccine that effectively targets methicillin-resistant Staphylococcus aureus (MRSA) is urgently needed, and has been the focus of studies by numerous research groups, but with limited success to date. Recently, our team found that exopolysaccharides derived from probiotic Lactobacillus casei strain WXD030 as an adjuvant-formulated OVA could upregulate IFN-gamma and IL-17 expression in CD4(+) T cells. In this study, we developed a vaccine (termed rMntC-EPS) composed of S. aureus antigen MntC and Lactobacillus casei exopolysaccharides, which conferred high levels of protection against S. aureus infection. Methods: Six-eight-week-old female mice were vaccinated with purified rMntC-EPS30. The immune protection function of rMntC-EPS30 was assessed by the protective effect of rMntC-EPS30 to S. aureus-induced pulmonary and cutaneous infection in mice, bacterial loads and H&E in injury site, and ELISA for inflammation-related cytokines. The protective mechanism of rMntC-EPS30 was assessed by ELISA for IgG in serum, cytokines in the spleen and lungs of vaccinated mice. In addition, flow cytometry was used for analyzing cellular immune response induced by rMntC-EPS30. For confirmation of our findings, three kinds of mice were used in this study: IL-17A knockout mice, IFN-gamma knockout mice and TCR gamma/delta knockout mice. Results: rMntC-EPS30 conferred up to 90% protection against S. aureus pulmonary infection and significantly reduced the abscess size in the S. aureus cutaneous model, with clearance of the pathogen. The rMntC-EPS vaccine could induce superior humoral immunity as well as significantly increase IL-17A and IFN-gamma production. In addition, we found that rMntC-EPS vaccination induced robust Th 17/gamma delta T 17 primary and recall responses. Interestingly, this protective effect was distinctly reduced in the IL-17A knockout mice but not in IFN-gamma knockout mice. Moreover, in TCR gamma/delta knockout mice, rMntC-EPS vaccination neither increased IL-17A secretion nor provided effective protection against S. aureus infection. Conclusions: These data demonstrated that the rMntC formulated with a novel Lactobacillus-derived Exopolysaccharides adjuvant provided high protection against Staphylococcus aureus. The rMntC-EPS vaccine induced gamma delta T cells and IL-17A might play substantial roles in anti-S. aureus immunity. Our findings provided direct evidence that rMntC-EPS vaccine is a promising candidate for future clinical application against S. aureus-induced pulmonary and cutaneous infection.	[Zhang, Haochi; Pan, Na; Ma, Cheng; Liu, Bohui; Xiu, Lei; Tong, He; Sheng, Shouxin; Liang, Yanchen; Li, Haotian; Ma, Fangfei; Bao, Xuemei; Hu, Wei; Wang, Xiao] Inner Mongolia Univ, State Key Lab Reprod Regulat & Breeding Grassland, Hohhot 010070, Peoples R China		Wang, X (通讯作者)，Inner Mongolia Univ, State Key Lab Reprod Regulat & Breeding Grassland, Hohhot 010070, Peoples R China.	21908028@mail.imu.edu.cn; 22008032@mail.imu.edu.cn; 31808081@mail.imu.edu.cn; 31808136@mail.imu.edu.cn; 21708020@mail.imu.edu.cn; 21908040@mail.imu.edu.cn; shouxins1230@mail.imu.edu.cn; yanchenliang@mail.imu.edu.cn; 31908093@mail.imu.edu.cn; 31908098@mail.imu.edu.cn; 31908096@mail.imu.edu.cn; huw@imu.edu.cn; wangxiao@imu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32060800, 31660706]; Science and Technology Major Project of Inner Mongolia Autonomous Region of China; State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock [2019ZD031, zdzx2018065]	This work was supported by the National Natural Science Foundation of China [grant number 32060800], [grant number 31660706]. This study is supported by the Science and Technology Major Project of Inner Mongolia Autonomous Region of China to the State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock [grant number 2019ZD031], [grant number zdzx2018065]. The authors are grateful to Zhinan Yin for providing IL-17A<SUP>-/-</SUP>, TCR gamma/beta<SUP>-/-</SUP>, and IFN-gamma<SUP>-/-</SUP> mice, and to S. Anderson for English editing of the manuscript.	Andreassen AES, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0232-x; Bagnoli F, 2015, P NATL ACAD SCI USA, V112, P3680, DOI 10.1073/pnas.1424924112; Bagnoli F, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00016; Begier E, 2017, VACCINE, V35, P1132, DOI 10.1016/j.vaccine.2017.01.024; Bennett MR, 2020, TOXINS, V12, DOI 10.3390/toxins12060408; Brown AF, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005226; Cheng P, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-38; Chiang SS, 2012, FOOD AGR IMMUNOL, V23, P183, DOI 10.1080/09540105.2011.609246; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Cibulski SP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31995-1; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Dennehy PH, 2007, INT J INFECT DIS, V11, pS36, DOI 10.1016/S1201-9712(07)60020-4; Dillen CA, 2018, J CLIN INVEST, V128, P1026, DOI 10.1172/JCI96481; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Ferraro A, 2019, HUM VACC IMMUNOTHER, V15, P2980, DOI 10.1080/21645515.2019.1613126; Giersing BK, 2016, VACCINE, V34, P2962, DOI 10.1016/j.vaccine.2016.03.110; Guerra-Maupome M, 2019, VET CLIN N AM-FOOD A, V35, P453, DOI 10.1016/j.cvfa.2019.08.001; Heim CE, 2020, NAT MICROBIOL, V5, P1271, DOI 10.1038/s41564-020-0756-3; Holley MM, 2012, J IMMUNOL, V188, P1360, DOI 10.4049/jimmunol.1101660; Howard LSGE, 2005, J INFECTION, V50, P107, DOI 10.1016/j.jinf.2004.05.003; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jing XQ, 2012, ASIAN J ANIM VET ADV, V7, P1266, DOI 10.3923/ajava.2012.1266.1278; Johansson MA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00273; Kim MR, 2012, ALLERGY, V67, P1271, DOI 10.1111/all.12001; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Kumar V, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1470-9; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Maher BM, 2013, INFECT IMMUN, V81, P4478, DOI 10.1128/IAI.01026-13; Matsuzaki C, 2015, J AGR FOOD CHEM, V63, P7009, DOI 10.1021/acs.jafc.5b01960; Melandri D, 2018, NAT IMMUNOL, V19, P1352, DOI 10.1038/s41590-018-0253-5; Moyer TJ, 2020, NAT MED, V26, P430, DOI 10.1038/s41591-020-0753-3; Murphy AG, 2014, J IMMUNOL, V192, P3697, DOI 10.4049/jimmunol.1303420; Nissen M, 2015, VACCINE, V33, P1846, DOI 10.1016/j.vaccine.2015.02.024; O'Brien EC, 2019, TRENDS MOL MED, V25, P171, DOI 10.1016/j.molmed.2018.12.010; OHKUBO Y, 1984, JPN J VET SCI, V46, P57; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Prince A, 2020, NAT MICROBIOL, V5, P1183, DOI 10.1038/s41564-020-00791-x; Saito S, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7030064; Wardenburg JB, 2007, INFECT IMMUN, V75, P1040, DOI 10.1128/IAI.01313-06; Wu S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00304; Xiu L, 2018, FOOD AGR IMMUNOL, V29, P1086, DOI 10.1080/09540105.2018.1513994	41	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							775	10.3390/vaccines9070775			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4VX	34358191	gold, Green Published			2022-04-29	WOS:000676912400001
J	Imai, T				Imai, Takashi			Single Amino Acid Deletion at N-Terminus of the Target Antigen in DNA Vaccine Induces Altered CD8(+) T Cell Responses against Tumor Antigen	VACCINES			English	Article						DNA vaccine; immunology; CD8(+) T cell; antigen presentation; proteasome; tumor; cancer; N-end rule	UBIQUITIN-PROTEASOME PATHWAY; PROTECTIVE IMMUNITY; IN-VIVO; PROTEIN; GENE; INDUCTION; IMMUNIZATION	Since CD8(+) T cells have immunological memory and can eliminate tumor or infected cells, antigen-specific CD8(+) T cell inducing DNA vaccines are potential next-generation vaccines. However, the relationship between single amino acid deletion of target antigens in plasmid DNA vaccines and vaccine efficacy is not completely understood. To address this knowledge disparity and improve DNA vaccine development, two constructs cytosolic form of ovalbumin, pOVAv (346 amino acids) and pOVAy (345 amino acids) were constructed and compared. OVA proteins from both constructs were detected in an in vitro experiment. Then, the efficacy of prophylactic DNA vaccination using a gene gun against OVA-expressing mouse thymoma cells was compared. Both constructs conferred protection against tumor challenge, and there was no significant difference between the efficacies of pOVAv and pOVAy. The pOVAv vaccine induced stronger antigen-specific cytotoxicity in vivo, while bone marrow-derived dendritic cells (BMDCs) transfected with pOVAv induced higher levels of IFN-gamma production from OT-I CD8(+) T cells in vitro compared to pOVAy. These results indicate that a single amino acid deletion at N-terminus of the target antigen in a DNA vaccine leads to a different immunological outcome. The small modification of the target antigen in the DNA vaccine might improve its efficacy against tumor or infectious diseases.	[Imai, Takashi] Kyushu Univ, Grad Sch Med Sci, Dept Microbiol & Immunol, Fukuoka 8128582, Japan; [Imai, Takashi] Gunma Univ, Grad Sch Med, Dept Infect Dis & Host Def, Maebashi, Gunma 3718511, Japan; [Imai, Takashi] Saitama Med Univ, Dept Microbiol, Moroyama, Saitama 3500495, Japan		Imai, T (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Microbiol & Immunol, Fukuoka 8128582, Japan.; Imai, T (通讯作者)，Gunma Univ, Grad Sch Med, Dept Infect Dis & Host Def, Maebashi, Gunma 3718511, Japan.; Imai, T (通讯作者)，Saitama Med Univ, Dept Microbiol, Moroyama, Saitama 3500495, Japan.	0521773@gmail.com		Imai, Takashi/0000-0001-9049-8102	SENSHIN Medical Research FoundationSENSHIN Medical Research Foundation	This research was supported by a research grant from the SENSHIN Medical Research Foundation to T.I.	Achenbach CJ, 2015, LANCET HIV, V2, pE82, DOI 10.1016/S2352-3018(15)00026-0; Andersson HA, 2004, MOL THER, V10, P432, DOI 10.1016/j.ymthe.2004.05.035; Bergmann-Leitner ES, 2015, METHODS MOL BIOL, V1325, P289, DOI 10.1007/978-1-4939-2815-6_22; Bins AD, 2007, J IMMUNOL, V179, P2126, DOI 10.4049/jimmunol.179.4.2126; Chang GJJ, 2007, VACCINE, V25, P2325, DOI 10.1016/j.vaccine.2006.11.056; Chou B, 2010, BIOCHEM BIOPH RES CO, V392, P277, DOI 10.1016/j.bbrc.2009.12.166; Dalmo RA, 2018, J FISH DIS, V41, P1, DOI 10.1111/jfd.12727; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442; Duan XF, 2006, INT IMMUNOL, V18, P679, DOI 10.1093/intimm/dxl005; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Elbahnasawy MA, 2020, MICROB PATHOGENESIS, V138, DOI 10.1016/j.micpath.2019.103824; Ferraro B, 2011, CLIN INFECT DIS, V53, P296, DOI 10.1093/cid/cir334; Graham BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059340; Haymaker CL, 2017, JOVE-J VIS EXP, DOI 10.3791/56255; Hitzeroth II, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00101; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Huang L, 2011, EMBO J, V30, P1634, DOI 10.1038/emboj.2011.62; Hwang CS, 2010, SCIENCE, V327, P973, DOI 10.1126/science.1183147; Imai T, 2008, BIOCHEM BIOPH RES CO, V365, P758, DOI 10.1016/j.bbrc.2007.11.034; Imai T, 2011, P NATL ACAD SCI USA, V108, P16363, DOI 10.1073/pnas.1108372108; Ishii K, 2006, MICROBES INFECT, V8, P1045, DOI 10.1016/j.micinf.2005.10.023; Kloetzel PM, 2004, BBA-MOL CELL RES, V1695, P225, DOI 10.1016/j.bbamcr.2004.10.004; Kocaturk NM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00128; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kumamoto T, 2002, NAT BIOTECHNOL, V20, P64, DOI 10.1038/nbt0102-64; Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762; Mbewana S, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00197; McLean JL, 2015, J S AFR VET ASSOC, V86, DOI 10.4102/jsava.v86i1.1246; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075; Salonius K, 2007, CURR OPIN INVEST DR, V8, P635; Schwartz AL, 1999, ANNU REV MED, V50, P57; Teramoto K, 2003, CANCER RES, V63, P7920; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Tobery T, 1999, J IMMUNOL, V162, P639; Varland S, 2015, PROTEOMICS, V15, P2385, DOI 10.1002/pmic.201400619; Varshavsky A, 2019, P NATL ACAD SCI USA, V116, P358, DOI 10.1073/pnas.1816596116; Varshavsky A, 2011, PROTEIN SCI, V20, P1298, DOI 10.1002/pro.666; Zhang M, 2005, GENE THER, V12, P1049, DOI 10.1038/sj.gt.3302490	41	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							540	10.3390/vaccines9060540			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA6UB	34063920	gold, Green Published			2022-04-29	WOS:000667382400001
J	Muzeniek, T; Perera, T; Siriwardana, S; Bas, D; Kaplan, F; Oruc, M; Becker-Ziaja, B; Schwarz, F; Premawansa, G; Premawansa, S; Perera, I; Yapa, W; Nitsche, A; Kohl, C				Muzeniek, Therese; Perera, Thejanee; Siriwardana, Sahan; Bas, Dilara; Kaplan, Fatimanur; Oeruc, Mizgin; Becker-Ziaja, Beate; Schwarz, Franziska; Premawansa, Gayani; Premawansa, Sunil; Perera, Inoka; Yapa, Wipula; Nitsche, Andreas; Kohl, Claudia			Detection of Alpha- and Betacoronaviruses in Miniopterus fuliginosus and Rousettus leschenaultii, two species of Sri Lankan Bats	VACCINES			English	Article						bat coronavirus; Miniopterus fuliginosus; Rousettus leschenaultii; Sri Lanka; cave-dwelling; sympatric colony; alphacoronavirus; betacoronavirus	CORONAVIRUSES; ORIGIN	Bats are known to be potential reservoirs of numerous human-pathogenic viruses. They have been identified as natural hosts for coronaviruses, causing Severe Acute Respiratory Syndrome (SARS) in humans. Since the emergence of SARS-CoV-2 in 2019 interest in the prevalence of coronaviruses in bats was newly raised. In this study we investigated different bat species living in a sympatric colony in the Wavul Galge cave (Koslanda, Sri Lanka). In three field sessions (in 2018 and 2019), 395 bats were captured (Miniopterus, Rousettus, Hipposideros and Rhinolophus spp.) and either rectal swabs or fecal samples were collected. From these overall 396 rectal swab and fecal samples, the screening for coronaviruses with nested PCR resulted in 33 positive samples, 31 of which originated from Miniopterus fuliginosus and two from Rousettus leschenaultii. Sanger sequencing and phylogenetic analysis of the obtained 384-nt fragment of the RNA-dependent RNA polymerase revealed that the examined M. fuliginosus bats excrete alphacoronaviruses and the examined R. leschenaultii bats excrete betacoronaviruses. Despite the sympatric roosting habitat, the coronaviruses showed host specificity and seemed to be limited to one species. Our results represent an important basis to better understand the prevalence of coronaviruses in Sri Lankan bats and may provide a basis for pursuing studies on particular bat species of interest.	[Muzeniek, Therese; Bas, Dilara; Kaplan, Fatimanur; Oeruc, Mizgin; Schwarz, Franziska; Nitsche, Andreas; Kohl, Claudia] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, Highly Pathogen Viruses ZBS 1, D-13353 Berlin, Germany; [Perera, Thejanee] Univ Colombo, Inst Biochem Mol Biol & Biotechnol, Colombo 00300, Sri Lanka; [Siriwardana, Sahan; Premawansa, Sunil; Perera, Inoka; Yapa, Wipula] Univ Colombo, Dept Zool & Environm Sci, IDEA Identificat Emerging Agents Lab, Colombo 00300, Sri Lanka; [Becker-Ziaja, Beate] Robert Koch Inst, Ctr Int Hlth Protect, Publ Hlth Lab Support ZIG 4, D-13353 Berlin, Germany; [Premawansa, Gayani] Colombo North Teaching Hosp, Ragama 11010, Sri Lanka		Kohl, C (通讯作者)，Robert Koch Inst, Ctr Biol Threats & Special Pathogens, Highly Pathogen Viruses ZBS 1, D-13353 Berlin, Germany.	muzeniekt@rki.de; Thejanee90@gmail.com; sahan@zoology.cmb.ac.lk; BasD@rki.de; KaplanF@rki.de; OerucM@rki.de; Becker-ZiajaB@rki.de; SchwarzF@rki.de; gavisprema@gmail.com; suviprema@gmail.com; icperera@sci.cmb.ac.lk; wipula@gmail.com; NitscheA@rki.de; KohlC@rki.de		Perera, Thejanee/0000-0002-4667-6466; Schwarz, Franziska/0000-0003-3848-9422; Bayram, Fatimanur/0000-0002-9249-5850; Nitsche, Andreas/0000-0001-8185-3176; Muzeniek, Therese/0000-0003-4429-1738; C. Perera, Inoka/0000-0002-2496-7385	Global Health Protection Programme (IDEA, Identification of Emerging Agents) of the German Federal Ministry of Health	This project has been partially funded through the Global Health Protection Programme (IDEA, Identification of Emerging Agents) of the German Federal Ministry of Health.	Amaratunga D, 2020, PROG DISASTER SCI, V8, DOI 10.1016/j.pdisas.2020.100133; Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0; Corman VM, 2015, J VIROL, V89, P11858, DOI 10.1128/JVI.01755-15; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06; Grange ZL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2002324118; Han HJ, 2015, VIRUS RES, V205, P1, DOI 10.1016/j.virusres.2015.05.006; Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1; Huang CP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005883; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kudagammana HDWS, 2018, TRANSBOUND EMERG DIS, V65, P1122, DOI 10.1111/tbed.12851; Latinne A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17687-3; Lau SKP, 2012, J VIROL, V86, P11906, DOI 10.1128/JVI.01305-12; Lim XF, 2019, J GEN VIROL, V100, P1363, DOI 10.1099/jgv.0.001307; Lin XD, 2017, VIROLOGY, V507, P1, DOI 10.1016/j.virol.2017.03.019; Martini G A, 1968, Ger Med Mon, V13, P457; Obameso JO, 2017, SCI CHINA LIFE SCI, V60, P1357, DOI 10.1007/s11427-017-9263-6; Plowright RK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.2124; Poudel U, 2020, OPEN VET J, V10, P239, DOI 10.4314/ovj.v10i3.1; Saez AM, 2015, EMBO MOL MED, V7, P17, DOI 10.15252/emmm.201404792; Subudhi S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020192; Valitutto MT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230802; Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076; Wibbelt G, 2007, J GEN VIROL, V88, P2651, DOI 10.1099/vir.0.83045-0; Wild TF, 2009, PATHOL BIOL, V57, P188, DOI 10.1016/j.patbio.2008.04.006; Wong ACP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020174; Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94; Yadav PD, 2020, INDIAN J MED RES, V151, P226, DOI 10.4103/ijmr.IJMR_795_20; Yapa W.B., 2006, U COLOMBO REV, V1, P63; Yapa W.B., 2017, FIELD GUIDE BATS SRI, V1st, P8	31	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							650	10.3390/vaccines9060650			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ1HC	34203592	Green Published, gold			2022-04-29	WOS:000666324400001
J	Pitini, E; Baccolini, V; Rosso, A; Massimi, A; De Vito, C; Marzuillo, C; Villari, P				Pitini, Erica; Baccolini, Valentina; Rosso, Annalisa; Massimi, Azzurra; De Vito, Corrado; Marzuillo, Carolina; Villari, Paolo			How Public Health Professionals View Mandatory Vaccination in Italy-A Cross-Sectional Survey	VACCINES			English	Article						mandatory vaccination; public health professionals; childhood vaccination; survey	IMMUNIZATION; LAW	In response to the decline in child vaccination coverage and the subsequent occurrence of large vaccine-preventable disease outbreaks, in 2017 Italy introduced a new law that made ten vaccines mandatory for children aged 0-16 years. The policy change initiated an ongoing debate among the general public, as well as in the political arena and the scientific community, over this major public health concern. Hence, we conducted a survey aimed at assessing Italian public health professionals' attitudes towards and opinions on mandatory vaccination. A validated online questionnaire was administered to 1350 members of the Italian Society of Hygiene, Preventive Medicine and Public Health. Among the 1044 responders (response rate 77%), a large majority were in favour of the Italian mandatory vaccination law (91%) and against its repeal (74%). Nevertheless, according to our sample, maintaining a high level of vaccination coverage without the need to mandate would be preferable, and thus efforts to promote vaccine confidence and proactive vaccine uptake are still needed.	[Pitini, Erica; Baccolini, Valentina; Rosso, Annalisa; Massimi, Azzurra; De Vito, Corrado; Marzuillo, Carolina; Villari, Paolo] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Ple A Moro 5, I-00185 Rome, Italy; [Pitini, Erica] Azienda Sanit Locale Roma 1, Local Hlth Unit, Borgo Santo Spirito 3, I-00193 Rome, Italy; [Rosso, Annalisa] Azienda Sanit Locale Roma 2, Local Hlth Unit, Vle B Bardanzellu 8, I-00155 Rome, Italy		Pitini, E (通讯作者)，Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Ple A Moro 5, I-00185 Rome, Italy.; Pitini, E (通讯作者)，Azienda Sanit Locale Roma 1, Local Hlth Unit, Borgo Santo Spirito 3, I-00193 Rome, Italy.	erica.pitini@uniroma1.it; valentina.baccolini@uniroma1.it; annalisa.rosso@uniroma1.it; azzurra.massimi@uniroma1.it; corrado.devito@uniroma1.it; carolina.marzuillo@uniroma1.it; paolo.villari@uniroma1.it	Rosso, Annalisa/AAC-3957-2022	Rosso, Annalisa/0000-0002-0537-5130; Baccolini, Valentina/0000-0002-7873-7817; Pitini, Erica/0000-0003-2018-3679; villari, paolo/0000-0002-3139-0668; MARZUILLO, CAROLINA/0000-0002-7299-5727	Sapienza University of Rome [RG11715C81FC58AD]	This work was supported by Sapienza University of Rome (University Research Projects 2017 (Progetti di Ricerca di Ateneo 2017), protocol no. RG11715C81FC58AD).	Adamo G, 2017, ANN IG MED PREV COMU, V29, P1, DOI 10.7416/ai.2017.2128; Adamo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226513; Adamo G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205147; Adamo G, 2016, EPIDEMIOL BIOSTAT PU, V13, DOI 10.2427/12075; [Anonymous], 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.29414; [Anonymous], 2020, WHO SPEC FEAT IMM CO; Baccolini V, 2020, HUM VACC IMMUNOTHER, V16, P2618, DOI 10.1080/21645515.2020.1737458; Bednarczyk RA, 2019, EXPERT REV VACCINES, V18, P175, DOI 10.1080/14760584.2019.1562344; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Bisordi Costanza, 2019, Ig Sanita Pubbl, V75, P249; Chirico F, 2018, ANN IG MED PREV COMU, V30, P251, DOI 10.7416/ai.2018.2217; D'Ancona F, 2019, EUROSURVEILLANCE, V24, P31, DOI 10.2807/1560-7917.ES.2019.24.25.1900371; Gentile L, 2021, J PUBLIC HEALTH-HEID, V29, P659, DOI 10.1007/s10389-019-01171-4; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Gur-Arie R, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004877; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Italian Ministry of Health, VACC ET PED AD COP V; Italian Ministry of Health, 2017, PIAN NAZ PREV VACC 2; Jae Jeong H., 2016, BIOMETRICS BIOSTATIS, V4, DOI [10.15406/bbij.2016.04.00100, DOI 10.15406/BBIJ.2016.04.00100]; Lee C, 2016, J INFECTION, V72, P659, DOI 10.1016/j.jinf.2016.04.002; Montalti M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010086; Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943; National Conference of State Legislatures -NCSL, STAT REL PHIL EX SCH; Nicolay N, 2008, VACCINE, V26, P5484, DOI 10.1016/j.vaccine.2008.07.058; Pitini E., 2020, EBPH, V17, P1; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; Rosso A, 2020, HUM VACC IMMUNOTHER, V16, P1969, DOI 10.1080/21645515.2019.1698901; Rosso A, 2019, VACCINE, V37, P1954, DOI 10.1016/j.vaccine.2019.02.049; Siani A, 2019, PREV MED, V121, P99, DOI 10.1016/j.ypmed.2019.02.011; Vaz OM, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0620; Yang YT, 2018, VACCINE, V36, P1323, DOI 10.1016/j.vaccine.2018.01.073	32	3	3	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							580	10.3390/vaccines9060580			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8IH	34205959	Green Published, gold			2022-04-29	WOS:000666124200001
J	Tanno, LK; Berard, F; Beaudoin, E; Didier, A; Demoly, P				Tanno, Luciana Kase; Berard, Frederic; Beaudoin, Etienne; Didier, Alain; Demoly, Pascal		Montpellier WHO Collaborating Ctr; French Allergy Soc SFA	SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center	VACCINES			English	Review						allergy; anaphylaxis; COVID-19; recommendations; SARS-CoV-2 vaccination; vaccine	INTERNATIONAL CLASSIFICATION; HYPERSENSITIVITY; CONSENSUS; DISEASES; EXTRACT	Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.	[Tanno, Luciana Kase; Demoly, Pascal] Univ Hosp Montpellier, Dept Pneumol & Addictol, Div Allergy, F-34295 Montpellier, France; [Tanno, Luciana Kase; Demoly, Pascal] Univ Hosp Montpellier, WHO Collaborating Ctr Classificat Sci Support, F-34295 Montpellier, France; [Tanno, Luciana Kase; Demoly, Pascal] Univ Montpellier, Desbrest Inst Epidemiol & Publ Hlth, UMR UA 11, INSERM, F-34093 Montpellier, France; [Berard, Frederic] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Inserm U1111 CIRI, F-69495 Lyon, France; [Beaudoin, Etienne] Metz Reg Hosp, Reg Inst Allerg & Environm Dis Clin Immunol, F-57000 Metz, France; [Didier, Alain] CHU Toulouse, Hop Larrey, Pole Voies Resp, F-31059 Toulouse 9, France; [Didier, Alain] Univ Toulouse III, Ctr Physiopathol Toulouse Purpan, INSERM U1043, CNRS UMR 5282, F-31024 Toulouse 3, France		Tanno, LK (通讯作者)，Univ Hosp Montpellier, Dept Pneumol & Addictol, Div Allergy, F-34295 Montpellier, France.; Tanno, LK (通讯作者)，Univ Hosp Montpellier, WHO Collaborating Ctr Classificat Sci Support, F-34295 Montpellier, France.; Tanno, LK (通讯作者)，Univ Montpellier, Desbrest Inst Epidemiol & Publ Hlth, UMR UA 11, INSERM, F-34093 Montpellier, France.	luciana.tanno@gmail.com; frederic.berard@chu-lyon.fr; beaudouin.etienne@wanadoo.fr; didier.a@chu-toulouse.fr; pascal.demoly@inserm.fr			APHITEM (Appel a Projet Interregional Thematique) through University Hospital of Montpellier (CHUM) administration; research AllerGOS (Reseau des allergies graves ou severes) grant	Pascal Demoly and Luciana Kase Tanno received an unrestricted APHITEM (Appel a Projet Interregional Thematique) grants through University Hospital of Montpellier (CHUM) administration. Luciana Kase Tanno received a research AllerGOS (Reseau des allergies graves ou severes) grant.	[Anonymous], 2020, US FDA TAKES ADDITIO; [Anonymous], 2020, PFIZER BIONTECH ACHI; [Anonymous], 2020, **NON-TRADITIONAL**; Blumenthal KG, 2021, JAMA-J AM MED ASSOC, V325, P1562, DOI 10.1001/jama.2021.3976; Bonadonna P., 2021, J ALLERGY CLIN IMMUN, V5, pS2198; Cardona V, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100472; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Demoly P, 2014, ALLERGY, V69, P559, DOI 10.1111/all.12386; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Demoly P, 2020, B ACAD NAT MED PARIS, V1, P97; DREBORG S, 1990, CRIT REV THER DRUG, V6, P315; Dreskin SC, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0120-5; Halsey Neal A, 2002, Semin Pediatr Infect Dis, V13, P205, DOI 10.1053/spid.2002.125864; JUNIPER EF, 1985, J ALLERGY CLIN IMMUN, V75, P578, DOI 10.1016/0091-6749(85)90033-8; MOSBECH H, 1990, ALLERGY, V45, P142, DOI 10.1111/j.1398-9995.1990.tb00472.x; Panesar SS, 2013, ALLERGY, V68, P1353, DOI 10.1111/all.12272; Sampath V, 2021, ALLERGY, V76, P1640, DOI 10.1111/all.14840; Sellaturay P, 2021, CLIN EXP ALLERGY, V51, P861, DOI 10.1111/cea.13874; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Tanno LK, 2017, ALLERGY, V72, P820, DOI 10.1111/all.13093; Tanno LK, 2015, ALLERGY, V70, P609, DOI 10.1111/all.12604; Tanno LK, 2012, ALLERGY, V67, P783, DOI 10.1111/j.1398-9995.2012.02829.x; Tanno LK, 2020, J ALLER CL IMM-PRACT, V8, P2144, DOI 10.1016/j.jaip.2020.05.002; Tanno LK, 2016, ALLERGY ASTHMA IMMUN, V8, P383, DOI 10.4168/aair.2016.8.4.383; Tanno LK, 2019, J ALLERGY CLIN IMMUN, V144, P627, DOI 10.1016/j.jaci.2019.05.013; Turner PJ, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100517; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760; Zhou ZH, 2021, J ALLER CL IMM-PRACT, V9, P1731, DOI 10.1016/j.jaip.2020.11.011	31	5	5	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							560	10.3390/vaccines9060560			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6XX	34072058	Green Published, gold			2022-04-29	WOS:000666706600001
J	Uccellini, MB; Aslam, S; Liu, STH; Alam, F; Garcia-Sastre, A				Uccellini, Melissa B.; Aslam, Sadaf; Liu, Sean T. H.; Alam, Fahmida; Garcia-Sastre, Adolfo			Development of a Macrophage-Based ADCC Assay	VACCINES			English	Article						ADCC; macrophage; influenza; hemagglutinin	CELL-MEDIATED-CYTOTOXICITY; EFFECTOR FUNCTIONS; ANTIBODIES; PHAGOCYTOSIS; RITUXIMAB	Fc-dependent effector functions are an important determinant of the in vivo potency of therapeutic antibodies. Effector function is determined by the combination of FcRs bound by the antibody and the cell expressing the relevant FcRs, leading to antibody-dependent cellular cytotoxicity (ADCC). A number of ADCC assays have been developed; however, they suffer from limitations in terms of throughput, reproducibility, and in vivo relevance. Existing assays measure NK cell-mediated ADCC activity; however, studies suggest that macrophages mediate the effector function of many antibodies in vivo. Here, we report the development of a macrophage-based ADCC assay that relies on luciferase expression in target cells as a measure of live cell number. In the presence of primary mouse macrophages and specific antibodies, loss of luciferase signal serves as a surrogate for ADCC-dependent killing. We show that the assay functions for a variety of mouse and human isotypes with a model antigen/antibody complex in agreement with the known effector function of the isotypes. We also use this assay to measure the activity of a number of influenza-specific antibodies and show that the assay correlates well with the known in vivo effector functions of these antibodies.	[Uccellini, Melissa B.; Aslam, Sadaf; Liu, Sean T. H.; Alam, Fahmida; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Uccellini, Melissa B.; Aslam, Sadaf; Alam, Fahmida; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Uccellini, Melissa B.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA		Garcia-Sastre, A (通讯作者)，Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Garcia-Sastre, A (通讯作者)，Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.; Garcia-Sastre, A (通讯作者)，Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.; Garcia-Sastre, A (通讯作者)，Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.	melissa.uccellini@mssm.edu; sadaf.aslam@mssm.edu; sean.liu@mountsinai.org; fahmida.alam@mssm.edu; adolfo.garcia-sastre@mssm.edu		Aslam, Sadaf/0000-0002-3748-4227; Garcia-Sastre, Adolfo/0000-0002-6551-1827; ALAM, FAHMIDA/0000-0002-1727-5356	National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN272201400008C]; Center for Research on Influenza Pathogenesis and Transmission (CRIPT) [75N93019R00028]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P01AI097092, 75N93019C00051]; Sinai-Emory Multi-Institutional CIVIC (Collaborative Influenza Vaccine Innovation Center)	This research was partly funded by the National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (M.B.U. and A.G.-S.), and by the Center for Research on Influenza Pathogenesis and Transmission (CRIPT, contract 75N93019R00028), one of the NIAID awarded Centers of Excellence for Influenza Research and Response (CEIRR), by the Sinai-Emory Multi-Institutional CIVIC (Collaborative Influenza Vaccine Innovation Center, NIAID contract 75N93019C00051) and NIAID grant P01AI097092 (A.G.-S.).	Ackerman ME, 2017, IMMUNOL REV, V275, P262, DOI 10.1111/imr.12503; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; Cartron G, 2008, J CLIN ONCOL, V26, P2725, DOI 10.1200/JCO.2007.13.7729; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Cheng ZJ, 2014, J IMMUNOL METHODS, V414, P69, DOI 10.1016/j.jim.2014.07.010; Chromikova V, 2020, VACCINE, V38, P1953, DOI 10.1016/j.vaccine.2020.01.008; De Nardo D, 2018, METHODS MOL BIOL, V1784, P35, DOI 10.1007/978-1-4939-7837-3_4; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Grugan KD, 2012, J IMMUNOL, V189, P5457, DOI 10.4049/jimmunol.1201889; Gul N, 2015, CANCER RES, V75, P5008, DOI 10.1158/0008-5472.CAN-15-1330; He WQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00928-3; Kantakamalakul W, 2006, J IMMUNOL METHODS, V315, P1, DOI 10.1016/j.jim.2006.06.005; Karimi MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089357; Leon PE, 2016, P NATL ACAD SCI USA, V113, pE5944, DOI 10.1073/pnas.1613225113; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Nelson DL, 2001, CURR PROTOC IMMUNOL, V7, P27, DOI [10.1002/0471142735.im0727s08, 10.1002/0471142735.IM0727S08, DOI 10.1002/0471142735.IM0727S08]; Oceguera-Yanez F, 2016, METHODS, V101, P43, DOI 10.1016/j.ymeth.2015.12.012; Parekh BS, 2012, MABS-AUSTIN, V4, P310, DOI 10.4161/mabs.19873; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Velders MP, 1998, BRIT J CANCER, V78, P478, DOI 10.1038/bjc.1998.518; Wang GG, 2006, NAT METHODS, V3, P287, DOI 10.1038/NMETH865; Weiskopf K, 2015, MABS-AUSTIN, V7, P303, DOI 10.1080/19420862.2015.1011450; Yamashita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19772	25	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							660	10.3390/vaccines9060660			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5BW	34204268	gold, Green Published			2022-04-29	WOS:000665904300001
J	Li, JH; Ma, SL; Li, Z; Yu, W; Zhou, P; Ye, X; Islam, MS; Zhang, YA; Zhou, Y; Li, JQ				Li, Jihong; Ma, Shilin; Li, Zhi; Yu, Wei; Zhou, Peng; Ye, Xiang; Islam, Md. Sharifull; Zhang, Yong-An; Zhou, Yang; Li, Jinquan			Construction and Characterization of an Aeromonas hydrophila Multi-Gene Deletion Strain and Evaluation of Its Potential as a Live-Attenuated Vaccine in Grass Carp	VACCINES			English	Article						Aeromonas hydrophila; live-attenuated vaccine; virulence; grass carp; immune response	HEMOLYTIC TOXIN GENES; DNA VACCINE; VIRULENCE; FISH; IMMUNITY; IMMUNOGENICITY; PATHOGENICITY; ENTEROTOXIN; RESISTANCE; RESPONSES	Aeromonas hydrophila is an important pathogen that causes motile Aeromonas septicemia (MAS) in the aquaculture industry. Aerolysin, hemolysin, serine protease and enterotoxins are considered to be the major virulence factors of A. hydrophila. In this study, we constructed a five-gene (aerA, hly, ahp, alt and ast) deletion mutant strain (named Aeromonas hydrophila five-gene deletion strain, AHFGDS) to observe the biological characteristics and detect its potential as a live-attenuated vaccine candidate. AHFGDS displayed highly attenuated and showed increased susceptibility to fish blood and skin mucus killing, while the wild-type strain ZYAH72 was highly virulent. In zebrafish (Danio rerio), AHFGDS showed a 240-fold higher 50% lethal dose (LD50) than that of the wild-type strain. Immunization with AHFGDS by intracelomic injection or immersion routes both provided grass carp (Ctenopharyngodon idella) significant protection against the challenge of the strain ZYAH72 or J-1 and protected the fish organs from serious injury. Further agglutinating antibody titer test supported that AHFGDS could elicit a host-adaptive immune response. These results suggested the potential of AHFGDS to serve as a live-attenuated vaccine to control A. hydrophila infection in aquaculture.	[Li, Jihong; Ma, Shilin; Yu, Wei; Zhou, Peng; Ye, Xiang; Zhang, Yong-An; Zhou, Yang] Huazhong Agr Univ, Coll Fisheries, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China; [Li, Jihong; Zhang, Yong-An] Chinese Acad Sci, Inst Hydrobiol, Wuhan 430070, Peoples R China; [Li, Zhi; Islam, Md. Sharifull; Li, Jinquan] Huazhong Agr Univ, Coll Food Sci & Technol, Wuhan 430070, Peoples R China; [Islam, Md. Sharifull] Huazhong Agr Univ, Coll Vet Med, Wuhan 430070, Peoples R China; [Zhang, Yong-An; Zhou, Yang] Minist Educ, Engn Res Ctr Green Dev Convent Aquat Biol Ind Yan, Wuhan 430070, Peoples R China		Zhou, Y (通讯作者)，Huazhong Agr Univ, Coll Fisheries, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China.; Zhou, Y (通讯作者)，Minist Educ, Engn Res Ctr Green Dev Convent Aquat Biol Ind Yan, Wuhan 430070, Peoples R China.	lijihong@ihb.ac.cn; msldzh-6265@webmail.hzau.edu.cn; mli_zhi@webmail.hzau.edu.cn; bigfishyoo@webmail.hzau.edu.cn; zhoupeng92@webmail.hzau.edu.cn; 2020202040147@whu.edu.cn; sharif@mail.hzau.edu.cn; yonganzhang@mail.hzau.edu.cn; zhouyang@mail.hzau.edu.cn; lijinquan@mail.hzau.edu.cn		Zhang, Yong-An/0000-0002-9956-3879	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31772889, 32073022, 31930114]; Special Fund for Technology Innovation of Hubei Province [2019AHB074]	The study was supported by the National Natural Science Foundation of China (31772889, 32073022 and 31930114), Special Fund for Technology Innovation of Hubei Province: 2019AHB074.	Acar U, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00596; Aguilera-Arreola MG, 2007, CAN J MICROBIOL, V53, P877, DOI 10.1139/W07-051; Balebona MC, 1998, APPL ENVIRON MICROB, V64, P4269; Bogwald J, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120627; Cao YS, 2020, AQUACULTURE, V523, DOI 10.1016/j.aquaculture.2020.735193; Chopra AK, 2000, INFECT IMMUN, V68, P2808, DOI 10.1128/IAI.68.5.2808-2818.2000; Detmer A, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-23; DOOLEY JSG, 1988, J BACTERIOL, V170, P499, DOI 10.1128/jb.170.2.499-506.1988; El-Bahar HM, 2019, INT MICROBIOL, V22, P479, DOI 10.1007/s10123-019-00075-3; Embregts CWE, 2016, DEV COMP IMMUNOL, V64, P118, DOI 10.1016/j.dci.2016.03.024; Fernandez-Bravo A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010129; Galindo Cristi L., 2006, Current Immunology Reviews, V2, P13, DOI 10.2174/157339506775471910; Han BQ, 2019, FISH SHELLFISH IMMUN, V84, P948, DOI 10.1016/j.fsi.2018.10.065; Heuzenroeder MW, 1999, FEMS MICROBIOL LETT, V174, P131, DOI 10.1016/S0378-1097(99)00130-5; Jiang XY, 2016, VACCINE, V34, P3087, DOI 10.1016/j.vaccine.2016.04.075; Kang HY, 2002, J BACTERIOL, V184, P307, DOI 10.1128/JB.184.1.307-312.2002; Kang SM, 2009, MOL CELLS, V27, P5, DOI 10.1007/s10059-009-0015-1; Kaskhedikar M., 2010, FOOD MICROBIOL, V28, P157; Kennedy MJ, 1999, INFECT IMMUN, V67, P4628, DOI 10.1128/IAI.67.9.4628-4636.1999; Klemm D.J., 1993, GUIDANCE ASSESSING C; Li J, 2011, J APPL MICROBIOL, V110, P823, DOI 10.1111/j.1365-2672.2011.04944.x; Li J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010040; Lin C, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918-014-0116-0; Liu L, 2016, FISH SHELLFISH IMMUN, V55, P516, DOI 10.1016/j.fsi.2016.06.026; Liu YJ, 2007, PREV VET MED, V78, P79, DOI 10.1016/j.prevetmed.2006.09.004; Magnadottir B, 2010, MAR BIOTECHNOL, V12, P361, DOI 10.1007/s10126-010-9279-x; Marshall BM, 2011, CLIN MICROBIOL REV, V24, P718, DOI 10.1128/CMR.00002-11; Merino S, 2006, FEMS MICROBIOL LETT, V263, P127, DOI 10.1111/j.1574-6968.2006.00403.x; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Munang'andu HM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00427; Mzula A, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3768948; Pang MB, 2015, SCI REP-UK, V5, DOI 10.1038/srep09833; Parrino V, 2020, NAT PROD RES, V34, P3226, DOI 10.1080/14786419.2018.1550769; Patil HJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01875; Pridgeon JW, 2012, J APPL MICROBIOL, V113, P1319, DOI 10.1111/j.1365-2672.2012.05430.x; Rao YV, 2006, FISH SHELLFISH IMMUN, V20, P263, DOI 10.1016/j.fsi.2005.04.006; Rasmussen-Ivey CR, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01615; SANTOS Y, 1988, INFECT IMMUN, V56, P3285, DOI 10.1128/IAI.56.12.3285-3293.1988; Schmitz ML, 2011, BBA-MOL CELL RES, V1813, P2165, DOI 10.1016/j.bbamcr.2011.06.019; Sha J, 2002, INFECT IMMUN, V70, P1924, DOI 10.1128/IAI.70.4.1924-1935.2002; Shoemaker CA, 2018, FISH SHELLFISH IMMUN, V82, P239, DOI 10.1016/j.fsi.2018.08.040; Song XH, 2014, AQUACULTURE, V434, P171, DOI 10.1016/j.aquaculture.2014.08.015; Swain P, 2010, VACCINE, V28, P4626, DOI 10.1016/j.vaccine.2010.04.078; Wang QC, 2020, FISH SHELLFISH IMMUN, V96, P223, DOI 10.1016/j.fsi.2019.12.010; Wong CYF, 1998, MICROBIOL-SGM, V144, P291, DOI 10.1099/00221287-144-2-291; Xie Q, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny218	46	1	1	13	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							451	10.3390/vaccines9050451			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1MG	34063680	Green Published			2022-04-29	WOS:000654589600001
J	Nohl, A; Afflerbach, C; Lurz, C; Brune, B; Ohmann, T; Weichert, V; Zeiger, S; Dudda, M				Nohl, Andre; Afflerbach, Christian; Lurz, Christian; Brune, Bastian; Ohmann, Tobias; Weichert, Veronika; Zeiger, Sascha; Dudda, Marcel			Acceptance of COVID-19 Vaccination among Front-Line Health Care Workers: A Nationwide Survey of Emergency Medical Services Personnel from Germany	VACCINES			English	Article						EMS; COVID-19; Corona; vaccination; front-line; health-care workers; emergency medical services; hesitancy; SARS-CoV-2	INFLUENZA VACCINATION; KNOWLEDGE; HESITANCY; TRANSMISSION; ATTITUDES	Introduction: The aim of this study was to evaluate the COVID-19 vaccination acceptance of emergency medical services (EMS) personnel as front-line health care workers (HCW) in Germany. Several studies have shown low willingness for vaccination (e.g., seasonal influenza) among HCWs and EMS personnel. Methods: We created a web-based survey. The questions were closed and standardized. Demographic data were collected (age, sex, federal state, profession). Experience with own COVID-19 infection, or infection in personal environment (family, friends) as well as willingness to vaccinate was queried. Results: The sample includes n = 1296 participants. A willingness to be vaccinated exists in 57%, 27.6% participants were undecided. Our results show a higher propensity to vaccinate among the following groups: male gender, higher medical education level, older age, own burden caused by the pandemic (p < 0.001). Conclusions: Due to the low overall acceptance of vaccination by HCWs, we recommend that the groups with vaccination hesitancy, in particular, be recruited for vaccination through interventions such as continuing education and awareness campaigns.	[Nohl, Andre; Afflerbach, Christian; Lurz, Christian] Fire Brigade Oberhausen, Emergency Med Serv, D-46047 Oberhausen, Germany; [Nohl, Andre; Zeiger, Sascha] BG Klinikum Duisburg, Dept Emergency Med, D-47249 Duisburg, Germany; [Nohl, Andre; Weichert, Veronika; Zeiger, Sascha; Dudda, Marcel] Helicopter Emergency Med Serv, D-47249 Duisburg, Germany; [Afflerbach, Christian] Evangel Krankenhaus, Dept Anesthesiol & Crit Care, D-46047 Oberhausen, Germany; [Brune, Bastian; Dudda, Marcel] Univ Hosp Essen, Dept Trauma Hand & Reconstruct Surg, D-45147 Essen, Germany; [Brune, Bastian; Dudda, Marcel] Fire Brigade Essen, Emergency Med Serv, D-45139 Essen, Germany; [Ohmann, Tobias] BG Klinikum Duisburg, Dept Res, D-47249 Duisburg, Germany; [Weichert, Veronika; Dudda, Marcel] BG Klinikum Duisburg, Dept Trauma Surg, D-47249 Duisburg, Germany; [Zeiger, Sascha] Fire Brigade Duisburg, Emergency Med Serv, D-47058 Duisburg, Germany		Dudda, M (通讯作者)，Helicopter Emergency Med Serv, D-47249 Duisburg, Germany.; Dudda, M (通讯作者)，Univ Hosp Essen, Dept Trauma Hand & Reconstruct Surg, D-45147 Essen, Germany.; Dudda, M (通讯作者)，Fire Brigade Essen, Emergency Med Serv, D-45139 Essen, Germany.; Dudda, M (通讯作者)，BG Klinikum Duisburg, Dept Trauma Surg, D-47249 Duisburg, Germany.	andre.nohl@bg-klinikum-duisburg.de; christian.afflerbach@oberhausen.de; christian.lurz@oberhausen.de; bastian.brune@uk-essen.de; tobias.ohmann@bg-klinikum-duisburg.de; veronika.weichert@bg-klinikum-duisburg.de; Sascha.Zeiger@bg-klinikum-duisburg.de; marcel.dudda@uk-essen.de	Ohmann, Tobias/AAB-9584-2022; Dudda, Marcel/AFV-5428-2022	Nohl, Andre/0000-0002-5106-4894; Dudda, Marcel/0000-0001-6641-5506	Open Access Publication Fund of the University of Duisburg-Essen	We acknowledge the support of the Open Access Publication Fund of the University of Duisburg-Essen.	Al-Tawil M M, 2013, Int J Risk Saf Med, V25, P135, DOI 10.3233/JRS-130592; Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; [Anonymous], Predictors of Seasonal Influenza Vaccination among Healthcare Workers in Hospitals: A Descriptive Meta-Analysis|Occupational & Environmental Medicine; [Anonymous], Wir Sind zum Handeln Gezwungen; [Anonymous], Impfbereitschaft Gegen Corona Nimmt in Europa ab; [Anonymous], Synthesis of the Major Realisations in EPI Communication for West and Central Francophone African Countries; [Anonymous], Rettungsdienste-Sozialversicherungspflichtig Beschaftigte in Deutschland bis 2020; [Anonymous], TA-8-2018-0188_EN.pdf; [Anonymous], 2020, HARV KENNEDY SCH MIS, DOI DOI 10.37016/MR-2020-38; [Anonymous], GERMAN NATL COVID 19, P2; [Anonymous], COVID-19 Fatalities among EMS Clinicians; Al Vwaidy ST, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040661; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Barry M, 2021, VACCINE, V39, P5762, DOI 10.1016/j.vaccine.2021.08.083; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bridgman A., 2020, COVID 19 MISINFORMAT, V1, DOI [10.37016/mr-2020-028, DOI 10.37016/MR-2020-028]; Caban-Martinez AJ, 2020, OCCUP ENVIRON MED, V77, P857, DOI 10.1136/oemed-2020-106676; Chen N., 2020, The Lancet, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Ciftci F, 2018, HUM VACC IMMUNOTHER, V14, P111, DOI 10.1080/21645515.2017.1387703; Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14; Ajenjo MC, 2010, INFECT CONT HOSP EP, V31, P233, DOI 10.1086/650449; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Aguilar-Diaz FD, 2011, ARCH MED RES, V42, P652, DOI 10.1016/j.arcmed.2011.12.006; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eysenbach G, 2020, J MED INTERNET RES, V22, DOI 10.2196/21820; Galvao J, 2021, LANCET INFECT DIS, V21, pE114, DOI 10.1016/S1473-3099(20)30721-0; Guthmann JP, 2012, VACCINE, V30, P4648, DOI 10.1016/j.vaccine.2012.04.098; Hagebusch P, 2020, NOTFALL RETTUNGSMED, V23, P604, DOI 10.1007/s10049-020-00679-7; Hamouda O., 2020, ERFASSUNG SARS COV 2; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Harris K, 2011, VACCINE, V29, P2978, DOI 10.1016/j.vaccine.2011.01.112; Harrison N, 2016, HUM VACC IMMUNOTHER, V12, P2459, DOI 10.1080/21645515.2016.1168959; Hubble MW, 2011, PREHOSP EMERG CARE, V15, P175, DOI 10.3109/10903127.2010.541982; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Lapolla P, 2021, INFECT CONT HOSP EP, V42, P364, DOI 10.1017/ice.2020.241; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Mercier H., 2020, SHARP RISE VACCINE H; Morawska L, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105832; Moser A, 2016, PREHOSP DISASTER MED, V31, P155, DOI 10.1017/S1049023X16000121; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Online-Redaktion, ONLINE REDAKTION; Papageorgiou AC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112343; Pichon M, 2019, J CLIN VIROL, V116, P29, DOI 10.1016/j.jcv.2019.04.008; Pruss BM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010030; Roessler M, 2006, RESUSCITATION, V68, P45, DOI 10.1016/j.resuscitation.2005.08.004; Roth K, 2022, GESUNDHEITSWESEN, V84, P199, DOI 10.1055/a-1276-0817; Sassano Michele, 2019, Ig Sanita Pubbl, V75, P158; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Spleen AM, 2012, J CANCER EDUC, V27, P312, DOI 10.1007/s13187-011-0294-z; Staff J., 2020, ETHICS PPE EMS COVID; Stitzer ML, 2010, DRUG ALCOHOL DEPEN, V107, P76, DOI 10.1016/j.drugalcdep.2009.09.006; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Tumban E, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010054; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang L, 2020, HUM VACC IMMUNOTHER, V16, P1498, DOI 10.1080/21645515.2019.1690331; Wang LX, 2007, B WORLD HEALTH ORGAN, V85, P688, DOI 10.2471/BLT.06.037002; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3; Yang X., 2020, Lancet Respir Med, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	70	26	26	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							424	10.3390/vaccines9050424			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LO	33922812	Green Published, gold			2022-04-29	WOS:000654587800001
J	Rabaan, AA; Al-Ahmed, SH; Muhammad, J; Khan, A; Sule, AA; Tirupathi, R; Al Mutair, A; Alhumaid, S; Al-Omari, A; Dhawan, M; Tiwari, R; Sharun, K; Mohapatra, RK; Mitra, S; Bilal, M; Alyami, SA; Bin Emran, T; Moni, MA; Dhama, K				Rabaan, Ali A.; Al-Ahmed, Shamsah H.; Muhammad, Javed; Khan, Amjad; Sule, Anupam A.; Tirupathi, Raghavendra; Al Mutair, Abbas; Alhumaid, Saad; Al-Omari, Awad; Dhawan, Manish; Tiwari, Ruchi; Sharun, Khan; Mohapatra, Ranjan K.; Mitra, Saikat; Bilal, Muhammad; Alyami, Salem A.; Bin Emran, Talha; Moni, Mohammad Ali; Dhama, Kuldeep			Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm	VACCINES			English	Review						COVID-19; inflammatory cytokines; cytokine storm; immunopathology; genomics; immunomodulatory drugs	RESPIRATORY-DISTRESS-SYNDROME; CONVERTING ENZYME; MAIN PROTEASE; SARS-COV; CORONAVIRUS; SARS-COV-2; DISEASE; PATHOGENESIS; INFECTION; MACROPHAGE	Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious tentacles of the disease have been disseminated worldwide with unknown complications and repercussions. Advanced COVID-19 syndrome is characterized by the uncontrolled and elevated release of pro-inflammatory cytokines and suppressed immunity, leading to the cytokine storm. The uncontrolled and dysregulated secretion of inflammatory and pro-inflammatory cytokines is positively associated with the severity of the viral infection and mortality rate. The secretion of various pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6 leads to a hyperinflammatory response by recruiting macrophages, T and B cells in the lung alveolar cells. Moreover, it has been hypothesized that immune cells such as macrophages recruit inflammatory monocytes in the alveolar cells and allow the production of large amounts of cytokines in the alveoli, leading to a hyperinflammatory response in severely ill patients with COVID-19. This cascade of events may lead to multiple organ failure, acute respiratory distress, or pneumonia. Although the disease has a higher survival rate than other chronic diseases, the incidence of complications in the geriatric population are considerably high, with more systemic complications. This review sheds light on the pivotal roles played by various inflammatory markers in COVID-19-related complications. Different molecular pathways, such as the activation of JAK and JAK/STAT signaling are crucial in the progression of cytokine storm; hence, various mechanisms, immunological pathways, and functions of cytokines and other inflammatory markers have been discussed. A thorough understanding of cytokines' molecular pathways and their activation procedures will add more insight into understanding immunopathology and designing appropriate drugs, therapies, and control measures to counter COVID-19. Recently, anti-inflammatory drugs and several antiviral drugs have been reported as effective therapeutic drug candidates to control hypercytokinemia or cytokine storm. Hence, the present review also discussed prospective anti-inflammatory and relevant immunomodulatory drugs currently in various trial phases and their possible implications.	[Rabaan, Ali A.] Johns Hopkins Aramco Healthcare, Mol Diagnost Lab, Dhahran 31311, Saudi Arabia; [Al-Ahmed, Shamsah H.] Qatif Cent Hosp, Specialty Paediat Med, Qatif 32654, Saudi Arabia; [Muhammad, Javed] Univ Haripur, Dept Microbiol, Khyber Pakhtunkhwa 22620, Pakistan; [Khan, Amjad] Univ Haripur, Dept Publ Hlth Nutr, Khyber Pakhtunkhwa 22620, Pakistan; [Sule, Anupam A.] St Joseph Mercy Oakland, Informat & Outcomes, Pontiac, MI 48341 USA; [Tirupathi, Raghavendra] Penn State Univ, Dept Med Keystone Hlth, Sch Med, Hershey, PA 16801 USA; [Tirupathi, Raghavendra] Wellspan Chambersburg & Waynesboro Pa Hosp, Dept Med, Chambersburg, PA 16801 USA; [Al Mutair, Abbas] Almoosa Specialist Hosp, Res Ctr, Alahsa 36342, Saudi Arabia; [Al Mutair, Abbas] Prince Nora Univ, Coll Nursing, Riyadh 11564, Saudi Arabia; [Al Mutair, Abbas] Wollongong Univ, Sch Nursing, Wollongong, NSW 2522, Australia; [Alhumaid, Saad] Minist Hlth, Adm Pharmaceut Care, Alahsa 31982, Saudi Arabia; [Al-Omari, Awad] Alfaisal Univ, Coll Med, Riyadh 11533, Saudi Arabia; [Al-Omari, Awad] Dr Sulaiman Al Habib Med Grp, Crit Care & Infect Control Dept, Res Ctr, Riyadh 11372, Saudi Arabia; [Dhawan, Manish] Punjab Agr Univ, Dept Microbiol, Ludhiana 141027, Punjab, India; [Dhawan, Manish] Trafford Grp Coll, Manchester WA14 5PQ, Lancs, England; [Tiwari, Ruchi] Pandit DeenDayal Upadhyaya PashuChikitsa Vigyan V, Coll Vet Sci, Dept Vet Microbiol & Immunol, Mathura 281001, Uttar Pradesh, India; [Sharun, Khan] ICAR Indian Vet Res Inst, Div Surg, Bareilly 243122, Uttar Pradesh, India; [Mohapatra, Ranjan K.] Govt Coll Engn, Dept Chem, Keonjhar 758002, Odisha, India; [Mitra, Saikat] Univ Dhaka, Fac Pharm, Dept Pharm, Dhaka 1000, Bangladesh; [Bilal, Muhammad] Huaiyin Inst Technol, Sch Life Sci & Food Engn, Huaian 223003, Peoples R China; [Alyami, Salem A.] Imam Mohammad Ibn Saud Islamic Univ, Dept Math & Stat, Riyadh 11432, Saudi Arabia; [Bin Emran, Talha] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh; [Moni, Mohammad Ali] UNSW Sydney, WHO Collaborating Ctr eHlth, UNSW Digital Hlth, Sch Publ Hlth & Community Med,Fac Med, Sydney, NSW 2052, Australia; [Dhama, Kuldeep] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India		Moni, MA (通讯作者)，UNSW Sydney, WHO Collaborating Ctr eHlth, UNSW Digital Hlth, Sch Publ Hlth & Community Med,Fac Med, Sydney, NSW 2052, Australia.; Dhama, K (通讯作者)，ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.	ali.rabaan@jhah.com; shalahmed@moh.gov.sa; javed.muhammad@uoh.edu.pk; dramjadkhan77@uoh.edu.pk; anupam.a.sule@stjoeshealth.org; drraghutg@gmail.com; abbas.almutair@almoosahospital.com.sa; saalhumaid@moh.gov.sa; awad.omari@drsulaimanalhabib.com; dhawanmanish501@gmail.com; ruchi.vet@gmail.com; sharunkhansk@gmail.com; rkmohapatra@gcekjr.ac.in; saikat-2018926336@pharmacy.du.ac.bd; bilaluaf@hyit.edu.cn; saalyami@imamu.edu.sa; talhabmb@bgctub.ac.bd; m.moni@unsw.edu.au; kdhama@rediffmail.com	Bilal, Muhammad/AAH-6461-2020; Mohapatra, Ranjan Kumar/S-6006-2019; Dhama, Kuldeep/B-7852-2015; Tiwari, Ruchi/ABG-9049-2021; Dhawan, Manish/AAH-4136-2021; Sharun, Khan/A-3084-2019; Bin Emran, Talha/P-9184-2016; Mitra, Saikat/ABB-8535-2021	Bilal, Muhammad/0000-0001-5388-3183; Dhama, Kuldeep/0000-0001-7469-4752; Tiwari, Ruchi/0000-0001-7763-5547; Dhawan, Manish/0000-0002-7783-7138; Sharun, Khan/0000-0003-1040-3746; Bin Emran, Talha/0000-0003-3188-2272; Mitra, Saikat/0000-0002-9502-0252; Rabaan, Ali/0000-0002-6774-9847; Muhammad, Javed/0000-0002-2785-8985; Sule, Anupam/0000-0002-5931-3381; ALHUMAID, SAAD/0000-0003-4552-4513; Moni, Mohammad Ali/0000-0003-0756-1006	Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU), Saudi Arabia [21-13-18-029]	This research was supported by the Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU), Saudi Arabia, Grant No. (21-13-18-029).	Arumugam VA, 2020, J PURE APPL MICROBIO, V14, P1623, DOI 10.22207/JPAM.14.3.01; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4; Bilal M., 2020, Journal of Experimental Biology and Agricultural Sciences, V8, pS190, DOI 10.18006/2020.8(Spl-1-SARS-CoV-2).S190.S201; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Brisse E, 2016, BRIT J HAEMATOL, V174, P203, DOI 10.1111/bjh.14147; Brocker Chad, 2010, Human Genomics, V5, P30; Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006; Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102; Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1; Capochiani E, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00466; Capodice JL, 2021, CHIN MED-UK, V16, DOI 10.1186/s13020-020-00419-6; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]; Chen Y, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00230-x; Chi Y, 2020, J INFECT DIS, V222, P746, DOI 10.1093/infdis/jiaa363; Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x; Chowdhury KH, 2021, BIOLOGY-BASEL, V10, DOI [10.3390/biology10010002, 10.3390/biology10010002/]; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Chugh H, 2021, EUR J PHARMACOL, V890, DOI 10.1016/j.ejphar.2020.173741; Coperchini F, 2021, CYTOKINE GROWTH F R, V58, P82, DOI 10.1016/j.cytogfr.2020.12.005; Coperchini F, 2019, ENDOCR-RELAT CANCER, V26, pR465, DOI 10.1530/ERC-19-0163; Dastoli S, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13681; De Backer D, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03360-0; Dhama K, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101755; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Dhama K, 2018, CURR DRUG METAB, V19, P236, DOI 10.2174/1389200219666180129145252; Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Douda DN, 2011, J IMMUNOL, V187, P1856, DOI 10.4049/jimmunol.1004201; Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3; Ebrahimi N, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107082; Epelman S, 2008, J AM COLL CARDIOL, V52, P750, DOI 10.1016/j.jacc.2008.02.088; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fara A, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200160; Fathi M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246190; Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8; Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC; Fensterl V, 2009, BIOFACTORS, V35, P14, DOI 10.1002/biof.6; Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432; FERRARA JLM, 1993, TRANSPLANT P, V25, P1216; Filbin MR, 2018, CRIT CARE MED, V46, P1592, DOI 10.1097/CCM.0000000000003260; Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001; Friedman RM, 2008, BRIT J CLIN PHARMACO, V65, P158, DOI 10.1111/j.1365-2125.2007.03055.x; Gangur V, 2002, VET IMMUNOL IMMUNOP, V86, P127, DOI 10.1016/S0165-2427(02)00018-1; Gao YM, 2021, J INTERN MED, V289, P147, DOI 10.1111/joim.13144; Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770; Gasparello J, 2021, MED HYPOTHESES, V146, DOI 10.1016/j.mehy.2020.110415; Gomez-Rios D., 2020, Journal of Applied Pharmaceutical Science, V10, P1, DOI 10.7324/JAPS.2020.10501; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Gupta A, 2020, HUM VACC IMMUNOTHER, V16, P2963, DOI 10.1080/21645515.2020.1808410; Gustine JN, 2021, AM J PATHOL, V191, P4, DOI 10.1016/j.ajpath.2020.08.009; Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921; Haberle H, 2021, J INTENSIVE CARE MED, V36, P681, DOI 10.1177/0885066621997365; Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; He SS, 2021, ENVIRON CHEM LETT, V19, P763, DOI 10.1007/s10311-020-01140-4; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang C, 2020, Lancet, V395, P497; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L; Iannone LF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241575; Iqbal M. S., 2020, Journal of Experimental Biology and Agricultural Sciences, V8, pS87, DOI 10.18006/2020.8(Spl-1-SARS-CoV-2).S87.S102; Iqbal M. S., 2020, Journal of Experimental Biology and Agricultural Sciences, V8, pS66, DOI 10.18006/2020.8(Spl-1-SARS-CoV-2).S66.S78; Yatoo MI, 2021, HUM VACC IMMUNOTHER, V17, P1897, DOI 10.1080/21645515.2020.1871295; Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567; Jeyaraman M, 2021, BBA-MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2020.166014; Jiao XM, 2019, CANCER RES, V79, P4801, DOI 10.1158/0008-5472.CAN-19-1167; Kaplon H, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1703531; Keam S, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2123; Khosroshahi LM, 2021, INT IMMUNOPHARMACOL, V93, DOI 10.1016/j.intimp.2020.107364; Kopf M, 2010, NAT REV DRUG DISCOV, V9, P703, DOI 10.1038/nrd2805; Kotliar D, 2019, ELIFE, V8, DOI 10.7554/eLife.43803; Kupani M, 2021, J CELL PHYSIOL, V236, P2255, DOI 10.1002/jcp.30029; Lakoh S., 2021, RESEARCH-CHINA, V146, P2110, DOI [10.21203/rs.3.rs-30474/v1, DOI 10.21203/RS.3.RS-30474/V1]; Lam Christopher W K, 2004, Clin Biochem Rev, V25, P121; Lam G, 2021, WORLD J STEM CELLS, V13, P139, DOI 10.4252/wjsc.v13.i2.139; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lauring AS, 2021, JAMA-J AM MED ASSOC, V325, P529, DOI 10.1001/jama.2020.27124; Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554; Lee K, 2009, GLOB INST, P1; Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374; Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761; Liu S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01678-8; Lu LG, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00677; Lu YY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00496-5; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Mahmud S, 2021, BRIEF BIOINFORM, V22, P1402, DOI 10.1093/bib/bbaa428; Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151; Malik YS, 2020, HUM VACC IMMUNOTHER, V16, P2954, DOI 10.1080/21645515.2020.1818522; Manish Dhawan, 2021, Journal of Applied Pharmaceutical Science, V11, P6, DOI 10.7324/JAPS.2021.110402; Marchingo JM, 2020, ELIFE, V9, DOI 10.7554/eLife.53725; Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472; Mattos-Silva P, 2020, RESP PHYSIOL NEUROBI, V280, DOI 10.1016/j.resp.2020.103492; McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Metcalfe Su M, 2020, Med Drug Discov, V5, P100019, DOI 10.1016/j.medidd.2020.100019; Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359; Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Moradimajd P, 2021, J MED VIROL, V93, P2675, DOI 10.1002/jmv.26727; Mustafa MI, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8198963; Nelson BN, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00037; Nguyen LS, 2021, INTENS CARE MED, V47, P619, DOI 10.1007/s00134-021-06377-3; Olejnik J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007390; Osterholm MT, 2005, FOREIGN AFF, V84, P24, DOI 10.2307/20034418; Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC; Pasrija R, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107225; Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3; Peng X, 2021, CARDIOVASC DRUG THER, V35, P231, DOI 10.1007/s10557-020-07120-8; Pottoo FH, 2021, SAUDI PHARM J, V29, P173, DOI 10.1016/j.jsps.2020.12.018; Prokunina-Olsson L, 2020, J EXP MED, V217, DOI 10.1084/jem.20200653; Pum A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010091; Qamar SA, 2020, J PURE APPL MICROBIO, V14, P1695, DOI 10.22207/JPAM.14.3.08; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767; Rabaan AA, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00384-w; Rakib A, 2021, BRIEF BIOINFORM, V22, P1476, DOI 10.1093/bib/bbab045; Rakib A, 2020, MOLECULES, V25, DOI 10.3390/molecules25215088; Rakib A, 2020, MOLECULES, V25, DOI 10.3390/molecules25173936; Rakib A, 2020, COMPUT BIOL MED, V124, DOI 10.1016/j.compbiomed.2020.103967; Rayman G, 2021, DIABETIC MED, V38, DOI 10.1111/dme.14378; Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2; Reyes M, 2020, NAT MED, V26, P333, DOI 10.1038/s41591-020-0752-4; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Richardson PJ, 2020, LANCET INFECT DIS, V20, P1013, DOI 10.1016/S1473-3099(20)30270-X; Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z; Rockx B, 2009, J VIROL, V83, P7062, DOI 10.1128/JVI.00127-09; Roe K, 2020, TRANSBOUND EMERG DIS, V67, P1414, DOI 10.1111/tbed.13594; Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554; Romero C, 2015, NAT REV ENDOCRINOL, V11, P242, DOI 10.1038/nrendo.2015.6; Rotondi M, 2007, ENDOCR REV, V28, P492, DOI 10.1210/er.2006-0044; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Sadeghi S, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118493; Sajna KV, 2021, CYTOTHERAPY, V23, P101, DOI 10.1016/j.jcyt.2020.08.009; Schulert GS, 2015, ANNU REV MED, V66, P145, DOI 10.1146/annurev-med-061813-012806; Scicluna BP, 2019, AM J RESP CRIT CARE, V199, P936, DOI 10.1164/rccm.201811-2148ED; Sellner J, 2020, EUR J NEUROL, V27, pE31, DOI 10.1111/ene.14257; Sepriano A, 2020, ANN RHEUM DIS, V79, P760, DOI 10.1136/annrheumdis-2019-216653; Sharun K, 2021, VET QUART, V41, P50, DOI 10.1080/01652176.2020.1867776; Sharun K, 2020, INT J SURG, V82, P179, DOI 10.1016/j.ijsu.2020.08.038; Sharun K, 2020, HUM VACC IMMUNOTHER, V16, P3043, DOI 10.1080/21645515.2020.1807802; Sharun K, 2020, EXPERT OPIN BIOL TH, V20, P1033, DOI 10.1080/14712598.2020.1796963; Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909; Shi MY, 2021, J INTEGR MED-JIM, V19, P226, DOI 10.1016/j.joim.2021.01.002; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Sly LM, 2020, INT J CLIN PHARM TH, V58, P678, DOI 10.5414/CP203890; Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756; Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017; Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002; Sweeney TE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03078-2; Tahmasbi SF, 2021, NURS CLIN N AM, V56, P79, DOI 10.1016/j.cnur.2020.10.007; Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020; Teijaro JR, 2014, P NATL ACAD SCI USA, V111, P3799, DOI 10.1073/pnas.1400593111; TIAN S, 2020, J THORAC ONCOL, V1556, P30132; Tiberio L, 2018, CELL MOL IMMUNOL, V15, P346, DOI 10.1038/s41423-018-0005-3; Tiwari R, 2018, CURR DRUG METAB, V19, P264, DOI 10.2174/1389200219666180129125436; Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246; Wan S., 2020, CHARACTERISTICS LYMP, DOI 10.1101/2020.02.10.20021832; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Wen F, 2020, J INFECTION, V80, P679, DOI 10.1016/j.jinf.2020.02.027; Wilk A.J., 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, DOI 10.1038/s41591-020-0944-y]; Xi YZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00310-8; Xiong J, 2021, CELL TRANSPLANT, V30, DOI 10.1177/0963689721995455; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015; Yao X H, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P411, DOI 10.3760/cma.j.cn112151-20200312-00193; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Yeleswaram S, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108517; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhang XH, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106749; Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017	182	35	35	7	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							436	10.3390/vaccines9050436			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1KU	33946736	Green Published, gold	Y	N	2022-04-29	WOS:000654585800001
J	Yu, ED; Grifoni, A; Sutherland, A; Voic, H; Wang, E; Frazier, A; Jimenez-Truque, N; Yoder, S; Welsh, S; Wooden, S; Koff, W; Creech, B; Sette, A; Antunes, RD				Yu, Esther Dawen; Grifoni, Alba; Sutherland, Aaron; Voic, Hannah; Wang, Eric; Frazier, April; Jimenez-Truque, Natalia; Yoder, Sandra; Welsh, Sabrina; Wooden, Stacey; Koff, Wayne; Creech, Buddy; Sette, Alessandro; da Silva Antunes, Ricardo			Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine	VACCINES			English	Article						T cells; protein immunodominance; cytokine polarization; influenza viruses; vaccine	ANTIBODY-RESPONSES; T-CELLS; PROTECTION; PATTERNS; CHILDREN	The role of T cell immunity has been acknowledged in recent vaccine development and evaluation. We tested the humoral and cellular immune responses to Flucelvax (R), a quadrivalent inactivated seasonal influenza vaccine containing two influenza A (H1N1 Singapore/GP1908/2015 IVR-180 and H3N2 North Carolina/04/2016) and two influenza B (Iowa/06/2017 and Singapore/INFTT-16-0610/2016) virus strains, using peripheral blood mononuclear cells stimulated by pools of peptides overlapping all the individual influenza viral protein components. Baseline reactivity was detected against all four strains both at the level of CD4 and CD8 responses and targeting different proteins. CD4 T cell reactivity was mostly directed to HA/NA proteins in influenza B strains, and NP/M1/M2/NS1/NEP proteins in the case of the Influenza A strains. CD8 responses to both influenza A and B viruses preferentially targeted the more conserved core viral proteins. Following vaccination, both CD4 and CD8 responses against the various influenza antigens were increased in day 15 to day 91 post vaccination period, and maintained a Th1 polarized profile. Importantly, no vaccine interference was detected, with the increased responses balanced across all four included viral strains for both CD4 and CD8 T cells, and targeting HA and multiple additional viral antigens.	[Yu, Esther Dawen; Grifoni, Alba; Sutherland, Aaron; Voic, Hannah; Wang, Eric; Frazier, April; Sette, Alessandro; da Silva Antunes, Ricardo] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA; [Jimenez-Truque, Natalia; Yoder, Sandra; Creech, Buddy] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Res Program, Nashville, TN 37232 USA; [Welsh, Sabrina; Koff, Wayne] Human Vaccines Project, New York, NY 10119 USA; [Wooden, Stacey] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Sette, Alessandro] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92037 USA		Sette, A; Antunes, RD (通讯作者)，La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA.; Sette, A (通讯作者)，Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92037 USA.	dyu@lji.org; agrifoni@lji.org; asutherland@lji.org; hannah.voic12@ncf.edu; ericwang@lji.org; afrazier@lji.org; natalia.jimenez@vumc.org; sandra.yoder@vumc.org; SWelsh@humanvaccinesproject.org; swooden@globalhealthalliance.org; wkoff@humanvaccinesproject.org; buddy.creech@vumc.org; alex@lji.org; rantunes@lji.org	Sette, Alessandro/AFO-8916-2022; Yu, Dawen/AAE-6444-2019; Grifoni, Alba/AAS-7620-2021	Yu, Dawen/0000-0002-3970-3753; Sutherland, Aaron/0000-0003-3772-5024; Wang, Eric/0000-0002-2378-9505; Frazier, April/0000-0002-4722-7304; da Silva Antunes, Ricardo/0000-0001-9785-5272	National Institute of Allergy and Infectious Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI142742]; Human Vaccines Project, Inc. (HVPI)	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI142742, as well as an award provided by the Human Vaccines Project, Inc. (HVPI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or HVPI.	[Anonymous], 2018, FLUC QUADR INFL VACC; [Anonymous], 2018, REC COMP INFL VIR VA; Antunes RD, 2021, CYTOKINE, V137, DOI 10.1016/j.cyto.2020.155313; Antunes RD, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8202067; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002; Bart S, 2016, HUM VACC IMMUNOTHER, V12, P2278, DOI 10.1080/21645515.2016.1182270; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461; CDC (Centers for Disease Control and Prevention) CDC (Centers for Disease Control and Prevention), 2016, ACIP VOT US LAIV 201; CDC (Centers for Disease Control and Prevention) CDC (Centers for Disease Control and Prevention), 2019, UPD INFL ACT US 2018; Chung JR, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3279; Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318; Dionne B, 2016, INFECT CONT HOSP EP, V37, P840, DOI 10.1017/ice.2016.77; Eichelberger MC, 2018, CURR OPIN IMMUNOL, V53, P38, DOI 10.1016/j.coi.2018.03.025; European Medicines Agency European Medicines Agency, 2018, FLUC TETR SUMMPROD C; Frey S, 2010, CLIN INFECT DIS, V51, P997, DOI 10.1086/656578; Greenshields-Watson A, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107885; Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC; He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06; Hensen L, 2020, FUTURE MICROBIOL, V15, P1045, DOI 10.2217/fmb-2019-0340; Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141; LAMB RA, 1983, ANNU REV BIOCHEM, V52, P467, DOI 10.1146/annurev.bi.52.070183.002343; Lamb YN, 2019, DRUGS, V79, P1337, DOI [10.1007/s40265-019-01176-z, 10.1007/s40265-019-01237-3]; Li ZRT, 2019, J VIROL, V93, DOI 10.1128/JVI.01534-18; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; MCMICHAEL AJ, 1981, CLIN EXP IMMUNOL, V43, P276; Nayak JL, 2013, J INFECT DIS, V207, P297, DOI 10.1093/infdis/jis684; Richards KA, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00227-x; Richards KA, 2020, J INFECT DIS, V222, P273, DOI 10.1093/infdis/jiz433; Sasaki S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002975; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Seqirus Inc. Holly Springs (NC) Seqirus Inc. Holly Springs (NC), 2018, FLUC QUADR INFL VACC; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; United States Census Bureau United States Census Bureau, 2019, QUICK FACTS TENN; Vidor E, 2007, J COMP PATHOL, V137, pS62, DOI 10.1016/j.jcpa.2007.04.014; Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289; Wooden SL, 2018, HUM VACC IMMUNOTHER, V14, P2214, DOI 10.1080/21645515.2018.1476813; Yam KK, 2013, CLIN VACCINE IMMUNOL, V20, P459, DOI 10.1128/CVI.00619-12; Zhang Y, 2017, NUCLEIC ACIDS RES, V45, pD466, DOI 10.1093/nar/gkw857	41	2	2	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							426	10.3390/vaccines9050426			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NO	33922875	gold, Green Submitted, Green Published			2022-04-29	WOS:000654593100001
J	Castro, LS; Lobo, GS; Pereira, P; Freire, MG; Neves, MC; Pedro, AQ				Castro, Leonor S.; Lobo, Guilherme S.; Pereira, Patricia; Freire, Mara G.; Neves, Marcia C.; Pedro, Augusto Q.			Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation	VACCINES			English	Review						Interferon; biopharmaceutical; recombinant DNA; production; purification; bioprocess development; formulation; excipient; drug delivery system; route of administration	RECOMBINANT PROTEIN EXPRESSION; HIGH-LEVEL EXPRESSION; HIGH-YIELD EXPRESSION; DRUG-DELIVERY SYSTEM; ESCHERICHIA-COLI; PICHIA-PASTORIS; FUSION PROTEIN; METHYLOTROPHIC YEAST; THERAPEUTIC PROTEINS; INCLUSION-BODIES	The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, and multiple sclerosis. Given their relevance and sustained market share, this review provides an overview on the evolution of interferon manufacture, comprising their production, purification, and formulation stages. Remarkable developments achieved in the last decades are herein discussed in three main sections: (i) an upstream stage, including genetically engineered genes, vectors, and hosts, and optimization of culture conditions (culture media, induction temperature, type and concentration of inducer, induction regimens, and scale); (ii) a downstream stage, focusing on single- and multiple-step chromatography, and emerging alternatives (e.g., aqueous two-phase systems); and (iii) formulation and delivery, providing an overview of improved bioactivities and extended half-lives and targeted delivery to the site of action. This review ends with an outlook and foreseeable prospects for underdeveloped aspects of biopharma research involving human interferons.	[Castro, Leonor S.; Lobo, Guilherme S.; Freire, Mara G.; Neves, Marcia C.; Pedro, Augusto Q.] Univ Aveiro, CICECO Aveiro Inst Mat, Chem Dept, Campus Univ Santiago, P-3810193 Aveiro, Portugal; [Pereira, Patricia] Univ Coimbra, Ctr Mech Engn Mat & Proc, Dept Chem Engn, Rua Silvio Lima Polo II, P-3030790 Coimbra, Portugal		Neves, MC; Pedro, AQ (通讯作者)，Univ Aveiro, CICECO Aveiro Inst Mat, Chem Dept, Campus Univ Santiago, P-3810193 Aveiro, Portugal.	l.castro@ua.pt; guilherme.lobo@ua.pt; nunespereirapatricia@gmail.com; maragfreire@ua.pt; mcneves@ua.pt; apedro@ua.pt	Pereira, Patrícia Alexandra/ABB-3354-2021; Neves, Márcia C./O-1691-2019; Freire, Mara/B-8458-2008	Neves, Márcia C./0000-0001-5611-4080; Castro, Leonor S./0000-0002-2183-3402; Pedro, Augusto/0000-0001-8194-6022; Freire, Mara/0000-0001-8895-0614; Pereira, Patricia/0000-0002-5665-5271	FEDER through COMPETE 2020-Programa Operacional Competitividade e Internacionalizacao (POCI); national funds (OE), through FCT/MCTES from the project "IL2BioPro" [PTDC/BII-BBF/30840/2017]; FCT/MCTESPortuguese Foundation for Science and TechnologyEuropean Commission [UIDB/50011/2020, UIDP/50011/2020, UID/EMS/00285/2020]; FEDER under the PT2020 Partnership Agreement; FCTPortuguese Foundation for Science and TechnologyEuropean Commission [2020/05090/BD];  [CEECIND/00383/2017]	This research was funded by FEDER through COMPETE 2020-Programa Operacional Competitividade e Internacionalizacao (POCI), and by national funds (OE), through FCT/MCTES from the project "IL2BioPro"-PTDC/BII-BBF/30840/2017. This work was developed within the scope of the projects CICECO-Aveiro Institute of Materials, UIDB/50011/2020 and UIDP/50011/2020, and CEMMPRE project UID/EMS/00285/2020, financed by national funds through FCT/MCTES and when appropriate co-financed by FEDER under the PT2020 Partnership Agreement. Marcia C. Neves acknowledges the research contract CEECIND/00383/2017, and Leonor S. Castro acknowledges FCT for her Ph.D. grant 2020/05090/BD.	Abd El-Baky N, 2015, PREP BIOCHEM BIOTECH, V45, P109, DOI 10.1080/10826068.2014.907175; Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; AlQahtani AD, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108750; Andersen JT, 2014, J BIOL CHEM, V289, P13492, DOI 10.1074/jbc.M114.549832; [Anonymous], 1980, NATURE, V286, P110; Ashnagar F, 2014, IRAN J BIOTECHNOL, V12, P26, DOI 10.15171/ijb.1157; Aslam MS, 2020, PREP BIOCHEM BIOTECH, V50, P281, DOI 10.1080/10826068.2019.1689509; Ayed A, 2008, ENZYME MICROB TECH, V42, P173, DOI 10.1016/j.enzmictec.2007.09.006; Babaeipour V, 2013, IRAN J PHARM RES, V12, P563; Bajracharya R, 2019, COMPUT STRUCT BIOTEC, V17, P1290, DOI 10.1016/j.csbj.2019.09.004; Bekisz J, 2010, PHARMACEUTICALS, V3, P994, DOI 10.3390/ph3040994; BOCCI V, 1984, CANC DRUG DEL, V1, P337, DOI 10.1089/cdd.1984.1.337; Bodratti AM, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010011; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Buckel P, 2001, MOLECULES, V6, P1063, DOI [10.3390/61201063, DOI 10.3390/61201063]; Caldorera-Moore M, 2019, J DRUG TARGET, V27, P582, DOI 10.1080/1061186X.2018.1547732; Canepa C, 2017, BIOMACROMOLECULES, V18, P3302, DOI 10.1021/acs.biomac.7b00959; Cao SJ, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1325-z; Cao Y, 2006, J CHROMATOGR B, V833, P236, DOI 10.1016/j.jchromb.2006.02.001; Castella L, 2020, AM J INFECT CONTROL, V48, P550, DOI 10.1016/j.ajic.2019.09.007; Castro LS, 2020, SEP PURIF TECHNOL, V248, DOI 10.1016/j.seppur.2020.117051; Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23; Dai J, 2018, DRUG DEV IND PHARM, V44, P89, DOI 10.1080/03639045.2017.1373803; Dashbolaghi A, 2015, TROP J PHARM RES, V14, P385, DOI 10.4314/tjpr.v14i3.5; De Leede LGJ, 2008, J INTERF CYTOK RES, V28, P113, DOI 10.1089/jir.2007.0073; Decker T, 2005, NAT REV IMMUNOL, V5, P675, DOI 10.1038/nri1684; Dutta RC, 2007, CURR PHARM DESIGN, V13, P761, DOI 10.2174/138161207780249119; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; Feczko T, 2016, NANOMEDICINE-UK, V11, P2029, DOI 10.2217/nnm-2016-0058; Foster GR, 2004, ALIMENT PHARM THER, V20, P825, DOI 10.1111/j.1365-2036.2004.02170.x; Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695; Gad HH, 2009, J BIOL CHEM, V284, P20869, DOI 10.1074/jbc.M109.002923; Gao F, 2013, APPL BIOCHEM MICRO+, V49, P11, DOI 10.1134/S0003683813010055; Garcia-Vega Y, 2012, BMC PHARMACOL TOXICO, V13, DOI 10.1186/2050-6511-13-20; Geng XD, 2004, J BIOTECHNOL, V113, P137, DOI 10.1016/j.jbiotec.2004.06.006; George PM, 2012, PHARMACOL THERAPEUT, V135, P44, DOI 10.1016/j.pharmthera.2012.03.006; Ghosalkar A, 2008, PROTEIN EXPRES PURIF, V60, P103, DOI 10.1016/j.pep.2008.02.006; Gibbert K, 2013, BRIT J PHARMACOL, V168, P1048, DOI 10.1111/bph.12010; Goncalves AM, 2013, J MICROBIOL BIOTECHN, V23, P587, DOI 10.4014/jmb.1210.10063; Gonzalez LF, 2021, J CONTROL RELEASE, V331, P443, DOI 10.1016/j.jconrel.2020.11.019; Graslund S, 2008, NAT METHODS, V5, P135, DOI 10.1038/nmeth.f.202; Graumann Klaus, 2006, Biotechnology Journal, V1, P164, DOI 10.1002/biot.200500051; Gu F, 2005, J CONTROL RELEASE, V102, P607, DOI 10.1016/j.jconrel.2004.10.020; Guan YX, 2005, BIOTECHNOL BIOPROC E, V10, P122, DOI 10.1007/BF02932581; Guiochon G, 2011, J CHROMATOGR A, V1218, P8836, DOI 10.1016/j.chroma.2011.09.008; Gulia M, 2014, ANTI-CANCER DRUG, V25, P63, DOI 10.1097/CAD.0000000000000026; Hanke AT, 2014, TRENDS BIOTECHNOL, V32, P210, DOI 10.1016/j.tibtech.2014.02.001; HAUPTMANN R, 1985, NUCLEIC ACIDS RES, V13, P4739, DOI 10.1093/nar/13.13.4739; Hernandez VEB, 2008, PROTEIN EXPRES PURIF, V59, P169, DOI 10.1016/j.pep.2008.01.019; Huang YS, 2007, EUR J PHARM BIOPHARM, V67, P301, DOI 10.1016/j.ejpb.2007.02.015; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jin T, 2005, WORLD J MICROB BIOT, V21, P797, DOI 10.1007/s11274-004-2181-9; Jiskoot W, 2012, J PHARM SCI-US, V101, P946, DOI 10.1002/jps.23018; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Joraholmen MW, 2017, EUR J PHARM BIOPHARM, V113, P132, DOI 10.1016/j.ejpb.2016.12.029; Jozala AF, 2016, BRAZ J MICROBIOL, V47, P51, DOI 10.1016/j.bjm.2016.10.007; Kamei N, 2009, J CONTROL RELEASE, V134, P98, DOI 10.1016/j.jconrel.2008.11.014; Karbalaei M, 2020, J CELL PHYSIOL, V235, P5867, DOI 10.1002/jcp.29583; Katla S, 2019, J APPL MICROBIOL, V126, P1438, DOI 10.1111/jam.14227; Kerwin BA, 2008, J PHARM SCI-US, V97, P2924, DOI 10.1002/jps.21190; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; Kondiah PPD, 2013, INT J PHARMACEUT, V456, P459, DOI 10.1016/j.ijpharm.2013.08.038; Kristo K, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118825; Lagasse H A Daniel, 2017, F1000Res, V6, P113, DOI 10.12688/f1000research.9970.1; Lavoie TB, 2011, CYTOKINE, V56, P282, DOI 10.1016/j.cyto.2011.07.019; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; Li ZP, 2011, INT J PHARMACEUT, V410, P48, DOI 10.1016/j.ijpharm.2011.03.016; Lin YK, 2013, SEP PURIF TECHNOL, V120, P362, DOI 10.1016/j.seppur.2013.09.038; Lin YK, 2012, SEP SCI TECHNOL, V47, P1023, DOI 10.1080/01496395.2011.644018; Lindenmann J., 1999, INTERFERON DAWN RECO, V7, P121; Lipiainen T, 2015, J PHARM SCI-US, V104, P307, DOI 10.1002/jps.24243; Liu HF, 2019, INT J NANOMED, V14, P5339, DOI 10.2147/IJN.S209646; Liu LM, 1996, BBA-PROTEIN STRUCT M, V1294, P55, DOI 10.1016/0167-4838(95)00262-6; Liu Q, 2020, INT J NANOMED, V15, P3669, DOI 10.2147/IJN.S249174; Mehta A, 2019, ENV CHEM SUSTAIN WOR, P163, DOI 10.1007/978-3-030-01881-8_6; Meng J, 2007, CYTOTHERAPY, V9, P60, DOI 10.1080/14653240601094322; Mitragotri S, 2014, NAT REV DRUG DISCOV, V13, P655, DOI 10.1038/nrd4363; Mohammadian-Mosaabadi J, 2005, BIOTECHNOL APPL BIOC, V41, P37; Montagner IM, 2016, J CONTROL RELEASE, V236, P79, DOI 10.1016/j.jconrel.2016.06.033; Morcol T, 2018, AAPS PHARMSCITECH, V19, P395, DOI 10.1208/s12249-017-0847-5; Morowvat MH, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.8(4)2015.16236; Nathan C, 2014, NEW ENGL J MED, V371, P1761, DOI 10.1056/NEJMp1408040; Nekoufar S, 2020, ADV PHARM BULL, V10, P233, DOI 10.34172/apb.2020.027; Overton TW, 2014, DRUG DISCOV TODAY, V19, P590, DOI 10.1016/j.drudis.2013.11.008; Owczarek B, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4216060; Pandey R, 2018, ENZYME MICROB TECH, V117, P23, DOI 10.1016/j.enzmictec.2018.06.001; Pandey R, 2018, SEP SCI TECHNOL, V53, P487, DOI 10.1080/01496395.2017.1395463; Patel H.R., 2009, INT J PHARMTECH RES, V1, P299, DOI DOI 10.1016/j.socscimed.2011.03.025; Maldonado LMTP, 2007, BIOMOL ENG, V24, P217, DOI 10.1016/j.bioeng.2006.10.001; Peciak K, 2014, PROTEIN EXPRES PURIF, V99, P18, DOI 10.1016/j.pep.2014.03.009; Pedro AQ, 2015, APPL BIOCHEM BIOTECH, V175, P3840, DOI 10.1007/s12010-015-1551-0; Pedro AQ, 2019, APPL MICROBIOL BIOT, V103, P5483, DOI 10.1007/s00253-019-09873-1; Peng FW, 2007, PROTEIN EXPRES PURIF, V53, P356, DOI 10.1016/j.pep.2006.12.013; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platis D, 2003, PROTEIN EXPRES PURIF, V31, P222, DOI 10.1016/S1046-5928(03)00187-6; Platis D., 2006, INTERFERONS, P73; Prabhu AA, 2016, PROCESS BIOCHEM, V51, P709, DOI 10.1016/j.procbio.2016.02.007; Qian J, 2008, J CHROMATOGR A, V1194, P48, DOI 10.1016/j.chroma.2008.01.040; Qiu J, 2005, ACTA PHARMACOL SIN, V26, P1395, DOI 10.1111/j.1745-7254.2005.00188.x; Rabhi-Essafi I, 2007, PROTEIN ENG DES SEL, V20, P201, DOI 10.1093/protein/gzm012; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; Ramanan RN, 2010, PROCESS BIOCHEM, V45, P196, DOI 10.1016/j.procbio.2009.09.007; Ramanan RN, 2008, BIOTECHNOL BIOPROC E, V13, P613, DOI 10.1007/s12257-008-0047-y; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; Roger SD, 2010, EXPERT OPIN BIOL TH, V10, P1011, DOI 10.1517/14712591003796553; Rosano GL, 2019, PROTEIN SCI, V28, P1412, DOI 10.1002/pro.3668; Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172; Rumjantsev A M, 2014, ScientificWorldJournal, V2014, P743615, DOI 10.1155/2014/743615; Ryff J.-C., 2019, PHARM BIOTECHNOLOGY, V5th ed., P619; Salunkhe S, 2010, PROTEIN EXPRES PURIF, V71, P139, DOI 10.1016/j.pep.2010.02.007; Samuel CE, 1998, CURR TOP MICROBIOL, V233, P125; Sanchez A, 2003, EUR J PHARM SCI, V18, P221, DOI 10.1016/S0928-0987(03)00019-8; Sanchez-Garcia L, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0437-3; Saraswat M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/312709; Shi LM, 2007, PROTEIN EXPRES PURIF, V54, P220, DOI 10.1016/j.pep.2007.03.005; Show, 2015, BIORESOUR BIOPROCESS, V2, P49, DOI [10.1186/s40643-015-0078-0, DOI 10.1186/S40643-015-0078-0]; Silva AC, 2020, ADV BIOCHEM ENG BIOT, V171, P87, DOI 10.1007/10_2019_105; Skoko N, 2003, BIOTECHNOL APPL BIOC, V38, P257, DOI 10.1042/BA20030065; Slouka C, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0997-5; Sola A, 2007, MICROBIOL-SGM, V153, P281, DOI 10.1099/mic.0.29263-0; Sola RJ, 2010, BIODRUGS, V24, P9, DOI 10.2165/11530550-000000000-00000; Sorensen HP, 2005, J BIOTECHNOL, V115, P113, DOI 10.1016/j.jbiotec.2004.08.004; Srivastava P, 2005, PROTEIN EXPRES PURIF, V41, P313, DOI 10.1016/j.pep.2004.12.018; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Subramanian GM, 2007, NAT BIOTECHNOL, V25, P1411, DOI 10.1038/nbt1364; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Vu TTT, 2016, J MOL MICROB BIOTECH, V26, P359, DOI 10.1159/000446962; Timmermann C, 2019, HIST PHIL LIFE SCI, V41, DOI 10.1007/s40656-019-0268-8; Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230-973X.96920; Uze G, 2007, BIOCHIMIE, V89, P729, DOI 10.1016/j.biochi.2007.01.008; Vaiphei ST, 2009, J IND MICROBIOL BIOT, V36, P1453, DOI 10.1007/s10295-009-0632-x; Vaishya R, 2015, EXPERT OPIN DRUG DEL, V12, P415, DOI 10.1517/17425247.2015.961420; Valente CA, 2006, PROTEIN EXPRES PURIF, V45, P226, DOI 10.1016/j.pep.2005.06.014; Valente CA, 2004, APPL ENVIRON MICROB, V70, P5033, DOI 10.1128/AEM.70.8.5033-5036.2004; Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0; Walsh G, 2018, NAT BIOTECHNOL, V36, P1136, DOI 10.1038/nbt.4305; Walther C, 2013, CHEM ENG SCI, V101, P631, DOI 10.1016/j.ces.2013.07.026; Wang D, 2014, MOL MED REP, V9, P715, DOI 10.3892/mmr.2013.1812; Wang FW, 2006, J CHROMATOGR A, V1115, P72, DOI 10.1016/j.chroma.2006.02.075; Wang W, 2015, PROTEIN SCI, V24, P1031, DOI 10.1002/pro.2684; Xie YF, 2007, J BIOTECHNOL, V129, P472, DOI 10.1016/j.jbiotec.2007.01.018; Xiong S, 2005, WORLD J GASTROENTERO, V11, P1077, DOI 10.3748/wjg.v11.i7.1077; Yamaguchi H, 2014, BIOMOLECULES, V4, P235, DOI 10.3390/biom4010235; Yan Z, 2006, APPL BIOCHEM BIOTECH, V133, P149, DOI 10.1385/ABAB:133:2:149; Yang J, 1997, J PHARM SCI, V86, P908, DOI 10.1021/js960480l; Yuan WM, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-017-0057-x	149	3	3	6	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							328	10.3390/vaccines9040328			51	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4WM	33915863	Green Published, gold			2022-04-29	WOS:000643781400001
J	Schwestka, J; Stoger, E				Schwestka, Jennifer; Stoger, Eva			Microparticles and Nanoparticles from Plants-The Benefits of Bioencapsulation	VACCINES			English	Review						bio-encapsulation; plant molecular farming; microparticles; protein bodies; virus-like particles; drug delivery vehicle	VIRUS-LIKE PARTICLES; COWPEA MOSAIC-VIRUS; ORAL TOLERANCE INDUCTION; B SURFACE-ANTIGEN; SEED OIL-BODIES; PROTEIN BODY; DRUG-DELIVERY; PHARMACEUTICAL PROTEINS; TRANSIENT EXPRESSION; MICROBIAL-CELLS	The efficacy of drugs and vaccines depends on their stability and ability to interact with their targets in vivo. Many drugs benefit from encapsulation, which protects them from harsh conditions and allows targeted delivery and controlled release. Although many encapsulation methods are inexpensive, such as the formulation of tablets for oral delivery, others require complex procedures that add significantly to production costs and require low-temperature transport and storage, making them inaccessible in developing countries. In this review we consider the benefits of encapsulation technologies based on plants. Plant-derived biopolymers such as starch and the maize storage protein zein are already used as protective coatings, but plant cells used as production host provide natural in vivo bioencapsulation that survives passage through the stomach and releases drugs in the intestine, due to the presence of microbes that can digest the cell wall. Proteins can also be encapsulated in subcellular compartments such as protein bodies, which ensure stability and activity while often conferring additional immunomodulatory effects. Finally, we consider the incorporation of drugs and vaccines into plant-derived nanoparticles assembled from the components of viruses. These are extremely versatile, allowing the display of epitopes and targeting peptides as well as carrying cargoes of drugs and imaging molecules.	[Schwestka, Jennifer; Stoger, Eva] Univ Nat Resources & Life Sci, Inst Plant Biotechnol & Cell Biol, Dept Appl Genet & Cell Biol, A-1190 Vienna, Austria		Stoger, E (通讯作者)，Univ Nat Resources & Life Sci, Inst Plant Biotechnol & Cell Biol, Dept Appl Genet & Cell Biol, A-1190 Vienna, Austria.	jennifer.schwestka@boku.ac.at; eva.stoger@boku.ac.at		Stoeger, Eva/0000-0002-7651-7992; Schwestka, Jennifer/0000-0001-8824-2159	Austrian Science Fund FWFAustrian Science Fund (FWF) [W1224]	The authors acknowledge funding by the Austrian Science Fund FWF (project W1224).	Ahmed S, 2018, STARCH-STARKE, V70, DOI 10.1002/star.201700113; Anselmo AC, 2019, NAT REV DRUG DISCOV, V18, P19, DOI 10.1038/nrd.2018.183; Arcalis E, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00439; ARGOS P, 1982, J BIOL CHEM, V257, P9984; Berardi A, 2018, NANOSCALE, V10, P1667, DOI 10.1039/c7nr07182e; Bock R, 2001, J MOL BIOL, V312, P425, DOI 10.1006/jmbi.2001.4960; Boyd BJ, 2008, EXPERT OPIN DRUG DEL, V5, P69, DOI 10.1517/17425247.5.1.69; Bull SE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat6086; Bundo M, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00731; Cai JB, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0433-2; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Chen MF, 1998, PLANT PHYSIOL, V116, P1563, DOI 10.1104/pp.116.4.1563; Chikwamba RK, 2003, P NATL ACAD SCI USA, V100, P11127, DOI 10.1073/pnas.1836901100; Chung YH, 2020, ADV DRUG DELIVER REV, V156, P214, DOI 10.1016/j.addr.2020.06.024; D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x; Daniell H, 2020, BIOMATERIALS, V233, DOI 10.1016/j.biomaterials.2019.119750; Daniell H, 2019, BIOTECHNOL ADV, V37, DOI 10.1016/j.biotechadv.2019.06.012; Daniell H, 2019, PLANT BIOTECHNOL J, V17, P1357, DOI 10.1111/pbi.13060; Daniell H, 2016, ANNU REV GENET, V50, P595, DOI 10.1146/annurev-genet-120215-035349; Dauvillee D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015424; de Lima IA, 2018, ARTIF CELL NANOMED B, V46, P993, DOI 10.1080/21691401.2018.1477788; de Virgilio M, 2008, J EXP BOT, V59, P2815, DOI 10.1093/jxb/ern143; Dennis SJ, 2018, VET RES, V49, DOI 10.1186/s13567-018-0600-4; Dennis SJ, 2018, PLANT BIOTECHNOL J, V16, P442, DOI 10.1111/pbi.12783; Diamos AG, 2020, VACCINE, V38, P3455, DOI 10.1016/j.vaccine.2020.02.089; Diego-Taboada A, 2012, J MATER CHEM, V22, P9767, DOI [10.1039/c2jmo0103a, 10.1039/c2jm00103a]; Duval KEA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.594614; Fernandez-Carneado J, 2004, ANGEW CHEM INT EDIT, V43, P1811, DOI 10.1002/anie.200352540; Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519; Frandsen GI, 2001, PHYSIOL PLANTARUM, V112, P301, DOI 10.1034/j.1399-3054.2001.1120301.x; Gallier S, 2012, FOOD FUNCT, V3, P547, DOI 10.1039/c2fo10259e; GELI MI, 1994, PLANT CELL, V6, P1911; Gunter CJ, 2019, PLANT BIOTECHNOL J, V17, P1751, DOI 10.1111/pbi.13097; Guo XM, 2013, PLANT PHYSIOL, V162, P1359, DOI 10.1104/pp.113.218941; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; He JY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010060; Herman EM, 1999, PLANT CELL, V11, P601, DOI 10.1105/tpc.11.4.601; Herzog RW, 2017, MOL THER, V25, P512, DOI 10.1016/j.ymthe.2016.11.009; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Hofbauer A, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00142; Huzair F, 2017, STUD HIST PHI PART C, V64, P11, DOI 10.1016/j.shpsc.2017.05.004; Ivanovsky D., 1882, ST PETERSBURG ACAD I, V35, P67, DOI DOI 10.1016/J.JPROT.2015.09.030; Jiao Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/426028; John RP, 2011, CRIT REV BIOTECHNOL, V31, P211, DOI 10.3109/07388551.2010.513327; Jones Dena, 2019, Adv Food Nutr Res, V88, P235, DOI 10.1016/bs.afnr.2019.02.014; Juarez P, 2012, PLANT BIOTECHNOL J, V10, P341, DOI 10.1111/j.1467-7652.2011.00666.x; Karthikeyan K, 2014, AAPS PHARMSCITECH, V15, P1172, DOI 10.1208/s12249-014-0151-6; Kausche G.A., 1939, BIOCHEM Z, V303, P211; Kim SH, 2017, CLIN EXP VACCINE RES, V6, P15, DOI [10.7774/cevr.2017.6.1.15., 10.7774/cevr.2017.6.1.15]; Kogan MJ, 2001, J MOL BIOL, V312, P907, DOI 10.1006/jmbi.2001.4999; Koudelka KJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000417; Kwon KC, 2016, MOL THER, V24, P1342, DOI 10.1038/mt.2016.115; Lakshmi PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054708; Lale SV, 2018, INT J PHARMACEUT, V552, P352, DOI 10.1016/j.ijpharm.2018.10.016; Lasserre-Ramassamy S., 2004, Patent, Patent No. [WO/2004/003207, 2004003207]; Ling H, 2007, BIOLOGIA, V62, P119, DOI 10.2478/s11756-007-0041-4; Liu JH, 1997, MOL BREEDING, V3, P463, DOI 10.1023/A:1009604119618; Lizotte PH, 2016, NAT NANOTECHNOL, V11, P295, DOI [10.1038/nnano.2015.292, 10.1038/NNANO.2015.292]; Llop-Tous I, 2010, J BIOL CHEM, V285, P35633, DOI 10.1074/jbc.M110.116285; Luo YC, 2011, COLLOID SURFACE B, V85, P145, DOI 10.1016/j.colsurfb.2011.02.020; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Mackenzie G, 2015, FRONT MATER, V2, DOI 10.3389/fmats.2015.00066; Majewski RL, 2016, J APPL BIOMATER FUNC, V14, pE395, DOI 10.5301/jabfm.5000299; Marsian J, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00880; Marsian J, 2016, CURR OPIN BIOTECH, V37, P201, DOI 10.1016/j.copbio.2015.12.007; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mohan T, 2017, SCI REP-UK, V7, DOI 10.1038/srep40226; Montesinos L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146919; Moreno-Mendieta S, 2017, VACCINE, V35, P5123, DOI 10.1016/j.vaccine.2017.08.012; MURRAY K, 1984, EMBO J, V3, P645, DOI 10.1002/j.1460-2075.1984.tb01861.x; Nandi S, 2005, TRANSGENIC RES, V14, P237, DOI 10.1007/s11248-004-8120-6; Naupu PN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040740; Nykiforuk CL, 2006, PLANT BIOTECHNOL J, V4, P77, DOI 10.1111/j.1467-7652.2005.00159.x; Pang EL, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00455; Park J, 2020, BIOMATERIALS, V233, DOI 10.1016/j.biomaterials.2019.119591; Parmenter DL, 1995, PLANT MOL BIOL, V29, P1167, DOI 10.1007/BF00020460; Patel A, 2010, SOFT MATTER, V6, P6192, DOI 10.1039/c0sm00800a; Penalva R, 2017, NANOMED-NANOTECHNOL, V13, P103, DOI 10.1016/j.nano.2016.08.033; Perry SL, 2020, MOLECULES, V25, DOI 10.3390/molecules25051161; Peters J, 2011, HUM VACCINES, V7, P367, DOI 10.4161/hv.7.3.14303; Peyret H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74105-w; Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751; Ponndorf D, 2021, PLANT BIOTECHNOL J, V19, P745, DOI 10.1111/pbi.13501; Pumpens P, 1995, INTERVIROLOGY, V38, P63, DOI 10.1159/000150415; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Qiang WD, 2020, GENES-BASEL, V11, DOI 10.3390/genes11090959; Qiang WD, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0387-5; Qiu C, 2020, INT J BIOL MACROMOL, V152, P117, DOI 10.1016/j.ijbiomac.2020.02.156; Raave R, 2018, J CONTROL RELEASE, V274, P1, DOI 10.1016/j.jconrel.2018.01.029; Richter LJ, 2000, NAT BIOTECHNOL, V18, P1167, DOI 10.1038/81153; Royo B.L., 2015, Patent EP, Patent No. [2 351 834 A2, 2351834]; Rybicki EP, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1587; Sahni N, 2016, WILEY SER DRUG DISC, P623; Sainsbury F, 2010, ANNU REV PHYTOPATHOL, V48, P437, DOI 10.1146/annurev-phyto-073009-114242; Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002; Schwestka J, 2020, BIOTECHNOL BIOENG, V117, P1037, DOI 10.1002/bit.27273; Scotti N, 2013, EXPERT REV VACCINES, V12, P211, DOI [10.1586/erv.12.147, 10.1586/ERV.12.147]; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; Shim S, 2020, MAR DRUGS, V18, DOI 10.3390/md18120605; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Shukla R, 2001, IND CROP PROD, V13, P171, DOI 10.1016/S0926-6690(00)00064-9; Shukla S, 2020, ANNU REV VIROL, V7, P559, DOI 10.1146/annurev-virology-010720-052252; SIJMONS PC, 1990, BIO-TECHNOL, V8, P217, DOI 10.1038/nbt0390-217; Snapper CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00598; Souto EB, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041449; Steinmetz NF, 2020, BIOMATER SCI-UK, V8, P2771, DOI 10.1039/d0bm00159g; Steinmetz NF, 2011, NANOMEDICINE-UK, V6, P351, DOI [10.2217/nnm.10.136, 10.2217/NNM.10.136]; Stoger E, 2005, CURR OPIN BIOTECH, V16, P167, DOI 10.1016/j.copbio.2005.01.005; Stump CT, 2021, CANCERS, V13, DOI 10.3390/cancers13040627; Su J, 2015, BIOMATERIALS, V70, P84, DOI 10.1016/j.biomaterials.2015.08.004; Sutradhar KB, 2014, ISRN NANOTECHNOL, V2014, P1, DOI DOI 10.1155/2014/939378; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Takagi H, 2010, PEPTIDES, V31, P1421, DOI 10.1016/j.peptides.2010.04.032; Takaiwa F, 2019, J AGR FOOD CHEM, V67, P13127, DOI 10.1021/acs.jafc.9b05421; Takaiwa F, 2017, PLANT SCI, V263, P201, DOI 10.1016/j.plantsci.2017.07.016; Thuenemann EC, 2013, CURR PHARM DESIGN, V19, P5564, DOI 10.2174/1381612811319310011; Topp E, 2016, BIOTECHNOL ADV, V34, P597, DOI 10.1016/j.biotechadv.2016.02.007; Torrent Margarita, 2009, V483, P193, DOI 10.1007/978-1-59745-407-0_11; Torrent M, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-5; Torres FG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205092; Tregoning JS, 2003, NUCLEIC ACIDS RES, V31, P1174, DOI 10.1093/nar/gkg221; Troncoso Omar P., 2020, Medical Devices & Sensors, V3, DOI 10.1002/mds3.10111; Tzen J., 2012, ISRN BOT, V16, P16, DOI DOI 10.5402/2012/173954; Uddin MJ, 2017, J CONTROL RELEASE, V268, P416, DOI 10.1016/j.jconrel.2017.10.019; Vacher G, 2013, MOL PHARMACEUT, V10, P1596, DOI 10.1021/mp300597g; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; Vamvaka E, 2016, PLANT BIOTECHNOL J, V14, P1427, DOI 10.1111/pbi.12507; van Eerde A, 2019, PLANT BIOTECHNOL J, V17, P1408, DOI 10.1111/pbi.13065; van Zyl AR, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0370-5; VANROOIJEN GJH, 1995, BIO-TECHNOL, V13, P72, DOI 10.1038/nbt0195-72; Vitale A, 1999, TRENDS PLANT SCI, V4, P149, DOI 10.1016/S1360-1385(99)01389-8; Wahlroos T, 2003, GENESIS, V35, P125, DOI 10.1002/gene.10172; Ward B.J., 2020, PHASE 1 TRIAL CANDID, DOI [DOI 10.1101/2020.11.04.20226282, 10.1101/2020.11.04.20226282]; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Ward BJ, 2014, VACCINE, V32, P6098, DOI [10.1016/j.vaccine.2014.08.079, 10.10]; Wen AM, 2016, CHEM SOC REV, V45, P4074, DOI 10.1039/c5cs00287g; Whitehead M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-367; Woo YM, 2001, PLANT CELL, V13, P2297, DOI 10.1105/tpc.13.10.2297; Yeung Andy Wai Kan, 2020, Current Research in Biotechnology, V2, P53, DOI 10.1016/j.crbiot.2020.04.002; Yi SY, 2015, PROTEIN EXPRES PURIF, V116, P127, DOI 10.1016/j.pep.2015.08.006; Yilmaz E, 2012, BIOPROC BIOSYST ENG, V35, P493, DOI 10.1007/s00449-011-0622-z; Zhu MT, 2014, HUM VACC IMMUNOTHER, V10, P2761, DOI 10.4161/hv.29589; Zhu Q, 2013, GUT MICROBES, V4, P246, DOI 10.4161/gmic.24197	145	0	0	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							369	10.3390/vaccines9040369			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4NV	33920425	gold, Green Published			2022-04-29	WOS:000643758700001
J	Cadenas-Fernandez, E; Sanchez-Vizcaino, JM; van den Born, E; Kosowska, A; van Kilsdonk, E; Fernandez-Pacheco, P; Gallardo, C; Arias, M; Barasona, JA				Cadenas-Fernandez, Estefania; Sanchez-Vizcaino, Jose M.; van den Born, Erwin; Kosowska, Aleksandra; van Kilsdonk, Emma; Fernandez-Pacheco, Paloma; Gallardo, Carmina; Arias, Marisa; Barasona, Jose A.			High Doses of Inactivated African Swine Fever Virus Are Safe, but Do Not Confer Protection against a Virulent Challenge	VACCINES			English	Article						African swine fever; inactivated virus; vaccine trial; domestic pigs		African swine fever (ASF) is currently the major concern of the global swine industry, as a consequence of which a reconsideration of the containment and prevention measures taken to date is urgently required. A great interest in developing an effective and safe vaccine against ASF virus (ASFV) infection has, therefore, recently appeared. The objective of the present study is to test an inactivated ASFV preparation under a vaccination strategy that has not previously been tested in order to improve its protective effect. The following have been considered: (i) virus inactivation by using a low binary ethyleneimine (BEI) concentration at a low temperature, (ii) the use of new and strong adjuvants; (iii) the use of very high doses (6 x 10(9) haemadsorption in 50% of infected cultures (HAD(50))), and (iv) simultaneous double inoculation by two different routes of administration: intradermal and intramuscular. Five groups of pigs were, therefore, inoculated with BEI- Pol16/DP/OUT21 in different adjuvant formulations, twice with a 4-week interval. Six weeks later, all groups were intramuscularly challenged with 10 HAD(50) of the virulent Pol16/DP/OUT21 ASFV isolate. All the animals had clinical signs and pathological findings consistent with ASF. This lack of effectiveness supports the claim that an inactivated virus strategy may not be a viable vaccine option with which to fight ASF.	[Cadenas-Fernandez, Estefania; Sanchez-Vizcaino, Jose M.; Kosowska, Aleksandra; Barasona, Jose A.] Univ Complutense Madrid, VISAVET Hlth Surveillance Ctr, Madrid 28040, Spain; [Cadenas-Fernandez, Estefania; Sanchez-Vizcaino, Jose M.; Kosowska, Aleksandra; Barasona, Jose A.] Univ Complutense Madrid, Fac Vet, Dept Anim Hlth, Madrid 28040, Spain; [van den Born, Erwin; van Kilsdonk, Emma] MSD Anim Hlth, POB 31, NL-5830 AA Boxmeer, Netherlands; [Fernandez-Pacheco, Paloma; Gallardo, Carmina; Arias, Marisa] Ctr Invest Sanidad Anim INIA CISA, European Union Reference Lab ASF, Madrid 28130, Spain		Cadenas-Fernandez, E; Barasona, JA (通讯作者)，Univ Complutense Madrid, VISAVET Hlth Surveillance Ctr, Madrid 28040, Spain.; Cadenas-Fernandez, E; Barasona, JA (通讯作者)，Univ Complutense Madrid, Fac Vet, Dept Anim Hlth, Madrid 28040, Spain.	estefania.cadenas@ucm.es; jmvizcaino@ucm.es; erwin.van.den.born@merck.com; alkosows@ucm.es; emma.vankilsdonk@merck.com; pacheco@inia.es; gallardo@inia.es; arias@inia.es; jbarason@ucm.es	Gallardo+Frontaura, Carmina/ABE-6878-2021; gallardo, Carmina/AAB-2386-2019; Arias, Marisa/X-7566-2018	gallardo, Carmina/0000-0003-3293-306X; Arias, Marisa/0000-0001-6044-2968; Barasona, Jose Angel/0000-0003-4066-8454; Cadenas-Fernandez, Estefania/0000-0001-8477-1299; Kosowska, Aleksandra/0000-0002-0016-8765	Intervet International B.V.Merck & CompanyIntervet International B.V. [50-2019]; Spanish Government by the Spanish Ministry of Education, Culture and Sports	This research was funded by Intervet International B.V. (50-2019). E.C.-F. is a recipient of a Spanish Government-funded PhD fellowship for the Training of Future Scholars (FPU) provided by the Spanish Ministry of Education, Culture and Sports.	Acharya KP, 2020, TRANSBOUND EMERG DIS, V67, P2269, DOI 10.1111/tbed.13720; Barasona JA, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-107; Argilaguet JM, 2013, ANTIVIR RES, V98, P61, DOI 10.1016/j.antiviral.2013.02.005; Argilaguet JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040942; Arias M, 2018, TRANSBOUND EMERG DIS, V65, P235, DOI 10.1111/tbed.12695; Arias M, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040035; BAHNEMANN HG, 1990, VACCINE, V8, P299, DOI 10.1016/0264-410X(90)90083-X; Barasona JA, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00137; Beer M, 2000, VET MICROBIOL, V77, P195, DOI 10.1016/S0378-1135(00)00276-5; Blome S, 2014, VACCINE, V32, P3879, DOI 10.1016/j.vaccine.2014.05.051; Borca MV, 2020, J VIROL, V94, DOI 10.1128/JVI.02017-19; Bosch-Camos L, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00154-2; Cadenas-Fernandez E, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030171; Gallardo MC, 2015, PORCINE HEALTH MANAG, V1, DOI 10.1186/s40813-015-0013-y; Chen WY, 2020, SCI CHINA LIFE SCI, V63, P623, DOI 10.1007/s11427-020-1657-9; DETRAY D. E., 1963, ADVANCES VETSCI, V8, P299; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Ehrensperger F., 1981, P CEC FAO RES SEM HE; Ferrari L, 2011, RES VET SCI, V90, P64, DOI 10.1016/j.rvsc.2010.04.026; Gallardo C, 2018, VET MICROBIOL, V219, P70, DOI 10.1016/j.vetmic.2018.04.001; Gallardo C, 2017, TRANSBOUND EMERG DIS, V64, P300, DOI 10.1111/tbed.12346; Gallardo C, 2018, VACCINE, V36, P2694, DOI 10.1016/j.vaccine.2018.03.040; Gaudreault NN, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020056; Giraudoux P, 2018, PACKAGE PGIRMESS SPA; Goatley LC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020234; Halasa T, 2016, VET MICROBIOL, V193, P7, DOI 10.1016/j.vetmic.2016.08.004; Jancovich JK, 2018, J VIROL, V92, DOI [10.1128/JVI.02219-17, 10.1128/jvi.02219-17]; Jurado C, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00077; Kedkovid R, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00159-x; King DP, 2003, J VIROL METHODS, V107, P53, DOI 10.1016/S0166-0934(02)00189-1; King K, 2011, VACCINE, V29, P4593, DOI 10.1016/j.vaccine.2011.04.052; Lacasta A, 2014, J VIROL, V88, P13322, DOI 10.1128/JVI.01893-14; Leitao A, 2001, J GEN VIROL, V82, P513, DOI 10.1099/0022-1317-82-3-513; Lokhandwala S, 2019, VET MICROBIOL, V235, P10, DOI 10.1016/j.vetmic.2019.06.006; MEBUS CA, 1988, ADV VIRUS RES, V35, P251; Mulumba-Mfumu LK, 2016, TRANSBOUND EMERG DIS, V63, pE323, DOI 10.1111/tbed.12303; Mulumba-Mfumu LK, 2019, TRANSBOUND EMERG DIS, V66, P1462, DOI 10.1111/tbed.13187; Murgia MV, 2019, ARCH VIROL, V164, P359, DOI 10.1007/s00705-018-4071-8; Netherton CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01318; Rock DL, 2017, VET MICROBIOL, V206, P52, DOI 10.1016/j.vetmic.2016.10.003; Saez-Llorens X, 2016, LANCET INFECT DIS, V16, P321, DOI 10.1016/S1473-3099(15)00488-0; Sanchez-Cordon PJ, 2018, VACCINE, V36, P707, DOI 10.1016/j.vaccine.2017.12.030; Sanchez-Cordon PJ, 2017, ANTIVIR RES, V138, P1, DOI 10.1016/j.antiviral.2016.11.021; Sanchez-Vizcaino J. M., 2019, DIS SWINE, P443, DOI [10.1002/9781119350927.ch25, DOI 10.1002/9781119350927.CH25]; Schloer G. M., 1982, Proceedings of the United States Animal Health Association, V86, P253; STONE SS, 1967, AM J VET RES, V28, P475; Sunwoo SY, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010012; Teklue T, 2020, TRANSBOUND EMERG DIS, V67, P529, DOI 10.1111/tbed.13364; Tizard I., 2017, VET IMMUNOLOGY, V10th; Zuur AF, 2010, METHODS ECOL EVOL, V1, P3, DOI 10.1111/j.2041-210X.2009.00001.x	50	4	4	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							242	10.3390/vaccines9030242			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5GP	33802021	gold, Green Published			2022-04-29	WOS:000634182700001
J	Papa, A; Scaldaferri, F; Vetrone, LM; Neri, M; Gasbarrini, A; Lopetuso, LR				Papa, Alfredo; Scaldaferri, Franco; Vetrone, Lorenzo Maria; Neri, Matteo; Gasbarrini, Antonio; Lopetuso, Loris Riccardo			How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists	VACCINES			English	Article						SARS-CoV-2; vaccines; IBD; COVID-19; acceptance	COVID-19; VACCINES	The severity of the COVID-19 pandemic has led to an unprecedented effort to develop vaccines against SARS-CoV-2 infection since this seems to be the most effective strategy to counter the pandemic. In the past weeks, the administration of vaccines has started in different parts of the world sustaining the hype of significantly containing the impact of SARS-CoV-2 infection. However, the rapid time lapse from vaccine development to distribution has raised several concerns on its safety and efficacy. This topic is particularly felt by patients with chronic conditions and immumodulating therapies that could compromise their immune system such as inflammatory bowel disease (IBD). Here, we explore the potential future implications of the SARS-CoV-2 vaccines introduction in the IBD field, touching upon the clinical experience coming from available data on vaccinations against other infections. We also dissect the factors associated with the acceptability of SARS-CoV-2 vaccination, describing the possible strategies that gastroenterologist should adopt to reach the highest rate of vaccinations in IBD patients.	[Papa, Alfredo; Scaldaferri, Franco; Vetrone, Lorenzo Maria; Gasbarrini, Antonio; Lopetuso, Loris Riccardo] Fdn Policlin Univ A Gemelli IRCCS, CEMAD Digest Dis Ctr, I-00168 Rome, Italy; [Papa, Alfredo; Scaldaferri, Franco; Vetrone, Lorenzo Maria; Gasbarrini, Antonio] Univ Cattolica Sacro Cuore, Dipartimento Sci Med & Chirurg, I-00168 Rome, Italy; [Neri, Matteo; Lopetuso, Loris Riccardo] G dAnnunzio Univ Chieti Pescara, Dept Med & Ageing Sci, I-66100 Chieti, Italy; [Neri, Matteo; Lopetuso, Loris Riccardo] G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol CAST, I-66100 Chieti, Italy		Papa, A (通讯作者)，Fdn Policlin Univ A Gemelli IRCCS, CEMAD Digest Dis Ctr, I-00168 Rome, Italy.; Papa, A (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Med & Chirurg, I-00168 Rome, Italy.	alfredo.papa@unicatt.it; francoscaldaferri@gmail.com; vetrone.md@gmail.com; mneri@unich.it; antonio.gasbarrini@unicatt.it; lopetusoloris@libero.it		Vetrone, Lorenzo Maria/0000-0002-9845-0004; scaldaferri, franco/0000-0001-8334-7541; Gasbarrini, Antonio/0000-0003-4863-6924; PAPA, Alfredo/0000-0002-4186-7298; NERI, Matteo/0000-0001-8856-7690			Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411; Coenen S, 2017, INFLAMM BOWEL DIS, V23, P318, DOI 10.1097/MIB.0000000000001013; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; D'Amico F, 2021, NAT REV GASTRO HEPAT, V18, P211, DOI 10.1038/s41575-021-00420-w; Dalal RS, 2021, CLIN GASTROENTEROL H, V19, P1730, DOI 10.1016/j.cgh.2021.02.004; Espeseth AS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0163-z; Farraye FA, 2017, AM J GASTROENTEROL, V112, P241, DOI 10.1038/ajg.2016.537; Galle F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103481; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kumar A, 2020, LANCET GASTROENTEROL, V5, P965, DOI 10.1016/S2468-1253(20)30295-8; Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl-2019-318484; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ledford H, 2020, NATURE, V588, P205, DOI 10.1038/d41586-020-03441-8; Lipsitch M, 2020, SCIENCE, V370, P763, DOI 10.1126/science.abe5938; Lopetuso Loris Riccardo, 2020, Endosc Int Open, V8, pE980, DOI 10.1055/a-1183-3073; Manser CN, 2020, DIGESTION, V101, P58, DOI 10.1159/000503253; Melmed GY, 2006, AM J GASTROENTEROL, V101, P1834, DOI 10.1111/j.1572-0241.2006.00646.x; Papa A, 2020, THER ADV GASTROENTER, V13, DOI 10.1177/1756284820968747; Papa A, 2020, AM J GASTROENTEROL, V115, P1722, DOI 10.14309/ajg.0000000000000830; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pugliese D, 2020, DIGEST LIVER DIS, V52, P1238, DOI 10.1016/j.dld.2020.05.053; Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Scaldaferri F, 2020, UNITED EUR GASTROENT, V8, P775, DOI 10.1177/2050640620929133; Ungaro RC, 2021, GUT, V70, P725, DOI 10.1136/gutjnl-2020-322539; Ura T, 2021, VACCINE, V39, P197, DOI 10.1016/j.vaccine.2020.11.054; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; Volpp KG, 2021, JAMA-J AM MED ASSOC, V325, P125, DOI 10.1001/jama.2020.24036; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Yeung JH, 2012, INFLAMM BOWEL DIS, V18, P34, DOI 10.1002/ibd.21668; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594	36	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							248	10.3390/vaccines9030248			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5XI	33808983	gold, Green Published			2022-04-29	WOS:000634226200001
J	Wang, PF				Wang, Pengfei			Natural and Synthetic Saponins as Vaccine Adjuvants	VACCINES			English	Review						adjuvant; saponin; mechanism; SAR; QS-21; VSA-1; VSA-2		Saponin adjuvants have been extensively studied for their use in veterinary and human vaccines. Among them, QS-21 stands out owing to its unique profile of immunostimulating activity, inducing a balanced Th1/Th2 immunity, which is valuable to a broad scope of applications in combating various microbial pathogens, cancers, and other diseases. It has recently been approved for use in human vaccines as a key component of combination adjuvants, e.g., AS01b in Shingrix(R) for herpes zoster. Despite its usefulness in research and clinic, the cellular and molecular mechanisms of QS-21 and other saponin adjuvants are poorly understood. Extensive efforts have been devoted to studies for understanding the mechanisms of QS-21 in different formulations and in different combinations with other adjuvants, and to medicinal chemistry studies for gaining mechanistic insights and development of practical alternatives to QS-21 that can circumvent its inherent drawbacks. In this review, we briefly summarize the current understandings of the mechanism underlying QS-21's adjuvanticity and the encouraging results from recent structure-activity-relationship (SAR) studies.	[Wang, Pengfei] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA		Wang, PF (通讯作者)，Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA.	wangp@uab.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM120159, AI099407]	This research was funded by NIH, GM120159, and AI099407.	Adams MM, 2010, J AM CHEM SOC, V132, P1939, DOI 10.1021/ja9082842; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Ballou WR, 2009, PARASITE IMMUNOL, V31, P492, DOI 10.1111/j.1365-3024.2009.01143.x; Banday AH, 2015, IMMUNOPHARM IMMUNOT, V37, P1, DOI 10.3109/08923973.2014.971963; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; Bastola R, 2017, ARCH PHARM RES, V40, P1238, DOI 10.1007/s12272-017-0969-z; Bengtsson KL, 2011, EXPERT REV VACCINES, V10, P401, DOI [10.1586/ERV.11.25, 10.1586/erv.11.25]; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Bottger S, 2013, BIOORGAN MED CHEM, V21, P7118, DOI 10.1016/j.bmc.2013.09.008; Bonam SR, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105684; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Brunner R, 2010, IMMUNOL LETT, V128, P29, DOI 10.1016/j.imlet.2009.10.005; Chen YF, 2020, EXP CELL RES, V396, DOI 10.1016/j.yexcr.2020.112292; Cleland JL, 1996, J PHARM SCI, V85, P22, DOI 10.1021/js9503136; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048; Cui J, 2014, HUM VACC IMMUNOTHER, V10, P3270, DOI 10.4161/21645515.2014.979640; De Geyter E, 2012, J INSECT PHYSIOL, V58, P18, DOI 10.1016/j.jinsphys.2011.09.005; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Delrieu J, 2012, J NEUROCHEM, V120, P186, DOI 10.1111/j.1471-4159.2011.07458.x; den Brok MH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13324; den Brok MH, 2012, VACCINE, V30, P737, DOI 10.1016/j.vaccine.2011.11.080; den Dunnen J, 2009, CANCER IMMUNOL IMMUN, V58, P1149, DOI 10.1007/s00262-008-0615-1; Deng K, 2008, ANGEW CHEM INT EDIT, V47, P6395, DOI 10.1002/anie.200801885; Deng K, 2008, J AM CHEM SOC, V130, P5860, DOI 10.1021/ja801008m; Detienne S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39475; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Fernandez-Tejada A, 2016, ACCOUNTS CHEM RES, V49, P1741, DOI 10.1021/acs.accounts.6b00242; Fernandez-Tejada A, 2014, NAT CHEM, V6, P636, DOI [10.1038/NCHEM.1963, 10.1038/nchem.1963]; Garcon N, 2011, PERSPECT VACCINOL, V1, P89, DOI [DOI 10.1016/J.PERVAC.2011.05.004, 10.1016/j.pervac.2011.05.004]; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Garcon N, 2010, CURR CANCER THER REV, V6, P126, DOI 10.2174/157339410791202574; Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/ERV.11.29, 10.1586/erv.11.29]; Genito CJ, 2017, VACCINE, V35, P3865, DOI 10.1016/j.vaccine.2017.05.070; Ghirardello M, 2020, CHEM COMMUN, V56, P719, DOI 10.1039/c9cc07781b; Glenny AT, 1926, J PATHOL BACTERIOL, V29, P31, DOI 10.1002/path.1700290106; Harandi AM, 2010, VACCINE, V28, P2363, DOI 10.1016/j.vaccine.2009.12.084; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Ivanov K, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9040252; IWAMOTO M, 1985, CHEM PHARM BULL, V33, P464; James SF, 2018, ANN PHARMACOTHER, V52, P673, DOI 10.1177/1060028018758431; Kamstrup S, 2000, VACCINE, V18, P2244, DOI 10.1016/S0264-410X(99)00560-5; Kensil CR, 2004, FRONT BIOSCI-LANDMRK, V9, P2972, DOI 10.2741/1452; KENSIL CR, 1991, J IMMUNOL, V146, P431; Kensil CR, 2006, INFEC DIS, P221; Kensil CR, 1996, CRIT REV THER DRUG, V13, P1; Kensil CR, 1998, DEV BIOL STAND, V92, P41; Kim SK, 2000, VACCINE, V19, P530, DOI 10.1016/S0264-410X(00)00195-X; Klebanoff CA, 2011, IMMUNOL REV, V239, P27, DOI 10.1111/j.1600-065X.2010.00979.x; Korchowiec B, 2015, BBA-BIOMEMBRANES, V1848, P1963, DOI 10.1016/j.bbamem.2015.06.007; KUMAZAWA Y, 1989, INT J IMMUNOPHARMACO, V11, P21; Lacaille-Dubois MA, 2019, PHYTOMEDICINE, V60, DOI 10.1016/j.phymed.2019.152905; LACAILLEDUBOIS MA, 1995, PHYTOCHEMISTRY, V40, P509, DOI 10.1016/0031-9422(95)00222-S; Leroux-Roels G, 2015, VACCINE, V33, P1084, DOI 10.1016/j.vaccine.2014.10.078; Leroux-Roels G, 2010, VACCINE, V28, pC25, DOI 10.1016/j.vaccine.2010.07.021; Leroux-Roels I, 2015, VACCINE, V33, P577, DOI 10.1016/j.vaccine.2013.10.052; Liu G, 2002, VACCINE, V20, P2808, DOI 10.1016/S0264-410X(02)00209-8; Lorent JH, 2014, ORG BIOMOL CHEM, V12, P8803, DOI 10.1039/c4ob01652a; Magnusson SE, 2018, IMMUNOL RES, V66, P224, DOI 10.1007/s12026-018-8991-x; Marciani DJ, 2018, TRENDS PHARMACOL SCI, V39, P573, DOI 10.1016/j.tips.2018.03.005; Marciani DJ, 2015, INT IMMUNOPHARMACOL, V29, P908, DOI 10.1016/j.intimp.2015.10.028; Marciani DJ, 2000, VACCINE, V18, P3141, DOI 10.1016/S0264-410X(00)00118-3; Marciani DJ, 2003, DRUG DISCOV TODAY, V8, P934, DOI 10.1016/S1359-6446(03)02864-2; Marciani DJ, 2003, VACCINE, V21, P3961, DOI 10.1016/S0264-410X(03)00298-6; Marciani DJ, 2002, INT IMMUNOPHARMACOL, V2, P1703, DOI 10.1016/S1567-5769(02)00192-3; Marciani DJ, 2002, VACCINE, V20, P3237, DOI 10.1016/S0264-410X(02)00298-0; Marciani DJ, 2001, INT IMMUNOPHARMACOL, V1, P813, DOI 10.1016/S1567-5769(01)00016-9; MARCIANI DJ, 1991, VACCINE, V9, P89, DOI 10.1016/0264-410X(91)90262-5; Marty-Roix R, 2016, J BIOL CHEM, V291, P1123, DOI 10.1074/jbc.M115.683011; May RD., 2000, STUDIES NATURAL PROD, P131; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Morelli AB, 2012, J MED MICROBIOL, V61, P935, DOI 10.1099/jmm.0.040857-0; NEWMAN MJ, 1992, J IMMUNOL, V148, P2357; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; O'Hagan DT, 2017, CURR OPIN IMMUNOL, V47, P93, DOI 10.1016/j.coi.2017.07.010; Oda K, 2003, VACCINE, V21, P2145, DOI 10.1016/S0264-410X(02)00739-9; Oda K, 2000, BIOL CHEM, V381, P67, DOI 10.1515/BC.2000.009; Pearse MJ, 2005, ADV DRUG DELIVER REV, V57, P465, DOI 10.1016/j.addr.2004.09.006; Pifferi C, 2021, NAT REV CHEM, V5, P197, DOI 10.1038/s41570-020-00244-3; Pillion DJ, 1996, J PHARM SCI, V85, P518, DOI 10.1021/js9504651; Pink J Richard, 2004, Vaccine, V22, P2097, DOI 10.1016/j.vaccine.2004.01.021; Polhemus ME, 2007, VACCINE, V25, P4203, DOI 10.1016/j.vaccine.2007.03.012; Ragupathi G, 2011, EXPERT REV VACCINES, V10, P463, DOI [10.1586/ERV.11.18, 10.1586/erv.11.18]; Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124; Reimer JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041451; Rhodes J, 1996, IMMUNOL TODAY, V17, P436, DOI 10.1016/0167-5699(96)10050-5; San Martin R, 1999, ECON BOT, V53, P302, DOI 10.1007/BF02866642; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Schijns V, 2020, IMMUNOL REV, V296, P169, DOI 10.1111/imr.12889; Sharp F.A., 2012, DEV THERAPEUTIC AGEN, V1st ed., P533; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Skalamera D, 2020, J ORG CHEM, V85, P15837, DOI 10.1021/acs.joc.0c00359; Slovin SF, 2005, VACCINE, V23, P3114, DOI 10.1016/j.vaccine.2005.01.072; Smith WS, 2017, BBA-BIOMEMBRANES, V1859, P993, DOI 10.1016/j.bbamem.2017.02.013; SOLTYSIK S, 1995, VACCINE, V13, P1403, DOI 10.1016/0264-410X(95)00077-E; Srivastava AD, 2020, CHEM-EUR J, V26, P15605, DOI 10.1002/chem.202002619; Steeghs L, 2006, CELL MICROBIOL, V8, P316, DOI 10.1111/j.1462-5822.2005.00623.x; Stewart VA, 2006, VACCINE, V24, P6483, DOI 10.1016/j.vaccine.2006.06.033; Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032; Svajger U, 2010, CELL SIGNAL, V22, P1397, DOI 10.1016/j.cellsig.2010.03.018; Temizoz B, 2016, INT IMMUNOL, V28, P329, DOI 10.1093/intimm/dxw015; Tielemans CL, 2011, VACCINE, V29, P1159, DOI 10.1016/j.vaccine.2010.12.009; Vandepapeliere P, 2005, VACCINE, V23, P2591, DOI 10.1016/j.vaccine.2004.11.034; Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038; Walkowicz WE, 2016, CHEM SCI, V7, P2371, DOI 10.1039/c5sc02978c; Wang PF, 2020, J MED CHEM, V63, P3290, DOI 10.1021/acs.jmedchem.9b02063; Wang PF, 2019, J MED CHEM, V62, P9976, DOI 10.1021/acs.jmedchem.9b01511; Wang PF, 2019, ACS INFECT DIS, V5, P974, DOI 10.1021/acsinfecdis.9b00039; Wang PF, 2019, J MED CHEM, V62, P1669, DOI 10.1021/acs.jmedchem.8b01997; Wang PF, 2016, J ORG CHEM, V81, P9560, DOI 10.1021/acs.joc.6b00922; Wang PF, 2013, J ORG CHEM, V78, P11525, DOI 10.1021/jo402118j; Wang PF, 2005, J AM CHEM SOC, V127, P3256, DOI 10.1021/ja0422007; Wang W., 2011, WORLD J VACCINE, V1, P33, DOI DOI 10.4236/WJV.2011.12007; Weeratna RD, 2011, EMERGING TRENDS IN ANTIBACTERIAL DISCOVERY: ANSWERING THE CALL TO ARMS, P303; Welsby I, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00663; Wen YM, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.40; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Wilson NS, 2014, J IMMUNOL, V192, P3259, DOI 10.4049/jimmunol.1302011; WU JY, 1994, CELL IMMUNOL, V154, P393, DOI 10.1006/cimm.1994.1086	123	11	11	14	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							222	10.3390/vaccines9030222			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5OE	33807582	Green Published, gold			2022-04-29	WOS:000634202400001
J	Anastasiou, OE; Heger, D				Anastasiou, Olympia E.; Heger, Doerte			Understanding the Influence of Individual and Systemic Factors on Vaccination Take-Up in European Citizens Aged 55 or Older	VACCINES			English	Article						vaccination; vaccination hesitancy; vaccine knowledge		Background: High vaccination coverage provides extensive public health benefits. Hence, increasing vaccination rates is an important policy goal within the EU and worldwide. We aim to evaluate individual and systemic parameters associated with vaccination in European Union citizens aged 55 or older, using data from the Special Eurobarometer 488. Methods: Linear probability and probit models are estimated to analyze the determinants of vaccination take-up. Further, descriptive analyses are used to explore how the reasons for not having a vaccination differ by welfare regime. Results: High knowledge about the effectiveness and safety of vaccination increases the probability of receiving a vaccination during the past five years by 26 percentage points (pp), medium knowledge increases it by 15 pp. Focusing on the specific case of the flu, official recommendations increase this probability by, on average, 6 pp; while having to pay out-of-pocket for a recommended vaccination decreases it by, on average, 10 pp. Furthermore, the differences for no vaccination differ widely across welfare systems and television is the primary source for information about vaccination. Conclusions: Reported vaccination rates in Europe fall far below targets set by official recommendations. Increasing vaccination knowledge and offering vaccinations free of charge can help to increase vaccination rates. A specific focus should be put on reaching individuals with potential difficulties of access such as those living alone and unemployed.	[Anastasiou, Olympia E.] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, D-45147 Essen, Germany; [Heger, Doerte] RWI Leibniz Inst Econ Res, D-45128 Essen, Germany		Anastasiou, OE (通讯作者)，Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, D-45147 Essen, Germany.	olympia.anastasiou@uni-due.de; doerte.heger@rwi-essen.de		Anastasiou, Olympia/0000-0003-2178-3182; Heger, Dorte/0000-0002-3880-6638	Open Access Publication Fund of the University of Duisburg-Essen	We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.	Alhalaseh L, 2020, VACCINE, V38, P7372, DOI 10.1016/j.vaccine.2020.09.002; Altpeter E, 2018, INT J PUBLIC HEALTH, V63, P589, DOI 10.1007/s00038-018-1102-x; Andersen R, 2014, CHANGING US HLTH CAR, V2007; Bertoldo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215978; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Blank Patricia, 2012, Hum Vaccin Immunother, V8, P328, DOI 10.4161/hv.18629; Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1970-4; Burns VE, 2005, VACCINE, V23, P3604, DOI 10.1016/j.vaccine.2004.12.031; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; D'Ancona F, 2019, EUROSURVEILLANCE, V24, P31, DOI 10.2807/1560-7917.ES.2019.24.25.1900371; de Gomensoro E, 2018, ANN MED, V50, P181, DOI 10.1080/07853890.2017.1417632; ECDC, 2016, LETS TALK HES ENH CO; ECDC, 2020, VACC SCHED; Endrich MM, 2009, VACCINE, V27, P4018, DOI 10.1016/j.vaccine.2009.04.029; Esping-Andersen Gosta., 1990, 3 WORLDS WELFARE CAP; European Centre for Disease Prevention and Control (ECDC), 2016, LETS TALK PROTECTION; European Centre for Disease Prevention and Control (ECDC), 2018, SEASONAL INFLUENZA V; European Commission, 2019, SPECIAL EUROBAROMETE; Fall E, 2018, PSYCHOL HEALTH, V33, P746, DOI 10.1080/08870446.2017.1401623; Farmanara N, 2018, CAN J PUBLIC HEALTH, V109, P369, DOI 10.17269/s41997-018-0018-9; FEDSON DS, 1995, VACCINE, V13, P623, DOI 10.1016/0264-410X(94)00041-K; FENGER HJM, 2007, CONT ISSUES IDEAS SO, V0003; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Kunze U, 2007, WIEN MED WOCHENSCHR, V157, P98, DOI 10.1007/s10354-007-0389-7; Loiacono MM, 2020, VACCINE-X, V4, DOI 10.1016/j.jvacx.2020.100054; Machado A, 2019, EUROSURVEILLANCE, V24, P28, DOI 10.2807/1560-7917.ES.2019.24.45.1900268; Mathieu P, 2019, EUROSURVEILLANCE, V24, P27, DOI 10.2807/1560-7917.ES.2019.24.25.1900053; Mc Hugh SM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1356-7; McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3; Miyachi T, 2020, LANCET, V395, P31, DOI 10.1016/S0140-6736(19)32686-8; Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388; Rey D, 2018, EUROSURVEILLANCE, V23, P30, DOI [10.2807/1560-7917.ES.23.17.17-00816, 10.2807/1560-7917.ES.2018.23.17.17-00816]; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; Sato APS, 2020, J INFECT PUBLIC HEAL, V13, P211, DOI 10.1016/j.jiph.2019.07.022; Schmitz H, 2011, HEALTH ECON, V20, P1281, DOI 10.1002/hec.1672; Shemesh AA, 2008, ARCH GERONTOL GERIAT, V47, P63, DOI 10.1016/j.archger.2007.07.001; World Health Organization, 2019, 10 THREATS GLOB HLTH; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	38	2	2	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							169	10.3390/vaccines9020169			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO7IR	33671437	Green Published, gold			2022-04-29	WOS:000623314000001
J	Ferreira, HL; Miller, PJ; Suarez, DL				Ferreira, Helena L.; Miller, Patti J.; Suarez, David L.			Protection against Different Genotypes of Newcastle Disease Viruses (NDV) Afforded by an Adenovirus-Vectored Fusion Protein and Live NDV Vaccines in Chickens	VACCINES			English	Article						vaccines; NDV; poultry; fusion; homologous; heterologous; immunity		The efficacy of an adenovirus-vectored Newcastle disease virus (NDV) vaccine expressing the fusion (F) NDV protein (adeno-F) was evaluated against challenges with virulent heterologous and homologous NDV strains to the F protein. In a preliminary study, two different doses (low and high) of adeno-F were tested against a virulent NDV strain containing the homologous NDV F protein, CA02. In a second study, at three weeks post-vaccination, the efficacy of the high dose of adeno-F was compared to a live attenuated NDV vaccine strain (LaSota) against three antigenically distinct virulent NDV challenge strains, one homologous (CA02) and two heterologous (TZ12, EG14) to F in the vectored vaccine. In both experiments, clinical signs, mortality, virus shedding, and humoral response were evaluated. In the first experiment, the survival rates from birds vaccinated with adeno-F at a high and low dose were 100% and 25%, respectively. In the second experiment, birds vaccinated with the high dose of adeno-F had a survival rate of 80%, 75%, and 65% after challenge with the CA02, TZ12, and EG14 viruses, respectively. All of the LaSota-vaccinated birds survived post-challenge no matter the NDV challenge strain. High antibody titers were detected after vaccination with LaSota by HI and ELISA tests. The majority of adeno-F-vaccinated birds had detectable antibodies using the ELISA test, but not using the HI test, before the challenge. The data show that both the similarity of the F protein of the adeno-F vaccine to the challenge virus and the adeno-F vaccination dose affect the efficacy of an adenovirus-vectored NDV vaccine against a virulent NDV challenge.	[Ferreira, Helena L.; Miller, Patti J.; Suarez, David L.] USDA ARS, Southeast Poultry Res Lab, US Natl Poultry Res Ctr, 934 Coll Stn Rd, Athens, GA 30605 USA; [Ferreira, Helena L.] Univ Sao Paulo, Dept Vet Med, FZEA USP, BR-13635900 Pirassununga, SP, Brazil; [Miller, Patti J.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA		Suarez, DL (通讯作者)，USDA ARS, Southeast Poultry Res Lab, US Natl Poultry Res Ctr, 934 Coll Stn Rd, Athens, GA 30605 USA.	hlage@usp.br; pjmdvm97@uga.edu; david.suarez@usda.gov	Ferreira, Helena Lage/A-2046-2010	Ferreira, Helena Lage/0000-0002-3261-3712; Suarez, David/0000-0003-4582-6116	U.S. Department of Agriculture, ARS CRIS Project [6612-32000-072-00D]; CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This research was funded by the U.S. Department of Agriculture, ARS CRIS Project 6612-32000-072-00D and by an appointment to the ORAU/ORISE. H.L.F is a recipient of the CNPq productivity scholarship.	Ababneh M, 2018, MICROBIOL RESOUR ANN, V7, DOI 10.1128/MRA.01136-18; Arora P, 2010, INDIAN J EXP BIOL, V48, P889; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Bose S, 2014, J VIROL, V88, P3925, DOI 10.1128/JVI.03741-13; BOURSNELL MEG, 1990, VIROLOGY, V178, P297, DOI 10.1016/0042-6822(90)90408-J; Butt SL, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1077-5; Cornax I, 2012, AVIAN DIS, V56, P464, DOI 10.1637/10043-122011-Reg.1; Das A, 2009, J VET DIAGN INVEST, V21, P771, DOI 10.1177/104063870902100603; Dimitrov KM, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.103917; Dimitrov KM, 2019, VIROLOGY, V531, P203, DOI 10.1016/j.virol.2019.03.010; Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019; Dimitrov KM, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0741-5; Dortmans JCFM, 2010, J VIROL, V84, P10113, DOI 10.1128/JVI.00097-10; Esaki M, 2013, AVIAN DIS, V57, P750, DOI 10.1637/10540-032613-Reg.1; Ferreira HL, 2020, VACCINE, V38, P5507, DOI 10.1016/j.vaccine.2020.06.004; Ferreira HL, 2019, VET MICROBIOL, V235, P25, DOI 10.1016/j.vetmic.2019.06.004; Ferreira HL, 2014, AVIAN PATHOL, V43, P68, DOI 10.1080/03079457.2013.873111; Firouzamandi M, 2016, J VET SCI, V17, P21, DOI 10.4142/jvs.2016.17.1.21; Gao WT, 2006, J VIROL, V80, P1959, DOI 10.1128/JVI.80.4.1959-1964.2006; Ge JP, 2016, J BIOTECHNOL, V231, P201, DOI 10.1016/j.jbiotec.2016.03.037; GIAMBRONE JJ, 1990, AVIAN DIS, V34, P114, DOI 10.2307/1591341; Grimes S.E., 2002, BASIC LAB MANUAL SMA; Huang ZH, 2004, J VIROL, V78, P4176, DOI 10.1128/JVI.78.8.4176-4184.2004; Jin JH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01607; Jin JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep36890; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; Kim SH, 2011, J VIROL, V85, P8582, DOI 10.1128/JVI.00652-11; Kuhn JH, 2019, NATURE, V566, P318, DOI 10.1038/d41586-019-00599-8; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Lamb R.A., 2013, FIELDS VIROLOGY, V6th ed., P957; Lamb R.A., 2007, FIELDS VIROLOGY, P1450; Liu JJ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080225; Loke CF, 2005, VET IMMUNOL IMMUNOP, V106, P259, DOI 10.1016/j.vetimm.2005.03.005; Martinez JCS, 2018, POULTRY SCI, V97, P455, DOI 10.3382/ps/pex339; Melanson VR, 2006, J VIROL, V80, P623, DOI 10.1128/JVI.80.2.623-633.2006; Miller P.J., 2013, DIS POULTRY, P89, DOI DOI 10.1002/9781119421481.CH3; Miller PJ, 2007, VACCINE, V25, P7238, DOI 10.1016/j.vaccine.2007.07.017; Miller PJ, 2013, DEV COMP IMMUNOL, V41, P505, DOI 10.1016/j.dci.2013.06.007; Miller PJ, 2009, AVIAN DIS, V53, P39, DOI 10.1637/8407-071208-Reg.1; MORGAN RW, 1993, AVIAN DIS, V37, P1032, DOI 10.2307/1591910; MORGAN RW, 1992, AVIAN DIS, V36, P858, DOI 10.2307/1591544; Msoffe PLM, 2019, AVIAN DIS, V63, P634, DOI 10.1637/aviandiseases-D-19-00089; Nei M.a.K.S., 2000, MOL EVOLUTION PHYLOG; OIE, 2017, MANUAL DIAGNOSTIC TE; OIE, 2014, TERRESTRIAL ANIMAL H; Palya V, 2012, AVIAN DIS, V56, P282, DOI 10.1637/9935-091511-Reg.1; Porotto M, 2012, J VIROL, V86, P5730, DOI 10.1128/JVI.06793-11; Reynolds DL, 2000, AVIAN DIS, V44, P145, DOI 10.2307/1592518; Senne DA, 2008, LAB MANUAL ISOLATION, P204; Shahar E, 2018, AVIAN PATHOL, V47, P467, DOI 10.1080/03079457.2018.1488240; STEWARD M, 1993, J GEN VIROL, V74, P2539, DOI 10.1099/0022-1317-74-12-2539; Suarez DL, 2012, AVIAN DIS, V56, P836, DOI 10.1637/10207-041512-Review.1; Sun HL, 2008, AVIAN DIS, V52, P111, DOI 10.1637/7998-041807-Reg; WESTBURY HA, 1984, AUST VET J, V61, P10, DOI 10.1111/j.1751-0813.1984.tb07121.x; Wise MG, 2004, J CLIN MICROBIOL, V42, P329, DOI 10.1128/JCM.42.1.329-338.2004; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	56	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							182	10.3390/vaccines9020182			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YV	33669907	gold, Green Published			2022-04-29	WOS:000623288200001
J	Jabang, S; Erhart, A; Darboe, S; Baldeh, AK; Delforge, V; Watson, G; Foster-Nyarko, E; Salaudeen, R; Lawal, B; Mackenzie, G; Botteaux, A; Antonio, M; Smeesters, PR				Jabang, Sona; Erhart, Annette; Darboe, Saffiatou; Baldeh, Aru-Kumba; Delforge, Valerie; Watson, Gabriella; Foster-Nyarko, Ebenezer; Salaudeen, Rasheed; Lawal, Bolarinde; Mackenzie, Grant; Botteaux, Anne; Antonio, Martin; Smeesters, Pierre R.		MRCG StrepA Study Grp	Molecular Epidemiology of Group A Streptococcus Infections in The Gambia	VACCINES			English	Article						group A streptococcus; emm-type; emm-cluster; vaccine; The Gambia		Molecular epidemiological data on Group A Streptococcus (GAS) infection in Africa is scarce. We characterized the emm-types and emm-clusters of 433 stored clinical GAS isolates from The Gambia collected between 2004 and 2018. To reduce the potential for strain mistyping, we used a newly published primer for emm-typing. There was considerable strain diversity, highlighting the need for vaccine development offering broad strain protection.	[Jabang, Sona; Erhart, Annette; Darboe, Saffiatou; Baldeh, Aru-Kumba; Watson, Gabriella; Foster-Nyarko, Ebenezer; Salaudeen, Rasheed; Lawal, Bolarinde; Mackenzie, Grant; Antonio, Martin] London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Banjul 273, Gambia; [Delforge, Valerie; Botteaux, Anne; Smeesters, Pierre R.] Univ Libre Bruxelles, IBMM, Lab Genet & Physiol Bacterienne, 12 Rue Prof Jenner & Brachet, B-6041 Gosselies, Belgium; [Watson, Gabriella] Southampton Univ Hosp, Southampton SO16 6YD, Hants, England; [Smeesters, Pierre R.] Univ Libre Bruxelles, Hop Univ Enfants Reine Fabiola, Dept Pediat, B-1050 Brussels, Belgium		Erhart, A (通讯作者)，London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Banjul 273, Gambia.	sjabang@mrc.gm; aerhart@mrc.gm; sdarboe@mrc.gm; arkbaldeh@mrc.gm; valerie.delforge@ulb.ac.be; Gabriella.watson@uhs.nhs.uk; Ebenezer.Foster-Nyarko@quadram.ac.uk; rsalaudeen@mrc.gm; blawal@mrc.gm; gmackenzie@mrc.gm; anne.botteaux@ulb.be; mantonio@mrc.gm; pierre.smeesters@huderf.be	DARBOE, SAFFIATOU/AAY-6423-2021	DARBOE, SAFFIATOU/0000-0002-4711-3307; Armitage, Edwin/0000-0003-1125-4260; Mackenzie, Grant/0000-0002-4994-2627; Foster-Nyarko, Ebenezer/0000-0001-6620-9403; JABANG, SONA/0000-0002-7596-706X	aWellcome Trust Seed Award [206061/Z17Z]	This study was funded by aWellcome Trust Seed Award [206061/Z17Z].	Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045; Davies MR, 2019, NAT GENET, V51, P1035, DOI 10.1038/s41588-019-0417-8; Frost HR, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.02.026; Jaiteh D.L., JAHA; Osowicki J, 2019, VACCINE, V37, P3485, DOI 10.1016/j.vaccine.2019.03.059; Salie T, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00429-20; Sanderson-Smith M, 2014, J INFECT DIS, V210, P1325, DOI 10.1093/infdis/jiu260; Shulman ST, 2014, CLIN INFECT DIS, V59, P1651, DOI 10.1093/cid/ciu649; Smeesters PR, 2009, EXPERT REV VACCINES, V8, P1705, DOI 10.1586/ERV.09.133; Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1; Vekemans J, 2019, CLIN INFECT DIS, V69, P877, DOI 10.1093/cid/ciy1143; Watkins DA, 2017, NEW ENGL J MED, V377, P713, DOI 10.1056/NEJMoa1603693	12	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							124	10.3390/vaccines9020124			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YO	33557233	Green Published			2022-04-29	WOS:000623287500001
J	Karpenko, LI; Rudometov, AP; Sharabrin, SV; Shcherbakov, DN; Borgoyakova, MB; Bazhan, SI; Volosnikova, EA; Rudometova, NB; Orlova, LA; Pyshnaya, IA; Zaitsev, BN; Volkova, NV; Azaev, MS; Zaykovskaya, AV; Pyankov, OV; Ilyichev, AA				Karpenko, Larisa, I; Rudometov, Andrey P.; Sharabrin, Sergei, V; Shcherbakov, Dmitry N.; Borgoyakova, Mariya B.; Bazhan, Sergei, I; Volosnikova, Ekaterina A.; Rudometova, Nadezhda B.; Orlova, Lyubov A.; Pyshnaya, Inna A.; Zaitsev, Boris N.; Volkova, Natalya V.; Azaev, Mamedyar Sh; Zaykovskaya, Anna, V; Pyankov, Oleg, V; Ilyichev, Alexander A.			Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate	VACCINES			English	Article						SARS-CoV-2; RBD; mRNA-vaccine; polyglucin; spermidine conjugate; anti-RBD antibodies		One of the key stages in the development of mRNA vaccines is their delivery. Along with liposome, other materials are being developed for mRNA delivery that can ensure both the safety and effectiveness of the vaccine, and also facilitate its storage and transportation. In this study, we investigated the polyglucin:spermidine conjugate as a carrier of an mRNA-RBD vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The conditions for the self-assembling of mRNA-PGS complexes were optimized, including the selection of the mRNA:PGS charge ratios. Using dynamic and electrophoretic light scattering it was shown that the most monodisperse suspension of nanoparticles was formed at the mRNA:PGS charge ratio equal to 1:5. The average hydrodynamic particles diameter was determined, and it was confirmed by electron microscopy. The evaluation of the zeta potential of the investigated complexes showed that the particles surface charge was close to the zero point. This may indicate that the positively charged PGS conjugate has completely packed the negatively charged mRNA molecules. It has been shown that the packaging of mRNA-RBD into the PGS envelope leads to increased production of specific antibodies with virus-neutralizing activity in immunized BALB/c mice. Our results showed that the proposed polycationic polyglucin:spermidine conjugate can be considered a promising and safe means to the delivery of mRNA vaccines, in particular mRNA vaccines against SARS-CoV-2.	[Karpenko, Larisa, I; Rudometov, Andrey P.; Sharabrin, Sergei, V; Shcherbakov, Dmitry N.; Borgoyakova, Mariya B.; Bazhan, Sergei, I; Volosnikova, Ekaterina A.; Rudometova, Nadezhda B.; Orlova, Lyubov A.; Zaitsev, Boris N.; Volkova, Natalya V.; Azaev, Mamedyar Sh; Zaykovskaya, Anna, V; Pyankov, Oleg, V; Ilyichev, Alexander A.] State Res Ctr Virol & Biotechnol Vector, Novosibirsk 630559, Russia; [Pyshnaya, Inna A.] Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk 630090, Russia		Karpenko, LI (通讯作者)，State Res Ctr Virol & Biotechnol Vector, Novosibirsk 630559, Russia.	lkarpenko@ngs.ru; rudometov_ap@vector.nsc.ru; sharabrin_sv@vector.nsc.ru; scherbakov_dn@vector.nsc.ru; borgoyakova_mb@vector.nsc.ru; bazhan@vector.nsc.ru; volosnikova_ea@vector.nsc.ru; andreeva_nb@vector.nsu.ru; orlova_la@vector.nsc.ru; pyshnaya@niboch.nsc.ru; zaitsev@vector.nsc.ru; wolkowa11.93@mail.ru; mamedyar50@mail.ru; zaykovskaya_av@vector.nsc.ru; pyankov_ov@vector.nsc.ru; ilyichev@vector.nsc.ru	Zaykovskaya, Anna Владимировна/AHB-2815-2022; Shcherbakov, Dmitry/U-4763-2019; Borgoyakova, Mariya/AAJ-1751-2021	Zaykovskaya, Anna Владимировна/0000-0002-0450-5212; Borgoyakova, Mariya/0000-0002-0768-1561; Karpenko, Larisa/0000-0003-4365-8809; Sharabrin, Sergei/0000-0003-0664-3587; Shcherbakov, Dmitry/0000-0001-8023-4453	FBRI SRC VB "Vector", Rospotrebnadzor	The study was conducted under the state assignment of FBRI SRC VB "Vector", Rospotrebnadzor. Please add the grant number here.	Ball RL, 2017, INT J NANOMED, V12, P305, DOI 10.2147/IJN.S123062; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766; Cohen S.S., 1998, GUIDE POLYAMINES; Dolgin E, 2021, NATURE, V589, P189, DOI 10.1038/d41586-021-00019-w; Farris E, 2016, EXP BIOL MED, V241, P919, DOI 10.1177/1535370216643771; Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0; Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478; Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111; Gomez-Aguado I, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10020364; Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010; Ihnatsyeu-Kachan A, 2017, COLLOID INTERFAC, V1, DOI 10.3390/colloids1010006; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jones KL, 2007, BIOTECHNIQUES, V43, P675, DOI 10.2144/000112593; Karpenko LI, 2016, RUSS J BIOORG CHEM+, V42, P170, DOI 10.1134/S1068162016020060; Karpenko L.I., 2018, INTECHOPEN, DOI [10.5772/intechopen.77031, DOI 10.5772/INTECHOPEN.77031]; Karpenko LI, 2007, VACCINE, V25, P4312, DOI 10.1016/j.vaccine.2007.02.058; Karpenko LI, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040718; Karpenko LI, 2003, VACCINE, V21, P386, DOI 10.1016/S0264-410X(02)00406-1; Landesman-Milo D, 2014, DRUG DELIV TRANSL RE, V4, P96, DOI 10.1007/s13346-013-0158-7; Lebedev LR, 2000, MOL BIOL+, V34, P413, DOI 10.1007/BF02759674; Lightfoot HL, 2014, NUCLEIC ACIDS RES, V42, P11275, DOI 10.1093/nar/gku837; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Perepelytsya S, 2019, NUCLEIC ACIDS RES, V47, P6084, DOI 10.1093/nar/gkz434; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Schoen F.J, 2013, BIOMATER SCI-UK, P1047, DOI 10.1016/B978-0-08-087780-8; Sedic M, 2018, VET PATHOL, V55, P341, DOI 10.1177/0300985817738095; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Singh DV, 2005, VET RES COMMUN, V29, P421, DOI 10.1007/s11259-005-1434-x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tai WB, 2020, CELL RES, V30, P932, DOI 10.1038/s41422-020-0387-5; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Volchkova VA, 2015, J INFECT DIS, V212, pS191, DOI 10.1093/infdis/jiv150; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; World Health Organization, NOV COR 2019 NCOV; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Xue HY, 2015, CURR PHARM DESIGN, V21, P3140, DOI 10.2174/1381612821666150531164540; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhao YN, 2017, J MATER CHEM B, V5, P7963, DOI 10.1039/c7tb01915g; Zhuang XY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010123	48	8	8	10	23	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							76	10.3390/vaccines9020076			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7FR	33494530	gold, Green Published			2022-04-29	WOS:000623306200001
J	Sempere, J; Llamosi, M; Menendez, ID; Ruiz, BL; Domenech, M; Gonzalez-Camacho, F				Sempere, Julio; Llamosi, Mirella; del Rio Menendez, Idoia; Lopez Ruiz, Beatriz; Domenech, Mirian; Gonzalez-Camacho, Fernando			Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates	VACCINES			English	Review						Streptococcus pneumoniae; choline-binding proteins; pneumococcal vaccines; protein vaccines	STREPTOCOCCUS-PNEUMONIAE INFECTION; TRIVALENT RECOMBINANT PCPA; CROSS-REACTIVE ANTIBODIES; MENINGOCOCCAL B VACCINE; SURFACE PROTEIN; CELL-WALL; MOLECULAR CHARACTERIZATION; INTRANASAL IMMUNIZATION; CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE	Streptococcus pneumoniae is a pathogen responsible for millions of deaths worldwide. Currently, the available vaccines for the prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV-23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes (up to 100 different serotypes have been identified) and are unable to protect against non-vaccine serotypes and non-encapsulated pneumococci. The emergence of antibiotic-resistant non-vaccine serotypes after these vaccines is an increasing threat. Therefore, there is an urgent need to develop new pneumococcal vaccines which could cover a wide range of serotypes. One of the vaccines most characterized as a prophylactic alternative to current PPV-23 or PCVs is a vaccine based on pneumococcal protein antigens. The choline-binding proteins (CBP) are found in all pneumococcal strains, giving them the characteristic to be potential vaccine candidates as they may protect against different serotypes. In this review, we have focused the attention on different CBPs as vaccine candidates because they are involved in the pathogenesis process, confirming their immunogenicity and protection against pneumococcal infection. The review summarizes the major contribution of these proteins to virulence and reinforces the fact that antibodies elicited against many of them may block or interfere with their role in the infection process.	[Sempere, Julio; Llamosi, Mirella; del Rio Menendez, Idoia; Lopez Ruiz, Beatriz; Domenech, Mirian; Gonzalez-Camacho, Fernando] Inst Salud Carlos III, Spanish Pneumococcal Reference Lab, Natl Ctr Microbiol, Majadahonda 28220, Spain; [Domenech, Mirian; Gonzalez-Camacho, Fernando] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain		Domenech, M; Gonzalez-Camacho, F (通讯作者)，Inst Salud Carlos III, Spanish Pneumococcal Reference Lab, Natl Ctr Microbiol, Majadahonda 28220, Spain.; Domenech, M; Gonzalez-Camacho, F (通讯作者)，Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain.	jsempere@isciii.es; mirella.llamosi@isciii.es; idoia.mnendz@gmail.com; b.lopezruiz@isciii.es; mdomenech@isciii.es; fgonzalezc@isciii.es	Sempere, Julio/AAE-8628-2020; González-Camacho, Fernando/P-1610-2014; Domenech, Mirian/G-2561-2018	Sempere, Julio/0000-0001-9340-6867; Gonzalez-Camacho, Fernando/0000-0003-3175-9004; Domenech, Mirian/0000-0002-0942-8180; Del Rio Menendez, Idoia/0000-0002-6605-6918	Ministerio de Economia, Industria y CompetitividadSpanish Government [SAF2017-83388]	This research was funded by Ministerio de Economia, Industria y Competitividad (Grant number SAF2017-83388).	Aberdein JD, 2013, CLIN EXP IMMUNOL, V174, P193, DOI 10.1111/cei.12170; Afshar D, 2016, IRAN J PUBLIC HEALTH, V45, P1610; Ali YM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002793; Anderson D, 2015, GENES IMMUN, V16, P289, DOI 10.1038/gene.2015.12; Andre GO, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00224; Ardanuy C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043619; Attali C, 2008, INFECT IMMUN, V76, P466, DOI 10.1128/IAI.01261-07; Bai XH, 2014, J BIOL CHEM, V289, P23403, DOI 10.1074/jbc.M114.579714; Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; Beghetto E, 2006, FEMS MICROBIOL LETT, V262, P14, DOI 10.1111/j.1574-6968.2006.00360.x; Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR; Berron S, 2005, J CLIN MICROBIOL, V43, P1694, DOI 10.1128/JCM.43.4.1694-1698.2005; Bidmos FA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02315; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Bologa M, 2012, VACCINE, V30, P7461, DOI 10.1016/j.vaccine.2012.10.076; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Briles DE, 2000, INFECT IMMUN, V68, P796, DOI 10.1128/IAI.68.2.796-800.2000; Brooks WA, 2015, VACCINE, V33, P4610, DOI 10.1016/j.vaccine.2015.06.078; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; Brown AO, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004383; Brown JS, 2002, P NATL ACAD SCI USA, V99, P16969, DOI 10.1073/pnas.012669199; Buchanan RM, 2001, VACCINE, V19, P2020, DOI 10.1016/S0264-410X(00)00421-7; Camilli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076309; CANVIN JR, 1995, J INFECT DIS, V172, P119, DOI 10.1093/infdis/172.1.119; Cao J, 2007, VACCINE, V25, P4996, DOI 10.1016/j.vaccine.2007.04.069; Chen A, 2015, CLIN VACCINE IMMUNOL, V22, P1079, DOI 10.1128/CVI.00293-15; Chien YW, 2013, PEDIATR INFECT DIS J, V32, P72, DOI 10.1097/INF.0b013e318270d850; Claverys JP, 2007, NAT REV MICROBIOL, V5, P219, DOI 10.1038/nrmicro1613; Cohen R, 2007, CLIN INFECT DIS, V45, P1583, DOI 10.1086/523734; Corsini B, 2016, VACCINE, V34, P6148, DOI 10.1016/j.vaccine.2016.11.001; CRAIN MJ, 1990, INFECT IMMUN, V58, P3293, DOI 10.1128/IAI.58.10.3293-3299.1990; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; De las Rivas B, 2002, J BACTERIOL, V184, P4988, DOI 10.1128/JB.184.18.4988-5000.2002; de Miguel S, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1483, DOI 10.1093/cid/ciaa1483]; Dieudonne-Vatran A, 2009, J IMMUNOL, V182, P7865, DOI 10.4049/jimmunol.0802376; Domenech M, 2020, APPL ENVIRON MICROB, V86, DOI 10.1128/AEM.00280-20; Dorosti H, 2019, J BIOMOL STRUCT DYN, V37, P3524, DOI 10.1080/07391102.2018.1519460; Du SS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79362-3; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Dunais B, 2015, PEDIATR INFECT DIS J, V34, P286, DOI 10.1097/INF.0000000000000559; Dunne EM, 2013, VACCINE, V31, P2333, DOI 10.1016/j.vaccine.2013.03.024; Ferreira DM, 2009, CLIN VACCINE IMMUNOL, V16, P636, DOI 10.1128/CVI.00395-08; Flacco ME, 2018, LANCET INFECT DIS, V18, P461, DOI 10.1016/S1473-3099(18)30048-3; Frey SE, 2013, VACCINE, V31, P4874, DOI 10.1016/j.vaccine.2013.07.049; Frolet C, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-190; Gamez G, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-017-4376-0; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; GARCIA P, 1990, GENE, V86, P81, DOI 10.1016/0378-1119(90)90116-9; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Georgieva M, 2018, MBIO, V9, DOI 10.1128/mBio.00264-18; Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168; Ginsburg AS, 2012, EXPERT REV VACCINES, V11, P279, DOI [10.1586/erv.12.5, 10.1586/ERV.12.5]; Glennie S, 2016, MUCOSAL IMMUNOL, V9, P56, DOI 10.1038/mi.2015.35; Glover DT, 2008, INFECT IMMUN, V76, P2767, DOI 10.1128/IAI.01126-07; Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000; Guiral S, 2005, P NATL ACAD SCI USA, V102, P8710, DOI 10.1073/pnas.0500879102; Hakenbeck R, 2009, FEMS MICROBIOL REV, V33, P572, DOI 10.1111/j.1574-6976.2009.00172.x; Hammerschmidt S, 1999, INFECT IMMUN, V67, P1683; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2007, J IMMUNOL, V178, P5848, DOI 10.4049/jimmunol.178.9.5848; Hayward Starla, 2016, J Patient Cent Res Rev, V3, P111; Henriques-Normark B, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a010215; Hernani MD, 2011, FEMS IMMUNOL MED MIC, V62, P263, DOI 10.1111/j.1574-695X.2011.00809.x; Hollingshead SK, 2000, INFECT IMMUN, V68, P5889, DOI 10.1128/IAI.68.10.5889-5900.2000; Hotomi M, 2016, J INFECT CHEMOTHER, V22, P72, DOI 10.1016/j.jiac.2015.10.006; HUMMELL DS, 1981, J IMMUNOL, V127, P1287; Hyams C, 2010, INFECT IMMUN, V78, P704, DOI 10.1128/IAI.00881-09; Hyams C, 2010, INFECT IMMUN, V78, P716, DOI 10.1128/IAI.01056-09; Iannelli F, 2002, GENE, V284, P63, DOI 10.1016/S0378-1119(01)00896-4; Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678; Jackson LA, 2013, VACCINE, V31, P3594, DOI 10.1016/j.vaccine.2013.04.084; Jang AY, 2017, VIRULENCE, V8, P875, DOI 10.1080/21505594.2016.1278334; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; Jarva H, 2002, J IMMUNOL, V168, P1886, DOI 10.4049/jimmunol.168.4.1886; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Kausmally L, 2005, J BACTERIOL, V187, P4338, DOI 10.1128/JB.187.13.4338-4345.2005; Kawaguchiya M, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040162; Kazemian H, 2018, IRAN J ALLERGY ASTHM, V17, P574; Keller LE, 2013, INFECT IMMUN, V81, P173, DOI 10.1128/IAI.00755-12; Keller LE, 2016, MBIO, V7, DOI 10.1128/mBio.01792-15; Keller LE, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu037; Kerr AR, 2006, INFECT IMMUN, V74, P5319, DOI 10.1128/IAI.00543-06; Kietzman CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10859; Kim JO, 1999, INFECT IMMUN, V67, P2327, DOI 10.1128/IAI.67.5.2327-2333.1999; Koedel U, 2002, LANCET INFECT DIS, V2, P721, DOI 10.1016/S1473-3099(02)00450-4; Kohler S, 2015, THROMB HAEMOSTASIS, V113, P125, DOI 10.1160/TH14-06-0561; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lee GM, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-110; Llull D, 2006, J CLIN MICROBIOL, V44, P1250, DOI 10.1128/JCM.44.4.1250-1256.2006; Loughran AJ, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0004-2018; Lu L, 2008, J IMMUNOL, V181, P7138, DOI 10.4049/jimmunol.181.10.7138; Maestro B, 2016, ANTIBIOTICS-BASEL, V5, DOI 10.3390/antibiotics5020021; Malley R, 2012, P NATL ACAD SCI USA, V109, P3623, DOI 10.1073/pnas.1121383109; Mann B, 2006, INFECT IMMUN, V74, P821, DOI 10.1128/IAI.74.2.821-829.2006; Mann B, 2014, J INFECT DIS, V209, P1116, DOI 10.1093/infdis/jit502; Marimon JM, 2013, CLIN MICROBIOL INFEC, V19, pE298, DOI 10.1111/1469-0691.12196; Martin CS, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy135; Martner A, 2008, INFECT IMMUN, V76, P4079, DOI 10.1128/IAI.01747-07; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; McDaniel LS, 2016, MBIO, V7, DOI 10.1128/mBio.00545-16; MCDANIEL LS, 1991, INFECT IMMUN, V59, P222, DOI 10.1128/IAI.59.1.222-228.1991; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Miyaji EN, 2013, CELL MOL LIFE SCI, V70, P3303, DOI 10.1007/s00018-012-1234-8; Moffitt Kristin L, 2012, Vaccine, V30, P4316, DOI 10.1016/j.vaccine.2012.01.034; Mohale T, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2808-x; Molina R, 2009, EMBO REP, V10, P246, DOI 10.1038/embor.2008.245; Morales M, 2010, J BACTERIOL, V192, P2624, DOI 10.1128/JB.01501-09; Moscoso M, 2005, APPL ENVIRON MICROB, V71, P8706, DOI 10.1128/AEM.71.12.8706-8713.2005; Moscoso M, 2006, J BACTERIOL, V188, P7785, DOI 10.1128/JB.00673-06; Mukerji R, 2012, J IMMUNOL, V189, P5327, DOI 10.4049/jimmunol.1201967; Nabors GS, 2000, VACCINE, V18, P1743, DOI 10.1016/S0264-410X(99)00530-7; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; Nunes S, 2005, J CLIN MICROBIOL, V43, P1285, DOI 10.1128/JCM.43.3.1285-1293.2005; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Ochs MM, 2016, HUM VACC IMMUNOTHER, V12, P2946, DOI 10.1080/21645515.2016.1202389; Odutola A, 2016, HUM VACC IMMUNOTHER, V12, P393, DOI 10.1080/21645515.2015.1111496; Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071; Orihuela CJ, 2009, J CLIN INVEST, V119, P1638, DOI 10.1172/JCI36759; Ostergaard L, 2017, NEW ENGL J MED, V377, P2349, DOI 10.1056/NEJMoa1614474; Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3; Park IH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097825; Paton JC, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0019-2018; Perez-Dorado I, 2012, MOL ORAL MICROBIOL, V27, P221, DOI 10.1111/j.2041-1014.2012.00655.x; Pimenta FC, 2011, J MED MICROBIOL, V60, P1455, DOI 10.1099/jmm.0.031450-0; Price KE, 2009, J BACTERIOL, V191, P2163, DOI 10.1128/JB.01489-08; Prymula R, 2017, VACCINE, V35, P4603, DOI 10.1016/j.vaccine.2017.07.008; Ramos-Sevillano E, 2021, AM J RESP CRIT CARE, V203, P1037, DOI 10.1164/rccm.202011-4161LE; Ramos-Sevillano E, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005500; Ramos-Sevillano E, 2015, INFECT IMMUN, V83, P591, DOI 10.1128/IAI.02811-14; Ramos-Sevillano E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023626; Reichmann P, 2011, J BACTERIOL, V193, P2888, DOI 10.1128/JB.00321-11; Ren B, 2004, INFECT IMMUN, V72, P114, DOI 10.1128/IAI.72.1.114-122.2004; Ren B, 2012, CLIN VACCINE IMMUNOL, V19, P1574, DOI 10.1128/CVI.00393-12; Ricci S, 2011, VACCINE, V29, P8241, DOI 10.1016/j.vaccine.2011.08.119; Rigden DJ, 2003, CRIT REV BIOCHEM MOL, V38, P143, DOI 10.1080/713609215; Sabharwal V, 2009, INFECT IMMUN, V77, P1121, DOI 10.1128/IAI.01148-08; Sakai F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067147; Sanchez-Beato AR, 1998, FEMS MICROBIOL LETT, V164, P207, DOI 10.1016/S0378-1097(98)00206-7; Sanchez-Tatay D, 2008, CLIN MICROBIOL INFEC, V14, P797, DOI 10.1111/j.1469-0691.2008.02025.x; Seiberling M, 2012, VACCINE, V30, P7455, DOI 10.1016/j.vaccine.2012.10.080; Sempere J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00309; Shekhar S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00747; Shenoy AT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006582; Spijkerman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039730; Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999; Valentino MD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6411; Verhoeven D, 2014, CLIN VACCINE IMMUNOL, V21, P1037, DOI 10.1128/CVI.00052-14; Verhoeven D, 2014, VACCINE, V32, P3205, DOI 10.1016/j.vaccine.2014.04.004; Visan L, 2018, HUM VACC IMMUNOTHER, V14, P489, DOI 10.1080/21645515.2017.1403698; Voss S, 2013, J BIOL CHEM, V288, P15614, DOI 10.1074/jbc.M112.443507; Wajima T, 2020, MICROBES INFECT, V22, P451, DOI 10.1016/j.micinf.2020.05.014; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8; Weiser JN, 2018, NAT REV MICROBIOL, V16, P354, DOI 10.1038/s41579-018-0001-8; White P, 1999, ORL J OTO-RHINO-LARY, V61, P206, DOI 10.1159/000027672; WINKELSTEIN JA, 1978, J IMMUNOL, V120, P174; Wizemann TM, 2001, INFECT IMMUN, V69, P1593, DOI 10.1128/IAI.69.3.1593-1598.2001; Wu HY, 1997, J INFECT DIS, V175, P839, DOI 10.1086/513980; Xu Q, 2015, MUCOSAL IMMUNOL, V8, P1110, DOI 10.1038/mi.2015.1; Xu Q, 2019, BIOCHEM BIOPH RES CO, V514, P1192, DOI 10.1016/j.bbrc.2019.05.053; Xu QF, 2017, VACCINE, V35, P337, DOI 10.1016/j.vaccine.2016.11.046; Xu QF, 2015, VACCINE, V33, P993, DOI 10.1016/j.vaccine.2015.01.014; Xu XY, 2014, J MICROBIOL, V52, P315, DOI 10.1007/s12275-014-3583-5; Yamaguchi M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0340-7; Yuan ZQ, 2011, IMMUNOL RES, V51, P108, DOI 10.1007/s12026-011-8234-x; Yuste J, 2005, J IMMUNOL, V175, P1813, DOI 10.4049/jimmunol.175.3.1813; Yuste J, 2008, INFECT IMMUN, V76, P3761, DOI 10.1128/IAI.00291-08; Zhang F, 2013, P NATL ACAD SCI USA, V110, P13564, DOI 10.1073/pnas.1307228110	172	3	3	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							181	10.3390/vaccines9020181			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6RK	33672701	Green Published, gold			2022-04-29	WOS:000623268600001
J	Sokaribo, AS; Perera, SR; Sereggela, Z; Krochak, R; Balezantis, LR; Xing, XH; Lam, S; Deck, W; Attah-Poku, S; Abbott, DW; Tamuly, S; White, AP				Sokaribo, Akosiererem S.; Perera, Sumudu R.; Sereggela, Zoe; Krochak, Ryan; Balezantis, Lindsay R.; Xing, Xiaohui; Lam, Shirley; Deck, William; Attah-Poku, Sam; Abbott, Dennis Wade; Tamuly, Shantanu; White, Aaron P.			A GMMA-CPS-Based Vaccine for Non-Typhoidal Salmonella	VACCINES			English	Article						vaccines; Salmonella; capsular polysaccharide; colanic acid; GMMAs		Non-typhoidal Salmonella are a major cause of gastroenteritis worldwide, as well as causing bloodstream infections in sub-Saharan Africa with a high fatality rate. No vaccine is currently available for human use. Current vaccine development strategies are focused on capsular polysaccharides (CPS) present on the surface of non-typhoidal Salmonella. This study aimed to boost the amount of CPS purified from S. Typhimurium for immunization trials. Random mutagenesis with Tn10 transposon increased the production of CPS colanic acid, by 10-fold compared to wildtype. Immunization with colanic acid or colanic acid conjugated to truncated glycoprotein D or inactivated diphtheria toxin did not induce a protective immune response in mice. However, immunization with Generalized Modules for Membrane Antigens (GMMAs) isolated from colanic acid overproducing isolates reduced Salmonella colonization in mice. Our results support the development of a GMMA-CPS-based vaccine against non-typhoidal Salmonella.	[Sokaribo, Akosiererem S.; Perera, Sumudu R.; Sereggela, Zoe; Krochak, Ryan; Balezantis, Lindsay R.; Lam, Shirley; Deck, William; Attah-Poku, Sam; White, Aaron P.] Vaccine & Infect Dis Org Int Vaccine Ctr, Saskatoon, SK S7N 5E3, Canada; [Sokaribo, Akosiererem S.; Perera, Sumudu R.; Sereggela, Zoe; Krochak, Ryan; Balezantis, Lindsay R.; White, Aaron P.] Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada; [Xing, Xiaohui; Abbott, Dennis Wade] Agr & Agri Food Canada, Lethbridge Res & Dev Ctr, Lethbridge, AB T1J 4B1, Canada; [Tamuly, Shantanu] Assam Agr Univ, Coll Vet Sci, Dept Vet Biochem, Gauhati 781022, Assam, India		White, AP (通讯作者)，Vaccine & Infect Dis Org Int Vaccine Ctr, Saskatoon, SK S7N 5E3, Canada.; White, AP (通讯作者)，Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada.	ats172@mail.usask.ca; sumudu.perera@usask.ca; zhs569@mail.usask.ca; rdk945@mail.usask.ca; lindsay.balezantis@usask.ca; xiaohui.xing@canada.ca; shirley.lam@usask.ca; will.deck@usask.ca; sam.attah-poku@usask.ca; wade.abbott@canada.ca; shantanu.tamuly@aau.ac.in; aaron.white@usask.ca		Xing, Xiaohui/0000-0002-9129-6542; Perera, Sumudu/0000-0003-0165-7189	Natural Sciences and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [2017-05737]; Jarislowsky Chair in Biotechnology; University of Saskatchewan	This research was supported by a Natural Sciences and Engineering Research Council (NSERC) Discovery grant (Grant #2017-05737 to A.P.W.), the Jarislowsky Chair in Biotechnology (A.P.W.), and the University of Saskatchewan (Graduate research fellowship to A.S.S.; Biomedical research awards to Z.S., R.K. and L.R.B.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAM O, 1995, ANAL BIOCHEM, V225, P321, DOI 10.1006/abio.1995.1161; Alaniz RC, 2007, J IMMUNOL, V179, P7692, DOI 10.4049/jimmunol.179.11.7692; ALLEN PM, 1987, J MED MICROBIOL, V24, P363, DOI 10.1099/00222615-24-4-363; Bai J, 2014, INFECT IMMUN, V82, P4001, DOI 10.1128/IAI.01416-13; Barak JD, 2007, MOL PLANT MICROBE IN, V20, P1083, DOI 10.1094/MPMI-20-9-1083; Bernadac A, 1998, J BACTERIOL, V180, P4872, DOI 10.1128/JB.180.18.4872-4878.1998; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; Bjarnason J, 2003, J BACTERIOL, V185, P4973, DOI 10.1128/JB.185.16.4973-4982.2003; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chen DJ, 2010, P NATL ACAD SCI USA, V107, P3099, DOI 10.1073/pnas.0805532107; Copeland S, 2005, CLIN DIAGN LAB IMMUN, V12, P60, DOI 10.1128/CDLI.12.1.60-67.2005; Crawford RW, 2008, INFECT IMMUN, V76, P5341, DOI 10.1128/IAI.00786-08; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Benedetto G, 2017, VACCINE, V35, P419, DOI 10.1016/j.vaccine.2016.11.089; Denger K, 2014, NATURE, V507, P114, DOI 10.1038/nature12947; DOWNS D, 1986, J BACTERIOL, V165, P193, DOI 10.1128/jb.165.1.193-197.1986; Dummer LA, 2014, VET RES, V45, DOI 10.1186/s13567-014-0111-x; ELLIOTT T, 1988, MOL GEN GENET, V213, P332, DOI 10.1007/BF00339599; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Eng SK, 2015, FRONT LIFE SCI, V8, P284, DOI 10.1080/21553769.2015.1051243; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Finn A, 2004, BRIT MED BULL, V70, P1, DOI 10.1093/bmb/ldh021; Flemming HC, 2016, MICROORGANISMS, V4, DOI 10.3390/microorganisms4040041; Gal-Mor O, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00391; Garg R, 2017, VACCINE, V35, P4486, DOI 10.1016/j.vaccine.2017.05.067; Gibson DL, 2006, J BACTERIOL, V188, P7722, DOI 10.1128/JB.00809-06; GOEBEL WF, 1963, P NATL ACAD SCI USA, V49, P464, DOI 10.1073/pnas.49.4.464; Goh YS, 2015, INFECT IMMUN, V83, P3722, DOI 10.1128/IAI.00547-15; Guzman CA, 2006, VACCINE, V24, P3804, DOI 10.1016/j.vaccine.2005.07.111; Henry T, 2004, RES MICROBIOL, V155, P437, DOI 10.1016/j.resmic.2004.04.007; Jan AT, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01053; Jones C, 2005, AN ACAD BRAS CIENC, V77, P293, DOI 10.1590/S0001-37652005000200009; Kaznadzey A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21534-3; Kim JY, 2008, J MOL BIOL, V380, P51, DOI 10.1016/j.jmb.2008.03.076; Kirk MD, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001921, 10.1371/journal.pmed.1001940]; Ledeboer NA, 2005, J BACTERIOL, V187, P3214, DOI 10.1128/JB.187.9.3214-3226.2005; Lei L, 2016, J IMMUNOL, V196, P792, DOI 10.4049/jimmunol.1500679; Lesinski Gregory B., 2001, Current Drug Targets - Infectious Disorders, V1, P325, DOI 10.2174/1568005014605964; LITTLEVANDENHURK V, 1994, VACCINE, V12, P1295, DOI 10.1016/S0264-410X(94)80055-5; Liu Q, 2016, INT J MED MICROBIOL, V306, P697, DOI 10.1016/j.ijmm.2016.08.004; Liu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep34776; Looijesteijn PJ, 1999, APPL ENVIRON MICROB, V65, P5003; Magalhaes PO, 2007, J PHARM PHARM SCI, V10, P388; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; Malabirade A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02015; Malito E, 2012, P NATL ACAD SCI USA, V109, P5229, DOI 10.1073/pnas.1201964109; Maloy S.R., 1996, GENETIC ANAL PATHOGE; Manoj S, 2003, VIROLOGY, V313, P296, DOI 10.1016/S0042-6822(03)00325-8; Marshall JM, 2015, INFECT IMMUN, V83, P3946, DOI 10.1128/IAI.00634-15; Marvasi M, 2013, MOL PLANT MICROBE IN, V26, P793, DOI 10.1094/MPMI-09-12-0208-R; Meloni E, 2015, J BIOTECHNOL, V198, P46, DOI 10.1016/j.jbiotec.2015.01.020; Mettu R, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0591-0; Micoli F, 2018, P NATL ACAD SCI USA, V115, P10428, DOI 10.1073/pnas.1807655115; Mozzi F, 2001, J APPL MICROBIOL, V91, P160, DOI 10.1046/j.1365-2672.2001.01367.x; Murray GL, 2003, MOL MICROBIOL, V47, P1395, DOI 10.1046/j.1365-2958.2003.03383.x; Ondari Edna M, 2019, Wellcome Open Res, V4, P74, DOI 10.12688/wellcomeopenres.15059.1; PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985; Pettolino FA, 2012, NAT PROTOC, V7, P1590, DOI 10.1038/nprot.2012.081; Phalipon A, 2009, J IMMUNOL, V182, P2241, DOI 10.4049/jimmunol.0803141; Qiao WL, 2015, VACCINE, V33, P2066, DOI 10.1016/j.vaccine.2015.02.045; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rappuoli R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4615; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Romero-Steiner S, 2001, CLIN DIAGN LAB IMMUN, V8, P1115, DOI 10.1128/CDLI.8.6.1115-1119.2001; Rondini S, 2015, INFECT IMMUN, V83, P996, DOI 10.1128/IAI.03079-14; Rondini S, 2013, MICROB PATHOGENESIS, V63, P19, DOI 10.1016/j.micpath.2013.05.014; Rossi O, 2016, CLIN VACCINE IMMUNOL, V23, P304, DOI 10.1128/CVI.00023-16; Sacoman JL, 2012, CARBOHYD RES, V362, P21, DOI 10.1016/j.carres.2012.09.014; Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525; Scorza FB, 2008, MOL CELL PROTEOMICS, V7, P473, DOI 10.1074/mcp.M700295-MCP200; Sengupta D, 2018, APPL MICROBIOL BIOT, V102, P1587, DOI 10.1007/s00253-018-8745-7; Shimada T, 2019, MICROBIOL-SGM, V165, P78, DOI 10.1099/mic.0.000740; Shivak DJ, 2016, APPL ENVIRON MICROB, V82, P4931, DOI 10.1128/AEM.01346-16; Snyder DS, 2006, CARBOHYD RES, V341, P2388, DOI 10.1016/j.carres.2006.06.010; Speciale G, 2016, NAT CHEM BIOL, V12, P215, DOI [10.1038/NCHEMBIO.2023, 10.1038/nchembio.2023]; Steenackers H, 2012, FOOD RES INT, V45, P502, DOI 10.1016/j.foodres.2011.01.038; Stevenson G, 2000, FEMS MICROBIOL LETT, V191, P11, DOI 10.1016/S0378-1097(00)00361-X; SUTHERLAND IW, 1969, BIOCHEM J, V115, P935, DOI 10.1042/bj1150935; Vipond C, 2005, HUM VACCINES, V1, P80, DOI 10.4161/hv.1.2.1651; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; White AP, 2008, INFECT IMMUN, V76, P1048, DOI 10.1128/IAI.01383-07; White AP, 2006, J BACTERIOL, V188, P3219, DOI 10.1128/JB.188.9.3219-3227.2006; Wood JA, 2018, PLANT CELL ENVIRON, V41, P2195, DOI 10.1111/pce.13196; Worley MJ, 2000, MOL MICROBIOL, V36, P749, DOI 10.1046/j.1365-2958.2000.01902.x	84	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							165	10.3390/vaccines9020165			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6RM	33671372	Green Published, gold			2022-04-29	WOS:000623268800001
J	Morandi, F; Sabatini, F; Podesta, M; Airoldi, I				Morandi, Fabio; Sabatini, Federica; Podesta, Marina; Airoldi, Irma			Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future	VACCINES			English	Review						neuroblastoma; immunotherapy; antibodies; CAR; NK; &#947; &#948; T cells		Neuroblastoma is the most common extracranial pediatric solid tumor with a heterogeneous clinical course, ranging from spontaneous regression to metastatic disease and death, irrespective of intensive chemotherapeutic regimen. On the basis of several parameters, children affected by neuroblastoma are stratified into low, intermediate and high risk. At present, more than 50% of high-risk patients with metastatic spread display an overall poor long-term outcome also complicated by devastating long-term morbidities. Thus, novel and more effective therapies are desperately needed to improve lifespan of high-risk patients. In this regard, adoptive cell therapy holds great promise and several clinical trials are ongoing, demonstrating safety and tolerability, with no toxicities. Starting from the immunological and clinical features of neuroblastoma, we here discuss the immunotherapeutic approaches currently adopted for high-risk patients and different innovative therapeutic strategies currently under investigation. The latter are based on the infusion of natural killer (NK) cells, as support of consolidation therapy in addition to standard treatments, or chimeric antigen receptor (CAR) T cells directed against neuroblastoma associated antigens (e.g., disialoganglioside GD2). Finally, future perspectives of adoptive cell therapies represented by gamma delta T lymphocyes and CAR NK cells are envisaged.	[Morandi, Fabio; Sabatini, Federica; Podesta, Marina; Airoldi, Irma] IRCCS, Ist Giannina Gaslini, Lab Cellule Staminali Postnatali & Terapie Cellul, Via G Gaslini 5, I-16147 Genoa, Italy		Airoldi, I (通讯作者)，IRCCS, Ist Giannina Gaslini, Lab Cellule Staminali Postnatali & Terapie Cellul, Via G Gaslini 5, I-16147 Genoa, Italy.	fabiomorandi@gaslini.org; federicasabatini@gaslini.org; marinapodesta@gaslini.org; irmaairoldi@gaslini.org	Podesta, Marina/K-3875-2016; Morandi, Fabio/I-1185-2012	Podesta, Marina/0000-0002-6755-613X; Morandi, Fabio/0000-0002-2849-7595	Italian Ministry of Health, Progetti di Ricerca Corrente 2020	This work was supported by Italian Ministry of Health, Progetti di Ricerca Corrente 2020.	Ali Tahir SM, 2001, J IMMUNOL, V167, P4046; Allegra A, 2016, BLOOD CELL MOL DIS, V62, P49, DOI 10.1016/j.bcmd.2016.11.001; Asgharzadeh S, 2012, J CLIN ONCOL, V30, P3525, DOI 10.1200/JCO.2011.40.9169; Bagatell R, 2011, J CLIN ONCOL, V29, P208, DOI 10.1200/JCO.2010.31.7107; Baker DL, 2010, NEW ENGL J MED, V363, P1313, DOI 10.1056/NEJMoa1001527; Barry WE, 2019, CLIN CANCER RES, V25, P325, DOI 10.1158/1078-0432.CCR-18-1317; BAUER M, 1995, CANCER, V75, P2959, DOI 10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R; Becher B, 2016, IMMUNITY, V45, P963, DOI 10.1016/j.immuni.2016.10.026; Berthold F, 2005, LANCET ONCOL, V6, P649, DOI 10.1016/S1470-2045(05)70291-6; Berzofsky JA, 2009, CURR MOL MED, V9, P667, DOI 10.2174/156652409788970706; Boissel L, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26527; Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267; Brenner MK, 2000, HUM GENE THER, V11, P1477; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Buccheri S, 2014, J BIOL REG HOMEOS AG, V28, P81; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Capsomidis A, 2018, MOL THER, V26, P354, DOI 10.1016/j.ymthe.2017.12.001; Castriconi R, 2004, CANCER RES, V64, P9180, DOI 10.1158/0008-5472.CAN-04-2682; Castriconi R, 2004, P NATL ACAD SCI USA, V101, P12640, DOI 10.1073/pnas.0405025101; Castriconi R, 2007, CANCER IMMUNOL IMMUN, V56, P1733, DOI 10.1007/s00262-007-0317-0; Chavez JC, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719841581; Chen XL, 2016, ONCOTARGET, V7, P27764, DOI 10.18632/oncotarget.8526; Chen YH, 2019, CLIN CANCER RES, V25, P2915, DOI 10.1158/1078-0432.CCR-18-1811; Chu J, 2014, LEUKEMIA, V28, P917, DOI 10.1038/leu.2013.279; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Colamartino ABL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02873; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Davey MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14760; Dhodapkar MV, 2003, J EXP MED, V197, P1667, DOI 10.1084/jem.20021650; Di Giannatale A, 2014, EUR J CANCER, V50, P170, DOI 10.1016/j.ejca.2013.08.012; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; Esser R, 2012, J CELL MOL MED, V16, P569, DOI 10.1111/j.1582-4934.2011.01343.x; Federico SM, 2017, CLIN CANCER RES, V23, P6441, DOI 10.1158/1078-0432.CCR-17-0379; Feichtinger Rene' G, 2011, Front Biosci (Elite Ed), V3, P179, DOI 10.2741/e231; Feichtinger RG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-149; Gargett T, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00235; GROSS G, 1989, TRANSPLANT P, V21, P127; Han JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11483; HANDGRETINGER R, 1992, CANCER IMMUNOL IMMUN, V35, P199, DOI 10.1007/BF01756188; Hartmann J, 2017, EMBO MOL MED, V9, P1183, DOI 10.15252/emmm.201607485; Heczey A, 2017, MOL THER, V25, P2214, DOI 10.1016/j.ymthe.2017.05.012; HEINER JP, 1987, CANCER RES, V47, P5377; Heinze A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02816; Herrera L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55239-y; Irwin MS, 2015, PEDIATR CLIN N AM, V62, P225, DOI 10.1016/j.pcl.2014.09.015; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; Kailayangiri S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1250050; Kalwak K, 2003, J INTERF CYTOK RES, V23, P173, DOI 10.1089/107999003765027375; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kayano D, 2018, NUCL MED MOLEC IMAG, V52, P254, DOI 10.1007/s13139-018-0523-z; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Kunkele A, 2017, CLIN CANCER RES, V23, P466, DOI 10.1158/1078-0432.CCR-16-0354; KUSHNER BH, 1989, BLOOD, V73, P1936; Kushner BH, 2001, J CLIN ONCOL, V19, P4189, DOI 10.1200/JCO.2001.19.22.4189; Kushner BH, 2006, J CLIN ONCOL, V24, P5271, DOI 10.1200/JCO.2006.06.7272; Kushner BH, 2018, JAMA ONCOL, V4, P1729, DOI 10.1001/jamaoncol.2018.4005; Ladenstein R, 2018, LANCET ONCOL, V19, P1617, DOI 10.1016/S1470-2045(18)30578-3; LAMMIE GA, 1993, INT J ONCOL, V3, P909; Li J, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0568-6; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Liu DF, 2012, J CLIN INVEST, V122, P2221, DOI 10.1172/JCI59535; Liu Y, 2013, CLIN CANCER RES, V19, P2132, DOI 10.1158/1078-0432.CCR-12-1243; Lo Presti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01395; London WB, 2005, J CLIN ONCOL, V23, P6459, DOI 10.1200/JCO.2005.05.571; London WB, 2010, J CLIN ONCOL, V28, P3808, DOI 10.1200/JCO.2009.27.5016; Loo D, 2012, CLIN CANCER RES, V18, P3834, DOI 10.1158/1078-0432.CCR-12-0715; Louis CU, 2011, BLOOD, V118, P6050, DOI 10.1182/blood-2011-05-354449; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Marimpietri D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075054; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matthay KK, 2010, BRIT J CANCER, V102, P1319, DOI 10.1038/sj.bjc.6605621; Matthay KK, 2007, J CLIN ONCOL, V25, P1054, DOI 10.1200/JCO.2006.09.3484; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Minculescu L, 2015, SCAND J IMMUNOL, V81, P459, DOI 10.1111/sji.12289; Mirzaei HR, 2016, CANCER LETT, V380, P413, DOI 10.1016/j.canlet.2016.07.001; Modak S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1461305; Mody R, 2017, LANCET ONCOL, V18, P946, DOI 10.1016/S1470-2045(17)30355-8; Morandi F, 2007, CANCER RES, V67, P6433, DOI 10.1158/0008-5472.CAN-06-4588; Morandi F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081757; Morandi F, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4326495; Moretta L, 2004, CURR OPIN IMMUNOL, V16, P626, DOI 10.1016/j.coi.2004.07.010; Morgenstern DA, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27363; Morgenstern DA, 2016, EUR J CANCER, V65, P1, DOI 10.1016/j.ejca.2016.06.005; Morscher RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129802; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; MUNN DH, 1989, J EXP MED, V170, P511, DOI 10.1084/jem.170.2.511; Nguyen R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000176; Nussbaumer O., 2019, IMMUNO ONCOL TECHNOL, V1, P3, DOI [DOI 10.1016/J.IOTECH.2019.06.002, 10.1016/j.iotech.2019.06.002]; Ozkaynak MF, 2000, J CLIN ONCOL, V18, P4077, DOI 10.1200/JCO.2000.18.24.4077; Park JA, 2020, J CLIN ONCOL, V38, P1836, DOI 10.1200/JCO.19.01410; Park JR, 2007, MOL THER, V15, P825, DOI 10.1038/sj.mt.6300104; Pelizzo G, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5082-2; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pinz KG, 2017, ONCOTARGET, V8, P112783, DOI 10.18632/oncotarget.22626; Ploessl C, 2016, ANN PHARMACOTHER, V50, P416, DOI 10.1177/1060028016632013; Polito VA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02717; Pritchard J, 2005, PEDIATR BLOOD CANCER, V44, P348, DOI 10.1002/pbc.20219; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; Quintarelli C, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433518; Raffaghello L, 2005, CANCER LETT, V228, P155, DOI 10.1016/j.canlet.2004.11.064; Rezvani K, 2017, MOL THER, V25, P1769, DOI 10.1016/j.ymthe.2017.06.012; Romanski A, 2016, J CELL MOL MED, V20, P1287, DOI 10.1111/jcmm.12810; ROPER M, 1992, AM J PEDIAT HEMATOL, V14, P305; Rousseau RF, 2003, BLOOD, V101, P1718, DOI 10.1182/blood-2002-08-2493; Rubie H, 2011, J CLIN ONCOL, V29, P449, DOI 10.1200/JCO.2010.29.5196; SAARINEN UM, 1985, CANCER RES, V45, P5969; Sabry M, 2020, STEM CELL TRANSL MED, V9, P974, DOI 10.1002/sctm.19-0423; Sano R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9732; Sawaisorn P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040753; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schulte JH, 2013, KLIN PADIATR, V225, P303, DOI 10.1055/s-0033-1357132; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Strother DR, 2012, J CLIN ONCOL, V30, P1842, DOI 10.1200/JCO.2011.37.9990; Suzuki M, 2015, EXPERT OPIN THER TAR, V19, P349, DOI 10.1517/14728222.2014.986459; Swann J, 2004, IMMUNOL CELL BIOL, V82, P323, DOI 10.1111/j.1440-1711.2004.01254.x; Swann JB, 2007, CURR TOP MICROBIOL, V314, P293; Talleur AC, 2017, BIOL BLOOD MARROW TR, V23, P1910, DOI 10.1016/j.bbmt.2017.07.011; Tang XW, 2018, AM J CANCER RES, V8, P1083; Tolbert VP, 2018, CELL TISSUE RES, V372, P195, DOI 10.1007/s00441-018-2821-2; Tran HC, 2017, CLIN CANCER RES, V23, P804, DOI 10.1158/1078-0432.CCR-16-1743; Vanichapol T, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1812535; Vermijlen D, 2018, SEMIN CELL DEV BIOL, V84, P75, DOI 10.1016/j.semcdb.2017.10.009; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Vo KT, 2014, J CLIN ONCOL, V32, P3169, DOI 10.1200/JCO.2014.56.1621; Voeller J, 2019, J PEDIAT HEMATOL ONC, V41, P163, DOI 10.1097/MPH.0000000000001369; Wilson JS, 2014, EUR J CANCER, V50, P801, DOI 10.1016/j.ejca.2013.11.016; Yanagisawa K, 2002, J IMMUNOL, V168, P6494, DOI 10.4049/jimmunol.168.12.6494; Yazdanifar M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051305; Yazdanifar Mahboubeh, 2016, Curr Trends Immunol, V17, P95; You FT, 2019, AM J CANCER RES, V9, P64; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Yu M, 2018, MOL THER, V26, P366, DOI 10.1016/j.ymthe.2017.12.012; Zhang CC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv375; Zhang ER, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0646-9; Zhang Q, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4263520; Zhou MJ, 2015, EUR J CANCER, V51, P2465, DOI 10.1016/j.ejca.2015.07.023	143	4	4	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							43	10.3390/vaccines9010043			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PY1YX	33450862	Green Published, gold			2022-04-29	WOS:000611847500001
J	Nishimura, K; Yamana, K; Fukushima, S; Fujioka, K; Miyabayashi, H; Murabayashi, M; Masunaga, K; Okahashi, A; Nagano, N; Morioka, I				Nishimura, Koji; Yamana, Keiji; Fukushima, Sachiyo; Fujioka, Kazumichi; Miyabayashi, Hiroshi; Murabayashi, Masao; Masunaga, Ken; Okahashi, Aya; Nagano, Nobuhiko; Morioka, Ichiro			Comparison of Two Hepatitis B Vaccination Strategies Targeting Vertical Transmission: A 10-Year Japanese Multicenter Prospective Cohort Study	VACCINES			English	Article						hepatitis B surface antigen; hepatitis B virus; immunogenic response; mother-to-child infection; prevention		In 1985, a hepatitis B (HB) vaccination strategy against vertical HB virus transmission was introduced in Japan that recommended vaccination of infants at two, three, and five months of age (delayed strategy). This schedule was revised in 2013, recommending to vaccinate at birth and at 1 and 6 months of age (non-delayed strategy). We aimed to compare the vertical HB virus transmission rates and immunogenic responses between these two vaccination strategies. This Japanese multicenter prospective cohort study included 222 infants born between 2008 and 2017 to serum hepatitis B surface (HBs) antigen (HBsAg)-positive mothers. During the study period, 136 and 86 infants received delayed and non-delayed strategies, respectively. A positive vertical HB virus transmission was defined as a positive serum HBsAg status. Seropositive immunogenic response was defined as a serum anti-HBs titer of >= 10 mIU/mL. Post-vaccination serum HBsAg positivity rates did not differ significantly between the delayed (0/136 [0.0%, 95% confidence interval, 0.0-2.7%]) and non-delayed (2/86 [2.3%, 95% confidence interval, 0.3-8.1%]) strategy groups. Seropositive immunogenic response rates were 100.0% (136/136) and 97.7% (84/86), respectively. Although this study was under-powered to detect a statistically significant result, no vertical HB virus transmission was observed in the delayed strategy.	[Nishimura, Koji; Okahashi, Aya; Nagano, Nobuhiko; Morioka, Ichiro] Nihon Univ, Sch Med, Dept Pediat & Child Hlth, Tokyo 1738610, Japan; [Yamana, Keiji; Fukushima, Sachiyo; Fujioka, Kazumichi] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Yamana, Keiji] Kakogawa Cent City Hosp, Dept Pediat, Kakogawa, Hyogo 6758611, Japan; [Miyabayashi, Hiroshi] Kasukabe Med Ctr, Dept Pediat, Kasukabe 3448588, Japan; [Murabayashi, Masao] Numazu City Hosp, Dept Pediat, Numazu 4100302, Japan; [Masunaga, Ken] Tokyo Metropolitan Otsuka Hosp, Div Neonatol, Tokyo 1708476, Japan		Morioka, I (通讯作者)，Nihon Univ, Sch Med, Dept Pediat & Child Hlth, Tokyo 1738610, Japan.	nishimura.koji@nihon-u.ac.jp; nishimura.koji@nihon-u.ac.jp; sachi4@med.kobe-u.ac.jp; fujiokak@med.kobe-u.ac.jp; miyabayashi@dr.memail.jp; numazuhp2451.shouni@bz04.plala.or.jp; ken_masunaga@tmhp.jp; okahashi.aya@nihon-u.ac.jp; nagano.nobuhiko@nihon-u.ac.jp; morioka.ichiro@nihon-u.ac.jp	; Nagano, Nobuhiko/H-3478-2017	Miyabayashi, Hiroshi/0000-0002-6657-6884; FUJIOKA, KAZUMICHI/0000-0002-9913-6447; Nagano, Nobuhiko/0000-0002-0890-1626; Morioka, Ichiro/0000-0002-5685-2670	Ministry of Health, Labor, and Welfare of JapanMinistry of Health, Labour and Welfare, Japan [H30-Kansei-Shitei-002]	This research was funded by the Ministry of Health, Labor, and Welfare of Japan, grant number H30-Kansei-Shitei-002.	BEASLEY RP, 1983, LANCET, V2, P1099; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; Dumolard L., 2008, Morbidity and Mortality Weekly Report, V57, P1249; ETO T, 1989, Acta Paediatrica Japonica, V31, P681; Hokama T, 1998, Asia Pac J Public Health, V10, P46, DOI 10.1177/101053959801000110; Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578; Japan Pediatric Society, 2013, NEW GUID PREV MOTH T; Japan Pediatric Society, 2014, PREV HEP B VIR MOTH; Kimberlin DW, 2015, RED BOOK 2015 REPORT, P400; Komatsu H., 2010, KANZO, V51, P92, DOI [10.2957/kanzo.51.92, DOI 10.2957/KANZO.51.92]; Komatsu H., 2016, J PEDIAT INFECT DIS, V28, P179; Kramvis A, 2005, VACCINE, V23, P2409, DOI 10.1016/j.vaccine.2004.10.045; Lin XF, 2014, PEDIATR INFECT DIS J, V33, P897, DOI 10.1097/INF.0000000000000315; Momose H., 2020, JPN J TRANSFUS CELL, V66, P629, DOI [10.3925/jjtc.66.629, DOI 10.3925/JJTC.66.629]; Nagano N, 2020, J INFECT CHEMOTHER, V26, P385, DOI 10.1016/j.jiac.2019.11.007; Nishida N, 2018, HEPATOLOGY, V68, P848, DOI 10.1002/hep.29876; Pan CQ, 2016, NEW ENGL J MED, V374, P2324, DOI 10.1056/NEJMoa1508660; Purdy Michael A, 2007, Asian J Transfus Sci, V1, P62, DOI 10.4103/0973-6247.33445; Saari TN, 2003, PEDIATRICS, V112, P193, DOI 10.1542/peds.112.1.193; Shiraki K, 1984, VIRAL HEPATITIS INFE, P189; Tamada Y, 2012, GUT, V61, P765, DOI 10.1136/gutjnl-2011-300832; The Japan Society of Hepatology, 2020, GUIDELINES TREATMENT; Tregnaghi M, 2004, REV PANAM SALUD PUBL, V15, P35, DOI 10.1590/S1020-49892004000100006; Wang C, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004390; West DJ, 1996, VACCINE, V14, P1019, DOI 10.1016/0264-410X(96)00062-X; World Health Organization, 2020, PREV MOTH TO CHILD T; Yamana K, 2018, PEDIATR INT, V60, P489, DOI 10.1111/ped.13547; Zhang L, 2014, VACCINE, V32, P6091, DOI 10.1016/j.vaccine.2014.08.078	28	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							58	10.3390/vaccines9010058			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TK	33477275	Green Published, gold			2022-04-29	WOS:000610804300001
J	Shao, S; Ortega-Rivera, OA; Ray, S; Pokorski, JK; Steinmetz, NF				Shao, Shuai; Ortega-Rivera, Oscar A.; Ray, Sayoni; Pokorski, Jonathan K.; Steinmetz, Nicole F.			A Scalable Manufacturing Approach to Single Dose Vaccination against HPV	VACCINES			English	Article						HPV vaccine candidate; L2 protein; Q&#946; virus-like particles (VLPs); PLGA implants; vaccine delivery device; hot melt extrusion		Human papillomavirus (HPV) is a globally prevalent sexually-transmitted pathogen, responsible for most cases of cervical cancer. HPV vaccination rates remain suboptimal, partly due to the need for multiple doses, leading to a lack of compliance and incomplete protection. To address the drawbacks of current HPV vaccines, we used a scalable manufacturing process to prepare implantable polymer-protein blends for single-administration with sustained delivery. Peptide epitopes from HPV16 capsid protein L2 were conjugated to the virus-like particles derived from bacteriophage Q beta, to enhance their immunogenicity. The HPV-Q beta particles were then encapsulated into poly(lactic-co-glycolic acid) (PLGA) implants, using a benchtop melt-processing system. The implants facilitated the slow and sustained release of HPV-Q beta particles without the loss of nanoparticle integrity, during high temperature melt processing. Mice vaccinated with the implants generated IgG titers comparable to the traditional soluble injections and achieved protection in a pseudovirus neutralization assay. HPV-Q beta implants offer a new vaccination platform; because the melt-processing is so versatile, the technology offers the opportunity for massive upscale into any geometric form factor. Notably, microneedle patches would allow for self-administration in the absence of a healthcare professional, within the developing world. The Q beta technology is highly adaptable, allowing the production of vaccine candidates and their delivery devices for multiple strains or types of viruses.	[Shao, Shuai; Ortega-Rivera, Oscar A.; Ray, Sayoni; Pokorski, Jonathan K.; Steinmetz, Nicole F.] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA; [Shao, Shuai; Ortega-Rivera, Oscar A.; Ray, Sayoni; Pokorski, Jonathan K.; Steinmetz, Nicole F.] Univ Calif San Diego, Ctr NanoimmunoEngn, La Jolla, CA 92093 USA; [Pokorski, Jonathan K.; Steinmetz, Nicole F.] Univ Calif San Diego, Inst Mat Discovery & Design, La Jolla, CA 92093 USA; [Steinmetz, Nicole F.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Steinmetz, Nicole F.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA; [Steinmetz, Nicole F.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA		Pokorski, JK; Steinmetz, NF (通讯作者)，Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA.; Pokorski, JK; Steinmetz, NF (通讯作者)，Univ Calif San Diego, Ctr NanoimmunoEngn, La Jolla, CA 92093 USA.; Pokorski, JK; Steinmetz, NF (通讯作者)，Univ Calif San Diego, Inst Mat Discovery & Design, La Jolla, CA 92093 USA.; Steinmetz, NF (通讯作者)，Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.; Steinmetz, NF (通讯作者)，Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.; Steinmetz, NF (通讯作者)，Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.	lovefavor0509@hotmail.com; oortegarivera@eng.ucsd.edu; saray@eng.ucsd.edu; jpokorski@eng.ucsd.edu; nsteinmetz@ucsd.edu		Steinmetz, Nicole/0000-0002-0130-0481; Ray, Sayoni/0000-0002-1947-181X; SHAO, SHUAI/0000-0002-2682-1830; Pokorski, Jonathan/0000-0001-5869-6942; Ortega-Rivera, Oscar/0000-0002-0773-0677	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21EB024874]; National Science FoundationNational Science Foundation (NSF) [CMMI-2027668]; UC MEXUS-CONACYT Postdoctoral Fellowship 2019-2020 [FE-19-58]	This work was funded in part by a grant from the National Institute of Health (R21EB024874 to JKP and NFS) and National Science Foundation (CMMI-2027668 to NFS and JKP). O.A.O.-R. acknowledges the UC MEXUS-CONACYT Postdoctoral Fellowship 2019-2020 number FE-19-58.	Ahlborg N, 1998, VACCINE, V16, P38, DOI 10.1016/S0264-410X(97)00155-2; Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P626; Bao Q, 2019, ADV DRUG DELIVER REV, V145, P40, DOI 10.1016/j.addr.2018.12.013; CDC (Centers for Disease Control and Prevention), 2012, HPV VACC INF CLIN FA; Centers for Disease Control and Prevention, 2014, GEN HPV INF CDC FACT; Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9; Cirelli KM, 2017, CURR OPIN IMMUNOL, V47, P64, DOI 10.1016/j.coi.2017.06.008; Day PM, 2012, CLIN VACCINE IMMUNOL, V19, P1075, DOI 10.1128/CVI.00139-12; Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041; Desai KGH, 2013, J CONTROL RELEASE, V165, P62, DOI 10.1016/j.jconrel.2012.10.012; European Medicines Agency, 2015, GARD 9 PUBL ASS REP; Irvine DJ, 2020, ADV DRUG DELIVER REV, V158, P91, DOI 10.1016/j.addr.2020.06.019; Isarov SA, 2016, BIOMACROMOLECULES, V17, P641, DOI 10.1021/acs.biomac.5b01582; Kirby T, 2015, LANCET ONCOL, V16, pE56, DOI 10.1016/S1470-2045(14)71191-X; Lee PW, 2017, ACS NANO, V11, P8777, DOI 10.1021/acsnano.7b02786; Mohsen MO, 2017, J CONTROL RELEASE, V251, P92, DOI 10.1016/j.jconrel.2017.02.031; Monso M, 2013, BIOCONJUGATE CHEM, V24, P578, DOI 10.1021/bc300515t; Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300; Reagan-Steiner S, 2015, MMWR-MORBID MORTAL W, V64, P784, DOI 10.15585/mmwr.mm6429a3; Shao S, 2015, NAT CHEM, V7, P438, DOI [10.1038/NCHEM.2236, 10.1038/nchem.2236]; Shukla S, 2017, BIOMATERIALS, V121, P15, DOI 10.1016/j.biomaterials.2016.12.030; Stokley S, 2014, MMWR-MORBID MORTAL W, V63, P620; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; Trus B., 2005, MICROSC MICROANAL, V11, P642, DOI [10.1017/S1431927605505592, DOI 10.1017/S1431927605505592]; Tumban E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023310; Tyler M, 2014, VACCINE, V32, P4267, DOI 10.1016/j.vaccine.2014.06.054; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2; Wigle J, 2016, PEDIATR CLIN N AM, V63, P81, DOI 10.1016/j.pcl.2015.08.004; Wirth DM, 2019, POLYMER, V181, DOI 10.1016/j.polymer.2019.121802; Xia YF, 2018, NAT MATER, V17, P187, DOI [10.1038/NMAT5057, 10.1038/nmat5057]; Yue H, 2015, VACCINE, V33, P5927, DOI 10.1016/j.vaccine.2015.07.100; Zhai LK, 2017, ANTIVIR RES, V147, P116, DOI 10.1016/j.antiviral.2017.09.012; Zhai LK, 2016, ANTIVIR RES, V130, P101, DOI 10.1016/j.antiviral.2016.03.016	33	7	7	9	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							66	10.3390/vaccines9010066			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6YG	33478147	gold, Green Published			2022-04-29	WOS:000610817100001
J	Verschoor, CP; Andrew, MK; Loeb, M; Pawelec, G; Haynes, L; Kuchel, GA; McElhaney, JE				Verschoor, Chris P.; Andrew, Melissa K.; Loeb, Mark; Pawelec, Graham; Haynes, Laura; Kuchel, George A.; McElhaney, Janet E.			Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults	VACCINES			English	Article						influenza; vaccination; older adults; correlates of protection; antibody; cell-mediated immunity		Despite efforts to design better vaccines for older adults, the risk for serious complications of influenza remains disproportionately high. Identifying correlates of vaccine effectiveness and understanding the heterogeneity of health outcomes in older adults are key to the vaccine development pipeline. We sought correlates of protection against laboratory-confirmed influenza illness (LCII) in a 4-year randomized trial of standard versus high-dose influenza vaccination of adults 65 years and older. To this end, we quantified serum hemagglutination-inhibition (HAI) titers and interferon-gamma (IFN gamma) and interleukin-10 (IL-10) secretion by virus-challenged peripheral blood mononuclear cells. Of the 608 participants included, 26 developed either A/H3N2-(n = 17) or B-LCII (n = 9) at 10-20 weeks post-vaccination. Antibody titres for A/H3N2 at 4-weeks post-vaccination were significantly associated with protection against LCII, where every 1-standard deviation increase reduced the odds of A/H3N2-LCII by 53%. Although B-titres did not correlate with protection against B-LCII, the fold-increase in IFN gamma:IL-10 ratios from pre- to 4-weeks post-vaccination was significantly associated with protection against B-LCII, where every 1-standard deviation increase reduced the odds by 71%. Our results suggest that both antibody and cell-mediated immune measures are valuable and potentially complementary correlates of protection against LCII in vaccinated older adults, although this may depend on the viral type causing infection.	[Verschoor, Chris P.; Pawelec, Graham; McElhaney, Janet E.] Hlth Sci North Res Inst, Sudbury, ON P3E 5J1, Canada; [Verschoor, Chris P.; McElhaney, Janet E.] Northern Ontario Sch Med, Sudbury, ON P3E 2C6, Canada; [Andrew, Melissa K.] Dalhousie Univ, Dept Med Geriatr, Halifax, NS B3H 2E1, Canada; [Loeb, Mark] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada; [Pawelec, Graham] Univ Tubingen, Dept Immunol, D-72074 Tubingen, Germany; [Haynes, Laura; Kuchel, George A.] Univ Connecticut, Sch Med, UConn Ctr Aging, Farmington, CT 06030 USA		Verschoor, CP (通讯作者)，Hlth Sci North Res Inst, Sudbury, ON P3E 5J1, Canada.; Verschoor, CP (通讯作者)，Northern Ontario Sch Med, Sudbury, ON P3E 2C6, Canada.	cverschoor@hsnri.ca; Melissa.Andrew@nshealth.ca; loebm@mcmaster.ca; graham.pawelec@uni-tuebingen.de; lhaynes@uchc.edu; kuchel@uchc.edu; jmcelhaney@hsnri.ca	Andrew, Melissa/AAR-7052-2021	Pawelec, Graham/0000-0002-3600-0163; Andrew, Melissa/0000-0001-7514-8972	NIA/National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG048023]; Health Sciences North Research Chair in Healthy Aging; Travelers Chair in Geriatrics and Gerontology	We would like to acknowledge the generous funding provided by the NIA/National Institutes of Health to Kuchel and McElhaney and co-investigators (R01 AG048023). McElhaney is supported by the Health Sciences North Research Chair in Healthy Aging and Kuchel is supported by the Travelers Chair in Geriatrics and Gerontology.	Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282; [Anonymous], CDC seasonal flu vaccine effectiveness studies; CDC Weekly U.S., CDC WEEKLY; Chen MI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012474; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Dunning AJ, 2016, CLIN VACCINE IMMUNOL, V23, P228, DOI 10.1128/CVI.00604-15; Ferdinands JM, 2019, J INFECT DIS, V220, P1265, DOI 10.1093/infdis/jiy723; Gijzen K, 2010, VACCINE, V28, P3416, DOI 10.1016/j.vaccine.2010.02.076; Gooch KE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38885-0; GRAVENSTEIN S, 1990, CLIN RES, V38, pA547; Haq K, 2017, J GERONTOL A-BIOL, V72, P1163, DOI 10.1093/gerona/glw216; He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113; Hoover M, 2013, HEALTH REP, V24, P10; Kissling E, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100042; Krammer F, 2020, INFLUENZA OTHER RESP, V14, P237, DOI 10.1111/irv.12706; Lancaster GI, 2014, TRENDS IMMUNOL, V35, P262, DOI 10.1016/j.it.2014.02.008; Li J, 2015, INT J INFECT DIS, V40, P17, DOI 10.1016/j.ijid.2015.09.013; Loeb N, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa148; McElhaney JE, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00181-1; McElhaney JE, 2015, METHODS MOL BIOL, V1343, P121, DOI 10.1007/978-1-4939-2963-4_11; McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333; McElhaney JE, 2004, VACCINE, V22, P681, DOI 10.1016/j.vaccine.2003.08.032; McNeil S., 2012, P IDWEEK 2012 M INF; Merani S, 2018, EXP GERONTOL, V107, P116, DOI 10.1016/j.exger.2017.09.015; Mitnitski A B, 2001, ScientificWorldJournal, V1, P323; Ruiz-Palacios GM, 2016, HUM VACC IMMUNOTHER, V12, P3043, DOI 10.1080/21645515.2016.1219809; Searle Samuel D, 2008, BMC Geriatr, V8, P24, DOI 10.1186/1471-2318-8-24; Segaloff HE, 2018, EPIDEMIOL INFECT, V146, P1350, DOI [10.1017/s0950268818001486, 10.1017/S0950268818001486]; Shahid Z, 2010, VACCINE, V28, P6145, DOI 10.1016/j.vaccine.2010.07.036; Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035; Skowronski DM, 2011, J INFECT DIS, V203, P158, DOI 10.1093/infdis/jiq039; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI [10.1016/S2213-2600(18)30496-X, 10.1016/s2213-2600(18)30496-x]; van de Sandt CE, 2014, J VIROL, V88, P1684, DOI 10.1128/JVI.02843-13; World Health Organization, 2002, WHO MAN AN INFL DIAG; Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635	38	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							25	10.3390/vaccines9010025			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TV	33430191	Green Published			2022-04-29	WOS:000610805400001
J	Barboza-Solis, C; Najimudeen, SM; Perez-Contreras, A; Ali, A; Joseph, T; King, R; Ravi, M; Peters, D; Fonseca, K; Gagnon, CA; van der Meer, F; Abdul-Careem, MF				Barboza-Solis, Catalina; Najimudeen, Shahnas M.; Perez-Contreras, Ana; Ali, Ahmed; Joseph, Tomy; King, Robin; Ravi, Madhu; Peters, Delores; Fonseca, Kevin; Gagnon, Carl A.; van der Meer, Frank; Abdul-Careem, Mohamed Faizal			Evaluation of Recombinant Herpesvirus of Turkey Laryngotracheitis (rHVT-LT) Vaccine against Genotype VI Canadian Wild-Type Infectious Laryngotracheitis Virus (ILTV) Infection	VACCINES			English	Article						infectious laryngotracheitis virus; rHVT-LT recombinant vaccine; chicken; immune response	IN-OVO; PATHOGEN-FREE; CHICKEN; PROTECTION; CHALLENGE; IMMUNITY; STRAINS; EFFICACY; LATENCY; PROLIFERATION	In Alberta, infectious laryngotracheitis virus (ILTV) infection is endemic in backyard poultry flocks; however, outbreaks are only sporadically observed in commercial flocks. In addition to ILTV vaccine revertant strains, wild-type strains are among the most common causes of infectious laryngotracheitis (ILT). Given the surge in live attenuated vaccine-related outbreaks, the goal of this study was to assess the efficacy of a recombinant herpesvirus of turkey (rHVT-LT) vaccine against a genotype VI Canadian wild-type ILTV infection. One-day-old specific pathogen-free (SPF) White Leghorn chickens were vaccinated with the rHVT-LT vaccine or mock vaccinated. At three weeks of age, half of the vaccinated and the mock-vaccinated animals were challenged. Throughout the experiment, weights were recorded, and feather tips, cloacal and oropharyngeal swabs were collected for ILTV genome quantification. Blood was collected to isolate peripheral blood mononuclear cells (PBMC) and quantify CD4+ and CD8+ T cells. At 14 dpi, the chickens were euthanized, and respiratory tissues were collected to quantify genome loads and histological examination. Results showed that the vaccine failed to decrease the clinical signs at 6 days post-infection. However, it was able to significantly reduce ILTV shedding through the oropharyngeal route. Overall, rHVT-LT produced a partial protection against genotype VI ILTV infection.	[Barboza-Solis, Catalina; Najimudeen, Shahnas M.; Perez-Contreras, Ana; Ali, Ahmed; van der Meer, Frank; Abdul-Careem, Mohamed Faizal] Univ Calgary, Hlth Res Innovat Ctr 2C53, Fac Vet Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Ali, Ahmed] Beni Suef Univ, Dept Pathol, Bani Suwayf 62511, Egypt; [Joseph, Tomy] Anim Hlth Ctr, Minist Agr Food & Fisheries, Abbotsford, BC V3G 2M3, Canada; [King, Robin] Alberta Agr & Forestry, Agri Food Labs, Edmonton, AB T6H 4P2, Canada; [Ravi, Madhu; Peters, Delores] Alberta Agr & Forestry, Anim Hlth & Assurance, Edmonton, AB T6H 4P2, Canada; [Fonseca, Kevin] Prov Lab Publ Hlth, Calgary, AB T2N 4W4, Canada; [Gagnon, Carl A.] Univ Montreal, Fac Vet Med, Swine & Poultry Infect Dis Res Ctr, 3200 Sicotte, St Hyacinthe, PQ J2S 2M2, Canada		Abdul-Careem, MF (通讯作者)，Univ Calgary, Hlth Res Innovat Ctr 2C53, Fac Vet Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	catalina.barboza@ucalgary.ca; fathimashahnas.moham@ucalgary.ca; ana.perezcontreras@ucalgary.ca; ahmed.ali@ucalgary.ca; tomy.joseph@gov.bc.ca; blking@telus.net; madhu.ravi@gov.ab.ca; delores.peters@gov.ab.ca; kevin.fonseca@albertaprecisionlabs.ca; carl.a.gagnon@umontreal.ca; fjvander@ucalgary.ca; faizal.abdulcareem@ucalgary.ca		Najimudeen, Shahnas/0000-0001-9767-8341; Gagnon, Carl A./0000-0003-4528-541X; Ali, Ahmed/0000-0002-8662-1291			Agnew-Crumpton R, 2016, INFECT GENET EVOL, V43, P67, DOI 10.1016/j.meegid.2016.05.023; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BAGUST TJ, 1986, AVIAN PATHOL, V15, P581, DOI 10.1080/03079458608436317; Bagust TJ, 2000, REV SCI TECH OIE, V19, P483, DOI 10.20506/rst.19.2.1229; Barboza-Solis C, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091634; Bayoumi M, 2020, ARCH VIROL, V165, P661, DOI 10.1007/s00705-019-04522-4; BENTON W. J., 1958, AVIAN DIS, V2, P383, DOI 10.2307/1587478; Centre F.B.C, DIS WATCH ILT NIAGAR; Chacon JL, 2009, VACCINE, V27, P6731, DOI 10.1016/j.vaccine.2009.08.083; Cover MS, 1996, AVIAN DIS, V40, P494, DOI 10.2307/1592256; CRUICKSHANK JG, 1963, VIROLOGY, V20, P376, DOI 10.1016/0042-6822(63)90129-6; Dalgaard TS, 2010, VET IMMUNOL IMMUNOP, V138, P85, DOI 10.1016/j.vetimm.2010.07.010; Davidson I, 2016, VACCINE, V34, P1630, DOI 10.1016/j.vaccine.2016.01.006; Davison S, 2006, AVIAN DIS, V50, P50, DOI 10.1637/7398-062105R.1; Devlin JM, 2006, ARCH VIROL, V151, P1281, DOI 10.1007/s00705-005-0721-8; Devlin JM, 2010, VACCINE, V28, P1325, DOI 10.1016/j.vaccine.2009.11.013; Esaki M, 2013, AVIAN DIS, V57, P192, DOI 10.1637/10383-092412-Reg.1; FAHEY KJ, 1990, J GEN VIROL, V71, P2401, DOI 10.1099/0022-1317-71-10-2401; FAHEY KJ, 1984, AVIAN PATHOL, V13, P265, DOI 10.1080/03079458408418530; FAHEY KJ, 1983, AVIAN PATHOL, V12, P505, DOI 10.1080/03079458308436195; Garcia M., 2013, DIS POULTRY, V13th ed., P161; Garcia M, 2019, AVIAN DIS, V63, P325, DOI 10.1637/11967-090218-Review.1; GELENCZEI EF, 1964, AVIAN DIS, V8, P105, DOI 10.2307/1587827; Gimeno IM, 2011, AVIAN PATHOL, V40, P395, DOI 10.1080/03079457.2011.588196; GUY JS, 1990, AVIAN DIS, V34, P106, DOI 10.2307/1591340; GUY JS, 1991, AVIAN DIS, V35, P348, DOI 10.2307/1591188; Hao XL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121396; Hein T., ILT OUTBREAKS HIT ON; HONDA T, 1994, J VET MED SCI, V56, P1051, DOI 10.1292/jvms.56.1051; Islam AFMF, 2008, AVIAN PATHOL, V37, P225, DOI 10.1080/03079450701802230; Johnson DI, 2010, AVIAN DIS, V54, P1251, DOI 10.1637/9401-052310-Reg.1; Koski DM, 2015, BIOLOGICALS, V43, P232, DOI 10.1016/j.biologicals.2015.05.005; La TM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211158; LANIER LL, 1981, J IMMUNOL METHODS, V47, P25, DOI 10.1016/0022-1759(81)90253-2; Lee SW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120282; Lin G., 2021, P 70 W POULTR DIS C, P116; Maekawa D, 2019, AVIAN PATHOL, V48, P573, DOI 10.1080/03079457.2019.1644449; Maekawa D, 2019, AVIAN DIS, V63, P351, DOI 10.1637/12029-011119-Reg.1; Marangon S, 2007, REV SCI TECH OIE, V26, P265, DOI 10.20506/rst.26.1.1742; Norup LR, 2011, SCAND J IMMUNOL, V74, P23, DOI 10.1111/j.1365-3083.2011.02534.x; Ojkic D, 2006, AVIAN PATHOL, V35, P286, DOI 10.1080/03079450600815481; Palomino-Tapia VA, 2019, AVIAN PATHOL, V48, P209, DOI 10.1080/03079457.2019.1568389; Contreras AP, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111302; Perez-Contreras A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040541; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rodenbaugh CI, 2019, AM J VET RES, V80, P441, DOI 10.2460/ajvr.80.5.441; SEDDON H. R., 1936, Australian Veterinary Journal, V12, P13, DOI 10.1111/j.1751-0813.1936.tb01095.x; Shehata AA, 2013, VIRUS GENES, V46, P423, DOI 10.1007/s11262-012-0870-2; Taebipour MJ, 2017, VET IMMUNOL IMMUNOP, V190, P31, DOI 10.1016/j.vetimm.2017.07.002; Thapa S, 2015, VET IMMUNOL IMMUNOP, V164, P170, DOI 10.1016/j.vetimm.2015.02.006; Thilakarathne DS, 2020, AVIAN PATHOL, V49, P369, DOI 10.1080/03079457.2020.1754331; Thilakarathne DS, 2020, VET MICROBIOL, V243, DOI 10.1016/j.vetmic.2020.108635; Thilakarathne DS, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113797; Vagnozzi A, 2012, AVIAN PATHOL, V41, P21, DOI 10.1080/03079457.2011.631983; Van Esch H., 2021, THESIS U CALGARY CAL; WILLIAMS RA, 1992, J GEN VIROL, V73, P2415, DOI 10.1099/0022-1317-73-9-2415; WINTERFIELD RW, 1968, AVIAN DIS, V12, P191, DOI 10.2307/1588100; YORK JJ, 1990, ARCH VIROL, V115, P289, DOI 10.1007/BF01310537; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P258, DOI 10.1016/S0167-5699(97)80017-5	59	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1425	10.3390/vaccines9121425			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ8DJ	34960175	Green Published, gold			2022-04-29	WOS:000737877400001
J	Gabutti, G; d'Anchera, E; De Motoli, F; Savio, M; Stefanati, A				Gabutti, Giovanni; d'Anchera, Erica; De Motoli, Francesco; Savio, Marta; Stefanati, Armando			Human Papilloma Virus Vaccination: Focus on the Italian Situation	VACCINES			English	Article						HPV; HPV vaccination; papilloma virus; vaccines; adolescents; infectious diseases; cervical cancer; COVID-19	GENITAL WARTS; HPV	Human papilloma virus (HPV) is a viral agent whose transmission occurs mainly by sexual means. It causes different pathological conditions in both males and females, ranging from benign pathologies up to cancers. The introduction of vaccination has certainly had a major impact in terms of reducing the incidence of both HPV infections and diseases but in the European Union and the European Economic Area (EU/EEA) there are still about more than 13,000 deaths due to cervical cancer each year. To date in Europe and in Italy there are three vaccines available (bi-, tetra-, and nonvalent vaccines). The vaccination campaign started irregularly in Europe and Italy in 2007, with pre-adolescent girls as the primary target. Later, other cohorts were introduced such as 12-year-old boys, additional cohorts of >25-year-old women, women who already underwent cervical surgery and other subjects entitled to free vaccination. The COVID-19 pandemic has strongly impacted on public health services, particularly on vaccinations that, especially during the first pandemic phase, have been often delayed and/or canceled. The most affected vaccinations by the pandemic have been the non-mandatory ones, particularly those addressing the adolescent and adult population, such as immunization against papillomavirus. To date the achievement of the coverage target set by the Italian National Immunization Plan (NIP) has not yet been achieved. The aim of this work is to summarize the current situation in Italy and to discuss the strategies that have been implemented to increase overall vaccination coverage rates.	[Gabutti, Giovanni; d'Anchera, Erica; De Motoli, Francesco; Savio, Marta; Stefanati, Armando] Italian Sci Soc Hyg Prevent Med & Publ Hlth SItI, Work Grp Immunizat & Vaccinal Policies, I-16033 Lavagna, Italy; [d'Anchera, Erica; De Motoli, Francesco; Savio, Marta] Univ Ferrara, Postgrad Sch Hyg & Prevent Med, I-44121 Ferrara, Italy; [Stefanati, Armando] Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy		Stefanati, A (通讯作者)，Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy.	gbtgnn@unife.it; dncrce@unife.it; dmtfnc@unife.it; svamrt@unife.it; armando.stefanati@unife.it		Gabutti, Giovanni/0000-0002-7259-4923; Savio, Marta/0000-0003-3404-8013; d'Anchera, Erica/0000-0002-1433-5480			[Anonymous], 2017, Wkly Epidemiol Rec, V92, P241; [Anonymous], 2016, BOARD CALENDARIO VIT; [Anonymous], MSD PAPILLOMAVIRUS N; [Anonymous], 2014, BOARD CALENDARIO VIT; [Anonymous], VACCINARSI VACCINO A; [Anonymous], AGENZIA ITALIANA FAR; [Anonymous], MINISTERO SALUTE IMP; [Anonymous], MINISTERO SALUTE COM; [Anonymous], MINISTERO SALUTE COP; Baldur-Felskov B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt460; Bollerup S, 2016, SEX TRANSM DIS, V43, P238, DOI 10.1097/OLQ.0000000000000418; Bruni L, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106399; Chow EPF, 2019, VACCINE, V37, P6907, DOI [10.1016/j.vaccine.2019.09.052, 10.1016/j.vaccine.2019.09]; Chow EPF, 2017, LANCET INFECT DIS, V17, P68, DOI 10.1016/S1473-3099(16)30116-5; Epicentro Hpv e Cervicocarcinoma i Papillomavirus, TRASMISSIONE PREVENZ; European Centre for Disease Prevention and Control, PREVENTION CONTROL M; European Centre for Disease Prevention and Control, 2020, GUID HPV VACC EU COU; Feiring B, 2018, J INFECT DIS, V218, P1900, DOI 10.1093/infdis/jiy432; Ghelardi A, 2018, GYNECOL ONCOL, V151, P229, DOI 10.1016/j.ygyno.2018.08.033; Goldstone S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.1553; Gruppo Italiano Screening del Cervicocarcinoma Associazione Italiana di Ostetricia Linee, GUIDA CONDIVISE PREV; Herweijer E, 2016, INT J CANCER, V138, P2867, DOI 10.1002/ijc.30035; Istituto Superiore di Sanita, 2015, STRATEGIE VACCINALI; Jacot-Guillarmod M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2867-x; Judlin P, 2016, SEX HEALTH, V13, P49, DOI 10.1071/SH14218; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Kjaer SK, 2021, HUM VACC IMMUNOTHER, V17, P943, DOI 10.1080/21645515.2020.1839292; Kjaer SK, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100401; Kjaer SK, 2018, CLIN INFECT DIS, V66, P339, DOI 10.1093/cid/cix797; Maria C., 2016, RIV OSTET GINECOL PR, VXXXI, P2; Ministero della Salute, PIAN NAZ PREV VACC 2; Ministry of Health, 2007, CONS SUP SAN SESS 46; Napolitano F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010063; Napolitano F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194920; Navarro-Illana E, 2017, VACCINE, V35, P3342, DOI 10.1016/j.vaccine.2017.04.080; Nguyen-Huu NH, 2020, VACCINE, V38, P1315, DOI 10.1016/j.vaccine.2019.11.081; Nygard M, 2015, CLIN VACCINE IMMUNOL, V22, P943, DOI 10.1128/CVI.00133-15; Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543; Plotnick M, 2017, J OBSTET GYNAECOL CA, V39, P361, DOI 10.1016/j.jogc.2017.01.015; Spinu AD, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10701; World Health Organization, 2020, GLOB STRAT ACC EL CE, V2, P1; World Health Organization, HUMAN PAPILLOMAVIRUS; World Health Organization, IMM COV; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016/j.vaccine.2008.05.064	44	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1374	10.3390/vaccines9121374			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9IB	34960120	Green Published, gold			2022-04-29	WOS:000737277000001
J	Griva, K; Tan, KYK; Chan, FHF; Periakaruppan, R; Ong, BWL; Soh, ASE; Chen, MIC				Griva, Konstadina; Tan, Kevin Y. K.; Chan, Frederick H. F.; Periakaruppan, Ramanathan; Ong, Brenda W. L.; Soh, Alexius S. E.; Chen, Mark IC.			Evaluating Rates and Determinants of COVID-19 Vaccine Hesitancy for Adults and Children in the Singapore Population: Strengthening Our Community's Resilience against Threats from Emerging Infections (SOCRATEs) Cohort	VACCINES			English	Article						vaccine hesitancy; parental hesitancy; COVID-19; sociodemographic factors; psychosocial factors	HEALTH BELIEF MODEL; DEPRESSION; BEHAVIOR	COVID-19 vaccines are crucial for achieving sufficient immunisation coverage to manage the pandemic, but vaccine hesitancy persists. This study aimed to investigate the prevalence and determinants of vaccine hesitancy in adults and in parents for vaccinating their children using an integrated social cognition model. A community-based cohort in Singapore [N = 1623] completed a survey (wave 25) between June and July 2021 which measured their risk perceptions, distress, trust, vaccination beliefs, and vaccine intentions/behaviours. Results indicated low rates of hesitancy (9.9%) for own vaccination, with most concerns citing side effects, safety, and hasty development. Remaining respondents were vaccinated (69%) or intended to vaccinate (21%). The multivariable model (non-vaccinated respondents) indicated that, living with people in poor health, subjective norm, moral norm, benefits, and necessity of vaccination were associated with lower vaccine hesitancy (R-2 Cox & Snell: 51.4%; p < 0.001). Hesitancy rates were higher for children's vaccination (15.9%), with male gender, lower perceived vaccine benefits, high COVID-19 risk perceptions, vaccination concerns, and necessity beliefs associated with higher odds of parental vaccine hesitancy (R-2 Cox & Snell = 36.4%; p < 0.001). While levels of vaccine acceptance are high, more targeted messages are needed. For adults' vaccination, more emphasis should be on benefits and social gains, while for parental hesitancy, messages related to safety should be prioritised.	[Griva, Konstadina; Tan, Kevin Y. K.; Chan, Frederick H. F.; Periakaruppan, Ramanathan] Nanyang Technol Univ, Lee Kong Chian Sch Med, Populat Global Hlth, Singapore 308232, Singapore; [Ong, Brenda W. L.; Soh, Alexius S. E.; Chen, Mark IC.] Natl Ctr Infect Dis, Infect Dis Res & Training Off, 16 Jln Tan Tock Seng, Singapore 308442, Singapore		Griva, K (通讯作者)，Nanyang Technol Univ, Lee Kong Chian Sch Med, Populat Global Hlth, Singapore 308232, Singapore.	konstadina.griva@ntu.edu.sg; kevin.tanyk@ntu.edu.sg; huifei001@e.ntu.edu.sg; rama0072@e.ntu.edu.sg; brenda_ONG@ncid.sg; alexius_matthias_se_soh@ncid.sg; mark_ic_chen@ncid.sg		Chen, Mark/0000-0001-9369-5830; Tan, Kevin/0000-0002-8110-4017; GRIVA, KONSTADINA/0000-0001-8173-5663	estate of the late Irene Tan Liang Kheng	This research was funded by estate of the late Irene Tan Liang Kheng.	Abdullah A.Z., PFIZER BIONTECH COVI; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Al-Metwali BZ, 2021, J EVAL CLIN PRACT, V27, P1112, DOI 10.1111/jep.13581; Alfieri NL, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11725-5; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Ang H.M., NCID NURSE BECOMES 1; Ang H.M., COVID 19 VACCINATION; Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139; BECKER MH, 1974, HEALTH EDUC QUART, V2, P409, DOI 10.1177/109019817400200407; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Chen H, 2021, J MED INTERNET RES, V23, DOI 10.2196/29329; Chirumbolo S, 2021, J MED VIROL, V93, P4049, DOI 10.1002/jmv.26922; Choi SH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e227; Cihan P, 2021, APPL SOFT COMPUT, V111, DOI 10.1016/j.asoc.2021.107708; Co C., COVID 19 VACC NOW OP; Davis R, 2015, HEALTH PSYCHOL REV, V9, P323, DOI 10.1080/17437199.2014.941722; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fernandes N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101161; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Glanz K, 2010, ANNU REV PUBL HEALTH, V31, P399, DOI 10.1146/annurev.publhealth.012809.103604; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Graupensperger S, 2021, VACCINE, V39, P2060, DOI 10.1016/j.vaccine.2021.03.018; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hussein IH, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00269; Jones CL, 2015, HEALTH COMMUN, V30, P566, DOI 10.1080/10410236.2013.873363; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lai L., SPORE APPROVES MODER; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lim VW, 2021, B WORLD HEALTH ORGAN, V99, P92, DOI 10.2471/BLT.20.269142; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Mahmud A.H., SINGAPOREANS AGED 12; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Ministry of Health (MOH), SING UPD LOC COVID 1; Ministry of Health (MOH), 2021, SING UPD SIT HEIGHT; Ministry of Health (MOH), SING COVID 19 SIT RE; Ministry of Health (MOH), SING UPD SING COVID; Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943; National Population and Talent Division (NPTD), SING POP TRENDS OV; Nomura S, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100223; Painter JE, 2008, ANN BEHAV MED, V35, P358, DOI 10.1007/s12160-008-9042-y; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pomara C, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11060955; Prickett KC, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100241; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Rodeghiero F, 2021, HAEMATOLOGICA, V106, P2040, DOI 10.3324/haematol.2021.279186; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; Ruggiero KM, 2021, J PEDIATR HEALTH CAR, V35, P509, DOI 10.1016/j.pedhc.2021.04.005; Scaife B, 2000, FAM PRACT, V17, P298, DOI 10.1093/fampra/17.4.298; Schneider J, 2021, INT J LEGAL MED, V135, P2335, DOI 10.1007/s00414-021-02706-9; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Singapore M.O.H, FAQS SAF EFF COVID 1; Singstats, 2021, POP TRENDS 2021, P1; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sowa P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080876; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stojanovic J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060661; Teo G., SINGAPORE STARTS VAC; Tjendro J, SUSPECTED ADVERSE EF; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Ursachi G, 2015, PROC ECON FINANC, V20, P679, DOI 10.1016/S2212-5671(15)00123-9; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang Q., 2021, VACCINESM, V9, P772, DOI [10.3390/vaccines9070772, DOI 10.3390/VACCINES9070772]; Wang YY, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003320; WHO, WHO COR COVID 19 DAS; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, REP SAGE WORK GROUP; Yan ZP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101097	77	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1415	10.3390/vaccines9121415			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	YB1EX	34960161	Green Published, gold			2022-04-29	WOS:000738765200001
J	Pasquale, S; Gregorio, GL; Caterina, A; Francesco, C; Beatrice, PM; Vincenzo, P; Caterina, PM				Pasquale, Sansone; Gregorio, Giaccari Luca; Caterina, Aurilio; Francesco, Coppolino; Beatrice, Passavanti Maria; Vincenzo, Pota; Caterina, Pace Maria			COVID-19 in Low- and Middle-Income Countries (LMICs): A Narrative Review from Prevention to Vaccination Strategy	VACCINES			English	Article						COVID-19; low-and middle-income countries (LMICs); infection prevention; triage; vaccine	RESPIRATORY SUPPORT; HEALTH	The management of the COVID-19 pandemic represents a challenging process, especially for low- and middle-income countries (LMICs) due to the serious economic and health resource problems it generates. In this article, we assess COVID-19 situation in LMICs and outline emerging problems and possible solutions. The prevention and control of COVID-19 would be based on focused tests exploiting those systems (e.g., GeneXpert(R)) already used in other scenarios. This would be less stressful for the healthcare system in LMICs. Avoiding close contact with people suffering from acute respiratory infections, frequent handwashing, and avoiding unprotected contact with farm or wild animals are recommended infection control interventions. The appropriate use of personal protective equipment (PPE) is required, despite its procurement being especially difficult in LMICs. Patients' triage should be based on a simple and rapid logarithm to decide who requires isolation and targeted testing for SARS-CoV-2. Being able to estimate which patients will develop severe disease would allow hospitals to better utilize the already limited resources more effectively. In LMICs, laboratories are often in the capital cities; therefore, early diagnosis and isolation become difficult. The number of ICU beds is often insufficient, and the equipment is often old and poorly serviced. LMICs will need access to COVID-19 treatments at minimal prices to ensure that all who need them can be treated. Year-to-date, different vaccines have been approved and are currently available. The main obstacle to accessing them is the limited ability of LMICs to purchase significant quantities of the vaccine.	[Pasquale, Sansone; Gregorio, Giaccari Luca; Caterina, Aurilio; Francesco, Coppolino; Beatrice, Passavanti Maria; Vincenzo, Pota; Caterina, Pace Maria] Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialized Surg, I-80138 Naples, Italy		Pasquale, S (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialized Surg, I-80138 Naples, Italy.	pasquale.sansone@unicampania.it; lucagregorio.giaccari@gmail.com; Caterina.aurilio@unicampania.it; francesco.coppolino@unicampania.it; MariaBeatrice.PASSAVANTI@unicampania.it; vincenzo.pota@inwind.it; mariacaterina.pace@unicampania.it	Sansone, Pasquale/AAL-4368-2020; POTA, VINCENZO/C-4837-2013	Sansone, Pasquale/0000-0003-0873-3586; Passavanti, Maria Beatrice/0000-0002-9659-0847; POTA, VINCENZO/0000-0001-9999-3388; Coppolino, Francesco/0000-0002-1362-7393			Anjum FR, 2020, HUM VACC IMMUNOTHER, V16, P2370, DOI 10.1080/21645515.2020.1766939; [Anonymous], WHO COR DIS COVID 19; Atreya Alok, 2020, Med Leg J, V88, P102, DOI 10.1177/0025817220923690; Ayebare RR, 2020, LANCET RESP MED, V8, pE22, DOI 10.1016/S2213-2600(20)30114-4; Barros LM, 2021, AM J TROP MED HYG, V104, P3, DOI 10.4269/ajtmh.20-1064; Bibiano-Guillen C, 2021, AM J EMERG MED, V39, P42, DOI 10.1016/j.ajem.2020.10.043; Centers for Disease Control and Prevention, AR WE PREP; Centers for Disease Control and Prevention, NEW TOOL DIAGN TUB X; Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003; Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004; Dagens A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1936; Dondorp AM, 2020, AM J TROP MED HYG, V102, P1191, DOI 10.4269/ajtmh.20-0283; FDA Veklury (Remdesivir), EUA LETT AUTH; FDA Veklury (Remdesivir), EUA LETT APPR; Federal Republic of Nigeria, NAT STRAT SCAL MED O; Harris C, 2020, J GLOB HEALTH, V10, DOI [10.7189/jogh.10-011001, 10.7189/jogh.10.011001]; Hill A, 2020, J VIRUS ERAD, V6, P61; Joebges S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02927-1; Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5; Krishnakumar B, 2020, J MICROBIOL IMMUNOL, V53, P389, DOI 10.1016/j.jmii.2020.03.024; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Lei ZN, 2020, PHARMACOL THERAPEUT, V216, DOI 10.1016/j.pharmthera.2020.107672; Lie RK, 2021, MILBANK Q, V99, P450, DOI 10.1111/1468-0009.12494; Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001; Marson FAL, 2020, PULMONOLOGY, V26, P241, DOI 10.1016/j.pulmoe.2020.04.008; McAdams D, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003627; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Monjur MR, 2020, INFECT CONT HOSP EP, V41, P1116, DOI 10.1017/ice.2020.147; Murthy S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116949; National Institutes of Health COVID-19 Treatment Guidelines Panel, COR DIS 2019 COVID 1; Nayan Neelabh, 2021, SN Compr Clin Med, P1, DOI 10.1007/s42399-020-00705-2; Quaresima V, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012488; Rakotosamimanana N, 2020, LANCET GLOB HEALTH, V8, pE1457, DOI 10.1016/S2214-109X(20)30428-9; Republic of Uganda Ministry of Health, MIN HLTH SCAL MED OX; Rouzier V, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMc2021362; Saha BK, 2020, AM J MED SCI, V360, P618, DOI 10.1016/j.amjms.2020.08.019; Salluh JIF, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03278-7; Sansone P, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020167; Siow WT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02890-x; So AD, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4750; Sudhir A, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020346; Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20; Wang MW, 2020, EUR REV MED PHARMACO, V24, P3397, DOI 10.26355/eurrev_202003_20707; Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180; WHO, OX SOURC DISTR COVID; WHO, WHAT IS PAND; World Bank, WORLD INC REG; World Health Organization, ALG COVID 19 TRIAG R; World Health Organization, WHO GUID STEPW LAB I; World Health Organization, SEV AC RESP INF TREA; World Health Organization. World health statistics, 2019, MON HLTH SDGS SUST D; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237	53	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1477	10.3390/vaccines9121477			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8PZ	34960223	gold, Green Published			2022-04-29	WOS:000737228800001
J	Boilesen, DR; Nielsen, KN; Holst, PJ				Boilesen, Ditte Rahbaek; Nielsen, Karen Norgaard; Holst, Peter Johannes			Novel Antigenic Targets of HPV Therapeutic Vaccines	VACCINES			English	Review						human papillomavirus; therapeutic vaccines	SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS 16; RISK HUMAN-PAPILLOMAVIRUS; REPLICATIVE HELICASE E1; T-CELL RESPONSE; OROPHARYNGEAL CANCER; MESSENGER-RNA; DNA VACCINE; NECK-CANCER; SINGLE-ARM	Human papillomavirus (HPV) infection is the cause of the majority of cervical cancers and head and neck cancers worldwide. Although prophylactic vaccines and cervical cancer screening programs have shown efficacy in preventing HPV-associated cervical cancer, cervical cancer is still a major cause of morbidity and mortality, especially in third world countries. Furthermore, head and neck cancer cases caused by HPV infection and associated mortality are increasing. The need for better therapy is clear, and therapeutic vaccination generating cytotoxic T cells against HPV proteins is a promising strategy. This review covers the current scene of HPV therapeutic vaccines in clinical development and discusses relevant considerations for the design of future HPV therapeutic vaccines and clinical trials, such as HPV protein expression patterns, immunogenicity, and exhaustion in relation to the different stages and types of HPV-associated lesions and cancers. Ultimately, while the majority of the HPV therapeutic vaccines currently in clinical testing target the two HPV oncoproteins E6 and E7, we suggest that there is a need to include more HPV antigens in future HPV therapeutic vaccines to increase efficacy and find that especially E1 and E2 could be promising novel targets.	[Boilesen, Ditte Rahbaek; Holst, Peter Johannes] Univ Copenhagen, Inst Immunol, Ctr Med Parasitol, DK-2200 Copenhagen, Denmark; [Boilesen, Ditte Rahbaek; Nielsen, Karen Norgaard; Holst, Peter Johannes] InProTher APS, DK-2200 Copenhagen, Denmark		Holst, PJ (通讯作者)，Univ Copenhagen, Inst Immunol, Ctr Med Parasitol, DK-2200 Copenhagen, Denmark.; Holst, PJ (通讯作者)，InProTher APS, DK-2200 Copenhagen, Denmark.	drb@sund.ku.dk; knn@inprother.com; pjh@inprother.com		Boilesen, Ditte Rahbaek/0000-0003-0675-3655; Holst, Peter Johannes/0000-0002-1279-304X; Nielsen, Karen Norgaard/0000-0002-9897-3972	Eurostars-2 joint programme; European UnionEuropean Commission [E!12151]	This research was funded by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme, grant number E!12151. The manuscript reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on data collection and analysis, decision to publish, or preparation of the manuscript.	Aklimunnessa K, 2006, JPN J CLIN ONCOL, V36, P511, DOI 10.1093/jjco/hyl060; Anayannis NV, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191581; Anderson KS, 2015, ORAL ONCOL, V51, P662, DOI 10.1016/j.oraloncology.2015.04.011; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; [Anonymous], 2020, POSTER SQZ PBMC HPV; [Anonymous], 2015, SCREENING LIVMODERHA; [Anonymous], 2020, BUSINESS WIRE; Arias-Pulido H, 2006, J CLIN MICROBIOL, V44, P1755, DOI 10.1128/JCM.44.5.1755-1762.2006; Baedyananda F, 2017, INTERVIROLOGY, V60, P171, DOI 10.1159/000487048; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Balaji H, 2021, CANCERS, V13, DOI 10.3390/cancers13164089; Basu P, 2018, INT J GYNECOL CANCER, V28, P764, DOI 10.1097/IGC.0000000000001235; Bauml J, 2017, J CLIN ONCOL, V35, P1542, DOI 10.1200/JCO.2016.70.1524; Bergvall M, 2013, VIROLOGY, V445, P35, DOI 10.1016/j.virol.2013.07.020; Bhatt KH, 2020, J EXP MED, V217, DOI 10.1084/jem.20200389; Bhuyan PK, 2021, HUM VACC IMMUNOTHER, V17, P1288, DOI 10.1080/21645515.2020.1823778; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruni L, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106399; Campo MS, 2010, VIROLOGY, V407, P137, DOI 10.1016/j.virol.2010.07.044; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chera BS, 2020, J CLIN ONCOL, V38, P1050, DOI 10.1200/JCO.19.02444; Choi YJ, 2020, CLIN CANCER RES, V26, P1616, DOI 10.1158/1078-0432.CCR-19-1513; Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265; ClinicalTrialsRegister.eu, 2019001898 EUDRACT; Cosper PF, 2020, INT J CANCER, V146, P2047, DOI 10.1002/ijc.32793; Cuburu N, 2016, HUM VACC IMMUNOTHER, V12, P2875, DOI 10.1080/21645515.2016.1199302; D'Souza G, 2019, CANCER PREV RES, V12, P689, DOI 10.1158/1940-6207.CAPR-19-0185; Dahlstrom KR, 2015, CLIN CANCER RES, V21, P2861, DOI 10.1158/1078-0432.CCR-14-3323; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; Dillon S, 2007, J GEN VIROL, V88, P803, DOI 10.1099/vir.0.82678-0; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; Dorta-Estremera S, 2018, CANCER RES, V78, P5327, DOI 10.1158/0008-5472.CAN-18-0892; Eberhardt CS, 2021, NATURE, V597, P279, DOI 10.1038/s41586-021-03862-z; Esposito I, 2019, J HEPATOL, V70, pE3, DOI 10.1016/S0618-8278(19)30005-2; Ewaisha R, 2017, THERANOSTICS, V7, P3814, DOI 10.7150/thno.21098; Ewaisha R, 2016, PROTEOMICS, V16, P1215, DOI 10.1002/pmic.201500376; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fontham ETH, 2020, CA-CANCER J CLIN, V70, P321, DOI 10.3322/caac.21628; Galicia-Carmona T, 2021, HUM VACC IMMUNOTHER, V17, P2617, DOI 10.1080/21645515.2021.1893036; Garcia-Hernandez E, 2006, CANCER GENE THER, V13, P592, DOI 10.1038/sj.cgt.7700937; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hancock G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55014-z; Hancock G, 2018, BEST PRACT RES CL OB, V47, P59, DOI 10.1016/j.bpobgyn.2017.09.008; Harper DM, 2019, GYNECOL ONCOL, V153, P521, DOI 10.1016/j.ygyno.2019.03.250; Hillemanns P, 2020, ANN ONCOL, V31, pS645, DOI 10.1016/j.annonc.2020.08.1020; Hillemanns P., 2019, P CLIN TRIALS AM ASS; Hladikova K, 2018, ORAL ONCOL, V82, P75, DOI 10.1016/j.oraloncology.2018.05.010; Ho AL, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2502; Holst PJ, 2008, J IMMUNOL, V180, P3339, DOI 10.4049/jimmunol.180.5.3339; Jimeno A, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2536; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Khwaja SS, 2016, INT J RADIAT ONCOL, V95, P1132, DOI 10.1016/j.ijrobp.2016.03.001; Kjems J, 2016, INT J RADIAT ONCOL, V94, P775, DOI 10.1016/j.ijrobp.2015.12.380; Kotturi MF, 2007, J VIROL, V81, P4928, DOI 10.1128/JVI.02632-06; Kreimer AR, 2018, CANCER-AM CANCER SOC, V124, P1859, DOI 10.1002/cncr.31256; Krishna, 2018, CANCER RES, V78, P6159, DOI 10.1158/0008-5472.CAN-18-0163; Kyndi M, 2006, ACTA OBSTET GYN SCAN, V85, P106, DOI 10.1080/00016340500324423; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; Leachman SA, 2002, J VIROL, V76, P7616, DOI 10.1128/JVI.76.15.7616-7624.2002; Lorenzon L, 2011, J CLIN VIROL, V52, P79, DOI 10.1016/j.jcv.2011.06.007; Lorusso D, 2014, GYNECOL ONCOL, V133, P117, DOI 10.1016/j.ygyno.2014.01.042; Lynge E, 2014, APMIS, V122, P667, DOI 10.1111/apm.12279; Ma MM, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0206-5; Malcles MH, 2002, J VIROL, V76, P11350, DOI 10.1128/JVI.76.22.11350-11358.2002; Maldonado L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007323; Massarelli E, 2019, JAMA ONCOL, V5, P67, DOI 10.1001/jamaoncol.2018.4051; Masterson L, 2016, EUR J CANCER, V67, P141, DOI 10.1016/j.ejca.2016.08.012; Mechali F, 2004, J VIROL, V78, P2615, DOI 10.1128/JVI.78.5.2615-2619.2004; Mehra R, 2018, BRIT J CANCER, V119, P153, DOI 10.1038/s41416-018-0131-9; Melief CJM, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz8235; Michler T, 2020, GASTROENTEROLOGY, V158, P1762, DOI 10.1053/j.gastro.2020.01.032; Morgan IM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080208; Nakagawa M, 2000, J INFECT DIS, V182, P595, DOI 10.1086/315706; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; New Zealand Government-Ministry of Health, 2017, PRIM HPV SCREEN; Nkili-Meyong AA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37871-2; Nkwabong E, 2019, TROP DOCT, V49, P34, DOI 10.1177/0049475518798532; PDS Biotechnology Corporation, 2021, GLOBE NEWSWIRE; Perkins RB, 2020, J LOW GENIT TRACT DI, V24, P102, DOI 10.1097/LGT.0000000000000525; Pett M, 2007, J PATHOL, V212, P356, DOI 10.1002/path.2192; Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388; Preville X, 2005, CANCER RES, V65, P641; Ragonnaud E, 2017, SCAND J IMMUNOL, V85, P182, DOI 10.1111/sji.12522; Ragonnaud E, 2017, J IMMUNOTHER, V40, P51, DOI 10.1097/CJI.0000000000000153; Ramqvist T, 2015, ORAL ONCOL, V51, P1126, DOI 10.1016/j.oraloncology.2015.09.007; Rijkaart DC, 2012, LANCET ONCOL, V13, P78, DOI 10.1016/S1470-2045(11)70296-0; Rodriguez-Freixinos Victor, 2015, Gynecol Oncol Res Pract, V2, P8, DOI 10.1186/s40661-015-0015-0; Rosales R, 2014, HUM GENE THER, V25, P1035, DOI 10.1089/hum.2014.024; Schiller JT, 2015, LANCET ONCOL, V16, pE217, DOI 10.1016/S1470-2045(14)71179-9; Schmitt M, 2011, MOL CELL PROBE, V25, P108, DOI 10.1016/j.mcp.2011.03.003; Spanos WC, 2009, ARCH OTOLARYNGOL, V135, P1137, DOI 10.1001/archoto.2009.159; Statens Serum Institut, 2018, SCREEN LIVM KRAEFT A; Steinau M, 2014, EMERG INFECT DIS, V20, P822, DOI 10.3201/eid2005.131311; Stevanovic S, 2017, SCIENCE, V356, P200, DOI 10.1126/science.aak9510; Strauss J, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2501; Swadling L, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030027; Todd RW, 2004, INT J CANCER, V108, P857, DOI 10.1002/ijc.11645; Tourneau C.L., ESMO IMMU NO ONC VIR; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1; UK Government, 2019, UK NAT SCREEN COMM R; Um SH, 2014, J CLIN VIROL, V61, P94, DOI 10.1016/j.jcv.2014.06.019; Van Damme P, 2016, CLIN CANCER RES, V22, P3238, DOI 10.1158/1078-0432.CCR-16-0085; van Poelgeest MIE, 2016, CLIN CANCER RES, V22, P2342, DOI 10.1158/1078-0432.CCR-15-2594; Verma V, 2019, NAT IMMUNOL, V20, P1231, DOI 10.1038/s41590-019-0441-y; Vinokurova S, 2008, CANCER RES, V68, P307, DOI 10.1158/0008-5472.CAN-07-2754; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; Wang RJ, 2020, CANCER LETT, V471, P88, DOI 10.1016/j.canlet.2019.11.039; Waxman AG, 2012, OBSTET GYNECOL, V120, P1465, DOI [http://10.1097/AOG.0b013e31827001d5, 10.1097/AOG.0b013e31827001d5]; Woo YL, 2010, INT J CANCER, V126, P133, DOI 10.1002/ijc.24804; World Health Organization (WHO), 2020, ACC EL CERV CANC GLO; Wuerdemann N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155228; Xu YM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645170; Xue YZ, 2010, CANCER RES, V70, P5316, DOI 10.1158/0008-5472.CAN-09-3789; Yajid Aidy Irman, 2017, Asian Pac J Cancer Prev, V18, P315; Youn JW, 2020, LANCET ONCOL, V21, P1653, DOI 10.1016/S1470-2045(20)30486-1; Zamani M, 2020, EUR J CANCER, V134, P52, DOI 10.1016/j.ejca.2020.04.027; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	117	2	2	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1262	10.3390/vaccines9111262			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XL0PF	34835193	Green Published, gold			2022-04-29	WOS:000727854900001
J	Chapman, R; van Diepen, M; Douglass, N; Galant, S; Jaffer, M; Margolin, E; Ximba, P; Hermanus, T; Moore, PL; Williamson, AL				Chapman, Ros; van Diepen, Michiel; Douglass, Nicola; Galant, Shireen; Jaffer, Mohamed; Margolin, Emmanuel; Ximba, Phindile; Hermanus, Tandile; Moore, Penny L.; Williamson, Anna-Lise			Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV	VACCINES			English	Article						LSDV; lumpy skin disease; vaccine; HIV-1; vector; poxvirus; VLP	BROADLY NEUTRALIZING ANTIBODIES; SKIN-DISEASE VIRUS; ENV TRIMERS; EFFICACY; IMMUNOGENICITY; CAPRIPOXVIRUS; CONSTRUCTION; PROTECTION; CHALLENGE; RESPONSES	The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5.	[Chapman, Ros; van Diepen, Michiel; Douglass, Nicola; Galant, Shireen; Margolin, Emmanuel; Ximba, Phindile; Williamson, Anna-Lise] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa; [Chapman, Ros; van Diepen, Michiel; Douglass, Nicola; Galant, Shireen; Margolin, Emmanuel; Ximba, Phindile; Williamson, Anna-Lise] Univ Cape Town, Dept Pathol, Div Med Virol, ZA-7925 Cape Town, South Africa; [Jaffer, Mohamed] Univ Cape Town, Electron Microscope Unit, ZA-7701 Rondebosch, South Africa; [Hermanus, Tandile; Moore, Penny L.] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Ctr HIV & STIs, ZA-2131 Johannesburg, South Africa; [Hermanus, Tandile; Moore, Penny L.] Univ Witwatersrand, Antibody Immun Res Unit, Fac Hlth Sci, ZA-2050 Johannesburg, South Africa; [Moore, Penny L.] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, ZA-4013 Durban, South Africa		Chapman, R (通讯作者)，Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.; Chapman, R (通讯作者)，Univ Cape Town, Dept Pathol, Div Med Virol, ZA-7925 Cape Town, South Africa.	ros.chapman@uct.ac.za; michiel.vandiepen@uct.ac.za; niki.douglass@uct.ac.za; shireen.galant@uct.ac.za; mohamed.jaffer@uct.ac.za; emmanuel.margolin@uct.ac.za; phindile.ximba@uct.ac.za; TandileH@nicd.ac.za; pennym@nicd.ac.za; anna-lise.williamson@uct.ac.za		van Diepen, Michiel/0000-0001-8156-4294; Williamson, Anna-Lise/0000-0002-5467-1200; Chapman, Rosamund/0000-0001-9162-2099; Douglass, Nicola/0000-0002-8929-6279	South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); South African Department of Science and Technology; National Research Foundation of South AfricaNational Research Foundation - South Africa [64815]; South African Research Chairs Initiative of the Department of Science and Technology; NRF [98341]	This research was funded by the South African Medical Research Council with funds received from the South African Department of Science and Technology; A.-L.W. is funded by the National Research Foundation of South Africa, grant number 64815; and P.L.M. is supported by the South African Research Chairs Initiative of the Department of Science and Technology and the NRF (Grant No 98341).	Alter G, 2018, CELL HOST MICROBE, V24, P25, DOI 10.1016/j.chom.2018.06.012; Andrabi R, 2015, IMMUNITY, V43, P959, DOI 10.1016/j.immuni.2015.10.014; Aspden K, 2003, J GEN VIROL, V84, P1985, DOI 10.1099/vir.0.19116-0; Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766; BAXBY D, 1972, J HYG-CAMB, V70, P353, DOI 10.1017/S0022172400022403; Beyrer C, 2021, LANCET, V397, P2142, DOI 10.1016/S0140-6736(21)01167-3; Bhiman JN, 2015, NAT MED, V21, P1332, DOI 10.1038/nm.3963; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Burgers WA, 2008, AIDS RES HUM RETROV, V24, P195, DOI 10.1089/aid.2007.0205; Burgers WA, 2014, J GEN VIROL, V95, P2267, DOI 10.1099/vir.0.067835-0; Burton S, 2019, J VIROL, V93, DOI 10.1128/JVI.01846-18; Burton SL, 2015, P NATL ACAD SCI USA, V112, P10780, DOI 10.1073/pnas.1509731112; Carulei O, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4315-0; Chang J, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e6; Chapman R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173352; Chapman R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010054; Chea LS, 2017, EXPERT REV VACCINES, V16, P973, DOI 10.1080/14760584.2017.1371594; Chege GK, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030397; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Douglass Nicola, 2021, Vaccines (Basel), V9, DOI 10.3390/vaccines9111215; Douglass N, 2021, VACCINE, V39, P463, DOI 10.1016/j.vaccine.2020.12.024; Douglass N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040664; Dubrovskaya V, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006614; Gomez CE, 2012, HUM VACC IMMUNOTHER, V8, P1192, DOI 10.4161/hv.20778; Eslamizar L, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00277-1; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Fouts TR, 2015, P NATL ACAD SCI USA, V112, pE992, DOI 10.1073/pnas.1423669112; Garcia-Arriaza J, 2015, J VIROL, V89, P8525, DOI 10.1128/JVI.01265-15; Gilchuk I, 2016, CELL, V167, P684, DOI 10.1016/j.cell.2016.09.049; Gorman J, 2016, NAT STRUCT MOL BIOL, V23, P81, DOI 10.1038/nsmb.3144; Gray GE, 2016, CLIN VACCINE IMMUNOL, V23, P496, DOI 10.1128/CVI.00717-15; Guenaga J, 2017, IMMUNITY, V46, P792, DOI 10.1016/j.immuni.2017.04.014; Guenaga J, 2016, J VIROL, V90, P2806, DOI 10.1128/JVI.02652-15; Hamdi J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9050902; Hamdi J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65856-7; Hamdi J, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108689; Heger E, 2018, ADV EXP MED BIOL, V1075, P3, DOI 10.1007/978-981-13-0484-2_1; Jones LD, 2020, CLIN THER, V42, P499, DOI 10.1016/j.clinthera.2020.01.009; Julien JP, 2015, P NATL ACAD SCI USA, V112, P11947, DOI 10.1073/pnas.1507793112; Kitching R.P, 2008, CAPRIPOXVIRUSES, P427; Levy Y, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008522; Liu FX, 2019, COMP IMMUNOL MICROB, V65, P181, DOI 10.1016/j.cimid.2019.05.013; Lundstrom K, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020317; Mackenzie JS, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/tropicalmed4020088; Martinez-Murillo P, 2017, IMMUNITY, V46, P804, DOI 10.1016/j.immuni.2017.04.021; Mok DZL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050520; Montefiori DC, 2018, CURR OPIN HIV AIDS, V13, P128, DOI [10.1097/COH.0000000000000442, 10.1097/coh.0000000000000442]; Moore PL, 2013, J VIROL, V87, P4882, DOI 10.1128/JVI.03424-12; Offerman K, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1659-1; Omar R., 2015, THESIS U CAPE TOWN C; Palli R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69007-w; PAOLETTI E, 1990, ANN NY ACAD SCI, V590, P309, DOI 10.1111/j.1749-6632.1990.tb42239.x; Rademeyer C, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005742; Ringe RP, 2017, J VIROL, V91, DOI 10.1128/JVI.00264-17; Ringe RP, 2015, J VIROL, V89, P12189, DOI 10.1128/JVI.01768-15; Ruprecht RM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040194; Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481; Sasso E, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101430; Shen YJ, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-265; Stephenson KE, 2020, ANNU REV IMMUNOL, V38, P673, DOI 10.1146/annurev-immunol-080219-023629; Tanzer FL, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-51; Tulman ER, 2004, J VIROL, V78, P353, DOI 10.1128/JVI.78.1.353-366.2004; Tuppurainen ESM, 2017, TRANSBOUND EMERG DIS, V64, P729, DOI 10.1111/tbed.12444; van Diepen M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101131; van Diepen MT, 2019, J VIROL, V93, DOI 10.1128/JVI.02155-18; van Diepen MT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208310; Veillette M, 2016, CURR HIV RES, V14, P9, DOI 10.2174/1570162X13666150827093449; Volkmann A, 2021, VACCINE, V39, P3067, DOI 10.1016/j.vaccine.2020.08.050; Wallace DB, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00256; Wen ZY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030511; Williamson AL, 2016, EXPERT REV VACCINES, V15, P585, DOI 10.1586/14760584.2016.1129904; Wines BD, 2017, CURR HIV RES, V15, P202, DOI [10.2174/1570162X15666170320112247, 10.2174/1570162x15666170329092848]; Xiao P, 2010, J VIROL, V84, P7161, DOI 10.1128/JVI.00410-10; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730	75	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1281	10.3390/vaccines9111281			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF3WR	34835214	Green Published, gold			2022-04-29	WOS:000724005000001
J	Heidari, S; Palmer-Ross, A; Goodman, T				Heidari, Shirin; Palmer-Ross, Alice; Goodman, Tracey			A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials	VACCINES			English	Review						COVID-19; vaccines; sex; gender; SAGER Guidelines	VACCINES; COHORT; HEALTH	Sex and gender have implications for COVID-19 vaccine efficacy and adverse effects from the vaccine. As vaccination is one of the key responses to the COVID-19 pandemic, it is vital that sex and gender differences be acknowledged, measured, and analysed in clinical research. Here, we systematically review published COVID-19 vaccine trials, both interventional and observational, to assess the quality of reporting of sex and gender. Of the 75 clinical trials on COVID-19 vaccines included in this review, only 24% presented their main outcome data disaggregated by sex, and only 13% included any discussion of the implications of their study for women and men. Considering the sex differences in adverse events after vaccination, and the gendered aspects of vaccine hesitancy, these oversights in clinical research on vaccines have implications for recovery from the COVID-19 pandemic and for wider public health.	[Heidari, Shirin] WHO, Gender Equ & Human Rights, CH-1211 Geneva, Switzerland; [Palmer-Ross, Alice; Goodman, Tracey] GENDRO, CH-1211 Geneva, Switzerland		Heidari, S (通讯作者)，WHO, Gender Equ & Human Rights, CH-1211 Geneva, Switzerland.	heidaris@who.int; alicepr26@gmail.com; goodmant@who.int		Heidari, Shirin/0000-0002-6837-491X; Palmer-Ross, Alice/0000-0003-3603-3157	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [INV-002735]	The analysis was partially supported by a grant from the Bill & Melinda Gates Foundation to the WHO Immunization, Vaccines and Biologicals department. Grant number: INV-002735.	[Anonymous], 2020, ALLERGIC REACTIONS I; [Anonymous], 2021, EASY FISHER EXACT TE; Avery E, 2016, LANCET, V388, P2839, DOI 10.1016/S0140-6736(16)32393-5; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bignucolo A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080825; Bischof E, 2020, J CLIN INVEST, V130, P3350, DOI 10.1172/JCI139306; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Brady E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24265-8; Bueno SM., 2021, INTERIM REPORT SAFET, DOI [10.1101/2021.03.31.21254494, DOI 10.1101/2021.03.31.21254494V1, DOI 10.1101/2021.03.31.21254494]; Campbell D., 2021, GUARDIAN 1011; Canadian Institutes of Health Research, 2020, STRAT PLAN 2018 2023; Centers for Disease Control and Prevention, 2021, CLIN CONS MYOC PER R; Curno MJ, 2016, JAIDS-J ACQ IMM DEF, V71, P181, DOI 10.1097/QAI.0000000000000842; Ella R, 2021, LANCET INFECT DIS, V21, P950, DOI 10.1016/S1473-3099(21)00070-0; Emary KRW, 2021, EFFICACY CHADOX1 NCO; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; EudraVigilance, EUR DAT SUSP ADV DRU; European Union, 2020, GENDER EQUALITY; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Fairleigh Dickinson University, 2021, FDU POLL FINDS MASC; Fink AL, 2015, PHYSIOLOGY, V30, P408, DOI 10.1152/physiol.00035.2015; Gartlehner G, 2006, CRITERIA DISTINGUISH; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Haverfield J, 2021, HEALTH RES POLICY SY, V19, DOI 10.1186/s12961-021-00741-x; Heidari S, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006854; Heidari Shirin, 2016, Res Integr Peer Rev, V1, P2, DOI 10.1186/s41073-016-0007-6; Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568; Juster R.-P, 2012, WHAT DIFFERENCE SEX; Kadali RAK, 2021, J MED VIROL, V93, P4420, DOI 10.1002/jmv.26996; Knight M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2107; Lacson E, 2021, J AM SOC NEPHROL, V32, P2735, DOI [10.1681/ASN.2021040432, 10.1101/2021.04.08.21254779]; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Li Fuhai, 2021, Res Sq, DOI 10.21203/rs.3.rs-936900/v1; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Male Victoria, 2021, BMJ, V374, pn2211, DOI 10.1136/bmj.n2211; Mauvais-Jarvis F, 2020, LANCET, V396, P565, DOI 10.1016/S0140-6736(20)31561-0; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; Morgan R, 2019, CURR OPIN VIROL, V35, P35, DOI 10.1016/j.coviro.2019.02.009; NIH, 2017, NIH POL GUID INCL WO; Ording AG, 2016, CLIN EPIDEMIOL, V8, P195, DOI 10.2147/CLEP.S97874; Ou MT, 2021, TRANSPLANTATION, V105, P2170, DOI 10.1097/TP.0000000000003780; Padoan A, 2021, CLIN CHIM ACTA, V519, P60, DOI 10.1016/j.cca.2021.04.006; Palmer-Ross A, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-004997; Pan D, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100404; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Richie C, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0341-0; Royal College of Obstetricians and Gynaecologists, 2021, COVID UNL WILL CREAT; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Rios SS, 2021, J AM GERIATR SOC, V69, P1441, DOI 10.1111/jgs.17153; Schiffer VMMM, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100652; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Simonson M., 2021, COVID STATES PROJECT; Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088-200948030-00001; Somiya M, 2021, VACCINE, V39, P3313, DOI 10.1016/j.vaccine.2021.04.066; Voigt EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00180; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, 2021, DRAFT LANDSC TRACK C; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Yakerson A, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-0954-x; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	63	5	5	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1322	10.3390/vaccines9111322			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XD9NG	34835253	gold, Green Published			2022-04-29	WOS:000723025900001
J	Royal, JM; Simpson, CA; McCormick, AA; Phillips, A; Hume, S; Morton, J; Shepherd, J; Oh, Y; Swope, K; DeBeauchamp, JL; Webby, RJ; Cross, RW; Borisevich, V; Geisbert, TW; Demarco, JK; Bratcher, B; Haydon, H; Pogue, GP				Royal, Joshua M.; Simpson, Carrie A.; McCormick, Alison A.; Phillips, Amanda; Hume, Steve; Morton, Josh; Shepherd, John; Oh, Youngjun; Swope, Kelsi; DeBeauchamp, Jennifer L.; Webby, Richard J.; Cross, Robert W.; Borisevich, Viktoriya; Geisbert, Thomas W.; Demarco, Jennifer K.; Bratcher, Barry; Haydon, Hugh; Pogue, Gregory P.			Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-Like Nano-Particle	VACCINES			English	Article						SARS-CoV-2 vaccine; nanoparticle; receptor-binding domain; plant-based manufacturing	NEUTRALIZING ANTIBODY-RESPONSES; CORONAVIRUS INFECTIONS; PROTEIN; GAMMA; PROTECTION; IMMUNITY; CELLS; TMV	Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a human IgG1 Fc domain (CoV-RBD121) and conjugated to a modified tobacco mosaic virus (TMV) nanoparticle. In vitro, CoV-RBD121 bound to the host virus receptor ACE2 and to the monoclonal antibody CR3022, a neutralizing antibody that blocks S binding to ACE2. The CoV-RBD121-NP vaccine candidate retained key SARS-CoV-2 spike protein epitopes, had consistent manufacturing release properties of safety, identity, and strength, and displayed stable potency when stored for 12 months at 2-8 & DEG;C or 22-28 & DEG;C. Immunogenicity studies revealed strong antibody responses in C57BL/6 mice with non-adjuvanted or adjuvanted (7909 CpG) formulations. The non-adjuvanted vaccine induced a balanced Th1/Th2 response and antibodies that recognized both the S1 domain and full S protein from SARS2-CoV-2, whereas the adjuvanted vaccine induced a Th1-biased response. Both adjuvanted and non-adjuvanted vaccines induced virus neutralizing titers as measured by three different assays. Collectively, these data showed the production of a stable candidate vaccine for COVID-19 through the association of the SARS-CoV-2 RBD with the TMV-like nanoparticle.	[Royal, Joshua M.; Simpson, Carrie A.; Phillips, Amanda; Hume, Steve; Morton, Josh; Shepherd, John; Oh, Youngjun; Swope, Kelsi; Bratcher, Barry; Haydon, Hugh; Pogue, Gregory P.] Kentucky BioProc Inc, Owensboro, KY 42301 USA; [McCormick, Alison A.] Touro Univ Calif, Dept Biol & Pharmaceut Sci, Vallejo, CA 95688 USA; [DeBeauchamp, Jennifer L.; Webby, Richard J.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; [Cross, Robert W.; Borisevich, Viktoriya; Geisbert, Thomas W.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston Natl Lab, Galveston, TX 77550 USA; [Demarco, Jennifer K.] Univ Louisville, Ctr Predict Med Biodef & Emerging Infect Dis, Sch Med, Louisville, KY 40202 USA; [Pogue, Gregory P.] Univ Texas Austin, IC2 Inst, Austin, TX 78805 USA		Royal, JM (通讯作者)，Kentucky BioProc Inc, Owensboro, KY 42301 USA.	royalj@kentuckybioprocessing.com; simpsoc3@kentuckybioprocessing.com; amccormi@touro.edu; phillia2@kentuckybioprocessing.com; humes@kentuckybioprocessing.com; mortonj2@kentuckybioprocessing.com; shephej@kentuckybioprocessing.com; ohy@kentuckybioprocessing.com; swopek@kentuckybioprocessing.com; Jennifer.DeBeauchamp@stjude.org; richard.webby@stjude.org; rwcross@UTMB.EDU; viborise@utmb.edu; twgeisbe@utmb.edu; jennifer.wolf.2@louisville.edu; bratchb1@rjrt.com; haydonh@kentuckybioprocessing.com; pogueg1@RJRT.com		Webby, Richard/0000-0002-4397-7132; Royal, Joshua/0000-0002-4243-2667; cross, robert w./0000-0001-7718-1522; Swope, Kelsi/0000-0003-1085-0319	British American Tobacco (BAT)	This work was funded by British American Tobacco (BAT).	Andreano E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01722; Arnaboldi PM, 2016, VACCINE, V34, P5768, DOI 10.1016/j.vaccine.2016.09.063; Banik S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130858; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Boyoglu-Barnum S, 2021, NATURE, V592, P623, DOI 10.1038/s41586-021-03365-x; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Bruun TUJ, 2018, ACS NANO, V12, P8855, DOI 10.1021/acsnano.8b02805; Burger M.I, 2020, REUTERS; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Cole Geoffrey A, 2005, Methods Mol Biol, V302, P191; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031; Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Hayat SMG, 2019, J CELL PHYSIOL, V234, P12530, DOI 10.1002/jcp.28120; Huang WC, 2020, ADV MATER, V32, DOI 10.1002/adma.202005637; Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31; Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011; Kemnade JO, 2014, VACCINE, V32, P4228, DOI 10.1016/j.vaccine.2014.04.051; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Krueger CC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00736; Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2; Lusingu J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014090; Mallajosyula JK, 2014, HUM VACC IMMUNOTHER, V10, P586, DOI 10.4161/hv.27567; Mansour AA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01195; Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046; McCormick AA, 2008, EXPERT REV VACCINES, V7, P33, DOI 10.1586/14760584.7.1.33; McCormick AA, 2006, VACCINE, V24, P6414, DOI 10.1016/j.vaccine.2006.06.003; McCormick AA, 2006, BIOCONJUGATE CHEM, V17, P1330, DOI 10.1021/bc060124m; Mekhaiel DNA, 2011, SCI REP-UK, V1, DOI 10.1038/srep00124; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI 10.1016/S1473-3099(10)70262-0; Palmer KE, 2006, VACCINE, V24, P5516, DOI 10.1016/j.vaccine.2006.04.058; Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732; Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026; Pewe L, 2005, J VIROL, V79, P11335, DOI 10.1128/JVI.79.17.11335-11342.2005; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Smith ML, 2006, VIROLOGY, V348, P475, DOI 10.1016/j.virol.2005.12.039; Steele JFC, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1447; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Walls AC, 2020, CELL, V183, P1367, DOI 10.1016/j.cell.2020.10.043; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Ward BJ, 2021, NAT MED, V27, P1071, DOI 10.1038/s41591-021-01370-1; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241	49	3	3	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1347	10.3390/vaccines9111347			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI0XW	34835278	Green Published, gold			2022-04-29	WOS:000725846900001
J	Zahid, MN				Zahid, Muhammad Nauman			Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study	VACCINES			English	Article						COVID-19; vaccines; side effects; Pfizer; AstraZeneca; Sinopharm; Sputnik	SELF-REPORTED SYMPTOMS; EPIDEMIOLOGY; TRANSMISSION; RESIDENTS; TRIAL	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) created a global pandemic (COVID-19) that has resulted in massive health and economic losses. The current unavailability of treatments leaves vaccination as the only way to control this disease. There are four vaccines (Sinopharm, Pfizer-BioNTech, Sputnik, and AstraZeneca) available in Bahrain. This project aimed to study the most common side effects resulting from the first and second doses of these four vaccines. Data were collected through an online questionnaire answered by 311 individuals who received both doses of one of these four vaccines. The results of this study revealed that regardless of the vaccine identity, participants experienced more side effects from the second dose. Among the different side effects, pain at the site of injection was primarily observed after the first dose of the Pfizer vaccine (43%), which was followed by the AstraZeneca vaccine (31%). Moreover, fever was observed in participants after the first dose of the Sputnik vaccine (37%), while headache was mainly observed after the first dose of the Pfizer vaccine (32%). It is important to note that fatigue was observed after the first dose of all four vaccines but was reported by the highest proportion of respondents in the Pfizer group (28%). Interestingly, there are some side effects, such as pain at the site of injection, that are correlated with fever (r = 0.909). Similarly, headache is correlated with fever (r = 0.801) and pain at the site of injection (r = 0.868). Overall, it was observed that recipients of the Sinopharm vaccine reported the mildest side effects among all four vaccines. The crucial finding of this study is that the first and second dosage post-vaccination side effects were modest and predictable with no occurrences of hospitalization; this information can assist in lessening vaccine apprehension.	[Zahid, Muhammad Nauman] Univ Bahrain, Coll Sci, Dept Biol, Sakhir 32038, Bahrain		Zahid, MN (通讯作者)，Univ Bahrain, Coll Sci, Dept Biol, Sakhir 32038, Bahrain.	nzahid@uob.edu.bh		zahid, muhammad nauman/0000-0002-8322-9294			Abu-Halaweh S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090950; Ahamed F, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11620-z; Alhazmi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060674; Almufty HB, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102207; Andrzejczak-Grzadko S, 2021, EUR REV MED PHARMACO, V25, P4418, DOI 10.26355/eurrev_202106_26153; Carli G, 2021, INTERN EMERG MED, V16, P803, DOI 10.1007/s11739-021-02685-0; Chakraborty S, 2021, ADV DRUG DELIVER REV, V172, P314, DOI 10.1016/j.addr.2021.01.014; Demeco A, 2020, J INT MED RES, V48, DOI 10.1177/0300060520948382; Chowdhury SD, 2020, J DIG ENDOSC, V11, P3, DOI 10.1055/s-0040-1712187; Diaz GA, 2021, JAMA-J AM MED ASSOC, V326, P1210, DOI 10.1001/jama.2021.13443; Dillman A, 2020, INFECT DRUG RESIST, V13, P4577, DOI 10.2147/IDR.S288399; El-Shitany NA, 2021, INT J GEN MED, V14, P1389, DOI 10.2147/IJGM.S310497; European Medicines Agency, 2021, COVID 19 VACC ASTRAZ; Galindo R, 2021, PEDIATR CLIN N AM, V68, P961, DOI 10.1016/j.pcl.2021.05.004; Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762; Ghiasi N, 2021, IMMUNOPATHOL PERSA, V7, DOI 10.34172/ipp.2021.31; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Hatmal MM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060556; Hause AM, 2021, MMWR-MORBID MORTAL W, V70, P1379, DOI 10.15585/mmwr.mm7039e4; Jayadevan R, SURVEY SYMPTOMS FOLL, V2021, DOI [10.1101/2021.02.08.21251366, DOI 10.1101/2021.02.08.21251366]; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Leite JA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253334; Li P, 2020, INT J INFECT DIS, V96, P452, DOI 10.1016/j.ijid.2020.03.027; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lu L, 2021, ACTA NEUROL SCAND, V144, P111, DOI 10.1111/ane.13444; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Nogrady B, 2021, NATURE, V595, P339, DOI 10.1038/d41586-021-01813-2; Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Saeed BQ, 2021, INT J INFECT DIS, V111, P219, DOI 10.1016/j.ijid.2021.08.013; Sanyaolu Adekunle, 2021, Infect Dis (Auckl), V14, p1178633721991260, DOI 10.1177/1178633721991260; Serwaa D, 2021, HUM VACC IMMUNOTHER, V17, P3881, DOI 10.1080/21645515.2021.1963600; Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005; Zhai Pan, 2020, Int J Antimicrob Agents, V55, P105955, DOI 10.1016/j.ijantimicag.2020.105955; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhou GB, 2020, FRONT MED-PRC, V14, P117, DOI 10.1007/s11684-020-0773-x; Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490	38	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1369	10.3390/vaccines9111369			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH8YP	34835300	gold, Green Published			2022-04-29	WOS:000725713600001
J	Azhar, A; Begum, NA; Husain, A				Azhar, Asim; Begum, Nasim A.; Husain, Afzal			Nucleotide Pool Imbalance and Antibody Gene Diversification	VACCINES			English	Review						dNTP; V(D)J recombination; SHM; CSR; antibody; SAMHD1	CLASS-SWITCH RECOMBINATION; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; AICARDI-GOUTIERES SYNDROME; RESTRICTION FACTOR SAMHD1; CYTIDINE DEAMINASE AID; DNA-POLYMERASE-ETA; RIBONUCLEOTIDE REDUCTASE; V(D)J RECOMBINATION; SOMATIC HYPERMUTATION; CELL-CYCLE	The availability and adequate balance of deoxyribonucleoside triphosphate (dNTP) is an important determinant of both the fidelity and the processivity of DNA polymerases. Therefore, maintaining an optimal balance of the dNTP pool is critical for genomic stability in replicating and quiescent cells. Since DNA synthesis is required not only in genomic replication but also in DNA damage repair and recombination, the abnormalities in the dNTP pool affect a wide range of chromosomal activities. The generation of antibody diversity relies on antigen-independent V(D)J recombination, as well as antigen-dependent somatic hypermutation and class switch recombination. These processes involve diverse sets of DNA polymerases, which are affected by the dNTP pool imbalances. This review discusses the role of the optimal dNTP pool balance in the diversification of antibody encoding genes.	[Azhar, Asim] Aligarh Muslim Univ, Fac Life Sci, Dept Biotechnol, Aligarh 202002, Uttar Pradesh, India; [Begum, Nasim A.] Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto 6068501, Japan; [Husain, Afzal] Aligarh Muslim Univ, Fac Life Sci, Dept Biochem, Aligarh 202002, Uttar Pradesh, India		Husain, A (通讯作者)，Aligarh Muslim Univ, Fac Life Sci, Dept Biochem, Aligarh 202002, Uttar Pradesh, India.	azharasim@gmail.com; nasim@mfour.med.kyoto-u.ac.jp; afzal.bc@amu.ac.in	Azhar, Asim/ABG-1503-2021	Azhar, Asim/0000-0001-9884-7645	Department of Science and Technology-Science and Engineering Research Board (DST-SERB) [SRG-2020-000819]	Start-Up Research Grant (SRG-2020-000819) from the Department of Science and Technology-Science and Engineering Research Board (DST-SERB).	Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Akimova E, 2021, NUCLEIC ACIDS RES, V49, P2598, DOI 10.1093/nar/gkab051; Aldrich MB, 2003, J IMMUNOL, V171, P5562, DOI 10.4049/jimmunol.171.10.5562; Amie SM, 2013, J BIOL CHEM, V288, P25001, DOI 10.1074/jbc.C113.493619; Antonucci JM, 2016, NAT MED, V22, P1072, DOI 10.1038/nm.4163; Apasov SG, 2001, J CLIN INVEST, V108, P131, DOI 10.1172/JCI200110360; Babbe H, 2009, J IMMUNOL, V182, P347, DOI 10.4049/jimmunol.182.1.347; Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Behrendt R, 2013, CELL REP, V4, P689, DOI 10.1016/j.celrep.2013.07.037; Beloglazova N, 2013, J BIOL CHEM, V288, P8101, DOI 10.1074/jbc.M112.431148; Benedict CL, 2000, IMMUNOL REV, V175, P150, DOI 10.1034/j.1600-065X.2000.017518.x; BENVENISTE P, 1995, J IMMUNOL, V155, P536; Bertocci B, 2006, IMMUNITY, V25, P31, DOI 10.1016/j.immuni.2006.04.013; Boboila C, 2012, ADV IMMUNOL, V116, P1, DOI 10.1016/B978-0-12-394300-2.00001-6; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; CHAN T, 1978, CELL, V14, P523, DOI 10.1016/0092-8674(78)90238-6; Chen JM, 2007, NAT REV GENET, V8, P762, DOI 10.1038/nrg2193; Chimploy K, 2001, J BIOL CHEM, V276, P7093, DOI 10.1074/jbc.M006232200; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Clifford R, 2014, BLOOD, V123, P1021, DOI 10.1182/blood-2013-04-490847; COHEN A, 1978, J CLIN INVEST, V61, P1405, DOI 10.1172/JCI109058; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Daddacha W, 2017, CELL REP, V20, P1921, DOI 10.1016/j.celrep.2017.08.008; de Almeida CR, 2018, MOL CELL, V70, P650, DOI 10.1016/j.molcel.2018.04.001; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dingler FA, 2014, EUR J IMMUNOL, V44, P1925, DOI 10.1002/eji.201444482; EDWARDS NL, 1985, MED CLIN N AM, V69, P505; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; Fairman JW, 2011, NAT STRUCT MOL BIOL, V18, P316, DOI 10.1038/nsmb.2007; Fasullo M, 2015, INT J MOL SCI, V16, P9431, DOI 10.3390/ijms16059431; Feng YQ, 2020, TRENDS IMMUNOL, V41, P586, DOI 10.1016/j.it.2020.04.009; Franzolin E, 2013, P NATL ACAD SCI USA, V110, P14272, DOI 10.1073/pnas.1312033110; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fujita T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026109; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623; Hanft VN, 2000, BLOOD, V95, P3589, DOI 10.1182/blood.V95.11.3589.011k38_3589_3593; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Hofer A, 2012, CRIT REV BIOCHEM MOL, V47, P50, DOI 10.3109/10409238.2011.630372; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Hu CM, 2012, CANCER CELL, V22, P36, DOI 10.1016/j.ccr.2012.04.038; Husain A, 2020, EMBO J, V39, DOI 10.15252/embj.2019102931; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kano C, 2012, INT IMMUNOL, V24, P169, DOI 10.1093/intimm/dxr109; Krijger PHL, 2013, EUR J IMMUNOL, V43, P2765, DOI 10.1002/eji.201243191; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lahouassa H, 2012, NAT IMMUNOL, V13, P223, DOI 10.1038/ni.2236; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEDER P, 1982, SCI AM, V246, P102, DOI 10.1038/scientificamerican0582-102; Lim J, 2017, CELL, V169, P525, DOI 10.1016/j.cell.2017.03.043; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; Lu H, 2007, NUCLEIC ACIDS RES, V35, P6917, DOI 10.1093/nar/gkm823; Malu S, 2012, IMMUNOL RES, V54, P233, DOI 10.1007/s12026-012-8329-z; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; Mathews CK, 2015, NAT REV CANCER, V15, P528, DOI 10.1038/nrc3981; Mathews CK, 2014, FASEB J, V28, P3832, DOI 10.1096/fj.14-251249; Methot SP, 2017, ADV IMMUNOL, V133, P37, DOI 10.1016/bs.ai.2016.11.002; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Motea EA, 2010, BBA-PROTEINS PROTEOM, V1804, P1151, DOI 10.1016/j.bbapap.2009.06.030; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Murphy K, 2017, JANEWAY'S IMMUNOBIOLOGY, 9TH EDITION, P1; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; Niida H, 2010, GENE DEV, V24, P333, DOI 10.1101/gad.1863810; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pieper K, 2017, NATURE, V548, P597, DOI 10.1038/nature23670; Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105; Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Rehwinkel J, 2013, EMBO J, V32, P2454, DOI 10.1038/emboj.2013.163; Rentoft M, 2016, P NATL ACAD SCI USA, V113, P4723, DOI 10.1073/pnas.1519128113; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Robbiani DF, 2013, ANNU REV PATHOL-MECH, V8, P79, DOI 10.1146/annurev-pathol-020712-164004; Rush JS, 2004, INT IMMUNOL, V16, P549, DOI 10.1093/intimm/dxh057; Ryoo J, 2014, NAT MED, V20, P936, DOI 10.1038/nm.3626; Sadofsky MJ, 2001, NUCLEIC ACIDS RES, V29, P1399, DOI 10.1093/nar/29.7.1399; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Seamon KJ, 2016, BIOCHEMISTRY-US, V55, P6087, DOI 10.1021/acs.biochem.6b00986; Sharbeen G, 2012, J EXP MED, V209, P965, DOI 10.1084/jem.20112379; Somech R, 2012, J ALLERGY CLIN IMMUN, V130, P539, DOI 10.1016/j.jaci.2012.03.038; Stavnezer J, 2014, P NATL ACAD SCI USA, V111, P9217, DOI 10.1073/pnas.1405590111; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tarlinton D, 2013, SCIENCE, V341, P1205, DOI 10.1126/science.1241146; Thientosapol ES, 2018, P NATL ACAD SCI USA, V115, P4921, DOI 10.1073/pnas.1719771115; Thomas-Claudepierre AS, 2013, J EXP MED, V210, P2495, DOI 10.1084/jem.20130166; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; Wang Q, 2017, J EXP MED, V214, P49, DOI 10.1084/jem.20161649; Watt DL, 2016, NUCLEIC ACIDS RES, V44, P1669, DOI 10.1093/nar/gkv1298; Weill JC, 2008, NAT REV IMMUNOL, V8, P302, DOI 10.1038/nri2281; Welbourn S, 2016, VIROLOGY, V488, P271, DOI 10.1016/j.virol.2015.11.022; Wyatt DW, 2016, MOL CELL, V63, P662, DOI 10.1016/j.molcel.2016.06.020; Yousefzadeh MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004654; Zelensky AN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00124-3; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zubani GG, 2017, J EXP MED, V214, P1169, DOI 10.1084/jem.20161576	108	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1050	10.3390/vaccines9101050			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN9WP	34696158	Green Published, gold			2022-04-29	WOS:000712115700001
J	Babicki, M; Pokorna-Kalwak, D; Doniec, Z; Mastalerz-Migas, A				Babicki, Mateusz; Pokorna-Kalwak, Dagmara; Doniec, Zbigniew; Mastalerz-Migas, Agnieszka			Attitudes of Parents with Regard to Vaccination of Children against COVID-19 in Poland. A Nationwide Online Survey	VACCINES			English	Article						COVID-19 vaccination; attitudes toward vaccination; COVID-19	SARS-COV-2 INFECTION; EUROPEAN COUNTRIES; TRACKING; RISK	Within a few months, the scientific world achieved a great success, developing effective and safe vaccines against COVID-19. Many countries with full access to vaccines have introduced recommendations for the vaccination of not only people who are at risk of developing severe COVID-19, i.e., the elderly and chronically ill, but all members of society, including children aged 12 and above as the currently registered preparations can be used above the said age. However, the use of COVID-19 vaccines in children arouses strong emotions, with their sense being frequently questioned. The aim of the paper was to assess the attitudes of Polish parents with regard to vaccinations against COVID-19 administered to their children. The study was conducted with the use of the authors' original questionnaire, which was distributed online. The questionnaire was completed 4732 times, and 4432 surveys were qualified for the final analysis. The vast majority of the respondents were women (77.6%), people aged 36-44 (40.3%), with higher education (86.2%) and people living in the city with more than 250,000 inhabitants (48%). The mean age of the study group was 37.5 & PLUSMN; 6.61 years. Out of the studied group, 28.2% of parents are healthcare professionals. The study was conducted prior to the EMA's decision that permitted the use of BNT162b2 in children. Results: The vast majority of the respondents were mothers, who showed significantly more favorable attitudes toward the vaccinations than fathers. Forty-four percent of parents want to vaccinate their children as soon as possible, while every fourth parent does not want to vaccinate their child at all. Main concerns about the vaccines include concerns that the preparation has not been adequately tested and that it is ineffective, as well as the lack of information concerning potential complications in the future. The main sources of information on childhood vaccinations are the media, including the Internet and television. Vaccination of the pediatric population against COVID-19 raises many emotions and doubts in parents and it is also debated by experts. The decision to vaccinate should rest on child's parents. Both the individual benefits of protection against COVID-19 and the population benefits of pandemic control must be considered. There is a need for ongoing monitoring of the safety of administering COVID-19 vaccinations in children, as well as for evaluating their effectiveness and benefits in reducing individual risk of severe course of COVID-19 and complications after this disease, and for evaluating the population benefits of vaccines in children.</p>	[Babicki, Mateusz; Pokorna-Kalwak, Dagmara; Mastalerz-Migas, Agnieszka] Wroclaw Med Univ, Dept Family Med, Syrokomli 1, PL-51141 Wroclaw, Poland; [Doniec, Zbigniew] Inst TB & Lung Dis, Reg Branch, Dept Pediat Pneumonol & Allergol, PL-34700 Rabka Zdroj, Poland; [Doniec, Zbigniew] Podhale State Coll Appl Sci, Med Inst, PL-34400 Nowy Targ, Poland		Babicki, M (通讯作者)，Wroclaw Med Univ, Dept Family Med, Syrokomli 1, PL-51141 Wroclaw, Poland.	ma.babicki@gmail.com; daga_kalwak@o2.pl; zdoniec1@gmail.com; agnieszka.mastalerz-migas@umed.wroc.pl	Babicki, Mateusz/AAG-9558-2020; Pokorna-Kalwak, Dagmara/S-9594-2018; Mastalerz-Migas, Agnieszka/W-5453-2018	Babicki, Mateusz/0000-0002-7719-6959; Pokorna-Kalwak, Dagmara/0000-0001-5976-6017; Mastalerz-Migas, Agnieszka/0000-0001-6600-2760	Wroclaw Medical University [SUB.C290.21.010]	This research was founded by the Wroclaw Medical University SUB.C290.21.010.	Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], Children and COVID-19: State Data Report. A Joint Report from the American Academy of Pediatrics and the Children's Hospital Association; Babicki M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050503; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Buglewicz K, 2015, ZESZ PRASOZN, V2015, P677; Cucunawangsih C, 2021, INT J INFECT DIS, V107, P268, DOI 10.1016/j.ijid.2021.05.020; Melo AD, 2021, TROP DIS TRAVEL MED, V7, DOI 10.1186/s40794-021-00137-3; de Souza TH, 2020, PEDIATR PULM, V55, P1892, DOI 10.1002/ppul.24885; Flisiak R, 2021, POL ARCH INTERN MED, V131, P487, DOI 10.20452/pamw.15979; Gallagher J., 2021, BBC; Hadjipanayis A, 2020, VACCINE, V38, P1505, DOI 10.1016/j.vaccine.2019.11.068; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harris RJ, 2021, NEW ENGL J MED, V385, P759, DOI 10.1056/NEJMc2107717; Hoste L, 2021, EUR J PEDIATR, V180, P2019, DOI 10.1007/s00431-021-03993-5; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Larson HJ, 2018, NAT HUM BEHAV, V2, P316, DOI 10.1038/s41562-018-0331-6; Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618; Lu D., 2021, GUARDIAN; Money. L., 2020, LOS ANGELES TIMES; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Okarska-Napierala M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113386; Patel NA, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102573; Pisaniak P, 2021, RISK MANAG HEALTHC P, V14, P1241, DOI 10.2147/RMHP.S283796; Ritchie H., 2020, STAT RES; Saxena S, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1866; Smith C., 2021, RES SQUARE; Stefanoff P, 2010, VACCINE, V28, P5731, DOI 10.1016/j.vaccine.2010.06.009; Tokarczyk E, 2013, AUTOBUSY TECH EKSPLO, V14, P513; Yasuhara J, 2021, PEDIATR PULM, V56, P837, DOI 10.1002/ppul.25245; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827; Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660	34	3	3	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1192	10.3390/vaccines9101192			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ8FX	34696300	gold, Green Published			2022-04-29	WOS:000714047600001
J	Held, J; Esse, J; Tascilar, K; Steininger, P; Schober, K; Irrgang, P; Alsalameh, R; Tenbusch, M; Seggewies, C; Bogdan, C				Held, Juergen; Esse, Jan; Tascilar, Koray; Steininger, Philipp; Schober, Kilian; Irrgang, Pascal; Alsalameh, Rayya; Tenbusch, Matthias; Seggewies, Christof; Bogdan, Christian			Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty(R))	VACCINES			English	Article						SARS-CoV-2; mRNA vaccine; side effects; adverse reactions; adverse effects; antibody; machine learning; BioNTech; Pfizer		mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as BNT162b2 (Comirnaty(R)), have proven to be highly immunogenic and efficient but also show marked reactogenicity, leading to adverse effects (AEs). Here, we analyzed whether the severity of AEs predicts the antibody response against the SARS-CoV-2 spike protein. Healthcare workers without prior SARS-CoV-2 infection, who received a prime-boost vaccination with BNT162b2, completed a standardized electronic questionnaire on the duration and severity of AEs. Serum specimens were collected two to four weeks after the boost vaccination and tested with the COVID-19 ELISA IgG (Vircell-IgG), the LIAISON(R) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin-IgG) and the iFlash-2019-nCoV NAb surrogate neutralization assay (Yhlo-NAb). A penalized linear regression model fitted by machine learning was used to correlate AEs with antibody levels. Eighty subjects were enrolled in the study. Systemic, but not local, AEs occurred more frequently after the boost vaccination. Elevated SARS-CoV-2 IgG antibody levels were measured in 92.5% of subjects with Vircell-IgG and in all subjects with DiaSorin-IgG and Yhlo-NAb. Gender, age and BMI showed no association with the antibody levels or with the AEs. The linear regression model identified headache, malaise and nausea as AEs with the greatest variable importance for higher antibody levels (Vircell-IgG and DiaSorin-IgG). However, the model performance for predicting antibody levels from AEs was very low for Vircell-IgG (squared correlation coefficient r(2) = 0.04) and DiaSorin-IgG (r(2) = 0.06). AEs did not predict the surrogate neutralization (Yhlo-NAb) results. In conclusion, AEs correlate only weakly with the SARS-CoV-2 spike protein antibody levels after COVID-19 vaccination with BNT162b2 mRNA.	[Held, Juergen; Esse, Jan; Schober, Kilian; Alsalameh, Rayya; Bogdan, Christian] Univ Klinikum Erlangen, Mikrobiol Inst Klin Mikrobiol Immunol & Hyg, Wasserturmstr 3-5, D-91054 Erlangen, Germany; [Held, Juergen; Esse, Jan; Schober, Kilian; Alsalameh, Rayya; Bogdan, Christian] Friedrich Alexander Univ FAU Erlangen Nurnberg, Wasserturmstr 3-5, D-91054 Erlangen, Germany; [Tascilar, Koray] Univ Klinikum Erlangen, Med Klin Rheumatol & Immunol 3, Ulmenweg 18, D-91054 Erlangen, Germany; [Tascilar, Koray] Friedrich Alexander Univ FAU Erlangen Nurnberg, Ulmenweg 18, D-91054 Erlangen, Germany; [Steininger, Philipp; Irrgang, Pascal; Tenbusch, Matthias] Univ Klinikum Erlangen, Virol Inst Klin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany; [Steininger, Philipp; Irrgang, Pascal; Tenbusch, Matthias] Friedrich Alexander Univ FAU Erlangen Nurnberg, Schlossgarten 4, D-91054 Erlangen, Germany; [Seggewies, Christof] Univ Klinikum Erlangen, Ctr Med Informat & Commun Technol, Krankenhausstr 12, D-91054 Erlangen, Germany		Held, J (通讯作者)，Univ Klinikum Erlangen, Mikrobiol Inst Klin Mikrobiol Immunol & Hyg, Wasserturmstr 3-5, D-91054 Erlangen, Germany.; Held, J (通讯作者)，Friedrich Alexander Univ FAU Erlangen Nurnberg, Wasserturmstr 3-5, D-91054 Erlangen, Germany.	juergen.held@uk-erlangen.de; jan.esse@uk-erlangen.de; koray.tascilar@uk-erlangen.de; philipp.steininger@uk-erlangen.de; kilian.schober@uk-erlangen.de; pascal.irrgang@uk-erlangen.de; rayya.alsalameh@uk-erlangen.de; matthias.tenbusch@uk-erlangen.de; christof.seggewies@uk-erlangen.de; christian.bogdan@uk-erlangen.de	; TASCILAR, Koray/F-9070-2015	Held, Jurgen/0000-0003-1130-9727; TASCILAR, Koray/0000-0002-8109-826X; Esse, Jan/0000-0003-0601-8837	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF)	This study was supported by the Deutsche Forschungsgemeinschaft (grant BO996/6-1). K.S. was supported by the German Federal Ministry of Education and Research (BMBF; project 01KI2013).	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Beran J, 2010, HUM VACCINES, V6, P578, DOI 10.4161/hv.6.7.11883; Burny W, 2017, FRONT IMMUNOL, V8, P14, DOI 10.3389/fimmu.2017.00943; Cai CJ, 2021, MOL THER, V29, P2794, DOI 10.1016/j.ymthe.2021.08.001; Cao Y, 2020, ACTA VIROL, V64, P245, DOI 10.4149/av_2020_201; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Christian LM, 2015, VACCINE, V33, P3360, DOI 10.1016/j.vaccine.2015.05.008; Colindres R, 2020, HUM VACC IMMUNOTHER, V16, P2628, DOI 10.1080/21645515.2020.1741312; Desmet CJ, 2012, NAT REV IMMUNOL, V12, P479, DOI 10.1038/nri3247; European Medicines Agency (EMA), APPR VACC EUR UN; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Haskins-Coulter T, 2017, HUM VACC IMMUNOTHER, V13, P1412, DOI 10.1080/21645515.2016.1277846; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Hwang YH, 2021, KOREAN J INTERN MED, V36, P1486, DOI 10.3904/kjim.2021.210; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Mitchell TC, 2017, CURR OPIN IMMUNOL, V47, P17, DOI 10.1016/j.coi.2017.06.009; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sofi Mohd Sharjeel, 2020, Biosaf Health, V2, P217, DOI 10.1016/j.bsheal.2020.11.002; Tenbusch M, 2021, LANCET INFECT DIS, V21, P1212, DOI 10.1016/S1473-3099(21)00420-5; Terpos E, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081942; Van Tilbeurgh M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060579; Vlatkovic I, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9050530; WHO, WHO COR COVID 19 DAS; Zeng Chunxi, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_217; Zhuang CL, 2021, EMERG MICROBES INFEC, V10, P365, DOI 10.1080/22221751.2021.1891002	30	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1063	10.3390/vaccines9101063			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI8JZ	34696171	Green Published, gold			2022-04-29	WOS:000726351800001
J	Liontos, M; Terpos, E; Markellos, C; Zagouri, F; Briasoulis, A; Katsiana, I; Skafida, E; Fiste, O; Kunadis, E; Andrikopoulou, A; Kaparelou, M; Koutsoukos, K; Gavriatopoulou, M; Kastritis, E; Trougakos, IP; Dimopoulos, MA				Liontos, Michalis; Terpos, Evangelos; Markellos, Christos; Zagouri, Flora; Briasoulis, Alexandros; Katsiana, Ioanna; Skafida, Efthymia; Fiste, Oraianthi; Kunadis, Elena; Andrikopoulou, Angeliki; Kaparelou, Maria; Koutsoukos, Konstantinos; Gavriatopoulou, Maria; Kastritis, Efstathios; Trougakos, Ioannis P.; Dimopoulos, Meletios-Athanasios			Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors	VACCINES			English	Article						ovarian cancer; SARS-CoV-2; vaccination; PARP inhibitors		Objective: Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups. Results: The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose. Conclusions: These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.</p>	[Liontos, Michalis; Terpos, Evangelos; Markellos, Christos; Zagouri, Flora; Briasoulis, Alexandros; Katsiana, Ioanna; Skafida, Efthymia; Fiste, Oraianthi; Kunadis, Elena; Andrikopoulou, Angeliki; Kaparelou, Maria; Koutsoukos, Konstantinos; Gavriatopoulou, Maria; Kastritis, Efstathios; Dimopoulos, Meletios-Athanasios] Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens 11528, Greece; [Trougakos, Ioannis P.] Natl & Kapodistrian Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 11528, Greece		Zagouri, F (通讯作者)，Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens 11528, Greece.	mliontos@gmail.com; eterpos@med.uoa.gr; chrismarkellos@hotmail.com; florazagouri@yahoo.co.uk; alexbriasoulis@gmail.com; iwannakatsiana@gmail.com; skafidaefi@gmail.com; oraianthifiste@gmail.com; kounadielena@gmail.com; aggandrikop@med.uoa.gr; mkaparelou@yahoo.com; koutsoukos.k@gmail.com; mgavria@med.uoa.gr; ekastritis@med.uoa.gr; itrougakos@biol.uoa.gr; mdimop@uoa.gr	; Trougakos, Ioannis/R-6149-2018	Terpos, Evangelos/0000-0001-5133-1422; Trougakos, Ioannis/0000-0002-6179-2772; Liontos, Michalis/0000-0001-7192-4575; Andrikopoulou, Angeliki/0000-0001-7857-5427; Kastritis, Efstathios/0000-0001-8191-5832	SYN-ENOSIS (Greece); AEGEAS (Greece); IEMBITHEK (Greece)	This research was funded by SYN-ENOSIS (Greece), AEGEAS (Greece) and IEMBITHEK (Greece).	Ayubi E, 2021, J GASTROINTEST CANC, V52, P499, DOI 10.1007/s12029-021-00643-9; Capoluongo E, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110536; Curtin N, 2020, BRIT J PHARMACOL, V177, P3635, DOI 10.1111/bph.15137; Hiam-Galvez KJ, 2021, NAT REV CANCER, V21, P345, DOI 10.1038/s41568-021-00347-z; Krause PR, 2021, NEW ENGL J MED, V385, P179, DOI 10.1056/NEJMsr2105280; Lee EK, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920944116; Mateo J, 2019, ANN ONCOL, V30, P1437, DOI 10.1093/annonc/mdz192; Mitra M, 2020, J PRIM CARE COMMUNIT, V11, DOI 10.1177/2150132720942705; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rodriguez GM, 2021, AM J CLIN ONCOL-CANC, V44, P580, DOI 10.1097/COC.0000000000000865; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Terpos E, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01099-x; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Waissengrin B, 2021, LANCET ONCOL, V22, P581, DOI 10.1016/S1470-2045(21)00155-8; Yang LD, 2021, CANCER BIOL MED, V18, P298, DOI 10.20892/j.issn.2095-3941.2020.0559; Yelamos J, 2020, CANCERS, V12, DOI 10.3390/cancers12020392; Yi M, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0154-9; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427	21	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1148	10.3390/vaccines9101148			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS3KO	34696256	Green Published, gold			2022-04-29	WOS:000715084100001
J	Luo, QP; Ahmed, W; Dai, YC; Mohsin, A; Hang, HF; Zhuang, YP; Guo, MJ				Luo, Qingping; Ahmed, Waqas; Dai, Yichen; Mohsin, Ali; Hang, Haifeng; Zhuang, Yingping; Guo, Meijin			Evaluation of a Virus-like Nanoparticle Porcine Circovirus Type-2 (PCV2) Capsid Protein Fused with the Pig Immunoglobulin Fc Fragment as a Novel Vaccine Candidate against PCV2 in Mice	VACCINES			English	Article						PCV2; capsid ( increment 1-41aa)-pFc fusion protein; virus-like nanoparticles	CONFORMATIONAL STABILITY; LACTOCOCCUS-LACTIS; SUBUNIT VACCINE; EXPRESSION; IMMUNOGENICITY; IMMUNITY; RECOGNITION; DNA	Porcine circovirus Type 2 (PCV2) is a primary etiological pathogen of post-weaning multi-systemic wasting syndrome (PMWS). The capsid protein of PCV2 is the crucial immunogenic protein which can induce antibody generation and immune responses. However, there is still a lack of efficient PCV2 vaccines with high immunogenicity. In the current study, we developed a novel engineered PCV2 capsid ( increment 1-41aa)-pFc fusion protein (PCFP), which comprised a truncated capsid protein of PCV2 and a porcine IgG Fc fragment, fused to the capsid protein of PCV2 at the C-terminus. We found that this novel fusion protein could auto-assemble into virus-like nanoparticles with an estimated mean diameter of 22.6 nm, characterized by transmission electron microscopy. Immunization of BALB/c mice with this fusion protein significantly increased the production levels of anti-PCV2-capsid protein antibody in serum. Besides, the virus-like nanoparticles, PCFP was demonstrated to induce efficient cellular immune responses in mice, as evident by the high specific T cell reactivity to the PCFP fusion protein and the high production of the immune cytokines IFN-gamma and IL-10 in an ex vivo re-stimulation system. Collectively, these findings demonstrate that the PCV2 truncated capsid subunit Fc-fusion protein can induce both cellular and humoral immune responses, and it displays great application potential.	[Luo, Qingping; Ahmed, Waqas; Dai, Yichen; Mohsin, Ali; Hang, Haifeng; Zhuang, Yingping; Guo, Meijin] East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China		Guo, MJ (通讯作者)，East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.	y10160102@mail.ecust.edu.cn; waqasahmed@mail.ecust.edu.cn; y30181184@mail.ecust.edu.cn; alimohsin@ecust.edu.cn; hanghaifeng@ecust.edu.cn; ypzhuang@ecust.edu.cn; guo_mj@ecust.edu.cn		Zhuang, Yingping/0000-0002-6772-7306	Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [19441912100]	FundingThis research was funded by Shanghai Science and Technology Committee, grant number 19441912100.	Allan GM, 1998, J VET DIAGN INVEST, V10, P3, DOI 10.1177/104063879801000102; Chen XH, 2016, BIOTECHNOL LETT, V38, P959, DOI 10.1007/s10529-016-2076-5; Constans M, 2015, BIOINFORM BIOL INSIG, V9, P1, DOI 10.4137/BBI.S30226; Cox GN, 2004, EXP HEMATOL, V32, P441, DOI 10.1016/j.exphem.2004.01.012; de Boisseson C, 2004, J GEN VIROL, V85, P293, DOI 10.1099/vir.0.19536-0; Firth C, 2009, J VIROL, V83, P12813, DOI 10.1128/JVI.01719-09; Fu F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-264; Gillespie J, 2009, J VET INTERN MED, V23, P1151, DOI 10.1111/j.1939-1676.2009.0389.x; Khayat R, 2011, J VIROL, V85, P11542, DOI 10.1128/JVI.05863-11; Konduru K, 2011, VACCINE, V29, P2968, DOI 10.1016/j.vaccine.2011.01.113; Kong WT, 2011, WORLD J MICROB BIOT, V27, P651, DOI 10.1007/s11274-010-0503-7; Li DL, 2017, VACCINE, V35, P4722, DOI 10.1016/j.vaccine.2017.07.031; Li Y., 2016, BIORESOUR BIOPROCESS, V3, P4565, DOI [10.1186/s40643-016-0114-8, DOI 10.1186/S40643-016-0114-8]; Liu JK, 2018, PEERJ, V6, DOI 10.7717/peerj.4476; Lopez-Vidal J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140039; Loureiro S, 2011, J VIROL, V85, P3010, DOI 10.1128/JVI.01241-10; Lu L, 2011, J VIROL, V85, P10542, DOI 10.1128/JVI.05441-11; Mahe D, 2000, J GEN VIROL, V81, P1815, DOI 10.1099/0022-1317-81-7-1815; Meehan BM, 1998, J GEN VIROL, V79, P2171, DOI 10.1099/0022-1317-79-9-2171; Mo XB, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007562; Ohkuri T, 2010, J IMMUNOL, V185, P4199, DOI 10.4049/jimmunol.0902249; Opriessnig T, 2010, VET MICROBIOL, V142, P177, DOI 10.1016/j.vetmic.2009.09.056; Park C, 2017, CAN J VET RES, V81, P171; Ramamoorthy Sheela, 2009, Animal Health Research Reviews, V10, P1, DOI 10.1017/S1466252308001461; Seo HW, 2011, CLIN VACCINE IMMUNOL, V18, P1091, DOI 10.1128/CVI.05027-11; Silva JG, 2014, J VIROL METHODS, V207, P226, DOI 10.1016/j.jviromet.2014.07.021; So T, 2001, IMMUNOLOGY, V104, P259, DOI 10.1046/j.1365-2567.2001.01314.x; Soleimanpour S, 2015, APPL MICROBIOL BIOT, V99, P10467, DOI 10.1007/s00253-015-6952-z; Tao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184425; Thai R, 2004, J BIOL CHEM, V279, P50257, DOI 10.1074/jbc.M405738200; Trible BR, 2012, J VIROL, V86, P13508, DOI 10.1128/JVI.01763-12; Tu YB, 2013, APPL MICROBIOL BIOT, V97, P2867, DOI 10.1007/s00253-012-4540-z; Wang K, 2008, J VIROL METHODS, V150, P1, DOI 10.1016/j.jviromet.2008.02.014; Xiao CT, 2016, VET MICROBIOL, V197, P72, DOI 10.1016/j.vetmic.2016.11.009; Xu PL, 2019, ARCH VIROL, V164, P1445, DOI 10.1007/s00705-019-04205-0; Yin SH, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-166; Zhang HW, 2015, VACCINE, V33, P2449, DOI 10.1016/j.vaccine.2015.03.090; Zhang MY, 2009, VACCINE, V27, P857, DOI 10.1016/j.vaccine.2008.11.083; Zhang YJ, 2019, ANTIVIR RES, V165, P11, DOI 10.1016/j.antiviral.2019.02.017; Zhou JY, 2005, J BIOTECHNOL, V118, P201, DOI 10.1016/j.jbiotec.2005.02.017	40	0	0	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1128	10.3390/vaccines9101128			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP0JX	34696236	gold, Green Published			2022-04-29	WOS:000712830000001
J	Matkowska-Kocjan, A; Owoc-Lempach, J; Chruszcz, J; Kuznik, E; Szenborn, F; Jurczenko, L; Wojcik, M; Banys, D; Szenborn, L; Ussowicz, M				Matkowska-Kocjan, Agnieszka; Owoc-Lempach, Joanna; Chruszcz, Joanna; Kuznik, Edwin; Szenborn, Filip; Jurczenko, Lidia; Wojcik, Marta; Banys, Dorota; Szenborn, Leszek; Ussowicz, Marek			The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation	VACCINES			English	Article						COVID-19; vaccinations; HSCT	ANTIBODY	Sixty five patients (18-31 years) who had received allogeneic haematopoietic stem cell transplantation (3-27 years from HSCT) were evaluated for the tolerance and immunogenicity of the COVID-19 mRNA BNT163b2 vaccine. Methods: Patients were vaccinated with two doses at 5 weeks interval. After each dose, patients completed a survey concerning adverse events (AE) and anti-SARS-CoV-2 IgG antibodies were measured before the first vaccine dose (1stVD) and 14-21 days after the second dose (2ndVD). AE reported after 1stVD and 2ndVD, respectively were: fever 0%, 1.7%; fatigue 15.4%, 25.8%; headache 15.4%, 24.1%; chills 6.1%, 12.0%; muscle pain 15.4%, 24.1%; joint pain 3.0%, 6.9%; nausea 6.1%, 6.9%; pain at injection site 30.7%, 34.4%; swelling 3.0%, 10.3%; redness 0, 3.4%; pruritus 0, 5.2%; and axillary lymphadenopathy 3.0%, 1.7%. After 2ndVD, 96.5% patients were positive for anti-SARS-CoV-2 (GMC 3290.94 BAU/mL). No correlation presented between the antibody titer and symptoms of chronic Graft-versus-Host disease, total IgG, lymphocyte CD4+, or AE. Significantly higher titers were observed in COVID-19 convalescents, and inverse correlation (R-2 = -0.0925, p = 0.02) between the time from HSCT and titers after 2ndVD was present. Conclusions: The young adults after HSCT tolerate the COVID-19 mRNA vaccine well and show immunologic response.	[Matkowska-Kocjan, Agnieszka; Chruszcz, Joanna; Wojcik, Marta; Banys, Dorota; Szenborn, Leszek] Wroclaw Med Univ, Dept & Clin Pediat Infect Dis, PL-50368 Wroclaw, Poland; [Owoc-Lempach, Joanna; Jurczenko, Lidia; Ussowicz, Marek] Wroclaw Med Univ, Dept & Clin Paediat Oncol Haematol & Bone Marrow, PL-50556 Wroclaw, Poland; [Kuznik, Edwin] Wroclaw Med Univ, Dept Angiol Hypertens & Diabetol, PL-50529 Wroclaw, Poland; [Szenborn, Filip] Wroclaw Univ Sci & Technol, Fac Elect, PL-50370 Wroclaw, Poland		Matkowska-Kocjan, A (通讯作者)，Wroclaw Med Univ, Dept & Clin Pediat Infect Dis, PL-50368 Wroclaw, Poland.	agnieszka.matkowska-kocjan@umed.wroc.pl; joanna.owoc-lempach@umed.wroc.pl; joanna.chruszcz@umed.wroc.pl; edvin@op.pl; filipyoyo@gmail.com; lidia.jurczenko@student.umed.wroc.pl; marta.wojcik@umed.wroc.pl; dorota.banys@umed.wroc.pl; leszek.szenborn@umed.wroc.pl; marek.ussowicz@umed.wroc.pl	Ussowicz, Marek/T-7487-2019	Ussowicz, Marek/0000-0001-5725-4835; Owoc-Lempach, Joanna/0000-0001-7329-4079; Szenborn, Leszek/0000-0001-6574-8229; Chruszcz, Joanna/0000-0003-1301-5589	Wroclaw Medical University [SUB.C200.21.058, SUB.C180.21.080]	Wroclaw Medical University statutory grant SUB.C200.21.058 and SUB.C180.21.080.	Adhikari B, 2021, LANCET INFECT DIS, V21, P1086, DOI 10.1016/S1473-3099(21)00390-X; Ali H, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.07.008; [Anonymous], 2021, COVID 19 VACCINES MO; Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; CDC, LOC REACT SYST REACT; Chevallier Patrice, 2021, EJHaem, DOI 10.1002/jha2.242; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; European Centre for Disease Prevention and Control, 2020, COVID 19 VACC PRIOR; Janeczko-Czarnecka M, 2020, CENT EUR J IMMUNOL, V45, P151, DOI 10.5114/ceji.2019.89843; Leclerc M, 2021, LANCET HAEMATOL, V8, pE163, DOI 10.1016/S2352-3026(21)00008-9; Muller L, 2021, CLIN INFECT DIS, V73, P2065, DOI 10.1093/cid/ciab381; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Redjoul R, 2021, LANCET, V398, P298, DOI 10.1016/S0140-6736(21)01594-4; United States Food and Drug Adminstration, PFIZ BIONTECH COVID; Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282; WHO, REP; Worldometer Worldometer, COVID 19 CORONAVIRUS	21	3	3	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1209	10.3390/vaccines9101209			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS6RZ	34696317	Green Published, gold			2022-04-29	WOS:000715307500001
J	Sultana, A; Shahriar, S; Tahsin, MR; Mim, SR; Fatema, KR; Saha, A; Yesmin, F; Bahar, NB; Samodder, M; Mamun, MAH; Rahman, MA; Ferdousy, S; Akter, T; Aktar, F; Kuddus, MR; Rahman, MM; Sarker, MMR; Buyuker, SM; Chowdhury, JA; Chowdhury, A; Kabir, S; Hossain, MA; Amran, MS				Sultana, Arifa; Shahriar, Saimon; Tahsin, Md. Rafat; Mim, Sabiha Rahman; Fatema, Kazi Rubiya; Saha, Ananya; Yesmin, Fahmida; Bahar, Nasiba Binte; Samodder, Mithun; Mamun, Md. Ariful Haque; Aknur Rahman, Md.; Ferdousy, Sonia; Akter, Tahmina; Aktar, Fahima; Kuddus, Md. Ruhul; Rahman, Md. Mustafizur; Sarker, Md. Moklesur Rahman; Buyuker, Sultan Mehtap; Chowdhury, Jakir Ahmed; Chowdhury, Abu Asad; Kabir, Shaila; Hossain, Md. Akter; Amran, Md. Shah			A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh	VACCINES			English	Article						pharmacovigilance; side-effects; SARS-CoV-2; adverse events following immunization; vaccines; cross-sectional study		Background: The Oxford-AstraZeneca vaccine (Covishield) was the first to be introduced in Bangladesh to fight the ongoing global COVID-19 pandemic. As this vaccine had shown some side-effects in its clinical trial, we aimed to conduct a study assessing short-term adverse events following immunization (AEFIs) in Bangladesh. Method: A cross-sectional study was conducted on social and electronic media platforms by delivering an online questionnaire among people who had taken at least one dose of the COVID-19 vaccine. The collected data were then analysed to evaluate various parameters related to the AEFIs of the respondents. Results: A total of 626 responses were collected. Of these, 623 were selected based on complete answers and used for the analysis. Most of the respondents were between 30-60 years of age, and 40.4% were female. We found that a total of 8.5% of the total respondents had been infected with the SARS-CoV-2 virus. Our survey revealed that out of 623 volunteers, 317 reported various side-effects after taking the vaccine, which is about 50.88% of the total participants. The majority of participants (37.07%, 231/623) reported swelling and pain at the injection site and fever (25.84%, 162/623); these were some of the common localized and generalized symptoms after the COVID-19 vaccine administration. Conclusion: The side-effects reported after receiving the Oxford-AstraZeneca vaccine (Covishield) are similar to those reported in clinical trials, demonstrating that the vaccines have a safe therapeutic window. Moreover, further research is needed to determine the efficacy of existing vaccines in preventing SARS-CoV-2 infections or after-infection hospitalization.</p>	[Sultana, Arifa; Saha, Ananya; Yesmin, Fahmida; Bahar, Nasiba Binte] Univ Dhaka, Dept Pharm, Fac Pharm, Dhaka 1000, Bangladesh; [Shahriar, Saimon; Mamun, Md. Ariful Haque; Aknur Rahman, Md.; Aktar, Fahima; Kuddus, Md. Ruhul; Chowdhury, Abu Asad; Kabir, Shaila; Amran, Md. Shah] Univ Dhaka, Dept Pharmaceut Chem, Mol Pharmacol & Herbal Drug Res Lab, Fac Pharm, Dhaka 1000, Bangladesh; [Tahsin, Md. Rafat; Fatema, Kazi Rubiya] North South Univ, Dept Pharmaceut Sci, Plot 15,Block B,Bashundhara R-A, Dhaka 1229, Bangladesh; [Mim, Sabiha Rahman] Uppsala Univ, Dept Pharmaceut Sci, S-75123 Uppsala, Sweden; [Samodder, Mithun; Sarker, Md. Moklesur Rahman] State Univ Bangladesh, Dept Pharm, 77 Satmasjid Rd, Dhaka 1205, Bangladesh; [Ferdousy, Sonia] Atish Dipankar Univ Sci & Technol, Dept Pharm, Dhaka 1230, Bangladesh; [Akter, Tahmina] Dhaka Med Coll, Dept Physiol, Dhaka 1000, Bangladesh; [Rahman, Md. Mustafizur] Khulna Univ, Sch Life Sci, Pharm Discipline, Khulna 9208, Bangladesh; [Buyuker, Sultan Mehtap] Uskudar Univ, Dept Pharm Serv, TR-34662 Istanbul, Turkey; [Chowdhury, Jakir Ahmed] Univ Dhaka, Dept Pharmaceut Technol, Fac Pharm, Dhaka 1000, Bangladesh; [Hossain, Md. Akter] Directorate Gen Drug Adm, Dhaka 1212, Bangladesh		Amran, MS (通讯作者)，Univ Dhaka, Dept Pharmaceut Chem, Mol Pharmacol & Herbal Drug Res Lab, Fac Pharm, Dhaka 1000, Bangladesh.	arifa.s.meem@gmail.com; saimonshahriar19@gmail.com; whitefang229@gmail.com; Sabiharahman.Mim.9635@student.uu.se; kazirubiya11@gmail.com; ananyasaha029dhk@gmail.com; fahmidayesmin189@gmail.com; nasibabintebahar@gmail.com; mithun286@gmail.com; mamunphr_du@yahoo.com; rahmanmdaknur@gmail.com; soniaferdousy@adust.edu.bd; tahmina.runa.akter1@gmail.com; fahima@du.ac.bd; ruhulkuddus@du.ac.bd; dipti0103@yahoo.com; moklesur2002@yahoo.com; sultanmehtap.buyuker@uskudar.edu.tr; jakir@du.ac.bd; asaddg27@du.ac.bd; shailakabir@du.ac.bd; akterh4@gmail.com; amranms@du.ac.bd	Sarker, Moklesur Rahman/G-2396-2014; Sarker, Prof. Dr. Md. Moklesur Rahman/G-2396-2014	Sarker, Moklesur Rahman/0000-0002-0787-0944; KUDDUS, DR MD RUHUL/0000-0002-7038-3399; Binte Bahar, Nasiba/0000-0002-5981-3220; Sarker, Prof. Dr. Md. Moklesur Rahman/0000-0001-9795-0608; Shahriar, Saimon/0000-0003-1460-3104; Samodder, Mithun/0000-0001-6057-7838; Rahman, Md Mustafizur/0000-0001-8585-263X; Sultana, Arifa/0000-0002-5855-8731			Abedin M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250495; Albert Elisabeth, 2021, Radiol Case Rep, V16, P2142, DOI 10.1016/j.radcr.2021.05.033; Baraniuk C, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n912; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n421; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; CDC, CAS DAT SURV; Cohen J, 2021, SCIENCE, DOI [10.1126/science.abg9559, DOI 10.1126/SCIENCE.ABG9559]; Dasgupta N, 2021, LANCET DIGIT HEALTH, V3, pE278, DOI 10.1016/S2589-7500(21)00021-2; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Goss AL, 2021, ANN NEUROL, V89, P856, DOI 10.1002/ana.26065; Islam MS, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.647386; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Khan YH, 2020, AM J TROP MED HYG, V103, P603, DOI 10.4269/ajtmh.20-0654; Klimek L., 2021, ALLERGO J INT, V30, P79, DOI [10.1007/ s40629-021-00165-7, 10.1007/s15007-021-4773-1]; Langer F, 2020, HAMOSTASEOLOGIE, V40, P264, DOI 10.1055/a-1178-3551; Lee GM, 2020, JAMA-J AM MED ASSOC, V324, P1937, DOI 10.1001/jama.2020.19692; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n338; Mallapaty S, 2021, NATURE, V593, P178, DOI 10.1038/d41586-021-01146-0; Monirul Islam, 2021, African Journal of Pharmacy and Pharmacology, V15, P84, DOI 10.5897/AJPP2021.5228; Nopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439; Oldenburg J, 2021, HAMOSTASEOLOGIE, V41, P184, DOI 10.1055/a-1469-7481; Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x; Sellaturay P, 2021, CLIN EXP ALLERGY, V51, P861, DOI 10.1111/cea.13874; Shahriar S, 2021, PHARM EDUC, V21, P267, DOI 10.46542/pe.2021.211.267275; Shahriar S, 2021, CURR PHARM DESIGN, V27, P3502, DOI 10.2174/1381612827666210224142446; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n149; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wolf ME, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081599; Wu QH, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02059-5	32	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1090	10.3390/vaccines9101090			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO3YZ	34696198	Green Published, gold			2022-04-29	WOS:000712395000001
J	van Diepen, M; Chapman, R; Douglass, N; Whittle, L; Chineka, N; Galant, S; Cotchobos, C; Suzuki, A; Williamson, AL				van Diepen, Michiel; Chapman, Rosamund; Douglass, Nicola; Whittle, Leah; Chineka, Nicole; Galant, Shireen; Cotchobos, Christian; Suzuki, Akiko; Williamson, Anna-Lise			Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector	VACCINES			English	Article						lumpy skin disease virus; vaccine vector; BHK-21 cells; RK13 cells; K1L host range	K1L GENE; MVA; PROMOTER; RESPONSES; IMMUNOGENICITY; CAPRIPOXVIRUS; INFECTION; GENOME; CELLS	Attenuated vaccine strains of lumpy skin disease virus (LSDV) have become increasingly popular as recombinant vaccine vectors, to target both LSDV, as well as other pathogens, including human infectious agents. Historically, these vaccine strains and recombinants were generated in primary (lamb) testis (LT) cells, Madin-Darby bovine kidney (MDBK) cells or in eggs. Growth in eggs is a laborious process, the use of primary cells has the potential to introduce pathogens and MDBK cells are known to harbor bovine viral diarrhea virus (BVDV). In this study, data is presented to show the growth of an attenuated LSDV strain in baby hamster kidney (BHK-21) cells. Subsequently, a recombinant LSDV vaccine was generated in BHK-21 cells. Partial growth was also observed in rabbit kidney cells (RK13), but only when the vaccinia virus host range gene K1L was expressed. Despite the limited growth, the expression of K1L was enough to serve as a positive selection marker for the generation of recombinant LSDV vaccines in RK13 cells. The simplification of generating (recombinant) LSDV vaccines shown here should increase the interest for this platform for future livestock vaccine development and, with BHK-21 cells approved for current good manufacturing practice, this can be expanded to human vaccines as well.</p>	[van Diepen, Michiel; Chapman, Rosamund; Douglass, Nicola; Whittle, Leah; Chineka, Nicole; Galant, Shireen; Cotchobos, Christian; Suzuki, Akiko; Williamson, Anna-Lise] Univ Cape Town, Fac Hlth Sci, Div Med Virol, Dept Pathol, ZA-7925 Cape Town, South Africa; [van Diepen, Michiel; Chapman, Rosamund; Douglass, Nicola; Whittle, Leah; Chineka, Nicole; Galant, Shireen; Cotchobos, Christian; Suzuki, Akiko; Williamson, Anna-Lise] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa		Douglass, N; Williamson, AL (通讯作者)，Univ Cape Town, Fac Hlth Sci, Div Med Virol, Dept Pathol, ZA-7925 Cape Town, South Africa.; Douglass, N; Williamson, AL (通讯作者)，Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.	michiel.vandiepen@uct.ac.za; ros.chapman@uct.ac.za; Niki.Douglass@uct.ac.za; whtlea002@myuct.ac.za; hnane006@myuct.ac.za; shireen.galant@uct.ac.za; ctcchr001@myuct.ac.za; SZKAKI001@myuct.ac.za; Anna-Lise.Williamson@uct.ac.za		van Diepen, Michiel/0000-0001-8156-4294; Douglass, Nicola/0000-0002-8929-6279; Chapman, Rosamund/0000-0001-9162-2099; Suzuki, Akiko/0000-0001-8885-0189; Whittle, Leah/0000-0001-9009-2698; Williamson, Anna-Lise/0000-0002-5467-1200	South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); South African Department of Science and Technology - National Research Foundation of South Africa [64815]; Technology Innovation Agency [TBS14-0020C]	FundingThis research was funded by the South African Medical Research Council with funds received from the South African Department of Science and Technology; A-L W is funded by the National Research Foundation of South Africa, grant number 64815 and N.D. was co-funded by the Technology Innovation Agency, project number TBS14-0020C.	Alharbi NK, 2019, HUM VACC IMMUNOTHER, V15, P203, DOI 10.1080/21645515.2018.1513439; Aspden K, 2003, J GEN VIROL, V84, P1985, DOI 10.1099/vir.0.19116-0; Aspden K, 2002, VACCINE, V20, P2693, DOI 10.1016/S0264-410X(02)00203-7; Burgers WA, 2008, AIDS RES HUM RETROV, V24, P195, DOI 10.1089/aid.2007.0205; Burgers WA, 2014, J GEN VIROL, V95, P2267, DOI 10.1099/vir.0.067835-0; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; Churchyard G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161753; COCHRAN MA, 1985, J VIROL, V54, P30, DOI 10.1128/JVI.54.1.30-37.1985; Cottingham MG, 2013, VACCINE, V31, P4247, DOI 10.1016/j.vaccine.2013.03.021; Cruz AGB, 2017, J VIROL, V91, DOI 10.1128/JVI.00542-17; Daniel DP, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14465; Di Pilato M, 2015, J GEN VIROL, V96, P2360, DOI 10.1099/vir.0.000183; Di Pilato M, 2013, J GEN VIROL, V94, P2771, DOI 10.1099/vir.0.057299-0; Douglass N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040664; El-Hage CM, 2013, EQUINE VET J, V45, P235, DOI 10.1111/j.2042-3306.2012.00605.x; Fay PC, 2020, J VIROL METHODS, V285, DOI 10.1016/j.jviromet.2020.113943; Gowripalan A, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01374-6; Gray GE, 2016, CLIN VACCINE IMMUNOL, V23, P496, DOI 10.1128/CVI.00717-15; Haegeman A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050473; Hamdi J, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108689; Jarrett O, 1996, AIDS RES HUM RETROV, V12, P435, DOI 10.1089/aid.1996.12.435; Kim JH, 2015, ANNU REV MED, V66, P423, DOI 10.1146/annurev-med-052912-123749; Kitching R. P., 2003, VVolume 114, P161; KUMAR S, 1990, VIROLOGY, V179, P151, DOI 10.1016/0042-6822(90)90284-X; Liu FX, 2019, COMP IMMUNOL MICROB, V65, P181, DOI 10.1016/j.cimid.2019.05.013; Lu YX, 2019, P NATL ACAD SCI USA, V116, P11997, DOI 10.1073/pnas.1816399116; MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031; Moss B, 2013, VACCINE, V31, P4220, DOI 10.1016/j.vaccine.2013.03.042; Munyanduki H, 2020, J VIROL METHODS, V275, DOI 10.1016/j.jviromet.2019.113752; Noyce RS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0188453; Offerman K, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1659-1; Okeke MI, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110318; Omar R., 2015, COMP 2 LUMPY SKIN DI; Prow NA, 2018, EXPERT REV VACCINES, V17, P925, DOI 10.1080/14760584.2018.1522255; Rhazi H, 2021, J VIROL METHODS, V293, DOI 10.1016/j.jviromet.2021.114164; Sanchez-Sampedro L, 2015, VIRUSES-BASEL, V7, P1726, DOI 10.3390/v7041726; Santra S, 2007, J VIROL, V81, P8563, DOI 10.1128/JVI.00744-07; Shen YJ, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-265; Shisler JL, 2004, J VIROL, V78, P3553, DOI 10.1128/JVI.78.7.3553-3560.2004; Soday L, 2019, CELL REP, V27, P1920, DOI 10.1016/j.celrep.2019.04.042; Staib C, 2000, BIOTECHNIQUES, V28, P1137, DOI 10.2144/00286st04; SUTTER G, 1994, J VIROL, V68, P4109, DOI 10.1128/JVI.68.7.4109-4116.1994; Tanzer FL, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-51; TARTAGLIA J, 1990, CRIT REV IMMUNOL, V10, P13; TAYLOR J, 1994, DEV BIOL STAND, V82, P131; Teigler JE, 2014, J VIROL, V88, P1809, DOI 10.1128/JVI.02386-13; Tulman ER, 2001, J VIROL, V75, P7122, DOI 10.1128/JVI.75.15.7122-7130.2001; van Diepen MT, 2019, J VIROL, V93, DOI 10.1128/JVI.02155-18; Volkmann A, 2021, VACCINE, V39, P3067, DOI 10.1016/j.vaccine.2020.08.050; Wallace DB, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00256; Willis KL, 2011, J BIOL CHEM, V286, P7765, DOI 10.1074/jbc.M110.194704; Wyatt LS, 1998, VIROLOGY, V251, P334, DOI 10.1006/viro.1998.9397; Wyatt LS, 1996, VACCINE, V14, P1451, DOI 10.1016/S0264-410X(96)00072-2; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730	54	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1131	10.3390/vaccines9101131			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO0YA	34696239	gold, Green Published			2022-04-29	WOS:000712187700001
J	Dettori, M; Arghittu, A; Deiana, G; Azara, A; Masia, MD; Palmieri, A; Spano, AL; Serra, A; Castiglia, P				Dettori, Marco; Arghittu, Antonella; Deiana, Giovanna; Azara, Antonio; Masia, Maria Dolores; Palmieri, Alessandra; Spano, Antonio Lorenzo; Serra, Antonello; Castiglia, Paolo			Influenza Vaccination Strategies in Healthcare Workers: A Cohort Study (2018-2021) in an Italian University Hospital	VACCINES			English	Article						flu vaccination; healthcare workers; vaccination coverage; on-site offer; vaccination strategies	HOME STAFF; PREVALENCE; RESIDENTS; MORTALITY; COVERAGE	Vaccinating healthcare workers (HCWs) is the most effective intervention for preventing nosocomial influenza infection. However, influenza vaccination coverage (VC%) among HCWs remains low. The aim of the study was to analyse the trend of VC% among healthcare workers in an Italian hospital through a three-year vaccination project covering three influenza seasons (2018-2019, 2019-2020, and 2020-2021). A gap analysis was performed at the case base (2018-2019), on-site vaccination was trialled in the 2019-2020 season, and an integrated vaccination offer (on-site vaccination and the classic offer at a vaccination clinic) was implemented for the 2020-2021 season. For each unit of vaccinated HCWs, the following variables were recorded: main demographic details, area of affiliation (medical/surgical/services), and professional category. Logistic regression analyses were performed to assess the relationship between outcome (undergoing vaccination in 2020-2021) and other variables related to the healthcare workers' characteristics. In the three seasons, VC% values of 13.2%. 27.7%, and 58.9% were recorded, respectively (p < 0.005). The highest VC% was recorded among physicians (94.93%), in the medical area (63.27%), and males (62.59%) and in general among the youngest HCWs. Comparison of the coverage values recorded in the three seasons showed that in the last season considered (2020-2021) about 80% of health workers preferred to be vaccinated in the workplace instead of using the standard vaccination delivery method (invitation to attend the vaccination clinic). Our study suggests that the integrated vaccination offer may lead to an increase in VC% among HCWs compared to the classical offer modalities.	[Dettori, Marco; Arghittu, Antonella; Azara, Antonio; Palmieri, Alessandra; Spano, Antonio Lorenzo; Serra, Antonello; Castiglia, Paolo] Univ Hosp Sassari, Dept Med Surg & Expt Sci, I-07100 Sassari, Italy; [Dettori, Marco; Azara, Antonio; Masia, Maria Dolores; Palmieri, Alessandra; Castiglia, Paolo] Univ Sassari, Dept Med Surg & Expt Sci, I-07100 Sassari, Italy; [Arghittu, Antonella; Deiana, Giovanna] Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy		Arghittu, A (通讯作者)，Univ Hosp Sassari, Dept Med Surg & Expt Sci, I-07100 Sassari, Italy.; Arghittu, A (通讯作者)，Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy.	madettori@uniss.it; arghittu.antonella@gmail.com; giovanna.deiana90@gmail.com; azara@uniss.it; mdmasia@uniss.it; luca@uniss.it; antonio.spano@aousassari.it; antonello.serra@aousassari.it; castigli@uniss.it	Dettori, Marco/N-8912-2018	Dettori, Marco/0000-0002-4901-2067; AZARA, Antonio Alfredo/0000-0001-9089-0817; Castiglia, Paolo/0000-0002-0972-4828; Deiana, Giovanna/0000-0003-1151-6830; PALMIERI, Alessandra/0000-0002-9202-7889; MASIA, Maria Dolores/0000-0003-2372-8136; Arghittu, Antonella/0000-0001-9257-1422	"Fondo di Ateneo per la Ricerca 2020", University of Sassari; Piano Regionale di Prevenzione 2014-2019, Regione Autonoma della Sardegna, P9.1 Sviluppo e potenziamento delle vaccinazioni	This study was supported by "Fondo di Ateneo per la Ricerca 2020", University of Sassari, and "Piano Regionale di Prevenzione 2014-2019, Regione Autonoma della Sardegna, P9.1 Sviluppo e potenziamento delle vaccinazioni".	Arghittu A, 2018, J Prev Med Hyg, V59, pE45, DOI 10.15167/2421-4248/jpmh2018.59.4s2.1077; Arghittu A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115642; Arghittu A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093185; Azara A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040749; Barbadoro P, 2013, HUM VACC IMMUNOTHER, V9, P911, DOI 10.4161/hv.22997; Barbara A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010085; Bartolozzi G., 2012, VACCINI VACCINAZIONI, V3rd ed.; Bellia C, 2013, INFLUENZA OTHER RESP, V7, P97, DOI 10.1111/irv.12088; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; Costantino C, 2020, J Prev Med Hyg, V61, pE1, DOI 10.15167/2421-4248/jpmh2020.61.1.1502; Costantino C, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.644008; Costantino C, 2020, HUM VACC IMMUNOTHER, V16, P2415, DOI 10.1080/21645515.2020.1728157; Deiana G, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-10093-w; Deiana G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124450; Dettori M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134870; Dettori M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16061004; Dettori M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071512; Dharmapalan D, 2020, INDIAN J PEDIATR, V87, P828, DOI 10.1007/s12098-020-03214-1; Di Giuseppe G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070766; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; ECDC/WHO, SEASONAL INFLUENZA V; ECDC/WHO Flu News Europe, JOINT ECDC WHO EUR W; Esposito S, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-422; Gasparini R, 2013, HUM VACC IMMUNOTHER, V9, P144, DOI 10.4161/hv.22231; Gentili D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17030911; Gilardi F, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050841; Hayward AC, 2006, BRIT MED J, V333, P1241, DOI 10.1136/bmj.39010.581354.55; Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056; Italian Government, UN TEXT HLTH SAF WOR; Italian Ministry of Health, PREV CONTR INFL REC; Italian Ministry of Health, NAT PLAN VACC PREV P; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kwok KO, 2019, J HOSP INFECT, V102, P337, DOI 10.1016/j.jhin.2018.11.017; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; La Torre G, 2011, HUM VACCINES, V7, P728, DOI 10.4161/hv.7.7.15413; Lemaitre M, 2009, J AM GERIATR SOC, V57, P1580, DOI 10.1111/j.1532-5415.2009.02402.x; Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046; Mannocci A, 2010, REV HEALTH CARE, V1, P27, DOI 10.7175/rhc.v1i1.15; Niu Shengmei, 2020, Arch Gerontol Geriatr, V89, P104058, DOI 10.1016/j.archger.2020.104058; Panatto D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010119; Perrone PM, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115874; Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722; Rosano A, 2019, INT J INFECT DIS, V88, P127, DOI 10.1016/j.ijid.2019.08.003; Saxen H, 1999, PEDIATR INFECT DIS J, V18, P779, DOI 10.1097/00006454-199909000-00007; Scardina G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070769; Vimercati L, 2019, HUM VACC IMMUNOTHER, V15, P2927, DOI 10.1080/21645515.2019.1625645; WHO, SAGE SEAS INFL VACC; World Health Organization, INFL GLOB INFL PROGR; World Health Organization, INFL GLOB INFL STRAT; World Health Organization, IMPL SEAS INFL VACC; World Health Organization, 2017, PAND INFL RISK MAN W; World Health Organization, SAGE WORK GROUP VACC; World Health Organization Outbreak Communication, 2004, BEST PRACTICES COMMU	53	7	7	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							971	10.3390/vaccines9090971			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW2MQ	34579208	Green Published, gold			2022-04-29	WOS:000699997200001
J	Polvere, I; Voccola, S; Parrella, A; Cardinale, G; Zerillo, L; Varricchio, R; Madera, JR; Stilo, R; Vito, P; Zotti, T				Polvere, Immacolata; Voccola, Serena; Parrella, Alfredina; Cardinale, Gaetano; Zerillo, Lucrezia; Varricchio, Romualdo; Madera, Jessica Raffaella; Stilo, Romania; Vito, Pasquale; Zotti, Tiziana			A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine	VACCINES			English	Article						COVID-19; vaccine; antibodies; ELISA; peptides		The coronavirus disease 2019 (COVID-19) mRNA vaccine developed by Pfizer/BioNTech has been shown to be capable of developing an excellent antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with good production of neutralizing antibodies. Herein, we analyzed differences in the antibody response elicited by inoculation of the Pfizer/BioNTech vaccine through a peptide-based enzyme-linked immunosorbent assay (ELISA) that utilizes synthetic peptides derived from the spike protein in the immuno-adsorbent phase. Immunoreactivity against synthetic peptides was measured at different time points from vaccination and was also correlated with the SARS-CoV-2 neutralizing capacity. Our results indicate that all vaccinated subjects except one show reactive antibodies to at least one peptide at both 30 and 60 days after injection of the first dose. Only one of the 19 analyzed subjects showed no antibody response toward any of the selected peptides, consistently with a lower neutralizing capacity. More importantly, our data showed that the antibody response elicited by inoculation of the two doses of the Pfizer vaccine appears to be qualitatively individual, both in the type of recognized peptides and in the temporal persistence of the antibody response. Together with previous published data, our findings suggest that for effective pandemic control, it is important to constantly monitor the antibody protection in the population, and the assay described here could be a valid tool for this purpose.	[Polvere, Immacolata; Zerillo, Lucrezia; Madera, Jessica Raffaella; Stilo, Romania; Vito, Pasquale; Zotti, Tiziana] Univ Sannio, Dipartimento Sci & Tecnol, Via Mulini, I-82100 Benevento, Italy; [Polvere, Immacolata; Voccola, Serena; Zerillo, Lucrezia; Varricchio, Romualdo; Vito, Pasquale; Zotti, Tiziana] Univ Sannio, Genus Biotech, I-82030 Ss Appia, Apollosa, Italy; [Voccola, Serena; Parrella, Alfredina; Cardinale, Gaetano] Consorzio Sannio Tech, I-82030 Ss Appia, Apollosa, Italy		Vito, P; Zotti, T (通讯作者)，Univ Sannio, Dipartimento Sci & Tecnol, Via Mulini, I-82100 Benevento, Italy.; Vito, P; Zotti, T (通讯作者)，Univ Sannio, Genus Biotech, I-82030 Ss Appia, Apollosa, Italy.	immapolvere88@gmail.com; serena.voccola@tecnobios.com; alfredina.parrella@tecnobios.com; gaetano.cardinale@tecnobios.com; lzerillo@unisannio.it; romualdovar@outlook.it; jrmadera@unisannio.it; romsti@unisannio.it; vito@unisannio.it; tzotti@unisannio.it	vito, pasquale/ABF-5505-2020; Zotti, Tiziana/AAV-6768-2021	Zotti, Tiziana/0000-0003-4753-116X; vito, pasquale/0000-0002-5721-7716; Varricchio, Romualdo/0000-0003-2288-1868	 [INBIOMED PON RI 2014-2020-MIUR-CUP F26C18000160005]	This research was partially funded by a INBIOMED PON RI 2014-2020-MIUR-CUP F26C18000160005 grant.	Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160; Amanat F, 2021, CELL, V184, P3936, DOI 10.1016/j.cell.2021.06.005; Edara VV, 2021, NEW ENGL J MED, V385, P664, DOI 10.1056/NEJMc2107799; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Gallagher Kathleen M E, 2021, bioRxiv, DOI 10.1101/2021.05.03.442455; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Polvere I, 2022, GENES DIS, V9, P275, DOI 10.1016/j.gendis.2021.01.008; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WHO, COR DIS COVID 19 DAS	14	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							987	10.3390/vaccines9090987			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3PW	34579224	Green Published, gold			2022-04-29	WOS:000702121400001
J	Shalash, AO; Becker, L; Yang, JR; Giacomin, P; Pearson, M; Hussein, WM; Loukas, A; Skwarczynski, M; Toth, I				Shalash, Ahmed O.; Becker, Luke; Yang, Jieru; Giacomin, Paul; Pearson, Mark; Hussein, Waleed M.; Loukas, Alex; Skwarczynski, Mariusz; Toth, Istvan			Oral Peptide Vaccine against Hookworm Infection: Correlation of Antibody Titers with Protective Efficacy	VACCINES			English	Article						aspartic protease-1; hookworm; infection challenge; oral vaccine; peptide-based vaccine	NEUTRALIZING ANTIBODIES; ASPARTIC PROTEASE; NANOPARTICLES; IMMUNITY; DISEASE; HEMOGLOBINASE; PUPS	Approximately 0.4 billion individuals worldwide are infected with hookworm. An effective vaccine is needed to not only improve the health of those affected and at high risk, but also to improve economic growth in disease-endemic areas. An ideal anti-hookworm therapeutic strategy for mass administration is a stable and orally administered vaccine. Oral vaccines are advantageous as they negate the need for trained medical staff for administration and do not require strict sterility conditions. Vaccination, therefore, can be carried out at a significantly reduced cost. One of the most promising current antigenic targets for hookworm vaccine development is the aspartic protease digestive enzyme (APR-1). Antibody-mediated neutralization of APR-1 deprives the worm of nourishment, leading to reduced worm burdens in vaccinated hosts. Previously, we demonstrated that, when incorporated into vaccine delivery systems, the APR-1-derived p3 epitope (TSLIAGPKAQVEAIQKYIGAEL) was able to greatly reduce worm burdens (>= 90%) in BALB/c mice; however, multiple, large doses of the vaccine were required. Here, we investigated a variety of p3-antigen conjugates to optimize antigen delivery and establish immune response/protective efficacy relationships. We synthesized, purified, and characterized four p3 peptide-based vaccine candidates with: (a) lipidic (lipid core peptide (LCP)); (b) classical polymeric (polymethylacrylate (PMA)); and (c) novel polymeric (polyleucine in a branched or linear arrangement, BL10 or LL10, respectively) groups as self-adjuvanting moieties. BL10 and LL10 induced the highest serum anti-p3 and anti-APR-1 IgG titers. Upon challenge with rodent hookworms, the highest significant reduction in worm burden was observed in mice immunized with LL10. APR-1-specific serum IgG titers correlated with worm burden reduction. Thus, we provide the first vaccine-triggered immune response-protection relationship for hookworm infection.	[Shalash, Ahmed O.; Yang, Jieru; Hussein, Waleed M.; Skwarczynski, Mariusz; Toth, Istvan] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Becker, Luke; Giacomin, Paul; Pearson, Mark; Loukas, Alex] James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld 4878, Australia; [Toth, Istvan] Univ Queensland, Sch Pharm, Woolloongabba, Qld 4102, Australia		Skwarczynski, M (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.	a.shalash@uqconnectedu.au; luke.becker@jcu.edu.au; j.yang@uq.net.au; paul.giacomin@jcu.edu.au; mark.pearson@jcu.edu.au; w.hussein@uq.edu.au; alex.loukas@jcu.edu.au; m.skwarczynski@uq.edu.au; i.toth@uq.edu.au	; Skwarczynski, Mariusz/A-6707-2009; Loukas, Alex/B-7355-2014	Pearson, Mark/0000-0002-0002-1544; Skwarczynski, Mariusz/0000-0001-7257-807X; Loukas, Alex/0000-0002-0896-8441; Shalash, Ahmed/0000-0003-3819-4798; Giacomin, Paul/0000-0002-6326-6792; Hussein, Waleed/0000-0001-5392-1880	Australia Research Council (ARC)Australian Research Council [DP21010280]; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1132975]; NHMRC senior principal research fellowshipNational Health and Medical Research Council (NHMRC) of Australia [1117504]	This work was supported by the Australia Research Council (ARC DP21010280) and the National Health and Medical Research Council (NHMRC Program Grant APP1132975). A.L. was supported by a NHMRC senior principal research fellowship (1117504).	Adegnika A, 2017, BMJ GLOB HLTH S2, V2, pA12, DOI DOI 10.1136/bmjgh-2016-000260.29; ALBONICO M, 1994, T ROY SOC TROP MED H, V88, P585, DOI 10.1016/0035-9203(94)90174-0; [Anonymous], 2008, Wkly Epidemiol Rec, V82, P237; Ansari MJ, 2016, DRUG DELIV, V23, P1972, DOI 10.3109/10717544.2015.1039666; Azuar A, 2021, J MED CHEM, V64, P2648, DOI 10.1021/acs.jmedchem.0c01660; Bartlett S, 2020, PREC NANOMED, V3, P471, DOI DOI 10.33218/PRNANO3(1).191210.1; Bartlett S, 2020, J INFECT DIS, V221, P934, DOI 10.1093/infdis/jiz528; Bartlett S, 2020, CURR MED CHEM, V27, P2887, DOI 10.2174/0929867325666181026100849; BEHNKE JM, 1987, PARASITOL TODAY, V3, P200, DOI 10.1016/0169-4758(87)90060-3; Bouchery T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006931; Camberis Mali, 2003, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1912s55; Chandrudu S, 2016, THER DELIV, V7, P601, DOI 10.4155/tde-2016-0037; Diemert DJ, 2012, J ALLERGY CLIN IMMUN, V130, P169, DOI 10.1016/j.jaci.2012.04.027; Faruck MO, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010023; Fitzsimmons CM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00061; Fuaad AAHA, 2015, CHEMMEDCHEM, V10, P1647, DOI 10.1002/cmdc.201500227; Ghosh S, 2001, IMMUNOLOGY, V104, P58, DOI 10.1046/j.0019-2805.2001.01271.x; Hotez PJ, 2016, VACCINE, V34, P3001, DOI 10.1016/j.vaccine.2016.03.078; Hotez PJ, 2010, NAT REV MICROBIOL, V8, P814, DOI 10.1038/nrmicro2438; Hotez PJ, 2003, INT J PARASITOL, V33, P1245, DOI 10.1016/S0020-7519(03)00158-9; KERKER M, 1963, J OPT SOC AM, V53, P758, DOI 10.1364/JOSA.53.000758; Knox D, 2011, ADV EXP MED BIOL, V712, P155, DOI 10.1007/978-1-4419-8414-2_10; Logan J, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008237; Loukas A, 2005, PLOS MED, V2, P1008, DOI 10.1371/journal.pmed.0020295; Marasini N, 2016, NANOMEDICINE-UK, V11, P3223, DOI 10.2217/nnm-2016-0291; Miles AJ, 2016, CHEM SOC REV, V45, P4859, DOI 10.1039/c5cs00084j; MILLER TA, 1967, IMMUNOLOGY, V12, P231; MILLER TA, 1965, J PARASITOL, V51, P705, DOI 10.2307/3276143; Pearson MS, 2015, HUM VACC IMMUNOTHER, V11, P1251, DOI 10.4161/21645515.2014.980199; Pearson MS, 2010, J INFECT DIS, V201, P1561, DOI 10.1086/651953; Pearson MS, 2009, FASEB J, V23, P3007, DOI 10.1096/fj.09-131433; Perera G, 2009, DRUG DELIV, V16, P254, DOI 10.1080/10717540902937471; Ranjit N, 2009, J INFECT DIS, V199, P904, DOI 10.1086/597048; Sarles MP, 1936, J INFECT DIS, V59, P207, DOI 10.1093/infdis/59.2.207; Schwenkenbecher JM, 2007, MOL BIOCHEM PARASIT, V156, P167, DOI 10.1016/j.molbiopara.2007.07.019; Skwarczynski M, 2020, EXPERT OPIN DRUG DEL, V17, P435, DOI 10.1080/17425247.2020.1731468; Skwarczynski M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2285; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Skwarczynski M, 2014, NANOMEDICINE-UK, V9, P2657, DOI [10.2217/NNM.14.187, 10.2217/nnm.14.187]; Skwarczynski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046870; Skwarczynski M, 2011, METHODS MOL BIOL, V751, P297, DOI 10.1007/978-1-61779-151-2_18; Suttiprapa S, 2009, INT J BIOCHEM CELL B, V41, P1148, DOI 10.1016/j.biocel.2008.10.013; Verity CK, 2001, PARASITE IMMUNOL, V23, P153, DOI 10.1046/j.1365-3024.2001.00369.x; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; WILLIAMS RW, 1990, J BIOL CHEM, V265, P2505; Xiao S, 2008, EXP PARASITOL, V118, P32, DOI 10.1016/j.exppara.2007.05.010; Yang HY, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2015.024	47	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1034	10.3390/vaccines9091034			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3DY	34579271	gold, Green Published, Green Accepted			2022-04-29	WOS:000702090100001
J	Chen, JX; Cai, YG; Chen, YC; Williams, AP; Gao, YF; Zeng, JS				Chen, Jiaxin; Cai, Yuangui; Chen, Yicong; Williams, Anthony P.; Gao, Yifang; Zeng, Jinsheng			Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials	VACCINES			English	Review						COVID-19; vaccine; adverse events; nervous system; muscular system	SARS-COV-2 VACCINES; HEALTHY-ADULTS; SAFETY; IMMUNOGENICITY	Background: Nervous and muscular adverse events (NMAEs) have garnered considerable attention after the vaccination against coronavirus disease (COVID-19). However, the incidences of NMAEs remain unclear. We aimed to calculate the pooled event rate of NMAEs after COVID-19 vaccination. Methods: A systematic review and meta-analysis of clinical trials on the incidences of NMAEs after COVID-19 vaccination was conducted. The PubMed, Medline, Embase, Cochrane Library, and Chinese National Knowledge Infrastructure databases were searched from inception to 2 June 2021. Two independent reviewers selected the study and extracted the data. Categorical variables were analyzed using Pearson's chi-square test. The pooled odds ratio (OR) with the corresponding 95% confidence intervals (CIs) were estimated and generated with random or fixed effects models. The protocol of the present study was registered on PROSPERO (CRD42021240450). Results: In 15 phase 1/2 trials, NMAEs occurred in 29.2% vs. 21.6% (p < 0.001) vaccinated participants and controls. Headache and myalgia accounted for 98.2% and 97.7%, and their incidences were 16.4% vs. 13.9% (OR = 1.97, 95% CI = 1.28-3.06, p = 0.002) and 16.0% vs. 7.9% (OR = 3.31, 95% CI = 2.05-5.35, p < 0.001) in the vaccine and control groups, respectively. Headache and myalgia were more frequent in the newly licensed vaccines (OR = 1.97, 95% CI = 1.28-3.06, p = 0.02 and OR = 3.31, 95% CI = 2.05-5.35, p < 0.001) and younger adults (OR = 1.40, 95% CI = 1.12-1.75, p = 0.003 and OR = 1.54, 95% CI = 1.20-1.96, p < 0.001). In four open-label trials, the incidences of headache, myalgia, and unsolicited NMAEs were 38.7%, 27.4%, and 1.5%. Following vaccination in phase 3 trials, headache and myalgia were still common with a rate of 29.5% and 19.2%, although the unsolicited NMAEs with incidence rates of <= 0.7% were not different from the control group in each study. Conclusions: Following the vaccination, NMAEs are common of which headache and myalgia comprised a considerable measure, although life-threatening unsolicited events are rare. NMAEs should be continuously monitored during the ongoing global COVID-19 vaccination program.	[Chen, Jiaxin; Cai, Yuangui; Chen, Yicong; Zeng, Jinsheng] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Diag & Treatment Major Neu, Dept Neurol, Guangzhou 510080, Peoples R China; [Williams, Anthony P.] Univ Hosp Southampton NHS Fdn Trust, Dept Immunol, Southampton SO16 6YD, Hants, England; [Williams, Anthony P.] Univ Southampton, Fac Med, Acad Unit Canc Sci, Southampton SO16 6YD, Hants, England; [Williams, Anthony P.] Southampton NIHR Expt Canc Med Ctr, Southampton SO16 6YD, Hants, England; [Gao, Yifang] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplantat Ctr, Guangzhou 510080, Peoples R China		Zeng, JS (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Diag & Treatment Major Neu, Dept Neurol, Guangzhou 510080, Peoples R China.; Gao, YF (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplantat Ctr, Guangzhou 510080, Peoples R China.	chenjx239@mail2.sysu.edu.cn; caiyg3@mail2.sysu.edu.cn; chenyc37@mail.sysu.edu.cn; apw3@soton.ac.uk; gaoyf26@mail.sysu.edu.cn; zengjsh@mail.sysu.edu.cn		zeng, jinsheng/0000-0003-4280-0439; Chen, Jia Xin/0000-0002-3507-6991	Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases [2020B1212060017]; Guangdong Provincial Clinical Research Center for Neurological Diseases [2020B1111170002]; Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases [2020A0505020004]; Guangzhou Clinical Research and Translational Center for Major Neurological Diseases [201604020010]; Guangdong Provincial Engineering Center for Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease	We express our gratitude to the Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases (2020B1212060017), Guangdong Provincial Clinical Research Center for Neurological Diseases (2020B1111170002), Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases (2020A0505020004), Guangzhou Clinical Research and Translational Center for Major Neurological Diseases (201604020010), Guangdong Provincial Engineering Center for Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease.	Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 8430 DEAD 354177 INJ; [Anonymous], COVID-19 Dashboard by the Center for Systems Science and Engineering (CSEE) at Johns Hopkins University (JHU); [Anonymous], 1 22M AMERICANS HAVE; [Anonymous], CORONAVIRUS VACCINE; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Blauenfeldt RA, 2021, J THROMB HAEMOST, V19, P1771, DOI 10.1111/jth.15347; Chandler RE, 2020, NAT REV IMMUNOL, V20, P451, DOI 10.1038/s41577-020-0372-8; Chappell Keith J, 2021, Lancet Infect Dis, V21, P1383, DOI 10.1016/S1473-3099(21)00200-0; Chen MS, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/s40249-021-00878-5; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Chen N., 2020, The Lancet, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Ciabattini A, 2020, SEMIN IMMUNOPATHOL, V42, P619, DOI 10.1007/s00281-020-00821-0; Dias L, 2021, J STROKE CEREBROVASC, V30, DOI 10.1016/j.jstrokecerebrovasdis.2021.105906; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Fan YH, 2020, STROKE VASC NEUROL, V5, P152, DOI 10.1136/svn-2020-000358; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fumery T, 2021, MULT SCLER RELAT DIS, V48, DOI 10.1016/j.msard.2020.102723; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hu JM, 2020, NEUROSCI BIOBEHAV R, V119, P184, DOI 10.1016/j.neubiorev.2020.10.012; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Ledgerwood JE, 2011, J INFECT DIS, V203, P1396, DOI 10.1093/infdis/jir054; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Malhotra HS, 2021, QJM-INT J MED, V114, P591, DOI 10.1093/qjmed/hcab069; Moreira FRR, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13060984; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Pushparajah D, 2021, ADV DRUG DELIVER REV, V170, P113, DOI 10.1016/j.addr.2021.01.003; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; See I, 2021, JAMA-J AM MED ASSOC, V325, P2448, DOI 10.1001/jama.2021.7517; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Thompson CN, 2021, MMWR-MORBID MORTAL W, V70, P712, DOI 10.15585/mmwr.mm7019e1; Tobaiqy M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040393; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Williams SV, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.27.2100626; World Health Organization, ANNEX 9 GUIDELINES C; Wu QH, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02059-5; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yuan Ping, 2020, medRxiv, DOI 10.1101/2020.11.03.20224998; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	54	4	4	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							939	10.3390/vaccines9080939			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8VI	34452064	gold, Green Published, Green Accepted			2022-04-29	WOS:000690200600001
J	Lin, YJ; Chou, WJ; Chang, YP; Yen, CF				Lin, Yen-Ju; Chou, Wen-Jiun; Chang, Yu-Ping; Yen, Cheng-Fang			Denial of Justification for Vaccination: Its Multiple Related Variables and Impacts on Intention to Get Vaccinated against COVID-19	VACCINES			English	Article						COVID-19; intention; perceived risk; vaccination; vaccine refusal	HEALTH; IMMUNIZATION; REFUSAL; RISK	The aims of the present study were (1) to identify the variables related to denying the justification for vaccination during the coronavirus disease 2019 (COVID-19) pandemic in Taiwan and (2) to examine the associations of such denial with perceived risk of COVID-19 and the extrinsic and intrinsic intentions to get vaccinated against COVID-19. We recruited 1047 participants by using a Facebook advertisement. We investigated whether the participants denied justification for vaccination as well as their sociodemographic characteristics, mental health status, sources of information about COVID-19 vaccination, perceived risk of COVID-19, and extrinsic and intrinsic intentions to get vaccinated against COVID-19. The results indicated that 20.0% of the participants denied justification for vaccination. Participants who were older, had an educational level below college, were not health care workers, were in poor general mental health state, or did not obtain information about COVID-19 vaccination from the Internet were more likely to deny justification for vaccination. Denial was negatively associated with both extrinsic and intrinsic intentions to get vaccinated against COVID-19 but not associated with the perceived risk of COVID-19. Multiple variables related to denying the justification for vaccination; the denial was negatively associated with the intention to get vaccinated against COVID-19.	[Lin, Yen-Ju; Yen, Cheng-Fang] Kaohsiung Med Univ, Sch Med, Dept Psychiat, Coll Med, Kaohsiung 80708, Taiwan; [Lin, Yen-Ju; Yen, Cheng-Fang] Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 80708, Taiwan; [Chou, Wen-Jiun] Chang Gung Univ, Sch Med, Taoyuan 33302, Taiwan; [Chou, Wen-Jiun] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Child & Adolescent Psychiat, Kaohsiung 83301, Taiwan; [Chang, Yu-Ping] SUNY Buffalo, Sch Nursing, Buffalo, NY 14214 USA		Yen, CF (通讯作者)，Kaohsiung Med Univ, Sch Med, Dept Psychiat, Coll Med, Kaohsiung 80708, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 80708, Taiwan.	1040457@kmuh.org.tw; wjchou@cgmh.org.tw; yc73@buffalo.edu; chfaye@cc.kmu.edu.tw		Yen, Cheng-Fang/0000-0003-1156-4939; Chang, Yu-Ping/0000-0003-2328-6876	Kaohsiung Medical University Hospital [KMUH109-9M54]	This study was supported by grants awarded by Kaohsiung Medical University Hospital (KMUH109-9M54).	Alessi EJ, 2010, SOC WORK RES, V34, P122, DOI 10.1093/swr/34.2.122; Bobkowski P, 2013, MEDIA CULT SOC, V35, P771, DOI 10.1177/0163443713491517; Brelsford D, 2017, J FAM PRACTICE, V66, pE12; Calandrillo Steve P, 2004, Univ Mich J Law Reform, V37, P353; Champion V.L., 2008, HLTH BEHAV HLTH ED T, V5th, P45; Chou WP, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249329; Crayne MP, 2020, PSYCHOL TRAUMA-US, V12, pS180, DOI 10.1037/tra0000852; Ernst M, 2005, BIOL PSYCHIAT, V58, P597, DOI 10.1016/j.biopsych.2005.06.004; Flaherty DK, 2011, ANN PHARMACOTHER, V45, P1302, DOI 10.1345/aph.1Q318; Honein MA, 2020, MMWR-MORBID MORTAL W, V69, P1860, DOI 10.15585/mmwr.mm6949e2; Imdad A, 2013, PEDIATRICS, V132, P37, DOI 10.1542/peds.2012-3449; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lee MB, 2003, J FORMOS MED ASSOC, V102, P687; Lin YJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050528; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Majid U, 2020, PUBLIC UNDERST SCI, V29, P777, DOI 10.1177/0963662520963365; Marcec R, 2021, POSTGRAD MED J, V97, P143, DOI 10.1136/postgradmedj-2020-138903; Marketers, AN SEX AG DISTR FAC; National Center for High-Performance Computing, TAIW REP COVID 19 PA; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Oksanen Atte, 2020, JMIR Public Health Surveill, V6, pe19218, DOI 10.2196/19218; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Pierik R, 2018, J APPL PHILOS, V35, P381, DOI 10.1111/japp.12215; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813; Science and Engineering at Johns Hopkins, MOD 2019 NCOV; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Taiwan Centers for Disease Control, 1 BATCH ASTRAZENECAS; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; World Health Organization, 2014, REP SAGE WORK GROUP; World Health Organization, COR DIS COVID 19 VAC; World Health Organization, WHO SAG ROADM PRIOR; Xiong JQ, 2020, J AFFECT DISORDERS, V277, P55, DOI 10.1016/j.jad.2020.08.001; Yeh YC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030297; Zhang YF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072381	40	0	0	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							822	10.3390/vaccines9080822			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4JT	34451947	gold, Green Published			2022-04-29	WOS:000689900100001
J	Nunez-Munoz, L; Marcelino-Perez, G; Calderon-Perez, B; Perez-Saldivar, M; Acosta-Virgen, K; Gonzalez-Conchillos, H; Vargas-Hernandez, B; Olivares-Martinez, A; Ruiz-Medrano, R; Roa-Velazquez, D; Morales-Rios, E; Ramos-Flores, J; Torres-Franco, G; Pelaez-Gonzalez, D; Fernandez-Hernandez, J; Espinosa-Cantellano, M; Tapia-Sidas, D; Ramirez-Pool, JA; Padilla-Viveros, A; Xoconostle-Cazares, B				Nunez-Munoz, Leandro; Marcelino-Perez, Gabriel; Calderon-Perez, Berenice; Perez-Saldivar, Miriam; Acosta-Virgen, Karla; Gonzalez-Conchillos, Hugo; Vargas-Hernandez, Brenda; Olivares-Martinez, Ana; Ruiz-Medrano, Roberto; Roa-Velazquez, Daniela; Morales-Rios, Edgar; Ramos-Flores, Jorge; Torres-Franco, Gustavo; Pelaez-Gonzalez, Diana; Fernandez-Hernandez, Jorge; Espinosa-Cantellano, Martha; Tapia-Sidas, Diana; Ramirez-Pool, Jose Abrahan; Padilla-Viveros, America; Xoconostle-Cazares, Beatriz			Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19	VACCINES			English	Article						SARS-CoV-2; receptor binding domain; Spike protein; vaccine; viral glycosylation; prokaryotic expression	ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; SIDE-CHAIN; CORONAVIRUS; PREDICTION; EXPRESSION; PROTEINS; IDENTIFICATION; RECOGNITION; ANTIBODIES	The Receptor-Binding Domain (RBD) of the Spike (S) protein from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has glycosylation sites which can limit the production of reliable antigens expressed in prokaryotic platforms, due to glycan-mediated evasion of the host immune response. However, protein regions without glycosylated residues capable of inducing neutralizing antibodies could be useful for antigen production in systems that do not carry the glycosylation machinery. To test this hypothesis, the potential antigens NG06 and NG19, located within the non-glycosylated S-RBD region, were selected and expressed in Escherichia coli, purified by FPLC and employed to determine their immunogenic potential through detection of antibodies in serum from immunized rabbits, mice, and COVID-19 patients. IgG antibodies from sera of COVID-19-recovered patients detected the recombinant antigens NG06 and NG19 (A(450 nm) = 0.80 +/- 0.33; 1.13 +/- 0.33; and 0.11 +/- 0.08 for and negatives controls, respectively). Also, the purified antigens were able to raise polyclonal antibodies in animal models evoking a strong immune response with neutralizing activity in mice model. This research highlights the usefulness of antigens based on the non-N-glycosylated region of RBD from SARS-CoV-2 for candidate vaccine development.	[Nunez-Munoz, Leandro; Marcelino-Perez, Gabriel; Calderon-Perez, Berenice; Vargas-Hernandez, Brenda; Olivares-Martinez, Ana; Ruiz-Medrano, Roberto; Tapia-Sidas, Diana; Ramirez-Pool, Jose Abrahan; Xoconostle-Cazares, Beatriz] Ctr Invest & Estudios Avanzados CINVESTAV, Dept Biotechnol & Bioengn, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico; [Marcelino-Perez, Gabriel; Roa-Velazquez, Daniela] Ctr Invest & Estudios Avanzados CINVESTAV, Doctoral Program Nanosci & Nanotechnol, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico; [Perez-Saldivar, Miriam; Acosta-Virgen, Karla; Gonzalez-Conchillos, Hugo; Espinosa-Cantellano, Martha] Ctr Invest & Estudios Avanzados CINVESTAV, Dept Infect & Mol Pathogenesis, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico; [Roa-Velazquez, Daniela; Morales-Rios, Edgar] Ctr Invest & Estudios Avanzados CINVESTAV, Dept Biochem, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico; [Ramos-Flores, Jorge; Torres-Franco, Gustavo; Pelaez-Gonzalez, Diana; Fernandez-Hernandez, Jorge] Ctr Invest & Estudios Avanzados CINVESTAV, Lab Anim Prod & Expt Unit, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico; [Padilla-Viveros, America] Ctr Invest & Estudios Avanzados CINVESTAV, Transdisciplinary Doctoral Program Sci & Technol, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico		Xoconostle-Cazares, B (通讯作者)，Ctr Invest & Estudios Avanzados CINVESTAV, Dept Biotechnol & Bioengn, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico.	leandro.nunez@cinvestav.mx; gabriel.marcelino@cinvestav.mx; berecalpe@yahoo.com.mx; mperezs@cinvestav.mx; kbacosta@cinvestav.mx; hdgonzalez@cinvestav.mx; byvargas@cinvestav.mx; olivaresmtz.ana@cinvestav.mx; rmedrano@cinvestav.mx; daniela.roa@cinvestav.mx; edgar.morales@cinvestav.mx; battousai_slayer@hotmail.com; franco308228727@gmail.com; dianapel94@hotmail.com; jofernan@cinvestav.mx; mespinosac@cinvestav.mx; dianaa.tapia@cinvestav.mx; jramirezp@cinvestav.mx; aviveros@cinvestav.mx; bxoconos@cinvestav.mx	Nuñez, Leandro/AGG-1805-2022	Perez-Saldivar, Miriam/0000-0002-6915-6578; Nunez Munoz, Leandro Alberto/0000-0002-5680-1945; Marcelino-Perez, Gabriel/0000-0002-6339-9931; Morales-Rios, Edgar/0000-0003-1139-2292	Asociacion Mexicana de Cooperacion para el Desarrollo (AMEXCID) [AMEXCID/2020-I]; Consejo Nacional de Ciencia y Tecnologia (CONACyT)Consejo Nacional de Ciencia y Tecnologia (CONACyT) [332010, 481492, 481481, 455481, 754735, 332017, 754736, 483659]	This research and APC were funded by Asociacion Mexicana de Cooperacion para el Desarrollo (AMEXCID), grant number: AMEXCID/2020-I. Consejo Nacional de Ciencia y Tecnologia (CONACyT) awarded fellowships to G.M.-P. (332010), M.P.-S. (481492), K.A.-V. (481481), H.G.-C. (455481), A.O.-L. (754735), D.R.-V. (332017), D.T.-S. (754736) and J.A.R.-P. (483659).	Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]; [Anonymous], Milken Institute COVID-19 Treatment and Vaccine Tracker; [Anonymous], 2020, RECOMBINANT SARS COV, DOI [10.1101/2020.08.21.262188, DOI 10.1101/2020.08.21.262188]; [Anonymous], 2020, NAT COMMUN; Baek M, 2017, NUCLEIC ACIDS RES, V45, pW320, DOI 10.1093/nar/gkx246; Baum LG, 2017, GLYCOBIOLOGY, V27, P619, DOI 10.1093/glycob/cwx036; Branco LM, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-306; Buchan DWA, 2019, NUCLEIC ACIDS RES, V47, pW402, DOI 10.1093/nar/gkz297; Butler Dorothy L, 2020, bioRxiv, DOI 10.1101/2020.10.15.341479; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Chen J, 2005, WORLD J GASTROENTERO, V11, P6159, DOI 10.3748/wjg.v11.i39.6159; Civardi C, 2020, J NEUROL NEUROSUR PS, V91, P1361, DOI 10.1136/jnnp-2020-324279; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Di Giacomo S, 2021, J MED VIROL, V93, P5638, DOI 10.1002/jmv.27062; Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018; Esposito D, 2006, CURR OPIN BIOTECH, V17, P353, DOI 10.1016/j.copbio.2006.06.003; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gasteiger E., 2005, PROTEOM PROTOC HDB, P571, DOI [10.1385/1-59259-890-0:571, 10.1385/1-59259-890, DOI 10.1385/1592598900]; Goulas T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112643; Grant OC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71748-7; Gu Y, 2017, VACCINE, V35, P4637, DOI 10.1016/j.vaccine.2017.06.084; Guilmot A, 2021, J NEUROL, V268, P751, DOI 10.1007/s00415-020-10108-x; Gur M, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0011141; Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619; He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; de la Cruz JJ, 2019, HUM VACC IMMUNOTHER, V15, P210, DOI 10.1080/21645515.2018.1520581; Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lennemann NJ, 2014, MBIO, V5, DOI 10.1128/mBio.00862-13; Li C, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00536-0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liang HB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194860; Liang MF, 2005, BIOMED ENVIRON SCI, V18, P363; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Miret J, 2020, BIOCHEM ENG J, V159, DOI 10.1016/j.bej.2020.107612; Muhuri M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00317-1; Nico D, 2018, FRONT MED-LAUSANNE, V5, DOI [10.3389/fmed.2018.00025, 10.3389/fmed2018.00025]; Patel A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043802; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Sahdev S, 2008, MOL CELL BIOCHEM, V307, P249, DOI 10.1007/s11010-007-9603-6; Sainz B, 2005, J VIROL, V79, P7195, DOI 10.1128/JVI.79.11.7195-7206.2005; Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010; van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121; Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Xu WX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565278; Yang JY, 2020, P NATL ACAD SCI USA, V117, P1496, DOI 10.1073/pnas.1914677117; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Zang JK, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00199-1; Zhao P, 2020, CELL HOST MICROBE, V28, P586, DOI [10.1016/j.chom.2020.08.004, 10.1101/2020.06.25.172403]; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	71	1	1	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							928	10.3390/vaccines9080928			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6XB	34452053	gold, Green Published			2022-04-29	WOS:000690069900001
J	Ouranidis, A; Choli-Papadopoulou, T; Papachristou, ET; Papi, R; Kostomitsopoulos, N				Ouranidis, Andreas; Choli-Papadopoulou, Theodora; Papachristou, Eleni T.; Papi, Rigini; Kostomitsopoulos, Nikolaos			Biopharmaceutics 4.0, Advanced Pre-Clinical Development of mRNA-Encoded Monoclonal Antibodies to Immunosuppressed Murine Models	VACCINES			English	Article						mRNA encoded antibodies; SARS-CoV-2; COVID-19; Trastuzumab; mRNA-vaccines; pharmacokinetics; immunodeficient; NOD/SCID/J; biopharmaceutics 4.0; IVT mRNA	PHARMACOKINETICS; TRIALS; TRASTUZUMAB	Administration of mRNA against SARS-CoV-2 has demonstrated sufficient efficacy, tolerability and clinical potential to disrupt the vaccination field. A multiple-arm, cohort randomized, mixed blind, placebo-controlled study was designed to investigate the in vivo expression of mRNA antibodies to immunosuppressed murine models to conduct efficacy, safety and bioavailability evaluation. Enabling 4.0 tools we reduced animal sacrifice, while interventions were designed compliant to HARRP and SPIRIT engagement: (a) Randomization, blinding; (b) pharmaceutical grade formulation, monitoring; (c) biochemical and histological analysis; and (d) theoretic, statistical analysis. Risk assessment molded the study orientations, according to the ARRIVE guidelines. The primary target of this protocol is the validation of the research hypothesis that autologous translation of Trastuzumab by in vitro transcribed mRNA-encoded antibodies to immunosuppressed animal models, is non-inferior to classical treatments. The secondary target is the comparative pharmacokinetic assessment of the novel scheme, between immunodeficient and healthy subjects. Herein, the debut clinical protocol, investigating the pharmacokinetic/pharmacodynamic impact of mRNA vaccination to immunodeficient organisms. Our design, contributes novel methodology to guide the preclinical development of RNA antibody modalities by resolving efficacy, tolerability and dose regime adjustment for special populations that are incapable of humoral defense.	[Ouranidis, Andreas] Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Technol, Thessaloniki 54124, Greece; [Ouranidis, Andreas] Aristotle Univ Thessaloniki, Dept Chem Engn, Polytech Sch, Thessaloniki 54124, Greece; [Choli-Papadopoulou, Theodora; Papachristou, Eleni T.; Papi, Rigini] Aristotle Univ Thessaloniki, Dept Chem, Thessaloniki 54124, Greece; [Kostomitsopoulos, Nikolaos] Acad Athens, Biomed Res Fdn, Ctr Clin Expt Surg & Translat Res, Athens 11527, Greece		Ouranidis, A (通讯作者)，Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Technol, Thessaloniki 54124, Greece.; Ouranidis, A (通讯作者)，Aristotle Univ Thessaloniki, Dept Chem Engn, Polytech Sch, Thessaloniki 54124, Greece.	ouranidis@auth.gr; tcholi@chem.auth.gr; epapachristou@chem.auth.gr; rigini@chem.auth.gr; nkostom@bioacademy.gr		Ouranidis, Andreas/0000-0002-7001-9052	European UnionEuropean Commission; Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation [T1EDK-02775]	This research work, has been scheduled and realized for the implementation of the corresponding authors' preparative action plan towards the "Spreading Excellence and Widening Participation Horizon Europe-Teaming 2021". This research has been co-financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T1EDK-02775).	Akashi H, 2001, CURR OPIN GENET DEV, V11, P660, DOI 10.1016/S0959-437X(00)00250-1; Awwad S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030083; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; BAXTER LT, 1994, CANCER RES, V54, P1517; Benedetti F, 2008, ANNU REV PHARMACOL, V48, P33, DOI 10.1146/annurev.pharmtox.48.113006.094711; Bespalov A., 2020, GOOD RES PRACTICE PH, DOI [10.1007/978-3-030-33656-1, DOI 10.1007/978-3-030-33656-1]; Brophy JAN, 2014, NAT METHODS, V11, P508, DOI [10.1038/NMETH.2926, 10.1038/nmeth.2926]; Bruno R, 2005, CANCER CHEMOTH PHARM, V56, P361, DOI 10.1007/s00280-005-1026-z; Bulitta J.B., 2014, METHODS APPL STAT CL, V2, P457; Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Council NR, 2011, GUIDE CARE USE LAB A; Cummings Jeffrey L., 2004, Current Alzheimer Research, V1, P323, DOI 10.2174/1567205043332027; Danial John S H, 2016, Glob Cardiol Sci Pract, V2016, pe201616, DOI 10.21542/gcsp.2016.16; de Taeye SW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00740; Dekkers G, 2017, MABS-AUSTIN, V9, P767, DOI 10.1080/19420862.2017.1323159; DeKosky BJ, 2015, NAT MED, V21, P86, DOI 10.1038/nm.3743; Denayer T, 2014, NEW HORIZ TRANSL MED, V2, P5, DOI 10.1016/j.nhtm.2014.08.001; Di Paola G, 2018, J THORAC DIS, V10, P1129, DOI 10.21037/jtd.2018.01.28; du Sert NP, 2020, PLOS BIOL, V18, DOI [10.1371/journal.pbio.3000410, 10.1186/s12917-020-02451-y]; EMEA, 2001, COMM VET MED PROD, P1; European Medicines Agency, GUID TEMPL QUAL PERS; European Medicines Agency, 2019, GUID QUAL NONCL CLIN, V44, P1; European Medicines Agency, 2012, EUR MED AGENCY, V224, P69634; Forssen P, 2020, ANAL CHEM, V92, P11520, DOI 10.1021/acs.analchem.0c02475; Forssen P, 2018, ANAL CHEM, V90, P5366, DOI 10.1021/acs.analchem.8b00504; Gao Yiling, 2018, J Immunoassay Immunochem, V39, P351, DOI 10.1080/15321819.2018.1515775; GCP V.T.G., 2000, GUID GOOD CLIN PRACT, P1; Grudzien E, 2004, RNA, V10, P1479, DOI 10.1261/rna.7380904; Hirst JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098856; Itti TP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52341-z; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Jani B, 2012, JOVE-J VIS EXP, DOI 10.3791/3702; Joller N, 2011, EUR J IMMUNOL, V41, P889, DOI 10.1002/eji.201041340; Kanda Y, 2007, GLYCOBIOLOGY, V17, P104, DOI 10.1093/glycob/cwl057; Kariko K, 2019, MOL THER, V27, P691, DOI 10.1016/j.ymthe.2019.03.009; KARLIN S, 1993, P NATL ACAD SCI USA, V90, P5873, DOI 10.1073/pnas.90.12.5873; Kauffman KJ, 2015, NANO LETT, V15, P7300, DOI 10.1021/acs.nanolett.5b02497; Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280-000000000-00000; Knoblaugh SE, 2018, ILAR J, V59, P40, DOI 10.1093/ilar/ilz001; Koyanagi Y, 1997, J VIROL, V71, P2417, DOI 10.1128/JVI.71.3.2417-2424.1997; Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180; Kwak SG, 2017, KOREAN J ANESTHESIOL, V70, P144, DOI 10.4097/kjae.2017.70.2.144; Li LZ, 2014, AAPS J, V16, P1097, DOI 10.1208/s12248-014-9640-5; Lindroth K, 2004, IMMUNOLOGY, V112, P413, DOI 10.1111/j.1365-2567.2004.01894.x; LIPTON RB, 1995, CEPHALALGIA, V15, P452, DOI 10.1046/j.1468-2982.1995.1506452.x; Liu HC, 2006, IMMUNOL LETT, V106, P144, DOI 10.1016/j.imlet.2006.05.011; Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100; Mccoy CE, 2017, WEST J EMERG MED, V18, P1075, DOI 10.5811/westjem.2017.8.35985; McHeyzer-Williams MG, 2000, IMMUNOL RES, V22, P223, DOI 10.1385/IR:22:2-3:223; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; Okada S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080889; Osborne N, 2018, EMBO REP, V19, DOI 10.15252/embr.201846069; Ouranidis A, 2021, PROCESSES, V9, DOI 10.3390/pr9060954; Ouranidis A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100969; Recino A, 2019, GENE THER, V26, P40, DOI 10.1038/s41434-018-0052-5; Rissanou AN, 2020, SOFT MATTER, V16, P6993, DOI 10.1039/d0sm00736f; Roces CB, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111095; Samaranayake H, 2009, ANN MED, V41, P322, DOI 10.1080/07853890802698842; Sanseviero E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101667; Schlake T, 2019, MOL THER, V27, P773, DOI 10.1016/j.ymthe.2019.03.002; Scott GB, 2010, MOBILE DNA-UK, V1, DOI 10.1186/1759-8753-1-9; Shah DK, 2012, J PHARMACOKINET PHAR, V39, P67, DOI 10.1007/s10928-011-9232-2; Song Hyun Keun, 2017, Lab Anim Res, V33, P119, DOI 10.5625/lar.2017.33.2.119; Staffans I., 2012, EVIDENCE EUROPEAN AS, P269; Starr D.A, 2011, PHYSIOL BEHAV, V176, P139, DOI [10.1016/j.physbeh.2017.03.040.v, DOI 10.1016/J.PHYSBEH.2017.03.040.V]; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; The European Medicines Agency's (EMEA's), OV COMM GUID SIM BIO; Tsong Y, 2007, J BIOPHARM STAT, V17, P279, DOI 10.1080/10543400601177384; Viala M, 2018, BRIT J CANCER, V118, P679, DOI 10.1038/bjc.2017.473; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wan M, 2013, ARCH DIS CHILD, V98, P656, DOI 10.1136/archdischild-2013-304037; Woodworth A., 2019, SYSMEX J INT, V29, P1; Yakes FM, 2002, CANCER RES, V62, P4132; Zhang XF, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc2315	78	2	2	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							890	10.3390/vaccines9080890			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9GX	34452015	Green Published, gold			2022-04-29	WOS:000690230700001
J	Saso, A; Kampmann, B; Roetynck, S				Saso, Anja; Kampmann, Beate; Roetynck, Sophie			Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines	VACCINES			English	Review						Bordetella pertussis; whooping cough; T-cells; B-cells; vaccination; immunity; correlate-of-protection; antigen-specific; epitope; colonisation	CD4(+) T-CELLS; ANTIGEN-SPECIFIC RESPONSES; ADENYLATE-CYCLASE TOXIN; OUTER-MEMBRANE VESICLES; CHILDREN 5 YEARS; WHOLE-CELL; PROTECTIVE IMMUNITY; MEDIATED-IMMUNITY; RESPIRATORY-INFECTION; BOOSTER VACCINATION	Pertussis (`whooping cough') is a severe respiratory tract infection that primarily affects young children and unimmunised infants. Despite widespread vaccine coverage, it remains one of the least well-controlled vaccine-preventable diseases, with a recent resurgence even in highly vaccinated populations. Although the exact underlying reasons are still not clear, emerging evidence suggests that a key factor is the replacement of the whole-cell (wP) by the acellular pertussis (aP) vaccine, which is less reactogenic but may induce suboptimal and waning immunity. Differences between vaccines are hypothesised to be cell-mediated, with polarisation of Th1/Th2/Th17 responses determined by the composition of the pertussis vaccine given in infancy. Moreover, aP vaccines elicit strong antibody responses but fail to protect against nasal colonisation and/or transmission, in animal models, thereby potentially leading to inadequate herd immunity. Our review summarises current knowledge on vaccine-induced cellular immune responses, based on mucosal and systemic data collected within experimental animal and human vaccine studies. In addition, we describe key factors that may influence cell-mediated immunity and how antigen-specific responses are measured quantitatively and qualitatively, at both cellular and molecular levels. Finally, we discuss how we can harness this emerging knowledge and novel tools to inform the design and testing of the next generation of improved infant pertussis vaccines.	[Saso, Anja; Kampmann, Beate; Roetynck, Sophie] London Sch Hyg Trop Med, Fac Infect & Trop Dis, Vaccine Ctr, London WC1 7HT, England; [Saso, Anja; Kampmann, Beate; Roetynck, Sophie] London Sch Hyg & Trop Med, MRC Unit, Vaccines & Immun Theme, POB 273, Banjul, Gambia		Saso, A (通讯作者)，London Sch Hyg Trop Med, Fac Infect & Trop Dis, Vaccine Ctr, London WC1 7HT, England.; Saso, A (通讯作者)，London Sch Hyg & Trop Med, MRC Unit, Vaccines & Immun Theme, POB 273, Banjul, Gambia.	anja.saso@lshtm.ac.uk; Beate.Kampmann@lshtm.ac.uk; sroetynck@mrc.gm		Kampmann, Beate/0000-0002-6546-4709	Trust Global Health Clinical Ph.D. Fellowship [220565/Z/20/Z]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_UP_A900/1122, MC_UP_A900/115, MR/K007602/1 MR/R005990/1, MC_PC_17221]	Trust Global Health Clinical Ph.D. Fellowship (220565/Z/20/Z). B.K. is a senior MRC researcher and funded by an MRC program grant (MC_UP_A900/1122; MC_UP_A900/115; and MR/K007602/1 MR/R005990/1 and MC_PC_17221). B.K.'s institution receives funding from a variety of donors, including industry for the conduct of vaccine-related research in women and children. Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of	Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495; Afik S, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx615; AFTANDELIANS R, 1973, J INFECT DIS, V128, P555, DOI 10.1093/infdis/128.4.555; Albrecht M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00555; Allen AC, 2018, MUCOSAL IMMUNOL, V11, P1763, DOI 10.1038/s41385-018-0080-x; Althouse BM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0382-8; Andreasen C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007079; [Anonymous], ASSESSING INFANT VAC; Antunes RD, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.141023; Antunes RD, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8202067; Antunes RD, 2018, J CLIN INVEST, V128, P3853, DOI 10.1172/JCI121309; Asensio CJA, 2011, VACCINE, V29, P1649, DOI 10.1016/j.vaccine.2010.12.068; Ausiello CA, 2003, CLIN DIAGN LAB IMMUN, V10, P637, DOI 10.1128/CDLI.10.4.637-642.2003; Ausiello CM, 1999, INFECT IMMUN, V67, P4064, DOI 10.1128/IAI.67.8.4064-4071.1999; Ausiello CM, 1997, INFECT IMMUN, V65, P2168, DOI 10.1128/IAI.65.6.2168-2174.1997; Bacher P, 2013, J IMMUNOL, V190, P3967, DOI 10.4049/jimmunol.1202221; Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002; Banus S, 2007, CLIN VACCINE IMMUNOL, V14, P1377, DOI 10.1128/CVI.00175-07; Barbic J, 1997, INFECT IMMUN, V65, P4904, DOI 10.1128/IAI.65.12.4904-4908.1997; Barko PC, 2018, J VET INTERN MED, V32, P9, DOI 10.1111/jvim.14875; Barkoff AM, 2019, ADV EXP MED BIOL, V1183, P19, DOI 10.1007/5584_2019_402; Barkoff AM, 2012, VACCINE, V30, P6897, DOI 10.1016/j.vaccine.2012.09.003; Barnard A, 1996, IMMUNOLOGY, V87, P372, DOI 10.1046/j.1365-2567.1996.497560.x; Bart MJ, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-627; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Benn CS, 2020, LANCET INFECT DIS, V20, pE274, DOI 10.1016/S1473-3099(19)30742-X; Bercovici N, 2000, CLIN DIAGN LAB IMMUN, V7, P859, DOI 10.1128/CDLI.7.6.859-864.2000; Berstad AKH, 2000, J MED MICROBIOL, V49, P157, DOI 10.1099/0022-1317-49-2-157; Bischoff AL, 2015, PEDIATR INFECT DIS J, V34, P84, DOI 10.1097/INF.0000000000000529; Boehm DT, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0136-2; Boehm DT, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00857-17; Borges-Almeida E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-38; Borkner L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01764; Bottero D, 2016, VACCINE, V34, P3303, DOI [10.1016/j.vaccine.2016.04.07, 10.1016/j.vaccine.2016.04.079]; Bowyer G, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030050; Breakwell L, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3973; Brummelman J, 2016, SCI REP-UK, V6, DOI 10.1038/srep25064; Bruno C, 2016, EUR J PHARM BIOPHARM, V105, P1, DOI 10.1016/j.ejpb.2016.05.013; Brynjolfsson SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02673; Carollo M, 2014, VACCINE, V32, P2093, DOI 10.1016/j.vaccine.2014.02.005; Carollo M, 2012, VACCINE, V30, P1667, DOI 10.1016/j.vaccine.2011.12.104; Cassone A, 2000, J INFECT DIS, V182, P1575, DOI 10.1086/315898; Chasaide CN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040621; Chattopadhyay PK, 2006, NAT PROTOC, V1, P1, DOI 10.1038/nprot.2006.1; Chatzis O, 2021, CLIN MICROBIOL INFEC, V27, P878, DOI 10.1016/j.cmi.2020.08.033; Chen ZY, 2017, HUM VACC IMMUNOTHER, V13, P744, DOI 10.1080/21645515.2016.1259780; Cheung GYC, 2006, INFECT IMMUN, V74, P6797, DOI 10.1128/IAI.01104-06; Chitkara AJ, 2020, INT J INFECT DIS, V96, P482, DOI 10.1016/j.ijid.2020.04.081; Chow MYK, 2016, CLIN INFECT DIS, V63, pS134, DOI 10.1093/cid/ciw529; Ciabattini A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01305; Cooling L, 2015, CLIN MICROBIOL REV, V28, P801, DOI 10.1128/CMR.00109-14; Craig R, 2020, CLIN INFECT DIS, V70, P152, DOI 10.1093/cid/ciz531; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318; Dauby N, 2012, LANCET INFECT DIS, V12, P330, DOI 10.1016/S1473-3099(11)70341-3; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002; de Gouw D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113322; De Graaf H., 2018, OPEN FORUM INFECT DI, V5, pS17, DOI [10.1093/ofid/ofy209.037, DOI 10.1093/OFID/OFY209.037]; de Graaf H, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018594; de Rond L, 2015, CLIN VACCINE IMMUNOL, V22, P561, DOI 10.1128/CVI.00695-14; de Silva TI, 2017, J IMMUNOL METHODS, V449, P1, DOI 10.1016/j.jim.2017.06.008; DeAngelis H, 2016, JAMA PEDIATR, V170, P459, DOI 10.1001/jamapediatrics.2016.0047; DEEN JL, 1995, CLIN INFECT DIS, V21, P1211, DOI 10.1093/clinids/21.5.1211; Deng N, 2019, INFECT DIS MODEL, V4, P215, DOI 10.1016/j.idm.2019.06.001; DEVILLE JG, 1995, CLIN INFECT DIS, V21, P639, DOI 10.1093/clinids/21.3.639; Dewan KK, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020217; Dhiman N, 2008, VACCINE, V26, P1731, DOI 10.1016/j.vaccine.2008.01.017; Di Blasi D, 2020, J IMMUNOL METHODS, V487, DOI 10.1016/j.jim.2020.112907; Di Mattia G, 2019, PAEDIATR RESPIR REV, V29, P68, DOI 10.1016/j.prrv.2018.03.011; Diavatopoulos DA, 2019, LANCET INFECT DIS, V19, pE179, DOI 10.1016/S1473-3099(18)30646-7; Diavatopoulos DA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029553; Dirix V, 2009, VACCINE, V27, P6042, DOI 10.1016/j.vaccine.2009.07.075; Dirix V, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/795958; Donnelly S, 2001, INFECT IMMUN, V69, P4217, DOI 10.1128/IAI.69.7.4217-4223.2001; Dubois V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701285; Dunne A, 2015, MUCOSAL IMMUNOL, V8, P607, DOI 10.1038/mi.2014.93; Dunne A, 2010, J IMMUNOL, V185, P1711, DOI 10.4049/jimmunol.1000105; Eberhardt CS, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029629; Edwards K.M., 2014, J INFECT DIS, V209, pS10, DOI [10.1093/infdis/jit560, DOI 10.1093/infdis/jit560]; Elahi S, 2005, INFECT IMMUN, V73, P3636, DOI 10.1128/IAI.73.6.3636-3645.2005; Elizagaray ML, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01879; Elliott AM, 2007, CLIN TRIALS, V4, P42, DOI 10.1177/1740774506075248; Elliott AM, 2010, VACCINE, V29, P247, DOI 10.1016/j.vaccine.2010.10.047; Gaillard ME, 2014, VACCINE, V32, P931, DOI 10.1016/j.vaccine.2013.12.048; Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344; Esposito S, 2018, HUM VACC IMMUNOTHER, V14, P2452, DOI 10.1080/21645515.2018.1480298; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Fadugba OO, 2014, CLIN VACCINE IMMUNOL, V21, P1613, DOI 10.1128/CVI.00438-14; Falconer O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00328; Fedele G, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv051; Feikin DR, 2016, REPROD MATERNAL NEWB, V2, P187, DOI DOI 10.1596/978-1-4648-0348-2; Fink K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00110; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Flaxman A, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030043; Flugge J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030381; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Furman D, 2015, VACCINE, V33, P5271, DOI 10.1016/j.vaccine.2015.06.117; Gaayeb L, 2014, VACCINE, V32, P3431, DOI 10.1016/j.vaccine.2014.03.086; Geiger R, 2009, J EXP MED, V206, P1525, DOI 10.1084/jem.20090504; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Geurtsen J, 2007, CLIN VACCINE IMMUNOL, V14, P821, DOI 10.1128/CVI.00074-07; Giacomini E, 1999, J MED MICROBIOL, V48, P1081, DOI 10.1099/00222615-48-12-1081; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; Gillard J, 2019, ADV EXP MED BIOL, V1183, P53, DOI 10.1007/5584_2019_404; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guiso N, 2007, VACCINE, V25, P1390, DOI 10.1016/j.vaccine.2006.10.048; Guiso N, 1999, VACCINE, V17, P2366, DOI 10.1016/S0264-410X(99)00037-7; Guiso N, 2020, VACCINE, V38, P1271, DOI 10.1016/j.vaccine.2019.11.022; Hendrikx LH, 2011, VACCINE, V30, P51, DOI 10.1016/j.vaccine.2011.10.048; Hendrikx LH, 2011, VACCINE, V29, P6874, DOI 10.1016/j.vaccine.2011.07.055; Hendrikx LH, 2011, VACCINE, V29, P5725, DOI 10.1016/j.vaccine.2011.05.094; Hendrikx LH, 2011, VACCINE, V29, P1431, DOI 10.1016/j.vaccine.2010.12.033; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; Hobeika AC, 2005, J IMMUNOTHER, V28, P63, DOI 10.1097/00002371-200501000-00008; Holubova J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040695; Hygino J, 2008, CLIN IMMUNOL, V127, P340, DOI 10.1016/j.clim.2008.01.020; Jaffar Z, 2009, J IMMUNOL, V182, P4507, DOI 10.4049/jimmunol.0900237; Jahnmatz M, 2013, J IMMUNOL METHODS, V391, P50, DOI 10.1016/j.jim.2013.02.009; Jahnmatz M, 2020, LANCET INFECT DIS, V20, P1290, DOI 10.1016/S1473-3099(20)30274-7; Janetzki Sylvia, 2014, Cells, V3, P1102, DOI 10.3390/cells3041102; Janoff EN, 2012, TRANSL RES, V160, P239, DOI 10.1016/j.trsl.2012.05.005; Jennewein MF, 2017, SEMIN IMMUNOPATHOL, V39, P605, DOI 10.1007/s00281-017-0653-x; Jennings-Gee J, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00935-17; Jochems SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169805; Kampmann B, 2016, CLIN INFECT DIS, V63, pS142, DOI 10.1093/cid/ciw560; Kanojia G, 2018, J CONTROL RELEASE, V286, P167, DOI 10.1016/j.jconrel.2018.07.035; Kidzeru EB, 2014, AIDS, V28, P1421, DOI 10.1097/QAD.0000000000000292; Kinder JM, 2017, NAT REV IMMUNOL, V17, P730, DOI 10.1038/nri.2017.117; Kinder JM, 2017, NAT REV IMMUNOL, V17, P483, DOI 10.1038/nri.2017.38; Kinder JM, 2015, CELL, V162, P505, DOI 10.1016/j.cell.2015.07.006; Kiravu A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02307; Kirmiz N, 2018, ANNU REV FOOD SCI T, V9, P429, DOI 10.1146/annurev-food-030216-030207; Klein NP, 2017, VACCINE, V35, P3395, DOI 10.1016/j.vaccine.2017.05.008; Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326; Klein NP, 2010, J INFECT DIS, V201, P214, DOI 10.1086/649590; Knuf M, 2008, J PEDIATR-US, V152, P655, DOI 10.1016/j.jpeds.2007.09.034; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kruiswijk C, 2020, HUM VACC IMMUNOTHER, V16, P277, DOI 10.1080/21645515.2019.1703453; LaBeaud AD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000442; Lam C, 2012, INFECT GENET EVOL, V12, P492, DOI 10.1016/j.meegid.2012.01.001; Lambert EE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020225; Lambert LC, 2014, J INFECT DIS, V209, pS4, DOI 10.1093/infdis/jit592; Le Doare K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00361; Lee KH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0207898; Leef M, 2000, J EXP MED, V191, P1841, DOI 10.1084/jem.191.11.1841; Leroux-Roels G, 2018, HUM VACC IMMUNOTHER, V14, P45, DOI 10.1080/21645515.2017.1385686; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Li P, 2016, INT J PHARMACEUT, V513, P183, DOI 10.1016/j.ijpharm.2016.08.059; Liko J, 2013, NEW ENGL J MED, V368, P581, DOI 10.1056/NEJMc1212006; Lima L, 2019, VACCINE, V37, P2569, DOI 10.1016/j.vaccine.2019.03.070; Lin A, 2020, J CLIN INVEST, V130, P2332, DOI 10.1172/JCI135020; Lin DX, 2018, METHODS MOL BIOL, V1678, P37, DOI 10.1007/978-1-4939-7346-0_3; Lindenstrom T, 2018, EBIOMEDICINE, V27, P27, DOI 10.1016/j.ebiom.2017.12.004; Lindenstrom T, 2012, INFECT IMMUN, V80, P3533, DOI 10.1128/IAI.00550-12; Lindsey BB, 2019, LANCET RESP MED, V7, P665, DOI 10.1016/S2213-2600(19)30086-4; Linnik JE, 2016, HUM VACC IMMUNOTHER, V12, P907, DOI 10.1080/21645515.2015.1119345; Locht C, 2016, CLIN MICROBIOL INFEC, V22, pS96, DOI 10.1016/j.cmi.2016.05.029; Locht C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030228; Locht C, 2017, J INFECT DIS, V216, P117, DOI 10.1093/infdis/jix254; Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; Macpherson AJ, 2017, NAT REV IMMUNOL, V17, P508, DOI 10.1038/nri.2017.58; Mahon BP, 2000, J INFECT DIS, V181, P2087, DOI 10.1086/315527; Mahon BP, 1997, J EXP MED, V186, P1843, DOI 10.1084/jem.186.11.1843; Malhotra I, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003466; Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116; Marchant A, 2017, LANCET INFECT DIS, V17, pE197, DOI 10.1016/S1473-3099(17)30229-3; Marr N, 2008, VACCINE, V26, P4306, DOI 10.1016/j.vaccine.2008.06.017; Mascart F, 2007, VACCINE, V25, P391, DOI 10.1016/j.vaccine.2006.06.046; McGuirk P, 2000, INFECT IMMUN, V68, P1383, DOI 10.1128/IAI.68.3.1383-1390.2000; [Медкова Алиса Юрьевна Medkova Alisa Yu.], 2020, [Журнал микробиологии, эпидемиологии и иммунобиологии, Journal of Microbiology Epidemiology Immunobiology, Zhurnal mikrobiologii, epidemiologii i immunobiologii], P312, DOI 10.36233/0372-9311-2020-97-4-3; Melvin JA, 2014, NAT REV MICROBIOL, V12, P274, DOI 10.1038/nrmicro3235; Merkel TJ, 2014, J INFECT DIS, V209, pS20, DOI 10.1093/infdis/jit493; Messele T, 2000, CLIN DIAGN LAB IMMUN, V7, P687, DOI 10.1128/CDLI.7.4.687-692.2000; Messina NL, 2019, CLIN MICROBIOL INFEC, V25, P1484, DOI 10.1016/j.cmi.2019.02.016; Mika M, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0302-6; Mika M, 2015, J ALLERGY CLIN IMMUN, V135, P905, DOI 10.1016/j.jaci.2014.12.1909; Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07; Mills K H, 1998, Dev Biol Stand, V95, P31; MILLS KHG, 1993, J MED MICROBIOL, V39, P163, DOI 10.1099/00222615-39-3-163; Mills KHG, 1998, INFECT IMMUN, V66, P594, DOI 10.1128/IAI.66.2.594-602.1998; MILLS KHG, 1993, INFECT IMMUN, V61, P399, DOI 10.1128/IAI.61.2.399-410.1993; Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6; Mills KHG, 2014, J INFECT DIS, V209, pS16, DOI 10.1093/infdis/jit488; Misiak A, 2017, VACCINE, V35, P5256, DOI 10.1016/j.vaccine.2017.08.009; Misiak A, 2017, J IMMUNOL, V198, P363, DOI 10.4049/jimmunol.1601024; Moles JP, 2017, NAT REV IMMUNOL, V17, P729, DOI 10.1038/nri.2017.115; Mooi FR, 2014, EPIDEMIOL INFECT, V142, P685, DOI 10.1017/S0950268813000071; Mooi FR, 1998, INFECT IMMUN, V66, P670, DOI 10.1128/IAI.66.2.670-675.1998; Moosa F, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3869-7; Muloiwa R, 2018, VACCINE, V36, P2385, DOI 10.1016/j.vaccine.2018.03.025; Munoz FM, 2019, OBSTET GYNECOL, V133, P739, DOI 10.1097/AOG.0000000000003161; Muruganandah V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01574; Nakaya HI, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0146; Nash S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005213; Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003; Newport MJ, 2005, EXPERT REV VACCINES, V4, P739, DOI 10.1586/14760584.4.5.739; Newport MJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00018; Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051; Nguyen QP, 2019, IMMUNOLOGY, V157, P3, DOI 10.1111/imm.13059; Noe A, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8624963; Obanewa O, 2017, FUTURE VIROL, V12, P525, DOI 10.2217/fvl-2017-0021; Olin P, 1997, LANCET, V350, P1569, DOI 10.1016/S0140-6736(97)06508-2; Orije MRP, 2020, VACCINE, V38, P20, DOI 10.1016/j.vaccine.2019.10.025; Ovsyannikova IG, 2010, HUM GENET, V127, P207, DOI 10.1007/s00439-009-0763-1; Palazzo R, 2016, NEW MICROBIOL, V39, P35; Park CO, 2015, NAT MED, V21, P688, DOI 10.1038/nm.3883; Pezeshki A, 2019, EXPERT REV VACCINES, V18, P253, DOI 10.1080/14760584.2019.1575208; Phetsouphanh C, 2015, INT J MOL SCI, V16, P18878, DOI 10.3390/ijms160818878; Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047; Pinto MV, 2017, J INFECTION, V74, pS114, DOI 10.1016/S0163-4453(17)30201-3; Plotkin SA, 2018, J CLIN INVEST, V128, P3742, DOI 10.1172/JCI122726; Plotkin SA, 2014, CLIN INFECT DIS, V58, P830, DOI 10.1093/cid/cit934; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Prendergast AJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0141; Pro SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196551; Queenan AM, 2019, VACCINE, V37, P80, DOI 10.1016/j.vaccine.2018.11.028; Queenan AM, 2014, EXPERT REV VACCINES, V13, P1265, DOI 10.1586/14760584.2014.938642; Raeven RHM, 2018, MUCOSAL IMMUNOL, V11, P979, DOI 10.1038/mi.2017.81; Raeven RHM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63998-2; Raeven RHM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38240; Raeven RHM, 2015, J PROTEOME RES, V14, P2929, DOI 10.1021/acs.jproteome.5b00258; Raeven RHM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104548; RAMSAY ME, 1995, ARCH DIS CHILD, V72, P230, DOI 10.1136/adc.72.3.230; Rastogi D, 2007, J CLIN INVEST, V117, P1637, DOI 10.1172/JCI29466; REDHEAD K, 1993, INFECT IMMUN, V61, P3190, DOI 10.1128/IAI.61.8.3190-3198.1993; Reeves PM, 2018, FASEB J, V32, P5, DOI 10.1096/fj.201700325R; Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998; Rieber N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017271; Ring N, 2019, ADV EXP MED BIOL, V1183, P1, DOI 10.1007/5584_2019_401; Roberts R, 2008, VACCINE, V26, P4639, DOI 10.1016/j.vaccine.2008.07.004; Roederer M, 2004, CLIN IMMUNOL, V110, P199, DOI 10.1016/j.clim.2003.11.015; Ross PJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003264; Rowe J, 2000, INFECT IMMUN, V68, P3873, DOI 10.1128/IAI.68.7.3873-3877.2000; Rowe J, 2005, INFECT IMMUN, V73, P8130, DOI 10.1128/IAI.73.12.8130-8135.2005; Ryan EJ, 1999, INFECT IMMUN, V67, P6270; Ryan EJ, 2000, CLIN EXP IMMUNOL, V121, P193, DOI 10.1046/j.1365-2249.2000.01306.x; Ryan M, 1998, IMMUNOLOGY, V93, P1, DOI 10.1046/j.1365-2567.1998.00401.x; Saadatian-Elahi M, 2016, VACCINE, V34, P3923, DOI 10.1016/j.vaccine.2016.06.020; Saade F, 2012, EXPERT REV VACCINES, V11, P1459, DOI [10.1586/ERV.12.125, 10.1586/erv.12.125]; Sadarangani SP, 2015, EXPERT REV VACCINES, V14, P1427, DOI 10.1586/14760584.2015.1082426; Saso A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01499; Saso A, 2017, SEMIN IMMUNOPATHOL, V39, P627, DOI 10.1007/s00281-017-0654-9; Savy M, 2009, J NUTR, V139, p2154S, DOI 10.3945/jn.109.105312; Scadding GW, 2012, J IMMUNOL METHODS, V384, P25, DOI 10.1016/j.jim.2012.06.013; Scanlon KM, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00355-17; Schloesser RL, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.5.e60; Schure RM, 2013, CLIN VACCINE IMMUNOL, V20, P1388, DOI 10.1128/CVI.00270-13; Schure RM, 2012, CLIN VACCINE IMMUNOL, V19, P1879, DOI 10.1128/CVI.00277-12; Seddiki N, 2014, EUR J IMMUNOL, V44, P1644, DOI 10.1002/eji.201344102; Sheridan SL, 2012, CLIN INFECT DIS, V55, P1434, DOI 10.1093/cid/cis672; Shi W, 2018, IMMUNOL LETT, V198, P26, DOI 10.1016/j.imlet.2018.03.012; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Sims S, 2010, EXPERT REV VACCINES, V9, P765, DOI [10.1586/erv.10.66, 10.1586/ERV.10.66]; Siota M, 2011, EXPERT REV VACCINES, V10, P299, DOI [10.1586/ERV.10.169, 10.1586/erv.10.169]; Skerry CM, 2011, CLIN VACCINE IMMUNOL, V18, P187, DOI 10.1128/CVI.00371-10; Slack MH, 2004, ARCH DIS CHILD-FETAL, V89, pF269, DOI 10.1136/adc.2003.030718; Smits K, 2013, VACCINE, V32, P111, DOI 10.1016/j.vaccine.2013.10.056; Soares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007; Solans L, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03068; Stenger RM, 2010, VACCINE, V28, P6637, DOI 10.1016/j.vaccine.2010.06.118; Suzuki K, 2017, MICROBIOL IMMUNOL, V61, P371, DOI 10.1111/1348-0421.12504; Tarabichi Y, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0133-2; Taranger J, 2000, J INFECT DIS, V181, P1010, DOI 10.1086/315318; Thorstensson R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083449; Thwaites RS, 2018, JOVE-J VIS EXP, V131, P56413, DOI DOI 10.3791/56413;PMID:29443104; Thwaites RS, 2018, AM J RESP CRIT CARE, V198, P1074, DOI 10.1164/rccm.201712-2567OC; Thwaites RS, 2017, J INFECT DIS, V215, P1240, DOI 10.1093/infdis/jix150; Tian Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02778; Tong M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023028; TUOMANEN EI, 1984, J CLIN MICROBIOL, V20, P167, DOI 10.1128/JCM.20.2.167-170.1984; van der Lee S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00681; van der Lee S, 2018, VACCINE, V36, P220, DOI 10.1016/j.vaccine.2017.11.066; van Twillert I, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv071; Vaughan K, 2014, HUM IMMUNOL, V75, P440, DOI 10.1016/j.humimm.2014.02.013; Vermeulen F, 2010, CLIN VACCINE IMMUNOL, V17, P258, DOI 10.1128/CVI.00328-09; Vidor E, 2007, J COMP PATHOL, V137, pS62, DOI 10.1016/j.jcpa.2007.04.014; Vono M, 2019, CELL REP, V28, P1773, DOI 10.1016/j.celrep.2019.07.047; Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638; Wanlapakorn N, 2020, CLIN INFECT DIS, V71, P72, DOI 10.1093/cid/ciz778; Warfel JM, 2013, MUCOSAL IMMUNOL, V6, P787, DOI 10.1038/mi.2012.117; Warfel JM, 2016, CLIN VACCINE IMMUNOL, V23, P47, DOI 10.1128/CVI.00449-15; Warfel JM, 2015, CURR OPIN IMMUNOL, V35, P48, DOI 10.1016/j.coi.2015.05.008; Warfel JM, 2014, EXPERT REV VACCINES, V13, P1241, DOI 10.1586/14760584.2014.946016; Warfel JM, 2014, J INFECT DIS, V210, P604, DOI 10.1093/infdis/jiu090; Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110; Warfel JM, 2012, J INFECT DIS, V206, P902, DOI 10.1093/infdis/jis443; Warfel JM, 2012, INFECT IMMUN, V80, P1530, DOI 10.1128/IAI.06310-11; Webb EL, 2011, LANCET, V377, P52, DOI 10.1016/S0140-6736(10)61457-2; Weingart CL, 2000, INFECT IMMUN, V68, P7175, DOI 10.1128/IAI.68.12.7175-7179.2000; Weiss AA, 2004, INFECT IMMUN, V72, P7346, DOI 10.1128/IAI.72.12.7346-7351.2004; Weyrich LS, 2014, J INFECT DIS, V209, P913, DOI 10.1093/infdis/jit597; White OJ, 2012, VACCINE, V30, P1865, DOI 10.1016/j.vaccine.2011.12.118; Wilcox CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01548; Wilk MM, 2019, EMERG MICROBES INFEC, V8, P169, DOI 10.1080/22221751.2018.1564630; Wilk MM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01860; Wilk MM, 2017, J IMMUNOL, V199, P233, DOI 10.4049/jimmunol.1602051; Witt MA, 2013, CLIN INFECT DIS, V56, P1248, DOI 10.1093/cid/cit046; Wolf MA, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00607-20; Wolfl M, 2007, BLOOD, V110, P201, DOI 10.1182/blood-2006-11-056168; Wood N, 2018, JAMA PEDIATR, V172, P1045, DOI 10.1001/jamapediatrics.2018.2349; Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0; Yucesoy B, 2013, VACCINE, V31, P5381, DOI 10.1016/j.vaccine.2013.09.026; Yucesoy B, 2009, VACCINE, V27, P6991, DOI 10.1016/j.vaccine.2009.09.076; Zepp F, 1996, INFECT IMMUN, V64, P4078, DOI 10.1128/IAI.64.10.4078-4084.1996; Zepp F, 1997, DEV BIOLOGICALS, V89, P307; Zhang XQ, 2011, INFECT IMMUN, V79, P527, DOI 10.1128/IAI.00590-10; Zhang YY, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00421-19; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	316	4	4	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							877	10.3390/vaccines9080877			41	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3NK	34452002	Green Accepted, gold, Green Published			2022-04-29	WOS:000689842000001
J	Guida, M; Terracciano, D; Cennamo, M; Aiello, F; La Civita, E; Esposito, G; Gargiulo, V; Maruotti, GM; Portella, G; Sarno, L				Guida, Maurizio; Terracciano, Daniela; Cennamo, Michele; Aiello, Federica; La Civita, Evelina; Esposito, Gennaro; Gargiulo, Valentina; Maruotti, Giuseppe M.; Portella, Giuseppe; Sarno, Laura			COVID-19 Vaccine mRNABNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women	VACCINES			English	Article						vaccine; milk; immunoglobulins; SARS-Cov-2		Objective: The objective of this research is to demonstrate the release of SARS-CoV-2 Spike (S) antibodies in human milk samples obtained by patients who have been vaccinated with mRNABNT162b2 vaccine. Methods: Milk and serum samples were collected in 10 volunteers 20 days after the first dose and 7 seven days after the second dose of the mRNABNT162b2 vaccine. Anti-SARS-CoV-2 S antibodies were measured by the Elecsys (R) Anti-SARS-CoV-2 S ECLIA assay (Roche Diagnostics AG, Rotkreuz, Switzerland), a quantitative electrochemiluminescence immunometric method. Results: At first sample, anti-SARS-CoV-2 S antibodies were detected in all serum samples (103.9 +/- 54.9 U/mL) and only in two (40%) milk samples with a low concentration (1.2 +/- 0.3 U/mL). At the second sample, collected 7 days after the second dose, anti-SARS-CoV-2 S antibodies were detected in all serum samples (3875.7 +/- 3504.6 UI/mL) and in all milk samples (41.5 +/- 47.5 UI/mL). No correlation was found between the level of serum and milk antibodies; the milk antibodies/serum antibodies ratio was on average 2% (range: 0.2-8.4%). Conclusion: We demonstrated a release of anti-SARS-CoV-2 S antibodies in the breast milk of women vaccinated with mRNABNT162b2. Vaccinating breastfeeding women could be a strategy to protect their infants from COVID-19 infection.	[Guida, Maurizio; Aiello, Federica; Maruotti, Giuseppe M.; Sarno, Laura] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, I-80131 Naples, Italy; [Terracciano, Daniela; Cennamo, Michele; La Civita, Evelina; Portella, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, I-80131 Naples, Italy; [Esposito, Gennaro] Univ Naples Federico II, Dept Publ Hlth, I-80131 Naples, Italy; [Gargiulo, Valentina] Univ Hosp Federico II, Dept Mother & Child, I-80131 Naples, Italy		Terracciano, D (通讯作者)，Univ Naples Federico II, Dept Translat Med Sci, I-80131 Naples, Italy.	mauguida@unina.it; daniela.terracciano@unina.it; michelecennamo1@gmail.com; federichella91@gmail.com; eva.lacivita@gmail.com; gennaroesposito17@gmail.com; valegargiulo@yahoo.it; gm.mar@tiscali.it; portella@unina.it; laurettasarno@gmail.com	Portella, Giuseppe/AFU-6826-2022; Terracciano, Daniela/AAB-9521-2022; La Civita, Evelina/AAC-4891-2022	Terracciano, Daniela/0000-0003-4296-429X; 			Academy of Breastfeeding Medicine, CONS COVID 19 VACC L; [Anonymous], 2020, ACOG PRACTICE ADVICE; [Anonymous], 2020, JOINT COMMITTEE VACC; CDC, INF COVID 19 VACC WO INF COVID 19 VACC WO; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Czosnykowska-Lukacka M, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00428; Davanzo R, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.13010; Demers-Mathieu V, 2021, J PERINATOL, V41, P850, DOI 10.1038/s41372-020-00805-w; Egger M, 2020, CLIN CHIM ACTA, V509, P18, DOI 10.1016/j.cca.2020.05.049; Fox A, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101735; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Kashte S, 2021, HUM CELL, V34, P711, DOI 10.1007/s13577-021-00512-4; Marchant A, 2017, LANCET INFECT DIS, V17, pE197, DOI 10.1016/S1473-3099(17)30229-3; Mazur NI, 2019, J INFECT DIS, V219, P59, DOI 10.1093/infdis/jiy477; Pace RM, 2021, MBIO, V12, DOI 10.1128/mBio.03192-20; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]	19	8	8	2	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							785	10.3390/vaccines9070785			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7BY	34358201	Green Published, gold			2022-04-29	WOS:000677063300001
J	Hussein, T; Hammad, MH; Fung, PL; Al-Kloub, M; Odeh, I; Zaidan, MA; Wraith, D				Hussein, Tareq; Hammad, Mahmoud H.; Fung, Pak Lun; Al-Kloub, Marwan; Odeh, Issam; Zaidan, Martha A.; Wraith, Darren			COVID-19 Pandemic Development in Jordan-Short-Term and Long-Term Forecasting	VACCINES			English	Article						linear forecast; white-box model; vaccination; public immunity		In this study, we proposed three simple approaches to forecast COVID-19 reported cases in a Middle Eastern society (Jordan). The first approach was a short-term forecast (STF) model based on a linear forecast model using the previous days as a learning data-base for forecasting. The second approach was a long-term forecast (LTF) model based on a mathematical formula that best described the current pandemic situation in Jordan. Both approaches can be seen as complementary: the STF can cope with sudden daily changes in the pandemic whereas the LTF can be utilized to predict the upcoming waves' occurrence and strength. As such, the third approach was a hybrid forecast (HF) model merging both the STF and the LTF models. The HF was shown to be an efficient forecast model with excellent accuracy. It is evident that the decision to enforce the curfew at an early stage followed by the planned lockdown has been effective in eliminating a serious wave in April 2020. Vaccination has been effective in combating COVID-19 by reducing infection rates. Based on the forecasting results, there is some possibility that Jordan may face a third wave of the pandemic during the Summer of 2021.	[Hussein, Tareq; Hammad, Mahmoud H.] Univ Jordan, Dept Phys, Amman 11942, Jordan; [Hussein, Tareq; Fung, Pak Lun; Zaidan, Martha A.] Univ Helsinki, Inst Atmospher & Earth Syst Res INAR Phys, FI-00014 Helsinki, Finland; [Al-Kloub, Marwan] Prince Faisal Tech Coll, Dept Phys, Amman 11134, Jordan; [Odeh, Issam] Al Zaytoonah Univ Jordan, Dept Basic Sci, Amman 11733, Jordan; [Zaidan, Martha A.] Nanjing Univ, Sch Atmospher Sci, Joint Int Res Lab Atmospher & Earth Syst Sci, Nanjing 210023, Peoples R China; [Wraith, Darren] Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld 4000, Australia		Hussein, T (通讯作者)，Univ Jordan, Dept Phys, Amman 11942, Jordan.; Hussein, T (通讯作者)，Univ Helsinki, Inst Atmospher & Earth Syst Res INAR Phys, FI-00014 Helsinki, Finland.	tareq.hussein@helsinki.fi; mhm0179430@ju.edu.jo; pak.fung@helsinki.fi; pftcmdr@rjaf.mil.jo; odehi.m@zuj.edu.jo; martha.zaidan@helsinki.fi; d.wraith@qut.edu.au	Fung, Pak Lun/ABG-9705-2021; Zaidan, Martha Arbayani/G-4575-2011	Fung, Pak Lun/0000-0003-3493-1383; Zaidan, Martha Arbayani/0000-0002-6348-1230; Hussein, Tareq/0000-0002-0241-6435; odeh, issam/0000-0002-7857-3103; Wraith, Darren/0000-0001-8755-6471	Deanship of Scientific Research at the University of Jordan; Finnish Academy (Academy of Finland) [337549]; University of Helsinki	This research was supported by generous funding by the Deanship of Scientific Research at the University of Jordan. This research was also supported by Finnish Academy (Academy of Finland Flagship funding, grant number 337549). The APC was funded by the University of Helsinki.	Adly AS, 2020, J MED INTERNET RES, V22, DOI 10.2196/19104; Aguiar M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74386-1; Alsayed A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114076; Godio A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103535; Hadid SB, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-02791-x; Handelman GS, 2018, J INTERN MED, V284, P603, DOI 10.1111/joim.12822; Kannan S, 2020, ARCH CLIN INFECT DIS, V15, DOI 10.5812/archcid.103232; Kheirallah KA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186530; Kumar S, 2021, MATH METHOD APPL SCI, DOI 10.1002/mma.7065; Lalmuanawma S, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110059; Li MY, 2021, SCI TOTAL ENVIRON, V764, DOI 10.1016/j.scitotenv.2020.142810; Mollalo A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124204; Parham PE, 2011, J THEOR BIOL, V271, P1, DOI 10.1016/j.jtbi.2010.11.015; Porgo TV, 2019, RES SYNTH METHODS, V10, P125, DOI 10.1002/jrsm.1333; Riley P., 2020, COVID 19 DEATHS WHIC, P1, DOI [10.1101/2020.06.11.20129007, DOI 10.1101/2020.06.11.20129007]; Saidan MN, 2020, INT J INFECT DIS, V98, P321, DOI 10.1016/j.ijid.2020.06.105; Sidey-Gibbons JAM, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0681-4; WHO, 2019, NONPH PUBL HLTH MEAS; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328	19	5	5	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							728	10.3390/vaccines9070728			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6IJ	34358145	Green Published, gold			2022-04-29	WOS:000677012400001
J	Ingrao, F; Duchatel, V; Rodil, IF; Steensels, M; Verleysen, E; Mast, J; Lambrecht, B				Ingrao, Fiona; Duchatel, Victoria; Rodil, Isabel Fernandez; Steensels, Mieke; Verleysen, Eveline; Mast, Jan; Lambrecht, Benedicte			The Expression of Hemagglutinin by a Recombinant Newcastle Disease Virus Causes Structural Changes and Alters Innate Immune Sensing	VACCINES			English	Article						Newcastle disease virus; avian influenza; vector vaccines; glycoproteins; innate immunity	CELL-MEDIATED-IMMUNITY; TOLL-LIKE RECEPTOR; AVIAN INFLUENZA; PROTECTS CHICKENS; INFLAMMATORY CYTOKINES; VECTORED VACCINES; GENE-EXPRESSION; V PROTEINS; RIG-I; NEURAMINIDASE	Recombinant Newcastle disease viruses (rNDV) have been used as bivalent vectors for vaccination against multiple economically important avian pathogens. NDV-vectored vaccines expressing the immunogenic H5 hemagglutinin (rNDV-H5) are considered attractive candidates to protect poultry from both highly pathogenic avian influenza (HPAI) and Newcastle disease (ND). However, the impact of the insertion of a recombinant protein, such as H5, on the biological characteristics of the parental NDV strain has been little investigated to date. The present study compared a rNDV-H5 vaccine and its parental NDV LaSota strain in terms of their structural and functional characteristics, as well as their recognition by the innate immune sensors. Structural analysis of the rNDV-H5 demonstrated a decreased number of fusion (F) and a higher number of hemagglutinin-neuraminidase (HN) glycoproteins compared to NDV LaSota. These structural differences were accompanied by increased hemagglutinating and neuraminidase activities of rNDV-H5. During in vitro rNDV-H5 infection, increased mRNA expression of TLR3, TLR7, MDA5, and LGP2 was observed, suggesting that the recombinant virus is recognized differently by sensors of innate immunity when compared with the parental NDV LaSota. Given the growing interest in using NDV as a vector against human and animal diseases, these data highlight the importance of thoroughly understanding the recombinant vaccines' structural organization, functional characteristics, and elicited immune responses.	[Ingrao, Fiona; Duchatel, Victoria; Steensels, Mieke; Lambrecht, Benedicte] Sciensano, Serv Avian Virol & Immunol, B-1180 Brussels, Belgium; [Rodil, Isabel Fernandez] Univ Libre Bruxelles, Inst Biol & Med Mol, B-6041 Gosselies, Belgium; [Verleysen, Eveline; Mast, Jan] Sciensano, Serv Trace Elements & Nanomat, B-1180 Brussels, Belgium		Ingrao, F (通讯作者)，Sciensano, Serv Avian Virol & Immunol, B-1180 Brussels, Belgium.	fiona.ingrao@sciensano.be; victoria.duchatel@sciensano.be; isabelherge@gmail.com; mieke.steensels@sciensano.be; eveline.verleysen@sciensano.be; jan.mast@sciensano.be; benedicte.lambrecht@sciensano.be		Mast, Jan/0000-0002-4879-3367; Verleysen, Eveline/0000-0003-1230-7301; Ingrao, Fiona/0000-0003-1843-3843	Interuniversity Attraction Poles (IAP) Program "Virus-host interplay at the early phases of infection" BELVIR [IAP 7/45]	This research was funded by the Interuniversity Attraction Poles (IAP) Program "Virus-host interplay at the early phases of infection" BELVIR (grant number IAP 7/45) and Sciensano.	Aguilar HC, 2016, CURR CLIN MICROBIOL, V3, P142, DOI 10.1007/s40588-016-0040-8; Astill J, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00263; Bello MB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7278459; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Cantin C, 2007, J GEN VIROL, V88, P559, DOI 10.1099/vir.0.82150-0; Chen S, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-82; Cheng JH, 2014, ARCH VIROL, V159, P2937, DOI 10.1007/s00705-014-2148-6; Childs K, 2007, VIROLOGY, V359, P190, DOI 10.1016/j.virol.2006.09.023; Childs K, 2012, J VIROL, V86, P3411, DOI 10.1128/JVI.06405-11; Childs KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064202; Connaris H, 2002, J VIROL, V76, P1816, DOI 10.1128/JVI.76.4.1816-1824.2002; Denney L, 2018, BIOMED J, V41, P218, DOI 10.1016/j.bj.2018.08.004; Dhingra MS, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00084; Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019; Dimitrov KM, 2016, J CLIN MICROBIOL, V54, P1228, DOI 10.1128/JCM.03044-15; Du WJ, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008816; Edinger TO, 2014, J GEN VIROL, V95, P263, DOI 10.1099/vir.0.059477-0; Ferreira HL, 2010, AVIAN DIS, V54, P565, DOI 10.1637/8750-033009-ResNote.1; Ge JY, 2007, J VIROL, V81, P150, DOI 10.1128/JVI.01514-06; Guo PJ, 2013, DEV COMP IMMUNOL, V41, P389, DOI 10.1016/j.dci.2013.05.009; He YN, 2016, VIROL SIN, V31, P57, DOI 10.1007/s12250-015-3696-y; Ingrao F, 2018, VACCINE, V36, P615, DOI 10.1016/j.vaccine.2017.12.059; Ingrao F, 2017, AVIAN PATHOL, V46, P289, DOI 10.1080/03079457.2016.1265083; Jin JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep36890; Kim SH, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030300; Kim SH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070183; Kortekaas J, 2010, VACCINE, V28, P2271, DOI 10.1016/j.vaccine.2010.01.001; Lardinois A, 2016, AVIAN DIS, V60, P191, DOI 10.1637/11133-050815-Reg; Lardinois A, 2012, AVIAN DIS, V56, P928, DOI 10.1637/10173-041012-ResNote.1; Liu T, 2019, VET MICROBIOL, V228, P53, DOI 10.1016/j.vetmic.2018.11.013; Liu YC, 2018, J VIROL, V92, DOI [10.1128/jvi.00143-18, 10.1128/JVI.00143-18]; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5; Melanson VR, 2004, J VIROL, V78, P13053, DOI 10.1128/JVI.78.23.13053-13061.2004; MEULEMANS G, 1987, ARCH VIROL, V92, P55, DOI 10.1007/BF01310062; Nagy A, 2016, VACCINE, V34, P2537, DOI 10.1016/j.vaccine.2016.04.022; Nayak B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006509; Nang NT, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-64; O'Neill LAJ, 2010, CURR BIOL, V20, pR328, DOI 10.1016/j.cub.2010.01.044; Park MS, 2006, P NATL ACAD SCI USA, V103, P8203, DOI 10.1073/pnas.0602566103; Peters MA, 2003, IMMUNOLOGY, V110, P358, DOI 10.1046/j.1365-2567.2003.01744.x; Philbin VJ, 2005, IMMUNOLOGY, V114, P507, DOI 10.1111/j.1365-2567.2005.02125.x; Ren XP, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-32; Richard M, 2011, ANTIMICROB AGENTS CH, V55, P2942, DOI 10.1128/AAC.01699-10; ROMAN JM, 1976, VIROLOGY, V69, P298, DOI 10.1016/0042-6822(76)90216-6; Romanutti C, 2020, VACCINE, V38, P6990, DOI 10.1016/j.vaccine.2020.09.013; Santhakumar D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00049; Shahsavandi S, 2013, CYTOTECHNOLOGY, V65, P419, DOI 10.1007/s10616-012-9495-5; Skiadopoulos MH, 2002, VIROLOGY, V297, P136, DOI 10.1006/viro.2002.1415; Spackman E., 2014, ANIMAL INFLUENZA VIR; Spackman E, 2014, VET J, V202, P408, DOI 10.1016/j.tvjl.2014.09.017; St Paul M, 2013, VET IMMUNOL IMMUNOP, V152, P191, DOI 10.1016/j.vetimm.2012.10.013; Staines K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160173; STEWARD M, 1993, J GEN VIROL, V74, P2539, DOI 10.1099/0022-1317-74-12-2539; Suarez DL, 2017, VET MICROBIOL, V206, P144, DOI 10.1016/j.vetmic.2016.11.025; Tappert MM, 2013, J VIROL, V87, P8962, DOI 10.1128/JVI.00739-13; Vasou A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070186; Veits J, 2006, P NATL ACAD SCI USA, V103, P8197, DOI 10.1073/pnas.0602461103; Vignuzzi M, 2019, NAT MICROBIOL, V4, P1075, DOI 10.1038/s41564-019-0465-y; Wang JY, 2015, VET MICROBIOL, V177, P302, DOI 10.1016/j.vetmic.2015.04.005; Wang XL, 2019, VIRUS GENES, V55, P233, DOI 10.1007/s11262-019-01637-3; Wen ZY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-331; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Willemsen A, 2019, VIRUS EVOL, V5, DOI 10.1093/ve/vez045; Xu R, 2012, J VIROL, V86, P9221, DOI 10.1128/JVI.00697-12; Zhang PZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00366; Zhao W, 2015, J GEN VIROL, V96, P40, DOI 10.1099/vir.0.068437-0	67	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							758	10.3390/vaccines9070758			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7CG	34358174	Green Published, gold, Green Submitted			2022-04-29	WOS:000677064100001
J	Lopez-Serrano, S; Cordoba, L; Perez-Maillo, M; Pleguezuelos, P; Remarque, EJ; Ebensen, T; Guzman, CA; Christensen, D; Segales, J; Darji, A				Lopez-Serrano, Sergi; Cordoba, Lorena; Perez-Maillo, Monica; Pleguezuelos, Patricia; Remarque, Edmond J.; Ebensen, Thomas; Guzman, Carlos A.; Christensen, Dennis; Segales, Joaquim; Darji, Ayub			Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF (R) 01 or CDA/alpha GalCerMPEG	VACCINES			English	Article						vaccine; adjuvants; influenza; immunity; pathology	CELL RESPONSES; ANTIBODY; POTENT; SWINE; MODEL	This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF (R) 01 or CDA/alpha GalCerMPEG (alpha GCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF (R) 01 or NG34 + CDA/alpha GCM. As controls, groups of animals (n = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund's adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 x 10(6) TCID50/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF (R) 01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/alpha GCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/alpha GCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF (R) 01 completely abolished virus from the lower respiratory tract. Similarly, higher IFN gamma secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF (R) 01 group as compared to the NG34 + CDA/alpha GCM. NG34-vaccinated pigs with adjuvanted CAF (R) 01 or CDA/alpha GCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding.	[Lopez-Serrano, Sergi; Cordoba, Lorena; Perez-Maillo, Monica; Pleguezuelos, Patricia; Segales, Joaquim; Darji, Ayub] IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain; [Remarque, Edmond J.] Biomed Primate Res Ctr, Dept Immunobiol, POB 3306, NL-2280 GH Rijswijk, Netherlands; [Ebensen, Thomas; Guzman, Carlos A.] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, Inhoffenstr 7, D-38124 Braunschweig, Germany; [Christensen, Dennis] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Virus Res & Dev Lab, Artillerivej 5, DK-2300 Copenhagen, Denmark; [Segales, Joaquim; Darji, Ayub] OIE Collaborating Ctr Res & Control Emerging & Re, Bellaterra 08193, Spain; [Segales, Joaquim] UAB, Dept Sanitat & Anat Anim, Fac Vet, Bellaterra 08193, Spain; [Darji, Ayub] Edifici CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain		Darji, A (通讯作者)，IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain.; Darji, A (通讯作者)，OIE Collaborating Ctr Res & Control Emerging & Re, Bellaterra 08193, Spain.; Darji, A (通讯作者)，Edifici CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain.	sergi.lopez@irta.cat; lorena.cordoba@irta.cat; monica.perez@irta.cat; patricia.pleguezuelos@irta.cat; remarque@bprc.nl; thomas.ebensen@helmholtz-hzi.de; Carlos.Guzman@helmholtz-hzi.de; den@ssi.dk; joaquim.segales@irta.cat; ayub.darji@irta.cat	Segales, Joaquim/A-4933-2011	Segales, Joaquim/0000-0002-1539-7261; Lopez-Serrano, Sergi/0000-0002-0968-7713	European Commission of the European Vaccine Initiative by the European Commission under the Horizon 2020 [TRANSVAC2-730964-INFRAIA-2016-1]; CERCA program from the Generalitat de Catalunya	This study was funded by the European Project TRANSVAC2-730964-INFRAIA-2016-1 of the European Vaccine Initiative funded by the European Commission under the Horizon 2020. IRTA-CReSA is also supported by the CERCA program from the Generalitat de Catalunya.	Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116; Artiaga BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23593; Bastola R, 2017, ARCH PHARM RES, V40, P1238, DOI 10.1007/s12272-017-0969-z; Canini L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008628; Christensen D, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01928; Christensen D, 2012, J CONTROL RELEASE, V160, P468, DOI 10.1016/j.jconrel.2012.03.016; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Donaldson B, 2015, ADV DEL SCI TECHNOL, P159, DOI 10.1007/978-1-4939-1417-3_9; Ebensen T, 2007, J IMMUNOL, V179, P2065, DOI 10.4049/jimmunol.179.4.2065; Ebensen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01223; Estrada LD, 2019, J IMMUNOL, V202, P392, DOI 10.4049/jimmunol.1801054; Garcia-Morante B, 2016, J COMP PATHOL, V154, P125, DOI 10.1016/j.jcpa.2015.11.003; Gauger PC, 2011, VACCINE, V29, P2712, DOI 10.1016/j.vaccine.2011.01.082; Gu WH, 2021, DEV COMP IMMUNOL, V114, DOI 10.1016/j.dci.2020.103843; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Jegaskanda S, 2013, J IMMUNOL, V190, P1837, DOI 10.4049/jimmunol.1201574; Jelinek I, 2011, J IMMUNOL, V186, P2422, DOI 10.4049/jimmunol.1002845; Keshavarz M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2014; Khatri M, 2010, J VIROL, V84, P11210, DOI 10.1128/JVI.01211-10; Kyriakis CS, 2010, VET MICROBIOL, V144, P67, DOI 10.1016/j.vetmic.2009.12.039; Larsen DL, 2000, VET MICROBIOL, V74, P117, DOI 10.1016/S0378-1135(00)00172-3; Le Bon A, 2008, CYTOKINE GROWTH F R, V19, P33, DOI 10.1016/j.cytogfr.2007.10.007; Long JS, 2019, NAT REV MICROBIOL, V17, P67, DOI 10.1038/s41579-018-0115-z; Lorenzen E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00628; Malik Peiris F.R.S., 2010, P IMM PROT EFF CAND P IMM PROT EFF CAND, P409; Martel CJM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022891; Matos MN, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005300; Nouri-Shirazi M, 2012, J IMMUNOL, V188, P2359, DOI 10.4049/jimmunol.1102552; Olafsdottir TA, 2016, SCI REP-UK, V6, DOI 10.1038/srep39097; Organisation International des Epizooties (OIE), 2019, MANUAL DIAGNOSTIC TE, P1594; Pedersen GK, 2018, SEMIN IMMUNOL, V39, P4, DOI 10.1016/j.smim.2018.10.003; Pellegrino P, 2015, AUTOIMMUN REV, V14, P880, DOI 10.1016/j.autrev.2015.05.014; Rajao DS, 2015, ILAR J, V56, P44, DOI 10.1093/ilar/ilv002; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y; Show C.A., 2013, IMMUNOL RES, V56, P304, DOI [DOI 10.1007/s12026-013-8403-1, 10.1007/s12026-013-8403-1]; Sistere-Oro M, 2020, VET RES, V51, DOI 10.1186/s13567-020-00770-4; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Van Reeth K., 2019, DIS SWINE; Van Roey GA, 2012, EUR J IMMUNOL, V42, P353, DOI 10.1002/eji.201141787; Veljkovic V, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472-6807-9-62; Vergara-Alert J, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-7; Vergara-Alert J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040524; Vidana B, 2021, INFLUENZA OTHER RESP, V15, P142, DOI 10.1111/irv.12784; Volckmar J, 2019, VACCINE, V37, P4963, DOI 10.1016/j.vaccine.2019.07.019; Wack A, 2008, VACCINE, V26, P552, DOI 10.1016/j.vaccine.2007.11.054; Waffarn EE, 2011, J IMMUNOL, V186, P3823, DOI 10.4049/jimmunol.1002090; Wallensten Anders, 2007, Microbial Ecology in Health and Disease, V19, P122, DOI 10.1080/08910600701406786; WHO, 2011, MAN LAB DIAGN VIR SU; Woodworth JS, 2019, MUCOSAL IMMUNOL, V12, P816, DOI 10.1038/s41385-019-0145-5; Zaks K, 2006, J IMMUNOL, V176, P7335, DOI 10.4049/jimmunol.176.12.7335	52	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							751	10.3390/vaccines9070751			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5SO	34358167	Green Published, gold			2022-04-29	WOS:000676971300001
J	Fulton, CM; Bailey, WJ				May Fulton, Corey; Bailey, Wendy J.			Live Viral Vaccine Neurovirulence Screening: Current and Future Models	VACCINES			English	Review						live viral vaccines; vaccine safety; neurovirulence; monkey neurovirulence test; live attenuated vaccines	MUMPS-VIRUS NEUROVIRULENCE; PLURIPOTENT STEM-CELLS; VENEZUELAN EQUINE ENCEPHALITIS; HUMAN POLIOVIRUS RECEPTOR; NEURAL PROGENITOR CELLS; YELLOW-FEVER VIRUS; SAFETY TEST; TRANSGENIC MICE; ATTENUATED VACCINES; RHESUS-MONKEYS	Live viral vaccines are one of the most successful methods for controlling viral infections but require strong evidence to indicate that they are properly attenuated. Screening for residual neurovirulence is an important aspect for live viral vaccines against potentially neurovirulent diseases. Approximately half of all emerging viral diseases have neurological effects, so testing of future vaccines will need to be rapid and accurate. The current method, the monkey neurovirulence test (MNVT), shows limited translatability for human diseases and does not account for different viral pathogenic mechanisms. This review discusses the MNVT and potential alternative models, including in vivo and in vitro methods. The advantages and disadvantages of these methods are discussed, and there are promising data indicating high levels of translatability. There is a need to investigate these models more thoroughly and to devise more accurate and rapid alternatives to the MNVT.	[May Fulton, Corey; Bailey, Wendy J.] Merck & Co Inc, Safety Assessment & Lab Anim Resources, West Point, PA 19486 USA		Fulton, CM (通讯作者)，Merck & Co Inc, Safety Assessment & Lab Anim Resources, West Point, PA 19486 USA.	corey.may.fulton@merck.com; wendy_bailey@merck.com					Abud EM, 2017, NEURON, V94, P278, DOI 10.1016/j.neuron.2017.03.042; Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008; Akay C, 2012, NEUROPATH APPL NEURO, V38, P175, DOI 10.1111/j.1365-2990.2011.01215.x; Arroyo J, 2004, J VIROL, V78, P12497, DOI 10.1128/JVI.78.22.12497-12507.2004; Arroyo J, 2001, J VIROL, V75, P934, DOI 10.1128/JVI.75.2.934-942.2001; Balraj V, 1995, REV MED VIROL, V5, P219, DOI 10.1002/rmv.1980050406; BARNETT EM, 1993, NEUROSCIENCE, V57, P1007, DOI 10.1016/0306-4522(93)90045-H; Brown E.G, 1998, REV MED VIROL, DOI 3.0.CO;2-Z; Burden N, 2015, J AM ASSOC LAB ANIM, V54, P198; Carbone KM, 2002, MOL PSYCHIATR, V7, pS36, DOI 10.1038/sj.mp.4001174; Chancey C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/376230; Charlton B, 2020, J INFECT DIS, V222, P1920, DOI 10.1093/infdis/jiaa299; Chin WX, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00282-y; Cho H, 2013, NAT MED, V19, P458, DOI 10.1038/nm.3108; Cho MS, 2008, NAT PROTOC, V3, P1888, DOI 10.1038/nprot.2008.188; CHUMAKOV K, 1993, DEV BIOL STAND, V78, P79; CHUMAKOV KM, 1991, P NATL ACAD SCI USA, V88, P199, DOI 10.1073/pnas.88.1.199; CHUMAKOV KM, 1992, J VIROL, V66, P966, DOI 10.1128/JVI.66.2.966-970.1992; Committee for Medicinal Products for Human Use (CHMP), EMACHMPVWP4572592014 EMACHMPVWP4572592014; CONTRERAS G, 1988, J BIOL STAND, V16, P195, DOI 10.1016/0092-1157(88)90007-8; D'Aiuto L, 2014, ORGANOGENESIS, V10, P365, DOI 10.1080/15476278.2015.1011921; Devine H, 2017, CELL BIOL TOXICOL, V33, P129, DOI 10.1007/s10565-016-9372-7; Doyle JP, 2008, CELL, V135, P749, DOI 10.1016/j.cell.2008.10.029; Dragunsky E, 2003, B WORLD HEALTH ORGAN, V81, P251; Du F, 2010, J CELL BIOCHEM, V109, P30, DOI 10.1002/jcb.22375; DUBOISDALCQ M, 1974, ARCH NEUROL-CHICAGO, V31, P355, DOI 10.1001/archneur.1974.00490420021001; Duggal NK, 2017, AM J TROP MED HYG, V97, P1410, DOI 10.4269/ajtmh.17-0263; Dupuy LC, 2012, CURR OPIN VIROL, V2, P363, DOI 10.1016/j.coviro.2012.02.014; Edwards MA, 2007, NEUROTOXICOLOGY, V28, P876, DOI 10.1016/j.neuro.2007.04.006; Engle SJ, 2018, NEURON, V100, P783, DOI 10.1016/j.neuron.2018.10.033; Ferren M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111017; Fine DL, 2008, VACCINE, V26, P3497, DOI 10.1016/j.vaccine.2008.04.044; Foo LC, 2011, NEURON, V71, P799, DOI 10.1016/j.neuron.2011.07.022; Fox JP, 1943, AM J HYG, V38, P152, DOI 10.1093/oxfordjournals.aje.a118877; Fox JP, 1942, AM J HYG, V36, P117, DOI 10.1093/oxfordjournals.aje.a118811; FURESZ J, 1993, DEV BIOL STAND, V78, P61; Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116; Garg RK, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2058; Geisbert TW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010690; Ginsberg SD, 2018, ANN NEUROL, V83, P406, DOI 10.1002/ana.25160; GOLDFIELD M, 1968, AM J EPIDEMIOL, V87, P32, DOI 10.1093/oxfordjournals.aje.a120807; Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001; Guttikonda SR, 2021, NAT NEUROSCI, V24, P343, DOI 10.1038/s41593-020-00796-z; Harschnitz O, 2021, NAT REV IMMUNOL, V21, P441, DOI 10.1038/s41577-020-00474-y; Hashimoto S, 2006, JPN J PUBLIC HLTH, V53, P794; Horie H, 1998, BIOLOGICALS, V26, P289, DOI 10.1006/biol.1998.0159; HORIE H, 1994, J VIROL, V68, P681, DOI 10.1128/JVI.68.2.681-688.1994; Hussain A, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3290; IABs, 2006, BIOLOGICALS, V34, P233, DOI 10.1016/j.biologicals.2005.08.005; Jacob F, 2020, CELL STEM CELL, V27, P937, DOI 10.1016/j.stem.2020.09.016; Jorgacevski J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44559-8; Kirwan P, 2015, DEVELOPMENT, V142, P3178, DOI 10.1242/dev.123851; Kitano T, 2021, HUM VACC IMMUNOTHER, V17, P205, DOI 10.1080/21645515.2020.1765619; KRISTENSSON K, 1984, J NEUROPATH EXP NEUR, V43, P131, DOI 10.1097/00005072-198403000-00003; Kuijlaars J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36529; Kweder H, 2014, ADV VIROL, V2014, DOI 10.1155/2014/205617; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Lafaille FG, 2012, NATURE, V491, P769, DOI 10.1038/nature11583; Ledur PF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57914-x; Lemon K, 2007, J VIROL, V81, P8293, DOI 10.1128/JVI.00266-07; LePage Keith T., 2005, Critical Reviews in Neurobiology, V17, P27; LEVENBOOK IS, 1987, J BIOL STAND, V15, P305, DOI 10.1016/S0092-1157(87)80003-3; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; Lindsey NP, 2018, AM J TROP MED HYG, V98, P1472, DOI 10.4269/ajtmh.17-0927; Mackenzie JS, 2007, PERSP MED V, V16, P201, DOI 10.1016/S0168-7069(06)16010-3; Mathieu C., 2021, MBIO, V12, DOI [10.1128/mbio.00799-21, DOI 10.1128/MBIO.00799-21]; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; McChesney MB, 1997, VIROLOGY, V233, P74, DOI 10.1006/viro.1997.8576; Meinhardt J, 2021, NAT NEUROSCI, V24, P168, DOI 10.1038/s41593-020-00758-5; Mertens J, 2018, ANNU REV GENET, V52, P271, DOI 10.1146/annurev-genet-120417-031534; Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006; Miller KD, 2019, J VIROL, V93, DOI 10.1128/JVI.00241-19; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Mire CE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001567; Monath TP, 2005, BIOLOGICALS, V33, P131, DOI 10.1016/j.biologicals.2005.03.009; Monath TP, 2000, J VIROL, V74, P1742, DOI 10.1128/JVI.74.4.1742-1751.2000; Monath TP, 1999, VACCINE, V17, P1869, DOI 10.1016/S0264-410X(98)00487-3; Mora-Bermudez F, 2016, ELIFE, V5, DOI 10.7554/eLife.18683; Morimoto K, 1999, J VIROL, V73, P510, DOI 10.1128/JVI.73.1.510-518.1999; Nemoto M, 2018, VACCINE, V36, P5551, DOI 10.1016/j.vaccine.2018.07.057; Nishino Y, 2002, J VIROL, V76, P8650, DOI 10.1128/JVI.76.17.8650-8658.2002; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Odawara A, 2014, BIOCHEM BIOPH RES CO, V443, P1176, DOI 10.1016/j.bbrc.2013.12.142; Olival KJ, 2005, J NEUROVIROL, V11, P441, DOI 10.1080/13550280591002450; Pandya H, 2017, NAT NEUROSCI, V20, P753, DOI 10.1038/nn.4534; Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915; Patterson JB, 2001, VIROLOGY, V291, P215, DOI 10.1006/viro.2001.1182; Prah J, 2019, J NEUROSCI METH, V320, P50, DOI 10.1016/j.jneumeth.2019.03.013; Pratt WD, 2003, VACCINE, V21, P3854, DOI 10.1016/S0264-410X(03)00328-1; Qi L, 2008, J NEUROVIROL, V14, P136, DOI 10.1080/13550280701885563; Racaniello VR, 2006, VIROLOGY, V344, P9, DOI 10.1016/j.virol.2005.09.015; Rall GF, 1997, P NATL ACAD SCI USA, V94, P4659, DOI 10.1073/pnas.94.9.4659; Reisen W.K, 2019, ARBOVIRUSES EPIDEMIO, P89, DOI [10.1201/9780429289200-4, DOI 10.1201/9780429289200-4]; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; Rockx B, 2010, J VIROL, V84, P9831, DOI 10.1128/JVI.01163-10; Rubin SA, 2005, J INFECT DIS, V191, P1123, DOI 10.1086/428098; Rubin SA, 1999, J INFECT DIS, V180, P521, DOI 10.1086/314905; Rubin SA, 2000, J VIROL, V74, P5382, DOI 10.1128/JVI.74.11.5382-5384.2000; Rubin SA, 2004, J NEUROVIROL, V10, P305, DOI 10.1080/13550280490499579; Rubin SA, 2011, PROCEDIA VACCINOL, V5, P261, DOI 10.1016/j.provac.2011.10.027; Ryan SK, 2020, STEM CELL REP, V14, P703, DOI [10.1016/j.stemcr.2020.02.010, 10.1016/j.stemcr.2020.04.006]; Sadaoka T, 2016, P NATL ACAD SCI USA, V113, pE2403, DOI 10.1073/pnas.1522575113; Sarathy VV, 2015, VACCINE, V33, P7051, DOI 10.1016/j.vaccine.2015.09.112; Sarathy VV, 2015, J VIROL, V89, P1254, DOI 10.1128/JVI.01320-14; Sarcey E, 2017, J VIROL METHODS, V246, P75, DOI 10.1016/j.jviromet.2017.04.016; Sauder CJ, 2006, VIROLOGY, V350, P48, DOI 10.1016/j.virol.2006.01.035; Sherwood CC, 2006, P NATL ACAD SCI USA, V103, P13606, DOI 10.1073/pnas.0605843103; Shi YC, 2012, NAT NEUROSCI, V15, P477, DOI 10.1038/nn.3041; Short SJ, 2010, BIOL PSYCHIAT, V67, P965, DOI 10.1016/j.biopsych.2009.11.026; Silva MTT, 2020, AM J TROP MED HYG, V103, P993, DOI 10.4269/ajtmh.20-0447; Smith AM, 2014, TRENDS NEUROSCI, V37, P125, DOI 10.1016/j.tins.2013.12.001; Smith DR, 2020, ANTIVIR RES, V182, DOI 10.1016/j.antiviral.2020.104875; Souza BSF, 2016, SCI REP-UK, V6, DOI 10.1038/srep39775; Sun AX, 2016, CELL REP, V16, P1942, DOI 10.1016/j.celrep.2016.07.035; TAKAHASHI M, 1995, J EXP MED, V181, P2161, DOI 10.1084/jem.181.6.2161; Vadodaria KC, 2016, MOL PSYCHIATR, V21, P49, DOI 10.1038/mp.2015.161; van Marle G, 2007, J VIROL, V81, P10933, DOI 10.1128/JVI.02422-06; VANBINNENDIJK RS, 1994, J INFECT DIS, V170, P443, DOI 10.1093/infdis/170.2.443; Walldorf JA, 2019, VACCINE, V37, P7190, DOI 10.1016/j.vaccine.2017.08.058; Watanabe S, 2019, TRENDS MICROBIOL, V27, P164, DOI 10.1016/j.tim.2018.08.010; Wells MF, 2016, CELL STEM CELL, V19, P703, DOI 10.1016/j.stem.2016.11.011; Wilson SN, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10040400; Wu YH, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006848; Xu P, 2013, J VIROL, V87, P8158, DOI 10.1128/JVI.01028-13; Zegenhagen L, 2016, CYTOKINE GROWTH F R, V30, P95, DOI 10.1016/j.cytogfr.2016.03.006; Zeng XK, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.113; Zhang PB, 2014, JOVE-J VIS EXP, DOI 10.3791/51737; Zhang YS, 2013, NEURON, V78, P785, DOI 10.1016/j.neuron.2013.05.029; Zhou ZQ, 2020, J NEUROL, V267, P2179, DOI 10.1007/s00415-020-09929-7	129	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							710	10.3390/vaccines9070710			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7SM	34209433	Green Published, gold			2022-04-29	WOS:000677106300001
J	Walach, H; Klement, RJ; Aukema, W				Walach, Harald; Klement, Rainer J.; Aukema, Wouter			The Safety of COVID-19 Vaccinations-We Should Rethink the Policy (Publication with Expression of Concern. See vol. 9, 2021)	VACCINES			English	Article; Publication with Expression of Concern						SARS-CoV2; COVID-19; vaccination; mRNA-vaccine; number needed to vaccinate; safety; side effects; adverse drug reaction; fatal side effects; EMA		Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database of the European Medicines Agency and of the Dutch National Register (lareb.nl) to extract the number of cases reporting severe side effects and the number of cases with fatal side effects. Result: The NNTV is between 200-700 to prevent one case of COVID-19 for the mRNA vaccine marketed by Pfizer, while the NNTV to prevent one death is between 9000 and 50,000 (95% confidence interval), with 16,000 as a point estimate. The number of cases experiencing adverse reactions has been reported to be 700 per 100,000 vaccinations. Currently, we see 16 serious side effects per 100,000 vaccinations, and the number of fatal side effects is at 4.11/100,000 vaccinations. For three deaths prevented by vaccination we have to accept two inflicted by vaccination. Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.	[Walach, Harald] Poznan Univ Med Sci, Pediat Hosp, PL-60572 Poznan, Poland; [Walach, Harald] Univ Witten Herdecke, Dept Psychol, D-58448 Witten, Germany; [Walach, Harald] Change Hlth Sci Inst, D-10178 Berlin, Germany; [Klement, Rainer J.] Leopoldina Hosp, Dept Radiat Oncol, D-97422 Schweinfurt, Germany; [Aukema, Wouter] Brinkenbergweg 1, NL-7351 BD Hoenderloo, Netherlands		Walach, H (通讯作者)，Poznan Univ Med Sci, Pediat Hosp, PL-60572 Poznan, Poland.; Walach, H (通讯作者)，Univ Witten Herdecke, Dept Psychol, D-58448 Witten, Germany.; Walach, H (通讯作者)，Change Hlth Sci Inst, D-10178 Berlin, Germany.	harald.walach@uni-wh.de; rainer_klement@gmx.de; wouter.aukema@gmail.com		Aukema, Wouter/0000-0001-7650-0093; Klement, Rainer/0000-0003-1401-4270			Alatawi YM, 2017, EXPERT OPIN DRUG SAF, V16, P761, DOI 10.1080/14740338.2017.1323867; Arvay C.G., 2020, SCHWEIZ AERZTEZEITUN, V101, P862, DOI DOI 10.4414/SAEZ.2020.18982; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bendavid E, 2021, INT J EPIDEMIOL, V50, P410, DOI 10.1093/ije/dyab010; Brandal LT, 2021, EUROSURVEILLANCE, V26, P2, DOI 10.2807/1560-7917.ES.2020.26.1.2002011; Cunningham A.S., 2020, BMJ-BRIT MED J, V371, pM4347; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Doshi P, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3563; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Eric K., 2021, RES SQ, DOI [10.21203/rs.3.rs-558954/v1, DOI 10.21203/RS.3.RS-558954/V1]; Farsalinos K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165807; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Havers FP, 2020, JAMA INTERN MED, V180, P1576, DOI 10.1001/jamainternmed.2020.4130; Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003; Ioannidis JPA, 2021, B WORLD HEALTH ORGAN, V99, P19, DOI 10.2471/BLT.20.265892; Ioannidis JPA, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109890; Klement RJ, 2021, ACTA BIOTHEOR, V69, P359, DOI 10.1007/s10441-020-09393-w; Lavine JS, 2021, SCIENCE, V371, P741, DOI 10.1126/science.abe6522; Lei YY, 2021, CIRC RES, V128, P1323, DOI 10.1161/CIRCRESAHA.121.318902; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lorent D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060541; Ludvigsson JF, 2021, NEW ENGL J MED, V384, P669, DOI 10.1056/NEJMc2026670; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Moore TJ, 2012, SEMIN THROMB HEMOST, V38, P905, DOI 10.1055/s-0032-1328890; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rose J., 2021, SCI PUBL HLTH POL LA, V2, P59; Seneff S., 2021, INT J VACCINE THEORY, V2, P38; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906	29	8	8	8	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							693	10.3390/vaccines9070693			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8HN		Green Published, gold			2022-04-29	WOS:000677145400001
J	Yahaghi, R; Ahmadizade, S; Fotuhi, R; Taherkhani, E; Ranjbaran, M; Buchali, Z; Jafari, R; Zamani, N; Shahbazkhania, A; Simiari, H; Rahmani, J; Yazdi, N; Alijani, H; Poorzolfaghar, L; Rajabi, F; Lin, CY; Brostrom, A; Griffiths, MD; Pakpour, AH				Yahaghi, Rafat; Ahmadizade, Safie; Fotuhi, Razie; Taherkhani, Elham; Ranjbaran, Mehdi; Buchali, Zeinab; Jafari, Robabe; Zamani, Narges; Shahbazkhania, Azam; Simiari, Hengame; Rahmani, Jalal; Yazdi, Nahid; Alijani, Hashem; Poorzolfaghar, Leila; Rajabi, Fatemeh; Lin, Chung-Ying; Brostrom, Anders; Griffiths, Mark D.; Pakpour, Amir H.			Fear of COVID-19 and Perceived COVID-19 Infectability Supplement Theory of Planned Behavior to Explain Iranians' Intention to Get COVID-19 Vaccinated	VACCINES			English	Article						COVID-19; fear; Iran; perceived infectability; theory of planned behavior; vaccine	SNIEHOTTA; PRESSEAU; RETIRE; HESITANCY; TIME	One of the most efficient methods to control the high infection rate of the coronavirus disease 2019 (COVID-19) is to have a high coverage of COVID-19 vaccination worldwide. Therefore, it is important to understand individuals' intention to get COVID-19 vaccinated. The present study applied the Theory of Planned Behavior (TPB) to explain the intention to get COVID-19 vaccinated among a representative sample in Qazvin, Iran. The TPB uses psychological constructs of attitude, subjective norm, and perceived behavioral control to explain an individual's intention to perform a behavior. Fear and perceived infectability were additionally incorporated into the TPB to explain the intention to get COVID-19 vaccinated. Utilizing multistage stratified cluster sampling, 10,843 participants (4092 males; 37.7%) with a mean age of 35.54 years (SD = 12.00) completed a survey. The survey assessed TPB constructs (including attitude, subjective norm, perceived behavioral control, and intention related to COVID-19 vaccination) together with fear of COVID-19 and perceived COVID-19 infectability. Structural equation modeling (SEM) was performed to examine whether fear of COVID-19, perceived infectability, and the TPB constructs explained individuals' intention to get COVID-19 vaccinated. The SEM demonstrated satisfactory fit (comparative fit index = 0.970; Tucker-Lewis index = 0.962; root mean square error of approximation = 0.040; standardized root mean square residual = 0.050). Moreover, perceived behavioral control, subjective norm, attitude, and perceived COVID-19 infectability significantly explained individuals' intention to get COVID-19 vaccinated. Perceived COVID-19 infectability and TPB constructs were all significant mediators in the relationship between fear of COVID-19 and intention to get COVID-19 vaccinated. Incorporating fear of COVID-19 and perceived COVID-19 infectability effectively into the TPB explained Iranians' intention to get COVID-19 vaccinated. Therefore, Iranians who have a strong belief in Muslim religion may improve their intention to get COVID-19 vaccinated via these constructs.	[Yahaghi, Rafat; Ahmadizade, Safie; Fotuhi, Razie; Taherkhani, Elham; Ranjbaran, Mehdi; Buchali, Zeinab; Jafari, Robabe; Zamani, Narges; Shahbazkhania, Azam; Simiari, Hengame; Rahmani, Jalal; Yazdi, Nahid; Alijani, Hashem; Poorzolfaghar, Leila; Rajabi, Fatemeh; Pakpour, Amir H.] Qazvin Univ Med Sci, Social Determinants Hlth Res Ctr, Res Inst Prevent Noncommunicable Dis, Qazvin 3419759811, Iran; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 70101, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 70101, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan; [Brostrom, Anders; Pakpour, Amir H.] Jonkoping Univ, Sch Hlth & Welf, Dept Nursing, SE-55111 Jonkoping, Sweden; [Brostrom, Anders] Linkoping Univ Hosp, Dept Clin Neurophysiol, SE-58183 Linkoping, Sweden; [Griffiths, Mark D.] Nottingham Trent Univ, Psychol Dept, Int Gaming Res Unit, Nottingham NG1 4FQ, England		Pakpour, AH (通讯作者)，Qazvin Univ Med Sci, Social Determinants Hlth Res Ctr, Res Inst Prevent Noncommunicable Dis, Qazvin 3419759811, Iran.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 70101, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 70101, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan.; Pakpour, AH (通讯作者)，Jonkoping Univ, Sch Hlth & Welf, Dept Nursing, SE-55111 Jonkoping, Sweden.	yahaghirafat@yahoo.com; ahmadizadehn@yahoo.com; m.r.a.mafi@gmail.com; Etaherkhani.mid1@gmail.com; mehdiranjbaran90@yahoo.com; bochalizeinab@gmail.com; ro.midewife@yahoo.com; Zamani.ee@gmail.com; Aazam.shahbazkhani@gmail.com; Hengame.Simiari@gmail.com; Jrahmani49@gmail.com; n.yazdi@qums.ac.ir; hs.alijani@gmail.com; Poorzolfaghar6565@gmail.com; Fatemeh_rajabi85@yahoo.com; cylin36933@gmail.com; anders.brostrom@ju.se; mark.griffiths@ntu.ac.uk; pakpour_amir@yahoo.com	Lin, Chung-Ying/I-5434-2016; Griffiths, Mark D./AAY-3546-2021; Pakpour, Amir H./C-6160-2014; Ranjbaran, Mehdi/D-5060-2016	Lin, Chung-Ying/0000-0002-2129-4242; Griffiths, Mark D./0000-0001-8880-6524; Pakpour, Amir H./0000-0002-8798-5345; Ranjbaran, Mehdi/0000-0002-0313-3373	Higher Education Sprout Project, Ministry of Education	The APC was funded by Higher Education Sprout Project, Ministry of Education to the Headquarters of University Advancement at National Cheng Kung University (NCKU).	Adeli O.A., 2021, J IRAN I HLTH SCI RE, V20, P1; Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I, 2015, HEALTH PSYCHOL REV, V9, P131, DOI 10.1080/17437199.2014.883474; [Anonymous], 2021, DRAFT LANDSCAPE COVI; Armitage CJ, 2015, HEALTH PSYCHOL REV, V9, P151, DOI 10.1080/17437199.2014.892148; Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Catalano HP, 2017, J AM COLL HEALTH, V65, P197, DOI 10.1080/07448481.2016.1269771; Chang KC, 2022, INT J MENT HEALTH AD, V20, P324, DOI 10.1007/s11469-020-00361-6; Conner M, 2015, HEALTH PSYCHOL REV, V9, P141, DOI 10.1080/17437199.2014.899060; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Crayne MP, 2020, PSYCHOL TRAUMA-US, V12, pS180, DOI 10.1037/tra0000852; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Hagger MS, 2021, PSYCHOL HEALTH, V36, P307, DOI 10.1080/08870446.2020.1784420; Hotez P, 2019, PEDIATR RES, V85, P912, DOI 10.1038/s41390-019-0354-3; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Lin CY, 2021, NURS OPEN, V8, P1892, DOI 10.1002/nop2.855; Ling M, 2019, SOC SCI MED, V233, P87, DOI 10.1016/j.socscimed.2019.06.002; McIntyre RS, 2020, WORLD PSYCHIATRY, V19, P250, DOI 10.1002/wps.20767; Ogden J, 2015, HEALTH PSYCHOL REV, V9, P165, DOI 10.1080/17437199.2014.898679; Oksanen Atte, 2020, JMIR Public Health Surveill, V6, pe19218, DOI 10.2196/19218; Prestwich A, 2015, CURR OPIN PSYCHOL, V5, P1, DOI 10.1016/j.copsyc.2015.02.011; Qiao Shan, 2020, medRxiv, DOI 10.1101/2020.11.26.20239483; Rich A, 2015, J BEHAV MED, V38, P673, DOI 10.1007/s10865-015-9644-3; Rogers R.W., 1983, SOCIAL PSYCHOPHYSIOL, P153; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; ROSENSTOCK IM, 1966, MILBANK FUND Q, V44, P94, DOI 10.2307/3348967; Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Sniehotta FF, 2014, HEALTH PSYCHOL REV, V8, P1, DOI 10.1080/17437199.2013.869710; Sturman D, 2021, HEALTH PROMOT J AUST, V32, P344, DOI 10.1002/hpja.443; Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212; Trogen B, 2020, JAMA-J AM MED ASSOC, V323, P2460, DOI 10.1001/jama.2020.8917; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wu AMS, 2020, J INFECT PUBLIC HEAL, V13, P970, DOI 10.1016/j.jiph.2020.04.009; Xiao XZ, 2020, VACCINE, V38, P5131, DOI 10.1016/j.vaccine.2020.04.076; Zhang KC, 2021, J MED INTERNET RES, V23, DOI 10.2196/24673	41	20	20	16	23	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							684	10.3390/vaccines9070684			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8KP	34206226	Green Published, Green Accepted, gold			2022-04-29	WOS:000677153400001
J	Dunagan, MM; Hardy, K; Takimoto, T				Dunagan, Megan M.; Hardy, Kala; Takimoto, Toru			Impact of Influenza A Virus Shutoff Proteins on Host Immune Responses	VACCINES			English	Article						influenza A virus; host shutoff; NS1; PA-X	RESPIRATORY SYNCYTIAL VIRUS; PA-X; T-CELLS; TERMINAL DOMAIN; NS1 PROTEIN; IDENTIFICATION; SUPPRESSION; INFECTION; REGION; MEMORY	Influenza A virus (IAV) is a significant human pathogen that causes seasonal epidemics. Although various types of vaccines are available, IAVs still circulate among human populations, possibly due to their ability to circumvent host immune responses. IAV expresses two host shutoff proteins, PA-X and NS1, which antagonize the host innate immune response. By transcriptomic analysis, we previously showed that PA-X is a major contributor for general shutoff, while shutoff active NS1 specifically inhibits the expression of host cytokines, MHC molecules, and genes involved in innate immunity in cultured human cells. So far, the impact of these shutoff proteins in the acquired immune response in vivo has not been determined in detail. In this study, we analyzed the effects of PA-X and NS1 shutoff activities on immune response using recombinant influenza A/California/04/2009 viruses containing mutations affecting the expression of shutoff active PA-X and NS1 in a mouse model. Our data indicate that the virus without shutoff activities induced the strongest T and B cell responses. Both PA-X and NS1 reduced host immune responses, but shutoff active NS1 most effectively suppressed lymphocyte migration to the lungs, antibody production, and the generation of IAV specific CD4(+) and CD8(+) T cells. NS1 also prevented the generation of protective immunity against a heterologous virus challenge. These data indicate that shutoff active NS1 plays a major role in suppressing host immune responses against IAV infection.	[Dunagan, Megan M.; Hardy, Kala; Takimoto, Toru] Univ Rochester, Dept Microbiol & Immunol, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA		Takimoto, T (通讯作者)，Univ Rochester, Dept Microbiol & Immunol, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.	Megan_Dunagan@urmc.rochester.edu; Kala_Harbaugh@urmc.rochester.edu; Toru_Takimoto@urmc.rochester.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI129988]	This research was funded by National Institute of Health through Grant number R01AI129988.	Alam S, 2014, J VIROL, V88, P314, DOI 10.1128/JVI.02077-13; Atkin-Smith GK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1035-6; Bavagnoli L, 2015, NUCLEIC ACIDS RES, V43, P9405, DOI 10.1093/nar/gkv926; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Chaimayo C, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007465; Christiaansen A, 2015, CURR OPIN IMMUNOL, V36, P54, DOI 10.1016/j.coi.2015.06.012; Das K, 2008, P NATL ACAD SCI USA, V105, P13093, DOI 10.1073/pnas.0805213105; Desmet EA, 2013, J VIROL, V87, P3108, DOI 10.1128/JVI.02826-12; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Hale BG, 2010, J VIROL, V84, P6909, DOI 10.1128/JVI.00081-10; Hayashi T, 2016, J VIROL, V90, P7131, DOI 10.1128/JVI.00954-16; Hayashi T, 2015, J VIROL, V89, P6442, DOI 10.1128/JVI.00319-15; Jagger BW, 2012, SCIENCE, V337, P199, DOI 10.1126/science.1222213; Khaperskyy DA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005427; Kurosaki T, 2015, NAT REV IMMUNOL, V15, P149, DOI 10.1038/nri3802; Lamichhane PP, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8028725; Mitra S, 2019, J VIROL, V93, DOI 10.1128/JVI.00917-19; Nayak JL, 2010, VIRAL IMMUNOL, V23, P169, DOI 10.1089/vim.2009.0099; Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Nogales A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120708; Oishi K, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00432; Oishi K, 2015, J VIROL, V89, P8661, DOI 10.1128/JVI.01132-15; Ostler T, 2002, EUR J IMMUNOL, V32, P2117, DOI 10.1002/1521-4141(200208)32:8<2117::AID-IMMU2117>3.0.CO;2-C; Padilla-Quirarte HO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01677; Prevention CfDCa, DIS BURD INFL; REED L. J., 1938, AMER JOUR HYG, V27, P493; Shah HB, 2015, METHODS MOL BIOL, V1312, P419, DOI 10.1007/978-1-4939-2694-7_42; Sun F, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2287; Twu KY, 2007, J VIROL, V81, P8112, DOI 10.1128/JVI.00006-07; Van Hoecke L, 2017, JOVE-J VIS EXP, DOI 10.3791/55398; Viant C, 2020, CELL, V183, P1298, DOI 10.1016/j.cell.2020.09.063; Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655; Wang J, 2018, CELL TISSUE RES, V371, P531, DOI 10.1007/s00441-017-2785-7	35	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							629	10.3390/vaccines9060629			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4ET	34200539	gold, Green Published			2022-04-29	WOS:000666521100001
J	Komla, E; Torres, OB; Jalah, R; Sulima, A; Beck, Z; Alving, CR; Jacobson, AE; Rice, KC; Matyas, GR				Komla, Essie; Torres, Oscar B.; Jalah, Rashmi; Sulima, Agnieszka; Beck, Zoltan; Alving, Carl R.; Jacobson, Arthur E.; Rice, Kenner C.; Matyas, Gary R.			Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice	VACCINES			English	Article						heroin vaccine; vaccine efficacy; conjugate vaccine; tetanus toxoid; preexisting immunity	INDUCED EPITOPIC SUPPRESSION; INVOLVED OVERDOSE DEATHS; CARRIER PROTEIN; ANTIBODY-RESPONSES; UNITED-STATES; CRM197; IMMUNOGENICITY; DIPHTHERIA; HAPTEN; IMMUNIZATION	Opioid use disorder (OUD) is a serious health problem that has dramatically increased over the last decade. Although current therapies for the management of OUD can be effective, they have limitations. The complementary strategy to combat the opioid crisis is the development of a conjugate vaccine to generate high affinity antibodies in order to neutralize opioids in circulation before reaching the brain. The components of an opioid vaccine include an opioid hapten (6-AmHap) that is conjugated to a carrier protein (tetanus toxoid) with the addition of adjuvants (Army Liposome Formulation adsorbed to aluminum hydroxide-ALFA). There is no consensus in the literature as to whether preexisting immunity to the carrier protein may impact the immunogenicity of the conjugate vaccine by inducing an enhanced or suppressed immune response to the hapten. Here, we investigated whether pre-exposure to tetanus toxoid would affect the immunogenicity and efficacy of the heroin vaccine, TT-6-AmHap. Mice were primed with diphtheria, tetanus, and acellular pertussis (DTaP) vaccine at weeks -4 and -2, then immunized with TT-6-AmHap vaccine at weeks 0, 3, and 6. Using ELISA and behavioral assays, we found that preexisting immunity to tetanus toxoid had no influence on the immunogenicity and efficacy of the TT-6-AmHap vaccine.	[Komla, Essie; Torres, Oscar B.; Jalah, Rashmi; Beck, Zoltan; Alving, Carl R.; Matyas, Gary R.] Walter Reed Army Inst Res, Lab Adjuvant & Antigen Res, US Mil HIV Res Program, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Komla, Essie; Torres, Oscar B.; Jalah, Rashmi; Beck, Zoltan] Henry M Jackson Fdn Adv Mil Med, US Mil HIV Res Program, 6720A Rockledge Dr, Bethesda, MD 20817 USA; [Sulima, Agnieszka; Jacobson, Arthur E.; Rice, Kenner C.] NIDA, Drug Design & Synth Sect, Mol Targets & Medicat Discovery Branch, Intramural Res Program,US Dept HHS,NIH, 9800 Med Ctr Dr, Bethesda, MD 20892 USA; [Sulima, Agnieszka; Jacobson, Arthur E.; Rice, Kenner C.] NIAAA, NIH, 9800 Med Ctr Dr, Bethesda, MD 20892 USA		Matyas, GR (通讯作者)，Walter Reed Army Inst Res, Lab Adjuvant & Antigen Res, US Mil HIV Res Program, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	ekomla@hivresearch.org; oscarbuenatorres@gmail.com; rjalah@gmail.com; agnieszka.sulima@nih.gov; zoltan.beck@gmail.com; calving@hivresearch.org; arthurj@nida.nih.gov; kennerr@mail.nih.gov; gmatyas@hivresearch.org		Matyas, Gary/0000-0002-2074-2373	National Institute on Drug Abuse (NIDA) of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [UG3DA048351]; NIDA (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1DP1DA034787-01]; Henry M. Jackson Foundation for the Advancement of Military Medicine [W81XWH-07-2-067]; U.S. Army Medical Research and Development Command (MRDC) [W81XWH-07-2-067]; NIH Intramural Research Program (IRP) of the National Institute on Drug Abuse; NIH Intramural Research Program (IRP) of National Institute of Alcohol Abuse and Alcoholism	The research reported in this publication was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number UG3DA048351 and by an Avant-Garde award to G.R.M. from NIDA (NIH grant no. 1DP1DA034787-01). The work of G.R.M., Z.B., O.B.T., C.R.A., E.K., and R.J. was supported through a Cooperative Agreement Award (no. W81XWH-07-2-067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Army Medical Research and Development Command (MRDC). The work of A.S., A.E.J., and K.C.R. was supported by the NIH Intramural Research Program (IRP) of the National Institute on Drug Abuse and the National Institute of Alcohol Abuse and Alcoholism.	Bannon Anthony W, 2007, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0809s41; BARINGTON T, 1991, INFECT IMMUN, V59, P1057, DOI 10.1128/IAI.59.3.1057-1064.1991; BARINGTON T, 1993, INFECT IMMUN, V61, P432, DOI 10.1128/IAI.61.2.432-438.1993; Ben-Yedidia T, 1998, IMMUNOL LETT, V64, P9, DOI 10.1016/S0165-2478(98)00073-X; Booy R, 1997, LANCET, V349, P1197, DOI 10.1016/S0140-6736(96)06392-1; Dagan R, 1998, INFECT IMMUN, V66, P2093, DOI 10.1128/IAI.66.5.2093-2098.1998; Jalah R, 2015, BIOCONJUGATE CHEM, V26, P1041, DOI 10.1021/acs.bioconjchem.5b00085; Jegerlehner A, 2010, VACCINE, V28, P5503, DOI 10.1016/j.vaccine.2010.02.103; Knuf M, 2011, VACCINE, V29, P4881, DOI 10.1016/j.vaccine.2011.04.053; Lee LH, 2012, CLIN VACCINE IMMUNOL, V19, P551, DOI 10.1128/CVI.05438-11; LIEBERMAN JM, 1995, J PEDIATR-US, V126, P198, DOI 10.1016/S0022-3476(95)70545-7; Matyas GR, 2003, METHOD ENZYMOL, V373, P34; Matyas GR, 2014, VACCINE, V32, P1473, DOI 10.1016/j.vaccine.2014.01.028; McCluskie MJ, 2016, IMMUNOPHARM IMMUNOT, V38, P184, DOI 10.3109/08923973.2016.1165246; Pecetta S, 2016, VACCINE, V34, P2334, DOI 10.1016/j.vaccine.2016.03.055; Pecetta S, 2015, VACCINE, V33, P314, DOI 10.1016/j.vaccine.2014.11.026; PEETERS CCAM, 1991, INFECT IMMUN, V59, P3504, DOI 10.1128/IAI.59.10.3504-3510.1991; Pobre K, 2014, VACCINE, V32, P1423, DOI 10.1016/j.vaccine.2014.01.047; Pollabauer EM, 2009, VACCINE, V27, P1674, DOI 10.1016/j.vaccine.2009.01.005; Rollier CS, 2011, CURR OPIN IMMUNOL, V23, P377, DOI 10.1016/j.coi.2011.03.006; Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; SCHUTZE MP, 1989, J IMMUNOL, V142, P2635; SCHUTZE MP, 1985, J IMMUNOL, V135, P2319; Sevil Domenech VE, 2007, MICROBES INFECT, V9, P1447, DOI 10.1016/j.micinf.2007.07.010; Sulima A, 2018, J MED CHEM, V61, P329, DOI 10.1021/acs.jmedchem.7b01427; Tontini M, 2013, VACCINE, V31, P4827, DOI 10.1016/j.vaccine.2013.07.078; Torres OB, 2014, ANAL BIOANAL CHEM, V406, P5927, DOI 10.1007/s00216-014-8035-x; Volkow ND, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan2595; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4; Zhang TT, 2015, VACCINE, V33, P3208, DOI 10.1016/j.vaccine.2015.04.094	31	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							573	10.3390/vaccines9060573			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7CV	34205869	gold, Green Published			2022-04-29	WOS:000666719400001
J	Park, SH; Lee, SY; Kim, JS; Kim, AY; Park, SY; Lee, JH; Lee, M; Kim, H; Lee, SI; Kang, NY; Park, JW; Kim, SM; Park, JH; Ko, YJ				Park, Sang-Hyun; Lee, Seo-Yong; Kim, Jae-Seok; Kim, Ah-Young; Park, Sun-Young; Lee, Ji-Hye; Lee, Mijung; Kim, Hyejin; Lee, Sim-In; Kang, Na-Young; Park, Jung-Won; Kim, Su-Mi; Park, Jong-Hyeon; Ko, Young-Joon			Scale-Up Production of Type O and A Foot-and-Mouth Disease Bivalent Vaccine and Its Protective Efficacy in Pigs	VACCINES			English	Article						FMD; foot-and-mouth disease; scale-up; bivalent vaccine; protective efficacy	HETEROLOGOUS CHALLENGE; IMMUNE-RESPONSES; SOUTHEAST-ASIA; EAST-ASIA; VIRUS	South Korea has experienced FMD outbreaks almost every year since 2014. Therefore, a novel local vaccine that can cover various topotypes of viruses is required. Two virus strains, O/Boeun/SKR/2017 and A/Yeoncheon/SKR/2017, were cultured up to the pilot scale based on the optimized conditions set up on the flask scale. FMDV particles (146S) of 2 mu g/mL or more were obtained from the virus culture supernatant using a 100 L bioreactor. The viruses were fully inactivated using binary ethylenimine within 16 h through two inactivation cycles and mixed with an adjuvant into a bivalent vaccine (types O and A) consisting of 15 mu g viruses per strain. The experimental bivalent vaccine showed a broad spectrum of high neutralizing antibody titers against heterologous viruses, including type O Cathay strain and type A Asia topotypes, except for GVII. The 50% protective dose was determined as 12.5 for O/Boeun/SKR/2017 and 15.6 for A/Yeoncheon/SKR/2017. Collectively, we expect that the bivalent vaccine could protect against FMDV types O and A circulating in South Korea and neighboring countries. To our knowledge, this is the first report demonstrating that the vaccine strains could be successfully scaled-up to a 100 L bioreactor, with the determination of its protective efficacy in pigs.	[Park, Sang-Hyun; Kim, Jae-Seok; Kim, Ah-Young; Park, Sun-Young; Kim, Hyejin; Lee, Sim-In; Kang, Na-Young; Park, Jung-Won; Kim, Su-Mi; Park, Jong-Hyeon; Ko, Young-Joon] Anim & Plant Quarantine Agcy, 177 Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea; [Lee, Seo-Yong; Lee, Ji-Hye; Lee, Mijung] FVC Vaccine Co, Res Unit, 521,5,Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea		Ko, YJ (通讯作者)，Anim & Plant Quarantine Agcy, 177 Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea.	shpark0205@korea.kr; sylee@gcfvc.com; silveryfox2@naver.com; mochsha@korea.kr; sun3730@korea.kr; jhlee@gcfvc.com; mjlee@gcfvc.com; hyejin86@korea.kr; lunark2@korea.kr; shdud9111@naver.com; parkjw6254@korea.kr; beliefsk@korea.kr; parkjhvet@korea.kr; koyoungjoon@korea.kr		KO, YOUNGJOON/0000-0002-3436-8175; Kim, Su-Mi/0000-0002-9242-2731; Kim, Ah-Young/0000-0003-0600-1816; Park, Jong-Hyeon/0000-0003-0825-8121	Animal and Plant Quarantine Agency, Republic of Korea [M-1543386-2020-22-01]	This research was funded by the Animal and Plant Quarantine Agency, Republic of Korea, grant number M-1543386-2020-22-01.	Aarthi D, 2004, BIOLOGICALS, V32, P153, DOI 10.1016/j.biologicals.2004.09.001; Alves MP, 2009, CLIN VACCINE IMMUNOL, V16, P1151, DOI 10.1128/CVI.00018-09; BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879; Blacksell SD, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268819000578, 10.1017/s0950268819000578]; Brito B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24870-6; Dekker A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010024; DOEL TR, 1981, ARCH VIROL, V70, P21, DOI 10.1007/BF01320790; Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7; Domingo E, 2002, COMP IMMUNOL MICROB, V25, P297, DOI 10.1016/S0147-9571(02)00027-9; Gallo-Ramirez LE, 2015, EXPERT REV VACCINES, V14, P1181, DOI 10.1586/14760584.2015.1067144; Genzel Y, 2014, VACCINE, V32, P2770, DOI 10.1016/j.vaccine.2014.02.016; Horsington J, 2015, VACCINE, V33, P422, DOI 10.1016/j.vaccine.2014.11.043; International Committee Biological Standards Commission International Office of Epizootics, 2018, Manual of Diagnostic Tests and Vaccines for Terrestrial Animals: Mammals, Birds, and Bees, P433; Jamal SM, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-116; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Kim AY, 2021, J APPL MICROBIOL, V131, P1113, DOI 10.1111/jam.15024; Ko EY, 2018, KOREAN J FOOD SCI AN, V38, P498, DOI 10.5851/kosfa.2018.38.3.498; Lee G, 2020, ANTIVIR RES, V182, DOI 10.1016/j.antiviral.2020.104920; Lee SY, 2017, J VIROL, V91, DOI [10.1128/JVI.00155-17, 10.1128/jvi.00155-17]; Li XR, 2019, VACCINE, V37, P6380, DOI 10.1016/j.vaccine.2019.09.013; Lyons NA, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00102; Mahapatra M, 2018, EXPERT REV VACCINES, V17, P577, DOI 10.1080/14760584.2018.1492378; Mahapatra M, 2017, VACCINE, V35, P7147, DOI 10.1016/j.vaccine.2017.10.099; Park JN, 2014, VACCINE, V32, P1882, DOI 10.1016/j.vaccine.2014.01.067; Park ME, 2017, J VET SCI, V18, P323, DOI [10.4142/jvs.2017.18.S1.323, 10.4142/jvs.2017.18.s1.323]; Singanallur NB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010080; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; Vierra D, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.01315-19	28	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							586	10.3390/vaccines9060586			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7BU	34199359	gold, Green Published			2022-04-29	WOS:000666716700001
J	Sousa, SA; Seixas, AMM; Marques, JMM; Leitao, JH				Sousa, Silvia A.; Seixas, Antonio M. M.; Marques, Joana M. M.; Leitao, Jorge H.			Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections	VACCINES			English	Review						Pseudomonas aeruginosa; Burkholderia cepacia complex; active immunization; passive immunotherapy; nosocomial infections; cystic fibrosis	OUTER-MEMBRANE PROTEINS; ANTIBIOTIC-RESISTANT BACTERIA; CYSTIC-FIBROSIS PATIENTS; ANTI-PCRV ANTIBODY; ANTIMICROBIAL SUSCEPTIBILITY; HOST INTERACTIONS; YOLK ANTIBODIES; DOUBLE-BLIND; VACCINE; CENOCEPACIA	Human infections caused by the opportunist pathogens Burkholderia cepacia complex and Pseudomonas aeruginosa are of particular concern due to their severity, their multiple antibiotic resistance, and the limited eradication efficiency of the current available treatments. New therapeutic options have been pursued, being vaccination strategies to prevent or limit these infections as a rational approach to tackle these infections. In this review, immunization and immunotherapy approaches currently available and under study against these bacterial pathogens is reviewed. Ongoing active and passive immunization clinical trials against P. aeruginosa infections is also reviewed. Novel identified bacterial targets and their possible exploitation for the development of immunization and immunotherapy strategies against P. aeruginosa and B. cepacia complex and infections are also presented and discussed.	[Sousa, Silvia A.; Seixas, Antonio M. M.; Marques, Joana M. M.; Leitao, Jorge H.] Univ Lisbon, Inst Super Tecn, IBB Inst Bioengn & Biosci, Dept Bioengn, Av Rovisco Pais, P-1049001 Lisbon, Portugal; [Sousa, Silvia A.; Seixas, Antonio M. M.; Leitao, Jorge H.] Univ Lisbon, Inst Super Tecn, i4HB Inst Hlth & Bioecon, Associate Lab, Av Rovisco Pais, P-1049001 Lisbon, Portugal		Sousa, SA; Leitao, JH (通讯作者)，Univ Lisbon, Inst Super Tecn, IBB Inst Bioengn & Biosci, Dept Bioengn, Av Rovisco Pais, P-1049001 Lisbon, Portugal.; Sousa, SA; Leitao, JH (通讯作者)，Univ Lisbon, Inst Super Tecn, i4HB Inst Hlth & Bioecon, Associate Lab, Av Rovisco Pais, P-1049001 Lisbon, Portugal.	sousasilvia@tecnico.ulisboa.pt; antonio.seixas@tecnico.ulisboa.pt; joanammmarques@tecnico.ulisboa.pt; jorgeleitao@tecnico.ulisboa.pt	Leitão, Jorge Humberto Gomes/A-5122-2012; Sousa, Silvia A/G-8502-2011; Seixas, Antonio/L-6651-2018	Leitão, Jorge Humberto Gomes/0000-0001-8850-274X; Sousa, Silvia A/0000-0001-9291-9169; Monteiro Marques, Joana/0000-0001-8944-3235; Seixas, Antonio/0000-0002-3484-3474	iBB-Institute for Bioengineering and Biosciences from Fundacao para a Ciencia e a Tecnologia (FCT) [UIDB/04565/2020]	The authors acknowledge financial support from the iBB-Institute for Bioengineering and Biosciences through project UIDB/04565/2020 from Fundacao para a Ciencia e a Tecnologia (FCT).	Adlbrecht C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2792-z; Ali SO, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.08.004; [Anonymous], EUDRACT NUMBER 2011; Baker SM, 2020, HUM VACC IMMUNOTHER, V16, P412, DOI 10.1080/21645515.2019.1650999; Bassetti Matteo, 2018, Drugs Context, V7, P212527, DOI 10.7573/dic.212527; Bazzini S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018902; Bertot GM, 2007, INFECT IMMUN, V75, P2740, DOI 10.1128/IAI.01668-06; Callaghan M, 2012, CURR OPIN MICROBIOL, V15, P71, DOI 10.1016/j.mib.2011.11.001; Campodonico VL, 2010, INFECT IMMUN, V78, P746, DOI 10.1128/IAI.00806-09; Carlander D, 2000, IMMUNOL RES, V21, P1, DOI 10.1385/IR:21:1:1; Cassin EK, 2019, J BACTERIOL, V201, DOI 10.1128/JB.00050-19; Chan YY, 2005, J BACTERIOL, V187, P4707, DOI 10.1128/JB.187.14.4707-4719.2005; Choh LC, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00005; Chu KK, 2002, INFECT IMMUN, V70, P2715, DOI 10.1128/IAI.70.5.2715-2720.2002; Coombes BK, 2004, CURR BIOL, V14, pR856, DOI 10.1016/j.cub.2004.09.043; COUTINHO A, 1974, J EXP MED, V139, P74, DOI 10.1084/jem.139.1.74; Cripps AW, 2006, INFECT IMMUN, V74, P968, DOI 10.1128/IAI.74.2.968-974.2006; Darwin AJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003388; DEGROOT R, 1987, CLIN PHARMACOKINET, V13, P228, DOI 10.2165/00003088-198713040-00002; Depoorter E, 2016, APPL MICROBIOL BIOT, V100, P5215, DOI 10.1007/s00253-016-7520-x; DiGiandomenico A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009655; Doring G, 2008, VACCINE, V26, P1011, DOI 10.1016/j.vaccine.2007.12.007; Doring G, 2007, P NATL ACAD SCI USA, V104, P11020, DOI 10.1073/pnas.0702403104; Duvall M, 2011, MABS-AUSTIN, V3, P203, DOI 10.4161/mabs.3.2.14774; El Zowalaty ME, 2015, FUTURE MICROBIOL, V10, P1683, DOI 10.2217/fmb.15.48; European Centre for Disease Prevention and Control, 2020, ANTIMICROBIAL RESIST; Festini F, 2006, J HOSP INFECT, V64, P1, DOI 10.1016/j.jhin.2006.02.021; Francois B, 2012, CRIT CARE MED, V40, P2320, DOI 10.1097/CCM.0b013e31825334f6; Garcia-Quintanilla M, 2016, TRENDS PHARMACOL SCI, V37, P143, DOI 10.1016/j.tips.2015.10.003; Garduno RA, 1998, INFECT IMMUN, V66, P4602; Gautam V, 2015, EXPERT REV ANTI-INFE, V13, P629, DOI 10.1586/14787210.2015.1025056; Gellatly SL, 2013, PATHOG DIS, V67, P159, DOI 10.1111/2049-632X.12033; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Gilchrist FJ, 2012, J CYST FIBROS, V11, P458, DOI 10.1016/j.jcf.2012.04.002; Gong Q, 2018, POULTRY SCI, V97, P4219, DOI 10.3382/ps/pey307; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; Harding SV, 2007, VACCINE, V25, P2664, DOI 10.1016/j.vaccine.2006.12.006; HATANO K, 1994, INFECT IMMUN, V62, P3608, DOI 10.1128/IAI.62.9.3608-3616.1994; Hewer SCL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004197.pub5; Horcajada JP, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00031-19; Horsley A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009529.pub3; Jain M, 2004, J CLIN MICROBIOL, V42, P5229, DOI 10.1128/JCM.42.11.5229-5237.2004; Jain R, 2018, J CYST FIBROS, V17, P484, DOI 10.1016/j.jcf.2017.12.006; Johansen HK, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001399.pub4; Jones AM, 2004, THORAX, V59, P948, DOI 10.1136/thx.2003.017210; Kamei A, 2011, INFECT IMMUN, V79, P1289, DOI 10.1128/IAI.01139-10; Keyt BA, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040053; Khan MN, 2009, FEMS IMMUNOL MED MIC, V56, P56, DOI 10.1111/j.1574-695X.2009.00548.x; Kim DK, 2000, VACCINE, V19, P1274, DOI 10.1016/S0264-410X(00)00235-8; LANGFORD DT, 1984, ARCH DIS CHILD, V59, P1131, DOI 10.1136/adc.59.12.1131; Lazar H, 2009, ANTIMICROB AGENTS CH, V53, P3442, DOI 10.1128/AAC.01699-08; Leitao JH, 2008, EUR J CLIN MICROBIOL, V27, P1101, DOI 10.1007/s10096-008-0552-0; Leitao JH, 2010, APPL MICROBIOL BIOT, V87, P31, DOI 10.1007/s00253-010-2528-0; Leiva CL, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106269; LiPuma JJ, 2010, CLIN MICROBIOL REV, V23, P299, DOI 10.1128/CMR.00068-09; Loots K, 2008, VACCINE, V26, P546, DOI 10.1016/j.vaccine.2007.11.030; Luyt, 2020, OPEN FORUM INFECT DI, V7, pS377, DOI [10.1093/ofid/ofaa439.829, DOI 10.1093/OFID/OFAA439.829]; Makidon PE, 2010, MED MICROBIOL IMMUN, V199, P81, DOI 10.1007/s00430-009-0137-2; Malhotra S, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00138-18; Mariappan V, 2010, VACCINE, V28, P1318, DOI 10.1016/j.vaccine.2009.11.027; McClean S, 2016, INFECT IMMUN, V84, P1424, DOI 10.1128/IAI.01248-15; Merakou C, 2018, SURG INFECT, V19, P757, DOI 10.1089/sur.2018.233; Milla CE, 2014, PEDIATR PULM, V49, P650, DOI 10.1002/ppul.22890; Motta S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112421; MUTHARIA LM, 1982, J INFECT DIS, V146, P770, DOI 10.1093/infdis/146.6.770; Naim HY, 2013, HUM VACC IMMUNOTHER, V9, P457, DOI 10.4161/hv.23220; Nieves W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014361; Nilsson E, 2008, PEDIATR PULM, V43, P892, DOI 10.1002/ppul.20875; Nzula S, 2002, J ANTIMICROB CHEMOTH, V50, P265, DOI 10.1093/jac/dkf137; Olekhnovich IN, 2004, J BACTERIOL, V186, P3249, DOI 10.1128/JB.186.10.3249-3253.2004; Patel N, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00198; Peeters E, 2009, J ANTIMICROB CHEMOTH, V64, P801, DOI 10.1093/jac/dkp253; PENNINGTON JE, 1975, AM J MED, V58, P629, DOI 10.1016/0002-9343(75)90498-2; Vidakovics ML, 2007, J PROTEOME RES, V6, P2518, DOI 10.1021/pr060681i; Pimenta AI, 2021, CELL MICROBIOL, V23, DOI 10.1111/cmi.13340; Pradenas GA, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040033; Pradenas GA, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020010; PRANDOTA J, 1987, PEDIATR INFECT DIS J, V6, P1111; Priebe GP, 2014, EXPERT REV VACCINES, V13, P507, DOI 10.1586/14760584.2014.890053; Que YA, 2014, EUR J CLIN MICROBIOL, V33, P1861, DOI 10.1007/s10096-014-2156-1; Ragupathi NKD, 2019, ANN CLIN MICROB ANTI, V18, DOI 10.1186/s12941-019-0306-0; Regan KH, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009876.pub4; Rello J, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1601-9; Saiman L, 2014, INFECT CONT HOSP EP, V35, pS1, DOI 10.1086/676882; Sainz-Mejias M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122617; Sanchez-Campillo M, 1999, ELECTROPHORESIS, V20, P2269, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2269::AID-ELPS2269>3.0.CO;2-D; Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006-2952(03)00002-9; Scoffone VC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01592; Sfeir MM, 2018, J INFECTION, V77, P166, DOI 10.1016/j.jinf.2018.07.006; Shinoy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080796; Sinha K, 2010, MOL IMMUNOL, V48, P264, DOI 10.1016/j.molimm.2010.08.001; Skurnik D, 2012, J INFECT DIS, V205, P1709, DOI 10.1093/infdis/jis254; Sonnenberg MG, 1997, INFECT IMMUN, V65, P4515, DOI 10.1128/IAI.65.11.4515-4524.1997; Sousa SA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030509; Sousa SA, 2020, NEW BIOTECHNOL, V54, P62, DOI 10.1016/j.nbt.2019.08.006; Sousa SA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020034; Sousa SA, 2016, AMB EXPRESS, V6, DOI 10.1186/s13568-016-0212-1; Sousa Silvia A, 2011, Int J Microbiol, V2011, DOI 10.1155/2011/607575; Southern SJ, 2015, MICROBIOL-SGM, V161, P2192, DOI 10.1099/mic.0.000175; Sriramulu DD, 2005, J MED MICROBIOL, V54, P667, DOI 10.1099/jmm.0.45969-0; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Tavares M, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00139-19; Thomsen K, 2016, J CYST FIBROS, V15, P171, DOI 10.1016/j.jcf.2015.08.002; Upritchard HG, 2008, INFECT IMMUN, V76, P4624, DOI 10.1128/IAI.01707-07; Wang GB, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122671; Warrener P, 2014, ANTIMICROB AGENTS CH, V58, P4384, DOI 10.1128/AAC.02643-14; Westritschnig K, 2014, HUM VACC IMMUNOTHER, V10, P170, DOI 10.4161/hv.26565; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Wu WH, 2012, AM J RESP CRIT CARE, V186, P420, DOI 10.1164/rccm.201202-0182OC; Yang F, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01062; Zuercher AW, 2006, FEMS IMMUNOL MED MIC, V47, P302, DOI 10.1111/j.1574-695X.2006.00103.x	112	3	3	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							670	10.3390/vaccines9060670			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8BT	34207253	gold, Green Published			2022-04-29	WOS:000666107200001
J	Yoon, D; Kim, J; Shin, J				Yoon, Dongwon; Kim, Juhwan; Shin, Juyoung			Differential Demographic and Clinical Characteristics between MMR Vaccinated and Unvaccinated Children in South Korea: A Nationwide Study	VACCINES			English	Article						measles; measles-mumps-rubella vaccine; vaccine uptake; vaccine hesitancy	IMMUNIZATION COVERAGE; PARENTS; HEALTH; INFORMATION; HESITANCY; MEASLES	In the context of recent measles outbreaks, substantial factors associated with measles-mumps-rubella (MMR) unvaccination need to be clarified. This study aimed to identify differential demographic and clinical characteristics between MMR vaccinated and unvaccinated groups. We used a large-linked database to identify children born between 2008 and 2016 by combining data from the Korea Immunization Registry Information System and National Health Information database. The MMR vaccination status was ascertained up to the age of 2 to define MMR vaccinated and unvaccinated groups. We conducted a multivariate logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) to identify factors associated with MMR unvaccination. Of 3,973,253 children, 75,674 (1.9%) did not receive the MMR vaccine. Compared with the MMR vaccinated group, the underutilization of healthcare resources was more notable in the MMR unvaccinated group (number of outpatient visits (5.73 +/- 12.1 vs. 25.8 +/- 17.06); days hospitalized (1.69 +/- 14.5 vs. 2.32 +/- 6.90)). Children were less likely to receive the MMR vaccine if they were born with congenital anomaly (OR 2.12; 95% CI 1.90-2.36), were never admitted to an intensive care unit (1.88; 1.78-1.98), or never visited an emergency room (3.57; 3.53-3.72). There were substantial factors associated with MMR unvaccination, underscoring a need to optimize targeted interventions tailored to the subset of children in South Korea.	[Yoon, Dongwon; Kim, Juhwan; Shin, Juyoung] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea; [Shin, Juyoung] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Seoul 06355, South Korea		Shin, J (通讯作者)，Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.; Shin, J (通讯作者)，Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Seoul 06355, South Korea.	dwyoon09@gmail.com; napa928@hotmail.com; shin.jy@skku.edu		Yoon, Dongwon/0000-0002-9369-0789; Kim, Ju Hwan/0000-0001-7253-6515	Government-wide R&D Fund project for infectious disease research (GFID), Korea [HG18C0068]	This research was supported by Government-wide R&D Fund project for infectious disease research (GFID), Korea (grant number: HG18C0068).	Ashkenazi S, 2020, VACCINE, V38, P7292, DOI 10.1016/j.vaccine.2020.09.044; Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341; Bugvi AS, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-232; Chang K, 2019, EPIDEMIOL HEALTH, V41, DOI 10.4178/epih.e2019031; Choe YJ, 2017, J KOREAN MED SCI, V32, P1876, DOI 10.3346/jkms.2017.32.11.1876; Cui FQ, 2007, VACCINE, V25, P664, DOI 10.1016/j.vaccine.2006.08.027; Dummer TJB, 2012, CAN J PUBLIC HEALTH, V103, pE363, DOI 10.1007/BF03404442; Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538; Kim KH, 2008, EPIDEMIOL HEALTH, V30, P110, DOI 10.4178/kje.2008.30.1.110; Lam CG, 2019, SCIENCE, V363, P1182, DOI 10.1126/science.aaw4892; Lee JY, 2019, PUBLIC HLTH WKLY REP, V12, P1548; Ntenda PAM, 2019, PEDIATR NEONATOL, V60, P623, DOI 10.1016/j.pedneo.2019.03.005; Park Bomi, 2018, J Prev Med Public Health, V51, P173, DOI 10.3961/jpmph.18.063; Park E., 2017, REPORT EVALUATION VA; Patel SR, 2007, CLIN INFECT DIS, V44, P635, DOI 10.1086/511636; Pearce A, 2008, BMJ-BRIT MED J, V336, P754, DOI 10.1136/bmj.39489.590671.25; Restivo V, 2015, HUM VACC IMMUNOTHER, V11, P140, DOI 10.4161/hv.34416; Saari TN, 2003, PEDIATRICS, V112, P193, DOI 10.1542/peds.112.1.193; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253; Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243; Siwon Choi E.H.C., 2019, PUBLIC HLTH WKLY REP, V13, P2445; Taylor JA, 2002, PEDIATRICS, V110, P1110, DOI 10.1542/peds.110.6.1110; Wei FF, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-18	24	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							653	10.3390/vaccines9060653			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2YD	34203834	gold, Green Published			2022-04-29	WOS:000666436300001
J	Babicki, M; Mastalerz-Migas, A				Babicki, Mateusz; Mastalerz-Migas, Agnieszka			Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland	VACCINES			English	Article						COVID-19 vaccination; attitudes toward vaccination; COVID-19	MORTALITY; WAVE	Despite the fact that more than a year has passed since the WHO declared the pandemic, there is still no effectivetreatment of COVID-19. According to current knowledge, the only method to stop the virus from spreading is prophylactic vaccination of the population. However, to achieve herd immunity, 60-72% of the population needs to be vaccinated, which is a significant challenge for current healthcare systems. As it has already been proven, having an effective vaccine is not the same as using it. Public acceptance is essential here. The study aimed to assess the changes in the attitudes of online respondents toward vaccination against COVID-19 over time. In the research, a questionnaire designed by the author of the study was used and it was distributed via the Internet in two stages. The questionnaire included a section assessing a sociodemographic status as well as the questions, designed by the author, evaluating the willingness of the respondents to get vaccinated and their main concerns associated with it. The first stage covered the period before the commencement of the population vaccination programme in Poland, i.e., 14-27 December 2020. Then, the survey was redistributed 2 months after the vaccination programme was started, i.e., 1-19 March 2021. Participation in the study was fully anonymous, voluntary and there was a possibility to opt out at any stage of the research. A total of 2048 respondents were surveyed and 26 persons refused to be involved in the research. A total number of 2022 responses were analysed. Stage I of the research involved 22.9% of the respondents (463 persons). The questions were answered by 1559 persons (72.9%) after the survey was redistributed. Among the participants of stage II of the study, 422 (27.1%) persons have already been vaccinated against COVID-19. A comparison of the responses that were collected from both stages of the study showed a slight increase in the willingness to get vaccinated against COVID-19 over time. It turned out that women, residents of large cities, people with a higher level of education and healthcare workers showed a more favourable attitude toward vaccination. According to the results of the survey, chronic diseases do not have a significant impact on the attitude toward vaccinations (p = 0.155). As the social vaccination promotion campaign continued, a slight increase in the willingness to get vaccinated was observed. According to the survey, women, residents of large cities and those with higher education demonstrated more favourable attitudes toward getting vaccinated against COVID-19. It should be stressed that despite the passage of time and the increasing experience with the new types of vaccines against COVID-19, the percentage of people who are afraid of the complications after the vaccination has not decreased significantly and the concern related to the ineffectiveness of vaccination has dramatically increased. This demonstrates the limited effectiveness of the current information system regarding passing the knowledge on of the safety and efficiency of vaccination and it indicates a necessity to modernise it as soon as possible.	[Babicki, Mateusz; Mastalerz-Migas, Agnieszka] Wroclaw Med Univ, Dept Family Med, PL-51141 Wroclaw, Poland		Babicki, M (通讯作者)，Wroclaw Med Univ, Dept Family Med, PL-51141 Wroclaw, Poland.	ma.babicki@gmail.com; agnieszka.mastalerz-migas@umed.wroc.pl	Babicki, Mateusz/AAG-9558-2020; Mastalerz-Migas, Agnieszka/W-5453-2018	Babicki, Mateusz/0000-0002-7719-6959; Mastalerz-Migas, Agnieszka/0000-0001-6600-2760	Wroclaw Medical University [SUB.C290.21.010]	This research was founded by Wroclaw Medical University SUB.C290.21.010.	Alzoughool F, 2020, INT J RISK SAF MED, V31, P47, DOI 10.3233/JRS-201017; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], COVID 19 VACCINE AST; [Anonymous], PFIZER ORAZ BIONTECH; [Anonymous], **NON-TRADITIONAL**; [Anonymous], Ruszaja Szczepienia Osob 70+. Ponad 60% Polakow Jest Na "Tak"-Szczepienie Przeciwko COVID-19-Portal Gov.pl; [Anonymous], W Polsce Ruszyly Szczepienia Przeciw COVID-19-"To Historyczny Moment"-Szczepienie Przeciwko COVID-19-Portal Gov.pl; [Anonymous], RAPORT SZCZEPIE PRZE; [Anonymous], CORONAVIRUS COVID 19; [Anonymous], AZ Covid-19 Vaccine Is Suspended by EU Countries; [Anonymous], EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU; Babicki M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052522; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Ceulemans M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073367; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; EMA, REC 1 COVID 19 VACC; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Grech Victor, 2020, Early Hum Dev, P105259, DOI 10.1016/j.earlhumdev.2020.105259; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Mancilla-Galindo J, 2021, EXCLI J, V20, P199, DOI 10.17179/excli2021-3413; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Tian T, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/s40249-020-00786-0; World Health Organization, 2020, WHO DIRECTOR GEN OPE; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	29	17	17	1	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							503	10.3390/vaccines9050503			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1UX	34068054	Green Published, gold			2022-04-29	WOS:000654612200001
J	Cannovo, N; Scendoni, R; Fede, MM; Siotto, F; Fedeli, P; Cingolani, M				Cannovo, Nunzia; Scendoni, Roberto; Fede, Marzia Maria; Siotto, Federico; Fedeli, Piergiorgio; Cingolani, Mariano			Nursing Home and Vaccination Consent: The Italian Perspective	VACCINES			English	Article						Covid-19 vaccination; elderly vaccination; informed consent to vaccination; capacity to consent	SUPPORTED DECISION-MAKING; SARS-COV-2 INFECTION; COVID-19 VACCINE; COMPETENCE; DEMENTIA	Since the beginning of the Covid-19 pandemic, many countries have begun vaccination campaigns, with different methods and timelines, with the goal of vaccinating over 75% of the population and thus achieving herd immunity. Initially it was necessary to identity the categories of citizens who should be the first to receive the vaccines, on the basis of scientific evidence. On the basis of this information, elderly residents in nursing homes and the staff who care for them should be the highest priority subjects for vaccination. In this context, obtaining informed consent to Covid-19 vaccination presents a considerable challenge, as the advanced age and frequent comorbidities of a significant number of the residents may mean that they are incapable of expressing consent themselves. The legislation of various Western nations substantially agrees on the general principle that those capable of judgement must be asked for their consent for healthcare services, and that even those with psychological weaknesses that limit their full ability to decide must be involved in these decision-making processes. The article can help systematize the processes to be implemented to protect the health of individuals as members of a close and fragile community.	[Cannovo, Nunzia] Federico II Univ Eth Comm, I-80131 Naples, Italy; [Scendoni, Roberto; Fede, Marzia Maria; Cingolani, Mariano] Macerata Univ, Legal Med Sect, Dept Law, I-62100 Macerata, Italy; [Siotto, Federico] Camerino Univ, Sch Law, Labour Law, I-62032 Camerino, Italy; [Fedeli, Piergiorgio] Camerino Univ, Sch Law, Legal Med, I-62032 Camerino, Italy		Cingolani, M (通讯作者)，Macerata Univ, Legal Med Sect, Dept Law, I-62100 Macerata, Italy.	nunzia.cannovo@gmail.com; roberto.scendoni@gmail.com; marziamaria.fede@gmail.com; federico.siotto@unicam.it; piergiorgio.fedeli@unicam.it; mariano.cingolani@unimc.it	Cingolani, Mariano/AFY-4601-2022; Cingolani, Mariano/Q-8492-2019	Cingolani, Mariano/0000-0003-1916-1819; , Roberto Scendoni/0000-0003-1910-2405; FEDELI, Piergiorgio/0000-0003-2287-2582			Alvaro LC, 2012, NEUROLOGIA, V27, P290, DOI 10.1016/j.nrl.2011.12.005; [Anonymous], 2021, COVID 19 VACCINATION; APPELBAUM PS, 1995, LAW HUMAN BEHAV, V19, P105, DOI 10.1007/BF01499321; Assemblea delle Nazioni Unite, CONV RIGHTS PERS DIS; Barstow C, 2018, AM FAM PHYSICIAN, V98, P40; Baumrucker SJ, 2018, AM J HOSP PALLIAT ME, V35, P908, DOI 10.1177/1049909117735308; Beattie BL, 2007, CAN J NEUROL SCI, V34, pS27, DOI 10.1017/S0317167100005527; Blanck P., 2015, INCLUSION, V3, P24, DOI [DOI 10.1352/2326-6988-3.1.24, 10.1352/2326-6988-3.1.24]; Blanck P., 2017, DISABILITY STUDIES Q, V37, DOI [10.18061/dsq.v37i1.5070, DOI 10.18061/DSQ.V37I1.5070]; Buchanan AllenE., 1989, DECIDING OTHERS ETHI; Carbajal E., NURSING HOMES STRUGG; Carroll DW, 2010, J GERONTOL NURS, V36, P47, DOI 10.3928/00989134-20100303-03; Cembrani F., 2018, PSICOGERIATRIA, V12, P1; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; D'Errico S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020110; Davidson G, 2015, INT J LAW PSYCHIAT, V38, P61, DOI 10.1016/j.ijlp.2015.01.008; Devi N, 2011, ALTER, V5, P249, DOI 10.1016/j.alter.2011.07.002; European Centre for Disease Prevention and Control, COVID 19 VACC PRIOR; European Centre for Disease Prevention and Control, KEY ASP REG INTR PRI; Gostin LO, 2021, JAMA-J AM MED ASSOC, V325, P532, DOI 10.1001/jama.2020.26553; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Graham NSN, 2020, J INFECTION, V81, P411, DOI 10.1016/j.jinf.2020.05.073; Haynes BF, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abe0948; Ingravallo F, 2020, INT J LEGAL MED, V134, P2319, DOI 10.1007/s00414-020-02368-z; Jameson JM, 2015, RES PRACT PERS SEV D, V40, P36, DOI 10.1177/1540796915586189; Jeste DV, 2018, PSYCHIATRY, V81, P28, DOI 10.1080/00332747.2017.1324697; Kim SYH, 2011, NAT REV NEUROL, V7, P410, DOI 10.1038/nrneurol.2011.76; Kim SYH, 2010, ALZHEIMERS DEMENT, V6, P342, DOI 10.1016/j.jalz.2009.06.001; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Ladhani SN, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100533; Ladhani SN, 2020, J INFECTION, V81, P621, DOI 10.1016/j.jinf.2020.07.027; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; Research Ethics during the COVID-19 Pandemics, 2020, CONSIDERATIONS OBSER; Ryan T, 2017, ANN PALLIAT MED, V6, P380, DOI 10.21037/apm.2017.06.15; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Tunzi M, 2001, AM FAM PHYSICIAN, V64, P299; Vergallo GM, 2018, PHARMACOL RES, V132, P69, DOI 10.1016/j.phrs.2018.04.001; Volpp KG, 2021, JAMA-J AM MED ASSOC, V325, P125, DOI 10.1001/jama.2020.24036; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organisation Europe, 2020, HLTH WORK RISK OLD A	43	0	0	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							429	10.3390/vaccines9050429			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1ZQ	33923367	Green Published, gold			2022-04-29	WOS:000654624500001
J	Gosset, A; Nishimwe, ML; Diallo, MY; Deroo, L; Diallo, A; Ba, E; Carrieri, PM; Sokhna, C; Vray, M; Shimakawa, Y; Boyer, S				Gosset, Andrea; Nishimwe, Marie Liberee; Diallo, Mamadou Yaya; Deroo, Lucas; Diallo, Aldiouma; Ba, El Hadji; Carrieri, Patrizia Maria; Sokhna, Cheikh; Vray, Muriel; Shimakawa, Yusuke; Boyer, Sylvie			The Costs of Introducing the Hepatitis B Birth Dose Vaccine into the National Immunization Programme in Senegal (NeoVac Study)	VACCINES			English	Article						hepatitis B vaccine; birth dose; mother-to-child transmission; costs; micro-costing; Senegal; Africa		Some African countries are still reluctant to introduce the hepatitis B vaccine birth dose (HepB-BD) into their expanded program of immunization (EPI), partly because of logistical, economic, and cost information constraints. To assist decision-makers in these countries, we assessed the economic and financial costs of HepB-BD introduction in Senegal in 2016. We performed a micro-costing study in a representative sample of Senegal's EPI sites at all levels in 2018. Information on EPI and HepB-BD activity-related inputs and costs was collected using standardized questionnaires and semi-structured interviews. Using inverse probability weighting, we computed weighted average costs associated with HepB-BD introduction for each EPI level, country-level aggregated costs and estimated costs per newborn. Economic and financial costs from a government perspective were estimated in US dollars for 2015, 2016 and 2017. Total economic costs were USD 143,364 in 2015, USD 759,406 in 2016 and USD 867,311 in 2017, while financial costs were USD 127,745, USD 82,519 and USD 29,853, respectively. When annualizing pre-introduction and initial training costs, the economic (financial) cost per vaccinated newborn was USD 2.10 (USD 0.30) in 2016 and USD 1.90 (USD 0.20) in 2017. Our estimates provide valuable information to implement HepB-BD in Sub-Saharan African countries that have not yet integrated this vaccine.	[Gosset, Andrea; Nishimwe, Marie Liberee; Diallo, Mamadou Yaya; Carrieri, Patrizia Maria; Boyer, Sylvie] Aix Marseille Univ, ISSPAM, INSERM, IRD,SESSTIM, F-13385 Marseille, France; [Deroo, Lucas; Vray, Muriel; Shimakawa, Yusuke] Inst Pasteur, Unite Epidemiol Malad Emergentes, F-75015 Paris, France; [Diallo, Aldiouma; Ba, El Hadji; Sokhna, Cheikh] VITROME, Vecteurs Infect Trop & Mediterranees, Campus IRD UCAD Hann,CP 18524, Dakar, Senegal; [Sokhna, Cheikh] Aix Marseille Univ, VITROME, IHU MI, AP HM,IRD,SSAS, F-13385 Marseille, France; [Vray, Muriel] Inst Pasteur, Unite Epidemiol Malad Infect, BP 220, Dakar, Senegal; [Vray, Muriel] INSERM, F-75013 Paris, France		Boyer, S (通讯作者)，Aix Marseille Univ, ISSPAM, INSERM, IRD,SESSTIM, F-13385 Marseille, France.	andrea.gosset@inserm.fr; marie.nishimwe@inserm.fr; mayadiallo2008@yahoo.fr; lucas.deroo@hec.ca; aldiouma.diallo@ird.fr; el-hadj.ba@ird.fr; pmcarrieri@aol.com; Cheikh.Sokhna@ird.fr; muriel.vray@pasteur.fr; yusuke.shimakawa@pasteur.fr; sylvie.boyer@inserm.fr		Gosset, Andrea/0000-0003-0743-2458; Carrieri, Patrizia/0000-0002-6794-4837; Shimakawa, Yusuke/0000-0002-4198-4785	Total FoundationTotal SA; ANRSANRSFrench National Research Agency (ANR); Institut PasteurEuropean Commission	The NeoVac research program was funded by the Total Foundation. A.G. received a scholarship from the ANRS. L.D. received a scholarship from the Institut Pasteur.	[Anonymous], DATA WORLD BANK OFFI; Bassoum O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020301; Brenzel L., 2013, COMMON APPROACH COST; Brenzel L, 2015, VACCINE, V33, pA13, DOI 10.1016/j.vaccine.2014.12.066; Creati M, 2007, VACCINE, V25, P5985, DOI 10.1016/j.vaccine.2007.05.055; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; GAVI the Vaccine Alliance, GAVI BOARD STARTS FR; Gosset A., 2021, VACCINE; Klingler C, 2012, VACCINE, V31, P252, DOI 10.1016/j.vaccine.2012.08.007; Ministry of Health of Senegal, 2017, RAPP ANN PERF UNPUB; Miyahara R, 2016, VACCINE, V34, P3335, DOI 10.1016/j.vaccine.2016.05.017; Moturi Edna, 2018, J Immunol Sci, VSuppl, P31; Okenwa UJ, 2019, VACCINE, V37, P6894, DOI 10.1016/j.vaccine.2019.09.056; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Seaman CP, 2020, LANCET GLOB HEALTH, V8, pE931, DOI 10.1016/S2214-109X(20)30231-X; Shimakawa Y, 2015, LIVER INT, V35, P2318, DOI 10.1111/liv.12814; Shimakawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069430; Spearman CW, 2017, LANCET GASTROENTEROL, V2, P900, DOI 10.1016/S2468-1253(17)30295-9; UNICEF, PERC DEL HLTH FAC; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO, 2020, UNICEF SEN WHO UNICE; WHO, 2016, GLOB HLTH SECT STRAT; World Health Organization, 2002, GUID EST COSTS INTR; Xeuatvongsa A, 2016, VACCINE, V34, P5777, DOI 10.1016/j.vaccine.2016.09.056	26	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							521	10.3390/vaccines9050521			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NN	34070184	Green Published, gold			2022-04-29	WOS:000654593000001
J	Grochowska, M; Ratajczak, A; Zdunek, G; Adamiec, A; Waszkiewicz, P; Feleszko, W				Grochowska, Magdalena; Ratajczak, Aleksandra; Zdunek, Gabriela; Adamiec, Aleksander; Waszkiewicz, Pawel; Feleszko, Wojciech			A Comparison of the Level of Acceptance and Hesitancy towards the Influenza Vaccine and the Forthcoming COVID-19 Vaccine in the Medical Community	VACCINES			English	Article						COVID-19; vaccine; vaccine hesitancy; healthcareworkers; flu vaccine; influenza; SARS-CoV-2	HEALTH-CARE WORKERS; KNOWLEDGE	Despite research conducted worldwide, there is no treatment specifically targeting SARS-CoV-2 infection with efficacy proven by randomized controlled trials. A chance for a breakthrough is vaccinating most of the global population. Public opinion surveys on vaccine hesitancy prompted our team to investigate Polish healthcare workers' (HCWs) attitudes towards the SARS-CoV-2 and influenza vaccinations. In-person and online surveys of HCWs: doctors, nurses, medical students, and other allied health professionals (n = 419) were conducted between 14 September 2020 and 5 November 2020. In our study, 68.7% of respondents would like to be vaccinated against COVID-19. The safety and efficacy of COVID-19 vaccinations would persuade 86.3% of hesitant and those who would refuse to be vaccinated. 3.1% of all respondents claimed that no argument would convince them to get vaccinated. 61.6% of respondents declared a willingness to receive an influenza vaccination, of which 83.3% were also inclined to receive COVID-19 vaccinations. Although most respondents-62.5% (262/419) indicated they trusted in the influenza vaccine more, more respondents intended to get vaccinated against COVID-19 in the 2020/2021 season. The study is limited by its nonrandom sample of HCWs but provides a preliminary description of attitudes towards SARS-CoV-2 vaccination.	[Grochowska, Magdalena; Ratajczak, Aleksandra; Zdunek, Gabriela; Adamiec, Aleksander; Feleszko, Wojciech] Med Univ Warsaw, Dept Pediat Pneumonol & Allergy, PL-02091 Warsaw, Poland; [Adamiec, Aleksander] Med Univ Warsaw, Doctoral Sch, PL-02091 Warsaw, Poland; [Waszkiewicz, Pawel] Univ Warsaw, Fac Law & Adm, Dept Criminalist, PL-02091 Warsaw, Poland		Feleszko, W (通讯作者)，Med Univ Warsaw, Dept Pediat Pneumonol & Allergy, PL-02091 Warsaw, Poland.	magdalena.grochowska01@gmail.com; olarurarz@gmail.com; zdugabriela@gmail.com; aleksander.adamiec@wum.edu.pl; p.waszkiewicz@uw.edu.pl; wojciech.feleszko@wum.edu.pl	Waszkiewicz, Paweł/AAV-3115-2021	Waszkiewicz, Paweł/0000-0001-9608-1586; Adamiec, Aleksander/0000-0001-9407-3419; Feleszko, Wojciech/0000-0001-6613-2012; Ratajczak, Aleksandra/0000-0003-1426-6136			Antczak A., 2013, SZCZEPIENIA PRZECIW, P8; Aveni E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184979; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Brenner PS, 2016, SOC PSYCHOL QUART, V79, P333, DOI 10.1177/0190272516628298; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Di Pumpo M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030276; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Dooling K, 2020, MMWR-MORBID MORTAL W, V69, P1857, DOI 10.15585/mmwr.mm6949e1; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gov.pl P, PIERWSZY MIESIAC SZC; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Jain V, 2020, INT J PUBLIC HEALTH, V65, P533, DOI 10.1007/s00038-020-01390-7; Kadoya Y, 2021, J CARDIOL, V77, P239, DOI 10.1016/j.jjcc.2020.07.029; Kose S, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13917; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; OECD, SCI ADV TIM COVID 19; Organization for Economic Co-Operation and Development (OECD), INFL VACC RAT IND; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; PZH (National Institute of Public Health-National Institute of Hygiene), PRZEK ZE SEZ 2014 20; Sahu AK, 2020, AM J EMERG MED, V38, P1727, DOI 10.1016/j.ajem.2020.05.113; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Tamang N, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-10025-8; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, COVID 19 VACC; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Yang J., 2020, INT J INFECT DIS, V94, P91, DOI [10.1016/J.ijid.2020.03.017, DOI 10.1016/J.IJID.2020.03.017]; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	41	17	17	10	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							475	10.3390/vaccines9050475			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1OS	34066790	Green Published, gold			2022-04-29	WOS:000654596100001
J	Li, L; Wang, J; Nicholas, S; Maitland, E; Leng, AL; Liu, RG				Li, Lu; Wang, Jian; Nicholas, Stephen; Maitland, Elizabeth; Leng, Anli; Liu, Rugang			The Intention to Receive the COVID-19 Vaccine in China: Insights from Protection Motivation Theory	VACCINES			English	Article						protection motivation theory; COVID-19; vaccination; intention; determinant	HEPATITIS-B-VACCINE; MIGRANT WORKERS; ACCEPTABILITY; ADOLESCENTS; ACCEPTANCE	(1) Background: More coronavirus disease 2019 (COVID-19) vaccines are gradually being developed and marketed. Improving the vaccination intention will be the key to increasing the vaccination rate in the future; (2) Methods: A self-designed questionnaire was used to collect data on COVID-19 vaccination intentions, protection motivation and control variables. Pearson Chi-square test and multivariate ordered logistic regression models were specified to analyze the determinants of intention to receive COVID-19 vaccine; (3) Results: Although the vaccine was free, 17.75% of the 2377 respondents did not want, or were hesitant, to receive the COVID-19 vaccine. Respondents' cognition of vaccine safety, external reward and response efficacy were positively related to COVID-19 vaccination intention, while age, income and response cost were negatively related to the intention to receive the COVID-19 vaccine. Professionals and people without medical insurance had the lowest intention to vaccinate; (4) Conclusions: The older aged, people without health insurance, those with higher incomes and professionals should be treated as the key intervention targets. Strengthening publicity and education about the safety and efficacy of COVID-19 vaccines, training vaccinated people and community leaders as propagandists for the vaccine, and improving the accessibility to the COVID-19 vaccine are recommended to improve COVID-19 vaccination intention.	[Li, Lu] Jiangsu Vocat Inst Commerce, Sch Business Adm, Nanjing 211168, Peoples R China; [Wang, Jian] Wuhan Univ, Dong Fureng Econ & Social Dev Sch, Beijing 100010, Peoples R China; [Wang, Jian] Wuhan Univ, Ctr Hlth Econ & Management, Sch Econ & Management, Wuhan 430072, Peoples R China; [Nicholas, Stephen] Australian Natl Inst Management & Commerce, Sydney, NSW 2015, Australia; [Nicholas, Stephen] Guangdong Univ Foreign Studies, Res Inst Int Strategies, Guangzhou 510420, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Econ, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Management, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Univ Newcastle, Newcastle Business Sch, Newcastle, NSW 2308, Australia; [Maitland, Elizabeth] Univ Liverpool, Sch Management, Chatham Bldg,Chatham St, Liverpool L697ZH, Merseyside, England; [Leng, Anli] Shandong Univ, Sch Polit Sci & Publ Adm, Inst Governance, Qingdao 266237, Peoples R China; [Liu, Rugang] Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China; [Liu, Rugang] Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China		Liu, RG (通讯作者)，Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China.; Liu, RG (通讯作者)，Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China.	200015@jvic.edu.cn; wangjian993@whu.edu.cn; stephen.nicholas@newcastle.edu.au; e.maitland@liverpool.ac.uk; lenganli@sdu.edu.cn; rugangliu@njmu.edu.cn	NICHOLAS, STEPHEN/ABE-4726-2021; Leng, Anli/ABG-3086-2021; Maitland, Elizabeth T/O-7703-2018	Maitland, Elizabeth T/0000-0003-1551-4787; Nicholas, Stephen/0000-0001-6770-7105; WANG, JIAN/0000-0001-8769-7928; leng, anli/0000-0002-6775-2085; Liu, Rugang/0000-0002-4270-9507	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71904089]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2019M662392]; Qingdao Postdoctoral Foundation	This research was funded by National Natural Science Foundation of China, grant number 71904089; China Postdoctoral Science Foundation, grant number 2019M662392; Qingdao Postdoctoral Foundation.	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; [Anonymous], 2020, PharmacoEcon Outcomes News, V858, P35, DOI 10.1007/s40274-020-7008-x; [Anonymous], Coronavirus Disease (COVID-2019) Situation Reports; [Anonymous], The Associated Press and NORC Expectations for a COVID-19 Vaccine; [Anonymous], COVID-19 Vaccination Free to Chinese Residents: Official; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bashirian S, 2020, J HOSP INFECT, V105, P430, DOI 10.1016/j.jhin.2020.04.035; Bassett Sandra F., 2011, Physiotherapy Theory and Practice, V27, P360, DOI 10.3109/09593985.2010.507238; BODENHEIMER HC, 1986, AM J PUBLIC HEALTH, V76, P252, DOI 10.2105/AJPH.76.3.252; Boer H, 2004, AIDS CARE, V16, P167, DOI 10.1080/09540120410001641011; Camerini AL, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.11.005; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Fisher A, 2012, PREV MED, V55, P514, DOI 10.1016/j.ypmed.2012.08.008; Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x; Frank K., 2020, CANADIANS WILLINGNES; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Ling M, 2019, SOC SCI MED, V233, P87, DOI 10.1016/j.socscimed.2019.06.002; Liu C, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09292-2; Liu RG, 2016, HUM VACC IMMUNOTHER, V12, P1155, DOI 10.1080/21645515.2015.1123358; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; Miyachi T, 2020, LANCET, V395, P31, DOI 10.1016/S0140-6736(19)32686-8; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Prestwich A, 2008, SOC SCI MED, V67, P1550, DOI 10.1016/j.socscimed.2008.07.019; Raftopoulos V, 2021, HUM VACC IMMUNOTHER, V17, P2397, DOI 10.1080/21645515.2021.1896907; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; ROSENTHAL SL, 1995, J ADOLESCENT HEALTH, V17, P248, DOI 10.1016/1054-139X(95)00164-N; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Prasetyo YT, 2020, INT J INFECT DIS, V99, P312, DOI 10.1016/j.ijid.2020.07.074; van der Veen YJJ, 2014, J IMMIGR MINOR HEALT, V16, P811, DOI 10.1007/s10903-013-9872-y; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wei H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1388; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yan YQ, 2014, ADDICT BEHAV, V39, P181, DOI 10.1016/j.addbeh.2013.09.027; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Zimet GD, 2000, INT J STD AIDS, V11, P143, DOI 10.1258/0956462001915570	48	9	9	14	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							445	10.3390/vaccines9050445			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1EJ	34063281	Green Published, gold			2022-04-29	WOS:000654569000001
J	Bell, RL; Turkington, HL; Cosby, SL				Bell, Rachael Lynda; Turkington, Hannah Louise; Cosby, Sara Louise			The Bacterial and Viral Agents of BRDC: Immune Evasion and Vaccine Developments	VACCINES			English	Review						bovine respiratory disease complex (BRDC); immunity; immune evasion; respiratory viruses; bacterial agents; vaccine development	RESPIRATORY SYNCYTIAL VIRUS; INFECTIOUS BOVINE-RHINOTRACHEITIS; PARAINFLUENZA TYPE-3 VIRUS; INFLUENZA D VIRUS; DIARRHEA-VIRUS; MODIFIED-LIVE; DISEASE COMPLEX; ALVEOLAR MACROPHAGES; HAEMOPHILUS-SOMNUS; HERPESVIRUS-1 INFECTION	Bovine respiratory disease complex (BRDC) is a multifactorial disease of cattle which presents as bacterial and viral pneumonia. The causative agents of BRDC work in synergy to suppress the host immune response and increase the colonisation of the lower respiratory tracts by pathogenic bacteria. Environmental stress and/or viral infection predispose cattle to secondary bacterial infections via suppression of key innate and adaptive immune mechanisms. This allows bacteria to descend the respiratory tract unchallenged. BRDC is the costliest disease among feedlot cattle, and whilst vaccines exist for individual pathogens, there is still a lack of evidence for the efficacy of these vaccines and uncertainty surrounding the optimum timing of delivery. This review outlines the immunosuppressive actions of the individual pathogens involved in BRDC and highlights the key issues in the development of vaccinations against them.	[Bell, Rachael Lynda; Turkington, Hannah Louise; Cosby, Sara Louise] Agrifood & Biosci Inst, Vet Sci Div, Belfast BT4 3SD, Antrim, North Ireland; [Cosby, Sara Louise] Queens Univ Belfast, Ctr Expt Med, Sch Med Dent & Biomed Sci, Belfast BT9 7BL, Antrim, North Ireland		Bell, RL (通讯作者)，Agrifood & Biosci Inst, Vet Sci Div, Belfast BT4 3SD, Antrim, North Ireland.	rachael.bell@afbini.gov.uk; hannah.turkington@afbini.gov.uk; Louise.Cosby@afbini.gov.uk		Cosby, Louise/0000-0002-2617-8603; Bell, Rachael/0000-0002-3687-2586	US-Ireland Research and Development Partnership in Agriculture grant BRDC-Seq; US-Ireland Research and Development Partnership in Agriculture grant BRDC-URTMVP	This research was funded by US-Ireland Research and Development Partnership in Agriculture grants BRDC-Seq and BRDC-URTMVP.	Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Ackermann MR, 2010, VET CLIN N AM-FOOD A, V26, P215, DOI 10.1016/j.cvfa.2010.03.001; ADAIR BM, 1992, VET IMMUNOL IMMUNOP, V30, P193, DOI 10.1016/0165-2427(92)90138-G; Adler B, 1997, J VIROL, V71, P3255, DOI 10.1128/JVI.71.4.3255-3258.1997; Agnes JT, 2013, INFECT IMMUN, V81, P2592, DOI 10.1128/IAI.00108-13; Agriculture and Horticulture Development Board, 2018, US VACC DAIR BEEF CA; Al-Haddawi A, 2007, VET IMMUNOL IMMUNOP, V116, P153, DOI 10.1016/j.vetimm.2007.01.007; Alvarez AE, 2013, J PEDIAT-BRAZIL, V89, P531, DOI 10.1016/j.jped.2013.02.022; Apley MD, 2015, VET CLIN N AM-FOOD A, V31, P441, DOI 10.1016/j.cvfa.2015.06.001; Babcock AH, 2013, CAN J VET RES, V77, P33; Babiuk LA, 1996, VET MICROBIOL, V53, P31, DOI 10.1016/S0378-1135(96)01232-1; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; BASARABA RJ, 1993, IMMUNOLOGY, V79, P179; Brodersen BW, 1999, VIRAL IMMUNOL, V12, P323, DOI 10.1089/vim.1999.12.323; BROWN GB, 1991, AM J VET RES, V52, P381; Bryant NA, 2003, EMBO J, V22, P833, DOI 10.1093/emboj/cdg092; Bryant T. C., 2008, Bovine Practitioner, V42, P98; Burciaga-Robles LO, 2010, J ANIM SCI, V88, P2166, DOI 10.2527/jas.2009-2005; Bystrom J, 2013, VIRUSES-BASEL, V5, P777, DOI 10.3390/v5030777; Carlos-Valdez L, 2016, J ANIM SCI, V94, P4799, DOI 10.2527/jas.2016-0712; Caswell JL, 2001, CAN J VET RES, V65, P229; Chamorro MF, 2020, VET CLIN N AM-FOOD A, V36, P461, DOI 10.1016/j.cvfa.2020.03.006; Chang J, 2002, NAT MED, V8, P54, DOI 10.1038/nm0102-54; Chang J, 2001, J IMMUNOL, V167, P4254, DOI 10.4049/jimmunol.167.8.4254; Charleston B, 2001, J GEN VIROL, V82, P1893, DOI 10.1099/0022-1317-82-8-1893; Chen MK, 2011, INT IMMUNOPHARMACOL, V11, P549, DOI 10.1016/j.intimp.2010.11.025; Childs T., 1946, CANADIAN JOUR COMP MED, V10, P316; Corbeil L.B, 1996, ANIM HEALTH RES REV, V10, P151; Cortjens B, 2016, J PATHOL, V238, P401, DOI 10.1002/path.4660; Cresswell E, 2014, Vet Rec Open, V1, pe000042, DOI 10.1136/vropen-2014-000042; Czuprynski Charles J., 2004, Animal Health Research Reviews, V5, P277, DOI 10.1079/AHR200483; CZUPRYNSKI CJ, 1985, INFECT IMMUN, V50, P431, DOI 10.1128/IAI.50.2.431-436.1985; DARBYSHIRE JH, 1965, NATURE, V208, P307, DOI 10.1038/208307a0; Dubrovsky SA, 2020, J DAIRY SCI, V103, P1583, DOI 10.3168/jds.2018-15501; Edwards TA, 2010, VET CLIN N AM-FOOD A, V26, P273, DOI 10.1016/j.cvfa.2010.03.005; Ellis JA, 2001, VET CLIN N AM-FOOD A, V17, P535, DOI 10.1016/S0749-0720(15)30005-0; Ellis J, 2007, JAVMA-J AM VET MED A, V230, P233, DOI 10.2460/javma.230.2.233; Ellis J, 2018, CAN VET J, V59, P1311; Ellis J, 2014, CAN VET J, V55, P1180; Ellis JA, 2010, JAVMA-J AM VET MED A, V236, P991, DOI 10.2460/javma.236.9.991; Endsley JJ, 2004, VIRAL IMMUNOL, V17, P13, DOI 10.1089/088282404322875421; Erickson N, 2020, CAN VET J, V61, P530; Fach SJ, 2010, VET IMMUNOL IMMUNOP, V136, P55, DOI 10.1016/j.vetimm.2010.02.008; Fent GM, 2002, AM J VET RES, V63, P976, DOI 10.2460/ajvr.2002.63.976; Ferguson L, 2016, J VIROL, V90, P5636, DOI 10.1128/JVI.03122-15; Fulton RW, 2000, CAN J VET RES, V64, P151; Funder JW, 1997, ANNU REV MED, V48, P231, DOI 10.1146/annurev.med.48.1.231; Gaddum RM, 2003, IMMUNOLOGY, V108, P220, DOI 10.1046/j.1365-2567.2003.01566.x; Gaudino SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00360; Gershwin LJ, 2012, COMP IMMUNOL MICROB, V35, P253, DOI 10.1016/j.cimid.2012.01.005; GILLIAM SE, 1993, ARCH VIROL, V128, P43, DOI 10.1007/BF01309787; Glew EJ, 2003, J GEN VIROL, V84, P1771, DOI 10.1099/vir.0.18964-0; Goris K, 2009, J VIROL, V83, P1962, DOI 10.1128/JVI.01271-08; GRIEBEL P J, 1987, Viral Immunology, V1, P287, DOI 10.1089/vim.1987.1.287; Griese M, 2002, VIRAL IMMUNOL, V15, P357, DOI 10.1089/08828240260066279; Griffin Courtney M, 2018, Bov Pract (Stillwater), V52, P26; Griffin D, 2010, VET CLIN N AM-FOOD A, V26, P381, DOI 10.1016/j.cvfa.2010.04.004; Grissett GP, 2015, J VET INTERN MED, V29, P770, DOI 10.1111/jvim.12597; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Guerra-Maupome M, 2019, VET CLIN N AM-FOOD A, V35, P453, DOI 10.1016/j.cvfa.2019.08.001; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Guzman E, 2015, MOL IMMUNOL, V66, P48, DOI 10.1016/j.molimm.2014.12.004; Hartel H, 2004, ACTA VET SCAND, V45, P193, DOI 10.1186/1751-0147-45-193; Hause BM, 2017, VET MICROBIOL, V199, P47, DOI 10.1016/j.vetmic.2016.12.024; Hause BM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121998; HESSE RA, 1983, AM J VET RES, V44, P1901; Hick PM, 2012, AUST VET J, V90, P381, DOI 10.1111/j.1751-0813.2012.00978.x; Hinkley S, 1998, VIRUS RES, V53, P91, DOI 10.1016/S0168-1702(97)00128-7; Howard MD, 2004, MICROB PATHOGENESIS, V37, P263, DOI 10.1016/j.micpath.2004.08.002; Huang HQ, 2015, IMMUNOL CELL BIOL, V93, P126, DOI 10.1038/icb.2014.79; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Inzana TJ, 2012, VET MICROBIOL, V161, P113, DOI 10.1016/j.vetmic.2012.07.008; Jobe F, 2020, J VIROL, V94, DOI 10.1128/JVI.01380-20; JOHNSON K, 1977, RES VET SCI, V22, P83, DOI 10.1016/S0034-5288(18)33318-6; Johnston D, 2021, BMC GENOMICS, V22, DOI 10.1186/s12864-020-07268-5; Johnston D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51094-z; Jones C, 1999, ADV VIRUS RES, V51, P81; Jones Clinton, 2007, Animal Health Research Reviews, V8, P187, DOI 10.1017/S146625230700134X; Jones C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01008; Kalina WV, 2004, VACCINE, V22, P1465, DOI 10.1016/j.vaccine.2003.10.024; Kelling CL, 2002, AM J VET RES, V63, P1379, DOI 10.2460/ajvr.2002.63.1379; Kirchhoff J, 2014, VET MICROBIOL, V170, P58, DOI 10.1016/j.vetmic.2014.01.038; Kirchhoff J, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-20; Komatsu T, 2007, MICROBES INFECT, V9, P954, DOI 10.1016/j.micinf.2007.03.014; Koppers-Lalic D, 2003, ARCH VIROL, V148, P2023, DOI 10.1007/s00705-003-0142-5; Lahti M, 2002, PEDIATR RES, V51, P696, DOI [10.1203/00006450-200206000-00006, 10.1023/01.PDR.0000015911.65104.93]; Lan HC, 1996, VET MICROBIOL, V49, P59, DOI 10.1016/0378-1135(95)00175-1; Larkin EK, 2015, FUTURE VIROL, V10, P883, DOI 10.2217/FVL.15.55; Lathrop SL, 2000, AM J VET RES, V61, P1062, DOI 10.2460/ajvr.2000.61.1062; Levings RL, 2013, ANIM HEALTH RES REV, V14, P88, DOI 10.1017/S1466252313000042; Levings RL, 2013, ANIM HEALTH RES REV, V14, P103, DOI 10.1017/S1466252313000054; Loneragan GH, 2001, J AM VET MED ASSOC, V219, P1122, DOI 10.2460/javma.2001.219.1122; Mahan SM, 2016, JAVMA-J AM VET MED A, V248, P1280, DOI 10.2460/javma.248.11.1280; Makoschey B, 2008, ACTA VET HUNG, V56, P485, DOI 10.1556/AVet.56.2008.4.6; MARTIN SW, 1986, CAN J VET RES, V50, P351; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McGill JL, 2020, VET CLIN N AM-FOOD A, V36, P333, DOI 10.1016/j.cvfa.2020.03.002; McGill JL, 2016, VET IMMUNOL IMMUNOP, V181, P24, DOI 10.1016/j.vetimm.2016.02.012; McGill JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151083; McGill JL, 2013, IMMUNOLOGY, V139, P227, DOI 10.1111/imm.12075; Mcinnes E, 1999, IMMUNOLOGY, V96, P396, DOI 10.1046/j.1365-2567.1999.00714.x; McMullen C, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00869-y; MENANTEAUHORTA AM, 1985, CAN J COMP MED, V49, P10; MILLEREDGE M, 1986, VET IMMUNOL IMMUNOP, V13, P1, DOI 10.1016/0165-2427(86)90044-9; Mitchell GB, 2007, INFECT IMMUN, V75, P1325, DOI 10.1128/IAI.00686-06; Molina V, 2013, RES VET SCI, V95, P115, DOI 10.1016/j.rvsc.2013.02.018; MORENOLOPEZ J, 1977, ZBL VET MED B, V24, P231; Mori K, 2020, J VET RES, V64, P223, DOI 10.2478/jvetres-2020-0042; Muylkens B, 2007, VET RES, V38, P181, DOI 10.1051/vetres:2006059; Nagai K, 2019, J VET MED SCI, V81, P1355, DOI 10.1292/jvms.19-0256; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nataraj C, 1997, VIRAL IMMUNOL, V10, P21, DOI 10.1089/vim.1997.10.21; Neibergs HL, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1164; Ng TFF, 2015, J VIROL, V89, P5340, DOI 10.1128/JVI.00064-15; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Nissly RH, 2020, VIROLOGY, V551, P10, DOI 10.1016/j.virol.2020.08.014; NYAGA PN, 1979, COMP IMMUNOL MICROB, V2, P587, DOI 10.1016/0147-9571(79)90100-0; OLAFSON P, 1946, CORNELL VET, V36, P205; ORR JP, 1992, CAN VET J, V33, P719; Pennock ND, 2013, ADV PHYSIOL EDUC, V37, P273, DOI 10.1152/advan.00066.2013; Poe K. D., 2013, Professional Animal Scientist, V29, P413; POTGIETER LND, 1984, AM J VET RES, V45, P1582; Puttur F, 2019, IMMUNOL CELL BIOL, V97, P246, DOI 10.1111/imcb.12235; Radi ZA, 2001, AM J VET RES, V62, P17, DOI 10.2460/ajvr.2001.62.17; RICHER L, 1988, CAN VET J, V29, P713; Richeson JT, 2016, J ANIM SCI, V94, P3501, DOI 10.2527/jas.2016-0572; Richeson JT, 2009, J ANIM SCI, V87, P2409, DOI 10.2527/jas.2008-1484; Richeson JT, 2020, VET CLIN N AM-FOOD A, V36, P473, DOI 10.1016/j.cvfa.2020.03.013; Ridpath JF, 2010, VET RES COMMUN, V34, P691, DOI 10.1007/s11259-010-9442-x; Rivera-Rivas JJ, 2009, VET IMMUNOL IMMUNOP, V131, P167, DOI 10.1016/j.vetimm.2009.04.002; ROTH JA, 1983, AM J VET RES, V44, P2366; Sacco RE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033074; Sano H, 2005, MOL IMMUNOL, V42, P279, DOI 10.1016/j.molimm.2004.07.014; Schaut RG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159491; Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005; Schoneveld OJLM, 2004, BBA-GENE STRUCT EXPR, V1680, P114, DOI 10.1016/j.bbaexp.2004.09.004; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schumaher TF, 2019, J ANIM SCI, V97, P620, DOI 10.1093/jas/sky466; Segovia J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029695; Singh K, 2011, VET PATHOL, V48, P338, DOI 10.1177/0300985810377182; Singh K, 2011, VET J, V188, P221, DOI 10.1016/j.tvjl.2010.05.015; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Step DL, 2009, JAVMA-J AM VET MED A, V235, P580, DOI 10.2460/javma.235.5.580; Stevens Elliot T., 2011, Bovine Practitioner, V45, P23; Stilwell G, 2008, PREV VET MED, V85, P151, DOI 10.1016/j.prevetmed.2008.02.002; Storz J, 2000, J AM VET MED ASSOC, V216, P1599, DOI 10.2460/javma.2000.216.1599; Storz J, 2000, J CLIN MICROBIOL, V38, P3291, DOI 10.1128/JCM.38.9.3291-3298.2000; Sudaryatma PE, 2019, VET MICROBIOL, V235, P80, DOI 10.1016/j.vetmic.2019.06.010; Sudaryatma PE, 2018, VET MICROBIOL, V220, P33, DOI 10.1016/j.vetmic.2018.04.031; Taylor G, 2014, J GEN VIROL, V95, P1244, DOI 10.1099/vir.0.064931-0; Taylor JD, 2010, CAN VET J, V51, P1095; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Theurer ME, 2015, JAVMA-J AM VET MED A, V246, P126, DOI 10.2460/javma.246.1.126; Urban-Chmiel R, 2012, J LIVEST SCI, V3, P27; Veterinary Laboratory Service Agri-Food & Biosciences Institute, 2020, ALL ISL AN DIS SURV; Viuff B, 1996, VET PATHOL, V33, P383, DOI 10.1177/030098589603300403; Voges H, 1998, VET MICROBIOL, V61, P165, DOI 10.1016/S0378-1135(98)00177-1; Walz PH, 2010, J VET INTERN MED, V24, P476, DOI 10.1111/j.1939-1676.2010.0502.x; Walz PW, 2001, AM J VET RES, V62, P1095, DOI 10.2460/ajvr.2001.62.1095; Wang JL, 2014, VIRUS RES, V185, P72, DOI 10.1016/j.virusres.2014.03.006; West K, 1999, VACCINE, V18, P907, DOI 10.1016/S0264-410X(99)00324-2; Wildman BK, 2008, CAN VET J, V49, P463; Williams PD, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1450-z; Winkler MTC, 1999, J VIROL, V73, P8657, DOI 10.1128/JVI.73.10.8657-8668.1999; Yang YF, 1998, MICROB PATHOGENESIS, V24, P351, DOI 10.1006/mpat.1998.0205; Zeilhofer HU, 2000, CURR OPIN HEMATOL, V7, P178, DOI 10.1097/00062752-200005000-00009; Zhang LQ, 2005, J VIROL, V79, P1113, DOI 10.1128/JVI.79.2.1113-1124.2005; Zhang MD, 2019, TRANSBOUND EMERG DIS, V66, P1379, DOI 10.1111/tbed.13172; Zimmerman Alicia D., 2009, Bovine Practitioner, V43, P35	169	6	6	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							337	10.3390/vaccines9040337			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5BP	33916119	gold, Green Published			2022-04-29	WOS:000643794700001
J	De Benedetti, S; Di Pisa, F; Fassi, EMA; Cretich, M; Musico, A; Frigerio, R; Mussida, A; Bombaci, M; Grifantini, R; Colombo, G; Bolognesi, M; Grande, R; Zanchetta, N; Gismondo, MR; Mileto, D; Mancon, A; Gourlay, LJ				De Benedetti, Stefano; Di Pisa, Flavio; Fassi, Enrico Mario Alessandro; Cretich, Marina; Musico, Angelo; Frigerio, Roberto; Mussida, Alessandro; Bombaci, Mauro; Grifantini, Renata; Colombo, Giorgio; Bolognesi, Martino; Grande, Romualdo; Zanchetta, Nadia; Gismondo, Maria Rita; Mileto, Davide; Mancon, Alessandro; Gourlay, Louise Jane			Structure, Immunoreactivity, and In Silico Epitope Determination of SmSPI S. mansoni Serpin for Immunodiagnostic Application	VACCINES			English	Article						Neglected Tropical Disease; circulating antigen; crystal structure; in silico epitope predictions; schistosomiasis; Serine protease inhibitor; immunodiagnostics		The human parasitic disease Schistosomiasis is caused by the Schistosoma trematode flatworm that infects freshwaters in tropical regions of the world, particularly in Sub-Saharan Africa, South America, and the Far-East. It has also been observed as an emerging disease in Europe, due to increased immigration. In addition to improved therapeutic strategies, it is imperative to develop novel, rapid, and sensitive diagnostic tests that can detect the Schistosoma parasite, allowing timely treatment. Present diagnosis is difficult and involves microscopy-based detection of Schistosoma eggs in the feces. In this context, we present the 3.22 angstrom resolution crystal structure of the circulating antigen Serine protease inhibitor from S. mansoni (SmSPI), and we describe it as a potential serodiagnostic marker. Moreover, we identify three potential immunoreactive epitopes using in silico-based epitope mapping methods. Here, we confirm effective immune sera reactivity of the recombinant antigen, suggesting the further investigation of the protein and/or its predicted epitopes as serodiagnostic Schistosomiasis biomarkers.	[De Benedetti, Stefano; Di Pisa, Flavio; Bolognesi, Martino; Gourlay, Louise Jane] Univ Milan, Dept Biosci, Via Celoria 26, I-20133 Milan, Italy; [Fassi, Enrico Mario Alessandro; Cretich, Marina; Musico, Angelo; Frigerio, Roberto; Mussida, Alessandro] CNR, Ist Sci & Tecnol Chim Giulio Natta SCITEC, Via Mario Bianco 9, I-20131 Milan, Italy; [Fassi, Enrico Mario Alessandro] Univ Milan, Dipartimento Sci Farmaceut, Via L Mangiagalli 25, I-20133 Milan, Italy; [Bombaci, Mauro; Grifantini, Renata] IRCCS Osped Maggiore Policlin, Padigl Romeo & Enr Invernizzi, Ist Nazl Genet Mol, I-20122 Milan, Italy; [Colombo, Giorgio] Univ Pavia, Dipartimento Chim, Vle Taramelli 12, I-27100 Pavia, Italy; [Bolognesi, Martino] Univ Milan, Ctr Ric Pediat Romeo & Enr Invernizzi, I-20133 Milan, Italy; [Grande, Romualdo; Zanchetta, Nadia; Gismondo, Maria Rita; Mileto, Davide; Mancon, Alessandro] Virol & Diagnost Bioemergenze ASST FBF Sacco, UOC Microbiol Clin, I-20157 Milan, Italy; [Gismondo, Maria Rita] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Clin Microbiol Virol & Bioemergency Unit, I-20157 Milan, Italy; [De Benedetti, Stefano] Univ Milan, Dept Food Environm & Nutr Sci, Via Celoria 2, I-20133 Milan, Italy; [Di Pisa, Flavio] IRCCS Sci Inst San Raffaele, Div Immunol Transplantat & Infect Dis, Biocrystallog Unit, I-20132 Milan, Italy		Gourlay, LJ (通讯作者)，Univ Milan, Dept Biosci, Via Celoria 26, I-20133 Milan, Italy.	stefano.debenedetti@unimi.it; DiPisa.Flavio@hsr.it; enrico.fassi@unimi.it; marina.cretich@cnr.it; angelo.musico94@gmail.com; roberto.frigerio94@gmail.com; alessandro.mussida@scitec.cnr.it; bombaci@ingm.org; grifantini@ingm.org; g.colombo@unipv.it; martino.bolognesi@unimi.it; grande.romualdo@asst-fbf-sacco.it; nadia.zanchetta@asst-fbf-sacco.it; mariarita.gismondo@unimi.it; davide.mileto@unimi.it; alessandro.mancon@unimi.it; louise.gourlay@unimi.it	Mancon, Alessandro/AAD-7379-2022; De Benedetti, Stefano/N-3662-2015; Renata, Grifantini/AAB-9969-2022; Cretich, Marina/AAA-8780-2022; Bombaci, Mauro/K-6106-2016	Mancon, Alessandro/0000-0002-1490-636X; De Benedetti, Stefano/0000-0002-7787-9645; Renata, Grifantini/0000-0003-0024-3355; Cretich, Marina/0000-0001-8251-5275; Mileto, Davide/0000-0002-9414-0287; Musico, Angelo/0000-0001-6193-4366; Fassi, Enrico Mario Alessandro/0000-0001-6282-4273; Bombaci, Mauro/0000-0002-9887-4165	Regione Lombardia (Regional Network for developing diagnostic methods in rapid response to emerging epidemics and bio-emergencies) [229472]; iNEXT [PID: 5912]	This research was funded by the Regione Lombardia (Regional Network for developing diagnostic methods in rapid response to emerging epidemics and bio-emergencies); Grant ID 229472. X-ray diffraction data collection was supported by iNEXT (PID: 5912).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Aqvist J, 2004, CHEM PHYS LETT, V384, P288, DOI 10.1016/j.cplett.2003.12.039; Bao JL, 2018, PEERJ, V6, DOI 10.7717/peerj.4557; Beltrame A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005593; Bergamaschi G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081921; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Capelli R, 2018, ANTIBODIES, V7, DOI 10.3390/antib7030026; Capelli R, 2017, ACS INFECT DIS, V3, P736, DOI 10.1021/acsinfecdis.7b00080; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Cretich M, 2012, PROTEOMICS, V12, P2963, DOI 10.1002/pmic.201200202; Cretich M, 2009, ANAL CHEM, V81, P5197, DOI 10.1021/ac900658c; CROWTHER D C, 1992, Current Opinion in Biotechnology, V3, P399, DOI 10.1016/0958-1669(92)90169-J; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.0.CO;2-M; Day TA, 2006, PARASITIC FLATWORMS: MOLECULAR BIOLOGY, BIOCHEMISTRY, IMMUNOLOGY AND PHYSIOLOGY, P256, DOI 10.1079/9780851990279.0256; DeLano WL., 2002, PYMOL MOL GRAPHICS S; DeVlas SJ, 1997, PARASITOLOGY, V114, P113, DOI 10.1017/S0031182096008207; Doenhoff MJ, 2003, ANN TROP MED PARASIT, V97, P697, DOI 10.1179/000349803225002354; El-Sayed A, 2020, ENVIRON SCI POLLUT R, V27, P22336, DOI 10.1007/s11356-020-08896-w; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gori A, 2016, BIOCONJUGATE CHEM, V27, P2669, DOI 10.1021/acs.bioconjchem.6b00426; Gourlay L, 2017, TRENDS BIOTECHNOL, V35, P1208, DOI 10.1016/j.tibtech.2017.06.018; Granzin J, 2012, ACTA CRYSTALLOGR D, V68, P686, DOI 10.1107/S0907444912008372; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Krishnarjuna B, 2016, SCI REP-UK, V6, DOI 10.1038/srep20613; Le Grand S, 2013, COMPUT PHYS COMMUN, V184, P374, DOI 10.1016/j.cpc.2012.09.022; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONCHARICH RJ, 1992, BIOPOLYMERS, V32, P523, DOI 10.1002/bip.360320508; Lu Y, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-115; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Pakchotanon P, 2016, PARASITOL RES, V115, P2981, DOI 10.1007/s00436-016-5053-y; Peri C, 2013, ACS CHEM BIOL, V8, P397, DOI 10.1021/cb300487u; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Quezada LAL, 2011, AN ACAD BRAS CIENC, V83, P663, DOI 10.1590/S0001-37652011000200025; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Ross AG, 2007, LANCET INFECT DIS, V7, P218, DOI 10.1016/S1473-3099(07)70053-1; Rubinstein ND, 2009, MOL IMMUNOL, V46, P840, DOI 10.1016/j.molimm.2008.09.009; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Scarabelli G, 2010, BIOPHYS J, V98, P1966, DOI 10.1016/j.bpj.2010.01.014; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Solihah B, 2020, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.275; Tan S Y, 2007, Singapore Med J, V48, P184; Tanigawa C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004021; ten Hove RJ, 2008, T ROY SOC TROP MED H, V102, P179, DOI 10.1016/j.trstmh.2007.10.011; Trainor-Moss S, 2016, EXPERT REV CLIN PHAR, V9, P157, DOI 10.1586/17512433.2015.1102051; Utzinger J, 2004, EXPERT OPIN PHARMACO, V5, P263, DOI 10.1517/eoph.5.2.263.26469; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235; Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043575; Zingaretti C, 2012, MOL CELL PROTEOMICS, V11, P1885, DOI 10.1074/mcp.M112.018713	52	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							322	10.3390/vaccines9040322			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5IR	33915716	Green Published, gold			2022-04-29	WOS:000643813200001
J	Krasselt, M; Baerwald, C; Liebert, UG; Seifert, O				Krasselt, Marco; Baerwald, Christoph; Liebert, Uwe G.; Seifert, Olga			Humoral Immunity to Varicella Zoster Virus in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Compared to Healthy Controls	VACCINES			English	Article						varicella zoster virus; VZV antibodies; shingles; herpes zoster; systemic lupus erythematosus; SLE; rheumatoid arthritis; RA	CELL-MEDIATED-IMMUNITY; SKIN-TEST REACTION; HERPES-ZOSTER; SUBUNIT VACCINE; AMERICAN-COLLEGE; RISK-FACTORS; B-CELLS; EFFICACY; ANTIBODY; IMMUNOGLOBULINS	Background: The prevalence of herpes zoster (HZ) is high in patients with rheumatic diseases. Systemic lupus erythematosus (SLE) doubles the risk for developing HZ. However, little is known about natural humoral immunity against varicella zoster virus (VZV) in patients with SLE. Hence, we compared VZV IgG antibody concentrations in a group of SLE patients with healthy controls and patients with rheumatoid arthritis (RA). Methods: n = 56 patients with SLE, n = 54 patients with RA, and n = 56 healthy controls were included in this study. The VZV IgG antibody concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The antibody concentrations were compared between the groups. Results: Overall IgG antibody titers for VZV in SLE patients were comparable to healthy controls but higher when compared to patients with rheumatoid arthritis (p = 0.0012). In consequence, antibody levels in controls were higher than in RA patients (p = 0.0097). Stratification by age revealed highest titers among SLE patients in the fourth life decade (p = 0.03 for controls, p = 0.0008 for RA patients) whereas RA patients in their sixth decade had the lowest antibody concentration (p = 0.03 for controls, p = 0.04 for SLE patients). Regarding the individual HZ history, antibody levels of SLE patients with a positive history exceeded all other groups. Conclusions: Although humoral VZV immunity in SLE patients is comparable to healthy controls it seems to be pronounced in young SLE patients between 30 and 39. The lowest VZV IgG levels were found in RA patients. HZ seems to induce antibody production, particularly in patients with SLE. Immunological processes might contribute to VZV antibody levels in SLE patients, but further investigations are needed to substantiate this hypothesis. Even though the increased HZ prevalence seems to be independent of humoral immunity in SLE patients, reduced humoral immunity might contribute to HZ in RA patients. The available HZ subunit vaccination might be an appropriate way to reduce the HZ risk in patients with rheumatic diseases.	[Krasselt, Marco; Baerwald, Christoph; Seifert, Olga] Univ Leipzig, Dept Internal Med Neurol & Dermatol, Clin Endocrinol Nephrol & Rheumatol, Rheumatol Unit, Liebigstr 20, D-04103 Leipzig, Germany; [Liebert, Uwe G.] Univ Leipzig, Inst Virol, Johannisallee 30, D-04103 Leipzig, Germany		Krasselt, M (通讯作者)，Univ Leipzig, Dept Internal Med Neurol & Dermatol, Clin Endocrinol Nephrol & Rheumatol, Rheumatol Unit, Liebigstr 20, D-04103 Leipzig, Germany.	marco.krasselt@medizin.uni-leipzig.de; christoph.baerwald@medizin.uni-leipzig.de; liebert@medizin.uni-leipzig.de; olga.seifert@medizin.uni-leipzig.de	Baerwald, Christoph/AAD-9013-2020; Krasselt, Marco/AAN-2557-2021	Baerwald, Christoph/0000-0002-1406-3024; Krasselt, Marco/0000-0002-1842-0754; Liebert, U.G./0000-0002-5129-0875	Leipzig University for Open Access Publishing	We acknowledge support from Leipzig University for Open Access Publishing.	Acharya S, 2019, ARTHRITIS RHEUMATOL, V71; Arvin AM, 2008, J INFECT DIS, V197, pS58, DOI 10.1086/522123; Asada H, 2019, VACCINE, V37, P6776, DOI 10.1016/j.vaccine.2019.09.031; Asada H, 2013, J DERMATOL SCI, V69, P243, DOI 10.1016/j.jdermsci.2012.10.015; Bastidas A, 2019, JAMA-J AM MED ASSOC, V322, P123, DOI 10.1001/jama.2019.9053; Bechman K, 2019, RHEUMATOLOGY, V58, P1755, DOI 10.1093/rheumatology/kez087; Berkowitz EM, 2015, J INFECT DIS, V211, P1279, DOI 10.1093/infdis/jiu606; BLAESE RM, 1980, AM J MED, V69, P345, DOI 10.1016/0002-9343(80)90003-0; Chehab G, 2018, RHEUMATOLOGY, V57, P1439, DOI 10.1093/rheumatology/key120; Cuadrado MJ, 2019, BMC RHEUMATOL, V3, DOI 10.1186/s41927-019-0079-2; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Dagnew AF, 2021, RHEUMATOLOGY, V60, P1226, DOI 10.1093/rheumatology/keaa424; Draborg AH, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/370516; FAUCI AS, 1981, ARTHRITIS RHEUM, V24, P577, DOI 10.1002/art.1780240402; Firestein GS, 2020, FIRESTEIN KELLEYS TX; Forbes HJ, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2911; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Gilbert PB, 2014, J INFECT DIS, V210, P1573, DOI 10.1093/infdis/jiu279; Harpaz R, 2020, J INFECT DIS, V222, P708, DOI 10.1093/infdis/jiz653; Hassan AB, 1998, J AUTOIMMUN, V11, P503, DOI 10.1006/jaut.1998.0236; Hata A, 2011, INFECTION, V39, P537, DOI 10.1007/s15010-011-0162-0; Imoto K, 2015, J DERMATOL SCI, V79, P235, DOI 10.1016/j.jdermsci.2015.05.011; Kallmark H, 2020, ARTHRITIS RHEUMATOL, V72; KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096; Kawai K, 2017, MAYO CLIN PROC, V92, P1806, DOI 10.1016/j.mayocp.2017.10.009; KAY RA, 1988, ANN RHEUM DIS, V47, P536, DOI 10.1136/ard.47.7.536; KELLY C, 1990, ANN RHEUM DIS, V49, P657, DOI 10.1136/ard.49.9.657; Korn T, 2017, NEW ENGL J MED, V376, P1680, DOI 10.1056/NEJMe1700720; Kraaij T, 2021, NEPHROL DIAL TRANSPL, V36, P1474, DOI 10.1093/ndt/gfaa117; Krasselt M, 2018, Z RHEUMATOL, V77, P727, DOI 10.1007/s00393-017-0410-5; Krasselt M, 2019, CLIN RHEUMATOL, V38, P2493, DOI 10.1007/s10067-019-04563-9; Krasselt M, 2019, CLIN REV ALLERG IMMU, V56, P346, DOI 10.1007/s12016-017-8631-6; Krasselt M, 2017, RHEUMATOL INT, V37, P229, DOI 10.1007/s00296-016-3608-y; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Levin MJ, 2008, J INFECT DIS, V197, P825, DOI 10.1086/528696; Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048; Liao TL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014032; Mok CC, 2019, ANN RHEUM DIS, V78, P1663, DOI 10.1136/annrheumdis-2019-215925; Mok CC, 2019, HUM VACC IMMUNOTHER, V15, P45, DOI 10.1080/21645515.2018.1514228; NAGASAWA K, 1990, ANN RHEUM DIS, V49, P630, DOI 10.1136/ard.49.8.630; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pappas DA, 2015, ARTHRIT CARE RES, V67, P1671, DOI 10.1002/acr.22628; Reichelt M, 2008, J VIROL, V82, P3971, DOI 10.1128/JVI.02592-07; RKI, 2020, STAND IMPFK EMPF STA, P1; Rondaan C, 2018, LUPUS, V27, P1271, DOI 10.1177/0961203318770535; Rondaan C, 2014, ARTHRITIS RHEUMATOL, V66, P3122, DOI 10.1002/art.38804; Scarsi M, 2014, J RHEUMATOL, V41, P666, DOI 10.3899/jrheum.130905; Schmedt N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220848; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Smitten AL, 2007, ARTHRIT RHEUM-ARTHR, V57, P1431, DOI 10.1002/art.23112; Stadtmauer EA, 2014, BLOOD, V124, P2921, DOI 10.1182/blood-2014-04-573048; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tavares-Da-Silva F, 2020, VACCINE, V38, P3489, DOI 10.1016/j.vaccine.2019.11.058; Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0; Tseng HF, 2020, J INFECT DIS, V222, P798, DOI 10.1093/infdis/jiz652; Veetil BMA, 2013, ARTHRIT CARE RES, V65, P854, DOI 10.1002/acr.21928; Vink P, 2017, OPEN FORUM INFECT S1, V4, pS417, DOI [DOI 10.1093/ofid/ofx163.1044, 10.1093/ofid/ofx163.1044]; Wagner N, 2019, BUNDESGESUNDHEITSBLA, V62, P494, DOI 10.1007/s00103-019-02905-1; Weyand CM, 2009, NAT REV RHEUMATOL, V5, P583, DOI 10.1038/nrrheum.2009.180; Zhang J, 2012, JAMA-J AM MED ASSOC, V308, P43, DOI 10.1001/jama.2012.7304; Zhang J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3497	61	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							325	10.3390/vaccines9040325			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5EX	33915820	gold, Green Published			2022-04-29	WOS:000643803400001
J	Petrini, S; Martucciello, A; Grandoni, F; De Matteis, G; Cappelli, G; Giammarioli, M; Scoccia, E; Grassi, C; Righi, C; Fusco, G; Galiero, G; Pela, M; De Mia, GM; De Carlo, E				Petrini, Stefano; Martucciello, Alessandra; Grandoni, Francesco; De Matteis, Giovanna; Cappelli, Giovanna; Giammarioli, Monica; Scoccia, Eleonora; Grassi, Carlo; Righi, Cecilia; Fusco, Giovanna; Galiero, Giorgio; Pela, Michela; De Mia, Gian Mario; De Carlo, Esterina			Evaluation of Safety and Efficacy of an Inactivated Marker Vaccine against Bovine alphaherpesvirus 1 (BoHV-1) in Water Buffalo (Bubalus bubalis)	VACCINES			English	Article						BoHV-1; marker vaccines; water buffalo	INFECTIOUS BOVINE-RHINOTRACHEITIS; HERPESVIRUS TYPE-1; CROSS-PROTECTION; GLYCOPROTEIN-E; ANTIBODIES; HERDS; GE; DIFFERENTIATION; EPIDEMIOLOGY; BUHV-1	Recent studies have explored the seropositivity of Bovine alphaherpesvirus 1 (BoHV-1) in water buffaloes, suggesting the urgency for developing strategies to eradicate the virus involving both cattle and water buffaloes. However, in Europe, the glycoprotein E (gE) deleted marker vaccines against BoHV-1 are commercially available only for the cattle industry. This study, for the first time, evaluated the safety and efficacy of a commercial inactivated gE-deleted marker vaccine in water buffalo. Five animals devoid of BoHV-1-neutralizing antibodies were vaccinated via intramuscular route. Five additional animals served as an unvaccinated control group. Sixty days after the first immunization, all animals were experimentally infected with a virulent BoHV-1via intranasal route. A detectable BoHV-1-humoral immune response was observed in the vaccinated group on post-vaccination day 30, whereas the antibodies appeared on post-challenge day 10 in the control group. Moreover, the vaccinated animals neither show viral shedding nor clinical signs compared to the control upon challenge. However, post-challenge, the BoHV-1-specific humoral and cell-mediated immune responses were significantly more increased in vaccinated animals than the control animals. Overall, the present study provides evidence of both the safety and efficacy of an inactivated gE-deleted marker vaccine against BoHV-1 in water buffaloes.	[Petrini, Stefano; Giammarioli, Monica; Scoccia, Eleonora; Righi, Cecilia; Pela, Michela; De Mia, Gian Mario] Ist Zooprofilatt Sperimentale Umbria Marche, Natl Reference Ctr Infect Bovine Rhinotracheitis, I-06126 Perugia, Italy; [Martucciello, Alessandra; Cappelli, Giovanna; Grassi, Carlo; Fusco, Giovanna; Galiero, Giorgio; De Carlo, Esterina] Ist Zooprofilatt Sperimentale Mezzogiorno, Natl Reference Ctr Hyg & Technol Breeding & Buffa, I-84131 Salerno, Italy; [Grandoni, Francesco; De Matteis, Giovanna] Res Ctr Anim Prod & Aquaculture, I-00015 Rome, Italy		Petrini, S (通讯作者)，Ist Zooprofilatt Sperimentale Umbria Marche, Natl Reference Ctr Infect Bovine Rhinotracheitis, I-06126 Perugia, Italy.	s.petrini@izsum.it; alessandra.martucciello@certizsmportici.it; francesco.grandoni@crea.gov.it; giovanna.dematteis@crea.gov.it; giovanna.cappelli@izsmportici.it; m.giammarioli@izsum.it; e.scoccia@izsum.it; carlo.grassi@izsmportici.it; c.righi@izsum.it; giovanna.fusco@cert.izsmportici.it; giorgio.galiero@cert.izsmportici.it; m.pela@izsum.it; gm.demia@izsum.it; esterina.decarlo@cert.izsmportici.it	De Matteis, Giovanna/ABD-1479-2020; Fusco, Giovanna/AAY-5344-2021; righi, cecilia/AAD-4022-2020; Petrini, Stefano/M-3397-2016; Giammarioli, Monica/F-1416-2019; Cappelli, Giovanna/ABH-9453-2020	Fusco, Giovanna/0000-0003-3139-7672; righi, cecilia/0000-0003-0286-7428; Petrini, Stefano/0000-0002-8689-832X; Giammarioli, Monica/0000-0002-3422-0699; GRANDONI, FRANCESCO/0000-0002-0650-7908; Cappelli, Giovanna/0000-0002-0197-4806; De Matteis, Giovanna/0000-0003-2963-3365	Italian Ministry for HealthMinistry of Health, Italy [RC IZSME 004/2017]	This research was funded by the Italian Ministry for Health, grant number Research Project RC IZSME 004/2017.	Amoroso MG, 2013, RES VET SCI, V94, P813, DOI 10.1016/j.rvsc.2012.12.009; [Anonymous], 2018, MANUAL DIAGNOSTIC TE; Bosch JC, 1997, VACCINE, V15, P1512, DOI 10.1016/S0264-410X(97)00092-3; Campos M., 1994, Cell-mediated immunity in ruminants., P229; Caruso C, 2016, VET QUART, V36, P184, DOI 10.1080/01652176.2016.1205236; Castrucci G, 2002, COMP IMMUNOL MICROB, V25, P29, DOI 10.1016/S0147-9571(01)00017-0; De Carlo E, 2004, VET REC, V154, P171, DOI 10.1136/vr.154.6.171; El-Kholy Alaa A, 2005, Egypt J Immunol, V12, P125; European Regulation (EC), 2016, OFF J EUR UNION L, V084, P1; FULTON RW, 1995, VACCINE, V13, P725, DOI 10.1016/0264-410X(94)00072-U; Fusco G, 2015, VET REC, V177, DOI 10.1136/vr.103139; Grandoni F, 2017, DEV COMP IMMUNOL, V74, P101, DOI 10.1016/j.dci.2017.04.013; Kerkhofs P, 2003, VET REC, V152, P681, DOI 10.1136/vr.152.22.681; Lage A P, 1996, Rev Elev Med Vet Pays Trop, V49, P195; Lemaire M, 1999, VET REC, V144, P172, DOI 10.1136/vr.144.7.172; Minervino AHH, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.570413; Mingala CN, 2009, RES VET SCI, V87, P213, DOI 10.1016/j.rvsc.2009.02.008; Montagnaro S, 2014, PREV VET MED, V116, P56, DOI 10.1016/j.prevetmed.2014.06.002; Muratore E, 2017, VET IMMUNOL IMMUNOP, V185, P1, DOI 10.1016/j.vetimm.2017.01.003; Nandi S., 2009, Animal Health Research Reviews, V10, P85, DOI 10.1017/S1466252309990028; Nogarol C, 2014, J VIROL METHODS, V207, P16, DOI 10.1016/j.jviromet.2014.06.023; Peshev R, 2000, ACTA VIROL, V44, P229; Petrini S, 2012, LARGE ANIM REV, V18, P113; Petrini S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010014; Petrini S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010023; Raaperi K, 2014, VET J, V201, P249, DOI 10.1016/j.tvjl.2014.05.040; Rana SK, 2011, VET ITAL, V47, P313; REED L. J., 1938, AMER JOUR HYG, V27, P493; Scicluna MT, 2007, ITAL J ANIM SCI, V6, P845; Scicluna MT, 2010, VET MICROBIOL, V143, P81, DOI 10.1016/j.vetmic.2010.02.016; Shah NH, 2001, VET REC, V149, P583, DOI 10.1136/vr.149.19.583; STRUBE W, 1995, DEV BIOL STAND, V84, P75; Thiry J, 2006, VET RES, V37, P169, DOI 10.1051/vetres:2005052; Turin L., 2003, VET B, V73, P15; VanOirschot JT, 1997, J VIROL METHODS, V67, P23, DOI 10.1016/S0166-0934(97)00073-6; vanOirschot JT, 1996, J BIOTECHNOL, V44, P75, DOI 10.1016/0168-1656(95)00129-8; Walker PJ, 2005, CURR TOP MICROBIOL, V292, P57	38	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							355	10.3390/vaccines9040355			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UB	33917160	Green Published, gold			2022-04-29	WOS:000643775000001
J	Vallee, A; Fourn, E; Majerholc, C; Touche, P; Zucman, D				Vallee, Alexandre; Fourn, Erwan; Majerholc, Catherine; Touche, Pauline; Zucman, David			COVID-19 Vaccine Hesitancy among French People Living with HIV	VACCINES			English	Article						COVID-19; COVID-19 vaccine; vaccine hesitancy; HIV	HERD-IMMUNITY; SARS-COV-2; ATTITUDES	People living with HIV are a high-risk population concerning the coronavirus 19 (COVID-19) infection, with a poorer prognosis. It is important to achieve high COVID-19 vaccination coverage rates in this group as soon as possible. This project used self-reporting to assess vaccine hesitancy and acceptance among people living with HIV towards the novel COVID-19 vaccine. Sixty-eight (28.7%) participants among the 237 declared their hesitancy to be vaccinated against COVID-19. Participants who expressed concerns about their health (p < 0.001), the requirement of mandatory COVID-19 vaccination (p = 0.017), and their chronic disease status (p = 0.026) were independently associated with the acceptance of vaccination. Conversely, participants presenting general vaccine refusal (p < 0.001), concerns about the serious side effects of COVID-19 vaccines (p < 0.001), and those already thinking having an immune status to COVID-19 (p = 0.008) were independently associated with COVID-19 vaccine hesitancy. Our results suggest that vaccine strategy would be more successful in France with a communication strategy emphasizing the collective benefits of herd immunity in the population living with HIV and reassuring patients with chronic diseases about the safety of the proposed vaccines.	[Vallee, Alexandre; Touche, Pauline] Foch Hosp, Dept Clin Res & Innovat, F-92150 Suresnes, France; [Fourn, Erwan; Majerholc, Catherine; Zucman, David] Foch Hosp, Dept Internal Med, Reseau Ville Hop Val de Seine, F-92150 Suresnes, France		Vallee, A (通讯作者)，Foch Hosp, Dept Clin Res & Innovat, F-92150 Suresnes, France.	alexandre.g.vallee@gmail.com; e.fourn@hopital-foch.com; c.majerholc@hopital-foch.com; p.touche@hopital-foch.com; d.zucnaan@hopital-foch.com		Vallee, Alexandre/0000-0001-9158-4467; zucman, david/0000-0002-7682-0115			Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Baumgaertner B, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003354; Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056; Bhaskaran K, 2021, LANCET HIV, V8, pe24, DOI 10.1016/S2352-3018(20)30305-2; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Cafiero F, 2021, SOC NETWORKS, V65, P63, DOI 10.1016/j.socnet.2020.11.004; Carrat F., 2020, MEDRXIV; Cordero DA, 2021, J PUBLIC HEALTH-UK, V43, pE303, DOI 10.1093/pubmed/fdab020; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eguia H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020170; Ekezie W, 2021, J PUBLIC HEALTH-UK, V43, pE258, DOI 10.1093/pubmed/fdaa196; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fung M, 2021, CLIN INFECT DIS, V72, P340, DOI 10.1093/cid/ciaa863; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gerussi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020172; Gori D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020173; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Moran KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164541; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Saad-Roy CM, 2020, SCIENCE, V370, P811, DOI 10.1126/science.abd7343; Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199; Sigel K, 2020, CLIN INFECT DIS, V71, P2933, DOI 10.1093/cid/ciaa880; Tesoriero JM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37069; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; Vergara RJD, 2021, J PUBLIC HEALTH-UK, V43, pE291, DOI 10.1093/pubmed/fdaa282; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Vizcarra P, 2020, LANCET HIV, V7, pE554, DOI 10.1016/S2352-3018(20)30164-8; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Ward JK, 2019, NAT IMMUNOL, V20, P1257, DOI 10.1038/s41590-019-0488-9; Waterfield KC, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10296-9; Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA, 2019, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1198, DOI 10.1093/CID/CIAA1198]; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	49	17	17	14	29	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							302	10.3390/vaccines9040302			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UL	33804808	gold, Green Published			2022-04-29	WOS:000643776000001
J	Yan, YX; Pang, YX; Lyu, ZY; Wang, RQ; Wu, XY; You, C; Zhao, HT; Manickam, S; Lester, E; Wu, T; Pang, CH				Yan, Yuxin; Pang, Yoongxin; Lyu, Zhuoyi; Wang, Ruiqi; Wu, Xinyun; You, Chong; Zhao, Haitao; Manickam, Sivakumar; Lester, Edward; Wu, Tao; Pang, Cheng Heng			The COVID-19 Vaccines: Recent Development, Challenges and Prospects	VACCINES			English	Review						vaccines; COVID-19; global pandemic; coronavirus; SARS-CoV-2	VACCINATION; CORONAVIRUS; SARS	The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the "new normal" and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public.	[Yan, Yuxin; Lyu, Zhuoyi; Wu, Tao] Univ Nottingham Ningbo China, Dept Chem & Environm Engn, Ningbo 315100, Peoples R China; [Pang, Yoongxin; Wang, Ruiqi; Wu, Xinyun; Pang, Cheng Heng] Univ Nottingham Ningbo China, New Mat Inst, Ningbo 315042, Peoples R China; [You, Chong] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China; [Zhao, Haitao] MIT, MITMECHE, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Manickam, Sivakumar] Univ Teknol Brunei, Fac Engn, Petr & Chem Engn, BE-1410 Bandar Seri Begawan, Brunei; [Lester, Edward] Univ Nottingham, Dept Chem & Environm Engn, Nottingham NG7 2RD, England; [Wu, Tao] Univ Nottingham Ningbo China, Key Lab Carbonaceous Wastes Proc & Proc Intensifi, Ningbo 315100, Peoples R China; [Pang, Cheng Heng] Univ Nottingham Ningbo China, Municipal Key Lab Clean Energy Convers Technol, Ningbo 315100, Peoples R China		Pang, CH (通讯作者)，Univ Nottingham Ningbo China, New Mat Inst, Ningbo 315042, Peoples R China.; Pang, CH (通讯作者)，Univ Nottingham Ningbo China, Municipal Key Lab Clean Energy Convers Technol, Ningbo 315100, Peoples R China.	yuxin.yan@nottingham.edu.cn; yoongxin.pang@nottingham.edu.cn; slyzl6@nottingham.edu.cn; shyrw2@nottingham.edu.cn; xinyun.wu@nottingham.edu.cn; chongy@pku.edu.cn; haitaoz@mit.edu; manickam.sivakumar@utb.edu.bn; edward.lester@nottingham.ac.uk; tao.wu@nottingham.edu.cn; chengheng.pang@nottingham.edu.cn	Wu, Tao/ABD-5166-2020; Manickam, Sivakumar/I-2228-2014	Wu, Tao/0000-0001-6469-9613; Manickam, Sivakumar/0000-0001-9102-4013; WU, Xinyun/0000-0003-4131-0577; Lester, Ed/0000-0003-1060-103X; Pang, Cheng Heng/0000-0003-1616-6614	S&T Innovation 2025 Major Special Programme [2018B10022]; Ningbo Natural Science Foundation Programme [2018A610069]; UNNC FoSE Faculty Inspiration Grant, China; Zhejiang Provincial Department of Science and Technology [2020E10018]; Ningbo Science and Technology Bureau, China	The authors also gratefully express gratitude to all parties who have contributed towards the success of this project, both financially and technically, especially the S&T Innovation 2025 Major Special Programme (grant number 2018B10022) and the Ningbo Natural Science Foundation Programme (grant number 2018A610069) funded by the Ningbo Science and Technology Bureau, China, as well as the UNNC FoSE Faculty Inspiration Grant, China. The Zhejiang Provincial Department of Science and Technology is also acknowledged for this research under its Provincial Key Laboratory Programme (2020E10018).	Alhazzani W, 2020, CRIT CARE MED, V48, pE440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; [Anonymous], 2021, BELTA NEWS 0119; Arthur R., 2020, BIOPHARMA REPORTER; Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209; BBC News, 2020, BBC NEWS 1231; BBC News, 2021, BBC NEWS 0113; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688; Bharat Biotech COVAXIN&REG;, 2021, INDI 1 IND COVID 19; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Callaway E, 2020, NATURE, V579, P183, DOI 10.1038/d41586-020-00698-x; Carl Zimmer J.C., 2021, CORONAVIRUS VACCINE; Centers for Disease Control and Prevention, 2021, EM SARS COV 2 VAR; Chen C, FAVIPIRAVIR VERSUS A, V2020, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]; Chen N., 2020, The Lancet, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2; Chinese Clinical Trial Registry, 2020, PHAS 3 CLIN TRIAL IN; COVID-19 Treatment Guidelines Panel, 2020, COVID 19 TREATM GUID; D'Agostini G., INFERRING VACCINE EF; De Soto J.A., 2020, J MED CLIN SCI, DOI [10.15520/arjmcs.v7i01.246, DOI 10.15520/ARJMCS.V7I01.246]; Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gao GF., 2021, BIORXIV; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Garvey L.H., 2020, BRIT J ANAESTH, DOI [10.1016/j.bja.2020.12.020, DOI 10.1016/J.BJA.2020.12.020]; Ghosh S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111840; Gibran Naiyyar Peshimam, 2021, REUTERS 0208; Gooch KE, 2021, VACCINE, V39, P4885, DOI 10.1016/j.vaccine.2021.06.057; Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056; Grant PR, 2003, NEW ENGL J MED, V349, P2468, DOI 10.1056/NEJM200312183492522; India National Institute of Medical Statistics, 2020, PROSP RAND AD PHAS 1; India National Institute of Medical Statistics, 2020, PHAS 3 RAND DOUBL BL; Jain U., 2021, ASA MONIT, V85, P32, DOI [10.1097/01.ASM.0000725884.36964.12, DOI 10.1097/01.ASM.0000725884.36964.12]; Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Lee Jong-Koo, 2020, Osong Public Health Res Perspect, V11, P343, DOI 10.24171/j.phrp.2020.11.6.01; Li S., 2021, TANDEM REPEAT DIMERI, DOI [10.1101/2021.03.11.434928, DOI 10.1101/2021.03.11.434928]; Li TY, 2020, ACTA OTO-LARYNGOL, V140, P570, DOI 10.1080/00016489.2020.1745271; Liu R., 2021, REUTERS 0224; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Ma CQ, 2020, MICROBES INFECT, V22, P245, DOI 10.1016/j.micinf.2020.05.004; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4944; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4552; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4362; Mallapaty S, 2021, NATURE, V590, P191, DOI 10.1038/d41586-021-00299-2; McIntyre P, 2021, AUST PRESCR, V44, P19, DOI 10.18773/austprescr.2020.084; Meir R, 2012, VIRAL IMMUNOL, V25, P55, DOI 10.1089/vim.2011.0050; Ministry of Science and Higher Education of the Russian Federation, 2021, CHUM FED SCI CTR RES; Moreira RA, 2020, MATERIALS, V13, DOI 10.3390/ma13235362; Moreira RA, 2020, NANOSCALE, V12, P16409, DOI 10.1039/d0nr03969a; Mueller S, 2020, VACCINE, V38, P2943, DOI 10.1016/j.vaccine.2020.02.056; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; National Medical Products Administration, 2021, NMPA COND APPR COVID; Omata M., 2021, DISCOVERY SARS COV 2, DOI [10.1101/2021.02.24.21251892, DOI 10.1101/2021.02.24.21251892]; Parker EPK, 2020, NAT REV IMMUNOL, V20, P650, DOI 10.1038/s41577-020-00455-1; Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2; Pharmaceuticals and Medical Devices Agency, 2014, REP DEL RES; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Poland GA, 2020, MAYO CLIN PROC, V95, P2172, DOI 10.1016/j.mayocp.2020.07.021; Qin J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1202; Rogers P., 2020, SELF AMPLIFYING RNA, V11, P1, DOI [10.1101/2020.04.22.055608v1, DOI 10.1101/2020.04.22.055608]; Roxby P, 2020, BBC NEWS; Sagonowsky E., 2020, HIGH IS BAR; Sah R, 2021, TRAVEL MED INFECT DI, V40, DOI 10.1016/j.tmaid.2021.101989; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015; Singh J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030439; Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722; Tsang KW, 2003, RESPIROLOGY, V8, P259, DOI 10.1046/j.1440-1843.2003.00486.x; Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211; U.S. Food and Drug Administration, 2021, COVID 19 VACC AD26 C; U.S. Food and Drug Administration, 2021, JANSS COVID 19 VACC; U.S. National Library of Medicine, 2020, STUD TOL SAF IMM PRE; U.S. National Library of Medicine, 2020, STUD AD26 COV2 S PRE; U.S. National Library of Medicine, 2020, STUD DET SAF EFF SAR; U.S. National Library of Medicine, 2020, STUD AD26 COV2; U.S. National Library of Medicine, 2020, STUD EV EFF SAF IMM; U.S. National Library of Medicine, 2020, STUD EV SAF REACT EF; U.S. National Library of Medicine, 2020, PHAS 2 3 STUDY COVID; U.S. National Library of Medicine, 2021, STUD GRAD COV2 PREV; U.S. National Library of Medicine, 2020, EFF SAF IMM STUD IN; U.S. National Library of Medicine, 2020, PHAS 3 CLIN TRIAL DE; U.S. National Library of Medicine, 2021, CONTR PHAS 2 3 STUD; U.S. National Library of Medicine, 2020, CLIN TRIAL EFF SAF S; U.S. National Library of Medicine, 2020, INV VACC COVID 19; U.S. National Library of Medicine, 2020, PHAS 3 TRIAL COVID 1; U.S. National Library of Medicine, 2020, IMM EFF SAF QAZCOVID; U.S. National Library of Medicine, 2020, CLIN TRIAL SARS COV; U.S. National Library of Medicine, 2021, PHAS 3 STUD EV SAF T; U.S. National Library of Medicine, 2021, STUD EV SAF TOL IMM; U.S. National Library of Medicine, 2020, STUD REC COR LIK PAR; U.S. National Library of Medicine, 2020, STUD DESCR SAF TOL I; U.S. National Library of Medicine Efficacy, 2020, SAF IMM STUD SARS CO; Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624; University of Pittsburgh Medical Center, 2020, RES PITTSB PAR VIENN; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; Vandenberghe LH, 2020, HUM GENE THER, V31, P605, DOI 10.1089/hum.2020.29125.lhv; Vasto Sonya, 2006, Immun Ageing, V3, P2, DOI 10.1186/1742-4933-3-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Watterson D., 2020, RES SQ PREPR, Vv1, DOI [10.21203/rs.3.rs-68892/v1, DOI 10.21203/RS.3.RS-68892/V1]; WHO, 2020, CLIN MAN SEV AC RESP; WHO, 2021, DRAFT LANDSC TRACK C; Won JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249775; World Health Organization, 2020, REP WHO CHIN JOINT M; Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xinhua, 2020, XIN HUA NEWS 0208; Yan YX, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072323; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9; Zhang Y., 2020, IMMUNOGENICITY SAFET, DOI [DOI 10.1101/2020.07.31.20161216, 10.1101/2020.07.31.20161216]; Zhao Q., 2020, BMJ-BRIT MED J, DOI DOI 10.1136/bmj.l6890; Zhao S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020388; Zheng NY, 2009, VACCINE, V27, P5001, DOI 10.1016/j.vaccine.2009.05.073; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	123	21	21	9	30	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							349	10.3390/vaccines9040349			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4QK	33916489	gold, Green Published, Green Accepted			2022-04-29	WOS:000643765400001
J	Biasio, LR; Bonaccorsi, G; Lorini, C; Mazzini, D; Pecorelli, S				Biasio, Luigi Roberto; Bonaccorsi, Guglielmo; Lorini, Chiara; Mazzini, Daniela; Pecorelli, Sergio			Italian Adults' Likelihood of Getting COVID-19 Vaccine: A Second Online Survey	VACCINES			English	Article						COVID-19; online surveys; vaccines; vaccine literacy		Rapid online surveys are an important tool for tracking the public's knowledge and perceptions during infectious disease outbreaks. In June 2020, during the early phases of COVID-19 vaccines development, we conducted a survey in 885 Italian adults that aimed at assessing their attitudes and opinions about vaccination, in addition to their vaccine literacy levels (i.e., skills in finding, understanding, and using information about vaccines). In January 2021, the same questionnaire was administered to a similar population (n = 160). Interactive vaccine literacy was significantly higher in January 2021 than in June 2020 (mean score 3.38 vs. 3.27 respectively, p = 0.0021). The percentage of participants willing to be vaccinated against COVID-19 assessed by either-or questions, was equally high in both surveys (>90%), which is quite reassuring, although metrics based on categorical scales cannot identify hesitant subjects.	[Biasio, Luigi Roberto; Pecorelli, Sergio] Giovanni Lorenzini Fdn, Viale Piave 35, I-20129 Milan, Italy; [Bonaccorsi, Guglielmo; Lorini, Chiara] Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy; [Mazzini, Daniela] Cent Tuscany Local Hlth Unit, I-50134 Florence, Italy		Biasio, LR (通讯作者)，Giovanni Lorenzini Fdn, Viale Piave 35, I-20129 Milan, Italy.	lrbiasio@gmail.com; guglielmo.bonaccorsi@unifi.it; chiara.lorini@unifi.it; daniela.mazzini@uslcentro.toscana.it; sergio.pecorelli@lorenzinifoundation.org	; Biasio, Luigi Roberto/AAH-7726-2019	Lorini, Chiara/0000-0003-3170-1857; Biasio, Luigi Roberto/0000-0001-8932-0411; bonaccorsi, guglielmo/0000-0002-5171-4308			Aharon AA, 2017, PATIENT EDUC COUNS, V100, P768, DOI 10.1016/j.pec.2016.11.016; [Anonymous], 2019, ISTAT CITTADINI ICT; [Anonymous], 2015, MEDCALC SOFTWARE BVB; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Graffigna G, 2020, VACCINE, V38, P7585, DOI 10.1016/j.vaccine.2020.10.025; Ishikawa H, 2008, DIABETES CARE, V31, P874, DOI 10.2337/dc07-1932; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Olsen F, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-52; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419	13	12	12	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							268	10.3390/vaccines9030268			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5WN	33802873	gold, Green Published			2022-04-29	WOS:000634224100001
J	Itatani, T; Horiike, R; Nakai, H; Taira, K; Honda, C; Shirai, F; Konishi, K				Itatani, Tomoya; Horiike, Ryo; Nakai, Hisao; Taira, Kazuya; Honda, Chika; Shirai, Fumie; Konishi, Kaoru			Model Comparisons of the Cost Effectiveness of Rubella Vaccination Method in Japanese Adults	VACCINES			English	Article						cost effectiveness; rubella; congenital rubella syndrome; vaccine	MEASLES; MUMPS	The number of rubella cases has increased in Japan, especially among adults. Rubella infection in pregnant females can lead to congenital rubella syndrome (CRS). The Japanese government is promoting vaccination to prevent CRS. This study performs a cost-effectiveness analysis of the following four methods: (1) females who wished to become pregnant and partners, with an antibody-titer test; (2) females only, with an antibody-titer test; (3) females and males, without an antibody-titer test; (4) females only, without an antibody-titer test. A decision tree model with a hypothetical cohort of 500 males and 500 females was used for the analysis, and the parameters were obtained from previous studies. The number of avoidances of CRS was defined as the effect. Compared to the case where methods were not implemented, the number of CRS cases that can be prevented by implementing the methods was 0.0115589 by (1) and (3) and 0.0147891 by (2) and (4). The cost effectiveness of (1) to (4) was 287,413,677 JPY, 135,050,529 JPY, 388,524,974 JPY, and 197,744,219 JPY, respectively (1 JPY = 0.00963247 USD). Method (2) was the most cost-effective and did not change by sensitivity analysis. We conclude that the vaccination for females only with an antibody-titer test is recommended.	[Itatani, Tomoya] Kanazawa Univ, Doctoral Course Grad Sch Med Pharmaceut & Hlth Sc, Div Hlth Sci, Kanazawa, Ishikawa 9200942, Japan; [Horiike, Ryo] Susaki Reg Welf & Hlth Ctr, Kochi, Kochi 7858585, Japan; [Nakai, Hisao] Kanazawa Med Univ, Nursing Dept, Uchinada, Ishikawa 9200265, Japan; [Taira, Kazuya] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Kyoto, Kyoto 6068501, Japan; [Honda, Chika] Osaka Univ, Ctr Twin Res, Grad Sch Med, Suita, Osaka 5650871, Japan; [Honda, Chika] Shiga Univ Med Sci, Fac Nursing, Otsu, Shiga 5202192, Japan; [Shirai, Fumie] Morinomiya Univ Med Sci, Dept Nursing, Osaka, Osaka 5598611, Japan; [Konishi, Kaoru] Osaka Univ, Grad Sch Med, Div Hlth Sci, Suita, Osaka 5650871, Japan		Itatani, T (通讯作者)，Kanazawa Univ, Doctoral Course Grad Sch Med Pharmaceut & Hlth Sc, Div Hlth Sci, Kanazawa, Ishikawa 9200942, Japan.	itatani@staff.kanazawa-u.ac.jp; spi4949@gmail.com; h-nakai@kanazawa-med.ac.jp; taira.kazuya.5m@kyoto-u.ac.jp; honda-ch@sahs.med.osaka-u.ac.jp; fumie_shirai@morinomiya-u.ac.jp; kkonishi@sahs.med.osaka-u.ac.jp	ITATANI, Tomoya/L-3716-2015	ITATANI, Tomoya/0000-0003-1359-2909	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP20H04027]	This work was supported by JSPS KAKENHI Grant Number JP20H04027.	Boccalini S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010060; Centers for Disease Control and Prevention (CDC), RUBELLA; Centers for Disease Control and Prevention (CDC), NATIONWIDE RUBELLA E; GHIDINI A, 1993, WESTERN J MED, V159, P366; Karadeniz A, 2020, J INFECT PUBLIC HEAL, V13, P480, DOI 10.1016/j.jiph.2020.01.309; Kato Hirofumi, 2013, Kansenshogaku Zasshi, V87, P603; Machida M, 2020, INT J INFECT DIS, V96, P371, DOI 10.1016/j.ijid.2020.05.039; Ministry of Health Labour and Welfare, ADDITIONAL MEASURES; Ministry of Health Labour and Welfare, SURVEY MEDICAL BENEF; National Institute of Infectious Diseases, RUBELLA CONGENITAL R; National Institute of Infectious Diseases, GUIDELINES RUBELLA V; National Institute of Infectious Diseases, INFECT DIS WEEKLY RE; National Institute of Infectious Diseases, EXAMINATION CORRELAT; National Institute of Infectious Diseases, CUMULATIVE RUBELLA C; National Institute of Infectious Diseases, REPORTS CONGENITAL R; National Institute of Infectious Diseases National Institute of Infectious Diseases, WHAT IS RUBELLA; Odemis I, 2019, REV ESP QUIM, V32, P525; Ohmori Y, 2014, J PLANT RES, V127, P57, DOI 10.1007/s10265-013-0616-9; Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002; Reef SE, 2000, CLIN INFECT DIS, V31, P85, DOI 10.1086/313928; Statistic Bureau Ministry of Internal Affairs and Communications, BASIC SURVEY WAGE ST; Taya K., TRANSITION CAVERAGE; Terada K., 2000, J JPN ASS INFECT DIS, V74, P1017; The National Statistics Center, E STAT POTAL SITE OF; Tokyo Metropolitan Infectious Diseases Surveillance Center, 2013, RUBELLA COMPLICATION	25	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							233	10.3390/vaccines9030233			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6DM	33800506	Green Published, gold			2022-04-29	WOS:000634242200001
J	Palmieri, E; Arato, V; Oldrini, D; Ricchetti, B; Aruta, MG; Pansegrau, W; Marchi, S; Giusti, F; Ferlenghi, I; Rossi, O; Alfini, R; Giannelli, C; Gasperini, G; Necchi, F; Micoli, F				Palmieri, Elena; Arato, Vanessa; Oldrini, Davide; Ricchetti, Beatrice; Aruta, Maria Grazia; Pansegrau, Werner; Marchi, Sara; Giusti, Fabiola; Ferlenghi, Ilaria; Rossi, Omar; Alfini, Renzo; Giannelli, Carlo; Gasperini, Gianmarco; Necchi, Francesca; Micoli, Francesca			Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropriate Methods to Detect Changes in Vaccine Potency	VACCINES			English	Article						outer membrane vesicles; GMMA; stability; vaccine		Ensuring the stability of vaccines is crucial to successfully performing global immunization programs. Outer Membrane Vesicles (OMV) are receiving great attention as vaccine platforms. OMV are complex molecules and few data have been collected so far on their stability. OMV produced by bacteria, genetically modified to increase their spontaneous release, simplifying their production, are also known as Generalized Modules for Membrane Antigens (GMMA). We have performed accelerated stability studies on GMMA from different pathogens and verified the ability of physico-chemical and immunological methods to detect possible changes. High-temperature conditions (100 degrees C for 40 min) did not affect GMMA stability and immunogenicity in mice, in contrast to the effect of milder temperatures for a longer period of time (37 degrees C or 50 degrees C for 4 weeks). We identified critical quality attributes to monitor during stability assessment that could impact vaccine efficacy. In particular, specific recognition of antigens by monoclonal antibodies through competitive ELISA assays may replace in vivo tests for the potency assessment of GMMA-based vaccines.	[Palmieri, Elena; Arato, Vanessa; Oldrini, Davide; Ricchetti, Beatrice; Aruta, Maria Grazia; Rossi, Omar; Alfini, Renzo; Giannelli, Carlo; Gasperini, Gianmarco; Necchi, Francesca; Micoli, Francesca] GSK Vaccines Inst Global Hlth GVGH Srl, Via Fiorentina 1, I-53100 Siena, Italy; [Pansegrau, Werner; Marchi, Sara; Giusti, Fabiola; Ferlenghi, Ilaria] GSK, Via Fiorentina 1, I-53100 Siena, Italy		Micoli, F (通讯作者)，GSK Vaccines Inst Global Hlth GVGH Srl, Via Fiorentina 1, I-53100 Siena, Italy.	elena.x.palmieri@gsk.com; vanessa.x.arato@gsk.com; davide.x.oldrini@gsk.com; b.ricchetti88@gmail.com; maria-grazia.x.aruta@gsk.com; werner.x.pansegrau@gsk.com; sara.x.marchi@gsk.com; fabiola.x.giusti@gsk.com; ilaria.x.ferlenghi@gsk.com; omar.x.rossi@gsk.com; renzo.x.alfini@gsk.com; carlo.x.giannelli@gsk.com; gianmarco.x.gasperini@gsk.com; francesca.x.necchi@gsk.com; francesca.x.micoli@gsk.com		Palmieri, Elena/0000-0002-1248-5389; Oldrini, Davide/0000-0001-7827-6582; Rossi, Omar/0000-0002-0170-1285; Arato, Vanessa/0000-0002-5923-6320	U.K. Department of Health and Social Care [EP/R013764/1]	This research was partially funded by U.K. Department of Health and Social Care, grant number EP/R013764/1.	Arigita C, 2004, VACCINE, V22, P629, DOI 10.1016/j.vaccine.2003.08.027; De Benedetto G, 2017, VACCINE, V35, P419, DOI 10.1016/j.vaccine.2016.11.089; De Benedetto G, 2017, ACS OMEGA, V2, P8282, DOI 10.1021/acsomega.7b01173; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Frasch CE, 2001, METH MOLEC MED, V66, P81, DOI 10.1385/1-59259-148-5:81; FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67; Gerke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134478; Giannelli C, 2020, ANAL CHEM, V92, P6304, DOI 10.1021/acs.analchem.9b05107; Gnopo YMD, 2020, J COLLOID INTERF SCI, V578, P522, DOI 10.1016/j.jcis.2020.04.068; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201970055; Koeberling O, 2014, VACCINE, V32, P2688, DOI 10.1016/j.vaccine.2014.03.068; Lanzilao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139847; Launay O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00335; Launay O, 2017, EBIOMEDICINE, V22, P164, DOI 10.1016/j.ebiom.2017.07.013; Li M, 2020, J CONTROL RELEASE, V323, P253, DOI 10.1016/j.jconrel.2020.04.031; Li YY, 2013, MAR DRUGS, V11, P3197, DOI 10.3390/md11093197; MacLennan CA, 2014, HUM VACC IMMUNOTHER, V10, P1478, DOI 10.4161/hv.29054; Mancini F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80421-y; Mancini F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124416; Mani S, 2016, VACCINE, V34, P2887, DOI 10.1016/j.vaccine.2016.02.075; Micoli F, 2013, ANAL BIOCHEM, V434, P136, DOI 10.1016/j.ab.2012.10.038; Micoli F, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101433; Micoli F, 2018, P NATL ACAD SCI USA, V115, P10428, DOI 10.1073/pnas.1807655115; Micoli F, 2014, CARBOHYD RES, V385, P1, DOI 10.1016/j.carres.2013.12.003; Nakao R, 2016, VACCINE, V34, P4626, DOI 10.1016/j.vaccine.2016.06.016; Necchi F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172163; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; O'Ryan M, 2014, DRUGS, V74, P15, DOI 10.1007/s40265-013-0155-7; Obiero CW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01884; Raso MM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020160; Rossi O, 2020, METHOD PROTOCOL, V3, DOI 10.3390/mps3030062; Rossi Omar, 2020, High Throughput, V9, DOI 10.3390/ht9020014; Rossi O, 2016, CLIN VACCINE IMMUNOL, V23, P304, DOI 10.1128/CVI.00023-16; Rossi O, 2014, J BIOL CHEM, V289, P24922, DOI 10.1074/jbc.M114.566570; Schager AE, 2018, MBIO, V9, DOI 10.1128/mBio.02379-17; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525; van de Waterbeemd B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065157; van der Pol L, 2015, BIOTECHNOL J, V10, P1689, DOI 10.1002/biot.201400395; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310; Yethon JA, 2000, INFECT IMMUN, V68, P4485, DOI 10.1128/IAI.68.8.4485-4491.2000; Yethon JA, 2001, J BIOL CHEM, V276, P5498, DOI 10.1074/jbc.M008255200	43	7	7	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							229	10.3390/vaccines9030229			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5GT	33800727	Green Published, gold			2022-04-29	WOS:000634183100001
J	Wang, L; Verschuuren, EAM; Paap, D; Rondaan, C; Raveling-Eelsing, E; Liu, SQ; Westra, J; Bos, NA				Wang, Lei; Verschuuren, Erik A. M.; Paap, Davy; Rondaan, Christien; Raveling-Eelsing, Elisabeth; Liu, Siqi; Westra, Johanna; Bos, Nicolaas A.			Ageing of Immune System and Response to a Live-Attenuated Herpes Zoster Vaccine in Lung Transplant Candidates	VACCINES			English	Article						lung transplantation; ageing; herpes zoster vaccine; age associated B cells	IMMUNOGENICITY; SAFETY; VIRUS; TOLERABILITY; ACCUMULATION; EFFICACY	The mean age of lung transplant recipients has significantly increased in recent decades. Elderly recipients have a higher risk of developing herpes zoster (HZ), and they have in general a worse response to vaccination than younger persons do. We investigated the relationship between the humoral and cellular immune response to a live-attenuated HZ vaccine (Zostavax(R), Merck Sharp and Dohme) and the frequencies of T and B cell subsets, especially aged cell subsets (CD28-T cells and age associated B cells, ABCs). In total, 37 patients awaiting lung transplantation received one dose of Zostavax(R), and peripheral blood was collected before and within 6 months after vaccination. We observed a robust immune response after vaccination. The frequencies of CD28-T cells before vaccination had no impact on the subsequent immune response to HZ vaccination. However, a higher frequency of ABCs before vaccination correlated with a lower immune response especially regarding the cellular immune response. Cytomegalovirus seropositivity was associated with increased frequencies of CD28-T cells but not with frequencies of ABCs in the patients. In conclusion, increased levels of ABCs might disturb the cellular immune response to HZ vaccination, which could lower the efficacy of such vaccination in elderly transplant recipients.	[Wang, Lei; Paap, Davy; Raveling-Eelsing, Elisabeth; Liu, Siqi; Westra, Johanna; Bos, Nicolaas A.] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9713 EZ Groningen, Netherlands; [Verschuuren, Erik A. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis & TB, NL-9713 EZ Groningen, Netherlands; [Paap, Davy] Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil Med, NL-9713 EZ Groningen, Netherlands; [Rondaan, Christien] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, NL-9713 EZ Groningen, Netherlands		Bos, NA (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9713 EZ Groningen, Netherlands.	l.wang@umcg.nl; e.a.m.verschuuren@umcg.nl; d.paap@umcg.nl; c.rondaan@umcg.nl; e.raveling-eelsing@umcg.NL; s.liu@umcg.nl; johanna.westra@umcg.nl; n.a.bos@umcg.nl	Paap, Davy/ABB-4366-2020	Paap, Davy/0000-0001-9076-3965; Westra, Johanna/0000-0002-6581-6508; WANG, LEI/0000-0003-4251-7473	Chinese Scholarship CouncilChina Scholarship Council [201606040177]; De Cock-Hadders Foundation [2018-53, 2019-71]	This work was supported by the Chinese Scholarship Council, grant number CSC NO. 201606040177, and the De Cock-Hadders Foundation, grant number 2018-53 and 2019-71.	Cancro MP, 2020, ANNU REV IMMUNOL, V38, P315, DOI 10.1146/annurev-immunol-092419-031130; Colvin MM, 2017, J CLIN INVEST, V127, P2523, DOI 10.1172/JCI90601; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Derhovanessian E, 2013, VACCINE, V31, P685, DOI 10.1016/j.vaccine.2012.11.041; Dugan HL, 2020, CELL IMMUNOL, V348, DOI 10.1016/j.cellimm.2019.103998; Frasca D, 2016, HUM VACC IMMUNOTHER, V12, P682, DOI 10.1080/21645515.2015.1105413; Frasca D, 2015, VACCINE, V33, P1433, DOI 10.1016/j.vaccine.2015.01.071; Hachem Ramsey R, 2015, Clin Transpl, V31, P239; Hao Y, 2011, BLOOD, V118, P1294, DOI 10.1182/blood-2011-01-330530; Hartert M, 2014, DTSCH ARZTEBL INT, V111, P107, DOI 10.3238/arztebl.2014.0107; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Levin MJ, 2019, HUM VACC IMMUNOTHER, V15, P772, DOI 10.1080/21645515.2018.1560918; Levin MJ, 2018, VACCINE, V36, P179, DOI 10.1016/j.vaccine.2017.08.029; Levin MJ, 2016, J INFECT DIS, V213, P14, DOI 10.1093/infdis/jiv480; Li SZ, 2017, CELL, V169, P862, DOI 10.1016/j.cell.2017.04.026; Lord JM, 2013, HUM VACC IMMUNOTHER, V9, P1364, DOI 10.4161/hv.24696; Nipper AJ, 2018, CLIN IMMUNOL, V193, P80, DOI 10.1016/j.clim.2018.02.003; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Racine E, 2020, VACCINE, V38, P6205, DOI 10.1016/j.vaccine.2020.07.049; Rondaan C, 2014, ARTHRITIS RHEUMATOL, V66, P3122, DOI 10.1002/art.38804; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Schmader KE, 2012, CLIN INFECT DIS, V54, P922, DOI 10.1093/cid/cir970; van der Heiden M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00046; Vermeulen JN, 2012, VACCINE, V30, P904, DOI 10.1016/j.vaccine.2011.11.096; Wang L, 2020, J HEART LUNG TRANSPL, V39, P1445, DOI 10.1016/j.healun.2020.09.013; Wang L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01632; Weinberg A, 2019, J VIROL, V93, DOI 10.1128/JVI.00305-19; Weinberg A, 2017, J IMMUNOL, V199, P604, DOI 10.4049/jimmunol.1700290; Weinberger B, 2009, IMMUNOL LETT, V127, P27, DOI 10.1016/j.imlet.2009.08.008; Young KA, 2019, CHEST, V155, P465, DOI 10.1016/j.chest.2018.08.1036; Yusen RD, 2013, J HEART LUNG TRANSPL, V32, P965, DOI 10.1016/j.healun.2013.08.007; Zerboni L, 2014, NAT REV MICROBIOL, V12, P197, DOI 10.1038/nrmicro3215	32	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							202	10.3390/vaccines9030202			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5HY	33671003	gold, Green Published			2022-04-29	WOS:000634186200001
J	Al Busaidi, N; Prakash, KP; Al-Jardani, A; Al-Sukaiti, N; Al Tamemi, S; Al-Rawahi, B; Al Hinai, Z; Alyaquobi, F; Al-Abri, S; Al-Maani, A				Al Busaidi, Noora; Prakash, K. P.; Al-Jardani, Amina; Al-Sukaiti, Nashat; Al Tamemi, Salem; Al-Rawahi, Bader; Al Hinai, Zaid; Alyaquobi, Fatma; Al-Abri, Seif; Al-Maani, Amal			The Spectrum of Bacille Calmette-Guerin Diseases in Children-A Decade of Data from Neonatal Vaccination Settings	VACCINES			English	Article						BCG; vaccine-related disease; children; abscess; lymphadenitis; immunodeficiency; disseminated disease; Oman	BCG VACCINATION; EXPERIENCE; MANAGEMENT; INFECTION; OMAN	In this paper, we present a multicentre record-based descriptive study used to estimate the incidence and characterize the spectrum of confirmed bacille Calmette-Guerin (BCG) vaccine-related disease among children in Oman. This study included all children (age <= 14 years) who had culture and/or polymerase chain reaction (PCR)-confirmed BCG disease from January 2006 to December 2018, as identified from Central Public Health Laboratory data and International Classification of Diseases coding of an electronic patient information system. In total, 88 children confirmed to have BCG disease were included in the study, making an average incidence of 9.2 cases per 100,000 vaccinated neonates. The males comprised 65.9%, Omanis 93.2%, and the median age of presentation was 4 months in children with BCG disease. The most common type of disease was BCG abscesses (72.4%). Children with immunodeficiency and those presenting within 6 months were found to have a more severe and disseminated disease. In total, 28 children had immunodeficiency. The age of presentation and type of BCG disease was significantly associated with immunodeficiency status. The majority of cases required therapy (both medical and surgical) and recovered well. The incidence of laboratory-confirmed BCG vaccine-related disease was low in Oman supporting continuing the use of the BCG vaccination practice at birth.	[Al Busaidi, Noora; Alyaquobi, Fatma; Al-Maani, Amal] Oman Med Specialty Board, Med Microbiol Program, Muscat 132, Oman; [Prakash, K. P.; Al-Jardani, Amina; Al-Rawahi, Bader; Alyaquobi, Fatma; Al-Abri, Seif; Al-Maani, Amal] Minist Hlth, Directorate Gen Dis Surveillance & Control, Muscat 100, Oman; [Al-Jardani, Amina] Minist Hlth, Directorate Gen Dis Surveillance & Control, Cent Publ Hlth Labs, Muscat 100, Oman; [Al-Sukaiti, Nashat; Al-Maani, Amal] Minist Hlth, Royal Hosp, Dept Child Hlth, Muscat 111, Oman; [Al Tamemi, Salem; Al Hinai, Zaid] Sultan Qaboos Univ Hosp, Dept Child Hlth, Al Khoud 123, Oman; [Al-Maani, Amal] Minist Hlth, Dept Infect Prevent & Control, Directorate Gen Dis Surveillance & Control, POB 393, Muscat 100, Oman		Al-Maani, A (通讯作者)，Oman Med Specialty Board, Med Microbiol Program, Muscat 132, Oman.; Al-Maani, A (通讯作者)，Minist Hlth, Directorate Gen Dis Surveillance & Control, Muscat 100, Oman.; Al-Maani, A (通讯作者)，Minist Hlth, Royal Hosp, Dept Child Hlth, Muscat 111, Oman.; Al-Maani, A (通讯作者)，Minist Hlth, Dept Infect Prevent & Control, Directorate Gen Dis Surveillance & Control, POB 393, Muscat 100, Oman.	noora9225@hotmail.com; drprakashkp@gmail.com; aksaljardani@gmail.com; nashatalsukaiti@yahoo.com; tamemi@squ.edu.om; baderalrawahi4@gmail.com; zaidhinai@gmail.com; fatmayaquobi@gmail.com; salabri@gmail.com; amalsaifalmaani@gmail.com	Maani, Amal SS Al/L-5202-2015; Al-Tamemi, Salem/T-7687-2017	Maani, Amal SS Al/0000-0001-8322-8331; Al-Abri, Seif/0000-0002-2669-6814; Al-Tamemi, Salem/0000-0002-7232-2629; Alhinai, Zaid/0000-0001-5938-9274; Al Busaidi, Noora/0000-0003-2516-3570			Al Abri S, 2020, INT J INFECT DIS, V92, pS60, DOI 10.1016/j.ijid.2020.02.042; Al Sawai A, 2020, INT J INFECT DIS, V97, P347, DOI 10.1016/j.ijid.2020.06.013; Al-Hammadi Suleiman, 2017, BMC Res Notes, V10, P177, DOI 10.1186/s13104-017-2499-7; Al-Maqbali Ali Abdullah, 2016, Oman Med J, V31, P315, DOI 10.5001/omj.2016.61; Al-Tamemi S, 2012, WORLD ALLERGY ORGAN, V5, P52, DOI 10.1097/WOX.0b013e318258830f; AlKhawaja S., 2017, EC MICROBIOL, V12, P8; [Anonymous], 2007, Wkly Epidemiol Rec, V82, P193; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; Barari-Savadkouhi Rahim, 2016, Caspian J Intern Med, V7, P48; Bennasrallah C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219991; Bolger T, 2006, ARCH DIS CHILD, V91, P594, DOI 10.1136/adc.2005.078972; Cuello C.A., COCHRANE DATABASE SY, V2013; Deeks SL, 2005, PEDIATR INFECT DIS J, V24, P538, DOI 10.1097/01.inf.0000164769.22033.2c; Fine P.E.M., 1999, BCG IMMUNIZATION POL; FitzGerald JM, 2000, CLIN INFECT DIS, V31, pS75, DOI 10.1086/314074; Moreira TDF, 2016, REV INST MED TROP SP, V58, DOI 10.1590/S1678-9946201658084; Goraya JS, 2002, POSTGRAD MED J, V78, P327, DOI 10.1136/pmj.78.920.327; Hengster P, 1997, WORLD J SURG, V21, P520, DOI 10.1007/PL00012279; Hesseling AC, 2006, CLIN INFECT DIS, V42, P548, DOI 10.1086/499953; Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020; Lotte A, 1988, Bull Int Union Tuberc Lung Dis, V63, P47; Lotte A, 1984, Adv Tuberc Res, V21, P107; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; Michelsen SW, 2014, THORAX, V69, P851, DOI 10.1136/thoraxjnl-2014-205688; Nuttall James J C, 2011, Tuberc Res Treat, V2011, P712736, DOI 10.1155/2011/712736; Patel PK, 2018, E MEDITERR HEALTH J, V24, P119, DOI 10.26719/2018.24.2.119; Qureshi S, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100133; Shahmohammadi S., 2014, J PEDIAT REV, V2, P47; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Tural-Kara T., 2017, INT CLIN PEDIAT, V6, P37; Venkataraman A, 2015, VACCINE, V33, P5470, DOI 10.1016/j.vaccine.2015.07.103; Ying WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094485; Zhou QH, 2018, J CLIN IMMUNOL, V38, P260, DOI 10.1007/s10875-018-0486-y	33	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							150	10.3390/vaccines9020150			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7IJ	33668524	Green Published, gold			2022-04-29	WOS:000623313200001
J	Ashraf, MU; Kim, Y; Kumar, S; Seo, D; Ashraf, M; Bae, YS				Ashraf, Muhammad Umer; Kim, Yeji; Kumar, Sunil; Seo, Dongyeob; Ashraf, Maryam; Bae, Yong-Soo			COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform	VACCINES			English	Review						COVID-19; vaccine candidates; licensed vaccines; humoral; CMI; oral-mucosal vaccine platform; RPS-CTP vector system	MESSENGER-RNA VACCINES; POLIOVIRUS VACCINES; INFLUENZA VACCINES; H1N1 INFLUENZA; UNITED-STATES; VIRUS-VACCINE; LIVE; SAFETY; IMMUNITY; CELL	There are several emerging strategies for the vaccination of COVID-19 (SARS-CoV-2) however, only a few have yet shown promising effects. Thus, choosing the right pathway and the best prophylactic options in preventing COVID-19 is still challenging at best. Approximately, more than two-hundred vaccines are being tested in different countries, and more than fifty clinical trials are currently undergoing. In this review, we have summarized the immune-based strategies for the development of COVID-19 vaccines and the different vaccine candidate platforms that are in clinical stages of evaluation, and up to the recently licensed mRNA-based COVID-19 vaccines of Pfizer-BioNtech and Moderna's. Lastly, we have briefly included the potentials of using the 'RPS-CTP vector system' for the development of a safe and effective oral mucosal COVID-19 vaccine as another vaccine platform.	[Ashraf, Muhammad Umer; Kim, Yeji; Kumar, Sunil; Seo, Dongyeob; Bae, Yong-Soo] Sungkyunkwan Univ, Dept Biol Sci, Suwon 16419, Gyeonggi Do, South Korea; [Ashraf, Muhammad Umer; Kim, Yeji; Kumar, Sunil; Seo, Dongyeob; Bae, Yong-Soo] Sungkyunkwan Univ, Sci Res Ctr SRC Immune Res Nonlymphoid Organ CIRN, Suwon 16419, Gyeonggi Do, South Korea; [Ashraf, Maryam] Pakistan Air Force PAF Hosp, Dept Dermatol, Islamabad 44000, Pakistan		Bae, YS (通讯作者)，Sungkyunkwan Univ, Dept Biol Sci, Suwon 16419, Gyeonggi Do, South Korea.; Bae, YS (通讯作者)，Sungkyunkwan Univ, Sci Res Ctr SRC Immune Res Nonlymphoid Organ CIRN, Suwon 16419, Gyeonggi Do, South Korea.	ashraf@skku.edu; kyw07043@gmail.com; sunilkumar@skku.edu; sdy2089@skku.edu; maryamashraf951@yahoo.com; ysbae04@skku.edu	Ashraf, Muhammad Umer/ABF-8425-2020; Kumar, Sunil/AAY-4214-2021	Ashraf, Muhammad Umer/0000-0002-8372-9424; Kumar, Sunil/0000-0001-8323-2525	National Research Foundation (NRF) - Korea Ministry of Science and ICTNational Research Foundation of Korea [SRC-2017R1A5A1014560]; Korean National Research FoundationNational Research Foundation of Korea [2018R1D1A1B07048567]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C1074]	This work was supported by a National Research Foundation (NRF) grant funded by the Korea Ministry of Science and ICT (SRC-2017R1A5A1014560) and Individual Basic Science and Engineering Research Program (2018R1D1A1B07048567) funded by the Korean National Research Foundation. This work was also supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI16C1074).	Akpede GO, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00170; Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Anez G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/678645; [Anonymous], 2017, Drug Ther Bull, V55, P114, DOI 10.1136/dtb.2017.10.0538; Armitage ET, 2018, VACCINE, V36, P1772, DOI 10.1016/j.vaccine.2018.02.037; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Ashraf MU, 2019, ARCH PHARM RES, V42, P582, DOI 10.1007/s12272-019-01145-w; Bahamondez-Canas TF, 2018, EUR J PHARM BIOPHARM, V122, P167, DOI 10.1016/j.ejpb.2017.11.001; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Bandyopadhyay AS, 2015, FUTURE MICROBIOL, V10, P791, DOI [10.2217/FMB.15.19, 10.2217/fmb.15.19]; Barnard Ross Thomas, 2010, Expert Rev Vaccines, V9, P461, DOI 10.1586/erv.10.48; Barrett PN, 2009, EXPERT REV VACCINES, V8, P607, DOI [10.1586/erv.09.19, 10.1586/ERV.09.19]; Bhandari R, 2021, EUR J PHARMACOL, V890, DOI 10.1016/j.ejphar.2020.173643; Broadbent AJ, 2016, VACCINE, V34, P563, DOI 10.1016/j.vaccine.2015.11.054; BRTZAEG P, 2011, AM J RESP CRIT CARE, V183, P1595, DOI DOI 10.1164/RCCM.201011-1783OC; Cardona-Ospina JA, 2019, INT J INFECT DIS, V88, P49, DOI 10.1016/j.ijid.2019.08.033; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Charu V, 2011, CLIN INFECT DIS, V53, P985, DOI 10.1093/cid/cir644; Chau NVV, 2020, CLIN INFECT DIS, V71, P2679, DOI [10.1093/cid/ciaa711, DOI 10.1093/CID/CIAA711]; Choudhry A, 2016, VACCINE, V34, P4558, DOI 10.1016/j.vaccine.2016.07.033; Chumakov K, 2020, SCIENCE, V368, P1187, DOI 10.1126/science.abc4262; Coltart CEM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0297; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595; Cox MMJ, 2008, INFLUENZA OTHER RESP, V2, P211, DOI 10.1111/j.1750-2659.2008.00053.x; Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; Du LY, 2011, JOVE-J VIS EXP, DOI 10.3791/2444; Dutta AK, 2020, INDIAN J PEDIATR, V87, P810, DOI 10.1007/s12098-020-03475-w; Esposito S, 2012, HUM VACC IMMUNOTHER, V8, P76, DOI 10.4161/hv.8.1.18809; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fung, HUMAN CORONAVIRUS 22; FURESZ J, 1995, CAN MED ASSOC J, V152, P343; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Grassly NC, 2012, J INFECT DIS, V205, P1554, DOI 10.1093/infdis/jis241; Griffin DE, 2018, VIRAL IMMUNOL, V31, P86, DOI 10.1089/vim.2017.0143; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Gurwith M, 2020, VACCINE, V38, P7702, DOI 10.1016/j.vaccine.2020.09.042; Halsey NA, 2015, VACCINE, V33, pF1, DOI 10.1016/j.vaccine.2015.10.080; Han SS, 2015, VACCINE, V33, P4827, DOI 10.1016/j.vaccine.2015.07.072; Hellfritzsch M, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080375; Henry C, 2019, J VIROL, V93, DOI 10.1128/JVI.01150-19; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Huber VC, 2014, EXPERT REV VACCINES, V13, P31, DOI 10.1586/14760584.2014.852476; Humphreys IR, 2018, IMMUNOLOGY, V153, P1, DOI 10.1111/imm.12829; Itani R, 2020, THERANOSTICS, V10, P5932, DOI 10.7150/thno.46691; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kumar S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092159; KUSOV YY, 1991, VACCINE, V9, P540, DOI 10.1016/0264-410X(91)90238-2; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Li Rui, 2011, Bioeng Bugs, V2, P315, DOI 10.4161/bbug.2.6.18167; Ligon B Lee, 2005, Semin Pediatr Infect Dis, V16, P219, DOI 10.1053/j.spid.2005.05.001; Liu ZZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00402-5; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Louie JK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018221; Lu J, 2020, CELL RES, V30, P936, DOI 10.1038/s41422-020-00392-7; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4826; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4780; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4552; Mardanova ES, 2018, CURR PHARM DESIGN, V24, P1317, DOI 10.2174/1381612824666180309125344; Martin C, 2020, NAT REV DRUG DISCOV, V19, P578, DOI 10.1038/d41573-020-00119-8; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Mohn KGI, 2018, HUM VACC IMMUNOTHER, V14, P571, DOI 10.1080/21645515.2017.1377376; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Murdin AD, 1996, VACCINE, V14, P735, DOI 10.1016/0264-410X(95)00211-I; Nascimento IP, 2012, BRAZ J MED BIOL RES, V45, P1102, DOI 10.1590/S0100-879X2012007500142; Nichol AA, 2020, AM J BIOETHICS, V20, pW2, DOI 10.1080/15265161.2020.1763696; NOMOTO A, 1982, P NATL ACAD SCI-BIOL, V79, P5793, DOI 10.1073/pnas.79.19.5793; O'Leary DR, 2004, VECTOR-BORNE ZOONOT, V4, P61, DOI 10.1089/153036604773083004; Okayasu H, 2011, VACCINE, V29, P8205, DOI 10.1016/j.vaccine.2011.08.059; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111; POL AG, 2020, LANCET, V396, P1595, DOI DOI 10.1016/S0140-6736(20)32137-1; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Possas C, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760180278; Qamar MTU, 2019, PLOS ONE, V17, P362, DOI [DOI 10.1186/S12967-019-2116-8, 10.1186/s12967-019-2116-8]; Rabaan AA, 2020, HUM VACC IMMUNOTHER, V16, P3011, DOI 10.1080/21645515.2020.1825896; Ramirez JEV, 2017, ADV DRUG DELIVER REV, V114, P116, DOI 10.1016/j.addr.2017.04.008; Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539; Remy KE, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140329; Renault P, 2008, EMERG INFECT DIS, V14, P1327, DOI 10.3201/eid1408.080201; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Saha RP, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01258; Sakaguchi W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176000; Sallenave JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01229; Sayedahmed EE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040574; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Seo SH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040584; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Sims AC, 2005, J VIROL, V79, P15511, DOI 10.1128/JVI.79.24.15511-15524.2005; SINGH DD, 2020, COMPUTER, DOI DOI 10.1016/J.CSBJ.2020.11.011; Singh DD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.580202; Sizun J, 2000, J HOSP INFECT, V46, P55, DOI 10.1053/jhin.2000.0795; Smith CL, 2005, J IMMUNOL, V175, P8431, DOI 10.4049/jimmunol.175.12.8431; Smith CL, 2005, INT J CANCER, V113, P259, DOI 10.1002/ijc.20569; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Talon J, 2000, P NATL ACAD SCI USA, V97, P4309, DOI 10.1073/pnas.070525997; Thomson SA, 1996, J IMMUNOL, V157, P822; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Trilla A, 2008, CLIN INFECT DIS, V47, P668, DOI 10.1086/590567; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; VOGEL FR, 1995, CLIN MICROBIOL REV, V8, P406, DOI 10.1128/CMR.8.3.406; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Wu WD, 2017, VACCINE, V35, P3666, DOI 10.1016/j.vaccine.2017.05.021; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xiao YH, 2017, VACCINE, V35, P5418, DOI 10.1016/j.vaccine.2016.12.061; Xie JG, 2017, ADV EXP MED BIOL, V1028, P89, DOI 10.1007/978-981-10-6041-0_6; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-X, 10.1038/s41368-020-0074-x]; Zeng CX, 2020, ADV MATER, V32, DOI 10.1002/adma.202004452; Zeng Chunxi, 2020, bioRxiv, DOI 10.1101/2020.04.01.019877; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zheng ZC, 2018, HUM VACC IMMUNOTHER, V14, P1717, DOI 10.1080/21645515.2018.1461296; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0	145	24	24	5	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							171	10.3390/vaccines9020171			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UR	33670630	Green Published, gold			2022-04-29	WOS:000623277100001
J	Daou, A				Daou, Anis			COVID-19 Vaccination: From Interesting Agent to the Patient	VACCINES			English	Review						COVID-19; vaccination; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); drug development and discovery; pandemic	CORONAVIRUS SPIKE PROTEIN; RECEPTOR-BINDING DOMAIN; NEUTRALIZING ANTIBODIES; PROTECTIVE IMMUNITY; CANDIDATE VACCINE; SARS; IMMUNIZATION; IMMUNOGENICITY; GLYCOPROTEIN; TARGET	The vaccination for the novel Coronavirus (COVID-19) is undergoing its final stages of analysis and testing. It is an impressive feat under the circumstances that we are on the verge of a potential breakthrough vaccination. This will help reduce the stress for millions of people around the globe, helping to restore worldwide normalcy. In this review, the analysis looks into how the new branch of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) came into the forefront of the world like a pandemic. This review will break down the details of what COVID-19 is, the viral family it belongs to and its background of how this family of viruses alters bodily functions by attacking vital human respiratory organs, the circulatory system, the central nervous system and the gastrointestinal tract. This review also looks at the process a new drug analogue undergoes, from (i) being a promising lead compound to (ii) being released into the market, from the drug development and discovery stage right through to FDA approval and aftermarket research. This review also addresses viable reasoning as to why the SARS-CoV-2 vaccine may have taken much less time than normal in order for it to be released for use.	[Daou, Anis] Qatar Univ, QU Hlth, Coll Pharm, Pharmaceut Sci Dept, POB 2713, Doha, Qatar; [Daou, Anis] Qatar Univ, QU Hlth, Biomed & Pharmaceut Res Unit, POB 2713, Doha, Qatar		Daou, A (通讯作者)，Qatar Univ, QU Hlth, Coll Pharm, Pharmaceut Sci Dept, POB 2713, Doha, Qatar.; Daou, A (通讯作者)，Qatar Univ, QU Hlth, Biomed & Pharmaceut Res Unit, POB 2713, Doha, Qatar.	adaou@qu.edu.qa		Daou, Anis/0000-0001-8495-3076			Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Agarwal Krishna Mohan, 2020, Sens Int, V1, P100037, DOI 10.1016/j.sintl.2020.100037; [Anonymous], 2020, OXFORD COVID 19 VACC; [Anonymous], 2015, METHODS MOL BIOL, DOI [DOI 10.1007/978-1-4939-2438-7_1, 10.1007/978-1-4939-2438-7_1]; [Anonymous], 2020, AD26COV2 S JANSSEN C; [Anonymous], 2020, COVID 19 SYMPT; [Anonymous], 2020, CORONAVIRUS DIS COVI; [Anonymous], 2020, SINOVACS CORONAVAC S; [Anonymous], 2020, PFIZER BIONTECH CHOO; [Anonymous], 2020, CONVIDICEA AD5 NCOV; Berkowitz EM, 2015, J INFECT DIS, V211, P1279, DOI 10.1093/infdis/jiu606; Binnicker MJ, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01695-20; Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X; Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005; Chlibek R, 2016, VACCINE, V34, P863, DOI 10.1016/j.vaccine.2015.09.073; Corley J.U.S., 2020, GOVT RESPONSE COVID; Davies NG, 2020, MEDRXIV, DOI [10.1101/2020.12.24.20248822, DOI 10.1101/2021.02.01.21250959, 10.1126/science.abg3055]; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031; Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603; Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587; Faqi AS, 2013, COMPREHENSIVE GUIDE TO TOXICOLOGY IN PRECLINICAL DRUG DEVELOPMENT, P1; FDA, 2018, STEP 3 CLIN RES; Guo XJ, 2015, IMMUNOLOGY, V145, P476, DOI 10.1111/imm.12462; Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283; He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908; He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034; He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052; Honek J., 2017, PRECLINICAL RES DRUG, V26, P6; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huber W, 2005, J MOL RECOGNIT, V18, P273, DOI 10.1002/jmr.744; Imming P, 2006, NAT REV DRUG DISCOV, V5, P821, DOI 10.1038/nrd2132; JACKSON IA, 2020, NEW ENGL J MED, V1, P1920, DOI DOI 10.1056/NEJMOA2022483; Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w; Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219; Keng CT, 2005, J VIROL, V79, P3289, DOI 10.1128/JVI.79.6.3289-3296.2005; Kim E, 2014, VACCINE, V32, P5975, DOI 10.1016/j.vaccine.2014.08.058; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Lan JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112602; Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lindsay MA, 2003, NAT REV DRUG DISCOV, V2, P831, DOI 10.1038/nrd1202; Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021; Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086; Ma CQ, 2014, VACCINE, V32, P2100, DOI 10.1016/j.vaccine.2014.02.004; Mehta, 2011, INT J DRUG DES DISCO, V2, P458; Moffat JG, 2017, NAT REV DRUG DISCOV, V16, P531, DOI 10.1038/nrd.2017.111; Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13; Mousavizadeh L, 2021, J MICROBIOL IMMUNOL, V54, P159, DOI 10.1016/j.jmii.2020.03.022; Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370; Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143; Qu D, 2005, VACCINE, V23, P924, DOI 10.1016/j.vaccine.2004.07.031; Richman D., 2009, INFECT DIS AGEING CL, V12, P1692; Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005; Sindoni D, 2009, J Prev Med Hyg, V50, P121; Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6; Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008; Song F, 2013, J VIROL, V87, P11950, DOI 10.1128/JVI.01672-13; Ullah H, 2021, Vacunas, V22, P106, DOI 10.1016/j.vacun.2020.09.009; Volz A, 2015, J VIROL, V89, P8651, DOI 10.1128/JVI.00614-15; Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712; Wang SX, 2005, J VIROL, V79, P1906, DOI 10.1128/JVI.79.3.1906-1910.2005; WHO, 2003, CONS DOC EP SEV AC R; Williams S., 2020, BRIEF HIST HUMAN COR; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; World Health Organization, 2020, STAT 2 M INT HLTH RE; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054; Xiong S, 2004, IMMUNOL LETT, V95, P139, DOI 10.1016/j.imlet.2004.06.014; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Zhong XF, 2005, J VIROL, V79, P3401, DOI 10.1128/JVI.79.6.3401-3408.2005; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	75	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							120	10.3390/vaccines9020120			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7KO	33546347	Green Published, gold			2022-04-29	WOS:000623319000001
J	Tang, AF; Enyindah-Asonye, G; Hioe, CE				Tang, Alex F.; Enyindah-Asonye, Gospel; Hioe, Catarina E.			Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases	VACCINES			English	Review						immune complex; antibodies; Fab; Fc; HIV-1; vaccine; steric; allosteric		Immune complexes (ICs) made of antibody-bound antigens exhibit immunomodulatory activities exploitable in a vaccination strategy to optimize vaccine efficacy. The modulatory effects of ICs are typically attributed to the Fc fragments of the antibody components, which engage Fc receptors, complement and complement receptors on various immune cells. These Fc-mediated functions facilitate the critical interplay between innate and adaptive immune systems to impact the quality and quantity of the elicited adaptive responses. In addition to the Fc contribution, the Fab fragment also plays an immunoregulation role. The antigen-binding domains of the Fab fragment can bind their specific epitopes at high affinity to sterically occlude these antigenic sites from recognition by other antibodies. Moreover, the Fab-mediated binding has been demonstrated to induce allosteric alterations at nearby or distant antigenic sites. In this review article, we survey published studies to illuminate how the immunomodulatory functions of ICs have been investigated or utilized in a vaccination strategy to fight against an array of infectious pathogens, culminating with IC vaccine designs aimed at preventing HIV-1 infection. In particular, we highlight IC vaccine candidates that exploit Fab-mediated steric and allosteric effects to direct antibody responses away or toward the V1V2 domain, the V3 loop, and other antigenic sites on the HIV-1 envelope gp120 glycoprotein. Like other HIV-1 vaccine approaches, the path for IC-based vaccines to reach the clinic faces major hurdles yet to be overcome; however, investigations into this vaccine strategy have provided insights into the multifaceted activities of antibodies beyond their conventional roles in the host defense against HIV-1 and other microbial pathogens.	[Tang, Alex F.] Univ Calif San Francisco, Sch Med, 533 Parnassus Ave, San Francisco, CA 94143 USA; [Tang, Alex F.; Enyindah-Asonye, Gospel; Hioe, Catarina E.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Hioe, Catarina E.] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA		Hioe, CE (通讯作者)，Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA.; Hioe, CE (通讯作者)，James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.	Alex.Tang@ucsf.edu; gospel.enyindah-asonye@mssm.edu; catarina.hioe@mssm.edu		Hioe, Catarina/0000-0002-9245-9788	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI114520, AI148327, AI140909]; US Department of Veterans AffairsUS Department of Veterans Affairs	The authors were supported in part by NIH grants AI114520, AI148327, AI140909, and a Research Career Scientist Award from the US Department of Veterans Affairs (CEH).	Agarwal A, 2011, VACCINE, V29, P6736, DOI 10.1016/j.vaccine.2010.12.052; Alber DG, 2000, VACCINE, V19, P895, DOI 10.1016/S0264-410X(00)00222-X; Balasubramanian P, 2017, VACCINE, V35, P1464, DOI 10.1016/j.vaccine.2016.11.107; Bastola R, 2017, ARCH PHARM RES, V40, P1238, DOI 10.1007/s12272-017-0969-z; Boune S, 2020, ANTIBODIES, V9, DOI 10.3390/antib9020022; Bournazos S, 2017, INT IMMUNOL, V29, P303, DOI 10.1093/intimm/dxx025; Bournazos S, 2017, IMMUNITY, V47, P224, DOI 10.1016/j.immuni.2017.07.009; Bournazos S, 2015, IMMUNOL REV, V268, P88, DOI 10.1111/imr.12343; Brito LA, 2013, SEMIN IMMUNOL, V25, P130, DOI 10.1016/j.smim.2013.05.007; Chen YJ, 2016, J IMMUNOL, V197, P3982, DOI 10.4049/jimmunol.1601134; Chien PC, 2004, J VIROL, V78, P7645, DOI 10.1128/JVI.78.14.7645-7652.2004; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; Doores KJ, 2015, J VIROL, V89, P1105, DOI 10.1128/JVI.02905-14; Doria-Rose NA, 2016, J VIROL, V90, P76, DOI 10.1128/JVI.01791-15; Gach JS, 2019, J VIROL, V93, DOI 10.1128/JVI.01188-19; Haigwood NL, 2004, J VIROL, V78, P5983, DOI 10.1128/JVI.78.11.5983-5995.2004; Han J, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016208; Hayes JM, 2016, J INFLAMM RES, V9, P209, DOI 10.2147/JIR.S121233; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Heesters BA, 2013, IMMUNITY, V38, P1164, DOI 10.1016/j.immuni.2013.02.023; Hessell AJ, 2019, CELL REP, V28, P877, DOI 10.1016/j.celrep.2019.06.074; HEYMAN B, 1990, IMMUNOL TODAY, V11, P310, DOI 10.1016/0167-5699(90)90126-T; Hioe CE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02441; Hioe CE, 2009, VACCINE, V28, P352, DOI 10.1016/j.vaccine.2009.10.040; Hioe CE, 2000, AIDS RES HUM RETROV, V16, P893, DOI 10.1089/08892220050042837; Jia MX, 2020, CELL HOST MICROBE, V27, P963, DOI 10.1016/j.chom.2020.03.024; Julien JP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003342; Kellner C, 2017, TRANSFUS MED HEMOTH, V44, P327, DOI 10.1159/000479980; Kosco M H, 1988, Adv Exp Med Biol, V237, P883; Kranich J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00225; Kumar R., 2012, J AIDS CLIN RES, VS8, P5512, DOI [10.4172/2155-6113.S8-002, DOI 10.4172/2155-6113.S8-002]; Kumar R, 2013, VACCINE, V31, P5413, DOI 10.1016/j.vaccine.2013.09.010; Kumar R, 2011, VACCINE, V29, P9064, DOI 10.1016/j.vaccine.2011.09.057; Lee CH, 2017, NAT IMMUNOL, V18, P889, DOI 10.1038/ni.3770; Lewis GK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01025; Li JQ, 2017, HUM VACC IMMUNOTHER, V13, P986, DOI 10.1080/21645515.2016.1276125; Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011; Liao HX, 2004, J VIROL, V78, P5270, DOI 10.1128/JVI.78.10.5270-5278.2004; Liu CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25629; Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627; Malherbe DC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00984; MANCA F, 1988, J IMMUNOL, V140, P2893; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; Mok DZL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050520; Ng CT, 2010, NAT MED, V16, P1117, DOI 10.1038/nm.2233; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Pan RM, 2015, J VIROL, V89, P8003, DOI 10.1128/JVI.00754-15; Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600; Peschke B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00646; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Rawool DB, 2008, J IMMUNOL, V180, P5548, DOI 10.4049/jimmunol.180.8.5548; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Roic B, 2006, J VET MED B, V53, P17, DOI 10.1111/j.1439-0450.2006.00907.x; Rosskopf S, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040063; Sedeik ME, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9030072; Shah RR, 2017, METHODS MOL BIOL, V1494, P1, DOI 10.1007/978-1-4939-6445-1_1; Sondermann P, 2013, P NATL ACAD SCI USA, V110, P9868, DOI 10.1073/pnas.1307864110; Suzuki K, 2009, J EXP MED, V206, P1485, DOI 10.1084/jem.20090209; Temming AR, 2019, J IMMUNOL, V203, P3126, DOI 10.4049/jimmunol.1900985; Thomann M, 2016, MOL IMMUNOL, V73, P69, DOI 10.1016/j.molimm.2016.03.002; Tolbert WD, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010069; Tsouchnikas G, 2015, J VIROL, V89, P7970, DOI 10.1128/JVI.00938-15; Tuen M, 2005, EUR J IMMUNOL, V35, P2541, DOI 10.1002/eji.200425859; UNAIDS, UN AIDS DATA 2020; Upadhyay C, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006812; van Eeden C, 2018, CELL REP, V25, P3123, DOI 10.1016/j.celrep.2018.11.058; Visciano ML, 2008, VIROLOGY, V372, P409, DOI 10.1016/j.virol.2007.10.044; Visciano Maria Luisa, 2008, Infect Agent Cancer, V3, P11, DOI 10.1186/1750-9378-3-11; Vorup-Jensen T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02716; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Wang TT, 2015, IMMUNITY, V42, P213, DOI 10.1016/j.immuni.2015.01.022; Wen YM, 2009, EXPERT OPIN BIOL TH, V9, P285, DOI [10.1517/14712590802715749, 10.1517/14712590802715749 ]; Wieland A, 2015, IMMUNITY, V42, P367, DOI 10.1016/j.immuni.2015.01.009; Xu DZ, 2013, J HEPATOL, V59, P450, DOI 10.1016/j.jhep.2013.05.003; Xu DZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002565; Xu DZ, 2005, VACCINE, V23, P2658, DOI 10.1016/j.vaccine.2004.10.040; Yamada DH, 2015, IMMUNITY, V42, P379, DOI 10.1016/j.immuni.2015.01.005; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Zhou CL, 2017, HUM VACC IMMUNOTHER, V13, P1989, DOI 10.1080/21645515.2017.1335840; Zolla-Pazner S, 2016, J VIROL, V90, P636, DOI 10.1128/JVI.01645-15	83	1	1	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							112	10.3390/vaccines9020112			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QC	33540685	Green Published, Green Submitted			2022-04-29	WOS:000623265200001
J	Mahmood, N; Nasir, SB; Hefferon, K				Mahmood, Nasir; Nasir, Sarah Bushra; Hefferon, Kathleen			Plant-Based Drugs and Vaccines for COVID-19	VACCINES			English	Review						coronavirus; antibodies; plants; vaccines; antivirals	CONVALESCENT PLASMA; CORONAVIRUS; OUTBREAK; INHIBITOR; PROTEIN; CHINA; T-705; WUHAN	The coronavirus SARS-CoV-2 has turned our own health and the world economy upside down. While several vaccine candidates are currently under development, antivirals with the potential to limit virus transmission or block infection are also being explored. Plant production platforms are being used to generate vaccines and antiviral proteins inexpensively and at mass scale. The following review discusses the biology and origins of the current coronavirus pandemic, and describes some of the conventional, synthetic, and plant-based approaches to address the challenge that it presents to our way of life.	[Mahmood, Nasir] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 2E8, Canada; [Mahmood, Nasir] Univ Hlth Sci, Dept Biochem, Lahore 54600, Pakistan; [Mahmood, Nasir; Hefferon, Kathleen] Forest Ridge Hlth Care Inc, Toronto, ON M5J 2V1, Canada; [Nasir, Sarah Bushra] Nusrat Jahan Coll, Abdus Salam Sch Sci, Dept Life Sci, Chenab Nagar 35460, Pakistan		Hefferon, K (通讯作者)，Forest Ridge Hlth Care Inc, Toronto, ON M5J 2V1, Canada.	nasir.sbs1@gmail.com; sarahbushra1@gmail.com; klh22@cornell.edu		Hefferon, Kathleen/0000-0003-3550-0366			Aboul-Ata AAE, 2014, ADV VIRUS RES, V89, P1, DOI 10.1016/B978-0-12-800172-1.00001-X; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; [Anonymous], EVERYTHING YOU NEED; [Anonymous], CHINESE COVID 19 VAC; [Anonymous], 2015, METHODS MOL BIOL, DOI [DOI 10.1007/978-1-4939-2438-7_1, 10.1007/978-1-4939-2438-7_1]; [Anonymous], OXFORD U S COVID 19; [Anonymous], CLOVER PRODUCES SUBU; Bai CQ, 2016, CLIN INFECT DIS, V63, P1288, DOI 10.1093/cid/ciw571; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Bailly C, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107618; Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; Cascella Marco, 2020, FEATURES EVALUATION, DOI DOI 10.2214/AJR.20.22954; CDC, 1 TRAVEL RELATED CAS; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chan SK, 2021, ACS NANO, V15, P1259, DOI 10.1021/acsnano.0c08430; Chen C, FAVIPIRAVIR VERSUS A, V2020, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]; Chen CJ, 2008, J ETHNOPHARMACOL, V120, P108, DOI 10.1016/j.jep.2008.07.048; Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9; Chojnacka K, 2020, J FUNCT FOODS, V73, DOI 10.1016/j.jff.2020.104146; Chung YH, 2020, ADV DRUG DELIVER REV, V156, P214, DOI 10.1016/j.addr.2020.06.024; Clemente V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103492; Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001; Dent SD, 2015, J GEN VIROL, V96, P3499, DOI 10.1099/jgv.0.000304; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117; FDA, CORONAVIRUS TREATMEN; Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519; Furuta Y, 2005, ANTIMICROB AGENTS CH, V49, P981, DOI 10.1128/AAC.49.3.981-986.2005; Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027; Fuzimoto AD, 2020, J TRADIT COMPL MED, V10, P405, DOI 10.1016/j.jtcme.2020.05.003; Geller C, 2012, VIRUSES-BASEL, V4, P3044, DOI 10.3390/v4113044; Grabowski GA, 2014, MOL GENET METAB, V112, P1, DOI 10.1016/j.ymgme.2014.02.011; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Gretler C., TOBACCO BASED CORONA; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Hefferon KL, 2014, VACCINES, V2, P642, DOI 10.3390/vaccines2030642; Hennebelle T, 2009, FITOTERAPIA, V80, P385, DOI 10.1016/j.fitote.2009.05.008; Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5; HUANG C, 2020, FAC OPIN POSTPUBL PE, V395, P497, DOI DOI 10.1016/S0140-6736(20)30183-5; Huang FF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104929; Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106; INO, INO 4800; Jian-ya G., 2020, CLIN CHARACTERISTICS, DOI 10.1101/2020.02.20.20025536; Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60; Kayembe JS, 2010, J MED PLANTS RES, V4, P991; Kazadi, 2012, J PLANT STUDIES, V1, P168, DOI [10.5539/jps.v1n2p168, DOI 10.5539/jps.v1n2p168]; Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243; Krenek P, 2015, BIOTECHNOL ADV, V33, P1024, DOI 10.1016/j.biotechadv.2015.03.012; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761; Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727; Lopez-Ramirez MA, 2020, ADV MATER, V32, DOI 10.1002/adma.201905740; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6; Ma L, 2020, MOLECULES, V25, DOI 10.3390/molecules25112627; Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396; Makay C., 2020, ALGAE TASKED WITH MA; Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989; Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3; McDonald KA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00782; Mohammadinejad R, 2019, GREEN CHEM, V21, P1845, DOI [10.1039/c9gc00335e, 10.1039/C9GC00335E]; Monkheang P, 2011, J MED PLANTS RES, V5, P6173, DOI 10.5897/JMPR11.1075; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Mullan K., 2020, TOBACCO GIANT BAT SA; Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929; Nogrady B., 2020, SCIENTIST; Oladeji OS, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/2580259; Palca J., 2020, TOBACCO PLANTS CONTR; Panyod S, 2020, J TRADIT COMPL MED, V10, P420, DOI 10.1016/j.jtcme.2020.05.004; Park JY, 2013, BIOORGAN MED CHEM, V21, P3730, DOI 10.1016/j.bmc.2013.04.026; Paul M, 2011, BIOTECHNOL APPL BIOC, V58, P58, DOI 10.1002/bab.6; Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757; Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Qin X, 2020, LANCET RESP MED, DOI 10.2139/SSRN.3541147; Rattanapisit K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74904-1; Rawat S., 2014, ADV BIOTECHNOL, P207, DOI DOI 10.1007/978-81-322-1554-7_12; Rosales-Mendoza S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020183; Rybicki E., 2018, Prospects of plant-based vaccines in veterinary medicine, P1; Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035; Sahin AR, 2020, EURASIAN J MED ONCOL, V4, P1, DOI 10.14744/ejmo.2020.12220; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Sintayehu, 2014, INT J PHARMACEUT, V1, P161; Soleimani V, 2019, PHYTOTHER RES, V33, P1627, DOI 10.1002/ptr.6361; Specht EA, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00060; Tan WJ, 2020, CHINA CDC WEEKLY, V2, P61; TNX, TNX 1800; Tohidi B, 2017, FOOD CHEM, V220, P153, DOI 10.1016/j.foodchem.2016.09.203; Tuse D, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.594019; WALLS AC, 2020, BIORXIV, V2, DOI DOI 10.1016/J.CELL.2020.02.058; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131; Wen Chih-Chun, 2011, J Tradit Complement Med, V1, P41; Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11; World Health Organization, 2020, WHO DIRECTOR GEN OPE; World Health Organization World Health Organization, 2020, NOVEL CORONAVIRUS JA; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006372; Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359; Zhou P, 2020, NATURE, DOI [DOI 10.1101/2020.01.22.914952, 10.1038/s41586-020-2012-7]; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	107	13	13	2	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							15	10.3390/vaccines9010015			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7BA	33396667	Green Published, gold			2022-04-29	WOS:000610824400001
J	Mathew, S; Faheem, M; Hassain, NA; Benslimane, FM; Al Thani, AA; Zaraket, H; Yassine, HM				Mathew, Shilu; Faheem, Muhammed; Hassain, Neeraja A.; Benslimane, Fatiha M.; Al Thani, Asmaa A.; Zaraket, Hassan; Yassine, Hadi M.			Platforms Exploited for SARS-CoV-2 Vaccine Development	VACCINES			English	Review						SARS-CoV-2; Covid-19; vaccines; clinical trials; vaccine platforms		The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the only zoonotic-origin coronavirus (CoV) that has reached the pandemic stage. The virus uses its spike (S) glycoprotein to attach to the host cells and initiate a cascade of events that leads to infection. It has sternly affected public health, economy, education, and social behavior around the world. Several scientific and medical communities have mounted concerted efforts to limit this pandemic and the subsequent wave of viral spread by developing preventative and potential vaccines. So far, no medicine or vaccine has been approved to prevent or treat coronavirus disease 2019 (COVID-19). This review describes the latest advances in the development of SARS-CoV-2 vaccines for humans, mainly focusing on the lead candidates in clinical trials. Moreover, we seek to provide both the advantages and the disadvantages of the leading platforms used in current vaccine development, based on past vaccine delivery efforts for non-SARS CoV-2 infections. We also highlight the population groups who should receive a vaccine against COVID-19 in a timely manner to eradicate the pandemic rapidly.	[Mathew, Shilu; Benslimane, Fatiha M.; Al Thani, Asmaa A.; Yassine, Hadi M.] Qatar Univ, Biomed Res Ctr, Doha 2173, Qatar; [Faheem, Muhammed] Hosp Sick Children, Genet & Genome Biol Program, Toronto, ON M5G 0A4, Canada; [Hassain, Neeraja A.] Jamal Mohamed Coll, Dept Biotechnol, Tiruchirappalli 620020, Tamil Nadu, India; [Al Thani, Asmaa A.; Yassine, Hadi M.] Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, Doha 2173, Qatar; [Zaraket, Hassan] Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut 110236, Lebanon; [Zaraket, Hassan] Amer Univ Beirut, Ctr Infect Dis Res, Beirut 110236, Lebanon		Yassine, HM (通讯作者)，Qatar Univ, Biomed Res Ctr, Doha 2173, Qatar.; Yassine, HM (通讯作者)，Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, Doha 2173, Qatar.	shilu.mathew@qu.edu.qa; a08faheem@gmail.com; neeraja.anandamyle@gmail.com; fatiha@qu.edu.qa; aaja@qu.edu.qa; hz34@aub.edu.lb; hyassine@qu.edu.qa	YASSINE, HADI M./AAW-6475-2020	YASSINE, HADI M./0000-0001-7592-2788; Zaraket, Hassan/0000-0003-3807-6409	Qatar University Internal Grant [QUHI-BRC-20/21-1]	This research was supported by Qatar University Internal Grant No. #QUHI-BRC-20/21-1. The findings achieved herein are solely the responsibility of the authors.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Ahluwalia P, 2020, EPMA J, V11, P581, DOI 10.1007/s13167-020-00230-1; Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011; Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2019.02.033, 10.1016/j.jiph.2020.02.033]; Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2020, MEDICAGO; Armengol G, 2004, MOL BIOTECHNOL, V27, P109, DOI 10.1385/MB:27:2:109; Ashish, 2020, CORONAVIRUSES, V1, P1, DOI [10.2174/2666796701999200813190838, DOI 10.2174/2666796701999200813190838]; Brazzoli M, 2016, J VIROL, V90, P332, DOI 10.1128/JVI.01786-15; Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X; Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Chinese Clinical Trial Registry, 2020, PHASE CLIN TRIAL EVA; Cohen J, 2020, SCIENCE, V369, P15, DOI 10.1126/science.369.6499.15; Condit RC, 2016, VACCINE, V34, P6610, DOI 10.1016/j.vaccine.2016.04.060; Crank MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123969; Crystal RG, 2014, HUM GENE THER, V25, P3, DOI 10.1089/hum.2013.2527; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06; Dolzhikova IV, 2017, ACTA NATURAE, V9, P4, DOI 10.32607/20758251-2017-9-3-4-11; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Duan LW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576622; Dutta NK, 2008, IMMUNOL LETT, V118, P65, DOI 10.1016/j.imlet.2008.03.003; Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI [10.15585/mmwr.mm6925a1, 10.15585/mmwr.mm6925a1externalicon]; Escriou N, 2014, VIROLOGY, V452, P32, DOI 10.1016/j.virol.2014.01.002; Feng Yu, 2007, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V23, P113; Figueroa JA, 2015, INT REV IMMUNOL, V34, P154, DOI 10.3109/08830185.2015.1018419; Flingai S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00354; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972; Graham SP, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00221-3; Guo YJ, 2005, DNA CELL BIOL, V24, P510, DOI 10.1089/dna.2005.24.510; He HX, 2005, DNA CELL BIOL, V24, P516, DOI 10.1089/dna.2005.24.516; He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106; Hekele A, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.54; Horner C., 2020, BIORXIV, DOI [10.1101/2020.07.11.198291, DOI 10.1101/2020.07.11.198291]; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jimenez GS, 2007, HUM VACCINES, V3, P157, DOI 10.4161/hv.3.5.4175; Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236; Kapadia SU, 2005, VIROLOGY, V340, P174, DOI 10.1016/j.virol.2005.06.016; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; Kibuuka H, 2015, LANCET, V385, P1545, DOI 10.1016/S0140-6736(14)62385-0; Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743; Kuo TY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77077-z; Lalor PA, 2008, J INFECT DIS, V197, P1643, DOI 10.1086/588431; Ledgerwood JE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125914; Lee LYY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01568; Li F, 2006, J VIROL, V80, P6794, DOI 10.1128/JVI.02744-05; [李疆 Li Jiang], 2005, [中华微生物学和免疫学杂志, Chinese Journal of Microbiology and Immunology], V25, P297; Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Menachery VD, 2018, J VIROL, V92, DOI 10.1128/JVI.00710-18; Menzella Francesco, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-6; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592; Muthumani K, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.21; Netland J, 2010, VIROLOGY, V399, P120, DOI 10.1016/j.virol.2010.01.004; Ng Wern Hann, 2020, F1000Res, V9, DOI 10.12688/f1000research.25998.1; Palacios R, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04775-4; Pandey SC, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117956; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Parks CL, 2013, CURR OPIN HIV AIDS, V8, P402, DOI 10.1097/COH.0b013e328363d389; Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Qi XX, 2020, CHEM COMMUN, V56, P8683, DOI 10.1039/d0cc03263h; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14; Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Sarwar UN, 2015, J INFECT DIS, V211, P549, DOI 10.1093/infdis/jiu511; Schalk JAC, 2006, HUM VACCINES, V2, P45, DOI 10.4161/hv.2.2.2620; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shi CX, 2006, J GENE MED, V8, P442, DOI 10.1002/jgm.867; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Stauffer Fausto, 2006, Recent Pat Antiinfect Drug Discov, V1, P291, DOI 10.2174/157489106778777673; Sternberg SH, 2015, MOL CELL, V58, P568, DOI 10.1016/j.molcel.2015.02.032; Sullivan NJ, 2006, PLOS MED, V3, P865, DOI 10.1371/journal.pmed.0030177; Tang J, 2015, HUM VACC IMMUNOTHER, V11, P1244, DOI 10.1080/21645515.2015.1021527; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Vartak A, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020012; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; [王瑞琳 WANG Ruilin], 2007, [中国生物制品学杂志, Chinese Journal of Biologicals], V20, P426; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xiong WD, 2006, J VIROL, V80, P27, DOI 10.1128/JVI.80.1.27-37.2006; Xiong W, 2008, MOL THER, V16, P343, DOI 10.1038/sj.mt.6300375; Yang WJ, 2020, EUR RADIOL, V30, P4874, DOI 10.1007/s00330-020-06827-4; Yu P, 2020, ANIM MODEL EXP MED, V3, P93, DOI 10.1002/ame2.12108; Zakhartchouk AN, 2007, VACCINE, V25, P136, DOI 10.1016/j.vaccine.2006.06.084; Zakhartchouk AN, 2005, VACCINE, V23, P4385, DOI 10.1016/j.vaccine.2005.04.011; Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9; Zhanga CH, 2005, VACCINE, V23, P3196, DOI 10.1016/j.vaccine.2004.11.073; Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016; Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu ZX, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01479-w	108	5	5	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							11	10.3390/vaccines9010011			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7AT	33375677	Green Published, gold			2022-04-29	WOS:000610823700001
J	Moeini, H; Afridi, SQ; Donakonda, S; Knolle, PA; Protzer, U; Hoffmann, D				Moeini, Hassan; Afridi, Suliman Qadir; Donakonda, Sainitin; Knolle, Percy A.; Protzer, Ulrike; Hoffmann, Dieter			Linear B-Cell Epitopes in Human Norovirus GII.4 Capsid Protein Elicit Blockade Antibodies	VACCINES			English	Article						norovirus; GII; 4 genotype; molecular dynamic simulation; linear blockade epitope		Human norovirus (HuNoV) is the leading cause of nonbacterial gastroenteritis worldwide with the GII.4 genotype accounting for over 80% of infections. The major capsid protein of GII.4 variants is evolving rapidly, resulting in new epidemic variants with altered antigenic potentials that must be considered for the development of an effective vaccine. In this study, we identify and characterize linear blockade B-cell epitopes in HuNoV GII.4. Five unique linear B-cell epitopes, namely P2A, P2B, P2C, P2D, and P2E, were predicted on the surface-exposed regions of the capsid protein. Evolving of the surface-exposed epitopes over time was found to correlate with the emergence of new GII.4 outbreak variants. Molecular dynamic simulation (MD) analysis and molecular docking revealed that amino acid substitutions in the putative epitopes P2B, P2C, and P2D could be associated with immune escape and the appearance of new GII.4 variants by affecting solvent accessibility and flexibility of the antigenic sites and histo-blood group antigens (HBAG) binding. Testing the synthetic peptides in wild-type mice, epitopes P2B (336-355), P2C (367-384), and P2D (390-400) were recognized as GII.4-specific linear blockade epitopes with the blocking rate of 68, 55 and 28%, respectively. Blocking rate was found to increase to 80% using the pooled serum of epitopes P2B and P2C. These data provide a strategy for expanding the broad blockade potential of vaccines for prevention of NoV infection.	[Moeini, Hassan; Afridi, Suliman Qadir; Protzer, Ulrike; Hoffmann, Dieter] Tech Univ Munich, Sch Med, Inst Virol, D-81675 Munich, Germany; [Donakonda, Sainitin; Knolle, Percy A.] Tech Univ Munich, Sch Med, Inst Mol Immunol, D-81675 Munich, Germany		Moeini, H (通讯作者)，Tech Univ Munich, Sch Med, Inst Virol, D-81675 Munich, Germany.	hassan.moeini@tum.de; suliman.afridi86@gmail.com; sainitin.donakonda@tum.de; percy.knolle@tum.de; protzer@tum.de; dieter.hoffmann@tum.de	; Protzer, Ulrike/D-5915-2015	Donakonda, Sainitin/0000-0003-3216-8759; Protzer, Ulrike/0000-0002-9421-1911	German Center for Infection Research (DZIF) [TTU06.804]; DZIF	This research was funded by the German Center for Infection Research (DZIF: http://www.dzif.de/en/); grant number TTU06.804. The APC was funded by DZIF.	Afridi SQ, 2020, BRAZ J MICROBIOL, V51, P183, DOI 10.1007/s42770-019-00176-1; Ahlers JD, 1997, P NATL ACAD SCI USA, V94, P10856, DOI 10.1073/pnas.94.20.10856; Allen DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001485; Allen DJ, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-150; Bartsch SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151219; Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709; Bok K, 2009, J VIROL, V83, P11890, DOI 10.1128/JVI.00864-09; Brinckerhoff LH, 1999, INT J CANCER, V83, P326, DOI 10.1002/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X; Bull RA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000831; Cannon JL, 2009, J VIROL, V83, P5363, DOI 10.1128/JVI.02518-08; Cao S, 2007, J VIROL, V81, P5949, DOI 10.1128/JVI.00219-07; Chhabra P, 2019, J GEN VIROL, V100, P1393, DOI 10.1099/jgv.0.001318; Debbink K, 2012, J VIROL, V86, P1214, DOI 10.1128/JVI.06189-11; Donaldson EF, 2008, IMMUNOL REV, V225, P190, DOI 10.1111/j.1600-065X.2008.00680.x; Donaldson EF, 2010, NAT REV MICROBIOL, V8, P231, DOI 10.1038/nrmicro2296; Drozdetskiy A, 2015, NUCLEIC ACIDS RES, V43, pW389, DOI 10.1093/nar/gkv332; El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Hall AJ, 2016, EXPERT REV VACCINES, V15, P949, DOI 10.1080/14760584.2016.1178069; Harrington PR, 2002, J VIROL, V76, P12335, DOI 10.1128/JVI.76.23.12335-12343.2002; Havelaar AH, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001923; Herbst-Kralovetz M, 2010, EXPERT REV VACCINES, V9, P299, DOI 10.1586/ERV.09.163; Huang PW, 2003, J INFECT DIS, V188, P19, DOI 10.1086/375742; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Klepeis JL, 2009, CURR OPIN STRUC BIOL, V19, P120, DOI 10.1016/j.sbi.2009.03.004; Kobayashi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29400; Koelle K, 2011, P ROY SOC B-BIOL SCI, V278, P3723, DOI 10.1098/rspb.2011.0435; Koelle K, 2006, SCIENCE, V314, P1898, DOI 10.1126/science.1132745; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Kroneman A, 2013, ARCH VIROL, V158, P2059, DOI 10.1007/s00705-013-1708-5; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Lindesmith L, 2003, NAT MED, V9, P548, DOI 10.1038/nm860; Lindesmith LC, 2008, PLOS MED, V5, P269, DOI 10.1371/journal.pmed.0050031; Lindesmith LC, 2013, J VIROL, V87, P2803, DOI 10.1128/JVI.03106-12; Lindesmith LC, 2012, J VIROL, V86, P873, DOI 10.1128/JVI.06200-11; Lindesmith LC, 2011, J VIROL, V85, P231, DOI 10.1128/JVI.01364-10; Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195; LoBue AD, 2006, VACCINE, V24, P5220, DOI 10.1016/j.vaccine.2006.03.080; Lopman BA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001999; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; POWELL MF, 1992, J PHARM SCI, V81, P731, DOI 10.1002/jps.2600810802; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; Shanker S, 2011, J VIROL, V85, P8635, DOI 10.1128/JVI.00848-11; Sun J, 2009, NUCLEIC ACIDS RES, V37, pW612, DOI 10.1093/nar/gkp417; Tamminen K, 2012, IMMUNOLOGY, V135, P89, DOI 10.1111/j.1365-2567.2011.03516.x; Tan M, 2008, VIROLOGY, V382, P115, DOI 10.1016/j.virol.2008.08.047; Tan M, 2011, J VIROL, V85, P753, DOI 10.1128/JVI.01835-10; Vinje J, 2015, J CLIN MICROBIOL, V53, P373, DOI 10.1128/JCM.01535-14; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zakikhany K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041625	56	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							52	10.3390/vaccines9010052			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6XF	33466932	Green Published, gold			2022-04-29	WOS:000610814400001
J	Ghattas, M; Dwivedi, G; Lavertu, M; Alameh, MG				Ghattas, Majed; Dwivedi, Garima; Lavertu, Marc; Alameh, Mohamad-Gabriel			Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities	VACCINES			English	Article						vaccine; vaccine types; vaccine platforms; inactivated vaccine; live attenuated vaccine; Virus-like Particles; toxoid vaccine; polysaccharide vaccine; next generation vaccines; viral vectored vaccine; DNA vaccine; mRNA vaccine	VIRUS-LIKE PARTICLES; TOLL-LIKE RECEPTORS; MESSENGER-RNA; IMMUNE-RESPONSE; STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; ANTIVIRAL IMMUNITY; CROSS-LINKING; MUSCLE-CELLS; DNA VACCINES	Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated, Virus-like Particles, synthetic peptide, polysaccharide, polysaccharide conjugate (glycoconjugate), viral vectored (vector-based), nucleic acids (DNA and mRNA) and bacterial vector/synthetic antigen presenting cells. Several processes are used in the manufacturing of vaccines and recent developments in medical/biomedical engineering, biology, immunology, and vaccinology have led to the emergence of innovative nucleic acid vaccines, a novel category added to conventional and subunit vaccines. In this review, we have summarized recent advances in vaccine technologies and platforms focusing on their mechanisms of action, advantages, and possible drawbacks.	[Ghattas, Majed; Lavertu, Marc] Polytech Montreal, Dept Chem Engn, Montreal, PQ H3T 1J4, Canada; [Ghattas, Majed; Lavertu, Marc] Polytech Montreal, Inst Biomed Engn, Montreal, PQ H3T 1J4, Canada; [Dwivedi, Garima] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Alameh, Mohamad-Gabriel] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA; [Alameh, Mohamad-Gabriel] AexeRNA Therapeut, Washington, DC 20001 USA		Lavertu, M (通讯作者)，Polytech Montreal, Dept Chem Engn, Montreal, PQ H3T 1J4, Canada.; Lavertu, M (通讯作者)，Polytech Montreal, Inst Biomed Engn, Montreal, PQ H3T 1J4, Canada.; Alameh, MG (通讯作者)，Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.; Alameh, MG (通讯作者)，AexeRNA Therapeut, Washington, DC 20001 USA.	majed.ghattas@polymtl.ca; gdwivedi@mit.edu; marc.lavertu@polymtl.ca; mg.alameh@pennmedicine.upenn.edu	Dwivedi, Garima/AAG-5334-2019	Dwivedi, Garima/0000-0002-6101-2481; Alameh, Mohamad-Gabriel/0000-0002-5672-6930			Agency E.M, ANN VAXZ ART 5 3 VIS; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Al-Amin M, 2020, MATER MANUF PROCESS, V35, P1789, DOI 10.1080/10426914.2020.1779939; Alameh MG, 2021, IMMUNITY, V54, P2877, DOI 10.1016/j.immuni.2021.11.001; Ali K, 2021, NEW ENGL J MED, V385, P2241, DOI 10.1056/NEJMoa2109522; Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051; Angsantikul P, 2018, BIOCONJUGATE CHEM, V29, P604, DOI 10.1021/acs.bioconjchem.7b00692; Asrani KH, 2018, RNA BIOL, V15, P756, DOI 10.1080/15476286.2018.1450054; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018; Baldwin WR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34735-7; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Baxter D, 2007, OCCUP MED-OXFORD, V57, P552, DOI 10.1093/occmed/kqm110; Beckert B, 2011, METHODS MOL BIOL, V703, P29, DOI 10.1007/978-1-59745-248-9_3; Bedino JH, 2003, CHAMPION EXPANDING E, V649, P2614; Beissert T, 2020, MOL THER, V28, P119, DOI 10.1016/j.ymthe.2019.09.009; Bellard E, 2012, J CONTROL RELEASE, V163, P396, DOI 10.1016/j.jconrel.2012.09.010; Bergman PJ, 2006, VACCINE, V24, P4582, DOI 10.1016/j.vaccine.2005.08.027; BIZZINI B, 1970, EUR J BIOCHEM, V17, P100, DOI 10.1111/j.1432-1033.1970.tb01141.x; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; CARDENAS L, 1992, CLIN MICROBIOL REV, V5, P328; Chaudhary N, 2021, NAT REV DRUG DISCOV, V20, P817, DOI 10.1038/s41573-021-00283-5; Chauveau A, 2020, IMMUNITY, V52, P794, DOI 10.1016/j.immuni.2020.03.010; Cimica V, 2017, CLIN IMMUNOL, V183, P99, DOI 10.1016/j.clim.2017.08.004; CONRY RM, 1995, CANCER RES, V55, P1397; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; da Silva AJ, 2014, BRAZ J MICROBIOL, V45, P1117, DOI 10.1590/S1517-83822014000400001; Dembinski JL, 2014, J VIROL METHODS, V207, P232, DOI 10.1016/j.jviromet.2014.07.003; DIMITRIADIS GJ, 1978, NATURE, V274, P923, DOI 10.1038/274923a0; Ding XW, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700324; Dolgin E, 2021, NATURE, V594, P483, DOI 10.1038/d41586-021-01661-0; Durno Laura, 2015, PDA J Pharm Sci Technol, V69, P163, DOI 10.5731/pdajpst.2015.01040; El Bissati K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73210-0; Embgenbroich M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01643; Ertl HCJ, 2016, CURR OPIN VIROL, V21, P1, DOI 10.1016/j.coviro.2016.06.001; Fehiner-Gardiner C, 2008, J WILDLIFE DIS, V44, P71, DOI 10.7589/0090-3558-44.1.71; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Folorunso OS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030341; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Garg H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61103-1; Gary EN, 2020, CURR OPIN IMMUNOL, V65, P21, DOI 10.1016/j.coi.2020.01.006; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Glezen W Paul, 2004, Expert Rev Vaccines, V3, P131, DOI 10.1586/14760584.3.2.131; Green MD, 2017, COMPREHENSIVE GUIDE TO TOXICOLOGY IN NONCLINICAL DRUG DEVELOPMENT, 2ND EDITION, P709, DOI 10.1016/B978-0-12-803620-4.00027-X; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Groenke N, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107586; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; HARDING CV, 1994, J IMMUNOL, V153, P4925; Hartmann G, 2017, ADV IMMUNOL, V133, P121, DOI 10.1016/bs.ai.2016.11.001; HENGGE UR, 1995, NAT GENET, V10, P161, DOI 10.1038/ng0695-161; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Hume AJ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070204; Humphreys IR, 2018, IMMUNOLOGY, V153, P1, DOI 10.1111/imm.12829; Ireton RC, 2011, VIRUSES-BASEL, V3, P906, DOI 10.3390/v3060906; Iversen PL, 2020, LANCET INFECT DIS, V21, P746, DOI 10.1016/S1473-3099(21)00020-7; Jonges M, 2010, J CLIN MICROBIOL, V48, P928, DOI 10.1128/JCM.02045-09; Jorritsma SHT, 2016, VACCINE, V34, P5488, DOI 10.1016/j.vaccine.2016.09.062; Kaijalainen T, 2008, CLIN MICROBIOL INFEC, V14, P507, DOI 10.1111/j.1469-0691.2008.01967.x; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kelly DF, 2004, IMMUNOLOGY, V113, P163, DOI 10.1111/j.1365-2567.2004.01971.x; Koff WC, 2013, SCIENCE, V340, DOI 10.1126/science.1232910; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Kunal S, 2022, POSTGRAD MED J, V98, pE99, DOI 10.1136/postgradmedj-2021-140648; Lambricht L, 2016, EXPERT OPIN DRUG DEL, V13, P295, DOI 10.1517/17425247.2016.1121990; Ledford H, 2021, NATURE, V592, P15, DOI 10.1038/d41586-021-00785-7; Lesinski GB, 2001, J MICROBIOL METH, V47, P135, DOI 10.1016/S0167-7012(01)00290-1; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159; Lupfer C, 2013, IMMUNOL REV, V255, P13, DOI 10.1111/imr.12089; Madhusudana SN, 2004, INT J INFECT DIS, V8, P21, DOI 10.1016/j.ijid.2003.09.002; Magini D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161193; Mak T.W., 2013, PRIMER IMMUNE RESPON; Mak TW, 2006, IMMUNE RESPONSE: BASIC AND CLINICAL PRINCIPLES, P695, DOI 10.1016/B978-012088451-3/50025-9; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Marino M, 2011, GENE THER, V18, P109, DOI 10.1038/gt.2010.124; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Mascellino MT, 2021, INFECT DRUG RESIST, V14, P3459, DOI 10.2147/IDR.S315727; Mayer S, 2002, IMMUNOBIOLOGY, V205, P282, DOI 10.1078/0171-2985-00131; McCarthy KA, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0937-y; MCGUCKEN PV, 1973, J APPL BACTERIOL, V36, P419, DOI 10.1111/j.1365-2672.1973.tb04123.x; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; Mendonca SA, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00356-x; Mevorach D, 2021, NEW ENGL J MED, V385, P2140, DOI 10.1056/NEJMoa2109730; Milicic A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07246-0; Miliotou AN, 2020, METHODS MOL BIOL, V2086, P87, DOI 10.1007/978-1-0716-0146-4_7; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Muller T, 2009, ARCH VIROL, V154, P1081, DOI 10.1007/s00705-009-0408-7; Nandal Savita, 2018, Proceedings of 2nd International Conference on Computer Vision & Image Processing. CVIP 2017. Advances in Intelligent Systems and Computing (704), P301, DOI 10.1007/978-981-10-7898-9_25; Ndeupen S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103479; Nishide M, 2011, INT J MOL MED, V27, P803, DOI 10.3892/ijmm.2011.668; Nooraei S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00806-7; Olbert M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36840; Paliwal R, 1996, BIOCHEMISTRY-US, V35, P2374, DOI 10.1021/bi952469q; PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Pichichero ME, 2013, HUM VACC IMMUNOTHER, V9, P2505, DOI 10.4161/hv.26109; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Prazeres DMF, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.PLAS-0022-2014; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720; Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551; Rappuoli R, 2019, P NATL ACAD SCI USA, V116, P14, DOI 10.1073/pnas.1819612116; Rappuoli R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4615; Resch TK, 2020, J VIROL, V94, DOI 10.1128/JVI.00889-20; RICHARDS FM, 1968, J MOL BIOL, V37, P231, DOI 10.1016/0022-2836(68)90086-7; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Salnikova MS, 2008, J PHARM SCI-US, V97, P3735, DOI 10.1002/jps.21261; Sanchez-Felipe L, 2021, NATURE, V590, DOI 10.1038/s41586-020-3035-9; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Sheets RL, 2006, TOXICOL SCI, V91, P620, DOI 10.1093/toxsci/kfj170; Shimizu H, 2004, J VIROL, V78, P13512, DOI 10.1128/JVI.78.24.13512-13521.2004; Shirota H, 2007, J IMMUNOL, V179, P329, DOI 10.4049/jimmunol.179.1.329; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; SINGH A, 2020, SCI REP-UK, V10, P1, DOI DOI 10.1101/2020.04.15.040618; Smith JM, 2004, AIDS RES HUM RETROV, V20, P1335, DOI 10.1089/aid.2004.20.1335; Stauffer Fausto, 2006, Recent Pat Antiinfect Drug Discov, V1, P291, DOI 10.2174/157489106778777673; STRASSBURG MA, 1982, AM J INFECT CONTROL, V10, P53, DOI 10.1016/0196-6553(82)90003-7; Swann H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78656-w; Swayne DE, 2004, AVIAN PATHOL, V33, P512, DOI 10.1080/03079450400003692; Syomin B V, 2019, Mol Biol (Mosk), V53, P367, DOI 10.1134/S0026898419030157; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tigra W, 2020, J NEUROENG REHABIL, V17, DOI 10.1186/s12984-020-00676-4; Ting JPY, 2010, SCIENCE, V327, P286, DOI 10.1126/science.1184004; Tombacz I, 2021, METHODS MOL BIOL, V2197, P13, DOI 10.1007/978-1-0716-0872-2_2; Trotman JB, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1504; Uittenbogaard JP, 2011, J BIOL CHEM, V286, P36198, DOI 10.1074/jbc.M111.279232; Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Wang H., 2018, J IMMUNOLOGICAL SCI, V2, P36, DOI [10.29245/2578-3009/2018/2.1118, DOI 10.29245/2578-3009/2018/2.1118]; Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213; Ward RL, 2009, CLIN INFECT DIS, V48, P222, DOI 10.1086/595702; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Weissman Drew, 2013, Methods Mol Biol, V969, P43, DOI 10.1007/978-1-62703-260-5_3; Who-World Health Organization, 1999, GUID TREATM DENG FEV, P1; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wu P, 2021, VET MICROBIOL, V252, DOI 10.1016/j.vetmic.2020.108928; Xu RD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00862; Yan J, 2007, MOL THER, V15, P411, DOI 10.1038/sj.mt.6300036; Young G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60415-6; Yurina V., 2018, MED SCI, V6, P27, DOI [10.3390/medsci6020027, DOI 10.3390/MEDSCI6020027]; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhou WY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01286-3; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	163	2	2	18	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1490	10.3390/vaccines9121490			31	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG4AR	34960236	Green Published, gold			2022-04-29	WOS:000742434200001
J	Lai, XZ; Zhu, H; Wang, JH; Huang, YZ; Jing, RZ; Lyu, Y; Zhang, HJ; Feng, HYF; Guo, J; Fang, H				Lai, Xiaozhen; Zhu, He; Wang, Jiahao; Huang, Yingzhe; Jing, Rize; Lyu, Yun; Zhang, Haijun; Feng, Huangyufei; Guo, Jia; Fang, Hai			Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study	VACCINES			English	Article						booster vaccination; China; COVID-19; health belief model; vaccine	WILLINGNESS-TO-PAY; HEALTH BELIEF MODEL; DETERMINANTS	Coronavirus disease 2019 (COVID-19) booster vaccination has been proposed in response to the new challenges of highly contagious variants, yet few studies have examined public acceptance of boosters. This study examined public acceptance of COVID-19 booster vaccination and its influencing factors by using the data from a self-administered online cross-sectional survey conducted in June 2021 in China. Multiple logistic analysis was used to examine the influencing factors of booster acceptance based on the health belief model (HBM). Among 1145 respondents, 84.80% reported to accept COVID-19 booster vaccination. Having COVID-19 vaccination history, perceiving high benefits and low barriers to booster vaccination, being younger (18-30 vs. 41-50), having a lower education level, being employed, and belonging to priority groups for vaccination were associated with increased odds of booster acceptance. The primary reason for refusing booster vaccination was concern about vaccine safety. The vast majority (92.8%) of respondents reported an annual willingness to pay between 0 and 300 CNY (0-46.29 USD) if the booster was not free. Our findings suggest that the acceptance rate of booster vaccination is relatively high in China, and the HBM-based analysis reveals that more efforts are needed to increase perceived benefits and reduce perceived barriers of vaccination to design effective and proper vaccination extension strategies when boosters become widely recommended.	[Lai, Xiaozhen; Wang, Jiahao; Lyu, Yun; Zhang, Haijun; Feng, Huangyufei; Guo, Jia] Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China; [Lai, Xiaozhen; Zhu, He; Wang, Jiahao; Lyu, Yun; Zhang, Haijun; Feng, Huangyufei; Guo, Jia; Fang, Hai] Peking Univ, China Ctr Hlth Dev Studies, Beijing 100191, Peoples R China; [Huang, Yingzhe] Beijing Weikexing Technol, Dept Stat & Modeling, Beijing 100191, Peoples R China; [Jing, Rize] Renmin Univ China, Sch Publ Adm & Policy, Beijing 100872, Peoples R China; [Fang, Hai] Peking Univ, Hlth Sci Ctr, Chinese Ctr Dis Control & Prevent, Joint Ctr Vaccine Econ, Beijing 100191, Peoples R China; [Fang, Hai] Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100191, Peoples R China		Fang, H (通讯作者)，Peking Univ, China Ctr Hlth Dev Studies, Beijing 100191, Peoples R China.; Fang, H (通讯作者)，Peking Univ, Hlth Sci Ctr, Chinese Ctr Dis Control & Prevent, Joint Ctr Vaccine Econ, Beijing 100191, Peoples R China.; Fang, H (通讯作者)，Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100191, Peoples R China.	laixiaozhen@pku.edu.cn; he.zhu@pku.edu.cn; jiahaowang@pku.edu.cn; yingzhe_huang@hotmail.com; rzjing@ruc.edu.cn; yun.lyu@bjmu.edu.cn; haijunzhang@pku.edu.cn; yffenghuang@pku.edu.cn; 1610306212@pku.edu.cn; hfang@hsc.pku.edu.cn		Jing, Rize/0000-0002-1469-909X; Wang, Jiahao/0000-0001-7575-6580	Special Research Fund of Peking University (PKU) for the Prevention and Control of COVID-19; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities	This research was funded by the Special Research Fund of Peking University (PKU) for the Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities.	Ahmed TF, 2021, EXPERT REV VACCINES, V20, P1185, DOI 10.1080/14760584.2021.1964963; [Anonymous], 2021, PRESS C JOINT PREV C; [Anonymous], 2020, PRESS C JOINT PREV C; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bureau of Disease Control Prevention National Health Commission of the People's Republic of China, 2021, CHIN J VIR DIS, V11, P161; Carpenter CJ, 2010, HEALTH COMMUN, V25, P661, DOI 10.1080/10410236.2010.521906; Cooper S, 2021, EXPERT REV VACCINES, V20, P921, DOI 10.1080/14760584.2021.1949291; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Dhanda S, 2022, BMJ EVID-BASED MED, V27, P1, DOI 10.1136/bmjebm-2020-111507; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x; Eysenbach G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e13; Frew EJ, 2004, HEALTH POLICY, V68, P289, DOI 10.1016/j.healthpol.2003.10.003; Glanz K., 2008, HLTH BEHAV HLTH ED T, V4; Goren A, 2021, MED HYPOTHESES, V146, DOI 10.1016/j.mehy.2020.110439; Guarascio F, WHO ESTIMATES COVID; Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lai XZ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030405; Lau JTF, 2010, VACCINE, V28, P4632, DOI 10.1016/j.vaccine.2010.04.076; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee GM, 2020, JAMA-J AM MED ASSOC, V324, P1937, DOI 10.1001/jama.2020.19692; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu TT, 2021, SCI BULL, V66, P2312, DOI 10.1016/j.scib.2021.07.033; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; ROSENSTOCK IM, 1966, MILBANK FUND Q, V44, P94, DOI 10.2307/3348967; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schmidt J, 2020, J ACAD MARKET SCI, V48, P499, DOI 10.1007/s11747-019-00666-6; Sypsa V, 2009, EUROSURVEILLANCE, V14, P2; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Wang JH, 2021, VACCINE, V39, P1968, DOI 10.1016/j.vaccine.2021.02.060; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Williams SV, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.27.2100626; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wyatt JC, 2000, J AM MED INFORM ASSN, V7, P426, DOI 10.1136/jamia.2000.0070426; Xiaoyu W, COVID 19 BOOSTERS MO; Yang ZJ, 2015, J HEALTH COMMUN, V20, P69, DOI 10.1080/10810730.2014.904023; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhao YM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101172; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2; Zijtregtop EAM, 2009, VACCINE, V28, P207, DOI 10.1016/j.vaccine.2009.09.099	50	3	3	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1461	10.3390/vaccines9121461			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2RK	34960208	Green Published, gold			2022-04-29	WOS:000737504900001
J	Liao, PW; Teng, CLJ; Chou, CW				Liao, Po-Wei; Teng, Chieh-Lin Jerry; Chou, Cheng-Wei			Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection	VACCINES			English	Article						SARS-CoV-2; immune thrombocytopenia; adenovirus vaccine; ischemic stroke; COVID-19	PRACTICES INTERIM RECOMMENDATION; COVID-19 VACCINE; ADVISORY-COMMITTEE; UNITED-STATES; PURPURA	We present a case of immune thrombocytopenia (ITP) induced by the chimpanzee adenovirus-vectored vaccine, without evidence of thrombosis, eight days after vaccine administration. The thrombocytopenia condition improved after administering steroid treatment. This adenovirus vaccine had been reported to induce rare side effects, such as immune thrombotic thrombocytopenia. This case report showed that it could also induce immune thrombocytopenia without the presence of thrombosis. Therefore, we should be cautious of this rare side effect as global vaccine administrations against coronavirus disease increase.	[Liao, Po-Wei; Teng, Chieh-Lin Jerry; Chou, Cheng-Wei] Taichung Vet Gen Hosp, Dept Internal Med, Div Hematol Med Oncol, Taichung 40705, Taiwan; [Teng, Chieh-Lin Jerry] Tunghai Univ, Dept Life Sci, Taichung 40705, Taiwan; [Teng, Chieh-Lin Jerry] Chung Shan Med Univ, Sch Med, Taichung 40705, Taiwan; [Chou, Cheng-Wei] China Med Univ, Grad Inst Biomed Sci, Taichung 40705, Taiwan		Chou, CW (通讯作者)，Taichung Vet Gen Hosp, Dept Internal Med, Div Hematol Med Oncol, Taichung 40705, Taiwan.; Chou, CW (通讯作者)，China Med Univ, Grad Inst Biomed Sci, Taichung 40705, Taiwan.			Teng, Chieh-Lin Jerry/0000-0001-9744-0368			Black C, 2003, BRIT J CLIN PHARMACO, V55, P107, DOI 10.1046/j.1365-2125.2003.01790.x; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Cines DB, 2009, BLOOD, V113, P6511, DOI 10.1182/blood-2009-01-129155; Elrashdy F, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102941; Fueyo-Rodriguez O, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242220; Ganzel C, 2021, ISR MED ASSOC J, V23, P341; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Huang WT, 2012, VACCINE, V30, P2168, DOI 10.1016/j.vaccine.2012.01.013; Julian JA, 2021, ANN EMERG MED, V77, P654, DOI 10.1016/j.annemergmed.2021.02.011; Kassim NA, 2017, CLIN APPL THROMB-HEM, V23, P998, DOI 10.1177/1076029616665165; Khan Ayesha M, 2017, P T, V42, P756; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Lundstrom K, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11071020; Malayala SV, 2021, CUREUS, V13, DOI 10.7759/cureus.14099; Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227; Moulis G, 2012, PLATELETS, V23, P490, DOI 10.3109/09537104.2011.633179; Nagasaki J, 2016, CASE REP HEMATOL, V2016, DOI 10.1155/2016/7913092; Oliver SE, 2021, MMWR-MORBID MORTAL W, V69, P1653, DOI 10.15585/mmwr.mm695152e1; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Pellegrino P, 2015, AUTOIMMUN REV, V14, P880, DOI 10.1016/j.autrev.2015.05.014; Perricone C, 2014, IMMUNOL RES, V60, P226, DOI 10.1007/s12026-014-8597-x; Reikine S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00342; Saudagar V, 2022, IRISH J MED SCI, V191, P919, DOI 10.1007/s11845-021-02614-2; Shah SRA, 2021, EXP HEMATOL ONCOL, V10, DOI 10.1186/s40164-021-00235-0; Tarawneh O, 2021, AM J HEMATOL, V96, pE133, DOI 10.1002/ajh.26106; Welsh KJ, 2021, VACCINE, V39, P3329, DOI 10.1016/j.vaccine.2021.04.054; Woolf SH, 2021, JAMA-J AM MED ASSOC, V325, P1786, DOI 10.1001/jama.2021.5199	28	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1486	10.3390/vaccines9121486			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9FX	34960232	gold, Green Published			2022-04-29	WOS:000737271400001
J	Lopes, PD; Okino, CH; Fernando, FS; Pavani, C; Mariguela, VC; Montassier, MDS; Montassier, HJ				Lopes, Priscila Diniz; Okino, Cintia Hiromi; Fernando, Filipe Santos; Pavani, Caren; Mariguela, Viviane Casagrande; Montassier, Maria de Fatima Silva; Montassier, Helio Jose			Comparative Evaluation of Immune Responses and Protection of Chitosan Nanoparticles and Oil-Emulsion Adjuvants in Avian Coronavirus Inactivated Vaccines in Chickens	VACCINES			English	Article						avian infectious bronchitis; cellular immune response; delivery carrier-adjuvant; mucosal immunization; oil adjuvant	INFECTIOUS-BRONCHITIS VIRUS; SALMONELLA SUBUNIT NANOVACCINE; ISA 71 VG; VACCINATION; MUCOSAL; EXPRESSION; LESIONS; PCR	Efficient vaccines are the main strategy to control the avian coronavirus (AvCoV), although several drawbacks related to traditional attenuated and inactivated vaccines have been reported. These counterpoints highlight the importance of developing new alternative vaccines against AvCoV, especially those able to induce long-lasting immune responses. This study evaluated and compared two inactivated vaccines formulated with AvCoV BR-I variants, one composed of chitosan nanoparticles (AvCoV-CS) and the second by Montanide oily adjuvant (AvCoV-O). Both developed vaccines were administered in a single dose or associated with the traditional Mass attenuated vaccine. The AvCoV-CS vaccine administered alone or associated with the Mass vaccine was able to induce strong humoral and cell-mediated immune (CMI) responses and complete protection against IBV virulent infection, wherein single administration was characterized by high IgA antibody levels in the mucosa, whereas when associated with the Mass vaccine, the serum IgG antibody was predominantly observed. On the other hand, single administration of the oily vaccine presented poor humoral and CMI responses and consequently incomplete protection against virulent challenge, but when associated with the Mass vaccine, immune responses were developed, and complete protection against infection was observed. Both of our experimental vaccines were able to induce full protection against virulent IBV challenge. A single dose of AvCoV-CS vaccine was sufficient to achieve complete protection, while AvCoV-O required a previous priming by a Mass strain to complete the protection.	[Lopes, Priscila Diniz; Fernando, Filipe Santos; Pavani, Caren; Mariguela, Viviane Casagrande; Montassier, Maria de Fatima Silva; Montassier, Helio Jose] Sao Paulo State Univ Unesp, Sch Agr & Veterinarian Sci, Dept Vet Pathol, BR-14884900 Jaboticabal, Brazil; [Okino, Cintia Hiromi] Brazilian Agr Res Corp Embrapa, Embrapa Southeast Livestock, BR-13560970 Sao Carlos, Brazil		Lopes, PD (通讯作者)，Sao Paulo State Univ Unesp, Sch Agr & Veterinarian Sci, Dept Vet Pathol, BR-14884900 Jaboticabal, Brazil.	prisciladiniz_vet@yahoo.com.br; cintia.okino@embrapa.br; filipe.fernando@yahoo.com.br; caren_pavani@hotmail.com; vivi.mariguela@gmail.com.br; fatimamontassier@gmail.com; helio.montassier@unesp.br	Okino, Cintia/N-9601-2019	Okino, Cintia/0000-0002-3692-3902; Lopes, Priscila/0000-0001-9121-8205	National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [140100/2015-6]	This work was supported by National Council for Scientific and Technological Development (CNPq) (Process Number: 140100/2015-6).	Al-Rasheed M, 2021, VET RES, V52, DOI 10.1186/s13567-021-01008-7; Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9; Balasubramaniam A, 2013, VET WORLD, V6, P134, DOI 10.5455/vetworld.2013.134-138; Bande F, 2020, MICROB PATHOGENESIS, V149, DOI 10.1016/j.micpath.2020.104560; Bhuiyan MSA, 2021, VET SCI, V8, DOI 10.3390/vetsci8030047; Bronzoni RVM, 2005, VIRAL IMMUNOL, V18, P569, DOI 10.1089/vim.2005.18.569; Chandrasekar SS, 2020, J VIROL, V94, DOI 10.1128/JVI.01016-20; Chen BY, 1996, AVIAN PATHOL, V25, P269, DOI 10.1080/03079459608419141; Chhabra R, 2015, VIRAL IMMUNOL, V28, P478, DOI 10.1089/vim.2015.0027; Chhabra R, 2015, CLIN VACCINE IMMUNOL, V22, P1050, DOI 10.1128/CVI.00368-15; Chousalkar KK, 2009, J VIROL METHODS, V155, P67, DOI 10.1016/j.jviromet.2008.09.028; dos Santos RM, 2019, J VET MED SCI, V81, P612, DOI 10.1292/jvms.18-0065; Ennaji Y, 2020, EMERGING AND REEMERGING VIRAL PATHOGENS, VOL 2: APPLIED VIROLOGY APPROACHES RELATED TO HUMAN, ANIMAL AND ENVIRONMENTAL PATHOGENS, P31, DOI 10.1016/B978-0-12-814966-9.00003-2; Fernando FS, 2015, PESQUI VET BRASIL, V35, P216, DOI 10.1590/S0100-736X2015000300002; Guo XH, 2008, VET IMMUNOL IMMUNOP, V121, P332, DOI 10.1016/j.vetimm.2007.09.016; Gurjar RS, 2013, DEV COMP IMMUNOL, V41, P715, DOI 10.1016/j.dci.2013.08.002; Guzman M, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10112058; Hajam IA, 2020, VET RES, V51, DOI 10.1186/s13567-020-00762-4; Jackwood M.W., 2020, DIS POULTRY, V14th; Jang SI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059786; Jang SI, 2011, EXP PARASITOL, V127, P178, DOI 10.1016/j.exppara.2010.07.021; Jordan B, 2017, VET MICROBIOL, V206, P137, DOI 10.1016/j.vetmic.2017.01.002; Kaikabo AA, 2017, POULTRY SCI, V96, P295, DOI 10.3382/ps/pew255; Klimka A, 2015, SCAND J IMMUNOL, V81, P291, DOI 10.1111/sji.12279; Legnardi M, 2020, VET SCI, V7, DOI 10.3390/vetsci7020079; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lone NA, 2017, VACCINE, V35, P3401, DOI 10.1016/j.vaccine.2017.05.010; Lopes PD, 2018, VACCINE, V36, P2630, DOI 10.1016/j.vaccine.2018.03.065; MCDOUGALL JS, 1969, VET REC, V85, P378, DOI 10.1136/vr.85.14.378; NAKAMURA K, 1991, AVIAN PATHOL, V20, P241, DOI 10.1080/03079459108418761; Okino CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172275; Okino CH, 2013, VIRAL IMMUNOL, V26, P259, DOI 10.1089/vim.2013.0015; OWEN RL, 1991, AVIAN PATHOL, V20, P663, DOI 10.1080/03079459108418805; Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011; Renu S, 2020, INT J NANOMED, V15, P761, DOI 10.2147/IJN.S238445; Renu S, 2018, INT J NANOMED, V13, P8195, DOI 10.2147/IJN.S185588; Sawaengsak C, 2014, AAPS PHARMSCITECH, V15, P317, DOI 10.1208/s12249-013-0058-7; Zhang WL, 2010, J MICROENCAPSUL, V27, P693, DOI 10.3109/02652048.2010.507881; Zhao K, 2016, SCI REP-UK, V6, DOI 10.1038/srep25720; Zhao K, 2014, INT J NANOMED, V9, P389, DOI 10.2147/IJN.S54226; Zhao K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053314; Zhu WZ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030465	42	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1457	10.3390/vaccines9121457			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YK5YI	34960203	gold, Green Published			2022-04-29	WOS:000745287400001
J	Matsoukas, J; Deraos, G; Kelaidonis, K; Hossain, MK; Feehan, J; Tzakos, AG; Matsoukas, E; Topoglidis, E; Apostolopoulos, V				Matsoukas, John; Deraos, George; Kelaidonis, Kostas; Hossain, Md Kamal; Feehan, Jack; Tzakos, Andreas G.; Matsoukas, Elizabeth; Topoglidis, Emmanuel; Apostolopoulos, Vasso			Myelin Peptide-Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient	VACCINES			English	Article						mannan; MOG(35-55); MBP83-99; PLP131-149; myelin; epitope; peptide; (KG)(5); conjugation; quantification; stability; UPLC-MS; MS; HPLC; electrochemistry	PHASE-III; FOLLOW-UP; IMMUNOTHERAPY; RESPONSES; PROTEASE; MBP8298; CELLS; TH1	Myelin peptide-mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present antigenic peptides at their surface in complex with MHC class I or class II resulting in T-cell stimulation. The conjugation of antigenic peptide with mannan occurs through the linker (Lys-Gly)5, which connects the peptide with the oxidized mannose units of mannan. This study describes novel methods for the quantification of the vaccine ingredient peptide within the conjugate, a prerequisite for approval of clinical trials in the pursuit of multiple sclerosis therapeutics. Myelin peptides, such as MOG(35-55), MBP83-99, and PLP131-145 in linear or cyclic form, as altered peptide ligands or conjugated to appropriate carriers, possess immunomodulatory properties in experimental models and are potential candidates for clinical trials.	[Matsoukas, John; Deraos, George; Kelaidonis, Kostas; Matsoukas, Elizabeth] NewfvDrug PC, Drug Discovery Lab, Patras Sci Pk, Patras 26504, Greece; [Matsoukas, John; Hossain, Md Kamal; Feehan, Jack; Apostolopoulos, Vasso] Victoria Univ, Inst Hlth & Sport, Werribee, Vic 3030, Australia; [Matsoukas, John] Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada; [Tzakos, Andreas G.] Univ Ioannina, Dept Chem, Ioannina 45110, Greece; [Topoglidis, Emmanuel] Univ Patras, Mat Sci Dept, Patras 26504, Greece; [Apostolopoulos, Vasso] Australian Inst Musculoskeletal Sci AIMSS, Program Immunol, Melbourne, Vic 3021, Australia		Matsoukas, J (通讯作者)，NewfvDrug PC, Drug Discovery Lab, Patras Sci Pk, Patras 26504, Greece.; Matsoukas, J; Apostolopoulos, V (通讯作者)，Victoria Univ, Inst Hlth & Sport, Werribee, Vic 3030, Australia.; Matsoukas, J (通讯作者)，Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada.; Apostolopoulos, V (通讯作者)，Australian Inst Musculoskeletal Sci AIMSS, Program Immunol, Melbourne, Vic 3021, Australia.	jack.feehan@vu.edu.au; atzakos@uoi.gr; etop@upatras.gr	Topoglidis, Emmanuel/V-1673-2017	Topoglidis, Emmanuel/0000-0002-0009-9309; Apostolopoulos, Vasso/0000-0001-6788-2771; Feehan, Jack/0000-0002-9627-1299; Matsoukas, John/0000-0001-5554-2964	General Secretariat for Research and TechnologyGreek Ministry of Development-GSRT; Patras Science Park; Region of Western Greece; Eli Lilly Greece and Uni-PharmaEli Lilly [COVID-19]; Institute for Health and Sport, Victoria University, Melbourne, Australia	J.M.M. would like to thank the General Secretariat for Research and Technology, the Patras Science Park, the Region of Western Greece (Research and Technology), and the pharmaceutical companies Eli Lilly Greece and Uni-Pharma for supporting this research in multiple sclerosis, hypertension, and COVID-19. V.A. would like to thank the Institute for Health and Sport, Victoria University, Melbourne, Australia, for their support. We thank Nikolaos Maniotis for typing and editing this manuscript	Apostolopoulos V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1505; Apostolopoulos V, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10110795; Benedek G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0342-4; Boyko A, 2021, MULT SCLER RELAT DIS, V50, DOI 10.1016/j.msard.2021.102778; Dagkonaki A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575451; Deskoulidis E, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10090577; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; Freedman MS, 2011, NEUROLOGY, V77, P1551, DOI 10.1212/WNL.0b013e318233b240; Gasperi C, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000827; Hausler D, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000698; Haines JD, 2011, MT SINAI J MED, V78, P231, DOI 10.1002/msj.20246; Horwitz DA, 2019, TRENDS IMMUNOL, V40, P888, DOI 10.1016/j.it.2019.08.003; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; Iberg CA, 2020, J IMMUNOL, V204, P733, DOI 10.4049/jimmunol.1901121; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Katsara M, 2008, MOL IMMUNOL, V45, P3661, DOI 10.1016/j.molimm.2008.04.024; Katsara M, 2009, J MED CHEM, V52, P214, DOI 10.1021/jm801250v; Klein T, 2018, CHEM REV, V118, P261, DOI 10.1021/acs.chemrev.7b00120; Lee JY, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0097-7; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Piatek P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121508; Rodi M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091398; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Tabansky I, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0017-6; Tseveleki V, 2015, EXP NEUROL, V267, P254, DOI 10.1016/j.expneurol.2014.10.019; Vassilaros S, 2013, IMMUNOTHERAPY-UK, V5, P1177, DOI [10.2217/IMT.13.126, 10.2217/imt.13.126]; Warren KG, 2006, EUR J NEUROL, V13, P887, DOI 10.1111/j.1468-1331.2006.01533.x; Zhou F, 2014, CLIN EXP IMMUNOL, V178, P447, DOI 10.1111/cei.12440; Ziello A, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11070890	30	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1456	10.3390/vaccines9121456			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0NZ	34960201	gold, Green Published			2022-04-29	WOS:000737360800001
J	Qiao, QL; Song, MZ; Song, CC; Zhang, YH; Wang, XD; Huang, Q; Wang, BY; Yang, PP; Zhao, SY; Li, YT; Wang, Z; Zhao, J				Qiao, Qilong; Song, Mingzhen; Song, Congcong; Zhang, Yihang; Wang, Xiangdong; Huang, Qing; Wang, Baiyu; Yang, Panpan; Zhao, Shiyi; Li, Yongtao; Wang, Zeng; Zhao, Jun			Single-Dose Vaccination of Recombinant Chimeric Newcastle Disease Virus (NDV) LaSota Vaccine Strain Expressing Infectious Bursal Disease Virus (IBDV) VP2 Gene Provides Full Protection against Genotype VII NDV and IBDV Challenge	VACCINES			English	Article						genotype VII Newcastle disease virus; infectious bursal disease virus; VP2 gene; chimeric LaSota vaccine strain	CHICKENS; PROTEIN; VIRULENCE; OUTBREAKS; AFRICA; CHINA	Newcastle disease virus (NDV) and infectious bursal disease virus (IBDV) are the two most important and widespread viruses causing huge economic losses in the global poultry industry. Outbreaks of genotype VII NDV and IBDV variants in vaccinated poultry flocks call for genetically matched vaccines. In the present study, a genetic matched chimeric NDV LaSota vaccine strain expressing VP2 gene of IBDV variant, rLaS-VIIF/HN-VP2 was generated for the first time, in which both the F and HN genes of LaSota were replaced with those of the genotype VII NDV strain FJSW. The cleavage site of the FJSW strain F protein in the rLaS-VIIF/HN-VP2 genome was mutated to the avirulent motif found in LaSota. Expression of IBDV VP2 protein was confirmed by western blot. The rLaS-VIIF/HN-VP2 maintained the efficient replication ability in embryonated eggs, low pathogenicity and genetic stability comparable to that of parental LaSota virus. One dose oculonasal vaccination of one-week-old SPF chickens with rLaS-VIIF/HN-VP2 induced full protection against genotype VII NDV and IBDV lethal challenge. These results indicate that the rLaS-VIIF/HN-VP2 is a promising bivalent vaccine to prevent infections of IBDV and genotype VII NDV.	[Qiao, Qilong; Song, Mingzhen; Song, Congcong; Zhang, Yihang; Wang, Xiangdong; Huang, Qing; Wang, Baiyu; Yang, Panpan; Zhao, Shiyi; Li, Yongtao; Wang, Zeng; Zhao, Jun] Henan Agr Univ, Coll Vet Med, Zhengzhou 450046, Peoples R China		Zhao, J (通讯作者)，Henan Agr Univ, Coll Vet Med, Zhengzhou 450046, Peoples R China.	zhaoj@henau.edu.cn			National Key R&D Program of China [2016YFD0500800]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31772771]	This research was funded by the National Key R & D Program of China, grant number 2016YFD0500800 and the National Natural Science Foundation of China, grant number 31772771.	Alexander DJ, 2000, REV SCI TECH OIE, V19, P443, DOI 10.20506/rst.19.2.1231; Bello MB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020270; Bello MB, 2018, ADV VIROL, V2018, DOI 10.1155/2018/6097291; Bello MB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7278459; Berhanu A, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-183; Bogoyavlenskiy A, 2009, VIRUS GENES, V39, P94, DOI 10.1007/s11262-009-0370-1; Bu YW, 2019, AVIAN PATHOL, V48, P91, DOI 10.1080/03079457.2018.1548754; Cho SH, 2008, CLIN VACCINE IMMUNOL, V15, P1572, DOI 10.1128/CVI.00156-08; Cornax I, 2012, AVIAN DIS, V56, P464, DOI 10.1637/10043-122011-Reg.1; Dey S, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040031; Dortmans JCFM, 2010, J VIROL, V84, P10113, DOI 10.1128/JVI.00097-10; Fan LJ, 2020, POULTRY SCI, V99, P6542, DOI 10.1016/j.psj.2020.09.037; Fan LJ, 2020, VET MICROBIOL, V240, DOI 10.1016/j.vetmic.2019.108507; Ge JY, 2014, VACCINE, V32, P1514, DOI 10.1016/j.vaccine.2014.01.020; Guo XC, 2021, TRANSBOUND EMERG DIS, V68, P3658, DOI 10.1111/tbed.13974; Herczeg J, 1999, ARCH VIROL, V144, P2087, DOI 10.1007/s007050050624; Huang ZH, 2004, J VIROL, V78, P10054, DOI 10.1128/JVI.78.18.10054-10063.2004; Kim SH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070183; Kim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074022; Kurukulsuriya S, 2016, RES VET SCI, V108, P54, DOI 10.1016/j.rvsc.2016.08.002; Li GP, 2020, AVIAN PATHOL, V49, P557, DOI 10.1080/03079457.2020.1791314; Liang R, 2002, VET MICROBIOL, V87, P193, DOI 10.1016/S0378-1135(02)00050-0; Mahgoub HA, 2012, ARCH VIROL, V157, P2047, DOI 10.1007/s00705-012-1377-9; Miller P.J., 2013, DIS POULTRY, V13th; Muller H, 2012, AVIAN PATHOL, V41, P133, DOI 10.1080/03079457.2012.661403; Office International des Epizooties, 2017, INF NEWC DIS VIR; Paldurai A, 2014, J VIROL, V88, P8579, DOI 10.1128/JVI.00666-14; Peeters BPH, 1999, J VIROL, V73, P5001, DOI 10.1128/JVI.73.6.5001-5009.1999; Roohani K, 2015, J VET SCI, V16, P447, DOI 10.4142/jvs.2015.16.4.447; Saikia DP, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030145; Samal S.K., 2020, AVIAN VIROLOGY CURRE; Sharma JM, 2000, DEV COMP IMMUNOL, V24, P223, DOI 10.1016/S0145-305X(99)00074-9; Snoeck CJ, 2013, J CLIN MICROBIOL, V51, P2250, DOI 10.1128/JCM.00684-13; Stoute ST, 2019, J VET DIAGN INVEST, V31, P371, DOI 10.1177/1040638719842193; Sun MH, 2018, VET MICROBIOL, V218, P60, DOI 10.1016/j.vetmic.2018.03.027; Sun WN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040771; Tan L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040564; Thai TN, 2021, AVIAN PATHOL, V50, P174, DOI 10.1080/03079457.2020.1869698; Tian KY, 2020, VACCINE, V38, P1989, DOI 10.1016/j.vaccine.2020.01.006; Vijayarani K, 2010, TROP ANIM HEALTH PRO, V42, P415, DOI 10.1007/s11250-009-9436-2; Wang JZ, 2015, VIRUS RES, V203, P77, DOI 10.1016/j.virusres.2015.04.006; Wang NN, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00648; Wang WW, 2021, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.14336; Xu XH, 2020, MICROB PATHOGENESIS, V139, DOI 10.1016/j.micpath.2019.103831; Yu XH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00161; Zhang R, 2010, VET MICROBIOL, V141, P246, DOI 10.1016/j.vetmic.2009.09.020	46	0	0	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1483	10.3390/vaccines9121483			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1VQ	34960229	Green Published, gold			2022-04-29	WOS:000737448300001
J	AlSaeed, AA; Rabbani, U				AlSaeed, Aseel Ali; Rabbani, Unaib			Explaining COVID-19 Vaccine Rejection Using Social Cognitive Theory in Qassim, Saudi Arabia	VACCINES			English	Article						COVID-19; vaccine hesitancy; barriers to vaccine; social cognitive theory; Saudi Arabia	HEALTH BELIEF MODEL; ACCEPTANCE; DETERMINANTS; POPULATION; RECEIVE	Acceptance of COVID-19 vaccines needs a health promotion approach to address various social, environmental and personal factors leading to vaccine hesitancy. We assessed the vaccine hesitancy rate and applied social cognitive theory (SCT) to understand COVID-19 vaccine rejection in Qassim, Saudi Arabia. A cross-sectional study was conducted among visitors of 10 randomly selected primary health care centers in Buraidah, Saudi Arabia. Data was collected by a self-administrated questionnaire. The variables were grouped into six constructs of SCT. Logistic regression was used to assess the predictors of vaccine rejection. Out of 486 participants included in the study, 30.5% rejected the vaccine. The most common reason for vaccine rejection was uncertainty about the vaccine's effectiveness (78%). Among various constructs of SCT, reciprocal determinism (nationality, income and suffering from COVID-19 infection), behavioral capability (knowledge about vaccine safety), self-efficacy (registered for vaccine), and observational learning (getting the vaccine after friends and family members) were significant predictors. Expectation and reinforcement constructs did not show significant association. There was high vaccine rejection in Qassim, KSA. This calls for further improving the mass education strategies. Social cognitive theory can be used to predict vaccine rejection and to develop strategies to increase the utilization of COVID-19 vaccines in Saudi Arabia.	[AlSaeed, Aseel Ali; Rabbani, Unaib] Family Med Acad, Qassim Hlth Cluster, Buraydah 52385, Saudi Arabia		AlSaeed, AA (通讯作者)，Family Med Acad, Qassim Hlth Cluster, Buraydah 52385, Saudi Arabia.	aseel_alsaeed@hotmail.com; rabbaniunaib@gmail.com		AlSaeed, Aseel/0000-0002-1961-1835; Rabbani, Unaib/0000-0002-0702-780X			Abebe H, 2021, INFECT DRUG RESIST, V14, P2015, DOI 10.2147/IDR.S312116; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Almaghaslah D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040330; Alobaidi S, 2021, J MULTIDISCIP HEALTH, V14, P1119, DOI 10.2147/JMDH.S306654; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871; Cheney MK, 2013, SAGE OPEN, V3, DOI 10.1177/2158244013484732; de Wit JBF, 2005, PREV MED, V40, P795, DOI 10.1016/j.ypmed.2004.09.026; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Kaadan MI, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00202-6; Khaled SM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050471; Lamptey E, 2021, CLIN EXP VACCINE RES, V10, P183, DOI 10.7774/cevr.2021.10.2.183; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Magadmi RM, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11501-5; Mahmud I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080864; Mohammed A.-M., 2021, FRONT PUBLIC HEALTH, V9, P794; Piltch-Loeb R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251095; Priest HM, 2015, INT Q COMMUNITY HEAL, V35, P371, DOI 10.1177/0272684X15583289; Puteh S.E.W., 2021, HAYA SAUDI J LIFE SC, V6, P184; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Sagor KH, 2018, SAUDI MED J, V39, P690, DOI 10.15537/smj.2018.7.22293; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; She R, 2021, INFECT CONT HOSP EP, DOI 10.1017/ice.2021.201; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Zampetakis LA, 2021, APPL PSYCHOL-HLTH WE, V13, P469, DOI 10.1111/aphw.12262	29	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1304	10.3390/vaccines9111304			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI5LT	34835235	gold, Green Published			2022-04-29	WOS:000726153600001
J	Koziel, E; Surowiecki, P; Przewodowska, A; Bujarski, JJ; Otulak-Koziel, K				Koziel, Edmund; Surowiecki, Przemyslaw; Przewodowska, Agnieszka; Bujarski, Jozef J.; Otulak-Koziel, Katarzyna			Modulation of Expression of PVYNTN RNA-Dependent RNA Polymerase (NIb) and Heat Shock Cognate Host Protein HSC70 in Susceptible and Hypersensitive Potato Cultivars	VACCINES			English	Article						plant-virus interaction; hypersensitive response; heat shock cognate 70 protein; nuclear inclusion b protein	TURNIP-MOSAIC-VIRUS; PVR4 RESISTANCE; PLANT-VIRUSES; VPG-PRO; REPLICATION; LOCALIZATION; TOBACCO; HSP70; INFECTION; PEPPER	Potato virus Y (PVY) belongs to the genus Potyvirus and is considered to be one of the most harmful and important plant pathogens. Its RNA-dependent RNA polymerase (RdRp) is known as nuclear inclusion protein b (NIb). The recent findings show that the genome of PVY replicates in the cytoplasm of the plant cell by binding the virus replication complex to the membranous structures of different organelles. In some potyviruses, NIb has been found to be localized in the nucleus and associated with the endoplasmic reticulum membranes. Moreover, NIb has been shown to interact with other host proteins that are particularly involved in promoting the virus infection cycle, such as the heat shock proteins (HSPs). HSP70 is the most conserved among the five major HSP families that are known to affect the plant-pathogen interactions. Some plant viruses can induce the production of HSP70 during the development of infection. To understand the molecular mechanisms underlying the interactive response to PVYNTN (necrotic tuber necrosis strain of PVY), the present study focused on StHSC70-8 and PVYNTN-NIb gene expression via localization of HSC70 and NIb proteins during compatible (susceptible) and incompatible (hypersensitive) potato-PVYNTN interactions. Our results demonstrate that NIb and HSC70 are involved in the response to PVYNTN infections and probably cooperate at some stages of the virus infection cycle. Enhanced deposition of HSC70 proteins during the infection cycle was associated with the dynamic induction of PVYNTN-NIb gene expression and NIb localization during susceptible infections. In hypersensitive response (HR), a significant increase in HSC70 expression was observed up to 3 days post-inoculation (dpi) in the nucleus and chloroplasts. Thereafter, between 3 and 21 dpi, the deposition of NIb decreased, which can be attributed to a reduction in the levels of both virus accumulation and PVYNTN-NIb gene expression. Therefore, we postulate that increase in the expression of both StHSC70-8 and PVYNTN-NIb induces the PVY infection during susceptible infections. In contrast, during HRs, HSC70 cooperates with PVYNTN only at the early stages of interaction and mediates the defense response signaling pathway at the later stages of infection.	[Koziel, Edmund; Otulak-Koziel, Katarzyna] Warsaw Univ Life Sci SGGW, Inst Biol, Fac Biol & Biotechnol, Dept Bot, Nowoursynowska St 159, PL-02776 Warsaw, Poland; [Surowiecki, Przemyslaw] Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5a, PL-02106 Warsaw, Poland; [Przewodowska, Agnieszka] Natl Res Inst, Bonin Res Ctr, Plant Breeding & Acclimatizat Inst, Lab Potato Gene Resources & Tissue Culture, PL-76009 Bonin, Poland; [Bujarski, Jozef J.] Northern Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA		Koziel, E; Otulak-Koziel, K (通讯作者)，Warsaw Univ Life Sci SGGW, Inst Biol, Fac Biol & Biotechnol, Dept Bot, Nowoursynowska St 159, PL-02776 Warsaw, Poland.	edmund_koziel@sggw.edu.pl; surowiecki@ibb.waw.pl; a.przewodowska@ihar.edu.pl; jbujarski@niu.edu; katarzyna_otulak@sggw.edu.pl		Otulak, Katarzyna/0000-0001-9424-1662; Koziel, Edmund/0000-0001-6646-1254; Przewodowska, Agnieszka/0000-0002-4645-3772; Surowiecki, Przemyslaw/0000-0001-8308-7153	National Science Center, PolandNational Science Centre, Poland [2019/03/X/NZ9/00499]; NCN [2018/02/X/NZ9/00832]	The work was supported by the National Science Center, Poland, NCN project number: 2019/03/X/NZ9/00499 awarded to E.K. and NCN project number: 2018/02/X/NZ9/00832 awarded to K.O.-K.	Acosta-Leal R, 2008, VIROLOGY, V379, P275, DOI 10.1016/j.virol.2008.06.026; Adams MJ, 2005, ARCH VIROL, V150, P459, DOI 10.1007/s00705-004-0440-6; Anaraki ZE, 2018, ENVIRON EXP BOT, V155, P142, DOI 10.1016/j.envexpbot.2018.06.031; Boevink P, 2005, PLANT PHYSIOL, V138, P1815, DOI 10.1104/pp.105.066761; Bolhassani A, 2019, CLIN CHIM ACTA, V498, P90, DOI 10.1016/j.cca.2019.08.015; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Calil IP, 2017, ANN BOT-LONDON, V119, P711, DOI 10.1093/aob/mcw200; Chen ZR, 2008, MOL PLANT PATHOL, V9, P809, DOI 10.1111/J.1364-3703.2008.00505.X; Chung BYW, 2008, P NATL ACAD SCI USA, V105, P5897, DOI 10.1073/pnas.0800468105; CLARK MF, 1977, J GEN VIROL, V34, P475, DOI 10.1099/0022-1317-34-3-475; Cordero T, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00611; Cui HG, 2019, ANNU REV VIROL, V6, P255, DOI 10.1146/annurev-virology-092818-015843; de Oliveira LC, 2019, P NATL ACAD SCI USA, V116, P24056, DOI 10.1073/pnas.1904752116; Dufresne PJ, 2008, VIROLOGY, V374, P217, DOI 10.1016/j.virol.2007.12.014; Fellers JP, 2002, MOL PLANT PATHOL, V3, P145, DOI 10.1046/j.1364-3703.2002.00106.x; Ferrer-Orta C, 2006, CURR OPIN STRUC BIOL, V16, P27, DOI 10.1016/j.sbi.2005.12.002; Gorovits R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070280; Grangeon Romain, 2010, Commun Integr Biol, V3, P363; Gupta D, 2011, PLANT SIGNAL BEHAV, V6, P232, DOI 10.4161/psb.6.2.15490; Gupta SC, 2010, LIFE SCI, V86, P377, DOI 10.1016/j.lfs.2009.12.015; Hafren A, 2010, PLANT CELL, V22, P523, DOI 10.1105/tpc.109.072413; Huang YP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00437; Huttner S, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00067; Hyskova V, 2021, PLANT BIOLOGY, V23, P131, DOI 10.1111/plb.13234; Ivanov KI, 2014, J GEN VIROL, V95, P1415, DOI 10.1099/vir.0.064220-0; Janzac B, 2009, PLANT PATHOL, V58, P443, DOI 10.1111/j.1365-3059.2008.01992.x; Janzac B, 2010, MOL PLANT MICROBE IN, V23, P823, DOI 10.1094/MPMI-23-6-0823; Kanzaki H, 2003, MOL PLANT PATHOL, V4, P383, DOI 10.1046/J.1364-3703.2003.00186.X; Kim SB, 2018, MOL PLANT MICROBE IN, V31, P906, DOI [10.1094/MPMI-12-17-0313-R, 10.1094/mpmi-12-17-0313-r]; Korner CJ, 2013, MOL PLANT MICROBE IN, V26, P1271, DOI 10.1094/MPMI-06-13-0179-R; Koziel E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010148; Koziel E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092570; Koziel E, 2017, EUR J PLANT PATHOL, V149, P653, DOI 10.1007/s10658-017-1215-8; Lacomme C, 2017, POTATO VIRUS Y BIODI, P207; Leonard S, 2004, J GEN VIROL, V85, P1055, DOI 10.1099/vir.0.19706-0; Li FF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03658-2; Li J, 2015, SCI REP-UK, V5, DOI 10.1038/srep14016; LI XH, 1995, P NATL ACAD SCI USA, V92, P457, DOI 10.1073/pnas.92.2.457; Li XH, 1997, J VIROL, V71, P1598, DOI 10.1128/JVI.71.2.1598-1607.1997; Li YZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep30297; Liu J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34878-7; Lohmus A, 2017, J VIROL, V91, DOI 10.1128/JVI.01316-16; Luschin-Ebengreuth N, 2016, ACTA PHYSIOL PLANT, V38, DOI 10.1007/s11738-016-2150-6; Makarova S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02582; MANDERS EMM, 1992, J CELL SCI, V103, P857; MARTIN MT, 1991, J GEN VIROL, V72, P785, DOI 10.1099/0022-1317-72-4-785; MARTIN MT, 1992, VIRUS RES, V25, P201, DOI 10.1016/0168-1702(92)90134-U; Mayhew TM, 2011, J EXP BOT, V62, P4101, DOI 10.1093/jxb/err176; Mayhew TM, 2011, HISTOCHEM CELL BIOL, V135, P317, DOI 10.1007/s00418-011-0788-0; Michel V, 2018, PLANT J, V95, P700, DOI 10.1111/tpj.13980; Mine A, 2012, CURR OPIN VIROL, V2, P669, DOI 10.1016/j.coviro.2012.09.014; Movahed N, 2019, PLANT PHYSIOL, V179, P507, DOI 10.1104/pp.18.01342; Niehl A, 2019, MOL PLANT PATHOL, V20, P1203, DOI 10.1111/mpp.12798; Niehl A, 2016, NEW PHYTOL, V211, P1008, DOI 10.1111/nph.13944; Olspert A, 2015, EMBO REP, V16, P995, DOI 10.15252/embr.201540509; Otulak K, 2016, J PHYTOPATHOL, V164, P226, DOI 10.1111/jph.12450; Otulak K, 2014, ACTA PHYSIOL PLANT, V36, P85, DOI 10.1007/s11738-013-1389-4; Otulak K, 2010, ACTA PHYSIOL PLANT, V32, P635, DOI 10.1007/s11738-009-0440-y; Otulak-Koziel K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228510; Otulak-Koziel K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010066; Otulak-Koziel K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112741; Otulak-Koziel K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082287; Otulak-Koziel K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030862; Park CJ, 2015, PLANT PATHOLOGY J, V31, P323, DOI 10.5423/PPJ.RW.08.2015.0150; Park SH, 2017, PLANT J, V92, P846, DOI 10.1111/tpj.13723; Revers F, 2015, ADV VIRUS RES, V92, P101, DOI 10.1016/bs.aivir.2014.11.006; Riedel D, 1998, ARCH VIROL, V143, P2133, DOI 10.1007/s007050050448; Rodamilans B, 2015, J VIROL, V89, P6965, DOI 10.1128/JVI.00337-15; Rodriguez-Pena R, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040677; Rybicki EP, 2015, ARCH VIROL, V160, P17, DOI 10.1007/s00705-014-2295-9; Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049; Scholthof KBG, 2011, MOL PLANT PATHOL, V12, P938, DOI [10.1111/j.1364-3703.2011.00752.x, 10.1111/J.1364-3703.2011.00752.X]; Shatskaya GS, 2013, BIOCHEMISTRY-MOSCOW+, V78, P96, DOI 10.1134/S0006297913010124; Szajko K, 2008, THEOR APPL GENET, V116, P297, DOI 10.1007/s00122-007-0667-1; Szajko K, 2014, MOL BREEDING, V34, P267, DOI 10.1007/s11032-014-0024-4; Thivierge K, 2008, VIROLOGY, V377, P216, DOI 10.1016/j.virol.2008.04.015; Turner KA, 2004, VIROLOGY, V320, P276, DOI 10.1016/j.virol.2003.12.006; ul Haq S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215321; Usman MG, 2017, BIOTECHNOL GENET ENG, V33, P26, DOI 10.1080/02648725.2017.1340546; Valkonen JPT, 2015, BREEDING SCI, V65, P69, DOI 10.1270/jsbbs.65.69; Valli AA, 2018, MOL PLANT PATHOL, V19, P744, DOI 10.1111/mpp.12553; Vives-Adrian L, 2014, J VIROL, V88, P5595, DOI 10.1128/JVI.03502-13; Wang X, 2000, VIROLOGY, V275, P433, DOI 10.1006/viro.2000.0509; Wang XL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22778-9; Wei TY, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003378; Wei TY, 2010, J VIROL, V84, P799, DOI 10.1128/JVI.01824-09; Wei TY, 2008, J VIROL, V82, P12252, DOI 10.1128/JVI.01329-08; Whitley D, 1999, J VASC SURG, V29, P748, DOI 10.1016/S0741-5214(99)70329-0; Wu XY, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030203; Wu Y, 2010, BIOPHYS J, V98, P493, DOI 10.1016/j.bpj.2009.10.037; Yang H, 2010, EUR J PLANT PATHOL, V127, P149, DOI 10.1007/s10658-010-9581-5; Zhang MZ, 2021, NEW PHYTOL, V232, P1382, DOI 10.1111/nph.17657; Zheng L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001586; Zimnoch-Guzowska E, 2013, AM J POTATO RES, V90, P21, DOI 10.1007/s12230-012-9289-5	94	2	2	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1254	10.3390/vaccines9111254			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF6DA	34835185	Green Published, gold			2022-04-29	WOS:000724158400001
J	Abravanel, F; Nicot, F; Lhomme, S; Cazabat, M; Drumel, T; Velay, A; Latour, J; Belliere, J; Cintas, P; Kamar, N; Izopet, J				Abravanel, Florence; Nicot, Florence; Lhomme, Sebastien; Cazabat, Michele; Drumel, Thomas; Velay, Aurelie; Latour, Justine; Belliere, Julie; Cintas, Pascal; Kamar, Nassim; Izopet, Jacques			Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations	VACCINES			English	Article						hepatitis E virus; quasispecies; chronic infection; cerebrospinal fluid; compartmentalization	POLYPROLINE REGION	Hepatitis E virus (HEV) infection can lead to a variety of neurological disorders. While HEV RNA is known to be present in the central nervous system, HEV quasispecies in serum and cerebrospinal fluid (CSF) have rarely been explored. We studied the virus' quasispecies in the blood and the CSF of five patients at the onset of their neurological symptoms. The samples of three patients suffering from meningitis, neuralgic amyotrophy and acute inflammatory polyradiculoneuropathy were taken at the acute phase of the HEV infection. The samples from the other two patients were taken during the chronic phase (5 years after HEV diagnosis) when they presented with clinical signs of encephalitis. We sequenced at least 20 randomly polyproline regions of the selected virus clones. Phylogenetic analysis of the virus variants in the blood and the CSF revealed no virus compartmentalization for the three acute-phase patients but there was clear evidence of HEV quasispecies compartmentalization in the CSF of the two patients during chronic infection. In conclusion, prolonged infection in the immunocompromised condition can lead to independent virus replication in the liver and the tissues, producing viruses in CSF.	[Abravanel, Florence; Lhomme, Sebastien; Cazabat, Michele; Kamar, Nassim; Izopet, Jacques] Univ Toulouse III, CNRS, UMR 5051, INSERM,URN1291,Inst Toulousain Malad Infect & Inf, F-31300 Toulouse, France; [Abravanel, Florence; Nicot, Florence; Lhomme, Sebastien; Cazabat, Michele; Latour, Justine; Izopet, Jacques] CHU Toulouse, Hop Purpan, Natl Reference Ctr Hepatitis E, Lab Virol, F-31300 Toulouse, France; [Drumel, Thomas] CHU Nantes, Lab Virol, F-44093 Nantes 1, France; [Velay, Aurelie] CHU Strasbourg, INSERM, UMR 1109, IRM,Lab Virol, F-67000 Strasbourg, France; [Belliere, Julie; Kamar, Nassim] CHU Toulouse, Hop Rangueil, Dept Nephrol Dialyse & Transplantat Multiorgane, F-31300 Toulouse, France; [Belliere, Julie] INSERM, U1048, Inst Malad Metabol & Cardiovasc, F-31300 Toulouse, France; [Cintas, Pascal] CHU Toulouse, Hop Purpan, Dept Neurol, F-31300 Toulouse, France		Abravanel, F (通讯作者)，Univ Toulouse III, CNRS, UMR 5051, INSERM,URN1291,Inst Toulousain Malad Infect & Inf, F-31300 Toulouse, France.; Abravanel, F (通讯作者)，CHU Toulouse, Hop Purpan, Natl Reference Ctr Hepatitis E, Lab Virol, F-31300 Toulouse, France.	abravanel.f@chu-toulouse.fr; nicot.f@chu-toulouse.fr; lhomme.s@chutoulouse.fr; cazabat.m@chu-toulouse.fr; thomas.drumel@chu-nantes.fr; aurelie.velay@chru-strasbourg.fr; latour.j@chu-toulouse.fr; belliere.j@chu-toulouse.fr; cintas.p@chu-toulouse.fr; kamar.n@chu-toulouse.fr; izopet.j@chu-toulouse.fr	Abrvaanel, florence/K-3776-2014; Lhomme, Sebastien/AAA-9426-2020; Velay, Aurélie/D-3309-2019; Kamar, Nassim/L-6462-2014	Lhomme, Sebastien/0000-0001-7908-1576; ABRAVANEL, Florence/0000-0002-1753-1065; IZOPET, JACQUES/0000-0002-8462-3234; Velay, Aurelie/0000-0002-9174-8959; Kamar, Nassim/0000-0003-1930-8964			Abrayanel F, 2018, J INFECTION, V77, P220, DOI 10.1016/j.jinf.2018.06.007; Belliere J, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12784; Dalton HR, 2016, NAT REV NEUROL, V12, P77, DOI 10.1038/nrneurol.2015.234; Domingo E, 2012, MICROBIOL MOL BIOL R, V76, P159, DOI 10.1128/MMBR.05023-11; Drave SA, 2016, J VIRAL HEPATITIS, V23, P512, DOI 10.1111/jvh.12515; Han J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099861; van Tong H, 2016, EBIOMEDICINE, V11, P31, DOI 10.1016/j.ebiom.2016.07.039; Horvatits T, 2021, J HEPATOL, V75, P55, DOI 10.1016/j.jhep.2020.12.030; Kamar N, 2010, AM J TRANSPLANT, V10, P1321, DOI 10.1111/j.1600-6143.2010.03068.x; Kamar N, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.86; Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005; Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290; Lhomme S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00001; Lhomme S, 2014, J VIROL, V88, P12017, DOI 10.1128/JVI.01625-14; Lhomme S, 2012, J VIROL, V86, P10006, DOI 10.1128/JVI.01003-12; Nicot F, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1987; Purdy MA, 2012, J VIROL, V86, P10186, DOI 10.1128/JVI.01374-12; Purdy MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035974; Shi R, 2016, J VIRAL HEPATITIS, V23, P930, DOI 10.1111/jvh.12557; Shukla P, 2012, J VIROL, V86, P5697, DOI 10.1128/JVI.00146-12; Shukla P, 2011, P NATL ACAD SCI USA, V108, P2438, DOI 10.1073/pnas.1018878108; Spindler KR, 2012, TRENDS MICROBIOL, V20, P282, DOI 10.1016/j.tim.2012.03.009; Tian JJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00052; Velay A, 2017, J NEUROVIROL, V23, P615, DOI 10.1007/s13365-017-0525-0; Zhou X, 2017, J INFECT DIS, V215, P1197, DOI 10.1093/infdis/jix079	25	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1205	10.3390/vaccines9101205			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE0RD	34696313	Green Published, gold			2022-04-29	WOS:000723103800001
J	Arya, A; Arora, SK				Arya, Aryandra; Arora, Sunil K.			A T-Cell Epitope-Based Multi-Epitope Vaccine Designed Using Human HLA Specific T Cell Epitopes Induces a Near-Sterile Immunity against Experimental Visceral Leishmaniasis in Hamsters	VACCINES			English	Article						Leishmania; vaccine; T cell; epitopes; hamster; IFN-gamma epitope; sterile immunity	PEPTIDE VACCINE; NEURAL-NETWORKS; CO-STIMULATION; CTL EPITOPES; TNF-ALPHA; RESPONSES; DONOVANI; ANTIGEN; PREDICTION; PROTECTION	Visceral leishmaniasis is a neglected tropical disease affecting 12 million people annually. Even in the second decade of the 21st century, it has remained without an effective vaccine for human use. In the current study, we designed three multiepitope vaccine candidates by the selection of multiple IFN-gamma inducing MHC-I and MHC-II binder T-cell specific epitopes from three previously identified antigen genes of Leishmania donovani from our lab by an immuno-informatic approach using IFNepitope, the Immune Epitope Database (IEDB) T cell epitope identification tools, NET-MHC-1, and NET MHC-2 webservers. We tested the protective potential of these three multiepitope proteins as a vaccine in a hamster model of visceral leishmaniasis. The immunization data revealed that the vaccine candidates induced a very high level of Th1 biased protective immune response in-vivo in a hamster model of experimental visceral leishmaniasis, with one of the candidates inducing a near-sterile immunity. The vaccinated animals displayed highly activated monocyte macrophages with the capability of clearing intracellular parasites due to increased respiratory burst. Additionally, these proteins induced activation of polyfunctional T cells secreting INF-gamma, TNF-alpha, and IL-2 in an ex-vivo stimulation of human peripheral blood mononuclear cells, further supporting the protective nature of the designed candidates.</p>	[Arya, Aryandra; Arora, Sunil K.] Post Grad Inst Med Educ & Res PGIMER, Dept Immunopathol, Mol Immunol, Chandigarh 160012, India		Arora, SK (通讯作者)，Post Grad Inst Med Educ & Res PGIMER, Dept Immunopathol, Mol Immunol, Chandigarh 160012, India.	aryandra.arya@gmail.com; arorasunilkumar@pgimer.edu.in		Arora, Sunil K/0000-0002-8294-5360	Indian Council of Medical Research (ICMR), New DelhiIndian Council of Medical Research (ICMR) [3/1/3JRF-2014/HRD-81(30327)]	The authors would like to acknowledge the Indian Council of Medical Research (ICMR), New Delhi for the research fellowship (Ref. No. 3/1/3JRF-2014/HRD-81(30327)) provided to A.A.	Abbas AK, 2017, CELLULAR MOL IMMUNOL, Vninth; Acuto O, 2003, NAT REV IMMUNOL, V3, P939, DOI 10.1038/nri1248; Adhikari UK, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6718083; Adhikari UK, 2017, INFECT GENET EVOL, V56, P75, DOI 10.1016/j.meegid.2017.10.022; Agallou M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030350; Ahlers JD, 2001, J CLIN INVEST, V108, P1677, DOI 10.1172/JCI13463; Altfeld MA, 2000, J VIROL, V74, P8541, DOI 10.1128/JVI.74.18.8541-8549.2000; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; [Anonymous], 2017, WHO WEEKLY EPIDEMIOL, V92, P557; Arora S.K., 2020, J VACCINES IMMUNOL, V6, P038, DOI [10.17352/jvi.000036, DOI 10.17352/JVI.000036]; Arora SK, 2005, EXP PARASITOL, V109, P163, DOI 10.1016/j.exppara.2004.12.009; Atapour A, 2021, INT J PEPT RES THER, V27, P1885, DOI 10.1007/s10989-021-10218-8; Ball WB, 2014, INT J BIOCHEM CELL B, V48, P66, DOI [10.1016/j.bioce1.2014.01.004, 10.1016/j.biocel.2014.01.004]; Banerjee A, 2018, J IMMUNOL, V200, P163, DOI 10.4049/jimmunol.1700674; Bhardwaj S, 2009, EXP PARASITOL, V121, P29, DOI 10.1016/j.exppara.2008.09.019; Bhattacharyya ND, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00624; Bi KM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9872095; BOLANDER ME, 1989, CALCIFIED TISSUE INT, V45, P74, DOI 10.1007/BF02561405; Bordbar A, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104189; Boyton RJ, 2002, TRENDS IMMUNOL, V23, P526, DOI 10.1016/S1471-4906(02)02319-0; Buckle AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02898; Burel JG, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87499; Butler NS, 2010, ADV EXP MED BIOL, V684, P42; Carpenter SM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005380; Chaturvedi P, 1996, INT IMMUNOL, V8, P745, DOI 10.1093/intimm/8.5.745; Chen F, 2014, NAT IMMUNOL, V15, P938, DOI 10.1038/ni.2984; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Coombs D, 2005, J COMPUT APPL MATH, V184, P121, DOI 10.1016/j.cam.2004.07.035; Coombs D, 2011, MATHEMATICAL MODELS AND IMMUNE CELL BIOLOGY, P25, DOI 10.1007/978-1-4419-7725-0_2; Courtney AH, 2018, TRENDS BIOCHEM SCI, V43, P108, DOI 10.1016/j.tibs.2017.11.008; da Silva HB, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/202816; Daniels MA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00617; Dayakar A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00670; De Brito RCF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01043; de Vrij N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030270; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dikhit MR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01763; Foley JF., 2012, SCI SIGNALING, V5, pec42, DOI [10.1126/scisignal.2002929, DOI 10.1126/SCISIGNAL.2002929]; Foroutan M, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101413; Han Q, 2012, P NATL ACAD SCI USA, V109, P1607, DOI 10.1073/pnas.1117194109; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; Huang Y, 2011, J LEUKOCYTE BIOL, V90, P87, DOI 10.1189/jlb.1210674; Hwang JR, 2020, EXP MOL MED, V52, P750, DOI 10.1038/s12276-020-0435-8; Jose ES, 2000, IMMUNITY, V12, P161, DOI 10.1016/S1074-7613(00)80169-7; Joshi Sumit, 2014, Front Immunol, V5, P380, DOI 10.3389/fimmu.2014.00380; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; Kesmir C, 2002, PROTEIN ENG, V15, P287, DOI 10.1093/protein/15.4.287; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kyriazis ID, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1701-4; Leonard Warren J, 2016, F1000Res, V5, DOI 10.12688/f1000research.7634.1; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Lo-Man R, 2000, INFECT IMMUN, V68, P3079, DOI 10.1128/IAI.68.6.3079-3089.2000; Ribeiro HDL, 2018, IEEE INT C BIOINFORM, P1425, DOI 10.1109/BIBM.2018.8621351; Lu CY, 2017, BRIT J HAEMATOL, V178, P413, DOI 10.1111/bjh.14686; Macedo ABB, 2012, CLIN EXP IMMUNOL, V167, P505, DOI 10.1111/j.1365-2249.2011.04536.x; Majidiani H, 2021, MICROB PATHOGENESIS, V155, DOI 10.1016/j.micpath.2021.104925; Masih S, 2011, EXP PARASITOL, V129, P55, DOI 10.1016/j.exppara.2011.05.014; Medina-Colorado AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169496; Mitran CJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00335; Moro-Garcia MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00339; Mortha A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00191; Mutiso JM, 2010, J BIOMED RES, V24, P16, DOI 10.1016/S1674-8301(10)60004-8; Natoli G, 2019, NAT IMMUNOL, V20, P783, DOI [10.1038/S41590-019-0399-9, 10.1038/s41590-019-0399-9]; Nelson D, 2000, J IMMUNOL, V165, P6123, DOI 10.4049/jimmunol.165.11.6123; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7; Olasz K, 2012, CLIN EXP IMMUNOL, V167, P346, DOI 10.1111/j.1365-2249.2011.04506.x; Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110; Parmigiani A, 2011, HUM IMMUNOL, V72, P115, DOI 10.1016/j.humimm.2010.10.015; Pentier JM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00133; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Piel LMW, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859-021-04181-w; Rabienia M, 2020, EUR J PHARM SCI, V152, DOI 10.1016/j.ejps.2020.105423; Raja MRC, 2016, RSC ADV, V6, P61777, DOI 10.1039/c6ra11510a; Ratna A, 2016, T ROY SOC TROP MED H, V110, P610, DOI 10.1093/trstmh/trw068; Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874; Rodrigues V, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1412-x; Rohrs JA, 2019, JCO CLIN CANCER INFO, V3, DOI 10.1200/CCI.18.00057; Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009; Saini S, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12768; Shermeh AS, 2021, EXP PARASITOL, V223, DOI 10.1016/j.exppara.2021.108082; Shibaki A, 2002, EXP DERMATOL, V11, P126, DOI 10.1034/j.1600-0625.2002.110204.x; Shibuya K, 1998, J IMMUNOL, V160, P1708; Singh B, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12669; Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108; Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236; Singh R, 2014, IMMUNOLOGY, V141, P514, DOI 10.1111/imm.12194; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Solaymani-Mohammadi S, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00401; Sousa J, 2000, EUR J IMMUNOL, V30, P3219, DOI 10.1002/1521-4141(200011)30:11<3219::AID-IMMU3219>3.0.CO;2-7; Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y; Stager S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00005; Sundar S, 2002, CLIN DIAGN LAB IMMUN, V9, P951, DOI 10.1128/CDLI.9.5.951-958.2002; Tamura T, 2004, INT IMMUNOL, V16, P1691, DOI 10.1093/intimm/dxh170; Tao X, 1997, J IMMUNOL, V159, P5956; Tercan H, 2021, ARTERIOSCL THROM VAS, V41, P55, DOI 10.1161/ATVBAHA.120.314212; Thakur Shivani, 2020, J Parasit Dis, V44, P253, DOI 10.1007/s12639-020-01212-w; Tian Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02778; Tomiotto-Pellissier F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02529; Tsai V, 1997, J IMMUNOL, V158, P1796; Vakili B, 2020, MED MICROBIOL IMMUN, V209, P69, DOI 10.1007/s00430-019-00640-7; Ostolin TLVD, 2021, VACCINE, V39, P2755, DOI 10.1016/j.vaccine.2021.04.004; van Panhuys N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00006; Westernberg L, 2016, J ALLERGY CLIN IMMUN, V138, P571, DOI 10.1016/j.jaci.2015.11.034; Xiong XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087206; Xu A., 2019, WORLD J VACCINES, V9, P1, DOI [10.4236/wjv.2019.91001, DOI 10.4236/WJV.2019.91001]; Yadav S, 2021, CELL IMMUNOL, V361, DOI 10.1016/j.cellimm.2020.104272; Zamboni DS, 2019, CURR OPIN MICROBIOL, V52, P70, DOI 10.1016/j.mib.2019.05.005; Zhang JH, 2021, IMMUNOBIOLOGY, V226, DOI 10.1016/j.imbio.2021.152085; Zhang JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230381; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zoete V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00268; Zohar Y, 2014, J CLIN INVEST, V124, P2009, DOI 10.1172/JCI71951; Zutshi S, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040156	116	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1058	10.3390/vaccines9101058			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO7NN	34696166	Green Published			2022-04-29	WOS:000712636600001
J	Markhorst, B; Zver, T; Malbasic, N; Dijkstra, R; Otto, D; van der Mei, R; Moeke, D				Markhorst, Berend; Zver, Tara; Malbasic, Nina; Dijkstra, Renze; Otto, Daan; van der Mei, Rob; Moeke, Dennis			A Data-Driven Digital Application to Enhance the Capacity Planning of the COVID-19 Vaccination Process	VACCINES			English	Article						COVID-19; vaccination planning; vaccination logistics; last-mile; decision support system	VACCINES	In this paper, a decision support system (DSS) is presented that focuses on the capacity planning of the COVID-19 vaccination process in the Netherlands. With the Dutch national vaccination priority list as the starting point, the DSS aims to minimize the per-class waiting-time with respect to (1) the locations of the medical hubs (i.e., the vaccination locations) and (2) the distribution of the available vaccines and healthcare professionals (over time). As the user is given the freedom to experiment with different starting positions and strategies, the DSS is ideally suited for providing support in the dynamic environment of the COVID-19 vaccination process. In addition to the DSS, a mathematical model to support the assignment of inhabitants to medical hubs is presented. This model has been satisfactorily implemented in practice in close collaboration with the Dutch Municipal and Regional Health Service (GGD GHOR Nederland).</p>	[Markhorst, Berend; Zver, Tara; Malbasic, Nina; Dijkstra, Renze; Otto, Daan; van der Mei, Rob] Vrije Univ Amsterdam, Dept Math, NL-1081 HV Amsterdam, Netherlands; [van der Mei, Rob] Ctr Math & Comp Sci, Stochast Grp, NL-1098 XG Amsterdam, Netherlands; [Moeke, Dennis] HAN Univ Appl Sci, Res Grp Logist & Alliances, NL-6826 CC Arnhem, Netherlands		Moeke, D (通讯作者)，HAN Univ Appl Sci, Res Grp Logist & Alliances, NL-6826 CC Arnhem, Netherlands.	b.t.markhorst@student.vu.nl; a.t.zver@student.vu.nl; n.malbasic@student.vu.nl; r.k.dijkstra@student.vu.nl; d.otto@student.vu.nl; Rob.van.der.Mei@cwi.nl; dennis.moeke@han.nl			TKI-Dinalog; GGD-GHOR; Center for Mathematics and Computer Science; Vrije Universiteit Amsterdam	Funding for this project has been provided by TKI-Dinalog, GGD-GHOR, the Center for Mathematics and Computer Science, and the Vrije Universiteit Amsterdam.	Aaby K, 2006, INTERFACES, V36, P569, DOI 10.1287/inte.1060.0229; Adeleke Olawale J., 2020, Recycling, V5, DOI 10.3390/recycling5020010; Arinaminpathy N, 2012, P NATL ACAD SCI USA, V109, P3173, DOI 10.1073/pnas.1113342109; Asgary A, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040469; Bertsimas D, 2022, NAV RES LOG, V69, P179, DOI 10.1002/nav.22007; Chowdhury P, 2021, TRANSPORT RES E-LOG, V148, DOI 10.1016/j.tre.2021.102271; Cormen T.H., 2009, INTRO ALGORITHMS; Dai TL, 2016, M&SOM-MANUF SERV OP, V18, P332, DOI 10.1287/msom.2015.0574; Daskin M. S, 2011, NETWORK DISCRETE LOC; Dela Cruz MDM, 2021, J PUBLIC HEALTH-UK, V43, pE381, DOI 10.1093/pubmed/fdab092; Ezugwu AE, 2021, ARTIF INTELL REV, V54, P4237, DOI 10.1007/s10462-020-09952-0; FEO TA, 1995, J GLOBAL OPTIM, V6, P109, DOI 10.1007/BF01096763; Fraser MR, 2021, J PUBLIC HEALTH MAN, V27, pS106, DOI 10.1097/PHH.0000000000001289; Goralnick E, 2021, NEW ENGL J MED, V384, pE67, DOI 10.1056/NEJMp2102535; Jacobson SH, 2006, VACCINE, V24, P3530, DOI 10.1016/j.vaccine.2006.02.004; KPMG, 5 WAYS OPT COVID 19; Krzysztofowicz S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115636; Lee EK, 2009, INTERFACES, V39, P476, DOI 10.1287/inte.1090.0463; Leithaeuser N., 2021, BMC HEALTH SERV RES, V21, P1; Lemaitre J.C., 2021, OPTIMIZING SPATIO TE, DOI [10.1101/2021.05.06.21256732, DOI 10.1101/2021.05.06.21256732]; Nesmachnow Sergio, 2014, INT J METAHEURISTICS, V3, P320, DOI [10.1504/IJMHEUR.2014.068914, DOI 10.1504/IJMHEUR.2014.068914]; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Stegherr H, 2020, NAT COMPUT, DOI 10.1007/s11047-020-09824-0; Stork J, 2020, NAT COMPUT, DOI 10.1007/s11047-020-09820-4; Sun Xu, 2021, Transp Res Interdiscip Perspect, V11, P100453, DOI 10.1016/j.trip.2021.100453; Talbi E.-G., 2009, METAHEURISTICS DESIG; Tavana M, 2021, ANN OPER RES, DOI 10.1007/s10479-021-04130-z	27	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1181	10.3390/vaccines9101181			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR4LL	34696289	Green Published, gold			2022-04-29	WOS:000714473100001
J	Gotlib, J; Sobierajski, T; Jaworski, M; Wawrzuta, D; Borowiak, E; Dobrowolska, B; Dyk, D; Gaworska-Krzeminska, A; Grochans, E; Kozka, M; Kulik, H; Lewko, J; Nowak-Starz, G; Wojciechowska, M; Uchmanowicz, I; Panczyk, M				Gotlib, Joanna; Sobierajski, Tomasz; Jaworski, Mariusz; Wawrzuta, Dominik; Borowiak, Ewa; Dobrowolska, Beata; Dyk, Danuta; Gaworska-Krzeminska, Aleksandra; Grochans, Elzbieta; Kozka, Maria; Kulik, Halina; Lewko, Jolanta; Nowak-Starz, Grazyna; Wojciechowska, Malgorzata; Uchmanowicz, Izabella; Panczyk, Mariusz			"Vaccinate, Do Not Hesitate!". Vaccination Readiness against COVID-19 among Polish Nursing Undergraduate Students: A National Cross-Sectional Survey	VACCINES			English	Article						COVID-19 vaccine; nursing students; level of knowledge; readiness; vaccine hesitancy	KNOWLEDGE	COVID-19 vaccination raises numerous concerns among the public, and also among medical personnel including nurses. As nurses play a crucial role in the process of vaccination, it is important to recognize the attitudes of students of nursing, nurses in spe, toward COVID-19 vaccination, as well as to define the factors influencing students' pro-vaccine choices. The study was conducted between March and April 2021 at all medical universities in Poland educating nurses in spe. The study included 793 first-degree students from 12 universities. The results revealed that the vast majority of students of nursing (77.2%) were vaccinated against COVID-19, as 61.2% received an mRNA vaccine and 16% a viral vector vaccine. Every other person in the non-vaccinated group declared their intention to get a vaccination. A trend was observed whereby people co-living with persons from the risk group, who are at risk of a severe form of COVID-19, showed greater willingness to get a vaccine. The study results identified the role of universities in increasing the vaccination rate among students, both in terms of education about vaccinations and in shaping pro-vaccine attitudes among students, as well as organizing vaccinations on university campuses to facilitate the process.	[Gotlib, Joanna; Jaworski, Mariusz; Wawrzuta, Dominik; Panczyk, Mariusz] Med Univ Warsaw, Dept Educ & Hlth Sci Res, PL-02091 Warsaw, Poland; [Sobierajski, Tomasz] Univ Warsaw, Fac Appl Social Sci & Resocializat, PL-00325 Warsaw, Poland; [Borowiak, Ewa] Med Univ Lodz, Dept Conservat Nursing, PL-90926 Lodz, Poland; [Dobrowolska, Beata] Med Univ Lublin, Dept Management Nursing, PL-20109 Lublin, Poland; [Dyk, Danuta] Med Univ Poznan, Dept Anaesthesiol & Intens Care Nursing, PL-61841 Poznan, Poland; [Gaworska-Krzeminska, Aleksandra] Med Univ Gdansk, Dept Nursing Management, PL-80803 Gdansk, Poland; [Grochans, Elzbieta] Pomeranian Med Univ, Dept Nursing, PL-70456 Szczecin, Poland; [Kozka, Maria] Jagiellonian Univ Med Coll, Dept Clin Nursing, PL-31007 Krakow, Poland; [Kulik, Halina] Med Univ Katowice, Dept Propaedeut Nursing, PL-41100 Katowice, Poland; [Lewko, Jolanta] Med Univ Bialystok, Fac Hlth Sci, Dept Primary Hlth Care, PL-15950 Bialystok, Poland; [Nowak-Starz, Grazyna] Jan Kochanowski Univ Humanities & Sci, Inst Publ Hlth, Med Coll, PL-25406 Kielce, Poland; [Wojciechowska, Malgorzata] Univ Phys Educ Warsaw, Dept Nursing, PL-00968 Warsaw, Poland; [Uchmanowicz, Izabella] Wroclaw Med Univ, Fac Hlth Sci, PL-50141 Wroclaw, Poland		Wawrzuta, D (通讯作者)，Med Univ Warsaw, Dept Educ & Hlth Sci Res, PL-02091 Warsaw, Poland.	joanna.gotlib@wum.edu.pl; tomasz.sobierajski@uw.edu.pl; mariusz.jaworski@wum.edu.pl; dwawrzuta@wum.edu.pl; ewa.borowiak@umed.lodz.pl; beata.dobrowolska@umlub.pl; dyk@ump.edu.pl; aleksandra.gaworska-krzeminska@gumed.edu.pl; grochans@pum.edu.pl; makozka@cm-uj.krakow.pl; hkulik@sum.edu.pl; jola.lewko@wp.pl; gnowakstarz@ujk.edu.pl; malgorzata.wojciechowska@awf.edu.pl; izabella.uchmanowicz@umed.wroc.pl; mariusz.panczyk@wum.edu.pl	Dobrowolska, Beata/U-3384-2018; Gaworska-Krzemińska, Aleksandra/AAL-6720-2020; Wawrzuta, Dominik/ABB-1890-2021; Panczyk, Mariusz/B-4412-2011; Uchmanowicz, Izabella/AAD-2232-2021; Grochans, Elzbieta/M-1593-2014	Dobrowolska, Beata/0000-0001-9178-9534; Gaworska-Krzemińska, Aleksandra/0000-0001-6705-6816; Gotlib, Joanna/0000-0002-2717-7741; Dyk, Danuta/0000-0003-2435-9424; Panczyk, Mariusz/0000-0003-1830-2114; Nowak-Starz, Grazyna/0000-0001-7804-2129; Uchmanowicz, Izabella/0000-0001-5452-0210; Wawrzuta, Dominik/0000-0002-0846-8906; Sobierajski, Tomasz/0000-0002-6853-9358; Kulik, Halina/0000-0002-1092-814X; Grochans, Elzbieta/0000-0002-3679-7002; Lewko, Jolanta/0000-0003-3074-1320; Borowiak, Ewa/0000-0003-1790-3516			[Anonymous], CBOS NEWS; Bai W, 2021, INT J BIOL SCI, V17, P1469, DOI 10.7150/ijbs.58835; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Evridiki P, 2021, FACTORS INFLUENCING, DOI [10.1101/2021.01.22.21250321, DOI 10.1101/2021.01.22.21250321]; Galanis PA, 2020, INTENTION HLTH CARE, DOI [10.1101/2020.12.08.20246041, DOI 10.1101/2020.12.08.20246041]; Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790; Gohel KH, 2021, CLIN EPIDEMIOL GLOB, V9, P104, DOI 10.1016/j.cegh.2020.07.008; Hlatshwako TG, 2021, LANCET DIGIT HEALTH, V3, pe76, DOI 10.1016/S2589-7500(21)00002-9; Ikhlaq A, 2020, PAK J MED SCI, V36, pS32, DOI 10.12669/pjms.36.COVID19-S4.2636; Kecojevic A, 2021, J COMMUN HEALTH, V46, P1059, DOI 10.1007/s10900-021-00992-3; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Manning ML, 2021, NURS OUTLOOK, V69, P565, DOI 10.1016/j.outlook.2021.01.019; Mascarenhas AK, 2021, J DENT EDUC, V85, P1504, DOI 10.1002/jdd.12632; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Mojally M, 2020, MED SCI, V24, P2861; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Petravic L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030247; Porcelli AJ, 2017, CURR OPIN BEHAV SCI, V14, P33, DOI 10.1016/j.cobeha.2016.11.015; Reyna VF, 2012, JUDGM DECIS MAK, V7, P332; Romer D, 2021, J MED INTERNET RES, V23, DOI 10.2196/25215; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Scholz N., 2021, COVID 19 VACCINATION; Tempski P, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248627; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wawrzuta D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050481; World Health Organization(WHO), 2021, STAT COVID 19 VACC W; Yuan T, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.925877	31	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1029	10.3390/vaccines9091029			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YE	34579265	Green Published, gold			2022-04-29	WOS:000702075100001
J	Hargrave, A; Mustafa, A; Hanif, A; Tunio, JH; Hanif, SNM				Hargrave, Anna; Mustafa, Abu Salim; Hanif, Asma; Tunio, Javed H.; Hanif, Shumaila Nida M.			Current Status of HIV-1 Vaccines	VACCINES			English	Review						HIV; vaccines; clinical phases	ANTIBODIES; EFFICACY; PROGRESS	HIV-1 infection and its progression to AIDS remains a significant global health challenge, particularly for low-income countries. Developing a vaccine to prevent HIV-1 infections has proven to be immensely challenging with complex biological acquisition and infection, unforeseen clinical trial disappointments, and funding issues. This paper discusses important landmarks of progress in HIV-1 vaccine development, various vaccine strategies, and clinical trials.	[Hargrave, Anna; Hanif, Shumaila Nida M.] Univ Pikeville, Kentucky Coll Osteopath Med, Dept Biomed Sci, Pikeville, KY 41501 USA; [Mustafa, Abu Salim] Kuwait Univ, Dept Microbiol, Coll Med, Kuwait 12037, Kuwait; [Hanif, Asma] Kuwait Univ, Dept Restorat Sci, Coll Dent, Kuwait 12037, Kuwait; [Tunio, Javed H.] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA		Hanif, SNM (通讯作者)，Univ Pikeville, Kentucky Coll Osteopath Med, Dept Biomed Sci, Pikeville, KY 41501 USA.	annahargrave@upike.edu; abu.mustafa@ku.edu.kw; Asma.h@hsc.edu.kw; Javed-tunio@uiowa.edu; shumailahanif@upike.edu		Mustafa, AbuSalim/0000-0002-6074-1041			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]; Bekker LG, 2020, LANCET, V395, P384, DOI 10.1016/S0140-6736(19)32682-0; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Eisinger RW, 2021, J INFECT DIS, V224, P1455, DOI 10.1093/infdis/jiab114; Esparza J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00124; Esparza J, 2013, VACCINE, V31, P3502, DOI 10.1016/j.vaccine.2013.05.018; Excler JL, 2019, EXPERT REV VACCINES, V18, P765, DOI 10.1080/14760584.2019.1640117; Fauci AS, 2020, NEW ENGL J MED, V383, P1, DOI 10.1056/NEJMp1916753; Gray G, 2010, CURR OPIN HIV AIDS, V5, P357, DOI 10.1097/COH.0b013e32833d2d2b; Gray GE, 2016, CURR OPIN VIROL, V17, P104, DOI 10.1016/j.coviro.2016.02.010; Hanke T, 2019, EXPERT REV VACCINES, V18, P1029, DOI 10.1080/14760584.2019.1675518; Haynes BF, 2021, NAT REV IMMUNOL, V21, P543, DOI 10.1038/s41577-021-00589-w; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hsu DC, 2017, HUM VACC IMMUNOTHER, V13, P1018, DOI 10.1080/21645515.2016.1276138; Jones LD, 2020, CLIN THER, V42, P499, DOI 10.1016/j.clinthera.2020.01.009; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; MAYR A, 1974, INFECTION, V2, P64, DOI 10.1007/BF01642023; Mu ZK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020134; Ng'uni T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590780; Palesch D, 2013, CELL, V155, P495, DOI 10.1016/j.cell.2013.10.012; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Priddy FH, 2019, LANCET HIV, V6, pE230, DOI 10.1016/S2352-3018(19)30003-7; Rezaei T, 2019, J CONTROL RELEASE, V316, P116, DOI 10.1016/j.jconrel.2019.10.045; Ross AL, 2010, LANCET INFECT DIS, V10, P305, DOI 10.1016/S1473-3099(10)70069-4; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Stephenson KE, 2013, IMMUNOL REV, V254, P295, DOI 10.1111/imr.12073; Venkatesan P, 2021, LANCET MICROBE, V2, pE95; Wang HB, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/503978; Zolla-Pazner S, 2021, LANCET HIV, V8, pE449, DOI 10.1016/S2352-3018(21)00073-4	34	1	1	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1026	10.3390/vaccines9091026			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW3TX	34579263	Green Published, gold			2022-04-29	WOS:000700083700001
J	Hernandez-Bello, J; Morales-Nunez, JJ; Machado-Sulbaran, AC; Diaz-Perez, SA; Torres-Hernandez, PC; Balcazar-Felix, P; Gutierrez-Brito, JA; Lomeli-Nieto, JA; Munoz-Valle, JF				Hernandez-Bello, Jorge; Javier Morales-Nunez, Jose; Carolina Machado-Sulbaran, Andrea; Alberto Diaz-Perez, Saul; Carolina Torres-Hernandez, Paola; Balcazar-Felix, Paulina; Alberto Gutierrez-Brito, Jesus; Alvaro Lomeli-Nieto, Jose; Francisco Munoz-Valle, Jose			Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2	VACCINES			English	Article						COVID-19; SARS-CoV-2; AD5-nCOV; neutralizing antibodies; vaccine; reactogenicity	SEVERITY; COVID-19; IMMUNITY	This is the first study outside of clinical trials (phase I-III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (117 with prior COVID-19 and 229 without prior COVID-19) vaccinated with Ad5-nCoV were recruited. The percentage of neutralizing antibodies against SARS-CoV-2 (Surrogate Virus Neutralization Test) and antibodies against Ad5 (ADV-Ad5 IgG ELISA) were quantified pre and post-vaccination effects. The Ad5-nCoV vaccine induces higher neutralizing antibodies percentage in individuals with prior COVID-19 than those without prior COVID-19 (median [IQR]: 98% [97-98.1] vs. 72% [54-90], respectively; p < 0.0001). Furthermore, a natural infection (before vaccination) induces more neutralizing antibodies percentage than immunized individuals without prior COVID-19 (p < 0.01). No patient had vaccine-severe adverse effects. The age, antidepressant, and immunosuppressive treatments, reactogenicity, and history of COVID-19 are associated with impaired antibody production. The anti-Ad5 antibodies increased after 21 days of post-vaccination in all groups (p < 0.01). We recommend the application of a booster dose of Ad5-nCoV, especially for those individuals without previous COVID-19 infection. Finally, the induction of anti-Ad5 antibodies after vaccination should be considered if a booster with the same vaccine is planned.	[Hernandez-Bello, Jorge; Javier Morales-Nunez, Jose; Alberto Diaz-Perez, Saul; Alberto Gutierrez-Brito, Jesus; Alvaro Lomeli-Nieto, Jose; Francisco Munoz-Valle, Jose] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Biomed Sci, Guadalajara 44340, Jalisco, Mexico; [Carolina Machado-Sulbaran, Andrea] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Canc Childhood & Adolescence, Guadalajara 44340, Jalisco, Mexico; [Carolina Torres-Hernandez, Paola; Balcazar-Felix, Paulina] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Immunol Lab, Guadalajara 44340, Jalisco, Mexico		Munoz-Valle, JF (通讯作者)，Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Biomed Sci, Guadalajara 44340, Jalisco, Mexico.	jorge89_5@hotmail.com; pepejavis_15@hotmail.com; andrea.machado5223@academicos.udg.mx; saulalberto95@outlook.com; carolina.torres.h@hotmail.com; paufe97@gmail.com; vabj_94@hotmail.com; loman_an@hotmail.com; biologiamolecular@hotmail.com		Lomeli Nieto, Jose Alvaro/0000-0002-6620-3017; Hernandez-Bello, Jorge/0000-0001-8004-1811; Diaz Perez, Saul Alberto/0000-0003-3225-5174; Munoz-Valle, Jose Francisco/0000-0002-2272-9260; Torres Hernandez, Paola Carolina/0000-0002-7725-4645; Morales Nunez, Jose Javier/0000-0001-5062-0310; Machado-Sulbaran, Andrea Carolina/0000-0001-7879-9316			Anichini G, 2021, NEW ENGL J MED, V385, P90, DOI 10.1056/NEJMc2103825; [Anonymous], COVID 19 MAP; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Barlow-Pay F, 2021, THER ADV DRUG SAF, V12, DOI 10.1177/2042098620985687; Blaser, 2014, MANDELL DOUGLAS BENN; Bull JJ, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006857; CanSino Biologics Inc, 2021, GLOB MULT RAND DOUBL; Carpinteiro A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100142; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Connors J, 2021, GEROSCIENCE, V43, P31, DOI 10.1007/s11357-021-00323-3; Coughlan L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00909; Cox LS, 2020, LANCET HEALTH LONGEV, V1, pE55, DOI 10.1016/S2666-7568(20)30011-8; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Deepak Parakkal, 2021, medRxiv, DOI 10.1101/2021.04.05.21254656; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Dorrington MG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00171; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Ejaz H, 2020, J INFECT PUBLIC HEAL, V13, P1833, DOI 10.1016/j.jiph.2020.07.014; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Garcia-Beltran Wilfredo F, 2020, medRxiv, DOI 10.1101/2020.10.15.20213512; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Heaton PM, 2020, NEW ENGL J MED, V383, P1986, DOI 10.1056/NEJMe2025111; Hoertel N, 2021, MOL PSYCHIATR, V26, P5199, DOI 10.1038/s41380-021-01021-4; Hojyo S, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00146-3; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Morales-Nunez JJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070742; Krammer F., 2021, ROBUST SPIKE ANTIBOD, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]; Lenze EJ, 2020, JAMA-J AM MED ASSOC, V324, P2292, DOI 10.1001/jama.2020.22760; Levaillant M, 2019, LANCET, V394, P467, DOI 10.1016/S0140-6736(19)31662-9; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Meyer B, 2020, EMERG MICROBES INFEC, V9, P2394, DOI 10.1080/22221751.2020.1835448; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Nwanegbo E, 2004, CLIN DIAGN LAB IMMUN, V11, P351, DOI 10.1128/CDLI.11.2.351-357.2004; Oomen M., 2021, SINGLE DOSE SARS COV, DOI [10.1101/2021.05.25.21257797, DOI 10.1101/2021.05.25.21257797]; Pawelec G, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979-021-00219-y; Rabeea SA, 2021, DARU, V29, P217, DOI 10.1007/s40199-021-00390-z; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Sanyaolu Adekunle, 2020, SN Compr Clin Med, V2, P1069, DOI 10.1007/s42399-020-00363-4; Schmidt T, 2021, NAT MED, V27, P1530, DOI 10.1038/s41591-021-01464-w; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; Spiera R, 2021, ANN RHEUM DIS, V80, P1357, DOI 10.1136/annrheumdis-2021-220604; Sprent J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj9256; van Aalst M, 2018, VACCINE, V36, P5832, DOI 10.1016/j.vaccine.2018.07.039; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wu SP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17972-1; Ye TT, 2020, ANGEW CHEM INT EDIT, V59, P18885, DOI 10.1002/anie.202008319; Yu SC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060588; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	56	4	4	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1047	10.3390/vaccines9091047			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3QM	34579284	Green Published, gold			2022-04-29	WOS:000702123000001
J	Nomura, Y; Sawahata, M; Nakamura, Y; Kurihara, M; Koike, R; Katsube, O; Hagiwara, K; Niho, S; Masuda, N; Tanaka, T; Sugiyama, K				Nomura, Yushi; Sawahata, Michiru; Nakamura, Yosikazu; Kurihara, Momoko; Koike, Ryousuke; Katsube, Otohiro; Hagiwara, Koichi; Niho, Seiji; Masuda, Norihiro; Tanaka, Takaaki; Sugiyama, Kumiya			Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine	VACCINES			English	Article						SARS-CoV-2; viral infection; clinical epidemiology		Objective: We aimed to determine antibody (Ab) titres 3 months after the second dose of the BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables predicting these titres in Japan. Methods: We enrolled 378 healthcare workers (255 women, 123 men) whose blood samples were collected 91 +/- 15 days after the second of two inoculations of the BNT162b2 COVID-19 mRNA vaccine (Pfizer/BioNTech) given 3 weeks apart. Medical histories and demographic characteristics were recorded using a structured self-reported questionnaire. The relationships between Ab titres and these factors were analysed. Results: Median age (interquartile range (IQR)) of the participants was 44 (32-54) years. Median Ab titre (IQR) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigen was 764 (423-1140) U/mL. Older participants had significantly lower Ab titres; median (IQR) Ab titres were 942 (675-1390) and 1095 (741-1613) U/mL in men and women in their 20s, respectively, but 490 (297-571) and 519 (285-761) U/mL in men and women in their 60-70s, respectively. In the age-adjusted analysis, the only risk factors for lower Ab titres were male sex and smoking. However, the sex difference may have arisen from the sex difference in smoking rate. Moreover, Ab titres were significantly lower in current smokers than in ex-smokers. Conclusions: The most important factors associated with low Ab titres were age and smoking habit. In particular, current smoking status caused lower Ab titres, and smoking cessation before vaccination may improve the individual efficacy of the BNT162b2 vaccine.	[Nomura, Yushi; Sawahata, Michiru; Kurihara, Momoko; Koike, Ryousuke; Katsube, Otohiro; Sugiyama, Kumiya] Natl Hosp Org, Dept Resp Med & Clin Immunol, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan; [Nomura, Yushi; Koike, Ryousuke; Niho, Seiji] Dokkyo Med Univ, Dept Pulm Med & Clin Immunol, Shimotsuga 3210293, Japan; [Sawahata, Michiru; Hagiwara, Koichi] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi 3290498, Japan; [Nakamura, Yosikazu] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi 3290498, Japan; [Masuda, Norihiro] Natl Hosp Org, Dept Surg, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan; [Tanaka, Takaaki] Natl Hosp Org, Dept Orthopaed Surg, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan; [Sugiyama, Kumiya] Dokkyo Med Univ, Saitama Med Ctr, Dept Resp Med & Clin Immunol, Shimotsuga 3210293, Japan		Sawahata, M (通讯作者)，Natl Hosp Org, Dept Resp Med & Clin Immunol, Utsunomiya Natl Hosp, Utsunomiya, Tochigi 3291193, Japan.; Sawahata, M (通讯作者)，Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi 3290498, Japan.	uc.nomura@gmail.com; sawahata@jichi.ac.jp; nakamuyk@jichi.ac.jp; momoko1005kurihara@gmail.com; ryou.k.1207@gmail.com; 5okatsube@gmail.com; hagiwark@me.com; siniho@dokkyomed.ac.jp; norim0507@gmail.com; tanaka.takaaki.vh@mail.hosp.go.jp; sugiyama@dokkyomed.ac.jp	Sawahata, Michiru/ABF-7918-2021	Sawahata, Michiru/0000-0001-9220-3419; Sugiyama, Kumiya/0000-0002-0624-946X; Nakamura, Yosikazu/0000-0001-6654-1481			Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Callegaro A, 2021, J MED VIROL, V93, P4612, DOI 10.1002/jmv.26982; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Iyer Anita S, 2020, medRxiv, DOI 10.1101/2020.07.18.20155374; Jiang SB, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.1; Kageyama T., 2021, MEDRXIV, DOI [10.1101/2021.06.01.21258188, DOI 10.1101/2021.06.01.21258188]; Kennedy NA, 2021, GUT, V70, P1884, DOI 10.1136/gutjnl-2021-324789; Ledford H, 2020, NATURE, V586, P488, DOI 10.1038/d41586-020-02946-6; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; MACKENZIE JS, 1976, J HYG-CAMBRIDGE, V77, P409, DOI 10.1017/S0022172400055790; Miyakawa K, 2021, J MOL CELL BIOL, V13, P918, DOI 10.1093/jmcb/mjab050; Monin-Aldama L., 2021, MEDRXIV, DOI [10.1101/2021.03.17.21253131, DOI 10.1101/2021.03.17.21253131]; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Pfizer, PFIZ BIONTECH CONF H; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; Watanabe M, 2022, DIABETES-METAB RES, V38, DOI 10.1002/dmrr.3465; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	24	11	11	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1042	10.3390/vaccines9091042			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3DZ	34579279	Green Published, gold, Green Submitted			2022-04-29	WOS:000702090200001
J	Wang, PP; Huang, SL; Hao, CW; Wang, ZH; Zhao, HR; Liu, MY; Tian, XR; Ge, LT; Wu, WX; Peng, C				Wang, Pengpeng; Huang, Shulin; Hao, Chengwu; Wang, Zhanhui; Zhao, Haoran; Liu, Mengyao; Tian, Xinrui; Ge, Letu; Wu, Wenxue; Peng, Chen			Establishment of a Suspension MDBK Cell Line in Serum-Free Medium for Production of Bovine Alphaherpesvirus-1	VACCINES			English	Article						serum-free suspension adaptation process; suspended MDBK cells; serum-free medium; bovine alphaherpesvirus-1 (BoHV-1); virus production; ultrasonic treatment	EXPRESSION; VIRUS; CORONAVIRUS; ADAPTATION; ANTIBODIES; CULTURES; SYSTEM; GROWTH	The Madin-Darby bovine kidney (MDBK) cell line is currently used for the production of bovine alphaherpesvirus-1 (BoHV-1) vaccine. For the purpose of vaccine manufacturing, suspension cells are preferred over adherent ones due to simplified sub-cultivation and an easier scale-up process, both of which could significantly reduce production cost. This study aimed to establish a procedure for the culture of BoHV-1 in the suspended MDBK cell line in serum-free medium. We screened several commercially available serum-free media and chose ST503 for subsequent experiments. We successfully adapted the adherent MDBK cells to suspended growth in ST503 in the absence of serum. The maximum density of suspension-adapted MDBK cells could reach 2.5 x 10(7) cells/mL in ST503 medium with optimal conditions. The average size of suspension-adapted cells increased to 18 +/- 1 mu m from 16 +/- 1 mu m. Moreover, we examined tumorigenicity of the suspended cells and found no sign of tumorigenicity post adaptation. Next, we developed a protocol for the culture of BoHV-1 in the cell line described above and found that ultrasonic treatment could facilitate virus release and enhance virus yield by 11-fold, with the virus titer reaching 8.0 +/- 0.2 log(10)TCID(50)/mL. Most importantly, the prototype inactivated BoHV-1 vaccine we generated using the suspension cultures of MDBK cells induced neutralizing antibodies to a titer comparable to that of the commercial inactivated BoHV-1 vaccine. Overall, we established and optimized a protocol for the production of inactivated BoHV-1 vaccine in MDBK cells adapted for suspension culture, which provides insights for future large-scale manufacturing of BoHV-1 vaccine.	[Wang, Pengpeng; Wang, Zhanhui; Zhao, Haoran; Liu, Mengyao; Tian, Xinrui; Ge, Letu; Wu, Wenxue; Peng, Chen] China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Beijing 100193, Peoples R China; [Huang, Shulin] China Anim Husb Ind Co Ltd, Beijing 100070, Peoples R China; [Hao, Chengwu] TECON Biopharmaceut Co Ltd, Urumqi 830011, Peoples R China		Wu, WX; Peng, C (通讯作者)，China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Beijing 100193, Peoples R China.	18754881870@163.com; hslcau@163.com; haochengwu@tecon-bio.com; wangzhanhui2016@163.com; zhaohrr@yeah.net; mengyaoliu@cau.edu.cn; tianxrui@163.com; 17600366745@163.com; labboard@126.com; chenpengup@outlook.com	Wang, Zhanhui/AAH-8601-2019		China Agriculture Research System of MOF and MARA	This work was supported by China Agriculture Research System of MOF and MARA.	Bastian M, 2011, VACCINE, V29, P5267, DOI 10.1016/j.vaccine.2011.05.012; Bell RL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040337; Benedictus L, 2017, EXPERT REV VACCINES, V16, P65, DOI 10.1080/14760584.2017.1249859; BENZEEV A, 1984, J CELL BIOL, V99, P1424, DOI 10.1083/jcb.99.4.1424; Cai S., 2018, Patent Application, VA, Patent No. [201711098901.9, 2017110989019]; Conceicao MM, 2007, VACCINE, V25, P7785, DOI 10.1016/j.vaccine.2007.08.048; Silva LCE, 2020, ENG REP, V2, DOI 10.1002/eng2.12172; Cowley DJB, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-40; Dill V, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060511; ELAZHARY MASY, 1977, VET MICROBIOL, V2, P283, DOI 10.1016/0378-1135(77)90039-6; Euler KN, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-18; Fernandes LG, 2019, PREV VET MED, V169, DOI 10.1016/j.prevetmed.2019.104705; Gelinas JF, 2019, VACCINE, V37, P6624, DOI 10.1016/j.vaccine.2019.09.044; Griffin D, 2010, VET CLIN N AM-FOOD A, V26, P381, DOI 10.1016/j.cvfa.2010.04.004; Han ZQ, 2016, J WILDLIFE DIS, V52, P164, DOI 10.7589/2015-01-018; Hao P., 2017, Patent, VA, Patent No. [201710154847.9, 2017101548479]; Huang D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141686; Iki S, 2005, VIROLOGY, V343, P106, DOI 10.1016/j.virol.2005.08.010; le Tu G., 2020, THESIS CHINA AGR U B; Lee SS, 2016, J THEOR BIOL, V404, P51, DOI 10.1016/j.jtbi.2016.05.025; LESKO J, 1993, ACTA VIROL, V37, P73; Li X, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00697-19; Li YY, 2017, ONCOTARGET, V8, P49238, DOI 10.18632/oncotarget.17493; MADIN SH, 1956, SCIENCE, V124, P721, DOI 10.1126/science.124.3225.721; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; Mastelic B, 2013, BIOLOGICALS, V41, P458, DOI 10.1016/j.biologicals.2013.08.006; Miles Delbert G., 2009, Animal Health Research Reviews, V10, P101, DOI 10.1017/S1466252309990090; Nyon MP, 2018, VACCINE, V36, P1853, DOI 10.1016/j.vaccine.2018.02.065; Ohmori K, 2007, VET IMMUNOL IMMUNOP, V115, P166, DOI 10.1016/j.vetimm.2006.10.005; PERRIN P, 1995, VACCINE, V13, P1244, DOI 10.1016/0264-410X(94)00022-F; Petiot E, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-84; Qin ZL, 2013, J VIROL METHODS, V193, P261, DOI 10.1016/j.jviromet.2013.06.024; Quattrocchi V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00037; Ramos I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134675; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sayers RG, 2017, J DAIRY SCI, V100, P1340, DOI 10.3168/jds.2016-11113; Shen CF, 2019, VACCINE, V37, P6996, DOI 10.1016/j.vaccine.2019.07.003; Sinacore MS, 2000, MOL BIOTECHNOL, V15, P249, DOI 10.1385/MB:15:3:249; Tekin S, 2005, AM J REPROD IMMUNOL, V53, P136, DOI 10.1111/j.1600-0897.2005.00257.x; Welter MW, 1998, ADV EXP MED BIOL, V440, P707; Wong VVT, 2004, CYTOTECHNOLOGY, V45, P107, DOI 10.1007/s10616-004-6173-2; Zhang GQ, 2017, CURR PHARM BIOTECHNO, V18, P351, DOI 10.2174/1389201018666170320110545; Zhang JY, 2006, BIOTECHNOL BIOENG, V95, P1188, DOI 10.1002/bit.21081; Zhong XL, 2012, CELL SIGNAL, V24, P393, DOI 10.1016/j.cellsig.2011.10.005	44	0	0	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1006	10.3390/vaccines9091006			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3GO	34579242	gold, Green Published			2022-04-29	WOS:000702097000001
J	Balint, A; Molnar, T; Kecskemeti, S; Kulcsar, G; Soos, T; Szabo, PM; Kaszab, E; Fornyos, K; Zadori, Z; Banyai, K; Szabo, I				Balint, Adam; Molnar, Tamas; Kecskemeti, Sandor; Kulcsar, Gabor; Soos, Tibor; Szabo, Peter M.; Kaszab, Eszter; Fornyos, Kinga; Zadori, Zoltan; Banyai, Krisztian; Szabo, Istvan			Genetic Variability of PRRSV Vaccine Strains Used in the National Eradication Programme, Hungary	VACCINES			English	Article						porcine reproductive and respiratory syndrome virus; molecular epidemiology; phylogenetic network	RESPIRATORY SYNDROME VIRUS; PROTECTION; SEQUENCE	Porcine reproductive and respiratory syndrome (PRRS) is a globally spread, highly infectious viral disease. Live, attenuated vaccines against PRRS virus (PRRSV) decrease virus excretion and evoke protective immunity reducing the economic damage caused by the disease. In a longitudinal molecular epidemiological study accompanying ongoing national eradication programme we evaluated the suitability of PRRSV ORF5 and ORF7 sequences to identify possible field strains of vaccine-origin. In total, 2342 ORF5 sequences and 478 ORF7 sequences were analysed. Vaccine strains were identified by sequence identity values and phylogenetic network analysis. Strains that shared greater than 98% nucleotide identity within ORF5 and/or ORF7 were considered to have originated from vaccine. A total of 882 (37.6%) ORF5 and 88 (18.4%) ORF7 sequences met these criteria. In detail, 618, 179 and 35 ORF5 and 51, 29 and 8 ORF7 sequences were related to Porcilis PRRS vaccine, Unistrain PRRS vaccine, and ReproCyc PRRS EU vaccine, respectively. Data showed that the Porcilis vaccine was genetically more stable. Whereas, the variability of the Unistrain and the ReproCyc strains was significantly higher. Given that ORF7 shares, in some instances, complete identity between a particular vaccine strain and some historic variants of field PRRSV strains, care must be taken when evaluating vaccine relatedness of a field isolate based on the ORF7. On the contrary, ORF5 sequences were more suitable to predict the vaccine origin making a distinction more robustly between field and vaccine strains. We conclude that ORF5 based molecular epidemiological studies support more efficiently the ongoing PRRS eradication programmes. The conclusions presented in this large-scale PRRS molecular epidemiological study provides a framework for future eradication programmes planned in other countries.	[Balint, Adam; Kecskemeti, Sandor] Natl Food Chain Safety Off, Vet Diagnost Directorate, H-1143 Budapest, Hungary; [Molnar, Tamas; Szabo, Istvan] Natl PRRS Eradicat Comm, H-1021 Budapest, Hungary; [Kulcsar, Gabor; Soos, Tibor] Natl Food Chain Safety Off, Directorate Vet Med Prod, H-1107 Budapest, Hungary; [Szabo, Peter M.] Hungarian Acad Sci, Mol Med Res Grp, H-1085 Budapest, Hungary; [Szabo, Peter M.] Semmelweis Univ, H-1085 Budapest, Hungary; [Kaszab, Eszter; Zadori, Zoltan; Banyai, Krisztian] Inst Vet Med Res, H-1143 Budapest, Hungary; [Fornyos, Kinga] MAH Food Controll Ltd, H-1211 Budapest, Hungary; [Banyai, Krisztian] Univ Vet Med, Dept Pharmacol & Toxicol, H-1078 Budapest, Hungary		Balint, A (通讯作者)，Natl Food Chain Safety Off, Vet Diagnost Directorate, H-1143 Budapest, Hungary.	balintad@nebih.gov.hu; iszabodr@t-online.hu; kecskemetis@nebih.gov.hu; kulcsarg@nebih.gov.hu; soost@nebih.gov.hu; dr.szabo.peter@gmail.com; kaszab.eszter@atk.hu; fornyos.kinga@vet-controll.hu; zadori.zoltan@atk.hu; banyai.krisztian@atk.hu; iszabodr@t-online.hu		Szabo, Istvan/0000-0003-4786-8475	National Research, Development, and Innovation OfficeNational Research, Development & Innovation Office (NRDIO) - Hungary [K 128247, FK 128252, K 119381]; Hungarian Academy of Sciences through the Lendulet/Momentum program	This research was funded by the National Research, Development, and Innovation Office grant K 119381 (awardee, Z.Z.). Additional funding was received from the Hungarian Academy of Sciences through the Lendulet/Momentum program (awardee, K.B.). This study was supported by the National Research, Development, and Innovation Office grants K 128247 to Z.B., FK 128252 to D.T. and K 119381 to Z.Z.	[Anonymous], 1992, VET REC, V130, P87; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; Botner A., 2000, Veterinary Research (Paris), V31, P72, DOI 10.1051/vetres:2000009; Brinton M.A., 2018, PROPOSAL 2017 012S V; Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23; Diaz I, 2006, VIROLOGY, V351, P249, DOI 10.1016/j.virol.2006.03.046; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Hanada K, 2005, MOL BIOL EVOL, V22, P1024, DOI 10.1093/molbev/msi089; Holtkamp D., 2012, ANIM IND REP, V658, P3, DOI [10.31274/ans_air-180814-28, DOI 10.31274/ANS_AIR-180814-28]; Hornyak A, 1997, AC REP VET COMM HUNG; Martinez-Lobo FJ, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-115; Keffaber K., 1989, AM ASS SWINE PRACT N, V1, P1; Lu WH, 2012, J VIROL, V86, P9543, DOI 10.1128/JVI.01341-12; Madsen KG, 1998, ARCH VIROL, V143, P1683, DOI 10.1007/s007050050409; Medveczky I., 1996, MAGY ALLATORV LAPJA, V57, P367; Ministry of Agriculture, 41 1997 V 28 DECR MI; Murtaugh MP, 2011, VACCINE, V29, P8192, DOI 10.1016/j.vaccine.2011.09.013; Nathues H, 2017, PREV VET MED, V142, P16, DOI 10.1016/j.prevetmed.2017.04.006; Nielsen HS, 2001, J GEN VIROL, V82, P1263, DOI 10.1099/0022-1317-82-6-1263; Roca M, 2012, VET J, V193, P92, DOI 10.1016/j.tvjl.2011.11.019; Szabo Istvan, 2020, Acta Vet Hung, V68, P257, DOI 10.1556/004.2020.00043; Szabo PM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75516-5; Valdes-Donoso P, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00102; Wang CM, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-146; Wang R, 2013, VACCINE, V31, P5537, DOI 10.1016/j.vaccine.2013.09.023; WENSVOORT G, 1993, VET RES, V24, P117; Zuckermann FA, 2007, VET MICROBIOL, V123, P69, DOI 10.1016/j.vetmic.2007.02.009	27	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							849	10.3390/vaccines9080849			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9AC	34451974	Green Published, gold			2022-04-29	WOS:000690213000001
J	Chemparthy, DT; Kannan, M; Gordon, L; Buch, S; Sil, S				Chemparthy, Divya T.; Kannan, Muthukumar; Gordon, Lila; Buch, Shilpa; Sil, Susmita			Alzheimer's-Like Pathology at the Crossroads of HIV-Associated Neurological Disorders	VACCINES			English	Review						HAND; AD; tauopathy; A beta 42; synaptodendritic alterations	BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; IMMUNODEFICIENCY-VIRUS TYPE-1; AMYLOID-BETA ACCUMULATION; CEREBROSPINAL-FLUID; ANTIRETROVIRAL THERAPY; NEUROCOGNITIVE DISORDERS; TRANSGENIC MICE; TAT PROTEIN; MEMORY DEFICITS	Despite the widespread success of combined antiretroviral therapy (cART) in suppressing viremia, the prevalence of human immunodeficiency virus (HIV)-associated neurological disorders (HAND) and associated comorbidities such as Alzheimer's disease (AD)-like symptomatology is higher among people living with HIV. The pathophysiology of observed deficits in HAND is well understood. However, it has been suggested that it is exacerbated by aging. Epidemiological studies have suggested comparable concentrations of the toxic amyloid protein, amyloid-beta 42 (A beta 42), in the cerebrospinal fluid (CSF) of HAND patients and in the brains of patients with dementia of the Alzheimer's type. Apart from abnormal amyloid-beta (A beta) metabolism in AD, a better understanding of the role of similar pathophysiologic processes in HAND could be of substantial value. The pathogenesis of HAND involves either the direct effects of the virus or the effect of viral proteins, such as Tat, Gp120, or Nef, as well as the effects of antiretrovirals on amyloid metabolism and tauopathy, leading, in turn, to synaptodendritic alterations and neuroinflammatory milieu in the brain. Additionally, there is a lack of knowledge regarding the causative or bystander role of Alzheimer's-like pathology in HAND, which is a barrier to the development of therapeutics for HAND. This review attempts to highlight the cause-effect relationship of Alzheimer's-like pathology with HAND, attempting to dissect the role of HIV-1, HIV viral proteins, and antiretrovirals in patient samples, animal models, and cell culture model systems. Biomarkers associated with Alzheimer's-like pathology can serve as a tool to assess the neuronal injury in the brain and the associated cognitive deficits. Understanding the factors contributing to the AD-like pathology associated with HAND could set the stage for the future development of therapeutics aimed at abrogating the disease process.	[Chemparthy, Divya T.; Kannan, Muthukumar; Gordon, Lila; Buch, Shilpa; Sil, Susmita] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA		Buch, S; Sil, S (通讯作者)，Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	divya.thomas@unmc.edu; mkannan@unmc.edu; lilagordon901@gmail.com; sbuch@unmc.edu; susmita.sil@unmc.edu			John Hopkins University [R25MH080661, RO1DA044586, DA040397, DA043138, DA047156, DA050545];  [R21AG069541]	R21AG069541 and John Hopkins University, R25MH080661 (S. Sil) and RO1DA044586, DA040397, DA043138, DA047156, DA050545 (S. Buch).	Acharya A, 2021, J VIROL, V95, DOI 10.1128/JVI.01657-20; Achim CL, 2009, J NEUROIMMUNE PHARM, V4, P190, DOI 10.1007/s11481-009-9152-8; Ahooyi TM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34539-9; Akkina R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020169; Aksenov MY, 2010, NEUROSCI LETT, V475, P174, DOI 10.1016/j.neulet.2010.03.073; Anderson ER, 2003, NEUROSCIENCE, V118, P359, DOI 10.1016/S0306-4522(02)00925-9; Andersson LM, 1999, J NEUROL SCI, V171, P92, DOI 10.1016/S0022-510X(99)00253-1; Andras IE, 2017, MOL CELL NEUROSCI, V79, P12, DOI 10.1016/j.mcn.2016.12.006; Andras IE, 2013, IUBMB LIFE, V65, P43, DOI 10.1002/iub.1106; Andras IE, 2012, BIOCHEM BIOPH RES CO, V421, P177, DOI 10.1016/j.bbrc.2012.03.128; Andras IE, 2010, MOL CELL NEUROSCI, V43, P232, DOI 10.1016/j.mcn.2009.11.004; Anesten B, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000300; Anthony IC, 2006, ACTA NEUROPATHOL, V111, P529, DOI 10.1007/s00401-006-0037-0; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Antinori A, 2013, CLIN INFECT DIS, V56, P1004, DOI 10.1093/cid/cis975; Armitage PA, 2011, MAGN RESON IMAGING, V29, P305, DOI 10.1016/j.mri.2010.09.002; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Asahchop EL, 2016, AIDS, V30, P2021, DOI 10.1097/QAD.0000000000001160; Bachis A, 2016, NEUROBIOL AGING, V46, P160, DOI 10.1016/j.neurobiolaging.2016.07.001; Banks WA, 2001, J VIROL, V75, P4681, DOI 10.1128/JVI.75.10.4681-4691.2001; Becker JT, 2004, AIDS, V18, pS11, DOI 10.1097/00002030-200401001-00003; Berger JR, 2000, NEUROLOGY, V54, P921, DOI 10.1212/WNL.54.4.921; Bertrand L, 2019, BRAIN, V142, P502, DOI 10.1093/brain/awy339; Borrajo A, 2021, ANN MED, V53, P43, DOI 10.1080/07853890.2020.1814962; Boska MD, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-58; Bracq L, 2017, J VIROL, V91, DOI 10.1128/JVI.01237-17; Brew BJ, 2005, NEUROLOGY, V65, P1490, DOI 10.1212/01.wnl.0000183293.95787.b7; Brew BJ, 2019, AIDS, V33, pS113, DOI 10.1097/QAD.0000000000002251; Calcagno A, 2016, J NEUROVIROL, V22, P88, DOI 10.1007/s13365-015-0371-x; Campbell LA, 2017, FEBS J, V284, P4096, DOI 10.1111/febs.14293; Canestri A, 2010, CLIN INFECT DIS, V50, P773, DOI 10.1086/650538; Canet G, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00307; Cantres-Rosario YM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44463-1; Cantres-Rosario YM, 2015, AIDS, V29, P2081, DOI 10.1097/QAD.0000000000000823; Carroll Antonia, 2017, F1000Res, V6, P312, DOI 10.12688/f1000research.10651.1; Castellano P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12758-w; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chaganti J, 2019, AIDS, V33, P1843, DOI 10.1097/QAD.0000000000002300; Chai QQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01795-8; Chen XS, 2013, NEUROBIOL AGING, V34, P2370, DOI 10.1016/j.neurobiolaging.2013.04.015; Chivero ET, 2017, J NEUROSCI, V37, P3599, DOI 10.1523/JNEUROSCI.3045-16.2017; Chompre G, 2013, NEUROBIOL DIS, V49, P128, DOI 10.1016/j.nbd.2012.08.007; Churchill MJ, 2009, ANN NEUROL, V66, P253, DOI 10.1002/ana.21697; Claiborne DT, 2019, J VIROL, V93, DOI 10.1128/JVI.00814-19; Cummings JL, 1996, NEUROLOGY, V47, P876, DOI 10.1212/WNL.47.4.876; Cusini A, 2013, JAIDS-J ACQ IMM DEF, V62, P28, DOI 10.1097/QAI.0b013e318274e2b0; Cysique LA, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0298-0; D'Hooge R, 1999, EUR J NEUROSCI, V11, P4398, DOI 10.1046/j.1460-9568.1999.00857.x; Dahl V, 2014, AIDS, V28, P2251, DOI 10.1097/QAD.0000000000000400; Darcis G, 2017, TRENDS IMMUNOL, V38, P217, DOI 10.1016/j.it.2016.12.003; Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011; Dias MC, 2021, J CELL SCI, V134, DOI 10.1242/jcs.253880; Dinarello C A, 1992, Eur Cytokine Netw, V3, P7; Ditiatkovski M, 2020, J BIOL CHEM, V295, P13377, DOI 10.1074/jbc.RA120.014642; Esiri MM, 1998, J NEUROL NEUROSUR PS, V65, P29, DOI 10.1136/jnnp.65.1.29; Espuny-Camacho I, 2017, NEURON, V93, P1066, DOI 10.1016/j.neuron.2017.02.001; Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882; Ferrell D, 2014, CELL MOL LIFE SCI, V71, P4387, DOI 10.1007/s00018-014-1702-4; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Fields JA, 2020, AIDS, V34, P1001, DOI 10.1097/QAD.0000000000002506; Fior J, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020013; Fulop T, 2019, J NEUROVIROL, V25, P634, DOI 10.1007/s13365-019-00732-3; Fulop T, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00224; Gelman BB, 2004, J NEUROVIROL, V10, P98, DOI 10.1080/13550280490279816; GENY C, 1991, NEUROPATH APPL NEURO, V17, P157, DOI 10.1111/j.1365-2990.1991.tb00707.x; GHANEM I, 1987, MED SCI LAW, V27, P187, DOI 10.1177/002580248702700310; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gisslen M, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-63; Giunta B, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-23; Giunta B, 2008, INT J CLIN EXP PATHO, V1, P260; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Gorantla S, 2010, AM J PATHOL, V177, P2938, DOI 10.2353/ajpath.2010.100536; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; Green DA, 2005, AIDS, V19, P407, DOI 10.1097/01.aids.0000161770.06158.5c; Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627; Gupta A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-68; Hansson O, 2007, DEMENT GERIATR COGN, V23, P316, DOI 10.1159/000100926; Hategan A, 2017, NAT STRUCT MOL BIOL, V24, P379, DOI 10.1038/nsmb.3379; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; HEATON RK, 1994, PSYCHOSOM MED, V56, P8, DOI 10.1097/00006842-199401000-00001; Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1; Hellmuth J, 2018, NEUROCASE, V24, P213, DOI 10.1080/13554794.2018.1530362; Henry BL, 2014, BEHAV PHARMACOL, V25, P12, DOI 10.1097/FBP.0000000000000012; Hong SZ, 2015, BRAIN BEHAV IMMUN, V45, P1, DOI 10.1016/j.bbi.2014.10.008; Hudson L, 2000, J NEUROVIROL, V6, P145, DOI 10.3109/13550280009013158; Ivey NS, 2009, J NEUROVIROL, V15, P111, DOI 10.1080/13550280902769764; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110; Jones MV, 2000, AIDS, V14, P2709, DOI 10.1097/00002030-200012010-00010; Kapur N, 2005, J NEUROL, V252, P1290, DOI [10.1007/s00415-005-0003-0, DOI 10.1007/S00415-005-0003-0]; Katuri A, 2019, EXP MOL PATHOL, V108, P64, DOI 10.1016/j.yexmp.2019.03.008; Khanal S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020475; Kim BO, 2003, AM J PATHOL, V162, P1693, DOI 10.1016/S0002-9440(10)64304-0; Kim J, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0077972, 10.1371/journal.pone.0060505, 10.1371/journal.pone.0062068]; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; Kindy MS, 2012, J ALZHEIMERS DIS, V29, P827, DOI 10.3233/JAD-2012-111604; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Klein RS, 2017, IMMUNITY, V46, P891, DOI 10.1016/j.immuni.2017.06.012; Kolanko MA, 2020, PRACT NEUROL, V20, P451, DOI 10.1136/practneurol-2019-002468; KOZIOROWSKA J, 1990, EXP CELL RES, V190, P290, DOI 10.1016/0014-4827(90)90199-K; Lamers SL, 2016, J VIROL, V90, P8968, DOI 10.1128/JVI.00674-16; Lee MH, 2011, NEUROBIOL DIS, V41, P678, DOI 10.1016/j.nbd.2010.12.002; Lehmann MH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02447; Lenart N, 2016, J CEREBR BLOOD F MET, V36, P1668, DOI 10.1177/0271678X16662043; Li M, 2009, J IMMUNOL, V182, P5778, DOI 10.4049/jimmunol.0803013; Limoges J, 2000, NEUROLOGY, V54, P379, DOI 10.1212/WNL.54.2.379; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Liu Y, 2004, J VIROL, V78, P4120, DOI 10.1128/JVI.78.8.4120-4133.2004; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Lohse N, 2016, ANN INTERN MED, V165, P749, DOI 10.7326/L16-0091; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Malherbe G, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/198413; Mankowski JL, 1997, J VIROL, V71, P6055, DOI 10.1128/JVI.71.8.6055-6060.1997; Marcario JK, 2016, J NEUROIMMUNE PHARM, V11, P348, DOI 10.1007/s11481-016-9667-8; Masliah E, 2004, J NEUROIMMUNOL, V157, P163, DOI 10.1016/j.jneuroim.2004.08.026; Mathews S, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0311-y; McGuire JL, 2015, J NEUROVIROL, V21, P439, DOI 10.1007/s13365-015-0333-3; Milanini B, 2017, CURR HIV-AIDS REP, V14, P123, DOI 10.1007/s11904-017-0361-0; Milanovic S, 2021, PHYSIOL MEAS, V42, DOI 10.1088/1361-6579/abfb0a; Minagar A, 2003, MULT SCLER J, V9, P540, DOI 10.1191/1352458503ms965oa; Miura Y, 2003, P NATL ACAD SCI USA, V100, P2777, DOI 10.1073/pnas.2628048100; Morgello S, 2018, J NEUROVIROL, V24, P629, DOI 10.1007/s13365-018-0663-z; MUCKE L, 1995, J EXP MED, V181, P1551, DOI 10.1084/jem.181.4.1551; Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365; Nakagawa S, 2012, J CELL MOL MED, V16, P2950, DOI 10.1111/j.1582-4934.2012.01622.x; Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V; Niu F, 2014, J NEUROSCI, V34, P11812, DOI 10.1523/JNEUROSCI.1139-14.2014; Noorbakhsh F, 2010, FASEB J, V24, P1799, DOI 10.1096/fj.09-147819; Olivetta E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093699; Ortega M, 2014, J NEUROIMMUNE PHARM, V9, P483, DOI 10.1007/s11481-014-9546-0; Pacifici M, 2013, J CELL PHYSIOL, V228, P1070, DOI 10.1002/jcp.24254; Pahan K, 2019, J NEUROIMMUNE PHARM, V14, P534, DOI 10.1007/s11481-019-09889-4; Park JS, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01180-z; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Peluso MJ, 2013, J INFECT DIS, V207, P1703, DOI 10.1093/infdis/jit088; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Periyasamy P, 2019, BRAIN BEHAV IMMUN, V80, P227, DOI 10.1016/j.bbi.2019.03.011; Persidsky Y, 2006, IMMUNOL REV, V213, P180, DOI 10.1111/j.1600-065X.2006.00440.x; Power C, 2012, J NEUROIMMUNE PHARM, V7, P319, DOI 10.1007/s11481-011-9310-7; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; Pulliam L, 2019, J NEUROVIROL, V25, P702, DOI 10.1007/s13365-018-0695-4; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; Raymond AD, 2016, J NEUROVIROL, V22, P129, DOI 10.1007/s13365-015-0397-0; Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298; Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004; Riddler SA, 2016, J INFECT DIS, V213, P556, DOI 10.1093/infdis/jiv433; Rivera J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225760; Robertson KR, 2007, AIDS, V21, P1915, DOI 10.1097/QAD.0b013e32828e4e27; Robertson KR, 2019, CLIN INFECT DIS, V68, P1733, DOI 10.1093/cid/ciy767; Roth MD, 2005, J LEUKOCYTE BIOL, V78, P1198, DOI 10.1189/jlb.0405219; Ryzhova EV, 2002, VIROLOGY, V297, P57, DOI 10.1006/viro.2002.1395; Sacktor N, 2016, NEUROLOGY, V86, P334, DOI 10.1212/WNL.0000000000002277; Sagare AP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3932; Saito T, 2014, NAT NEUROSCI, V17, P661, DOI 10.1038/nn.3697; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI [10.1038/nrneurol.2016.53, 10.1038/nrneurol.2016.27]; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schwartz C, 2017, BIOCHEM PHARMACOL, V146, P10, DOI 10.1016/j.bcp.2017.07.001; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Selvakumar GP, 2019, J NEUROIMMUNE PHARM, V14, P537, DOI 10.1007/s11481-019-09833-6; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Shimizu F, 2012, NEUROCHEM RES, V37, P401, DOI 10.1007/s11064-011-0626-8; Sil S, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000660; Sindberg GM, 2019, J NEUROIMMUNE PHARM, V14, P200, DOI 10.1007/s11481-018-9805-6; Singhal T, 2012, SEMIN NEUROL, V32, P421, DOI 10.1055/s-0032-1331813; Smith LK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248309; Smyth LCD, 2018, J CHEM NEUROANAT, V92, P48, DOI 10.1016/j.jchemneu.2018.06.001; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Soulas C, 2011, AM J PATHOL, V178, P2121, DOI 10.1016/j.ajpath.2011.01.023; Spudich S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007120; Stern AL, 2018, J NEUROSCI, V38, P4288, DOI 10.1523/JNEUROSCI.1280-17.2018; Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015; Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5; Sun B, 2017, AIDS, V31, pF9, DOI [10.1097/QAD.0000000000001595, 10.1097/qad.0000000000001595]; Sundelof J, 2010, J ALZHEIMERS DIS, V22, P1223, DOI 10.3233/JAD-2010-101023; Taheri S, 2011, STROKE, V42, P2158, DOI 10.1161/STROKEAHA.110.611731; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548; Ton Hoai, 2013, J AIDS Clin Res, V4, P255; Torres L, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-53; Tozzi V, 2007, JAIDS-J ACQ IMM DEF, V45, P174, DOI 10.1097/QAI.0b013e318042e1ee; Trillo-Pazos G, 2003, BRAIN PATHOL, V13, P144; Ujiie M, 2003, MICROCIRCULATION, V10, P463, DOI 10.1038/sj.mn.7800212; Vago L, 2002, AIDS, V16, P1925, DOI 10.1097/00002030-200209270-00009; Valcour V, 2004, J NEUROIMMUNOL, V157, P197, DOI 10.1016/j.jneuroim.2004.08.029; Valcour V, 2012, J INFECT DIS, V206, P275, DOI 10.1093/infdis/jis326; Vandenberghe R, 2013, NEUROIMAGE-CLIN, V2, P497, DOI 10.1016/j.nicl.2013.03.014; Vera JH, 2017, EUR J NUCL MED MOL I, V44, P895, DOI 10.1007/s00259-016-3602-3; Wang YH, 2020, NEUROLOGY, V95, pE2610, DOI 10.1212/WNL.0000000000010752; WICOMB WN, 1988, TRANSPLANT P, V20, P39; Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866; Wing EJ, 2016, INT J INFECT DIS, V53, P61, DOI 10.1016/j.ijid.2016.10.004; Witwer KW, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-5; Woods SP, 2011, REHABIL PSYCHOL, V56, P77, DOI 10.1037/a0022753; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yang Yuan-Han, 2020, Frontiers in Cell and Developmental Biology, V8, P768, DOI 10.3389/fcell.2020.00768; Yu CJ, 2017, AGING CELL, V16, P956, DOI 10.1111/acel.12593; Zhang JD, 2011, J NEUROIMMUNE PHARM, V6, P650, DOI 10.1007/s11481-011-9259-6	202	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							930	10.3390/vaccines9080930			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4EN	34452054	gold, Green Published			2022-04-29	WOS:000689886500001
J	Dula, J; Mulhanga, A; Nhanombe, A; Cumbi, L; Junior, A; Gwatsvaira, J; Fodjo, JNS; Villela, EFD; Chicumbe, S; Colebunders, R				Dula, Janeth; Mulhanga, Alexandre; Nhanombe, Armindo; Cumbi, Laurentino; Junior, Antonio; Gwatsvaira, Joe; Fodjo, Joseph Nelson Siewe; Faria de Moura Villela, Edlaine; Chicumbe, Sergio; Colebunders, Robert			COVID-19 Vaccine Acceptability and Its Determinants in Mozambique: An Online Survey	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccine acceptability; Mozambique; online survey	ACCEPTANCE	A high worldwide SARS-CoV-2 vaccine coverage must be attained to stop the COVID-19 pandemic. In this study, we assessed the level of willingness of Mozambicans to be vaccinated against COVID-19. Data were collected between 11 and 20 March 2021, through a self-administered online survey. Of the 1878 respondents, 30.1% were healthcare workers, 58.3% were aged between 18 and 35 years, 60% were male, and 38.5% were single. Up to 43% had been tested for COVID-19 and 29% had tested positive. Overall vaccine acceptability was 71.4% (86.6% among healthcare workers, 64.8% among other respondents; p < 0.001). Reasons for vaccine hesitancy included: fear of vaccine side effects (29.6%) and the belief that the vaccine is not effective (52%). The acceptability of the SARS-CoV-2 vaccine increased with increasing vaccine efficacy. Using logistic regression, determinants for acceptability of the vaccine were: older age, a past COVID-19 test, a concern of becoming (re)infected by COVID-19, having a chronic disease, and considering vaccination important for personal and community health. In conclusion, vaccine acceptability in Mozambique was relatively high among healthcare workers but significantly lower in the rest of the population. This suggests that there is a need to educate the general population about SARS-CoV-2 vaccination and its importance.	[Dula, Janeth; Mulhanga, Alexandre; Nhanombe, Armindo; Cumbi, Laurentino; Junior, Antonio; Chicumbe, Sergio] Natl Inst Hlth, Hlth Policy & Syst Program, Maputo 1120, Mozambique; [Gwatsvaira, Joe] Univ Limerick, Dept Math & Stat, Limerick V94 T9PX, Ireland; [Fodjo, Joseph Nelson Siewe; Colebunders, Robert] Univ Antwerp, Global Hlth Inst, B-2000 Antwerp, Belgium; [Faria de Moura Villela, Edlaine] Sao Paulo State Hlth Dept, Dis Control Coordinat, BR-01246000 Sao Paulo, Brazil; [Faria de Moura Villela, Edlaine] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, BR-74605050 Goiania, Go, Brazil		Colebunders, R (通讯作者)，Univ Antwerp, Global Hlth Inst, B-2000 Antwerp, Belgium.	janet.dula@ins.gov.mz; alexandre.mulhanga@ins.gov.mz; armindo.nhanombe@ins.gov.mz; laurentino.cumbi@ins.gov.mz; antonio.junior@ins.gov.mz; joweygwatsv@gmail.com; JosephNelson.SieweFodjo@uantwerpen.be; edlaine@alumni.usp.br; sergio.chicumbe@ins.gov.mz; robert.colebunders@uantwerpen.be		Faria de Moura Villela, Edlaine/0000-0002-7043-2007; Colebunders, Robert/0000-0002-1919-1340; Siewe Fodjo, Joseph Nelson/0000-0003-3544-1239	VLIRUOS (Flemish Interuniversity Council for University Development Cooperation)	The study was supported by a grant from the VLIRUOS (Flemish Interuniversity Council for University Development Cooperation). The study sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the paper for publication.	Adebisi YA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.230.27325; Adeniyi OV, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060666; Ahmed MAM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060543; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; [Anonymous], 2020, LANCET, V395, P922, DOI 10.1016/S0140-6736(20)30644-9; [Anonymous], 2021, LATEST GLOBAL CORONA; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Castro MC, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103700118; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Cooper S, 2021, EXPERT REV VACCINES, V20, P921, DOI 10.1080/14760584.2021.1949291; Di Giuseppe G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030275; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Echoru I, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11197-7; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Joao M., 2011, ANALISE ESTATISTICA, V5th; Khaled SM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050471; Lamptey E, 2021, CLIN EXP VACCINE RES, V10, P183, DOI 10.7774/cevr.2021.10.2.183; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Mohamed-Hussein A.A., 2021, NATL SURVEY POTENTIA, DOI [10.1101/2021.01.11.21249324, DOI 10.1101/2021.01.11.21249324]; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; WHO, 2021, GHAN WHO UNICEF EST, P1; World Health Organization, 2021, 33 WHO REG UPD COVID, P1; Zewude B, 2021, PRAGMAT OBS RES, V12, P37, DOI 10.2147/POR.S313991	28	5	5	8	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							828	10.3390/vaccines9080828			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3DB	34451953	gold, Green Published			2022-04-29	WOS:000689815100001
J	Enwezor, CH; Peacock, JE; Seals, AL; Edelstein, SL; Hinkelman, AN; Wierzba, TF; Munawar, I; Maguire, PD; Lagarde, WH; Runyon, MS; Gibbs, MA; Gallaher, TR; Sanders, JW; Herrington, DM				Enwezor, Chukwunyelu H.; Peacock, James E., Jr.; Seals, Austin L.; Edelstein, Sharon L.; Hinkelman, Amy N.; Wierzba, Thomas F.; Munawar, Iqra; Maguire, Patrick D.; Lagarde, William H.; Runyon, Michael S.; Gibbs, Michael A.; Gallaher, Thomas R.; Sanders, John W., III; Herrington, David M.			Changing Attitudes toward the COVID-19 Vaccine among North Carolina Participants in the COVID-19 Community Research Partnership	VACCINES			English	Article						vaccine hesitancy; vaccine intent; COVID-19; survey; North Carolina; vaccination; vaccine uptake; demographic groups	STATES	Coronavirus Disease-2019 (COVID-19) vaccine acceptance is variable. We surveyed participants in the COVID-19 Community Research Partnership from 17 December 2020 to 13 January 2021 to assess vaccine receptiveness. Vaccine uptake was then monitored until 15 May 2021; 20,232 participants responded to the receptiveness survey with vaccination status accessed in 18,874 participants via daily follow-up surveys (participants not completing daily surveys >= 30 days to 15 May 2021, were excluded). In the initial survey, 4802 (23.8%) were vaccine hesitant. Hesitancy was most apparent in women (Adjusted RR 0.93, p < 0.001), Black Americans (Adjusted RR 1.39, 1.41, 1.31 to non-Hispanic Whites, Other, and Hispanic or Latino, respectively p < 0.001), healthcare workers (Adjusted RR 0.93, p < 0.001), suburbanites (ref. Urban Adjusted RR 0.85, 0.90 to urban and rural dwellers, respectively, p < 0.01), and those previously diagnosed with COVID-19 (RR 1.20, p < 0.01). Those <50 years were also less accepting of vaccination. Subsequent vaccine uptake was 99% in non-hesitant participants. For those who were unsure, preferred not to answer, or answered "no", vaccination rates were 80% (Adjusted RR 0.86, p < 0.0001), 78% (Adjusted RR 0.83, p < 0.0001), and 52.7% (Adjusted RR 0.65, p < 0.0001), respectively. These findings suggest that initial intent did not correlate with vaccine uptake in our cohort.	[Enwezor, Chukwunyelu H.; Peacock, James E., Jr.; Wierzba, Thomas F.; Munawar, Iqra; Sanders, John W., III] Wake Forest Sch Med, Dept Internal Med, Sect Infect Dis, Winston Salem, NC 27517 USA; [Seals, Austin L.; Herrington, David M.] Wake Forest Sch Med, Dept Internal Med, Sect Cardiovasc Med, Winston Salem, NC 27517 USA; [Edelstein, Sharon L.] George Washington Univ, Biostat Ctr, Milken Sch Publ Hlth, Washington, DC 20052 USA; [Hinkelman, Amy N.] Campbell Univ, Jerry M Wallace Sch Osteopath Med, Lillington, NC 27546 USA; [Maguire, Patrick D.] New Hanover Reg Med Ctr, Wilmington, NC 28401 USA; [Lagarde, William H.] Wake Med Hlth & Hosp, Raleigh, NC 27610 USA; [Runyon, Michael S.; Gibbs, Michael A.] Atrium Hlth, Charlotte, NC 28204 USA; [Gallaher, Thomas R.] Vidant Hlth, Greenville, NC 27834 USA		Enwezor, CH (通讯作者)，Wake Forest Sch Med, Dept Internal Med, Sect Infect Dis, Winston Salem, NC 27517 USA.	cenwezor@wakehealth.edu; jpeacock@wakehealth.edu; aseals@wakehealth.edu; sharone@bsc.gwu.edu; hinkelman@campbell.edu; twierzba@wakehealth.edu; imunawar@wakehealth.edu; patrick.maguire@nhrmc.org; blagarde@wakemed.org; michael.runyon@atriumhealth.org; michael.gibbs@atriumhealth.org; thomas.gallaher@vidanthealth.com; jwsander@wakehealth.edu; dherring@wakehealth.edu		Enwezor, Chukwunyelu/0000-0001-7963-6068; Herrington, David/0000-0002-7670-6400	Coronavirus Aid, Relief, and Economic Security (CARES) Act by the U.S. Department of the Treasury; NC DHHS GTS [49927]	This work was supported by the Coronavirus Aid, Relief, and Economic Security (CARES) Act by the U.S. Department of the Treasury. NC DHHS GTS #49927.	APM Research Lab Staff, 2021, COL COR COVID 19 DEA; Bunn C., 2021, NBC NEWS; CDC COVID-19 Task Force, 2021, BUILDING CONFIDENCE; Craig Palosky, 2020, VACCINE MONITOR SOME; Debruyn J., 2021, POLLS SHOW N CAROLIN; Fletcher M.A, 2020, NEW POLL SHOWS BLACK; Funk G., 2021, GROWING SHARE AMERIC; Gold JAW, 2020, MMWR-MORBID MORTAL W, V69, P1517, DOI 10.15585/mmwr.mm6942e1; Hamel Liz, KFF COVID 19 VACCINE; Huetteman E., 2021, COVID VACCINE HESITA; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Mascola JR, 2021, JAMA-J AM MED ASSOC, V325, P1261, DOI [10.3171/2021.7.JNS211323, 10.1001/jama.2021.2088]; NC Rural Center, N CAR COUNT; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; O'Neal L., 2020, HALF BLACK ADULTS SA; Salvanto A., 2021, MANY WOULD GET COVID; Summers J., 2021, POLL FINDS 0312; Violette R, 2019, CAN PHARM J, V152, P391, DOI 10.1177/1715163519878745; Working Group on Equity in COVID-19 Vaccination John Hopkins School of Public Health, 2021, EQ VACC PLAN WORK CO	20	2	2	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							916	10.3390/vaccines9080916			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5DW	34452041	Green Published, gold			2022-04-29	WOS:000689952400001
J	Hoffmann, MA; Wieler, HJ; Enders, P; Buchholz, HG; Plachter, B				Hoffmann, Manuela A.; Wieler, Helmut J.; Enders, Peter; Buchholz, Hans-Georg; Plachter, Bodo			Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany	VACCINES			English	Article						COVID-19 vaccination; mRNA vaccine BNT162b2; vaccination side effects; age- and sex-graded data evaluation; vaccination strategy		A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany's vaccination campaign started on December 2020, vaccination prioritization was initially carried out starting with older population groups. Side effect rates in 1065 individuals who had received the first dose of the messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- and gender-graded data analysis showed clear age and gender differences with regard to vaccine-related adverse effects. In 77% of all individuals over 80 years of age, no local or systemic side effects were reported after the first vaccination, whereas in the age group up to 80 years, only 37% showed no side effects. In the whole study population, 64% of females and 73% of males reported no adverse effects. The initial vaccination with mRNA vaccine BNT162b2 shows an overall low profile of side effects. Particularly in those over 80 years, an extraordinarily good tolerance with equally good effectiveness is evident. The sex comparison showed that women suffer more often from adverse vaccination reactions. In order to achieve sufficient herd immunity, both age- and gender-dependent vaccination reactions and any difference in the maintenance of immunity should be considered in future vaccination strategies.	[Hoffmann, Manuela A.] Fed Minist Def, Dept Occupat Hlth & Safety, D-53123 Bonn, Germany; [Hoffmann, Manuela A.; Buchholz, Hans-Georg] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Clin Nucl Med, D-55101 Mainz, Germany; [Wieler, Helmut J.; Enders, Peter] Vaccinat Ctr Wissen, D-57537 Wissen, Germany; [Plachter, Bodo] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Virol, D-55101 Mainz, Germany		Hoffmann, MA (通讯作者)，Fed Minist Def, Dept Occupat Hlth & Safety, D-53123 Bonn, Germany.; Hoffmann, MA (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Clin Nucl Med, D-55101 Mainz, Germany.	manuela1hoffmann@bmvg.bund.de; helmut.wieler@web.de; peter.enders@kreis-ak.de; hans-georg.buchholz@unimedizin-mainz.de; plachter@uni-mainz.de	PD Dr. Hoffmann, Manuela Andrea/ADP-6302-2022	Hoffmann, Manuela Andrea/0000-0002-8867-5525			Abu Mouch S, 2021, VACCINE, V39, P3790, DOI 10.1016/j.vaccine.2021.05.087; Bundesinstitut fur Impfstoffe und Biomedizinische Arzneimittel, SICH VERD NEB IMPFK; Bundesministerium fur Gesundheit, VER ZUM ANSPR SCHUTZ; Bundeszentrale fur Politische Bildung, GENESIS ONL BEV ALT; Deutsches Register Klinischer Studien, 2021, REG; Effros Rita B, 2005, Immun Ageing, V2, P7, DOI 10.1186/1742-4933-2-7; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Gerbershagen HJ, 2014, ANESTHESIOLOGY, V120, P1237, DOI 10.1097/ALN.0000000000000108; Hainz U, 2005, VACCINE, V23, P3232, DOI 10.1016/j.vaccine.2005.01.085; Johns Hopkins University. The Center for Systems Science and Engineering (CSSE), COVID 19 DASHB; Lenzen-Schulte M, 2021, DTSCH ARZTEBL, V118, P780; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lundstrom K, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11071020; Ministerium fur Soziales Arbeit Gesundheit und Demografie des Landes Rheinland-Pfalz, 2021, IMPFD RHEINL PFALZ; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; Nittner-Marszalska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060553; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6; Robert Koch-Institut, 2021, AUFKL SCHUTZ GEG COV; Robert Koch-Institut, 2021, COVID 19 DASHB; Robert Koch-Institut Bundesministerium fur Gesundheit, 2021, IMPFD; Schnabel A, 2020, PAIN REP, V5, DOI 10.1097/PR9.0000000000000831; Schuler M., 2014, DTSCH ARZTEBL, V111, P4; Statista, UMFR COR IMPFB DEUTS; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Thalhammer F., 2008, AZ, V11, P1; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1016/S1525-8610(04)70258-3; Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2; Yale Institute for Global Health, COVID 19 SNAPSH MON	30	5	5	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							911	10.3390/vaccines9080911			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6LU	34452036	gold, Green Published			2022-04-29	WOS:000690040600001
J	Park, C; Sakong, J; Jo, S; Kim, M; Baek, K				Park, Chulyong; Sakong, Joon; Jo, Seongmin; Kim, Minkeun; Baek, Kiook			Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses	VACCINES			English	Article						COVID-19; side effect; vaccine	SYMPTOMS; PAIN	In this study, we assessed the adverse effects and the work and daily life interference associated with each dose of the ChAdOx1 and BNT162b2 COVID-19 vaccines. Questionnaires were distributed to workers after they received both doses; only those who worked the day after receiving the vaccine were included in the analysis. Overall, 368 ChAdOx1-vaccinated and 27 BNT162b2-vaccinated participants were included. Among the ChAdOx1-vaccinated participants, the incidence of adverse effects was significantly lower after the second dose than after the first dose. Among the BNT162b2-vaccinated participants, however, no differences in adverse effects or work and daily life interference were found between the doses. After the first and second dose, the numeric scale score (0-10) for interference with work was 3.9 +/- 2.9 and 1.6 +/- 1.9 for the ChAdOx1 and 3.2 +/- 2.5 and 3.6 +/- 3.0 for the BNT162b2 vaccine, respectively. A similar trend was observed for interference with daily life. Factors associated with work and daily life interference in the multivariate model were age, vaccine dose (first or second), and the interaction term of vaccine type and dose. These results could be used to inform the general population of the adverse effects associated with these vaccinations.	[Park, Chulyong; Sakong, Joon; Jo, Seongmin; Kim, Minkeun] Yeungnam Univ Hosp, Dept Occupat & Environm Med, Daegu 42415, South Korea; [Park, Chulyong; Sakong, Joon] Yeungnam Univ, Coll Med, Dept Prevent Med & Publ Hlth, Daegu 42415, South Korea; [Baek, Kiook] Korea Univ, Med Ctr, Ansan Hosp, Dept Occupat & Environm Med, Ansan 15355, South Korea		Baek, K (通讯作者)，Korea Univ, Med Ctr, Ansan Hosp, Dept Occupat & Environm Med, Ansan 15355, South Korea.	ironyong@gmail.com; jsakong@yu.ac.kr; josm1129@ymc.yu.ac.kr; 21420007@ynu.ac.kr; bko8899@kumc.or.kr	Sakong, Joon/AFE-2002-2022	Park, Chulyong/0000-0001-8584-5376; Baek, Kiook/0000-0003-2822-8480; Jo, Seongmin/0000-0001-7270-8268			Abu-Hammad O, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060577; AlBahrani S., 2021, J GLOB INFECT DIS, DOI [10.1016/j.ijid.2021.07.052, DOI 10.1016/J.IJID.2021.07.052]; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Broderick JE, 2008, PAIN, V139, P146, DOI 10.1016/j.pain.2008.03.024; Chae J, 2007, ARCH PHYS MED REHAB, V88, P298, DOI 10.1016/j.apmr.2006.12.007; Dittmann S, 2001, VACCINE, V19, P2446, DOI 10.1016/S0264-410X(00)00470-9; Eyre DW, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.041; Habersaat KB, 2020, BUNDESGESUNDHEITSBLA, V63, P32, DOI 10.1007/s00103-019-03063-0; Haralambieva IH, 2013, HUM IMMUNOL, V74, P1263, DOI 10.1016/j.humimm.2013.06.031; Hillus D, 2021, LANCET RESP MED, V9, P1255, DOI 10.1016/S2213-2600(21)00357-X; Huang J, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00539; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Kamal Deep, 2021, Med J Armed Forces India, V77, pS283, DOI 10.1016/j.mjafi.2021.06.014; Kim SH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e107; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Korea Disease Control and Prevention Agency, UPD COVID 19 REP KOR; Lee YW, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e153; LEVENTHAL EA, 1986, J AM GERIATR SOC, V34, P185; LOFTUS GR, 1978, MEM COGNITION, V6, P312, DOI 10.3758/BF03197461; Long B, 2021, AM J EMERG MED, V49, P58, DOI 10.1016/j.ajem.2021.05.054; MacKrill K, 2021, J PSYCHOSOM RES, V141, DOI 10.1016/j.jpsychores.2020.110340; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Modenese A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060652; Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Shrestha S., 2021, J PATAN ACAD HLTH SC, V8, P9, DOI [10.3126/jpahs.v8i1.36242, DOI 10.3126/JPAHS.V8I1.36242]; Simpson CR, 2021, NAT MED, V27, P1290, DOI 10.1038/s41591-021-01408-4; Sjogren JJ, 2019, INT ENDOD J, V52, P1264, DOI 10.1111/iej.13124; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walker AN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060585	30	1	1	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							926	10.3390/vaccines9080926			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9UY	34452051	gold, Green Published			2022-04-29	WOS:000690267200001
J	Amboree, TL; Sonawane, K; Deshmukh, AA; Montealegre, JR				Amboree, Trisha L.; Sonawane, Kalyani; Deshmukh, Ashish A.; Montealegre, Jane R.			Regular Healthcare Provider Status Does Not Moderate Racial/Ethnic Differences in Human Papillomavirus (HPV) and HPV Vaccine Knowledge	VACCINES			English	Article						HPV; human papillomavirus; HPV vaccine; health disparities; racial/ethnic minority	CERVICAL-CANCER; UNITED-STATES; HESITANCY; COMMUNICATION; IMMUNIZATION; GIRLS; WOMEN; RECOMMENDATIONS; FACILITATORS; PERSPECTIVES	Background: Racial/ethnic minorities generally have a lower knowledge of human papillomavirus (HPV) and the HPV vaccine than non-Hispanic Whites. They are also less likely to have a regular healthcare provider (HCP). Given the role of HCPs in disseminating health information, we evaluated whether racial/ethnic disparities in HPV knowledge are moderated by regular HCP status. Methods: Data from the Health Information National Trends Survey Five (HINTS 5) Cycles One and Two (2017-2018) were analyzed. HPV and HPV vaccine knowledge were compared by regular HCP status across race/ethnicities. Independent partially-adjusted multivariable logistic regression models were used to assess the association between race/ethnicity and knowledge after controlling for sociodemographic characteristics. The resulting adjusted odds ratios were compared to those from fully-adjusted models that included HCP status. Results: After adjusting for regular HCP status, differences in knowledge persisted between racial/ethnic groups. Compared to Whites, Hispanics and Other race/ethnicities had significantly lower odds of having heard of HPV. Blacks, Hispanics, and Other race/ethnicities had significantly lower odds of having heard of the HPV vaccine. Conclusion: Racial/ethnic minorities had significantly lower levels of knowledge despite HCP status. These data suggest the need to address disparities in health information and strengthen provider-patient communication regarding HPV and the HPV vaccine.	[Amboree, Trisha L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Epidemiol, Houston, TX 77030 USA; [Sonawane, Kalyani; Deshmukh, Ashish A.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Management Policy & Community Hlth, Houston, TX 77030 USA; [Montealegre, Jane R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Montealegre, Jane R.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77054 USA		Montealegre, JR (通讯作者)，Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.; Montealegre, JR (通讯作者)，Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77054 USA.	Trisha.L.Amboree@uth.tmc.edu; kalyani.b.sonawane@uth.tmc.edu; ashish.a.deshmukh@uth.tmc.edu; jrmontea@bcm.edu	Sonawane, Kalyani/AAI-1592-2020	Sonawane, Kalyani/0000-0001-5501-3034; Deshmukh, Ashish/0000-0001-8936-8108; Amboree, Trisha/0000-0003-4015-4912	National Institute of Mi	The research reported in this publication was supported by the National Institute of Mi.	Amboree TL, 2021, J RACIAL ETHN HEALTH, V8, P1192, DOI 10.1007/s40615-020-00877-6; American Cancer Society, 2018, CANC FACTS FIG HISP; [Anonymous], 2017, WESTAT HINTS 5 CYCLE; [Anonymous], 2018, WESTAT HINTS 5 CYCLE; Berman TA, 2017, CANCER-AM CANCER SOC, V123, P2219, DOI 10.1002/cncr.30588; Breitkopf CR, 2016, CANCER MED-US, V5, P3346, DOI 10.1002/cam4.933; Byrd TL, 2007, ETHNIC DIS, V17, P129; Centers for Disease Control and Prevention, 2020, NAT REG STAT SEL LOC NAT REG STAT SEL LOC; Centers for Disease Control and Prevention, 2020, CANC ASS HUM PAP US; Centers for Disease Control and Prevention, 2021, HUMAN PAPILLOMAVIRUS; Centers for Disease Control and Prevention, SUPPL TABL EST VACC SUPPL TABL EST VACC; Cunningham-Erves J, 2019, JMIR CANCER, V5, DOI 10.2196/13832; Deshmukh AA, 2020, JNCI-J NATL CANCER I, V112, P829, DOI 10.1093/jnci/djz219; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Escoffery C, 2019, PREV CHRONIC DIS, V16, DOI 10.5888/pcd16.180406; Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700; Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023; Gopalani SV, 2020, J NATL MED ASSOC, V112, P632, DOI 10.1016/j.jnma.2020.06.007; Harrington N, 2021, AIMS PUBLIC HEALTH, V8, P352, DOI 10.3934/publichealth.2021027; Health Information National Trends Survey, 2017, AN REC HINTS 5 CYCL AN REC HINTS 5 CYCL; Health Information National Trends Survey, 2018, AN REC HINTS 5 CYCL AN REC HINTS 5 CYCL; Healy CM, 2014, VACCINE, V32, P579, DOI 10.1016/j.vaccine.2013.11.076; Kahn JA, 2005, J ADOLESCENT HEALTH, V37, P502, DOI 10.1016/j.jadohealth.2005.07.014; Kempe A, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1475; Kessels SJM, 2012, VACCINE, V30, P3546, DOI 10.1016/j.vaccine.2012.03.063; Lee HY, 2020, ETHNIC HEALTH, DOI 10.1080/13557858.2020.1850648; Leung SOA, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100037; MacDonald NE, 2015, EBIOMEDICINE, V2, P792, DOI 10.1016/j.ebiom.2015.06.028; McCave EL, 2010, J COMMUN HEALTH, V35, P645, DOI 10.1007/s10900-010-9255-4; McGee LU, 2020, ACAD PEDIATR, V21, P1118, DOI 10.1016/j.acap.2020.12.003; McRee AL, 2014, J PEDIATR HEALTH CAR, V28, P541, DOI 10.1016/j.pedhc.2014.05.003; McSherry LA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208482; Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI [10.15585/mmwr.mm6832a3, 10.1111/ajt.15633]; Merck Co Inc., 2020, GARDASILTM 9 HUM PAP GARDASILTM 9 HUM PAP; Moss JL, 2016, HUM VACC IMMUNOTHER, V12, P1476, DOI 10.1080/21645515.2015.1128601; Mullins TLK, 2013, VACCINE, V31, P4894, DOI 10.1016/j.vaccine.2013.07.033; National Academies of Sciences Engineering and Medicine, 2018, FACT AFF HLTH CAR UT FACT AFF HLTH CAR UT; O'Connor M, 2014, FAM PRACT, V31, P475, DOI 10.1093/fampra/cmu029; Ojeaga A, 2019, J CANCER EDUC, V34, P66, DOI 10.1007/s13187-017-1268-6; Opel DJ, 2013, PEDIATRICS, V132, P1037, DOI 10.1542/peds.2013-2037; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Perkins RB, 2016, HUM VACC IMMUNOTHER, V12, P1528, DOI 10.1080/21645515.2015.1118594; Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009; Riedesel J M, 2005, J Pediatr Adolesc Gynecol, V18, P391, DOI 10.1016/j.jpag.2005.09.004; SAS Institute Inc, 2021, SAS PROGR SOFTW SAS PROGR SOFTW; Sonawane K, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-026286; Sonawane K, 2020, LANCET PUBLIC HEALTH, V5, pE484, DOI 10.1016/S2468-2667(20)30139-0; Vadaparampil ST, 2014, AM J PREV MED, V46, P80, DOI 10.1016/j.amepre.2013.07.009; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; White Leah, 2016, Pediatr Nurs, V42, P21; Ylitalo KR, 2013, AM J PUBLIC HEALTH, V103, P164, DOI 10.2105/AJPH.2011.300600	51	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							802	10.3390/vaccines9070802			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8LW	34358219	gold, Green Published			2022-04-29	WOS:000677156700001
J	Caceres, CJ; Cardenas-Garcia, S; Jain, A; Gay, LC; Carnaccini, S; Seibert, B; Ferreri, LM; Geiger, G; Jasinskas, A; Nakajima, R; Rajao, DS; Isakova-Sivak, I; Rudenko, L; Vincent, AL; Davies, DH; Perez, DR				Caceres, C. Joaquin; Cardenas-Garcia, Stivalis; Jain, Aarti; Gay, L. Claire; Carnaccini, Silvia; Seibert, Brittany; Ferreri, Lucas M.; Geiger, Ginger; Jasinskas, Algimantas; Nakajima, Rie; Rajao, Daniela S.; Isakova-Sivak, Irina; Rudenko, Larisa; Vincent, Amy L.; Davies, D. Huw; Perez, Daniel R.			Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein	VACCINES			English	Article						LAIV; influenza; HA; IGIP; IgA; IgG; vaccine; natural adjuvant	SEASONAL INFLUENZA; CROSS-REACT; INFECTION; BURDEN; IMPACT; DONOR; APRIL; BAFF	Live attenuated influenza virus (LAIV) vaccines elicit a combination of systemic and mucosal immunity by mimicking a natural infection. To further enhance protective mucosal responses, we incorporated the gene encoding the IgA-inducing protein (IGIP) into the LAIV genomes of the cold-adapted A/Leningrad/134/17/57 (H2N2) strain (caLen) and the experimental attenuated backbone A/turkey/Ohio/313053/04 (H3N2) (OH/04att). Incorporation of IGIP into the caLen background led to a virus that grew poorly in prototypical substrates. In contrast, IGIP in the OH/04att background (IGIP-H1att) virus grew to titers comparable to the isogenic backbone H1att (H1N1) without IGIP. IGIP-H1att- and H1caLen-vaccinated mice were protected against lethal challenge with a homologous virus. The IGIP-H1att vaccine generated robust serum HAI responses in naive mice against the homologous virus, equal or better than those obtained with the H1caLen vaccine. Analyses of IgG and IgA responses using a protein microarray revealed qualitative differences in humoral and mucosal responses between vaccine groups. Overall, serum and bronchoalveolar lavage samples from the IGIP-H1att group showed trends towards increased stimulation of IgG and IgA responses compared to H1caLen samples. In summary, the introduction of genes encoding immunomodulatory functions into a candidate LAIV can serve as natural adjuvants to improve overall vaccine safety and efficacy.	[Caceres, C. Joaquin; Cardenas-Garcia, Stivalis; Gay, L. Claire; Seibert, Brittany; Ferreri, Lucas M.; Geiger, Ginger; Rajao, Daniela S.; Perez, Daniel R.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA; [Jain, Aarti; Jasinskas, Algimantas; Nakajima, Rie; Davies, D. Huw] Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; [Carnaccini, Silvia] Univ Georgia, Coll Vet Med, Tifton Diagnost Lab, Tifton, GA 31793 USA; [Isakova-Sivak, Irina; Rudenko, Larisa] Inst Expt Med, Dept Virol, 12 Acad Pavlov St, St Petersburg 197376, Russia; [Vincent, Amy L.] USDA ARS, Natl Anim Dis Ctr, 1920 Dayton Ave, Ames, IA 50010 USA		Perez, DR (通讯作者)，Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA.	cjoaquincaceres@uga.edu; stivalis@uga.edu; aartij@hs.uci.edu; lindsey.gay@uga.edu; scarnaccini@uga.edu; baseibert@uga.edu; lucas.matias.ferreri@emory.edu; imginger@uga.edu; ajasinsk@hs.uci.edu; rie3@hs.uci.edu; daniela.rajao@uga.edu; isakova.sivak@gmail.com; vaccine@mail.ru; amy.vincent@usda.gov; ddavies@uci.edu; dperez1@uga.edu	Isakova-Sivak, Irina/C-1034-2014; Caceres, C. Joaquin/AAR-1810-2021; Perez, Daniel/D-5044-2016	Isakova-Sivak, Irina/0000-0002-2801-1508; Caceres, C. Joaquin/0000-0001-8508-6592; Ferreri, Lucas/0000-0002-1069-9500; Seibert, Brittany/0000-0002-5721-5382; Gay, L. Claire/0000-0003-4360-0519; Cardenas Garcia, Stivalis/0000-0002-7613-8642; Perez, Daniel/0000-0002-6569-5689; Geiger, Ginger/0000-0002-4927-8084	Center for Research on Influenza Pathogenesis (CRIP) from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [1R21AI146448-01]	This research was funded by a subcontract from the Center for Research on Influenza Pathogenesis (CRIP) to D.R.P. under contract HHSN272201400008C from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) and grant 1R21AI146448-01 from NIAID to D.R.P.	Abente EJ, 2018, J VIROL, V92, DOI 10.1128/JVI.01323-18; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Austin AS, 2003, J IMMUNOL, V171, P1336, DOI 10.4049/jimmunol.171.3.1336; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Chan W, 2008, VIROLOGY, V380, P304, DOI 10.1016/j.virol.2008.07.027; Chung JR, 2020, CLIN INFECT DIS, V71, pE368, DOI 10.1093/cid/ciz1244; Corthesy B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00185; Dawood FS, 2020, MMWR-MORBID MORTAL W, V69, P177, DOI 10.15585/mmwr.mm6907a1; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Endsley MA, 2009, J IMMUNOL, V182, P1854, DOI 10.4049/jimmunol.0801973; Estes DM, 2010, VET IMMUNOL IMMUNOP, V138, P312, DOI 10.1016/j.vetimm.2010.10.009; Ferreri LM, 2019, ECOL EVOL, V9, P6534, DOI 10.1002/ece3.5232; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Gasparini R, 2012, HUM VACC IMMUNOTHER, V8, P21, DOI 10.4161/hv.8.1.17622; Gauger PC, 2014, VIROLOGY, V471, P93, DOI 10.1016/j.virol.2014.10.003; GHENDON YZ, 1984, INFECT IMMUN, V44, P730, DOI 10.1128/IAI.44.3.730-733.1984; Girard MP, 2005, VACCINE, V23, P5708, DOI 10.1016/j.vaccine.2005.07.046; Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137; Golde WT, 2005, LAB ANIMAL, V34, P39, DOI 10.1038/laban1005-39; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Hollingsworth JW, 2007, IMMUNOGENETICS, V59, P713, DOI 10.1007/s00251-007-0242-6; Isakova-Sivak I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030061; Isakova-Sivak I, 2011, VIROLOGY, V412, P297, DOI 10.1016/j.virol.2011.01.004; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Liu L, 2017, J INFECT DIS, V215, P518, DOI 10.1093/infdis/jiw608; Lopez CE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030434; Loving CL, 2013, J VIROL, V87, P9895, DOI 10.1128/JVI.01038-13; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; McMahon M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02005; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Nakajima R, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00592-18; Pena L, 2011, J VIROL, V85, P456, DOI 10.1128/JVI.01503-10; Pica N, 2011, J VIROL, V85, P12825, DOI 10.1128/JVI.05930-11; Pleguezuelos O, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0174-9; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Santos JJS, 2019, J VIROL, V93, DOI 10.1128/JVI.01413-18; Santos JJS, 2017, J VIROL, V91, DOI 10.1128/JVI.00056-17; Solorzano A, 2010, J VIROL, V84, P4587, DOI 10.1128/JVI.00101-10; Srivastava B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004857; Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112; van de Sandt CE, 2014, J VIROL, V88, P1684, DOI 10.1128/JVI.02843-13; Wan Z, 2018, J VIROL, V92, DOI 10.1128/JVI.01025-18; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; Ye JQ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001145	48	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							703	10.3390/vaccines9070703			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8QC	34198994	Green Submitted, gold, Green Published			2022-04-29	WOS:000677167700001
J	Huang, Y; Franca, MS; Allen, JD; Shi, H; Ross, TM				Huang, Ying; Franca, Monique S.; Allen, James D.; Shi, Hua; Ross, Ted M.			Next Generation of Computationally Optimized Broadly Reactive HA Vaccines Elicited Cross-Reactive Immune Responses and Provided Protection against H1N1 Virus Infection	VACCINES			English	Article						influenza virus; vaccination; protection; immune responses; mice	INFLUENZA-A VIRUS; SEASONAL INFLUENZA; ANTIBODIES; HEMAGGLUTININ; ENHANCEMENT; VACCINATION; FERRETS	Vaccination is the best way to prevent influenza virus infections, but the diversity of antigenically distinct isolates is a persistent challenge for vaccine development. In order to conquer the antigenic variability and improve influenza virus vaccine efficacy, our research group has developed computationally optimized broadly reactive antigens (COBRAs) in the form of recombinant hemagglutinins (rHAs) to elicit broader immune responses. However, previous COBRA H1N1 vaccines do not elicit immune responses that neutralize H1N1 virus strains in circulation during the recent years. In order to update our COBRA vaccine, two new candidate COBRA HA vaccines, Y2 and Y4, were generated using a new seasonal-based COBRA methodology derived from H1N1 isolates that circulated during 2013-2019. In this study, the effectiveness of COBRA Y2 and Y4 vaccines were evaluated in mice, and the elicited immune responses were compared to those generated by historical H1 COBRA HA and wild-type H1N1 HA vaccines. Mice vaccinated with the next generation COBRA HA vaccines effectively protected against morbidity and mortality after infection with H1N1 influenza viruses. The antibodies elicited by the COBRA HA vaccines were highly cross-reactive with influenza A (H1N1) pdm09-like viruses isolated from 2009 to 2021, especially with the most recent circulating viruses from 2019 to 2021. Furthermore, viral loads in lungs of mice vaccinated with Y2 and Y4 were dramatically reduced to low or undetectable levels, resulting in minimal lung injury compared to wild-type HA vaccines following H1N1 influenza virus infection.	[Huang, Ying; Allen, James D.; Shi, Hua; Ross, Ted M.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Franca, Monique S.] Univ Georgia, Poultry Diagnost & Res Ctr, Dept Populat Hlth, Athens, GA 30602 USA; [Ross, Ted M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA		Ross, TM (通讯作者)，Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA.; Ross, TM (通讯作者)，Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.	yhuang0@uga.edu; mfranca@uga.edu; jdallen@uga.edu; Hua.Shi1@uga.edu; tedross@uga.edu	Franca, Monique/J-3927-2019	Ross, Ted/0000-0003-1947-7469	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [75N93019C00052]; Georgia Research Alliance [GRA-001]; University of Georgia [UGA-001]	This research was funded by National Institutes of Health, contract number 75N93019C00052". Georgia Research Alliance: GRA-001, University of Georgia: UGA-001.	Aeffner F, 2015, TOXICOL PATHOL, V43, P1074, DOI 10.1177/0192623315598399; Aguilera ER, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00105; Allen JD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79590-7; Allen JD, 2019, J VIROL, V93, DOI 10.1128/JVI.00946-18; Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Brandenburg B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080034; Carter DM, 2017, J VIROL, V91, DOI [10.1128/JVI.01283-17, 10.1128/jvi.01283-17]; Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15; Carter DM, 2013, J VIROL, V87, P1400, DOI 10.1128/JVI.02257-12; Centers for Disease Control and Prevention, 2020, VACC EFF WELL DO FLU; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Dorigatti I, 2013, P NATL ACAD SCI USA, V110, P13422, DOI 10.1073/pnas.1303117110; Doyle JD, 2021, CLIN INFECT DIS, V72, P995, DOI 10.1093/cid/ciaa160; Duwe Susanne, 2017, GMS Infect Dis, V5, pDoc04, DOI 10.3205/id000030; Ecker JW, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030462; Ellebedy AH, 2009, VACCINE, V27, pD65, DOI 10.1016/j.vaccine.2009.08.038; European Medicines Agency, 2014, GUID INFL VACC NONC GUID INFL VACC NONC; Franquet T, 2011, RADIOLOGY, V260, P18, DOI 10.1148/radiol.11092149; Giles BM, 2012, J INFECT DIS, V205, P1562, DOI 10.1093/infdis/jis232; Giles BM, 2012, CLIN VACCINE IMMUNOL, V19, P128, DOI 10.1128/CVI.05533-11; Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100; Gotts JE, 2014, AM J PHYSIOL-LUNG C, V307, pL395, DOI 10.1152/ajplung.00110.2014; Green TD, 2003, J VIROL, V77, P2046, DOI 10.1128/JVI.77.3.2046-2055.2003; He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113; He WQ, 2015, J VIROL, V89, P3610, DOI 10.1128/JVI.03099-14; Hirst GK, 1942, J EXP MED, V75, P49, DOI 10.1084/jem.75.1.49; Huang Y, 2020, J VIROL, V94, DOI 10.1128/JVI.01432-19; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; KellyKeating S.R.Z, 2018, PULMONARY PATHOLOGY, V2nd ed., P224; Kirchenbaum GA, 2017, J IMMUNOL, V199, P3798, DOI 10.4049/jimmunol.1701174; Kirchenbaum GA, 2016, J VIROL, V90, P1116, DOI 10.1128/JVI.02372-15; Kirchenbaum GA, 2014, CURR OPIN IMMUNOL, V28, P71, DOI 10.1016/j.coi.2014.02.005; Koel BF, 2015, J VIROL, V89, P3763, DOI 10.1128/JVI.02962-14; Krammer F, 2012, J VIROL, V86, P10302, DOI 10.1128/JVI.01336-12; Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025; Luo J, 2013, J WILDLIFE DIS, V49, P375, DOI 10.7589/2012-03-079; Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63; Monto AS, 2010, VACCINE, V28, pD33, DOI 10.1016/j.vaccine.2010.08.027; Mytton OT, 2012, EUROSURVEILLANCE, V17, P11; Nicol MQ, 2019, VIROLOGY, V526, P155, DOI 10.1016/j.virol.2018.10.017; Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462; Pica N, 2012, P NATL ACAD SCI USA, V109, P2573, DOI 10.1073/pnas.1200039109; Powers K.A., 2021, PHYSL PULMONARY VENT; Reneer ZB, 2021, J VIROL, V95, DOI 10.1128/JVI.01526-20; Sullivan K, 2012, J VIROL METHODS, V179, P81, DOI 10.1016/j.jviromet.2011.10.003; Sun HL, 2020, P NATL ACAD SCI USA, V117, P17204, DOI 10.1073/pnas.1921186117; Tavares LP, 2017, INFLAMM RES, V66, P283, DOI 10.1007/s00011-016-0996-0; WALLS HH, 1986, J CLIN MICROBIOL, V23, P240, DOI 10.1128/JCM.23.2.240-245.1986; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WHO Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU; Wong TM, 2017, J VIROL, V91, DOI 10.1128/JVI.01581-17	54	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							793	10.3390/vaccines9070793			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5XI	34358209	gold, Green Published			2022-04-29	WOS:000676983700001
J	Kenzaka, T; Yahata, S; Goda, K; Kumabe, A; Kamada, M; Okayama, M				Kenzaka, Tsuneaki; Yahata, Shinsuke; Goda, Ken; Kumabe, Ayako; Kamada, Momoka; Okayama, Masanobu			Effects of Vaccination Day Routine Activities on Influenza Vaccine Efficacy and Vaccination-Induced Adverse Reaction Incidence: A Cohort Study	VACCINES			English	Article						influenza; vaccination; routine activity; bath; smoking; alcohol consumption; caffeine intake; exercise	NASAL RESPONSES; IMMUNE-SYSTEM; VIRUS; EXERCISE	We aimed to investigate the effect of vaccination day routine activities on the influenza vaccine efficacy and vaccination-induced adverse reaction incidence. Study participants were workers at three hospitals in the Hyogo Prefecture, Japan, who received the influenza vaccine between October and November, 2018 and 2019. Their data were collected using a questionnaire. The main factors, which were examined for vaccination day routine activities, were personal hygiene (bathing), smoking, alcohol consumption, caffeine intake, and exercise. The main outcome markers included influenza incidence during the winter season and vaccination-induced local or systemic adverse reaction incidence. The risk ratio for the main factors of vaccination day routine activities was calculated against the main outcome markers using the modified Poisson regression. Overall, 3780 people received the influenza vaccination, and 2731 submitted the questionnaire. We found that vaccination day routine activities did not affect the influenza vaccine efficacy, and engaging in strenuous exercise on the vaccination day tended to cause systemic adverse reactions. Moreover, lifestyle-related activities had no impact on the incidence of systemic or local adverse reactions. Therefore, it is advisable to only avoid strenuous physical exercise, and no other lifestyle-related restrictions are necessary on the day of influenza vaccination.	[Kenzaka, Tsuneaki; Goda, Ken; Kumabe, Ayako] Kobe Univ, Div Community Med & Career Dev, Grad Sch Med, Kobe, Hyogo 6520032, Japan; [Kenzaka, Tsuneaki; Goda, Ken; Kamada, Momoka] Hyogo Prefectural Tamba Med Ctr, Dept Internal Med, Tamba, Hyogo 6693495, Japan; [Yahata, Shinsuke; Okayama, Masanobu] Kobe Univ, Div Community Med & Med Educ, Grad Sch Med, Kobe, Hyogo 6520032, Japan; [Yahata, Shinsuke] Shiso Municipal Hosp, Dept Internal Med, Shiso, Hyogo 6712576, Japan; [Kumabe, Ayako] Toyooka Publ Hosp, Dept Internal Med, Toyooka, Hyogo 6688501, Japan		Kenzaka, T (通讯作者)，Kobe Univ, Div Community Med & Career Dev, Grad Sch Med, Kobe, Hyogo 6520032, Japan.; Kenzaka, T (通讯作者)，Hyogo Prefectural Tamba Med Ctr, Dept Internal Med, Tamba, Hyogo 6693495, Japan.	smile.kenzaka@jichi.ac.jp; yahata-jci@umin.ac.jp; kenkenpetneed@yahoo.co.jp; kumabe-kmm@umin.ac.jp; m08018mo@jichi.ac.jp; okayamam@med.kobe-u.ac.jp		Kenzaka, Tsuneaki/0000-0002-3120-6605			Cadorna-Carlos JB, 2015, VACCINE, V33, P2485, DOI 10.1016/j.vaccine.2015.03.065; Christian LM, 2015, VACCINE, V33, P3360, DOI 10.1016/j.vaccine.2015.05.008; Hwang SM, 2011, JPN J INFECT DIS, V64, P183; Japan Tobacco Inc, NAT TOB SMOK RAT SUR NAT TOB SMOK RAT SUR; Kenzaka T, 2017, GERIATR GERONTOL INT, V17, P810, DOI 10.1111/ggi.12792; Kohut ML, 2002, J GERONTOL A-BIOL, V57, pM557, DOI 10.1093/gerona/57.9.M557; Lawrence H, 2019, J INFECTION, V79, P401, DOI 10.1016/j.jinf.2019.08.014; Meyerholz DK, 2008, J IMMUNOL, V181, P641, DOI 10.4049/jimmunol.181.1.641; Ministry of Health Labour and Welfare Japan, STAT EX HAB STAT EX HAB; Ministry of Health Labour and Welfare Japan, STAT DRINK HAB STAT DRINK HAB; National Institute of Infectious Diseases, 2020, INF AG SURV REP IASR INF AG SURV REP IASR, V41, P191; Noah TL, 2012, CURR OPIN ALLERGY CL, V12, P24, DOI 10.1097/ACI.0b013e32834ecc80; Noah TL, 2011, ENVIRON HEALTH PERSP, V119, P78, DOI 10.1289/ehp.1002258; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; SHINKAI S, 1995, MED SCI SPORT EXER, V27, P1516; The Review Committee for Vaccination Guidelines, 1994, VACC GUID 1994 VERS VACC GUID 1994 VERS; Watanabe K., 2016, JPN J ENV INFECT, V31, P397, DOI [10.4058/jsei.31.397, DOI 10.4058/JSEI.31.397]; Wong CM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002108; Woolpert T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102154; Zimmer P, 2016, EUR J HAEMATOL, V96, P152, DOI 10.1111/ejh.12561	20	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							753	10.3390/vaccines9070753			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6HE	34358169	Green Published, gold			2022-04-29	WOS:000677009300001
J	Massari, M; Spila-Alegiani, S; Fabiani, M; Belleudi, V; Trifiro, G; Kirchmayer, U; Poggi, FR; Mancuso, P; Menniti-Ippolito, F; Gini, R; Bartolini, C; Leoni, O; Ercolanoni, M; Da-Re, F; Guzzinati, S; Luxi, N; Riccardo, F; Giorgi-Rossi, P				Massari, Marco; Spila-Alegiani, Stefania; Fabiani, Massimo; Belleudi, Valeria; Trifiro, Gianluca; Kirchmayer, Ursula; Poggi, Francesca Romana; Mancuso, Pamela; Menniti-Ippolito, Francesca; Gini, Rosa; Bartolini, Claudia; Leoni, Olivia; Ercolanoni, Michele; Da-Re, Filippo; Guzzinati, Stefano; Luxi, Nicoletta; Riccardo, Flavia; Giorgi-Rossi, Paolo			Association of Influenza Vaccination and Prognosis in Patients Testing Positive to SARS-COV-2 Swab Test: A Large-Scale Italian Multi-Database Cohort Study	VACCINES			English	Article						influenza vaccine; COVID-19; prognosis; health database; Italy	VACCINES	To investigate the association of the 2019-2020 influenza vaccine with prognosis of patients positive for SARS-CoV-2A, a large multi-database cohort study was conducted in four Italian regions (i.e., Lazio, Lombardy, Veneto, and Tuscany) and the Reggio Emilia province (Emilia-Romagna). More than 21 million adults were residing in the study area (42% of the population). We included 115,945 COVID-19 cases diagnosed during the first wave of the pandemic (February-May, 2020); 34.6% of these had been vaccinated against influenza. Three outcomes were considered: hospitalization, death, and intensive care unit (ICU) admission/death. The adjusted relative risk (RR) of being hospitalized in the vaccinated group when compared with the non-vaccinated group was 0.87 (95% CI: 0.86-0.88). This reduction in risk was not confirmed for death (RR = 1.04; 95% CI: 1.01-1.06), or for the combined outcome of ICU admission or death. In conclusion, our study, conducted on the vast majority of the population during the first wave of the pandemic in Italy, showed a 13% statistically significant reduction in the risk of hospitalization in some geographical areas and in the younger population. No impact of seasonal influenza vaccination on COVID-19 prognosis in terms of death and death or ICU admission was estimated.	[Massari, Marco; Spila-Alegiani, Stefania; Menniti-Ippolito, Francesca] Ist Super Sanita, Pharmacoepidemiol Unit, Natl Ctr Drug Res & Evaluat CNRVF, Viale Regina Elena 299, I-00161 Rome, Italy; [Fabiani, Massimo; Riccardo, Flavia] Ist Super Sanita, Dept Infect Dis DMI, Viale Regina Elena 299, I-00161 Rome, Italy; [Belleudi, Valeria; Kirchmayer, Ursula; Poggi, Francesca Romana] Lazio Reg Hlth Serv, Dept Epidemiol ASL Roma 1, Via Cristoforo Colombo 112, I-00147 Rome, Italy; [Trifiro, Gianluca] Univ Verona, Dept Diagnost & Publ Hlth, Piazzale LA Scuro 3, I-37134 Verona, Italy; [Trifiro, Gianluca] Italian Soc Pharmacol, Via Giovanni Pascoli 3, I-20129 Milan, Italy; [Mancuso, Pamela; Giorgi-Rossi, Paolo] Azienda Unita Sanitaria Locale IRCCS Reggio Emili, Epidemiol Unit, Via Giovanni Amendola 2, I-42122 Reggio Emilia, Italy; [Gini, Rosa; Bartolini, Claudia] Agenzia Reg Sanita Toscana, Via Pietro Dazzi 1, I-50141 Florence, Italy; [Leoni, Olivia; Ercolanoni, Michele] Dept Hlth Lombardy Reg, Epidemiol Observ, Piazza Citta Lombardia 1, I-20124 Milan, Italy; [Da-Re, Filippo] Reg Directorate Prevent Food Safety Vet Publ Hlth, Rio Novo Dorsoduro 3493, I-30123 Venice, Italy; [Guzzinati, Stefano] Azienda Zero, Passaggio Luigi Gaudenzio 1, I-35131 Padua, Italy; [Luxi, Nicoletta] Univ Messina, Dept BIOMORF, Piazza Pugliatti 1, I-98122 Messina, Italy		Spila-Alegiani, S (通讯作者)，Ist Super Sanita, Pharmacoepidemiol Unit, Natl Ctr Drug Res & Evaluat CNRVF, Viale Regina Elena 299, I-00161 Rome, Italy.	marco.massari@iss.it; stefania.spila@iss.it; massimo.fabiani@iss.it; v.belleudi@deplazio.it; gianluca.trifiro@univr.it; u.kirchmayer@deplazio.it; f.poggi@deplazio.it; pamela.mancuso@ausl.re.it; francesca.menniti@iss.it; rosa.gini@ars.toscana.it; claudia.bartolini@ars.toscana.it; Olivia_Leoni@regione.lombardia.it; michele.ercolanoni@ariaspa.it; filippo.dare@regione.veneto.it; stefano.guzzinati@azero.veneto.it; nicoletta.luxi@unime.it; flavia.riccardo@iss.it; paolo.giorgirossi@ausl.re.it	Belleudi, Valeria/J-9070-2016; Rossi, Paolo Giorgi/K-6367-2016; belleudi, valeria/AAR-4553-2021; Mancuso, Pamela/J-5408-2016; Trifiro, Gianluca/K-9744-2016	Belleudi, Valeria/0000-0002-8286-443X; Rossi, Paolo Giorgi/0000-0001-9703-2460; belleudi, valeria/0000-0002-8286-443X; guzzinati, stefano/0000-0002-4908-5506; Mancuso, Pamela/0000-0003-1609-2440; Spila Alegiani, Stefania/0000-0003-0656-1346; Massari, Marco/0000-0001-8442-4238; Trifiro, Gianluca/0000-0003-1147-7296			Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; Arokiaraj MC, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00444; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christenson B, 2004, EUR RESPIR J, V23, P363, DOI 10.1183/09031936.04.00063504; Chumakov K, 2020, SCIENCE, V368, P1187, DOI 10.1126/science.abc4262; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Escobar Luis E, 2020, medRxiv, DOI [10.1073/pnas.2008410117, 10.1101/2020.05.05.20091975]; European Centre for Disease Prevention and Control, COVID 19; Fink G., 2020, INACTIVATED TRIVALEN, DOI 10.1136/bmjebm-2020-111549; Green I, 2021, HUM VACC IMMUNOTHER, V17, P2169, DOI 10.1080/21645515.2020.1852010; Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4; Istituto Nazionale di Statistica, GEO DEMO DEM FIG; Istituto Superiore di Sanita, EP COVID 19 AGG NAZ EP COVID 19 AGG NAZ; Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Martinez-Baz I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040611; Menniti, 2020, BOLL EPIDEMIOL NAZ, V1, P39; R Core Team, 2020, R LANGUAGE ENV STAT; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Sultana J, 2020, EXPERT REV VACCINES, V19, P919, DOI 10.1080/14760584.2020.1825951; World Health Organization, COVID 19 CLIN MAN LI; World Health Organization, INT GUID CERT CLASS; World Health Organization (WHO), NAM COR DIS COVID 19; World Health Organization (WHO), ARCH WHO TIM COVID 1; Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817	26	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							716	10.3390/vaccines9070716			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7VZ	34358133	Green Published, gold			2022-04-29	WOS:000677115400001
J	Stephenson, R; Sullivan, SP; Pitter, RA; Hunter, AS; Chavanduka, TM				Stephenson, Rob; Sullivan, Stephen P.; Pitter, Renee A.; Hunter, Alexis S.; Chavanduka, Tanaka Md			COVID-19 Pandemic Optimism and Vaccine Willingness among an Online Sample of US Gay, Bisexual, and Other Men Who Have Sex with Men	VACCINES			English	Article						COVID-19; gay and bisexual men; vaccine	MEDICAL MISTRUST; ALCOHOL	This paper presents data from an online sample of U.S gay, bisexual, and other men who have sex with men (GBMSM), to explore the factors associated with three dimensions of vaccine beliefs: perception of the likelihood of a COVID-19 vaccine becoming available, perception of when a COVID-19 vaccine would become available, and the likelihood of taking a COVID-19 vaccine. Data are taken from the Love and Sex in the Time of COVID-19 study, collected from November 2020 to January 2021. A sample of 290 GBMSM is analyzed, modeling three binary outcomes: belief that there will be a COVID-19 vaccine, belief that the COVID-19 vaccine will be available in 6 months, and being very likely to take the COVID-19 vaccine. In contrast to other studies, Black/African Americans and GBMSM living with HIV had higher levels of pandemic optimism and were more likely to be willing to accept a vaccine. Men who perceived a higher prevalence of COVID-19 among their friends and sex partners, and those who had reduced their sex partners, were more likely to be willing to take a COVID-19 vaccine. There remained a small percentage of participants (14%) who did not think the pandemic would end, that there would not be a vaccine and were unlikely to take a vaccine. To reach the levels of vaccination necessary to control the pandemic, it is imperative to understand the characteristics of those experiencing vaccine hesitancy and then tailor public health messages to their unique set of barriers and motivations.	[Stephenson, Rob] Univ Michigan, Sch Nursing, Ctr Sexual & Hlth Dispar, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA; [Sullivan, Stephen P.; Pitter, Renee A.; Hunter, Alexis S.; Chavanduka, Tanaka Md] Univ Michigan, Ctr Sexual & Hlth Dispar, Ann Arbor, MI 48109 USA		Stephenson, R (通讯作者)，Univ Michigan, Sch Nursing, Ctr Sexual & Hlth Dispar, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA.	rbsteph@umich.edu; ssulliv@umich.edu; raltrine@umich.edu; ahun@umich.edu; tanakac@umich.edu		Chavanduka, Tanaka/0000-0003-0167-3867; Stephenson, Rob/0000-0002-9239-2640			Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; CDC, 2020, KEY UPD WEEK; CDC, 2021, CAS US; CDC, COVID DAT TRACK; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; da Silva DT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030204; Daly M, 2021, AM J PREV MED, V60, P766, DOI 10.1016/j.amepre.2021.01.008; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Drew, 2020, BUSINESS INSIDER; Eaton LA, 2015, AM J PUBLIC HEALTH, V105, pE75, DOI 10.2105/AJPH.2014.302322; Ehde DM, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102788; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Jarrett Brooke A, 2020, medRxiv, DOI 10.1101/2020.11.02.20224709; Khan R, 2011, EUR ADDICT RES, V17, P190, DOI 10.1159/000326073; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Latkin CA, 2021, SOC SCI MED, V270, DOI 10.1016/j.socscimed.2021.113684; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mervosh S., 2020, NY TIMES; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reiter PL, 2015, AM J PUBLIC HEALTH, V105, P96, DOI 10.2105/AJPH.2014.302095; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Santos GM, 2021, AIDS BEHAV, V25, P311, DOI 10.1007/s10461-020-02969-0; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; The U.S. Food and Drug Administration, COVID 19 VACC; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Ziemer C.T., 2020, SCI TRUST RISK ASSES	35	4	4	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							745	10.3390/vaccines9070745			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO7MS	34358161	Green Published, gold			2022-04-29	WOS:000677091300001
J	Bhatia, B; Furuyama, W; Hoenen, T; Feldmann, H; Marzi, A				Bhatia, Bharti; Furuyama, Wakako; Hoenen, Thomas; Feldmann, Heinz; Marzi, Andrea			Ebola Virus Glycoprotein Domains Associated with Protective Efficacy	VACCINES			English	Article						vesicular stomatitis virus; VSV; EBOV; filovirus; mucin-like domain; glycan cap	MOUSE MODEL; VACCINE; ANTIBODIES; MICE	Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and the best-characterized virus in the filovirus family. The West African epidemic accelerated the clinical development of vaccines and therapeutics, leading to licensure of vaccines and antibody-based therapeutics for human use in recent years. The most widely used vaccine is based on vesicular stomatitis virus (VSV) expressing the EBOV glycoprotein (GP) (VSV-EBOV). Due to its favorable immune cell targeting, this vaccine has also been used as a base vector for the development of second generation VSV-based vaccines against Influenza, Nipah, and Zika viruses. However, in these situations, it may be beneficial if the immunogenicity against EBOV GP is minimized to induce a better protective immune response against the other foreign immunogen. Here, we analyzed if EBOV GP can be truncated to be less immunogenic, yet still able to drive replication of the vaccine vector. We found that the EBOV GP glycan cap and the mucin-like domain are both dispensable for VSV-EBOV replication. The glycan cap, however, appears critical for mediating a protective immune response against lethal EBOV challenge in mice.	[Bhatia, Bharti; Furuyama, Wakako; Feldmann, Heinz; Marzi, Andrea] NIAID, Lab Virol, Div Intramural Res, NIH, Hamilton, MT 59840 USA; [Hoenen, Thomas] Friedrich Loeffler Inst, Inst Mol Virol & Cell Biol, D-17493 Greifswald, Germany		Marzi, A (通讯作者)，NIAID, Lab Virol, Div Intramural Res, NIH, Hamilton, MT 59840 USA.	bhartibhatia2007@gmail.com; wakakofuruyama@gmail.com; thomas.hoenen@fli.de; feldmannh@niaid.nih.gov; marzia@niaid.nih.gov	; Hoenen, Thomas/H-8990-2019	Feldmann, Heinz/0000-0001-9448-8227; Marzi, Andrea/0000-0003-0186-9587; Hoenen, Thomas/0000-0002-5829-6305	Intramural Research Program, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)	This research was funded by Intramural Research Program, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).	Bornholdt ZA, 2016, SCIENCE, V351, P1078, DOI 10.1126/science.aad5788; Bray M, 1999, J INFECT DIS, V179, pS248, DOI 10.1086/514292; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Davidson E, 2015, J VIROL, V89, P10982, DOI 10.1128/JVI.01490-15; DeBuysscher BL, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.2; DeBuysscher BL, 2014, VACCINE, V32, P2637, DOI 10.1016/j.vaccine.2014.02.087; Emanuel J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29401-x; Feldmann F, 2019, AM J TROP MED HYG, V100, P1275, DOI 10.4269/ajtmh.18-0937; Feldmann H, 2018, ANNU REV MICROBIOL, V72, P423, DOI 10.1146/annurev-micro-090817-062414; Fischer K, 2018, J INFECT DIS, V218, pS305, DOI 10.1093/infdis/jiy330; Furuyama Wakako, 2021, bioRxiv, DOI 10.1101/2021.01.19.426885; Furuyama W, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0155-z; Furuyama W, 2019, ANNU REV VIROL, V6, P435, DOI 10.1146/annurev-virology-092818-015708; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Haddock E, 2018, J INFECT DIS, V218, pS453, DOI 10.1093/infdis/jiy208; Heppner G., 2019, P NIP VIR INT C SING; Jacob ST, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0147-3; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Jones SM, 2007, J INFECT DIS, V196, pS404, DOI 10.1086/520591; Kimble JB, 2019, J VIROL, V93, DOI 10.1128/JVI.01845-18; Kuhn JH, 2019, J GEN VIROL, V100, P911, DOI 10.1099/jgv.0.001252; Marzi A, 2006, J VIROL, V80, P6305, DOI 10.1128/JVI.02545-05; Marzi A, 2015, J INFECT DIS, V212, pS404, DOI 10.1093/infdis/jiv188; Marzi A, 2015, SCIENCE, V349, P739, DOI 10.1126/science.aab3920; Marzi A, 2015, EMERG INFECT DIS, V21, P305, DOI 10.3201/eid2102.141649; Marzi A, 2013, P NATL ACAD SCI USA, V110, P1893, DOI 10.1073/pnas.1209591110; Marzi A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001923; Marzi A, 2011, J INFECT DIS, V204, pS1066, DOI 10.1093/infdis/jir348; Meyer M, 2018, CELL REP, V24, P1816, DOI 10.1016/j.celrep.2018.07.044; Murin CD, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108984; Murin CD, 2014, P NATL ACAD SCI USA, V111, P17182, DOI 10.1073/pnas.1414164111; Nakayama E, 2010, CLIN VACCINE IMMUNOL, V17, P1723, DOI 10.1128/CVI.00170-10; Saphire EO, 2018, CELL, V174, P938, DOI 10.1016/j.cell.2018.07.033; Schmidt ML, 2018, J INFECT DIS, V218, pS360, DOI 10.1093/infdis/jiy405; WHO, WHO 4 COUNTRIES AFRI; WHO, 2021, WEEKL B OUTBR OTH EM, P4; Wolf J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030190; World Health Organization (WHO), 2016, EB SIT REP; Zhang X, 2020, J VIROL, V94, DOI 10.1128/JVI.01967-19	39	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							630	10.3390/vaccines9060630			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8IV	34200548	Green Submitted, gold, Green Published			2022-04-29	WOS:000666802600001
J	Janssen, C; Maillard, A; Bodelet, C; Claudel, AL; Gaillat, J; Delory, T				Janssen, Cecile; Maillard, Alexis; Bodelet, Celine; Claudel, Anne-Laure; Gaillat, Jacques; Delory, Tristan		ACV Alpin Study Grp	Hesitancy towards COVID-19 Vaccination among Healthcare Workers: A Multi-Centric Survey in France	VACCINES			English	Article						COVID-19; vaccination; hesitancy; healthcare workers; cross-sectional survey; clustering; unsupervised learning	INFLUENZA VACCINATION; SARS-COV-2; WILLINGNESS	Vaccination programs against COVID-19 are being scaled up. We aimed to assess the effects of vaccine characteristics on vaccine hesitancy among healthcare workers in a multi-center survey conducted within French healthcare facilities from 1 December 2020 to 26 March 2021. We invited any healthcare workers naive of COVID-19 vaccination to complete an online self-questionnaire. They reported on their socio-demographic characteristics, as well as their perception and beliefs towards vaccination. We measured their willingness to get vaccinated in eight scenarios for candidates' vaccines presented sequentially (1 to 4-point scale). Candidates' vaccines varied for efficacy (25%, 50%, 100%), length of immunization (1 year or lifetime), frequency (<1/100, <1/10,000), and severity (none, moderate, severe) of adverse events. We analyzed 4349 healthcare workers' responses with interpretable questionnaires. The crude willingness to get vaccinated was 53.2% and increased over time. We clustered the trajectories of responses using an unsupervised classification algorithm (k-means) and identified four groups of healthcare workers: those willing to get vaccinated in any scenario (18%), those not willing to get vaccinated at all (22%), and those hesitating but more likely to accept (32%) or reject (28%) the vaccination depending on the scenario. In these last two subgroups, vaccine acceptance was growing with age, educational background and was higher among men with condition. Compared to an ideal vaccine candidate, a 50% reduced efficacy resulted in an average drop in acceptance by 0.8 (SD +/- 0.8, -23.5%), while it was ranging from 1.4 (SD +/- 1.0, -38.4%) to 2.1 (SD +/- 1.0, -58.4%) in case of severe but rare adverse event. The acceptance of a mandatory immunization program was 29.6% overall and was positively correlated to the willingness to get vaccinated, ranging from 2.4% to 60.0%. Even if healthcare workers represent a heterogeneous population, most (80%) could accept the vaccination against COVID-19. Their willingness to get the vaccine increased over time and as immunization programs became available. Among hesitant professionals, the fear of adverse events was the main concern. Targeted information campaigns reassuring about adverse events may increase vaccine coverage, in a population with a strong opinion about mandatory immunization programs.	[Janssen, Cecile] Ctr Hosp Annecy Genevois, Infect Dis Unit, F-74374 Annecy, France; [Maillard, Alexis; Claudel, Anne-Laure; Gaillat, Jacques; Delory, Tristan] Ctr Hosp Annecy Genevois, Clin Res Unit, F-74374 Annecy, France; [Bodelet, Celine] Univ Grenoble, Lab Interuniv Psychol LIP PC2S, Alpes 1251 Ave Cent, F-38400 St Martin Dheres, France		Delory, T (通讯作者)，Ctr Hosp Annecy Genevois, Clin Res Unit, F-74374 Annecy, France.	cjanssen@ch-annecygenevois.fr; maillard.alexis@laposte.net; celine.bodelet@univ-grenoble-alpes.fr; alclaudel@ch-annecygenevois.fr; jgaillat@ch-annecygenevois.fr; tdelory@ch-annecygenevois.fr	DELORY, Tristan/H-8110-2019	DELORY, Tristan/0000-0002-0165-8934	Alpine Arc area	This study was funded by an academic grant from the Alpine Arc area obtained in 2020. The funding played no role in any of the following: design, data collection, analysis, interpretation, or any aspect pertinent to the study.	Amin DP, 2021, AM J EMERG MED, V48, P372, DOI 10.1016/j.ajem.2021.01.089; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2020, SEASONAL INFLUENZA V; Atti A., 2021, EFFECTIVENESS BNT162; Blasi F, 2012, CLIN MICROBIOL INFEC, V18, P37, DOI 10.1111/j.1469-0691.2012.03941.x; Borgey F, 2019, VACCINE, V37, P1260, DOI 10.1016/j.vaccine.2019.01.066; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Edara Venkata Viswanadh, 2021, bioRxiv, DOI 10.1101/2021.02.20.432046; European Medicine Agiencies, 2021, COVID 19 VACC SAF UP; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Genolini C, 2010, COMPUTATION STAT, V25, P317, DOI 10.1007/s00180-009-0178-4; Giannattasio A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1090-x; Goldman RD, 2020, CLIN THER, V42, P2124, DOI 10.1016/j.clinthera.2020.09.012; Haute Autoritu de Santu, 2020, STRAT VACC CONTR COV; Kasozi KI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030253; Kukreti S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030246; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lanoix JP, 2019, INFECT DIS-NOR, V51, P302, DOI 10.1080/23744235.2018.1548774; Levy-Bruhl D, 2019, B SANT PUBLIQUE VACC; Martin C, 2020, J HOSP INFECT, V106, P102, DOI 10.1016/j.jhin.2020.06.028; Morley, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab054, DOI 10.1093/cid/ciab054]; Nicolas H.O, CURR BIOL; Nohl A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050424; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Papagiannis D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144925; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446; Robbins T, 2021, J HOSP INFECT, V112, P45, DOI 10.1016/j.jhin.2021.02.024; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Santu Publique France, COVID 19 VACC COV HE; Schrading WA, 2021, ACAD EMERG MED, V28, P455, DOI 10.1111/acem.14236; Shah ASV, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3582; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Verger P, 2021, LANCET PUBLIC HEALTH, V6, pE195, DOI 10.1016/S2468-2667(21)00029-3; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; World Health Organization, 2020, WHO SAGE VAL FRAM AL	42	12	12	3	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							547	10.3390/vaccines9060547			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5TA	34067490	gold, Green Published			2022-04-29	WOS:000665948900001
J	Liu, TR; He, ZL; Huang, J; Yan, N; Chen, Q; Huang, FQ; Zhang, YJ; Akinwunmi, OM; Akinwunmi, BO; Zhang, CJP; Wu, YB; Ming, WK				Liu, Taoran; He, Zonglin; Huang, Jian; Yan, Ni; Chen, Qian; Huang, Fengqiu; Zhang, Yuejia; Akinwunmi, Omolola M.; Akinwunmi, Babatunde O.; Zhang, Casper J. P.; Wu, Yibo; Ming, Wai-Kit			A Comparison of Vaccine Hesitancy of COVID-19 Vaccination in China and the United States	VACCINES			English	Article						global health; COVID-19; vaccine hesitancy; public health; health policy; vaccine preference	ACCEPTANCE	Objectives: To investigate the differences in vaccine hesitancy and preference of the currently available COVID-19 vaccines between two countries, namely, China and the United States (U.S.). Method: A cross-national survey was conducted in both China and the United States, and discrete choice experiments, as well as Likert scales, were utilized to assess vaccine preference and the underlying factors contributing to vaccination acceptance. Propensity score matching (PSM) was performed to enable a direct comparison between the two countries. Results: A total of 9077 (5375 and 3702 from China and the United States, respectively) respondents completed the survey. After propensity score matching, over 82.0% of respondents from China positively accepted the COVID-19 vaccination, while 72.2% of respondents from the United States positively accepted it. Specifically, only 31.9% of Chinese respondents were recommended by a doctor to have COVID-19 vaccination, while more than half of the U.S. respondents were recommended by a doctor (50.2%), local health board (59.4%), or friends and families (64.8%). The discrete choice experiments revealed that respondents from the United States attached the greatest importance to the efficacy of COVID-19 vaccines (44.41%), followed by the cost of vaccination (29.57%), whereas those from China held a different viewpoint, that the cost of vaccination covered the largest proportion in their trade-off (30.66%), and efficacy ranked as the second most important attribute (26.34%). Additionally, respondents from China tended to be much more concerned about the adverse effect of vaccination (19.68% vs. 6.12%) and have a lower perceived severity of being infected with COVID-19. Conclusion: Although the overall acceptance and hesitancy of COVID-19 vaccination in both countries are high, underpinned distinctions between these countries were observed. Owing to the differences in COVID-19 incidence rates, cultural backgrounds, and the availability of specific COVID-19 vaccines in the two countries, vaccine rollout strategies should be nation-dependent.	[Liu, Taoran; Yan, Ni; Chen, Qian; Huang, Fengqiu; Ming, Wai-Kit] Jinan Univ, Sch Med, Dept Publ Hlth & Prevent Med, Guangzhou 510632, Peoples R China; [He, Zonglin] Jinan Univ, Int Sch, Guangzhou 510632, Peoples R China; [Huang, Jian] ASTAR, Singapore Inst Clin Sci SICS, Singapore 138632, Singapore; [Huang, Jian] Imperial Coll London, Fac Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London W2 1PG, England; [Zhang, Yuejia] Jinan Univ, Sch Med, Guangzhou 510632, Peoples R China; [Akinwunmi, Omolola M.] Univ Ibadan Nigeria, Coll Med, Dept Radiol, Ibadan, Nigeria; [Akinwunmi, Omolola M.] Univ Coll Hosp, Dept Radiol, Ibadan, Nigeria; [Akinwunmi, Babatunde O.] Brigham & Womens Hosp Boston, Dept Obstet & Gynecol, Boston, MA 02115 USA; [Akinwunmi, Babatunde O.] Harvard Univ, Massachusetts Gen Hosp, Ctr Genom Med CGM, Harvard Med Sch, Boston, MA 02115 USA; [Zhang, Casper J. P.] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China; [Wu, Yibo] Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China; [Wu, Yibo] Hlth Culture Res Ctr Shaanxi, Key Res Base Philosophy & Social Sci Shaanxi Prov, Xian 712046, Peoples R China		Ming, WK (通讯作者)，Jinan Univ, Sch Med, Dept Publ Hlth & Prevent Med, Guangzhou 510632, Peoples R China.; Wu, YB (通讯作者)，Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China.; Wu, YB (通讯作者)，Hlth Culture Res Ctr Shaanxi, Key Res Base Philosophy & Social Sci Shaanxi Prov, Xian 712046, Peoples R China.	t.liu.10@student.rug.nl; hezonglin0leon@stu2015.jnu.edu.cn; jian.huang@imperial.ac.uk; yanni666@stu2019.Mu.edu.cn; chenqian@stu2020.jnu.edu.cn; fengqiu@stu2020.jnu.edu.cn; zhangyuejia69@stu2019.jnu.edu.cn; omololakinwunmi@gmail.com; bakinwunmi@bwh.harvard.edu; casperzl@connect.hku.hk; bjmuwuyibo@outlook.com; wkming@connect.hku.hk	Wu, Yibo/AAR-7374-2021; Huang, Jian/AAV-1355-2021; Ming, Wai-kit/AAH-5989-2019	Wu, Yibo/0000-0001-9607-313X; Huang, Jian/0000-0002-3931-5013; Ming, Wai-kit/0000-0002-8846-7515; He, Zonglin/0000-0001-7650-1459; Zhang, Casper/0000-0003-1047-0287; Yan, Ni/0000-0002-3256-341X; Liu, Taoran/0000-0002-7806-1263	Qingdao Key Health Discipline Development Fund [2020B047]	Qingdao Key Health Discipline Development Fund (Grand: 2020B047).	[Anonymous], 2014, COUNTRY CLASSIFICATI, P143; [Anonymous], 2021, FINANCE SINA NOT BEI; [Anonymous], 2020, C REPORT 9 IMPACT NO; Bump JB, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n180; Centers for Disease Control and Prevention, 2021, COVID DAT TRACK; Centers for Disease Control and Prevention, 2021, VAR VIR CAUS COVID 1; Centers for Disease Control and Prevention, 2021, SCI BRIEF EM SARS CO; Centers for Disease Control and Prevention, 2021, DIFF COVID 19 VACC; Chodosh S., WHY ONLY HALF AM SAY; Coe Antoinette B, 2012, Innov Pharm, V3, P1; Davies NG, 2020, LANCET PUBLIC HEALTH, V5, pE375, DOI 10.1016/S2468-2667(20)30133-X; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Eskola J, 2015, VACCINE, V33, P4215, DOI 10.1016/j.vaccine.2015.04.043; Fong MW, 2020, EMERG INFECT DIS, V26, P976, DOI 10.3201/eid2605.190995; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Imai Natsuko, 2020, Wellcome Open Res, V5, P59, DOI 10.12688/wellcomeopenres.15808.1; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lew L., 2021, CHINAS LOW VACCINATI; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Malcom, 2021, OVERCOMING COVID 19; McCredie MN, 2019, ASSESSMENT, V26, P759, DOI 10.1177/1073191118760709; McElveen CLaR, 2021, 10 REAS US CHIN SHOU; McFadden SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231808; McNeil, 2021, MUCH HERD IMMUNITY I; Michel JP, 2021, J NUTR HEALTH AGING, V25, P698, DOI 10.1007/s12603-021-1627-1; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; National Health Commission of People's Republic of China, 2021, VACC STAT; NewsPoints FirstWord Pharma, 2020, FAUC SAYS HERD IMM C; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Nowak GJ, 2015, VACCINE, V33, P4204, DOI 10.1016/j.vaccine.2015.04.039; Randolph JJ., 2014, PRACT ASSESS RES EVA, V19, P1; Remmel A, 2021, NATURE, V590, P538, DOI 10.1038/d41586-021-00290-x; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Times, 2021, SINOVACS COVID 19 VA; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n149; Volpp KG, 2021, JAMA-J AM MED ASSOC, V325, P125, DOI 10.1001/jama.2020.24036; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, WHO COR COVID 19 DAS; Wilson M, 2021, WILL COVID 19 PANDEM; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, TIM WHOS COVID 19 RE; World Health Organization, 2014, REP SAGE WORK GROUP; Worldometer, 2021, COUNTR COVID 19 HAS; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Xinhua Net, 2020, CHIN MAK COVID 19 VA; Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434; Yuan N.S., 2020, CHINA INT STRAT REV, V2, P14, DOI [10.1007/s42533-020-00049-5, DOI 10.1007/S42533-020-00049-5]; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zijtregtop EAM, 2009, VACCINE, V28, P207, DOI 10.1016/j.vaccine.2009.09.099	56	13	13	14	30	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							649	10.3390/vaccines9060649			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0YI	34198716	gold, Green Submitted, Green Published			2022-04-29	WOS:000666301600001
J	Nittner-Marszalska, M; Rosiek-Biegus, M; Kopec, A; Pawlowicz, R; Kosinska, M; Lata, A; Szenborn, L				Nittner-Marszalska, Marita; Rosiek-Biegus, Marta; Kopec, Agnieszka; Pawlowicz, Robert; Kosinska, Magdalena; Lata, Aleksandra; Szenborn, Leszek			Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals	VACCINES			English	Article						COVID-19; vaccination; allergic reaction	UNITED-STATES; ANAPHYLAXIS	Individuals with a history of allergy are potentially at risk of suffering from adverse effects after COVID-19 vaccination. We sought to assess the tolerance towards the Pfizer-BioNTech vaccine in allergic patients. To address this issue, we used a questionnaire conducted on-line in a group of medical professionals who were vaccinated with the Pfizer-BioNTech vaccine. A total of 1808 respondents, out of whom 1707 received two doses of the vaccine, returned the questionnaire. Local reactions after injection were more frequent in allergic individuals after both doses (swelling p = 0.0003). Systemic adverse events (AE-SYS) occurred more often after the second than the first dose in both groups (allergic persons: 77.29% vs. 41.06%); vomiting and arthralgia occurred more often in allergic subjects (p = 0.0009). AE-SYS in allergic individuals lasted longer than in non-allergic ones after the first (p = 0.01) and the second dose (p = 0.0009). Allergic reactions after vaccination were reported more frequently in allergic subjects: after the first dose (p = 0.00001) and after the second dose (p = 0.001). Rhinitis was the most frequent symptom observed more often in allergic patients. No severe allergic reactions occurred during the full cycle of vaccination. Although the Pfizer-BioNTech vaccine is tolerated worse by allergic than non-allergic individuals, the occurring adverse symptoms are mild and do not preclude a successful completion of the vaccination cycle. The presence of symptoms suggestive of allergy does not constitute a condition of increased risk of developing clinically significant adverse events following Pfizer COVID-19 vaccination.	[Nittner-Marszalska, Marita; Rosiek-Biegus, Marta; Kopec, Agnieszka; Pawlowicz, Robert; Kosinska, Magdalena; Lata, Aleksandra] Wroclaw Med Univ, Dept & Clin Internal Med Pneumol & Allergol, Str Marii Sklodowskiej Curie 66, PL-50369 Wroclaw, Poland; [Szenborn, Leszek] Wroclaw Med Univ, Dept Paediat & Infect Dis, Str Chalubinskiego 2-2a, PL-50368 Wroclaw, Poland		Pawlowicz, R (通讯作者)，Wroclaw Med Univ, Dept & Clin Internal Med Pneumol & Allergol, Str Marii Sklodowskiej Curie 66, PL-50369 Wroclaw, Poland.	marita.nittner-marszalska@umed.wroc.pl; marta.rosiek-biegus@umed.wroc.pl; agnieszka.kopec@umed.wroc.pl; robert.pawlowicz@umed.wroc.pl; magdalena.kosinska@umed.wroc.pl; lataaleksandra@gmail.com; leszek.szenborn@umed.wroc.pl		Rosiek-Biegus, Marta/0000-0003-4839-446X; Kopec, Agnieszka/0000-0002-5771-2530; Kosinska, Magdalena/0000-0001-9413-4381; Szenborn, Leszek/0000-0001-6574-8229			[Anonymous], 2021, MED LETT DRUGS THER, V63, P1; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Cabanillas Beatriz, 2021, Allergy, V76, P1617, DOI 10.1111/all.14711; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Centers for Disease Control and Prevention, INT CLIN CONS US MRN; Chilamakuri R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020206; *CTRS DIS CONTR PR, 2021, MMWR-MORBID MORTAL W, V70, P46; de Silva D, 2021, ALLERGY, V76, P1493, DOI 10.1111/all.14580; Dreskin SC, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0120-5; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Kelso JM, 2021, VACCINE, V39, P865, DOI 10.1016/j.vaccine.2020.12.084; Klimek Ludger, 2021, Allergo J Int, V30, P51, DOI 10.1007/s40629-020-00160-4; Kruszewski J, 2021, ALERGOL POL, V8, P1, DOI 10.5114/pja.2021.104220; LEEK TKV, 2021, ALLERGY ASTHMA CL IM, V17, P1, DOI DOI 10.1186/S13223-021-00529-2; McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Murphy KR, 2021, ANN ALLERG ASTHMA IM, V126, P319, DOI 10.1016/j.anai.2021.01.017; Nilsson L, 2017, PEDIAT ALLERG IMM-UK, V28, P628, DOI 10.1111/pai.12762; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sellaturay P, 2021, J ALLER CL IMM-PRACT, V9, P670, DOI 10.1016/j.jaip.2020.09.029; Shimabukuro T, 2021, AM J TRANSPLANT, V21, P1332, DOI 10.1111/ajt.16516; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Singh R, 2021, FASEB J, V35, DOI 10.1096/fj.202002662R; Sokolowska M, 2021, ALLERGY, V76, P1629, DOI 10.1111/all.14739; Su JR, 2019, J ALLERGY CLIN IMMUN, V143, P1465, DOI 10.1016/j.jaci.2018.12.1003; Turner PJ, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100517; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760	30	7	7	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							553	10.3390/vaccines9060553			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8EX	34070671	Green Published, gold			2022-04-29	WOS:000666115400001
J	Peer, V; Muhsen, K; Betser, M; Green, MS				Peer, Victoria; Muhsen, Khitam; Betser, Moshe; Green, Manfred S.			Antibody Response to Pertussis Vaccination in Pregnant and Non-Pregnant Women-The Role of Sex Hormones	VACCINES			English	Article						pertussis; vaccination; estrogen; progesterone; pregnancy; hormones	BORDETELLA-PERTUSSIS; IMMUNE-RESPONSES; B-LYMPHOPOIESIS; PROGESTERONE; CELLS; ESTRIOL; IMMUNIZATION; ESTRADIOL; ESTROGEN; IMMUNOGENICITY	Pertussis containing vaccine is recommended for pregnant women to protect neonates prior to being fully immunized against the disease. The immune response during pregnancy may be impacted by changes in the hormonal status. The aim of this study was to evaluate the immune response to pertussis immunization in pregnancy and to assess the role of sex hormones. In a cross-sectional study, blood samples were drawn from 174 pregnant and 74 non-pregnant women 45-60 days following immunization. Anti-pertussis toxin (Anti-PT) IgG antibody levels, estrogen, and progestogen concentrations were compared between the two groups. Multiple logistic regression analysis was used to examine the association between serum antibody and sex hormone concentrations in each group, controlling for age, body mass index (BMI), and smoking status. The geometric mean concentration (GMC) of anti-PT IgG antibody was significantly higher in non-pregnant women compared with pregnant women (median of 2.09 and 1.86, interquartile range = 2.36-1.8 and 2.11-1.16 respectively, p < 0.0001). Among pregnant women, the anti-PT IgG antibody GMC was negatively associated with both progesterone (odds ratio = 0.300, 95% CI = 0.116, 0.772, p = 0.013) and estrogen (odds ratio = 0.071, 95% CI = 0.017, 0.292, p < 0.0001), after controlling for age, BMI, and smoking. Pregnancy was associated with lower anti-PT IgG antibody levels (odds ratio = 0.413, 95% CI = -0.190, 0.899, p = 0.026). This appears to be at least partially explained by the higher levels of hormones during pregnancy. These findings demonstrate the important role of sex hormones in the response to pertussis vaccine during pregnancy and can help to evaluate the optimum vaccination schedule.	[Peer, Victoria; Green, Manfred S.] Univ Haifa, Sch Publ Hlth, Abba Khoushy 199, IL-3498838 Haifa, Israel; [Muhsen, Khitam] Tel Aviv Univ Ramat Aviv, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-6139001 Tel Aviv, Israel; [Betser, Moshe] Yitzhak Shamir Med Ctr, Dept Obstet & Gynecol, IL-70300 Zerifin, Israel		Peer, V (通讯作者)，Univ Haifa, Sch Publ Hlth, Abba Khoushy 199, IL-3498838 Haifa, Israel.	victoriapapi@yahoo.com; kmuhsen@tauex.tau.ac.il; betserm@shamir.gov.il; manfred.s.green@gmail.com		Muhsen, Khitam/0000-0003-1086-7559			Anis E, 2018, J PUBLIC HEALTH POL, V39, P304, DOI 10.1057/s41271-018-0130-3; Anraad C, 2020, VACCINE, V38, P6254, DOI 10.1016/j.vaccine.2020.07.047; Antunes RD, 2018, J CLIN INVEST, V128, P3853, DOI 10.1172/JCI121309; Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002; BORODITSKY RS, 1978, OBSTET GYNECOL, V51, P686; Chang IF, 2019, J MICROBIOL IMMUNOL, V52, P542, DOI 10.1016/j.jmii.2019.06.002; Craney T. A., 2002, Quality Engineering, V14, P391, DOI 10.1081/QEN-120001878; Cvoro A, 2008, J IMMUNOL, V180, P630, DOI 10.4049/jimmunol.180.1.630; Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344; Fortner KB, 2018, VACCINE, V36, P6354, DOI 10.1016/j.vaccine.2018.07.012; Fu BQ, 2014, CELL MOL IMMUNOL, V11, P564, DOI 10.1038/cmi.2014.54; Hendrikx LH, 2011, VACCINE, V29, P1431, DOI 10.1016/j.vaccine.2010.12.033; Higgs R, 2012, MUCOSAL IMMUNOL, V5, P485, DOI 10.1038/mi.2012.54; Hlobenova T, 2012, DEV COMP IMMUNOL, V36, P385, DOI 10.1016/j.dci.2011.07.009; Huygen K, 2015, VACCINE, V33, P4117, DOI 10.1016/j.vaccine.2015.06.108; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Konopka CK, 2013, BRAZ J MED BIOL RES, V46, P91, DOI 10.1590/1414-431X20122453; Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1; Langsam D, 2020, VACCINE, V38, P2700, DOI 10.1016/j.vaccine.2020.01.095; Leef M, 2000, J EXP MED, V191, P1841, DOI 10.1084/jem.191.11.1841; Lima J, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0927-7; Maeda Y, 2013, VET RES COMMUN, V37, P43, DOI 10.1007/s11259-012-9545-7; Marcellini V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01158; MATHUR RS, 1980, AM J OBSTET GYNECOL, V136, P25, DOI 10.1016/0002-9378(80)90558-X; McCracken SA, 2018, BJOG-INT J OBSTET GY, V125, P1388, DOI 10.1111/1471-0528.15210; MEDINA KL, 1994, P NATL ACAD SCI USA, V91, P5382, DOI 10.1073/pnas.91.12.5382; MEDINA KL, 1993, J EXP MED, V178, P1507, DOI 10.1084/jem.178.5.1507; Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924; Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6; Mills KHG, 2014, TRENDS MICROBIOL, V22, P49, DOI 10.1016/j.tim.2013.11.007; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; Nieves DJ, 2016, EMERGING INFECTIONS 10, P311, DOI 10.1128/microbiolspec.EI10-0008-2015; Ohfuji S, 2011, J INFECT DIS, V203, P1301, DOI 10.1093/infdis/jir026; OTTESEN B, 1979, ACTA OBSTET GYN SCAN, V58, P423, DOI 10.3109/00016347909154060; Rendi-Wagner P, 2010, VACCINE, V28, P3285, DOI 10.1016/j.vaccine.2010.02.104; Robinson DP, 2012, HORM BEHAV, V62, P263, DOI 10.1016/j.yhbeh.2012.02.023; Sakala IG, 2016, HUM VACC IMMUNOTHER, V12, P3065, DOI 10.1080/21645515.2016.1215392; Sappenfield Elisabeth, 2013, Infect Dis Obstet Gynecol, V2013, P752852, DOI 10.1155/2013/752852; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Schlaudecker EP, 2012, J INFECT DIS, V206, P1670, DOI 10.1093/infdis/jis592; Smith R, 2009, J CLIN ENDOCR METAB, V94, P2066, DOI 10.1210/jc.2008-2257; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Svensson-Arvelund J, 2014, TOXICOL PATHOL, V42, P327, DOI 10.1177/0192623313482205; SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3; Zhang L, 2014, INT J CLIN EXP PATHO, V7, P123	46	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							637	10.3390/vaccines9060637			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5OI	34200795	Green Published, gold			2022-04-29	WOS:000665936700001
J	Rapisarda, V; Vella, F; Ledda, C; Barattucci, M; Ramaci, T				Rapisarda, Venerando; Vella, Francesca; Ledda, Caterina; Barattucci, Massimiliano; Ramaci, Tiziana			What Prompts Doctors to Recommend COVID-19 Vaccines: Is It a Question of Positive Emotion?	VACCINES			English	Article						trust; vaccine; recommendation; locus of control; emotion; work; doctors	HEALTH-CARE WORKERS; INFLUENZA VACCINATION; PREVENTABLE DISEASES; NEGATIVE AFFECT; ATTITUDES; IMPACT; PREVALENCE; PERCEPTION; HESITANCY; COVERAGE	Vaccines are among the most successful and cost-effective public health tools and have greatly contributed to eliminating or controlling several serious vaccine-treatable diseases over the past century. To curb the spread of COVID-19, efficacious vaccination is emerging as essential in mitigating the disease and preventing deaths. Health care workers (HCW) are one of the first groups to receive vaccinations, so it is important to consider their attitudes to COVID-19 vaccination to better address barriers to widespread vaccination acceptance. This study aimed to evaluate variables that are linked with the recommendation of vaccines and intention to take-up vaccination against COVID-19 among the HCWs, in the context of the current pandemic. The study was conducted during the first week of the vaccination campaign dedicated to Italian HCWs, beginning in December 2020, and it involved all doctors in a public hospital in Sicily. The following questionnaires were administered: (1) The perceived vaccine trust questionnaire, measuring the degree of trust in vaccines by healthcare professionals both in general and for the protection of healthcare professionals themselves and patients; (2) the positive and negative affect scale-state (PANAS), for assessing positive and negative emotions in relation to their work as "frontline care providers"; (3) The locus of control of behaviour (LCB) to measure the extent to which subjects perceive responsibility for their personal behaviour (internal vs. external); (4) recommendation vaccines item, referring to the intention to recommend vaccination. The findings suggest that socio-demographic control variables (age, gender, and seniority) showed little or no predictive power in vaccine recommendation, while vaccine confidence, positive emotions, and internal locus of control were excellent predictors of vaccine recommendations by doctors. Younger doctors, both in age and experience, are more confident in vaccines and recommend them more frequently. It is essential to improve institutional communication addressed to doctors to enhance their role as vaccination facilitators.	[Rapisarda, Venerando; Vella, Francesca; Ledda, Caterina] Univ Catania, Dept Clin & Expt Med, Occupat Med, I-95121 Catania, Italy; [Vella, Francesca; Ramaci, Tiziana] Univ Enna Kore, Fac Human & Social Sci, I-94100 Enna, Italy; [Barattucci, Massimiliano] E Campus Univ, Fac Psychol, I-22060 Novedrate, Italy		Barattucci, M (通讯作者)，E Campus Univ, Fac Psychol, I-22060 Novedrate, Italy.	vrapisarda@unict.it; francesca.vella@unikore.it; cledda@unict.it; massimiliano.barattucci@uniecampus.it; tiziana.ramaci@unikore.it	RAMACI, TIZIANA/AAD-3672-2019; BARATTUCCI, MASSIMILIANO/C-5798-2016; rapisarda, venerando/AFV-5934-2022; Ledda, Caterina/A-1118-2011	RAMACI, TIZIANA/0000-0002-0745-2013; BARATTUCCI, MASSIMILIANO/0000-0003-2650-3661; Vella, Francesca/0000-0003-4057-6568; Ledda, Caterina/0000-0003-0739-8798; Rapisarda, Venerando/0000-0002-3482-1136			Barattucci M, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.554561; Barbara A, 2019, HUM VACC IMMUNOTHER, V15, P967, DOI 10.1080/21645515.2018.1556076; Benet T, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-30; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Boccalini S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040644; Cortinovis, 2000, RICERCA PSICOTERAPIA, V3, P147; Costantino C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040686; CRAIG AR, 1984, BRIT J MED PSYCHOL, V57, P173, DOI 10.1111/j.2044-8341.1984.tb01597.x; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Douchleff M., 2014, How Vaccine Fears Fueled the Resurgence of Preventable Diseases.; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Engin C, 2020, POPUL REV, V59, P156, DOI 10.1353/prv.2020.0007; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gallup, 2019, WELLC GLOB MON 1 WAV; Goodwin R, 2011, INT J BEHAV MED, V18, P88, DOI 10.1007/s12529-010-9083-z; Grohskopf Lisa, 2011, Morbidity and Mortality Weekly Report, V60, P1128; Immunization of health-care personnel, 2011, MMWR, V60, P1; INAIL I, DAT DEN COVID 19 MON; Israel Ministry of Health, INFL VACC INF CHILDR; Istituto Superiore di Sanita, 2012, ISTISAN1217 I SUP SA; Jiang XY, 2009, INT J BEHAV MED, V16, P58, DOI 10.1007/s12529-008-9005-5; La Torre G, 2011, HUM VACCINES, V7, P728, DOI 10.4161/hv.7.7.15413; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Ledda C, 2021, EUR J PUBLIC HEALTH, V31, P52, DOI 10.1093/eurpub/ckaa179; Ledda C, 2021, TROP MED INFECT DIS, V6, DOI 10.3390/tropicalmed6010021; Ledda C, 2019, FUTURE MICROBIOL, V14, P33, DOI 10.2217/fmb-2018-0263; Leppin A, 2009, INT J BEHAV MED, V16, P7, DOI 10.1007/s12529-008-9002-8; Loulergue P, 2009, VACCINE, V27, P4240, DOI 10.1016/j.vaccine.2009.03.039; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Maraqa B, 2021, PREV MED, V149, DOI 10.1016/j.ypmed.2021.106618; Merino JG, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6712; Ministero della Salute, 2014, PIAN NAZ PREV ACC 20; Muller AE, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113441; Murphy J., 2020, PSYARXIV, DOI DOI 10.31234/OSF.IO/PEV2B; Music T, 2012, INT NURS REV, V59, P161, DOI 10.1111/j.1466-7657.2011.00961.x; Napolitano F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010063; Nohl A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050424; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Parajuli Janaki, 2020, J Nepal Health Res Counc, V18, P466, DOI 10.33314/jnhrc.v18i3.2816; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Poletti P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016460; Ramaci T, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12093834; Rapisarda V, 2019, FUTURE MICROBIOL, V14, P41, DOI 10.2217/fmb-2018-0240; Rapisarda V, 2019, FUTURE MICROBIOL, V14, P1, DOI 10.2217/fmb-2018-0235; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Shook E, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050831; Siani A, 2019, PREV MED, V121, P99, DOI 10.1016/j.ypmed.2019.02.011; Signorelli C, 2017, ANN I SUPER SANITA, V53, P231, DOI 10.4415/ANN_17_03_09; Skea ZC, 2008, SOC SCI MED, V67, P1382, DOI 10.1016/j.socscimed.2008.07.006; Stuhlinger M, 2021, GROUP ORGAN MANAGE, V46, P38, DOI 10.1177/1059601120983964; Tamburrano A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16112006; Terracciano A, 2003, EUR J PSYCHOL ASSESS, V19, P131, DOI 10.1027//1015-5759.19.2.131; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Vella F, 2020, EUR REV MED PHARMACO, V24, P7889, DOI 10.26355/eurrev_202007_22296; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; World Health Organization, NO COR 2019 NCOV; World Health Organization, 2021, COR DIS COVID 19 WEE; World Health Organization, 2020, INFECT PREVENTION CO	60	4	4	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							578	10.3390/vaccines9060578			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8QB	34205935	Green Published, gold			2022-04-29	WOS:000666144500001
J	Torrente-Lopez, A; Hermosilla, J; Navas, N; Cuadros-Rodriguez, L; Cabeza, J; Salmeron-Garcia, A				Torrente-Lopez, Anabel; Hermosilla, Jesus; Navas, Natalia; Cuadros-Rodriguez, Luis; Cabeza, Jose; Salmeron-Garcia, Antonio			The Relevance of Monoclonal Antibodies in the Treatment of COVID-19	VACCINES			English	Review						COVID-19 treatment; clinical trials; monoclonal antibodies; non-SARS-CoV-2 specific; SARS-CoV-2 specific	TOCILIZUMAB; SARS-COV-2; MORTALITY	Major efforts have been made in the search for effective treatments since the outbreak of the COVID-19 infection in December 2019. Extensive research has been conducted on drugs that are already available and new treatments are also under development. Within this context, therapeutic monoclonal antibodies (mAbs) have been the subject of widespread investigation focusing on two target-based groups, i.e., non-SARS-CoV-2 specific mAbs, that target immune system responses, and SARS-CoV-2 specific mAbs, designed to neutralize the virus protein structure. Here we review the latest literature about the use of mAbs in order to describe the state of the art of the clinical trials and the benefits of using these biotherapeutics in the treatment of COVID-19. The clinical trials considered in the present review include both observational and randomized studies. We begin by presenting the studies conducted using non-SARS-CoV-2 specific mAbs for treating different immune disorders that were already on the market. Within this group of mAbs, we focus particularly on anti-IL-6/IL-6R. This is followed by a discussion of the studies on SARS-CoV-2 specific mAbs. Our findings indicate that SARS-CoV-2 specific mAbs are significantly more effective than non-specific ones.	[Torrente-Lopez, Anabel; Hermosilla, Jesus; Navas, Natalia; Cuadros-Rodriguez, Luis] Univ Granada, Biohlth Res Inst Ibs GRANADA, Sci Fac, Dept Analyt Chem, E-18071 Granada, Spain; [Cabeza, Jose; Salmeron-Garcia, Antonio] San Cecilio Univ Hosp, Biohlth Res Inst Ibs GRANADA, Dept Clin Pharm, E-18012 Granada, Spain		Navas, N (通讯作者)，Univ Granada, Biohlth Res Inst Ibs GRANADA, Sci Fac, Dept Analyt Chem, E-18071 Granada, Spain.	anabeltl@ugr.es; herfer@correo.ugr.es; natalia@ugr.es; lcuadros@ugr.es; jose.cabeza.sspa@juntadeandalucia.es; asalgar6@gmail.com	Torrente, Anabel/AAS-2723-2021; Fernández, Jesús Hermosilla/AAY-6426-2020; navas, Natalia/O-2262-2018; Cuadros Rodriguez, Luis/B-9677-2017	Torrente, Anabel/0000-0002-2507-6760; Fernández, Jesús Hermosilla/0000-0002-2390-2360; CABEZA BARRERA, JOSE/0000-0002-2161-930X; navas, Natalia/0000-0002-2536-1430; Cuadros Rodriguez, Luis/0000-0003-0162-7211	Institute of Health 'Carlos III', Ministry of Economy and Competitiveness, Spain - European Regional Development Funds (ERDF) [FIS: PI-17/00547]	This study was partially funded by Project FIS: PI-17/00547 (Institute of Health 'Carlos III', Ministry of Economy and Competitiveness, Spain), which means that it was also partially supported by European Regional Development Funds (ERDF).	An Z., 2009, THERAPEUTIC MONOCLON; Atyeo C, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.143129; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Benucci M, 2020, J MED VIROL, V92, P2368, DOI 10.1002/jmv.26062; Berardicurti O, 2020, CLIN EXP RHEUMATOL, V38, P1247; Boregowda U, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.586221; Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017; Cantini F, 2020, DRUGS, V80, P1929, DOI 10.1007/s40265-020-01421-w; Castelnovo L, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000023582; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cortegiani A, 2021, PULMONOLOGY, V27, P52, DOI 10.1016/j.pulmoe.2020.07.003; Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218724, 10.1136/annrheumdis-2020-218759]; European Medicines Agency, TREATM VACC COVID 19 TREATM VACC COVID 19; European Medicines Agency, SILT SUMM PROD CHAR; European Medicines Agency, TOC SUMM PROD CHAR; European Medicines Agency, SAR SUMM PROD CHAR S; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fazakerley I., COVID 19 THERAPEUTIC; FDA, 2021, COR COVID 19 UPD FDA; Fda, 2020, COR COVID 19 UPD FDA; Gavriatopoulou M, 2021, CLIN EXP MED, V21, P167, DOI 10.1007/s10238-020-00671-y; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI 10.1056/NEJMoa2100433; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Gremese E, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100553; Gritti G., 2020, IL 6 SIGNALLING PATH, p04.01.20048561, DOI [10.1101/2020.04.01.20048561v4, DOI 10.1101/2020.04.01.20048561, 10.1101/2020.04.01.20048561]; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Ho Mitchell, 2020, Antib Ther, V3, P109, DOI 10.1093/abt/tbaa009; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Jahanshahlu L, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110337; Khan FA, 2021, THORAX, V76, P907, DOI 10.1136/thoraxjnl-2020-215266; Khiali S, 2021, EXPERT OPIN BIOL TH, V21, P615, DOI 10.1080/14712598.2021.1847269; Kow CS, 2022, EXPERT REV ANTI-INFE, V20, P567, DOI [10.1080/14787210.2022.2000861, 10.1007/s00228-021-03087-z]; Lescure FX, 2021, LANCET RESP MED, V9, P522, DOI 10.1016/S2213-2600(21)00099-0; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Marovich M, 2020, JAMA-J AM MED ASSOC, V324, P131, DOI 10.1001/jama.2020.10245; Montesarchio V, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001089; Owji H, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106924; Renn A, 2020, TRENDS PHARMACOL SCI, V41, P815, DOI 10.1016/j.tips.2020.07.004; Saif LJ, 2020, NAT BIOTECHNOL, V38, P1242, DOI 10.1038/s41587-020-0732-8; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI 10.1056/NEJMoa2030340; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Soin AS, 2021, LANCET RESP MED, V9, P511, DOI 10.1016/S2213-2600(21)00081-3; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069; Ucciferri C, 2020, WORLD J CLIN CASES, V8, P4280, DOI 10.12998/wjcc.v8.i19.4280; Valdez-Cruz NA, 2021, MICROB CELL FACT, V20, DOI 10.1186/s12934-021-01576-5; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Wang P., 2021, NATURE, V593, P130, DOI DOI 10.1038/s41586-021-03398-2; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wrobel AG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19146-5; Wu Nicholas C, 2020, PLoS Pathog, V16, pe1009089, DOI 10.1371/journal.ppat.1009089; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Ye G, 2020, ANTIBODY THERAPEUTIC, DOI [DOI 10.1093/ABT/TBAA007, 10.1093/abt/tbaa007]; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Zarkali A, 2014, CURR MED RES OPIN, V30, P471, DOI 10.1185/03007995.2013.855186; Zhou DM, 2020, NAT STRUCT MOL BIOL, V27, P950, DOI 10.1038/s41594-020-0480-y	64	1	1	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							557	10.3390/vaccines9060557			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3ZW	34073559	gold, Green Published			2022-04-29	WOS:000666508400001
J	Bosch-Camos, L; Lopez, E; Collado, J; Navas, MJ; Blanco-Fuertes, M; Pina-Pedrero, S; Accensi, F; Salas, ML; Mundt, E; Nikolin, V; Rodriguez, F				Bosch-Camos, Laia; Lopez, Elisabet; Collado, Javier; Navas, Maria J.; Blanco-Fuertes, Miguel; Pina-Pedrero, Sonia; Accensi, Francesc; Salas, Maria Luisa; Mundt, Egbert; Nikolin, Veljko; Rodriguez, Fernando			M448R and MGF505-7R: Two African Swine Fever Virus Antigens Commonly Recognized by ASFV-Specific T-Cells and with Protective Potential	VACCINES			English	Article						African swine fever; antigen discovery; T-cells; DNA immunization; live attenuated virus; protection; immunopeptidomics	CRYO-EM STRUCTURE; DNA IMMUNIZATION; RNA LIGASE; WILD BOAR; IN-VITRO; EXPRESSION; CHALLENGE; GENOME; IMMUNOGENICITY; IDENTIFICATION	African swine fever (ASF) is today's number one threat for the global swine industry. Neither commercial vaccine nor treatment is available against ASF and, thus far, only live attenuated viruses (LAV) have provided robust protection against lethal ASF virus (ASFV) challenge infections. Identification of ASFV proteins inducing protective immune responses is one of the major challenges to develop safer and efficient subunit vaccines. Immunopeptidomic studies recently performed in our laboratory allowed identifying ASFV antigens recognized by ASFV-specific CD8(+) T-cells. Here, we used data from the SLAI-peptide repertoire presented by a single set of ASFV-infected porcine alveolar macrophages to generate a complex DNA vaccine composed by 15 plasmids encoding the individual peptide-bearing ORFs. DNA vaccine priming improved the protection afforded by a suboptimal dose of the BA71 Delta CD2 LAV given as booster vaccination, against Georgia2007/1 lethal challenge. Interestingly, M448R was the only protein promiscuously recognized by the induced ASFV-specific T-cells. Furthermore, priming pigs with DNA plasmids encoding M488R and MGF505-7R, a CD8+ T-cell antigen previously described, confirmed these two proteins as T-cell antigens with protective potential. These studies might be useful to pave the road for designing safe and more efficient vaccine formulations in the future.	[Bosch-Camos, Laia; Lopez, Elisabet; Navas, Maria J.; Blanco-Fuertes, Miguel; Pina-Pedrero, Sonia; Accensi, Francesc; Rodriguez, Fernando] IRTA, Ctr Recerca Sanitat Anim, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain; [Bosch-Camos, Laia; Lopez, Elisabet; Navas, Maria J.; Blanco-Fuertes, Miguel; Pina-Pedrero, Sonia; Rodriguez, Fernando] IRTA, CReSA, OIE Collaborating Ctr Res & Control Emerging & Re, Bellaterra 08193, Spain; [Collado, Javier] Dept Biol Cellular Fisiol & Immunol, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain; [Accensi, Francesc] UAB, IRTA, Ctr Recerca Sanitat Anim, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain; [Salas, Maria Luisa] CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; [Salas, Maria Luisa] Univ Autonoma Madrid, Madrid 28049, Spain; [Mundt, Egbert; Nikolin, Veljko] Boehringer Ingelheim Vet Res Ctr GmbH & Co KG, D-30559 Hannover, Germany		Rodriguez, F (通讯作者)，IRTA, Ctr Recerca Sanitat Anim, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain.; Rodriguez, F (通讯作者)，IRTA, CReSA, OIE Collaborating Ctr Res & Control Emerging & Re, Bellaterra 08193, Spain.	laia.bosch@irta.cat; elisabeth.lopezf@gmail.com; javiercolladomiguens@gmail.com; mariajesus.navas@irta.cat; miguel.blanco@irta.cat; sonia.pina@irta.cat; francesc.accensi@irta.cat; mlsalas@cbm.csic.es; egbert.mundt@boehringer-ingelheim.com; veljko.nikolin@boehringer-ingelheim.com; fernando.rodriguez@irta.cat	Lopez Fernandez, elisabet/AGX-1992-2022; Bosch-Camós, Laia/AAD-6373-2022; Accensi, Francesc/C-7051-2008; Pina-Pedrero, Sonia/U-2217-2017	Lopez Fernandez, Elisabet/0000-0003-4253-330X; Rodriguez, Fernando/0000-0001-7361-8408; Accensi, Francesc/0000-0001-9068-0377; Blanco-Fuertes, Miguel/0000-0002-8251-0682; Pina-Pedrero, Sonia/0000-0001-5475-4770	Departament d'Economia i Coneixement de la Generalitat de Catalunya (Spain)Generalitat de Catalunya [2015 DI 037]; Boehringer Ingelheim Veterinary Research Center (BIVRC) GmbH Co. KGBoehringer Ingelheim; Ministerio de Ciencia e Innovacion of SpainSpanish Government [AGL2016-78169-C2-1-R, PID2019-107616RB-I00]; Red de Investigacion en Sanidad Animal (RISA)	This research was funded by Departament d'Economia i Coneixement de la Generalitat de Catalunya (Spain), grant number 2015 DI 037. Studies were co-financed by Boehringer Ingelheim Veterinary Research Center (BIVRC) GmbH & Co. KG, the Ministerio de Ciencia e Innovacion of Spain (grant numbers AGL2016-78169-C2-1-R and PID2019-107616RB-I00) and Red de Investigacion en Sanidad Animal (RISA).	Abrams CC, 2013, VIROLOGY, V443, P99, DOI 10.1016/j.virol.2013.04.028; Alejo A, 2018, J VIROL, V92, DOI 10.1128/JVI.01293-18; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Andres G, 2020, J BIOL CHEM, V295, P1, DOI 10.1074/jbc.AC119.011196; [Anonymous], AFRICAN SWINE FEVER; Argilaguet JM, 2011, VACCINE, V29, P5379, DOI 10.1016/j.vaccine.2011.05.084; Argilaguet JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040942; Arias M.L., 2017, BLUEPRINT ROADMAP BR; Arias M, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040035; Barasona JA, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00137; BELTRANALCRUDO D, 2008, FAO EMPRES WATCH, P1, DOI DOI 10.13140/RG.2.1.3579.1200; Borca MV, 2020, J VIROL, V94, DOI 10.1128/JVI.02017-19; Borca MV, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57455-3; Bosch-Camos L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010029; Bosch-Camos L, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00154-2; Chapman DAG, 2008, J GEN VIROL, V89, P397, DOI 10.1099/vir.0.83343-0; Chapman DAG, 2011, EMERG INFECT DIS, V17, P599, DOI 10.3201/eid1704.101283; Chen WY, 2020, SCI CHINA LIFE SCI, V63, P623, DOI 10.1007/s11427-020-1657-9; Correia S, 2013, VIRUS RES, V173, P87, DOI 10.1016/j.virusres.2012.10.013; Cwynar P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040310; Einhauer A, 2001, J BIOCHEM BIOPH METH, V49, P455, DOI 10.1016/S0165-022X(01)00213-5; Escribano JM, 2013, VIRUS RES, V173, P101, DOI 10.1016/j.virusres.2012.10.012; Franzoni G, 2017, VET MICROBIOL, V198, P88, DOI 10.1016/j.vetmic.2016.12.010; Galindo-Cardiel I, 2013, VIRUS RES, V173, P180, DOI 10.1016/j.virusres.2012.12.018; Gallardo C, 2013, VET MICROBIOL, V162, P32, DOI 10.1016/j.vetmic.2012.08.011; Gallardo C, 2018, VACCINE, V36, P2694, DOI 10.1016/j.vaccine.2018.03.040; Gil S, 2008, ARCH VIROL, V153, P1845, DOI 10.1007/s00705-008-0196-5; Gil S, 2003, ARCH VIROL, V148, P2077, DOI 10.1007/s00705-003-0182-x; Goatley LC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020234; Gogin A, 2013, VIRUS RES, V173, P198, DOI 10.1016/j.virusres.2012.12.007; GONZALVO FR, 1986, AM J VET RES, V47, P1858; Halasa T, 2016, VET MICROBIOL, V193, P7, DOI 10.1016/j.vetmic.2016.08.004; Iyer LA, 2006, VIRUS RES, V117, P156, DOI 10.1016/j.virusres.2006.01.009; Jancovich JK, 2018, J VIROL, V92, DOI [10.1128/JVI.02219-17, 10.1128/jvi.02219-17]; Kim SH, 2020, EMERG MICROBES INFEC, V9, P628, DOI 10.1080/22221751.2020.1738904; Lacasta A, 2014, J VIROL, V88, P13322, DOI 10.1128/JVI.01893-14; Li XD, 2018, VET REC, V183, P300, DOI 10.1136/vr.k3774; Liu S, 2019, CELL HOST MICROBE, V26, P836, DOI 10.1016/j.chom.2019.11.004; Lokhandwala S, 2019, VET MICROBIOL, V235, P10, DOI 10.1016/j.vetmic.2019.06.006; Lopera-Madrid J, 2017, VET IMMUNOL IMMUNOP, V185, P20, DOI 10.1016/j.vetimm.2017.01.004; Lopez E, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121474; Martins A, 2004, J BIOL CHEM, V279, P18220, DOI 10.1074/jbc.M313386200; Monteagudo PL, 2017, J VIROL, V91, DOI [10.1128/JVI.01058-17, 10.1128/jvi.01058-17]; Mulumba-Mfumu LK, 2019, TRANSBOUND EMERG DIS, V66, P1462, DOI 10.1111/tbed.13187; Murgia MV, 2019, ARCH VIROL, V164, P359, DOI 10.1007/s00705-018-4071-8; Netherton CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01318; O'Donnell V, 2017, J VIROL, V91, DOI 10.1128/JVI.01760-16; ONISK DV, 1994, VIROLOGY, V198, P350, DOI 10.1006/viro.1994.1040; Oura CAL, 2005, J GEN VIROL, V86, P2445, DOI 10.1099/vir.0.81038-0; Peregrin-Alvarez JM, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r63; Rodriguez F, 2001, J VIROL, V75, P7399, DOI 10.1128/JVI.75.16.7399-7409.2001; RStudio Team, 2020, RSTUDIO INT DEV R; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Takashima A, 2001, Curr Protoc Cell Biol, VChapter 2, DOI 10.1002/0471143030.cb0201s00; Teklue T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040763; Therneau T., **DATA OBJECT**; Wickham H., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/joss.01686]; Yutin N, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-223; Zhang FQ, 2006, J VIROL, V80, P10514, DOI 10.1128/JVI.00485-06	59	3	3	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							508	10.3390/vaccines9050508			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1IM	34069239	Green Published, gold			2022-04-29	WOS:000654579800001
J	Grau, S; Ferrandez, O; Martin-Garcia, E; Maldonado, R				Grau, Santiago; Ferrandez, Olivia; Martin-Garcia, Elena; Maldonado, Rafael			Accidental Interruption of the Cold Chain for the Preservation of the Moderna COVID-19 Vaccine	VACCINES			English	Editorial Material									[Grau, Santiago; Ferrandez, Olivia] Hosp del Mar, Pharm Dept, Barcelona 08003, Spain; [Grau, Santiago; Martin-Garcia, Elena; Maldonado, Rafael] Hosp del Mar Med Res Inst IMIM, Barcelona 08003, Spain; [Martin-Garcia, Elena; Maldonado, Rafael] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Lab Neuropharmacol Neurophar, Barcelona 08003, Spain		Grau, S (通讯作者)，Hosp del Mar, Pharm Dept, Barcelona 08003, Spain.; Grau, S; Maldonado, R (通讯作者)，Hosp del Mar Med Res Inst IMIM, Barcelona 08003, Spain.; Maldonado, R (通讯作者)，Univ Pompeu Fabra, Dept Expt & Hlth Sci, Lab Neuropharmacol Neurophar, Barcelona 08003, Spain.	sgrau@psmar.cat; oferrandez@psmar.cat; elena.martin@upf.edu; rafael.maldonado@upf.edu	Martin-Garcia, Elena/H-5406-2013; Maldonado, Rafael/F-5657-2014	Martin-Garcia, Elena/0000-0002-4487-3028; Maldonado, Rafael/0000-0002-4359-8773	ICREA Academia 2020	ICREA Academia 2020.	[Anonymous], BUSINES WIRE; Kaiser J., TEMPERATURE CONCERNS; MartYn-GarcYa, 2021, MEDRXIV, DOI [10.1101/2021.03.09.21253129, DOI 10.1101/2021.03.09.21253129]	3	2	2	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							512	10.3390/vaccines9050512			2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1ZD	34067511	gold, Green Published			2022-04-29	WOS:000654623200001
J	Colomer, MA; Margalida, A; Alos, F; Oliva-Vidal, P; Vilella, A; Fraile, L				Angels Colomer, Ma; Margalida, Antoni; Alos, Francesc; Oliva-Vidal, Pilar; Vilella, Anna; Fraile, Lorenzo			Modeling of Vaccination and Contact Tracing as Tools to Control the COVID-19 Outbreak in Spain	VACCINES			English	Article						control measures; vaccination; population dynamic P system; Spain	TRANSMISSION	We developed an agent-based stochastic model, based on P Systems methodology, to decipher the effects of vaccination and contact tracing on the control of COVID-19 outbreak at population level under different control measures (social distancing, mask wearing and hand hygiene) and epidemiological scenarios. Our findings suggest that without the application of protection social measures, 56.1% of the Spanish population would contract the disease with a mortality of 0.4%. Assuming that 20% of the population was protected by vaccination by the end of the summer of 2021, it would be expected that 45% of the population would contract the disease and 0.3% of the population would die. However, both of these percentages are significantly lower when social measures were adopted, being the best results when social measures are in place and 40% of contacts traced. Our model shows that if 40% of the population can be vaccinated, even without social control measures, the percentage of people who die or recover from infection would fall from 0.41% and 56.1% to 0.16% and 33.5%, respectively compared with an unvaccinated population. When social control measures were applied in concert with vaccination the percentage of people who die or recover from infection diminishes until 0.10% and 14.5%, after vaccinating 40% of the population. Vaccination alone can be crucial in controlling this disease, but it is necessary to vaccinate a significant part of the population and to back this up with social control measures.	[Angels Colomer, Ma; Oliva-Vidal, Pilar] Univ Lleida, Dept Math, ETSEA, E-25198 Lleida, Spain; [Margalida, Antoni; Oliva-Vidal, Pilar] IREC CSIC UCLM JCCM, Dept Game Resources & Wildlife Management, Inst Game & Wildlife Res, E-13005 Ciudad Real, Spain; [Alos, Francesc] Primary Hlth Ctr, Barcelona 08010, Spain; [Vilella, Anna] Hosp Clin Barcelona, Publ Hlth Dept, Barcelona 08036, Spain; [Fraile, Lorenzo] Univ Lleida, Dept Anim Sci, ETSEA, Lleida 25198, Spain; [Fraile, Lorenzo] Univ Lleida, Dept Anim Sci, Agrotecnio, Lleida 25198, Spain		Margalida, A (通讯作者)，IREC CSIC UCLM JCCM, Dept Game Resources & Wildlife Management, Inst Game & Wildlife Res, E-13005 Ciudad Real, Spain.	colomer@matematica.udl.cat; a.margalida@csic.es; fralos.bcn.ics@gencat.cat; pilaroliva@ca.udl.cat; avilella@clinic.cat; lorenzo.fraile@udl.cat	Margalida, Antoni/AAG-5337-2020; Fraile, Lorenzo/AGE-2172-2022; Fraile, Lorenzo/A-1142-2009; Margalida, Antoni/A-2723-2011	Fraile, Lorenzo/0000-0002-8980-5862; Fraile, Lorenzo/0000-0002-8980-5862; Margalida, Antoni/0000-0002-0576-3993; Alos Colomer, Francesc/0000-0002-8350-062X	University of Lleida	This research was funded by University of Lleida.	Aleta A, 2020, NAT HUM BEHAV, V4, P964, DOI 10.1038/s41562-020-0931-9; Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; Colomer MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060698; [Anonymous], COVID-19 Real Time Learning Network; [Anonymous], Clinical Trials; [Anonymous], COVID-19 Coronavirus: Top Ten Most-Affected Countries; [Anonymous], Coronavirus: The Economic impact-10 July 2020; Aschwanden C, 2020, NATURE, V587, P26, DOI 10.1038/d41586-020-02948-4; Baum F, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n91; Bitsouni V, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220738; Bohm R, 2019, J BEHAV MED, V42, P381, DOI 10.1007/s10865-018-9985-9; Bonaccorsi G, 2020, P NATL ACAD SCI USA, V117, P15530, DOI 10.1073/pnas.2007658117; Casas-Rojo JM, 2020, REV CLIN ESP, V220, P480, DOI 10.1016/j.rce.2020.07.003; Casini L, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20247319; Chang S, 2021, NATURE, V589, P82, DOI 10.1038/s41586-020-2923-3; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Colomer M.A, MODELING SARS COV2; Colomer MA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46339-w; Colomer MA, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10050909; Davies NG, 2020, LANCET PUBLIC HEALTH, V5, pE375, DOI 10.1016/S2468-2667(20)30133-X; Giabbanelli P.J., 2020, IDENTIFYING SYNERGIS, DOI [10.1101/ 2020.12.11.20247825, DOI 10.1101/2020.12.11.20247825]; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Hoertel Nicolas, 2020, medRxiv, DOI 10.1101/2020.04.30.20086264; Huang JP, 2020, SCI BULL, V65, P1884, DOI 10.1016/j.scib.2020.08.002; Jewell NP, 2020, JAMA-J AM MED ASSOC, V323, P1893, DOI 10.1001/jama.2020.6585; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Koren M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239113; Kretzschmar ME, 2020, LANCET PUBLIC HEALTH, V5, pE452, DOI 10.1016/S2468-2667(20)30157-2; Lahariya Chandrakant, 2015, J Family Med Prim Care, V4, P487, DOI 10.4103/2249-4863.174263; Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976; Laing T, 2020, EXTRACT IND SOC, V7, P580, DOI 10.1016/j.exis.2020.04.003; Leung NHL, 2020, NAT MED, V26, P676, DOI 10.1038/s41591-020-0843-2; Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744; Madewell ZJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.31756; Marroquin B, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113419; Martin GP, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2017; Meyerowitz EA, 2021, ANN INTERN MED, V174, P69, DOI 10.7326/M20-5008; Mizumoto K, 2020, INT J INFECT DIS, V97, P96, DOI 10.1016/j.ijid.2020.05.091; Ollila H.M., 2020, FACE MASKS PREVENT, DOI [10.1101/2020.07.31.20166116, DOI 10.1101/2020.07.31.20166116]; Pan KY, 2021, LANCET PSYCHIAT, V8, P121, DOI 10.1016/S2215-0366(20)30491-0; Pillai S, 2020, ARCH MED RES, V51, P723, DOI 10.1016/j.arcmed.2020.05.015; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poletto C, 2020, LANCET DIGIT HEALTH, V2, pE498, DOI 10.1016/S2589-7500(20)30196-5; Prather KA, 2020, SCIENCE, V370, P303, DOI 10.1126/science.abf0521; Press WH, 2020, SCIENCE, V370, DOI 10.1126/science.abf7914; R Core Team, 2020, R LANGUAGE ENV STAT; Rahman MM, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12219101; Roy S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241165; Sarkar S, 2021, J SOCIAL EC DEV, V23, P366, DOI 10.1007/s40847-020-00129-7; Sorci G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75848-2; Sun KY, 2021, SCIENCE, V371, P254, DOI 10.1126/science.abe2424; Thunstrom L, 2020, J BENEFIT-COST ANAL, V11, P179, DOI 10.1017/bca.2020.12; WHO, 2020, CLIN MAN SEV AC RESP; World Health Organization, 2020, MASK USE CONTEXT COV; Zhang X, 2020, J INFECTION, V80, pE39, DOI 10.1016/j.jinf.2020.03.032	56	2	2	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							386	10.3390/vaccines9040386			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4ZA	33920027	gold, Green Published			2022-04-29	WOS:000643788000001
J	Ahmad, S; Shahid, F; Tahir ul Qamar, M; Rehman, HU; Abbasi, SW; Sajjad, W; Ismail, S; Alrumaihi, F; Allemailem, KS; Almatroudi, A; Saeed, HFU				Ahmad, Sajjad; Shahid, Farah; Tahir ul Qamar, Muhammad; Rehman, Habib ur; Abbasi, Sumra Wajid; Sajjad, Wasim; Ismail, Saba; Alrumaihi, Faris; Allemailem, Khaled S.; Almatroudi, Ahmad; Ullah Saeed, Hafiz Fahad			Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design	VACCINES			English	Article						hepatitis C virus; immuno-informatics; docking; molecular dynamics simulation	HEPATITIS-C VIRUS; MOLECULAR-DYNAMICS SIMULATION; MULTI-EPITOPE VACCINE; GLOBAL EPIDEMIOLOGY; PROTEIN-STRUCTURE; CODON USAGE; EXPRESSION; PREDICTION; SERVER; PREVALENCE	Hepatitis C virus (HCV) causes chronic and acute hepatitis infections. As there is extreme variability in the HCV genome, no approved HCV vaccine has been available so far. An effective polypeptide vaccine based on the functionally conserved epitopes will be greatly helpful in curing disease. For this purpose, an immuno-informatics study is performed based on the published HCV subtype-3a from Pakistan. First, the virus genome was translated to a polyprotein followed by a subsequent prediction of T-cell epitopes. Non-allergenic, IFN-gamma producer, and antigenic epitopes were shortlisted, including 5 HTL epitopes and 4 CTL, which were linked to the final vaccine by GPGPG and AAY linkers, respectively. Beta defensin was included as an adjuvant through the EAAAK linker to improve the immunogenicity of the polypeptide. To ensure its safety and immunogenicity profile, antigenicity, allergenicity, and various physiochemical attributes of the polypeptide were evaluated. Molecular docking was conducted between TLR4 and vaccine to evaluate the binding affinity and molecular interactions. For stability assessment and binding of the vaccine-TLR4 docked complex, molecular dynamics (MD) simulation and MMGBSA binding free-energy analyses were conducted. Finally, the candidate vaccine was cloned in silico to ensure its effectiveness. The current vaccine requires future experimental confirmation to validate its effectiveness. The vaccine construct produced might be useful in providing immune protection against HCV-related infections.	[Ahmad, Sajjad] Abasyn Univ, Dept Hlth & Biol Sci, Peshawar 25000, Pakistan; [Shahid, Farah] Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan; [Tahir ul Qamar, Muhammad] Guangxi Univ, Coll Life Sci & Technol, Nanning 530004, Peoples R China; [Rehman, Habib ur] Faisalabad Med Univ, DHQ Hosp, Dept Med, Faisalabad 38000, Pakistan; [Abbasi, Sumra Wajid; Sajjad, Wasim; Ismail, Saba] Natl Univ Med Sci, NUMS Dept Biol Sci, Rawalpindi 46000, Pakistan; [Alrumaihi, Faris; Allemailem, Khaled S.; Almatroudi, Ahmad] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 51452, Saudi Arabia; [Ullah Saeed, Hafiz Fahad] King Edward Med Univ, Lahore 54000, Pakistan		Tahir ul Qamar, M (通讯作者)，Guangxi Univ, Coll Life Sci & Technol, Nanning 530004, Peoples R China.	sajjad.ahmad@abasyn.edu.pk; farahshahid24@gcuf.edu.pk; m.tahirulqamar@gxu.edu.cn; habiburrehman229@gmail.com; sumra.abbasi@numspak.edu.pk; sajjadw@numspak.edu.pk; sabaismail7@gmail.com; f_alrumaihi@qu.edu.sa; K.allemailem@qu.edu.sa; aamtrody@qu.edu.sa; fahadullah008@gmail.com	Ahmad, Sajjad/ABG-7863-2020; Rehman, Habib Ur/AAS-6886-2021; Tahir ul Qamar, Muhammad/E-5803-2015; Ismail, Saba/AAW-4921-2021	Ahmad, Sajjad/0000-0003-0754-1742; Rehman, Habib Ur/0000-0002-7223-6712; Tahir ul Qamar, Muhammad/0000-0003-4832-4250; Almatroudi, Ahmad/0000-0002-1491-6402; Alrumaihi, Faris/0000-0002-0850-5500; Ismail, saba/0000-0002-8793-2972; Allemailem, Khaled/0000-0002-6486-9835	Qassim University, Saudi Arabia	The APC was funded by Qassim University, Saudi Arabia.	Akache B, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040204; Al Kanaani Zaina, 2018, R Soc Open Sci, V5, P180257, DOI 10.1098/rsos.180257; Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w; Ali SA, 2009, INT J INFECT DIS, V13, P9, DOI 10.1016/j.ijid.2008.06.019; Angov E, 2011, BIOTECHNOL J, V6, P650, DOI 10.1002/biot.201000332; Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529; Ashfaq UA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245072; Ashfaq UA, 2016, NAT PROD RES, V30, P1866, DOI 10.1080/14786419.2015.1075527; Beaumont E, 2013, HEPATOLOGY, V57, P1303, DOI 10.1002/hep.26132; Benson D.A., 2011, NUCLEIC ACIDS RES, V39, pD32, DOI [DOI 10.1093/nar/gkq1079, 10.1093/nar/gkq1079]; Bin Sayed S, 2020, INT J PEPT RES THER, V26, P2089, DOI 10.1007/s10989-019-10003-8; Case D.A., 2018, AMBER 18 REFERENCE M; Center RJ, 2020, J BIOL CHEM, V295, P7179, DOI 10.1074/jbc.RA120.013015; Chen R, 2012, BIOTECHNOL ADV, V30, P1102, DOI 10.1016/j.biotechadv.2011.09.013; Chen Stephen L, 2006, Int J Med Sci, V3, P47; Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396; Csete J., 2008, VIRAL TIME BOMB HLTH; Davis GL, 2003, HEPATOLOGY, V38, P645, DOI 10.1053/jhep.2003.50364; Dawood RM, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4571-5; Dickson CJ, 2012, SOFT MATTER, V8, P9617, DOI 10.1039/c2sm26007g; Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Durdagi S, 2018, J MOL GRAPH MODEL, V85, P122, DOI 10.1016/j.jmgm.2018.07.010; Enayatkhani M, 2021, J BIOMOL STRUCT DYN, V39, P2857, DOI [10.1080/07391102.2020.1756411, 10.1080/07391102.2020.1857843]; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Filskov J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50365-z; Ford N, 2012, B WORLD HEALTH ORGAN, V90, P540, DOI 10.2471/BLT.11.097147; Forns X, 2000, HEPATOLOGY, V32, P618, DOI 10.1053/jhep.2000.9877; Frey SE, 2010, VACCINE, V28, P6367, DOI 10.1016/j.vaccine.2010.06.084; Garcia-Valtanen P, 2014, ANTIVIR RES, V101, P136, DOI 10.1016/j.antiviral.2013.11.009; Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936; Goodman AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025938; Gori A, 2013, AMINO ACIDS, V45, P257, DOI 10.1007/s00726-013-1526-9; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Houghton M, 2009, J HEPATOL, V51, P939, DOI 10.1016/j.jhep.2009.08.004; Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5; Jayasekera CR, 2014, NEW ENGL J MED, V370, P1869, DOI 10.1056/NEJMp1400160; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Johnson LS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-431; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Lin CL, 2011, J GASTROEN HEPATOL, V26, P123, DOI 10.1111/j.1440-1746.2010.06541.x; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Machida K, 2006, J VIROL, V80, P866, DOI 10.1128/JVI.80.2.866-874.2006; Manns MP, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.6; Maria R., 2017, IMPACT BIOINFORMATIC; Marin MQ, 2019, J VIROL, V93, DOI 10.1128/JVI.00055-19; Masavuli MG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01145; Memarnejadian A, 2009, PROTEIN PEPTIDE LETT, V16, P842, DOI 10.2174/092986609788681788; Memon MI, 2002, J VIRAL HEPATITIS, V9, P84, DOI 10.1046/j.1365-2893.2002.00329.x; Messina JP, 2015, HEPATOLOGY, V61, P77, DOI 10.1002/hep.27259; Meza B, 2017, INFECT GENET EVOL, V49, P309, DOI 10.1016/j.meegid.2017.02.007; Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h; Mittal A, 2020, INT J PEPT RES THER, V26, P2231, DOI 10.1007/s10989-020-10020-y; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Ojha R, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105375; Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042; Petruzziello A, 2016, WORLD J GASTROENTERO, V22, P7824, DOI 10.3748/wjg.v22.i34.7824; Probst A, 2011, J VIRAL HEPATITIS, V18, P745, DOI 10.1111/j.1365-2893.2011.01481.x; ProtParam E., 2017, EXPASY PROTPARAM TOO; Rajhi M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248249; Razavi H, 2020, GASTROENTEROL CLIN N, V49, P179, DOI 10.1016/j.gtc.2020.01.001; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Rogo L.D., 2011, BAYERO J PURE APPL, V4, P72, DOI [10.4314/bajopas.v4i1.16, DOI 10.4314/BAJOPAS.V4I1.16]; Roohvand F, 2011, EXPERT OPIN THER PAT, V21, P1811, DOI 10.1517/13543776.2011.630662; Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172; Rueckert C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003001; Sabet LP, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.22215; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Sarrazin C, 2010, GASTROENTEROLOGY, V138, P447, DOI 10.1053/j.gastro.2009.11.055; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Serviddio G., 2013, PRACTICAL MANAGEMENT; Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199; Shamriz S, 2016, COMPUT BIOL MED, V76, P24, DOI 10.1016/j.compbiomed.2016.06.015; Shehzadi A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-55; Sugiarto H, 2004, BIOCHEM BIOPH RES CO, V323, P721, DOI 10.1016/j.bbrc.2004.08.162; Tahir Ul Qamar Muhammad, 2020, PLoS One, V15, pe0244176, DOI 10.1371/journal.pone.0244176; ul Qamar MT, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00752-w; ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288; Thrift AP, 2017, NAT REV GASTRO HEPAT, V14, P122, DOI 10.1038/nrgastro.2016.176; Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8; ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7; Van Regenmortal Marc H. V., 1996, Methods (Orlando), V9, P465, DOI 10.1006/meth.1996.0054; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Waheed Y, 2009, WORLD J GASTROENTERO, V15, P5647, DOI 10.3748/wjg.15.5647; Wei Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148181; Wijesundara DK, 2018, J VIROL, V92, DOI 10.1128/JVI.02133-17; Williams R, 2006, HEPATOLOGY, V44, P521, DOI 10.1002/hep.21347; Yau AHL, 2014, CAN J GASTROENTEROL, V28, P445, DOI 10.1155/2014/549624; Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40	95	14	14	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							293	10.3390/vaccines9030293			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5QG	33801143	Green Published, gold			2022-04-29	WOS:000634207800001
J	Craxi, L; Casuccio, A; Amodio, E; Restivo, V				Craxi, Lucia; Casuccio, Alessandra; Amodio, Emanuele; Restivo, Vincenzo			Who Should Get COVID-19 Vaccine First? A Survey to Evaluate Hospital Workers' Opinion	VACCINES			English	Article						COVID-19 vaccine; prioritization; allocation; distribution; public health ethics; healthcare workers	ALLOCATION; STATES; CARE	Prospective planning of COVID-19 vaccines allocation will be essential to maximize public health and societal benefits while preserving equity. Decisions about how to allocate limited supplies of vaccines need to be clear about the criteria used in setting priorities, with a specific commitment to transparency and communication. The aim of our study was to think through these competing demands, focusing on the opinion of healthcare workers (HCWs). The primary endpoint of the study was to assess the opinion of all the HCWs in a University based Italian Hospital about the fairest priority order to COVID 19 vaccines and to understand on which criteria the prioritization preferences of HCWs are implicitly based. The secondary endpoints were to assess whether HCWs approach differs from national guidelines and to assess the attitude of HCWs towards mandatory vaccination. An online survey accounting with multiple choice single answer questions and ranking questions was administered to all the HCWs of the University Hospital P. Giaccone of Palermo (Italy) and completed by a total of 465 participants. Almost all respondents confirmed the need for prioritization in COVID-19 vaccination for HCWs (n = 444; 95.5%), essential services and law enforcement (both n = 428; 92%). Clinically vulnerable individuals, HCWs and population over 65 years have been considered the first three groups to be involved in getting vaccination, being indicated as first position group by 26.5%, 32.5% and 21.9% of respondents, respectively. A large majority of respondents (85%) asked for a consistent, transparent and detailed order of priority at a national level. After adjusting for potential confounding due to sex and age, physicians have been found to be statistically significantly associated with the choice of mandatory vaccination (odds ratio (OR): 10.2; 95% confidence interval (CI) = 2.7-39.1) or with other strategies different from voluntary (OR = 7.2; 95% CI = 1.9-27.3). The broad consensus expressed by respondents towards mandatory vaccination for HCWs is extremely relevant at a time when vaccination hesitation is one of the biggest obstacles to achieving herd immunity. Data show a mismatch in the position attributed to long-term care residents compared to the position of absolute priority assigned by most of national distribution plans, impelling us to reflect on the issue of maximizing benefit from limited healthcare resources. Our findings clearly indicate a preference for COVID-19 frontline health professionals as the first tier of recipients, since they better meet all the criteria (higher risk, immediate system stability). As the guidelines are likely to directly affect a considerable number of citizens, our results call for policy interventions to inform people on the ethical rationale behind vaccine distribution decisions, to avoid resentment and feelings of unfairness.	[Craxi, Lucia] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, I-90127 Palermo, Italy; [Casuccio, Alessandra; Amodio, Emanuele; Restivo, Vincenzo] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, I-90127 Palermo, Italy		Casuccio, A (通讯作者)，Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, I-90127 Palermo, Italy.	lucia.craxi@unipa.it; alessandra.casuccio@unipa.it; emanuele.amodio@unipa.it; vincenzo.restivo@unipa.it	; Craxi, Lucia/F-2269-2018	Restivo, Vincenzo/0000-0002-5406-884X; Craxi, Lucia/0000-0002-3997-1504; casuccio, alessandra/0000-0002-5676-9535; Amodio, Emanuele/0000-0001-5482-5268			[Anonymous], EUROPEAN MED AGENCY; [Anonymous], INDEPENDENT REPORT J; [Anonymous], ANELLI FNOMCEO PREOC; [Anonymous], Ministero della Salute Presidenza del Consiglio dei Ministri Istituto Superiore di Sanita Agenzia Nazionale per i Servizi Sanitari Regionali Agenzia Italiana del Farmaco Vaccinazione anti-SARS-CoV-2/COVID-19. Piano Strategico; Arora C, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0152-y; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; CDC, 2020, CTR DIS CONTROL PREV; Craxi L., BENEFICENCE EQUITY C; Craxi L, 2020, ASIAN BIOETHICS REV, V12, P325, DOI 10.1007/s41649-020-00127-1; Cushman F, 2006, PSYCHOL SCI, V17, P1082, DOI 10.1111/j.1467-9280.2006.01834.x; Department of Health and Social Care, UK COVID 19 VACC DEL; Dooling K, 2021, MMWR-MORBID MORTAL W, V69, P1657, DOI 10.15585/mmwr.mm695152e2; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; European Centre for Disease Prevention and Control European Centre for Disease Prevention and Control, OV COVID 19 VACC STR; Fallucchi F, 2021, J MED ETHICS, V47, P3, DOI 10.1136/medethics-2020-106524; Faravelli M, 2007, J PUBLIC ECON, V91, P1399, DOI 10.1016/j.jpubeco.2007.01.004; Kahn B., 2020, FRAMEWORK EQUITABLE, DOI [10.17226/25917, DOI 10.17226/25917]; Kambhampati AK, 2020, MMWR-MORBID MORTAL W, V69, P1576, DOI 10.15585/mmwr.mm6943e3; Konow J, 2003, J ECON LIT, V41, P1188, DOI 10.1257/002205103771800013; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lahner E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124417; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; R DEVELOPMENT CORE TEAM, 2008, R LANGUAGE ENV STAT; Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492; The Centers for Disease Control and Prevention, COVID 19 VACC PROGR; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1	28	8	8	1	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							189	10.3390/vaccines9030189			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE6GE	33668695	gold, Green Published			2022-04-29	WOS:000634249200001
J	Francica, JR; Shi, W; Chuang, GY; Chen, SJ; Pereira, LD; Farney, SK; Flynn, BJ; Ou, L; Stephens, T; Tsybovsky, Y; Wang, LT; Anderson, A; Beck, Z; Dillon, M; Idris, AH; Hurlburt, N; Liu, T; Zhang, BS; Alving, CR; Matyas, GR; Pancera, M; Mascola, JR; Kwong, PD; Seder, RA				Francica, Joseph R.; Shi, Wei; Chuang, Gwo-Yu; Chen, Steven J.; Da Silva Pereira, Lais; Farney, S. Katie; Flynn, Barbara J.; Ou, Li; Stephens, Tyler; Tsybovsky, Yaroslav; Wang, Lawrence T.; Anderson, Alexander; Beck, Zoltan; Dillon, Marlon; Idris, Azza H.; Hurlburt, Nicholas; Liu, Tracy; Zhang, Baoshan; Alving, Carl R.; Matyas, Gary R.; Pancera, Marie; Mascola, John R.; Kwong, Peter D.; Seder, Robert A.			Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria	VACCINES			English	Article						junctional epitope; malaria; neutralizing antibodies; parasite; Plasmodium falciparum; vaccines; virus-like particle		The most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the Plasmodium falciparum circumsporozoite protein (PfCSP). We have recently isolated human antibodies that target the junctional region between the N-terminal and repeat domains that are not included in RTS,S. Due to the fact that these antibodies protect against malaria challenge in mice, their epitopes could be effective vaccine targets. Here, we developed immunogens displaying PfCSP junctional epitopes by genetic fusion to either the N-terminus or B domain loop of the E2 protein from chikungunya (CHIK) alphavirus and produced CHIK virus-like particles (CHIK-VLPs). The structural integrity of these junctional-epitope-CHIK-VLP immunogens was confirmed by negative-stain electron microscopy. Immunization of these CHIK-VLP immunogens reduced parasite liver load by up to 95% in a mouse model of malaria infection and elicited better protection than when displayed on keyhole limpet hemocyanin, a commonly used immunogenic carrier. Protection correlated with PfCSP serum titer. Of note, different junctional sequences elicited qualitatively different reactivities to overlapping PfCSP peptides. Overall, these results show that the junctional epitopes of PfCSP can induce protective responses when displayed on CHIK-VLP immunogens and provide a basis for the development of a next generation malaria vaccine to expand the breadth of anti-PfCSP immunity.	[Francica, Joseph R.; Shi, Wei; Chuang, Gwo-Yu; Chen, Steven J.; Da Silva Pereira, Lais; Farney, S. Katie; Flynn, Barbara J.; Ou, Li; Wang, Lawrence T.; Dillon, Marlon; Idris, Azza H.; Liu, Tracy; Zhang, Baoshan; Pancera, Marie; Mascola, John R.; Kwong, Peter D.; Seder, Robert A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Stephens, Tyler; Tsybovsky, Yaroslav] NCI, Electron Microscopy Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA; [Anderson, Alexander; Beck, Zoltan; Alving, Carl R.; Matyas, Gary R.] US Mil HIV Res Program, Lab Adjuvant & Antigen Res, Walter Reed Army Inst Res, Silver Spring, MD 20910 USA; [Hurlburt, Nicholas; Pancera, Marie] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA; [Beck, Zoltan] Pfizer, 401 N Middletown Rd, Pearl River, NY 10965 USA		Kwong, PD; Seder, RA (通讯作者)，NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	joe.francica@nih.gov; shiw@mail.nih.gov; gwo-yu.chuang@nih.gov; steven.chen2@nih.gov; lais.dasilvapereira@nih.gov; katie.farney@nih.gov; bflynn@mail.nih.gov; li.ou@nih.gov; tyler.stephens@nih.gov; yaroslav.tsybovsky@nih.gov; lawrence.wang@nih.gov; aanderson@hivresearch.org; zoltan.beck@gmail.com; dillonm@mail.nih.gov; azza.idris@nih.gov; nhurlbur@fredhutch.org; tracy.liu@nih.gov; baoshan.zhang@nih.gov; calving@hivresearch.org; gmatyas@hivresearch.org; mpancera@fredhutch.org; jmascola@nih.gov; pdkwong@nih.gov; rseder@mail.nih.gov		Idris, Azza/0000-0003-1847-5488; Farney, Katie/0000-0002-8785-8039; Kwong, Peter/0000-0003-3560-232X; Alving, Carl/0000-0002-1913-3909; Hurlburt, Nicholas/0000-0001-9891-916X	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Frederick National Laboratory for Cancer Research, NIH [HHSN261200800001E]; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1156262]	This research was funded by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA, by Federal funds from Frederick National Laboratory for Cancer Research, NIH, under Contract No. HHSN261200800001E (T. Stephens and Y. Tsybovsky), and by a grant from the Bill and Melinda Gates Foundation OPP1156262 (N. Hurlburt and M. Pancera).	Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105; Alving CR, 2020, EXPERT REV VACCINES, V19, P279, DOI 10.1080/14760584.2020.1745636; Calvo-Calle JM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00272-6; Cawlfield A, 2019, VACCINE, V37, P3793, DOI 10.1016/j.vaccine.2019.05.059; Chaturvedi N, 2016, INDIAN J MED RES, V143, P696, DOI 10.4103/0971-5916.191927; Chaudhury S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1348-9; Chen GL, 2020, JAMA-J AM MED ASSOC, V323, P1369, DOI 10.1001/jama.2020.2477; Cheng C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215163; Chuang GY, 2020, J VIROL, V94, DOI 10.1128/JVI.00074-20; Cisse B, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002175; Cockburn IA, 2018, NAT IMMUNOL, V19, P1199, DOI 10.1038/s41590-018-0228-6; Collins KA, 2017, SCI REP-UK, V7, DOI 10.1038/srep46621; Dobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-z; Epstein JE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89154; Flores-Garcia Y, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-3055-9; Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/ERV.11.29, 10.1586/erv.11.29]; Genito CJ, 2017, VACCINE, V35, P3865, DOI 10.1016/j.vaccine.2017.05.070; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Illingworth JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01254; Jelinkova L, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00274-4; Jongo SA, 2018, AM J TROP MED HYG, V99, P338, DOI 10.4269/ajtmh.17-1014; KASLOW DC, 1994, BIO-TECHNOL, V12, P494, DOI 10.1038/nbt0594-494; Kisalu NK, 2018, NAT MED, V24, P408, DOI 10.1038/nm.4512; Kong R, 2019, CELL, V178, P567, DOI 10.1016/j.cell.2019.06.030; Langowski MD, 2020, P NATL ACAD SCI USA, V117, P3114, DOI 10.1073/pnas.1911792117; Mendis K, 2009, TROP MED INT HEALTH, V14, P802, DOI 10.1111/j.1365-3156.2009.02287.x; Murugan R, 2020, NAT MED, V26, P1135, DOI 10.1038/s41591-020-0881-9; Oyen D, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008373; Oyen D, 2017, P NATL ACAD SCI USA, V114, pE10438, DOI 10.1073/pnas.1715812114; Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96381; Phoicharee T, 2020, J MOL BIOL, V432, P1048, DOI 10.1016/j.jmb.2019.12.029; Programme G.M., 2019, WORLD MALARIA REPORT 2012, P232; Regules JA, 2016, J INFECT DIS, V214, P762, DOI 10.1093/infdis/jiw237; Schwenk R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111020; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Shimp RL, 2013, VACCINE, V31, P2954, DOI 10.1016/j.vaccine.2013.04.034; Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/S1473-3099(17)30104-4, 10.1016/s1473-3099(17)30104-4]; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Strode C, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001619; Tan J, 2018, NAT MED, V24, P401, DOI 10.1038/nm.4513; Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009; Thompson HA, 2020, VACCINE, V38, P7498, DOI 10.1016/j.vaccine.2020.09.069; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Urakami A, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00090-17; Voss JE, 2010, NATURE, V468, P709, DOI 10.1038/nature09555; Wang LT, 2020, IMMUNITY, V53, P733, DOI 10.1016/j.immuni.2020.08.014; White MT, 2015, LANCET INFECT DIS, V15, P1450, DOI 10.1016/S1473-3099(15)00239-X; White MT, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0117-2; White MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061395; World Health Organization, 2020, MALARIA; Xu K, 2018, NAT MED, V24, P857, DOI 10.1038/s41591-018-0042-6	52	6	6	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							272	10.3390/vaccines9030272			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5WF	33803622	Green Published, gold			2022-04-29	WOS:000634223300001
J	Herrera, C; McRaven, MD; Laing, KG; Dennis, J; Hope, TJ; Shattock, RJ				Herrera, Carolina; McRaven, Mike D.; Laing, Ken G.; Dennis, Jayne; Hope, Thomas J.; Shattock, Robin J.			Early Colorectal Responses to HIV-1 and Modulation by Antiretroviral Drugs	VACCINES			English	Article						HIV-1; mucosal tissue; antiretrovirals; pre-exposure prophylaxis		Innate responses during acute HIV infection correlate with disease progression and pathogenesis. However, limited information is available about the events occurring during the first hours of infection in the mucosal sites of transmission. With an ex vivo HIV-1 challenge model of human colorectal tissue we assessed the mucosal responses induced by R5- and X4-tropic HIV-1 isolates in the first 24 h of exposure. Microscopy studies demonstrated virus penetration of up to 39 mu m into the lamina propia within 6 h of inoculation. A rapid, 6 h post-challenge, increase in the level of secretion of inflammatory cytokines, chemokines, interferon- gamma (IFN-gamma), and granulocyte-macrophage colony-stimulating factor (GM-CSF) was observed following exposure to R5- or X4-tropic isolates. This profile persisted at the later time point measured of 24 h. However, exposure to the X4-tropic isolate tested induced greater changes at the proteomic and transcriptomic levels than the R5-tropic. The X4-isolate induced greater levels of CCR5 ligands (RANTES, MIP-1 alpha and MIP-1 beta) secretion than R5-HIV-1. Potential drugs candidates for colorectal microbicides, including entry, fusion or reverse transcriptase inhibitors demonstrated differential capacity to modulate these responses. Our findings indicate that in colorectal tissue, inflammatory responses and a Th1 cytokine profile are induced in the first 24 h following viral exposure.	[Herrera, Carolina; Shattock, Robin J.] St Georges Univ London, Div Clin Sci, Ctr Infect & Immun, London SW17 0RE, England; [McRaven, Mike D.; Hope, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Laing, Ken G.; Dennis, Jayne] St Georges Univ London, Div Clin Sci, London SW17 0RE, England; [Herrera, Carolina; Shattock, Robin J.] Imperial Coll London, Dept Med, London W2 1PG, England; [Dennis, Jayne] Queen Mary Univ London, Sch Biol & Chem Sci, London E1 4NS, England		Herrera, C (通讯作者)，St Georges Univ London, Div Clin Sci, Ctr Infect & Immun, London SW17 0RE, England.; Herrera, C (通讯作者)，Imperial Coll London, Dept Med, London W2 1PG, England.	cherrer1@imperial.ac.uk; mcraven@northwestern.edu; klaing@sgul.ac.uk; jayne.dennis@qmul.ac.uk; thope@northwestern.edu; r.shattock@imperial.ac.uk		Dennis, Jayne/0000-0002-2170-7617; Herrera, Carolina/0000-0003-3701-752X; McRaven, Michael/0000-0002-3098-1394	amfAR [106756-41-RFMT]; NIH IPCP grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U19 AI060614]	This research was funded by amfAR, grant number 106756-41-RFMT and support from NIH IPCP grant U19 AI060614.	Abel K, 2005, J VIROL, V79, P12164, DOI 10.1128/JVI.79.19.12164-12172.2005; Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Anton PA, 2000, AIDS, V14, P1761, DOI 10.1097/00002030-200008180-00011; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Bebell LM, 2008, J INFECT DIS, V198, P710, DOI 10.1086/590503; Biswas N, 2014, ANTIMICROB AGENTS CH, V58, P6444, DOI 10.1128/AAC.03270-14; Brand RM, 2018, J IMMUNOL METHODS, V463, P39, DOI 10.1016/j.jim.2018.08.009; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Carias AM, 2013, J VIROL, V87, P11388, DOI 10.1128/JVI.01377-13; Chaillon A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew012; Colin P, 2013, P NATL ACAD SCI USA, V110, P9475, DOI 10.1073/pnas.1222205110; Deeks SG, 2013, IMMUNITY, V39, P633, DOI 10.1016/j.immuni.2013.10.001; Duncan CJA, 2011, VIRUSES-BASEL, V3, P2255, DOI 10.3390/v3112255; Fletcher PS, 2006, AIDS, V20, P1237, DOI 10.1097/01.aids.0000232230.96134.80; Francis SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0143109; Gordon CJ, 1999, J VIROL, V73, P684, DOI 10.1128/JVI.73.1.684-694.1999; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grivel JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S6; Harman S, 2012, ANTIMICROB AGENTS CH, V56, P2347, DOI 10.1128/AAC.06108-11; Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08; Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1; Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302; Hladik F, 2015, ELIFE, V4, DOI 10.7554/eLife.04525; Ito Y, 2004, J INFECT DIS, V189, P506, DOI 10.1086/381153; Kalichman SC, 2002, INT J STD AIDS, V13, P677, DOI 10.1258/095646202760326426; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kelley CF, 2017, MUCOSAL IMMUNOL, V10, P996, DOI 10.1038/mi.2016.97; Lapenta C, 1999, EUR J IMMUNOL, V29, P1202, DOI 10.1002/(SICI)1521-4141(199904)29:04<1202::AID-IMMU1202>3.0.CO;2-O; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lee C, 2003, J LEUKOCYTE BIOL, V74, P676, DOI 10.1189/jlb.0503206; Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564; Li H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000890; Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Marozsan AJ, 2005, VIROLOGY, V338, P182, DOI 10.1016/j.virol.2005.04.035; McClure CP, 2013, HIV MED, V14, P108, DOI 10.1111/hiv.12002; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Nicol MR, 2018, J CLIN PHARMACOL, V58, P1381, DOI 10.1002/jcph.1270; Olsson J, 2000, J INFECT DIS, V182, P1625, DOI 10.1086/317625; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Poles MA, 2001, J VIROL, V75, P8390, DOI 10.1128/JVI.75.18.8390-8399.2001; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Shanmugasundaram U, 2014, AM J REPROD IMMUNOL, V71, P95, DOI 10.1111/aji.12182; Shen RZ, 2014, J VIROL, V88, P7683, DOI 10.1128/JVI.00766-14; Shen RZ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002060; Shen RZ, 2010, J LEUKOCYTE BIOL, V87, P663, DOI 10.1189/jlb.0909605; Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08; Smith PD, 2011, MUCOSAL IMMUNOL, V4, P31, DOI 10.1038/mi.2010.66; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003	55	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							231	10.3390/vaccines9030231			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6AN	33800213	Green Published, gold, Green Accepted			2022-04-29	WOS:000634234500001
J	Boszormenyi, K; Hirsch, J; Kayere, GK; Fagrouch, Z; Heijmans, N; Garcia, RR; Dwarka, S; van Dijke, A; Aaldijk, B; Limpens, R; Barcena, M; Koster, B; Verstrepen, B; Bogers, W; Kocken, C; Cornellissen, G; Verschoor, E; Faber, B				Boszormenyi, Kinga; Hirsch, Janet; Kayere, Gwendoline Kiemenyi; Fagrouch, Zahra; Heijmans, Nicole; Garcia, Roberto Rodriguez; Dwarka, Soesjiel; van Dijke, Amy; Aaldijk, Boyd; Limpens, Ronald; Barcena, Montserrat; Koster, Bram; Verstrepen, Babs; Bogers, Willy; Kocken, Clemens; Cornellissen, Gesine; Verschoor, Ernst; Faber, Bart			A Bacterially-Expressed Recombinant Envelope Protein from Usutu Virus Induces Neutralizing Antibodies in Rabbits	VACCINES			English	Article						Usutu virus; USUV; vaccine development; flavivirus; emerging disease; recombinant E protein; neutralizing antibodies	WEST-NILE; EMERGENCE; INFECTION; FLAVIVIRUS; AUSTRIA; FRANCE; EUROPE; SPREAD; SPAIN	Background: Recently, an emerging flavivirus, Usutu virus (USUV), has caused an epidemic among birds in Europe, resulting in a massive die-off in Eurasian blackbirds. Currently found only in Europe and Africa, it can be envisioned that Usutu virus will follow the path of other flaviviruses, like West Nile virus and Zika virus, and will spread via its mosquito vectors and bird hosts to other parts of the world. Several cases of human infections by Usutu virus have already been published. Anticipating this spread, development of an efficacious vaccine would be highly desirable. Method: This study describes the production in E. coli, purification, and refolding of a partial USUV envelope protein. Prior to immunization, the protein was characterized using size exclusion chromatography, transmission electron microscopy and dynamic light scattering, showing the limited presence of virus-like structures, indicating that the protein solution is probably a mixture of mono and multimeric envelope proteins. Results: Immunizations of two rabbits with the refolded E-protein fraction, mixed with a strong adjuvant, resulted in the generation of neutralizing antibodies, as evidenced in an in vitro assay. Discussion: The way forward towards a subunit vaccine against Usutu virus infection is discussed.	[Boszormenyi, Kinga; Kayere, Gwendoline Kiemenyi; Fagrouch, Zahra; Verstrepen, Babs; Bogers, Willy; Verschoor, Ernst] Biomed Primate Res Ctr, Dept Virol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands; [Hirsch, Janet; Cornellissen, Gesine] Hamburg Univ Appl Sci, Dept Biotechnol, Ulmenliet 20, D-21033 Hamburg, Germany; [Heijmans, Nicole; Garcia, Roberto Rodriguez; Dwarka, Soesjiel; van Dijke, Amy; Aaldijk, Boyd; Kocken, Clemens; Faber, Bart] Biomed Primate Res Ctr, Dept Parasitol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands; [Limpens, Ronald; Barcena, Montserrat; Koster, Bram] Leiden Univ, Sect Electron Microscopy, Med Ctr, Einthovenweg 20, NL-2300 RC Leiden, Netherlands		Boszormenyi, K (通讯作者)，Biomed Primate Res Ctr, Dept Virol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands.; Faber, B (通讯作者)，Biomed Primate Res Ctr, Dept Parasitol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands.	Boszormenyi@bprc.nl; janet.medina.hirsch@gmail.com; kayere@bprc.nl; Fagrouch@bprc.nl; n.heijmans@bprc.nl; Rodriguez@bprc.nl; soesjieldwarka@gmail.com; amyvdijke@gmail.com; boydaaldijk@gmail.com; r.w.a.l.limpens@lumc.nl; M.Barcena@lumc.nl; A.J.Koster@lumc.nl; verstrepen@bprc.nl; bogers@bprc.nl; Kocken@bprc.nl; gesine.cornelissen@haw-hamburg.de; Verschoor@bprc.nl; Faber@bprc.nl	Barcena, Montserrat/B-5823-2012	Barcena, Montserrat/0000-0002-7719-4443; Limpens, Ronald/0000-0002-6243-6729; Boszormenyi, Kinga/0000-0001-5330-2617; Verschoor, Ernst/0000-0003-0912-2074; Verstrepen, Babs E/0000-0002-4666-0798; Bogers, Willy/0000-0002-4563-8513; Kocken, Clemens/0000-0002-4784-1734; Faber, Bart/0000-0001-6808-1204	European Union's Marie Sklodowska-Curie Innovative Training Network HONOURs [721367]	K.B. was supported by the European Union's Marie Sklodowska-Curie Innovative Training Network HONOURs; grant agreement no. 721367.	Ashraf U, 2015, VIRUSES-BASEL, V7, P219, DOI 10.3390/v7010219; Bakonyi T, 2007, J CLIN MICROBIOL, V45, P3870, DOI 10.1128/JCM.01390-07; Bakonyi T, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.41.17-00644; Bakonyi T, 2014, VECTOR-BORNE ZOONOT, V14, P324, DOI 10.1089/vbz.2013.1510; Bazanow B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020087; Becker N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032604; Brault AC, 2007, NAT GENET, V39, P1162, DOI 10.1038/ng2097; Cadar D, 2017, EUROSURVEILLANCE, V22, P9, DOI [10.2807/1560-7917.es.2017.22.14.30501, 10.2807/1560-7917.ES.2017.22.14.30501]; Cavrini F, 2009, EUROSURVEILLANCE, V14, P17; Chvala S, 2007, VET MICROBIOL, V122, P237, DOI 10.1016/j.vetmic.2007.01.029; Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058; Engel D, 2016, MBIO, V7, DOI 10.1128/mBio.01938-15; Faggioni G, 2018, J MED VIROL, V90, P1666, DOI 10.1002/jmv.25230; Gaibani P, 2017, MICROBES INFECT, V19, P382, DOI 10.1016/j.micinf.2017.05.003; Garigliany MM, 2014, VET J, V199, P191, DOI 10.1016/j.tvjl.2013.10.017; Grottola A, 2017, CLIN MICROBIOL INFEC, V23, P33, DOI 10.1016/j.cmi.2016.09.019; Guerrero NAS, 2018, ANTIVIR RES, V160, P137, DOI 10.1016/j.antiviral.2018.10.026; Hirsch J, 2020, VACCINE, V38, P3305, DOI 10.1016/j.vaccine.2020.03.003; Hubalek Z, 2014, TRANSBOUND EMERG DIS, V61, P273, DOI 10.1111/tbed.12025; Jost H, 2011, AM J TROP MED HYG, V85, P551, DOI 10.4269/ajtmh.2011.11-0248; Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998; Lecollinet S, 2016, EMERG INFECT DIS, V22, P2225, DOI 10.3201/eid2212.161272; Luhken R, 2017, EMERG INFECT DIS, V23, P1991, DOI 10.3201/eid2312.171257; Mani S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064595; Martin-Acebes MA, 2016, VACCINE, V34, P2066, DOI 10.1016/j.vaccine.2016.03.015; Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402; Metz SW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12677-6; Mooij P, 2019, VACCINE, V37, P817, DOI 10.1016/j.vaccine.2018.12.049; Musso D, 2018, LANCET INFECT DIS, V18, pE355, DOI [10.1016/S1473-3099(18)30269-X, 10.1016/s1473-3099(18)30269-x]; Nagy A, 2019, EUROSURVEILLANCE, V24, P24, DOI 10.2807/1560-7917.ES.2019.24.28.1900038; Nikolay B, 2015, T ROY SOC TROP MED H, V109, P609, DOI 10.1093/trstmh/trv066; Nikolay B, 2011, VECTOR-BORNE ZOONOT, V11, P1417, DOI 10.1089/vbz.2011.0631; Nybakken GE, 2006, J VIROL, V80, P11467, DOI 10.1128/JVI.01125-06; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pauli G, 2014, TRANSFUS MED HEMOTH, V41, P73, DOI 10.1159/000357106; Pecorari M, 2009, EUROSURVEILLANCE, V14, P15; Percivalle E, 2017, VECTOR-BORNE ZOONOT, V17, P658, DOI 10.1089/vbz.2017.2126; Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; REED L. J., 1938, AMER JOUR HYG, V27, P493; Remarque EJ, 2008, INFECT IMMUN, V76, P2660, DOI 10.1128/IAI.00170-08; Rijks J, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.45.30391; Salinas S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005913; Simonin Y, 2018, EMERG INFECT DIS, V24, P875, DOI 10.3201/eid2405.171122; Sobh A, 2016, J ALLER CL IMM-PRACT, V4, P1066, DOI 10.1016/j.jaip.2016.09.012; Steinmetz HW, 2011, VET MICROBIOL, V148, P207, DOI 10.1016/j.vetmic.2010.09.018; Tsetsarkin KA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002412; Vazquez A, 2011, AM J TROP MED HYG, V85, P178, DOI 10.4269/ajtmh.2011.11-0042; Venter M, 2018, CURR OPIN VIROL, V28, P74, DOI 10.1016/j.coviro.2017.11.004; Weissenbock H, 2003, MICROBES INFECT, V5, P1132, DOI 10.1016/S1286-4579(03)00204-1; Weissenbock H, 2002, EMERG INFECT DIS, V8, P652, DOI 10.3201/eid0807.020094; Weissenbock H, 2013, EMERG INFECT DIS, V19, P274, DOI 10.3201/eid1902.121191; Zhang XC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110338	53	1	1	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							157	10.3390/vaccines9020157			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7EL	33669414	Green Published, gold			2022-04-29	WOS:000623303000001
J	Miccoli, A; Manni, M; Picchietti, S; Scapigliati, G				Miccoli, Andrea; Manni, Matteo; Picchietti, Simona; Scapigliati, Giuseppe			State-of-the-Art Vaccine Research for Aquaculture Use: The Case of Three Economically Relevant Fish Species	VACCINES			English	Review						adjuvants; aquaculture; experimental challenge; fish immunology; fish welfare; infectious diseases; vaccines		In the last three decades, the aquaculture sector has experienced a 527% growth, producing 82 million tons for a first sale value estimated at 250 billion USD. Infectious diseases caused by bacteria, viruses, or parasites are the major causes of mortality and economic losses in commercial aquaculture. Some pathologies, especially those of bacterial origin, can be treated with commercially available drugs, while others are poorly managed. In fact, despite having been recognized as a useful preventive measure, no effective vaccination against many economically relevant diseases exist yet, such as for viral and parasitic infections. The objective of the present review is to provide the reader with an updated perspective on the most significant and innovative vaccine research on three key aquaculture commodities. European sea bass (Dicentrarchus labrax), Nile tilapia (Oreochromis niloticus), and Atlantic salmon (Salmo salar) were chosen because of their economic relevance, geographical distinctiveness, and representativeness of different culture systems. Scientific papers about vaccines against bacterial, viral, and parasitic diseases will be objectively presented; their results critically discussed and compared; and suggestions for future directions given.	[Miccoli, Andrea; Manni, Matteo; Picchietti, Simona; Scapigliati, Giuseppe] Univ Tuscia, Dept Innovat Biol Agrofood & Forest Syst, Largo Univ Snc, I-01100 Viterbo, Italy		Miccoli, A (通讯作者)，Univ Tuscia, Dept Innovat Biol Agrofood & Forest Syst, Largo Univ Snc, I-01100 Viterbo, Italy.	andrea.miccoli@unitus.it; mmanni17@gmail.com; picchietti@unitus.it; scapigg@unitus.it	Miccoli, Andrea/AAA-9006-2020	Miccoli, Andrea/0000-0002-4545-7229; scapigliati, giuseppe/0000-0001-9730-9394; PICCHIETTI, Simona/0000-0002-6116-213X	Italian Ministry of Education, University and Research, DIBAF-Department for Innovation in Biological, Agro-food and Forest Systems, University of Tuscia	This research was supported by the "Department of Excellence-2018" Program (Dipartimenti di Eccellenza) of the Italian Ministry of Education, University and Research, DIBAF-Department for Innovation in Biological, Agro-food and Forest Systems, University of Tuscia, Project "Landscape 4.0-food, wellbeing and environment".	Abu-Elala NM, 2019, FISH SHELLFISH IMMUN, V88, P293, DOI 10.1016/j.fsi.2019.02.042; Amenyogbe E, 2020, AQUACULT INT, V28, P1017, DOI 10.1007/s10499-020-00509-0; [Anonymous], 2020, STATE WORLD FISHERIE; [Anonymous], GILL DIS COST SALMON; [Anonymous], YIELD IMPROVEMENT SE; Avendano-Herrera R, 2006, DIS AQUAT ORGAN, V71, P255, DOI 10.3354/dao071255; Bactol IDC, 2018, INT J AGRIC BIOL, V20, P846, DOI 10.17957/IJAB/15.0575; Ballesteros NA, 2015, FISH SHELLFISH IMMUN, V45, P877, DOI 10.1016/j.fsi.2015.05.045; Barnes AC, 2005, DEV BIOLOGICALS, V121, P75; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Boerlage AS, 2020, REV AQUACULT, V12, P2140, DOI 10.1111/raq.12426; Bogwald J, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120627; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Brudeseth BE, 2013, FISH SHELLFISH IMMUN, V35, P1759, DOI 10.1016/j.fsi.2013.05.029; Byadgi O, 2019, FISH SHELLFISH IMMUN, V84, P62, DOI 10.1016/j.fsi.2018.09.069; Cabillon NAR, 2019, FISHES-BASEL, V4, DOI 10.3390/fishes4010002; Carpio Y, 2011, VACCINE, V29, P2810, DOI 10.1016/j.vaccine.2011.01.109; Caruffo M, 2016, FISH SHELLFISH IMMUN, V54, P54, DOI 10.1016/j.fsi.2016.03.009; Chang CJ, 2017, J FISH DIS, V40, P1775, DOI 10.1111/jfd.12644; Chang CJ, 2015, VACCINE, V33, P2442, DOI 10.1016/j.vaccine.2015.03.093; Chin A, 2005, PARASITOL RES, V95, P299, DOI 10.1007/s00436-004-1270-x; Criollo-Joaquin Mónica, 2019, Rev. peru biol., V26, P301, DOI 10.15381/rpb.v26i3.15516; Das PK, 2020, FISH SHELLFISH IMMUN, V104, P165, DOI 10.1016/j.fsi.2020.05.076; Daskalov GM, 2007, P NATL ACAD SCI USA, V104, P10518, DOI 10.1073/pnas.0701100104; Eichner C, 2014, EXP PARASITOL, V140, P44, DOI 10.1016/j.exppara.2014.03.014; Galindo-Villegas J, 2013, FISH SHELLFISH IMMUN, V35, P1260, DOI 10.1016/j.fsi.2013.07.046; Gao LY, 2006, INFECT IMMUN, V74, P1757, DOI 10.1128/IAI.74.3.1757-1767.2006; Gauthier DT, 2009, VET J, V180, P33, DOI 10.1016/j.tvjl.2008.05.012; Gonzalez-Silvera D, 2019, FISH SHELLFISH IMMUN, V88, P458, DOI 10.1016/j.fsi.2019.03.013; Gudding R, 2013, FISH SHELLFISH IMMUN, V35, P1683, DOI 10.1016/j.fsi.2013.09.031; Gupta M.V., 2004, AQUAC ASIA, VIX, P1; Haatveit HM, 2018, VACCINE, V36, P7599, DOI 10.1016/j.vaccine.2018.10.094; Hoare R, 2019, FISH SHELLFISH IMMUN, V85, P44, DOI 10.1016/j.fsi.2017.10.005; Huang LY, 2014, FISH SHELLFISH IMMUN, V38, P34, DOI 10.1016/j.fsi.2014.02.017; Igarashi A, 2002, FISH PATHOL, V37, P145, DOI 10.3147/jsfp.37.145; Ina-Salwany MY, 2019, J AQUAT ANIM HEALTH, V31, P3, DOI 10.1002/aah.10045; Irhayyim T, 2020, J CENT EUR AGRIC, V21, P246, DOI 10.5513/JCEA01/21.2.2672; Iversen A, 2020, AQUACULTURE, V522, DOI 10.1016/j.aquaculture.2020.735089; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jia B, 2017, AQUACULTURE, V471, P146, DOI 10.1016/j.aquaculture.2017.01.016; Kayansamruaj P, 2017, AQUACULTURE, V468, P102, DOI 10.1016/j.aquaculture.2016.10.001; Khalil RH, 2018, AQUAC RES, V49, P2357, DOI 10.1111/are.13689; Kharat AS, 2003, INFECT IMMUN, V71, P2758, DOI 10.1128/IAI.71.5.2758-2765.2003; Klesius P.H., 1999, ADV VET MED; Kobayashi M, 2015, AQUACULT ECON MANAG, V19, P282, DOI 10.1080/13657305.2015.994240; Kwon HC, 2016, AQUACULTURE, V454, P125, DOI 10.1016/j.aquaculture.2015.12.005; Lai YX, 2014, VET IMMUNOL IMMUNOP, V157, P87, DOI 10.1016/j.vetimm.2013.10.003; Leal Y, 2019, FISH SHELLFISH IMMUN, V92, P322, DOI 10.1016/j.fsi.2019.06.018; Leung TLF, 2013, J APPL ECOL, V50, P215, DOI 10.1111/1365-2644.12017; Li LP, 2015, FISH SHELLFISH IMMUN, V45, P955, DOI 10.1016/j.fsi.2015.06.014; LI S, 1995, VET IMMUNOL IMMUNOP, V48, P343, DOI 10.1016/0165-2427(95)05445-C; Lin CS, 2001, VIROLOGY, V290, P50, DOI 10.1006/viro.2001.1157; Liu L, 2019, J FISH DIS, V42, P693, DOI 10.1111/jfd.12977; Lulijwa R, 2020, REV AQUACULT, V12, P640, DOI 10.1111/raq.12344; Lund H, 2019, MOL IMMUNOL, V106, P99, DOI 10.1016/j.molimm.2018.12.018; Lund M, 2016, VET RES, V47, DOI 10.1186/s13567-016-0389-y; Ma J, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7110569; Marsian J, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00880; Miccoli A, 2019, FISH SHELLFISH IMMUN, V94, P800, DOI 10.1016/j.fsi.2019.09.065; Mohammed H, 2013, VACCINE, V31, P5276, DOI 10.1016/j.vaccine.2013.08.052; Mohanty BR, 2007, J BIOSCIENCES, V32, P1331, DOI 10.1007/s12038-007-0143-8; Mugimba KK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73781-y; Munang'andu HM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573771; Munang'andu HM, 2019, FISH SHELLFISH IMMUN, V85, P132, DOI 10.1016/j.fsi.2018.03.060; Muniesa A, 2020, TRANSBOUND EMERG DIS, V67, P1089, DOI 10.1111/tbed.13482; Nguyen TD, 2018, J FISH DIS, V41, P1173, DOI 10.1111/jfd.12803; Nozzi V, 2016, FISH SHELLFISH IMMUN, V57, P179, DOI 10.1016/j.fsi.2016.07.036; Nunez-Ortiz N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0376-3; Pachiappan P., 2015, ADV MARINE BRACKISHW, DOI [10.1007/978-81-322-2271-2_23, DOI 10.1007/978-81-322-2271-2_23]; Parra D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00354; Pascoli F, 2019, FISH SHELLFISH IMMUN, V85, P85, DOI 10.1016/j.fsi.2017.10.033; Picchietti S, 2021, FISH SHELLFISH IMMUN, V108, P94, DOI 10.1016/j.fsi.2020.12.001; Prabu E., 2019, ANN RES REV BIOL, V31, P1, DOI [10.9734/arrb/2019/v31i330052, DOI 10.9734/ARRB/2019/V31I330052]; Pridgeon JW, 2011, VACCINE, V29, P7896, DOI 10.1016/j.vaccine.2011.08.082; Pridgeon JW, 2011, VACCINE, V29, P5986, DOI 10.1016/j.vaccine.2011.06.036; Pulpipat T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020163; Ramirez-Paredes JG, 2020, INT J SYST EVOL MICR, V70, P2034, DOI 10.1099/ijsem.0.004009; Ramirez-Paredes JG, 2019, J FISH DIS, V42, P1191, DOI 10.1111/jfd.13041; Ravid-Peretz S, 2019, FISH SHELLFISH IMMUN, V90, P317, DOI 10.1016/j.fsi.2019.04.057; Reyes M, 2017, VACCINE, V35, P626, DOI 10.1016/j.vaccine.2016.12.013; Robertsen B, 2016, FISH SHELLFISH IMMUN, V54, P328, DOI 10.1016/j.fsi.2016.04.027; Salati F, 2005, FISHERIES SCI, V71, P563, DOI 10.1111/j.1444-2906.2005.01000.x; Shahin K, 2019, FISH SHELLFISH IMMUN, V89, P217, DOI 10.1016/j.fsi.2019.03.071; Sharma M., 2012, INT RES J PHARM, V3, P123; Sharrer MJ, 2007, AQUACULT ENG, V37, P180, DOI 10.1016/j.aquaeng.2007.05.001; Shelby RA, 2002, J FISH DIS, V25, P1, DOI 10.1046/j.1365-2761.2002.00327.x; Shoemaker CA, 2010, J FISH DIS, V33, P537, DOI 10.1111/j.1365-2761.2010.01148.x; Shoemaker CA, 2007, VACCINE, V25, P1126, DOI 10.1016/j.vaccine.2006.09.055; Shoemaker CA, 2006, AQUACULTURE, V255, P151, DOI 10.1016/j.aquaculture.2005.12.016; Smage SB, 2018, AQUACULTURE, V495, P858, DOI 10.1016/j.aquaculture.2018.06.063; Sommerset I, 2005, EXPERT REV VACCINES, V4, P89, DOI 10.1586/14760584.4.1.89; Spinos E, 2017, AQUACULTURE, V471, P172, DOI 10.1016/j.aquaculture.2017.01.017; Stokes WS, 2011, PROCEDIA VACCINOL, V5, P84, DOI 10.1016/j.provac.2011.10.006; Stormoen M, 2013, J FISH DIS, V36, P639, DOI 10.1111/jfd.12060; Swain JK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239827; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029; Cao TT, 2014, J GEN APPL MICROBIOL, V60, P241, DOI 10.2323/jgam.60.241; Thiery R, 2006, J VIROL, V80, P10201, DOI 10.1128/JVI.01098-06; Tobar I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00244; United Nations, 2019, WORLD POP PROSP; Valdenegro-Vega VA, 2015, FISH SHELLFISH IMMUN, V44, P592, DOI 10.1016/j.fsi.2015.03.016; Valdenegro-Vega VA, 2014, FISH SHELLFISH IMMUN, V38, P294, DOI 10.1016/j.fsi.2014.03.034; Valero Y, 2018, DEV COMP IMMUNOL, V86, P171, DOI 10.1016/j.dci.2018.05.013; Valero Y, 2016, DEV COMP IMMUNOL, V65, P64, DOI 10.1016/j.dci.2016.06.021; Vandeputte M, 2019, ANIM GENET, V50, P195, DOI 10.1111/age.12779; Vanier G, 2008, VET MICROBIOL, V127, P417, DOI 10.1016/j.vetmic.2007.08.032; Vendramin N, 2018, VET RES, V49, DOI 10.1186/s13567-018-0524-z; Wang J, 2014, FISH SHELLFISH IMMUN, V40, P392, DOI 10.1016/j.fsi.2014.07.028; Wang W, 2017, AQUAC RES, V48, P1, DOI 10.1111/are.13161; Weiss WJ, 2004, J ANTIMICROB CHEMOTH, V53, P480, DOI 10.1093/jac/dkh078; Wessel O, 2018, J FISH DIS, V41, P1411, DOI 10.1111/jfd.12835; Woo PTK, 2003, J FISH DIS, V26, P627, DOI 10.1046/j.1365-2761.2003.00500.x; Xu Z, 2013, P NATL ACAD SCI USA, V110, P13097, DOI 10.1073/pnas.1304319110; Yu YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.567941; Ziklo N, 2018, J AQUAT ANIM HEALTH, V30, P312, DOI 10.1002/aah.10042	116	6	6	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							140	10.3390/vaccines9020140			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7EW	33578766	gold, Green Published			2022-04-29	WOS:000623304100001
J	Shekhar, R; Sheikh, A; Upadhyay, S; Singh, M; Kottewar, S; Mir, H; Barrett, E; Pal, S				Shekhar, Rahul; Sheikh, Abu Baker; Upadhyay, Shubhra; Singh, Mriganka; Kottewar, Saket; Mir, Hamza; Barrett, Eileen; Pal, Suman			COVID-19 Vaccine Acceptance among Health Care Workers in the United States	VACCINES			English	Article						Covid-19; vaccine; healthcare workers; United States	INFLUENZA VACCINATION; SEASONAL INFLUENZA; IMMUNIZATION; REFUSAL; ATTITUDES	Background: Acceptance of the COVID-19 vaccine will play a major role in combating the pandemic. Healthcare workers (HCWs) are among the first group to receive vaccination, so it is important to consider their attitudes about COVID-19 vaccination to better address barriers to widespread vaccination acceptance. Methods: We conducted a cross sectional study to assess the attitude of HCWs toward COVID-19 vaccination. Data were collected between 7 October and 9 November 2020. We received 4080 responses out of which 3479 were complete responses and were included in the final analysis. Results: 36% of respondents were willing to take the vaccine as soon as it became available while 56% were not sure or would wait to review more data. Only 8% of HCWs do not plan to get vaccine. Vaccine acceptance increased with increasing age, education, and income level. A smaller percentage of female (31%), Black (19%), Lantinx (30%), and rural (26%) HCWs were willing to take the vaccine as soon as it became available than the overall study population. Direct medical care providers had higher vaccine acceptance (49%). Safety (69%), effectiveness (69%), and speed of development/approval (74%) were noted as the most common concerns regarding COVID-19 vaccination in our survey.	[Shekhar, Rahul; Sheikh, Abu Baker; Upadhyay, Shubhra; Barrett, Eileen; Pal, Suman] Univ New Mexico, Dept Internal Med, Hlth Sci Ctr, Albuquerque, NM 87106 USA; [Singh, Mriganka] Case Western Reserve Univ, Univ Hosp, Dept Med, Cleveland, OH 44139 USA; [Kottewar, Saket] Univ Texas Hlth San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA; [Mir, Hamza] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87106 USA		Sheikh, A (通讯作者)，Univ New Mexico, Dept Internal Med, Hlth Sci Ctr, Albuquerque, NM 87106 USA.	rshekhar@salud.unm.edu; absheikh@salud.unm.edu; supadhyay@salud.unm.edu; mriganka.singh@uhhospitals.org; kottewar@uthscsa.edu; hmir@salud.unm.edu; ebarrett@salud.unm.edu; spal@salud.unm.edu	Pal, Suman/AAC-2172-2019; , Abu Baker Sheikh/AAQ-5454-2021; SHEKHAR, RAHUL/AAF-1096-2021; Kottewar, Saket/AAO-4334-2021; kottewar, saket/ABC-5891-2021	Pal, Suman/0000-0002-2051-9788; SHEKHAR, RAHUL/0000-0002-1200-6886; Kottewar, Saket/0000-0002-6195-0101; Sheikh, Abu Baker/0000-0003-0503-6961; Mir, Hamza/0000-0002-8204-5952			[Anonymous], A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ClinicalTrials.gov Identifier: NCT04505722; [Anonymous], NCT NUMBER NCT043862; [Anonymous], NCT04405076; [Anonymous], CLINICALTRIALSGOV ID; Aguilar-Diaz FD, 2011, ARCH MED RES, V42, P652, DOI 10.1016/j.arcmed.2011.12.006; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Imai Chisato, 2018, PLoS One, V13, pe0198685, DOI 10.1371/journal.pone.0198685; Johns Hopkins Coronavirus Resource Center, GLOBAL MAP; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; LaVela SL, 2004, INFECT CONT HOSP EP, V25, P933, DOI 10.1086/502323; Lemaitre M, 2009, J AM GERIATR SOC, V57, P1580, DOI 10.1111/j.1532-5415.2009.02402.x; Likert R., 1932, ARCH PSYCHOL, V140, P1; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Murti M, 2019, VACCINE, V37, P4001, DOI 10.1016/j.vaccine.2019.06.014; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Quinn SC, 2017, VACCINE, V35, P7154, DOI 10.1016/j.vaccine.2017.10.083; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470; Tse SC, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.180101; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598; Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959; Zaffina S, 2019, EXPERT REV VACCINES, V18, P411, DOI 10.1080/14760584.2019.1586541; Zhang J, 2011, INT J NURS STUD, V48, P1281, DOI 10.1016/j.ijnurstu.2011.03.002	30	149	151	12	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							119	10.3390/vaccines9020119			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6WT	33546165	Green Published, Green Submitted, gold	Y	N	2022-04-29	WOS:000623282700001
J	Baldo, V; Reno, C; Cocchio, S; Fantini, MP				Baldo, Vincenzo; Reno, Chiara; Cocchio, Silvia; Fantini, Maria Pia			SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead	VACCINES			English	Editorial Material									[Baldo, Vincenzo; Cocchio, Silvia] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Hyg & Publ Hlth Unit, I-35100 Padua, Italy; [Reno, Chiara; Fantini, Maria Pia] Alma Mater Studiorum Univ Bologna, Dept Biomed & Neuromotor Sci, I-40126 Bologna, Italy		Baldo, V (通讯作者)，Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Hyg & Publ Hlth Unit, I-35100 Padua, Italy.	vincenzo.baldo@unipd.it; chiara.reno@studio.unibo.it; silvia.cocchio@unipd.it; mariapia.fantini@unibo.it	Reno, Chiara/ABA-5613-2020; Baldo, Vincenzo/D-7822-2018	Reno, Chiara/0000-0002-7933-2141; Baldo, Vincenzo/0000-0001-6012-9453; Fantini, Maria Pia/0000-0002-3257-6552			Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; European Centre for Disease Prevention and Control, 2020, KEY ASP REG INTR PRI; European Centre for Disease Prevention and Control, 2020, OV COVID 19 VACC STR; Jain S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040649; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X; Speiser DE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030404	9	6	6	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							21	10.3390/vaccines9010021			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UM	33406785	Green Published, gold			2022-04-29	WOS:000610807100001
J	Kis, Z; Kontoravdi, C; Shattock, R; Shah, NI				Kis, Zoltan; Kontoravdi, Cleo; Shattock, Robin; Shah, Nilay			Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand	VACCINES			English	Article						RNA vaccines; mRNA vaccines; saRNA vaccines; pandemic-response vaccine production; COVID-19; production process modelling; techno-economic analysis		To overcome pandemics, such as COVID-19, vaccines are urgently needed at very high volumes. Here we assess the techno-economic feasibility of producing RNA vaccines for the demand associated with a global vaccination campaign. Production process performance is assessed for three messenger RNA (mRNA) and one self-amplifying RNA (saRNA) vaccines, all currently under clinical development, as well as for a hypothetical next-generation saRNA vaccine. The impact of key process design and operation uncertainties on the performance of the production process was assessed. The RNA vaccine drug substance (DS) production rates, volumes and costs are mostly impacted by the RNA amount per vaccine dose and to a lesser extent by the scale and titre in the production process. The resources, production scale and speed required to meet global demand vary substantially in function of the RNA amount per dose. For lower dose saRNA vaccines, global demand can be met using a production process at a scale of below 10 L bioreactor working volume. Consequently, these small-scale processes require a low amount of resources to set up and operate. RNA DS production can be faster than fill-to-finish into multidose vials; hence the latter may constitute a bottleneck.	[Kis, Zoltan; Kontoravdi, Cleo; Shah, Nilay] Imperial Coll London, Fac Engn, Dept Chem Engn, Ctr Proc Syst Engn, London SW7 2AZ, England; [Shattock, Robin] Imperial Coll London, Fac Med, Dept Infect Dis, London W2 1PG, England		Kis, Z (通讯作者)，Imperial Coll London, Fac Engn, Dept Chem Engn, Ctr Proc Syst Engn, London SW7 2AZ, England.	z.kis10@imperial.ac.uk; cleo.kontoravdi98@imperial.ac.uk; r.shattock@imperial.ac.uk; n.shah@imperial.ac.uk	Kis, Zoltán/H-3611-2016	Kis, Zoltán/0000-0002-6598-8369; Kontoravdi, Cleo/0000-0003-0213-4830	Department of Health and Social Care using UK Aid; Engineering and Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/R013764/1]; UK Research and Innovation (UKRI) via EPSRC [EP/V01479X/1]; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/R013764/1] Funding Source: UKRI	This research is funded by the Department of Health and Social Care using UK Aid funding and is managed by the Engineering and Physical Sciences Research Council (EPSRC, grant number: EP/R013764/1). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. Funding from UK Research and Innovation (UKRI) via EPSRC grant number EP/V01479X/1 on COVID-19/SARS-CoV-2 vaccine manufacturing and supply chain optimisation is thankfully acknowledged.	Bancel S, 2014, Patent No. [WO/2014/152027, 2014152027]; Blakney AK, 2019, GENE THER, V26, P363, DOI 10.1038/s41434-019-0095-2; Brito LA, 2015, ADV GENET, V89, P179, DOI 10.1016/bs.adgen.2014.10.005; CureVac AG, PHAS 1 PART BLIND PL; CureVac AG, 2020, COVID 19 PHAS 2A PAR; Dammes N, 2020, TRENDS PHARMACOL SCI, V41, P755, DOI 10.1016/j.tips.2020.08.004; Dolgin Elie, 2020, Nat Biotechnol, DOI 10.1038/d41587-020-00022-y; Fletcher J., 2020, ISRCTN REGIST; Funkner A., 2016, A Method for Producing and Purifying RNA, Comprising at Least One Step of Tangential Flow Filtration, Patent No. [PCT/EP2016/062152, 2016062152]; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Heartlein M., 2014, Methods for Purification of Messenger RNA, Patent No. [DK14714150.1T, 147141501]; Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Karbowniczek K, 2017, CELL GENE THERAPY IN, V3, P731; Karda R, 2019, GENE THER, V26, P86, DOI 10.1038/s41434-018-0056-1; Kis Zoltan, 2020, J Adv Manuf Process, V2, pe10060, DOI 10.1002/amp2.10060; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800376; Kremsner P., 2020, PHASE 1 ASSESSMENT S; Kroll P, 2017, PHARM RES-DORDR, V34, P2596, DOI 10.1007/s11095-017-2308-y; Ljungberg K, 2015, EXPERT REV VACCINES, V14, P177, DOI 10.1586/14760584.2015.965690; Maeki M, 2018, ADV DRUG DELIVER REV, V128, P84, DOI 10.1016/j.addr.2018.03.008; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; MEDInstill, 2020, EM TEL CORR EXP MEDI; MEDInstill, 2020, INTACTTM MOD FILL IM; Mesbah A, 2017, ORG PROCESS RES DEV, V21, P844, DOI 10.1021/acs.oprd.7b00058; Moderna T. X., PHASE 2A RANDOMIZED; Moderna T. X., PHASE 3 RANDOMIZED S; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; O'Hare R., 2020, 1 NOVEL COVID 19 VAC; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Payne J.E., 2014, Ionizable Cationic Lipid for Rna Delivery USA: WIPO (PCT), Patent No. [WO2015074085A1, 2015074085]; Petrides D., 2013, SUPERPRO DESIGNER US; Petrides D., BIOPHARMACEUTICAL PR, P154; Petrides D., 2015, BIOSEPARATIONS SCI E, V2nd, P1; Pfizer, 2020, **NON-TRADITIONAL**; Prazeres DMF, 1999, TRENDS BIOTECHNOL, V17, P169, DOI 10.1016/S0167-7799(98)01291-8; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Reuters, 2020, REUTERS HEALTHC PHAR; Reuters, REUTERS HLTH NEWS; Roces CB, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111095; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Schmeer M, 2017, HUM GENE THER, V28, P856, DOI 10.1089/hum.2017.159; Scorza F. B., 2016, RNA purification methods, Patent No. [EP2970948A1, 2970948]; Servick K., 2020, AM ASS ADV SCI; Sommeregger W, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201600546; Touchlight Genetics Ltd, 2020, OUR UN SYNTH DNA VEC; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Webb C, 2020, INT J PHARMACEUT, V582, DOI 10.1016/j.ijpharm.2020.119266; Wen EP, 2015, VACCINE DEV MANUFACT; Wochner A, 2017, Patent No. [US 2017/0114378 A1, 20170114378]; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Ye TT, 2020, ANGEW CHEM INT EDIT, V59, P18885, DOI 10.1002/anie.202008319	57	26	26	29	42	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							3	10.3390/vaccines9010003			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UF	33374802	Green Published, gold, Green Accepted	Y	N	2022-04-29	WOS:000610806400001
J	Liu, WC; Nachbagauer, R; Stadlbauer, D; Strohmeier, S; Solorzano, A; Berlanda-Scorza, F; Innis, BL; Garcia-Sastre, A; Palese, P; Krammer, F; Albrecht, RA				Liu, Wen-Chun; Nachbagauer, Raffael; Stadlbauer, Daniel; Strohmeier, Shirin; Solorzano, Alicia; Berlanda-Scorza, Francesco; Innis, Bruce L.; Garcia-Sastre, Adolfo; Palese, Peter; Krammer, Florian; Albrecht, Randy A.			Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model	VACCINES			English	Article						universal influenza virus vaccine; ferret; hemagglutinin stalk antibody; chimeric hemagglutinin; long-lived immunity	SEASONAL INFLUENZA; UNITED-STATES; ANTIBODIES; IMMUNIZATION; INFECTION	Epidemic or pandemic influenza can annually cause significant morbidity and mortality in humans. We developed novel chimeric hemagglutinin (cHA)-based universal influenza virus vaccines, which contain a conserved HA stalk domain from a 2009 pandemic H1N1 (pH1N1) strain combined with globular head domains from avian influenza A viruses. Our previous reports demonstrated that prime-boost sequential immunizations induced robust antibody responses directed toward the conserved HA stalk domain in ferrets. Herein, we further followed vaccinated animals for one year to compare the efficacy and durability of these vaccines in the preclinical ferret model of influenza. Although all cHA-based immunization regimens induced durable HA stalk-specific and heterosubtypic antibody responses in ferrets, sequential immunization with live-attenuated influenza virus vaccines (LAIV-LAIV) conferred the best protection against upper respiratory tract infection by a pH1N1 influenza A virus. The findings from this study suggest that our sequential immunization strategy for a cHA-based universal influenza virus vaccine provides durable protective humoral and cellular immunity against influenza virus infection.	[Liu, Wen-Chun; Nachbagauer, Raffael; Stadlbauer, Daniel; Strohmeier, Shirin; Solorzano, Alicia; Garcia-Sastre, Adolfo; Palese, Peter; Krammer, Florian; Albrecht, Randy A.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Liu, Wen-Chun; Garcia-Sastre, Adolfo; Albrecht, Randy A.] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA; [Liu, Wen-Chun; Innis, Bruce L.] Acad Sinica, Biomed Translat Res Ctr, Taipei 11571, Taiwan; [Nachbagauer, Raffael] Moderna Therapeut Inc, Cambridge, MA 02141 USA; [Berlanda-Scorza, Francesco] PATH US, Seattle, WA 98121 USA; [Berlanda-Scorza, Francesco] GSK Vaccine Inst Global Hlth GVGH, I-53100 Siena, Italy; [Garcia-Sastre, Adolfo; Palese, Peter] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA		Albrecht, RA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Albrecht, RA (通讯作者)，Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.	wenchun0617@gmail.com; raffael.nachbagauer@gmail.com; daniel.stadlbauer@mssm.edu; shirin.strohmeier@mssm.edu; alicia.solorzano.2010@gmail.com; francesco.x.berlandascorza@gsk.com; binnis@path.org; Adolfo.Garcia-Sastre@mssm.edu; peter.palese@mssm.edu; florian.krammer@mssm.edu; randy.albrecht@mssm.edu	Krammer, Florian/H-3237-2019; Liu, Wen-Chun/AAU-3193-2021; LIU, WEN-CHUN/ABC-8722-2020; Nachbagauer, Raffael/H-7798-2019	Krammer, Florian/0000-0003-4121-776X; Liu, Wen-Chun/0000-0003-0344-4371; Nachbagauer, Raffael/0000-0001-5568-5420; Garcia-Sastre, Adolfo/0000-0002-6551-1827; Albrecht, Randy/0000-0003-4008-503X; Palese, Peter/0000-0002-0337-5823	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1084518]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19 AI109946, R01 AI145870, P01 AI097092, R03 AI142046-02]; Centers of Influenza Virus Research and Surveillance (CEIRS) [HHSN272201400008C]; Collaborative Influenza Vaccine Innovation Center (CIVIC) [75N93019C00051]; PATH [GAT.1878-01162340-COL]; GlaxoSmithKline Biologicals SAGlaxoSmithKline	This research was funded in part by the Bill & Melinda Gates Foundation (OPP1084518 to A.G.-S., P.P., F.K.), NIAID grants U19 AI109946 (P.P.), R01 AI145870 (P.P.), P01 AI097092 (P.P., A.G.-S., R.A.A.) and R03 AI142046-02 (R.A.A.), the Centers of Influenza Virus Research and Surveillance (CEIRS) contract HHSN272201400008C (A.G.-S., P.P., F.K., W.-C.L., R.A.A.), Collaborative Influenza Vaccine Innovation Center (CIVIC) contract 75N93019C00051 (A.G.-S., P.P., F.K.), and PATH (GAT.1878-01162340-COL to A.G.-S., P.P., F.K.). This study was also partly funded by a research contract from GlaxoSmithKline Biologicals SA. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the funders. Fluarix is a trade name of the GlaxoSmithKline group of companies.	Alan H, 2017, VACCINE, V35, P1104, DOI 10.1016/j.vaccine.2017.01.018; Belongia EA, 2015, VACCINE, V33, P246, DOI 10.1016/j.vaccine.2014.06.052; Belser JA, 2016, MICROBIOL MOL BIOL R, V80, P733, DOI 10.1128/MMBR.00022-16; Belser JA, 2011, DIS MODEL MECH, V4, P575, DOI 10.1242/dmm.007823; Bernstein DI, 2020, LANCET INFECT DIS, V20, P80, DOI 10.1016/S1473-3099(19)30393-7; Boonnak K, 2017, J VIROL, V91, DOI 10.1128/JVI.00547-17; Choi Angela, 2019, Immunohorizons, V3, P133, DOI 10.4049/immunohorizons.1900022; Chow EJ, 2018, MMWR-MORBID MORTAL W, V67, P1178, DOI 10.15585/mmwr.mm6742a3; Coughlan L, 2018, CELL HOST MICROBE, V24, P18, DOI 10.1016/j.chom.2018.06.016; Elbahesh H, 2019, CURR OPIN VIROL, V34, P1, DOI 10.1016/j.coviro.2018.11.005; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Estrada LD, 2019, J IMMUNOL, V202, P392, DOI 10.4049/jimmunol.1801054; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Isakova-Sivak I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030061; Isakova-Sivak I, 2018, VIROLOGY, V518, P313, DOI 10.1016/j.virol.2018.03.013; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jansen JM, 2019, J CLIN VIROL, V119, P44, DOI 10.1016/j.jcv.2019.08.009; Kissling E, 2013, EUROSURVEILLANCE, V18, P33; Kissling E, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.16.30201; Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Hoa LNM, 2016, J VIROL, V90, P6549, DOI 10.1128/JVI.00093-16; Leroux-Roels I, 2010, VACCINE, V28, P849, DOI 10.1016/j.vaccine.2009.10.017; Liu WC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00756; Liu WC, 2018, METHODS MOL BIOL, V1836, P487, DOI 10.1007/978-1-4939-8678-1_23; Margine I, 2013, JOVE-J VIS EXP, DOI 10.3791/51112; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030047; Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4; Nachbagauer R, 2017, NAT IMMUNOL, V18, P464, DOI 10.1038/ni.3684; Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15; Nachbagauer R, 2016, J VIROL, V90, P3268, DOI 10.1128/JVI.02481-15; Oh DY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00080; Ortiz JR, 2018, VACCINE, V36, P932, DOI 10.1016/j.vaccine.2017.11.061; Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916; Paules CI, 2017, IMMUNITY, V47, P599, DOI 10.1016/j.immuni.2017.09.007; Petrie JG, 2016, J INFECT DIS, V214, P1142, DOI 10.1093/infdis/jiw105; Petrie JG, 2015, J INFECT DIS, V212, P1914, DOI 10.1093/infdis/jiv313; Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035; Sui J, 2011, CLIN INFECT DIS, V52, P1003, DOI 10.1093/cid/cir121; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383; Xu XJ, 2008, J VIROL, V82, P10493, DOI 10.1128/JVI.00959-08; Xu XY, 2019, MMWR-MORBID MORTAL W, V68, P544, DOI 10.15585/mmwr.mm6824a3; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; Yan LM, 2018, VIROLOGY, V525, P73, DOI 10.1016/j.virol.2018.09.007; Zelner J, 2019, J INFECT DIS, V220, P12, DOI 10.1093/infdis/jiz055; Zhan LJ, 2012, INDIAN J VIROL, V23, P270, DOI 10.1007/s13337-012-0076-1	53	8	8	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							40	10.3390/vaccines9010040			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WC	33440898	gold, Green Published			2022-04-29	WOS:000610811400001
J	Gackler, A; Mulling, N; Volk, K; Wilde, B; Eisenberger, U; Rohn, H; Horn, PA; Witzke, O; Lindemann, M				Gaeckler, Anja; Muelling, Nils; Voelk, Kim; Wilde, Benjamin; Eisenberger, Ute; Rohn, Hana; Horn, Peter A.; Witzke, Oliver; Lindemann, Monika			Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients	VACCINES			English	Article						pneumococcal conjugate and polysaccharide vaccines; sequential vaccination; kidney transplant recipients; serotype specific cellular immunity; interferon-gamma ELISpot	PNEUMOCOCCAL CONJUGATE; RESPONSES; POLYSACCHARIDE; PROTEIN; IMMUNIZATION; ACTIVATION; LINK	In organ transplant recipients, the rate of invasive pneumococcal diseases is 25 times greater than in the general population. Vaccination against S. pneumoniae is recommended in this cohort because it reduces the incidence of this severe form of pneumococcal infection. Previous studies indicate that transplant recipients can produce specific antibodies after pneumococcal vaccination. However, it remains unclear if vaccination also induces specific cellular immunity. In the current study on 38 kidney transplant recipients, we established an interferon-gamma ELISpot assay that can detect serotype-specific cellular responses against S. pneumoniae. The results indicate that sequential vaccination with the conjugated vaccine Prevenar 13 and the polysaccharide vaccine Pneumovax 23 led to an increase of serotype-specific cellular immunity. We observed the strongest responses against the serotypes 9N and 14, which are both components of Pneumovax 23. Cellular responses against S. pneumoniae correlated positively with specific IgG antibodies (r = 0.32, p = 0.12). In conclusion, this is the first report indicating that kidney transplant recipients can mount specific cellular responses after pneumococcal vaccination. The ELISpot we established will allow for further investigations. These could help to define, for example, factors influencing specific cellular immunity in immunocompromised cohorts or the duration of cellular immunity after vaccination.	[Gaeckler, Anja; Muelling, Nils; Voelk, Kim; Wilde, Benjamin; Eisenberger, Ute] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, D-45147 Essen, Germany; [Voelk, Kim; Horn, Peter A.; Lindemann, Monika] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, D-45147 Essen, Germany; [Voelk, Kim; Rohn, Hana; Witzke, Oliver] Univ Essen Duisburg, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, D-45147 Essen, Germany		Lindemann, M (通讯作者)，Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, D-45147 Essen, Germany.	Anja.Gaeckler@uk-essen.de; Nils.Muelling@uk-essen.de; Kim.Voelk@stud.uni-due.de; Benjamin.Wilde@uk-essen.de; Ute.Eisenberger@uk-essen.de; Hana.Rohn@uk-essen.de; Peter.Horn@uk-essen.de; Oliver.Witzke@uk-essen.de; Monika.Lindemann@uk-essen.de		Mulling, Nils/0000-0002-3534-233X; Lindemann, Monika/0000-0001-6708-4390	Stiftung Universitatsmedizin; RudolfAckermann-Stiftung (Stiftung fur Klinische Infektiologie)	This research received no external funding. A.G. is supported by a research grant from the Stiftung Universitatsmedizin. O.W. is supported by an unrestricted grant from the RudolfAckermann-Stiftung (Stiftung fur Klinische Infektiologie).	Arora Swati, 2019, World J Transplant, V9, P1, DOI 10.5500/wjt.v9.i1.1; Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535; Baril L, 2006, CLIN EXP IMMUNOL, V145, P277, DOI 10.1111/j.1365-2249.2006.03148.x; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Blanchard-Rohner G, 2021, VACCINE, V39, P3459, DOI 10.1016/j.vaccine.2021.05.030; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Dendle C, 2018, VACCINE, V36, P6253, DOI 10.1016/j.vaccine.2018.08.069; European Medicines Agency, ASS REP PREV 13; Gazi U, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13077; Glennie SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025610; Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1728, DOI 10.1128/CVI.05252-11; Groneck L, 2009, INFECT IMMUN, V77, P3705, DOI 10.1128/IAI.01492-08; Hoffman TW, 2020, TRANSPLANT DIRECT, V6, DOI 10.1097/TXD.0000000000001003; Holtmeier Wolfgang, 2005, V86, P151, DOI 10.1159/000086659; Jaat FG, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0811-2; Kanevskiy LM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00011; Karasartova D, 2017, J CLIN IMMUNOL, V37, P388, DOI 10.1007/s10875-017-0397-3; Kirby AC, 2007, EUR J IMMUNOL, V37, P3404, DOI 10.1002/eji.200737216; Lindemann M, 2002, VIROLOGY, V297, P245, DOI 10.1006/viro.2002.1467; Lindemann M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101075; Lindemann M, 2010, TRANSPLANTATION, V90, P1463, DOI 10.1097/TP.0b013e3181f5d878; Niehues T, 2017, BUNDESGESUNDHEITSBLA, V60, P674, DOI 10.1007/s00103-017-2555-4; Oesterreich S, 2020, VACCINE, V38, P3339, DOI 10.1016/j.vaccine.2020.02.088; Rabian C, 2010, CLIN INFECT DIS, V50, P1174, DOI 10.1086/651418; Robert KochInstitut, 2016, EPID B, V37, P385; Sepako E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100640; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]; Soininen A, 1999, VACCINE, V17, P1889, DOI 10.1016/S0264-410X(98)00475-7; Sun XM, 2019, P NATL ACAD SCI USA, V116, P193, DOI 10.1073/pnas.1816401115; Tobudic S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046133; Wuorimaa T, 2001, SCAND J IMMUNOL, V53, P422, DOI 10.1046/j.1365-3083.2001.00882.x	31	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1438	10.3390/vaccines9121438			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9TC	34960184	gold, Green Published			2022-04-29	WOS:000778383000001
J	Pletz, MW; Trommer, S; Kolanos, S; Rose, N; Kinne, V; Spott, R; Baier, M; Lange, I				Pletz, Mathias W.; Trommer, Sabine; Kolanos, Steffi; Rose, Norman; Kinne, Veit; Spott, Riccardo; Baier, Michael; Lange, Isabel			Group Vaccination Five Days before a COVID-19 Outbreak in a Long-Term Care Facility	VACCINES			English	Article						COVID-19; outbreaks; mass vaccination; long-term care facility; pre-symptomatic patients		Rapid vaccination may be of benefit in long-term care facilities (LTCF) that are affected by an ongoing COVID-19 outbreak. However, there are concerns regarding the safety and effectiveness of such an approach, particularly regarding the vaccination of pre-symptomatic patients. Here, we report the effectiveness of vaccination in a German LTCF hit by an outbreak that was detected 5 days after the first vaccine doses were administered. In detail, 66.7% of the unvaccinated patients experienced an unfavorable course; this proportion was much lower (33.3%) among the vaccinated patients. Even though this study is limited by a small number of patients, the observation and the comparison with related published data shows that vaccination (i) is safe and (ii) may still be of benefit when given shortly before an infection or even in pre-symptomatic LTCF-patients.	[Pletz, Mathias W.; Kolanos, Steffi; Rose, Norman; Kinne, Veit; Spott, Riccardo; Lange, Isabel] Friedrich Schiller Univ, Jena Univ Hosp, Inst Infect Dis & Infect Control, D-07747 Jena, Germany; [Pletz, Mathias W.; Rose, Norman] Friedrich Schiller Univ, Jena Univ Hosp, Ctr Sepsis Control & Care, D-07747 Jena, Germany; [Trommer, Sabine] Publ Hlth Dept, D-07743 Jena, Germany; [Baier, Michael] Friedrich Schiller Univ, Jena Univ Hosp, Inst Med Microbiol, D-07747 Jena, Germany		Pletz, MW (通讯作者)，Friedrich Schiller Univ, Jena Univ Hosp, Inst Infect Dis & Infect Control, D-07747 Jena, Germany.; Pletz, MW (通讯作者)，Friedrich Schiller Univ, Jena Univ Hosp, Ctr Sepsis Control & Care, D-07747 Jena, Germany.	mathias.pletz@med.uni-jena.de; Sabine.Trommer@jena.de; Steffi.Kolanos@med.uni-jena.de; norman.rose@med.uni-jena.de; Veit.Kinne@med.uni-jena.de; Riccardo.Spott@med.uni-jena.de; michael.baier@med.uni-jena.de; Isabel.Lange@med.uni-jena.de		Baier, Michael/0000-0002-3625-1544; Pletz, Mathias/0000-0001-8157-2753; Lange, Isabel/0000-0002-4069-6634			Brandt C, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.711437; Burton JK, 2020, LANCET HEALTH LONGEV, V1, pE21, DOI 10.1016/S2666-7568(20)30012-X; Chodick G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15985; Danis K, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.22.2000956; Hwang J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123932; Mateo-Urdiales A, 2020, EUROSURVEILLANCE, V26, P1, DOI 10.2807/1560-7917.ES.2021.26.25.2100507; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Shallcross L, 2021, LANCET HEALTH LONGEV, V2, pE129, DOI 10.1016/S2666-7568(20)30065-9; Shrotri M, 2021, LANCET INFECT DIS, V21, P1529, DOI 10.1016/S1473-3099(21)00289-9; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2	12	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1450	10.3390/vaccines9121450			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YA3ZO	34960196	Green Published, gold			2022-04-29	WOS:000738275600001
J	Zhang, XT; Zhang, RH; Wang, JY; Sui, NA; Xu, GG; Yan, H; Zhu, YL; Xie, ZJ; Jiang, SJ				Zhang, Xiaoting; Zhang, Ruihua; Wang, Jingyu; Sui, Nana; Xu, Guige; Yan, Hui; Zhu, Yanli; Xie, Zhijing; Jiang, Shijin			Construction of Recombinant Lactococcus lactis Strain Expressing VP1 Fusion Protein of Duck Hepatitis A Virus Type 1 and Evaluation of Its Immune Effect	VACCINES			English	Article						duck hepatitis A virus type 1; VP1 protein; Lactococcus lactis; mucosal immune	MOLECULAR ANALYSIS; SECRETION; GENE; IDENTIFICATION; PROVINCE; RNA	With the continuous development of duck farming and the increasing breeding density, the incidence of duck hepatitis A virus type 1 (DHAV-1) has been on the rise, seriously endangering the development of duck farming. To reduce the use of antibiotics in duck breeding, susceptibility risks and mortality, and avoid virulence recovery and immune failure risk, this study aims to develop a new type of mucosal immune probiotics and make full use of molecular biology techniques, on the level of genetic engineering, to modify Lactococcus lactis (L. lactis). In this study, a secretory recombinant L. lactis named MG1363-VP1 with an enhanced Green Fluorescent Protein (eGFP) and translation enhancer T7g10L was constructed, which could express the VP1-eGFP fusion protein of DHAV-1. The animal experiment in ducklings was performed to detect the immune response and protection effect of oral microecologics by recombinant L. lactis. The results showed that oral L. lactis MG1363-VP1 significantly induced the body's humoral immune system and mucosal immune system to produce specific anti-VP1 IgG antibodies and mucosal secretory immunoglobulin A (sIgA) for DHAV-1 in ducklings, and cytokines including interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10), and interferon gamma (IFN-gamma). The mortality rate was monitored simultaneously by the natural infestation in the process of production and breeding; notably, the ducklings vaccinated with L. lactis MG1363-VP1 were effectively protected against the nature infection of DHAV-1. The recombinant L. lactis MG1363-VP1 constructed in this study provides a new means of preventing and controlling DHAV-1 infection in the future.	[Zhang, Xiaoting; Zhang, Ruihua; Wang, Jingyu; Sui, Nana; Xu, Guige; Yan, Hui; Zhu, Yanli; Xie, Zhijing; Jiang, Shijin] Shandong Agr Univ, Dept Prevent Vet Med, Coll Vet Med, Tai An 271018, Shandong, Peoples R China; [Zhang, Xiaoting] Shandong Key Lab Anim Microecol Preparat, Tai An 271000, Shandong, Peoples R China; [Zhang, Ruihua; Wang, Jingyu; Sui, Nana; Xu, Guige; Yan, Hui; Zhu, Yanli; Xie, Zhijing; Jiang, Shijin] Shandong Prov Key Lab Anim Biotechnol & Dis Contr, Tai An 271000, Shandong, Peoples R China		Jiang, SJ (通讯作者)，Shandong Agr Univ, Dept Prevent Vet Med, Coll Vet Med, Tai An 271018, Shandong, Peoples R China.; Jiang, SJ (通讯作者)，Shandong Prov Key Lab Anim Biotechnol & Dis Contr, Tai An 271000, Shandong, Peoples R China.	xtzhang2021@126.com; rhzhang@sdau.edu.cn; jywang676@163.com; sn17763223251@163.com; sdxuguige@163.com; 17863805800@163.com; ylz@sdau.edu.cn; xiezhj@sdau.edu.cn; sjjiang@sdau.edu.cn	Jiang, Shijin/E-5096-2013	Jiang, Shijin/0000-0002-4747-8410	Shandong Provincial Natural Science Foundation, ChinaNatural Science Foundation of Shandong Province [ZR2020QC015]; Science and Technology Innovation Major Project of Taian, China [2021ZDZX032]; Shandong Modern Agricultural Technology and Industry System, China [SDAIT-11-15]	FundingThis study was supported by Shandong Provincial Natural Science Foundation, China (ZR2020QC015), Science and Technology Innovation Major Project of Taian, China (2021ZDZX032), Shandong Modern Agricultural Technology and Industry System, China (SDAIT-11-15).	Alonso C, 2014, ADV EXP MED BIOL, V817, P73, DOI 10.1007/978-1-4939-0897-4_4; Avall-Jaaskelainen S, 2006, VET MICROBIOL, V115, P278, DOI 10.1016/j.vetmic.2006.02.007; Bahey-El-Din M, 2010, J MED MICROBIOL, V59, P904, DOI 10.1099/jmm.0.018770-0; Bosch A., 2011, CLASSIFICATION NOMEN, P953; Budin-Verneuil A, 2005, PROTEOMICS, V5, P4794, DOI 10.1002/pmic.200401327; Chai Y.B., 1997, LETT BIOTECHNOL, V8, P138; Chen GW, 2021, J SCI FOOD AGR, V101, P5807, DOI 10.1002/jsfa.11231; Ding CY, 2007, VIROLOGY, V361, P9, DOI 10.1016/j.virol.2007.01.007; Freitas DA, 2005, BRAZ J MED BIOL RES, V38, P1585, DOI 10.1590/S0100-879X2005001100004; Fu Y, 2008, VET MICROBIOL, V131, P247, DOI 10.1016/j.vetmic.2008.03.011; Gao Jiming, 2012, Virologica Sinica, V27, P248, DOI 10.1007/s12250-012-3255-8; Jin X, 2008, RES VET SCI, V85, P595, DOI 10.1016/j.rvsc.2008.01.001; Kim MC, 2007, ARCH VIROL, V152, P2059, DOI 10.1007/s00705-007-1023-0; Kim MC, 2006, J GEN VIROL, V87, P3307, DOI 10.1099/vir.0.81804-0; Lei H, 2010, VIROLOGY, V407, P319, DOI 10.1016/j.virol.2010.08.007; Galdeano CM, 2019, ANN NUTR METAB, V74, P115, DOI 10.1159/000496426; Maqsood I, 2018, J APPL MICROBIOL, V125, P1670, DOI 10.1111/jam.14073; Moorthy SAV, 2009, VACCINE, V27, P4947, DOI 10.1016/j.vaccine.2009.06.011; Morello E, 2008, J MOL MICROB BIOTECH, V14, P48, DOI 10.1159/000106082; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Ng DTW, 2013, APPL ENVIRON MICROB, V79, P347, DOI 10.1128/AEM.02667-12; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1989, J BIOL CHEM, V264, P16973; Parlane NA, 2011, APPL ENVIRON MICROB, V77, P8516, DOI 10.1128/AEM.06420-11; Pontes DS, 2011, PROTEIN EXPRES PURIF, V79, P165, DOI 10.1016/j.pep.2011.06.005; Quigley BR, 2010, INFECT IMMUN, V78, P1294, DOI 10.1128/IAI.01037-09; Rezaei M, 2020, CAN J MICROBIOL, V66, P39, DOI 10.1139/cjm-2019-0261; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Song SS, 2019, VACCINE, V37, P4364, DOI 10.1016/j.vaccine.2019.06.026; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Tseng CH, 2007, VIRUS RES, V123, P190, DOI 10.1016/j.virusres.2006.09.007; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; VANDEGUCHTE M, 1990, APPL ENVIRON MICROB, V56, P2606, DOI 10.1128/AEM.56.9.2606-2611.1990; Villatoro-Hernandez J, 2012, METHODS MOL BIOL, V824, P155, DOI 10.1007/978-1-61779-433-9_8; Wang C, 2005, HLTH RES, V34, P214; Wells J, 2011, ANNU REV FOOD SCI T, V2, P423, DOI 10.1146/annurev-food-022510-133640; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; Zhang RH, 2015, VET MICROBIOL, V180, P196, DOI 10.1016/j.vetmic.2015.09.008	39	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1479	10.3390/vaccines9121479			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0PT	34960225	Green Published, gold			2022-04-29	WOS:000737365400001
J	Chauhan, H; Gupta, D; Gupta, S; Singh, A; Aljahdali, HM; Goyal, N; Noya, ID; Kadry, S				Chauhan, Harsha; Gupta, Deepali; Gupta, Sheifali; Singh, Aman; Aljahdali, Hani Moaiteq; Goyal, Nitin; Noya, Irene Delgado; Kadry, Seifedine			Blockchain Enabled Transparent and Anti-Counterfeiting Supply of COVID-19 Vaccine Vials	VACCINES			English	Article						blockchain; COVID-19; vaccine supply; transparency; Ethereum; smart contract		The COVID-19 pandemic has profoundly affected almost all facets of peoples' lives, various economic areas and regions of the world. In such a situation implementation of a vaccination can be viewed as essential but its success will be dependent on availability and transparency in the distribution process that will be shared among the stakeholders. Various distributed ledgers (DLTs) such as blockchain provide an open, public, immutable system that has numerous applications due the mentioned abilities. In this paper the authors have proposed a solution based on blockchain to increase the security and transparency in the tracing of COVID-19 vaccination vials. Smart contracts have been developed to monitor the supply, distribution of vaccination vials. The proposed solution will help to generate a tamper-proof and secure environment for the distribution of COVID-19 vaccination vials. Proof of delivery is used as a consensus mechanism for the proposed solution. A feedback feature is also implemented in order to track the vials lot in case of any side effect cause to the patient. The authors have implemented and tested the proposed solution using Ethereum test network, RinkeyBy, MetaMask, one clicks DApp. The proposed solution shows promising results in terms of throughput and scalability.	[Chauhan, Harsha; Gupta, Deepali; Gupta, Sheifali; Goyal, Nitin] Chitkara Univ, Chitkara Univ Inst Engn & Technol, Rajpura 140401, India; [Singh, Aman] Lovely Profess Univ, Dept Comp Sci & Engn, Jalandhar 144001, Punjab, India; [Aljahdali, Hani Moaiteq] King Abdulaziz Univ, Fac Comp & Informat Technol, Jeddah 37848, Saudi Arabia; [Noya, Irene Delgado] Univ Europea Atlantico, Higher Polytech Sch, C Isabel Torres 21, Santander 39011, Spain; [Noya, Irene Delgado] Univ Int Iberoamer, Dept Project Management, Campeche 24560, Mexico; [Kadry, Seifedine] Noroff Univ Coll, Fac Appl Comp & Technol, N-0459 Kristiansand, Norway		Goyal, N (通讯作者)，Chitkara Univ, Chitkara Univ Inst Engn & Technol, Rajpura 140401, India.	harsha.chauhan@chitkara.edu.in; deepali.gupta@chitkara.edu.in; sheifali.gupta@chitkara.edu.in; aman.16826@lpu.co.in; Hmaljahdali@kau.edu.sa; nitin.goyal@chitkara.edu.in; irene.delgado@uneatlantico.es; seifedine.kadry@noroff.no		Gupta, Deepali/0000-0002-3207-5248; GOYAL, NITIN/0000-0001-7878-363X	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah [D-339-830-1442]	FundingThis project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (D-339-830-1442). The authors, therefore, gratefully acknowledge DSR technical and financial support.	Abbas K, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9050852; Akram SV, 2021, SECUR COMMUN NETW, V2021, DOI 10.1155/2021/6952121; Ali MS, 2019, IEEE COMMUN SURV TUT, V21, P1676, DOI 10.1109/COMST.2018.2886932; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; [Anonymous], 2020, CONVERSATION NOV; [Anonymous], ETHEREUM IDE 1 DOCUM; [Anonymous], 2018, NASDAQ; Asgary A, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040469; Buterin V., 2013, GITHUB REPOS, V1, P22; Chauhan Harsha, 2021, IOP Conference Series: Materials Science and Engineering, V1022, DOI 10.1088/1757-899X/1022/1/012051; Chen SI, 2014, IIE TRANS, V46, P853, DOI 10.1080/0740817X.2013.813094; Chen YM, 2021, BIOSCI TRENDS, V15, P64, DOI 10.5582/bst.2021.01061; Enayati S, 2020, EUR J OPER RES, V283, P714, DOI 10.1016/j.ejor.2019.11.025; Fusco A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197167; Golosova J, 2018, 2018 IEEE 6TH WORKSHOP ON ADVANCES IN INFORMATION, ELECTRONIC AND ELECTRICAL ENGINEERING (AIEEE); Gonczol P, 2020, IEEE ACCESS, V8, P11856, DOI 10.1109/ACCESS.2020.2964880; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Haque A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040739; Hasan H, 2019, COMPUT IND ENG, V136, P149, DOI 10.1016/j.cie.2019.07.022; Hasanat R.T., 2020, 2020 IEEE E W DES TE, P1; Holbl M, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10100470; Ignaciuk P, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10217851; Kalla Anshuman, 2020, IEEE Engineering Management Review, V48, P85, DOI 10.1109/EMR.2020.3014052; Kartoglu UH, 2020, VACCINE, V38, P5393, DOI 10.1016/j.vaccine.2020.06.056; Keeling MJ, 2012, EPIDEMICS-NETH, V4, P78, DOI 10.1016/j.epidem.2012.03.001; Khezr S, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9091736; Kuo TT, 2017, J AM MED INFORM ASSN, V24, P1211, DOI 10.1093/jamia/ocx068; Lovett L., 2020, MOBIHEALTHNEWS; Manoj MK, 2020, IEEE GLOBE WORK, DOI 10.1109/GCWkshps50303.2020.9367469; Marbouh D, 2020, ARAB J SCI ENG, V45, P9895, DOI 10.1007/s13369-020-04950-4; McGrail S., 2020, HIT INFRASTRUCTU OCT; MERKLE RC, 1988, LECT NOTES COMPUT SC, V293, P369; Modi R., 2018, SOLIDITY PROGRAMMING; Poland GA, 2021, VACCINE, V39, P457, DOI 10.1016/j.vaccine.2020.12.017; Pollet J, 2021, ADV DRUG DELIVER REV, V170, P71, DOI 10.1016/j.addr.2021.01.001; Rahi M, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100501; Ramirez Lopez L.J., BLOCKCHAIN APPL DIST; Rauf A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218155; Riewpaiboon A, 2015, PUBLIC HEALTH, V129, P899, DOI 10.1016/j.puhe.2015.04.016; Rinkeby, ETH TESTN; Singh R, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20143951; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Swain M, 2021, AGRONOMY-BASEL, V11, DOI 10.3390/agronomy11050820; Tseng JH, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061055; Vora J, 2018, IEEE GLOBE WORK; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; WHO, COR DIS COVID 19 DAS; Yang YW, 2021, OMEGA-INT J MANAGE S, V99, DOI 10.1016/j.omega.2020.102197; Yong BB, 2020, INT J INFORM MANAGE, V52, DOI 10.1016/j.ijinfomgt.2019.10.009; Zhang JX, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9101746	50	0	0	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1239	10.3390/vaccines9111239			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XT7DP	34835170	Green Published, gold			2022-04-29	WOS:000733743800001
J	Collatuzzo, G; Melloni, R; Zanotti, C; de Simone, G; Pilastro, D; Lodi, V; Boffetta, P				Collatuzzo, Giulia; Melloni, Riccardo; Zanotti, Chiara; de Simone, Giulio; Pilastro, Danila; Lodi, Vittorio; Boffetta, Paolo			Comparing the Attitude toward the COVID-19 and the 2020/21 and 2019/20 Flu Vaccination Campaigns among Italian Healthcare Workers	VACCINES			English	Article						COVID-19; vaccination; vaccine hesitancy; flu; health care workers	INFLUENZA	Background: While the uptake of the COVID-19 vaccine among healthcare workers (HCWs) is suboptimal, vaccine hesitancy has not been characterized in detail in this population. Objective: The aim of this study was to compare the prevalence of health-related conditions reported by HCWs during the COVID-19, 2020/21 flu, and 2019/20 flu vaccination campaigns, so to test the hypothesis that HCWs were more prone to report health conditions during the COVID-19 campaign. Methods: We analyzed vaccination questionnaires of 176 hospital-based HCWs who underwent the COVID-19 and the 2020/21 flu vaccinations; 2019/20 flu vaccination questionnaires were available for 130 of them. Outcomes included self-reported allergies, chronic diseases, and use of medications. We tested for prevalence equality, analyzed differences using the kappa statistics and concordance correlation, and explored factors associated with differences in reporting. Results: There was no difference in the proportion of HCWs reporting allergies in the three questionnaires, while chronic diseases were more frequently reported in the COVID-19 than in both 2020/21 (p = 0.04) and 2019/20 flu questionnaires (p = 0.02). Furthermore, a higher proportion of HCWs reported medications use in the COVID-19 vaccination questionnaire, compared to both the 2020/21 and the 2019/20 flu vaccination questionnaires (p < 0.001 for both). In each vaccine campaign, women reported more conditions than men, and the difference between chronic disease reports was greater for women than for men. Conclusions: Our results show more frequent reporting of health conditions during the COVID-19 than the flu vaccination campaigns, providing quantitative evidence of hesitancy of HCWs towards the COVID-19 vaccine.	[Collatuzzo, Giulia; Melloni, Riccardo; Zanotti, Chiara; de Simone, Giulio; Pilastro, Danila; Lodi, Vittorio; Boffetta, Paolo] Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy; [Lodi, Vittorio] St Orsola Malpighi Hosp, Unit Occupat Med, I-40138 Bologna, Italy; [Boffetta, Paolo] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA		Boffetta, P (通讯作者)，Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy.; Boffetta, P (通讯作者)，SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.	giulia.collatuzzo@studio.unibo.it; riccardo.melloni@studio.unibo.it; chiara.zanotti4@studio.unibo.it; giulio.desimone2@studio.unibo.it; danila.pilastro@studio.unibo.it; vittorio.lodi@unibo.it; paolo.boffetta@stonybrookmedicine.edu		collatuzzo, giulia/0000-0002-2309-7365			Batabyal RA, 2017, INFECT CONT HOSP EP, V38, P1361, DOI 10.1017/ice.2017.182; Chen YT, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18147491; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802; Grochowska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050475; Guillari A., 2021, ACTA BIOMED, V92; Hajure M, 2021, INFECT DRUG RESIST, V14, P3883, DOI 10.2147/IDR.S332792; Kumar R, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.727748; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Stokel-Walker C, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1645; Talbot TR, 2010, INFECT CONT HOSP EP, V31, P987, DOI 10.1086/656558; Aurilio MT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050500	16	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1312	10.3390/vaccines9111312			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI1YM	34835242	gold, Green Published			2022-04-29	WOS:000725916200001
J	Oyekale, AS				Oyekale, Abayomi Samuel			Compliance Indicators of COVID-19 Prevention and Vaccines Hesitancy in Kenya: A Random-Effects Endogenous Probit Model	VACCINES			English	Article						compliance indicator; COVID-19; vaccine hesitancy; random-effects; probit model; endogenous; Kenya	UNITED-STATES; DETERMINANTS; ACCEPTANCE; LEVEL	Vaccine hesitancy remains a major public health concern in the effort towards addressing the COVID-19 pandemic. This study analyzed the effects of indicators of compliance with preventive practices on the willingness to take COVID-19 vaccines in Kenya. The data were from the COVID-19 Rapid Response Phone Surveys conducted between January and June 2021 during the fourth and fifth waves. The data were analyzed with the random-effects endogenous Probit regression model, with estimated parameters tested for robustness and stability. The results showed that willingness to take vaccines increased between the fourth and fifth waves. Compliance with many of the preventive practices also improved, although the utilizations of immune system-promoting practices were very low. The panel Probit regression results showed that compliance indicators were truly endogenous and there was existence of random effects. Immune system-boosting and contact-prevention indicators significantly increased and decreased the willingness to take vaccines, respectively (p < 0.01). The experience of mental health disorders in the form of nervousness and hopelessness also significantly influenced vaccine hesitancy (p < 0.10). Willingness to take vaccines also significantly increased among older people and those with a formal education (p < 0.01). Different forms of association exist between vaccine hesitancy and the prevention compliance indicators. There is a need to properly sensitize the people to the need to complement compliance with COVID-19 contact-prevention indicators with vaccination. Addressing mental health disorders in the form of loneliness, nervousness, depression, hopelessness and anxiety should also become the focus of public health, while efforts to reduce vaccine hesitancy should focus on individuals without formal education, males and youths.	[Oyekale, Abayomi Samuel] North West Univ, Dept Agr Econ & Extens, Mafikeng Campus, ZA-2735 Mmabatho, South Africa		Oyekale, AS (通讯作者)，North West Univ, Dept Agr Econ & Extens, Mafikeng Campus, ZA-2735 Mmabatho, South Africa.	abayomi.oyekale@nwu.ac.za					Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Al-Rahimi JS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250554; Amado Daieni Alves Vieira, 2019, Braz. J. Food Technol., V22, pe2018044, DOI 10.1590/1981-6723.04418; Arreola R, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/401630; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Calder Philip C, 2020, BMJ Nutr Prev Health, V3, P74, DOI 10.1136/bmjnph-2020-000085; Calder PC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041181; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Chen TE, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1876814; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Deeks A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-213; Derbyshire Emma, 2020, BMJ Nutr Prev Health, V3, P100, DOI 10.1136/bmjnph-2020-000071; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dryhurst S, 2020, J RISK RES, V23, P994, DOI 10.1080/13669877.2020.1758193; Ezeh A, 2017, LANCET, V389, P547, DOI 10.1016/S0140-6736(16)31650-6; Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI 10.1016/s2214-109x(17)30072-4; Gombart AF, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010236; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Hampton L., 2020, YOU STOP PANDEMIC; Hursh SR, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.608852; Jaadi Z, STEP BY STEP EXPLANA; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202; Kashiouris MG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020292; Kejriwal M., 2021, COVID 19 VACCINE HES, DOI [10.31234/osf.io/nkvhs, DOI 10.31234/OSF.IO/NKVHS]; Kollamparambil U, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250269; Kumar P, 2021, INFLAMMOPHARMACOLOGY, V29, P1001, DOI 10.1007/s10787-021-00826-7; Kumar Vipul, 2021, VirusDisease, V32, DOI 10.1007/s13337-020-00643-6; Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500; Larson Heidi J, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452; Machado Paulo R. L., 2004, An. Bras. Dermatol., V79, P647, DOI 10.1590/S0365-05962004000600002; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583; McAbee L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101109; Mehmel M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061616; Ministry of Health, NAT EM RESP COMM COR; Ministry of Health, 1 CAS COR DIS CONF K; Ministry of Health, NAT POL GUID IMM 201; Monye I., 2020, LIFESTY MED, V1, pe7, DOI [10.1002/lim2.7, DOI 10.1002/LIM2.7]; Mwai P., 2021, CORONAVIRUS AFRICA C; Negahdaripour M., 2020, ROLE FOLIC ACID MANA; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; OECD Enhancing Public, 2021, TRUST COVID 19 VACC; Ogunleye OO, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01205; Ong SWX, 2021, LANCET INFECT DIS, V21, P1195, DOI 10.1016/S1473-3099(21)00201-2; Opanga SA, SCH ACAD J PHARM, V10, P36, DOI [10.36347/sajp.2021.v10i03.001, DOI 10.36347/SAJP.2021.V10I03.001]; Orangi S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080936; Padidar S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253954; Pandey K., 2021, COVID 19 AFRICA NEAR; Pape U.J., KENYA COVID 19 RAPID; Patterson T, 2021, AGING DIS, V12, P14, DOI 10.14336/AD.2020.0918; Perez-Arce F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256406; Petherick A, 2021, NAT HUM BEHAV, V5, P1145, DOI 10.1038/s41562-021-01181-x; Pinchoff J, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-042749; Posel D, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249352; Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772; Rachul C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040989; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Robles AS, 2021, J INVEST MED, V69, P235, DOI 10.1136/jim-2021-WRMC.296; Rogers R.W., 1983, COGNITIVE PHYSIOLOGI; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; SAKETKHOO K, 1978, CHEST, V74, P408, DOI 10.1378/chest.74.4.408; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Shakoor H, 2021, MATURITAS, V144, P108, DOI 10.1016/j.maturitas.2020.08.007; Shimizu C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40253-x; StataCorp, XTPROB RAND EFF POP; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; United Nations, 2021, COVID 19 AFR 3 WAV N; Vaidya V, 2012, J WOMENS HEALTH, V21, P140, DOI 10.1089/jwh.2011.2876; Valenti GD, 2021, PSYCHOL RES BEHAV MA, V14, P1325, DOI 10.2147/PRBM.S323617; Wako A., 2021, KENYA COVID 19 AS 4; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wise T, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.200742; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062; Wooldridge J., 2012, INTRO ECONOMETRICS M; World Bank, 2021, SOCIOECONOMIC IMPACT; World Health Organisation, 2020, OV PUBL HLTH SOC MEA	87	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1359	10.3390/vaccines9111359			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF6IZ	34835290	Green Published, gold			2022-04-29	WOS:000724174300001
J	Rzymski, P; Poniedzialek, B; Fal, A				Rzymski, Piotr; Poniedzialek, Barbara; Fal, Andrzej			Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland	VACCINES			English	Article						COVID-19 vaccine; booster dose; vaccine hesitancy; mRNA vaccines; vector vaccines; SARS-CoV-2	GENDER-DIFFERENCES; ATTITUDES	COVID-19 vaccinations are essential to mitigate the pandemic and prevent severe SARS-CoV-2 infections. However, the serum antibody levels in vaccinated individuals gradually decrease over time, while SARS-CoV-2 is undergoing an evolution toward more transmissible variants, such as B.1.617.2, ultimately increasing the risk of breakthrough infections and further virus spread. This cross-sectional online study of adult Poles (n = 2427) was conducted in September 2021 (before a general recommendation to administer a booster COVID-19 vaccine dose in Poland was issued) to assess the attitude of individuals who completed the current vaccination regime toward a potential booster dose of the COVID-19 vaccine and identify potential factors that may influence it. Overall, 71% of participants declared willingness to receive a booster COVID-19 dose, with a low median level of fear of receiving it of 1.0 (measured by the 10-point Likert-type scale), which was increased particularly in those having a worse experience (in terms of severity of side effects and associated fear) with past COVID-19 vaccination. The lowest frequency of willingness to receive a booster dose (26.7%) was seen in the group previously vaccinated with Ad26.COV2.S. The majority of individuals vaccinated previously with mRNA vaccines wished to receive the same vaccine, while in the case of AZD1222, such accordance was observed only in 9.1%. The main reasons against accepting a booster COVID-19 dose included the side effects experienced after previous doses, the opinion that further vaccination is unnecessary, and safety uncertainties. Women, older individuals (& GE;50 years), subjects with obesity, chronic diseases, and pre-vaccination and post-vaccination SARS-CoV-2 infections, and those with a history of vaccination against influenza were significantly more frequently willing to receive a booster COVID-19 dose. Moreover, the majority of immunosuppressed individuals (88%) were willing to receive an additional dose. The results emphasize some hesitancy toward potential further COVID-19 vaccination in the studied group of Poles and indicate the main groups to be targeted with effective science communication regarding the booster doses.	[Rzymski, Piotr; Poniedzialek, Barbara] Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland; [Rzymski, Piotr] Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland; [Fal, Andrzej] Cardinal Stefan Wyszynski Univ, Coll Med, Warsaw Fac Med, PL-01938 Warsaw, Poland		Rzymski, P (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland.; Rzymski, P (通讯作者)，Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland.	rzymskipiotr@ump.edu.pl; bpon@ump.edu.pl; amfal@wp.pl	; Rzymski, Piotr/I-2240-2012	Poniedzialek, Barbara/0000-0002-1601-1703; Rzymski, Piotr/0000-0002-4713-0801; Fal, Andrzej/0000-0002-9675-7942			Albano L, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-208; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bates TA, 2021, JAMA-J AM MED ASSOC, V326, P868, DOI 10.1001/jama.2021.11656; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Burki TK, 2021, LANCET RESP MED, V9, pE83, DOI 10.1016/S2213-2600(21)00328-3; Cascini F, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101113; CBOS, ATT VACC COVID 19; Chagla Z, 2021, NAT MED, V27, P1659, DOI 10.1038/s41591-021-01494-4; Chia Po Ying, 2022, Clin Microbiol Infect, V28, DOI 10.1016/j.cmi.2021.11.010; Cochran WG, 1977, SAMPLING TECHNIQUES; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Costantino C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155362; Di Giuseppe G, 2008, BRIT J CANCER, V99, P225, DOI 10.1038/sj.bjc.6604454; Dieguez-Campa CE, 2021, ARCH CARDIOL MEX, V91, P1, DOI 10.24875/ACM.20000370; Eshun-Wilson I, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256394; European Medicine Agency, ECDC EMA HIGHL CONS; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Galasso V, 2020, P NATL ACAD SCI USA, V117, P27285, DOI 10.1073/pnas.2012520117; Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790; Grochowska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050475; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Krasnicka J, 2018, HUM VACC IMMUNOTHER, V14, P2884, DOI 10.1080/21645515.2018.1496766; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Krempovych, 2021, ASTRAZENECA VACCINE, P2021, DOI [10.1101/2021.04.08.21255107, DOI 10.1101/2021.04.08.21255107]; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Liu Y, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab124; Lockhart, 2021, 6 MONTH SAFETY EFFIC, DOI [10.1101/2021.07.28.21261159, DOI 10.1101/2021.07.28.21261159]; McLean CP, 2009, CLIN PSYCHOL REV, V29, P496, DOI 10.1016/j.cpr.2009.05.003; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Napolitano CL, 1999, SOC INDIC RES, V46, P191, DOI 10.1023/A:1006845025370; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Nitsch-Osuch A, 2017, ADV EXP MED BIOL, V968, P19, DOI 10.1007/5584_2016_193; Nowakowska J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110451; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pouwels KB., 2021, IMPACT DELTA VIRAL B, DOI [DOI 10.1101/2021.08.18.21262237V1, 10.1101/2021.08.18.21262237v1]; Raciborski F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080832; Racine-Brzostek SE, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.151477; Riemersma KK., 2021, SHEDDING INFECT SARS, DOI [10.1101/2021.07.31.21261387, DOI 10.1101/2021.07.31.21261387]; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070781; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060559; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Sadoff J., 2021, DURABILITY ANTIBODY, DOI [10.1101/2021.08.25.21262569, DOI 10.1101/2021.08.25.21262569]; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Schmidt T, 2021, AM J TRANSPLANT, V21, P3990, DOI 10.1111/ajt.16818; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Simon RM, 2010, PUBLIC UNDERST SCI, V19, P642, DOI 10.1177/0963662509335449; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Tang P., 2021, BNT162B2 MRNA 1273 C, DOI [10.1101/2021.08.11.21261885, DOI 10.1101/2021.08.11.21261885V1, DOI 10.1101/2021.08.11.21261885]; Teyssou E, 2021, J INFECTION, V83, pE1, DOI 10.1016/j.jinf.2021.08.027; Thuluvath PJ, 2021, J HEPATOL, V75, P1434, DOI 10.1016/j.jhep.2021.08.008; Trougakos IP, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02090-6; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang ZJ, 2021, NATURE, V595, P426, DOI 10.1038/s41586-021-03696-9; Yamayoshi S, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100734	58	9	9	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1286	10.3390/vaccines9111286			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG6OR	34835217	gold, Green Published			2022-04-29	WOS:000724870500001
J	Allemailem, KS				Allemailem, Khaled S.			A Comprehensive Computer Aided Vaccine Design Approach to Propose a Multi-Epitopes Subunit Vaccine against Genus Klebsiella Using Pan-Genomics, Reverse Vaccinology, and Biophysical Techniques	VACCINES			English	Article						Klebsiella; pan-proteome; multi-epitopes vaccine; immunoinformatics; molecular dynamics simulations	PROTEIN-STRUCTURE; SIDE-CHAIN; PREDICTION; ENTEROBACTERIACEAE; IDENTIFICATION; EPIDEMIOLOGY; REFINEMENT; RESISTANCE; PATHOGENS; SOFTWARE	Klebsiella is a genus of nosocomial bacterial pathogens and is placed in the most critical list of World Health Organization (WHO) for development of novel therapeutics. The pathogens of the genus are associated with high mortality and morbidity. Owing to their strong resistance profile against different classes of antibiotics and nonavailability of a licensed vaccine, urgent efforts are required to develop a novel vaccine candidate that can tackle all pathogenic species of the Klebsiella genus. The present study aims to design a broad-spectrum vaccine against all species of the Klebsiella genus with objectives to identify the core proteome of pathogen species, prioritize potential core vaccine proteins, analyze immunoinformatics of the vaccine proteins, construct a multi-epitopes vaccine, and provide its biophysical analysis. Herein, we investigated all reference species of the genus to reveal their core proteome. The core proteins were then subjected to multiple reverse vaccinology checks that are mandatory for the prioritization of potential vaccine candidates. Two proteins (TonB-dependent siderophore receptor and siderophore enterobactin receptor FepA) were found to fulfill all vaccine parameters. Both these proteins harbor several potent B-cell-derived T-cell epitopes that are antigenic, nonallergic, nontoxic, virulent, water soluble, IFN-gamma producer, and efficient binder of DRB*0101 allele. The selected epitopes were modeled into a multi-epitope peptide comprising linkers and Cholera Toxin B adjuvant. For docking with innate immune and MHC receptors and afterward molecular dynamics simulations and binding free energy analysis, the vaccine structure was modeled for tertiary structure and refined for structural errors. To assess the binding affinity and presentation of the designed vaccine construct, binding mode and interactions analysis were performed using molecular docking and molecular dynamics simulation techniques. These biophysical approaches illustrated the vaccine as a good binder to the immune receptors and revealed robust interactions energies. The vaccine sequence was further translated to nucleotide sequence and cloned into an appropriate vector for expressing it at high rate in Escherichia coli K12 strain. In addition, the vaccine was illustrated to generate a good level of primary, secondary, and tertiary immune responses, proving good immunogenicity of the vaccine. Based on the reported results, the vaccine can be a good candidate to be evaluated for effectiveness in wet laboratory validation studies.	[Allemailem, Khaled S.] Qassim Univ, Dept Med Labs, Coll Appl Med Sci, Buraydah 51452, Saudi Arabia		Allemailem, KS (通讯作者)，Qassim Univ, Dept Med Labs, Coll Appl Med Sci, Buraydah 51452, Saudi Arabia.	k.allemailem@qu.edu.sa		Allemailem, Khaled/0000-0002-6486-9835			Ah YM, 2014, INT J ANTIMICROB AG, V44, P8, DOI 10.1016/j.ijantimicag.2014.02.016; Ahmad S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030293; Ahmad S, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105387; Ahmad S, 2019, EUR J PHARM SCI, V132, P1, DOI 10.1016/j.ejps.2019.02.023; Ahmad S, 2018, J MOL GRAPH MODEL, V82, P74, DOI 10.1016/j.jmgm.2018.04.005; Ahmad S, 2017, J MOL GRAPH MODEL, V77, P72, DOI 10.1016/j.jmgm.2017.07.024; Barh D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052773; Baseer S, 2017, BIOLOGICALS, V50, P87, DOI 10.1016/j.biologicals.2017.08.004; Bijker MS, 2007, EXPERT REV VACCINES, V6, P591, DOI 10.1586/14760584.6.4.591; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Case DA, 2020, AMBER 2020; Chaudhari NM, 2016, SCI REP-UK, V6, DOI 10.1038/srep24373; Chaudhary U, 2004, Indian J Med Microbiol, V22, P75; Chen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008; Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396; Choi M, 2019, EXPERT REV VACCINES, V18, P681, DOI 10.1080/14760584.2019.1635460; Chung PY, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw219; Cilloniz C, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2371-3; Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346; Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Diago-Navarro E, 2018, MBIO, V9, DOI 10.1128/mBio.01005-18; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4; Dombkowski AA, 2014, FEBS LETT, V588, P206, DOI 10.1016/j.febslet.2013.11.024; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Fazeli H, 2015, HIPPOKRATIA, V19, P205; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Garg A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-62; Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Grundmann H, 2010, EUROSURVEILLANCE, V15, P22; Guan PP, 2003, NUCLEIC ACIDS RES, V31, P3621, DOI 10.1093/nar/gkg510; Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Hassan A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2951-4; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Ismail S, 2021, COMPUT BIOL MED, V136, DOI 10.1016/j.compbiomed.2021.104705; Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996; Jagt E.W., 2021, PEDIAT CRITICAL CARE, P1105; Jaiswal AK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020402; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Khan AA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020859; Khan AU, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1012-8; Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V; Lee CH, 2006, J ANTIMICROB CHEMOTH, V58, P1074, DOI 10.1093/jac/dkl381; Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185; Li WL, 2015, IEEE T AERO ELEC SYS, V51, P1811, DOI 10.1109/TAES.2015.140542; Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195; Logan LK, 2017, J INFECT DIS, V215, pS28, DOI 10.1093/infdis/jiw282; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186; Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h; Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027; Naz K, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2713-9; NCBI Resource Coordinators, 2017, NUCLEIC ACIDS RES, V45, pD12, DOI 10.1093/nar/gkw1071; Norgaard SM, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0624-1; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Podschun R, 1998, CLIN MICROBIOL REV, V11, P589, DOI 10.1128/CMR.11.4.589; ProtParam E., 2017, EXPASY PROTPARAM TOO; Rapin N., C IMMSIM 101 SERVER; Rashid T, 2013, INT J RHEUMATOL, V2013, DOI 10.1155/2013/610393; Rathi C.R., SYNTHESIS SILVER NAN; Reche PA, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/256784; Rehman A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060658; Ribeiro SM, 2015, ANTIMICROB AGENTS CH, V59, P3906, DOI 10.1128/AAC.00092-15; Rice LB, 2012, MAYO CLIN PROC, V87, P198, DOI 10.1016/j.mayocp.2011.12.003; Rinaudo CD, 2009, J CLIN INVEST, V119, P2515, DOI 10.1172/JCI38330; Rizwan M, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1540-0; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Ryan KJ, 2004, MED MICROBIOLOGY, P370; Sachdeva G, 2005, BIOINFORMATICS, V21, P483, DOI 10.1093/bioinformatics/bti028; Sanober G, 2017, GENE REP, V7, P147, DOI 10.1016/j.genrep.2017.04.008; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Sheth H B, 1995, Biomed Pept Proteins Nucleic Acids, V1, P141; Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579; ul Qamar MT, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00752-w; ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Ul Qamar MT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669812; ul Qamar MT, 2021, COMPUT BIOL MED, V132, DOI 10.1016/j.compbiomed.2021.104389; ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292; Wizemann TM, 1999, EMERG INFECT DIS, V5, P395, DOI 10.3201/eid0503.990310; Wu M, 2015, MOL MED MICROBIOLOGY, P1547; Yu NY, 2010, BIOINFORMATICS, V26, P1608, DOI 10.1093/bioinformatics/btq249	89	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1087	10.3390/vaccines9101087			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP5MZ	34696195	Green Published, gold			2022-04-29	WOS:000713176900001
J	Nielsen, S; Sujan, HM; Benn, CS; Aaby, P; Hanifi, SMA				Nielsen, Sebastian; Sujan, Hasan Mahmud; Benn, Christine Stabell; Aaby, Peter; Hanifi, Syed Manzoor Ahmed			Oral Polio Vaccine Campaigns May Reduce the Risk of Death from Respiratory Infections	VACCINES			English	Article						Bangladesh; non-specific effects of vaccines; cause of death; respiratory infections; campaigns; OPV; oral polio vaccine	MORTALITY	Oral polio vaccine (OPV) campaigns, but not other campaigns, have been associated with major reductions in child mortality. Studies have shown that OPV reduces the risk of respiratory infections. We analysed the causes of death at 0-2 years of age in Chakaria, a health and demographic surveillance Systems in Bangladesh, in the period 2012-2019 where 13 national campaigns with combinations of OPV (n = 4), vitamin A supplementation (n = 9), measles vaccine (MV) (n = 2), and albendazole (n = 2) were implemented. OPV-only campaigns reduced overall mortality by 30% (95% confidence interval: -10-56%). Deaths from respiratory infections were reduced by 62% (20-82%, p = 0.01) in the post-neonatal period (1-35 months), whereas there was as slight increase of 19% (-37-127%, p = 0.54) for deaths from other causes. There was no benefit of other types of campaigns. Hence, the hypothesis that OPV may have beneficial non-specific effects, protecting particularly against respiratory infections, was confirmed.	[Nielsen, Sebastian; Benn, Christine Stabell; Aaby, Peter] OPEN Odense Patient Data Explorat Network, Inst Clin Res, Bandim Hlth Project, Studiestr 6, DK-1455 Copenhagen, Denmark; [Nielsen, Sebastian; Aaby, Peter] Indepth Network, Bandim Hlth Project, Apartado 861, Bissau 1004, Guinea Bissau; [Sujan, Hasan Mahmud; Hanifi, Syed Manzoor Ahmed] Shaheed Tajuddin Ahmed Sarani, Int Ctr Diarrhoeal Dis Res, Hlth Syst & Populat Studies Div, Bangladesh Icddr B, Dhaka 1212, Bangladesh; [Benn, Christine Stabell] Odense Univ Hosp, Danish Inst Adv Sci, Campusvej 55, DK-5230 Odense, Denmark; [Benn, Christine Stabell] Univ Southern Denmark, Campusvej 55, DK-5230 Odense, Denmark		Nielsen, S (通讯作者)，OPEN Odense Patient Data Explorat Network, Inst Clin Res, Bandim Hlth Project, Studiestr 6, DK-1455 Copenhagen, Denmark.; Nielsen, S (通讯作者)，Indepth Network, Bandim Hlth Project, Apartado 861, Bissau 1004, Guinea Bissau.	senielsen@health.sdu.dk; hanifi@icddrb.org; cbenn@health.sdu.dk; p.aaby@bandim.org; hanifi@icddrb.org		Aaby, Peter/0000-0001-8331-1389; Nielsen, Sebastian/0000-0003-3384-7489; Mahmud Sujan, Hasan/0000-0001-5693-3828	Danish Council for Development Research, Ministry of Foreign Affairs, Denmark [104.Dan.8.f.]; Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited; European UnionEuropean Commission [Health-F3-2011-261375]	This research study is funded by core donors who provide unrestricted support to icddr,b for its operations and research. icddr,b is grateful to the Government of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. The authors are grateful to the villages for their cooperation in providing invaluable information. The untiring efforts of the team members of the Chakaria HDSS in maintaining the surveillance system are gratefully acknowledged. The work on non-specific effects of vaccines has been supported by the Danish Council for Development Research, Ministry of Foreign Affairs, Denmark (grant number 104.Dan.8.f.), Novo Nordisk Foundation and European Union FP7 support for OPTIMUNISE (grant: Health-F3-2011-261375).	Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009; Andersen A, 2021, CLIN INFECT DIS, V72, pE596, DOI 10.1093/cid/ciaa1351; Andersen A, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00013; Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525; Byass P, 2003, SCAND J PUBLIC HEALT, V31, P32, DOI 10.1080/14034950310015086; Chumakov K, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101718118; Chumakov M.P., 1992, J MICROBIOL EPIDEMIO, V12, P37; Contreras G, 1974, Bull Pan Am Health Organ, V8, P123; Hanifi SMA, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25473; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Martins CL, 2014, J INFECT DIS, V209, P1731, DOI 10.1093/infdis/jit804; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nielsen S, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100886; Prentice S, 2021, LANCET INFECT DIS, V21, P993, DOI 10.1016/S1473-3099(20)30653-8; Schaltz-Buchholzer F, 2019, J INFECT DIS, V219, P624, DOI 10.1093/infdis/jiy544; Schoeps A, 2018, VACCINE, V36, P1965, DOI 10.1016/j.vaccine.2018.02.104; Seppala E, 2011, VACCINE, V29, P8615, DOI 10.1016/j.vaccine.2011.09.015; Sorup S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofv204; Upfill-Brown A, 2017, CLIN INFECT DIS, V65, P414, DOI 10.1093/cid/cix354; VOROSHILOVA MK, 1989, PROG MED VIROL, V36, P191; Welaga P, 2017, VACCINE, V35, P2496, DOI 10.1016/j.vaccine.2017.03.004	21	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1133	10.3390/vaccines9101133			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP2ZC	34696241	Green Published, gold			2022-04-29	WOS:000713004700001
J	Sung, M; Huang, YM; Duan, YQ; Liu, FJ; Jin, YZ; Zheng, ZJ				Sung, Meekang; Huang, Yangmu; Duan, Yuqi; Liu, Fangjing; Jin, Yinzi; Zheng, Zhijie			Pharmaceutical Industry's Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers	VACCINES			English	Article						corporate social responsibility; COVID-19; vaccines; global health; COVAX; pharmaceutical companies	COMMUNITY; BUSINESS; CSR	(1) Objectives: Inequality in the global distribution of COVID-19 vaccines has brought about great challenges in terms of resolving the pandemic. Although vaccine manufacturers are undoubtedly some of the most influential players, studies on their role in global vaccine distribution have been scarce. This study examined whether the pharmaceutical industry is acting according to the principles of corporate social responsibility (CSR) during the pandemic. (2) Methods: Three categories were used to analyze the CSR of vaccine developers. The first was research and development: effectiveness, funding, and profits were measured. The second was transparency and accountability: the transparency of clinical trials and vaccine contracts was analyzed. The final was vaccine delivery: the status of the provision of vaccines to COVAX and lower-income countries, intellectual property management, manufacturing agreements, and equitable pricing were measured. (3) Results: Vaccine developers have acquired large profits. The vaccine delivery category faces the most challenges. Participation of pharmaceutical companies through COVAX was significantly low, and most vaccine supply agreements were secretive, bilateral deals. It was not clear if companies were maintaining equitable pricing. The evaluation indicated that the companies' CSR practices have differed during the pandemic. (4) Conclusions: Our study contributes to the methodology of assessing the CSR of vaccine developers. This would help understand the current COVID-19 vaccine distribution inequality and propose that pharmaceutical companies re-examine their roles and social responsibilities.	[Sung, Meekang] Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro 38 Gil, Seoul 08826, South Korea; [Huang, Yangmu; Duan, Yuqi; Liu, Fangjing; Jin, Yinzi; Zheng, Zhijie] Peking Univ, Sch Publ Hlth, Dept Global Hlth, 38 Xue Yuan Rd, Beijing 100191, Peoples R China; [Huang, Yangmu; Duan, Yuqi; Liu, Fangjing; Jin, Yinzi; Zheng, Zhijie] Peking Univ, Inst Global Hlth & Dev, Beijing 100871, Peoples R China		Jin, YZ (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Global Hlth, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.; Jin, YZ (通讯作者)，Peking Univ, Inst Global Hlth & Dev, Beijing 100871, Peoples R China.	meekangs@snu.ac.kr; ymhuang@bjmu.edu.cn; 18811318259@163.com; liufangjing@pku.edu.cn; yzjin@bjmu.edu.cn; zhengzj@bjmu.edu.cn		Zheng, Zhijie/0000-0002-0233-5010; Sung, Meekang/0000-0001-5067-5792; Jin, Yinzi/0000-0003-0634-3955	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [72042014]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [INV-016183]	FundingThis study was funded by the National Natural Science Foundation of China (No. 72042014) and the Bill & Melinda Gates Foundation (INV-016183). The study sponsors had no role in the study design, data analysis or the interpretation of data; the writing of manuscript; or the decision to submit the paper for publication.	Amin Lucas, 2017, MAKING CASE OPEN CON; [Anonymous], 2021, NATURE, V593, P478, DOI 10.1038/d41586-021-01242-1; [Anonymous], 2015, 2015 METH 2017 ACC V; [Anonymous], 2021, STAT COVID 19 VACC W; [Anonymous], 2021, UN NEWS; [Anonymous], 2021, RAC GLOB COVID 19 VA; [Anonymous], 2021, DOW JON SUST WORLD I; Armstrong D., 2020, BLOOMBERG; AstraZeneca, 2021, H1 2021 RES; Bangalee V, 2020, S AFR FAM PRACT, V62, DOI 10.4102/safp.v62i1.5152; Berkley S., COVAX EXPLAINED; Bluestone K., 2002, PHILANTHROPY PHARM I, V1st ed; Bourla A., OPEN LETT PFIZER CHA; Brammer S, 2020, ACAD MANAGE PERSPECT, V34, P493, DOI 10.5465/amp.2019.0053; Brulhart F, 2019, J BUS ETHICS, V158, P25, DOI 10.1007/s10551-017-3732-y; Carroll A.B., 1999, BUS SOC, V38, P268, DOI [10.1177/000765039903800303, DOI 10.1177/000765039903800303]; Carroll A.B., 1991, BUS HORIZONS, V34, P39, DOI 10.1016/0007-6813(91)90005-G; Carstens A., 2005, P REG WORKSH TRANSP; Centre G.H., 2021, COVID 19 VACC R D IN; Coles L.C., 2016, INDEPENDENT REPORT D; Council for Trade-Related Aspects of Intellectual Property Rights, P COMM PLUR STAT BOL; Cuesta-Valino P, 2019, CORP SOC RESP ENV MA, V26, P761, DOI 10.1002/csr.1718; Deng XM, 2020, CORP SOC RESP ENV MA, V27, P393, DOI 10.1002/csr.1877; Dreisbach Tom, 2020, NPR; Droppert H, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0100-5; Dunn A., 2020, THE INSIDER; Eakin B., 2021, LAW360; Eccleston-Turner M, 2021, MILBANK Q, V99, P426, DOI 10.1111/1468-0009.12503; Edwards D., 2021, METHODOLOGY 2021 ACC; Elfarouk O, 2022, J IND PROD ENG, V39, P109, DOI 10.1080/21681015.2021.1963338; Fidler DP, 2020, SCIENCE, V369, P749, DOI 10.1126/science.abe2275; Garcia-Sanchez Isabel-Maria., 2020, J OPEN INNOV-TECHNOL, V6, DOI [10.3390/joitmc6040126, DOI 10.3390/JOITMC6040126]; Gavi, 2021, GAV SIGNS AGR SIN SI; George R.D., 1981, PHILOS EXCH, V12, P3; Gruskin S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000310; Guzman J, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005347; Haessler P, 2020, ADM SCI, V10, DOI 10.3390/admsci10030063; Hickey K.J., 2021, PREP ACT COVID 19 LI; Hurst DJ, 2017, MED HEALTH CARE PHIL, V20, P105, DOI 10.1007/s11019-016-9743-0; Idemudia U, 2009, J BUS ETHICS, V90, P91, DOI 10.1007/s10551-008-9916-8; International Organization for Standardization, 2018, SOCIAL RESPONSIBILIT; JohnsonJohnson, 2021, JOHNS JOHNS REP 2021; JohnsonJohnson, 2021, JOHNS JOHNS REP Q2 2; Kanwar AVS, 2019, J LAW MED, V26, P750; Kapalan T., 2021, NEW YORK TIMES; Kapelus P, 2002, J BUS ETHICS, V39, P275, DOI 10.1023/A:1016570929359; Kochhar SK, 2014, ASIAN J COMMUN, V24, P421, DOI 10.1080/01292986.2014.905612; Lins KV, 2017, J FINANC, V72, P1785, DOI 10.1111/jofi.12505; Loftus P, 2020, WALL STR J; Macklin R., 2004, DOUBLE STANDARDS MED; Mahmud A, 2020, SAGE OPEN, V10, DOI 10.1177/2158244020924046; Mancini D.P., 2020, FINANCIAL TIMES 1123; Matten D, 2008, ACAD MANAGE REV, V33, P404, DOI 10.5465/AMR.2008.31193458; McCarthy S., 2021, S CHINA MORNING POST; McIntosh T., TRANSPARENCY BECOMES; McNeil D.G., 2001, NEW YORK TIMES; Medecins Sans Frontieres, 2014, UNT ANT PRIC RED; Min M, 2017, J MANAG DEV, V36, P58, DOI 10.1108/JMD-09-2014-0103; Moderna, 2021, 10 Q Q REP Q2; Moderna, 2021, 10 Q Q REP Q1; Moon S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-39; MSCI, 2021, ESG RAT CORP SEARCH; Oxford University Innovation, EXP ACC COVID 19 REL; Pangalos M., 2020, PATHWAY VACCINE EFFO; Parton J., 2021, BLOOMBERG; Pfizer, 2021, PFIZ REP STRONG 1 QU; Pfizer, 2021, PFIZ REP 2 QUART 202; RAND Corporation, COVID 19 COST VACC N; Resnik D.B., 2014, ENCY GLOBAL BIOETHIC, P2606; Rhodes N., 2021, WHOSE BENEFIT TRANSP; Roberts M., 2020, BBC NEWS ONLINE; Ruchir Agarwal G.G., 2021, INT MONETARY FUND; Sagonowsky E., 2020, FIERCEPHARMA 0721; Senz K., 2021, WHAT DOES ESG SCORE; Shapiro E., 2020, TIME; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; Sinopharm, 2021, 2021 INT REP; Skouloudis A, 2015, MANAGE DECIS, V53, P375, DOI 10.1108/MD-12-2013-0637; Smith NC, 2003, CALIF MANAGE REV, V45, P52, DOI 10.2307/41166188; Tan Y., 2021, BBC NEWS 0114; Taylor P., 2020, PHARMAPHORUM; UNICEF, 2021, COVID 19 VACC MARK D; Verma S, 2020, J BUS RES, V118, P253, DOI 10.1016/j.jbusres.2020.06.057; WHO, 2021, COVAX ANN NEW AGR PL; WHO Team, 2020, COVAX FAC EXPL; World Bank, 2020, WORLD BANK COUNTR LE; World Health Organization, INT STAT COVID 19 VA; Zhang S., CORONAVIRUS IS HERE	88	1	1	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1183	10.3390/vaccines9101183			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ6XI	34696293	Green Published, gold			2022-04-29	WOS:000713956900001
J	Gao, JJ; Tseng, HP; Lin, CL; Shiu, JS; Lee, MH; Liu, CH				Gao, Jhih-Jian; Tseng, Hung-Pin; Lin, Chun-Liang; Shiu, Jr-Shiang; Lee, Ming-Hsun; Liu, Ching-Hsiung			Acute Transverse Myelitis Following COVID-19 Vaccination	VACCINES			English	Article						myelitis; LETM; COVID-19; COVID-19 vaccination; mRNA vaccine; vitamin B12	SUBACUTE COMBINED DEGENERATION; INVERTED V SIGN; IMMUNIZATION; VACCINES; IGG	An increasing number of people are undergoing vaccination for COVID-19 because of the ongoing pandemic. The newly developed, genetically engineered mRNA vaccines are critical for controlling the epidemic disease. However, major adverse effects, including neuroimmunological disorders, are being attributed to this vaccine. For instance, several cases of acute transverse myelitis (ATM) after COVID-19 vaccination have been reported in clinical trials. Here, we report an exceedingly rare case of longitudinally extensive transverse myelitis (LETM), a rare subtype of ATM involving three or more vertebral segments, that occurred shortly after vaccination with the Moderna COVID-19 (mRNA-1273) vaccine, with a comorbidity of vitamin B12 deficiency. The findings of subsequent investigations suggest the possibility that autoimmune responses are triggered by the reactions between anti-SARS-CoV-2 spike protein antibodies and tissue proteins, as well as the interaction between spike proteins and angiotensin-converting enzyme 2 receptors.	[Gao, Jhih-Jian; Tseng, Hung-Pin; Lin, Chun-Liang; Liu, Ching-Hsiung] Lotung Poh Ai Hosp, Dept Neurol, Ilan 26546, Taiwan; [Shiu, Jr-Shiang] Lotung Poh Ai Hosp, Dept Emergency Med, Ilan 26546, Taiwan; [Lee, Ming-Hsun] Lotung Poh Ai Hosp, Dept Radiol, Ilan 26546, Taiwan		Liu, CH (通讯作者)，Lotung Poh Ai Hosp, Dept Neurol, Ilan 26546, Taiwan.	c087001@mail.pohai.org.tw; 1913@mail.pohai.org.tw; c923001@mail.pohai.org.tw; mrblack@mail.pohai.org.tw; 985003@mail.pohai.org.tw; chl@mail.pohai.org.tw		Gao, Jhih-Jian/0000-0003-3981-3028			Agmon-Levin N, 2009, LUPUS, V18, P1198, DOI 10.1177/0961203309345730; Austin A, 2015, ISR MED ASSOC J, V17, P120; Baxter R, 2016, CLIN INFECT DIS, V63, P1456, DOI 10.1093/cid/ciw607; Daroff R., 2015, BRADLEY DAROFFS NEUR, V7th, P496; Devi A, 2019, CLIN NEUROL NEUROSUR, V181, P33, DOI 10.1016/j.clineuro.2019.04.002; Fitzsimmons W., 2021, SUDDEN ONSET MYELITI, DOI [10.2139/ssrn.3841558, DOI 10.2139/SSRN.3841558]; Goldish D, 2018, PM&R, V10, P320, DOI 10.1016/j.pmrj.2017.07.076; Goss AL, 2021, ANN NEUROL, V89, P856, DOI 10.1002/ana.26065; Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0718-0; JEFFERY DR, 1993, ARCH NEUROL-CHICAGO, V50, P532, DOI 10.1001/archneur.1993.00540050074019; Kitley JL, 2012, MULT SCLER J, V18, P271, DOI 10.1177/1352458511406165; [Краснов Владимир Сергеевич Krasnov Vladimir Sergeevich], 2016, [Неврология, нейропсихиатрия, психосоматика, Nevrologiya, neiropsikhiatriya, psikhosomatika], V8, P71, DOI 10.14412/2074-2711-2016-3-71-75; Kumar Neha, 2020, Int J MS Care, V22, P85, DOI 10.7224/1537-2073.2018-104; Malhotra HS, 2021, QJM-INT J MED, V114, P591, DOI 10.1093/qjmed/hcab069; Marino S, 2021, EURASIAN J MED ONCOL, V5, P91, DOI 10.14744/ejmo.2021.78845; Matsuura H, 2018, QJM-INT J MED, V111, P65, DOI 10.1093/qjmed/hcx189; McDonald I, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00336-1; Miller A, 2005, J NEUROL SCI, V233, P93, DOI 10.1016/j.jns.2005.03.009; Narra R, 2015, J CLIN DIAGN RES, V9, pTJ1, DOI 10.7860/JCDR/2015/14028.5889; Nemoto W, 2020, EUR J PHARMACOL, V872, DOI 10.1016/j.ejphar.2020.172950; Pagenkopf C, 2021, J NEUROIMMUNOL, V358, DOI 10.1016/j.jneuroim.2021.577606; Roman GC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653786; Sejvar JJ, 2007, VACCINE, V25, P5771, DOI 10.1016/j.vaccine.2007.04.060; Shah S, 2018, NEUROLOGY, V90; Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480; Weinshenker BG, 2006, ANN NEUROL, V59, P566, DOI 10.1002/ana.20770; Wingerchuk Dean M, 2013, Continuum (Minneap Minn), V19, P944, DOI 10.1212/01.CON.0000433289.38339.a2; Zanoni G, 2002, EUR J NEUROL, V9, P696, DOI 10.1046/j.1468-1331.2002.00447_9.x	28	9	9	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1008	10.3390/vaccines9091008			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UV9TY	34579245	gold, Green Published			2022-04-29	WOS:000699813200001
J	Raciborski, F; Samel-Kowalik, P; Gujski, M; Pinkas, J; Arcimowicz, M; Jankowski, M				Raciborski, Filip; Samel-Kowalik, Piotr; Gujski, Mariusz; Pinkas, Jaroslaw; Arcimowicz, Magdalena; Jankowski, Mateusz			Factors Associated with a Lack of Willingness to Vaccinate against COVID-19 in Poland: A 2021 Nationwide Cross-Sectional Survey	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccinations; vaccine hesitancy; vaccines; Poland	EUROPEAN REGION; ACCEPTANCE; HESITANCY	We aimed to assess the factors associated with a lack of willingness to vaccinate against COVID-19 among adults in Poland three months after the introduction of mass vaccination against COVID-19 in Poland. This cross-sectional study was carried out between 8 and 18 April 2021 on a representative nationwide sample of 1131 inhabitants of Poland aged 18 and over. Almost one-third of adult inhabitants of Poland (30%; 95%CI: 27.4-32.7%) declared a lack of willingness to vaccinate against COVID-19. Females had higher odds of refusing COVID-19 vaccination compared with males (OR = 1.68; 95%CI: 1.25-2.27). The lack of higher education was significantly (p < 0.001) associated with greater odds of refusing the COVID-19 vaccination. Participants living in rural areas compared with those living in the largest cities (over 500,000 inhabitants) had three times higher odds of refusing the COVID-19 vaccination (OR = 3.20; 95%CI: 1.71-6.01). Respondents who declared willingness to vote for one of the right-wing political parties publicly supporting the anti-vaccination movement in Poland had eight times higher odds (OR = 8.01; 95%CI: 3.65-17.60) of refusing the COVID-19 vaccination compared with other groups. Moreover, those who had three children or more, respondents who declared passivity towards participating in religious practices as well as active internet users had significantly higher odds of refusing the COVID-19 vaccination.	[Raciborski, Filip; Samel-Kowalik, Piotr] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, PL-02091 Warsaw, Poland; [Gujski, Mariusz] Med Univ Warsaw, Dept Publ Hlth, PL-02097 Warsaw, Poland; [Pinkas, Jaroslaw; Jankowski, Mateusz] Ctr Postgrad Med Educ, Sch Publ Hlth, PL-01826 Warsaw, Poland; [Arcimowicz, Magdalena] Med Univ Warsaw, Dept Otorhinolaryngol Head & Neck Surg, PL-02097 Warsaw, Poland		Gujski, M (通讯作者)，Med Univ Warsaw, Dept Publ Hlth, PL-02097 Warsaw, Poland.	filip.raciborski@wum.edu.pl; piotr.samel@wum.edu.pl; mariusz.gujski@wum.edu.pl; jpinkas@cmkp.edu.pl; magdalena.arcimowicz@wum.edu.pl; mjankowski@cmkp.edu.pl	; Samel-Kowalik, Piotr/M-3239-2018; Gujski, Mariusz/A-3222-2019; Jankowski, Mateusz/N-7536-2018	Raciborski, Filip/0000-0003-0562-0260; Samel-Kowalik, Piotr/0000-0002-9047-0414; Gujski, Mariusz/0000-0002-2938-4795; Jankowski, Mateusz/0000-0002-7142-5167	National Center for Research and Development as part of the Strategic Program of Scientific Research and Development "Social and economic development of Poland in the conditions of globalizing markets" [GOSPOSTRATEG-II/0007/2020-00]	This research was funded by the National Center for Research and Development as part of the Strategic Program of Scientific Research and Development "Social and economic development of Poland in the conditions of globalizing markets", grant number GOSPOSTRATEG-II/0007/2020-00".	Babicki M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050503; de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6; European Centre for Disease Prevention and Control, 2018, SEASONAL INFLUENZA V; Furman FM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124565; Hernandez-Garcia I, 2020, JMIR PUBLIC HLTH SUR, V6, P110, DOI 10.2196/18717; Holeva V, 2022, PSYCHOL HEALTH MED, V27, P113, DOI 10.1080/13548506.2021.1948579; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kluge H, 2021, LANCET, V397, P1689, DOI 10.1016/S0140-6736(21)00709-1; Krawczyk A., WHOS POLISH ANTIVACC; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Li YY, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105221; Montagni I, 2021, J PUBLIC HEALTH-UK, V43, P695, DOI 10.1093/pubmed/fdab028; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Paul R, 2020, J RURAL HEALTH, V36, P591, DOI 10.1111/jrh.12486; Prickett KC, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100241; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Szarowska A, 2021, POL ARCH INTERN MED, V131, P101, DOI 10.20452/pamw.15734; Szilagyi PG, 2021, PREV MED, V153, DOI 10.1016/j.ypmed.2021.106727; Wlodarska A, 2021, INT J OCCUP MED ENV, V34, P121, DOI 10.13075/ijomeh.1896.01671; Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444	20	7	7	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1000	10.3390/vaccines9091000			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW1HF	34579237	Green Published, gold			2022-04-29	WOS:000699915400001
J	Riad, A; Pokorna, A; Antalova, N; Krobot, M; Zviadadze, N; Serdiuk, I; Koscik, M; Klugar, M				Riad, Abanoub; Pokorna, Andrea; Antalova, Natalia; Krobot, Martin; Zviadadze, Nutsa; Serdiuk, Iryna; Koscik, Michal; Klugar, Miloslav			Prevalence and Drivers of COVID-19 Vaccine Hesitancy among Czech University Students: National Cross-Sectional Study	VACCINES			English	Article						COVID-19 vaccines; cross-sectional studies; Czech Republic; decision making; mass vaccination; university students; vaccine hesitancy	ATTITUDES; HEALTH	Background: university students are believed to retain the highest levels of health literacy. They are perceived as the opinion leaders within their communities; therefore, their health-related beliefs and attitudes are deemed important for public health campaigns. This study aimed to investigate the COVID-19 vaccine hesitancy drivers among university students in the Czech Republic. Methods: a cross-sectional study using a self-administered questionnaire was carried out in the weeks before the unrestricted vaccine deployment to Czech adults. The questionnaire had 21 multiple-choice items stratified in 4 categories; demographic characteristics, COVID-19-related anamnesis and influenza vaccine experience, attitudes towards COVID-19 vaccination, and the possible drivers of COVID-19 vaccine hesitancy suggested by the WHO-SAGE. Results: out of the 1351 included students, 66.8% were females, 84.5% were Czech nationals, and 40.6% enrolled in healthcare programs. The overall COVID-19 vaccine acceptance level was 73.3%, 19.3% of participants were vaccine-resistant, and only 7.4% were vaccine-hesitant. Trust in the pharmaceutical industry, trust in healthcare providers, and perceived knowledge sufficiency predicted higher odds of vaccine acceptance. In contrast, media and social media, personal beliefs, immunity misconception, previous COVID-19 infection, and suspicions about novel vaccines and the local availability predicted higher odds of vaccine hesitancy. Conclusions: The findings of this study predict a fair probability to achieve community immunity (herd immunity) among the target population group. The primary prevention strategies in the Czech Republic need to be culturally sensitive and inclusive for foreign nationals. As one-quarter of the participating students are dependent on vaccine safety data, this study findings support the call for independent studies evaluating the side effects of COVID-19 vaccines.	[Riad, Abanoub; Antalova, Natalia; Krobot, Martin; Zviadadze, Nutsa; Serdiuk, Iryna; Koscik, Michal; Klugar, Miloslav] Masaryk Univ, Fac Med, Dept Publ Hlth, Kamenice 5, Brno 62500, Czech Republic; [Riad, Abanoub; Pokorna, Andrea; Klugar, Miloslav] Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Cochrane Czech Republ,GRADE Ctr,Fac Med, Inst Biostat & Anal,Czech EBHC JBI Ctr Excellence, Kamenice 5, Brno 62500, Czech Republic; [Pokorna, Andrea; Antalova, Natalia] Masaryk Univ, Fac Med, Dept Nursing & Midwifery, Kamenice 5, Brno 62500, Czech Republic		Riad, A (通讯作者)，Masaryk Univ, Fac Med, Dept Publ Hlth, Kamenice 5, Brno 62500, Czech Republic.; Riad, A (通讯作者)，Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Cochrane Czech Republ,GRADE Ctr,Fac Med, Inst Biostat & Anal,Czech EBHC JBI Ctr Excellence, Kamenice 5, Brno 62500, Czech Republic.	abanoub.riad@med.muni.cz; apokorna@med.muni.cz; natalia.antalova@med.muni.cz; krobot@med.muni.cz; nutsa.zviadadze@mail.muni.cz; iryna.serdiuk@mail.muni.cz; koscik@med.muni.cz; klugar@med.muni.cz	Pokorna, Andrea/E-5483-2019; Krobot, Martin/AAV-3553-2021; Riad, Abanoub/AAU-7046-2020; Krobot, Martin/ABD-1287-2021; Klugar, Miloslav/E-5748-2018	Pokorna, Andrea/0000-0002-1305-6455; Riad, Abanoub/0000-0001-5918-8966; Krobot, Martin/0000-0001-8007-0786; Klugar, Miloslav/0000-0002-2804-7295	Masaryk University [MUNI/IGA/1543/2020, MUNI/A/1608/2020]; INTER-EXCELLENCE grant [LTC20031]	This study was funded by Masaryk University, grant numbers MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of A.R., A.P., and M.K. (Miloslav Klugar) was supported by the INTER-EXCELLENCE grant number LTC20031-"Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic".	Abrams JY, 2020, J PEDIATR-US, V226, P45, DOI 10.1016/j.jpeds.2020.08.003; Ackerson BK, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2020-047092; Al-Khanati N.M., 2020, BRAZ J ORAL SCI, V19, pE201354, DOI [10.20396/bjos.v19i0.8661354, DOI 10.20396/BJOS.V19I0.8661354]; Al-Mulla R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060665; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Alawia R., 2021, J ORAL MED ORAL SURG, V27, P17, DOI [10.1051/mbcb/2020056, DOI 10.1051/MBCB/2020056]; Alawia R, 2022, ORAL DIS, V28, P975, DOI 10.1111/odi.13593; [Anonymous], DW; [Anonymous], 2020, COLL RESP COVID 19 E, DOI [10.1002/14651858.cd202002, DOI 10.1002/14651858.CD202002]; Astrom AN, 2000, ACTA ODONTOL SCAND, V58, P11, DOI 10.1080/000163500429370; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bonnevie E., 2021, Journal of Communication in Healthcare, V14, P12, DOI 10.1080/17538068.2020.1858222; Czech Statistical Office, YEARSB; da Silva DT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030204; EurekAlert, SCI NEWS; European Comission, EURYDICE; Eurostat, STAT EXPLAINED; Gavi-The Vaccine Alliance, IMM STRENGTH PRIM HE; Geoghegan S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00372; Gerussi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020172; Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802; Griffith J, 2021, J MED INTERNET RES, V23, DOI 10.2196/26874; Hockova B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040581; Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Jeskowiak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050502; Juvinya-Canal D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072273; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; Klugar M, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10080752; KoBoToolbox.org, HARV HUM IN; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Loulergue P, 2013, VACCINE, V31, P2835, DOI 10.1016/j.vaccine.2013.04.004; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Masaryk University, CLUBS ASS FAC MED; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Ministerstvo Vnitra, COV PORT; Ministry of Health of the Czech Republic (MZCR), AKT INF COVID 19; National Institutes of Health (NIH), HLTH LIT CLEAR COMM; Olanipekun T, 2021, J GEN INTERN MED, V36, P2186, DOI 10.1007/s11606-021-06787-5; Papagiannis D, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030323; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P893, DOI 10.15585/mmwr.mm6840e2; Patelarou E, 2021, NURS EDUC TODAY, V104, DOI 10.1016/j.nedt.2021.105010; Riad A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18157859; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122629; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060673; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060566; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Riad A, 2021, J COSMET DERMATOL-US, V20, P1580, DOI 10.1111/jocd.14066; Riad A, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14735; Riad A, 2021, SPEC CARE DENT, V41, P282, DOI 10.1111/scd.12547; Riad A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.14479; Riad A, 2022, ORAL DIS, V28, P999, DOI 10.1111/odi.13675; Riad Abanoub, 2020, Oral Surg, DOI 10.1111/ors.12561; Riad A, 2022, ORAL DIS, V28, P988, DOI 10.1111/odi.13635; Riad A, 2022, ORAL DIS, V28, P968, DOI 10.1111/odi.13571; Riad A, 2022, ORAL DIS, V28, P940, DOI 10.1111/odi.13516; Robert M., REUTERS; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052407; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Sovicova M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18136815; SPSS Inc, IBM SPSS STAT 27; Strategic Advisory Group of Experts on Immunization (SAGE), VACC HES SURV QUEST; Synnott K., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3753756, DOI 10.2139/SSRN.3753756]; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Tavolacci MP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060654; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120, 10.1371/journal.pmed.0040296]; Vozikis A, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-15; Walker AN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060585; Wollina U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13549; Wollina U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13430; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yildiz Sinem, 2011, Eur J Dent, V5, P253	76	11	11	7	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							948	10.3390/vaccines9090948			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3KE	34579185	Green Published, gold			2022-04-29	WOS:000702106500001
J	Takova, K; Koynarski, T; Minkov, G; Toneva, V; Mardanova, E; Ravin, N; Lukov, GL; Zahmanova, G				Takova, Katerina; Koynarski, Tsvetoslav; Minkov, George; Toneva, Valentina; Mardanova, Eugenia; Ravin, Nikolai; Lukov, Georgi L.; Zahmanova, Gergana			Development and Optimization of an Enzyme Immunoassay to Detect Serum Antibodies against the Hepatitis E Virus in Pigs, Using Plant-Derived ORF2 Recombinant Protein	VACCINES			English	Article						hepatitis E virus; detection of serum antibodies; transient expression; plant molecular farming; ORF2 capsid protein; diagnostic antigen	CAPSID PROTEIN; EXPRESSION; SWINE; IDENTIFICATION; TRANSMISSION; INFECTION; HUMANS; IGG; HEV	Hepatitis E is an emerging global disease, mainly transmitted via the fecal-oral route in developing countries, and in a zoonotic manner in the developed world. Pigs and wild boar constitute the primary Hepatitis E virus (HEV) zoonotic reservoir. Consumption of undercooked animal meat or direct contact with infected animals is the most common source of HEV infection in European countries. The purpose of this study is to develop an enzyme immunoassay (EIA) for the detection of anti-hepatitis E virus IgG in pig serum, using plant-produced recombinant HEV-3 ORF2 as an antigenic coating protein, and also to evaluate the sensitivity and specificity of this assay. A recombinant HEV-3 ORF2 110-610_6his capsid protein, transiently expressed by pEff vector in Nicotiana benthamiana plants was used to develop an in-house HEV EIA. The plant-derived HEV-3 ORF2 110-610_6his protein proved to be antigenically similar to the HEV ORF2 capsid protein and it can self-assemble into heterogeneous particulate structures. The optimal conditions for the in-house EIA (iEIA) were determined as follows: HEV-3 ORF2 110-610_6his antigen concentration (4 mu g/mL), serum dilution (1:50), 3% BSA as a blocking agent, and secondary antibody dilution (1:20 000). The iEIA developed for this study showed a sensitivity of 97.1% (95% Cl: 89.9-99.65) and a specificity of 98.6% (95% Cl: 92.5-99.96) with a Youden index of 0.9571. A comparison between our iEIA and a commercial assay (PrioCHECK (TM) Porcine HEV Ab ELISA Kit, ThermoFisher Scientific, MA, USA) showed 97.8% agreement with a kappa index of 0.9399. The plant-based HEV-3 ORF2 iEIA assay was able to detect anti-HEV IgG in pig serum with a very good agreement compared to the commercially available kit.	[Takova, Katerina; Minkov, George; Toneva, Valentina; Zahmanova, Gergana] Paisij Hilendarski Univ Plovdiv, Dept Plant Physiol & Mol Biol, Plovdiv 4000, Bulgaria; [Koynarski, Tsvetoslav] Trakia Univ, Fac Vet Med, Dept Anim Genet, Stara Zagora 6000, Bulgaria; [Minkov, George; Toneva, Valentina] Inst Mol Biol & Biotechnol, Markovo 4108, Bulgaria; [Mardanova, Eugenia; Ravin, Nikolai] Russian Acad Sci, Inst Bioengn, Res Ctr Biotechnol, Moscow 119071, Russia; [Lukov, Georgi L.] Brigham Young Univ Hawaii, Fac Sci, Laie, HI 96762 USA; [Zahmanova, Gergana] Ctr Plant Syst Biol & Biotechnol, Plovdiv 4000, Bulgaria		Zahmanova, G (通讯作者)，Paisij Hilendarski Univ Plovdiv, Dept Plant Physiol & Mol Biol, Plovdiv 4000, Bulgaria.; Zahmanova, G (通讯作者)，Ctr Plant Syst Biol & Biotechnol, Plovdiv 4000, Bulgaria.	katerina.takova@uni-ploydiv.bg; tkoynarski@gmail.com; george-minkov@uni-ploydiv.bg; toneva@plantgene.eu; mardanovaes@mail.ru; nravin@mail.ru; georgi.lukov@byuh.edu; gerganaz@uni-ploydiv.bg	Zahmanova, Gergana/AAB-7405-2022; , Evgeniia/H-8473-2014	Zahmanova, Gergana/0000-0002-7667-9924; , Evgeniia/0000-0003-2148-7658; Ravin, Nikolai/0000-0002-1456-1832	European UnionEuropean Commission [739582, 664620]; European Regional Development Fund through the Bulgarian "Science and Education for Smart Growth" Operational Programme [BG05M2OP001-1.003-001-C01]; Ministry of Science and Higher Education of the Russian Federation [075-15-2020-907]; Federal budget of the Russian Federation; World-class Scientific Center "Agrotechnologies for the Future"; Research Fund at the University of Plovdiv, competition "Young Scientists and Doctoral Students" [MU21-BF-022]	This research was funded by the European Union's Horizon 2020 Research and Innova-tion Programme, project PlantaSYST (SGA-CSA No. 739582 under FPA No. 664620) and by the European Regional Development Fund through the Bulgarian "Science and Education for Smart Growth" Operational Programme (project BG05M2OP001-1.003-001-C01), Research Fund at the University of Plovdiv, competition "Young Scientists and Doctoral Students" MU21-BF-022. The work of the Russian group (E.M. and N.R.) was supported by the Ministry of Science and Higher Education of the Russian Federation in accordance with agreement ? 075-15-2020-907, November 16 2020, on providing a grant in the form of subsidies from the Federal budget of the Russian Federation. The grant was provided for state support for the creation and development of a World-class Scientific Center "Agrotechnologies for the Future".	Abravanel F, 2017, EMERG INFECT DIS, V23, P1191, DOI 10.3201/eid2307.170318; Baymakova M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030492; Byrne MJ, 2019, STRUCTURE, V27, P1761, DOI 10.1016/j.str.2019.09.010; Castilho A, 2021, BIOTECHNOL J, V16, DOI 10.1002/biot.202000566; Colson P, 2010, J INFECT DIS, V202, P825, DOI 10.1086/655898; de Deus N, 2008, VET MICROBIOL, V129, P163, DOI 10.1016/j.vetmic.2007.11.002; Debing Y, 2016, J HEPATOL, V65, P200, DOI 10.1016/j.jhep.2016.02.045; Dichtl K, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10060689; Engle RE, 2002, J CLIN MICROBIOL, V40, P4576, DOI 10.1128/JCM.40.12.4576-4580.2002; Folgado A, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9020147; Ge Shengxiang, 2003, Weishengwu Xuebao, V43, P35; Giritch A, 2006, P NATL ACAD SCI USA, V103, P14701, DOI 10.1073/pnas.0606631103; Gupta J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00141; Haim-Boukobza S, 2012, J HEPATOL, V57, P1374, DOI 10.1016/j.jhep.2012.08.001; He JY, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/106783; Izopet J, 2012, EMERG INFECT DIS, V18, P1274, DOI 10.3201/eid1808.120057; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; Kenney SP, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a031724; Kumar M, 2021, PLANTS-BASEL, V10, DOI 10.3390/plants10061213; Lee WJ, 2013, J VET SCI, V14, P467, DOI 10.4142/jvs.2013.14.4.467; Li SW, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000537; Lomonossoff GP, 2016, SCIENCE, V353, P1237, DOI 10.1126/science.aaf6638; Ma JX, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.699442; Maloney BJ, 2005, VACCINE, V23, P1870, DOI 10.1016/j.vaccine.2004.11.020; Mardanova ES, 2020, BIOTECHNOL LETT, V42, P2441, DOI 10.1007/s10529-020-02995-x; Mardanova ES, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00247; Marion O, 2016, CURR INFECT DIS REP, V18, DOI 10.1007/s11908-016-0515-z; Marques LEC, 2020, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01674; Mazalovska M, 2017, ANN LAB MED, V37, P313, DOI 10.3343/alm.2017.37.4.313; Mbewana S, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0489-z; Montpellier C, 2018, GASTROENTEROLOGY, V154, P211, DOI 10.1053/j.gastro.2017.09.020; Myint KSA, 2006, J CLIN MICROBIOL, V44, P1581, DOI 10.1128/JCM.44.4.1581-1583.2006; Oliveira EF, 2014, VET MICROBIOL, V174, P233, DOI 10.1016/j.vetmic.2014.09.011; Pandolfi R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176409; Arce LP, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02481; Peyret H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070780; Pishmisheva M., 2019, PREV MED, V7, P10; Pishmisheva M, 2018, CR ACAD BULG SCI, V71, P1001, DOI 10.7546/CRABS.2018.07.18; Ponterio E, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-133; Primadharsini PP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050456; Purdy MA, 2017, J GEN VIROL, V98, P2645, DOI 10.1099/jgv.0.000940; Riddell MA, 2000, J VIROL, V74, P8011, DOI 10.1128/JVI.74.17.8011-8017.2000; Rutjes SA, 2010, J VIROL METHODS, V168, P197, DOI 10.1016/j.jviromet.2010.05.014; Sainsbury F, 2008, PLANT PHYSIOL, V148, P1212, DOI 10.1104/pp.108.126284; Sainsbury F, 2013, PLANT BIOTECHNOL J, V11, P1058, DOI 10.1111/pbi.12098; Sainsbury Frank, 2009, V483, P25, DOI 10.1007/978-1-59745-407-0_2; Schnegg A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062980; Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842; Shrestha AC, 2016, TRANSFUSION, V56, P3086, DOI 10.1111/trf.13799; Siew QY, 2021, BIOSENS BIOELECTRON, V176, DOI 10.1016/j.bios.2020.112895; Simanavicius M, 2018, APPL MICROBIOL BIOT, V102, P185, DOI 10.1007/s00253-017-8622-9; Smith DB, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031880; Smith DB, 2016, J MED VIROL, V88, P915, DOI 10.1002/jmv.24403; Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272; Takova K, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091521; Tang XH, 2011, P NATL ACAD SCI USA, V108, P10266, DOI 10.1073/pnas.1101309108; Tarazona AAP, 2021, FEBS LETT, V595, P379, DOI 10.1002/1873-3468.14014; Tei S, 2003, LANCET, V362, P371, DOI 10.1016/S0140-6736(03)14025-1; Tsachev I, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110911; Tsachev I, 2019, VECTOR-BORNE ZOONOT, V19, P767, DOI 10.1089/vbz.2018.2430; Tschofen M, 2016, ANNU REV ANAL CHEM, V9, P271, DOI 10.1146/annurev-anchem-071015-041706; Van der Poel WHM, 2013, WOODHEAD PUBL FOOD S, V249, P401, DOI 10.1533/9780857098870.4.401; Wei MX, 2014, VACCINE, V32, P2859, DOI 10.1016/j.vaccine.2014.02.025; Wu CC, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01343-9; Zahmanova GG, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9010029; Zhang YF, 1997, CLIN DIAGN LAB IMMUN, V4, P423, DOI 10.1128/CDLI.4.4.423-428.1997	66	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							991	10.3390/vaccines9090991			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3QA	34579228	Green Published, gold			2022-04-29	WOS:000702121800001
J	Zhao, K; Gao, Y; Hu, GW; Wang, L; Cui, SJ; Jin, Z				Zhao, Kai; Gao, Yuan; Hu, Gaowei; Wang, Lei; Cui, Shangjin; Jin, Zheng			N-2-Hydroxypropyl Trimethyl Ammonium Chloride Chitosan as Adjuvant Enhances the Immunogenicity of a VP2 Subunit Vaccine against Porcine Parvovirus Infection in Sows	VACCINES			English	Article						porcine Parvovirus; VP2 protein; vaccine adjuvant; N-2-Hydroxypropyl trimethyl ammonium chloride chitosan; subunit vaccine	IMMUNOLOGICAL EFFECTIVENESS; VIRUS-VACCINE; NANOPARTICLES; SWINE; POLYSACCHARIDE; PREVENTION; DELIVERY; IMMUNITY; CELLS	Porcine parvovirus (PPV) is the most important infectious agent causing infertility in pigs, which can be prevented by routine vaccination. Successful vaccination depends on the association with potent adjuvants that can enhance the immunogenicity of antigen and activate the immune system. Polysaccharide adjuvant has low toxicity and high safety, and they can enhance the humoral, cellular and mucosal immune responses. In the present study, we prepared the VP2 protein subunit vaccine against PPV (PPV/VP2/N-2-HACC) using water-soluble N-2-Hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC) as the vaccine adjuvant, and the ability of the PPV/VP2/N-2-HACC to induce immune responses and protect sows from PPV infection was evaluated. In vivo immunization showed that the sows immunized with the PPV/VP2/N-2-HACC by intramuscular injection produced higher HI antibody levels and long-term immune protection compared with the other groups, while the subunit vaccine did not stimulate the proliferation of CD4+ and CD8+ T lymphocytes to trigger the secretion of higher levels of IL-2, IL-4, IFN-alpha, IFN-beta, and IFN-gamma, indicating that the PPV/VP2/N-2-HACC mainly induced humoral immunity rather than cellular immunity. PPV was not detected in the viscera of the sows immunized with the PPV/VP2/N-2-HACC, and the protective efficacy was 100%. Collectively, our findings suggested that the N-2-HACC was a potential candidate adjuvant, and the PPV/VP2/N-2-HACC had immense application value for the control of PPV.	[Zhao, Kai; Gao, Yuan; Hu, Gaowei; Wang, Lei; Jin, Zheng] Taizhou Univ, Sch Life Sci, Inst Nanobiomat & Immunol, Taizhou 318000, Peoples R China; [Cui, Shangjin] Chinese Acad Agr Sci, Inst Anim Sci, State Key Lab Anim Nutr, Beijing 100193, Peoples R China		Jin, Z (通讯作者)，Taizhou Univ, Sch Life Sci, Inst Nanobiomat & Immunol, Taizhou 318000, Peoples R China.	zhaokai@tzc.edu.cn; gaoyuan@tzc.edu.cn; hugaowei68@1.63.com; leiwang@chnu.edu.cn; cuishangjin@caas.cn; jinzheng@tzc.edu.cn			Zhejiang Provincial Key R&D Program of China [2021C02049]; Young Eagle Plan for Cultivation Special Project of Scientific and Technological Enterprise in Harbin [2020CYJBCG0306]	This work was supported in part by the Zhejiang Provincial Key R&D Program of China (2021C02049) and Young Eagle Plan for Cultivation Special Project of Scientific and Technological Enterprise in Harbin (2020CYJBCG0306).	Aiki-Raji C.O., 2017, BENI SUEF U J BASIC, V7, P80, DOI [10.1016/j.bjbas.2017.07.006, DOI 10.1016/J.BJBAS.2017.07.006]; Feria-Romero IA, 2011, ARCH MED RES, V42, P563, DOI 10.1016/j.arcmed.2011.10.009; Brown DM, 2010, CELL IMMUNOL, V262, P89, DOI 10.1016/j.cellimm.2010.02.008; Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1; Coughlan L, 2015, VACCINES-BASEL, V3, P293, DOI 10.3390/vaccines3020293; da Silva SB, 2018, CARBOHYD POLYM, V186, P299, DOI 10.1016/j.carbpol.2018.01.050; Fan YP, 2016, INT J BIOL MACROMOL, V82, P264, DOI 10.1016/j.ijbiomac.2015.10.084; Gardner IA, 1996, J AM VET MED ASSOC, V208, P863; Huang Y, 2013, CARBOHYD POLYM, V96, P516, DOI 10.1016/j.carbpol.2013.04.018; Hueffer K, 2003, CURR OPIN MICROBIOL, V6, P392, DOI 10.1016/S1369-5274(03)00083-3; Jin Z, 2017, CARBOHYD POLYM, V171, P267, DOI 10.1016/j.carbpol.2017.05.022; Jin Z, 2013, CHEM ENG J, V221, P331, DOI 10.1016/j.cej.2013.02.011; Krakowka S, 2000, VET PATHOL, V37, P254, DOI 10.1354/vp.37-3-254; Ladekjaer-Mikkelsen AS, 2002, VIRAL IMMUNOL, V15, P373, DOI 10.1089/08828240260066297; Lima KM, 2004, VACCINE, V22, P2374, DOI 10.1016/j.vaccine.2003.12.030; Ma X, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/472876; Ma X, 2011, CELL IMMUNOL, V270, P13, DOI 10.1016/j.cellimm.2011.03.020; Mckee AS, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-37; MENGELING WL, 1979, AM J VET RES, V40, P204; Mohamed SH, 2018, BIOLOGICALS, V51, P46, DOI 10.1016/j.biologicals.2017.10.004; Oritani K, 2005, J CELL MOL MED, V9, P244, DOI 10.1111/j.1582-4934.2005.tb00353.x; PARKE CR, 1993, AUST VET J, V70, P177, DOI 10.1111/j.1751-0813.1993.tb06124.x; Pinto RA, 2006, PEDIATRICS, V117, pE878, DOI 10.1542/peds.2005-2119; Qi T, 2009, VIRUS GENES, V39, P217, DOI 10.1007/s11262-009-0378-6; RANZ AI, 1989, J GEN VIROL, V70, P2541, DOI 10.1099/0022-1317-70-10-2541; Ren XF, 2013, VIRUS RES, V178, P392, DOI 10.1016/j.virusres.2013.09.014; Saikia C., 2015, J MOL GENET MED, Vs4, DOI [DOI 10.4172/1747-0862.S4-006, 10.4172/1747-0862.S4-006]; SENDA M, 1986, VET MICROBIOL, V12, P1, DOI 10.1016/0378-1135(86)90035-0; Sharma R, 2010, TROP ANIM HEALTH PRO, V42, P515, DOI 10.1007/s11250-009-9454-0; Shen C, 2017, INT J NANOMED, V12, P5443, DOI 10.2147/IJN.S137980; Srinivas S, 2008, IMMUNOLOGY, V125, P492, DOI 10.1111/j.1365-2567.2008.02862.x; Streck AF, 2015, J VIROL METHODS, V218, P46, DOI 10.1016/j.jviromet.2015.03.003; Sun BN, 2018, VACCINE, V36, P5226, DOI 10.1016/j.vaccine.2018.07.040; Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298; Wang FF, 2014, ACS APPL MATER INTER, V6, P21397, DOI 10.1021/am5064052; WRATHALL AE, 1984, RES VET SCI, V36, P136, DOI 10.1016/S0034-5288(18)31968-4; Xu YG, 2013, RES VET SCI, V94, P219, DOI 10.1016/j.rvsc.2012.09.003; Yao SY, 2014, J IMMUNOL, V192, P2120, DOI 10.4049/jimmunol.1301373; Zhao K, 2018, MOL PHARMACEUT, V15, P226, DOI 10.1021/acs.molpharmaceut.7b00826; Zhao K, 2016, CARBOHYD POLYM, V149, P28, DOI 10.1016/j.carbpol.2016.04.085; Zhao K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082648; Zhao K, 2011, VACCINE, V29, P8549, DOI 10.1016/j.vaccine.2011.09.029; Zhao K, 2010, J MICROENCAPSUL, V27, P178, DOI 10.3109/02652040903059239; Zhou HC, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-366	44	0	0	8	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1027	10.3390/vaccines9091027			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3AU	34579264	gold, Green Published			2022-04-29	WOS:000702081900001
J	Zhou, KH; Li, CQ; Shi, W; Hu, XD; Nandakumar, KS; Jiang, SB; Zhang, NR				Zhou, Kehui; Li, Chaoqun; Shi, Wen; Hu, Xiaodan; Nandakumar, Kutty Selva; Jiang, Shibo; Zhang, Naru			Current Progress in the Development of Zika Virus Vaccines	VACCINES			English	Review						Zika virus; vaccine; different strategies	NEUTRALIZING ANTIBODIES; CYSTEINE PROTEINASE; DNA VACCINE; MOUSE MODEL; INFECTION; PROTECTION; IMMUNOGENICITY; SPECIFICITY; DAMAGES; SAFETY	Zika virus (ZIKV) is an arbovirus first discovered in the Americas. ZIKV infection is insidious based on its mild clinical symptoms observed after infection. In Brazil, after 2015, ZIKV infection broke out on a large scale, and many infected pregnant women gave birth to babies with microcephaly. The teratogenic effects of the virus on the fetus and its effects on nerves and the immune system have attracted great attention. Currently, no specific prophylactics or therapeutics are clinically available to treat ZIKV infection. Development of a safe and effective vaccine is essential to prevent the rise of any potential pandemic. In this review, we summarize the latest research on Zika vaccine development based on different strategies, including DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles (VLPs), mRNA-based vaccines, and others. We anticipate that this review will facilitate further progress toward the development of effective and safe vaccines against ZIKV infection.	[Zhou, Kehui; Li, Chaoqun; Shi, Wen; Hu, Xiaodan; Zhang, Naru] Zhejiang Univ City Coll, Sch Med, Dept Clin Med, Hangzhou 310015, Peoples R China; [Nandakumar, Kutty Selva] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China; [Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Shanghai Inst Infect Dis & Biosecur, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China		Zhang, NR (通讯作者)，Zhejiang Univ City Coll, Sch Med, Dept Clin Med, Hangzhou 310015, Peoples R China.; Nandakumar, KS (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China.; Jiang, SB (通讯作者)，Fudan Univ, Sch Basic Med Sci, Shanghai Inst Infect Dis & Biosecur, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.	31704257@stu.zucc.edu.cn; 31704246@stu.zucc.edu.cn; 31704195@stu.zucc.edu.cn; 31704244@stu.zucc.edu.cn; nandakumar@smu.edu.cn; shibojiang@fudan.edu.cn; zhangnr@zucc.edu.cn	Nandakumar, Kutty Selva/D-5438-2011; Jiang, Shibo/L-4500-2014	Nandakumar, Kutty Selva/0000-0001-7790-8197; Jiang, Shibo/0000-0001-8283-7135	Zhejiang University City College; Hangzhou Science and Technology Bureau [J-202106]; Southern Medical University [C1034211, C1051004]	Naru Zhang would like to thank Zhejiang University City College and Hangzhou Science and Technology Bureau for providing her with the startup grants (J-202106). Kutty Selva Nandakumar is grateful to Southern Medical University for providing him with the intramural grants (Grant numbers C1034211 and C1051004).	Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163; Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157; Abbink P, 2015, J VIROL, V89, P1512, DOI 10.1128/JVI.02950-14; Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004750, 10.1371/journal.pntd.0004682]; Alvarado MG, 2017, ARCH PATHOL LAB MED, V141, P26, DOI 10.5858/arpa.2016-0382-RA; Austin AL, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040188; Baldwin WR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34735-7; Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608; Boutin S, 2010, HUM GENE THER, V21, P704, DOI 10.1089/hum.2009.182; Bullard BL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60238-5; Bullard BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35755-z; Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630; Collins ND, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020161; Dai SY, 2018, VIROL SIN, V33, P213, DOI 10.1007/s12250-018-0030-5; Danko JR, 2011, VACCINE, V29, P7261, DOI 10.1016/j.vaccine.2011.07.019; de La Vega MA, 2019, J INFECT DIS, V219, P365, DOI 10.1093/infdis/jiy336; de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085; Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137; Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824; Durbin A, 2017, EXPERT REV VACCINES, V16, P781, DOI 10.1080/14760584.2017.1345309; Dussupt V, 2020, NAT MED, V26, P228, DOI 10.1038/s41591-019-0746-2; Espinosa D, 2018, EBIOMEDICINE, V27, P61, DOI 10.1016/j.ebiom.2017.12.010; Fontes-Garfias CR, 2017, CELL REP, V21, P1180, DOI 10.1016/j.celrep.2017.10.016; Garg H, 2017, J VIROL, V91, DOI 10.1128/JVI.00834-17; Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7; Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556; Griffin BD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15743; Grubor-Bauk B, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2388; Guo Q, 2018, J INFECT DIS, V218, P365, DOI 10.1093/infdis/jiy187; Han JF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10595-5; Hraber P, 2018, VACCINE, V36, P6911, DOI 10.1016/j.vaccine.2018.10.022; Kizlik-Masson C, 2019, BLOOD, V133, P2427, DOI 10.1182/blood.2019000437; Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010; Leborgne C, 2020, NAT MED, V26, P1096, DOI 10.1038/s41591-020-0911-7; Lecouturier V, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0167-8; Lecouturier V, 2019, VACCINE, V37, P2679, DOI 10.1016/j.vaccine.2019.04.013; Li AZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05276-4; Li C, 2012, GENE THER, V19, P288, DOI 10.1038/gt.2011.90; Lin HH, 2018, BIOTECHNOL ADV, V36, P47, DOI 10.1016/j.biotechadv.2017.09.004; Lopez-Camacho C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04859-5; Lorant T, 2018, AM J TRANSPLANT, V18, P2752, DOI 10.1111/ajt.14733; Ma WQ, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.009; Medina LO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02464; Meliani A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06621-3; Mingozzi F, 2017, ANNU REV VIROL, V4, P511, DOI 10.1146/annurev-virology-101416-041936; Nandakumar KS, 2008, TRENDS IMMUNOL, V29, P173, DOI 10.1016/j.it.2008.01.007; Nandy A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050666; Pang W, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2020.04.021; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Rayner JO, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050229; Regla-Nava JA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007080; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V169, P176, DOI 10.1016/j.cell.2017.03.016; Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024; Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111; Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8; Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322; Shi XD, 2019, VIROL SIN, V34, P106, DOI 10.1007/s12250-019-00083-7; Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001; Steffen T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020170; Stephenson KE, 2020, LANCET INFECT DIS, V20, P1061, DOI 10.1016/S1473-3099(20)30085-2; Sumathy K, 2017, SCI REP-UK, V7, DOI 10.1038/srep46375; Tai WB, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0007-8; To A, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00576-17; von Pawel-Rammingen U, 2002, EMBO J, V21, P1607, DOI 10.1093/emboj/21.7.1607; Wang R, 2018, VACCINE, V36, P3522, DOI 10.1016/j.vaccine.2018.04.051; Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36; Wenig K, 2004, P NATL ACAD SCI USA, V101, P17371, DOI 10.1073/pnas.0407965101; Xie XP, 2018, CELL HOST MICROBE, V24, P487, DOI 10.1016/j.chom.2018.09.008; Xie XP, 2017, MBIO, V8, DOI [10.1128/mBio.02134-16, 10.1128/mbio.02134-16]; Yang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08247-9; Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052; Yang YJ, 2017, EBIOMEDICINE, V17, P145, DOI 10.1016/j.ebiom.2017.02.003; Young G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60415-6; Zhang C, 2016, HUM VACC IMMUNOTHER, V12, P2064, DOI 10.1080/21645515.2016.1165908; Zhang NR, 2015, MICROBES INFECT, V17, P123, DOI 10.1016/j.micinf.2014.12.006; Zhong ZF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030096; Zhu JG, 2007, J IMMUNOL, V178, P3505, DOI 10.4049/jimmunol.178.6.3505; Zhu XL, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0572-7; Zompi S, 2012, J IMMUNOL, V188, P404, DOI 10.4049/jimmunol.1102124; Zou J, 2018, EBIOMEDICINE, V36, P92, DOI 10.1016/j.ebiom.2018.08.056	81	3	3	17	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1004	10.3390/vaccines9091004			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3MZ	34579241	gold, Green Published			2022-04-29	WOS:000702113800001
J	Al Hamada, A; Bruce, M; Barnes, A; Habib, I; Robertson, ID				Al Hamada, Ali; Bruce, Mieghan; Barnes, Anne; Habib, Ihab; D. Robertson, Ian			Cost-Benefit Analysis of a Mass Vaccination Strategy to Control Brucellosis in Sheep and Goats in Northern Iraq	VACCINES			English	Article						brucellosis; economic analysis; vaccination; small ruminants; Iraq	REV 1 VACCINE; BOVINE BRUCELLOSIS; HEALTH; ECONOMICS; LIVESTOCK; REGION; IMPACT	Brucellosis is a major economic and production-limiting disease for livestock owners and the community in Iraq. A cost-benefit analysis was conducted to evaluate the impact of an expanded annual mass vaccination programme of sheep and goats that involves all female and male sheep and goats over the age of 3 months with Rev. 1 vaccine. The proposed expanded vaccination programme was compared to the current annual vaccination program, which involved only vaccinating female sheep and goats between the ages of 3 and 6 months of age with Rev. 1. The cost-benefit analysis model was developed utilizing data collected in Dohuk Governorate, northern Iraq. The seroprevalence in small ruminants (using Rose Bengal test and ELISA in series) was predicted to decrease from 9.22% to 0.73% after 20 years of implementing the proposed annual mass vaccination program. The net present value of the mass vaccination program was estimated to be US$ 10,564,828 (95% Confidence Interval (CI): -16,203,454 to 37,049,245), the benefit-cost ratio was estimated to be 4.25 (95% CI: -2.71 to 11.22), and the internal rate of return was 91.38% (95% CI:11.71 to 190.62%). The proposed vaccination strategy was predicted to decrease the overall financial loss caused by brucellosis from 1.75 to 0.55 US$ per adult female animal. The results of this economic analysis highlight the benefit of implementing an annual mass vaccination program of small ruminants with Rev. 1 vaccine to reduce the prevalence of brucellosis in northern Iraq.	[Al Hamada, Ali; Bruce, Mieghan; Barnes, Anne; Habib, Ihab; D. Robertson, Ian] Murdoch Univ, Sch Vet Med, Perth, WA 6150, Australia; [Al Hamada, Ali] Univ Mosul, Coll Vet Med, Mosul 41002, Iraq; [Bruce, Mieghan; Barnes, Anne] Murdoch Univ, Food Futures Inst, Ctr Anim Prod & Hlth, Perth, WA 6150, Australia; [Habib, Ihab] United Arab Emirates Univ UAEU, Coll Food & Agr, Dept Vet Med, POB 1555, Al Ain, U Arab Emirates; [D. Robertson, Ian] Huazhong Agr Univ, Coll Vet Med, Wuhan 430070, Peoples R China		Barnes, A; Habib, I (通讯作者)，Murdoch Univ, Sch Vet Med, Perth, WA 6150, Australia.; Barnes, A (通讯作者)，Murdoch Univ, Food Futures Inst, Ctr Anim Prod & Hlth, Perth, WA 6150, Australia.; Habib, I (通讯作者)，United Arab Emirates Univ UAEU, Coll Food & Agr, Dept Vet Med, POB 1555, Al Ain, U Arab Emirates.	Gaddan76@gmail.com; Mieghan.Bruce@murdoch.edu.au; A.Barnes@murdoch.edu.au; i.habib@uaeu.ac.ae; i.robertson@murdoch.edu.au		Robertson, Ian/0000-0002-4255-4752; Habib, Ihab/0000-0002-0938-0607; Al Hamada, Ali/0000-0002-6863-8233; Bruce, Mieghan/0000-0003-3176-2094	Higher Committee for Education Development in Iraq	We want to thank the livestock farmers and local veterinarians in Dohuk who agreed to participate in this study to facilitate data collection. Ali. J. Al-Hamada is indebted to the research fund from the Higher Committee for Education Development in Iraq through a Ph.D. Scholarship grant.	Al Hamada A, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11030836; Al-Majali AM, 2009, J VET SCI, V10, P61, DOI 10.4142/jvs.2009.10.1.61; Alhamada Ali G, 2017, Vet Sci, V4, DOI 10.3390/vetsci4040065; Alshwany E.A.A., 2019, THESIS MURDOCH U PER; Alves AJS, 2015, PREV VET MED, V118, P351, DOI 10.1016/j.prevetmed.2014.12.010; Atluri VL, 2011, ANNU REV MICROBIOL, V65, P523, DOI 10.1146/annurev-micro-090110-102905; Bamaiyi P. H., 2015, Research Opinions in Animal and Veterinary Sciences, V5, P57; Beauvais W, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1327-6; Bechtol D, 2011, ZOONOSES PUBLIC HLTH, V58, P489, DOI 10.1111/j.1863-2378.2011.01399.x; Benkirane A, 2014, OPEN VET J, V4, P96; Blasco J M, 2010, Prilozi, V31, P145; Blasco JM, 1997, PREV VET MED, V31, P275, DOI 10.1016/S0167-5877(96)01110-5; Blasco JM, 2011, VET CLIN N AM-FOOD A, V27, P95, DOI 10.1016/j.cvfa.2010.10.003; Corbel M.J., 2006, BRUC HUM AN; Dean AS, 2012, PLOS NEGLECT TROP D, V6, DOI [10.1371/journal.pntd.0001865, 10.1371/journal.pntd.0001929]; EFSA, 2006, EFSA J, V432, P1; Franc KA, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-5016-y; Galal S, 2008, SMALL RUMINANT RES, V79, P99, DOI 10.1016/j.smallrumres.2008.07.018; Hegazy YM, 2009, EPIDEMIOL INFECT, V137, P1436, DOI 10.1017/S0950268809002301; Iniguez L, 2005, CHARACTERIZATION SMA, V2; Jansen W, 2019, FOOD CONTROL, V100, P130, DOI 10.1016/j.foodcont.2019.01.022; Khan MZ, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3020065; Marsh W, 1999, REV SCI TECH OIE, V18, P357, DOI 10.20506/rst.18.2.1170; McDermott J, 2013, REV SCI TECH OIE, V32, P249; Minas A, 2004, PREV VET MED, V64, P41, DOI 10.1016/j.prevetmed.2004.03.007; Montiel D.O., 2014, THESIS WAGENINGEN UR; Montiel DO, 2015, PREV VET MED, V118, P247, DOI 10.1016/j.prevetmed.2014.11.014; Nielsen K, 2004, REV SCI TECH OIE, V23, P979, DOI 10.20506/rst.23.3.1532; Pacinovski N., 2016, Biotechnology in Animal Husbandry, V32, P145; Perrett LL, 2004, SMALL RUMINANT RES, V51, P221, DOI 10.1016/S0921-4488(03)00233-5; Rossetti CA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005692; Roth F, 2003, B WORLD HEALTH ORGAN, V81, P867; Saeedzadeh A., 2013, Comparative Clinical Pathology, V22, P409, DOI 10.1007/s00580-012-1424-7; Samadi Assadullah, 2010, Vet Med Int, V2010, P458695, DOI 10.4061/2010/458695; Scharp DW, 1999, TROP ANIM HEALTH PRO, V31, P135, DOI 10.1023/A:1005113412431; Seleem MN, 2010, VET MICROBIOL, V140, P392, DOI 10.1016/j.vetmic.2009.06.021; Singh BB, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006488; Sulima M., 2010, Tamilnadu Journal of Veterinary and Animal Sciences, V6, P191; Yacoub A. A-H., 2006, Eastern Mediterranean Health Journal, V12, P112; Zangana I.K., 2013, BAS J VET RES, V12, P54; ZUNDEL E, 1992, ANN RECH VET, V23, P177	41	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							878	10.3390/vaccines9080878			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7OZ	34452003	Green Published, gold			2022-04-29	WOS:000690116500001
J	Alluhaybi, KA; Alharbi, RH; Alhabbab, RY; Aljehani, ND; Alamri, SS; Basabrain, M; Alharbi, R; Abdulaal, WH; Alfaleh, MA; Tamming, L; Zhang, WY; Hassanain, M; Algaissi, A; Abuzenadah, AM; Li, XG; Hashem, AM				Alluhaybi, Khalid A.; Alharbi, Rahaf H.; Alhabbab, Rowa Y.; Aljehani, Najwa D.; Alamri, Sawsan S.; Basabrain, Mohammad; Alharbi, Rehaf; Abdulaal, Wesam H.; Alfaleh, Mohamed A.; Tamming, Levi; Zhang, Wanyue; Hassanain, Mazen; Algaissi, Abdullah; Abuzenadah, Adel M.; Li, Xuguang; Hashem, Anwar M.			Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1	VACCINES			English	Article						SARS-CoV-2 vaccine; cellular and humoral immunogenicity; DNA vaccine	ACUTE RESPIRATORY SYNDROME; FELINE INFECTIOUS PERITONITIS; CORONAVIRUS; VIRUS; OUTBREAK; EFFICACY; HEALTH; SAFETY	The urgent need for effective, safe and equitably accessible vaccines to tackle the ongoing spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of immunogens of SARS-CoV-2. Because of its crucial role in mediating binding and entry to host cell and its proven safety profile, the subunit 1 (S1) of the spike protein represents an attractive immunogen for vaccine development. Here, we developed and assessed the immunogenicity of a DNA vaccine encoding the SARS-CoV-2 S1. Following in vitro confirmation and characterization, the humoral and cellular immune responses of our vaccine candidate (pVAX-S1) was evaluated in BALB/c mice using two different doses, 25 mu g and 50 mu g. Our data showed high levels of SARS-CoV-2 specific IgG and neutralizing antibodies in mice immunized with three doses of pVAX-S1. Analysis of the induced IgG subclasses showed a Th1-polarized immune response, as demonstrated by the significant elevation of spike-specific IgG2a and IgG2b, compared to IgG1. Furthermore, we found that the immunization of mice with three doses of 50 mu g of pVAX-S1 could elicit significant memory CD4(+) and CD8(+) T cell responses. Taken together, our data indicate that pVAX-S1 is immunogenic and safe in mice and is worthy of further preclinical and clinical evaluation.	[Alluhaybi, Khalid A.; Alharbi, Rahaf H.; Alhabbab, Rowa Y.; Aljehani, Najwa D.; Alamri, Sawsan S.; Basabrain, Mohammad; Alharbi, Rehaf; Alfaleh, Mohamed A.; Hashem, Anwar M.] King Abdulaziz Univ, Vaccines & Immunotherapy Unit, King Fahd Med Res Ctr, Jeddah 21859, Saudi Arabia; [Alluhaybi, Khalid A.; Alfaleh, Mohamed A.] King Abdulaziz Univ, Fac Pharm, Jeddah 21859, Saudi Arabia; [Alhabbab, Rowa Y.; Abuzenadah, Adel M.] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah 21859, Saudi Arabia; [Aljehani, Najwa D.; Alamri, Sawsan S.; Abdulaal, Wesam H.] King Abdulaziz Univ, Dept Biochem, Fac Sci, Jeddah 21859, Saudi Arabia; [Tamming, Levi; Zhang, Wanyue; Li, Xuguang] Hlth Canada, Hlth Prod & Food Branch HPFB, Ctr Biol Evaluat, Biol & Radiopharmaceut Drug Directorate, Ottawa, ON K1A 0K9, Canada; [Tamming, Levi; Zhang, Wanyue; Li, Xuguang] WHO Collaborating Ctr Standardizat & Evaluat Biol, Ottawa, ON K1A 0K9, Canada; [Tamming, Levi; Zhang, Wanyue; Li, Xuguang] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada; [Hassanain, Mazen] King Saud Univ, Dept Surg, Fac Med, Riyadh 11451, Saudi Arabia; [Algaissi, Abdullah] Jazan Univ, Dept Med Labs Technol, Coll Appl Med Sci, Jazan 45142, Saudi Arabia; [Algaissi, Abdullah] Jazan Univ, Med Res Ctr, Jazan 45142, Saudi Arabia; [Hashem, Anwar M.] King Abdulaziz Univ, Dept Med Microbiol & Parasitol, Fac Med, Jeddah 21859, Saudi Arabia		Hashem, AM (通讯作者)，King Abdulaziz Univ, Vaccines & Immunotherapy Unit, King Fahd Med Res Ctr, Jeddah 21859, Saudi Arabia.; Hashem, AM (通讯作者)，King Abdulaziz Univ, Dept Med Microbiol & Parasitol, Fac Med, Jeddah 21859, Saudi Arabia.	Kalluhaybi@kau.edu.sa; rahafh_h@live.com; ralhabbab2@gmail.com; naljehani0053@stu.kau.edu.sa; sawsan522@hotmail.com; mohammad.basabrain@gmail.com; rehaf-sa@hotmail.com; whabdulaal@kau.edu.sa; maalfaleh@kau.edu.sa; ltamm055@uottawa.ca; aliciazhang112@gmail.com; mhassanain@ksu.edu.sa; aalgaissi@jazanu.edu.sa; maalfaleh@kau.edu.sa; sean.li@canada.ca; amhashem@kau.edu.sa	Hashem, Anwar M/B-2301-2017; Hassanain, Mazen/C-7256-2011	Hashem, Anwar M/0000-0002-8471-7011; Hassanain, Mazen/0000-0002-2441-5142; Alfaleh, Mohamed/0000-0003-3716-0019; Tamming, Levi/0000-0003-2851-7311; Abdulaal, Wesam/0000-0002-2510-1946; Algaissi, Abdullah/0000-0002-5386-406X; Alharbi, Rahaf/0000-0002-9119-8360	Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah [GCV19-43-1441]	This project was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah under Grant Number GCV19-43-1441. The authors therefore acknowledge with thanks DSR for financial and technical support.	Ababneh M, 2019, VET WORLD, V12, P1554, DOI 10.14202/vetworld.2019.1554-1562; Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Al-amri SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44875; Almahboub SA, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02020; [Anonymous], 2021, FATAL COVID 19 OUTCO, DOI [DOI 10.1101/2021.05.04.21256571, 10.1101/2021.05.04.21256571]; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Fang YT, 2010, MOL IMMUNOL, V47, P1000, DOI 10.1016/j.molimm.2009.11.019; Fernandez A, 2021, ACS PHARMACOL TRANSL, V4, P1016, DOI 10.1021/acsptsci.1c00036; Goodman AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025938; Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137; He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hotez PJ, 2014, MICROBES INFECT, V16, P529, DOI 10.1016/j.micinf.2014.05.002; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31; Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Mor G, 1997, HUM GENE THER, V8, P293, DOI 10.1089/hum.1997.8.3-293; Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462; Oboho IK, 2015, NEW ENGL J MED, V372, P846, DOI 10.1056/NEJMoa1408636; OLSEN CW, 1993, VET MICROBIOL, V36, P1, DOI 10.1016/0378-1135(93)90126-R; Perez P, 2021, EMERG MICROBES INFEC, V10, P1441, DOI 10.1080/22221751.2021.1951624; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Pushparajah D, 2021, ADV DRUG DELIVER REV, V170, P113, DOI 10.1016/j.addr.2021.01.003; Ren WL, 2020, VACCINE, V38, P5653, DOI 10.1016/j.vaccine.2020.06.066; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sanchez-Felipe L, 2021, NATURE, V590, DOI 10.1038/s41586-020-3035-9; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Vasireddy Deepa, 2021, J Clin Med Res, V13, P204, DOI 10.14740/jocmr4490; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004; WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5; Williams JA, 2013, VACCINES, V1, P225, DOI 10.3390/vaccines1030225; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yang Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00523-5; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153; Zheng BJ, 2004, EMERG INFECT DIS, V10, P176, DOI 10.3201/eid1002.030533; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	45	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							852	10.3390/vaccines9080852			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7MM	34451977	Green Published, Green Submitted, gold			2022-04-29	WOS:000690110000001
J	Chu, KB; Kang, HJ; Yoon, KW; Lee, HA; Moon, EK; Han, BK; Quan, FS				Chu, Ki-Back; Kang, Hae-Ji; Yoon, Keon-Woong; Lee, Hae-Ahm; Moon, Eun-Kyung; Han, Beom-Ku; Quan, Fu-Shi			Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains	VACCINES			English	Article						COVID-19; SARS-CoV-2; virus-like particle; vaccine; antibody; neutralization	INFECTION; ANTIBODIES; IMMUNITY	The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic had brought disastrous consequences throughout the entire world. While several manufactured vaccines have been approved for emergency use, continuous efforts to generate novel vaccines are needed. In this study, we developed SARS-CoV-2 virus-like particles (VLPs) containing the full length of spike (S) glycoprotein (S full), S1, or S2 together with the influenza matrix protein 1 (M1) as a core protein. Successfully constructed VLPs expressing the S full, S1, and S2 via Sf9 cell transfections were confirmed and characterized by Western blot and transmission electron microscopy (TEM). VLP immunization in mice induced higher levels of spike protein-specific IgG and its subclasses compared to naive control, with IgG2a being the most predominant subclass. S full and S1 immune sera elicited virus-neutralizing activities, but these were not strong enough to fully inhibit receptor-ligand binding of the SARS-CoV-2. Neutralizing activities were not observed from the S2 VLP immune sera. Overall, our findings revealed that S full or S1 containing VLPs can be developed into effective vaccines.	[Chu, Ki-Back; Kang, Hae-Ji; Yoon, Keon-Woong] Kyung Hee Univ, Grad Sch, Dept Biomed Sci, Seoul 02447, South Korea; [Lee, Hae-Ahm; Quan, Fu-Shi] Kyung Hee Univ, Grad Sch, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Seoul 02447, South Korea; [Lee, Hae-Ahm; Quan, Fu-Shi] Kyung Hee Univ, Biomed Sci Inst, Seoul 02447, South Korea; [Moon, Eun-Kyung; Quan, Fu-Shi] Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 02447, South Korea; [Han, Beom-Ku] Optipharm Inc, Cheongju 28158, South Korea		Quan, FS (通讯作者)，Kyung Hee Univ, Grad Sch, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Seoul 02447, South Korea.; Quan, FS (通讯作者)，Kyung Hee Univ, Biomed Sci Inst, Seoul 02447, South Korea.; Quan, FS (通讯作者)，Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 02447, South Korea.	kbchu@khu.ac.kr; haedi1202@naver.com; kgang92@gmail.com; hae.ahm.lee@gmail.com; kgang92@gmail.com; bkhanhs@gmail.com; fsquan@khu.ac.kr			National Research Foundation of Korea (NRF)National Research Foundation of Korea [2018R1A6A1A03025124]; Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [HV20C0085, HV20C0142]	a This research was funded by the National Research Foundation of Korea (NRF) (2018R1A6A1A03025124), the Ministry of Health & Welfare, Republic of Korea (HV20C0085, HV20C0142).	Anderson AM, 2018, J IMMUNOL, V200, P2057, DOI 10.4049/jimmunol.1701088; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Arunkumar GA, 2019, J VIROL, V93, DOI 10.1128/JVI.01696-18; Berry JD, 2010, MABS-AUSTIN, V2, P53, DOI 10.4161/mabs.2.1.10788; Chan SK, 2021, ACS NANO, V15, P1259, DOI 10.1021/acsnano.0c08430; Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218; Chu KB, 2021, CURR TOP MICROBIOL, V433, P77, DOI 10.1007/82_2021_232; Chu KB, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051314; Ding SL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111214; Fang JX, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.7; Galloway SE, 2021, MMWR-MORBID MORTAL W, V70, P95, DOI [10.15585/mmwr.mm7003e2externalicon, 10.15585/mmwr.mm7003e2]; Gao T, 2021, MICROB CELL FACT, V20, DOI 10.1186/s12934-021-01584-5; Johansen MD, 2020, MUCOSAL IMMUNOL, V13, P877, DOI 10.1038/s41385-020-00340-z; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Kang HJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216871; Karthik K, 2020, HUM VACC IMMUNOTHER, V16, P3055, DOI 10.1080/21645515.2020.1796425; Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13; Kumar A, 2021, CURR INFECT DIS REP, V23, DOI 10.1007/s11908-021-00752-3; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Lee SH, 2018, VACCINE, V36, P5692, DOI 10.1016/j.vaccine.2018.08.016; Lim SA, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2021.1893426; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Makela Anna R, 2010, Cold Spring Harb Protoc, V2010, DOI 10.1101/pdb.prot5395; Mansour AA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01195; Mantus G, 2021, J IMMUNOL, V206, P2605, DOI 10.4049/jimmunol.2001420; Margine I, 2013, J VIROL, V87, P10435, DOI 10.1128/JVI.01715-13; Martinez ME, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246770; Moon EK, 2019, IMMUNOL INVEST, V48, P355, DOI 10.1080/08820139.2018.1544640; Nooraei S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00806-7; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roubidoux EK, 2021, MBIO, V12, DOI 10.1128/mBio.03617-20; Roy S, 2021, VIRUS RES, V295, DOI 10.1016/j.virusres.2021.198305; Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Tan TK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20654-7; Tang JLW, 2021, J INFECTION, V82, pE27, DOI 10.1016/j.jinf.2020.12.024; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; van der Hoek L, 2007, ANTIVIR THER, V12, P651; Wang BZ, 2008, J VIROL, V82, P11813, DOI 10.1128/JVI.01076-08; WHO, WHO COR COVID 19 DAS; Wu F, 2020, JAMA INTERN MED, V180, P1356, DOI 10.1001/jamainternmed.2020.4616; Xu RD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00862; Yang F, 2020, EMERG MICROBES INFEC, V9, P664, DOI 10.1080/22221751.2020.1742076; Yang YP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020073; Zhong L, 2009, BIOCHEM BIOPH RES CO, V390, P1056, DOI 10.1016/j.bbrc.2009.10.115; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	53	4	4	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							920	10.3390/vaccines9080920			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6LG	34452044	gold, Green Published			2022-04-29	WOS:000690039200001
J	Gandolfo, C; Prathyumn, S; Terrosi, C; Anichini, G; Savellini, GG; Corti, D; Bracci, L; Lanzavecchia, A; Roman-Sosa, G; Cusi, MG				Gandolfo, Claudia; Prathyumn, Shibily; Terrosi, Chiara; Anichini, Gabriele; Gori Savellini, Gianni; Corti, Davide; Bracci, Luisa; Lanzavecchia, Antonio; Roman-Sosa, Gleyder; Cusi, Maria Grazia			Identification of a Neutralizing Epitope on TOSV Gn Glycoprotein	VACCINES			English	Article						Toscana virus; glycoprotein; epitope; vaccine	TOSCANA VIRUS-INFECTION; MONOCLONAL-ANTIBODIES; EFFICIENT METHOD; FEVER; SEGMENT	Emerging and re-emerging viral infections have been an important public health problem in recent years. We focused our attention on Toscana virus (TOSV), an emergent neurotropic negative-strand RNA virus of the Phenuiviridae family. The mechanisms of protection against phlebovirus natural infection are not known; however, it is supposed that a virus-neutralizing antibody response against viral glycoproteins would be useful to block the first stages of infection. By using an improved memory B cell immortalization method, we obtained a panel of human mAbs which reacted with TOSV antigens. We identified three epitopes of TOSV Gn glycoproteins by neutralizing mAbs using synthetic peptide arrays on membrane support (SPOT synthesis). These epitopes, separated in primary structure, might be exposed near one another as a conformational epitope in their native structure. In vivo studies were conducted to evaluate the humoral response elicited in mice immunized with the identified peptides. The results underlined the hypothesis that the first two peptides located in the NH2 terminus could form a conformational epitope, while the third, located near the transmembrane sequence in the carboxyl terminus, was necessary to strengthen neutralizing activity. Our results emphasize the importance of identifying neutralizing epitopes shared among the various phleboviruses, which could be exploited for the development of a potential epitope-based diagnostic assay or a polyvalent protective vaccine against different phleboviruses.	[Gandolfo, Claudia; Prathyumn, Shibily; Terrosi, Chiara; Anichini, Gabriele; Gori Savellini, Gianni; Cusi, Maria Grazia] Univ Siena, Dept Med Biotechnol, Virol Unit, I-53100 Siena, Italy; [Corti, Davide; Lanzavecchia, Antonio] Inst Res Biomed, CH-6501 Bellinzona, Switzerland; [Bracci, Luisa] Univ Siena, Dept Med Biotechnol, Biochem Unit, I-53100 Siena, Italy; [Roman-Sosa, Gleyder] Inst Pasteur, Virol Dept, Struct Virol Unit, 25-28 Rue Du Dr Roux, F-75015 Paris, France; [Roman-Sosa, Gleyder] Justus Liebig Univ Giessen, Inst Virol FB10, Schubert Str 81, D-35392 Giessen, Germany		Cusi, MG (通讯作者)，Univ Siena, Dept Med Biotechnol, Virol Unit, I-53100 Siena, Italy.	claudia.gandolfo@unisi.it; shibily.prathyumn@student.unisi.it; chiara.terrosi@unisi.it; gabriele.anichini@student.unisi.it; gianni.gori@unisi.it; davide.corti@humabs.ch; luisa.bracci@unisi.it; alanzavecchia@vir.bio; gleyder.roman-sosa@vetmed.uni-giessen.de; mariagrazia.cusi@unisi.it	Savellini, Gianni Gori/D-1904-2019; CUSI, MARIA GRAZIA/K-2377-2018; BRACCI, LUISA/V-9913-2018; Gandolfo, Claudia/U-4982-2019	Savellini, Gianni Gori/0000-0003-2287-9258; CUSI, MARIA GRAZIA/0000-0001-8869-8164; Roman Sosa, Gleyder/0000-0003-1810-1347; MARITTI, MICAELA/0000-0003-0606-6353; BRACCI, LUISA/0000-0002-0738-5746; Gandolfo, Claudia/0000-0003-2174-0713; Anichini, Gabriele/0000-0001-9895-2488; PRATHYUMNAN, SHIBILY/0000-0002-9807-3595	Italian Ministry of Education, Universities and Research (MIUR)Ministry of Education, Universities and Research (MIUR) [2017KM79NN]	This research was partly funded by the Italian Ministry of Education, Universities and Research (MIUR), grant number 2017KM79NN.	Abudurexiti A, 2019, ARCH VIROL, V164, P1949, DOI 10.1007/s00705-019-04253-6; ACCARDI L, 1993, VIRUS RES, V27, P119, DOI 10.1016/0168-1702(93)90076-Y; ARIKAWA J, 1989, J GEN VIROL, V70, P615, DOI 10.1099/0022-1317-70-3-615; Backovic M, 2010, PROTEIN ENG DES SEL, V23, P169, DOI 10.1093/protein/gzp088; Charrel Remi N, 2012, World J Virol, V1, P135, DOI 10.5501/wjv.v1.i5.135; Charrel RN, 2005, EMERG INFECT DIS, V11, P1657, DOI 10.3201/eid1111.050869; Cusi M.G., 2002, P 1 SIV INT WORKSH N; Cusi Maria G, 2010, Open Virol J, V4, P22, DOI 10.2174/1874357901004020022; Cusi MG, 2001, J MED VIROL, V63, P72, DOI 10.1002/1096-9071(200101)63:1<72::AID-JMV1011>3.3.CO;2-J; Di Bonito P, 2002, J MED VIROL, V68, P615, DOI 10.1002/jmv.10227; Di Bonito P, 1999, ARCH VIROL, V144, P1947, DOI 10.1007/s007050050717; DiBonito P, 1997, J GEN VIROL, V78, P77, DOI 10.1099/0022-1317-78-1-77; Elliott RM, 2014, CURR OPIN VIROL, V5, P50, DOI 10.1016/j.coviro.2014.01.011; GIORGI C, 1991, VIROLOGY, V180, P738, DOI 10.1016/0042-6822(91)90087-R; GONZALEZSCARANO F, 1982, VIROLOGY, V120, P42, DOI 10.1016/0042-6822(82)90005-8; GRADY LJ, 1985, J GEN VIROL, V66, P2773, DOI 10.1099/0022-1317-66-12-2773; Gro MC, 1997, VIRUS RES, V51, P81, DOI 10.1016/S0168-1702(97)00076-2; Hilpert K, 2007, NAT PROTOC, V2, P1333, DOI 10.1038/nprot.2007.160; Hlavacek WS, 1999, BIOPHYS J, V76, P3031, DOI 10.1016/S0006-3495(99)77456-4; Lin M, 2010, J GEN VIROL, V91, P2928, DOI 10.1099/vir.0.023259-0; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rizk RZ, 2008, J GEN VIROL, V89, P117, DOI 10.1099/vir.0.83145-0; SALUZZO JF, 1989, RES VIROLOGY, V140, P155, DOI 10.1016/S0923-2516(89)80093-7; SALUZZO JF, 1989, T ROY SOC TROP MED H, V83, P701, DOI 10.1016/0035-9203(89)90402-1; Sanbonmatsu-Gamez S, 2009, EMERG INFECT DIS, V15, P347, DOI 10.3201/eid1502.081001; Soldateschi D, 1999, J CLIN MICROBIOL, V37, P649, DOI 10.1128/JCM.37.3.649-652.1999; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; Valassina M, 2003, J NEUROVIROL, V9, P577, DOI 10.1080/jnv.9.6.577.583; Valassina M, 2003, CLIN DIAGN LAB IMMUN, V10, P483, DOI 10.1128/CDLI.10.3.483-484.2003; Verani P., 1982, Annali dell'Istituto Superiore di Sanita, V18, P397; VERANI P, 1988, AM J TROP MED HYG, V38, P433, DOI 10.4269/ajtmh.1988.38.433; VERANI P, 1984, ACTA VIROL, V28, P39; Winkler Dirk F. H., 2008, V494, P47, DOI 10.1007/978-1-59745-419-3_4	33	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							924	10.3390/vaccines9080924			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7JM	34452049	Green Published, gold			2022-04-29	WOS:000690102200001
J	Leoni, G; D'Alise, AM; Tucci, FG; Micarelli, E; Garzia, I; De Lucia, M; Langone, F; Nocchi, L; Cotugno, G; Bartolomeo, R; Romano, G; Allocca, S; Troise, F; Nicosia, A; Lahm, A; Scarselli, E				Leoni, Guido; D'Alise, Anna Morena; Tucci, Fabio Giovanni; Micarelli, Elisa; Garzia, Irene; De Lucia, Maria; Langone, Francesca; Nocchi, Linda; Cotugno, Gabriella; Bartolomeo, Rosa; Romano, Giuseppina; Allocca, Simona; Troise, Fulvia; Nicosia, Alfredo; Lahm, Armin; Scarselli, Elisa			VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction	VACCINES			English	Article						neoantigen; cancer vaccine; VENUS; prediction; MC38	MUTATIONAL LANDSCAPE; MASS-SPECTROMETRY; CANCER; BLOCKADE; VACCINE; IMMUNOGENICITY; IDENTIFICATION; ALIGNMENT	Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes. Previous studies demonstrated that only a limited subset of mutations generates neoantigens in microsatellite stable tumors. We developed a method, called VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection), to prioritize mutated peptides with high potential to be neoantigens. Our method assigns to each mutation a weighted score that combines the mutation allelic frequency, the abundance of the transcript coding for the mutation, and the likelihood to bind the patient's class-I major histocompatibility complex alleles. By ranking mutated peptides encoded by mutations detected in nine cancer patients, VENUS was able to select in the top 60 ranked peptides, the 95% of neoantigens experimentally validated including both CD8 and CD4 T cell specificities. VENUS was evaluated in a murine model in the context of vaccination with an adeno vector encoding the top ranked mutations prioritized in the MC38 cell line. Efficacy studies demonstrated anti tumoral activity of the vaccine when used in combination with checkpoint inhibitors. The results obtained highlight the importance of a combined scoring system taking into account multiple features of each tumor mutation to improve the accuracy of neoantigen prediction.	[Leoni, Guido; D'Alise, Anna Morena; Tucci, Fabio Giovanni; Micarelli, Elisa; Garzia, Irene; De Lucia, Maria; Langone, Francesca; Nocchi, Linda; Cotugno, Gabriella; Bartolomeo, Rosa; Romano, Giuseppina; Allocca, Simona; Troise, Fulvia; Lahm, Armin; Scarselli, Elisa] Nouscom SRL, Via Castel Romano, I-00100 Rome, Italy; [Nicosia, Alfredo] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Via Federico Pansini, I-80131 Naples, Italy; [Nicosia, Alfredo] CEINGE, Via Comunale Margherita, I-80131 Naples, Italy		Leoni, G (通讯作者)，Nouscom SRL, Via Castel Romano, I-00100 Rome, Italy.	g.leoni@nouscom.com; m.dalise@nouscom.com; fg.tucci@nouscom.com; e.micarelli@nouscom.com; i.garzia@nouscom.com; m.delucia@nouscom.com; f.langone@nouscom.com; l.nocchi@nouscom.com; g.cotugno@nouscom.com; r.bartolomeo@nouscom.com; g.romano@nouscom.com; s.allocca@nouscom.com; f.troise@nouscom.com; alfredo.nicosia@unina.it; a.lahm@nouscom.com; e.scarselli@nouscom.com	D'Alise, Anna Morena/AFF-8421-2022	D'Alise, Anna Morena/0000-0002-0763-6269			Barnes E, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003155; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Bassani-Sternberg M, 2015, MOL CELL PROTEOMICS, V14, P658, DOI 10.1074/mcp.M114.042812; Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bonsack M, 2019, CANCER IMMUNOL RES, V7, P719, DOI 10.1158/2326-6066.CIR-18-0584; Borthwick N, 2014, MOL THER, V22, P464, DOI 10.1038/mt.2013.248; D'Alise AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10594-2; Danecek P, 2021, GIGASCIENCE, V10, DOI 10.1093/gigascience/giab008; Fang H, 2016, NAT PROTOC, V11, P2529, DOI 10.1038/nprot.2016.150; Gajewski TF, 2006, J IMMUNOTHER, V29, P233, DOI 10.1097/01.cji.0000199193.29048.56; Gros A, 2019, J CLIN INVEST, V129, P4992, DOI 10.1172/JCI127967; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Gupta RG, 2021, CANCER DISCOV, V11, P1024, DOI 10.1158/2159-8290.CD-20-1575; Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Wei X, 2019, TRANSL ONCOL, V12, P733, DOI 10.1016/j.tranon.2019.02.008; Wells DK, 2020, CELL, V183, P818, DOI 10.1016/j.cell.2020.09.015; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444	34	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							880	10.3390/vaccines9080880			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5TX	34452005	gold, Green Published			2022-04-29	WOS:000689994100001
J	Sobkowicz, P; Sobkowicz, A				Sobkowicz, Pawel; Sobkowicz, Antoni			Agent Based Model of Anti-Vaccination Movements: Simulations and Comparison with Empirical Data	VACCINES			English	Article						anti-vaccination; vaccine hesitancy; social networks; simulation; agent based model; MMR	CONSENSUS ACHIEVEMENT; MISINFORMATION; INFORMATION; IMPACT; MESSAGES; INSIGHTS; PARENTS; SUPPORT; ZEALOTS; SEARCH	Background: A realistic description of the social processes leading to the increasing reluctance to various forms of vaccination is a very challenging task. This is due to the complexity of the psychological and social mechanisms determining the positioning of individuals and groups against vaccination and associated activities. Understanding the role played by social media and the Internet in the current spread of the anti-vaccination (AV) movement is of crucial importance. Methods: We present novel, long-term Big Data analyses of Internet activity connected with the AV movement for such different societies as the US and Poland. The datasets we analyzed cover multiyear periods preceding the COVID-19 pandemic, documenting the behavior of vaccine related Internet activity with high temporal resolution. To understand the empirical observations, in particular the mechanism driving the peaks of AV activity, we propose an Agent Based Model (ABM) of the AV movement. The model includes the interplay between multiple driving factors: contacts with medical practitioners and public vaccination campaigns, interpersonal communication, and the influence of the infosphere (social networks, WEB pages, user comments, etc.). The model takes into account the difference between the rational approach of the pro-vaccination information providers and the largely emotional appeal of anti-vaccination propaganda. Results: The datasets studied show the presence of short-lived, high intensity activity peaks, much higher than the low activity background. The peaks are seemingly random in size and time separation. Such behavior strongly suggests a nonlinear nature for the social interactions driving the AV movement instead of the slow, gradual growth typical of linear processes. The ABM simulations reproduce the observed temporal behavior of the AV interest very closely. For a range of parameters, the simulations result in a relatively small fraction of people refusing vaccination, but a slight change in critical parameters (such as willingness to post anti-vaccination information) may lead to a catastrophic breakdown of vaccination support in the model society, due to nonlinear feedback effects. The model allows the effectiveness of strategies combating the anti-vaccination movement to be studied. An increase in intensity of standard pro-vaccination communications by government agencies and medical personnel is found to have little effect. On the other hand, focused campaigns using the Internet and social media and copying the highly emotional and narrative-focused format used by the anti-vaccination activists can diminish the AV influence. Similar effects result from censoring and taking down anti-vaccination communications by social media platforms. The benefit of such tactics might, however, be offset by their social cost, for example, the increased polarization and potential to exploit it for political goals, or increased 'persecution' and 'martyrdom' tropes.	[Sobkowicz, Pawel] NOMATEN Ctr Excellence, Natl Ctr Nucl Resarch, PL-05400 Otwock, Poland; [Sobkowicz, Antoni] Natl Informat Proc Inst OPI, PL-00608 Warsaw, Poland		Sobkowicz, P (通讯作者)，NOMATEN Ctr Excellence, Natl Ctr Nucl Resarch, PL-05400 Otwock, Poland.	pawel.sobkowicz@ncbj.gov.pl; a.sobkowicz@outlook.com	Sobkowicz, Pawel/G-5276-2010	Sobkowicz, Pawel/0000-0002-7275-7235	Foundation for Polish Science International Research Agenda PLUS program [MAB PLUS/2018/8]	This research was partially funded by the Foundation for Polish Science International Research Agenda PLUS program Grant No. MAB PLUS/2018/8.	[Anonymous], 2020, FAIL ACT TECH GIANTS; Aquino F, 2017, VACCINE, V35, P4494, DOI 10.1016/j.vaccine.2017.07.029; Arendt F, 2019, J HEALTH COMMUN, V24, P654, DOI 10.1080/10810730.2019.1652709; Ashwell D, 2020, VACCINE, V38, P5627, DOI 10.1016/j.vaccine.2020.06.070; Badham J., 2015, 20152 U SURR CTR RES; Badham J, 2018, HEALTH PLACE, V54, P170, DOI 10.1016/j.healthplace.2018.08.022; Bandari R, 2017, COMPUTER, V50, P60, DOI 10.1109/MC.2017.4041354; Barabasi AL, 2005, NATURE, V435, P207, DOI 10.1038/nature03459; Bessi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134641; Bessi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118093; Betsch C, 2015, JUDGM DECIS MAK, V10, P241; Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387; Betsch C, 2011, MED DECIS MAKING, V31, P742, DOI 10.1177/0272989X11400419; Bragazzi NL, 2017, HUM VACC IMMUNOTHER, V13, P464, DOI 10.1080/21645515.2017.1264742; Brunson EK, 2020, HEALTH SECUR, V18, P338, DOI 10.1089/hs.2020.0106; Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Capurro G, 2018, CAN J SOCIOL, V43, P25, DOI 10.29173/cjs29301; CCDH, 2021, MALG HOW INST ALG PU; Colaiori F, 2016, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2016/03/033401; Costa AF, 2017, ACM T KNOWL DISCOV D, V11, DOI 10.1145/3064884; Crane R, 2008, P NATL ACAD SCI USA, V105, P15649, DOI 10.1073/pnas.0803685105; Crokidakis N, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.062122; Czarnek G, 2021, NAT CLIM CHANGE, V11, P9, DOI 10.1038/s41558-020-00930-6; Dahlstrom MF, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.1914085117; De Domenico M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61523-z; De Raadt A, 2019, EDUC PSYCHOL MEAS, V79, P558, DOI 10.1177/0013164418823249; Dorso CO, 2017, PHYSICA A, V482, P433, DOI 10.1016/j.physa.2017.04.112; Driscoll D, 2019, SOC SCI QUART, V100, P1699, DOI 10.1111/ssqu.12683; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Dwoskin Elizabeth, 2021, WASH POST; Edelstein M, 2020, VACCINE, V38, P5297, DOI 10.1016/j.vaccine.2020.05.082; El-Sayed Abdulrahman M, 2012, Epidemiol Perspect Innov, V9, P1, DOI 10.1186/1742-5573-9-1; Eubank S, 2004, NATURE, V429, P180, DOI 10.1038/nature02541; Evanega S., 2020, JMIR PREPR; Fotouhi B, 2013, IEEE J-STSP, V7, P347, DOI 10.1109/JSTSP.2013.2245629; Fudolig MID, 2014, PHYSICA A, V413, P626, DOI 10.1016/j.physa.2014.07.033; Fusick AJ, 2021, J PUBLIC HEALTH-HEID, V29, P1301, DOI 10.1007/s10389-020-01244-9; Galam S., 2016, MIND SOC, V15, P117, DOI [10.1007/s11299-015-0175-y, DOI 10.1007/S11299-015-0175-Y]; Galam S, 2007, PHYSICA A, V381, P366, DOI 10.1016/j.physa.2007.03.034; Gayle H, 2020, FRAMEWORK EQUITABLE; Grefenstette JJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-940; Gunaratne K, 2019, VACCINE, V37, P4867, DOI 10.1016/j.vaccine.2019.06.086; Hornsey MJ, 2016, NAT CLIM CHANGE, V6, P622, DOI [10.1038/nclimate2943, 10.1038/NCLIMATE2943]; Huang X, 2017, AAAI JOINT WORKSH HL; Hunter E, 2017, JASSS-J ARTIF SOC S, V20, DOI 10.18564/jasss.3414; Jamison A.M., 2020, HARV KENNEDY SCH MIS, P1, DOI [10.37016/mr-2020-38, DOI 10.37016/MR-2020-38]; Jamison A, 2020, AM J PUBLIC HEALTH, V110, pS331, DOI 10.2105/AJPH.2020.305940; Jemielniak D., 2021, ASTRA ZENECA VACCINE; Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453; Kahan D.M, 2016, EMERGING TRENDS SOCI, P1, DOI DOI 10.1002/9781118900772.ETRDS0417; Kahan DM, 2017, POLIT PSYCHOL, V38, P179, DOI 10.1111/pops.12396; Kahneman Daniel., 2011, THINKING FAST SLOW; Kashisaz H, 2014, PHYSICA A, V402, P49, DOI 10.1016/j.physa.2014.01.055; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a; Leask J, 2006, VACCINE, V24, P7238, DOI 10.1016/j.vaccine.2006.05.010; Lewandowsky S, 2016, CURR DIR PSYCHOL SCI, V25, P217, DOI 10.1177/0963721416654436; Majewski S., 2013, TRACKING ANTI VACCIN; McKeever BW, 2016, MASS COMMUN SOC, V19, P476, DOI 10.1080/15205436.2016.1148172; Medvedev A.N., 2019, DYNAMICS COMPLEX NET, P183, DOI 10.1007/978-3-030-14683-2_9; Mitra Tanushree, 2016, P 10 INT AAAI C WEB, P269; Mobilia M, 2007, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2007/08/P08029; Mobilia M, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.012803; Newhagen J.E., 2020, HARVARD KENNEDY SCH, DOI [10.37016/mr-2020-44, DOI 10.37016/MR-2020-44]; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Ochoa, 2018, BDCC, V2, P2, DOI [DOI 10.3390/BDCC2010002, https://doi.org/10.3390/bdcc2010002]; Oka M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109293; Okuhara T, 2020, PREV MED REP, V20, DOI 10.1016/j.pmedr.2020.101205; Rand William., 2015, INTRO AGENT BASED MO; Rodriguez NJ, 2016, GLOB QUALIT NURS RES, V3, DOI 10.1177/2333393616663304; Rozbroj T, 2019, VACCINE, V37, P5986, DOI [10.1016/j.vaccine.2019.08.023, 10.1016/j.vaccin]; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Shin J, 2018, COMPUT HUM BEHAV, V83, P278, DOI 10.1016/j.chb.2018.02.008; Stolle LB, 2020, ADV THER, V37, P4481, DOI 10.1007/s12325-020-01502-y; Streefland PH, 2001, HEALTH POLICY, V55, P159, DOI 10.1016/S0168-8510(00)00132-9; Sturm T, 2021, ANTHROPOL MED, V28, P122, DOI 10.1080/13648470.2020.1833684; Sznajd-Weron K, 2011, EPL-EUROPHYS LETT, V96, DOI 10.1209/0295-5075/96/48002; Tafuri S, 2014, VACCINE, V32, P4860, DOI 10.1016/j.vaccine.2013.11.006; Tayloe David T Jr, 2021, N C Med J, V82, P118, DOI 10.18043/ncm.82.2.118; Thukral S, 2018, 2018 IEEE/ACM INTERNATIONAL CONFERENCE ON ADVANCES IN SOCIAL NETWORKS ANALYSIS AND MINING (ASONAM), P662, DOI 10.1109/ASONAM.2018.8508687; van Ackere A, 2020, SOCIO-ECON PLAN SCI, V71, DOI 10.1016/j.seps.2019.100750; Van Prooijen JW, 2015, APPL COGNITIVE PSYCH, V29, P753, DOI 10.1002/acp.3161; Vazquez A, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.036127; Verma G, 2014, PHYSICA A, V395, P310, DOI 10.1016/j.physa.2013.09.045; Vosoughi S, 2018, SCIENCE, V359, P1146, DOI 10.1126/science.aap9559; Wang E, 2015, VACCINE, V33, P6703, DOI 10.1016/j.vaccine.2015.10.090; Wang YX, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112552; Ward JK, 2015, VACCINE, V33, P1063, DOI 10.1016/j.vaccine.2014.12.064; Wilensky U., 1999, NETLOGO CTR CONNECTE; Wilson K, 2005, VACCINE, V23, P3010, DOI 10.1016/j.vaccine.2004.12.002; Wolfe RM, 2005, J HEALTH COMMUN, V10, P537, DOI 10.1080/10810730500228847; Young L.E., 2021, AM J PUBLIC HEALTH, pE1	93	0	0	10	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							809	10.3390/vaccines9080809			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UH9KB	34451934	Green Published			2022-04-29	WOS:000690238900001
J	Mo, J; Cardenas-Garcia, S; Santos, JJS; Ferreri, LM; Caceres, CJ; Geiger, G; Perez, DR; Rajao, DS				Mo, Jongsuk; Cardenas-Garcia, Stivalis; Santos, Jefferson J. S.; Ferreri, Lucas M.; Caceres, C. Joaquin; Geiger, Ginger; Perez, Daniel R.; Rajao, Daniela S.			Mutation E48K in PB1 Polymerase Subunit Improves Stability of a Candidate Live Attenuated Influenza B Virus Vaccine	VACCINES			English	Article						Influenza B; LAIV; PB1; vaccine stability	SEASONAL INFLUENZA; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; UNITED-STATES; RECOMMENDATIONS; PREVENTION; PROTECTION; INFECTION; CHILDREN; EFFICACY	Influenza B virus (IBV) is a major respiratory pathogen of humans, particularly in the elderly and children, and vaccines are the most effective way to control it. In previous work, incorporation of two mutations (E580G, S660A) along with the addition of an HA epitope tag in the PB1 segment of B/Brisbane/60/2008 (B/Bris) resulted in an attenuated strain that was safe and effective as a live attenuated vaccine. A third attempted mutation (K391E) in PB1 was not always stable. Interestingly, viruses that maintained the K391E mutation were associated with the mutation E48K. To explore the contribution of the E48K mutation to stability of the K391E mutation, a vaccine candidate was generated by inserting both mutations, along with attenuating mutations E580G and S660A, in PB1 of B/Bris (B/Bris PB1att 4M). Serial passages of the B/Bris PB1att 4M vaccine candidate in eggs and MDCK indicated high stability. In silico structural analysis revealed a potential interaction between amino acids at positions 48 and 391. In mice, B/Bris PB1att 4M was safe and provided complete protection against homologous challenge. These results confirm the compensatory effect of mutation E48K to stabilize the K391E mutation, resulting in a safer, yet still protective, IBV LAIV vaccine.	[Mo, Jongsuk; Cardenas-Garcia, Stivalis; Santos, Jefferson J. S.; Ferreri, Lucas M.; Caceres, C. Joaquin; Geiger, Ginger; Perez, Daniel R.; Rajao, Daniela S.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA		Rajao, DS (通讯作者)，Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA.	jm45001@uga.edu; stivalis@uga.edu; jefferson.dasilvasantos@nih.gov; lucas.matias.ferreri@emory.edu; cjoaquincaceres@uga.edu; imginger@uga.edu; dperez1@uga.edu; daniela.rajao@uga.edu	Caceres, C. Joaquin/AAR-1810-2021; Perez, Daniel/D-5044-2016	Caceres, C. Joaquin/0000-0001-8508-6592; Perez, Daniel/0000-0002-6569-5689; Ferreri, Lucas/0000-0002-1069-9500; Geiger, Ginger/0000-0002-4927-8084; Cardenas Garcia, Stivalis/0000-0002-7613-8642	Center for Research on Influenza Pathogenesis (CRIP) [HHSN272201400008C]; National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) [1R21AI146448-01]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)	This study was supported by a subcontract from the Center for Research on Influenza Pathogenesis (CRIP) under contract HHSN272201400008C from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) and grant 1R21AI146448-01 from NIAID.	Ashkenazi S, 2006, PEDIATR INFECT DIS J, V25, P870, DOI 10.1097/01.inf.0000237829.66310.85; Belshe RB, 2010, VACCINE, V28, pD45, DOI 10.1016/j.vaccine.2010.08.028; Bianchi E, 2005, J VIROL, V79, P7380, DOI 10.1128/JVI.79.12.7380-7388.2005; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Caini S, 2015, INFLUENZA OTHER RESP, V9, P3, DOI 10.1111/irv.12319; Cha HJ, 2013, MOL CELLS, V36, P39, DOI 10.1007/s10059-013-0013-1; Cheng X, 2013, J INFECT DIS, V208, P594, DOI 10.1093/infdis/jit207; Davis BH, 2009, P R SOC B, V276, P1823, DOI 10.1098/rspb.2008.1846; Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17; Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Grohskopf LA, 2013, MMWR RECOMM REP, V62, P1; Hatta M, 2004, J VIROL, V78, P5576, DOI 10.1128/JVI.78.11.5576-5583.2004; Jin H, 2014, CURR OPIN VIROL, V6, P34, DOI 10.1016/j.coviro.2014.02.008; Kajikawa T, 2012, BIOCHEM BIOPH RES CO, V422, P152, DOI 10.1016/j.bbrc.2012.04.127; Langat Pinky, 2017, PLoS Pathog, V13, pe1006749, DOI 10.1371/journal.ppat.1006749; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Loving CL, 2013, J VIROL, V87, P9895, DOI 10.1128/JVI.01038-13; Loving CL, 2012, VACCINE, V30, P5830, DOI 10.1016/j.vaccine.2012.07.033; Martin S, 1992, Nurse Pract, V17, P10, DOI 10.1097/00006205-199204000-00003; Mena I, 2016, ELIFE, V5, DOI 10.7554/eLife.16777; Nohynek H, 2016, EUROSURVEILLANCE, V21, P33, DOI 10.2807/1560-7917.ES.2016.21.38.30346; Owusu D, 2020, AM J TRANSPLANT, V20, P606, DOI 10.1111/ajt.15782; Pena L, 2013, J VIROL, V87, P5118, DOI 10.1128/JVI.02490-12; Pena L, 2011, J VIROL, V85, P456, DOI 10.1128/JVI.01503-10; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reed C, 2012, VACCINE, V30, P1993, DOI 10.1016/j.vaccine.2011.12.098; REED L. J., 1938, AMER JOUR HYG, V27, P493; RITCHEY MB, 1976, J VIROL, V18, P738, DOI 10.1128/JVI.18.2.738-744.1976; Santos JJS, 2017, J VIROL, V91, DOI 10.1128/JVI.00056-17; Shannon I, 2020, J PEDIAT INF DIS SOC, V9, pS10, DOI 10.1093/jpids/piz083; Shaw MW, 2002, VIROLOGY, V303, P1, DOI 10.1006/viro.2002.1719; Solorzano A, 2010, J VIROL, V84, P4587, DOI 10.1128/JVI.00101-10; Song H, 2007, J VIROL, V81, P9238, DOI 10.1128/JVI.00893-07; Soskine M, 2010, NAT REV GENET, V11, P572, DOI 10.1038/nrg2808; Szamecz B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001935; Wan Z, 2018, J VIROL, V92, DOI 10.1128/JVI.01025-18; World Health Organization, WHO MAN AN INFL DIAG; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zhao XH, 2016, EPIDEMIOLOGY, V27, P143, DOI 10.1097/EDE.0000000000000402	41	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							800	10.3390/vaccines9070800			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7QL	34358217	Green Published, Green Submitted, gold			2022-04-29	WOS:000677101000001
J	Cieslewicz, A; Dudek, M; Krela-Kazmierczak, I; Jablecka, A; Lesiak, M; Korzeniowska, K				Cieslewicz, Artur; Dudek, Magdalena; Krela-Kazmierczak, Iwona; Jablecka, Anna; Lesiak, Maciej; Korzeniowska, Katarzyna			Pancreatic Injury after COVID-19 Vaccine-A Case Report	VACCINES			English	Article						pancreatitis; pancreatic injury; COVID-19; coronavirus vaccine; Comirnaty; COVID-19 mRNA vaccine		The COVID-19 pandemic has caused more than 3 million deaths worldwide. Recently developed genetically engineered vaccines are the most critical solution for controlling the pandemic. Clinical trials on a large number of participants confirmed their safety and efficacy. However, with the growing number of vaccinated people, new infrequent adverse effects have been reported, not described in the medicinal product characteristics. We would like to report a case of acute pancreatic injury that occurred shortly after administering Pfizer BioNTech COVID-19 mRNA vaccine (Comirnaty). The report points out the potential need for close monitoring of patients reporting abdominal pain after vaccination (unresponsive to standard oral painkillers) because such symptom can be associated with acute pancreatitis.	[Cieslewicz, Artur; Jablecka, Anna; Korzeniowska, Katarzyna] Poznan Univ Med Sci, Dept Clin Pharmacol, PL-61861 Poznan, Poland; [Dudek, Magdalena; Lesiak, Maciej] Poznan Univ Med Sci, Dept Cardiol 1, PL-61848 Poznan, Poland; [Krela-Kazmierczak, Iwona] Poznan Univ Med Sci, Dept Gastroenterol Dietet & Internal Dis, PL-60355 Poznan, Poland		Cieslewicz, A (通讯作者)，Poznan Univ Med Sci, Dept Clin Pharmacol, PL-61861 Poznan, Poland.	artcies@ump.edu.pl; magdalena.dudek@skpp.edu.pl; ikrela-kazmierczak@ump.edu.pl; ajablecka@ump.edu.pl; maciej.lesiak@ump.edu.pl; katakorz@wp.pl	Dudek, Magdalena/N-9951-2019	Dudek, Magdalena/0000-0001-6550-6182; Lesiak, Maciej/0000-0003-2630-5016; Cieslewicz, Artur/0000-0001-9918-5989			[Anonymous], 2020, VRBPAC BRIEF DOC PFI; Bizjak M, 2017, IMMUNOL RES, V65, P164, DOI 10.1007/s12026-016-8823-9; Bogdanos Dimitrios-Petrou, 2005, Clin Dev Immunol, V12, P217, DOI 10.1080/17402520500285247; Comirnaty, SUMMARY PRODUCT CHAR; COVID-19 Vaccine Moderna, SUMMARY PRODUCT CHAR; de-Madaria E, 2021, NAT REV GASTRO HEPAT, V18, P3, DOI 10.1038/s41575-020-00389-y; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Kottanattu L, 2016, J CLIN VIROL, V82, P51, DOI 10.1016/j.jcv.2016.06.017; Patel KP, 2020, J CLIN VIROL, V128; Perisetti A, 2020, DIGEST ENDOSC, V32, P715, DOI 10.1111/den.13693; Rawla P, 2017, GASTROENTEROL RES, V10, P153, DOI 10.14740/gr858w; Shlomovitz E, 2007, CAN MED ASSOC J, V176, P339, DOI 10.1503/cmaj.060360; Singh A., 2017, CLIN PEDIATR, V2, P1, DOI [10.4172/2572-0775.1000117, DOI 10.4172/2572-0775.1000117]; Vojdani A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.617089; Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480; Wang F, 2020, GASTROENTEROLOGY, V159, P367, DOI 10.1053/j.gastro.2020.03.055	16	6	6	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							576	10.3390/vaccines9060576			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0NW	34205898	Green Published, gold			2022-04-29	WOS:000666274400001
J	Diop, NS; Bonong, PRE; Buteau, C; Duval, M; Lacroix, J; Laporte, L; Tucci, M; Robitaille, N; Spinella, PC; Cuvelier, G; Vercauteren, SM; Lewis, V; Alfieri, C; Trottier, H				Diop, Ndeye Soukeyna; Bonong, Pascal Roland Enok; Buteau, Chantal; Duval, Michel; Lacroix, Jacques; Laporte, Louise; Tucci, Marisa; Robitaille, Nancy; Spinella, Philip C.; Cuvelier, Geoffrey; Vercauteren, Suzanne M.; Lewis, Victor; Alfieri, Caroline; Trottier, Helen			Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein-Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant	VACCINES			English	Article						antiviral prophylaxis; hematopoietic stem cell transplantation; Epstein-Barr virus; cytomegalovirus; human herpesvirus; pediatric	BONE-MARROW-TRANSPLANTATION; VARICELLA-ZOSTER-VIRUS; LOW-DOSE ACYCLOVIR; LONG-TERM ACYCLOVIR; VIRAL-INFECTIONS; RISK-FACTORS; DOUBLE-BLIND; HERPES INFECTIONS; ACUTE-LEUKEMIA; PREVENTION	Background: Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections can have serious consequences during the period of aplasia and lymphopenia following hematopoietic stem cell transplantation (HSCT). Large pediatric cohort studies examining the effect of antiviral prophylaxis against these viruses are scarce. The present study aimed to analyse the potential effect of antiviral prophylaxis (acyclovir and famciclovir) on active post-transplant EBV and CMV infection in a pediatric cohort of allogeneic HSCT recipients. Methods: We used data from the TREASuRE cohort, consisting of 156 patients who had a first allogeneic HSCT, enrolled in four pediatric centers in Canada between July 2013 and March 2017. Follow-up was performed from the time of transplant up to 100 days post-transplant. Adjusted hazard ratio (HR) with 95% confidence intervals (CI) for the association between antiviral prophylaxis with acyclovir and/or famciclovir and EBV and CMV DNAemia was estimated using multivariate Cox regression models. Results: The post-transplant cumulative incidence of EBV and CMV DNAemia at 100 days of follow-up were, respectively, 34.5% (95% CI: 27.6-42.6) and 19.9% (95% CI: 14.5-27.1). For acyclovir, the adjusted hazard ratio (HR) for CMV and EBV DNAemia was 0.55 (95% CI: 0.24-1.26) and 1.41 (95% CI: 0.63-3.14), respectively. For famciclovir, the adjusted HR were 0.82 (95% CI: 0.30-2.29) and 0.79 (95% CI: 0.36-1.72) for CMV and EBV DNAemia, respectively. Conclusion: The antivirals famciclovir and acyclovir did not reduce the risk of post-transplant CMV and EBV DNAemia among HSCT recipients in our pediatric population.	[Diop, Ndeye Soukeyna; Bonong, Pascal Roland Enok; Trottier, Helen] Univ Montreal, Dept Social & Prevent Med, CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada; [Buteau, Chantal] Univ Montreal, Dept Pediat, Div Infect Dis, CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada; [Duval, Michel] Univ Montreal, Dept Pediat, Div Hematol Oncol, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Lacroix, Jacques; Tucci, Marisa] Univ Montreal, Dept Pediat, Div Pediat Intens Care Med, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Laporte, Louise] CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada; [Robitaille, Nancy] Univ Montreal, CHU St Justine, Div Hematol Oncol, Dept Pediat, St Laurent, PQ H4R 2W7, Canada; [Robitaille, Nancy] Hema Quebec, Med Affairs, Transfus Med, St Laurent, PQ H4R 2W7, Canada; [Spinella, Philip C.] Washington Univ, Sch Med, St Louis Childrens Hosp, St Louis, MO 63110 USA; [Cuvelier, Geoffrey] Univ Manitoba, Dept Pediat & Child Hlth, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada; [Vercauteren, Suzanne M.] Univ British Columbia, BC Childrens Hosp, Dept Pathol & Lab Med, Vancouver, BC V6H 3N1, Canada; [Lewis, Victor] Univ Calgary, Alberta Childrens Hosp, Dept Pediat, Calgary, AB T3B 6A8, Canada; [Lewis, Victor] Univ Calgary, Alberta Childrens Hosp, Dept Oncol, Calgary, AB T3B 6A8, Canada; [Alfieri, Caroline] Univ Montreal, Dept Microbiol Infectiol & Immunol, CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada		Trottier, H (通讯作者)，Univ Montreal, Dept Social & Prevent Med, CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada.	Soukeyna.diop@recherche-ste-justine.qc.ca; pascal.roland.enok.bonong@umontreal.ca; chantal.buteau.hsj@ssss.gouv.qc.ca; michel.duval@umontreal.ca; jacques.lacroix.med@ssss.gouv.qc.ca; louise.laporte.hsj@ssss.gouv.qc.ca; marisa.tucci.med@ssss.gouv.qc.ca; nancy.robitaille@umontreal.ca; pspinella@wustl.edu; gcuvelier@cancercare.mb.ca; svercauteren2@cw.bc.ca; Victor.Lewis@albertahealthservices.ca; carolina.alfieri@umontreal.ca; helen.trottier@umontreal.ca	Spinella, Philip/AAV-8531-2021; Robitaille, Nancy/AAA-8418-2022		Canadian Blood Services (CBS); Fonds de la recherche du Quebec en sante (FRQS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Faculty of Graduate Studies, Universite de Montreal	TREASuRE study was supported by a grant from Canadian Blood Services (CBS). HT holds a salary award (Research Scholar) from the Fonds de la recherche du Quebec en sante (FRQS) and a new Investigator Salary Award from the Canadian Institutes of Health Research (CIHR). PREB received a doctoral end-of-studies grant from the Faculty of Graduate Studies, Universite de Montreal.	AlDabbagh MA, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14020; Advisory Committee on Immunization Practices, 2000, MMWR Recomm Rep, V49, P1; Asano-Mori Y, 2008, AM J HEMATOL, V83, P472, DOI 10.1002/ajh.21152; Bjorklund A, 2007, BONE MARROW TRANSPL, V40, P1055, DOI 10.1038/sj.bmt.1705856; Boeckh M, 2006, BLOOD, V107, P1800, DOI 10.1182/blood-2005-09-3624; Bordon V, 2012, PEDIATR TRANSPLANT, V16, P144, DOI 10.1111/j.1399-3046.2011.01634.x; Catalan Paula, 2012, Rev Chilena Infectol, V29 Suppl 1, pS29, DOI 10.4067/S0716-10182012000500005; Czyzewski K, 2019, INFECT DRUG RESIST, V12, P3893, DOI 10.2147/IDR.S224291; Dominietto A, 2002, BLOOD, V100, P3930, DOI 10.1182/blood-2002-01-0339; Duver F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228451; Eapen M, 2006, J CLIN ONCOL, V24, P145, DOI 10.1200/JCO.2005.02.4612; Bonong PER, 2021, TRANSFUSION, V61, P144, DOI 10.1111/trf.16149; Erard V, 2007, J INFECT DIS, V196, P266, DOI 10.1086/518938; Frassoni F, 1996, BONE MARROW TRANSPL, V17, P13; GLUCKMAN E, 1983, LANCET, V2, P706; Graef T, 2005, BLOOD, V106, p427B; Gratwohl A, 2005, BONE MARROW TRANSPL, V36, P757, DOI 10.1038/sj.bmt.1705140; Haastrup E, 2005, PEDIATR TRANSPLANT, V9, P734, DOI 10.1111/j.1399-3046.2005.00370.x; HANN IM, 1983, BMJ-BRIT MED J, V287, P384, DOI 10.1136/bmj.287.6389.384; Jamani K, 2016, BLOOD ADV, V1, P152, DOI 10.1182/bloodadvances.2016000836; Kanda Y, 2001, BONE MARROW TRANSPL, V28, P689, DOI 10.1038/sj.bmt.1703214; Kawamura K, 2013, TRANSPL INFECT DIS, V15, P457, DOI 10.1111/tid.12118; Kim DH, 2008, CLIN TRANSPLANT, V22, P770, DOI 10.1111/j.1399-0012.2008.00877.x; Klein A, 2011, BONE MARROW TRANSPL, V46, P294, DOI 10.1038/bmt.2010.99; Lewalle P, 2019, B CANCER, V106, pS23, DOI 10.1016/j.bulcan.2018.08.017; LJUNGMAN P, 1986, BONE MARROW TRANSPL, V1, P185; LUNDGREN G, 1985, SCAND J INFECT DIS, P137; Marty FM, 2017, NEW ENGL J MED, V377, P2433, DOI 10.1056/NEJMoa1706640; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MILLER W, 1986, BLOOD, V67, P1162; OCHS L, 1995, BLOOD, V86, P3979, DOI 10.1182/blood.V86.10.3979.bloodjournal86103979; Olkinuora HA, 2010, PEDIATR TRANSPLANT, V14, P242, DOI 10.1111/j.1399-3046.2009.01226.x; Pagano JS, 2018, CANCERS, V10, DOI 10.3390/cancers10060197; Pai VB, 2013, BIOL BLOOD MARROW TR, V19, pS378, DOI 10.1016/j.bbmt.2012.11.614; Paintsil E, 2019, ANTIVIRAL AGENTS ENC, V4th ed., P176; PRENTICE HG, 1994, LANCET, V343, P749, DOI 10.1016/S0140-6736(94)91835-X; PRENTICE HG, 1983, J ANTIMICROB CHEMOTH, V12, P153, DOI 10.1093/jac/12.suppl_B.153; Rieger CT, 2009, TRANSPL INFECT DIS, V11, P220, DOI 10.1111/j.1399-3062.2009.00379.x; Rosenzwajg M, 1999, BONE MARROW TRANSPL, V24, P351, DOI 10.1038/sj.bmt.1701931; Sala I, 2011, PEDIATR TRANSPLANT, V15, pE8, DOI 10.1111/j.1399-3046.2010.01315.x; SELBY PJ, 1989, BRIT J CANCER, V59, P434, DOI 10.1038/bjc.1989.88; Shiley K, 2010, INFECT DIS CLIN N AM, V24, P373, DOI 10.1016/j.idc.2010.01.003; Steer CB, 2000, BONE MARROW TRANSPL, V25, P657, DOI 10.1038/sj.bmt.1702190; Styczynski J, 2009, BONE MARROW TRANSPL, V43, P757, DOI 10.1038/bmt.2008.386; Sullivan K M, 2001, Hematology Am Soc Hematol Educ Program, P392, DOI 10.1182/asheducation-2001.1.392; Tan B, 2012, PEDIATR INFECT DIS J, V31, P956, DOI 10.1097/INF.0b013e318260cc4d; Tsoumakas K, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13095; TUTSCHKA PJ, 1988, PEDIATR INFECT DIS J, V7, pS22; Ullmann AJ, 2016, ANN HEMATOL, V95, P1435, DOI 10.1007/s00277-016-2711-1; Verdeguer A, 2011, BONE MARROW TRANSPL, V46, P119, DOI 10.1038/bmt.2010.52; WASSERMAN R, 1988, PEDIATR INFECT DIS J, V7, P109, DOI 10.1097/00006454-198802000-00009; Welniak LA, 2007, ANNU REV IMMUNOL, V25, P139, DOI 10.1146/annurev.immunol.25.022106.141606; Yoon HS, 2009, PEDIATR TRANSPLANT, V13, P898, DOI 10.1111/j.1399-3046.2008.01084.x; ZUTTER MM, 1988, BLOOD, V72, P520	55	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							610	10.3390/vaccines9060610			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6AG	34200239	Green Published, gold			2022-04-29	WOS:000666645100001
J	Langsam, D; Kahana, D; Shmueli, E; Yamin, D				Langsam, Dean; Kahana, Dor; Shmueli, Erez; Yamin, Dan			Cost-Effectiveness of Pertussis Vaccination Schedule in Israel	VACCINES			English	Article						transmission model; vaccine allocation; pertussis; waning immunity; population model; cost-effectiveness analysis	DIPHTHERIA; RESURGENCE; TETANUS; EPIDEMIOLOGY; TRANSMISSION; PREGNANCY; COMMUNITY; VACCINES	Pertussis is a highly contagious bacterial disease that primarily affects infants. To optimize the pertussis vaccination schedule in Israel and evaluate the cost-effectiveness of alternative strategies that add or remove booster doses, we developed an age-structured model for pertussis transmission. Our model was calibrated using 16 years of data from laboratory-confirmed pertussis cases in Israel. Costs and quality-adjusted life years (QALYs) projected by the model within 12 years from the implementation of the considered interventions were compared with the current vaccination schedule. We found that by using the same number of vaccines administered today, the targeting of children at the age of six instead of seven would be predicted to be the optimal schedule to decrease both outpatient visits and hospitalizations. We also found that any increase in maternal vaccination coverage is likely to be cost-effective, with an incremental cost-effectiveness ratio of $77,000-$97,000 per QALY. By contrast, the contribution of the second booster dose is limited, with a probability of only 0.6 to be cost-effective at $110,000/QALY saved. Additional effort should be invested to encourage maternal vaccination against pertussis. We recommend moving the first booster to age six and prudently considering the necessity of the second booster dose.	[Langsam, Dean; Kahana, Dor; Shmueli, Erez; Yamin, Dan] Tel Aviv Univ, Dept Ind Engn, IL-6997801 Tel Aviv, Israel		Yamin, D (通讯作者)，Tel Aviv Univ, Dept Ind Engn, IL-6997801 Tel Aviv, Israel.	deanla@gmail.com; kahana.d@gmail.com; erez.shmueli@gmail.com; dan.yamin@gmail.com		Shmueli, Erez/0000-0003-3193-5768	James B. Crystal/Lillian Yaros Philanthropic fund; Israeli National Institute for Health Policy Research (NIHP) [164-16]	This study was supported by the James B. Crystal/Lillian Yaros Philanthropic fund and the Israeli National Institute for Health Policy Research (NIHP) as part of project number 164-16. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Althouse BM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0382-8; Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3; [Anonymous], 2014, VACC GUID ISR; Atkins KE, 2016, AM J EPIDEMIOL, V183, P1159, DOI 10.1093/aje/kwv347; Bellido-Blasco J, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.22.30545; Broutin H, 2010, P ROY SOC B-BIOL SCI, V277, P3239, DOI 10.1098/rspb.2010.0994; Choi YH, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0665-8; Clark TA, 2014, J INFECT DIS, V209, P978, DOI 10.1093/infdis/jiu001; Dan YM, 2014, VACCINE, V32, P4198, DOI 10.1016/j.vaccine.2014.05.015; DeAngelis H, 2016, JAMA PEDIATR, V170, P459, DOI 10.1001/jamapediatrics.2016.0047; Edwards KM, 2014, P NATL ACAD SCI USA, V111, P575, DOI 10.1073/pnas.1321360111; Fitzpatrick MC, 2016, VACCINE, V34, P3405, DOI 10.1016/j.vaccine.2016.04.010; Ginsberg GM, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8334-4; GORDON JE, 1951, AM J MED SCI, V222, P333, DOI 10.1097/00000441-195109000-00011; Hendrikx LH, 2011, VACCINE, V29, P1431, DOI 10.1016/j.vaccine.2010.12.033; Huang H, 2015, EPIDEMIOL INFECT, V143, P1950, DOI 10.1017/S095026881400260X; Keeling MJ., 2011, MODELING INFECT DIS; Koepke R, 2014, J INFECT DIS, V210, P942, DOI 10.1093/infdis/jiu322; Langsam D, 2020, VACCINE, V38, P2700, DOI 10.1016/j.vaccine.2020.01.095; Magpantay FMG, 2015, AM J EPIDEMIOL, V181, P921, DOI 10.1093/aje/kwv024; Misegades LK, 2012, JAMA-J AM MED ASSOC, V308, P2126, DOI 10.1001/jama.2012.14939; Mooi FR, 2014, EPIDEMIOL INFECT, V142, P685, DOI 10.1017/S0950268813000071; Moshel S, 2018, DIABETES, V67, DOI 10.2337/db18-1297-P; Palazzo R, 2016, NEW MICROBIOL, V39, P35; Pichichero ME, 2006, PEDIATRICS, V117, P1084, DOI 10.1542/peds.2005-1759; Pichichero ME, 2005, JAMA-J AM MED ASSOC, V293, P3003, DOI 10.1001/jama.293.24.3003; Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057; Rendi-Wagner P, 2010, VACCINE, V28, P3285, DOI 10.1016/j.vaccine.2010.02.104; Rohani P, 2011, EPIDEMICS-NETH, V3, P183, DOI 10.1016/j.epidem.2011.10.001; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Skoff TH, 2019, CLIN INFECT DIS, V68, P1634, DOI 10.1093/cid/ciy757; Skoff TH, 2012, ARCH PEDIAT ADOL MED, V166, P344, DOI 10.1001/archpediatrics.2011.1093; Vynnycky E., 2010, INTRO INFECT DIS MOD; Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110; Wendelboe Aaron M, 2005, Pediatr Infect Dis J, V24, pS58, DOI 10.1097/01.inf.0000160914.59160.41; Yechezkel M, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01926-5; Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0	37	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							590	10.3390/vaccines9060590			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2YA	34199574	Green Published, gold			2022-04-29	WOS:000666436000001
J	Piniaeva, A; Ignatyev, G; Kozlovskaya, L; Ivin, Y; Kovpak, A; Ivanov, A; Shishova, A; Antonova, L; Khapchaev, Y; Feldblium, I; Ivanova, O; Siniugina, A; Ishmukhametov, A				Piniaeva, Anastasia; Ignatyev, Georgy; Kozlovskaya, Liubov; Ivin, Yury; Kovpak, Anastasia; Ivanov, Alexander; Shishova, Anna; Antonova, Liliia; Khapchaev, Yusuf; Feldblium, Irina; Ivanova, Olga; Siniugina, Aleksandra; Ishmukhametov, Aydar			Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine "PoliovacSin": Clinical Trials Phase I and II	VACCINES			English	Article						Sabin strain; inactivated vaccine; IPV; poliovirus; clinical trial	POLIOMYELITIS VACCINE; ERADICATION; GENERATION; ANTIBODIES; FUTURE; SERUM	Global polio eradication requires both safe and effective vaccines, and safe production processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result in poliomyelitis outbreaks, and conventional inactivated poliomyelitis vaccine (Salk-IPV) production includes accumulation of large stocks of neurovirulent wild polioviruses. Therefore, IPV based on attenuated OPV strains seems a viable option. To increase the global supply of affordable inactivated vaccine in the still not-polio free world we developed an IPV made from the Sabin strains-PoliovacSin. Clinical trials included participants 18-60 years of age. A phase I single-center, randomized, double-blind placebo-controlled clinical trial included 60 participants, who received one dose of PoliovacSin or Placebo. A phase II multicenter, randomized, double-blind, comparative clinical trial included 200 participants, who received one dose of PoliovacSin or Imovax Polio. All vaccinations were well tolerated, and PoliovacSin had a comparable safety profile to the Placebo or the reference Imovax Polio preparations. A significant increase in neutralizing antibody levels to polioviruses types 1-3 (Sabin and wild) was observed in PoliovacSin and Imovax Polio vaccinated groups. Therefore, clinical trials confirmed good tolerability, low reactogenicity, and high safety profile of the PoliovacSin and its pronounced immunogenic properties. The preparation was approved for clinical trials involving infants.	[Piniaeva, Anastasia; Ignatyev, Georgy; Kozlovskaya, Liubov; Ivin, Yury; Kovpak, Anastasia; Ivanov, Alexander; Shishova, Anna; Antonova, Liliia; Khapchaev, Yusuf; Ivanova, Olga; Siniugina, Aleksandra; Ishmukhametov, Aydar] Chumakov Fed Sci Ctr Res & Dev Immune & Biol Prod, Moscow 108819, Russia; [Kozlovskaya, Liubov; Shishova, Anna; Ivanova, Olga; Ishmukhametov, Aydar] Sechenov Univ, Moscow State Med Univ 1, Inst Translat Med & Biotechnol, Moscow 117418, Russia; [Feldblium, Irina] Perm State Med Univ, Perm 614990, Russia		Piniaeva, A (通讯作者)，Chumakov Fed Sci Ctr Res & Dev Immune & Biol Prod, Moscow 108819, Russia.	pinyaeva_anl@chumakovs.su; ignatjev_gm@chumakovs.su; lubov_i_k@mail.ru; ivin_uu@chumakovs.su; kovpak_aa@chumakovs.su; ivanov_ap@chumakovs.su; shishova_aa@chumakovs.su; antonova_lp@chumakovs.su; hapchaev_uh@chumakovs.su; irinablum@mail.ru; ivanova_oe@chumakovs.su; sinyugina@chumakovs.su; ishmukhametov@chumakovs.su	Feldblium, Irina/AAC-9432-2022; Kozlovskaya, Liubov I/E-2368-2014; Ivanova, Olga E/D-9734-2014	Kozlovskaya, Liubov I/0000-0002-3029-1035; Ivanova, Olga E/0000-0003-1784-4827; Antonova, Liliia/0000-0002-1221-1134; Shishova, Anna/0000-0002-5907-0615	Ministry of Science and Higher Education of the Russian Federation [0837-2019-0005]	The neutralizing antibody testing was funded as a part of a project supported by Ministry of Science and Higher Education of the Russian Federation, No. 0837-2019-0005.	[Anonymous], 2001, Wkly Epidemiol Rec, V76, P95; [Anonymous], 2001, MMWR Recomm Rep, V50, P1; Bahl S, 2014, MMWR-MORBID MORTAL W, V63, pCOVER1; Burns CC, 2014, J INFECT DIS, V210, pS283, DOI 10.1093/infdis/jiu295; Centers for Disease Control and Prevention, 1994, MMWR MORB MORTAL WKL, V43, P720; Centers for Disease Control and Prevention (CDC), 2002, MMWR MORB MORTAL WKL, V51, P572; Dowdle WR, 2003, REV MED VIROL, V13, P277, DOI 10.1002/rmv.401; Hotta C, 2019, HUM VACC IMMUNOTHER, V15, P1154, DOI 10.1080/21645515.2019.1572408; [Иванов А.П. Ivanov A.P.], 2016, [Эпидемиология и вакцинопрофилактика, Epidemiologiya i vaktsinoprofilaktika], V15, P59; Ivanov A. P., 2014, Voprosy Virusologii, V59, P39; Ivanova O. E., 2016, Voprosy Virusologii, V61, P9, DOI 10.18821/0507-4088-2016-61-1-9-15; Jiang RJ, 2021, VACCINE, V39, P1463, DOI 10.1016/j.vaccine.2021.01.027; Okayasu H, 2016, BIOLOGICALS, V44, P581, DOI 10.1016/j.biologicals.2016.08.005; Puligedda RD, 2017, VACCINE, V35, P5455, DOI 10.1016/j.vaccine.2017.03.038; Saez-Llorens X, 2016, LANCET INFECT DIS, V16, P321, DOI 10.1016/S1473-3099(15)00488-0; Sanders BP, 2015, VACCINE, V33, P6611, DOI 10.1016/j.vaccine.2015.10.091; Shimizu H, 2016, VACCINE, V34, P1975, DOI 10.1016/j.vaccine.2014.11.015; Shin WJ, 2018, MBIO, V9, DOI 10.1128/mBio.02287-18; Sun MB, 2017, CLIN INFECT DIS, V64, P1317, DOI 10.1093/cid/cix110; Sutter R.W., 2018, VACCINES, P866, DOI DOI 10.1016/B978-0-323-35761-6.00048-1; Sutter RW, 2017, CLIN INFECT DIS, V64, P1326, DOI 10.1093/cid/cix116; Thomassen YE, 2013, BIOTECHNOL BIOENG, V110, P1354, DOI 10.1002/bit.24798; Thomassen YE, 2010, BIOTECHNOL BIOENG, V107, P96, DOI 10.1002/bit.22788; Torisu T, 2021, J PHARM SCI-US, V110, P2121, DOI 10.1016/j.xphs.2020.12.012; UNICEF, 2019, IN POL VACC IPV SUPP; Verdijk P, 2011, EXPERT REV VACCINES, V10, P635, DOI [10.1586/ERV.11.51, 10.1586/erv.11.51]; World Health Organization, 2019, 20 M GLOB COMM CERT; World Health Organization (WHO), 1997, WHOEPIGEN971; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; Yakovenko ML, 2014, EUROSURVEILLANCE, V19, P41, DOI 10.2807/1560-7917.ES2014.19.7.20706	30	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							565	10.3390/vaccines9060565			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5TO	34072466	gold, Green Published			2022-04-29	WOS:000665950300001
J	Kawaguchi, H; Sakamoto, T; Koya, T; Togi, M; Date, I; Watanabe, A; Yoshida, K; Kato, T; Nakamura, Y; Ishigaki, Y; Shimodaira, S				Kawaguchi, Haruhiko; Sakamoto, Takuya; Koya, Terutsugu; Togi, Misa; Date, Ippei; Watanabe, Asuka; Yoshida, Kenichi; Kato, Tomohisa, Jr.; Nakamura, Yuka; Ishigaki, Yasuhito; Shimodaira, Shigetaka			Quality Verification with a Cluster-Controlled Manufacturing System to Generate Monocyte-Derived Dendritic Cells	VACCINES			English	Article						immunotherapy; dendritic cells; vaccine; cluster formation; cluster control	STEM-CELLS; T-CELLS; OK-432; CULTURE; IMMUNOTHERAPY; ACTIVATION; MATURATION	Dendritic cell (DC) vaccines for cancer immunotherapy have been actively developed to improve clinical efficacy. In our previous report, monocyte-derived DCs induced by interleukin (IL)-4 with a low-adherence dish (low-adherent IL-4-DCs: la-IL-4-DCs) improved the yield and viability, as well as relatively prolonged survival in vitro, compared to IL-4-DCs developed using an adherent culture protocol. However, la-IL-4-DCs exhibit remarkable cluster formation and display heterogeneous immature phenotypes. Therefore, cluster formation in la-IL-4-DCs needs to be optimized for the clinical development of DC vaccines. In this study, we examined the effects of cluster control in the generation of mature IL-4-DCs, using cell culture vessels and measuring spheroid formation, survival, cytokine secretion, and gene expression of IL-4-DCs. Mature IL-4-DCs in cell culture vessels (cluster-controlled IL-4-DCs: cc-IL-4-DCs) displayed increased levels of CD80, CD86, and CD40 compared with that of la-IL-4-DCs. cc-IL-4-DCs induced antigen-specific cytotoxic T lymphocytes (CTLs) with a human leukocyte antigen (HLA)-restricted melanoma antigen recognized by T cells 1 (MART-1) peptide. Additionally, cc-IL-4-DCs produced higher levels of IFN-gamma, possessing the CTL induction. Furthermore, DNA microarrays revealed the upregulation of BCL2A1, a pro-survival gene. According to these findings, the cc-IL-4-DCs are useful for generating homogeneous and functional IL-4-DCs that would be expected to promote long-lasting effects in DC vaccines.	[Kawaguchi, Haruhiko; Sakamoto, Takuya; Koya, Terutsugu; Togi, Misa; Date, Ippei; Watanabe, Asuka; Shimodaira, Shigetaka] Kanazawa Med Univ, Dept Regenerat Med, Kahoku, Ishikawa 9200293, Japan; [Sakamoto, Takuya; Koya, Terutsugu; Togi, Misa; Yoshida, Kenichi; Shimodaira, Shigetaka] Kanazawa Med Univ Hosp, Ctr Regenerat Med, Kahoku, Ishikawa 9200293, Japan; [Kato, Tomohisa, Jr.; Nakamura, Yuka; Ishigaki, Yasuhito] Kanazawa Med Univ, Med Res Inst, Kahoku, Ishikawa 9200293, Japan		Shimodaira, S (通讯作者)，Kanazawa Med Univ, Dept Regenerat Med, Kahoku, Ishikawa 9200293, Japan.; Shimodaira, S (通讯作者)，Kanazawa Med Univ Hosp, Ctr Regenerat Med, Kahoku, Ishikawa 9200293, Japan.	harukawa@kanazawa-med.ac.jp; taku0731@kanazawa-med.ac.jp; koya@kanazawa-med.ac.jp; m-togi@kanazawa-med.ac.jp; dat-pey@kanazawa-med.ac.jp; asuka-w@kanazawa-med.ac.jp; ken1-y@kanazawa-med.ac.jp; tkato@kanazawa-med.ac.jp; yuka-n@kanazawa-med.ac.jp; ishigaki@kanazawa-med.ac.jp; shimodai@kanazawa-med.ac.jp		Shimodaira, Shigetaka/0000-0002-6612-6912; Sakamoto, Takuya/0000-0003-2519-4510; Ishigaki, Yasuhito/0000-0003-1012-8430	ALP Institute for Regenerative Medicine Inc.; Program on Open Innovation Platform with Enterprises, Research Institutes, and Academia of the JST [JPMJOP1722]	This research was funded by ALP Institute for Regenerative Medicine Inc., and the Program on Open Innovation Platform with Enterprises, Research Institutes, and Academia of the JST, grant number JPMJOP1722.	Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; Akefeldt SO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056865; Anguille S, 2014, LANCET ONCOL, V15, pE257, DOI 10.1016/S1470-2045(13)70585-0; Audiger C, 2017, J IMMUNOL, V198, P2223, DOI 10.4049/jimmunol.1601629; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bhang SH, 2012, TISSUE ENG PT A, V18, P2138, DOI [10.1089/ten.tea.2011.0640, 10.1089/ten.TEA.2011.0640]; Butterfield LH, 2011, CLIN CANCER RES, V17, P3064, DOI 10.1158/1078-0432.CCR-10-2234; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Cesarz Z, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9176357; Date I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010010; Draube A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018801; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Frith JE, 2010, TISSUE ENG PART C-ME, V16, P735, DOI [10.1089/ten.tec.2009.0432, 10.1089/ten.TEC.2009.0432]; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Higuchi Y, 2015, BIOMEDICINES, V3, DOI 10.3390/biomedicines3040304; Hill KS, 2008, J IMMUNOL, V181, P3108, DOI 10.4049/jimmunol.181.5.3108; Huang CL, 2018, EXP THER MED, V15, P2499, DOI 10.3892/etm.2018.5697; Janikashvili N, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/430394; Jensen C, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00033; Koya T, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040305; Kuroki H, 2003, CANCER IMMUNOL IMMUN, V52, P561, DOI 10.1007/s00262-003-0394-7; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Murphy KC, 2017, STEM CELLS, V35, P1493, DOI 10.1002/stem.2606; Nakahara S, 2003, CANCER RES, V63, P4112; Nesselhut J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3092; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Pan K, 2014, IMMUNOL CELL BIOL, V92, P263, DOI 10.1038/icb.2013.87; Pettinato G, 2016, SCI REP-UK, V6, DOI 10.1038/srep32888; Ribas A, 2009, CLIN CANCER RES, V15, P6267, DOI 10.1158/1078-0432.CCR-09-1254; Ryoma Y, 2004, ANTICANCER RES, V24, P3295; Ryu NE, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121620; Santos PM, 2018, J IMMUNOL, V200, P443, DOI 10.4049/jimmunol.1701024; Sasai Y, 2013, CELL STEM CELL, V12, P520, DOI 10.1016/j.stem.2013.04.009; Sato K, 1999, J IMMUNOL, V162, P3865; Sato M, 2003, CANCER SCI, V94, P1091, DOI 10.1111/j.1349-7006.2003.tb01405.x; Sauter A, 2015, SCAND J IMMUNOL, V81, P56, DOI 10.1111/sji.12246; Sauter A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02352; Schmidt SV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00274; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shimodaira S., 2015, PHARM ANAL ACTA, V7, P8, DOI [10.4172/2153-2435.1000465, DOI 10.4172/2153-2435.1000465]; Shimodaira S., 2015, PHARM REG AFF, V4, DOI [10.4172/2167-7689.1000143, DOI 10.4172/2167-7689.1000143]; Shimodaira S, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030120; Shimodaira S, 2015, VACCINES-BASEL, V3, P1004, DOI 10.3390/vaccines3041004; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; Tanyi JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5931; Torizal FG, 2019, REGEN THER, V12, P66, DOI 10.1016/j.reth.2019.04.011; Tsai AC, 2015, TISSUE ENG PT A, V21, P1705, DOI [10.1089/ten.tea.2014.0314, 10.1089/ten.TEA.2014.0314]; Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158; Wang J, 2017, MOL MED REP, V16, P6787, DOI 10.3892/mmr.2017.7448; Wang Q, 2010, MOL IMMUNOL, V47, P922, DOI 10.1016/j.molimm.2009.09.038; Zammit DJ, 2005, IMMUNITY, V22, P561, DOI 10.1016/j.immuni.2005.03.005	51	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							533	10.3390/vaccines9050533			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1IB	34065520	Green Published, gold			2022-04-29	WOS:000654578700001
J	Park, Y; Oh, Y; Wang, MM; Ganges, L; Bohorquez, JA; Park, S; Gu, S; Park, J; Lee, S; Kim, J; Sohn, EJ				Park, Youngmin; Oh, Yeonsu; Wang, Miaomiao; Ganges, Llilianne; Bohorquez, Jose Alejandro; Park, Soohong; Gu, Sungmin; Park, Jungae; Lee, Sangmin; Kim, Jongkook; Sohn, Eun-Ju			A Novel E2 Glycoprotein Subunit Marker Vaccine Produced in Plant Is Able to Prevent Classical Swine Fever Virus Vertical Transmission after Double Vaccination	VACCINES			English	Article						classical swine fever virus; E2 glycoprotein; marker vaccine; vertical transmission; plant; protection	INFECTIONS; EFFICACY; CHALLENGE; CP7-E2ALF; ANTIBODY; ASSAY	The efficacy of a novel subunit vaccine candidate, based in the CSFV E2 glycoprotein produced in plants to prevent classical swine fever virus (CSFV) vertical transmission, was evaluated. A Nicotiana benthamiana tissue culture system was used to obtain a stable production of the E2-glycoprotein fused to the porcine Fc region of IgG. Ten pregnant sows were divided into three groups: Groups 1 and 2 (four sows each) were vaccinated with either 100 mu g/dose or 300 mu g/dose of the subunit vaccine at 64 days of pregnancy. Group 3 (two sows) was injected with PBS. Groups 1 and 2 were boosted with the same vaccine dose. At 10 days post second vaccination, the sows in Groups 2 and 3 were challenged with a highly virulent CSFV strain. The vaccinated sows remained clinically healthy and seroconverted rapidly, showing efficient neutralizing antibodies. The fetuses from vaccinated sows did not show gross lesions, and all analyzed tissue samples tested negative for CSFV replication. However, fetuses of non-vaccinated sows had high CSFV replication in tested tissue samples. The results suggested that in vaccinated sows, the plant produced E2 marker vaccine induced the protective immunogenicity at challenge, leading to protection from vertical transmission to fetuses.	[Park, Youngmin; Park, Soohong; Gu, Sungmin; Park, Jungae; Lee, Sangmin; Kim, Jongkook; Sohn, Eun-Ju] BioApplications Inc, Pohang 37668, South Korea; [Oh, Yeonsu] Kangwon Natl Univ, Inst Vet Sci, Coll Vet Med, Chunchon 24341, South Korea; [Wang, Miaomiao; Ganges, Llilianne; Bohorquez, Jose Alejandro] IRTA CReSA, OIE Reference Lab Class Swine Fever, Barcelona 08193, Spain		Sohn, EJ (通讯作者)，BioApplications Inc, Pohang 37668, South Korea.	ympark86@postech.ac.kr; yeonoh@kangwon.ac.kr; miaomiao.wang@irta.cat; llilianne.ganges@irta.cat; josealejandro.bohorquez@irta.cat; saysh13@bioapp.co.kr; gusungmin@bioapp.co.kr; oh@bioapp.co.kr; lsm1978@bioapp.co.kr; bio2020@bioapp.co.kr; ejsohn@bioapp.co.kr	; Ganges, Llilianne/O-7342-2017	Oh, Yeonsu/0000-0001-5743-5396; Park, Youngmin/0000-0003-1174-3793; Ganges, Llilianne/0000-0002-8644-3560; Bohorquez Garzon, Jose Alejandro/0000-0002-6715-1757	Ministerio de Ciencia e Innovacion, from the Spanish governmentSpanish Government; CSC scholarship (2017), from the Chinese government	J.A.B has a pre-doctoral fellowship, FPI 2016, Ministerio de Ciencia e Innovacion, from the Spanish government. M.W. has a pre-doctoral fellowship, CSC scholarship (2017), from the Chinese government.	Abid M, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040279; Ahrens U, 2000, VET MICROBIOL, V77, P83, DOI 10.1016/S0378-1135(00)00265-0; Beltran-Alcrudo D, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1800-5; Blome S, 2014, VET MICROBIOL, V169, P8, DOI 10.1016/j.vetmic.2013.12.002; Bouma A, 2000, VACCINE, V18, P1374, DOI 10.1016/S0264-410X(99)00398-9; Bouma A, 1999, VET MICROBIOL, V66, P101, DOI 10.1016/S0378-1135(99)00003-6; Coronado L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020154; Coronado L, 2017, VET MICROBIOL, V201, P103, DOI 10.1016/j.vetmic.2017.01.013; Depner KR, 2001, VET MICROBIOL, V83, P107, DOI 10.1016/S0378-1135(01)00410-2; Dewulf J, 2002, J VET MED B, V49, P452, DOI 10.1046/j.1439-0450.2002.00593.x; Gabriel C, 2012, VACCINE, V30, P2928, DOI 10.1016/j.vaccine.2012.02.065; Ganges L, 2008, VET J, V177, P169, DOI 10.1016/j.tvjl.2007.01.030; Gavier-Widen D., 2012, INFECT DIS WILD MAMM; Giangaspero M, 2020, OPEN VET J, V10, P94, DOI 10.4314/ovj.v10i1.15; Hoffmann B, 2005, J VIROL METHODS, V130, P36, DOI 10.1016/j.jviromet.2005.05.030; Lei JL, 2016, IMMUNOL LETT, V174, P63, DOI 10.1016/j.imlet.2016.04.014; LIESS B, 1984, PREV VET MED, V2, P109, DOI 10.1016/0167-5877(84)90054-0; Lin HX, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00081; Lindenbach B., 2001, FLAVIVIRIDAE VIRUSES, V1; Meuwissen MPM, 1999, PREV VET MED, V42, P249, DOI 10.1016/S0167-5877(99)00079-3; Munoz-Gonzalez S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125692; Park Y, 2020, BIOTECHNOL LETT, V42, P1247, DOI 10.1007/s10529-020-02892-3; Postel A, 2013, VET MICROBIOL, V161, P334, DOI 10.1016/j.vetmic.2012.07.045; REED L. J., 1938, AMER JOUR HYG, V27, P493; Risatti GR, 2007, J VIROL, V81, P924, DOI 10.1128/JVI.01824-06; Smith DB, 2017, J GEN VIROL, V98, P2106, DOI 10.1099/jgv.0.000873; Sordo-Puga Y., 2021, VACCINES-BASEL, V9, P167, DOI [10.3390/vaccines9020167, DOI 10.3390/vaccines9020167]; TERPSTRA C, 1988, VET MICROBIOL, V16, P123, DOI 10.1016/0378-1135(88)90036-3; TERPSTRA C, 1984, VET MICROBIOL, V9, P113, DOI 10.1016/0378-1135(84)90026-9; Trautwein G., 1988, Classical swine fever and related viral infections, P27; Van Oirschot J., 1977, VET MICROBIOL, V2, P121, DOI 10.1016/0378-1135(77)90003-7; van Oirschot JT, 2003, VET MICROBIOL, V96, P367, DOI 10.1016/j.vetmic.2003.09.008; van Rijn PA, 2007, VET MICROBIOL, V125, P150, DOI 10.1016/j.vetmic.2007.05.001; VANOIRSCHOT JT, 1979, VET MICROBIOL, V4, P133, DOI 10.1016/0378-1135(79)90049-X; VANOIRSCHOT JT, 1979, VET MICROBIOL, V4, P117, DOI 10.1016/0378-1135(79)90048-8; Wang MM, 2020, J VIROL, V94, DOI 10.1128/JVI.01214-19; Yoo SJ, 2018, TRANSBOUND EMERG DIS, V65, P735, DOI 10.1111/tbed.12798	37	3	3	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							418	10.3390/vaccines9050418			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1EQ	33922120	Green Published, gold			2022-04-29	WOS:000654569700001
J	Bierrenbach, AL; Choi, Y; Batista, PD; Serra, FB; Parellada, CI; Julian, GS; Nakajima, K; Moreira, TDF				Bierrenbach, Ana Luiza; Choi, Yoonyoung; Batista, Paula de Mendonca; Serra, Fernando Brandao; Parellada, Cintia Irene; Julian, Guilherme Silva; Nakajima, Karina; Fraga Moreira, Thais das Neves			The Impact of an Inactivated Hepatitis A Vaccine with One Dose in Brazil: A Retrospective Time-Series	VACCINES			English	Article						hepatitis A; national immunization program; interrupted time-series analysis	MENDOZA PROVINCE; VIRAL-HEPATITIS; CHILDREN; ARGENTINA; IMMUNIZATION; EPIDEMIOLOGY; PERSISTENCE; ANTIBODY; FAILURE	Background: In 2014, a recommended one-dose of inactivated hepatitis A vaccine was included in the Brazilian National Immunization Program targeting children 12-24 months. This decision addressed the low to intermediate endemicity status of hepatitis A across Brazil and the high rate of infection in children and adolescents between 5 and 19 years old. The aim of the study was to conduct a time-series analysis on hepatitis A incidence across age groups and to assess the hepatitis A distribution throughout Brazilian geographic regions. Methods: An interrupted time-series analysis was performed to assess hepatitis A incidence rates before (2010-2013) and after (2015-2018) hepatitis A vaccine program implementation. The time-series analysis was stratified by age groups while a secondary analysis examined geographic distribution of hepatitis A cases. Results: Overall incidence of hepatitis A decreased from 3.19/100.000 in the pre-vaccine period to 0.87/100.000 (p = 0.022) post-vaccine introduction. Incidence rate reduction was higher among children aged 1-4 years old, with an annual reduction of 67.6% in the post-vaccination period against a 7.7% annual reduction in the pre-vaccination period (p < 0.001). Between 2015 and 2018, the vaccination program prevented 14,468 hepatitis A cases. Conclusion: Our study highlighted the positive impact of a recommended one-dose inactivated hepatitis A vaccine for 1-4-years-old in controlling hepatitis A at national level.	[Bierrenbach, Ana Luiza] Hosp Sirio Libanes, Inst Ensino & Pesquisa, BR-01308050 Sao Paulo, SP, Brazil; [Choi, Yoonyoung] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Batista, Paula de Mendonca; Serra, Fernando Brandao; Parellada, Cintia Irene; Fraga Moreira, Thais das Neves] MSD Brazil, BR-04717004 Sao Paulo, SP, Brazil; [Julian, Guilherme Silva; Nakajima, Karina] IQVIA Brazil, BR-04719002 Sao Paulo, SP, Brazil		Bierrenbach, AL (通讯作者)，Hosp Sirio Libanes, Inst Ensino & Pesquisa, BR-01308050 Sao Paulo, SP, Brazil.	albierrenbach@yahoo.com.br; yoon.young.choi2@merck.com; paula.de.mendonca.batista@merck.com; fernando.brandao.serra@merck.com; cintia.parellada@merck.com; guilherme.julian@iqvia.com; karina.nakajima@iqvia.com; thais.moreira@merck.com	; Bierrenbach, Ana/F-3185-2014	Julian, Guilherme/0000-0002-3487-2240; Parellada, Cintia Irene/0000-0002-8536-9274; Bierrenbach, Ana/0000-0002-6837-0636	MSD Brazil	This study was funded by MSD Brazil.	Andani A, 2020, EXPERT REV VACCINES, V19, P795, DOI 10.1080/14760584.2020.1813575; [Anonymous], 2012, Wkly Epidemiol Rec, V87; [Anonymous], 2016, B EP HEP VIR, V15, P1; [Anonymous], 2018, B EPIDEMIOLOGICO, P52; [Anonymous], 2017, GLOB HEP REP; Brito Wagner Izidoro de, 2020, Rev. bras. epidemiol., V23, pe200073, DOI 10.1590/1980-549720200073; Cervio G, 2011, HEPATIC MED-EVID RES, V3, P99, DOI 10.2147/HMER.S22309; Ximenes RAD, 2008, INT J EPIDEMIOL, V37, P852, DOI 10.1093/ije/dyn114; Ximenes RAD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094622; de Brito WI, 2018, BRAZ J INFECT DIS, V22, P166, DOI 10.1016/j.bjid.2018.04.001; De Oliveira TM, 2020, J MED VIROL, V92, P1343, DOI 10.1002/jmv.25694; Souto FJD, 2019, VACCINE, V37, P771, DOI 10.1016/j.vaccine.2018.12.054; Espul C, 2020, VACCINE, V38, P1715, DOI 10.1016/j.vaccine.2019.12.049; Espul C, 2017, HUM VACC IMMUNOTHER, V13, P2707, DOI 10.1080/21645515.2017.1358326; Ferreira DC, 2021, SCI TOTAL ENVIRON, V779, DOI 10.1016/j.scitotenv.2021.146279; Global Burden of Disease Collaborative Network, 2021, GLOBAL BURDEN DIS ST, DOI [10.6069/1D4Y-YQ37, DOI 10.6069/1D4Y-YQ37]; Lemon SM, 2018, J HEPATOL, V68, P167, DOI 10.1016/j.jhep.2017.08.034; Lopez EL, 2015, PEDIATR INFECT DIS J, V34, P417, DOI 10.1097/INF.0000000000000605; Lopez EL, 2010, PEDIATR INFECT DIS J, V29, P568, DOI 10.1097/INF.0b013e3181d57a85; Mikhailov MI, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040780; Ministeres des affaires etrangeres et la guerre, 1919, B EPIDEMIOL, P1, DOI DOI 10.1007/S13398-014-0173-7.2; Ndumbi P, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.33.1700641; Nelson NP, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6905a1; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Parellada C, 2018, INT J INFECT DIS, V73, P361, DOI 10.1016/j.ijid.2018.04.4233; Petrecz M, 2019, HUM VACC IMMUNOTHER, V15, P426, DOI 10.1080/21645515.2018.1530934; Regan DG, 2016, EPIDEMIOL INFECT, V144, P1528, DOI 10.1017/S0950268815002605; Rivas V, 2018, EUROSURVEILLANCE, V23, P14, DOI 10.2807/1560-7917.ES.2018.23.9.18-00060; Sedhom D, 2018, CLIN LIVER DIS, V22, P289, DOI 10.1016/j.cld.2018.01.005; Shin EC, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031708; Theeten H, 2015, VACCINE, V33, P5723, DOI 10.1016/j.vaccine.2015.07.008; Uruena A, 2016, PEDIATR INFECT DIS J, V35, P1339, DOI 10.1097/INF.0000000000001322; Vacchino MN, 2008, J VIRAL HEPATITIS, V15, P47, DOI 10.1111/j.1365-2893.2008.01029.x; Vizzotti C, 2014, PEDIATR INFECT DIS J, V33, P84, DOI 10.1097/INF.0000000000000042; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; Zimmermann R, 2021, INT J INFECT DIS, V103, P146, DOI 10.1016/j.ijid.2020.11.133	36	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							407	10.3390/vaccines9040407			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4SK	33924029	Green Published, gold			2022-04-29	WOS:000643770700001
J	Ikeda, Y; Adachi, K; Tomio, K; Eguchi-Kojima, S; Tsuruga, T; Uchino-Mori, M; Taguchi, A; Komatsu, A; Nagamatsu, T; Oda, K; Kawana-Tachikawa, A; Uemura, Y; Igimi, S; Osuga, Y; Fujii, T; Kawana, K				Ikeda, Yuji; Adachi, Katsuyuki; Tomio, Kensuke; Eguchi-Kojima, Satoko; Tsuruga, Tetsushi; Uchino-Mori, Mayuyo; Taguchi, Ayumi; Komatsu, Atsushi; Nagamatsu, Takeshi; Oda, Katsutoshi; Kawana-Tachikawa, Ai; Uemura, Yukari; Igimi, Shizunobu; Osuga, Yutaka; Fujii, Tomoyuki; Kawana, Kei			A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing Lactobacillus, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)	VACCINES			English	Article						Human Papillomavirus (HPV); therapeutic vaccine; mucosal immunity; Cervical Intraepithelial Neoplasia 2 (CIN2); cervical cancer; lactobacillus-based vaccine		Cervical intraepithelial neoplasia (CIN), a precursor lesion to cervical cancer, is caused by high-risk human papillomavirus (HPV); high-grade CIN lesions (CIN2-3) are precancerous and require treatment. No globally approved therapy is available for CIN2-3 treatment. This study is a placebo-controlled randomized clinical trial of GLBL101c treatment for CIN2 in 40 patients with HPV16-positive CIN2 who were 1:1 randomized to receive GLBL101c (1 g/daily) or placebo for 5 days at 1, 2, 4, and 8 weeks. No differences were noted between the GLBL101c and placebo groups for patient background and adverse events. Moreover, no statistically significant difference was noted between the two groups at the primary endpoint, pathological regression after 16 weeks of the first oral dose; however, only in the GLBL101c group, two patients had complete regression (CR; regression to normal within 16 weeks). IFN gamma production was significantly correlated with the number of spots identified by the interferon gamma enzyme-linked immunospot (IFN gamma-ELISPOT) assay using cervical lymphocytes (CxLs) or peripheral blood mononuclear cells. In the two cases of CR, E7-specific Th1 immune responses were observed at week 16. Therefore, we concluded as a novel Lactobacillus-based vaccine with stronger immunogenicity than GLBL101c should be developed.	[Ikeda, Yuji; Komatsu, Atsushi; Kawana, Kei] Nihon Univ, Dept Obstet & Gynecol, Sch Med, Itabashi Ku, 30-1 Oyaguchi Kamimachi, Tokyo 1738610, Japan; [Adachi, Katsuyuki; Tomio, Kensuke; Eguchi-Kojima, Satoko; Tsuruga, Tetsushi; Uchino-Mori, Mayuyo; Taguchi, Ayumi; Komatsu, Atsushi; Nagamatsu, Takeshi; Oda, Katsutoshi; Osuga, Yutaka; Fujii, Tomoyuki; Kawana, Kei] Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan; [Kawana-Tachikawa, Ai] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan; [Uemura, Yukari] Natl Ctr Global Hlth & Med, Clin Res Ctr, Biostat Sect, Tokyo 1628655, Japan; [Igimi, Shizunobu] Tokyo Univ Agr, Dept Appl Biol & Chem, Setagaya Ku, 1-1-1 Sakuragaoka, Tokyo 1568502, Japan		Kawana, K (通讯作者)，Nihon Univ, Dept Obstet & Gynecol, Sch Med, Itabashi Ku, 30-1 Oyaguchi Kamimachi, Tokyo 1738610, Japan.; Kawana, K (通讯作者)，Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	Ikeda.yuji@nihon-u.ac.jp; kadachi-gyn@umin.org; k-tomio@umin.ac.jp; satokojolly@yahoo.co.jp; tsurugatetsushi@gmail.com; mayuyo1976@gmail.com; ayumikidu246@gmail.com; komatsu.atsushi@nihon-u.ac.jp; tnag-tky@umin.ac.jp; katsutoshi-tky@umin.ac.jp; aiktachi@niid.go.jp; yukariuemura-tky@umin.ac.jp; s3igimi@nodai.ac.jp; yutakaos-tky@umin.ac.jp; fujiit-tky@umin.org; kkawana-tky@umin.org		IKEDA, YUJI/0000-0003-1633-5385; Oda, Katsutoshi/0000-0002-2468-9573	Project Promoting Clinical Trials for Development of New Drugs from Japan; Agency for Medical Research and Development (AMED), JapanJapan Agency for Medical Research and Development (AMED) [JP15lk0201019h0003, JP17lk0201019h0105]	This research was funded by the Project Promoting Clinical Trials for Development of New Drugs from Japan, Agency for Medical Research and Development (AMED), Japan, under grant numbers JP15lk0201019h0003 and JP17lk0201019h0105.	Adachi K, 2010, VACCINE, V28, P2810, DOI 10.1016/j.vaccine.2010.02.005; Bogani G, 2020, GYNECOL ONCOL, V159, P636, DOI 10.1016/j.ygyno.2020.08.025; Bogani G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040717; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; BUCKLEY CH, 1982, J CLIN PATHOL, V35, P1, DOI 10.1136/jcp.35.1.1; Cohen PA, 2019, LANCET, V393, P169, DOI 10.1016/S0140-6736(18)32470-X; Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813, DOI 10.1001/jama.297.8.813; Einstein MH, 2007, GYNECOL ONCOL, V106, P453, DOI 10.1016/j.ygyno.2007.04.038; Ferenczy A, 2002, LANCET ONCOL, V3, P11, DOI 10.1016/S1470-2045(01)00617-9; Han CY, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-38; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; Ikeda Y, 2019, JPN J CLIN ONCOL, V49, P877, DOI 10.1093/jjco/hyz095; Kawana K, 2014, VACCINE, V32, P6233, DOI 10.1016/j.vaccine.2014.09.020; Kawana K, 2009, INDIAN J MED RES, V130, P341; Kojima S, 2011, AM J REPROD IMMUNOL, V66, P435, DOI 10.1111/j.1600-0897.2011.01041.x; Komatsu A, 2018, VACCINE, V36, P3423, DOI 10.1016/j.vaccine.2018.05.009; Kong LH, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07483-z; Kyrgiou M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012847; Liu SL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193061; Matsumoto K, 2011, INT J CANCER, V128, P2898, DOI 10.1002/ijc.25630; Poo H, 2006, INT J CANCER, V119, P1702, DOI 10.1002/ijc.22035; Ressler S, 2007, CLIN CANCER RES, V13, P7067, DOI 10.1158/1078-0432.CCR-07-1222; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1; Wang-Johanning F, 2002, CANCER-AM CANCER SOC, V94, P2199, DOI 10.1002/cncr.10439	24	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							329	10.3390/vaccines9040329			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4SE	33915901	gold, Green Published			2022-04-29	WOS:000643770100001
J	Militzer, N; Bartel, A; Clausen, PH; Hoffmann-Kohler, P; Nijhof, AM				Militzer, Nina; Bartel, Alexander; Clausen, Peter-Henning; Hoffmann-Kohler, Peggy; Nijhof, Ard M.			Artificial Feeding of All Consecutive Life Stages of Ixodes ricinus	VACCINES			English	Article						Ixodes ricinus; artificial tick feeding; in vitro tick feeding; vitamin B; life cycle	RHIPICEPHALUS MICROPLUS LARVAE; IN-VITRO; TICKS ACARI; IXODIDAE; SCAPULARIS; RESPONSES; MEMBRANE; BLOOD; TRANSMISSION; REPRODUCTION	The hard tick Ixodes ricinus is an obligate hematophagous arthropod and the main vector for several zoonotic diseases. The life cycle of this three-host tick species was completed for the first time in vitro by feeding all consecutive life stages using an artificial tick feeding system (ATFS) on heparinized bovine blood supplemented with glucose, adenosine triphosphate, and gentamicin. Relevant physiological parameters were compared to ticks fed on cattle (in vivo). All in vitro feedings lasted significantly longer and the mean engorgement weight of F-0 adults and F-1 larvae and nymphs was significantly lower compared to ticks fed in vivo. The proportions of engorged ticks were significantly lower for in vitro fed adults and nymphs as well, but higher for in vitro fed larvae. F-1-females fed on blood supplemented with vitamin B had a higher detachment proportion and engorgement weight compared to F-1-females fed on blood without vitamin B, suggesting that vitamin B supplementation is essential in the artificial feeding of I. ricinus ticks previously exposed to gentamicin.	[Militzer, Nina; Clausen, Peter-Henning; Hoffmann-Kohler, Peggy; Nijhof, Ard M.] Free Univ Berlin, Inst Parasitol & Trop Vet Med, D-14163 Berlin, Germany; [Bartel, Alexander] Free Univ Berlin, Inst Vet Epidemiol & Biostat, D-14163 Berlin, Germany		Nijhof, AM (通讯作者)，Free Univ Berlin, Inst Parasitol & Trop Vet Med, D-14163 Berlin, Germany.	Nina.Militzer@fu-berlin.de; alexander.bartel@fu-berlin.de; Peter-Henning.Clausen@fu-berlin.de; peggy.koehler@fu-berlin.de; ard.nijhof@fu-berlin.de		Bartel, Alexander/0000-0002-1280-6138	German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [01KI1720]	This study was funded by the German Federal Ministry of Education and Research (BMBF, grant number 01KI1720) as part of the Junior Research Group "Tick-borne Zoonoses".	Abraham NM, 2017, P NATL ACAD SCI USA, V114, pE781, DOI 10.1073/pnas.1613422114; Andrade JJ, 2014, J MED ENTOMOL, V51, P878, DOI 10.1603/ME13180; Antunes S, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-42; BEDFORD G. A. H., 1931, PARASITOLOGY, V23, P230, DOI 10.1017/S0031182000013573; Bohme B, 2018, PARASITOL RES, V117, P565, DOI 10.1007/s00436-017-5648-y; Bonnet S, 2007, PARASITOLOGY, V134, P197, DOI 10.1017/S0031182006001545; Brugger K, 2016, J MED ENTOMOL, V53, P1292, DOI 10.1093/jme/tjw116; Campbell EM, 2010, INT J PARASITOL, V40, P15, DOI 10.1016/j.ijpara.2009.06.010; Contreras M, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00360; DeVries ZC, 2016, J EXP BIOL, V219, P3773, DOI 10.1242/jeb.143487; Duron O, 2020, TRENDS PARASITOL, V36, P816, DOI 10.1016/j.pt.2020.07.007; Duron O, 2018, CURR BIOL, V28, P1896, DOI 10.1016/j.cub.2018.04.038; Estrada-Pena A, 1999, EXP APPL ACAROL, V23, P685, DOI 10.1023/A:1006241108739; Ferreira HCD, 2014, TICKS TICK-BORNE DIS, V5, P582, DOI 10.1016/j.ttbdis.2013.12.012; Fourie JJ, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3396-9; Gonzalez J, 2017, EXP APPL ACAROL, V72, P449, DOI 10.1007/s10493-017-0167-1; Gray J. S., 1991, Review of Medical and Veterinary Entomology, V79, P323; Grenacher S, 2001, EXP APPL ACAROL, V25, P641, DOI 10.1023/A:1016145805759; Guglielmone AA, 2010, ZOOTAXA, P1, DOI 10.11646/zootaxa.2528.1.1; Guizzo MG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17309-x; Habedank B., 1993, Dermatologische Monatsschrift, V179, P292; HOKAMA Y, 1987, J MED ENTOMOL, V24, P319, DOI 10.1093/jmedent/24.3.319; Hosokawa T, 2010, P NATL ACAD SCI USA, V107, P769, DOI 10.1073/pnas.0911476107; Hu RJ, 2000, J MED ENTOMOL, V37, P198, DOI 10.1603/0022-2585-37.1.198; Hughes VL, 2001, J PARASITOL, V87, P49, DOI 10.1645/0022-3395(2001)087[0049:TDIAAR]2.0.CO;2; JAENSON TGT, 1994, J MED ENTOMOL, V31, P240, DOI 10.1093/jmedent/31.2.240; Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967; KAHL O, 1990, EXP APPL ACAROL, V9, P239, DOI 10.1007/BF01193431; KEMP DH, 1986, INT J PARASITOL, V16, P115, DOI 10.1016/0020-7519(86)90096-2; Knorr S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01696; Kocan KM, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1185-7; Korner S, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-3956-z; Krober T, 2007, TRENDS PARASITOL, V23, P445, DOI 10.1016/j.pt.2007.07.010; Krober T, 2007, PEST MANAG SCI, V63, P17, DOI 10.1002/ps.1293; Krull C, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2000-4; KUHNERT F, 1995, INT J PARASITOL, V25, P887, DOI 10.1016/0020-7519(95)00009-Q; Kuhnert Frank, 1996, ALTEX, V13, P76; LAKE P, 1968, J INSECT PHYSIOL, V14, P543, DOI 10.1016/0022-1910(68)90070-X; LEES AD, 1948, J EXP BIOL, V25, P145; Levin ML, 2016, EXP APPL ACAROL, V70, P343, DOI 10.1007/s10493-016-0084-8; Lew-Tabor AE, 2014, TICKS TICK-BORNE DIS, V5, P500, DOI 10.1016/j.ttbdis.2014.03.005; Lu S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36849-4; Mac S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210280; Mans BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023675; MATUSCHKA FR, 1990, PARASITOL RES, V76, P540, DOI 10.1007/BF00931062; MATUSCHKA FR, 1992, EXP PARASITOL, V74, P151, DOI 10.1016/0014-4894(92)90042-9; MILNE A, 1949, PARASITOLOGY, V39, P167, DOI 10.1017/S0031182000083724; Musyoki JM, 2004, EXP APPL ACAROL, V32, P51, DOI 10.1023/B:APPA.0000018159.47700.e4; Nijhof AM, 2018, DRUG DISCOV INFEC DI, P187; Nikoh N, 2014, P NATL ACAD SCI USA, V111, P10257, DOI 10.1073/pnas.1409284111; Oliver JD, 2016, J MED ENTOMOL, V53, P409, DOI 10.1093/jme/tjv241; Olivieri E, 2019, TICKS TICK-BORNE DIS, V10, P1070, DOI 10.1016/j.ttbdis.2019.05.019; Petney TN, 2012, SYST APPL ACAROL-UK, V17, P115; Romano D, 2018, ACTA TROP, V183, P43, DOI 10.1016/j.actatropica.2018.04.009; Ross PA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224268; RUTLEDGE L. C., 1964, MOSQUITO NEWS, V24, P407; SCHWAN EV, 1991, EXP APPL ACAROL, V13, P107, DOI 10.1007/BF01193661; Smith TA, 2015, GENOME BIOL EVOL, V7, P831, DOI 10.1093/gbe/evv016; Talleklint L, 1997, EXP APPL ACAROL, V21, P755, DOI 10.1023/A:1018473122070; TAYLOR SM, 1990, MED VET ENTOMOL, V4, P147, DOI 10.1111/j.1365-2915.1990.tb00272.x; Totze R., 1933, Zeitschrift fuer Vergleichende Physiologie, V19, P110; Trentelman JJA, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3616-3; Trentelman JJA, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2081-0; Van Duijvendijk G, 2017, MED VET ENTOMOL, V31, P220, DOI 10.1111/mve.12214; VOIGT WP, 1993, PARASITOLOGY, V107, P257, DOI 10.1017/S0031182000079233; Waladde S.M., 1982, Current Themes in Tropical Science, V1, P71; WALADDE SM, 1991, EXP APPL ACAROL, V11, P297, DOI 10.1007/BF01202876; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Zhang CM, 2017, EXP APPL ACAROL, V73, P429, DOI 10.1007/s10493-017-0194-y; Zhong JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000405	70	1	1	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							385	10.3390/vaccines9040385			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5FJ	33919961	Green Published, gold			2022-04-29	WOS:000643804600001
J	Di Pumpo, M; Vetrugno, G; Pascucci, D; Carini, E; Beccia, V; Sguera, A; Zega, M; Pani, M; Cambieri, A; Nurchis, MC; Floriana, D; Damiani, G; Laurenti, P				Di Pumpo, Marcello; Vetrugno, Giuseppe; Pascucci, Domenico; Carini, Elettra; Beccia, Viria; Sguera, Anna; Zega, Maurizio; Pani, Marcello; Cambieri, Andrea; Nurchis, Mario Cesare; Floriana, D.; Damiani, Gianfranco; Laurenti, Patrizia			Is COVID-19 a Real Incentive for Flu Vaccination? Let the Numbers Speak for Themselves	VACCINES			English	Article						flu vaccination; COVID-19; healthcare workers; adherence; vaccination coverage		Seasonal flu vaccination is one of the most important strategies for preventing influenza. The attitude towards flu vaccination in light of the COVID-19 pandemic has so far been studied in the literature mostly with the help of surveys and questionnaires. Whether a person chooses to be vaccinated or not during the COVID-19 pandemic, however, speaks louder than any declaration of intention. In our teaching hospital, we registered a statistically significant increase in flu vaccination coverage across all professional categories between the 2019/2020 and the 2020/2021 campaign (24.19% vs. 54.56%, p < 0.0001). A linear regression model, based on data from four previous campaigns, predicted for the 2020/2021 campaign a total flu vaccination coverage of 30.35%. A coverage of 54.46% was, instead, observed, with a statistically significant difference from the predicted value (p < 0.0001). The COVID-19 pandemic can, therefore, be considered as an incentive that significantly and dramatically increased adherence to flu vaccination among our healthcare workers.	[Di Pumpo, Marcello; Vetrugno, Giuseppe; Pascucci, Domenico; Carini, Elettra; Floriana, D.; Damiani, Gianfranco; Laurenti, Patrizia] Univ Cattolica Sacro Cuore, Univ Dept Life Sci & Publ Hlth, Sect Hyg, I-00168 Rome, Italy; [Vetrugno, Giuseppe; Sguera, Anna; Zega, Maurizio; Pani, Marcello; Cambieri, Andrea] Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy; [Beccia, Viria] Univ Cattolica Sacro Cuore, I-00168 Rome, Italy; [Nurchis, Mario Cesare; Damiani, Gianfranco; Laurenti, Patrizia] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth, I-00168 Rome, Italy; [Nurchis, Mario Cesare; Damiani, Gianfranco; Laurenti, Patrizia] Fdn Policlin Univ A Gemelli IRCCS, Publ Hlth Publ Hlth Area, I-00168 Rome, Italy		Di Pumpo, M (通讯作者)，Univ Cattolica Sacro Cuore, Univ Dept Life Sci & Publ Hlth, Sect Hyg, I-00168 Rome, Italy.	dipumpomarcello@gmail.com; giuseppe.vetrugno@policlinicogemelli.it; domenico.pascucci@outlook.it; elettra.carini@policlinicogemelli.it; viria.beccia@gmail.com; anna.sguera@policlinicogemelli.it; maurizio.zega@policlinicogemelli.it; marcello.pani@policlinicogemelli.it; andrea.cambieri@policlinicogemelli.it; mariocesare.nurchis@unicatt.it; florianadambrosio@libero.it; gianfranco.damiani@unicatt.it; patrizia.laurenti@unicatt.it	vetrugno, giuseppe/M-3468-2017; LAURENTI, Patrizia/AAB-8268-2022; D'Ambrosio, Floriana/AAL-1999-2021; Damiani, Gianfranco/K-2782-2016	vetrugno, giuseppe/0000-0003-0181-2855; LAURENTI, Patrizia/0000-0002-8532-0593; D'Ambrosio, Floriana/0000-0002-0347-088X; Domenico, Pascucci/0000-0002-5804-2284; Damiani, Gianfranco/0000-0003-3028-6188; Nurchis, Mario Cesare/0000-0002-9345-4292			Barbara A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010085; Corson S, 2019, INFLUENZA OTHER RESP, V13, P354, DOI 10.1111/irv.12583; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Gianino MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182510; Jaklevic MC, 2020, JAMA-J AM MED ASSOC, V324, P926, DOI 10.1001/jama.2020.15444; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Rittle C, 2014, WORKPLACE HEALTH SAF, V62, P508, DOI 10.3928/21650799-20140909-02; Sokol RL, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-022871; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021	12	8	8	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							276	10.3390/vaccines9030276			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4YZ	33803755	Green Published, gold			2022-04-29	WOS:000634162900001
J	Bonong, PRE; Zahreddine, M; Buteau, C; Duval, M; Laporte, L; Lacroix, J; Alfieri, C; Trottier, H				Enok Bonong, Pascal Roland; Zahreddine, Monica; Buteau, Chantal; Duval, Michel; Laporte, Louise; Lacroix, Jacques; Alfieri, Caroline; Trottier, Helen			Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis	VACCINES			English	Review						Epstein-Barr virus (EBV); human herpesvirus-4 (HHV-4); risk factors; post-transplant lymphoproliferative disease (PTLD); EBV reactivation; hematopoietic stem cell transplant (HSCT)	VERSUS-HOST-DISEASE; RABBIT ANTITHYMOCYTE GLOBULIN; CORD BLOOD TRANSPLANTATION; EBV REACTIVATION; RISK-FACTORS; VIRAL-LOAD; ALLO-SCT; PEDIATRIC RECIPIENTS; PREEMPTIVE THERAPY; DNA LEVELS	This systematic review was undertaken to identify risk factors associated with post-transplant Epstein-Barr virus (EBV) active infection and post-transplant lymphoproliferative disease (PTLD) in pediatric and adult recipients of hematopoietic stem cell transplants (HSCT). A literature search was conducted in PubMed and EMBASE to identify studies published until 30 June 2020. Descriptive information was extracted for each individual study, and data were compiled for individual risk factors, including, when possible, relative risks with 95% confidence intervals and/or p-values. Meta-analyses were planned when possible. The methodological quality and potential for bias of included studies were also evaluated. Of the 3362 titles retrieved, 77 were included (62 for EBV infection and 22 for PTLD). The overall quality of the studies was strong. Several risk factors were explored in these studies, but few statistically significant associations were identified. The use of anti-thymocyte globulin (ATG) was identified as the most important risk factor positively associated with post-transplant active EBV infection and with PTLD. The pooled relative risks obtained using the random-effect model were 5.26 (95% CI: 2.92-9.45) and 4.17 (95% CI: 2.61-6.68) for the association between ATG and post-transplant EBV infection and PTLD, respectively. Other risk factors for EBV and PTLD were found in the included studies, such as graft-versus-host disease, type of conditioning regimen or type of donor, but results are conflicting. In conclusion, the results of this systematic review indicate that ATG increases the risk of EBV infection and PTLD, but the link with all other factors is either nonexistent or much less convincing.	[Enok Bonong, Pascal Roland; Zahreddine, Monica; Trottier, Helen] Univ Montreal, Dept Social & Prevent Med, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Buteau, Chantal] Univ Montreal, Dept Pediat, Div Infect Dis, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Duval, Michel] Univ Montreal, Dept Pediat, Div Hematol Oncol, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Laporte, Louise] CHU St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada; [Lacroix, Jacques] Univ Montreal, Dept Pediat, Div Pediat Intens Care Med, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Alfieri, Caroline] Univ Montreal, Dept Microbiol Infectiol & Immunol, CHU St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada		Trottier, H (通讯作者)，Univ Montreal, Dept Social & Prevent Med, CHU St Justine, Montreal, PQ H3T 1C5, Canada.	pascal.roland.enok.bonong@umontreal.ca; monica.zahreddine@umontreal.ca; chantal.buteau.hsj@ssss.gouv.qc.ca; michel.duval@umontreal.ca; louise.laporte.hsj@ssss.gouv.qc.ca; jacques.lacroix.med@ssss.gouv.qc.ca; carolina.alfieri@umontreal.ca; helen.trottier@umontreal.ca			Canadian Blood Services [201209293922]; Cancer Research Society; C17 Council [23276]; CHU Sainte-Justine; Universite de Montreal; Fonds de la recherche du Quebec en sante (FRQ-S); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This study was supported by a grant from the Canadian Blood Services (grant CBS #201209293922) to HT, CB, MD, JL, CA, as well as by an operating grant from the Cancer Research Society and the C17 Council (OG #23276) to CA for review of the pediatric studies. PREB was supported by doctoral awards from the CHU Sainte-Justine and Universite de Montreal (tuition fee waiver scholarships for international students and graduate scholarship for the final year of PhD studies). HT holds a salary award (Chercheur-Boursier, Junior-2) from the Fonds de la recherche du Quebec en sante (FRQ-S) and from Canadian Institutes of Health Research (CIHR) (New investigator salary award).	Aalto SM, 2007, CLIN INFECT DIS, V45, P1305, DOI 10.1086/522531; Ali S, 2019, PEDIATR TRANSPLANT, V23, DOI 10.1111/petr.13319; Althubaiti S, 2019, PEDIATR TRANSPLANT, V23, DOI 10.1111/petr.13574; Andreoli AL, 2010, HEMATOLOGIE, V16, P420; Atay D, 2018, PEDIATR TRANSPLANT, V22, DOI 10.1111/petr.13109; Auger S, 2014, EUR J HAEMATOL, V92, P421, DOI 10.1111/ejh.12260; Blaes AH, 2010, BIOL BLOOD MARROW TR, V16, P287, DOI 10.1016/j.bbmt.2009.10.008; Bogunia-Kubik K, 2007, BONE MARROW TRANSPL, V40, P145, DOI 10.1038/sj.bmt.1705703; Bogunia-Kubik K, 2006, BRIT J HAEMATOL, V132, P326, DOI 10.1111/j.1365-2141.2005.05875.x; Bordon V, 2012, PEDIATR TRANSPLANT, V16, P144, DOI 10.1111/j.1399-3046.2011.01634.x; Borenstein M., 2009, INTRO META ANAL; Brunstein CG, 2006, BLOOD, V108, P2874, DOI 10.1182/blood-2006-03-011791; Burns DM, 2016, BONE MARROW TRANSPL, V51, P825, DOI 10.1038/bmt.2016.19; Buyck HCE, 2009, BONE MARROW TRANSPL, V43, P813, DOI 10.1038/bmt.2008.394; Carpenter B, 2010, TRANSPLANTATION, V90, P564, DOI 10.1097/TP.0b013e3181e7a3bf; Cesaro S, 2005, BRIT J HAEMATOL, V128, P224, DOI 10.1111/j.1365-2141.2004.05287.x; Cesaro S, 2010, TRANSPLANTATION, V89, P1533, DOI 10.1097/TP.0b013e3181dd6c0a; Chiereghin A, 2016, TRANSPL INFECT DIS, V18, P44, DOI 10.1111/tid.12485; Chiereghin A, 2019, MED MICROBIOL IMMUN, V208, P825, DOI 10.1007/s00430-019-00629-2; Christopeit M, 2013, LEUKEMIA LYMPHOMA, V54, P133, DOI 10.3109/10428194.2012.705001; Cickusic E, 2007, BOSNIAN J BASIC MED, V7, P58, DOI 10.17305/bjbms.2007.3092; Cohen J, 2005, BRIT J HAEMATOL, V129, P229, DOI 10.1111/j.1365-2141.2005.05439.x; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005; Comoli P, 2007, AM J TRANSPLANT, V7, P1648, DOI 10.1111/j.1600-6143.2007.01823.x; Corssmit EPM, 1997, J NEUROVIROL, V3, P460, DOI 10.3109/13550289709031193; Curtis RE, 1999, BLOOD, V94, P2208; Czyzewski K, 2019, ANN HEMATOL, V98, P2197, DOI 10.1007/s00277-019-03755-2; D'Aveni M, 2011, TRANSPL IMMUNOL, V24, P224, DOI 10.1016/j.trim.2011.03.002; Duver F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228451; Dumas PY, 2013, BONE MARROW TRANSPL, V48, P253, DOI 10.1038/bmt.2012.117; Effective Public Health Practice Project, QUALITY ASSESSMENT T; Effective Public Health Practice Project, DICT EFFECTIVE PUBLI; Elmahdi S, 2016, PEDIATR TRANSPLANT, V20, P105, DOI 10.1111/petr.12620; Bonong PER, 2021, TRANSFUSION, V61, P144, DOI 10.1111/trf.16149; Fan J, 2016, INT J INFECT DIS, V46, P89, DOI 10.1016/j.ijid.2016.03.025; Faraci M, 2010, BONE MARROW TRANSPL, V45, P1052, DOI 10.1038/bmt.2009.302; Faye Albert, 2005, Paediatr Drugs, V7, P55, DOI 10.2165/00148581-200507010-00005; Figgins B, 2019, BIOL BLOOD MARROW TR, V25, P1837, DOI 10.1016/j.bbmt.2019.05.020; Fujimoto A, 2019, BIOL BLOOD MARROW TR, V25, P1441, DOI 10.1016/j.bbmt.2019.02.016; Gao XN, 2019, ANN HEMATOL, V98, P2163, DOI 10.1007/s00277-019-03742-7; Garcia-Cadenas I, 2015, BONE MARROW TRANSPL, V50, P579, DOI 10.1038/bmt.2014.298; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; Greenfield HM, 2006, PEDIATR BLOOD CANCER, V47, P200, DOI 10.1002/pbc.20604; Hakim H, 2007, J CLIN MICROBIOL, V45, P2151, DOI 10.1128/JCM.02308-06; Han SB, 2014, INT J HEMATOL, V100, P188, DOI 10.1007/s12185-014-1613-z; Harrer M., 2019, DOING META ANAL R HA; Herreman A, 2013, LEUKEMIA LYMPHOMA, V54, P2190, DOI 10.3109/10428194.2013.775436; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hiwarkar P, 2013, BONE MARROW TRANSPL, V48, P803, DOI 10.1038/bmt.2012.221; Hoegh-Petersen M, 2013, BONE MARROW TRANSPL, V48, P105, DOI 10.1038/bmt.2012.99; Hoegh-Petersen M, 2011, BONE MARROW TRANSPL, V46, P1104, DOI 10.1038/bmt.2010.272; Hoshino Y, 2001, BRIT J HAEMATOL, V115, P105, DOI 10.1046/j.1365-2141.2001.03087.x; Hussein K, 2013, PATHOBIOLOGY, V80, P289, DOI 10.1159/000350331; International Agency for Research on Cancer (IARC), 1997, P IARC WORK GROUP EV, V70, P1; Islam MS, 2010, HEMATOLOGY, V15, P344, DOI 10.1179/102453310X12647083621047; Issa H, 2019, BIOL BLOOD MARROW TR, V25, P1993, DOI 10.1016/j.bbmt.2019.06.014; Jaskula E, 2010, TRANSPL P, V42, P3273, DOI 10.1016/j.transproceed.2010.07.027; Jenson HB, 2000, CURR OPIN PEDIATR, V12, P263, DOI 10.1097/00008480-200006000-00016; Juvonen E, 2007, HAEMATOLOGICA, V92, P819, DOI 10.3324/haematol.10751; Kalra A, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13150; Kekre N, 2017, BLOOD ADV, V1, P573, DOI 10.1182/bloodadvances.2016001552; Kinch A, 2007, SCAND J INFECT DIS, V39, P235, DOI 10.1080/00365540600978906; Kullberg-Lindh C, 2011, TRANSPL INFECT DIS, V13, P122, DOI 10.1111/j.1399-3062.2010.00564.x; Laberko A, 2017, BIOL BLOOD MARROW TR, V23, P483, DOI 10.1016/j.bbmt.2016.12.635; Landgren O, 2009, BLOOD, V113, P4992, DOI 10.1182/blood-2008-09-178046; Li SD, 2018, PEDIATR TRANSPLANT, V22, DOI 10.1111/petr.13204; Lin R, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1393-7; Liu JY, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000208; Liu JY, 2018, BRIT J HAEMATOL, V180, P276, DOI 10.1111/bjh.15037; Liu QF, 2013, TRANSPL INFECT DIS, V15, P379, DOI 10.1111/tid.12090; Liu QF, 2013, AM J HEMATOL, V88, P550, DOI 10.1002/ajh.23452; Marinho-Dias J, 2019, MOL MED REP, V19, P1435, DOI 10.3892/mmr.2018.9794; Meijer E, 2004, Transpl Infect Dis, V6, P171, DOI 10.1111/j.1399-3062.2004.00075.x; Mohty M, 2007, LEUKEMIA, V21, P1387, DOI 10.1038/sj.leu.2404683; Mountjoy L, 2020, LEUKEMIA LYMPHOMA, V61, P1996, DOI 10.1080/10428194.2020.1747067; Neumann T, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12822; Nowak J, 2019, HLA, V94, P40, DOI 10.1111/tan.13770; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Omar H, 2009, TRANSPL INFECT DIS, V11, P393, DOI 10.1111/j.1399-3062.2009.00410.x; Pagliuca S, 2019, BIOL BLOOD MARROW TR, V25, P2490, DOI 10.1016/j.bbmt.2019.08.006; Pariente M, 2007, ENFERM INFEC MICR CL, V25, P108, DOI 10.1157/13098571; Park J, 2020, KOREAN J INTERN MED, V35, P957, DOI 10.3904/kjim.2018.414; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Patriarca F, 2013, TRANSPL INFECT DIS, V15, P259, DOI 10.1111/tid.12061; Peric Z, 2012, BONE MARROW TRANSPL, V47, P251, DOI 10.1038/bmt.2011.64; Peric Z, 2011, LEUKEMIA, V25, P932, DOI 10.1038/leu.2011.26; Ram R, 2013, LEUKEMIA LYMPHOMA, V54, P1591, DOI 10.3109/10428194.2012.762978; Rasche L, 2014, BONE MARROW TRANSPL, V49, P163, DOI 10.1038/bmt.2013.96; Reddy N, 2011, BIOL BLOOD MARROW TR, V17, P591, DOI 10.1016/j.bbmt.2010.08.007; Ru YH, 2020, BONE MARROW TRANSPL, V55, P1754, DOI 10.1038/s41409-020-0831-7; Rustia E, 2016, BIOL BLOOD MARROW TR, V22, P1646, DOI 10.1016/j.bbmt.2016.05.014; Sanz J, 2014, BONE MARROW TRANSPL, V49, P397, DOI 10.1038/bmt.2013.190; Shimabukuro-Vornhagen A, 2009, BLOOD, V114, P4919, DOI 10.1182/blood-2008-10-161638; Sirvent-von Bueltzingsloewen A, 2002, BONE MARROW TRANSPL, V29, P21, DOI 10.1038/sj.bmt.1703331; Societe Francaise de Greffe de Moelle et Therapie Cellulaire, 2013, GREFFE CELLULES SOUC; Styczynski J, 2009, TRANSPL INFECT DIS, V11, P383, DOI 10.1111/j.1399-3062.2009.00411.x; Styczynski J, 2013, CLIN INFECT DIS, V57, P794, DOI 10.1093/cid/cit391; Sundin M, 2006, HAEMATOLOGICA, V91, P1059; Tanner J E, 2001, Transpl Infect Dis, V3, P60, DOI 10.1034/j.1399-3062.2001.003002060.x; Torre-Cisneros J, 2004, J INFECT DIS, V190, P1596, DOI 10.1086/424602; Trottier H, 2012, TRANSFUSION, V52, P2653, DOI 10.1111/j.1537-2995.2012.03611.x; Tsoumakas K, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13095; Uhlin M, 2014, HAEMATOLOGICA, V99, P346, DOI 10.3324/haematol.2013.087338; van der Velden WJFM, 2013, BONE MARROW TRANSPL, V48, P1465, DOI 10.1038/bmt.2013.84; van Esser JWJ, 2001, BLOOD, V98, P972, DOI 10.1182/blood.V98.4.972; Wang H, 2019, ANN HEMATOL, V98, P987, DOI 10.1007/s00277-019-03603-3; Xu LP, 2015, BIOL BLOOD MARROW TR, V21, P2185, DOI 10.1016/j.bbmt.2015.07.035; Xuan L, 2013, TRANSPLANTATION, V96, P560, DOI 10.1097/TP.0b013e31829d38af; Xuan L, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-46; Yu XX, 2019, CLIN IMMUNOL, V205, P49, DOI 10.1016/j.clim.2019.05.010; Zajac-Spychala O, 2020, PEDIAT ALLERG IMM-UK, V31, P537, DOI 10.1111/pai.13239; Zallio F, 2013, CLIN TRANSPLANT, V27, pE491, DOI 10.1111/ctr.12172; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zhou L, 2020, ANN HEMATOL, V99, P1389, DOI 10.1007/s00277-020-04014-5; Zhou L, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.13856	116	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							288	10.3390/vaccines9030288			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5NW	33808928	gold, Green Published			2022-04-29	WOS:000634201600001
J	Joyce, JD; Patel, AK; Murphy, B; Carr, DJJ; Gershburg, E; Bertke, AS				Joyce, Jonathan D.; Patel, Anant K.; Murphy, Brandie; Carr, Daniel J. J.; Gershburg, Edward; Bertke, Andrea S.			Assessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs	VACCINES			English	Article						herpes simplex virus; HSV-2; vaccine; latency; dorsal root ganglia; guinea pig; immunofluorescence; fluorescent in situ hybridization; explant reactivation; RT-qPCR; qPCR		Treatment to ameliorate the symptoms of infection with herpes simplex virus 2 (HSV-2) and to suppress reactivation has been available for decades. However, a safe and effective preventative or therapeutic vaccine has eluded development. Two novel live-attenuated HSV-2 vaccine candidates (RVx201 and RVx202) have been tested preclinically for safety. Hartley guinea pigs were inoculated vaginally (n = 3) or intradermally (n = 16) with either vaccine candidate (2 x 10(7) PFU) and observed for disease for 28 days. All animals survived to study end without developing HSV-2-associated disease. Neither vaccine candidate established latency in dorsal root or sacral sympathetic ganglia, as determined by viral DNA quantification, LAT expression, or explant reactivation. Infectious virus was shed in vaginal secretions for three days following vaginal inoculation with RVx202, but not RVx201, although active or latent HSV-2 was not detected at study end. In contrast, guinea pigs inoculated with wild-type HSV-2 MS (2 x 10(5) PFU) vaginally (n = 5) or intradermally (n = 16) developed acute disease, neurological signs, shed virus in vaginal secretions, experienced periodic recurrences throughout the study period, and had latent HSV-2 in their dorsal root and sacral sympathetic ganglia at study end. Both vaccine candidates generated neutralizing antibody. Taken together, these findings suggest that these novel vaccine candidates are safe in guinea pigs and should be tested for efficacy as preventative and/or therapeutic anti-HSV-2 vaccines.	[Joyce, Jonathan D.] Virginia Polytech Inst & State Univ, Translat Biol Med & Hlth, Blacksburg, VA 24061 USA; [Patel, Anant K.; Bertke, Andrea S.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Populat Hlth Sci, Blacksburg, VA 24061 USA; [Murphy, Brandie; Gershburg, Edward] Rat Vaccines Inc, Cambridge, MA 02139 USA; [Carr, Daniel J. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol, Oklahoma City, OK 73034 USA; [Carr, Daniel J. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Immunol, Oklahoma City, OK 73034 USA; [Carr, Daniel J. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73034 USA		Bertke, AS (通讯作者)，Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Populat Hlth Sci, Blacksburg, VA 24061 USA.	jjoyce84@vt.edu; anantpatel96@vt.edu; brandie.murphy@rationalvaccines.com; dan-carr@ouhsc.edu; ed.gershburg@rationalvaccines.com; asbertke@vt.edu		Joyce, Jonathan/0000-0002-2243-3793; Carr, Daniel JJ/0000-0003-1954-2478; Bertke, Andrea/0000-0002-8941-8010	Rational Vaccines Inc.; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AI053108]	This research was funded by Rational Vaccines Inc. (to A.S.B.) and National Institutes of Health (R01 AI053108 to D.J.J.C.).	Agenus Inc, TRIAL EV SAF TOL IMM; Agenus Inc, BIOL EFF STUD HERPV; Akinyi B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178907; Allergy N.I.o., HERPEVAC NEONATAL SU; Andrei G, 2013, CURR OPIN INFECT DIS, V26, P551, DOI 10.1097/QCO.0000000000000015; Aravantinou M, 2017, J MED PRIMATOL, V46, P121, DOI 10.1111/jmp.12293; Arinze F, 2017, INFECTION, V45, P705, DOI 10.1007/s15010-017-1027-y; Awasthi S, 2012, J VIROL, V86, P4586, DOI 10.1128/JVI.07203-11; Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151; BERGSTROM T, 1990, J INFECT DIS, V162, P322, DOI 10.1093/infdis/162.2.322; Bernstein DI, 2019, VACCINE, V37, P3443, DOI 10.1016/j.vaccine.2019.05.009; Bertke AS, 2011, J VIROL, V85, P6669, DOI 10.1128/JVI.00204-11; Bookhout C, 2016, IDCases, V6, P65, DOI 10.1016/j.idcr.2016.09.013; Aschner CB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020277; Casanova G, 2002, CUTIS, V70, P235; CHAMBERS ST, 1994, NEW ZEAL MED J, V107, P367; Chandra J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226320; Chi RC, 2010, CLIN INFECT DIS, V50, P1331, DOI 10.1086/652144; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; Corey L, 2009, NEW ENGL J MED, V361, P1376, DOI 10.1056/NEJMra0807633; Da Costa X, 2000, J VIROL, V74, P7963, DOI 10.1128/JVI.74.17.7963-7971.2000; Delagrave S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046714; Desai DV, 2015, VIRAL IMMUNOL, V28, P546, DOI 10.1089/vim.2015.0012; Dropulic LK, 2019, J INFECT DIS, V220, P990, DOI 10.1093/infdis/jiz225; Dutton JL, 2016, HUM VACC IMMUNOTHER, V12, P3079, DOI 10.1080/21645515.2016.1221872; Dutton JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076407; Engelberg R, 2003, SEX TRANSM DIS, V30, P174, DOI 10.1097/00007435-200302000-00015; Fred Hutchinson Cancer Research Center University of Washington, SAN PAST HSV529 VACC; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Genocea Biosciences Inc, DOS RANG SAF EFF THE; Genocea Biosciences Inc, SAF IMM STUD THER HS; Genocea Biosciences Inc, ROLL TRIAL PLAC SUBJ; Genocea Biosciences Inc, EV NEW FORM THER HSV; Genocea Biosciences Inc, MAINT DOS STUD GEN 0; Genocea Biosciences Inc, LONG TERM FOLL UP GE; GlaxoSmithKline, HUM CELL IMM RESP HE; GlaxoSmithKline, SAF STUD HERP SIMPL; GlaxoSmithKline, HERPEVAC TRIAL YOUNG; GlaxoSmithKline, EV IMM REACT SAF HER; GlaxoSmithKline, EV SAF CAND GD VACC; GlaxoSmithKline, SAF HERP SIMPL CAND; GlaxoSmithKline, SAF EV HERP SIMPL CA; GlaxoSmithKline, STUD COMP SAF IMM CO; GUDNADOTTIR M, 1964, EXP NEUROL, V9, P85, DOI 10.1016/0014-4886(64)90008-1; Gyotoku T, 2002, VACCINE, V20, P2796, DOI 10.1016/S0264-410X(02)00199-8; Halford WP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065523; Halford WP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017748; Halford WP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012251; Halford WP, 1997, VIROLOGY, V236, P328, DOI 10.1006/viro.1997.8738; Handisurya A, 2016, BRIT J CANCER, V114, P409, DOI 10.1038/bjc.2015.462; Hu K, 2017, J GEN VIROL, V98, P2351, DOI 10.1099/jgv.0.000895; James C, 2020, B WORLD HEALTH ORGAN, V98, P315, DOI 10.2471/BLT.19.237149; Johnston C, 2016, CLIN MICROBIOL REV, V29, P149, DOI 10.1128/CMR.00043-15; Johnston C, 2014, VACCINE, V32, P1553, DOI 10.1016/j.vaccine.2013.08.066; Kemble G., 2007, HERPES SIMPLEX VACCI; LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001; Looker KJ, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0140765, 10.1371/journal.pone.0114989]; Mariani L, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-105; McQuillan Geraldine, 2018, NCHS Data Brief, P1; Mertz GJ, 2008, J INFECT DIS, V198, P1098, DOI 10.1086/591914; Mo A, 2011, VACCINE, V29, P8530, DOI 10.1016/j.vaccine.2011.07.011; Muller WJ, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01460-18; Muller WJ, 2009, J GEN VIROL, V90, P1153, DOI 10.1099/vir.0.008771-0; Nakamura Yoshitsugu, 2016, Rinsho Shinkeigaku, V56, P785; National Institute of Allergy and Infectious Diseases, SAN PAST NAT I HLTH; Odegard JM, 2016, VACCINE, V34, P101, DOI 10.1016/j.vaccine.2015.10.137; Patel SM, 2010, VACCINE, V28, P3025, DOI 10.1016/j.vaccine.2009.10.152; Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10; PowderMed, SAF STUD HSV2 DNA VA; PowderMed, SAF STUD ASS DNA VAC; Richardus JH, 2013, VACCINE, V31, P6136, DOI 10.1016/j.vaccine.2013.06.081; Roberts CM, 2003, SEX TRANSM DIS, V30, P797, DOI 10.1097/01.OLQ.0000092387.58746.C7; Samaniego LA, 1998, J VIROL, V72, P3307, DOI 10.1128/JVI.72.4.3307-3320.1998; Sanofi Pasteur Immune, DES SAF EFF 4 INV HS; Sauerbrei A, 2016, GEBURTSH FRAUENHEILK, V76, P1310, DOI 10.1055/s-0042-116494; Schiffer JT, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0160; Scoular A, 2002, BRIT MED J, V324, P1366, DOI 10.1136/bmj.324.7350.1366; Sen P, 2007, BMJ-BRIT MED J, V334, P1048, DOI 10.1136/bmj.39189.504306.55; Shlapobersky M, 2012, J GEN VIROL, V93, P1305, DOI 10.1099/vir.0.040055-0; Skoberne M, 2013, J VIROL, V87, P3930, DOI 10.1128/JVI.02745-12; SKOLDENBERG B, 1975, SCAND J INFECT DIS, V7, P227, DOI 10.3109/inf.1975.7.issue-4.01; Smith CC, 1998, J VIROL, V72, P9131, DOI 10.1128/JVI.72.11.9131-9141.1998; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; TEDDER DG, 1994, ANN INTERN MED, V121, P334, DOI 10.7326/0003-4819-121-5-199409010-00004; Tronstein E, 2011, JAMA-J AM MED ASSOC, V305, P1441, DOI 10.1001/jama.2011.420; Vassantachart Janna M, 2016, Proc (Bayl Univ Med Cent), V29, P48; Vical, SAF EFF TRIAL DNA VA; Vical, SAF EFF STUD HERP SI; Visalli RJ, 2014, VACCINE, V32, P1398, DOI 10.1016/j.vaccine.2013.10.079; Wachsman M, 2001, VACCINE, V19, P1879, DOI 10.1016/S0264-410X(00)00446-1; Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203; Wald A, 2011, VACCINE, V29, P8520, DOI 10.1016/j.vaccine.2011.09.046; Wang Lili, 2016, Ther Adv Vaccines, V4, P20, DOI 10.1177/2051013616655980; Warren-Gash C, 2017, EXPERT REV VACCINES, V16, P1191, DOI 10.1080/14760584.2017.1394843; Whitley Richard, 2018, F1000Res, V7, DOI 10.12688/f1000research.16157.1; Widener RW, 2014, HAND CLINIC, V123, P251, DOI 10.1016/B978-0-444-53488-0.00011-0; Wilck MB, 2010, J INFECT DIS, V201, P1361, DOI 10.1086/651561; Woestenberg PJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1707-8; Zhu XP, 2014, VIRUSES-BASEL, V6, P371, DOI 10.3390/v6020371	99	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							258	10.3390/vaccines9030258			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5EE	33805768	Green Published, gold			2022-04-29	WOS:000634176400001
J	Ramos-Sevillano, E; Ercoli, G; Guerra-Assuncao, JA; Felgner, P; de Assis, RR; Nakajima, R; Goldblatt, D; Tetteh, KKA; Heyderman, RS; Gordon, SB; Ferreria, DM; Brown, JS				Ramos-Sevillano, Elisa; Ercoli, Giuseppe; Guerra-Assuncao, Jose Afonso; Felgner, Philip; Ramiro de Assis, Rafael; Nakajima, Rie; Goldblatt, David; Tetteh, Kevin Kweku Adjei; Heyderman, Robert Simon; Gordon, Stephen Brian; Ferreria, Daniela Mulari; Brown, Jeremy Stuart			Protective Effect of Nasal Colonisation with Delta cps/piaA and Delta cps/proABC Streptococcus pneumoniae Strains against Recolonisation and Invasive Infection	VACCINES			English	Article						Streptococcus pneumoniae; capsule; vaccine; psaA; proABC; colonisation; immunity	ACQUIRED-IMMUNITY; NASOPHARYNGEAL COLONIZATION; EPIDEMIOLOGIC EVIDENCE; PNEUMOCOCCAL VACCINE; VIRULENCE; CARRIAGE; ANTIGENS; EFFICACY; ANTIBODY; CAPSULE	Rationale: Nasopharyngeal administration of live virulence-attenuated Streptococcus pneumoniae strains is a potential novel preventative strategy. One target for creating reduced virulence S. pneumoniae strains is the capsule, but loss of the capsule reduces the duration of S. pneumoniae colonisation in mice which could impair protective efficacy against subsequent infection. Objectives: To assess protective efficacy of nasopharyngeal administration of unencapsulated S. pneumoniae strains in murine infection models. Methods: Strains containing cps locus deletions combined with the S. pneumoniae virulence factors psaA (reduces colonisation) or proABC (no effect on colonisation) were constructed and their virulence phenotypes and ability to prevent recolonisation or invasive infection assessed using mouse infection models. Serological responses to colonisation were compared between strains using ELISAs, immunoblots and 254 S. pneumoniae protein antigen array. Measurements and Main Results: The increment cps/piaA and increment cps/proABC strains were strongly attenuated in virulence in both invasive infection models and had a reduced ability to colonise the nasopharynx. ELISAs, immunoblots and protein arrays showed colonisation with either strain stimulated weaker serological responses than the wild type strain. Mice previously colonised with these strains were protected against septicaemic pneumonia but, unlike mice colonised with the wild type strain, not against S. pneumoniae recolonisation. Conclusions: Colonisation with the increment cps/piaA and increment cps/proABC strains prevented subsequent septicaemia, but in contrast, to published data for encapsulated double mutant strains they did not prevent recolonisation with S. pneumoniae. These data suggest targeting the cps locus is a less effective option for creating live attenuated strains that prevent S. pneumoniae infections.	[Ramos-Sevillano, Elisa; Ercoli, Giuseppe; Brown, Jeremy Stuart] UCL, Rayne Inst, UCL Resp, Ctr Inflammat & Tissue Repair,Div Med, London WC1E 6JF, England; [Guerra-Assuncao, Jose Afonso] Univ Coll London UCL, Great Ormond St Inst Child Hlth, London WC1N 1EH, England; [Felgner, Philip; Ramiro de Assis, Rafael; Nakajima, Rie] Univ Calif Irvine, Dept Physiol & Biophys, Vaccine Res & Dev Ctr, Irvine, CA 92697 USA; [Goldblatt, David] UCL Great Ormond St Inst Child Hlth, NIHR Biomed Res Ctr, Immunobiol Sect, London WC1N 1EH, England; [Tetteh, Kevin Kweku Adjei] London Sch Trop Med & Hyg, Fac Infect & Trop Dis, London WC1E 7HT, England; [Heyderman, Robert Simon; Gordon, Stephen Brian] UCL, Rayne Inst, Div Infect & Immun, Res Dept Infect, London WC1E 6JF, England; [Ferreria, Daniela Mulari] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 30096, Malawi; [Brown, Jeremy Stuart] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England		Ramos-Sevillano, E (通讯作者)，UCL, Rayne Inst, UCL Resp, Ctr Inflammat & Tissue Repair,Div Med, London WC1E 6JF, England.	e.ramos-sevillano@ucl.ac.uk; g.ercoli@ucl.ac.uk; a.guerra@ucl.ac.uk; pfelgner@hs.uci.edu; rafael.assis@outlook.com; rie3@hs.uci.edu; d.goldblatt@ucl.ac.uk; Kevin.Tetteh@lshtm.ac.uk; r.heyderman@ucl.ac.uk; sgordon@mlw.mw; Daniela.Ferreira@lstmed.ac.uk; jeremy.brown@ucl.ac.uk	Ferreira, Daniela M/AAE-9881-2022; Guerra-Assuncao, Jose Afonso/F-3887-2011; Ramos Sevillano, Elisa/J-4824-2016; Goldblatt, David/C-5972-2008	Guerra-Assuncao, Jose Afonso/0000-0001-6593-403X; Ramos Sevillano, Elisa/0000-0003-0803-2755; Goldblatt, David/0000-0002-0769-5242	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [R/N02687X/1]; Department of Health's NIHR Biomedical Research Centre's funding schemeNational Institute for Health Research (NIHR);  [MR/R001871/1]	E.R.-S., J.S.B., D.M.F., S.B.G. and R.S.H. were supported by MRC grant R/N02687X/1 and GE and JSB by MR/R001871/1. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre's funding scheme.	Abdullahi O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030787; Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113; Basset A, 2007, J CLIN MICROBIOL, V45, P1684, DOI 10.1128/JCM.00265-07; Belitsky BR, 2001, J BACTERIOL, V183, P4389, DOI 10.1128/JB.183.14.4389-4392.2001; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; Bidossi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033320; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Bradshaw JL, 2018, MBIO, V9, DOI 10.1128/mBio.02097-17; Brooks LRK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01366; Brown JS, 2020, AM J RESP CRIT CARE, V201, P268, DOI 10.1164/rccm.201910-2047ED; Brown JS, 2001, MOL MICROBIOL, V40, P572, DOI 10.1046/j.1365-2958.2001.02414.x; Campo JJ, 2018, ELIFE, V7, DOI 10.7554/eLife.37015; Chan WY, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00846-18; Chimalapati S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041393; Chimalapati S, 2011, INFECT IMMUN, V79, P4965, DOI 10.1128/IAI.05923-11; Cobey S, 2012, SCIENCE, V335, P1376, DOI 10.1126/science.1215947; Cohen JM, 2013, VACCINE, V31, P2328, DOI 10.1016/j.vaccine.2013.03.013; Cohen JM, 2012, VACCINE, V30, P4453, DOI 10.1016/j.vaccine.2012.04.080; Cohen JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025558; Croucher NJ, 2017, P NATL ACAD SCI USA, V114, pE357, DOI 10.1073/pnas.1613937114; David SC, 2019, IMMUNOL CELL BIOL, V97, P726, DOI 10.1111/imcb.12257; Ercoli G, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611661; Ferreira DM, 2013, AM J RESP CRIT CARE, V187, P855, DOI 10.1164/rccm.201212-2277OC; Garcha DS, 2012, THORAX, V67, P1075, DOI 10.1136/thoraxjnl-2012-201924; Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524; Granat SM, 2009, J INFECT DIS, V200, P99, DOI 10.1086/599364; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; Hyams C, 2010, INFECT IMMUN, V78, P704, DOI 10.1128/IAI.00881-09; Jochems SP, 2019, J CLIN INVEST, V129, P4523, DOI 10.1172/JCI128865; Kim SJ, 2019, VACCINE, V37, P90, DOI 10.1016/j.vaccine.2018.11.027; LeMieux J, 2006, INFECT IMMUN, V74, P2453, DOI 10.1128/IAI.74.4.2453-2456.2006; Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296; Lipsitch M, 2005, PLOS MED, V2, P62, DOI 10.1371/journal.pmed.0020015; Lochen A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75691-5; McCool TL, 2002, J EXP MED, V195, P359, DOI 10.1084/jem.20011576; Melegaro A, 2006, J INFECTION, V52, P37, DOI 10.1016/j.jinf.2005.02.008; Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1; Mitsi E, 2020, AM J RESP CRIT CARE, V201, P335, DOI 10.1164/rccm.201903-0607OC; Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3; Reglinski M, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0090-4; Roche AM, 2007, INFECT IMMUN, V75, P2469, DOI 10.1128/IAI.01972-06; Rosch JW, 2014, EMBO MOL MED, V6, P141, DOI 10.1002/emmm.201202150; Tseng HJ, 2002, INFECT IMMUN, V70, P1635, DOI 10.1128/IAI.70.3.1635-1639.2002; van Opijnen T, 2012, GENOME RES, V22, P2541, DOI 10.1101/gr.137430.112; Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941; Wilson R, 2015, MUCOSAL IMMUNOL, V8, P627, DOI 10.1038/mi.2014.95; Wilson R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006137; Wright AKA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003274; Wright AKA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002622; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	51	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							261	10.3390/vaccines9030261			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5DA		Green Accepted, gold, Green Published			2022-04-29	WOS:000634173400001
J	Bruno, S; Carducci, B; Quaranta, G; Beccia, V; Di Pilla, A; La Milia, DI; Di Pumpo, M; Carini, E; Masini, L; Tamburrini, E; Spadea, A; Damiani, G; Lanzone, A; Laurenti, P				Bruno, Stefania; Carducci, Brigida; Quaranta, Gianluigi; Beccia, Viria; Di Pilla, Andrea; La Milia, Daniele Ignazio; Di Pumpo, Marcello; Carini, Elettra; Masini, Lucia; Tamburrini, Enrica; Spadea, Antonietta; Damiani, Gianfranco; Lanzone, Antonio; Laurenti, Patrizia			Enhancement of Vaccination Attitude and Flu Vaccination Coverage among Pregnant Women Attending Birthing Preparation Course	VACCINES			English	Article						awareness; flu vaccinations; on-site vaccinations; birthing preparation course; pregnant women	SEASONAL INFLUENZA VACCINATION; HESITANCY; PERTUSSIS; KNOWLEDGE	Most vaccinations are recommended within the 15th month of life, in order to reduce risks and to protect children from the initial stages of their lives. A vaccination training session was carried out during the birthing preparation course, aimed at increasing the attitude toward vaccination in maternal-child age. A questionnaire on vaccination awareness was administered before and after the training session and on-site flu vaccination was offered to women and their companions. The percentage of participants who consider the preparatory course a useful tool to obtain information about vaccines increases significantly from 30.34% at pre-intervention to 64.56% at post-intervention (p < 0.001). There is a significant increase in the mean number of vaccinations that the participants want their children to get. The number of participants believing that there is no relationship between vaccination and autism rose from 41.05 to 72.97% (p < 0.001). In total, 48 out of 119 (40.34%) pregnant women participating in the course and 39 companions were vaccinated for influenza. Vaccination knowledge and attitude significantly increased after a training session dedicated to vaccination as a part of the pregnant pre-birth course, whose aim can be therefore extended to the management of the health of the child, well beyond the period of pregnancy, according to the life-course approach to health.	[Bruno, Stefania; Carducci, Brigida; Quaranta, Gianluigi; La Milia, Daniele Ignazio; Masini, Lucia; Tamburrini, Enrica; Damiani, Gianfranco; Lanzone, Antonio; Laurenti, Patrizia] Fdn Polidin Univ A Gemelli IRCCS, Women Children & Publ Hlth Sci Dept, I-00168 Rome, Italy; [Bruno, Stefania; Carducci, Brigida; Quaranta, Gianluigi; Beccia, Viria; Di Pilla, Andrea; Di Pumpo, Marcello; Carini, Elettra; Masini, Lucia; Tamburrini, Enrica; Damiani, Gianfranco; Lanzone, Antonio; Laurenti, Patrizia] Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & San Pubbl, I-00168 Rome, Italy; [Spadea, Antonietta] ASL ROMA 1, Local Hlth Author, Dist 14, I-00135 Rome, Italy		Di Pilla, A (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & San Pubbl, I-00168 Rome, Italy.	stefania.bruno@unicatt.it; brigida.carducci@policlinicogemelli.it; gianluigi.quaranta@unicatt.it; viria.beccia01@icatt.it; andrea.dipilla01@icatt.it; danieleignaziolamilia@polidinicogemelli.it; marcello.dipumpoOl@icatt.it; elettra.carini01@icatt.it; lucia.masini@polidinicogemelli.it; enrica.tamburrini@policlinicogemelli.it; antonietta.spadea@aslroma1.it; gianfranco.damiani@unicatt.it; Antonio.Lanzone@unicatt.it; patrizia.laurenti@unicatt.it	LAURENTI, Patrizia/AAB-8268-2022; Damiani, Gianfranco/K-2782-2016	LAURENTI, Patrizia/0000-0002-8532-0593; Carini, Elettra/0000-0002-9422-3285; LANZONE, Antonio/0000-0003-4119-414X; Masini, Lucia/0000-0002-8230-4985; DI PILLA, ANDREA/0000-0002-5951-9056; Bruno, Stefania/0000-0002-1551-4771; Damiani, Gianfranco/0000-0003-3028-6188			ACIP (Advisory Committee on Immunization Practices), 2016, PREGN GUID REC VACC; Ames HMR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011787.pub2; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; [Anonymous], 2018, VACC RACC DONN FERT; Bechini A, 2019, J Prev Med Hyg, V60, pE5, DOI 10.15167/2421-4248/jpmh2019.60.1.1093; Bert F, 2020, EUR J PUBLIC HEALTH, V30, P286, DOI 10.1093/eurpub/ckz209; Bratton KN, 2015, CLIN INFECT DIS, V60, pE11, DOI 10.1093/cid/ciu915; Costa-Pinto JC, 2018, J PAEDIATR CHILD H, V54, P522, DOI 10.1111/jpc.13790; D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809; Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Geoghegan S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00372; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Legge A, 2014, CAN MED ASSOC J, V186, pE157, DOI 10.1503/cmaj.130499; Lindley MC, 2019, MMWR-MORBID MORTAL W, V68, P885, DOI 10.15585/mmwr.mm6840e1; McNeil DA, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6338-0; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Omer SB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000441; Psarris A, 2019, EUR J OBSTET GYN R B, V243, P36, DOI 10.1016/j.ejogrb.2019.10.012; Ricco M, 2019, MINERVA GINECOL, V71, P288, DOI 10.23736/S0026-4784.19.04294-1; Rizzo C, 2018, HUM VACC IMMUNOTHER, V14, P693, DOI 10.1080/21645515.2017.1367463; Rosso A, 2019, VACCINE, V37, P1954, DOI 10.1016/j.vaccine.2019.02.049; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Thompson MG, 2019, CLIN INFECT DIS, V68, P1444, DOI 10.1093/cid/ciy737; Tognetto A, 2020, HUM VACC IMMUNOTHER, V16, P81, DOI 10.1080/21645515.2019.1632684; Vila-Candel R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3823-1; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/S0140-6736(07)61602-X; World Health Organization, 2020, REG OFF EUR GUID ROU; World Health Organization Summary WHO, 2015, WHO SAGE CONCL REC V	33	0	0	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							183	10.3390/vaccines9020183			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6PR	33670085	Green Published, gold			2022-04-29	WOS:000623264100001
J	Kudo, R; Sekine, M; Yamaguchi, M; Hara, M; Hanley, SJB; Ueda, Y; Yagi, A; Adachi, S; Kurosawa, M; Miyagi, E; Enomoto, T				Kudo, Risa; Sekine, Masayuki; Yamaguchi, Manako; Hara, Megumi; Hanley, Sharon J. B.; Ueda, Yutaka; Yagi, Asami; Adachi, Sosuke; Kurosawa, Megumi; Miyagi, Etsuko; Enomoto, Takayuki			Internet Survey of Awareness and Behavior Related to HPV Vaccination in Japan	VACCINES			English	Article						HPV vaccination; cervical cancer; Internet survey; sexual behavior; cancer screening		Recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears in Japan. We aimed to clarify the differences between vaccinated and unvaccinated females in their awareness, knowledge, and behaviors toward cervical cancer, HPV vaccination and sex. Questionnaires were administered online to women aged 16 to 20. We conducted investigations for the following: awareness, knowledge, and actions for cervical cancer, HPV vaccination, and sexual activity, as well as items related to participants' social background. The survey in 828 girls revealed three points. The first is that more than half of the surveyed Japanese girls had poor knowledge about cervical cancer screening, HPV, or HPV vaccines. The second is that those in the unvaccinated group had a particularly poor knowledge of the subject and tended to have higher sexual activity. The final is that only 0.5% of the girls experienced changes in awareness about sexual activity after vaccination. In conclusion, this is the first large-scale survey analyzing the association between HPV vaccination and sexual activity in Japanese girls. Not only do unvaccinated girls not benefit from vaccines, but they also tend to engage in high-risk sexual behavior, and thus it is even more important to provide information on the effectiveness of vaccines and the usefulness of cancer screening.	[Kudo, Risa; Sekine, Masayuki; Yamaguchi, Manako; Adachi, Sosuke; Kurosawa, Megumi; Enomoto, Takayuki] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Hara, Megumi] Saga Univ, Fac Med, Dept Prevent Med, Saga 8498501, Japan; [Hanley, Sharon J. B.] Hokkaido Univ, Dept Obstet & Gynecol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; [Ueda, Yutaka; Yagi, Asami] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka 5650871, Japan; [Miyagi, Etsuko] Yokohama City Univ, Dept Obstet & Gynecol, Sch Med, Yokohama, Kanagawa 2360004, Japan		Sekine, M (通讯作者)，Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan.	pearpear@med.niigata-u.ac.jp; masa@med.niigata-u.ac.jp; manako0131@med.niigata-u.ac.jp; harameg@cc.saga-u.ac.jp; sjbh1810@med.hokudai.ac.jp; y.ueda@gyne.med.osaka-u.ac.jp; a.yagi@gyne.med.osaka-u.ac.jp; sadachi@med.niigata-u.ac.jp; m-kurosawa@med.niigata-u.ac.jp; emiyagi@yokohama-cu.ac.jp; enomoto@med.niigata-u.ac.jp	Hara, Masayuki/AAH-4361-2019; Sekine, Masayuki/AAB-8321-2022	Sekine, Masayuki/0000-0003-0751-6395; Ueda, Yutaka/0000-0001-8760-6379	Health and Labor Sciences Research GrantMinistry of Health, Labour and Welfare, Japan [26272001]; Japanese Agency for Medical Research and Development [JP15ck0106103]	This work was supported by the Health and Labor Sciences Research Grant No. 26272001 and the Japanese Agency for Medical Research and Development (JP15ck0106103).	[Anonymous], CANC REGISTRY STAT C; Arbyn M, 2018, EXPERT REV VACCINES, V17, P1085, DOI 10.1080/14760584.2018.1548282; Benard VB, 2017, JAMA ONCOL, V3, P833, DOI 10.1001/jamaoncol.2016.3609; Brouwer AF, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7134-1; Chua GT, 2020, VACCINE, V38, P1025, DOI 10.1016/j.vaccine.2019.11.044; Ciavattini A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030354; Drolet M, 2013, CANCER EPIDEM BIOMAR, V22, P641, DOI 10.1158/1055-9965.EPI-12-1173; Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7; Ikeda S, 2020, CANCER SCI; Kudo R, 2019, J INFECT DIS, V219, P382, DOI 10.1093/infdis/jiy516; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Liverani CA, 2020, J ONCOL, V2020, DOI 10.1155/2020/8887672; Mascaro V, 2019, VACCINE, V37, P3310, DOI 10.1016/j.vaccine.2019.04.081; Ministry of Education Culture Sports Science and Technology, COURSES STUDY UPPER; Motoki Y, 2015, CANCER EPIDEMIOL, V39, P700, DOI 10.1016/j.canep.2015.08.001; Nakagawa S, 2020, CANCER SCI, V111, P2156, DOI 10.1111/cas.14406; Nishioka Emiko, 2018, Nihon Eiseigaku Zasshi, V73, P178, DOI 10.1265/jjh.73.178; Palmer T, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1161; Ruiz-Munoz D, 2013, ANN EPIDEMIOL, V23, P620, DOI 10.1016/j.annepidem.2013.07.005; Samandari G, 2010, INT PERSPECT SEX R H, V36, P26, DOI 10.1363/ipsrh.36.026.10; Santelli JS, 2000, AM J PUBLIC HEALTH, V90, P1582, DOI 10.2105/AJPH.90.10.1582; Scarinci IC, 2007, J WOMENS HEALTH, V16, P1224, DOI 10.1089/jwh.2006.0175; Sekine M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030362; Suryadevara M, 2015, VACCINE, V33, P6629, DOI 10.1016/j.vaccine.2015.10.096; Taniguchi M, 2019, VACCINE, V37, P4424, DOI 10.1016/j.vaccine.2019.06.064; The United Nations Educational Scientific and Cultural Organization, 2018, INT TECHNICAL GUIDAN; Triandis HC, 2002, ANNU REV PSYCHOL, V53, P133, DOI 10.1146/annurev.psych.53.100901.135200; White CN, 2015, J ADOLESCENT HEALTH, V56, P231, DOI 10.1016/j.jadohealth.2014.09.017; WHO, HPV VACCINES SAFETY; Yagi A, 2019, VACCINE, V37, P2889, DOI 10.1016/j.vaccine.2019.04.044; Yamaguchi M, 2018, PAPILLOMAVIRUS RES, V6, P6, DOI 10.1016/j.pvr.2018.05.002	31	2	2	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							87	10.3390/vaccines9020087			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6WJ	33503989	gold, Green Published			2022-04-29	WOS:000623281600001
J	Lambert, GS; Upadhyay, C				Lambert, Gregory S.; Upadhyay, Chitra			HIV-1 Envelope Glycosylation and the Signal Peptide	VACCINES			English	Review						HIV-1; HIV envelope; glycosylation; signal peptide; PNGS; broadly neutralizing antibodies; vaccine		The RV144 trial represents the only vaccine trial to demonstrate any protective effect against HIV-1 infection. While the reason(s) for this protection are still being evaluated, it serves as justification for widespread efforts aimed at developing new, more effective HIV-1 vaccines. Advances in our knowledge of HIV-1 immunogens and host antibody responses to these immunogens are crucial to informing vaccine design. While the envelope (Env) protein is the only viral protein present on the surface of virions, it exists in a complex trimeric conformation and is decorated with an array of variable N-linked glycans, making it an important but difficult target for vaccine design. Thus far, efforts to elicit a protective humoral immune response using structural mimics of native Env trimers have been unsuccessful. Notably, the aforementioned N-linked glycans serve as a component of many of the epitopes crucial for the induction of potentially protective broadly neutralizing antibodies (bnAbs). Thus, a greater understanding of Env structural determinants, most critically Env glycosylation, will no doubt be of importance in generating effective immunogens. Recent studies have identified the HIV-1 Env signal peptide (SP) as an important contributor to Env glycosylation. Further investigation into the mechanisms by which the SP directs glycosylation will be important, both in the context of understanding HIV-1 biology and in order to inform HIV-1 vaccine design.	[Lambert, Gregory S.; Upadhyay, Chitra] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA		Upadhyay, C (通讯作者)，Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA.	gregory.lambert@mssm.edu; chitra.upadhyay@mssm.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI140909]	The authors were supported by NIH grant AI140909 (CU).	Alam SM, 2013, J VIROL, V87, P1554, DOI 10.1128/JVI.00718-12; Asmal M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023673; Baalwa J, 2013, VIROLOGY, V436, P33, DOI 10.1016/j.virol.2012.10.009; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bar KJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002721; Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10; Barnett SW, 2010, J VIROL, V84, P5975, DOI 10.1128/JVI.02533-09; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]; Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766; Behrens AJ, 2017, EXPERT REV PROTEOMIC, V14, P881, DOI 10.1080/14789450.2017.1376658; Behrens AJ, 2016, CELL REP, V14, P2695, DOI 10.1016/j.celrep.2016.02.058; Bekker LG, 2018, LANCET HIV, V5, pE366, DOI 10.1016/S2352-3018(18)30071-7; BERMAN PW, 1988, J VIROL, V62, P3135, DOI 10.1128/JVI.62.9.3135-3142.1988; Binley JM, 2010, J VIROL, V84, P5637, DOI 10.1128/JVI.00105-10; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Blazkova J, 2019, J CLIN INVEST, V129, P4832, DOI 10.1172/JCI125955; Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521; Bonsignori M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7514; BROOMESMITH JK, 1994, MOL MEMBR BIOL, V11, P3, DOI 10.3109/09687689409161023; Cao LW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06121-4; Cao LW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14954; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chandramouli B, 2012, J BIOMOL STRUCT DYN, V29, P879; Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042; Chohan B, 2005, J VIROL, V79, P6528, DOI 10.1128/JVI.79.10.6528-6531.2005; Cohen J, 2009, SCIENCE, V326, P652, DOI 10.1126/science.326_652; Cohen M, 2015, BIOMOLECULES, V5, P2056, DOI 10.3390/biom5032056; Crispin M, 2013, NAT STRUCT MOL BIOL, V20, P771, DOI 10.1038/nsmb.2627; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; da Silva JX, 2011, PEPTIDES, V32, P1800, DOI 10.1016/j.peptides.2011.07.014; Dacheux L, 2004, J VIROL, V78, P12625, DOI 10.1128/JVI.78.22.12625-12637.2004; de la Pena AT, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007920; Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137; Deruaz M, 2016, J INFECT DIS, V214, P612, DOI 10.1093/infdis/jiw203; Desrosiers RC, 2017, J VIROL, V91, DOI 10.1128/JVI.00905-17; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; Doores KJ, 2015, J VIROL, V89, P1105, DOI 10.1128/JVI.02905-14; Doores KJ, 2010, J VIROL, V84, P10510, DOI 10.1128/JVI.00552-10; Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107; Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030; Finzi A, 2012, J VIROL, V86, P8974, DOI 10.1128/JVI.01076-12; FORTHAL DN, 1995, AIDS RES HUM RETROV, V11, P1095, DOI 10.1089/aid.1995.11.1095; Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287; Freund NT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2144; Frost SDW, 2005, J VIROL, V79, P6523, DOI 10.1128/JVI.79.10.6523-6527.2005; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Gautam R, 2016, NATURE, V533, P105, DOI 10.1038/nature17677; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gilbert PB, 2011, J INFECT DIS, V203, P969, DOI 10.1093/infdis/jiq152; Gnanakaran S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002209; Go EP, 2017, J VIROL, V91, DOI 10.1128/JVI.02428-16; Go EP, 2015, J VIROL, V89, P8245, DOI 10.1128/JVI.00628-15; Go EP, 2013, J PROTEOME RES, V12, P1223, DOI 10.1021/pr300870t; Gonzalez MW, 2015, J VIROL, V89, P3619, DOI 10.1128/JVI.03235-14; Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11; Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778; Gristick HB, 2016, NAT STRUCT MOL BIOL, V23, P906, DOI 10.1038/nsmb.3291; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Haynes BF, 2014, SCIENCE, V344, P588, DOI 10.1126/science.1254990; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; Herrera AM, 2000, BIOCHEM BIOPH RES CO, V273, P557, DOI 10.1006/bbrc.2000.2974; Hess R, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020153; Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09; Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974; Hiss JA, 2009, BRIEF BIOINFORM, V10, P569, DOI 10.1093/bib/bbp030; Iyidogan P, 2014, VIRUSES-BASEL, V6, P4095, DOI 10.3390/v6104095; Jan M, 2019, ISCIENCE, V21, P413, DOI 10.1016/j.isci.2019.10.030; Jan M, 2017, AIDS RES HUM RETROV, V33, P941, DOI [10.1089/aid.2016.0262, 10.1089/AID.2016.0262]; Jan M, 2017, AIDS RES HUM RETROV, V33, P765, DOI 10.1089/aid.2016.0290; Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418; Joseph SB, 2015, NAT REV MICROBIOL, V13, P414, DOI 10.1038/nrmicro3471; Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1321; Kafando A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111012; Kaleebu P, 2007, JAIDS-J ACQ IMM DEF, V45, P28, DOI 10.1097/QAI.0b013e3180385aa0; Karasavvas N, 2012, AIDS RES HUM RETROV, V28, P1444, DOI 10.1089/aid.2012.0103; Kariuki SM, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0343-8; Karnasuta C, 2005, VACCINE, V23, P2522, DOI 10.1016/j.vaccine.2004.10.028; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kong L, 2010, J MOL BIOL, V403, P131, DOI 10.1016/j.jmb.2010.08.033; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Laher F, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003038; Land A, 2003, FASEB J, V17, P1058, DOI 10.1096/fj.02-0811com; Land A, 2001, BIOCHIMIE, V83, P783, DOI 10.1016/S0300-9084(01)01314-1; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; Lemmin T, 2017, STRUCTURE, V25, P1631, DOI 10.1016/j.str.2017.07.018; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; LI Y, 1993, J VIROL, V67, P584, DOI 10.1128/JVI.67.1.584-588.1993; Li Y, 2000, VIROLOGY, V272, P417, DOI 10.1006/viro.2000.0357; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; Liang Y, 2016, J VIROL, V90, P9224, DOI 10.1128/JVI.01116-16; Liu Y, 2008, VIROLOGY, V374, P229, DOI 10.1016/j.virol.2008.01.029; Liu YB, 2020, EMERG MICROBES INFEC, V9, P194, DOI 10.1080/22221751.2020.1713707; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MOORE JP, 1994, J VIROL, V68, P6836, DOI 10.1128/JVI.68.11.6836-6847.1994; Moore PL, 2012, NAT MED, V18, P1688, DOI 10.1038/nm.2985; Moore PL, 2009, CURR OPIN HIV AIDS, V4, P358, DOI 10.1097/COH.0b013e32832ea7e8; Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006; Nitayaphan S, 2004, J INFECT DIS, V190, P702, DOI 10.1086/422258; Owji H, 2018, EUR J CELL BIOL, V97, P422, DOI 10.1016/j.ejcb.2018.06.003; Ozorowski G, 2017, NATURE, V547, P360, DOI 10.1038/nature23010; Pancera M, 2005, VIROLOGY, V332, P145, DOI 10.1016/j.virol.2004.10.042; Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808; PARREN PWHI, 1995, AIDS, V9, pF1, DOI 10.1097/00002030-199506000-00001; Parren PWHI, 1997, NAT MED, V3, P366, DOI 10.1038/nm0497-366d; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Pegu A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008992; Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256; Pfeiffer T, 2006, FEBS LETT, V580, P3775, DOI 10.1016/j.febslet.2006.05.070; Pham Hanh Thi, 2018, Drugs Context, V7, P212522, DOI 10.7573/dic.212522; Pietzsch J, 2012, P NATL ACAD SCI USA, V109, P15859, DOI 10.1073/pnas.1213409109; Pitisuttithum P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027837; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Powell RLR, 2017, J VIROL, V91, DOI 10.1128/JVI.00410-17; Pritchard LK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8479; Rantalainen K, 2018, CELL REP, V23, P3249, DOI 10.1016/j.celrep.2018.05.046; Rapoport TA, 2017, ANNU REV CELL DEV BI, V33, P369, DOI 10.1146/annurev-cellbio-100616-060439; Raska M, 2010, J BIOL CHEM, V285, P20860, DOI 10.1074/jbc.M109.085472; Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rong R, 2007, J VIROL, V81, P1350, DOI 10.1128/JVI.01839-06; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Sagar M, 2009, J INFECT DIS, V199, P580, DOI 10.1086/596557; Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; Saunders KO, 2015, J VIROL, V89, P5895, DOI 10.1128/JVI.00210-15; Seabright GE, 2019, J MOL BIOL, V431, P2223, DOI 10.1016/j.jmb.2019.04.016; Shaw GM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006965; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494; Snapp EL, 2017, ELIFE, V6, DOI 10.7554/eLife.26067; Stamatatos L, 2017, IMMUNOL REV, V275, P203, DOI 10.1111/imr.12483; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016; Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010; Stoddart CA, 2014, VIROLOGY, V462, P115, DOI 10.1016/j.virol.2014.05.036; Struwe WB, 2018, CELL REP, V24, P1958, DOI 10.1016/j.celrep.2018.07.080; Sun M, 2016, ARCH VIROL, V161, P2449, DOI 10.1007/s00705-016-2942-4; Tian JH, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005094; Trickey A, 2017, LANCET HIV, V4, pE349, DOI 10.1016/S2352-3018(17)30066-8; Upadhyay C, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009185; Upadhyay C, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006812; van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009; van Montfort T, 2011, J IMMUNOL, V187, P4676, DOI 10.4049/jimmunol.1101876; Veselinovic M, 2012, VIROLOGY, V432, P505, DOI 10.1016/j.virol.2012.06.025; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wagh K, 2018, CELL REP, V25, P893, DOI 10.1016/j.celrep.2018.09.087; Wang HQ, 2018, CELL HOST MICROBE, V24, P579, DOI 10.1016/j.chom.2018.09.003; Wang Q, 2020, TRENDS MICROBIOL, V28, P655, DOI 10.1016/j.tim.2020.03.007; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wilen CB, 2011, J VIROL, V85, P8514, DOI 10.1128/JVI.00736-11; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Yang MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04532-9; Yolitz J, 2018, P NATL ACAD SCI USA, V115, P2443, DOI 10.1073/pnas.1722627115; Yue L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004565; Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817; Zolla-Pazner S, 2019, J VIROL, V93, DOI 10.1128/JVI.00629-19; Zolla-Pazner S, 2016, J VIROL, V90, P636, DOI 10.1128/JVI.01645-15; Zolla-Pazner S, 2010, NAT REV IMMUNOL, V10, P527, DOI 10.1038/nri2801	173	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							176	10.3390/vaccines9020176			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UO	33669676	Green Submitted, gold, Green Published			2022-04-29	WOS:000623276800001
J	Lawes-Wickwar, S; Ghio, D; Tang, MY; Keyworth, C; Stanescu, S; Westbrook, J; Jenkinson, E; Kassianos, AP; Scanlan, D; Garnett, N; Laidlaw, L; Howlett, N; Carr, N; Stanulewicz, N; Guest, E; Watson, D; Sutherland, L; Byrne-Davis, L; Chater, A; Hart, J; Armitage, CJ; Shorter, GW; Swanson, V; Epton, T				Lawes-Wickwar, Sadie; Ghio, Daniela; Tang, Mei Yee; Keyworth, Chris; Stanescu, Sabina; Westbrook, Juliette; Jenkinson, Elizabeth; Kassianos, Angelos P.; Scanlan, Daniel; Garnett, Natalie; Laidlaw, Lynn; Howlett, Neil; Carr, Natalie; Stanulewicz, Natalia; Guest, Ella; Watson, Daniella; Sutherland, Lisa; Byrne-Davis, Lucie; Chater, Angel; Hart, Jo; Armitage, Christopher J.; Shorter, Gillian W.; Swanson, Vivien; Epton, Tracy			A Rapid Systematic Review of Public Responses to Health Messages Encouraging Vaccination against Infectious Diseases in a Pandemic or Epidemic	VACCINES			English	Review						public health messaging; vaccine uptake; vaccine hesitancy; pandemics; epidemics; systematic review		Public health teams need to understand how the public responds to vaccination messages in a pandemic or epidemic to inform successful campaigns encouraging the uptake of new vaccines as they become available. A rapid systematic review was performed by searching PsycINFO, MEDLINE, healthevidence.org, OSF Preprints and PsyArXiv Preprints in May 2020 for studies including at least one health message promoting vaccine uptake of airborne-, droplet- and fomite-spread viruses. Included studies were assessed for quality using the Mixed Methods Appraisal Tool (MMAT) or the Assessment of Multiple Systematic Reviews (AMSTAR), and for patient and public involvement (PPI) in the research. Thirty-five articles were included. Most reported messages for seasonal influenza (n = 11; 31%) or H1N1 (n = 11; 31%). Evidence from moderate to high quality studies for improving vaccine uptake included providing information about virus risks and vaccination safety, as well as addressing vaccine misunderstandings, offering vaccination reminders, including vaccination clinic details, and delivering mixed media campaigns across hospitals or communities. Behavioural influences (beliefs and intentions) were improved when: shorter, risk-reducing or relative risk framing messages were used; the benefits of vaccination to society were emphasised; and beliefs about capability and concerns among target populations (e.g., vaccine safety) were addressed. Clear, credible, messages in a language target groups can understand were associated with higher acceptability. Two studies (6%) described PPI in the research process. Future campaigns should consider the beliefs and information needs of target populations in their design, including ensuring that vaccine eligibility and availability is clear, and messages are accessible. More high quality research is needed to demonstrate the effects of messaging interventions on actual vaccine uptake.	[Lawes-Wickwar, Sadie] UCL, Dept Primary Care & Populat Hlth, London NW3 2PF, England; [Ghio, Daniela] Univ Salford, Fac Hlth & Soc, Dept Psychol, Manchester M6 6PU, Lancs, England; [Tang, Mei Yee] Newcastle Univ, Behav Sci Policy Res Unit, Populat Hlth Sci, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England; [Keyworth, Chris; Byrne-Davis, Lucie; Hart, Jo; Armitage, Christopher J.; Epton, Tracy] Univ Manchester, Manchester Ctr Hlth Psychol, Manchester M13 9PL, Lancs, England; [Stanescu, Sabina] Univ Southampton, Sch Psychol, Southampton SO17 1BJ, Hants, England; [Westbrook, Juliette] Univ Bath, Dept Psychol, Bath BA2 7AY, Avon, England; [Jenkinson, Elizabeth; Garnett, Natalie; Guest, Ella] Univ West England, Dept Hlth & Social Sci, Bristol BS16 1QY, Avon, England; [Kassianos, Angelos P.] UCL, Dept Appl Hlth Res, London WC1E 6BT, England; [Scanlan, Daniel] Dept Commun Policy & Res, Educ Support, London N5 1EW, England; [Laidlaw, Lynn] Hlth Psychol Exchange Patient & Publ Involvement, London, England; [Howlett, Neil] Univ Hertfordshire, Sch Life & Med Sci, Dept Psychol Sports & Geog, Coll Lane, Hatfield AL10 9AB, Herts, England; [Carr, Natalie] Manchester Metropolitan Univ, Fac Hlth Psychol & Social Care, Manchester M15 6BH, Lancs, England; [Stanulewicz, Natalia] De Montfort Univ, Fac Hlth & Life Sci, Sch Appl Social Sci, Leicester LE1 9BH, Leics, England; [Watson, Daniella] Univ Southampton, Fac Med, Global Hlth Res Inst, Human Dev & Hlth, Southampton SO16 6YD, Hants, England; [Sutherland, Lisa] Behav Insight, Edinburgh EH9 3EY, Midlothian, Scotland; [Byrne-Davis, Lucie; Hart, Jo] Univ Manchester, Div Med Educ, Manchester M13 9PT, Lancs, England; [Chater, Angel] Univ Bedfordshire, Ctr Hlth Wellbeing & Behav Change, Bedford MK41 9EA, Beds, England; [Armitage, Christopher J.] Manchester Univ NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England; [Armitage, Christopher J.] Hlth Innovat Manchester, Manchester Acad Hlth Sci Ctr, Manchester M13 9NQ, Lancs, England; [Shorter, Gillian W.] Queens Univ Belfast, Ctr Improving Hlth Related Qual Life, Belfast BT7 1NN, Antrim, North Ireland; [Swanson, Vivien] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland		Lawes-Wickwar, S (通讯作者)，UCL, Dept Primary Care & Populat Hlth, London NW3 2PF, England.	sadie.lawes-wickwar@ucl.ac.uk; d.ghio@salford.ac.uk; meiyee.tang@newcastle.ac.uk; chris.keyworth@manchester.ac.uk; s.stanescu@soton.ac.uk; jsw46@bath.ac.uk; elizabeth2.jenkinson@uwe.ac.uk; angelos.kassianos@ucl.ac.uk; Daniel.scanlan00@gmail.com; natalie2.Garnett@live.uwe.ac.uk; lynnlaidlaw0@gmail.com; n.howlett@herts.ac.uk; nataliecarr_1@hotmail.co.uk; natalia.stanulewicz@dmu.ac.uk; ella.guest@uwe.ac.uk; d.watson@soton.ac.uk; lisaasutherland@googlemail.com; lucie.byrne-davis@manchester.ac.uk; angel.chater@beds.ac.uk; jo.hart@manchester.ac.uk; chris.armitage@manchester.ac.uk; g.shorter@qub.ac.uk; vivien.swanson@stir.ac.uk; tracy.epton@manchester.ac.uk	Kassianos, Angelos/AAN-5911-2021; Jenkinson, Elizabeth/AAQ-7591-2021; Shorter, Gillian W/H-1929-2015; Epton, Tracy/H-3301-2017; Ghio, Daniela/H-5105-2015	Kassianos, Angelos/0000-0001-6428-2623; Jenkinson, Elizabeth/0000-0001-5686-5132; Shorter, Gillian W/0000-0001-5752-2297; Byrne-Davis, Lucie/0000-0002-9658-5394; Epton, Tracy/0000-0002-1653-191X; Howlett, Neil/0000-0002-6502-9969; Keyworth, Chris/0000-0002-7815-6174; Stanescu, Sabina/0000-0003-0792-8939; Ghio, Daniela/0000-0002-0580-0205; Chater, Angel Marie/0000-0002-9043-2565; Watson, Daniella/0000-0001-6353-7495; Hart, Jo/0000-0001-9985-5137; Guest, Ella/0000-0001-8940-2871; Lawes-Wickwar, Sadie/0000-0001-9307-4532	NIHR Manchester biomedical Research CentreNational Institute for Health Research (NIHR); NIHR Greater Manchester Patient Safety Translational Research Centre	This review was an unfunded project. CJA receives support from NIHR Manchester biomedical Research Centre and NIHR Greater Manchester Patient Safety Translational Research Centre.	Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Arden M., 2020, PSYARXIV, DOI [10.31234/osf.io/fs9wk, DOI 10.31234/OSF.IO/FS9WK]; Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Baskin E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192594; Booth A, 2006, LIBR HI TECH, V24, P355, DOI 10.1108/07378830610692127; Bults M, 2015, DISASTER MED PUBLIC, V9, P207, DOI 10.1017/dmp.2014.160; Bushar JA, 2017, AM J PREV MED, V53, P845, DOI 10.1016/j.amepre.2017.06.021; Cameron KA, 2013, PATIENT EDUC COUNS, V92, P381, DOI 10.1016/j.pec.2013.06.017; Chai SJ, 2013, AM J PREV MED, V45, P190, DOI 10.1016/j.amepre.2013.03.014; Chien YH, 2011, SOC BEHAV PERSONAL, V39, P1063, DOI 10.2224/sbp.2011.39.8.1063; Cummings CL, 2019, J HEALTH COMMUN, V24, P456, DOI 10.1080/10810730.2019.1630527; Daly, 2020, INT ESTIMATES INTEND, DOI [10.1101/2020.12.01.20241729, DOI 10.1101/2020.12.01.20241729]; DiBonaventura MD, 2005, PSYCHOL HEALTH, V20, P761, DOI 10.1080/14768320500183368; Driedger SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071106; Fitzpatrick-Lewis D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-67; Food and Drug Administration, 2020, FDA TAK KEY ACT FIGH; Food and Drug Administration, 2020, FDA TAK ADD ACT FIGH; Ghio D., 2020, PSYARXIV PREPR, DOI [10.31234/osf.io/nz7tr, DOI 10.31234/OSF.IO/NZ7TR]; Godinho CA, 2016, PREV MED, V89, P104, DOI 10.1016/j.ypmed.2016.05.025; Han PKJ, 2018, J HEALTH COMMUN, V23, P435, DOI 10.1080/10810730.2018.1461961; Herrett E., 2016, BMJ Open, V6, pe010069, DOI 10.1136/bmjopen-2015-010069; Hong QN, 2018, EDUC INFORM, V34, P285, DOI 10.3233/EFI-180221; Humair JP, 2002, FAM PRACT, V19, P383, DOI 10.1093/fampra/19.4.383; Ipsos,, 2020, GLOB ATT COVID 19 VA; Jhummon-Mahadnac Namrata Devi, 2012, BMC Res Notes, V5, P377, DOI 10.1186/1756-0500-5-377; Kelly BJ, 2016, HEALTH COMMUN, V31, P1284, DOI 10.1080/10410236.2015.1062976; Kim S, 2019, HEALTH COMMUN, V34, P21, DOI 10.1080/10410236.2017.1384353; Kononova A, 2017, HEALTH COMMUN, V32, P759, DOI 10.1080/10410236.2016.1172289; Lapka C, 2008, HEALTH EDUC RES, V23, P467, DOI 10.1093/her/cym089; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee YI, 2018, SOC MARK Q, V24, P89, DOI 10.1177/1524500418771283; Lin L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-484; Llupia A, 2010, AM J INFECT CONTROL, V38, P476, DOI 10.1016/j.ajic.2010.01.013; Looijmans-van den Akker I, 2010, VACCINE, V28, P5086, DOI 10.1016/j.vaccine.2010.05.003; Lynch MM, 2012, MATERN CHILD HLTH J, V16, P1657, DOI 10.1007/s10995-011-0865-y; MacDonald L, 2013, J HEALTH COMMUN, V18, P1523, DOI 10.1080/10810730.2013.840697; Malmvall B.-E., 2006, QUAL MANAG HEALTH CA, V16, P51, DOI [10.1097/00019514-200701000-00007, DOI 10.1097/00019514-200701000-00007]; Mayweg-Paus E, 2015, PSYCHOL HEALTH MED, V20, P989, DOI 10.1080/13548506.2014.986139; Miczo N, 2013, WESTERN J COMM, V77, P625, DOI 10.1080/10570314.2013.776099; Mowbray F, 2016, VACCINE, V34, P3268, DOI 10.1016/j.vaccine.2016.05.006; Nan XL, 2012, HEALTH COMMUN, V27, P559, DOI 10.1080/10410236.2011.617243; Natter H.M., 2005, PSYCHOL, V10, P326, DOI [10.1080/13548500500093407, DOI 10.1080/13548500500093407]; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Nuffield Trust, AD FLU VACC COV; Ort A, 2018, BRIT J HEALTH PSYCH, V23, P665, DOI 10.1111/bjhp.12310; Ou SM, 2014, ASIA-PAC J PUBLIC HE, V26, P85, DOI 10.1177/1010539512466427; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Oxford University, 2020, OXF U BREAKTHR GLOB; Payaprom Y, 2011, HEALTH PSYCHOL, V30, P492, DOI 10.1037/a0023580; Phillips AL, 2014, PREV MED, V69, P117, DOI 10.1016/j.ypmed.2014.09.009; Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015; Pomery EA, 2009, PERS SOC PSYCHOL B, V35, P894, DOI 10.1177/0146167209335166; Prati G, 2012, HEALTH COMMUN, V27, P413, DOI 10.1080/10410236.2011.606523; Prati G, 2011, HEALTH EDUC RES, V26, P761, DOI 10.1093/her/cyr035; Price A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020452; Public Health England, 2020, COVID 19 VACC GUID W; Public Health England, 2020, SEASONAL INFLUENZA V; Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120; Royal Society of Public Health, 2020, ON 5 PUBL UNS GETT C; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Sheeran P, 2016, SOC PERSONAL PSYCHOL, V10, P503, DOI 10.1111/spc3.12265; Shenson D, 2001, J COMMUN HEALTH, V26, P191, DOI 10.1023/A:1010321128990; Teasdale E, 2011, PATIENT EDUC COUNS, V85, P413, DOI 10.1016/j.pec.2010.12.026; The British Psychological Society, 2020, DEL EFF PUBL HLTH CA; Torreele E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3209; Wolf ER, 2015, EXPERT REV VACCINES, V14, P923, DOI 10.1586/14760584.2015.1037289; World Health Organization, 2017, COMM RISK PUBL HLTH; World Health Organization, 2020, BEH CONS ACC UPT COV; World Health Organization (WHO), 2020, WHO ISS ITS 1 EM US; Yu N, 2013, HEALTH COMMUN, V28, P133, DOI 10.1080/10410236.2012.662147	71	17	17	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							72	10.3390/vaccines9020072			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6UJ	33498395	Green Published, Green Submitted, Green Accepted, gold			2022-04-29	WOS:000623276300001
J	Lozano, JM; Parra, ZR; Hernandez-Martinez, S; Yasnot-Acosta, MF; Rojas, AP; Marin-Waldo, LS; Rincon, JE				Manuel Lozano, Jose; Rodriguez Parra, Zully; Hernandez-Martinez, Salvador; Fernanda Yasnot-Acosta, Maria; Patricia Rojas, Angela; Stella Marin-Waldo, Luz; Edilberto Rincon, Juan			The Search of a Malaria Vaccine: The Time for Modified Immuno-Potentiating Probes	VACCINES			English	Review						malaria vaccine; Plasmodium spp; structurally modified antigen; non-natural elements	PLASMODIUM-FALCIPARUM MALARIA; MEROZOITE SURFACE PROTEIN-1; APICAL MEMBRANE ANTIGEN-1; FUNCTIONAL ANTIBODIES; CIRCUMSPOROZOITE PROTEIN; IRRADIATED SPOROZOITES; PROTECTIVE IMMUNITY; ACQUIRED-IMMUNITY; DOUBLE-BLIND; PARASITE	Malaria is a deadly disease that takes the lives of more than 420,000 people a year and is responsible for more than 229 million clinical cases globally. In 2019, 95% of malaria morbidity occurred in African countries. The development of a highly protective vaccine is an urgent task that remains to be solved. Many vaccine candidates have been developed, from the use of the entire attenuated and irradiated pre-erythrocytic parasite forms (or recombinantly expressed antigens thereof) to synthetic candidates formulated in a variety of adjuvants and delivery systems, however these have unfortunately proven a limited efficacy. At present, some vaccine candidates are finishing safety and protective efficacy trials, such as the PfSPZ and the RTS,S/AS01 which are being introduced in Africa. We propose a strategy for introducing non-natural elements into target antigens representing key epitopes of Plasmodium spp. Accordingly, chemical strategies and knowledge of host immunity to Plasmodium spp. have served as the basis. Evidence is obtained after being tested in experimental rodent models for malaria infection and recognized for human sera from malaria-endemic regions. This encourages us to propose such an immune-potentiating strategy to be further considered in the search for new vaccine candidates.	[Manuel Lozano, Jose; Rodriguez Parra, Zully] Univ Nacl Colombia, Dept Farm, Grp Invest Mimetismo Mol Agentes Infecciosos, Sede Bogota, Bogota 111321, Colombia; [Hernandez-Martinez, Salvador] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Direcc Infecc & Inmunidad, Cuernavaca 62508, Morelos, Mexico; [Fernanda Yasnot-Acosta, Maria] Univ Cordoba, Grp Invest Microbiol & Biomed Cordoba, Monteria 230002, Colombia; [Patricia Rojas, Angela] Univ Nacl Colombia, Dept Farm, Grp Invest Biol Celular & Autoinmuniad, Sede Bogota, Bogota 111321, Colombia; [Stella Marin-Waldo, Luz] Ctr Salud San Pedro Claver, Nuqui 276057, Choco, Colombia; [Edilberto Rincon, Juan] Univ Nacl Colombia, Dept Ingn & Mecatron, Sede Bogota, Bogota 111321, Colombia		Lozano, JM (通讯作者)，Univ Nacl Colombia, Dept Farm, Grp Invest Mimetismo Mol Agentes Infecciosos, Sede Bogota, Bogota 111321, Colombia.	jmlozanom@unal.edu.co; zjrodriguezp@unal.edu.co; shernand@insp.mx; myasnot@correo.unicordoba.edu.co; aprojasr@unal.edu.co; lustmawa@hotmail.com; jerinconp@unal.edu.co		Lozano, Jose Manuel/0000-0001-6039-0213; Hernandez-Martinez, Salvador/0000-0003-1276-9397; Rojas, Angela P/0000-0002-7178-3204; Rodriguez Parra, Zully Johana/0000-0001-6517-4640	Universidad Nacional de Colombia, Vicerrectoria de Investigacion HERMES [48164, 42129, 35925]; Colciencias (Minciencias) Programa de Doctorados NacionalesDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias [727]; Universidad de Cordoba [FCS-01-14]	This work was supported by Universidad Nacional de Colombia, Vicerrectoria de Investigacion HERMES grant numbers 48164, 42129, and 35925; Colciencias (Minciencias) Programa de Doctorados Nacionales 727, 2015 and Universidad de Cordoba, grant number FCS-01-14.	Abraham EG, 2004, INSECT BIOCHEM MOLEC, V34, P667, DOI 10.1016/j.ibmb.2004.03.019; Aly ASI, 2009, ANNU REV MICROBIOL, V63, P195, DOI 10.1146/annurev.micro.091208.073403; ALYAMAN F, 1994, AM J TROP MED HYG, V51, P593, DOI 10.4269/ajtmh.1994.51.593; Aminake M., 2013, CHAPTER ANTIMALARIAL, P269; Arrighi RBG, 2005, J EXP BIOL, V208, P2497, DOI 10.1242/jeb.01664; Ascarateil S., 2015, J IMMUNOTHER CANCER, V3, pP428, DOI [10.1186/2051-1426-3-S2-P428, DOI 10.1186/2051-1426-3-S2-P428]; Baird JK, 1998, ANN TROP MED PARASIT, V92, P367, DOI 10.1080/00034989859366; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Bastiaens GJH, 2016, AM J TROP MED HYG, V94, P663, DOI 10.4269/ajtmh.15-0621; Batista-Duharte A, 2014, ENFERM INFEC MICR CL, V32, P106, DOI 10.1016/j.eimc.2012.11.012; Baton Luke A., 2008, P74, DOI 10.1007/978-0-387-76717-8_7; Battle KE, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-144; Beeson JG, 2016, FEMS MICROBIOL REV, V40, P343, DOI 10.1093/femsre/fuw001; Beeson JG, 2002, CELL MOL LIFE SCI, V59, P258, DOI 10.1007/s00018-002-8421-y; Belard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022525; Belnoue E, 2004, J IMMUNOL, V172, P2487, DOI 10.4049/jimmunol.172.4.2487; Bergmann-Leitner E., 2012, MALARIA PARASITES, P202, DOI 10.5772/33130; BERZINS K, 1986, P NATL ACAD SCI USA, V83, P1065, DOI 10.1073/pnas.83.4.1065; Billker O, 1997, PARASITOLOGY, V115, P1, DOI 10.1017/S0031182097008895; Birkett AJ, 2016, VACCINE, V34, P2915, DOI 10.1016/j.vaccine.2015.12.074; Black CG, 2003, MOL BIOCHEM PARASIT, V127, P59, DOI 10.1016/S0166-6851(02)00308-0; Black CG, 2001, MOL BIOCHEM PARASIT, V114, P217, DOI 10.1016/S0166-6851(01)00265-1; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P35, DOI 10.1016/0166-6851(91)90128-S; Bonam SR, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105684; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S; Bousema T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014114; Boyle MJ, 2014, INFECT IMMUN, V82, P924, DOI 10.1128/IAI.00866-13; Canepa GE, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0065-5; Carter V, 2007, INT J PARASITOL, V37, P1221, DOI 10.1016/j.ijpara.2007.03.005; CLYDE DF, 1990, B WORLD HEALTH ORGAN, V68, P9; Coelho CH, 2020, TRENDS PARASITOL, V36, P880, DOI 10.1016/j.pt.2020.08.009; Coelho CH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0035-3; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; COLLINS WE, 1972, NATURE-NEW BIOL, V236, P176, DOI 10.1038/newbio236176a0; Coppi A, 2005, J EXP MED, V201, P27, DOI 10.1084/jem.20040989; Coppi A, 2011, J EXP MED, V208, P341, DOI 10.1084/jem.20101488; Cowman AF, 2012, J CELL BIOL, V198, P961, DOI 10.1083/jcb.201206112; Croft NP, 2011, EXPERT REV VACCINES, V10, P211, DOI [10.1586/erv.10.161, 10.1586/ERV.10.161]; Crompton PD, 2010, J CLIN INVEST, V120, P4168, DOI 10.1172/JCI44423; Cross S, 2009, ABSTR PAP AM CHEM S, V238; CULVENOR JG, 1991, INFECT IMMUN, V59, P1183, DOI 10.1128/IAI.59.3.1183-1187.1991; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Dinko B., 2016, ADV, V06, P82, DOI DOI 10.4236/AID.2016.62011; Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08; Doolan DL, 2001, INT J PARASITOL, V31, P753, DOI 10.1016/S0020-7519(01)00184-9; Draper SJ, 2015, VACCINE, V33, P7433, DOI 10.1016/j.vaccine.2015.09.093; Drew DR, 2015, TRENDS PARASITOL, V31, P87, DOI 10.1016/j.pt.2015.02.001; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; Epstein JE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89154; Erdman LK, 2008, MOL BIOCHEM PARASIT, V162, P105, DOI 10.1016/j.molbiopara.2008.08.006; Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P1777, DOI 10.1080/21645515.2016.1150396; FALGUNEE K, 2011, AM, V84, P1, DOI DOI 10.4269/AJTMH.2011.09-0781; Farooq F, 2015, CLIN IMMUNOL, V161, P136, DOI 10.1016/j.clim.2015.08.015; Fonseca JA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34527; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Grau GER, 2012, FUTURE MICROBIOL, V7, P291, DOI [10.2217/FMB.11.155, 10.2217/fmb.11.155]; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Hauguel TM, 2008, FRONT BIOSCI-LANDMRK, V13, P2806, DOI 10.2741/2887; Hermsen CC, 2007, VACCINE, V25, P2930, DOI 10.1016/j.vaccine.2006.06.081; Hernandez-Martinez S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38631-6; Hernandez-Martinez S, 2013, CELL TISSUE RES, V351, P127, DOI 10.1007/s00441-012-1505-6; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Hoffman SL, 2015, VACCINE, V33, pD13, DOI 10.1016/j.vaccine.2015.07.091; Hoffman SL, 2010, HUM VACCINES, V6, P97, DOI 10.4161/hv.6.1.10396; Howes RE, 2016, AM J TROP MED HYG, V95, P15, DOI 10.4269/ajtmh.16-0141; Irani V, 2015, CLIN INFECT DIS, V61, P1244, DOI 10.1093/cid/civ525; Kapulu MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep11193; Kengne-Ouafo JA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00136; Koram KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163066; Kublin JG, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aad9099; Kurup SP, 2019, NAT REV IMMUNOL, V19, P457, DOI 10.1038/s41577-019-0158-z; Kushwaha A, 2001, PARASITE IMMUNOL, V23, P435, DOI 10.1046/j.1365-3024.2001.00390.x; Lawson LB, 2011, CURR OPIN IMMUNOL, V23, P414, DOI 10.1016/j.coi.2011.03.009; Leroux-Roels G, 2010, VACCINE, V28, pC25, DOI 10.1016/j.vaccine.2010.07.021; Long CA, 2016, CURR OPIN MICROBIOL, V32, P96, DOI 10.1016/j.mib.2016.04.006; Lopaticki S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00571-y; Lozano JM, 1998, J PEPT RES, V52, P457; Lozano JM, 2007, MICROBES INFECT, V9, P751, DOI 10.1016/j.micinf.2007.02.004; Lyon JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002830; MacDonald NJ, 2016, J BIOL CHEM, V291, P19913, DOI 10.1074/jbc.M116.732305; Malaguarnera L, 2002, LANCET INFECT DIS, V2, P472, DOI 10.1016/S1473-3099(02)00344-4; Lozano JM, 2013, AMINO ACIDS, V45, P913, DOI 10.1007/s00726-013-1541-x; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; Mikolajczak SA, 2014, MOL THER, V22, P1707, DOI 10.1038/mt.2014.85; Miller JL, 2014, CELL REP, V7, P436, DOI 10.1016/j.celrep.2014.03.018; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Mishra S, 2012, J IMMUNOL METHODS, V377, P47, DOI 10.1016/j.jim.2012.01.009; Miura K, 2016, EXPERT REV VACCINES, V15, P765, DOI 10.1586/14760584.2016.1141680; Moorthy VS, 2004, LANCET, V363, P150, DOI 10.1016/S0140-6736(03)15267-1; Mordmuller B, 2017, NATURE, V542, P445, DOI 10.1038/nature21060; Moreno A, 2015, CURR OPIN IMMUNOL, V35, P98, DOI 10.1016/j.coi.2015.06.008; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; Mueller I, 2015, VACCINE, V33, P7489, DOI 10.1016/j.vaccine.2015.09.060; Nikolaeva D, 2015, EXPERT REV VACCINES, V14, P653, DOI 10.1586/14760584.2015.993383; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; O'Donnell RA, 2005, CURR OPIN MICROBIOL, V8, P422, DOI 10.1016/j.mib.2005.06.018; Paaijmans KP, 2010, P NATL ACAD SCI USA, V107, P15135, DOI 10.1073/pnas.1006422107; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pacheco MA, 2012, INFECT GENET EVOL, V12, P978, DOI 10.1016/j.meegid.2012.02.009; Palacpac NMQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064073; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93683; Pearce JA, 2004, INFECT IMMUN, V72, P2321, DOI 10.1128/IAI.72.4.2321-2328.2004; Perez O, 2007, SCAND J IMMUNOL, V66, P271, DOI 10.1111/j.1365-3083.2007.01981.x; Perez O, 2012, BRAZ J MED BIOL RES, V45, P681, DOI 10.1590/S0100-879X2012007500067; Perez O, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00407; Perraut R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101737; Pimenta PFP, 2015, MEM I OSWALDO CRUZ, V110, P23, DOI 10.1590/0074-02760140266; Preiser P, 2000, MICROBES INFECT, V2, P1461, DOI 10.1016/S1286-4579(00)01301-0; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; QUAKYI IA, 1987, J IMMUNOL, V139, P4213; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; RENIA L, 1991, P NATL ACAD SCI USA, V88, P7963, DOI 10.1073/pnas.88.18.7963; Richards JS, 2013, J IMMUNOL, V191, P795, DOI 10.4049/jimmunol.1300778; Richie TL, 2015, VACCINE, V33, P7452, DOI 10.1016/j.vaccine.2015.09.096; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Riley EM, 2013, NAT MED, V19, P168, DOI 10.1038/nm.3083; SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297, DOI 10.4269/ajtmh.1991.45.297; Sagara I, 2009, VACCINE, V27, P3090, DOI 10.1016/j.vaccine.2009.03.014; Santos-Vega M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005155; Schijns V, 2020, IMMUNOL REV, V296, P169, DOI 10.1111/imr.12889; Schmid-Hempel P, 2005, ANNU REV ENTOMOL, V50, P529, DOI 10.1146/annurev.ento.50.071803.130420; Sedegah M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163026; Sharma P, 1998, INFECT IMMUN, V66, P2895, DOI 10.1128/IAI.66.6.2895-2904.1998; Sheehy SH, 2012, MOL THER, V20, P2355, DOI 10.1038/mt.2012.223; Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200; Sinden RE, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-70; Singh S, 2004, J INFECT DIS, V190, P1010, DOI 10.1086/423208; Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-72; Sirima SB, 2020, LANCET INFECT DIS, V20, P585, DOI 10.1016/S1473-3099(19)30739-X; Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/S1473-3099(17)30104-4, 10.1016/s1473-3099(17)30104-4]; Smith RC, 2016, TRENDS PARASITOL, V32, P979, DOI 10.1016/j.pt.2016.08.012; Smith RC, 2014, MEM I OSWALDO CRUZ, V109, P644, DOI 10.1590/0074-0276130597; Sonko ST, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-449; Spring MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005254; Srinivasan P, 2008, CELL MICROBIOL, V10, P1304, DOI 10.1111/j.1462-5822.2008.01127.x; Takashima E, 2016, EXPERT REV VACCINES, V15, P1, DOI 10.1586/14760584.2016.1112744; Talaat KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163144; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; Teo A, 2016, TRENDS PARASITOL, V32, P887, DOI 10.1016/j.pt.2016.07.003; Tham WH, 2017, INT J PARASITOL, V47, P111, DOI 10.1016/j.ijpara.2016.09.006; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471; Ukegbu CV, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00139-17, 10.1128/iai.00139-17]; Vallejo AF, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004807; Van Braeckel-Budimir N, 2016, CURR OPIN IMMUNOL, V42, P91, DOI 10.1016/j.coi.2016.06.008; Vanegas M, 2014, BIOCHEM BIOPH RES CO, V451, P15, DOI 10.1016/j.bbrc.2014.06.143; VERBERG J, 2009, VACCINE, V27, P2, DOI DOI 10.1016/J.VACCINE.2008.10.028; Vlachou D, 2004, CELL MICROBIOL, V6, P671, DOI 10.1111/j.1462-5822.2004.00394.x; WAHLIN B, 1992, INFECT IMMUN, V60, P443; WEBER JL, 1988, J BIOL CHEM, V263, P11421; WILLIAMSON KC, 1993, MOL BIOCHEM PARASIT, V58, P355, DOI 10.1016/0166-6851(93)90058-6; World Health Organization, 2020, WORLD MALARIA REPORT; Wu TQ, 1999, MOL BIOCHEM PARASIT, V103, P243, DOI 10.1016/S0166-6851(99)00134-6; Wu YM, 2015, ADV PARASIT, V89, P109, DOI 10.1016/bs.apar.2015.04.001; Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636	164	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							115	10.3390/vaccines9020115			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7ER	33540947	Green Published, Green Submitted			2022-04-29	WOS:000623303600001
J	Mu, ZK; Haynes, BF; Cain, DW				Mu, Zekun; Haynes, Barton F.; Cain, Derek W.			HIV mRNA Vaccines-Progress and Future Paths	VACCINES			English	Review						HIV; vaccine; messenger RNA		The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host's cells to manufacture protein immunogens which, in turn, are targets for antibody and cytotoxic T cell responses. mRNA-based vaccines have been the subject of research for over three decades as a platform to protect against or treat a variety of cancers, amyloidosis and infectious diseases. In this review, we discuss mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV. We examine the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV. Lastly, we outline an mRNA-based HIV vaccination strategy based on the immunobiology of broadly neutralizing antibody development.	[Mu, Zekun; Haynes, Barton F.; Cain, Derek W.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA; [Mu, Zekun; Haynes, Barton F.] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA		Cain, DW (通讯作者)，Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA.	zekun.mu@duke.edu; barton.haynes@duke.edu; derek.cain@duke.edu		Mu, Zekun/0000-0003-4093-8346	Consortium for HIV/AIDS Vaccine Development (CHAVD) [UM1AI144371]	Supported by Consortium for HIV/AIDS Vaccine Development (CHAVD) Grant UM1AI144371.	Abbasi J, 2020, JAMA-J AM MED ASSOC, V324, P1125, DOI 10.1001/jama.2020.16866; Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202; Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Anderson BR, 2011, NUCLEIC ACIDS RES, V39, P9329, DOI 10.1093/nar/gkr586; Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andrabi R, 2018, CURR OPIN IMMUNOL, V53, P143, DOI 10.1016/j.coi.2018.04.025; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Barouch DH, 2014, NAT REV MICROBIOL, V12, P765, DOI 10.1038/nrmicro3360; Barre-Sinoussi F, 2013, NAT REV MICROBIOL, V11, P877, DOI 10.1038/nrmicro3132; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Bogers WM, 2015, J INFECT DIS, V211, P947, DOI 10.1093/infdis/jiu522; Bonsignori M, 2018, IMMUNITY, V49, P1162, DOI 10.1016/j.immuni.2018.10.015; Bonsignori M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7514; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Borthwick N, 2014, MOL THER, V22, P464, DOI 10.1038/mt.2013.248; Bradley T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14670-w; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Churchill MJ, 2016, NAT REV MICROBIOL, V14, P55, DOI 10.1038/nrmicro.2015.5; Cirelli KM, 2020, CELL, V180, P206, DOI 10.1016/j.cell.2019.12.027; Coolen AL, 2019, BIOMATERIALS, V195, P23, DOI 10.1016/j.biomaterials.2018.12.019; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cu Y, 2013, VACCINES, V1, P367, DOI 10.3390/vaccines1030367; D'haese S, 2021, J CONTROL RELEASE, V330, P1016, DOI 10.1016/j.jconrel.2020.11.009; D'Souza WN, 2002, J IMMUNOL, V168, P5566, DOI 10.4049/jimmunol.168.11.5566; de Jong W, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040209; Do Kwon Y, 2015, NAT STRUCT MOL BIOL, V22, P522, DOI 10.1038/nsmb.3051; Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Dosenovic P, 2015, CELL, V161, P1505, DOI 10.1016/j.cell.2015.06.003; Doyle-Cooper C, 2013, J IMMUNOL, V191, P3186, DOI 10.4049/jimmunol.1301285; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; Escolano A, 2017, J EXP MED, V214, P3, DOI 10.1084/jem.20161765; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Fruh K, 2017, CURR OPIN IMMUNOL, V47, P52, DOI 10.1016/j.coi.2017.06.010; Gandhi RT, 2016, JAIDS-J ACQ IMM DEF, V71, P246, DOI 10.1097/QAI.0000000000000852; Gause KT, 2017, ACS NANO, V11, P54, DOI 10.1021/acsnano.6b07343; Gay CL, 2018, AIDS RES HUM RETROV, V34, P111, DOI 10.1089/aid.2017.0071; Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Guardo AC, 2017, AIDS, V31, P321, DOI 10.1097/QAD.0000000000001276; Gulick RM, 2019, ANNU REV MED, V70, P137, DOI 10.1146/annurev-med-041217-013717; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; HANSEN SG, 2019, SCI, V11, DOI DOI 10.1126/scitranslmed.aaw2607; Hardtke S, 2005, BLOOD, V106, P1924, DOI 10.1182/blood-2004-11-4494; Havenar-Daughton C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0381; Haynes BF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaz2686; Haynes BF, 2017, SCIENCE, V355, P1129, DOI 10.1126/science.aan0662; Haynes BF, 2016, CELL HOST MICROBE, V19, P292, DOI 10.1016/j.chom.2016.02.002; Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041; Henderson R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14196-w; Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Jacobson JM, 2016, JAIDS-J ACQ IMM DEF, V72, P31, DOI 10.1097/QAI.0000000000000926; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; JERNE N K, 1951, Acta Pathol Microbiol Scand Suppl, V87, P1; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2020, UNAIDS DAT; Jones LD, 2020, CLIN THER, V42, P499, DOI 10.1016/j.clinthera.2020.01.009; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kauffman KJ, 2016, BIOMATERIALS, V109, P78, DOI 10.1016/j.biomaterials.2016.09.006; Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017; Kelsoe G, 2017, IMMUNOL REV, V275, P79, DOI 10.1111/imr.12508; Kepler TB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00170; Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Korber B, 2020, HUM VACC IMMUNOTHER, V16, P713, DOI 10.1080/21645515.2019.1666957; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; Koup RA, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007252; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; LaBranche CC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008026; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Li M, 2016, J CONTROL RELEASE, V228, P9, DOI 10.1016/j.jconrel.2016.02.043; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; McCoy LE, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0453-y; McGuire AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10618; McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674; Medina-Ramirez M, 2017, J EXP MED, V214, P2573, DOI 10.1084/jem.20161160; Meyerhoff RR, 2017, AIDS RES HUM RETROV, V33, P859, DOI [10.1089/aid.2016.0294, 10.1089/AID.2016.0294]; Montefiori DC, 2018, CURR OPIN HIV AIDS, V13, P128, DOI [10.1097/COH.0000000000000442, 10.1097/coh.0000000000000442]; Moore PL, 2012, NAT MED, V18, P1688, DOI 10.1038/nm.2985; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083; Moyo N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030360; Moyo N, 2019, MOL THER-METH CLIN D, V12, P32, DOI 10.1016/j.omtm.2018.10.010; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; NIH, EXP HIV VACC REG IN; Nishimura Y, 2017, CELL HOST MICROBE, V22, P207, DOI 10.1016/j.chom.2017.07.010; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Ondondo B, 2016, MOL THER, V24, P832, DOI 10.1038/mt.2016.3; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Pardi N, 2019, MOL THER-NUCL ACIDS, V15, P36, DOI 10.1016/j.omtn.2019.03.003; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Pardi N, 2017, METHODS MOL BIOL, V1499, P109, DOI 10.1007/978-1-4939-6481-9_6; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Roark RS, 2021, SCIENCE, V371, P142, DOI 10.1126/science.abd2638; Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009; Saeboe-Larssen S, 2002, J IMMUNOL METHODS, V259, P191, DOI 10.1016/S0022-1759(01)00506-3; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Saunders Kevin O, 2020, bioRxiv, DOI 10.1101/2020.12.30.424745; Saunders KO, 2019, SCIENCE, V366, P1215, DOI 10.1126/science.aay7199; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09; Shi B, 2014, THEOR BIOL MED MODEL, V11, DOI 10.1186/1742-4682-11-30; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4; Smith CM, 2004, NAT IMMUNOL, V5, P1143, DOI 10.1038/ni1129; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; TEW JG, 1980, IMMUNOLOGY, V40, P425; Theiler J, 2016, SCI REP-UK, V6, DOI 10.1038/srep33987; Tuosto L, 1998, EUR J IMMUNOL, V28, P2131, DOI 10.1002/(SICI)1521-4141(199807)28:07<2131::AID-IMMU2131>3.0.CO;2-Q; Tyler B, 2016, ADV DRUG DELIVER REV, V107, P163, DOI 10.1016/j.addr.2016.06.018; Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49; Verbeke R, 2019, NANO TODAY, V28, DOI 10.1016/j.nantod.2019.100766; Verkoczy L, 2011, J IMMUNOL, V187, P3785, DOI 10.4049/jimmunol.1101633; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710; Weissman Drew, 2013, Methods Mol Biol, V969, P43, DOI 10.1007/978-1-62703-260-5_3; Wibmer CK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003738; Wiehe K, 2018, CELL HOST MICROBE, V23, P759, DOI 10.1016/j.chom.2018.04.018; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328; Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029; Zeng Q, 2015, J CONTROL RELEASE, V200, P1, DOI 10.1016/j.jconrel.2014.12.024; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594; Zhang P, 2018, CELL HOST MICROBE, V23, P832, DOI 10.1016/j.chom.2018.05.002; Zhao MN, 2016, DRUG DELIV, V23, P2596, DOI 10.3109/10717544.2015.1038856	171	13	13	27	51	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							134	10.3390/vaccines9020134			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6RQ	33562203	Green Published, gold			2022-04-29	WOS:000623269200001
J	Santoro, F; Donato, A; Lucchesi, S; Sorgi, S; Gerlini, A; Haks, MC; Ottenhoff, THM; Gonzalez-Dias, P; Nakaya, HI; Huttner, A; Siegrist, CA; Medaglini, D; Pozzi, G				Santoro, Francesco; Donato, Alessia; Lucchesi, Simone; Sorgi, Sara; Gerlini, Alice; Haks, Marielle C.; Ottenhoff, Tom H. M.; Gonzalez-Dias, Patricia; Nakaya, Helder, I; Huttner, Angela; Siegrist, Claire-Anne; Medaglini, Donata; Pozzi, Gianni		VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium	Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine	VACCINES			English	Article						Ebolavirus Disease; transcriptomics; recombinant VSV; VSV-ZEBOV; vaccine; live viral vector	DIFFERENTIAL EXPRESSION ANALYSIS; DOUBLE-BLIND; IMMUNE SIGNATURE; VIRUS DISEASE; IMMUNOGENICITY; SAFETY; CANDIDATE; FEVER	Ebolavirus Disease (EVD) is a severe haemorrhagic fever that occurs in epidemic outbreaks, with a high fatality rate and no specific therapies available. rVSV Delta G-ZEBOV-GP (Ervebo(R)), a live-attenuated recombinant vesicular stomatitis virus vector expressing the glycoprotein G of Zaire Ebolavirus, is the first vaccine approved for prevention of EVD. Both innate and adaptive responses are deemed to be involved in vaccine-induced protection, yet the mechanisms are not fully elucidated. A global transcriptomic approach was used to profile the blood host-response in 51 healthy volunteers enrolled in a phase 1/2 clinical trial. Signatures of the host responses were investigated assessing the enrichment in differentially expressed genes (DEGs) of specific "blood transcription modules" (BTM). Comparison of gene-expression levels showed that vaccination produces a peak of 5469 DEGs at day one, representing 38.6% of the expressed genes. Out of 346 BTMs, 144 were significantly affected by vaccination. Innate immunity pathways were induced from day 1 to day 14. At days 2 and 3, neutrophil modules were downregulated and complement-related modules upregulated. T-cell and cell-cycle associated modules were upregulated at days 7 and 14, while at day 28, no modules remained activated. At day 14, a direct correlation was observed between ZEBOV glycoprotein-specific antibody titres and activation of seven BTMs, including two related to B-cell activation and B cell receptor signalling. Transcriptomic analysis identified an rVSV Delta G-ZEBOV-GP-induced signature and demonstrated a direct correlation of blood transcriptomic changes with ZEBOV glycoprotein-specific antibody titres.	[Santoro, Francesco; Donato, Alessia; Lucchesi, Simone; Sorgi, Sara; Medaglini, Donata; Pozzi, Gianni] Univ Siena, Dept Med Biotechnol, Lab Mol Microbiol & Biotechnol LAMMB, I-53100 Siena, Italy; [Gerlini, Alice] Microbiotec srl, I-53100 Siena, Italy; [Haks, Marielle C.; Ottenhoff, Tom H. M.] Leiden Univ, Dept Infect Dis, Med Ctr, NL-2333 Leiden, Netherlands; [Gonzalez-Dias, Patricia; Nakaya, Helder, I] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508020 Sao Paulo, Brazil; [Nakaya, Helder, I] Sci Platform Pasteur USP, BR-05508020 Sao Paulo, Brazil; [Huttner, Angela; Siegrist, Claire-Anne] Univ Geneva, Fac Med, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland; [Huttner, Angela] Geneva Univ Hosp, Infect Dis Serv, CH-1205 Geneva, Switzerland; [Siegrist, Claire-Anne] Univ Geneva, Fac Med, WHO Collaborating Ctr Vaccine Immunol, CH-1200 Geneva, Switzerland		Santoro, F; Pozzi, G (通讯作者)，Univ Siena, Dept Med Biotechnol, Lab Mol Microbiol & Biotechnol LAMMB, I-53100 Siena, Italy.	santorof@unisi.it; alessia.donato@student.unisi.it; lucchesi5@student.unisi.it; sara.sorgi@student.unisi.it; alice.gerlini@microbiotec.eu; M.C.Haks@lumc.nl; t.h.m.ottenhoff@lumc.nl; patricia.gonzalez@usp.br; hnakaya@usp.br; angela.huttner@hcuge.ch; claire-anne.siegrist@unige.ch; donata.medaglini@unisi.it; gianni.pozzi@unisi.it	Nakaya, Helder I/A-1397-2010; Nakaya, Helder/AAF-1738-2020; Haks, Marielle/G-1813-2014; POZZI, GIANNI/Q-2713-2018; MEDAGLINI, DONATA/R-1149-2018; Santoro, Francesco/A-4681-2015	Nakaya, Helder I/0000-0001-5297-9108; Nakaya, Helder/0000-0001-5297-9108; Haks, Marielle/0000-0002-7538-1800; POZZI, GIANNI/0000-0002-9557-4714; MEDAGLINI, DONATA/0000-0003-1729-7325; Lucchesi, Simone/0000-0003-3545-7433; Gonzalez-Dias, Patricia/0000-0002-6434-3841; Ottenhoff, T.H.M./0000-0003-3706-3403; Santoro, Francesco/0000-0003-3052-3518	Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under the VSV-EBOVAC [115842, 116068]; IMI Ebola+ program	This research was supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under the VSV-EBOVAC (grant number 115842) and VSV-EBOPLUS (grant number 116068) projects within the IMI Ebola+ program.	Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924; Chen Y., 2020, BIOCONDUCTOR VERSION; Clarke DK, 2016, VACCINE, V34, P6597, DOI 10.1016/j.vaccine.2016.06.071; Coller BAG, 2017, VACCINE, V35, P4465, DOI 10.1016/j.vaccine.2017.05.097; Davis C, 2020, CLIN INFECT DIS, V71, P2872, DOI 10.1093/cid/ciz1165; Dixon MG, 2014, MMWR-MORBID MORTAL W, V63, P548; Domaszewska T, 2016, TMOD R PACKAGE GEN M; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Halperin SA, 2019, J INFECT DIS, V220, P1127, DOI 10.1093/infdis/jiz241; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Heppner DG, 2017, LANCET INFECT DIS, V17, P854, DOI [10.1016/s1473-3099(17)30313-4, 10.1016/S1473-3099(17)30313-4]; Huttner A, 2018, LANCET INFECT DIS, V18, P738, DOI 10.1016/S1473-3099(18)30165-8; Huttner A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1701; Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; Lun ATL, 2016, METHODS MOL BIOL, V1418, P391, DOI 10.1007/978-1-4939-3578-9_19; Marzi A, 2019, EBIOMEDICINE, V49, P223, DOI 10.1016/j.ebiom.2019.09.055; McElroy AK, 2014, J INFECT DIS, V210, P558, DOI 10.1093/infdis/jiu088; McKay PF, 2019, ELIFE, V8, DOI 10.7554/eLife.46149; Medaglini D, 2018, SEMIN IMMUNOL, V39, P65, DOI 10.1016/j.smim.2018.07.003; Medaglini D, 2017, CURR OPIN VIROL, V23, P88, DOI 10.1016/j.coviro.2017.03.008; Medaglini D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3106; Menicucci AR, 2019, MBIO, V10, DOI 10.1128/mBio.00597-19; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Pejoski D, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0179-4; Perez-Zsolt D, 2019, NAT MICROBIOL, V4, P1558, DOI 10.1038/s41564-019-0453-2; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rechtien A, 2017, CELL REP, V20, P2251, DOI 10.1016/j.celrep.2017.08.023; Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruibal P, 2016, NATURE, V533, P100, DOI 10.1038/nature17949; Santoro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01248; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Scheuermann RH, 2017, EXPERT REV VACCINES, V16, P535, DOI 10.1080/14760584.2017.1322752	36	2	2	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							67	10.3390/vaccines9020067			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6WK	33498214	gold, Green Published			2022-04-29	WOS:000623281700001
J	Caminati, M; Guarnieri, G; Senna, G				Caminati, Marco; Guarnieri, Gabriella; Senna, Gianenrico			Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?	VACCINES			English	Editorial Material							CHILDREN; ALLERGY; ADULTS		[Caminati, Marco; Senna, Gianenrico] Univ Verona, Dept Med, Piazzale LA Scuro 10, I-37134 Verona, Italy; [Caminati, Marco; Senna, Gianenrico] Verona Univ Hosp, Piazzale LA Scuro 10, I-37134 Verona, Italy; [Guarnieri, Gabriella] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Resp Pathophysiol Unit, I-35121 Padua, Italy; [Senna, Gianenrico] Univ Verona, Allergy Unit, I-37134 Verona, Italy; [Senna, Gianenrico] Univ Verona, Asthma Ctr, I-37134 Verona, Italy		Caminati, M (通讯作者)，Univ Verona, Dept Med, Piazzale LA Scuro 10, I-37134 Verona, Italy.; Caminati, M (通讯作者)，Verona Univ Hosp, Piazzale LA Scuro 10, I-37134 Verona, Italy.	marco.caminati@univr.it; gabriella.guarnieri@unipd.it; gianenrico.senna@aovr.veneto.it	Caminati, Marco/AAC-6302-2022	Caminati, Marco/0000-0001-7383-1487			American College of Allergy Asthma and Immunology Releases, REL GUID RISK ALL RE; [Anonymous], UPD COVID 19 PRACT A; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Bonadonna P, 2018, IMMUNOL ALLERGY CLIN, V38, P455, DOI 10.1016/j.iac.2018.04.010; Cabanillas B, 2020, ALLERGY; Chiricozzi A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040769; cura di Giovanni Gallo A., 2009, RAPP ISTISAN, V9, P13; de Silva D, 2014, ALLERGY, V69, P972; Gisondi P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040728; Lega S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020224; MAHASE E, 2020, BMJ-BRIT MED J, V371, DOI DOI 10.1136/BMJ.M4552; Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290; Nawrat A., ALLERGY ISSUE FLAGGE; Nilsson L, 2017, PEDIAT ALLERG IMM-UK, V28, P628, DOI 10.1111/pai.12762; Raine J., 2020, MEDICINES HEALTHCARE; Tanno LK, 2019, CURR OPIN ALLERGY CL, V19, P447, DOI 10.1097/ACI.0000000000000566; Vaccines, SPEC TISS WHEN VACC; Yu JE, 2018, CLIN REV ALLERG IMMU, V54, P366, DOI 10.1007/s12016-015-8503-x; Zanoni G, 2017, CLIN EXP ALLERGY, V47, P593, DOI 10.1111/cea.12882	19	9	9	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							38	10.3390/vaccines9010038			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TI	33440794	Green Published, gold			2022-04-29	WOS:000610804100001
J	Sallam, M; Dababseh, D; Eid, H; Al-Mahzoum, K; Al-Haidar, A; Taim, D; Yaseen, A; Ababneh, NA; Bakri, FG; Mahafzah, A				Sallam, Malik; Dababseh, Deema; Eid, Huda; Al-Mahzoum, Kholoud; Al-Haidar, Ayat; Taim, Duaa; Yaseen, Alaa; Ababneh, Nidaa A.; Bakri, Faris G.; Mahafzah, Azmi			High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries	VACCINES			English	Article						vaccine acceptance; vaccine hesitance; vaccine confidence; anti-vaxxer; conspiracy; COVID-19 vaccine; influenza vaccine	POPULATION; CHALLENGES; ACCEPTANCE; MEASLES; ADULTS	Vaccination could be an effective strategy for slowing the spread of the current coronavirus disease 2019 (COVID-19) pandemic. Vaccine hesitancy could pose a serious problem for COVID-19 prevention, due to the spread of misinformation surrounding the ongoing pandemic. The aim of this study was to assess the attitudes towards the prospective COVID-19 vaccines among the general public in Jordan, Kuwait and other Arab countries. We also aimed to assess the association between COVID-19 vaccine acceptance and conspiracy beliefs. This study used an online survey distributed in December 2020, with items assessing conspiracies regarding COVID-19's origin and vaccination. Attitudes towards COVID-19 vaccines were assessed using the Vaccine Conspiracy Belief Scale (VCBS), with higher scores indicating a greater belief in vaccine conspiracy. A total of 3414 respondents completed the survey, the majority being residents of Jordan (n = 2173, 63.6%), Kuwait (n = 771, 22.6%) and Saudi Arabia (n = 154, 4.5%). The acceptance rates for COVID-19 and influenza vaccines were 29.4% and 30.9%, respectively. Males, respondents with higher educational levels and those with histories of chronic disease had higher rates of COVID-19 vaccine acceptance. Beliefs that COVID-19 vaccines are intended to inject microchips into recipients and that the vaccines are related to infertility were found in 27.7% and 23.4% of respondents, respectively. Higher VCBS scores were found among females, respondents with lower educational levels and respondents relying on social media platforms as the main source of information. The high rates of vaccine hesitancy in Jordan and Kuwait, among other Arab countries, are alarming. They could hinder the proper control of COVID-19 in the region. The harmful effect of COVID-19 misinformation and conspiracy beliefs was manifested in vaccine hesitancy. This may represent a massive obstacle to the successful control of the pandemic. A reliance on social media as the main source of information about COVID-19 vaccines was associated with vaccine hesitancy. This should alert governments, policy makers and the general public to the importance of vigilant fact checking.	[Sallam, Malik; Mahafzah, Azmi] Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan; [Sallam, Malik; Mahafzah, Azmi] Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan; [Sallam, Malik] Lund Univ, Dept Translat Med, Fac Med, S-22184 Malmo, Sweden; [Dababseh, Deema] Jordan Univ Hosp, Dept Dent, Amman 11942, Jordan; [Eid, Huda; Al-Haidar, Ayat; Taim, Duaa] Univ Jordan, Sch Dent, Amman 11942, Jordan; [Al-Mahzoum, Kholoud] Univ Jordan, Sch Med, Amman 11942, Jordan; [Yaseen, Alaa] Univ Jordan, Sch Sci, Amman 11942, Jordan; [Ababneh, Nidaa A.] Univ Jordan, Cell Therapy Ctr CTC, Amman 11942, Jordan; [Bakri, Faris G.] Univ Jordan, Sch Med, Dept Internal Med, Amman 11942, Jordan; [Bakri, Faris G.] Jordan Univ Hosp, Dept Internal Med, Amman 11942, Jordan; [Bakri, Faris G.] Univ Jordan, Infect Dis & Vaccine Ctr, Amman 11942, Jordan		Sallam, M (通讯作者)，Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan.; Sallam, M (通讯作者)，Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan.; Sallam, M (通讯作者)，Lund Univ, Dept Translat Med, Fac Med, S-22184 Malmo, Sweden.	malik.sallam@ju.edu.jo; deemahameddababseh@gmail.com; hda0175066@ju.edu.jo; Klo0180363@ju.edu.jo; aya0160237@ju.edu.jo; duaa.taim@yahoo.com; alaa.yaseen@ju.edu.jo; n.ababneh@ju.edu.jo; Fbakri@ju.edu.jo; mahafzaa@ju.edu.jo	Eid, Huda/ABD-9884-2021; Sallam, Malik/O-5021-2014; Bakri, Faris/M-7862-2016	Sallam, Malik/0000-0002-0165-9670; Bakri, Faris/0000-0001-5447-5245; Dababseh, Deema/0000-0001-7678-302X			Abo SMC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040761; Abu-Gharbieh Eman, 2010, Int J Med Sci, V7, P319; Ahmed W, 2020, J MED INTERNET RES, V22, DOI 10.2196/19458; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Aschwanden C, 2020, NATURE, V587, P26, DOI 10.1038/d41586-020-02948-4; Al Vwaidy ST, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040661; Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Bednarczyk RA, 2015, VACCINE, V33, P1659, DOI 10.1016/j.vaccine.2015.02.033; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Bhopal S, 2021, ARCH DIS CHILD, V106, P113, DOI 10.1136/archdischild-2020-318988; Billah MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242128; Blaskiewicz R., 2013, MED WRITING, V22, P259, DOI [10.1179/2047480613Z.000000000142, DOI 10.1179/2047480613Z.000000000142]; Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309; Crescitelli MED, 2020, PUBLIC HEALTH, V180, P38, DOI 10.1016/j.puhe.2019.10.027; Dabak S.V., 2020, COVID VACCINATION LO; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Earnshaw VA, 2020, TRANSL BEHAV MED, V10, P850, DOI 10.1093/tbm/ibaa090; Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x; European Centre for Disease Prevention and Control, THREAT ASS BRIEF RAP; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hornsey MJ, 2020, SOC SCI MED, V255, DOI 10.1016/j.socscimed.2020.113019; Huang C., 2020, Lancet, V395; Jahanshahi AA, 2020, BRAIN BEHAV IMMUN, V87, P124, DOI 10.1016/j.bbi.2020.04.081; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Khan YH, 2020, AM J TROP MED HYG, V103, P603, DOI 10.4269/ajtmh.20-0654; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4347; Malpass D., CONFRONTING EC FINAN; Maurer J, 2010, PREV MED, V51, P185, DOI 10.1016/j.ypmed.2010.05.008; Morgantini LA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238217; Mukaetova-Ladinska EB, 2021, EUR ARCH PSY CLIN N, V271, P235, DOI 10.1007/s00406-020-01210-2; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Oliver JE, 2014, JAMA INTERN MED, V174, P817, DOI 10.1001/jamainternmed.2014.190; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243264; Sallam M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144915; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shahsavari S, 2020, J COMPUT SOC SCI, V3, P279, DOI 10.1007/s42001-020-00086-5; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Uscinski J.E., 2020, HARVARD KENNEDY SCH, V1, DOI 10.37016/mr-2020-015; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; World Health Organization, DRAFT LANDSC COVID 1; Worldometer, COVID 19 COR PAND; Xiong JQ, 2020, J AFFECT DISORDERS, V277, P55, DOI 10.1016/j.jad.2020.08.001; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017	78	158	161	18	57	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							42	10.3390/vaccines9010042			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PW6VA	33445581	Green Published, gold	Y	N	2022-04-29	WOS:000610808600001
J	Yoda, T; Katsuyama, H				Yoda, Takeshi; Katsuyama, Hironobu			Willingness to Receive COVID-19 Vaccination in Japan	VACCINES			English	Article						COVID-19; vaccine; willingness; hesitancy; Japan	HESITANCY; EFFICACY	In the wake of the COVID-19 pandemic, vaccines are being developed by many countries for the safety of their population. However, people of various nations have revealed hesitancy towards being vaccinated, citing reasons such as side effects, safety, a lack of trust in vaccine effectiveness, etc. This study aimed to explore the willingness of people in Japan to be vaccinated or not be vaccinated and the reasons for either decision. A sample of 1100 respondents was drawn from an internet research panel, and a questionnaire survey was administered to evaluate their willingness to be vaccinated by gender, age group, place of living, and underlying illness history. After using descriptive statistics and the chi-squared test to evaluate categorical variables, 65.7% of the participants indicated a willingness to be vaccinated; among them were older age groups, those in rural areas, and those with underlying medical conditions. In addition, males showed less hesitancy towards being vaccinated. Although selectivity bias exists, this study is the first to examine the willingness of Japanese people to be vaccinated. Since vaccine hesitancy and refusal ratio were found to be higher in Japan than in other countries, policy efforts are needed to make the country's vaccination program viable.	[Yoda, Takeshi; Katsuyama, Hironobu] Kawasaki Med Sch, Dept Publ Hlth, Kurashiki, Okayama 7010192, Japan; [Yoda, Takeshi] Kawasaki Univ Med Welf, Dept Hlth & Sports Sci, Kurashiki, Okayama 7010193, Japan		Yoda, T (通讯作者)，Kawasaki Med Sch, Dept Publ Hlth, Kurashiki, Okayama 7010192, Japan.; Yoda, T (通讯作者)，Kawasaki Univ Med Welf, Dept Hlth & Sports Sci, Kurashiki, Okayama 7010193, Japan.	tyoda@med.kawasaki-m.ac.jp; katsu@med.kawasaki-m.ac.jp	Yoda, Takeshi/AAW-5384-2021	Yoda, Takeshi/0000-0001-6950-5056; Katsuyama, Hironobu/0000-0001-7387-3089			Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Bucci E, 2020, LANCET, V396, pE53, DOI 10.1016/S0140-6736(20)31960-7; Caddy S, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3270; Darden PM, 2013, PEDIATRICS, V131, P645, DOI 10.1542/peds.2012-2384; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Eskew EA, 2020, LANCET PLANET HEALTH, V4, pE215, DOI 10.1016/S2542-5196(20)30123-6; Hiraishi K., DISGUST SENSITIVITY; Hirota Y, 2008, VACCINE, V26, P6451, DOI 10.1016/j.vaccine.2008.06.042; HIROTA Y, 1994, LANCET, V344, P408, DOI 10.1016/S0140-6736(94)91436-2; Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310; Muto K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234292; Nawa N, 2016, VACCINE, V34, P3207, DOI 10.1016/j.vaccine.2016.01.008; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sotiriadis A, 2012, ARCH GYNECOL OBSTET, V285, P1719, DOI 10.1007/s00404-011-2208-z; Statistics Bureau of Japan, 2017, POPULATION HOUSEHOLD, P60; Taherdoost H, 2017, INT J EC MANAG SYST, V2, P3; Thomson A, 2016, VACCINE, V34, P1989, DOI 10.1016/j.vaccine.2015.12.049; Wong MCS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071827; Yagi A, 2018, HUM VACC IMMUNOTHER, V14, P2497, DOI 10.1080/21645515.2018.1480240; Zhan SY, 2020, EMERG MICROBES INFEC, V9, P534, DOI 10.1080/22221751.2020.1732232; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	24	83	85	10	27	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							48	10.3390/vaccines9010048			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7AG	33466675	gold, Green Published	Y	N	2022-04-29	WOS:000610822400001
J	Bagella, CF; Corda, DG; Zara, P; Elia, AE; Ruiu, E; Sechi, E; Solla, P				Bagella, Caterina Francesca; Corda, Davide G.; Zara, Pietro; Elia, Antonio Emanuele; Ruiu, Elisa; Sechi, Elia; Solla, Paolo			Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination	VACCINES			English	Article						chronic inflammatory demyelinating polyneuropathy; Guillain-Barre syndrome; bifacial weakness; COVID-19; SARS-CoV-2 vaccine	GUILLAIN-BARRE-SYNDROME; COVID-19	Recently several patients, who developed Guillain-Barre syndrome characterized by prominent bifacial weakness after ChAdOx1 nCoV-19 vaccination, were described from different centers. We recently observed a patient who developed a similar syndrome, later in the follow up he showed worsening of the neuropathy two months after the initial presentation. Repeat EMG showed reduced nerve sensory and motor conduction velocities of both upper and lower limbs, and a diagnosis of chronic inflammatory demyelinating polyneuropathy (typical CIDP) was made according to established criteria. Our report expands on the possible outcomes in patients who develop Guillain-Barre syndrome after COVID-19 vaccinations and suggest that close monitoring after the acute phase is needed in these patients to exclude a chronic evolution of the disease, which has important implications for long-term treatment.	[Bagella, Caterina Francesca; Corda, Davide G.; Zara, Pietro; Ruiu, Elisa; Sechi, Elia; Solla, Paolo] Univ Sassari, Dept Med Surg & Expt Sci, Unit Neurol, Azienda Osped Univ Sassari, I-07100 Sassari, Italy; [Elia, Antonio Emanuele] Fdn IRCCS Ist Neurol Carlo Besta, Dept Clin Neurosci, Parkinson & Movement Disorders Unit, I-20133 Milan, Italy		Bagella, CF; Corda, DG (通讯作者)，Univ Sassari, Dept Med Surg & Expt Sci, Unit Neurol, Azienda Osped Univ Sassari, I-07100 Sassari, Italy.	caterina.bagella@aousassari.it; dvcorda@tiscali.it; pietrozara93@gmail.com; antonio.elia@istituto-besta.it; elisa.ruiu@tiscali.it; eliasechi87@gmail.com; paolo.solla@aousassari.it					Allen CM, 2021, ANN NEUROL, V90, P315, DOI 10.1002/ana.26144; Bonifacio GB, 2022, J NEUROL NEUROSUR PS, V93, P341, DOI 10.1136/jnnp-2021-327027; Doneddu PE, 2020, EUR J NEUROL, V27, P136, DOI 10.1111/ene.14044; Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960; Gable Karissa L, 2013, J Clin Neuromuscul Dis, V14, P117, DOI 10.1097/CND.0b013e318285256b; Caamano DSJ, 2020, J CLIN NEUROSCI, V77, P230, DOI 10.1016/j.jocn.2020.05.016; Leonhard SE, 2019, NAT REV NEUROL, V15, P671, DOI 10.1038/s41582-019-0250-9; Lunn Michael P, 2021, Brain, V144, P357, DOI 10.1093/brain/awaa444; Maramattom BV, 2021, ANN NEUROL, V90, P312, DOI 10.1002/ana.26143; Mathew T, 2019, MUSCLE NERVE, V59, pE48, DOI 10.1002/mus.26477; McKean N, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-244125; Nasuelli NA, 2021, NEUROL SCI, V42, P4747, DOI 10.1007/s10072-021-05467-w; Oo WM, 2021, J NEUROIMMUNOL, V360, DOI 10.1016/j.jneuroim.2021.577719; Palaiodimou L, 2021, EUR J NEUROL, V28, P3517, DOI 10.1111/ene.14860; Pascual-Goni E, 2019, CURR OPIN NEUROL, V32, P651, DOI 10.1097/WCO.0000000000000725; Pavord S, 2021, NEW ENGL J MED, V385, P1680, DOI 10.1056/NEJMoa2109908; Pegat A, 2022, ANN NEUROL, V91, P162, DOI 10.1002/ana.26258; Principi N, 2019, VACCINE, V37, P5544, DOI 10.1016/j.vaccine.2018.05.119; Ruts L, 2010, NEUROLOGY, V74, P1680, DOI 10.1212/WNL.0b013e3181e07d14; Shui IM, 2012, NEUROEPIDEMIOLOGY, V39, P109, DOI 10.1159/000339248; Van den Bergh PYK, 2021, J PERIPHER NERV SYST, V26, P242, DOI 10.1111/jns.12455; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138	23	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1502	10.3390/vaccines9121502			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1IL	34960248	gold, Green Published			2022-04-29	WOS:000737414000001
J	Hara, M; Ishibashi, M; Nakane, A; Nakano, T; Hirota, Y				Hara, Megumi; Ishibashi, Motoki; Nakane, Atsushi; Nakano, Takashi; Hirota, Yoshio			Differences in COVID-19 Vaccine Acceptance, Hesitancy, and Confidence between Healthcare Workers and the General Population in Japan	VACCINES			English	Article						COVID-19 vaccine; vaccine hesitancy; vaccine acceptance; health literacy; immunization		Little is known about the differences in coronavirus disease (COVID-19) vaccine acceptance and hesitancy between the general population and healthcare workers in Japan. To compare these differences, a nationwide web-based cross-sectional survey was conducted on 19 January 2021, shortly before the initiation of COVID-19 vaccinations in Japan. A total of 6180 men and women aged 20-69 years and 1030 healthcare workers aged 20-69 years were enrolled. Data on COVID-19 vaccine acceptance, basic characteristics, including socioeconomic factors, and confidence in immunization in general were collected. COVID-19 vaccine acceptance was also evaluated under hypothetical vaccine effectiveness and adverse event frequencies. Factors associated with vaccine hesitancy were examined using multinomial logistic regression analysis. The COVID-19 vaccine acceptance rate was 48.6% among the general population and was lower among nurses (45.5%) and medical clerks (40.7%). Women and young adults had significantly higher COVID-19 vaccine hesitancy odds ratios, and current smokers had significantly lower odds ratios. The frequency of adverse events was a COVID-19 vaccine hesitancy factor. Even if these factors were adjusted, COVID-19 vaccine hesitancy among nurses was 1.4 times higher than that among the general population. Thus, interventions to improve health literacy and vaccine hesitancy among the general population and healthcare workers, especially nurses, are needed.	[Hara, Megumi] Saga Univ, Fac Med, Dept Prevent Med, Saga 8498501, Japan; [Ishibashi, Motoki; Nakane, Atsushi; Hirota, Yoshio] Med Co LTA, Clin Epidemiol Res Ctr, Fukuoka 8130017, Japan; [Nakano, Takashi] Kawasaki Med Sch, Dept Pediat, Okayama 7010192, Japan		Hara, M (通讯作者)，Saga Univ, Fac Med, Dept Prevent Med, Saga 8498501, Japan.	harameg@cc.saga-u.ac.jp; ndhkk029@ybb.ne.jp	Hara, Masayuki/AAH-4361-2019	Hara, Megumi/0000-0002-8708-3237	Ministry of Health, Labor and Welfare, JapanMinistry of Health, Labour and Welfare, Japan [20HA2001]	This study was funded by a research grant for Research on Emerging and Re-emerging Infectious Diseases, Health and Labour Science Research Grants from the Ministry of Health, Labor and Welfare, Japan (20HA2001). The funding body had no role in the design of the study, collection, analysis, and interpretation of data, or in writing the manuscript.	Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Kadoya Y, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094864; Kawata K, 2021, SSM-POPUL HLTH, V15, DOI 10.1016/j.ssmph.2021.100902; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Larson H., 2018, STATE VACCINE CONFID, P1; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Luo CX, 2021, AM J INFECT CONTROL, V49, P1295, DOI 10.1016/j.ajic.2021.06.020; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nomura S, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100223; Okubo R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060662; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Takamatsu A, 2021, INFECT CONT HOSP EP, DOI 10.1017/ice.2021.325; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	25	3	3	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1389	10.3390/vaccines9121389			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0BG	34960135	Green Published, gold			2022-04-29	WOS:000737327600001
J	Kamolratanakul, S; Pitisuttithum, P				Kamolratanakul, Supitcha; Pitisuttithum, Punnee			Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer	VACCINES			English	Article						human papillomavirus (HPV); HPV vaccine; cervical cancer; other HPV-related cancers; vaccine efficacy; vaccine effectiveness	(HPV)-16/18 AS04-ADJUVANTED VACCINE; ORAL HUMAN-PAPILLOMAVIRUS; QUADRIVALENT HPV VACCINE; 18 RECOMBINANT VACCINE; TERM-FOLLOW-UP; UNITED-STATES; GENITAL WARTS; YOUNG-WOMEN; INTRAEPITHELIAL NEOPLASIA; PARTICLE VACCINE	Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. However, cervical cancer remains one of the most common cancers in women, especially in developing countries. Three HPV vaccines have been licensed: bivalent (Cervarix, GSK, Rixensart, Belgium), quadrivalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)), and nonavalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)). The current HPV vaccine recommendations apply to 9 years old and above through the age of 26 years and adults aged 27-45 years who might be at risk of new HPV infection and benefit from vaccination. The primary target population for HPV vaccination recommended by the WHO is girls aged 9-14 years, prior to their becoming sexually active, to undergo a two-dose schedule and girls >= 15 years of age, to undergo a three-dose schedule. Safety data for HPV vaccines have indicated that they are safe. The most common adverse side-effect was local symptoms. HPV vaccines are highly immunogenic. The efficacy and effectiveness of vaccines has been remarkably high among young women who were HPV seronegative before vaccination. Vaccine efficacy was lower among women regardless of HPV DNA when vaccinated and among adult women. Comparisons of the efficacy of bivalent, quadrivalent, and nonavalent vaccines against HPV 16/18 showed that they are similar. However, the nonavalent vaccine can provide additional protection against HPV 31/33/45/52/58. In a real-world setting, the notable decrease of HPV 6/11/16/18 among vaccinated women compared with unvaccinated women shows the vaccine to be highly effective. Moreover, the direct effect of the nonavalent vaccine with the cross-protection of bivalent and quadrivalent vaccines results in the reduction of HPV 6/11/16/18/31/33/45/52/58. HPV vaccination has been shown to provide herd protection as well. Two-dose HPV vaccine schedules showed no difference in seroconversion from three-dose schedules. However, the use of a single-dose HPV vaccination schedule remains controversial. For males, the quadrivalent HPV vaccine possibly reduces the incidence of external genital lesions and persistent infection with HPV 6/11/16/18. Evidence regarding the efficacy and risk of HPV vaccination and HIV infection remains limited. HPV vaccination has been shown to be highly effective against oral HPV type 16/18 infection, with a significant percentage of participants developing IgG antibodies in the oral fluid post vaccination. However, the vaccines' effectiveness in reducing the incidence of and mortality rates from HPV-related head and neck cancers should be observed in the long term. In anal infections and anal intraepithelial neoplasia, the vaccines demonstrate high efficacy. While HPV vaccines are very effective, screening for related cancers, as per guidelines, is still recommended.	[Kamolratanakul, Supitcha; Pitisuttithum, Punnee] Mahidol Univ, Fac Trop Med, Vaccine Trial Ctr, 420-6 Ratchawithi Rd, Bangkok 10400, Thailand		Pitisuttithum, P (通讯作者)，Mahidol Univ, Fac Trop Med, Vaccine Trial Ctr, 420-6 Ratchawithi Rd, Bangkok 10400, Thailand.	punnee.pit@mahidol.ac.th		Kamolratanakul, Supitcha/0000-0002-0428-2354			Alphs HH, 2008, P NATL ACAD SCI USA, V105, P5850, DOI 10.1073/pnas.0800868105; Angelo MG, 2014, PHARMACOEPIDEM DR S, V23, P456, DOI 10.1002/pds.3593; [Anonymous], HPV VACCINE SAFETY E; [Anonymous], GLOBAL STRATEGY ACCE; [Anonymous], WEEKLY EPIDEMIOLOGIC; [Anonymous], Working Group on potential contribution of Human Papillomavirus (HPV) vaccines and immunization towards cervical cancer elimination Strategic Advisory Group of Experts (SAGE) on Immunizationa; Araldi RP, 2018, BIOMED PHARMACOTHER, V106, P1537, DOI 10.1016/j.biopha.2018.06.149; Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Baandrup L, 2013, SEX TRANSM DIS, V40, P130, DOI 10.1097/OLQ.0b013e31827bd66b; Baldur-Felskov B, 2014, CANCER CAUSE CONTROL, V25, P915, DOI 10.1007/s10552-014-0392-4; Baldur-Felskov B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt460; Basu P, 2021, LANCET ONCOL, V22, P1518, DOI 10.1016/S1470-2045(21)00453-8; Bavinck JNB, 2000, BRIT J DERMATOL, V142, P103, DOI 10.1046/j.1365-2133.2000.03248.x; Bhuyan PK, 2021, HUM VACC IMMUNOTHER, V17, P1288, DOI 10.1080/21645515.2020.1823778; Block SL, 2006, PEDIATRICS, V118, P2135, DOI 10.1542/peds.2006-0461; Bogaards JA, 2019, J INFECT DIS, V220, P1141, DOI 10.1093/infdis/jiz280; Bonde U, 2016, HUM VACC IMMUNOTHER, V12, P1960, DOI 10.1080/21645515.2016.1160178; Brotherton JML, 2015, PAPILLOMAVIRUS RES, V1, P59, DOI 10.1016/j.pvr.2015.05.005; Bruggink SC, 2012, J CLIN VIROL, V55, P250, DOI 10.1016/j.jcv.2012.07.014; Canadian Immunization C., 2014, CAN COMMUN DIS REP, V40, P152, DOI [10.14745/ccdr.v40i08a02, DOI 10.14745/CCDR.V40I08A02]; Castellsague X, 2015, VACCINE, V33, P6892, DOI 10.1016/j.vaccine.2015.06.088; Castellsague X, 2011, BRIT J CANCER, V105, P28, DOI 10.1038/bjc.2011.185; Chaturvedi AK, 2018, J CLIN ONCOL, V36, P262, DOI 10.1200/JCO.2017.75.0141; Chow EPF, 2015, SEX TRANSM INFECT, V91, P214, DOI 10.1136/sextrans-2014-051813; Chu NR, 2000, CELL STRESS CHAPERON, V5, P401, DOI 10.1379/1466-1268(2000)005<0401:IOAHPT>2.0.CO;2; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Diana G, 2021, ORAL ONCOL, V115, DOI 10.1016/j.oraloncology.2020.105168; Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625; Donahue JG, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1808; Donegan K, 2013, VACCINE, V31, P4961, DOI 10.1016/j.vaccine.2013.08.024; Donken R, 2018, J INFECT DIS, V217, P1579, DOI 10.1093/infdis/jiy067; Dorta-Estremera S, 2018, CANCER RES, V78, P5327, DOI 10.1158/0008-5472.CAN-18-0892; Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4; Edelstein ZR, 2011, J INFECT DIS, V204, P209, DOI 10.1093/infdis/jir242; Einstein MH, 2014, HUM VACC IMMUNOTHER, V10, P3435, DOI 10.4161/hv.36121; Garland SM, 2018, J INFECT DIS, V218, P95, DOI 10.1093/infdis/jiy133; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Gee J, 2011, VACCINE, V29, P8279, DOI 10.1016/j.vaccine.2011.08.106; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z; Herweijer E, 2016, INT J CANCER, V138, P2867, DOI 10.1002/ijc.30035; Hillman RJ, 2012, CLIN VACCINE IMMUNOL, V19, P261, DOI 10.1128/CVI.05208-11; Hirth JM, 2017, VACCINE, V35, P3446, DOI 10.1016/j.vaccine.2017.05.025; Hu YM, 2020, ASIA-PAC J CLIN ONCO, V16, P392, DOI 10.1111/ajco.13398; Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4; Iannacone MR, 2014, INT J CANCER, V134, P2231, DOI 10.1002/ijc.28552; Iannacone MR, 2013, J INVEST DERMATOL, V133, P1512, DOI 10.1038/jid.2012.478; Ikeda Y, 2019, JPN J CLIN ONCOL, V49, P877, DOI 10.1093/jjco/hyz095; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; King EM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157976; Kjaer SK, 2021, JNCI-J NATL CANCER I, V113, P1329, DOI 10.1093/jnci/djab080; Kreimer AR, 2020, JNCI-J NATL CANCER I, V112, DOI 10.1093/jnci/djaa011; Kudo R, 2019, J INFECT DIS, V219, P382, DOI 10.1093/infdis/jiy516; Lehtinen M, 2020, INT J CANCER, V147, P170, DOI 10.1002/ijc.32791; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Lin CQ, 2018, LANCET INFECT DIS, V18, P198, DOI [10.1016/s1473-3099(17)30653-9, 10.1016/S1473-3099(17)30653-9]; Lukacs A, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08753-y; Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1; Ruiz-Sternberg AM, 2018, PAPILLOMAVIRUS RES, V5, P63, DOI 10.1016/j.pvr.2017.12.004; Markowitz LE, 2013, J INFECT DIS, V208, P385, DOI 10.1093/infdis/jit192; Martinez-Lavin M, 2017, CLIN RHEUMATOL, V36, P2397, DOI 10.1007/s10067-017-3782-7; McCormack PL, 2011, BIODRUGS, V25, P339, DOI 10.2165/11205060-000000000-00000; Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI [10.15585/mmwr.mm6832a3, 10.1111/ajt.15633]; Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030; Mix JM, 2021, CANCER EPIDEM BIOMAR, V30, P30, DOI 10.1158/1055-9965.EPI-20-0846; Mooij SH, 2013, AIDS, V27, P2117, DOI 10.1097/QAD.0b013e328362395c; Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7; Naud PS, 2014, HUM VACC IMMUNOTHER, V10, P2147, DOI 10.4161/hv.29532; Oliver SE, 2017, J INFECT DIS, V216, P594, DOI 10.1093/infdis/jix244; Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Patel AS, 2008, J INVEST DERMATOL, V128, P2888, DOI 10.1038/jid.2008.162; Pinto LA, 2018, VACCINE, V36, P4792, DOI 10.1016/j.vaccine.2017.11.089; Pinto LA, 2016, J INFECT DIS, V214, P1276, DOI 10.1093/infdis/jiw359; Porras C, 2020, LANCET ONCOL, V21, P1643, DOI 10.1016/S1470-2045(20)30524-6; Public Health England (PHE), PROD EST SIZ LGB POP; Radley D, 2016, HUM VACC IMMUNOTHER, V12, P768, DOI 10.1080/21645515.2015.1088616; Regional Office for South-East Asia, 2019, ACC EL CERV CANC GLO; Rosenblum HG, 2021, MMWR-MORBID MORTAL W, V70, P415, DOI 10.15585/mmwr.mm7012a2externalicon; Rosillon D, 2020, PHARMACOEPIDEM DR S, V29, P1159, DOI 10.1002/pds.5063; Safaeian M, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx158; Safaeian M, 2013, CANCER PREV RES, V6, P1242, DOI 10.1158/1940-6207.CAPR-13-0203; Schellenbacher C, 2013, J INVEST DERMATOL, V133, P2706, DOI 10.1038/jid.2013.253; Shimabukuro TT, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1791; Signorelli C, 2017, EPIDEMIOL INFECT, V145, P1962, DOI [10.1017/S0950268817000747, 10.1017/s0950268817000747]; Spinner C, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1902; Stanley MA, 2014, EXPERT REV VACCINES, V13, P1027, DOI 10.1586/14760584.2014.935767; Steinau M, 2013, J LOW GENIT TRACT DI, V17, P397, DOI 10.1097/LGT.0b013e31827ed372; Struijk L, 2006, CANCER EPIDEM BIOMAR, V15, P529, DOI 10.1158/1055-9965.EPI-05-0747; Swedish KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093393; Swedish KA, 2012, CLIN INFECT DIS, V54, P891, DOI 10.1093/cid/cir1036; Taylor S, 2016, HUM VACC IMMUNOTHER, V12, P1943, DOI 10.1080/21645515.2016.1151598; Toh ZQ, 2019, INFECT DRUG RESIST, V12, P1951, DOI 10.2147/IDR.S178381; van Aar F, 2013, AIDS, V27, P2921, DOI 10.1097/01.aids.0000432541.67409.3c; Verdoodt F, 2020, CLIN INFECT DIS, V70, P608, DOI 10.1093/cid/ciz239; Vermaelen K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00008; Verstraeten T, 2008, VACCINE, V26, P6630, DOI 10.1016/j.vaccine.2008.09.049; Villa A, 2020, J AM DENT ASSOC, V151, P245, DOI 10.1016/j.adaj.2019.10.010; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Vinzon SE, 2015, HUM VACC IMMUNOTHER, V11, P353, DOI 10.4161/21645515.2014.983858; Vinzon SE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003924; Wei FX, 2021, LANCET HIV, V8, pE531, DOI 10.1016/S2352-3018(21)00108-9; Willame C, 2016, HUM VACC IMMUNOTHER, V12, P2862, DOI 10.1080/21645515.2016.1199308; Yeo-Teh NSL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061706; Yih WK, 2016, VACCINE, V34, P172, DOI 10.1016/j.vaccine.2015.09.087; You EL, 2019, CURR ONCOL, V26, P119, DOI 10.3747/co.26.4819; Zhang Q, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11550-w; Zhang XX, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10907-5; Zhou YG, 2021, EUR J CLIN MICROBIOL, V40, P1357, DOI 10.1007/s10096-021-04229-y; Zizza A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83727-7	112	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1413	10.3390/vaccines9121413			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0FB	34960159	gold, Green Published			2022-04-29	WOS:000737337500001
J	Papadopoli, R; De Sarro, C; Palleria, C; Gallelli, L; Pileggi, C; De Sarro, G				Papadopoli, Rosa; De Sarro, Caterina; Palleria, Caterina; Gallelli, Luca; Pileggi, Claudia; De Sarro, Giovambattista			Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population	VACCINES			English	Article						anti-spike antibodies; messenger RNA vaccine; neutralizing antibody response; SARS-CoV-2; seroconversion	SEX-DIFFERENCES	Background: This study aims to investigate the extent of the BNT162b2 mRNA vaccine-induced antibodies against SARS-CoV-2 in a large cohort of Italian subjects belonging to the early vaccinated cohort in Italy. Methods: A prospective study was conducted between December 2020 and May 2021. Three blood samples were collected for each participant: one at the time of the first vaccine dose (T0), one at the time of the second vaccine dose, (T1) and the third 30 days after this last dose (T2). Results: We enrolled 2591 fully vaccinated subjects; 16.5% were frail subjects, and 9.8% were over 80 years old. Overall, 98.1% of subjects were seropositive when tested at T2, and 76.3% developed an anti-S IgG titer >= 4160 AU/mL, which is adequate to develop viral neutralizing antibodies. Seronegative subjects at T1 were more likely to remain seronegative at T2 or to develop a low-intermediate anti-S IgG titer (51-4159 AU/mL). Conclusions: In summary, vaccination leads to detectable anti-S IgG titer in nearly all vaccine recipients. Stratification of the seroconversion level could be useful to promptly identify high-risk groups who may not develop a viral neutralizing response, even in the presence of seroconversion, and therefore may remain at higher risk of infection, despite vaccination.	[Papadopoli, Rosa; De Sarro, Caterina; Palleria, Caterina; Gallelli, Luca; Pileggi, Claudia; De Sarro, Giovambattista] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Campus Salvatore Venuta, I-88100 Catanzaro, Italy		Pileggi, C (通讯作者)，Univ Catanzaro Magna Graecia, Dept Hlth Sci, Campus Salvatore Venuta, I-88100 Catanzaro, Italy.	rosapapadopoli@unicz.it; caterina.desarro@studenti.unicz.it; palleria@unicz.it; gallelli@unicz.it; claudiapileggi@unicz.it; desarro@unicz.it	PILEGGI, Claudia/AGU-6397-2022	PILEGGI, Claudia/0000-0002-6288-5540; De Sarro, Caterina/0000-0002-3596-0090			Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Adam L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040365; Addeo A, 2021, CANCER CELL, V39, P1091, DOI 10.1016/j.ccell.2021.06.009; Amodio E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070714; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; [Anonymous], 2001, MMWR Recomm Rep, V50, P1; Attias P, 2021, KIDNEY INT, V99, P1490, DOI [10.1016/j.kint.2021.04.009, 10.1016/j.klint.2021.04.009]; Bosaeed M, 2018, HUM VACC IMMUNOTHER, V14, P1311, DOI 10.1080/21645515.2018.1445446; Duysburgh E, 2021, LANCET INFECT DIS, V21, P163, DOI 10.1016/S1473-3099(20)30943-9; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Eyre DW, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.041; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Fraley E, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02055-9; Gallelli L, 2020, J CLIN PHARMACOL, V60, P815, DOI 10.1002/jcph.1644; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Hanlon P, 2018, LANCET PUBLIC HEALTH, V3, pE323, DOI 10.1016/S2468-2667(18)30091-4; Horowitz RI, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109851; Johansson MA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35057; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Klein SL, 2014, J INFECT DIS, V209, pS114, DOI 10.1093/infdis/jiu066; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Morgan R, 2019, CURR OPIN VIROL, V35, P35, DOI 10.1016/j.coviro.2019.02.009; Napolitano F, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094761; Oran DP, 2021, ANN INTERN MED, V174, P655, DOI 10.7326/M20-6976; Papadopoli R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020227; Pellini R, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100928; Pileggi C, 2017, VACCINE, V35, P6302, DOI 10.1016/j.vaccine.2017.09.076; Pimpinelli F, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01090-6; Pinto LA, 2018, VACCINE, V36, P4792, DOI 10.1016/j.vaccine.2017.11.089; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Salzberger B, 2021, INFECTION, V49, P233, DOI 10.1007/s15010-020-01531-3; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Vassallo Amy, 2021, Front Glob Womens Health, V2, P761511, DOI 10.3389/fgwh.2021.761511; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x; Yang X., 2020, Lancet Respir Med, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	40	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1494	10.3390/vaccines9121494			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1HU	34960240	gold, Green Published			2022-04-29	WOS:000737412300001
J	Shi, J; Jin, XX; Ding, Y; Liu, XT; Shen, AR; Wu, YD; Peng, M; Shen, CL				Shi, Juan; Jin, Xiaoxiao; Ding, Yan; Liu, Xiaotao; Shen, Anran; Wu, Yandan; Peng, Min; Shen, Chuanlai			Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice	VACCINES			English	Article						SARS-CoV-2; variants; spike protein; receptor-binding domain; immunogenicity; neutralizing antibodies	NEUTRALIZATION; CONVALESCENT; MUTATIONS; B.1.1.7; VACCINE; P.1	Multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this study, nine receptor-binding domain (RBD) proteins of the SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1 lineages) were constructed and fused with the Fc fragment of human IgG (RBD-Fc). These RBD-Fc proteins contained single or multiple amino acid substitutions at prevalent mutation points of spike protein, which enabled them to bind strongly to the polyclonal antibodies specific for wild-type RBD and to the recombinant human ACE2 protein. In the BALB/c, mice were immunized with the wild-type RBD-Fc protein first and boosted twice with the indicated mutant RBD-Fc proteins later. All mutant RBD-Fc proteins elicited high-level IgG antibodies and cross-neutralizing antibodies. The RBD-Fc proteins with multiple substitutions tended to induce higher antibody titers and neutralizing-antibody titers than the single-mutant RBD-Fc proteins. Meanwhile, both wild-type RBD-Fc protein and mutant RBD-Fc proteins induced significantly decreased neutralization capacity to the pseudovirus of B.1.351 and P.1 lineages than to the wild-type one. These data will facilitate the design and development of RBD-based subunit vaccines against SARS-COV-2 and its variants.	[Shi, Juan; Jin, Xiaoxiao; Ding, Yan; Liu, Xiaotao; Wu, Yandan; Peng, Min; Shen, Chuanlai] Southeast Univ, Sch Med, Dept Microbiol & Immunol, Nanjing 210009, Peoples R China; [Shen, Anran] Southeast Univ, Zhongda Hosp, Sch Med, Inst Nephrol, Nanjing 210009, Peoples R China; [Shen, Chuanlai] Southeast Univ, Zhongda Hosp, Dept Crit Care Med, Jiangsu Prov Key Lab Crit Care Med,Med Sch, Nanjing 210009, Peoples R China		Shen, CL (通讯作者)，Southeast Univ, Sch Med, Dept Microbiol & Immunol, Nanjing 210009, Peoples R China.; Shen, CL (通讯作者)，Southeast Univ, Zhongda Hosp, Dept Crit Care Med, Jiangsu Prov Key Lab Crit Care Med,Med Sch, Nanjing 210009, Peoples R China.	230198727@seu.edu.cn; xiaoxiaojin@seu.edu.cn; 230189322@seu.edu.cn; 220193625@seu.edu.cn; 220193648@seu.edu.cn; 220203902@seu.edu.cn; pengminseu@163.com; chuanlaishen@seu.edu.cn		Shi, Juan/0000-0002-8795-4709; shen, chuanlai/0000-0002-3748-3742	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82041006]; Jiangsu Provincial Science and Technology Fund of China [BE2017714]	FundingThis work was supported by the National Nature Science Foundation of China (82041006) and partially supported by the Jiangsu Provincial Science and Technology Fund of China (BE2017714). The sponsors had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to submit the article for publication.	Amanat F, 2021, MBIO, V12, DOI 10.1128/mBio.01002-21; Benton DJ, 2020, NATURE, V588, DOI 10.1038/s41586-020-2772-0; Boehm E, 2021, CLIN MICROBIOL INFEC, V27, P1109, DOI 10.1016/j.cmi.2021.05.022; Cascella M., 2021, FEATURES EVALUATION; Cele S, 2021, NATURE, V593, P142, DOI 10.1038/s41586-021-03471-w; Chakraborty S, 2021, BIOCHEM BIOPH RES CO, V534, P374, DOI 10.1016/j.bbrc.2020.11.075; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Galloway SE, 2021, MMWR-MORBID MORTAL W, V70, P95, DOI [10.15585/mmwr.mm7003e2externalicon, 10.15585/mmwr.mm7003e2]; Gidari A, 2021, J INFECTION, V83, P467, DOI 10.1016/j.jinf.2021.07.019; Gu HJ, 2020, SCIENCE, V369, P1603, DOI 10.1126/science.abc4730; Han YQ, 2021, COMPUT STRUCT BIOTEC, V19, P4184, DOI 10.1016/j.csbj.2021.07.026; Laffeber C, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.167058; Li LF, 2021, HUM VACC IMMUNOTHER, V17, P644, DOI 10.1080/21645515.2020.1804777; Liu C, 2021, CELL, V184, P4220, DOI 10.1016/j.cell.2021.06.020; Liu ZZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00402-5; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Nguyen HT, 2021, J VIROL, V95, DOI 10.1128/JVI.02304-20; Russell RL, 2021, CAN J MICROBIOL, V67, P189, DOI 10.1139/cjm-2020-0465; Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.02.18.431897; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Ura T, 2021, VACCINE, V39, P197, DOI 10.1016/j.vaccine.2020.11.054; Vidal SJ, 2021, J VIROL, V95, DOI 10.1128/JVI.00404-21; Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang PF, 2021, CELL HOST MICROBE, V29, P747, DOI 10.1016/j.chom.2021.04.007; World Health Organization, TRACK SARS COV 2 VAR; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8	30	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1383	10.3390/vaccines9121383			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YF9BD	34960131	Green Published, gold			2022-04-29	WOS:000742094200001
J	Barrios, Y; Rodriguez, A; Franco, A; Alava-Cruz, C; Marrero-Miranda, D; Perez-Tamajon, L; Matheu, V				Barrios, Yvelise; Rodriguez, Aurelio; Franco, Andres; Alava-Cruz, Cristina; Marrero-Miranda, Domingo; Perez-Tamajon, Lourdes; Matheu, Victor			Optimizing a Protocol to Assess Immune Responses after SARS-CoV-2 Vaccination in Kidney-Transplanted Patients: In Vivo DTH Cutaneous Test as the Initial Screening Method	VACCINES			English	Article						delayed-type hypersensitivity; DTH; skin test; SARS-CoV-2; vaccination; kidney transplant; immunosuppression; T-cell response		Previously, the delayed-type hypersensitivity (DTH) cutaneous test with the spike protein of SARS-CoV-2 has been shown to be a simple in vivo method to measure T-cell functionality after natural infection and in vaccinated individuals. Methods: Twenty-five kidney-transplanted recipients were immunized with two doses of the mRNA-based Pfizer-BioNTech COVID19 vaccine three weeks apart. Cell-immune response (CIR) was evaluated ten weeks later using an in vivo DTH skin test and in vitro with an interferon gamma release assay (IGRA). Humoral Immune Response (HIR) was determined by the measurement of specific IgG anti-S1 SARS-CoV-2. Results: Ten weeks after the second dose of the vaccine, 23 out of 25 transplanted patients had a positive DTH skin test, while in vitro CIR was considered positive in 20 patients. Unspecific stimulation was positive in all 25 patients, showing no T-cell defect. Seven out of twenty-five patients had a negative specific anti-spike IgG. CIR was positive in all immune-competent control patients. Conclusions: DTH is a useful, simple, and cheaper tool that can be used to assess cellular immune response, with an excellent correlation with the in vitro CIR. CIR assessment after vaccination in these immunocompromised patients is an excellent complement to HIR-based methods. This skin test could be used if classical in vitro methods cannot be applied.	[Barrios, Yvelise; Franco, Andres] Main Hosp Univ Canarias, Dept Immunol, San Cristobal De La Lagu 38320, Spain; [Rodriguez, Aurelio; Marrero-Miranda, Domingo; Perez-Tamajon, Lourdes] Hosp Univ Canarias, Dept Nephrol, San Cristobal De La Lagu 38320, Spain; [Alava-Cruz, Cristina; Matheu, Victor] Hosp Univ Canarias, Dept Allergy, San Cristobal De La Lagu 38320, Spain		Matheu, V (通讯作者)，Hosp Univ Canarias, Dept Allergy, San Cristobal De La Lagu 38320, Spain.	ybarpin@gobiernodecanarias.org; arodherl@gobiernodecanarias.org; aframas@gobiernodecanarias.org; calacru@gobiernodecanarias.org; dmarrero72@hotmail.com; mpertam@gobiernodecanarias.org; vmatheu@ull.edu.es	Barrios, Yvelise/AGR-9501-2022; Matheu, Victor/AAU-3043-2020	Barrios, Yvelise/0000-0002-6994-2034; Matheu, Victor/0000-0002-0469-800X; Perez Tamajon, Maria Lourdes/0000-0001-9812-5706	Spanish Society of Allergy and Clinical Immunology (SEAIC) [Beca20A4]	This research was partially self-funded and partially funded by the Spanish Society of Allergy and Clinical Immunology (SEAIC 2021 Beca20A4).	Badaro R, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01068-6; Barrios Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060575; Barrios Y, 2021, CLIN IMMUNOL, V226, DOI 10.1016/j.clim.2021.108730; Benotmane I, 2021, KIDNEY INT, V99, P1498, DOI 10.1016/j.kint.2021.04.005; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Broseta JJ, 2021, AM J KIDNEY DIS, V78, P571, DOI 10.1053/j.ajkd.2021.06.002; Cucchiari D, 2021, AM J TRANSPLANT, V21, P2727, DOI 10.1111/ajt.16701; Haas MK, 2019, CLIN CHEST MED, V40, P829, DOI 10.1016/j.ccm.2019.07.007; Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Montagud-Marrahi E, 2021, TRANSPLANTATION, V105, pE278, DOI 10.1097/TP.0000000000003927; Rincon-Arevalo H, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1031; Stavri H, 2012, INDIAN J MED RES, V136, P799; Stumpf J, 2021, TRANSPLANTATION, V105, pE267, DOI 10.1097/TP.0000000000003903	16	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1315	10.3390/vaccines9111315			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ9AC	34835246	gold, Green Published			2022-04-29	WOS:000727070300001
J	Liu, DL; Zhang, S; Poteet, E; Marin-Muller, C; Chen, CY; Yao, QZ				Liu, Dongliang; Zhang, Sheng; Poteet, Ethan; Marin-Muller, Christian; Chen, Changyi; Yao, Qizhi			Sublingual Immunization with Chimeric C1q/CD40 Ligand/HIV Virus-like Particles Induces Strong Mucosal Immune Responses against HIV	VACCINES			English	Article						HIV; virus-like particles; vaccine; mucosal immunization; immune response; IgA	BLOOD DENDRITIC CELLS; PROTECTS MICE; T-CELLS; VACCINATION; VACCINES; CD91	Development of a vaccine that can elicit robust HIV specific antibody responses in the mucosal compartments is desired for effective prevention of HIV via sexual transmission. However, the current mucosal vaccines have either poor immunogenicity when administered orally or invite safety concerns when administered intranasally. Sublingual immunization has received more attention in recent years based on its efficiency in inducing systemic and mucosal immune responses in both mucosal and extra-mucosal tissues. To facilitate the transport of the immunogen across the sub-mucosal epithelial barrier, we found that CD91, the receptor of C1q, is prevalently expressed in the sublingual mucosal lining, and thus, a modified chimeric C1q surface conjugated CD40L/HIV VLP was generated. The ability of this chimeric C1q/CD40L/HIV VLP to bind, cross the epithelial layer, access and activate the sub-mucosal layer dendritic cells (DCs), and ultimately induce enhanced mucosal and systemic immune responses against HIV is evaluated in this study. We found that C1q/CD40L/HIV VLPs have enhanced binding, increased transport across the epithelial layer, and upregulate DC activation markers as compared to CD40L/HIV VLPs alone. Mice immunized with C1q/CD40L/HIV VLPs by sublingual administration showed higher levels of IgA salivary antibodies against both HIV Gag and Env than mice immunized with CD40L/HIV VLPs. Moreover, sublingual immunization with C1q/CD40L/HIV VLPs induced more Env- and Gag-specific IFN-gamma producing T cells than the CD40L/HIV VLPs group. Interestingly, C1q/CD40L/HIV VLP immunization can also induce more mucosal homing T cells than that in CD40L/HIV VLP group. Our data suggest that incorporation of C1q to CD40L/HIV VLPs is a promising novel strategy and that the sublingual immunization can be a favorite immunization route for HIV mucosal vaccines.	[Liu, Dongliang; Zhang, Sheng; Poteet, Ethan; Marin-Muller, Christian; Chen, Changyi; Yao, Qizhi] Baylor Coll Med, Div Surg Res, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Yao, Qizhi] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis CTRID, Houston, TX 77030 USA		Yao, QZ (通讯作者)，Baylor Coll Med, Div Surg Res, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.; Yao, QZ (通讯作者)，Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis CTRID, Houston, TX 77030 USA.	Dongliang.Liu@bcm.edu; sheng.zhang@bcm.edu; ethan.poteet@bcm.edu; marinmul@bcm.edu; jchen@bcm.edu; qizhiyao@bcm.edu	Liu, Dongliang/AAM-9595-2021	Liu, Dongliang/0000-0001-5843-5451; Yao, Cathy/0000-0002-2267-0588	VA Merit AwardUS Department of Veterans Affairs [HIV-1BaL gp120];  [HIV-1IIIB pr55];  [1I01BX001474-01A1]	This research was funded by a VA Merit Award 1I01BX001474-01A1 (PI: Yao). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams DH, 2006, NAT REV IMMUNOL, V6, P244, DOI 10.1038/nri1784; Appledorn DM, 2011, CLIN VACCINE IMMUNOL, V18, P150, DOI 10.1128/CVI.00341-10; Bekri S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00063; Bourazopoulou E, 2009, J AUTOIMMUN, V33, P141, DOI 10.1016/j.jaut.2009.06.004; Caldeira JC, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050488; Chatzigeorgiou A, 2009, BIOFACTORS, V35, P474, DOI 10.1002/biof.62; Cho HJ, 2010, VACCINE, V28, P2598, DOI 10.1016/j.vaccine.2010.01.013; Collins KA, 2017, SCI REP-UK, V7, DOI 10.1038/srep46621; Cubas R, 2011, J IMMUNOTHER, V34, P251, DOI 10.1097/CJI.0b013e318209ee72; Cuburu N, 2007, VACCINE, V25, P8598, DOI 10.1016/j.vaccine.2007.09.073; Cuburu N, 2009, J IMMUNOL, V183, P7851, DOI 10.4049/jimmunol.0803740; Czerkinsky C, 2011, HUM VACCINES, V7, P110, DOI 10.4161/hv.7.1.13739; De Calisto J, 2011, METHODS MOL BIOL, V757, P411, DOI 10.1007/978-1-61779-166-6_24; Domm W, 2011, VACCINE, V29, P7080, DOI 10.1016/j.vaccine.2011.07.008; Duus K, 2010, FEBS J, V277, P3526, DOI 10.1111/j.1742-4658.2010.07762.x; Eickhoff CS, 2019, VACCINE, V37, P5364, DOI 10.1016/j.vaccine.2019.07.034; Guo LZ, 2003, VIROLOGY, V313, P502, DOI 10.1016/S0042-6822(03)00372-6; Hammonds J, 2007, VACCINE, V25, P8036, DOI 10.1016/j.vaccine.2007.09.016; Hart JP, 2004, J IMMUNOL, V172, P70, DOI 10.4049/jimmunol.172.1.70; Hervouet C, 2014, MUCOSAL IMMUNOL, V7, P280, DOI 10.1038/mi.2013.45; Hervouet C, 2010, VACCINE, V28, P5582, DOI 10.1016/j.vaccine.2010.06.033; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Karagianni P, 2019, J AUTOIMMUN, V104, DOI 10.1016/j.jaut.2019.102315; Ko EJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010024; Kozlowski Pamela A., 2019, Current Immunology Reviews, V15, P102, DOI 10.2174/1573395514666180605092054; Li M, 2020, IMMUNOL LETT, V217, P116, DOI 10.1016/j.imlet.2019.10.013; Li Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79172-7; Lu L, 2011, J VIROL, V85, P10542, DOI 10.1128/JVI.05441-11; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Maniecki MB, 2006, IMMUNOBIOLOGY, V211, P407, DOI 10.1016/j.imbio.2006.05.019; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Paris AL, 2021, J CONTROL RELEASE, V332, P553, DOI 10.1016/j.jconrel.2021.03.017; Pearson RM, 2017, ADV DRUG DELIVER REV, V114, P240, DOI 10.1016/j.addr.2017.04.005; Song JH, 2008, P NATL ACAD SCI USA, V105, P1644, DOI 10.1073/pnas.0708684105; Song JH, 2009, J IMMUNOL, V182, P6851, DOI 10.4049/jimmunol.0803568; Spohn G, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-146; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Sui Y, 2019, J CLIN INVEST, V129, P1314, DOI 10.1172/JCI122110; Trincado V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101177; Zhang L, 2012, VACCINE, V30, P2301, DOI 10.1016/j.vaccine.2012.01.061; Zhang RX, 2010, VACCINE, V28, P5114, DOI 10.1016/j.vaccine.2010.03.079; Zhang RX, 2004, VACCINE, V23, P139, DOI 10.1016/j.vaccine.2004.05.036	42	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1236	10.3390/vaccines9111236			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF7HY	34835167	Green Published, gold			2022-04-29	WOS:000724240200001
J	Tan, HM; Hue, SSS; Wee, A; See, KC				Tan, Hui Min; Hue, Susan Swee-Shan; Wee, Aileen; See, Kay Choong			Kikuchi-Fujimoto Disease Post COVID-19 Vaccination: Case Report and Review of Literature	VACCINES			English	Review						Kikuchi-Fujimoto disease; necrotizing histiocytic lymphadenitis; COVID-19; COVID-19 vaccine; lymphadenopathy	LYMPHADENITIS	With the rapid development of various coronavirus disease 2019 (COVID-19) vaccines in a bid to counter and contain the COVID-19 pandemic, unusual and uncommon side effects of COVID-19 vaccination have been increasingly reported in the literature. Ipsilateral lymphadenopathy is a fairly common side effect of vaccination of any kind, with its etiology most commonly related to reactive lymphadenopathy. However, Kikuchi-Fujimoto Disease (KFD) or necrotizing histiocytic lymphadenitis is rarely observed post-vaccination, with only one other case of KFD post COVID-19 vaccination reported to date. We report two more cases of KFD post COVID-19 vaccination in the Asian population, highlighting the clinical course and salient clinical, radiological and histologic findings. In addition, we provide a literature review of the existing cases of lymphadenopathy post COVID-19 vaccination with cytologic and/or histologic correlation.	[Tan, Hui Min; Hue, Susan Swee-Shan; Wee, Aileen] Natl Univ Singapore Hosp, Dept Pathol, Singapore 119074, Singapore; [See, Kay Choong] Natl Univ Singapore Hosp, Div Resp & Crit Care Med, Dept Med, Singapore 119074, Singapore		See, KC (通讯作者)，Natl Univ Singapore Hosp, Div Resp & Crit Care Med, Dept Med, Singapore 119074, Singapore.	hui_min_tan@nuhs.edu.sg; swee_shan_hue@nuhs.edu.sg; patweea@nus.edu.sg; kay_choong_see@nuhs.edu.sg		See, Kay Choong/0000-0003-2528-7282			Al Soub H, 2021, IDCASES, V25, DOI 10.1016/j.idcr.2021.e01253; ASANO S, 1990, HEMATOL ONCOL, V8, P251, DOI 10.1002/hon.2900080503; Bosch X, 2004, AM J CLIN PATHOL, V122, P141, DOI 10.1309/YF081L4TKYWVYVPQ; Cardoso F, 2021, CUREUS, V13, DOI 10.7759/cureus.15050; Cristina H, 2021, SWISS MED WKLY, V151, DOI 10.4414/smw.2021.20557; HARTSOCK RJ, 1968, CANCER, V21, P632, DOI 10.1002/1097-0142(196804)21:4<632::AID-CNCR2820210415>3.0.CO;2-O; Jaseb K, 2021, CLIN CASE REP, V9, P1279, DOI 10.1002/ccr3.3748; Lehman CD, 2021, J AM COLL RADIOL, V18, P843, DOI 10.1016/j.jacr.2021.03.001; Ozutemiz C, 2021, RADIOLOGY, V300, pE296, DOI 10.1148/radiol.2021210275; Perry AM, 2018, ARCH PATHOL LAB MED, V142, P1341, DOI 10.5858/arpa.2018-0219-RA; Placke JM, 2021, EUR J CANCER, V154, P167, DOI 10.1016/j.ejca.2021.06.023; Podugu A, 2013, CHEST, V144, DOI 10.1378/chest.1703273; Stimson L, 2021, BRIT J HAEMATOL, V192, pE124, DOI 10.1111/bjh.17292; Tan NJH, 2021, DIAGN CYTOPATHOL, V49, pE467, DOI 10.1002/dc.24863; Tintle Suzanne, 2021, EJHaem, DOI 10.1002/jha2.265; Watanabe T, 2012, EUR J PEDIATR, V171, P1409, DOI 10.1007/s00431-012-1729-1	16	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1251	10.3390/vaccines9111251			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG6RH	34835182	gold, Green Published			2022-04-29	WOS:000724877300001
J	Ahn, YH; Chathuranga, WAG; Shim, YJ; Haluwana, DK; Kim, EH; Yoon, IJ; Lim, YT; Shin, SH; Jo, H; Hwang, SY; Kim, HM; Lee, MJ; Park, JH; Yoo, SS; Lee, JS				Ahn, Young-Hoon; Chathuranga, W. A. Gayan; Shim, Young-Jung; Haluwana, D. K.; Kim, Eun-Hee; Yoon, In-Joong; Lim, Yong-Taik; Shin, Sung Ho; Jo, Hyundong; Hwang, Seong Yun; Kim, Hyun Mi; Lee, Min Ja; Park, Jong-Hyeon; Yoo, Sung-Sik; Lee, Jong-Soo			The Potential Adjuvanticity of CAvant(R)SOE for Foot-and-Mouth Disease Vaccine	VACCINES			English	Article						foot-and-mouth disease virus; vaccine; adjuvant; water-in-oil emulsion; CAvantSOE	IMMUNE-RESPONSE; HETEROLOGOUS CHALLENGE; OIL ADJUVANT; FMD VACCINE; SEROTYPE-O; ISA 206; VIRUS; PROTECTION; PIGS; STRATEGIES	Foot-and-mouth disease (FMD) is a notifiable contagious disease of cloven-hoofed mammals. A high potency vaccine that stimulates the host immune response is the foremost strategy used to prevent disease persistence in endemic regions. FMD vaccines comprise inactivated virus antigens whose immunogenicity is potentiated by immunogenic adjuvants. Oil-based adjuvants have clear advantages over traditional adjuvant vaccines; however, there is potential to develop novel adjuvants to increase the potency of FMD vaccines. Thus, we aimed to evaluate the efficacy of a novel water-in-oil emulsion, called CAvant(R)SOE, as a novel vaccine adjuvant for use with inactivated FMD vaccines. In this study, we found that inactivated A22 Iraq virus plus CAvant(R)SOE (iA22 Iraq-CAvant(R)SOE) induced effective antigen-specific humoral (IgG, IgG1, and IgG2a) and cell-mediated immune responses (IFN-gamma and IL-4) in mice. Immunization of pigs with a single dose of iA22 Iraq-CAvant(R)SOE also elicited effective protection, with no detectable clinical symptoms against challenge with heterologous A/SKR/GP/2018 FMDV. Levels of protection are strongly in line with vaccine-induced neutralizing antibody titers. Collectively, these results indicate that CAvant(R)SOE-adjuvanted vaccine is a promising candidate for control of FMD in pigs.	[Ahn, Young-Hoon; Shim, Young-Jung; Kim, Eun-Hee; Yoon, In-Joong; Yoo, Sung-Sik] Choong Ang Vaccine Lab Co Ltd, Daejeon 34055, South Korea; [Chathuranga, W. A. Gayan; Haluwana, D. K.; Lee, Jong-Soo] Chungnam Natl Univ, Coll Vet Med, Daejeon 34314, South Korea; [Lim, Yong-Taik] Sungkyunkwan Univ, Dept Nano Engn, Suwon 16419, South Korea; [Shin, Sung Ho; Jo, Hyundong; Hwang, Seong Yun; Kim, Hyun Mi; Lee, Min Ja; Park, Jong-Hyeon] Anim & Plant Quarantine Agcy, Gimcheon 39660, South Korea		Yoo, SS (通讯作者)，Choong Ang Vaccine Lab Co Ltd, Daejeon 34055, South Korea.; Lee, JS (通讯作者)，Chungnam Natl Univ, Coll Vet Med, Daejeon 34314, South Korea.	hi-ayh@cavac.co.kr; gayachathu123@gmail.com; younggirl58@cavac.co.kr; dhammikaaz@gmail.com; ehkim@cavac.co.kr; iyoon@cavac.co.kr; yongtaik@skku.edu; ikarus121@korea.kr; jhd0327@korea.kr; hsy8592@korea.kr; khm852456@korea.kr; herb12@korea.kr; parkjhvet@korea.kr; saintyoo@cavac.co.kr; jongsool@cnu.ac.kr			National Research Foundation of Korea (NRF) - Korea government (MEST)Ministry of Education, Science and Technology, Republic of KoreaNational Research Foundation of KoreaKorean Government [2018M3A9H4078692, 2018M3A9H4078703, 2021R1A6A1A03045495]	This research was funded by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2018M3A9H4078692, 2018M3A9H4078703, 2021R1A6A1A03045495).	Alves MP, 2009, CLIN VACCINE IMMUNOL, V16, P1151, DOI 10.1128/CVI.00018-09; Barnard AL, 2005, VACCINE, V23, P1037, DOI 10.1016/j.vaccine.2004.07.034; Barnett PV, 1996, VACCINE, V14, P1187, DOI 10.1016/S0264-410X(96)00055-2; Cao YM, 2016, EXPERT REV VACCINES, V15, P783, DOI 10.1586/14760584.2016.1140042; Cao YM, 2014, EXPERT REV VACCINES, V13, P1377, DOI 10.1586/14760584.2014.963562; Chen ZH, 2017, ARTIF CELL NANOMED B, V45, P897, DOI 10.1080/21691401.2016.1188396; Cloete M, 2008, ONDERSTEPOORT J VET, V75, P17; Cokcaliskan C, 2016, CLIN EXP VACCINE RES, V5, P138, DOI 10.7774/cevr.2016.5.2.138; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; Dar P, 2013, VACCINE, V31, P3327, DOI 10.1016/j.vaccine.2013.05.078; Doel TR, 1999, VACCINE, V17, P1767, DOI 10.1016/S0264-410X(98)00444-7; Feng SY, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00129; Forth LF, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9010063; Golde WT, 2005, VACCINE, V23, P5775, DOI 10.1016/j.vaccine.2005.07.043; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Horsington J, 2015, VACCINE, V33, P422, DOI 10.1016/j.vaccine.2014.11.043; Ibrahim EES, 2015, VET WORLD, V8, P1189, DOI 10.14202/vetworld.2015.1189-1198; Iyer AV, 2000, VACCINE, V19, P1097, DOI 10.1016/S0264-410X(00)00337-6; Kamel M, 2019, ARCH VIROL, V164, P1501, DOI 10.1007/s00705-019-04216-x; Kenneth C., 2004, FOOT MOUTH DIS CURRE; Khorasani A, 2016, IRAN J VET RES, V17, P8; Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5; Liu, 2013, J BIOSCI MED, V1, P22, DOI DOI 10.4236/jbm.2013.13005; London CA, 1998, VET IMMUNOL IMMUNOP, V63, P37, DOI 10.1016/S0165-2427(98)00080-4; Lyons NA, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00102; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; MCCULLOUGH KC, 1986, IMMUNOLOGY, V58, P421; McKercher P D, 1976, Dev Biol Stand, V35, P107; Mowat N, 1999, VACCINE MANUAL PRODU; Oem JK, 2008, J COMP PATHOL, V138, P204, DOI 10.1016/j.jcpa.2008.01.007; Oh Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044365; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; Park JN, 2014, VACCINE, V32, P1882, DOI 10.1016/j.vaccine.2014.01.067; Park ME, 2014, VACCINE, V32, P5221, DOI 10.1016/j.vaccine.2014.07.040; Park MinEun, 2016, Trials in Vaccinology, V5, P97, DOI 10.1016/j.trivac.2016.04.006; Pattnaik B, 2012, AGR RES, V1, P132, DOI 10.1007/s40003-012-0012-z; da Cunha CEP, 2017, MEM I OSWALDO CRUZ, V112, P812, DOI 10.1590/0074-02760170133; SADIR AM, 1988, EPIDEMIOL INFECT, V100, P135, DOI 10.1017/S0950268800065626; Saeed Ali, 2015, Journal of Animal Science and Technology, V57, P1, DOI 10.1186/s40781-015-0042-8; Singh RK, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030090; SPATH EJA, 1995, VACCINE, V13, P909, DOI 10.1016/0264-410X(95)00009-P; Stenfeldt C, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00041; Wang ZB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010128; World Organisation for Animal Health, 2018, OIE LIST DIS INF FOR; Yoon H, 2018, PREV VET MED, V149, P140, DOI 10.1016/j.prevetmed.2017.12.006	45	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1091	10.3390/vaccines9101091			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP5QT	34696199	gold, Green Published			2022-04-29	WOS:000713186700001
J	Al-Suhaimi, EA; Aljafary, MA; Alkhulaifi, FM; Aldossary, HA; Alshammari, T; AL-Qaaneh, A; Aldahhan, R; Alkhalifah, Z; Gaymalov, ZZ; Shehzad, A; Homeida, AM				Al-Suhaimi, Ebtesam A.; Aljafary, Meneerah A.; Alkhulaifi, Fadwa M.; Aldossary, Hanan A.; Alshammari, Thamer; AL-Qaaneh, Ayman; Aldahhan, Razan; Alkhalifah, Zahra; Gaymalov, Zagit Z.; Shehzad, Adeeb; Homeida, Abdelgadir M.			Thymus Gland: A Double Edge Sword for Coronaviruses	VACCINES			English	Review						hedging; transaction costs; dynamic programming; risk management; post-decision state variable	SARS-CORONAVIRUS; RESPIRATORY SYNDROME; THYMOSIN ALPHA-1; T-CELLS; PROTHYMOSIN-ALPHA; IMMUNE-RESPONSES; INTERFERON-GAMMA; EPITHELIAL-CELLS; DENDRITIC CELLS; INNATE IMMUNITY	The thymus is the main lymphoid organ that regulates the immune and endocrine systems by controlling thymic cell proliferation and differentiation. The gland is a primary lymphoid organ responsible for generating mature T cells into CD4+ or CD8+ single-positive (SP) T cells, contributing to cellular immunity. Regarding humoral immunity, the thymic plasma cells almost exclusively secrete IgG1 and IgG3, the two main complement-fixing effector IgG subclasses. Deformity in the thymus can lead to inflammatory diseases. Hassall's corpuscles' epithelial lining produces thymic stromal lymphopoietin, which induces differentiation of CDs thymocytes into regulatory T cells within the thymus medulla. Thymic B lymphocytes produce immunoglobulins and immunoregulating hormones, including thymosin. Modulation in T cell and naive T cells decrement due to thymus deformity induce alteration in the secretion of various inflammatory factors, resulting in multiple diseases. Influenza virus activates thymic CD4+ CD8+ thymocytes and a large amount of IFN gamma. IFNs limit virus spread, enhance macrophages' phagocytosis, and promote the natural killer cell restriction activity against infected cells. Th2 lymphocytes-produced cytokine IL-4 can bind to antiviral INF gamma, decreasing the cell susceptibility and downregulating viral receptors. COVID-19 epitopes (S, M, and N proteins) with & GE;90% identity to the SARS-CoV sequence have been predicted. These epitopes trigger immunity for antibodies production. Boosting the immune system by improving thymus function can be a therapeutic strategy for preventing virus-related diseases. This review aims to summarize the endocrine-immunoregulatory functions of the thymus and the underlying mechanisms in the prevention of COVID-19.</p>	[Al-Suhaimi, Ebtesam A.; Aljafary, Meneerah A.; Alkhulaifi, Fadwa M.; Homeida, Abdelgadir M.] Imam Abdulrahman Bin Faisal Univ, Coll Sci, Biol Dept, POB 1982, Dammam 31441, Saudi Arabia; [Aldossary, Hanan A.] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Epidm Dis Res Dept, POB 1982, Dammam 31441, Saudi Arabia; [Alshammari, Thamer; AL-Qaaneh, Ayman; Alkhalifah, Zahra] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Genet Res Dept, POB 1982, Dammam 31441, Saudi Arabia; [AL-Qaaneh, Ayman] Johns Hopkins Aramco Healthcare JHAH, Dept Pharm Serv, Clin Pharm Serv Div, Dhahran 31311, Saudi Arabia; [Aldahhan, Razan] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Stem Cell Res Dept, POB 1982, Dammam 31441, Saudi Arabia; [Gaymalov, Zagit Z.] Earlystage OU, Lasnamae Linnaosa, Sepapaja Tn 6, Tallinn 15551, Estonia; [Shehzad, Adeeb] Imam Abdulrahman Bin Faisal Univ, Clin Pharm Res Dept Inst Res & Med Consultat IRMC, POB 1982, Dammam 31441, Saudi Arabia		Al-Suhaimi, EA (通讯作者)，Imam Abdulrahman Bin Faisal Univ, Coll Sci, Biol Dept, POB 1982, Dammam 31441, Saudi Arabia.	ealsuhaimi@iau.edu.sa; maljafary@iau.edu.sa; falkhulaifi@iau.edu.sa; 2200500232@iau.edu.sa; tmjalshammari@iau.edu.sa; Ayman.qaaneh@JHAH.com; raaldahhan@gmail.com; 2200500002@iau.edu.sa; z@earlystage.co; asmsiar@iau.edu.sa; amhomeida@iau.edu.sa	Al-Qaaneh, Ayman/AAD-2182-2022; Al-Suhaimi, Ebtesam/C-6054-2015	Al-Qaaneh, Ayman/0000-0002-6342-6573; Al-Suhaimi, Ebtesam/0000-0003-1614-0211; Alshammari, Thamer/0000-0002-4007-1984; AlDossary, Hanan/0000-0002-6692-3161			Abdul-Rasool Sahar, 2010, Open Virol J, V4, P76, DOI 10.2174/1874357901004010076; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Aslam MS, 2021, MATERIALS, V14, DOI 10.3390/ma14123318; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bhat MA, 2021, CURR PHARM DESIGN, V27, P3435, DOI 10.2174/1381612826666201118112912; Budd R.C., 2017, KELLEY FIRESTEINS TX, P189; Callard R.E., 2001, CYTOKINE FACTSBOOK W, DOI [10.1016/B978-0-12-155142-1.X5000-3, DOI 10.1016/B978-0-12-155142-1.X5000-3]; Camerini R, 2015, EXPERT OPIN BIOL TH, V15, pS117, DOI 10.1517/14712598.2015.1033393; CAO M, 2020, LANCET, V395, P497; Chen X, 2016, INT IMMUNOPHARMACOL, V34, P244, DOI 10.1016/j.intimp.2016.03.009; Cuvelier P, 2021, CRIT CARE, V25, DOI 10.1186/s13054-020-03440-1; da Silva AL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay7973; da Silva AL, 2014, J CONTROL RELEASE, V180, P125, DOI 10.1016/j.jconrel.2014.02.010; de Lang A, 2006, VIROLOGY, V353, P474, DOI 10.1016/j.virol.2006.06.011; Dembic Z, 2015, CYTOKINES IMMUNE SYS; Drljaca JN, 2020, ARCH BIOL SCI, V72, P5, DOI 10.2298/ABS190716060D; Edston E, 2020, AM J FOREN MED PATH, V41, P32, DOI 10.1097/PAF.0000000000000530; Fan Li, 2020, Chin J Acad Radiol, P1, DOI 10.1007/s42058-020-00031-5; Fisher D, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01533-w; Frasca D, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-14; Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015; Garaci E, 2007, ANN NY ACAD SCI, V1112, P225, DOI 10.1196/annals.1415.044; Garaci E, 2012, ANN NY ACAD SCI, V1269, P26, DOI 10.1111/j.1749-6632.2012.06697.x; Goldstein AL, 2004, EXPERT OPIN BIOL TH, V4, P559, DOI 10.1517/eobt.4.4.559.29800; Goldstein AL, 2007, ANN NY ACAD SCI, V1112, P1, DOI 10.1196/annals.1415.045; Guan WD, 2015, EMERG INFECT DIS, V21, P2278, DOI 10.3201/eid2112.151232; He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014; HENRY L, 1990, J ANAT, V168, P185; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; Holdsworth SR, 2015, CLIN J AM SOC NEPHRO, V10, P2243, DOI 10.2215/CJN.07590714; Hotez PJ, 2020, MICROBES INFECT, V22, P165, DOI 10.1016/j.micinf.2020.04.005; Husby S, 2013, MADAME CURIE BIOSCIE; Inaba H, 2004, J PEDIAT HEMATOL ONC, V26, P108, DOI 10.1097/00043426-200402000-00008; Isaacson P G, 1987, Lancet, V2, P1488; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Jia R, 2019, BIOSCI TRENDS, V13, P516, DOI 10.5582/bst.2019.01286; Klimpel G.R., 1996, MED MICROBIOLOGY, V4th; Lalle M, 2009, ANN HEMATOL, V88, P847, DOI 10.1007/s00277-008-0693-3; Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166; LE PT, 1991, J EXP MED, V174, P1147, DOI 10.1084/jem.174.5.1147; Le Rouzic O, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02434-2016; Li BX, 2020, GENES-BASEL, V11, DOI 10.3390/genes11020147; Liu B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.323; Liu QJ, 2020, PROTEIN CELL, V11, P549, DOI 10.1007/s13238-020-00707-9; Lo AWI, 2006, J PATHOL, V208, P142, DOI 10.1002/path.1897; Longhi MP, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000006; Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318; Lunin SM, 2010, EXPERT OPIN THER TAR, V14, P775, DOI 10.1517/14728222.2010.499127; Maddur MS, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1005508; Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379; Miller J, 2020, CELL DEATH DIFFER, V27, P396, DOI 10.1038/s41418-019-0462-y; Minakshi R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.575404; MISHALANI SH, 1995, ARCH PATHOL LAB MED, V119, P467; Nakhlband A, 2021, N-S ARCH PHARMACOL, V394, P829, DOI 10.1007/s00210-021-02061-x; NAPARSTEK Y, 1982, NATURE, V300, P262, DOI 10.1038/300262a0; Nowacki TM, 2007, CELL IMMUNOL, V247, P36, DOI 10.1016/j.cellimm.2007.07.004; Nunez S, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah4447; Nutt SL, 2011, SEMIN IMMUNOL, V23, P341, DOI 10.1016/j.smim.2011.08.010; Odaka C, 2013, INT IMMUNOL, V25, P633, DOI 10.1093/intimm/dxt026; Okabayashi T, 2006, J MED VIROL, V78, P417, DOI 10.1002/jmv.20556; PALASZYNSKI EW, 1983, PEPTIDES, V4, P463, DOI 10.1016/0196-9781(83)90050-5; Paquette SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038214; Perera J, 2015, CELL MOL LIFE SCI, V72, P2657, DOI 10.1007/s00018-015-1895-1; Perera J, 2013, P NATL ACAD SCI USA, V110, P17011, DOI 10.1073/pnas.1313001110; Pica F, 2016, CLIN EXP IMMUNOL, V186, P39, DOI 10.1111/cei.12833; Pillai S., 2017, CELL MOL IMMUNOL; Pluddemann A, 2011, IMMUNOL REV, V240, P11, DOI 10.1111/j.1600-065X.2010.00989.x; Principi N, 2010, EMERG INFECT DIS, V16, P183, DOI 10.3201/eid1602.090469; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Rafie C, 2011, AIDS RES HUM RETROV, V27, P815, DOI [10.1089/aid.2010.0086, 10.1089/AID.2010.0086]; Rathore JS, 2016, VACCINE, V34, P1504, DOI 10.1016/j.vaccine.2016.02.021; Rehman S, 2020, SAUDI J BIOL SCI, V27, P2567, DOI 10.1016/j.sjbs.2020.05.024; Rish i, 2020, UNDERSTANDING THETHY; Romani L, 2004, BLOOD, V103, P4232, DOI 10.1182/blood-2003-11-4036; Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Samara P, 2016, VITAM HORM, V102, P179, DOI 10.1016/bs.vh.2016.04.008; Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337; Savini P, P 6 INT EXP FOR IMM; Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Severa M, 2019, MULT SCLER RELAT DIS, V27, P52, DOI 10.1016/j.msard.2018.09.035; Shibabaw T, 2020, J INFLAMM RES, V13, P507, DOI 10.2147/JIR.S267280; Shlomchik M, 2001, IMMUNOBIOLOGY 3; Skopeliti M, 2009, MOL IMMUNOL, V46, P784, DOI 10.1016/j.molimm.2008.09.014; Sodhi A, 2002, INT IMMUNOPHARMACOL, V2, P47, DOI 10.1016/S1567-5769(01)00139-4; SPENCER J, 1992, IMMUNOLOGY, V75, P596; Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597; Swerdlow SH, 2014, AM J SURG PATHOL, V38, pE60, DOI 10.1097/PAS.0000000000000295; Thapa P, 2019, THORAC SURG CLIN, V29, P123, DOI 10.1016/j.thorsurg.2018.12.001; Tian Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02125; Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069; Wang J, 2015, CELL MOL IMMUNOL, V12, P633, DOI 10.1038/cmi.2014.80; Weyand C.M., 2019, CLIN IMMUNOLOGY E BO; Woodford P., 2013, WHEATERS FUNCTIONAL, P204; Wu HX, 2010, HUM REPROD, V25, P1146, DOI 10.1093/humrep/deq051; Xia HJ, 2020, J INTERF CYTOK RES, V40, P543, DOI 10.1089/jir.2020.0214; Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071; Yamano T, 2015, IMMUNITY, V42, P1048, DOI 10.1016/j.immuni.2015.05.013; Yan FG, 2017, MOL MED REP, V16, P7175, DOI 10.3892/mmr.2017.7525; Yao Q, 2007, IMMUNOL LETT, V110, P110, DOI 10.1016/j.imlet.2007.04.007; Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08; You J, 2006, WORLD J GASTROENTERO, V12, P6715, DOI 10.3748/wjg.v12.i41.6715; Zhang P, 2005, EMBO REP, V6, P531, DOI 10.1038/sj.embor.7400433; Zhou YT, 2017, J CELL PHYSIOL, V232, P3050, DOI 10.1002/jcp.25516	107	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1119	10.3390/vaccines9101119			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP0TG	34696231	gold, Green Published			2022-04-29	WOS:000712854300001
